Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"
A2M	"CPAMD5, FWP007, S863-7"	ENSG00000175899	Alpha-2-macroglobulin	P01023	12	9067664-9116229	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 231.0;lung: 227.4"	"Group enriched"	"Detected in some"	5	"AF22: 111.0;ASC diff: 33.0;Hep G2: 89.4;SK-MEL-30: 32.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 4.4"	"Group enriched"	"Detected in many"	7	"dendritic cells: 1.4;T-cells: 4.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA002265, CAB017621"	Supported				"Secreted to blood"	220000000000	220000000000			"CAB017621: AB_1118894, HPA002265: AB_1078142"	"unprognostic (1.73e-2)"	"unprognostic (1.05e-3)"	"unprognostic (1.72e-1)"	"unprognostic (2.29e-2)"	"unprognostic (7.36e-2)"	"unprognostic (3.91e-2)"	"unprognostic (7.95e-2)"	"unprognostic (3.65e-2)"	"unprognostic (2.38e-1)"	"unprognostic (7.19e-2)"	"unprognostic (4.71e-2)"	"unprognostic (2.06e-2)"	"unprognostic (1.28e-2)"	"unprognostic (8.04e-3)"	"unprognostic (2.32e-2)"	"unprognostic (8.58e-2)"	"unprognostic (9.03e-3)"	77.4	20.5	12.5	14.7	16.8	0.3	39.6	6.1	16.1	41.8	27.3	25.3	10.5	15.0	54.6	28.2	39.5	30.6	49.7	68.0	12.4	10.2	50.0	231.0	227.4	14.9	16.9	8.0	40.8	13.0	20.9	20.4	48.0	20.5	77.3	35.9	47.5	20.5	26.3	26.0	10.2	23.1	57.7	20.9	42.3	25.8	26.2	13.0	4.0	29.5	17.0	8.6	68.9	59.0	0.2	1.4	0.0	0.4	0.0	4.4	0.3	0.0	0.0	111.0	0.0	33.0	2.4	0.3	13.2	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	89.4	0.0	0.1	0.1	5.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.2	0.1	0.1	0.0	0.0	0.0	0.1	0.2	0.0	32.1	0.0	0.0	0.0	0.0	0.9	0.2	0.0	0.1	0.0	0.1	0.0	0.0	2.1	0.0	0.4	0.0	4.4	0.2	2.6	0.2	0.5	1.2	0.3	0.0	0.1	0.7	0.0	0.0	0.0	1.4	0.0	0.3	12.5	16.8	6.1	16.1	12.4	10.2	16.9	8.0	20.5	13.0
AARS2	"AARSL, bA444E17.1, KIAA1270"	ENSG00000124608	"Alanyl-tRNA synthetase 2, mitochondrial"	Q5JTZ9	6	44299654-44313326	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Protein biosynthesis"	"Aminoacyl-tRNA synthetase, Ligase, RNA-binding, tRNA-binding"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Premature ovarian failure, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035636, HPA061396"	Approved		Enhanced	Mitochondria				Mitochondria		"HPA035636: AB_10670837, HPA061396: "	"unprognostic (1.56e-1)"	"unprognostic (3.24e-2)"	"unprognostic (2.58e-2)"	"unprognostic (2.04e-3)"	"unprognostic (2.83e-1)"	"unprognostic (1.69e-1)"	"unprognostic (8.83e-3)"	"unprognostic (5.12e-2)"	"unprognostic (3.64e-2)"	"unprognostic (1.38e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.02e-1)"	8.6	10.7	15.9	16.2	11.8	11.4	9.9	23.5	19.8	11.4	14.5	11.4	13.0	15.3	14.1	10.4	17.2	13.4	15.9	10.4	13.2	8.9	10.3	12.6	10.9	13.4	12.4	14.3	17.1	13.8	16.2	14.2	10.1	11.1	13.2	9.8	11.2	14.4	14.6	10.2	16.8	18.3	12.1	8.8	14.1	12.3	12.9	14.1	14.7	12.3	10.4	13.4	10.2	13.9	7.1	3.2	3.7	3.4	3.7	5.5	2.8	10.4	7.9	10.3	19.0	6.1	5.7	13.7	8.7	4.5	9.2	8.9	8.5	5.7	11.5	13.9	3.7	7.9	11.4	12.4	3.6	8.1	18.3	13.4	7.7	10.0	4.0	12.4	11.9	4.8	7.9	7.4	7.9	7.8	15.8	11.3	4.9	11.7	10.4	10.7	7.7	7.7	12.4	6.3	7.9	4.8	9.5	24.6	8.9	7.5	8.4	11.6	7.8	16.2	6.6	10.0	10.0	6.1	10.8	6.7	6.2	11.9	5.6	11.0	17.1	3.7	2.4	0.0	3.4	3.3	5.5	3.6	4.8	4.4	2.6	7.1	4.7	4.3	0.7	3.7	3.4	3.2	3.0	2.8	15.9	11.8	23.5	19.8	13.2	8.9	12.4	14.3	11.1	14.1
ABCB1	"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1"	ENSG00000085563	"ATP binding cassette subfamily B member 1"	P08183	7	87503633-87713323	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 57.8;intestine: 49.6"	"Cell line enhanced"	"Detected in some"		"CACO-2: 29.4;HEK 293: 9.0;HEL: 16.3;Hep G2: 8.1;RPTEC TERT1: 11.3;SH-SY5Y: 36.0"	"Cancer enhanced"	"Detected in many"		"renal cancer: 14.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 19.2"	"Group enriched"	"Detected in many"	8	"NK-cells: 11.4;T-cells: 19.2"									"CAB001716, HPA002199"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Focal adhesion sites, Cytosol"		"CAB001716: , HPA002199: AB_1844428"	"unprognostic (5.38e-3)"	"unprognostic (2.45e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.25e-2)"	"unprognostic (9.99e-5)"	"unprognostic (2.23e-3)"	"unprognostic (5.65e-3)"	"unprognostic (1.14e-1)"	"unprognostic (5.17e-2)"	"prognostic favourable (3.33e-4)"	"unprognostic (5.19e-1)"	"prognostic favourable (2.95e-4)"	"unprognostic (2.06e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.83e-1)"	"unprognostic (6.12e-2)"	2.6	57.8	9.4	3.2	11.5	1.2	3.4	5.1	10.5	5.5	22.7	3.8	2.0	14.4	9.4	3.5	2.0	3.2	9.0	1.8	9.2	6.6	19.1	15.6	3.8	2.2	9.4	5.7	2.2	1.5	1.7	1.3	3.1	11.1	2.7	10.7	7.6	1.5	2.1	1.1	1.3	49.6	5.7	9.0	2.4	1.7	1.3	8.6	0.1	2.4	1.4	2.2	2.6	5.9	1.9	0.0	0.1	0.0	11.4	19.2	1.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	29.4	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	9.0	16.3	1.9	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	11.3	0.0	0.4	36.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.8	0.0	0.4	3.2	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	7.8	0.0	19.2	0.4	2.0	4.7	0.0	1.9	1.2	4.8	0.1	11.4	0.0	0.0	0.0	1.5	9.4	11.5	5.1	10.5	9.2	6.6	9.4	5.7	11.1	8.6
ABCC1	"GS-X, MRP, MRP1"	ENSG00000103222	"ATP binding cassette subfamily C member 1"	P33527	16	15949577-16143074	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	Transport	Hydrolase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"EFO-21: 38.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 7.5;eosinophil: 3.1;T-reg: 2.1"	"Group enriched"	"Detected in many"	7	"granulocytes: 7.5;T-cells: 2.1"	"Low region specificity"	"Detected in all"							HPA002380	Uncertain		Supported	"Plasma membrane"				"Plasma membrane"		"HPA002380: AB_1844432"	"unprognostic (9.97e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.05e-2)"	"unprognostic (2.94e-1)"	"unprognostic (4.89e-2)"	"unprognostic (1.15e-1)"	"prognostic unfavourable (5.42e-5)"	"unprognostic (3.42e-1)"	"unprognostic (3.31e-1)"	"unprognostic (4.07e-2)"	"unprognostic (9.78e-3)"	"unprognostic (7.19e-2)"	"prognostic unfavourable (1.55e-6)"	"unprognostic (1.84e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.43e-2)"	"unprognostic (1.80e-2)"	8.9	8.2	2.4	8.3	3.1	8.4	9.6	4.4	5.0	8.3	10.7	2.6	15.5	3.5	10.5	12.7	14.7	5.6	9.6	8.0	2.1	2.4	4.5	1.6	10.9	12.2	3.0	2.1	6.8	5.8	18.4	4.2	5.2	4.1	9.6	4.1	12.0	16.9	10.9	20.8	6.6	8.2	16.4	4.0	9.2	10.9	15.1	2.3	26.8	15.7	12.6	15.6	15.3	11.8	0.7	0.5	7.5	0.5	0.4	2.1	0.2	2.2	24.2	0.1	6.3	5.6	3.5	1.3	7.1	8.7	6.2	6.4	3.8	17.5	6.6	38.2	13.7	6.5	2.0	7.0	4.7	11.5	2.2	8.1	14.2	14.0	16.7	2.9	21.1	7.3	4.7	1.8	1.0	6.8	8.2	3.4	1.9	4.5	5.2	2.7	3.8	3.6	18.5	3.6	3.2	2.3	8.2	3.5	5.8	9.0	9.8	2.4	3.4	1.5	0.6	0.4	1.4	5.1	5.7	6.3	3.2	2.2	3.2	3.0	0.7	7.5	0.1	3.1	0.6	0.4	0.6	0.7	0.5	0.6	0.5	0.3	0.6	0.6	0.0	0.4	0.5	0.3	2.1	0.2	2.4	3.1	4.4	5.0	2.1	2.4	3.0	2.1	4.1	2.3
ABCC2	"CMOAT, cMRP, DJS, MRP2"	ENSG00000023839	"ATP binding cassette subfamily C member 2"	Q92887	10	99782732-99852192	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 28.4;kidney: 25.6;liver: 74.3"	"Group enriched"	"Detected in some"	5	"A549: 59.0;Hep G2: 58.8"	"Cancer enhanced"	"Detected in many"		"liver cancer: 24.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 4.1"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 4.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA004860, CAB037271"	Enhanced									"CAB037271: AB_2221326, HPA004860: AB_1844433"	"unprognostic (1.49e-3)"	"unprognostic (5.92e-2)"	"unprognostic (1.59e-1)"	"unprognostic (3.67e-1)"	"unprognostic (1.93e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.51e-1)"	"unprognostic (7.15e-3)"	"unprognostic (5.68e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.30e-1)"	"unprognostic (1.40e-3)"	"prognostic unfavourable (1.93e-5)"	"unprognostic (1.31e-1)"	"unprognostic (3.22e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.26e-2)"	0.8	0.3	0.1	0.1	0.1	0.1	1.1	0.3	0.1	0.2	13.4	0.1	0.1	16.1	0.3	0.5	0.2	0.4	13.7	0.2	0.1	0.1	25.6	74.3	0.3	0.1	0.1	0.1	0.2	0.6	0.0	0.1	1.2	0.1	0.3	0.0	0.1	0.3	0.1	0.6	0.6	28.4	0.1	0.2	0.8	0.4	0.4	0.1	0.1	0.3	0.4	0.1	0.7	0.3	0.3	0.7	4.1	0.2	0.1	0.5	0.0	0.0	59.0	0.9	2.9	4.5	3.5	1.0	0.1	0.3	0.1	0.2	12.6	0.1	0.1	0.1	0.2	0.3	0.1	0.1	0.2	0.1	0.1	0.0	0.2	58.8	0.1	0.0	0.2	0.5	4.1	0.4	0.4	0.1	0.0	0.1	0.0	0.2	0.0	0.4	0.1	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.1	0.9	7.3	0.0	0.1	0.1	0.1	0.1	0.3	0.1	0.2	0.0	0.0	4.8	0.9	0.3	4.1	0.2	0.3	0.3	0.0	0.4	0.2	0.3	0.1	0.3	0.3	0.3	0.1	1.3	0.1	0.1	0.7	0.5	0.0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1
ABCC3	"cMOAT2, EST90757, MLP2, MOAT-D, MRP3"	ENSG00000108846	"ATP binding cassette subfamily C member 3"	O15438	17	50634777-50692252	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 53.5;liver: 66.2"	"Cell line enhanced"	"Detected in many"		"A549: 33.9;CAPAN-2: 25.9;HeLa: 14.3;RPTEC TERT1: 14.8;RT4: 14.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 6.2;non-classical monocyte: 7.6"	"Lineage enriched"	"Detected in many"	5	"monocytes: 7.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB037136, HPA048483"	Enhanced		Supported	"Plasma membrane"				"Plasma membrane"		"CAB037136: AB_477165, HPA048483: "	"unprognostic (1.57e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.65e-2)"	"unprognostic (9.67e-3)"	"unprognostic (6.19e-3)"	"unprognostic (7.44e-3)"	"unprognostic (8.20e-2)"	"unprognostic (3.18e-1)"	"unprognostic (5.13e-2)"	"prognostic unfavourable (9.57e-4)"	"unprognostic (1.60e-3)"	"prognostic unfavourable (4.68e-6)"	"unprognostic (3.42e-1)"	"unprognostic (4.77e-2)"	"unprognostic (4.44e-2)"	"unprognostic (1.57e-3)"	3.5	36.0	0.4	17.0	0.4	0.5	7.7	0.3	0.4	1.9	23.9	0.8	14.1	10.3	1.6	4.6	5.3	1.0	53.5	0.8	0.4	0.4	13.5	66.2	9.0	10.3	0.6	0.0	1.0	22.2	1.7	0.8	3.5	1.5	5.4	7.7	0.8	4.7	23.6	0.4	4.8	37.0	2.5	4.6	4.9	12.8	1.0	0.0	0.8	4.5	7.0	7.9	7.1	3.5	0.0	1.6	1.3	7.6	0.3	0.5	7.4	2.4	33.9	0.0	0.1	1.9	3.0	0.0	4.5	5.7	0.3	0.3	1.8	25.9	0.0	3.5	8.8	6.2	0.0	0.4	0.4	0.0	0.0	0.7	14.3	10.3	7.7	0.0	0.0	3.4	2.5	1.3	2.8	0.6	0.0	0.0	3.5	7.9	0.0	0.0	0.0	4.5	0.0	0.0	0.1	14.8	14.7	0.0	0.3	8.2	1.4	0.0	1.1	0.0	7.5	0.2	1.5	0.1	3.6	0.0	0.0	0.0	3.7	0.0	0.3	0.3	2.8	0.0	0.0	6.2	0.0	0.0	0.1	0.0	1.6	0.0	0.0	0.0	1.3	0.3	7.6	0.2	0.5	7.4	0.4	0.4	0.3	0.4	0.4	0.4	0.6	0.0	1.5	0.0
ABCC5	"EST277145, MOAT-C, MRP5, SMRP"	ENSG00000114770	"ATP binding cassette subfamily C member 5"	O15440	3	183919934-184018015	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RT4: 47.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA044067, HPA052295"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"				"Plasma membrane, Cell Junctions"	Nucleoplasm	"HPA044067: , HPA052295: "	"unprognostic (9.39e-2)"	"unprognostic (6.23e-3)"	"unprognostic (3.83e-2)"	"unprognostic (1.10e-3)"	"unprognostic (2.28e-2)"	"unprognostic (2.07e-1)"	"prognostic unfavourable (6.78e-8)"	"unprognostic (4.46e-2)"	"unprognostic (6.07e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.91e-3)"	"prognostic unfavourable (3.40e-4)"	"unprognostic (1.10e-1)"	"unprognostic (9.05e-3)"	"unprognostic (1.64e-1)"	"unprognostic (3.33e-2)"	"unprognostic (1.24e-2)"	7.9	11.2	24.7	9.6	26.2	12.0	6.7	42.8	28.6	7.7	11.4	12.0	13.4	6.8	14.1	7.0	17.1	6.1	11.6	16.0	19.1	13.7	12.8	3.6	9.4	7.3	20.5	18.5	11.8	4.9	22.4	20.5	10.8	21.7	10.6	14.4	31.1	7.4	9.3	41.0	14.5	8.5	10.5	12.9	16.3	48.5	9.4	20.9	9.3	5.5	7.3	7.4	18.1	12.7	4.2	3.5	15.8	4.5	5.0	7.0	4.5	7.3	4.0	9.3	11.1	9.3	10.6	14.4	5.9	4.7	5.3	5.8	6.3	5.6	7.9	14.0	5.6	29.5	11.4	6.5	7.0	8.6	11.1	16.7	10.1	5.7	3.8	5.1	13.1	16.9	6.6	5.7	3.8	6.2	15.5	11.0	9.1	19.3	13.9	5.8	9.6	7.8	9.7	3.1	4.7	19.4	47.5	17.0	10.1	6.1	33.6	10.0	20.2	1.6	7.1	6.2	6.1	7.9	8.1	4.2	8.2	7.3	4.6	10.2	6.3	10.7	4.5	7.7	7.0	2.1	4.5	3.2	4.0	3.1	3.5	4.2	4.6	6.3	15.8	5.0	3.5	1.3	5.0	4.5	24.7	26.2	42.8	28.6	19.1	13.7	20.5	18.5	21.7	20.9
ABCC6	"ARA, EST349056, MLP1, MRP6, PXE, URG7"	ENSG00000091262	"ATP binding cassette subfamily C member 6"	O95255	16	16148928-16223522	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Sensory transduction, Transport, Vision"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 27.4"	"Cell line enriched"	"Detected in some"	8	"Hep G2: 37.7"	"Cancer enhanced"	"Detected in many"		"liver cancer: 16.7"					"Cell type enriched"	"Detected in some"	5	"classical monocyte: 7.3"	"Lineage enriched"	"Detected in many"	5	"monocytes: 7.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA038105			Supported	"Plasma membrane"				"Plasma membrane"		"HPA038105: "	"unprognostic (1.32e-1)"	"unprognostic (1.11e-1)"	"unprognostic (5.98e-2)"	"unprognostic (3.15e-2)"	"unprognostic (1.59e-1)"	"unprognostic (3.09e-1)"	"prognostic favourable (3.82e-4)"	"unprognostic (6.54e-3)"	"unprognostic (3.64e-1)"	"unprognostic (9.10e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.12e-3)"	"unprognostic (3.42e-1)"	"unprognostic (2.00e-1)"	"unprognostic (4.91e-2)"	"unprognostic (1.41e-1)"	2.3	1.4	0.2	0.0	0.2	0.0	1.1	0.0	0.0	0.1	1.5			7.0	0.0	0.0	0.0	0.3	1.2	0.8	0.1	0.1	9.0	27.4	2.8	0.0	0.2		0.1	6.7	0.5	0.1	0.0		0.7	1.2		6.7	0.2	1.7	0.0	3.7	0.0	0.2	0.1	2.2	0.0			2.2		0.0	0.0	0.0	0.2	0.9	1.3	7.3	0.6	0.1	1.2	0.0	0.9	0.4	0.0	0.0	0.5	1.1	0.0	0.2	0.5	0.9	3.7	1.4	0.0	0.5	0.0	0.0	0.4	0.0	0.3	0.0	0.4	1.1	0.1	37.7	0.2	0.0	0.2	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.9	0.2	0.0	0.0	0.0	0.0	1.3	0.0	0.1	0.6	0.0	0.4	0.1	4.8	3.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.0	7.3	0.3	0.0	1.0	0.0	0.0	0.1	0.0	0.9	0.2	0.1	0.1	1.3	0.6	0.1	0.1	0.0	1.2										
ABCG2	"ABCP, BCRP, CD338, EST157481, MXR"	ENSG00000118777	"ATP binding cassette subfamily G member 2 (Junior blood group)"	Q9UNQ0	4	88090264-88231322	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 49.6;intestine: 56.6;seminal vesicle: 61.0"	"Cell line enhanced"	"Detected in many"		"A549: 19.9;BEWO: 34.7;MCF7: 11.5;RPMI-8226: 17.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 5.7"	"Low lineage specificity"	"Detected in many"											"CAB037299, HPA054719"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"				"Plasma membrane"	Nucleoplasm	"CAB037299: AB_476804, HPA054719: "	"unprognostic (5.04e-1)"	"unprognostic (3.05e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.01e-3)"	"unprognostic (9.19e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.30e-1)"	"unprognostic (9.14e-2)"	"unprognostic (1.37e-1)"	"unprognostic (3.01e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.67e-3)"	"unprognostic (8.82e-3)"	"unprognostic (7.04e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.92e-1)"	2.8	2.5	11.6	0.8	14.8	1.2	2.4	4.3	9.7	13.6	12.5	8.4	49.6	24.9	14.4	4.2	1.5	6.1	3.3	2.0	16.0	12.2	2.3	19.7	3.0	0.8	17.6	5.6	5.6	0.6	3.2	7.0	12.3	17.0	5.5	8.1	6.9	2.9	61.0	0.4	0.6	56.6	11.8	15.7	0.9	1.2	1.9	5.5	0.0	3.8	0.8	1.3	2.0	3.1	1.2	0.5	0.0	0.2	2.4	5.7	0.7	0.7	19.9	5.9	0.0	0.2	0.0	34.7	0.7	0.6	1.0	1.7	4.4	0.2	0.0	0.2	0.1	5.8	0.2	0.6	1.5	5.6	0.9	0.2	0.1	5.9	0.0	0.3	0.0	0.1	2.4	2.3	0.1	1.8	0.4	0.0	0.6	11.5	2.7	0.1	2.0	0.0	1.3	0.0	17.4	0.0	4.2	0.1	0.2	4.1	0.4	0.5	0.1	0.0	0.0	0.8	0.7	0.2	0.0	5.5	2.1	0.0	1.5	0.0	0.8	0.0	0.0	0.0	1.9	0.0	5.7	0.1	0.7	0.6	0.0	1.2	0.7	0.3	0.0	2.4	0.2	0.5	1.7	0.7	11.6	14.8	4.3	9.7	16.0	12.2	17.6	5.6	17.0	5.5
ABI1	"ABI-1, E3B1, SSH3BP1"	ENSG00000136754	"Abl interactor 1"	Q8IZP0	10	26746593-26861087	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008375, HPA029973, HPA068407"	Approved		Enhanced	"Plasma membrane,Cell Junctions,Cytosol"		400000	400000	"Plasma membrane, Cell Junctions"	Cytosol	"CAB008375: AB_592744, HPA029973: , HPA068407: "	"unprognostic (2.83e-3)"	"unprognostic (8.69e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.96e-1)"	"unprognostic (2.51e-2)"	"unprognostic (9.24e-3)"	"unprognostic (1.88e-3)"	"unprognostic (2.03e-1)"	"unprognostic (6.04e-2)"	"unprognostic (4.38e-1)"	"unprognostic (2.40e-2)"	"unprognostic (5.48e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.18e-1)"	24.0	14.0	32.0	28.1	32.6	54.1	21.4	28.2	35.5	22.5	22.7	19.8	14.8	24.8	23.9	15.4	45.1	20.3	21.6	14.1	47.3	23.1	21.9	17.8	22.5	32.1	25.0	26.4	25.3	17.0	19.1	14.4	22.7	20.9	19.1	24.8	26.7	30.9	17.0	16.6	33.0	26.0	21.6	27.5	25.5	23.9	12.4	20.5	43.5	18.8	27.3	40.9	25.2	30.3	36.1	26.8	51.5	28.0	20.5	44.5	31.5	23.2	13.1	10.7	10.5	16.2	20.0	16.0	23.6	16.1	17.5	20.4	15.3	27.6	42.8	12.1	25.0	26.1	12.9	15.3	19.5	28.5	11.5	18.8	8.9	10.8	11.1	9.1	19.0	13.6	19.5	17.1	10.2	21.1	13.8	27.4	17.8	10.0	21.3	8.7	8.8	6.3	23.1	19.9	27.5	18.6	10.8	8.9	9.5	19.6	19.2	19.7	12.4	14.5	26.2	13.4	16.5	16.9	12.0	6.1	9.8	50.9	19.3	23.3	9.6	35.5	23.8	51.5	27.0	28.0	25.8	36.1	25.9	30.0	26.8	28.6	24.4	26.5	37.9	20.5	26.7	22.3	44.5	31.5	32.0	32.6	28.2	31.9	47.3	23.1	25.0	26.4	20.9	20.5
ABL1	"ABL, c-ABL, JTK7, p150"	ENSG00000097007	"ABL proto-oncogene 1, non-receptor tyrosine kinase"	P00519	9	130713946-130887675	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis"	"DNA-binding, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002686, HPA027251, HPA027280, HPA028409"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"				Nucleoplasm	"Nuclear bodies"	"CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011"	"unprognostic (4.82e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.55e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.75e-3)"	"unprognostic (1.89e-3)"	"unprognostic (2.34e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.06e-1)"	20.1	11.6	12.4	15.0	18.1	10.7	22.0	6.7	16.0	28.9	34.3	29.1	12.1	11.9	26.6	16.9	21.4	20.8	30.9	14.2	10.3	8.4	9.9	6.7	13.8	8.7	24.1	9.4	24.2	12.2	27.7	14.5	13.6	17.1	27.3	15.8	19.4	14.6	18.0	10.8	14.2	17.0	66.6	14.3	10.8	21.9	9.8	21.2	5.8	19.5	11.4	9.1	35.8	31.9	3.1	3.1	1.1	5.0	2.4	2.6	1.6	7.0	15.7	16.9	20.4	24.8	30.3	6.2	12.4	19.5	14.6	12.4	12.3	9.2	11.6	7.2	16.5	13.7	8.5	11.5	10.8	7.3	5.3	7.6	26.9	10.5	16.9	11.7	10.7	22.1	12.7	26.1	16.2	20.2	42.6	9.3	17.8	13.4	14.8	9.6	18.7	11.6	17.2	21.9	12.6	14.7	8.3	15.8	19.7	20.8	8.1	10.0	15.9	10.8	23.1	56.0	14.5	21.4	19.5	2.8	6.6	15.6	23.1	9.7	17.7	0.2	2.1	1.1	2.0	1.2	2.6	3.1	2.0	1.9	2.0	1.4	1.9	1.7	0.2	2.4	5.0	3.1	0.9	1.6	12.4	18.1	6.7	16.0	10.3	8.4	24.1	9.4	17.1	21.2
ABL2	"ABLL, ARG"	ENSG00000143322	"ABL proto-oncogene 2, non-receptor tyrosine kinase"	P42684	1	179099327-179229684	"Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins"	"Cell adhesion"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 31.7;TIME: 29.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001866, CAB017106, HPA072754"	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"CAB017106: , HPA001866: AB_1078082, HPA072754: "	"unprognostic (3.05e-1)"	"prognostic unfavourable (3.50e-4)"	"unprognostic (1.07e-1)"	"unprognostic (4.71e-2)"	"unprognostic (9.45e-2)"	"unprognostic (8.23e-3)"	"unprognostic (1.91e-2)"	"unprognostic (4.81e-3)"	"unprognostic (1.26e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.73e-1)"	"prognostic unfavourable (1.78e-7)"	"unprognostic (4.76e-2)"	"unprognostic (4.14e-2)"	"unprognostic (6.08e-2)"	"prognostic unfavourable (8.40e-4)"	14.3	5.2	8.6	7.4	13.7	3.7	8.3	14.9	10.6	9.2	6.6	5.8	4.5	4.0	5.4	4.7	3.9	4.3	18.8	6.8	9.7	3.9	4.9	4.3	11.5	3.7	6.5	6.1	5.6	8.4	9.2	8.4	6.1	8.1	5.1	5.2	5.8	4.5	4.4	5.2	6.6	3.7	6.9	6.2	3.9	4.7	9.2	8.6	3.6	5.8	3.1	3.6	6.7	11.2	2.8	2.0	3.8	1.2	1.8	2.2	0.6	10.0	5.5	3.7	2.5	3.2	7.3	2.3	11.1	9.1	13.7	9.9	4.0	3.1	5.8	8.2	7.9	5.0	5.2	3.7	19.4	3.6	4.8	2.8	5.0	2.0	5.8	3.1	0.9	6.7	4.9	19.4	31.7	15.1	6.6	1.7	17.7	2.6	2.4	1.6	3.6	1.8	3.7	6.2	2.8	4.6	1.6	2.3	5.1	9.2	2.9	22.8	2.6	2.6	29.5	14.2	10.6	6.8	17.8	3.1	3.8	6.0	6.7	1.7	13.7	3.8	1.2	0.4	2.2	0.4	1.0	1.8	1.4	1.4	0.9	2.8	1.9	2.0	2.6	1.8	0.5	2.0	0.8	0.6	8.6	13.7	14.9	10.6	9.7	3.9	6.5	6.1	8.1	8.6
ACAP1	"CENTB1, KIAA0050"	ENSG00000072818	"ArfGAP with coiled-coil, ankyrin repeat and PH domains 1"	Q15027	17	7336529-7351478	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"	"GTPase activation"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.4;bone marrow: 30.3;lymphoid tissue: 51.5"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.5;HDLM-2: 24.4;Karpas-707: 24.1;NB-4: 29.8;REH: 11.9;U-937: 19.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA075570	Approved		Approved	"Golgi apparatus"				"Golgi apparatus"		"HPA075570: "	"unprognostic (1.20e-2)"	"prognostic favourable (3.66e-4)"	"unprognostic (2.49e-1)"	"prognostic favourable (2.97e-5)"	"unprognostic (4.43e-4)"	"prognostic favourable (4.17e-5)"	"unprognostic (5.66e-3)"	"unprognostic (1.11e-2)"	"unprognostic (4.67e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.91e-1)"	"prognostic unfavourable (1.65e-10)"	"unprognostic (1.14e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.90e-1)"	"unprognostic (8.61e-3)"	2.6	0.6	0.6	31.4	1.3	30.3	1.1	1.0	1.2	1.4	4.5	0.4	0.4	3.2	0.9	1.5	3.3	2.0	3.1	1.4	0.6	0.6	2.9	2.3	7.3	29.3	2.7	0.1	1.0	0.7	0.0	0.8	0.5	1.2	1.8	1.5	1.7	9.6	1.3	0.5	1.2	19.2	0.8	1.3	44.9	3.7	1.4	0.9	51.5	2.5	1.0	33.9	3.7	1.8	17.8	13.3	22.4	5.9	23.7	29.4	16.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.0	18.5	0.1	0.0	0.0	0.0	0.0	0.0	24.4	0.0	7.0	0.1	0.0	0.0	9.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	24.1	0.0	0.0	11.2	29.8	0.3	0.0	11.9	0.1	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.1	0.0	0.0	7.5	6.3	8.4	0.1	19.7	0.0	17.0	5.9	22.4	24.6	1.8	27.5	16.6	25.8	26.1	10.5	17.8	22.7	22.4	17.7	23.7	0.2	13.3	29.4	16.1	0.6	1.3	1.0	1.2	0.6	0.6	2.7	0.1	1.2	0.9
ACKR3	"CMKOR1, CXCR7, GPR159, RDC1"	ENSG00000144476	"Atypical chemokine receptor 3"	P25106	2	236567787-236582358	"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HeLa: 22.8;MCF7: 16.8;RT4: 66.7;SiHa: 20.4;U-2197: 70.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"NK-cells: 6.1;T-cells: 6.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA032003, HPA049718"	Approved		Supported	"Vesicles,Plasma membrane"				"Vesicles, Plasma membrane"		"HPA032003: , HPA049718: "	"unprognostic (1.65e-2)"	"prognostic unfavourable (4.64e-4)"	"unprognostic (2.50e-1)"	"unprognostic (1.92e-3)"	"unprognostic (2.10e-1)"	"unprognostic (1.23e-1)"	"unprognostic (7.34e-3)"	"unprognostic (1.55e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.35e-1)"	"unprognostic (9.70e-3)"	"unprognostic (6.69e-2)"	"prognostic unfavourable (1.76e-6)"	"prognostic unfavourable (2.01e-4)"	"unprognostic (9.71e-2)"	"unprognostic (8.57e-3)"	"prognostic unfavourable (2.93e-4)"	56.1	2.9	5.4	6.9	5.6	1.7	28.5	2.2	6.4	10.7	15.2	8.9	9.1	5.7	9.9	20.4	23.6	14.6	15.3	30.2	8.4	3.0	3.8	29.6	10.9	7.2	3.8	6.5	19.3	25.7	2.2	10.7	59.6	8.4	14.2	12.8	25.2	8.9	8.9	36.4	16.0	15.7	32.6	7.2	70.9	12.6	9.4	5.5	0.2	34.3	22.3	8.6	59.2	17.8	1.0	0.2	0.1	0.5	6.1	6.1	0.6	0.0	0.0	1.3	0.0	2.3	0.0	9.8	0.5	0.3	0.4	1.0	0.1	0.0	0.0	1.1	0.0	14.3	0.0	5.1	0.0	0.0	0.0	0.0	22.8	0.0	0.0	0.0	0.0	0.6	13.1	0.0	0.0	2.3	0.2	0.0	0.0	16.8	0.0	0.0	2.3	0.1	0.0	1.6	0.1	0.0	66.7	0.0	0.0	20.4	0.1	0.0	0.0	0.0	0.0	0.1	5.3	70.1	0.0	0.2	0.0	0.0	0.2	1.4	0.1	0.0	0.1	0.0	4.1	0.3	6.1	0.6	2.1	5.0	0.2	1.0	1.8	2.3	0.1	6.1	0.5	0.0	3.1	0.6	5.4	5.6	2.2	6.4	8.4	3.0	3.8	6.5	8.4	5.5
ACLY	"ACL, ATPCL, CLATP"	ENSG00000131473	"ATP citrate lyase"	P53396	17	41866908-41930542	"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Lipid biosynthesis, Lipid metabolism"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007783, HPA022434, HPA022953, HPA022959, HPA028758"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		2100000	2100000	"Plasma membrane, Cytosol"	Nucleoplasm	"CAB007783: AB_562242, HPA022434: AB_1844513, HPA022953: AB_1844514, HPA022959: AB_1844515, HPA028758: AB_10603575"	"unprognostic (2.21e-2)"	"prognostic unfavourable (1.79e-4)"	"unprognostic (1.41e-1)"	"unprognostic (1.21e-2)"	"unprognostic (2.83e-1)"	"unprognostic (8.94e-3)"	"prognostic unfavourable (3.66e-4)"	"unprognostic (3.38e-3)"	"unprognostic (4.11e-2)"	"unprognostic (5.94e-3)"	"unprognostic (2.13e-2)"	"unprognostic (3.01e-2)"	"unprognostic (3.88e-3)"	"unprognostic (1.66e-1)"	"unprognostic (9.36e-2)"	"unprognostic (3.90e-2)"	"unprognostic (4.67e-3)"	38.3	24.0	16.7	26.2	22.9	19.1	35.7	21.5	29.1	22.9	22.2	25.1	18.0	30.7	27.0	24.9	23.2	23.7	28.2	18.4	18.3	33.7	37.8	22.2	23.3	27.4	23.1	17.9	19.0	30.6	27.1	19.5	26.7	49.0	41.3	23.2	15.6	25.4	19.6	10.9	19.6	29.6	27.2	26.2	24.5	24.6	20.7	21.4	32.0	21.3	18.2	24.6	20.3	21.3	16.1	23.9	25.2	26.3	16.0	23.9	21.4	23.2	79.1	37.4	32.2	57.8	54.3	34.4	32.7	35.8	41.2	51.8	40.1	26.8	37.8	21.0	45.8	37.0	48.2	56.0	34.5	34.0	46.1	21.6	45.6	41.7	26.9	34.9	28.3	43.1	16.9	72.4	14.6	43.4	26.6	30.2	34.1	23.7	57.4	19.6	24.3	14.4	37.7	45.2	48.4	42.2	41.4	70.4	38.7	23.3	73.0	25.0	43.5	33.4	46.6	32.2	26.5	32.3	53.6	17.7	22.5	35.9	54.4	27.1	26.1	18.9	20.7	25.2	23.8	22.1	22.5	16.1	19.0	21.3	23.9	13.8	14.6	16.1	10.7	16.0	26.3	13.9	23.9	21.4	16.7	22.9	21.5	27.7	18.3	33.7	23.1	17.9	49.0	21.4
ACO1	"IREB1, IREBP, IRP1"	ENSG00000122729	"Aconitase 1"	P21399	9	32384603-32454769	"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Tricarboxylic acid cycle"	"Lyase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 80.9"	"Cell line enhanced"	"Detected in many"		"ASC diff: 52.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019371, HPA024157"	Enhanced		Supported	Mitochondria,Cytosol		8000000	8000000	"Mitochondria, Cytosol"		"HPA019371: AB_1844519, HPA024157: AB_1844520"	"unprognostic (2.11e-1)"	"unprognostic (5.61e-2)"	"unprognostic (8.38e-2)"	"unprognostic (9.12e-2)"	"unprognostic (2.63e-1)"	"unprognostic (3.12e-2)"	"unprognostic (4.25e-3)"	"unprognostic (2.61e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.19e-1)"	"unprognostic (2.55e-1)"	"unprognostic (3.08e-1)"	"prognostic favourable (5.73e-5)"	"unprognostic (2.54e-1)"	"unprognostic (6.58e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.23e-2)"	41.4	27.2	9.6	7.1	9.4	1.5	30.1	8.9	8.1	9.3	19.7	6.2	6.4	21.9	12.8	14.6	12.8	7.2	8.9	15.1	6.5	7.6	40.5	80.9	9.2	9.4	6.1	6.2	14.1	27.9	8.9	8.7	11.3	7.7	10.7	9.8	11.7	11.7	9.5	11.2	5.5	28.4	14.5	6.0	6.4	13.5	11.4	5.9	6.0	18.4	7.2	5.1	13.9	11.7	4.7	7.1	21.4	8.8	4.7	7.4	6.2	9.4	8.7	6.7	10.6	52.5	28.5	3.0	17.9	44.1	8.2	6.5	9.1	2.9	1.9	5.7	18.7	1.3	13.3	17.1	16.6	6.0	3.6	13.8	9.4	9.9	26.4	1.3	5.6	24.8	5.3	21.2	15.0	21.3	4.9	4.1	23.4	2.4	7.3	6.6	7.0	9.2	5.7	10.0	1.9	31.4	8.7	0.8	2.8	18.6	0.7	1.9	4.3	3.4	23.0	30.1	10.2	10.0	4.6	2.0	3.8	3.7	21.0	4.6	2.6	21.4	8.7	2.4	7.4	8.8	6.4	4.7	5.2	5.7	7.1	4.2	6.8	7.0	1.0	4.7	7.2	3.4	2.8	6.2	9.6	9.4	8.9	8.1	6.5	7.6	6.1	6.2	7.7	5.9
ACPP	"ACP-3, ACP3, PAP"	ENSG00000014257	"Acid phosphatase, prostate"	P15309	3	132317367-132368298	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"prostate: 345.2"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 10.2;NB-4: 7.7;RPMI-8226: 32.3;U-698: 9.4;U-87 MG: 9.0"	"Cancer enriched"	"Detected in many"	275	"prostate cancer: 1227.2"	"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"eosinophil: 43.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"							"CAB000071, HPA004335, HPA063916"	Enhanced				"Secreted to blood"	9200	9200			"CAB000071: , HPA004335: AB_1079684, HPA063916: "	"unprognostic (6.67e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.76e-1)"	"unprognostic (7.77e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.58e-2)"	"unprognostic (2.46e-1)"	"unprognostic (7.41e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.78e-3)"	"unprognostic (2.14e-1)"	"unprognostic (5.95e-2)"	"unprognostic (9.38e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.91e-2)"	"unprognostic (1.71e-1)"	0.4	0.6	0.4	0.7	1.6	1.4	0.8	0.3	0.7	3.9	0.4	0.2	0.0	0.4	0.3	2.5	14.7	0.6	0.2	0.9	0.3	0.3	6.2	0.3	2.0	2.7	0.6	0.8	0.4	0.8	0.5	0.3	5.3	0.7	345.2	0.7	0.8	9.1	0.2	0.3	2.5	0.4	0.4	2.2	1.0	0.5	1.0	0.6	0.2	1.3	6.6	6.8	0.5	1.5	0.2	11.2	43.1	9.7	0.9	0.0	2.9	0.2	0.0	0.0	0.0	0.1	0.6	7.0	0.1	10.2	0.0	0.0	0.2	0.2	5.7	0.4	0.0	2.9	0.0	0.0	0.0	0.0	0.3	1.1	0.2	0.1	0.1	4.1	0.1	0.6	0.8	0.0	0.0	0.0	0.1	1.6	0.1	0.1	0.0	7.7	0.4	1.2	0.0	0.0	32.3	3.1	3.8	0.0	2.5	0.0	1.2	0.3	0.2	3.7	0.0	0.0	0.1	1.5	0.0	0.4	0.2	9.4	9.0	7.3	0.1	0.0	9.7	43.1	0.0	8.6	0.0	0.2	0.0	0.0	11.2	0.0	0.0	0.0	8.5	0.9	7.7	0.8	0.0	2.9	0.4	1.6	0.3	0.7	0.3	0.3	0.6	0.8	0.7	0.6
ACSL3	"ACS3, FACL3, PRO2194"	ENSG00000123983	"Acyl-CoA synthetase long chain family member 3"	O95573	2	222860934-222944639	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism"	Ligase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"parathyroid gland: 206.1"	"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 92.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011315, HPA071021"	Approved		Approved	"Nucleoli,Lipid droplets"				Nucleoli	"Lipid droplets"	"HPA011315: AB_1848344, HPA071021: "	"unprognostic (1.87e-1)"	"unprognostic (5.64e-2)"	"unprognostic (2.36e-1)"	"unprognostic (9.35e-3)"	"unprognostic (7.53e-2)"	"unprognostic (2.07e-2)"	"prognostic unfavourable (2.75e-4)"	"prognostic unfavourable (8.78e-4)"	"unprognostic (3.90e-2)"	"unprognostic (2.50e-1)"	"unprognostic (2.64e-1)"	"unprognostic (4.26e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.36e-1)"	"unprognostic (2.72e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.60e-1)"	14.7	17.0	22.8	9.9	26.0	16.3	51.5	19.4	45.9	15.3	16.5	16.1	11.6	12.7	10.9	18.4	28.3	9.0	11.8	22.7	20.9	22.8	17.9	22.3	15.6	10.5	19.6	21.2	11.7	10.3	206.1	8.8	19.1	24.4	44.4	16.7	14.4	34.2	15.5	19.1	11.4	12.7	12.2	22.2	9.7	28.3	13.7	14.2	13.5	17.3	11.2	8.7	14.6	15.4	15.0	22.5	21.8	16.8	16.6	20.1	16.5	9.9	17.6	27.0	29.3	11.8	29.3	7.5	12.7	33.0	15.2	32.2	15.8	25.7	4.8	7.4	12.1	29.4	5.8	28.3	19.8	8.6	11.1	11.2	14.3	17.7	26.0	7.4	5.5	15.1	40.1	25.2	44.0	16.6	21.2	18.3	21.5	21.2	14.4	8.7	13.7	9.2	7.9	22.9	8.1	21.9	40.9	14.2	10.6	7.5	20.3	92.7	10.2	18.1	11.4	10.2	16.3	8.8	9.3	6.5	3.1	16.5	11.0	6.9	30.9	16.6	14.6	21.8	20.1	16.8	19.3	11.6	12.8	14.6	15.7	15.0	18.7	16.7	21.8	16.6	15.9	22.5	9.5	16.5	22.8	26.0	19.4	45.9	20.9	22.8	19.6	21.2	24.4	14.2
ACVR1	"ACVR1A, ACVRLK2, ALK2, SKR1"	ENSG00000115170	"Activin A receptor type 1"	Q04771	2	157736444-157875862	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007505, HPA046514"	Approved		Approved	Nucleoli,Cytosol				Nucleoli	Cytosol	"HPA007505: AB_1844752, HPA046514: "	"unprognostic (6.99e-2)"	"unprognostic (3.32e-2)"	"unprognostic (3.02e-1)"	"unprognostic (1.19e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.09e-2)"	"unprognostic (3.66e-3)"	"unprognostic (1.08e-1)"	"unprognostic (3.99e-1)"	"unprognostic (3.20e-1)"	"unprognostic (2.65e-2)"	"unprognostic (4.29e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.43e-3)"	"unprognostic (3.17e-1)"	"unprognostic (1.76e-2)"	"prognostic unfavourable (5.17e-4)"	18.9	9.2	18.0	10.0	12.7	1.6	38.7	15.3	12.2	25.2	14.4	7.4	8.4	8.9	24.8	26.8	11.0	16.6	20.5	18.8	18.7	8.6	21.7	18.9	22.5	15.1	10.4	7.9	18.5	12.3	11.3	17.0	14.2	12.3	16.8	10.5	14.3	18.1	13.6	15.6	12.8	11.5	29.2	12.3	9.2	11.8	8.8	10.9	7.5	34.0	14.6	6.9	16.1	32.5	1.4	2.4	3.8	2.6	1.9	10.0	1.6	2.1	4.2	4.9	6.4	25.0	26.1	6.9	15.1	25.2	12.1	13.0	3.3	4.7	0.0	7.0	16.4	5.9	3.5	8.2	13.1	14.5	3.0	8.6	2.5	4.8	19.8	0.6	10.2	32.6	15.6	24.9	31.8	13.2	3.1	2.4	15.3	3.7	0.1	0.2	7.4	7.7	1.4	6.6	1.8	15.8	7.9	4.4	5.4	5.8	3.3	20.7	1.7	2.3	19.0	18.5	6.1	9.1	5.7	1.6	1.2	0.1	19.0	0.5	19.9	3.8	2.6	0.2	1.1	1.7	1.2	1.4	7.8	2.5	1.8	0.8	3.1	1.5	0.8	1.9	2.3	2.4	10.0	1.6	18.0	12.7	15.3	12.2	18.7	8.6	10.4	7.9	12.3	10.9
ACVR1B	"ActRIB, ACVRLK4, ALK4, SKR2"	ENSG00000135503	"Activin A receptor type 1B"	P36896	12	51951667-51997078	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB026126, HPA063761"	Approved		Approved	Cytosol				Cytosol		"CAB026126: , HPA063761: "	"unprognostic (8.66e-2)"	"unprognostic (5.72e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.23e-3)"	"unprognostic (2.34e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.21e-3)"	"unprognostic (1.00e-1)"	"unprognostic (7.68e-2)"	"unprognostic (5.29e-2)"	"unprognostic (2.56e-1)"	"unprognostic (2.37e-1)"	"unprognostic (4.52e-2)"	"unprognostic (9.02e-2)"	"unprognostic (6.60e-2)"	"unprognostic (8.96e-2)"	"unprognostic (4.79e-2)"	11.1	7.4	12.0	6.4	14.6	7.9	14.3	14.2	24.4	8.6	16.7	5.1	28.0	19.2	6.7	13.1	14.4	10.9	11.1	7.6	11.2	10.5	24.6	21.0	10.3	7.1	8.1	14.7	7.1	35.1	24.9	10.9	7.5	7.3	10.0	17.1	8.7	21.7	34.3	11.7	30.6	19.8	8.2	5.8	6.7	17.2	10.6	4.8	3.9	9.9	5.8	8.4	10.1	12.1	0.5	1.3	6.8	4.0	0.1	1.6	0.6	6.2	13.8	10.7	5.9	12.3	9.7	6.1	7.1	8.1	7.6	5.8	27.8	9.7	2.7	10.0	7.7	11.1	10.2	8.6	7.9	4.0	12.0	6.8	3.5	8.6	14.1	10.9	25.5	18.9	11.2	8.6	10.9	10.7	7.2	8.6	6.7	12.8	10.4	9.5	10.4	4.8	5.6	8.3	3.5	21.5	9.6	13.7	11.4	7.7	11.0	5.0	12.1	7.1	6.7	5.2	8.0	5.9	3.4	5.2	3.7	3.8	5.6	5.3	6.7	4.5	2.2	6.8	0.7	3.3	1.0	0.1	0.6	0.7	1.3	0.5	1.6	0.9	1.9	0.1	4.0	0.7	1.0	0.6	12.0	14.6	14.2	24.4	11.2	10.5	8.1	14.7	7.3	4.8
ACVR2A	"ACTRII, ACVR2"	ENSG00000121989	"Activin A receptor type 2A"	P27037	2	147844517-147930826	"Cancer-related genes, Enzymes, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 20.5;RH-30: 17.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA046997	Approved		Approved	Cytosol				Cytosol		"HPA046997: AB_10970077"	"unprognostic (4.55e-2)"	"unprognostic (2.26e-2)"	"unprognostic (2.09e-1)"	"unprognostic (7.34e-3)"	"unprognostic (2.75e-1)"	"unprognostic (1.17e-1)"	"unprognostic (4.41e-3)"	"unprognostic (8.73e-3)"	"unprognostic (1.30e-2)"	"unprognostic (3.61e-1)"	"unprognostic (1.34e-2)"	"unprognostic (1.52e-1)"	"prognostic favourable (1.62e-4)"	"unprognostic (1.16e-1)"	"unprognostic (1.40e-1)"	"unprognostic (3.95e-1)"	"unprognostic (3.99e-2)"	12.0	6.0	13.6	8.2	9.9	3.8	10.7	14.5	14.2	10.2	14.1	4.7	9.7	10.4	9.3	9.9	13.6	7.6	17.7	5.6	10.0	9.0	9.0	10.3	7.5	4.7	5.9	10.6	7.6	9.8	8.6	15.9	10.6	7.3	12.2	9.1	7.6	12.2	12.0	19.6	29.5	17.8	13.8	5.4	6.5	9.3	11.0	6.4	1.5	9.5	6.9	6.8	13.5	11.8	0.7	3.0	0.5	3.6	7.7	4.6	1.4	1.3	1.5	9.8	3.6	5.8	3.7	4.0	3.0	3.6	5.2	9.1	4.2	5.9	0.0	2.7	4.8	4.6	8.9	4.4	6.7	1.0	5.4	0.6	2.7	7.3	20.5	0.6	0.7	6.2	5.6	3.3	6.7	3.9	1.4	2.5	3.5	3.4	0.3	0.5	11.0	2.6	0.1	17.1	0.9	4.2	8.3	9.7	5.5	2.5	3.1	3.7	1.9	1.0	3.0	4.8	5.7	4.5	2.1	0.7	0.2	1.8	3.0	0.3	3.8	0.4	3.0	0.5	1.2	3.6	0.5	0.3	4.6	2.1	2.3	0.7	3.0	0.7	0.1	7.7	3.1	3.0	0.4	1.4	13.6	9.9	14.5	14.2	10.0	9.0	5.9	10.6	7.3	6.4
ACVR2B	ActR-IIB	ENSG00000114739	"Activin A receptor type 2B"	Q13705	3	38453851-38493142	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Heterotaxy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 16.6;NTERA-2: 20.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA007398, CAB025115, HPA040384"	Approved		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"				"Nucleoplasm, Cytosol"	"Nuclear bodies"	"CAB025115: , HPA007398: , HPA040384: "	"unprognostic (5.11e-2)"	"unprognostic (1.54e-1)"	"unprognostic (3.47e-1)"	"unprognostic (8.73e-2)"	"unprognostic (9.24e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.25e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.53e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.08e-3)"	"unprognostic (1.64e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.83e-1)"	"unprognostic (4.75e-1)"	2.8	7.4	5.5	4.6	7.9	1.1	5.5	13.2	7.5	5.2	3.4	7.2	4.5	2.8	4.7	5.1	2.5	5.6	3.3	3.9	5.9	5.4	5.3	5.4	6.9	2.2	5.9	5.4	8.3	6.1	11.3	5.1	16.0	6.5	3.9	3.6	5.0	4.6	4.2	15.9	2.4	2.8	4.6	4.7	3.1	4.0	9.1	9.1	12.8	4.8	1.7	2.2	4.2	10.3	0.3	0.3	0.5	0.2	0.5	1.6	0.3	0.8	1.4	16.6	1.4	0.6	0.4	8.9	0.3	0.5	0.3	0.7	2.4	1.1	0.1	1.3	0.4	1.0	6.3	1.0	0.9	2.4	4.1	4.2	2.6	3.5	0.8	3.0	1.6	0.7	0.9	0.5	1.8	1.1	7.0	1.4	0.3	1.3	5.1	1.9	20.5	0.7	1.7	5.5	1.0	1.1	2.0	3.9	6.8	0.5	2.5	2.2	1.4	4.0	0.9	0.6	2.7	0.4	1.4	4.0	5.4	0.9	0.6	2.5	1.1	0.5	0.1	0.1	0.4	0.2	0.6	0.2	1.0	0.5	0.0	0.3	1.6	1.5	0.3	0.5	0.2	0.3	0.7	0.3	5.5	7.9	13.2	7.0	5.9	5.4	5.9	5.4	6.5	9.1
ADAM10	"CD156c, HsT18717, kuz, MADM"	ENSG00000137845	"ADAM metallopeptidase domain 10"	O14672	15	58588807-58749978	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Notch signaling pathway"	"Hydrolase, Metalloprotease, Protease"	"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-2197: 76.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001709, HPA050670"	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"	"Intracellular and membrane"	8200000	8200000	"Plasma membrane"	"Nucleoplasm, Vesicles"	"CAB001709: , HPA050670: "	"unprognostic (1.43e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.77e-1)"	"unprognostic (5.04e-2)"	"unprognostic (3.09e-1)"	"unprognostic (2.70e-3)"	"unprognostic (7.48e-2)"	"prognostic unfavourable (8.46e-5)"	"unprognostic (3.99e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (1.90e-4)"	"unprognostic (6.69e-2)"	"unprognostic (2.57e-2)"	"unprognostic (2.57e-3)"	"unprognostic (9.14e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.60e-2)"	25.9	11.1	15.5	17.1	17.7	15.6	20.0	25.2	17.6	18.6	20.1	15.7	12.7	13.9	19.9	11.8	17.1	13.8	18.0	18.8	17.6	13.7	20.8	14.8	25.0	26.1	23.1	12.4	13.9	13.1	10.9	11.6	36.1	14.5	23.6	16.7	14.6	12.4	19.1	8.9	15.4	15.6	12.8	30.4	40.4	18.4	8.5	18.9	38.5	27.3	9.2	14.9	30.0	19.1	6.2	12.7	26.9	23.7	9.8	12.2	12.8	11.8	26.9	7.3	8.0	9.4	13.6	18.5	10.2	30.4	7.5	10.5	12.4	15.7	5.5	31.6	9.1	24.3	4.4	10.8	10.0	8.2	5.6	9.4	9.8	11.5	10.5	6.6	27.2	11.9	8.0	5.2	7.7	14.6	5.9	15.0	13.2	4.4	21.9	7.6	10.0	3.8	9.1	24.0	14.1	17.5	32.1	8.0	5.2	11.1	12.9	17.6	7.7	13.3	10.3	9.9	11.0	76.0	9.8	8.4	18.1	6.0	13.8	12.9	17.3	12.9	18.8	10.4	8.1	21.5	12.2	5.3	8.0	7.1	12.7	6.2	8.4	7.0	26.9	9.8	23.7	5.8	10.3	12.8	15.5	17.7	25.2	16.9	17.6	13.7	23.1	12.4	14.5	18.9
ADAM9	"CORD9, KIAA0021, MCMP, MDC9, Mltng"	ENSG00000168615	"ADAM metallopeptidase domain 9"	Q13443	8	38996869-39105144	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Cone-rod dystrophy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 11.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004000			Approved	"Endoplasmic reticulum,Vesicles"	"Secreted - unknown location"	640000	640000	Vesicles	"Endoplasmic reticulum"	"HPA004000: AB_1844584"	"prognostic unfavourable (1.14e-4)"	"prognostic unfavourable (2.25e-4)"	"unprognostic (1.32e-3)"	"unprognostic (1.27e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (7.21e-6)"	"unprognostic (5.77e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.48e-2)"	"prognostic unfavourable (2.52e-5)"	"unprognostic (5.83e-2)"	"prognostic unfavourable (3.99e-4)"	"unprognostic (2.80e-1)"	"unprognostic (5.76e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.23e-2)"	36.7	25.0	14.7	21.7	13.6	10.4	17.1	20.9	14.4	21.8	24.4	13.2	21.8	19.4	24.9	19.8	24.1	15.5	31.7	28.5	12.5	10.1	29.4	11.6	39.2	20.3	19.2	12.9	17.6	11.1	37.5	10.4	30.1	15.8	23.8	23.8	15.4	44.5	21.4	18.3	12.8	25.4	32.8	22.0	25.7	33.2	13.7	12.7	2.4	24.0	14.9	11.7	34.8	19.2	0.6	8.1	3.4	11.4	3.1	0.8	2.8	41.1	29.8	11.8	7.2	19.1	61.6	15.3	55.9	61.1	31.4	29.4	14.1	29.9	2.1	21.1	38.4	17.6	5.0	39.5	60.9	2.0	5.1	2.2	20.7	12.2	38.7	1.6	4.8	47.4	23.5	30.9	35.2	42.7	4.3	14.0	65.3	4.0	1.6	1.0	1.7	9.6	1.4	21.3	7.1	51.0	11.8	1.6	2.4	14.9	17.9	13.6	14.5	3.0	73.4	24.0	23.1	45.3	25.6	4.5	6.9	2.3	39.8	2.7	16.3	1.4	11.4	2.2	0.6	6.1	0.3	0.1	0.3	0.8	8.1	0.6	0.1	0.6	3.4	3.1	2.6	2.7	0.4	2.8	14.7	13.6	20.9	14.4	12.5	10.1	19.2	12.9	15.8	12.7
ADAMTS1	"C3-C5, KIAA1346, METH1"	ENSG00000154734	"ADAM metallopeptidase with thrombospondin type 1 motif 1"	Q9UHI8	21	26835747-26845409	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"		"Heparin-binding, Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 112.8"	"Cell line enhanced"	"Detected in many"		"ASC diff: 60.9;BJ: 71.0;hTEC/SVTERT24-B: 49.0;hTERT-HME1: 44.6;RPTEC TERT1: 41.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"gdT-cell: 8.0;NK-cell: 9.0"	"Group enriched"	"Detected in many"	85	"NK-cells: 9.0;T-cells: 8.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"CAB016394, HPA031498"	Uncertain		Approved	"Plasma membrane"	"Secreted to extracellular matrix"	1900000	1900000	"Plasma membrane"		"CAB016394: AB_626637, HPA031498: "	"unprognostic (6.82e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.18e-2)"	"prognostic unfavourable (5.13e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.28e-1)"	"unprognostic (2.37e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.75e-1)"	"unprognostic (4.55e-2)"	"unprognostic (9.70e-3)"	"unprognostic (8.27e-3)"	"unprognostic (1.12e-1)"	"unprognostic (6.76e-2)"	"unprognostic (1.57e-1)"	70.6	13.4	8.2	18.7	14.0	0.7	29.0	6.3	9.2	22.0	18.2	9.5	4.8	3.3	27.7	25.8	30.0	45.8	62.3	40.9	7.6	4.8	15.4	22.8	25.0	10.9	12.7	3.7	112.8	9.3	6.3	7.6	56.8	13.2	23.3	16.5	7.8	5.8	8.1	25.7	6.1	16.2	46.4	10.2	7.2	16.8	12.8	11.4	0.0	14.3	18.1	2.7	32.7	45.3	0.0	0.0	0.0	0.0	9.0	8.0	1.4	0.0	0.0	1.1	0.0	60.9	15.1	3.7	71.0	24.8	12.3	8.1	0.0	0.0	0.0	4.9	22.5	1.3	0.8	3.6	21.7	0.0	22.6	0.0	7.4	0.0	11.7	2.8	0.0	16.9	0.0	49.0	44.6	5.0	1.2	0.0	36.4	0.0	0.3	0.0	4.0	2.8	0.0	28.1	0.2	41.6	4.0	0.0	5.5	3.3	0.0	0.3	0.1	0.7	5.1	17.5	0.9	27.2	10.5	0.1	0.0	0.0	14.4	0.0	5.3	0.0	0.0	0.0	8.0	0.0	0.8	0.0	0.3	0.6	0.0	0.0	0.0	1.5	0.0	9.0	0.0	0.0	0.0	1.4	8.2	14.0	6.3	9.2	7.6	4.8	12.7	3.7	13.2	11.4
ADAMTS14		ENSG00000138316	"ADAM metallopeptidase with thrombospondin type 1 motif 14"	Q8WXS8	10	70672803-70762441	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 13.4;gallbladder: 12.3;placenta: 13.5"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 10.2;K-562: 11.4;RH-30: 6.2;U-138 MG: 10.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"intermediate monocyte: 1.1"	"Lineage enriched"	"Detected in single"	11	"monocytes: 1.1"	"Region enriched"	"Detected in single"	5	"hippocampal formation: 0.4"	"Low region specificity"	"Detected in many"								"Secreted to extracellular matrix"						"unprognostic (1.30e-1)"	"unprognostic (1.04e-2)"	"unprognostic (5.98e-3)"	"unprognostic (3.54e-3)"	"unprognostic (2.17e-3)"	"unprognostic (2.40e-1)"	"unprognostic (5.33e-3)"	"unprognostic (2.35e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.28e-2)"	"unprognostic (3.98e-2)"	"unprognostic (6.81e-2)"	"unprognostic (3.84e-13)"	"unprognostic (3.90e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.16e-2)"	1.7	0.5	4.6	5.4	10.7	1.1	0.6	1.0	4.7	1.3	3.3	13.4	1.0	4.1	1.4	1.0	1.8	1.1	12.3	2.8	7.2	3.0	0.7	0.5	2.7	2.0	8.1	5.7	0.7	0.5	0.2	0.4	13.5	4.0	1.1	3.6	2.6	1.6	0.4	0.4	2.5	5.7	3.9	4.6	0.8	2.6	0.9	5.9	0.5	0.4	2.3	2.3	6.7	0.8	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.3	4.7	0.0	1.2	3.6	0.3	2.0	0.0	10.2	0.0	0.8	1.8	0.8	0.0	0.0	0.1	3.9	0.0	0.4	0.0	0.3	0.0	0.0	2.7	0.4	0.1	0.9	0.2	0.0	11.4	0.0	1.4	0.0	0.0	1.0	0.4	0.0	0.0	6.2	0.2	0.0	0.0	3.9	0.6	0.0	0.1	0.3	0.0	0.0	0.0	10.3	0.1	0.8	0.5	0.9	0.0	0.0	0.5	1.1	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	4.6	10.7	1.0	4.7	7.2	3.0	8.1	5.7	4.0	5.9
ADAMTS18	ADAMTS21	ENSG00000140873	"ADAM metallopeptidase with thrombospondin type 1 motif 18"	Q8TE60	16	77247813-77435114	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"adipose tissue: 16.1;brain: 31.9;placenta: 27.6"	"Group enriched"	"Detected in some"	8	"HUVEC TERT2: 12.1;TIME: 3.7;U-87 MG: 7.4"	"Low cancer specificity"	"Detected in single"			"Region enriched"	"Detected in all"	5	"cerebellum: 31.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	5	"cerebellum: 3.7"	"Not detected"	"Not detected"			HPA044326	Uncertain		Approved	"Midbody,Mitotic spindle"	"Secreted to extracellular matrix"			"Midbody, Mitotic spindle"		"HPA044326: AB_10961006"	"unprognostic (1.10e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.50e-1)"	"unprognostic (8.13e-2)"	"unprognostic (2.05e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.27e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.98e-1)"	"unprognostic (4.11e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.17e-4)"	"unprognostic (1.77e-5)"	"unprognostic (2.17e-1)"	"unprognostic (3.41e-1)"	"unprognostic (2.47e-4)"	16.1	0.6	1.1	0.8	5.1	0.4	3.2	31.9	3.3	2.2	0.4	8.2	0.0	0.5	1.6	0.4	0.5	0.7	1.1	0.4	2.0	1.3	0.5	0.3	0.5	0.5	1.8	1.4	0.5	0.8	0.4	1.4	27.6	6.4	1.0	0.4	0.2	2.1	0.5	1.0	0.4	0.4	1.2	3.7	0.3	0.3	0.7	2.4	0.0	0.4	0.0	0.3	0.8	0.4	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.8	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.7	3.7	0.1	0.0	0.0	0.0	0.0	0.0	0.3	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.1	5.1	31.9	3.3	2.0	1.3	1.8	1.4	6.4	2.4
ADAMTS20	GON-1	ENSG00000173157	"ADAM metallopeptidase with thrombospondin type 1 motif 20"	P59510	12	43353866-43551921	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Group enriched"	"Detected in some"	8	"brain: 5.1;placenta: 3.6;retina: 1.5;testis: 2.3"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.4;Karpas-707: 6.6;NB-4: 2.9;NTERA-2: 5.2;U-266/70: 7.5;U-266/84: 3.8"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"pons and medulla: 5.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027608, HPA027609"	Uncertain				"Secreted to extracellular matrix"					"HPA027608: AB_10600098, HPA027609: AB_10599024"	"unprognostic (3.18e-2)"			"unprognostic (1.19e-1)"	"unprognostic (1.91e-2)"	"unprognostic (2.04e-1)"		"unprognostic (9.61e-2)"	"unprognostic (3.29e-1)"	"unprognostic (6.67e-2)"	"unprognostic (2.26e-1)"		"unprognostic (1.05e-4)"	"unprognostic (7.42e-2)"	"unprognostic (2.02e-1)"	"unprognostic (9.81e-3)"	"unprognostic (2.57e-1)"	0.2	0.0	0.7	0.1	1.4	0.1	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.0	0.0	0.1	0.0	0.6	0.0	0.3	0.0	0.2	0.0	3.6	5.1	0.0	0.0	1.5	0.2	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	2.3	1.1	0.0	0.1	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.6	0.2	0.0	0.0	2.9	5.2	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.7	0.0	0.0	0.1	1.4	0.0	0.0	0.0	0.7	0.0	0.0	7.5	3.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.4	0.0	1.2	0.3	0.7	0.6	0.0	5.1	1.1
ADAMTS3	"ADAMTS-4, KIAA0366"	ENSG00000156140	"ADAM metallopeptidase with thrombospondin type 1 motif 3"	O15072	4	72280969-72569386	"Cancer-related genes, Predicted secreted proteins"		"Heparin-binding, Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AF22: 12.3;AN3-CA: 7.1;HEL: 12.7;K-562: 10.8;SH-SY5Y: 6.5;U-2 OS: 7.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA021368, HPA021369"	Uncertain		Approved	"Intermediate filaments"	"Secreted to extracellular matrix"			"Intermediate filaments"		"HPA021368: , HPA021369: "	"unprognostic (1.93e-1)"	"unprognostic (3.47e-3)"	"unprognostic (1.41e-1)"	"unprognostic (1.05e-3)"	"unprognostic (6.11e-2)"	"unprognostic (2.60e-1)"	"unprognostic (3.26e-3)"	"unprognostic (1.60e-3)"	"unprognostic (5.92e-4)"	"unprognostic (3.11e-2)"	"unprognostic (1.93e-1)"	"unprognostic (2.60e-1)"	"unprognostic (8.63e-3)"	"unprognostic (1.65e-3)"	"unprognostic (1.17e-1)"	"unprognostic (2.72e-1)"	"unprognostic (1.50e-4)"	5.3	2.6	3.3	4.4	5.6	2.1	7.8	0.3	4.6	4.4	2.3	1.1	1.9	0.5	9.6	14.4	1.0	7.5	1.9	2.8	1.3	0.9	4.7	2.7	3.1	2.0	0.7	2.2	7.5	1.0	12.4	1.1	8.2	2.2	2.6	1.1	3.9	1.4	3.4	0.8	1.5	0.9	4.6	1.8	1.9	1.6	5.6	1.3	0.6	4.4	0.8	1.0	2.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	7.1	0.1	0.3	0.1	0.6	2.0	1.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	1.7	0.0	1.6	12.7	0.9	0.0	0.2	0.0	0.0	1.6	0.1	0.6	0.1	0.0	10.8	0.0	0.0	0.0	1.1	0.0	2.0	3.7	0.0	2.5	0.0	4.2	0.0	0.5	6.5	0.0	0.5	0.1	0.1	0.1	0.1	5.3	7.9	0.0	0.6	0.0	0.0	0.0	1.1	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	5.6	0.3	4.6	1.3	0.9	0.7	2.2	2.2	1.3
ADAMTS4	"ADAMTS-2, ADMP-1, KIAA0688"	ENSG00000158859	"ADAM metallopeptidase with thrombospondin type 1 motif 4"	O75173	1	161184308-161199056	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 58.0"	"Cell line enhanced"	"Detected in some"		"hTEC/SVTERT24-B: 10.7;HUVEC TERT2: 12.9;SH-SY5Y: 7.2;TIME: 10.8;U-251 MG: 9.6"	"Low cancer specificity"	"Detected in all"			"Group enriched"	"Detected in all"	5	"basal ganglia: 20.7;cerebral cortex: 10.0;midbrain: 28.6;pons and medulla: 20.5;thalamus: 15.7"	"Cell type enriched"	"Detected in some"	8	"plasmacytoid DC: 8.0"	"Lineage enriched"	"Detected in many"	8	"dendritic cells: 8.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB025876, HPA051296, HPA068374"	Uncertain		Supported	"Nuclear speckles"	"Secreted to extracellular matrix"			"Nuclear speckles"		"CAB025876: , HPA051296: , HPA068374: "	"unprognostic (2.70e-2)"	"unprognostic (8.10e-3)"	"unprognostic (3.00e-3)"	"unprognostic (2.75e-1)"	"unprognostic (9.95e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.07e-1)"	"prognostic unfavourable (5.00e-4)"	"unprognostic (1.20e-2)"	"unprognostic (9.59e-3)"	"unprognostic (2.48e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavourable (7.27e-7)"	"unprognostic (1.10e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.44e-3)"	"unprognostic (3.13e-2)"	58.0	9.7	2.6	18.1	20.7	1.8	14.6	1.5	10.7	7.8	6.3	33.4	0.0	1.9	5.8	2.0	7.7	14.2	16.4	19.5	3.4	2.3	3.1	11.0	15.7	2.7	28.6	3.5	35.7	10.6	4.7	4.9	4.4	20.5	5.8	3.4	0.0	1.7	1.7	7.7	1.7	3.0	12.0	15.5	1.9	8.1	1.7	15.7	0.0	7.5	1.2	1.4	8.7	4.0	0.5	8.0	1.0	0.2	0.4	0.6	0.2	0.0	0.0	0.2	0.1	6.0	3.8	0.5	4.8	0.2	0.4	2.8	0.1	0.1	0.2	4.1	1.5	0.1	0.0	0.0	1.7	0.1	0.3	0.1	0.4	1.2	0.6	0.0	0.1	4.2	0.0	10.7	0.1	12.9	0.1	0.3	0.3	0.1	0.0	0.2	4.8	0.0	0.1	4.7	0.1	0.0	0.1	0.1	7.2	0.0	0.1	0.1	0.2	0.5	10.8	6.8	0.1	0.3	9.6	0.2	0.1	0.1	2.1	0.1	0.1	0.7	0.2	0.2	0.6	0.1	0.3	0.3	0.3	0.3	0.1	0.5	0.4	0.4	1.0	0.4	0.1	8.0	0.3	0.2	2.6	20.7	1.5	10.0	3.4	2.3	28.6	3.5	20.5	15.7
ADAMTS5	"ADAMTS11, ADMP-2"	ENSG00000154736	"ADAM metallopeptidase with thrombospondin type 1 motif 5"	Q9UNA0	21	26917912-26966513	"Cancer-related genes, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 21.2;placenta: 20.9"	"Cell line enhanced"	"Detected in some"		"ASC diff: 23.3;ASC TERT1: 9.9;fHDF/TERT166: 9.3;RH-30: 24.7;U-87 MG: 8.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	6	"classical monocyte: 1.5"	"Lineage enriched"	"Detected in single"	6	"monocytes: 1.5"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			"HPA005661, CAB025996, HPA030906, HPA030908"	Approved		Supported	Nucleoplasm	"Secreted to extracellular matrix"	18000	18000	Nucleoplasm		"CAB025996: , HPA005661: AB_1078101, HPA030906: , HPA030908: "	"unprognostic (1.97e-1)"	"unprognostic (2.88e-3)"	"unprognostic (2.69e-2)"	"unprognostic (4.01e-2)"	"unprognostic (4.67e-1)"	"unprognostic (2.10e-2)"	"unprognostic (4.38e-8)"	"unprognostic (1.11e-3)"	"unprognostic (7.66e-2)"	"unprognostic (6.17e-2)"	"unprognostic (8.13e-2)"	"unprognostic (7.76e-2)"	"prognostic unfavourable (2.46e-4)"	"unprognostic (6.69e-3)"	"unprognostic (3.01e-1)"	"prognostic unfavourable (8.54e-4)"	"unprognostic (1.15e-1)"	14.1	0.4	1.0	1.6	0.6	0.0	21.2	2.5	0.9	5.5	2.3	0.4	7.2	0.3	10.7	8.2	1.2	3.3	1.0	6.9	1.0	0.0	1.6	0.8	1.2	0.4	1.1	0.4	14.9	0.4	0.1	0.4	20.9	1.5	2.2	0.8	2.3	1.8	9.7	11.0	3.3	2.4	6.2	1.1	6.4	1.8	2.3	0.4	0.6	5.3	1.5	0.6	2.8	3.1	0.0	0.2	0.0	1.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	23.3	9.9	0.0	1.2	0.2	1.4	0.5	0.0	0.0	0.0	0.0	9.3	0.0	0.0	0.0	2.0	0.0	0.9	0.0	0.3	0.0	2.4	0.0	0.0	5.4	0.0	0.9	0.1	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.1	0.0	0.0	24.7	0.0	2.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.3	1.3	0.5	0.0	0.0	0.0	8.9	0.1	1.1	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.0	0.6	2.5	0.9	1.0	0.0	1.1	0.4	1.5	0.4
ADAMTS6	ADAM-TS6	ENSG00000049192	"ADAM metallopeptidase with thrombospondin type 1 motif 6"	Q9UKP5	5	65148736-65481920	"Cancer-related genes, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"placenta: 32.4"	"Cell line enhanced"	"Detected in many"		"BJ: 9.8;HBF TERT88: 10.8;hTEC/SVTERT24-B: 10.0;hTERT-HME1: 11.9;TIME: 11.2;U-2197: 12.8"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 4.8;naive B-cell: 3.6"	"Group enriched"	"Detected in many"	13	"B-cells: 4.8;T-cells: 1.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA043441	Enhanced				"Secreted to extracellular matrix"					"HPA043441: "	"unprognostic (1.53e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.70e-3)"	"unprognostic (4.33e-2)"	"unprognostic (1.03e-2)"	"unprognostic (2.39e-2)"	"unprognostic (8.24e-2)"	"unprognostic (1.65e-2)"	"unprognostic (4.77e-2)"	"unprognostic (8.04e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.13e-6)"	"unprognostic (3.23e-5)"	"unprognostic (2.09e-1)"	"unprognostic (3.02e-4)"	"unprognostic (4.18e-3)"	2.2	0.7	0.9	2.0	0.8	0.3	1.8	0.2	1.8	2.9	1.4	0.8	1.6	0.6	5.1	3.0	1.0	2.7	6.3	2.3	0.8	0.9	1.5	0.5	2.3	1.7	0.8	1.4	1.8	0.5	0.4	2.0	32.4	2.9	2.3	0.9	1.4	0.6	0.9	0.4	0.8	2.4	5.4	3.2	3.4	1.8	1.9	0.7	3.3	0.9	1.2	1.9	3.6	1.7	4.8	0.2	0.0	0.0	0.0	1.4	0.1	2.0	0.0	0.5	0.5	0.0	1.6	0.0	9.8	5.8	6.1	7.2	0.0	0.2	0.0	0.0	3.7	0.4	0.1	1.9	10.8	1.5	0.0	0.1	3.6	0.2	0.3	0.0	0.5	0.7	0.0	10.0	11.9	5.4	0.0	0.0	3.7	0.0	0.5	0.0	0.0	0.0	0.3	2.1	0.0	0.0	0.0	0.3	0.4	0.2	0.0	0.0	0.0	0.0	11.2	2.4	3.6	12.8	7.8	0.0	0.0	0.0	2.7	0.5	0.0	0.0	0.0	0.0	1.3	0.0	1.0	4.8	0.3	0.5	0.0	3.6	1.3	1.4	0.0	0.0	0.0	0.2	0.0	0.1	0.9	0.8	0.2	1.4	0.8	0.9	0.8	1.4	2.9	0.7
ADAMTS8	"ADAM-TS8, FLJ41712, METH2"	ENSG00000134917	"ADAM metallopeptidase with thrombospondin type 1 motif 8"	Q9UP79	11	130404925-130428993	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Heparin-binding, Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 13.0;lung: 21.0"	"Cell line enhanced"	"Detected in some"		"HEK 293: 1.9;HMC-1: 5.7;NTERA-2: 2.8;U-2 OS: 12.9"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 5.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"amygdala: 6.4;cerebral cortex: 7.6;hippocampal formation: 7.3;olfactory region: 5.2"	HPA066349	Approved				"Secreted to extracellular matrix"	2200000	2200000			"HPA066349: "	"unprognostic (4.76e-6)"	"unprognostic (3.92e-2)"	"unprognostic (6.13e-2)"	"prognostic favourable (1.38e-4)"	"unprognostic (2.41e-1)"	"unprognostic (7.81e-2)"	"unprognostic (3.09e-2)"	"unprognostic (9.83e-2)"	"unprognostic (1.09e-4)"	"unprognostic (3.05e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.40e-1)"	"unprognostic (4.66e-3)"	"unprognostic (4.03e-3)"	"unprognostic (5.23e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.41e-1)"	2.1	0.1	1.5	10.2	2.5	0.0	0.5	0.6	4.4	1.3	5.3	0.5	0.2	1.1	2.6	1.5	3.1	1.7	13.0	3.9	1.6	0.6	2.1	0.2	21.0	0.2	0.7	0.2	1.0	0.7	0.0	0.8	2.7	0.9	2.9	0.5	0.7	0.3	5.7	0.4	0.1	1.6	7.4	0.8	0.9	5.6	0.2	0.4	0.2	0.4	0.2	0.4	3.8	3.4	0.0	0.0	0.2	0.0	0.1	0.6	0.0	0.0	0.3	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	1.9	0.0	1.8	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.1	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	2.5	0.6	3.2	1.6	0.6	0.7	0.2	0.9	0.4
ADAMTS9	KIAA1312	ENSG00000163638	"ADAM metallopeptidase with thrombospondin type 1 motif 9"	Q9P2N4	3	64515654-64688000	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"ER-Golgi transport, Protein transport, Transport"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 51.4"	"Cell line enriched"	"Detected in some"	5	"SH-SY5Y: 52.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA028567, HPA028577, HPA028601"	Approved		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"			Vesicles	"Endoplasmic reticulum"	"HPA028567: AB_10599275, HPA028577: AB_10600330, HPA028601: "	"unprognostic (2.21e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.41e-1)"	"unprognostic (4.83e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.37e-2)"	"unprognostic (7.80e-3)"	"unprognostic (5.85e-2)"	"unprognostic (2.77e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.11e-1)"	"unprognostic (7.67e-2)"	"unprognostic (3.16e-3)"	"unprognostic (1.46e-2)"	"unprognostic (3.01e-1)"	"unprognostic (1.98e-3)"	"unprognostic (5.00e-3)"	51.4	4.7	5.6	12.0	11.5	0.5	15.2	3.9	8.0	10.4	10.4	2.8	7.2	1.6	13.9	5.6	6.8	7.7	8.2	29.6	5.7	2.7	9.0	3.1	11.5	7.7	6.8	0.3	17.4	9.9	17.2	2.4	30.5	12.4	7.4	3.2	0.7	3.5	4.3	10.8	2.6	3.2	12.2	12.6	4.4	4.6	3.1	5.9	0.0	6.4	3.7	1.6	19.6	29.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.5	5.6	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.9	0.1	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	3.5	1.0	0.0	0.0	0.2	9.4	0.2	0.0	0.1	0.0	0.0	0.0	3.0	0.0	0.0	0.9	0.0	11.2	0.1	0.0	52.2	0.0	0.0	0.0	0.0	0.2	2.1	0.3	0.1	0.0	0.3	0.0	0.0	0.0	0.2	0.0	11.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	5.6	11.5	3.9	8.0	5.7	2.7	6.8	0.3	12.4	5.9
ADCY1	"AC1, DFNB44"	ENSG00000164742	"Adenylate cyclase 1"	Q08828	7	45574140-45723116	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Biological rhythms, cAMP biosynthesis"	"Calmodulin-binding, Lyase"	"Cancer-related genes, Deafness, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 29.0"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 15.0;SCLC-21H: 9.1;SH-SY5Y: 17.3;SK-MEL-30: 19.9;WM-115: 11.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018364, HPA068274"	Uncertain		Approved	Mitochondria				Mitochondria		"CAB018364: AB_2223098, HPA068274: "	"unprognostic (9.41e-3)"	"unprognostic (7.30e-4)"	"unprognostic (9.31e-2)"	"unprognostic (2.98e-1)"	"unprognostic (4.18e-2)"	"unprognostic (3.07e-3)"	"unprognostic (1.32e-1)"	"unprognostic (7.31e-2)"	"unprognostic (1.64e-3)"	"unprognostic (2.89e-1)"	"unprognostic (7.73e-3)"	"unprognostic (1.54e-1)"	"unprognostic (4.74e-6)"	"unprognostic (2.49e-1)"	"unprognostic (7.65e-3)"	"unprognostic (2.87e-1)"	"unprognostic (2.23e-1)"	2.8	2.8	11.5	0.7	11.7	0.4	6.8	22.7	29.0	7.8	0.9	2.0	0.0	0.7	2.7	1.1	1.2	2.4	1.2	4.0	11.6	4.0	1.8	9.6	1.0	0.8	5.8	13.4	1.2	3.6	1.0	1.5	0.9	6.2	4.1	1.0	5.0	0.8	2.1	9.2	0.6	0.7	1.6	2.2	1.0	1.8	3.9	1.2	0.0	3.0	0.2	0.8	1.0	1.5	0.5	0.4	0.6	0.1	0.0	0.2	0.0	0.5	3.8	1.4	2.2	2.8	0.0	2.7	0.1	0.0	0.5	0.2	0.4	0.0	0.0	0.2	0.1	1.2	2.5	0.1	0.0	6.9	1.8	0.0	0.0	0.3	0.0	0.1	0.0	3.4	1.9	0.3	15.0	0.1	0.2	4.6	0.2	4.6	0.0	0.0	5.6	0.0	0.0	0.0	7.5	0.0	3.7	9.1	17.3	1.4	0.0	19.9	1.3	2.3	0.0	0.4	2.9	0.3	2.3	0.0	0.0	0.0	0.0	0.0	11.3	0.4	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.2	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	11.5	11.7	22.7	29.0	11.6	4.0	5.8	13.4	6.2	1.2
ADGRB1	BAI1	ENSG00000181790	"Adhesion G protein-coupled receptor B1"	O14514	8	142449430-142545009	"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Immunity, Innate immunity, Myogenesis, Neurogenesis, Phagocytosis"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"brain: 27.4"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 11.5;MCF7: 4.2;NB-4: 5.6;RPMI-8226: 15.9;U-2 OS: 10.9"	"Cancer enhanced"	"Detected in many"		"glioma: 11.3"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted in brain"						"unprognostic (9.57e-4)"	"unprognostic (1.28e-1)"	"unprognostic (3.87e-3)"	"unprognostic (8.50e-3)"	"unprognostic (9.98e-2)"	"unprognostic (5.87e-2)"	"unprognostic (3.39e-1)"	"unprognostic (2.14e-2)"	"unprognostic (2.76e-1)"	"unprognostic (2.55e-1)"	"unprognostic (6.48e-2)"	"unprognostic (3.43e-1)"	"unprognostic (7.30e-11)"	"unprognostic (6.27e-2)"	"unprognostic (7.42e-2)"	"unprognostic (4.52e-3)"	"unprognostic (3.29e-2)"	1.0	3.4	13.6	1.4	18.1	0.9	1.1	5.4	27.4	2.0	1.0	3.1	0.1	1.4	1.8	2.3	0.9	1.4	0.9	0.9	11.0	11.9	1.1	0.8	1.2	1.6	8.7	9.2	1.6	1.1	0.9	2.7	2.5	9.1	1.3	0.9	0.9	2.6	1.9	0.7	3.1	1.4	1.0	2.3	3.7	1.5	2.1	3.2	0.0	0.9	0.0	1.0	0.9	0.4	0.2	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.1	0.0	11.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.9	0.0	0.0	0.8	0.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	5.6	1.8	0.0	0.1	0.0	15.9	0.0	0.0	3.1	3.1	0.0	0.0	0.2	0.1	0.3	0.0	0.1	10.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.6	18.1	5.4	19.5	11.0	11.9	8.7	9.2	9.1	3.2
ADM	AM	ENSG00000148926	Adrenomedullin	P35318	11	10304680-10307397	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 133.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 107.9;fHDF/TERT166: 53.9;HSkMC: 65.9;U-138 MG: 56.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	19	"neutrophil: 62.3"	"Lineage enriched"	"Detected in many"	19	"granulocytes: 62.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			CAB016075	Approved				"Secreted to blood"	46000	46000			"CAB016075: AB_628693"	"unprognostic (1.67e-1)"	"unprognostic (2.89e-2)"	"unprognostic (1.78e-1)"	"unprognostic (5.22e-2)"	"unprognostic (1.55e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavourable (7.56e-4)"	"unprognostic (1.78e-3)"	"unprognostic (1.06e-1)"	"unprognostic (2.83e-1)"	"unprognostic (8.13e-3)"	"unprognostic (3.12e-1)"	"prognostic unfavourable (6.33e-4)"	"unprognostic (9.70e-3)"	"unprognostic (2.01e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.62e-2)"	65.2	18.3	6.8	18.3	12.4	21.1	52.1	2.5	15.0	28.3	23.3	5.9	1.6	4.8	11.6	8.0	26.5	7.9	18.7	28.3	4.7	3.5	17.3	26.1	34.3	15.2	8.0	2.0	19.0	16.0	10.8	8.4	133.1	14.2	13.8	7.0	23.5	9.6	2.1	92.3	28.7	8.0	11.8	12.7	14.6	10.7	11.6	9.9	0.3	15.9	13.3	10.1	76.1	32.4	0.1	0.6	62.3	3.2	0.0	0.0	0.4	5.3	4.2	5.1	1.4	107.9	46.3	8.0	40.8	38.2	38.6	26.6	21.4	6.5	0.0	1.8	53.9	7.6	1.4	6.3	32.5	0.1	1.6	0.1	2.0	2.5	13.7	0.2	0.1	65.9	5.1	4.4	7.1	8.7	0.0	0.0	9.6	0.1	0.0	1.2	9.6	1.6	0.1	0.1	7.6	2.3	7.3	0.1	0.4	15.5	3.4	0.0	4.7	0.0	2.5	56.8	0.8	35.5	5.9	0.4	4.3	1.4	17.0	0.0	16.9	0.0	1.7	0.0	0.0	1.9	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	62.3	0.0	3.2	0.0	0.0	0.4	6.8	12.4	2.5	15.0	4.7	3.5	8.0	2.0	14.2	9.9
ADNP	"ADNP1, KIAA0784"	ENSG00000101126	"Activity dependent neuroprotector homeobox"	Q9H2P0	20	50888916-50931421	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Autism spectrum disorder, Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006371	Supported		Approved	Nucleoplasm				Nucleoplasm		"HPA006371: AB_1078105"	"unprognostic (3.40e-2)"	"unprognostic (6.81e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.06e-2)"	"unprognostic (1.68e-1)"	"unprognostic (6.68e-2)"	"prognostic unfavourable (1.65e-5)"	"unprognostic (1.73e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.38e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.39e-2)"	"unprognostic (1.29e-1)"	"unprognostic (4.91e-2)"	"unprognostic (3.63e-1)"	"unprognostic (1.90e-2)"	"unprognostic (1.08e-1)"	23.7	26.5	32.2	28.1	29.3	21.3	32.4	46.0	35.4	26.3	24.2	23.0	34.2	18.4	32.6	38.7	27.8	28.4	25.5	19.9	27.2	21.1	23.7	22.7	27.9	29.0	29.0	28.5	38.8	21.7	49.2	32.4	23.5	25.6	27.4	22.4	26.1	25.3	30.6	31.8	28.6	25.6	28.6	23.9	28.6	24.9	33.4	28.2	50.2	28.4	17.4	31.1	32.1	33.1	16.4	28.7	15.0	24.6	15.1	30.9	8.1	20.5	19.5	37.0	19.4	18.4	18.2	15.9	15.4	17.4	30.3	22.3	27.9	16.3	26.9	20.2	18.4	23.7	31.1	29.4	35.8	12.9	11.1	19.2	21.8	21.5	17.9	30.6	16.7	17.2	36.6	18.5	33.5	20.1	25.4	19.1	19.0	20.8	30.1	20.3	18.5	15.6	28.1	20.5	19.7	17.7	27.8	30.8	23.2	35.2	50.7	25.9	24.1	28.7	17.1	27.0	29.1	20.4	16.6	13.9	16.1	45.8	15.2	18.0	18.4	15.0	12.3	10.6	20.8	18.5	22.5	13.6	23.4	19.0	13.9	16.4	23.4	30.9	6.3	15.1	24.6	28.7	15.4	8.1	32.2	29.3	46.0	35.4	27.2	21.1	29.0	28.5	25.6	28.2
ADORA2A	"ADORA2, RDC8"	ENSG00000128271	"Adenosine A2a receptor"	P29274	22	24417879-24442360	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0"	"Cell line enhanced"	"Detected in many"		"Daudi: 15.0;Karpas-707: 20.7;RPMI-8226: 14.6;SK-BR-3: 29.7;U-266/70: 20.8;U-266/84: 27.1;U-698: 21.2"	"Not detected"	"Not detected"			"Region enriched"	"Detected in all"	8	"basal ganglia: 43.9"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Region enriched"	"Detected in some"	10	"basal ganglia: 357.5"	"Region enriched"	"Detected in single"	95	"basal ganglia: 166.0"	"CAB001943, HPA065566, HPA075997"	Enhanced	Supported								"CAB001943: , HPA065566: , HPA075997: "	"unprognostic (7.30e-2)"	"unprognostic (2.42e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.44e-2)"	"unprognostic (1.88e-3)"	"unprognostic (9.85e-2)"	"unprognostic (3.63e-1)"	"unprognostic (2.88e-2)"	"unprognostic (4.57e-3)"	"unprognostic (2.15e-3)"	"unprognostic (1.87e-3)"	"unprognostic (6.81e-4)"	"unprognostic (1.50e-1)"	"unprognostic (9.78e-3)"	"unprognostic (1.30e-1)"	"unprognostic (7.10e-3)"	1.0	2.4	1.9	10.4	43.9	28.1	1.5	3.4	3.8	0.8	2.0	1.7	0.3	5.4	1.4	1.4	1.0	0.9	2.4	3.5	2.4	1.8	3.5	4.3	5.1	14.8	2.6	1.6	1.2	0.8	0.0	2.1	1.4	2.3	1.6	0.8	3.3	2.7	1.5	1.2	0.9	2.6	0.7	1.3	7.5	2.8	2.0	5.7	59.0	1.3	0.9	8.6	3.8	1.3	17.7	1.1	13.7	9.0	2.2	22.8	11.2	0.2	0.3	0.4	0.1	0.2	0.1	0.4	0.2	9.3	0.5	0.9	1.7	0.1	15.0	1.0	0.2	0.3	0.9	0.0	0.0	1.8	2.6	0.2	0.0	2.1	0.1	0.3	7.5	0.1	0.0	2.8	0.0	3.3	0.1	20.7	0.0	0.2	5.2	1.6	0.6	0.0	0.1	0.7	14.6	0.0	0.1	1.5	8.7	0.4	29.7	0.1	0.3	1.4	0.2	0.9	1.4	0.2	0.1	20.8	27.1	21.2	4.7	5.1	0.1	3.0	0.8	4.8	8.6	2.6	20.1	9.6	16.1	16.9	1.1	17.7	22.8	18.3	13.7	2.2	9.0	1.1	21.4	11.2	1.9	43.9	3.4	3.8	2.4	1.8	2.6	1.6	2.3	5.7
ADRA1B		ENSG00000170214	"Adrenoceptor alpha 1B"	P35368	5	159865080-159972544	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 21.6;liver: 20.3;lymphoid tissue: 17.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 13.0;HaCaT: 6.6;TIME: 11.0;U-2 OS: 9.2;U-251 MG: 7.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA074416			Supported	"Plasma membrane"				"Plasma membrane"		"HPA074416: "	"unprognostic (4.93e-3)"	"unprognostic (2.94e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavourable (6.00e-5)"	"prognostic unfavourable (6.98e-4)"	"unprognostic (4.08e-3)"	"unprognostic (1.67e-3)"	"unprognostic (1.68e-1)"	"unprognostic (6.12e-2)"	"prognostic favourable (2.67e-4)"	"unprognostic (2.28e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (1.40e-6)"	"unprognostic (5.24e-4)"	"unprognostic (2.54e-1)"	"prognostic favourable (3.19e-5)"	"unprognostic (1.59e-2)"	5.3	2.9	5.3	0.9	9.0	0.4	2.3	1.3	21.6	0.9	1.2	0.7	0.8	1.2	1.5	3.6	1.1	3.6	1.3	3.3	6.2	5.8	7.4	20.3	4.7	2.3	1.2	13.9	6.2	0.8	1.0	0.8	1.1	5.2	1.6	1.1	0.9	1.0	1.9	1.6	1.3	1.7	1.2	0.9	17.4	0.9	0.8	0.5	0.0	2.0	0.0	1.1	0.8	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.7	0.3	0.0	2.4	0.9	0.1	0.5	0.2	0.6	0.3	0.0	4.2	0.0	13.0	3.8	6.6	0.0	0.5	0.3	0.0	0.3	0.0	1.6	0.0	5.0	0.0	0.0	2.8	0.0	0.0	0.2	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.1	0.6	0.0	0.7	0.0	4.5	0.0	0.4	0.0	0.0	0.3	0.4	0.1	0.0	11.0	0.1	9.2	0.0	7.0	0.0	0.0	0.0	3.3	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	9.0	1.3	21.6	6.2	5.8	1.2	13.9	5.2	0.5
AFDN	"AF-6, AF6, MLLT4"	ENSG00000130396	"Afadin, adherens junction formation factor"	P55196	6	167826922-167972023	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Cell adhesion"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868"	Approved		Enhanced	"Nucleoplasm,Plasma membrane,Cell Junctions"				"Plasma membrane, Cell Junctions"	Nucleoplasm	"CAB013496: , HPA030212: AB_10599291, HPA030213: AB_10601340, HPA030214: AB_10601005, HPA030215: AB_10601556, HPA049868: "	"prognostic unfavourable (7.43e-5)"	"unprognostic (2.66e-3)"	"unprognostic (2.07e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.13e-1)"	"unprognostic (9.06e-2)"	"unprognostic (4.12e-1)"	"unprognostic (3.12e-2)"	"unprognostic (4.12e-1)"	"unprognostic (1.09e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.73e-2)"	"unprognostic (5.56e-2)"	"unprognostic (5.43e-3)"	"unprognostic (1.59e-1)"	"unprognostic (4.72e-2)"	"unprognostic (5.68e-2)"	17.0	7.4	14.9	13.0	17.2	1.8	23.5	17.8	19.3	19.6	26.3	16.1	25.5	22.2	15.8	17.7	59.5	27.9	18.2	13.9	15.6	7.2	20.6	29.3	26.3	5.1	17.1	12.5	16.2	29.7	16.4	27.4	18.7	16.1	20.9	27.2	15.3	38.6	18.6	12.7	24.8	42.3	17.4	13.0	13.5	21.1	16.3	15.2	2.1	25.7	13.7	24.5	16.3	27.9	3.5	0.6	2.9	0.5	0.0	1.2	0.0	19.4	6.1	42.4	15.1	4.1	3.5	31.6	7.9	4.0	6.8	8.5	25.9	12.1	3.4	14.7	4.7	9.4	17.6	16.2	12.3	21.9	18.2	0.1	2.6	19.6	6.2	2.1	9.3	2.4	10.9	11.5	27.1	12.6	38.9	13.6	4.4	8.3	0.2	0.1	10.4	2.8	12.5	11.1	14.7	12.5	9.5	19.7	12.0	8.0	30.5	12.0	3.6	0.8	18.5	3.2	15.4	13.7	13.0	0.2	16.5	7.1	9.5	4.5	27.8	0.0	0.5	0.0	1.0	0.5	0.6	3.5	1.2	0.4	0.6	2.7	0.0	0.5	2.9	0.0	0.3	0.0	0.6	0.0	14.9	17.2	17.8	19.3	15.6	7.2	17.1	12.5	16.1	15.2
AFF1	"AF-4, AF4, MLLT2, PBM1"	ENSG00000172493	"AF4/FMR2 family member 1"	P51825	4	86935002-87141054	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 121.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA069947			Approved	Nucleoplasm,Mitochondria				"Nucleoplasm, Mitochondria"		"HPA069947: "	"unprognostic (1.01e-1)"	"unprognostic (7.56e-2)"	"unprognostic (2.57e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.79e-1)"	"unprognostic (6.23e-2)"	"unprognostic (6.09e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.24e-1)"	"unprognostic (8.32e-3)"	"unprognostic (5.86e-2)"	"unprognostic (1.33e-2)"	"unprognostic (4.41e-1)"	"unprognostic (2.55e-1)"	"unprognostic (2.71e-2)"	33.7	16.6	8.0	11.8	9.5	19.5	26.5	6.5	12.2	20.2	21.0	10.5	18.9	11.1	27.4	16.6	15.8	18.6	15.3	22.4	10.3	5.3	27.6	15.5	18.4	12.9	9.3	5.5	24.7	19.0	28.6	18.5	121.7	9.5	16.8	14.3	27.0	16.0	25.6	58.8	18.6	16.2	20.3	11.5	13.9	15.0	6.7	10.3	17.0	38.8	21.1	13.9	19.5	26.5	11.3	14.6	21.1	5.4	5.1	8.8	2.8	7.8	7.2	6.0	6.3	9.9	11.8	8.5	7.9	11.6	6.0	9.0	7.6	14.5	8.9	10.8	9.6	3.6	9.4	11.9	8.4	15.1	3.7	18.4	18.7	6.3	7.7	17.6	14.6	9.6	8.6	10.3	9.1	22.1	11.3	25.1	2.5	2.1	15.9	5.1	7.9	2.5	12.6	3.5	11.3	17.7	7.5	13.6	2.5	12.0	7.9	3.8	4.7	14.8	11.0	11.2	10.2	6.8	4.3	21.8	12.1	15.3	9.2	20.4	4.0	3.5	5.4	11.7	6.7	4.1	7.4	8.0	8.8	6.6	6.0	11.3	4.7	4.4	21.1	5.1	2.2	14.6	7.5	2.8	8.0	9.5	6.5	12.2	10.3	5.3	9.3	5.5	9.5	10.3
AFF3	"LAF4, MLLT2-like"	ENSG00000144218	"AF4/FMR2 family member 3"	P51826	2	99545419-100142739	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 43.6"	"Cell line enhanced"	"Detected in many"		"Daudi: 23.3;T-47d: 11.7;U-698: 34.5"	"Cancer enhanced"	"Detected in many"		"breast cancer: 11.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"memory B-cell: 16.2;naive B-cell: 27.5;plasmacytoid DC: 12.8"	"Group enriched"	"Detected in many"	16	"B-cells: 27.5;dendritic cells: 12.8"	"Low region specificity"	"Detected in all"							"HPA044512, HPA053379"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA044512: AB_10795984, HPA053379: "	"unprognostic (1.05e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.30e-1)"	"unprognostic (4.88e-3)"	"unprognostic (1.02e-1)"	"unprognostic (4.98e-5)"	"unprognostic (1.11e-3)"	"unprognostic (3.04e-2)"	"unprognostic (8.75e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.95e-3)"	"unprognostic (7.57e-2)"	"prognostic unfavourable (5.64e-4)"	"unprognostic (6.40e-3)"	"unprognostic (6.79e-2)"	"unprognostic (3.69e-2)"	"unprognostic (7.87e-3)"	3.2	2.4	6.0	40.2	6.1	10.3	16.6	20.5	9.9	4.2	4.2	1.8	0.8	1.2	8.9	1.7	4.1	4.1	2.3	4.9	6.3	6.2	1.8	2.4	7.6	23.3	5.4	6.8	7.5	1.1	0.3	5.2	6.9	4.4	18.9	2.3	5.5	6.6	3.3	1.0	1.0	5.9	8.6	6.6	43.6	4.8	6.0	2.5	34.7	1.7	0.7	42.0	7.4	2.7	27.5	12.8	0.2	0.2	0.9	1.2	0.4	0.1	0.0	9.8	3.4	0.0	0.4	0.0	1.3	0.3	2.9	1.0	0.0	0.0	23.3	0.1	1.5	0.1	0.2	0.0	1.7	5.9	2.8	0.0	0.1	0.0	0.2	0.1	6.7	0.6	0.0	6.1	0.1	0.0	0.1	0.0	0.0	0.1	1.9	0.3	1.3	1.6	3.2	0.0	0.1	0.0	0.0	9.7	3.4	0.1	0.1	6.3	11.7	10.7	3.9	9.3	2.5	0.3	1.5	0.2	0.0	34.5	8.7	0.8	0.7	0.2	0.2	0.0	0.0	0.2	0.2	16.2	0.1	0.0	2.9	27.5	1.2	0.0	0.1	0.9	0.2	12.8	0.0	0.4	6.0	6.1	20.5	9.9	6.3	6.2	5.4	6.8	4.4	2.5
AFF4	"AF5Q31, MCEF"	ENSG00000072364	"AF4/FMR2 family member 4"	Q9UHB7	5	132875379-132963634	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Disease mutation, Dwarfism, Obesity, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023690, HPA029634"	Approved		Supported	"Nucleoplasm,Nucleoli fibrillar center"				"Nucleoplasm, Nucleoli fibrillar center"		"HPA023690: AB_1844633, HPA029634: "	"unprognostic (3.24e-2)"	"unprognostic (1.86e-2)"	"unprognostic (6.17e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.56e-2)"	"unprognostic (7.37e-2)"	"unprognostic (1.18e-1)"	"unprognostic (6.13e-2)"	"unprognostic (4.94e-2)"	"unprognostic (3.52e-1)"	"unprognostic (1.16e-2)"	"unprognostic (2.77e-2)"	"unprognostic (3.25e-2)"	"prognostic unfavourable (6.44e-4)"	"unprognostic (1.69e-1)"	22.9	29.6	22.8	19.1	38.7	38.3	23.6	37.8	25.6	26.2	21.8	25.2	22.1	14.6	27.6	19.5	29.8	20.8	26.8	21.3	18.7	18.7	25.7	24.2	24.8	19.6	19.0	19.7	34.0	24.9	48.8	40.1	20.4	18.3	26.7	18.5	27.5	25.2	25.1	32.1	22.2	17.8	24.4	18.8	17.3	24.8	17.6	24.4	26.6	33.9	15.7	19.2	26.3	24.7	8.7	5.2	12.2	4.9	3.8	5.5	1.5	16.8	13.6	18.8	20.8	14.5	17.5	14.7	18.3	19.7	16.9	21.6	20.1	11.1	8.6	21.8	23.9	8.5	15.1	22.6	28.3	6.1	9.7	10.6	18.6	7.1	18.6	3.7	11.1	20.5	15.1	29.2	29.8	16.1	7.6	7.3	21.0	6.4	10.2	4.0	7.2	5.6	6.9	18.3	3.2	14.7	23.8	14.7	15.5	20.8	5.1	20.7	10.8	6.0	22.7	20.3	17.3	17.8	19.4	10.1	17.2	7.8	19.1	6.9	13.8	12.2	2.4	3.8	5.5	2.0	4.1	7.7	5.1	3.7	2.9	8.7	5.3	4.6	5.2	3.8	4.9	5.2	2.5	1.5	22.8	38.7	37.8	25.6	18.7	18.7	19.0	19.7	18.3	24.4
AFP	"FETA, HPAFP"	ENSG00000081051	"Alpha fetoprotein"	P02771	4	73431138-73456174	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"heart muscle: 4.3;liver: 9.6;lung: 2.9"	"Cell line enriched"	"Detected in some"	190	"Hep G2: 214.4"	"Group enriched"	"Detected in some"	14	"liver cancer: 208.8;testis cancer: 49.4"	"Region enhanced"	"Detected in single"		"basal ganglia: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"cerebellum: 0.8"	"Not detected"	"Not detected"			"HPA010607, HPA023600, CAB024283, CAB025339"	Approved		Approved	"Golgi apparatus,Cytosol"	"Secreted to blood"	930000	930000	"Golgi apparatus"	Cytosol	"CAB024283: AB_2650473, CAB025339: , HPA010607: AB_1078141, HPA023600: AB_1844769"	"unprognostic (4.69e-1)"	"unprognostic (1.87e-1)"	"unprognostic (3.34e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.48e-3)"	"unprognostic (2.95e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.54e-1)"		"unprognostic (3.81e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.63e-6)"	"unprognostic (1.98e-2)"	"unprognostic (5.80e-2)"		"unprognostic (1.14e-1)"	0.0	0.4	0.1	0.0	1.0	0.0	1.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	4.3	0.3	0.0	0.0	9.6	2.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	214.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0
AGER	"RAGE, SCARJ1"	ENSG00000204305	"Advanced glycosylation end-product specific receptor"	Q15109	6	32180968-32184324	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Inflammatory response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"lung: 178.6"	"Cell line enhanced"	"Detected in some"		"HEK 293: 5.3;MCF7: 4.5;RPTEC TERT1: 5.5;U-266/70: 6.6"	"Cancer enhanced"	"Detected in all"		"lung cancer: 27.2"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB011682, HPA064436, HPA069474"	Enhanced		Approved	"Nucleoli fibrillar center,Plasma membrane,Cell Junctions"	"Secreted in other tissues"	140000	140000	"Plasma membrane, Cell Junctions"	"Nucleoli fibrillar center"	"CAB011682: AB_2258049, HPA064436: , HPA069474: "	"unprognostic (9.37e-2)"	"unprognostic (3.70e-1)"	"unprognostic (2.37e-2)"	"unprognostic (1.14e-1)"	"unprognostic (4.55e-2)"	"unprognostic (1.59e-3)"	"unprognostic (4.36e-2)"	"unprognostic (1.00e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.27e-1)"	"prognostic favourable (3.41e-4)"	"unprognostic (1.24e-1)"	"prognostic unfavourable (9.01e-7)"	"unprognostic (3.57e-1)"	"unprognostic (3.70e-2)"	"unprognostic (4.44e-2)"	"prognostic favourable (2.74e-6)"	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.9	0.2	0.3	0.3	0.2	0.2	0.2	0.3	0.6	0.4	0.4	0.2	0.2	0.2	0.0	0.5	0.2	178.6	0.2	0.2	0.2	0.5	0.3	0.1	0.7	0.4	0.4	0.5	0.3	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	1.0	0.2	0.2	0.2	0.2	22.6	0.2	0.2	0.2	0.3	0.7	0.7	1.0	0.3	0.1	0.5	0.1	0.2	0.2	0.0	0.6	0.3	2.1	2.9	0.1	0.3	0.1	0.2	0.1	0.5	0.2	2.3	0.5	2.3	0.2	1.2	0.4	0.4	5.3	1.4	0.1	0.0	0.0	0.6	2.4	0.3	0.3	0.1	0.2	0.4	0.0	0.8	0.3	4.5	0.3	1.7	0.0	0.0	0.1	0.3	0.3	5.5	0.1	0.1	0.5	0.1	0.0	2.0	1.3	0.1	0.3	0.0	1.6	1.6	0.2	6.6	3.4	2.4	2.3	0.5	0.6	0.0	0.3	0.0	0.5	0.0	0.1	0.0	0.3	0.2	0.0	0.7	0.4	0.3	1.0	0.1	0.2	0.7	0.0	0.1	0.2	0.2	0.9	0.2	0.2	0.0	0.2	0.2	0.4	0.2
AHNAK2	C14orf78	ENSG00000185567	"AHNAK nucleoprotein 2"	Q8IVF2	14	104937244-104978357	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"skin 1: 131.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 28.1;ASC TERT1: 32.0;HBEC3-KT: 28.1;hTCEpi: 70.8;hTERT-HME1: 30.2;TIME: 31.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	12	"plasmacytoid DC: 1.6"	"Lineage enriched"	"Detected in single"	17	"dendritic cells: 1.6"									"HPA000878, HPA002940, HPA004145, HPA020111"	Enhanced		Enhanced	"Plasma membrane,Cytosol"				Cytosol	"Plasma membrane"	"HPA000878: , HPA002940: AB_1859547, HPA004145: AB_1859546, HPA020111: "	"unprognostic (3.56e-1)"	"unprognostic (6.04e-2)"	"unprognostic (6.19e-3)"	"unprognostic (1.31e-3)"	"unprognostic (9.55e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.36e-1)"	"prognostic unfavourable (2.79e-5)"	"unprognostic (3.43e-1)"	"unprognostic (3.06e-3)"	"prognostic unfavourable (4.05e-6)"	"unprognostic (1.48e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.39e-2)"	"unprognostic (6.97e-2)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (2.23e-5)"	6.9	1.8	2.9	2.0	5.6	1.0	8.5	3.0	13.7	17.2	23.0	2.9	5.7	1.7	16.3	2.9	25.8	7.1	3.2	1.5	2.4	3.1	1.1	10.8	2.3	1.0	2.7	11.6	1.8	1.2	1.2	0.7	1.8	23.3	5.7	5.1	10.1	6.0	14.6	1.6	131.1	4.8	19.9	4.8	1.1	7.1	3.2	0.8	0.0	1.2	14.4	3.0	10.0	19.5	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.6	19.7	0.0	1.3	28.1	32.0	0.0	2.4	5.0	0.8	0.4	0.0	8.8	0.0	3.3	18.5	14.2	0.0	28.1	0.4	0.0	0.1	0.0	13.0	0.1	2.6	0.0	0.9	4.1	70.8	2.8	30.2	12.3	0.0	0.0	14.2	1.6	0.0	0.0	0.0	9.7	0.0	1.3	0.0	19.2	0.0	0.1	0.1	10.4	0.0	0.4	1.3	0.0	31.7	6.8	4.2	7.7	2.1	0.0	0.0	0.0	20.7	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	2.9	5.6	3.0	13.7	2.4	3.1	2.7	11.6	23.3	0.8
AHR	bHLHe76	ENSG00000106546	"Aryl hydrocarbon receptor"	P35869	7	16916359-17346152	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Cell cycle, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor, Repressor"	"Cancer-related genes, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 69.6"	"Cell line enhanced"	"Detected in many"		"hTCEpi: 28.3;hTERT-HME1: 29.5;RT4: 24.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB005072, HPA029722, HPA029723"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB005072: AB_633731, HPA029722: AB_10599189, HPA029723: AB_10599025"	"unprognostic (1.29e-2)"	"unprognostic (1.21e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.39e-2)"	"unprognostic (7.28e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.39e-1)"	"unprognostic (4.32e-2)"	"unprognostic (9.98e-2)"	"unprognostic (1.24e-3)"	"unprognostic (2.89e-1)"	"unprognostic (7.53e-3)"	"unprognostic (2.00e-1)"	"unprognostic (2.82e-3)"	"unprognostic (3.25e-2)"	"unprognostic (9.45e-2)"	23.1	12.2	2.5	13.2	3.5	19.8	19.1	1.6	3.5	14.6	14.0	5.7	8.7	8.5	11.9	10.1	14.2	11.2	22.2	14.8	3.2	2.2	7.3	23.9	26.4	20.0	6.5	2.5	21.3	6.8	4.5	3.8	69.6	3.7	21.4	8.9	10.9	11.1	8.5	5.2	16.6	13.7	12.1	4.8	15.6	13.3	6.8	4.0	7.1	12.4	7.9	12.3	26.7	26.6	1.1	9.3	5.6	7.6	3.1	2.9	2.0	3.0	2.5	1.0	0.0	7.7	5.3	0.4	6.3	9.2	2.9	4.3	3.1	6.8	0.0	1.9	9.3	8.5	0.6	5.8	7.8	0.1	1.4	1.8	3.2	2.7	14.5	3.0	4.5	7.2	28.3	11.2	29.5	9.8	0.2	0.0	13.3	1.6	0.0	4.8	0.8	4.0	0.0	0.0	0.1	9.4	24.3	0.9	0.0	4.7	5.2	4.6	3.6	1.0	1.6	1.2	0.0	16.1	0.0	1.3	0.0	0.0	20.6	11.9	20.2	0.7	7.6	5.6	0.7	3.6	1.1	0.8	2.6	1.4	9.3	1.1	1.5	1.1	0.8	3.1	1.3	2.2	2.9	2.0	2.5	3.5	1.6	3.5	3.2	2.2	6.5	2.5	3.7	4.0
AHSG	"A2HS, FETUA, HSGA"	ENSG00000145192	"Alpha 2-HS glycoprotein"	P02765	3	186612923-186621318	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Mineral balance"		"Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	269	"liver: 402.0"	"Cell line enriched"	"Detected in some"	77	"Hep G2: 210.3"	"Cancer enriched"	"Detected in some"	284	"liver cancer: 1231.6"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"NK-cell: 1.4"	"Lineage enhanced"	"Detected in single"		"NK-cells: 1.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001524, HPA001525, CAB026209"	Enhanced		Enhanced	"Golgi apparatus"	"Secreted to blood"	140000000000	140000000000	"Golgi apparatus"		"CAB026209: , HPA001524: AB_1078851, HPA001525: AB_1078849"		"unprognostic (6.40e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.03e-2)"	"unprognostic (3.20e-2)"	"unprognostic (1.07e-2)"	"unprognostic (1.16e-2)"	"unprognostic (7.47e-3)"	"unprognostic (3.05e-1)"	"unprognostic (5.27e-2)"	"unprognostic (8.64e-2)"		"unprognostic (3.99e-7)"	"unprognostic (5.21e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.04e-1)"		0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	402.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	210.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
AJUBA	"JUB, MGC15563"	ENSG00000129474	"Ajuba LIM protein"	Q96IF1	14	22971174-22982642	"Cancer-related genes, Predicted intracellular proteins"	"Cell adhesion, Cell cycle, RNA-mediated gene silencing, Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 55.0"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 49.0;hTCEpi: 51.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			HPA006171	Approved		Approved	"Nucleoplasm,Golgi apparatus"				"Nucleoplasm, Golgi apparatus"		"HPA006171: AB_1852044"	"unprognostic (1.15e-1)"	"unprognostic (2.99e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.24e-3)"	"unprognostic (9.81e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.73e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.86e-1)"	"prognostic unfavourable (5.67e-4)"	"unprognostic (1.47e-1)"	"unprognostic (3.19e-3)"	"unprognostic (2.94e-1)"	"unprognostic (2.68e-1)"	"unprognostic (9.35e-3)"	"unprognostic (2.07e-1)"	2.9	2.0	1.1	2.4	1.8	0.0	4.1	1.1	1.6	11.1	2.0	1.6	4.9	0.5	8.8	4.4	12.3	4.7	7.9	3.2	2.3	0.6	15.6	55.0	8.5	2.2	1.5	1.3	8.2	5.6	5.5	1.4	12.5	2.6	9.2	1.1	7.1	5.5	11.0	1.5	31.3	1.7	4.3	0.5	2.9	2.6	4.1	1.3	7.1	15.4	5.3	6.6	3.7	10.0	1.3	1.0	2.6	1.2	2.9	2.5	0.6	10.2	12.2	16.3	6.2	1.6	2.9	13.1	10.1	13.4	23.7	21.3	26.0	10.7	0.2	10.6	20.8	33.4	12.4	49.0	29.0	0.9	1.1	0.7	19.8	29.2	18.6	1.0	0.7	9.1	51.3	9.9	38.3	9.1	0.4	0.6	21.9	8.2	1.0	1.2	1.0	16.8	2.8	13.6	0.2	23.8	16.0	0.0	1.4	30.5	9.0	1.9	12.6	1.0	8.1	10.3	20.8	1.6	9.6	0.1	0.3	0.1	1.6	0.9	4.6	2.2	1.2	0.5	1.4	0.5	0.5	0.4	1.2	2.5	0.4	1.3	1.5	0.9	2.6	2.9	0.8	1.0	0.2	0.6	1.1	1.8	1.1	1.6	2.3	0.6	1.5	1.3	2.6	1.3
AK9	"AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954"	ENSG00000155085	"Adenylate kinase 9"	Q5TCS8	6	109492856-109691217	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Nucleotide metabolism"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"							"HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711"	Enhanced		Enhanced	"Nucleoplasm,Nuclear membrane"				"Nucleoplasm, Nuclear membrane"		"HPA030804: , HPA030805: , HPA031779: AB_10603674, HPA031781: , HPA036324: , HPA036711: "	"unprognostic (9.68e-3)"	"unprognostic (2.15e-1)"	"unprognostic (1.66e-2)"	"unprognostic (2.36e-2)"	"unprognostic (3.42e-1)"	"unprognostic (7.28e-2)"	"unprognostic (1.41e-3)"	"unprognostic (6.76e-3)"	"unprognostic (1.89e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.67e-4)"	"unprognostic (2.58e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.30e-1)"	"unprognostic (8.39e-2)"	"unprognostic (5.56e-2)"	4.6	4.7	7.7	5.6	8.4	4.7	8.3	13.5	8.7	5.0	6.5	8.5	4.1	5.0	6.3	11.1	6.2	11.3	5.2	6.9	9.1	10.3	7.6	4.5	6.7	5.5	9.4	4.9	6.7	4.6	15.4	33.3	4.4	11.5	5.9	6.7	3.7	7.0	6.3	6.1	5.5	6.2	5.7	11.7	6.5	6.1	22.0	7.7	20.5	11.4	4.1	5.0	5.9	4.4	11.2	2.9	15.1	4.1	4.9	6.4	1.6	2.6	1.8	7.7	13.7	7.2	4.5	5.7	4.0	5.0	4.2	5.8	2.9	5.3	5.6	2.1	3.8	4.6	2.2	4.4	9.0	11.9	4.8	4.2	4.5	2.9	5.9	5.3	2.6	3.6	8.5	7.8	10.2	5.5	4.0	4.7	3.1	5.3	4.6	3.6	1.7	2.9	6.1	4.3	5.2	6.2	5.1	9.4	8.0	4.9	4.7	6.7	6.0	6.5	5.9	4.1	2.7	5.9	2.6	2.5	2.1	3.3	8.2	6.7	2.2	15.1	2.8	6.5	5.1	1.5	4.4	10.5	5.1	6.1	2.0	11.2	6.4	5.5	5.4	4.9	4.1	2.9	3.6	1.6	7.7	8.4	13.5	8.7	9.1	10.3	9.4	4.9	11.5	7.7
AKAP12	"AKAP250, SSeCKS"	ENSG00000131016	"A-kinase anchoring protein 12"	Q02952	6	151239999-151358557	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Calmodulin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"REH: 43.1;TIME: 42.9;U-251 MG: 45.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	184	"basophil: 20.4"	"Lineage enriched"	"Detected in single"	184	"granulocytes: 20.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006344, CAB026379, HPA056230"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		6400000	6400000	"Plasma membrane, Cytosol"		"CAB026379: , HPA006344: AB_1078118, HPA056230: AB_2683073"	"unprognostic (6.66e-2)"	"unprognostic (1.51e-1)"	"unprognostic (9.90e-3)"	"prognostic unfavourable (7.08e-4)"	"unprognostic (2.61e-2)"	"unprognostic (8.88e-2)"	"unprognostic (5.05e-2)"	"prognostic unfavourable (6.34e-5)"	"unprognostic (1.34e-1)"	"unprognostic (8.26e-3)"	"unprognostic (2.59e-1)"	"unprognostic (4.72e-2)"	"unprognostic (4.51e-3)"	"unprognostic (1.10e-3)"	"unprognostic (3.51e-1)"	"unprognostic (7.03e-3)"	"unprognostic (2.34e-2)"	52.5	11.2	11.5	11.0	18.1	2.0	38.5	31.3	21.2	11.5	23.4	1.9	5.9	6.1	20.5	13.6	12.8	15.6	32.3	22.8	9.8	17.4	14.9	20.6	18.2	6.9	11.4	9.9	49.0	7.6	2.0	11.1	24.1	28.7	13.5	9.4	26.6	3.3	14.7	11.3	4.1	10.6	27.9	14.1	8.1	12.4	62.0	6.6	0.3	11.4	6.6	2.8	34.5	24.7	0.0	0.0	20.4	0.0	0.0	0.1	0.0	1.7	8.6	12.4	0.0	23.4	35.1	4.3	10.0	5.4	4.5	4.5	0.2	32.5	0.0	4.0	7.5	0.2	23.5	7.4	4.0	11.1	8.6	0.1	9.6	7.9	2.6	0.0	2.2	24.8	0.0	19.1	1.0	29.4	2.1	0.2	16.3	0.1	0.0	0.0	7.7	10.1	43.1	0.5	0.0	26.1	1.4	8.8	5.1	3.2	0.1	5.7	0.6	0.1	42.9	0.6	8.0	25.6	45.9	0.0	0.0	0.0	14.9	0.0	8.6	20.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.5	18.1	31.3	19.1	9.8	17.4	11.4	9.9	28.7	6.6
AKAP9	"AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO"	ENSG00000127914	"A-kinase anchoring protein 9"	Q99996	7	91940867-92110673	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Long QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008548, CAB012909, HPA026109"	Supported		Enhanced	"Golgi apparatus,Vesicles,Centrosome"				"Golgi apparatus"	"Vesicles, Centrosome"	"CAB012909: AB_2533235, HPA008548: AB_1078121, HPA026109: AB_1844688"	"unprognostic (9.57e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.13e-1)"	"unprognostic (5.97e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.47e-1)"	"unprognostic (4.75e-2)"	"unprognostic (1.31e-2)"	"unprognostic (1.28e-1)"	"unprognostic (6.59e-2)"	"unprognostic (7.59e-2)"	"unprognostic (6.32e-2)"	"prognostic favourable (2.10e-6)"	"unprognostic (8.89e-2)"	"unprognostic (1.73e-1)"	"unprognostic (7.77e-2)"	"unprognostic (3.96e-2)"	13.7	15.9	18.0	22.6	17.1	14.9	15.6	35.8	17.5	14.4	24.5	4.7	17.2	25.5	13.0	17.1	15.3	12.4	15.0	14.8	13.3	7.0	19.5	25.1	19.9	13.2	12.4	12.3	22.3	21.3	22.1	40.5	12.9	14.0	11.9	25.3	11.1	20.1	25.9	29.6	16.1	29.1	12.0	11.1	10.4	15.0	6.9	14.4	10.3	14.9	15.7	8.6	14.0	14.2	34.4	39.5	31.9	16.6	10.6	20.3	3.4	11.2	7.0	10.4	6.6	14.9	11.0	7.4	8.4	5.7	4.3	5.5	11.9	9.8	10.2	12.2	7.4	10.4	10.0	5.5	8.1	9.2	8.5	11.2	12.2	7.8	6.1	18.5	11.9	6.9	8.8	8.9	10.2	9.3	16.6	16.7	7.3	16.3	12.6	7.3	8.0	8.7	7.7	17.4	8.2	5.9	12.4	17.0	11.9	17.8	20.0	8.6	5.2	9.0	17.1	8.7	11.2	15.2	11.4	12.0	13.2	13.7	7.7	9.4	9.8	31.9	16.6	21.4	18.4	9.3	15.4	31.4	18.7	16.7	7.2	34.4	20.3	19.3	23.2	10.6	16.3	39.5	14.9	3.4	18.0	17.1	35.8	17.5	13.3	7.0	12.4	12.3	14.0	14.4
AKR1B1	"ALDR1, AR"	ENSG00000085662	"Aldo-keto reductase family 1 member B"	P15121	7	134442350-134459284	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"adrenal gland: 302.2;seminal vesicle: 109.3"	"Cell line enhanced"	"Detected in many"		"A549: 121.0;BJ hTERT+: 222.0;RPTEC TERT1: 105.0;U-87 MG: 99.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026425, CAB027391, CAB047353, HPA052751"	Enhanced		Supported	Nucleoplasm,Cytosol		1700000	1700000	Cytosol	Nucleoplasm	"CAB027391: , CAB047353: , HPA026425: AB_10601563, HPA052751: "	"unprognostic (2.76e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.02e-2)"	"unprognostic (1.37e-2)"	"unprognostic (6.81e-2)"	"unprognostic (2.26e-1)"	"unprognostic (4.18e-2)"	"unprognostic (5.09e-2)"	"unprognostic (2.51e-3)"	"unprognostic (2.47e-1)"	"unprognostic (2.98e-2)"	"unprognostic (8.78e-2)"	"unprognostic (2.81e-2)"	"prognostic unfavourable (2.44e-5)"	"unprognostic (2.03e-1)"	"unprognostic (1.39e-1)"	"prognostic unfavourable (7.00e-4)"	5.9	302.2	7.5	4.7	13.7	2.5	9.5	6.9	10.9	4.4	3.9	8.2	50.4	2.7	4.6	6.1	4.2	4.6	5.2	24.2	7.3	8.4	17.7	2.5	6.9	10.0	9.5	9.0	8.2	7.2	9.4	8.0	24.8	11.9	5.5	4.1	5.8	4.4	109.3	37.6	2.8	4.8	5.6	7.9	6.7	5.0	5.2	5.9	7.3	6.0	10.3	7.6	7.1	3.7	31.4	34.8	22.5	26.0	26.3	42.7	47.2	13.3	121.0	13.6	19.3	58.9	16.0	36.3	13.0	222.0	19.1	24.8	5.6	12.3	0.0	6.0	21.7	5.7	14.8	12.9	15.2	4.8	13.6	6.8	18.2	16.4	84.4	0.0	0.0	14.9	9.7	27.3	7.3	26.9	0.0	4.5	21.1	0.2	20.0	9.2	22.7	0.1	20.9	8.7	10.1	105.0	65.4	10.2	22.7	90.9	0.1	9.5	0.0	10.2	21.2	18.9	8.8	1.7	14.1	12.5	13.7	33.8	99.9	0.0	11.3	22.5	26.0	1.2	37.9	17.0	34.0	31.4	32.4	36.7	34.8	28.5	42.7	41.1	2.1	26.3	8.9	4.9	22.0	47.2	7.5	13.7	6.9	10.9	7.3	8.4	9.5	9.0	11.9	5.9
AKT1	"AKT, PKB, PRKBA, RAC"	ENSG00000142208	"AKT serine/threonine kinase 1"	P31749	14	104769349-104795751	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Neurogenesis, Sugar transport, Translation regulation, Transport"	"Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 113.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 30.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 30.7"	"Low region specificity"	"Detected in all"							"HPA002891, CAB003765"	Supported		Supported	Nucleoplasm,Microtubules				Nucleoplasm	Microtubules	"CAB003765: AB_562035, HPA002891: AB_1078123"	"unprognostic (3.30e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.84e-1)"	"unprognostic (3.70e-1)"	"unprognostic (9.17e-3)"	"unprognostic (1.55e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.47e-1)"	"prognostic favourable (4.83e-4)"	"unprognostic (3.58e-2)"	"unprognostic (1.90e-2)"	"prognostic favourable (2.12e-4)"	"unprognostic (7.14e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.41e-1)"	31.7	45.4	22.9	24.2	23.6	20.3	40.0	20.9	29.5	24.7	32.6	20.0	30.8	22.5	27.0	21.5	33.0	25.5	30.3	47.7	22.9	19.1	26.3	49.2	31.3	21.0	22.1	14.7	25.9	43.0	20.3	16.7	28.4	21.5	31.1	18.2	25.3	30.4	36.1	23.8	20.4	24.0	40.5	17.5	35.4	32.6	16.2	18.8	26.3	32.7	22.4	29.3	36.7	35.9	3.2	5.2	30.7	5.8	5.7	6.2	3.0	15.1	30.3	25.0	37.2	19.4	20.1	28.0	27.9	34.0	41.3	33.1	19.8	18.3	18.3	21.5	38.2	19.7	17.7	26.0	18.0	41.8	7.2	13.9	18.1	21.3	21.5	22.6	36.3	28.8	21.9	20.7	13.8	30.8	12.1	20.4	26.4	113.2	28.4	28.9	6.5	21.7	26.8	23.2	12.5	19.1	37.7	28.7	23.9	23.3	30.5	17.5	39.9	33.7	24.6	27.7	13.3	39.4	28.0	22.2	10.7	15.8	23.3	19.1	33.3	3.3	5.3	30.7	5.4	5.2	4.0	2.9	4.8	6.2	3.6	3.2	2.5	5.7	11.8	5.7	5.8	5.2	4.7	3.0	22.9	23.6	20.9	29.5	22.9	19.1	22.1	14.7	21.5	18.8
AKT2		ENSG00000105221	"AKT serine/threonine kinase 2"	P31751	19	40230317-40285536	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Sugar transport, Translation regulation, Transport"	"Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Diabetes mellitus, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004204, HPA064521"	Uncertain		Supported	Nucleoplasm,Vesicles,Cytosol				"Nucleoplasm, Vesicles, Cytosol"		"CAB004204: AB_626659, HPA064521: "	"unprognostic (6.13e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.56e-1)"	"prognostic unfavourable (1.05e-6)"	"unprognostic (2.85e-1)"	"unprognostic (6.40e-3)"	"unprognostic (9.59e-2)"	"unprognostic (1.22e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.49e-2)"	"unprognostic (3.02e-1)"	"prognostic unfavourable (4.74e-4)"	"unprognostic (1.30e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.28e-1)"	"unprognostic (6.16e-2)"	"unprognostic (2.00e-1)"	31.1	20.3	15.4	17.6	15.2	21.3	18.2	46.3	18.2	23.3	18.2	23.4	21.2	12.3	22.8	28.0	22.1	22.7	14.0	23.1	15.4	10.0	23.0	62.5	14.6	17.8	17.9	13.3	27.8	24.5	21.1	24.0	17.5	14.7	19.7	12.3	26.8	18.5	24.3	48.5	18.3	17.1	20.0	16.8	18.7	15.5	21.3	15.7	26.6	52.6	29.5	23.6	19.6	19.9	6.3	8.8	7.7	4.4	3.2	4.9	2.4	22.4	55.4	21.1	21.7	26.3	32.2	11.7	15.0	22.2	31.1	27.8	24.3	20.9	22.9	13.4	33.1	9.8	23.4	31.3	20.1	21.9	26.7	15.0	35.1	15.3	16.5	17.2	18.1	29.7	18.8	21.1	20.1	6.7	19.3	24.0	17.3	18.7	27.3	8.4	11.4	14.9	18.2	11.5	16.5	24.2	36.8	29.1	17.8	15.4	26.4	12.5	20.8	22.2	6.7	19.0	18.8	17.0	23.5	22.4	19.2	18.8	18.6	20.4	15.5	7.6	4.4	3.6	4.5	2.0	4.5	3.9	3.6	3.0	3.0	6.3	3.5	4.9	7.7	3.2	2.6	8.8	2.7	2.4	15.4	15.2	46.3	18.2	15.4	10.0	17.9	13.3	14.7	15.7
AKT3	"PKBG, PRKBG, RAC-gamma"	ENSG00000117020	"AKT serine/threonine kinase 3"	Q9Y243	1	243488233-243851079	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013090, HPA026441"	Approved		Supported	Cytosol				Cytosol		"CAB013090: AB_2533692, HPA026441: AB_1844711"	"unprognostic (1.33e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.40e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.96e-1)"	"unprognostic (3.77e-1)"	"unprognostic (2.32e-1)"	"unprognostic (2.28e-1)"	"unprognostic (5.47e-3)"	"unprognostic (1.37e-1)"	"unprognostic (6.71e-2)"	"unprognostic (3.64e-3)"	"unprognostic (1.29e-1)"	"unprognostic (8.14e-2)"	"prognostic unfavourable (9.27e-4)"	15.4	17.0	16.0	7.8	15.2	2.2	11.0	39.9	33.4	16.9	16.1	12.4	17.4	4.1	19.7	12.3	10.0	11.8	12.1	9.8	15.5	13.6	12.8	4.0	11.3	7.9	14.2	15.8	29.8	4.4	15.1	14.6	17.0	18.4	19.4	6.6	8.9	4.1	23.9	4.8	4.7	8.1	20.4	12.1	9.9	8.7	10.4	14.8	2.9	17.7	5.0	6.2	17.2	18.6	1.9	0.8	1.2	0.9	3.8	3.6	0.6	23.5	2.4	14.9	0.0	11.0	12.6	7.9	13.3	12.2	8.6	7.6	0.1	9.7	0.0	0.0	16.8	0.3	8.2	5.3	11.4	5.9	6.4	0.3	0.0	0.0	5.7	0.1	2.6	6.5	0.0	10.7	9.7	17.6	0.0	0.1	3.9	0.0	5.0	1.1	6.3	3.7	2.7	9.1	0.1	2.9	0.8	19.1	25.3	0.1	0.0	23.8	0.0	8.0	13.8	15.3	11.8	0.1	11.0	1.3	0.4	2.8	11.2	1.2	12.8	1.2	0.9	0.5	2.3	0.3	3.6	1.0	2.2	2.5	0.8	1.9	1.9	1.7	0.2	3.8	0.7	0.6	0.7	0.6	16.0	15.2	39.9	22.9	15.5	13.6	14.2	15.8	18.4	14.8
AL035425.2		ENSG00000260548			X	108722070-108732687	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"				"Tissue enhanced"	"Detected in some"		"ovary: 13.0;pituitary gland: 7.4;thyroid gland: 8.9"	"Cell line enhanced"	"Detected in some"		"HEK 293: 18.6;NTERA-2: 2.6;RT4: 4.8;WM-115: 4.9"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"																																							0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.6	2.9	0.0			0.0	3.9	0.9	0.0	0.5	0.0	0.0	0.1	5.1	0.0	0.0	0.0	0.0	0.5		13.0	0.9	0.0	7.4	0.0		0.1	0.0		0.0	0.7	0.0	1.1	0.0	1.5	0.1	0.0	0.4	0.0			8.9		0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	18.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
ALB		ENSG00000163631	Albumin	P02768	4	73397114-73421412	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	81	"liver: 3075.8"	"Cell line enriched"	"Detected in some"	39	"Hep G2: 308.4"	"Cancer enriched"	"Detected in many"	384	"liver cancer: 14213.7"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	13	"naive CD4 T-cell: 1.3"	"Lineage enriched"	"Detected in single"	13	"T-cells: 1.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB006262, HPA031024, HPA031025"	Enhanced		Enhanced	"Endoplasmic reticulum,Golgi apparatus"	"Secreted to blood"			"Golgi apparatus"	"Endoplasmic reticulum"	"CAB006262: AB_425297, HPA031024: AB_2673703, HPA031025: AB_2673704"	"unprognostic (1.38e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.60e-1)"	"unprognostic (4.44e-1)"	"unprognostic (2.46e-1)"	"unprognostic (9.53e-3)"	"unprognostic (2.16e-2)"	"unprognostic (2.40e-1)"	"unprognostic (6.43e-2)"	"unprognostic (3.84e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavourable (7.87e-4)"	"unprognostic (7.23e-2)"	"unprognostic (1.05e-3)"	"unprognostic (1.02e-2)"	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.1	0.8	0.1	0.0	0.1	0.1	0.1	0.0	4.9	3075.8	0.1	0.1	0.1	0.1	0.1	38.0	0.0	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	1.0	0.0	0.3	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.1	0.1	308.4	0.0	7.9	0.2	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.1	6.8	0.0	0.0	0.2	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.0	0.5	0.0	2.5	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.1	0.0	0.1	0.1	0.2	0.1
ALCAM	"CD166, MEMD"	ENSG00000170017	"Activated leukocyte cell adhesion molecule"	Q13740	3	105366909-105576900	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Adaptive immunity, Cell adhesion, Immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 122.5"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 64.6;U-138 MG: 77.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 20.7"	"Lineage enriched"	"Detected in many"	6	"dendritic cells: 20.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002148, HPA010926"	Enhanced				"Intracellular and membrane"	1800000000	1800000000			"CAB002148: AB_442053, HPA010926: AB_1078449"	"unprognostic (6.82e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.13e-1)"	"unprognostic (2.19e-1)"	"unprognostic (9.48e-3)"	"unprognostic (2.08e-2)"	"unprognostic (1.63e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.75e-1)"	"unprognostic (4.01e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.07e-1)"	"prognostic favourable (3.15e-4)"	"unprognostic (3.15e-1)"	"unprognostic (4.47e-2)"	"unprognostic (9.57e-2)"	"unprognostic (7.76e-2)"	16.6	14.1	23.6	5.2	31.1	4.2	34.2	4.2	25.3	12.9	8.2	25.0	13.9	7.2	7.0	15.4	4.0	20.6	9.9	4.7	23.2	24.3	9.6	19.4	29.6	4.2	45.1	19.7	24.6	15.3	122.5	11.9	5.3	31.5	14.0	6.6	3.0	17.9	17.5	0.9	5.9	7.3	10.8	35.3	3.0	14.2	2.3	43.8	2.2	25.6	2.7	6.2	9.9	5.5	3.5	20.7	3.7	3.2	0.4	1.6	2.0	38.4	14.8	10.7	5.4	16.2	7.1	0.1	31.5	18.4	20.3	28.6	0.1	8.0	2.7	13.1	44.3	29.8	1.7	25.0	60.2	2.5	2.6	0.3	11.4	0.7	18.2	15.6	0.1	12.6	18.7	26.0	64.6	22.3	0.0	4.6	26.6	2.6	2.2	5.7	2.2	16.8	1.4	0.9	0.1	30.8	4.3	7.7	21.5	3.2	3.1	2.0	6.0	10.3	46.2	77.9	26.6	3.4	37.2	0.0	0.0	0.2	17.7	3.3	33.2	0.0	3.2	2.4	0.4	1.5	1.4	3.5	1.1	0.7	20.7	2.2	0.2	0.2	3.7	0.4	0.8	7.4	1.6	2.0	23.6	31.1	4.2	24.6	23.2	24.3	45.1	19.7	31.5	43.8
ALDOA		ENSG00000149925	"Aldolase, fructose-bisphosphate A"	P04075	16	30064164-30070457	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Glycolysis	Lyase	"Cancer-related genes, Disease mutation, Glycogen storage disease, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"skeletal muscle: 1296.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA004177, CAB006252"	Enhanced		Supported	Cytosol		1200000000	1200000000	Cytosol		"CAB006252: AB_437007, HPA004177: AB_1078128"	"unprognostic (2.63e-2)"	"unprognostic (3.22e-2)"	"unprognostic (6.80e-2)"	"unprognostic (1.33e-1)"	"unprognostic (6.74e-3)"	"unprognostic (4.28e-3)"	"prognostic unfavourable (5.79e-5)"	"prognostic unfavourable (7.32e-5)"	"unprognostic (1.68e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.22e-1)"	"unprognostic (2.19e-3)"	"unprognostic (4.48e-2)"	27.9	30.9	34.7	24.2	42.3	36.0	25.3	31.2	59.7	21.0	32.8	16.3	25.9	29.4	21.9	33.9	73.5	22.1	24.4	109.3	31.6	33.4	28.2	11.1	17.9	34.0	35.0	49.6	23.4	19.4	51.0	25.2	19.9	38.0	23.6	23.5	24.6	37.9	36.9	1296.2	28.4	21.5	30.1	22.7	17.4	24.4	9.2	18.9	18.5	26.6	189.8	29.0	36.8	27.7	61.1	142.9	165.7	166.3	50.5	93.2	217.0	138.7	104.6	31.5	101.2	48.3	55.1	100.7	84.0	87.6	85.7	107.2	73.9	107.0	94.6	137.8	84.8	106.0	63.1	183.2	62.9	41.6	83.0	77.4	83.9	163.2	75.4	112.5	83.1	75.5	64.7	96.2	64.7	63.1	66.6	62.5	90.8	197.9	68.4	93.0	78.3	88.2	102.1	50.6	211.5	106.7	79.0	63.1	44.4	52.4	221.1	78.4	94.0	76.3	75.0	126.6	50.5	69.0	90.8	123.5	84.3	86.6	235.6	109.3	99.9	106.7	164.0	130.3	70.2	156.8	79.1	61.1	76.8	72.5	142.9	55.5	73.8	70.3	165.7	50.5	166.3	53.8	93.2	217.0	34.7	42.3	31.2	59.7	31.6	33.4	35.0	49.6	38.0	18.9
ALDOA		ENSG00000285043	"Aldolase, fructose-bisphosphate A"	P04075	16	30053090-30070420	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Glycolysis	Lyase	"Cancer-related genes, Disease mutation, Glycogen storage disease, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"											"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA004177	Uncertain		Supported	Cytosol		1200000000	1200000000	Cytosol		"HPA004177: AB_1078128"																		1.8	0.9	2.7	1.1	5.0	2.1	7.2	0.7	7.7	4.9	1.5	2.0	2.4	0.0	2.5	3.9	0.9	3.6	1.6	5.3	2.3		1.3	0.0	2.3	2.0	0.8	4.4	2.2	0.8	0.8	3.0	1.4	4.0	2.4	0.5	2.8	1.6	7.5	10.6	0.6	0.1	1.9	0.4	1.7	1.3	11.6	0.8	1.2	4.7	0.2	2.7	1.2	1.0	7.0	6.6	0.9	6.2	4.2	8.5	12.5	3.7	8.8	1.9	6.2	1.5	5.2	1.5	4.0	6.9	5.4	21.6	3.6	5.0	24.5	5.9	6.8	6.3	14.0	10.9	3.8	4.3	7.9	6.0	8.2	5.9	11.5	10.5	2.3	5.1	0.5	10.7	12.2	7.7	1.2	7.1	13.4	3.9	4.9	8.0	2.1	5.5	7.6	4.0	22.4	15.1	0.7	6.1	5.0	1.0	1.6	1.5	5.1	4.0	1.7	8.0	2.4	3.7	5.3	7.3	5.5	8.0	7.6	11.4	3.5	0.1	6.2	0.1	5.3	2.6	7.4	7.0	7.0	5.7	6.6	6.2	8.5	6.6	0.9	4.2	2.3	5.6	5.4	12.5										
ALDOB		ENSG00000136872	"Aldolase, fructose-bisphosphate B"	P05062	9	101420578-101435823	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Glycolysis	Lyase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	30	"intestine: 804.1;kidney: 253.1;liver: 598.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 14.1;NB-4: 13.2;RPMI-8226: 15.2;SH-SY5Y: 13.2"	"Cancer enriched"	"Detected in many"	31	"liver cancer: 1414.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"HPA002198, CAB020827"	Enhanced					930000000	930000000			"CAB020827: , HPA002198: AB_1078129"	"unprognostic (6.58e-3)"	"unprognostic (2.83e-1)"	"unprognostic (1.43e-3)"	"unprognostic (1.03e-1)"	"unprognostic (8.10e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.44e-3)"	"unprognostic (4.34e-2)"	"unprognostic (4.57e-2)"	"unprognostic (2.66e-1)"	"unprognostic (5.79e-2)"	"unprognostic (7.48e-2)"	"unprognostic (1.66e-2)"	"unprognostic (2.02e-1)"	"unprognostic (2.58e-1)"	"unprognostic (5.19e-2)"	"unprognostic (1.96e-2)"	0.1	0.1	0.1	0.6	0.1	0.0	0.1	0.1	0.2	0.1	334.5	0.2	0.2	145.9	0.2	0.6	0.1	0.1	5.7	0.1	0.1	0.1	253.1	598.8	0.1	0.1	0.1	0.1	0.1	18.3	0.0	0.4	0.1	0.4	0.1	0.0	0.2	0.2	0.1	0.1	0.1	804.1	0.1	0.1	0.2	1.5	0.3	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	14.1	0.0	0.0	0.0	0.0	0.3	0.0	2.9	1.4	0.0	0.4	0.0	0.0	0.0	0.3	0.0	1.3	0.0	0.4	0.0	3.5	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.2	13.2	0.2	0.0	0.2	3.1	15.2	0.0	0.0	2.5	13.2	1.5	0.0	0.0	0.0	0.1	0.7	0.0	0.7	5.3	0.2	0.4	0.2	1.6	0.0	1.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.4	0.1
ALDOC		ENSG00000109107	"Aldolase, fructose-bisphosphate C"	P09972	17	28573115-28577264	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Glycolysis	Lyase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 166.7;heart muscle: 56.9"	"Cell line enhanced"	"Detected in many"		"RPMI-8226: 62.2;U-266/70: 42.9"	"Cancer enriched"	"Detected in all"	6	"glioma: 128.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003282, CAB020828, HPA067442"	Enhanced	Supported	Approved	"Nucleoplasm,Nucleoli fibrillar center,Vesicles,Cytosol"		280000000	280000000	"Nucleoplasm, Nucleoli fibrillar center"	"Vesicles, Cytosol"	"CAB020828: , HPA003282: AB_1078130, HPA067442: "	"unprognostic (2.90e-1)"	"unprognostic (4.45e-3)"	"unprognostic (5.69e-3)"	"unprognostic (1.43e-1)"	"unprognostic (3.56e-1)"	"prognostic unfavourable (9.80e-4)"	"unprognostic (1.03e-1)"	"unprognostic (1.70e-1)"	"unprognostic (1.30e-1)"	"unprognostic (6.03e-3)"	"unprognostic (3.90e-1)"	"unprognostic (3.24e-2)"	"prognostic unfavourable (1.29e-7)"	"unprognostic (1.28e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.74e-2)"	"unprognostic (1.23e-1)"	26.0	9.4	86.7	4.8	78.9	7.5	9.8	100.1	166.7	3.8	5.3	17.4	0.3	7.0	4.4	4.6	7.1	3.9	4.4	56.9	64.6	54.3	3.3	26.2	4.6	6.5	69.9	51.4	12.8	1.6	4.7	2.3	2.1	98.1	6.0	5.6	16.5	4.2	6.1	1.7	12.5	15.0	4.6	34.4	6.7	8.7	4.6	23.4	0.0	2.1	0.5	10.0	3.4	3.5	12.2	4.6	8.8	4.1	13.7	20.5	8.8	7.4	0.5	3.5	14.4	7.2	7.4	0.7	3.8	8.6	2.9	18.1	4.3	0.7	3.5	4.6	3.4	9.7	2.3	23.6	5.5	3.0	2.2	6.7	2.7	7.4	6.8	2.4	7.8	6.8	3.3	0.3	5.9	1.3	4.6	18.8	2.5	3.5	2.8	8.1	5.4	3.9	2.4	0.4	62.2	0.4	1.0	9.2	16.4	2.2	17.7	0.1	9.6	5.5	0.9	0.3	1.4	0.5	0.6	42.9	12.3	2.6	28.1	7.0	0.5	0.1	3.5	1.4	11.4	4.1	16.2	12.2	15.6	9.2	4.6	11.5	20.5	15.1	8.8	13.7	2.3	2.2	19.5	8.8	86.7	78.9	100.1	78.5	64.6	54.3	69.9	51.4	98.1	23.4
ALK	CD246	ENSG00000171094	"ALK receptor tyrosine kinase"	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;pituitary gland: 17.9"	"Cell line enriched"	"Detected in some"	6	"SH-SY5Y: 26.4"	"Group enriched"	"Detected in some"	5	"glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010694	Approved		Supported	"Plasma membrane"				"Plasma membrane"		"HPA010694: AB_1078133"	"unprognostic (4.96e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.56e-7)"	"unprognostic (7.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (9.07e-3)"	"unprognostic (6.29e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-4)"	"unprognostic (3.70e-2)"	"unprognostic (2.06e-2)"	"unprognostic (7.15e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.61e-2)"	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2.0	0.0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0.0	1.6	0.0	0.3	0.6	1.2	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	3.5	0.0	0.0	0.1	0.3	26.4	0.0	0.0	0.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	3.1	0.0	4.0	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9
ALKBH6	MGC15677	ENSG00000239382	"AlkB homolog 6"	Q3KRA9	19	36009120-36014239	"Cancer-related genes, Predicted intracellular proteins"		"Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA073835, HPA074340"	Approved		Supported	"Nucleoplasm,Focal adhesion sites"				Nucleoplasm	"Focal adhesion sites"	"HPA073835: , HPA074340: "	"unprognostic (1.90e-3)"	"unprognostic (1.82e-1)"	"unprognostic (5.16e-3)"	"unprognostic (1.12e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.86e-5)"	"unprognostic (6.21e-2)"	"unprognostic (4.53e-2)"	"unprognostic (3.95e-1)"	"unprognostic (3.56e-2)"	"unprognostic (8.78e-4)"	"unprognostic (1.77e-2)"	"unprognostic (2.31e-5)"	"unprognostic (9.34e-2)"	"unprognostic (2.15e-1)"	"unprognostic (3.82e-1)"	"unprognostic (1.05e-3)"	8.4	7.0	14.1	6.4	15.2	6.8	6.3	7.8	18.9	5.8	8.2	7.8	2.5	6.6	6.5	6.6	6.5	8.2	7.7	9.2	13.0	14.9	5.7	12.6	6.8	8.7	14.8	12.5	5.4	3.4	8.2	8.5	6.2	19.5	9.7	4.6	6.5	8.7	9.9	6.3	5.8	6.4	8.5	10.5	8.9	9.6	4.2	4.9	5.7	6.2	3.7	8.4	7.2	4.7	18.1	13.5	29.5	15.0	15.7	19.5	9.4	10.3	11.1	4.2	6.2	6.6	4.0	7.1	10.3	6.9	12.1	12.3	4.6	5.5	9.1	16.5	5.7	4.1	4.4	11.9	6.4	14.3	8.0	5.2	4.2	4.9	7.5	4.5	16.0	6.0	8.6	10.0	3.4	8.2	8.1	6.9	6.5	10.8	10.8	5.9	3.3	7.2	6.9	5.8	6.5	8.7	4.6	5.1	5.3	7.0	8.4	8.6	6.7	10.2	3.5	6.3	9.3	14.3	10.0	13.0	7.7	6.4	13.7	5.1	6.7	29.5	11.4	27.3	17.1	15.0	13.0	18.1	15.5	16.1	9.6	14.6	13.2	12.8	9.6	15.7	11.7	13.5	19.5	9.4	14.1	15.2	7.8	18.9	13.0	14.9	14.8	12.5	19.5	4.9
ALPK2	HAK	ENSG00000198796	"Alpha kinase 2"	Q86TB3	18	58481247-58628957	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"heart muscle: 35.3;skeletal muscle: 35.3;tongue: 12.4"	"Cell line enhanced"	"Detected in many"		"BJ: 26.0;BJ hTERT+: 15.8;fHDF/TERT166: 23.5;U-138 MG: 13.3"	"Cancer enriched"	"Detected in some"	6	"renal cancer: 7.3"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"non-classical monocyte: 1.8"	"Low lineage specificity"	"Detected in single"			"Region enhanced"	"Detected in single"		"cerebellum: 1.1"	"Low region specificity"	"Detected in many"			"HPA027377, HPA027976, HPA028084, HPA029801"	Uncertain		Approved	Cytosol				Cytosol		"HPA027377: AB_10600635, HPA027976: AB_10611246, HPA028084: AB_10601996, HPA029801: AB_10602006"	"unprognostic (7.35e-2)"	"unprognostic (4.91e-2)"	"unprognostic (1.64e-1)"	"unprognostic (4.60e-3)"	"unprognostic (2.64e-1)"	"unprognostic (8.27e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.41e-1)"	"unprognostic (3.44e-1)"	"unprognostic (1.06e-1)"	"unprognostic (5.13e-2)"	"unprognostic (1.33e-2)"	"prognostic unfavourable (8.20e-5)"	"unprognostic (5.27e-3)"	"unprognostic (2.50e-1)"	"unprognostic (4.73e-2)"	"unprognostic (3.20e-2)"	0.8	0.0	0.1	2.8	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.9	0.8	0.0	0.4	35.3	0.1	0.0	5.2	2.8	0.1	3.3	0.1	0.1	0.1	0.1	0.0	0.1	0.5	0.1	0.1	0.0	0.2	0.4	0.1	35.3	0.3	0.6	0.1	0.1	0.2	1.2	0.6	0.1	5.5	0.3	12.4	7.9	0.5	0.1	0.0	0.5	0.0	1.8	0.0	0.3	0.0	0.0	6.9	0.5	0.0	0.2	1.8	0.1	26.0	15.8	11.0	9.5	1.6	0.0	0.0	2.7	23.5	0.0	0.0	0.0	11.3	5.6	0.0	0.0	2.1	0.9	1.4	0.0	0.0	1.6	0.0	3.3	0.1	0.0	0.0	0.2	7.0	0.0	0.0	0.0	0.1	0.0	0.0	5.7	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	13.3	5.8	1.8	4.4	10.7	9.2	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.5	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1
ALPL	"HOPS, TNSALP"	ENSG00000162551	"Alkaline phosphatase, liver/bone/kidney"	P05186	1	21509372-21578412	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Biomineralization	Hydrolase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 73.3;liver: 52.7;lung: 45.1"	"Cell line enhanced"	"Detected in some"		"HSkMC: 52.2;hTEC/SVTERT24-B: 40.8;LHCN-M2: 29.7;SCLC-21H: 26.0"	"Cancer enhanced"	"Detected in all"		"testis cancer: 199.6"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	91	"neutrophil: 73.3"	"Lineage enriched"	"Detected in single"	127	"granulocytes: 73.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA007105, HPA008765, CAB020829"	Enhanced		Approved	Cytosol	"Intracellular and membrane"	7300000	7300000	Cytosol		"CAB020829: , HPA007105: AB_1078137, HPA008765: AB_1078138"	"unprognostic (3.89e-2)"	"unprognostic (1.27e-1)"	"unprognostic (5.57e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (7.57e-4)"	"unprognostic (3.05e-3)"	"unprognostic (6.50e-3)"	"unprognostic (1.01e-1)"	"prognostic unfavourable (7.08e-4)"	"unprognostic (1.17e-2)"	"unprognostic (2.48e-3)"	"unprognostic (1.74e-1)"	"unprognostic (7.28e-2)"	"unprognostic (1.73e-2)"	"unprognostic (2.27e-1)"	"unprognostic (9.70e-3)"	"unprognostic (2.58e-1)"	15.9	22.7	4.5	17.6	6.0	2.6	10.6	2.2	7.8	2.2	2.1	4.1	0.7	1.9	3.7	1.1	2.0	5.7	2.8	10.9	5.7	4.2	29.7	52.7	45.1	28.1	5.3	4.8	1.2	4.3	2.4	4.1	2.2	7.7	2.6	1.3	18.3	3.1	6.6	0.9	1.8	2.7	2.5	3.8	19.6	1.8	2.9	2.7	0.5	3.7	1.7	3.9	7.1	8.4	0.5	0.0	73.3	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.2	1.9	3.3	0.1	0.7	0.2	0.4	0.2	0.0	0.6	2.2	0.0	0.0	8.9	0.0	0.1	0.0	0.6	0.0	1.1	1.0	0.5	0.0	0.2	52.2	0.0	40.8	0.1	0.0	0.0	0.0	29.7	0.0	0.0	0.0	11.9	0.0	0.0	1.1	0.0	0.0	0.0	26.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	1.5	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	73.3	0.0	0.0	0.0	0.0	0.0	4.5	6.0	2.2	7.8	5.7	4.2	5.3	4.8	7.7	2.7
ALPP		ENSG00000163283	"Alkaline phosphatase, placental"	P05187	2	232378534-232382889	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	17	"placenta: 240.2"	"Group enriched"	"Detected in some"	6	"HaCaT: 86.1;SiHa: 23.7"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 15.3"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"											"CAB026327, HPA038764, HPA038765, HPA051699"	Enhanced		Approved	"Plasma membrane"	"Intracellular and membrane"			"Plasma membrane"		"CAB026327: , HPA038764: , HPA038765: , HPA051699: "		"unprognostic (4.86e-2)"	"unprognostic (5.19e-3)"	"unprognostic (6.67e-3)"		"unprognostic (2.60e-1)"		"unprognostic (2.44e-3)"		"unprognostic (1.26e-2)"	"prognostic unfavourable (4.33e-4)"	"unprognostic (1.44e-1)"		"unprognostic (4.09e-1)"	"unprognostic (2.12e-1)"		"unprognostic (1.27e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	14.5	0.1	0.0	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	9.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	240.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.0	0.5	1.6	0.5	1.1	0.5	0.3	0.4	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.1	9.7	0.0	0.0	0.0	86.1	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	23.7	8.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	0.7	0.5	0.2	0.5	0.3	0.3	0.3	0.1	1.0	0.4	0.4	1.6	1.1	0.5	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AMER1	"FAM123B, FLJ39827, RP11-403E24.2, WTX"	ENSG00000184675	"APC membrane recruitment protein 1"	Q5JTC6	X	64185117-64205744	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 15.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065214, HPA065265"	Approved		Supported	"Nuclear bodies,Vesicles,Plasma membrane"				"Nuclear bodies"	"Vesicles, Plasma membrane"	"HPA065214: , HPA065265: "	"unprognostic (1.56e-2)"	"unprognostic (8.85e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.74e-1)"	"unprognostic (2.12e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.48e-1)"	"unprognostic (8.02e-2)"	"unprognostic (1.75e-1)"	"unprognostic (6.31e-2)"	"unprognostic (3.43e-1)"	"unprognostic (4.69e-4)"	"unprognostic (1.26e-1)"	"unprognostic (1.13e-1)"	"unprognostic (6.19e-2)"	"unprognostic (2.89e-1)"	3.0	3.4	3.0	2.8	5.6	2.3	3.0	8.8	4.9	6.8	4.7	3.1	7.8	3.3	9.8	11.3	6.9	5.2	2.4	3.5	3.0	3.4	4.2	7.1	2.8	2.6	4.5	1.6	15.5	8.1	5.1	3.9	2.0	6.3	4.5	3.2	6.8	7.0	5.3	9.0	4.8	3.7	6.6	2.9	3.7	5.1	1.4	4.3	2.4	3.4	6.5	3.4	4.3	5.7	0.4	0.2	0.0	0.3	2.0	1.0	0.1	2.9	2.2	5.6	4.5	2.2	2.1	4.5	1.4	1.2	2.0	1.3	7.1	1.0	5.6	1.8	2.9	4.1	12.0	3.9	2.0	2.6	2.4	3.4	4.4	4.5	1.6	7.2	0.9	3.0	5.2	1.5	3.1	1.2	5.2	5.7	1.1	3.4	4.7	3.9	15.1	4.3	11.3	9.2	4.1	0.9	0.9	2.5	3.8	3.5	4.8	1.9	1.5	2.1	0.7	2.5	5.8	6.5	1.8	2.9	2.0	4.3	1.1	8.2	0.0	0.0	0.3	0.0	0.4	0.1	0.0	0.4	0.0	0.4	0.0	0.3	1.0	0.0	0.0	2.0	0.0	0.2	0.9	0.1	3.0	5.6	8.8	4.9	3.0	3.4	4.5	1.6	6.3	4.3
AMPH		ENSG00000078053	Amphiphysin	P49418	7	38383704-38631567	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 57.2"	"Cell line enhanced"	"Detected in some"		"ASC diff: 31.8;ASC TERT1: 18.8;BJ hTERT+ SV40 Large T+: 12.3;BJ hTERT+ SV40 Large T+ RasG12V: 14.6;HBF TERT88: 11.3;HSkMC: 11.0;U-138 MG: 12.1;WM-115: 10.8"	"Cancer enhanced"	"Detected in many"		"glioma: 3.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008559, HPA019828, HPA019829"	Enhanced		Supported	"Plasma membrane,Cytosol"				Cytosol	"Plasma membrane"	"CAB008559: AB_1611845, HPA019828: AB_1844801, HPA019829: AB_1844802"	"unprognostic (1.76e-2)"	"unprognostic (1.59e-1)"	"unprognostic (5.94e-2)"	"unprognostic (7.36e-2)"	"unprognostic (3.24e-3)"	"unprognostic (2.92e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.55e-2)"	"unprognostic (4.37e-1)"	"unprognostic (1.08e-1)"	"prognostic favourable (9.96e-4)"	"unprognostic (5.06e-2)"	"unprognostic (5.81e-5)"	"unprognostic (1.23e-2)"	"unprognostic (5.63e-2)"	"unprognostic (8.03e-2)"	"unprognostic (1.68e-3)"	3.8	2.4	17.4	2.5	17.7	1.0	2.8	29.7	57.2	7.7	2.2	1.8	0.0	1.4	5.1	4.7	4.5	5.7	4.2	6.5	13.5	16.0	3.7	1.4	1.6	1.3	10.4	20.4	1.7	2.9	1.2	12.6	1.0	26.5	2.4	2.5	4.8	1.5	4.2	2.9	1.3	1.9	5.0	4.9	1.9	2.0	3.5	1.5	0.0	1.2	0.2	1.1	2.9	1.7	0.2	1.6	0.0	0.8	0.7	2.9	0.2	0.0	0.0	8.0	0.0	31.8	18.8	0.0	1.1	0.0	12.3	14.6	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	11.3	0.0	0.9	0.1	0.0	0.0	0.0	0.1	0.0	11.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.1	0.0	0.1	4.0	0.0	0.0	0.0	0.9	0.0	0.0	2.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	12.1	8.5	4.2	4.5	0.0	0.1	0.0	8.2	0.1	10.8	0.0	0.8	0.0	2.9	0.2	1.7	0.0	1.0	1.5	0.2	0.2	0.4	2.0	0.0	0.7	0.2	1.6	0.2	0.2	17.4	17.7	29.7	32.9	13.5	16.0	10.4	20.4	26.5	1.5
ANAPC1	"APC1, MCPR, TSG24"	ENSG00000153107	"Anaphase promoting complex subunit 1"	Q9H1A4	2	111611639-111884690	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, Cell division, Mitosis, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036329, HPA036330, HPA042998"	Approved		Approved	Vesicles				Vesicles		"HPA036329: AB_10670714, HPA036330: , HPA042998: "	"unprognostic (1.74e-1)"	"unprognostic (5.04e-2)"	"unprognostic (1.10e-2)"	"prognostic unfavourable (1.34e-4)"	"unprognostic (3.49e-1)"	"unprognostic (2.15e-1)"	"unprognostic (2.16e-4)"	"unprognostic (1.23e-1)"	"unprognostic (3.94e-2)"	"unprognostic (2.59e-1)"	"unprognostic (3.65e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.92e-1)"	4.9	4.4	3.2	6.1	4.4	4.3	5.8	6.0	4.6	4.9	6.0			5.6	5.6	2.5	6.5	5.2	3.4	4.5	3.5	3.2	3.8	4.0	4.1	7.5	3.0		6.7	5.3	8.7	4.1	4.8		4.1	7.3		4.7	3.7	7.5	5.2	5.5	4.8	2.9	6.0	4.5	6.5			3.9		8.4	5.4	4.9	6.3	5.6	0.7	3.0	6.4	8.7	4.5	18.1	12.9	14.5	10.1	6.1	8.1	14.3	11.0	7.9	13.6	11.9	25.8	11.7	30.9	9.0	9.8	15.6	21.9	12.0	17.3	13.8	12.4	33.1	12.4	13.9	6.3	35.9	11.9	5.6	5.7	20.0	18.8	12.3	31.0	13.6	9.2	7.6	20.8	9.1	22.0	11.1	21.8	16.9	17.6	7.4	17.4	11.9	6.9	11.2	9.9	9.5	6.4	12.3	8.6	11.3	12.8	9.6	11.4	10.5	21.0	28.3	9.5	15.2	9.6	0.0	2.7	0.7	5.9	3.0	8.7	6.3	5.3	5.0	5.6	4.2	8.6	7.3	0.5	6.4	2.4	2.2	2.3	4.5										
ANG	"RAA1, RNASE5"	ENSG00000214274	Angiogenin	P03950	14	20684177-20698971	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Angiogenesis, Differentiation, Stress response"	"Developmental protein, DNA-binding, Endonuclease, Hydrolase, Nuclease, Protein synthesis inhibitor"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	18	"liver: 371.4"	"Cell line enriched"	"Detected in many"	5	"Hep G2: 56.6"	"Cancer enriched"	"Detected in all"	17	"liver cancer: 279.2"	"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 18.1;myeloid DC: 10.4"	"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in many"			HPA055896			Approved	"Nucleoli,Actin filaments"	"Secreted to blood"	230000000	230000000	Nucleoli	"Actin filaments"	"HPA055896: "	"unprognostic (2.50e-2)"	"unprognostic (1.82e-1)"	"unprognostic (9.77e-2)"	"prognostic favourable (6.85e-4)"	"unprognostic (5.71e-3)"	"unprognostic (6.99e-2)"	"prognostic favourable (7.83e-5)"	"unprognostic (1.16e-1)"	"unprognostic (3.20e-3)"	"unprognostic (9.19e-3)"	"unprognostic (1.31e-1)"	"unprognostic (3.69e-1)"	"unprognostic (6.65e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.39e-1)"	"unprognostic (2.00e-1)"	"unprognostic (3.09e-1)"	17.0	0.9	0.7	2.6	0.7	0.7	16.4	0.5	0.7	14.4	9.0	0.7	6.6	3.5	10.7	10.3	8.0	3.8	13.3	3.8	0.8	0.7	10.6	371.4	6.9	2.3	1.0	0.1	17.7	9.0	1.3	1.1	1.9	0.8	17.5	6.5	5.5	20.2	7.7	3.5	4.0	7.4	9.7	1.5	1.5	7.9	7.1	0.4	0.0	4.2	5.5	3.6	14.3	15.0	4.5	10.4	0.3	18.1	0.0	0.9	4.8	1.4	3.7	0.9	0.0	9.3	11.2	0.1	1.6	3.2	0.4	1.5	2.2	1.9	0.1	0.4	4.5	1.4	1.0	1.1	0.5	6.2	1.4	0.3	2.0	56.6	2.0	1.4	0.2	9.0	0.9	0.5	1.9	2.1	0.0	10.4	1.3	0.2	0.3	0.4	0.2	4.1	0.2	1.5	4.2	0.9	1.1	0.0	0.1	1.6	0.6	2.5	1.5	0.2	1.8	0.6	1.1	0.5	0.2	2.2	1.7	0.2	1.1	0.7	1.8	0.0	18.1	0.0	0.3	2.1	0.2	4.5	0.9	0.8	10.4	2.4	0.2	0.2	0.3	0.0	0.1	1.6	0.4	4.8	0.7	0.7	0.5	0.6	0.8	0.7	1.0	0.1	0.8	0.4
ANGPT1	"Ang1, KIAA0003"	ENSG00000154188	"Angiopoietin 1"	Q15389	8	107249482-107498055	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 30.2;HEL: 16.9;HSkMC: 50.2;U-138 MG: 24.2;WM-115: 15.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	4	"neutrophil: 9.3"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 9.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017815, HPA018793, HPA018816"	Approved				"Secreted to blood"					"CAB017815: , HPA018793: AB_1844820, HPA018816: AB_1844821"	"unprognostic (7.71e-2)"	"unprognostic (2.13e-1)"	"unprognostic (6.37e-2)"	"unprognostic (4.11e-3)"	"unprognostic (7.36e-2)"	"unprognostic (3.80e-2)"	"unprognostic (2.22e-3)"	"unprognostic (3.29e-2)"	"unprognostic (1.07e-2)"	"unprognostic (5.54e-2)"	"unprognostic (2.62e-1)"	"unprognostic (1.44e-1)"	"prognostic favourable (4.40e-4)"	"unprognostic (4.56e-3)"	"unprognostic (1.69e-1)"	"unprognostic (3.24e-1)"	"unprognostic (1.76e-1)"	23.3	3.9	3.4	5.4	2.3	0.4	5.9	14.2	2.6	9.1	3.8	5.1	22.3	1.4	2.9	8.0	7.3	3.2	11.2	5.8	8.5	2.1	8.0	1.4	25.1	0.8	2.4	4.3	7.3	1.5	1.2	35.0	14.2	6.2	23.8	2.3	13.0	7.6	28.5	14.1	1.9	2.6	5.2	4.7	7.4	5.2	2.3	4.7	0.7	5.2	3.1	0.7	5.8	5.6	0.3	0.5	9.3	2.2	0.3	0.4	1.1	0.0	0.8	3.1	1.8	30.2	10.5	2.3	10.0	8.5	2.7	4.0	2.0	0.0	0.0	0.0	5.2	0.0	1.3	0.0	3.5	0.0	0.4	16.9	0.2	0.0	8.6	0.2	0.0	50.2	0.0	1.7	0.2	0.2	9.0	1.8	3.5	0.0	0.3	2.5	3.2	0.3	0.0	0.0	1.0	0.0	0.0	0.0	1.4	0.3	0.2	0.0	0.7	0.0	0.1	24.2	0.3	0.8	0.2	0.1	1.0	0.0	3.4	0.3	15.8	0.3	2.0	0.0	0.3	2.2	0.4	0.1	0.3	0.3	0.5	0.3	0.1	0.1	9.3	0.3	0.9	0.5	0.1	1.1	3.4	2.3	14.2	2.6	8.5	2.1	2.4	4.3	6.2	4.7
ANGPT2	Ang2	ENSG00000091879	"Angiopoietin 2"	O15123	8	6499651-6563409	"Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"HMC-1: 9.9;HSkMC: 23.6;HUVEC TERT2: 36.5;WM-115: 11.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB011437, CAB017626"	Approved				"Secreted to blood"	31000	31000			"CAB011437: , CAB017626: AB_1118956"	"unprognostic (1.28e-1)"	"prognostic unfavourable (7.99e-5)"	"unprognostic (1.93e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.85e-1)"	"unprognostic (4.86e-2)"	"prognostic unfavourable (6.36e-5)"	"unprognostic (1.66e-3)"	"prognostic unfavourable (4.48e-4)"	"unprognostic (2.94e-3)"	"unprognostic (6.19e-3)"	"unprognostic (1.38e-1)"	"prognostic unfavourable (1.52e-7)"	"prognostic unfavourable (3.87e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.46e-2)"	"unprognostic (6.44e-2)"	15.8	0.8	5.3	5.0	20.6	0.6	17.9	10.4	19.5	9.3	3.5	0.5	2.2	1.6	6.2	2.8	3.8	5.8	7.2	10.1	6.1	5.9	3.0	4.1	4.6	8.3	13.1	1.0	3.0	1.2	1.9	1.1	20.0	20.8	4.3	2.7	0.5	2.8	4.4	17.7	3.3	2.6	9.9	9.4	2.3	2.3	1.4	12.4	2.9	10.5	2.2	3.9	14.8	8.1	1.9	1.1	5.4	0.7	0.8	1.2	0.2	0.0	0.1	0.1	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	2.5	0.2	0.0	0.5	0.0	9.9	23.6	0.0	0.0	0.0	36.5	0.0	0.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	11.9	5.4	0.7	0.6	0.9	0.4	0.9	0.7	0.8	0.8	0.1	1.9	0.9	1.2	0.8	0.8	0.4	1.1	0.2	0.2	5.3	20.6	10.4	19.5	6.1	5.9	13.1	1.0	20.8	12.4
ANK3		ENSG00000151150	"Ankyrin 3"	Q12955	10	60026298-60733490	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Autism spectrum disorder, Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 95.4;parathyroid gland: 74.4"	"Cell line enhanced"	"Detected in many"		"RT4: 24.3;SK-BR-3: 24.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											"CAB013249, CAB015179, HPA038455"	Enhanced		Supported	"Plasma membrane"				"Plasma membrane"		"CAB013249: AB_2533145, CAB015179: AB_633909, HPA038455: "	"unprognostic (1.91e-1)"	"unprognostic (5.33e-3)"	"unprognostic (6.76e-3)"	"unprognostic (1.94e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.70e-3)"	"unprognostic (3.47e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.21e-2)"	"unprognostic (3.83e-1)"	"unprognostic (2.28e-2)"	"prognostic favourable (8.88e-16)"	"unprognostic (5.75e-2)"	"unprognostic (2.59e-1)"	"unprognostic (1.00e-1)"	"unprognostic (2.83e-2)"	2.7	3.1	21.1	3.1	24.8	1.1	9.1	95.4	29.1	5.5	10.5	21.5	19.4	15.7	9.7	52.9	7.1	8.2	8.9	31.2	24.4	16.4	38.9	6.6	10.1	2.5	26.8	19.8	5.2	5.0	74.4	10.5	31.9	31.9	8.6	8.8	6.5	16.1	19.4	29.2	16.0	10.6	5.9	16.5	5.9	6.3	3.4	30.0	0.6	17.2	4.6	3.4	5.6	6.6	6.2	3.5	1.7	0.4	2.1	7.7	1.3	4.1	2.4	15.0	0.2	0.0	0.9	11.6	0.3	0.2	0.0	0.3	10.7	8.1	0.2	4.9	0.3	5.9	8.0	7.2	0.2	0.2	5.4	0.1	4.6	0.0	3.1	0.0	0.2	7.4	4.6	3.8	0.2	1.7	2.0	10.1	3.4	13.8	0.0	0.4	6.8	13.0	0.0	10.8	2.0	2.7	24.3	7.8	1.4	0.3	24.4	0.0	14.2	0.0	4.9	0.4	1.5	6.6	0.7	0.4	0.0	0.0	2.7	0.1	9.3	1.7	0.4	0.6	4.1	0.3	3.7	6.2	7.0	2.2	0.2	1.9	7.7	1.9	1.1	2.1	0.4	3.5	1.0	1.3	21.1	24.8	95.4	29.1	24.4	16.4	26.8	19.8	31.9	30.0
ANKRD12	"FLJ20053, GAC-1, KIAA0874"	ENSG00000101745	"Ankyrin repeat domain 12"	Q6UB98	18	9136228-9285985	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 45.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA040705	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA040705: AB_10673301"	"unprognostic (2.20e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.41e-3)"	"unprognostic (7.25e-2)"	"unprognostic (6.17e-2)"	"prognostic unfavourable (6.71e-4)"	"unprognostic (1.24e-2)"	"unprognostic (1.55e-1)"	"unprognostic (3.38e-1)"	"unprognostic (2.39e-2)"	"unprognostic (4.62e-1)"	"unprognostic (1.56e-1)"	"unprognostic (3.03e-1)"	"unprognostic (1.03e-2)"	17.0	10.9	22.2	23.1	26.1	19.6	15.4	48.1	25.4	17.8	18.8	10.1	18.2	13.7	14.6	15.4	16.1	12.1	16.1	12.3	19.9	13.5	14.7	16.5	14.6	22.1	20.2	18.3	16.3	16.7	15.5	16.4	19.2	17.4	15.9	13.6	9.5	15.7	20.6	25.8	21.8	18.1	17.2	21.3	20.3	15.3	29.3	23.8	11.4	18.2	13.0	19.5	24.2	22.6	18.7	19.2	51.2	10.7	8.8	19.0	5.2	4.1	2.8	3.9	2.6	6.3	6.5	3.2	6.5	6.1	2.3	3.2	2.5	3.2	5.8	3.8	4.5	3.9	2.9	2.5	6.3	6.1	3.5	2.6	2.0	3.7	4.6	6.1	8.5	3.4	5.7	3.3	5.4	3.9	6.0	45.8	5.7	2.3	4.1	4.2	1.4	2.9	3.7	5.5	21.1	3.0	6.6	9.1	3.3	6.4	3.2	4.6	3.9	5.2	8.4	17.3	8.0	13.8	6.0	13.4	20.6	10.8	8.5	3.3	6.5	27.4	8.7	25.5	14.5	7.7	16.1	18.7	18.7	13.9	5.9	17.3	19.0	14.8	51.2	8.8	10.7	19.2	13.0	5.2	22.2	26.1	48.1	25.4	19.9	13.5	20.2	18.3	17.4	23.8
ANXA1	"ANX1, LPC1"	ENSG00000135046	"Annexin A1"	P04083	9	73151757-73170393	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Adaptive immunity, Immunity, Inflammatory response, Innate immunity"	"Phospholipase A2 inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 432.6;tongue: 235.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011271, HPA011272, CAB013023, CAB035987, CAB058693"	Enhanced		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	77000000	77000000	"Plasma membrane, Cytosol"	Nucleoplasm	"CAB013023: AB_2533983, CAB035987: , CAB058693: , HPA011271: AB_1844883, HPA011272: AB_1844884"	"unprognostic (2.53e-2)"	"unprognostic (1.31e-1)"	"unprognostic (9.08e-2)"	"prognostic favourable (5.71e-5)"	"unprognostic (1.53e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.54e-3)"	"unprognostic (1.47e-1)"	"unprognostic (9.82e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.55e-2)"	"prognostic favourable (4.57e-5)"	"prognostic unfavourable (6.19e-6)"	52.7	3.5	2.7	11.5	3.3	81.4	45.9	0.9	2.5	61.5	8.5	3.6	5.5	2.4	6.9	11.2	432.6	11.9	14.9	8.9	3.2	2.5	9.1	2.1	37.3	7.6	4.3	1.9	11.7	2.4	0.5	6.3	149.5	13.5	12.9	4.4	6.4	93.0	7.2	7.9	11.6	6.4	12.3	6.5	5.9	5.9	5.6	3.1	3.9	21.7	235.4	153.3	18.0	83.1	0.7	98.9	146.2	79.1	27.3	52.5	102.8	65.9	104.2	4.7	4.9	66.5	63.3	0.3	114.3	71.4	47.3	32.1	3.0	59.7	0.1	37.8	99.7	81.2	10.1	69.2	37.5	37.3	0.7	5.0	31.0	0.1	53.1	11.0	2.5	36.4	57.4	47.8	94.0	67.0	20.9	2.8	58.3	0.2	19.4	6.0	5.9	42.4	0.0	26.6	0.2	106.4	14.0	0.0	0.0	39.3	1.0	26.4	0.2	1.7	82.7	55.5	34.9	76.2	58.6	0.4	0.1	0.2	128.1	10.2	83.4	146.2	79.1	141.1	52.2	21.5	52.5	0.7	47.0	45.9	98.9	0.2	13.7	25.4	8.6	27.3	19.3	3.5	8.3	102.8	2.7	3.3	0.9	2.5	3.2	2.5	4.3	1.9	13.5	3.1
ANXA11	ANX11	ENSG00000122359	"Annexin A11"	P50995	10	80150889-80205572	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division"		"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB004851, HPA027545"	Supported		Supported	Nucleoplasm,Cytosol		530000	530000	Nucleoplasm	Cytosol	"CAB004851: AB_626682, HPA027545: AB_1844851"	"unprognostic (1.85e-2)"	"unprognostic (2.85e-2)"	"unprognostic (5.35e-3)"	"unprognostic (5.06e-2)"	"unprognostic (8.18e-3)"	"unprognostic (1.99e-1)"	"unprognostic (4.01e-3)"	"unprognostic (6.28e-2)"	"unprognostic (2.32e-2)"	"unprognostic (4.88e-2)"	"unprognostic (3.46e-2)"	"unprognostic (2.56e-2)"	"prognostic favourable (6.69e-8)"	"unprognostic (2.69e-3)"	"unprognostic (1.84e-1)"	"unprognostic (6.79e-2)"	"unprognostic (2.02e-1)"	44.1	7.3	19.4	27.8	23.8	37.0	61.1	22.8	24.4	26.4	34.4	8.6	18.4	28.6	20.2	36.4	49.5	23.9	47.5	57.1	17.2	8.3	39.1	21.9	35.1	38.1	10.8	14.2	27.3	24.0	26.2	9.7	35.0	7.5	28.9	27.6	16.7	20.2	27.8	39.5	18.6	44.1	28.1	11.2	22.9	29.3	15.1	6.6	45.7	18.9	39.2	31.8	34.9	39.6	12.7	14.4	77.9	12.1	11.6	21.9	13.0	34.7	30.5	1.8	9.0	39.1	38.6	19.5	26.0	67.0	16.2	16.8	27.6	54.4	2.3	18.8	38.9	45.5	7.8	21.7	9.8	59.1	13.9	14.2	18.1	21.4	22.9	15.6	35.3	40.7	13.2	9.0	6.9	23.0	13.9	26.4	12.8	20.7	19.0	34.5	3.3	64.7	14.5	2.7	52.6	27.4	32.3	0.8	6.3	11.2	45.0	25.4	13.3	19.2	27.7	11.4	17.1	26.0	13.6	16.1	21.9	15.1	11.9	26.1	7.5	22.6	12.1	77.9	14.5	9.6	15.3	12.7	18.3	20.3	9.1	10.9	17.3	14.9	43.8	11.6	10.7	14.4	21.9	13.0	19.4	23.8	22.8	24.4	17.2	8.3	10.8	14.2	7.5	6.6
ANXA2	"ANX2, ANX2L4, CAL1H, LIP2, LPC2D"	ENSG00000182718	"Annexin A2"	P07355	15	60347134-60402883	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Host-virus interaction"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB004311, HPA046964, HPA061798"	Enhanced		Approved	"Plasma membrane,Cytosol"	"Secreted to blood"	16000000	16000000	"Plasma membrane"	Cytosol	"CAB004311: AB_626677, HPA046964: AB_2732537, HPA061798: AB_2732671"	"unprognostic (1.61e-1)"	"unprognostic (1.31e-3)"	"unprognostic (1.84e-1)"	"prognostic favourable (6.88e-5)"	"unprognostic (4.06e-3)"	"unprognostic (5.42e-3)"	"prognostic unfavourable (2.54e-5)"	"prognostic unfavourable (7.51e-4)"	"unprognostic (2.94e-1)"	"unprognostic (4.10e-3)"	"prognostic unfavourable (8.47e-6)"	"unprognostic (5.16e-2)"	"prognostic unfavourable (2.11e-6)"	"unprognostic (7.74e-2)"	"unprognostic (2.55e-1)"	"unprognostic (7.41e-2)"	"prognostic unfavourable (6.59e-5)"	91.7	29.8	4.9	23.5	7.1	6.6	50.1	4.5	5.6	65.1	39.1	8.6	38.2	26.4	38.3	40.3	158.8	26.2	54.9	29.9	4.7	5.5	36.7	28.5	62.0	46.6	10.8	5.7	23.3	94.3	29.7	12.8	84.1	25.7	29.5	35.2	31.7	74.7	27.9	22.7	77.3	71.9	37.1	15.1	32.6	25.6	18.7	7.1	14.6	31.0	122.7	81.4	34.0	87.4	35.5	209.6	183.3	138.0	15.2	83.9	150.8	142.1	158.7	8.4	3.7	114.7	184.1	36.5	169.9	109.6	108.0	94.8	75.2	68.6	0.3	139.9	219.8	152.1	37.3	319.1	118.4	30.3	3.9	2.8	76.4	29.2	69.2	0.1	2.1	89.8	87.1	76.7	165.4	201.2	11.3	16.6	230.6	16.5	0.6	8.4	18.2	123.6	1.6	46.1	7.9	191.4	86.7	11.0	6.2	67.2	15.3	66.7	32.8	5.9	229.5	92.1	125.5	308.8	166.8	6.2	20.3	2.7	86.8	1.6	183.2	183.3	138.0	17.7	33.4	122.6	36.5	35.5	38.5	38.5	209.6	16.9	4.5	18.1	3.9	15.2	129.1	32.0	83.9	150.8	4.9	7.1	4.5	5.6	4.7	5.5	10.8	5.7	25.7	7.1
ANXA4	ANX4	ENSG00000196975	"Annexin A4"	P09525	2	69644425-69827100	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"gallbladder: 212.1;pancreas: 160.1"	"Cell line enhanced"	"Detected in many"		"EFO-21: 67.4;Hep G2: 70.3;RPTEC TERT1: 98.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB005076, HPA007393, CAB017560"	Enhanced		Approved	Cytosol		580000	580000	Cytosol		"CAB005076: AB_630869, CAB017560: AB_2227370, HPA007393: AB_1078168"	"prognostic unfavourable (8.55e-4)"	"unprognostic (3.37e-2)"	"unprognostic (4.82e-2)"	"unprognostic (9.03e-2)"	"unprognostic (1.62e-3)"	"unprognostic (1.66e-1)"	"unprognostic (3.57e-1)"	"unprognostic (3.21e-1)"	"unprognostic (4.52e-2)"	"prognostic unfavourable (2.38e-4)"	"unprognostic (7.23e-3)"	"unprognostic (1.29e-1)"	"prognostic unfavourable (6.05e-4)"	"unprognostic (1.79e-1)"	"unprognostic (8.85e-2)"	"unprognostic (3.60e-2)"	"unprognostic (3.97e-2)"	18.7	5.9	4.2	12.2	4.3	4.1	9.7	1.3	3.0	16.9	32.7	5.3	12.9	43.2	22.8	11.5	16.1	11.9	212.1	6.8	4.3	3.1	36.2	30.9	19.2	5.9	5.1	2.4	12.3	160.1	5.8	3.3	50.9	11.8	18.1	14.9	10.3	11.7	11.4	6.9	12.9	85.7	12.3	6.5	7.2	16.9	5.6	3.6	4.0	24.7	12.9	8.3	11.0	13.2	17.6	21.3	27.6	23.7	3.6	10.3	8.9	10.7	39.0	0.5	4.8	30.0	25.9	1.8	10.4	15.7	4.2	6.1	5.8	19.4	3.5	67.4	16.9	16.6	3.7	16.7	4.5	9.9	3.1	5.3	3.5	70.3	21.3	1.8	6.9	15.4	16.6	5.8	14.1	11.0	0.3	3.2	11.7	9.7	2.7	3.4	0.9	5.4	2.9	1.0	4.3	98.6	15.6	0.8	3.6	11.5	16.0	15.7	5.3	24.3	15.9	7.9	3.8	10.5	5.8	1.3	1.4	0.1	12.3	9.2	5.3	27.6	14.8	11.9	10.3	17.4	7.8	17.6	5.3	7.7	21.3	15.9	0.9	5.8	2.0	3.6	23.7	6.4	5.9	8.9	4.2	4.3	1.3	3.0	4.3	3.1	5.1	2.4	11.8	3.6
ANXA7	ANX7	ENSG00000138279	"Annexin A7"	P20073	10	73375101-73414076	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"PC-3: 122.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004312, HPA064290"	Approved		Approved	Nucleoplasm,Cytosol		540000	540000	Nucleoplasm	Cytosol	"CAB004312: AB_626681, HPA064290: "	"unprognostic (1.48e-1)"	"unprognostic (4.70e-2)"	"unprognostic (1.90e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.06e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.67e-1)"	"prognostic favourable (1.98e-4)"	"unprognostic (1.63e-1)"	"unprognostic (8.37e-2)"	"unprognostic (6.93e-2)"	"unprognostic (3.06e-2)"	27.4	27.1	28.0	18.5	28.7	24.1	29.3	23.5	33.1	25.2	21.1	25.0	15.5	13.0	25.1	28.2	24.7	19.7	20.7	36.6	27.2	26.8	39.4	40.8	21.5	33.0	26.0	28.8	26.2	24.2	103.3	28.1	23.3	24.9	24.1	25.4	22.8	26.0	25.3	75.4	21.5	17.3	32.3	25.4	21.3	18.0	11.7	15.5	17.1	30.2	28.2	26.7	27.6	20.5	35.3	36.4	53.0	34.9	33.0	44.4	42.5	24.2	17.6	6.9	16.8	27.0	26.6	15.0	16.2	42.9	21.3	18.0	25.6	28.8	9.7	16.5	30.6	20.4	12.8	19.2	21.2	23.9	9.5	13.7	8.8	22.8	23.8	19.5	6.3	16.5	18.7	26.6	47.7	18.9	17.8	27.6	27.0	19.4	11.0	12.6	7.7	122.1	9.1	19.6	17.6	36.9	14.9	5.5	7.6	18.3	42.3	15.3	26.4	10.4	17.6	8.7	15.8	26.3	20.9	17.9	25.4	13.7	20.6	25.3	6.7	53.0	34.9	45.1	22.2	26.2	30.1	35.3	34.4	27.7	36.4	24.0	31.5	27.7	35.4	33.0	25.6	15.6	44.4	42.5	28.0	28.7	23.5	33.1	27.2	26.8	26.0	28.8	24.9	15.5
AOC3	"HPAO, VAP-1, VAP1"	ENSG00000131471	"Amine oxidase, copper containing 3"	Q16853	17	42851184-42858130	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	18	"ASC diff: 83.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	13	"neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	13	"granulocytes: 1.2"	"Low region specificity"	"Detected in many"							"HPA000980, CAB025797"	Enhanced		Approved	"Golgi apparatus,Cytosol"	"Secreted - unknown location"	240000000	240000000	Cytosol	"Golgi apparatus"	"CAB025797: , HPA000980: AB_1078170"	"unprognostic (2.20e-1)"	"unprognostic (4.49e-2)"	"prognostic unfavourable (3.68e-4)"	"unprognostic (2.97e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.15e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.00e-2)"	"unprognostic (2.95e-1)"	"unprognostic (9.02e-2)"	"prognostic unfavourable (1.79e-5)"	"unprognostic (5.61e-2)"	"unprognostic (1.67e-1)"	"unprognostic (8.39e-2)"	"prognostic unfavourable (6.98e-4)"	97.0	11.5	0.4	18.7	1.0	0.0	67.7	0.5	1.3	26.9	44.3	1.0	16.3	3.6	44.7	34.8	36.1	18.5	50.9	12.1	0.4	0.4	5.8	8.3	48.0	7.9	0.5	1.2	23.8	2.4	2.2	1.3	10.8	2.0	36.5	9.4	32.1	8.0	24.7	7.7	5.5	15.0	79.2	0.6	7.5	17.7	16.2	0.3	1.0	6.6	11.6	2.6	75.9	20.9	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	83.5	0.1	1.3	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.2	0.0	0.1	0.2	0.0	0.2	0.3	1.4	0.1	0.1	4.6	0.2	0.0	0.2	0.9	0.2	0.1	0.2	0.0	0.0	0.4	0.1	0.0	0.0	0.3	0.1	0.1	0.2	0.2	0.7	0.0	0.5	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.7	0.3	0.1	1.2	1.3	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	1.0	0.5	1.3	0.4	0.4	0.5	1.2	2.0	0.3
AP2B1	"ADTB2, CLAPB1"	ENSG00000006125	"Adaptor related protein complex 2 beta 1 subunit"	P63010	17	35578046-35726409	"Cancer-related genes, Predicted intracellular proteins"	"Endocytosis, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017631, HPA056733, HPA067983"	Approved		Supported	Vesicles		680000	680000	Vesicles		"CAB017631: AB_2058201, HPA056733: , HPA067983: "	"unprognostic (1.49e-2)"	"unprognostic (4.04e-3)"	"unprognostic (2.15e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.01e-2)"	"unprognostic (1.51e-3)"	"unprognostic (2.64e-2)"	"unprognostic (1.06e-1)"	"unprognostic (4.73e-2)"	"unprognostic (2.58e-2)"	"unprognostic (2.50e-1)"	"prognostic favourable (2.62e-4)"	"unprognostic (1.70e-1)"	"unprognostic (1.10e-1)"	"unprognostic (3.25e-2)"	"unprognostic (1.57e-2)"	20.1	19.9	36.6	16.3	51.3	18.6	27.6	32.8	59.0	27.8	29.8	35.2	17.0	15.1	20.0	33.1	13.1	22.9	20.2	30.3	36.8	36.1	32.9	16.0	23.6	16.0	35.5	39.9	28.7	15.4	75.6	30.0	30.6	40.7	20.0	39.0	21.8	18.7	25.3	23.3	13.1	16.7	26.1	37.0	18.4	21.6	45.3	27.4	18.5	31.5	10.6	20.1	19.6	21.5	12.6	10.7	15.8	15.4	9.5	19.4	10.3	42.4	54.5	28.1	32.9	46.4	51.0	12.0	21.9	33.5	32.3	34.9	30.5	37.2	20.7	19.5	40.8	40.6	38.4	62.8	46.2	24.7	35.5	28.0	39.9	16.6	26.6	26.9	19.8	32.5	24.9	32.7	49.7	50.8	42.4	30.0	50.5	8.6	26.1	13.1	22.6	39.3	22.0	40.1	15.1	40.7	24.6	23.1	28.4	27.2	9.6	29.9	39.2	18.2	50.4	24.6	22.7	26.5	32.7	12.7	23.0	19.5	31.5	20.1	26.0	15.0	11.3	15.8	16.6	15.4	17.8	12.6	14.9	14.9	10.6	11.5	6.9	8.7	13.3	9.5	15.1	10.7	19.4	10.3	36.6	51.3	32.8	59.0	36.8	36.1	35.5	39.9	40.7	27.4
APAF1	"APAF-1, CED4"	ENSG00000120868	"Apoptotic peptidase activating factor 1"	O14727	12	98645141-98735433	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 33.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031373, CAB069399"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus,Cytosol"				"Nucleoplasm, Cytosol"	"Golgi apparatus"	"CAB069399: AB_1611908, HPA031373: AB_10602230"	"unprognostic (1.32e-1)"	"unprognostic (5.12e-2)"	"prognostic favourable (5.90e-4)"	"unprognostic (2.21e-1)"	"unprognostic (3.94e-1)"	"unprognostic (8.21e-3)"	"unprognostic (2.03e-3)"	"unprognostic (1.35e-1)"	"unprognostic (2.26e-2)"	"unprognostic (5.92e-3)"	"unprognostic (5.63e-2)"	"unprognostic (6.04e-2)"	"unprognostic (9.93e-3)"	"unprognostic (3.47e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.53e-2)"	"unprognostic (3.07e-2)"	10.5	4.7	10.3	11.0	11.0	36.1	8.8	13.4	11.5	10.8	11.6	8.2	5.5	7.0	10.6	7.5	6.2	6.3	11.6	5.8	10.2	8.6	5.8	6.8	11.8	11.2	8.8	6.7	10.8	7.4	5.7	6.2	10.1	8.2	9.1	12.9	8.5	8.2	6.4	6.0	7.5	14.9	7.2	10.9	15.9	8.6	6.1	9.3	15.7	7.0	3.9	14.2	9.5	9.0	2.8	6.3	33.0	8.7	1.1	1.9	1.5	4.3	6.6	20.2	7.7	6.9	12.2	5.6	11.0	8.3	8.4	8.5	4.2	3.2	6.6	3.1	9.2	7.3	14.1	8.0	10.6	4.6	5.7	12.0	6.3	5.2	2.4	11.7	15.5	5.0	2.5	8.5	4.4	14.4	5.6	3.4	12.3	1.2	6.2	12.3	5.5	3.8	7.8	16.1	2.1	4.9	7.8	2.9	5.0	8.6	3.6	3.2	6.3	17.6	11.1	5.7	4.5	6.5	3.5	2.3	4.3	7.3	2.2	16.5	7.5	6.2	8.7	7.2	1.9	3.6	1.5	2.4	1.4	1.1	6.3	2.8	1.4	0.9	33.0	1.1	3.6	4.6	0.9	1.5	10.3	11.0	13.4	11.5	10.2	8.6	8.8	6.7	8.2	9.3
APC	"DP2, DP2.5, DP3, PPP1R46"	ENSG00000134982	"APC, WNT signaling pathway regulator"	P25054	5	112707498-112846239	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 40.9"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA013349	Supported									"HPA013349: AB_1844913"	"unprognostic (4.80e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.72e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.10e-1)"	"unprognostic (7.09e-3)"	"unprognostic (1.62e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.35e-1)"	"unprognostic (4.85e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.35e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.96e-1)"	7.2	5.4	40.9	6.4	21.7	8.5	6.3	19.1	39.7	6.8	7.1	10.3	2.0	6.6	6.3	3.9	8.4	5.0	5.5	7.4	37.9	12.9	6.9	6.2	6.7	5.6	23.6	20.7	7.6	4.6	13.8	7.2	5.5	39.1	5.9	6.9	4.0	4.0	4.9	7.0	6.1	8.8	8.1	19.1	6.2	5.4	5.3	20.6	3.6	6.5	2.7	6.2	6.2	3.9	3.8	3.0	12.9	2.9	3.0	3.4	1.1	8.3	7.7	12.8	9.3	10.6	8.8	5.2	13.5	6.4	7.5	8.9	6.1	6.8	16.1	13.1	17.2	6.8	13.1	11.0	12.4	9.6	8.9	12.2	11.1	4.6	5.2	6.1	6.7	7.4	7.6	12.7	8.4	10.4	15.0	5.6	10.9	5.8	7.0	3.1	4.6	2.7	6.0	15.9	7.8	6.9	10.6	13.0	7.8	12.8	5.0	5.5	6.9	5.0	16.6	15.3	7.4	15.0	10.2	4.4	6.6	6.3	8.5	11.4	8.5	10.4	2.9	5.0	3.4	1.4	2.9	3.1	1.8	2.1	2.3	3.8	2.9	2.8	12.9	3.0	2.5	3.0	1.6	1.1	40.9	21.7	19.1	31.4	37.9	12.9	23.6	20.7	39.1	20.6
APEX1	"APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1"	ENSG00000100823	"Apurinic/apyrimidinic endodeoxyribonuclease 1"	P27695	14	20455191-20457772	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair, Transcription, Transcription regulation"	"Activator, DNA-binding, Endonuclease, Exonuclease, Hydrolase, Lyase, Nuclease, Repressor, RNA-binding"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA000956, HPA002564, CAB004294, CAB047307"	Supported		Supported	Nucleoplasm		98000	98000	Nucleoplasm		"CAB004294: AB_626685, CAB047307: , HPA000956: , HPA002564: AB_1078174"	"unprognostic (2.80e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.55e-2)"	"unprognostic (4.74e-3)"	"unprognostic (1.97e-2)"	"unprognostic (5.88e-2)"	"prognostic unfavourable (7.82e-5)"	"unprognostic (4.21e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.42e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.83e-2)"	"unprognostic (2.54e-1)"	"unprognostic (7.08e-2)"	43.9	52.8	30.6	33.2	32.5	55.6	43.6	24.1	44.9	38.5	41.9	37.3	28.4	44.1	53.2	30.1	40.7	42.9	46.4	34.4	28.0	27.4	44.4	61.3	31.8	44.5	30.2	31.1	64.7	48.4	31.8	21.7	29.4	34.4	36.1	39.8	36.0	35.5	38.9	53.2	41.2	37.6	40.9	30.1	51.0	41.7	20.9	28.3	73.2	51.2	38.5	48.4	41.8	32.7	35.0	53.0	1.5	23.7	20.6	32.5	38.4	43.9	54.1	48.5	44.7	34.1	49.3	41.8	41.3	44.5	61.6	53.5	39.4	43.7	84.9	36.9	31.5	47.2	57.7	43.7	57.2	37.9	24.6	34.4	32.0	65.6	35.9	109.2	35.8	50.9	48.3	40.1	39.8	51.4	39.9	28.0	49.3	42.8	69.9	46.0	47.8	48.9	77.8	54.5	35.6	51.7	59.3	58.5	37.3	44.8	55.9	44.4	34.0	49.4	33.1	32.5	54.5	32.7	38.5	37.6	65.1	57.3	14.5	69.4	41.0	0.1	23.7	1.5	19.0	20.5	25.9	35.0	23.8	22.6	46.8	31.4	32.5	28.3	1.5	20.6	12.4	53.0	14.1	38.4	30.6	32.5	24.1	44.9	28.0	27.4	30.2	31.1	34.4	28.3
APOA1		ENSG00000118137	"Apolipoprotein A1"	P02647	11	116835751-116837950	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport"		"Amyloidosis, Atherosclerosis, Cancer-related genes, Disease mutation, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"liver: 573.5"	"Cell line enriched"	"Detected in some"	18	"Hep G2: 247.4"	"Cancer enriched"	"Detected in many"	48	"liver cancer: 4515.8"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 3.6"	"Group enriched"	"Detected in many"	4	"dendritic cells: 3.6;T-cells: 2.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB016778, HPA046715"	Supported		Approved	Vesicles,Cytosol	"Secreted to blood"	220000000000	220000000000	Vesicles	Cytosol	"CAB016778: , HPA046715: "	"unprognostic (1.88e-3)"	"unprognostic (4.53e-2)"	"unprognostic (7.46e-2)"	"unprognostic (4.00e-3)"	"unprognostic (3.70e-2)"	"unprognostic (1.41e-1)"	"prognostic favourable (5.05e-4)"	"unprognostic (5.40e-2)"	"unprognostic (1.89e-1)"	"unprognostic (9.60e-3)"	"unprognostic (1.59e-3)"	"unprognostic (7.02e-2)"	"prognostic unfavourable (1.67e-8)"	"unprognostic (3.46e-3)"	"unprognostic (1.15e-1)"	"unprognostic (6.24e-2)"	"unprognostic (9.54e-2)"	0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	24.6	0.2	0.2	55.6	0.2	0.3	0.2	0.1	0.3	1.3	0.2	0.0	0.2	573.5	0.2	0.2	0.2	0.2	0.7	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.2	0.3	0.2	0.2	0.0	127.9	0.2	0.2	0.4	0.3	11.8	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.5	3.6	0.0	0.7	0.7	2.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	13.8	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	247.4	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.1	0.0	0.0	1.2	1.5	0.0	0.2	0.4	1.7	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.4	0.0	0.4	0.0	0.0	0.2	0.0	2.4	0.7	0.3	0.0	0.2	1.8	0.8	0.5	0.8	1.7	0.0	0.7	0.0	3.6	2.1	0.5	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
APOA2		ENSG00000158874	"Apolipoprotein A2"	P02652	1	161222292-161223631	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Host-virus interaction, Lipid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	321	"liver: 932.2"	"Cell line enriched"	"Detected in some"	9	"Hep G2: 596.2"	"Cancer enriched"	"Detected in many"	329	"liver cancer: 11230.1"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 2.1;neutrophil: 2.9"	"Group enriched"	"Detected in many"	20	"dendritic cells: 1.0;granulocytes: 2.9;monocytes: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			CAB025885	Supported				"Secreted to blood"	210000000000	210000000000			"CAB025885: "		"unprognostic (2.05e-1)"	"unprognostic (4.70e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.99e-1)"		"unprognostic (9.82e-2)"	"unprognostic (1.92e-1)"	"unprognostic (3.16e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.57e-2)"		"unprognostic (4.40e-3)"	"unprognostic (3.16e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.60e-1)"	"unprognostic (6.09e-2)"	0.1	0.0	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.0	0.2	932.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.3	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	1.0	2.9	2.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	65.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	596.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.0	1.1	0.0	0.0	2.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.9	0.0	0.8	0.7	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
APOBEC3B	"FLJ21201, PHRBNL"	ENSG00000179750	"Apolipoprotein B mRNA editing enzyme catalytic subunit 3B"	Q9UH17	22	38982347-38992804	"Cancer-related genes, Predicted intracellular proteins"	"Antiviral defense, Immunity, Innate immunity"	"Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 20.1"	"Cell line enhanced"	"Detected in many"		"A-431: 59.6;Karpas-707: 67.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 10.2"	"Low lineage specificity"	"Detected in many"											"HPA056980, HPA066719"			Approved	Nucleoplasm				Nucleoplasm		"HPA056980: , HPA066719: "	"unprognostic (2.92e-2)"	"prognostic favourable (2.58e-5)"	"unprognostic (4.29e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.35e-1)"	"unprognostic (6.36e-2)"	"unprognostic (1.08e-2)"	"unprognostic (5.88e-2)"	"prognostic unfavourable (2.78e-4)"	"unprognostic (8.47e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.04e-1)"	1.6	2.3	0.3	4.4	2.2	20.1	1.4	0.3	1.2	2.3	9.9	0.7	0.3	5.8	2.0	2.4	4.6	1.2	2.2	1.6	0.6	0.2	3.6	0.9	2.5	4.3	0.3	0.3	1.7	5.7	0.4	0.3	6.4	0.8	2.1	10.0	1.3	4.8	0.3	4.1	1.9	8.8	1.0	0.7	10.4	3.8	2.0	0.3	5.9	3.3	0.3	12.0	2.0	2.4	10.2	0.8	1.7	5.8	2.2	3.8	5.9	59.6	6.7	2.6	16.1	0.3	1.5	4.5	5.5	4.8	10.6	13.9	12.8	10.9	0.6	5.0	5.5	25.6	0.3	1.1	10.7	21.6	0.6	17.2	1.4	3.3	0.1	14.2	10.4	0.5	0.1	11.0	0.5	4.1	9.6	67.6	16.4	1.6	0.0	8.0	0.0	6.0	0.4	25.8	21.5	2.1	10.1	0.4	0.0	0.0	0.0	3.7	7.9	4.1	2.5	11.7	20.4	1.8	0.1	15.0	4.1	0.0	8.3	15.9	23.7	0.5	1.3	0.0	0.3	5.8	0.0	10.2	0.8	0.5	0.8	3.2	0.0	0.4	1.7	2.2	1.8	0.1	3.8	5.9	0.3	2.2	0.3	1.2	0.6	0.2	0.3	0.3	0.8	0.3
APOC1		ENSG00000130208	"Apolipoprotein C1"	P02654	19	44914247-44919349	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Lipid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"liver: 702.7"	"Cell line enhanced"	"Detected in many"		"Hep G2: 98.0;HSkMC: 60.7;K-562: 25.5;SK-MEL-30: 45.2"	"Cancer enriched"	"Detected in all"	21	"liver cancer: 3253.7"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"myeloid DC: 8.9"	"Lineage enriched"	"Detected in single"	13	"dendritic cells: 8.9"	"Low region specificity"	"Detected in many"							HPA051518	Supported				"Secreted to blood"	26000000000	26000000000			"HPA051518: "	"unprognostic (3.51e-2)"	"unprognostic (3.31e-3)"	"unprognostic (1.14e-1)"	"unprognostic (2.59e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.47e-1)"	"prognostic favourable (1.15e-7)"	"unprognostic (9.51e-3)"	"unprognostic (1.30e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.52e-1)"	"unprognostic (7.13e-3)"	"unprognostic (3.48e-3)"	"unprognostic (1.65e-1)"	"unprognostic (2.01e-3)"	"unprognostic (1.65e-1)"	1.5	58.9	6.6	1.6	30.0	2.4	3.6	0.6	4.4	1.5	1.8	4.9	0.3	0.9	0.6	2.5	0.4	0.8	1.8	0.4	4.1	7.8	0.6	702.7	12.6	6.1	20.2	1.0	4.1	1.1	0.4	2.6	2.3	6.6	0.6	1.1	1.3	2.0	0.4	1.2	1.4	1.0	0.5	11.7	9.6	1.3	1.0	5.2	1.0	0.7	0.5	1.9	1.2	0.3	0.2	8.9	0.0	0.6	0.2	0.0	0.6	0.4	4.6	2.1	0.8	6.7	7.0	19.8	0.2	0.3	0.8	1.3	9.7	8.7	1.4	1.7	0.1	0.3	2.7	0.3	0.4	0.0	11.2	6.2	0.6	98.0	6.0	4.6	3.2	60.7	0.5	0.8	0.3	0.2	25.5	0.1	0.3	0.6	0.2	0.3	20.0	0.9	1.0	2.8	0.1	1.2	0.3	0.9	0.5	3.3	0.0	45.2	0.4	17.0	0.7	0.0	0.3	0.0	0.2	0.8	0.8	1.5	0.1	1.3	0.5	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	8.9	0.2	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.6	6.6	30.0	0.6	3.1	4.1	7.8	20.2	1.0	6.6	5.2
APOC3		ENSG00000110245	"Apolipoprotein C3"	P02656	11	116829706-116833072	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism, Lipid transport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"liver: 714.1"	"Group enriched"	"Detected in some"	19	"CACO-2: 27.8;Hep G2: 75.2"	"Cancer enriched"	"Detected in many"	643	"liver cancer: 4021.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"HPA065365, HPA073918"	Supported		Approved	"Nucleoplasm,Nucleoli,Cell Junctions"	"Secreted to blood"	97000000000	97000000000	Nucleoplasm	"Nucleoli, Cell Junctions"	"HPA065365: , HPA073918: "							"prognostic favourable (3.77e-4)"				"unprognostic (2.33e-1)"		"prognostic unfavourable (6.87e-5)"	"unprognostic (1.60e-2)"	"unprognostic (5.21e-2)"			0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	38.7	0.1	0.1	31.7	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.0	0.4	714.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	91.3	0.1	0.1	0.3	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	27.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	75.2	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.6	0.9	0.0	0.0	0.3	1.0	1.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.2	0.1
APOD		ENSG00000189058	"Apolipoprotein D"	P05090	3	195568702-195584205	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"breast: 840.7"	"Group enriched"	"Detected in some"	7	"ASC diff: 233.9;ASC TERT1: 126.0"	"Cancer enhanced"	"Detected in all"		"melanoma: 925.2"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	10	"memory B-cell: 6.7"	"Lineage enriched"	"Detected in single"	10	"B-cells: 6.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA040520	Enhanced		Approved	"Plasma membrane"	"Secreted to blood"	220000000000	220000000000	"Plasma membrane"		"HPA040520: "	"prognostic favourable (5.51e-4)"	"unprognostic (7.62e-3)"	"unprognostic (7.85e-3)"	"unprognostic (3.34e-3)"	"unprognostic (2.20e-1)"	"unprognostic (1.02e-2)"	"unprognostic (3.09e-2)"	"unprognostic (2.06e-3)"	"unprognostic (1.26e-1)"	"unprognostic (3.45e-1)"	"unprognostic (3.38e-1)"	"unprognostic (3.19e-1)"	"unprognostic (6.90e-3)"	"prognostic unfavourable (6.02e-4)"	"unprognostic (1.38e-1)"	"prognostic unfavourable (4.12e-4)"	"unprognostic (1.71e-3)"	134.4	15.2	39.7	5.7	39.9	3.4	840.7	14.7	66.1	75.0	16.4	79.7	10.9	12.9	36.6	30.0	46.1	42.9	36.4	124.7	45.5	29.2	8.5	3.5	11.8	6.5	96.9	28.2	19.4	28.3	9.0	14.3	59.6	50.9	39.7	13.1	99.1	152.5	35.1	110.4	66.0	7.2	30.4	81.6	3.6	28.7	32.0	56.5	0.0	87.7	42.2	6.6	62.1	95.7	6.7	0.1	0.4	0.6	0.0	0.1	0.1	0.0	0.1	0.0	0.0	233.9	126.0	0.3	2.0	0.5	0.0	0.0	12.9	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	6.4	1.4	0.0	1.1	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.3	2.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	25.3	0.4	0.1	0.0	0.1	0.1	0.0	6.7	0.0	0.0	0.0	0.6	0.0	0.0	0.3	0.0	0.6	0.1	0.0	0.1	39.7	39.9	14.7	39.5	45.5	29.2	96.9	28.2	50.9	56.5
APOE	AD2	ENSG00000130203	"Apolipoprotein E"	P02649	19	44905754-44909393	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport"	Heparin-binding	"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Hyperlipidemia, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 226.8;liver: 508.1"	"Cell line enhanced"	"Detected in some"		"ASC diff: 163.3;Hep G2: 75.9;HSkMC: 119.7;SK-MEL-30: 151.8"	"Cancer enhanced"	"Detected in all"		"liver cancer: 3183.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008363, HPA065539, HPA068768, CAB069921"	Enhanced		Approved	Vesicles	"Secreted to blood"	63000000000	63000000000	Vesicles		"CAB008363: AB_590560, CAB069921: AB_920623, HPA065539: AB_2685509, HPA068768: AB_2686029"	"unprognostic (8.98e-2)"	"unprognostic (2.32e-2)"	"unprognostic (2.49e-2)"	"unprognostic (5.28e-2)"	"unprognostic (3.77e-2)"	"unprognostic (7.25e-2)"	"unprognostic (5.22e-3)"	"unprognostic (6.13e-2)"	"unprognostic (5.06e-2)"	"unprognostic (4.13e-1)"	"unprognostic (5.78e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.74e-1)"	"unprognostic (7.76e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.12e-3)"	"unprognostic (4.13e-2)"	76.8	226.8	78.4	14.6	106.8	9.7	12.8	26.6	109.8	13.6	15.1	40.3	0.8	7.7	9.4	10.9	2.6	4.3	17.1	6.9	41.4	57.9	121.8	508.1	21.5	46.0	104.0	34.5	23.5	5.2	2.7	4.9	17.2	54.1	6.6	5.2	11.2	8.5	3.4	5.7	33.0	10.2	3.6	35.1	89.2	13.4	12.6	33.9	4.9	6.0	1.3	8.6	11.8	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.8	0.2	163.3	6.7	5.9	0.1	0.3	0.7	0.1	38.7	0.2	0.1	0.8	0.0	0.5	1.0	0.1	0.0	0.1	0.3	0.2	0.1	75.9	16.8	0.5	0.1	119.7	0.2	1.2	0.1	0.0	9.9	0.2	0.1	0.2	0.1	0.2	20.4	0.1	0.2	0.6	0.1	0.2	0.0	0.4	0.2	0.3	0.1	151.8	14.0	4.3	0.2	1.1	0.2	0.1	0.1	0.4	0.6	0.3	0.5	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	78.4	106.8	26.6	53.4	41.4	57.9	104.0	34.5	54.1	33.9
APOL2	APOL-II	ENSG00000128335	"Apolipoprotein L2"	Q9BQE5	22	36226203-36239954	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA001078	Uncertain		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"		10000000	10000000	"Nucleoplasm, Cytosol"	"Nuclear bodies"	"HPA001078: AB_10602432"	"unprognostic (4.19e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.50e-2)"	"unprognostic (4.26e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.62e-1)"	"unprognostic (3.95e-2)"	"unprognostic (2.38e-2)"	"unprognostic (7.39e-2)"	"unprognostic (2.14e-2)"	"unprognostic (1.70e-2)"	"unprognostic (1.14e-1)"	"prognostic unfavourable (1.22e-7)"	"unprognostic (1.80e-1)"	"unprognostic (6.79e-2)"	"unprognostic (2.66e-2)"	"prognostic favourable (5.06e-6)"	21.5	14.2	17.4	25.3	12.0	6.9	20.3	26.5	30.1	16.7	15.6	11.1	11.1	25.0	20.3	17.9	10.2	15.3	25.6	17.3	15.1	19.3	18.2	39.7	23.6	22.0	20.2	11.9	12.6	10.1	11.2	57.1	14.6	28.7	19.0	16.1	15.9	15.2	18.8	16.5	9.6	21.7	22.2	16.2	26.2	22.7	7.2	12.0	14.9	23.0	12.7	17.0	25.8	19.4	6.2	6.0	43.0	17.0	9.9	15.5	4.6	7.4	5.5	5.4	4.1	21.2	16.5	10.3	10.1	23.7	27.6	37.5	2.2	6.1	9.0	17.2	18.2	3.5	5.9	8.1	13.7	30.4	6.7	4.2	11.7	10.4	35.8	9.0	8.2	20.8	5.5	19.3	5.1	17.9	7.5	25.6	17.2	2.7	9.1	4.0	2.0	5.1	9.4	7.0	5.3	27.8	19.7	9.8	2.8	6.9	13.2	5.4	4.1	1.3	17.3	16.7	8.3	3.4	5.6	15.5	7.7	2.8	14.4	4.7	6.3	8.9	8.6	5.8	15.5	17.0	14.1	6.2	11.2	12.7	6.0	4.1	6.5	10.9	43.0	9.9	11.4	3.7	10.5	4.6	17.4	12.0	26.5	30.1	15.1	19.3	20.2	11.9	28.7	12.0
APPBP2	"Hs.84084, KIAA0228, PAT1"	ENSG00000062725	"Amyloid beta precursor protein binding protein 2"	Q92624	17	60443149-60526219	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 47.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA066777			Uncertain	"Centriolar satellite"				"Centriolar satellite"		"HPA066777: "	"unprognostic (1.43e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.40e-3)"	"unprognostic (2.97e-2)"	"unprognostic (2.93e-2)"	"unprognostic (4.53e-2)"	"prognostic unfavourable (3.65e-4)"	"unprognostic (7.67e-2)"	"unprognostic (9.24e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.90e-3)"	"unprognostic (6.87e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.84e-1)"	"unprognostic (1.31e-1)"	"unprognostic (9.36e-2)"	18.8	16.0	16.1	13.2	22.6	5.3	15.9	28.1	27.3	17.5	13.9	25.4	12.9	10.1	18.5	13.8	14.5	14.5	16.1	10.1	16.6	16.0	18.4	15.0	16.4	10.9	20.8	15.4	27.9	17.1	23.4	20.4	24.3	25.1	19.4	12.8	13.4	13.0	15.0	14.5	12.6	10.8	16.7	18.5	15.4	14.5	30.8	21.2	17.9	17.8	7.2	11.0	15.8	15.3	12.7	12.0	15.7	14.2	15.6	16.7	9.3	6.9	9.5	10.0	8.3	10.7	11.3	5.6	11.0	7.6	6.1	7.9	4.6	6.1	7.3	18.6	9.2	6.0	7.0	3.8	10.9	6.4	5.4	9.2	8.9	9.4	11.4	7.5	10.2	11.0	5.1	6.4	6.3	9.5	6.8	8.5	8.9	47.1	10.6	3.8	2.2	4.2	7.1	16.7	8.4	9.5	11.5	10.9	9.3	9.5	1.6	7.9	13.3	5.2	12.3	13.9	17.0	9.5	8.3	9.1	28.6	6.0	9.2	4.5	9.8	13.5	12.0	15.0	10.2	8.7	11.7	9.7	12.0	11.2	12.0	12.7	16.7	12.2	15.7	15.6	14.2	7.2	11.5	9.3	16.1	22.6	28.1	24.1	16.6	16.0	20.8	15.4	25.1	21.2
AR	"AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1"	ENSG00000169083	"Androgen receptor"	P10275	X	67544032-67730619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 49.0"	"Cell line enhanced"	"Detected in some"		"AF22: 11.0;BJ hTERT+: 9.6;HAP1: 14.1;LHCN-M2: 12.4;RH-30: 20.5;T-47d: 8.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"plasmacytoid DC: 5.4"	"Lineage enriched"	"Detected in single"	16	"dendritic cells: 5.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000001, HPA065701, CAB065764"	Enhanced		Approved	Mitochondria				Mitochondria		"CAB000001: AB_2060174, CAB065764: AB_10620739, HPA065701: "	"unprognostic (1.34e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.49e-2)"	"unprognostic (5.95e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.35e-2)"	"prognostic favourable (8.77e-4)"	"unprognostic (4.99e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.29e-1)"	"prognostic favourable (1.03e-8)"	"unprognostic (8.23e-3)"	"unprognostic (8.90e-2)"	"unprognostic (4.23e-2)"	"unprognostic (7.97e-2)"	10.1	1.2	0.9	1.6	0.9	0.1	10.7	0.4	1.6	34.4	1.9	2.4	25.4	0.2	20.5	20.5	2.2	17.5	4.3	5.7	0.9	1.5	6.3	49.0	1.5	0.2	1.2	0.7	14.4	1.0	0.1	2.3	0.3	1.9	28.0	0.5	3.8	1.6	36.1	8.1	3.9	1.1	7.6	1.9	0.9	1.6	9.3	1.2	5.4	3.1	2.0	1.2	6.3	13.1	0.0	5.4	0.3	0.0	0.1	0.0	0.1	0.0	4.6	11.0	0.0	0.0	0.1	0.0	5.8	9.6	0.4	0.1	0.2	0.0	0.0	0.0	0.7	0.0	14.1	0.0	0.1	0.0	1.8	0.0	1.1	0.0	0.6	0.0	0.0	4.5	0.0	1.6	0.0	3.4	4.0	1.8	12.4	1.2	0.0	0.0	4.4	0.0	0.0	20.5	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	8.6	5.2	0.2	0.2	2.0	0.1	2.9	0.0	0.0	0.0	4.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	5.4	0.0	0.1	0.9	0.9	0.4	1.6	0.9	1.5	1.2	0.7	1.9	1.2
AREG	"AREGB, SDGF"	ENSG00000109321	Amphiregulin	P15514	4	74445134-74455009	"Cancer-related genes, Predicted membrane proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 83.5"	"Cell line enhanced"	"Detected in some"		"CACO-2: 41.8;HBEC3-KT: 72.5;hTCEpi: 73.7;hTERT-HME1: 157.7;MCF7: 45.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	9	"basophil: 8.2;eosinophil: 11.6;NK-cell: 3.3"	"Group enriched"	"Detected in many"	9	"granulocytes: 11.6;NK-cells: 3.3"	"Region enriched"	"Detected in single"	4	"olfactory region: 1.5"	"Low region specificity"	"Detected in all"			"HPA008720, CAB023519"	Approved		Approved	Mitochondria				Mitochondria		"CAB023519: AB_2060673, HPA008720: AB_1844978"	"unprognostic (1.44e-2)"	"unprognostic (1.84e-3)"	"unprognostic (3.36e-2)"	"unprognostic (2.26e-1)"	"unprognostic (3.54e-3)"	"prognostic unfavourable (2.61e-5)"	"unprognostic (1.02e-2)"	"prognostic unfavourable (1.05e-5)"	"unprognostic (2.90e-1)"	"unprognostic (8.06e-2)"	"prognostic unfavourable (8.32e-5)"	"unprognostic (2.56e-2)"	"unprognostic (2.49e-3)"	"unprognostic (2.40e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.23e-1)"	"unprognostic (6.83e-3)"	19.5	1.1	0.4	9.2	2.1	28.9	20.3	0.3	0.4	5.7	6.7	0.2	0.2	0.7	1.7	1.6	22.3	6.0	34.8	13.6	0.5	0.4	2.5	1.7	14.4	13.3	0.4	0.0	5.8	1.0	0.0	7.8	83.5	1.3	1.9	5.0	1.4	3.9	0.9	9.9	3.4	10.0	1.5	1.0	11.3	5.3	4.6	0.0	1.6	1.2	13.4	13.6	8.7	4.6	0.4	0.8	11.6	0.0	3.3	0.4	0.1	1.7	11.9	0.0	0.0	0.1	0.1	0.0	0.3	0.5	0.0	0.3	41.8	6.7	0.0	0.9	0.0	1.9	0.0	72.5	0.7	0.0	0.0	0.0	0.3	1.9	22.5	0.2	0.0	0.6	73.7	4.3	157.7	0.0	0.1	0.0	1.6	45.5	0.0	0.0	0.0	4.8	0.0	0.0	0.0	4.1	0.3	0.0	0.0	2.4	0.1	0.0	1.3	0.0	0.1	0.0	1.7	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.1	8.2	0.0	11.6	0.0	0.0	0.0	0.3	0.4	0.0	0.8	0.4	0.2	0.0	0.1	3.3	0.0	0.1	0.0	0.1	0.4	2.1	0.3	0.4	0.5	0.4	0.4	0.0	1.3	0.0
ARG2		ENSG00000081181	"Arginase 2"	P78540	14	67619798-67651720	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Adaptive immunity, Arginine metabolism, Immunity, Innate immunity, Urea cycle"	Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 53.7;thyroid gland: 75.4"	"Cell line enhanced"	"Detected in many"		"HAP1: 25.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 49.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA000663, CAB009435"	Enhanced		Supported	Mitochondria				Mitochondria		"CAB009435: AB_2059089, HPA000663: AB_1078192"	"unprognostic (8.74e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.35e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.30e-1)"	"unprognostic (9.13e-2)"	"unprognostic (1.10e-2)"	"unprognostic (3.43e-3)"	"unprognostic (4.62e-3)"	"unprognostic (5.37e-2)"	"unprognostic (4.66e-3)"	"unprognostic (1.72e-1)"	"unprognostic (9.39e-2)"	"unprognostic (4.26e-1)"	"unprognostic (2.31e-1)"	"unprognostic (4.34e-1)"	"unprognostic (1.26e-1)"	1.5	3.9	2.4	1.7	6.4	0.6	2.7	8.3	5.3	9.3	5.4	0.5	2.0	2.1	3.7	2.3	7.3	0.8	4.9	2.1	3.3	5.5	41.4	2.0	1.7	0.6	3.2	1.7	8.8	2.6	32.1	22.5	4.4	4.6	53.7	1.1	3.4	26.6	3.8	17.2	0.8	10.4	2.2	3.9	0.7	1.4	1.9	2.1	0.1	75.4	13.6	2.2	5.3	4.1	2.5	1.7	2.0	1.4	0.3	2.9	3.4	3.5	0.5	6.2	4.0	0.9	0.0	8.4	2.8	7.5	9.1	15.4	15.3	1.8	6.0	0.7	1.8	0.8	25.0	11.3	11.0	0.2	6.2	2.7	1.1	17.5	2.7	0.6	16.4	0.4	14.8	4.4	21.6	15.3	7.9	0.0	0.6	1.7	0.9	0.6	11.8	0.2	0.2	0.8	6.9	7.4	6.0	13.8	5.2	1.7	1.7	2.6	6.4	0.2	3.1	2.7	6.9	0.2	2.0	0.5	0.9	2.0	5.5	3.1	4.6	0.3	1.4	2.0	1.1	0.5	0.5	0.7	0.3	0.9	1.7	2.5	0.6	0.6	1.7	0.3	1.2	0.1	2.9	3.4	2.4	6.4	8.3	5.3	3.3	5.5	3.2	1.7	4.6	2.1
ARHGAP26	"GRAF, KIAA0621, OPHN1L, OPHN1L1"	ENSG00000145819	"Rho GTPase activating protein 26"	Q9UNA1	5	142770377-143229011	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 39.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"neutrophil: 19.6;NK-cell: 5.8"	"Group enriched"	"Detected in many"	4	"granulocytes: 19.6;NK-cells: 5.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035106, HPA035107"	Enhanced		Approved	Cytosol				Cytosol		"HPA035106: , HPA035107: AB_10669855"	"prognostic favourable (2.05e-4)"	"prognostic favourable (1.36e-4)"	"prognostic favourable (6.95e-4)"	"prognostic favourable (5.93e-6)"	"unprognostic (1.19e-1)"	"unprognostic (1.93e-2)"	"unprognostic (4.19e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.22e-1)"	"unprognostic (9.43e-3)"	"unprognostic (7.19e-3)"	"unprognostic (8.65e-2)"	"unprognostic (3.21e-3)"	"unprognostic (5.67e-2)"	"unprognostic (2.70e-2)"	"unprognostic (2.95e-2)"	"prognostic favourable (2.88e-6)"	13.3	5.7	18.4	18.6	22.7	33.9	13.0	29.2	23.9	15.9	14.2	7.5	9.9	13.2	9.4	10.9	7.6	18.5	16.4	17.0	12.8	10.5	8.0	7.7	20.0	8.8	12.9	15.4	4.8	5.5	4.8	15.1	22.4	11.9	8.5	14.8	8.8	14.6	11.2	14.0	8.5	12.6	11.1	12.6	18.9	17.0	16.1	12.2	10.3	10.0	5.4	13.6	9.4	10.6	0.3	2.0	19.6	2.8	5.8	3.0	1.0	6.8	13.7	3.8	3.5	5.7	6.3	5.9	0.8	1.1	3.3	5.8	18.8	15.5	0.9	6.8	2.2	3.3	1.9	6.4	4.1	14.1	2.2	0.0	1.7	11.9	3.6	10.1	1.3	2.3	11.4	6.1	14.1	4.9	0.2	39.0	1.0	1.0	5.7	4.2	1.8	3.5	2.2	5.7	16.3	9.7	10.5	1.5	2.4	1.7	1.9	3.2	1.0	3.1	9.4	1.8	2.6	0.2	3.6	1.7	5.5	0.2	4.7	9.5	2.5	2.9	2.8	1.6	3.0	1.7	1.3	0.2	0.6	1.8	2.0	0.3	0.2	0.8	19.6	5.8	1.0	0.5	0.2	1.0	18.4	22.7	29.2	23.9	12.8	10.5	12.9	15.4	11.9	12.2
ARHGAP32	"GC-GAP, GRIT, KIAA0712, MGC1892, RICS"	ENSG00000134909	"Rho GTPase activating protein 32"	A7KAX9	11	128965060-129279324	"Cancer-related genes, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 46.9"	"Cell line enhanced"	"Detected in many"		"RT4: 21.4;SK-BR-3: 23.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038382, HPA038389, HPA061505"	Approved		Approved	"Nucleoplasm,Nucleoli fibrillar center,Golgi apparatus"				"Golgi apparatus"	"Nucleoplasm, Nucleoli fibrillar center"	"HPA038382: , HPA038389: AB_10670972, HPA061505: "	"unprognostic (1.17e-1)"	"unprognostic (3.58e-2)"	"unprognostic (2.54e-2)"	"unprognostic (1.82e-1)"	"unprognostic (3.89e-2)"	"unprognostic (5.64e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.97e-2)"	"unprognostic (7.32e-2)"	"unprognostic (1.34e-1)"	"prognostic unfavourable (6.64e-4)"	"unprognostic (1.47e-1)"	"unprognostic (6.17e-3)"	"unprognostic (1.17e-1)"	"unprognostic (4.01e-1)"	"unprognostic (5.80e-2)"	"unprognostic (1.64e-2)"	4.0	5.9	22.1	3.4	32.8	1.7	9.4	4.7	46.9	8.2	12.3	5.1	1.5	18.4	7.3	8.4	21.9	12.2	6.8	3.8	9.9	6.8	6.5	4.5	5.2	1.5	6.4	21.7	10.2	13.3	14.9	5.3	7.5	5.4	6.0	14.3	4.5	13.4	4.1	6.2	16.0	19.0	5.5	4.3	2.6	10.8	9.2	8.4	5.8	3.6	12.8	12.9	8.0	13.1	1.3	1.6	0.7	2.1	3.0	1.2	0.6	6.5	3.5	10.9	0.0	3.6	3.6	7.9	2.4	3.4	1.6	1.9	8.0	13.5	0.0	3.8	4.7	14.9	5.0	6.2	3.0	0.0	1.7	0.1	1.7	3.0	1.7	0.0	0.0	3.5	8.1	1.5	9.2	1.9	0.3	0.1	2.7	5.0	5.3	0.1	2.9	3.7	13.2	3.3	1.3	1.7	21.4	10.8	4.4	3.7	23.4	4.5	12.1	2.1	3.6	5.6	2.9	3.3	4.7	0.1	0.0	0.0	2.4	14.9	3.5	0.0	0.4	0.0	0.3	2.1	1.2	0.0	0.4	0.6	1.0	1.3	0.8	0.2	0.7	3.0	0.7	1.6	0.4	0.6	22.1	32.8	4.7	46.9	9.9	6.8	6.4	21.7	5.4	8.4
ARHGAP35	"GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP"	ENSG00000160007	"Rho GTPase activating protein 35"	Q9NRY4	19	46918676-47005077	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, GTPase activation, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037311, HPA055184, HPA056470"	Approved		Supported	"Nuclear bodies,Aggresome"				"Nuclear bodies"	Aggresome	"CAB037311: AB_477435, HPA055184: , HPA056470: "	"unprognostic (5.47e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.40e-2)"	"unprognostic (2.01e-2)"	"unprognostic (7.78e-3)"	"unprognostic (9.82e-3)"	"unprognostic (4.41e-2)"	"unprognostic (2.71e-1)"	"unprognostic (2.73e-2)"	"unprognostic (3.25e-2)"	"unprognostic (1.92e-1)"	"prognostic favourable (5.55e-8)"	"unprognostic (2.78e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.16e-1)"	4.0	3.1	11.9	1.9	9.0	0.8	5.4	6.1	11.7	4.5	4.4			3.9	3.9	3.3	5.3	4.3	2.6	8.7	10.7	9.9	6.7	7.7	4.8	2.1	8.4		6.2	4.2	17.3	4.4	2.0		4.4	3.9		4.8	5.6	9.0	3.4	5.1	4.2	4.6	2.2	3.1	13.8			7.0		2.4	4.5	2.2	1.1	1.4	0.9	1.2	1.0	3.1	1.1	20.0	22.8	15.4	13.6	14.1	11.8	2.6	10.9	15.7	11.1	12.8	12.2	7.2	10.8	7.8	44.7	12.3	14.2	14.2	15.4	7.4	5.9	14.6	16.0	9.4	13.2	8.6	12.4	11.9	14.3	12.6	13.5	10.0	9.7	3.9	12.7	11.8	8.3	13.5	8.0	8.4	9.3	10.5	3.3	9.3	40.2	15.5	14.7	20.2	19.0	8.1	17.9	10.5	12.5	9.8	7.8	10.6	12.9	4.1	7.4	8.8	22.0	9.0	23.9	0.9	1.0	0.9	2.8	0.8	2.9	0.8	2.6	3.1	1.3	1.1	1.0	1.2	0.4	1.0	1.2	1.4	0.8	1.1										
ARHGEF12	"KIAA0382, LARG"	ENSG00000196914	"Rho guanine nucleotide exchange factor 12"	Q9NZN5	11	120336914-120489936	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"GTPase activation, Guanine-nucleotide releasing factor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 2.2"	"Group enriched"	"Detected in many"	5	"granulocytes: 2.2;NK-cells: 1.5;T-cells: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018911, CAB025581"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoplasm	"CAB025581: , HPA018911: AB_1845003"	"unprognostic (1.55e-1)"	"unprognostic (1.29e-1)"	"unprognostic (6.91e-3)"	"unprognostic (1.28e-1)"	"unprognostic (7.28e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.56e-1)"	"unprognostic (5.55e-2)"	"unprognostic (4.79e-2)"	"unprognostic (7.77e-2)"	"unprognostic (4.34e-3)"	"unprognostic (4.78e-2)"	"prognostic favourable (5.43e-6)"	"unprognostic (1.29e-1)"	"unprognostic (4.38e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.48e-1)"	17.6	19.2	27.6	8.3	32.5	5.9	19.6	40.4	41.5	21.7	16.4	12.4	15.7	14.9	17.5	15.9	17.8	18.6	17.3	23.4	21.8	17.7	41.2	38.8	24.1	6.5	15.8	26.3	16.3	16.9	55.8	17.2	25.4	21.1	16.8	17.8	20.7	16.7	20.0	24.1	29.0	14.8	18.6	10.8	12.4	19.0	6.7	13.0	3.0	31.3	15.0	10.9	19.4	22.9	0.3	0.3	2.2	0.1	1.5	1.0	0.4	12.9	10.9	14.7	14.0	19.9	19.9	6.1	15.3	17.3	9.3	11.9	12.7	9.5	1.1	18.8	27.3	9.8	18.8	19.4	18.2	10.7	9.2	21.1	11.7	9.8	17.8	0.0	15.7	18.9	14.1	20.4	22.7	28.2	17.8	43.3	23.5	9.0	0.0	0.0	4.0	9.4	4.6	16.8	4.1	22.9	22.6	10.8	13.3	21.4	18.0	5.6	15.3	1.7	27.8	20.7	8.9	13.4	11.1	12.7	5.1	7.2	8.5	2.7	15.6	2.2	0.0	0.0	1.0	0.1	0.2	0.3	0.6	0.6	0.0	0.3	0.0	0.5	0.0	1.5	0.1	0.3	0.7	0.4	27.6	32.5	40.4	41.5	21.8	17.7	15.8	26.3	21.1	13.0
ARHGEF6	"alpha-PIX, alphaPIX, Cool-2, Cool2, KIAA0006, MRX46"	ENSG00000129675	"Rac/Cdc42 guanine nucleotide exchange factor 6"	Q15052	X	136665547-136782088	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 21.7;HL-60: 27.0;HMC-1: 103.2;U-937: 29.0"	"Cancer enhanced"	"Detected in all"		"glioma: 24.7"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003578	Approved		Approved	Cytosol				Cytosol		"HPA003578: AB_1078203"	"unprognostic (9.64e-2)"	"unprognostic (3.47e-2)"	"unprognostic (3.32e-2)"	"unprognostic (1.29e-2)"	"unprognostic (7.28e-2)"	"unprognostic (2.06e-3)"	"unprognostic (9.08e-2)"	"unprognostic (7.87e-3)"	"unprognostic (4.21e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.69e-3)"	"unprognostic (5.29e-2)"	"unprognostic (1.35e-2)"	"unprognostic (2.64e-1)"	"unprognostic (1.28e-3)"	22.0	10.4	16.9	15.3	15.4	14.8	13.9	6.4	14.6	6.4	8.3	12.8	3.7	4.0	8.4	6.1	4.4	4.5	9.5	27.0	21.7	13.6	5.0	4.5	13.8	20.6	20.7	10.2	9.5	2.7	8.8	4.8	24.4	15.1	6.4	6.3	8.4	6.2	5.1	37.5	4.3	9.6	9.3	14.6	20.2	6.4	3.2	14.6	2.6	4.1	8.6	20.5	8.8	7.9	3.1	8.8	31.5	8.8	5.5	9.9	6.2	0.2	0.0	1.0	0.0	2.2	5.8	0.0	0.3	1.8	0.3	1.6	0.0	0.0	1.0	0.4	1.5	0.1	1.2	0.0	0.3	5.0	0.3	21.7	0.0	0.0	0.8	27.0	103.2	6.2	0.0	1.0	0.0	0.5	0.1	4.3	3.9	0.0	12.7	16.6	0.9	0.4	4.8	7.3	0.0	0.3	5.4	0.0	1.3	0.0	0.2	0.7	0.6	11.3	0.1	1.5	0.2	1.8	1.3	0.7	0.0	10.4	6.9	29.0	2.0	20.2	7.2	31.5	6.8	8.8	8.0	3.1	7.6	5.5	8.8	2.6	7.0	6.1	4.2	5.5	6.8	2.8	9.9	6.2	16.9	15.4	6.4	14.0	21.7	13.6	20.7	10.2	15.1	14.6
ARID1A	"B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1"	ENSG00000117713	"AT-rich interaction domain 1A"	O14497	1	26693236-26782110	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Neurogenesis, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005456, CAB016334"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB016334: AB_673396, HPA005456: AB_1078205"	"unprognostic (2.83e-1)"	"unprognostic (1.81e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.41e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.89e-2)"	"prognostic unfavourable (4.18e-4)"	"unprognostic (3.02e-1)"	"unprognostic (3.66e-2)"	"unprognostic (1.34e-1)"	"unprognostic (9.69e-2)"	"unprognostic (7.76e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.62e-2)"	"unprognostic (6.05e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.54e-2)"	18.6	18.4	17.4	24.9	17.0	33.8	27.8	23.6	19.1	20.3	23.7	21.7	23.9	15.8	24.1	17.3	23.2	20.6	21.9	15.5	14.8	12.8	13.7	15.9	18.8	35.6	20.3	19.2	24.1	23.9	27.5	15.8	19.3	17.2	16.5	16.4	18.9	21.4	23.1	22.6	20.6	20.7	18.4	15.4	25.9	19.5	16.5	19.8	57.3	24.8	14.2	24.5	24.4	20.4	4.3	5.3	7.4	3.3	4.7	5.1	3.5	18.9	18.0	25.6	26.6	7.4	7.1	12.0	8.9	7.7	12.2	8.7	13.2	12.8	26.8	7.8	11.5	11.5	22.2	9.8	14.3	33.2	8.7	22.8	11.7	8.8	6.1	33.7	7.3	8.2	7.0	14.4	10.3	10.5	27.2	30.0	7.9	9.0	28.4	13.1	27.0	8.4	29.7	16.9	15.2	7.6	12.8	23.9	19.7	15.6	13.2	10.7	3.9	19.2	18.4	13.1	12.7	12.2	14.4	14.3	18.8	12.3	8.0	21.6	11.6	0.4	3.3	2.9	4.0	2.9	5.1	4.3	3.2	4.9	3.1	4.3	4.0	4.4	7.4	4.7	2.8	5.3	1.5	3.5	17.4	17.0	23.6	19.1	14.8	12.8	20.3	19.2	17.2	19.8
ARID1B	"6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R"	ENSG00000049618	"AT-rich interaction domain 1B"	Q8NFD5	6	156777374-157210779	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Neurogenesis, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016511, HPA075291"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA016511: AB_1845008, HPA075291: "	"prognostic unfavourable (1.04e-4)"	"unprognostic (9.82e-2)"	"unprognostic (1.73e-1)"	"unprognostic (5.42e-2)"	"unprognostic (7.47e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.73e-2)"	"unprognostic (2.89e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (4.16e-4)"	"unprognostic (2.53e-1)"	"unprognostic (5.33e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.46e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.53e-1)"	"unprognostic (1.16e-1)"	18.3	15.0	20.2	18.8	20.9	25.8	19.3	42.1	32.8	20.0	17.4	26.3	21.7	15.3	23.0	14.2	18.6	20.7	15.9	16.8	20.4	11.3	14.2	10.6	17.0	18.3	19.4	16.7	30.2	18.5	47.4	29.2	12.2	17.7	17.7	13.3	24.0	20.0	20.2	30.6	27.3	17.8	21.7	14.9	21.1	15.0	10.7	24.6	24.0	23.8	13.3	26.3	23.5	21.0	9.5	11.9	5.6	3.0	2.7	5.6	1.6	7.0	10.9	16.1	21.9	13.2	12.2	11.0	7.5	9.9	9.8	9.8	9.6	10.3	22.4	4.7	12.8	9.0	13.7	12.3	9.7	22.5	9.7	16.2	11.0	11.4	9.3	13.5	11.9	13.8	9.9	14.9	13.3	13.6	19.0	17.5	7.0	8.3	15.6	15.2	8.1	5.8	35.6	6.9	12.1	6.7	13.2	14.8	18.9	15.1	15.9	8.8	10.7	21.2	13.9	12.4	13.2	11.4	14.7	12.1	10.8	28.7	10.8	16.2	16.6	5.6	3.0	2.5	5.4	2.4	5.0	6.8	4.7	3.8	2.3	9.5	4.0	5.6	5.5	2.7	2.6	11.9	4.6	1.6	20.2	20.9	42.1	32.8	20.4	11.3	19.4	16.7	17.7	24.6
ARID2	"BAF200, DKFZp686G052, FLJ30619, KIAA1557"	ENSG00000189079	"AT-rich interaction domain 2"	Q68CP9	12	45729665-45908040	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063044			Supported	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"HPA063044: "	"unprognostic (8.41e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.02e-2)"	"unprognostic (3.94e-2)"	"unprognostic (4.15e-2)"	"prognostic favourable (5.75e-4)"	"unprognostic (1.26e-2)"	"unprognostic (9.71e-2)"	"unprognostic (9.04e-2)"	"unprognostic (5.57e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.47e-1)"	"unprognostic (1.12e-2)"	"unprognostic (9.21e-2)"	"unprognostic (3.02e-1)"	"unprognostic (2.00e-1)"	"unprognostic (6.53e-2)"	9.0	7.9	7.1	14.6	7.2	14.0	11.8	15.7	8.8	10.2	11.4	8.2	17.9	6.4	12.2	10.7	11.5	8.8	10.6	8.2	7.4	5.8	8.7	6.9	10.2	13.0	9.6	3.8	12.2	10.7	18.4	15.1	10.3	7.5	9.9	8.1	10.1	9.7	20.6	8.6	13.5	12.6	12.5	7.3	10.2	9.0	30.9	11.0	33.3	11.5	8.2	11.2	10.0	10.0	2.1	5.3	10.5	4.9	3.1	4.4	1.3	5.4	7.8	14.0	6.1	6.0	4.2	7.6	3.8	5.4	5.3	5.0	11.1	5.6	10.5	7.0	5.2	6.6	11.3	6.4	7.7	4.6	5.4	13.9	8.6	5.4	4.1	10.9	6.4	3.4	4.9	6.7	10.7	5.4	11.7	10.9	4.7	7.1	15.6	7.8	8.3	4.2	12.1	10.0	10.1	5.1	9.0	7.6	9.7	6.2	7.2	6.0	10.9	21.9	6.4	5.7	6.9	3.8	4.9	7.3	6.0	29.3	4.4	28.7	4.0	10.5	1.7	4.2	4.1	2.2	4.3	1.7	3.7	4.4	2.4	2.1	3.6	3.3	2.4	3.1	4.9	5.3	3.1	1.3	7.1	7.2	15.7	8.8	7.4	5.8	9.6	3.8	7.5	11.0
ARID5B	"FLJ21150, MRF2"	ENSG00000150347	"AT-rich interaction domain 5B"	Q14865	10	61901300-62096944	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 88.6"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 44.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA015037	Uncertain		Approved	"Nucleoplasm,Endoplasmic reticulum,Plasma membrane,Cytosol"				"Endoplasmic reticulum"	"Nucleoplasm, Plasma membrane, Cytosol"	"HPA015037: AB_1845015"	"unprognostic (3.31e-1)"	"unprognostic (1.99e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.17e-1)"	"unprognostic (5.60e-2)"	"unprognostic (1.50e-2)"	"unprognostic (4.90e-2)"	"unprognostic (3.90e-1)"	"unprognostic (6.03e-2)"	"unprognostic (1.97e-1)"	"unprognostic (5.75e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.94e-1)"	"unprognostic (3.93e-2)"	43.3	5.6	7.8	13.8	9.9	4.2	22.6	3.3	11.5	27.5	14.0	9.5	4.4	6.8	29.4	10.4	14.0	15.6	27.2	16.0	5.9	5.1	14.6	5.7	14.6	14.4	11.8	6.5	18.6	4.3	14.7	11.4	22.4	9.4	16.6	8.2	6.9	14.5	7.3	88.6	15.0	12.1	29.4	10.4	12.7	9.4	7.7	10.5	8.6	7.5	11.7	18.0	22.5	17.1	21.2	1.0	4.3	3.6	5.7	14.7	2.6	0.8	0.3	2.3	5.7	5.1	13.7	0.4	16.6	44.8	11.8	9.3	20.1	0.9	1.4	4.0	15.9	5.5	8.0	2.5	14.3	5.2	2.4	0.7	4.1	5.0	9.5	0.2	9.9	17.3	1.3	7.0	8.0	1.4	0.7	2.2	3.8	2.8	5.4	0.4	0.4	5.2	6.6	3.8	0.4	7.8	9.0	1.3	1.7	7.4	4.1	4.8	3.4	0.2	1.2	6.6	8.9	9.9	4.2	0.1	0.0	4.3	5.7	0.3	2.1	4.3	0.6	0.4	7.3	1.4	0.9	19.0	10.5	6.3	1.0	21.2	6.9	4.5	1.2	5.7	3.6	0.5	14.7	2.6	7.8	9.9	3.3	11.5	5.9	5.1	11.8	6.5	9.4	10.5
ARNT	"bHLHe2, HIF-1beta"	ENSG00000143437	"Aryl hydrocarbon receptor nuclear translocator"	P27540	1	150809705-150876768	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in many"	7	"U-698: 94.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001759, CAB004318"	Supported		Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB004318: AB_626698, HPA001759: AB_1078213"	"unprognostic (1.81e-1)"	"unprognostic (8.14e-2)"	"unprognostic (6.87e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.10e-2)"	"unprognostic (9.43e-2)"	"unprognostic (5.27e-3)"	"unprognostic (5.05e-1)"	"unprognostic (3.42e-2)"	"unprognostic (1.22e-1)"	"unprognostic (9.52e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.68e-1)"	"unprognostic (4.67e-1)"	"unprognostic (6.45e-2)"	"unprognostic (6.92e-2)"	23.5	20.8	12.1	14.5	12.6	11.3	25.1	25.4	14.4	28.0	17.2	18.7	12.8	10.9	26.1	14.4	16.6	20.4	17.9	20.0	10.2	8.2	14.4	32.2	21.6	12.0	11.6	9.5	31.8	22.4	16.5	22.9	31.7	12.3	18.2	16.4	28.3	15.2	16.3	25.5	21.9	15.2	22.6	14.0	19.2	16.5	14.9	12.3	18.8	16.1	13.9	18.0	23.0	24.4	6.6	12.7	23.9	15.6	8.0	8.8	9.7	4.0	4.1	6.2	4.7	13.4	12.9	8.4	4.5	9.0	6.2	5.7	3.5	4.1	4.2	4.1	8.1	4.6	5.6	5.1	5.4	6.7	3.4	5.0	7.0	4.1	7.7	6.0	5.9	10.0	4.8	7.5	6.7	7.6	6.5	8.5	6.4	7.8	4.8	3.3	5.1	3.2	6.0	7.5	6.0	4.9	4.1	4.1	6.1	8.8	6.0	3.5	7.7	13.1	5.4	5.2	4.6	4.1	3.9	9.7	7.0	94.7	6.3	0.2	3.5	23.9	15.6	13.9	8.8	14.7	7.9	6.2	7.2	8.4	12.7	6.6	7.0	7.1	8.1	8.0	14.7	5.2	7.2	9.7	12.1	12.6	25.4	14.4	10.2	8.2	11.6	9.5	12.3	12.3
ASPH	"BAH, CASQ2BP1, HAAH, JCTN"	ENSG00000198363	"Aspartate beta-hydroxylase"	Q12797	8	61500556-61714640	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"Dioxygenase, Oxidoreductase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-87 MG: 102.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 21.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055161, HPA059303"	Uncertain		Enhanced	"Endoplasmic reticulum"		900000	900000	"Endoplasmic reticulum"		"HPA055161: , HPA059303: "	"unprognostic (8.07e-2)"	"prognostic unfavourable (8.07e-5)"	"unprognostic (1.73e-2)"	"unprognostic (4.48e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.85e-2)"	"unprognostic (2.82e-2)"	"prognostic unfavourable (3.61e-4)"	"unprognostic (6.39e-2)"	"unprognostic (3.64e-1)"	"prognostic unfavourable (1.75e-4)"	"unprognostic (9.50e-2)"	"prognostic unfavourable (1.57e-5)"	"unprognostic (8.96e-2)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (4.24e-4)"	"unprognostic (2.74e-2)"	104.6	60.4	27.3	15.0	29.5	4.8	84.3	35.2	31.3	22.3	23.8	10.6	18.3	14.0	16.8	17.8	22.4	16.5	19.1	33.9	26.1	22.4	19.0	23.0	22.5	10.9	21.1	22.2	20.5	13.8	12.5	15.7	14.7	20.5	17.3	26.8	23.6	28.8	23.4	103.1	12.0	13.9	26.1	16.7	12.8	30.5	6.4	19.6	2.9	31.7	36.0	13.7	30.0	25.4	3.3	21.0	15.9	5.2	4.9	3.4	2.3	50.0	72.7	10.2	6.2	45.8	43.5	3.5	89.8	83.5	38.5	40.4	12.4	66.7	3.8	6.2	52.6	18.7	6.3	31.3	65.8	1.4	6.4	8.9	44.2	34.0	29.4	1.3	1.4	35.7	7.1	21.4	27.3	16.2	2.4	3.6	33.8	10.6	0.3	1.8	5.8	42.9	2.4	11.0	0.8	23.5	41.5	10.6	3.7	27.9	13.2	11.1	5.4	2.4	50.8	39.0	20.0	35.6	31.6	2.3	2.9	0.1	102.6	0.8	26.0	1.1	5.2	0.1	1.6	1.9	3.1	3.3	2.3	1.6	6.1	3.3	3.4	1.6	15.9	4.9	1.0	21.0	2.3	2.3	27.3	29.5	35.2	31.3	26.1	22.4	21.1	22.2	20.5	19.6
ASPM	"ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5"	ENSG00000066279	"Abnormal spindle microtubule assembly"	Q8IZT6	1	197084128-197146694	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	Calmodulin-binding	"Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 62.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"plasmacytoid DC: 1.5;T-reg: 2.4"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.5;T-cells: 2.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			CAB017816			Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB017816: "	"unprognostic (3.24e-1)"	"unprognostic (1.56e-1)"	"unprognostic (2.81e-2)"	"prognostic unfavourable (1.97e-4)"	"unprognostic (3.67e-1)"	"unprognostic (3.47e-2)"	"prognostic unfavourable (1.25e-4)"	"prognostic unfavourable (2.41e-4)"	"unprognostic (4.67e-3)"	"unprognostic (9.29e-2)"	"prognostic unfavourable (2.40e-4)"	"unprognostic (1.03e-1)"	"unprognostic (0.00e+0)"	"unprognostic (7.31e-3)"	"unprognostic (1.23e-1)"	"unprognostic (4.94e-2)"	"unprognostic (3.66e-2)"	0.7	0.7	0.2	12.4	0.4	13.8	1.5	0.2	0.4	1.2	2.8	0.2	0.2	2.8	0.3	1.5	8.7	0.2	0.4	0.6	0.2	0.2	0.5	1.3	1.9	7.0	0.3	0.2	0.5	0.3	0.0	0.2	1.8	0.5	0.4	2.8	0.3	1.5	0.2	0.5	4.6	3.1	0.8	0.5	4.3	1.7	6.3	0.2	62.8	0.3	5.0	6.9	1.2	2.3	0.0	1.5	0.0	0.0	0.3	2.4	0.0	19.8	11.1	18.1	11.0	1.0	2.5	6.8	15.9	11.2	15.8	12.5	7.7	15.5	20.3	5.7	12.4	20.1	15.5	6.3	19.7	18.2	11.8	14.2	26.2	7.4	0.2	21.2	10.1	0.2	0.6	12.7	8.9	16.6	17.8	24.1	16.2	7.8	17.0	9.9	8.2	3.0	13.0	24.8	14.9	5.7	5.5	9.5	13.5	22.6	11.7	5.1	13.0	8.8	12.6	9.8	9.5	16.8	28.9	6.9	9.4	11.7	7.7	5.8	19.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.5	2.4	0.0	0.2	0.4	0.2	0.4	0.2	0.2	0.3	0.2	0.5	0.2
ASPSCR1	"ASPL, ASPS, TUG, UBXD9, UBXN9"	ENSG00000169696	"ASPSCR1, UBX domain containing tether for SLC2A4"	Q9BZE9	17	81976807-82017406	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	5	"Hep G2: 80.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA026749	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"				Nucleoplasm	"Vesicles, Plasma membrane"	"HPA026749: AB_1845114"	"unprognostic (5.01e-2)"	"unprognostic (1.19e-3)"	"unprognostic (7.61e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.36e-1)"	"prognostic favourable (8.55e-4)"	"unprognostic (2.02e-1)"	"unprognostic (2.07e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.71e-3)"	"prognostic favourable (2.67e-4)"	"unprognostic (1.13e-1)"	"prognostic unfavourable (1.26e-4)"	"unprognostic (3.16e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.01e-2)"	10.3	12.6	14.3	12.6	14.5	16.8	10.6	16.5	20.8	9.9	12.9	16.7	11.8	17.5	10.1	15.8	11.9	9.3	15.1	11.5	13.1	12.6	15.8	31.9	14.1	14.8	18.9	12.9	8.8	17.8	17.0	19.7	21.8	14.8	13.2	7.1	14.4	22.6	9.9	25.1	15.5	14.4	9.1	12.6	13.2	13.0	16.9	14.6	9.8	16.4	12.9	13.0	9.7	8.3	8.1	14.6	15.7	11.3	7.2	10.5	5.2	4.9	8.8	3.4	5.0	2.2	2.7	14.9	4.7	3.6	5.7	5.6	5.1	5.8	5.1	4.9	3.4	2.4	3.7	3.6	1.8	3.5	11.2	5.7	7.2	80.8	7.1	5.0	8.3	3.1	3.9	2.9	2.0	5.5	5.7	7.3	3.2	17.0	4.6	10.9	4.3	6.4	5.1	5.0	10.4	5.6	4.6	9.2	9.4	3.9	12.3	8.8	7.4	12.0	4.5	9.9	6.8	7.2	5.9	5.3	3.2	5.7	5.3	5.1	5.9	15.7	11.3	8.0	6.7	7.6	4.0	7.9	10.5	9.0	14.6	8.1	8.0	6.0	2.9	7.2	9.3	9.1	4.9	5.2	14.3	14.5	16.5	20.8	13.1	12.6	18.9	12.9	14.8	14.6
ASXL1	KIAA0978	ENSG00000171456	"Additional sex combs like 1, transcriptional regulator"	Q8IXJ9	20	32358330-32439319	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"Chromatin regulator, Repressor"	"Cancer-related genes, Craniosynostosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA064156			Approved	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"HPA064156: "	"unprognostic (1.49e-1)"	"unprognostic (5.97e-2)"	"unprognostic (8.36e-2)"	"prognostic unfavourable (2.86e-4)"	"unprognostic (6.69e-2)"	"prognostic favourable (9.16e-4)"	"unprognostic (2.01e-3)"	"unprognostic (2.89e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.38e-1)"	"unprognostic (4.32e-2)"	"unprognostic (3.21e-2)"	"unprognostic (1.84e-3)"	"unprognostic (5.47e-2)"	"unprognostic (1.90e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.06e-1)"	24.3	19.6	19.0	35.0	18.2	39.0	24.7	28.3	23.8	32.4	22.7	17.7	16.9	15.6	32.4	22.2	14.3	20.5	21.6	17.9	19.7	10.7	21.2	25.2	27.3	26.7	20.3	14.7	28.1	27.1	21.2	16.3	19.8	18.2	20.6	16.4	16.6	17.4	23.3	25.5	18.2	21.8	21.8	12.2	28.2	19.7	32.1	23.0	47.4	26.8	15.8	29.0	23.2	35.3	9.8	3.1	1.3	0.8	1.7	14.6	1.9	22.6	13.2	20.7	11.4	9.5	11.8	18.0	15.2	13.0	26.6	19.7	39.1	14.6	21.4	9.8	18.7	15.8	17.4	14.6	21.7	32.0	9.4	34.2	20.9	21.4	8.5	14.2	14.2	13.1	9.8	18.5	13.9	14.6	16.5	11.6	12.3	6.9	19.4	11.5	5.0	15.2	11.3	24.7	9.2	10.9	10.9	9.5	14.9	27.6	9.2	12.1	13.1	10.1	15.1	28.3	24.7	13.0	16.9	13.6	14.5	15.8	14.3	37.9	10.8	0.0	0.8	1.3	4.4	0.7	3.5	9.8	5.2	5.6	0.7	5.8	5.8	5.9	0.9	1.7	0.7	3.1	14.6	1.9	19.0	18.2	28.3	23.8	19.7	10.7	20.3	14.7	18.2	23.0
ASXL2	"ASXH2, FLJ10898, KIAA1685"	ENSG00000143970	"Additional sex combs like 2, transcriptional regulator"	Q76L83	2	25733753-25878516	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA034646, HPA058040"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA034646: , HPA058040: "	"unprognostic (4.78e-2)"	"unprognostic (3.41e-2)"	"unprognostic (2.23e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.88e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.80e-1)"	"unprognostic (2.68e-3)"	"unprognostic (3.17e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.33e-3)"	"unprognostic (1.82e-1)"	"unprognostic (1.58e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.75e-2)"	15.0	14.9	14.5	14.1	16.5	10.4	13.1	23.0	16.1	14.4	13.9	15.7	13.0	9.8	14.7	9.9	17.5	12.1	10.0	14.2	15.2	8.9	14.7	10.2	13.1	15.3	14.3	8.5	11.4	12.1	28.0	17.4	17.4	13.9	10.5	14.2	12.6	15.3	14.1	20.5	14.2	12.9	13.3	12.3	15.4	12.1	20.7	18.0	26.2	16.5	10.7	17.0	16.7	13.5	3.0	3.7	4.7	2.7	1.8	4.5	1.3	15.4	9.3	7.2	5.1	7.2	10.1	9.3	8.6	13.4	8.4	7.6	10.3	8.4	9.7	5.0	9.7	9.7	14.2	10.5	12.2	9.6	6.5	17.1	8.4	11.4	6.1	18.9	17.1	5.0	10.9	12.8	10.2	10.7	14.9	7.8	8.9	6.3	8.9	6.3	10.2	6.7	10.0	24.7	7.8	7.7	10.6	7.9	8.9	10.4	9.8	8.7	5.5	8.1	14.2	11.9	13.6	10.3	12.3	15.9	15.6	20.2	11.1	16.0	8.5	2.1	2.4	3.7	4.5	2.7	3.6	2.7	3.5	3.9	2.3	3.0	3.0	3.6	4.7	1.8	2.4	3.7	2.5	1.3	14.5	16.5	23.0	16.1	15.2	8.9	14.3	8.5	13.9	18.0
ATF1	TREB36	ENSG00000123268	"Activating transcription factor 1"	P18846	12	50763710-50821122	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016222, HPA055069, HPA055406"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB016222: AB_2290030, HPA055069: , HPA055406: "	"unprognostic (1.71e-1)"	"unprognostic (1.50e-3)"	"unprognostic (1.50e-1)"	"unprognostic (9.05e-2)"	"unprognostic (6.68e-2)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (1.53e-5)"	"unprognostic (3.65e-1)"	"unprognostic (8.17e-3)"	"unprognostic (5.94e-2)"	"unprognostic (4.31e-3)"	"unprognostic (5.52e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.74e-2)"	"unprognostic (2.46e-1)"	"unprognostic (2.27e-1)"	"unprognostic (8.75e-2)"	24.4	20.7	9.8	13.7	9.5	10.2	16.2	28.1	10.6	22.4	19.7	8.1	14.6	12.3	19.2	14.2	16.2	15.5	13.4	20.0	10.8	8.0	17.7	19.8	15.1	15.8	12.2	6.0	24.7	11.8	18.1	15.2	36.1	11.9	20.7	15.1	12.5	16.3	14.2	37.9	12.9	18.8	13.4	12.3	22.9	12.7	9.3	13.9	34.4	30.8	16.3	16.2	21.6	20.0	13.3	13.6	26.3	12.3	12.2	18.8	11.6	13.4	9.7	10.3	10.5	14.9	15.8	25.6	14.3	24.6	22.6	17.8	19.9	21.3	18.5	23.6	16.5	11.2	12.1	14.7	24.2	18.2	12.6	20.4	22.0	10.6	28.5	29.3	19.6	16.9	23.3	16.1	26.6	10.9	24.8	17.9	16.7	19.9	18.4	18.6	15.0	15.6	17.7	16.0	21.9	17.2	9.3	13.9	7.5	30.2	13.2	21.5	18.3	17.9	7.5	15.9	19.3	13.4	11.3	9.9	11.7	29.7	15.4	16.5	7.5	4.2	11.5	26.3	13.9	12.3	15.8	13.0	15.1	16.4	13.6	13.3	18.8	14.3	7.3	12.2	7.7	6.2	17.9	11.6	9.8	9.5	28.1	10.6	10.8	8.0	12.2	6.0	11.9	13.9
ATG13	KIAA0652	ENSG00000175224	"Autophagy related 13"	O75143	11	46617527-46674818	"Cancer-related genes, Predicted intracellular proteins, Transporters"	Autophagy		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA039350			Approved	"Nucleoplasm,Plasma membrane,Cytosol"				Cytosol	"Nucleoplasm, Plasma membrane"	"HPA039350: AB_10673142"	"unprognostic (3.66e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.65e-1)"	"unprognostic (5.36e-2)"	"unprognostic (2.31e-1)"	"prognostic unfavourable (8.59e-5)"	"unprognostic (1.05e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.35e-1)"	"unprognostic (7.57e-2)"	"unprognostic (2.44e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.14e-1)"	"unprognostic (7.68e-2)"	"unprognostic (3.47e-1)"	13.8	15.8	20.2	11.9	27.3	25.8	12.5	32.8	37.0	13.2	12.6	39.5	9.2	14.3	12.9	16.8	14.9	16.6	14.5	17.8	19.5	16.3	14.3	21.1	11.5	13.6	31.8	18.2	15.6	19.7	24.4	23.1	13.5	27.2	12.8	12.0	21.3	17.0	13.5	20.9	16.3	12.4	12.3	15.7	16.2	16.5	60.6	34.9	14.8	18.6	8.8	15.8	12.5	13.0	15.8	20.0	38.9	24.0	17.0	24.7	20.3	13.7	25.2	19.4	11.4	27.1	31.8	19.6	16.0	28.4	19.8	25.4	17.2	13.7	12.9	11.4	24.1	16.8	18.6	21.7	20.1	24.4	35.5	13.8	17.6	30.0	30.4	18.4	24.1	38.2	25.9	13.6	30.2	19.5	24.1	29.5	17.7	20.6	18.3	27.3	24.2	21.9	17.5	25.1	22.5	13.3	15.1	18.5	18.6	22.1	17.8	23.6	25.4	38.1	19.1	24.4	15.0	22.5	17.5	26.9	29.8	16.3	30.3	16.7	17.9	21.2	20.7	26.9	21.3	24.0	17.2	15.8	19.2	16.8	20.0	12.7	16.6	18.3	38.9	17.0	18.7	14.9	24.7	20.3	20.2	27.3	32.8	37.0	19.5	16.3	31.8	18.2	27.2	34.9
ATIC	"AICARFT, IMPCHASE, PURH"	ENSG00000138363	"5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase"	P31939	2	215311817-215349773	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Purine biosynthesis"	"Hydrolase, Multifunctional enzyme, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013462, HPA021012"	Supported		Enhanced	"Plasma membrane,Cytosol"		3400000	3400000	"Plasma membrane, Cytosol"		"CAB013462: , HPA021012: AB_1845169"	"unprognostic (1.41e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.13e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.81e-2)"	"prognostic unfavourable (1.99e-7)"	"unprognostic (1.86e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.31e-3)"	"unprognostic (9.21e-2)"	"prognostic unfavourable (8.77e-4)"	"unprognostic (1.00e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.18e-2)"	"unprognostic (4.39e-3)"	19.4	27.4	21.1	23.0	28.4	16.9	24.8	12.1	32.3	20.6	26.7	29.1	18.1	23.4	27.9	15.6	19.1	21.9	19.1	18.2	20.3	21.1	23.1	35.6	17.3	36.1	29.7	19.9	23.4	32.9	25.1	21.1	31.1	24.4	21.9	35.9	19.5	14.4	29.4	35.5	17.0	20.6	26.7	21.7	29.0	20.4	15.0	28.0	46.3	16.1	13.5	35.3	27.6	18.0	21.7	13.4	2.9	8.9	19.6	22.8	10.0	20.2	30.7	17.1	29.1	23.0	23.3	8.6	20.7	18.0	23.7	27.2	59.1	31.8	29.5	25.7	21.6	21.3	37.6	31.2	34.0	21.9	36.4	35.9	26.3	53.0	29.8	44.9	18.4	19.7	24.0	31.6	38.2	15.8	46.3	24.6	32.5	29.9	39.1	21.8	65.9	17.2	36.4	24.7	26.4	25.1	32.7	26.9	18.6	16.6	20.5	23.4	33.6	16.0	13.9	20.1	20.8	25.9	13.0	31.1	40.6	61.2	17.5	25.1	29.0	2.9	6.0	0.1	13.2	8.9	22.8	21.7	18.6	20.0	13.4	13.2	18.9	17.5	0.7	19.6	7.4	11.7	17.7	10.0	21.1	28.4	12.1	32.3	20.3	21.1	29.7	19.9	24.4	28.0
ATM	"ATA, ATC, ATD, ATDC, TEL1, TELO1"	ENSG00000149311	"ATM serine/threonine kinase"	Q13315	11	108222484-108369102	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, DNA damage"	"DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Neurodegeneration, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 47.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000102, HPA067142"	Supported		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB000102: , HPA067142: "	"unprognostic (9.77e-2)"	"unprognostic (1.47e-1)"	"unprognostic (3.04e-1)"	"unprognostic (2.36e-1)"	"unprognostic (5.70e-2)"	"unprognostic (2.86e-2)"	"unprognostic (6.32e-3)"	"unprognostic (1.05e-1)"	"unprognostic (8.19e-2)"	"unprognostic (1.63e-1)"	"unprognostic (7.68e-2)"	"unprognostic (6.16e-2)"	"unprognostic (2.17e-3)"	"unprognostic (3.10e-1)"	"unprognostic (7.87e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.81e-1)"	8.3	10.9	12.7	26.5	19.3	16.8	9.4	17.7	14.4	10.9	8.5	10.9	8.8	6.0	11.2	11.4	6.9	9.5	9.2	9.6	12.4	8.5	7.7	9.5	10.1	33.4	19.6	6.7	20.5	20.7	15.7	29.2	8.8	14.5	9.1	7.9	7.2	15.1	9.8	6.2	8.4	16.5	10.6	23.4	22.6	8.9	6.1	17.9	19.5	10.7	5.1	26.9	10.7	10.7	13.7	6.1	13.5	12.5	7.6	18.5	4.4	2.6	3.8	7.5	4.0	9.8	14.3	1.9	6.0	6.7	3.5	5.8	4.7	6.3	9.4	8.9	4.8	4.0	5.7	5.0	5.4	7.5	3.3	8.5	4.7	4.7	5.1	10.2	9.2	9.2	3.1	5.2	10.2	7.2	8.2	6.4	6.8	1.9	7.0	9.4	6.1	3.8	5.5	5.2	14.8	3.9	5.4	5.1	6.3	6.9	3.2	10.3	4.9	5.8	11.3	8.6	4.8	4.9	5.6	4.3	4.5	47.4	5.7	11.3	9.6	13.5	5.7	3.8	14.9	5.3	10.4	11.1	10.5	11.3	2.7	13.7	18.5	17.9	10.8	7.6	12.5	6.1	5.3	4.4	12.7	19.3	17.7	14.4	12.4	8.5	19.6	6.7	14.5	17.9
ATOH1	"bHLHa14, HATH1, MATH-1, Math1"	ENSG00000172238	"Atonal bHLH transcription factor 1"	Q92858	4	93828753-93830964	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	5	"intestine: 29.5"	"Cell line enhanced"	"Detected in some"		"HAP1: 3.6;HL-60: 2.3"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 9.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"																"prognostic favourable (3.26e-5)"								"unprognostic (5.20e-1)"	"unprognostic (2.69e-1)"		"unprognostic (1.26e-1)"	"unprognostic (2.70e-1)"			0.0	0.0	0.1	6.4	0.1	0.0	0.1	0.1	0.1	0.1	22.5	0.0	0.0	8.8	0.1	0.0	0.1	0.1	2.7	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	15.0	0.0	0.1	0.0	0.0	0.1	29.5	0.2	0.1	0.1	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.6	0.3	0.0	0.0	2.3	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.8	0.5	0.0	0.2	0.1	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
ATP1A1		ENSG00000163399	"ATPase Na+/K+ transporting subunit alpha 1"	P05023	1	116372668-116410261	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"		"Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 195.4;parathyroid gland: 194.4"	"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 248.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018702, CAB069993"	Enhanced					380000	380000			"CAB018702: AB_626713, CAB069993: AB_2060979"	"unprognostic (6.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (6.91e-2)"	"unprognostic (1.42e-2)"	"unprognostic (6.80e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavourable (1.42e-4)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.65e-1)"	"prognostic favourable (8.98e-8)"	"unprognostic (4.75e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.11e-2)"	"prognostic unfavourable (4.01e-4)"	17.4	25.6	22.4	16.2	40.3	10.5	26.9	74.2	67.4	17.8	121.9	14.2	56.1	92.3	13.1	38.3	34.9	17.7	65.8	41.1	26.1	18.7	162.7	34.6	35.1	9.6	19.2	27.6	17.4	78.6	194.4	25.0	19.2	34.1	22.1	65.7	24.1	84.4	53.7	19.0	40.5	195.4	17.7	20.7	13.7	25.0	17.0	13.9	9.1	101.2	13.7	16.2	14.2	23.1	10.3	22.0	6.4	29.7	10.4	30.2	17.2	32.9	12.2	12.7	6.3	25.5	24.7	65.2	19.8	39.4	24.4	34.7	48.7	23.7	26.1	28.0	23.4	43.1	25.0	41.7	35.5	9.6	27.7	15.2	23.0	41.1	19.5	38.1	21.4	27.5	69.9	28.4	37.5	29.9	25.0	25.3	21.6	65.6	15.4	13.8	29.8	24.5	14.9	29.6	23.1	88.1	34.0	12.5	11.0	30.7	58.4	248.8	15.3	22.1	26.3	13.9	19.5	35.9	40.0	12.2	9.5	20.1	42.7	22.0	81.6	6.4	13.3	6.1	23.2	20.9	24.8	10.3	26.4	24.9	22.0	5.3	30.2	22.0	1.6	10.4	29.7	11.1	20.3	17.2	22.4	40.3	74.2	67.4	26.1	18.7	19.2	27.6	34.1	13.9
ATP2B3	"CFAP39, CLA2, PMCA3, SCAX1"	ENSG00000067842	"ATPase plasma membrane Ca2+ transporting 3"	Q16720	X	153517676-153582939	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"	"Calcium transport, Ion transport, Transport"	Calmodulin-binding	"Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 18.6;brain: 23.2"	"Cell line enhanced"	"Detected in some"		"SCLC-21H: 14.3;SH-SY5Y: 4.2;THP-1: 3.5;U-937: 3.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001583	Enhanced									"HPA001583: AB_1079641"	"unprognostic (1.35e-1)"	"unprognostic (3.07e-2)"	"unprognostic (3.28e-1)"	"unprognostic (6.82e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.32e-2)"	"unprognostic (2.67e-1)"	"unprognostic (6.34e-2)"	"unprognostic (2.68e-2)"	"unprognostic (8.58e-2)"	"unprognostic (1.38e-3)"	"unprognostic (3.44e-1)"	"unprognostic (2.71e-12)"	"unprognostic (1.44e-3)"	"unprognostic (2.04e-1)"		"unprognostic (2.42e-2)"	0.8	18.6	5.4	0.9	11.3	0.8	0.8	16.1	23.2	0.8	0.9	3.9	0.0	0.9	0.9	2.6	0.8	3.1	0.8	0.8	7.8	5.5	1.0	0.8	0.8	0.8	4.3	11.5	0.8	0.9	0.8	1.2	1.7	13.6	0.8	0.8	1.4	1.3	1.3	0.8	0.9	0.9	0.9	1.4	0.8	0.8	1.1	0.9	0.0	0.8	0.0	0.8	0.8	0.1	0.0	0.5	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	14.3	4.2	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.4	11.3	16.1	20.7	7.8	5.5	4.3	11.5	13.6	0.9
ATP7B	WND	ENSG00000123191	"ATPase copper transporting beta"	P35670	13	51930436-52012125	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters"	"Copper transport, Ion transport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 18.5;liver: 13.5"	"Cell line enhanced"	"Detected in many"		"BEWO: 18.8;CACO-2: 10.8;HEL: 28.6;Hep G2: 9.9;RPTEC TERT1: 16.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"							"HPA009137, HPA013187"	Supported		Supported	"Golgi apparatus"				"Golgi apparatus"		"HPA009137: , HPA013187: AB_1845206"	"unprognostic (1.13e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.15e-1)"	"prognostic unfavourable (5.01e-4)"	"unprognostic (3.49e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.24e-1)"	"unprognostic (5.77e-2)"	"unprognostic (8.29e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.26e-3)"	"unprognostic (4.66e-2)"	"unprognostic (3.54e-1)"	"unprognostic (6.21e-3)"	"unprognostic (1.40e-1)"	3.4	0.7	1.8	2.4	2.9	1.8	1.6	7.0	2.8	1.4	6.8	1.1	1.1	10.5	1.6	1.9	1.1	1.9	18.5	1.8	2.1	2.1	2.1	13.5	1.2	1.1	1.6	1.1	2.0	1.7	7.7	1.2	7.1	3.5	1.9	2.6	1.4	3.0	1.1	1.1	0.7	9.6	1.5	1.1	1.6	4.5	7.1	1.6	1.1	1.1	1.1	1.1	2.1	1.1	0.0	0.0	1.0	0.3	0.0	0.5	0.1	0.4	1.6	2.9	2.6	0.6	0.5	18.8	0.8	0.2	0.9	0.6	10.8	0.1	0.0	0.3	1.4	0.2	2.0	2.4	0.6	0.2	4.0	28.6	0.3	9.9	0.9	0.3	6.7	1.2	2.8	0.1	1.1	2.0	7.6	0.0	0.8	0.5	0.1	0.7	0.9	0.9	1.0	0.8	0.0	16.7	1.8	2.2	1.2	1.0	1.6	1.1	4.5	0.2	1.1	0.1	1.0	1.6	0.3	0.3	0.4	0.1	0.0	0.1	0.4	0.0	0.3	0.0	0.0	0.0	0.5	0.0	0.3	0.1	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.1	1.8	2.9	7.0	2.8	2.1	2.1	1.6	1.1	3.5	1.6
ATR	"FRP1, MEC1, SCKL, SCKL1"	ENSG00000175054	"ATR serine/threonine kinase"	Q13535	3	142449235-142578826	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA repair"	"DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054320			Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"HPA054320: "	"unprognostic (1.47e-1)"	"unprognostic (8.90e-2)"	"unprognostic (2.90e-1)"	"unprognostic (4.23e-2)"	"unprognostic (2.25e-2)"	"unprognostic (6.42e-2)"	"prognostic unfavourable (8.39e-5)"	"unprognostic (3.44e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.02e-1)"	"prognostic unfavourable (1.23e-5)"	"unprognostic (1.94e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.55e-1)"	"unprognostic (1.69e-2)"	"unprognostic (1.43e-1)"	10.5	24.3	7.7	11.4	15.9	10.1	14.8	11.3	14.6	10.1	8.5	10.0	10.4	6.0	14.7	16.8	9.4	12.1	9.3	8.8	9.8	7.1	9.6	12.0	10.3	16.0	10.0	8.1	12.3	13.6	18.0	22.5	8.8	12.5	11.0	11.2	9.5	12.5	10.8	7.7	11.2	10.9	9.8	8.8	14.2	9.0	15.3	9.7	19.0	13.8	7.7	15.1	10.9	10.6	5.8	2.8	2.2	4.0	6.7	6.0	0.8	22.5	11.1	7.4	8.4	10.6	11.6	8.8	12.4	7.0	9.3	9.6	5.2	7.2	18.4	12.9	8.8	14.6	10.9	11.5	14.1	5.9	7.2	10.1	8.4	5.0	4.7	16.9	5.7	9.1	6.4	8.8	10.5	9.6	7.0	8.3	9.5	9.9	12.7	7.0	7.1	7.9	10.6	10.8	13.3	9.4	10.5	5.3	5.3	22.9	8.3	8.1	12.1	6.9	12.4	9.5	4.8	12.3	13.3	10.8	6.4	17.1	12.3	6.6	7.5	0.7	2.7	2.2	4.4	4.0	6.0	3.1	3.2	4.2	2.8	5.8	4.1	4.0	1.7	6.7	2.5	2.5	2.4	0.8	7.7	15.9	11.3	14.6	9.8	7.1	10.0	8.1	12.5	9.7
ATRX	"JMS, MRX52, RAD54, XH2, XNP"	ENSG00000085224	"ATRX, chromatin remodeler"	P46100	X	77504878-77786269	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"DNA damage, DNA repair, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001906, CAB009372, HPA064684, CAB068176"	Supported		Supported	"Nuclear bodies"				"Nuclear bodies"		"CAB009372: AB_2061023, CAB068176: , HPA001906: AB_1078249, HPA064684: "	"unprognostic (1.77e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.65e-2)"	"unprognostic (4.37e-2)"	"unprognostic (1.67e-1)"	"unprognostic (9.69e-2)"	"unprognostic (8.11e-2)"	"unprognostic (1.15e-2)"	"unprognostic (6.04e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.80e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.50e-1)"	"unprognostic (6.19e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.24e-1)"	16.4	16.6	24.5	18.9	29.3	24.3	16.3	48.2	26.4	20.6	15.4	7.1	18.9	10.2	20.2	17.1	13.5	13.8	13.4	15.1	22.9	15.8	16.6	12.2	15.9	18.6	21.1	21.3	25.4	18.3	35.7	28.1	15.9	20.2	18.4	12.6	7.1	15.8	16.5	20.1	14.1	13.5	22.3	15.3	20.1	15.6	6.5	22.4	23.7	19.8	12.7	16.5	19.9	21.1	21.9	12.8	21.5	11.5	14.6	17.7	5.7	15.1	24.4	25.1	16.8	12.5	16.8	8.9	13.1	12.1	9.7	11.5	8.3	13.3	21.0	13.5	13.9	13.5	20.0	7.8	16.6	11.8	13.1	12.7	29.0	6.1	6.8	16.5	4.4	11.1	7.7	14.3	13.7	17.1	14.9	24.2	12.1	11.9	12.7	8.6	18.1	18.9	20.6	34.6	10.8	9.5	20.3	14.3	24.7	26.4	10.4	8.7	8.3	8.4	23.6	13.7	21.3	15.4	9.2	7.2	22.3	18.9	10.1	13.1	12.1	21.3	6.9	13.8	17.7	8.7	17.1	19.2	16.3	13.7	5.1	21.9	16.8	13.5	21.5	14.6	11.5	12.8	12.8	5.7	24.5	29.3	48.2	26.4	22.9	15.8	21.1	21.3	20.2	22.4
AURKA	"AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7"	ENSG00000087586	"Aurora kinase A"	O14965	20	56369389-56392337	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Cilium biogenesis/degradation, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"lymphoid tissue: 32.3;testis: 41.1"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"							"CAB001454, HPA002636"	Enhanced		Approved	Nucleoplasm,Centrosome,Cytosol				"Nucleoplasm, Centrosome, Cytosol"		"CAB001454: AB_563420, HPA002636: AB_1845217"	"unprognostic (7.73e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.76e-2)"	"prognostic unfavourable (9.40e-5)"	"unprognostic (1.92e-1)"	"unprognostic (2.11e-2)"	"prognostic unfavourable (1.49e-4)"	"unprognostic (4.69e-3)"	"unprognostic (2.42e-1)"	"unprognostic (6.88e-2)"	"prognostic unfavourable (6.13e-4)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (1.47e-8)"	"unprognostic (1.67e-1)"	"unprognostic (6.83e-2)"	"unprognostic (9.00e-2)"	"unprognostic (5.14e-2)"	3.7	2.3	1.5	12.7	1.3	8.3	3.0	1.3	1.8	1.4	6.7	1.3	0.8	7.3	1.8	1.2	7.7	1.1	3.7	4.1	1.1	1.1	2.4	5.1	2.9	12.3	1.6	0.9	8.3	1.4	0.3	0.7	6.1	1.5	1.0	8.3	1.5	2.7	0.5	6.9	2.1	7.2	2.7	1.3	7.4	4.3	41.1	1.1	32.3	1.2	5.9	13.3	2.4	2.4	3.9	5.2	6.0	8.7	2.0	6.6	2.6	32.5	24.0	16.1	11.3	0.9	2.1	20.4	26.7	12.5	64.7	27.3	67.2	22.8	10.7	18.4	10.9	26.3	28.5	17.9	69.0	9.6	10.9	19.0	24.6	41.8	0.5	25.4	26.8	1.0	1.9	22.4	20.1	15.1	21.5	8.5	27.5	33.2	15.2	19.7	14.7	24.8	11.6	31.1	11.8	10.3	8.6	13.9	7.5	37.3	43.0	17.9	25.5	15.9	8.6	28.1	27.9	15.5	37.6	11.9	13.8	18.5	15.2	14.8	23.2	0.2	5.3	6.0	1.9	8.7	2.9	3.9	3.3	1.9	5.2	1.4	1.5	1.5	3.7	2.0	4.8	1.2	6.6	2.6	1.5	1.3	1.3	1.8	1.1	1.1	1.6	0.9	1.5	1.1
AURKB	"Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5"	ENSG00000178999	"Aurora kinase B"	Q96GD4	17	8204733-8210600	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 19.7;lymphoid tissue: 59.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 10.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB005862, HPA037708"	Enhanced		Supported	Nucleoplasm,Midbody				"Nucleoplasm, Midbody"		"CAB005862: AB_449204, HPA037708: "	"unprognostic (4.76e-2)"	"unprognostic (3.61e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.05e-2)"	"prognostic unfavourable (1.24e-4)"	"unprognostic (1.99e-3)"	"unprognostic (9.41e-3)"	"unprognostic (3.47e-2)"	"unprognostic (4.61e-3)"	"unprognostic (1.01e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (7.77e-2)"	"unprognostic (2.93e-1)"	"unprognostic (6.76e-2)"	"unprognostic (3.77e-1)"	1.2	1.3	0.4	22.1	0.6	19.7	2.0	0.6	0.6	2.6	5.8	0.5	0.9	5.9	0.9	1.3	17.1	0.3	2.2	1.0	0.4	0.2	1.4	1.8	2.4	17.8	0.4	0.4	0.8	0.6	0.0	0.4	3.8	0.8	0.9	5.5	0.7	2.7	0.4	2.1	5.0	8.1	1.3	0.7	11.2	4.2	1.2	0.4	59.9	0.5	8.0	19.1	2.1	5.0	2.3	0.8	1.2	0.6	0.5	10.9	1.4	41.0	28.2	42.0	20.2	0.9	1.4	16.1	19.7	10.6	40.8	37.7	36.5	12.4	41.0	10.2	7.8	30.2	30.5	13.5	33.8	18.0	50.1	24.4	16.1	30.8	0.1	12.9	24.0	0.7	0.6	23.9	15.0	18.8	15.2	15.9	17.9	19.5	46.8	18.3	26.1	12.6	31.7	38.7	17.0	8.9	8.1	9.1	13.0	17.5	7.9	13.4	13.8	8.7	7.3	16.4	16.9	14.7	51.2	11.6	7.7	30.8	7.9	19.6	33.1	0.0	0.6	0.9	0.6	0.4	0.2	1.6	1.9	3.1	0.8	2.3	0.2	1.0	1.2	0.5	0.3	0.2	10.9	1.4	0.4	0.6	0.6	0.6	0.4	0.2	0.4	0.4	0.8	0.4
AXIN1	PPP1R49	ENSG00000103126	"Axin 1"	O15169	16	287440-352673	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB012987	Approved		Supported	Nucleoli,Vesicles				"Nucleoli, Vesicles"		"CAB012987: AB_2533178"	"unprognostic (3.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.90e-1)"	"unprognostic (7.64e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.06e-1)"	"prognostic unfavourable (3.38e-5)"	"unprognostic (1.23e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.56e-1)"	"unprognostic (4.58e-2)"	"unprognostic (2.02e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.03e-1)"	10.8	8.3	13.7	18.9	17.1	28.1	21.0	26.4	13.6	10.4	15.8	12.7	9.4	17.3	12.6	8.5	14.1	10.7	12.7	11.0	11.5	7.7	9.8	9.6	13.6	13.4	15.6	10.6	13.3	17.7	11.1	11.9	8.4	13.9	11.4	10.2	9.6	13.9	9.5	17.7	16.9	17.6	18.9	9.6	15.1	15.2	9.6	14.6	17.5	12.7	7.5	14.5	11.9	22.9	1.8	1.4	5.5	1.1	3.6	10.4	2.4	9.4	13.8	7.3	12.9	5.5	5.1	15.5	6.4	5.9	8.9	7.7	20.2	11.1	14.7	9.9	6.6	13.7	11.5	10.0	4.0	14.4	18.8	9.5	11.5	14.7	9.4	10.9	10.6	5.0	17.5	9.2	11.3	5.8	23.7	8.1	4.0	25.4	11.7	7.6	16.8	8.4	22.2	6.7	20.4	6.7	5.6	16.8	10.3	12.2	13.7	20.1	9.0	13.9	6.6	8.9	9.5	10.2	9.2	9.4	9.2	18.0	4.2	7.3	8.7	1.4	1.1	5.5	10.4	0.9	9.5	1.8	3.0	7.0	0.8	1.6	3.2	4.3	3.2	3.6	0.7	1.4	3.0	2.4	13.7	17.1	26.4	13.6	11.5	7.7	15.6	10.6	13.9	14.6
AXIN2	"DKFZp781B0869, MGC126582"	ENSG00000168646	"Axin 2"	Q9Y2T1	17	65528563-65561647	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 13.3;CACO-2: 24.7;Hep G2: 36.9"	"Cancer enhanced"	"Detected in all"		"colorectal cancer: 33.4"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 5.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012283, CAB017783"	Approved		Uncertain	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Plasma membrane"	Cytosol	"CAB012283: AB_2290204, CAB017783: "	"unprognostic (1.31e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.45e-3)"	"unprognostic (4.48e-1)"	"unprognostic (9.81e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.82e-1)"	"unprognostic (4.57e-2)"	"unprognostic (8.84e-3)"	"prognostic favourable (6.58e-4)"	"unprognostic (1.98e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.45e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.25e-1)"	7.4	10.1	9.0	7.0	8.9	0.9	5.2	8.2	13.1	16.5	12.2	8.7	10.5	7.2	29.0	7.7	6.5	18.6	6.9	7.3	7.9	5.7	3.5	2.5	15.2	3.4	5.3	10.3	14.7	3.9	3.2	5.8	18.2	10.6	14.8	15.2	7.8	4.6	9.8	12.4	14.9	7.5	18.0	4.8	6.9	14.6	6.8	9.0	27.6	11.3	3.6	3.8	11.8	8.7	4.1	0.0	4.4	0.0	1.9	5.1	0.8	0.0	6.6	13.3	0.2	4.8	2.0	5.9	0.2	0.6	0.4	0.8	24.7	2.4	0.4	0.8	3.8	0.2	2.7	0.0	0.9	1.1	1.5	0.0	1.1	36.9	0.5	0.0	0.0	1.2	1.0	1.0	0.3	1.1	0.1	0.6	0.6	0.1	6.4	0.0	2.6	0.3	4.6	0.7	0.0	1.2	0.1	4.1	2.7	0.2	0.1	2.3	0.4	0.1	3.0	2.6	4.8	3.7	0.8	0.0	1.3	1.7	1.2	0.3	1.2	4.4	0.0	0.0	0.3	0.0	0.8	1.0	2.3	0.4	0.0	4.1	5.1	0.8	0.0	1.9	0.0	0.0	0.0	0.8	9.0	8.9	8.2	13.1	7.9	5.7	5.3	10.3	10.6	9.0
AZGP1	"ZA2G, ZAG"	ENSG00000160862	"Alpha-2-glycoprotein 1, zinc-binding"	P25311	7	99966720-99976157	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 158.8;salivary gland: 270.5"	"Cell line enhanced"	"Detected in some"		"Hep G2: 19.8;Karpas-707: 11.3;RPMI-8226: 45.9;SK-BR-3: 9.3;T-47d: 15.4"	"Group enriched"	"Detected in many"	12	"breast cancer: 412.6;liver cancer: 273.6;prostate cancer: 469.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	4	"olfactory region: 0.9"					"HPA012582, CAB016087, CAB032276"	Enhanced				"Secreted to blood"	160000000000	160000000000			"CAB016087: AB_667849, CAB032276: AB_2062580, HPA012582: AB_1845226"	"unprognostic (8.14e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.41e-1)"	"unprognostic (5.42e-3)"	"unprognostic (4.98e-2)"	"unprognostic (5.74e-3)"	"prognostic favourable (2.90e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.85e-1)"	"unprognostic (2.19e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.79e-1)"	"prognostic favourable (1.53e-4)"	"unprognostic (2.18e-1)"	"unprognostic (2.08e-2)"	"unprognostic (9.80e-2)"	"unprognostic (3.51e-3)"	6.4	0.0	1.1	1.3	1.7	0.0	64.1	1.1	1.4	1.1	1.4	1.5	0.9	1.4	0.9	1.2	1.3	0.0	2.2	9.0	1.2	0.4	18.0	158.8	3.0	0.9	2.7	1.2	1.0	55.3	0.0	0.9	1.0	1.3	62.4	0.0	1.6	270.5	2.5	1.0	11.5	1.5	0.9	1.1	0.9	14.4	1.2	1.7	0.9	1.0	3.0	3.2	1.0	1.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	2.0	0.0	0.0	0.0	0.0	0.0	1.4	5.1	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.8	1.9	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.1	11.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.6	45.9	0.0	0.0	0.0	0.7	0.3	9.3	4.5	15.4	0.0	0.0	0.1	0.0	0.7	0.3	0.7	0.3	0.1	0.0	0.1	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.1	1.7	1.1	1.4	1.2	0.4	2.7	1.2	1.3	1.7
B2M		ENSG00000166710	Beta-2-microglobulin	P61769	15	44711477-44718877	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	Immunity		"Amyloidosis, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"THP-1: 175.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002572, HPA006361"	Enhanced		Enhanced	"Golgi apparatus,Plasma membrane,Cytosol"	"Intracellular and membrane"	3200000000	3200000000	"Golgi apparatus, Plasma membrane"	Cytosol	"CAB002572: AB_563434, HPA006361: AB_1078278"	"unprognostic (9.45e-2)"	"unprognostic (5.63e-2)"	"unprognostic (3.02e-1)"	"unprognostic (8.14e-2)"	"unprognostic (1.18e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.44e-3)"	"unprognostic (2.02e-2)"	"unprognostic (4.77e-2)"	"unprognostic (2.39e-1)"	"unprognostic (5.25e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.17e-2)"	127.2	50.9	24.2	109.2	29.8	131.1	85.2	11.8	23.1	70.5	111.4	29.1	43.3	79.1	72.7	74.7	80.5	36.8	112.8	73.6	26.0	23.1	109.7	140.3	191.2	172.1	42.2	18.8	54.8	42.7	7.8	40.5	91.9	33.1	78.7	128.9	53.5	121.5	40.9	45.7	94.1	178.5	55.1	56.7	272.8	52.5	30.0	29.5	108.0	97.7	71.5	131.6	135.9	73.5	138.9	74.9	341.3	132.8	128.8	215.8	323.7	33.1	14.7	1.4	8.3	54.6	73.6	52.1	22.0	44.9	35.8	60.9	19.1	77.4	15.8	31.1	21.4	29.3	5.5	9.8	17.2	110.7	13.0	60.2	89.2	22.1	41.6	33.7	36.1	37.2	9.1	11.0	11.8	24.4	15.3	2.2	39.6	17.7	13.8	89.0	2.4	31.4	16.8	36.0	100.3	31.2	137.5	5.8	2.1	23.0	18.7	25.9	6.2	175.3	48.5	70.3	7.8	92.6	42.9	41.0	93.8	29.5	68.5	111.3	33.6	221.2	90.4	210.9	126.8	132.8	125.9	138.9	171.7	141.1	58.9	109.4	137.0	167.5	341.3	128.8	106.5	74.9	215.8	323.7	24.2	29.8	11.8	23.1	26.0	23.1	42.2	18.8	33.1	29.5
BAD	"BBC2, BCL2L8"	ENSG00000002330	"BCL2 associated agonist of cell death"	Q92934	11	64269830-64284704	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004205, HPA028185, HPA062105"	Approved		Enhanced	Mitochondria				Mitochondria		"CAB004205: AB_626717, HPA028185: AB_10603445, HPA062105: "	"unprognostic (1.47e-1)"	"unprognostic (3.08e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.24e-3)"	"unprognostic (2.60e-1)"	"unprognostic (6.73e-2)"	"unprognostic (1.24e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.14e-1)"	"unprognostic (8.26e-2)"	"unprognostic (9.04e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.48e-1)"	"unprognostic (7.95e-2)"	23.1	23.2	35.3	12.6	30.7	17.7	20.6	15.9	43.9	21.2	25.7	22.7	20.1	24.0	18.3	19.7	18.8	23.2	22.5	30.3	32.7	23.8	21.4	22.3	17.7	14.3	29.6	20.2	18.8	26.9	19.4	15.2	24.9	18.4	22.9	13.6	23.1	39.9	27.0	23.9	20.4	21.1	17.2	22.9	14.9	37.8	18.6	14.8	19.3	29.2	15.8	14.1	18.2	14.4	26.5	42.0	43.5	32.3	24.0	30.7	23.1	31.9	30.1	8.8	13.2	10.7	13.1	12.9	13.6	15.9	21.0	16.7	18.3	18.4	6.9	24.5	12.7	17.0	5.7	21.4	4.2	26.7	21.0	8.5	27.2	8.7	16.5	7.4	16.0	12.6	18.5	16.1	9.9	13.2	3.2	14.9	9.1	31.8	16.5	16.7	3.4	38.5	15.7	5.2	19.3	12.7	15.1	18.2	24.4	13.7	16.3	16.6	24.5	11.1	10.9	25.7	17.4	39.8	14.9	28.3	21.0	7.0	21.0	5.3	14.0	32.5	32.3	43.5	25.3	24.0	25.8	26.0	26.9	24.6	22.5	26.5	19.4	20.0	41.7	24.0	22.6	42.0	30.7	23.1	35.3	30.7	15.9	43.9	32.7	23.8	29.6	20.2	18.4	14.8
BAG1		ENSG00000107262	"BCL2 associated athanogene 1"	Q99933	9	33247820-33264720	"Cancer-related genes, Predicted intracellular proteins"	Apoptosis	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HeLa: 81.3;NB-4: 77.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002486, HPA018121"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB002486: AB_563422, HPA018121: AB_1845255"	"unprognostic (4.49e-3)"	"unprognostic (4.52e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.32e-3)"	"unprognostic (5.46e-2)"	"unprognostic (3.67e-3)"	"unprognostic (2.10e-1)"	"unprognostic (1.34e-2)"	"unprognostic (4.62e-2)"	"unprognostic (7.21e-2)"	"unprognostic (4.24e-1)"	"unprognostic (2.23e-1)"	"prognostic favourable (2.22e-16)"	"unprognostic (4.45e-2)"	"unprognostic (4.03e-1)"	"unprognostic (7.64e-3)"	"unprognostic (1.07e-2)"	21.5	22.1	30.0	14.6	34.3	25.2	28.6	21.2	25.0	21.4	32.0	18.3	19.5	20.8	15.5	20.4	26.9	17.4	34.8	48.6	25.0	24.3	41.9	34.5	21.2	14.1	33.8	20.1	14.4	43.2	40.9	24.9	16.6	20.0	24.7	27.7	18.2	38.5	26.4	93.2	26.7	27.2	22.2	27.7	21.4	32.5	46.0	20.5	14.9	29.7	41.9	21.2	30.8	27.3	10.2	18.8	29.4	11.6	8.2	9.0	5.1	10.4	10.4	8.9	19.5	13.6	8.0	12.4	8.5	12.2	13.1	13.5	7.3	10.1	34.7	6.4	8.6	13.2	10.3	7.0	8.7	17.5	9.7	17.3	81.3	11.4	11.5	39.5	21.1	8.1	39.3	6.1	14.8	15.5	19.9	17.4	10.8	16.4	27.0	77.7	17.2	15.3	14.2	12.7	22.3	16.6	30.6	28.5	17.1	38.0	33.5	8.5	15.2	48.2	8.2	5.9	7.5	17.2	14.8	13.9	21.5	18.8	4.9	21.4	3.3	12.2	11.5	29.4	5.8	11.6	5.2	6.8	6.6	6.9	14.0	10.2	9.0	5.4	7.0	8.2	11.2	18.8	7.8	5.1	30.0	34.3	21.2	25.0	25.0	24.3	33.8	20.1	20.0	20.5
BAP1	"hucep-6, KIAA0272, UCHL2"	ENSG00000163930	"BRCA1 associated protein 1"	Q92560	3	52401013-52410350	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Chromatin regulator, Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004322, HPA028814, HPA028815, HPA055560"	Approved		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB004322: AB_626723, HPA028814: AB_10602393, HPA028815: , HPA055560: "	"unprognostic (1.52e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.96e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.55e-2)"	"unprognostic (9.41e-3)"	"unprognostic (8.53e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.64e-3)"	"unprognostic (3.30e-3)"	"prognostic favourable (3.29e-7)"	"unprognostic (6.37e-2)"	"unprognostic (1.91e-1)"	"unprognostic (5.54e-2)"	"unprognostic (2.92e-1)"	13.8	17.6	35.6	14.7	33.3	37.3	13.5	21.8	50.4	12.5	17.0	16.3	11.5	12.4	14.7	14.6	21.2	12.1	15.7	16.4	41.5	15.5	16.6	19.0	14.9	15.2	19.4	27.6	16.9	16.3	30.0	11.1	14.8	19.6	14.4	14.9	15.6	17.9	14.6	24.8	40.5	13.9	14.5	10.0	16.1	13.3	37.3	14.7	18.6	15.3	12.9	16.0	14.1	11.7	5.5	8.4	11.3	5.0	3.0	8.5	3.9	15.3	17.5	21.2	18.0	20.5	13.2	23.9	15.2	19.7	24.7	19.2	21.1	14.4	22.0	7.6	21.2	12.5	22.3	24.5	15.8	21.8	21.1	27.3	37.0	21.8	19.1	25.6	24.3	19.7	32.9	27.3	14.7	19.7	23.3	19.5	18.6	13.3	30.3	35.1	23.9	21.3	13.1	17.2	21.7	15.2	24.9	8.1	26.1	18.7	5.4	22.2	15.3	35.4	21.1	22.4	20.6	26.8	28.2	29.6	38.9	31.5	24.4	27.0	26.4	3.4	5.0	7.4	8.5	3.9	4.0	5.0	6.8	6.9	3.3	5.5	4.9	6.4	11.3	3.0	3.1	8.4	6.0	3.9	35.6	33.3	21.8	50.4	41.5	15.5	19.4	27.6	19.6	14.7
BARD1		ENSG00000138376	"BRCA1 associated RING domain 1"	Q99728	2	214725646-214809711	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB034106, HPA035354, HPA044864"	Enhanced		Supported	"Nuclear speckles,Cytoplasmic bodies"				"Nuclear speckles"	"Cytoplasmic bodies"	"CAB034106: AB_2061237, HPA035354: , HPA044864: "	"unprognostic (4.85e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.74e-2)"	"unprognostic (8.37e-3)"	"unprognostic (2.57e-2)"	"unprognostic (1.03e-2)"	"unprognostic (6.25e-4)"	"unprognostic (1.99e-1)"	"unprognostic (2.16e-2)"	"unprognostic (3.92e-3)"	"unprognostic (2.80e-2)"	"unprognostic (7.41e-2)"	"unprognostic (1.94e-8)"	"unprognostic (3.94e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.08e-1)"	4.4	1.9	3.2	11.8	4.8	16.1	4.9	1.2	5.8	7.3	5.4	5.4	3.6	3.7	6.8	5.0	10.0	4.1	3.9	3.6	3.4	2.8	2.2	2.1	5.3	8.2	5.1	1.9	5.8	3.7	3.6	6.3	3.8	4.5	5.7	6.1	1.9	4.7	6.5	12.4	16.3	4.5	7.5	5.3	4.7	3.8	9.5	3.9	25.8	4.0	8.0	9.9	8.3	7.8	9.7	6.6	6.0	3.4	6.1	16.0	2.0	7.7	4.3	11.7	6.0	1.6	2.0	8.0	9.4	5.5	9.3	10.7	5.4	7.7	8.3	4.5	3.9	8.5	8.4	5.5	13.3	6.6	4.4	8.3	7.9	5.7	0.6	9.2	8.4	2.7	0.8	8.2	4.5	3.1	4.6	23.5	8.9	6.4	16.5	9.6	9.2	2.2	14.3	11.8	7.5	2.7	6.5	3.7	5.9	8.6	9.9	3.4	10.2	9.2	2.7	12.0	8.4	7.0	8.5	7.1	7.9	16.9	4.8	7.0	8.0	2.9	1.7	6.0	4.8	3.4	3.1	8.9	5.3	5.2	3.0	9.7	2.5	3.6	0.5	6.1	2.9	6.6	16.0	2.0	3.2	4.8	1.2	5.8	3.4	2.8	5.1	1.9	4.5	3.9
BAX	BCL2L4	ENSG00000087088	"BCL2 associated X, apoptosis regulator"	Q07812	19	48954815-48961798	"Cancer-related genes, Predicted intracellular proteins, Transporters"	"Apoptosis, Host-virus interaction"		"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004206, HPA027878"	Approved					1300000	1300000			"CAB004206: AB_626729, HPA027878: AB_10601687"	"unprognostic (4.11e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.50e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.82e-1)"	"prognostic unfavourable (1.63e-5)"	"unprognostic (4.92e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.66e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.19e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.47e-3)"	"unprognostic (6.22e-2)"	15.2	20.0	12.3	26.0	13.2	25.3	20.2	7.6	13.6	14.9	33.3	15.1	13.5	30.7	19.3	11.2	21.4	15.5	40.4	14.9	11.3	10.2	19.5	26.1	26.6	25.9	18.7	12.5	16.4	16.2	8.8	10.0	21.5	14.9	16.6	27.8	10.3	16.5	13.3	11.6	17.1	28.7	16.3	15.1	37.8	19.6	10.7	13.2	37.8	17.7	16.3	26.5	19.1	19.5	6.6	10.6	11.1	16.5	9.1	6.4	6.6	34.0	56.6	34.3	30.0	34.2	33.6	56.5	23.3	46.7	30.6	43.0	15.0	33.4	41.6	10.9	35.5	18.5	15.5	45.3	25.5	32.1	35.8	17.7	11.5	55.4	55.0	18.4	56.9	45.9	32.5	25.4	15.3	70.5	17.3	17.1	52.6	24.1	29.8	28.9	26.5	16.2	21.0	22.7	16.0	32.2	33.1	19.7	23.3	19.5	14.0	10.7	11.2	33.3	41.3	39.6	43.0	24.1	31.8	19.7	25.1	27.0	24.0	25.1	54.6	4.3	10.4	10.5	6.0	15.3	4.3	6.6	3.4	6.4	10.4	5.8	2.3	5.3	11.1	9.1	16.5	10.6	6.3	6.6	12.3	13.2	7.6	13.6	11.3	10.2	18.7	12.5	14.9	13.2
BCL10	"c-E10, CARMEN, CIPER, CLAP, mE10"	ENSG00000142867	"B cell CLL/lymphoma 10"	O95999	1	85266248-85277090	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Immunity"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HUVEC TERT2: 40.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001944, HPA017925"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB001944: , HPA017925: AB_1845312"	"unprognostic (3.78e-3)"	"unprognostic (2.53e-1)"	"prognostic favourable (2.51e-4)"	"unprognostic (1.61e-1)"	"unprognostic (3.47e-1)"	"unprognostic (2.61e-2)"	"prognostic unfavourable (7.21e-7)"	"unprognostic (7.06e-2)"	"unprognostic (2.36e-1)"	"unprognostic (9.46e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.73e-1)"	"unprognostic (4.92e-3)"	"unprognostic (3.18e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-1)"	17.2	10.7	5.8	16.4	6.0	19.6	20.7	5.8	8.6	14.7	21.5	7.5	9.5	12.2	14.8	10.0	29.0	8.5	16.7	7.5	5.9	5.4	11.9	11.4	20.4	21.5	6.5	5.2	11.6	9.1	5.4	6.3	11.8	5.9	11.6	20.4	6.4	11.8	12.4	5.0	14.6	27.6	9.9	6.1	18.5	13.0	8.5	5.1	18.3	11.3	12.7	22.1	14.3	17.6	22.4	14.2	37.5	18.2	10.4	13.3	9.0	15.7	3.3	4.6	4.9	6.6	9.8	7.8	12.1	11.0	8.8	12.2	4.0	6.4	7.1	8.6	9.5	8.6	5.2	12.9	12.8	6.0	4.0	7.4	3.3	5.5	10.3	7.3	7.0	7.8	14.3	13.1	11.7	40.0	5.3	6.4	14.7	3.0	7.0	6.0	8.0	11.2	5.0	10.5	4.5	30.6	12.2	3.1	4.1	3.7	12.5	11.5	4.2	5.0	19.9	9.1	6.4	11.1	12.0	5.2	2.8	6.9	4.5	6.4	6.2	25.2	15.1	20.1	10.0	18.2	11.1	22.4	13.1	11.3	14.2	20.3	12.4	11.4	37.5	10.4	13.5	12.0	13.3	9.0	5.8	6.0	5.8	8.6	5.9	5.4	6.5	5.2	5.9	5.1
BCL11A	"BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856"	ENSG00000119866	"B cell CLL/lymphoma 11A"	Q9H165	2	60450520-60555154	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 107.1"	"Cell line enhanced"	"Detected in some"		"Daudi: 20.3;MOLT-4: 18.7;REH: 19.1;U-698: 41.8;U-937: 13.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"memory B-cell: 39.6;naive B-cell: 53.7;plasmacytoid DC: 107.1"	"Group enriched"	"Detected in many"	16	"B-cells: 53.7;dendritic cells: 107.1"	"Group enriched"	"Detected in all"	5	"amygdala: 42.3;basal ganglia: 57.1;cerebral cortex: 62.7;hippocampal formation: 65.3;olfactory region: 101.8"	"Group enriched"	"Detected in all"	4	"basal ganglia: 58.3;cerebral cortex: 93.2;hippocampal formation: 97.2;olfactory region: 128.9"	"CAB014891, HPA029003"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"				Nucleoplasm	"Nuclear bodies"	"CAB014891: , HPA029003: "	"unprognostic (4.10e-3)"	"unprognostic (6.72e-2)"	"unprognostic (4.50e-2)"	"unprognostic (9.41e-3)"	"unprognostic (2.37e-1)"	"unprognostic (4.47e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.45e-1)"	"unprognostic (4.27e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.35e-2)"	"unprognostic (3.59e-2)"	"unprognostic (2.26e-1)"	"unprognostic (4.40e-2)"	"unprognostic (2.99e-2)"	1.5	2.4	6.6	13.9	14.6	17.0	5.5	1.8	34.5	3.9	8.6	0.2	0.1	7.6	1.8	1.4	13.6	4.8	2.2	4.7	14.5	3.4	1.7	1.5	3.0	21.2	3.5	14.4	1.6	11.3	1.2	3.9	0.9	9.6	4.8	5.1	0.0	11.4	2.0	1.4	24.9	11.4	2.9	2.0	13.5	3.3	2.0	2.6	20.9	2.4	4.0	30.4	3.6	7.8	53.7	107.1	1.3	5.1	1.0	0.1	1.2	0.2	0.0	1.7	0.0	0.3	0.3	0.1	0.6	0.0	0.0	0.0	0.0	0.0	20.3	0.1	0.0	4.1	6.3	3.0	0.0	0.3	6.0	0.0	0.2	0.1	0.0	7.3	0.0	0.7	1.6	0.0	1.0	1.0	0.3	0.1	0.0	0.0	18.7	7.4	11.5	0.1	19.1	0.5	7.7	0.0	0.3	8.2	2.0	0.1	0.1	0.1	0.1	3.5	0.5	0.1	4.8	0.1	0.0	0.3	0.0	41.8	0.0	13.4	0.6	0.4	2.9	0.5	0.0	5.1	0.1	39.6	0.0	0.0	10.7	53.7	0.1	0.1	1.3	1.0	3.7	107.1	0.1	1.2	6.6	14.6	1.8	34.5	14.5	3.4	3.5	14.4	9.6	2.6
BCL11B	"CTIP-2, CTIP2, hRIT1-alpha, ZNF856B"	ENSG00000127152	"B cell CLL/lymphoma 11B"	Q9C0K0	14	99169287-99271524	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Disease mutation, Mental retardation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6"	"Cell line enriched"	"Detected in some"	6	"MOLT-4: 32.6"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 13.7"	"Group enriched"	"Detected in many"	8	"gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0"	"Lineage enriched"	"Detected in single"	14	"T-cells: 7.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA049117	Enhanced	Supported	Approved	"Nucleoplasm,Nucleoli fibrillar center"				Nucleoplasm	"Nucleoli fibrillar center"	"HPA049117: AB_2680639"	"unprognostic (1.64e-5)"	"unprognostic (4.66e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.87e-2)"	"unprognostic (9.37e-2)"	"unprognostic (5.97e-2)"	"unprognostic (4.75e-2)"	"unprognostic (6.07e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.60e-6)"	"unprognostic (1.07e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.31e-3)"	"prognostic favourable (7.48e-4)"	0.3	0.4	4.4	6.6	13.7	5.2	1.3	0.3	3.8	0.8	1.3	0.1	0.0	2.3	1.9	0.8	3.9	0.3	3.0	0.8	4.8	1.0	0.3	0.5	1.1	10.8	0.8	2.6	0.2	0.1	0.0	0.1	0.0	0.6	0.6	1.7	0.3	5.0	0.7	0.1	17.6	3.0	0.2	0.7	4.9	2.1	0.4	1.6	25.4	0.9	1.5	8.8	2.0	2.3	0.0	0.0	0.1	0.0	0.5	7.4	1.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.3	1.2	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.3	0.0	0.1	0.0	0.0	3.0	0.0	1.8	32.6	0.5	0.3	0.0	5.1	0.0	0.0	0.0	1.8	2.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.1	0.0	2.0	0.0	0.0	1.4	0.4	0.0	0.0	0.0	0.1	3.3	0.0	3.0	0.0	4.5	3.7	0.0	0.0	7.4	4.9	0.0	0.5	0.0	0.0	3.0	1.1	4.4	13.7	0.3	3.8	4.8	1.0	0.8	2.6	0.6	1.6
BCL2	"Bcl-2, PPP1R50"	ENSG00000171791	"BCL2, apoptosis regulator"	P10415	18	63123346-63320128	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis		"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 22.3;U-266/70: 77.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7"	"Group enriched"	"Detected in many"	8	"B-cells: 5.2;T-cells: 7.6"	"Low region specificity"	"Detected in all"							"CAB000003, HPA055295"	Enhanced		Supported	"Nucleoplasm,Nuclear membrane"				"Nuclear membrane"	Nucleoplasm	"CAB000003: AB_2064429, HPA055295: "	"unprognostic (1.11e-3)"	"prognostic favourable (5.13e-5)"	"unprognostic (5.49e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.05e-3)"	"unprognostic (2.88e-1)"	"unprognostic (1.93e-3)"	"unprognostic (4.78e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.23e-2)"	"unprognostic (8.51e-2)"	"prognostic favourable (1.29e-8)"	"unprognostic (6.67e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (2.47e-4)"	"unprognostic (2.63e-1)"	12.9	3.0	10.1	15.7	9.4	5.3	24.6	4.7	8.4	14.8	7.8	7.4	9.1	5.0	17.1	9.3	4.7	12.2	9.2	6.5	10.0	8.1	8.5	2.3	5.0	14.6	10.8	5.6	18.2	2.9	19.6	7.0	22.4	9.2	8.4	5.9	10.8	5.4	15.7	20.0	6.3	10.5	8.6	9.3	17.8	5.4	3.5	10.5	21.0	35.6	2.9	13.4	7.9	16.4	5.2	0.3	0.7	0.2	0.7	7.6	1.9	0.4	0.1	2.3	1.8	2.7	0.4	0.8	0.2	0.2	0.7	0.5	1.1	0.1	0.0	0.4	0.2	0.1	2.0	0.3	0.4	13.3	0.4	0.0	0.6	0.2	0.5	12.1	1.8	0.5	0.2	0.9	1.9	0.2	0.2	22.3	0.4	0.4	2.5	5.2	0.5	0.4	11.4	0.5	8.6	3.8	1.8	1.9	1.8	0.0	0.0	2.7	0.1	10.2	0.1	3.0	1.0	0.3	1.5	77.6	10.2	0.8	0.5	8.6	1.7	0.7	0.0	0.0	2.3	0.0	7.6	5.2	6.3	3.8	0.1	4.1	5.1	4.5	0.1	0.7	0.2	0.3	6.7	1.9	10.1	9.4	4.7	8.4	10.0	8.1	10.8	5.6	9.2	10.5
BCL2A1	"ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1"	ENSG00000140379	"BCL2 related protein A1"	Q16548	15	79960889-79971446	"Cancer-related genes, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 72.7;bone marrow: 105.7;lung: 45.6"	"Cell line enriched"	"Detected in some"	5	"SK-MEL-30: 94.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 39.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"eosinophil: 37.1;intermediate monocyte: 25.3;neutrophil: 72.7;non-classical monocyte: 47.2"	"Group enriched"	"Detected in all"	6	"granulocytes: 72.7;monocytes: 47.2"																				"unprognostic (3.19e-3)"	"unprognostic (2.61e-1)"	"unprognostic (3.99e-2)"	"unprognostic (3.54e-3)"	"unprognostic (9.65e-3)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.78e-2)"	"unprognostic (4.01e-2)"	"unprognostic (2.09e-1)"	"prognostic unfavourable (2.77e-5)"	"unprognostic (4.61e-2)"	"unprognostic (8.96e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.87e-1)"	21.6	0.9	1.9	22.6	4.0	105.7	1.8	0.5	1.8	1.0	2.0	0.4	0.0	1.0	0.7	1.0	3.0	4.9	3.6	9.8	2.2	1.3	1.8	5.2	45.6	24.9	11.8	0.0	3.7	1.0	0.2	2.2	3.8	3.8	1.6	1.3	0.8	2.3	0.3	1.4	0.6	4.4	2.7	8.2	32.8	1.9	4.6	4.0	4.3	2.3	1.4	11.1	4.8	7.1	9.3	3.4	72.7	47.2	2.8	5.7	5.8	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	2.6	0.7	0.2	0.0	0.0	0.0	0.2	0.4	0.5	20.1	0.2	0.0	1.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	94.5	0.0	0.9	0.0	10.3	0.8	0.0	0.1	0.1	0.0	0.7	0.4	6.4	4.8	3.3	5.6	37.1	3.6	25.3	2.0	9.3	4.7	4.7	3.4	5.9	5.7	5.3	72.7	2.8	47.2	0.6	1.0	5.8	1.9	4.0	0.5	1.8	2.2	1.3	11.8	0.0	3.8	4.0
BCL2L1	"Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52"	ENSG00000171552	"BCL2 like 1"	Q07817	20	31664452-31723989	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Apoptosis, Endocytosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035734, CAB072801"	Approved		Approved	Mitochondria				Mitochondria		"CAB072801: , HPA035734: "	"unprognostic (2.29e-1)"	"unprognostic (5.40e-3)"	"unprognostic (1.78e-2)"	"prognostic unfavourable (9.10e-4)"	"unprognostic (1.37e-1)"	"unprognostic (1.09e-1)"	"unprognostic (5.04e-2)"	"unprognostic (7.82e-3)"	"prognostic favourable (9.57e-4)"	"unprognostic (1.67e-1)"	"prognostic unfavourable (5.87e-4)"	"unprognostic (1.06e-1)"	"prognostic favourable (8.89e-5)"	"unprognostic (9.67e-2)"	"unprognostic (3.03e-2)"	"unprognostic (2.02e-2)"	"unprognostic (3.32e-2)"	30.8	21.4	25.1	16.4	34.3	57.0	40.7	27.7	40.7	28.2	22.6	37.0	13.0	31.3	18.7	12.2	36.9	31.5	35.9	26.9	27.0	23.7	42.6	39.3	40.6	17.8	43.4	24.3	11.5	28.5	17.5	22.8	29.0	33.4	24.8	21.4	31.5	33.8	21.5	21.9	26.1	30.4	19.2	28.8	26.6	28.0	30.2	38.4	56.4	25.8	15.4	20.7	24.5	22.4	3.9	7.8	17.0	8.9	12.5	27.2	16.5	62.7	37.4	6.9	6.6	37.3	27.0	22.1	15.0	24.6	15.7	15.1	88.2	30.5	10.3	38.4	21.7	21.2	9.2	42.5	11.1	10.8	2.4	47.0	8.0	43.9	27.9	4.7	27.9	19.3	17.7	19.9	43.3	22.5	29.1	7.9	53.2	17.9	13.8	4.5	9.5	33.4	8.7	20.8	32.6	64.5	17.5	18.0	8.4	18.4	18.2	8.6	36.2	5.4	31.1	19.9	23.0	7.9	27.0	5.2	29.1	8.5	29.3	20.7	12.5	17.0	8.1	15.4	27.2	8.2	21.0	3.9	12.4	18.1	7.8	3.7	5.7	13.0	9.8	12.5	8.9	4.7	13.8	16.5	25.1	34.3	27.7	40.7	27.0	23.7	43.4	24.3	33.4	38.4
BCL2L2	"BCL-W, KIAA0271, PPP1R51"	ENSG00000129473	"BCL2 like 2"	Q92843	14	23298790-23311759	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB040539, HPA048740"	Approved		Uncertain	Nucleoplasm				Nucleoplasm		"CAB040539: , HPA048740: "	"unprognostic (8.23e-3)"	"unprognostic (9.85e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.08e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.64e-1)"	"unprognostic (3.47e-3)"	"unprognostic (1.53e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.91e-3)"	"unprognostic (1.50e-3)"	"unprognostic (2.60e-1)"	"prognostic favourable (1.99e-6)"	"unprognostic (2.44e-1)"	"unprognostic (2.00e-1)"	"unprognostic (6.60e-2)"	"unprognostic (5.38e-2)"	29.9	22.8	38.2	15.6	33.6	7.4	25.1	27.3	44.8	13.7	32.3	27.4	21.9	19.4	19.0	20.6	32.8	16.6	17.6	23.8	36.2	32.9	22.3	9.0	18.6	8.6	43.3	39.5	17.5	30.6	34.1	16.5	15.1	32.8	31.8	20.4	15.0	36.5	31.9	10.6	29.2	19.0	34.8	40.9	11.3	22.3	14.9	28.1	1.2	25.6	11.8	10.1	23.0	23.2	1.3	1.8	0.6	1.8	0.1	0.3	1.3	11.8	12.7	11.6	8.4	22.3	19.5	10.5	21.4	13.1	10.7	11.7	7.8	18.8	7.7	7.7	11.7	21.9	7.2	13.4	13.4	3.9	6.8	8.4	17.0	15.3	13.9	9.2	15.1	15.1	26.5	8.0	12.9	9.0	8.3	7.5	12.6	8.9	0.7	6.2	4.4	24.9	5.5	14.2	3.4	9.3	20.1	15.3	9.2	9.6	15.4	17.4	9.7	7.4	17.4	19.0	11.9	12.9	11.0	9.7	5.8	1.1	12.0	7.6	21.5	0.0	1.8	0.4	0.3	1.8	0.2	1.3	0.0	0.2	1.8	1.0	0.3	0.0	0.6	0.1	1.0	0.9	0.1	1.3	38.2	33.6	27.3	44.8	36.2	32.9	43.3	39.5	32.8	28.1
BCL2L2-PABPN1		ENSG00000258643	"BCL2L2-PABPN1 readthrough"	Q92843	14	23306835-23325369	"Cancer-related genes, Predicted intracellular proteins, Transporters"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+: 21.2;BJ hTERT+ SV40 Large T+ RasG12V: 23.1"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA000637, HPA048740"	Approved		Uncertain	"Nucleoplasm,Nuclear speckles"				Nucleoplasm	"Nuclear speckles"	"HPA000637: AB_1079553, HPA048740: "	"unprognostic (1.32e-2)"	"unprognostic (8.74e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.32e-3)"	"unprognostic (9.82e-3)"	"unprognostic (2.85e-2)"	"unprognostic (1.05e-6)"	"unprognostic (4.39e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.84e-3)"	"unprognostic (7.61e-2)"	"unprognostic (3.47e-2)"	"unprognostic (1.72e-7)"	"unprognostic (3.13e-2)"	"unprognostic (8.77e-2)"	"unprognostic (3.46e-3)"	"unprognostic (4.95e-2)"	11.4	5.3	14.2	5.8	17.7	12.0	17.7	16.4	24.2	17.9	21.0	14.4	11.4	4.5	13.7	6.9	14.4	16.1	16.0	11.2	17.8	9.5	7.1	6.9	10.3	6.4	13.1	21.2	8.0	21.4	29.1	11.4	18.0	17.5	16.3	5.6	7.5	22.1	37.7	7.0	14.5	7.7	18.6	20.2	9.7	13.0	15.0	14.8	0.0	14.4	5.7	5.4	16.6	12.1	1.9	1.1	2.1	4.4	3.5	0.3	1.1	5.1	6.5	4.2	3.4	0.3	9.5	3.3	1.4	13.6	21.2	23.1	5.3	16.7	1.7	1.2	7.1	7.2	4.8	6.5	5.5	3.5	5.3	0.4	0.9	8.6	2.9	1.8	10.3	8.6	12.0	7.8	1.4	5.0	1.5	5.0	6.5	7.8	0.2	1.0	5.2	4.2	3.1	0.1	1.1	3.7	2.1	7.0	2.8	2.1	7.1	1.9	3.7	2.7	1.8	5.5	4.4	5.4	3.6	2.8	2.6	0.5	2.3	3.8	8.5	2.1	4.4	0.3	0.2	1.6	0.2	1.4	0.0	0.0	0.6	1.9	0.3	0.1	0.8	3.5	2.6	1.1	0.0	1.1	14.2	17.7	16.4	24.2	17.8	9.5	13.1	21.2	17.5	14.8
BCL3	"BCL4, D19S37"	ENSG00000069399	"B cell CLL/lymphoma 3"	P20749	19	44747705-44760044	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 26.5;Karpas-707: 22.0;SiHa: 28.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 16.5"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 16.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002051, HPA047514"	Approved		Supported	Nucleoplasm,Vesicles,Midbody				Nucleoplasm	"Vesicles, Midbody"	"CAB002051: AB_563428, HPA047514: "	"prognostic favourable (9.67e-4)"	"unprognostic (8.82e-2)"	"unprognostic (2.81e-1)"	"unprognostic (7.54e-2)"	"prognostic unfavourable (4.01e-4)"	"unprognostic (3.49e-2)"	"unprognostic (2.34e-3)"	"unprognostic (2.79e-1)"	"prognostic favourable (3.74e-4)"	"unprognostic (2.09e-2)"	"unprognostic (9.23e-2)"	"unprognostic (1.81e-1)"	"prognostic unfavourable (3.13e-14)"	"unprognostic (8.24e-2)"	"unprognostic (1.36e-1)"	"unprognostic (3.77e-2)"	"unprognostic (3.04e-2)"	17.7	13.0	4.0	21.1	5.6	35.2	18.7	1.4	4.7	11.7	14.9	2.4	5.9	24.5	10.4	9.7	27.1	12.5	22.7	20.1	3.9	2.0	17.8	52.1	36.4	20.5	4.3	0.5	26.5	13.2	2.4	9.2	9.5	5.6	16.0	8.0	8.8	13.7	13.7	20.2	9.0	35.5	11.5	6.5	41.6	15.0	8.3	4.0	6.5	13.9	22.9	37.0	18.7	11.9	1.3	2.6	16.5	2.4	1.8	1.5	0.7	3.8	13.4	0.3	7.1	2.6	5.4	0.6	2.4	2.6	1.5	2.2	2.8	7.1	3.8	5.5	4.7	4.3	0.9	4.0	0.9	26.5	0.2	0.4	7.0	3.6	6.2	0.3	11.4	9.4	3.2	3.3	4.2	4.0	0.5	22.0	0.9	3.2	0.0	2.9	0.3	5.6	1.7	2.7	1.4	6.8	8.1	0.0	0.4	28.2	14.4	0.7	5.0	2.9	6.7	4.8	5.0	7.5	0.9	20.9	8.2	3.9	8.9	0.5	3.6	0.2	2.4	4.2	0.7	1.6	1.0	1.3	0.9	1.1	2.1	1.1	0.5	0.6	16.5	1.8	0.9	2.6	1.5	0.7	4.0	5.6	1.4	4.7	3.9	2.0	4.3	0.5	5.6	4.0
BCL6	"BCL5, BCL6A, LAZ3, ZBTB27, ZNF51"	ENSG00000113916	"B cell CLL/lymphoma 6"	P41182	3	187721377-187745727	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Immunity, Inflammatory response, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 114.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 26.8;Daudi: 42.1;HSkMC: 30.6;U-698: 58.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"neutrophil: 63.4"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 63.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000307, HPA004899, HPA050645"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: "	"unprognostic (5.36e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.63e-3)"	"unprognostic (2.49e-1)"	"unprognostic (2.85e-1)"	"unprognostic (6.34e-3)"	"unprognostic (2.62e-2)"	"unprognostic (3.33e-3)"	"unprognostic (8.75e-2)"	"unprognostic (2.04e-2)"	"unprognostic (1.63e-3)"	"unprognostic (1.29e-1)"	"prognostic unfavourable (1.27e-9)"	"unprognostic (5.22e-2)"	"unprognostic (7.82e-2)"	"unprognostic (5.67e-2)"	"unprognostic (2.58e-2)"	47.1	14.3	21.8	23.2	25.9	50.6	48.0	58.7	23.7	21.2	21.2	19.2	11.5	4.1	17.7	8.8	20.9	28.3	22.3	18.6	21.5	8.0	10.1	20.1	26.3	24.5	31.6	9.3	20.2	15.6	9.1	23.3	7.5	28.5	17.3	5.8	15.9	19.1	11.8	114.3	36.4	8.1	24.4	50.1	27.2	16.1	10.2	26.6	18.9	14.8	10.4	22.4	24.9	20.0	3.9	5.6	63.4	15.4	0.9	1.3	5.2	1.2	3.6	3.5	0.8	26.8	21.4	3.9	4.2	10.4	4.9	5.2	2.5	2.0	42.1	3.1	5.3	2.0	1.1	2.8	4.2	8.9	1.4	0.0	1.7	6.0	13.9	0.5	0.2	30.6	17.9	6.0	9.2	2.7	0.4	7.3	4.7	1.4	1.4	0.3	0.3	2.7	11.7	1.8	0.2	3.4	6.2	0.8	0.0	4.9	2.1	2.7	9.2	1.5	5.5	11.9	1.9	4.3	1.9	5.4	1.7	58.5	6.5	1.5	8.4	1.6	6.9	4.1	1.3	8.7	1.3	1.4	0.8	1.2	5.6	3.9	0.5	0.6	63.4	0.9	15.4	0.9	0.6	5.2	21.8	25.9	58.7	23.7	21.5	8.0	31.6	9.3	28.5	26.6
BCL7A	BCL7	ENSG00000110987	"BCL tumor suppressor 7A"	Q4VC05	12	122019422-122062044	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 25.9;MOLT-4: 19.0;U-698: 29.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 8.4;plasmacytoid DC: 9.7"	"Group enriched"	"Detected in many"	10	"B-cells: 8.4;dendritic cells: 9.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019762	Approved		Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA019762: AB_10962489"	"unprognostic (3.27e-1)"	"unprognostic (2.97e-2)"	"prognostic unfavourable (6.81e-4)"	"unprognostic (1.35e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.23e-1)"	"prognostic unfavourable (2.04e-4)"	"unprognostic (5.18e-1)"	"unprognostic (5.13e-2)"	"unprognostic (1.06e-2)"	"unprognostic (3.13e-1)"	"unprognostic (3.11e-1)"	"prognostic favourable (1.54e-6)"	"unprognostic (4.86e-2)"	"unprognostic (8.56e-2)"	"unprognostic (6.16e-3)"	"unprognostic (1.51e-2)"	3.8	3.7	13.0	9.8	14.5	9.9	6.5	19.8	18.2	6.7	4.2	6.8	3.3	3.6	6.0	7.4	3.3	10.3	4.3	9.4	9.5	7.5	10.7	5.3	5.1	19.4	6.6	15.9	4.9	11.7	8.3	6.1	2.8	6.8	6.3	3.8	3.8	8.2	7.2	12.8	8.2	3.4	4.1	5.1	6.5	4.4	3.1	7.9	26.4	11.1	3.5	15.8	6.9	5.4	8.4	9.7	0.1	0.1	0.5	0.9	0.6	1.7	2.4	7.9	5.6	0.5	0.3	1.7	1.0	1.0	1.7	1.5	1.0	0.7	25.9	2.9	0.8	2.3	5.7	5.5	1.4	0.0	9.4	1.3	0.2	1.4	1.7	4.0	2.3	1.2	5.2	1.2	7.1	2.1	5.8	0.0	1.0	3.6	19.0	0.3	2.8	4.0	10.5	2.7	0.3	3.1	4.4	7.9	8.9	1.3	0.3	3.3	5.3	3.3	1.9	0.3	1.7	2.9	1.7	2.7	1.8	29.9	0.5	2.5	1.8	0.1	0.0	0.0	0.1	0.0	0.0	2.9	0.2	0.2	2.2	8.4	0.9	0.6	0.1	0.5	0.1	9.7	0.0	0.6	13.0	14.5	19.8	18.0	9.5	7.5	6.6	15.9	6.8	7.9
BCL9		ENSG00000116128	"B cell CLL/lymphoma 9"	O00512	1	147541412-147626216	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 24.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020274	Approved		Approved	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA020274: "	"unprognostic (2.31e-1)"	"unprognostic (1.52e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (6.74e-4)"	"unprognostic (1.03e-1)"	"unprognostic (2.78e-1)"	"unprognostic (2.29e-1)"	"unprognostic (4.78e-3)"	"unprognostic (3.92e-2)"	"unprognostic (1.64e-3)"	"unprognostic (2.58e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.60e-2)"	4.5	7.8	10.2	5.9	9.2	3.1	4.8	22.3	12.6	18.2	9.4	8.1	10.9	5.3	23.9	15.9	6.8	18.9	5.2	8.3	8.0	7.4	9.6	4.3	5.0	4.0	5.9	8.7	17.0	6.1	14.6	10.6	4.5	6.8	10.5	7.9	11.8	8.1	13.2	7.9	7.8	5.5	15.7	5.4	3.8	7.6	6.1	6.5	22.4	7.8	8.0	6.0	9.6	8.0	0.4	0.0	0.6	0.3	0.1	2.6	1.0	3.0	2.9	20.9	15.5	2.4	2.8	4.1	2.5	3.9	2.7	2.6	3.8	4.5	2.9	5.5	2.3	2.4	13.2	4.5	2.6	6.8	3.7	1.4	3.2	2.5	2.0	0.8	4.1	2.8	3.8	3.2	2.3	4.2	2.7	4.7	2.4	6.8	7.1	0.7	24.6	6.5	7.6	5.2	5.5	10.6	3.4	5.7	12.3	2.8	5.1	4.8	6.5	1.4	3.0	1.9	9.1	5.4	3.9	21.1	5.3	5.4	4.8	0.8	9.2	0.0	0.3	0.6	1.0	0.0	0.9	0.2	1.2	1.2	0.0	0.4	2.6	1.6	0.2	0.1	0.1	0.0	0.9	1.0	10.2	9.2	22.3	12.6	8.0	7.4	5.9	8.7	6.8	6.5
BCL9L	DLNB11	ENSG00000186174	"B cell CLL/lymphoma 9 like"	Q86UU0	11	118893875-118925608	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049370, HPA053421"	Uncertain		Enhanced	Nucleoplasm				Nucleoplasm		"HPA049370: , HPA053421: "	"unprognostic (1.67e-2)"	"unprognostic (1.48e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.71e-1)"	"unprognostic (2.87e-1)"	"unprognostic (1.90e-1)"	"unprognostic (6.61e-3)"	"unprognostic (1.17e-3)"	"unprognostic (1.03e-1)"	"unprognostic (4.61e-2)"	"unprognostic (4.66e-3)"	"unprognostic (1.39e-1)"	"unprognostic (2.83e-3)"	"unprognostic (4.85e-3)"	"unprognostic (2.24e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.90e-3)"	18.4	18.9	10.2	17.2	10.0	13.3	23.8	31.7	9.9	27.4	16.4	6.7	15.8	13.2	22.3	12.8	18.9	22.2	21.2	15.6	9.0	4.1	10.9	9.0	17.1	13.8	9.5	7.7	22.2	16.4	9.0	6.5	31.9	9.1	16.1	4.1	14.5	21.5	14.7	19.1	19.9	14.6	22.8	7.9	13.9	14.0	9.0	8.6	13.0	12.2	11.9	16.7	21.9	25.6	0.6	0.6	1.1	0.5	0.7	2.2	0.8	12.2	22.2	3.2	5.8	10.4	10.1	20.4	16.9	13.1	5.4	3.1	23.6	24.4	3.3	22.6	17.7	23.7	1.5	31.0	1.4	4.0	0.8	3.3	12.4	8.1	11.7	1.1	3.2	12.7	19.4	6.4	13.0	4.7	4.2	3.9	3.7	20.5	2.4	0.9	3.8	12.8	5.2	1.3	2.2	5.6	8.5	1.7	2.5	23.8	36.2	3.4	28.4	1.4	15.8	17.2	13.2	5.2	14.3	0.8	0.0	0.9	9.3	3.8	9.8	0.0	0.5	0.0	2.2	0.0	1.5	0.3	1.2	1.3	0.1	0.6	1.9	1.5	1.1	0.7	0.0	0.6	0.2	0.8	10.2	10.0	31.7	9.9	9.0	4.1	9.5	7.7	9.1	8.6
BCLAF1	"BTF, KIAA0164"	ENSG00000029363	"BCL2 associated transcription factor 1"	Q9NYF8	6	136256627-136289851	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006484, HPA006669, HPA027770"	Enhanced		Enhanced	"Nuclear speckles"		190000	190000	"Nuclear speckles"		"HPA006484: , HPA006669: AB_1078302, HPA027770: AB_1845484"	"prognostic unfavourable (1.64e-4)"	"unprognostic (1.60e-1)"	"prognostic favourable (3.44e-4)"	"unprognostic (1.45e-1)"	"unprognostic (9.46e-3)"	"unprognostic (2.29e-1)"	"unprognostic (2.13e-3)"	"unprognostic (1.63e-1)"	"unprognostic (5.07e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.40e-1)"	"unprognostic (7.20e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.56e-1)"	"unprognostic (7.93e-2)"	"unprognostic (4.19e-3)"	22.6	20.9	19.3	20.6	33.6	93.9	26.8	56.9	31.0	27.6	23.2	13.3	18.1	15.2	25.8	21.3	22.7	22.9	12.4	17.0	20.4	19.0	19.3	22.0	19.9	22.7	24.4	19.5	33.5	20.5	34.8	50.2	25.5	27.8	21.4	23.7	14.2	23.5	18.2	26.8	22.2	20.8	23.1	22.4	22.7	22.2	16.7	27.2	38.6	24.7	21.5	25.4	24.0	23.2	22.2	25.2	35.7	20.4	29.1	24.9	13.4	18.2	15.9	37.7	31.4	12.0	10.2	19.2	34.9	21.7	23.5	25.1	22.6	12.4	38.5	21.8	26.7	17.8	42.2	23.0	29.6	21.2	26.2	47.9	22.9	24.5	13.9	80.1	30.5	13.9	11.5	33.2	20.8	20.8	42.5	19.1	24.6	21.8	31.9	9.1	27.7	16.6	29.0	47.4	17.1	17.6	35.1	32.1	22.2	34.2	16.5	13.3	15.4	16.2	28.6	18.7	27.4	22.3	34.0	16.2	29.2	53.1	11.1	25.8	21.6	15.4	16.4	24.2	21.1	20.4	21.0	22.2	19.4	17.6	25.2	19.8	24.9	22.3	35.7	29.1	19.7	14.9	14.7	13.4	19.3	33.6	56.9	31.0	20.4	19.0	24.4	19.5	27.8	27.2
BCOR	"FLJ20285, KIAA1575"	ENSG00000183337	"BCL6 corepressor"	Q6W2J9	X	40049815-40177329	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA056308, HPA073591"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA056308: , HPA073591: "	"unprognostic (2.75e-2)"	"unprognostic (2.83e-1)"	"unprognostic (2.45e-1)"	"unprognostic (9.26e-2)"	"unprognostic (1.55e-1)"	"unprognostic (9.80e-3)"	"prognostic unfavourable (1.30e-5)"	"unprognostic (3.82e-3)"	"unprognostic (6.86e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.91e-3)"	"unprognostic (6.83e-2)"	"unprognostic (9.57e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.55e-1)"	9.1	12.8	8.7	8.7	10.5	20.6	13.3	11.5	12.0	10.0	12.6	22.7	11.9	7.8	11.1	13.9	13.6	10.4	8.6	13.0	7.1	5.4	11.2	13.3	11.4	15.2	12.9	8.4	19.8	13.6	19.7	11.9	12.5	10.7	13.2	8.2	13.7	11.1	16.5	28.8	13.6	10.3	12.9	8.6	11.4	11.5	9.8	15.8	18.4	16.0	11.4	13.5	13.8	25.5	6.5	7.3	7.6	7.1	8.2	6.8	11.8	12.9	8.6	17.5	21.4	2.0	1.5	3.0	4.4	7.0	5.6	4.6	3.6	5.2	11.8	5.2	8.2	12.1	28.5	3.7	5.0	20.6	25.9	13.1	13.2	14.1	3.4	10.6	7.6	2.6	5.5	6.2	3.6	7.6	33.7	28.5	6.9	8.3	24.0	22.2	17.2	13.4	11.7	18.1	13.3	10.3	8.2	12.5	22.7	9.2	8.2	6.9	8.8	23.4	6.2	6.1	7.7	8.9	4.9	16.9	13.1	12.3	5.3	9.7	9.3	7.6	5.0	4.5	6.8	6.1	4.3	6.5	4.7	3.9	7.3	5.5	4.7	4.8	1.1	8.2	7.1	3.1	5.5	11.8	8.7	10.5	11.5	12.0	7.1	5.4	12.9	8.4	10.7	15.8
BCORL1	"CXorf10, FLJ11362"	ENSG00000085185	"BCL6 corepressor like 1"	Q5H9F3	X	129981107-130058083	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 20.0;HAP1: 30.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031775, HPA031777, HPA068568"	Uncertain		Approved	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"HPA031775: AB_10602332, HPA031777: AB_10671578, HPA068568: "	"unprognostic (8.07e-2)"	"unprognostic (2.78e-2)"	"unprognostic (7.09e-2)"	"prognostic unfavourable (2.20e-5)"	"unprognostic (4.58e-1)"	"unprognostic (1.68e-3)"	"unprognostic (1.96e-3)"	"unprognostic (5.56e-3)"	"unprognostic (2.39e-1)"	"unprognostic (8.02e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.04e-1)"	"prognostic unfavourable (5.00e-4)"	"unprognostic (9.18e-2)"	"unprognostic (2.60e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.41e-2)"	7.5	7.9	7.7	5.2	9.1	9.8	9.1	19.8	10.5	8.7	8.3	10.7	8.1	5.4	9.2	5.4	5.8	9.3	4.2	6.9	8.4	4.5	7.5	4.7	6.7	5.3	7.6	5.9	11.4	8.9	13.4	15.0	28.9	7.5	8.1	4.5	6.0	6.5	8.4	6.0	6.5	6.0	8.8	5.3	7.7	6.6	26.1	8.1	6.8	10.3	2.2	5.1	6.7	8.5	1.2	1.6	3.5	1.3	0.8	1.3	0.7	2.2	5.4	12.7	20.0	7.5	5.4	3.5	2.9	3.5	3.8	4.4	6.5	1.4	1.0	6.6	5.9	1.3	30.1	1.2	3.6	2.2	4.4	10.3	2.6	2.2	3.7	2.5	3.0	3.3	2.5	7.5	0.4	4.6	4.9	10.6	2.5	1.3	3.8	7.8	3.5	3.8	8.1	5.1	1.4	2.1	0.3	2.1	7.2	1.6	0.4	1.9	4.4	3.9	3.8	3.1	4.0	3.8	2.8	3.4	6.2	1.6	2.1	5.3	1.4	0.1	1.3	2.8	1.3	0.2	1.0	1.2	0.9	0.8	1.6	1.0	0.6	0.7	3.5	0.8	0.5	0.7	0.2	0.7	7.7	9.1	19.8	10.5	8.4	4.5	7.6	5.9	7.5	8.1
BCR	"ALL, BCR1, CML, D22S11, D22S662, PHL"	ENSG00000186716	"BCR, RhoGEF and GTPase activating protein"	P11274	22	23179704-23318037	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"K-562: 43.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010421, CAB018545, HPA038337"	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795"	"unprognostic (7.46e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.15e-3)"	"unprognostic (1.16e-1)"	"unprognostic (5.35e-2)"	"unprognostic (1.45e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.44e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.81e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.39e-2)"	"prognostic favourable (9.15e-10)"	"unprognostic (1.47e-1)"	"unprognostic (7.10e-2)"	"unprognostic (4.10e-2)"	"unprognostic (7.43e-2)"	14.5	8.4	24.0	9.1	41.2	26.7	10.5	14.2	26.5	13.6	9.7	10.3	10.6	8.7	9.2	13.9	19.3	10.8	8.3	7.8	20.9	13.0	16.3	8.3	11.3	10.9	16.0	15.6	8.8	12.9	14.5	14.9	15.7	14.2	7.0	6.8	8.3	15.5	9.7	3.4	12.8	8.7	9.0	9.5	9.1	14.0	9.6	15.4	11.8	16.6	5.5	9.2	9.2	8.8	1.5	0.8	1.2	1.0	2.8	6.6	2.5	18.6	8.1	12.4	12.7	7.4	5.1	18.8	6.8	6.3	6.3	5.1	14.1	7.5	13.0	12.6	5.7	19.2	1.3	18.8	1.8	24.9	12.9	11.4	11.1	11.2	9.7	10.5	6.0	4.3	12.7	9.4	8.2	21.8	43.5	6.1	2.8	12.3	9.8	8.2	10.5	7.9	12.9	5.0	8.6	9.7	11.8	11.4	10.8	12.4	10.7	5.1	6.7	8.6	24.6	3.8	0.4	6.1	5.5	1.4	5.6	4.6	9.7	8.0	5.8	0.0	1.0	0.0	6.6	0.4	2.3	1.4	3.3	3.3	0.8	1.5	2.6	3.6	1.2	2.8	1.0	0.8	1.6	2.5	24.0	41.2	14.2	24.9	20.9	13.0	16.0	15.6	14.2	15.4
BDNF		ENSG00000176697	"Brain derived neurotrophic factor"	P23560	11	27654893-27722058	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 14.5;smooth muscle: 10.5"	"Cell line enhanced"	"Detected in many"		"BJ: 22.4;BJ hTERT+ SV40 Large T+: 17.2;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 16.5;U-138 MG: 24.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009564, HPA031440, HPA056104"	Enhanced		Supported	"Nuclear speckles,Mitochondria"	"Secreted to blood"			"Nuclear speckles, Mitochondria"		"CAB009564: AB_2064213, HPA031440: , HPA056104: "	"unprognostic (1.25e-2)"	"unprognostic (2.84e-1)"	"unprognostic (4.35e-2)"	"unprognostic (2.54e-2)"	"unprognostic (1.01e-2)"	"unprognostic (6.82e-2)"	"unprognostic (2.39e-2)"	"unprognostic (2.21e-1)"	"unprognostic (3.20e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.22e-2)"	"unprognostic (2.65e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.88e-2)"	"unprognostic (5.88e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.84e-3)"	0.9	1.3	5.0	0.6	4.5	0.5	0.6	9.4	14.5	1.6	0.8	0.6	0.7	0.8	0.7	8.2	1.4	0.5	2.1	5.8	8.5	5.7	0.9	0.5	4.1	0.4	2.5	4.7	1.2	1.0	0.2	2.3	3.7	12.7	4.9	0.4	3.0	0.9	4.2	1.3	2.1	0.5	10.5	1.0	0.6	0.9	1.3	0.0	0.0	2.3	0.0	0.4	3.2	1.2	0.1	0.4	0.0	0.2	0.1	1.0	0.1	1.6	6.6	0.2	0.0	2.3	1.9	0.0	22.4	4.3	17.2	13.1	0.0	2.6	0.0	2.1	8.1	1.0	0.1	0.2	16.5	0.1	0.1	0.0	2.2	0.0	10.0	0.1	0.1	5.8	2.2	3.8	2.2	0.7	0.0	0.0	2.7	0.0	0.0	0.0	2.1	1.8	0.0	1.3	0.0	2.5	0.0	0.1	0.6	4.3	0.0	0.0	0.1	0.0	7.4	24.1	4.0	9.3	5.0	0.3	0.0	0.0	9.3	0.6	1.3	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.0	0.6	0.2	0.1	0.7	0.4	0.0	0.1	0.0	0.4	1.0	0.1	5.0	4.5	9.4	9.4	8.5	5.7	2.5	4.7	12.7	0.0
BHMT2		ENSG00000132840	"Betaine--homocysteine S-methyltransferase 2"	Q9H2M3	5	79069717-79089466	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"kidney: 87.9;liver: 122.9"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 8.9;Hep G2: 37.2;hTEC/SVTERT24-B: 22.8;U-87 MG: 9.6"	"Group enriched"	"Detected in many"	14	"liver cancer: 79.6;renal cancer: 52.9"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA044573	Enhanced					1400000	1400000			"HPA044573: AB_10795044"	"unprognostic (5.03e-2)"	"unprognostic (4.42e-2)"	"unprognostic (2.60e-2)"	"unprognostic (3.76e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.90e-3)"	"unprognostic (1.56e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.87e-2)"	"unprognostic (2.45e-3)"	"unprognostic (1.41e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.76e-2)"	"unprognostic (5.05e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.06e-3)"	9.3	4.4	1.7	0.9	2.0	0.2	8.2	1.1	1.0	1.7	3.4	1.1	2.9	0.6	3.2	10.5	3.5	1.4	2.9	3.3	1.5	1.5	87.9	122.9	0.6	0.4	1.6	1.0	1.9	0.5	0.5	3.2	0.3	3.5	3.0	0.8	8.2	0.8	4.0	2.2	0.4	1.3	10.5	2.2	0.3	2.4	1.4	0.9	0.0	4.6	1.9	0.4	6.4	4.4	0.9	0.5	3.2	0.4	2.4	0.7	0.3	0.0	0.0	0.0	0.0	4.3	3.1	1.4	3.7	8.9	2.1	4.1	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	3.0	0.0	0.0	0.1	0.1	37.2	3.4	0.2	0.0	3.8	0.0	22.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	9.6	0.2	0.0	2.5	0.4	0.7	0.4	0.3	0.5	0.5	0.6	0.4	0.2	0.9	0.6	0.7	3.2	2.4	0.2	0.5	0.4	0.3	1.7	2.0	1.1	1.0	1.5	1.5	1.6	1.0	3.5	0.9
BIRC2	"API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48"	ENSG00000110330	"Baculoviral IAP repeat containing 2"	Q13490	11	102347211-102378670	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway"	"Activator, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA005513, CAB020661"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"				"Nucleoli fibrillar center, Cytosol"	Nucleoplasm	"CAB020661: , HPA005513: AB_1846746"	"unprognostic (1.36e-1)"	"unprognostic (3.29e-1)"	"unprognostic (9.52e-3)"	"unprognostic (1.62e-1)"	"unprognostic (1.37e-1)"	"unprognostic (7.02e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.17e-2)"	"unprognostic (9.59e-2)"	"unprognostic (1.05e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.07e-1)"	"unprognostic (9.20e-2)"	"unprognostic (5.00e-2)"	"unprognostic (1.64e-2)"	20.9	25.8	19.1	23.3	24.1	25.9	57.0	20.5	28.5	25.1	22.2	18.4	18.7	19.3	24.6	31.1	18.6	17.0	21.1	39.2	19.1	18.3	24.3	36.8	34.0	47.2	23.3	15.8	21.5	40.8	22.0	27.3	24.3	22.3	19.6	22.2	14.3	21.9	22.1	38.8	17.3	24.4	23.8	26.3	27.6	19.0	19.7	15.5	51.2	18.9	17.3	21.9	22.2	20.2	5.8	12.6	37.5	16.6	12.2	12.0	9.8	9.6	7.2	11.1	8.7	14.1	19.5	7.1	37.5	14.4	21.5	13.1	8.9	24.1	10.6	37.2	17.2	10.7	7.2	9.9	25.9	14.2	3.7	10.7	5.3	10.8	14.4	6.4	6.9	12.4	19.3	12.3	15.8	14.7	9.6	0.0	38.7	3.1	6.8	5.7	5.3	7.0	3.4	14.4	7.1	16.6	11.2	4.6	6.1	13.1	8.0	11.2	12.6	7.8	24.1	45.6	10.3	13.7	24.2	4.4	6.0	7.3	9.8	8.2	33.2	31.7	16.6	37.5	9.1	15.2	7.5	5.8	8.7	8.4	12.6	5.6	11.3	11.3	25.5	12.2	16.3	7.6	12.0	9.8	19.1	24.1	20.5	28.5	19.1	18.3	23.3	15.8	22.3	15.5
BIRC3	"API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49"	ENSG00000023445	"Baculoviral IAP repeat containing 3"	Q13489	11	102317450-102339403	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 46.0;lymphoid tissue: 46.3"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 37.5;Daudi: 33.0;HDLM-2: 31.2;hTERT-HME1: 32.8;U-266/70: 22.0;U-266/84: 18.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 32.9;naive B-cell: 32.9"	"Group enriched"	"Detected in many"	10	"B-cells: 32.9;T-cells: 17.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002317	Enhanced	Approved	Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA002317: AB_1846748"	"prognostic favourable (3.60e-4)"	"unprognostic (2.89e-1)"	"prognostic favourable (9.35e-4)"	"unprognostic (3.28e-2)"	"prognostic unfavourable (7.28e-4)"	"unprognostic (5.83e-3)"	"unprognostic (2.23e-1)"	"unprognostic (3.88e-3)"	"unprognostic (9.62e-2)"	"unprognostic (1.29e-1)"	"prognostic unfavourable (3.03e-4)"	"unprognostic (3.21e-1)"	"prognostic unfavourable (6.66e-6)"	"unprognostic (6.42e-2)"	"unprognostic (6.23e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.85e-2)"	6.9	3.3	1.4	43.9	2.3	5.1	5.4	0.5	2.0	5.3	13.1	0.5	2.8	6.8	2.9	3.7	8.4	3.9	13.9	6.0	2.2	1.3	10.8	12.5	21.8	46.3	2.8	1.2	3.4	7.0	1.1	14.5	0.9	2.2	8.7	6.2	1.1	9.2	4.7	2.2	5.5	46.0	7.3	3.0	34.9	15.9	3.2	2.7	34.2	3.0	4.1	34.0	12.6	6.2	32.9	0.8	2.0	2.6	2.5	17.1	2.8	6.3	5.1	0.0	0.1	0.1	0.7	0.6	0.5	4.3	0.6	0.7	0.9	37.5	33.0	17.0	0.3	3.6	0.0	0.9	2.1	31.2	0.1	0.1	1.5	0.2	6.5	0.5	0.7	0.7	4.6	2.1	32.8	0.1	0.1	0.0	0.8	0.0	2.2	0.3	0.1	0.2	0.0	0.3	1.6	8.5	3.3	0.0	0.1	0.5	0.5	0.3	1.6	0.3	1.7	7.2	0.7	0.4	6.5	22.0	18.8	11.6	1.3	1.8	0.8	2.0	0.9	0.4	1.4	2.2	2.5	32.9	10.7	3.5	0.8	32.9	7.5	2.2	0.5	2.5	2.6	0.3	17.1	2.8	1.4	2.3	0.5	2.0	2.2	1.3	2.8	1.2	2.2	2.7
BIRC5	"API4, EPR-1, survivin"	ENSG00000089685	"Baculoviral IAP repeat containing 5"	O15392	17	78214186-78225636	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation"	"Protease inhibitor, Repressor, Thiol protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 61.6;testis: 51.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"T-reg: 14.0"	"Lineage enriched"	"Detected in many"	6	"T-cells: 14.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA002830, CAB004270"	Enhanced		Supported	"Cytokinetic bridge"				"Cytokinetic bridge"		"CAB004270: AB_628302, HPA002830: AB_1857672"	"unprognostic (8.04e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.48e-3)"	"unprognostic (2.72e-3)"	"unprognostic (3.37e-1)"	"unprognostic (3.84e-2)"	"prognostic unfavourable (5.28e-6)"	"prognostic unfavourable (4.49e-4)"	"unprognostic (3.56e-3)"	"unprognostic (4.53e-3)"	"unprognostic (2.87e-3)"	"unprognostic (6.67e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (3.77e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.16e-1)"	2.3	1.5	0.4	14.1	0.7	20.8	5.3	0.7	0.6	1.9	4.8	0.3	0.2	4.6	0.9	1.4	13.4	0.4	2.2	2.4	0.5	0.4	1.3	2.2	2.4	9.7	0.6	0.2	0.9	0.8	0.0	0.4	6.1	0.5	0.9	5.2	0.2	2.1	0.2	0.6	3.5	4.7	2.4	0.7	6.3	3.2	51.4	0.3	61.6	0.5	14.4	11.7	2.0	3.2	2.5	0.8	0.5	0.0	2.2	14.0	3.0	31.6	29.6	26.7	28.9	1.7	2.8	9.8	24.4	13.7	34.8	22.9	24.2	12.5	32.6	9.9	14.1	16.9	27.0	15.6	30.5	11.0	37.5	21.5	17.5	28.4	0.2	20.7	16.2	0.9	1.1	19.3	14.3	24.6	26.9	27.6	26.7	18.3	44.0	19.8	19.9	52.1	23.0	43.4	25.2	8.2	11.7	33.0	22.8	18.7	21.2	16.6	28.0	19.6	9.2	42.2	37.4	18.2	34.6	20.0	16.1	37.7	15.4	8.7	36.6	0.0	0.0	0.0	0.7	0.0	0.2	2.5	4.3	2.8	0.8	0.3	0.0	0.4	0.5	2.2	0.0	0.3	14.0	3.0	0.4	0.7	0.7	0.6	0.5	0.4	0.6	0.2	0.5	0.3
BIRC6	BRUCE	ENSG00000115760	"Baculoviral IAP repeat containing 6"	Q9NR09	2	32357028-32618899	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Mitosis, Ubl conjugation pathway"	"Protease inhibitor, Thiol protease inhibitor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA074409, HPA074738"			Supported	"Golgi apparatus,Vesicles,Mitotic spindle"				"Golgi apparatus, Vesicles"	"Mitotic spindle"	"HPA074409: , HPA074738: "	"unprognostic (3.38e-2)"	"unprognostic (8.13e-3)"	"unprognostic (8.88e-2)"	"unprognostic (7.06e-3)"	"unprognostic (6.69e-3)"	"unprognostic (9.01e-2)"	"unprognostic (4.51e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.49e-2)"	"unprognostic (4.00e-2)"	"unprognostic (2.07e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.61e-1)"	"unprognostic (7.32e-2)"	"unprognostic (3.37e-1)"	15.0	16.7	10.3	20.7	14.4	18.4	16.1	21.9	13.7	16.2	13.0	15.3	15.6	8.7	17.2	13.9	13.2	13.1	11.7	11.4	9.8	7.3	14.1	14.8	12.5	16.1	13.9	11.8	23.6	24.8	32.5	17.4	14.1	14.8	11.3	13.6	11.5	14.7	17.1	20.9	14.9	16.0	12.5	13.3	16.1	13.9	13.0	14.4	23.1	21.5	9.2	17.2	16.2	12.0	3.8	2.8	10.6	2.4	2.3	3.4	0.7	15.1	12.7	11.8	5.1	9.3	13.2	7.1	6.7	9.5	8.3	7.9	8.7	3.6	16.3	5.4	12.6	7.0	16.5	10.0	10.3	13.0	7.5	22.0	8.0	7.2	5.1	20.4	7.8	8.8	4.9	13.0	11.6	12.3	17.8	7.0	7.7	5.8	10.2	4.7	7.9	7.5	10.4	19.0	5.5	6.0	15.6	8.8	13.5	13.3	6.9	6.1	4.6	7.3	19.2	8.7	9.8	5.9	10.2	9.4	13.1	21.8	6.3	10.1	5.7	10.6	1.6	0.9	2.7	1.2	3.4	1.7	2.1	2.3	1.3	3.8	2.3	2.6	2.7	2.3	2.4	2.8	1.6	0.7	10.3	14.4	21.9	13.7	9.8	7.3	13.9	11.8	14.8	14.4
BLK	MGC10442	ENSG00000136573	"BLK proto-oncogene, Src family tyrosine kinase"	P51451	8	11486894-11564604	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	15	"blood: 47.8;intestine: 23.5;lymphoid tissue: 39.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 43.0;REH: 11.6;RPMI-8226: 14.2;U-698: 21.0;U-87 MG: 8.9"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"memory B-cell: 47.8;naive B-cell: 33.9"	"Lineage enriched"	"Detected in many"	5	"B-cells: 47.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005093, HPA069571"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB005093: AB_2274756, HPA069571: "	"unprognostic (6.50e-5)"	"unprognostic (4.22e-3)"	"unprognostic (5.64e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.45e-1)"	"unprognostic (5.98e-6)"	"unprognostic (1.59e-2)"	"unprognostic (8.94e-4)"	"unprognostic (1.02e-3)"	"unprognostic (9.83e-3)"	"unprognostic (1.22e-2)"	"unprognostic (4.66e-2)"	"unprognostic (9.05e-6)"	"unprognostic (5.62e-2)"	"unprognostic (5.43e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.16e-1)"	0.5	0.2	0.1	32.3	0.1	1.7	0.2	0.1	0.1	0.1	1.2	0.0	0.0	0.3	0.1	0.0	1.9	0.2	0.4	0.3	0.1	0.1	1.3	0.5	0.6	27.6	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.4	0.4	0.3	2.4	0.0	0.1	0.1	23.5	0.0	0.1	31.9	1.4	0.2	0.0	3.9	0.7	0.4	39.8	2.5	0.4	47.8	4.3	0.1	0.0	0.0	9.8	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	43.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	11.6	0.0	14.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	2.2	3.7	21.0	8.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	9.8	47.8	0.3	1.1	0.0	33.9	0.2	0.1	0.1	0.0	0.0	4.3	0.4	1.9	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0
BLM	"BS, RECQ2, RECQL3"	ENSG00000197299	"Bloom syndrome RecQ like helicase"	P54132	15	90717327-90816165	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 36.7"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005689	Approved		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA005689: AB_1845372"	"unprognostic (2.77e-1)"	"unprognostic (3.82e-3)"	"unprognostic (4.03e-2)"	"unprognostic (2.98e-2)"	"unprognostic (4.75e-2)"	"unprognostic (9.89e-2)"	"unprognostic (6.12e-5)"	"unprognostic (2.82e-2)"	"unprognostic (4.55e-3)"	"unprognostic (5.24e-3)"	"unprognostic (1.80e-3)"	"unprognostic (9.12e-2)"	"unprognostic (1.55e-15)"	"unprognostic (6.53e-3)"	"unprognostic (6.55e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.83e-2)"	1.8	0.4	3.1	11.4	1.5	5.5	0.6	4.7	2.6	0.7	1.9	0.9	0.5	1.4	1.2	1.1	2.9	0.4	1.3	1.0	2.3	2.4	0.9	0.5	2.0	7.7	2.8	0.2	0.9	0.4	0.0	1.2	3.6	0.5	0.7	2.5	0.7	7.8	0.0	1.7	0.6	2.8	0.5	1.9	6.7	1.4	4.9	0.5	36.7	0.6	3.1	9.3	1.4	0.7	7.4	1.2	4.3	1.6	4.6	5.0	1.6	5.4	7.8	8.7	5.1	0.0	0.4	5.5	4.1	1.2	4.7	5.1	6.8	3.8	14.1	2.6	1.1	9.1	13.4	3.7	6.1	8.5	9.9	14.7	8.4	2.2	0.0	14.1	7.3	0.0	0.0	4.7	2.4	3.3	12.7	4.4	4.9	3.4	10.6	7.8	9.3	1.7	10.8	16.4	5.4	1.1	9.8	6.5	6.1	3.3	4.4	2.6	3.1	11.6	1.8	3.4	6.3	3.5	8.7	3.2	13.1	14.7	1.9	10.0	5.8	2.5	1.0	4.3	3.1	1.2	4.8	7.4	2.8	3.8	1.2	4.3	2.0	2.2	0.8	4.6	1.6	1.2	5.0	1.6	3.1	1.5	4.7	1.7	2.3	2.4	2.8	0.2	0.5	0.5
BLMH	BH	ENSG00000108578	"Bleomycin hydrolase"	Q13867	17	30248195-30292056	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skin 1: 67.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"HPA039548, HPA064307"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"		59000000	59000000	"Nucleoplasm, Nuclear bodies, Cytosol"		"HPA039548: AB_10805479, HPA064307: AB_2685241"	"unprognostic (6.85e-2)"	"unprognostic (2.79e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.54e-2)"	"unprognostic (3.91e-3)"	"unprognostic (2.07e-1)"	"unprognostic (2.05e-3)"	"unprognostic (6.69e-3)"	"unprognostic (1.95e-3)"	"unprognostic (2.14e-2)"	"unprognostic (2.14e-2)"	"unprognostic (1.22e-3)"	"unprognostic (1.05e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.44e-1)"	11.2	8.3	9.0	17.1	10.2	8.5	14.2	12.1	14.5	10.5	9.8	8.5	9.6	6.7	13.1	12.2	15.7	8.4	10.1	9.7	7.5	7.2	13.6	7.5	13.6	20.3	9.5	8.5	8.8	15.3	15.0	8.3	14.6	9.2	8.4	8.5	7.3	12.8	9.5	15.0	67.5	10.0	15.7	11.1	13.2	9.2	12.4	8.6	24.7	9.3	15.5	13.6	10.8	11.7	4.6	6.6	0.9	5.7	9.8	17.3	6.3	10.1	16.1	15.6	10.8	10.7	11.5	7.5	9.5	5.9	15.0	13.0	23.6	3.0	30.3	17.0	7.6	7.1	33.7	13.0	12.7	8.0	26.5	18.6	14.5	20.0	15.6	33.8	11.5	13.5	0.9	11.7	6.8	22.0	39.6	12.4	6.2	7.7	41.8	24.7	14.9	7.5	36.3	40.5	20.0	12.0	9.1	36.0	12.9	8.4	16.4	10.3	11.2	17.5	14.0	9.3	18.7	4.1	16.8	15.0	30.8	40.9	7.1	0.0	12.4	0.0	5.7	0.9	10.5	3.9	17.3	4.6	12.6	13.7	6.5	4.2	11.6	12.3	0.7	9.8	1.9	6.6	12.4	6.3	9.0	10.2	12.1	14.5	7.5	7.2	9.5	8.5	9.2	8.6
BMI1	"PCGF4, RNF51"	ENSG00000168283	"BMI1 proto-oncogene, polycomb ring finger"	P35226	10	22321211-22331484	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 87.1;U-937: 102.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB011120, HPA030471, HPA030472"	Supported		Approved	"Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol"				"Nucleoplasm, Nuclear bodies"	"Nucleoli, Cytosol"	"CAB011120: , HPA030471: , HPA030472: AB_10601090"	"unprognostic (5.44e-1)"	"unprognostic (2.98e-1)"	"unprognostic (4.24e-2)"	"unprognostic (4.37e-2)"	"unprognostic (2.76e-3)"	"unprognostic (6.93e-2)"	"prognostic unfavourable (2.60e-8)"	"unprognostic (9.43e-2)"	"unprognostic (7.95e-2)"	"unprognostic (7.84e-2)"	"unprognostic (8.23e-2)"	"unprognostic (1.56e-1)"	"unprognostic (7.44e-2)"	"unprognostic (9.73e-2)"	"unprognostic (8.56e-2)"	"unprognostic (7.91e-3)"	"unprognostic (3.41e-2)"	19.7	23.5	28.0	17.0	35.0	13.3	26.5	26.1	33.7	21.6	22.3	26.3	11.6	14.1	23.9	22.8	16.0	17.0	17.4	15.1	28.3	24.2	19.2	25.5	16.7	17.9	42.3	27.7	18.8	18.6	40.0	37.6	20.6	24.8	25.5	16.0	16.5	15.7	20.3	28.5	10.3	14.6	26.3	34.8	24.6	16.5	24.3	40.7	12.9	17.6	10.6	18.8	21.5	25.9	5.0	1.8	13.0	3.4	6.2	8.4	2.4	12.7	6.2	7.1	2.2	12.5	10.1	7.2	8.6	3.9	6.6	7.8	6.5	16.0	6.5	5.9	7.8	4.5	10.3	6.1	8.2	87.1	12.8	18.0	5.3	7.3	7.5	6.6	10.0	6.5	10.6	7.2	8.0	4.6	17.8	11.1	8.7	5.1	17.8	1.9	1.6	14.8	13.3	10.2	6.2	6.2	4.2	6.0	11.9	5.7	7.5	9.6	6.7	26.7	9.8	7.4	22.2	17.7	11.6	13.7	17.8	14.4	10.5	102.3	4.8	13.0	1.5	2.5	6.1	3.4	8.4	5.0	6.4	5.8	1.0	2.6	5.5	5.2	0.6	6.2	2.1	1.8	4.3	2.4	28.0	35.0	26.1	33.7	28.3	24.2	42.3	27.7	24.8	40.7
BMP2	BMP2A	ENSG00000125845	"Bone morphogenetic protein 2"	P12643	20	6767664-6780280	"Cancer-related genes, Predicted secreted proteins"	"Chondrogenesis, Differentiation, Osteogenesis"	"Cytokine, Developmental protein, Growth factor"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CACO-2: 20.7;HeLa: 13.5;hTERT-HME1: 12.2;RT4: 16.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"NK-cell: 2.2"	"Lineage enriched"	"Detected in single"	7	"NK-cells: 2.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA058610, CAB078457"			Enhanced	Vesicles	"Secreted to blood"			Vesicles		"CAB078457: AB_2532532, HPA058610: "	"unprognostic (2.22e-2)"	"unprognostic (9.32e-2)"	"unprognostic (6.12e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.94e-2)"	"unprognostic (2.48e-1)"	"unprognostic (3.70e-3)"	"unprognostic (3.12e-3)"	"unprognostic (8.51e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.53e-3)"	"unprognostic (5.39e-3)"	"unprognostic (7.81e-2)"	"unprognostic (3.76e-1)"	"unprognostic (2.77e-1)"	"unprognostic (3.01e-2)"	"unprognostic (7.49e-2)"	11.1	1.1	1.6	10.5	3.1	0.6	5.3	1.8	7.5	3.7	13.1	2.6	1.9	4.2	3.4	6.7	3.7	3.7	15.6	3.9	2.4	1.6	3.6	3.8	12.8	1.3	2.9	1.3	3.1	9.2	4.7	2.3	7.6	2.7	8.8	9.5	18.3	2.0	1.2	2.6	9.1	13.4	3.4	1.4	8.0	13.8	1.1	2.7	0.3	13.2	6.2	3.1	14.1	9.1	0.0	0.0	0.3	0.0	2.2	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.1	0.0	0.5	2.3	0.0	0.0	20.7	0.0	0.0	0.3	0.7	6.9	4.1	1.8	0.0	0.0	3.7	0.0	13.5	0.0	1.0	0.0	0.5	0.1	6.3	0.0	12.2	4.2	0.0	0.0	0.1	0.0	0.0	3.9	0.5	0.5	4.0	0.0	0.3	1.5	16.5	0.7	1.0	4.9	0.0	0.0	0.0	4.3	1.0	1.2	1.8	0.0	0.5	0.2	0.5	0.0	2.1	1.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.2	0.0	0.0	0.0	0.0	1.6	3.1	1.8	3.3	2.4	1.6	2.9	1.3	2.7	2.7
BMP4	BMP2B	ENSG00000125378	"Bone morphogenetic protein 4"	P12644	14	53949736-53958761	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Chondrogenesis, Differentiation, Osteogenesis"	"Cytokine, Developmental protein, Growth factor"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 72.4"	"Cell line enhanced"	"Detected in many"		"CACO-2: 26.0;CAPAN-2: 65.2;EFO-21: 21.7;Hep G2: 69.4;U-2 OS: 20.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"classical monocyte: 1.8;intermediate monocyte: 2.9;memory CD4 T-cell: 2.5;naive CD4 T-cell: 3.3;naive CD8 T-cell: 1.1;non-classical monocyte: 4.3"	"Group enriched"	"Detected in many"	12	"monocytes: 4.3;T-cells: 3.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB006863, HPA066235"	Enhanced				"Secreted to blood"					"CAB006863: , HPA066235: "	"unprognostic (1.30e-1)"	"unprognostic (3.27e-2)"	"unprognostic (1.29e-1)"	"unprognostic (5.20e-3)"	"unprognostic (3.39e-2)"	"unprognostic (3.32e-1)"	"unprognostic (2.78e-2)"	"unprognostic (3.11e-1)"	"unprognostic (3.45e-3)"	"unprognostic (7.67e-2)"	"unprognostic (2.45e-3)"	"unprognostic (7.06e-2)"	"unprognostic (1.58e-2)"	"unprognostic (2.93e-3)"	"unprognostic (1.37e-1)"	"unprognostic (3.22e-1)"	"unprognostic (1.24e-1)"	7.9	7.8	1.2	3.6	2.0	0.0	10.3	8.1	3.1	8.6	11.7	3.6	3.5	7.8	5.9	2.7	6.0	5.4	9.9	8.3	2.1	0.8	6.1	2.8	8.2	3.4	2.4	2.6	12.0	2.1	0.0	4.1	21.4	11.9	18.0	14.5	72.4	6.4	9.4	7.3	9.4	11.0	11.0	3.7	2.7	11.9	2.4	2.6	1.6	7.3	4.5	4.0	13.0	22.5	0.0	0.3	0.0	4.3	0.0	3.3	0.9	3.3	8.7	0.4	0.4	0.1	0.0	0.1	1.7	7.4	4.4	3.4	26.0	65.2	0.0	21.7	0.0	15.9	1.8	0.2	2.4	0.8	1.3	0.0	1.7	69.4	4.4	0.0	0.2	0.0	0.6	2.1	0.1	13.0	0.0	0.0	2.1	1.5	1.1	0.0	3.0	0.7	0.0	2.3	0.0	6.2	0.2	0.0	0.0	0.0	0.2	0.2	8.5	0.3	0.6	0.1	20.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.9	0.0	1.8	0.0	0.3	2.9	0.0	0.0	2.5	0.5	0.3	0.0	3.3	1.1	0.0	0.0	4.3	0.1	0.0	0.9	1.2	2.0	8.1	3.1	2.1	0.8	2.4	2.6	11.9	2.6
BMPR1A	"ACVRLK3, ALK3, CD292"	ENSG00000107779	"Bone morphogenetic protein receptor type 1A"	P36894	10	86756601-86932838	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB019398	Approved		Approved	Cytosol				Cytosol		"CAB019398: "	"unprognostic (1.36e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.34e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.05e-3)"	"unprognostic (9.34e-2)"	"prognostic unfavourable (8.93e-4)"	"unprognostic (3.64e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.24e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.07e-1)"	8.9	7.0	9.4	7.9	12.4	0.9	10.7	14.1	9.2	19.4	20.6	10.9	7.7	6.2	16.3	12.3	8.4	10.9	10.8	11.0	7.7	6.1	8.2	4.6	7.4	2.9	7.3	7.6	16.1	10.6	10.0	14.0	7.4	8.5	12.8	9.3	10.9	12.6	14.2	8.4	11.3	9.8	16.5	12.2	3.4	12.1	7.8	9.2	0.3	19.4	7.8	5.7	16.0	11.4	1.8	1.1	3.6	0.8	0.9	1.4	0.3	7.5	3.8	14.7	12.5	7.7	5.0	2.6	7.6	8.0	4.5	5.2	6.5	6.7	2.3	3.5	9.7	8.1	6.5	8.3	6.6	2.5	3.7	2.9	3.6	10.7	4.1	4.0	20.4	4.4	3.5	6.0	4.4	0.0	4.5	1.6	5.2	3.2	2.6	3.2	8.0	1.8	0.0	5.8	0.0	9.2	7.2	1.5	4.8	8.5	4.3	5.1	7.3	2.0	3.8	3.2	5.2	6.6	7.0	0.4	7.0	2.9	2.8	2.7	2.6	2.0	0.8	0.6	1.4	0.5	0.9	1.8	1.4	1.2	0.3	1.5	1.0	1.1	3.6	0.9	0.6	1.1	0.7	0.3	9.4	12.4	14.1	9.2	7.7	6.1	7.3	7.6	8.5	9.2
BNIP3	Nip3	ENSG00000176171	"BCL2 interacting protein 3"	Q12983	10	131966455-131982013	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 122.7"	"Cell line enhanced"	"Detected in many"		"A-431: 73.3;HBF TERT88: 51.0;U-87 MG: 69.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003015, CAB011676"	Supported		Uncertain	Cytosol				Cytosol		"CAB011676: , HPA003015: AB_1078290"	"unprognostic (1.01e-3)"	"unprognostic (1.42e-3)"	"unprognostic (1.46e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.58e-2)"	"unprognostic (1.62e-3)"	"unprognostic (6.57e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.64e-2)"	"prognostic unfavourable (4.55e-4)"	"unprognostic (2.37e-3)"	"unprognostic (1.04e-1)"	"unprognostic (3.29e-2)"	"unprognostic (2.98e-1)"	19.3	12.0	18.3	4.0	18.6	3.0	8.7	13.5	28.3	7.7	4.6	13.0	5.1	4.0	6.0	11.4	8.1	6.0	7.9	43.3	16.9	14.6	27.6	53.4	6.7	4.6	16.5	14.2	19.3	122.7	6.0	7.3	13.0	22.6	18.2	2.9	5.2	19.2	6.6	48.0	9.0	4.5	6.0	13.3	4.9	6.4	6.0	11.1	3.3	10.8	6.2	4.0	9.2	7.3	6.1	3.0	5.1	3.5	2.2	23.4	8.9	73.3	5.9	4.2	11.9	11.4	12.1	21.9	17.9	16.6	13.5	38.7	1.2	1.6	0.1	29.1	10.3	4.5	9.0	25.4	51.0	3.9	6.8	2.6	3.8	17.0	15.3	3.3	2.1	8.4	6.4	13.1	13.3	9.4	6.7	0.2	22.0	5.8	1.7	18.7	3.6	17.8	4.1	2.1	6.2	14.8	1.2	5.6	13.2	3.6	7.6	10.1	4.6	4.7	10.7	19.2	6.4	7.2	14.1	12.6	10.7	10.2	69.4	0.1	3.2	2.2	3.5	5.1	9.8	2.3	10.4	5.7	13.9	10.3	3.0	6.1	23.4	15.4	0.9	2.2	3.1	2.3	13.2	8.9	18.3	18.6	13.5	28.3	16.9	14.6	16.5	14.2	22.6	11.1
BNIP3L	"BNIP3a, Nix"	ENSG00000104765	"BCL2 interacting protein 3 like"	O60238	8	26382898-26505636	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Apoptosis, Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015652, CAB025371"	Enhanced		Supported	"Nuclear speckles,Mitochondria"				Mitochondria	"Nuclear speckles"	"CAB025371: , HPA015652: AB_1845406"	"unprognostic (1.02e-1)"	"unprognostic (2.90e-1)"	"unprognostic (2.00e-1)"	"unprognostic (8.36e-2)"	"unprognostic (6.24e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.64e-3)"	"unprognostic (1.46e-2)"	"unprognostic (5.04e-2)"	"unprognostic (2.02e-1)"	"unprognostic (2.06e-2)"	"unprognostic (2.97e-2)"	"prognostic unfavourable (5.92e-5)"	"unprognostic (8.72e-3)"	"unprognostic (5.16e-2)"	"prognostic unfavourable (3.95e-4)"	"unprognostic (7.59e-3)"	61.7	27.8	32.7	18.2	39.1	79.4	40.1	26.1	39.0	35.0	19.9	32.3	30.7	11.5	27.3	34.0	26.7	26.4	28.0	36.0	36.0	27.4	39.9	22.9	31.3	20.7	43.1	31.9	63.4	10.4	26.8	16.0	51.2	41.0	23.7	14.9	20.9	22.1	39.2	21.0	38.1	14.5	26.5	47.9	19.5	16.7	33.0	43.9	17.8	21.5	12.4	25.2	48.3	30.8	14.2	30.4	68.7	53.9	7.8	17.6	36.3	18.1	6.9	16.6	11.2	46.3	29.2	14.0	18.4	54.1	17.3	38.3	3.1	8.8	5.6	17.4	34.6	9.3	8.2	23.6	57.6	3.6	4.5	23.2	7.2	5.4	25.8	2.0	40.3	35.0	18.6	19.6	11.8	22.1	10.4	13.6	36.2	7.9	14.3	7.6	5.3	7.6	7.7	21.1	11.0	17.9	11.8	17.7	15.8	8.9	1.8	13.9	9.1	4.4	28.9	32.5	14.1	20.3	4.1	20.0	9.0	7.5	49.4	4.2	7.3	49.9	53.9	32.1	7.6	27.8	6.7	12.4	11.4	8.3	30.4	14.2	17.6	12.8	68.7	7.8	17.4	6.9	15.0	36.3	32.7	39.1	26.1	39.0	36.0	27.4	43.1	31.9	41.0	43.9
BRAF	BRAF1	ENSG00000157764	"B-Raf proto-oncogene, serine/threonine kinase"	P15056	7	140719327-140924928	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001328, CAB004552, HPA071048"	Approved		Approved	Vesicles,Cytosol				Vesicles	Cytosol	"CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: "	"unprognostic (2.98e-3)"	"unprognostic (5.66e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.66e-3)"	"unprognostic (2.44e-1)"	"unprognostic (1.48e-2)"	"unprognostic (2.07e-2)"	"unprognostic (4.23e-2)"	"unprognostic (4.07e-2)"	"unprognostic (1.58e-2)"	"unprognostic (6.53e-2)"	"unprognostic (1.91e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.08e-1)"	"unprognostic (1.76e-1)"	"unprognostic (8.01e-2)"	"unprognostic (5.46e-2)"	13.1	12.1	20.1	16.5	20.4	27.8	14.2	29.9	21.5	12.4	12.3	9.5	12.5	9.3	15.3	17.0	11.8	11.5	12.0	13.6	13.2	12.2	13.7	12.8	15.9	13.3	9.9	17.8	16.8	13.2	28.9	24.8	13.7	15.3	14.5	11.0	10.7	11.6	16.6	12.9	15.6	10.5	13.0	10.9	12.3	12.0	24.9	12.2	13.5	16.6	7.5	12.1	18.6	18.1	2.6	1.9	7.5	2.4	7.0	5.6	1.1	5.4	4.6	6.8	8.1	8.3	10.7	10.9	6.1	6.5	4.9	7.1	5.0	5.9	9.3	4.7	6.2	3.0	6.0	4.8	9.0	8.6	4.9	6.0	4.5	4.6	7.0	9.8	6.1	7.1	5.4	5.2	10.8	5.7	9.5	16.7	8.7	2.9	13.0	10.3	6.3	2.9	8.5	5.8	7.6	4.8	10.4	7.9	6.6	7.0	4.3	6.3	4.0	6.7	8.4	5.3	4.1	11.5	4.9	19.4	11.0	14.8	8.7	9.9	5.7	3.3	2.0	7.5	3.1	1.7	2.1	2.6	3.0	2.4	1.6	2.6	5.6	2.8	4.1	7.0	2.4	1.9	2.7	1.1	20.1	20.4	29.9	21.5	13.2	12.2	9.9	17.8	15.3	12.2
BRCA1	"BRCC1, FANCS, PPP1R53, RNF53"	ENSG00000012048	"BRCA1, DNA repair associated"	P38398	17	43044295-43170245	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA recombination, DNA repair, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transcription, Transcription regulation, Ubl conjugation pathway"	"Activator, DNA-binding, Transferase"	"Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in all"	5	"dendritic cells: 9.1;granulocytes: 9.7;monocytes: 12.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001946, HPA004840, HPA034966, HPA057371"	Approved		Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB001946: , HPA004840: , HPA034966: AB_10795287, HPA057371: "	"unprognostic (7.87e-3)"	"unprognostic (6.97e-2)"	"unprognostic (3.53e-3)"	"unprognostic (2.39e-1)"	"unprognostic (5.42e-2)"	"unprognostic (7.07e-3)"	"unprognostic (1.56e-3)"	"unprognostic (4.14e-3)"	"unprognostic (9.62e-3)"	"unprognostic (2.47e-1)"	"unprognostic (5.53e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.08e-4)"	"unprognostic (1.08e-3)"	"unprognostic (1.48e-1)"	"unprognostic (2.12e-1)"	"unprognostic (8.31e-2)"	4.8	4.3	6.0	9.6	11.3	15.3	5.1	12.9	10.6	5.4	9.2	3.4	6.8	4.3	5.4	5.5	9.1	5.5	3.3	6.5	6.6	5.3	4.2	7.7	4.9	13.0	7.5	5.9	5.1	4.7	4.2	11.0	5.3	10.5	4.1	10.4	3.7	5.4	7.4	7.3	8.3	6.7	5.5	9.2	5.9	5.1	17.6	7.0	10.9	15.6	7.3	14.6	5.5	5.6	2.0	9.1	9.7	12.7	1.4	1.3	10.7	15.5	25.2	13.9	11.1	2.3	5.2	13.6	18.3	7.9	15.4	14.7	15.3	12.1	35.9	3.4	7.0	18.0	18.9	10.2	25.9	16.4	13.8	16.9	19.8	13.2	0.5	30.1	14.7	1.4	1.7	23.2	7.4	7.9	25.4	15.4	14.5	10.3	25.2	9.9	7.6	6.7	17.4	29.3	14.7	5.7	15.1	9.6	10.3	14.1	4.7	6.9	12.4	13.9	5.2	13.8	11.2	17.8	19.1	7.2	17.6	27.6	11.1	17.9	14.4	4.6	12.7	1.8	1.3	4.0	1.3	1.1	1.3	1.0	9.1	2.0	1.2	1.3	9.7	1.4	1.5	1.4	0.4	10.7	6.0	11.3	12.9	10.6	6.6	5.3	7.5	5.9	10.5	7.0
BRCA2	"BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11"	ENSG00000139618	"BRCA2, DNA repair associated"	P51587	13	32315474-32400266	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 23.2;testis: 16.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA026815	Uncertain		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA026815: AB_10602692"	"unprognostic (9.36e-2)"	"unprognostic (2.50e-1)"	"unprognostic (4.50e-3)"	"unprognostic (1.06e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.60e-2)"	"unprognostic (2.01e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.06e-2)"	"unprognostic (3.07e-9)"	"unprognostic (2.36e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.32e-1)"	2.4	1.0	0.6	13.8	0.6	11.6	3.2	0.6	0.6	1.8	4.0	0.2	0.2	1.4	1.5	2.7	3.0	1.0	0.7	2.1	0.6	0.7	1.0	1.4	3.5	5.3	0.7	0.5	1.4	3.3	0.4	0.7	7.0	0.8	0.9	2.0	0.1	1.8	0.3	3.3	1.8	3.2	0.8	2.1	6.6	1.5	16.9	0.1	23.2	0.9	4.8	4.2	1.3	1.7	1.3	1.9	0.4	0.2	1.5	0.8	0.0	3.9	3.5	6.0	4.5	0.6	1.6	6.2	4.3	2.7	5.0	4.6	8.2	5.3	14.0	2.8	2.1	5.4	4.9	2.5	9.6	9.1	2.6	8.9	2.2	3.2	0.2	12.7	4.4	0.3	0.3	9.1	6.3	4.0	5.8	4.9	5.7	4.5	10.1	7.5	7.2	1.9	10.0	15.5	2.7	1.3	4.3	2.3	4.3	5.2	2.2	2.1	2.6	6.3	3.1	5.7	6.1	6.3	5.9	1.9	2.9	7.2	2.9	5.1	5.4	0.1	0.2	0.2	0.3	0.2	0.1	0.9	0.4	0.2	0.2	1.3	0.6	0.8	0.4	1.5	0.2	1.9	0.4	0.0	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.5	0.8	0.1
BRD3	"KIAA0043, ORFX, RING3L"	ENSG00000169925	"Bromodomain containing 3"	Q15059	9	134030305-134068535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051830	Approved		Approved	"Nuclear bodies"				"Nuclear bodies"		"HPA051830: "	"unprognostic (3.53e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.90e-1)"	"unprognostic (6.20e-2)"	"unprognostic (2.60e-2)"	"unprognostic (2.98e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.11e-2)"	"unprognostic (6.75e-2)"	"unprognostic (2.79e-1)"	"unprognostic (1.98e-1)"	"prognostic favourable (2.71e-7)"	"unprognostic (1.00e-1)"	"unprognostic (4.71e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.42e-1)"	16.3	15.7	18.0	12.0	20.0	12.3	14.2	21.8	21.8	21.0	20.3	26.7	17.3	13.8	21.7	17.4	14.6	17.7	12.6	17.1	19.9	14.8	11.3	14.5	14.6	11.9	15.8	15.8	19.1	18.7	21.8	15.8	15.7	15.6	19.9	10.3	16.6	16.5	22.5	29.2	19.6	12.9	16.3	17.8	20.1	14.8	17.8	18.2	35.4	18.7	9.2	10.3	17.9	14.1	7.3	16.6	14.6	12.9	15.4	11.9	7.8	4.0	12.4	15.8	12.3	8.8	7.2	14.5	4.2	4.7	4.6	4.7	10.3	6.8	1.5	4.4	3.8	14.2	14.6	5.7	3.7	9.6	8.2	8.8	14.0	11.6	7.9	11.5	7.9	7.6	7.1	5.3	6.1	7.5	7.9	4.6	4.7	13.7	21.3	15.5	21.1	9.6	15.8	22.8	7.7	6.5	4.3	23.2	21.4	18.6	7.0	4.9	10.1	19.2	9.6	11.3	6.3	7.3	3.7	2.5	2.6	1.4	5.7	8.0	7.5	5.9	12.9	14.5	11.9	9.8	10.0	7.1	9.6	10.6	12.5	7.3	9.1	9.7	14.6	15.4	7.9	16.6	4.4	7.8	18.0	20.0	21.8	21.8	19.9	14.8	15.8	15.8	15.6	18.2
BRD4	"CAP, HUNK1, HUNKI, MCAP"	ENSG00000141867	"Bromodomain containing 4"	O60885	19	15235519-15332545	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015055, HPA061646, CAB068177, CAB068178"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB068177: , CAB068178: , HPA015055: AB_1845435, HPA061646: "	"unprognostic (2.83e-3)"	"unprognostic (2.39e-2)"	"unprognostic (6.37e-3)"	"unprognostic (3.38e-2)"	"unprognostic (2.15e-1)"	"unprognostic (9.53e-3)"	"unprognostic (3.03e-3)"	"unprognostic (6.13e-2)"	"unprognostic (7.63e-2)"	"unprognostic (2.72e-2)"	"unprognostic (3.98e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.83e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.22e-1)"	23.0	20.7	27.8	25.6	30.1	25.2	20.4	32.1	29.9	20.8	19.6	17.2	18.9	17.6	23.4	12.5	22.9	18.6	15.8	21.3	20.3	12.4	18.1	25.3	22.5	22.7	14.8	17.6	27.3	31.3	19.1	18.8	34.0	17.6	20.8	10.7	18.9	22.0	19.3	47.7	27.3	21.0	20.3	13.9	26.8	20.2	20.1	16.8	34.2	21.5	11.6	23.7	20.9	24.8	6.9	4.3	11.6	4.4	4.9	3.5	2.0	20.5	20.7	12.9	24.4	12.4	8.8	15.6	15.1	12.4	12.0	12.6	21.9	31.0	25.8	25.1	16.5	20.6	15.0	14.3	10.4	25.8	9.9	24.4	18.2	19.0	18.9	24.0	27.2	12.9	14.8	14.8	29.3	11.6	41.3	26.2	7.6	26.6	22.6	17.4	26.4	24.4	28.4	13.6	16.1	9.5	22.2	15.6	14.2	20.0	14.7	17.1	14.7	16.5	18.4	31.3	15.0	27.8	23.8	21.4	18.8	13.1	17.3	19.6	24.2	5.2	3.6	3.9	3.5	4.4	2.7	5.4	3.1	2.9	2.1	6.9	3.1	2.9	11.6	4.9	3.9	4.3	2.2	2.0	27.8	30.1	32.1	29.9	20.3	12.4	14.8	17.6	17.6	16.8
BRIP1	"BACH1, FANCJ, OF"	ENSG00000136492	"BRCA1 interacting protein C-terminal helicase 1"	Q9BX63	17	61681266-61863521	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 30.1"	"Cell line enhanced"	"Detected in many"		"MCF7: 41.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"B-cells: 2.2;granulocytes: 2.1;T-cells: 3.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005474	Approved		Supported	"Nucleoplasm,Nuclear membrane"				"Nucleoplasm, Nuclear membrane"		"HPA005474: AB_2667333"	"unprognostic (1.88e-1)"	"unprognostic (1.55e-2)"	"prognostic favourable (3.45e-5)"	"unprognostic (6.85e-4)"	"unprognostic (3.09e-1)"	"prognostic favourable (3.62e-4)"	"unprognostic (2.60e-3)"	"unprognostic (5.60e-2)"	"unprognostic (5.66e-3)"	"unprognostic (6.71e-2)"	"unprognostic (1.50e-3)"	"unprognostic (2.75e-2)"	"unprognostic (3.41e-12)"	"unprognostic (1.19e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.96e-2)"	"unprognostic (3.62e-3)"	1.0	0.9	0.7	6.3	3.5	9.1	1.1	0.6	1.4	1.4	2.6	0.2	0.6	2.8	1.5	1.2	3.7	0.8	1.8	0.4	0.5	0.5	0.6	2.3	1.3	4.0	0.5	0.9	2.1	1.3	0.1	0.4	1.7	0.7	1.0	2.8	0.4	1.4	0.0	0.4	2.7	5.5	1.0	0.5	2.3	1.3	10.8	0.4	30.1	0.4	2.0	6.6	1.3	1.7	2.2	0.5	2.1	0.3	0.6	3.7	0.5	12.3	4.2	12.2	6.9	0.4	1.1	2.7	11.4	6.7	12.2	15.8	4.3	3.9	7.3	2.6	2.4	4.5	6.3	2.3	16.4	1.8	7.7	7.5	6.7	5.3	0.1	9.6	4.4	0.2	0.1	9.7	2.6	2.6	5.2	5.0	7.6	41.4	15.2	3.3	2.6	3.6	9.5	23.4	3.5	1.6	5.6	4.9	12.7	4.4	1.5	1.8	4.1	3.7	2.2	18.0	13.1	6.6	13.1	3.1	6.0	7.9	3.7	4.6	4.5	2.1	0.3	1.5	0.5	0.2	0.6	2.2	1.2	0.6	0.4	1.8	1.8	0.9	1.0	0.6	0.2	0.5	3.7	0.5	0.7	3.5	0.6	1.4	0.5	0.5	0.5	0.9	0.7	0.4
BRMS1	DKFZP564A063	ENSG00000174744	"Breast cancer metastasis suppressor 1"	Q9HCU9	11	66337333-66345125	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010824, HPA019637"	Approved		Approved	Centrosome				Centrosome		"CAB010824: , HPA019637: AB_1845448"	"unprognostic (1.75e-1)"	"unprognostic (2.64e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.31e-2)"	"unprognostic (1.72e-2)"	"unprognostic (5.50e-2)"	"prognostic unfavourable (6.74e-4)"	"unprognostic (2.99e-1)"	"unprognostic (2.62e-1)"	"unprognostic (4.48e-1)"	"unprognostic (2.24e-1)"	"unprognostic (2.39e-1)"	"unprognostic (1.27e-1)"	"unprognostic (5.67e-3)"	"unprognostic (2.54e-1)"	"unprognostic (6.32e-2)"	"unprognostic (1.61e-1)"	17.2	18.9	16.7	23.4	24.5	37.0	20.5	9.1	18.7	13.7	19.7	14.5	24.7	21.0	14.6	21.0	24.1	16.1	26.0	13.7	16.6	10.7	23.4	22.2	16.7	25.8	20.1	16.1	14.0	37.6	17.6	12.6	24.1	17.6	22.3	16.0	12.8	23.9	29.8	24.2	26.1	22.6	13.0	16.2	26.3	19.6	37.4	20.9	25.3	20.8	29.3	21.4	16.2	17.5	38.5	32.1	50.7	38.0	22.2	37.2	28.9	24.2	31.8	10.7	17.9	11.4	11.9	15.2	16.7	18.6	30.7	20.6	25.9	16.0	16.4	25.3	16.6	28.6	20.4	30.9	14.5	19.4	17.0	14.9	17.0	18.8	21.3	21.5	17.5	13.4	33.3	30.9	23.2	18.8	17.7	7.7	18.2	39.1	26.2	51.4	23.2	30.0	22.3	19.7	30.7	19.0	14.1	22.7	18.2	21.0	21.7	54.5	26.4	13.4	18.1	23.1	21.9	37.1	21.0	16.0	15.8	25.9	29.9	14.1	24.7	19.0	38.0	36.7	31.1	36.2	33.2	38.5	33.5	29.6	29.8	36.1	29.7	28.0	50.7	22.2	31.0	32.1	37.2	28.9	16.7	24.5	9.1	18.7	16.6	10.7	20.1	16.1	17.6	20.9
BTG1	APRO2	ENSG00000133639	"BTG anti-proliferation factor 1"	P62324	12	92140278-92145897	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 190.7"	"Cell line enhanced"	"Detected in all"		"ASC TERT1: 49.6"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"cerebellum: 66.8"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005972			Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA005972: AB_1078303"	"prognostic favourable (4.36e-5)"	"unprognostic (1.43e-1)"	"unprognostic (2.32e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-3)"	"unprognostic (1.10e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.34e-2)"	"unprognostic (2.50e-1)"	"unprognostic (4.94e-2)"	"prognostic unfavourable (1.95e-7)"	"unprognostic (1.14e-1)"	"unprognostic (1.56e-1)"	"unprognostic (5.79e-2)"	"unprognostic (9.81e-2)"	52.0	22.1	11.5	58.3	13.4	126.9	114.4	66.8	10.4	41.7	40.1	5.5	21.9	15.5	30.1	22.0	28.7	27.9	39.9	49.2	11.9	8.1	22.2	58.1	85.6	190.7	10.4	8.2	29.1	64.2	17.6	17.1	23.4	13.3	28.7	18.1	21.0	19.0	25.9	31.6	70.6	34.3	26.0	24.6	77.1	26.4	19.0	8.9	148.9	15.7	14.3	58.2	54.2	35.2	58.3	6.6	94.3	14.0	47.1	95.2	26.1	6.8	8.6	9.5	1.1	35.7	49.6	4.1	7.7	17.1	5.2	5.2	5.1	2.4	7.4	1.6	8.2	4.7	3.1	8.7	9.7	8.9	6.7	1.4	6.0	2.6	36.2	5.4	2.5	42.3	26.2	11.9	36.9	10.4	5.1	9.8	5.9	7.1	3.8	17.4	2.3	9.9	13.1	5.3	2.3	16.0	14.3	5.3	10.6	9.7	7.5	25.0	31.4	12.6	3.3	5.9	1.8	4.5	4.7	13.6	7.2	12.3	4.6	4.3	6.6	22.3	13.6	94.3	17.0	10.6	20.1	44.5	34.3	29.8	6.6	58.3	95.2	39.1	52.3	47.1	14.0	6.2	39.2	26.1	11.5	13.4	66.8	10.4	11.9	8.1	10.4	8.2	13.3	8.9
BTG2	"APRO1, MGC126063, MGC126064, PC3, TIS21"	ENSG00000159388	"BTG anti-proliferation factor 2"	P78543	1	203305491-203309602	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 36.9;HMC-1: 38.6;U-266/70: 59.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002355	Uncertain		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"HPA002355: AB_1078304"	"prognostic favourable (8.53e-4)"	"unprognostic (1.54e-1)"	"unprognostic (4.63e-2)"	"unprognostic (4.81e-3)"	"unprognostic (5.91e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.47e-1)"	"unprognostic (7.87e-3)"	"unprognostic (4.72e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.18e-2)"	"unprognostic (4.46e-2)"	"unprognostic (6.22e-2)"	"unprognostic (4.34e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.86e-3)"	61.6	45.9	10.1	61.4	20.6	46.9	27.8	13.0	10.4	23.0	53.3	27.8	27.0	15.2	27.1	24.6	55.7	103.7	76.1	65.3	10.4	10.0	22.3	4.3	40.7	20.0	12.2	5.5	102.0	117.6	7.0	52.2	42.7	28.3	61.0	38.5	30.4	18.1	104.1	98.9	30.5	36.6	50.8	22.7	32.7	67.1	11.5	9.9	82.9	36.7	45.2	49.0	64.7	21.5	14.1	17.3	34.5	14.2	5.7	8.5	7.1	0.9	1.4	2.6	1.0	3.3	2.4	21.7	2.5	5.0	0.6	2.5	1.9	0.4	36.9	1.8	0.8	16.2	9.4	9.9	1.2	2.4	4.6	19.3	2.7	4.2	7.2	0.1	38.6	2.4	18.4	2.4	4.5	13.5	8.9	25.6	6.7	0.8	4.0	1.2	1.1	0.2	2.5	8.7	18.5	1.2	30.1	0.4	2.7	2.0	0.8	0.3	2.1	2.3	3.3	0.0	4.3	0.6	0.1	59.8	30.2	23.6	0.5	0.9	1.5	3.2	8.1	9.9	4.7	12.1	7.1	14.1	5.3	4.8	5.1	13.1	8.5	5.9	34.5	5.7	14.2	17.3	4.9	7.1	10.1	20.6	13.0	10.4	10.4	10.0	12.2	5.5	28.3	9.9
BTK	"AGMX1, ATK, IMD1, PSCTK1, XLA"	ENSG00000010671	"Bruton tyrosine kinase"	Q06187	X	101349447-101390796	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 77.5;lymphoid tissue: 37.0"	"Cell line enhanced"	"Detected in some"		"Daudi: 28.8;HEL: 40.0;HMC-1: 144.1;U-937: 20.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 77.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001198, HPA002028, CAB016689"	Enhanced		Supported	"Plasma membrane,Cytosol"		610000	610000	"Plasma membrane, Cytosol"		"CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306"	"unprognostic (3.19e-2)"	"unprognostic (2.51e-3)"	"unprognostic (1.06e-2)"	"unprognostic (3.66e-2)"	"unprognostic (5.69e-2)"	"unprognostic (3.76e-3)"	"unprognostic (6.55e-2)"	"unprognostic (3.58e-3)"	"unprognostic (6.02e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.08e-3)"	"unprognostic (7.80e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.14e-2)"	7.3	2.4	3.3	23.5	5.6	14.0	2.6	0.8	3.6	2.3	3.0	4.7	0.3	2.2	1.9	2.6	2.4	2.0	3.7	3.3	3.3	2.5	2.2	2.5	10.7	25.1	5.4	1.2	1.2	1.5	0.2	1.4	3.2	4.1	2.5	4.5	1.5	3.2	1.0	1.0	2.5	12.9	3.3	10.8	37.0	3.1	1.3	6.3	4.0	1.7	1.8	36.7	5.8	2.0	13.7	13.2	77.5	20.7	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.0	0.0	0.0	0.0	16.0	144.1	0.0	0.0	0.0	0.0	0.0	8.4	0.3	0.0	0.0	0.0	11.2	0.2	0.0	12.1	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.5	0.0	0.0	0.0	0.0	0.0	0.3	0.1	13.7	0.0	20.9	0.0	77.5	11.3	19.3	0.0	18.1	0.0	13.7	0.0	0.0	13.2	13.7	0.0	0.0	4.5	0.0	20.7	6.0	0.0	6.1	3.3	5.6	0.8	3.6	3.3	2.5	5.4	1.2	4.1	6.3
BUB1B	"Bub1A, BUBR1, MAD3L, SSK1"	ENSG00000156970	"BUB1 mitotic checkpoint serine/threonine kinase B"	O60566	15	40161023-40221136	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 49.5;testis: 25.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 2.8;plasmacytoid DC: 2.8"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA008419			Supported	Cytosol				Cytosol		"HPA008419: AB_1078308"	"unprognostic (4.40e-2)"	"unprognostic (2.23e-1)"	"unprognostic (4.65e-2)"	"unprognostic (2.44e-3)"	"unprognostic (9.66e-2)"	"unprognostic (3.52e-2)"	"prognostic unfavourable (7.43e-6)"	"prognostic unfavourable (3.56e-4)"	"unprognostic (3.69e-3)"	"unprognostic (2.32e-1)"	"prognostic unfavourable (1.79e-4)"	"unprognostic (1.76e-2)"	"unprognostic (0.00e+0)"	"unprognostic (3.75e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.20e-1)"	"unprognostic (3.94e-2)"	1.0	0.9	0.3	18.4	0.6	11.4	1.5	0.4	0.5	1.3	4.0	0.4	0.1	3.3	1.1	0.8	6.5	0.5	1.1	0.6	0.4	0.4	0.8	0.7	1.8	8.7	0.4	0.3	0.6	0.5	0.0	0.4	3.4	0.5	0.6	4.4	0.3	1.6	0.1	0.7	2.3	2.9	1.2	0.6	5.4	1.7	25.6	0.1	49.5	0.5	3.1	10.6	1.1	2.0	2.8	2.8	0.0	0.2	0.7	0.7	0.5	21.6	11.0	35.1	13.9	0.8	2.5	11.3	20.5	11.5	22.0	19.1	16.0	8.3	19.6	11.5	7.4	24.4	33.1	11.1	24.0	16.8	17.8	28.6	28.4	14.9	0.0	25.7	15.7	0.5	0.6	13.4	12.7	15.9	24.6	20.9	21.9	7.3	20.2	15.7	23.7	12.5	21.7	28.8	14.8	6.7	11.0	22.9	14.1	12.7	12.1	4.5	14.1	13.4	9.2	16.9	17.9	16.8	18.2	10.9	18.5	32.0	9.0	29.0	21.9	0.0	0.0	0.0	0.2	0.2	0.3	2.4	0.7	0.6	0.7	2.8	0.1	0.4	0.0	0.7	0.1	2.8	0.0	0.5	0.3	0.6	0.4	0.5	0.4	0.4	0.4	0.3	0.5	0.1
C1QBP	"gC1Q-R, gC1qR, HABP1, p32, SF2p32"	ENSG00000108561	"Complement C1q binding protein"	Q07021	17	5432777-5448830	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Adaptive immunity, Apoptosis, Complement pathway, Host-virus interaction, Immunity, Innate immunity, mRNA processing, mRNA splicing, Ribosome biogenesis, Transcription, Transcription regulation"		"Cancer-related genes, Disease mutation, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA026483	Supported		Approved	"Plasma membrane,Mitochondria"	"Intracellular and membrane"	930000	930000	"Plasma membrane"	Mitochondria	"HPA026483: AB_1847108"	"unprognostic (2.18e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.80e-2)"	"unprognostic (6.40e-2)"	"unprognostic (2.60e-1)"	"unprognostic (6.76e-2)"	"unprognostic (7.47e-2)"	"unprognostic (4.62e-2)"	"unprognostic (2.40e-3)"	"unprognostic (6.03e-2)"	"unprognostic (4.60e-3)"	"unprognostic (3.08e-2)"	"unprognostic (7.80e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.13e-1)"	"unprognostic (3.28e-1)"	"unprognostic (3.97e-1)"	24.1	51.6	34.0	51.0	31.4	36.3	42.3	25.8	46.2	22.0	48.8	21.1	22.5	33.9	25.8	25.7	51.1	27.1	33.0	47.1	34.8	35.4	48.4	69.0	26.6	81.1	35.4	25.1	25.2	51.9	32.7	31.2	26.7	36.6	23.8	52.2	24.9	25.1	28.0	55.0	27.3	30.0	29.2	27.8	43.8	26.4	21.3	17.2	55.4	28.1	71.9	46.0	25.5	25.4	59.5	68.1	9.9	35.8	39.0	55.6	65.7	48.8	76.0	26.9	43.4	20.1	24.8	36.4	37.5	30.7	87.4	53.8	72.7	16.4	105.0	37.1	28.3	43.8	86.4	50.9	80.9	24.0	148.7	48.3	39.5	84.5	32.1	58.9	38.5	27.4	46.8	48.0	69.5	44.5	57.4	26.9	33.9	34.1	83.6	42.6	60.6	45.5	66.7	38.1	57.3	50.4	37.0	21.6	40.5	30.8	39.6	52.2	25.0	29.8	26.1	28.1	25.6	31.9	81.4	14.1	21.5	46.2	26.8	56.7	43.0	9.9	34.7	8.3	40.1	35.8	52.5	59.5	45.0	39.9	68.1	49.4	55.6	46.3	2.8	39.0	26.9	56.9	34.3	65.7	34.0	31.4	25.8	46.2	34.8	35.4	35.4	25.1	36.6	17.2
C3orf70		ENSG00000187068	"Chromosome 3 open reading frame 70"	A6NLC5	3	185078050-185153014	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 26.6"	"Cell line enhanced"	"Detected in some"		"SCLC-21H: 19.0;SK-BR-3: 8.3;WM-115: 10.2"	"Cancer enhanced"	"Detected in many"		"glioma: 10.5"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041861	Uncertain		Approved	Cytosol				Cytosol		"HPA041861: AB_10804119"	"unprognostic (1.45e-1)"	"unprognostic (2.17e-3)"	"unprognostic (3.92e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.31e-1)"	"unprognostic (6.62e-4)"	"unprognostic (5.56e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.32e-1)"	"unprognostic (5.98e-3)"	"unprognostic (9.91e-2)"	"prognostic unfavourable (6.40e-6)"	"unprognostic (1.06e-1)"	"unprognostic (8.48e-2)"	"unprognostic (6.57e-2)"	"unprognostic (7.84e-2)"	4.6	2.3	14.4	4.7	13.8	0.9	2.0	7.9	18.2	7.2	12.1	11.1	7.9	5.3	12.1	6.1	10.1	6.8	6.1	3.3	11.1	10.2	1.6	1.3	2.4	1.3	11.4	7.1	5.9	1.1	4.0	1.4	2.9	10.5	10.2	8.2	5.2	5.5	16.4	1.5	2.9	6.5	26.6	11.1	4.2	4.4	7.5	7.0	0.0	2.4	1.0	1.7	13.2	3.3	1.2	1.2	3.4	1.6	1.7	1.1	0.5	0.0	0.1	2.2	0.0	0.0	0.1	0.1	2.9	0.1	0.5	0.0	1.3	0.0	0.0	0.0	0.3	0.1	1.0	0.0	0.2	0.0	0.7	2.5	0.1	0.7	0.0	0.4	4.2	0.3	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.1	1.0	0.2	0.1	4.6	0.1	0.0	0.4	19.0	0.2	0.9	8.3	0.5	0.6	2.1	0.8	0.0	2.2	0.1	1.4	0.0	0.0	0.0	0.0	0.0	10.2	3.4	1.2	1.7	0.8	1.0	1.0	1.0	0.8	0.8	0.6	1.2	1.0	1.1	3.3	1.7	1.6	1.2	0.7	0.5	14.4	13.8	7.9	9.6	11.1	10.2	11.4	7.1	10.5	7.0
C6		ENSG00000039537	"Complement C6"	P13671	5	41142234-41261438	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters"	"Complement pathway, Cytolysis, Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"liver: 176.1"	"Group enriched"	"Detected in some"	13	"ASC diff: 5.1;ASC TERT1: 7.1;HSkMC: 18.8"	"Group enriched"	"Detected in many"	7	"liver cancer: 49.0;pancreatic cancer: 12.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA043823, CAB069427"	Enhanced				"Secreted to blood"	7600000000	7600000000			"CAB069427: AB_1614336, HPA043823: AB_10960262"	"unprognostic (9.79e-2)"	"unprognostic (1.96e-2)"	"unprognostic (5.94e-3)"	"unprognostic (3.02e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.12e-3)"	"unprognostic (4.66e-2)"	"unprognostic (3.72e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.34e-1)"	"unprognostic (3.04e-3)"	"prognostic favourable (4.31e-4)"	"unprognostic (2.69e-4)"	"unprognostic (1.61e-1)"	"unprognostic (1.40e-2)"	"unprognostic (3.51e-2)"	2.3	0.1	0.2	0.1	0.2	0.0	1.0	0.1	0.2	0.3	0.5	0.5	0.1	0.1	0.2	2.7	0.3	8.8	2.4	24.1	0.2	0.0	5.2	176.1	0.9	0.8	0.1	0.1	3.2	10.1	0.0	0.4	0.4	0.6	0.2	0.0	0.2	0.1	0.1	0.2	0.0	0.8	0.1	0.2	0.1	0.4	1.7	0.1	0.1	0.4	0.7	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	7.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.2	0.0	18.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1	0.2	0.2	0.0	0.1	0.1	0.6	0.1
C7		ENSG00000112936	"Complement C7"	P10643	5	40909252-40982939	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 199.9"	"Group enriched"	"Detected in some"	9	"ASC diff: 37.6;HHSteC: 49.7;HSkMC: 68.4;SH-SY5Y: 46.4"	"Cancer enhanced"	"Detected in all"		"pancreatic cancer: 73.8"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			HPA001465	Approved				"Secreted to blood"	67000000000	67000000000			"HPA001465: AB_1078554"	"unprognostic (5.01e-2)"	"unprognostic (3.74e-2)"	"unprognostic (7.40e-2)"	"unprognostic (4.68e-3)"	"unprognostic (5.35e-2)"	"unprognostic (1.43e-3)"	"prognostic favourable (5.89e-4)"	"unprognostic (6.67e-2)"	"unprognostic (3.45e-1)"	"unprognostic (2.21e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.93e-3)"	"unprognostic (2.24e-2)"	"unprognostic (6.10e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.06e-3)"	54.4	99.5	0.8	7.4	1.6	0.0	10.5	1.1	1.0	30.2	34.7	3.1	14.8	2.5	36.8	48.6	55.3	47.7	48.2	79.7	0.9	0.3	81.3	41.0	29.1	69.0	3.9	1.5	199.9	32.4	3.0	5.2	55.4	3.7	52.5	4.8	1.4	5.1	17.5	1.9	1.8	17.0	43.3	3.2	33.6	17.9	44.6	0.7	3.1	32.4	1.1	7.2	39.9	29.6	0.7	0.4	1.6	0.3	1.5	0.4	0.0	0.0	0.0	0.0	0.0	37.6	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.7	0.0	0.0	68.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	46.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.3	0.4	0.2	0.3	0.1	0.2	0.2	0.2	0.0	0.7	0.3	0.4	1.1	1.5	0.3	0.4	0.0	0.0	0.8	1.6	1.1	1.0	0.9	0.3	3.9	1.5	3.7	0.7
CA8	"CALS, CARP"	ENSG00000178538	"Carbonic anhydrase 8"	P35219	8	60187347-60281412	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 41.0;brain: 26.8;parathyroid gland: 56.8"	"Cell line enhanced"	"Detected in some"		"HEK 293: 12.6;K-562: 22.7;NB-4: 13.1;WM-115: 6.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	20	"basophil: 41.0"	"Lineage enriched"	"Detected in many"	20	"granulocytes: 41.0"	"Region enriched"	"Detected in some"	37	"cerebellum: 1413.4"	"Region enriched"	"Detected in all"	9	"cerebellum: 163.0"	"HPA024748, CAB025545, CAB047309"	Enhanced									"CAB025545: , CAB047309: , HPA024748: AB_1846003"	"unprognostic (1.55e-1)"	"unprognostic (2.89e-2)"	"unprognostic (4.43e-2)"	"unprognostic (3.46e-3)"	"unprognostic (6.67e-2)"	"unprognostic (3.19e-1)"	"unprognostic (3.85e-2)"	"unprognostic (3.54e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.19e-1)"	"prognostic favourable (5.79e-5)"	"unprognostic (3.23e-2)"	"unprognostic (1.68e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.41e-1)"	2.3	1.5	9.2	1.1	11.6	1.1	6.5	26.8	6.9	6.3	2.2	3.6	0.6	1.8	2.8	12.8	0.9	2.5	1.0	3.8	7.8	6.0	7.4	0.6	1.6	1.0	4.2	5.3	0.7	3.0	56.8	9.8	8.1	3.4	3.3	3.1	1.5	6.6	0.9	2.0	0.9	1.7	1.3	1.9	1.3	5.9	9.3	6.2	1.7	0.7	1.3	1.0	1.3	2.1	0.1	2.0	41.0	0.0	0.0	0.0	0.0	0.0	2.9	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.8	0.0	0.0	1.3	0.0	0.1	0.0	12.6	5.2	0.0	0.0	4.2	2.1	1.4	0.0	0.0	0.0	0.0	0.0	22.7	0.2	0.0	0.0	3.6	13.1	0.2	0.0	0.0	0.0	0.3	0.5	1.0	5.8	0.0	0.0	1.2	0.0	5.3	0.8	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	6.6	41.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	9.2	11.6	26.8	6.9	7.8	6.0	4.2	5.3	3.4	6.2
CACNA1D	"CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2"	ENSG00000157388	"Calcium voltage-gated channel subunit alpha1 D"	Q01668	3	53328963-53813733	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HMC-1: 14.1;RPMI-8226: 32.8;SK-BR-3: 6.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	9	"basophil: 7.2"	"Lineage enriched"	"Detected in single"	20	"granulocytes: 7.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA020215	Uncertain		Approved	"Nuclear membrane"				"Nuclear membrane"		"HPA020215: AB_1845860"	"unprognostic (5.85e-2)"	"unprognostic (4.90e-3)"	"unprognostic (5.09e-2)"	"unprognostic (2.24e-2)"	"unprognostic (7.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.32e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.42e-2)"	"unprognostic (3.90e-3)"	"unprognostic (1.53e-1)"	"prognostic favourable (8.34e-8)"	"unprognostic (1.14e-1)"	"unprognostic (3.05e-2)"	"unprognostic (8.09e-3)"	"unprognostic (6.70e-3)"	0.6	13.4	10.0	0.8	12.6	1.4	3.6	12.2	16.5	11.2	2.8	3.7	0.1	3.3	6.8	13.2	1.2	14.9	6.2	1.8	5.3	3.5	4.2	3.0	9.0	0.5	2.5	9.6	1.2	5.3	3.0	13.6	1.4	8.7	5.7	3.1	10.1	1.1	3.5	0.6	1.5	4.2	1.7	2.2	4.4	1.8	3.0	1.6	0.0	5.2	0.0	0.6	2.3	0.6	0.1	0.3	7.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	1.5	1.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	14.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.2	0.0	0.0	0.1	32.8	0.3	2.2	3.0	1.3	0.2	6.2	0.7	1.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	7.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	10.0	12.6	12.2	16.5	5.3	3.5	2.5	9.6	8.7	1.6
CAD	GATD4	ENSG00000084774	"Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase"	P27708	2	27217390-27243943	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Pyrimidine biosynthesis"	"Allosteric enzyme, Hydrolase, Ligase, Multifunctional enzyme, Transferase"	"Cancer-related genes, Congenital disorder of glycosylation, Disease mutation, Epilepsy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007781, HPA057266, HPA069341"	Supported		Supported	Nucleoplasm		26000	26000	Nucleoplasm		"CAB007781: AB_562057, HPA057266: AB_2683387, HPA069341: AB_2686125"	"unprognostic (1.69e-1)"	"unprognostic (7.34e-2)"	"unprognostic (1.49e-1)"	"unprognostic (4.71e-3)"	"unprognostic (2.55e-1)"	"unprognostic (1.92e-1)"	"prognostic unfavourable (1.72e-11)"	"unprognostic (1.25e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.37e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"prognostic unfavourable (1.82e-4)"	"unprognostic (6.94e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.14e-1)"	"unprognostic (5.93e-3)"	12.0	11.9	10.1	23.1	12.4	11.1	18.9	13.3	13.1	14.6	12.4	10.9	9.7	12.1	21.0	18.0	16.3	16.6	15.8	9.8	8.6	8.8	13.1	22.9	13.0	27.9	11.8	9.5	24.4	18.1	10.7	16.4	10.6	10.1	12.5	11.6	12.9	11.7	18.3	12.3	26.0	13.2	17.3	12.5	18.7	11.4	21.3	10.8	35.2	13.8	14.1	18.5	12.7	13.1	5.1	4.9	0.8	2.3	3.7	7.9	2.6	25.2	22.9	10.2	20.4	16.6	13.7	8.1	10.7	7.5	13.6	9.7	25.9	10.1	22.6	9.7	9.8	14.3	30.0	14.2	10.2	14.8	24.2	32.3	17.4	13.5	8.3	25.4	16.3	10.4	11.7	19.7	22.5	14.5	22.7	12.6	11.9	25.4	16.2	37.8	24.5	17.4	28.4	30.6	23.5	10.0	12.9	20.5	10.3	15.0	10.7	12.5	8.3	10.7	13.0	20.6	17.0	16.0	21.5	26.2	16.9	46.2	8.3	24.5	17.7	0.0	1.2	0.5	4.7	2.3	4.0	5.1	6.5	7.7	2.7	5.0	4.3	4.3	0.8	3.7	1.2	4.9	7.9	2.6	10.1	12.4	13.3	13.1	8.6	8.8	11.8	9.5	10.1	10.8
CALCA	CALC1	ENSG00000110680	"Calcitonin related polypeptide alpha"	"P01258, P06881"	11	14966668-14972354	"Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"parathyroid gland: 122.2;thyroid gland: 55.3"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.8;hTERT-HME1: 1.7;Karpas-707: 1.8;SCLC-21H: 3.4"	"Cancer enriched"	"Detected in many"	7	"lung cancer: 64.7"	"Region enriched"	"Detected in single"	48	"pons and medulla: 19.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	5	"pons and medulla: 60.6"					HPA059886		Supported			"Secreted to blood"					"HPA059886: "			"unprognostic (1.97e-1)"	"prognostic unfavourable (4.49e-5)"	"unprognostic (5.99e-2)"		"unprognostic (2.42e-1)"	"unprognostic (1.17e-1)"		"unprognostic (6.45e-2)"	"unprognostic (1.28e-1)"	"unprognostic (7.66e-2)"	"unprognostic (3.33e-2)"	"unprognostic (7.49e-2)"	"unprognostic (6.74e-2)"	"unprognostic (2.53e-3)"	"unprognostic (1.02e-2)"	0.2	0.0	0.1	0.3	0.4	0.0	0.8	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.2	6.2	16.8	0.6	0.0	0.1	0.0	0.0	0.1	122.2	0.2	0.0	19.8	1.2	0.0	0.3	0.4	0.0	0.3	0.0	0.0	0.3	1.5	4.6	0.0	0.0	0.0	0.6	55.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.6	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	1.8	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	3.4	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.4	0.1	0.2	0.0	0.2	0.1	0.0	19.8	0.0
CALR	"cC1qR, CRT, FLJ26680, RO, SSA"	ENSG00000179218	Calreticulin	P27797	19	12938578-12944489	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001513, HPA002242, CAB019952, CAB079775"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	450000000	450000000	"Endoplasmic reticulum"		"CAB001513: , CAB019952: AB_2069792, CAB079775: AB_303403, HPA002242: AB_1078384"	"unprognostic (1.49e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.46e-2)"	"unprognostic (4.25e-2)"	"unprognostic (9.44e-3)"	"unprognostic (6.93e-2)"	"unprognostic (2.47e-2)"	"unprognostic (4.60e-2)"	"unprognostic (2.61e-1)"	"prognostic favourable (1.10e-4)"	"unprognostic (2.07e-1)"	"unprognostic (3.76e-1)"	"prognostic unfavourable (1.11e-16)"	"unprognostic (2.37e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.37e-1)"	"unprognostic (5.27e-2)"	67.5	55.5	31.9	58.9	36.1	86.4	64.6	20.9	38.9	50.2	52.3	42.5	65.7	44.1	61.6	108.4	65.2	49.1	67.5	62.5	31.6	35.2	81.9	302.6	61.8	83.6	33.5	33.4	59.6	124.3	56.4	60.3	98.0	35.7	53.1	60.0	43.2	121.0	68.6	25.1	34.2	53.8	56.9	42.1	66.6	49.7	65.0	32.7	61.6	250.6	55.0	65.2	39.4	68.0	25.1	57.2	16.1	38.6	26.3	48.4	16.2	116.3	46.0	63.2	137.7	79.9	72.1	57.9	155.6	127.8	93.8	136.6	70.3	93.7	74.7	143.7	180.5	46.4	69.1	99.2	95.0	55.5	39.4	62.2	56.0	106.9	188.8	249.7	84.4	66.8	46.0	86.9	73.6	112.8	53.2	37.9	76.1	80.4	69.3	163.3	56.2	65.3	53.6	53.6	90.4	82.4	66.7	24.0	51.4	96.5	53.1	31.8	71.0	103.6	97.6	78.4	49.4	111.4	69.5	47.3	42.2	75.1	110.4	109.0	86.1	16.1	19.5	10.1	48.4	38.6	34.3	25.1	29.2	36.7	20.4	22.4	21.6	39.2	6.6	26.3	30.8	57.2	21.5	16.2	31.9	36.1	20.9	38.9	31.6	35.2	33.5	33.4	35.7	32.7
CAMTA1	KIAA0833	ENSG00000171735	"Calmodulin binding transcription activator 1"	Q9Y6Y1	1	6785324-7769706	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036342, HPA036343"	Approved		Supported	Cytosol				Cytosol		"HPA036342: , HPA036343: AB_10671839"	"unprognostic (1.11e-1)"	"unprognostic (6.31e-2)"	"unprognostic (5.80e-2)"	"unprognostic (4.14e-3)"	"unprognostic (3.10e-2)"	"unprognostic (1.47e-2)"	"prognostic unfavourable (5.25e-4)"	"unprognostic (1.08e-2)"	"unprognostic (3.59e-1)"	"prognostic favourable (4.10e-4)"	"unprognostic (3.90e-3)"	"unprognostic (8.84e-2)"	"unprognostic (1.35e-3)"	"unprognostic (2.17e-2)"	"unprognostic (9.19e-3)"	"unprognostic (1.42e-1)"	"unprognostic (9.03e-3)"	18.4	24.3	31.6	12.2	30.7	12.1	21.7	24.4	37.1	16.5	30.2	19.9	13.2	28.3	20.0	46.7	22.7	16.8	17.7	58.1	26.4	27.6	36.7	37.2	16.5	13.3	31.2	26.5	17.1	18.6	22.0	17.6	14.3	47.5	22.2	27.1	25.0	27.1	29.6	48.0	12.9	30.4	38.4	23.9	15.7	21.5	23.0	19.4	14.7	30.8	20.5	17.5	31.3	18.7	19.8	32.3	28.3	32.4	10.3	18.1	18.9	21.5	12.2	33.9	17.2	17.5	26.8	9.5	23.5	18.1	25.3	21.4	14.7	27.5	18.0	18.5	24.5	13.4	17.7	24.2	36.2	13.4	19.2	20.2	28.8	28.7	28.5	15.3	14.7	18.0	16.9	18.2	28.1	28.1	14.2	24.4	29.1	20.9	20.3	42.0	23.4	14.3	13.6	30.2	39.7	34.1	12.6	35.1	28.3	16.6	24.7	36.0	13.4	19.2	16.4	18.0	15.2	18.5	14.6	18.7	23.0	48.2	26.9	34.5	10.1	27.5	32.4	28.3	11.5	19.4	12.5	19.8	18.0	14.2	30.6	16.2	14.7	12.8	6.6	10.3	14.7	32.3	18.1	18.9	31.6	30.7	24.4	37.1	26.4	27.6	31.2	26.5	47.5	19.4
CANT1	"SCAN-1, SHAPY"	ENSG00000171302	"Calcium activated nucleotidase 1"	Q8WVQ1	17	78991717-79009867	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"T-47d: 71.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019627, HPA019639, HPA022818"	Enhanced					2300000	2300000			"HPA019627: AB_1845969, HPA019639: AB_1845970, HPA022818: AB_1845971"	"unprognostic (1.98e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.50e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.13e-2)"	"unprognostic (2.21e-2)"	"prognostic unfavourable (1.41e-4)"	"prognostic unfavourable (2.90e-4)"	"unprognostic (1.76e-1)"	"unprognostic (9.00e-2)"	"unprognostic (3.30e-1)"	"unprognostic (2.49e-1)"	"prognostic unfavourable (6.21e-4)"	"unprognostic (7.04e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.23e-2)"	13.8	15.3	9.6	13.1	10.2	8.1	13.0	12.2	10.8	17.7	43.8	12.3	25.4	25.5	12.0	14.3	27.5	10.0	19.5	10.8	9.0	6.9	10.3	17.7	11.1	11.5	12.5	7.7	10.4	14.7	13.1	11.8	33.0	12.0	36.7	41.5	7.9	30.3	41.4	9.0	8.9	27.2	8.0	12.4	18.1	25.8	19.0	10.3	14.1	12.4	8.9	14.4	10.3	13.7	4.1	3.8	17.5	4.4	3.1	6.2	4.4	26.4	29.0	8.1	11.7	7.7	9.2	10.4	16.3	14.3	17.6	14.9	13.7	25.0	6.4	9.6	11.4	13.4	6.9	12.9	17.6	10.6	12.6	8.3	8.8	11.4	6.6	7.9	13.1	9.5	8.3	16.2	8.8	30.3	10.4	10.9	11.7	14.3	12.0	4.7	5.5	30.9	6.7	13.3	7.2	7.7	13.3	11.7	11.7	8.7	57.8	12.3	71.4	9.5	15.1	26.3	23.8	11.8	20.4	12.9	10.7	6.2	16.8	6.1	16.4	6.1	3.8	8.1	6.2	4.4	6.1	4.1	4.6	5.2	3.8	2.9	4.5	4.4	17.5	3.1	2.9	2.7	3.8	4.4	9.6	10.2	12.2	10.8	9.0	6.9	12.5	7.7	12.0	10.3
CANX	"CNX, IP90, P90"	ENSG00000127022	Calnexin	P27824	5	179678628-179730925	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 107.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004738, HPA009433, HPA009696"	Enhanced		Enhanced	"Endoplasmic reticulum"		82000000	82000000	"Endoplasmic reticulum"		"CAB004738: AB_626784, HPA009433: AB_1078380, HPA009696: AB_1078379"	"unprognostic (6.56e-2)"	"unprognostic (9.34e-3)"	"prognostic favourable (1.38e-4)"	"unprognostic (1.19e-1)"	"unprognostic (7.86e-2)"	"unprognostic (1.41e-2)"	"unprognostic (4.66e-3)"	"unprognostic (8.57e-2)"	"unprognostic (4.34e-2)"	"unprognostic (1.25e-2)"	"unprognostic (2.17e-3)"	"unprognostic (4.48e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.87e-1)"	"unprognostic (7.12e-2)"	"prognostic unfavourable (3.17e-4)"	"unprognostic (2.15e-1)"	49.3	35.4	40.0	35.8	40.9	57.6	37.8	27.3	49.1	93.0	33.6	37.1	48.3	44.0	42.7	115.4	31.6	31.7	30.0	51.3	36.9	50.9	61.6	120.8	34.7	30.1	47.5	27.9	41.0	78.2	13.7	33.0	70.5	44.9	33.5	55.1	32.2	121.5	48.5	28.5	23.4	68.5	60.5	48.8	38.2	31.7	34.3	30.0	31.0	113.4	25.9	29.9	41.4	47.6	10.1	26.3	25.9	28.9	18.7	22.6	30.0	8.2	23.4	19.9	12.1	42.8	31.8	10.1	42.8	47.0	49.4	42.0	20.3	19.2	62.9	60.1	34.3	5.7	31.2	23.3	56.5	16.1	9.5	10.1	58.4	13.2	58.3	19.3	9.6	6.2	42.9	26.5	77.2	20.4	7.9	24.5	5.4	7.7	9.7	0.3	4.0	1.4	10.1	14.4	6.8	36.4	24.5	10.0	2.4	12.0	5.2	107.2	40.5	8.5	38.0	11.3	18.9	12.8	33.2	7.4	25.8	15.9	17.1	12.6	11.0	25.9	28.9	8.8	17.7	21.2	22.6	10.1	13.9	16.3	26.3	7.7	9.5	10.6	6.1	18.7	18.0	25.3	10.1	30.0	40.0	40.9	27.3	33.3	36.9	50.9	47.5	27.9	44.9	30.0
CAP2		ENSG00000112186	"Cyclase associated actin cytoskeleton regulatory protein 2"	P40123	6	17393216-17557792	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"skeletal muscle: 165.7"	"Cell line enhanced"	"Detected in many"		"LHCN-M2: 33.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"MAIT T-cell: 2.9"	"Lineage enriched"	"Detected in single"	29	"T-cells: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA050530, HPA054147"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Cytosol"	"Plasma membrane"	"HPA050530: AB_2681159, HPA054147: AB_2682400"	"unprognostic (7.27e-2)"	"unprognostic (5.71e-3)"	"unprognostic (1.63e-2)"	"unprognostic (1.55e-1)"	"unprognostic (4.86e-1)"	"unprognostic (2.23e-2)"	"unprognostic (9.94e-2)"	"unprognostic (3.58e-2)"	"unprognostic (7.72e-2)"	"unprognostic (1.65e-1)"	"unprognostic (6.43e-2)"	"unprognostic (2.30e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.06e-2)"	"unprognostic (1.47e-1)"	"unprognostic (8.05e-2)"	"unprognostic (1.75e-3)"	5.8	4.1	13.8	3.0	20.1	0.7	3.9	7.5	26.4	5.6	7.7	1.9	2.0	1.9	9.2	5.9	7.0	5.8	3.8	31.2	19.9	8.7	3.3	2.0	2.1	1.1	5.3	17.3	2.1	1.6	3.2	1.7	6.2	8.6	8.4	3.6	2.9	2.5	10.1	165.7	0.9	2.6	13.1	2.0	1.6	3.3	1.1	1.3	0.0	2.3	14.5	1.3	4.6	6.4	0.0	0.0	0.0	0.0	0.0	2.9	0.1	5.4	8.4	16.3	19.6	0.1	0.0	3.5	19.3	14.1	15.9	14.5	2.8	2.4	0.0	18.2	20.7	2.8	7.2	7.2	23.0	0.0	2.7	0.0	5.4	9.2	1.5	0.0	0.0	1.2	3.5	8.0	3.5	0.7	0.0	0.0	33.5	8.7	0.0	0.0	6.2	4.8	1.8	21.7	0.3	8.3	2.2	2.1	4.1	6.5	21.0	11.4	23.2	3.9	0.0	12.9	12.3	0.3	16.9	0.0	0.0	0.0	4.2	0.0	17.5	0.0	0.0	0.0	0.1	0.0	2.9	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	13.8	20.1	7.5	26.4	19.9	8.7	5.3	17.3	8.6	1.3
CAPN6	"CalpM, CANPX, CAPNX"	ENSG00000077274	"Calpain 6"	Q9Y6Q1	X	111245103-111270523	"Cancer-related genes, Enzymes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"epididymis: 62.9;placenta: 173.5"	"Cell line enhanced"	"Detected in some"		"HAP1: 3.5;HDLM-2: 11.0;NTERA-2: 17.3"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 25.9"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"NK-cell: 1.2;plasmacytoid DC: 2.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA040259			Approved	Vesicles				Vesicles		"HPA040259: "	"unprognostic (1.27e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.69e-2)"	"unprognostic (5.77e-3)"	"unprognostic (2.07e-1)"	"unprognostic (9.93e-2)"	"unprognostic (8.39e-3)"	"unprognostic (1.06e-1)"	"unprognostic (2.08e-1)"	"unprognostic (9.45e-3)"	"unprognostic (5.12e-1)"	"unprognostic (6.25e-2)"	"unprognostic (7.67e-2)"	"unprognostic (6.50e-2)"	"unprognostic (5.02e-3)"	"unprognostic (2.66e-1)"	"unprognostic (6.30e-2)"	1.7	0.0	0.2	1.7	0.2	0.0	6.0	0.3	0.3	3.9	4.2	0.2	23.4	0.2	18.2	62.9	2.4	2.9	2.6	0.4	0.2	0.0	5.1	0.4	0.3	1.1	0.2	0.4	1.9	4.1	0.0	0.2	173.5	0.3	3.6	2.2	2.1	5.6	21.7	1.7	1.0	1.3	2.0	0.3	1.0	7.2	2.8	0.2	0.5	1.7	4.7	2.9	1.4	2.6	0.1	2.0	0.8	0.0	1.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	17.3	0.0	0.0	0.0	0.1	1.5	0.0	0.1	0.4	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.8	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	2.0	0.1	0.0	0.2	0.2	0.3	0.3	0.2	0.0	0.2	0.4	0.3	0.2
CARD11	"BIMP3, CARMA1"	ENSG00000198286	"Caspase recruitment domain family member 11"	Q9BXL7	7	2906141-3043945	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 21.4;lymphoid tissue: 44.7"	"Cell line enhanced"	"Detected in some"		"Daudi: 39.7;K-562: 15.8;RT4: 29.9;U-698: 35.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 21.4"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA052984	Approved									"HPA052984: AB_2682005"	"unprognostic (3.12e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.17e-1)"	"unprognostic (8.46e-3)"	"unprognostic (4.81e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.71e-1)"	"unprognostic (2.31e-1)"	"unprognostic (5.65e-2)"	"unprognostic (5.11e-2)"	"unprognostic (2.09e-2)"	"unprognostic (3.09e-1)"	"prognostic unfavourable (6.68e-8)"	"unprognostic (3.74e-2)"	"unprognostic (4.75e-2)"	"unprognostic (1.31e-1)"	"prognostic favourable (1.10e-4)"	1.2	1.7	1.4	44.7	1.0	9.0	0.9	0.7	1.4	1.7	1.4	1.2	0.6	1.9	0.8	0.5	2.7	1.2	11.4	0.8	1.4	2.3	1.9	1.4	3.8	25.0	2.1	0.5	0.9	1.4	0.1	1.0	0.5	1.1	2.8	1.2	1.2	6.7	1.0	0.3	0.5	14.2	1.4	2.9	27.4	3.9	1.4	1.5	22.8	1.3	1.7	28.6	9.4	5.2	4.6	21.4	0.3	0.0	3.3	5.5	1.8	5.3	0.8	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.2	0.0	10.5	11.7	39.7	9.9	0.0	8.9	0.0	0.1	0.1	13.5	0.3	0.0	1.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	7.6	15.8	0.0	0.0	0.1	1.5	0.0	15.0	0.0	1.9	0.0	9.9	3.8	29.9	0.1	0.5	0.0	0.0	0.0	0.0	0.8	5.0	0.0	4.0	0.0	0.0	4.1	0.0	35.4	0.0	0.0	0.0	0.3	0.0	0.0	5.5	0.0	5.2	3.8	3.2	3.6	0.6	4.6	2.1	3.8	0.1	3.3	0.0	21.4	2.2	1.8	1.4	1.0	0.7	1.4	1.4	2.3	2.1	0.5	1.1	1.5
CARM1	PRMT4	ENSG00000142453	"Coactivator associated arginine methyltransferase 1"	Q86X55	19	10871513-10923070	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 64.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB032961, HPA043561, HPA048073"	Supported		Enhanced	Nucleoplasm	"Intracellular and membrane"			Nucleoplasm		"CAB032961: AB_2068446, HPA043561: , HPA048073: "	"unprognostic (9.46e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.94e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.69e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.66e-3)"	"unprognostic (3.76e-2)"	"unprognostic (7.81e-2)"	"unprognostic (6.18e-2)"	"unprognostic (9.31e-2)"	"unprognostic (7.25e-2)"	"prognostic unfavourable (7.88e-6)"	"unprognostic (1.71e-2)"	"unprognostic (6.26e-2)"	"unprognostic (1.00e-1)"	"prognostic unfavourable (8.37e-4)"	12.2	8.8	12.3	12.6	16.1	13.2	9.6	12.5	17.7	15.8	14.0	9.3	9.0	11.5	19.6	9.1	20.5	14.8	12.4	14.7	11.2	7.2	9.3	14.5	8.9	12.4	7.8	10.2	13.0	16.9	8.2	6.9	15.3	9.5	12.6	10.2	12.0	11.4	13.2	64.3	12.5	12.0	15.6	6.6	9.8	11.1	17.5	8.6	9.4	10.0	12.7	15.6	15.8	15.9	1.3	1.6	0.3	1.4	0.1	2.6	0.4	22.4	16.7	24.1	32.6	20.1	27.5	23.1	16.2	28.1	24.1	23.2	25.8	8.3	31.0	19.4	28.2	21.5	24.5	24.3	15.2	34.7	20.0	9.5	10.9	31.3	17.2	14.3	12.4	18.8	15.9	16.4	19.8	30.4	22.8	27.9	14.1	40.7	24.9	12.3	29.7	27.9	34.9	12.3	36.0	14.5	11.7	17.5	16.8	11.6	14.0	15.6	14.0	12.3	18.2	29.0	16.4	27.5	18.9	27.2	21.4	27.1	19.1	23.0	12.6	0.0	1.4	0.2	1.2	1.4	0.5	1.3	0.9	2.6	1.3	1.3	1.0	0.9	0.3	0.1	0.7	1.6	0.8	0.4	12.3	16.1	12.5	17.7	11.2	7.2	7.8	10.2	9.5	8.6
CARS	CARS1	ENSG00000110619	"Cysteinyl-tRNA synthetase"	P49589	11	3000922-3057613	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Protein biosynthesis"	"Aminoacyl-tRNA synthetase, Ligase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737"	Enhanced		Enhanced	Cytosol		110000	110000	Cytosol		"CAB075734: , CAB075735: , CAB075736: , CAB075737: , HPA002383: AB_1078399, HPA002384: AB_1846033"	"unprognostic (9.10e-3)"	"unprognostic (1.83e-1)"	"unprognostic (4.16e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.00e-2)"	"unprognostic (7.97e-2)"	"prognostic unfavourable (5.16e-4)"	"unprognostic (1.41e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.00e-2)"	"unprognostic (5.51e-2)"	"unprognostic (2.45e-1)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (5.37e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.48e-1)"	"unprognostic (3.46e-1)"	24.9	15.9	15.8	15.8	17.7	9.0	15.9	9.5	29.1	13.4	16.3	19.1	11.1	15.9	14.0	10.7	16.0	10.8	14.2	12.5	15.3	18.7	10.7	22.1	15.1	17.2	23.3	15.9	14.5	42.5	14.9	15.9	14.0	23.0	10.8	17.6	7.4	20.3	14.8	24.6	18.8	17.8	21.0	16.1	14.8	22.8	13.4	17.3	9.8	23.0	14.5	22.7	14.4	19.4	8.3	13.3	18.0	23.9	16.4	18.1	11.6	7.5	3.8	5.0	15.0	19.5	18.0	4.5	19.3	22.0	13.3	24.1	9.4	18.0	11.7	5.7	24.3	19.4	16.3	21.9	18.4	34.1	3.7	6.6	6.6	7.2	46.8	13.7	14.5	29.6	17.3	11.5	12.9	17.5	11.0	41.5	13.1	11.5	9.6	0.0	18.7	6.9	4.6	8.3	14.6	0.0	12.6	10.7	14.2	4.7	13.6	21.1	0.0	0.0	6.0	5.5	5.1	13.6	0.2	30.9	28.1	7.4	0.0	7.2	10.8	7.7	12.0	8.8	15.2	10.5	13.0	8.3	13.6	13.6	13.3	6.0	7.5	12.1	18.0	16.4	23.9	5.2	18.1	11.6	15.8	17.7	9.5	29.1	15.3	18.7	23.3	15.9	23.0	17.3
CASC3	"BTZ, MLN51"	ENSG00000108349	"Cancer susceptibility 3"	O15234	17	40140318-40172183	"Cancer-related genes, Predicted intracellular proteins, Transporters"	"mRNA processing, mRNA splicing, mRNA transport, Nonsense-mediated mRNA decay, Stress response, Translation regulation, Transport"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA024592, HPA050262"	Approved		Approved	"Nuclear membrane"				"Nuclear membrane"		"HPA024592: AB_1846034, HPA050262: "	"unprognostic (3.76e-2)"	"unprognostic (3.18e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.77e-2)"	"unprognostic (1.48e-3)"	"unprognostic (3.40e-3)"	"unprognostic (3.38e-1)"	"unprognostic (1.16e-2)"	"unprognostic (3.29e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.15e-1)"	"unprognostic (3.41e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.48e-2)"	27.4	21.0	37.8	20.4	34.8	22.6	26.8	30.0	36.5	30.1	27.3	40.7	19.3	16.4	35.9	26.8	22.2	35.1	21.7	17.8	36.6	32.7	21.6	14.7	23.2	21.8	39.9	27.7	42.1	22.7	31.8	32.6	21.4	29.4	27.4	23.4	25.7	22.5	36.6	50.9	23.0	19.6	35.0	40.7	23.2	22.7	59.7	31.0	19.6	29.4	18.1	25.5	34.1	29.7	6.5	7.2	26.1	11.5	6.8	9.2	5.6	13.3	13.7	17.7	19.8	14.3	15.1	11.3	13.6	12.2	18.7	16.2	14.9	11.7	25.0	21.8	17.1	24.1	21.5	14.4	25.7	17.0	19.0	18.0	17.1	14.9	13.1	22.0	12.2	15.6	13.3	18.3	28.8	23.2	19.4	18.8	15.3	7.7	32.2	12.4	13.9	8.4	20.2	23.6	25.7	9.7	11.8	27.7	15.9	20.3	73.3	17.9	24.1	17.4	15.4	16.3	17.1	15.4	21.4	18.0	16.6	25.3	15.6	12.0	17.7	5.8	5.9	8.6	9.2	8.0	8.3	6.5	6.9	8.3	7.2	6.5	7.9	7.4	26.1	6.8	11.5	3.9	6.4	5.6	37.8	34.8	30.0	36.5	36.6	32.7	39.9	27.7	29.4	31.0
CASP1	"ICE, IL1BC"	ENSG00000137752	"Caspase 1"	P29466	11	105025443-105035250	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 64.2;lymphoid tissue: 40.7"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 37.8;HBEC3-KT: 17.9;HHSteC: 20.3;U-937: 44.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"olfactory region: 22.8"	"Low region specificity"	"Detected in all"			"CAB002685, HPA003056"	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB002685: , HPA003056: AB_1846037"	"unprognostic (1.21e-3)"	"unprognostic (3.02e-1)"	"unprognostic (9.47e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.21e-1)"	"unprognostic (5.24e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.66e-1)"	"unprognostic (6.67e-2)"	"unprognostic (2.75e-2)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (3.11e-4)"	"unprognostic (9.03e-2)"	"unprognostic (2.30e-2)"	"unprognostic (3.18e-1)"	"unprognostic (5.19e-2)"	7.4	3.9	6.6	15.1	17.0	8.2	6.9	3.5	7.0	4.1	12.8	2.2	2.9	34.0	3.0	4.2	10.6	4.3	7.3	4.9	9.3	3.0	6.4	5.8	20.5	16.2	16.7	2.6	4.4	3.4	0.2	3.7	8.7	13.3	6.1	13.9	3.7	7.0	3.2	1.6	9.9	37.2	5.2	17.4	40.7	5.6	1.5	11.0	4.1	3.7	5.6	9.0	9.7	13.2	7.3	39.6	40.5	64.2	11.1	34.3	31.2	0.4	0.1	0.0	1.8	2.0	4.2	0.3	1.9	37.8	4.8	13.2	0.0	0.2	6.1	0.7	2.1	2.7	0.0	17.9	1.1	4.0	0.0	0.3	0.2	0.4	20.3	7.1	0.0	7.2	12.7	3.9	10.4	2.0	0.0	0.0	1.1	0.0	0.2	9.9	0.0	0.1	5.9	0.1	4.8	0.1	2.9	0.1	0.1	5.6	0.3	8.3	0.4	16.4	2.4	4.4	0.2	0.4	0.5	0.0	1.7	0.0	2.7	44.7	0.9	12.3	42.8	23.2	25.4	64.2	34.3	7.3	18.1	22.0	39.6	6.0	9.9	16.4	40.5	11.1	64.0	1.4	22.2	31.2	6.6	17.0	3.5	7.0	9.3	3.0	16.7	2.6	13.3	11.0
CASP10	MCH4	ENSG00000003400	"Caspase 10"	Q92851	2	201182881-201229406	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 42.4"	"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 17.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB003780, HPA017059"	Approved		Approved	"Golgi apparatus,Vesicles"				"Golgi apparatus"	Vesicles	"CAB003780: AB_289592, HPA017059: AB_1846040"	"unprognostic (4.01e-2)"	"unprognostic (8.24e-2)"	"unprognostic (4.80e-1)"	"unprognostic (1.28e-3)"	"unprognostic (4.74e-2)"	"unprognostic (2.25e-1)"	"prognostic unfavourable (8.54e-4)"	"unprognostic (1.73e-2)"	"unprognostic (1.48e-2)"	"unprognostic (3.68e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.04e-1)"	"prognostic unfavourable (6.05e-7)"	"unprognostic (3.23e-2)"	"unprognostic (2.19e-2)"	"unprognostic (4.49e-2)"	"unprognostic (1.38e-2)"	16.0	3.3	3.4	10.1	3.4	14.9	7.6	1.9	3.3	7.0	17.7	4.4	4.3	18.6	8.3	8.2	10.4	4.9	7.2	4.8	3.6	3.0	10.3	7.8	14.2	10.4	4.1	1.4	3.4	6.1	1.4	2.1	8.5	4.7	5.0	11.9	4.1	6.9	6.9	3.6	5.4	42.4	4.8	5.6	26.1	8.7	2.1	2.5	17.1	6.8	8.2	17.9	9.4	6.1	7.8	6.0	4.7	15.4	7.1	7.1	5.8	2.9	2.3	0.1	0.2	0.1	0.2	5.1	0.5	3.4	0.3	1.3	3.1	6.8	0.2	4.9	1.7	1.9	0.1	1.6	0.9	1.4	3.3	8.2	2.4	10.2	1.1	5.4	8.9	0.3	1.4	3.7	0.3	17.7	9.8	12.1	0.3	0.1	10.5	5.1	0.3	1.5	5.7	0.3	12.1	6.2	4.1	0.1	0.1	2.8	0.1	1.3	0.0	5.2	7.1	0.2	0.5	2.3	0.1	13.2	7.8	0.3	3.3	4.2	0.1	4.7	9.6	0.6	6.2	13.5	5.2	7.8	5.2	3.4	5.3	5.0	7.1	6.0	1.9	7.1	15.4	6.0	1.0	5.8	3.4	3.4	1.9	3.3	3.6	3.0	4.1	1.4	4.7	2.5
CASP2	"ICH1, MGC2181, NEDD2, PPP1R57"	ENSG00000106144	"Caspase 2"	P42575	7	143288215-143307696	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 45.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB012175, HPA050678"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB012175: , HPA050678: "	"unprognostic (6.96e-2)"	"prognostic favourable (7.38e-4)"	"unprognostic (2.74e-2)"	"unprognostic (7.51e-2)"	"unprognostic (4.24e-2)"	"unprognostic (2.39e-2)"	"prognostic unfavourable (2.34e-4)"	"unprognostic (1.74e-2)"	"unprognostic (1.34e-2)"	"prognostic favourable (2.89e-4)"	"unprognostic (1.91e-2)"	"unprognostic (1.64e-1)"	"prognostic unfavourable (5.01e-6)"	"unprognostic (2.66e-3)"	"unprognostic (9.48e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.64e-1)"	10.5	6.5	6.6	10.7	6.7	26.8	10.2	9.6	10.9	9.6	8.5	9.0	8.2	8.2	10.8	7.8	14.1	8.4	5.7	6.1	5.7	4.1	7.3	5.8	9.8	15.8	6.9	6.1	8.7	8.1	12.1	6.6	11.3	7.3	7.6	10.2	10.1	11.6	5.8	4.3	14.2	14.0	7.4	6.3	18.6	7.5	8.6	6.9	45.7	8.9	8.0	23.0	7.4	10.2	18.5	11.8	33.2	17.7	13.4	21.4	7.6	10.7	10.1	11.4	20.2	6.4	7.6	6.1	11.1	5.0	10.2	11.2	10.1	12.3	20.5	10.5	7.0	10.6	11.4	8.7	13.6	17.9	8.8	12.1	16.0	6.9	3.4	23.6	15.2	5.2	7.2	12.3	4.4	8.7	10.1	13.1	10.8	10.6	41.0	24.9	14.3	10.3	30.2	5.9	12.5	6.0	9.2	12.5	14.1	22.0	9.6	7.0	10.5	9.0	9.7	9.0	6.3	16.2	11.0	10.9	10.7	23.8	10.2	28.1	16.4	33.2	10.8	9.3	14.9	11.9	14.6	15.8	20.6	15.4	9.8	18.5	15.4	17.8	12.3	13.4	17.7	11.8	21.4	7.6	6.6	6.7	9.6	10.9	5.7	4.1	6.9	6.1	7.3	6.9
CASP3	"apopain, CPP32, CPP32B, Yama"	ENSG00000164305	"Caspase 3"	P42574	4	184627696-184649509	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 76.7"	"Cell line enhanced"	"Detected in all"		"Karpas-707: 72.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	7	"basophil: 76.7;eosinophil: 62.8"	"Lineage enriched"	"Detected in all"	7	"granulocytes: 76.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000091, HPA002643, CAB008381"	Enhanced		Supported	Nucleoplasm,Mitochondria		310000	310000	"Nucleoplasm, Mitochondria"		"CAB000091: , CAB008381: AB_590737, HPA002643: AB_1846048"	"unprognostic (1.38e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.21e-2)"	"prognostic favourable (2.24e-4)"	"unprognostic (2.29e-3)"	"unprognostic (3.58e-2)"	"unprognostic (9.57e-3)"	"unprognostic (5.86e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.70e-2)"	"unprognostic (2.41e-1)"	"prognostic unfavourable (2.30e-5)"	"unprognostic (1.41e-2)"	"unprognostic (5.74e-3)"	"unprognostic (1.30e-1)"	"unprognostic (4.05e-3)"	20.7	11.6	10.8	16.9	10.5	16.7	10.0	22.3	9.2	10.4	25.4	12.8	12.5	32.3	13.9	11.5	22.8	8.9	12.0	8.8	10.0	8.8	10.6	18.7	12.4	23.6	10.2	8.5	8.3	10.0	4.6	13.6	29.4	9.7	8.8	20.9	8.2	13.0	10.0	12.6	9.5	49.7	9.3	12.6	26.5	18.7	6.4	10.9	44.7	7.8	13.5	24.3	16.2	11.0	4.2	5.2	76.7	10.6	9.2	9.9	7.0	8.2	4.6	18.3	8.7	11.4	15.2	10.6	24.8	18.8	17.4	10.1	8.3	6.9	11.5	3.9	12.1	7.0	14.5	8.8	19.9	29.4	7.9	18.3	3.6	19.3	13.6	14.9	17.5	20.7	10.8	11.0	9.0	21.5	15.1	72.7	17.9	3.5	23.5	13.9	18.1	5.8	17.0	8.6	11.0	15.0	13.5	10.5	11.4	10.7	9.8	13.9	5.3	9.7	14.6	8.0	7.3	5.9	11.4	33.8	31.7	7.9	9.7	10.4	11.3	76.7	4.2	62.8	5.5	6.8	5.7	4.2	5.1	7.8	5.2	3.1	3.9	5.8	5.8	9.2	10.6	4.1	9.9	7.0	10.8	10.5	22.3	9.2	10.0	8.8	10.2	8.5	9.7	10.9
CASP4	"ICE(rel)II, ICH-2, TX"	ENSG00000196954	"Caspase 4"	P49662	11	104942866-104969436	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Immunity, Inflammatory response, Innate immunity, Necrosis"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 82.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA027588, CAB037167"	Approved		Approved	"Plasma membrane,Cytosol"	"Intracellular and membrane"			Cytosol	"Plasma membrane"	"CAB037167: AB_258864, HPA027588: AB_10603781"	"unprognostic (1.19e-2)"	"unprognostic (3.73e-1)"	"unprognostic (3.44e-1)"	"unprognostic (1.99e-2)"	"unprognostic (7.19e-3)"	"unprognostic (2.63e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.56e-2)"	"unprognostic (5.31e-2)"	"unprognostic (2.71e-1)"	"unprognostic (2.38e-3)"	"unprognostic (8.39e-3)"	"prognostic unfavourable (3.27e-11)"	"unprognostic (6.75e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.79e-2)"	"unprognostic (4.08e-3)"	10.6	6.3	0.5	9.7	0.5	6.1	9.4	0.0	0.0	4.7	3.5			8.9	3.5	5.9	14.1	5.8	7.3	4.9	0.5	0.5	6.7	16.5	14.0	10.5	1.0		7.5	16.8	0.0	3.0	10.7		5.8	4.0		11.2	1.9	1.6	10.4	8.8	4.3	2.0	19.0	8.2	0.2			4.2		11.3	8.2	8.0	20.5	29.3	82.8	43.2	29.6	35.7	46.8	6.3	2.1	0.0	2.8	13.7	31.2	5.3	11.0	21.5	17.7	24.8	5.3	29.0	3.3	23.7	14.2	10.6	0.0	19.0	16.9	3.7	0.1	8.6	1.6	13.8	33.6	8.6	4.2	28.3	28.5	21.1	29.5	30.7	0.2	0.0	13.5	0.6	5.0	10.2	0.0	6.3	3.8	4.1	2.9	14.8	10.1	0.1	0.0	10.1	7.2	10.0	2.9	12.6	15.9	18.7	6.5	16.4	7.7	0.0	0.0	0.0	9.5	19.7	13.0	14.9	39.1	7.0	31.5	43.2	34.6	20.5	24.2	30.1	29.3	20.0	14.8	22.0	82.8	29.6	33.5	4.9	35.7	46.8										
CASP5	ICE(rel)III	ENSG00000137757	"Caspase 5"	P51878	11	104994235-105023168	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"blood: 22.3;intestine: 31.0;lymphoid tissue: 12.3"	"Cell line enriched"	"Detected in some"	7	"HHSteC: 9.1"	"Group enriched"	"Detected in some"	7	"colorectal cancer: 3.9;stomach cancer: 1.3"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	13	"intermediate monocyte: 10.5;neutrophil: 7.8;non-classical monocyte: 22.3"	"Group enriched"	"Detected in many"	14	"granulocytes: 7.8;monocytes: 22.3"																				"unprognostic (4.30e-2)"	"unprognostic (8.86e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.22e-2)"	"unprognostic (9.90e-2)"	"unprognostic (8.29e-3)"	"unprognostic (1.47e-1)"	"unprognostic (4.38e-3)"	"unprognostic (7.39e-3)"	"unprognostic (3.25e-1)"	"unprognostic (1.82e-9)"	"unprognostic (7.30e-2)"	"unprognostic (2.67e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.50e-1)"	0.6	0.3	0.3	11.8	1.0	0.0	0.3	0.2	0.8	0.2	13.3	0.2	0.0	8.2	0.2	0.2	0.3	0.5	0.1	0.4	2.9	0.3	0.4	1.2	2.7	10.5	0.4	0.2	0.2	0.3	0.0	0.9	0.5	2.0	0.4	11.3	0.2	0.3	0.0	0.8	0.2	31.0	1.4	2.1	12.3	0.4	0.3	0.3	0.3	0.3	0.3	0.1	0.9	0.3	0.0	1.0	7.8	22.3	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.8	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	9.1	0.0	0.0	0.3	1.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.0	0.0	0.0	10.5	0.1	0.0	0.0	0.0	1.0	0.0	0.0	0.0	7.8	0.0	22.3	0.3	0.0	0.6	0.3	1.0	0.2	0.8	2.9	0.3	0.4	0.2	2.0	0.3
CASP6	MCH2	ENSG00000138794	"Caspase 6"	P55212	4	109688622-109703583	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 42.8"	"Cell line enhanced"	"Detected in all"		"Karpas-707: 38.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003775, HPA011337, HPA024303"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB003775: AB_562064, HPA011337: AB_1846053, HPA024303: AB_1846052"	"unprognostic (1.07e-1)"	"unprognostic (1.91e-1)"	"prognostic favourable (2.64e-5)"	"unprognostic (1.45e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.03e-3)"	"unprognostic (9.87e-2)"	"unprognostic (2.73e-2)"	"unprognostic (2.59e-3)"	"unprognostic (1.15e-2)"	"unprognostic (6.78e-2)"	"unprognostic (2.44e-1)"	"unprognostic (8.74e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.41e-1)"	"prognostic favourable (9.93e-4)"	8.1	6.1	3.6	6.7	4.3	5.3	14.3	2.8	3.8	6.9	25.5	2.8	4.5	23.4	5.9	4.3	8.7	5.3	11.7	4.9	4.0	2.0	11.0	14.3	5.6	8.5	5.0	1.6	7.0	13.0	2.3	6.4	4.3	4.5	8.1	19.5	3.4	8.0	10.3	3.4	6.5	42.8	14.0	6.6	9.1	9.2	2.7	4.3	14.5	11.2	3.3	8.4	8.2	12.7	4.4	8.0	8.5	7.0	5.6	21.3	8.0	12.4	4.0	8.3	7.5	6.1	6.0	12.3	7.0	4.8	6.2	6.8	6.7	25.6	1.3	8.1	7.1	5.8	9.9	11.0	5.0	19.7	6.5	10.9	3.6	5.9	4.9	10.9	7.7	6.6	8.2	6.0	1.5	11.8	14.1	38.8	10.1	7.0	28.1	6.9	6.3	7.3	9.8	5.3	6.8	20.6	11.8	8.8	6.6	7.4	13.3	4.1	5.7	4.0	10.0	6.9	7.4	3.3	7.9	5.7	10.3	1.4	9.0	13.1	3.5	8.5	5.3	6.3	4.9	4.8	5.3	4.1	17.8	9.3	6.0	4.4	21.3	11.8	1.1	5.6	7.0	8.0	16.4	8.0	3.6	4.3	2.8	3.8	4.0	2.0	5.0	1.6	4.5	4.3
CASP7	"CMH-1, ICE-LAP3, MCH3"	ENSG00000165806	"Caspase 7"	P55210	10	113679162-113730907	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 64.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			CAB025563	Approved									"CAB025563: "	"prognostic favourable (2.11e-4)"	"unprognostic (3.18e-2)"	"unprognostic (2.82e-2)"	"unprognostic (2.18e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.63e-3)"	"unprognostic (3.96e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.22e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.35e-2)"	"prognostic unfavourable (5.90e-4)"	"unprognostic (5.45e-3)"	"unprognostic (2.62e-1)"	"unprognostic (2.86e-1)"	"unprognostic (4.33e-3)"	16.5	7.8	8.6	12.3	8.7	3.4	22.1	4.7	11.3	13.3	35.5	5.9	9.8	30.8	12.6	6.1	12.0	9.5	7.8	9.0	7.6	3.9	14.1	15.7	16.2	12.2	7.3	2.7	11.0	18.4	5.7	9.6	10.2	9.1	11.9	28.5	5.8	21.8	10.5	9.7	10.9	64.8	9.3	12.4	12.3	21.0	4.3	8.0	12.0	8.4	8.1	11.3	10.6	36.6	9.6	8.6	14.6	17.1	5.4	12.2	7.4	10.8	11.7	9.6	5.1	17.6	15.5	6.7	12.6	19.7	22.5	28.3	8.7	18.8	11.5	7.5	11.4	9.6	11.8	9.5	16.0	17.8	15.9	7.4	8.7	14.5	11.8	7.9	9.8	10.0	6.4	12.8	5.3	29.7	1.9	15.7	8.3	14.6	18.7	6.2	1.7	7.2	19.1	39.1	6.9	17.8	8.0	0.7	5.7	9.7	14.1	6.6	16.7	7.0	14.2	5.0	9.6	5.2	10.3	11.6	7.3	0.3	5.1	14.9	5.6	14.6	12.5	9.4	9.6	17.1	8.4	9.6	8.3	12.2	8.6	7.3	6.5	8.7	2.1	5.4	14.0	1.1	11.1	7.4	8.6	8.7	4.7	11.3	7.6	3.9	7.3	2.7	9.1	8.0
CASP8	"Casp-8, FLICE, MACH, MCH5"	ENSG00000064012	"Caspase 8"	Q14790	2	201233443-201287711	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 52.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001302, CAB002047, HPA005688, HPA006191"	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB002047: AB_563465, HPA001302: AB_1846057, HPA005688: AB_1846056, HPA006191: "	"unprognostic (5.21e-3)"	"unprognostic (2.10e-1)"	"unprognostic (1.83e-2)"	"unprognostic (9.69e-3)"	"unprognostic (2.09e-1)"	"unprognostic (5.60e-2)"	"prognostic unfavourable (3.02e-4)"	"unprognostic (2.10e-1)"	"unprognostic (4.79e-2)"	"prognostic favourable (1.25e-4)"	"unprognostic (7.75e-2)"	"unprognostic (5.11e-2)"	"prognostic unfavourable (1.27e-6)"	"unprognostic (7.67e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.53e-1)"	"unprognostic (4.53e-3)"	14.1	10.6	2.0	31.6	2.6	27.1	10.2	1.4	1.8	7.9	18.5	3.9	7.0	9.6	9.6	12.0	11.7	9.1	12.1	4.4	2.1	2.3	16.4	14.8	17.1	28.3	3.9	1.1	8.2	7.6	1.8	5.9	12.3	3.2	9.8	8.7	4.4	9.6	8.4	2.7	7.4	34.7	5.1	5.0	37.7	7.4	3.8	2.7	43.7	6.7	10.7	43.4	9.6	7.3	13.8	13.7	52.5	17.0	22.2	26.4	12.0	14.3	12.2	3.6	9.9	10.0	14.6	5.5	6.3	6.2	7.5	12.4	16.4	25.0	1.6	13.9	4.9	7.3	7.8	7.5	14.8	9.3	7.1	14.0	9.9	15.6	8.1	10.8	15.2	12.7	18.5	14.2	11.1	7.1	12.5	31.2	6.8	5.9	14.1	11.5	5.8	10.9	10.6	7.4	25.5	14.1	16.0	1.0	0.5	8.2	13.6	8.1	3.6	8.5	8.8	8.1	8.4	4.2	4.9	28.3	12.6	9.7	12.2	14.6	7.6	20.7	13.0	24.9	25.0	17.0	23.1	13.8	20.5	26.4	13.7	7.8	13.3	16.9	52.5	22.2	15.6	6.1	24.0	12.0	2.0	2.6	1.4	1.8	2.1	2.3	3.9	1.1	3.2	2.7
CASP9	"APAF-3, ICE-LAP6, MCH6, PPP1R56"	ENSG00000132906	"Caspase 9"	P55211	1	15490832-15526534	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	Apoptosis	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001473, CAB004348, HPA046488"	Approved		Approved	Mitochondria				Mitochondria		"CAB004348: AB_673489, HPA001473: AB_1078401, HPA046488: "	"prognostic favourable (5.91e-4)"	"unprognostic (2.42e-1)"	"unprognostic (8.94e-3)"	"unprognostic (7.84e-2)"	"unprognostic (1.93e-2)"	"unprognostic (8.54e-3)"	"unprognostic (1.90e-3)"	"unprognostic (6.75e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.09e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.39e-2)"	"unprognostic (2.35e-1)"	"unprognostic (3.21e-2)"	"unprognostic (5.48e-2)"	"prognostic favourable (1.67e-5)"	7.4	24.1	7.8	8.2	9.3	8.9	5.5	11.1	8.7	8.3	9.3	10.2	18.9	5.2	11.9	16.5	7.5	13.4	29.1	10.2	8.3	7.2	11.6	9.4	10.8	12.6	10.7	4.3	33.4	29.0	15.6	18.5	14.7	8.8	10.2	6.4	8.7	6.6	19.0	8.2	2.8	13.3	7.8	9.0	11.0	6.7	14.4	7.1	6.2	14.8	7.2	14.6	7.3	8.1	11.2	11.7	23.3	11.2	13.0	5.1	6.1	7.1	10.4	4.1	7.1	9.3	4.6	3.7	5.2	6.9	7.8	10.0	7.3	8.6	10.4	12.3	7.1	2.5	6.8	5.5	9.0	3.6	8.5	7.4	23.2	7.3	8.7	7.2	8.7	6.3	10.2	11.9	3.6	8.3	16.7	9.7	4.6	3.6	2.4	8.2	4.0	5.8	4.8	10.2	12.1	9.6	4.1	3.5	6.8	7.4	1.8	12.3	4.4	5.2	3.3	10.4	4.8	11.2	3.4	9.4	14.1	11.7	7.9	7.8	3.4	22.7	11.2	23.3	5.1	8.2	3.7	9.6	3.0	3.6	11.7	11.2	1.7	2.6	16.0	13.0	7.9	5.2	2.8	6.1	7.8	9.3	11.1	8.7	8.3	7.2	10.7	4.3	8.8	7.1
CAST		ENSG00000153113	Calpastatin	P20810	5	96525267-96779595	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 201.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009491, HPA036881, HPA036882"	Approved		Enhanced	"Endoplasmic reticulum,Cytosol"		18000000	18000000	"Endoplasmic reticulum, Cytosol"		"CAB009491: AB_2259755, HPA036881: , HPA036882: "	"unprognostic (2.17e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.44e-2)"	"unprognostic (1.91e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.79e-1)"	"unprognostic (4.53e-3)"	"unprognostic (1.94e-2)"	"unprognostic (6.11e-3)"	"prognostic unfavourable (9.27e-5)"	"unprognostic (2.66e-2)"	"unprognostic (1.69e-2)"	"prognostic unfavourable (1.20e-5)"	"unprognostic (1.16e-1)"	"unprognostic (2.79e-1)"	"prognostic unfavourable (4.98e-4)"	38.3	20.7	10.4	25.0	16.3	22.1	32.0	8.7	21.7	38.0	44.6	10.5	18.6	25.6	24.8	25.9	87.4	19.5	25.5	98.5	11.9	10.6	27.2	38.2	29.5	21.1	14.3	12.5	26.9	14.8	22.3	25.3	52.6	24.8	30.0	34.5	12.7	38.7	23.2	201.9	40.7	56.3	36.2	18.7	21.7	22.2	21.2	15.6	10.1	25.6	51.2	34.1	42.2	57.0	24.5	32.7	12.4	48.0	18.3	26.6	27.2	47.9	39.6	6.7	17.5	40.6	75.7	23.7	34.2	48.4	27.4	35.7	9.7	29.3	6.9	32.4	46.3	81.7	12.7	46.5	33.2	44.6	12.0	8.9	41.9	11.6	31.2	5.8	15.5	34.2	43.1	39.3	64.1	30.6	7.5	22.4	33.3	15.1	2.8	0.2	5.2	14.7	2.7	22.7	11.8	54.4	20.3	28.4	6.8	34.9	19.2	22.3	11.7	6.3	40.6	37.4	15.9	24.9	34.5	7.5	20.0	3.2	42.4	3.1	10.3	2.5	48.0	7.0	26.6	29.0	25.2	24.5	23.9	26.5	32.7	22.7	12.2	16.3	12.4	18.3	32.2	9.0	24.2	27.2	10.4	16.3	8.7	21.7	11.9	10.6	14.3	12.5	24.8	15.6
CAT		ENSG00000121691	Catalase	P04040	11	34438925-34472062	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Hydrogen peroxide"	"Mitogen, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 258.3;liver: 184.8"	"Cell line enhanced"	"Detected in many"		"HL-60: 75.2;THP-1: 62.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	13	"eosinophil: 258.3"	"Lineage enriched"	"Detected in all"	13	"granulocytes: 258.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001515, HPA051282, HPA055838"	Enhanced		Enhanced	Vesicles		960000000	960000000	Vesicles		"CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937"	"unprognostic (3.62e-2)"	"unprognostic (2.72e-1)"	"unprognostic (3.59e-3)"	"unprognostic (5.43e-2)"	"unprognostic (4.44e-2)"	"unprognostic (5.80e-3)"	"prognostic favourable (9.67e-4)"	"unprognostic (9.95e-3)"	"unprognostic (3.22e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.34e-2)"	"unprognostic (9.77e-2)"	"prognostic favourable (1.96e-8)"	"unprognostic (1.01e-1)"	"unprognostic (7.31e-2)"	"unprognostic (4.77e-2)"	"unprognostic (6.59e-3)"	70.0	33.0	9.4	10.1	9.6	54.2	36.1	3.1	7.7	15.3	26.6	18.6	15.7	22.2	13.5	9.5	14.8	14.2	19.0	22.4	10.7	5.2	50.4	184.8	26.1	21.3	14.5	6.0	11.0	24.7	7.1	5.0	16.4	10.2	23.2	11.3	11.4	14.5	13.2	27.8	19.7	29.2	11.6	11.3	17.9	15.9	6.2	11.6	23.4	41.7	14.9	11.5	20.4	24.9	7.6	19.9	258.3	17.5	5.5	5.0	17.8	6.1	6.8	5.0	7.8	48.4	21.1	10.6	7.8	9.9	8.8	9.7	3.8	6.2	15.2	7.6	15.5	14.7	8.4	8.5	9.8	13.2	7.7	12.8	7.3	21.9	5.7	75.2	6.4	11.3	5.9	2.6	1.0	10.6	26.5	6.3	11.1	5.8	15.4	13.4	0.0	16.6	10.9	23.8	12.4	24.1	23.3	2.6	4.0	8.8	14.2	11.6	20.3	62.8	7.5	5.3	5.2	13.2	4.6	5.1	2.9	3.2	10.4	51.8	3.8	12.5	17.5	258.3	3.2	14.7	3.8	7.6	3.8	3.6	19.9	6.8	3.8	4.0	17.1	5.5	15.5	13.4	5.0	17.8	9.4	9.6	3.1	7.7	10.7	5.2	14.5	6.0	10.2	11.6
CAV1	CAV	ENSG00000105974	"Caveolin 1"	Q03135	7	116524785-116561184	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Host-virus interaction"		"Cancer-related genes, Congenital generalized lipodystrophy, Diabetes mellitus, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 142.2;BJ hTERT+: 149.8;HBEC3-KT: 145.9;LHCN-M2: 152.1;U-138 MG: 121.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 10.6;memory B-cell: 6.0"	"Group enriched"	"Detected in many"	37	"B-cells: 6.0;granulocytes: 10.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003791, HPA049326"	Enhanced		Supported	"Golgi apparatus"				"Golgi apparatus"		"CAB003791: AB_562068, HPA049326: "	"unprognostic (5.98e-2)"	"unprognostic (1.35e-3)"	"unprognostic (3.35e-1)"	"unprognostic (5.37e-2)"	"unprognostic (4.62e-3)"	"unprognostic (2.35e-3)"	"unprognostic (8.07e-2)"	"prognostic unfavourable (7.17e-5)"	"unprognostic (1.31e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.79e-3)"	"unprognostic (7.92e-2)"	"prognostic unfavourable (1.29e-4)"	"unprognostic (1.65e-3)"	"unprognostic (2.72e-1)"	"unprognostic (7.40e-2)"	"unprognostic (6.14e-3)"	143.9	2.3	2.4	27.5	5.9	0.0	70.5	1.0	3.8	73.8	57.4	2.6	32.3	4.3	84.6	40.9	51.1	31.4	42.0	60.2	2.7	2.3	5.7	4.2	132.7	8.6	7.9	4.5	26.6	3.8	2.0	1.9	92.0	4.2	42.3	13.7	13.6	12.8	26.5	33.3	21.7	18.6	104.0	5.5	28.6	30.1	21.5	5.2	2.8	92.1	34.7	6.6	85.9	33.7	6.0	0.1	10.6	0.0	0.0	0.2	1.1	27.4	22.4	0.6	0.2	92.9	142.2	1.3	65.5	149.8	36.2	38.2	0.1	40.9	0.0	23.2	77.0	51.8	0.1	145.9	55.1	1.8	1.2	0.0	8.9	0.0	12.8	0.0	0.1	48.5	31.0	52.8	35.0	109.0	0.0	1.5	152.1	2.8	0.0	0.0	2.1	10.8	0.3	1.5	15.6	20.5	0.1	0.0	0.0	20.1	1.3	3.2	0.1	0.2	83.7	121.4	13.9	46.3	18.0	6.1	0.9	0.1	48.9	0.0	43.8	10.6	0.0	0.0	0.0	0.0	0.0	6.0	0.2	0.1	0.0	1.3	0.1	0.0	0.0	0.0	0.0	0.1	0.0	1.1	2.4	5.9	1.0	3.8	2.7	2.3	7.9	4.5	4.2	5.2
CBFA2T3	"ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4"	ENSG00000129993	"CBFA2/RUNX1 translocation partner 3"	O75081	16	88874858-88977204	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 75.9"	"Cell line enhanced"	"Detected in some"		"HEL: 21.0;K-562: 36.7;MCF7: 17.0;MOLT-4: 18.6;NB-4: 22.7;REH: 36.9;T-47d: 16.8"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in all"		"cerebellum: 26.0"	"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 11.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA059931, HPA062423, HPA065890"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"HPA059931: , HPA062423: , HPA065890: "	"unprognostic (2.47e-1)"	"unprognostic (2.03e-2)"	"unprognostic (9.24e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.98e-1)"	"prognostic favourable (3.95e-4)"	"unprognostic (1.13e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.10e-1)"	"unprognostic (7.30e-3)"	"unprognostic (2.38e-1)"	"unprognostic (7.04e-5)"	"unprognostic (2.18e-1)"	"unprognostic (4.08e-2)"	"unprognostic (4.62e-2)"	"unprognostic (9.35e-3)"	10.0	1.7	3.6	11.3	7.4	8.2	6.1	26.0	5.4	2.3	3.9	1.3	1.4	3.9	3.2	2.1	2.1	1.9	2.5	6.2	3.0	3.0	0.7	2.0	6.4	9.5	2.0	3.8	0.9	24.9	0.7	2.7	3.8	2.3	3.7	1.5	3.1	4.5	2.9	14.2	2.6	5.5	1.5	1.2	14.7	3.5	3.2	2.2	75.9	2.4	2.0	10.3	3.6	4.8	3.7	11.6	3.6	4.9	0.1	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	21.0	0.0	0.0	0.0	5.5	10.4	0.0	0.0	0.0	0.0	0.0	36.7	0.1	0.0	17.0	18.6	22.7	0.4	0.0	36.9	0.2	3.7	0.0	0.0	7.2	1.6	0.8	0.1	0.1	16.8	5.8	0.1	0.0	0.1	0.1	0.0	0.1	0.1	12.2	0.0	6.4	0.0	1.1	2.7	2.7	0.0	3.2	0.0	3.7	0.0	0.0	7.1	2.1	0.0	0.0	3.6	0.1	4.9	11.6	0.0	1.7	3.6	7.4	26.0	5.4	3.0	3.0	2.0	3.8	2.3	2.2
CBFB	PEBP2B	ENSG00000067955	"Core-binding factor beta subunit"	Q13951	16	67029116-67101058	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 99.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038852	Uncertain		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA038852: AB_10795358"	"unprognostic (1.05e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.22e-2)"	"unprognostic (4.66e-2)"	"unprognostic (3.80e-3)"	"prognostic unfavourable (2.83e-4)"	"unprognostic (1.63e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.11e-1)"	"unprognostic (4.46e-3)"	"unprognostic (1.88e-2)"	"prognostic unfavourable (2.89e-8)"	"unprognostic (1.03e-1)"	"unprognostic (4.31e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.20e-1)"	15.9	10.9	15.9	26.4	25.1	20.5	15.0	9.5	14.3	15.4	10.6	23.3	11.8	8.8	15.3	10.2	20.5	14.3	16.3	21.5	16.2	13.2	12.1	14.4	16.1	32.6	23.6	12.4	17.3	13.6	40.4	18.8	13.2	17.5	14.6	11.1	13.7	19.6	10.3	33.3	14.8	12.2	11.7	22.4	18.2	17.1	7.3	24.2	42.2	17.0	14.8	31.0	15.9	18.8	6.5	9.1	20.5	9.2	14.8	7.0	5.1	15.4	10.3	9.0	14.7	6.6	8.5	14.5	17.9	10.7	16.9	15.0	20.7	17.7	34.2	17.1	15.2	15.4	16.1	10.1	22.8	11.7	9.2	23.7	8.8	16.4	9.4	30.9	51.1	8.5	6.9	18.9	14.6	13.7	25.2	12.2	17.5	11.7	31.8	16.6	8.8	14.6	64.5	39.1	29.0	11.9	13.8	13.3	11.9	45.9	7.0	18.3	6.3	22.2	18.9	26.3	18.0	14.9	24.0	16.7	29.7	99.9	20.0	21.2	23.6	20.5	7.4	7.4	6.7	9.2	7.0	6.5	6.6	7.0	9.1	6.4	6.3	5.3	4.6	14.8	6.1	3.3	7.0	5.1	15.9	25.1	9.5	14.3	16.2	13.2	23.6	12.4	17.5	24.2
CBL	"c-Cbl, CBL2, RNF55"	ENSG00000110395	"Cbl proto-oncogene"	P22681	11	119206276-119313926	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 40.9"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 11.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004350, HPA027956"	Enhanced		Supported	Cytosol				Cytosol		"CAB004350: AB_2244054, HPA027956: AB_10601094"	"unprognostic (2.52e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.92e-1)"	"unprognostic (4.10e-3)"	"unprognostic (9.75e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.03e-2)"	"unprognostic (5.23e-2)"	"unprognostic (5.21e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.85e-2)"	9.9	5.5	9.1	17.0	11.1	11.1	8.8	10.7	12.0	6.2	7.5	8.7	3.0	5.7	9.9	5.3	7.5	7.4	6.3	5.9	8.0	9.6	5.5	4.0	10.3	16.3	8.1	6.9	6.3	5.6	16.6	4.1	9.1	9.3	5.3	7.5	6.4	5.4	7.1	3.9	7.4	8.6	10.6	8.9	13.3	7.3	32.3	5.1	40.9	6.0	5.5	15.6	7.6	7.7	1.8	3.3	11.8	3.7	0.6	1.9	1.0	6.3	4.8	16.8	10.5	5.0	6.0	9.9	6.8	7.1	6.6	6.6	10.2	7.8	15.0	6.2	8.6	9.3	11.5	5.8	14.5	8.5	2.7	15.4	3.6	3.1	6.2	17.9	17.6	5.2	6.5	16.9	18.2	16.3	12.4	6.3	11.9	6.8	9.5	10.0	8.7	5.3	10.3	8.4	2.8	5.9	5.1	2.3	7.0	12.7	5.5	4.5	5.8	15.1	13.6	10.3	7.3	7.2	8.9	2.1	3.1	12.2	4.2	15.5	7.3	0.8	3.2	2.4	1.3	3.7	1.1	1.8	1.6	1.3	3.3	1.8	1.8	1.9	11.8	0.6	3.1	1.8	1.4	1.0	9.1	11.1	10.7	12.0	8.0	9.6	8.1	6.9	9.3	5.1
CBLB	"Cbl-b, RNF56"	ENSG00000114423	"Cbl proto-oncogene B"	Q13191	3	105655461-105869552	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-138 MG: 23.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018327, HPA019880"	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"HPA018327: AB_1846097, HPA019880: AB_1846099"	"unprognostic (2.65e-1)"	"unprognostic (9.42e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.38e-1)"	"unprognostic (5.89e-3)"	"unprognostic (2.80e-2)"	"unprognostic (8.18e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.05e-2)"	"unprognostic (1.66e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.43e-2)"	"unprognostic (8.21e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.09e-2)"	38.4	9.0	3.7	19.5	4.9	15.5	16.3	24.4	3.8	13.7	18.7	5.9	7.7	9.3	13.8	12.2	8.3	12.5	13.4	27.5	3.8	4.8	7.4	6.7	16.3	19.1	4.4	1.9	17.7	6.8	3.4	13.5	25.4	7.9	12.9	8.0	11.6	9.1	6.3	10.3	8.5	13.8	25.6	5.7	16.4	12.4	9.2	5.2	11.6	13.5	7.0	18.0	24.9	24.1	5.1	3.1	2.8	2.1	10.3	9.9	1.6	1.6	2.2	7.6	3.7	8.7	8.8	4.9	5.6	2.8	1.6	2.7	2.9	1.9	3.6	4.0	3.0	2.8	1.0	1.0	2.0	2.7	2.9	1.9	11.7	1.8	12.8	1.3	1.4	8.4	3.0	4.4	12.0	5.5	2.0	11.5	3.5	2.0	1.9	0.9	2.7	3.2	4.1	2.3	0.6	4.0	7.2	5.8	6.4	6.7	0.8	8.8	1.6	2.9	3.1	23.4	2.0	3.2	1.3	6.5	0.5	5.6	6.2	1.2	1.5	0.7	1.5	2.8	9.9	0.9	8.8	2.2	5.1	5.6	1.3	5.1	4.4	8.0	1.0	10.3	2.1	3.1	5.6	1.6	3.7	4.9	24.4	3.8	3.8	4.8	4.4	1.9	7.9	5.2
CBLC	"CBL-3, CBL-SL, RNF57"	ENSG00000142273	"Cbl proto-oncogene C"	Q9ULV8	19	44777869-44800634	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 66.8"	"Cell line enhanced"	"Detected in some"		"A-431: 19.0;BEWO: 13.1;CACO-2: 12.8;CAPAN-2: 26.3;HaCaT: 18.4;HBEC3-KT: 16.0;hTCEpi: 12.2;RT4: 16.0;SK-BR-3: 14.6;T-47d: 10.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB008087, HPA035266"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB008087: AB_2228531, HPA035266: "	"unprognostic (1.58e-1)"	"unprognostic (2.25e-1)"	"unprognostic (8.21e-3)"	"unprognostic (1.55e-1)"	"unprognostic (3.04e-2)"	"unprognostic (3.91e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.82e-1)"	"unprognostic (7.39e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.85e-1)"	"prognostic favourable (3.11e-6)"	"unprognostic (3.50e-1)"	"unprognostic (8.25e-3)"	"unprognostic (2.90e-2)"	"unprognostic (2.21e-3)"	0.1	0.0	0.5	8.5	0.2	0.0	4.8	0.1	0.4	4.4	39.5	0.1	3.2	29.5	1.7	1.7	22.0	1.4	18.8	0.1	0.6	0.0	4.9	15.1	1.3	0.1	0.1	0.3	0.8	18.1	0.9	0.7	4.1	0.2	6.9	6.9	0.5	11.4	5.2	0.1	20.8	66.8	0.4	0.1	0.1	10.2	1.6	0.1	0.5	1.9	13.2	15.7	7.6	8.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	19.0	0.0	0.0	0.0	0.0	0.0	13.1	0.0	0.0	0.0	0.0	12.8	26.3	0.0	0.0	0.0	18.4	0.0	16.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	12.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	16.0	0.1	0.0	0.0	14.6	0.0	10.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.1	0.4	0.6	0.0	0.1	0.3	0.2	0.1
CCAR1	"CARP-1, CARP1, FLJ10590"	ENSG00000060339	"Cell division cycle and apoptosis regulator 1"	Q8IX12	10	68721012-68792377	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Transcription, Transcription regulation"	"Activator, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007856, HPA048513"	Supported		Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"HPA007856: AB_1078415, HPA048513: "	"unprognostic (1.71e-1)"	"unprognostic (1.22e-1)"	"unprognostic (2.34e-2)"	"unprognostic (1.86e-1)"	"unprognostic (5.15e-3)"	"unprognostic (1.71e-2)"	"prognostic unfavourable (1.41e-5)"	"unprognostic (1.10e-1)"	"unprognostic (3.25e-2)"	"prognostic favourable (4.05e-5)"	"unprognostic (2.89e-2)"	"unprognostic (3.21e-3)"	"prognostic unfavourable (1.37e-4)"	"unprognostic (1.67e-1)"	"unprognostic (2.36e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.41e-2)"	24.2	28.0	22.6	38.7	27.9	27.8	24.6	36.9	31.7	26.0	28.7	21.5	24.7	22.7	23.9	23.7	26.5	19.7	23.2	21.6	21.3	20.5	27.4	22.3	23.4	37.5	31.7	17.9	32.1	22.9	28.6	44.3	29.2	23.6	25.0	31.1	26.0	26.7	37.9	47.0	32.3	25.4	24.5	30.4	28.6	23.5	18.9	29.9	42.1	28.5	20.6	37.4	28.8	25.0	12.4	18.6	12.3	12.8	8.8	16.0	9.1	26.4	27.7	32.0	21.4	13.9	13.4	24.9	23.7	20.4	25.9	17.8	36.5	21.6	31.2	13.1	16.3	20.9	33.4	18.8	28.4	21.3	21.0	25.0	19.1	22.6	15.8	39.4	29.4	13.4	23.4	21.8	26.9	20.7	34.0	20.2	24.9	19.1	26.2	25.0	31.9	25.9	30.7	19.1	18.6	22.6	20.2	18.5	16.1	23.3	38.4	23.3	26.0	24.2	20.2	16.1	20.3	17.3	25.5	14.0	18.4	33.5	13.5	26.6	15.2	4.9	12.8	12.3	15.5	11.5	13.8	12.3	11.0	14.9	18.6	12.4	13.3	14.0	3.1	8.8	12.8	11.8	16.0	9.1	22.6	27.9	36.9	31.7	21.3	20.5	31.7	17.9	23.6	29.9
CCDC120	JM11	ENSG00000147144	"Coiled-coil domain containing 120"	Q96HB5	X	49053572-49069857	"Cancer-related genes, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 14.1;BEWO: 20.3;HaCaT: 13.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000561			Uncertain	Mitochondria				Mitochondria		"HPA000561: AB_2244190"	"unprognostic (1.65e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.19e-1)"	"unprognostic (7.59e-3)"	"unprognostic (1.80e-3)"	"unprognostic (1.08e-2)"	"unprognostic (2.59e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.66e-2)"	"unprognostic (4.85e-2)"	"unprognostic (2.64e-2)"	"unprognostic (3.82e-3)"	"unprognostic (4.54e-3)"	"unprognostic (2.34e-3)"	3.3	3.1	5.8	3.1	4.7	2.9	5.0	17.3	5.8	8.4	6.8	1.6	10.4	12.0	5.5	9.9	27.6	5.1	4.1	2.1	4.0	1.6	7.0	4.8	4.4	2.6	1.5	3.3	6.5	7.0	6.1	12.2	13.3	4.0	6.0	3.3	4.7	11.4	10.2	1.5	26.1	12.5	2.5	1.8	3.8	7.7	5.8	1.5	6.0	5.6	8.8	15.1	7.4	12.2	2.5	2.2	3.9	0.8	1.6	1.5	0.4	14.1	1.9	3.1	0.1	0.0	0.0	20.3	0.5	0.7	1.1	1.7	4.7	6.1	0.5	2.2	0.8	13.7	2.4	8.0	0.1	3.6	4.6	1.3	3.3	1.6	1.0	0.0	2.4	1.8	6.4	1.3	0.4	1.7	1.9	0.2	0.0	11.9	4.9	0.3	3.6	0.1	4.4	2.3	1.3	6.1	7.6	4.3	3.3	2.5	5.1	1.4	12.4	1.9	0.8	0.1	3.7	0.1	0.1	4.6	3.1	0.1	0.1	0.0	0.6	2.9	0.8	1.5	1.4	0.2	0.9	0.8	1.5	1.3	0.3	2.5	1.5	1.4	3.9	1.6	0.4	2.2	0.5	0.4	5.8	4.7	17.3	5.8	4.0	1.6	1.5	3.3	4.0	1.5
CCDC6	"D10S170, H4, PTC, TPC, TST1"	ENSG00000108091	"Coiled-coil domain containing 6"	Q16204	10	59788763-59906656	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019049, HPA019051"	Enhanced		Supported	Cytosol				Cytosol		"HPA019049: AB_1846163, HPA019051: AB_1846164"	"unprognostic (1.88e-2)"	"unprognostic (1.72e-2)"	"unprognostic (4.41e-2)"	"unprognostic (1.25e-3)"	"unprognostic (5.98e-3)"	"prognostic favourable (5.48e-4)"	"prognostic unfavourable (1.11e-4)"	"unprognostic (7.39e-2)"	"unprognostic (2.45e-1)"	"unprognostic (2.28e-1)"	"prognostic unfavourable (3.95e-4)"	"unprognostic (4.08e-1)"	"unprognostic (4.69e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.56e-1)"	"unprognostic (9.95e-2)"	"unprognostic (4.19e-2)"	13.7	13.3	22.8	11.7	41.8	12.8	20.7	13.8	27.1	23.0	23.9	11.3	10.7	20.4	28.4	16.6	33.2	23.6	16.2	11.2	17.0	18.1	19.4	10.9	15.5	18.7	13.8	17.6	19.8	22.5	16.8	13.7	13.3	14.5	18.7	18.4	9.6	25.5	14.0	18.2	26.0	20.4	28.1	11.8	14.5	16.6	12.6	12.3	10.6	19.1	14.8	20.7	21.7	23.8	7.1	7.3	0.2	3.4	1.2	2.3	1.4	15.8	14.3	7.2	16.1	11.0	16.6	14.7	7.8	10.4	7.8	9.2	27.8	31.1	13.6	11.8	13.0	23.5	14.4	14.2	11.7	20.3	7.2	11.1	11.6	16.9	13.3	12.6	10.4	12.0	18.9	13.0	32.0	11.5	8.3	8.7	10.1	21.3	5.2	7.3	11.5	9.8	7.1	11.8	8.5	13.1	13.6	7.4	6.4	9.8	41.5	8.7	26.3	6.8	11.7	7.3	13.4	11.3	13.0	4.6	5.3	6.2	11.6	24.2	4.5	0.0	2.9	0.0	1.5	3.4	1.8	6.7	2.3	2.1	7.3	7.1	2.2	1.6	0.2	1.2	1.9	1.9	2.1	1.4	22.8	41.8	13.8	27.1	17.0	18.1	13.8	17.6	14.5	12.3
CCKBR		ENSG00000110148	"Cholecystokinin B receptor"	P32239	11	6259736-6272127	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	24	"brain: 12.9;pancreas: 34.7;stomach 1: 21.4"	"Cell line enriched"	"Detected in some"	9	"NTERA-2: 39.2"	"Cancer enriched"	"Detected in some"	8	"testis cancer: 9.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"amygdala: 15.5;basal ganglia: 15.3;cerebral cortex: 31.4;hippocampal formation: 26.8;olfactory region: 19.2"												"unprognostic (2.82e-1)"			"unprognostic (4.62e-2)"	"unprognostic (1.79e-3)"	"unprognostic (2.19e-1)"		"unprognostic (1.95e-1)"	"unprognostic (6.34e-4)"	"unprognostic (8.01e-2)"	"unprognostic (3.01e-2)"	"unprognostic (9.00e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.30e-2)"		0.3	0.4	6.5	0.3	5.6	0.3	0.3	10.8	12.9	0.3	0.3	0.0	0.0	0.6	0.4	0.3	0.3	0.6	0.4	0.3	3.3	0.8	0.3	0.3	0.3	0.3	1.0	6.9	0.3	34.7	0.3	0.4	0.4	2.1	0.9	0.3	0.3	0.3	0.4	0.4	0.8	0.3	0.3	0.3	0.3	21.4	0.6	0.0	0.0	0.6	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.5	5.6	10.8	12.9	3.3	0.8	1.0	6.9	2.1	0.0
CCL11	"eotaxin, MGC22554, SCYA11"	ENSG00000172156	"C-C motif chemokine ligand 11"	P51671	17	34285668-34288334	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"heart muscle: 31.0;intestine: 29.6;lymphoid tissue: 29.2"	"Cell line enriched"	"Detected in single"	21	"BJ hTERT+: 13.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"												"Secreted to blood"						"unprognostic (4.61e-2)"	"unprognostic (1.45e-1)"	"prognostic favourable (8.70e-4)"	"unprognostic (8.18e-2)"		"prognostic favourable (1.99e-4)"	"unprognostic (9.91e-2)"	"unprognostic (8.09e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.82e-2)"	"unprognostic (1.45e-1)"	"unprognostic (9.64e-8)"	"unprognostic (2.66e-2)"	"unprognostic (1.05e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.72e-2)"	2.6	0.4	0.2	29.2	0.2	0.0	0.2	0.2	0.2	4.5	29.6	0.4	0.6	17.3	3.5	0.0	20.7	0.8	12.0	31.0	0.2	0.2	7.0	1.2	7.3	0.3	0.2	0.0	2.6	11.6	0.2	1.1	0.0	0.2	16.1	8.0	0.0	0.2	0.3	0.5	0.2	18.7	10.2	0.2	1.2	18.2	0.6	0.0	0.7	0.4	0.0	0.8	12.1	5.8	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	13.9	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.0
CCL13	"CKb10, MCP-4, MGC17134, NCC-1, SCYA13, SCYL1"	ENSG00000181374	"C-C motif chemokine ligand 13"	Q99616	17	34356452-34358610	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 4.6;BJ hTERT+: 4.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HMC-1: 3.5;HSkMC: 4.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	14	"classical monocyte: 1.3"	"Lineage enriched"	"Detected in single"	14	"monocytes: 1.3"														"Secreted to blood"						"unprognostic (2.22e-2)"	"unprognostic (3.56e-2)"	"unprognostic (8.41e-3)"	"unprognostic (1.49e-3)"	"unprognostic (4.43e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.58e-2)"	"unprognostic (8.49e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.83e-2)"	"unprognostic (1.35e-2)"	"unprognostic (5.98e-2)"	"unprognostic (8.63e-8)"	"unprognostic (2.26e-1)"	"unprognostic (2.57e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.71e-2)"	12.5	4.1	0.3	3.0	0.5	0.0	9.6	0.3	0.5	3.1	17.0	0.5	2.7	10.5	1.0	16.1	5.9	4.5	3.1	20.0	0.3	0.1	3.4	0.7	14.5	1.3	0.3	0.3	1.8	2.1	0.8	0.3	7.3	0.4	3.6	13.3	0.5	2.5	0.3	4.4	3.9	17.0	4.1	0.3	0.3	1.9	2.7	0.3	5.7	5.8	5.2	1.6	11.1	2.4	0.0	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.6	0.2	0.0	0.6	4.2	0.7	2.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	1.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	3.5	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.3	0.5	0.3	0.1	0.3	0.3	0.4	0.3
CCL14	"CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2"	ENSG00000276409	"C-C motif chemokine ligand 14"	Q16627	17	35983291-35987004	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 80.7;lymphoid tissue: 98.4"	"Cell line enriched"	"Detected in single"	52	"HUVEC TERT2: 35.0"	"Low cancer specificity"	"Detected in some"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB004423, HPA030268"	Uncertain				"Secreted to blood"	19000000	19000000			"CAB004423: AB_627716, HPA030268: AB_10603782"	"unprognostic (4.13e-2)"	"unprognostic (5.85e-2)"	"unprognostic (4.86e-2)"	"unprognostic (3.55e-3)"	"unprognostic (2.50e-1)"	"unprognostic (1.99e-2)"	"unprognostic (8.79e-5)"	"unprognostic (1.44e-1)"	"unprognostic (1.53e-1)"	"unprognostic (8.10e-2)"	"unprognostic (6.33e-3)"	"unprognostic (3.00e-2)"	"unprognostic (7.27e-3)"	"unprognostic (1.36e-2)"	"unprognostic (3.95e-1)"	"unprognostic (3.52e-1)"	"unprognostic (1.14e-1)"	56.3	5.1	0.0	5.9	0.0	0.0	80.7	0.0	0.0	37.6	8.4	0.0	16.6	0.0	37.6	11.1	20.9	9.1	17.3	27.5	0.0		8.7	34.2	26.4	39.1	0.0	0.0	12.4	0.8	2.0	6.5	0.0	0.0	23.5	0.7	4.1	6.5	11.4	21.9	7.5	3.9	19.1	0.0	98.4	0.2	15.0	0.0	1.3	17.6	16.7	6.2	25.3	45.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CCL16	"CKb12, HCC-4, LCC-1, LEC, LMC, Mtn-1, NCC-4, SCYA16, SCYL4"	ENSG00000275152	"C-C motif chemokine ligand 16"	O15467	17	35976493-35981496	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	127	"liver: 79.1"	"Cell line enriched"	"Detected in single"	23	"Hep G2: 14.6"	"Cancer enriched"	"Detected in single"	154	"liver cancer: 49.0"					"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in all"								"Secreted to blood"	20000000	20000000				"unprognostic (3.85e-1)"	"unprognostic (4.71e-1)"	"unprognostic (1.49e-1)"	"unprognostic (3.75e-2)"		"unprognostic (2.72e-1)"	"unprognostic (4.58e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.91e-2)"	"unprognostic (3.57e-1)"	"unprognostic (1.40e-3)"	"unprognostic (1.66e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.09e-1)"	"unprognostic (4.08e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	79.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.2										
CCL18	"AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18"	ENSG00000275385	"C-C motif chemokine ligand 18"	P55774	17	36064280-36072032	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 41.4;lung: 77.9;lymphoid tissue: 61.9"	"Cell line enhanced"	"Detected in single"		"SK-MEL-30: 1.5"	"Low cancer specificity"	"Detected in all"							"Not detected"	"Not detected"			"Not detected"	"Not detected"																"Secreted to blood"	940000	940000				"unprognostic (8.91e-2)"	"unprognostic (2.96e-2)"	"unprognostic (5.71e-2)"	"unprognostic (9.64e-2)"	"unprognostic (1.60e-2)"	"unprognostic (3.28e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.96e-1)"	"unprognostic (2.50e-1)"	"unprognostic (3.11e-2)"	"unprognostic (1.21e-2)"	"unprognostic (4.06e-2)"	"unprognostic (2.95e-3)"	"unprognostic (2.49e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.63e-1)"	"unprognostic (4.87e-2)"	18.2	0.0	0.0	1.3	0.0	0.0	0.3	0.0	0.2	0.0	3.1	0.0	0.0	1.6	0.0	5.8	3.2	0.0	0.4	41.4	0.0		0.0	1.3	77.9	61.9	0.0	0.0	3.7	0.3	0.0	0.0	5.9	0.0	0.2	2.5	0.0	0.2	0.0	0.0	0.3	3.4	4.1	0.0	3.7	0.3	1.6	0.0	43.8	2.2	4.3	16.7	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CCL19	"CKb11, ELC, exodus-3, MIP-3b, SCYA19"	ENSG00000172724	"C-C motif chemokine ligand 19"	Q99731	9	34689567-34691277	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"lymphoid tissue: 418.9"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 1.9;Daudi: 2.5;HDLM-2: 7.5;HL-60: 1.9;TIME: 3.7"	"Cancer enhanced"	"Detected in all"		"testis cancer: 118.4"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	4	"intermediate monocyte: 2.3"	"Lineage enriched"	"Detected in single"	6	"monocytes: 2.3"					"Low region specificity"	"Detected in many"			HPA067758	Enhanced				"Secreted to blood"					"HPA067758: "	"prognostic favourable (2.88e-5)"	"prognostic favourable (9.91e-6)"	"unprognostic (8.25e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.67e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.17e-2)"	"unprognostic (8.36e-3)"	"unprognostic (8.31e-2)"	"unprognostic (2.43e-1)"	"prognostic unfavourable (8.63e-7)"	"unprognostic (7.98e-2)"	"unprognostic (1.68e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.87e-1)"	22.5	0.6	1.2	82.3	1.1	0.0	10.2	0.8	1.3	5.8	4.7	1.5	1.5	1.0	1.5	5.9	16.3	3.4	10.4	16.5	0.8	0.7	11.8	12.8	13.6	418.9	2.1	1.0	3.4	1.7	0.0	2.0	0.6	1.5	7.0	11.0	7.4	23.1	1.0	0.7	8.7	40.2	4.5	2.2	8.2	9.0	2.8	0.6	73.1	14.9	9.9	90.9	13.4	2.3	0.0	0.0	0.3	2.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	0.4	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.4	0.0	0.0	0.0	7.5	0.0	0.6	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.9	0.0	1.6	0.4	0.0	0.0	0.3	0.0	0.4	0.0	0.7	0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.1	0.3	0.4	0.0	0.0	0.0	0.9	0.0	0.0	0.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	1.2	1.1	0.8	1.3	0.8	0.7	2.1	1.0	1.5	0.6
CCL2	"GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF"	ENSG00000108691	"C-C motif chemokine ligand 2"	P13500	17	34255218-34257203	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"BJ hTERT+: 159.2;HMC-1: 207.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"classical monocyte: 10.3;eosinophil: 3.9"	"Group enriched"	"Detected in many"	6	"granulocytes: 3.9;monocytes: 10.3"					"Low region specificity"	"Detected in many"			"CAB013676, HPA019163"	Approved		Approved	"Golgi apparatus,Vesicles"	"Secreted to blood"			"Golgi apparatus"	Vesicles	"CAB013676: , HPA019163: AB_1846179"	"unprognostic (6.43e-2)"	"unprognostic (4.14e-2)"	"unprognostic (4.78e-2)"	"unprognostic (5.57e-2)"	"unprognostic (2.37e-3)"	"unprognostic (8.64e-2)"	"unprognostic (2.78e-2)"	"unprognostic (7.53e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.19e-1)"	"unprognostic (9.33e-2)"	"unprognostic (2.65e-1)"	"prognostic unfavourable (4.51e-4)"	"unprognostic (1.33e-1)"	"unprognostic (2.50e-2)"	"unprognostic (1.81e-1)"	"unprognostic (4.92e-2)"	78.1	31.2	10.3	52.3	50.6	19.1	19.0	1.5	23.3	9.7	41.9	28.6	3.0	9.4	7.2	7.6	14.4	25.8	62.0	76.9	45.1	6.7	32.5	38.4	105.2	16.9	16.0	2.0	28.6	32.8	15.2	17.3	22.8	63.6	42.0	25.3	22.3	13.5	13.4	17.8	10.5	16.7	34.6	85.4	16.1	30.2	4.6	8.6	4.8	20.8	21.6	19.1	27.2	9.0	0.0	1.1	3.9	10.3	0.0	0.1	2.3	0.0	1.2	3.4	0.0	9.6	8.2	0.0	9.7	159.2	20.7	44.4	0.5	0.0	0.0	7.7	2.2	5.3	0.3	0.0	10.5	0.0	0.0	0.0	1.1	0.0	0.3	0.0	207.5	9.1	0.0	4.3	0.2	9.4	0.5	1.7	0.0	0.0	0.0	1.5	0.4	0.0	0.0	0.2	1.7	29.6	0.0	0.0	0.6	0.0	0.5	0.2	0.3	0.2	0.5	11.1	0.4	0.3	0.0	0.1	0.0	0.0	6.5	3.0	7.0	0.0	10.3	3.9	0.0	0.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.1	0.7	0.0	0.0	0.3	0.0	2.3	10.3	50.6	1.5	23.3	45.1	6.7	16.0	2.0	63.6	8.6
CCL21	"6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4"	ENSG00000137077	"C-C motif chemokine ligand 21"	O00585	9	34709005-34710124	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 430.9"	"Cell line enhanced"	"Detected in some"		"Daudi: 3.6;HL-60: 2.3;K-562: 3.8;RH-30: 2.4;U-937: 1.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in all"			"CAB005067, HPA051210"	Enhanced				"Secreted to blood"	770000	770000			"CAB005067: AB_2071925, HPA051210: "	"unprognostic (3.06e-3)"	"unprognostic (7.19e-3)"	"unprognostic (9.89e-2)"	"unprognostic (5.50e-2)"		"unprognostic (4.51e-3)"	"unprognostic (1.21e-2)"	"unprognostic (1.04e-2)"	"unprognostic (8.07e-2)"	"unprognostic (4.15e-2)"	"unprognostic (2.49e-2)"	"unprognostic (3.70e-1)"	"unprognostic (8.99e-3)"	"unprognostic (3.50e-3)"	"unprognostic (1.58e-1)"	"unprognostic (2.66e-2)"	"unprognostic (8.91e-2)"	24.4	6.5	0.3	83.5	0.4	0.0	18.0	0.3	0.4	13.6	25.5	0.4	5.9	3.7	26.8	23.7	80.1	23.0	23.2	18.8	0.3	0.0	19.6	11.0	30.5	430.9	0.3	0.3	13.8	3.3	0.0	0.4	7.4	0.5	9.4	11.9	0.7	96.9	4.1	4.7	7.6	71.2	10.6	0.3	35.9	10.7	5.5	0.3	2.3	91.0	44.8	181.2	15.7	9.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.3	0.0	0.4	0.0	0.0	0.0	0.3	0.0	1.3	0.0	0.0	0.7	2.3	0.3	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	1.2	0.8	0.0	0.9	2.4	0.6	0.0	0.0	0.3	0.5	1.0	0.0	0.0	0.0	0.0	1.5	0.0	0.2	0.5	0.0	0.8	0.0	0.8	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.3	0.4	0.3	0.0	0.3	0.3	0.5	0.3
CCL23	"Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23"	ENSG00000274736	"C-C motif chemokine ligand 23"	P55773	17	36013056-36017968	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	"Cytokine, Heparin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 50.3"	"Group enriched"	"Detected in some"	4	"HEL: 12.6;THP-1: 26.9"	"Low cancer specificity"	"Detected in some"							"Cell type enriched"	"Detected in single"	173	"eosinophil: 50.3"	"Lineage enriched"	"Detected in single"	173	"granulocytes: 50.3"									HPA042015	Uncertain				"Secreted to blood"	57000	57000			"HPA042015: AB_10794039"	"unprognostic (1.65e-3)"	"unprognostic (1.43e-2)"	"unprognostic (1.04e-1)"	"unprognostic (9.50e-2)"	"unprognostic (3.59e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.20e-4)"	"unprognostic (2.17e-1)"	"unprognostic (6.49e-2)"	"unprognostic (1.08e-2)"	"unprognostic (7.05e-2)"	"unprognostic (6.93e-2)"	"unprognostic (1.35e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.76e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.95e-1)"	5.8	0.5	0.0	13.1	0.0	2.1	3.7	0.0	0.5	2.1	2.0	0.0	1.0	0.0	1.8	3.0	1.3	1.5	2.2	4.6	0.0		3.0	5.9	7.9	8.0	0.3	0.0	1.2	0.0	0.0	0.5	1.5	0.2	1.7	7.2	0.7	0.0	1.1	0.5	0.4	1.0	8.4	0.0	2.0	0.0	0.1	0.0	0.4	1.1	0.6	0.5	3.0	0.0	0.2	0.1	50.3	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.0	1.6	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.2	0.2	50.3	0.0	0.2	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.2	0.0	0.0	0.0										
CCL3	"G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3"	ENSG00000277632	"C-C motif chemokine ligand 3"	P10147	17	36088256-36090169	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 35.7;lymphoid tissue: 18.0"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 26.7;U-266/70: 45.9;U-266/84: 116.1"	"Low cancer specificity"	"Detected in all"							"Cell type enhanced"	"Detected in many"		"gdT-cell: 10.2"	"Group enriched"	"Detected in many"	5	"B-cells: 4.5;granulocytes: 4.0;T-cells: 10.2"														"Secreted to blood"						"unprognostic (2.41e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.45e-1)"	"unprognostic (7.44e-3)"	"unprognostic (1.44e-1)"	"unprognostic (1.66e-1)"	"unprognostic (3.54e-1)"	"unprognostic (8.90e-2)"	"unprognostic (7.92e-3)"	"unprognostic (2.00e-1)"	"unprognostic (7.20e-2)"	"unprognostic (2.05e-1)"	"unprognostic (8.92e-3)"	"unprognostic (1.08e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.23e-2)"	5.3	4.3	0.0	5.7	1.6	35.7	2.4	0.5	6.0	0.9	0.9	11.6	0.0	0.8	0.7	1.4	0.4	0.4	3.5	3.4	0.0		0.5	7.9	15.1	5.8	0.0	0.0	2.0	0.4	1.8	0.0	5.7	3.7	0.5	0.9	1.7	1.0	0.2	1.2	0.0	0.8	1.1	0.0	18.0	0.2	3.7	0.0	1.8	0.8	0.5	1.8	2.3	0.0	4.5	0.2	4.0	0.8	1.1	10.2	4.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	26.7	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.4	0.0	0.0	0.1	45.9	116.1	0.0	0.2	0.0	0.0	0.1	0.8	4.0	10.2	0.5	0.3	1.4	0.3	2.8	0.2	4.5	0.0	3.0	4.0	1.1	0.5	0.0	0.0	4.6										
CCL4	"Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4"	ENSG00000275302	"C-C motif chemokine ligand 4"	P13236	17	36103590-36105621	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	4	"blood: 69.3;lung: 23.1;lymphoid tissue: 20.8"	"Group enriched"	"Detected in some"	23	"Karpas-707: 5.1;U-266/70: 11.2;U-266/84: 5.4"	"Low cancer specificity"	"Detected in all"							"Group enriched"	"Detected in many"	5	"gdT-cell: 69.3;MAIT T-cell: 21.8;memory CD8 T-cell: 40.6;naive CD8 T-cell: 30.5"	"Lineage enriched"	"Detected in many"	17	"T-cells: 69.3"									CAB007805	Approved				"Secreted to blood"					"CAB007805: AB_598177"	"unprognostic (6.03e-2)"	"unprognostic (2.48e-2)"	"prognostic favourable (3.54e-4)"	"prognostic favourable (1.97e-5)"	"unprognostic (2.06e-1)"	"unprognostic (7.02e-2)"	"unprognostic (9.08e-2)"	"unprognostic (2.69e-1)"	"prognostic favourable (3.97e-4)"	"unprognostic (3.45e-1)"	"unprognostic (8.57e-2)"	"unprognostic (1.61e-1)"	"prognostic unfavourable (1.68e-4)"	"unprognostic (3.71e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.18e-2)"	2.3	2.6	0.0	3.7	0.4	9.3	5.7	0.1	3.6	0.9	2.9	1.4	0.5	0.2	1.6	0.8	1.7	1.6	4.4	3.8	0.0		1.3	5.7	23.1	20.8	1.1	0.0	3.4	0.9	0.0	0.2	4.3	0.9	1.1	1.0	3.9	1.6	1.6	0.5	0.0	0.9	1.4	1.5	10.4	2.3	0.3	0.0	1.0	1.6	2.0	4.3	1.9	0.8	1.8	0.4	4.0	0.6	3.0	69.3	11.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.2	5.4	0.3	0.0	0.0	0.0	1.7	0.2	4.0	69.3	0.0	21.8	0.9	7.7	40.6	0.1	1.8	2.3	30.5	1.6	3.0	0.6	0.4	0.0	11.6										
CCL5	"D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228"	ENSG00000271503	"C-C motif chemokine ligand 5"	P13501	17	35871491-35880793	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 169.0"	"Cell line enriched"	"Detected in some"	4	"NB-4: 71.3"	"Low cancer specificity"	"Detected in all"							"Cell type enhanced"	"Detected in many"		"gdT-cell: 157.7;memory CD8 T-cell: 169.0"	"Lineage enriched"	"Detected in many"	4	"T-cells: 169.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"								"Secreted to blood"	8200000	8200000				"unprognostic (3.91e-3)"	"unprognostic (1.50e-3)"	"unprognostic (8.63e-2)"	"prognostic favourable (1.34e-5)"	"unprognostic (1.36e-3)"	"unprognostic (6.37e-3)"	"unprognostic (8.70e-2)"	"unprognostic (2.64e-2)"	"prognostic favourable (2.42e-4)"	"unprognostic (3.26e-3)"	"unprognostic (1.64e-2)"	"unprognostic (2.88e-1)"	"prognostic unfavourable (3.61e-7)"	"unprognostic (1.70e-2)"	"unprognostic (7.55e-2)"	"unprognostic (8.56e-3)"	"unprognostic (3.73e-2)"	3.6	2.4	0.0	28.8	0.1	17.1	2.6	0.0	0.2	6.0	14.7	1.0	0.6	7.1	5.0	7.2	5.2	1.7	20.5	7.5	0.0		2.7	4.7	29.8	33.5	2.8	0.0	5.9	2.3	0.0	0.1	4.8	1.7	7.8	4.0	8.0	5.5	6.4	2.8	0.0	38.7	2.3	2.2	38.8	6.9	1.9	0.0	12.2	1.6	5.5	27.9	11.5	0.0	1.2	1.1	9.9	0.6	40.8	169.0	106.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	2.4	2.8	0.0	0.2	0.0	0.2	0.1	0.1	0.0	0.0	0.2	0.7	0.0	0.0	0.2	0.0	0.1	11.3	0.1	0.0	0.0	0.7	0.0	0.0	0.0	1.6	0.0	0.0	0.0	71.3	0.0	0.0	0.0	0.0	1.5	0.0	0.1	0.0	0.0	0.0	0.1	1.7	0.0	16.7	0.0	0.0	0.0	0.1	0.0	2.1	0.7	0.1	0.0	15.3	0.1	9.9	0.6	0.7	157.7	0.4	103.8	1.2	36.7	169.0	1.1	0.7	8.8	99.3	4.6	40.8	0.5	0.9	0.5	106.5										
CCL7	"FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7"	ENSG00000108688	"C-C motif chemokine ligand 7"	P80098	17	34270221-34272242	"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	"Cytokine, Heparin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"adipose tissue: 11.5;bone marrow: 22.3"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 15.1;BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.9;HSkMC: 4.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"classical monocyte: 1.1"	"Lineage enriched"	"Detected in single"	12	"monocytes: 1.1"	"Low region specificity"	"Detected in many"												"Secreted to blood"						"unprognostic (7.66e-2)"	"unprognostic (1.05e-2)"	"unprognostic (8.53e-2)"	"unprognostic (4.65e-2)"	"unprognostic (2.54e-2)"	"unprognostic (9.54e-2)"		"unprognostic (4.18e-2)"	"unprognostic (2.13e-1)"	"unprognostic (2.63e-2)"	"unprognostic (2.27e-3)"	"unprognostic (7.04e-2)"	"unprognostic (1.99e-8)"	"unprognostic (2.83e-1)"	"unprognostic (8.74e-2)"	"unprognostic (3.74e-1)"	"unprognostic (1.79e-2)"	11.5	0.6	0.0	2.6	0.0	22.3	0.3	0.0	0.0	0.3	0.6	0.0	0.0	0.0	0.3	0.0	0.1	0.5	0.7	0.9	0.1	0.1	0.5	0.2	1.2	0.0	0.1	0.0	1.3	0.4	0.0	0.1	1.7	0.3	0.5	1.0	0.0	0.2	0.0	0.1	0.2	0.2	2.2	0.1	0.1	1.2	0.5	0.0	1.4	0.3	0.0	0.0	0.5	0.4	0.0	0.0	0.0	1.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	2.3	0.0	1.7	15.1	3.2	3.9	0.0	0.0	0.0	0.5	1.0	1.4	0.0	0.0	1.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	4.6	0.0	1.3	0.0	1.4	0.0	1.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.0
CCL8	"HC14, MCP-2, SCYA8"	ENSG00000108700	"C-C motif chemokine ligand 8"	P80075	17	34319036-34321402	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	"Cytokine, Heparin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 19.7"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 1.9;BJ hTERT+ SV40 Large T+ RasG12V: 1.8;EFO-21: 4.0;HSkMC: 6.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	8	"classical monocyte: 5.8"	"Lineage enriched"	"Detected in single"	8	"monocytes: 5.8"					"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (7.51e-2)"	"unprognostic (3.20e-1)"	"unprognostic (1.90e-2)"	"unprognostic (4.03e-2)"	"unprognostic (8.00e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.65e-1)"	"unprognostic (9.97e-2)"	"unprognostic (1.67e-3)"	"unprognostic (1.46e-1)"	"unprognostic (2.13e-1)"	"prognostic unfavourable (1.05e-7)"	"unprognostic (1.39e-1)"	"unprognostic (1.88e-2)"	"unprognostic (5.65e-2)"	"unprognostic (3.41e-2)"	10.6	2.8	1.0	7.2	1.2	0.2	4.4	0.6	1.6	0.8	12.0	1.4	1.1	6.9	3.4	3.8	1.2	2.9	3.7	2.4	0.8	0.7	2.8	2.1	8.4	1.3	0.8	0.9	5.3	0.8	6.0	1.6	19.7	1.1	1.5	8.0	5.0	1.1	2.9	1.5	1.3	13.1	4.1	2.4	3.1	1.9	1.6	0.2	2.1	3.0	4.0	2.7	4.4	0.8	0.7	0.2	0.0	5.8	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.9	0.5	0.1	0.0	1.9	0.0	1.8	0.0	0.0	0.0	4.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.0	1.2	0.6	1.6	0.8	0.7	0.8	0.9	1.1	0.2
CCNA1	CT146	ENSG00000133101	"Cyclin A1"	P78396	13	36431520-36442882	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.5;parathyroid gland: 24.2;testis: 50.4"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 85.1"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 20.7;ovarian cancer: 18.6"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	108	"basophil: 24.5"	"Lineage enriched"	"Detected in single"	233	"granulocytes: 24.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA060646, HPA077614"	Enhanced		Approved	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA060646: , HPA077614: "	"unprognostic (1.92e-3)"	"unprognostic (1.21e-1)"	"unprognostic (4.69e-3)"	"unprognostic (1.89e-3)"	"unprognostic (5.46e-2)"	"prognostic unfavourable (1.70e-4)"		"unprognostic (1.51e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.24e-1)"	"unprognostic (4.01e-3)"	"unprognostic (1.64e-1)"	"unprognostic (4.04e-6)"	"unprognostic (7.04e-3)"	"unprognostic (2.45e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.63e-2)"	0.4	0.8	7.3	0.4	6.2	1.3	0.6	0.2	4.7	4.0	0.3	1.6	0.0	0.4	2.6	4.7	0.3	11.1	0.6	0.3	4.5	5.9	0.3	0.2	1.0	1.0	1.9	5.5	1.2	0.5	24.2	4.8	0.2	3.1	0.3	0.3	0.1	0.4	0.2	1.3	0.2	0.3	5.1	1.0	0.3	0.4	50.4	0.4	0.2	0.4	0.0	0.5	0.4	0.6	0.1	0.0	24.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.2	3.0	0.3	0.0	0.0	0.1	0.0	0.1	0.0	0.1	1.7	85.1	0.0	8.3	0.1	0.7	0.2	0.0	0.1	0.0	1.0	0.1	16.6	0.5	2.1	0.0	2.0	0.0	0.5	0.0	0.6	1.4	0.0	2.0	0.0	0.0	16.6	1.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.0	21.0	0.1	24.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	6.2	0.2	4.7	4.5	5.9	1.9	5.5	3.1	0.4
CCNA2	"CCN1, CCNA"	ENSG00000145386	"Cyclin A2"	P20248	4	121816444-121823933	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Host-virus interaction, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lymphoid tissue: 122.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"T-reg: 6.8"	"Group enriched"	"Detected in many"	5	"NK-cells: 1.7;T-cells: 6.8"	"Low region specificity"	"Detected in single"							"CAB000114, HPA020626"	Enhanced		Enhanced	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB000114: AB_563675, HPA020626: AB_1847376"	"unprognostic (4.02e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.66e-3)"	"prognostic unfavourable (8.78e-4)"	"unprognostic (1.25e-1)"	"unprognostic (1.67e-2)"	"prognostic unfavourable (9.17e-5)"	"prognostic unfavourable (4.27e-4)"	"unprognostic (3.92e-3)"	"unprognostic (2.65e-2)"	"prognostic unfavourable (4.43e-6)"	"unprognostic (8.38e-3)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (1.65e-1)"	"unprognostic (1.82e-1)"	"unprognostic (6.07e-2)"	"unprognostic (1.59e-1)"	3.2	1.5	1.3	18.6	1.7	21.6	1.8	5.1	1.2	2.5	6.3	1.0	0.8	6.6	2.2	2.1	11.7	1.7	2.4	3.2	1.8	1.8	1.7	1.6	3.4	15.6	1.6	0.8	4.5	0.9	0.5	3.2	12.0	1.3	2.2	7.8	1.0	2.1	0.8	1.1	4.2	7.4	2.4	1.8	8.9	2.9	8.4	0.8	122.3	1.4	18.8	18.4	2.5	5.1	0.3	0.9	0.6	0.3	1.7	6.8	1.9	38.1	9.9	27.3	11.6	1.4	3.8	22.3	26.6	11.7	35.5	26.4	21.6	23.7	35.1	7.2	14.0	12.9	34.3	15.7	29.2	16.8	15.8	28.2	13.2	21.0	0.3	42.4	20.0	0.9	1.2	14.6	8.8	21.2	40.0	35.3	28.1	13.7	54.0	24.6	21.5	11.1	24.8	52.8	17.1	10.0	7.6	11.6	12.3	14.0	17.1	7.4	14.3	18.0	12.4	16.6	25.2	17.5	25.4	22.4	23.7	40.2	9.5	43.2	18.4	0.0	0.3	0.6	0.2	0.1	0.1	0.3	2.0	1.4	0.9	0.1	0.0	0.5	0.3	1.7	0.3	0.1	6.8	1.9	1.3	1.7	5.1	1.2	1.8	1.8	1.6	0.8	1.3	0.8
CCNB1	CCNB	ENSG00000134057	"Cyclin B1"	P14635	5	69167010-69178245	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 71.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB000115, CAB003804, HPA030741, HPA061448"	Enhanced		Enhanced	Cytosol				Cytosol		"CAB000115: , CAB003804: AB_562272, HPA030741: , HPA061448: "	"unprognostic (4.12e-2)"	"unprognostic (2.75e-2)"	"unprognostic (1.91e-3)"	"unprognostic (4.08e-3)"	"unprognostic (2.78e-1)"	"unprognostic (1.39e-1)"	"prognostic unfavourable (1.54e-7)"	"prognostic unfavourable (3.38e-4)"	"unprognostic (1.43e-2)"	"unprognostic (1.63e-2)"	"unprognostic (2.49e-3)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (1.11e-16)"	"unprognostic (2.44e-1)"	"unprognostic (3.73e-1)"	"unprognostic (1.44e-1)"	"unprognostic (5.15e-3)"	3.2	4.6	2.7	23.9	4.8	20.5	4.6	6.5	5.6	4.4	9.9	1.6	1.6	9.3	3.5	2.8	28.8	3.3	3.5	1.9	3.5	4.2	4.6	2.9	3.4	23.6	4.0	4.2	3.7	4.0	1.6	2.6	12.1	11.5	2.6	14.2	1.7	5.3	1.7	2.0	6.4	8.7	6.4	2.5	9.1	7.1	21.7	1.3	71.4	6.3	23.3	30.1	5.3	7.5	13.2	5.1	2.4	4.1	6.5	14.7	5.5	58.7	40.7	55.8	49.6	2.9	5.0	131.9	26.0	19.5	68.7	58.1	60.1	55.4	36.1	31.7	24.0	37.1	56.1	56.9	77.1	35.4	27.8	22.9	33.9	41.4	0.9	19.9	26.2	2.2	3.6	39.4	27.5	36.6	27.7	28.7	55.9	55.9	27.3	23.8	31.1	25.8	28.7	40.3	37.0	25.1	21.7	28.4	17.9	44.8	21.1	19.3	40.3	20.9	15.4	15.3	49.8	27.6	65.0	14.4	26.6	50.4	21.2	35.0	47.0	2.4	1.8	1.2	2.8	4.1	4.0	13.2	7.6	6.7	5.1	8.6	2.5	2.4	1.0	6.5	1.9	4.2	14.7	5.5	2.7	4.8	6.5	5.6	3.5	4.2	4.0	4.2	11.5	1.3
CCNB1IP1	"C14orf18, HEI10"	ENSG00000100814	"Cyclin B1 interacting protein 1"	Q9NPC3	14	20311368-20333312	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Meiosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-HME1: 86.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"														"unprognostic (4.79e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.37e-2)"	"unprognostic (5.46e-3)"	"unprognostic (2.79e-2)"	"unprognostic (8.43e-2)"	"unprognostic (5.88e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.88e-2)"	"unprognostic (4.87e-2)"	"unprognostic (4.77e-2)"	"prognostic favourable (5.18e-6)"	"unprognostic (2.12e-1)"	"unprognostic (1.54e-2)"	"unprognostic (4.43e-1)"	"unprognostic (1.52e-1)"	12.6	9.7	10.9	9.8	13.7	14.2	27.2	14.5	16.4	20.3	13.4	13.2	17.2	9.9	20.4	24.2	17.4	18.8	12.4	33.8	11.1	11.2	31.2	34.4	15.4	11.2	13.4	11.1	49.1	20.6	14.5	12.1	14.4	15.9	18.0	14.5	15.8	14.0	12.3	20.6	14.6	10.0	27.6	15.8	11.3	13.0	9.7	13.9	11.2	35.8	15.3	16.1	33.6	17.7	9.3	13.7	3.5	3.1	4.4	10.7	3.0	6.5	5.4	30.8	29.6	15.8	21.8	24.9	8.1	16.3	12.5	16.5	18.3	7.3	23.0	5.4	5.9	11.9	21.4	15.3	16.9	6.6	18.1	13.5	5.1	17.2	46.5	24.9	12.7	29.6	25.8	8.9	86.7	9.4	16.5	18.2	8.2	10.5	14.4	17.0	18.5	10.3	17.8	15.2	9.6	13.0	9.7	24.6	25.6	5.6	13.0	36.3	4.1	18.3	4.0	7.1	9.1	8.6	10.5	8.6	10.7	15.7	2.4	21.1	8.2	3.5	3.1	0.0	6.7	1.1	9.1	9.3	7.4	8.3	13.7	8.4	7.7	10.7	0.5	4.4	1.1	13.7	9.9	3.0	10.9	13.7	14.5	16.4	11.1	11.2	13.4	11.1	15.9	13.9
CCNB2	HsT17299	ENSG00000157456	"Cyclin B2"	O95067	15	59105078-59125045	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 70.2;testis: 73.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in many"	4	"T-reg: 17.8"	"Lineage enriched"	"Detected in many"	6	"T-cells: 17.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA008873, CAB009575"	Enhanced		Enhanced	"Golgi apparatus,Cytosol"				Cytosol	"Golgi apparatus"	"CAB009575: AB_2072392, HPA008873: AB_1078604"	"unprognostic (2.69e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.65e-2)"	"prognostic unfavourable (2.83e-4)"	"prognostic unfavourable (4.63e-4)"	"prognostic unfavourable (3.21e-5)"	"unprognostic (1.09e-1)"	"prognostic unfavourable (1.74e-5)"	"unprognostic (4.48e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (1.96e-1)"	"unprognostic (1.41e-1)"	"unprognostic (3.98e-2)"	"unprognostic (4.44e-1)"	2.0	1.1	0.4	21.0	0.4	24.7	2.5	0.3	0.6	1.8	5.5	0.5	0.2	5.2	1.0	1.5	11.3	0.5	1.6	1.2	0.4	0.4	1.0	1.0	1.9	12.0	0.4	0.3	0.8	0.7	0.0	0.4	6.7	0.4	1.1	6.3	0.4	2.1	0.6	0.4	3.6	5.1	2.0	1.3	5.2	3.0	73.9	0.2	70.2	0.8	10.3	16.0	1.8	3.4	1.8	2.3	0.7	0.1	3.0	17.8	1.8	28.4	25.1	41.3	10.2	1.8	3.8	21.9	23.6	15.2	36.6	30.1	40.6	17.6	26.5	17.1	15.2	35.2	39.0	20.1	34.6	27.5	20.9	34.3	29.4	23.0	0.5	25.5	22.1	1.4	2.7	15.7	20.1	24.8	34.6	42.6	27.6	20.7	29.1	37.2	30.5	14.9	34.0	58.4	26.9	11.5	20.2	25.7	17.4	32.4	17.6	21.3	30.5	25.5	12.9	18.2	31.0	20.1	44.9	19.0	28.4	47.1	11.9	58.4	25.7	0.0	0.1	0.6	0.1	0.0	0.2	1.8	3.9	4.1	2.3	0.9	0.0	0.1	0.7	3.0	0.0	0.1	17.8	1.8	0.4	0.4	0.3	0.6	0.4	0.4	0.4	0.3	0.4	0.2
CCND1	"BCL1, D11S287E, PRAD1, U21B31"	ENSG00000110092	"Cyclin D1"	P24385	11	69641087-69654474	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation"	"Cyclin, Repressor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-266/70: 94.3;WM-115: 131.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.0;myeloid DC: 3.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000024, HPA027802"	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"CAB000024: AB_563678, HPA027802: "	"unprognostic (4.90e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.62e-2)"	"unprognostic (1.39e-2)"	"unprognostic (2.18e-1)"	"prognostic unfavourable (5.51e-4)"	"unprognostic (1.38e-1)"	"unprognostic (2.53e-2)"	"unprognostic (9.46e-2)"	"unprognostic (4.84e-3)"	"prognostic unfavourable (1.96e-4)"	"unprognostic (4.39e-2)"	"unprognostic (2.61e-3)"	"unprognostic (4.38e-3)"	"unprognostic (1.16e-1)"	"unprognostic (6.40e-3)"	"unprognostic (2.57e-1)"	52.0	11.6	9.7	6.0	9.7	0.7	22.8	3.4	7.7	15.4	8.9	15.4	19.9	8.4	18.8	23.1	37.7	11.8	31.0	23.9	10.8	8.8	14.5	68.1	22.2	3.7	12.4	5.6	6.5	31.5	83.2	16.6	38.1	10.0	30.7	6.8	24.8	25.6	21.7	2.0	43.6	10.4	16.5	12.6	12.9	19.2	4.0	7.5	9.0	17.1	23.1	23.6	21.4	22.1	3.0	3.4	0.8	0.0	0.0	0.9	0.3	47.6	19.1	6.3	0.1	19.6	20.7	13.7	75.6	28.1	8.8	5.2	21.4	37.0	0.0	34.3	39.3	34.9	0.6	20.5	15.9	0.1	3.8	0.0	4.7	21.7	4.7	0.3	0.7	11.7	4.0	12.4	4.8	15.1	0.0	0.1	69.5	20.2	0.0	2.7	11.6	21.1	0.1	20.2	1.1	41.0	29.5	1.0	25.0	0.9	17.9	47.0	10.9	0.9	63.0	43.4	12.1	18.8	51.3	94.3	56.3	0.1	37.1	0.6	131.3	0.8	0.0	0.0	0.9	0.0	0.1	3.0	0.4	0.2	3.4	2.5	0.8	0.2	0.2	0.0	0.0	0.0	0.0	0.3	9.7	9.7	3.4	7.7	10.8	8.8	12.4	5.6	10.0	7.5
CCND2		ENSG00000118971	"Cyclin D2"	P30279	12	4273772-4305350	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 32.3;HBEC3-KT: 29.5;HDLM-2: 49.7;Karpas-707: 71.7;RH-30: 46.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA049138, HPA054196"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"HPA049138: , HPA054196: "	"unprognostic (2.98e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.21e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.70e-2)"	"unprognostic (4.82e-2)"	"unprognostic (4.94e-2)"	"unprognostic (2.01e-3)"	"unprognostic (3.16e-2)"	"unprognostic (1.66e-2)"	"prognostic favourable (2.52e-4)"	"unprognostic (1.75e-1)"	"unprognostic (1.25e-1)"	"unprognostic (8.23e-2)"	"unprognostic (4.52e-1)"	"prognostic favourable (9.76e-5)"	"unprognostic (7.06e-2)"	13.7	39.3	20.8	12.0	15.9	23.6	10.4	6.1	22.3	14.4	28.3	8.1	24.3	18.5	21.9	41.9	12.2	16.5	9.1	36.9	17.5	7.3	6.0	5.7	12.8	24.5	7.9	17.0	11.6	18.4	8.3	19.2	23.5	9.3	16.4	24.2	14.1	8.3	22.4	2.0	9.2	19.6	45.5	14.0	16.5	11.1	5.2	8.6	6.2	18.5	6.9	13.6	22.3	16.3	3.9	2.1	4.6	1.0	9.1	14.8	5.4	0.0	0.0	32.3	0.0	5.6	0.8	0.0	0.0	0.0	0.0	0.0	13.8	0.0	0.0	0.2	0.0	4.1	0.9	29.5	0.0	49.7	0.8	0.3	0.0	0.2	0.1	12.6	2.7	10.8	4.9	0.0	22.3	0.0	3.4	71.7	6.2	0.0	0.0	16.6	13.3	0.0	0.0	46.9	23.4	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.3	0.0	9.4	0.0	0.0	1.2	12.1	0.0	0.1	9.1	0.0	4.1	1.0	4.6	9.1	0.2	13.7	3.9	13.0	11.0	2.1	1.5	8.2	9.8	1.5	9.1	0.1	1.0	14.8	5.4	20.8	15.9	6.1	22.3	17.5	7.3	7.9	17.0	9.3	8.6
CCND3		ENSG00000112576	"Cyclin D3"	P30281	6	41934933-42050357	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 129.2;lymphoid tissue: 142.5"	"Cell line enhanced"	"Detected in all"		"MOLT-4: 92.5;REH: 87.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000116, HPA071369"	Approved		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"				"Nucleoplasm, Nuclear bodies"	Cytosol	"CAB000116: , HPA071369: "	"unprognostic (4.53e-2)"	"unprognostic (4.45e-2)"	"unprognostic (2.45e-1)"	"unprognostic (4.40e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.40e-2)"	"unprognostic (5.25e-2)"	"unprognostic (7.76e-2)"	"unprognostic (3.45e-1)"	"unprognostic (9.17e-2)"	"unprognostic (6.39e-2)"	"unprognostic (2.45e-3)"	"unprognostic (9.12e-2)"	"unprognostic (1.71e-1)"	"prognostic favourable (8.08e-6)"	"unprognostic (2.11e-1)"	20.2	39.8	16.1	28.9	17.5	74.7	36.0	13.3	19.8	13.3	17.3	11.3	14.1	16.0	10.8	10.4	13.5	13.4	19.0	16.3	15.4	14.5	13.7	8.0	32.1	83.8	14.1	15.5	11.1	10.9	5.0	10.1	21.9	9.3	14.2	11.4	10.2	18.1	14.4	6.5	14.6	22.0	11.7	11.5	51.2	18.0	7.4	10.0	142.5	26.8	9.3	32.8	13.0	16.6	24.1	42.4	129.2	45.8	39.0	52.8	66.2	9.0	33.1	3.5	7.7	6.3	12.9	40.2	10.6	6.1	11.0	8.1	6.2	4.1	39.0	18.0	7.1	5.6	9.2	13.0	5.7	6.6	6.0	61.8	14.8	5.0	13.9	10.1	54.6	12.3	8.5	10.6	4.0	13.5	31.1	3.8	15.7	12.2	92.5	48.5	1.5	7.1	87.9	13.5	4.3	25.4	6.1	11.8	3.1	9.0	11.6	5.2	7.1	39.5	22.5	12.2	6.7	10.6	11.9	2.5	1.9	60.9	7.1	21.3	7.4	129.2	30.5	87.7	52.8	35.1	37.0	16.4	36.4	42.5	42.4	24.1	42.8	45.0	42.8	39.0	45.8	27.8	23.2	66.2	16.1	17.5	13.3	19.8	15.4	14.5	14.1	15.5	9.3	10.0
CCNE1	CCNE	ENSG00000105173	"Cyclin E1"	P24864	19	29811898-29824308	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 23.3;placenta: 46.7"	"Cell line enhanced"	"Detected in many"		"BEWO: 79.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB000308, CAB016682, HPA018169"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000308: , CAB016682: AB_1614564, HPA018169: AB_1847384"	"unprognostic (2.90e-3)"	"unprognostic (1.33e-2)"	"unprognostic (1.47e-3)"	"prognostic unfavourable (6.35e-6)"	"unprognostic (5.78e-2)"	"unprognostic (4.77e-2)"	"prognostic unfavourable (3.89e-5)"	"unprognostic (1.26e-3)"	"unprognostic (3.14e-3)"	"prognostic unfavourable (2.97e-4)"	"unprognostic (3.29e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.11e-16)"	"unprognostic (5.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (6.63e-2)"	"unprognostic (1.46e-1)"	1.6	6.8	2.4	4.5	2.9	23.3	0.6	6.3	3.3	0.8	3.0	1.7	1.1	2.3	1.2	0.6	4.7	0.7	2.2	4.4	2.3	2.8	1.2	0.7	1.1	4.6	1.9	1.9	0.9	1.4	1.7	1.0	46.7	2.8	1.1	3.8	1.5	3.2	1.2	2.2	4.4	2.5	3.0	1.7	4.6	2.0	12.3	1.6	4.1	1.6	2.1	5.9	2.7	2.5	2.7	1.6	1.6	1.9	0.0	1.4	0.5	4.0	8.4	6.5	9.2	1.4	1.6	79.9	6.5	1.4	2.9	3.5	8.5	8.2	3.4	15.3	2.8	1.2	7.6	3.3	4.1	10.8	4.7	2.9	8.2	8.9	1.1	11.3	7.7	1.6	1.8	3.9	0.5	3.5	11.6	1.5	4.3	6.0	6.2	3.2	10.8	2.0	9.3	7.6	2.6	2.2	6.5	5.5	4.6	9.3	11.5	1.0	2.5	8.4	2.0	6.7	25.4	4.0	4.3	6.5	4.5	23.4	3.8	1.4	3.6	0.0	0.1	0.0	0.6	1.9	1.1	2.7	0.5	0.4	1.6	0.2	0.1	0.9	1.6	0.0	1.9	0.0	1.4	0.5	2.4	2.9	6.3	3.3	2.3	2.8	1.9	1.9	2.8	1.6
CCNE2	CYCE2	ENSG00000175305	"Cyclin E2"	O96020	8	94879770-94896678	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 24.2;brain: 22.2;testis: 18.9"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 39.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 8.8"	"Group enriched"	"Detected in many"	4	"NK-cells: 2.2;T-cells: 8.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007825, CAB019374"	Enhanced									"CAB007825: AB_598148, CAB019374: "	"unprognostic (1.80e-2)"	"unprognostic (4.81e-2)"	"unprognostic (7.49e-2)"	"unprognostic (2.08e-2)"	"unprognostic (2.36e-1)"	"prognostic favourable (5.87e-4)"	"unprognostic (8.37e-4)"	"prognostic unfavourable (8.77e-4)"	"unprognostic (3.18e-2)"	"unprognostic (2.19e-2)"	"unprognostic (3.64e-2)"	"unprognostic (1.04e-2)"	"unprognostic (7.01e-12)"	"unprognostic (1.81e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.06e-2)"	"unprognostic (3.03e-1)"	1.3	0.9	3.1	4.9	11.3	24.2	1.5	3.3	6.3	1.7	4.0	10.4	0.0	2.6	1.3	0.1	3.6	1.0	1.7	0.9	5.7	3.5	0.9	1.6	1.7	7.9	8.0	6.5	1.4	2.3	0.5	1.1	3.1	11.8	1.3	4.3	0.6	1.5	0.0	0.8	4.4	3.1	1.4	22.2	1.9	2.9	18.9	4.9	12.7	1.1	2.4	7.0	1.9	1.9	1.1	1.3	1.1	0.3	2.2	8.8	1.1	17.7	2.4	9.5	5.9	1.1	2.1	6.5	18.3	6.4	11.5	11.3	4.2	8.0	9.3	12.5	7.7	9.4	7.3	6.7	15.6	6.5	6.8	18.8	10.0	1.6	0.1	7.5	11.5	0.6	0.4	8.3	0.8	5.9	8.0	39.3	16.3	5.1	28.7	3.5	3.2	5.5	20.5	16.4	4.4	3.2	10.0	13.8	5.8	12.3	3.3	2.3	16.5	8.0	5.0	12.2	8.0	9.0	16.3	7.5	7.8	22.7	9.9	13.8	8.9	0.0	0.3	0.2	1.6	0.3	0.5	0.7	2.0	2.3	1.3	1.1	0.6	1.3	1.1	2.2	0.3	0.1	8.8	1.1	3.1	11.3	3.3	5.7	5.7	3.5	8.0	6.5	11.8	4.9
CCNG1	CCNG	ENSG00000113328	"Cyclin G1"	P51959	5	163437569-163446151	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB000350	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB000350: "	"unprognostic (2.49e-2)"	"unprognostic (1.64e-1)"	"prognostic favourable (7.00e-4)"	"unprognostic (2.92e-2)"	"unprognostic (9.04e-2)"	"unprognostic (2.26e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.58e-1)"	"unprognostic (6.15e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.38e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.19e-1)"	"unprognostic (7.89e-2)"	32.3	24.8	11.1	16.0	14.6	9.6	20.5	9.0	9.7	27.9	43.5	11.0	14.1	41.4	22.3	23.6	24.7	19.4	25.8	29.8	11.5	10.3	40.4	46.6	20.7	26.0	22.5	9.1	44.1	42.5	13.5	12.6	17.9	17.0	39.3	26.9	12.6	25.6	18.1	51.7	10.2	68.7	35.8	27.1	22.7	24.6	17.0	15.8	26.5	38.3	29.7	15.6	48.1	21.4	23.2	23.3	15.9	14.0	15.4	36.5	22.8	9.5	10.7	44.6	25.0	38.6	74.4	47.0	13.2	32.4	13.5	30.5	23.1	19.5	23.4	13.5	17.6	3.9	24.6	33.0	19.9	11.2	31.1	18.5	14.2	40.1	42.2	8.5	12.5	80.7	19.1	13.3	13.7	43.2	15.8	16.7	45.6	5.9	14.9	11.5	20.4	9.7	13.0	21.9	12.9	32.7	37.0	10.6	12.0	0.0	5.5	26.9	20.9	27.4	25.1	8.7	18.8	7.3	11.5	14.9	5.8	15.8	15.5	14.4	14.5	15.9	10.3	11.8	15.1	14.0	22.3	23.2	26.6	20.6	23.3	14.5	36.5	29.8	4.2	15.4	13.0	8.9	31.3	22.8	11.1	14.6	9.0	9.7	11.5	10.3	22.5	9.1	17.0	15.8
CCNG2		ENSG00000138764	"Cyclin G2"	Q16589	4	77157151-77433388	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 16.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 99.1"	HPA034684	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA034684: AB_10669894"	"unprognostic (2.58e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.29e-1)"	"unprognostic (5.73e-2)"	"unprognostic (8.15e-2)"	"unprognostic (8.40e-3)"	"unprognostic (1.72e-2)"	"unprognostic (1.20e-2)"	"unprognostic (3.06e-1)"	"prognostic unfavourable (8.57e-4)"	"unprognostic (2.04e-1)"	"prognostic favourable (2.47e-5)"	"unprognostic (7.98e-2)"	"unprognostic (2.20e-1)"	"unprognostic (2.28e-1)"	"unprognostic (1.05e-3)"	18.4	8.1	11.3	13.5	15.1	25.9	26.7	53.0	17.2	15.1	12.3	8.9	9.6	8.6	16.4	10.7	45.2	8.0	10.4	6.3	9.6	5.4	23.0	3.4	12.8	21.4	7.3	10.6	12.5	7.2	8.8	7.7	20.0	7.3	26.1	11.0	12.2	18.4	10.5	7.5	12.8	9.8	13.5	7.4	14.2	7.7	8.0	7.8	25.3	17.3	7.2	22.6	20.3	18.6	4.8	2.2	16.0	2.3	1.6	4.6	0.6	10.2	1.3	23.1	12.2	15.3	19.7	15.7	8.6	24.9	6.7	12.6	1.5	14.9	20.7	14.0	8.0	7.4	6.0	28.5	13.1	14.3	4.0	1.7	6.0	3.0	8.0	3.0	21.6	16.6	14.2	3.1	7.0	10.1	0.9	12.7	12.4	4.0	14.0	6.5	2.3	1.4	8.1	22.5	1.3	42.5	28.5	6.1	19.6	10.2	16.2	6.0	12.0	4.6	9.3	9.2	9.4	6.6	1.4	9.3	7.1	14.6	6.4	4.8	4.6	11.4	1.5	16.0	0.8	2.0	1.9	2.7	1.2	0.8	1.5	4.8	0.9	0.5	6.5	1.6	2.3	2.2	4.6	0.6	11.3	15.1	53.0	17.2	9.6	5.4	7.3	10.6	7.3	7.8
CCNH	"CycH, p34, p37"	ENSG00000134480	"Cyclin H"	P51946	5	87318416-87413019	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Transcription, Transcription regulation"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019416, HPA044138"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB019416: AB_2259936, HPA044138: "	"unprognostic (5.65e-2)"	"unprognostic (3.94e-3)"	"unprognostic (4.01e-3)"	"unprognostic (4.12e-1)"	"unprognostic (1.10e-1)"	"unprognostic (9.30e-2)"	"unprognostic (3.93e-2)"	"unprognostic (6.43e-2)"	"unprognostic (8.79e-2)"	"prognostic unfavourable (4.35e-4)"	"unprognostic (4.16e-2)"	"unprognostic (2.27e-2)"	"prognostic unfavourable (3.92e-5)"	"unprognostic (1.48e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.61e-1)"	"unprognostic (9.62e-2)"	32.4	25.8	18.7	16.1	25.2	28.9	25.5	40.9	29.9	16.3	14.7	19.2	16.9	16.0	15.5	23.7	17.4	14.9	23.2	20.3	23.4	19.4	22.6	33.8	21.7	19.6	20.8	21.4	24.3	21.0	24.3	32.5	14.8	27.3	25.3	19.0	16.6	17.9	20.5	24.4	13.7	18.8	15.7	22.1	17.2	16.3	46.9	22.3	28.4	25.7	13.9	23.6	19.7	16.4	19.9	23.1	33.5	25.7	16.7	22.8	19.0	19.4	9.3	9.2	6.1	13.4	9.5	9.4	14.1	18.4	25.0	34.8	15.7	11.0	13.2	4.9	21.9	9.9	11.5	22.9	23.6	14.5	14.6	23.5	16.7	15.2	24.2	18.8	19.1	13.2	8.6	13.1	31.8	21.9	15.5	22.5	20.7	11.6	13.2	15.6	3.7	36.3	11.0	21.4	19.4	21.0	10.5	9.2	5.8	7.8	7.0	17.0	17.1	14.8	15.0	24.4	9.4	14.1	12.4	7.2	6.8	19.7	15.7	17.8	10.8	20.1	21.8	33.5	15.3	24.9	22.7	19.9	20.3	20.6	23.1	16.6	21.0	20.1	18.2	16.7	25.7	13.7	22.8	19.0	18.7	25.2	40.9	29.9	23.4	19.4	20.8	21.4	27.3	22.3
CCR10	GPR2	ENSG00000184451	"C-C motif chemokine receptor 10"	P46092	17	42678889-42683917	"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 31.1"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 8.6;RPMI-8226: 6.2;U-266/70: 17.7;U-266/84: 8.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 31.1"	"Group enriched"	"Detected in many"	9	"dendritic cells: 10.9;T-cells: 31.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB011684, HPA048007, HPA069188"	Uncertain		Supported	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"CAB011684: AB_731502, HPA048007: , HPA069188: "	"unprognostic (3.25e-2)"	"unprognostic (2.71e-2)"	"unprognostic (5.70e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.25e-2)"	"unprognostic (2.23e-3)"	"unprognostic (5.18e-4)"	"unprognostic (1.15e-1)"	"unprognostic (9.55e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.21e-3)"	"unprognostic (1.01e-2)"	"unprognostic (2.32e-11)"	"unprognostic (2.84e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.87e-1)"	10.0	5.4	5.7	4.8	5.3	0.7	3.0	7.3	7.3	3.9	9.7	0.9	1.5	5.1	5.8	1.4	1.5	4.5	1.5	2.5	3.5	5.0	1.6	0.5	2.2	12.5	1.9	5.0	5.2	2.6	0.4	14.0	2.3	4.1	2.1	1.0	1.1	4.0	2.0	9.1	1.1	8.7	1.8	4.4	4.3	5.0	2.2	1.2	0.5	1.5	0.3	3.6	1.0	2.0	2.3	10.9	0.1	0.3	0.0	31.1	0.7	0.5	0.8	1.1	4.9	0.3	0.8	1.1	2.4	0.5	0.2	0.4	0.7	0.3	0.1	0.3	0.3	0.9	0.0	0.1	0.1	2.3	1.2	0.0	3.1	0.4	0.7	0.0	0.3	0.8	0.0	0.4	0.0	0.1	2.6	8.6	0.0	0.3	0.1	2.3	0.6	1.2	0.6	0.2	6.2	1.1	0.0	0.8	1.1	0.7	0.0	0.2	0.8	0.9	2.4	2.9	0.6	0.9	0.3	17.7	8.0	2.5	1.4	0.7	0.9	0.0	0.3	0.1	0.2	0.0	0.1	2.3	5.2	2.6	0.2	2.1	0.6	0.8	0.0	0.0	0.1	10.9	31.1	0.7	5.7	5.3	7.3	7.3	3.5	5.0	1.9	5.0	4.1	1.2
CCR7	"BLR2, CD197, CDw197, CMKBR7, EBI1"	ENSG00000126353	"C-C motif chemokine receptor 7"	P32248	17	40553769-40565472	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	11	"blood: 252.3;lymphoid tissue: 110.6"	"Cell line enriched"	"Detected in some"	79	"HDLM-2: 171.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 252.3"	"Lineage enriched"	"Detected in many"	4	"T-cells: 252.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB003796, HPA031383, HPA074467"	Enhanced		Approved	Mitochondria				Mitochondria		"CAB003796: AB_562261, HPA031383: , HPA074467: "	"prognostic favourable (3.84e-4)"	"prognostic favourable (8.03e-6)"	"unprognostic (2.26e-3)"	"unprognostic (1.32e-3)"	"unprognostic (2.35e-3)"	"prognostic favourable (7.61e-7)"	"unprognostic (2.71e-4)"	"unprognostic (2.58e-2)"	"unprognostic (4.48e-2)"	"unprognostic (4.68e-4)"	"unprognostic (1.10e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.08e-3)"	"unprognostic (3.12e-1)"	"prognostic unfavourable (7.72e-4)"	"unprognostic (1.02e-1)"	"unprognostic (7.95e-2)"	2.8	0.4	0.2	26.0	0.2	5.2	1.7	0.2	0.3	2.2	1.2	0.3	0.8	0.3	1.2	0.5	1.4	2.3	2.0	1.9	0.2	0.2	1.5	1.7	3.4	110.6	0.3	0.2	1.5	0.3	0.0	1.0	1.0	0.4	1.3	2.1	0.7	8.4	0.2	0.2	1.1	16.2	0.2	0.4	20.3	1.8	1.2	0.3	57.1	2.0	1.2	53.8	4.2	1.3	58.8	2.9	2.3	0.3	44.1	252.3	109.3	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	171.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.9	0.1	1.1	0.2	0.0	0.0	1.1	0.3	0.2	3.1	0.1	3.6	37.2	53.3	15.3	0.2	58.8	252.3	133.9	2.3	44.1	0.2	2.9	30.3	109.3	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.4	0.3
CD14		ENSG00000170458	"CD14 molecule"	P08571	5	140631728-140633701	"Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins"	"Immunity, Inflammatory response, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"blood: 189.4;liver: 165.8"	"Cell line enhanced"	"Detected in many"		"A549: 8.9;CACO-2: 13.6;SiHa: 16.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 189.4"	"Group enriched"	"Detected in many"	5	"granulocytes: 52.3;monocytes: 189.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001887, HPA002127, CAB033631, CAB072865, CAB072866"	Enhanced		Supported	Vesicles	"Secreted to blood"	15000000000	15000000000	Vesicles		"CAB033631: AB_781932, CAB072865: , CAB072866: , HPA001887: AB_1078442, HPA002127: AB_1078440"	"unprognostic (1.92e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.42e-3)"	"unprognostic (3.89e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.54e-1)"	"unprognostic (4.71e-3)"	"unprognostic (4.88e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.43e-1)"	"prognostic unfavourable (6.80e-5)"	"unprognostic (1.20e-2)"	"unprognostic (6.87e-3)"	"unprognostic (8.12e-2)"	"unprognostic (6.92e-2)"	27.9	44.1	9.0	42.7	25.2	9.8	11.7	3.5	8.9	5.6	10.0	6.0	1.8	5.4	5.6	24.0	4.5	12.0	14.6	18.9	11.7	7.4	12.7	165.8	23.8	34.7	21.6	2.9	14.2	5.3	4.3	10.1	37.3	18.9	8.5	9.2	14.6	28.5	5.8	10.2	3.5	12.1	21.4	18.2	35.5	6.6	6.5	17.3	2.2	7.9	5.8	6.6	15.9	3.8	0.5	23.6	52.3	189.4	0.2	0.4	124.2	0.1	8.9	0.1	0.5	1.2	0.3	0.4	0.8	4.1	1.3	1.6	13.6	2.1	0.4	0.6	4.9	3.8	0.0	1.6	0.2	0.1	0.9	0.3	0.5	1.8	4.8	1.0	0.4	3.9	0.2	0.2	1.3	0.0	0.2	0.2	1.2	0.3	0.0	0.5	0.2	0.3	0.3	0.4	1.1	0.2	0.0	2.4	1.0	16.3	0.4	0.5	0.3	1.7	0.6	0.2	0.3	1.5	1.2	0.7	0.9	0.5	0.4	0.4	0.1	0.4	189.4	1.0	0.3	36.6	0.4	0.5	0.2	0.2	23.6	0.1	0.3	0.2	52.3	0.2	4.8	1.3	0.1	124.2	9.0	25.2	3.5	8.9	11.7	7.4	21.6	2.9	18.9	17.3
CD1D		ENSG00000158473	"CD1d molecule"	P15813	1	158179947-158184896	"Cancer-related genes, CD markers, Predicted membrane proteins"	"Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 49.5;lymphoid tissue: 17.8"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 9.1;HHSteC: 14.1;MOLT-4: 18.6;THP-1: 11.4"	"Low cancer specificity"	"Detected in many"							"Group enriched"	"Detected in many"	6	"classical monocyte: 49.5;intermediate monocyte: 22.4;myeloid DC: 49.5"	"Group enriched"	"Detected in many"	8	"dendritic cells: 49.5;monocytes: 49.5"					"Low region specificity"	"Detected in all"			"CAB016107, HPA072662"	Enhanced		Supported	"Endoplasmic reticulum"		720000	720000	"Endoplasmic reticulum"		"CAB016107: AB_626960, HPA072662: "	"unprognostic (8.67e-2)"	"unprognostic (6.99e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.85e-1)"	"unprognostic (9.67e-3)"	"unprognostic (2.37e-1)"	"unprognostic (3.52e-1)"	"unprognostic (2.23e-2)"	"unprognostic (4.46e-2)"	"prognostic unfavourable (2.12e-5)"	"unprognostic (9.31e-3)"	"unprognostic (2.35e-1)"	"unprognostic (2.32e-2)"	"unprognostic (3.38e-1)"	1.5	1.2	0.0	8.6	0.0	2.6	1.2	0.0	0.0	0.8	2.5			9.5	1.5	0.0	0.4	1.4	2.0	1.4	0.0	0.1	1.6	10.5	2.3	5.5	0.2		0.3	0.7	0.0	0.6	0.0		1.4	3.7		0.7	0.3	0.6	0.0	12.2	2.2	0.4	17.8	1.4	1.4			1.8		3.4	1.6	0.5	6.3	49.5	2.5	49.5	0.1	0.1	23.5	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	3.2	0.0	4.8	0.0	9.1	0.0	0.0	0.1	0.2	0.0	0.0	14.1	0.1	0.0	5.3	0.7	0.0	1.1	0.0	0.0	0.0	0.0	0.0	18.6	1.8	0.8	0.0	0.0	0.0	0.0	0.9	0.0	1.8	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	2.9	0.0	0.0	0.5	0.0	0.5	0.0	5.2	0.7	0.0	49.5	0.1	0.0	22.4	0.1	6.3	0.0	0.0	49.5	4.7	0.0	0.0	2.5	0.1	3.6	0.5	0.0	23.5										
CD27	"S152, TNFRSF7, Tp55"	ENSG00000139193	"CD27 molecule"	P26842	12	6444867-6451718	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 82.3;lymphoid tissue: 60.4"	"Group enriched"	"Detected in some"	141	"Daudi: 63.7;U-698: 35.3"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 82.3"	"Group enriched"	"Detected in many"	7	"B-cells: 41.8;T-cells: 82.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002420, HPA038936"	Enhanced					28000	28000			"CAB002420: AB_563539, HPA038936: "	"unprognostic (2.75e-3)"	"prognostic favourable (3.77e-5)"	"unprognostic (8.87e-3)"	"prognostic favourable (2.90e-4)"	"unprognostic (2.35e-1)"	"prognostic favourable (6.65e-7)"	"unprognostic (3.56e-2)"	"unprognostic (9.37e-2)"	"prognostic favourable (5.50e-4)"	"unprognostic (1.31e-3)"	"unprognostic (4.32e-2)"	"unprognostic (2.74e-1)"	"prognostic unfavourable (1.19e-6)"	"unprognostic (2.80e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.28e-1)"	"unprognostic (7.35e-2)"	1.1	0.6	0.4	40.8	0.5	2.0	1.2	0.4	0.4	1.7	10.0	0.2	0.5	5.3	0.8	0.6	4.9	1.6	3.7	0.9	0.4	0.4	1.7	1.0	2.9	49.5	0.4	0.1	1.0	0.5	0.0	0.6	0.4	0.2	1.3	2.9	1.2	10.7	1.4	0.4	0.6	19.4	0.2	0.6	45.7	3.7	0.5	0.1	33.5	3.1	2.3	60.4	9.1	1.2	41.8	0.3	0.8	0.1	8.3	82.3	22.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	63.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.3	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	35.3	0.0	0.0	0.0	0.8	0.1	0.1	16.7	0.1	28.7	41.8	40.1	37.5	0.1	10.5	55.6	39.1	0.8	8.3	0.1	0.3	82.3	22.1	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.1	0.2	0.1
CD274	"B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1"	ENSG00000120217	"CD274 molecule"	Q9NZQ7	9	5450503-5470566	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lung: 23.9;placenta: 56.0"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 33.4;HHSteC: 22.3;U-251 MG: 37.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 8.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 8.4;T-cells: 2.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB076385	Enhanced									"CAB076385: AB_2687655"	"prognostic favourable (8.89e-4)"	"unprognostic (4.54e-2)"	"prognostic favourable (1.64e-5)"	"unprognostic (1.27e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.61e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.67e-4)"	"unprognostic (7.39e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.67e-1)"	"unprognostic (9.02e-2)"	3.4	2.1	1.7	10.8	3.2	1.4	2.2	2.5	3.3	2.0	2.3	2.5	2.8	2.6	1.7	2.4	3.0	1.9	4.3	9.5	1.4	3.7	3.0	3.6	23.9	6.4	2.3	0.7	1.7	2.7	3.8	7.4	56.0	3.2	2.9	2.2	3.3	1.7	1.6	4.3	1.3	2.7	2.3	2.4	12.8	1.9	1.2	1.0	11.6	3.7	2.1	5.8	3.1	1.9	0.9	0.0	8.4	0.1	0.4	2.4	0.7	5.8	0.1	0.0	0.2	0.0	0.0	0.0	11.7	9.9	3.0	4.1	0.0	1.9	0.0	0.2	0.3	0.2	0.0	5.0	9.7	33.4	0.0	3.3	0.1	0.0	22.3	0.0	0.0	0.2	0.0	6.1	9.1	5.7	0.0	1.1	9.0	0.0	0.1	0.0	0.0	0.1	0.0	1.6	0.3	0.6	0.1	0.0	0.1	0.1	0.9	0.7	0.0	0.1	10.7	6.3	2.0	0.1	37.0	0.2	0.1	0.1	2.1	0.1	0.0	8.4	0.1	0.3	1.2	0.1	2.1	0.9	2.4	1.8	0.0	0.2	1.3	0.7	5.7	0.4	0.0	0.0	1.1	0.7	1.7	3.2	2.5	3.3	1.4	3.7	2.3	0.7	3.2	1.0
CD36	"FAT, GP3B, GP4, GPIV, SCARB3"	ENSG00000135218	"CD36 molecule"	P16671	7	80369575-80679277	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Cell adhesion, Transport"	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 464.3;breast: 156.1"	"Group enriched"	"Detected in some"	5	"ASC diff: 80.8;HEL: 38.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"classical monocyte: 104.4;intermediate monocyte: 30.4;myeloid DC: 56.9"	"Group enriched"	"Detected in many"	45	"dendritic cells: 56.9;monocytes: 104.4"	"Low region specificity"	"Detected in many"							"HPA002018, CAB025866, HPA071026"	Enhanced		Enhanced	"Golgi apparatus"		92000000	92000000	"Golgi apparatus"		"CAB025866: , HPA002018: AB_1078464, HPA071026: "	"unprognostic (7.16e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.06e-3)"	"unprognostic (6.52e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.63e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.84e-3)"	"prognostic unfavourable (4.47e-4)"	"unprognostic (7.05e-3)"	"unprognostic (4.87e-2)"	"unprognostic (2.73e-3)"	464.3	3.6	1.2	8.9	1.3	10.9	156.1	0.5	0.5	1.8	31.8	0.6	3.3	9.8	1.8	7.5	7.5	3.3	7.2	76.8	1.8	1.9	2.2	13.3	11.5	4.8	0.6	0.3	2.5	3.9	3.1	0.8	37.9	2.9	9.2	3.5	0.8	4.6	2.3	23.6	5.4	23.4	4.7	0.8	42.8	5.0	6.0	0.5	2.7	13.6	15.3	1.4	9.4	19.2	0.3	56.9	1.8	104.4	0.7	0.2	60.2	0.0	0.0	0.2	0.1	80.8	0.8	0.1	0.2	2.7	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	1.0	0.1	0.0	0.1	0.1	38.4	0.1	6.1	0.0	0.0	0.0	7.8	3.1	0.0	0.0	0.2	1.3	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.3	0.2	0.1	0.0	2.7	4.4	0.0	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	13.2	10.2	0.9	104.4	0.3	0.2	30.4	0.2	0.3	0.0	0.0	56.9	0.0	0.1	0.0	1.8	0.7	7.5	14.3	0.1	60.2	1.2	1.3	0.5	0.5	1.8	1.9	0.6	0.3	2.9	0.5
CD38		ENSG00000004468	"CD38 molecule"	P28907	4	15778275-15853230	"Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins"		"Hydrolase, Receptor, Transferase"	"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"lymphoid tissue: 94.9;seminal vesicle: 104.1"	"Cell line enhanced"	"Detected in some"		"Daudi: 49.8;Karpas-707: 13.9;MOLT-4: 12.6;REH: 10.0;U-266/70: 10.8;U-698: 9.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"NK-cell: 15.3"	"Group enriched"	"Detected in all"	4	"B-cells: 9.0;dendritic cells: 5.1;NK-cells: 15.3"	"Low region specificity"	"Detected in all"							"CAB002493, HPA022132, CAB025255, HPA052381"	Enhanced		Supported	"Plasma membrane"				"Plasma membrane"		"CAB002493: AB_563556, CAB025255: , HPA022132: AB_1846300, HPA052381: AB_2681807"	"unprognostic (1.27e-2)"	"unprognostic (8.06e-3)"	"unprognostic (1.06e-2)"	"prognostic favourable (9.68e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.82e-3)"	"unprognostic (2.74e-1)"	"unprognostic (8.51e-2)"	"unprognostic (5.87e-2)"	"unprognostic (6.15e-6)"	"unprognostic (5.23e-1)"	"unprognostic (4.34e-1)"	"unprognostic (6.63e-6)"	"unprognostic (1.79e-1)"	"unprognostic (5.74e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.13e-1)"	4.1	3.3	3.8	17.6	8.5	9.3	2.6	0.7	12.0	1.0	3.2	10.4	14.6	4.3	0.7	0.9	2.3	2.4	1.5	5.0	4.0	4.2	1.2	5.4	4.7	16.1	4.9	3.1	0.6	0.7	0.0	2.5	0.6	3.1	10.8	2.7	4.4	2.8	104.1	14.2	0.5	6.2	0.9	1.8	20.6	2.0	0.7	2.5	94.9	2.8	2.0	13.2	7.6	0.9	9.0	5.1	1.3	2.2	15.3	2.3	3.7	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	49.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	13.9	0.0	0.0	12.6	3.0	0.0	0.0	10.0	0.0	7.8	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	2.2	0.2	0.0	0.0	0.0	0.0	10.8	0.1	9.4	0.1	2.4	0.1	0.0	1.7	0.0	1.1	2.2	0.3	9.0	1.4	1.2	4.1	6.6	2.3	1.8	1.3	15.3	1.4	5.1	2.1	3.7	3.8	8.5	0.7	6.2	4.0	4.2	4.9	3.1	3.1	2.5
CD40	"Bp50, p50, TNFRSF5"	ENSG00000101017	"CD40 molecule"	P25942	20	46118272-46129863	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 26.7;EFO-21: 46.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 36.1;naive B-cell: 41.3"	"Group enriched"	"Detected in many"	6	"B-cells: 41.3;monocytes: 10.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB002495, HPA031567, HPA031568, CAB072868"	Enhanced				"Secreted to blood"	16000	16000			"CAB002495: AB_563562, CAB072868: , HPA031567: AB_2673936, HPA031568: AB_2673937"	"unprognostic (6.41e-2)"	"unprognostic (1.55e-2)"	"unprognostic (7.08e-3)"	"unprognostic (6.21e-2)"	"unprognostic (4.23e-3)"	"unprognostic (1.25e-1)"	"unprognostic (7.64e-3)"	"unprognostic (1.34e-1)"	"unprognostic (4.15e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.48e-2)"	"unprognostic (7.04e-2)"	"prognostic unfavourable (4.48e-4)"	"unprognostic (1.22e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.60e-2)"	"unprognostic (2.28e-2)"	13.0	4.6	3.6	38.6	4.7	1.1	11.6	9.7	4.4	11.3	9.2	3.6	7.8	6.5	9.6	8.6	9.9	9.7	8.6	9.5	4.5	2.6	10.0	10.0	18.8	34.7	3.3	3.2	14.8	14.0	12.1	5.9	6.5	5.4	14.7	5.2	13.7	13.0	11.6	7.5	9.0	11.8	10.0	4.6	30.1	8.4	4.4	4.4	11.5	16.5	6.7	46.0	12.5	13.8	41.3	4.1	1.0	10.8	0.6	1.4	4.8	9.0	1.4	0.0	4.5	1.7	0.9	1.8	1.6	0.5	1.3	1.3	0.0	26.7	14.5	46.9	0.3	1.1	0.8	5.7	1.4	9.7	0.0	3.4	0.0	2.5	13.4	0.0	4.6	6.0	2.2	5.5	0.0	10.1	1.1	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.3	0.3	1.5	11.8	0.1	0.0	0.0	7.9	4.5	0.0	0.9	4.8	0.0	0.0	15.0	0.0	0.0	0.0	0.0	9.9	3.4	1.7	0.0	1.0	7.7	0.1	1.3	10.8	0.9	36.1	0.7	0.5	4.1	41.3	1.4	1.0	0.7	0.6	7.5	2.1	1.0	4.8	3.6	4.7	9.7	4.4	4.5	2.6	3.3	3.2	5.4	4.4
CD40LG	"CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP"	ENSG00000102245	"CD40 ligand"	P29965	X	136648193-136660390	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 29.2;intestine: 8.7;lymphoid tissue: 33.7"	"Cell line enriched"	"Detected in single"	72	"MOLT-4: 22.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 9.4;MAIT T-cell: 22.9;memory CD4 T-cell: 29.2;naive CD4 T-cell: 28.1"	"Lineage enriched"	"Detected in single"	58	"T-cells: 29.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA045827	Enhanced				"Secreted to blood"					"HPA045827: AB_10959606"	"unprognostic (1.94e-5)"	"unprognostic (1.24e-2)"	"unprognostic (3.26e-1)"	"unprognostic (1.27e-3)"	"unprognostic (4.71e-2)"	"unprognostic (3.56e-5)"	"unprognostic (3.66e-2)"	"unprognostic (5.48e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.14e-4)"	"unprognostic (1.87e-1)"	"unprognostic (1.55e-1)"	"unprognostic (6.70e-4)"	"unprognostic (2.15e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.36e-3)"	"unprognostic (2.92e-2)"	2.0	0.5	0.3	22.4	0.3	1.4	1.2	0.3	0.3	2.0	3.3	0.1	0.0	1.7	1.5	1.3	1.6	1.6	2.6	1.1	0.4	0.4	1.6	1.1	4.0	14.6	0.4	0.0	0.7	0.6	0.0	0.4	0.2	0.3	1.0	3.1	1.0	4.9	1.3	0.4	1.1	8.7	0.5	0.6	9.9	1.7	0.6	0.1	33.7	1.4	2.0	26.1	3.0	1.4	0.0	0.0	0.5	0.0	0.2	29.2	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	9.4	0.0	22.9	0.0	29.2	4.1	0.0	0.0	28.1	0.2	0.5	0.2	0.0	0.0	3.3	4.7	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.0	0.3	0.1
CD44	"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1"	ENSG00000026508	"CD44 molecule (Indian blood group)"	P16070	11	35138870-35232402	"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Blood group antigen, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000112, CAB000316, HPA005785"	Enhanced		Enhanced	"Golgi apparatus,Plasma membrane"	"Secreted - unknown location"	2400000000	2400000000	"Plasma membrane"	"Golgi apparatus"	"CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467"	"unprognostic (5.33e-2)"	"unprognostic (1.85e-1)"	"unprognostic (4.97e-2)"	"unprognostic (9.90e-3)"	"unprognostic (3.50e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.51e-3)"	"unprognostic (4.63e-2)"	"prognostic unfavourable (1.78e-8)"	"unprognostic (6.41e-2)"	"unprognostic (4.14e-2)"	"unprognostic (3.93e-2)"	"unprognostic (7.98e-2)"	45.5	9.0	10.5	42.5	21.7	53.0	35.6	4.7	13.4	43.2	19.5	26.3	8.3	10.6	80.5	20.3	66.5	18.6	48.0	11.7	14.9	9.3	12.4	9.1	43.4	48.4	31.5	6.1	12.8	83.9	0.8	3.8	19.4	40.7	30.1	24.5	30.2	148.2	22.4	15.9	107.7	18.9	44.5	100.5	30.9	19.9	7.2	20.3	17.9	20.6	53.9	53.7	55.0	54.2	22.7	41.0	19.1	65.2	54.6	53.1	59.9	41.5	37.6	0.3	0.1	22.7	62.8	0.1	81.5	63.8	45.4	25.3	2.5	13.1	0.0	10.9	115.5	71.7	0.8	88.6	62.4	8.9	0.4	1.5	18.5	0.0	22.4	21.1	97.8	28.3	70.0	61.1	49.6	15.9	0.3	13.6	43.5	0.2	1.9	13.9	0.8	11.1	0.1	7.7	0.6	66.5	12.0	0.1	0.1	15.4	0.4	36.9	2.2	1.2	45.6	56.6	10.2	69.4	83.7	23.6	25.4	0.2	85.9	11.9	82.2	19.1	65.2	6.0	26.2	45.7	37.0	22.7	39.8	34.9	41.0	16.2	34.5	28.7	16.4	54.6	59.3	14.2	53.1	59.9	10.5	21.7	4.7	13.4	14.9	9.3	31.5	6.1	40.7	20.3
CD46	"MCP, MGC26544, MIC10, TLX, TRA2.10"	ENSG00000117335	"CD46 molecule"	P15529	1	207752057-207795513	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Complement pathway, Fertilization, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"basophil: 41.7;eosinophil: 63.7;neutrophil: 69.8"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 69.8"									"CAB010401, HPA016903"	Enhanced		Uncertain	"Plasma membrane"		1000000	1000000	"Plasma membrane"		"CAB010401: AB_2291289, HPA016903: AB_1846309"	"unprognostic (1.42e-2)"	"prognostic unfavourable (8.54e-5)"	"unprognostic (3.94e-2)"	"unprognostic (2.14e-2)"	"unprognostic (3.28e-2)"	"unprognostic (6.30e-2)"	"unprognostic (1.91e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.25e-1)"	"unprognostic (2.74e-1)"	"unprognostic (8.79e-2)"	"unprognostic (2.50e-1)"	"unprognostic (6.78e-3)"	"prognostic favourable (2.38e-4)"	"unprognostic (1.76e-1)"	"unprognostic (8.23e-2)"	"unprognostic (1.49e-2)"	38.0	78.0	13.0	22.9	20.5	18.5	57.0	12.9	17.8	27.5	35.4	25.3	64.3	32.9	39.7	32.6	43.2	30.4	25.2	20.6	16.1	15.5	50.8	57.8	43.6	25.0	21.4	13.2	27.6	47.9	86.6	32.7	119.6	29.1	47.0	28.5	26.7	68.4	60.5	18.8	18.4	39.8	25.0	21.8	26.9	33.9	16.5	20.7	20.3	25.3	21.8	30.3	37.2	27.0	7.7	8.1	69.8	14.1	7.5	13.5	14.9	26.2	14.8	13.9	6.4	44.0	43.5	21.2	19.7	28.7	13.0	17.7	14.6	69.9	4.0	20.1	19.6	35.6	10.4	27.0	19.9	20.2	14.8	8.7	16.3	26.1	28.0	19.0	30.4	37.4	40.3	19.6	15.5	36.4	18.3	17.5	20.0	12.3	9.0	16.7	15.9	14.8	6.1	22.1	24.7	53.3	52.0	14.1	9.6	24.9	56.1	32.3	44.1	16.3	31.2	14.0	12.5	29.4	22.4	23.6	28.5	12.1	20.5	12.5	13.1	41.7	13.5	63.7	9.2	14.0	12.5	7.7	11.7	10.1	8.1	6.0	13.5	11.2	69.8	7.5	14.1	4.2	10.1	14.9	13.0	20.5	12.9	17.8	16.1	15.5	21.4	13.2	29.1	20.7
CD52	"CDW52, EDDM5, HE5"	ENSG00000169442	"CD52 molecule"	P31358	1	26317957-26320523	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"			"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"blood: 495.7;epididymis: 978.9"	"Group enriched"	"Detected in some"	9	"Daudi: 74.4;REH: 108.7;U-266/84: 108.6;U-698: 120.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"																						"prognostic favourable (1.85e-5)"	"unprognostic (3.28e-3)"	"unprognostic (1.93e-2)"	"prognostic favourable (2.06e-4)"	"unprognostic (4.18e-2)"	"prognostic favourable (4.45e-4)"	"unprognostic (9.11e-2)"	"unprognostic (2.98e-2)"	"unprognostic (7.73e-3)"	"unprognostic (6.27e-2)"	"unprognostic (4.58e-1)"	"unprognostic (1.70e-1)"	"prognostic unfavourable (5.85e-4)"	"unprognostic (3.64e-1)"	"unprognostic (6.14e-2)"	"unprognostic (7.95e-2)"	"unprognostic (1.26e-1)"	9.5	0.9	0.8	23.0	1.4	5.7	4.7	0.3	0.8	0.9	3.7	0.3	93.2	1.0	1.1	978.9	2.9	1.5	2.2	1.5	0.6	0.2	3.5	3.2	43.4	54.6	0.8	0.6	0.8	1.0	0.0	0.7	0.7	0.7	1.7	2.5	1.3	5.7	2.9	0.4	1.9	39.6	1.1	1.2	98.7	2.7	5.3	0.4	24.7	3.2	2.1	30.4	4.3	1.7	292.0	87.6	258.4	194.6	94.3	308.1	495.7	0.2	0.0	0.0	0.0	0.0	0.1	1.5	0.0	0.1	0.0	0.0	0.0	0.0	74.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.1	0.0	0.7	11.6	0.0	0.0	0.0	0.0	0.0	2.4	0.1	0.0	0.4	0.8	6.6	0.3	0.0	108.7	0.1	1.6	0.0	0.0	0.2	1.0	0.0	0.1	0.1	0.0	1.3	0.1	0.0	0.2	0.0	0.1	0.3	108.6	120.3	0.0	1.8	0.0	12.4	126.8	258.4	194.7	194.6	155.1	292.0	244.1	190.3	87.6	273.7	166.6	171.2	9.6	94.3	167.6	28.6	308.1	495.7	0.8	1.4	0.3	0.8	0.6	0.2	0.8	0.6	0.7	0.4
CD59	"16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20"	ENSG00000085063	"CD59 molecule (CD59 blood group)"	P13987	11	33703010-33736491	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 285.5"	"Cell line enhanced"	"Detected in many"		"TIME: 213.3;U-2197: 176.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB001448, HPA026494"	Supported		Uncertain	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	98000000	98000000	"Golgi apparatus, Vesicles"		"CAB001448: AB_563604, HPA026494: AB_1846321"	"unprognostic (2.07e-2)"	"prognostic unfavourable (3.81e-5)"	"unprognostic (7.40e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.11e-2)"	"prognostic unfavourable (3.10e-5)"	"unprognostic (5.65e-2)"	"unprognostic (1.46e-1)"	"unprognostic (4.47e-2)"	"unprognostic (2.98e-1)"	"prognostic unfavourable (2.92e-5)"	"unprognostic (1.66e-2)"	"prognostic favourable (1.39e-10)"	"prognostic unfavourable (9.03e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.03e-2)"	"unprognostic (3.09e-1)"	96.7	41.0	36.7	26.3	44.3	23.8	76.0	25.9	32.7	44.8	36.9	24.0	57.9	16.5	45.4	132.8	68.4	53.2	67.6	90.5	35.6	38.4	100.0	61.0	86.4	39.8	39.7	25.8	39.3	52.3	60.6	48.0	285.5	68.7	47.4	37.7	51.4	114.8	62.6	70.6	43.4	25.0	52.4	32.9	26.2	54.7	28.1	23.1	16.1	85.9	57.7	40.0	51.2	63.4	13.5	20.5	42.8	4.8	17.7	60.4	11.1	16.5	15.5	4.6	13.5	107.8	84.5	2.7	94.2	105.1	23.6	27.7	7.2	49.8	1.2	16.8	101.4	18.7	8.5	93.9	33.2	26.3	12.9	1.7	54.9	10.8	29.4	9.9	5.7	39.2	23.8	20.0	96.4	144.0	11.6	38.3	148.6	15.1	4.6	4.1	2.5	80.9	1.7	14.4	13.3	71.3	28.3	3.2	4.3	32.8	15.2	17.3	11.6	1.0	213.3	54.3	13.0	176.7	32.6	17.0	33.2	1.6	46.7	0.0	94.3	30.5	4.8	42.8	11.3	1.6	14.4	13.5	24.0	12.7	20.5	10.6	15.7	9.3	28.4	17.7	0.9	10.5	60.4	11.1	36.7	44.3	25.9	32.7	35.6	38.4	39.7	25.8	68.7	23.1
CD70	"CD27L, CD27LG, TNFSF7"	ENSG00000125726	"CD70 molecule"	P32970	19	6583183-6604103	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Cytokine	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 23.3;lymphoid tissue: 12.7"	"Cell line enhanced"	"Detected in many"		"SiHa: 36.0;THP-1: 29.6;U-251 MG: 43.8;U-266/70: 78.0;U-266/84: 56.4"	"Cancer enhanced"	"Detected in many"		"renal cancer: 24.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 13.9;T-reg: 23.3"	"Group enriched"	"Detected in many"	38	"B-cells: 13.9;T-cells: 23.3"									HPA046582			Uncertain	Nucleoplasm				Nucleoplasm		"HPA046582: "	"unprognostic (8.71e-2)"	"unprognostic (9.91e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.33e-4)"	"unprognostic (1.73e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.61e-1)"	"prognostic unfavourable (6.29e-4)"	"unprognostic (1.36e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.92e-1)"	"unprognostic (1.72e-1)"	"prognostic unfavourable (3.22e-4)"	"unprognostic (2.57e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.27e-1)"	"unprognostic (2.08e-1)"	5.3	0.2	0.2	9.3	0.2	1.4	2.2	0.9	0.9	1.4	4.1	0.2	0.1	1.0	0.4	1.8	4.0	0.7	0.8	0.4	0.2	0.2	1.7	0.4	1.9	6.1	0.4	0.1	0.3	0.4	0.0	0.3	0.3	0.2	0.9	3.1	0.2	3.1	1.2	1.2	3.3	5.2	0.7	0.5	11.8	1.7	1.9	0.1	3.2	0.8	1.8	12.7	3.1	1.1	13.9	0.1	0.2	0.0	0.4	23.3	0.9	0.2	7.4	0.0	14.5	0.3	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.1	13.9	0.8	0.0	10.1	8.9	0.7	0.0	0.0	0.3	0.0	11.0	0.0	0.0	0.0	0.4	0.1	0.0	8.5	6.1	0.0	0.2	0.4	0.2	0.0	0.2	17.5	0.1	13.4	3.7	0.0	3.0	4.7	0.0	0.0	0.0	36.0	0.0	0.1	0.1	29.6	0.2	0.1	6.5	0.0	43.8	78.0	56.4	25.1	8.0	4.4	2.8	0.2	0.0	0.0	1.9	0.0	4.8	13.9	3.2	5.0	0.0	4.0	0.4	1.3	0.1	0.4	0.0	0.1	23.3	0.9	0.2	0.2	0.9	0.9	0.2	0.2	0.4	0.1	0.2	0.1
CD74	DHLAG	ENSG00000019582	"CD74 molecule"	P04233	5	150401637-150412929	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 504.7"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 115.7;Daudi: 178.0;HDLM-2: 255.6;REH: 154.1;RPMI-8226: 104.9;U-266/70: 85.9;U-698: 98.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2"	"Group enriched"	"Detected in all"	5	"B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002506, HPA010592"	Enhanced		Supported	"Golgi apparatus"		90000	90000	"Golgi apparatus"		"CAB002506: AB_563630, HPA010592: AB_1078482"	"prognostic favourable (1.06e-4)"	"unprognostic (1.48e-2)"	"unprognostic (4.80e-3)"	"prognostic favourable (6.53e-6)"	"unprognostic (1.41e-1)"	"unprognostic (4.53e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.69e-3)"	"unprognostic (1.54e-2)"	"unprognostic (3.48e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.64e-1)"	"unprognostic (5.44e-3)"	"unprognostic (1.73e-1)"	"unprognostic (4.95e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.24e-2)"	137.8	95.7	53.2	177.0	81.4	40.7	104.2	8.4	43.5	89.6	68.2	79.0	30.0	98.3	60.0	73.9	43.6	68.1	81.3	104.1	46.9	43.5	168.3	60.1	222.5	310.1	78.3	23.1	53.4	34.1	15.1	51.0	27.9	79.8	72.6	63.6	72.9	123.0	55.4	40.5	56.6	182.8	55.1	123.1	372.1	77.3	23.7	68.1	201.1	83.4	45.6	288.2	91.7	47.0	504.7	437.9	76.1	303.5	42.2	41.2	238.1	1.9	0.0	0.0	0.1	0.1	0.1	0.6	0.0	0.0	0.0	0.0	23.1	115.7	178.0	7.2	0.0	0.5	0.0	0.0	0.0	255.6	0.0	5.8	0.1	14.1	0.3	0.4	0.3	1.4	0.0	0.0	0.0	0.0	0.4	70.9	0.0	0.0	0.2	0.8	0.3	0.0	154.1	0.2	104.9	0.5	7.5	0.2	0.5	0.3	0.2	5.1	4.7	21.3	0.2	0.6	0.5	0.5	0.2	85.9	9.2	98.6	41.3	8.0	37.7	6.3	191.6	76.1	16.8	303.5	18.7	467.7	14.8	24.8	437.9	504.7	7.8	13.5	16.8	42.2	140.0	303.2	41.2	238.1	53.2	81.4	8.4	43.5	46.9	43.5	78.3	23.1	79.8	68.1
CD79A	"IGA, MB-1"	ENSG00000105369	"CD79a molecule"	P11912	19	41877120-41881372	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2"	"Group enriched"	"Detected in some"	24	"Daudi: 155.5;REH: 48.3;U-698: 135.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	38	"memory B-cell: 106.4;naive B-cell: 125.3"	"Lineage enriched"	"Detected in many"	41	"B-cells: 125.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB000019	Enhanced									"CAB000019: AB_2244527"	"prognostic favourable (8.45e-5)"	"unprognostic (1.63e-3)"	"unprognostic (4.13e-3)"	"unprognostic (1.31e-3)"	"unprognostic (2.02e-1)"	"prognostic favourable (1.18e-5)"	"unprognostic (1.23e-2)"	"unprognostic (8.11e-3)"	"unprognostic (9.41e-3)"	"unprognostic (1.12e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.32e-1)"	"prognostic unfavourable (2.15e-5)"	"unprognostic (6.08e-2)"	"unprognostic (3.39e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.46e-1)"	1.3	0.6	0.5	103.8	0.5	5.4	1.3	0.5	0.5	1.8	6.3	0.1	0.1	4.9	0.6	0.2	4.4	1.0	2.3	0.8	0.5	0.5	2.3	0.9	4.3	114.9	0.5	0.1	0.6	0.6	0.0	0.5	0.5	0.1	1.0	3.4	1.8	13.6	1.2	0.5	0.5	43.5	0.2	0.5	108.1	9.7	0.8	0.1	32.0	2.4	1.9	119.2	6.8	1.0	125.3	3.0	0.7	0.3	0.2	2.3	4.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	155.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.1	0.9	0.0	0.0	48.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.1	0.0	0.4	0.0	0.0	0.7	0.1	135.4	0.0	4.6	0.0	0.7	0.1	0.5	0.1	0.1	0.0	106.4	0.3	0.1	0.2	125.3	0.4	2.3	0.4	0.2	0.3	3.0	0.8	4.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.1	0.1	0.1
CD79B	"B29, IGB"	ENSG00000007312	"CD79b molecule"	P40259	17	63928740-63932354	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 138.8;lymphoid tissue: 56.6"	"Cell line enhanced"	"Detected in some"		"Daudi: 114.9;REH: 37.8;U-698: 157.4"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"memory B-cell: 100.6;naive B-cell: 138.8"	"Lineage enriched"	"Detected in many"	6	"B-cells: 138.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA009178, CAB009751"	Enhanced									"CAB009751: AB_2275844, HPA009178: AB_1078483"	"unprognostic (3.90e-3)"	"unprognostic (1.61e-3)"	"unprognostic (5.21e-2)"	"unprognostic (3.45e-3)"	"unprognostic (4.22e-3)"	"prognostic favourable (2.35e-4)"	"unprognostic (1.82e-1)"	"unprognostic (9.25e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.87e-2)"	"unprognostic (2.50e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.44e-1)"	"unprognostic (4.28e-2)"	"unprognostic (2.75e-1)"	1.7	0.7	0.4	50.6	0.4	11.1	1.2	0.3	0.4	0.6	1.7	0.3	0.3	0.7	0.6	0.5	2.6	0.6	1.4	3.4	0.4	0.2	2.3	1.7	1.3	56.6	0.4	0.3	0.6	1.6	0.0	9.0	0.5	0.3	1.0	1.3	0.8	8.9	0.9	1.2	0.9	22.4	0.5	0.4	56.0	1.8	0.6	0.3	3.7	1.4	1.7	46.6	4.5	0.9	138.8	4.2	0.5	25.0	3.4	9.2	9.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	114.9	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	6.3	0.0	0.0	0.0	2.4	0.0	0.0	37.8	0.1	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.7	0.1	0.0	0.4	0.0	0.0	5.8	5.6	157.4	0.0	0.2	0.0	0.5	1.1	0.0	4.2	16.5	4.8	100.6	5.4	2.8	4.2	138.8	3.7	2.2	0.5	3.4	25.0	0.6	9.2	9.0	0.4	0.4	0.3	0.4	0.4	0.2	0.4	0.3	0.3	0.3
CD82	"IA4, KAI1, R2, ST6, TSPAN27"	ENSG00000085117	"CD82 molecule"	P27701	11	44564427-44620363	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 77.3;LHCN-M2: 45.7;U-87 MG: 54.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 80.5"	"Group enriched"	"Detected in all"	6	"B-cells: 51.1;granulocytes: 80.5;T-cells: 25.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002508, HPA028900, HPA061418"	Supported		Approved	Vesicles				Vesicles		"CAB002508: AB_563640, HPA028900: AB_10603558, HPA061418: "	"unprognostic (5.31e-2)"	"unprognostic (4.62e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.78e-1)"	"unprognostic (7.29e-2)"	"unprognostic (3.48e-1)"	"unprognostic (2.97e-1)"	"unprognostic (2.58e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.48e-3)"	"unprognostic (1.86e-3)"	"unprognostic (2.33e-2)"	"unprognostic (2.88e-2)"	"unprognostic (6.30e-2)"	14.7	4.9	16.3	21.6	23.1	43.6	13.8	6.3	13.6	17.5	20.7	23.0	53.0	25.9	4.8	13.5	58.3	19.8	21.7	12.7	16.9	13.3	10.2	18.8	38.8	22.8	17.9	9.2	9.0	11.6	2.8	3.9	20.7	14.0	14.3	6.8	18.6	29.8	55.2	10.5	34.6	36.0	8.9	10.2	21.9	22.5	4.5	12.6	23.9	8.3	23.5	33.5	16.3	28.1	51.1	6.7	80.5	9.1	7.2	25.6	9.5	5.0	0.7	6.6	1.3	4.5	17.2	0.2	2.9	23.6	5.1	13.0	0.3	3.4	5.2	3.5	1.4	19.2	0.9	15.0	11.8	23.2	0.4	32.5	1.5	0.1	3.3	8.9	77.3	23.7	17.6	21.4	11.4	9.0	0.2	1.6	45.7	3.6	8.6	16.7	0.2	0.3	0.2	27.6	7.3	3.0	4.9	0.2	0.3	1.8	27.6	3.8	26.3	8.8	5.0	16.2	2.1	0.3	27.5	0.6	0.0	0.1	54.7	4.9	8.6	48.4	9.1	16.0	4.9	4.8	8.5	51.1	24.9	11.6	2.2	30.9	8.6	3.8	80.5	7.2	3.4	6.7	25.6	9.5	16.3	23.1	6.3	13.6	16.9	13.3	17.9	9.2	14.0	12.6
CD9	"BA2, MIC3, MRP-1, P24, TSPAN29"	ENSG00000010278	"CD9 molecule"	P21926	12	6199715-6238271	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Fertilization"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 127.8;HUVEC TERT2: 82.6;RT4: 94.7;TIME: 188.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	21	"basophil: 137.8;eosinophil: 98.3"	"Lineage enriched"	"Detected in many"	24	"granulocytes: 137.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002490	Supported		Supported	"Plasma membrane"		68000000	68000000	"Plasma membrane"		"CAB002490: AB_563643"	"unprognostic (1.38e-1)"	"unprognostic (6.36e-3)"	"unprognostic (8.27e-3)"	"unprognostic (6.98e-3)"	"unprognostic (3.89e-1)"	"unprognostic (2.81e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.08e-2)"	"unprognostic (2.90e-1)"	"unprognostic (2.60e-2)"	"prognostic unfavourable (1.59e-4)"	"unprognostic (2.30e-1)"	"prognostic favourable (6.49e-5)"	"unprognostic (6.10e-2)"	"unprognostic (1.77e-1)"	"prognostic favourable (8.93e-5)"	"unprognostic (9.26e-2)"	38.1	44.5	20.0	24.1	36.2	3.1	48.2	6.8	29.6	55.0	68.3	63.1	151.6	19.5	36.2	43.4	139.8	38.4	23.2	39.2	30.3	15.6	39.9	12.2	61.1	8.2	43.3	23.3	14.1	23.3	89.5	15.2	13.0	28.7	77.9	73.5	25.5	91.6	180.4	11.3	60.1	29.6	62.2	48.9	12.2	27.7	10.4	47.7	6.0	63.6	112.3	85.8	54.5	76.0	1.9	0.9	137.8	5.6	0.2	1.1	5.6	33.9	14.9	0.3	9.2	14.7	15.1	12.9	20.1	40.2	6.9	10.6	10.9	127.8	0.1	5.0	4.3	74.5	7.8	40.2	5.3	1.7	5.5	0.1	11.3	2.3	6.3	0.1	42.8	0.0	29.9	12.6	10.9	82.6	1.5	0.1	4.3	48.6	0.1	3.7	11.6	15.0	0.3	24.6	43.2	67.6	94.7	0.0	2.9	20.0	16.6	17.2	7.7	3.5	188.9	0.7	18.9	0.7	2.4	0.1	0.1	5.1	11.8	0.0	18.6	137.8	5.6	98.3	0.1	1.8	0.2	0.5	0.1	0.1	0.9	1.9	0.4	1.1	2.6	0.2	0.0	0.3	0.0	5.6	20.0	36.2	6.8	29.6	30.3	15.6	43.3	23.3	28.7	47.7
CDC16	"ANAPC6, APC6, CUT9"	ENSG00000130177	"Cell division cycle 16"	Q13042	13	114234887-114272723	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042826	Approved									"HPA042826: AB_10793987"	"unprognostic (7.32e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.18e-3)"	"unprognostic (1.50e-1)"	"unprognostic (7.19e-3)"	"unprognostic (6.82e-3)"	"unprognostic (9.86e-2)"	"unprognostic (7.64e-2)"	"unprognostic (4.07e-1)"	"unprognostic (1.27e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.99e-3)"	"unprognostic (2.48e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.11e-3)"	"unprognostic (1.51e-2)"	27.0	28.2	29.2	24.7	38.0	19.1	33.8	27.2	31.7	30.2	30.7	37.1	29.7	22.5	34.1	44.9	24.6	39.6	27.9	27.4	27.4	26.2	29.4	41.6	25.3	28.5	37.9	28.2	33.8	47.4	22.1	30.6	29.4	32.4	28.4	33.0	27.5	23.8	36.1	30.0	35.0	29.5	33.7	33.0	33.0	27.1	34.5	30.0	27.9	30.1	22.8	31.8	25.2	26.5	9.2	7.5	4.1	3.8	13.3	5.6	2.6	29.1	14.2	22.2	22.6	28.5	36.3	12.8	26.8	21.9	27.4	26.8	13.7	20.9	23.5	10.2	35.9	14.4	19.3	25.2	36.5	14.1	22.7	19.9	18.9	13.1	29.9	35.5	26.9	25.9	27.2	19.0	24.2	26.1	16.1	9.1	37.7	11.5	15.4	16.4	25.1	13.3	8.0	11.3	17.0	32.8	17.9	23.2	20.6	14.4	26.4	42.3	18.6	42.5	21.4	12.3	21.7	10.0	16.1	13.5	10.8	25.0	29.0	21.2	16.6	2.7	3.8	4.1	4.4	3.6	4.1	9.2	2.9	5.6	5.4	7.2	3.2	3.5	0.9	13.3	3.1	7.5	5.3	2.6	29.2	38.0	27.2	31.7	27.4	26.2	37.9	28.2	32.4	30.0
CDC20	"CDC20A, p55CDC"	ENSG00000117399	"Cell division cycle 20"	Q12834	1	43358955-43363203	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation, Mitosis, Neurogenesis, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 42.0;testis: 73.2"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"memory B-cell: 4.5;memory CD4 T-cell: 3.3;memory CD8 T-cell: 3.6;NK-cell: 9.8;T-reg: 11.2"	"Group enriched"	"Detected in many"	9	"B-cells: 4.5;NK-cells: 9.8;T-cells: 11.2"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"CAB004525, HPA045842, HPA055288"	Enhanced		Enhanced	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB004525: AB_628089, HPA045842: , HPA055288: "	"unprognostic (1.66e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.14e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.09e-1)"	"prognostic unfavourable (4.00e-8)"	"unprognostic (9.06e-3)"	"unprognostic (1.17e-2)"	"unprognostic (1.23e-2)"	"prognostic unfavourable (1.32e-4)"	"unprognostic (8.55e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (2.84e-2)"	"unprognostic (2.28e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.29e-2)"	1.3	1.2	0.6	16.6	1.1	20.2	1.8	0.8	1.3	2.1	6.2	2.8	0.4	5.8	1.1	1.6	17.8	0.4	1.9	1.2	0.9	0.5	2.2	1.2	1.8	13.4	1.1	0.7	0.9	0.5	0.0	0.4	3.9	1.2	0.8	7.0	0.4	2.9	0.4	0.6	4.6	6.4	2.8	1.2	7.8	4.4	73.2	0.7	42.0	1.2	11.7	21.7	1.9	4.2	4.5	0.9	0.8	0.1	9.8	11.2	2.7	51.7	25.3	35.3	23.0	1.2	3.1	33.9	24.0	21.6	70.1	37.4	39.6	43.2	30.0	14.1	22.0	36.5	38.6	45.8	58.5	23.5	28.5	43.9	25.0	24.5	0.3	30.6	16.0	1.0	2.1	48.6	44.1	29.7	19.8	20.6	31.7	20.0	29.4	18.8	44.7	34.1	42.8	48.5	19.0	17.1	13.8	20.9	10.3	42.5	28.7	13.3	20.1	38.8	15.4	21.0	49.2	23.3	74.5	15.9	14.0	31.1	15.0	38.2	31.2	0.0	0.1	0.0	0.4	0.0	0.0	4.5	3.3	3.6	0.9	0.9	0.1	0.3	0.8	9.8	0.0	0.2	11.2	2.7	0.6	1.1	0.8	1.3	0.9	0.5	1.1	0.7	1.2	0.7
CDC25A		ENSG00000164045	"Cell division cycle 25A"	P30304	3	48157146-48188402	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 13.0;lymphoid tissue: 23.0;testis: 19.4"	"Low cell line specificity"	"Detected in many"			"Cancer enhanced"	"Detected in many"		"testis cancer: 19.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 1.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005855			Approved	"Nucleoplasm,Golgi apparatus,Vesicles"				"Golgi apparatus"	"Nucleoplasm, Vesicles"	"HPA005855: AB_1846364"	"unprognostic (1.49e-1)"	"unprognostic (8.13e-2)"	"unprognostic (1.20e-2)"	"unprognostic (1.43e-3)"	"unprognostic (2.14e-1)"	"unprognostic (9.51e-2)"	"unprognostic (7.05e-7)"	"unprognostic (1.35e-2)"	"unprognostic (4.32e-3)"	"unprognostic (8.92e-3)"	"unprognostic (4.41e-2)"	"unprognostic (9.09e-2)"	"unprognostic (4.41e-3)"	"unprognostic (1.57e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.72e-1)"	0.8	1.2	1.1	5.5	1.1	13.0	0.8	0.7	1.2	1.1	3.3	0.6	1.0	1.8	0.6	0.9	3.9	0.4	2.2	0.7	1.3	2.4	1.2	0.9	0.7	4.1	1.4	0.2	2.1	3.6	0.4	2.3	4.2	1.2	1.0	4.0	1.5	1.8	0.5	0.7	0.8	2.1	0.8	0.7	3.6	1.3	19.4	0.2	23.0	1.6	8.8	7.4	0.8	1.3	1.7	0.9	0.5	0.1	0.0	1.0	0.1	7.5	3.7	17.8	9.6	0.6	1.2	12.3	10.5	4.0	13.2	10.7	16.1	3.9	22.4	4.1	2.7	5.7	30.5	7.2	13.9	7.3	16.0	28.7	6.8	7.9	0.6	20.2	8.3	0.6	1.1	16.4	7.1	5.0	22.8	11.9	7.1	4.0	25.2	15.7	26.0	8.5	11.3	11.7	12.2	3.3	7.1	8.4	10.4	6.5	7.6	3.3	4.0	14.3	2.5	6.5	10.0	7.2	14.2	6.0	17.9	35.2	4.8	22.5	5.4	0.0	0.0	0.5	0.4	0.0	0.0	1.7	0.6	0.2	0.9	0.0	0.0	1.0	0.0	0.0	0.1	0.5	0.0	0.1	1.1	1.1	0.7	1.2	1.3	2.4	1.4	0.2	1.2	0.2
CDC25B		ENSG00000101224	"Cell division cycle 25B"	P30305	20	3786772-3806121	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in all"	5	"B-cells: 4.5;NK-cells: 9.3;T-cells: 15.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038892, HPA038893, HPA075215"	Enhanced		Supported	"Vesicles,Mitotic spindle"				Vesicles	"Mitotic spindle"	"HPA038892: , HPA038893: , HPA075215: "	"unprognostic (4.69e-2)"	"unprognostic (5.74e-2)"	"unprognostic (2.93e-2)"	"prognostic unfavourable (4.76e-4)"	"unprognostic (1.13e-1)"	"unprognostic (4.23e-1)"	"prognostic unfavourable (1.19e-4)"	"unprognostic (1.31e-2)"	"unprognostic (4.92e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.67e-1)"	"unprognostic (6.03e-2)"	"prognostic unfavourable (2.94e-13)"	"unprognostic (1.15e-1)"	"unprognostic (2.38e-1)"	"unprognostic (3.94e-1)"	"unprognostic (9.46e-2)"	12.1	8.7	15.1	27.7	23.3	26.0	28.8	49.6	21.1	13.0	14.7	12.8	4.6	14.9	17.0	10.3	11.7	13.0	18.6	7.5	15.7	12.5	13.3	11.0	33.0	42.8	21.9	12.5	17.3	5.7	7.5	21.0	30.3	13.8	11.0	12.0	7.7	7.4	10.2	6.2	19.8	16.8	14.8	14.7	24.5	14.1	6.3	22.3	33.3	18.7	20.8	31.6	15.3	16.3	4.5	1.3	1.5	1.8	9.3	15.5	5.9	29.8	64.5	8.6	14.3	10.6	10.4	4.3	14.8	22.2	24.8	18.5	11.2	43.3	20.8	6.4	15.1	43.7	11.7	24.6	11.7	8.0	12.6	11.2	20.7	13.5	42.3	8.7	5.8	10.2	19.8	23.0	27.2	13.7	7.2	55.1	14.6	24.0	27.1	12.7	6.4	27.6	14.2	24.4	14.9	16.9	2.8	6.2	13.5	35.1	33.5	17.2	11.3	4.5	11.3	13.3	16.1	24.1	19.6	13.4	21.2	8.4	6.8	8.6	12.8	1.5	1.4	0.0	13.6	1.8	12.7	3.5	13.6	13.7	1.3	4.5	11.4	13.2	0.1	9.3	0.9	0.7	15.5	5.9	15.1	23.3	49.6	21.1	15.7	12.5	21.9	12.5	13.8	22.3
CDC25C	"CDC25, PPP1R60"	ENSG00000158402	"Cell division cycle 25C"	P30307	5	138285265-138338355	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Cell division, Host-virus interaction, Mitosis"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"lymphoid tissue: 23.3;testis: 22.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.1;T-reg: 2.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB003800, HPA066991"	Approved		Supported	"Nuclear speckles"				"Nuclear speckles"		"CAB003800: AB_562081, HPA066991: "	"unprognostic (2.45e-3)"	"unprognostic (5.89e-3)"	"prognostic favourable (2.49e-4)"	"unprognostic (9.72e-3)"	"unprognostic (2.17e-1)"	"unprognostic (1.53e-1)"	"prognostic unfavourable (3.03e-6)"	"prognostic unfavourable (4.38e-4)"	"unprognostic (5.56e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.70e-3)"	"unprognostic (1.00e-1)"	"unprognostic (0.00e+0)"	"unprognostic (5.04e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.59e-1)"	"unprognostic (3.06e-1)"	1.1	0.6	0.3	6.7	0.4	5.2	1.1	0.4	0.6	0.6	3.3	0.1	0.7	3.0	0.3	0.6	2.5	0.2	0.4	0.7	0.4	0.4	0.4	0.6	0.7	2.6	0.4	0.3	0.3	0.3	0.0	0.4	1.9	0.3	0.4	4.0	0.0	1.2	0.7	0.2	1.1	3.7	0.5	0.3	1.7	1.2	22.3	0.2	23.3	0.3	1.8	5.0	0.6	0.9	1.0	0.1	0.7	0.0	2.1	2.7	0.5	13.5	5.6	19.0	14.6	0.4	1.9	4.8	8.1	8.8	18.6	25.7	13.6	26.3	6.3	6.9	4.9	7.3	15.6	12.5	18.0	5.2	10.7	4.8	7.7	10.1	0.1	3.2	4.9	0.4	0.5	11.0	9.0	11.9	7.0	12.4	11.3	7.4	8.8	8.1	4.9	6.2	5.8	17.3	7.3	3.2	4.1	9.6	5.9	18.3	5.6	8.7	9.3	6.7	3.6	10.3	8.7	7.1	13.0	7.6	6.2	6.2	4.1	6.9	7.8	0.0	0.0	0.1	0.6	0.0	0.0	1.0	0.5	0.3	0.0	0.2	0.0	0.0	0.7	2.1	0.0	0.1	2.7	0.5	0.3	0.4	0.4	0.6	0.4	0.4	0.4	0.3	0.3	0.2
CDC27	"ANAPC3, APC3, D0S1430E, D17S978E, NUC2"	ENSG00000004897	"Cell division cycle 27"	P30260	17	47117703-47189422	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016315, HPA028129, HPA052399, HPA065835"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB016315: AB_627228, HPA028129: AB_10603559, HPA052399: , HPA065835: "	"unprognostic (2.34e-2)"	"unprognostic (8.83e-3)"	"prognostic favourable (1.77e-4)"	"unprognostic (4.26e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.93e-3)"	"prognostic unfavourable (4.38e-4)"	"prognostic unfavourable (8.15e-4)"	"unprognostic (1.98e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.05e-3)"	"unprognostic (6.17e-2)"	"prognostic unfavourable (6.39e-5)"	"unprognostic (2.64e-1)"	"unprognostic (1.58e-1)"	"unprognostic (7.95e-2)"	"unprognostic (3.66e-2)"	29.2	18.9	19.4	18.7	25.2	23.0	23.3	26.0	33.0	23.7	17.2	14.8	13.8	14.4	23.2	19.6	17.6	17.6	18.6	22.8	18.3	22.6	16.8	23.8	20.4	21.3	19.4	23.9	19.5	14.3	27.8	26.8	25.0	31.5	17.6	18.2	14.6	15.7	16.5	31.6	15.5	15.3	24.4	17.7	24.2	16.1	23.5	17.4	25.2	42.8	15.5	22.9	23.6	17.3	9.0	7.7	9.6	10.3	12.8	11.6	5.4	23.2	24.9	20.9	16.9	14.1	22.5	12.4	32.9	29.7	31.5	32.3	15.9	12.3	31.3	22.2	27.6	11.2	22.5	18.6	43.4	45.0	23.1	36.4	26.4	14.1	15.3	21.4	16.6	16.3	9.2	28.3	22.4	32.5	29.0	17.5	25.6	19.8	26.2	9.7	9.9	20.4	14.1	53.8	13.9	18.9	14.7	13.9	17.0	16.5	5.8	18.3	17.6	15.1	34.5	32.9	28.6	20.8	24.3	17.9	31.0	28.5	18.2	12.8	22.7	9.6	4.4	6.2	8.1	10.3	7.8	6.0	6.8	8.5	6.0	9.0	6.7	7.6	5.7	12.8	7.4	7.7	11.6	5.4	19.4	25.2	26.0	33.0	18.3	22.6	19.4	23.9	31.5	17.4
CDC34	"E2-CDC34, UBC3, UBE2R1"	ENSG00000099804	"Cell division cycle 34"	P49427	19	531712-542092	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA002382, CAB005109, CAB047311"	Approved		Supported	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"CAB005109: AB_2276050, CAB047311: , HPA002382: AB_1846370"	"unprognostic (4.65e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.41e-1)"	"unprognostic (8.72e-2)"	"unprognostic (2.84e-1)"	"unprognostic (5.73e-2)"	"prognostic unfavourable (7.57e-4)"	"unprognostic (2.20e-1)"	"unprognostic (3.11e-1)"	"unprognostic (3.83e-2)"	"unprognostic (2.09e-2)"	"unprognostic (3.06e-2)"	"unprognostic (3.02e-2)"	"unprognostic (8.87e-3)"	"unprognostic (9.68e-2)"	"unprognostic (7.82e-3)"	"unprognostic (3.33e-2)"	16.5	15.9	21.3	11.3	19.1	24.7	20.4	25.7	30.9	16.0	20.5	19.5	10.5	15.4	13.3	13.4	15.6	14.5	13.6	35.6	21.1	18.2	12.1	36.0	13.0	9.9	18.5	19.8	17.0	37.4	11.3	17.0	24.9	16.2	17.2	10.6	15.3	26.4	18.5	63.9	19.0	13.2	18.6	14.3	12.7	15.7	43.6	15.0	12.2	13.1	17.0	8.7	19.2	16.4	2.9	2.8	11.5	4.5	1.5	4.1	1.3	18.4	18.4	23.7	19.5	10.8	10.3	23.7	16.6	12.7	17.9	18.7	28.6	11.3	10.2	17.4	11.8	12.8	18.6	14.0	9.2	16.6	50.0	9.4	12.2	30.9	26.9	13.2	11.4	13.3	21.0	15.1	15.8	21.3	40.2	20.4	11.8	26.4	18.0	17.6	29.9	17.9	16.7	12.2	17.1	13.5	11.0	30.9	22.9	14.4	15.0	27.6	12.0	19.4	17.4	13.1	15.6	30.4	22.1	20.4	15.6	13.6	17.9	18.7	13.5	4.5	3.5	6.2	2.3	3.4	1.7	2.9	3.2	4.1	2.8	1.7	2.5	2.4	11.5	1.5	4.5	2.3	3.1	1.3	21.3	19.1	25.7	30.9	21.1	18.2	18.5	19.8	16.2	15.0
CDC37	P50CDC37	ENSG00000105401	"Cell division cycle 37"	Q16543	19	10391134-10420121	"Cancer-related genes, Predicted intracellular proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003928, CAB004214"	Supported		Supported	Cytosol		260000	260000	Cytosol		"CAB004214: AB_627232, HPA003928: AB_1846373"	"unprognostic (2.40e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.33e-2)"	"unprognostic (2.46e-3)"	"unprognostic (6.21e-2)"	"unprognostic (1.37e-1)"	"unprognostic (7.90e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.61e-3)"	"unprognostic (1.96e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.84e-2)"	"prognostic favourable (2.33e-4)"	"unprognostic (5.80e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.02e-2)"	47.3	29.7	33.0	41.6	33.0	41.8	42.0	35.8	46.8	31.9	35.5	17.8	32.7	31.8	36.3	34.8	37.9	30.1	42.8	49.5	28.1	31.3	33.6	35.6	38.2	33.4	26.6	36.4	34.4	34.2	26.8	24.2	34.3	32.9	31.5	27.7	21.6	37.0	34.4	148.6	29.3	31.3	28.7	23.0	43.5	34.0	23.4	29.8	32.6	33.5	50.7	34.6	33.0	48.0	33.2	45.2	40.0	46.0	40.2	52.3	53.0	52.9	35.2	19.0	27.1	26.2	22.9	24.5	62.9	28.6	39.7	34.1	40.2	20.9	31.6	51.1	38.4	33.1	25.7	40.8	27.5	25.4	75.8	60.0	28.5	56.9	41.4	34.7	27.5	27.9	22.4	46.3	20.9	50.8	46.5	38.3	30.6	50.4	34.6	85.5	46.5	62.5	34.5	25.5	36.2	36.3	34.6	22.2	32.4	29.5	31.2	26.9	21.4	37.5	56.4	46.5	26.7	63.7	50.2	52.2	51.3	39.1	36.5	56.5	37.5	29.2	46.0	40.0	52.3	45.8	47.3	33.2	42.3	46.9	45.2	29.1	33.0	38.1	26.6	40.2	44.1	38.4	44.0	53.0	33.0	33.0	35.8	46.8	28.1	31.3	26.6	36.4	32.9	29.8
CDC6	CDC18L	ENSG00000094804	"Cell division cycle 6"	Q99741	17	40287633-40304657	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA replication, Mitosis"		"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 30.0"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 85.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 6.2"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.2;NK-cells: 2.2;T-cells: 3.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA050114, HPA065070"	Approved		Supported	"Nucleoplasm,Cytokinetic bridge,Mitotic spindle,Cytosol"				"Nucleoplasm, Cytosol"	"Cytokinetic bridge, Mitotic spindle"	"HPA050114: , HPA065070: "	"unprognostic (1.29e-1)"	"unprognostic (7.22e-2)"	"unprognostic (1.23e-3)"	"unprognostic (7.97e-2)"	"unprognostic (7.12e-2)"	"unprognostic (2.89e-2)"	"prognostic unfavourable (5.96e-8)"	"unprognostic (2.31e-3)"	"unprognostic (1.46e-3)"	"unprognostic (1.41e-1)"	"prognostic unfavourable (2.90e-4)"	"unprognostic (5.47e-2)"	"unprognostic (3.00e-15)"	"unprognostic (1.86e-2)"	"unprognostic (1.35e-1)"	"unprognostic (3.95e-3)"	"unprognostic (3.88e-2)"	1.8	2.9	3.1	10.8	2.6	16.8	1.5	2.3	6.0	2.7	5.8	0.8	2.7	5.3	1.9	1.6	9.0	1.3	5.4	1.6	1.9	1.4	1.8	5.1	2.8	10.6	1.0	1.5	1.5	3.6	1.1	1.2	9.4	0.8	1.4	5.6	0.2	3.2	4.1	0.9	2.3	7.9	2.4	1.6	7.7	2.7	14.8	1.2	30.0	1.3	5.0	10.1	4.1	3.0	0.7	6.2	0.2	0.3	2.2	3.4	1.2	25.0	17.3	21.0	14.9	1.1	2.3	19.1	27.3	8.2	23.9	29.0	19.6	11.2	20.2	17.1	5.8	36.4	18.1	12.4	23.8	10.7	14.2	16.4	20.7	17.6	0.7	22.4	10.1	0.5	0.9	27.7	16.7	7.2	29.9	19.0	11.6	13.1	32.5	5.4	17.2	6.4	24.0	51.0	19.1	4.0	28.2	14.4	12.9	24.8	85.2	8.4	17.3	19.4	6.0	17.3	24.7	28.3	32.3	7.9	17.2	39.0	15.0	14.8	18.9	0.1	0.3	0.0	1.3	0.0	0.9	0.7	1.2	2.1	1.4	0.7	0.9	2.1	0.2	2.2	0.0	6.2	3.4	1.2	3.1	2.6	2.3	6.0	1.9	1.4	1.0	1.5	0.8	1.2
CDC73	"C1orf28, FIHP, HRPT1, HRPT2, parafibromin"	ENSG00000134371	"Cell division cycle 73"	Q6P1J9	1	193121997-193253901	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016359, HPA030772"	Supported		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB016359: AB_628102, HPA030772: "	"unprognostic (4.41e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.30e-2)"	"unprognostic (2.88e-3)"	"unprognostic (3.53e-2)"	"unprognostic (2.48e-3)"	"unprognostic (5.74e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.40e-1)"	"unprognostic (7.23e-3)"	"unprognostic (2.17e-1)"	"unprognostic (5.44e-3)"	"unprognostic (3.47e-1)"	"unprognostic (2.49e-1)"	"unprognostic (6.73e-3)"	"unprognostic (2.98e-3)"	23.4	20.0	18.1	16.8	22.9	21.0	20.1	25.6	22.6	20.4	20.1	14.5	16.3	12.0	26.8	15.2	20.6	14.9	16.4	21.4	18.4	15.0	18.8	17.1	17.2	16.6	19.7	15.9	23.3	14.5	27.1	24.8	17.3	19.4	26.9	16.2	13.6	17.3	19.0	44.5	15.0	14.5	25.6	23.9	16.0	15.7	16.3	22.1	20.6	27.1	14.1	15.8	26.8	35.0	6.6	6.7	10.2	7.0	9.0	12.5	5.2	13.3	12.0	15.9	10.2	14.9	14.5	12.2	14.4	14.0	17.4	15.3	8.2	15.9	17.4	10.2	17.7	13.1	14.4	13.6	21.3	11.0	6.8	12.6	10.9	8.0	14.0	17.1	12.6	11.8	13.2	16.3	15.6	14.8	19.1	14.1	23.3	12.3	13.9	8.5	15.3	4.5	12.5	9.6	16.6	20.4	9.3	4.8	13.1	18.0	22.2	20.5	19.1	12.4	16.5	17.0	3.9	14.4	14.7	13.2	9.8	14.3	10.2	10.5	29.6	6.6	7.0	10.2	9.3	6.8	12.5	6.6	9.2	9.2	6.7	5.4	8.4	8.7	7.4	9.0	5.7	4.9	9.3	5.2	18.1	22.9	25.6	22.6	18.4	15.0	19.7	15.9	19.4	22.1
CDH1	"CD324, UVO, uvomorulin"	ENSG00000039068	"Cadherin 1"	P12830	16	68737225-68835548	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 125.5"	"Cell line enhanced"	"Detected in some"		"BEWO: 105.6;CACO-2: 35.5;CAPAN-2: 49.6;HaCaT: 47.9;hTCEpi: 33.8;MCF7: 29.3;RT4: 36.5;T-47d: 31.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"myeloid DC: 2.8;plasmacytoid DC: 8.5"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 8.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857"	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cell Junctions"		22000000	22000000	"Plasma membrane, Cell Junctions"	"Golgi apparatus"	"CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: , CAB072856: , CAB072857: , HPA004812: AB_1078369"	"unprognostic (3.95e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.78e-1)"	"unprognostic (5.04e-3)"	"unprognostic (1.63e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.85e-1)"	"unprognostic (1.19e-2)"	"unprognostic (3.61e-1)"	"prognostic favourable (2.06e-4)"	"unprognostic (1.21e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.51e-1)"	"unprognostic (5.92e-2)"	1.1	0.7	1.3	14.8	1.5	0.5	15.3	0.8	1.1	14.4	63.8	1.8	42.4	25.5	4.7	18.6	48.5	9.7	48.9	0.8	1.5	1.0	24.2	64.9	24.4	0.5	1.8	0.9	5.6	71.5	62.2	13.2	55.2	2.8	28.9	25.9	11.8	66.6	43.7	0.8	30.5	125.5	1.5	1.1	3.5	21.6	2.1	1.8	11.7	83.0	26.2	32.6	16.8	21.7	0.0	8.5	0.0	0.0	0.3	0.4	0.1	21.3	2.2	0.0	0.0	0.0	0.0	105.6	0.0	0.0	0.0	0.0	35.5	49.6	0.0	0.4	0.0	47.9	0.0	23.8	0.0	4.1	0.6	0.0	0.1	7.6	0.0	0.0	0.2	0.0	33.8	0.0	0.0	0.0	0.0	0.0	0.0	29.3	0.0	0.1	0.8	0.1	0.0	0.0	0.3	8.7	36.5	1.3	0.1	0.2	0.0	9.0	31.5	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	2.8	0.0	0.0	0.0	0.0	0.3	0.0	8.5	0.1	0.1	1.3	1.5	0.8	1.1	1.5	1.0	1.8	0.9	2.8	1.8
CDH11	"CAD11, OB"	ENSG00000140937	"Cadherin 11"	P55287	16	64943753-65126112	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Deafness, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 71.0"	"Cell line enhanced"	"Detected in many"		"BJ: 47.1;fHDF/TERT166: 64.3;HSkMC: 44.3;PC-3: 55.3;U-2197: 37.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013072	Enhanced					70000	70000			"CAB013072: AB_2533068"	"unprognostic (1.77e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.93e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.02e-1)"	"unprognostic (6.96e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.09e-1)"	"unprognostic (2.30e-2)"	"unprognostic (3.74e-2)"	"unprognostic (6.75e-2)"	"prognostic unfavourable (2.48e-9)"	"unprognostic (1.43e-3)"	"unprognostic (3.20e-2)"	"unprognostic (1.26e-1)"	"unprognostic (5.07e-3)"	8.1	3.6	5.5	9.2	12.1	0.3	6.1	5.5	8.8	24.1	4.3	7.5	2.4	2.7	25.9	5.9	3.0	6.8	22.4	4.6	7.3	5.1	4.8	1.0	20.8	5.9	7.8	8.5	71.0	1.7	1.2	6.0	44.2	8.3	8.0	4.9	22.2	7.3	9.7	2.5	5.7	3.4	20.5	10.6	35.1	5.1	4.0	5.4	0.1	4.8	1.9	4.9	18.4	11.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	10.2	0.0	7.3	15.9	0.0	47.1	27.3	12.1	6.9	0.8	0.0	0.0	0.0	64.3	0.0	0.0	0.3	8.7	0.0	0.4	0.0	0.2	0.0	6.0	0.0	2.8	44.3	0.0	14.8	3.0	3.4	0.0	0.0	6.4	0.0	0.0	0.0	3.7	55.3	0.1	7.3	0.0	0.0	0.0	0.1	7.0	0.0	0.0	0.0	0.0	0.0	0.0	25.0	3.4	37.8	13.3	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	12.1	5.5	8.8	7.3	5.1	7.8	8.5	8.3	5.4
CDH17	"cadherin, HPT-1"	ENSG00000079112	"Cadherin 17"	Q12864	8	94127171-94217303	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"intestine: 184.4"	"Group enriched"	"Detected in some"	7	"CACO-2: 33.3;U-266/70: 55.3"	"Group enriched"	"Detected in many"	6	"colorectal cancer: 156.4;stomach cancer: 54.9"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 12.1"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 12.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA023614, HPA023616, CAB025143, HPA026556"	Enhanced		Enhanced	"Nucleoplasm,Cell Junctions"		3400000	3400000	"Cell Junctions"	Nucleoplasm	"CAB025143: , HPA023614: AB_1845896, HPA023616: AB_1845895, HPA026556: AB_1845897"	"unprognostic (2.08e-1)"	"unprognostic (5.00e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.09e-1)"	"unprognostic (3.02e-1)"	"unprognostic (3.06e-2)"	"unprognostic (5.60e-2)"	"unprognostic (3.38e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.47e-2)"	"unprognostic (3.74e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.31e-1)"	"unprognostic (7.33e-2)"	"unprognostic (1.46e-2)"	0.3	0.2	0.2	17.6	0.3	0.3	0.3	0.2	0.2	0.3	88.9	0.2	0.2	54.5	0.4	0.3	0.4	0.4	7.0	0.6	0.2	0.3	0.3	0.3	0.3	0.5	0.2	0.2	0.3	0.4	0.0	0.3	0.2	0.2	0.4	44.0	0.2	0.3	0.2	0.3	0.2	184.4	1.4	0.2	0.6	0.3	0.3	0.2	0.3	0.2	0.2	0.5	0.4	0.3	1.5	0.8	12.1	1.0	1.4	0.6	0.1	0.1	6.1	0.3	0.4	0.0	0.1	0.5	0.1	0.1	0.0	0.1	33.3	1.5	0.2	0.1	0.0	0.4	0.1	0.1	0.1	0.1	0.5	0.1	0.6	0.2	0.1	0.1	1.7	0.0	0.0	0.1	0.0	0.0	0.2	0.7	0.0	0.4	0.2	0.5	0.2	0.2	0.4	0.1	1.0	0.1	0.1	0.6	0.4	0.2	0.2	0.2	0.3	0.3	0.2	0.3	0.3	0.5	0.2	55.3	0.1	0.1	0.1	0.2	0.3	2.5	1.0	1.2	0.5	0.8	0.3	0.6	0.5	0.4	0.8	1.5	0.5	0.6	12.1	1.4	0.5	0.7	0.5	0.1	0.2	0.3	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2
CDH5	"7B4, CD144"	ENSG00000179776	"Cadherin 5"	P33151	16	66366622-66404786	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 96.6"	"Group enriched"	"Detected in some"	6	"HUVEC TERT2: 111.2;TIME: 95.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB028366, HPA075875"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Plasma membrane"		1000000000	1000000000	"Plasma membrane"	"Nucleoplasm, Nuclear membrane"	"CAB028366: AB_2276033, HPA075875: "	"unprognostic (1.05e-1)"	"unprognostic (8.13e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.89e-2)"	"unprognostic (4.96e-2)"	"unprognostic (5.50e-3)"	"unprognostic (9.38e-2)"	"unprognostic (5.28e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.33e-2)"	"unprognostic (2.32e-1)"	"prognostic unfavourable (5.14e-4)"	"unprognostic (9.49e-3)"	"unprognostic (3.01e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.15e-2)"	48.7	5.6	4.0	6.2	5.8	0.6	28.1	2.6	4.8	11.1	6.6	3.4	5.5	3.7	18.7	11.2	8.4	7.2	12.6	21.7	4.5	4.3	7.8	12.7	43.7	9.7	6.5	2.8	7.7	3.6	5.0	3.5	96.6	7.6	9.0	4.8	8.5	5.2	4.4	19.0	7.0	6.8	12.1	5.4	10.8	5.7	6.7	3.3	1.2	16.6	15.7	4.5	11.7	11.3	0.0	0.6	0.4	0.8	0.1	0.1	1.1	0.0	0.0	0.6	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	111.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	95.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.4	0.1	0.0	0.6	0.1	1.1	4.0	5.8	2.6	4.8	4.5	4.3	6.5	2.8	7.6	3.3
CDK1	"CDC2, CDC28A"	ENSG00000170312	"Cyclin dependent kinase 1"	P06493	10	60778331-60794852	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Apoptosis, Biological rhythms, Cell cycle, Cell division, Host-virus interaction, Mitosis"	"Host cell receptor for virus entry, Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 88.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"NK-cell: 6.1;T-reg: 5.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.7;NK-cells: 6.1;T-cells: 5.7"	"Low region specificity"	"Detected in single"							"HPA003387, CAB003799"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB003799: AB_344898, HPA003387: AB_1846356"	"unprognostic (6.34e-2)"	"prognostic favourable (8.81e-4)"	"unprognostic (1.90e-1)"	"unprognostic (6.82e-2)"	"unprognostic (6.67e-2)"	"unprognostic (3.83e-2)"	"prognostic unfavourable (1.10e-6)"	"prognostic unfavourable (7.88e-4)"	"unprognostic (1.30e-2)"	"unprognostic (1.30e-1)"	"prognostic unfavourable (4.15e-6)"	"unprognostic (1.80e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (2.27e-1)"	"unprognostic (2.75e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.60e-1)"	4.1	2.2	0.8	17.8	2.4	17.8	4.4	0.7	1.6	4.2	6.5	1.1	3.4	6.1	2.9	4.8	19.0	1.5	2.4	2.3	0.9	0.7	3.1	1.7	5.7	15.1	1.7	0.6	2.2	1.0	0.5	4.4	13.3	1.2	1.5	8.3	1.0	3.8	2.9	1.0	4.9	8.3	2.7	2.5	8.3	5.0	13.8	1.2	88.4	1.8	16.7	20.1	3.2	6.9	0.9	1.7	0.0	0.2	6.1	5.7	1.8	48.2	18.4	48.9	19.3	3.2	4.9	20.1	36.5	26.6	44.5	42.9	43.0	42.7	44.2	14.2	10.0	30.0	33.2	21.2	46.4	31.4	24.2	23.2	18.1	24.9	0.5	35.5	24.0	0.9	2.1	28.8	28.1	26.7	35.3	54.5	49.5	12.8	44.6	25.5	21.5	38.7	38.8	45.5	21.7	17.0	16.0	22.9	20.1	24.5	37.3	18.9	40.2	21.8	11.0	19.0	40.6	20.0	49.8	21.4	34.3	39.9	16.4	39.8	23.6	0.0	0.0	0.0	0.5	0.2	0.5	0.9	1.5	2.7	0.5	0.5	0.5	1.5	0.0	6.1	0.2	1.7	5.7	1.8	0.8	2.4	0.7	1.6	0.9	0.7	1.7	0.6	1.2	1.2
CDK12	"CRK7, CRKR, CRKRS, KIAA0904"	ENSG00000167258	"Cyclin dependent kinase 12"	Q9NYV4	17	39461511-39564907	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 85.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008038, HPA073305"	Supported		Enhanced	"Nucleoplasm,Nuclear speckles"				"Nucleoplasm, Nuclear speckles"		"HPA008038: AB_1078570, HPA073305: "	"unprognostic (2.02e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.19e-1)"	"unprognostic (2.56e-3)"	"unprognostic (2.37e-2)"	"unprognostic (3.86e-2)"	"unprognostic (3.00e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.86e-1)"	"unprognostic (3.06e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.22e-2)"	"unprognostic (5.32e-1)"	16.0	13.1	12.4	17.4	9.2	32.4	14.0	23.4	17.8	18.2	17.6	9.6	15.7	11.1	15.7	12.0	16.9	12.2	12.5	11.0	10.1	6.7	10.2	18.5	13.5	15.2	10.9	14.3	17.4	11.3	19.0	12.2	18.4	9.5	12.7	11.7	10.4	15.6	11.1	11.1	17.0	16.5	11.0	10.6	16.3	11.8	18.9	8.3	29.0	15.0	5.4	17.3	16.3	20.5	5.1	4.0	10.4	2.9	6.6	4.0	0.9	8.7	10.8	6.5	6.1	4.8	5.4	6.1	7.9	6.7	10.9	8.1	13.3	5.4	12.4	7.0	8.3	14.2	13.0	10.0	10.5	8.1	11.2	13.4	7.4	10.3	4.7	18.3	9.4	5.8	6.9	13.2	10.5	6.6	22.7	8.2	6.2	4.1	14.9	4.7	6.8	4.9	9.9	14.1	7.0	4.1	10.5	7.0	4.5	10.1	85.6	6.9	11.0	7.9	7.1	9.9	7.9	6.9	10.2	6.7	4.8	17.5	7.0	7.8	6.4	10.4	2.9	4.1	4.0	2.2	3.0	2.9	2.5	2.7	1.8	5.1	2.9	2.7	9.7	6.6	1.8	4.0	2.0	0.9	12.4	9.2	23.4	17.8	10.1	6.7	10.9	14.3	9.5	8.3
CDK2		ENSG00000123374	"Cyclin dependent kinase 2"	P24941	12	55966769-55972784	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 105.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 88.3"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB013115, HPA066915"	Enhanced		Enhanced	Nucleoplasm,Centrosome,Cytosol				Nucleoplasm	"Centrosome, Cytosol"	"CAB013115: AB_2536375, HPA066915: "	"unprognostic (2.36e-2)"	"unprognostic (2.60e-1)"	"unprognostic (3.71e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.75e-1)"	"prognostic unfavourable (9.94e-4)"	"prognostic unfavourable (8.61e-5)"	"unprognostic (3.48e-2)"	"unprognostic (1.31e-1)"	"unprognostic (4.67e-2)"	"unprognostic (5.38e-3)"	"unprognostic (4.69e-3)"	"prognostic unfavourable (1.46e-10)"	"unprognostic (1.05e-1)"	"unprognostic (1.76e-1)"	"unprognostic (6.16e-2)"	"unprognostic (6.75e-2)"	10.7	7.6	4.5	20.8	6.5	18.7	11.5	4.2	4.3	12.6	11.6	3.5	6.0	6.1	10.7	6.4	13.6	10.8	12.6	10.1	5.4	2.2	8.3	16.7	19.5	12.2	6.0	2.0	14.2	8.3	5.2	4.2	49.0	7.3	10.8	9.1	51.2	9.3	9.9	10.8	14.6	9.3	11.8	5.0	12.5	10.1	7.8	5.1	39.3	9.5	10.7	14.7	16.7	10.1	9.3	10.8	5.2	3.9	4.5	7.6	4.3	16.5	8.9	19.6	10.9	4.0	5.2	36.2	20.6	10.8	25.6	24.0	18.7	15.9	15.7	15.5	7.6	10.6	14.9	9.0	26.1	18.5	14.6	18.1	14.8	7.1	1.3	14.3	13.1	2.7	2.3	17.3	6.0	12.9	17.2	14.3	17.8	12.7	29.6	12.1	7.8	13.3	29.0	18.9	11.8	7.4	16.2	8.1	10.5	23.5	8.6	105.5	18.6	10.5	7.2	17.7	17.2	13.6	15.0	8.2	9.4	19.6	10.0	10.5	15.2	5.2	3.6	3.1	7.0	3.9	7.0	9.3	3.2	5.0	2.7	6.1	3.0	5.3	1.7	4.5	1.6	10.8	7.6	4.3	4.5	6.5	4.2	4.3	5.4	2.2	6.0	2.0	7.3	5.1
CDK4	PSK-J3	ENSG00000135446	"Cyclin dependent kinase 4"	P11802	12	57747727-57756013	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in all"	10	"HBEC3-KT: 125.1;LHCN-M2: 138.1;RH-30: 434.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006024, CAB013116, CAB069405"	Supported		Supported	"Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol"				Cytosol	"Nucleoplasm, Nuclear membrane, Nucleoli"	"CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: "	"unprognostic (8.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (5.27e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (2.09e-7)"	"unprognostic (7.39e-2)"	"unprognostic (3.23e-3)"	"unprognostic (2.93e-2)"	"unprognostic (3.19e-2)"	"unprognostic (9.10e-2)"	"prognostic unfavourable (3.15e-5)"	"unprognostic (3.32e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.57e-2)"	32.2	43.1	13.8	22.2	15.7	24.0	45.0	13.1	17.9	36.3	28.2	20.1	22.8	15.2	51.4	28.1	29.9	31.0	32.3	27.4	14.5	12.1	24.0	36.9	26.8	26.4	18.3	13.7	61.4	54.4	18.9	34.2	25.0	16.0	37.2	26.9	26.2	29.3	24.1	27.8	25.6	20.7	34.1	13.5	27.2	23.9	24.6	17.5	29.2	54.3	32.1	27.5	33.6	30.9	29.6	25.5	2.6	19.9	15.8	32.1	22.2	9.3	10.8	14.3	12.7	13.1	11.5	9.5	5.4	17.6	23.8	19.8	15.4	8.9	13.6	9.7	8.4	7.2	19.7	125.1	18.1	6.7	9.1	12.7	7.3	10.8	15.4	14.4	8.8	11.3	9.2	14.6	16.8	15.3	13.5	11.7	138.1	13.5	13.7	11.7	16.8	11.0	12.4	434.6	12.6	7.4	14.7	12.9	12.1	9.5	7.2	14.4	9.6	17.5	6.9	11.2	10.5	12.6	10.9	5.8	9.5	20.9	10.3	13.3	13.4	1.7	14.3	2.6	26.2	19.9	27.0	29.6	23.1	23.7	21.0	28.1	32.1	28.5	1.2	15.8	12.0	25.5	16.6	22.2	13.8	15.7	13.1	17.9	14.5	12.1	18.3	13.7	16.0	17.5
CDK6	PLSTIRE	ENSG00000105810	"Cyclin dependent kinase 6"	Q00534	7	92604921-92836594	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 74.6"	"Cell line enhanced"	"Detected in many"		"MOLT-4: 91.7;REH: 44.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA002637, CAB004363"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB004363: AB_627242, HPA002637: AB_1846432"	"unprognostic (1.29e-1)"	"unprognostic (5.98e-3)"	"unprognostic (9.07e-2)"	"unprognostic (2.78e-3)"	"unprognostic (2.56e-2)"	"unprognostic (3.24e-2)"	"unprognostic (3.39e-1)"	"unprognostic (2.42e-3)"	"unprognostic (7.19e-2)"	"unprognostic (7.78e-3)"	"prognostic unfavourable (3.86e-6)"	"unprognostic (4.06e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.09e-1)"	"unprognostic (7.88e-2)"	"unprognostic (1.93e-1)"	"prognostic unfavourable (2.33e-5)"	6.6	11.3	6.0	9.1	7.5	22.5	5.9	2.4	6.0	7.8	10.0	9.6	5.7	7.5	6.0	5.9	8.5	4.6	7.8	6.6	6.9	4.2	6.5	7.5	7.3	7.4	7.0	5.2	5.0	10.0	25.7	4.2	20.5	7.5	6.1	9.2	4.4	10.9	6.1	2.0	11.6	9.4	9.8	7.5	6.3	10.8	5.4	8.0	74.6	4.3	9.2	10.3	6.7	9.0	3.6	5.6	6.5	4.8	3.9	7.1	2.3	6.0	2.8	7.8	5.0	2.3	2.6	1.6	6.3	3.9	3.1	3.0	7.7	4.7	4.7	3.6	4.2	3.8	4.3	9.0	7.4	10.3	3.0	11.8	5.4	7.4	1.4	7.3	0.5	2.5	4.9	4.2	20.0	1.2	11.2	13.0	5.6	1.2	91.7	0.7	2.4	2.6	44.8	27.6	7.9	4.3	0.1	4.1	26.8	0.7	2.1	3.7	0.1	12.0	4.6	10.3	16.1	4.0	12.6	7.0	0.1	6.3	1.5	25.0	13.6	4.9	1.9	6.5	5.2	3.9	5.9	2.0	5.5	5.6	4.0	3.6	7.1	4.0	1.1	3.9	4.8	5.6	2.8	2.3	6.0	7.5	2.4	6.0	6.9	4.2	7.0	5.2	7.5	8.0
CDK7	"CAK, CAK1, CDKN7, MO15, STK1"	ENSG00000134058	"Cyclin dependent kinase 7"	P50613	5	69234795-69277430	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA repair, Transcription, Transcription regulation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004364, HPA007932"	Enhanced									"CAB004364: AB_627243, HPA007932: AB_1078492"	"unprognostic (3.12e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.87e-2)"	"unprognostic (4.53e-2)"	"unprognostic (3.29e-2)"	"unprognostic (4.64e-2)"	"unprognostic (2.49e-3)"	"unprognostic (1.64e-2)"	"unprognostic (7.77e-3)"	"unprognostic (1.81e-2)"	"prognostic unfavourable (3.09e-4)"	"unprognostic (3.40e-2)"	"prognostic unfavourable (9.42e-7)"	"unprognostic (2.61e-1)"	"unprognostic (2.38e-1)"	"unprognostic (3.86e-2)"	"unprognostic (1.55e-2)"	7.9	12.9	10.9	6.2	15.2	44.1	14.0	10.8	14.7	9.4	12.7	6.0	6.3	15.8	9.4	8.6	23.4	18.5	16.5	8.1	11.5	9.3	13.8	10.6	10.1	8.8	7.6	9.7	7.7	9.1	3.3	16.2	22.9	11.2	11.2	14.8	6.6	13.2	6.5	15.9	15.4	9.8	12.1	9.2	7.9	13.9	29.0	7.8	12.1	20.0	15.6	15.5	10.7	11.7	15.6	15.0	22.4	11.3	12.4	15.3	7.8	3.7	7.8	1.8	0.5	2.4	11.6	14.7	6.5	7.7	10.8	17.5	16.7	1.9	2.8	10.2	1.7	2.5	1.4	2.8	5.9	1.3	7.0	0.4	8.2	7.9	0.4	6.7	3.2	14.3	13.9	9.0	2.8	13.6	10.4	4.5	4.9	0.7	4.1	14.8	1.7	7.5	6.7	0.4	1.1	1.6	1.0	0.6	6.5	1.5	5.8	3.4	11.6	0.6	2.6	0.1	3.2	0.9	5.1	4.8	8.4	3.7	0.8	4.0	0.8	7.3	10.9	22.4	8.6	11.3	14.8	12.4	12.9	15.3	15.0	15.6	11.1	13.2	10.0	12.4	8.0	11.2	12.8	7.8	10.9	15.2	10.8	12.7	11.5	9.3	7.6	9.7	11.2	7.8
CDKN1A	"CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1"	ENSG00000124762	"Cyclin dependent kinase inhibitor 1A"	P38936	6	36676460-36687339	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle"	"Protein kinase inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 97.4;HSkMC: 71.6;hTCEpi: 92.6;LHCN-M2: 72.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 21.0;non-classical monocyte: 27.7"	"Group enriched"	"Detected in many"	8	"B-cells: 8.8;dendritic cells: 8.5;monocytes: 27.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000064, HPA005946, CAB069401"	Supported		Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB000064: , CAB069401: AB_1620493, HPA005946: "	"unprognostic (7.99e-3)"	"unprognostic (4.01e-2)"	"unprognostic (1.58e-1)"	"prognostic favourable (3.14e-5)"	"unprognostic (1.57e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.39e-2)"	"prognostic unfavourable (7.05e-4)"	"unprognostic (1.30e-1)"	"unprognostic (7.27e-2)"	"unprognostic (2.79e-2)"	"unprognostic (7.55e-3)"	"prognostic favourable (4.95e-5)"	"unprognostic (8.32e-2)"	"unprognostic (6.52e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.21e-2)"	81.2	27.0	8.2	21.9	29.8	22.0	38.0	4.8	13.7	25.2	60.8	13.9	10.2	39.8	17.5	17.7	63.5	49.4	47.3	35.9	22.2	8.4	29.1	102.2	55.8	6.3	16.6	4.9	59.1	45.5	12.8	22.8	38.6	44.1	42.0	40.7	8.8	18.0	11.4	98.6	43.5	144.9	40.2	29.6	13.6	25.2	25.3	10.3	6.6	22.7	42.2	27.4	50.5	44.4	8.8	8.5	1.8	27.7	0.2	1.1	13.3	3.0	12.4	9.6	0.2	33.8	60.5	17.6	50.3	40.8	6.2	24.5	1.1	2.9	2.0	1.8	31.5	6.9	0.4	55.5	10.1	4.0	2.5	0.3	10.3	15.4	97.4	0.0	15.1	71.6	92.6	57.1	18.0	32.4	0.5	14.2	72.2	6.4	0.4	1.2	1.2	1.8	6.1	7.9	3.5	11.0	23.1	4.3	4.2	11.6	1.0	2.3	3.8	12.6	17.9	10.9	10.3	0.7	4.1	23.9	4.6	6.1	14.1	1.1	30.3	0.0	9.3	0.2	0.2	21.0	0.3	8.8	0.4	0.3	8.0	5.7	0.1	0.1	1.8	0.2	27.7	8.5	1.1	13.3	8.2	29.8	4.8	13.7	22.2	8.4	16.6	4.9	44.1	10.3
CDKN1B	"KIP1, P27KIP1"	ENSG00000111276	"Cyclin dependent kinase inhibitor 1B"	P46527	12	12715058-12722371	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle"	"Protein kinase inhibitor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003691, CAB021888, HPA059086"	Approved		Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB003691: AB_425362, CAB021888: , HPA059086: "	"unprognostic (5.67e-2)"	"unprognostic (9.76e-2)"	"prognostic favourable (5.15e-4)"	"unprognostic (6.90e-3)"	"unprognostic (5.84e-3)"	"unprognostic (1.03e-2)"	"prognostic unfavourable (3.25e-4)"	"unprognostic (4.04e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.85e-3)"	"unprognostic (9.23e-3)"	"unprognostic (2.96e-1)"	"prognostic unfavourable (8.39e-4)"	"unprognostic (1.23e-1)"	"unprognostic (8.68e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.15e-1)"	29.8	30.9	30.2	25.0	30.0	40.2	45.3	64.5	50.6	31.6	34.4	35.6	19.9	29.2	33.1	19.8	26.0	24.3	24.3	21.2	33.0	29.5	20.8	23.3	29.2	38.5	42.9	25.1	46.2	15.1	22.2	15.9	26.8	26.3	25.1	22.2	31.4	23.5	24.2	48.8	26.1	26.4	19.4	46.0	34.3	19.4	19.2	39.0	43.0	29.4	21.4	25.5	34.1	29.1	6.2	3.3	19.2	4.5	6.2	10.6	2.9	12.8	6.4	34.3	5.9	11.8	6.7	16.8	12.1	19.2	16.7	20.6	18.3	14.6	0.1	4.6	6.9	12.3	16.0	5.9	15.0	21.8	11.3	10.0	17.6	18.4	15.8	8.5	7.1	7.4	12.8	5.5	16.1	9.9	10.7	36.7	5.9	16.5	11.9	12.2	13.7	6.0	8.8	11.2	21.5	8.0	13.9	13.0	21.4	17.3	12.5	22.6	6.6	19.1	6.7	8.3	13.2	7.5	11.7	31.8	21.0	11.6	10.3	12.8	8.0	4.5	3.1	6.8	5.4	3.1	5.6	6.2	6.9	6.5	3.2	4.8	7.4	5.2	19.2	6.2	4.5	3.3	10.6	2.9	30.2	30.0	64.5	50.6	33.0	29.5	42.9	25.1	26.3	39.0
CDKN1C	"BWCR, BWS, KIP2, P57"	ENSG00000129757	"Cyclin dependent kinase inhibitor 1C"	P49918	11	2883213-2885773	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle"	"Protein kinase inhibitor"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 60.3;placenta: 105.6"	"Cell line enhanced"	"Detected in many"		"EFO-21: 8.3;HeLa: 8.5;RPMI-8226: 11.2;SH-SY5Y: 22.8;SiHa: 15.9;SK-MEL-30: 8.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"intermediate monocyte: 26.1;non-classical monocyte: 60.3"	"Lineage enriched"	"Detected in many"	12	"monocytes: 60.3"									HPA002924	Enhanced		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"				"Nucleoplasm, Nuclear bodies, Cytosol"		"HPA002924: AB_1079548"	"unprognostic (5.49e-3)"	"unprognostic (2.62e-1)"	"unprognostic (9.82e-3)"	"unprognostic (5.79e-3)"	"unprognostic (4.15e-1)"	"unprognostic (2.84e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.85e-1)"	"unprognostic (3.13e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.95e-1)"	"unprognostic (3.39e-2)"	"unprognostic (2.15e-1)"	"unprognostic (3.31e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.93e-1)"	"unprognostic (2.94e-1)"	53.6	20.7	3.3	5.4	11.9	3.4	13.0	0.9	9.2	10.6	6.9	18.4	3.9	3.3	8.3	5.2	9.9	8.5	7.7	6.9	8.5	5.4	22.7	3.0	5.1	1.8	28.7	4.9	30.9	7.9	1.5	4.0	105.6	11.5	7.2	1.9	8.3	3.1	5.9	27.6	3.0	7.9	6.3	27.9	7.1	7.4	4.3	14.5	0.3	2.0	7.6	2.1	11.2	9.8	0.0	5.0	1.4	60.3	0.0	0.3	2.5	0.1	0.0	1.1	0.0	0.3	0.3	1.2	0.2	0.4	0.2	0.0	2.2	0.2	0.0	8.3	0.1	0.3	0.2	0.2	0.1	3.7	0.8	0.1	8.5	0.0	2.3	0.0	1.0	1.7	1.1	0.0	0.1	0.2	1.8	0.6	0.3	0.0	0.0	3.9	7.4	2.7	1.4	0.0	11.2	0.4	0.0	2.4	22.8	15.9	0.2	8.7	0.1	1.8	0.3	0.0	1.5	0.0	0.0	4.8	0.0	0.0	0.0	1.2	4.5	1.4	0.2	0.2	0.1	26.1	0.3	0.0	0.1	0.1	5.0	0.0	0.2	0.0	0.3	0.0	60.3	0.0	0.1	2.5	3.3	11.9	0.9	5.6	8.5	5.4	28.7	4.9	11.5	14.5
CDKN2A	"ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf"	ENSG00000147889	"Cyclin dependent kinase inhibitor 2A"	"P42771, Q8N726"	9	21967753-21995301	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway"	DNA-binding	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 22.6;pituitary gland: 39.3"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 50.0;HEK 293: 56.7;HeLa: 53.1;SK-MEL-30: 53.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 22.6"	"Group enriched"	"Detected in many"	8	"B-cells: 7.2;T-cells: 22.6"					"Low region specificity"	"Detected in many"			"CAB000093, CAB000445, CAB018232, HPA047838"	Enhanced		Supported	Nucleoli				Nucleoli		"CAB000093: AB_442119, CAB000445: , CAB018232: AB_785018, HPA047838: "	"unprognostic (3.41e-2)"	"unprognostic (4.51e-2)"	"unprognostic (3.00e-3)"	"prognostic unfavourable (1.82e-7)"	"unprognostic (5.22e-2)"	"prognostic favourable (5.19e-4)"	"prognostic unfavourable (2.17e-4)"	"unprognostic (1.25e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.56e-2)"	"prognostic unfavourable (5.76e-7)"	"unprognostic (9.41e-2)"	"unprognostic (1.22e-2)"	"unprognostic (3.05e-2)"	"unprognostic (3.55e-1)"	5.4	8.6	2.9	4.5	3.9	1.8	5.3	1.7	3.1	1.2	2.5	4.4	0.1	1.2	1.2	1.9	6.3	3.0	2.6	0.7	1.7	1.0	0.9	1.2	3.0	3.0	3.6	1.6	1.5	1.5	8.5	39.3	6.7	5.0	1.9	1.1	1.2	2.4	2.9	0.9	1.3	3.7	1.0	3.0	8.9	6.0	13.0	1.9	3.9	1.4	3.0	14.0	2.7	1.5	7.2	0.2	0.8	1.8	0.4	22.6	2.2	2.1	0.0	0.3	14.1	0.1	0.1	6.1	2.3	0.0	19.6	34.9	3.5	50.0	7.2	32.2	1.6	6.0	5.9	36.4	15.8	30.9	56.7	0.0	53.1	2.3	1.5	3.5	3.0	3.8	0.0	19.8	11.0	2.0	0.0	32.9	17.9	0.1	0.3	0.0	0.4	29.2	0.0	13.3	26.4	4.0	0.0	33.0	2.3	38.0	6.3	53.0	7.5	0.1	6.5	0.1	0.4	0.0	0.1	14.7	8.3	29.4	0.0	9.4	0.1	0.8	1.3	0.2	6.2	0.6	9.7	7.2	8.0	11.0	0.2	7.0	0.5	4.7	0.4	0.4	1.8	0.0	22.6	2.2	2.9	3.9	1.7	3.1	1.7	1.0	3.6	1.6	5.0	1.9
CDKN2C	"INK4C, p18"	ENSG00000123080	"Cyclin dependent kinase inhibitor 2C"	P42773	1	50960745-50974633	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-937: 52.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB005303, CAB018398, HPA019057, HPA019764"	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB005303: AB_2078729, CAB018398: AB_2078731, HPA019057: AB_1854865, HPA019764: AB_1854866"	"unprognostic (4.07e-2)"	"unprognostic (1.47e-3)"	"unprognostic (2.89e-1)"	"unprognostic (4.86e-2)"	"unprognostic (6.70e-2)"	"unprognostic (4.76e-3)"	"prognostic unfavourable (1.58e-4)"	"unprognostic (1.59e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.28e-1)"	"unprognostic (2.38e-1)"	"prognostic unfavourable (1.70e-10)"	"unprognostic (2.55e-2)"	"unprognostic (2.12e-1)"	"unprognostic (6.45e-2)"	"unprognostic (1.24e-1)"	42.1	12.6	5.9	10.7	7.9	14.9	31.7	4.3	5.7	13.1	13.0	8.7	7.7	6.6	17.1	13.9	11.5	8.4	13.7	20.1	5.7	3.1	7.4	3.3	7.9	11.0	13.7	5.3	22.5	9.4	23.1	5.7	3.1	3.9	10.3	5.7	6.0	5.4	12.2	9.2	8.5	7.9	15.1	7.5	8.5	5.3	5.3	8.9	54.2	8.0	4.9	9.8	17.4	21.7	3.4	7.4	12.2	2.5	6.0	14.1	3.8	13.8	5.7	1.0	19.1	19.7	2.8	0.2	13.2	13.4	22.2	19.5	0.3	4.7	27.2	11.9	11.2	1.7	12.9	1.7	10.9	16.4	17.3	20.6	43.6	3.5	1.0	14.3	9.4	1.0	0.3	6.0	2.6	5.8	9.2	0.0	12.9	3.4	18.4	6.9	0.0	14.0	22.0	18.0	0.0	7.0	5.8	9.7	22.7	18.0	12.7	4.2	6.3	48.6	4.6	25.5	9.8	15.4	0.2	27.9	26.5	22.4	0.0	52.3	22.4	12.2	2.5	11.0	5.2	1.4	6.0	3.4	7.7	6.8	6.1	1.9	4.3	4.1	0.2	6.0	0.6	7.4	14.1	3.8	5.9	7.9	4.3	5.7	5.7	3.1	13.7	5.3	3.9	8.9
CDX2	CDX3	ENSG00000165556	"Caudal type homeobox 2"	Q99626	13	27962137-27971139	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"intestine: 21.2"	"Group enriched"	"Detected in some"	6	"CACO-2: 14.4;CAPAN-2: 4.8;HEK 293: 8.0"	"Cancer enriched"	"Detected in many"	6	"colorectal cancer: 63.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB002221, HPA045669, HPA049580"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002221: AB_563649, HPA045669: , HPA049580: "		"unprognostic (1.42e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.92e-1)"		"unprognostic (8.11e-3)"	"unprognostic (4.19e-6)"	"unprognostic (1.73e-4)"		"unprognostic (1.71e-1)"	"unprognostic (1.58e-1)"	"unprognostic (5.51e-2)"		"unprognostic (6.07e-3)"	"unprognostic (1.13e-1)"		"unprognostic (1.09e-1)"	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	21.2			13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	1.6	0.0	0.0	0.0		0.1	14.3		0.0	0.0	0.0	0.0	16.3	0.3	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	14.4	4.8	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	8.0	0.0	0.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CEACAM5	"CD66e, CEA"	ENSG00000105388	"Carcinoembryonic antigen related cell adhesion molecule 5"	P06731	19	41708585-41729798	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 103.5;intestine: 118.2;lymphoid tissue: 100.6"	"Cell line enriched"	"Detected in some"	6	"HaCaT: 17.0"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 1007.1"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"											"CAB000021, CAB000022, HPA011041, HPA019758"	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	19000000	19000000	"Plasma membrane"		"CAB000021: , CAB000022: AB_2335697, HPA011041: AB_1078481, HPA019758: AB_1846326"	"unprognostic (1.54e-2)"	"unprognostic (7.59e-2)"	"unprognostic (5.49e-3)"	"unprognostic (1.80e-1)"		"unprognostic (1.38e-2)"		"unprognostic (2.22e-1)"	"unprognostic (3.49e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.19e-2)"	"unprognostic (2.89e-1)"	"unprognostic (8.67e-9)"	"unprognostic (2.92e-1)"	"unprognostic (2.71e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.85e-1)"	0.1	0.1	0.1	78.8	0.1	0.0	0.1	0.1	0.2	12.5	117.1	0.2	0.1	2.5	0.9	0.1	103.5	0.3	1.2	0.1	0.1	0.1	0.1	0.1	3.3	0.1	0.1	0.1	0.2	0.2	0.0	0.2	0.5	0.1	0.3	118.2	0.2	6.8	0.1	0.1	0.6	12.8	3.3	0.1	0.1	20.1	0.2	0.1	0.6	0.2	29.4	100.6	2.0	14.1	0.6	0.6	1.8	0.7	0.6	0.5	0.3	0.0	0.2	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.7	2.6	0.0	0.1	0.0	17.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	1.2	0.2	0.0	0.4	1.4	0.3	0.0	0.1	0.0	0.5	0.9	0.2	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.4	0.0	0.4	0.4	0.0	0.0	0.1	0.1	0.2	1.2	0.3	0.8	0.3	0.2	0.1	0.5	0.2	0.3	0.6	0.6	0.4	0.5	1.8	0.6	0.7	0.5	0.3	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1
CEACAM6	"CD66c, NCA"	ENSG00000086548	"Carcinoembryonic antigen related cell adhesion molecule 6"	P40199	19	41750977-41772208	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 81.4;gallbladder: 75.7;lung: 129.1"	"Cell line enriched"	"Detected in some"	8	"A549: 57.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.6"	"Group enriched"	"Detected in many"	6	"granulocytes: 2.6;monocytes: 1.3"									"CAB008370, HPA011041"	Enhanced					79000000	79000000			"CAB008370: AB_592067, HPA011041: AB_1078481"	"unprognostic (1.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.62e-2)"	"unprognostic (8.22e-2)"	"unprognostic (1.39e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.32e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.49e-1)"	"unprognostic (5.22e-2)"	"unprognostic (3.70e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.42e-4)"	"unprognostic (4.08e-1)"	"unprognostic (8.71e-3)"	"unprognostic (2.85e-1)"	"unprognostic (7.68e-2)"	0.3	0.3	0.3	7.4	0.3	29.7	0.3	0.3	0.3	16.8	35.3	0.2	0.1	5.8	0.9	0.2	81.4	1.1	75.7	2.3	0.3	0.3	0.3	0.8	129.1	0.1	0.3	0.1	0.3	1.7	0.0	0.3	32.1	0.2	0.9	43.1	0.2	50.1	0.1	0.3	2.1	12.8	0.9	0.3	0.8	2.6	0.3	0.1	1.0	0.3	25.3	58.1	2.3	21.0	0.1	0.3	2.6	1.3	0.1	0.3	5.2	0.0	57.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.9	1.6	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.9	0.0	0.0	0.1	1.6	0.0	0.0	0.0	0.3	0.2	0.6	0.0	0.0	1.5	0.0	0.2	0.6	0.1	0.0	0.1	0.2	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.1	0.3	1.3	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	2.6	0.1	0.5	0.3	0.0	5.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.2	0.1
CEBPA	"C/EBP-alpha, CEBP"	ENSG00000245848	"CCAAT/enhancer binding protein alpha"	P49715	19	33299934-33302564	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 52.3;liver: 44.3"	"Cell line enhanced"	"Detected in some"		"BEWO: 42.6;Hep G2: 22.8;NB-4: 23.5;THP-1: 85.0;U-937: 27.2"	"Cancer enhanced"	"Detected in all"		"liver cancer: 70.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 11.0;non-classical monocyte: 11.8"	"Group enriched"	"Detected in many"	13	"dendritic cells: 4.1;granulocytes: 11.0;monocytes: 11.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA052734, HPA065037, HPA067937"	Approved		Approved	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA052734: , HPA065037: , HPA067937: "	"unprognostic (1.80e-1)"	"unprognostic (7.62e-3)"	"unprognostic (2.09e-3)"	"unprognostic (2.21e-2)"	"unprognostic (3.38e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.43e-3)"	"unprognostic (5.95e-2)"	"unprognostic (3.96e-2)"	"unprognostic (3.09e-1)"	"unprognostic (9.45e-2)"	"unprognostic (8.02e-3)"	"unprognostic (2.19e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.49e-2)"	"unprognostic (2.72e-2)"	40.7	1.5	2.3	7.6	4.6	8.4	52.3	2.1	4.0	3.5	9.0	5.2	1.1	9.0	2.2	2.1	6.1	2.4	6.4	6.6	3.9	2.4	2.0	44.3	39.9	10.3	4.1	3.1	1.3	9.0	4.5	1.7	17.4	2.7	3.8	5.1	1.9	5.6	1.6	15.4	23.7	12.7	2.9	6.6	3.0	3.5	1.2	2.6	2.2	2.5	10.7	3.5	5.4	7.9	0.1	4.1	11.0	11.8	0.0	0.6	1.5	0.5	1.0	0.0	1.5	12.3	0.0	42.6	0.0	0.3	0.0	0.0	5.1	0.0	0.0	0.6	0.0	1.9	1.2	0.1	0.0	7.3	1.5	0.0	0.0	22.8	0.2	7.5	9.1	0.4	5.5	0.0	0.0	0.0	0.4	0.0	0.0	2.6	0.0	23.5	1.0	0.5	0.0	0.0	0.2	0.0	3.7	0.0	0.3	0.1	0.1	0.1	2.9	85.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	27.2	0.0	11.0	6.0	0.0	0.6	9.4	0.6	0.0	0.1	0.4	4.1	0.1	0.2	0.4	2.1	0.0	11.8	0.2	0.0	1.5	2.3	4.6	2.1	4.0	3.9	2.4	4.1	3.1	2.7	2.6
CENPF	hcp-1	ENSG00000117724	"Centromere protein F"	P49454	1	214603195-214664588	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation, DNA synthesis, Mitosis, Myogenesis"	"Developmental protein"	"Cancer-related genes, Ciliopathy, Primary ciliary dyskinesia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"bone marrow: 19.5;lymphoid tissue: 67.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA052382, HPA064308, CAB070134"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB070134: AB_2229328, HPA052382: , HPA064308: "	"unprognostic (2.80e-1)"	"unprognostic (2.16e-1)"	"unprognostic (2.65e-1)"	"unprognostic (5.30e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.40e-2)"	"prognostic unfavourable (2.29e-5)"	"unprognostic (1.13e-2)"	"unprognostic (2.58e-3)"	"unprognostic (1.11e-1)"	"prognostic unfavourable (1.39e-4)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (3.92e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.89e-2)"	"unprognostic (4.12e-1)"	1.6	1.5	1.0	10.7	1.3	19.5	1.1	0.4	0.9	2.1	5.6	0.3	0.0	4.6	1.2	1.7	9.4	0.8	0.4	1.7	0.6	0.6	1.0	0.8	3.2	6.2	0.6	0.5	1.4	0.6	0.0	0.4	6.4	0.8	0.7	4.5	0.4	1.9	0.0	0.5	4.7	6.4	1.6	1.5	3.8	2.3	9.4	0.6	67.5	0.6	7.6	7.6	1.4	2.9	0.3	0.3	0.0	0.0	0.7	1.9	0.2	32.2	18.3	39.5	20.6	1.5	2.0	15.4	20.0	8.2	12.0	11.9	14.5	20.0	30.8	11.9	11.1	20.1	24.3	13.1	20.5	26.8	15.3	25.3	28.1	20.7	0.2	35.7	13.8	0.7	1.0	17.3	20.0	12.6	22.7	18.4	21.5	12.3	21.1	14.3	35.0	8.1	22.5	55.8	10.1	11.8	8.0	18.5	25.2	27.0	18.0	10.4	21.5	13.7	16.5	21.9	25.8	18.1	41.3	14.2	15.3	29.6	9.5	25.8	19.3	0.0	0.0	0.0	0.4	0.0	0.1	0.2	1.4	0.4	0.3	0.3	1.9	0.8	0.0	0.7	0.0	0.3	1.7	0.2	1.0	1.3	0.4	0.9	0.6	0.6	0.6	0.5	0.8	0.6
CEP76	"C18orf9, FLJ12542, HsT1705"	ENSG00000101624	"Centrosomal protein 76"	Q8TAP6	18	12661833-12702777	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Region enriched"	"Detected in many"	11	"cerebellum: 70.6"					HPA039395	Approved									"HPA039395: AB_10673357"	"unprognostic (3.39e-1)"	"unprognostic (2.99e-2)"	"unprognostic (2.26e-1)"	"unprognostic (9.31e-3)"	"unprognostic (1.65e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.57e-4)"	"unprognostic (2.99e-1)"	"unprognostic (4.00e-4)"	"unprognostic (7.88e-3)"	"unprognostic (2.45e-1)"	"unprognostic (8.70e-2)"	"unprognostic (1.67e-2)"	"unprognostic (4.39e-2)"	"unprognostic (2.37e-1)"	"unprognostic (5.70e-2)"	"unprognostic (8.21e-2)"	6.1	7.5	6.2	6.8	9.9	10.4	7.9	18.6	10.2	7.8	5.9	4.4	5.2	5.3	7.0	11.0	12.0	5.9	5.4	5.4	5.4	6.3	6.5	9.6	5.6	7.1	5.3	9.1	7.9	6.7	6.5	9.9	6.9	8.8	6.0	8.3	5.0	8.2	7.9	11.4	10.3	6.4	7.1	5.3	6.1	6.8	18.4	5.9	15.7	7.6	6.0	9.3	7.0	7.4	4.4	3.6	3.5	7.1	6.0	6.6	3.7	5.8	6.1	10.4	5.0	6.1	3.3	10.1	6.9	8.0	13.8	10.7	13.8	7.2	8.0	6.3	4.5	4.8	10.0	4.5	11.9	4.9	8.3	7.2	7.4	11.8	4.7	16.0	8.3	2.6	4.5	8.1	5.3	7.2	11.7	12.2	8.9	4.5	14.1	11.6	7.6	4.1	10.0	9.0	8.6	7.2	6.0	7.8	7.0	8.8	5.7	5.6	4.1	9.1	6.7	9.4	19.0	9.0	8.3	6.9	11.8	9.4	4.7	8.1	6.1	0.8	3.9	3.5	4.9	7.1	6.6	3.4	5.3	5.8	3.6	4.4	5.3	6.0	1.4	6.0	2.9	2.0	5.8	3.7	6.2	9.9	18.6	10.2	5.4	6.3	5.3	9.1	8.8	5.9
CFH	"ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS"	ENSG00000000971	"Complement factor H"	P08603	1	196651878-196747504	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Complement alternate pathway, Host-virus interaction, Immunity, Innate immunity"		"Age-related macular degeneration, Cancer-related genes, Disease mutation, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"liver: 295.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 25.2;HHSteC: 31.8;HSkMC: 31.0;RH-30: 23.2;RT4: 56.3"	"Cancer enriched"	"Detected in all"	9	"liver cancer: 151.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 16.5"	"Lineage enriched"	"Detected in single"	27	"T-cells: 16.5"									"CAB016385, CAB016769, HPA038922, HPA049176, HPA053326"	Supported		Approved	Vesicles	"Secreted to blood"	110000000000	110000000000	Vesicles		"CAB016385: AB_627572, CAB016769: , HPA038922: , HPA049176: , HPA053326: "	"unprognostic (2.40e-1)"	"unprognostic (9.86e-2)"	"unprognostic (1.22e-1)"	"unprognostic (8.39e-2)"	"unprognostic (5.40e-3)"	"unprognostic (1.80e-1)"	"unprognostic (3.75e-3)"	"unprognostic (7.40e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.04e-1)"	"unprognostic (9.08e-2)"	"unprognostic (2.08e-1)"	"prognostic unfavourable (1.92e-6)"	"unprognostic (6.50e-3)"	"unprognostic (4.49e-3)"	"unprognostic (1.73e-1)"	"unprognostic (1.37e-1)"	28.6	5.5	1.6	3.7	3.8	0.1	8.8	2.6	2.7	10.4	9.1	1.0	3.9	3.7	2.5	8.7	15.2	3.4	17.0	47.3	2.0	1.2	7.0	295.2	11.0	10.3	5.3	1.7	40.9	1.9	1.7	4.3	5.1	5.3	10.3	10.4	6.3	19.0	3.3	10.0	11.5	8.1	12.6	4.2	3.3	5.8	6.4	2.9	0.7	22.0	22.8	5.8	17.2	16.8	0.0	0.1	0.6	0.1	0.0	16.5	1.0	0.0	16.1	0.0	0.0	25.2	14.3	0.0	6.5	15.9	0.9	3.5	0.0	3.0	0.0	2.4	0.0	0.5	0.0	5.9	0.6	0.3	0.0	4.8	19.1	0.0	31.8	0.2	0.0	31.0	0.1	4.7	2.0	19.8	18.1	0.6	22.5	0.0	0.1	0.0	0.1	0.0	0.0	23.2	5.1	0.0	56.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.4	19.2	0.2	0.2	0.2	0.2	0.0	0.0	3.4	0.0	1.4	0.0	0.1	0.0	1.8	0.0	16.5	0.0	6.0	3.5	0.1	0.0	0.4	1.4	0.6	0.0	0.0	0.0	0.0	1.0	1.6	3.8	2.6	2.7	2.0	1.2	5.3	1.7	5.3	2.9
CFHR1	"CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2"	ENSG00000244414	"Complement factor H related 1"	Q03591	1	196819757-196832189	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"			"Cancer-related genes, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	174	"liver: 218.9"	"Cell line enhanced"	"Detected in some"		"ASC diff: 2.6;HeLa: 3.1;HL-60: 4.7;U-266/70: 6.2"	"Cancer enriched"	"Detected in single"	798	"liver cancer: 182.4"					"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA038915, HPA038922, HPA040726"	Supported		Approved	Vesicles	"Secreted to blood"	15000000000	15000000000	Vesicles		"HPA038915: , HPA038922: , HPA040726: "	"unprognostic (2.28e-1)"	"unprognostic (3.18e-1)"			"unprognostic (3.50e-2)"	"unprognostic (1.88e-2)"	"prognostic favourable (8.71e-6)"	"unprognostic (3.02e-1)"	"unprognostic (3.70e-1)"	"unprognostic (2.50e-1)"	"unprognostic (8.48e-2)"		"unprognostic (7.21e-4)"	"unprognostic (7.01e-4)"	"unprognostic (1.13e-1)"		"unprognostic (6.41e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	218.9	0.0	0.5	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.1	0.0	0.0	0.3	0.2	2.6	1.0	0.0	0.0	0.1	0.0	0.4	0.0	0.1	0.2	0.0	0.6	0.5	0.0	0.0	0.0	0.0	0.0	1.6	3.1	0.2	0.2	4.7	0.8	0.1	0.0	0.0	0.0	0.1	0.3	2.3	0.8	0.0	1.4	0.0	0.8	0.0	0.8	2.0	0.0	0.0	0.3	0.0	0.1	0.9	0.0	0.2	0.4	0.0	1.4	0.9	0.4	0.2	0.2	6.2	0.0	1.1	0.0	0.4	0.9	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.3	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1										
CFLAR	"c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT"	ENSG00000003402	"CASP8 and FADD like apoptosis regulator"	O15519	2	201116104-201176687	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-266/70: 54.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	5	"neutrophil: 79.2"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 79.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019044, CAB022157, CAB025216"	Uncertain		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"				"Nucleoplasm, Plasma membrane, Cytosol"	"Nuclear bodies"	"CAB022157: , CAB025216: , HPA019044: AB_10696204"	"unprognostic (4.61e-2)"	"unprognostic (5.32e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.44e-1)"	"unprognostic (2.95e-2)"	"prognostic favourable (2.79e-4)"	"unprognostic (7.46e-2)"	"unprognostic (9.01e-2)"	"unprognostic (1.76e-1)"	"unprognostic (6.12e-2)"	"unprognostic (3.08e-2)"	"unprognostic (4.91e-2)"	"unprognostic (2.90e-2)"	"unprognostic (7.83e-2)"	"unprognostic (9.13e-2)"	"unprognostic (6.84e-2)"	"unprognostic (2.24e-2)"	35.4	17.6	13.7	29.8	17.4	66.8	31.6	26.9	12.6	20.5	25.7	13.5	31.3	17.5	24.7	27.6	21.0	19.2	22.1	58.1	14.7	7.7	24.9	18.9	58.5	34.3	16.8	8.9	14.6	14.3	9.1	18.7	28.3	12.6	23.2	17.7	20.9	21.8	27.4	113.7	16.7	26.8	30.5	13.8	35.7	19.4	10.9	14.8	17.2	31.2	26.2	31.4	24.1	33.7	5.3	6.6	79.2	12.6	8.7	11.8	7.8	5.1	10.6	7.6	4.5	23.6	18.1	9.4	13.1	22.9	8.7	10.6	12.2	19.4	1.4	12.5	15.2	3.8	2.4	9.9	13.9	38.8	7.4	7.8	9.1	19.8	16.5	5.8	25.9	19.7	9.8	14.6	12.9	44.0	26.3	32.7	15.7	4.3	2.7	23.2	2.6	8.0	2.8	1.8	11.1	10.8	10.7	1.7	3.0	8.8	7.8	10.3	5.5	10.9	47.7	18.2	7.6	6.7	6.4	54.5	17.9	8.7	12.9	4.7	9.0	16.3	12.1	13.5	11.7	12.3	10.3	5.3	10.1	11.0	6.6	4.0	6.4	8.3	79.2	8.7	12.6	4.6	11.8	7.8	13.7	17.4	26.9	12.6	14.7	7.7	16.8	8.9	12.6	14.8
CFTR	"ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR"	ENSG00000001626	"Cystic fibrosis transmembrane conductance regulator"	P13569	7	117465784-117715971	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Isomerase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"pancreas: 103.0"	"Group enriched"	"Detected in some"	22	"CACO-2: 12.5;MOLT-4: 47.0;U-266/70: 25.7"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 23.9;pancreatic cancer: 28.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"olfactory region: 6.3"	"CAB001951, HPA021939"	Enhanced									"CAB001951: , HPA021939: AB_1846578"	"unprognostic (6.38e-3)"	"unprognostic (9.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.44e-2)"	"unprognostic (8.74e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavourable (9.44e-4)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.89e-2)"	"unprognostic (1.55e-2)"	"unprognostic (2.14e-2)"	"unprognostic (4.78e-3)"	"unprognostic (1.24e-1)"	"unprognostic (2.58e-1)"	"unprognostic (9.08e-2)"	"unprognostic (6.64e-2)"	0.4	0.2	0.4	10.5	0.4	0.0	0.3	0.3	0.3	2.5	19.8	0.1	0.8	10.5	0.6	2.1	0.4	0.4	15.8	0.3	0.4	0.3	1.1	1.4	5.7	0.1	0.5	0.1	0.3	103.0	0.0	0.3	0.1	0.1	1.5	12.5	0.1	22.4	0.1	0.3	1.1	24.2	0.3	0.7	0.3	0.6	0.9	0.1	0.1	0.3	0.2	0.3	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.3	0.3	0.4	0.3	0.5	0.1	0.1	0.1
CGA	"FSHA, GPHa, GPHA1, HCG, LHA, TSHA"	ENSG00000135346	"Glycoprotein hormones, alpha polypeptide"	P01215	6	87085498-87095406	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	62	"pituitary gland: 398.8;placenta: 489.3"	"Cell line enriched"	"Detected in some"	19	"BEWO: 105.3"	"Cancer enhanced"	"Detected in many"		"testis cancer: 13.0"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	11	"hypothalamus: 69.2"	"CAB023350, HPA029698"	Enhanced				"Secreted to blood"					"CAB023350: AB_617281, HPA029698: "	"unprognostic (1.66e-1)"	"unprognostic (2.10e-1)"		"unprognostic (3.22e-5)"	"unprognostic (1.46e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.69e-2)"	"unprognostic (3.17e-1)"			"unprognostic (7.04e-3)"	"unprognostic (1.51e-1)"		"unprognostic (2.85e-1)"	"unprognostic (4.32e-2)"	"unprognostic (8.32e-2)"	"unprognostic (9.15e-3)"	0.1	0.1	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	3.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	398.8	489.3	0.2	0.1	0.0	0.0	0.1	0.1	0.2	0.2	0.0	0.6	0.0	0.1	7.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	2.2	1.9	3.5	1.5	1.1	2.1	0.2	0.0	0.2	0.0	0.0	0.0	0.0	105.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.2	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.5	0.0	0.1	0.0	0.0	0.0	2.3	1.1	1.0	1.7	0.5	0.7	1.3	0.8	1.4	0.6	2.2	1.2	2.1	3.5	1.1	1.5	1.9	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0
CHCHD7	"COX23, MGC2217"	ENSG00000170791	"Coiled-coil-helix-coiled-coil-helix domain containing 7"	Q9BUK0	8	56211686-56218798	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA050783	Approved		Approved	"Cell Junctions,Aggresome"				"Cell Junctions"	Aggresome	"HPA050783: "	"unprognostic (1.64e-2)"	"unprognostic (3.23e-2)"	"unprognostic (3.18e-2)"	"prognostic unfavourable (1.39e-6)"	"unprognostic (4.46e-2)"	"unprognostic (2.43e-1)"	"unprognostic (5.04e-2)"	"unprognostic (8.38e-3)"	"unprognostic (1.62e-1)"	"unprognostic (9.03e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.15e-1)"	"prognostic favourable (9.47e-5)"	"unprognostic (1.94e-1)"	"unprognostic (5.07e-1)"	"unprognostic (1.77e-2)"	"unprognostic (2.50e-1)"	16.6	14.8	24.1	19.6	29.4	17.6	18.9	27.1	23.3	17.6	20.7	18.3	22.8	22.5	13.1	34.3	15.7	17.6	12.3	27.0	21.0	19.5	23.4	18.0	19.4	24.4	27.0	16.0	36.3	20.0	22.5	48.3	13.3	26.7	19.2	21.3	19.2	34.5	18.0	23.2	14.6	26.2	14.8	32.0	33.0	17.7	7.6	24.8	27.4	19.8	18.3	24.9	15.5	16.4	31.0	33.6	26.2	20.6	24.2	31.1	17.3	18.8	6.0	13.5	4.4	36.0	25.6	14.0	13.5	12.7	10.8	8.1	15.4	23.1	17.8	11.9	7.9	10.6	14.0	20.7	13.4	7.7	26.9	27.2	14.4	21.3	18.3	23.2	17.5	30.5	19.1	7.6	34.2	11.2	13.3	11.7	25.3	9.4	23.1	34.4	11.9	8.7	26.6	4.1	14.8	19.8	20.4	3.5	2.3	7.1	11.0	10.0	11.5	13.0	16.2	5.7	12.1	18.3	12.6	12.4	12.6	29.7	16.0	34.5	9.7	21.5	20.6	26.2	23.2	19.0	22.5	31.0	26.0	23.6	22.8	26.4	31.1	27.8	7.9	24.2	16.6	33.6	29.7	17.3	24.1	29.4	27.1	23.3	21.0	19.5	27.0	16.0	26.7	24.8
CHD4	"Mi-2b, Mi2-BETA"	ENSG00000111642	"Chromodomain helicase DNA binding protein 4"	Q14839	12	6570082-6614524	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012008	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA012008: AB_1846633"	"unprognostic (6.11e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.40e-3)"	"unprognostic (8.99e-2)"	"unprognostic (3.36e-3)"	"prognostic unfavourable (6.03e-6)"	"unprognostic (2.66e-2)"	"unprognostic (1.05e-1)"	"unprognostic (6.85e-2)"	"unprognostic (3.15e-1)"	"unprognostic (3.94e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.33e-1)"	"unprognostic (1.82e-1)"	"unprognostic (9.84e-2)"	"unprognostic (1.66e-1)"	23.5	34.9	21.9	50.0	33.5	27.2	25.9	29.4	25.1	28.1	29.5	29.3	38.5	18.6	37.2	35.4	29.1	28.0	40.3	52.8	23.5	19.2	29.5	25.0	25.5	30.9	33.6	19.4	34.6	27.4	58.4	25.3	29.5	27.2	21.5	26.0	26.5	24.8	46.2	33.7	31.1	24.4	36.6	30.3	29.4	27.2	29.7	28.9	75.7	38.4	33.7	38.4	34.7	24.3	12.6	16.8	12.8	9.1	13.5	16.7	5.8	20.5	18.7	46.5	17.4	19.1	21.5	27.3	22.8	22.2	25.2	23.2	31.2	16.0	44.2	9.1	25.7	18.4	43.6	25.1	34.0	33.0	22.4	61.7	29.1	19.5	16.6	48.4	29.6	20.7	12.5	24.3	17.1	29.3	48.5	22.1	23.9	25.7	45.9	15.8	44.5	17.7	39.4	28.6	24.1	15.9	24.3	22.0	28.3	29.3	32.6	22.6	14.9	27.6	27.2	25.7	54.8	18.8	26.6	35.8	21.3	56.4	17.0	29.6	18.8	9.0	7.7	9.2	12.2	9.1	12.0	10.5	10.3	11.1	7.9	12.6	13.0	12.3	12.8	13.5	8.1	16.8	16.7	5.8	21.9	33.5	29.4	25.1	23.5	19.2	33.6	19.4	27.2	28.9
CHD7	"CRG, FLJ20357, FLJ20361, KIAA1416"	ENSG00000171316	"Chromodomain helicase DNA binding protein 7"	Q9P2D1	8	60678778-60868028	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"rRNA processing, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 47.1"	"Cell line enhanced"	"Detected in many"		"AF22: 25.8;SCLC-21H: 23.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	15	"B-cells: 12.2;granulocytes: 12.6;T-cells: 5.5"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in all"	4	"cerebellum: 110.3"	HPA053075			Supported	Nucleoplasm,Nucleoli				Nucleoplasm	Nucleoli	"HPA053075: "	"unprognostic (3.77e-2)"	"unprognostic (3.28e-3)"	"unprognostic (3.17e-2)"	"prognostic unfavourable (5.34e-5)"	"unprognostic (9.59e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.86e-3)"	"unprognostic (3.41e-2)"	"unprognostic (3.06e-1)"	"unprognostic (2.73e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.33e-1)"	"unprognostic (9.09e-2)"	"unprognostic (9.21e-2)"	"unprognostic (1.75e-1)"	"unprognostic (8.20e-2)"	"unprognostic (2.17e-1)"	3.9	2.2	7.0	7.9	11.2	25.1	4.1	47.1	9.0	2.3	5.7	13.4	3.1	5.9	2.6	3.2	5.1	3.2	3.1	4.1	8.1	4.3	3.6	3.6	4.7	7.0	8.1	3.3	1.4	6.4	12.4	9.9	5.6	9.9	2.9	5.5	6.4	5.7	2.8	10.3	5.7	6.6	2.4	7.5	6.1	4.5	4.3	12.2	1.6	5.4	2.2	7.3	2.9	5.9	12.2	0.6	12.6	0.6	0.0	5.5	0.4	3.8	1.9	25.8	4.5	0.0	0.0	8.1	0.2	0.0	0.9	0.8	4.8	3.6	7.5	0.4	0.0	2.3	13.2	3.8	0.8	2.8	7.1	17.6	3.2	6.3	1.1	5.3	3.3	0.5	2.9	0.0	4.3	3.8	1.3	6.7	0.6	3.9	8.3	6.0	17.7	0.9	17.3	6.1	2.4	2.0	4.4	23.6	11.7	0.7	2.9	7.2	5.2	5.0	4.4	0.2	4.2	0.2	2.1	7.1	4.1	11.7	1.5	0.6	6.6	10.4	0.3	12.6	2.6	0.1	3.3	8.0	2.9	0.9	0.1	12.2	5.5	2.0	7.1	0.0	0.6	0.6	0.2	0.4	7.0	11.2	47.1	6.5	8.1	4.3	8.1	3.3	9.9	12.2
CHD8	"DUPLIN, HELSNF1, KIAA1564"	ENSG00000100888	"Chromodomain helicase DNA binding protein 8"	Q9HCK8	14	21385194-21456126	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, Chromatin regulator, DNA-binding, Helicase, Hydrolase, Repressor"	"Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA052186, HPA076133"			Enhanced	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"HPA052186: , HPA076133: "	"unprognostic (3.45e-1)"	"unprognostic (9.71e-2)"	"unprognostic (3.31e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.43e-1)"	"prognostic unfavourable (4.94e-4)"	"unprognostic (7.31e-2)"	"unprognostic (9.22e-2)"	"prognostic favourable (8.35e-4)"	"unprognostic (1.64e-1)"	"unprognostic (2.63e-2)"	"unprognostic (2.54e-3)"	"unprognostic (2.88e-1)"	"unprognostic (9.24e-2)"	"unprognostic (2.51e-1)"	"unprognostic (8.07e-3)"	13.9	14.5	13.0	14.8	21.5	34.8	17.0	28.9	25.7	15.8	14.4	26.6	14.1	11.1	18.3	13.4	17.4	15.9	11.7	12.3	13.5	13.3	14.0	11.2	15.5	18.5	15.4	15.2	20.7	19.0	34.7	25.3	15.2	20.3	16.3	14.6	19.3	15.7	14.9	16.9	24.5	16.4	17.2	13.1	19.2	16.1	15.2	18.1	29.9	17.4	10.4	24.8	16.6	14.5	12.3	7.8	12.8	7.4	8.7	8.6	3.0	16.2	21.3	23.6	11.0	15.1	13.1	13.4	12.9	14.9	19.7	19.7	18.5	14.1	26.9	8.2	17.3	20.0	28.9	18.2	25.0	20.6	13.2	23.6	14.3	22.4	14.0	32.6	22.5	17.6	14.8	22.1	15.9	17.5	16.4	14.4	14.9	17.5	23.4	13.3	18.0	18.1	22.0	17.9	9.1	14.6	30.1	17.3	16.6	20.3	15.8	11.2	11.1	15.8	20.5	16.4	12.6	9.6	15.3	16.4	19.5	26.9	6.6	12.1	16.3	12.8	4.8	12.1	7.7	5.0	8.6	5.8	6.8	7.5	3.3	12.3	7.4	6.4	11.0	8.7	7.4	7.8	5.7	3.0	13.0	21.5	28.9	25.7	13.5	13.3	15.4	15.2	20.3	18.1
CHEK1	CHK1	ENSG00000149554	"Checkpoint kinase 1"	O14757	11	125625136-125676255	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"ductus deferens: 80.0;seminal vesicle: 66.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 11.7"	"Lineage enriched"	"Detected in many"	6	"T-cells: 11.7"	"Low region specificity"	"Detected in single"							HPA044364			Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA044364: "	"unprognostic (6.74e-2)"	"unprognostic (3.63e-1)"	"prognostic favourable (3.62e-4)"	"unprognostic (5.54e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.03e-1)"	"prognostic unfavourable (3.70e-6)"	"unprognostic (3.95e-3)"	"unprognostic (1.26e-3)"	"unprognostic (2.54e-2)"	"prognostic unfavourable (3.10e-6)"	"unprognostic (1.75e-1)"	"prognostic unfavourable (1.04e-8)"	"unprognostic (2.89e-2)"	"unprognostic (2.64e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.33e-1)"	3.0	2.5	2.5	9.0	2.8	14.9	2.1	1.1	2.2	2.5	5.2	1.3	80.0	5.0	1.9	10.2	6.5	1.7	3.6	1.5	2.4	2.4	3.7	2.0	1.8	9.6	3.0	1.2	3.8	4.0	25.5	3.5	3.8	1.5	2.9	6.3	1.6	2.6	66.8	1.2	2.9	5.2	2.3	3.0	3.6	2.8	7.2	1.5	22.4	1.8	4.5	8.8	3.8	3.3	1.9	1.8	1.9	0.7	1.2	11.7	1.0	12.7	10.4	23.4	14.2	4.8	10.3	10.2	17.9	8.6	11.5	12.4	25.4	28.3	33.4	18.5	7.0	15.4	14.3	9.4	14.2	20.9	6.6	61.9	8.7	13.0	1.5	31.6	11.8	5.3	2.0	14.5	10.3	13.6	31.3	29.4	15.1	6.6	46.9	15.5	23.7	9.4	28.6	21.9	17.5	10.6	17.0	14.8	15.7	14.7	10.2	4.3	27.5	10.3	9.1	16.6	14.1	8.0	16.4	6.6	11.8	47.6	6.1	23.8	19.4	1.9	0.5	0.3	1.3	0.7	1.2	1.9	3.5	1.6	1.1	1.5	3.3	2.0	0.4	1.2	0.4	1.8	11.7	1.0	2.5	2.8	1.1	2.2	2.4	2.4	3.0	1.2	1.5	1.5
CHEK2	"bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53"	ENSG00000183765	"Checkpoint kinase 2"	O96017	22	28687743-28742422	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001878, CAB002030"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"CAB002030: AB_563660, HPA001878: AB_1078514"	"unprognostic (1.54e-1)"	"unprognostic (2.20e-1)"	"unprognostic (5.83e-2)"	"unprognostic (2.93e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.83e-2)"	"unprognostic (1.49e-3)"	"unprognostic (5.08e-3)"	"unprognostic (3.33e-3)"	"unprognostic (9.62e-3)"	"unprognostic (1.28e-2)"	"unprognostic (3.13e-1)"	"prognostic unfavourable (7.80e-9)"	"unprognostic (2.38e-2)"	"unprognostic (1.78e-1)"	"unprognostic (7.27e-2)"	"unprognostic (6.79e-3)"	5.6	8.3	2.5	13.0	7.0	13.7	5.6	0.7	5.6	6.6	9.8	2.5	4.8	6.8	4.8	10.9	10.0	4.3	6.0	6.0	4.1	2.3	5.3	6.5	7.9	10.1	6.7	1.6	12.9	6.7	1.2	4.2	10.1	5.1	8.3	10.6	8.7	7.0	5.8	2.2	6.3	8.5	5.4	5.0	9.8	5.8	9.7	3.6	13.1	7.5	4.8	13.7	6.2	6.7	11.8	8.7	6.5	8.4	2.9	4.4	3.7	14.7	4.7	13.5	16.7	3.8	19.2	8.7	7.3	8.6	9.7	14.2	12.0	10.1	17.4	6.2	5.1	14.2	20.5	13.4	11.3	12.4	15.7	22.9	9.0	19.8	3.8	14.5	16.8	8.1	6.2	12.4	11.0	10.7	13.8	15.2	9.0	20.7	11.6	23.3	19.0	12.0	25.3	9.2	20.3	6.0	6.1	7.9	4.5	8.1	14.5	8.0	9.9	13.4	3.7	7.8	9.3	6.8	3.8	9.2	16.2	34.0	7.4	15.2	9.9	6.5	3.7	1.2	1.1	8.4	2.3	11.8	2.2	2.1	8.7	8.4	4.4	2.8	0.3	2.9	4.1	7.0	2.8	3.7	2.5	7.0	0.7	5.6	4.1	2.3	6.7	1.6	5.1	3.6
CHFR	"FLJ10796, RNF196"	ENSG00000072609	"Checkpoint with forkhead and ring finger domains"	Q96EP1	12	132822187-132956304	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045768, HPA073826"	Approved		Uncertain	"Nuclear bodies,Microtubules"				"Nuclear bodies, Microtubules"		"HPA045768: , HPA073826: "	"unprognostic (1.46e-1)"	"unprognostic (2.11e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.86e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.14e-3)"	"unprognostic (6.56e-4)"	"unprognostic (1.94e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.00e-2)"	"unprognostic (3.98e-3)"	"prognostic unfavourable (4.21e-9)"	"unprognostic (5.03e-1)"	"unprognostic (8.46e-2)"	"unprognostic (6.71e-2)"	"unprognostic (1.11e-2)"	13.7	11.4	14.1	19.0	15.0	25.8	12.5	20.0	16.9	12.1	15.2	16.5	13.4	19.0	15.6	16.7	21.6	12.6	14.3	13.7	12.5	9.8	12.8	13.4	17.0	21.7	15.1	12.6	9.6	16.8	9.6	20.6	22.9	13.0	14.3	12.8	15.5	13.9	14.7	21.0	16.7	18.7	17.8	15.1	24.9	16.8	19.2	14.2	22.3	13.5	12.7	18.4	18.6	14.2	6.6	12.1	19.7	17.0	12.3	12.5	10.1	4.4	10.8	9.1	0.8	8.0	10.7	17.0	9.1	7.6	9.7	10.1	8.5	3.8	0.1	8.8	10.6	7.1	1.1	9.2	5.6	0.6	9.6	14.4	7.4	8.6	17.5	0.6	25.0	14.4	8.4	8.8	6.6	11.8	6.1	0.0	6.7	14.8	10.4	11.2	10.9	8.6	1.4	1.3	4.4	6.4	20.9	8.9	11.4	7.5	7.7	7.0	13.8	14.9	13.2	0.6	2.2	5.0	3.3	15.9	0.0	2.1	0.0	3.0	8.7	17.6	14.2	19.7	10.8	16.9	10.0	6.6	8.7	11.6	12.1	4.5	8.3	9.1	18.9	12.3	17.0	6.6	12.5	10.1	14.1	15.0	20.0	16.9	12.5	9.8	15.1	12.6	13.0	14.2
CHGA		ENSG00000100604	"Chromogranin A"	P10645	14	92923080-92935293	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins"		"Antibiotic, Antimicrobial, Fungicide"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"parathyroid gland: 577.6"	"Group enriched"	"Detected in some"	134	"SCLC-21H: 43.3;SH-SY5Y: 117.9"	"Cancer enhanced"	"Detected in many"		"pancreatic cancer: 114.8"	"Region enhanced"	"Detected in many"		"cerebral cortex: 97.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000023, HPA017369, CAB040544, CAB055506, CAB058688"	Enhanced		Supported	Vesicles	"Intracellular and membrane"	78000000	78000000	Vesicles		"CAB000023: , CAB040544: , CAB055506: AB_2081135, CAB058688: , HPA017369: AB_1846698"	"prognostic favourable (7.85e-5)"	"unprognostic (4.89e-2)"	"unprognostic (5.96e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.43e-2)"	"unprognostic (5.95e-2)"	"prognostic unfavourable (2.40e-4)"	"unprognostic (1.74e-1)"	"unprognostic (2.23e-1)"	"unprognostic (4.56e-2)"	"prognostic favourable (4.07e-4)"	"unprognostic (1.85e-1)"	"unprognostic (8.81e-13)"	"unprognostic (1.07e-2)"	"unprognostic (1.77e-1)"	"unprognostic (9.17e-2)"	"prognostic unfavourable (3.99e-4)"	2.0	81.9	6.6	3.1	18.7	1.3	1.3	0.5	97.9	1.9	36.1	4.0	0.0	15.8	1.3	1.3	1.2	1.3	1.3	1.2	11.2	14.0	1.3	1.2	1.4	1.2	8.0	36.1	1.2	15.9	577.6	81.1	1.2	17.1	2.0	7.9	0.4	1.3	1.3	1.2	1.3	38.8	1.3	2.5	1.3	51.9	32.5	0.7	0.0	5.9	0.0	1.2	1.3	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	43.3	117.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	6.6	18.7	0.5	97.9	11.2	14.0	8.0	36.1	17.1	0.7
CHI3L1	"GP39, YKL40"	ENSG00000133048	"Chitinase 3 like 1"	P36222	1	203178931-203186749	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Inflammatory response"	Antimicrobial	"Asthma, Cancer-related genes, Schizophrenia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"liver: 336.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 39.8;ASC TERT1: 88.7;HSkMC: 78.7;THP-1: 125.5;U-138 MG: 37.2;U-87 MG: 37.1"	"Cancer enriched"	"Detected in all"	8	"glioma: 1313.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	490	"neutrophil: 81.3"	"Lineage enriched"	"Detected in single"	490	"granulocytes: 81.3"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in single"	13	"olfactory region: 10.7"	HPA077365			Approved	"Golgi apparatus"	"Secreted to blood"	230000000	230000000	"Golgi apparatus"		"HPA077365: "	"unprognostic (2.11e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.07e-1)"	"unprognostic (6.01e-3)"	"unprognostic (8.81e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.48e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.30e-1)"	"unprognostic (7.98e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.98e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.14e-2)"	"unprognostic (9.39e-3)"	19.0	0.8	20.3	53.4	58.0	81.6	23.9	1.2	69.4	4.3	2.1	5.0	0.0	0.9	4.3	25.5	3.5	10.2	1.9	2.6	9.1	17.8	11.9	336.4	10.0	12.4	32.3	3.6	4.5	2.5	0.8	22.9	4.7	66.4	1.5	1.6	9.1	19.3	1.1	10.5	10.0	2.2	3.3	23.5	2.9	1.7	3.4	6.5	0.9	2.0	1.7	14.6	61.5	4.0	0.0	0.0	81.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	39.8	88.7	0.0	0.0	0.0	0.0	0.0	8.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.0	0.0	78.7	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	125.5	0.0	37.2	0.1	0.0	0.0	0.2	4.7	0.0	37.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	81.3	0.0	0.1	0.0	0.0	0.1	20.3	58.0	1.2	28.9	9.1	17.8	32.3	3.6	66.4	6.5
CHP2		ENSG00000166869	"Calcineurin like EF-hand protein 2"	O43745	16	23754627-23758951	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"intestine: 105.8;skin 1: 36.8"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 9.2;NB-4: 10.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 10.4"	"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB072806	Approved									"CAB072806: "	"unprognostic (4.82e-1)"	"unprognostic (3.40e-1)"	"unprognostic (4.93e-2)"	"unprognostic (1.01e-2)"	"unprognostic (8.85e-2)"	"unprognostic (3.54e-1)"		"unprognostic (4.54e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.38e-1)"	"unprognostic (5.31e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.44e-5)"	"unprognostic (2.21e-1)"	"unprognostic (5.97e-2)"	"unprognostic (7.84e-2)"	"unprognostic (9.01e-2)"	0.3	0.0	0.3	8.8	0.5	0.0	0.5	0.4	0.7	2.3	37.4	0.7	0.8	54.8	0.4	0.6	0.4	0.1	0.3	0.3	0.3	0.1	0.5	0.3	0.5	0.3	1.2	0.3	0.3	0.3	0.0	0.3	0.8	0.8	1.4	26.2	0.4	0.6	0.5	0.3	36.8	105.8	0.9	0.9	0.3	0.0	2.9	0.6	0.5	0.3	0.5	0.4	6.2	1.4	1.5	1.3	2.5	0.9	0.4	0.9	0.1	1.2	2.7	0.9	0.8	1.7	1.7	1.6	3.6	1.4	0.6	1.3	0.8	2.9	0.6	1.2	3.1	1.8	0.6	3.5	0.8	0.8	0.3	0.6	5.1	2.1	2.1	0.5	0.9	1.2	1.1	3.2	9.2	1.5	1.5	1.3	1.6	0.2	0.1	10.6	0.5	2.6	0.3	0.2	1.7	1.4	1.5	0.8	1.0	1.1	0.3	0.1	0.3	0.2	1.6	0.7	1.0	1.0	0.2	0.6	0.2	0.3	0.0	0.7	0.7	1.2	0.9	0.2	0.9	0.5	0.5	0.7	0.6	0.7	0.4	1.5	0.9	0.8	2.5	0.4	0.5	1.3	0.3	0.1	0.3	0.5	0.4	0.7	0.3	0.1	1.2	0.3	0.8	0.6
CIB2	"DFNB48, KIP2, USH1J"	ENSG00000136425	"Calcium and integrin binding family member 2"	O75838	15	78104606-78131544	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness, Retinitis pigmentosa, Usher syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"heart muscle: 45.5;intestine: 48.5"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 21.0;HAP1: 18.4;NTERA-2: 15.3;SCLC-21H: 19.0;SH-SY5Y: 20.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	51	"plasmacytoid DC: 16.1"	"Lineage enriched"	"Detected in single"	51	"dendritic cells: 16.1"	"Low region specificity"	"Detected in all"							HPA036697	Approved									"HPA036697: AB_10672475"	"unprognostic (5.77e-2)"	"unprognostic (1.83e-2)"	"unprognostic (2.81e-2)"	"prognostic unfavourable (7.05e-4)"	"unprognostic (1.46e-1)"	"unprognostic (2.57e-1)"	"unprognostic (1.11e-2)"	"unprognostic (6.73e-3)"	"unprognostic (1.66e-1)"	"unprognostic (9.94e-3)"	"unprognostic (3.18e-1)"	"unprognostic (7.49e-2)"	"prognostic favourable (6.16e-4)"	"unprognostic (9.78e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.68e-1)"	"unprognostic (7.64e-3)"	5.8	8.8	9.7	3.4	6.7	1.2	6.0	5.1	8.2	9.6	11.0	3.5	2.8	16.0	6.1	3.2	4.2	4.3	3.2	45.5	7.2	6.8	7.0	0.8	1.9	3.3	6.9	4.9	6.9	13.0	9.2	7.1	4.8	9.1	7.9	6.3	4.2	6.8	8.2	6.3	4.2	48.5	7.5	4.1	3.7	2.7	13.4	2.0	35.0	3.0	1.9	5.4	6.0	7.9	0.0	16.1	0.1	0.0	0.0	0.3	0.1	1.8	4.1	11.8	21.0	0.5	0.7	9.0	1.2	0.4	1.0	2.1	0.0	4.6	0.2	2.4	5.4	1.0	18.4	3.6	0.3	10.4	13.2	1.2	0.7	0.6	2.1	0.0	1.7	1.1	1.6	1.7	1.0	2.1	4.2	0.1	1.9	0.3	0.5	0.2	15.3	0.1	7.8	0.0	0.5	1.3	0.4	19.0	20.0	3.1	1.5	1.6	0.3	1.2	0.1	0.0	10.2	1.1	0.1	0.2	0.2	3.4	0.5	0.0	2.6	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.0	16.1	0.0	0.1	9.7	6.7	5.1	8.2	7.2	6.8	6.9	4.9	9.1	2.0
CIC	KIAA0306	ENSG00000079432	"Capicua transcriptional repressor"	Q96RK0	19	42268537-42295797	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB026388, HPA044341, HPA064725"	Approved		Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB026388: , HPA044341: , HPA064725: "	"unprognostic (2.02e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.41e-2)"	"unprognostic (3.54e-3)"	"unprognostic (3.67e-1)"	"unprognostic (4.17e-3)"	"unprognostic (1.49e-1)"	"unprognostic (2.06e-1)"	"unprognostic (4.87e-1)"	"unprognostic (1.85e-2)"	"unprognostic (1.72e-3)"	"unprognostic (3.10e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.00e-1)"	"unprognostic (2.38e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.56e-1)"	18.6	15.7	30.5	22.8	29.9	28.1	20.3	46.8	31.6	17.5	14.7	24.7	13.0	16.5	28.6	12.3	12.3	22.1	17.4	12.1	25.5	15.2	14.9	15.1	15.8	21.5	25.2	20.1	31.5	22.6	16.6	22.6	13.2	20.4	14.4	6.2	19.0	23.8	20.8	21.0	34.1	16.1	16.3	16.5	24.7	14.5	31.5	25.6	13.6	16.8	10.6	13.4	13.6	17.4	2.3	2.0	5.0	2.6	0.6	2.5	1.6	17.6	32.0	12.3	16.9	8.0	15.1	6.0	13.5	11.3	11.4	10.6	9.0	10.9	12.3	12.9	10.6	8.6	6.8	20.4	3.7	29.8	9.2	10.3	20.2	10.7	10.1	5.8	29.4	18.0	12.0	12.9	7.6	10.4	10.1	25.9	6.4	16.8	11.4	11.1	7.7	18.2	9.8	10.5	7.3	9.5	16.6	15.9	13.1	12.8	8.0	10.1	9.5	12.5	19.9	27.3	22.2	9.3	16.4	21.5	14.8	8.4	21.2	9.2	16.1	3.4	1.8	1.0	2.5	2.6	1.9	1.7	1.3	1.6	1.7	2.3	0.9	1.5	5.0	0.6	1.9	2.0	0.5	1.6	30.5	29.9	46.8	31.6	25.5	15.2	25.2	20.1	20.4	25.6
CIITA	"C2TA, MHC2TA, NLRA"	ENSG00000179583	"Class II major histocompatibility complex transactivator"	P33076	16	10866222-10943021	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Kinase, Transferase"	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 67.2"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 22.8;REH: 40.0;U-698: 11.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB016084, HPA054757"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB016084: AB_627261, HPA054757: "	"unprognostic (1.45e-3)"	"unprognostic (1.38e-2)"	"unprognostic (8.22e-3)"	"unprognostic (1.12e-2)"	"unprognostic (5.66e-2)"	"unprognostic (2.88e-3)"	"unprognostic (2.92e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.15e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.23e-1)"	"unprognostic (3.72e-1)"	"unprognostic (1.64e-2)"	"unprognostic (2.72e-2)"	"unprognostic (6.33e-3)"	"unprognostic (2.74e-1)"	"unprognostic (1.05e-2)"	8.0	5.9	4.6	47.7	7.1	4.3	6.8	1.5	5.5	6.3	3.7	10.6	4.2	10.4	8.1	10.4	4.8	5.2	8.1	4.9	4.7	3.5	8.8	2.9	15.0	27.0	9.4	1.1	2.5	3.5	1.9	4.0	1.2	6.6	5.5	4.3	5.5	13.3	4.3	2.9	4.4	17.4	3.7	15.6	25.9	6.2	1.5	7.4	12.6	6.1	5.2	67.2	6.3	6.8	27.3	19.0	6.5	11.9	0.7	0.5	1.7	0.1	0.2	0.3	0.3	0.1	0.0	0.2	0.1	0.0	0.1	0.1	0.3	5.5	5.0	0.8	0.0	0.9	0.0	0.0	0.1	22.8	0.2	2.9	1.0	0.6	0.0	0.4	0.4	1.0	0.0	0.1	0.0	0.0	0.3	2.0	0.1	0.3	0.2	0.4	0.1	0.1	40.0	0.3	3.5	0.0	1.6	0.9	0.1	0.9	0.3	0.9	0.5	1.6	0.3	2.1	0.3	0.6	0.2	8.4	0.6	11.8	7.5	0.5	6.8	0.2	11.9	6.5	0.3	9.5	0.1	17.9	0.1	0.5	17.7	27.3	0.1	0.2	2.8	0.7	10.0	19.0	0.4	1.7	4.6	7.1	1.5	5.5	4.7	3.5	9.4	1.1	6.6	7.4
CKB	CKBB	ENSG00000166165	"Creatine kinase B"	P12277	14	103519659-103523111	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 158.5"	"Cell line enhanced"	"Detected in many"		"CACO-2: 53.1;HEK 293: 135.1;SCLC-21H: 76.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	10	"non-classical monocyte: 50.0"	"Lineage enriched"	"Detected in many"	17	"monocytes: 50.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001254, CAB047313"	Enhanced		Supported	Cytosol		50000000	50000000	Cytosol		"CAB047313: , HPA001254: AB_1078528"	"unprognostic (9.97e-2)"	"unprognostic (1.33e-3)"	"unprognostic (4.25e-3)"	"unprognostic (1.10e-1)"	"unprognostic (7.63e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.24e-1)"	"unprognostic (4.60e-2)"	"unprognostic (2.68e-3)"	"unprognostic (9.89e-3)"	"prognostic favourable (4.02e-8)"	"unprognostic (2.62e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.13e-1)"	32.4	27.3	75.4	10.4	114.6	3.1	5.3	94.3	158.5	29.1	121.5	51.4	23.8	17.6	37.3	8.9	28.6	35.7	17.8	36.4	60.7	43.2	26.7	3.4	12.8	3.6	63.4	93.3	15.8	10.2	20.3	9.7	3.7	63.3	107.5	55.0	43.9	18.3	92.1	19.1	14.4	17.5	53.2	31.9	3.6	66.7	22.1	50.9	0.0	19.8	7.8	3.9	43.0	13.0	0.0	2.9	1.4	50.0	0.0	0.1	0.9	0.3	6.7	26.9	1.4	0.2	0.2	0.5	2.9	0.0	0.3	0.1	53.1	0.8	0.0	3.2	2.0	5.9	7.8	0.1	0.0	1.2	135.1	10.0	29.7	18.2	1.1	0.0	8.2	1.0	0.0	0.2	0.1	0.0	17.4	0.4	0.4	2.2	0.2	0.3	10.5	21.0	1.7	0.5	27.6	4.9	0.2	76.9	31.6	5.7	0.9	2.1	2.5	4.1	0.1	0.1	5.2	0.5	12.6	1.3	0.3	0.9	0.7	0.2	0.9	0.3	0.1	1.4	0.0	5.1	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.1	0.0	50.0	0.0	0.1	0.9	75.4	114.6	94.3	152.7	60.7	43.2	63.4	93.3	63.3	50.9
CKS1B	"CKS1, ckshs1"	ENSG00000173207	"CDC28 protein kinase regulatory subunit 1B"	P61024	1	154974653-154979249	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"HPA003424, HPA030762"	Approved		Approved	Nucleoplasm,Vesicles,Mitochondria,Cytosol				"Mitochondria, Cytosol"	"Nucleoplasm, Vesicles"	"HPA003424: , HPA030762: AB_10670044"	"unprognostic (1.06e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.84e-1)"	"prognostic unfavourable (7.89e-4)"	"unprognostic (1.34e-1)"	"unprognostic (2.59e-2)"	"prognostic unfavourable (2.94e-5)"	"unprognostic (2.01e-3)"	"prognostic unfavourable (3.12e-5)"	"unprognostic (3.63e-2)"	"prognostic unfavourable (6.13e-4)"	"unprognostic (3.19e-1)"	"prognostic unfavourable (6.03e-7)"	"unprognostic (3.12e-2)"	"unprognostic (1.44e-1)"	"prognostic favourable (4.87e-4)"	"unprognostic (1.37e-1)"	25.3	14.5	13.5	13.4	19.0	36.4	24.8	4.2	14.6	15.6	17.4	12.4	19.8	14.7	14.7	13.8	28.2	15.2	14.1	16.5	15.3	8.0	16.6	29.5	12.9	23.8	29.5	8.8	14.2	12.8	8.3	9.4	35.6	15.9	11.7	18.8	7.5	12.8	13.1	5.9	22.6	22.9	12.5	19.8	18.0	14.7	22.8	21.5	30.2	15.5	19.3	25.5	11.1	23.3	23.9	30.4	2.2	32.8	9.0	12.2	8.7	59.4	82.1	61.5	33.3	8.9	9.1	49.2	27.7	21.5	60.1	48.2	79.3	88.0	56.7	47.4	18.3	55.2	61.0	39.7	56.5	50.9	39.5	38.3	36.5	55.7	2.7	46.1	35.3	5.3	17.2	51.4	71.3	30.1	62.2	77.1	45.2	59.2	43.2	35.6	78.0	74.1	43.5	50.7	72.6	21.4	21.8	25.1	63.4	41.9	39.7	45.8	53.1	64.6	16.8	39.1	40.5	32.2	65.9	47.6	92.3	80.0	24.8	39.3	53.9	0.7	4.4	2.2	7.0	26.0	8.4	23.9	9.9	9.5	7.2	22.6	12.2	11.5	0.6	9.0	32.8	30.4	10.6	8.7	13.5	19.0	4.2	14.6	15.3	8.0	29.5	8.8	15.9	21.5
CKS2		ENSG00000123975	"CDC28 protein kinase regulatory subunit 2"	P33552	9	89311198-89316703	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 54.6;testis: 103.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"plasmacytoid DC: 54.6"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003424, HPA030762"	Approved		Approved	Nucleoplasm,Vesicles,Mitochondria,Cytosol				"Mitochondria, Cytosol"	"Nucleoplasm, Vesicles"	"HPA003424: , HPA030762: AB_10670044"	"unprognostic (8.30e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.80e-2)"	"unprognostic (2.96e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (2.51e-6)"	"unprognostic (3.57e-3)"	"unprognostic (7.04e-2)"	"unprognostic (1.34e-2)"	"prognostic unfavourable (6.85e-4)"	"unprognostic (1.24e-2)"	"prognostic unfavourable (1.78e-5)"	"unprognostic (2.13e-3)"	"unprognostic (1.44e-1)"	"unprognostic (2.84e-1)"	"unprognostic (1.84e-1)"	4.8	22.4	4.2	22.7	6.1	38.1	10.7	4.0	7.5	3.6	10.8	3.0	16.7	10.8	4.6	4.4	20.4	2.8	4.7	3.3	6.1	3.2	11.0	10.2	9.5	24.6	5.2	4.3	3.9	2.6	7.0	2.2	12.4	5.0	4.8	10.7	3.2	4.4	7.6	3.6	6.1	9.3	4.1	5.4	12.6	6.8	103.2	3.6	41.6	4.6	13.5	20.8	8.1	16.7	18.3	54.6	12.4	7.5	11.6	17.9	6.5	86.6	74.3	45.5	30.4	13.4	12.2	33.2	51.6	27.9	57.2	45.8	30.5	43.0	64.9	30.6	19.3	61.0	54.5	39.7	65.8	50.6	44.1	32.9	54.4	80.9	5.8	67.0	37.5	4.4	9.2	40.9	36.2	52.9	39.2	56.9	73.2	65.0	52.6	118.1	66.4	68.6	45.6	50.0	38.7	44.9	19.9	38.5	22.9	42.8	41.6	41.6	50.1	39.0	30.0	24.7	47.0	59.7	75.0	46.1	93.5	52.4	36.5	38.8	35.2	10.5	5.9	12.4	7.0	7.5	7.9	18.3	9.6	6.7	6.5	13.5	5.2	6.8	4.2	11.6	4.1	54.6	17.9	6.5	4.2	6.1	4.0	7.5	6.1	3.2	5.2	4.3	5.0	3.6
CLDN3	"C7orf1, CPE-R2, CPETR2, HRVP1, RVP1"	ENSG00000165215	"Claudin 3"	O15551	7	73768997-73770270	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"			"Cancer-related genes, Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 100.4;thyroid gland: 91.6"	"Cell line enhanced"	"Detected in some"		"MCF7: 65.0;PC-3: 13.9;RPMI-8226: 11.1;SCLC-21H: 17.2;T-47d: 30.9"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"cerebellum: 3.1;pons and medulla: 3.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							HPA014361	Enhanced		Supported	"Cell Junctions"		15000	15000	"Cell Junctions"		"HPA014361: "	"unprognostic (1.84e-1)"	"unprognostic (4.83e-2)"	"unprognostic (2.05e-1)"	"unprognostic (5.27e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.31e-1)"	"unprognostic (2.79e-2)"	"unprognostic (8.26e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.28e-3)"	"unprognostic (1.42e-1)"	"prognostic favourable (3.39e-5)"	"unprognostic (1.46e-2)"	"unprognostic (1.87e-1)"	"unprognostic (5.18e-2)"	"unprognostic (6.72e-2)"	0.3	0.1	0.1	11.5	0.1	0.2	7.1	3.1	0.2	3.8	77.9	1.6	21.8	24.3	2.8	8.8	0.3	9.4	11.3	0.1	0.2	0.4	20.7	16.0	6.0	0.2	0.0	0.0	4.3	38.0	0.2	7.4	3.1	3.0	14.6	8.0	1.9	31.1	32.1	0.1	2.1	100.4	0.5	0.0	0.1	0.7	1.2	0.0	2.2	91.6	0.9	3.6	0.8	0.4	0.2	0.0	0.1	0.0	0.0	0.1	0.5	0.7	1.0	0.0	0.1	0.0	0.0	5.2	0.0	0.0	0.0	0.0	1.2	10.3	0.0	2.9	0.0	0.3	0.1	0.0	0.0	0.0	1.4	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	65.0	0.1	0.3	0.6	13.9	0.0	0.0	11.1	0.6	0.0	17.2	0.2	0.0	9.9	0.0	30.9	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.1	0.1	3.1	0.2	0.2	0.4	0.0	0.0	3.0	0.0
CLDN4	"CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8"	ENSG00000189143	"Claudin 4"	O14493	7	73799542-73832693	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"Cancer-related genes, Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"thyroid gland: 141.0"	"Cell line enhanced"	"Detected in some"		"A-431: 43.1;BEWO: 50.7;CAPAN-2: 94.7;MCF7: 48.3;PC-3: 61.7;RT4: 41.7;SK-BR-3: 80.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB002610	Enhanced		Supported	"Plasma membrane"				"Plasma membrane"		"CAB002610: "	"unprognostic (1.14e-1)"	"unprognostic (2.79e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.60e-2)"	"unprognostic (7.09e-2)"	"unprognostic (3.07e-1)"	"prognostic unfavourable (3.28e-4)"	"unprognostic (2.16e-3)"	"unprognostic (5.11e-1)"	"prognostic favourable (3.46e-10)"	"unprognostic (5.77e-2)"	"unprognostic (1.37e-1)"	"unprognostic (9.38e-2)"	"unprognostic (4.63e-2)"	0.7	0.2	0.4	17.1	0.4	0.0	17.1	0.4	0.5	17.5	53.7	0.7	23.2	25.0	5.1	15.9	62.3	15.4	15.4	0.5	0.4	0.3	30.2	2.0	28.8	0.4	0.4	0.4	5.5	32.4	2.7	3.5	78.1	1.3	31.8	24.7	0.7	52.0	25.7	0.6	35.3	93.3	2.7	0.4	0.4	2.7	2.5	0.4	3.8	141.0	60.9	55.7	38.5	21.0	0.1	0.1	0.2	0.1	0.1	0.6	0.0	43.1	0.5	0.0	0.2	0.0	0.0	50.7	0.4	0.0	0.0	0.0	22.5	94.7	0.0	3.5	0.0	23.8	0.0	0.0	0.0	0.0	0.0	0.0	2.6	15.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	48.3	0.0	0.2	0.0	61.7	0.0	0.8	1.0	11.6	41.7	10.1	0.2	0.0	80.3	0.1	31.4	0.1	0.0	0.1	1.8	0.4	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.6	0.2	0.1	0.0	0.1	0.0	0.0	0.4	0.4	0.4	0.5	0.4	0.3	0.4	0.4	1.3	0.4
CLDN7	"CEPTRL2, CPETRL2, Hs.84359"	ENSG00000181885	"Claudin 7"	O95471	17	7259903-7263983	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 166.7"	"Cell line enhanced"	"Detected in some"		"BEWO: 26.6;CACO-2: 27.7;CAPAN-2: 53.9;HaCaT: 113.3;MCF7: 39.4;SK-BR-3: 47.2"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB013063, HPA014703, HPA073662"	Enhanced		Approved	"Vesicles,Cell Junctions"				Vesicles	"Cell Junctions"	"CAB013063: , HPA014703: AB_1846873, HPA073662: "	"unprognostic (5.47e-2)"	"unprognostic (2.22e-1)"	"unprognostic (4.12e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.05e-1)"	"unprognostic (8.67e-2)"	"unprognostic (3.41e-2)"	"unprognostic (1.98e-2)"	"unprognostic (5.64e-3)"	"unprognostic (8.34e-2)"	"unprognostic (4.89e-3)"	"unprognostic (1.62e-2)"	"prognostic favourable (8.96e-11)"	"prognostic favourable (4.09e-4)"	"unprognostic (1.87e-1)"	"prognostic favourable (1.85e-4)"	"unprognostic (1.62e-1)"	1.6	2.0	0.4	28.0	0.4	0.0	9.5	0.4	0.4	9.9	71.4	0.4	47.6	47.2	2.4	49.3	73.4	13.4	47.2	0.7	0.4	0.3	30.0	12.1	32.3	0.8	0.4	0.4	3.4	70.9	12.3	7.3	25.0	0.4	9.8	42.5	0.7	40.9	42.2	0.9	2.9	166.7	1.8	0.5	1.4	1.2	1.8	0.4	1.5	40.5	28.3	45.6	12.2	19.3	3.8	1.6	0.0	3.0	2.2	6.7	2.3	3.2	0.3	0.0	0.0	0.0	0.2	26.6	0.0	0.0	0.0	0.0	27.7	53.9	0.0	1.0	0.1	113.3	0.0	3.4	0.0	0.0	0.6	0.0	0.7	0.0	2.1	0.0	0.2	0.5	5.4	0.0	0.2	2.5	0.3	0.1	0.0	39.4	0.0	0.3	0.1	1.0	0.0	0.0	0.7	0.0	0.0	6.5	0.1	0.3	47.2	0.0	17.2	0.4	5.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.0	0.0	2.2	3.0	4.8	0.5	1.5	3.3	1.6	3.8	3.7	6.7	0.0	2.2	0.1	0.2	0.9	2.3	0.4	0.4	0.4	0.4	0.4	0.3	0.4	0.4	0.4	0.4
CLEC3B	"TN, TNA"	ENSG00000163815	"C-type lectin domain family 3 member B"	P05452	3	45001548-45036071	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 185.2;lung: 216.5"	"Cell line enhanced"	"Detected in some"		"ASC diff: 50.0;ASC TERT1: 99.6;U-2197: 20.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002582, HPA034794"	Approved				"Secreted to blood"	46000000000	46000000000			"CAB002582: AB_564027, HPA034794: "	"unprognostic (2.04e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.58e-1)"	"unprognostic (4.57e-2)"	"unprognostic (7.75e-2)"	"prognostic favourable (1.53e-4)"	"prognostic favourable (9.99e-9)"	"unprognostic (1.75e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.02e-1)"	"prognostic favourable (5.68e-4)"	"unprognostic (9.33e-2)"	"unprognostic (2.39e-2)"	"unprognostic (7.46e-2)"	"unprognostic (1.39e-1)"	"unprognostic (5.54e-2)"	"unprognostic (4.21e-2)"	70.8	11.5	6.6	16.9	8.9	0.5	185.2	5.9	10.2	17.4	20.3	4.8	39.0	8.4	15.7	54.2	17.2	6.9	38.8	72.8	8.1	6.8	20.6	7.0	216.5	8.3	8.8	7.4	5.1	6.1	2.1	5.0	37.7	13.2	7.4	10.1	17.7	9.7	19.2	26.5	27.6	16.3	90.3	10.0	65.5	8.3	24.9	1.5	2.3	15.8	40.8	5.4	28.0	24.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.0	50.0	99.6	0.0	6.5	10.3	0.2	1.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	7.9	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.0	20.1	0.0	0.2	0.2	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	6.6	8.9	5.9	10.2	8.1	6.8	8.8	7.4	13.2	1.5
CLIC1	"G6, NCC27, p64CLCP"	ENSG00000213719	"Chloride intracellular channel 1"	O00299	6	31730581-31739763	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Voltage-gated channel"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB020825, CAB040557"	Enhanced		Supported	Cytosol		78000000	78000000	Cytosol		"CAB020825: , CAB040557: "	"unprognostic (7.26e-2)"	"unprognostic (9.32e-2)"	"unprognostic (2.78e-3)"	"unprognostic (7.29e-2)"	"unprognostic (6.93e-2)"	"unprognostic (2.73e-2)"	"prognostic unfavourable (8.90e-7)"	"unprognostic (2.58e-2)"	"unprognostic (8.51e-2)"	"unprognostic (8.71e-3)"	"unprognostic (1.19e-3)"	"unprognostic (1.34e-1)"	"prognostic unfavourable (8.11e-5)"	"unprognostic (4.51e-2)"	"unprognostic (2.89e-1)"	"unprognostic (1.35e-2)"	"unprognostic (7.31e-2)"	64.5	22.9	7.4	33.7	11.3	35.3	41.1	2.5	8.3	38.7	50.3	9.0	27.1	24.5	30.0	29.2	59.0	26.3	60.8	35.5	7.9	7.7	70.8	28.3	58.6	59.6	13.9	3.7	34.8	30.3	11.1	17.0	72.3	12.1	42.2	43.5	20.0	37.7	33.6	18.3	45.0	54.9	31.5	13.6	79.9	34.8	16.7	9.2	52.9	46.1	37.4	58.5	49.2	40.0	39.0	30.5	70.9	39.4	33.5	37.2	67.9	26.7	12.4	20.4	10.6	13.6	28.8	10.2	11.9	24.5	21.9	18.4	28.5	20.1	11.0	17.4	42.5	16.2	15.2	35.7	29.6	8.7	8.0	21.0	10.7	24.6	17.6	36.6	29.7	17.8	18.9	36.9	35.3	36.6	24.2	34.9	42.0	17.8	17.0	47.7	1.8	18.2	3.0	11.2	25.9	49.2	16.7	3.9	4.6	9.9	11.4	16.6	7.8	51.9	24.2	30.5	21.5	9.5	37.6	11.4	21.3	14.8	14.7	27.6	31.3	45.8	36.5	48.1	37.2	39.4	30.3	39.0	22.5	34.5	30.5	30.4	7.0	21.9	70.9	33.5	33.8	17.2	31.0	67.9	7.4	11.3	2.5	8.3	7.9	7.7	13.9	3.7	12.1	9.2
CLIP1	"CLIP, CLIP-170, CLIP170, CYLN1, RSN"	ENSG00000130779	"CAP-Gly domain containing linker protein 1"	P30622	12	122271432-122422632	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 96.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004399, HPA026678"	Approved		Supported	"Microtubule ends,Cytosol"		7700	7700	"Microtubule ends, Cytosol"		"CAB004399: AB_671001, HPA026678: AB_1846954"	"unprognostic (1.18e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.72e-1)"	"unprognostic (4.91e-2)"	"unprognostic (6.28e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.20e-1)"	"unprognostic (4.73e-2)"	"unprognostic (2.51e-1)"	"unprognostic (7.62e-2)"	"unprognostic (2.31e-2)"	"unprognostic (8.97e-2)"	"unprognostic (3.26e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.63e-1)"	"unprognostic (3.37e-1)"	"unprognostic (2.52e-3)"	14.4	12.6	9.8	9.1	10.9	6.4	11.7	44.5	11.5	11.6	19.5	4.3	13.9	5.7	14.3	10.1	24.8	7.5	7.7	11.8	9.3	7.5	10.0	15.2	10.0	5.8	6.5	9.5	6.3	9.1	37.8	10.9	36.5	8.7	13.2	7.1	6.7	11.8	15.1	96.5	16.8	9.1	31.1	7.2	5.9	9.6	6.1	6.9	3.7	24.1	25.9	10.1	22.2	16.6	5.3	5.4	18.2	10.6	3.9	7.2	3.7	15.3	19.4	12.0	12.1	10.3	15.9	20.9	21.9	20.9	14.9	9.3	9.0	7.6	6.9	14.8	28.4	19.7	7.6	9.0	16.9	28.9	5.5	2.3	12.9	9.5	20.5	7.9	12.7	10.5	31.0	17.1	25.9	14.9	8.6	4.7	14.9	8.9	4.9	2.8	4.5	17.2	4.6	9.3	3.4	13.4	17.6	4.6	2.9	47.0	11.5	19.2	9.9	4.7	28.8	11.3	12.2	26.5	14.3	5.3	4.1	4.1	19.4	4.0	7.8	3.6	6.5	5.2	7.2	10.6	5.4	5.3	6.7	6.5	5.4	3.6	5.0	3.7	18.2	3.9	8.6	3.5	5.8	3.7	9.8	10.9	44.5	11.5	9.3	7.5	6.5	9.5	8.7	6.9
CLSTN1	"CDHR12, CSTN1, KIAA0911"	ENSG00000171603	"Calsyntenin 1"	O94985	1	9729026-9824526	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 102.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012412	Enhanced					70000000	70000000			"HPA012412: AB_1846981"	"unprognostic (4.63e-2)"	"unprognostic (2.89e-1)"	"unprognostic (9.76e-2)"	"unprognostic (1.43e-1)"	"unprognostic (9.79e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.44e-3)"	"unprognostic (3.07e-2)"	"unprognostic (2.54e-1)"	"unprognostic (3.24e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.25e-1)"	"prognostic favourable (4.10e-7)"	"unprognostic (1.12e-1)"	"unprognostic (2.65e-1)"	"unprognostic (4.05e-2)"	"unprognostic (4.72e-2)"	13.6	20.1	38.2	15.0	51.2	5.2	15.4	90.5	102.0	24.2	28.6	25.1	11.7	16.7	35.9	14.2	21.0	35.1	25.6	16.3	32.1	31.2	23.3	4.7	16.0	16.4	25.8	53.8	33.6	31.1	27.8	21.0	22.8	32.3	33.6	26.1	29.8	30.0	24.9	10.3	45.6	18.6	28.8	22.0	14.4	15.1	8.1	21.6	15.3	20.9	12.9	16.1	18.0	23.6	2.5	2.7	8.5	1.7	0.9	6.3	2.5	27.2	16.2	23.4	21.8	25.0	16.6	7.7	17.4	19.5	22.3	20.4	11.4	65.8	21.5	45.6	34.3	39.0	13.7	61.5	17.9	24.4	16.7	6.4	20.4	12.0	34.7	12.0	10.4	16.9	42.4	28.8	19.6	31.1	2.9	16.8	10.9	12.7	13.3	6.2	9.8	13.0	20.1	8.6	10.3	27.6	7.9	25.0	15.8	25.1	48.4	19.4	9.8	20.6	46.3	26.4	21.0	17.6	28.8	17.1	15.8	31.1	22.6	19.3	29.8	8.5	1.4	4.3	6.3	1.7	3.3	2.3	4.0	4.7	2.7	2.5	2.9	2.6	0.8	0.9	1.7	1.7	3.6	2.5	38.2	51.2	90.5	99.9	32.1	31.2	25.8	53.8	32.3	21.6
CLTC	"CLTCL2, Hc"	ENSG00000141367	"Clathrin heavy chain"	Q00610	17	59619689-59696956	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Autophagy, Cell cycle, Cell division, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB010389, CAB011571, CAB017155, HPA059143"	Approved		Enhanced	"Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol"		51000000	51000000	"Vesicles, Endosomes, Lysosomes"	"Mitotic spindle, Cytosol"	"CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: "	"unprognostic (1.56e-1)"	"prognostic unfavourable (7.35e-4)"	"prognostic favourable (7.65e-4)"	"unprognostic (1.03e-1)"	"unprognostic (2.62e-1)"	"unprognostic (5.23e-3)"	"prognostic unfavourable (5.54e-4)"	"unprognostic (1.11e-1)"	"unprognostic (6.43e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (2.02e-4)"	39.5	45.7	47.4	35.1	57.6	30.7	57.9	59.1	83.6	38.1	45.0	25.1	47.7	27.9	38.7	52.3	32.1	30.9	34.1	39.9	47.1	53.7	48.6	46.0	46.5	60.7	53.9	59.3	29.8	23.3	96.1	30.0	51.5	57.0	38.9	48.9	22.7	28.6	54.4	44.2	30.5	27.7	45.8	47.8	28.0	34.2	29.4	28.8	28.0	43.7	26.6	31.2	37.1	40.6	10.0	24.6	13.9	24.6	12.3	15.6	13.1	46.9	71.1	35.1	34.7	59.3	48.3	40.1	50.5	53.3	45.3	47.3	43.5	28.9	32.7	58.0	71.7	31.0	52.2	42.0	60.5	35.1	28.1	53.6	45.0	67.5	45.2	36.6	31.0	45.7	25.7	68.8	44.4	50.0	53.3	46.3	70.5	83.7	21.7	10.9	30.2	41.5	19.3	58.8	39.6	50.7	66.7	31.5	37.5	31.3	20.5	29.9	48.7	23.1	63.9	83.1	49.6	39.6	51.7	36.5	51.2	30.2	60.9	24.8	50.7	10.5	20.9	13.9	12.7	24.6	15.6	10.0	11.7	13.7	24.6	9.1	10.0	11.0	13.4	12.3	20.7	16.1	14.5	13.1	47.4	57.6	59.1	83.6	47.1	53.7	53.9	59.3	57.0	28.8
CLTCL1	"CHC22, CLH22, CLTCL, CLTD"	ENSG00000070371	"Clathrin heavy chain like 1"	P53675	22	19179473-19291716	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 53.0"	"Cell line enhanced"	"Detected in many"		"HMC-1: 34.3;K-562: 16.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	8	"classical monocyte: 3.3;neutrophil: 8.4"	"Group enriched"	"Detected in many"	15	"granulocytes: 8.4;monocytes: 3.3"									"HPA075327, HPA075795"	Enhanced		Approved	Vesicles				Vesicles		"HPA075327: , HPA075795: "	"unprognostic (1.29e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.93e-2)"	"unprognostic (3.16e-3)"	"unprognostic (8.20e-2)"	"unprognostic (6.93e-3)"	"unprognostic (1.60e-1)"	"unprognostic (3.28e-1)"	"unprognostic (4.42e-2)"	"unprognostic (2.93e-3)"	"unprognostic (3.14e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.20e-1)"	"unprognostic (8.71e-4)"	"unprognostic (1.61e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.06e-1)"	2.9	3.3	1.1	0.9	2.0	9.7	1.6	3.4	1.8	1.3	1.0	3.7	1.2	0.4	2.3	3.1	2.2	1.4	0.9	5.6	1.3	1.7	1.0	1.7	1.2	0.6	2.7	1.4	1.4	0.9	2.1	14.9	1.1	4.1	1.8	0.8	4.2	1.5	1.1	53.0	2.1	0.9	2.4	3.6	0.9	1.0	17.2	1.2	1.3	2.7	10.4	0.7	1.2	1.3	0.2	0.3	8.4	3.3	0.0	0.3	0.6	2.2	2.3	1.5	2.5	5.8	3.2	0.7	1.6	1.7	2.3	3.4	0.8	0.7	0.9	0.2	3.6	0.8	2.4	4.5	1.8	0.1	2.4	0.1	2.2	2.7	2.9	3.2	34.3	13.7	3.7	4.1	5.8	1.4	16.0	0.9	5.2	1.8	0.4	11.4	2.0	1.9	1.2	13.1	0.0	1.7	0.9	3.7	0.6	3.4	2.1	0.2	4.6	13.8	0.4	4.0	8.6	2.2	2.6	1.8	4.2	0.4	2.4	8.8	0.8	0.0	3.3	0.3	0.1	0.7	0.0	0.0	0.1	0.3	0.3	0.2	0.3	0.0	8.4	0.0	0.0	0.1	0.0	0.6	1.1	2.0	3.4	1.8	1.3	1.7	2.7	1.4	4.1	1.2
CLU	"APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2"	ENSG00000120885	Clusterin	P10909	8	27596917-27615031	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Complement pathway, Immunity, Innate immunity"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"epididymis: 580.4;liver: 590.5"	"Cell line enhanced"	"Detected in many"		"HeLa: 233.1;SK-BR-3: 203.8;T-47d: 148.7;U-2 OS: 133.0"	"Cancer enhanced"	"Detected in all"		"glioma: 1485.6"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	7	"basophil: 69.2"	"Lineage enriched"	"Detected in many"	25	"granulocytes: 69.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000572, CAB016253"	Enhanced				"Secreted to blood"	36000000000	36000000000			"CAB016253: AB_673562, HPA000572: AB_1078539"	"unprognostic (1.10e-2)"	"unprognostic (1.81e-2)"	"unprognostic (1.14e-3)"	"unprognostic (2.74e-2)"	"unprognostic (5.59e-2)"	"unprognostic (4.13e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.87e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.80e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.72e-1)"	"prognostic favourable (7.66e-5)"	"unprognostic (5.29e-2)"	82.5	217.4	233.5	50.2	280.3	3.4	90.4	141.2	414.7	78.3	47.9	139.5	184.6	19.9	55.4	580.4	48.3	217.2	172.7	24.6	176.2	154.7	69.8	590.5	30.5	127.3	209.0	173.1	49.6	134.8	220.4	34.3	8.5	189.0	63.4	18.0	125.4	62.2	359.2	7.7	12.8	24.0	87.9	255.2	17.2	56.6	161.5	113.5	5.3	106.6	11.8	134.8	72.2	54.7	0.1	1.3	69.2	2.1	0.9	2.7	110.6	0.7	96.0	4.2	4.9	23.8	32.8	13.4	17.0	33.6	4.5	2.3	18.4	15.2	0.3	68.3	15.1	32.2	18.2	2.7	2.9	70.8	17.6	41.6	233.1	22.6	20.8	1.0	111.1	54.9	11.0	19.4	5.6	59.1	0.5	49.0	1.5	16.1	0.3	3.1	35.0	11.4	0.3	16.1	13.3	44.4	69.3	3.9	2.4	23.6	203.8	1.0	148.7	0.6	8.7	1.3	133.0	7.6	5.7	6.3	22.4	0.7	107.0	6.9	0.6	69.2	2.1	0.9	2.3	0.6	0.8	0.0	2.7	2.5	0.7	0.1	0.3	0.8	9.6	0.9	0.1	1.3	0.7	110.6	233.5	280.3	141.2	223.1	176.2	154.7	209.0	173.1	189.0	113.5
CNBD1	FLJ35802	ENSG00000176571	"Cyclic nucleotide binding domain containing 1"	Q8NA66	8	86866442-87615219	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	14	"testis: 16.9"	"Group enriched"	"Detected in some"	11	"Karpas-707: 9.1;U-266/70: 5.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA025037, HPA027469, HPA027786"	Uncertain				"Secreted in male reproductive system"					"HPA025037: AB_10794318, HPA027469: AB_10599492, HPA027786: AB_10600231"															"unprognostic (1.89e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.2	16.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CNBP	"CNBP1, DM2, RNF163, ZCCHC22, ZNF9"	ENSG00000169714	"CCHC-type zinc finger nucleic acid binding protein"	P62633	3	129169484-129183922	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063097			Supported	Nucleoplasm,Cytosol		43000	43000	"Nucleoplasm, Cytosol"		"HPA063097: "	"unprognostic (1.74e-1)"	"unprognostic (3.11e-2)"	"unprognostic (4.84e-1)"	"unprognostic (3.35e-2)"	"unprognostic (6.28e-2)"	"unprognostic (7.38e-2)"	"unprognostic (7.02e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.06e-3)"	"unprognostic (6.39e-2)"	"prognostic unfavourable (3.51e-4)"	"unprognostic (4.72e-3)"	"unprognostic (4.62e-3)"	"unprognostic (1.89e-1)"	"unprognostic (2.03e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.58e-1)"	54.2	52.8	36.4	33.6	33.7	35.9	46.6	43.5	35.6	58.1	47.1	34.5	40.5	32.4	54.5	49.4	55.6	40.9	48.5	78.2	33.0	32.0	38.0	71.6	47.5	40.6	39.7	30.3	67.4	65.4	39.3	33.5	41.5	33.3	62.3	37.1	41.3	48.9	50.9	182.1	46.7	40.6	71.9	38.0	43.2	43.1	32.1	33.1	39.0	67.3	81.1	41.2	76.1	63.5	74.3	60.3	120.1	84.1	61.7	83.4	172.9	61.2	36.3	53.0	42.0	53.0	45.5	41.8	48.2	76.5	52.6	60.5	53.2	43.2	81.5	41.4	44.8	46.1	69.2	55.9	71.3	54.7	50.4	78.7	37.5	57.2	52.8	84.4	45.3	43.9	65.6	36.8	133.0	46.4	58.9	56.1	55.0	73.3	78.2	62.1	64.6	61.4	68.8	49.2	97.1	54.4	59.1	72.2	57.8	38.0	37.6	102.2	43.3	58.1	48.8	39.0	38.4	53.5	48.7	52.8	48.0	128.2	40.1	57.9	51.4	93.4	84.1	96.8	64.1	63.8	80.6	74.3	77.4	68.9	60.3	62.7	83.4	72.0	120.1	61.7	48.9	35.1	73.9	172.9	36.4	33.7	43.5	35.6	33.0	32.0	39.7	30.3	33.3	33.1
CNKSR1	"CNK, CNK1, KSR"	ENSG00000142675	"Connector enhancer of kinase suppressor of Ras 1"	Q969H4	1	26177403-26189886	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A-431: 11.6;BEWO: 10.1;CAPAN-2: 17.9;HaCaT: 13.2;hTCEpi: 11.4;SK-BR-3: 11.6;T-47d: 10.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"memory B-cell: 2.1;memory CD4 T-cell: 2.4;naive CD4 T-cell: 1.4;T-reg: 2.6"	"Group enriched"	"Detected in many"	8	"B-cells: 2.1;T-cells: 2.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA030847	Uncertain		Approved	Cytosol				Cytosol		"HPA030847: AB_10601100"	"unprognostic (2.73e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.19e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.61e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.37e-1)"	"unprognostic (3.68e-1)"	"unprognostic (2.49e-3)"	"unprognostic (1.69e-3)"	"unprognostic (1.90e-2)"	"unprognostic (3.27e-2)"	"unprognostic (2.91e-1)"	"prognostic favourable (5.91e-4)"	0.7	0.0	1.0	3.5	1.4	0.0	4.5	5.4	1.1	4.4	19.1	0.8	12.8	8.6	1.9	11.9	15.4	6.1	13.3	0.7	1.4	1.2	10.0	2.9	10.2	0.7	0.9	0.7	2.5	27.6	10.2	12.6	32.4	1.2	10.3	5.4	0.7	15.7	18.9	17.7	11.9	22.6	1.0	1.3	1.3	7.3	1.5	0.7	1.9	20.6	11.9	15.9	6.1	5.3	2.1	0.0	0.0	0.0	0.2	2.6	0.5	11.6	0.0	0.2	0.1	0.2	0.0	10.1	0.3	0.0	0.4	0.0	1.8	17.9	1.9	6.0	0.0	13.2	0.3	8.4	0.3	0.4	0.6	0.2	4.3	5.0	0.1	0.1	0.2	0.0	11.4	0.0	3.2	0.0	1.5	0.1	0.0	5.4	0.1	0.6	5.2	1.1	0.1	0.1	0.0	1.0	6.8	2.5	0.6	0.0	11.6	0.2	10.9	0.0	0.0	0.0	1.8	0.7	0.1	4.1	0.7	0.5	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.4	0.0	0.0	0.3	1.4	0.1	0.0	0.2	0.0	0.0	2.6	0.5	1.0	1.4	5.4	1.1	1.4	1.2	0.9	0.7	1.2	0.7
CNN1	"Sm-Calp, SMCC"	ENSG00000130176	"Calponin 1"	P51911	19	11538717-11550323	"Cancer-related genes, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 489.2;urinary bladder: 357.9"	"Cell line enhanced"	"Detected in some"		"BJ: 34.6;BJ hTERT+: 13.3;BJ hTERT+ SV40 Large T+: 18.1;BJ hTERT+ SV40 Large T+ RasG12V: 25.1;HBF TERT88: 28.0;K-562: 12.9;U-2 OS: 13.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 142.1"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000007, HPA014263"	Enhanced		Approved	"Actin filaments"				"Actin filaments"		"CAB000007: AB_2082148, HPA014263: AB_1847039"	"unprognostic (4.98e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.04e-3)"	"unprognostic (1.95e-1)"	"unprognostic (2.47e-1)"	"unprognostic (4.20e-1)"	"unprognostic (5.10e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.35e-1)"	"unprognostic (7.06e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.01e-1)"	"prognostic unfavourable (5.43e-6)"	"unprognostic (1.70e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.78e-3)"	"unprognostic (6.11e-3)"	9.3	4.1	0.5	34.9	0.9	0.0	7.9	0.5	1.2	90.5	193.4	1.3	78.1	9.4	182.6	50.6	140.5	52.2	105.7	22.2	0.6	0.6	6.2	1.0	9.5	2.2	0.7	1.8	36.5	1.3	0.0	0.7	4.0	2.2	120.1	26.4	8.8	9.1	125.2	4.8	4.5	37.1	489.2	1.0	1.2	66.5	16.4	0.5	0.4	3.2	4.5	3.3	357.9	26.8	0.0	0.4	0.0	0.1	0.0	0.0	5.2	0.0	0.5	2.2	0.4	0.2	0.0	1.4	34.6	13.3	18.1	25.1	9.8	0.0	0.1	1.0	9.8	0.1	0.0	0.0	28.0	0.0	0.0	0.0	0.0	0.8	0.9	0.0	0.1	1.2	0.0	11.1	0.0	0.0	12.9	0.0	0.0	0.0	0.1	1.7	1.1	0.2	0.1	0.4	1.3	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.1	0.1	13.0	0.5	0.4	0.0	0.1	0.0	1.2	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.5	0.9	0.5	1.2	0.6	0.6	0.7	1.8	2.2	0.5
CNOT3	"KIAA0691, LENG2, NOT3, NOT3H"	ENSG00000088038	"CCR4-NOT transcription complex subunit 3"	O75175	19	54137717-54155708	"Cancer-related genes, Predicted intracellular proteins"	"RNA-mediated gene silencing, Transcription, Transcription regulation, Translation regulation"	"Developmental protein, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEK 293: 71.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006408	Approved		Approved	Cytosol				Cytosol		"HPA006408: AB_1078543"	"unprognostic (1.23e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.86e-2)"	"unprognostic (1.90e-1)"	"prognostic unfavourable (2.22e-4)"	"unprognostic (9.06e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.65e-2)"	"unprognostic (9.30e-3)"	"unprognostic (4.08e-3)"	"prognostic unfavourable (2.77e-4)"	"unprognostic (2.18e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.66e-2)"	18.1	25.2	25.5	23.6	26.4	21.4	20.2	46.8	27.9	22.1	20.7	24.5	27.7	21.3	25.0	26.5	22.1	23.6	19.7	16.2	21.9	15.6	21.3	20.2	17.9	23.9	25.5	20.8	28.0	22.7	27.6	30.2	24.2	20.3	23.3	17.5	20.7	22.4	31.4	20.2	25.2	21.4	22.0	16.7	26.3	21.9	34.4	26.9	33.6	26.3	14.3	23.3	23.8	29.9	3.2	6.7	8.4	3.1	1.6	3.6	2.9	13.6	22.0	22.8	13.1	8.5	8.6	16.0	12.8	22.2	17.2	15.4	14.1	11.8	16.8	8.2	14.8	14.4	25.3	12.5	17.8	17.4	71.4	26.1	14.3	12.5	14.8	14.9	18.3	10.9	12.0	15.3	25.9	13.6	19.2	15.8	12.6	16.9	18.4	8.8	13.9	17.7	18.4	17.5	10.9	11.5	27.7	14.7	12.5	24.7	17.8	8.1	10.2	16.0	12.1	14.6	16.9	7.7	17.3	14.8	16.2	23.2	12.7	11.4	15.4	1.4	3.1	5.2	3.6	2.2	2.5	2.9	2.4	3.2	2.8	3.2	2.7	2.6	8.4	1.6	2.6	6.7	2.5	2.9	25.5	26.4	46.8	27.9	21.9	15.6	25.5	20.8	20.3	26.9
CNTF	HCNTF	ENSG00000242689	"Ciliary neurotrophic factor"	P26441	11	58622673-58625733	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	5	"brain: 47.5"	"Cell line enhanced"	"Detected in many"		"U-2197: 12.7"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"midbrain: 47.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"							HPA019654	Approved		Approved	Vesicles				Vesicles		"HPA019654: AB_1859050"	"unprognostic (1.88e-1)"	"unprognostic (2.64e-3)"	"unprognostic (1.01e-2)"	"unprognostic (4.37e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.91e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.24e-2)"	"unprognostic (5.87e-2)"	"unprognostic (1.63e-1)"	"unprognostic (8.25e-4)"	"unprognostic (5.42e-2)"	"unprognostic (8.50e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.91e-1)"	"unprognostic (9.50e-2)"	"unprognostic (9.67e-2)"	2.0	0.7	1.4	0.9	4.8	10.0	0.8	1.2	1.6	0.3	0.9	2.5	1.1	1.4	0.3	1.4	0.9	8.3	0.8	2.5	1.8	1.6	0.9	0.9	0.8	0.6	47.5	0.9	0.3	0.5	1.2	0.5	0.6	9.3	0.6	1.3	3.1	1.3	0.4	3.7	0.9	0.9	0.6	22.8	0.6	0.5	0.7	1.2	0.2	1.0	3.7	0.6	0.6	0.3	0.4	0.0	0.0	0.3	0.0	0.7	0.2	2.1	0.8	3.4	3.5	1.0	0.3	1.7	1.6	2.2	1.6	1.2	2.9	2.9	4.3	1.2	2.2	3.8	3.6	3.9	3.2	3.0	2.1	2.3	4.3	1.6	0.4	3.3	4.2	1.0	1.3	5.3	1.7	1.7	3.4	1.0	2.0	0.9	3.2	3.1	2.1	1.5	2.2	2.4	3.0	1.9	2.5	1.5	4.2	2.2	2.3	5.8	2.9	2.4	1.2	2.5	1.9	12.7	4.0	2.4	4.9	3.7	6.6	1.7	2.9	0.0	0.3	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	1.4	4.8	1.2	1.4	1.8	1.6	47.5	0.9	9.3	1.2
CNTRL	"CEP1, CEP110"	ENSG00000119397	Centriolin	Q7Z7A1	9	121074863-121177610	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HL-60: 34.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA020468, HPA020480, HPA051583"	Approved		Supported	Centrosome,Cytosol				Centrosome	Cytosol	"HPA020468: , HPA020480: , HPA051583: "	"unprognostic (4.33e-3)"	"unprognostic (2.89e-3)"	"unprognostic (2.09e-2)"	"unprognostic (7.97e-2)"	"unprognostic (1.17e-2)"	"prognostic favourable (9.21e-5)"	"unprognostic (1.05e-2)"	"unprognostic (3.22e-3)"	"unprognostic (3.74e-3)"	"unprognostic (2.02e-1)"	"unprognostic (1.78e-2)"	"unprognostic (5.47e-2)"	"unprognostic (3.60e-3)"	"unprognostic (9.83e-3)"	"unprognostic (2.43e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.13e-2)"	7.7	4.7	5.5	22.2	11.7	24.0	6.8	10.9	8.7	8.4	5.5	4.9	5.9	3.8	7.3	6.4	5.6	8.4	5.1	4.4	6.6	4.3	4.0	3.8	9.3	20.3	8.1	4.1	10.6	5.2	4.0	17.3	5.8	7.0	7.2	5.5	4.4	6.3	8.6	2.8	5.2	8.8	5.7	9.7	14.8	7.1	30.2	9.8	26.7	6.2	4.2	19.2	8.6	7.1	12.7	10.5	15.0	6.9	4.8	10.4	2.5	5.3	3.6	10.0	7.2	1.5	2.3	1.7	3.7	2.8	2.9	2.5	2.1	5.9	24.6	1.4	2.7	11.3	3.3	2.2	4.8	14.9	2.6	12.8	6.5	2.5	2.1	34.8	15.6	1.4	1.7	3.1	7.5	6.4	8.3	14.1	2.8	3.4	13.6	11.9	3.4	2.9	12.9	15.1	7.0	1.4	2.5	3.8	5.7	12.7	2.3	2.9	4.9	16.7	4.7	3.1	5.4	4.8	6.8	9.8	10.7	16.7	2.6	14.4	7.1	12.2	6.9	15.0	7.5	4.5	5.7	10.8	7.7	5.5	3.4	12.7	9.3	6.6	2.7	4.8	5.8	10.5	10.4	2.5	5.5	11.7	10.9	8.7	6.6	4.3	8.1	4.1	7.0	9.8
COL11A1	"CO11A1, COLL6, STL2"	ENSG00000060718	"Collagen type XI alpha 1 chain"	P12107	1	102876467-103108872	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, Stickler syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 33.3"	"Cell line enhanced"	"Detected in some"		"AF22: 38.3;BJ: 13.5;BJ hTERT+ SV40 Large T+ RasG12V: 28.6;HBF TERT88: 16.2;HSkMC: 48.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			HPA058335			Approved	"Endoplasmic reticulum"	"Secreted to extracellular matrix"	270000	270000	"Endoplasmic reticulum"		"HPA058335: "	"unprognostic (2.60e-3)"	"unprognostic (6.61e-4)"	"unprognostic (9.58e-2)"	"unprognostic (5.06e-5)"	"unprognostic (2.83e-1)"	"unprognostic (2.85e-2)"	"unprognostic (6.03e-3)"	"unprognostic (2.23e-3)"	"unprognostic (9.08e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.94e-2)"	"unprognostic (3.01e-12)"	"unprognostic (1.27e-2)"	"unprognostic (3.53e-1)"	"unprognostic (3.54e-2)"	"unprognostic (2.32e-2)"	1.2	1.8	8.6	1.3	9.1	0.8	1.5	2.0	7.9	2.3	1.1	4.1	0.0	1.0	1.8	1.0	0.8	0.8	5.9	0.8	8.3	8.6	1.0	0.8	1.2	0.9	8.1	5.9	1.2	1.9	1.0	5.5	33.3	11.1	1.1	1.4	5.9	3.3	2.2	0.9	2.4	0.9	1.3	9.0	2.2	0.9	4.7	5.8	0.0	0.9	0.6	0.8	1.1	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	38.3	0.0	1.5	2.0	0.0	13.5	5.1	7.7	28.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	16.2	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	48.2	0.0	0.3	0.0	0.0	0.0	0.0	10.3	0.0	0.0	0.0	2.7	0.0	0.0	2.3	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	8.9	0.0	1.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	8.6	9.1	2.0	7.9	8.3	8.6	8.1	5.9	11.1	5.8
COL17A1	"BP180, BPAG2"	ENSG00000065618	"Collagen type XVII alpha 1 chain"	Q9UMD9	10	104031286-104086002	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 85.8;skin 1: 123.2;tongue: 64.0"	"Cell line enhanced"	"Detected in some"		"HaCaT: 55.3;HBEC3-KT: 88.6;hTCEpi: 115.1;hTERT-HME1: 98.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 227.4"	"Region enriched"	"Detected in single"	4	"basal ganglia: 1.2"	"Cell type enriched"	"Detected in single"	15	"neutrophil: 3.7"	"Lineage enriched"	"Detected in single"	15	"granulocytes: 3.7"	"Region enriched"	"Detected in single"	4	"cerebellum: 1.1"	"Not detected"	"Not detected"			"HPA043673, HPA052963"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"	"Secreted to extracellular matrix"			"Plasma membrane"	"Golgi apparatus"	"HPA043673: AB_10960893, HPA052963: "	"prognostic favourable (1.38e-4)"	"unprognostic (1.33e-1)"	"unprognostic (4.01e-1)"	"unprognostic (1.01e-1)"	"unprognostic (9.65e-2)"	"unprognostic (3.75e-1)"	"unprognostic (2.13e-1)"	"unprognostic (6.82e-3)"	"unprognostic (1.63e-1)"	"unprognostic (7.85e-3)"	"prognostic unfavourable (1.86e-4)"	"unprognostic (2.12e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.23e-1)"	"unprognostic (3.75e-2)"	"unprognostic (8.35e-2)"	0.2	0.0	0.2	4.4	1.2	7.5	8.1	0.2	0.2	15.2	9.3	0.2	0.9	2.0	0.6	2.6	31.5	0.1	1.2	0.2	0.2	0.1	0.4	0.2	0.7	0.2	0.2	0.2	0.2	0.2	0.0	0.6	85.8	0.2	5.0	5.4	0.2	15.5	7.3	0.5	123.2	23.2	0.8	0.2	0.3	3.9	4.0	0.2	18.1	2.0	64.0	24.7	3.0	17.3	0.0	0.0	3.7	0.2	0.0	0.0	0.8	3.1	0.0	0.1	0.0	0.0	0.0	9.8	0.0	0.0	0.0	0.0	0.0	24.3	0.0	0.7	0.0	55.3	0.0	88.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	115.1	0.0	98.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	5.0	3.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.2	0.0	0.0	0.8	0.2	1.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2
COL18A1	"KNO, KNO1, KS"	ENSG00000182871	"Collagen type XVIII alpha 1 chain"	P39060	21	45405137-45513720	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 273.2"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 31.2;EFO-21: 70.3;NTERA-2: 39.1;TIME: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	5	"neutrophil: 7.3"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 7.3"	"Region enriched"	"Detected in many"	6	"cerebellum: 24.8"	"Low region specificity"	"Detected in all"			"CAB001961, HPA011025, HPA036104"	Approved		Approved	"Golgi apparatus"	"Secreted to extracellular matrix"	250000000	250000000	"Golgi apparatus"		"CAB001961: , HPA011025: AB_1078551, HPA036104: "	"unprognostic (4.32e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.47e-2)"	"unprognostic (3.25e-2)"	"unprognostic (5.55e-2)"	"prognostic favourable (6.16e-4)"	"unprognostic (4.23e-3)"	"unprognostic (9.93e-2)"	"unprognostic (3.48e-1)"	"unprognostic (2.77e-1)"	"unprognostic (5.50e-2)"	"unprognostic (1.70e-1)"	"unprognostic (1.83e-2)"	"unprognostic (9.44e-2)"	"unprognostic (9.10e-3)"	"unprognostic (2.25e-3)"	25.5	14.4	2.2	12.7	13.0	5.6	17.7	3.4	8.5	40.4	12.7	26.0	19.6	12.6	22.2	72.5	12.0	18.8	25.3	18.5	3.5	5.3	36.2	273.2	11.9	7.6	35.5	3.5	43.3	21.8	2.6	17.8	16.5	20.8	13.9	2.3	17.3	8.8	20.2	8.1	23.1	10.6	33.4	31.9	14.5	7.1	11.0	23.6	2.3	16.0	12.0	6.7	28.7	18.2	0.4	0.4	7.3	0.4	0.0	1.2	0.2	2.5	19.1	4.8	4.3	8.9	7.4	1.0	18.4	31.2	8.8	2.4	11.9	6.8	0.5	70.3	18.2	8.6	1.0	1.1	1.7	0.2	5.3	11.0	0.3	16.2	8.6	0.4	1.1	8.7	0.7	0.8	1.0	27.1	11.1	0.1	3.2	4.4	0.4	1.1	39.1	7.1	0.5	3.0	1.1	29.7	0.4	5.4	4.1	1.8	2.0	5.8	1.8	3.0	41.3	0.2	2.8	0.1	4.3	0.1	0.2	0.3	0.0	0.9	7.6	1.0	0.4	1.5	0.1	0.4	0.2	0.4	0.4	0.0	0.1	0.1	1.2	0.6	7.3	0.0	0.3	0.4	0.0	0.2	2.2	13.0	3.4	8.5	3.5	5.3	35.5	3.5	20.8	23.6
COL1A1	OI4	ENSG00000108821	"Collagen type I alpha 1 chain"	P02452	17	50183289-50201632	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 415.7"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 89.7;BJ: 172.4;fHDF/TERT166: 260.2;HSkMC: 131.8;U-138 MG: 140.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			HPA011795	Approved		Approved	Vesicles,Cytosol	"Secreted to extracellular matrix"	58000000	58000000	Cytosol	Vesicles	"HPA011795: AB_1847088"	"unprognostic (1.61e-1)"	"unprognostic (3.60e-3)"	"unprognostic (8.29e-2)"	"unprognostic (5.52e-2)"	"unprognostic (7.74e-2)"	"unprognostic (2.22e-1)"	"unprognostic (6.01e-2)"	"prognostic unfavourable (4.43e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.55e-2)"	"unprognostic (8.53e-2)"	"unprognostic (9.90e-2)"	"prognostic unfavourable (7.19e-12)"	"unprognostic (2.74e-2)"	"unprognostic (4.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.87e-3)"	30.2	5.7	0.7	28.2	4.0	0.1	31.7	0.6	0.9	415.7	25.7	1.6	23.9	3.0	121.8	70.9	17.4	33.0	110.3	43.9	0.7	0.1	7.5	4.6	18.8	38.5	0.7	1.2	73.6	10.5	1.0	10.7	89.1	2.2	31.5	4.0	9.2	9.1	21.0	11.0	35.5	10.6	88.0	1.3	13.7	15.0	44.6	0.7	7.7	6.7	15.5	8.7	67.3	49.7	0.2	0.0	0.0	0.0	0.0	1.1	0.0	0.3	0.2	0.9	0.1	36.9	89.7	1.5	172.4	46.8	43.0	27.0	3.4	0.8	0.0	0.4	260.2	0.5	0.4	0.1	7.7	0.2	0.3	0.0	4.3	0.2	70.3	0.0	0.0	131.8	2.5	52.5	0.2	0.0	0.1	0.0	21.6	0.4	0.0	0.0	0.9	0.5	0.3	0.1	0.1	0.2	0.0	0.1	0.4	0.3	0.2	0.0	2.2	0.0	0.0	140.1	30.6	20.9	0.8	0.1	0.3	0.0	10.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.0	0.6	0.9	0.7	0.1	0.7	1.2	2.2	0.7
COL1A2	OI4	ENSG00000164692	"Collagen type I alpha 2 chain"	P08123	7	94394561-94431232	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 244.6"	"Cell line enhanced"	"Detected in some"		"ASC diff: 150.8;ASC TERT1: 181.0;BJ: 148.1;BJ hTERT+: 108.7;fHDF/TERT166: 501.0;HSkMC: 157.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"CAB032650, HPA059738"	Approved		Supported	"Endoplasmic reticulum"	"Secreted to extracellular matrix"	21000000	21000000	"Endoplasmic reticulum"		"CAB032650: AB_2082039, HPA059738: "	"unprognostic (1.20e-1)"	"unprognostic (6.34e-2)"	"unprognostic (1.32e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.86e-2)"	"unprognostic (2.81e-1)"	"unprognostic (5.15e-2)"	"unprognostic (7.38e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.40e-2)"	"unprognostic (5.83e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavourable (1.51e-9)"	"unprognostic (1.35e-2)"	"unprognostic (5.25e-2)"	"unprognostic (1.15e-1)"	"unprognostic (3.31e-3)"	44.7	9.8	1.2	34.9	4.3	0.0	33.4	1.7	2.4	244.6	26.5	2.1	54.1	3.8	166.9	139.1	28.2	36.6	101.4	45.1	1.3	0.8	10.2	4.1	37.1	20.4	1.8	2.8	68.3	10.9	1.8	6.0	70.6	3.8	40.3	10.1	23.0	17.5	28.0	12.1	35.6	15.2	100.7	3.2	16.4	16.1	49.7	1.1	5.6	14.7	42.7	12.6	62.4	55.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	55.8	150.8	181.0	0.0	148.1	108.7	24.4	32.5	0.0	0.1	0.0	0.1	501.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	39.5	0.0	0.0	157.1	0.0	19.2	0.0	0.0	0.0	0.0	20.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	62.2	0.0	38.5	4.2	0.0	0.0	0.0	15.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	4.3	1.7	2.4	1.3	0.8	1.8	2.8	3.8	1.1
COL2A1	"AOM, SEDC, STL1"	ENSG00000139219	"Collagen type II alpha 1 chain"	P02458	12	47972965-48004554	"Cancer-related genes, Disease related genes, Predicted secreted proteins"			"Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3"	"Cell line enhanced"	"Detected in some"		"AF22: 54.0;HAP1: 33.8;HEK 293: 12.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002214, HPA055753"	Supported		Approved	Nucleoplasm	"Secreted to extracellular matrix"			Nucleoplasm		"CAB002214: AB_563666, HPA055753: "	"unprognostic (7.25e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.58e-1)"	"unprognostic (3.44e-1)"	"unprognostic (2.88e-2)"	"unprognostic (3.08e-2)"	"unprognostic (8.63e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.12e-2)"	"unprognostic (1.31e-4)"	"unprognostic (2.64e-1)"	"unprognostic (3.44e-3)"	"unprognostic (1.89e-1)"	"unprognostic (2.93e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.02e-1)"	0.0	0.0	0.1	2.2	0.3	0.0	0.7	0.9	0.9	0.0	0.2	0.3	0.0	0.0	0.3	22.7	0.0	0.0	0.0	0.0	0.5	1.3	0.0	0.0	1.4	0.0	0.0	0.7	1.3	0.0	0.0	11.0	0.4	1.9	2.6	0.4	8.1	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	11.3	2.8	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	54.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.2	0.0	0.0	33.8	0.0	0.0	0.0	12.5	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.0	1.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.9	0.9	0.5	1.3	0.0	0.7	1.9	0.0
COL4A2	"DKFZp686I14213, FLJ22259"	ENSG00000134871	"Collagen type IV alpha 2 chain"	P08572	13	110305812-110513027	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Angiogenesis		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 125.7"	"Cell line enhanced"	"Detected in many"		"EFO-21: 142.4;WM-115: 60.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB010751, HPA029118"	Enhanced		Supported	Vesicles	"Secreted to extracellular matrix"	1900000	1900000	Vesicles		"CAB010751: AB_476828, HPA029118: "	"unprognostic (2.43e-1)"	"unprognostic (4.13e-3)"	"unprognostic (8.04e-2)"	"unprognostic (6.03e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.64e-2)"	"unprognostic (3.45e-2)"	"unprognostic (1.15e-2)"	"unprognostic (3.50e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (3.49e-5)"	"unprognostic (1.33e-2)"	"unprognostic (1.57e-2)"	"unprognostic (6.95e-2)"	"prognostic unfavourable (9.25e-4)"	87.2	9.5	4.6	26.1	3.3	0.1	50.1	2.0	3.0	37.2	53.1	1.9	30.3	7.6	48.4	25.5	23.0	26.3	52.4	26.6	3.6	1.4	18.4	5.7	35.9	17.5	3.8	1.7	25.7	8.3	7.3	3.8	125.7	5.0	26.9	5.5	12.2	7.6	29.3	26.3	9.2	16.9	84.1	2.8	58.5	23.4	11.0	1.9	4.2	16.0	8.0	5.7	65.3	20.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	11.4	6.5	29.5	0.0	38.5	16.0	46.5	40.1	14.5	23.9	11.2	0.7	0.0	0.0	142.4	9.3	11.2	0.0	12.0	4.6	1.5	6.1	0.0	11.0	0.3	28.4	0.0	0.1	7.2	0.7	16.7	11.5	24.9	0.0	0.0	3.9	0.2	0.0	1.0	4.6	2.3	0.0	12.2	0.0	26.3	0.2	0.9	4.8	0.0	0.1	12.5	0.0	0.5	42.8	13.1	33.4	0.3	21.7	0.0	0.2	0.5	0.3	0.0	60.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.6	3.3	2.0	3.0	3.6	1.4	3.8	1.7	5.0	1.9
COL4A3		ENSG00000169031	"Collagen type IV alpha 3 chain"	Q01955	2	227164565-227314792	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"		"Alport syndrome, Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 27.9"	"Cell line enhanced"	"Detected in some"		"HeLa: 16.1;Karpas-707: 9.5;RPTEC TERT1: 10.7;U-266/70: 8.8"	"Group enriched"	"Detected in some"	6	"lung cancer: 1.7;renal cancer: 3.0;thyroid cancer: 5.0"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"memory B-cell: 3.8;naive B-cell: 1.6"	"Lineage enriched"	"Detected in single"	7	"B-cells: 3.8"	"Not detected"	"Not detected"							HPA042064	Approved		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"			Vesicles	"Endoplasmic reticulum"	"HPA042064: AB_10794410"	"unprognostic (4.81e-2)"	"unprognostic (2.25e-1)"	"unprognostic (2.23e-1)"	"unprognostic (9.28e-6)"	"unprognostic (1.43e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.84e-2)"	"unprognostic (7.07e-3)"	"unprognostic (2.30e-1)"	"unprognostic (9.09e-3)"	"unprognostic (9.30e-2)"	"unprognostic (3.02e-2)"	"prognostic favourable (2.51e-7)"	"unprognostic (1.78e-1)"	"unprognostic (3.10e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.26e-1)"	0.7	9.5	0.9	5.4	2.9	0.3	0.9	1.4	2.9	0.7	0.7	1.7	12.0	0.7	1.5	15.3	1.1	1.5	5.3	6.7	1.6	1.2	27.9	0.7	15.0	3.6	2.4	0.0	3.6	4.4	0.2	16.7	0.2	7.5	4.9	1.0	20.9	1.1	11.2	17.8	0.6	5.0	2.9	3.1	6.1	1.5	1.5	3.4	0.0	16.2	9.4	5.8	1.8	1.2	3.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.8	0.0	0.0	0.2	1.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.5	0.0	0.4	0.0	0.1	1.3	0.0	0.0	0.0	2.9	10.7	2.1	0.5	0.0	0.8	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	8.8	3.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.5	3.8	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.9	1.4	2.9	1.6	1.2	2.4	0.0	7.5	3.4
COL4A4	CA44	ENSG00000081052	"Collagen type IV alpha 4 chain"	P53420	2	227002711-227164453	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"			"Alport syndrome, Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 28.7"	"Cell line enhanced"	"Detected in some"		"HeLa: 25.0;Karpas-707: 6.9;RPTEC TERT1: 11.4;U-266/70: 5.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	7	"memory B-cell: 8.0"	"Lineage enriched"	"Detected in many"	7	"B-cells: 8.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"						"unprognostic (7.31e-2)"	"unprognostic (7.56e-2)"	"unprognostic (6.65e-2)"	"unprognostic (4.88e-5)"	"unprognostic (1.12e-1)"	"unprognostic (2.92e-2)"	"unprognostic (8.50e-3)"	"unprognostic (5.14e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.69e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.91e-2)"	"prognostic favourable (2.30e-13)"	"unprognostic (1.53e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.15e-2)"	1.6	8.8	1.2	7.2	2.4	0.2	1.3	1.0	1.8	1.0	1.1	0.7	16.1	1.2	4.8	12.7	2.4	3.0	13.7	11.5	1.4	1.5	28.7	1.9	15.8	13.0	2.4	0.0	3.2	6.6	0.5	15.3	0.7	7.4	7.2	1.2	8.3	1.4	10.9	7.5	0.9	3.3	12.0	4.6	3.7	1.9	1.9	1.5	0.9	12.1	6.6	6.2	3.9	3.7	8.0	0.0	0.1	0.0	1.1	0.5	0.0	0.0	0.6	0.0	0.0	0.1	0.2	0.0	0.2	0.1	0.1	0.5	0.0	0.5	0.0	1.3	0.0	0.1	2.3	0.8	0.2	0.0	2.6	0.0	25.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.2	0.0	0.0	0.8	0.0	0.0	0.0	2.1	11.4	4.2	0.6	0.0	1.6	0.1	0.0	0.3	0.0	0.0	0.0	2.1	0.0	0.2	5.2	3.8	0.0	0.0	0.0	2.7	0.1	0.0	0.0	0.5	0.0	0.0	8.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	1.2	2.4	1.0	1.8	1.4	1.5	2.4	0.0	7.4	1.5
COL4A5	"ASLN, ATS"	ENSG00000188153	"Collagen type IV alpha 5 chain"	P29400	X	108439844-108697545	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Alport syndrome, Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 47.2"	"Cell line enhanced"	"Detected in many"		"HeLa: 28.6;HHSteC: 32.9;HUVEC TERT2: 30.9;TIME: 29.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"						"unprognostic (2.58e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.64e-2)"	"unprognostic (3.98e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.97e-2)"	"unprognostic (7.27e-2)"	"unprognostic (2.70e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.26e-1)"	"prognostic unfavourable (2.41e-5)"	"unprognostic (2.10e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.61e-2)"	"unprognostic (1.06e-1)"	3.3	2.7	13.1	1.7	27.7	0.3	5.8	1.8	16.1	16.9	3.7	47.2	9.5	2.7	31.4	18.2	6.9	19.3	12.6	5.9	13.9	6.2	5.9	1.7	5.9	0.9	46.6	15.7	11.5	2.8	22.3	10.2	9.7	19.5	18.0	4.1	5.8	3.7	23.9	4.8	17.5	3.1	32.8	20.5	2.8	17.7	2.8	40.5	0.0	5.4	0.9	0.9	23.9	11.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	8.9	15.9	5.0	6.2	3.6	0.1	0.9	3.9	4.8	7.9	7.9	0.6	1.4	0.0	0.6	7.2	4.4	14.9	6.1	2.1	3.9	1.1	28.6	0.9	32.9	0.0	4.5	17.0	18.2	5.9	12.7	30.9	0.0	0.0	4.6	0.6	0.0	0.1	4.7	5.3	0.0	0.0	0.0	12.0	8.8	0.0	0.0	23.1	0.7	1.9	4.3	0.0	29.2	3.2	1.0	2.1	1.3	0.6	0.0	0.0	2.8	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.1	27.7	1.8	16.1	13.9	6.2	46.6	15.7	19.5	40.5
COL5A1		ENSG00000130635	"Collagen type V alpha 1 chain"	P20908	9	134641774-134844843	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Heparin-binding	"Cancer-related genes, Disease mutation, Ehlers-Danlos syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 110.7"	"Cell line enhanced"	"Detected in many"		"BJ: 71.5;fHDF/TERT166: 66.4;HeLa: 47.4;HHSteC: 45.1;SiHa: 47.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	7	"MAIT T-cell: 2.3"	"Lineage enriched"	"Detected in single"	23	"T-cells: 2.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			HPA030769	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	12000000	12000000	Vesicles		"HPA030769: "	"unprognostic (7.77e-2)"	"unprognostic (4.55e-3)"	"unprognostic (2.22e-2)"	"unprognostic (2.33e-1)"	"prognostic unfavourable (9.56e-4)"	"unprognostic (8.07e-2)"	"unprognostic (8.09e-2)"	"unprognostic (2.38e-3)"	"unprognostic (1.54e-2)"	"unprognostic (5.03e-3)"	"unprognostic (5.05e-2)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (2.07e-12)"	"unprognostic (2.02e-2)"	"unprognostic (4.73e-2)"	"unprognostic (1.65e-2)"	"unprognostic (2.50e-3)"	11.5	4.2	1.5	13.7	1.4	0.0	9.5	3.0	1.2	110.7	20.9	1.4	11.8	3.6	42.1	24.1	12.3	20.5	31.8	12.2	1.8	0.9	4.3	3.4	13.4	7.8	3.0	1.3	19.5	3.7	3.7	2.6	53.8	2.2	23.3	4.7	9.1	5.1	9.9	5.0	6.9	8.7	26.7	1.5	6.5	12.5	9.5	1.1	2.7	4.1	10.1	4.0	21.8	22.9	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.1	2.7	2.1	3.4	32.1	34.6	1.3	71.5	14.4	12.2	13.1	0.0	0.0	0.0	15.8	66.4	0.9	0.0	0.0	3.5	0.0	0.1	0.0	47.4	0.0	45.1	0.0	0.4	33.9	0.0	11.8	0.9	14.5	0.0	0.2	6.4	0.6	0.0	0.1	1.2	1.3	2.5	8.3	0.2	0.0	0.0	0.9	0.4	47.1	0.3	0.0	0.1	0.0	24.7	25.7	10.6	31.4	14.9	0.0	0.0	0.0	20.4	0.0	4.3	0.0	0.0	0.0	0.3	0.0	2.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	1.4	3.0	1.2	1.8	0.9	3.0	1.3	2.2	1.1
COL5A3		ENSG00000080573	"Collagen type V alpha 3 chain"	P25940	19	9959561-10010471	"Cancer-related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 48.9"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 23.4;BJ: 13.5;BJ hTERT+: 15.1;BJ hTERT+ SV40 Large T+: 8.4;HSkMC: 16.8;WM-115: 15.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	5	"MAIT T-cell: 1.7"	"Lineage enriched"	"Detected in single"	18	"T-cells: 1.7"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			HPA048256	Approved				"Secreted to extracellular matrix"	210000	210000			"HPA048256: "	"unprognostic (1.17e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.63e-2)"	"unprognostic (3.24e-2)"	"unprognostic (6.84e-3)"	"unprognostic (3.01e-1)"	"unprognostic (7.47e-2)"	"unprognostic (1.79e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.27e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.09e-1)"	"prognostic unfavourable (7.17e-8)"	"unprognostic (3.25e-2)"	"unprognostic (7.31e-3)"	"unprognostic (6.00e-2)"	"prognostic unfavourable (6.87e-5)"	48.9	2.6	11.6	10.8	15.9	0.4	27.0	3.2	11.9	24.5	7.8	3.2	3.1	3.6	17.5	9.8	11.3	8.1	10.7	9.5	10.1	3.0	1.9	4.1	6.4	9.2	5.2	3.5	3.4	3.8	3.2	0.9	30.2	4.5	6.8	2.2	9.7	5.1	9.1	15.4	19.0	3.9	9.6	2.5	1.3	3.4	5.3	2.6	1.6	4.5	11.5	4.7	7.3	10.2	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.3	0.0	7.4	23.4	0.0	13.5	15.1	8.4	3.4	0.0	0.0	0.0	0.1	2.5	1.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	16.8	0.3	3.0	3.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.7	0.0	0.0	0.0	6.9	3.2	0.2	0.0	0.0	0.0	0.0	0.9	0.0	15.1	0.0	0.0	0.0	0.3	0.0	1.7	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	11.6	15.9	3.2	11.9	10.1	3.0	5.2	3.5	4.5	2.6
COL6A1		ENSG00000142156	"Collagen type VI alpha 1 chain"	P12109	21	45981737-46005050	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes, Congenital muscular dystrophy, Disease mutation, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 92.0;ASC TERT1: 187.3;BJ: 70.3;HHSteC: 81.7;HSkMC: 136.9;U-138 MG: 102.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 1.0;memory CD8 T-cell: 1.7"	"Lineage enriched"	"Detected in single"	18	"T-cells: 1.7"	"Low region specificity"	"Detected in all"							"HPA019142, HPA029401"	Enhanced		Approved	Cytosol	"Secreted to extracellular matrix"	250000000	250000000	Cytosol		"HPA019142: AB_1847093, HPA029401: AB_10601361"	"unprognostic (3.45e-1)"	"unprognostic (4.09e-2)"	"unprognostic (8.71e-2)"	"unprognostic (1.72e-1)"	"unprognostic (5.79e-3)"	"unprognostic (2.12e-1)"	"unprognostic (6.27e-2)"	"unprognostic (1.09e-2)"	"unprognostic (4.47e-2)"	"unprognostic (3.69e-2)"	"unprognostic (6.06e-3)"	"unprognostic (3.86e-1)"	"prognostic unfavourable (1.07e-8)"	"unprognostic (5.16e-2)"	"unprognostic (7.39e-2)"	"unprognostic (3.53e-3)"	"prognostic unfavourable (4.54e-4)"	73.4	10.8	6.8	45.5	7.1	0.1	85.4	31.9	9.1	100.7	111.6	5.1	34.7	17.1	98.8	75.0	54.5	64.7	89.7	39.7	6.0	5.6	10.2	9.9	21.6	24.7	4.8	5.4	83.0	13.5	6.2	19.8	65.7	9.2	59.6	9.9	18.6	23.1	36.4	20.0	28.2	33.8	147.8	4.7	15.9	40.9	20.2	5.5	9.4	15.9	23.4	12.8	86.9	49.5	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.2	1.5	2.4	7.7	92.0	187.3	0.3	70.3	45.4	18.1	6.3	1.2	4.8	0.0	5.8	39.5	0.3	1.0	0.1	1.5	0.0	1.0	0.0	0.2	0.3	81.7	0.0	0.1	136.9	0.0	45.0	0.6	0.4	0.0	0.0	4.6	0.1	0.0	0.2	1.7	19.7	0.0	1.4	0.3	0.1	0.8	0.0	3.0	6.5	0.0	1.3	0.3	0.3	0.0	102.6	6.8	28.1	26.8	0.0	0.0	0.0	36.6	0.5	8.9	0.0	0.0	0.0	0.7	0.0	1.0	0.0	0.3	1.7	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	6.8	7.1	31.9	9.1	6.0	5.6	4.8	5.4	9.2	5.5
COX17		ENSG00000138495	"COX17, cytochrome c oxidase copper chaperone"	Q14061	3	119654513-119677454	"Cancer-related genes, Predicted intracellular proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA042226, HPA048158"	Supported		Supported	Mitochondria		1000000	1000000	Mitochondria		"HPA042226: , HPA048158: "	"unprognostic (1.98e-2)"	"unprognostic (3.49e-2)"	"unprognostic (1.96e-2)"	"unprognostic (8.29e-2)"	"unprognostic (2.88e-2)"	"unprognostic (6.63e-3)"	"unprognostic (3.49e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.36e-1)"	"unprognostic (7.11e-3)"	"unprognostic (2.12e-1)"	"unprognostic (4.45e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.15e-2)"	"unprognostic (1.65e-1)"	"unprognostic (9.19e-2)"	"unprognostic (2.64e-2)"	16.6	42.9	20.0	18.2	19.4	21.2	30.4	21.1	20.4	10.2	16.8	9.2	43.5	22.0	11.9	22.9	11.7	11.0	13.6	53.5	17.2	23.0	27.6	37.0	17.8	20.3	23.2	15.2	7.9	39.9	21.1	45.7	18.2	33.7	17.2	16.2	19.4	25.6	33.3	80.4	8.7	21.0	15.4	20.8	15.3	22.3	13.4	16.7	11.1	16.6	37.1	17.2	13.7	20.1	35.6	53.5	52.8	46.9	19.8	33.9	22.0	27.2	28.5	15.6	3.8	6.0	5.6	5.6	15.2	9.2	14.1	14.7	25.1	19.8	19.7	18.5	7.2	10.3	15.4	15.5	8.5	24.8	18.5	17.1	22.6	19.8	6.9	24.9	32.0	6.4	15.0	8.8	12.1	9.1	13.9	47.5	16.3	44.4	25.0	35.9	17.5	47.6	11.1	10.5	32.6	21.9	16.1	26.0	11.4	18.8	18.1	22.8	22.7	39.7	7.2	12.1	19.0	7.6	20.9	33.8	33.7	41.8	17.2	19.1	20.8	50.1	22.4	52.8	21.8	33.2	23.0	35.6	27.2	24.7	22.9	27.2	21.7	22.6	17.7	19.8	46.9	53.5	33.9	22.0	20.0	19.4	21.1	20.4	17.2	23.0	23.2	15.2	33.7	16.7
CP		ENSG00000047457	Ceruloplasmin	P00450	3	149162410-149222055	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	"Copper transport, Ion transport, Transport"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	20	"liver: 311.1"	"Cell line enriched"	"Detected in some"	9	"EFO-21: 80.4"	"Cancer enhanced"	"Detected in many"		"liver cancer: 98.3"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001834, CAB008591"	Supported				"Secreted to blood"	830000000000	830000000000			"CAB008591: AB_1613734, HPA001834: AB_1078502"	"unprognostic (3.58e-1)"	"unprognostic (4.24e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.80e-2)"	"unprognostic (4.14e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.97e-2)"	"unprognostic (2.07e-1)"	"unprognostic (8.75e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.70e-1)"	"prognostic unfavourable (1.14e-7)"	"unprognostic (2.68e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.70e-1)"	1.8	0.7	2.6	0.6	5.7	0.4	3.5	2.6	3.5	10.5	2.0	2.5	0.0	1.7	2.3	0.3	1.1	1.5	0.5	6.6	3.6	1.7	1.6	311.1	2.1	2.4	4.2	0.9	0.4	1.2	1.4	5.3	1.9	9.4	2.1	2.7	15.5	6.9	0.4	1.2	2.0	2.6	0.7	4.8	3.5	0.7	0.5	4.4	0.0	2.8	0.4	3.0	3.2	2.9	1.3	0.8	0.6	1.0	0.3	1.3	0.4	0.0	4.7	4.8	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	80.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	1.7	4.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	1.0	0.5	0.8	0.6	0.8	0.9	0.4	0.5	0.6	1.3	0.4	1.3	0.4	0.3	0.4	0.8	0.4	0.4	2.6	5.7	2.6	3.5	3.6	1.7	4.2	0.9	9.4	4.4
CRABP1	"CRABP, CRABP-I, CRABPI, RBP5"	ENSG00000166426	"Cellular retinoic acid binding protein 1"	P29762	15	78340324-78348230	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 40.1;retina: 73.2;thyroid gland: 80.6"	"Group enriched"	"Detected in some"	8	"AF22: 143.3;NTERA-2: 42.9"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 117.2"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	13	"myeloid DC: 1.2"	"Lineage enriched"	"Detected in single"	13	"dendritic cells: 1.2"	"Group enriched"	"Detected in many"	5	"amygdala: 6.6;basal ganglia: 20.9;hypothalamus: 15.5;olfactory region: 15.7;pons and medulla: 7.8"	"Low region specificity"	"Detected in some"			HPA017203	Enhanced	Supported								"HPA017203: AB_1846512"	"unprognostic (1.23e-1)"	"unprognostic (3.76e-3)"	"unprognostic (1.46e-1)"	"prognostic unfavourable (4.72e-4)"	"unprognostic (2.01e-1)"	"unprognostic (4.35e-2)"		"unprognostic (1.05e-1)"	"unprognostic (1.35e-1)"	"unprognostic (2.45e-2)"	"unprognostic (9.79e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.79e-2)"	"unprognostic (9.37e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.69e-1)"	0.7	1.3	6.3	1.8	25.6	0.6	24.8	2.8	12.4	1.2	1.9	3.3	0.3	0.9	1.5	1.9	0.7	0.5	1.2	0.7	1.1	21.9	4.2	0.5	0.8	0.6	16.9	4.5	0.7	0.7	0.5	6.3	7.0	40.1	1.0	1.3	73.2	0.6	24.8	0.5	12.3	2.3	1.3	7.3	21.1	1.9	0.6	2.4	0.4	80.6	2.4	1.0	0.7	0.4	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	143.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.1	0.0	0.9	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	7.6	0.0	42.9	0.1	0.0	0.0	0.0	0.0	0.2	12.0	8.1	0.0	0.0	0.0	0.2	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	25.6	2.8	12.4	1.1	21.9	16.9	4.5	40.1	2.4
CRADD	RAIDD	ENSG00000169372	"CASP2 and RIPK1 domain containing adaptor with death domain"	P78560	12	93677375-93894840	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005337	Uncertain		Approved	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB005337: AB_2085481"	"unprognostic (1.07e-2)"	"prognostic favourable (9.06e-5)"	"unprognostic (9.65e-3)"	"unprognostic (5.51e-2)"	"unprognostic (2.88e-1)"	"unprognostic (3.10e-1)"	"unprognostic (3.79e-2)"	"unprognostic (8.99e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.89e-2)"	"unprognostic (6.06e-2)"	"unprognostic (3.18e-2)"	"prognostic favourable (4.04e-9)"	"unprognostic (2.57e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.08e-1)"	"unprognostic (3.02e-2)"	7.8	15.9	11.0	4.4	14.2	7.1	10.4	12.5	10.4	8.8	9.3	11.5	16.7	14.8	10.6	11.9	9.9	8.3	9.6	35.7	12.3	8.9	14.8	31.4	7.5	7.1	9.8	9.7	8.5	9.7	18.7	21.2	6.5	13.3	9.4	7.5	11.3	10.3	8.8	22.1	8.0	15.4	12.2	11.5	8.3	9.5	15.0	13.2	9.7	8.6	15.5	5.5	10.2	8.4	8.6	7.6	25.3	12.2	10.8	15.0	6.8	6.1	13.9	6.9	7.8	10.0	18.1	8.7	7.0	8.7	6.2	7.3	13.0	2.5	10.9	4.4	8.1	6.3	7.4	9.3	8.1	11.5	10.0	5.8	5.9	9.5	10.3	5.3	5.6	16.4	14.2	10.0	7.9	7.5	16.4	5.2	7.3	9.8	7.7	9.5	8.8	10.7	13.1	3.5	15.1	6.0	4.5	10.6	10.2	9.5	9.4	16.8	16.6	10.4	7.9	14.5	7.2	6.9	7.1	12.3	6.7	10.1	6.8	7.9	6.8	24.9	6.9	25.3	14.7	8.3	13.0	8.6	10.3	15.0	5.6	7.2	11.1	8.2	19.4	10.8	12.2	7.6	11.5	6.8	11.0	14.2	12.5	10.4	12.3	8.9	9.8	9.7	13.3	13.2
CREB1		ENSG00000118260	"CAMP responsive element binding protein 1"	P16220	2	207529737-207603431	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Differentiation, Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003803, HPA019150"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB003803: AB_562092, HPA019150: AB_1847220"	"unprognostic (1.20e-1)"	"unprognostic (3.15e-1)"	"unprognostic (3.30e-2)"	"unprognostic (2.69e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.03e-1)"	"prognostic unfavourable (2.77e-5)"	"unprognostic (8.41e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.53e-1)"	"unprognostic (9.58e-2)"	"unprognostic (1.74e-2)"	"unprognostic (4.82e-3)"	"unprognostic (5.53e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.77e-1)"	"unprognostic (8.45e-2)"	21.2	12.9	19.4	24.8	17.0	22.9	16.7	25.5	18.7	17.6	15.7	14.3	14.7	12.6	19.3	14.9	17.9	15.4	15.5	14.4	15.4	14.5	14.6	13.1	17.7	21.7	15.8	17.7	20.5	12.9	19.8	20.0	19.8	16.1	16.3	16.2	11.2	16.2	14.9	11.6	14.3	15.2	19.5	19.8	19.0	13.3	39.2	18.5	38.4	19.7	13.3	27.7	16.1	23.6	22.1	20.7	34.8	19.1	28.4	22.5	14.5	15.4	13.8	25.7	9.8	15.1	15.5	14.6	9.9	14.9	17.3	18.2	14.0	15.7	10.0	13.4	14.6	13.5	23.2	13.6	25.5	16.0	8.4	18.4	12.4	14.3	12.6	17.3	13.5	11.1	10.1	14.3	21.3	24.3	12.9	14.7	21.3	10.6	26.4	10.3	18.3	8.4	20.6	14.0	13.2	15.4	16.0	17.7	15.4	13.8	10.1	11.9	11.3	19.0	11.6	14.1	15.1	14.8	12.7	13.3	16.8	23.1	17.4	16.0	14.8	16.9	17.0	16.8	17.3	18.0	15.4	22.1	16.6	16.7	20.7	20.2	19.9	13.5	34.8	28.4	19.1	11.3	22.5	14.5	19.4	17.0	25.5	18.7	15.4	14.5	15.8	17.7	16.1	18.5
CREB3L1	OASIS	ENSG00000157613	"CAMP responsive element binding protein 3 like 1"	Q96BA8	11	46277661-46321422	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 60.7"	"Cell line enhanced"	"Detected in many"		"BJ: 30.0;BJ hTERT+: 29.5;BJ hTERT+ SV40 Large T+: 27.6;fHDF/TERT166: 71.4;HHSteC: 26.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA024069, CAB026151"	Enhanced									"CAB026151: , HPA024069: AB_1854750"	"unprognostic (2.46e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.34e-1)"	"prognostic favourable (3.92e-4)"	"unprognostic (1.66e-3)"	"unprognostic (2.93e-1)"	"unprognostic (5.41e-2)"	"unprognostic (2.75e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-1)"	"prognostic unfavourable (2.97e-4)"	"unprognostic (2.62e-1)"	"unprognostic (1.93e-1)"	"prognostic unfavourable (8.59e-4)"	"unprognostic (1.12e-2)"	2.5	3.6	3.7	3.1	2.3	0.0	3.0	1.6	2.9	17.2	13.1	0.9	9.5	8.6	9.7	9.2	2.2	1.7	37.6	4.8	3.3	3.5	1.4	1.5	10.4	0.5	3.4	1.7	9.7	60.7	0.0	3.3	8.2	0.6	17.6	14.1	1.8	28.3	14.3	1.6	2.3	12.9	12.8	1.8	2.2	22.1	3.8	0.2	0.4	1.8	2.2	13.0	15.1	3.4	0.0	0.1	0.0	0.4	0.1	0.0	0.0	0.2	0.1	0.3	5.9	19.1	18.3	0.1	30.0	29.5	27.6	19.2	3.0	0.0	0.0	0.1	71.4	0.0	0.3	0.0	15.4	0.0	0.3	0.4	0.1	0.0	26.6	0.0	0.4	17.5	0.0	15.6	0.5	0.2	2.4	0.0	23.1	0.0	0.0	0.0	3.8	3.1	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.0	1.0	0.0	14.5	4.3	11.1	18.2	0.0	0.0	0.0	17.3	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	3.7	2.3	1.6	2.9	3.3	3.5	3.4	1.7	0.6	0.2
CREB3L2	"BBF2H7, TCAG_1951439"	ENSG00000182158	"CAMP responsive element binding protein 3 like 2"	Q70SY1	7	137874979-138002067	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 81.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA015068, HPA015534"	Uncertain		Supported	"Nucleoplasm,Endoplasmic reticulum"				"Nucleoplasm, Endoplasmic reticulum"		"HPA015068: AB_1847224, HPA015534: "	"unprognostic (8.50e-2)"	"unprognostic (3.70e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.50e-3)"	"unprognostic (9.88e-2)"	"unprognostic (9.09e-2)"	"unprognostic (5.17e-2)"	"unprognostic (4.50e-1)"	"unprognostic (4.77e-1)"	"unprognostic (8.93e-2)"	"unprognostic (9.48e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.08e-3)"	"unprognostic (7.65e-2)"	"unprognostic (2.59e-2)"	"unprognostic (1.32e-2)"	14.9	19.8	4.7	17.1	9.8	10.8	15.7	1.9	6.0	25.4	16.7	11.4	18.7	11.6	28.2	25.5	12.8	16.2	16.2	20.4	5.6	4.3	17.0	11.7	14.6	15.2	11.8	3.7	25.9	16.0	38.4	28.8	81.6	9.8	15.9	9.5	24.9	26.5	23.3	5.0	6.9	17.5	17.7	6.2	12.1	14.1	9.8	9.1	7.0	35.8	10.9	18.1	21.3	15.7	4.6	12.4	7.4	5.6	6.5	11.8	3.2	4.0	6.2	11.8	0.2	20.2	20.1	8.9	20.0	32.5	14.1	14.2	8.5	3.6	0.8	5.4	21.7	2.1	6.9	14.7	27.6	5.8	3.4	25.3	8.5	20.2	13.4	7.6	36.3	8.3	9.4	17.7	20.8	18.5	13.0	11.8	16.4	7.2	2.4	9.4	4.2	4.4	5.3	6.4	6.7	11.0	4.1	3.0	7.1	6.5	16.9	8.9	2.4	5.7	19.7	18.9	2.9	22.7	7.3	14.0	4.8	5.3	22.7	21.5	41.9	7.4	5.6	5.9	8.2	2.9	10.6	4.0	6.0	8.6	5.8	4.6	2.2	3.8	2.1	6.5	1.5	12.4	11.8	3.2	4.7	9.8	1.9	6.0	5.6	4.3	11.8	3.7	9.8	9.1
CREBBP	"CBP, KAT3A, RSTS, RTS"	ENSG00000005339	"CREB binding protein"	Q92793	16	3725054-3880726	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004212, HPA055861"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"				Nucleoplasm	"Nuclear bodies"	"CAB004212: AB_626817, HPA055861: "	"unprognostic (1.17e-1)"	"unprognostic (8.51e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.49e-1)"	"unprognostic (5.09e-2)"	"unprognostic (9.59e-3)"	"unprognostic (6.98e-2)"	"unprognostic (8.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.84e-1)"	"prognostic favourable (6.24e-5)"	"unprognostic (1.47e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.97e-2)"	"unprognostic (8.23e-2)"	18.5	10.9	17.2	22.8	17.5	37.0	17.4	42.6	18.8	20.1	17.2	16.8	17.1	9.9	25.1	15.2	14.1	18.9	21.3	14.5	17.1	8.7	11.1	12.3	16.9	14.4	20.5	12.0	31.6	23.4	24.3	13.0	13.3	15.8	18.4	11.6	14.6	14.9	16.7	28.2	20.4	16.4	17.0	13.6	17.4	14.7	29.1	20.2	29.6	19.5	13.8	16.1	19.0	29.9	4.7	2.3	10.6	3.8	2.0	2.7	1.1	5.5	14.3	18.6	8.2	11.4	11.3	9.6	8.0	13.5	13.9	13.5	12.9	10.5	15.4	9.6	15.3	10.8	21.4	6.6	15.8	26.0	8.6	12.1	13.2	8.2	12.6	12.1	17.4	10.0	6.7	15.4	18.6	10.4	13.7	21.1	7.5	19.1	8.0	5.8	15.2	5.9	37.8	14.7	11.8	5.4	7.5	15.5	10.2	13.7	13.5	8.1	12.0	11.9	16.1	17.0	16.9	8.7	7.3	9.9	10.6	29.9	3.4	7.3	11.9	2.9	1.7	1.3	2.7	2.2	1.4	4.7	1.3	2.0	1.0	3.3	1.4	1.7	10.6	2.0	3.8	2.3	1.3	1.1	17.2	17.5	42.6	18.8	17.1	8.7	20.5	12.0	15.8	20.2
CRLF2	"CRL2, TSLPR"	ENSG00000205755	"Cytokine receptor like factor 2"	Q9HC73	X	1187549-1212750	"Cancer-related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"endometrium 1: 7.8"	"Cell line enhanced"	"Detected in some"		"HMC-1: 18.1;RPMI-8226: 4.6;U-698: 3.9"	"Cancer enhanced"	"Detected in single"		"thyroid cancer: 1.0"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	43	"plasmacytoid DC: 4.3"	"Lineage enriched"	"Detected in single"	43	"dendritic cells: 4.3"														"Intracellular and membrane"						"unprognostic (7.84e-2)"	"unprognostic (7.99e-4)"	"unprognostic (6.02e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.15e-3)"	"unprognostic (2.31e-6)"	"unprognostic (1.72e-1)"	"unprognostic (5.10e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.46e-2)"	"unprognostic (9.72e-3)"	"unprognostic (6.88e-5)"	"unprognostic (7.09e-3)"	"unprognostic (4.81e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.62e-1)"	0.8	0.0	0.2	4.1	0.2	4.1	0.6	0.2	0.2	3.0	0.7	0.2	0.2	0.2	7.8	0.2	0.9	0.2	3.7	0.2	0.2	0.1	0.9	0.2	1.9	0.2	0.2	0.2	0.2	0.2	0.0	0.2	1.0	0.2	0.6	0.9	0.2	0.8	0.2	0.2	0.7	1.5	0.3	0.2	0.6	1.0	0.2	0.2	0.2	0.2	0.2	1.4	1.3	0.6	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.0	0.6	1.0	0.2	0.3	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.1	0.0	0.0	0.0	18.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.5	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.7	1.0	3.9	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2
CRP	PTX1	ENSG00000132693	"C-reactive protein"	P02741	1	159712289-159714589	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	66	"liver: 1139.7"	"Cell line enhanced"	"Detected in some"		"EFO-21: 8.0;HDLM-2: 7.6;U-2 OS: 5.4;U-266/84: 12.8"	"Cancer enriched"	"Detected in some"	13	"liver cancer: 1010.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005036, HPA027367, HPA027396"	Supported		Approved	"Nucleoplasm,Vesicles,Intermediate filaments"	"Secreted to blood"	5400000000	5400000000	"Nucleoplasm, Vesicles"	"Intermediate filaments"	"CAB005036: AB_562362, HPA027367: AB_1847216, HPA027396: AB_1847217"	"unprognostic (3.74e-1)"	"unprognostic (5.31e-2)"				"unprognostic (2.97e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.57e-2)"			"unprognostic (1.33e-2)"	"unprognostic (3.13e-1)"	"prognostic unfavourable (4.17e-10)"	"unprognostic (3.39e-2)"	"unprognostic (3.48e-1)"	"unprognostic (5.60e-2)"	"unprognostic (6.61e-2)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.4	0.1	0.1	0.0	17.2	0.1	0.1	0.0	0.1	1139.7	0.1	0.1	0.1	0.1	0.1	7.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.3	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.3	0.0	0.0	0.0	7.6	0.0	0.3	0.0	0.0	0.0	0.3	0.1	1.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.1	0.0	5.4	0.1	0.9	0.0	12.8	2.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
CRTC1	"FLJ14027, KIAA0616, MECT1, TORC1"	ENSG00000105662	"CREB regulated transcription coactivator 1"	Q6UUV9	19	18683677-18782333	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 40.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA022035	Enhanced		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"				"Nucleoplasm, Nuclear bodies"	"Plasma membrane, Cytosol"	"HPA022035: AB_1847255"	"unprognostic (5.95e-3)"	"unprognostic (2.57e-1)"	"unprognostic (9.94e-2)"	"unprognostic (8.62e-3)"	"unprognostic (9.07e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.04e-1)"	"unprognostic (5.57e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.68e-2)"	"prognostic favourable (1.80e-5)"	"unprognostic (3.37e-2)"	"prognostic favourable (3.83e-5)"	"unprognostic (6.83e-3)"	"unprognostic (1.02e-1)"	"unprognostic (2.51e-2)"	"unprognostic (2.03e-2)"	8.6	7.7	26.0	7.4	38.8	3.2	3.8	40.7	30.1	5.0	4.4	6.5	4.3	6.5	6.8	5.6	3.1	10.5	5.5	5.6	17.7	7.8	6.6	4.5	5.7	6.3	6.4	18.1	6.7	10.0	8.4	11.3	6.4	6.0	7.0	2.6	5.1	8.8	9.4	12.4	5.5	6.2	4.3	4.8	8.1	8.0	7.5	10.2	1.9	7.4	1.1	3.7	4.6	3.5	4.1	3.8	1.8	3.4	1.1	3.0	1.3	4.3	8.0	5.8	9.3	5.4	4.6	16.5	4.8	3.2	4.6	4.5	5.4	5.7	6.1	10.2	4.6	4.7	1.7	3.0	1.1	2.7	13.9	5.1	7.1	8.8	5.2	7.0	14.5	7.4	2.9	4.0	1.2	2.6	4.0	5.6	2.6	16.0	4.5	8.1	7.5	11.8	7.2	2.5	6.7	2.9	7.8	10.7	9.6	5.4	5.2	5.8	5.8	4.3	4.6	5.3	8.1	9.6	5.5	3.8	3.0	4.0	6.1	7.6	4.0	1.5	3.4	1.8	1.7	1.3	1.8	2.3	2.7	3.0	3.0	4.1	2.3	1.8	1.7	1.1	1.9	3.8	1.8	1.3	26.0	38.8	40.7	30.1	17.7	7.8	6.4	18.1	6.0	10.2
CRTC3	FLJ21868	ENSG00000140577	"CREB regulated transcription coactivator 3"	Q6UUV7	15	90529925-90645345	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HeLa: 39.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 16.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043735, HPA063691"	Uncertain		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA043735: AB_10794286, HPA063691: "	"unprognostic (7.60e-2)"	"unprognostic (6.13e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.31e-2)"	"unprognostic (5.12e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.69e-1)"	"unprognostic (6.48e-2)"	"unprognostic (3.60e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.23e-1)"	"unprognostic (5.22e-3)"	"unprognostic (4.67e-2)"	"unprognostic (9.32e-2)"	"unprognostic (9.51e-2)"	"unprognostic (2.30e-1)"	22.3	14.0	13.7	17.0	20.9	11.4	26.6	15.0	16.2	21.2	22.2	27.5	15.3	8.9	23.9	14.5	15.1	19.4	21.5	17.2	14.0	9.7	10.7	11.7	19.2	21.7	24.1	10.9	45.9	13.9	17.1	9.6	20.2	15.7	18.2	11.7	17.4	19.9	22.0	16.1	15.8	13.7	31.8	20.3	13.1	14.2	15.3	23.6	12.8	22.7	9.2	18.1	24.0	29.6	5.3	2.1	16.0	2.5	3.3	6.6	3.0	4.7	7.9	5.4	8.8	11.7	8.7	24.7	6.1	8.9	9.6	9.1	6.5	4.8	0.1	4.4	12.6	8.0	8.6	5.3	7.6	8.2	10.0	12.1	39.3	3.0	13.3	3.1	20.7	9.7	8.5	7.9	10.7	6.9	6.4	2.8	7.1	5.5	1.3	4.5	1.9	3.7	4.1	8.6	0.2	3.4	10.1	9.9	8.8	17.8	5.9	9.9	5.9	5.9	8.5	10.7	7.9	9.9	7.0	3.7	5.0	3.6	4.4	6.3	5.1	16.0	2.5	1.4	3.7	0.8	4.2	3.1	4.5	4.0	1.6	5.3	6.6	4.1	0.5	3.3	0.3	2.1	4.2	3.0	13.7	20.9	15.0	16.2	14.0	9.7	24.1	10.9	15.7	23.6
CRYAB	"CRYA2, HSPB5"	ENSG00000109846	"Crystallin alpha B"	P02511	11	111908565-111923722	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Chaperone, Eye lens protein"	"Cancer-related genes, Cardiomyopathy, Cataract, Disease mutation, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 743.1;skeletal muscle: 581.1"	"Group enriched"	"Detected in some"	5	"ASC diff: 230.1;fHDF/TERT166: 75.0"	"Group enriched"	"Detected in all"	6	"glioma: 426.4;renal cancer: 575.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB002053, CAB040560, HPA057100"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		12000	12000	"Plasma membrane, Cytosol"		"CAB002053: AB_442024, CAB040560: , HPA057100: "	"unprognostic (1.06e-2)"	"unprognostic (2.26e-1)"	"prognostic unfavourable (4.90e-5)"	"unprognostic (2.46e-2)"	"unprognostic (3.02e-2)"	"unprognostic (8.41e-3)"	"unprognostic (9.29e-3)"	"unprognostic (7.35e-2)"	"unprognostic (8.91e-2)"	"unprognostic (1.55e-2)"	"unprognostic (6.68e-2)"	"unprognostic (7.02e-2)"	"unprognostic (3.68e-2)"	"unprognostic (7.92e-2)"	"unprognostic (8.83e-2)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (1.70e-5)"	107.4	11.5	47.8	16.7	82.3	2.1	69.5	24.8	153.7	22.4	23.6	132.9	7.2	5.5	14.8	25.9	41.9	13.5	14.0	743.1	65.9	44.0	151.8	3.8	8.4	3.9	139.2	29.7	8.8	6.6	3.3	8.6	16.1	80.7	30.3	12.9	23.3	30.6	75.1	581.1	18.1	6.2	45.2	168.0	5.5	11.6	3.9	101.8	0.0	40.7	94.1	9.2	16.2	53.6	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	4.3	230.1	10.1	1.6	6.4	0.2	0.1	0.2	0.1	0.0	0.0	3.8	75.0	0.1	0.2	0.2	0.1	0.0	0.0	0.0	1.2	0.6	1.9	0.0	0.0	8.1	1.0	0.0	0.5	0.0	0.5	0.2	18.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.4	0.8	3.4	0.5	0.0	0.1	29.8	10.7	0.8	0.3	0.1	0.0	0.0	0.6	0.1	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.8	82.3	24.8	48.5	65.9	44.0	139.2	29.7	80.7	101.8
CSDE1	"D1S155E, UNR"	ENSG00000009307	"Cold shock domain containing E1"	O75534	1	114716913-114758676	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 266.5"	"Cell line enhanced"	"Detected in all"		"MCF7: 222.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018846, HPA052221"	Supported		Enhanced	"Plasma membrane,Cytosol"		13000	13000	"Plasma membrane, Cytosol"		"HPA018846: AB_1847266, HPA052221: "	"unprognostic (2.84e-1)"	"unprognostic (9.18e-3)"	"unprognostic (4.86e-3)"	"unprognostic (3.30e-3)"	"unprognostic (2.83e-2)"	"unprognostic (4.51e-2)"	"unprognostic (5.32e-3)"	"unprognostic (5.16e-2)"	"unprognostic (1.78e-1)"	"unprognostic (5.19e-2)"	"unprognostic (3.24e-2)"	"unprognostic (2.40e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.18e-1)"	"unprognostic (5.17e-3)"	"unprognostic (2.54e-2)"	71.2	31.4	33.5	25.8	33.2	37.9	42.1	29.6	35.4	39.0	64.7	29.6	35.9	29.5	46.4	38.9	58.8	30.3	29.4	64.2	33.2	31.7	37.4	39.5	34.2	31.4	41.6	31.4	43.9	37.2	50.3	38.4	38.8	44.4	52.6	32.9	32.0	43.2	42.0	266.5	33.8	46.5	88.3	42.4	32.2	39.9	41.5	35.1	39.6	55.7	73.9	31.9	75.4	45.5	43.9	59.0	57.9	65.2	48.1	62.3	80.5	60.6	21.4	38.1	38.0	43.5	56.6	53.3	53.6	40.1	36.1	29.4	31.3	18.4	47.8	45.3	51.1	25.8	42.2	41.6	52.7	58.4	28.8	46.9	39.0	27.7	38.5	34.8	28.0	41.0	45.3	43.2	57.1	41.3	47.5	31.4	44.1	222.4	46.7	22.2	72.6	28.9	35.0	118.0	22.5	28.7	47.8	47.1	31.3	52.5	43.8	40.6	22.5	55.7	49.7	42.7	58.9	56.0	58.8	48.0	52.2	53.6	55.2	39.6	130.2	46.4	57.7	57.9	40.9	60.8	55.5	43.9	52.2	49.7	59.0	34.7	62.3	52.3	40.9	48.1	65.2	23.0	56.7	80.5	33.5	33.2	29.6	35.4	33.2	31.7	41.6	31.4	44.4	35.1
CSE1L	"CAS, CSE1, XPO2"	ENSG00000124207	"Chromosome segregation 1 like"	P55060	20	49046246-49096960	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002140, HPA038059, HPA038060"	Enhanced		Enhanced	Nucleoplasm,Cytosol		64000	64000	"Nucleoplasm, Cytosol"		"CAB002140: AB_563461, HPA038059: AB_2675811, HPA038060: AB_2675812"	"unprognostic (4.01e-2)"	"unprognostic (3.15e-2)"	"unprognostic (5.63e-2)"	"prognostic unfavourable (2.91e-5)"	"unprognostic (4.86e-1)"	"unprognostic (4.91e-2)"	"prognostic unfavourable (2.42e-8)"	"unprognostic (3.44e-2)"	"unprognostic (1.45e-2)"	"unprognostic (2.63e-2)"	"unprognostic (2.72e-3)"	"unprognostic (2.54e-2)"	"prognostic unfavourable (1.89e-4)"	"unprognostic (2.59e-1)"	"unprognostic (4.84e-1)"	"unprognostic (5.71e-1)"	"prognostic unfavourable (6.91e-4)"	15.7	18.9	19.5	18.7	23.7	13.7	21.2	24.9	31.3	17.5	14.2	13.4	14.0	12.0	19.5	15.5	25.5	17.3	11.8	17.8	20.0	17.7	18.8	18.7	12.8	24.0	27.3	19.4	18.7	17.3	23.2	16.8	23.1	24.2	16.7	18.4	8.4	15.5	17.0	34.3	20.9	12.4	21.7	31.3	12.6	17.1	50.9	21.0	27.0	14.7	28.1	25.3	18.3	17.5	12.8	14.8	9.4	15.9	16.8	18.0	12.8	35.5	24.8	30.3	23.3	11.8	15.2	32.9	28.1	14.9	88.5	37.5	81.0	28.8	36.5	37.7	17.8	41.3	44.5	52.8	84.5	5.9	21.6	25.3	29.1	39.2	7.2	27.8	13.9	8.5	19.8	43.2	25.1	29.2	35.7	14.4	33.1	12.2	33.5	14.4	25.5	37.0	21.4	49.9	28.4	19.4	24.9	26.7	15.5	44.9	48.7	16.0	40.6	18.2	18.8	47.1	39.6	27.7	39.8	8.4	20.4	34.2	28.1	22.5	25.0	9.4	11.8	2.7	11.0	15.2	16.5	12.8	16.8	13.4	14.8	10.4	18.0	15.3	3.3	16.8	15.9	6.6	14.4	12.8	19.5	23.7	24.9	31.3	20.0	17.7	27.3	19.4	24.2	21.0
CSF1	"M-CSF, MCSF, MGC31930"	ENSG00000184371	"Colony stimulating factor 1"	P09603	1	109910242-109930992	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Immunity, Inflammatory response, Innate immunity"	"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 46.6;ASC TERT1: 29.3;BJ hTERT+: 30.7;HHSteC: 70.9;HSkMC: 45.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	11	"basophil: 7.0;eosinophil: 16.5"	"Lineage enriched"	"Detected in many"	16	"granulocytes: 16.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA076624			Supported	"Nuclear bodies,Plasma membrane"	"Secreted to blood"	17000000	17000000	"Plasma membrane"	"Nuclear bodies"	"HPA076624: "	"unprognostic (2.35e-3)"	"unprognostic (2.14e-1)"	"unprognostic (7.36e-2)"	"unprognostic (4.19e-1)"	"unprognostic (3.60e-1)"	"unprognostic (1.64e-2)"	"prognostic unfavourable (4.25e-5)"	"unprognostic (1.04e-1)"	"unprognostic (1.75e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.72e-1)"	"unprognostic (5.10e-2)"	"prognostic unfavourable (1.00e-11)"	"unprognostic (2.03e-1)"	"unprognostic (1.88e-2)"	"unprognostic (4.01e-1)"	"unprognostic (3.16e-2)"	38.1	21.4	11.5	14.6	16.7	10.1	36.5	4.3	14.6	13.8	12.8	28.2	3.6	8.5	12.0	10.1	11.3	15.7	20.6	16.0	11.4	5.8	10.7	10.3	23.5	16.9	24.3	5.4	16.9	11.3	6.7	5.2	26.0	19.2	16.3	11.0	12.2	12.4	11.6	12.7	10.4	12.7	16.0	21.9	25.8	11.9	7.5	20.3	2.9	12.4	7.8	11.0	20.6	29.2	0.0	0.0	16.5	0.0	0.0	1.0	0.1	1.5	5.7	2.9	1.1	46.6	29.3	1.0	6.7	30.7	5.3	4.9	0.2	0.8	0.0	8.4	16.4	1.2	1.2	2.2	2.0	18.6	0.9	2.0	3.3	1.9	70.9	0.0	2.6	45.3	0.6	11.7	7.1	1.0	0.4	1.1	6.3	0.1	0.0	0.3	1.0	0.5	0.2	1.5	0.1	2.2	1.5	0.1	0.3	1.9	0.5	2.3	0.4	0.2	3.5	5.6	1.9	24.5	3.7	0.5	0.2	0.0	14.1	0.0	20.7	7.0	0.0	16.5	0.2	0.0	0.5	0.0	0.7	0.5	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	1.0	0.1	11.5	16.7	4.3	14.6	11.4	5.8	24.3	5.4	19.2	20.3
CSF1R	"C-FMS, CD115, CSFR, FMS"	ENSG00000182578	"Colony stimulating factor 1 receptor"	P07333	5	150053291-150113372	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Immunity, Inflammatory response, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 82.5;lymphoid tissue: 82.6"	"Group enriched"	"Detected in some"	5	"BEWO: 50.6;SK-BR-3: 19.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 60.7;non-classical monocyte: 82.5"	"Lineage enriched"	"Detected in many"	4	"monocytes: 82.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008970, HPA012323"	Uncertain		Supported	"Vesicles,Plasma membrane"	"Intracellular and membrane"	1500000000	1500000000	"Vesicles, Plasma membrane"		"CAB008970: , HPA012323: AB_1848977"	"unprognostic (3.82e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.86e-3)"	"unprognostic (9.83e-2)"	"unprognostic (1.20e-1)"	"unprognostic (7.33e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.45e-1)"	"unprognostic (9.37e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (1.08e-4)"	"unprognostic (3.67e-2)"	"prognostic unfavourable (4.92e-4)"	"unprognostic (1.72e-2)"	"unprognostic (4.61e-2)"	20.9	12.4	18.2	28.1	18.9	1.8	7.7	2.8	13.5	9.3	8.3	25.4	1.1	9.2	5.9	13.1	8.4	7.9	16.1	8.7	16.4	13.7	7.8	15.1	13.7	25.4	21.3	6.0	5.3	5.2	5.9	6.4	52.1	17.1	8.5	8.4	16.8	8.0	8.7	3.0	5.8	14.5	16.2	25.8	82.6	9.0	4.9	23.0	3.1	4.2	2.9	8.2	16.4	4.7	0.0	19.1	2.9	82.5	0.0	0.1	13.9	1.7	0.0	0.0	0.0	0.8	0.2	50.6	0.1	0.0	0.0	0.0	1.5	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.1	0.0	19.3	0.0	0.0	7.2	0.0	0.3	0.0	0.0	1.3	0.0	0.1	0.0	2.6	0.9	0.0	0.4	18.1	0.5	0.1	60.7	0.0	0.0	0.0	0.0	19.1	0.0	0.0	0.0	2.9	0.0	82.5	1.4	0.0	13.9	18.2	18.9	2.8	13.4	16.4	13.7	21.3	6.0	17.1	23.0
CSF2	"GM-CSF, GMCSF"	ENSG00000164400	"Colony stimulating factor 2"	P04141	5	132073790-132076170	"Cancer-related genes, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 9.5;lung: 6.8;pancreas: 4.5"	"Cell line enriched"	"Detected in some"	4	"BJ hTERT+: 44.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	11	"NK-cell: 9.5"	"Lineage enriched"	"Detected in single"	11	"NK-cells: 9.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA057404, HPA062006"			Enhanced	Vesicles	"Secreted to blood"			Vesicles		"HPA057404: , HPA062006: "	"unprognostic (7.29e-2)"	"unprognostic (2.49e-3)"	"unprognostic (8.77e-2)"	"unprognostic (2.09e-2)"		"unprognostic (1.05e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.47e-2)"	"unprognostic (2.64e-1)"	"unprognostic (3.68e-3)"		"unprognostic (1.87e-8)"	"unprognostic (4.81e-2)"	"unprognostic (1.22e-1)"	"unprognostic (9.07e-2)"	"unprognostic (2.06e-2)"	0.2	0.1	0.1	3.9	0.1	1.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.7	0.0	1.5	0.1	1.1	0.2	0.1	0.1	0.3	0.9	6.8	0.3	0.1	0.0	0.1	4.5	0.0	0.1	0.5	0.0	0.2	0.7	0.0	1.9	0.0	0.1	0.4	1.0	0.6	0.1	1.0	0.2	0.2	0.0	0.4	0.2	0.0	1.8	2.3	0.1	0.0	0.0	0.0	0.0	9.5	0.8	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.0	0.0	2.5	0.0	3.5	0.0	0.7	0.0	0.1	0.0	3.2	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	10.2	6.8	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	0.1	1.8	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	9.5	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
CSF2RA	"alphaGMR, CD116, CSF2R"	ENSG00000198223	"Colony stimulating factor 2 receptor alpha subunit"	P15509	X	1268800-1310381	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 60.2;placenta: 79.5"	"Group enriched"	"Detected in some"	7	"BEWO: 59.0;HMC-1: 17.7;SK-MEL-30: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5"	"Group enriched"	"Detected in many"	28	"dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0"									CAB016148	Uncertain				"Secreted to blood"	9400000	9400000			"CAB016148: AB_626868"	"unprognostic (4.19e-2)"	"prognostic favourable (2.38e-5)"	"unprognostic (5.47e-2)"	"unprognostic (4.33e-2)"	"unprognostic (4.88e-2)"	"prognostic favourable (2.81e-4)"	"unprognostic (8.24e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.55e-2)"	"unprognostic (8.48e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.80e-1)"	"unprognostic (2.89e-2)"	"unprognostic (8.91e-3)"	"prognostic unfavourable (5.53e-4)"	"unprognostic (3.60e-1)"	"unprognostic (9.44e-2)"	8.7	2.3	11.8	11.1	11.1	8.9	17.7	3.4	9.6	3.1	2.2	0.6	0.6	2.2	4.4	0.6	2.1	2.2	5.7	3.7	15.0	4.7	2.4	1.7	11.2	8.3	18.8	6.5	3.5	1.0	0.2	2.1	79.5	13.2	1.5	3.3	0.6	3.1	1.0	0.6	1.8	3.3	2.9	25.5	12.6	1.7	0.6	16.3	0.6	2.5	0.6	10.4	4.2	1.5	0.3	31.9	60.2	30.0	1.4	0.2	10.1	0.1	3.4	0.2	0.0	0.0	0.0	59.0	0.0	0.1	0.1	0.0	1.2	0.3	0.0	3.8	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	2.4	0.0	0.0	1.3	17.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	5.4	0.5	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	1.0	0.0	41.3	2.7	4.9	0.0	0.0	1.7	0.3	0.0	0.1	0.1	0.1	0.0	5.3	0.0	2.4	30.0	36.0	0.0	17.7	0.2	0.3	0.0	0.0	31.9	0.1	0.0	0.0	60.2	1.4	8.4	30.5	0.1	10.1	11.8	11.1	3.4	9.6	15.0	4.7	18.8	6.5	13.2	16.3
CSF3	"C17orf33, G-CSF, GCSF, MGC45931"	ENSG00000108342	"Colony stimulating factor 3"	P09919	17	40015361-40017813	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 27.9;lung: 60.9"	"Group enriched"	"Detected in some"	5	"BJ hTERT+: 19.5;U-87 MG: 76.7"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"pons and medulla: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to blood"						"unprognostic (3.59e-3)"	"unprognostic (1.57e-2)"	"unprognostic (1.73e-1)"	"prognostic favourable (8.45e-4)"	"unprognostic (1.06e-2)"	"unprognostic (3.40e-2)"		"unprognostic (1.10e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.26e-1)"	"unprognostic (2.82e-2)"	"unprognostic (7.40e-4)"	"unprognostic (1.21e-1)"	"unprognostic (1.96e-1)"	"unprognostic (4.10e-2)"	"unprognostic (4.80e-3)"	12.4	1.5	1.0	13.8	1.3	3.0	2.8	0.8	1.6	27.9	3.0	1.4	0.0	0.2	2.3	2.2	5.9	2.9	2.1	6.9	1.1	1.0	0.2	0.5	60.9	0.5	1.2	0.1	3.3	4.1	0.2	3.8	2.6	7.4	4.3	0.7	1.6	0.6	0.3	20.6	0.4	1.4	1.6	2.6	1.0	2.0	1.1	1.2	0.1	0.7	8.8	7.0	7.2	1.8	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.5	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	9.6	3.1	2.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	76.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.0	1.3	0.8	1.6	1.1	1.0	1.2	0.1	7.4	1.2
CSF3R	"CD114, GCSFR"	ENSG00000119535	"Colony stimulating factor 3 receptor"	Q99062	1	36466043-36483278	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7"	"Group enriched"	"Detected in some"	18	"BEWO: 34.1;NB-4: 9.2;THP-1: 22.4;U-937: 21.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 167.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 167.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB017116, HPA048086"	Enhanced				"Intracellular and membrane"					"CAB017116: , HPA048086: "	"unprognostic (5.57e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.88e-1)"	"unprognostic (2.92e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.83e-1)"	"unprognostic (5.65e-2)"	"unprognostic (2.47e-1)"	"unprognostic (3.44e-1)"	"prognostic unfavourable (5.72e-4)"	"unprognostic (6.33e-2)"	"prognostic unfavourable (3.79e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.31e-2)"	8.5	1.5	2.9	39.5	3.2	88.9	2.4	0.7	2.9	1.1	1.1	4.2	0.4	0.6	0.7	1.1	1.2	6.9	4.3	5.6	2.6	2.0	1.7	4.5	26.9	27.5	7.2	1.1	1.1	1.3	0.3	1.1	152.7	3.8	1.3	0.5	2.1	1.6	0.5	0.6	0.3	1.6	3.1	7.1	71.4	2.2	1.4	3.3	1.1	1.0	0.4	0.9	4.6	3.9	0.0	8.2	167.3	22.1	0.2	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	34.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	9.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	22.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	21.6	0.0	0.0	22.1	0.6	0.0	4.8	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	167.3	0.2	1.8	0.2	0.0	10.3	2.9	3.2	0.7	2.9	2.6	2.0	7.2	1.1	3.8	3.3
CSN1S1	"CASA, CSN1"	ENSG00000126545	"Casein alpha s1"	P47710	4	69931081-69946574	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Milk protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"breast: 184.8"	"Cell line enhanced"	"Detected in some"		"ASC diff: 2.4;HL-60: 1.4;U-266/70: 1.4"	"Cancer enriched"	"Detected in some"	10	"breast cancer: 17.1"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	6	"NK-cell: 1.6;plasmacytoid DC: 3.2"	"Group enriched"	"Detected in many"	11	"dendritic cells: 3.2;NK-cells: 1.6"									"HPA035659, HPA057031"	Enhanced				"Secreted in female reproductive system"					"HPA035659: AB_10696356, HPA057031: AB_2683315"					"unprognostic (1.52e-2)"										"unprognostic (1.01e-1)"			44.7	0.0	0.0	0.0	0.1	0.0	184.8	0.0	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.1	1.2	0.0	0.0	0.0	0.5	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	3.2	0.2	0.1	1.6	0.0	0.2	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.4	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	1.6	0.0	3.2	0.0	0.2	0.0	0.1	0.0	0.9	0.1	1.2	0.6	0.0	0.1	0.0
CSNK1E	"CKIE, CKIepsilon, HCKIE"	ENSG00000213923	"Casein kinase 1 epsilon"	P49674	22	38290691-38318084	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 15.7"	"Low lineage specificity"	"Detected in all"											"CAB009626, HPA026288"	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB009626: AB_2084517, HPA026288: AB_1847276"	"unprognostic (2.32e-1)"	"unprognostic (8.41e-2)"	"unprognostic (5.14e-2)"	"unprognostic (5.01e-3)"	"unprognostic (1.95e-2)"	"unprognostic (4.50e-3)"	"prognostic unfavourable (8.20e-5)"	"unprognostic (2.08e-3)"	"unprognostic (3.69e-1)"	"unprognostic (1.22e-1)"	"unprognostic (9.63e-2)"	"unprognostic (4.16e-3)"	"prognostic unfavourable (4.67e-6)"	"unprognostic (1.91e-1)"	"unprognostic (1.66e-1)"	"unprognostic (2.58e-1)"	"unprognostic (3.25e-3)"	28.5	22.9	30.7	18.3	32.5	21.4	28.6	40.1	42.6	26.4	21.5	32.3	15.7	19.0	37.3	27.3	23.4	28.0	22.1	28.8	31.7	22.3	17.3	11.8	28.4	17.3	28.6	30.1	38.1	25.4	56.2	29.2	33.1	28.7	26.2	17.4	30.5	23.9	23.1	26.3	35.3	17.1	24.0	23.2	20.9	21.8	13.0	33.9	13.3	21.4	14.2	17.4	25.5	28.8	3.7	15.7	4.8	1.8	5.9	4.0	1.2	23.3	11.4	31.0	29.7	15.5	23.8	23.3	30.5	39.1	27.8	27.0	14.6	18.3	17.6	13.3	28.8	20.0	23.5	42.2	20.2	28.1	51.1	5.6	37.7	11.2	32.0	12.3	15.0	22.7	35.8	42.3	57.3	29.5	12.4	36.4	26.8	15.6	17.1	15.1	22.7	16.5	32.0	22.2	27.6	25.5	19.6	45.9	18.0	26.0	27.0	30.5	13.8	17.9	33.5	25.2	27.5	14.5	24.3	16.3	23.3	24.8	37.4	13.9	42.2	3.8	1.8	3.4	3.4	0.8	4.0	2.5	3.8	3.4	1.8	3.7	2.1	3.1	4.8	5.9	0.6	15.7	1.7	1.2	30.7	32.5	40.1	38.8	31.7	22.3	28.6	30.1	28.7	33.9
CSNK2A2	"CK2alpha', CSNK2A1"	ENSG00000070770	"Casein kinase 2 alpha 2"	P19784	16	58157907-58197920	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (9.49e-2)"	"unprognostic (1.87e-1)"	"unprognostic (5.45e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.08e-1)"	"prognostic unfavourable (1.40e-5)"	"prognostic unfavourable (1.80e-4)"	"unprognostic (6.84e-3)"	"unprognostic (2.93e-3)"	"unprognostic (2.40e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.63e-1)"	"unprognostic (5.89e-2)"	"unprognostic (2.06e-3)"	"unprognostic (7.07e-2)"	"unprognostic (3.23e-1)"	"unprognostic (3.14e-2)"	22.8	14.5	15.2	15.2	14.2	14.8	33.5	11.1	17.0	20.4	22.2	12.6	15.1	11.7	19.0	21.4	20.2	15.8	18.7	19.7	12.8	11.5	16.2	21.1	20.0	28.7	10.8	13.9	23.9	28.1	34.3	14.4	29.1	11.6	22.0	15.0	12.9	15.6	15.2	25.4	50.5	18.0	18.8	11.2	26.6	21.1	69.1	10.2	44.3	25.9	12.0	18.5	28.9	33.8	8.9	8.0	8.7	14.1	12.8	14.5	11.7	18.5	20.8	16.1	19.2	22.8	32.3	28.5	14.4	22.1	28.6	18.1	39.0	15.8	33.8	20.2	20.1	21.8	29.0	25.9	36.4	11.1	15.8	18.6	14.0	34.8	35.1	29.9	19.1	31.6	38.8	21.6	38.6	29.9	37.3	9.9	17.3	12.9	29.5	24.8	25.9	24.2	40.2	32.9	17.8	21.2	20.6	13.7	15.5	34.4	16.1	27.4	10.1	25.1	24.5	19.6	23.3	15.4	19.1	22.6	18.6	48.0	17.4	20.7	18.2	8.7	14.1	7.4	11.9	12.4	13.5	8.9	14.2	11.6	8.0	7.8	14.3	14.5	0.7	12.8	10.8	7.6	10.7	11.7	15.2	14.2	11.1	17.0	12.8	11.5	10.8	13.9	11.6	10.2
CSNK2B	"Ckb1, Ckb2"	ENSG00000204435	"Casein kinase 2 beta"	P67870	6	31665236-31670343	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB004349, HPA005944, CAB013087, CAB016059"	Approved									"CAB004349: AB_626791, CAB013087: AB_2533571, CAB016059: AB_626792, HPA005944: AB_1847290"	"unprognostic (1.61e-1)"	"unprognostic (3.21e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.55e-3)"	"unprognostic (9.51e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.03e-3)"	"unprognostic (1.60e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.62e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (1.06e-5)"	"unprognostic (5.88e-2)"	"unprognostic (1.72e-1)"	"unprognostic (9.67e-2)"	"unprognostic (3.72e-2)"	28.1	30.5	26.6	28.8	28.0	30.3	27.6	26.9	42.9	29.9	32.7	30.8	24.0	13.9	26.2	101.7	51.5	30.1	32.0	43.8	24.4	23.1	41.1	49.8	34.4	33.8	25.4	24.6	32.9	42.1	3.5	26.4	39.6	23.6	34.3	26.0	30.4	30.3	32.5	40.8	58.3	31.6	32.2	26.6	33.3	26.9	66.0	20.8	60.2	38.5	41.8	33.4	28.3	25.9	20.6	24.9	21.3	22.8	16.3	20.2	16.0	0.0	6.5	0.0	10.7	6.5	10.9	8.0	15.0	26.0	30.7	29.0	0.0	9.4	23.1	8.1	11.0	0.0	0.0	26.5	30.1	11.2	26.9	0.0	0.0	0.0	16.6	25.3	0.0	21.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	14.4	0.0	7.7	0.0	11.7	0.0	14.7	14.7	8.7	0.0	18.3	0.1	0.0	11.5	0.1	0.0	7.4	12.8	15.6	14.6	0.0	9.5	14.8	14.7	9.1	0.0	11.6	16.5	22.8	21.3	16.2	22.3	16.0	20.6	16.7	16.7	21.1	16.4	14.4	12.7	18.4	16.3	14.1	24.9	20.2	16.0	26.6	28.0	26.9	42.9	24.4	23.1	25.4	24.6	23.6	20.8
CST3		ENSG00000101439	"Cystatin C"	P01034	20	23626706-23638473	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Thiol protease inhibitor"	"Age-related macular degeneration, Amyloidosis, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 160.1;ASC TERT1: 109.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	7	"classical monocyte: 163.9;intermediate monocyte: 211.0;myeloid DC: 269.6;non-classical monocyte: 135.1;plasmacytoid DC: 153.5"	"Group enriched"	"Detected in many"	9	"dendritic cells: 269.6;monocytes: 211.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000118, HPA013143"	Enhanced		Supported	"Golgi apparatus,Vesicles"	"Secreted to blood"	4100000000	4100000000	"Golgi apparatus, Vesicles"		"CAB000118: , HPA013143: AB_1847417"	"unprognostic (3.89e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.45e-1)"	"prognostic favourable (1.83e-4)"	"unprognostic (8.53e-2)"	"unprognostic (4.06e-2)"	"unprognostic (2.10e-2)"	"unprognostic (2.18e-2)"	"unprognostic (3.46e-2)"	"unprognostic (3.72e-1)"	"unprognostic (2.29e-3)"	"unprognostic (3.51e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.97e-1)"	"unprognostic (5.01e-2)"	"prognostic favourable (8.77e-4)"	95.8	72.6	229.0	37.9	254.7	22.2	68.6	61.4	196.7	76.6	78.2	75.4	39.5	59.4	47.6	143.6	73.8	64.9	89.4	79.7	157.4	96.2	35.9	67.3	58.0	91.2	148.3	90.6	51.4	142.1	34.5	45.6	25.8	69.9	55.2	66.1	195.0	338.2	74.2	44.2	44.9	77.9	57.3	73.3	85.5	105.5	57.4	68.4	40.7	43.2	40.1	31.9	49.4	50.2	0.6	269.6	27.4	211.0	6.4	2.4	106.7	12.6	28.8	6.7	15.5	160.1	109.6	12.6	22.1	30.8	15.2	12.3	54.7	19.6	0.0	20.8	30.1	43.0	6.2	44.1	4.7	0.0	21.3	13.0	5.7	93.0	57.3	0.6	21.9	84.8	37.2	20.4	21.9	23.7	11.8	0.3	21.1	20.2	0.1	13.8	9.0	63.2	0.4	8.2	17.5	62.4	28.7	7.4	8.5	16.1	4.8	27.4	13.6	47.7	59.8	14.4	10.4	20.1	8.2	13.6	0.4	0.1	12.3	28.6	16.2	1.4	163.9	1.0	2.4	211.0	0.9	0.6	0.6	1.6	269.6	0.5	0.6	1.2	27.4	6.4	135.1	153.5	0.4	106.7	229.0	254.7	61.4	196.7	157.4	96.2	148.3	90.6	69.9	68.4
CST6		ENSG00000175315	"Cystatin E/M"	Q15828	11	66011841-66013505	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"skin 1: 124.5"	"Group enriched"	"Detected in some"	6	"A-431: 26.2;CAPAN-2: 73.1"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 171.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"classical monocyte: 1.6"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB019316, HPA044963"	Enhanced		Approved	"Plasma membrane,Cytosol"	"Secreted in other tissues"	110000000	110000000	"Plasma membrane"	Cytosol	"CAB019316: , HPA044963: "	"unprognostic (3.01e-2)"	"unprognostic (5.10e-2)"	"unprognostic (1.14e-1)"	"unprognostic (3.59e-2)"	"unprognostic (5.00e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.38e-2)"	"unprognostic (5.02e-1)"	"unprognostic (8.89e-3)"	"unprognostic (1.29e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.74e-3)"	"unprognostic (5.89e-3)"	"unprognostic (1.83e-1)"	"unprognostic (1.64e-2)"	"unprognostic (2.59e-2)"	0.6	0.2	0.1	1.5	0.1	0.2	8.7	0.4	0.2	5.5	0.2	0.0	1.4	0.1	0.3	0.8	11.3	4.3	0.7	2.4	0.1	0.2	1.0	0.1	27.2	1.2	0.1	0.0	1.3	0.2	0.5	0.4	26.5	0.2	0.9	0.1	1.1	1.3	26.5	0.7	124.5	0.2	0.2	0.2	0.2	0.2	1.0	0.0	2.8	14.6	13.6	4.4	0.5	3.7	0.4	0.9	0.0	1.6	0.0	0.2	0.7	26.2	0.0	0.0	0.1	0.0	0.0	7.8	0.2	0.0	0.0	0.0	0.1	73.1	0.0	0.4	0.9	0.9	0.0	6.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.0	0.0	7.3	0.1	0.1	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.9	0.4	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.7	0.1	0.1	0.4	0.1	0.1	0.2	0.1	0.0	0.2	0.0
CSTA	"STF1, STFA"	ENSG00000121552	"Cystatin A"	P01040	3	122325244-122341972	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes, Ichthyosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 312.4;tongue: 421.9"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 33.1;hTCEpi: 146.6;THP-1: 91.6;U-698: 58.3;U-937: 29.1"	"Cancer enhanced"	"Detected in all"		"head and neck cancer: 405.0"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	20	"classical monocyte: 74.6;intermediate monocyte: 37.5;myeloid DC: 54.6;neutrophil: 36.0;non-classical monocyte: 21.6"	"Group enriched"	"Detected in many"	193	"dendritic cells: 54.6;granulocytes: 36.0;monocytes: 74.6"									"CAB000469, HPA001031, CAB047315"	Enhanced		Approved	Nucleoplasm,Cytosol		39000000	39000000	"Nucleoplasm, Cytosol"		"CAB000469: , CAB047315: , HPA001031: AB_1078610"	"unprognostic (5.22e-3)"	"unprognostic (6.10e-2)"	"unprognostic (2.64e-1)"	"unprognostic (6.07e-2)"	"unprognostic (7.79e-3)"	"prognostic favourable (5.86e-4)"	"unprognostic (4.46e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.78e-1)"	"unprognostic (7.99e-2)"	"unprognostic (2.56e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavourable (2.60e-6)"	"unprognostic (8.89e-2)"	"unprognostic (3.43e-2)"	"unprognostic (9.24e-3)"	"unprognostic (1.99e-1)"	2.0	0.2	0.3	4.4	0.8	19.8	4.5	0.2	0.5	55.4	0.4	0.2	1.1	0.0	4.7	1.7	312.4	0.2	0.7	1.0	0.3	0.0	0.4	3.4	6.8	4.8	1.1	0.2	1.8	0.2	0.0	0.3	1.3	0.5	1.3	0.1	0.3	57.4	0.7	0.7	28.2	0.3	0.4	0.7	2.0	2.2	0.3	0.6	2.2	0.3	421.9	99.0	1.5	93.5	0.1	54.6	36.0	74.6	0.2	0.2	32.0	1.6	0.1	0.0	0.3	3.8	7.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.9	0.6	10.2	0.0	33.1	0.0	0.0	0.0	0.0	0.0	0.7	0.8	13.3	0.2	3.7	146.6	0.3	14.4	0.0	0.0	3.5	0.0	0.0	0.0	12.4	0.0	0.0	0.0	0.1	0.0	0.0	16.4	0.0	0.0	1.6	0.8	1.1	0.1	91.6	0.0	0.2	2.4	0.0	0.1	0.0	0.1	58.3	3.2	29.1	0.0	0.7	74.6	2.2	0.0	37.5	0.2	0.1	0.1	0.1	54.6	0.0	0.0	0.1	36.0	0.2	21.6	1.0	0.1	32.0	0.3	0.8	0.2	0.5	0.3	0.0	1.1	0.2	0.5	0.6
CSTB	"CST6, EPM1, PME, STFB"	ENSG00000160213	"Cystatin B"	P04080	21	43772511-43776445	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"		"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes, Disease mutation, Epilepsy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 365.3;lymphoid tissue: 130.6;tongue: 138.8"	"Cell line enhanced"	"Detected in all"		"RT4: 90.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017380, CAB047320, HPA058557"	Enhanced		Supported	Nucleoli,Cytosol		6100000	6100000	Cytosol	Nucleoli	"CAB047320: , HPA017380: AB_1847414, HPA058557: "	"unprognostic (1.69e-1)"	"unprognostic (3.35e-1)"	"unprognostic (2.09e-1)"	"unprognostic (3.05e-2)"	"unprognostic (3.05e-2)"	"unprognostic (5.92e-2)"	"prognostic unfavourable (6.66e-5)"	"unprognostic (1.90e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.27e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavourable (2.10e-4)"	"unprognostic (3.63e-1)"	"unprognostic (4.88e-1)"	"unprognostic (4.24e-2)"	"unprognostic (1.24e-1)"	21.1	7.5	5.6	6.1	5.9	3.2	13.6	3.0	5.3	57.8	8.8	4.4	3.9	5.6	6.1	6.4	365.3	6.0	7.2	6.5	4.6	5.0	9.6	17.3	17.2	11.2	5.3	4.9	7.8	5.0	3.2	7.6	5.2	5.8	7.1	7.2	7.8	65.2	6.2	4.8	9.4	7.5	6.3	5.1	7.4	10.4	4.1	4.1	8.6	11.6	138.8	130.6	14.0	81.5	11.4	43.2	25.4	69.1	7.7	22.3	21.3	57.8	17.5	5.8	7.3	30.9	25.4	14.4	12.5	14.5	7.9	7.9	13.5	32.5	4.7	9.7	19.5	10.4	13.3	14.0	5.0	19.4	15.8	13.1	13.5	15.6	27.6	3.2	10.9	26.9	14.6	21.8	10.8	11.0	9.7	25.8	11.6	14.6	4.1	10.1	14.0	30.2	6.8	3.3	53.1	22.7	90.4	5.5	4.9	16.5	8.8	35.2	8.2	8.1	16.9	13.2	6.9	12.3	7.9	6.4	11.2	8.7	57.4	15.2	9.2	16.8	28.2	16.9	14.5	45.9	13.3	11.4	18.6	15.0	43.2	9.7	13.2	13.0	25.4	7.7	69.1	5.3	22.3	21.3	5.6	5.9	3.0	5.3	4.6	5.0	5.3	4.9	5.8	4.1
CTAG1A	"ESO1, LAGE2A"	ENSG00000268651	"Cancer/testis antigen 1A"	P78358	X	154585143-154586821	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"heart muscle: 3.0;testis: 8.1"	"Cell line enriched"	"Detected in some"	4	"U-266/70: 120.8"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											CAB013061	Enhanced									"CAB013061: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0		0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	120.8	28.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0										
CTAG1B	"CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1"	ENSG00000184033	"Cancer/testis antigen 1B"	P78358	X	154617609-154619282	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	56	"testis: 12.0"	"Cell line enriched"	"Detected in some"	4	"U-266/70: 128.5"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											CAB015453	Enhanced									"CAB015453: AB_784921"																		0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	12.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	128.5	31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CTAG2	"CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803"	ENSG00000126890	"Cancer/testis antigen 2"	O75638	X	154651972-154653579	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"heart muscle: 8.5;skeletal muscle: 5.7;testis: 11.9"	"Group enriched"	"Detected in some"	37	"K-562: 28.2;RPMI-8226: 62.9;SK-BR-3: 41.1;U-266/84: 71.2"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA071467, HPA076586"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies,Vesicles"				"Nucleoplasm, Vesicles"	"Nuclear bodies"	"HPA071467: , HPA076586: "							"prognostic unfavourable (2.35e-4)"		"unprognostic (3.87e-1)"						"unprognostic (1.00e-1)"		"unprognostic (1.25e-2)"	0.2	1.0	0.4	0.0	0.0	0.2	0.1	0.2	0.5	0.0	0.2			0.0	0.0	0.0	1.0	2.9	0.0	8.5	0.0	0.0	0.1	0.8	0.2	0.0	0.2		0.8	3.6	0.0	0.4	4.4		0.2	0.0		0.1	0.0	5.7	0.2	0.0	0.0	0.0	0.3	0.6	11.9			0.0		0.0	0.0	0.6	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	62.9	0.0	0.0	0.0	0.0	0.0	41.1	0.0	0.0	0.1	0.0	1.3	0.0	0.1	0.0	0.5	71.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CTCF		ENSG00000102974	"CCCTC-binding factor"	P49711	16	67562407-67639185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Chromosome partition, Transcription, Transcription regulation"	"Activator, Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004122, CAB062550, CAB068181, CAB068182"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB062550: , CAB068181: , CAB068182: , HPA004122: "	"unprognostic (2.70e-1)"	"unprognostic (4.21e-2)"	"unprognostic (3.41e-2)"	"unprognostic (4.70e-2)"	"unprognostic (4.41e-2)"	"unprognostic (2.70e-1)"	"prognostic unfavourable (4.21e-4)"	"unprognostic (1.71e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.36e-2)"	"unprognostic (1.99e-2)"	"prognostic favourable (4.06e-4)"	"unprognostic (3.47e-1)"	"unprognostic (5.99e-2)"	"unprognostic (4.58e-2)"	"unprognostic (1.11e-2)"	19.1	17.5	22.3	35.0	24.3	32.2	20.2	31.6	26.6	23.0	19.4	20.5	21.0	16.5	24.2	15.4	23.1	21.7	20.3	17.6	21.8	16.7	19.5	19.5	17.2	27.9	22.3	21.0	24.6	21.2	42.4	21.8	23.5	17.9	19.4	23.2	14.3	19.9	24.9	29.4	25.2	21.4	22.0	20.2	26.1	18.5	14.8	22.9	68.8	20.7	16.2	35.5	22.6	26.7	10.1	7.9	9.6	6.2	4.9	7.2	1.9	10.9	16.9	22.5	8.9	10.3	8.8	18.3	10.5	11.1	15.5	14.9	13.8	11.4	34.4	8.5	9.1	14.2	21.7	11.8	17.6	12.2	14.3	20.8	9.6	15.8	7.0	23.6	20.0	7.1	14.3	11.6	13.0	11.8	18.2	14.4	12.8	21.5	49.5	9.0	19.5	11.3	36.2	18.5	18.9	9.5	15.9	19.3	13.4	19.0	11.1	9.3	13.7	14.7	11.2	13.4	13.9	10.2	11.5	12.6	15.8	50.1	7.7	14.2	14.3	9.4	3.4	4.9	6.7	3.4	6.3	7.9	7.2	5.4	3.1	10.1	5.9	6.7	9.6	4.9	6.2	7.9	5.4	1.9	22.3	24.3	31.6	26.6	21.8	16.7	22.3	21.0	17.9	22.9
CTGF	"CCN2, IGFBP8"	ENSG00000118523	"Connective tissue growth factor"	P29279	6	131948176-131951373	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion, DNA synthesis"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"EFO-21: 128.3;HUVEC TERT2: 107.9;TIME: 222.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	11	"naive B-cell: 11.6"	"Lineage enriched"	"Detected in single"	117	"B-cells: 11.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB005123, HPA031074, HPA031075"	Approved		Approved	"Golgi apparatus,Vesicles"	"Secreted in other tissues"	5200000	5200000	"Golgi apparatus, Vesicles"		"CAB005123: AB_638805, HPA031074: AB_10599618, HPA031075: AB_10611248"	"unprognostic (2.87e-1)"	"unprognostic (1.43e-1)"	"unprognostic (4.41e-2)"	"unprognostic (5.68e-2)"	"unprognostic (9.79e-2)"	"unprognostic (1.82e-2)"	"unprognostic (3.38e-1)"	"unprognostic (4.96e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.89e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.06e-1)"	"unprognostic (1.27e-3)"	"prognostic unfavourable (5.04e-4)"	"unprognostic (1.62e-1)"	"unprognostic (1.77e-2)"	"unprognostic (3.84e-3)"	51.9	15.5	3.5	48.2	7.6	0.0	39.2	1.6	7.1	84.0	26.9	7.2	27.5	5.8	84.9	50.1	38.9	56.3	82.5	73.6	8.8	3.6	83.5	18.8	45.8	53.3	4.7	9.4	30.7	26.3	4.7	9.7	44.0	13.8	54.5	19.7	55.0	28.2	45.3	29.4	30.1	28.7	123.4	12.0	169.8	41.6	24.4	2.3	5.9	66.9	46.9	9.8	48.5	23.3	11.6	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	10.0	0.2	22.7	12.9	0.1	29.0	13.9	18.0	9.6	0.0	0.9	0.0	128.3	37.2	0.4	0.3	2.0	17.0	0.1	0.2	0.0	4.1	10.4	8.9	0.0	0.0	18.8	0.4	13.0	3.2	107.9	0.0	0.0	51.0	0.1	0.0	0.0	4.8	1.7	2.4	0.4	0.0	6.5	0.0	0.0	0.0	2.9	4.9	1.3	0.4	0.2	222.6	25.0	19.5	31.4	53.4	0.9	0.1	0.2	3.4	0.0	31.2	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	11.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	3.5	7.6	1.6	7.1	8.8	3.6	4.7	9.4	13.8	2.3
CTNNB1	"armadillo, beta-catenin, CTNNB"	ENSG00000168036	"Catenin beta 1"	P35222	3	41194741-41260096	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway"	Activator	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000108, CAB001950, HPA029159, HPA029160"	Supported		Enhanced	"Plasma membrane"		1000000	1000000	"Plasma membrane"		"CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996"	"unprognostic (2.47e-1)"	"unprognostic (3.48e-2)"	"prognostic favourable (7.54e-4)"	"unprognostic (1.61e-1)"	"unprognostic (9.55e-2)"	"unprognostic (1.05e-2)"	"unprognostic (3.20e-3)"	"unprognostic (2.79e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.88e-2)"	"unprognostic (9.05e-2)"	"unprognostic (1.97e-3)"	"unprognostic (1.82e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.61e-1)"	"unprognostic (9.79e-2)"	52.9	54.5	38.8	33.5	45.9	46.3	70.5	78.8	59.3	71.7	49.6	57.3	34.2	48.7	79.2	42.5	46.3	49.8	45.0	42.1	38.6	41.5	46.9	53.2	53.6	31.6	37.0	47.0	84.2	38.6	59.2	44.0	82.6	41.5	50.8	50.1	75.9	53.9	49.7	31.2	44.7	70.4	66.5	39.4	41.0	37.3	29.0	39.3	40.1	62.3	44.5	36.6	46.9	54.2	10.1	13.5	7.5	14.5	11.1	13.5	4.8	22.6	30.2	63.7	35.6	34.4	28.2	48.9	25.6	36.4	42.8	42.5	20.8	32.4	18.6	23.4	45.2	17.0	46.1	73.9	45.9	17.2	31.4	30.0	40.1	74.3	25.7	17.0	14.4	41.0	33.5	51.1	31.1	37.6	21.2	11.6	47.4	23.0	11.9	9.2	58.0	23.5	9.0	41.5	12.4	26.5	70.9	15.2	25.8	42.4	21.6	113.7	35.4	35.4	48.4	32.2	24.7	20.6	37.5	7.2	11.2	19.8	33.0	21.5	53.7	4.3	8.1	6.9	11.2	14.5	13.5	9.6	10.5	12.1	13.5	10.1	10.7	10.8	7.5	11.1	13.7	11.7	12.6	4.8	38.8	45.9	78.8	59.3	38.6	41.5	37.0	47.0	41.5	39.3
CTNNBL1	"C20orf33, FLJ21108, NAP, NYD-SP19, P14, P14L"	ENSG00000132792	"Catenin beta like 1"	Q8WYA6	20	37693955-37872129	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, mRNA processing, mRNA splicing"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 74.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004742, HPA027906, HPA027907"	Approved		Enhanced	Nucleoplasm,Centrosome,Cytosol				Nucleoplasm	"Centrosome, Cytosol"	"HPA004742: AB_1847323, HPA027906: , HPA027907: AB_10601362"	"unprognostic (2.81e-1)"	"unprognostic (3.42e-1)"	"unprognostic (8.80e-2)"	"unprognostic (1.88e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.55e-2)"	"unprognostic (1.44e-1)"	"unprognostic (5.11e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.79e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.06e-3)"	"unprognostic (1.62e-1)"	"unprognostic (1.67e-1)"	"unprognostic (2.81e-1)"	"unprognostic (5.31e-2)"	21.0	14.7	19.6	25.8	21.4	27.3	18.9	20.9	21.3	20.3	23.5	18.4	31.7	16.1	25.4	25.2	18.9	21.0	17.7	25.6	17.5	15.8	19.3	35.3	19.3	26.9	17.9	14.7	21.7	14.6	14.5	22.6	22.4	17.5	19.4	18.1	16.1	15.5	34.3	27.3	20.1	19.7	23.8	16.6	49.5	25.9	35.5	20.6	31.0	15.9	15.5	29.7	22.2	29.3	24.9	31.4	60.3	29.1	21.7	18.2	18.4	15.3	14.2	13.6	10.6	9.8	8.1	21.5	9.8	10.3	23.6	20.9	52.9	12.4	17.1	14.4	9.9	16.5	18.2	23.2	25.5	8.2	9.1	56.1	7.8	25.8	10.2	17.7	74.6	8.6	13.8	13.3	13.3	14.1	15.1	7.0	12.6	12.7	28.7	23.6	12.2	20.6	20.2	26.3	12.9	10.3	12.9	10.9	13.0	17.0	24.5	17.2	12.0	14.3	10.4	23.7	14.1	15.5	15.9	8.2	10.4	19.9	16.6	11.1	12.5	60.3	22.3	27.9	15.8	29.1	15.0	24.9	15.4	16.2	31.4	23.4	15.5	16.6	4.9	21.7	28.7	24.7	18.2	18.4	19.6	21.4	20.9	21.3	17.5	15.8	17.9	14.7	17.5	20.6
CTNND1	"CTNND, KIAA0384, p120, p120cas, p120ctn"	ENSG00000198561	"Catenin delta 1"	O60716	11	57753243-57819546	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Transcription, Transcription regulation, Wnt signaling pathway"		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 12.5;non-classical monocyte: 11.9"	"Group enriched"	"Detected in many"	8	"dendritic cells: 10.2;monocytes: 12.5"					"Low region specificity"	"Detected in all"			"CAB003837, HPA015954, HPA015955"	Enhanced		Enhanced	"Plasma membrane"		15000	15000	"Plasma membrane"		"CAB003837: AB_562066, HPA015954: AB_2669326, HPA015955: AB_1846068"	"unprognostic (1.06e-2)"	"unprognostic (1.60e-2)"	"unprognostic (5.17e-3)"	"unprognostic (4.87e-2)"	"unprognostic (7.81e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.98e-2)"	"unprognostic (3.52e-3)"	"unprognostic (4.17e-1)"	"unprognostic (2.89e-2)"	"prognostic unfavourable (3.02e-4)"	"unprognostic (2.75e-1)"	"prognostic favourable (3.54e-4)"	"unprognostic (7.17e-2)"	"unprognostic (4.09e-2)"	"unprognostic (3.34e-1)"	"unprognostic (7.33e-2)"	39.7	19.9	15.1	20.4	17.0	3.2	31.4	15.0	20.5	28.8	41.9	25.7	49.2	37.5	32.7	32.7	76.3	22.9	28.8	18.2	15.6	10.3	30.6	31.2	34.0	11.6	14.4	12.8	23.3	50.4	41.9	34.5	49.8	16.4	29.7	39.8	34.4	46.4	39.1	11.8	48.7	82.0	22.8	17.2	25.9	39.4	27.8	14.7	7.1	38.4	34.9	45.6	32.3	38.9	1.4	10.2	0.4	12.5	0.4	0.5	2.3	37.4	28.1	25.1	16.8	13.6	18.6	35.6	17.2	19.4	15.6	14.9	21.8	41.6	0.7	30.4	21.3	49.2	20.2	26.1	20.0	0.4	6.6	9.3	11.0	24.6	14.1	2.0	14.7	20.5	31.6	19.7	20.2	47.4	14.0	0.4	17.2	12.1	0.7	3.5	17.9	15.1	0.7	21.2	0.8	23.3	40.0	2.3	11.2	24.3	33.3	25.4	35.0	2.5	40.1	15.0	12.9	14.7	9.7	1.3	0.8	1.1	14.0	1.2	26.4	0.0	6.9	0.2	0.2	12.5	0.5	1.0	0.1	0.4	10.2	1.4	0.2	0.3	0.4	0.4	11.9	3.1	0.2	2.3	15.1	17.0	15.0	20.5	15.6	10.3	14.4	12.8	16.4	14.7
CTSB		ENSG00000164733	"Cathepsin B"	P07858	8	11842524-11869448	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"thyroid gland: 297.0"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 237.0;fHDF/TERT166: 137.7"	"Cancer enhanced"	"Detected in all"		"thyroid cancer: 1446.9"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"basophil: 53.1;classical monocyte: 127.4;intermediate monocyte: 97.0;myeloid DC: 68.0;non-classical monocyte: 54.7;plasmacytoid DC: 95.4"	"Group enriched"	"Detected in all"	5	"dendritic cells: 95.4;granulocytes: 53.1;monocytes: 127.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000457, HPA018156, HPA048998"	Enhanced		Supported	Nucleoli,Vesicles	"Secreted to blood"	130000000	130000000	Vesicles	Nucleoli	"CAB000457: , HPA018156: AB_1846069, HPA048998: "	"unprognostic (5.74e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.38e-2)"	"unprognostic (2.17e-2)"	"unprognostic (2.98e-3)"	"unprognostic (5.96e-2)"	"unprognostic (1.36e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.82e-2)"	"unprognostic (1.06e-1)"	"unprognostic (7.61e-2)"	"unprognostic (8.30e-2)"	"unprognostic (2.85e-1)"	"unprognostic (7.39e-2)"	"unprognostic (4.12e-2)"	"prognostic favourable (5.76e-4)"	"prognostic unfavourable (9.02e-4)"	227.9	42.1	19.6	67.2	24.4	14.7	67.6	14.9	31.4	76.7	49.1	30.1	22.7	29.9	53.2	44.8	54.2	52.4	43.6	120.7	18.3	23.7	95.6	167.8	94.3	175.1	29.1	16.5	44.2	31.6	13.8	21.6	68.7	24.8	42.6	27.9	33.8	63.7	33.6	41.3	22.8	51.2	51.1	35.9	116.4	26.7	21.5	20.4	18.1	297.0	25.9	38.4	56.8	62.2	7.9	95.4	53.1	127.4	5.3	17.1	108.5	6.4	29.1	3.7	16.0	65.8	74.1	11.6	121.4	237.0	42.5	50.4	13.9	37.9	0.1	17.6	137.7	35.4	5.1	33.5	26.9	3.1	5.0	9.4	3.4	34.1	67.0	2.1	7.0	81.1	45.7	38.4	34.4	83.1	7.8	21.5	35.3	5.1	0.8	3.4	3.1	9.8	3.3	3.8	16.4	12.9	10.1	1.6	9.5	14.0	7.6	63.3	12.3	6.3	115.1	72.3	24.5	23.1	22.6	21.4	15.5	0.5	82.9	8.1	33.8	53.1	127.4	16.3	5.2	97.0	7.2	7.9	17.1	5.8	68.0	6.1	9.6	4.1	18.5	5.3	54.7	95.4	13.4	108.5	19.6	24.4	14.9	28.0	18.3	23.7	29.1	16.5	24.8	20.4
CTSD	"CLN10, CPSD"	ENSG00000117984	"Cathepsin D"	P07339	11	1752752-1764573	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Aspartyl protease, Hydrolase, Protease"	"Alzheimer disease, Cancer-related genes, Disease mutation, Neurodegeneration, Neuronal ceroid lipofuscinosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"CAPAN-2: 215.7;SK-BR-3: 206.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB000109, HPA003001"	Supported				"Secreted to blood"	540000000	540000000			"CAB000109: , HPA003001: AB_1078404"	"unprognostic (9.95e-2)"	"unprognostic (1.62e-1)"	"prognostic unfavourable (2.46e-4)"	"unprognostic (1.09e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.65e-2)"	"unprognostic (9.40e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.86e-2)"	"prognostic favourable (4.93e-5)"	"unprognostic (8.98e-2)"	"unprognostic (3.39e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.60e-1)"	151.9	148.7	21.4	32.8	27.0	83.7	67.7	18.6	47.4	56.3	59.3	41.4	41.9	61.6	25.9	48.2	46.2	34.2	90.0	86.0	25.3	27.6	150.5	163.5	102.6	81.1	49.6	25.7	41.2	62.3	21.3	24.9	56.1	42.8	33.9	33.7	234.4	64.1	42.3	76.2	50.8	90.9	23.3	36.7	87.6	47.0	29.8	29.7	21.1	36.3	42.9	41.4	64.6	43.5	4.9	22.7	51.1	83.8	28.4	26.1	58.7	15.6	42.4	4.9	20.4	62.1	21.2	7.9	11.6	36.2	15.6	18.5	10.5	215.7	3.8	30.1	29.9	84.4	7.1	13.0	4.3	16.1	15.4	5.8	8.0	13.2	65.5	13.3	61.6	34.2	57.0	8.4	15.5	11.4	6.9	23.2	27.6	57.7	3.4	7.5	11.6	17.0	4.9	6.0	14.1	55.0	49.0	6.8	6.7	13.8	206.2	39.1	80.7	18.4	14.3	47.5	7.3	6.5	18.6	32.0	40.1	2.4	69.2	36.1	39.8	29.0	83.8	25.2	26.1	47.6	15.1	4.9	12.2	18.3	22.7	3.2	14.3	18.3	51.1	28.4	38.5	19.2	13.5	58.7	21.4	27.0	18.6	47.4	25.3	27.6	49.6	25.7	42.8	29.7
CTSH	"ACC-4, ACC-5, ACC4, ACC5, CPSB"	ENSG00000103811	"Cathepsin H"	P09668	15	78921058-78949574	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lung: 82.6"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 42.5;HaCaT: 31.0;RT4: 118.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 42.8"	"Group enriched"	"Detected in all"	5	"B-cells: 20.6;dendritic cells: 41.2;monocytes: 42.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000458, HPA003524"	Enhanced		Supported	"Vesicles,Cytosol,Cytoplasmic bodies"	"Intracellular and membrane"	10000000	10000000	"Vesicles, Cytosol, Cytoplasmic bodies"		"CAB000458: , HPA003524: AB_1846075"	"unprognostic (6.47e-2)"	"unprognostic (4.65e-3)"	"unprognostic (1.05e-1)"	"prognostic favourable (6.90e-4)"	"unprognostic (4.37e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.18e-2)"	"unprognostic (3.30e-3)"	"unprognostic (2.22e-1)"	"unprognostic (5.96e-2)"	"unprognostic (4.10e-2)"	"unprognostic (3.89e-2)"	"unprognostic (6.63e-3)"	"unprognostic (3.83e-1)"	"unprognostic (4.42e-2)"	"unprognostic (2.70e-3)"	"unprognostic (1.79e-3)"	16.7	10.6	9.5	24.2	7.0	5.4	23.9	4.5	9.8	25.1	11.4	17.7	14.7	10.6	10.3	17.1	7.8	13.1	29.2	16.5	14.8	6.7	66.7	18.7	82.6	65.4	12.1	11.6	14.6	25.8	12.3	6.5	7.7	9.4	18.6	6.6	6.7	15.4	15.9	7.0	13.5	16.6	9.8	10.8	20.3	15.6	6.7	15.7	6.6	8.5	4.8	34.8	39.6	13.5	20.6	41.2	1.4	42.8	1.3	7.6	27.3	16.0	1.1	0.4	4.7	1.1	0.0	5.2	1.6	0.6	2.8	1.5	7.0	42.5	5.6	1.7	0.1	31.0	2.0	7.7	2.3	23.6	0.1	0.1	0.2	16.2	1.6	0.0	1.0	0.8	2.2	0.0	0.0	0.2	11.4	0.0	3.8	1.7	3.6	9.8	1.2	0.3	0.0	0.3	0.9	9.8	118.0	0.5	1.1	6.9	3.9	9.6	1.5	5.3	2.2	0.0	1.0	0.0	0.7	0.1	12.2	3.1	0.0	10.3	1.7	0.0	42.8	0.4	1.4	28.3	7.6	20.6	4.1	2.1	41.2	12.0	0.4	0.7	1.4	1.3	17.0	4.2	3.1	27.3	9.5	7.0	4.5	9.8	14.8	6.7	12.1	11.6	9.4	15.7
CTSL	"CTSL1, FLJ31037"	ENSG00000135047	"Cathepsin L"	P07711	9	87725519-87731393	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 237.0"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 198.5;HSkMC: 91.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"intermediate monocyte: 31.0;non-classical monocyte: 44.3"	"Lineage enriched"	"Detected in many"	10	"monocytes: 44.3"									"CAB000459, HPA070413"	Enhanced		Approved	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	17000000	17000000	"Golgi apparatus"	Vesicles	"CAB000459: AB_2292484, HPA070413: "	"unprognostic (1.05e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.24e-2)"	"unprognostic (1.53e-1)"	"prognostic unfavourable (3.73e-4)"	"unprognostic (1.19e-3)"	"unprognostic (8.12e-3)"	"prognostic unfavourable (5.15e-5)"	"unprognostic (2.09e-1)"	"unprognostic (3.15e-1)"	"unprognostic (6.80e-2)"	"unprognostic (3.21e-1)"	"prognostic favourable (4.34e-4)"	"unprognostic (5.64e-3)"	"unprognostic (2.26e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.11e-3)"	60.3	21.5	10.4	27.2	24.6	18.4	23.3	6.9	12.3	14.8	23.2	14.1	13.7	9.0	24.1	22.3	11.4	25.7	20.7	37.7	10.7	11.4	65.4	98.0	53.1	80.5	18.9	7.7	25.0	14.3	18.8	18.0	237.0	18.4	19.4	13.0	23.2	22.0	23.5	29.3	9.1	12.0	36.6	16.1	108.1	17.5	14.1	15.7	6.8	19.2	9.4	10.1	41.3	26.5	0.0	1.7	0.1	44.3	0.0	4.3	2.4	6.3	36.8	2.5	4.3	46.3	198.5	15.4	20.5	59.7	17.6	22.1	3.5	5.9	0.0	9.6	26.5	5.4	3.3	6.6	14.5	0.1	3.2	1.1	10.4	8.6	30.0	0.0	4.4	91.8	11.2	28.8	11.2	13.8	11.9	0.0	25.3	10.6	0.0	0.7	4.9	7.0	1.5	1.5	0.0	12.3	3.3	3.7	4.5	4.3	9.6	23.5	1.1	7.3	21.7	15.8	8.6	57.5	8.6	1.6	5.9	0.0	57.8	0.0	5.2	0.1	3.5	0.1	0.0	31.0	0.0	0.0	1.8	0.0	1.7	0.0	4.3	0.3	0.1	0.0	44.3	0.1	0.3	2.4	10.4	24.6	6.9	11.7	10.7	11.4	18.9	7.7	18.4	15.7
CTTN	EMS1	ENSG00000085733	Cortactin	Q14247	11	70398404-70436584	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 128.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 4.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011235, HPA057242"	Supported		Supported	"Golgi apparatus,Vesicles,Plasma membrane,Cytosol"		34000000	34000000	"Plasma membrane, Cytosol"	"Golgi apparatus, Vesicles"	"CAB011235: , HPA057242: "	"unprognostic (6.34e-2)"	"unprognostic (2.65e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.13e-2)"	"unprognostic (5.81e-2)"	"prognostic unfavourable (2.19e-6)"	"prognostic unfavourable (4.45e-4)"	"unprognostic (6.10e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.50e-2)"	"unprognostic (6.97e-2)"	"unprognostic (2.79e-1)"	"unprognostic (3.72e-3)"	"unprognostic (1.94e-1)"	37.5	53.6	33.0	19.7	36.7	5.7	32.0	33.3	41.1	41.3	35.3	42.3	33.7	37.1	48.8	40.2	49.4	35.5	56.2	37.3	28.5	23.5	47.2	24.9	30.5	13.7	45.0	32.0	46.3	40.0	28.9	38.3	32.3	37.2	38.9	32.4	24.4	38.0	38.5	31.5	52.9	39.2	43.1	36.0	21.4	51.3	30.2	38.6	7.7	36.0	44.5	26.7	33.2	38.2	0.1	0.8	4.6	0.2	0.0	0.4	13.9	128.4	28.3	9.6	11.0	16.2	25.3	15.8	27.5	27.5	24.3	19.2	37.4	32.4	5.0	27.3	35.2	28.6	11.4	28.9	17.8	10.1	11.5	0.5	21.1	17.5	35.0	0.1	6.8	35.7	20.4	26.8	15.2	20.3	14.4	0.9	23.9	35.1	0.2	1.8	10.4	17.3	0.0	11.8	4.0	27.1	41.9	7.9	13.5	20.1	27.6	45.7	22.5	0.5	25.3	21.4	13.7	33.2	18.3	2.2	1.4	0.3	42.7	0.1	29.2	1.4	0.2	0.2	0.0	0.1	0.0	0.1	0.2	0.0	0.2	0.0	0.4	0.0	4.6	0.0	0.2	0.8	0.0	13.9	33.0	36.7	33.3	41.1	28.5	23.5	45.0	32.0	37.2	38.6
CUL1		ENSG00000055130	"Cullin 1"	Q13616	7	148697914-148801036	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002676, HPA064584"	Supported		Supported	Nucleoplasm,Nucleoli		190000	190000	Nucleoplasm	Nucleoli	"CAB002676: , HPA064584: "	"unprognostic (3.59e-2)"	"unprognostic (1.23e-1)"	"unprognostic (5.23e-1)"	"unprognostic (1.19e-1)"	"unprognostic (5.06e-3)"	"unprognostic (9.45e-2)"	"unprognostic (1.41e-2)"	"unprognostic (8.23e-2)"	"unprognostic (2.40e-2)"	"unprognostic (3.65e-2)"	"unprognostic (3.40e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.18e-2)"	"unprognostic (3.88e-2)"	"unprognostic (1.48e-1)"	"unprognostic (2.40e-1)"	"unprognostic (7.24e-3)"	26.0	20.9	21.2	20.4	22.4	22.3	27.5	27.5	26.2	23.9	25.8	19.5	22.5	16.7	30.2	23.7	22.7	21.2	18.7	25.7	21.1	21.8	16.9	35.2	20.5	26.5	21.7	16.7	25.0	17.9	24.9	30.7	32.0	21.0	23.9	18.8	22.7	19.6	25.0	58.9	20.5	21.2	37.7	26.3	21.9	22.4	65.6	23.7	16.9	24.5	24.6	24.5	26.1	28.8	16.8	24.1	13.4	17.1	22.1	20.8	16.1	30.7	23.9	23.5	36.3	18.5	20.8	29.8	25.4	30.0	25.7	24.5	25.4	21.5	42.2	20.4	25.1	20.8	33.5	23.7	30.3	27.5	28.5	24.9	16.9	24.6	21.7	28.2	23.7	17.0	23.3	18.8	19.1	28.0	38.4	32.6	28.0	29.4	24.5	32.3	44.0	22.9	29.8	20.7	40.6	21.1	22.5	33.8	24.8	29.6	35.3	20.0	11.6	22.4	21.5	18.4	6.4	37.2	29.2	30.6	21.2	41.8	37.4	31.5	27.1	13.4	15.2	12.0	16.1	17.1	18.6	16.8	16.7	18.6	24.1	14.4	20.8	16.7	2.1	22.1	14.5	5.5	15.9	16.1	21.2	22.4	27.5	26.2	21.1	21.8	21.7	16.7	21.0	23.7
CUL2		ENSG00000108094	"Cullin 2"	Q13617	10	35008551-35090642	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002677, HPA024578"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002677: , HPA024578: AB_1847338"	"unprognostic (8.11e-3)"	"unprognostic (1.12e-1)"	"unprognostic (9.77e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.53e-2)"	"unprognostic (1.59e-2)"	"prognostic unfavourable (8.24e-6)"	"unprognostic (2.18e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.20e-1)"	"unprognostic (4.70e-2)"	"unprognostic (6.94e-2)"	"prognostic unfavourable (9.32e-5)"	"unprognostic (2.26e-2)"	"unprognostic (2.31e-1)"	"unprognostic (3.70e-1)"	"unprognostic (2.29e-1)"	16.2	14.9	17.2	12.6	22.6	14.3	13.6	16.8	20.9	11.6	14.3	9.0	18.1	11.9	13.6	9.5	14.3	12.1	10.1	15.7	15.4	15.1	12.2	17.2	11.9	15.4	14.3	20.8	12.9	17.7	21.4	19.3	21.9	17.3	13.3	13.0	7.0	12.8	14.1	33.7	14.2	12.4	16.1	14.0	15.1	14.5	27.9	15.4	20.3	13.7	14.4	16.6	15.6	12.3	11.4	11.9	10.0	13.7	11.3	17.4	7.7	19.6	11.6	15.4	13.2	17.6	19.4	16.3	23.2	13.0	23.0	23.3	15.5	18.9	15.7	12.9	24.5	18.2	22.3	21.4	26.5	18.4	14.5	20.4	12.6	13.7	19.3	11.1	13.4	18.7	17.9	25.2	8.8	25.6	23.3	14.3	25.2	13.4	18.3	6.2	5.6	47.7	15.5	24.9	9.8	21.2	15.5	7.5	10.0	13.0	16.4	18.3	12.5	12.7	23.4	14.3	15.9	24.3	15.1	6.0	8.1	18.9	27.4	25.1	10.0	9.6	9.3	10.0	12.3	13.7	17.4	10.8	14.0	14.7	11.9	11.4	16.7	15.5	4.4	11.3	13.3	5.4	16.6	7.7	17.2	22.6	16.8	20.9	15.4	15.1	14.3	20.8	17.3	15.4
CUL4B		ENSG00000158290	"Cullin 4B"	Q13620	X	120524609-120575794	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair, Ubl conjugation pathway"		"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"fHDF/TERT166: 62.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003046, HPA011880, CAB017786, HPA058979"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB017786: , HPA003046: , HPA011880: AB_1847340, HPA058979: "	"unprognostic (2.34e-2)"	"unprognostic (2.74e-2)"	"unprognostic (2.69e-2)"	"unprognostic (7.73e-3)"	"unprognostic (9.66e-2)"	"unprognostic (3.91e-1)"	"unprognostic (3.88e-3)"	"unprognostic (8.99e-2)"	"unprognostic (8.12e-3)"	"unprognostic (3.20e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.87e-3)"	"unprognostic (3.83e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.82e-2)"	"unprognostic (2.84e-1)"	20.9	24.0	19.0	19.2	28.1	12.2	25.3	28.9	25.7	32.6	20.5	12.1	25.7	14.0	24.2	47.2	29.3	19.6	18.5	19.4	18.5	20.2	19.1	20.4	23.8	23.5	17.3	20.4	30.1	18.8	34.4	48.3	17.0	18.4	30.8	17.2	15.7	17.3	27.3	10.8	17.7	16.3	36.0	20.5	19.9	17.0	34.0	17.3	29.8	18.8	13.9	24.1	40.4	22.5	7.6	12.5	15.4	4.3	5.5	8.3	4.9	12.0	10.2	8.5	9.0	37.5	19.0	6.9	27.3	32.8	22.6	23.7	9.2	34.2	12.1	9.4	62.8	9.0	17.4	8.0	25.8	7.0	9.0	5.9	14.8	6.5	16.2	6.3	8.4	21.3	6.1	13.0	11.3	40.4	9.1	9.4	21.8	6.4	8.3	6.6	12.9	10.3	7.0	8.4	12.3	7.5	6.0	9.7	8.1	20.2	9.9	10.0	8.4	5.8	53.2	16.3	9.0	21.7	24.4	6.0	10.4	15.1	17.6	8.6	14.6	5.8	4.3	9.0	7.2	3.8	7.7	7.6	7.0	6.6	5.1	5.7	7.9	8.3	15.4	5.5	2.7	12.5	8.2	4.9	19.0	28.1	28.9	25.7	18.5	20.2	17.3	20.4	18.4	17.3
CUL5	VACM-1	ENSG00000166266	"Cullin 5"	Q93034	11	108008733-108107776	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002185, CAB017787"	Approved		Approved	"Golgi apparatus,Cytosol"				"Golgi apparatus, Cytosol"		"CAB017787: , HPA002185: AB_1078587"	"unprognostic (5.66e-2)"	"unprognostic (6.58e-2)"	"unprognostic (7.16e-3)"	"unprognostic (1.30e-1)"	"unprognostic (5.54e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.32e-2)"	"unprognostic (2.80e-1)"	"unprognostic (5.97e-3)"	"unprognostic (1.78e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.77e-2)"	"prognostic favourable (1.06e-5)"	"unprognostic (3.83e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.10e-1)"	11.6	13.2	10.8	9.0	14.8	25.0	13.4	17.1	19.3	13.1	10.8	12.7	11.0	9.0	13.6	10.7	11.2	10.9	8.7	14.8	11.3	10.6	16.7	15.3	9.7	10.2	12.5	12.3	13.2	11.2	17.8	14.6	12.6	19.5	12.9	9.5	11.2	11.4	10.9	41.6	11.5	11.2	11.8	13.1	12.5	10.3	6.5	12.7	23.1	14.6	15.1	10.0	10.8	13.6	6.4	5.9	4.1	6.7	4.0	6.2	3.6	9.7	4.6	13.8	10.6	9.1	14.6	6.9	10.3	11.4	9.5	10.7	14.6	11.5	13.7	19.3	12.9	12.5	12.8	8.6	13.9	8.8	7.8	12.9	4.4	10.8	15.6	14.5	10.5	11.5	11.8	9.9	13.2	13.0	16.5	5.1	14.9	5.4	13.9	12.6	7.2	8.1	10.1	10.3	14.9	12.0	14.8	10.0	14.2	14.0	14.9	8.4	21.7	12.0	13.5	17.6	8.2	12.4	11.0	5.2	4.0	17.9	6.9	16.6	11.1	1.9	6.7	4.1	5.4	5.2	4.9	4.4	5.6	5.3	5.9	6.4	6.1	6.2	1.2	4.0	6.0	5.9	4.0	3.6	10.8	14.8	17.1	19.3	11.3	10.6	12.5	12.3	19.5	12.7
CUX1	"CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6"	ENSG00000257923	"Cut like homeobox 1"	"Q13948, P39880"	7	101815904-102283958	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation, Transport"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"non-classical monocyte: 21.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003277, HPA003317"	Approved		Supported	"Nucleoplasm,Golgi apparatus"				"Nucleoplasm, Golgi apparatus"		"HPA003277: AB_10601804, HPA003317: "	"unprognostic (5.86e-2)"	"unprognostic (5.39e-3)"	"unprognostic (9.62e-3)"	"unprognostic (1.73e-1)"	"prognostic unfavourable (7.51e-4)"	"unprognostic (5.85e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.89e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.50e-1)"	"prognostic favourable (5.72e-7)"	"unprognostic (1.12e-1)"	"unprognostic (8.85e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.97e-1)"	19.3	12.7	22.9	19.2	24.4	19.5	12.3	48.6	29.9	31.6	26.4	23.1	17.3	22.2	52.1	17.4	23.9	24.5	23.2	53.8	18.8	18.3	27.4	16.0	22.0	11.8	20.4	11.7	33.0	41.4	34.4	30.2	24.4	16.9	22.8	17.2	26.8	26.3	16.9	31.0	15.9	25.3	27.5	31.6	15.0	23.4	8.3	17.1	44.0	33.5	23.2	24.1	31.8	21.9	2.0	12.1	4.7	21.0	3.0	2.2	4.5	14.3	15.4	10.9	13.4	8.8	18.3	6.8	14.4	15.3	6.1	4.0	9.1	9.2	18.5	23.2	14.2	11.8	6.9	11.6	3.7	8.9	7.7	6.5	11.4	7.6	23.5	8.4	3.6	12.7	23.7	4.7	10.7	7.9	15.1	15.8	5.7	29.5	27.3	10.3	4.4	16.1	18.1	9.0	22.0	10.1	16.4	10.0	29.8	12.6	31.6	12.3	6.2	10.1	11.7	25.9	17.5	19.5	8.2	10.3	4.9	40.1	23.9	7.8	18.0	2.1	8.6	1.5	2.1	8.8	2.2	2.0	1.6	2.2	7.0	1.7	1.6	2.2	4.7	3.0	21.0	12.1	1.5	4.5	22.9	24.4	48.6	29.9	18.8	18.3	20.4	11.7	16.9	17.1
CXCL1	"FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1"	ENSG00000163739	"C-X-C motif chemokine ligand 1"	P09341	4	73869393-73871242	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Inflammatory response"	"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 124.8"	"Group enriched"	"Detected in some"	6	"BJ hTERT+: 78.9;EFO-21: 201.6;RPTEC TERT1: 72.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	253	"neutrophil: 25.3"	"Lineage enriched"	"Detected in single"	253	"granulocytes: 25.3"														"Secreted to blood"						"prognostic favourable (7.83e-4)"	"prognostic unfavourable (7.23e-4)"	"unprognostic (5.24e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.33e-2)"	"unprognostic (4.23e-3)"	"prognostic unfavourable (2.91e-4)"	"unprognostic (1.36e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.33e-1)"	"unprognostic (5.45e-2)"	"unprognostic (2.04e-2)"	"prognostic unfavourable (1.60e-4)"	"unprognostic (1.17e-1)"	"unprognostic (5.30e-2)"	"unprognostic (7.41e-2)"	"unprognostic (9.41e-2)"	12.0	0.8	1.3	22.5	2.2	14.8	4.1	0.8	1.4	49.2	7.7	1.0	0.7	4.3	0.9	2.1	27.8	6.1	11.2	12.1	1.7	1.3	8.9	4.2	23.0	10.9	3.1	1.0	3.8	13.0	0.0	0.7	26.1	3.9	8.7	7.1	2.1	8.1	4.1	3.2	0.8	10.8	1.2	3.8	124.8	3.1	2.1	1.7	1.7	0.7	7.9	22.6	29.9	6.6	0.0	0.0	25.3	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.4	1.3	0.0	2.1	78.9	1.9	2.0	0.0	1.4	0.0	201.6	0.1	4.0	0.0	0.3	10.2	0.2	0.0	0.0	0.1	0.0	0.4	0.0	0.0	1.0	0.1	14.2	1.1	15.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	72.8	1.7	0.0	0.0	0.1	0.0	3.9	0.0	0.1	18.2	0.0	0.6	3.9	0.1	0.0	0.1	0.3	0.2	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.3	0.0	0.0	0.0	0.0	0.0	1.3	2.2	0.8	1.4	1.7	1.3	3.1	1.0	3.9	1.7
CXCL10	"C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10"	ENSG00000169245	"C-X-C motif chemokine ligand 10"	P02778	4	76021117-76023497	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 36.2;lymphoid tissue: 34.8;prostate: 34.6"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 9.6;BJ hTERT+ SV40 Large T+: 3.6;BJ hTERT+ SV40 Large T+ RasG12V: 3.5;Daudi: 3.1;RPMI-8226: 6.6;RT4: 3.7;THP-1: 4.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	10	"classical monocyte: 10.6;intermediate monocyte: 25.5;non-classical monocyte: 15.9"	"Lineage enriched"	"Detected in many"	15	"monocytes: 25.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (1.94e-1)"	"unprognostic (5.32e-2)"	"unprognostic (9.98e-3)"	"unprognostic (6.30e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.35e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.51e-1)"	"unprognostic (7.59e-2)"	"prognostic favourable (1.12e-5)"	"prognostic unfavourable (4.61e-4)"	"unprognostic (2.75e-1)"	"prognostic unfavourable (1.16e-6)"	"unprognostic (1.03e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.66e-2)"	4.3	2.1	2.7	34.8	2.5	0.0	7.3	1.8	4.8	8.1	3.5	0.9	0.2	3.8	2.3	6.7	4.7	1.2	3.8	7.6	1.2	1.2	7.5	10.6	36.2	21.7	3.2	1.6	3.9	1.2	0.0	2.3	5.6	3.0	34.6	6.0	2.6	9.1	2.1	7.3	2.1	4.1	5.5	11.3	15.8	6.4	1.3	0.9	15.0	25.7	5.4	9.2	9.2	2.2	0.5	1.6	0.6	25.5	0.0	0.1	3.7	0.7	0.0	0.0	0.3	0.0	0.2	0.0	0.0	9.6	3.6	3.5	0.3	0.1	3.1	0.4	0.0	0.0	0.0	0.2	0.2	2.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	6.6	0.1	3.7	0.0	0.0	0.0	0.7	2.1	0.2	4.6	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.9	0.0	0.0	10.6	0.0	0.0	25.5	0.0	0.5	0.1	0.0	1.6	0.0	0.0	0.0	0.6	0.0	15.9	0.0	0.0	3.7	2.7	2.5	1.8	4.8	1.2	1.2	3.2	1.6	3.0	0.9
CXCL13	"ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13"	ENSG00000156234	"C-X-C motif chemokine ligand 13"	O43927	4	77511753-77611834	"Cancer-related genes, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"lymphoid tissue: 82.5"	"Cell line enhanced"	"Detected in some"		"HL-60: 1.4;RH-30: 1.2;U-266/70: 5.3"	"Low cancer specificity"	"Detected in all"							"Cell type enhanced"	"Detected in single"		"memory CD8 T-cell: 1.0"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.0"									HPA052613	Uncertain				"Secreted to blood"					"HPA052613: "	"unprognostic (5.25e-3)"	"unprognostic (1.19e-2)"	"prognostic favourable (9.12e-4)"	"prognostic favourable (5.52e-4)"	"unprognostic (1.53e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.49e-1)"	"unprognostic (6.41e-3)"	"unprognostic (9.82e-3)"	"prognostic favourable (5.41e-4)"	"unprognostic (1.13e-1)"	"unprognostic (2.07e-1)"	"prognostic unfavourable (1.16e-10)"	"unprognostic (2.04e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.37e-1)"	"unprognostic (6.68e-3)"	0.2	0.1	0.0	15.3	0.2	0.0	1.5	0.3	0.0	0.1	1.1			0.0	0.8	0.0	0.6	0.2	0.2	0.0	0.0	0.0	0.3	4.3	0.2	65.1	0.0		0.2	0.0	0.0	0.8	0.0		3.8	1.8		0.8	0.0	0.0	0.1	15.5	0.0	0.0	82.5	3.7	0.3			0.5		57.5	6.2	0.2	0.0	0.3	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	1.4	0.1	0.3	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.0	0.1	0.1	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	5.3	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0										
CXCL2	"CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2"	ENSG00000081041	"C-X-C motif chemokine ligand 2"	P19875	4	74097035-74099293	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"liver: 113.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 24.4;HHSteC: 17.2;hTCEpi: 18.1;hTEC/SVTERT24-B: 12.9;hTERT-HME1: 17.6;RPTEC TERT1: 12.3;U-87 MG: 14.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 3.0;non-classical monocyte: 3.5"	"Group enriched"	"Detected in many"	25	"granulocytes: 1.4;monocytes: 3.5"														"Secreted to blood"						"prognostic favourable (5.93e-5)"	"prognostic unfavourable (1.41e-4)"	"unprognostic (5.28e-3)"	"unprognostic (1.36e-1)"	"unprognostic (2.64e-3)"	"unprognostic (1.27e-1)"	"unprognostic (7.14e-3)"	"unprognostic (3.00e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.49e-1)"	"unprognostic (6.72e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (2.07e-6)"	"unprognostic (1.05e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.59e-1)"	22.8	3.8	2.4	19.9	4.3	20.7	10.9	0.8	1.7	20.4	5.7	2.3	0.9	0.9	4.4	3.8	6.2	5.8	15.2	14.2	1.7	2.0	3.2	113.1	22.4	35.0	2.8	0.5	5.8	24.9	0.6	2.3	1.4	4.3	5.1	6.4	5.1	4.8	3.6	30.9	1.3	3.8	4.1	4.6	3.7	7.5	3.1	1.6	0.0	2.1	18.5	1.8	11.7	4.1	0.0	0.0	1.4	3.5	0.0	0.0	0.1	0.6	1.7	0.1	0.0	0.6	2.1	0.0	1.9	24.4	1.0	2.9	0.1	3.8	0.0	3.4	0.1	0.0	0.1	5.3	4.0	0.0	0.0	1.5	2.0	0.0	17.2	0.6	0.0	1.9	18.1	12.9	17.6	2.1	0.1	0.0	0.5	0.0	0.2	0.3	0.0	0.6	0.0	0.0	0.0	12.3	0.0	0.0	0.0	1.1	0.1	0.5	0.0	0.1	3.2	0.9	0.3	3.8	1.8	0.0	0.0	0.0	14.9	4.0	0.1	1.4	0.6	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	3.5	0.0	0.0	0.1	2.4	4.3	0.8	1.7	1.7	2.0	2.8	0.5	4.3	1.6
CXCL5	"ENA-78, SCYB5"	ENSG00000163735	"C-X-C motif chemokine ligand 5"	P42830	4	73995642-73998779	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 20.0;lymphoid tissue: 28.0;salivary gland: 31.2"	"Cell line enhanced"	"Detected in some"		"A549: 33.7;EFO-21: 28.4;HSkMC: 20.5;hTEC/SVTERT24-B: 14.7;RPTEC TERT1: 108.7"	"Cancer enhanced"	"Detected in many"		"stomach cancer: 74.0"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 1.1"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 1.1"									HPA065474	Approved				"Secreted to blood"					"HPA065474: "	"unprognostic (5.56e-3)"	"prognostic unfavourable (3.43e-4)"	"unprognostic (1.80e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.04e-3)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (1.39e-4)"	"unprognostic (1.06e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.87e-1)"	"prognostic unfavourable (2.23e-4)"	"unprognostic (7.99e-2)"	"prognostic unfavourable (2.45e-5)"	"unprognostic (3.72e-1)"	"unprognostic (3.07e-1)"	"unprognostic (2.72e-2)"	"unprognostic (9.30e-2)"	1.7	0.3	1.6	28.0	6.0	0.7	2.4	0.4	1.4	10.5	0.7	1.5	0.2	0.6	0.3	0.0	0.6	0.4	3.9	1.4	4.3	2.8	0.4	2.1	20.0	13.6	1.2	0.1	0.3	0.8	0.0	0.3	1.5	7.4	1.5	0.2	0.0	31.2	0.5	0.3	0.3	1.8	0.1	2.6	5.2	6.4	5.4	0.2	1.0	0.3	10.8	0.8	10.9	0.3	0.0	0.0	1.1	0.1	0.0	0.2	5.5	0.0	33.7	0.1	0.0	0.0	1.2	0.0	0.6	0.5	0.2	0.5	0.1	0.3	0.0	28.4	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	20.5	0.0	14.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	108.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.2	5.5	1.6	6.0	0.4	1.0	4.3	2.8	1.2	0.1	7.4	0.2
CXCL8	"3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1"	ENSG00000169429	"C-X-C motif chemokine ligand 8"	P10145	4	73740506-73743716	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 79.4;bone marrow: 300.7;lung: 106.1"	"Cell line enriched"	"Detected in many"	7	"BJ hTERT+: 288.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	428	"neutrophil: 79.4"	"Lineage enriched"	"Detected in single"	794	"granulocytes: 79.4"					"Not detected"	"Not detected"			HPA057179	Supported				"Secreted to blood"					"HPA057179: "	"unprognostic (3.42e-1)"	"prognostic unfavourable (1.18e-5)"	"unprognostic (3.91e-3)"	"unprognostic (8.49e-2)"	"unprognostic (3.29e-2)"	"unprognostic (3.03e-3)"	"prognostic unfavourable (1.19e-5)"	"unprognostic (1.37e-3)"	"unprognostic (3.19e-1)"	"unprognostic (4.46e-1)"	"unprognostic (7.19e-3)"	"unprognostic (7.16e-2)"	"prognostic unfavourable (3.13e-6)"	"unprognostic (4.73e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.64e-2)"	"unprognostic (6.15e-2)"	13.4	1.6	1.8	21.9	1.9	300.7	1.7	0.4	1.5	6.5	1.4	0.8	0.0	0.5	4.5	0.9	6.7	3.9	18.9	17.7	1.3	1.1	2.4	8.4	106.1	2.3	2.4	0.9	4.4	4.3	0.3	1.1	9.6	7.8	4.3	1.0	1.9	7.4	0.3	2.9	0.5	1.6	1.4	5.5	1.6	2.8	13.5	1.1	1.0	1.1	9.3	7.7	27.9	1.5	0.0	0.0	79.4	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.2	1.4	0.0	1.8	288.7	2.6	8.5	0.0	0.9	0.0	39.6	0.0	3.4	0.0	0.0	41.2	0.1	0.0	0.0	0.0	0.4	0.5	2.6	0.1	0.9	0.1	8.6	0.2	8.9	0.0	0.0	0.0	0.0	0.0	3.8	0.0	1.4	0.0	0.0	0.0	22.9	1.2	0.0	0.0	0.1	0.0	3.9	0.0	0.3	22.2	4.1	0.3	1.1	3.7	0.0	0.0	0.1	18.6	2.1	6.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	79.4	0.0	0.0	0.0	0.0	0.0	1.8	1.9	0.4	1.5	1.3	1.1	2.4	0.9	7.8	1.1
CXCL9	"CMK, crg-10, Humig, MIG, SCYB9"	ENSG00000138755	"C-X-C motif chemokine ligand 9"	Q07325	4	76001275-76007488	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 70.6;thyroid gland: 28.6"	"Cell line enriched"	"Detected in single"	8	"RPMI-8226: 4.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 1.2;non-classical monocyte: 2.6"	"Lineage enriched"	"Detected in single"	27	"monocytes: 2.6"	"Region enhanced"	"Detected in single"		"olfactory region: 0.6"	"Low region specificity"	"Detected in many"								"Secreted to blood"						"prognostic favourable (6.36e-4)"	"unprognostic (6.86e-3)"	"unprognostic (1.25e-2)"	"prognostic favourable (2.07e-4)"	"unprognostic (2.97e-1)"	"unprognostic (3.78e-3)"	"unprognostic (8.79e-2)"	"unprognostic (4.93e-2)"	"unprognostic (1.46e-2)"	"prognostic favourable (8.06e-4)"	"unprognostic (2.18e-3)"	"unprognostic (1.88e-1)"	"prognostic unfavourable (5.15e-6)"	"unprognostic (4.76e-2)"	"unprognostic (4.14e-2)"	"unprognostic (1.57e-2)"	"unprognostic (6.54e-2)"	6.3	0.4	0.5	30.8	0.8	0.0	4.4	0.4	0.4	6.0	2.4	0.4	1.0	0.5	1.1	3.6	2.5	0.5	2.1	5.3	0.5	0.4	9.9	5.9	16.4	70.6	0.3	0.5	4.5	1.0	0.0	1.5	2.1	1.3	5.0	7.3	2.9	4.9	0.6	7.0	2.2	6.6	3.4	2.6	18.6	4.1	1.9	0.4	17.3	28.6	3.5	15.7	4.3	1.6	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.2	4.8	0.0	0.0	0.1	0.2	0.1	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.5	0.1	0.0	0.5	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.5	0.8	0.4	0.4	0.5	0.4	0.3	0.5	1.3	0.4
CXCR1	"CD181, CDw128a, CKR-1, CMKAR1, IL8RA"	ENSG00000163464	"C-X-C motif chemokine receptor 1"	P25024	2	218162845-218166995	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 144.6"	"Cell line enriched"	"Detected in single"	26	"HMC-1: 11.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in some"	16	"neutrophil: 144.6"	"Lineage enriched"	"Detected in many"	59	"granulocytes: 144.6"	"Not detected"	"Not detected"							HPA031991	Uncertain									"HPA031991: "	"unprognostic (2.80e-1)"	"unprognostic (2.91e-2)"	"unprognostic (3.53e-2)"	"unprognostic (5.74e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.14e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.27e-2)"	"unprognostic (2.15e-2)"	"unprognostic (2.88e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.97e-1)"	"unprognostic (1.30e-1)"	"unprognostic (8.85e-2)"	11.5	0.4	0.8	21.1	0.7	7.3	0.6	0.9	2.6	0.6	0.6	0.2	0.0	0.0	0.5	0.1	1.3	2.8	3.6	3.8	0.9	0.6	0.7	2.9	20.3	33.4	5.9	0.0	1.7	1.2	0.0	0.8	2.1	2.3	0.9	0.1	1.4	0.6	0.0	1.0	0.5	0.6	1.4	3.4	33.7	1.0	1.4	0.7	0.1	0.9	0.6	0.4	4.5	4.1	0.0	0.0	144.6	0.2	0.1	2.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.3	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.2	0.2	2.4	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.9	144.6	0.1	0.2	0.0	0.0	0.7	0.8	0.7	0.9	2.6	0.9	0.6	5.9	0.0	2.3	0.7
CXCR2	"CD182, CMKAR2, IL8RB"	ENSG00000180871	"C-X-C motif chemokine receptor 2"	P25025	2	218125289-218137253	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"blood: 216.1"	"Group enriched"	"Detected in some"	11	"BEWO: 12.1;HL-60: 6.7;HMC-1: 14.1;THP-1: 12.8;U-937: 12.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	59	"neutrophil: 216.1"	"Lineage enriched"	"Detected in many"	109	"granulocytes: 216.1"	"Low region specificity"	"Detected in single"							"CAB016268, HPA031999, HPA032017"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Microtubules,Mitotic spindle"				"Plasma membrane"	"Nucleoplasm, Microtubules, Mitotic spindle"	"CAB016268: AB_626893, HPA031999: AB_2674105, HPA032017: AB_2674112"	"unprognostic (4.89e-2)"	"unprognostic (2.01e-1)"	"unprognostic (5.63e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.13e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.22e-2)"	"unprognostic (5.67e-2)"	"unprognostic (1.41e-1)"	"unprognostic (7.54e-2)"	"unprognostic (1.04e-1)"	"unprognostic (7.23e-2)"	"unprognostic (8.18e-2)"	"unprognostic (5.48e-2)"	9.3	0.9	1.3	25.6	1.5	4.0	0.6	1.2	1.3	5.2	0.6	0.5	2.5	0.0	0.8	1.1	18.1	3.3	5.2	4.3	1.5	0.6	0.7	4.6	16.7	40.5	6.6	0.0	1.2	1.7	0.0	0.7	4.5	1.7	1.9	0.3	1.8	3.3	2.6	0.6	3.0	0.7	1.4	4.1	30.6	1.0	1.1	0.7	0.6	0.6	4.8	10.1	5.4	6.4	0.0	1.6	216.1	1.9	0.4	1.9	1.0	0.0	0.0	0.1	0.0	0.0	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.7	14.1	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	1.0	0.2	0.0	0.3	0.0	1.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	12.8	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	12.6	0.0	3.6	1.9	3.2	1.9	0.5	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.7	216.1	0.4	0.2	1.6	0.0	1.0	1.3	1.5	1.2	1.3	1.5	0.6	6.6	0.0	1.7	0.7
CXCR4	"CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R"	ENSG00000121966	"C-X-C motif chemokine receptor 4"	P61073	2	136114349-136118165	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 149.9;lymphoid tissue: 186.3"	"Cell line enhanced"	"Detected in many"		"Daudi: 75.5;Karpas-707: 40.5;MOLT-4: 68.5;REH: 36.3;U-266/70: 87.9;U-698: 88.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"														"unprognostic (1.19e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.69e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.12e-2)"	"unprognostic (4.99e-2)"	"unprognostic (9.25e-2)"	"unprognostic (6.06e-2)"	"prognostic favourable (2.05e-4)"	"unprognostic (1.23e-1)"	"unprognostic (2.66e-1)"	"prognostic unfavourable (1.41e-7)"	"prognostic unfavourable (5.67e-4)"	"unprognostic (1.57e-1)"	"unprognostic (3.47e-2)"	"unprognostic (9.33e-2)"	15.4	26.5	3.0	39.1	3.4	149.9	9.7	0.8	2.1	7.7	8.7	6.8	1.5	1.6	8.3	3.8	16.4	9.1	12.0	5.4	4.1	4.7	8.2	7.1	29.3	94.5	6.5	1.3	6.3	3.1	0.7	8.1	7.8	6.1	6.8	7.0	10.0	10.6	2.2	3.2	2.3	57.8	3.8	22.9	82.4	8.0	7.2	3.4	186.3	9.2	4.6	97.5	50.0	6.6	47.3	16.8	37.8	7.2	4.0	32.0	11.9	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	75.5	0.2	0.0	0.0	0.2	0.0	0.0	3.8	0.9	4.5	12.0	0.0	0.0	10.4	8.2	0.0	0.0	0.0	0.0	7.2	0.1	40.5	0.0	0.2	68.5	9.3	1.2	0.3	36.3	8.4	13.2	0.6	0.0	4.2	3.5	0.0	0.2	0.0	0.0	20.5	1.0	0.0	0.2	0.0	0.0	87.9	14.8	88.4	0.0	17.2	0.0	17.9	7.2	29.6	22.9	3.8	18.7	30.1	21.1	21.7	6.6	47.3	32.0	30.1	37.8	4.0	2.1	16.8	18.9	11.9	3.0	3.4	0.8	2.1	4.1	4.7	6.5	1.3	6.1	3.4
CYB5R3	DIA1	ENSG00000100243	"Cytochrome b5 reductase 3"	P00387	22	42617840-42649568	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism"	Oxidoreductase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 115.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001566	Approved		Supported	"Endoplasmic reticulum"		67000000	67000000	"Endoplasmic reticulum"		"HPA001566: AB_1078601"	"unprognostic (4.73e-2)"	"unprognostic (2.93e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.04e-2)"	"prognostic unfavourable (2.13e-5)"	"unprognostic (2.45e-1)"	"unprognostic (8.22e-3)"	"unprognostic (3.01e-1)"	"unprognostic (2.72e-2)"	"unprognostic (6.76e-2)"	"unprognostic (3.33e-3)"	"unprognostic (1.31e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.92e-1)"	"unprognostic (5.24e-2)"	79.7	57.1	33.2	22.8	32.6	19.3	86.8	19.5	33.1	52.4	31.9	37.6	51.8	25.9	51.9	35.0	39.1	39.3	38.6	86.4	31.3	24.1	43.3	78.2	43.5	30.3	31.8	25.4	58.8	21.9	15.1	27.2	32.1	33.9	40.6	21.3	37.9	29.3	96.4	34.4	43.1	32.5	55.5	36.3	20.2	33.7	44.0	25.9	14.1	30.1	28.4	23.2	43.4	53.5	28.6	37.6	70.3	39.7	14.2	22.3	19.7	16.2	10.4	17.2	10.5	115.5	91.8	10.1	47.8	44.4	35.7	31.9	13.6	12.8	7.7	21.4	88.4	15.0	11.4	23.7	18.4	8.3	25.6	10.9	18.0	26.2	29.4	15.2	20.4	55.3	18.8	25.7	17.1	29.5	9.4	40.0	48.5	17.9	14.9	14.0	6.8	19.2	11.0	20.9	17.0	27.5	11.9	7.6	9.9	15.8	15.3	17.4	12.2	14.7	45.2	38.8	24.2	26.1	18.0	10.6	11.5	9.4	45.2	8.9	31.9	26.3	25.7	70.3	19.7	32.4	19.9	28.6	19.1	21.6	37.6	26.4	13.6	14.3	13.4	14.2	39.7	34.3	22.3	19.7	33.2	32.6	19.5	33.1	31.3	24.1	31.8	25.4	33.9	25.9
CYLD	"CYLD1, KIAA0849, USPL2"	ENSG00000083799	"CYLD lysine 63 deubiquitinase"	Q9NQC7	16	50742050-50801935	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Immunity, Innate immunity, Ubl conjugation pathway, Wnt signaling pathway"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 46.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011713, HPA050095"	Approved		Supported	"Nucleoplasm,Centriolar satellite"				"Centriolar satellite"	Nucleoplasm	"CAB011713: AB_731794, HPA050095: "	"unprognostic (9.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (5.01e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.84e-1)"	"unprognostic (5.06e-2)"	"unprognostic (3.87e-2)"	"unprognostic (3.24e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.18e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.43e-2)"	"unprognostic (6.83e-2)"	"unprognostic (8.42e-2)"	9.3	16.2	13.9	22.9	26.4	51.1	9.1	14.2	20.9	9.2	10.3	18.8	12.8	10.2	16.1	8.1	15.3	8.5	13.3	12.7	15.7	17.0	9.4	13.2	15.6	30.7	16.3	14.3	11.5	12.2	20.3	27.8	9.8	20.0	11.0	12.7	13.3	12.6	10.9	31.7	12.4	14.2	12.5	16.3	23.4	12.4	22.6	13.7	16.9	16.2	8.0	29.3	14.1	12.6	9.2	10.2	31.4	9.8	13.6	19.1	10.2	9.1	2.9	3.3	3.7	5.3	7.7	3.0	13.6	19.9	14.2	8.4	2.4	4.3	10.6	4.9	13.2	3.6	3.9	8.2	21.1	46.4	6.0	5.3	5.1	1.9	10.6	5.2	24.9	8.4	6.7	17.1	17.9	5.7	2.2	9.2	19.8	1.3	5.1	7.6	3.5	4.8	4.6	6.8	10.1	4.6	3.2	4.3	3.3	11.5	3.9	3.3	3.9	6.6	6.4	24.3	5.5	8.5	5.5	24.3	23.1	11.8	17.8	5.9	5.1	31.4	8.6	20.8	10.7	9.8	12.9	9.2	15.8	14.4	10.2	6.2	14.7	11.4	19.4	13.6	9.5	6.2	19.1	10.2	13.9	26.4	14.2	20.9	15.7	17.0	16.3	14.3	20.0	13.7
CYP19A1	"ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM"	ENSG00000137869	"Cytochrome P450 family 19 subfamily A member 1"	P11511	15	51208057-51338610	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Monooxygenase, Oxidoreductase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	49	"placenta: 440.1"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 44.8;HDLM-2: 7.8;HSkMC: 15.0"	"Low cancer specificity"	"Detected in single"			"Region enriched"	"Detected in single"	8	"basal ganglia: 5.9"	"Cell type enriched"	"Detected in single"	17	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 1.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000355, HPA051194"	Enhanced		Approved	Mitochondria				Mitochondria		"CAB000355: , HPA051194: "	"unprognostic (9.41e-2)"	"unprognostic (7.44e-2)"	"unprognostic (9.52e-5)"	"unprognostic (6.81e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.25e-4)"	"unprognostic (5.18e-5)"	"unprognostic (1.54e-3)"	"unprognostic (2.38e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.97e-1)"	"unprognostic (5.37e-2)"	"unprognostic (1.54e-5)"	"unprognostic (2.52e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.11e-1)"	9.0	4.6	0.2	0.2	5.9	0.1	2.1	0.2	0.3	0.9	0.3	0.3	0.2	0.4	0.2	0.3	0.3	0.2	0.3	1.3	0.2	0.7	0.3	0.2	0.6	0.2	0.2	0.2	4.4	0.6	0.1	0.2	440.1	0.2	0.5	0.1	0.2	0.9	1.4	0.8	2.3	0.2	0.7	0.5	0.5	0.1	3.0	0.2	0.3	3.0	0.2	0.2	1.2	0.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	44.8	2.8	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	7.8	0.0	0.3	0.1	3.7	0.2	0.0	0.0	15.0	0.0	0.1	1.8	0.0	0.0	0.3	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	1.4	0.6	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.2	5.9	0.2	0.3	0.2	0.7	0.2	0.2	0.2	0.2
CYP1A2	"CP12, P3-450"	ENSG00000140505	"Cytochrome P450 family 1 subfamily A member 2"	P05177	15	74748844-74756202	"Cancer-related genes, Enzymes, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Lyase, Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	31	"liver: 143.0"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 6.0"	"Group enriched"	"Detected in some"	22	"liver cancer: 25.3;urothelial cancer: 6.5"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB016531	Enhanced									"CAB016531: AB_629359"				"unprognostic (1.54e-4)"			"unprognostic (1.29e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.59e-2)"		"unprognostic (1.76e-1)"	"unprognostic (1.17e-2)"	"unprognostic (5.48e-2)"	"unprognostic (2.33e-2)"	"unprognostic (7.41e-2)"	"unprognostic (2.53e-1)"	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	1.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	143.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.7	1.1	4.5	1.2	1.1	0.7	0.3	1.1	1.0	2.7	2.2	0.2	0.0	1.6	0.7	0.0	0.0	0.2	0.6	1.3	2.2	0.5	0.0	1.2	0.1	0.2	0.1	0.6	1.2	2.8	1.6	0.8	0.1	1.9	1.1	0.4	0.3	0.1	0.0	0.2	1.9	4.1	0.0	0.8	2.5	1.3	1.7	0.6	2.6	2.4	0.9	0.0	2.3	2.2	1.1	2.1	6.0	0.4	1.6	1.0	0.4	1.1	1.4	1.1	1.2	1.0	0.7	1.6	1.1	2.4	1.2	3.2	1.2	1.2	0.6	0.6	0.5	0.8	0.7	0.5	0.4	1.7	0.7	0.7	4.5	1.1	0.8	1.1	0.4	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
CYP2C19	"CPCJ, CYP2C, P450IIC19"	ENSG00000165841	"Cytochrome P450 family 2 subfamily C member 19"	P33261	10	94762681-94853205	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism"	"Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	16	"intestine: 47.7;liver: 76.4"	"Cell line enhanced"	"Detected in some"		"CACO-2: 1.8;RPMI-8226: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA015066	Supported				"Intracellular and membrane"					"HPA015066: AB_1847433"			"unprognostic (3.15e-2)"			"unprognostic (2.13e-1)"	"unprognostic (2.48e-1)"				"unprognostic (1.83e-2)"			"unprognostic (1.53e-1)"				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	30.0	0.0	0.0	14.7	0.0	0.0	1.0	0.0	3.7	0.0	0.0	0.0	0.0	76.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	47.7	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.5	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
CYP2E1	CYP2E	ENSG00000130649	"Cytochrome P450 family 2 subfamily E member 1"	P05181	10	133520406-133561220	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism"	"Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	87	"liver: 802.4"	"Cell line enhanced"	"Detected in many"		"HaCaT: 9.6;HL-60: 7.4;HMC-1: 7.9;NB-4: 20.2"	"Cancer enriched"	"Detected in some"	278	"liver cancer: 265.3"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 3.9;myeloid DC: 9.1"	"Group enriched"	"Detected in many"	17	"dendritic cells: 9.1;T-cells: 3.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA009128, HPA029564"	Enhanced				"Intracellular and membrane"					"HPA009128: AB_1078613, HPA029564: AB_10602213"	"unprognostic (6.32e-2)"	"unprognostic (1.51e-2)"	"unprognostic (3.83e-5)"	"unprognostic (1.27e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.92e-3)"	"unprognostic (6.36e-3)"	"unprognostic (2.41e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.63e-1)"	"unprognostic (3.21e-2)"	"unprognostic (1.70e-4)"	"unprognostic (1.72e-1)"	"unprognostic (8.36e-2)"	"unprognostic (3.78e-1)"	"unprognostic (9.59e-2)"	0.1	0.0	0.1	0.1	0.2	0.0	0.1	0.6	0.3	0.1	0.1	0.2	0.7	0.0	0.1	0.3	0.8	0.2	1.3	0.1	0.1	0.1	0.3	802.4	0.1	0.1	0.1	0.1	0.1	0.4	0.0	0.1	0.1	0.3	0.1	0.0	0.2	0.1	1.1	0.1	0.6	0.1	0.1	0.1	0.4	0.1	0.3	0.1	0.1	0.2	0.2	1.5	0.1	0.1	0.0	9.1	0.0	0.3	0.2	3.9	0.3	0.1	0.0	0.3	0.9	3.2	1.8	0.6	1.4	3.9	0.0	0.3	0.0	2.3	1.2	0.2	0.4	9.6	0.0	0.2	0.3	0.2	1.3	1.5	0.1	1.1	0.5	7.4	7.9	0.9	0.2	0.0	0.6	0.0	0.4	0.3	0.9	0.6	0.5	20.2	5.5	0.3	0.3	5.4	0.0	1.7	0.0	0.0	0.0	3.7	0.0	0.6	0.2	0.8	0.0	1.2	0.4	2.0	0.9	2.0	0.8	2.7	1.3	6.3	0.1	0.0	0.0	0.0	0.1	0.0	3.9	0.0	1.7	1.0	9.1	0.0	0.1	0.0	0.0	0.2	0.3	0.1	0.0	0.3	0.1	0.2	0.6	0.3	0.1	0.1	0.1	0.1	0.3	0.1
CYP3A4	CYP3A3	ENSG00000160868	"Cytochrome P450 family 3 subfamily A member 4"	P08684	7	99756960-99784265	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol metabolism"	"Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	45	"intestine: 145.3;liver: 464.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 4.1;NB-4: 4.4;RPMI-8226: 6.6;SCLC-21H: 2.5;SH-SY5Y: 4.9"	"Cancer enriched"	"Detected in some"	240	"liver cancer: 351.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB033671, HPA072245"	Enhanced		Uncertain	Cytosol				Cytosol		"CAB033671: AB_782375, HPA072245: "	"unprognostic (4.55e-2)"	"unprognostic (8.95e-2)"	"unprognostic (8.08e-2)"	"unprognostic (1.63e-1)"	"unprognostic (5.89e-2)"	"unprognostic (5.37e-2)"	"unprognostic (7.07e-3)"	"unprognostic (9.09e-2)"	"unprognostic (8.27e-3)"	"unprognostic (4.92e-2)"	"unprognostic (3.78e-2)"	"unprognostic (6.42e-2)"	"unprognostic (1.89e-8)"	"unprognostic (2.59e-1)"	"unprognostic (1.75e-2)"	"unprognostic (9.79e-2)"	"unprognostic (6.82e-2)"	0.1	0.4	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	145.3	0.1	0.1	56.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.2	464.6	0.1	0.1	0.1	0.1	0.1	6.8	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	126.7	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0.2	0.6	0.2	0.6	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.3	0.1	0.2	0.0	1.9	0.4	0.0	1.2	0.0	0.4	0.0	0.5	0.0	0.5	0.0	0.1	4.4	0.3	0.0	0.0	2.1	6.6	0.0	0.4	2.5	4.9	0.4	0.0	0.0	0.1	0.0	0.8	0.0	0.0	1.3	0.0	0.7	0.0	0.7	0.1	0.7	0.1	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.2	0.6	0.6	0.0	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
CYP3A5	"CP35, P450PCN3, PCN3"	ENSG00000106258	"Cytochrome P450 family 3 subfamily A member 5"	P20815	7	99648194-99680026	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Steroid metabolism"	"Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"intestine: 72.9;liver: 73.4;stomach 1: 21.3"	"Cell line enhanced"	"Detected in some"		"A549: 3.1;CACO-2: 12.1;CAPAN-2: 8.1;Hep G2: 8.4"	"Cancer enhanced"	"Detected in many"		"liver cancer: 38.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA072245			Uncertain	Cytosol				Cytosol		"HPA072245: "	"unprognostic (2.13e-1)"	"unprognostic (4.36e-2)"	"unprognostic (4.04e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.06e-2)"	"unprognostic (2.73e-1)"	"prognostic favourable (3.72e-5)"	"unprognostic (1.37e-3)"	"unprognostic (1.21e-2)"	"unprognostic (7.29e-3)"	"unprognostic (3.85e-1)"	"unprognostic (4.05e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.93e-1)"	"unprognostic (2.39e-4)"	"unprognostic (6.58e-3)"	1.0	3.3	0.4	2.0	0.5	0.0	1.3	0.6	0.6	1.9	32.6	0.6	1.0	30.3	0.7	0.5	5.2	0.5	8.2	0.4	0.4	0.0	6.8	73.4	2.4	0.8	0.4	0.4	0.6	12.1	0.0	1.8	0.6	0.8	4.9	5.1	0.4	0.6	1.3	0.4	4.3	72.9	0.6	0.5	0.4	21.3	0.7	0.4	0.5	0.4	2.2	4.0	3.0	2.7	0.0	0.2	0.1	0.6	0.0	0.7	0.2	0.0	3.1	0.0	0.0	0.5	0.8	0.1	0.0	0.0	0.0	0.0	12.1	8.1	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.4	0.1	0.1	0.2	0.0	2.6	0.0	0.1	0.0	2.6	0.2	0.0	0.1	0.0	0.5	0.2	0.0	0.1	0.0	0.8	0.7	0.6	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.3	1.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.6	0.0	0.0	0.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.2	0.4	0.5	0.6	0.6	0.4	0.0	0.4	0.4	0.8	0.4
DAD1	OST2	ENSG00000129562	"Defender against cell death 1"	P61803	14	22564905-22589269	"Cancer-related genes, Predicted membrane proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028882	Uncertain		Approved	Cytosol		14000	14000	Cytosol		"HPA028882: AB_10602214"	"unprognostic (2.76e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.97e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.18e-3)"	"prognostic unfavourable (7.73e-4)"	"unprognostic (9.43e-3)"	"unprognostic (3.06e-2)"	"unprognostic (6.09e-2)"	"unprognostic (1.99e-2)"	"unprognostic (9.64e-2)"	"unprognostic (6.62e-3)"	"unprognostic (1.19e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.37e-3)"	48.1	64.7	47.9	36.4	49.4	26.4	61.2	19.3	39.5	59.0	46.7	55.9	93.6	39.7	49.8	118.7	61.2	56.5	54.9	55.2	45.9	43.1	85.1	123.6	48.4	54.6	51.5	25.1	55.4	114.1	35.6	57.0	54.6	51.9	48.3	51.5	43.5	81.9	100.1	39.7	35.6	73.4	49.6	65.3	57.4	48.0	56.7	33.6	84.6	107.0	50.7	52.2	49.3	43.4	80.2	121.1	75.3	65.9	61.5	95.6	122.5	48.8	45.8	37.7	51.2	103.1	74.1	32.6	52.2	63.4	46.4	65.7	28.8	70.3	30.8	33.5	60.0	44.7	39.0	50.1	74.4	41.8	35.7	30.1	26.9	114.7	71.9	42.0	43.7	55.1	67.5	48.5	62.6	67.6	22.7	72.9	68.3	59.9	19.9	51.4	23.2	75.0	28.0	31.9	40.2	68.2	40.4	29.0	36.3	39.7	56.9	57.6	34.3	42.9	51.1	40.5	32.5	49.2	32.8	54.6	63.3	39.8	36.6	29.5	58.4	66.0	65.9	68.1	86.7	56.2	85.1	80.2	90.9	81.7	62.0	71.2	95.6	83.8	75.3	61.5	47.8	121.1	83.5	122.5	47.9	49.4	19.3	39.5	45.9	43.1	51.5	25.1	51.9	33.6
DAPK1	"DAPK, ROCO3"	ENSG00000196730	"Death associated protein kinase 1"	P53355	9	87497228-87708633	"Cancer-related genes, Enzymes, Predicted membrane proteins"	"Apoptosis, Translation regulation"	"Calmodulin-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 94.7"	"Cell line enhanced"	"Detected in many"		"HMC-1: 38.7;HUVEC TERT2: 21.9;RPTEC TERT1: 20.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 5.3;eosinophil: 6.9;intermediate monocyte: 11.9;myeloid DC: 4.0;non-classical monocyte: 11.7;plasmacytoid DC: 5.3"	"Group enriched"	"Detected in many"	55	"dendritic cells: 5.3;granulocytes: 6.9;monocytes: 11.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB037302, HPA040472, HPA048436"	Approved		Approved	Centrosome				Centrosome		"CAB037302: AB_1078622, HPA040472: , HPA048436: "	"unprognostic (2.55e-1)"	"unprognostic (1.47e-1)"	"prognostic unfavourable (2.48e-5)"	"unprognostic (2.77e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.47e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.88e-2)"	"unprognostic (5.77e-3)"	"unprognostic (2.19e-2)"	"unprognostic (2.77e-3)"	"unprognostic (8.31e-3)"	"unprognostic (8.76e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.09e-3)"	14.6	4.9	10.4	8.8	25.5	3.8	4.1	2.9	17.6	8.1	16.6	6.5	8.1	7.8	8.7	16.1	4.5	12.2	21.6	4.1	12.4	8.1	14.7	21.3	28.6	8.5	4.6	10.4	32.7	21.2	4.8	16.6	94.7	6.6	5.1	7.5	5.9	9.3	7.3	1.5	3.7	11.0	8.1	4.8	16.4	15.0	6.3	7.3	34.5	7.2	1.5	5.2	13.2	10.5	0.1	5.3	6.9	11.9	0.1	0.1	2.1	0.0	18.2	8.8	6.1	0.2	0.1	14.0	1.2	1.7	7.2	8.1	2.6	0.1	0.1	1.8	0.3	17.0	5.4	0.4	3.1	0.1	4.4	8.8	2.5	8.9	7.8	0.0	38.7	0.5	2.9	1.3	0.5	21.9	6.6	3.7	6.0	0.5	2.6	0.0	9.9	0.0	0.7	7.8	0.0	20.0	18.2	4.0	4.5	0.0	1.8	7.7	0.0	5.8	0.1	0.0	0.1	0.0	0.0	14.6	3.0	0.0	0.1	2.4	1.2	1.3	5.3	6.9	0.0	11.9	0.0	0.1	0.0	0.0	4.0	0.0	0.0	0.1	1.6	0.1	11.7	5.3	0.0	2.1	10.4	25.5	2.9	17.6	12.4	8.1	4.6	10.4	6.6	7.3
DAXX	DAP6	ENSG00000204209	"Death domain associated protein"	Q9UER7	6	33318558-33323016	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction, Transcription, Transcription regulation"	"Chaperone, Chromatin regulator, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002224, HPA008736, HPA008797, CAB025546, HPA065779"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB002224: AB_563688, CAB025546: , HPA008736: AB_1078625, HPA008797: , HPA065779: "	"prognostic favourable (6.05e-4)"	"unprognostic (2.90e-1)"	"unprognostic (9.66e-2)"	"unprognostic (4.04e-2)"	"unprognostic (8.55e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.46e-3)"	"unprognostic (3.48e-1)"	"unprognostic (1.92e-1)"	"unprognostic (8.58e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.01e-2)"	"prognostic unfavourable (6.32e-7)"	"unprognostic (2.43e-1)"	"unprognostic (5.37e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.04e-1)"	10.4	14.3	10.7	13.5	11.9	8.8	10.8	11.3	14.8	11.8	12.2	9.4	7.3	11.2	13.2	43.7	13.5	12.6	12.1	9.1	9.7	7.3	9.2	12.0	10.3	18.3	10.2	8.5	13.8	18.6	24.4	10.4	11.6	11.6	13.0	14.1	7.3	10.7	15.2	14.8	11.6	12.7	15.5	8.1	20.4	10.5	20.2	11.5	25.0	16.1	6.8	30.9	11.5	10.9	17.0	5.9	12.6	11.2	15.3	18.2	21.8	2.2	0.0	7.1	2.9	1.2	2.3	4.7	7.0	23.1	18.0	13.3	0.8	2.4	7.0	2.5	5.4	1.3	0.1	5.7	16.7	8.3	15.7	9.1	12.5	11.2	3.9	9.6	2.6	6.1	8.5	2.0	5.4	0.5	5.0	4.5	5.6	5.3	3.8	21.5	0.4	3.3	5.9	0.1	7.8	1.4	0.7	8.6	2.2	0.0	0.4	3.7	2.2	0.2	5.9	4.5	5.6	0.2	0.1	7.8	16.3	15.1	3.3	4.4	4.7	7.8	7.5	12.6	16.3	8.0	18.2	16.6	15.4	15.8	5.9	17.0	13.9	14.1	7.4	15.3	11.2	5.9	17.1	21.8	10.7	11.9	11.3	14.8	9.7	7.3	10.2	8.5	11.6	11.5
DBI	"ACBD1, ACBP"	ENSG00000155368	"Diazepam binding inhibitor, acyl-CoA binding protein"	P07108	2	119366921-119372560	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 222.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA051428	Approved					7100000	7100000			"HPA051428: "	"unprognostic (1.24e-1)"	"prognostic favourable (5.77e-5)"	"unprognostic (4.93e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.92e-2)"	"unprognostic (7.28e-3)"	"unprognostic (1.70e-3)"	"unprognostic (1.71e-1)"	"unprognostic (2.85e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.56e-2)"	"prognostic unfavourable (3.73e-5)"	"unprognostic (1.03e-1)"	"unprognostic (2.27e-1)"	"unprognostic (5.75e-2)"	"unprognostic (1.45e-1)"	55.3	22.5	87.5	25.0	53.9	17.1	122.9	47.3	55.4	27.9	52.5	55.2	108.2	50.8	11.2	113.8	90.5	14.0	33.0	78.6	79.8	52.4	90.5	157.2	41.0	27.4	74.1	45.5	12.7	25.3	71.8	11.5	19.0	61.9	77.5	50.1	16.7	53.3	113.7	39.8	57.5	39.1	16.3	87.7	18.3	29.6	24.6	68.8	11.9	22.4	101.0	50.9	18.6	41.6	66.2	99.6	129.8	60.0	53.1	74.9	82.8	46.1	24.2	49.7	22.7	122.4	104.4	31.3	24.6	62.6	34.7	67.4	50.3	37.6	64.3	28.1	38.2	24.3	34.9	51.4	31.2	42.5	23.1	55.0	24.7	66.3	30.7	17.4	222.3	59.1	33.6	53.2	20.0	40.9	6.4	60.3	49.3	47.7	36.7	49.9	32.9	37.9	13.4	48.3	55.9	83.9	71.0	23.6	18.9	20.6	48.6	52.5	29.9	82.2	29.0	23.4	29.9	25.7	29.7	19.8	14.0	52.4	33.0	31.5	27.7	116.9	57.6	129.8	63.9	60.0	46.3	55.9	50.5	61.9	94.2	66.2	38.8	58.3	36.7	53.1	47.2	99.6	74.9	82.8	87.5	53.9	47.3	50.6	79.8	52.4	74.1	45.5	61.9	68.8
DCC	"IGDCC1, NTN1R1"	ENSG00000187323	"DCC netrin 1 receptor"	P43146	18	52340172-53535903	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis	"Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 22.0;testis: 16.5"	"Group enriched"	"Detected in some"	4	"AF22: 15.1;U-266/70: 46.8;U-266/84: 22.0"	"Cancer enhanced"	"Detected in single"		"glioma: 0.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA055376, HPA069552"	Enhanced		Supported	"Golgi apparatus"		25000	25000	"Golgi apparatus"		"HPA055376: , HPA069552: "	"unprognostic (1.96e-3)"	"unprognostic (1.69e-2)"	"unprognostic (3.13e-1)"	"unprognostic (3.90e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.35e-3)"	"unprognostic (2.59e-1)"	"unprognostic (5.59e-2)"	"unprognostic (2.00e-1)"	"unprognostic (2.58e-1)"	"unprognostic (8.22e-4)"	"unprognostic (4.14e-2)"	"unprognostic (1.27e-4)"	"unprognostic (7.21e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.69e-3)"	0.5	1.9	6.3	0.8	22.0	0.4	0.6	0.7	10.1	0.8	0.9	1.3	0.0	0.5	0.4	1.0	0.7	0.7	0.5	0.5	18.4	2.0	0.9	0.5	3.8	0.4	1.5	9.9	0.7	1.2	0.6	1.1	0.4	5.3	1.3	0.8	0.0	0.8	3.5	0.4	0.8	0.7	0.5	2.4	0.8	0.8	16.5	6.5	0.7	0.5	0.0	1.1	0.8	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	46.8	22.0	0.0	2.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	22.0	0.7	10.1	18.4	2.0	1.5	9.9	5.3	6.5
DCDC1		ENSG00000170959	"Doublecortin domain containing 1"	P59894	11	30830369-31369810	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"brain: 19.2;pituitary gland: 26.7"	"Cell line enhanced"	"Detected in some"		"RPTEC TERT1: 2.8;U-266/70: 5.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"basal ganglia: 5.6;pons and medulla: 19.2"	"Cell type enhanced"	"Detected in single"		"basophil: 1.4"	"Low lineage specificity"	"Detected in single"							"Low region specificity"	"Detected in many"														"unprognostic (1.01e-2)"	"unprognostic (1.57e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.55e-2)"	"unprognostic (9.78e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.06e-2)"	"unprognostic (5.68e-2)"	"unprognostic (4.73e-1)"	"unprognostic (3.17e-1)"	"unprognostic (4.47e-3)"	"unprognostic (6.84e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.31e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.09e-3)"	"unprognostic (2.61e-1)"	0.6	0.6	1.0	0.1	5.6	0.2	1.0	0.4	1.0	1.3	0.5	2.7	3.3	0.1	1.3	13.3	0.4	9.9	4.3	0.5	1.9	1.6	3.4	6.4	4.8	0.2	0.6	0.2	4.2	2.4	3.9	26.7	0.2	19.2	0.6	0.2	2.8	0.7	2.0	0.4	0.5	0.4	0.2	0.6	0.4	0.5	11.5	1.1	0.0	2.8	0.0	0.2	0.5	1.3	0.0	0.0	1.4	0.0	0.0	0.9	0.0	0.2	1.1	0.8	0.6	0.2	0.0	0.5	0.1	0.1	0.0	0.0	0.0	0.1	0.6	0.1	0.0	0.4	0.1	0.1	1.0	0.4	0.5	0.0	0.1	1.4	0.0	0.1	0.3	0.7	0.0	0.3	0.3	0.0	0.3	0.1	0.2	0.1	0.2	0.0	1.4	0.0	0.0	0.3	0.0	2.8	0.0	0.8	0.1	1.4	0.0	0.1	0.2	0.0	0.1	0.5	0.7	1.1	0.2	5.4	0.3	0.2	1.2	0.0	0.3	1.4	0.0	0.0	0.4	0.0	0.9	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.0	5.6	0.4	1.0	1.9	1.6	0.6	0.2	19.2	1.1
DCN	"DSPG2, SLRR1B"	ENSG00000011465	Decorin	P07585	12	91140484-91183123	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Corneal dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 227.5;ASC TERT1: 175.3;BJ hTERT+: 175.9;HSkMC: 159.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	7	"basophil: 18.7"	"Lineage enriched"	"Detected in single"	21	"granulocytes: 18.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"HPA003315, CAB017118, HPA064736, CAB068930"	Enhanced				"Secreted to extracellular matrix"	1300000	1300000			"CAB017118: , CAB068930: AB_425394, HPA003315: AB_1078639, HPA064736: AB_2685340"	"unprognostic (1.73e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.43e-1)"	"unprognostic (3.22e-2)"	"unprognostic (8.63e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.01e-2)"	"unprognostic (2.68e-1)"	"unprognostic (1.98e-1)"	"unprognostic (6.12e-2)"	"unprognostic (1.65e-1)"	"unprognostic (5.15e-2)"	"prognostic unfavourable (1.46e-5)"	"unprognostic (3.06e-3)"	"unprognostic (5.37e-2)"	"unprognostic (1.59e-3)"	"unprognostic (7.56e-3)"	152.8	64.6	4.8	52.8	8.3	0.0	137.1	4.5	5.8	177.7	60.6	5.1	105.8	7.8	124.0	266.8	142.9	113.6	94.3	190.2	5.2	4.0	35.4	35.1	107.0	27.5	16.7	9.1	265.5	25.7	1.5	12.7	192.0	12.4	130.7	28.3	40.7	32.7	51.8	77.2	76.0	34.9	222.4	24.9	1.8	47.5	116.5	6.0	3.3	74.2	99.4	29.3	187.8	113.8	0.8	0.6	18.7	0.3	0.5	0.4	0.0	0.0	0.0	0.2	0.0	227.5	175.3	0.3	40.3	175.9	1.9	2.0	0.0	0.0	0.0	0.0	34.3	0.1	0.0	0.1	0.3	0.0	0.0	0.0	1.3	0.0	48.6	0.0	0.0	159.5	0.4	5.1	2.4	0.0	0.0	0.0	3.9	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.7	0.5	0.0	0.0	0.0	0.0	0.0	9.1	0.0	32.4	0.0	0.1	0.1	0.1	0.5	0.1	0.0	18.7	0.3	0.6	0.4	0.2	0.3	0.4	0.3	0.3	0.1	0.8	0.4	0.4	2.7	0.5	0.2	0.6	0.3	0.0	4.8	8.3	4.5	5.8	5.2	4.0	16.7	9.1	12.4	6.0
DCTN1		ENSG00000204843	"Dynactin subunit 1"	Q14203	2	74361154-74392087	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Transport"		"Amyotrophic lateral sclerosis, Cancer-related genes, Neurodegeneration, Neuropathy, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009108, HPA034635, HPA071875"	Approved		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		220000	220000	Microtubules	"Cytokinetic bridge, Mitotic spindle"	"CAB009108: AB_2090601, HPA034635: , HPA071875: "	"unprognostic (1.14e-1)"	"unprognostic (7.19e-2)"	"unprognostic (1.33e-3)"	"unprognostic (4.08e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.67e-1)"	"unprognostic (4.61e-3)"	"unprognostic (2.11e-2)"	"unprognostic (2.79e-1)"	"unprognostic (3.73e-3)"	"unprognostic (1.87e-1)"	"unprognostic (2.26e-1)"	"prognostic favourable (2.34e-7)"	"unprognostic (5.41e-2)"	"unprognostic (3.11e-1)"	"unprognostic (7.86e-3)"	"unprognostic (1.12e-3)"	20.7	21.1	36.0	13.7	54.6	11.1	14.0	45.9	70.9	23.5	17.1	37.8	8.9	11.8	18.5	9.8	22.9	19.7	15.1	37.7	39.5	35.8	13.5	10.0	18.9	10.9	37.7	40.3	21.9	15.2	70.2	21.6	17.2	54.6	16.5	14.0	13.2	23.5	21.7	39.5	19.9	13.7	26.5	32.2	12.4	16.0	25.5	26.7	9.4	17.0	9.5	12.8	17.2	18.0	11.6	12.1	12.9	15.8	9.8	16.7	15.5	18.7	22.0	20.7	21.6	38.0	28.3	16.7	30.3	31.6	38.6	27.6	29.2	14.5	25.9	12.4	62.8	18.8	25.2	38.4	29.5	32.1	25.4	26.8	17.7	24.5	29.3	14.6	33.2	34.0	18.8	41.9	25.1	33.0	11.5	18.5	29.1	16.1	26.5	15.1	22.3	23.4	23.8	36.4	18.5	21.4	11.6	25.5	22.6	16.9	20.4	18.2	13.1	10.6	24.9	35.2	25.6	15.1	22.4	11.5	9.1	23.5	32.9	23.8	24.6	7.3	11.4	12.9	16.7	14.2	13.5	11.6	9.5	12.4	12.1	8.6	6.8	7.5	9.8	9.8	15.8	9.6	8.1	15.5	36.0	54.6	45.9	70.9	39.5	35.8	37.7	40.3	54.6	26.7
DDB2	"DDBB, FLJ34321, UV-DDB2, XPE"	ENSG00000134574	"Damage specific DNA binding protein 2"	Q92466	11	47214465-47239240	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB025912, HPA058406"	Enhanced		Supported	"Nucleoplasm,Cell Junctions"				"Nucleoplasm, Cell Junctions"		"CAB025912: , HPA058406: "	"prognostic favourable (7.29e-4)"	"prognostic favourable (1.58e-4)"	"unprognostic (1.49e-1)"	"prognostic favourable (1.20e-4)"	"unprognostic (4.29e-2)"	"unprognostic (2.04e-2)"	"unprognostic (2.96e-2)"	"unprognostic (6.18e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.58e-3)"	"unprognostic (3.53e-1)"	"unprognostic (1.94e-1)"	"unprognostic (4.57e-3)"	"unprognostic (1.21e-2)"	"unprognostic (4.25e-2)"	"unprognostic (9.82e-3)"	"unprognostic (1.07e-1)"	12.2	22.2	5.3	13.3	8.6	8.1	11.3	11.0	8.2	16.8	13.5	7.3	13.4	6.0	18.2	14.1	25.4	14.3	13.0	6.1	4.7	2.9	6.6	20.8	11.3	16.1	15.0	5.0	9.8	15.6	6.1	8.6	5.5	6.3	20.9	12.3	8.1	17.6	14.8	6.3	36.9	11.0	19.0	17.6	15.1	9.1	7.6	7.6	23.3	6.6	16.7	26.0	17.3	15.2	11.4	6.1	11.5	11.0	7.4	27.0	9.0	8.2	22.3	9.3	7.0	6.0	12.2	11.0	9.1	21.3	11.6	13.7	3.6	4.8	19.9	1.9	8.3	14.6	5.3	18.5	5.8	4.9	10.0	4.7	21.3	16.5	5.9	5.4	12.4	16.3	21.0	5.8	13.0	34.0	1.2	9.7	19.0	15.6	20.7	2.6	3.0	8.1	10.4	2.3	10.7	4.9	8.2	4.9	6.1	11.1	3.2	2.9	20.4	1.8	14.6	35.7	16.3	7.8	4.2	10.2	7.7	4.4	13.4	6.9	12.8	5.9	8.1	11.5	12.1	11.0	11.7	11.4	12.7	11.7	6.1	7.4	9.4	10.1	2.2	7.4	9.2	0.1	27.0	9.0	5.3	8.6	11.0	8.2	4.7	2.9	15.0	5.0	6.3	7.6
DDIT3	"CHOP, CHOP10, GADD153"	ENSG00000175197	"DNA damage inducible transcript 3"	P35638	12	57516588-57521737	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Cell cycle, Growth arrest, Stress response, Transcription, Transcription regulation, Unfolded protein response, Wnt signaling pathway"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HHSteC: 122.9;hTERT-HME1: 61.8;SK-MEL-30: 57.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 50.8"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058416, HPA068416"	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA058416: , HPA068416: "	"unprognostic (1.12e-1)"	"unprognostic (5.33e-2)"	"unprognostic (2.20e-3)"	"unprognostic (4.92e-2)"	"unprognostic (7.86e-3)"	"unprognostic (2.28e-1)"	"prognostic unfavourable (6.55e-4)"	"unprognostic (8.55e-2)"	"unprognostic (1.26e-3)"	"unprognostic (9.40e-3)"	"unprognostic (4.92e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.52e-2)"	"unprognostic (3.70e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.56e-1)"	"unprognostic (6.76e-2)"	19.1	25.5	15.9	8.3	29.9	82.2	21.4	16.7	25.2	14.8	13.5	20.1	15.7	10.6	19.5	55.8	13.0	13.1	16.0	25.8	18.6	19.8	28.8	26.1	17.1	8.8	34.4	15.5	27.3	13.0	13.5	26.8	18.0	32.1	22.8	13.9	27.3	20.7	13.9	18.0	16.3	10.9	15.4	21.8	11.2	14.7	14.3	35.3	2.9	88.9	12.6	9.4	30.2	17.0	13.8	4.6	50.8	5.4	9.2	10.9	5.1	2.5	2.4	1.5	5.2	14.1	9.6	8.2	7.2	15.9	10.7	10.1	8.4	6.8	3.7	7.2	2.1	3.2	5.8	1.1	11.1	3.0	2.3	2.9	2.6	6.1	122.9	4.6	4.5	27.4	23.3	18.1	61.8	2.5	12.4	14.2	4.7	1.5	3.0	6.0	3.0	5.6	1.7	33.7	3.2	3.8	3.3	3.2	2.3	2.1	2.4	57.3	5.2	12.2	1.4	7.3	3.1	6.9	6.2	25.2	8.4	3.9	8.8	4.3	12.9	27.5	5.4	13.5	8.0	4.6	7.0	13.8	5.7	7.3	3.7	13.1	10.9	9.9	50.8	9.2	5.1	4.6	6.5	5.1	15.9	29.9	16.7	25.2	18.6	19.8	34.4	15.5	32.1	35.3
DDR2	"NTRKR3, TKT, TYRO10"	ENSG00000162733	"Discoidin domain receptor tyrosine kinase 2"	Q16832	1	162631373-162787400	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Osteogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 60.6;ASC TERT1: 59.9;BJ hTERT+: 44.3;fHDF/TERT166: 31.7;HSkMC: 42.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;MAIT T-cell: 1.3"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070112			Supported	"Plasma membrane,Actin filaments"		850000	850000	"Plasma membrane, Actin filaments"		"HPA070112: "	"unprognostic (4.12e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.62e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavourable (1.73e-7)"	"unprognostic (1.56e-3)"	"unprognostic (8.26e-3)"	"unprognostic (7.57e-2)"	"unprognostic (4.10e-3)"	42.1	43.5	4.7	10.9	6.9	0.2	15.6	7.9	7.1	30.3	30.4	9.0	18.6	3.3	24.2	17.7	25.0	13.4	16.6	15.4	7.9	4.7	4.0	3.3	8.9	5.1	12.9	3.4	26.4	2.2	2.1	4.0	6.6	12.7	21.8	9.1	30.7	6.4	19.3	5.2	6.1	10.1	34.3	19.7	3.4	14.1	8.3	7.5	0.0	8.6	12.8	4.1	29.0	18.3	0.1	0.2	0.0	0.0	0.2	1.3	0.0	0.1	0.0	0.0	16.0	60.6	59.9	0.2	23.6	44.3	10.3	14.9	0.0	0.0	0.0	0.0	31.7	0.0	0.0	0.1	14.1	12.7	0.1	0.0	0.0	0.0	26.3	0.0	0.0	42.5	0.1	18.2	0.4	11.8	0.1	5.0	9.4	0.0	0.0	0.0	0.1	0.1	0.0	6.7	0.1	0.0	0.0	0.0	9.7	0.0	0.0	0.8	0.0	0.0	0.6	16.5	3.6	8.3	3.2	0.7	1.3	0.0	14.9	0.0	16.7	0.0	0.0	0.0	1.1	0.0	1.3	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	4.7	6.9	7.9	7.1	7.9	4.7	12.9	3.4	12.7	7.5
DDX10	"Dbp4, HRH-J8"	ENSG00000178105	"DEAD-box helicase 10"	Q13206	11	108665025-108940930	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 57.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004691	Approved		Approved	Nucleoli				Nucleoli		"HPA004691: AB_1078629"	"unprognostic (9.49e-2)"	"unprognostic (9.32e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.58e-1)"	"unprognostic (7.97e-2)"	"unprognostic (1.48e-2)"	"prognostic unfavourable (2.52e-5)"	"unprognostic (2.86e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavourable (5.75e-4)"	"unprognostic (1.00e-1)"	"prognostic favourable (2.14e-5)"	"unprognostic (5.20e-2)"	"unprognostic (1.98e-1)"	"unprognostic (4.64e-1)"	"unprognostic (2.43e-3)"	14.0	11.9	17.3	15.0	20.3	10.4	15.5	20.5	18.3	14.3	12.2	8.1	11.7	8.8	18.4	12.8	12.6	16.8	8.8	12.1	13.5	11.5	19.6	12.5	10.6	13.1	12.2	16.3	18.6	18.0	16.7	22.2	12.9	13.1	12.4	13.3	7.9	10.6	14.7	13.6	14.8	9.1	16.8	13.3	15.0	11.3	25.1	12.6	13.8	13.4	8.8	14.2	14.3	18.8	11.6	8.4	1.4	6.7	9.4	11.3	4.3	7.2	7.1	6.8	9.5	6.7	5.5	7.1	7.8	4.2	9.5	9.4	20.3	10.7	24.7	14.8	6.0	8.2	19.4	9.5	13.7	9.4	8.7	16.8	4.2	7.6	12.0	17.1	8.0	4.9	7.5	10.8	13.5	8.6	23.5	2.7	9.3	4.7	14.3	14.4	8.8	10.9	12.2	11.1	23.1	5.8	6.3	12.6	6.7	11.0	9.7	4.1	11.7	6.0	9.1	10.0	10.2	9.5	10.6	4.2	7.3	57.2	3.4	20.6	10.1	1.4	5.0	1.0	8.6	6.7	11.3	10.4	7.5	10.1	8.4	11.6	8.1	7.8	0.7	9.4	6.4	8.2	6.3	4.3	17.3	20.3	20.5	18.3	13.5	11.5	12.2	16.3	13.1	12.6
DDX3X	"DBX, DDX14, DDX3, HLP2"	ENSG00000215301	"DEAD-box helicase 3, X-linked"	O00571	X	41333284-41364472	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation"	"DNA-binding, Helicase, Hydrolase, RNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001648, HPA005631, HPA059585"	Supported	Supported	Approved	Nucleoplasm,Cytosol		110000	110000	Cytosol	Nucleoplasm	"HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: "	"unprognostic (2.42e-2)"	"unprognostic (1.11e-1)"	"unprognostic (8.01e-3)"	"unprognostic (1.66e-1)"	"unprognostic (8.12e-2)"	"unprognostic (6.43e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.88e-1)"	"unprognostic (9.80e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.25e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.95e-1)"	"unprognostic (4.77e-1)"	"unprognostic (9.44e-2)"	"unprognostic (2.93e-2)"	80.9	49.3	26.1	40.0	34.5	49.3	46.5	31.1	36.2	52.4	43.3	35.1	21.3	29.5	56.4	25.9	53.5	56.3	42.6	47.6	30.8	24.5	55.6	77.9	45.3	40.4	41.4	29.0	60.1	30.9	68.7	60.2	79.9	37.9	30.0	29.2	30.8	37.4	26.5	63.4	42.2	54.0	57.2	53.9	46.1	43.0	27.0	39.0	49.2	45.6	44.0	42.6	55.8	50.2	13.1	20.5	32.0	21.6	17.3	21.5	17.9	45.4	50.5	47.2	25.9	55.6	47.2	28.8	33.1	46.6	34.0	27.4	51.9	30.6	0.5	23.7	37.1	30.7	57.7	46.6	56.7	26.9	45.0	28.9	50.3	31.2	28.9	54.1	52.0	34.1	33.1	57.3	55.4	53.3	53.0	28.6	31.6	34.4	34.1	16.9	45.4	20.4	40.0	50.3	37.0	32.0	61.2	32.3	48.9	75.0	38.5	39.7	34.6	36.8	48.1	35.1	37.6	37.5	39.3	33.4	39.6	44.9	35.4	32.8	33.2	22.5	20.2	17.5	14.8	21.1	21.5	13.1	14.5	16.3	20.5	9.0	16.3	15.1	32.0	17.3	21.6	6.9	14.3	17.9	26.1	34.5	31.1	36.2	30.8	24.5	41.4	29.0	37.9	39.0
DDX5	"G17P1, HLR1, p68"	ENSG00000108654	"DEAD-box helicase 5"	P17844	17	64499616-64508199	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005868, HPA020043"	Supported		Enhanced	Nucleoplasm		150000	150000	Nucleoplasm		"CAB005868: AB_446484, HPA020043: AB_1847572"	"unprognostic (6.64e-2)"	"unprognostic (6.98e-2)"	"prognostic favourable (2.12e-4)"	"unprognostic (8.94e-2)"	"unprognostic (5.08e-2)"	"unprognostic (9.85e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.17e-2)"	"unprognostic (4.71e-2)"	"unprognostic (3.03e-3)"	"unprognostic (1.44e-1)"	"unprognostic (4.00e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.17e-1)"	"unprognostic (9.28e-3)"	91.6	61.4	46.9	80.0	68.0	108.3	94.7	61.6	58.9	81.6	81.1	53.3	104.2	27.4	106.7	94.5	64.5	96.9	101.4	53.9	48.5	30.6	53.1	68.0	84.8	70.9	62.8	44.1	74.0	49.3	88.9	110.5	56.6	73.1	59.5	55.4	50.9	62.2	103.6	77.6	59.7	54.7	113.1	71.0	67.6	69.0	39.7	57.8	82.1	81.1	77.7	69.3	91.0	63.9	46.9	59.6	66.4	66.2	40.3	60.8	109.8	54.0	20.4	61.8	39.1	57.2	53.9	39.3	53.6	69.2	65.7	65.9	22.1	33.1	79.3	30.7	70.4	32.2	66.5	61.7	74.4	28.1	47.7	51.6	15.5	16.9	41.9	65.6	55.0	60.7	53.3	60.1	46.9	70.2	40.8	67.8	50.6	32.2	137.1	19.1	36.0	63.0	85.9	65.2	55.8	40.3	25.9	43.4	72.9	52.0	50.5	65.3	47.3	36.9	49.3	40.0	44.7	43.1	55.5	37.9	74.6	140.0	42.4	32.3	47.1	66.4	62.5	66.4	53.7	56.9	60.8	46.9	42.9	51.7	59.6	46.8	44.5	43.1	37.8	40.3	66.2	37.0	50.2	109.8	46.9	68.0	61.6	58.9	48.5	30.6	62.8	44.1	73.1	57.8
DDX6	"HLR2, RCK"	ENSG00000110367	"DEAD-box helicase 6"	P26196	11	118747766-118791149	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004668, HPA024201, HPA026644"	Approved		Supported	"Cytosol,Cytoplasmic bodies"				"Cytoplasmic bodies"	Cytosol	"CAB004668: AB_436960, HPA024201: AB_10603562, HPA026644: AB_1847582"	"unprognostic (1.26e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.40e-2)"	"unprognostic (4.12e-2)"	"unprognostic (5.82e-2)"	"prognostic unfavourable (6.56e-4)"	"unprognostic (3.43e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.00e-1)"	"unprognostic (7.76e-2)"	"unprognostic (1.98e-1)"	"unprognostic (4.91e-3)"	"unprognostic (1.88e-1)"	"unprognostic (9.58e-2)"	"unprognostic (4.55e-2)"	29.8	23.0	25.0	24.1	41.0	43.3	25.1	41.9	39.2	26.9	23.2	29.4	14.5	17.1	30.1	22.9	31.8	23.4	17.5	26.8	25.5	25.1	22.8	24.6	23.4	32.2	21.9	27.1	38.2	27.9	30.9	43.2	26.1	29.6	24.9	20.8	25.4	26.8	22.9	43.8	23.9	24.1	27.8	30.4	30.6	21.2	19.9	24.0	46.0	27.9	19.4	42.8	33.0	25.7	12.2	6.5	17.8	10.3	7.2	12.6	5.7	11.7	16.0	25.8	25.4	22.6	23.3	16.9	15.9	20.9	14.8	14.1	23.3	18.1	26.9	16.7	26.0	18.8	30.1	23.2	23.9	20.2	6.0	51.8	10.3	18.9	15.0	37.1	20.0	24.6	17.1	21.9	35.7	23.6	23.8	39.1	20.9	32.0	27.0	17.2	18.3	11.8	29.8	20.8	21.5	17.3	30.4	17.1	23.6	30.0	24.1	9.5	28.2	14.6	26.9	24.6	13.5	14.0	16.0	12.2	15.8	32.1	9.8	17.9	21.0	10.5	4.1	11.6	10.1	5.7	12.6	11.4	9.9	10.4	4.7	12.2	12.4	10.8	17.8	7.2	10.3	6.5	8.9	5.7	25.0	41.0	41.9	39.2	25.5	25.1	21.9	27.1	29.6	24.0
DEFA1	"DEF1, DEFA2, HNP-1, MRS"	ENSG00000206047	"Defensin alpha 1"	P59665	8	6977649-6980080	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Antiviral defense"	"Antibiotic, Antimicrobial, Defensin, Fungicide"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	7	"bone marrow: 825.5"	"Cell line enriched"	"Detected in single"	17	"NB-4: 6.6"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"memory CD4 T-cell: 1.3"	"Low lineage specificity"	"Detected in single"											"CAB032548, HPA052517"	Enhanced				"Intracellular and membrane"					"CAB032548: AB_2277258, HPA052517: "																		1.3	0.1	0.2	0.1	0.6	825.5	0.6	0.0	0.4	0.1	0.1			0.1	0.4	0.1	0.1	0.1	0.1	2.3	0.2	0.2	0.2	6.0	41.9	0.3	0.3		0.1	0.1	0.1	1.0	0.6		0.1	0.1		0.6	0.1	0.5	1.8	0.1	0.1	0.0	115.5	0.1	0.1			0.6		0.1	0.1	0.0	0.1	0.3	0.5	0.7	0.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.3	0.1	0.0	0.2	0.0	0.3	0.7	0.0	0.3	0.0										
DEFA1B		ENSG00000240247	"Defensin alpha 1B"	P59665	8	6996766-6999195	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Antiviral defense"	"Antibiotic, Antimicrobial, Defensin, Fungicide"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	15	"bone marrow: 734.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in some"		"memory B-cell: 1.8"	"Low lineage specificity"	"Detected in many"											HPA052517	Supported				"Intracellular and membrane"					"HPA052517: "																		0.4	0.0	0.0	0.0	0.0	734.0	0.1	0.0	0.2	0.0	0.0			0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	2.0	16.0	0.0	0.0		0.0	0.0	0.0	0.3	0.5		0.0	0.0		1.8	0.0	0.0	0.5	0.0	0.0	0.0	49.1	0.0	0.0			0.2		0.0	0.0	0.0	1.8	1.2	0.8	0.1	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	1.8	0.5	1.1	1.2	0.3	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0										
DEFA3	"DEF3, HNP-3"	ENSG00000239839	"Defensin alpha 3"	P59666	8	7015869-7018301	"Cancer-related genes, Predicted intracellular proteins"	"Antiviral defense"	"Antibiotic, Antimicrobial, Defensin, Fungicide"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"blood: 235.0;bone marrow: 924.7"	"Cell line enriched"	"Detected in single"	8	"NB-4: 5.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in some"	18	"neutrophil: 51.5"	"Lineage enriched"	"Detected in many"	18	"granulocytes: 51.5"									HPA052517	Supported				"Intracellular and membrane"					"HPA052517: "					"unprognostic (8.21e-2)"													0.7	0.0	0.3	0.3	1.0	924.7	0.3	0.3	0.9	0.3	0.3	0.3	0.3	0.0	0.6	0.3	0.3	0.0	0.3	10.1	0.3	0.2	0.3	3.4	25.6	0.3	0.3	0.3	0.3	0.3	0.0	0.8	2.5	2.3	0.3	0.0	0.6	0.7	0.3	0.3	1.2	0.3	0.3	0.3	81.5	0.0	0.3	0.3	2.0	0.7	0.3	0.3	0.3	0.3	0.1	0.0	51.5	1.6	0.0	2.7	235.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.6	0.1	2.7	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.4	0.0	51.5	0.0	0.1	0.0	0.0	235.0	0.3	1.0	0.3	0.9	0.3	0.2	0.3	0.3	2.3	0.3
DEK	D6S231E	ENSG00000124795	"DEK proto-oncogene"	P35659	6	18223868-18264823	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Chromatin regulator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB015226, HPA054505, HPA057799"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB015226: , HPA054505: , HPA057799: "	"unprognostic (6.35e-2)"	"unprognostic (6.11e-2)"	"unprognostic (5.04e-3)"	"unprognostic (1.40e-2)"	"unprognostic (3.66e-1)"	"unprognostic (5.02e-3)"	"prognostic unfavourable (9.65e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.61e-3)"	"unprognostic (6.49e-3)"	"unprognostic (1.12e-2)"	"prognostic unfavourable (3.45e-4)"	"unprognostic (1.59e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.78e-1)"	30.9	20.0	22.9	41.8	29.5	50.8	28.9	41.5	30.2	31.0	35.8	11.4	24.0	28.2	32.9	19.7	31.0	23.8	19.2	33.5	26.8	14.1	19.3	23.8	29.2	42.7	30.7	17.6	28.3	19.3	20.5	27.8	24.3	27.7	33.9	29.9	11.0	26.8	21.4	40.2	23.2	35.9	51.3	28.1	29.8	24.2	12.6	32.9	58.8	44.9	33.9	38.4	45.1	43.3	40.0	40.2	57.7	49.3	34.0	46.3	35.0	59.7	17.6	46.7	38.9	9.4	16.4	27.1	55.1	30.5	49.8	67.5	28.8	22.5	68.1	58.5	24.8	35.9	34.5	27.3	83.8	45.8	33.0	42.1	31.7	33.6	9.2	64.1	34.3	8.1	13.6	34.3	27.1	23.8	51.1	0.0	31.7	21.5	46.2	28.8	28.6	19.7	61.6	62.0	39.9	24.0	34.6	28.6	26.3	49.7	43.2	30.1	38.9	26.4	24.1	58.4	32.4	32.5	68.6	4.2	10.0	71.8	13.9	32.7	54.0	51.1	49.3	21.9	41.4	39.3	46.3	40.0	42.1	42.5	40.2	33.2	33.5	32.0	57.7	34.0	43.9	31.0	40.6	35.0	22.9	29.5	41.5	30.2	26.8	14.1	30.7	17.6	27.7	32.9
DES	"CMD1I, CSM1, CSM2"	ENSG00000175084	Desmin	P17661	2	219418377-219426739	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Muscle protein"	"Cancer-related genes, Cardiomyopathy, Desmin-related myopathy, Disease mutation, Limb-girdle muscular dystrophy, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 531.0;skeletal muscle: 600.8;smooth muscle: 439.9"	"Cell line enhanced"	"Detected in some"		"HSkMC: 17.6;LHCN-M2: 35.2;RH-30: 81.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 562.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"classical monocyte: 2.7;intermediate monocyte: 1.9;non-classical monocyte: 1.4"	"Lineage enriched"	"Detected in single"	6	"monocytes: 2.7"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"midbrain: 45.7"	"CAB000034, HPA018803"	Enhanced		Supported	"Intermediate filaments"		1300000	1300000	"Intermediate filaments"		"CAB000034: , HPA018803: AB_1847616"	"unprognostic (1.75e-1)"	"unprognostic (1.95e-3)"	"unprognostic (3.43e-2)"	"unprognostic (8.76e-2)"	"unprognostic (7.75e-3)"	"unprognostic (6.61e-3)"	"unprognostic (1.55e-1)"	"unprognostic (2.72e-2)"	"unprognostic (4.67e-1)"	"unprognostic (3.84e-2)"	"unprognostic (2.57e-1)"	"unprognostic (7.43e-2)"	"prognostic unfavourable (5.08e-4)"	"unprognostic (3.49e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.22e-1)"	"unprognostic (9.25e-3)"	9.1	2.5	0.1	35.1	0.2	0.1	1.9	0.1	0.3	41.3	238.3	0.4	69.1	12.6	95.6	80.2	209.7	33.0	149.8	531.0	0.1	0.1	2.1	0.3	4.8	3.0	0.3	0.8	20.3	0.7	0.0	0.1	2.4	0.8	101.0	11.2	3.8	11.9	104.2	600.8	4.2	43.2	439.9	0.3	0.6	72.6	10.9	0.0	0.0	9.4	161.2	12.5	343.7	34.4	0.0	0.2	0.4	2.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.5	1.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.3	17.6	0.0	0.0	0.0	0.0	0.6	0.0	35.2	0.0	0.0	9.2	0.1	0.0	0.0	81.8	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.7	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	1.4	0.0	0.0	0.7	0.1	0.2	0.1	0.3	0.1	0.1	0.3	0.8	0.8	0.0
DHFR		ENSG00000228716	"Dihydrofolate reductase"	P00374	5	80626228-80654983	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Methotrexate resistance, One-carbon metabolism"	"Oxidoreductase, RNA-binding"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB037129, HPA051465"	Uncertain		Supported	Mitochondria				Mitochondria		"CAB037129: AB_439683, HPA051465: "	"unprognostic (1.44e-2)"	"unprognostic (1.03e-2)"	"unprognostic (2.24e-3)"	"unprognostic (2.91e-3)"	"unprognostic (3.27e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.83e-2)"	"unprognostic (2.35e-2)"	"unprognostic (2.02e-2)"	"unprognostic (4.19e-3)"	"unprognostic (1.83e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.82e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.09e-1)"	17.7	6.1	16.0	11.6	13.9	28.3	10.9	10.2	14.0	7.5	12.6	18.1	11.7	14.5	5.9	9.0	9.8	4.7	6.9	9.7	17.3	14.4	13.1	35.5	8.6	23.2	18.9	9.4	7.5	4.9	9.6	7.2	8.5	13.0	5.9	15.5	8.6	8.0	8.4	10.4	5.9	14.5	7.3	25.3	9.1	7.4	10.5	11.5	13.4	9.2	2.3	22.8	7.9	6.1	2.4	3.3	3.5	2.6	2.1	4.0	2.1	19.6	13.6	34.6	25.6	6.6	6.9	12.7	15.7	12.1	27.4	31.7	12.9	23.7	39.8	6.9	9.1	13.8	44.4	20.3	44.4	17.6	27.4	19.1	22.6	12.0	1.4	22.2	8.5	4.8	2.1	24.5	2.7	13.2	21.4	30.6	27.7	19.7	54.7	9.0	17.4	8.0	35.5	67.9	39.4	15.7	12.5	28.3	19.8	22.2	10.4	11.2	20.5	22.0	7.9	8.7	13.2	24.3	30.0	14.4	28.8	43.1	19.4	45.2	22.3	0.8	1.2	1.1	2.3	2.6	1.1	2.1	2.7	3.2	1.9	2.4	2.1	2.7	3.5	2.1	1.7	3.3	4.0	2.1	16.0	13.9	10.2	14.0	17.3	14.4	18.9	9.4	13.0	11.5
DHX9	"DDX9, LKP, RHA"	ENSG00000135829	"DExH-box helicase 9"	Q08211	1	182839369-182887751	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, DNA replication, Host-virus interaction, Immunity, Inflammatory response, Innate immunity, mRNA processing, mRNA splicing, mRNA transport, RNA-mediated gene silencing, Transcription, Transcription regulation, Transcription termination, Translation regulation, Transport"	"Activator, DNA-binding, Helicase, Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011819, HPA028050"	Supported		Supported	Nucleoplasm		97000	97000	Nucleoplasm		"CAB011819: AB_777725, HPA028050: AB_10603564"	"unprognostic (8.14e-2)"	"unprognostic (9.32e-2)"	"unprognostic (1.84e-2)"	"unprognostic (4.80e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.40e-2)"	"prognostic unfavourable (3.17e-4)"	"unprognostic (9.98e-2)"	"prognostic unfavourable (6.04e-4)"	"unprognostic (2.76e-1)"	"unprognostic (2.88e-2)"	"unprognostic (5.53e-2)"	"unprognostic (7.51e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.70e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.99e-1)"	30.2	25.9	25.7	28.5	28.6	68.9	32.9	42.5	33.1	31.9	24.5	23.3	25.2	19.8	38.2	24.2	27.7	30.6	19.7	22.9	24.4	22.6	36.2	31.4	27.8	32.0	34.2	23.1	37.5	24.9	51.8	35.8	28.5	28.0	25.7	30.1	21.1	28.2	29.4	27.6	26.6	27.0	31.6	25.3	32.8	26.5	29.4	37.4	68.3	30.1	31.6	41.2	32.4	31.9	16.8	22.9	12.0	17.4	14.7	21.9	15.0	35.1	34.5	49.5	27.2	25.9	20.1	48.9	31.2	28.6	45.4	30.8	38.5	27.2	56.5	30.5	28.0	30.5	75.1	33.8	50.8	22.9	37.3	37.6	28.2	26.0	14.6	54.4	25.8	17.9	17.0	44.5	12.1	35.4	59.0	20.3	36.3	30.9	55.0	13.4	62.7	21.3	50.2	46.2	32.3	29.3	40.9	35.7	41.0	44.2	28.0	18.2	32.7	30.8	27.6	28.2	31.5	28.6	42.2	21.3	34.8	67.1	17.7	29.9	38.2	5.6	16.0	12.0	19.2	17.4	21.9	16.8	16.8	17.6	22.9	14.6	18.4	19.9	6.5	14.7	14.3	11.1	15.4	15.0	25.7	28.6	42.5	33.1	24.4	22.6	34.2	23.1	28.0	37.4
DIAPH1	"DFNA1, hDIA1, LFHL1"	ENSG00000131504	"Diaphanous related formin 1"	O60610	5	141515016-141619055	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	Hearing	Actin-binding	"Cancer-related genes, Deafness, Disease mutation, Epilepsy, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 79.8"	"Cell line enhanced"	"Detected in all"		"HMC-1: 105.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA004916, HPA076913"	Approved		Approved	"Plasma membrane"		10000000	10000000	"Plasma membrane"		"HPA004916: AB_1847668, HPA076913: "	"unprognostic (6.79e-2)"	"unprognostic (2.99e-1)"	"unprognostic (2.12e-3)"	"unprognostic (3.73e-2)"	"unprognostic (4.18e-2)"	"unprognostic (1.54e-1)"	"unprognostic (2.08e-1)"	"unprognostic (4.54e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.27e-2)"	"prognostic unfavourable (7.81e-5)"	"unprognostic (2.88e-3)"	"prognostic favourable (1.29e-5)"	"unprognostic (1.64e-2)"	"unprognostic (1.84e-2)"	"unprognostic (7.00e-2)"	"unprognostic (1.65e-1)"	14.5	10.0	5.2	22.3	10.4	27.9	10.6	8.8	7.8	11.6	17.1	3.9	11.4	14.2	9.9	16.8	26.5	9.1	15.7	21.3	5.1	6.3	30.1	48.7	22.4	21.7	3.8	4.3	9.7	20.2	17.6	22.1	28.2	7.2	7.8	11.0	8.8	18.0	13.8	79.8	19.1	24.1	9.6	3.4	20.2	15.5	12.1	2.9	44.2	14.9	23.8	34.1	12.3	13.3	5.9	8.6	19.2	9.3	8.2	22.7	9.3	25.5	16.6	9.6	12.6	7.7	10.4	13.3	10.5	11.2	12.3	12.9	56.6	24.5	28.6	16.1	15.4	28.5	21.4	35.8	15.6	15.4	11.9	49.3	21.9	18.4	7.3	34.3	105.8	6.6	19.0	17.7	17.9	16.1	17.3	20.2	12.1	24.9	38.1	44.8	9.5	11.0	42.8	15.8	15.8	23.6	28.2	12.8	6.8	26.0	34.7	10.4	14.5	16.6	9.3	17.3	9.2	9.5	21.4	10.1	16.0	19.8	9.4	27.5	10.7	12.7	8.6	19.2	22.7	9.2	15.2	5.9	14.4	17.6	8.6	5.0	10.5	17.3	9.4	8.2	9.3	6.6	11.9	9.3	5.2	10.4	8.8	7.8	5.1	6.3	3.8	4.3	7.2	2.9
DIAPH3	"AN, AUNA1, DRF3, FLJ34705, NSDAN"	ENSG00000139734	"Diaphanous related formin 3"	Q9NSV4	13	59665583-60163987	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Deafness, Neuropathy, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 35.2;testis: 19.6"	"Cell line enhanced"	"Detected in many"		"HBF TERT88: 38.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	4	"plasmacytoid DC: 2.0"	"Lineage enriched"	"Detected in single"	4	"dendritic cells: 2.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			HPA032151			Supported	"Plasma membrane,Microtubules"				"Plasma membrane, Microtubules"		"HPA032151: "	"unprognostic (3.78e-2)"	"unprognostic (1.28e-2)"	"prognostic favourable (9.04e-4)"	"prognostic unfavourable (4.18e-4)"	"unprognostic (2.78e-1)"	"unprognostic (4.69e-2)"	"unprognostic (1.27e-4)"	"prognostic unfavourable (3.72e-4)"	"unprognostic (1.74e-2)"	"unprognostic (2.19e-1)"	"unprognostic (5.22e-5)"	"unprognostic (3.59e-3)"	"unprognostic (5.31e-5)"	"unprognostic (4.30e-2)"	"unprognostic (2.37e-1)"	"unprognostic (4.07e-1)"	"unprognostic (2.74e-3)"	1.8	0.4	1.7	11.5	1.8	6.7	1.6	0.1	1.4	0.9	4.7	0.2	0.4	2.0	1.4	1.1	7.1	0.3	2.5	1.1	1.0	1.6	1.7	0.4	4.1	2.9	1.0	0.0	0.4	0.4	0.5	0.2	9.4	0.2	0.4	2.3	0.0	1.6	0.0	0.1	1.8	4.3	2.7	0.3	2.5	3.1	19.6	0.0	35.2	0.2	5.3	5.9	0.8	1.5	0.4	2.0	0.4	0.2	0.0	0.5	0.2	17.9	6.0	6.2	3.5	1.1	2.9	10.6	25.2	11.2	25.5	22.3	15.9	12.2	6.0	2.0	12.9	12.3	10.1	9.9	38.9	6.8	7.0	8.6	15.4	3.6	1.6	11.7	6.9	1.1	0.2	15.5	10.5	11.4	6.6	8.6	24.2	2.6	10.4	5.0	5.8	3.5	7.1	15.4	4.9	8.3	3.7	3.3	5.7	12.8	8.9	3.9	6.5	6.4	11.3	16.2	10.4	5.4	20.8	5.8	6.3	9.4	4.3	5.8	12.2	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	2.0	0.5	0.2	1.7	1.8	0.1	1.4	1.0	1.6	1.0	0.0	0.2	0.0
DICER1	"Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1"	ENSG00000100697	"Dicer 1, ribonuclease III"	Q9UPY3	14	95086228-95158010	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"RNA-mediated gene silencing"	"Endonuclease, Helicase, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000694, CAB068185"	Approved		Supported	Cytosol				Cytosol		"CAB068185: , HPA000694: AB_1078661"	"unprognostic (2.97e-1)"	"unprognostic (2.70e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.72e-1)"	"unprognostic (6.75e-2)"	"unprognostic (9.62e-2)"	"unprognostic (1.96e-2)"	"unprognostic (7.73e-2)"	"unprognostic (1.21e-1)"	"unprognostic (8.52e-3)"	"unprognostic (5.73e-2)"	"unprognostic (9.22e-2)"	"unprognostic (4.22e-2)"	"unprognostic (9.07e-2)"	"unprognostic (2.58e-1)"	"unprognostic (6.04e-3)"	"unprognostic (3.74e-2)"	23.2	12.5	18.4	22.4	33.3	20.5	23.2	28.5	29.9	19.0	18.1	31.4	22.4	13.0	20.8	20.6	23.4	18.5	16.2	15.3	22.0	14.1	19.5	23.6	22.4	20.3	29.7	19.6	23.8	19.8	26.9	30.9	29.9	23.2	20.3	19.7	14.5	19.5	18.9	28.0	20.7	17.3	19.0	26.8	20.7	17.1	20.6	32.0	17.0	23.8	14.7	20.3	20.7	24.1	2.5	1.8	10.7	7.2	1.2	3.3	1.0	12.8	13.4	25.1	9.3	6.5	9.8	19.9	10.6	6.4	6.8	8.2	17.0	9.9	14.5	11.5	9.8	15.2	19.9	10.0	14.2	22.5	8.9	21.9	7.4	12.2	6.6	13.4	13.5	9.1	8.3	9.1	13.9	10.1	9.2	12.9	11.4	18.0	15.0	8.9	7.1	6.6	12.0	20.5	8.0	9.0	20.5	20.8	11.8	10.7	11.0	12.0	12.4	9.9	10.0	5.2	10.3	10.1	11.9	14.8	21.1	20.6	5.4	10.9	9.3	3.1	3.0	1.2	1.6	3.1	3.3	1.9	1.5	1.2	1.8	2.5	1.5	1.3	10.7	1.2	7.2	1.6	1.6	1.0	18.4	33.3	28.5	29.9	22.0	14.1	29.7	19.6	23.2	32.0
DIS3	"dis3p, EXOSC11, KIAA1008, RRP44"	ENSG00000083520	"DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease"	Q9Y2L1	13	72752169-72782096	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"rRNA processing"	"Endonuclease, Exonuclease, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039281, HPA058762"	Approved		Enhanced	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA039281: AB_10795583, HPA058762: "	"unprognostic (1.61e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.97e-2)"	"unprognostic (8.14e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.84e-1)"	"unprognostic (6.38e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.32e-3)"	"unprognostic (3.35e-3)"	"unprognostic (1.02e-1)"	"unprognostic (2.37e-2)"	"unprognostic (3.69e-2)"	"unprognostic (7.88e-2)"	"unprognostic (1.03e-1)"	25.5	14.7	11.7	17.6	24.8	23.8	22.4	23.4	19.4	20.3	18.8	11.6	17.0	11.8	18.0	19.3	23.1	17.8	16.0	21.6	12.4	13.6	20.2	25.6	19.3	22.2	13.9	17.0	23.4	15.3	15.8	22.8	26.3	18.7	18.0	15.6	9.8	17.4	19.3	19.9	17.3	17.9	17.5	12.9	22.8	16.2	27.7	14.6	23.7	21.3	19.1	23.0	26.7	19.3	6.9	6.8	11.1	9.7	10.3	10.0	5.0	15.6	7.3	14.4	12.1	15.4	18.4	9.5	14.0	17.1	14.3	17.6	11.2	13.1	19.1	12.2	14.3	13.1	19.7	16.1	23.2	15.6	14.5	22.4	15.7	10.1	19.2	37.8	13.0	19.1	11.3	16.2	21.4	15.3	14.9	8.0	17.4	5.5	16.0	18.6	13.5	8.6	13.0	11.0	8.6	14.4	12.6	13.1	17.2	11.5	9.6	13.5	9.3	17.3	14.3	8.7	7.0	9.7	14.8	15.5	17.4	15.3	24.2	18.0	12.5	11.1	5.5	7.8	6.5	9.7	9.4	6.9	8.5	7.3	6.8	6.0	8.1	7.6	3.4	10.3	7.6	4.3	10.0	5.0	11.7	24.8	23.4	19.4	12.4	13.6	13.9	17.0	18.7	14.6
DLC1	"ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12"	ENSG00000164741	"DLC1 Rho GTPase activating protein"	Q96QB1	8	13083361-13604610	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 18.7;hTERT-HME1: 13.8;HUVEC TERT2: 18.8;U-2197: 18.6;WM-115: 13.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	5	"basophil: 6.5"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 6.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017753	Uncertain		Approved	"Nucleoplasm,Golgi apparatus,Vesicles"				"Nucleoplasm, Golgi apparatus, Vesicles"		"HPA017753: AB_10600805"	"unprognostic (1.83e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.29e-1)"	"prognostic favourable (1.11e-4)"	"unprognostic (7.47e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.11e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.12e-1)"	"unprognostic (8.46e-3)"	"unprognostic (6.49e-2)"	"unprognostic (2.02e-2)"	"unprognostic (3.56e-3)"	"unprognostic (2.79e-2)"	"unprognostic (7.33e-2)"	"unprognostic (1.67e-1)"	33.9	8.0	8.5	8.8	15.4	4.9	31.9	3.1	11.4	13.6	13.1	16.0	2.0	6.1	12.4	7.4	8.6	10.4	13.1	15.1	10.0	7.3	9.2	24.1	32.4	5.6	18.0	6.8	8.0	6.3	6.3	4.4	22.3	16.2	5.7	4.5	13.6	4.9	4.1	7.6	5.4	8.5	18.7	15.0	16.6	11.1	5.5	16.5	0.0	12.0	6.1	2.9	17.1	17.2	0.0	0.2	6.5	1.3	0.0	0.1	0.0	0.0	0.1	1.6	0.0	12.3	7.0	5.9	0.6	0.1	0.2	0.5	3.9	2.4	0.0	0.2	11.7	2.0	1.0	1.6	1.1	0.0	0.9	0.3	0.0	4.1	6.4	0.0	3.5	5.4	0.1	18.7	13.8	18.8	1.0	0.0	5.6	0.3	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.4	5.9	0.0	0.8	0.0	0.2	6.2	0.0	0.0	1.9	13.5	7.3	18.6	4.4	0.0	0.0	0.0	10.4	0.0	13.7	6.5	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	8.5	15.4	3.1	11.0	10.0	7.3	18.0	6.8	16.2	16.5
DMD	"BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85"	ENSG00000198947	Dystrophin	P11532	X	31097677-33339441	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"		Actin-binding	"Cancer-related genes, Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 16.1;Hep G2: 14.7;RH-30: 20.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"memory B-cell: 2.6;naive B-cell: 4.9;plasmacytoid DC: 1.6"	"Group enriched"	"Detected in many"	18	"B-cells: 4.9;dendritic cells: 1.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000119, HPA002725, HPA023885"	Enhanced									"CAB000119: , HPA002725: AB_1078714, HPA023885: AB_1847931"	"unprognostic (3.91e-3)"	"unprognostic (2.29e-1)"	"unprognostic (1.83e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.17e-1)"	"unprognostic (7.58e-2)"	"unprognostic (3.41e-1)"	"unprognostic (2.60e-4)"	"unprognostic (6.98e-2)"	"unprognostic (1.25e-1)"	"unprognostic (5.84e-3)"	"unprognostic (2.38e-1)"	"unprognostic (1.15e-2)"	"unprognostic (8.76e-3)"	"unprognostic (1.82e-1)"	"unprognostic (9.83e-2)"	"unprognostic (1.51e-2)"	19.8	11.8	12.5	11.6	11.1	0.7	11.8	15.6	11.6	18.9	25.6	6.8	30.3	4.5	22.2	10.0	13.1	12.5	22.3	27.5	10.0	7.6	4.4	36.2	5.9	3.7	8.5	9.8	11.7	34.5	4.9	4.1	10.3	7.8	14.5	6.8	10.7	19.7	31.6	57.7	8.5	7.4	48.2	6.1	1.9	11.9	4.6	7.4	0.0	6.2	34.5	4.7	32.6	7.9	4.9	1.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	16.1	0.0	0.1	0.1	4.8	3.2	0.3	1.7	1.9	8.0	0.0	0.2	0.0	8.8	5.4	6.4	8.2	2.7	4.7	5.1	0.2	7.3	14.7	9.3	0.0	1.5	2.1	6.0	3.0	11.3	4.3	0.6	0.1	4.6	0.3	2.5	0.0	8.1	7.4	0.1	20.3	0.0	0.1	1.3	0.3	4.5	0.0	1.2	2.3	1.1	0.0	0.5	0.1	0.0	0.2	3.3	0.1	6.6	0.3	0.4	0.0	8.8	0.0	0.0	0.0	0.0	0.1	0.0	2.6	0.1	0.0	0.7	4.9	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.0	12.5	11.1	15.6	11.6	10.0	7.6	8.5	9.8	7.8	7.4
DNAH12	"DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19"	ENSG00000174844	"Dynein axonemal heavy chain 12"	Q6ZR08	3	57293699-57544344	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Motor protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 23.0;fallopian tube: 16.7;lung: 17.5;testis: 17.6"	"Cell line enhanced"	"Detected in some"		"CACO-2: 3.1;LHCN-M2: 2.1"	"Cancer enhanced"	"Detected in single"		"endometrial cancer: 0.6"	"Region enriched"	"Detected in many"	8	"pons and medulla: 23.0"	"Cell type enhanced"	"Detected in single"		"NK-cell: 1.2"	"Low lineage specificity"	"Detected in single"											"HPA037493, HPA058203, HPA061365"	Enhanced									"HPA037493: AB_10671758, HPA058203: AB_2683637, HPA061365: "	"unprognostic (4.85e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.18e-3)"	"unprognostic (2.96e-2)"	"unprognostic (2.17e-1)"	"unprognostic (2.80e-2)"	"unprognostic (1.51e-3)"	"unprognostic (3.06e-2)"	"unprognostic (3.21e-1)"	"unprognostic (4.40e-2)"	"unprognostic (5.90e-2)"	"unprognostic (3.43e-5)"	"unprognostic (2.82e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.53e-2)"	"unprognostic (5.47e-2)"	0.2	0.3	0.6	0.1	3.0	0.1	0.4	0.2	0.5	1.3	0.2	5.3	0.0	0.1	1.4	11.6	0.2	16.7	0.5	0.1	2.9	0.8	0.2	0.3	17.5	0.2	0.4	0.0	7.6	3.1	0.1	8.9	0.1	23.0	0.2	0.2	0.0	0.3	0.2	0.2	0.3	0.2	0.2	0.4	0.2	0.2	17.6	1.0	0.0	0.3	0.0	0.1	0.2	0.2	0.5	0.5	0.0	0.0	1.2	0.9	0.1	0.3	0.7	0.0	0.0	0.9	0.3	0.1	0.0	0.2	0.3	0.0	3.1	0.3	0.1	0.0	0.4	0.4	0.0	0.3	0.2	0.7	0.2	0.0	0.0	0.0	0.3	0.2	0.0	0.2	0.6	0.1	0.4	0.2	0.2	0.1	2.1	0.0	0.0	0.4	0.0	0.5	0.0	0.2	0.0	0.4	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.3	0.0	0.9	0.1	0.0	0.8	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.3	0.1	0.0	0.0	0.5	0.2	0.0	0.0	1.2	0.0	0.5	0.0	0.1	0.6	3.0	0.2	0.3	2.9	0.8	0.4	0.0	23.0	1.0
DNAJB1	"Hsp40, HSPF1, RSPH16B, Sis1"	ENSG00000132002	"DnaJ heat shock protein family (Hsp40) member B1"	P25685	19	14514770-14529770	"Cancer-related genes, Predicted intracellular proteins"	"Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 291.1"	"Cell line enhanced"	"Detected in all"		"Karpas-707: 109.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017450, HPA063247"	Enhanced		Supported	Nucleoplasm		9600	9600	Nucleoplasm		"CAB017450: AB_10631418, HPA063247: "	"unprognostic (3.75e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.74e-2)"	"unprognostic (3.83e-1)"	"unprognostic (1.85e-1)"	"unprognostic (7.91e-3)"	"unprognostic (2.17e-1)"	"prognostic favourable (5.96e-4)"	"unprognostic (2.20e-2)"	"unprognostic (4.44e-2)"	"unprognostic (2.00e-2)"	"unprognostic (6.77e-2)"	29.2	76.9	28.5	13.2	30.0	36.2	67.0	41.4	29.4	19.3	15.5	21.5	14.5	10.5	20.4	11.8	72.3	21.7	56.4	23.5	28.2	31.6	23.4	37.7	35.7	10.7	53.4	12.0	32.3	22.6	18.3	25.0	33.5	45.8	29.6	13.1	12.2	18.4	40.8	16.1	25.3	9.5	24.0	40.2	9.4	19.1	37.5	37.9	15.0	28.9	18.0	31.1	19.2	291.1	19.7	15.2	28.2	31.6	23.0	61.6	56.7	36.6	39.0	14.1	15.0	26.0	20.9	8.8	24.4	18.1	38.7	29.3	23.0	20.7	10.1	28.0	20.8	27.9	28.8	17.5	27.4	10.6	14.3	16.1	25.8	48.2	17.7	11.4	15.3	11.6	42.1	14.9	13.1	12.7	23.9	109.8	21.3	23.2	18.3	10.6	15.0	42.0	14.0	19.9	22.8	17.6	12.6	13.0	9.6	22.1	43.8	24.0	12.0	11.1	13.2	31.4	18.9	36.2	51.2	48.9	30.0	13.3	22.4	19.8	28.0	11.5	18.9	22.3	36.6	31.1	38.9	19.4	52.5	45.4	15.2	19.7	61.6	47.6	28.2	23.0	31.6	9.1	51.8	56.7	28.5	30.0	41.4	29.4	28.2	31.6	53.4	12.0	45.8	37.9
DNAJC2	"MPHOSPH11, MPP11, ZRF1, ZUO1, zuotin"	ENSG00000105821	"DnaJ heat shock protein family (Hsp40) member C2"	Q99543	7	103312474-103344873	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chaperone, Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020454	Approved		Supported	Cytosol				Cytosol		"HPA020454: AB_1859492"	"unprognostic (1.07e-1)"	"unprognostic (1.66e-1)"	"unprognostic (5.53e-2)"	"unprognostic (2.20e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.71e-2)"	"unprognostic (2.13e-3)"	"unprognostic (2.13e-3)"	"unprognostic (1.63e-2)"	"unprognostic (5.35e-2)"	"unprognostic (2.21e-2)"	"unprognostic (1.27e-2)"	"prognostic unfavourable (1.12e-5)"	"unprognostic (1.11e-1)"	"unprognostic (2.30e-1)"	"unprognostic (3.51e-1)"	"unprognostic (3.28e-1)"	12.8	12.5	12.8	21.5	14.2	37.0	13.6	12.9	16.8	13.3	15.0	5.1	10.7	14.3	13.4	12.5	13.6	11.8	11.5	13.6	11.4	11.0	16.2	25.2	10.7	15.5	13.3	12.7	16.4	13.2	12.2	28.5	13.8	16.1	12.0	13.0	5.6	12.6	9.1	29.4	12.7	18.6	13.1	12.2	19.7	12.8	30.6	15.7	17.6	13.0	12.0	13.6	16.6	16.5	9.1	7.1	28.6	9.1	10.0	8.8	3.7	17.3	12.6	7.2	13.8	5.8	8.1	14.8	12.0	8.7	13.4	10.0	18.7	12.8	24.6	19.3	8.2	11.8	19.5	8.7	20.5	13.1	16.1	18.2	11.9	15.8	10.5	32.0	14.5	7.0	7.6	15.6	14.0	8.7	42.1	16.1	10.9	29.1	30.5	33.1	25.8	19.5	19.6	14.9	22.9	7.9	8.3	14.2	13.2	16.2	22.6	12.5	9.6	16.3	10.3	13.3	21.3	28.7	23.4	17.1	22.5	49.3	9.5	33.4	16.6	28.6	6.0	5.5	7.6	6.5	8.4	7.8	7.6	7.9	5.9	9.1	8.8	8.8	2.4	10.0	9.1	7.1	8.1	3.7	12.8	14.2	12.9	16.8	11.4	11.0	13.3	12.7	16.1	15.7
DNER	"bet, UNQ26"	ENSG00000187957	"Delta/notch like EGF repeat containing"	Q8NFT8	2	229357629-229714558	"Cancer-related genes, Predicted membrane proteins"	"Notch signaling pathway"	"Activator, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adrenal gland: 45.6;brain: 85.2;salivary gland: 46.1"	"Group enriched"	"Detected in some"	5	"hTERT-HME1: 39.4;U-138 MG: 66.4;U-87 MG: 39.3"	"Cancer enriched"	"Detected in many"	32	"glioma: 73.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.4"	"Lineage enhanced"	"Detected in single"		"dendritic cells: 1.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017320	Enhanced					2700000	2700000			"HPA017320: AB_1847808"	"unprognostic (4.39e-2)"	"unprognostic (1.83e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.00e-3)"	"unprognostic (8.73e-2)"	"unprognostic (6.23e-2)"	"prognostic unfavourable (1.05e-4)"	"unprognostic (4.23e-3)"	"unprognostic (2.97e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.60e-1)"	"unprognostic (8.60e-2)"	"prognostic unfavourable (3.42e-4)"	"unprognostic (2.59e-2)"	"unprognostic (7.32e-2)"	"unprognostic (5.63e-2)"	"unprognostic (5.13e-3)"	1.7	45.6	25.4	2.2	26.8	1.3	3.1	19.5	85.2	2.2	2.3	38.4	0.0	1.6	2.1	5.7	1.5	4.1	1.5	6.8	23.9	36.8	9.7	1.3	2.0	1.5	39.8	15.2	1.6	1.9	1.7	9.6	1.5	30.0	2.8	2.2	2.5	46.1	1.6	1.3	2.5	1.9	2.2	26.4	1.3	8.3	2.0	30.4	0.0	1.4	0.0	2.1	1.4	0.2	0.0	1.4	0.0	0.3	0.0	0.0	0.0	0.1	0.5	1.0	0.0	0.1	0.1	0.0	0.0	0.3	2.2	0.7	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.3	1.1	0.0	0.0	0.0	3.5	0.0	0.3	0.0	0.0	0.7	2.4	1.7	39.4	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.6	3.6	0.0	0.4	0.0	3.7	0.0	7.9	0.6	0.2	0.0	0.2	0.0	0.0	0.0	66.4	0.0	2.2	9.9	0.0	0.0	0.0	39.3	0.0	2.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.3	1.4	0.0	0.0	25.4	26.8	19.5	26.6	23.9	36.8	39.8	15.2	30.0	30.4
DNM2	"CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII"	ENSG00000079805	"Dynamin 2"	P50570	19	10718079-10833488	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Endocytosis, Phagocytosis"	"Hydrolase, Motor protein"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054246	Supported		Approved	"Golgi apparatus,Cytosol"		500000	500000	"Golgi apparatus, Cytosol"		"HPA054246: "	"unprognostic (2.30e-1)"	"unprognostic (5.23e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.76e-1)"	"prognostic favourable (8.91e-4)"	"prognostic unfavourable (3.63e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.79e-1)"	"unprognostic (1.89e-1)"	"unprognostic (4.75e-2)"	"unprognostic (5.35e-2)"	"unprognostic (5.47e-2)"	"unprognostic (5.40e-3)"	"unprognostic (2.68e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.99e-3)"	23.8	32.6	18.5	29.3	31.2	53.4	20.4	25.7	29.7	20.1	51.4	57.5	46.0	32.1	20.4	16.8	29.9	19.7	27.0	35.0	20.8	18.0	38.5	25.1	39.2	28.2	48.3	18.0	17.9	32.2	19.5	20.0	32.3	32.2	24.0	42.5	24.5	24.7	37.7	46.6	40.6	50.8	18.6	43.1	37.6	48.2	23.3	36.4	39.1	23.5	21.1	41.5	35.7	31.5	3.4	11.1	8.6	9.8	10.1	5.8	4.6	34.9	28.9	21.2	16.9	21.9	21.5	27.2	23.4	22.2	34.7	29.5	28.8	23.1	25.4	42.2	25.2	30.7	28.9	25.4	29.1	31.1	23.0	48.7	25.8	32.2	27.0	26.7	46.3	22.0	19.6	26.5	25.0	33.7	39.1	43.7	21.3	42.3	37.2	25.5	24.1	35.0	37.8	23.0	28.6	22.8	52.7	30.6	20.0	26.7	22.9	16.7	18.4	31.8	30.5	38.1	12.9	53.5	30.9	36.2	36.9	23.4	28.5	40.9	18.8	3.0	4.5	8.6	5.6	8.2	5.1	3.4	4.2	5.8	5.3	3.1	2.4	4.1	8.5	10.1	9.8	11.1	4.8	4.6	18.5	31.2	25.7	29.7	20.8	18.0	48.3	18.0	32.2	36.4
DNMT3A		ENSG00000119772	"DNA methyltransferase 3 alpha"	Q9Y6K1	2	25227855-25342590	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors"		"Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 25.5;REH: 25.1;SH-SY5Y: 31.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009469, HPA026588"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB009469: AB_2093990, HPA026588: AB_1847812"	"unprognostic (2.38e-1)"	"unprognostic (2.94e-1)"	"unprognostic (5.65e-2)"	"prognostic unfavourable (1.55e-4)"	"unprognostic (8.38e-2)"	"unprognostic (7.27e-2)"	"prognostic unfavourable (1.58e-4)"	"unprognostic (2.24e-1)"	"unprognostic (7.25e-2)"	"unprognostic (2.72e-1)"	"prognostic favourable (1.18e-4)"	"unprognostic (2.35e-2)"	"prognostic unfavourable (2.49e-4)"	"unprognostic (1.43e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.70e-2)"	7.8	12.4	13.7	12.7	15.5	10.8	8.6	21.6	20.1	9.0	12.7	14.5	7.6	9.1	13.0	12.2	8.0	9.6	8.9	8.2	12.3	6.7	9.4	6.9	9.5	13.6	15.3	10.1	18.3	12.1	6.3	12.6	20.8	10.7	9.3	9.2	12.0	8.5	9.2	29.1	6.6	11.4	11.3	7.9	17.5	11.6	6.6	15.2	20.8	9.1	10.5	11.8	9.8	8.4	3.0	4.1	4.9	4.1	8.7	8.3	2.3	1.0	3.5	14.7	3.6	1.6	1.2	19.4	1.0	0.9	2.0	1.6	8.7	5.7	0.0	2.2	1.9	0.9	1.6	2.2	1.2	3.6	2.5	6.3	5.3	10.4	3.8	1.3	4.1	3.6	1.1	2.6	0.9	8.2	7.3	1.3	1.5	8.4	13.8	14.9	25.5	1.9	25.1	16.2	2.1	1.2	1.5	8.8	31.0	1.2	8.4	2.6	0.9	6.7	2.8	2.5	3.2	0.6	1.3	3.1	2.2	8.5	0.9	3.8	2.6	4.7	1.8	3.1	5.2	3.0	7.0	2.3	3.4	4.9	2.0	3.0	8.3	6.6	4.9	8.7	4.1	4.1	2.8	2.3	13.7	15.5	21.6	20.1	12.3	6.7	15.3	10.1	10.7	15.2
DOCK2	KIAA0209	ENSG00000134516	"Dedicator of cytokinesis 2"	Q92608	5	169637247-170083382	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 31.0;bone marrow: 29.8;lymphoid tissue: 50.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 31.9;HDLM-2: 40.1;HL-60: 31.8;HMC-1: 37.0;MOLT-4: 24.2;U-698: 28.2;U-937: 22.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA036469	Enhanced									"HPA036469: "	"unprognostic (3.45e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.90e-3)"	"unprognostic (2.04e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.92e-3)"	"unprognostic (3.47e-1)"	"unprognostic (1.61e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.10e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.31e-1)"	"unprognostic (2.03e-3)"	"unprognostic (1.47e-1)"	"unprognostic (2.22e-2)"	"unprognostic (6.95e-2)"	"unprognostic (7.24e-2)"	7.3	3.1	2.9	30.7	4.8	29.8	4.1	1.0	2.7	2.2	3.5	5.8	1.2	2.6	2.9	2.7	2.4	2.9	4.9	2.7	3.4	2.5	3.1	2.9	12.6	22.6	4.8	1.3	1.9	1.9	0.7	2.2	3.8	4.1	3.3	4.5	2.6	6.6	1.2	1.3	2.0	13.7	3.6	8.5	28.0	3.6	1.8	3.7	50.3	2.8	1.7	31.5	6.2	2.5	6.4	14.0	12.7	31.0	6.6	6.6	9.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.6	3.2	0.0	0.0	31.9	0.6	2.5	0.0	0.0	0.0	4.0	40.1	0.0	17.7	0.3	0.0	0.0	31.8	37.0	0.0	0.0	0.7	0.0	0.0	0.3	16.0	0.8	0.0	24.2	8.2	0.0	0.0	15.1	0.5	12.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8	0.1	0.3	1.0	0.4	0.7	5.0	7.8	28.2	0.6	22.1	0.0	6.2	12.7	10.0	6.4	23.0	6.6	6.4	5.9	6.3	14.0	5.3	4.3	5.0	12.7	6.6	31.0	4.8	5.3	9.4	2.9	4.8	1.0	2.7	3.4	2.5	4.8	1.3	4.1	3.7
DROSHA	"Etohi2, HSA242976, RN3, RNASE3L, RNASEN"	ENSG00000113360	"Drosha ribonuclease III"	Q9NRR4	5	31400497-31532196	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ribosome biogenesis, RNA-mediated gene silencing"	"Endonuclease, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (8.37e-3)"	"unprognostic (1.81e-1)"	"unprognostic (9.56e-2)"	"prognostic unfavourable (6.79e-4)"	"unprognostic (5.40e-2)"	"unprognostic (6.03e-2)"	"prognostic unfavourable (1.39e-4)"	"unprognostic (3.11e-1)"	"unprognostic (4.08e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.86e-1)"	"unprognostic (5.43e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.74e-1)"	"unprognostic (2.39e-1)"	"unprognostic (6.94e-2)"	"unprognostic (2.32e-2)"	15.7	16.8	18.4	17.7	32.1	12.2	16.1	33.7	33.7	17.4	16.3	19.1	12.2	15.9	22.3	25.8	16.0	18.2	14.1	15.2	16.6	15.1	15.3	11.7	13.9	17.8	13.6	16.4	26.7	17.8	23.9	38.9	17.0	18.9	17.2	19.2	23.7	17.5	19.2	23.6	16.0	17.5	16.9	19.4	16.8	16.0	12.8	16.4	25.6	21.9	13.4	19.8	18.2	16.2	4.7	6.4	3.3	4.8	4.8	6.4	3.1	12.1	15.4	17.0	23.2	9.1	11.1	24.6	16.1	7.9	15.1	11.3	16.2	15.9	13.7	18.6	11.8	10.7	20.9	12.2	16.8	12.8	14.8	16.8	50.5	11.7	8.2	18.8	50.3	8.8	8.6	16.8	8.1	12.8	21.4	6.5	13.2	12.1	18.1	14.1	16.1	12.3	16.5	32.6	9.9	8.5	13.9	8.9	11.8	41.0	16.8	9.9	15.5	10.8	11.1	14.5	16.9	13.1	15.3	11.8	19.4	15.1	10.1	21.2	13.9	1.8	2.4	3.3	5.2	2.6	5.5	4.2	5.4	6.0	5.2	4.7	6.4	4.4	0.8	4.8	4.8	6.4	5.1	3.1	18.4	32.1	33.7	33.7	16.6	15.1	13.6	16.4	18.9	16.4
DST	"BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2"	ENSG00000151914	Dystonin	Q03001	6	56457987-56954628	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	"Actin-binding, Muscle protein"	"Cancer-related genes, Epidermolysis bullosa, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 92.5;hTERT-HME1: 68.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 5.3"	"Group enriched"	"Detected in many"	5	"dendritic cells: 5.3;monocytes: 1.7;NK-cells: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030200	Uncertain		Approved	Nucleoplasm,Microtubules,Cytosol				"Nucleoplasm, Microtubules"	Cytosol	"HPA030200: AB_10601901"	"unprognostic (4.87e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.25e-2)"	"unprognostic (3.60e-2)"	"unprognostic (5.78e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.75e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.69e-1)"	"unprognostic (4.39e-2)"	"unprognostic (5.13e-3)"	"unprognostic (1.46e-1)"	"unprognostic (2.66e-1)"	"unprognostic (7.62e-2)"	26.5	29.2	43.4	11.7	57.1	2.5	59.2	43.6	52.4	53.8	31.5	32.1	11.5	15.1	53.6	21.7	37.1	19.4	16.8	28.1	41.2	36.2	18.0	26.6	29.4	5.4	56.5	28.9	30.3	14.0	32.1	28.2	15.1	53.9	22.6	17.4	8.4	23.6	25.3	57.5	81.8	16.9	53.6	54.9	12.8	14.8	11.7	66.5	6.1	7.6	33.6	7.7	19.7	23.7	0.6	5.3	0.3	1.7	2.1	0.4	0.3	11.9	5.7	7.7	4.4	12.8	20.2	4.4	16.1	15.4	6.7	7.5	3.3	3.2	1.8	6.7	36.4	8.4	6.5	28.4	13.2	11.4	9.7	3.4	10.4	6.1	11.5	3.2	0.0	8.9	92.5	16.2	68.5	12.6	2.7	7.9	17.3	3.3	0.9	1.3	5.9	4.2	0.0	6.0	2.7	20.2	15.4	10.3	7.7	6.9	2.4	11.0	3.7	5.2	33.8	14.8	12.4	7.0	13.3	8.9	6.3	0.9	10.5	1.7	7.0	0.3	1.7	0.0	0.3	1.3	0.1	0.2	0.4	0.0	3.2	0.6	0.1	0.2	0.1	2.1	1.0	5.3	0.0	0.3	43.4	57.1	43.6	52.4	41.2	36.2	56.5	28.9	53.9	66.5
DUSP1	"CL100, HVH1, MKP-1, PTPN10"	ENSG00000120129	"Dual specificity phosphatase 1"	P28562	5	172768090-172771195	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Stress response"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 43.1;hTCEpi: 75.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 326.0"	"Lineage enriched"	"Detected in all"	10	"granulocytes: 326.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA069577			Approved	Nucleoli,Cytosol				Nucleoli	Cytosol	"HPA069577: "	"unprognostic (1.51e-1)"	"unprognostic (1.24e-1)"	"unprognostic (9.73e-2)"	"unprognostic (8.17e-2)"	"unprognostic (4.64e-1)"	"unprognostic (1.58e-3)"	"unprognostic (4.18e-2)"	"unprognostic (6.94e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.43e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.76e-2)"	"prognostic unfavourable (3.11e-5)"	"unprognostic (2.69e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.41e-3)"	158.4	78.0	12.4	68.5	14.0	89.7	91.8	17.4	14.9	81.4	37.1	32.4	48.5	9.4	55.4	71.6	82.7	94.8	138.8	49.2	12.5	11.4	29.8	115.4	135.0	43.5	30.6	9.7	69.4	34.4	26.6	40.8	93.7	29.3	67.1	34.2	61.0	38.1	192.8	54.8	116.1	27.6	65.0	29.5	36.1	53.6	45.9	18.7	10.8	90.4	104.1	46.9	69.0	109.7	2.4	11.5	326.0	31.8	4.5	9.8	14.0	2.1	5.4	1.7	2.3	37.5	22.0	2.9	34.9	10.2	23.5	9.5	5.9	2.5	0.7	10.2	24.5	0.9	1.6	8.6	11.0	19.1	4.6	0.4	11.9	2.5	43.1	0.2	0.8	21.0	75.3	10.6	17.3	7.3	1.7	13.7	15.1	2.5	1.1	1.0	1.5	1.6	40.5	3.2	6.3	16.7	1.1	7.4	3.1	9.4	16.1	1.2	1.3	0.4	19.2	16.7	8.3	16.2	2.6	2.8	1.6	0.6	14.8	0.3	0.6	33.3	24.6	69.8	3.9	25.0	9.8	2.4	3.5	4.0	11.5	2.1	1.7	1.9	326.0	4.5	31.8	0.6	2.8	14.0	12.4	14.0	17.4	14.9	12.5	11.4	30.6	9.7	29.3	18.7
DUSP14	"MKP-L, MKP6"	ENSG00000276023	"Dual specificity phosphatase 14"	O95147	17	37489831-37513501	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+: 10.7;BJ hTERT+ SV40 Large T+ RasG12V: 12.5;HBF TERT88: 17.9;WM-115: 10.3"	"Low cancer specificity"	"Detected in all"							"Cell type enhanced"	"Detected in single"		"neutrophil: 3.2"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 3.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019911	Approved		Approved	Nucleoplasm,Cytosol		44000	44000	"Nucleoplasm, Cytosol"		"HPA019911: AB_1847888"	"unprognostic (1.32e-1)"	"unprognostic (3.06e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.60e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.43e-3)"	"unprognostic (2.02e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.59e-1)"	"unprognostic (7.02e-3)"	"unprognostic (3.81e-1)"	"prognostic unfavourable (6.97e-9)"	"unprognostic (7.93e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.41e-3)"	4.7	3.7	3.3	2.1	6.6	1.1	3.9	1.8	8.0	3.3	1.0	1.5	0.1	0.7	2.7	1.2	7.2	11.7	5.1	2.6	2.3		2.1	6.5	2.4	1.0	1.9	2.5	3.0	2.9	1.7	3.3	11.6	2.6	1.4	1.4	1.6	2.8	1.1	1.7	8.4	0.9	3.5	2.7	1.7	1.0	3.5	0.8	2.3	8.3	6.1	4.3	1.9	1.0	0.5	0.0	3.2	0.0	0.4	0.4	0.5	1.7	0.1	0.4	0.8	0.0	0.5	1.5	8.0	6.1	10.7	12.5	0.9	1.8	0.1	0.7	5.8	1.3	0.1	4.7	17.9	0.1	0.5	0.0	1.0	2.0	0.8	0.4	1.2	4.7	2.9	3.8	2.0	0.2	0.4	0.0	7.9	0.3	0.8	0.2	0.2	0.0	0.7	0.5	0.2	2.6	0.7	1.3	0.1	0.4	0.7	1.1	0.6	1.0	0.7	8.6	2.0	0.1	4.0	0.0	0.2	0.1	0.0	0.0	10.3	0.0	0.0	0.9	0.4	0.0	0.2	0.5	0.1	0.0	0.0	0.2	0.3	0.2	3.2	0.4	0.0	0.0	0.0	0.5										
DUSP4	"HVH2, MKP-2, TYP"	ENSG00000120875	"Dual specificity phosphatase 4"	Q13115	8	29333064-29350668	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 46.7;pancreas: 78.6;seminal vesicle: 63.5"	"Cell line enhanced"	"Detected in many"		"A549: 30.0;SK-MEL-30: 46.2;WM-115: 37.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"T-reg: 9.6"	"Lineage enriched"	"Detected in single"	18	"T-cells: 9.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA061967			Supported	Nucleoplasm				Nucleoplasm		"HPA061967: "	"unprognostic (1.92e-1)"	"unprognostic (5.97e-3)"	"unprognostic (3.24e-1)"	"unprognostic (6.54e-2)"	"unprognostic (2.18e-2)"	"unprognostic (7.66e-3)"	"unprognostic (7.30e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.83e-2)"	"unprognostic (9.73e-3)"	"unprognostic (9.60e-3)"	"unprognostic (3.15e-2)"	"prognostic unfavourable (4.19e-4)"	"unprognostic (6.88e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.08e-2)"	"unprognostic (6.07e-2)"	10.9	3.4	1.2	3.6	1.1	3.4	17.1	4.8	2.7	4.6	1.7	1.0	46.7	0.8	3.2	0.7	1.6	1.3	13.1	1.5	4.6	0.8	0.7	0.4	3.7	1.8	0.8	0.8	1.2	78.6	0.1	3.7	17.7	0.7	4.3	0.9	17.1	8.9	63.5	2.7	3.5	1.3	1.5	1.1	0.6	20.6	1.7	0.2	3.9	1.2	2.0	4.7	7.4	3.0	0.0	0.5	0.0	0.0	0.2	9.6	0.1	11.1	30.0	17.8	0.8	2.3	0.0	1.5	2.3	12.8	7.0	3.1	0.3	5.7	0.0	6.3	1.0	3.6	0.2	7.7	4.2	0.3	0.6	0.0	1.0	0.2	0.0	0.1	14.6	1.4	5.1	2.2	13.1	5.7	0.1	1.3	14.0	12.6	0.0	2.1	3.1	18.4	0.3	0.6	2.3	16.1	5.9	0.1	9.9	3.2	15.2	46.2	3.2	0.3	16.0	5.2	0.0	0.0	1.6	3.6	0.4	0.0	15.6	2.6	37.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	9.6	0.1	1.2	1.1	4.8	2.7	4.6	0.8	0.8	0.8	0.7	0.2
DVL3	KIAA0208	ENSG00000161202	"Dishevelled segment polarity protein 3"	Q92997	3	184155388-184173610	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB046486, HPA058265"	Approved		Approved	"Intermediate filaments,Midbody ring,Centrosome"				"Midbody ring, Centrosome"	"Intermediate filaments"	"CAB046486: AB_10610845, HPA058265: "	"unprognostic (2.20e-1)"	"unprognostic (1.52e-1)"	"prognostic unfavourable (1.90e-4)"	"unprognostic (1.88e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (8.41e-4)"	"unprognostic (8.61e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.49e-1)"	"unprognostic (3.14e-1)"	"prognostic unfavourable (4.77e-5)"	"prognostic unfavourable (1.53e-8)"	"unprognostic (1.87e-1)"	"unprognostic (4.10e-1)"	"unprognostic (8.41e-2)"	"unprognostic (3.95e-1)"	22.8	18.5	18.0	16.8	19.4	15.3	25.1	18.3	23.2	22.6	27.6	24.7	23.9	16.2	32.1	16.4	20.0	22.2	22.2	27.9	19.9	12.3	16.8	13.1	20.6	12.1	21.4	16.0	30.0	22.7	17.2	17.8	56.0	17.4	19.7	15.8	31.1	18.7	26.2	26.3	27.6	19.1	30.3	16.4	17.8	19.4	15.6	20.1	7.3	20.9	13.3	14.6	24.5	26.3	2.5	2.7	4.1	4.0	1.5	3.1	1.2	19.8	6.5	15.8	17.9	16.4	16.4	40.7	11.8	12.1	14.3	11.9	19.1	8.0	13.9	31.7	15.4	17.0	12.9	9.4	10.0	21.9	13.5	15.5	9.8	11.5	24.6	8.6	12.1	16.5	16.9	10.4	11.9	10.4	15.5	19.3	15.0	19.0	12.7	10.2	13.9	9.4	20.3	18.3	12.1	13.3	16.4	17.1	21.7	14.7	17.0	28.8	42.5	11.0	10.2	13.0	12.7	13.6	18.3	20.7	15.3	15.5	12.9	9.2	10.0	0.2	2.4	4.1	2.3	4.0	3.1	2.5	1.5	2.4	2.3	2.0	2.0	1.3	3.6	1.5	2.8	2.7	1.1	1.2	18.0	19.4	18.3	23.2	19.9	12.3	21.4	16.0	17.4	20.1
DYNLL1	"DLC1, DLC8, DNCL1, hdlc1, LC8, PIN"	ENSG00000088986	"Dynein light chain LC8-type 1"	P63167	12	120469850-120498493	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction, Transcription, Transcription regulation, Transport"	"Activator, Motor protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA039954			Approved	"Nucleoplasm,Nuclear bodies,Cytosol"		650000	650000	"Nucleoplasm, Cytosol"	"Nuclear bodies"	"HPA039954: "	"unprognostic (1.94e-1)"	"unprognostic (1.08e-1)"	"unprognostic (3.43e-2)"	"unprognostic (2.88e-2)"	"unprognostic (5.63e-2)"	"unprognostic (7.09e-2)"	"prognostic unfavourable (7.33e-5)"	"unprognostic (4.41e-3)"	"unprognostic (4.64e-2)"	"unprognostic (6.17e-3)"	"unprognostic (1.61e-2)"	"unprognostic (9.10e-2)"	"prognostic unfavourable (7.97e-7)"	"unprognostic (4.91e-2)"	"unprognostic (2.80e-2)"	"unprognostic (7.91e-2)"	"unprognostic (1.62e-1)"	45.5	48.5	128.5	34.4	97.8	21.9	54.3	48.4	120.5	50.6	61.8	61.9	31.1	31.6	47.2	64.9	113.7	107.1	46.7	44.2	124.1	105.2	49.7	40.7	40.3	41.2	92.9	90.7	49.0	45.7	30.4	46.4	49.8	67.4	39.9	64.5	24.8	34.0	54.9	15.0	117.3	38.9	75.2	93.6	30.4	45.1	59.4	56.8	35.4	37.1	84.3	65.6	59.0	63.0	55.0	80.6	73.6	55.0	46.7	63.4	50.8	78.4	89.7	89.0	68.2	78.2	83.0	28.6	108.6	50.2	88.7	53.2	84.5	52.9	44.0	58.7	103.7	70.8	105.7	90.8	88.7	58.3	69.2	43.0	64.3	114.3	79.0	44.8	71.5	50.4	97.2	66.5	54.6	92.1	53.9	50.7	117.0	103.9	58.5	97.6	73.0	104.7	59.8	46.1	54.6	126.7	72.7	61.2	45.2	88.5	76.9	98.6	76.2	65.6	70.8	68.3	58.3	60.2	93.5	30.6	58.7	43.7	75.7	70.1	87.4	73.6	49.5	63.6	37.7	51.4	28.7	55.0	39.0	39.0	49.1	36.5	25.2	31.5	9.1	46.7	55.0	80.6	63.4	50.8	128.5	97.8	48.4	120.5	124.1	105.2	92.9	90.7	67.4	56.8
DYRK2		ENSG00000127334	"Dual specificity tyrosine phosphorylation regulated kinase 2"	Q92630	12	67648338-67665406	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Ubl conjugation pathway"	"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA027230, HPA056902"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA027230: AB_1847925, HPA056902: "	"unprognostic (5.86e-3)"	"unprognostic (4.18e-1)"	"unprognostic (4.08e-3)"	"unprognostic (2.56e-3)"	"unprognostic (1.18e-2)"	"unprognostic (1.69e-1)"	"unprognostic (3.37e-3)"	"unprognostic (7.83e-2)"	"unprognostic (2.83e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.47e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.03e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.35e-1)"	12.2	5.3	4.5	20.1	4.8	8.6	8.1	4.4	6.6	10.1	21.3	4.1	8.3	13.7	14.6	9.6	9.6	9.1	16.9	26.1	4.7	3.2	6.3	4.6	10.1	17.9	4.0	3.3	7.6	8.5	3.6	4.4	13.0	5.0	7.1	15.3	6.6	7.2	6.6	23.7	9.4	26.0	11.2	5.3	10.3	14.0	4.4	3.9	34.3	7.6	12.5	17.2	11.1	12.2	2.7	1.9	5.9	1.3	6.9	6.8	1.6	13.5	7.7	11.5	8.3	5.8	7.9	9.2	13.8	9.0	6.8	3.9	10.1	7.5	25.4	17.1	20.0	15.9	9.2	5.4	7.3	10.9	12.0	4.1	5.1	3.8	2.2	9.2	8.9	6.5	7.8	18.2	14.6	3.8	5.0	13.3	8.6	7.8	7.9	4.5	10.0	12.4	21.1	11.4	11.2	7.9	17.1	15.2	18.0	5.8	7.8	8.0	5.3	7.8	5.6	10.8	10.2	7.4	10.9	6.3	1.0	14.1	10.4	6.3	11.1	3.2	0.5	5.9	5.2	1.3	4.0	2.7	3.9	6.8	1.9	2.7	3.3	6.1	0.7	6.9	1.3	0.8	3.1	1.6	4.5	4.8	4.4	6.6	4.7	3.2	4.0	3.3	5.0	3.9
E2F1	"RBBP3, RBP3"	ENSG00000101412	"E2F transcription factor 1"	Q01094	20	33675683-33686404	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 32.5;lymphoid tissue: 21.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 3.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000329, HPA008003, CAB019308, HPA029735"	Enhanced		Enhanced	Nucleoplasm,Centrosome				"Nucleoplasm, Centrosome"		"CAB000329: AB_627476, CAB019308: , HPA008003: AB_1847936, HPA029735: "	"unprognostic (7.46e-2)"	"prognostic favourable (9.22e-6)"	"unprognostic (2.11e-2)"	"prognostic unfavourable (4.33e-5)"	"unprognostic (1.51e-1)"	"unprognostic (1.21e-2)"	"prognostic unfavourable (3.83e-5)"	"unprognostic (1.25e-2)"	"unprognostic (8.23e-2)"	"unprognostic (9.66e-2)"	"prognostic unfavourable (4.18e-4)"	"unprognostic (3.15e-2)"	"prognostic unfavourable (8.99e-5)"	"unprognostic (1.05e-2)"	"unprognostic (7.50e-2)"	"prognostic favourable (1.62e-4)"	"unprognostic (1.91e-1)"	2.4	5.3	6.8	12.7	9.7	32.5	2.1	1.1	6.4	1.2	4.4	5.1	0.7	3.9	1.4	0.8	5.1	1.5	4.1	2.0	7.1	3.6	0.9	1.7	8.1	9.3	6.2	2.9	3.4	1.2	2.3	0.3	3.3	5.9	1.7	4.8	0.3	1.6	1.4	1.4	5.4	4.9	3.3	6.2	4.8	3.4	12.1	6.0	21.9	1.0	4.9	7.7	1.9	3.1	2.2	0.6	0.7	3.7	1.4	1.2	0.6	15.9	15.5	18.0	14.0	1.8	1.3	13.7	15.3	7.4	19.6	16.5	27.4	16.5	29.4	15.5	6.8	12.0	8.7	8.1	8.8	8.8	12.5	24.0	23.1	15.9	0.1	11.2	15.2	1.0	0.5	10.7	1.9	5.0	6.3	20.8	12.1	14.1	23.8	23.8	5.4	22.3	23.8	49.1	12.1	3.3	9.8	26.9	18.9	18.6	13.0	7.6	16.3	14.2	2.7	22.9	13.4	15.8	21.7	20.3	13.7	24.2	19.0	6.7	13.5	0.0	0.0	0.7	0.1	0.9	0.0	2.2	0.6	0.4	0.2	0.2	0.2	1.2	0.3	1.4	3.7	0.6	0.8	0.6	6.8	9.7	1.1	6.4	7.1	3.6	6.2	2.9	5.9	6.0
E2F3		ENSG00000112242	"E2F transcription factor 3"	O00716	6	20401906-20493715	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029779, HPA065012"			Supported	"Nucleoplasm,Nuclear speckles,Cytosol"				"Nucleoplasm, Nuclear speckles"	Cytosol	"HPA029779: , HPA065012: "	"unprognostic (4.10e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.96e-1)"	"unprognostic (9.14e-2)"	"unprognostic (8.99e-3)"	"unprognostic (9.13e-2)"	"unprognostic (1.10e-1)"	"prognostic favourable (1.69e-4)"	"unprognostic (1.14e-2)"	"unprognostic (5.64e-2)"	"prognostic unfavourable (1.63e-8)"	"unprognostic (1.23e-1)"	"unprognostic (2.16e-1)"	"unprognostic (3.50e-1)"	"unprognostic (5.99e-3)"	9.5	8.4	7.6	12.2	13.4	22.1	10.8	1.7	10.1	4.8	7.1	2.9	3.2	6.8	6.3	6.9	8.0	4.9	9.9	11.1	8.3	6.8	14.6	6.1	7.8	19.7	5.8	7.3	4.0	3.6	2.9	3.2	7.4	7.9	5.0	8.6	5.1	4.7	4.5	15.1	4.3	8.0	7.9	5.0	16.9	5.0	8.9	3.1	17.7	11.4	10.2	12.0	9.2	4.8	0.7	3.7	10.3	3.1	4.8	3.6	1.5	6.7	5.5	15.9	17.0	5.3	5.9	11.0	9.1	7.9	8.8	9.7	6.8	4.2	15.1	17.7	8.5	7.1	18.1	8.2	14.8	5.9	12.8	27.5	9.1	7.5	5.7	18.0	16.5	4.7	6.1	8.6	10.5	6.0	30.4	9.4	9.9	6.9	20.4	20.1	11.9	5.7	22.2	14.0	17.4	10.5	11.8	11.5	21.0	8.5	11.7	12.0	6.0	10.9	8.0	14.2	8.9	7.0	14.5	5.9	18.7	19.0	3.5	11.2	20.1	6.9	3.1	1.4	2.3	2.3	3.1	0.7	1.5	3.6	3.7	0.7	1.3	2.8	10.3	4.8	1.5	1.6	2.2	1.5	7.6	13.4	1.7	10.1	8.3	6.8	5.8	7.3	7.9	3.1
E2F5		ENSG00000133740	"E2F transcription factor 5"	Q15329	8	85177225-85217158	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Cilium biogenesis/degradation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 27.0;Daudi: 53.1;U-698: 25.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	7	"memory B-cell: 13.3;naive B-cell: 7.6"	"Lineage enriched"	"Detected in many"	9	"B-cells: 13.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055723, HPA065441"			Enhanced	Nucleoplasm,Nucleoli,Vesicles				Nucleoplasm	"Nucleoli, Vesicles"	"HPA055723: , HPA065441: "	"unprognostic (8.73e-2)"	"unprognostic (3.45e-1)"	"unprognostic (3.15e-2)"	"unprognostic (1.02e-3)"	"unprognostic (6.73e-3)"	"unprognostic (1.62e-1)"	"unprognostic (3.36e-5)"	"unprognostic (1.23e-1)"	"unprognostic (9.53e-2)"	"unprognostic (1.28e-1)"	"unprognostic (3.18e-1)"	"unprognostic (3.87e-2)"	"prognostic unfavourable (1.89e-6)"	"unprognostic (2.88e-2)"	"unprognostic (3.25e-2)"	"unprognostic (3.64e-1)"	"unprognostic (2.95e-3)"	3.0	9.0	6.4	22.2	8.1	1.5	5.9	2.6	5.3	5.0	5.9	4.0	3.4	4.6	5.4	7.4	4.7	7.2	6.6	3.2	5.6	5.6	9.0	4.5	5.1	22.4	4.6	2.7	8.3	14.6	12.7	10.6	4.3	3.8	5.1	7.2	3.4	5.7	5.9	1.1	1.7	7.3	3.8	4.5	9.9	5.1	10.5	3.2	13.6	10.2	3.0	26.0	6.0	7.6	13.3	1.4	0.0	0.0	1.1	0.6	0.6	4.8	5.2	27.0	10.0	0.5	0.7	8.7	0.9	2.1	0.8	2.3	3.1	5.7	53.1	3.8	1.1	1.0	15.7	1.3	1.0	5.5	7.2	5.3	2.9	7.3	4.3	1.6	0.0	1.0	2.1	1.0	3.8	0.8	11.2	0.4	1.4	3.1	5.4	3.5	8.7	4.6	4.3	1.1	5.7	8.7	3.4	3.3	10.4	0.6	1.8	8.0	11.3	1.7	0.0	1.3	1.0	1.5	3.5	10.0	6.7	25.4	1.5	1.3	2.6	0.0	0.0	0.0	0.1	0.0	0.0	13.3	0.0	0.0	0.1	7.6	0.2	0.4	0.0	1.1	0.0	1.4	0.6	0.6	6.4	8.1	2.6	4.5	5.6	5.6	4.6	2.7	3.8	3.2
EBAG9	"EB9, RCAS1"	ENSG00000147654	"Estrogen receptor binding site associated, antigen, 9"	O00559	8	109539711-109565996	"Cancer-related genes, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA021153, HPA021154, CAB072810, CAB072811, CAB072812"	Enhanced		Enhanced	"Golgi apparatus"	"Intracellular and membrane"			"Golgi apparatus"		"CAB072810: , CAB072811: , CAB072812: , HPA021153: AB_1856151, HPA021154: AB_1856152"	"unprognostic (3.04e-2)"	"unprognostic (9.99e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.99e-1)"	"unprognostic (5.06e-2)"	"unprognostic (8.13e-2)"	"unprognostic (2.63e-1)"	"unprognostic (3.17e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.22e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.72e-1)"	"unprognostic (9.72e-3)"	"unprognostic (6.46e-2)"	"unprognostic (5.16e-1)"	"unprognostic (3.53e-1)"	"unprognostic (3.71e-2)"	17.1	23.7	24.4	19.8	23.4	10.7	24.1	24.2	25.6	28.1	20.3	13.3	24.9	16.9	17.0	34.2	15.6	20.7	16.0	23.9	21.4	21.5	27.1	31.9	22.7	19.2	20.2	21.9	18.2	32.1	24.1	27.4	19.2	18.2	21.2	23.2	15.1	29.0	36.3	34.1	12.9	21.0	16.1	20.8	20.7	19.0	17.4	15.5	17.0	42.4	20.1	18.7	22.5	15.0	21.8	13.0	7.8	10.3	15.4	20.2	7.9	16.2	11.5	11.7	8.0	7.3	11.9	9.1	8.9	6.7	12.6	11.9	11.6	17.4	23.2	15.5	6.2	11.5	11.2	14.2	13.4	25.6	12.3	25.5	7.5	17.6	16.3	8.8	7.5	9.5	28.1	10.8	22.2	11.8	26.2	17.1	11.0	24.8	25.5	14.0	7.3	11.6	13.7	9.3	19.4	14.5	10.7	12.9	10.3	9.7	10.4	12.1	20.6	11.5	7.9	9.8	7.1	8.8	6.5	25.7	16.5	21.8	10.0	23.7	9.0	2.7	7.4	7.8	11.3	10.3	19.8	21.8	15.9	15.6	12.2	20.2	20.2	17.8	1.5	15.4	8.9	13.0	17.1	7.9	24.4	23.4	24.2	25.6	21.4	21.5	20.2	21.9	18.2	15.5
EBF1	"EBF, OLF1"	ENSG00000164330	"Early B cell factor 1"	Q9UH73	5	158695916-159099761	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 19.0;HSkMC: 14.8;REH: 39.7"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	5	"cerebellum: 23.6"	"Group enriched"	"Detected in some"	62	"memory B-cell: 11.8;naive B-cell: 10.4"	"Lineage enriched"	"Detected in single"	66	"B-cells: 11.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA061169			Approved	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA061169: "	"unprognostic (7.86e-2)"	"unprognostic (3.08e-2)"	"unprognostic (7.29e-2)"	"unprognostic (4.70e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.39e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.60e-1)"	"unprognostic (5.75e-2)"	"unprognostic (1.60e-1)"	"unprognostic (4.58e-2)"	"unprognostic (1.02e-1)"	"prognostic unfavourable (9.62e-7)"	"prognostic unfavourable (7.80e-4)"	"unprognostic (5.75e-2)"	"unprognostic (5.81e-2)"	"unprognostic (4.37e-3)"	33.7	3.3	1.9	9.7	2.5	3.1	25.0	23.6	2.0	15.9	5.8	1.1	9.0	1.2	19.7	13.0	5.0	8.5	9.4	15.5	2.0	2.4	3.3	0.9	5.2	12.7	3.2	1.2	7.4	3.7	1.8	2.6	10.7	4.7	8.5	3.4	10.4	4.7	10.8	15.5	4.8	4.5	25.7	6.6	5.4	3.4	8.4	1.0	0.1	6.8	13.2	9.1	11.7	12.5	11.8	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.2	6.1	0.0	19.0	8.2	0.0	0.0	0.0	0.2	0.5	0.0	0.0	5.4	0.0	2.2	0.0	0.2	0.0	0.1	1.2	0.0	0.0	1.6	0.0	0.3	0.0	0.0	14.8	0.0	5.8	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	39.7	0.2	0.0	0.0	0.0	3.2	0.8	0.3	0.0	0.0	0.0	0.0	0.0	7.3	0.8	8.3	0.1	0.0	0.0	5.5	4.8	0.4	6.6	0.1	0.0	0.1	0.0	0.0	0.0	11.8	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.9	2.5	23.6	1.6	2.0	2.4	3.2	1.2	4.7	1.0
EDN1	ET1	ENSG00000078401	"Endothelin 1"	P05305	6	12290363-12297194	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"		"Vasoactive, Vasoconstrictor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"EFO-21: 107.5;HUVEC TERT2: 71.2;T-47d: 22.0;TIME: 52.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	6	"non-classical monocyte: 7.9"	"Lineage enriched"	"Detected in many"	6	"monocytes: 7.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031976, CAB032500, CAB037291"	Approved		Approved	"Nucleoplasm,Nucleoli,Golgi apparatus"	"Secreted to blood"			"Nucleoli, Golgi apparatus"	Nucleoplasm	"CAB032500: AB_2096241, CAB037291: AB_259277, HPA031976: AB_10602489"	"unprognostic (1.51e-2)"	"unprognostic (2.38e-1)"	"unprognostic (3.95e-2)"	"unprognostic (9.72e-2)"	"unprognostic (3.40e-1)"	"unprognostic (1.91e-1)"	"unprognostic (6.24e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.42e-1)"	"unprognostic (8.92e-2)"	"unprognostic (4.19e-2)"	"unprognostic (3.17e-1)"	"unprognostic (8.02e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.34e-1)"	"unprognostic (3.47e-1)"	35.7	1.5	8.4	6.2	30.8	3.6	19.2	3.2	22.0	8.2	9.2	4.2	1.1	9.0	7.2	15.3	10.8	8.6	11.9	5.2	19.0	6.2	5.7	2.8	25.1	6.7	10.9	5.5	4.3	8.2	1.6	1.0	16.0	25.1	5.4	12.9	6.9	9.7	8.5	25.6	8.2	6.7	9.7	13.5	10.2	6.8	4.8	5.6	0.2	2.9	3.8	2.1	5.3	4.1	0.2	0.2	1.2	7.9	0.0	0.2	0.0	1.5	9.0	0.1	0.0	0.0	0.0	0.0	2.8	2.5	2.4	2.0	11.6	1.3	0.0	107.5	1.1	0.8	0.0	1.6	1.7	0.1	0.0	0.0	0.3	0.3	0.1	0.0	0.0	0.0	1.0	0.4	0.3	71.2	0.0	0.0	9.0	0.2	0.0	0.0	0.1	0.1	0.0	0.8	0.0	5.6	1.4	0.1	0.0	0.2	8.5	0.0	22.0	0.1	52.7	6.0	4.8	0.1	3.6	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	1.2	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	0.0	0.0	7.9	0.1	0.0	0.0	8.4	30.8	3.2	22.0	19.0	6.2	10.9	5.5	25.1	5.6
EEF1A1	"EE1A1, EEF1A, EF1A, LENG7"	ENSG00000156508	"Eukaryotic translation elongation factor 1 alpha 1"	P68104	6	73515750-73523797	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Protein biosynthesis, Transcription, Transcription regulation"	"Elongation factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA051759, HPA053862, HPA056990"	Supported		Supported	Cytosol				Cytosol		"HPA051759: , HPA053862: , HPA056990: "	"unprognostic (6.47e-2)"	"unprognostic (7.86e-3)"	"unprognostic (2.53e-2)"	"unprognostic (9.64e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (5.57e-4)"	"unprognostic (3.13e-1)"	"unprognostic (1.61e-1)"	"unprognostic (2.77e-1)"	"unprognostic (1.41e-1)"	"unprognostic (3.47e-1)"	"unprognostic (8.61e-2)"	"unprognostic (1.65e-1)"	"unprognostic (8.00e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.73e-2)"	134.1	124.1	80.2	136.0	75.6	140.9	182.0	103.3	106.2	149.6	133.3	94.9	93.7	81.7	152.0	127.3	136.4	143.1	102.4	88.2	71.5	58.0	130.9	123.1	169.6	135.6	74.3	93.2	240.8	227.6	106.3	111.2	89.1	79.7	115.0	114.7	105.0	133.3	123.6	51.3	139.8	101.6	121.6	108.6	111.3	121.5	129.9	71.6	125.1	132.4	143.1	169.7	151.1	134.8	258.9	209.7	54.6	187.6	184.6	366.8	517.5	111.1	141.0	200.2	273.4	410.7	679.5	159.4	166.6	430.1	213.7	205.1	218.7	153.9	454.1	222.8	281.5	118.0	244.5	318.4	206.0	79.2	153.0	169.5	115.0	243.6	356.6	315.0	185.1	587.0	541.5	157.3	530.9	289.4	313.2	143.7	258.2	148.2	134.8	330.2	214.2	98.0	268.8	337.3	509.0	274.5	235.6	164.3	182.4	83.5	196.4	329.6	133.5	509.2	240.4	91.3	130.0	67.6	189.1	161.4	143.4	106.6	94.8	261.3	143.4	54.6	187.6	20.8	198.7	165.4	366.8	258.9	288.8	250.9	209.7	199.5	323.8	277.8	17.0	184.6	169.0	161.7	202.9	517.5	80.2	75.6	103.3	106.2	71.5	58.0	74.3	93.2	79.7	71.6
EEF2	"EEF-2, EF2"	ENSG00000167658	"Eukaryotic translation elongation factor 2"	P13639	19	3976056-3985469	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Protein biosynthesis"	"Elongation factor"	"Cancer-related genes, Disease mutation, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007795, HPA040534, HPA057351"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		9700000	9700000	"Plasma membrane, Cytosol"		"CAB007795: AB_598149, HPA040534: AB_2677024, HPA057351: AB_2683417"	"unprognostic (5.47e-2)"	"unprognostic (9.59e-2)"	"unprognostic (3.75e-1)"	"prognostic favourable (1.81e-6)"	"unprognostic (2.06e-2)"	"unprognostic (3.26e-1)"	"unprognostic (1.53e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.77e-2)"	"unprognostic (1.25e-2)"	"unprognostic (1.42e-1)"	"prognostic favourable (1.25e-5)"	"unprognostic (4.46e-2)"	"unprognostic (5.60e-2)"	"unprognostic (6.82e-2)"	"unprognostic (9.86e-2)"	104.2	84.9	64.0	66.7	57.1	92.7	77.5	55.7	96.2	93.4	91.3	55.8	80.8	95.4	100.1	75.1	115.1	83.4	88.6	104.1	51.6	44.4	65.5	161.0	67.7	108.9	51.4	38.3	167.1	395.7	45.1	72.3	63.7	47.5	105.6	41.3	67.7	191.3	64.4	260.8	87.2	100.9	112.3	46.8	85.4	98.5	70.9	32.4	123.4	127.1	112.5	108.3	111.8	94.7	84.9	60.0	10.0	58.4	48.3	76.3	83.7	95.2	68.4	39.8	105.1	106.7	192.3	57.3	74.9	101.4	71.7	70.6	107.8	44.2	199.0	44.6	69.1	72.3	62.8	116.0	38.0	49.6	104.2	50.8	65.7	110.7	156.0	109.1	88.4	248.2	122.7	63.1	97.7	74.2	99.1	146.7	43.6	138.2	97.9	83.7	105.3	69.2	109.1	59.2	126.5	59.0	85.2	109.0	101.3	47.1	94.3	135.0	91.9	132.7	88.9	51.4	53.7	104.4	115.2	157.4	105.6	99.0	76.6	137.2	67.0	10.0	58.4	8.3	38.6	45.8	68.7	84.9	67.7	50.8	60.0	70.7	76.3	59.4	6.1	48.3	43.8	50.5	58.4	83.7	64.0	57.1	55.7	96.2	51.6	44.4	51.4	38.3	47.5	32.4
EFNA1	"ECKLG, EPLG1, LERK1, TNFAIP4"	ENSG00000169242	"Ephrin A1"	P20827	1	155127460-155134857	"Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis		"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 123.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 57.1;HaCaT: 19.9;SiHa: 32.9;SK-BR-3: 50.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	8	"naive CD4 T-cell: 12.1;naive CD8 T-cell: 6.0"	"Lineage enriched"	"Detected in single"	26	"T-cells: 12.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB032498	Uncertain				"Secreted to blood"	2100000	2100000			"CAB032498: AB_2262137"	"unprognostic (5.14e-2)"	"unprognostic (3.04e-3)"	"unprognostic (5.03e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.59e-1)"	"unprognostic (2.47e-2)"	"unprognostic (1.78e-2)"	"unprognostic (5.80e-3)"	"unprognostic (1.53e-1)"	"unprognostic (4.56e-2)"	"unprognostic (2.00e-2)"	"unprognostic (2.23e-1)"	"unprognostic (4.44e-2)"	"unprognostic (3.58e-1)"	"unprognostic (1.93e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.32e-1)"	16.2	6.1	6.8	2.9	14.5	0.4	29.5	4.4	10.9	7.1	27.6	11.8	10.7	21.7	7.2	11.7	12.6	8.0	8.7	13.3	6.4	4.6	16.1	123.2	27.0	2.7	15.7	4.3	5.7	14.0	4.9	5.3	38.2	13.8	18.6	20.2	5.0	17.7	17.2	10.4	27.5	27.5	5.1	9.6	2.3	13.1	3.3	14.8	3.7	30.2	7.8	4.1	10.7	12.7	0.3	0.0	0.4	0.0	0.3	12.1	2.0	3.1	1.3	0.1	2.4	0.4	0.0	57.1	0.0	0.0	0.0	0.0	3.2	7.0	0.0	5.7	0.0	19.9	1.3	6.9	0.0	1.9	0.4	0.0	4.4	17.2	0.1	0.0	0.3	0.9	17.0	0.0	5.9	10.7	0.5	0.1	0.0	11.4	0.0	0.2	0.4	4.2	1.2	0.3	1.9	13.5	4.9	2.0	3.0	32.9	50.5	1.2	10.6	0.0	1.3	0.0	2.0	0.1	0.3	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.0	1.0	0.7	0.0	0.3	12.1	6.0	0.4	0.3	0.0	0.0	0.0	2.0	6.8	14.5	4.4	10.9	6.4	4.6	15.7	4.3	13.8	14.8
EFNA2	"ELF-1, EPLG6, LERK6"	ENSG00000099617	"Ephrin A2"	O43921	19	1286154-1300237	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	5	"gallbladder: 10.0;intestine: 30.3;liver: 14.2"	"Cell line enhanced"	"Detected in some"		"AF22: 4.8;BEWO: 4.9;Hep G2: 9.3;NTERA-2: 5.4;REH: 7.1;SH-SY5Y: 16.8;U-2 OS: 5.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 11.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA067567			Approved	Mitochondria,Cytosol	"Intracellular and membrane"			"Mitochondria, Cytosol"		"HPA067567: "	"unprognostic (1.98e-1)"	"unprognostic (3.26e-1)"	"unprognostic (2.87e-3)"	"unprognostic (1.96e-2)"	"unprognostic (4.04e-2)"	"unprognostic (3.90e-1)"	"unprognostic (7.19e-2)"	"unprognostic (2.34e-3)"	"unprognostic (3.58e-2)"	"unprognostic (6.82e-2)"	"unprognostic (8.48e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.61e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.03e-1)"	"unprognostic (2.82e-4)"	"unprognostic (1.94e-1)"	0.2	0.1	1.5	3.4	2.2	0.2	0.1	1.5	2.0	0.1	10.7	2.0	0.0	12.0	0.2	0.1	0.4	0.1	10.0	0.1	1.0	1.6	0.3	14.2	0.1	0.1	1.2	0.5	0.1	0.1	0.1	0.3	0.2	1.1	0.1	2.3	1.9	0.1	0.2	0.2	0.1	30.3	0.2	0.9	0.2	0.6	0.6	0.7	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	4.8	1.7	0.0	0.0	4.9	0.2	0.0	0.0	0.0	3.5	0.0	0.0	2.3	0.0	0.0	2.2	0.0	0.0	0.1	2.1	0.0	0.0	9.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	5.4	0.0	7.1	0.6	0.0	0.0	0.1	0.0	16.8	0.2	0.0	0.1	0.2	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.2	1.5	2.0	1.0	1.6	1.2	0.5	1.1	0.7
EFNA5	"AF1, EPLG7, LERK7"	ENSG00000184349	"Ephrin A5"	P52803	5	107376889-107670895	"Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 19.3;RPTEC TERT1: 29.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 3.5;memory CD8 T-cell: 3.0"	"Group enriched"	"Detected in many"	7	"NK-cells: 2.5;T-cells: 3.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013282, HPA054047"	Approved		Approved	Vesicles,Cytosol				"Vesicles, Cytosol"		"CAB013282: AB_2533353, HPA054047: "	"unprognostic (1.67e-1)"	"unprognostic (4.04e-2)"	"unprognostic (7.52e-2)"	"unprognostic (2.15e-3)"	"unprognostic (3.98e-3)"	"unprognostic (2.74e-2)"	"unprognostic (8.91e-4)"	"unprognostic (9.46e-3)"	"unprognostic (4.92e-1)"	"unprognostic (2.28e-3)"	"unprognostic (1.26e-3)"	"unprognostic (1.47e-1)"	"prognostic unfavourable (1.92e-7)"	"prognostic unfavourable (3.77e-4)"	"unprognostic (1.52e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.27e-1)"	5.3	1.9	1.9	2.3	6.0	0.0	7.3	10.1	22.2	15.0	4.2	0.9	2.5	1.2	1.6	2.8	9.1	3.9	3.6	8.3	2.5	5.3	5.3	0.6	7.0	3.2	2.1	8.9	5.5	0.7	6.9	18.5	3.1	4.8	6.2	3.6	3.3	11.2	6.8	1.1	13.3	2.3	2.8	3.5	6.3	3.1	1.8	1.1	0.1	2.5	6.0	3.3	4.0	8.1	0.0	0.0	0.4	0.1	2.5	3.5	0.4	6.2	11.1	19.3	0.0	9.3	8.1	1.8	0.2	3.3	2.4	6.0	0.1	7.0	0.0	10.6	1.2	6.5	10.7	9.2	2.3	0.0	6.5	0.0	6.1	0.0	1.8	0.3	0.0	8.6	8.8	0.0	7.8	7.6	0.0	0.0	4.6	6.0	0.0	0.0	2.3	0.9	0.0	8.7	0.2	29.4	8.1	2.9	7.7	3.0	4.5	1.9	1.9	1.2	0.1	14.6	2.6	8.9	3.5	0.5	0.0	4.0	6.4	0.4	15.7	0.2	0.0	0.1	3.5	0.0	0.0	0.0	0.8	3.0	0.0	0.0	0.3	1.4	0.4	2.5	0.1	0.0	0.1	0.4	1.9	6.0	10.1	22.2	2.5	5.3	2.1	8.9	4.8	1.1
EFNB1	"CFNS, Elk-L, EPLG2, LERK2"	ENSG00000090776	"Ephrin B1"	P98172	X	68828997-68842147	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes, Craniosynostosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 35.4;hTCEpi: 27.6;PC-3: 26.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 7.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB031489, HPA067188"	Uncertain		Supported	"Plasma membrane"		790000	790000	"Plasma membrane"		"CAB031489: AB_631414, HPA067188: "	"unprognostic (2.00e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.77e-2)"	"prognostic unfavourable (3.32e-5)"	"unprognostic (1.04e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.05e-3)"	"unprognostic (2.15e-1)"	"prognostic unfavourable (8.68e-4)"	"unprognostic (3.94e-2)"	"prognostic unfavourable (4.29e-4)"	"unprognostic (1.29e-1)"	"unprognostic (2.17e-3)"	"unprognostic (2.76e-2)"	"unprognostic (8.03e-2)"	"unprognostic (1.72e-3)"	"unprognostic (1.86e-2)"	36.5	13.2	5.0	11.5	4.5	1.3	26.5	2.3	4.7	19.5	21.1	4.7	13.1	14.0	15.2	14.9	17.4	15.2	33.7	16.0	3.6	2.7	25.5	15.3	23.0	5.2	4.7	3.5	21.6	4.5	15.0	6.4	34.3	3.9	15.9	10.1	14.9	7.0	13.2	9.1	26.4	24.0	12.3	2.6	15.3	13.3	7.4	4.2	4.8	11.9	22.0	11.2	16.7	14.8	0.5	7.1	0.6	3.4	1.3	1.0	1.0	3.7	1.9	15.6	5.7	8.3	5.1	8.2	3.2	3.5	1.4	1.0	1.7	6.9	0.9	21.2	1.2	19.8	14.7	35.4	0.8	1.5	3.7	0.9	0.8	3.0	7.6	0.7	8.0	9.5	27.6	3.5	16.0	10.8	1.0	0.0	1.2	3.0	1.5	0.7	10.8	26.2	6.6	1.6	5.9	5.9	13.1	5.8	2.8	2.4	0.7	0.9	0.6	1.3	18.1	2.7	3.3	7.2	1.2	0.0	0.8	0.9	1.3	4.0	1.7	0.0	1.3	0.6	1.0	3.4	0.6	0.5	0.9	0.9	7.1	0.4	0.8	0.4	0.3	1.3	2.1	1.0	0.4	1.0	5.0	4.5	2.3	4.7	3.6	2.7	4.7	3.5	3.9	4.2
EFNB2	"EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228"	ENSG00000125266	"Ephrin B2"	P52799	13	106489731-106535662	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Differentiation, Host-virus interaction, Neurogenesis"	"Developmental protein, Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 49.4;SH-SY5Y: 24.8;U-87 MG: 22.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"NK-cell: 1.5"	"Lineage enhanced"	"Detected in single"		"NK-cells: 1.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008999, CAB009368"	Supported		Supported	Nucleoplasm,Cytosol		760000	760000	Nucleoplasm	Cytosol	"CAB009368: AB_2095700, HPA008999: AB_1078721"	"unprognostic (1.70e-1)"	"unprognostic (1.95e-3)"	"unprognostic (1.72e-1)"	"unprognostic (5.22e-3)"	"unprognostic (4.52e-3)"	"prognostic unfavourable (3.11e-6)"	"unprognostic (2.32e-2)"	"prognostic unfavourable (8.43e-4)"	"unprognostic (2.09e-1)"	"unprognostic (1.11e-1)"	"prognostic unfavourable (8.70e-5)"	"unprognostic (1.60e-1)"	"unprognostic (1.09e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.07e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.27e-3)"	15.7	4.9	11.2	8.2	11.0	0.8	21.8	8.3	14.0	13.2	23.1	5.8	13.1	13.9	10.8	5.2	11.4	13.6	11.2	11.8	10.4	6.5	9.3	11.8	50.1	7.8	6.2	11.5	8.4	3.7	5.7	6.1	27.7	5.2	11.8	18.4	15.2	12.7	20.6	6.6	14.3	20.6	10.5	5.0	9.3	21.3	7.2	5.9	7.3	11.2	8.8	5.9	7.7	12.4	0.2	0.0	0.4	0.0	1.5	0.0	0.0	11.8	1.1	49.4	0.0	0.1	0.4	0.2	5.4	3.4	5.3	3.1	11.9	18.1	0.0	5.2	1.6	14.1	1.8	6.9	5.8	0.0	10.6	0.0	4.1	0.0	1.0	3.9	0.3	2.3	12.4	0.2	10.6	6.7	0.0	0.0	5.8	2.0	0.1	0.0	2.6	2.4	9.9	2.0	0.0	7.6	1.5	3.5	24.8	2.0	1.0	0.0	0.6	0.1	5.2	10.6	0.0	0.3	12.1	0.1	0.0	0.0	22.2	0.2	2.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	1.5	0.0	0.0	0.0	0.0	11.2	11.0	8.3	14.0	10.4	6.5	6.2	11.5	5.2	5.9
EFNB3	"EPLG8, LERK-8"	ENSG00000108947	"Ephrin B3"	Q15768	17	7705202-7711378	"Cancer-related genes, Predicted membrane proteins"	"Differentiation, Host-virus interaction, Neurogenesis"	"Developmental protein, Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 34.6"	"Cell line enhanced"	"Detected in many"		"AF22: 30.7;AN3-CA: 18.2;SH-SY5Y: 16.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA001623	Approved									"HPA001623: AB_1848026"	"unprognostic (5.17e-2)"	"unprognostic (7.15e-2)"	"unprognostic (6.08e-2)"	"prognostic unfavourable (5.52e-4)"	"unprognostic (3.27e-1)"	"unprognostic (1.62e-2)"	"unprognostic (5.63e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.14e-1)"	"prognostic favourable (8.21e-4)"	"unprognostic (3.71e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.56e-2)"	"unprognostic (3.00e-1)"	"unprognostic (8.56e-2)"	"unprognostic (2.20e-2)"	1.7	2.8	10.6	1.1	26.5	0.4	4.3	1.1	34.6	4.8	1.0	4.0	0.0	0.8	12.3	1.0	2.2	6.7	1.8	1.1	10.9	19.0	1.4	2.3	1.5	0.7	3.0	11.8	3.2	1.8	1.1	3.0	1.8	4.3	2.7	1.1	1.4	1.7	1.0	0.8	6.9	1.0	4.7	1.3	0.5	1.3	2.1	2.1	0.0	1.2	0.1	1.4	2.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	30.7	18.2	0.6	0.4	0.2	0.3	4.0	2.7	1.8	1.1	1.9	0.0	0.6	1.1	0.2	7.8	3.8	1.6	0.0	3.8	0.1	0.0	0.0	0.9	0.0	0.0	1.8	0.8	0.8	0.6	0.2	0.0	0.0	0.5	2.9	0.0	0.0	2.7	0.6	0.1	0.1	0.0	4.2	0.4	1.9	16.1	0.0	0.0	0.6	1.6	0.0	0.0	1.8	6.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	10.6	26.5	1.1	26.3	10.9	19.0	3.0	11.8	4.3	2.1
EGF		ENSG00000138798	"Epidermal growth factor"	P01133	4	109912884-110012266	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"kidney: 48.4;pancreas: 41.2;skeletal muscle: 19.8"	"Cell line enhanced"	"Detected in some"		"EFO-21: 8.0;SK-BR-3: 14.6;U-251 MG: 4.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 1.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in single"									25000	25000				"unprognostic (2.83e-2)"	"unprognostic (1.02e-2)"	"unprognostic (8.50e-3)"	"unprognostic (1.88e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.64e-3)"	"unprognostic (5.06e-4)"	"unprognostic (8.30e-2)"	"unprognostic (2.21e-3)"	"unprognostic (4.25e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.95e-1)"	"unprognostic (7.72e-3)"	"unprognostic (4.64e-5)"	"unprognostic (2.63e-1)"	"unprognostic (9.80e-5)"	"unprognostic (3.92e-3)"	0.8	0.1	0.4	0.0	0.4	0.0	5.9	0.1	0.9	0.2	0.2	0.3	0.3	0.0	0.3	2.6	0.9	0.2	0.3	2.3	0.8	0.3	48.4	0.0	0.6	0.0	1.2	0.7	0.0	41.2	0.0	0.4	0.0	1.4	0.6	0.4	3.9	8.4	0.1	19.8	0.5	0.2	1.9	0.6	0.2	0.0	0.2	0.2	0.0	1.2	4.5	0.4	0.4	0.5	0.0	0.4	1.7	0.0	0.0	0.0	2.6	0.2	0.3	2.4	0.1	0.0	0.1	0.0	0.6	1.5	0.8	0.5	0.1	0.0	0.0	8.0	0.8	0.0	0.3	0.0	0.6	0.1	0.4	0.1	0.9	1.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.6	0.2	0.8	0.1	0.0	0.0	2.9	0.5	0.2	0.1	0.6	0.6	0.2	0.0	0.0	0.0	14.6	0.5	3.5	0.0	0.0	1.2	2.0	0.0	4.6	0.0	0.0	0.0	1.4	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.4	0.0	2.6	0.4	0.4	0.1	0.9	0.8	0.3	1.2	0.7	1.4	0.2
EGFR	"ERBB, ERBB1"	ENSG00000146648	"Epidermal growth factor receptor"	P00533	7	55019021-55211628	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Host-virus interaction"	"Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 102.3"	"Cell line enriched"	"Detected in many"	12	"A-431: 337.7"	"Cancer enhanced"	"Detected in all"		"glioma: 136.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534"	Enhanced		Enhanced	"Plasma membrane,Cell Junctions"	"Secreted to blood"	93000000	93000000	"Plasma membrane, Cell Junctions"		"CAB000035: , CAB068186: , CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044"	"unprognostic (2.62e-2)"	"unprognostic (9.56e-3)"	"unprognostic (1.59e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.27e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.88e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.30e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.98e-3)"	"unprognostic (1.72e-1)"	"unprognostic (6.62e-2)"	"prognostic unfavourable (2.04e-5)"	16.2	8.4	4.9	7.5	6.8	0.1	39.8	5.1	8.5	13.8	7.8	3.3	10.7	3.6	8.2	11.7	15.6	8.8	8.5	4.8	6.8	2.7	7.6	23.5	14.2	2.3	4.1	3.9	10.4	10.1	1.8	2.1	102.3	5.6	10.9	6.7	9.2	15.4	12.9	10.7	32.5	6.3	15.5	3.5	3.3	7.8	5.5	5.9	3.2	12.8	15.5	8.0	10.2	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	337.7	4.3	1.1	1.5	6.9	4.3	1.1	3.3	4.5	2.0	1.6	0.8	3.7	0.2	0.8	2.8	13.5	0.0	14.9	2.5	0.1	0.2	0.0	1.8	0.2	1.8	0.0	0.0	2.1	13.7	5.2	27.9	0.2	0.0	0.0	4.4	0.2	0.0	0.0	0.3	2.2	0.0	0.6	0.0	2.5	3.6	0.0	1.3	2.8	3.4	0.6	0.3	0.7	1.0	1.9	0.5	14.6	3.1	0.0	0.3	0.1	2.5	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	6.8	5.1	6.6	6.8	2.7	4.1	3.9	5.6	5.9
EGR1	"AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268, ZNF225"	ENSG00000120738	"Early growth response 1"	P18146	5	138465490-138469315	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 39.2;hTCEpi: 57.1;U-266/84: 86.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"classical monocyte: 3.5;intermediate monocyte: 5.1;neutrophil: 9.9"	"Group enriched"	"Detected in many"	8	"granulocytes: 9.9;monocytes: 5.1"	"Group enriched"	"Detected in all"	6	"amygdala: 88.4;basal ganglia: 148.1;cerebral cortex: 237.4;hippocampal formation: 138.8;olfactory region: 126.1"	"Low region specificity"	"Detected in all"			"CAB019427, HPA029937, HPA029938"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB019427: AB_2097038, HPA029937: , HPA029938: "	"unprognostic (5.47e-2)"	"unprognostic (4.09e-1)"	"unprognostic (1.57e-1)"	"unprognostic (7.74e-2)"	"unprognostic (6.32e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.96e-1)"	"unprognostic (7.36e-2)"	"unprognostic (2.97e-3)"	"unprognostic (1.75e-1)"	"unprognostic (2.94e-2)"	"unprognostic (3.51e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.98e-3)"	78.7	47.9	5.5	114.3	23.3	18.3	28.7	23.7	25.0	61.8	40.5	31.6	8.0	6.8	51.7	15.6	47.2	187.3	158.4	42.9	7.0	8.1	22.0	68.8	39.7	18.6	4.9	7.0	130.9	23.0	15.8	43.3	24.3	17.8	45.2	21.7	56.1	18.7	100.5	19.4	54.2	29.8	60.8	4.4	8.8	46.1	14.7	2.8	19.4	76.6	67.5	26.6	43.2	20.3	0.9	0.9	9.9	5.1	0.1	0.2	0.4	4.1	0.1	8.9	13.2	24.2	39.2	1.0	7.1	4.4	9.6	7.8	5.0	3.6	0.2	1.1	15.4	1.9	0.5	14.4	4.4	0.2	0.6	0.5	1.7	1.4	3.1	1.5	11.4	3.0	57.1	8.5	1.9	0.8	20.9	5.1	2.8	20.5	0.6	6.4	0.8	0.0	0.1	1.3	0.7	7.3	2.5	11.2	1.2	8.6	23.9	18.5	0.3	1.2	0.3	3.5	4.5	1.7	2.7	11.9	86.2	1.7	4.0	19.6	1.0	0.0	3.5	0.4	0.2	5.1	0.0	0.9	0.1	0.1	0.9	0.3	0.2	0.2	9.9	0.1	1.4	0.0	0.2	0.4	5.5	23.3	23.7	25.0	7.0	8.1	4.9	7.0	17.8	2.8
EI24	"EPG4, PIG8, TP53I8"	ENSG00000149547	"EI24, autophagy associated transmembrane protein"	O14681	11	125569216-125584687	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Autophagy"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 164.6"	"Cell line enhanced"	"Detected in all"		"HEL: 117.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047165, HPA051029"	Approved		Supported	"Endoplasmic reticulum,Golgi apparatus,Cytosol"				"Endoplasmic reticulum, Cytosol"	"Golgi apparatus"	"HPA047165: AB_2679965, HPA051029: AB_2681317"	"unprognostic (2.04e-3)"	"unprognostic (2.69e-2)"	"unprognostic (1.25e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.78e-2)"	"unprognostic (5.02e-2)"	"unprognostic (6.38e-2)"	"unprognostic (6.74e-2)"	"unprognostic (1.17e-2)"	"prognostic unfavourable (9.28e-4)"	"unprognostic (3.50e-2)"	"unprognostic (1.35e-1)"	"unprognostic (4.58e-2)"	"unprognostic (8.35e-2)"	"unprognostic (2.07e-1)"	"unprognostic (3.01e-1)"	13.4	10.2	13.3	8.9	16.2	4.6	16.7	11.2	22.1	12.7	17.0	14.4	13.8	11.3	13.6	12.9	22.7	12.1	15.8	16.4	10.6	10.7	14.6	55.5	12.1	11.2	12.0	11.1	13.1	34.2	164.6	9.2	11.9	11.0	13.7	18.9	13.2	20.9	14.3	26.5	17.2	16.1	15.9	9.2	10.5	17.7	10.4	10.5	9.9	12.0	14.2	13.0	16.2	12.9	8.5	15.5	5.4	7.3	6.5	10.0	4.9	24.5	18.7	21.4	25.8	35.2	26.8	26.8	25.2	19.1	17.4	15.7	28.4	49.6	24.7	42.9	23.7	28.4	32.5	53.0	22.6	6.5	20.6	117.8	13.4	26.6	26.2	26.5	12.8	25.0	48.6	26.1	38.6	36.7	53.4	10.1	24.4	17.3	12.1	13.6	28.2	20.5	17.8	25.3	21.0	29.0	44.0	20.0	19.2	29.5	35.2	9.5	71.9	26.5	30.5	22.4	15.2	15.6	20.3	6.3	12.7	32.2	9.8	40.8	29.8	4.1	7.3	5.4	8.2	7.0	8.1	8.5	6.5	10.0	11.6	7.3	9.4	7.6	0.9	6.5	5.1	15.5	9.0	4.9	13.3	16.2	11.2	22.1	10.6	10.7	12.0	11.1	11.0	10.5
EIF2S2	"EIF2, EIF2beta, PPP1R67"	ENSG00000125977	"Eukaryotic translation initiation factor 2 subunit beta"	P20042	20	34088298-34112332	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034415, HPA041262, HPA041332"	Approved		Supported	"Nucleoli,Endoplasmic reticulum"				"Endoplasmic reticulum"	Nucleoli	"CAB034415: AB_2095998, HPA041262: , HPA041332: "	"unprognostic (5.76e-3)"	"unprognostic (7.12e-2)"	"unprognostic (2.66e-2)"	"prognostic unfavourable (8.74e-4)"	"unprognostic (1.02e-1)"	"unprognostic (1.47e-3)"	"prognostic unfavourable (3.23e-5)"	"unprognostic (9.36e-3)"	"unprognostic (2.39e-1)"	"unprognostic (6.55e-3)"	"unprognostic (3.04e-3)"	"unprognostic (1.25e-2)"	"prognostic unfavourable (9.64e-10)"	"unprognostic (2.52e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.12e-2)"	25.9	30.1	32.8	23.3	40.7	21.4	38.1	20.2	37.7	21.1	24.3	10.9	27.1	21.2	21.2	22.4	36.3	17.0	18.3	36.3	30.1	20.4	22.0	40.1	27.2	37.7	40.0	26.2	19.9	45.4	18.7	22.4	29.9	35.8	20.4	24.7	7.4	26.3	25.5	101.8	21.2	20.4	37.0	50.2	23.0	28.1	19.6	35.6	18.2	24.1	32.7	30.1	25.0	30.7	38.8	48.5	28.1	39.3	32.4	42.4	27.3	38.9	26.2	19.9	24.0	19.5	29.7	38.0	35.7	34.3	35.6	36.0	92.0	27.4	35.0	26.3	32.2	36.9	32.3	58.7	43.3	11.2	17.6	69.3	21.6	47.0	50.4	44.3	22.6	30.3	50.1	35.2	52.7	37.2	40.6	33.5	29.2	25.0	41.0	37.0	19.3	47.9	23.7	33.9	32.3	28.1	32.7	20.3	13.8	39.5	24.0	73.2	36.3	52.5	25.0	40.8	25.1	25.5	33.4	31.5	27.7	36.5	38.3	34.5	29.5	21.2	37.0	28.1	26.9	39.3	32.9	38.8	38.2	37.6	34.7	31.8	36.4	36.5	21.9	32.4	35.6	48.5	42.4	27.3	32.8	40.7	20.2	37.7	30.1	20.4	40.0	26.2	35.8	35.6
EIF3E	"eIF3-p48, eIF3e, EIF3S6, INT6"	ENSG00000104408	"Eukaryotic translation initiation factor 3 subunit E"	P60228	8	108201216-108435333	"Cancer-related genes, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023973	Approved		Supported	Cytosol				Cytosol		"HPA023973: AB_1848083"	"unprognostic (8.18e-2)"	"unprognostic (4.28e-2)"	"unprognostic (6.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.52e-3)"	"unprognostic (6.93e-3)"	"unprognostic (2.29e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.47e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.67e-3)"	"unprognostic (3.63e-1)"	"prognostic unfavourable (3.06e-7)"	"unprognostic (2.46e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.77e-2)"	88.2	44.0	27.6	49.2	38.2	57.8	75.1	41.5	25.2	101.6	73.6	14.6	47.2	34.4	55.5	47.6	111.2	45.4	41.0	39.5	23.9	22.4	51.8	63.6	60.3	75.3	33.0	19.5	127.6	90.2	29.2	72.5	54.6	28.9	100.1	40.3	22.8	56.9	45.5	100.4	46.7	56.3	73.7	38.4	63.9	49.7	52.7	31.5	100.5	93.8	70.8	50.7	121.7	69.2	49.0	51.7	14.0	39.5	38.7	78.1	59.4	62.0	30.6	41.0	50.7	69.9	147.9	28.0	32.4	50.6	48.2	50.4	38.3	62.5	106.9	42.6	36.4	38.6	54.0	63.6	64.2	42.0	55.0	85.3	32.4	54.6	56.0	50.8	40.0	111.7	94.1	36.4	101.0	73.3	71.8	44.4	54.2	61.3	65.8	96.3	40.9	48.9	61.2	50.8	83.2	63.0	37.4	46.4	42.3	18.2	15.4	72.2	65.5	73.7	46.5	28.2	48.7	29.2	40.7	33.5	25.0	61.2	34.9	88.8	31.4	14.0	39.5	7.4	26.6	36.2	52.0	49.0	52.6	37.7	51.7	40.4	78.1	56.1	3.7	38.7	33.6	27.3	45.2	59.4	27.6	38.2	41.5	25.2	23.9	22.4	33.0	19.5	28.9	31.5
EIF3H	"eIF3-gamma, eIF3-p40, eIF3h, EIF3S3"	ENSG00000147677	"Eukaryotic translation initiation factor 3 subunit H"	O15372	8	116642130-116766925	"Cancer-related genes, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 201.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023117, HPA023553"	Approved		Approved	Cytosol		3300000	3300000	Cytosol		"HPA023117: AB_1848076, HPA023553: AB_1848077"	"prognostic unfavourable (5.26e-4)"	"prognostic unfavourable (8.07e-4)"	"unprognostic (1.81e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.69e-2)"	"unprognostic (1.11e-2)"	"prognostic unfavourable (8.34e-4)"	"unprognostic (3.63e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.12e-3)"	"unprognostic (3.08e-1)"	"unprognostic (3.77e-2)"	"unprognostic (6.36e-2)"	"unprognostic (1.48e-1)"	"unprognostic (9.19e-2)"	"unprognostic (1.11e-1)"	63.1	41.3	39.4	41.3	47.6	65.8	56.8	39.5	39.9	69.2	52.8	35.1	30.8	38.8	53.1	43.6	80.9	49.7	36.4	52.9	33.2	33.0	53.4	55.6	44.2	58.0	38.6	26.7	96.0	65.4	37.6	52.6	52.0	40.1	77.1	47.0	34.9	51.5	38.5	94.6	44.8	56.2	68.3	45.4	56.0	46.3	44.9	31.6	90.0	72.3	59.3	74.7	83.7	57.6	69.1	73.6	21.6	55.3	47.1	88.5	76.7	48.4	28.0	33.8	29.4	44.7	78.5	33.7	32.1	41.5	35.6	34.7	28.9	57.5	77.6	32.6	33.4	31.3	37.1	48.8	44.9	50.2	30.1	68.5	25.1	43.0	56.0	29.5	36.6	72.2	68.0	32.1	74.7	38.5	57.8	41.1	39.9	36.0	82.1	41.5	34.4	44.8	47.6	22.6	55.0	53.4	35.7	38.4	46.5	16.8	201.6	53.5	59.8	59.6	35.3	22.8	42.6	33.7	41.9	66.5	59.9	64.1	31.7	52.3	31.1	21.6	55.3	19.8	36.7	54.8	60.3	69.1	66.5	53.1	73.6	59.1	88.5	71.9	12.0	47.1	53.3	41.1	73.2	76.7	39.4	47.6	39.5	39.9	33.2	33.0	38.6	26.7	40.1	31.6
EIF4A2	"BM-010, DDX2B, EIF4A, EIF4F"	ENSG00000156976	"Eukaryotic translation initiation factor 4A2"	Q14240	3	186783205-186789900	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Protein biosynthesis"	"Helicase, Hydrolase, Initiation factor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"EFO-21: 106.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB011690, HPA068286"	Uncertain		Approved	Cytosol		1000000	1000000	Cytosol		"CAB011690: AB_732123, HPA068286: "	"unprognostic (1.49e-1)"	"unprognostic (9.62e-2)"	"unprognostic (3.78e-2)"	"unprognostic (9.50e-3)"	"unprognostic (2.82e-2)"	"unprognostic (1.10e-2)"	"unprognostic (4.46e-2)"	"unprognostic (6.27e-2)"	"unprognostic (4.32e-3)"	"unprognostic (1.00e-1)"	"unprognostic (6.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (6.36e-2)"	"unprognostic (3.22e-1)"	"unprognostic (3.03e-1)"	"unprognostic (4.67e-2)"	"unprognostic (2.62e-2)"	34.6	66.1	61.2	27.7	79.9	1.9	53.5	121.1	111.5	65.1	52.1	26.5	30.1	30.3	73.1	45.5	44.5	73.9	45.1	83.7	58.4	71.9	63.9	43.5	33.7	36.1	48.9	61.7	142.0	59.0	30.9	84.1	47.3	69.6	57.9	40.1	31.8	43.7	62.8	126.7	19.8	35.6	57.1	41.9	32.5	39.0	32.9	39.5	23.9	67.8	36.4	35.4	61.1	51.7	55.1	19.3	39.4	24.8	33.0	63.4	51.3	10.5	5.3	22.3	3.6	85.9	81.0	6.8	19.0	17.2	20.2	26.6	19.6	3.8	23.6	106.5	27.3	17.8	32.7	8.0	35.6	22.0	17.2	38.0	7.1	26.3	33.7	8.0	26.7	54.2	38.5	5.8	48.6	35.8	12.8	39.8	65.6	1.8	12.7	3.9	22.1	25.5	16.3	15.8	14.3	40.0	12.9	43.9	8.8	30.9	21.3	40.4	33.2	29.3	26.1	16.0	8.0	15.4	11.6	31.7	44.8	10.8	11.0	8.4	7.5	39.4	16.0	18.5	28.5	18.2	45.3	55.1	41.9	34.8	19.3	46.1	63.4	50.2	11.0	33.0	24.8	17.4	38.6	51.3	61.2	79.9	121.1	111.5	58.4	71.9	48.9	61.7	69.6	39.5
EIF4E	"EIF4E1, EIF4EL1, EIF4F"	ENSG00000151247	"Eukaryotic translation initiation factor 4E"	P06730	4	98871684-98930637	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Protein biosynthesis, Translation regulation"	"Initiation factor, RNA-binding"	"Autism, Autism spectrum disorder, Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB004077, CAB016316, HPA051311"	Supported		Enhanced	"Cytosol,Cytoplasmic bodies"		580000	580000	"Cytosol, Cytoplasmic bodies"		"CAB004077: AB_823488, CAB016316: AB_627502, HPA051311: "	"unprognostic (3.07e-3)"	"unprognostic (1.43e-1)"	"unprognostic (6.53e-3)"	"unprognostic (7.52e-2)"	"unprognostic (1.41e-1)"	"unprognostic (2.43e-3)"	"unprognostic (2.03e-5)"	"unprognostic (6.55e-3)"	"unprognostic (1.09e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.10e-3)"	"unprognostic (5.40e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.31e-2)"	"unprognostic (1.28e-1)"	22.3	26.8	25.7	20.1	35.3	25.2	23.1	40.8	38.4	21.4	27.2	23.3	19.1	19.8	21.7	21.4	39.6	19.9	18.8	23.0	26.0	29.9	29.3	26.2	18.8	24.4	27.7	28.4	18.8	16.1	24.7	25.6	21.8	35.3	19.9	33.2	15.4	23.2	21.0	29.8	19.1	19.5	24.8	31.0	19.4	20.6	39.1	23.4	22.4	33.4	27.1	34.2	22.1	24.2	31.3	25.4	36.6	32.0	32.6	32.2	30.0	25.6	22.5	38.4	25.5	21.9	23.0	23.0	48.9	30.7	40.5	30.5	30.2	32.5	52.0	15.8	30.0	13.0	52.8	36.8	49.5	34.3	15.3	35.4	15.7	27.5	18.8	50.8	26.8	16.4	23.5	31.2	24.7	31.1	58.8	24.3	35.8	22.0	47.0	19.7	30.2	21.0	29.7	26.0	23.1	35.7	22.9	32.5	21.4	22.8	48.4	15.8	23.6	20.1	22.8	29.3	31.5	26.3	39.4	18.2	46.1	47.0	26.1	26.1	33.1	23.3	22.3	36.6	26.3	25.9	30.5	31.3	29.2	27.0	25.4	26.9	32.2	31.9	16.2	32.6	32.0	21.4	28.7	30.0	25.7	35.3	40.8	38.4	26.0	29.9	27.7	28.4	35.3	23.4
EIF4EBP1	"4E-BP1, PHAS-I"	ENSG00000187840	"Eukaryotic translation initiation factor 4E binding protein 1"	Q13541	8	38030341-38060365	"Cancer-related genes, Predicted intracellular proteins"	"Translation regulation"	"Protein synthesis inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 94.7;salivary gland: 109.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 53.5;eosinophil: 31.3;intermediate monocyte: 41.2;memory B-cell: 16.3;myeloid DC: 41.3;naive B-cell: 13.5;non-classical monocyte: 31.4;plasmacytoid DC: 31.3"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB005032, CAB005039, HPA023501"	Supported		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB005032: AB_562030, CAB005039: AB_562029, HPA023501: AB_1848095"	"unprognostic (1.55e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (8.86e-4)"	"unprognostic (6.94e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.94e-2)"	"unprognostic (3.27e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.16e-2)"	"unprognostic (3.18e-3)"	"unprognostic (7.21e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (7.98e-2)"	"unprognostic (3.01e-1)"	"unprognostic (4.57e-2)"	"unprognostic (5.72e-3)"	17.7	3.4	2.5	4.9	3.6	9.2	21.7	1.8	3.2	5.5	15.4	2.0	7.7	6.2	5.3	2.1	22.2	5.0	7.0	9.4	2.2	1.8	6.0	39.6	6.9	7.4	4.3	1.4	9.3	94.7	1.7	2.2	8.7	2.8	7.4	4.6	2.8	109.8	8.0	38.4	4.9	9.0	7.1	4.2	9.3	10.6	3.0	2.7	2.7	3.7	12.6	9.2	11.3	11.1	16.3	41.3	31.3	53.5	4.0	7.6	28.0	20.4	10.6	3.1	18.4	4.0	3.5	13.6	22.7	10.6	12.3	19.7	7.0	5.3	8.0	15.9	11.3	10.9	10.3	18.5	7.3	6.1	33.5	46.8	4.7	9.6	41.8	15.1	7.5	9.8	30.2	13.6	25.5	19.7	25.5	21.4	5.1	12.8	13.2	36.8	22.9	42.7	11.6	13.0	28.2	4.6	2.0	43.2	32.8	4.6	7.5	53.4	10.0	17.8	18.5	7.4	24.3	21.9	17.2	30.8	16.7	9.2	17.3	26.8	16.0	5.1	53.5	31.3	3.9	41.2	3.5	16.3	4.5	4.0	41.3	13.5	3.6	3.6	4.7	4.0	31.4	31.3	7.6	28.0	2.5	3.6	1.8	3.2	2.2	1.8	4.3	1.4	2.8	2.7
EIF4G1	"EIF4F, EIF4G, p220, PARK18"	ENSG00000114867	"Eukaryotic translation initiation factor 4 gamma 1"	Q04637	3	184314495-184335358	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Protein biosynthesis, Translation regulation"	"Initiation factor, RNA-binding, Translational shunt"	"Cancer-related genes, Disease mutation, Neurodegeneration, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB014774, HPA028487, HPA043866"	Approved		Enhanced	Cytosol		17000	17000	Cytosol		"CAB014774: , HPA028487: AB_10602219, HPA043866: "	"unprognostic (4.14e-3)"	"unprognostic (2.10e-2)"	"unprognostic (6.01e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.25e-1)"	"unprognostic (2.41e-3)"	"prognostic unfavourable (7.99e-4)"	"unprognostic (4.27e-3)"	"unprognostic (2.35e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.55e-3)"	"unprognostic (7.06e-3)"	"unprognostic (2.42e-1)"	"unprognostic (7.15e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.31e-1)"	"unprognostic (2.33e-3)"	30.2	33.1	18.3	26.4	18.9	26.3	30.3	18.0	23.2	24.1	25.2	19.6	33.6	21.9	24.5	30.5	45.2	20.9	31.1	33.0	16.9	16.9	40.6	108.0	26.0	21.0	19.4	15.9	29.3	46.4	47.5	21.9	34.6	18.3	24.0	21.8	19.9	31.4	34.1	103.7	39.0	31.6	26.8	15.7	33.1	27.1	30.8	18.0	25.8	30.0	46.2	34.3	28.6	27.6	8.8	15.9	5.5	17.0	8.1	11.4	9.1	90.2	37.9	31.8	36.1	35.5	35.1	55.1	49.8	35.2	55.4	42.2	80.3	29.5	57.8	66.4	61.8	48.9	54.9	61.1	43.2	61.0	57.7	52.2	38.8	35.5	30.8	52.2	36.6	35.4	35.6	50.4	48.2	48.3	37.9	45.8	36.6	67.1	35.4	18.8	62.6	30.7	36.4	31.3	46.3	29.3	55.1	33.4	29.7	42.5	70.4	33.8	75.0	37.4	60.4	39.4	39.8	51.5	93.3	35.7	43.1	106.8	44.3	45.9	43.0	4.8	13.6	5.5	11.4	13.9	11.0	7.6	7.7	9.2	12.2	8.8	7.1	7.0	5.1	8.1	17.0	15.9	5.4	9.1	18.3	18.9	18.0	23.2	16.9	16.9	19.4	15.9	18.3	18.0
EIF4H	"KIAA0038, WBSCR1, WSCR1"	ENSG00000106682	"Eukaryotic translation initiation factor 4H"	Q15056	7	74174245-74197101	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Protein biosynthesis"	"Initiation factor, RNA-binding"	"Cancer-related genes, Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030542	Approved		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"		520000	520000	"Nucleoplasm, Nuclear bodies, Cytosol"		"HPA030542: AB_10601368"	"unprognostic (2.83e-1)"	"unprognostic (9.50e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.50e-2)"	"prognostic unfavourable (3.89e-4)"	"prognostic unfavourable (2.15e-4)"	"unprognostic (1.61e-2)"	"unprognostic (2.72e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.99e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.07e-2)"	"unprognostic (3.04e-1)"	"unprognostic (2.23e-1)"	"unprognostic (5.68e-2)"	"unprognostic (1.27e-2)"	46.8	42.7	47.6	37.6	52.8	82.3	42.8	56.0	89.5	39.8	44.5	46.6	36.2	43.1	48.1	37.9	58.6	44.4	40.7	47.4	45.6	41.4	34.5	50.7	37.4	42.8	45.4	54.6	54.2	74.3	54.3	30.1	72.2	47.6	44.8	35.1	35.6	60.3	45.4	89.6	53.0	41.5	43.4	59.9	34.6	45.4	52.5	32.1	46.8	43.5	57.9	44.2	43.4	41.4	38.4	57.6	60.2	64.2	46.7	52.0	80.6	86.2	57.5	43.9	53.2	39.1	41.7	49.9	61.7	46.9	51.1	50.3	70.4	66.5	74.1	16.9	56.9	45.8	48.3	82.0	48.4	49.8	56.6	41.3	54.0	56.5	44.8	69.6	41.7	48.7	52.1	56.7	80.8	55.9	72.5	32.2	52.3	73.6	54.9	82.6	58.5	56.9	64.4	58.8	66.9	42.5	55.2	44.6	56.4	57.5	72.7	48.9	82.2	45.1	58.2	73.3	49.8	61.2	77.5	38.3	45.7	126.5	57.3	73.1	75.2	45.7	58.4	60.2	43.5	64.2	44.9	38.4	44.7	43.0	57.6	35.3	52.0	42.4	39.0	46.7	63.6	24.4	47.6	80.6	47.6	52.8	56.0	89.5	45.6	41.4	45.4	54.6	47.6	32.1
EIF5A	"EIF-5A, EIF5A1, MGC104255, MGC99547"	ENSG00000132507	"Eukaryotic translation initiation factor 5A"	P63241	17	7306999-7312463	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"mRNA transport, Protein biosynthesis, Protein transport, Translocation, Transport"	"Elongation factor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB005042, HPA061298"	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB005042: AB_562281, HPA061298: "	"unprognostic (3.72e-1)"	"unprognostic (1.67e-1)"	"unprognostic (8.10e-2)"	"unprognostic (2.80e-1)"	"unprognostic (6.95e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.06e-2)"	"prognostic unfavourable (9.04e-4)"	"unprognostic (4.10e-1)"	"unprognostic (4.11e-2)"	"unprognostic (1.64e-2)"	"unprognostic (8.25e-2)"	"prognostic unfavourable (1.63e-5)"	"unprognostic (3.53e-1)"	"unprognostic (2.79e-1)"	"unprognostic (6.01e-2)"	"unprognostic (7.65e-2)"	69.0	55.6	37.9	57.0	40.4	83.1	44.5	35.0	59.8	44.6	54.8	37.5	39.8	47.4	47.2	45.5	107.0	38.1	52.9	55.8	35.6	33.6	58.5	192.9	46.6	67.2	34.3	35.9	50.3	126.0	26.0	34.1	73.9	34.0	38.0	57.2	40.7	87.7	40.7	100.6	71.1	49.0	45.4	29.5	65.5	42.9	56.8	24.2	77.9	57.9	105.4	79.0	48.6	50.7	64.7	87.7	44.4	75.7	75.2	79.3	64.3	133.0	166.1	51.2	102.5	39.6	51.0	72.0	100.5	66.3	135.9	95.1	99.3	56.8	129.0	65.1	77.2	91.0	111.3	129.5	123.7	71.7	161.6	77.6	137.6	127.2	70.2	58.9	80.3	54.1	68.0	100.3	136.3	87.2	106.7	36.1	91.9	82.5	69.2	85.2	97.2	82.0	68.5	62.3	118.9	82.0	74.0	59.6	77.5	64.4	78.5	62.2	62.1	45.4	81.7	95.8	69.0	63.6	158.7	30.4	41.5	83.4	90.6	88.7	109.1	44.4	56.0	38.9	65.1	75.7	79.3	64.7	67.1	57.7	85.8	62.6	62.3	62.6	25.1	75.2	68.6	87.7	58.9	64.3	37.9	40.4	35.0	59.8	35.6	33.6	34.3	35.9	34.0	24.2
ELANE	"ELA2, HLE, HNE, NE"	ENSG00000197561	"Elastase, neutrophil expressed"	P08246	19	851014-856247	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"bone marrow: 244.3"	"Cell line enriched"	"Detected in some"	65	"THP-1: 193.2"	"Group enriched"	"Detected in some"	7	"pancreatic cancer: 3.5;stomach cancer: 3.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"classical monocyte: 3.2;neutrophil: 6.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 6.9;monocytes: 3.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB015409, HPA066836"	Enhanced				"Secreted to blood"	59000	59000			"CAB015409: AB_831596, HPA066836: "	"unprognostic (3.46e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.42e-3)"	"unprognostic (2.09e-2)"	"unprognostic (1.80e-3)"	"unprognostic (3.43e-2)"	"unprognostic (3.92e-1)"	"unprognostic (6.38e-3)"	"unprognostic (5.80e-1)"	"unprognostic (2.54e-2)"	"unprognostic (4.06e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.19e-10)"	"unprognostic (6.27e-3)"	"unprognostic (4.00e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.75e-3)"	1.5	0.3	0.1	0.3	0.1	244.3	1.6	0.2	0.6	0.3	0.6	0.7	0.0	0.3	0.3	0.7	0.5	0.6	0.8	31.2	0.0	0.0	0.3	1.5	17.8	1.6	0.0	0.0	0.3	1.8	0.3	0.4	4.7	0.5	1.4	0.3	1.0	0.7	0.3	1.1	2.1	0.5	0.5	0.0	22.5	0.5	0.3	0.0	23.0	2.3	0.9	0.3	1.0	0.2	0.0	0.0	6.9	3.2	0.0	0.5	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	193.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	3.2	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	11.2	0.1	0.1	0.2	0.6	0.0	0.0	0.0	0.0	0.5	0.0
ELF3	"EPR-1, ERT, ESE-1, ESX"	ENSG00000163435	"E74 like ETS transcription factor 3"	P78545	1	202007945-202017188	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Inflammatory response, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 100.8"	"Cell line enhanced"	"Detected in some"		"A549: 40.4;CAPAN-2: 57.6;RT4: 41.4;SK-BR-3: 79.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.0"	"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA003316, HPA003479"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA003316: AB_1078757, HPA003479: AB_1078756"	"unprognostic (9.90e-3)"	"unprognostic (1.72e-1)"	"unprognostic (7.50e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.96e-3)"	"unprognostic (3.88e-2)"	"unprognostic (1.38e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.69e-1)"	"unprognostic (5.05e-3)"	"unprognostic (7.67e-3)"	"unprognostic (7.07e-2)"	"unprognostic (9.92e-3)"	"unprognostic (4.03e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.85e-1)"	"unprognostic (3.37e-3)"	0.3	0.1	0.1	16.0	0.2	0.0	34.0	0.2	0.2	13.2	80.7	0.2	12.5	34.4	3.8	8.9	59.3	8.6	67.7	1.1	0.1	0.1	38.1	33.3	24.6	0.1	0.1	0.1	5.8	38.4	1.1	1.7	16.7	0.3	39.9	31.3	0.7	37.9	11.3	0.7	3.5	100.8	9.5	0.3	0.2	29.9	1.9	0.1	0.6	5.7	25.5	43.5	44.7	22.7	0.3	0.8	2.0	0.3	0.2	0.3	0.0	10.5	40.4	0.0	0.0	0.0	0.0	12.6	0.0	1.5	0.0	0.0	9.0	57.6	0.0	4.7	0.0	10.5	0.0	0.0	0.0	1.2	0.0	0.0	7.3	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6	0.0	0.1	0.6	3.4	0.0	0.0	0.5	15.3	41.4	0.0	0.0	0.4	79.9	0.0	5.6	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.7	0.0	0.0	0.0	0.0	0.8	0.3	0.2	0.2	0.1	0.3	0.1	0.1	0.1	0.8	0.3	0.2	0.1	2.0	0.2	0.3	0.2	0.0	0.0	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.3	0.1
ELF4	"ELFR, MEF"	ENSG00000102034	"E74 like ETS transcription factor 4"	Q99607	X	130064874-130110716	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA058595, HPA060277"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"				"Nuclear bodies"	Nucleoplasm	"HPA058595: , HPA060277: "	"unprognostic (1.33e-1)"	"unprognostic (8.51e-2)"	"unprognostic (3.83e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.43e-3)"	"unprognostic (7.86e-3)"	"unprognostic (3.50e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.29e-2)"	"unprognostic (3.95e-1)"	"prognostic unfavourable (6.49e-6)"	"unprognostic (1.43e-1)"	"unprognostic (5.46e-2)"	"unprognostic (2.51e-1)"	"prognostic favourable (1.42e-4)"	16.9	3.6	2.0	18.1	2.5	27.6	16.9	0.5	3.0	7.7	10.8	3.1	7.0	8.4	10.5	8.1	10.5	9.5	11.0	7.3	3.1	1.2	5.9	2.5	21.9	33.3	3.8	0.9	12.7	4.5	3.8	4.2	23.5	3.0	6.6	10.9	3.6	5.4	7.9	5.7	9.1	16.3	6.4	4.2	18.9	12.3	3.5	2.9	18.1	3.9	7.4	11.5	11.7	14.4	3.9	6.1	9.4	10.3	8.4	10.3	5.1	22.5	8.4	1.5	0.1	3.9	8.4	22.0	10.5	13.4	12.8	14.2	11.6	16.1	11.6	21.1	14.2	14.7	8.4	12.4	12.6	12.4	7.0	22.7	11.2	5.4	8.7	19.8	29.1	8.7	13.9	20.5	20.3	12.3	8.7	3.2	6.9	13.1	3.2	11.3	1.0	8.3	7.0	2.7	4.9	7.8	26.1	5.8	2.5	9.4	9.1	2.9	4.5	19.1	11.4	9.0	7.1	16.7	19.4	1.7	0.7	9.3	10.6	18.2	2.0	1.6	5.4	7.8	10.3	10.3	8.3	3.9	6.2	8.8	6.1	3.5	6.2	7.2	9.4	8.4	7.0	3.7	6.3	5.1	2.0	2.5	0.5	3.0	3.1	1.2	3.8	0.9	3.0	2.9
ELK3	"ERP, NET, SAP2"	ENSG00000111145	"ELK3, ETS transcription factor"	P41970	12	96194382-96269835	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001600	Approved		Supported	Nucleoplasm,Mitochondria				Nucleoplasm	Mitochondria	"HPA001600: AB_1078752"	"unprognostic (3.11e-1)"	"unprognostic (8.81e-3)"	"unprognostic (6.38e-2)"	"unprognostic (5.77e-2)"	"unprognostic (7.18e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.15e-1)"	"unprognostic (5.10e-3)"	"unprognostic (7.39e-2)"	"prognostic unfavourable (4.93e-4)"	"unprognostic (2.29e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.20e-3)"	"unprognostic (2.90e-3)"	"unprognostic (1.61e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.05e-2)"	36.9	9.3	5.0	20.9	6.7	8.3	23.5	12.9	4.5	29.2	12.6	7.3	12.0	4.6	45.2	15.6	25.7	15.0	16.3	15.5	4.8	5.1	13.3	8.2	17.1	20.6	6.1	2.8	13.3	5.8	6.6	6.0	15.9	8.9	18.1	7.5	15.7	14.1	8.6	10.5	8.7	11.1	20.8	13.1	32.7	9.1	8.6	6.3	17.4	19.7	25.1	32.1	15.9	20.9	11.3	9.4	4.1	12.8	10.5	24.1	6.3	12.8	7.7	7.9	4.2	20.2	38.0	2.0	16.4	31.4	13.1	10.1	0.4	9.6	2.0	5.6	18.3	4.6	0.8	26.2	23.1	5.6	3.0	0.6	3.2	2.9	6.1	6.2	1.5	22.3	4.9	26.9	20.4	31.2	1.5	8.6	44.1	1.9	1.2	4.2	9.7	10.3	10.2	13.4	2.3	11.2	3.4	0.4	8.4	5.3	2.4	8.2	1.3	3.4	19.2	36.0	14.1	22.1	14.2	16.6	13.7	0.5	12.7	7.3	24.9	3.3	12.8	0.3	6.2	6.9	24.1	11.3	14.7	8.4	9.4	9.9	8.9	6.5	4.1	10.5	5.9	3.8	23.4	6.3	5.0	6.7	12.9	4.5	4.8	5.1	6.1	2.8	8.9	6.3
ELK4	SAP1	ENSG00000158711	"ELK4, ETS transcription factor"	P28324	1	205597556-205631962	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 8.7"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028863	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA028863: AB_10602492"	"unprognostic (2.08e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.59e-1)"	"unprognostic (2.15e-1)"	"prognostic favourable (4.65e-4)"	"unprognostic (2.97e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.53e-1)"	"unprognostic (1.27e-2)"	"unprognostic (2.64e-1)"	"prognostic unfavourable (2.94e-6)"	"unprognostic (2.21e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.08e-1)"	"unprognostic (5.58e-3)"	14.1	7.1	10.0	14.7	12.7	12.0	13.8	16.2	10.4	10.1	8.9	10.4	8.6	7.3	11.3	9.2	11.7	9.5	11.4	10.8	10.6	5.0	15.2	15.6	13.8	19.1	10.0	6.9	13.1	12.4	13.6	16.8	9.5	9.5	32.6	8.7	12.2	12.4	8.2	14.7	17.6	13.5	10.5	8.2	18.3	9.4	8.4	11.0	24.4	10.8	8.3	19.6	15.1	13.2	2.2	1.5	8.7	1.1	1.2	3.1	0.6	8.2	7.4	2.9	7.6	7.0	9.1	7.5	5.5	5.8	4.4	5.2	3.2	8.3	17.4	5.2	6.9	10.3	6.2	6.8	7.7	19.8	4.4	7.5	12.1	6.7	9.6	14.1	30.1	7.9	8.4	7.0	14.3	18.4	6.9	14.7	6.1	11.1	11.6	5.3	4.9	4.5	8.6	18.2	14.2	5.9	18.0	3.4	4.1	14.3	7.9	9.4	7.3	4.7	13.3	8.9	10.5	7.9	10.5	11.0	10.0	11.8	7.8	5.8	10.4	8.7	0.8	1.2	1.6	1.1	2.1	1.4	1.8	2.1	1.1	2.2	2.2	3.1	0.4	1.2	0.6	1.5	1.8	0.6	10.0	12.7	16.2	10.4	10.6	5.0	10.0	6.9	9.5	11.0
ELL	"C19orf17, ELL1, Men, PPP1R68"	ENSG00000105656	"Elongation factor for RNA polymerase II"	P55199	19	18442663-18522127	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA046076	Uncertain									"HPA046076: "	"unprognostic (9.49e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.26e-3)"	"unprognostic (2.07e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.10e-1)"	"unprognostic (8.26e-2)"	"unprognostic (2.71e-1)"	"unprognostic (2.34e-1)"	"unprognostic (3.00e-2)"	"unprognostic (6.28e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.57e-1)"	"unprognostic (2.07e-1)"	"unprognostic (5.12e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.06e-1)"	19.9	7.7	5.1	13.4	9.9	38.4	10.8	17.0	9.7	11.9	13.5	7.7	8.6	10.4	12.6	9.5	9.3	9.1	10.9	9.5	5.8	4.4	9.8	11.6	14.2	10.7	6.2	3.5	12.7	14.6	6.2	10.5	27.0	6.3	10.4	4.4	9.1	10.6	9.0	20.3	13.3	10.9	10.0	5.1	15.9	9.3	31.7	7.7	11.0	7.8	7.2	13.6	18.5	13.2	3.1	8.6	17.2	5.6	2.1	7.9	3.3	8.8	4.3	2.2	4.8	2.5	3.2	16.8	7.0	6.2	5.3	5.2	4.9	7.0	11.1	8.7	4.6	6.2	3.3	7.7	2.7	9.1	7.9	6.7	4.3	4.3	3.8	7.3	8.6	6.4	6.6	6.9	5.5	3.7	9.3	15.4	2.8	7.5	8.5	8.0	7.6	12.4	7.4	3.7	11.7	3.8	6.2	4.1	4.5	5.1	8.9	7.6	4.5	9.1	6.2	6.2	4.8	8.5	6.5	25.1	15.8	8.3	8.2	12.4	8.8	0.3	5.6	3.8	4.7	4.1	7.9	3.1	2.9	4.2	4.7	2.3	1.9	2.9	17.2	2.1	2.1	8.6	3.0	3.3	5.1	9.9	17.0	9.7	5.8	4.4	6.2	3.5	6.3	7.7
EML4	"C2orf2, ELP120, ROPP120"	ENSG00000143924	"Echinoderm microtubule associated protein like 4"	Q9HC35	2	42169350-42332548	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 60.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036687, HPA036688, HPA065337"	Enhanced		Supported	"Intermediate filaments,Microtubules,Cytosol"		41000	41000	Microtubules	"Intermediate filaments, Cytosol"	"HPA036687: AB_2675251, HPA036688: AB_10671968, HPA065337: AB_2685474"	"unprognostic (1.70e-1)"	"unprognostic (1.38e-1)"	"unprognostic (8.17e-2)"	"unprognostic (3.53e-3)"	"unprognostic (1.79e-2)"	"unprognostic (9.19e-2)"	"unprognostic (8.61e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.96e-3)"	"unprognostic (6.80e-2)"	"unprognostic (7.44e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.13e-2)"	11.3	17.3	5.8	29.3	6.8	19.2	10.5	4.6	5.2	9.4	21.6	6.7	6.8	20.3	13.6	11.6	10.7	8.7	20.3	6.5	5.1	3.9	11.7	26.4	19.3	27.7	4.6	4.0	12.5	37.8	10.8	11.6	26.9	6.5	8.5	12.8	12.1	17.7	8.9	4.3	17.9	33.5	9.2	5.0	30.9	11.7	14.2	5.3	17.4	13.2	6.9	30.0	14.0	9.0	11.5	4.2	10.0	11.0	9.4	17.5	5.9	14.4	25.1	14.6	11.6	5.3	8.8	16.0	9.0	7.1	10.0	9.7	26.2	18.2	13.2	6.2	8.8	7.5	12.6	8.6	17.5	25.8	10.5	12.1	7.8	60.0	6.8	9.1	12.5	9.6	3.3	13.2	9.0	6.9	12.0	13.4	10.7	8.5	8.6	2.4	14.9	7.2	8.9	23.2	7.8	8.2	21.0	14.5	29.2	8.8	9.2	6.8	4.8	3.7	8.0	10.2	13.7	8.1	8.1	15.1	10.5	11.4	8.9	8.8	7.1	4.4	3.9	7.7	7.8	10.9	16.3	11.5	13.0	12.7	3.3	7.9	11.4	8.3	10.0	9.4	11.0	4.2	17.5	5.9	5.8	6.8	4.6	5.2	5.1	3.9	4.6	4.0	6.5	5.3
ENC1	"ENC-1, KLHL37, NRPB, PIG10, TP53I10"	ENSG00000171617	"Ectodermal-neural cortex 1"	O14682	5	74627406-74641424	"Cancer-related genes, Predicted intracellular proteins"		"Actin-binding, Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"brain: 106.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Group enriched"	"Detected in all"	7	"amygdala: 39.7;basal ganglia: 42.7;cerebral cortex: 86.4;hippocampal formation: 44.1;olfactory region: 43.9"	"Group enriched"	"Detected in many"	6	"classical monocyte: 5.4;eosinophil: 3.4;gdT-cell: 2.3;intermediate monocyte: 4.8;memory CD8 T-cell: 3.0;myeloid DC: 2.4;naive CD8 T-cell: 2.5;neutrophil: 1.4;NK-cell: 2.8;non-classical monocyte: 1.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA078061			Uncertain	"Plasma membrane"				"Plasma membrane"		"HPA078061: "	"prognostic unfavourable (3.88e-4)"	"unprognostic (4.90e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.00e-3)"	"unprognostic (1.05e-1)"	"unprognostic (2.22e-3)"	"unprognostic (1.36e-1)"	"unprognostic (9.74e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.59e-1)"	"unprognostic (4.98e-2)"	"unprognostic (8.08e-2)"	"prognostic unfavourable (2.95e-5)"	"unprognostic (9.69e-2)"	"unprognostic (3.08e-1)"	"unprognostic (2.88e-1)"	"unprognostic (5.65e-2)"	2.2	1.1	39.7	4.7	42.7	5.4	1.8	1.3	106.8	4.2	5.2	2.4	2.1	6.4	2.9	1.6	2.5	1.3	7.5	3.2	44.1	7.7	2.2	6.4	4.8	2.2	4.6	43.9	6.0	12.3	1.0	2.4	4.2	4.9	4.3	8.1	0.8	5.4	7.4	1.7	1.7	8.1	3.0	2.3	4.0	9.8	4.5	1.5	0.5	1.3	0.3	2.0	6.5	1.3	0.4	2.4	3.4	5.4	2.8	3.0	1.4	11.9	14.8	14.8	7.0	6.4	1.6	31.9	8.0	9.1	9.2	6.8	23.9	20.2	0.0	10.0	6.8	9.7	0.2	15.5	20.1	0.2	1.1	13.2	2.8	10.4	0.6	1.3	0.1	2.5	1.0	24.4	2.4	7.5	2.9	7.7	24.0	2.9	1.2	1.7	15.4	13.3	1.5	9.7	1.2	5.0	9.1	19.9	8.1	1.4	6.6	0.7	3.1	1.6	17.8	15.6	26.1	9.2	25.8	0.1	0.0	0.2	18.0	1.1	23.7	0.0	5.4	3.4	2.3	4.8	0.0	0.1	0.5	3.0	2.4	0.4	0.2	2.5	1.4	2.8	1.3	0.0	0.0	1.4	39.7	42.7	1.3	86.4	44.1	7.7	4.6	43.9	4.9	1.5
ENG	"CD105, END, HHT1, ORW, ORW1"	ENSG00000106991	Endoglin	P17813	9	127815012-127854756	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Cell adhesion"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 66.9;TIME: 136.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 12.2;intermediate monocyte: 17.7;myeloid DC: 6.4;NK-cell: 4.6;non-classical monocyte: 13.0"	"Group enriched"	"Detected in many"	4	"dendritic cells: 6.4;monocytes: 17.7;NK-cells: 4.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000096, HPA011862, HPA067440, CAB072873"	Enhanced		Supported	"Nuclear bodies,Plasma membrane"		260000000	260000000	"Plasma membrane"	"Nuclear bodies"	"CAB000096: AB_563482, CAB072873: , HPA011862: AB_1846217, HPA067440: "	"unprognostic (2.28e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.77e-1)"	"prognostic favourable (6.61e-4)"	"prognostic favourable (5.62e-6)"	"unprognostic (2.15e-1)"	"unprognostic (4.06e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.98e-2)"	"prognostic unfavourable (4.26e-4)"	"unprognostic (3.33e-3)"	"unprognostic (7.35e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.27e-1)"	40.3	19.3	6.4	26.6	10.5	5.5	52.7	3.9	8.6	26.3	14.0	7.6	18.5	11.2	27.0	25.2	17.2	23.2	28.3	105.4	8.0	5.0	40.8	26.8	66.7	44.1	10.6	7.0	66.4	9.6	8.6	12.5	60.2	10.1	23.1	6.4	35.5	9.9	51.7	24.1	10.1	14.5	23.1	8.7	52.4	11.6	37.2	7.7	6.7	35.4	19.3	11.0	20.3	44.8	1.1	6.4	0.3	17.7	4.6	2.3	4.6	0.1	0.1	0.9	0.0	16.8	11.5	29.6	19.5	14.0	10.4	6.1	0.0	0.1	0.1	9.5	35.8	0.3	0.0	3.1	3.4	0.0	0.0	5.5	11.0	0.6	13.1	2.6	0.0	19.7	0.7	13.5	4.9	66.9	0.0	0.1	12.1	0.1	0.0	0.2	0.2	0.5	8.7	1.7	0.1	0.0	0.0	0.1	0.2	10.3	9.0	2.6	1.8	3.9	136.5	34.1	1.8	22.2	0.0	0.7	0.1	0.1	9.2	6.8	11.2	0.0	12.2	0.3	1.3	17.7	0.4	0.4	2.1	2.3	6.4	1.1	1.3	2.0	0.3	4.6	13.0	2.4	0.8	4.6	6.4	10.5	3.9	8.6	8.0	5.0	10.6	7.0	10.1	7.7
ENO1	"ENO1L1, MBP-1, MPB1, PPH"	ENSG00000074800	"Enolase 1"	P06733	1	8861000-8879250	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Glycolysis, Plasminogen activation, Transcription, Transcription regulation"	"DNA-binding, Lyase, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB018614, HPA068284, HPA068721, CAB069394"	Supported		Enhanced	"Plasma membrane,Cytosol"		490000000	490000000	"Plasma membrane, Cytosol"		"CAB018614: AB_2099061, CAB069394: , HPA068284: , HPA068721: "	"unprognostic (6.51e-3)"	"unprognostic (9.50e-3)"	"unprognostic (3.56e-2)"	"unprognostic (1.86e-1)"	"prognostic unfavourable (2.71e-4)"	"unprognostic (1.82e-2)"	"prognostic unfavourable (1.30e-8)"	"unprognostic (2.37e-2)"	"unprognostic (5.58e-2)"	"unprognostic (9.72e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.46e-1)"	"unprognostic (7.53e-2)"	"unprognostic (6.20e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.36e-3)"	68.6	57.7	92.7	94.9	109.6	121.8	73.4	46.6	119.4	47.3	63.8	74.6	21.7	71.3	44.9	24.2	138.2	52.2	55.0	45.2	79.1	70.7	180.4	165.4	64.8	80.3	74.9	62.7	58.2	31.6	52.7	35.5	70.5	88.6	38.6	66.4	62.6	106.1	69.1	45.0	74.6	70.3	84.0	56.4	80.0	44.3	31.7	48.8	98.8	55.4	91.0	119.3	73.5	62.9	38.7	114.1	22.1	105.4	55.5	63.7	159.3	180.7	158.0	76.2	65.2	63.8	71.3	69.1	98.3	109.0	211.8	199.1	101.1	105.0	130.3	131.2	118.2	89.2	129.4	262.3	216.0	88.9	136.7	110.0	160.5	125.6	95.9	219.2	67.8	73.6	79.6	167.7	255.0	135.6	120.5	51.0	137.3	89.5	82.6	117.4	83.1	158.6	85.6	113.6	212.8	250.7	43.1	103.1	63.7	115.3	167.9	121.2	84.1	65.7	123.9	146.7	129.9	125.1	167.1	145.5	103.2	197.7	227.8	179.8	123.1	13.9	105.4	20.8	52.3	75.8	59.1	38.7	55.8	53.8	114.1	32.7	45.6	47.8	22.1	55.5	72.4	31.2	63.7	159.3	92.7	109.6	46.6	119.4	79.1	70.7	74.9	62.7	88.6	48.8
ENO2		ENSG00000111674	"Enolase 2"	P09104	12	6913745-6923698	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Glycolysis	Lyase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 119.2"	"Cell line enhanced"	"Detected in many"		"U-87 MG: 81.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 8.2;MAIT T-cell: 9.7;memory B-cell: 5.6;memory CD4 T-cell: 10.8;memory CD8 T-cell: 9.6;naive B-cell: 3.3;naive CD4 T-cell: 7.1;naive CD8 T-cell: 7.4;neutrophil: 6.2;T-reg: 5.5"	"Group enriched"	"Detected in many"	7	"B-cells: 5.6;granulocytes: 6.2;T-cells: 10.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000063, HPA068284, HPA068721, CAB073539, CAB079023"	Enhanced	Supported	Supported	"Plasma membrane,Cytosol"		89000000	89000000	"Plasma membrane, Cytosol"		"CAB000063: AB_2099322, CAB073539: , CAB079023: , HPA068284: , HPA068721: "	"unprognostic (8.96e-2)"	"unprognostic (8.28e-2)"	"prognostic unfavourable (6.96e-4)"	"unprognostic (1.28e-1)"	"unprognostic (7.95e-3)"	"unprognostic (1.39e-2)"	"prognostic unfavourable (5.15e-4)"	"unprognostic (1.48e-1)"	"unprognostic (9.43e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.02e-2)"	"prognostic unfavourable (7.89e-11)"	"unprognostic (7.61e-2)"	"unprognostic (3.06e-1)"	"unprognostic (8.10e-3)"	"unprognostic (1.24e-1)"	4.2	20.7	31.2	8.3	48.0	4.0	4.9	115.2	119.2	7.6	7.9	10.9	2.6	4.9	11.7	6.3	5.9	9.4	8.0	10.3	30.2	39.2	3.5	2.0	10.1	10.5	29.6	47.4	3.7	4.1	19.1	15.5	4.8	47.7	8.0	7.4	28.6	3.1	15.3	2.1	5.8	6.0	15.2	15.7	5.8	6.4	3.2	13.3	1.7	14.2	0.3	10.3	7.1	5.0	5.6	1.0	6.2	0.2	0.4	10.8	4.5	14.0	8.9	3.2	0.1	4.8	5.2	0.2	10.9	7.0	16.2	25.0	1.7	1.1	19.8	1.8	4.7	2.1	33.7	3.0	24.6	39.6	3.1	27.3	9.1	11.8	3.5	1.6	32.9	2.6	0.1	11.9	2.4	3.4	1.8	0.2	10.8	1.9	12.8	1.7	17.1	5.0	14.2	2.7	4.3	7.9	1.9	25.9	18.2	2.8	0.2	18.6	0.9	0.8	4.3	14.2	15.0	19.1	14.1	14.5	14.5	2.9	81.3	0.0	2.9	1.3	0.0	0.1	8.2	0.0	9.7	5.6	10.8	9.6	0.0	3.3	7.1	7.4	6.2	0.4	0.2	1.0	5.5	4.5	31.2	48.0	115.2	91.3	30.2	39.2	29.6	47.4	47.7	13.3
ENPP2	"ATX, PD-IALPHA, PDNP2"	ENSG00000136960	"Ectonucleotide pyrophosphatase/phosphodiesterase 2"	Q13822	8	119557086-119673453	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Chemotaxis, Lipid degradation, Lipid metabolism"	Hydrolase	"Cancer-related genes, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 103.7;placenta: 79.0"	"Cell line enhanced"	"Detected in some"		"AF22: 24.7;ASC diff: 33.8;ASC TERT1: 72.2;BJ hTERT+: 41.5;fHDF/TERT166: 26.8;HSkMC: 33.1"	"Cancer enhanced"	"Detected in all"		"renal cancer: 46.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	5	"basophil: 26.8"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 26.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023700, HPA053652"	Approved		Approved	"Nucleoplasm,Golgi apparatus,Actin filaments"	"Intracellular and membrane"	1100000000	1100000000	"Nucleoplasm, Golgi apparatus"	"Actin filaments"	"HPA023700: AB_1848170, HPA053652: "	"unprognostic (1.17e-2)"	"unprognostic (6.29e-2)"	"unprognostic (3.63e-2)"	"unprognostic (3.93e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.37e-1)"	"unprognostic (9.70e-3)"	"unprognostic (7.14e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.26e-1)"	"prognostic favourable (2.07e-5)"	"unprognostic (5.54e-2)"	"unprognostic (3.14e-1)"	"unprognostic (2.37e-1)"	"unprognostic (5.18e-2)"	"unprognostic (2.37e-2)"	"unprognostic (1.50e-1)"	29.9	15.4	24.0	18.2	42.0	0.7	26.2	4.4	33.3	19.6	8.1	103.7	1.7	20.8	44.8	6.4	2.9	18.7	12.7	3.6	39.8	21.5	24.9	8.9	13.5	31.0	71.5	20.9	5.3	5.2	0.9	4.1	79.0	59.7	8.5	10.6	67.6	3.4	9.2	3.0	5.4	12.1	28.9	102.4	17.3	8.3	9.7	63.9	3.6	3.7	0.8	26.1	13.4	5.7	0.2	3.8	26.8	0.1	0.2	1.8	0.3	0.0	0.0	24.7	0.0	33.8	72.2	0.0	22.7	41.5	9.8	9.4	0.0	0.0	0.0	0.3	26.8	0.0	0.5	0.0	6.9	1.8	0.7	0.0	0.0	0.6	15.1	0.0	0.1	33.1	0.2	20.0	1.0	0.1	0.0	4.0	0.5	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	19.9	0.4	23.9	0.1	0.2	0.0	0.0	16.8	0.1	0.5	26.8	0.1	5.2	0.0	0.0	0.0	0.2	0.2	0.0	0.5	0.0	1.8	0.6	0.3	0.2	0.0	3.8	0.0	0.3	24.0	42.0	4.4	33.3	39.8	21.5	71.5	20.9	59.7	63.9
EP300	"KAT3B, p300"	ENSG00000100393	"E1A binding protein p300"	Q09472	22	41091786-41180079	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000146, HPA003128, HPA004112"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746"	"unprognostic (7.67e-2)"	"unprognostic (5.56e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.52e-1)"	"unprognostic (6.10e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.21e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.54e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.74e-2)"	"unprognostic (8.54e-2)"	"prognostic favourable (7.45e-5)"	"unprognostic (7.97e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.01e-1)"	"unprognostic (8.66e-2)"	16.8	14.8	19.1	13.9	15.5	45.3	14.5	33.0	20.6	14.8	16.8	15.6	18.9	11.1	18.1	11.6	16.8	15.7	16.5	10.7	16.6	8.3	11.5	12.2	14.1	12.9	16.9	12.7	20.2	15.7	26.4	14.5	27.7	13.8	13.2	12.2	12.3	15.3	17.9	19.5	18.2	17.4	13.8	12.7	15.9	14.7	20.6	18.6	29.3	16.9	10.9	14.1	18.7	22.5	4.3	4.4	9.8	3.9	5.7	3.9	2.3	15.5	11.2	19.0	11.8	12.1	13.0	17.0	7.5	10.9	11.3	10.8	14.2	5.7	16.2	6.6	14.8	12.5	27.4	10.3	12.5	15.8	18.2	12.2	12.8	11.1	13.7	28.8	13.8	12.7	10.8	16.3	13.6	12.5	12.8	22.3	8.9	5.7	8.3	9.0	13.7	7.8	17.1	8.9	10.1	10.7	20.7	6.1	6.4	26.6	13.6	13.0	9.6	16.8	16.1	11.3	13.7	8.0	10.6	15.3	7.2	25.3	8.3	8.9	10.7	5.0	3.2	3.0	3.7	3.9	3.2	4.3	3.6	3.9	4.4	2.9	3.1	2.6	9.8	5.7	2.1	3.0	2.6	2.3	19.1	15.5	33.0	20.6	16.6	8.3	16.9	12.7	13.8	18.6
EPAS1	"bHLHe73, HIF2A, HLF, MOP2, PASD2"	ENSG00000116016	"Endothelial PAS domain protein 1"	Q99814	2	46293667-46386703	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Angiogenesis, Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Congenital erythrocytosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 200.8"	"Cell line enhanced"	"Detected in many"		"BEWO: 45.9;HHSteC: 57.5;RT4: 56.9;TIME: 56.7;U-138 MG: 49.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"basophil: 14.9;eosinophil: 7.1"	"Lineage enriched"	"Detected in single"	21	"granulocytes: 14.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031200, HPA069697"			Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA031200: , HPA069697: "	"unprognostic (1.74e-1)"	"unprognostic (9.47e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.74e-1)"	"unprognostic (5.25e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.22e-2)"	"unprognostic (8.67e-2)"	"unprognostic (6.00e-2)"	"unprognostic (9.72e-2)"	"unprognostic (1.55e-2)"	"unprognostic (9.29e-2)"	"prognostic favourable (2.63e-4)"	"unprognostic (6.66e-3)"	"unprognostic (7.75e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.36e-1)"	71.2	14.2	12.5	17.1	15.7	0.8	101.7	5.3	13.9	24.9	20.9	8.9	11.3	12.0	28.8	13.0	21.6	24.8	35.2	40.0	12.8	11.0	35.2	31.2	200.8	27.2	14.3	11.1	20.2	15.5	18.1	9.4	119.6	18.4	20.7	11.5	41.2	13.3	18.7	25.2	13.0	15.6	19.2	12.5	20.5	12.8	13.8	8.0	1.1	43.8	15.2	10.3	32.2	39.3	0.0	0.0	14.9	0.1	0.7	0.1	0.1	5.2	5.6	0.3	0.4	27.0	17.4	45.9	16.6	45.2	9.5	10.4	0.9	0.9	0.0	4.1	31.5	2.5	0.1	13.3	7.1	0.1	0.2	0.0	1.8	11.7	57.5	0.0	3.4	25.5	18.3	18.6	13.1	32.7	0.5	0.0	5.8	4.5	0.1	0.1	0.2	3.1	0.1	0.6	1.7	5.9	56.9	0.2	11.8	13.0	29.9	3.6	2.0	2.3	56.7	49.3	1.4	6.5	1.3	0.0	0.0	0.0	36.0	0.9	1.2	14.9	0.1	7.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.1	0.1	12.5	15.7	5.3	12.6	12.8	11.0	14.3	11.1	18.4	8.0
EPCAM	"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1"	ENSG00000119888	"Epithelial cell adhesion molecule"	P16422	2	47345158-47387601	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Tumor antigen"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 303.2"	"Cell line enhanced"	"Detected in many"		"A-431: 58.3;CACO-2: 75.6;CAPAN-2: 106.4;RPTEC TERT1: 45.4;SCLC-21H: 41.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.9"	"Lineage enriched"	"Detected in single"	5	"dendritic cells: 1.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463"	Enhanced		Supported	"Plasma membrane"				"Plasma membrane"		"CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: "	"unprognostic (6.79e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.49e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.61e-2)"	"unprognostic (3.40e-1)"	"prognostic favourable (3.30e-4)"	"unprognostic (5.27e-2)"	"unprognostic (3.28e-2)"	"prognostic favourable (1.04e-6)"	"unprognostic (6.38e-3)"	"unprognostic (1.28e-1)"	"unprognostic (6.45e-3)"	"unprognostic (6.08e-2)"	0.4	2.1	1.8	49.8	3.0	0.2	8.9	0.6	1.0	10.8	155.8	0.7	31.5	66.8	4.4	35.2	2.8	10.2	41.6	0.4	1.7	2.7	60.2	1.2	22.6	0.4	1.2	0.4	3.8	54.1	19.8	38.7	2.2	0.9	9.0	70.5	0.7	47.2	25.0	0.5	2.0	303.2	1.7	1.4	0.5	15.3	5.5	0.9	1.7	83.6	4.2	4.1	4.1	2.1	0.2	1.9	0.4	0.2	0.0	0.0	0.6	58.3	0.6	0.0	0.1	0.0	0.0	37.0	0.0	0.0	0.0	0.0	75.6	106.4	0.0	16.4	0.1	27.5	0.5	6.9	0.2	0.0	6.7	0.0	0.3	29.7	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.1	17.4	0.0	0.0	29.8	0.0	2.8	19.1	3.8	0.0	0.0	14.8	45.4	25.8	41.1	0.3	0.4	21.7	0.0	18.3	0.1	0.0	0.0	0.7	0.2	0.1	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	1.9	0.0	0.6	1.8	3.0	0.6	1.0	1.7	2.7	1.2	0.4	0.9	0.9
EPHA1	"EPH, EPHT, EPHT1"	ENSG00000146904	"EPH receptor A1"	P21709	7	143390289-143408892	"Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Cell adhesion"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 104.4"	"Cell line enhanced"	"Detected in some"		"CACO-2: 10.3;HaCaT: 9.6;HBEC3-KT: 7.8;MCF7: 8.5;NTERA-2: 32.1"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"pons and medulla: 1.1"	"Group enriched"	"Detected in some"	6	"memory CD4 T-cell: 3.4;naive CD4 T-cell: 6.9;naive CD8 T-cell: 5.1"	"Lineage enriched"	"Detected in single"	9	"T-cells: 6.9"	"Not detected"	"Not detected"							CAB026144	Uncertain					24000000	24000000			"CAB026144: "	"unprognostic (1.54e-2)"	"unprognostic (3.04e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.58e-3)"	"unprognostic (5.82e-3)"	"unprognostic (2.45e-2)"	"unprognostic (9.56e-2)"	"unprognostic (1.81e-2)"	"unprognostic (5.09e-1)"	"unprognostic (7.59e-3)"	"unprognostic (6.54e-2)"	"unprognostic (3.24e-3)"	"prognostic favourable (1.14e-6)"	"unprognostic (3.73e-2)"	"unprognostic (3.28e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.21e-1)"	0.4	0.4	0.0	2.0	0.1	0.5	1.2	0.9	0.3	5.7	7.9	0.0	3.3	3.3	0.9	1.4	29.3	1.6	7.9	0.4	0.0	0.0	2.8	10.6	2.9	5.8	0.0	0.0	1.2	2.9	104.4	1.3	5.5	1.1	2.1	0.9	1.3	5.8	3.9	0.3	9.5	12.3	0.4	0.2	0.5	1.8	0.8	0.0	5.1	6.0	16.4	17.2	1.6	11.8	0.0	0.7	0.2	0.1	0.2	6.9	1.6	4.9	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	10.3	4.1	0.0	0.0	0.0	9.6	0.0	7.8	0.0	0.0	0.0	1.0	0.0	0.9	0.0	0.4	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	1.0	32.1	0.0	0.0	0.0	0.0	0.6	3.9	0.1	0.0	0.0	4.8	0.0	2.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	3.4	0.9	0.4	0.0	6.9	5.1	0.2	0.2	0.0	0.7	0.2	1.6	0.0	0.1	0.9	0.1	0.0	0.0	0.0	0.0	1.1	0.0
EPHA2	ECK	ENSG00000142627	"EPH receptor A2"	P29317	1	16124337-16156087	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Host-virus interaction"	"Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 51.2"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 41.9;EFO-21: 40.4;PC-3: 48.0;U-251 MG: 49.2;WM-115: 53.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	115	"plasmacytoid DC: 11.4"	"Lineage enriched"	"Detected in single"	115	"dendritic cells: 11.4"					"Low region specificity"	"Detected in all"			CAB010464			Supported	"Nuclear speckles,Golgi apparatus,Plasma membrane,Cell Junctions"				"Plasma membrane, Cell Junctions"	"Nuclear speckles, Golgi apparatus"	"CAB010464: AB_631436"	"unprognostic (9.41e-2)"	"unprognostic (1.67e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.67e-2)"	"unprognostic (6.22e-2)"	"unprognostic (9.12e-2)"	"unprognostic (5.24e-2)"	"unprognostic (1.29e-3)"	"unprognostic (2.52e-2)"	"unprognostic (7.05e-3)"	"unprognostic (1.52e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.73e-1)"	"unprognostic (4.77e-3)"	"unprognostic (4.40e-2)"	6.7	3.4	1.3	3.1	2.6	0.0	5.2	0.5	2.1	12.1	4.9	1.6	1.9	4.3	7.8	3.8	51.2	4.6	16.7	6.4	1.1	0.8	5.7	8.2	6.6	4.7	2.7	1.3	4.5	10.2	2.2	2.8	8.9	3.4	5.8	2.6	5.4	31.0	2.8	3.4	12.7	13.1	2.7	3.0	2.8	6.8	2.4	1.2	1.2	5.7	21.8	25.5	15.2	18.5	0.0	11.4	0.0	0.0	0.0	0.0	0.0	15.4	31.3	8.7	4.2	0.6	0.7	5.1	9.3	13.3	17.0	10.8	13.0	41.9	0.0	40.4	5.3	6.3	2.0	21.6	5.9	0.0	1.4	0.0	9.1	8.3	11.1	0.0	0.0	1.0	8.1	9.2	20.5	18.1	0.0	0.0	10.7	4.9	0.0	0.0	4.2	48.0	0.0	7.9	0.0	18.0	8.0	0.0	1.3	18.2	4.4	1.2	0.6	0.1	22.3	6.1	16.3	0.4	49.2	0.0	0.1	0.1	4.7	0.0	53.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	1.3	2.6	0.5	2.1	1.1	0.8	2.7	1.3	3.4	1.2
EPHA3	"ETK, ETK1, HEK, HEK4, TYRO4"	ENSG00000044524	"EPH receptor A3"	P29320	3	89107524-89482134	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 39.0"	"Cell line enriched"	"Detected in some"	6	"AF22: 65.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB010462, HPA069390"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Plasma membrane,Actin filaments,Cytosol"	"Intracellular and membrane"			"Nuclear membrane, Plasma membrane, Cytosol"	"Nucleoplasm, Actin filaments"	"CAB010462: AB_2099218, HPA069390: "	"unprognostic (1.48e-3)"	"unprognostic (2.30e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.90e-1)"	"unprognostic (2.96e-2)"	"unprognostic (1.47e-2)"	"unprognostic (2.03e-1)"	"unprognostic (9.10e-3)"	"unprognostic (1.24e-3)"	"unprognostic (7.43e-2)"	"unprognostic (1.83e-1)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (3.28e-7)"	"unprognostic (3.63e-2)"	"unprognostic (1.88e-2)"	"unprognostic (4.05e-2)"	"unprognostic (1.20e-2)"	9.7	1.1	2.3	1.7	4.5	0.2	5.1	1.3	8.7	12.3	5.8	0.6	1.4	2.2	13.9	1.3	6.3	2.6	17.2	10.0	2.2	2.5	1.5	4.4	2.7	3.0	2.5	3.4	4.2	2.8	1.2	3.4	17.5	11.9	39.0	5.9	5.4	3.8	6.8	1.7	1.7	3.5	17.3	2.9	1.2	3.7	1.3	2.0	0.0	16.3	6.0	3.0	11.8	12.2	0.3	0.1	0.5	0.1	0.3	0.2	0.0	0.0	0.0	65.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	3.7	0.0	0.2	0.0	0.8	0.0	0.0	4.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.8	0.0	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	11.5	0.0	0.0	0.0	0.5	0.0	0.5	0.2	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.5	0.3	0.1	0.1	0.0	0.0	2.3	4.5	1.3	8.7	2.2	2.5	2.5	3.4	11.9	2.0
EPHA4	"Hek8, TYRO1"	ENSG00000116106	"EPH receptor A4"	P54764	2	221418027-221574202	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 29.6"	"Cell line enhanced"	"Detected in many"		"AF22: 35.0;ASC diff: 15.5;CACO-2: 25.6;U-2197: 17.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	8	"basophil: 3.0;gdT-cell: 3.4;MAIT T-cell: 3.4;memory B-cell: 2.5;memory CD4 T-cell: 5.0;memory CD8 T-cell: 3.3;naive B-cell: 1.8;naive CD4 T-cell: 1.9;NK-cell: 6.0;T-reg: 2.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB028368	Enhanced					8400000	8400000			"CAB028368: AB_2099353"	"unprognostic (1.28e-1)"	"unprognostic (5.87e-2)"	"unprognostic (2.28e-1)"	"unprognostic (2.46e-2)"	"unprognostic (5.99e-2)"	"unprognostic (1.33e-1)"	"unprognostic (7.05e-4)"	"unprognostic (1.80e-2)"	"unprognostic (2.40e-1)"	"prognostic unfavourable (9.56e-4)"	"unprognostic (1.12e-1)"	"unprognostic (2.85e-2)"	"prognostic favourable (5.67e-4)"	"unprognostic (3.12e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.36e-1)"	"unprognostic (8.66e-2)"	7.1	1.8	8.1	1.9	18.3	3.5	5.2	14.7	29.6	4.9	5.9	3.1	3.2	1.1	6.5	3.1	5.0	6.6	3.3	16.7	19.9	4.4	5.2	0.9	3.7	2.5	2.4	16.4	11.7	1.2	2.0	1.2	1.7	4.9	5.9	4.7	0.8	3.7	6.7	3.1	12.8	4.1	8.2	2.1	3.3	4.0	11.4	2.6	0.5	9.8	3.7	3.2	4.6	4.9	2.5	0.2	3.0	0.0	6.0	5.0	0.7	1.1	1.0	35.0	0.0	15.5	9.6	0.0	8.3	3.6	7.5	2.8	25.6	0.4	0.0	0.0	11.6	3.0	5.4	0.0	3.2	4.1	3.0	0.0	0.3	0.0	0.4	0.0	0.6	3.8	1.9	2.3	0.0	7.1	0.0	0.0	1.9	4.1	0.1	0.0	2.5	0.7	0.0	3.8	0.0	11.7	1.8	6.2	0.0	2.7	0.5	0.6	1.3	0.0	0.0	0.8	1.4	17.1	0.4	0.0	0.0	0.0	3.1	0.0	1.5	3.0	0.0	0.0	3.4	0.0	3.4	2.5	5.0	3.3	0.0	1.8	1.9	0.3	0.2	6.0	0.0	0.2	2.1	0.7	8.1	18.3	14.7	29.6	19.9	4.4	2.4	16.4	4.9	2.6
EPHA7	Hek11	ENSG00000135333	"EPH receptor A7"	Q15375	6	93240020-93419547	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"parathyroid gland: 110.4"	"Group enriched"	"Detected in some"	4	"AF22: 8.7;HEK 293: 25.0;RH-30: 23.8;THP-1: 20.3"	"Cancer enhanced"	"Detected in many"		"renal cancer: 6.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB010496	Approved				"Intracellular and membrane"	340000	340000			"CAB010496: AB_2099673"	"unprognostic (3.34e-1)"	"unprognostic (7.82e-2)"	"unprognostic (1.41e-1)"	"unprognostic (9.32e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.56e-2)"		"unprognostic (1.62e-2)"	"unprognostic (4.07e-1)"	"unprognostic (4.16e-2)"	"unprognostic (3.19e-2)"	"unprognostic (5.69e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.74e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.56e-2)"	"unprognostic (4.82e-2)"	1.3	1.3	6.0	1.7	24.6	1.2	2.2	21.6	8.6	2.4	24.6	0.0	0.1	2.5	2.0	7.5	14.7	1.7	3.1	4.2	13.8	2.9	6.9	1.3	1.5	1.3	2.4	5.8	3.0	1.3	110.4	5.6	1.6	6.7	17.9	3.6	0.4	8.2	1.9	1.3	1.4	6.5	20.2	4.8	4.7	14.9	2.1	4.4	0.0	1.3	0.0	1.3	9.7	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	25.0	0.0	2.4	0.0	0.0	0.0	0.0	0.3	0.0	3.6	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.5	0.6	4.4	23.8	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	20.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	6.0	24.6	21.6	8.6	13.8	2.9	2.4	5.8	6.7	4.4
EPHA8	"EEK, Hek3"	ENSG00000070886	"EPH receptor A8"	P29322	1	22563564-22603594	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"adrenal gland: 9.4;brain: 5.3;lymphoid tissue: 10.3;pancreas: 8.3;testis: 3.5"	"Cell line enriched"	"Detected in some"	12	"SCLC-21H: 36.4"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"cerebellum: 25.0"	"CAB009660, HPA031433"	Uncertain				"Intracellular and membrane"					"CAB009660: AB_2099696, HPA031433: AB_10601371"	"unprognostic (8.58e-2)"	"unprognostic (8.59e-2)"	"unprognostic (3.72e-1)"	"unprognostic (1.15e-2)"	"unprognostic (4.69e-4)"	"unprognostic (3.58e-1)"		"unprognostic (7.14e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.75e-2)"	"unprognostic (9.80e-2)"	"unprognostic (2.10e-1)"	"unprognostic (9.84e-14)"	"unprognostic (2.14e-3)"	"unprognostic (1.69e-1)"	"unprognostic (2.76e-1)"	"unprognostic (8.68e-2)"	0.2	9.4	1.6	0.2	3.1	0.2	0.1	1.8	3.9	0.2	0.2	2.2	0.0	1.7	0.1	0.3	0.2	0.1	0.2	0.2	2.0	2.6	0.1	0.1	0.2	0.2	2.1	4.1	0.1	8.3	0.2	1.7	0.1	5.3	0.2	0.2	1.6	0.8	0.2	0.3	0.4	0.2	0.1	1.3	10.3	0.2	3.5	0.6	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	36.4	2.9	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.6	3.1	1.8	3.9	2.0	2.6	2.1	4.1	5.3	0.6
EPHB2	"DRT, EPHT3, ERK, Hek5, Tyro5"	ENSG00000133216	"EPH receptor B2"	P29323	1	22710839-22921500	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Neurogenesis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 25.0"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 22.8;HUVEC TERT2: 31.1;TIME: 30.7;U-251 MG: 26.8"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 23.7"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 2.5;intermediate monocyte: 2.1"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB013647, HPA071200"	Approved		Supported	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	290000	290000	"Plasma membrane"	Nucleoplasm	"CAB013647: , HPA071200: "	"unprognostic (2.47e-2)"	"unprognostic (2.43e-2)"	"prognostic favourable (4.98e-4)"	"prognostic unfavourable (1.05e-5)"	"unprognostic (3.99e-2)"	"unprognostic (8.91e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.33e-3)"	"unprognostic (1.56e-1)"	"unprognostic (7.73e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.15e-2)"	"unprognostic (2.16e-4)"	"unprognostic (1.45e-1)"	"unprognostic (8.07e-2)"	"unprognostic (2.58e-1)"	"unprognostic (3.46e-2)"	3.7	2.9	3.4	15.4	5.4	0.9	2.5	1.9	8.2	3.8	23.9	16.2	4.6	21.6	2.5	3.2	1.1	5.4	4.4	5.4	5.6	6.5	3.5	1.1	3.0	5.5	12.7	3.8	17.9	5.4	6.1	5.4	12.0	8.2	3.3	25.0	2.2	6.6	4.0	0.7	1.8	22.6	4.0	12.1	3.3	2.3	2.9	9.3	0.1	8.4	1.0	2.1	5.3	3.3	0.1	0.6	0.3	2.5	0.1	0.1	0.4	16.7	7.1	6.8	10.9	0.6	0.6	0.0	3.9	0.2	11.8	2.5	2.4	6.7	0.2	8.4	1.7	15.8	4.6	22.8	3.1	0.0	1.6	0.0	0.7	0.0	7.1	0.0	1.7	2.3	7.3	21.1	0.1	31.1	0.6	0.0	2.3	2.5	0.3	0.1	1.6	4.6	2.0	7.0	0.3	5.8	1.6	7.4	7.8	6.8	0.2	0.1	0.4	0.2	30.7	4.7	12.4	11.9	26.8	0.0	0.1	0.0	8.8	0.3	0.1	0.3	2.5	0.1	0.1	2.1	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.4	3.4	5.4	1.9	8.2	5.6	6.5	12.7	3.8	8.2	9.3
EPHB3	"ETK2, Hek2, Tyro6"	ENSG00000182580	"EPH receptor B3"	P54753	3	184561784-184582409	"Cancer-related genes, Enzymes, Predicted membrane proteins"	"Angiogenesis, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 49.3"	"Cell line enhanced"	"Detected in many"		"BEWO: 17.2;HaCaT: 23.6;SK-BR-3: 18.3;T-47d: 12.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"classical monocyte: 1.1;myeloid DC: 3.1"	"Group enriched"	"Detected in many"	5	"dendritic cells: 3.1;monocytes: 1.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA007698, HPA008184, CAB034350"	Enhanced					20000	20000			"CAB034350: AB_2262377, HPA007698: AB_1848205, HPA008184: AB_1848206"	"unprognostic (2.94e-2)"	"unprognostic (5.88e-2)"	"unprognostic (2.17e-2)"	"unprognostic (7.80e-2)"	"unprognostic (1.52e-1)"	"unprognostic (9.19e-2)"	"unprognostic (8.35e-2)"	"unprognostic (1.94e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.76e-1)"	"unprognostic (7.42e-2)"	"unprognostic (3.31e-1)"	"prognostic unfavourable (7.88e-5)"	"unprognostic (8.83e-3)"	"unprognostic (3.03e-2)"	"unprognostic (9.59e-3)"	"unprognostic (2.10e-3)"	1.4	0.9	4.5	5.0	2.6	0.5	9.0	9.7	5.7	22.7	8.8	2.3	1.7	5.7	10.0	1.9	19.9	3.0	9.7	1.6	4.7	1.8	1.7	1.0	4.7	1.0	3.3	3.7	9.0	49.3	1.1	1.7	6.3	7.2	7.7	9.7	3.8	27.7	3.5	0.7	32.3	5.6	3.5	1.3	1.2	16.0	1.1	4.0	0.2	1.0	15.7	8.4	4.0	13.6	0.0	3.1	0.3	1.1	0.0	0.4	0.4	3.8	1.3	8.9	0.9	2.7	0.2	17.2	0.6	1.1	1.3	0.7	1.2	0.1	0.0	1.7	3.6	23.6	3.2	1.2	0.3	0.1	0.7	0.0	0.2	0.0	0.2	0.0	0.2	0.7	7.7	1.1	0.1	0.0	0.0	0.0	0.6	10.1	0.0	3.8	0.9	1.5	0.9	5.4	0.0	0.0	3.4	1.1	1.3	0.7	18.3	0.8	12.1	0.1	0.0	2.2	3.2	1.1	1.4	0.0	0.0	0.1	0.2	0.0	8.4	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	3.1	0.0	0.1	0.4	0.3	0.0	0.0	0.0	0.0	0.4	4.5	2.6	9.7	5.7	4.7	1.8	3.3	3.7	7.2	4.0
EPHB4	"HTK, Tyro11"	ENSG00000196411	"EPH receptor B4"	P54760	7	100802565-100827521	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Angiogenesis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 3.6;neutrophil: 7.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013537	Uncertain					1000000	1000000			"CAB013537: "	"prognostic unfavourable (8.56e-4)"	"unprognostic (1.05e-2)"	"prognostic unfavourable (4.33e-4)"	"unprognostic (1.33e-1)"	"unprognostic (5.23e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.84e-1)"	"unprognostic (8.16e-3)"	"unprognostic (1.43e-1)"	"unprognostic (9.51e-3)"	"unprognostic (6.63e-2)"	"unprognostic (3.13e-1)"	"unprognostic (2.07e-2)"	"prognostic unfavourable (8.84e-4)"	14.0	20.7	1.8	4.2	2.9	2.2	17.1	1.9	3.0	29.1	9.5	2.9	14.6	4.1	28.8	10.3	11.0	13.1	35.0	19.0	3.4	1.1	16.8	29.8	16.5	12.0	2.2	0.9	24.6	11.6	5.6	3.1	35.5	3.2	13.7	5.4	11.6	10.8	14.7	5.1	14.2	7.0	12.4	2.2	50.5	8.6	12.2	2.1	2.3	10.2	13.1	7.0	7.7	21.5	0.0	1.6	7.4	3.6	0.0	0.0	1.2	12.5	11.1	11.1	32.2	7.1	4.6	32.9	4.9	10.7	7.7	10.1	9.1	9.6	1.6	22.4	5.0	13.1	4.8	12.9	4.1	2.0	8.9	0.4	6.4	14.1	4.1	0.2	0.3	5.4	19.5	4.9	11.4	28.7	23.6	0.6	6.2	21.8	0.2	4.9	19.0	16.7	17.0	5.5	2.9	9.8	6.6	0.0	9.6	7.5	3.5	7.3	8.9	2.2	24.1	9.6	15.3	17.7	7.2	0.1	0.2	0.5	1.4	4.1	17.4	0.0	3.6	0.0	0.0	0.9	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	7.4	0.0	0.2	0.3	0.0	1.2	1.8	2.9	1.9	3.0	3.4	1.1	2.2	0.9	3.2	2.1
EPHX1	EPHX	ENSG00000143819	"Epoxide hydrolase 1"	P07099	1	225810092-225845563	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Aromatic hydrocarbons catabolism, Detoxification"	Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 156.4;liver: 265.0"	"Cell line enhanced"	"Detected in many"		"ASC diff: 153.8;SiHa: 73.1"	"Cancer enriched"	"Detected in all"	6	"liver cancer: 1047.0"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 6.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020593, HPA048847"	Enhanced					83000	83000			"HPA020593: AB_10601373, HPA048847: AB_2680538"	"unprognostic (2.85e-2)"	"unprognostic (2.52e-2)"	"unprognostic (2.00e-2)"	"unprognostic (2.53e-3)"	"unprognostic (2.50e-1)"	"unprognostic (6.60e-2)"	"unprognostic (3.92e-2)"	"prognostic favourable (7.02e-5)"	"unprognostic (1.02e-1)"	"unprognostic (2.53e-2)"	"unprognostic (1.01e-1)"	"prognostic favourable (1.32e-4)"	"unprognostic (8.10e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.65e-1)"	"unprognostic (5.15e-2)"	"unprognostic (1.88e-2)"	39.5	156.4	16.8	5.7	20.1	3.4	31.3	8.3	25.1	31.3	12.6	28.7	15.3	16.6	21.8	15.7	24.9	26.2	17.8	11.5	16.3	11.2	36.8	265.0	24.1	6.9	17.1	14.5	45.6	85.0	39.5	14.0	5.4	23.6	25.9	8.4	27.3	26.3	21.3	16.4	8.8	9.6	18.6	10.7	8.3	12.1	22.7	12.6	3.6	24.9	15.6	14.9	20.9	32.3	0.5	2.2	0.5	6.6	1.4	1.3	2.3	4.4	42.3	1.6	15.6	153.8	16.0	3.4	5.1	6.4	3.7	5.2	8.7	45.0	0.1	19.3	19.2	4.9	4.6	2.4	1.5	0.9	8.0	3.1	17.9	48.8	16.7	1.9	1.8	15.0	5.6	10.5	1.0	2.7	2.2	3.9	6.6	5.1	1.9	3.6	9.1	11.9	4.1	2.0	12.8	11.1	27.9	14.6	1.9	73.1	26.2	6.7	19.4	5.7	8.1	6.3	5.1	8.5	8.1	1.3	6.7	0.5	9.5	2.1	8.3	0.0	6.6	0.2	0.5	1.9	0.9	0.3	0.9	0.5	1.5	0.5	1.3	1.0	0.5	1.4	0.8	2.2	0.7	2.3	16.8	20.1	8.3	25.1	16.3	11.2	17.1	14.5	23.6	12.6
EPO	EP	ENSG00000130427	Erythropoietin	P01588	7	100720800-100723700	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins"	"Erythrocyte maturation"	Hormone	"Cancer-related genes, Congenital erythrocytosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"cervix, uterine: 10.9;endometrium 1: 8.7;liver: 29.3"	"Group enriched"	"Detected in some"	7	"BEWO: 3.5;Hep G2: 13.0"	"Group enriched"	"Detected in many"	5	"liver cancer: 2.7;renal cancer: 5.4"	"Region enriched"	"Detected in single"	9	"cerebral cortex: 4.4"	"Cell type enriched"	"Detected in single"	13	"non-classical monocyte: 1.2"	"Lineage enriched"	"Detected in single"	13	"monocytes: 1.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			CAB010336	Supported				"Secreted to blood"					"CAB010336: AB_2098408"	"unprognostic (2.93e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.08e-3)"	"unprognostic (7.30e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.78e-3)"	"prognostic unfavourable (5.67e-5)"	"unprognostic (3.52e-2)"	"unprognostic (5.16e-2)"	"unprognostic (9.70e-2)"	"unprognostic (2.44e-3)"	"unprognostic (3.31e-1)"	"prognostic unfavourable (2.18e-6)"	"unprognostic (4.80e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.59e-2)"	"unprognostic (3.34e-1)"	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	4.4	10.9	0.0	0.0	0.0	0.0	8.7	0.6	0.4	0.0	0.0	0.1	0.0	0.0	2.8	29.3	0.0	0.0	0.0	0.0	0.1	7.8	0.0	0.0	0.7	0.0	1.6	0.0	0.7	0.9	1.6	0.0	0.7	0.0	0.6	0.0	0.0	0.0	2.4	0.4	0.3	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	3.5	0.1	0.0	0.0	0.0	0.8	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.1	1.1	0.1	0.0	0.0	13.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.2	0.2	0.2	0.0	0.0	0.6	0.4	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.6	0.2	0.0	0.1	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.5	0.1	4.4	0.0	0.0	0.0	0.0	0.0	0.4
EPOR		ENSG00000187266	"Erythropoietin receptor"	P19235	19	11377205-11384342	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins"		Receptor	"Cancer-related genes, Congenital erythrocytosis, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA077654			Supported	"Nuclear speckles,Plasma membrane"	"Intracellular and membrane"			"Plasma membrane"	"Nuclear speckles"	"HPA077654: "	"unprognostic (9.13e-2)"	"unprognostic (7.14e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.70e-1)"	"unprognostic (1.50e-2)"	"unprognostic (5.60e-2)"	"unprognostic (9.00e-2)"	"prognostic favourable (3.17e-5)"	"unprognostic (6.37e-3)"	"unprognostic (1.59e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.00e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.01e-3)"	5.5	8.6	2.1	1.1	2.9	14.7	2.6	1.3	1.7	3.9	3.3	2.8	13.3	1.0	3.6	11.6	2.4	3.2	1.8	11.2	1.9	1.4	12.1	8.4	8.5	6.9	1.9	1.6	1.9	9.2	28.1	5.2	12.7	2.3	3.1	1.4	3.3	8.7	18.3	2.0	1.1	1.7	1.5	4.0	8.0	3.7	2.2	1.0	1.6	21.5	1.0	1.5	1.9	2.1	2.6	2.5	12.2	7.7	0.9	4.8	2.9	3.4	1.1	3.5	4.1	5.3	3.4	2.1	2.2	6.8	3.5	4.5	1.2	1.3	2.4	3.9	3.9	0.9	2.7	1.3	4.1	1.9	1.6	13.0	1.1	2.0	3.8	2.7	5.4	2.5	0.5	4.7	3.3	8.2	11.4	11.6	3.9	3.1	2.5	3.2	1.9	9.3	6.7	5.9	5.2	3.3	1.8	1.4	10.9	1.4	2.0	6.0	3.5	4.7	3.4	1.9	2.6	6.5	1.9	5.9	4.3	2.6	10.3	2.6	2.0	8.1	4.2	3.3	2.1	5.1	4.5	2.6	4.2	3.1	2.5	1.6	4.8	2.8	12.2	0.9	7.7	0.1	3.7	2.9	2.1	2.9	1.3	1.7	1.9	1.4	1.9	1.6	2.3	1.0
EPS15	"AF-1P, MLLT5"	ENSG00000085832	"Epidermal growth factor receptor pathway substrate 15"	P42566	1	51354263-51519328	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Endocytosis, Host-virus interaction, Protein transport, Transport"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008451, CAB010164, HPA061431"	Approved		Enhanced	Vesicles,Cytosol	"Intracellular and membrane"	67000	67000	"Vesicles, Cytosol"		"CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: "	"unprognostic (1.45e-2)"	"prognostic unfavourable (6.44e-4)"	"unprognostic (1.05e-2)"	"unprognostic (7.72e-3)"	"unprognostic (3.99e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.96e-3)"	"unprognostic (9.26e-2)"	"unprognostic (4.13e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.41e-1)"	"unprognostic (5.36e-2)"	"unprognostic (8.73e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.24e-1)"	39.0	26.9	35.5	25.3	27.8	13.2	19.3	22.2	41.0	25.7	16.7	35.7	16.2	11.4	21.8	21.3	19.6	14.1	19.3	18.9	40.7	26.0	21.0	19.1	24.4	30.7	36.2	11.2	22.4	10.9	17.0	14.6	22.8	20.3	22.5	15.5	25.7	24.3	16.4	30.9	18.1	19.3	18.2	36.8	33.8	15.2	32.4	33.1	25.0	20.3	23.4	32.1	25.3	17.0	16.1	10.8	14.9	12.2	10.7	18.7	8.0	14.7	4.4	9.6	9.0	22.2	22.2	23.9	10.3	16.4	8.5	12.6	6.0	8.2	30.2	10.7	16.2	14.1	12.4	9.9	12.9	34.1	7.8	26.9	7.6	7.2	20.9	15.2	24.8	18.0	9.2	14.8	20.2	15.8	16.6	13.8	12.9	7.2	12.2	8.3	13.1	7.2	10.0	14.5	6.6	11.2	18.4	6.6	9.2	12.3	21.9	17.9	8.9	10.8	21.8	7.9	8.5	15.8	8.6	16.5	16.7	20.4	11.7	17.3	6.9	14.9	10.1	11.6	10.1	10.7	15.3	16.1	12.2	15.6	10.8	10.0	7.3	10.5	7.8	10.7	12.2	7.1	18.7	8.0	35.5	27.8	22.2	41.0	40.7	26.0	36.2	11.2	20.3	33.1
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	"Erb-b2 receptor tyrosine kinase 2"	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in many"	27	"SK-BR-3: 263.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.8"	"Lineage enriched"	"Detected in many"	4	"T-cells: 8.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Supported	"Plasma membrane,Cytosol"		430000	430000	"Plasma membrane"	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500"	"unprognostic (1.97e-1)"	"unprognostic (6.60e-3)"	"unprognostic (6.21e-2)"	"prognostic unfavourable (8.99e-8)"	"unprognostic (2.96e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavourable (9.17e-4)"	"unprognostic (3.92e-1)"	"prognostic favourable (2.41e-14)"	"unprognostic (9.29e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.96e-1)"	5.8	2.4	5.2	10.4	7.0	0.1	20.1	4.2	7.0	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4.0	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	3.1	3.8	4.2	2.7	5.1	3.6	5.7	2.2	3.7	4.9	4.2	2.8	8.6	0.2	4.6	5.1	9.8	0.2	5.1	2.3	0.4	3.2	0.1	3.0	4.5	3.0	0.0	0.0	3.5	4.8	3.0	1.8	2.0	0.4	0.1	3.6	4.8	0.5	0.2	7.6	0.9	0.3	1.7	0.4	5.0	9.8	0.8	0.2	4.2	263.9	1.3	7.4	0.1	0.2	2.5	3.3	3.2	1.4	0.4	0.2	0.2	0.2	0.0	8.2	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1.0	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7.0	4.2	7.0	6.3	3.1	5.1	5.6	7.5	3.7
ERBB3	"HER3, LCCS2"	ENSG00000065361	"Erb-b2 receptor tyrosine kinase 3"	P21860	12	56076799-56103505	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Hep G2: 31.1;MCF7: 20.3;RT4: 24.3;SK-BR-3: 28.6;SK-MEL-30: 38.1;T-47d: 31.7;WM-115: 40.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.3"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 5.3"	"Low region specificity"	"Detected in many"							"CAB025331, HPA045396"	Uncertain		Approved	"Plasma membrane,Actin filaments"	"Secreted - unknown location"	420000	420000	"Actin filaments"	"Plasma membrane"	"CAB025331: , HPA045396: "	"unprognostic (2.97e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.91e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-3)"	"unprognostic (2.31e-3)"	"unprognostic (2.66e-2)"	"unprognostic (9.89e-2)"	"unprognostic (4.30e-2)"	"unprognostic (4.76e-3)"	"unprognostic (5.77e-2)"	"unprognostic (1.06e-2)"	"unprognostic (4.56e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.72e-3)"	"unprognostic (2.07e-2)"	1.1	1.4	11.6	12.6	16.5	0.6	26.8	2.0	16.7	6.8	40.5	40.3	12.0	37.7	2.8	7.5	29.4	5.7	22.9	3.4	18.6	9.0	16.5	33.9	13.4	0.5	23.5	9.3	0.9	21.5	11.4	1.0	15.4	14.9	16.8	29.7	5.5	36.8	22.3	1.1	30.7	41.3	3.2	27.4	0.5	32.9	1.2	23.8	0.0	4.5	7.4	8.5	11.8	14.4	0.9	0.7	5.3	0.6	1.2	1.2	0.2	10.1	0.6	0.8	0.3	0.0	0.0	16.5	0.8	1.9	1.1	1.1	5.5	18.3	0.0	0.2	0.2	8.6	1.2	1.9	0.6	0.2	0.8	0.0	0.3	31.1	0.0	0.0	0.1	0.4	2.5	0.2	0.0	0.0	0.7	0.3	0.1	20.3	0.1	0.3	2.8	0.4	0.1	1.9	0.5	2.1	24.3	0.9	0.3	0.7	28.6	38.1	31.7	0.1	0.0	0.1	1.1	0.6	0.1	0.3	0.1	0.1	0.1	0.0	40.5	5.3	0.4	0.8	0.9	0.4	0.4	0.4	0.7	0.3	0.3	0.9	0.6	1.2	3.3	1.2	0.6	0.7	0.8	0.2	11.6	16.5	2.0	16.7	18.6	9.0	23.5	9.3	14.9	23.8
ERBB4	"ALS19, HER4"	ENSG00000178568	"Erb-b2 receptor tyrosine kinase 4"	Q15303	2	211375717-212538841	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Lactation, Transcription, Transcription regulation"	"Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 24.5"	"Cell line enhanced"	"Detected in some"		"AF22: 9.4;EFO-21: 7.0;HEK 293: 5.2;RPTEC TERT1: 7.7;SCLC-21H: 4.3;T-47d: 6.9"	"Cancer enhanced"	"Detected in many"		"breast cancer: 4.1"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000276, HPA012016, CAB025522"	Enhanced					140000	140000			"CAB000276: , CAB025522: , HPA012016: AB_1846541"	"unprognostic (1.48e-1)"	"unprognostic (3.28e-1)"	"unprognostic (4.31e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.59e-1)"	"unprognostic (2.75e-1)"	"unprognostic (2.88e-1)"	"unprognostic (9.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.67e-3)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.49e-3)"	"unprognostic (1.41e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.11e-2)"	1.6	1.9	15.1	1.2	15.0	1.0	13.4	18.6	14.1	7.8	1.1	7.6	8.8	1.1	1.5	1.2	1.3	24.5	1.2	7.0	14.3	6.5	11.9	1.1	2.9	1.2	7.8	10.7	1.3	2.4	10.8	5.1	1.3	8.8	1.7	1.1	2.0	9.7	18.1	3.8	1.8	1.2	1.1	7.3	1.2	1.5	7.6	12.0	0.0	4.5	1.1	1.2	1.4	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	9.4	0.2	0.0	0.0	0.0	0.0	0.3	0.5	0.1	0.0	0.0	0.0	7.0	1.0	0.4	0.2	0.0	0.0	0.1	5.2	0.0	1.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	7.7	0.4	4.3	0.2	0.0	0.1	0.1	6.9	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.1	15.0	18.6	14.1	14.3	6.5	7.8	10.7	8.8	12.0
ERC1	"CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2"	ENSG00000082805	"ELKS/RAB6-interacting/CAST family member 1"	Q8IUD2	12	990509-1495933	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019513, HPA019523, HPA024130"	Approved		Supported	"Vesicles,Plasma membrane,Cytosol"				Cytosol	"Vesicles, Plasma membrane"	"HPA019513: AB_1856012, HPA019523: AB_1856013, HPA024130: AB_1856014"	"unprognostic (2.41e-1)"	"unprognostic (4.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (5.70e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.32e-1)"	"unprognostic (5.50e-2)"	"unprognostic (8.49e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.26e-2)"	"unprognostic (1.04e-1)"	"unprognostic (6.79e-2)"	"unprognostic (3.75e-3)"	"unprognostic (4.19e-2)"	"unprognostic (3.01e-1)"	"unprognostic (7.37e-2)"	"prognostic unfavourable (7.01e-4)"	12.6	11.4	10.3	12.5	14.7	7.4	15.1	41.7	10.4	11.2	11.9	8.5	9.2	4.3	17.1	11.0	13.7	9.8	9.9	14.7	10.0	11.2	11.2	8.0	8.8	5.4	9.0	6.4	12.5	8.6	24.3	19.4	13.2	10.7	11.4	7.5	10.1	9.3	14.4	9.2	9.9	6.4	22.1	8.5	7.3	8.6	11.0	9.9	9.8	15.3	7.2	8.6	15.7	15.3	8.6	2.9	2.1	3.8	1.1	3.5	0.5	2.9	7.3	3.9	2.6	10.4	8.8	5.4	9.2	7.4	6.3	5.8	6.4	3.6	4.5	1.3	11.9	5.0	8.3	7.1	8.8	9.5	4.2	11.1	7.3	3.2	7.9	5.7	2.6	7.1	6.2	11.1	20.8	8.1	3.3	9.0	4.7	3.2	1.8	1.2	6.2	3.5	3.6	14.8	1.4	6.2	5.3	2.3	4.6	14.4	3.3	5.2	3.4	2.4	15.0	10.9	11.1	8.0	8.6	2.4	4.5	6.7	7.1	3.4	4.8	1.4	2.8	2.1	1.6	1.0	2.2	8.6	2.4	2.4	2.4	5.6	3.5	2.6	2.1	1.1	3.8	2.9	2.2	0.5	10.3	14.7	41.7	10.4	10.0	11.2	9.0	6.4	10.7	9.9
ERCC1	RAD10	ENSG00000012061	"ERCC excision repair 1, endonuclease non-catalytic subunit"	P07992	19	45407333-45478828	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Cataract"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004390, HPA029773, HPA050182, CAB072859, CAB072860"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB004390: AB_2278023, CAB072859: , CAB072860: , HPA029773: AB_10602129, HPA050182: "	"unprognostic (1.54e-3)"	"unprognostic (5.99e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.97e-1)"	"prognostic unfavourable (9.69e-4)"	"unprognostic (2.57e-1)"	"unprognostic (5.80e-2)"	"unprognostic (7.37e-2)"	"unprognostic (1.93e-2)"	"unprognostic (2.75e-2)"	"prognostic unfavourable (9.00e-5)"	"unprognostic (6.19e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.43e-1)"	25.0	28.2	25.9	20.2	27.5	20.8	30.6	28.4	34.8	26.4	21.5	35.4	20.6	20.8	27.4	34.6	28.6	30.9	24.0	63.5	24.7	24.4	22.9	24.2	21.3	26.3	28.3	25.0	37.6	42.9	31.6	32.0	20.3	27.4	29.1	17.1	29.1	53.8	24.4	43.3	43.5	20.4	26.1	23.5	24.3	22.4	21.6	26.7	22.6	28.4	25.7	25.1	22.0	26.0	16.6	69.0	5.3	29.7	12.6	14.2	17.9	13.7	23.7	20.1	29.4	13.8	26.3	6.4	20.6	27.6	25.1	33.4	2.6	13.5	8.1	5.8	21.9	10.6	6.4	65.7	15.5	17.7	6.5	12.1	9.0	8.0	28.9	12.2	22.8	19.6	14.1	26.2	23.7	27.2	7.4	16.3	39.3	9.2	11.5	9.8	4.7	9.4	17.4	9.4	10.9	18.4	8.8	8.6	18.2	13.1	11.2	18.0	13.6	23.4	15.6	22.6	21.6	13.8	20.8	12.1	9.7	8.7	26.0	10.6	68.1	4.7	29.2	5.3	14.2	29.7	9.6	16.4	8.7	11.0	29.3	16.6	7.0	11.3	4.0	12.6	21.8	69.0	10.2	17.9	25.9	27.5	28.4	34.8	24.7	24.4	28.3	25.0	27.4	26.7
ERCC2	"EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD"	ENSG00000104884	"ERCC excision repair 2, TFIIH core complex helicase subunit"	P18074	19	45349837-45370918	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Chromosome partition, DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005375, HPA038057, HPA069266"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB005375: AB_2100152, HPA038057: , HPA069266: "	"unprognostic (1.10e-1)"	"unprognostic (5.48e-1)"	"unprognostic (5.08e-2)"	"unprognostic (9.92e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.67e-3)"	"unprognostic (1.46e-1)"	"unprognostic (3.41e-1)"	"unprognostic (1.06e-1)"	"prognostic favourable (3.26e-4)"	"unprognostic (3.36e-2)"	"unprognostic (2.44e-3)"	"unprognostic (1.94e-1)"	"unprognostic (5.47e-1)"	"unprognostic (8.99e-2)"	"unprognostic (3.45e-2)"	7.4	15.6	11.4	10.6	17.7	6.7	7.1	9.5	23.8	9.4	8.1	11.7	7.8	7.9	11.7	6.0	6.7	10.0	10.1	7.9	9.4	9.1	8.7	13.2	6.5	9.9	8.2	10.5	9.5	13.1	12.9	10.9	7.2	14.0	8.2	6.4	12.5	9.5	11.8	15.9	10.7	7.1	11.2	5.3	9.7	8.3	17.2	7.8	10.8	10.2	5.1	8.3	9.3	6.6	7.8	17.2	5.0	13.9	11.3	9.8	8.7	12.3	6.0	12.6	17.7	7.5	8.9	6.7	17.6	12.1	22.8	17.5	14.0	8.5	4.4	10.1	17.1	6.4	8.8	14.8	8.7	10.6	14.5	7.5	11.5	14.7	15.9	11.9	13.3	10.2	2.3	26.0	14.8	13.2	18.2	5.0	15.7	6.0	7.0	7.9	5.8	10.6	13.5	8.9	3.7	6.5	10.9	7.4	8.0	15.6	11.1	6.2	10.5	15.8	17.1	21.8	11.9	9.2	39.1	11.6	6.7	6.4	6.4	7.3	9.6	0.0	13.3	5.0	7.7	13.9	9.8	7.8	7.4	7.4	17.2	5.8	7.1	7.4	0.4	11.3	10.9	8.3	7.4	8.7	11.4	17.7	9.5	23.8	9.4	9.1	8.2	10.5	14.0	7.8
ERCC3	"BTF2, GTF2H, RAD25, TFIIH, XPB"	ENSG00000163161	"ERCC excision repair 3, TFIIH core complex helicase subunit"	P19447	2	127257290-127294176	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037153, HPA046077"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB037153: AB_796181, HPA046077: "	"unprognostic (2.31e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.07e-3)"	"unprognostic (1.05e-1)"	"unprognostic (8.85e-2)"	"prognostic unfavourable (1.62e-7)"	"unprognostic (2.74e-1)"	"unprognostic (9.13e-3)"	"unprognostic (9.25e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.46e-2)"	"prognostic unfavourable (4.30e-6)"	"unprognostic (3.71e-1)"	"unprognostic (8.50e-2)"	"unprognostic (5.73e-2)"	"unprognostic (3.92e-2)"	17.4	20.0	26.1	23.8	28.9	20.5	21.0	35.9	32.0	22.1	19.4	19.7	17.1	11.5	21.6	15.7	19.1	23.6	20.4	20.4	23.2	18.8	17.5	17.4	19.4	23.1	19.7	25.8	23.3	22.4	32.0	26.4	16.3	21.5	20.1	17.1	18.3	18.0	21.8	30.1	19.7	17.3	26.1	16.0	24.5	17.4	39.5	20.1	24.1	19.3	15.8	25.9	22.4	20.8	11.8	13.9	7.2	9.7	18.8	16.2	11.7	21.8	15.1	18.6	19.7	20.8	14.2	23.1	20.1	26.2	32.6	31.6	22.9	16.0	16.6	16.7	18.3	19.6	28.4	21.2	28.4	25.9	25.4	20.8	18.4	24.2	15.4	18.1	22.7	14.7	19.9	37.7	16.1	20.9	20.2	10.9	20.5	21.6	25.7	19.5	27.1	23.5	21.2	21.4	13.7	18.2	20.4	22.6	24.4	17.2	26.2	26.3	14.1	20.8	16.6	19.6	22.5	17.8	23.9	19.5	38.1	26.0	17.3	8.7	20.9	6.6	9.5	7.2	16.0	9.7	16.2	11.5	11.8	13.5	13.9	11.8	15.8	10.9	3.1	18.8	7.9	11.3	16.1	11.7	26.1	28.9	35.9	32.0	23.2	18.8	19.7	25.8	21.5	20.1
ERCC4	"FANCQ, RAD1, XPF"	ENSG00000175595	"ERCC excision repair 4, endonuclease catalytic subunit"	Q92889	16	13920157-13952345	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Cockayne syndrome, Disease mutation, Dwarfism, Fanconi anemia, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000156, HPA045828"	Approved		Supported	"Nucleoplasm,Nuclear bodies,Cell Junctions"				"Nucleoplasm, Nuclear bodies"	"Cell Junctions"	"CAB000156: , HPA045828: "	"unprognostic (2.05e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.12e-3)"	"unprognostic (9.41e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.26e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.49e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.30e-2)"	"unprognostic (5.88e-4)"	8.4	12.7	8.6	7.0	11.3	5.3	6.4	8.9	9.7	8.1	6.7	9.9	6.0	4.1	8.5	6.8	6.7	8.5	6.8	7.8	7.2	7.1	6.9	7.2	6.9	6.8	10.5	8.8	9.9	7.6	13.3	13.0	5.9	9.6	8.3	5.4	7.1	6.4	7.0	31.3	6.9	5.7	8.5	10.3	7.7	6.6	14.2	8.9	13.7	9.7	5.6	6.4	9.1	7.8	8.4	7.9	8.3	6.8	8.9	7.4	2.6	5.4	7.0	6.4	9.2	10.7	10.1	5.0	7.2	7.7	6.5	8.3	2.4	5.4	9.1	10.4	6.3	6.9	9.5	4.9	10.1	12.3	5.6	4.5	7.8	6.0	9.8	6.0	5.1	7.6	6.9	8.6	7.3	8.6	7.0	10.7	9.1	4.5	8.0	4.1	4.7	3.7	9.2	13.0	11.2	4.0	3.7	5.3	6.3	8.8	7.2	6.7	9.1	4.6	9.7	9.6	7.1	8.6	6.3	9.5	11.1	6.3	9.2	7.3	9.7	8.3	6.2	5.4	6.8	6.8	7.4	6.2	6.4	5.1	5.5	8.4	6.4	6.9	7.2	8.9	5.7	7.9	5.8	2.6	8.6	11.3	8.9	9.7	7.2	7.1	10.5	8.8	9.6	8.9
ERCC5	"ERCM2, XPGC"	ENSG00000134899	"ERCC excision repair 5, endonuclease"	P28715	13	102807146-102876001	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045845, HPA050126, HPA050374"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA045845: , HPA050126: , HPA050374: "	"unprognostic (1.28e-3)"	"unprognostic (1.32e-3)"	"unprognostic (1.86e-2)"	"unprognostic (9.28e-3)"	"unprognostic (6.19e-2)"	"unprognostic (8.73e-2)"	"unprognostic (1.23e-1)"	"unprognostic (8.72e-2)"	"unprognostic (2.52e-1)"	"unprognostic (2.55e-1)"	"unprognostic (7.77e-3)"	"unprognostic (5.76e-3)"	"prognostic unfavourable (2.96e-6)"	"unprognostic (3.56e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.67e-1)"	"prognostic favourable (6.82e-4)"	22.3	19.1	15.9	16.1	17.8	23.7	20.1	26.4	20.8	19.7	27.0	17.9	27.0	25.0	22.1	25.7	21.0	15.1	21.1	15.4	14.6	13.1	18.7	28.1	19.9	26.4	17.1	16.2	22.9	22.3	15.7	25.6	17.9	19.0	20.1	23.1	15.9	20.5	24.7	14.6	25.8	31.1	17.0	19.4	30.6	21.9	14.0	17.8	40.8	21.8	16.6	26.0	22.4	19.6	10.1	10.8	23.4	17.4	17.7	17.5	12.0	14.7	5.4	10.8	6.7	21.5	20.2	6.5	14.9	19.9	8.7	11.3	8.2	20.6	9.3	7.5	15.1	15.4	9.5	13.7	9.1	14.0	5.3	13.8	15.6	7.2	10.5	28.0	18.0	19.2	13.2	10.0	15.6	15.1	6.4	8.5	15.2	4.0	15.1	19.5	4.6	7.5	8.2	8.0	9.3	17.9	8.2	7.2	10.7	7.8	13.2	8.0	11.8	26.2	15.2	6.7	3.4	5.6	9.4	12.4	3.7	4.7	26.2	11.4	8.4	23.4	9.8	18.3	16.7	12.3	15.5	9.6	15.5	17.5	10.8	10.1	16.6	16.1	7.2	17.7	17.4	7.7	16.6	12.0	15.9	17.8	26.4	20.8	14.6	13.1	17.1	16.2	19.0	17.8
ERCC6	"ARMD5, CKN2, CSB, RAD26"	ENSG00000225830	"ERCC excision repair 6, chromatin remodeling factor"	"Q03468, P0DP91, Q8N328"	10	49455368-49539538	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Neurogenesis, Transcription, Transcription regulation"	"DNA-binding, Helicase, Hydrolase"	"Age-related macular degeneration, Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Mental retardation, Premature ovarian failure, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 34.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA071297			Approved	"Nucleoplasm,Nuclear bodies"				Nucleoplasm	"Nuclear bodies"	"HPA071297: "	"unprognostic (1.92e-2)"	"unprognostic (1.85e-1)"	"unprognostic (9.79e-3)"	"unprognostic (7.26e-2)"	"unprognostic (5.45e-2)"	"unprognostic (2.95e-2)"	"unprognostic (3.03e-2)"	"unprognostic (2.99e-2)"	"unprognostic (1.71e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.57e-2)"	"unprognostic (1.04e-1)"	"unprognostic (8.61e-2)"	"unprognostic (4.75e-2)"	"unprognostic (1.73e-1)"	"unprognostic (7.05e-2)"	7.9	6.9	11.5	6.0	12.3	13.9	11.1	21.0	13.9	9.8	7.0	8.9	10.6	6.4	9.3	8.6	13.5	8.1	7.7	9.1	12.7	6.5	10.1	10.0	8.0	7.9	9.2	11.4	12.5	13.1	20.3	14.2	9.7	10.1	10.5	8.8	9.2	10.5	13.7	9.6	14.4	9.1	7.9	11.8	9.2	7.6	7.8	12.4	7.8	13.6	8.2	9.6	9.9	11.6	7.9	5.1	10.9	8.1	1.6	5.3	2.1	6.6	3.5	2.6	1.6	4.5	7.6	2.1	11.9	16.5	8.2	5.8	3.6	4.1	2.9	2.2	10.7	6.2	3.7	9.4	8.3	4.6	2.4	2.2	13.1	2.0	2.6	3.0	2.3	2.6	12.9	8.0	34.2	11.9	4.3	0.8	10.6	4.9	2.1	1.7	2.4	6.2	2.0	3.8	1.7	2.8	4.7	3.5	3.6	8.8	3.2	5.3	5.8	1.7	22.8	4.6	3.8	5.5	3.0	3.2	3.0	2.8	5.6	3.3	3.4	10.9	4.1	9.7	5.3	3.7	4.2	7.9	3.1	2.9	5.1	6.3	3.8	1.8	9.8	1.6	8.1	2.8	4.0	2.1	11.5	12.3	21.0	13.9	12.7	6.5	9.2	11.4	10.1	12.4
ERG	"erg-3, p55"	ENSG00000157554	"ERG, ETS transcription factor"	P11308	21	38380027-38661780	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"HUVEC TERT2: 42.7;MOLT-4: 14.0;REH: 45.3;TIME: 34.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 18.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"myeloid DC: 1.7;NK-cell: 1.0"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.7;NK-cells: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB018377, HPA046598"	Approved		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB018377: AB_675518, HPA046598: "	"unprognostic (2.14e-1)"	"prognostic unfavourable (6.18e-6)"	"unprognostic (6.44e-3)"	"unprognostic (8.64e-3)"	"unprognostic (5.65e-2)"	"unprognostic (1.91e-1)"	"unprognostic (9.03e-4)"	"unprognostic (4.30e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavourable (3.94e-4)"	"unprognostic (4.31e-3)"	"unprognostic (3.88e-2)"	"unprognostic (2.64e-2)"	"unprognostic (5.63e-3)"	39.1	4.2	5.7	6.5	8.5	6.6	20.5	3.6	7.0	17.9	5.2	2.3	5.6	3.3	16.9	9.0	6.2	9.2	11.6	10.1	6.2	3.6	10.8	6.0	19.9	7.4	8.0	1.8	7.7	4.8	2.3	3.9	23.2	8.0	8.1	3.6	7.8	4.2	5.6	13.5	5.3	6.2	11.8	4.7	32.5	5.0	4.8	5.0	2.4	10.8	9.1	3.6	9.6	15.8	0.0	1.7	0.0	0.2	1.0	0.0	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	7.0	0.0	0.0	0.3	0.0	42.7	0.0	0.0	0.0	0.3	14.0	0.0	0.1	0.0	45.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	34.6	0.2	0.7	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.4	5.7	8.5	3.6	7.0	6.2	3.6	8.0	1.8	8.0	5.0
ESR1	"ER-alpha, Era, ESR, NR3A1"	ENSG00000091831	"Estrogen receptor 1"	P03372	6	151656691-152129619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 64.5;endometrium 1: 68.9"	"Group enriched"	"Detected in some"	9	"MCF7: 24.3;T-47d: 31.5"	"Group enriched"	"Detected in many"	9	"breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB000037, HPA000449, HPA000450, CAB055099, CAB072858"	Enhanced		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: , HPA000449: AB_1078753, HPA000450: AB_1078754"	"unprognostic (8.28e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.43e-2)"	"prognostic favourable (5.47e-7)"	"unprognostic (4.79e-1)"	"unprognostic (2.43e-3)"	"unprognostic (4.10e-5)"	"unprognostic (9.92e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.17e-2)"	"unprognostic (7.35e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.20e-2)"	"unprognostic (7.91e-3)"	"unprognostic (6.45e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.52e-1)"	3.0	0.9	0.5	1.6	0.5	0.2	16.2	0.8	0.4	64.5	1.5	0.2	2.2	0.1	68.9	27.7	1.1	26.7	1.9	1.1	0.5	0.8	1.5	6.6	3.6	1.6	0.4	0.1	14.2	0.4	0.0	9.3	0.9	0.6	3.6	0.1	2.6	1.6	4.1	2.0	0.6	0.5	20.8	0.4	1.6	0.3	1.9	0.4	1.9	1.3	2.2	2.5	3.8	23.7	0.6	1.0	0.0	0.8	0.3	2.5	1.0	0.3	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.6	0.0	24.3	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	1.8	0.0	0.0	0.0	0.3	0.0	31.5	0.0	0.0	0.1	0.1	0.3	0.0	2.9	0.5	0.0	0.1	0.2	0.0	0.0	0.8	0.0	0.3	0.2	1.0	0.6	1.3	0.4	1.0	0.4	2.5	0.9	0.0	0.3	0.0	0.0	0.3	1.0	0.5	0.5	0.8	0.4	0.5	0.8	0.4	0.1	0.6	0.4
ESR2	"ER-beta, Erb, NR3A2"	ENSG00000140009	"Estrogen receptor 2"	Q92731	14	64084232-64338112	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"ovary: 19.1;testis: 30.2;vagina: 14.3"	"Cell line enhanced"	"Detected in some"		"U-266/70: 10.5;U-698: 17.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"cerebellum: 17.8"	CAB079300	Enhanced									"CAB079300: "	"unprognostic (7.63e-3)"	"unprognostic (2.28e-3)"	"unprognostic (8.27e-3)"	"unprognostic (5.41e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.75e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.03e-5)"	"unprognostic (1.57e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.21e-2)"	"unprognostic (5.89e-2)"	2.1	9.4	0.2	2.3	0.8	1.0	3.7	0.8	0.6	1.3	2.9	0.6	0.2	1.4	1.7	0.7	1.7	1.1	0.6	1.0	1.1	0.4	1.4	0.7	1.3	2.8	0.2	0.2	19.1	2.5	0.0	1.6	0.7	1.4	2.2	1.5	0.5	1.5	0.9	1.4	1.2	1.5	0.6	1.0	3.0	1.3	30.2	0.6	5.0	0.6	0.2	2.9	1.8	14.3	2.4	4.0	1.1	0.3	0.4	1.3	0.2	0.7	0.3	0.7	0.6	0.0	0.1	1.3	0.1	0.0	0.1	0.1	0.2	0.8	2.8	0.1	0.0	1.0	0.9	0.0	0.1	0.7	0.3	0.3	0.7	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.2	0.2	0.6	4.0	0.1	0.7	0.4	0.2	0.7	0.4	0.5	0.3	0.2	0.1	1.3	2.4	0.7	0.5	0.2	1.1	0.8	0.0	0.4	0.5	0.9	0.2	0.1	10.5	3.2	17.2	0.2	0.1	0.7	0.3	0.3	1.0	0.8	0.2	0.6	1.7	0.6	1.1	0.1	2.4	1.3	1.0	1.1	0.4	0.2	4.0	0.5	0.2	0.2	0.8	0.8	0.6	1.1	0.4	0.2	0.2	1.4	0.6
ETNK1	"EKI, EKI1"	ENSG00000139163	"Ethanolamine kinase 1"	Q9HBU6	12	22625075-22690665	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010712, HPA029407"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoplasm	"HPA010712: , HPA029407: "	"unprognostic (2.06e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.23e-3)"	"unprognostic (2.19e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.31e-2)"	"prognostic unfavourable (5.85e-4)"	"unprognostic (3.98e-3)"	"unprognostic (8.30e-2)"	"unprognostic (7.97e-3)"	"unprognostic (2.01e-1)"	"unprognostic (1.64e-2)"	"unprognostic (4.53e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.91e-1)"	"unprognostic (3.01e-1)"	"prognostic favourable (1.75e-4)"	15.7	17.7	15.2	41.1	19.4	13.7	16.9	19.7	22.2	12.9	33.2	16.4	14.6	27.2	16.6	24.1	14.7	13.1	27.3	10.4	15.6	23.9	22.0	30.2	19.6	18.5	17.2	15.8	17.2	14.9	15.8	30.6	13.4	18.9	13.8	19.5	15.9	16.7	14.7	8.2	17.8	24.5	10.0	17.1	18.3	53.7	22.3	17.5	33.4	17.6	8.2	16.5	14.2	18.6	16.2	10.7	28.1	17.6	14.0	15.7	13.4	6.7	14.0	15.5	14.3	11.2	11.4	11.6	8.0	6.0	8.3	8.5	10.8	17.0	20.0	7.2	5.2	5.1	13.6	3.8	14.9	16.6	11.0	16.5	6.1	9.2	10.7	15.8	15.2	7.4	3.7	11.1	9.5	10.2	19.8	8.5	10.9	4.6	17.2	32.2	30.0	9.1	15.6	13.8	16.1	13.7	9.1	5.0	8.8	8.7	7.5	12.5	11.8	15.3	8.8	6.6	10.6	8.9	12.0	6.2	7.7	21.5	8.4	10.3	11.0	28.1	11.7	12.1	12.9	17.5	12.7	16.2	14.1	11.9	10.7	13.0	15.7	15.5	11.5	14.0	17.6	9.7	15.3	13.4	15.2	19.4	19.7	22.2	15.6	23.9	17.2	15.8	18.9	17.5
ETV1	ER81	ENSG00000006468	"ETS variant 1"	P50549	7	13891228-13991425	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 90.0;salivary gland: 45.8"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 22.2;SCLC-21H: 26.3;U-87 MG: 51.9;WM-115: 25.6"	"Cancer enhanced"	"Detected in all"		"glioma: 22.5"	"Region enriched"	"Detected in all"	8	"cerebellum: 90.0"	"Cell type enriched"	"Detected in single"	5	"T-reg: 3.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 3.1"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 418.9"	"HPA068389, HPA077249"		Supported	Approved	Nucleoplasm				Nucleoplasm		"HPA068389: , HPA077249: "	"unprognostic (2.45e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.64e-7)"	"unprognostic (7.08e-3)"	"unprognostic (7.21e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.01e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.51e-3)"	"unprognostic (2.21e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.20e-2)"	2.5	12.4	8.1	1.1	11.7	0.2	4.4	90.0	35.2	1.4	2.4	3.1	0.1	1.2	2.4	1.3	1.5	1.1	9.2	18.0	7.0	4.5	2.1	2.0	14.9	0.7	4.5	6.9	1.0	1.6	11.4	7.4	1.9	8.3	3.1	2.4	0.9	45.8	7.1	0.9	1.5	1.9	2.0	3.5	4.5	1.7	4.5	2.9	0.3	6.5	0.9	4.7	1.8	1.3	0.0	0.0	0.0	0.6	0.0	3.1	0.2	0.0	1.6	11.7	22.2	4.1	12.2	0.0	1.0	3.9	0.6	2.6	0.0	5.3	0.0	1.2	1.8	0.1	0.4	1.2	1.4	0.3	0.5	0.6	1.0	0.0	2.4	3.8	1.5	3.6	0.0	7.6	0.6	5.0	3.4	0.1	4.7	0.0	0.0	0.0	17.5	11.8	0.0	7.1	0.9	7.9	0.1	26.3	5.1	0.0	0.4	6.3	0.4	0.1	2.7	2.3	0.7	4.5	4.3	4.0	1.2	0.0	51.9	0.2	25.6	0.0	0.2	0.0	0.1	0.6	0.3	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.2	8.1	11.7	90.0	10.9	7.0	4.5	4.5	6.9	8.3	2.9
ETV4	"E1A-F, E1AF, PEA3"	ENSG00000175832	"ETS variant 4"	P43268	17	43527844-43579620	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 38.4"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 45.0;Hep G2: 42.2;SK-MEL-30: 48.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA005768	Approved		Supported	Nucleoli				Nucleoli		"HPA005768: AB_1848294"	"unprognostic (2.32e-1)"	"unprognostic (7.33e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.97e-2)"	"unprognostic (3.14e-3)"	"prognostic unfavourable (2.48e-4)"	"unprognostic (1.58e-2)"	"unprognostic (5.34e-2)"	"unprognostic (8.13e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.01e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.03e-1)"	"unprognostic (7.08e-2)"	"prognostic favourable (7.60e-4)"	"unprognostic (1.69e-1)"	0.6	2.4	1.4	0.9	1.4	0.0	6.8	1.6	8.3	3.6	3.3	0.4	1.3	5.7	3.4	2.2	9.9	2.4	38.4	2.6	1.8	1.3	7.8	1.4	2.5	0.4	2.3	1.1	1.2	23.8	19.3	19.7	11.6	2.7	4.7	1.6	1.7	4.9	4.5	1.3	6.7	3.8	1.2	1.8	0.5	3.6	1.3	0.5	0.3	6.6	15.0	12.1	3.1	5.3	0.2	0.0	1.3	0.2	0.0	0.6	0.1	5.9	16.7	20.5	45.0	0.8	5.3	4.5	1.9	5.3	3.8	3.9	9.4	8.5	0.0	1.1	1.0	10.9	0.6	10.0	3.4	0.2	0.1	0.5	2.6	42.2	1.1	11.4	5.3	0.9	0.3	14.5	9.0	8.1	11.7	0.0	7.8	2.3	0.0	20.2	29.6	28.0	24.4	2.4	14.3	8.4	4.3	0.0	18.3	0.5	1.1	48.7	0.2	3.4	3.7	2.7	13.4	4.0	5.4	1.8	11.2	0.0	4.9	2.2	15.8	0.0	0.0	0.0	0.0	0.2	0.5	0.2	0.1	0.0	0.0	0.0	0.2	0.6	1.3	0.0	0.0	0.0	0.0	0.1	1.4	1.4	1.6	3.6	1.8	1.3	2.3	1.1	2.7	0.5
ETV5	ERM	ENSG00000244405	"ETS variant 5"	P41161	3	186046308-186110318	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 55.3"	"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 55.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 3.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009590, HPA063065"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB009590: AB_2101008, HPA063065: "	"unprognostic (3.85e-1)"	"unprognostic (5.81e-2)"	"unprognostic (1.54e-2)"	"unprognostic (3.30e-1)"	"unprognostic (9.00e-2)"	"unprognostic (2.56e-3)"	"prognostic unfavourable (7.85e-9)"	"unprognostic (3.52e-3)"	"unprognostic (2.97e-1)"	"unprognostic (1.22e-2)"	"unprognostic (4.18e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.57e-3)"	"unprognostic (6.80e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.84e-3)"	5.8	30.3	13.2	5.5	21.7	1.6	11.3	12.1	35.2	4.7	3.0	15.7	1.3	5.1	6.8	6.2	3.8	4.6	4.8	8.8	13.6	9.4	7.1	6.2	21.9	8.9	9.9	11.0	2.5	25.4	55.3	28.1	24.3	11.5	6.3	3.1	7.4	5.5	5.1	9.8	5.3	2.8	6.1	9.6	10.0	11.9	7.2	6.1	2.0	16.6	1.7	3.6	3.6	3.6	0.6	1.8	0.9	3.1	0.1	0.3	0.5	12.8	8.9	11.4	24.8	7.0	7.3	0.8	11.0	12.4	8.7	9.5	9.7	7.9	0.3	14.8	10.7	2.2	0.2	8.4	13.0	2.8	0.3	3.7	0.3	10.9	11.7	9.3	7.0	6.4	1.3	13.9	17.1	12.8	3.4	4.6	14.9	5.9	1.2	14.3	17.0	10.1	26.2	11.4	8.6	7.2	3.0	0.5	14.7	2.7	0.1	55.7	0.0	5.2	12.3	4.8	7.8	12.1	21.6	3.5	14.4	0.0	14.7	7.5	28.6	0.0	0.3	0.1	0.3	3.1	0.0	0.6	0.0	0.0	1.8	0.1	0.0	0.0	0.9	0.1	1.5	1.6	0.0	0.5	13.2	21.7	12.1	31.7	13.6	9.4	9.9	11.0	11.5	6.1
ETV6	TEL	ENSG00000139083	"ETS variant 6"	P41212	12	11649854-11895402	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 38.9;NB-4: 20.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000264	Enhanced		Approved	Nucleoli,Cytosol				Nucleoli	Cytosol	"HPA000264: AB_1078763"	"unprognostic (4.03e-3)"	"unprognostic (3.08e-2)"	"unprognostic (7.54e-3)"	"unprognostic (2.60e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.35e-3)"	"unprognostic (2.74e-2)"	"unprognostic (4.02e-2)"	"unprognostic (3.16e-1)"	"unprognostic (9.46e-2)"	"prognostic unfavourable (9.38e-5)"	"unprognostic (1.15e-1)"	"prognostic unfavourable (4.66e-8)"	"unprognostic (1.33e-2)"	"unprognostic (5.99e-2)"	"unprognostic (8.92e-2)"	"prognostic favourable (1.54e-5)"	17.2	8.9	5.1	20.0	7.6	32.8	20.4	1.6	9.1	10.5	14.5	6.0	9.8	7.2	10.8	14.2	11.3	8.9	15.3	6.7	5.6	3.8	9.2	9.6	16.0	13.4	6.0	3.1	10.5	10.4	8.4	8.7	7.7	7.4	14.9	11.0	8.0	41.9	12.4	6.9	23.9	14.6	25.0	9.4	17.8	9.7	4.7	5.7	30.6	10.0	10.0	19.9	19.0	15.8	2.9	6.2	11.4	7.1	2.4	2.2	1.3	2.5	3.5	3.2	5.5	2.4	2.3	3.8	1.9	3.2	2.5	3.0	0.2	12.2	2.1	1.9	3.2	3.3	1.4	5.8	3.0	38.9	0.7	13.7	1.9	1.3	3.0	14.4	15.0	4.5	3.6	2.4	5.1	7.5	1.0	7.3	2.2	1.6	8.1	20.7	5.1	0.9	2.3	3.0	5.6	5.7	16.2	0.6	3.2	3.8	3.7	3.5	1.2	9.1	8.5	5.6	4.8	1.8	4.0	3.2	2.4	1.2	3.6	0.1	6.4	5.6	5.7	6.6	1.5	6.6	2.0	2.9	2.2	1.4	4.1	2.3	1.3	0.8	11.4	2.4	7.1	6.2	1.4	1.3	5.1	7.6	1.6	9.1	5.6	3.8	6.0	3.1	7.4	5.7
EWSR1	EWS	ENSG00000182944	"EWS RNA binding protein 1"	Q01844	22	29268009-29300525	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Calmodulin-binding, Repressor, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004230, HPA051771, HPA062953"	Enhanced		Enhanced	Nucleoplasm,Nucleoli				Nucleoplasm	Nucleoli	"CAB004230: AB_675526, HPA051771: AB_2681602, HPA062953: AB_2684910"	"unprognostic (1.96e-1)"	"unprognostic (6.39e-3)"	"unprognostic (1.32e-1)"	"unprognostic (3.93e-2)"	"unprognostic (3.59e-1)"	"unprognostic (3.15e-2)"	"prognostic unfavourable (1.27e-6)"	"unprognostic (1.33e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.71e-2)"	"unprognostic (7.04e-2)"	"unprognostic (9.30e-2)"	"prognostic unfavourable (1.21e-5)"	"unprognostic (7.33e-3)"	"unprognostic (1.79e-1)"	"unprognostic (3.67e-2)"	"unprognostic (1.50e-3)"	35.3	43.2	45.3	41.3	51.3	67.5	32.1	58.2	48.6	32.4	39.8	43.2	31.3	41.0	45.1	38.5	40.8	37.6	25.9	40.7	40.1	32.8	33.0	48.5	33.4	50.5	32.7	49.9	38.4	32.0	47.2	44.3	34.0	41.7	35.0	39.9	41.5	32.3	38.2	52.8	34.8	36.6	40.5	33.8	44.1	34.5	85.6	32.5	39.9	32.5	30.9	55.4	36.4	34.5	52.0	65.8	50.6	81.1	58.4	67.8	76.1	56.4	44.0	60.5	47.0	30.9	25.6	41.6	34.4	55.0	57.1	49.0	50.1	29.3	77.2	21.8	52.7	44.4	86.2	70.4	58.8	52.5	61.5	58.3	39.0	47.9	46.2	89.6	41.7	39.1	29.7	47.6	77.3	44.1	43.6	34.9	42.2	56.7	90.0	34.4	42.5	33.5	63.2	58.3	46.6	52.5	60.0	49.6	47.4	42.8	50.2	37.1	32.2	48.8	45.0	34.9	38.8	21.9	49.9	45.4	36.4	71.6	33.2	39.9	42.4	48.4	57.9	50.6	60.2	81.1	60.7	50.4	56.6	59.6	65.8	52.0	55.8	53.6	43.3	58.4	78.6	35.3	67.8	76.1	45.3	51.3	58.2	48.6	40.1	32.8	32.7	49.9	41.7	32.5
EXT1	"LGCR, LGS, ttv"	ENSG00000182197	"Exostosin glycosyltransferase 1"	Q16394	8	117794490-118111853	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Hereditary multiple exostoses, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 66.4"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 55.1;fHDF/TERT166: 55.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044394	Uncertain					9600000	9600000			"HPA044394: AB_10963838"	"unprognostic (1.29e-2)"	"prognostic unfavourable (7.04e-4)"	"unprognostic (2.73e-2)"	"unprognostic (2.02e-3)"	"unprognostic (2.19e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.99e-1)"	"prognostic unfavourable (1.20e-5)"	"unprognostic (1.70e-1)"	"unprognostic (3.01e-2)"	"unprognostic (1.31e-2)"	"unprognostic (6.58e-2)"	"unprognostic (1.27e-2)"	"unprognostic (9.84e-2)"	"unprognostic (9.49e-2)"	"prognostic unfavourable (4.64e-4)"	"unprognostic (1.85e-1)"	13.8	11.9	5.8	20.5	4.6	2.1	16.5	7.3	7.4	13.3	17.1	4.1	8.7	23.2	11.5	12.5	11.2	8.8	19.3	14.4	4.6	3.1	8.8	66.4	19.9	8.3	3.0	6.8	10.4	17.9	7.1	6.4	15.6	4.8	9.8	16.0	13.2	9.8	13.3	4.2	12.3	32.0	16.8	4.3	20.1	11.5	5.0	2.7	8.7	12.0	10.3	7.2	11.0	18.5	0.8	1.7	1.2	4.5	0.7	2.4	1.0	17.2	5.0	7.5	2.9	13.6	11.0	3.4	32.3	55.1	23.8	21.9	5.1	1.7	0.3	14.5	55.7	10.9	3.3	18.9	33.5	6.5	5.6	0.6	4.7	4.1	6.4	0.0	1.2	6.9	5.1	28.9	26.6	14.6	0.4	4.8	11.0	1.4	0.8	0.0	2.4	6.4	0.0	2.8	0.5	9.4	6.3	2.3	2.2	4.9	2.3	4.8	3.2	0.2	19.4	20.1	18.4	18.4	9.5	2.7	2.7	1.6	18.6	0.0	5.3	0.3	4.4	0.2	0.2	4.5	1.3	0.8	0.5	0.6	1.0	0.1	0.5	0.9	1.2	0.7	2.2	1.7	2.4	1.0	5.8	4.6	7.3	7.4	4.6	3.1	3.0	6.8	4.8	2.7
EXT2	SOTV	ENSG00000151348	"Exostosin glycosyltransferase 2"	Q93063	11	44095549-44245429	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, Hereditary multiple exostoses, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA078409			Supported	"Golgi apparatus"		20000000	20000000	"Golgi apparatus"		"HPA078409: "	"unprognostic (5.87e-2)"	"unprognostic (3.05e-3)"	"unprognostic (3.48e-2)"	"unprognostic (3.94e-1)"	"unprognostic (1.42e-1)"	"prognostic unfavourable (2.50e-4)"	"unprognostic (1.77e-3)"	"unprognostic (2.22e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.70e-2)"	"prognostic unfavourable (5.36e-6)"	"unprognostic (7.07e-3)"	"unprognostic (2.97e-1)"	"unprognostic (3.85e-1)"	"unprognostic (1.36e-2)"	24.5	19.5	11.6	17.2	18.5	6.6	25.8	14.5	23.0	26.8	25.0	15.5	17.5	17.6	37.1	25.5	16.7	26.0	23.4	22.7	11.7	13.0	19.2	36.3	22.3	16.8	11.8	12.3	29.3	21.8	25.7	17.3	58.0	16.2	23.7	20.6	22.9	24.7	22.8	16.9	20.2	34.0	35.0	12.2	18.7	19.3	20.0	11.4	16.2	24.7	16.7	13.0	20.2	23.2	6.7	14.9	13.0	12.0	17.8	17.6	9.8	12.9	17.9	9.7	30.2	44.8	33.0	13.4	40.2	50.3	23.8	32.4	12.7	8.9	8.9	18.3	47.0	20.6	10.4	28.5	28.8	17.9	14.3	8.2	9.4	9.7	17.7	8.2	17.8	25.6	18.9	14.4	22.5	33.8	11.0	16.2	17.3	9.9	5.7	5.0	10.4	12.8	7.2	27.8	4.5	13.7	12.3	7.0	7.8	25.4	10.4	6.7	17.3	8.8	30.5	32.2	21.1	31.5	25.7	7.3	9.5	6.5	21.2	6.4	34.3	9.3	11.9	13.0	15.6	12.0	17.6	6.4	12.5	14.4	14.9	6.7	11.9	11.7	2.6	17.8	8.5	5.1	9.6	9.8	11.6	18.5	14.5	23.0	11.7	13.0	11.8	12.3	16.2	11.4
EZH1	"KIAA0388, KMT6B"	ENSG00000108799	"Enhancer of zeste 1 polycomb repressive complex 2 subunit"	Q92800	17	42700275-42745049	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 31.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005478, HPA077684"	Supported		Supported	Nucleoplasm				Nucleoplasm		"HPA005478: AB_1848340, HPA077684: "	"unprognostic (1.01e-1)"	"unprognostic (6.02e-2)"	"unprognostic (2.19e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.84e-3)"	"unprognostic (1.76e-2)"	"unprognostic (1.18e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.55e-3)"	"unprognostic (5.22e-3)"	"unprognostic (4.11e-3)"	"unprognostic (1.48e-2)"	"unprognostic (4.60e-2)"	"unprognostic (3.29e-1)"	"unprognostic (5.39e-2)"	"unprognostic (4.74e-2)"	21.7	10.4	15.0	10.1	25.0	9.9	18.7	39.6	26.1	18.4	15.1	21.4	10.0	9.7	29.8	21.2	10.6	18.8	9.7	17.2	19.0	11.2	13.6	5.3	12.6	14.0	13.7	22.0	38.2	8.1	20.0	19.1	9.3	25.6	13.1	12.1	21.5	10.7	19.3	25.4	16.0	14.0	16.4	19.9	16.0	10.6	8.6	16.7	11.9	15.0	7.5	14.9	16.0	15.9	6.2	6.0	18.8	5.4	4.8	8.3	2.3	5.4	5.8	7.9	5.4	31.7	19.2	6.7	8.8	8.1	7.3	7.5	2.7	6.8	8.3	5.5	9.3	12.4	5.1	5.9	10.6	9.2	9.2	2.8	10.7	3.3	10.9	6.2	6.9	10.9	10.7	5.5	13.4	5.9	7.5	11.7	6.4	2.3	10.0	7.9	2.1	3.0	6.6	8.0	8.8	7.6	5.8	5.4	4.3	4.9	2.4	5.8	8.4	4.0	6.1	7.9	3.3	9.2	5.5	12.3	6.2	4.9	5.6	6.4	4.0	10.2	5.2	6.9	5.9	5.4	8.3	5.7	5.2	6.0	1.9	6.2	7.7	5.7	18.8	4.8	3.3	6.0	5.7	2.3	15.0	25.0	39.6	26.1	19.0	11.2	13.7	22.0	25.6	16.7
EZH2	"ENX-1, EZH1, KMT6, KMT6A"	ENSG00000106462	"Enhancer of zeste 2 polycomb repressive complex 2 subunit"	Q15910	7	148807383-148884321	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 25.5;lymphoid tissue: 44.1"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009589	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB009589: "	"unprognostic (2.42e-1)"	"unprognostic (3.95e-3)"	"unprognostic (1.57e-1)"	"unprognostic (3.30e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.85e-3)"	"prognostic unfavourable (2.11e-6)"	"unprognostic (2.21e-2)"	"prognostic unfavourable (1.96e-4)"	"unprognostic (2.32e-3)"	"unprognostic (1.58e-3)"	"unprognostic (1.69e-3)"	"prognostic unfavourable (8.18e-12)"	"prognostic favourable (6.97e-4)"	"unprognostic (1.83e-1)"	"unprognostic (2.12e-1)"	"unprognostic (6.67e-2)"	2.0	1.7	1.8	10.6	1.6	25.5	1.4	4.9	2.7	2.6	4.8	1.1	0.1	3.8	1.7	2.8	11.0	0.9	3.0	0.9	0.8	0.6	1.7	3.3	2.3	12.6	1.3	0.3	2.2	3.8	0.6	1.7	3.4	1.4	1.4	5.1	1.8	3.2	1.6	3.7	6.4	4.8	1.5	1.2	5.8	2.7	19.6	1.3	44.1	0.9	5.5	12.4	2.6	3.5	1.5	4.7	1.3	3.9	8.5	10.3	1.7	16.9	7.9	27.1	18.0	0.8	1.4	14.8	13.2	5.3	10.9	11.0	11.9	19.6	29.9	6.4	4.9	10.4	13.9	4.5	13.9	42.8	13.9	12.7	9.8	9.2	2.2	28.4	10.5	1.2	2.6	8.1	4.3	6.4	27.1	19.9	9.7	19.2	55.1	23.7	21.5	10.7	34.1	15.2	18.5	5.0	8.1	25.9	16.5	16.6	12.6	4.3	9.2	12.2	3.9	11.6	5.4	23.1	23.6	17.9	19.4	30.1	10.6	19.4	22.7	0.5	2.2	1.3	1.7	1.5	1.3	1.5	3.4	2.9	4.7	0.8	1.9	1.2	0.2	8.5	3.9	1.0	10.3	1.7	1.8	1.6	4.9	2.7	0.8	0.6	1.3	0.3	1.4	1.3
EZR	VIL2	ENSG00000092820	Ezrin	P15311	6	158765741-158819412	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell shape"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004035, HPA021616, CAB047324, CAB075739"	Enhanced		Enhanced	"Plasma membrane"		75000000	75000000	"Plasma membrane"		"CAB004035: AB_2100309, CAB047324: , CAB075739: , HPA021616: AB_1848342"	"unprognostic (4.79e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.97e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.31e-3)"	"unprognostic (1.76e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.32e-1)"	"unprognostic (7.53e-2)"	"prognostic unfavourable (1.70e-4)"	"unprognostic (5.59e-2)"	"prognostic favourable (9.56e-8)"	"unprognostic (1.16e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.34e-2)"	"unprognostic (9.00e-2)"	22.8	56.4	30.9	31.2	31.4	24.7	13.3	4.0	21.5	18.0	45.5	28.2	35.2	33.8	9.8	25.8	71.8	25.1	30.2	34.3	37.6	13.9	53.5	16.2	44.3	36.7	14.8	19.0	20.7	33.0	77.1	14.6	125.1	23.5	21.7	22.8	37.0	27.4	32.0	13.6	47.5	87.9	22.8	12.8	26.0	55.4	21.4	22.2	41.6	37.1	34.4	75.6	38.2	25.3	81.7	30.0	24.3	31.2	20.7	61.7	41.1	87.0	47.6	11.8	16.9	1.3	1.4	68.9	27.4	9.0	30.9	26.1	55.7	48.3	87.7	27.2	31.3	66.8	23.2	30.5	35.9	30.6	15.0	1.8	28.9	24.6	31.4	21.7	13.5	2.3	23.7	29.1	28.3	20.2	17.3	43.0	17.9	22.9	30.7	26.2	19.6	15.9	23.1	5.5	19.9	63.5	26.5	21.4	17.5	47.9	69.1	5.2	16.8	28.7	26.1	10.0	32.1	13.7	42.1	29.7	27.0	75.2	6.2	11.2	11.9	24.3	14.0	16.4	34.8	31.2	41.0	81.7	36.7	42.9	30.0	67.5	19.9	26.5	6.1	20.7	30.6	14.0	61.7	41.1	30.9	31.4	4.0	21.5	37.6	13.9	14.8	19.0	23.5	22.2
F13A1	F13A	ENSG00000124491	"Coagulation factor XIII A chain"	P00488	6	6144085-6321013	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 110.1"	"Cell line enhanced"	"Detected in some"		"AF22: 15.3;LHCN-M2: 5.7;RH-30: 28.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 27.6;myeloid DC: 33.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 33.7;monocytes: 27.6"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA001804, CAB002155"	Enhanced				"Secreted to blood"	1400000000	1400000000			"CAB002155: AB_564077, HPA001804: AB_1078792"	"unprognostic (4.44e-1)"	"unprognostic (5.90e-2)"	"unprognostic (2.65e-2)"	"unprognostic (3.93e-2)"	"unprognostic (5.02e-2)"	"unprognostic (3.75e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.68e-2)"	"unprognostic (6.84e-3)"	"unprognostic (4.96e-2)"	"unprognostic (1.97e-1)"	"prognostic unfavourable (6.61e-6)"	"unprognostic (2.79e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.54e-3)"	56.6	19.4	2.2	11.4	6.5	3.1	57.9	2.2	1.8	13.3	21.8	2.6	2.5	2.2	4.7	35.6	13.4	16.8	12.6	55.4	2.0	2.2	17.5	1.3	14.5	52.7	5.8	1.4	10.2	8.9	5.3	9.3	110.1	7.5	16.4	15.1	11.6	11.5	3.3	18.5	10.4	10.6	20.1	5.0	5.1	11.5	16.7	2.5	2.7	22.4	8.3	6.1	23.7	6.5	0.0	33.7	6.6	27.6	0.0	0.1	63.5	0.0	0.0	15.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.1	0.0	0.0	0.0	28.9	0.5	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.0	2.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.7	27.6	0.2	0.1	4.9	0.1	0.0	0.0	0.0	33.7	0.0	0.0	0.0	6.6	0.0	0.1	2.4	0.0	63.5	2.2	6.5	2.2	1.8	2.0	2.2	5.8	1.4	7.5	2.5
F13B	FXIIIB	ENSG00000143278	"Coagulation factor XIII B chain"	P05160	1	197039191-197067267	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	95	"liver: 76.3"	"Cell line enhanced"	"Detected in some"		"A549: 1.8;Hep G2: 2.2"	"Cancer enriched"	"Detected in single"	816	"liver cancer: 46.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA003827, HPA052139"	Supported				"Secreted to blood"	3400000000	3400000000			"HPA003827: AB_1078794, HPA052139: "					"unprognostic (1.46e-1)"		"prognostic favourable (6.78e-5)"							"unprognostic (1.21e-2)"				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	76.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.3	2.2	0.0	0.5	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
F2		ENSG00000180210	"Coagulation factor II, thrombin"	P00734	11	46719180-46739506	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	593	"liver: 324.8"	"Cell line enriched"	"Detected in some"	21	"Hep G2: 76.5"	"Cancer enriched"	"Detected in some"	110	"liver cancer: 508.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB016780, CAB018650, HPA051476, HPA054698"	Enhanced				"Secreted to blood"	43000000000	43000000000			"CAB016780: , CAB018650: AB_2246689, HPA051476: , HPA054698: "	"unprognostic (1.98e-1)"	"unprognostic (2.52e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.23e-2)"	"unprognostic (3.94e-2)"		"unprognostic (5.79e-2)"	"unprognostic (8.29e-2)"	"unprognostic (4.46e-2)"	"prognostic unfavourable (6.75e-12)"	"unprognostic (5.65e-3)"	"unprognostic (5.80e-2)"		"unprognostic (1.54e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	324.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	76.5	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.5	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
F3	"CD142, TF"	ENSG00000117525	"Coagulation factor III, tissue factor"	P13726	1	94529225-94541800	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 115.2;HaCaT: 54.6;HBEC3-KT: 141.7;U-2197: 53.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.8"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB009438, HPA049292, HPA069132"	Uncertain		Approved	Vesicles	"Secreted to blood"			Vesicles		"CAB009438: AB_668005, HPA049292: , HPA069132: "	"unprognostic (3.86e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.23e-3)"	"unprognostic (4.93e-2)"	"unprognostic (8.00e-2)"	"unprognostic (5.88e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (1.07e-4)"	"unprognostic (1.25e-1)"	"prognostic unfavourable (2.02e-8)"	"unprognostic (4.84e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.08e-1)"	45.5	9.8	27.0	14.1	42.9	2.1	55.1	3.4	27.9	14.8	18.7	20.9	18.7	18.3	30.5	23.7	21.3	25.4	30.9	18.8	26.9	14.5	6.6	2.8	31.4	5.8	14.1	20.3	41.6	35.0	6.1	28.8	65.4	39.2	29.7	22.2	49.9	29.2	33.0	2.4	17.7	19.2	5.9	46.3	2.9	18.2	16.4	16.0	0.0	21.8	17.3	11.9	24.7	22.3	0.5	0.9	2.8	0.8	0.7	0.4	0.2	115.2	0.2	0.2	0.0	12.6	6.2	6.5	16.4	9.8	17.8	19.4	2.0	24.7	0.0	8.4	20.3	54.6	1.4	141.7	29.3	0.1	0.1	0.0	3.5	0.3	4.2	0.0	0.0	10.7	3.2	8.4	41.1	0.1	0.1	0.1	12.4	0.2	0.1	2.4	1.1	0.2	0.1	1.1	0.0	2.2	0.3	0.1	0.3	13.1	5.4	0.4	0.1	1.5	0.0	10.8	0.3	53.8	4.9	0.1	0.1	0.0	8.2	0.6	0.4	1.7	0.8	0.1	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.5	0.3	0.3	2.8	0.7	0.2	0.9	0.2	0.2	27.0	42.9	3.4	27.1	26.9	14.5	14.1	20.3	39.2	16.0
FABP1	L-FABP	ENSG00000163586	"Fatty acid binding protein 1"	P07148	2	88122982-88128116	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"intestine: 453.2;liver: 370.7"	"Group enriched"	"Detected in some"	7	"CACO-2: 25.6;Hep G2: 81.3"	"Group enriched"	"Detected in many"	14	"colorectal cancer: 175.1;liver cancer: 437.4"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	23	"neutrophil: 2.3"	"Lineage enriched"	"Detected in single"	23	"granulocytes: 2.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002305, HPA028275"	Enhanced		Approved	Nucleoplasm,Cytosol		32000000	32000000	"Nucleoplasm, Cytosol"		"CAB002305: AB_563728, HPA028275: AB_10600909"			"unprognostic (1.91e-1)"		"unprognostic (7.91e-3)"		"unprognostic (5.47e-2)"			"unprognostic (1.96e-1)"	"unprognostic (2.03e-2)"		"unprognostic (2.35e-1)"	"unprognostic (7.99e-2)"	"unprognostic (8.92e-2)"	"unprognostic (2.29e-1)"		0.4	0.1	0.4	33.9	0.4	0.0	0.4	0.4	0.5	0.4	153.5	0.4	0.4	137.9	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.2	57.6	370.7	0.4	0.4	0.4	0.4	0.4	0.4	0.0	0.4	0.4	0.4	0.4	97.7	0.4	0.5	0.4	0.4	0.1	453.2	6.7	0.4	0.4	0.2	0.5	0.4	0.4	0.5	0.5	0.4	0.4	0.4	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	25.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	81.3	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	7.0	0.1	0.0	0.0	1.4	7.5	0.0	0.1	0.8	5.6	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.0	2.6	0.1	0.0	0.0	0.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.4	0.5	0.4	0.2	0.4	0.4	0.4	0.4
FABP2	I-FABP	ENSG00000145384	"Fatty acid binding protein 2"	P12104	4	119317250-119322390	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	47	"intestine: 358.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 2.8;Hep G2: 2.4;NB-4: 3.8;RPMI-8226: 3.2;SH-SY5Y: 2.6"	"Group enriched"	"Detected in some"	9	"colorectal cancer: 3.2;pancreatic cancer: 1.6;stomach cancer: 2.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"basophil: 2.1;neutrophil: 7.6"	"Lineage enriched"	"Detected in single"	8	"granulocytes: 7.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA034607, CAB047325, CAB047326"	Enhanced		Approved	"Plasma membrane,Actin filaments,Cytosol"		46000	46000	"Actin filaments, Cytosol"	"Plasma membrane"	"CAB047325: , CAB047326: , HPA034607: AB_10601317"		"unprognostic (3.94e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.05e-1)"				"unprognostic (4.58e-1)"		"unprognostic (1.51e-2)"	"unprognostic (2.61e-2)"		"unprognostic (1.69e-4)"	"unprognostic (1.93e-1)"	"unprognostic (1.02e-1)"			0.1	0.2	0.1	0.8	0.1	0.0	0.1	0.1	0.1	0.1	47.0	0.0	0.0	50.0	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	5.9	0.1	0.1	0.0	0.1	0.1	358.6	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.5	0.5	7.6	0.7	0.9	0.5	0.0	0.2	0.3	0.2	0.4	0.0	0.0	2.8	0.4	0.0	0.0	0.0	0.4	0.3	0.4	0.1	0.0	0.3	0.0	0.2	0.1	0.1	0.3	0.1	0.4	2.4	0.0	0.5	0.4	0.2	0.0	0.2	0.1	0.0	0.2	0.5	0.0	0.1	0.4	3.8	0.2	0.5	0.3	0.2	3.2	0.0	0.5	1.0	2.6	0.1	0.4	0.0	0.3	0.1	0.9	0.4	0.4	1.4	0.1	0.7	0.2	0.6	0.3	0.2	0.1	2.1	0.7	0.7	0.4	0.3	0.4	0.2	0.4	0.3	0.2	0.5	0.5	0.5	7.6	0.9	0.2	0.5	0.5	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
FABP4	"A-FABP, aP2"	ENSG00000170323	"Fatty acid binding protein 4"	P15090	8	81478419-81483263	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"adipose tissue: 492.7;breast: 545.8"	"Group enriched"	"Detected in some"	325	"ASC diff: 275.5;RT4: 136.3"	"Group enriched"	"Detected in all"	7	"breast cancer: 42.1;cervical cancer: 141.7;head and neck cancer: 133.8;urothelial cancer: 65.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA002188, CAB024961"	Enhanced					30000000	30000000			"CAB024961: , HPA002188: AB_1078822"	"unprognostic (4.81e-2)"	"unprognostic (2.30e-3)"	"unprognostic (1.64e-3)"	"unprognostic (2.63e-2)"	"unprognostic (2.58e-1)"	"unprognostic (8.70e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.36e-1)"	"unprognostic (9.32e-2)"	"unprognostic (1.56e-1)"	"unprognostic (8.76e-2)"	"unprognostic (1.13e-3)"	"unprognostic (4.48e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.39e-1)"	492.7	3.5	0.3	16.1	0.3	0.1	545.8	0.2	0.2	0.9	42.2	0.0	1.8	0.2	0.6	2.9	4.8	1.0	7.6	15.6	0.3	0.3	1.2	0.4	9.3	4.7	0.3	0.0	0.7	1.3	2.2	0.3	15.9	0.3	7.7	2.9	0.1	7.6	1.7	13.0	5.5	4.5	3.3	0.3	0.7	2.2	6.1	0.0	0.7	7.4	7.3	0.1	15.4	60.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	275.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	136.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.2	0.3	0.3	0.3	0.0	0.3	0.0
FABP5	"E-FABP, KFABP, PA-FABP"	ENSG00000164687	"Fatty acid binding protein 5"	Q01469	8	81280363-81284777	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 237.0;tongue: 204.1;vagina: 141.9"	"Cell line enhanced"	"Detected in many"		"Daudi: 92.9;MOLT-4: 90.8"	"Cancer enhanced"	"Detected in all"		"cervical cancer: 268.3;head and neck cancer: 288.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB017831, CAB040577, HPA051895"	Enhanced		Supported	"Plasma membrane,Cytosol"	"Intracellular and membrane"	28000000	28000000	Cytosol	"Plasma membrane"	"CAB017831: , CAB040577: , HPA051895: "	"unprognostic (8.76e-2)"	"unprognostic (7.28e-2)"	"unprognostic (1.54e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.33e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.95e-3)"	"unprognostic (4.03e-3)"	"unprognostic (2.71e-1)"	"unprognostic (3.13e-1)"	"unprognostic (6.16e-2)"	"unprognostic (3.57e-2)"	"prognostic unfavourable (4.69e-10)"	"unprognostic (1.99e-1)"	"unprognostic (3.72e-1)"	"unprognostic (1.61e-1)"	"unprognostic (6.60e-2)"	41.4	1.5	8.5	11.8	13.2	8.5	37.3	5.5	8.9	78.7	20.6	7.9	2.2	8.0	5.7	3.1	237.0	2.1	8.5	27.1	8.5	9.8	1.6	2.7	24.8	15.1	7.6	5.0	2.0	8.7	0.7	1.9	30.0	19.1	4.4	18.2	4.2	32.9	1.6	9.4	42.9	9.7	4.5	23.0	14.9	15.6	3.8	10.6	6.6	4.4	204.1	25.7	19.5	141.9	6.8	20.3	2.5	5.9	8.2	5.2	4.3	5.7	16.5	10.1	0.0	48.4	4.5	0.0	11.8	0.6	9.2	11.7	0.1	7.9	92.9	6.8	2.9	5.4	24.6	18.9	7.9	47.2	53.4	33.5	11.8	25.0	4.3	32.0	8.7	3.5	38.9	11.4	23.5	53.0	9.6	10.1	5.5	5.6	90.8	16.4	13.4	64.3	40.5	0.0	9.8	14.8	71.8	42.0	15.9	5.7	1.9	4.4	0.0	16.5	7.5	0.0	26.3	0.1	0.1	12.5	4.9	66.2	4.2	30.7	14.8	2.5	5.0	0.3	2.3	5.9	3.7	6.8	2.7	5.2	20.3	3.3	1.3	4.5	2.0	8.2	2.0	20.1	3.5	4.3	8.5	13.2	5.5	8.9	8.5	9.8	7.6	5.0	19.1	10.6
FADD	"GIG3, MORT1"	ENSG00000168040	"Fas associated via death domain"	Q13158	11	70203163-70207390	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction, Immunity, Innate immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"A-431: 81.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001464, CAB010209"	Supported		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB010209: AB_2100622, HPA001464: AB_1848348"	"unprognostic (2.08e-1)"	"prognostic unfavourable (6.35e-4)"	"unprognostic (6.91e-2)"	"unprognostic (9.51e-2)"	"unprognostic (3.89e-1)"	"prognostic unfavourable (8.22e-5)"	"unprognostic (7.25e-3)"	"prognostic unfavourable (2.21e-5)"	"unprognostic (1.16e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.45e-3)"	"unprognostic (2.78e-3)"	"unprognostic (1.29e-1)"	"unprognostic (2.04e-2)"	"unprognostic (2.07e-1)"	"prognostic favourable (3.45e-4)"	"unprognostic (7.29e-2)"	16.1	20.2	7.9	13.3	8.9	7.1	13.5	10.9	11.8	13.7	16.2	10.9	20.8	13.5	18.0	18.7	18.8	13.3	19.7	11.4	7.8	8.0	17.9	17.4	11.0	19.2	10.5	6.6	12.9	24.9	9.1	9.3	26.3	7.9	12.5	12.7	10.1	14.4	14.5	10.3	13.7	16.9	10.1	8.3	18.8	14.0	8.7	7.4	33.5	16.9	12.4	19.8	14.6	15.1	18.6	17.6	42.7	19.5	16.6	24.6	16.0	81.8	13.8	6.9	6.2	8.4	6.8	6.2	14.1	11.1	12.3	8.3	11.8	13.4	12.2	13.6	9.3	12.1	6.7	12.5	9.6	11.3	7.4	5.5	7.9	6.0	7.5	6.9	7.4	6.7	8.9	13.3	16.9	11.6	9.0	6.3	10.8	12.0	8.4	12.2	10.9	22.9	6.5	16.7	11.6	12.1	6.0	6.1	5.8	10.4	9.8	28.9	10.6	7.7	12.9	9.6	9.4	14.7	13.4	8.8	6.7	7.1	14.0	7.0	13.5	15.0	17.1	12.7	21.0	17.7	24.1	18.6	22.3	24.6	17.6	16.4	23.2	20.9	42.7	16.6	19.5	16.0	20.7	16.0	7.9	8.9	10.9	11.8	7.8	8.0	10.5	6.6	7.9	7.4
FAF1	"CGI-03, hFAF1, HFAF1s, UBXD12, UBXN3A"	ENSG00000185104	"Fas associated factor 1"	Q9UNN5	1	50437028-50960263	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018253, CAB072814"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB072814: , HPA018253: AB_1848351"	"unprognostic (1.52e-1)"	"unprognostic (1.25e-2)"	"unprognostic (6.49e-3)"	"unprognostic (4.69e-2)"	"unprognostic (6.35e-2)"	"unprognostic (1.19e-2)"	"prognostic unfavourable (1.87e-5)"	"unprognostic (2.51e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.82e-1)"	"unprognostic (9.52e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.17e-1)"	"unprognostic (9.00e-2)"	"unprognostic (2.01e-3)"	"unprognostic (6.42e-3)"	16.0	13.6	11.6	18.0	13.4	17.4	16.7	20.0	16.3	14.1	14.6	19.1	14.5	12.2	17.2	12.9	16.9	13.3	12.2	22.3	11.1	10.8	13.2	14.7	13.3	14.9	16.4	13.3	17.0	21.3	22.8	21.5	12.0	13.1	13.9	13.0	12.5	18.0	17.3	58.4	19.0	15.8	17.3	13.1	10.6	14.5	29.7	15.7	29.6	15.6	19.6	17.8	19.4	14.0	5.6	5.4	7.3	5.0	6.1	9.1	2.4	14.3	10.6	9.2	15.6	9.2	8.8	13.6	14.0	12.7	21.8	19.9	11.8	10.3	23.2	10.4	11.9	10.7	14.8	13.0	18.7	15.4	13.3	19.3	14.1	12.2	15.0	20.7	11.5	8.1	11.8	22.9	28.2	11.7	22.4	0.0	11.1	5.7	21.4	16.5	12.2	7.6	20.1	20.4	0.0	21.9	12.9	0.1	11.5	12.7	26.0	21.3	8.1	24.8	7.1	12.3	15.1	15.1	0.1	18.2	19.0	27.0	0.0	30.2	14.1	1.4	3.4	7.3	6.6	4.1	8.7	4.0	5.9	6.4	5.4	5.6	7.0	4.7	1.2	6.1	5.0	4.5	9.1	2.4	11.6	13.4	20.0	16.3	11.1	10.8	16.4	13.3	13.1	15.7
FAM129A	"C1orf24, GIG39, NIBAN"	ENSG00000135842	"Family with sequence similarity 129 member A"	Q9BZQ8	1	184790724-184974550	"Cancer-related genes, Predicted intracellular proteins"	"Stress response, Translation regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 129.1;urinary bladder: 90.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 32.7"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 32.7"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA028172, HPA028231, HPA028657"	Approved		Supported	"Plasma membrane,Cytosol"		40000	40000	"Plasma membrane, Cytosol"		"HPA028172: AB_10599602, HPA028231: AB_10601886, HPA028657: AB_10601680"	"unprognostic (4.61e-3)"	"unprognostic (3.45e-2)"	"unprognostic (1.64e-3)"	"unprognostic (9.46e-2)"	"unprognostic (2.77e-1)"	"unprognostic (3.87e-1)"	"unprognostic (3.23e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.68e-1)"	"unprognostic (6.32e-2)"	"unprognostic (4.12e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.94e-3)"	"unprognostic (9.01e-3)"	"unprognostic (4.38e-2)"	"unprognostic (3.73e-2)"	"prognostic unfavourable (4.52e-4)"	10.1	3.5	1.1	16.9	1.8	2.3	7.8	0.8	1.3	13.0	39.3	1.0	14.9	2.5	14.6	11.0	32.3	10.7	30.4	52.2	1.1	1.1	1.8	1.2	6.1	10.7	3.0	0.5	8.0	27.3	0.8	1.9	2.9	1.7	34.6	5.1	13.8	59.3	14.7	21.4	4.1	8.3	129.1	2.1	6.5	30.0	4.1	1.3	4.9	4.7	14.7	8.7	90.3	20.3	0.5	2.3	32.7	1.5	2.6	5.3	0.8	13.6	0.1	0.0	0.0	9.8	14.9	0.5	7.0	14.4	6.1	7.7	0.0	5.8	0.0	4.6	18.0	15.4	0.8	0.5	9.8	27.2	1.1	5.7	2.9	0.0	22.8	18.5	6.5	13.6	22.3	17.7	21.5	0.0	1.3	28.9	0.1	0.0	0.6	3.2	3.7	1.4	4.3	3.3	0.2	8.4	0.2	0.7	0.7	0.1	0.0	10.0	3.0	5.9	1.1	12.1	0.0	2.1	14.4	24.3	9.6	2.9	23.7	7.7	11.8	7.1	1.5	4.7	2.5	0.9	2.1	0.5	2.2	2.3	2.3	0.1	0.2	0.9	32.7	2.6	0.3	0.2	5.3	0.8	1.1	1.8	0.8	1.3	1.1	1.1	3.0	0.5	1.7	1.3
FAM166A		ENSG00000188163	"Family with sequence similarity 166 member A"	Q6J272	9	137243584-137247770	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	53	"testis: 54.2"	"Cell line enhanced"	"Detected in some"		"T-47d: 3.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA023307	Enhanced									"HPA023307: AB_1848930"	"unprognostic (2.22e-1)"	"unprognostic (8.39e-2)"	"unprognostic (1.01e-3)"	"unprognostic (1.37e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.15e-1)"	"unprognostic (9.83e-2)"	"unprognostic (2.18e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.49e-1)"	"unprognostic (2.67e-4)"	"unprognostic (7.81e-2)"	"unprognostic (1.77e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.02e-2)"	"unprognostic (2.09e-1)"	"unprognostic (4.18e-3)"	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.3	0.1	1.0	0.1	0.0	0.1	0.1	0.1	0.1	0.4	0.7	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.4	0.1	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	54.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.9	0.0	0.0	0.1	0.0	0.0	1.4	0.5	1.2	0.8	0.0	0.7	0.0	0.5	0.0	0.0	0.5	2.0	0.6	0.1	0.0	1.0	0.0	0.0	0.0	1.1	0.7	0.5	1.2	1.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.2	0.9	0.0	0.3	0.3	0.3	0.3	0.1	0.6	0.1	0.8	0.8	0.8	0.3	1.0	0.8	3.2	0.9	0.7	0.8	1.0	0.3	0.1	0.8	1.2	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1
FAM46C	FLJ20202	ENSG00000183508	"Family with sequence similarity 46 member C"	Q5VWP2	1	117605934-117628372	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction"	"Nucleotidyltransferase, RNA-binding, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 114.0"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 73.1;RPMI-8226: 43.6;U-266/70: 20.3;U-266/84: 16.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 16.3"	"Group enriched"	"Detected in many"	17	"B-cells: 9.7;granulocytes: 16.3;T-cells: 9.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA054049	Uncertain		Approved	Nucleoplasm				Nucleoplasm		"HPA054049: "	"unprognostic (3.76e-2)"	"unprognostic (3.85e-3)"	"unprognostic (3.24e-3)"	"prognostic favourable (3.75e-5)"	"unprognostic (1.17e-1)"	"unprognostic (1.55e-3)"	"unprognostic (3.29e-1)"	"unprognostic (2.88e-2)"	"unprognostic (5.75e-2)"	"unprognostic (1.36e-3)"	"unprognostic (9.41e-3)"	"unprognostic (3.91e-2)"	"prognostic favourable (2.77e-5)"	"unprognostic (6.26e-2)"	"unprognostic (3.16e-2)"	"unprognostic (3.08e-2)"	"unprognostic (1.10e-2)"	3.2	1.8	1.2	24.5	1.1	28.9	4.4	1.1	1.1	8.1	16.1	1.8	8.4	5.6	4.8	16.6	6.9	3.3	9.7	6.4	1.2	1.1	5.0	5.5	11.2	16.3	1.2	0.1	8.3	114.0	7.2	5.3	10.6	3.9	6.4	9.5	4.4	37.8	11.9	10.0	1.8	10.6	4.7	1.4	19.1	12.2	34.0	0.2	1.5	10.3	10.9	37.0	9.5	8.6	9.7	0.2	16.3	0.0	0.6	9.2	2.1	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.1	6.6	0.1	0.0	0.4	0.0	1.1	0.0	0.1	0.0	0.0	0.1	0.0	4.1	0.4	9.0	0.0	0.0	0.0	5.2	11.7	0.0	0.0	0.1	0.0	0.0	1.2	73.1	0.0	0.9	0.0	5.4	0.9	0.5	0.0	0.0	43.6	0.0	0.8	0.5	0.0	0.4	0.5	0.4	0.4	0.0	0.1	0.0	0.5	0.0	0.1	20.3	16.8	0.4	0.4	1.9	0.6	16.3	0.0	10.5	2.5	0.0	2.2	9.7	2.5	3.1	0.0	8.0	0.3	1.4	1.1	0.6	0.0	0.2	9.2	2.1	1.2	1.1	1.1	1.1	1.2	1.1	1.2	0.1	3.9	0.2
FANCA	"FA-H, FAA, FACA, FAH, FANCH"	ENSG00000187741	"Fanconi anemia complementation group A"	O15360	16	89737549-89816657	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 20.6;testis: 28.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA063236			Supported	Nucleoplasm				Nucleoplasm		"HPA063236: "	"unprognostic (5.99e-2)"	"unprognostic (5.68e-2)"	"unprognostic (2.36e-1)"	"unprognostic (5.12e-2)"	"unprognostic (1.87e-1)"	"unprognostic (7.11e-2)"	"unprognostic (1.45e-4)"	"unprognostic (9.21e-2)"	"unprognostic (1.58e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.82e-3)"	"unprognostic (8.48e-4)"	"unprognostic (7.82e-10)"	"unprognostic (3.67e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.62e-1)"	2.1	2.0	2.2	16.5	3.7	17.1	1.7	5.7	6.6	1.7	5.1	1.1	0.6	5.0	1.7	3.1	6.6	1.9	1.6	1.7	1.8	1.4	2.1	5.8	3.3	11.1	1.3	2.7	1.6	1.8	2.3	1.9	11.2	2.4	1.7	6.3	1.5	2.2	0.5	0.7	5.0	5.4	2.0	1.6	6.9	3.5	28.8	0.8	20.6	1.7	4.6	17.6	2.9	2.5	7.4	6.5	9.9	9.2	7.5	9.5	4.2	9.2	14.2	17.0	14.9	1.1	2.2	13.0	11.5	6.3	19.5	8.2	12.4	15.4	22.7	5.4	3.9	14.2	11.4	8.6	20.6	5.3	19.2	6.7	18.2	25.4	0.7	6.8	7.4	0.7	0.9	15.8	5.0	6.1	16.1	7.0	10.1	21.4	13.6	29.5	11.0	8.9	24.8	13.7	4.1	4.8	8.7	15.3	8.3	17.2	5.1	2.2	9.3	12.3	4.5	15.7	16.5	8.7	12.0	6.3	7.3	22.6	7.4	15.3	14.8	2.6	7.9	9.9	4.7	8.8	3.3	7.4	2.8	4.1	6.5	5.5	0.7	3.0	9.8	7.5	9.2	0.4	9.5	4.2	2.2	3.7	5.7	6.6	1.8	1.4	1.3	2.7	2.4	0.8
FANCC	"FA3, FAC, FACC"	ENSG00000158169	"Fanconi anemia complementation group C"	Q00597	9	95099054-95426796	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 29.7"	"Cell line enhanced"	"Detected in all"		"RH-30: 31.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"basophil: 10.4"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 10.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017793, HPA030771"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB017793: , HPA030771: "	"unprognostic (1.48e-2)"	"unprognostic (4.33e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.63e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.32e-2)"	"unprognostic (3.41e-3)"	"unprognostic (1.26e-2)"	"unprognostic (7.45e-3)"	"unprognostic (1.37e-1)"	"unprognostic (8.00e-3)"	"unprognostic (3.19e-2)"	"prognostic favourable (6.03e-6)"	"unprognostic (2.35e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.49e-1)"	"unprognostic (5.71e-2)"	4.9	2.7	4.3	8.6	7.0	3.6	4.6	29.7	7.7	4.6	6.4	4.9	5.1	7.1	6.3	4.1	4.5	3.6	5.2	3.2	4.0	2.7	10.0	25.7	6.7	3.7	7.3	1.6	3.3	5.4	2.9	12.1	4.3	6.7	4.4	6.1	4.0	4.0	4.2	4.5	7.7	8.1	2.9	6.4	3.4	4.4	19.6	7.3	7.9	4.3	3.2	6.0	3.5	4.0	1.0	1.3	10.4	1.7	0.3	1.5	0.7	13.4	9.1	12.0	10.5	1.2	3.2	7.6	5.9	3.8	9.4	8.7	10.4	5.7	7.7	4.1	4.3	16.5	12.2	5.1	5.1	7.3	5.7	6.0	10.2	5.3	2.0	6.0	6.8	2.7	2.1	7.5	3.3	5.2	9.0	3.4	6.7	9.5	5.6	3.5	5.8	5.2	12.1	31.2	3.6	3.9	3.5	17.5	9.3	11.1	4.0	3.4	4.1	5.1	2.5	8.3	12.0	9.0	8.3	3.5	6.5	4.0	4.4	5.5	9.7	10.4	0.4	0.0	1.3	0.8	1.3	1.0	0.7	1.5	0.4	1.0	1.2	1.0	0.1	0.3	1.7	1.3	1.3	0.7	4.3	7.0	29.7	7.7	4.0	2.7	7.3	1.6	6.7	7.3
FANCD2	"FA-D2, FACD, FAD, FANCD"	ENSG00000144554	"Fanconi anemia complementation group D2"	Q9BXW9	3	10026414-10101930	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 24.4;testis: 23.3"	"Cell line enhanced"	"Detected in many"		"BEWO: 45.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB016117, HPA063742"	Approved		Supported	"Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol"				Nucleoplasm	"Nucleoli, Nuclear bodies, Cytosol"	"CAB016117: AB_2278211, HPA063742: "	"unprognostic (3.25e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.21e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.92e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.08e-5)"	"unprognostic (2.96e-2)"	"unprognostic (1.59e-3)"	"prognostic unfavourable (5.00e-5)"	"unprognostic (1.23e-2)"	"unprognostic (9.14e-2)"	"unprognostic (4.41e-10)"	"unprognostic (9.11e-3)"	"unprognostic (3.99e-1)"	"unprognostic (7.76e-2)"	"unprognostic (2.89e-2)"	2.0	1.3	0.8	10.3	2.6	12.2	2.4	1.6	2.7	1.7	2.9	1.1	1.0	2.2	2.2	1.8	4.7	2.4	2.5	1.1	0.8	0.9	2.3	1.0	2.4	9.5	1.3	1.2	3.5	3.5	0.6	1.1	5.3	1.4	2.2	4.9	1.6	3.3	0.4	3.0	3.3	6.2	1.2	2.0	7.3	2.4	23.3	1.6	24.4	1.6	5.6	14.6	2.2	2.4	6.8	3.7	5.3	2.6	2.1	2.9	1.0	8.5	9.1	17.5	4.9	0.9	1.3	45.3	7.9	3.5	11.4	9.3	6.8	8.5	16.8	3.7	2.6	7.5	18.0	6.1	11.4	8.0	12.2	23.0	14.0	6.5	0.1	17.0	14.4	0.4	1.0	12.8	7.1	6.8	14.0	19.3	8.5	9.9	14.2	6.5	21.1	6.4	15.5	14.2	11.9	3.9	9.7	4.9	9.6	9.7	7.6	3.1	11.6	10.8	3.9	9.4	10.8	5.7	11.4	8.2	16.0	28.5	5.4	17.5	16.1	5.3	1.4	3.7	1.5	1.0	1.3	4.9	2.0	1.2	0.9	6.8	2.5	1.9	3.3	2.1	2.6	3.7	2.9	1.0	0.8	2.6	1.6	2.7	0.8	0.9	1.3	1.2	1.4	1.6
FANCE	"FACE, FAE"	ENSG00000112039	"Fanconi anemia complementation group E"	Q9HB96	6	35452361-35467103	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											CAB014893	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB014893: "	"unprognostic (2.66e-1)"	"unprognostic (8.01e-3)"	"unprognostic (7.73e-2)"	"prognostic unfavourable (6.25e-4)"	"unprognostic (1.99e-1)"	"unprognostic (2.80e-3)"	"prognostic unfavourable (2.08e-9)"	"unprognostic (8.90e-2)"	"unprognostic (5.70e-3)"	"unprognostic (8.41e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.70e-1)"	"unprognostic (3.05e-1)"	"unprognostic (2.44e-2)"	"unprognostic (5.14e-2)"	7.2	2.1	2.6	7.0	3.8	7.2	8.5	5.5	3.9	6.7	4.1	4.8	1.5	3.1	6.1	4.7	10.0	4.9	5.4	4.1	2.8	3.2	2.4	1.7	5.5	5.4	2.4	1.8	10.8	6.9	2.7	4.0	21.3	3.9	6.7	4.1	3.7	5.3	4.0	20.8	16.8	4.7	4.1	3.7	4.6	3.8	12.1	3.5	3.0	5.9	10.1	8.5	6.7	15.0	2.4	1.8	1.0	1.0	2.6	3.6	0.9	5.6	2.8	7.7	17.3	5.6	10.0	20.7	6.8	5.8	8.9	7.8	6.6	3.2	19.3	4.5	4.2	4.2	8.6	5.8	8.6	6.5	7.5	13.5	6.7	4.3	3.0	7.9	5.5	6.3	17.5	10.9	16.8	5.2	12.4	7.2	7.4	6.6	3.7	9.9	3.2	4.4	10.9	7.3	7.2	2.0	6.2	7.7	7.2	3.9	5.5	6.1	5.4	25.8	3.2	10.8	9.0	6.9	10.6	4.8	16.6	7.0	2.4	14.6	10.1	0.7	1.0	1.0	2.2	0.6	3.0	0.7	2.8	3.6	0.6	2.4	1.9	1.9	0.6	2.6	0.6	1.8	1.7	0.9	2.6	3.8	5.5	3.9	2.8	3.2	2.4	1.8	3.9	3.5
FANCF	FAF	ENSG00000183161	"Fanconi anemia complementation group F"	Q9NPI8	11	22622519-22626787	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 15.2"	"Cell line enhanced"	"Detected in many"		"SCLC-21H: 20.9"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA008899			Supported	Nucleoplasm				Nucleoplasm		"HPA008899: "	"unprognostic (1.16e-2)"	"unprognostic (4.10e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.37e-2)"	"unprognostic (4.55e-2)"	"unprognostic (8.84e-2)"	"prognostic unfavourable (2.27e-4)"	"unprognostic (4.29e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.74e-3)"	"unprognostic (3.95e-1)"	"unprognostic (1.67e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.81e-1)"	"unprognostic (9.14e-2)"	"unprognostic (7.64e-3)"	1.2	4.1	2.9	3.1	2.8	1.1	3.2	1.0	2.7	3.1	3.4			5.3	3.0	6.0	3.0	6.1	1.7	1.9	2.9	3.9	3.2	4.2	1.8	4.9	3.3		4.2	9.0	3.4	4.5	1.5		2.9	3.7		3.8	3.1	0.4	3.1	4.9	1.1	3.5	5.4	4.6	4.3			3.6		4.8	2.6	2.0	15.2	9.7	11.5	5.7	10.0	15.1	7.3	1.4	4.3	5.6	6.1	2.9	3.5	2.3	2.8	3.3	3.2	3.5	2.8	2.2	7.2	0.7	2.8	6.2	4.5	4.6	1.6	11.7	2.1	2.7	1.8	4.9	3.4	4.9	2.9	3.4	9.0	1.1	4.9	5.0	6.8	9.4	2.0	4.5	12.5	4.6	6.4	5.4	10.9	2.6	8.0	6.0	5.6	20.9	9.8	1.5	4.9	4.8	9.9	4.5	3.6	3.3	3.5	5.9	4.0	5.4	6.9	2.1	5.4	2.0	7.6	5.7	5.4	11.5	11.5	5.5	13.5	11.8	10.8	10.8	6.4	15.2	15.1	12.4	0.8	10.0	5.7	9.7	7.3	7.3										
FANCG	"FAG, XRCC9"	ENSG00000221829	"Fanconi anemia complementation group G"	O15287	9	35073835-35080016	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008105, HPA045335"	Approved		Supported	"Nucleoli,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoli	"CAB008105: AB_2231542, HPA045335: "	"unprognostic (9.41e-2)"	"unprognostic (2.62e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.83e-3)"	"prognostic unfavourable (2.02e-4)"	"unprognostic (8.92e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.27e-3)"	"unprognostic (9.01e-2)"	"unprognostic (5.62e-2)"	"prognostic unfavourable (2.38e-7)"	"unprognostic (1.14e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.10e-1)"	5.8	5.0	4.4	7.1	6.5	14.9	7.5	13.9	8.5	6.2	5.9	5.3	8.4	6.7	6.8	3.2	9.2	8.6	4.7	5.9	7.6	4.0	5.2	4.5	5.1	9.9	8.7	4.4	9.2	17.0	6.7	4.8	7.6	6.6	7.0	5.5	3.5	8.7	9.7	2.9	8.9	6.5	6.4	4.2	8.6	5.8	8.9	7.6	25.6	9.3	4.8	9.2	6.8	6.9	6.8	4.8	8.9	2.5	8.8	9.2	3.4	15.7	19.5	14.3	13.2	3.2	5.1	12.0	11.1	8.0	21.8	20.9	9.3	9.9	15.6	7.7	3.5	9.7	11.9	10.2	8.3	18.2	7.2	11.1	20.9	5.7	0.9	11.3	12.9	4.2	2.0	19.0	8.6	11.1	7.3	21.0	10.9	14.0	19.1	15.5	14.9	15.1	19.8	16.9	11.0	5.1	6.7	6.9	12.6	7.3	10.4	4.1	13.5	8.1	6.7	10.3	20.7	13.2	14.9	5.7	10.8	9.4	9.2	8.4	14.1	8.9	0.8	7.7	7.4	2.5	6.5	6.8	6.1	5.7	2.2	6.5	4.8	5.0	1.3	8.8	2.3	4.8	9.2	3.4	4.4	6.5	13.9	8.5	7.6	4.0	8.7	4.4	6.6	7.6
FAP	DPPIV	ENSG00000078098	"Fibroblast activation protein alpha"	Q12884	2	162170684-162245151	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Angiogenesis, Apoptosis, Cell adhesion"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 30.0"	"Cell line enhanced"	"Detected in some"		"ASC diff: 47.0;ASC TERT1: 49.9;BJ hTERT+: 39.4;TIME: 19.7;U-138 MG: 40.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA059739	Uncertain				"Secreted to blood"	34000000	34000000			"HPA059739: "	"unprognostic (7.48e-3)"	"unprognostic (7.87e-3)"	"unprognostic (4.10e-2)"	"unprognostic (5.04e-2)"	"unprognostic (1.49e-2)"	"prognostic unfavourable (4.82e-4)"	"unprognostic (2.01e-2)"	"unprognostic (1.05e-2)"	"unprognostic (3.30e-2)"	"unprognostic (4.89e-2)"	"unprognostic (4.59e-2)"	"unprognostic (3.52e-1)"	"unprognostic (7.32e-11)"	"unprognostic (1.72e-3)"	"unprognostic (9.84e-3)"	"unprognostic (7.97e-2)"	"unprognostic (4.49e-3)"	19.8	0.7	2.6	3.2	1.2	0.0	7.5	0.6	3.7	17.6	4.5	0.4	4.0	0.1	30.0	13.7	4.1	5.1	14.9	5.2	3.1	0.9	2.0	0.9	4.7	0.8	2.6	1.2	4.1	2.3	0.5	1.0	17.0	1.9	4.1	1.5	2.4	5.3	3.9	8.1	2.9	1.4	17.9	2.2	0.9	1.7	9.8	3.4	0.0	3.5	9.0	0.8	12.4	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.0	49.9	0.0	19.2	39.4	4.0	6.1	0.0	0.0	0.0	0.1	7.3	0.0	0.0	1.2	1.9	0.0	0.0	0.0	0.2	0.0	4.7	0.0	0.0	16.1	0.3	6.7	1.2	0.0	0.0	0.0	12.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.0	0.0	2.0	0.0	0.0	19.7	40.1	0.8	9.7	0.0	0.0	0.0	0.0	9.0	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	1.2	0.6	3.7	3.1	0.9	2.6	1.2	1.9	3.4
FAS	"APO-1, APT1, CD95, FAS1, TNFRSF6"	ENSG00000026103	"Fas cell surface death receptor"	P25445	10	88990582-89015785	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	"Calmodulin-binding, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 43.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 40.1"	"Group enriched"	"Detected in all"	5	"granulocytes: 40.1;T-cells: 30.9"					"Low region specificity"	"Detected in all"			HPA027444	Uncertain		Supported	"Nuclear bodies,Plasma membrane,Cytosol"	"Secreted to blood"	450000	450000	"Plasma membrane"	"Nuclear bodies, Cytosol"	"HPA027444: AB_10601378"	"unprognostic (6.84e-2)"	"unprognostic (2.88e-3)"	"unprognostic (8.38e-3)"	"unprognostic (1.94e-1)"	"unprognostic (2.35e-2)"	"unprognostic (9.56e-2)"	"unprognostic (7.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.01e-1)"	"unprognostic (7.70e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.52e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.32e-2)"	"unprognostic (4.95e-3)"	"unprognostic (1.65e-1)"	13.5	26.3	6.1	17.3	7.7	12.4	10.6	2.1	7.2	15.6	14.2	6.1	7.0	5.9	15.7	16.6	14.1	14.2	14.5	8.9	8.2	2.7	11.7	21.9	28.6	15.6	6.0	3.9	24.7	4.1	4.5	4.6	9.0	7.5	22.3	21.3	4.4	7.1	8.5	4.3	9.6	16.3	12.5	10.2	15.3	5.0	7.3	5.1	12.5	10.0	15.8	14.4	14.8	21.4	3.0	4.0	40.1	6.8	1.2	30.9	3.9	8.5	3.3	1.7	5.5	14.2	21.0	0.0	18.9	19.1	0.7	3.7	0.0	9.3	1.7	7.3	17.7	1.3	0.3	15.8	1.3	27.5	2.7	0.1	1.8	5.6	13.6	0.9	0.4	26.0	14.2	11.8	25.5	1.6	0.0	43.8	19.2	0.7	2.7	1.4	0.2	0.9	0.1	0.1	1.7	26.5	2.7	0.1	0.1	2.7	0.0	0.3	6.0	0.3	4.1	6.0	3.4	5.6	4.3	17.2	1.7	0.1	5.0	3.4	1.8	11.3	3.2	9.4	3.3	3.9	4.8	3.0	10.4	7.2	4.0	0.7	1.2	3.4	40.1	1.2	6.8	0.0	30.9	3.9	6.1	7.7	2.1	7.2	8.2	2.7	6.0	3.9	7.5	5.1
FASLG	"APT1LG1, CD178, FasL, TNFSF6"	ENSG00000117560	"Fas ligand"	P48023	1	172659018-172666874	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Apoptosis, Transcription, Transcription regulation"	"Cytokine, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 25.6;lymphoid tissue: 13.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 1.0;LHCN-M2: 2.4;NB-4: 1.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 25.6"	"Group enriched"	"Detected in many"	12	"NK-cells: 16.0;T-cells: 25.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA054959	Approved				"Secreted to blood"					"HPA054959: "	"unprognostic (1.09e-3)"	"unprognostic (1.41e-2)"	"unprognostic (8.69e-2)"	"unprognostic (1.54e-7)"	"unprognostic (3.29e-1)"	"unprognostic (2.23e-3)"	"unprognostic (5.44e-2)"	"unprognostic (1.84e-2)"	"unprognostic (4.67e-2)"	"unprognostic (4.76e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.07e-1)"	"prognostic unfavourable (1.59e-6)"	"unprognostic (3.49e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.15e-2)"	"unprognostic (3.82e-3)"	0.9	1.1	0.5	1.9	0.7	3.6	1.8	0.5	0.8	0.7	2.6	0.6	0.0	3.0	3.9	1.2	1.0	0.8	1.6	1.2	0.5	0.5	1.2	2.2	6.8	7.7	1.4	0.0	1.5	0.6	0.0	0.7	2.4	0.6	4.7	1.2	2.8	1.9	0.3	0.4	0.5	3.8	1.9	1.7	13.4	2.1	0.4	0.0	1.2	1.1	0.0	10.1	1.4	0.9	0.0	0.0	1.6	0.0	16.0	25.6	5.5	0.0	0.0	0.3	0.1	1.0	0.0	0.5	0.2	0.0	0.0	0.1	0.0	0.5	0.5	0.1	0.0	0.8	0.0	0.2	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.2	0.1	0.0	0.2	0.4	0.7	0.0	0.2	0.6	2.4	0.0	0.0	1.2	0.4	0.0	0.0	0.0	0.1	1.0	0.2	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.3	0.3	0.7	0.0	0.0	0.0	0.1	0.1	1.6	0.0	0.0	25.6	0.0	15.8	0.0	5.4	13.7	0.0	0.0	1.1	11.7	0.8	16.0	0.0	0.0	0.1	5.5	0.5	0.7	0.5	0.8	0.5	0.5	1.4	0.0	0.6	0.0
FASN	"FAS, SDR27X1"	ENSG00000169710	"Fatty acid synthase"	P49327	17	82078333-82098332	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism"	"Hydrolase, Lyase, Multifunctional enzyme, Oxidoreductase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adipose tissue: 147.6"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 152.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005192, HPA006461, CAB015417, HPA056108"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		1600000	1600000	"Plasma membrane, Cytosol"		"CAB005192: AB_2101095, CAB015417: AB_2231427, HPA006461: AB_1848437, HPA056108: AB_2683039"	"unprognostic (3.35e-2)"	"prognostic unfavourable (1.42e-5)"	"unprognostic (9.69e-3)"	"unprognostic (4.09e-2)"	"unprognostic (3.46e-3)"	"unprognostic (1.55e-2)"	"unprognostic (3.09e-2)"	"unprognostic (4.74e-3)"	"unprognostic (3.15e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.87e-3)"	"unprognostic (1.05e-1)"	"prognostic unfavourable (7.16e-5)"	"unprognostic (4.50e-2)"	"unprognostic (9.62e-2)"	"unprognostic (1.35e-2)"	"unprognostic (7.03e-3)"	147.6	7.8	8.2	14.2	11.5	11.1	57.5	19.1	23.0	6.6	27.7	17.0	14.1	8.2	4.7	14.2	17.1	4.3	19.4	6.3	7.9	6.7	3.7	30.8	26.8	9.8	7.3	11.5	6.4	10.4	6.7	15.3	8.4	21.7	28.8	3.4	7.6	16.9	10.8	7.5	17.2	6.5	4.6	8.4	5.1	11.9	6.6	8.8	1.9	5.1	10.7	5.4	8.0	6.6	0.5	1.4	0.0	0.8	0.2	1.9	0.8	23.1	24.3	11.3	7.8	18.3	12.4	24.2	4.6	6.0	4.9	9.0	25.4	15.8	7.7	3.8	3.5	19.4	10.9	21.3	0.9	3.6	47.4	16.0	18.2	33.9	5.2	8.6	2.4	11.9	5.6	12.5	2.9	5.5	24.1	6.9	1.7	40.1	9.4	13.7	21.9	14.2	8.3	6.4	15.3	5.5	29.7	28.1	15.6	6.8	152.8	12.4	27.2	16.5	9.6	7.2	14.8	5.9	11.0	9.3	2.0	8.0	4.3	9.4	10.6	0.0	0.8	0.0	1.2	0.5	0.7	0.5	1.9	1.4	1.4	0.2	0.7	0.6	0.0	0.2	0.4	1.1	0.6	0.8	8.2	11.5	19.1	23.0	7.9	6.7	7.3	11.5	21.7	8.8
FAT1	"CDHF7, CDHR8, FAT"	ENSG00000083857	"FAT atypical cadherin 1"	Q14517	4	186587783-186726722	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 76.4"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 63.5;LHCN-M2: 46.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001869, HPA023882"	Enhanced				"Intracellular and membrane"	120000	120000			"HPA001869: AB_1078818, HPA023882: AB_1848429"	"unprognostic (1.98e-1)"	"unprognostic (4.91e-2)"	"unprognostic (2.50e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.53e-2)"	"unprognostic (5.82e-3)"	"unprognostic (2.31e-1)"	"prognostic unfavourable (4.22e-4)"	"unprognostic (6.10e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.15e-3)"	"unprognostic (6.80e-2)"	"unprognostic (3.57e-2)"	"unprognostic (8.03e-3)"	"unprognostic (9.41e-2)"	"unprognostic (6.25e-3)"	"unprognostic (4.27e-2)"	15.5	1.3	7.9	12.3	9.8	0.4	15.4	11.9	8.4	15.9	40.4	11.8	8.1	17.9	20.6	14.0	9.7	9.6	28.2	21.1	10.0	6.0	29.1	13.3	10.9	1.4	11.4	6.2	9.7	13.8	7.5	10.5	14.6	24.7	15.9	22.9	5.0	13.9	18.2	3.0	13.1	76.4	18.3	12.8	1.7	11.5	7.0	11.2	1.3	10.5	10.2	6.7	17.5	9.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	18.6	18.4	0.0	18.5	22.3	4.5	24.8	41.0	12.1	7.7	11.0	11.0	0.0	6.0	63.5	9.0	7.2	30.6	16.5	0.0	2.9	0.0	6.6	11.1	9.2	8.0	6.6	8.0	11.1	22.5	14.7	0.2	0.1	0.0	46.6	5.9	14.3	0.0	4.1	3.1	0.0	5.1	0.3	18.2	17.5	1.9	7.4	4.3	7.3	2.9	0.0	2.9	5.3	34.6	13.4	0.4	15.4	0.1	0.0	0.1	7.9	0.0	11.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	9.8	11.9	8.4	10.0	6.0	11.4	6.2	24.7	11.2
FAT4	"CDHF14, CDHR11, FAT-J"	ENSG00000196159	"FAT atypical cadherin 4"	Q6V0I7	4	125316399-125492932	"Cancer-related genes, Disease related genes, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Deafness, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 12.1;ASC TERT1: 9.0;fHDF/TERT166: 8.8;HSkMC: 10.4;HUVEC TERT2: 10.9;TIME: 17.1"	"Low cancer specificity"	"Detected in many"							"Cell type enriched"	"Detected in single"	12	"NK-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"NK-cells: 1.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA052819	Approved		Approved	Cytosol		7900000	7900000	Cytosol		"HPA052819: "	"unprognostic (1.18e-1)"	"unprognostic (1.77e-1)"	"unprognostic (7.99e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.31e-1)"	"unprognostic (2.81e-4)"	"unprognostic (6.17e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.77e-2)"	"unprognostic (2.78e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.39e-1)"	"prognostic favourable (1.89e-4)"	"unprognostic (2.38e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.49e-3)"	3.8	0.5	0.9	0.8	0.7	0.0	3.2	0.0	0.5	4.4	7.1			0.3	2.7	0.6	1.9	2.1	4.1	5.0	1.0	0.4	2.6	2.0	5.3	0.1	0.9		5.3	0.5	6.7	0.4	2.5		3.6	1.9		1.0	2.3	1.1	1.4	2.4	3.3	0.6	2.1	2.4	0.1			3.9		0.2	3.0	2.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.7	5.9	0.6	12.1	9.0	0.0	2.0	2.3	0.9	1.0	0.0	0.3	0.0	2.4	8.8	0.0	2.2	2.5	0.6	0.0	1.0	1.3	2.5	0.0	3.9	0.8	0.0	10.4	1.3	0.5	5.5	10.9	0.0	1.6	5.0	0.1	0.4	0.0	0.4	0.2	0.7	1.2	0.0	0.1	0.0	0.1	1.2	0.3	0.0	0.0	0.0	0.0	17.1	6.0	1.7	2.1	0.9	0.2	0.0	0.0	1.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0										
FBN2	"CCA, DA9"	ENSG00000138829	"Fibrillin 2"	P35556	5	128257909-128659185	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	22	"placenta: 175.9"	"Cell line enhanced"	"Detected in many"		"HHSteC: 37.3;HSkMC: 26.6;hTERT-HME1: 58.9;HUVEC TERT2: 33.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 2.5;non-classical monocyte: 5.0"	"Lineage enriched"	"Detected in many"	5	"monocytes: 5.0"	"Region enhanced"	"Detected in single"		"olfactory region: 2.6"	"Low region specificity"	"Detected in some"			"HPA012853, CAB026401"	Enhanced		Approved	Nucleoplasm,Cytosol	"Secreted to extracellular matrix"	4600000	4600000	Cytosol	Nucleoplasm	"CAB026401: , HPA012853: AB_1848588"	"unprognostic (2.49e-1)"	"unprognostic (1.14e-1)"	"unprognostic (7.29e-3)"	"unprognostic (1.79e-3)"	"unprognostic (6.74e-2)"	"unprognostic (2.33e-1)"	"unprognostic (4.92e-3)"	"unprognostic (9.41e-2)"	"unprognostic (1.06e-2)"	"unprognostic (4.66e-1)"	"unprognostic (1.12e-1)"	"unprognostic (8.69e-2)"	"unprognostic (8.60e-5)"	"unprognostic (1.04e-2)"	"unprognostic (3.19e-2)"	"unprognostic (1.00e-1)"	"prognostic unfavourable (7.41e-5)"	0.3	7.9	0.3	1.0	0.3	1.6	0.1	0.2	0.3	1.5	0.7	0.4	1.0	0.2	2.9	0.6	1.1	0.6	0.2	6.7	0.2	0.5	0.2	0.2	0.2	1.3	0.2	0.4	0.9	0.1	0.0	1.3	175.9	0.4	1.0	0.8	6.2	0.4	0.9	0.2	0.3	0.5	0.8	0.4	0.6	0.5	4.6	0.2	0.3	0.9	0.4	0.7	0.4	1.2	0.0	1.1	0.6	5.0	0.0	0.0	0.4	0.0	4.4	16.1	0.0	2.6	4.6	3.3	17.6	0.0	15.6	11.7	0.0	0.0	0.0	0.0	23.5	2.6	10.4	2.6	14.7	0.0	4.2	0.0	7.4	0.0	37.3	2.3	0.0	26.6	1.4	6.6	58.9	33.1	0.0	0.0	9.6	0.0	0.0	0.8	6.9	5.3	5.1	5.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	4.9	0.0	6.3	12.0	17.9	0.0	0.0	0.0	0.0	1.8	0.0	6.6	0.0	2.5	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.6	0.0	5.0	0.0	0.0	0.4	0.3	0.3	0.2	0.3	0.2	0.5	0.2	0.4	0.4	0.2
FBXO11	"FBX11, UBR6"	ENSG00000138081	"F-box protein 11"	Q86XK2	2	47789316-47905793	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002690			Supported	Nucleoplasm				Nucleoplasm		"HPA002690: AB_1848448"	"unprognostic (1.18e-1)"	"unprognostic (8.65e-3)"	"unprognostic (3.93e-2)"	"unprognostic (2.05e-2)"	"unprognostic (7.92e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.85e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.55e-2)"	"unprognostic (9.82e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.33e-2)"	"unprognostic (3.21e-2)"	"unprognostic (1.55e-1)"	"unprognostic (3.71e-1)"	"unprognostic (2.19e-1)"	"unprognostic (3.20e-2)"	18.0	13.8	18.6	15.7	18.8	17.5	26.1	42.2	31.7	21.3	15.3	12.7	15.1	10.4	28.9	16.8	14.5	16.3	15.0	14.1	16.9	13.6	14.3	17.0	22.3	15.0	17.4	21.7	28.9	12.4	25.2	14.4	14.5	19.7	15.3	13.3	12.0	15.6	16.5	22.9	14.5	13.5	19.9	16.4	14.5	13.3	25.1	16.0	14.6	17.3	9.8	17.2	19.3	21.9	4.7	4.3	8.2	2.7	4.8	6.6	2.0	25.5	13.3	32.0	27.2	22.5	21.2	19.1	17.9	24.7	16.8	16.6	11.2	13.1	16.6	23.5	25.2	12.8	21.8	18.9	24.8	11.0	10.9	15.4	11.0	17.8	21.5	16.0	16.4	20.6	21.4	14.9	25.3	21.5	15.0	17.2	20.5	12.3	15.4	15.7	19.5	13.2	20.1	29.7	12.3	24.0	20.9	22.6	26.7	17.0	15.9	26.2	7.4	13.7	23.1	20.8	19.2	14.0	19.6	14.9	7.7	30.2	14.1	15.1	21.2	8.2	2.3	4.3	3.8	2.7	3.8	4.7	3.4	4.1	3.1	3.6	6.6	4.1	4.1	4.8	2.4	4.3	3.6	2.0	18.6	18.8	42.2	31.7	16.9	13.6	17.4	21.7	19.7	16.0
FBXO6	"FBG2, FBS2, FBX6, Fbx6b"	ENSG00000116663	"F-box protein 6"	Q9NRD1	1	11664124-11674354	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway, Unfolded protein response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051175	Approved									"HPA051175: "	"unprognostic (3.23e-3)"	"unprognostic (2.58e-2)"	"unprognostic (8.27e-2)"	"unprognostic (2.69e-3)"	"unprognostic (1.11e-1)"	"unprognostic (6.64e-2)"	"unprognostic (9.46e-3)"	"unprognostic (1.22e-1)"	"unprognostic (1.18e-1)"	"prognostic favourable (7.12e-4)"	"unprognostic (1.47e-2)"	"unprognostic (3.40e-1)"	"prognostic unfavourable (7.83e-6)"	"unprognostic (2.65e-2)"	"unprognostic (2.11e-1)"	"unprognostic (5.23e-2)"	"prognostic favourable (5.90e-4)"	9.1	11.8	10.8	12.2	17.4	19.7	13.2	9.5	11.6	7.6	11.6	4.4	9.8	14.6	5.4	9.1	14.1	15.7	11.1	14.4	9.5	12.6	8.9	17.5	12.2	17.5	9.4	12.2	6.8	25.9	10.4	6.8	5.0	9.1	11.4	7.5	8.9	13.8	9.9	16.8	9.3	9.9	10.6	6.6	14.9	9.8	9.9	8.5	5.8	13.0	13.2	12.1	10.5	6.9	6.0	25.1	23.5	31.0	14.4	18.7	12.2	6.1	4.6	0.5	0.2	1.4	4.5	3.0	2.6	4.1	12.9	6.0	4.7	5.4	0.2	12.1	4.4	0.1	4.3	4.7	0.9	16.3	0.6	0.1	0.6	4.7	10.1	5.7	0.0	5.2	10.1	1.6	4.1	1.7	13.7	12.1	1.1	11.8	2.1	4.9	0.5	6.1	1.4	0.1	0.4	4.4	0.9	1.1	1.3	5.8	7.0	8.7	6.7	6.5	1.3	0.6	0.5	1.8	0.2	6.5	4.5	2.4	0.8	13.4	1.1	5.6	19.1	23.5	18.7	28.0	10.3	6.0	5.0	12.5	25.1	5.2	3.0	10.0	15.6	14.4	31.0	9.9	4.7	12.2	10.8	17.4	9.5	11.6	9.5	12.6	9.4	12.2	9.1	8.5
FBXW7	"AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10"	ENSG00000109670	"F-box and WD repeat domain containing 7"	Q969H0	4	152320544-152536063	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 60.1;skin 1: 45.0"	"Cell line enhanced"	"Detected in all"		"U-266/70: 37.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013793, CAB029987"	Supported		Supported	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB013793: AB_2533451, CAB029987: AB_2246842"	"unprognostic (3.32e-1)"	"unprognostic (9.02e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.08e-2)"	"unprognostic (3.87e-1)"	"unprognostic (1.36e-3)"	"unprognostic (4.37e-1)"	"unprognostic (1.94e-1)"	"unprognostic (8.28e-2)"	"unprognostic (3.29e-1)"	"unprognostic (5.32e-3)"	"unprognostic (3.19e-2)"	"prognostic unfavourable (1.52e-4)"	"unprognostic (3.38e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.49e-3)"	"unprognostic (2.17e-3)"	9.2	6.8	27.0	8.9	27.9	11.1	9.8	27.2	60.1	5.5	6.1	3.6	3.8	4.9	6.0	18.3	9.8	10.6	6.3	10.9	21.4	10.1	4.1	7.3	6.9	9.8	9.1	40.5	6.4	8.0	6.4	7.3	6.2	37.2	5.1	6.9	2.8	7.6	5.3	15.8	45.0	6.5	6.1	6.4	10.1	8.0	13.7	5.7	6.5	6.8	10.6	12.3	7.9	6.5	2.9	2.2	16.6	3.4	7.8	5.0	1.3	4.9	3.9	10.2	7.4	7.1	5.1	8.4	7.1	6.5	4.4	4.2	7.9	6.3	12.7	2.0	6.8	2.9	8.7	16.0	6.2	7.2	4.1	5.9	4.8	5.6	7.2	14.4	5.4	8.1	25.3	7.6	12.9	7.7	9.3	13.6	5.5	6.9	16.5	5.7	5.0	3.1	16.6	4.3	2.5	5.4	8.5	6.5	5.6	4.5	6.2	3.9	3.4	6.8	8.1	6.0	6.8	3.1	4.0	37.4	21.3	12.4	4.8	4.7	4.3	16.6	3.1	1.7	5.0	3.4	3.3	2.9	3.7	3.2	1.8	2.4	3.9	3.2	5.5	7.8	2.5	2.2	3.3	1.3	27.0	27.9	27.2	60.1	21.4	10.1	9.1	40.5	37.2	5.7
FCER2	"CD23, CD23A, CLEC4J, FCE2"	ENSG00000104921	"Fc fragment of IgE receptor II"	P06734	19	7688758-7702146	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgE-binding protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"blood: 87.2;lymphoid tissue: 38.4"	"Cell line enriched"	"Detected in some"	14	"HDLM-2: 97.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"memory B-cell: 28.2;naive B-cell: 87.2"	"Lineage enriched"	"Detected in many"	34	"B-cells: 87.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB002624, HPA008928"	Enhanced				"Secreted to blood"	59000	59000			"CAB002624: , HPA008928: AB_1846285"	"unprognostic (3.20e-4)"	"unprognostic (1.87e-3)"	"unprognostic (1.95e-2)"	"unprognostic (2.44e-2)"	"unprognostic (4.77e-2)"	"unprognostic (1.77e-3)"	"unprognostic (1.64e-1)"	"unprognostic (1.89e-3)"	"unprognostic (2.71e-1)"	"unprognostic (1.88e-1)"	"unprognostic (2.04e-2)"	"unprognostic (8.55e-2)"	"unprognostic (2.46e-4)"	"unprognostic (2.99e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.89e-2)"	"unprognostic (5.17e-2)"	2.4	0.3	0.5	17.1	0.5	2.3	1.2	0.3	1.1	0.3	1.0	0.1	0.4	1.3	0.3	2.3	1.0	0.4	0.5	0.8	0.3	0.3	0.6	0.6	0.8	21.1	0.3	0.0	0.4	0.3	0.0	0.3	0.3	0.1	0.3	0.8	0.0	7.5	0.7	0.4	0.6	7.7	0.4	0.3	38.4	0.8	0.5	0.0	6.3	0.7	0.0	33.8	2.0	0.5	87.2	0.7	0.2	2.5	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	97.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.5	0.0	0.0	2.5	0.0	28.2	0.0	0.0	0.7	87.2	0.0	0.0	0.2	0.0	0.7	0.1	0.0	3.0	0.5	0.5	0.3	0.3	0.3	0.3	0.3	0.0	0.1	0.0
FCGR2B	"CD32, CD32B, FCG2, FCGR2"	ENSG00000072694	"Fc fragment of IgG receptor IIb"	P31994	1	161663147-161678654	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Host-virus interaction"	"IgG-binding protein, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 53.3;placenta: 83.2"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.2;HMC-1: 23.0;NB-4: 5.1;RPMI-8226: 8.2"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"basophil: 53.3;memory B-cell: 42.2"	"Group enriched"	"Detected in many"	18	"B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3"									"CAB007796, HPA014730"	Enhanced									"CAB007796: AB_562288, HPA014730: "	"unprognostic (1.58e-1)"	"unprognostic (5.14e-2)"	"unprognostic (3.32e-3)"	"unprognostic (3.12e-2)"	"unprognostic (6.79e-3)"	"unprognostic (4.05e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.65e-3)"	"unprognostic (1.91e-1)"	"unprognostic (4.72e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavourable (8.82e-4)"	"unprognostic (3.51e-2)"	"unprognostic (6.36e-2)"	"unprognostic (4.31e-1)"	"unprognostic (3.37e-1)"	11.3	2.4	0.0	2.0	0.2	0.0	4.1	0.0	0.0	1.9	3.4			0.2	0.9	0.2	2.1	2.1	2.3	3.7	0.0	0.2	2.0	9.5	5.6	2.5	0.5		0.8	0.6	0.0	0.3	83.2		0.3	2.0		3.3	0.2	0.5	2.0	4.6	3.1	4.7	6.7	1.5	0.1			1.7		5.6	3.3	1.2	42.2	14.5	53.3	1.9	0.1	0.3	2.4	0.0	0.1	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	5.1	0.1	0.0	0.0	0.0	8.2	0.0	0.0	0.1	0.1	0.0	0.0	1.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	2.2	0.0	53.3	1.8	5.4	0.3	1.9	0.1	42.2	0.1	0.2	14.5	34.3	0.0	0.3	11.2	0.1	1.7	0.0	0.0	2.4										
FCRL4	"CD307d, FCRH4, IGFP2, IRTA1"	ENSG00000163518	"Fc receptor like 4"	Q96PJ5	1	157573749-157598080	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"intestine: 5.4;lymphoid tissue: 15.6"	"Cell line enriched"	"Detected in single"	102	"U-266/70: 10.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"memory B-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"B-cells: 1.1"					"Low region specificity"	"Detected in many"			HPA054030	Approved									"HPA054030: "	"unprognostic (6.06e-2)"	"unprognostic (3.41e-3)"	"unprognostic (2.57e-1)"	"unprognostic (5.08e-2)"		"unprognostic (4.69e-4)"		"unprognostic (2.06e-2)"			"unprognostic (6.38e-2)"			"unprognostic (1.99e-1)"	"unprognostic (2.14e-1)"	"unprognostic (3.37e-1)"	"unprognostic (6.77e-2)"	0.1	0.1	0.1	15.6	0.1	0.0	0.1	0.1	0.2	0.1	0.3	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	5.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.4	0.0	2.5	0.0	0.1	0.1	5.4	0.0	0.1	2.2	0.3	0.1	0.0	1.1	0.1	1.9	14.9	0.4	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.0	0.0
FEN1	"FEN-1, MF1, RAD2"	ENSG00000168496	"Flap structure-specific endonuclease 1"	P39748	11	61792637-61797244	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"Endonuclease, Exonuclease, Hydrolase, Nuclease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 36.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002262, HPA006748"	Enhanced		Enhanced	Nucleoplasm,Nucleoli		38000	38000	Nucleoplasm	Nucleoli	"CAB002262: AB_563729, HPA006748: AB_1848494"	"unprognostic (1.82e-1)"	"unprognostic (2.71e-2)"	"unprognostic (3.76e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.26e-1)"	"unprognostic (6.45e-2)"	"prognostic unfavourable (3.39e-6)"	"unprognostic (1.50e-2)"	"unprognostic (9.82e-2)"	"prognostic favourable (7.85e-4)"	"unprognostic (2.82e-3)"	"unprognostic (5.86e-2)"	"prognostic unfavourable (5.73e-6)"	"prognostic favourable (9.46e-4)"	"unprognostic (1.10e-1)"	"unprognostic (4.49e-3)"	"unprognostic (4.04e-2)"	4.8	9.6	7.9	14.6	8.5	23.9	7.4	16.9	14.9	4.9	11.0	8.5	5.0	8.1	5.0	6.6	13.3	4.2	7.0	4.6	8.6	8.5	4.9	9.3	5.0	22.5	8.3	9.8	3.9	6.3	5.2	7.9	11.2	12.6	4.7	12.0	7.3	9.3	4.6	11.2	6.8	8.2	6.4	7.1	12.3	7.2	16.2	5.9	36.3	3.5	10.6	25.5	6.1	4.2	11.5	18.1	14.5	9.4	13.3	18.0	7.3	31.0	28.6	31.4	16.9	3.1	3.9	20.0	27.5	15.7	33.7	38.4	25.0	23.4	44.9	21.5	11.7	32.9	44.2	24.1	34.6	23.6	24.3	23.7	39.1	25.4	2.4	36.8	24.5	2.7	3.3	31.1	8.3	13.1	35.8	32.5	28.0	39.1	51.2	33.1	34.5	28.1	35.2	36.4	46.3	13.4	29.5	35.8	29.7	18.3	24.1	15.8	34.9	25.9	8.8	30.0	37.9	38.2	27.7	25.7	39.9	46.6	20.9	24.7	25.8	14.5	5.0	10.2	12.4	9.4	13.1	11.5	10.0	11.8	5.8	11.5	11.2	11.3	2.1	13.3	8.8	18.1	18.0	7.3	7.9	8.5	16.9	14.9	8.6	8.5	8.3	9.8	12.6	5.9
FES	FPS	ENSG00000182511	"FES proto-oncogene, tyrosine kinase"	P07332	15	90883695-90895776	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 60.8;lymphoid tissue: 49.7"	"Cell line enhanced"	"Detected in many"		"HEL: 20.9;HL-60: 18.6;HMC-1: 39.8;NB-4: 24.4;THP-1: 36.6;U-937: 15.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 60.8"	"Group enriched"	"Detected in many"	4	"dendritic cells: 32.6;granulocytes: 60.8;monocytes: 30.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA001376	Approved		Approved	Nucleoplasm,Vesicles,Cytosol				"Nucleoplasm, Cytosol"	Vesicles	"HPA001376: AB_1078847"	"unprognostic (1.07e-2)"	"unprognostic (2.54e-2)"	"prognostic unfavourable (5.78e-4)"	"unprognostic (2.31e-2)"	"unprognostic (4.05e-3)"	"unprognostic (7.33e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.58e-3)"	"unprognostic (1.35e-1)"	"unprognostic (4.66e-2)"	"unprognostic (5.15e-3)"	"unprognostic (1.78e-3)"	"unprognostic (2.53e-3)"	"unprognostic (6.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.40e-1)"	14.9	3.4	4.8	9.7	4.1	38.3	12.7	2.4	5.7	6.8	5.4	3.2	4.7	3.0	7.4	5.6	4.9	7.6	7.3	7.9	4.2	2.2	5.2	11.8	12.7	23.3	3.7	0.9	6.4	3.7	1.8	2.7	8.1	7.2	7.7	2.4	5.3	33.8	6.3	3.4	3.5	5.2	5.4	6.9	49.7	4.3	3.2	4.7	3.1	7.2	4.1	4.5	7.2	9.4	1.1	32.6	60.8	30.5	9.3	0.1	13.8	0.1	0.2	0.3	3.5	1.0	3.1	6.0	0.9	0.0	1.7	1.0	0.8	0.0	2.2	0.1	2.0	0.5	0.6	0.1	0.5	1.1	0.3	20.9	0.0	3.7	2.0	18.6	39.8	3.0	0.0	2.6	0.0	10.5	0.6	0.0	0.0	6.8	0.5	24.4	1.0	0.0	2.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.8	0.0	36.6	8.3	0.0	3.6	0.1	0.0	0.0	2.6	0.8	0.1	15.8	0.8	10.4	30.5	60.8	0.1	17.6	0.0	1.1	0.0	0.0	32.6	0.9	0.0	0.0	20.0	9.3	7.3	12.9	0.0	13.8	4.8	4.1	2.4	5.7	4.2	2.2	3.7	0.9	7.2	4.7
FEV	Pet-1	ENSG00000163497	"FEV, ETS transcription factor"	Q99581	2	218981087-218985657	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1"	"Group enriched"	"Detected in some"	6	"HMC-1: 18.7;SH-SY5Y: 23.9"	"Group enriched"	"Detected in some"	10	"pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4"	"Region enhanced"	"Detected in many"		"pons and medulla: 6.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	13	"midbrain: 2.3;pons and medulla: 0.9"	"Group enriched"	"Detected in some"	34	"midbrain: 7.3;pons and medulla: 3.9"	HPA067679		Supported	Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA067679: "			"unprognostic (4.58e-1)"		"unprognostic (1.60e-1)"					"unprognostic (7.21e-2)"	"prognostic favourable (4.85e-4)"	"unprognostic (2.87e-1)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.15e-1)"			0.1	4.1	0.0	1.2	3.5	0.0	0.0	0.0	2.6	0.0	2.0	0.7	0.0	7.0	0.1	0.0	0.0	0.1	0.0	0.0	1.1	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	4.2	0.0	5.4	0.0	6.9	4.0	3.2	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.1	0.0	6.1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	23.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	2.6	1.1	0.2	0.2	0.0	6.9	1.0
FGA		ENSG00000171560	"Fibrinogen alpha chain"	P02671	4	154583126-154590766	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	740	"liver: 2009.3"	"Cell line enriched"	"Detected in some"	15	"Hep G2: 94.6"	"Cancer enriched"	"Detected in many"	43	"liver cancer: 2431.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"CAB016776, HPA051370, HPA064755"	Supported		Approved	"Endoplasmic reticulum"	"Secreted to blood"	170000000000	170000000000	"Endoplasmic reticulum"		"CAB016776: , HPA051370: , HPA064755: "		"unprognostic (5.95e-2)"	"unprognostic (6.25e-2)"	"unprognostic (2.02e-1)"		"unprognostic (5.68e-2)"	"prognostic favourable (7.33e-4)"	"unprognostic (1.29e-3)"			"unprognostic (1.84e-1)"		"prognostic unfavourable (4.23e-6)"	"unprognostic (4.20e-1)"	"unprognostic (1.41e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	2.7	2009.3	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	94.6	0.0	1.3	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.4	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0
FGB		ENSG00000171564	"Fibrinogen beta chain"	P02675	4	154562956-154571086	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	189	"liver: 1908.6"	"Cell line enriched"	"Detected in some"	12	"Hep G2: 75.9"	"Cancer enriched"	"Detected in many"	42	"liver cancer: 2262.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA001900, HPA001901, CAB008624"	Enhanced		Enhanced	"Endoplasmic reticulum"	"Secreted to blood"	120000000000	120000000000	"Endoplasmic reticulum"		"CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864"	"unprognostic (1.16e-1)"	"unprognostic (3.89e-2)"	"unprognostic (4.65e-2)"	"unprognostic (3.44e-1)"			"unprognostic (2.20e-3)"	"unprognostic (1.42e-2)"			"unprognostic (1.79e-1)"		"prognostic unfavourable (5.72e-5)"	"unprognostic (2.48e-2)"	"unprognostic (7.91e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	10.1	1908.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	75.9	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.2	0.0	0.7	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FGF1	"AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1"	ENSG00000113578	"Fibroblast growth factor 1"	P05230	5	142592178-142698070	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 65.0;heart muscle: 35.5;kidney: 41.5"	"Cell line enhanced"	"Detected in some"		"BJ: 19.3;BJ hTERT+: 14.4;BJ hTERT+ SV40 Large T+: 16.0;BJ hTERT+ SV40 Large T+ RasG12V: 20.2;HBF TERT88: 28.8;hTEC/SVTERT24-B: 20.1;LHCN-M2: 13.4;U-2 OS: 14.4"	"Cancer enriched"	"Detected in many"	12	"glioma: 33.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003265, CAB017519"	Enhanced		Supported	Nucleoplasm	"Secreted in other tissues"			Nucleoplasm		"CAB017519: AB_629473, HPA003265: AB_1848522"	"unprognostic (1.25e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.41e-3)"	"unprognostic (2.55e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.39e-1)"	"unprognostic (3.63e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.54e-1)"	"prognostic favourable (2.59e-5)"	"unprognostic (3.72e-4)"	"unprognostic (2.49e-1)"	"prognostic favourable (3.45e-5)"	"unprognostic (3.01e-4)"	7.3	3.5	44.2	2.0	43.1	1.5	9.7	10.5	59.9	1.8	1.7	65.0	0.0	1.6	3.1	8.7	2.3	2.1	2.7	35.5	47.4	33.0	41.5	2.0	2.9	1.4	62.6	13.8	1.5	1.4	3.4	1.6	2.3	36.3	2.2	1.8	0.8	5.8	2.6	2.3	2.0	1.7	2.6	57.7	5.5	1.1	2.2	48.6	0.0	4.9	0.8	2.2	1.7	0.4	1.2	1.0	1.8	0.6	0.1	2.3	0.2	2.3	0.1	0.1	0.7	0.5	1.5	0.8	19.3	14.4	16.0	20.2	0.1	0.1	0.5	1.4	6.6	0.3	0.0	1.5	28.8	0.1	0.0	0.0	0.3	0.1	0.2	0.0	0.2	0.7	0.5	20.1	1.2	0.0	0.0	0.7	13.4	0.3	0.0	0.4	0.6	0.6	0.1	0.6	0.2	0.6	0.1	0.5	1.0	0.0	0.4	0.2	0.0	0.1	0.4	2.6	14.4	0.3	9.1	0.3	0.1	0.1	3.6	0.1	0.7	0.3	0.3	1.8	2.3	0.1	1.8	0.4	0.8	0.9	0.2	1.2	0.9	1.9	1.7	0.1	0.6	1.0	0.5	0.2	44.2	43.1	10.5	22.6	47.4	33.0	62.6	13.8	36.3	48.6
FGF17	FGF-13	ENSG00000158815	"Fibroblast growth factor 17"	O60258	8	22042398-22048809	"Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins"		"Developmental protein, Growth factor"	"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"brain: 31.3"	"Cell line enhanced"	"Detected in some"		"HaCaT: 3.2;Hep G2: 2.3;MOLT-4: 2.2;RPMI-8226: 4.4"	"Cancer enhanced"	"Detected in some"		"testis cancer: 3.9"	"Region enriched"	"Detected in many"	4	"cerebellum: 31.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	4	"basal ganglia: 2.2"	"Low region specificity"	"Detected in some"			HPA052600	Uncertain				"Secreted in brain"					"HPA052600: "	"unprognostic (3.45e-2)"	"unprognostic (1.64e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.33e-2)"	"unprognostic (3.51e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.78e-2)"	"unprognostic (5.65e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.92e-5)"	"unprognostic (6.85e-2)"	"unprognostic (2.58e-4)"	"unprognostic (6.55e-3)"	"unprognostic (7.18e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.95e-3)"	0.4	4.9	2.5	0.4	3.2	0.2	0.4	31.3	7.7	0.5	0.4	0.4	0.4	0.2	2.2	0.6	0.4	0.7	0.6	0.4	2.2	4.7	0.4	0.4	0.5	0.4	1.3	2.9	0.5	2.6	3.6	2.1	0.4	3.3	1.2	0.2	0.4	2.4	0.5	0.4	0.9	0.4	1.0	0.9	3.0	0.8	0.6	0.4	1.6	2.3	0.4	0.4	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.2	0.6	0.6	1.0	0.3	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.6	0.0	3.2	0.0	0.0	0.0	0.0	0.9	0.7	0.0	2.3	0.1	0.0	1.5	0.0	0.3	0.0	0.1	0.0	0.1	0.1	0.0	0.7	2.2	0.8	0.0	0.0	0.0	0.0	4.4	0.0	0.0	1.0	1.5	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.1	0.6	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	3.2	31.3	7.7	2.2	4.7	1.3	2.9	3.3	0.4
FGF18	"FGF-18, ZFGF5"	ENSG00000156427	"Fibroblast growth factor 18"	O76093	5	171419656-171457623	"Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"heart muscle: 23.0"	"Cell line enriched"	"Detected in some"	57	"EFO-21: 65.1"	"Group enriched"	"Detected in many"	6	"endometrial cancer: 19.0;ovarian cancer: 21.9"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA018795	Uncertain				"Secreted in other tissues"					"HPA018795: AB_1848523"	"unprognostic (3.01e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.66e-3)"	"unprognostic (6.62e-3)"	"unprognostic (1.50e-1)"	"unprognostic (3.20e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.98e-3)"	"unprognostic (3.65e-2)"	"unprognostic (3.18e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.37e-8)"	"unprognostic (7.33e-2)"	"unprognostic (2.58e-1)"	"unprognostic (3.19e-1)"	"unprognostic (2.76e-2)"	4.4	0.6	0.6	2.8	0.6	0.1	2.0	0.4	1.2	1.3	0.8	0.5	0.0	1.1	1.6	1.5	0.9	2.0	1.4	23.0	0.5	0.4	1.3	0.4	2.9	0.5	0.4	0.0	1.6	0.9	0.1	1.8	0.9	1.6	2.2	0.3	0.3	1.0	0.7	5.4	1.8	2.2	1.2	0.9	1.1	0.7	1.0	0.3	0.2	2.2	2.5	0.8	2.2	0.5	0.9	0.1	0.2	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.1	0.1	0.0	65.1	0.0	0.1	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.9	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.6	0.6	0.4	1.2	0.5	0.4	0.4	0.0	1.6	0.3
FGF19		ENSG00000162344	"Fibroblast growth factor 19"	O95750	11	69698232-69704642	"Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	13	"gallbladder: 62.4"	"Cell line enriched"	"Detected in some"	16	"CAPAN-2: 46.7"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"basal ganglia: 0.8"	"Region enriched"	"Detected in single"	18	"basal ganglia: 0.9"	HPA036082	Approved				"Secreted to blood"					"HPA036082: AB_10669665"	"unprognostic (7.46e-3)"	"unprognostic (2.43e-3)"	"unprognostic (5.52e-3)"	"unprognostic (1.22e-1)"		"unprognostic (4.68e-3)"	"unprognostic (6.45e-2)"	"unprognostic (5.72e-3)"		"unprognostic (2.26e-1)"	"unprognostic (6.39e-3)"			"unprognostic (1.66e-2)"	"unprognostic (8.82e-3)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	62.4	0.0	0.0	0.4	0.0	2.8	0.0	0.0	0.0		0.0	0.1	0.4	0.4	0.0		0.0	0.0		0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.5			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
FGF2	FGFB	ENSG00000138685	"Fibroblast growth factor 2"	P09038	4	122826708-122898236	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 56.5;BJ hTERT+: 33.1;fHDF/TERT166: 61.3;hTERT-HME1: 33.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000125, HPA065502"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"	"Secreted in other tissues"			"Nucleoplasm, Nuclear bodies"		"CAB000125: , HPA065502: "	"unprognostic (1.53e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.08e-1)"	"unprognostic (7.42e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.33e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.79e-1)"	"prognostic unfavourable (9.85e-4)"	"unprognostic (3.37e-1)"	"unprognostic (4.61e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.81e-1)"	"unprognostic (4.45e-2)"	"unprognostic (3.45e-3)"	28.1	3.8	19.4	6.9	21.3	0.7	12.1	6.5	15.3	10.2	14.2	10.3	1.9	2.6	17.9	6.3	6.4	10.1	9.4	5.6	17.1	11.0	5.5	2.9	8.3	2.5	9.9	10.7	16.8	2.4	10.1	4.0	8.1	18.6	10.3	5.6	7.5	4.6	11.9	2.0	2.3	4.1	16.2	17.3	1.9	7.6	3.0	12.3	0.0	3.1	3.8	2.7	7.5	14.5	0.8	0.8	0.5	0.5	0.3	1.0	0.0	1.2	3.1	1.7	6.8	4.3	7.2	0.0	56.5	33.1	23.7	13.8	0.0	0.1	0.0	6.6	61.3	0.2	1.8	0.1	23.9	4.4	0.8	0.0	6.4	0.0	12.8	0.3	0.0	3.9	0.3	23.4	33.8	2.6	1.7	1.9	6.1	0.0	0.0	0.0	5.1	1.3	0.0	0.9	0.0	7.5	0.0	1.0	0.9	10.9	0.0	0.4	0.0	0.1	2.3	19.6	3.8	7.2	4.8	3.3	3.6	0.0	5.6	0.0	2.0	0.5	0.5	0.4	0.3	0.4	0.2	0.4	0.5	0.4	0.2	0.8	0.7	1.0	0.4	0.3	0.4	0.8	0.7	0.0	19.4	21.3	6.5	15.3	17.1	11.0	9.9	10.7	18.6	12.3
FGF23		ENSG00000118972	"Fibroblast growth factor 23"	Q9GZV9	12	4368227-4379728	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters"	Differentiation	"Growth factor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 11.1;heart muscle: 9.1;liver: 10.1;urinary bladder: 6.7"	"Cell line enhanced"	"Detected in many"		"AF22: 5.4;HBEC3-KT: 3.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"								"Secreted to blood"									"unprognostic (1.31e-1)"						"unprognostic (2.18e-2)"				"unprognostic (1.44e-1)"	"unprognostic (1.67e-1)"			0.3	0.4	0.2	0.2	0.2	0.8	0.2	0.2	0.8	0.2	0.2	0.2	0.2	0.4	0.5	3.5	1.2	0.5	0.2	9.1	0.2	0.2	0.3	10.1	0.3	2.6	0.2	0.2	0.3	0.2	0.1	0.4	0.3	0.2	0.2	1.4	0.2	1.0	0.2	2.5	0.4	0.3	0.7	0.2	1.1	0.2	0.9	0.2	0.6	0.3	0.2	1.3	6.7	0.2	3.1	2.9	11.1	3.6	3.4	3.1	1.7	0.2	0.0	5.4	1.8	2.8	0.6	0.8	0.1	0.1	0.0	0.2	1.0	1.9	0.3	0.2	0.9	1.2	0.8	3.9	0.2	0.2	0.6	0.2	0.7	0.6	1.6	1.1	0.5	1.6	0.1	2.5	3.2	0.4	0.5	2.3	0.1	0.0	0.7	1.3	1.4	0.2	0.9	0.1	0.8	0.6	1.1	1.2	1.1	0.0	1.8	0.2	1.3	0.8	0.0	2.0	0.5	1.4	0.3	0.1	0.2	0.3	1.2	0.4	1.3	11.1	2.3	2.9	2.6	2.4	3.1	2.9	2.5	2.0	1.8	3.1	2.8	2.9	7.2	3.4	3.6	2.9	2.3	1.7	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
FGF3	"HBGF-3, INT2"	ENSG00000186895	"Fibroblast growth factor 3"	P11487	11	69809969-69819024	"Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins"	Differentiation	"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	43	"brain: 16.6"	"Cell line enriched"	"Detected in single"	48	"CAPAN-2: 4.8"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	38	"cerebellum: 16.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"basal ganglia: 2.7"	"Not detected"	"Not detected"			HPA012692	Enhanced				"Secreted in brain"					"HPA012692: AB_1848526"				"unprognostic (6.42e-3)"						"unprognostic (7.82e-2)"	"unprognostic (1.89e-1)"			"unprognostic (3.61e-1)"	"unprognostic (7.75e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	0.4	0.0
FGF4	"HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF"	ENSG00000075388	"Fibroblast growth factor 4"	P08620	11	69771016-69775403	"Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins"	Differentiation	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 2.6;intestine: 1.6;testis: 2.4;tongue: 2.0"	"Cell line enriched"	"Detected in single"	93	"NTERA-2: 18.6"	"Cancer enriched"	"Detected in some"	5	"testis cancer: 13.9"	"Group enriched"	"Detected in some"	19	"midbrain: 2.6;pons and medulla: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA011209	Uncertain				"Secreted in other tissues"					"HPA011209: AB_1848527"			"unprognostic (1.47e-2)"	"unprognostic (6.22e-2)"										"unprognostic (7.77e-2)"	"unprognostic (8.56e-2)"			0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.1	2.6	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.4	0.0	1.2	0.8	0.1	2.4	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	1.2	0.0
FGF6		ENSG00000111241	"Fibroblast growth factor 6"	P10767	12	4428155-4445614	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"skeletal muscle: 24.6;tongue: 6.9"	"Group enriched"	"Detected in some"	7	"NB-4: 1.7;NTERA-2: 6.0;REH: 6.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Secreted in other tissues"																				"unprognostic (4.29e-2)"			0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.9	0.0	24.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	6.9	0.2	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	6.0	0.0	6.4	0.1	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FGF7	KGF	ENSG00000140285	"Fibroblast growth factor 7"	P21781	15	49423096-49488775	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 23.7;ASC TERT1: 21.8;fHDF/TERT166: 9.8;HSkMC: 22.2;RH-30: 17.6;U-138 MG: 12.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in single"		"basophil: 1.6"	"Low lineage specificity"	"Detected in single"			"Region enriched"	"Detected in single"	9	"cerebellum: 9.7"					HPA043605	Uncertain		Approved	Nucleoplasm,Nucleoli	"Secreted in other tissues"			"Nucleoplasm, Nucleoli"		"HPA043605: AB_10960215"	"unprognostic (4.65e-1)"	"unprognostic (7.62e-2)"	"unprognostic (2.50e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.62e-2)"	"unprognostic (5.74e-3)"	"unprognostic (2.56e-2)"	"unprognostic (7.30e-2)"	"unprognostic (5.79e-2)"	"unprognostic (1.91e-3)"	"unprognostic (1.22e-3)"	"unprognostic (7.59e-2)"	"unprognostic (1.98e-3)"	"unprognostic (1.63e-3)"	39.7	2.7	0.6	9.9	0.6	0.0	16.5	0.6	2.4	73.3	22.2	0.0	10.1	1.1	13.1	16.1	25.2	14.1	25.4	19.1	0.6	0.6	5.9	1.2	44.8	5.5	2.1	0.0	43.7	2.5	2.9	2.8	9.1	0.8	42.5	4.5	2.7	6.4	8.1	25.6	3.6	4.2	38.3	1.4	1.0	6.6	12.7	0.0	0.0	23.2	24.7	2.9	72.2	32.4	0.2	0.1	1.6	0.2	0.3	0.5	0.0	0.1	0.0	0.1	0.1	23.7	21.8	0.0	7.2	4.4	0.0	0.0	0.0	0.1	0.0	0.1	9.8	0.4	0.0	0.1	0.0	0.0	0.1	0.0	0.2	0.0	2.0	0.1	0.0	22.2	0.4	1.9	0.0	0.0	0.0	0.1	1.5	0.0	0.0	0.0	0.1	0.1	0.0	17.6	0.0	0.0	0.0	0.9	0.3	0.2	0.0	0.0	0.1	0.1	0.1	12.0	0.2	0.4	0.0	0.2	0.1	0.0	3.3	0.0	0.2	1.6	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.3	0.0	0.2	0.5	0.2	0.0	0.3	0.2	0.1	0.4	0.0	0.6	0.6	0.6	0.6	0.6	0.6	2.1	0.0	0.8	0.0
FGF8	AIGF	ENSG00000107831	"Fibroblast growth factor 8"	P55075	10	101770130-101780369	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	Differentiation	"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism, Kallmann syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	6	"skeletal muscle: 30.5"	"Cell line enriched"	"Detected in some"	20	"RH-30: 30.6"	"Group enriched"	"Detected in some"	8	"endometrial cancer: 2.1;testis cancer: 3.3;urothelial cancer: 0.7"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"								"Secreted in other tissues"						"unprognostic (1.56e-1)"	"unprognostic (3.90e-3)"	"unprognostic (1.12e-2)"	"unprognostic (4.88e-1)"	"unprognostic (2.47e-2)"	"unprognostic (9.09e-2)"		"unprognostic (8.75e-3)"	"unprognostic (8.12e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.95e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.35e-9)"	"unprognostic (6.17e-3)"	"unprognostic (9.01e-2)"		"unprognostic (1.97e-1)"	0.3	0.0	0.6	0.1	0.6	0.0	0.2	0.1	2.2	0.1	0.1	0.9	0.1	0.1	0.1	0.1	0.6	0.0	0.1	0.1	1.9	1.9	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	30.5	0.0	0.1	0.1	0.2	0.3	0.0	3.1	0.1	1.1	0.1	0.1	0.1	0.1	0.1	2.1	1.6	4.8	3.0	2.6	2.5	1.3	0.4	0.1	0.2	1.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.5	0.5	0.3	0.5	0.0	0.4	0.2	0.0	0.0	0.7	0.7	0.2	0.1	0.3	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.2	0.6	0.0	0.3	0.4	1.5	0.1	0.0	0.4	30.6	0.6	0.0	0.2	0.6	0.6	0.0	0.4	0.3	0.5	0.0	0.4	0.5	0.9	0.6	0.1	0.1	0.5	0.9	0.6	0.5	0.6	4.8	1.5	1.8	1.2	1.9	2.5	1.6	1.9	1.5	1.4	2.1	2.4	2.3	4.2	2.6	3.0	1.6	1.7	1.3	0.6	0.6	0.1	2.2	1.9	1.9	0.3	0.1	0.1	0.1
FGF9		ENSG00000102678	"Fibroblast growth factor 9"	P31371	13	21671383-21704498	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	Differentiation	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 17.7;kidney: 21.7"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 2.4;HEK 293: 2.4;RPMI-8226: 3.6;RPTEC TERT1: 5.5;SCLC-21H: 11.4"	"Cancer enhanced"	"Detected in some"		"endometrial cancer: 3.7"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Group enriched"	"Detected in many"	5	"B-cells: 1.0;T-cells: 1.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA067007	Enhanced				"Secreted in other tissues"					"HPA067007: "	"unprognostic (6.59e-3)"	"unprognostic (9.09e-3)"	"unprognostic (2.15e-2)"	"unprognostic (9.24e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.37e-2)"	"unprognostic (7.42e-4)"	"unprognostic (1.98e-1)"	"unprognostic (2.86e-1)"	"unprognostic (3.86e-1)"	"unprognostic (2.38e-3)"	"unprognostic (7.93e-2)"	"prognostic favourable (1.70e-6)"	"unprognostic (5.38e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.49e-1)"	"unprognostic (6.92e-2)"	3.1	7.3	2.1	1.0	4.4	0.8	0.7	17.7	7.3	3.8	2.1	0.3	0.5	1.8	3.7	0.9	0.9	1.0	1.2	5.5	3.7	2.6	21.7	0.5	2.6	0.6	2.6	2.5	2.3	1.8	0.5	12.0	0.7	12.6	1.1	3.1	2.4	1.2	1.6	1.4	0.5	4.0	4.0	2.5	0.6	2.2	1.5	0.3	0.0	0.6	0.0	0.5	3.0	1.4	1.0	0.0	0.0	0.2	0.0	1.7	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	2.4	0.0	1.6	0.9	0.0	0.5	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.1	3.6	5.5	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.6	0.7	1.4	1.7	0.0	1.0	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.2	2.1	4.4	17.7	7.3	3.7	2.6	2.6	2.5	12.6	0.3
FGFBP1	"FGFBP, HBP17"	ENSG00000137440	"Fibroblast growth factor binding protein 1"	Q14512	4	15935569-15938740	"Cancer-related genes, Predicted secreted proteins"		"Growth factor binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 106.6;lymphoid tissue: 56.8;tongue: 133.1"	"Group enriched"	"Detected in some"	4	"HaCaT: 77.2;HBEC3-KT: 133.6"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 246.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA004332	Enhanced				"Secreted in other tissues"					"HPA004332: AB_1078856"	"unprognostic (2.87e-3)"	"unprognostic (3.55e-1)"	"unprognostic (5.03e-2)"	"unprognostic (6.99e-2)"		"unprognostic (1.86e-2)"		"unprognostic (1.97e-2)"	"unprognostic (3.60e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (5.03e-4)"	"unprognostic (1.03e-1)"	"unprognostic (1.34e-2)"	"unprognostic (2.04e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.36e-1)"	"unprognostic (3.31e-3)"	0.2	0.0	0.2	0.6	0.2	0.0	4.1	0.2	0.2	27.1	5.1	0.2	0.2	0.4	1.1	0.2	106.6	0.1	0.3	0.2	0.2	0.0	0.3	0.2	1.9	0.2	0.2	0.2	0.3	0.2	0.0	0.2	0.7	0.2	0.3	4.6	0.4	14.1	0.2	0.2	14.6	1.3	0.3	0.2	0.2	0.5	0.2	0.2	0.2	0.3	133.1	56.8	1.8	31.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	20.2	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.2	0.0	1.5	0.0	77.2	0.0	133.6	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	19.8	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	13.0	0.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
FGFR1	"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM"	ENSG00000077782	"Fibroblast growth factor receptor 1"	P11362	8	38411138-38468834	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Transcription, Transcription regulation"	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 109.2;BJ hTERT+: 49.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033614, HPA056402"	Approved					120000000	120000000			"CAB033614: AB_783377, HPA056402: "	"unprognostic (9.53e-2)"	"unprognostic (7.33e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.23e-3)"	"unprognostic (7.02e-2)"	"unprognostic (6.59e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.99e-2)"	"unprognostic (7.97e-3)"	"unprognostic (4.59e-2)"	"unprognostic (7.69e-2)"	"unprognostic (6.87e-3)"	"unprognostic (5.60e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.05e-3)"	41.1	8.6	12.5	14.5	12.2	7.2	39.5	45.0	10.5	36.0	31.5	10.1	11.6	5.5	29.3	20.6	22.9	29.4	32.4	31.7	12.8	10.1	11.8	5.4	18.6	9.7	11.4	14.3	42.0	51.2	11.5	22.3	28.4	20.0	28.2	10.8	35.8	14.0	31.6	12.0	12.9	14.4	52.4	15.6	4.5	16.4	16.4	8.5	11.3	12.6	13.0	9.8	39.6	41.2	1.6	0.7	1.8	1.1	0.8	5.7	0.7	2.4	9.3	40.3	109.2	25.1	17.9	26.6	24.8	49.8	17.3	18.0	6.0	1.4	0.3	6.9	23.8	0.0	19.1	1.2	20.0	6.5	4.2	0.0	1.5	5.9	14.1	5.8	0.1	16.2	0.1	14.0	2.8	16.6	2.2	0.1	8.1	2.8	17.0	1.9	28.4	3.9	15.7	4.2	0.0	8.4	0.0	1.6	3.6	4.4	0.2	1.0	2.2	1.1	10.4	11.3	6.2	31.2	5.9	0.4	0.7	0.0	13.4	0.3	5.9	1.4	1.1	0.4	5.7	0.3	3.9	0.7	2.7	3.7	0.1	1.6	1.5	4.1	1.8	0.8	0.5	0.7	2.2	0.7	12.5	12.2	45.0	10.5	12.8	10.1	11.4	14.3	20.0	8.5
FGFR1OP	FOP	ENSG00000213066	"FGFR1 oncogene partner"	O95684	6	166999182-167094789	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cilium biogenesis/degradation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 50.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA071876			Supported	Centrosome				Centrosome		"HPA071876: "	"unprognostic (9.14e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.98e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.69e-2)"	"unprognostic (9.59e-2)"	"unprognostic (1.00e-1)"	"unprognostic (6.95e-2)"	"unprognostic (8.83e-2)"	"unprognostic (1.08e-3)"	"unprognostic (4.06e-2)"	"prognostic unfavourable (7.32e-4)"	"unprognostic (1.29e-2)"	"unprognostic (2.49e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.09e-3)"	6.2	12.2	11.2	12.9	12.5	9.8	10.2	11.9	13.0	10.1	9.5	6.9	11.8	10.8	13.6	14.1	8.8	19.1	7.9	6.4	10.8	9.1	12.2	24.9	6.7	9.4	6.4	11.5	11.8	10.2	8.2	17.2	6.6	9.4	7.4	12.1	8.9	8.1	11.6	5.8	7.9	13.0	7.4	7.4	9.4	7.8	50.3	8.0	14.5	12.5	6.2	11.8	7.0	8.2	6.8	10.0	24.1	4.1	3.5	6.8	3.0	12.0	6.7	17.0	11.6	10.0	7.5	20.7	15.6	10.5	12.8	12.4	24.9	10.3	14.4	8.9	9.5	11.4	14.9	11.0	24.1	9.0	12.9	9.9	12.1	27.0	5.4	17.6	10.5	4.1	8.2	26.2	12.3	8.8	32.3	12.4	16.3	11.1	14.1	25.8	14.5	5.2	16.3	11.6	11.9	13.3	6.5	12.7	12.8	12.7	13.7	5.4	11.2	21.8	5.7	12.8	21.3	15.2	19.5	10.6	14.5	14.6	14.4	16.5	15.6	0.2	4.1	13.5	3.3	3.6	4.9	6.8	3.9	3.1	6.5	5.0	2.3	3.7	24.1	3.5	3.6	10.0	6.8	3.0	11.2	12.5	11.9	13.0	10.8	9.1	6.4	11.5	9.4	8.0
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	"Fibroblast growth factor receptor 2"	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 57.8;BEWO: 19.4;CACO-2: 15.1;HaCaT: 17.4;HAP1: 18.7;NTERA-2: 18.5;T-47d: 15.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	15	"basophil: 10.8;eosinophil: 4.6"	"Lineage enriched"	"Detected in single"	35	"granulocytes: 10.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	"Secreted - unknown location"	500000	500000	"Cell Junctions"	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	"unprognostic (5.53e-2)"	"prognostic favourable (8.79e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.73e-1)"	"prognostic favourable (9.32e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"unprognostic (2.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (2.25e-1)"	2.1	8.8	16.4	3.0	30.3	0.0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22.0	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1.0	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0.0	2.2	0.1	9.0	57.8	0.0	0.0	19.4	0.1	0.0	0.0	0.0	15.1	0.3	0.0	4.1	0.9	17.4	18.7	4.0	0.0	0.0	4.0	0.0	0.0	0.3	0.4	0.0	3.8	0.0	8.4	0.0	0.2	0.0	0.0	0.0	0.0	3.5	0.0	0.0	18.5	0.0	0.0	0.0	2.2	5.6	4.9	0.1	0.1	0.1	10.6	0.0	15.5	0.0	0.0	0.1	2.8	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	10.8	0.1	4.6	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.0	0.0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1
FGFR3	"ACH, CD333, CEK2, JTK4"	ENSG00000068078	"Fibroblast growth factor receptor 3"	P22607	4	1793293-1808872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Apoptosis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"skin 1: 131.7"	"Cell line enhanced"	"Detected in many"		"CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004231, HPA067204"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	670000	670000	"Endoplasmic reticulum"		"CAB004231: AB_627596, HPA067204: "	"unprognostic (1.34e-1)"	"unprognostic (5.29e-3)"	"unprognostic (1.49e-1)"	"prognostic unfavourable (3.77e-4)"	"unprognostic (5.90e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.22e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.30e-1)"	"unprognostic (9.11e-3)"	"unprognostic (1.98e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.97e-1)"	1.5	1.5	24.7	1.7	30.3	1.6	4.2	10.2	22.0	4.1	4.9	15.8	3.4	9.9	1.8	2.7	26.9	2.0	5.0	2.0	21.6	11.7	9.6	7.4	4.5	1.3	17.6	21.5	1.1	23.0	1.2	3.0	5.6	15.1	3.7	3.8	1.7	3.8	9.0	1.7	131.7	7.4	1.3	9.0	2.1	4.9	8.1	10.6	0.1	1.3	8.5	7.3	8.5	10.1	0.1	0.6	0.1	0.1	0.2	0.3	0.0	0.0	1.5	9.0	2.6	0.0	0.1	9.2	1.0	0.1	0.4	0.2	19.1	0.4	0.0	7.6	0.3	14.9	2.6	0.1	0.1	0.1	9.6	5.9	1.5	32.1	0.0	0.0	0.1	0.0	5.0	0.1	0.0	0.0	6.4	0.0	0.0	9.5	0.3	0.2	15.6	0.0	0.5	0.5	0.1	1.3	19.1	2.6	0.7	0.8	1.6	0.0	8.9	1.1	0.4	0.0	0.9	0.2	0.6	0.0	0.0	0.0	0.1	0.7	0.5	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.6	0.1	0.0	24.7	30.3	10.2	22.0	21.6	11.7	17.6	21.5	15.1	10.6
FGFR4	"CD334, JTK2"	ENSG00000160867	"Fibroblast growth factor receptor 4"	P22455	5	177086886-177098144	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 33.6;kidney: 37.7;liver: 45.3"	"Group enriched"	"Detected in many"	4	"CACO-2: 42.0;Hep G2: 42.0;RH-30: 67.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.0"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005196, HPA027273, HPA027369, HPA028251"	Approved				"Intracellular and membrane"	4300000	4300000			"CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221"	"unprognostic (1.96e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.95e-2)"	"unprognostic (7.85e-3)"	"unprognostic (9.19e-2)"	"unprognostic (4.25e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.48e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.41e-1)"	"unprognostic (5.75e-2)"	"unprognostic (4.68e-2)"	0.5	5.7	0.7	14.3	0.6	0.1	1.6	2.6	0.5	2.8	10.4	0.9	0.7	13.5	0.9	4.8	1.6	1.7	33.6	0.7	0.8	0.3	37.7	45.3	25.3	2.5	0.7	1.0	13.6	26.0	0.0	0.7	1.3	0.8	4.0	3.7	2.0	1.6	0.3	4.3	0.5	17.3	1.6	0.8	11.2	5.4	2.9	0.4	0.3	0.8	2.3	0.7	1.9	3.6	1.1	0.9	3.0	1.1	0.4	0.4	0.0	0.7	11.8	0.2	2.9	0.0	0.0	5.8	0.0	0.0	0.0	0.0	42.0	1.6	1.2	5.5	0.0	0.6	2.3	0.4	0.0	0.7	2.8	0.1	0.6	42.0	1.3	0.1	1.0	0.2	0.0	2.1	0.0	0.0	3.9	0.1	0.9	9.6	0.0	0.8	7.1	1.0	1.9	67.6	7.1	5.7	0.1	0.4	0.7	0.4	3.0	1.4	2.9	0.6	0.2	0.0	5.7	0.0	0.1	0.4	0.4	0.7	0.0	0.2	0.5	1.5	1.1	0.4	0.4	0.3	0.3	1.1	0.4	0.0	0.1	0.6	0.4	0.4	3.0	0.4	0.3	0.9	0.2	0.0	0.7	0.6	2.6	0.5	0.8	0.3	0.7	1.0	0.8	0.4
FGG		ENSG00000171557	"Fibrinogen gamma chain"	P02679	4	154604134-154612967	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	495	"liver: 2225.7"	"Cell line enriched"	"Detected in some"	55	"Hep G2: 125.7"	"Cancer enriched"	"Detected in many"	19	"liver cancer: 1503.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA027529, CAB033120, HPA074638"	Supported		Approved	"Endoplasmic reticulum"	"Secreted to blood"	68000000000	68000000000	"Endoplasmic reticulum"		"CAB033120: AB_2103818, HPA027529: AB_10601322, HPA074638: "	"unprognostic (1.26e-2)"				"unprognostic (4.77e-3)"	"unprognostic (6.33e-3)"	"unprognostic (3.69e-3)"	"unprognostic (2.18e-3)"		"unprognostic (9.63e-2)"	"unprognostic (7.57e-3)"		"prognostic unfavourable (1.00e-6)"	"unprognostic (1.75e-3)"	"unprognostic (3.21e-1)"		"unprognostic (1.14e-1)"	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	2.7	2225.7	4.4	0.0	0.0	0.0	0.2	0.7	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	125.7	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0
FH	fumarase	ENSG00000091483	"Fumarate hydratase"	P07954	1	241497603-241519761	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, Tricarboxylic acid cycle"	Lyase	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 93.4"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017785, HPA025770, HPA025948, HPA027341"	Enhanced	Supported	Enhanced	Mitochondria		2800000	2800000	Mitochondria		"CAB017785: , HPA025770: AB_10599603, HPA025948: AB_10602177, HPA027341: AB_10601222"	"unprognostic (1.03e-2)"	"unprognostic (3.82e-2)"	"unprognostic (9.46e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.55e-1)"	"unprognostic (5.14e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.09e-1)"	"prognostic favourable (2.76e-7)"	"unprognostic (1.05e-1)"	"unprognostic (1.05e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.24e-2)"	14.3	28.1	15.7	10.4	20.2	9.3	13.3	15.7	24.4	10.5	22.7	9.9	16.7	23.2	13.7	10.7	17.7	10.3	9.5	59.0	22.9	13.9	35.0	93.4	9.9	13.3	15.2	19.4	9.4	13.9	25.2	11.4	14.3	18.4	12.3	24.4	10.2	18.4	20.6	65.1	13.4	21.4	14.7	14.4	11.1	17.5	14.0	11.7	13.8	12.3	45.2	13.4	13.4	11.2	16.0	26.4	4.5	18.8	10.4	13.9	8.9	29.2	24.5	23.3	21.0	22.9	27.0	36.9	36.3	28.5	41.0	25.8	35.1	18.3	18.6	24.1	27.8	41.7	35.6	27.0	35.8	21.2	11.5	17.4	26.0	29.9	20.5	40.7	15.9	19.5	16.8	23.0	26.0	25.2	53.0	24.1	29.8	14.6	35.1	27.2	24.7	52.7	29.0	25.5	83.5	39.5	24.9	30.0	25.9	30.6	36.3	23.2	27.6	27.7	24.7	18.4	23.8	32.5	60.5	21.6	23.1	22.6	20.6	46.8	26.4	4.5	12.8	2.7	9.7	18.8	12.6	16.0	11.4	9.0	26.4	14.1	13.9	12.7	0.7	10.4	15.7	13.2	13.2	8.9	15.7	20.2	15.7	24.4	22.9	13.9	15.2	19.4	18.4	11.7
FHIT	"AP3Aase, FRA3B"	ENSG00000189283	"Fragile histidine triad"	P49789	3	59749310-61251459	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation"	Hydrolase	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 11.9;U-266/70: 24.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"naive CD4 T-cell: 38.3"	"Lineage enriched"	"Detected in all"	14	"T-cells: 38.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002684, HPA018840, HPA018909"	Enhanced		Approved	"Nucleoli fibrillar center,Plasma membrane"				"Nucleoli fibrillar center, Plasma membrane"		"CAB002684: , HPA018840: AB_1848538, HPA018909: AB_1848537"	"unprognostic (2.36e-3)"	"unprognostic (6.38e-2)"	"unprognostic (1.59e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.16e-2)"	"unprognostic (2.77e-2)"	"unprognostic (8.49e-2)"	"unprognostic (2.36e-1)"	"unprognostic (6.77e-2)"	"prognostic favourable (1.36e-4)"	"unprognostic (1.54e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.80e-2)"	6.4	24.0	13.7	8.0	17.5	9.0	12.1	4.7	13.3	7.9	8.0	21.0	12.4	8.2	6.2	9.5	5.1	9.2	13.0	14.9	15.3	13.8	30.9	10.7	5.2	9.3	19.5	9.3	8.9	11.8	16.3	15.2	4.1	14.4	5.8	7.8	14.0	11.4	9.9	11.6	7.0	7.6	9.1	17.1	6.0	8.1	10.5	18.2	3.7	15.6	5.7	6.9	7.3	6.1	1.6	2.4	1.8	1.8	2.6	38.3	4.7	0.0	0.0	1.0	0.0	0.6	0.0	1.6	0.1	0.1	0.0	0.0	1.8	3.0	2.6	0.5	0.1	0.0	10.0	2.1	0.0	1.4	3.4	2.2	1.3	4.1	2.6	5.6	0.1	6.8	4.1	0.1	5.1	0.0	1.6	8.3	0.1	2.5	10.1	4.5	0.8	0.6	7.5	0.0	11.9	11.2	1.3	2.1	2.8	1.0	6.9	6.5	0.4	0.1	0.0	1.2	0.4	0.1	1.5	24.4	7.4	0.0	2.7	0.0	1.4	1.8	1.8	0.2	0.9	1.2	0.5	1.6	6.9	0.7	2.2	1.4	38.3	6.7	0.3	2.6	0.4	2.4	7.4	4.7	13.7	17.5	4.7	13.3	15.3	13.8	19.5	9.3	14.4	18.2
FIP1L1	"DKFZp586K0717, FIP1"	ENSG00000145216	"Factor interacting with PAPOLA and CPSF1"	Q6UN15	4	53377643-53460861	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"mRNA processing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA037475, HPA058202"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA037475: AB_10696933, HPA058202: "	"unprognostic (3.80e-1)"	"unprognostic (5.46e-2)"	"unprognostic (5.60e-3)"	"unprognostic (1.40e-1)"	"unprognostic (7.18e-2)"	"unprognostic (4.71e-2)"	"prognostic unfavourable (1.51e-4)"	"unprognostic (1.87e-1)"	"unprognostic (9.00e-3)"	"unprognostic (1.14e-2)"	"unprognostic (5.48e-2)"	"unprognostic (1.42e-1)"	"unprognostic (4.07e-1)"	"unprognostic (1.10e-1)"	"unprognostic (8.66e-3)"	"unprognostic (3.10e-2)"	"unprognostic (1.39e-1)"	25.7	24.4	20.2	27.6	25.8	35.8	24.0	23.0	25.1	24.5	18.0	19.4	16.1	16.0	27.4	17.7	23.4	22.4	16.2	19.7	17.1	16.6	19.7	19.0	20.3	24.5	20.1	26.0	32.2	16.9	26.6	26.6	28.2	20.9	21.7	21.0	16.2	21.5	18.0	33.9	24.5	20.0	23.5	19.4	24.5	20.4	40.2	22.4	42.4	22.7	17.8	29.2	26.6	22.6	26.5	32.7	36.5	24.0	33.7	32.4	21.3	17.9	11.8	21.7	13.0	16.4	16.8	27.7	22.7	28.7	18.6	14.4	17.2	16.7	33.0	17.7	24.3	11.3	23.5	16.9	24.1	11.4	12.8	26.0	9.8	15.9	26.1	38.6	22.3	19.1	15.4	23.5	24.1	13.6	29.9	15.4	14.6	13.2	34.8	17.8	14.2	11.7	31.2	9.8	14.5	15.1	16.2	16.9	18.3	15.9	18.4	26.1	10.4	14.3	14.4	19.1	16.6	17.7	27.2	19.4	11.2	41.6	16.5	24.2	33.9	25.8	16.9	36.5	25.7	17.8	29.2	26.5	25.8	25.1	22.6	24.2	28.9	25.4	20.7	33.7	24.0	32.7	32.4	21.3	20.2	25.8	23.0	25.1	17.1	16.6	20.1	26.0	20.9	22.4
FKBP5	"FKBP51, FKBP54, P54, PPIase, Ptg-10"	ENSG00000096060	"FK506 binding protein 5"	Q13451	6	35573585-35728583	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Chaperone, Isomerase, Rotamase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 277.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 101.4;ASC TERT1: 63.1;HHSteC: 79.4;HSkMC: 95.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009315, HPA031092, HPA031093, HPA031095"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB009315: AB_2278350, HPA031092: AB_10600195, HPA031093: AB_10601748, HPA031095: "	"unprognostic (2.09e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.93e-1)"	"unprognostic (4.72e-1)"	"unprognostic (6.30e-3)"	"unprognostic (3.70e-3)"	"unprognostic (1.47e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.73e-1)"	"unprognostic (7.48e-3)"	"unprognostic (2.18e-3)"	"unprognostic (8.31e-2)"	"unprognostic (4.22e-2)"	"unprognostic (6.90e-3)"	78.8	20.7	9.5	14.2	15.6	4.9	36.7	2.4	10.9	16.5	29.0	5.1	29.8	2.2	18.6	16.9	29.2	19.4	17.9	26.3	10.6	4.2	44.9	30.7	19.7	55.9	15.7	3.6	27.2	43.7	8.6	33.8	6.0	13.1	18.3	8.2	11.8	30.4	25.1	277.2	20.2	36.7	18.6	18.2	32.3	25.0	14.3	12.4	20.1	24.2	9.8	16.8	22.5	18.4	4.0	30.6	24.9	31.2	11.8	42.3	39.9	4.9	2.1	9.5	14.2	101.4	63.1	0.1	2.7	0.1	1.7	4.1	3.7	0.8	24.5	2.5	0.5	0.0	5.6	11.9	4.2	9.6	5.3	10.5	1.8	5.2	79.4	6.6	1.0	95.9	48.2	3.1	29.1	10.3	11.2	10.0	18.6	3.1	27.3	12.4	2.4	1.6	12.2	2.4	11.9	7.9	3.0	3.6	2.2	2.2	2.5	0.5	14.0	7.8	22.7	2.5	2.2	0.3	3.7	4.5	5.2	31.1	0.8	12.9	0.9	13.7	31.2	19.4	20.0	27.0	23.8	3.0	28.2	20.8	30.6	4.0	42.3	30.2	24.9	11.8	12.0	9.2	10.3	39.9	9.5	15.6	2.4	10.9	10.6	4.2	15.7	3.6	13.1	12.4
FKBP8	"FKBP38, FKBPr38"	ENSG00000105701	"FK506 binding protein 8"	Q14318	19	18531751-18544077	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Host-virus interaction"	"Isomerase, Rotamase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	5	"eosinophil: 32.5;neutrophil: 31.0"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 32.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025346, HPA045177"	Supported		Supported	"Endoplasmic reticulum,Mitochondria,Cytosol"				Mitochondria	"Endoplasmic reticulum, Cytosol"	"CAB025346: , HPA045177: "	"unprognostic (1.61e-1)"	"unprognostic (1.33e-1)"	"prognostic unfavourable (1.24e-4)"	"unprognostic (8.93e-2)"	"unprognostic (2.73e-1)"	"unprognostic (9.22e-2)"	"unprognostic (2.54e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.49e-1)"	"prognostic favourable (7.76e-4)"	"unprognostic (8.51e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.97e-1)"	"unprognostic (6.89e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.32e-1)"	44.3	38.1	75.9	27.5	82.1	82.5	26.5	43.4	113.7	35.2	31.9	41.2	34.6	31.1	31.4	27.2	48.7	39.3	34.5	43.4	69.6	62.1	28.9	42.7	34.3	31.1	55.3	54.3	56.1	60.4	28.8	42.2	36.6	51.2	36.5	12.9	31.9	73.1	46.1	56.7	35.1	31.6	34.6	46.3	36.7	31.9	49.5	26.9	32.1	38.8	24.2	30.7	36.3	45.8	4.3	4.3	32.5	6.9	3.1	6.6	9.1	36.6	26.3	20.6	39.1	21.3	33.5	51.7	29.7	31.6	22.7	31.5	24.9	50.0	21.0	48.3	36.4	19.9	12.7	41.3	6.4	25.6	60.3	19.6	34.3	29.9	36.7	19.4	43.2	43.7	39.9	20.4	13.0	23.3	41.1	50.0	19.7	61.0	35.2	58.1	42.1	38.2	37.0	17.1	71.8	30.5	24.0	22.9	41.7	20.8	17.2	37.0	20.2	56.7	27.1	28.4	26.0	55.4	22.5	38.3	21.9	24.4	64.3	31.2	25.2	6.3	5.6	32.5	6.0	5.8	5.5	4.1	6.1	6.6	4.3	4.3	4.7	5.3	31.0	3.1	6.9	4.3	6.0	9.1	75.9	82.1	43.4	113.7	69.6	62.1	55.3	54.3	51.2	26.9
FLCN	"BHD, MGC17998, MGC23445"	ENSG00000154803	Folliculin	Q8NFG4	17	17212212-17237188	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB015158, HPA028760"	Supported		Supported	"Plasma membrane,Cytosol"				Cytosol	"Plasma membrane"	"CAB015158: AB_2231645, HPA028760: AB_10601323"	"unprognostic (1.99e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.74e-1)"	"unprognostic (3.85e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.32e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.90e-1)"	"prognostic favourable (4.49e-4)"	"unprognostic (6.45e-3)"	"unprognostic (2.55e-3)"	"unprognostic (1.92e-1)"	"unprognostic (9.71e-2)"	"unprognostic (2.62e-2)"	"unprognostic (1.65e-1)"	11.9	15.3	23.6	10.8	41.6	15.6	13.9	49.4	26.9	18.0	21.3	18.5	10.4	25.0	22.1	15.8	11.0	14.5	17.6	17.2	17.2	8.6	9.6	15.5	15.6	11.6	24.2	13.5	25.2	13.7	6.1	20.3	13.3	18.1	15.4	10.7	14.8	10.5	14.8	22.7	12.6	20.2	15.4	14.8	16.5	15.3	12.5	29.1	6.6	15.8	3.9	8.0	15.0	14.8	6.0	2.4	10.5	6.8	4.5	5.0	3.1	6.4	15.7	5.8	7.5	18.9	10.8	8.5	5.8	9.7	9.2	12.8	11.9	5.4	3.2	8.1	7.0	7.5	7.0	3.6	4.8	6.1	5.9	6.5	4.6	6.8	17.5	2.4	18.3	15.8	12.4	14.4	10.7	7.5	8.9	8.3	8.8	8.3	4.3	4.1	5.9	3.9	8.6	26.8	3.7	5.5	7.1	7.0	4.5	6.1	3.7	10.1	5.6	4.5	8.8	21.7	9.4	29.9	7.6	4.1	3.9	3.0	13.7	5.5	8.5	3.6	4.7	2.8	2.9	6.8	4.1	5.3	3.5	2.5	2.4	6.0	3.9	3.4	10.5	4.5	2.2	2.4	5.0	3.1	23.6	41.6	49.4	26.9	17.2	8.6	24.2	13.5	18.1	29.1
FLG		ENSG00000143631	Filaggrin	P20930	1	152302175-152325203	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes, Ichthyosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 21.9;skin 1: 109.7;tongue: 38.6"	"Cell line enhanced"	"Detected in some"		"HaCaT: 14.0;NTERA-2: 4.4;TIME: 3.0;U-2 OS: 3.4;U-2197: 3.6"	"Cancer enriched"	"Detected in some"	7	"melanoma: 11.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB002210, HPA027505, HPA030188, HPA030189"	Enhanced		Enhanced	"Cytoplasmic bodies"		500000	500000	"Cytoplasmic bodies"		"CAB002210: AB_563731, HPA027505: AB_10600107, HPA030188: AB_10601749, HPA030189: AB_10601999"	"unprognostic (3.37e-2)"	"unprognostic (3.76e-1)"	"unprognostic (8.83e-2)"	"unprognostic (2.96e-3)"	"unprognostic (9.65e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.02e-1)"	"unprognostic (4.03e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.98e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.40e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.28e-2)"	"unprognostic (4.15e-2)"	"unprognostic (7.41e-3)"	0.1	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.1	2.1	0.0	0.0	0.0	0.0	0.8	0.0	21.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.5	0.0	0.4	109.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	38.6	7.3	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.7	14.0	0.0	0.0	0.0	1.5	0.1	1.1	0.1	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.4	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.1	3.0	1.2	3.4	3.6	2.6	0.0	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
FLI1	"EWSR2, SIC-1"	ENSG00000151702	"Fli-1 proto-oncogene, ETS transcription factor"	Q01543	11	128686535-128813267	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 40.2"	"Cell line enhanced"	"Detected in many"		"HEL: 40.2;HUVEC TERT2: 22.3;REH: 18.8;TIME: 23.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA073099			Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA073099: "	"unprognostic (1.38e-2)"	"unprognostic (7.46e-2)"	"unprognostic (6.16e-2)"	"unprognostic (3.74e-2)"	"unprognostic (6.22e-2)"	"unprognostic (4.26e-3)"	"unprognostic (1.33e-1)"	"unprognostic (8.32e-3)"	"unprognostic (2.97e-1)"	"unprognostic (9.91e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.42e-1)"	"prognostic unfavourable (4.60e-4)"	"unprognostic (4.79e-2)"	"unprognostic (2.07e-2)"	"unprognostic (2.62e-1)"	"unprognostic (4.79e-2)"	14.7	2.5	3.5	15.8	4.4	10.6	9.9	1.4	3.2	6.7	5.1	3.8	2.1	3.3	7.8	6.5	4.8	5.3	6.0	7.5	3.8	3.1	4.2	3.6	17.4	24.4	6.2	1.6	4.0	3.2	2.5	2.0	11.4	3.8	4.3	3.1	4.8	4.2	3.3	5.2	3.2	6.9	5.7	6.6	40.2	4.1	2.7	4.6	26.8	5.7	2.8	17.9	6.2	6.7	4.5	13.1	20.1	12.0	7.8	8.8	11.6	0.0	0.0	2.0	0.0	0.2	0.4	0.0	1.2	3.4	1.4	1.2	0.0	0.0	6.8	12.2	4.0	0.0	0.3	5.0	1.6	3.2	0.1	40.2	0.2	0.0	2.4	4.8	5.7	0.3	0.4	2.9	6.8	22.3	0.0	8.8	0.3	0.0	4.8	2.7	0.6	1.2	18.8	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	7.8	23.1	0.2	0.0	0.1	1.2	2.8	5.9	5.9	0.0	11.7	1.8	20.1	9.5	16.1	7.2	10.3	8.8	4.5	6.2	5.8	13.1	3.6	2.6	5.6	7.8	7.8	12.0	2.2	7.4	11.6	3.5	4.4	1.4	3.2	3.8	3.1	6.2	1.6	3.8	4.6
FLT1	"FLT, VEGFR1"	ENSG00000102755	"Fms related tyrosine kinase 1"	P17948	13	28300344-28495145	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Chemotaxis, Differentiation"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	8	"placenta: 155.3"	"Cell line enhanced"	"Detected in some"		"BJ: 17.0;BJ hTERT+: 13.5;HMC-1: 84.6;HUVEC TERT2: 15.3;WM-115: 30.3"	"Cancer enhanced"	"Detected in all"		"renal cancer: 28.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"memory B-cell: 1.1;naive B-cell: 3.7;neutrophil: 2.1"	"Group enriched"	"Detected in many"	5	"B-cells: 3.7;granulocytes: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011740, HPA014290, CAB068189, CAB068190"	Enhanced		Supported	"Plasma membrane,Actin filaments"	"Secreted to blood"	54000	54000	"Plasma membrane, Actin filaments"		"CAB068189: , CAB068190: , HPA011740: AB_1858737, HPA014290: AB_1858738"	"unprognostic (3.33e-2)"	"unprognostic (3.52e-3)"	"unprognostic (1.13e-3)"	"unprognostic (5.02e-2)"	"unprognostic (3.65e-1)"	"unprognostic (5.03e-2)"	"unprognostic (8.25e-2)"	"unprognostic (2.27e-3)"	"unprognostic (9.91e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavourable (2.19e-4)"	"unprognostic (4.20e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.32e-2)"	18.9	4.0	9.9	4.0	14.3	1.2	13.5	8.0	15.9	7.1	4.6	3.5	1.7	3.5	7.2	2.2	3.4	4.0	6.9	18.3	11.4	7.3	10.3	7.6	12.3	2.5	10.3	3.2	5.1	5.4	13.4	3.7	155.3	13.8	5.1	3.1	9.1	3.0	5.0	12.5	2.6	3.4	7.3	9.6	7.2	4.6	6.8	10.2	0.0	19.1	3.8	2.8	7.6	9.2	3.7	0.5	2.1	0.1	0.2	0.4	0.2	0.0	0.0	0.0	0.1	0.1	0.2	0.0	17.0	13.5	6.2	3.6	0.0	0.0	0.0	0.0	2.2	0.0	1.6	0.0	11.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	84.6	0.1	0.0	0.0	0.2	15.3	0.4	0.0	0.0	0.0	1.0	0.8	9.0	0.0	0.6	0.0	0.0	0.0	0.0	1.9	0.1	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.2	0.0	0.0	0.5	0.2	0.0	0.1	0.0	30.3	0.2	0.1	0.1	0.1	0.1	0.0	1.1	0.1	0.1	0.0	3.7	0.4	0.4	2.1	0.2	0.1	0.5	0.2	0.2	9.9	14.3	8.0	15.9	11.4	7.3	10.3	3.2	13.8	10.2
FLT3	"CD135, FLK2, STK1"	ENSG00000122025	"Fms related tyrosine kinase 3"	P36888	13	28003274-28100592	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.9;brain: 19.3;lymphoid tissue: 15.0"	"Group enriched"	"Detected in some"	11	"REH: 27.8;THP-1: 17.1"	"Cancer enhanced"	"Detected in some"		"breast cancer: 1.8"	"Region enhanced"	"Detected in many"		"cerebellum: 19.3"	"Group enriched"	"Detected in some"	11	"myeloid DC: 29.9;plasmacytoid DC: 12.1"	"Lineage enriched"	"Detected in many"	16	"dendritic cells: 29.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA047539			Approved	"Endoplasmic reticulum"		180000	180000	"Endoplasmic reticulum"		"HPA047539: "	"unprognostic (2.19e-3)"	"unprognostic (3.16e-3)"	"unprognostic (6.54e-3)"	"unprognostic (9.96e-2)"	"unprognostic (3.88e-1)"	"unprognostic (3.96e-7)"	"unprognostic (7.99e-3)"	"unprognostic (1.65e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.56e-2)"	"unprognostic (3.65e-1)"	"unprognostic (3.91e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	0.9	0.6	0.6	7.2	1.1	7.5	2.6	19.3	3.5	0.9	1.2	0.1	0.1	0.4	0.8	0.8	1.0	1.2	4.6	0.5	0.9	1.7	2.8	0.7	2.7	15.0	1.8	1.1	0.5	5.7	0.0	0.4	0.0	7.4	0.6	1.4	0.1	2.3	0.6	0.4	1.2	3.0	1.3	4.4	8.8	0.9	1.2	0.0	8.2	0.6	0.0	5.8	2.4	0.7	0.1	29.9	1.4	1.8	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.0	0.5	0.0	27.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	17.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	1.4	0.0	0.3	0.0	0.1	0.0	0.0	29.9	0.0	0.0	0.0	0.0	0.8	0.0	12.1	0.0	1.2	0.6	1.1	19.3	3.5	0.9	1.7	1.8	1.1	7.4	0.0
FLT4	"PCL, VEGFR3"	ENSG00000037280	"Fms related tyrosine kinase 4"	P35916	5	180601506-180649624	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 56.3"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;BEWO: 10.2;HEK 293: 12.6;HL-60: 7.4;HUVEC TERT2: 8.1;T-47d: 12.0;TIME: 12.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"MAIT T-cell: 7.7"	"Lineage enriched"	"Detected in single"	35	"T-cells: 7.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000099, HPA046519, HPA067906"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Secreted to blood"	270000000	270000000	"Plasma membrane"	"Nucleoplasm, Cell Junctions"	"CAB000099: , HPA046519: , HPA067906: "	"unprognostic (7.35e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.45e-3)"	"unprognostic (3.81e-1)"	"unprognostic (9.26e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.69e-1)"	"unprognostic (1.88e-2)"	"unprognostic (9.41e-3)"	"unprognostic (1.83e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.32e-1)"	14.8	7.1	1.6	4.9	6.0	0.7	28.5	1.3	2.7	6.3	7.3	1.9	2.1	3.1	7.3	6.2	5.7	9.2	5.3	6.4	1.7	0.9	11.7	10.2	14.1	23.6	2.0	0.8	5.8	2.3	2.3	6.2	56.3	2.1	4.9	1.4	6.7	3.3	4.4	4.8	2.8	4.7	4.7	1.5	14.5	2.4	3.5	2.0	0.3	19.4	4.4	2.3	6.1	14.7	0.0	0.1	0.2	0.0	0.0	7.7	0.2	0.1	2.0	2.7	8.3	0.0	0.0	10.2	0.2	0.1	0.0	0.0	0.3	0.3	0.2	0.8	0.1	0.3	2.8	0.1	0.2	0.1	12.6	1.0	0.4	0.4	0.1	7.4	0.2	0.2	0.0	0.1	0.3	8.1	0.3	0.3	1.7	4.5	0.1	0.4	5.8	0.5	6.5	0.0	0.1	0.1	0.2	0.2	0.9	0.1	0.2	0.0	12.0	0.2	12.7	0.1	5.9	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.9	0.0	7.7	0.0	0.4	1.6	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	1.6	6.0	1.3	2.7	1.7	0.9	2.0	0.8	2.1	2.0
FMO5		ENSG00000131781	"Flavin containing monooxygenase 5"	P49326	1	147175351-147243050	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Monooxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"intestine: 61.1;liver: 119.4;stomach 1: 38.6"	"Cell line enhanced"	"Detected in some"		"Hep G2: 28.4;HMC-1: 6.4;THP-1: 7.2"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 43.0"	"Group enriched"	"Detected in many"	6	"basal ganglia: 5.5;cerebral cortex: 4.5;midbrain: 17.1;pons and medulla: 5.2;thalamus: 6.0"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012373	Enhanced		Supported	"Endoplasmic reticulum,Cytosol"				"Endoplasmic reticulum, Cytosol"		"HPA012373: AB_1848975"	"unprognostic (2.70e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.06e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.96e-2)"	"unprognostic (2.43e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.85e-2)"	"unprognostic (2.93e-1)"	"unprognostic (1.13e-1)"	"prognostic favourable (1.34e-6)"	"unprognostic (3.77e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.85e-1)"	"unprognostic (4.11e-2)"	1.1	2.4	1.1	1.9	5.5	0.2	8.6	0.6	4.5	1.3	61.1	1.5	0.8	12.5	1.0	1.3	0.7	1.1	8.5	1.0	1.3	0.5	9.0	119.4	17.0	0.8	17.1	0.5	1.0	11.9	8.8	4.9	0.6	5.2	1.9	8.2	0.5	9.7	0.6	0.4	4.2	53.6	0.9	7.1	1.2	38.6	1.2	6.0	0.2	1.1	1.5	0.5	1.9	0.8	9.2	4.9	6.2	12.1	1.0	2.0	3.6	0.1	0.7	0.5	0.0	1.9	0.5	0.6	0.4	0.3	0.2	0.6	0.4	1.5	0.3	0.5	0.4	0.3	0.0	0.0	0.0	1.0	0.1	1.1	0.0	28.4	0.6	0.9	6.4	0.9	0.1	0.3	0.0	0.4	0.1	0.1	1.1	0.9	0.2	0.5	2.0	0.5	0.3	0.3	0.2	2.4	0.4	0.4	0.2	0.6	1.9	0.9	1.4	7.2	0.7	0.0	0.2	0.6	0.0	0.2	0.0	0.2	0.7	0.3	0.2	6.2	12.1	3.5	2.0	5.6	0.3	3.6	0.5	0.6	4.9	9.2	0.3	1.3	1.2	1.0	1.6	2.4	1.4	3.6	1.1	5.5	0.6	4.5	1.3	0.5	17.1	0.5	5.2	6.0
FN1	"CIG, FINC, GFND2, LETS, MSF"	ENSG00000115414	"Fibronectin 1"	P02751	2	215360440-215436172	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Angiogenesis, Cell adhesion, Cell shape"	Heparin-binding	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 235.4;placenta: 433.0"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 837.5;HSkMC: 391.7;hTERT-HME1: 230.4"	"Cancer enhanced"	"Detected in all"		"thyroid cancer: 833.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000126, HPA027066"	Enhanced				"Secreted to blood"	47000000000	47000000000			"CAB000126: , HPA027066: AB_10602500"	"unprognostic (8.08e-2)"	"unprognostic (1.09e-3)"	"unprognostic (2.20e-2)"	"unprognostic (3.45e-3)"	"unprognostic (1.82e-2)"	"unprognostic (3.47e-3)"	"unprognostic (3.36e-2)"	"unprognostic (5.91e-3)"	"unprognostic (2.96e-2)"	"unprognostic (2.91e-3)"	"unprognostic (1.41e-2)"	"unprognostic (2.84e-1)"	"prognostic unfavourable (3.44e-8)"	"prognostic unfavourable (8.82e-5)"	"unprognostic (7.88e-2)"	"unprognostic (7.74e-2)"	"prognostic unfavourable (3.33e-4)"	20.2	4.5	3.1	13.0	5.2	0.2	13.1	2.2	4.3	21.9	57.1	4.4	235.4	3.5	25.1	27.5	37.4	26.5	20.9	57.3	3.9	2.9	5.8	166.3	81.5	7.9	4.6	5.0	16.9	3.3	1.7	3.5	433.0	6.1	17.1	25.1	5.1	10.4	141.2	9.8	7.0	13.5	114.9	4.6	1.9	21.8	9.0	2.7	9.4	5.4	17.4	2.6	64.7	16.9	0.2	0.8	0.0	0.6	0.0	0.3	0.0	0.2	1.9	2.6	0.5	106.3	837.5	0.1	43.2	28.8	43.7	31.2	26.1	1.0	0.0	0.2	143.6	4.4	0.4	98.4	23.6	0.0	0.1	0.0	0.6	81.5	76.9	0.0	0.1	391.7	0.6	103.4	230.4	50.7	0.1	0.1	87.2	0.3	0.0	0.0	1.2	0.3	0.0	0.0	0.1	1.1	0.3	0.1	0.6	5.1	2.7	28.0	0.4	0.0	97.2	63.4	6.7	69.3	8.0	0.1	0.0	0.0	75.3	0.0	16.4	0.0	0.6	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.8	0.0	0.0	3.1	5.2	2.2	4.3	3.9	2.9	4.6	5.0	6.1	2.7
FOLH1	"FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA"	ENSG00000086205	"Folate hydrolase 1"	Q04609	11	49146635-49208670	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Carboxypeptidase, Dipeptidase, Hydrolase, Metalloprotease, Multifunctional enzyme, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 37.7;intestine: 111.2;prostate: 33.8"	"Cell line enhanced"	"Detected in some"		"HAP1: 5.3;RPMI-8226: 3.7;SK-BR-3: 4.4;TIME: 2.8;WM-115: 5.3"	"Cancer enriched"	"Detected in many"	27	"prostate cancer: 142.7"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001451, HPA010593"	Enhanced									"CAB001451: AB_563979, HPA010593: AB_1079685"	"unprognostic (1.33e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.24e-1)"	"prognostic favourable (5.24e-5)"	"unprognostic (2.55e-1)"	"unprognostic (8.31e-2)"	"prognostic favourable (4.25e-4)"	"unprognostic (1.32e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.67e-3)"	"unprognostic (2.13e-2)"	"unprognostic (2.72e-1)"	"prognostic unfavourable (1.30e-6)"	"unprognostic (4.81e-2)"	"unprognostic (7.27e-2)"	"unprognostic (4.74e-3)"	"unprognostic (4.04e-1)"	1.2	1.0	10.4	0.9	16.4	0.8	2.5	1.4	12.7	1.4	67.6	37.7	0.0	111.2	1.3	0.8	1.2	2.1	5.0	0.7	16.9	8.7	6.1	15.7	1.1	0.9	19.0	9.1	1.0	0.7	0.7	0.4	0.7	17.7	33.8	0.8	0.6	20.7	0.8	0.6	1.2	61.1	1.0	33.0	1.5	1.0	0.9	16.2	0.0	1.0	0.0	0.8	1.2	0.5	0.9	0.1	0.3	0.8	1.4	1.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	2.6	0.3	0.0	0.0	0.0	0.0	0.9	0.2	0.6	0.0	0.2	5.3	0.5	0.0	1.2	0.9	0.0	0.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.1	1.0	0.0	0.3	0.3	3.7	0.0	0.0	0.4	1.6	0.0	4.4	1.0	1.0	0.0	2.8	0.2	2.7	0.4	0.3	0.1	0.5	0.1	0.0	0.9	5.3	0.1	0.8	0.3	0.9	0.6	0.2	0.6	1.2	0.5	0.0	0.9	0.7	0.3	0.2	1.4	0.5	0.1	0.4	0.0	10.4	16.4	1.4	12.7	16.9	8.7	19.0	9.1	17.7	16.2
FOS	"AP-1, c-fos"	ENSG00000170345	"Fos proto-oncogene, AP-1 transcription factor subunit"	P01100	14	75278774-75282230	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in many"	5	"hTCEpi: 98.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"neutrophil: 84.5"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 84.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA018531	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA018531: AB_1846576"	"unprognostic (1.18e-2)"	"unprognostic (8.70e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.80e-1)"	"unprognostic (3.08e-2)"	"unprognostic (4.82e-2)"	"unprognostic (2.09e-1)"	"unprognostic (3.30e-1)"	"unprognostic (9.55e-3)"	"unprognostic (4.20e-3)"	"unprognostic (1.04e-1)"	"prognostic favourable (7.81e-4)"	"unprognostic (3.20e-2)"	"unprognostic (1.52e-2)"	"unprognostic (3.22e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.66e-2)"	104.8	58.4	17.0	143.7	30.0	157.6	40.7	24.0	21.3	132.3	48.7	52.3	22.1	17.4	79.7	50.5	93.6	239.5	271.8	56.8	17.5	21.4	22.7	47.9	70.7	31.0	23.9	10.6	94.5	32.7	40.9	52.9	130.2	44.6	60.6	49.3	64.4	42.8	255.8	37.5	156.2	44.1	98.1	43.7	18.5	60.7	33.2	26.8	10.1	77.5	226.7	28.1	60.8	54.0	0.0	11.6	84.5	12.3	0.7	0.1	3.3	0.4	0.3	1.5	2.2	13.2	4.0	9.1	1.3	0.5	0.9	0.7	0.9	2.6	0.1	0.4	9.2	0.6	0.7	15.9	0.2	0.2	0.2	0.2	3.8	0.3	6.1	0.5	9.3	9.9	98.7	0.8	6.0	0.5	0.4	4.2	0.2	5.4	0.1	2.6	1.6	0.5	0.4	0.3	4.8	4.1	4.3	11.3	0.7	2.0	18.3	7.8	0.3	1.9	1.3	0.1	1.2	0.8	0.4	11.4	11.9	2.0	0.6	1.6	1.2	6.0	12.3	14.6	0.0	3.5	0.0	0.0	0.0	0.1	11.6	0.0	0.0	0.0	84.5	0.7	0.4	0.2	0.0	3.3	17.0	30.0	24.0	21.3	17.5	21.4	23.9	10.6	44.6	26.8
FOSL1	fra-1	ENSG00000175592	"FOS like 1, AP-1 transcription factor subunit"	P15407	11	65892049-65900573	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 35.2;tongue: 46.8"	"Cell line enhanced"	"Detected in many"		"PC-3: 92.9;U-2197: 62.3;WM-115: 140.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	4	"myeloid DC: 6.9"	"Lineage enriched"	"Detected in many"	4	"dendritic cells: 6.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB004396, HPA030728"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB004396: AB_627632, HPA030728: "	"unprognostic (2.88e-2)"	"unprognostic (1.56e-1)"	"unprognostic (9.46e-2)"	"unprognostic (1.33e-1)"	"prognostic unfavourable (1.80e-4)"	"prognostic unfavourable (2.05e-4)"	"unprognostic (2.70e-1)"	"prognostic unfavourable (1.95e-4)"	"unprognostic (1.12e-1)"	"unprognostic (2.11e-1)"	"prognostic unfavourable (9.26e-5)"	"unprognostic (7.85e-2)"	"prognostic unfavourable (6.40e-6)"	"unprognostic (2.23e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.28e-1)"	"unprognostic (2.82e-2)"	22.4	3.7	1.5	8.2	3.1	17.9	3.6	1.1	2.8	5.4	2.8	1.5	0.2	0.8	2.1	2.0	35.2	4.4	24.4	5.8	2.3	1.3	2.2	4.4	7.7	1.7	2.6	0.5	2.6	9.9	0.4	2.0	3.2	6.5	3.1	1.7	0.6	5.4	1.0	6.6	9.2	2.0	3.6	3.5	1.6	8.7	1.5	2.3	0.3	2.1	46.8	16.5	16.6	4.6	0.0	6.9	1.0	1.6	0.0	0.6	1.1	36.0	5.3	0.6	2.4	5.4	5.4	5.2	33.8	31.0	29.3	16.4	1.6	30.1	0.0	7.4	23.4	6.8	2.2	27.2	25.2	1.1	0.0	2.2	0.5	4.0	6.8	1.4	0.8	2.3	2.7	22.9	34.7	9.4	5.2	0.2	38.4	1.5	0.0	3.0	2.5	92.9	0.1	2.9	0.1	13.6	2.4	0.0	0.0	2.0	0.0	25.4	0.1	1.3	23.3	34.7	7.1	62.3	49.5	0.0	0.1	0.1	48.8	0.6	140.9	0.0	1.6	0.0	0.3	1.1	0.2	0.0	0.6	0.3	6.9	0.0	0.6	0.0	1.0	0.0	0.5	0.8	0.0	1.1	1.5	3.1	1.1	2.7	2.3	1.3	2.6	0.5	6.5	2.3
FOXA1	HNF3A	ENSG00000129514	"Forkhead box A1"	P55317	14	37589984-37596059	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 47.0;prostate: 44.4"	"Cell line enhanced"	"Detected in some"		"Hep G2: 16.3;MCF7: 35.4;PC-3: 24.7;RT4: 33.1;SK-BR-3: 33.5;T-47d: 47.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 127.0"	"Region enriched"	"Detected in single"	6	"midbrain: 2.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	15	"hypothalamus: 1.0;midbrain: 1.3;thalamus: 1.1"	"Region enriched"	"Detected in some"	6	"midbrain: 6.1"	"CAB011595, HPA050505"	Enhanced		Supported	"Nucleoplasm,Nucleoli fibrillar center"				Nucleoplasm	"Nucleoli fibrillar center"	"CAB011595: AB_2104842, HPA050505: "	"unprognostic (1.61e-1)"	"unprognostic (8.80e-2)"	"unprognostic (1.12e-1)"	"unprognostic (4.65e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.54e-2)"	"unprognostic (6.30e-2)"	"unprognostic (0.00e+0)"	"unprognostic (3.67e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.69e-2)"	"prognostic favourable (1.00e-4)"	0.1	0.0	0.1	6.1	0.1	0.0	23.5	0.1	0.3	1.5	9.4	0.1	0.1	4.6	0.1	0.5	7.2	1.3	6.5	0.1	0.1	0.3	0.4	47.0	13.2	0.1	2.0	0.1	0.6	0.2	0.0	1.1	0.1	0.2	44.4	6.0	0.2	9.4	0.7	0.1	0.7	5.1	2.4	0.1	0.1	13.0	0.6	0.1	0.2	0.1	4.4	9.9	12.5	11.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.5	0.0	0.9	0.0	0.0	0.2	0.0	0.1	0.0	0.0	7.3	0.9	0.0	0.5	0.0	8.2	4.6	1.1	0.0	0.0	8.1	0.0	1.4	16.3	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.3	0.0	0.0	35.4	0.0	0.1	0.0	24.7	0.0	0.3	0.1	3.4	33.1	4.2	0.0	1.6	33.5	0.0	47.5	0.1	0.0	0.3	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.1	0.3	2.0	0.1	0.2	0.1
FOXA2	HNF3B	ENSG00000125798	"Forkhead box A2"	Q9Y261	20	22581005-22585455	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 44.4;pancreas: 47.9;stomach 1: 20.7"	"Cell line enhanced"	"Detected in some"		"A549: 10.2;HBEC3-KT: 11.7;Hep G2: 16.2;hTERT-HME1: 7.9;PC-3: 15.1;SCLC-21H: 26.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"midbrain: 1.1"	"Region enriched"	"Detected in single"	7	"midbrain: 4.9"	"CAB001388, HPA066846"	Enhanced		Supported	"Nucleoplasm,Cell Junctions"				"Nucleoplasm, Cell Junctions"		"CAB001388: AB_2262810, HPA066846: "		"unprognostic (1.19e-1)"	"unprognostic (1.99e-1)"	"prognostic favourable (7.57e-6)"	"unprognostic (6.82e-2)"	"unprognostic (1.50e-6)"	"unprognostic (1.38e-1)"	"unprognostic (8.17e-2)"		"prognostic favourable (6.28e-4)"	"prognostic favourable (2.34e-4)"	"unprognostic (3.18e-1)"	"unprognostic (2.55e-15)"	"unprognostic (2.50e-2)"	"unprognostic (1.68e-1)"	"unprognostic (7.12e-2)"	"unprognostic (3.93e-3)"	0.2	0.0	0.2	1.3	0.2	0.0	0.2	0.2	0.3	9.7	4.5	0.2	0.2	2.2	1.8	0.2	0.2	3.8	13.1	0.2	0.2	0.1	0.2	44.4	15.9	0.2	1.4	0.2	3.4	47.9	0.0	0.4	0.3	0.4	0.5	6.0	0.2	0.2	0.2	0.2	0.0	1.8	0.2	0.2	0.2	20.7	0.3	0.2	0.2	2.2	0.2	0.9	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.3	0.0	0.1	0.0	0.0	0.0	11.7	0.0	0.0	0.7	0.0	0.0	16.2	0.0	0.0	0.0	0.0	6.3	0.0	7.9	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	15.1	0.0	0.0	0.0	0.5	0.0	26.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.3	0.2	0.1	1.4	0.2	0.4	0.2
FOXJ1	"FKHL13, HFH-4, HFH4"	ENSG00000129654	"Forkhead box J1"	Q92949	17	76136333-76141299	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Cilium biogenesis/degradation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 19.9;epididymis: 20.4;fallopian tube: 45.9"	"Group enriched"	"Detected in some"	9	"BEWO: 22.4;CAPAN-2: 18.7"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 73.7"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"naive CD8 T-cell: 2.6"	"Lineage enriched"	"Detected in single"	9	"T-cells: 2.6"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"midbrain: 55.6"	HPA005714	Enhanced									"HPA005714: AB_1078902"	"prognostic favourable (9.39e-4)"	"unprognostic (4.97e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.77e-3)"	"unprognostic (1.19e-1)"	"unprognostic (2.54e-3)"	"unprognostic (1.71e-3)"	"unprognostic (6.15e-2)"	"unprognostic (1.00e-2)"	"unprognostic (7.84e-3)"	"unprognostic (1.43e-2)"	"unprognostic (1.63e-1)"	"prognostic unfavourable (2.03e-5)"	"unprognostic (7.49e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.91e-1)"	0.4	0.4	4.1	0.5	8.9	0.6	0.4	0.1	2.2	5.1	0.9	19.9	0.4	0.6	2.4	20.4	0.4	45.9	0.4	0.4	6.5	6.6	1.5	0.4	17.0	0.4	2.0	1.2	14.7	1.2	0.4	1.2	0.4	19.6	0.6	0.6	0.1	0.4	2.8	0.4	0.8	0.6	0.5	1.8	0.4	0.9	15.2	3.4	0.0	2.9	0.0	0.4	1.1	0.2	0.0	0.0	0.0	0.0	0.2	2.6	0.1	0.0	0.4	1.3	0.0	0.0	0.0	22.4	0.0	0.0	0.0	0.0	2.3	18.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.2	0.0	0.4	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.6	2.6	0.0	0.2	0.0	0.0	0.0	0.1	4.1	8.9	0.1	2.2	6.5	6.6	2.0	1.2	19.6	3.4
FOXL2	"BPES, BPES1"	ENSG00000183770	"Forkhead box L2"	P58012	3	138944224-138947140	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Premature ovarian failure"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 13.9;ovary: 55.5;parathyroid gland: 15.3"	"Cell line enhanced"	"Detected in some"		"A-431: 5.4;fHDF/TERT166: 6.3;HEL: 9.0;hTCEpi: 8.3;K-562: 9.2;SiHa: 6.4;THP-1: 6.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							HPA069613	Enhanced		Supported	"Nucleoplasm,Cytokinetic bridge"				Nucleoplasm	"Cytokinetic bridge"	"HPA069613: "	"unprognostic (1.46e-1)"	"unprognostic (3.28e-2)"		"unprognostic (4.76e-3)"	"unprognostic (2.05e-1)"	"unprognostic (5.16e-4)"		"unprognostic (3.55e-2)"	"unprognostic (2.35e-3)"	"unprognostic (5.08e-2)"	"unprognostic (3.79e-2)"	"unprognostic (2.19e-1)"	"unprognostic (9.63e-8)"	"unprognostic (2.16e-2)"	"unprognostic (4.65e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.61e-2)"	0.0	1.5	0.3	0.0	1.2	0.0	0.0	0.3	1.0	13.9	0.0	0.6	0.0	0.0	10.0	0.4	0.1	6.4	0.0	0.1	0.4	0.2	0.0	0.0	0.0	0.0	0.3	0.4	55.5	0.6	15.3	13.1	1.4	0.8	0.2	0.0	1.7	0.0	0.4	0.0	0.2	0.0	0.9	0.3	0.0	0.0	0.8	0.2	0.0	0.2	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	2.1	0.3	3.9	0.1	0.0	1.7	0.2	0.0	0.4	0.1	0.0	0.4	0.0	2.6	6.3	1.2	0.0	0.0	0.1	0.0	0.0	9.0	1.1	0.0	0.0	0.1	0.0	0.0	8.3	0.0	0.0	0.0	9.2	0.0	3.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.4	1.8	0.0	0.0	6.4	0.0	0.0	0.0	6.6	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.3	1.0	0.4	0.2	0.3	0.4	0.8	0.2
FOXM1	"FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident"	ENSG00000111206	"Forkhead box M1"	Q08050	12	2857681-2877155	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Cell cycle, DNA damage, DNA repair, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 47.5;testis: 40.1"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			CAB017832	Uncertain		Supported	Nucleoplasm,Nucleoli,Cytosol				"Nucleoplasm, Nucleoli"	Cytosol	"CAB017832: "	"unprognostic (3.18e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.22e-2)"	"unprognostic (1.09e-2)"	"unprognostic (4.30e-2)"	"unprognostic (3.75e-2)"	"prognostic unfavourable (1.95e-6)"	"prognostic unfavourable (2.92e-4)"	"unprognostic (1.01e-2)"	"unprognostic (3.25e-2)"	"prognostic unfavourable (3.03e-5)"	"unprognostic (6.09e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (2.80e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.94e-1)"	1.7	1.7	1.0	9.3	0.9	13.8	2.4	0.4	1.2	2.0	6.5	0.4	1.1	6.0	1.2	2.1	13.5	0.4	4.1	1.2	0.8	0.6	1.3	1.6	2.8	6.6	0.8	0.3	0.8	0.6	0.0	0.5	3.9	0.9	0.9	8.2	0.6	2.6	1.1	0.7	3.7	7.1	4.4	1.2	5.0	3.2	40.1	0.4	47.5	0.6	11.4	11.6	2.0	3.7	0.7	0.6	1.0	0.6	0.4	1.9	0.1	28.6	29.1	22.6	20.7	3.4	4.5	28.8	18.7	18.5	38.1	34.5	36.7	25.7	18.5	4.0	26.8	22.3	33.8	17.2	37.3	34.6	18.1	20.9	27.9	15.7	0.5	16.8	17.1	2.3	1.9	35.3	24.9	26.8	11.7	41.7	29.9	26.9	22.8	8.0	49.8	21.7	16.6	34.3	9.7	9.0	18.4	12.7	20.2	24.0	20.1	11.0	19.7	18.8	10.7	30.9	47.0	36.1	65.0	5.5	9.1	26.8	14.3	16.1	32.7	0.4	0.6	0.1	0.4	0.2	0.4	0.7	0.5	0.4	0.2	0.7	0.9	0.3	1.0	0.4	0.1	0.6	1.9	0.1	1.0	0.9	0.4	1.2	0.8	0.6	0.8	0.3	0.9	0.4
FOXO1	"FKH1, FKHR, FOXO1A"	ENSG00000150907	"Forkhead box O1"	Q12778	13	40469953-40666597	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 85.9"	"Cell line enhanced"	"Detected in many"		"ASC diff: 18.9;Daudi: 20.0;HSkMC: 25.2;U-698: 25.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001252, CAB022326"	Approved	Approved	Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB022326: , HPA001252: AB_1078906"	"unprognostic (4.72e-2)"	"unprognostic (1.81e-1)"	"unprognostic (8.54e-2)"	"unprognostic (4.35e-1)"	"unprognostic (2.42e-1)"	"unprognostic (2.52e-1)"	"prognostic favourable (3.74e-4)"	"unprognostic (6.35e-2)"	"unprognostic (1.60e-1)"	"unprognostic (8.65e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.31e-1)"	"prognostic favourable (1.33e-5)"	"unprognostic (1.93e-1)"	"unprognostic (5.44e-1)"	"unprognostic (9.09e-2)"	"unprognostic (9.63e-2)"	41.6	6.9	7.0	18.4	11.2	8.0	35.5	2.3	5.0	21.4	13.4	8.4	7.7	3.5	27.4	9.8	9.5	17.2	13.3	9.9	7.8	3.9	8.3	25.6	15.3	22.4	8.3	3.9	46.0	12.2	3.8	6.2	9.5	6.5	7.9	6.8	5.7	7.5	9.3	85.9	12.3	7.6	18.6	9.7	10.8	7.4	12.3	9.0	9.4	13.1	9.0	15.6	14.4	16.2	6.1	0.5	2.8	1.6	1.1	7.1	1.0	0.3	0.6	5.6	0.1	18.9	3.7	5.4	0.8	1.1	0.2	0.1	1.4	1.3	20.0	3.7	0.5	4.8	4.4	2.4	0.3	9.1	4.6	0.0	0.6	4.4	9.0	0.1	0.5	25.2	16.4	0.1	3.1	14.2	0.3	6.4	1.4	0.7	0.0	0.2	8.2	1.4	14.2	6.5	1.5	10.5	2.5	1.2	0.3	0.7	3.8	0.8	0.6	0.5	8.3	0.1	1.1	0.0	0.5	3.6	1.3	25.9	0.5	0.9	2.6	0.9	0.8	0.5	1.5	1.0	2.3	3.2	3.9	2.2	0.5	6.1	7.1	5.3	2.8	1.1	1.6	0.0	5.5	1.0	7.0	11.2	2.3	5.0	7.8	3.9	8.3	3.9	6.5	9.0
FOXO3	"AF6q21, FKHRL1, FOXO2, FOXO3A"	ENSG00000118689	"Forkhead box O3"	O43524	6	108559835-108684774	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 39.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 15.7"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004074, HPA063104"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB004074: AB_2106672, HPA063104: "	"unprognostic (3.42e-2)"	"unprognostic (3.76e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.96e-2)"	"unprognostic (6.68e-2)"	"unprognostic (4.63e-2)"	"unprognostic (4.08e-3)"	"unprognostic (1.73e-1)"	"unprognostic (3.81e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.98e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.54e-2)"	"unprognostic (9.09e-2)"	"unprognostic (1.13e-1)"	"unprognostic (5.81e-2)"	"unprognostic (5.68e-2)"	29.6	7.7	11.5	12.2	12.6	36.7	35.4	28.0	18.1	19.9	16.1	12.6	9.8	7.8	17.4	16.1	22.3	16.5	18.0	12.9	9.7	7.7	10.7	14.0	21.1	16.8	12.4	14.0	28.8	52.3	14.3	8.8	13.1	10.3	13.8	11.0	14.3	21.2	10.5	54.7	20.3	11.3	13.9	7.9	14.2	14.8	13.1	13.2	11.6	13.1	12.7	10.2	17.1	20.3	1.8	2.7	15.7	4.6	3.4	4.0	1.0	8.9	3.3	5.9	9.5	18.3	21.9	7.4	7.5	7.9	6.6	9.1	5.8	8.2	5.8	6.4	8.7	6.6	6.1	9.1	9.8	5.2	8.8	14.4	2.9	4.4	21.3	3.4	10.6	24.9	18.4	13.4	18.5	4.9	9.7	39.3	11.9	5.1	4.8	5.3	3.8	4.9	5.5	16.7	19.3	13.0	6.8	10.4	27.1	6.3	5.2	7.4	5.7	11.5	7.9	11.2	6.3	6.8	9.6	0.7	6.7	5.5	6.1	6.9	7.6	6.7	2.9	5.7	3.6	1.5	4.0	1.0	1.9	3.0	1.7	1.8	1.7	2.3	15.7	3.4	4.6	2.7	1.8	1.0	11.5	12.6	28.0	18.1	9.7	7.7	12.4	14.0	10.3	13.2
FOXO4	"AFX1, MLLT7"	ENSG00000184481	"Forkhead box O4"	P98177	X	71096197-71103535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 98.6"	"Cell line enriched"	"Detected in many"	5	"BEWO: 60.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039560, HPA040232"	Enhanced		Supported	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"HPA039560: , HPA040232: "	"unprognostic (4.64e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.49e-1)"	"unprognostic (4.79e-2)"	"prognostic favourable (4.61e-4)"	"unprognostic (1.09e-1)"	"unprognostic (3.20e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.18e-2)"	"unprognostic (2.13e-2)"	"unprognostic (8.16e-2)"	"prognostic favourable (3.46e-4)"	"unprognostic (2.45e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.75e-3)"	8.5	13.2	21.7	3.8	21.5	9.9	5.1	9.1	15.6	4.8	8.4	9.1	11.9	6.3	6.8	10.2	7.3	7.7	5.8	9.7	21.4	14.5	5.2	3.6	5.5	3.6	22.8	8.4	13.4	6.8	8.7	3.0	98.6	9.2	7.0	4.7	4.9	8.5	11.3	33.8	5.5	6.6	9.4	17.3	6.0	5.2	13.9	13.1	4.4	5.9	7.5	4.2	7.5	11.0	0.9	0.2	3.4	0.6	1.0	1.8	0.9	1.7	0.5	1.4	1.8	3.3	2.3	60.0	1.4	1.6	0.7	1.7	1.2	2.4	2.3	1.8	1.8	0.8	3.6	1.6	0.8	2.3	5.5	3.4	11.2	1.9	1.9	1.9	2.7	1.9	3.8	0.6	0.4	1.8	6.9	4.6	0.3	0.3	3.0	3.1	6.5	2.1	2.1	3.5	3.6	1.2	1.0	1.0	2.9	2.9	0.4	3.1	0.7	1.2	1.7	0.4	0.9	3.1	0.3	3.0	1.6	0.4	1.6	5.2	0.5	0.2	0.6	3.2	0.9	0.6	0.3	0.8	0.5	0.9	0.2	0.9	0.4	1.8	3.4	1.0	0.3	0.0	1.3	0.9	21.7	21.5	9.1	15.6	21.4	14.5	22.8	8.4	9.2	13.1
FOXP1	"12CC4, hFKH1B, HSPC215, QRF1"	ENSG00000114861	"Forkhead box P1"	Q9H334	3	70952817-71583993	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 39.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA003876, CAB011501"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB011501: AB_732428, HPA003876: AB_1078907"	"unprognostic (2.31e-1)"	"unprognostic (4.35e-3)"	"unprognostic (2.09e-2)"	"unprognostic (3.54e-2)"	"unprognostic (2.69e-1)"	"unprognostic (2.81e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.03e-1)"	"unprognostic (4.38e-3)"	"unprognostic (3.40e-1)"	"unprognostic (6.14e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.65e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.05e-2)"	24.6	5.1	7.0	30.2	19.2	32.7	21.9	7.2	13.1	16.3	29.3	8.7	10.3	10.1	19.8	9.9	19.6	13.1	19.3	15.5	8.4	5.9	7.6	12.9	26.1	34.0	7.6	10.2	30.3	14.7	7.2	25.7	11.4	7.4	21.6	21.6	11.3	24.6	11.2	12.7	12.2	16.7	34.3	7.9	18.6	20.4	11.7	10.1	38.1	19.8	13.1	27.0	28.5	31.8	29.9	8.4	14.4	9.9	9.2	29.6	11.2	3.7	2.8	7.0	4.7	3.3	9.4	3.3	11.2	12.9	9.8	7.2	20.9	4.4	10.1	1.7	5.0	2.6	12.9	9.6	16.6	3.1	5.3	5.2	7.0	19.7	8.1	9.8	12.8	9.6	4.0	39.5	17.5	14.6	5.2	14.9	4.4	16.5	4.8	3.9	8.6	18.3	14.6	12.0	1.8	8.0	11.9	5.9	10.7	11.7	3.2	0.7	2.3	7.2	18.4	13.6	5.9	19.0	15.5	3.7	2.8	14.3	8.7	12.5	2.9	14.4	5.7	6.0	8.3	5.7	9.3	25.8	18.3	10.3	5.3	29.9	29.6	18.9	8.3	9.2	9.9	8.4	15.9	11.2	7.0	19.2	7.2	13.1	8.4	5.9	7.6	10.2	7.4	10.1
FOXQ1	HFH1	ENSG00000164379	"Forkhead box Q1"	Q9C009	6	1312440-1314748	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"stomach 1: 65.5;vagina: 39.9"	"Cell line enhanced"	"Detected in some"		"CACO-2: 16.4;CAPAN-2: 9.9;HaCaT: 19.2;Hep G2: 40.4;RT4: 17.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA059700			Supported	Nucleoplasm				Nucleoplasm		"HPA059700: "	"unprognostic (2.04e-3)"	"unprognostic (3.44e-1)"	"unprognostic (1.10e-1)"	"unprognostic (7.18e-2)"	"unprognostic (1.50e-3)"	"unprognostic (2.15e-1)"	"unprognostic (3.26e-2)"	"unprognostic (1.15e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.06e-1)"	"unprognostic (7.65e-3)"	"prognostic favourable (6.68e-4)"	"unprognostic (1.49e-2)"	"unprognostic (3.16e-3)"	"unprognostic (2.82e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.96e-2)"	0.6	0.5	2.3	0.6	4.0	0.5	1.4	1.6	5.9	7.1	1.9	3.2	0.0	6.9	1.1	0.7	7.2	3.2	31.8	0.5	2.2	1.9	7.1	3.6	5.8	0.5	2.7	1.5	0.5	10.1	0.5	1.8	1.2	3.8	18.2	0.8	7.5	35.8	1.3	0.6	16.8	0.8	6.6	1.9	0.5	65.5	0.6	0.8	0.8	3.1	7.8	11.7	26.3	39.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.5	0.0	0.0	0.0	0.0	0.0	0.3	6.6	0.0	0.0	16.4	9.9	0.0	0.2	0.0	19.2	0.0	0.8	0.0	0.0	0.5	0.0	3.5	40.4	0.0	0.0	1.0	0.0	7.9	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.2	17.0	0.1	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	4.0	1.6	5.9	2.2	1.9	2.7	1.5	3.8	0.8
FRMD7	"FLJ43346, NYS, NYS1"	ENSG00000165694	"FERM domain containing 7"	Q6ZUT3	X	132076993-132128020	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Neurogenesis		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	6	"endometrium 1: 7.4;kidney: 6.6;smooth muscle: 5.5"	"Cell line enhanced"	"Detected in some"		"AF22: 1.1;HSkMC: 1.7;U-87 MG: 5.8"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	29	"olfactory region: 80.8"	"Region enriched"	"Detected in single"	100	"olfactory region: 45.5"	HPA000886	Uncertain									"HPA000886: AB_1079269"	"unprognostic (3.08e-2)"	"unprognostic (1.27e-1)"			"unprognostic (1.36e-1)"	"unprognostic (3.07e-1)"	"unprognostic (4.02e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.28e-1)"	"unprognostic (2.18e-2)"	"unprognostic (3.84e-1)"	"unprognostic (3.54e-2)"			"unprognostic (3.00e-1)"			0.2	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.3	0.0			0.0	7.4	1.1	0.0	1.1	0.0	0.1	0.0	0.1	6.6	1.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.5	0.0		0.0	1.1	0.0	0.5	0.0	5.5	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.1	0.2	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0										
FSCN1	"FLJ38511, p55, SNL"	ENSG00000075618	"Fascin actin-bundling protein 1"	Q16658	7	5592823-5606655	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 56.9"	"Cell line enhanced"	"Detected in many"		"BEWO: 80.6;K-562: 67.5;NB-4: 76.7;PC-3: 67.5;SH-SY5Y: 64.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 5.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000121, HPA005723, CAB035991, HPA050654"	Enhanced		Supported	"Plasma membrane,Cytosol"		4500000	4500000	Cytosol	"Plasma membrane"	"CAB000121: AB_2278596, CAB035991: , HPA005723: AB_1849159, HPA050654: "	"unprognostic (1.91e-1)"	"unprognostic (2.03e-2)"	"unprognostic (3.12e-2)"	"unprognostic (5.00e-3)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (5.76e-4)"	"unprognostic (2.16e-3)"	"prognostic unfavourable (2.28e-4)"	"unprognostic (6.31e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.27e-3)"	"unprognostic (1.54e-1)"	"prognostic unfavourable (8.15e-7)"	"unprognostic (1.21e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.05e-2)"	"unprognostic (6.93e-3)"	26.3	13.3	23.7	29.6	30.1	6.3	8.1	5.5	56.9	9.9	5.5	35.1	0.0	5.4	11.7	2.3	22.3	5.9	8.9	10.6	27.7	16.8	5.5	7.1	11.3	15.2	26.9	23.6	21.8	5.1	2.3	7.0	29.4	20.1	4.1	3.0	8.1	11.0	3.9	7.8	17.3	6.6	7.0	29.6	39.3	7.6	15.9	28.3	9.3	8.5	15.9	11.4	14.7	12.3	0.2	5.4	1.0	1.9	0.0	0.1	1.4	7.8	18.3	12.2	43.7	4.7	9.1	80.6	18.9	8.4	3.2	3.5	12.7	2.0	0.1	23.2	8.3	30.0	7.0	30.4	0.2	9.0	3.8	0.5	19.4	59.7	2.5	0.0	1.5	5.6	9.0	6.1	5.0	15.9	67.5	0.1	4.2	0.8	0.2	76.7	31.9	67.5	17.8	2.9	0.3	4.7	0.7	9.8	64.8	15.9	0.2	0.6	0.4	4.8	32.3	22.5	39.6	13.0	19.4	0.1	0.1	0.0	14.5	0.0	42.2	0.0	1.9	0.1	0.0	0.5	0.0	0.2	0.1	0.0	5.4	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.0	1.4	23.7	30.1	5.5	41.3	27.7	16.8	26.9	23.6	20.1	28.3
FSHB		ENSG00000131808	"Follicle stimulating hormone beta subunit"	P01225	11	30231016-30235261	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		Hormone	"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	90	"pituitary gland: 70.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"CAB023410, HPA069703"	Enhanced				"Secreted to blood"	47000	47000			"CAB023410: AB_324983, HPA069703: "												"unprognostic (1.04e-1)"						0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.5	0.0	0.5	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	70.7	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.5	0.0	0.0	0.3	0.3	0.0
FST	FS	ENSG00000134363	Follistatin	P19883	5	53480409-53487134	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 42.7"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 58.2;HaCaT: 49.3;HBEC3-KT: 31.5;HMC-1: 35.4;PC-3: 95.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"memory CD4 T-cell: 1.0;naive CD4 T-cell: 2.0;non-classical monocyte: 1.0"	"Group enriched"	"Detected in many"	5	"monocytes: 1.0;T-cells: 2.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			CAB026025	Approved				"Secreted to blood"	1800000	1800000			"CAB026025: "	"unprognostic (1.43e-1)"	"unprognostic (6.50e-2)"	"unprognostic (1.44e-1)"	"unprognostic (7.73e-3)"	"unprognostic (2.30e-1)"	"unprognostic (1.50e-3)"	"unprognostic (8.02e-2)"	"unprognostic (2.32e-2)"	"unprognostic (3.06e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.94e-1)"	"prognostic unfavourable (4.44e-5)"	"unprognostic (1.21e-3)"	"unprognostic (2.48e-1)"	"unprognostic (2.07e-2)"	"unprognostic (2.18e-1)"	12.4	3.2	2.0	3.1	0.8	0.1	7.1	0.2	0.7	3.5	5.2	0.3	1.1	0.9	2.3	9.5	3.6	4.9	4.1	5.6	1.0	1.0	1.7	42.7	4.3	0.8	0.4	0.6	20.7	19.4	0.0	2.9	13.5	1.0	9.3	1.7	5.7	5.5	6.5	12.6	9.0	4.3	3.7	0.4	0.2	4.8	4.9	0.5	1.2	2.0	6.7	7.1	6.2	13.8	0.1	0.2	0.0	1.0	0.0	2.0	0.1	3.2	0.3	5.8	0.0	6.6	2.3	9.6	12.7	58.2	7.8	7.7	0.0	0.0	0.0	0.1	3.3	49.3	0.0	31.5	5.6	0.1	0.0	0.6	0.2	5.2	3.5	0.0	35.4	5.4	0.0	14.4	9.4	6.6	0.0	0.1	4.9	0.0	0.0	0.2	8.9	95.2	0.6	7.4	0.0	0.0	5.4	0.0	0.0	0.5	0.0	0.3	0.0	0.0	0.0	21.6	6.2	2.2	1.8	0.0	0.0	0.0	2.5	0.6	19.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.2	0.1	2.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	2.0	0.8	0.2	0.7	1.0	1.0	0.4	0.6	1.0	0.5
FSTL3	"FLRG, FSRP"	ENSG00000070404	"Follistatin like 3"	O95633	19	676365-683399	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Osteogenesis, Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"placenta: 201.0"	"Cell line enhanced"	"Detected in many"		"BEWO: 35.5;hTCEpi: 39.2;SiHa: 72.5;U-2197: 37.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB024899, HPA045378"	Approved		Approved	Nucleoplasm	"Secreted in other tissues"	6800000	6800000	Nucleoplasm		"CAB024899: , HPA045378: "	"unprognostic (9.86e-3)"	"unprognostic (1.32e-3)"	"prognostic unfavourable (3.01e-4)"	"prognostic unfavourable (3.03e-4)"	"unprognostic (2.19e-3)"	"unprognostic (1.51e-3)"	"unprognostic (8.64e-3)"	"prognostic unfavourable (4.61e-7)"	"unprognostic (9.50e-2)"	"prognostic unfavourable (1.65e-4)"	"unprognostic (3.50e-2)"	"unprognostic (5.91e-2)"	"unprognostic (1.03e-3)"	"unprognostic (7.22e-3)"	"unprognostic (3.07e-1)"	"unprognostic (3.75e-1)"	"unprognostic (5.89e-3)"	19.9	29.1	4.0	10.7	6.2	5.6	24.7	1.3	4.2	13.1	14.9	3.8	8.1	3.8	12.8	15.6	12.7	14.1	13.1	27.0	5.0	2.0	13.7	5.1	26.9	8.7	7.3	4.5	16.8	11.7	1.4	5.3	201.0	6.0	14.3	3.1	12.0	4.5	11.0	4.1	6.2	6.5	20.6	10.4	3.9	9.1	34.5	4.9	0.7	7.2	5.5	1.4	16.7	18.3	0.9	2.2	0.1	4.4	0.6	2.6	2.0	1.9	15.6	1.1	0.8	4.9	12.6	35.5	26.5	3.9	6.6	2.4	5.7	3.0	0.8	10.7	17.8	13.7	0.8	22.6	2.2	1.6	1.8	0.7	21.8	4.6	21.2	1.3	2.6	15.7	39.2	7.3	30.7	1.1	1.6	1.1	10.0	6.8	0.5	0.8	1.3	5.4	1.4	0.7	1.7	9.2	0.3	0.7	1.2	72.5	1.4	0.8	1.3	0.7	15.9	6.7	23.1	37.4	9.7	1.8	0.8	0.4	1.0	4.2	3.0	0.0	4.4	0.0	1.0	4.4	0.2	0.3	1.4	1.1	2.2	0.9	2.6	1.6	0.1	0.6	3.2	0.9	0.2	2.0	4.0	6.2	1.3	4.2	5.0	2.0	7.3	4.5	6.0	4.9
FTH1	"FHC, FTH, FTHL6, PIG15, PLIF"	ENSG00000167996	"Ferritin heavy chain 1"	P02794	11	61959718-61967660	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Iron storage"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 756.2"	"Cell line enhanced"	"Detected in all"		"ASC diff: 547.1;HHSteC: 570.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 756.2"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							CAB008623	Approved		Approved	Microtubules		9000000	9000000	Microtubules		"CAB008623: "	"unprognostic (7.15e-2)"	"unprognostic (1.52e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.00e-2)"	"unprognostic (2.53e-1)"	"prognostic unfavourable (7.56e-5)"	"prognostic unfavourable (6.18e-4)"	"unprognostic (3.08e-2)"	"unprognostic (2.48e-2)"	"unprognostic (6.65e-2)"	"unprognostic (2.44e-2)"	"unprognostic (8.13e-2)"	"prognostic unfavourable (5.20e-5)"	"unprognostic (2.99e-1)"	"unprognostic (4.89e-2)"	"unprognostic (3.44e-1)"	"unprognostic (5.83e-2)"	155.1	118.0	177.6	138.9	92.6	162.0	302.9	38.5	163.7	104.2	142.4	97.8	72.0	72.2	81.6	102.4	88.8	70.6	83.5	236.1	124.7	91.2	113.5	128.2	297.3	394.0	118.5	110.6	81.7	150.8	49.7	46.7	70.1	77.5	60.9	138.5	79.5	180.5	65.1	124.1	42.5	110.0	140.0	182.1	84.4	81.0	67.8	88.2	58.5	100.3	64.1	48.9	106.7	94.0	69.5	163.3	756.2	424.5	30.7	69.2	284.2	64.4	181.0	27.6	73.0	547.1	265.0	152.3	59.1	254.1	60.4	61.0	21.9	89.5	7.5	375.8	170.2	110.4	24.6	48.9	39.2	30.7	12.1	37.5	250.9	142.9	570.0	17.6	59.0	358.9	240.3	120.5	226.6	75.5	55.9	86.0	210.8	87.2	19.7	28.8	47.2	306.1	19.6	34.1	53.6	308.6	175.5	23.5	29.7	203.3	22.4	96.2	39.8	23.7	84.1	188.8	45.2	83.5	37.1	14.9	51.2	23.1	257.4	7.8	44.9	401.9	297.7	247.4	40.8	367.6	40.2	68.6	58.3	40.4	163.3	69.5	49.3	38.2	756.2	30.7	424.5	121.2	69.2	284.2	177.6	92.6	38.5	163.7	124.7	91.2	118.5	110.6	77.5	88.2
FTL	"MGC71996, NBIA3"	ENSG00000087086	"Ferritin light chain"	P02792	19	48965301-48966878	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Iron storage"		"Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 1149.4"	"Cell line enhanced"	"Detected in all"		"HHSteC: 570.4;HSkMC: 477.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"granulocytes: 1149.4;monocytes: 890.5"									"CAB020769, HPA041602"	Enhanced		Approved	Cytosol		240000000	240000000	Cytosol		"CAB020769: , HPA041602: "	"unprognostic (2.95e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.56e-3)"	"unprognostic (7.48e-2)"	"unprognostic (5.28e-2)"	"unprognostic (2.16e-3)"	"unprognostic (6.17e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.66e-1)"	"unprognostic (2.96e-1)"	"prognostic unfavourable (4.40e-5)"	"unprognostic (1.32e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.30e-2)"	"unprognostic (1.87e-2)"	326.0	111.3	147.1	113.6	130.9	179.8	321.8	25.8	101.3	105.7	107.5	134.7	58.2	120.5	54.9	85.4	85.0	71.3	214.6	140.8	111.7	88.2	295.2	526.9	391.6	444.6	139.4	49.6	126.8	108.0	27.0	63.6	166.3	89.0	108.0	92.3	114.4	59.4	75.4	75.6	48.3	159.4	149.2	194.5	317.9	105.2	53.9	74.5	45.1	130.0	57.5	67.5	159.8	172.1	147.8	231.2	1149.4	890.5	41.5	86.1	674.1	18.5	282.8	21.2	32.4	367.1	381.0	38.0	48.2	283.8	69.5	156.5	61.9	75.4	14.1	92.8	287.8	11.1	17.4	28.5	62.8	190.6	11.2	37.5	73.8	404.9	570.4	88.0	126.2	477.2	38.7	118.2	52.1	100.6	69.3	29.6	137.1	4.5	24.3	51.4	38.5	28.9	20.3	14.4	145.7	44.1	11.8	27.2	15.8	126.6	6.9	26.3	4.0	184.1	75.2	76.1	40.0	97.6	65.9	128.1	282.4	13.2	80.7	92.8	133.0	488.0	642.5	675.8	63.9	890.5	72.6	147.8	71.3	68.3	231.2	132.2	86.1	74.8	1149.4	41.5	768.3	97.2	83.8	674.1	147.1	130.9	25.8	101.3	111.7	88.2	139.4	49.6	89.0	74.5
FUBP1	"FBP, FUBP"	ENSG00000162613	"Far upstream element binding protein 1"	Q96AE4	1	77944055-77979110	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006149	Supported		Enhanced	Nucleoplasm		200000	200000	Nucleoplasm		"HPA006149: AB_1849172"	"unprognostic (4.17e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.35e-3)"	"unprognostic (3.89e-2)"	"unprognostic (3.77e-1)"	"unprognostic (5.65e-2)"	"prognostic unfavourable (9.83e-9)"	"unprognostic (2.32e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.31e-3)"	"unprognostic (9.80e-3)"	"unprognostic (9.02e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.67e-1)"	"unprognostic (6.24e-2)"	"unprognostic (9.46e-2)"	23.9	35.5	21.8	42.4	26.9	56.8	27.0	34.0	31.8	24.3	19.6	18.1	23.0	21.8	29.4	35.0	23.5	25.2	18.4	27.5	22.0	22.3	26.6	16.3	27.2	37.6	17.5	28.8	44.4	31.6	36.0	41.5	27.3	26.3	22.4	28.3	22.0	28.2	35.6	27.4	21.3	24.0	22.7	31.3	28.6	22.6	17.6	19.9	64.9	35.0	26.2	40.3	24.0	29.1	16.1	11.3	10.8	16.1	23.5	22.2	12.8	21.8	19.2	45.6	18.1	7.1	8.9	37.4	22.6	13.5	21.7	15.8	19.5	24.4	39.1	10.6	16.8	21.8	30.5	24.9	29.1	43.0	15.5	25.0	32.0	28.6	15.3	42.8	10.5	11.7	20.6	23.2	18.4	17.3	28.6	17.4	17.1	22.1	34.0	20.7	35.6	13.8	41.7	36.1	15.0	22.5	21.5	24.1	22.7	21.0	19.9	17.8	24.3	15.5	22.2	21.0	30.7	5.9	27.0	16.7	18.0	50.7	9.1	18.9	21.4	3.8	9.6	10.8	18.7	15.7	22.2	16.1	18.3	19.4	8.7	13.1	17.9	20.9	4.0	23.5	16.1	11.3	21.3	12.8	21.8	26.9	34.0	31.8	22.0	22.3	17.5	28.8	26.3	19.9
FUS	"ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS"	ENSG00000089280	"FUS RNA binding protein"	P35637	16	31180110-31194871	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"DNA-binding, RNA-binding"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008784, CAB033036, CAB058691"	Supported		Enhanced	Nucleoplasm		190000	190000	Nucleoplasm		"CAB033036: AB_2105208, CAB058691: , HPA008784: AB_1849181"	"unprognostic (3.06e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.86e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.44e-1)"	"unprognostic (8.03e-2)"	"prognostic unfavourable (4.38e-4)"	"unprognostic (2.15e-2)"	"unprognostic (1.00e-1)"	"unprognostic (5.22e-3)"	"unprognostic (1.01e-1)"	"unprognostic (1.01e-3)"	"unprognostic (1.12e-3)"	"unprognostic (1.87e-1)"	"unprognostic (5.27e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.49e-2)"	44.0	24.2	35.0	47.1	43.3	41.7	29.9	64.1	59.0	39.7	32.4	48.6	22.6	28.0	54.5	44.7	29.6	48.6	35.9	32.0	32.7	34.6	30.3	24.4	27.7	51.3	31.1	39.0	66.7	28.8	41.7	24.8	44.1	39.2	29.1	30.2	39.3	27.6	30.5	43.6	24.3	28.7	46.5	33.7	36.2	27.7	40.7	30.7	66.3	29.1	40.1	49.6	30.3	31.4	16.4	22.3	24.2	29.0	14.2	24.8	9.4	47.8	41.5	54.7	35.5	13.5	11.5	58.2	64.4	23.4	29.5	22.5	56.0	32.2	73.7	46.0	32.5	20.9	54.5	41.7	28.2	43.8	35.4	62.3	31.4	56.4	22.5	66.2	42.9	23.2	11.5	42.5	28.9	28.1	66.0	25.1	36.6	58.6	48.1	58.6	83.3	45.6	79.0	72.8	42.2	32.9	35.1	35.7	64.0	42.3	29.9	31.9	36.0	73.7	34.8	47.2	47.4	31.1	68.1	23.4	44.7	103.8	26.4	45.1	57.0	5.6	17.5	24.2	24.8	29.0	24.0	12.8	17.4	21.8	19.3	16.4	20.3	21.1	14.9	14.2	25.1	22.3	13.9	9.4	35.0	43.3	64.1	59.0	32.7	34.6	31.1	39.0	39.2	30.7
FZD1	DKFZp564G072	ENSG00000157240	"Frizzled class receptor 1"	Q9UP38	7	91264364-91271326	"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"	"Wnt signaling pathway"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"thyroid gland: 61.2"	"Cell line enhanced"	"Detected in many"		"AF22: 16.3;HSkMC: 21.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 4.2;non-classical monocyte: 5.4"	"Lineage enriched"	"Detected in many"	4	"monocytes: 5.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013008	Approved		Supported	"Plasma membrane"				"Plasma membrane"		"CAB013008: "	"unprognostic (1.46e-1)"	"unprognostic (1.70e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.16e-2)"	"unprognostic (4.51e-3)"	"unprognostic (2.09e-1)"	"unprognostic (5.29e-3)"	"unprognostic (3.70e-2)"	"unprognostic (2.36e-2)"	"unprognostic (5.48e-3)"	"unprognostic (2.14e-1)"	"unprognostic (7.39e-3)"	"prognostic favourable (8.87e-7)"	"unprognostic (1.05e-2)"	"unprognostic (4.16e-2)"	"unprognostic (5.53e-2)"	"unprognostic (4.13e-2)"	5.8	4.6	2.6	4.9	3.5	0.9	10.7	8.2	2.8	17.6	8.5	4.1	9.3	4.9	10.1	9.9	7.8	6.1	11.0	12.3	6.1	1.8	15.3	3.9	10.5	1.4	2.0	3.2	15.0	7.9	2.5	4.6	10.0	5.7	12.3	3.7	11.1	9.2	17.5	3.1	10.7	8.3	7.2	4.6	3.4	4.5	4.4	3.5	1.4	61.2	6.5	2.9	10.4	13.9	0.1	1.3	0.2	5.4	0.0	0.0	0.4	0.5	1.6	16.3	1.7	13.3	11.5	3.0	5.9	3.8	2.2	1.5	0.7	2.8	0.0	1.4	3.8	3.0	2.5	1.3	1.4	0.0	3.2	0.1	3.1	0.8	0.9	2.6	0.7	21.8	2.3	5.0	1.6	0.5	0.9	2.3	6.3	3.9	0.4	0.7	4.2	2.7	3.2	10.0	0.2	3.5	7.6	2.2	4.3	4.5	3.7	0.9	1.9	2.4	2.4	9.3	7.0	9.8	2.4	2.2	1.5	0.2	10.0	2.2	10.7	0.0	1.4	0.0	0.0	4.2	0.0	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.2	0.0	5.4	0.1	0.0	0.4	2.6	3.5	8.2	2.8	6.1	1.8	2.0	3.2	5.7	3.5
FZD2		ENSG00000180340	"Frizzled class receptor 2"	Q14332	17	44557459-44559570	"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins"	"Wnt signaling pathway"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 25.7;BJ hTERT+ SV40 Large T+: 25.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"classical monocyte: 3.5;myeloid DC: 5.6;plasmacytoid DC: 2.6"	"Group enriched"	"Detected in many"	6	"dendritic cells: 5.6;monocytes: 3.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA057667	Uncertain		Approved	"Nucleoplasm,Nuclear bodies,Cell Junctions"				"Nucleoplasm, Nuclear bodies"	"Cell Junctions"	"HPA057667: "	"unprognostic (6.94e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.04e-2)"	"unprognostic (8.83e-3)"	"unprognostic (2.04e-1)"	"unprognostic (5.29e-3)"	"unprognostic (1.44e-2)"	"unprognostic (2.29e-1)"	"unprognostic (9.45e-2)"	"unprognostic (5.61e-2)"	"unprognostic (1.15e-2)"	"unprognostic (1.86e-1)"	"unprognostic (5.10e-3)"	"unprognostic (1.19e-2)"	"unprognostic (6.35e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.17e-3)"	2.3	2.8	2.3	3.9	5.8	0.9	3.2	0.7	3.1	16.1	2.9	2.1	3.0	2.9	10.8	7.6	2.4	6.6	7.7	5.8	3.2	1.5	5.0	0.5	6.9	3.1	2.1	2.9	12.1	2.7	1.6	1.9	8.4	4.9	4.2	0.8	14.3	2.9	7.9	1.8	1.1	3.6	3.3	2.0	3.7	2.1	6.5	1.8	1.1	5.3	2.4	3.1	3.8	4.3	0.2	5.6	0.0	3.5	0.0	0.8	0.6	7.5	25.7	14.7	8.4	3.3	2.9	0.3	21.3	13.0	25.5	18.4	19.8	4.4	0.0	6.7	5.3	3.5	1.7	1.8	6.1	1.9	5.0	0.8	4.2	0.1	4.3	0.1	4.4	5.5	1.4	6.2	4.2	1.0	1.6	0.2	6.4	4.0	3.4	1.9	16.1	4.8	9.8	4.4	1.3	3.3	0.3	1.9	6.4	2.7	0.7	1.6	8.2	3.6	0.4	13.8	12.2	2.6	12.5	0.6	0.4	1.8	2.5	1.4	6.3	0.0	3.5	0.0	0.1	0.2	0.0	0.0	0.0	0.8	5.6	0.2	0.0	0.2	0.0	0.0	0.2	2.6	0.0	0.6	2.3	5.8	0.7	2.1	3.2	1.5	2.1	2.9	4.9	1.8
G6PD	G6PD1	ENSG00000160211	"Glucose-6-phosphate dehydrogenase"	P11413	X	154531391-154547572	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Carbohydrate metabolism, Glucose metabolism"	Oxidoreductase	"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 83.1"	"Cell line enhanced"	"Detected in all"		"A549: 225.5;MCF7: 85.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 77.3"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 77.3"					"Low region specificity"	"Detected in all"			"HPA000247, HPA000834"	Enhanced		Enhanced	"Centriolar satellite,Cytosol"		12000000	12000000	Cytosol	"Centriolar satellite"	"HPA000247: AB_1078978, HPA000834: AB_1078977"	"unprognostic (1.73e-2)"	"unprognostic (1.53e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.02e-1)"	"unprognostic (7.78e-2)"	"unprognostic (4.34e-2)"	"prognostic unfavourable (9.45e-13)"	"unprognostic (2.78e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.76e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.66e-1)"	"unprognostic (2.89e-3)"	"unprognostic (2.83e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.47e-1)"	"unprognostic (7.25e-2)"	21.9	29.4	10.4	15.6	10.7	51.4	18.2	8.4	14.7	12.2	7.5	13.6	4.8	7.2	14.0	13.2	29.0	11.0	24.7	10.1	8.8	10.1	15.4	3.7	20.8	31.0	10.3	8.0	19.8	7.9	5.9	20.7	9.2	10.9	11.3	7.3	17.8	13.9	8.6	4.4	11.3	7.3	17.5	11.1	20.3	9.9	83.1	9.5	22.5	24.6	44.8	25.7	24.1	19.0	3.6	7.6	77.3	16.2	12.7	10.3	11.8	15.4	225.5	4.6	17.8	19.5	26.7	4.1	10.8	31.0	11.0	19.1	10.3	5.8	10.0	16.8	24.7	13.8	7.2	18.3	5.7	10.2	5.0	10.6	51.0	23.2	38.2	10.6	36.4	12.9	5.4	21.6	4.6	22.9	6.3	4.4	19.9	85.5	6.8	7.6	3.3	16.7	6.7	2.6	10.9	33.2	19.3	4.7	5.9	10.8	42.1	9.0	6.3	8.9	27.2	7.0	24.7	9.7	16.6	5.3	6.9	17.1	19.4	7.0	14.3	29.3	16.2	77.3	10.3	13.6	6.6	3.4	2.7	7.4	7.6	3.6	3.5	5.9	27.1	12.7	11.1	3.5	3.5	11.8	10.4	10.7	8.4	14.7	8.8	10.1	10.3	8.0	10.9	9.5
GADD45A	"DDIT1, GADD45"	ENSG00000116717	"Growth arrest and DNA damage inducible alpha"	P24522	1	67685061-67688338	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, Growth arrest"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 86.7;skeletal muscle: 102.1"	"Cell line enhanced"	"Detected in many"		"HHSteC: 59.4;hTERT-HME1: 91.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 24.9"	"Group enriched"	"Detected in all"	5	"granulocytes: 24.9;T-cells: 9.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			HPA053420			Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA053420: "	"unprognostic (1.36e-2)"	"unprognostic (3.29e-2)"	"unprognostic (9.58e-2)"	"unprognostic (3.76e-3)"	"unprognostic (5.81e-2)"	"unprognostic (1.36e-2)"	"unprognostic (1.57e-3)"	"unprognostic (2.80e-3)"	"unprognostic (1.42e-1)"	"unprognostic (6.26e-2)"	"unprognostic (3.43e-2)"	"unprognostic (5.21e-2)"	"prognostic favourable (8.06e-6)"	"unprognostic (6.11e-2)"	"unprognostic (2.89e-1)"	"unprognostic (3.43e-3)"	"unprognostic (1.93e-1)"	29.6	6.8	10.7	8.2	20.9	46.2	20.9	1.7	15.8	11.7	10.8	5.8	18.8	10.1	23.3	13.8	12.2	8.8	16.7	12.9	18.1	9.8	86.7	66.9	17.1	4.9	11.4	4.1	13.8	8.3	4.1	5.1	10.8	21.2	16.5	9.0	9.4	9.5	15.6	102.1	14.8	20.4	16.1	15.5	7.4	14.1	9.2	7.5	9.2	26.2	10.1	10.9	23.9	11.1	1.1	2.2	24.9	3.2	3.1	9.3	4.8	21.9	1.4	3.7	1.1	6.7	7.0	35.4	39.1	18.2	13.0	14.2	7.7	3.7	9.5	12.0	6.3	13.2	0.4	33.4	24.6	6.9	3.8	11.8	3.5	7.7	59.4	3.4	1.1	11.8	16.9	16.5	91.6	9.3	25.3	16.9	15.3	0.7	1.0	4.2	4.8	15.5	2.5	29.1	9.7	6.7	16.6	16.2	2.8	8.2	2.3	23.4	0.4	3.7	9.6	13.6	18.3	14.4	27.3	43.3	8.4	17.2	6.0	1.6	13.3	7.2	3.2	24.9	3.7	1.5	3.0	1.1	2.5	3.0	1.4	0.7	0.7	1.2	4.1	3.1	1.0	2.2	9.3	4.8	10.7	20.9	1.7	15.8	18.1	9.8	11.4	4.1	21.2	7.5
GADD45G	"CR6, DDIT2, GADD45gamma, GRP17"	ENSG00000130222	"Growth arrest and DNA damage inducible gamma"	O95257	9	89605013-89606555	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in all"		"placenta: 65.6"	"Group enriched"	"Detected in some"	4	"HDLM-2: 46.7;SCLC-21H: 24.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 79.8"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	7	"eosinophil: 8.0"	"Lineage enriched"	"Detected in single"	22	"granulocytes: 8.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023606	Approved									"HPA023606: AB_1849409"	"unprognostic (5.84e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.08e-2)"	"prognostic favourable (7.06e-4)"	"unprognostic (4.45e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.77e-3)"	"unprognostic (3.75e-2)"	"unprognostic (7.65e-3)"	"unprognostic (4.16e-3)"	"prognostic favourable (3.80e-5)"	"unprognostic (1.11e-1)"	"unprognostic (1.63e-2)"	"unprognostic (4.95e-1)"	"unprognostic (3.88e-2)"	"unprognostic (3.41e-1)"	"unprognostic (1.22e-1)"	7.0	23.6	4.6	4.4	7.7	8.4	6.7	4.8	5.4	23.3	7.4	2.8	12.0	4.2	21.3	6.5	6.1	6.4	5.9	53.4	4.1	3.8	6.7	48.4	4.6	1.5	5.3	3.7	14.1	28.7	4.9	25.4	65.6	7.4	12.7	1.6	3.0	14.7	10.2	58.0	5.5	6.0	5.5	6.7	1.3	6.5	13.0	3.0	0.8	8.4	26.8	2.6	5.1	6.2	0.0	0.2	8.0	0.3	0.0	0.1	0.1	1.2	0.0	6.7	0.0	0.0	0.0	8.8	0.4	0.0	0.0	0.0	1.0	0.1	0.0	1.0	0.0	0.9	2.2	0.0	0.0	46.7	0.4	0.1	0.1	0.0	0.3	0.0	0.1	0.1	0.8	0.0	0.0	0.1	0.1	0.0	0.0	1.9	0.1	0.4	6.1	0.1	0.5	1.9	0.4	0.0	0.3	24.6	5.6	0.4	2.6	0.0	1.0	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	8.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.2	0.1	0.1	4.6	7.7	4.8	5.4	4.1	3.8	5.3	3.7	7.4	3.0
GAS1		ENSG00000180447	"Growth arrest specific 1"	P54826	9	86944363-86947189	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Growth arrest"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 61.8"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 19.3;ASC diff: 13.3;BJ hTERT+: 26.2;HSkMC: 18.7;RH-30: 39.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB024164, HPA036085, HPA066902"	Approved		Approved	"Nuclear speckles"				"Nuclear speckles"		"CAB024164: AB_2107950, HPA036085: , HPA066902: "	"unprognostic (2.78e-1)"	"unprognostic (1.63e-1)"	"prognostic unfavourable (1.55e-4)"	"unprognostic (1.97e-2)"	"unprognostic (6.15e-2)"	"unprognostic (2.84e-2)"	"unprognostic (6.46e-2)"	"unprognostic (6.91e-2)"	"unprognostic (3.32e-1)"	"unprognostic (1.28e-3)"	"unprognostic (2.25e-3)"	"unprognostic (4.30e-2)"	"prognostic unfavourable (1.96e-5)"	"prognostic unfavourable (8.26e-4)"	"unprognostic (6.73e-2)"	"prognostic unfavourable (1.13e-5)"	"unprognostic (3.59e-2)"	26.5	2.9	0.9	8.3	1.1	0.0	14.0	1.3	1.3	26.4	9.1	2.1	15.0	0.9	61.8	37.1	10.0	20.9	11.8	9.9	1.0	0.5	4.5	0.8	4.1	5.7	1.8	0.8	31.5	4.3	0.8	3.2	50.1	2.0	18.1	1.0	8.7	4.8	8.9	8.1	10.1	3.4	24.5	0.9	1.2	6.3	18.9	0.5	3.6	6.0	3.8	1.6	11.3	15.6	0.0	0.8	0.0	0.0	0.1	0.6	0.0	0.0	0.0	3.3	19.3	13.3	5.0	0.3	3.6	26.2	1.3	1.1	0.0	0.0	0.0	0.2	6.7	0.2	0.0	0.1	0.5	2.1	7.4	0.0	10.8	0.0	6.7	0.0	0.3	18.7	2.8	0.4	2.3	0.0	0.0	0.0	5.5	0.0	0.0	0.1	4.0	0.0	3.8	39.9	0.0	0.2	0.0	0.4	1.7	5.4	0.0	5.7	0.0	0.1	0.0	5.6	1.6	0.4	1.2	0.0	0.0	0.0	0.2	0.2	1.8	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.9	1.1	1.3	1.2	1.0	0.5	1.8	0.8	2.0	0.5
GAS7	"KIAA0394, MGC1348"	ENSG00000007237	"Growth arrest specific 7"	O60861	17	9910609-10198551	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 86.2"	"Cell line enriched"	"Detected in some"	9	"WM-115: 107.7"	"Cancer enhanced"	"Detected in all"		"melanoma: 54.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 17.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004838, HPA064678"	Enhanced		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"				"Plasma membrane"	"Actin filaments, Focal adhesion sites"	"HPA004838: AB_2667263, HPA064678: "	"unprognostic (1.68e-2)"	"unprognostic (2.84e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.01e-2)"	"unprognostic (7.32e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.94e-3)"	"unprognostic (6.48e-2)"	"unprognostic (8.78e-2)"	"unprognostic (3.08e-2)"	"prognostic unfavourable (6.89e-4)"	19.1	6.5	22.1	15.4	40.3	18.7	10.8	86.2	64.7	22.6	9.3	33.4	1.7	5.2	9.7	4.4	17.0	12.6	11.5	23.1	25.8	15.0	1.5	2.1	9.9	5.9	28.1	25.0	5.9	2.8	1.4	1.7	11.0	14.2	3.7	8.7	7.7	4.0	8.2	3.9	21.2	7.4	16.3	33.8	10.0	4.2	11.8	22.2	2.7	2.5	2.7	7.2	11.7	7.8	0.4	3.6	11.0	17.6	2.8	2.1	4.4	0.0	0.1	0.1	0.2	3.4	4.8	0.0	0.1	0.0	0.5	0.2	0.0	0.0	1.3	0.3	1.3	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.2	0.1	1.1	0.3	9.9	0.9	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	10.4	3.1	0.5	0.0	2.7	0.0	9.6	0.0	0.0	0.0	0.6	0.0	0.0	12.4	0.5	4.9	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	7.0	107.7	0.4	17.6	10.8	2.1	4.7	0.7	0.3	0.2	1.0	3.6	0.4	0.2	1.0	11.0	2.8	3.1	0.6	0.0	4.4	22.1	40.3	86.2	38.8	25.8	15.0	28.1	25.0	14.2	22.2
GAST	GAS	ENSG00000184502	Gastrin	P01350	17	41712326-41715969	"Cancer-related genes, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	61	"stomach 1: 529.2"	"Group enriched"	"Detected in some"	6	"BEWO: 5.0;HaCaT: 9.5;hTCEpi: 5.9"	"Group enriched"	"Detected in many"	6	"pancreatic cancer: 38.8;stomach cancer: 23.5"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			CAB000038	Enhanced				"Secreted to digestive system"	43000	43000			"CAB000038: "		"unprognostic (1.27e-1)"	"unprognostic (4.27e-3)"		"unprognostic (1.12e-1)"	"unprognostic (1.07e-2)"		"unprognostic (2.75e-2)"		"unprognostic (5.68e-2)"	"unprognostic (2.11e-1)"			"unprognostic (2.85e-1)"	"unprognostic (3.17e-1)"		"unprognostic (9.07e-2)"	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	1.2	0.1	1.7	6.9	0.0	2.4	7.3	0.0	0.0	0.0	2.6	0.0	0.1	0.3	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.3	529.2	0.1	0.0	8.6	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.0	0.3	0.0	0.0	0.0	0.6	0.0	0.2	0.7	0.0	9.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	1.2	0.1	0.3	0.1	0.0	0.0	0.0
GATA1	"ERYF1, GATA-1, GF1, NF-E1, NFE1"	ENSG00000102145	"GATA binding protein 1"	P15976	X	48786554-48794311	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"blood: 78.3;bone marrow: 37.0"	"Group enriched"	"Detected in some"	9	"HEL: 49.6;HMC-1: 51.2;K-562: 52.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	6	"eosinophil: 78.3"	"Lineage enriched"	"Detected in single"	784	"granulocytes: 78.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA000232, HPA000233, CAB009195"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB009195: AB_2232148, HPA000232: AB_1078949, HPA000233: AB_1078951"	"unprognostic (1.93e-1)"	"unprognostic (7.54e-2)"	"unprognostic (8.95e-3)"	"unprognostic (3.84e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.00e-4)"	"unprognostic (4.87e-2)"	"unprognostic (3.48e-2)"	"unprognostic (4.44e-2)"	"unprognostic (1.95e-2)"	"unprognostic (6.04e-2)"	"unprognostic (7.71e-3)"	"unprognostic (4.13e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.78e-1)"	"unprognostic (9.10e-2)"	"unprognostic (2.71e-2)"	0.7	0.2	0.1	2.4	0.7	37.0	0.3	0.0	0.3	0.7	0.3	0.0	0.0	0.6	4.9	2.4	0.4	0.3	0.6	2.3	0.1	0.3	0.4	0.8	5.6	0.2	0.6	0.0	0.1	0.1	0.1	0.5	2.8	0.3	1.4	0.4	1.6	0.3	0.2	0.1	0.6	0.8	2.4	0.3	4.9	0.5	3.1	0.0	1.5	0.6	1.1	0.6	0.9	0.6	0.0	0.0	78.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.6	0.0	0.0	0.0	0.0	51.2	0.0	0.0	0.0	0.0	0.0	52.8	0.1	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.2	0.0	78.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.7	0.1	0.7	0.0	0.3	0.1	0.3	0.6	0.0	0.3	0.0
GATA2	NFE1B	ENSG00000179348	"GATA binding protein 2"	P23769	3	128479427-128493185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Phagocytosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1"	"Cell line enhanced"	"Detected in many"		"BEWO: 55.8;HEL: 68.8;HMC-1: 37.2;SH-SY5Y: 65.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 36.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	339	"basophil: 81.2"	"Lineage enriched"	"Detected in single"	813	"granulocytes: 81.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA005633, CAB024847"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB024847: , HPA005633: AB_1078954"	"unprognostic (1.71e-1)"	"unprognostic (8.90e-2)"	"unprognostic (1.12e-1)"	"unprognostic (8.61e-2)"	"unprognostic (8.67e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.96e-3)"	"unprognostic (7.30e-2)"	"unprognostic (3.98e-2)"	"unprognostic (4.12e-2)"	"unprognostic (3.58e-2)"	"unprognostic (3.04e-1)"	"prognostic favourable (2.04e-4)"	"unprognostic (2.50e-1)"	"unprognostic (8.07e-2)"	"unprognostic (2.08e-1)"	"prognostic favourable (5.22e-5)"	7.0	6.2	2.1	1.5	2.4	2.5	7.9	1.2	1.9	22.4	2.8	1.4	85.8	2.5	20.6	5.4	3.2	23.0	9.7	4.8	1.5	1.0	7.6	0.6	16.1	2.2	1.8	1.1	4.6	5.8	3.4	4.5	51.8	2.4	27.8	1.8	6.1	1.9	209.1	3.5	4.1	3.4	8.4	1.4	5.1	2.9	2.7	1.5	0.4	3.3	2.7	1.5	22.4	12.4	0.0	0.0	81.2	0.0	0.0	0.0	0.4	4.6	1.1	0.2	3.1	0.4	0.1	55.8	10.4	8.9	3.6	1.3	1.9	2.0	0.1	2.9	6.1	4.9	2.9	0.0	1.5	0.0	1.6	68.8	7.6	3.0	0.8	6.9	37.2	0.0	0.0	0.1	0.0	5.6	18.0	0.1	0.0	1.7	0.0	14.1	0.2	0.3	0.0	1.3	0.0	0.1	4.1	4.3	65.0	2.6	13.8	0.4	2.6	2.8	10.0	0.2	0.1	2.5	1.4	0.0	0.0	0.0	0.1	0.4	0.7	81.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.1	2.4	1.2	1.9	1.5	1.0	1.8	1.1	2.4	1.5
GATA3	HDR	ENSG00000107485	"GATA binding protein 3"	P23771	10	8045378-8075203	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 97.8;skin 1: 61.7"	"Cell line enhanced"	"Detected in some"		"BEWO: 32.6;MCF7: 77.8;RT4: 31.8;SH-SY5Y: 27.3;T-47d: 101.3"	"Group enriched"	"Detected in many"	24	"breast cancer: 190.0;urothelial cancer: 87.0"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	42	"gdT-cell: 9.7;MAIT T-cell: 13.3;memory CD4 T-cell: 18.2;memory CD8 T-cell: 14.1;naive CD4 T-cell: 10.0;naive CD8 T-cell: 9.0;NK-cell: 16.6;T-reg: 18.9"	"Group enriched"	"Detected in many"	54	"NK-cells: 16.6;T-cells: 18.9"	"Region enriched"	"Detected in single"	6	"midbrain: 7.3"	"Group enriched"	"Detected in some"	46	"midbrain: 25.5;pons and medulla: 17.5;thalamus: 20.0"	"CAB016217, HPA029730"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB016217: AB_2108591, HPA029730: AB_10601907"	"unprognostic (1.70e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.00e-1)"	"unprognostic (7.03e-3)"	"unprognostic (4.68e-3)"	"unprognostic (4.23e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-1)"	"unprognostic (3.83e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavourable (3.13e-4)"	"unprognostic (1.48e-1)"	"unprognostic (5.16e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.82e-3)"	2.0	2.0	0.3	3.4	0.3	0.9	17.8	0.3	0.3	1.8	0.5	0.1	44.4	0.1	0.4	13.5	0.8	0.4	0.4	0.9	0.3	0.4	12.9	0.7	1.6	2.7	0.8	0.0	0.3	0.4	55.0	3.8	53.4	1.4	8.1	0.0	1.8	8.9	97.8	0.8	61.7	1.2	3.4	0.4	2.7	0.5	0.8	0.1	42.4	3.3	0.6	3.4	26.9	16.4	0.2	0.0	0.3	0.0	16.6	18.9	3.0	5.4	1.3	0.0	0.0	0.0	0.0	32.6	0.1	0.0	0.0	0.0	2.0	4.9	0.0	0.0	0.0	4.7	0.5	0.1	0.0	15.6	1.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.1	0.0	0.3	2.5	0.0	0.0	0.0	77.8	8.5	0.0	0.5	0.7	0.4	0.4	0.1	0.0	31.8	1.6	27.3	0.0	4.4	0.0	101.3	0.0	0.0	0.4	1.0	0.2	0.6	0.1	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	9.7	0.0	13.3	0.2	18.2	14.1	0.0	0.0	10.0	9.0	0.3	16.6	0.0	0.0	18.9	3.0	0.3	0.3	0.3	0.3	0.3	0.4	0.8	0.0	1.4	0.1
GCLM	GLCLR	ENSG00000023909	"Glutamate-cysteine ligase modifier subunit"	P48507	1	93885205-93909456	"Cancer-related genes, Predicted intracellular proteins"	"Glutathione biosynthesis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009568, HPA023696, CAB040554"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		1000000	1000000	"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB009568: AB_2107835, CAB040554: , HPA023696: AB_1849560"	"unprognostic (2.31e-1)"	"unprognostic (7.92e-2)"	"unprognostic (8.85e-3)"	"unprognostic (1.56e-2)"	"unprognostic (2.83e-2)"	"unprognostic (4.64e-2)"	"prognostic unfavourable (9.83e-6)"	"unprognostic (2.37e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.53e-1)"	"unprognostic (3.51e-2)"	"unprognostic (3.89e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.34e-3)"	10.3	17.5	7.0	6.0	7.7	11.3	23.9	5.7	8.9	4.5	22.8	4.2	11.5	16.6	3.5	6.5	8.8	12.8	12.5	7.7	6.8	8.9	17.8	41.7	8.4	10.4	9.2	5.7	4.6	6.9	6.3	5.1	10.3	8.7	5.3	5.2	6.4	6.7	6.4	19.2	3.4	20.0	3.4	7.7	6.9	6.1	3.2	2.8	5.6	15.0	23.0	8.6	8.9	8.0	3.2	1.9	3.3	0.7	4.6	6.7	1.2	14.0	22.2	2.4	4.8	8.3	5.2	9.5	16.8	10.5	12.8	9.6	3.7	8.3	5.3	33.7	10.8	14.2	3.6	6.8	10.3	14.4	4.9	37.1	15.2	16.0	15.6	13.6	5.9	6.4	2.6	26.0	4.2	13.9	14.7	7.9	9.2	2.7	9.8	3.1	8.4	10.6	4.6	7.4	7.8	9.1	16.4	5.8	2.4	15.8	12.5	5.8	2.8	8.5	14.6	13.4	7.9	25.2	25.1	7.1	9.1	5.5	11.1	7.7	4.7	3.3	0.7	1.3	5.3	0.4	3.1	2.6	5.0	6.7	0.6	3.2	3.2	3.2	2.9	4.6	0.5	1.9	1.3	1.2	7.0	7.7	5.7	8.9	6.8	8.9	9.2	5.7	8.7	2.8
GDF15	"MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB"	ENSG00000130513	"Growth differentiation factor 15"	Q99988	19	18374731-18389176	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"placenta: 463.0"	"Cell line enhanced"	"Detected in many"		"BEWO: 70.7;Hep G2: 36.4;HHSteC: 98.3;TIME: 35.3"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in single"	10	"pons and medulla: 6.5"	"Cell type enhanced"	"Detected in some"		"neutrophil: 6.3"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.3;monocytes: 2.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA011191, CAB062554, HPA070957"	Enhanced		Enhanced	"Golgi apparatus"	"Secreted to blood"	890000	890000	"Golgi apparatus"		"CAB062554: , HPA011191: AB_1078962, HPA070957: "	"unprognostic (1.04e-1)"	"unprognostic (1.89e-2)"	"unprognostic (3.45e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.04e-2)"	"unprognostic (2.39e-2)"	"unprognostic (2.03e-2)"	"unprognostic (2.30e-2)"	"unprognostic (2.80e-1)"	"unprognostic (2.89e-1)"	"unprognostic (5.09e-2)"	"unprognostic (1.46e-1)"	"unprognostic (6.55e-3)"	"unprognostic (3.81e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.04e-3)"	13.4	2.2	0.4	1.0	0.6	0.0	13.1	0.4	0.5	3.9	13.0	1.0	1.9	1.8	5.9	1.9	2.4	1.1	13.1	1.2	0.5	0.0	64.7	24.1	12.6	0.8	0.4	0.5	2.9	21.9	0.3	2.4	463.0	6.5	25.5	11.0	1.6	2.4	5.1	13.6	1.1	1.8	4.8	1.2	1.4	12.0	2.5	0.4	0.4	5.2	0.5	0.8	47.0	2.7	0.2	0.8	6.3	2.3	0.0	0.0	0.3	0.3	15.8	1.5	0.5	3.8	3.2	70.7	5.5	3.0	0.2	3.2	0.7	4.9	0.0	10.0	0.4	0.1	0.0	2.0	0.8	0.0	0.3	0.2	1.5	36.4	98.3	0.0	6.1	8.4	23.8	15.4	10.0	16.7	24.3	0.1	3.8	3.8	0.0	0.1	0.9	8.9	0.0	0.6	0.0	11.7	15.6	0.1	0.1	0.0	0.9	19.8	0.4	0.0	35.3	0.0	1.3	0.3	0.2	0.2	0.6	0.0	8.9	0.0	4.6	0.0	1.8	2.1	0.0	1.4	0.0	0.0	0.0	0.0	0.8	0.2	0.0	0.0	6.3	0.0	2.3	0.0	0.0	0.3	0.4	0.6	0.4	0.5	0.5	0.0	0.4	0.5	6.5	0.4
GDNF	"ATF1, ATF2, HFB1-GDNF"	ENSG00000168621	"Glial cell derived neurotrophic factor"	P39905	5	37812677-37839686	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes, Disease mutation, Hirschsprung disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 14.1;skeletal muscle: 12.4"	"Cell line enhanced"	"Detected in some"		"hTEC/SVTERT24-B: 24.6;U-87 MG: 7.4;WM-115: 27.0"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	6	"cerebellum: 14.1"	"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Region enhanced"	"Detected in single"		"basal ganglia: 2.5"	"Low region specificity"	"Detected in many"			"CAB005210, HPA070283"	Supported		Approved	Nucleoplasm,Vesicles	"Secreted in other tissues"			Vesicles	Nucleoplasm	"CAB005210: AB_2247684, HPA070283: "	"unprognostic (1.08e-1)"	"unprognostic (6.30e-2)"	"unprognostic (3.54e-2)"	"unprognostic (8.87e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.08e-1)"	"unprognostic (5.33e-2)"	"unprognostic (1.92e-1)"	"unprognostic (3.71e-2)"	"unprognostic (2.01e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.10e-1)"	"unprognostic (1.16e-4)"	"unprognostic (2.04e-1)"	"unprognostic (8.86e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.42e-2)"	1.9	0.3	0.6	1.9	2.3	0.0	0.4	14.1	1.3	0.8	9.4	0.4	0.4	1.6	1.7	3.4	1.0	0.9	0.9	0.9	0.6	0.4	1.0	0.7	0.4	0.4	0.6	1.2	4.5	0.4	0.0	0.4	6.3	1.4	1.6	3.1	1.1	0.4	6.3	12.4	1.4	2.5	2.5	0.5	0.4	1.9	3.9	2.4	0.4	0.4	1.5	0.4	0.6	1.1	0.8	0.4	1.2	0.3	0.9	0.4	0.0	0.0	0.0	0.0	0.0	1.1	0.4	0.0	3.3	2.1	0.6	0.9	0.0	0.0	0.0	0.0	4.4	0.1	0.0	0.0	1.2	0.0	0.1	0.0	0.2	0.3	0.1	0.0	0.0	1.0	0.1	24.6	0.0	0.0	0.0	0.0	1.3	0.1	0.0	0.0	0.2	0.0	0.0	5.3	0.0	0.0	0.1	0.2	0.0	0.1	0.1	1.6	0.0	0.0	0.0	3.3	0.0	0.8	3.8	2.3	0.0	0.0	7.4	0.0	27.0	0.4	0.3	0.2	0.3	0.2	0.3	0.2	0.3	0.3	0.1	0.8	0.2	0.4	1.2	0.9	0.2	0.4	0.1	0.0	0.6	2.3	14.1	1.3	0.6	0.4	0.6	1.2	1.4	2.4
GH1	"GH, GH-N, GHN, hGH-N"	ENSG00000259384	"Growth hormone 1"	P01241	17	63917200-63918838	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"pituitary gland: 994.5"	"Cell line enriched"	"Detected in some"	5	"U-698: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 2.1;T-reg: 2.2"	"Group enriched"	"Detected in many"	4	"B-cells: 2.1;T-cells: 2.2"									HPA043715	Supported				"Secreted to blood"	180000	180000			"HPA043715: "	"unprognostic (1.91e-2)"							"unprognostic (3.51e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.98e-1)"	"unprognostic (9.45e-4)"	"unprognostic (2.48e-1)"	"unprognostic (2.09e-4)"	"unprognostic (2.03e-2)"	"unprognostic (6.57e-2)"	"unprognostic (2.33e-1)"		0.3	0.0	0.0	0.5	0.0	1.1	0.2	0.1	0.1	0.4	0.4	0.0	0.0	3.3	1.0	0.0	0.2	0.5	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.6	0.0	0.0	0.0	0.0	0.3	994.5	217.7	0.1	0.2	0.5	0.0	0.1	0.2	0.8	0.9	0.4	0.1	0.0	1.6	0.3	0.5	0.0	0.0	0.0	0.0	0.6	0.1	0.0	2.1	0.0	0.0	0.5	0.0	2.2	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	1.5	7.4	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.6	0.0	0.0	2.1	0.3	0.0	0.0	0.0	0.5	0.0	2.2	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0
GH2	"GH-V, GHL, GHV, hGH-V"	ENSG00000136487	"Growth hormone 2"	P01242	17	63880215-63881935	"Cancer-related genes, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	309	"pituitary gland: 47.3;placenta: 138.4"	"Cell line enriched"	"Detected in single"	20	"BEWO: 13.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA043715	Supported				"Secreted to blood"					"HPA043715: "															"unprognostic (1.02e-1)"			0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.3	138.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GJA1	"CX43, GJAL, ODD, ODDD, ODOD, SDTY3"	ENSG00000152661	"Gap junction protein alpha 1"	P17302	6	121435692-121449727	"Cancer-related genes, Disease related genes, Predicted membrane proteins"			"Cancer-related genes, Cataract, Disease mutation, Hypotrichosis, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 48.8;HUVEC TERT2: 61.6;NTERA-2: 62.7;TIME: 45.3;U-87 MG: 61.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010753, HPA035097, HPA047551, HPA069245"	Enhanced	Supported	Supported	"Nucleoplasm,Vesicles,Cell Junctions"				"Vesicles, Cell Junctions"	Nucleoplasm	"CAB010753: AB_476857, HPA035097: , HPA047551: , HPA069245: "	"unprognostic (3.37e-2)"	"unprognostic (3.41e-3)"	"unprognostic (2.95e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.48e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.78e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.56e-1)"	"unprognostic (5.47e-2)"	"unprognostic (1.00e-1)"	"unprognostic (4.88e-2)"	"prognostic unfavourable (4.99e-5)"	"unprognostic (2.39e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.00e-3)"	19.7	65.2	78.6	5.5	69.7	0.4	14.2	32.4	44.4	64.5	4.0	23.8	6.1	4.2	23.5	5.5	17.3	7.8	23.0	36.0	87.3	25.5	3.6	2.5	15.2	4.4	42.9	39.9	10.5	4.5	94.7	5.7	63.8	53.7	20.0	4.8	26.3	7.1	35.7	3.4	86.3	4.4	25.6	38.7	1.1	6.4	8.3	64.3	0.5	38.9	9.9	7.6	14.8	32.2	0.5	0.5	0.4	0.5	0.0	0.4	0.0	0.0	7.2	32.1	0.0	17.5	10.9	0.0	24.0	48.8	8.1	19.8	0.1	0.0	0.0	2.7	9.3	3.1	0.8	14.7	26.4	0.0	8.8	0.3	2.9	0.0	21.9	0.0	0.0	29.0	15.9	29.6	10.7	61.6	0.0	0.7	1.6	1.3	0.0	12.9	62.7	8.0	0.0	0.0	0.6	32.4	3.5	0.0	0.5	0.0	0.0	0.0	2.5	0.0	45.3	25.0	6.9	21.1	15.5	0.0	0.0	0.0	61.0	0.0	3.5	0.4	0.5	0.0	0.2	0.0	0.2	0.0	0.3	0.0	0.2	0.5	0.4	0.4	0.0	0.0	0.1	0.5	0.1	0.0	78.6	69.7	32.4	42.8	87.3	25.5	42.9	39.9	53.7	64.3
GJB5	CX31.1	ENSG00000189280	"Gap junction protein beta 5"	O95377	1	34755047-34758512	"Cancer-related genes, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"esophagus: 39.0;lymphoid tissue: 26.1;skin 1: 37.7;tongue: 28.0"	"Cell line enhanced"	"Detected in some"		"A-431: 9.7;HaCaT: 31.1;HBEC3-KT: 13.9;hTCEpi: 51.5;RT4: 17.3"	"Group enriched"	"Detected in many"	5	"cervical cancer: 36.7;head and neck cancer: 57.5;lung cancer: 13.7;urothelial cancer: 21.1"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA038146	Uncertain									"HPA038146: AB_10697242"	"unprognostic (2.62e-1)"	"unprognostic (1.63e-1)"	"unprognostic (3.48e-1)"	"unprognostic (5.71e-2)"	"unprognostic (8.26e-2)"	"unprognostic (3.12e-1)"	"unprognostic (7.89e-2)"	"unprognostic (2.76e-2)"	"unprognostic (5.35e-2)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (1.54e-4)"	"unprognostic (4.30e-2)"	"unprognostic (1.09e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.41e-3)"	"unprognostic (5.59e-2)"	"unprognostic (5.67e-3)"	0.0	0.1	0.7	0.0	0.5	0.1	2.6	0.6	2.3	7.5	0.1	0.0	0.5	0.0	0.1	2.1	39.0	0.4	3.3	0.1	0.8	0.1	0.1	0.1	0.3	0.0	0.2	0.5	0.1	0.6	0.0	0.4	7.0	0.2	3.0	0.1	0.0	5.6	2.1	0.2	37.7	0.1	0.3	0.1	0.0	0.1	0.8	0.0	0.6	0.6	28.0	26.1	3.4	11.7	0.0	0.0	0.0	0.8	0.0	0.1	0.8	9.7	0.1	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	31.1	0.0	13.9	0.0	0.0	0.0	2.3	0.3	0.0	0.0	0.0	0.0	0.0	51.5	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	17.3	0.0	0.0	1.2	0.5	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.8	0.7	0.5	0.6	2.3	0.8	0.1	0.2	0.5	0.2	0.0
GLO1	GLOD1	ENSG00000124767	"Glyoxalase I"	Q04760	6	38675925-38703141	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Lyase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	4	"HMC-1: 244.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB040541, CAB040542, HPA059791"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		1600000	1600000	"Nucleoplasm, Plasma membrane, Cytosol"		"CAB040541: , CAB040542: , HPA059791: "	"unprognostic (4.33e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.08e-2)"	"unprognostic (3.96e-3)"	"unprognostic (2.51e-1)"	"prognostic unfavourable (5.21e-4)"	"unprognostic (5.09e-2)"	"unprognostic (2.10e-2)"	"unprognostic (1.28e-2)"	"unprognostic (2.61e-2)"	"unprognostic (8.71e-2)"	"unprognostic (1.20e-2)"	"unprognostic (9.29e-2)"	"unprognostic (1.83e-1)"	"unprognostic (2.54e-1)"	"unprognostic (6.21e-2)"	22.2	30.5	42.1	19.5	42.3	11.4	32.0	25.4	42.3	27.1	42.1	19.7	22.9	48.1	25.3	49.2	28.2	31.5	17.8	39.2	37.8	37.7	37.1	65.3	30.7	31.6	38.9	29.7	37.6	25.9	33.2	12.6	26.7	40.6	74.0	22.7	21.7	21.7	28.2	57.5	31.3	64.3	28.9	37.6	25.6	21.3	12.9	21.4	19.8	32.6	42.5	24.3	28.6	24.7	25.9	28.6	8.5	15.6	10.8	24.4	14.7	18.1	8.4	24.2	24.0	11.5	20.8	21.4	15.8	15.0	22.3	23.2	20.5	7.0	20.2	12.5	12.6	12.0	20.7	20.4	28.3	18.3	32.0	29.9	10.9	19.1	17.3	11.3	244.2	17.7	12.6	21.1	15.1	24.0	23.5	13.4	20.8	15.3	17.7	14.4	17.4	16.5	15.4	29.3	13.2	20.3	13.7	18.9	19.1	11.1	15.5	29.8	18.0	57.1	9.9	17.4	16.0	15.0	25.0	10.6	20.0	55.5	6.3	29.4	27.9	8.5	9.8	6.9	18.0	15.6	24.4	24.7	18.1	18.3	18.3	25.9	17.1	17.9	1.2	10.8	12.1	28.6	15.7	14.7	42.1	42.3	25.4	42.3	37.8	37.7	38.9	29.7	40.6	21.4
GMNN	Gem	ENSG00000112312	"Geminin, DNA replication inhibitor"	O75496	6	24774931-24786099	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle"	"DNA replication inhibitor"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 95.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011458, CAB047327, CAB047328, HPA049977, HPA054597"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB011458: AB_2110946, CAB047327: , CAB047328: , HPA049977: , HPA054597: "	"unprognostic (1.37e-1)"	"unprognostic (3.43e-3)"	"unprognostic (3.91e-3)"	"unprognostic (1.52e-2)"	"unprognostic (1.28e-1)"	"unprognostic (4.37e-2)"	"unprognostic (2.90e-3)"	"unprognostic (8.29e-2)"	"unprognostic (1.23e-3)"	"prognostic favourable (4.13e-4)"	"prognostic unfavourable (9.77e-4)"	"unprognostic (1.33e-2)"	"prognostic unfavourable (7.82e-5)"	"unprognostic (2.25e-1)"	"unprognostic (7.92e-2)"	"unprognostic (3.63e-2)"	"unprognostic (5.90e-3)"	4.5	3.9	10.7	11.2	19.0	24.1	10.7	15.6	9.4	4.9	17.1	3.2	9.7	7.6	5.3	6.3	8.0	7.3	4.7	3.7	11.0	10.2	10.8	8.4	4.4	12.0	13.6	9.8	7.2	95.0	2.6	7.5	7.9	10.7	18.4	18.9	3.4	4.2	11.6	3.7	17.3	7.4	5.7	7.9	12.6	9.7	19.6	11.9	26.1	13.2	11.0	9.7	15.2	7.4	8.5	9.2	15.8	6.7	5.3	15.2	5.6	24.5	14.6	37.0	15.2	5.2	5.6	24.7	24.1	12.8	29.0	31.9	28.2	8.8	24.7	30.8	7.7	14.4	31.9	17.7	31.3	9.1	33.4	33.8	25.9	46.2	4.9	26.2	12.4	4.5	5.8	17.6	6.9	14.2	42.5	13.1	20.4	19.2	49.2	28.4	20.2	11.5	28.7	28.9	31.7	12.2	21.4	29.7	18.3	10.8	17.8	21.2	18.7	16.1	7.0	17.8	18.0	20.5	40.8	14.6	45.0	46.3	5.4	49.6	25.5	5.3	5.3	15.8	4.6	6.7	5.8	8.5	8.9	7.1	7.4	4.5	6.6	7.3	3.0	5.3	4.7	9.2	15.2	5.6	10.7	19.0	15.6	9.4	11.0	10.2	13.6	9.8	10.7	11.9
GNA11	"FBH, FBH2, FHH2, HHC2"	ENSG00000088256	"G protein subunit alpha 11"	P29992	19	3094410-3124004	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 103.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 9.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048886	Approved									"HPA048886: "	"unprognostic (4.64e-3)"	"unprognostic (2.21e-1)"	"unprognostic (3.12e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.53e-2)"	"prognostic unfavourable (4.86e-4)"	"unprognostic (2.56e-2)"	"unprognostic (1.40e-1)"	"unprognostic (6.26e-2)"	"unprognostic (7.85e-3)"	"unprognostic (2.43e-1)"	"prognostic favourable (1.48e-11)"	"unprognostic (1.05e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.47e-1)"	"unprognostic (3.02e-1)"	19.3	14.2	17.3	13.7	17.1	5.9	14.2	38.5	28.0	16.1	40.8	18.6	18.3	65.9	19.8	14.5	17.2	19.8	19.5	21.9	16.0	12.8	17.8	16.6	15.1	5.0	11.7	12.6	19.4	19.6	14.2	13.8	20.0	14.1	18.2	23.0	27.1	17.5	30.5	27.3	20.0	103.3	17.6	12.2	10.5	17.2	20.1	12.5	3.9	18.0	13.5	7.6	19.2	22.1	2.4	3.9	9.1	2.4	0.7	2.2	0.4	20.3	12.4	11.3	19.6	16.7	11.1	12.5	20.2	20.1	27.4	22.5	15.6	10.5	5.0	11.2	28.2	14.8	14.2	16.2	17.5	11.0	8.4	1.4	13.4	8.9	16.5	1.3	4.6	15.2	14.1	18.5	11.2	21.8	10.2	1.0	18.3	9.4	1.4	6.0	7.8	11.2	8.9	10.0	4.6	13.3	16.0	25.5	16.1	14.5	17.4	10.1	12.5	2.9	18.6	18.1	12.9	32.6	27.0	0.5	1.4	3.3	12.9	1.1	19.6	2.8	2.4	0.5	1.1	1.3	1.4	1.3	0.9	1.1	0.4	2.4	2.2	1.6	9.1	0.7	2.4	3.9	0.3	0.4	17.3	17.1	38.5	28.0	16.0	12.8	11.7	12.6	14.1	12.5
GNA13	"G13, MGC46138"	ENSG00000120063	"G protein subunit alpha 13"	Q14344	17	65010715-65056839	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Transducer	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 75.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA010087	Approved		Supported	Cytosol		4000000	4000000	Cytosol		"HPA010087: AB_10601478"	"unprognostic (2.55e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.33e-3)"	"unprognostic (1.23e-3)"	"unprognostic (8.21e-2)"	"unprognostic (7.05e-2)"	"unprognostic (4.22e-3)"	"unprognostic (1.09e-1)"	"unprognostic (7.77e-2)"	"unprognostic (4.66e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.59e-1)"	28.2	17.4	16.4	25.3	17.5	75.6	15.1	15.1	15.0	14.2	19.1	23.0	13.0	14.0	12.9	12.1	13.2	12.1	17.7	15.4	16.8	13.3	12.4	17.4	27.6	27.5	18.5	9.4	16.3	10.0	12.1	10.0	25.0	14.8	16.8	17.3	10.7	10.5	13.9	35.0	11.4	17.5	15.9	32.1	22.5	13.6	11.3	20.4	34.9	11.9	9.0	27.5	28.3	26.0	5.7	5.5	15.8	13.4	7.8	11.2	4.4	11.6	13.2	12.1	8.2	12.6	11.4	12.5	9.1	10.6	12.5	14.3	7.4	7.8	47.6	6.0	9.8	8.1	12.9	11.1	19.3	12.3	7.5	24.8	8.0	14.5	18.2	18.5	16.5	9.6	17.0	12.0	16.6	18.8	10.0	29.7	14.4	11.0	28.4	6.7	7.5	9.8	16.5	24.3	17.3	12.6	19.1	8.9	18.8	6.6	13.8	15.6	14.2	18.1	13.4	20.8	18.3	8.9	11.9	22.0	26.1	54.0	7.6	12.0	11.0	7.1	6.4	8.5	7.2	13.4	7.3	5.7	8.9	8.5	5.5	4.8	5.2	5.7	15.8	7.8	8.3	2.5	11.2	4.4	16.4	17.5	15.1	15.0	16.8	13.3	18.5	9.4	14.8	20.4
GNAI1		ENSG00000127955	"G protein subunit alpha i1"	P63096	7	80133955-80219402	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Transport"	Transducer	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	5	"NK-cell: 20.0"	"Lineage enriched"	"Detected in many"	5	"NK-cells: 20.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022449, HPA042141"	Approved		Supported	Nucleoplasm,Nucleoli,Centrosome		9000000	9000000	Centrosome	"Nucleoplasm, Nucleoli"	"CAB022449: , HPA042141: "	"unprognostic (2.29e-1)"	"unprognostic (2.83e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.05e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.92e-2)"	"unprognostic (2.08e-2)"	"prognostic unfavourable (5.09e-4)"	"unprognostic (9.78e-2)"	"unprognostic (1.26e-1)"	"unprognostic (4.48e-1)"	"unprognostic (9.41e-3)"	"prognostic unfavourable (6.47e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.94e-2)"	"unprognostic (1.53e-1)"	33.2	23.4	17.2	5.4	26.2	1.5	14.4	14.4	33.7	9.4	10.5	36.9	3.0	6.9	10.0	3.0	16.6	9.0	8.6	5.7	23.8	18.3	25.9	13.1	10.3	3.4	40.3	21.9	14.3	5.4	2.5	7.3	30.4	26.2	10.1	9.0	2.8	4.9	9.5	4.2	32.4	5.3	12.2	49.7	5.7	8.3	11.1	32.0	0.9	11.1	3.2	4.6	15.5	9.0	0.1	3.7	2.1	1.5	20.0	2.3	0.7	2.9	20.5	18.8	0.1	23.4	15.0	8.6	12.5	15.1	11.1	13.7	0.0	3.2	0.1	4.0	13.4	3.0	10.4	12.8	14.7	0.1	9.6	17.6	18.1	1.2	23.7	2.2	3.8	16.1	32.4	5.9	17.1	7.4	1.4	0.0	20.7	0.5	0.1	0.1	5.4	7.4	8.2	7.2	8.8	33.1	9.9	13.8	9.5	13.4	0.2	10.6	2.5	0.4	13.1	24.8	17.5	5.7	4.7	0.1	0.0	0.1	6.5	1.3	11.0	2.1	0.7	0.7	0.1	0.7	0.0	0.0	0.3	0.2	3.7	0.1	2.3	0.9	0.3	20.0	1.5	0.3	0.2	0.7	17.2	26.2	14.4	25.5	23.8	18.3	40.3	21.9	26.2	32.0
GNAQ	"G-ALPHA-q, GAQ"	ENSG00000156052	"G protein subunit alpha q"	P50148	9	77716087-78031458	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 18.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 18.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010036, HPA048886"	Uncertain		Approved	"Nuclear speckles,Plasma membrane,Cytosol"		28000000	28000000	"Nuclear speckles"	"Plasma membrane, Cytosol"	"CAB010036: AB_631536, HPA048886: "	"unprognostic (2.10e-1)"	"unprognostic (8.53e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.87e-1)"	"unprognostic (6.83e-3)"	"unprognostic (1.05e-1)"	"unprognostic (3.84e-2)"	"unprognostic (2.46e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.44e-1)"	"prognostic favourable (1.11e-7)"	"unprognostic (1.90e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.01e-1)"	12.7	12.6	24.3	9.9	20.8	21.8	11.6	12.5	29.6	13.1	16.6	17.1	9.1	7.9	13.7	11.2	13.1	10.0	11.6	5.6	24.2	18.3	12.1	12.3	23.1	11.8	19.1	14.6	13.5	8.5	12.7	7.6	12.1	14.3	13.0	16.0	10.4	9.8	15.9	5.9	5.1	9.0	18.2	23.9	5.8	15.5	6.0	14.8	18.6	13.3	4.0	4.8	14.5	13.1	0.8	2.8	18.4	3.5	3.3	2.0	1.2	12.1	13.9	12.3	13.5	15.6	16.0	17.8	16.5	12.5	7.3	8.8	4.2	10.0	0.0	13.4	15.1	20.0	9.1	10.0	9.1	0.4	5.3	33.3	12.1	8.5	14.1	20.3	12.5	10.9	12.3	14.1	14.4	17.8	5.8	0.1	12.8	15.4	23.4	12.9	10.0	2.0	8.7	15.1	0.1	16.5	26.1	13.8	21.1	11.9	10.1	12.4	9.1	7.6	22.3	12.8	0.8	17.4	9.6	0.1	0.0	0.1	8.8	12.0	13.2	18.4	2.2	4.6	0.8	1.9	1.6	0.8	1.8	1.0	2.4	0.8	2.0	1.6	7.7	3.3	3.5	2.8	1.9	1.2	24.3	20.8	12.5	24.0	24.2	18.3	19.1	14.6	14.3	14.8
GNAS	"GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI"	ENSG00000087460	"GNAS complex locus"	"O95467, P63092, P84996, Q5JWF2"	20	58839718-58911192	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters"		Transducer	"Cancer-related genes, Cushing syndrome, Disease mutation, Dwarfism, Obesity, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pituitary gland: 303.3;thyroid gland: 304.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010337, HPA018122, HPA027478, HPA028386"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cytosol"	"Intracellular and membrane"			Nucleoplasm	"Plasma membrane, Cytosol"	"CAB010337: AB_631538, HPA018122: AB_1849236, HPA027478: AB_10599284, HPA028386: AB_10601983"	"unprognostic (7.48e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.90e-2)"	"unprognostic (4.77e-2)"	"unprognostic (8.37e-3)"	"unprognostic (2.82e-2)"	"unprognostic (4.53e-3)"	"unprognostic (8.01e-2)"	"unprognostic (4.29e-2)"	"prognostic favourable (8.76e-4)"	"unprognostic (2.07e-2)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (3.49e-4)"	"unprognostic (5.24e-3)"	"unprognostic (1.61e-1)"	"unprognostic (8.25e-2)"	"unprognostic (1.36e-1)"	56.2	79.0	84.2	34.4	44.5	42.1	87.4	86.0	107.4	43.2	42.3	25.4	27.0	33.2	37.2	44.7	41.0	43.6	34.4	106.0	71.0	144.0	39.6	35.3	46.6	44.6	75.8	64.7	43.6	118.1	120.9	303.3	49.8	85.6	36.3	31.5	42.7	171.6	31.1	172.9	26.3	34.9	40.5	61.4	36.9	42.4	18.2	27.4	56.0	304.5	80.6	41.0	37.3	44.6	27.3	41.5	29.9	36.2	25.3	24.2	24.6	9.6	32.5	54.8	25.5	93.1	42.6	49.2	55.8	51.0	63.9	45.8	94.7	50.1	31.7	86.9	72.5	41.8	50.2	74.3	43.3	20.9	30.2	35.2	49.4	62.0	43.1	20.4	22.2	50.7	37.8	31.0	41.7	48.3	30.9	43.3	42.0	132.2	104.3	50.1	17.4	34.4	64.2	48.0	55.9	51.2	38.2	68.0	155.7	77.6	77.0	62.2	58.9	56.1	53.1	84.8	76.2	30.5	52.5	75.9	49.0	66.9	37.2	10.0	43.2	29.9	24.8	29.5	20.7	35.7	22.1	26.7	22.0	22.2	37.8	27.3	21.3	24.2	29.1	25.3	36.2	41.5	23.3	24.6	84.2	44.5	86.0	107.4	71.0	144.0	75.8	64.7	85.6	27.4
GNB1		ENSG00000078369	"G protein subunit beta 1"	P62873	1	1785285-1891117	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins, Transporters"		Transducer	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA040736	Supported		Approved	"Golgi apparatus,Plasma membrane"		60000000	60000000	"Plasma membrane"	"Golgi apparatus"	"HPA040736: "	"unprognostic (9.49e-2)"	"unprognostic (4.91e-3)"	"unprognostic (1.24e-1)"	"unprognostic (1.56e-1)"	"unprognostic (3.34e-1)"	"unprognostic (9.07e-3)"	"prognostic unfavourable (3.61e-6)"	"unprognostic (1.99e-2)"	"unprognostic (3.60e-1)"	"unprognostic (7.27e-2)"	"unprognostic (8.47e-3)"	"unprognostic (1.95e-1)"	"unprognostic (9.76e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.62e-2)"	"unprognostic (1.14e-1)"	"unprognostic (7.90e-2)"	55.2	42.1	84.7	55.1	82.3	41.7	37.8	78.8	112.5	44.0	52.1	46.4	26.0	55.4	44.3	31.2	41.7	38.8	36.6	39.6	74.7	65.7	43.9	38.7	47.1	47.1	68.5	52.1	45.0	33.9	48.9	36.9	45.3	56.6	40.1	41.0	70.7	37.6	41.7	19.7	35.5	65.3	51.2	61.0	51.0	40.8	31.4	39.2	44.5	37.6	19.5	45.6	42.2	54.1	7.7	18.8	18.4	13.2	10.6	9.9	6.0	54.0	51.2	60.8	42.4	34.8	38.3	23.5	76.8	51.3	69.8	54.8	41.7	54.2	56.5	56.6	77.4	28.6	60.9	55.7	63.8	86.6	30.0	54.8	48.5	47.4	43.8	32.9	60.2	33.8	39.3	66.6	62.0	56.6	33.9	51.1	66.5	33.7	72.1	25.9	35.0	41.5	70.4	47.0	44.6	47.8	33.7	74.8	85.3	71.2	46.4	62.3	32.4	45.2	86.2	61.5	41.3	47.8	55.7	34.7	60.4	129.3	52.6	69.5	34.6	7.4	11.1	17.1	8.7	13.2	8.0	7.4	8.7	9.7	10.9	7.7	5.9	6.5	18.4	10.6	13.2	18.8	9.9	6.0	84.7	82.3	78.8	112.5	74.7	65.7	68.5	52.1	56.6	39.2
GNPTAB	"GNPTA, KIAA1208, MGC4170"	ENSG00000111670	"N-acetylglucosamine-1-phosphate transferase alpha and beta subunits"	Q3T906	12	101745497-101830938	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Transferase	"Cancer-related genes, Disease mutation, Mucolipidosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA014558, HPA042343"	Approved		Supported	"Golgi apparatus"		47000	47000	"Golgi apparatus"		"HPA014558: , HPA042343: "	"unprognostic (6.72e-2)"	"unprognostic (1.66e-1)"	"unprognostic (8.71e-3)"	"prognostic favourable (8.48e-4)"	"unprognostic (1.39e-1)"	"unprognostic (8.37e-2)"	"unprognostic (2.73e-1)"	"unprognostic (8.57e-2)"	"unprognostic (3.73e-2)"	"unprognostic (1.09e-2)"	"unprognostic (2.28e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.86e-2)"	"unprognostic (3.44e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.44e-2)"	"unprognostic (4.98e-2)"	15.2	6.5	21.9	11.9	23.0	15.2	12.2	13.9	25.6	14.0	21.3	10.3	5.9	10.3	9.0	6.5	11.7	7.1	11.0	15.9	17.9	13.7	11.0	7.3	19.6	20.3	14.4	13.0	6.6	11.4	29.9	9.0	10.8	10.9	15.6	22.5	11.3	37.6	10.2	10.8	18.1	14.5	11.7	13.1	15.4	15.2	7.4	10.8	24.5	10.5	8.6	12.6	14.7	14.8	3.9	5.8	5.9	3.4	14.2	16.4	2.7	8.3	8.1	3.0	5.1	25.6	12.2	9.4	11.9	24.6	11.8	15.5	6.2	5.9	17.5	8.6	16.3	10.9	14.0	15.3	18.5	8.2	7.3	7.5	7.5	8.8	4.8	6.8	15.2	9.4	8.5	11.2	6.6	20.7	11.6	5.2	11.0	12.7	20.4	9.6	10.4	5.9	4.8	15.5	23.5	19.0	21.7	6.6	5.4	19.8	14.1	28.0	14.5	4.5	20.3	11.2	6.1	9.3	6.6	14.3	14.6	10.0	12.7	10.1	6.9	5.9	3.1	3.4	16.4	2.9	5.4	2.4	3.6	8.9	5.8	3.9	4.6	7.1	1.2	14.2	3.4	5.8	2.6	2.7	21.9	23.0	13.9	25.6	17.9	13.7	14.4	13.0	10.9	10.8
GOLGA5	"golgin-84, GOLIM5, ret-II, rfg5"	ENSG00000066455	"Golgin A5"	Q8TBA6	14	92794231-92839963	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000992, HPA063876"	Enhanced	Supported	Supported	"Golgi apparatus"				"Golgi apparatus"		"HPA000992: AB_1079009, HPA063876: AB_2685140"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.77e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.78e-1)"	"unprognostic (5.02e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.83e-2)"	"unprognostic (7.67e-2)"	"unprognostic (6.44e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.06e-2)"	"unprognostic (2.49e-2)"	20.8	20.3	16.8	15.7	17.3	6.5	24.4	11.6	17.5	24.9	20.4	17.2	25.5	16.5	18.2	41.7	21.2	15.3	17.5	18.3	17.5	15.6	21.5	51.0	16.6	18.2	18.6	14.6	18.9	26.8	23.6	27.2	44.4	16.4	23.4	23.7	12.7	24.3	30.2	20.6	18.9	25.6	18.9	19.4	16.9	23.0	23.5	17.6	13.5	24.8	17.8	16.4	20.7	15.8	9.7	9.7	22.2	12.7	8.1	12.4	6.3	12.6	11.6	10.5	9.6	22.1	30.0	18.1	17.5	32.3	17.1	20.2	8.5	17.4	8.2	14.4	27.8	13.3	9.3	14.3	23.3	10.0	4.4	7.7	5.8	11.4	25.7	9.0	13.0	23.0	26.0	12.0	24.9	16.8	6.8	11.1	18.7	23.4	6.9	7.8	6.5	12.5	5.4	15.5	8.2	17.4	15.4	7.5	10.6	15.9	12.0	17.8	20.6	10.0	13.9	9.8	6.5	12.7	8.7	13.6	10.5	7.2	22.6	7.2	16.4	9.1	9.8	22.2	10.9	12.7	12.3	9.7	11.1	11.1	9.7	9.2	9.9	8.6	8.7	8.1	10.8	9.1	12.4	6.3	16.8	17.3	11.6	17.5	17.5	15.6	18.6	14.6	16.4	17.6
GOPC	"CAL, dJ94G16.2, FIG, GOPC1, PIST"	ENSG00000047932	"Golgi associated PDZ and coiled-coil motif containing"	Q9HD26	6	117560269-117602542	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA019477, HPA024018"	Approved		Enhanced	"Golgi apparatus"				"Golgi apparatus"		"HPA019477: AB_1849890, HPA024018: AB_1849891"	"unprognostic (2.48e-2)"	"unprognostic (1.63e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.17e-2)"	"unprognostic (3.12e-2)"	"unprognostic (9.21e-2)"	"unprognostic (6.22e-2)"	"unprognostic (6.77e-2)"	"unprognostic (8.23e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.67e-2)"	"unprognostic (1.38e-1)"	"unprognostic (9.55e-2)"	"unprognostic (3.01e-2)"	18.4	15.6	17.2	21.1	22.2	6.5	21.5	30.0	27.8	26.9	19.3	17.0	25.7	12.7	25.3	20.1	15.1	20.3	17.3	22.8	18.9	17.8	15.6	19.2	14.1	19.0	18.6	21.8	28.3	16.9	32.6	34.2	21.2	21.2	18.0	21.8	10.7	17.5	24.6	17.6	19.5	17.3	20.7	18.7	18.5	15.5	17.6	18.3	32.1	25.3	13.2	17.4	18.7	26.4	9.9	11.0	9.8	5.5	10.6	11.9	4.9	5.8	6.3	8.3	11.0	18.1	21.5	13.1	24.3	17.9	13.3	13.8	9.6	6.6	17.6	10.6	13.6	13.2	15.9	11.7	18.8	8.8	8.9	16.1	16.5	15.5	19.0	21.4	10.8	25.5	32.7	9.8	28.9	11.3	15.0	7.2	26.8	5.3	8.9	16.7	7.1	6.8	13.7	16.0	12.7	10.1	5.4	11.8	9.2	24.4	8.5	6.5	6.1	20.9	13.4	0.9	12.2	12.3	26.0	13.0	11.6	15.0	16.6	18.2	10.2	9.8	5.0	3.8	8.4	4.5	11.9	9.7	9.1	8.9	6.6	9.9	10.7	10.8	3.7	10.6	5.5	11.0	8.9	4.9	17.2	22.2	30.0	27.8	18.9	17.8	18.6	21.8	21.2	18.3
GOT1	AST1	ENSG00000120053	"Glutamic-oxaloacetic transaminase 1"	P17174	10	99396870-99430624	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Amino-acid biosynthesis"	"Aminotransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 116.9;liver: 82.9;skeletal muscle: 102.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA064532, HPA072629"	Enhanced		Supported	Nucleoplasm,Cytosol		130000000	130000000	Nucleoplasm	Cytosol	"HPA064532: AB_2685279, HPA072629: AB_2686540"	"unprognostic (6.40e-2)"	"prognostic favourable (6.23e-4)"	"unprognostic (5.99e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.82e-1)"	"unprognostic (2.96e-2)"	"unprognostic (5.25e-2)"	"unprognostic (1.08e-3)"	"unprognostic (6.67e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.79e-2)"	"unprognostic (1.79e-1)"	"prognostic favourable (3.72e-13)"	"unprognostic (1.93e-2)"	"unprognostic (4.23e-1)"	"unprognostic (6.85e-2)"	"unprognostic (1.00e-1)"	3.3	14.0	15.7	3.6	32.1	2.0	5.9	22.9	56.4	13.5	12.0	9.7	5.9	14.7	3.4	7.0	10.3	4.6	12.2	116.9	19.4	19.0	34.6	82.9	3.5	3.4	17.8	16.4	3.8	8.2	15.9	4.9	3.7	49.9	5.9	14.7	9.0	12.4	7.2	102.1	4.5	12.7	5.4	7.7	3.6	10.1	9.3	4.7	3.3	11.7	31.3	7.1	4.9	4.0	10.6	21.4	3.9	16.8	11.4	15.6	8.8	16.9	9.4	11.1	28.0	8.6	7.4	31.4	13.9	25.6	24.3	26.5	21.3	13.8	16.6	4.8	11.7	21.3	25.3	18.3	26.8	5.7	10.8	6.3	12.1	27.7	45.6	18.0	10.8	11.6	19.8	20.6	55.9	11.7	16.2	26.0	15.5	15.3	9.6	13.5	7.1	13.1	10.5	10.6	17.3	42.4	9.3	4.8	7.1	10.5	14.9	51.9	28.5	6.2	5.4	6.2	13.8	6.7	15.9	18.6	21.9	16.9	16.3	9.4	8.2	2.4	5.3	3.9	12.4	14.7	11.4	10.6	13.5	12.9	12.9	10.2	10.2	14.5	0.5	11.4	16.8	21.4	15.6	8.8	15.7	32.1	22.9	56.4	19.4	19.0	17.8	16.4	49.9	4.7
GOT2	"KAT4, KATIV, KYAT4, mitAAT"	ENSG00000125166	"Glutamic-oxaloacetic transaminase 2"	P00505	16	58707131-58734357	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Lipid transport, Transport"	"Aminotransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 167.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA018139	Enhanced				"Intracellular and membrane"	7000000	7000000			"HPA018139: AB_1849903"	"unprognostic (1.50e-2)"	"unprognostic (4.79e-2)"	"unprognostic (2.73e-3)"	"unprognostic (2.63e-3)"	"unprognostic (3.02e-2)"	"prognostic unfavourable (1.61e-4)"	"prognostic favourable (5.75e-5)"	"unprognostic (1.12e-2)"	"unprognostic (3.19e-1)"	"unprognostic (3.72e-2)"	"unprognostic (2.27e-1)"	"unprognostic (3.00e-1)"	"prognostic favourable (2.90e-9)"	"unprognostic (1.16e-1)"	"unprognostic (1.48e-1)"	"unprognostic (5.56e-2)"	"unprognostic (2.22e-1)"	6.1	21.0	12.7	8.0	19.1	5.5	10.7	19.4	35.7	10.6	15.9	16.0	33.3	10.6	10.4	19.5	17.7	13.5	8.9	78.1	15.8	16.7	24.6	85.5	7.1	11.1	16.2	17.8	8.7	8.8	27.0	13.0	7.3	27.7	17.2	18.8	23.4	13.0	20.5	167.8	10.4	9.4	13.5	12.3	8.0	13.6	10.8	9.9	10.7	12.3	53.9	15.0	15.5	11.2	14.3	17.6	3.5	9.9	14.5	24.5	14.3	27.1	36.9	19.5	23.6	14.1	12.8	25.5	20.9	22.3	41.2	22.6	31.9	24.6	60.8	24.9	23.1	40.2	41.6	40.6	52.6	16.7	38.2	16.4	20.1	35.6	17.9	26.2	15.1	12.3	23.1	25.9	22.7	41.3	32.8	6.3	20.9	24.3	32.6	25.4	26.4	71.7	35.8	29.7	58.3	38.9	40.0	31.1	22.6	40.0	43.1	15.0	21.8	8.6	16.6	15.0	27.5	11.7	26.5	14.6	13.5	49.8	16.1	26.3	15.1	2.3	9.9	3.5	15.2	8.6	23.5	14.3	18.0	18.4	17.6	10.6	16.7	15.3	0.9	14.5	8.5	15.5	24.5	14.3	12.7	19.1	19.4	35.7	15.8	16.7	16.2	17.8	27.7	9.9
GPA33	A33	ENSG00000143167	"Glycoprotein A33"	Q99795	1	167052836-167166479	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"intestine: 101.1"	"Cell line enhanced"	"Detected in some"		"HL-60: 1.9;MOLT-4: 2.3;NB-4: 1.1;NTERA-2: 4.0;RPMI-8226: 2.9;THP-1: 1.1"	"Cancer enriched"	"Detected in many"	6	"colorectal cancer: 84.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 17.8;T-reg: 13.0"	"Lineage enriched"	"Detected in many"	7	"T-cells: 17.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA018858, CAB025943"	Enhanced									"CAB025943: , HPA018858: AB_1849909"	"unprognostic (2.41e-2)"	"unprognostic (1.71e-3)"	"unprognostic (1.08e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.06e-1)"	"unprognostic (8.39e-4)"	"unprognostic (1.55e-1)"	"unprognostic (8.34e-2)"	"unprognostic (1.00e-2)"	"unprognostic (9.63e-2)"	"unprognostic (2.10e-2)"	"unprognostic (9.44e-2)"	"unprognostic (6.75e-2)"	"unprognostic (5.22e-3)"	"unprognostic (3.13e-1)"	"unprognostic (9.68e-3)"	"unprognostic (2.96e-3)"	0.2	0.2	0.2	12.1	0.2	0.0	0.2	0.2	0.2	0.2	46.9	0.2	0.1	31.6	0.2	0.1	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	1.2	1.6	0.2	0.1	0.2	0.2	0.0	0.2	0.3	0.2	0.2	43.5	0.2	0.3	0.1	0.2	0.2	101.1	1.4	0.2	0.6	0.2	0.2	0.1	0.6	0.2	0.1	0.6	0.2	0.2	1.7	1.7	0.1	2.5	0.1	17.8	4.6	0.0	0.0	0.2	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.1	4.0	0.1	0.0	0.0	2.9	0.0	0.0	0.3	0.6	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.0	2.5	1.1	0.1	7.6	3.9	1.7	1.7	17.8	2.4	0.1	0.1	1.6	0.0	13.0	4.6	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1
GPC3	"DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1"	ENSG00000147257	"Glypican 3"	P51654	X	133535745-133985895	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"placenta: 262.7"	"Group enriched"	"Detected in some"	8	"HAP1: 53.1;Hep G2: 209.8"	"Cancer enhanced"	"Detected in all"		"liver cancer: 269.0"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	4	"naive CD4 T-cell: 5.0;naive CD8 T-cell: 3.5;NK-cell: 1.7"	"Group enriched"	"Detected in many"	12	"NK-cells: 1.7;T-cells: 5.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA006316			Supported	"Plasma membrane"	"Intracellular and membrane"			"Plasma membrane"		"HPA006316: AB_1078994"	"unprognostic (2.06e-1)"	"unprognostic (2.36e-1)"	"unprognostic (9.51e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.46e-1)"	"unprognostic (6.10e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.07e-2)"	"unprognostic (3.92e-3)"	"unprognostic (6.06e-2)"	"unprognostic (1.71e-1)"	"unprognostic (3.81e-3)"	"prognostic unfavourable (4.83e-4)"	"unprognostic (1.43e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.60e-1)"	30.1	5.9	0.4	3.6	0.7	0.0	50.2	0.6	0.4	3.3	4.5	0.5	2.2	0.5	2.5	11.7	2.0	3.4	9.2	8.0	0.4	1.1	21.2	1.1	37.0	1.9	1.6	0.4	6.0	4.6	0.3	16.9	262.7	1.6	3.6	1.0	6.3	3.8	2.3	4.1	5.5	1.8	3.3	2.1	0.9	4.0	2.1	0.3	2.3	7.2	11.2	3.0	7.6	8.0	0.0	0.2	0.0	0.0	1.7	5.0	0.6	0.0	0.0	2.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.4	0.0	0.0	0.0	0.0	0.0	53.1	0.0	0.0	0.0	2.4	0.0	0.1	209.8	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.0	0.0	14.5	0.6	1.7	4.3	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.5	0.2	0.0	5.0	3.5	0.0	1.7	0.0	0.0	0.0	0.6	0.4	0.7	0.6	0.4	0.4	1.1	1.6	0.4	1.6	0.3
GPHN	KIAA1385	ENSG00000171723	Gephyrin	Q9NQX3	14	66507407-67181803	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Molybdenum cofactor biosynthesis"	"Multifunctional enzyme, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003116, CAB004419, HPA024694"	Enhanced		Uncertain	"Cytoplasmic bodies"				"Cytoplasmic bodies"		"CAB004419: AB_627670, HPA003116: AB_1078963, HPA024694: AB_1849616"	"unprognostic (8.37e-2)"	"unprognostic (2.53e-2)"	"unprognostic (2.42e-1)"	"unprognostic (1.20e-1)"	"unprognostic (5.14e-2)"	"unprognostic (4.89e-3)"	"unprognostic (8.29e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.23e-1)"	"unprognostic (2.49e-2)"	"unprognostic (8.54e-2)"	"prognostic favourable (5.25e-12)"	"unprognostic (9.81e-2)"	"unprognostic (2.27e-1)"	"unprognostic (7.50e-2)"	"prognostic unfavourable (4.61e-5)"	13.0	12.4	26.1	10.9	31.1	5.2	17.1	40.9	31.2	11.0	18.2	9.3	15.6	11.1	12.3	20.8	8.6	7.5	8.2	11.9	26.4	22.9	34.5	49.0	14.1	7.3	18.3	11.5	7.2	22.9	17.4	24.5	5.8	13.9	11.1	13.2	7.4	10.8	21.3	23.4	10.7	10.8	11.6	16.4	5.6	13.5	7.8	16.2	3.1	12.2	10.0	6.8	7.4	15.1	3.1	3.0	0.5	2.5	2.3	6.2	1.5	22.3	4.4	7.8	8.6	9.3	7.9	5.0	6.4	3.1	6.5	6.6	1.3	10.1	0.0	1.1	3.1	7.9	7.8	12.4	8.6	6.8	8.5	6.6	6.3	13.6	4.8	3.7	9.9	6.7	7.3	1.8	7.2	7.6	4.5	8.5	3.6	11.9	6.6	14.0	3.3	10.2	0.0	15.1	6.5	10.5	4.4	13.9	5.4	4.3	19.0	7.0	10.2	6.4	2.8	6.6	14.6	6.4	6.5	11.3	4.8	0.1	5.2	0.5	6.3	0.0	1.3	0.5	3.9	2.5	6.2	2.4	4.9	2.9	1.9	3.1	3.5	3.3	0.0	2.3	1.9	3.0	5.3	1.5	26.1	31.1	40.9	27.0	26.4	22.9	18.3	11.5	13.9	16.2
GPI	"AMF, NLK"	ENSG00000105220	"Glucose-6-phosphate isomerase"	P06744	19	34359480-34402413	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Gluconeogenesis, Glycolysis"	"Cytokine, Growth factor, Isomerase"	"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB018655, HPA024305, CAB040563, HPA052171"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	140000000	140000000	"Plasma membrane, Cytosol"	Nucleoplasm	"CAB018655: AB_2112653, CAB040563: , HPA024305: AB_1849922, HPA052171: AB_2681748"	"unprognostic (1.03e-1)"	"unprognostic (8.39e-3)"	"unprognostic (2.39e-2)"	"unprognostic (1.38e-2)"	"unprognostic (4.52e-2)"	"unprognostic (6.45e-3)"	"unprognostic (1.95e-2)"	"unprognostic (8.52e-3)"	"unprognostic (3.18e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.93e-2)"	"unprognostic (2.75e-1)"	"unprognostic (3.24e-3)"	"unprognostic (2.62e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.60e-3)"	"unprognostic (2.88e-2)"	62.1	66.6	43.4	27.6	58.2	83.3	34.8	62.6	88.7	20.6	36.6	20.8	23.7	48.2	21.1	20.6	45.3	24.2	33.5	107.2	42.0	45.6	51.3	77.9	19.6	29.6	39.3	64.3	22.5	21.4	66.9	33.7	20.4	50.2	23.7	37.2	36.2	34.6	33.9	144.7	29.4	44.3	34.2	22.8	23.1	26.7	19.7	19.0	23.8	26.1	68.5	32.6	32.5	25.2	16.2	26.3	74.8	40.9	14.5	27.5	24.6	76.1	107.4	9.4	73.5	30.9	23.0	22.5	29.4	23.2	37.1	44.8	60.5	27.0	50.2	43.7	28.8	53.1	56.8	63.9	42.2	55.8	22.9	64.5	51.8	63.6	20.0	83.5	42.0	31.5	26.4	43.9	22.8	34.6	32.8	39.8	26.1	64.6	36.3	29.2	25.4	38.0	34.0	24.9	94.8	46.5	51.3	51.4	29.9	59.3	104.6	21.4	23.7	26.6	29.8	14.0	30.9	39.8	45.3	73.5	41.7	45.5	46.8	63.5	28.4	38.5	22.9	74.8	22.5	35.2	27.5	16.2	20.7	25.5	26.3	13.3	17.5	20.7	1.6	14.5	40.9	8.7	21.6	24.6	43.4	58.2	62.6	88.7	42.0	45.6	39.3	64.3	50.2	19.0
GPS2		ENSG00000132522	"G protein pathway suppressor 2"	Q13227	17	7311324-7315564	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, Repressor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA067540	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA067540: "	"unprognostic (1.53e-2)"	"unprognostic (3.43e-1)"	"unprognostic (3.33e-2)"	"unprognostic (1.71e-3)"	"unprognostic (1.55e-1)"	"unprognostic (1.53e-4)"	"unprognostic (1.37e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.18e-2)"	"unprognostic (2.84e-1)"	"prognostic favourable (7.50e-5)"	"unprognostic (1.37e-2)"	"prognostic unfavourable (3.42e-5)"	"unprognostic (2.09e-1)"	"unprognostic (1.44e-1)"	"unprognostic (6.87e-2)"	"unprognostic (1.28e-3)"	21.8	22.8	21.1	17.6	20.9	27.8	25.0	18.2	25.4	18.5	23.4	19.1	14.4	14.4	20.0	15.5	24.6	19.9	15.5	35.3	19.9	17.1	28.7	30.1	18.5	15.2	19.5	16.9	20.9	23.0	26.6	21.1	21.9	16.5	17.5	20.2	14.3	19.7	21.5	72.4	23.0	25.7	18.2	21.2	20.6	18.0	45.8	22.1	21.2	22.4	21.0	21.1	19.2	25.0	55.2	48.3	58.1	46.4	28.2	57.0	38.8	19.4	37.8	12.1	16.5	24.1	13.6	13.9	14.1	16.7	28.6	24.7	26.2	10.0	22.0	10.7	19.4	26.7	15.3	27.5	22.2	26.8	24.1	20.4	35.9	32.4	17.1	12.2	23.7	12.8	19.1	39.3	10.5	16.7	12.3	5.2	29.6	16.4	23.7	12.9	16.5	15.8	18.2	22.4	22.5	21.2	22.0	16.1	27.0	23.0	14.8	19.3	14.5	11.9	10.0	13.4	13.8	18.5	32.8	17.2	24.4	14.7	20.1	14.4	23.4	44.1	35.3	58.1	40.8	43.0	38.4	55.2	45.5	45.8	29.5	43.3	42.5	38.5	56.4	28.2	46.4	48.3	57.0	38.8	21.1	20.9	18.2	25.4	19.9	17.1	19.5	16.9	16.5	22.1
GPX2	GSHPX-GI	ENSG00000176153	"Glutathione peroxidase 2"	P18283	14	64939152-64942905	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Oxidoreductase, Peroxidase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 126.9;liver: 195.2"	"Group enriched"	"Detected in some"	20	"A549: 120.7;HaCaT: 33.4;Hep G2: 112.0;RT4: 79.8;SCLC-21H: 36.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"NK-cell: 2.4"	"Low lineage specificity"	"Detected in single"			"Region enhanced"	"Detected in single"		"pons and medulla: 1.3"	"Low region specificity"	"Detected in single"			HPA003545	Enhanced		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA003545: AB_10962695"	"unprognostic (3.54e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.90e-3)"	"unprognostic (4.75e-3)"	"prognostic unfavourable (5.10e-4)"	"unprognostic (2.96e-2)"	"unprognostic (2.93e-2)"	"unprognostic (7.87e-2)"	"unprognostic (1.54e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.77e-2)"	"unprognostic (4.39e-2)"	"unprognostic (3.39e-2)"	"unprognostic (6.66e-4)"	"unprognostic (1.73e-2)"	0.1	0.0	0.1	23.8	0.2	0.0	0.8	0.2	0.1	5.5	50.4	0.5	2.0	14.4	0.3	1.0	53.0	0.6	126.9	0.2	0.1	0.2	29.4	195.2	2.0	0.1	0.1	0.1	0.9	7.0	0.0	0.2	0.1	0.2	16.8	71.6	0.1	59.7	4.1	0.3	3.9	35.4	5.6	0.2	0.1	57.8	0.4	0.1	0.5	0.2	44.0	7.4	56.3	15.0	0.2	0.0	0.5	0.8	2.4	0.1	0.0	0.0	120.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	1.0	0.0	0.7	0.0	33.4	0.0	0.5	0.0	0.0	0.0	0.0	0.1	112.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	79.8	36.1	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.5	2.4	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1
GRB10		ENSG00000106070	"Growth factor receptor bound protein 10"	Q13322	7	50590063-50793462	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 65.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	12	"basophil: 11.4;eosinophil: 3.5"	"Lineage enriched"	"Detected in single"	26	"granulocytes: 11.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019423, HPA027502, HPA031818"	Approved		Supported	Vesicles				Vesicles		"CAB019423: AB_2112883, HPA027502: AB_10602325, HPA031818: "	"unprognostic (2.82e-2)"	"unprognostic (1.69e-3)"	"unprognostic (1.25e-2)"	"unprognostic (1.45e-2)"	"unprognostic (3.68e-2)"	"unprognostic (1.60e-1)"	"unprognostic (6.83e-2)"	"unprognostic (5.91e-3)"	"unprognostic (1.67e-2)"	"unprognostic (2.31e-3)"	"unprognostic (4.44e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.73e-3)"	"unprognostic (8.16e-3)"	"unprognostic (2.63e-2)"	"unprognostic (8.50e-2)"	14.3	14.6	14.7	4.9	26.7	6.5	18.8	22.0	20.9	9.7	10.5	14.6	2.0	12.3	8.9	8.0	7.3	9.0	15.6	19.1	13.8	14.8	19.8	15.6	8.3	4.3	19.8	10.7	6.5	65.8	6.0	21.5	10.6	20.9	10.6	5.1	16.5	7.0	11.7	35.7	3.7	8.4	13.0	9.9	15.9	7.2	11.4	16.9	0.4	18.3	4.2	3.2	12.7	17.3	0.0	0.1	11.4	0.2	0.0	0.4	0.1	0.1	10.6	17.4	7.0	8.2	6.3	9.2	4.3	3.7	8.3	10.1	6.4	0.1	0.2	7.6	5.4	1.0	17.9	4.5	4.1	0.1	7.2	18.3	10.8	4.6	17.4	11.4	28.3	16.3	7.1	12.8	12.7	21.2	34.5	0.2	6.3	1.2	2.0	15.4	19.0	18.4	5.3	0.0	0.1	5.5	4.2	7.6	0.0	0.5	2.7	22.7	9.2	23.2	25.9	7.4	10.1	15.0	16.2	0.7	0.2	0.1	23.4	10.4	24.9	11.4	0.1	3.5	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.1	0.0	0.1	14.7	26.7	22.0	20.9	13.8	14.8	19.8	10.7	20.9	16.9
GRB2	NCKAP2	ENSG00000177885	"Growth factor receptor bound protein 2"	P62993	17	75318076-75405709	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002589, HPA030749, HPA030750"	Approved		Enhanced	Nucleoplasm		1900000	1900000	Nucleoplasm		"CAB002589: AB_10693935, HPA030749: AB_2673590, HPA030750: AB_2673591"	"unprognostic (4.83e-3)"	"unprognostic (1.85e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.42e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.06e-1)"	"prognostic unfavourable (6.04e-7)"	"unprognostic (1.01e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.89e-2)"	"unprognostic (1.08e-2)"	"unprognostic (8.13e-2)"	"unprognostic (3.40e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.58e-1)"	29.0	29.2	36.1	48.2	40.3	56.3	23.6	42.2	41.6	18.5	27.8	28.2	19.1	29.2	28.3	19.4	27.0	22.1	22.5	32.2	34.7	33.9	24.9	32.2	33.7	54.8	30.9	29.2	21.8	16.7	21.8	21.8	33.1	26.9	21.4	27.9	21.8	21.2	25.6	27.8	18.6	30.5	30.6	42.6	56.7	22.8	10.8	27.1	45.8	20.4	15.6	53.1	29.8	19.2	24.7	25.0	64.9	42.8	12.0	13.4	20.7	24.8	21.7	14.9	18.0	16.5	15.5	34.0	26.3	21.4	27.7	26.6	18.6	16.7	32.5	15.6	24.0	14.9	21.5	18.9	28.8	16.0	19.7	34.8	14.3	27.1	14.9	40.0	68.0	14.3	19.8	28.9	14.5	33.2	23.5	22.6	20.1	31.0	46.8	38.7	10.3	22.1	28.1	32.0	23.5	21.1	18.6	18.0	26.0	22.2	21.7	27.7	24.0	64.7	21.1	26.6	20.2	21.0	26.7	41.5	31.9	52.2	20.5	31.3	19.0	25.1	32.1	38.5	13.4	38.4	11.7	23.7	12.1	13.2	25.0	24.7	12.7	12.0	64.9	12.0	42.8	16.7	13.2	20.7	36.1	40.3	42.2	41.6	34.7	33.9	30.9	29.2	26.9	27.1
GRB7		ENSG00000141738	"Growth factor receptor bound protein 7"	Q14451	17	39737927-39747291	"Cancer-related genes, Predicted intracellular proteins"		"Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 53.9"	"Cell line enriched"	"Detected in some"	9	"SK-BR-3: 89.5"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in some"	4	"cerebellum: 7.4"	"Cell type enriched"	"Detected in single"	20	"naive B-cell: 2.0"	"Lineage enriched"	"Detected in single"	20	"B-cells: 2.0"	"Region enhanced"	"Detected in some"		"cerebellum: 9.3"	"Low region specificity"	"Detected in all"			"CAB005226, HPA057084, CAB073538"	Approved		Supported	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB005226: AB_2113278, CAB073538: , HPA057084: "	"unprognostic (8.46e-2)"	"unprognostic (2.06e-2)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (6.60e-7)"	"unprognostic (7.06e-3)"	"unprognostic (2.09e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.85e-1)"	"unprognostic (2.02e-1)"	"prognostic unfavourable (3.10e-4)"	"prognostic unfavourable (6.90e-4)"	"unprognostic (2.59e-2)"	"prognostic favourable (8.23e-5)"	"unprognostic (1.83e-2)"	"unprognostic (4.77e-2)"	"unprognostic (5.49e-3)"	"unprognostic (4.01e-2)"	2.9	0.1	0.1	2.8	0.6	0.0	16.1	7.4	1.2	6.7	12.7	0.3	25.0	6.7	2.6	8.1	53.9	14.5	16.3	0.8	0.2	0.1	23.4	5.2	12.3	0.1	0.1	0.4	3.1	20.5	5.8	3.7	42.6	1.6	10.2	6.4	0.7	14.0	25.5	0.5	19.1	12.4	2.0	0.1	0.3	7.2	2.3	0.3	0.5	8.5	6.5	17.2	7.2	11.7	2.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	3.4	0.0	0.0	0.0	0.0	4.4	0.0	0.2	0.0	0.1	10.4	5.9	0.0	0.9	0.1	5.6	0.0	3.9	0.0	0.0	0.5	0.0	1.3	9.0	0.0	0.0	0.0	0.0	3.4	0.0	0.9	0.0	0.0	0.0	0.0	2.7	0.0	0.0	1.2	0.8	0.0	0.0	4.1	4.6	3.3	2.3	0.0	4.5	89.5	0.0	3.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	7.4	1.2	0.2	0.1	0.1	0.4	1.6	0.3
GRIN2A	"GluN2A, NMDAR2A"	ENSG00000183454	"Glutamate ionotropic receptor NMDA type subunit 2A"	Q12879	16	9753404-10182754	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 25.2"	"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 7.7;RPMI-8226: 2.9;U-138 MG: 8.4"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB022725	Enhanced									"CAB022725: "	"unprognostic (6.43e-2)"	"unprognostic (2.47e-1)"	"unprognostic (5.97e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.08e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.75e-3)"	"unprognostic (4.79e-3)"	"unprognostic (2.05e-1)"	"unprognostic (3.92e-3)"	"unprognostic (3.33e-2)"	0.9	1.0	5.4	0.5	5.9	0.4	0.6	8.5	25.2	0.6	0.7	1.5	0.0	0.9	0.8	4.5	2.1	4.1	0.5	4.0	8.0	1.9	0.9	0.4	1.0	0.5	1.7	10.3	0.5	0.6	0.4	0.3	0.4	1.4	0.5	0.7	1.4	0.7	1.0	0.5	1.2	0.7	0.9	1.2	0.4	1.1	5.2	0.8	0.0	0.8	0.0	0.7	0.6	0.5	0.6	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.1	1.8	0.5	1.4	0.0	0.1	0.0	0.0	7.7	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.8	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	5.4	5.9	8.5	17.9	8.0	1.9	1.7	10.3	1.4	0.8
GSK3A		ENSG00000105723	"Glycogen synthase kinase 3 alpha"	P49840	19	42230186-42242625	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Carbohydrate metabolism, Glycogen metabolism, Neurogenesis, Wnt signaling pathway"	"Kinase, Serine/threonine-protein kinase, Signal transduction inhibitor, Transferase"	"Alzheimer disease, Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004422, HPA028423"	Approved		Approved	Cytosol				Cytosol		"CAB004422: AB_627680, HPA028423: AB_10612116"	"unprognostic (5.46e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (4.02e-4)"	"unprognostic (1.35e-1)"	"unprognostic (3.96e-2)"	"prognostic unfavourable (1.13e-4)"	"unprognostic (3.80e-3)"	"unprognostic (2.27e-1)"	"unprognostic (2.87e-1)"	"unprognostic (4.99e-2)"	"unprognostic (3.36e-1)"	"unprognostic (2.69e-1)"	"unprognostic (2.77e-2)"	"unprognostic (4.49e-2)"	"unprognostic (7.22e-2)"	"unprognostic (8.22e-3)"	15.3	19.8	31.0	16.8	38.0	14.4	12.0	31.4	62.2	15.9	16.8	24.3	11.4	28.6	16.9	18.0	17.3	16.7	11.8	21.3	31.3	23.6	17.5	13.1	14.2	15.0	21.8	26.3	20.0	19.3	16.1	14.2	14.7	31.7	15.8	16.1	15.5	18.1	20.3	41.0	25.1	27.0	18.5	18.0	14.5	14.7	19.1	17.7	16.6	15.8	11.9	15.8	15.8	15.5	1.6	2.2	4.0	1.9	1.7	2.0	1.0	23.6	42.0	24.1	22.3	14.4	12.9	10.2	16.7	15.9	22.1	20.0	15.7	15.1	17.1	17.2	13.1	10.9	19.8	19.4	15.5	13.8	31.8	17.8	13.5	15.5	19.0	20.2	21.8	12.6	20.6	18.1	20.7	20.0	29.9	25.6	18.9	28.7	26.2	17.9	17.8	17.4	23.9	14.0	13.2	20.4	24.8	28.1	28.4	22.9	30.0	15.2	17.3	26.8	17.7	22.8	17.1	13.2	29.5	26.2	30.0	13.4	26.5	20.4	25.0	2.5	1.5	1.6	2.0	1.9	1.4	1.2	1.2	1.3	1.4	1.6	0.7	1.5	4.0	1.7	1.1	2.2	1.0	1.0	31.0	38.0	31.4	62.2	31.3	23.6	21.8	26.3	31.7	17.7
GSN	DKFZp313L0718	ENSG00000148180	Gelsolin	P06396	9	121207794-121332843	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cilium biogenesis/degradation"	"Actin capping, Actin-binding"	"Amyloidosis, Cancer-related genes, Corneal dystrophy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 167.4;HaCaT: 66.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 133.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010823, CAB016728, CAB036009, HPA054026"	Supported		Supported	"Actin filaments"	"Secreted to blood"	510000000000	510000000000	"Actin filaments"		"CAB010823: , CAB016728: , CAB036009: , HPA054026: "	"unprognostic (3.25e-2)"	"unprognostic (4.44e-3)"	"unprognostic (1.22e-1)"	"unprognostic (3.10e-3)"	"unprognostic (4.23e-2)"	"unprognostic (4.85e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.20e-1)"	"unprognostic (6.54e-2)"	"unprognostic (6.56e-2)"	"unprognostic (3.06e-2)"	"unprognostic (8.01e-3)"	"unprognostic (4.98e-2)"	"unprognostic (1.23e-2)"	"prognostic unfavourable (1.79e-5)"	187.8	23.1	14.1	23.7	21.4	26.6	186.2	7.3	20.0	81.9	69.6	53.7	48.0	22.3	88.1	64.7	99.6	57.8	59.6	235.1	17.6	11.9	14.8	3.9	30.6	12.9	42.8	16.5	40.8	20.4	7.4	25.7	17.5	33.4	74.0	29.0	83.0	44.8	63.2	48.1	55.6	32.7	154.8	33.4	12.4	45.0	32.5	29.9	5.6	67.7	46.4	20.9	113.5	109.0	2.2	43.3	133.9	15.2	24.4	0.4	11.8	5.8	8.0	5.9	16.9	167.4	55.1	3.8	19.5	43.1	4.7	9.5	8.1	17.5	0.4	5.3	25.7	66.5	0.4	13.4	2.7	1.0	1.0	4.7	7.4	18.4	4.6	1.0	22.9	20.5	12.8	7.8	4.9	17.0	1.4	0.6	21.0	10.5	0.0	34.3	2.0	6.2	1.1	2.0	0.5	22.2	9.0	0.9	1.5	8.8	9.5	25.6	37.7	20.9	30.9	13.7	4.8	1.2	1.9	0.2	0.2	0.4	15.2	2.3	37.7	30.2	15.2	133.9	0.2	10.2	0.1	2.2	0.1	0.1	43.3	0.6	0.0	0.0	37.0	24.4	2.6	28.7	0.4	11.8	14.1	21.4	7.3	20.0	17.6	11.9	42.8	16.5	33.4	29.9
GSR		ENSG00000104687	"Glutathione-disulfide reductase"	P00390	8	30678061-30727999	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001538, CAB008632"	Approved		Supported	"Plasma membrane,Cytosol"		110000000	110000000	Cytosol	"Plasma membrane"	"CAB008632: AB_1616690, HPA001538: AB_1078986"	"unprognostic (1.23e-1)"	"prognostic favourable (3.37e-4)"	"prognostic favourable (4.08e-5)"	"unprognostic (2.89e-3)"	"unprognostic (1.62e-1)"	"unprognostic (3.50e-1)"	"prognostic unfavourable (3.26e-5)"	"unprognostic (3.61e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.15e-2)"	"unprognostic (2.83e-2)"	"unprognostic (6.92e-3)"	"prognostic favourable (1.80e-4)"	"unprognostic (2.31e-3)"	"unprognostic (2.26e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.29e-1)"	8.9	14.4	6.8	10.7	9.1	7.9	6.2	9.1	11.8	18.6	18.7	7.1	18.4	20.4	13.2	12.0	19.4	8.8	17.3	11.9	5.0	5.7	27.9	17.8	10.8	9.7	4.9	6.0	11.8	17.6	22.9	7.2	8.9	6.8	16.4	17.2	10.9	12.0	17.4	14.7	6.5	31.8	9.3	4.5	13.6	17.7	7.9	4.2	17.0	9.2	11.8	12.0	23.9	14.5	2.5	4.7	19.0	5.7	2.6	7.3	2.1	12.0	51.0	8.3	6.4	8.9	10.0	8.0	5.4	11.8	7.7	10.3	15.0	6.4	23.6	26.7	6.9	13.6	12.5	11.7	8.4	6.1	11.6	23.7	17.6	50.1	24.0	7.2	38.3	16.6	7.4	11.5	4.6	10.9	19.6	10.5	17.3	11.0	25.5	8.5	14.7	9.1	9.8	9.5	11.4	15.2	30.6	6.3	8.1	7.4	17.3	12.9	7.5	8.2	14.7	3.2	8.9	7.6	8.0	5.8	6.4	15.1	10.2	10.2	10.5	19.0	4.6	11.5	4.2	4.2	7.3	2.5	3.8	4.6	4.7	2.0	2.4	3.1	6.5	2.6	5.7	2.9	3.2	2.1	6.8	9.1	9.1	11.8	5.0	5.7	4.9	6.0	6.8	4.2
GSTM1	"GST1, H-B, MU"	ENSG00000134184	"Glutathione S-transferase mu 1"	P09488	1	109687814-109709039	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 163.2;seminal vesicle: 101.4"	"Cell line enhanced"	"Detected in some"		"HEL: 26.6;HeLa: 31.8;HHSteC: 25.4;hTEC/SVTERT24-B: 23.0;HUVEC TERT2: 19.5;MOLT-4: 34.3"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 63.1"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB022669, CAB047357, HPA048652, HPA055972, HPA055973"	Approved		Approved	Cytosol				Cytosol		"CAB022669: , CAB047357: , HPA048652: , HPA055972: , HPA055973: "	"unprognostic (2.22e-2)"	"unprognostic (5.35e-2)"	"unprognostic (3.87e-3)"	"unprognostic (3.20e-1)"	"unprognostic (4.95e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.56e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.41e-1)"	"unprognostic (6.55e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.45e-1)"	"unprognostic (3.17e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.18e-1)"	"unprognostic (4.72e-3)"	14.5	25.4	15.2	6.9	15.6	2.9	8.2	5.6	19.2	22.0	7.8	16.9	0.0	7.7	9.8	20.2	22.5	13.8	8.2	6.4	14.4	6.8	14.1	163.2	7.7	1.0	7.8	32.1	29.0	18.2	41.4	5.3	2.9	8.2	38.1	6.6	25.7	11.8	101.4	25.1	18.8	17.7	18.2	6.8	21.7	7.5	15.1	11.2	10.9	7.6	1.6	14.5	30.8	19.5	14.6	34.9	14.1	18.9	13.3	17.3	10.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.2	2.2	8.2	0.0	12.7	0.4	0.0	0.1	0.2	0.0	0.1	26.6	31.8	0.5	25.4	0.0	0.2	0.0	0.0	23.0	0.1	19.5	0.0	17.8	0.7	0.0	34.3	0.2	17.1	0.0	0.1	0.1	3.3	2.8	0.0	1.6	0.2	0.0	0.1	0.1	0.3	14.0	0.0	11.4	0.6	0.2	0.0	14.3	18.8	1.1	9.8	0.3	0.6	0.7	12.2	14.1	14.8	18.9	15.7	14.6	15.8	13.7	34.9	14.6	16.5	15.6	1.0	13.3	7.4	19.2	17.3	10.0	15.2	15.6	5.6	19.2	14.4	6.8	7.8	32.1	8.2	11.2
GSTM3	GST5	ENSG00000134202	"Glutathione S-transferase mu 3"	P21266	1	109733932-109741038	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 115.3;testis: 96.0"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 44.8;T-47d: 94.8;WM-115: 36.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 11.1"	"Group enriched"	"Detected in many"	7	"granulocytes: 4.1;T-cells: 11.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB017130, HPA035190, CAB040583, HPA055972"	Enhanced		Supported	Cytosol		560000	560000	Cytosol		"CAB017130: , CAB040583: , HPA035190: AB_10795023, HPA055972: "	"unprognostic (2.13e-2)"	"unprognostic (2.76e-2)"	"unprognostic (1.95e-1)"	"unprognostic (5.87e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.28e-2)"	"unprognostic (3.28e-3)"	"unprognostic (1.98e-1)"	"prognostic unfavourable (1.89e-4)"	"unprognostic (3.45e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.30e-1)"	"unprognostic (6.16e-3)"	"unprognostic (1.38e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.90e-2)"	"unprognostic (3.48e-2)"	7.5	11.3	21.4	2.9	27.8	0.9	23.1	8.5	18.4	15.4	11.7	9.9	51.0	12.6	9.0	67.2	11.1	8.8	12.3	27.6	14.0	14.4	54.0	5.3	5.2	2.4	9.6	22.0	32.3	26.5	7.3	9.4	5.8	30.7	13.6	5.6	13.4	4.5	115.3	15.5	15.0	7.5	15.9	13.3	3.3	14.2	96.0	6.4	0.1	15.8	15.6	3.3	17.4	12.0	0.6	0.8	4.1	0.3	1.0	11.1	1.4	0.0	1.3	9.7	0.0	13.2	8.1	1.6	10.5	1.8	11.5	11.2	4.2	0.3	0.0	6.1	5.3	0.5	1.9	4.3	16.0	0.0	2.9	9.8	31.8	6.3	14.1	0.0	22.8	8.1	5.3	17.3	0.0	14.2	0.8	0.1	5.1	5.7	2.6	0.2	1.0	18.2	0.0	6.2	0.4	3.2	22.5	17.1	9.2	21.9	44.8	2.0	94.8	14.3	11.1	0.1	4.2	11.8	6.9	1.5	2.4	0.0	0.1	0.0	36.8	0.8	0.3	4.1	4.2	0.1	1.2	0.6	5.3	3.1	0.1	0.6	11.1	5.5	2.0	1.0	0.2	0.8	2.3	1.4	21.4	27.8	8.5	18.4	14.0	14.4	9.6	22.0	30.7	6.4
GSTP1	"FAEES3, GST3, GSTP"	ENSG00000084207	"Glutathione S-transferase pi 1"	P09211	11	67583595-67586656	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 298.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA019779, HPA019869"	Enhanced		Supported	Mitochondria,Cytosol		120000000	120000000	"Mitochondria, Cytosol"		"HPA019779: AB_1849799, HPA019869: AB_1849801"	"unprognostic (9.81e-2)"	"unprognostic (6.52e-2)"	"unprognostic (7.24e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.30e-3)"	"unprognostic (3.27e-1)"	"unprognostic (4.98e-2)"	"unprognostic (1.28e-1)"	"unprognostic (5.16e-3)"	"unprognostic (2.14e-3)"	"unprognostic (9.37e-2)"	"unprognostic (5.72e-2)"	"unprognostic (7.78e-2)"	"unprognostic (2.23e-1)"	"unprognostic (6.72e-3)"	"unprognostic (1.48e-1)"	24.2	25.3	20.2	23.8	21.7	46.2	39.5	15.5	19.8	51.8	51.9	23.5	125.4	35.2	43.5	41.9	181.6	60.8	51.1	45.3	18.3	23.5	44.2	5.9	61.0	39.4	25.5	19.9	33.4	60.7	44.1	33.8	57.9	46.0	37.0	17.9	59.9	50.2	110.8	33.7	58.5	34.0	30.1	22.8	25.1	48.5	15.4	15.4	29.8	91.6	131.5	75.6	40.8	79.5	25.3	191.4	12.4	168.2	70.1	40.7	167.2	68.1	93.0	45.3	70.5	35.1	39.6	41.9	29.8	40.0	45.6	35.5	170.8	71.7	0.1	68.4	47.1	99.7	122.4	131.2	12.9	47.5	44.5	3.3	67.7	0.0	52.1	22.4	39.9	49.1	298.4	36.3	35.1	68.3	73.9	19.0	35.6	0.2	51.3	62.5	86.7	39.9	47.9	7.6	0.2	72.5	0.2	15.4	44.0	41.8	13.6	135.0	0.2	37.7	36.8	21.0	53.4	44.0	21.6	11.8	73.8	25.0	23.9	37.1	43.6	2.3	168.2	12.4	40.7	125.7	15.0	25.3	18.4	33.3	191.4	24.3	15.3	27.3	7.0	70.1	79.4	76.2	18.3	167.2	20.2	21.7	15.5	19.8	18.3	23.5	25.5	19.9	46.0	15.4
GTF2H1	"BTF2, P62, TFIIH"	ENSG00000110768	"General transcription factor IIH subunit 1"	P32780	11	18322295-18367044	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004637, HPA046660"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB004637: AB_425470, HPA046660: "	"unprognostic (2.25e-1)"	"unprognostic (2.33e-1)"	"unprognostic (9.78e-2)"	"unprognostic (2.38e-1)"	"unprognostic (2.63e-1)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (5.98e-9)"	"unprognostic (7.71e-2)"	"unprognostic (4.24e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.26e-2)"	"unprognostic (7.42e-3)"	"unprognostic (8.31e-2)"	"unprognostic (1.24e-1)"	"unprognostic (7.90e-2)"	"unprognostic (2.94e-1)"	27.1	26.4	24.1	18.2	28.8	10.5	33.0	32.6	35.7	21.5	21.6	19.3	24.1	18.0	23.5	23.1	26.2	18.6	22.9	21.4	24.1	20.4	25.9	25.0	19.1	23.7	19.6	22.2	27.2	24.3	27.1	32.4	24.3	27.4	22.5	20.9	21.2	25.8	26.0	20.8	32.4	21.7	20.6	21.1	23.4	20.5	38.5	23.3	22.7	29.3	21.7	25.7	22.9	22.2	12.0	11.8	20.3	12.1	15.9	13.9	8.8	12.2	11.4	9.5	13.6	21.9	17.5	12.0	18.4	19.8	16.3	18.9	11.8	4.8	20.5	7.4	18.9	17.1	15.6	16.8	21.2	9.0	15.5	13.3	11.6	11.9	31.3	25.5	14.5	19.7	20.2	10.1	32.1	14.4	20.4	10.9	23.5	11.4	12.8	20.3	8.4	16.4	13.2	20.3	9.5	13.4	16.9	11.0	11.8	15.2	14.7	22.7	7.7	15.0	10.6	22.1	10.7	39.5	14.9	5.6	13.2	15.1	19.1	20.0	21.0	20.3	10.9	11.3	9.1	11.0	9.8	11.7	11.5	10.1	11.8	12.0	13.9	11.1	7.9	15.9	12.1	6.5	11.0	8.8	24.1	28.8	32.6	35.7	24.1	20.4	19.6	22.2	27.4	23.3
GUSB		ENSG00000169919	"Glucuronidase beta"	P08236	7	65960684-65982314	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Glycosidase, Hydrolase"	"Cancer-related genes, Disease mutation, Mucopolysaccharidosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 55.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036322, HPA036323"	Approved		Supported	Vesicles	"Intracellular and membrane"	48000	48000	Vesicles		"HPA036322: AB_10670796, HPA036323: "	"unprognostic (1.54e-2)"	"unprognostic (6.49e-2)"	"unprognostic (1.18e-2)"	"unprognostic (3.50e-1)"	"unprognostic (2.58e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.89e-1)"	"unprognostic (1.56e-3)"	"unprognostic (1.32e-1)"	"unprognostic (2.32e-1)"	"unprognostic (7.00e-3)"	"unprognostic (1.91e-1)"	"unprognostic (3.34e-2)"	"unprognostic (8.83e-3)"	"unprognostic (1.98e-1)"	"unprognostic (5.06e-1)"	"unprognostic (1.45e-1)"	23.5	12.0	3.7	7.9	5.5	20.7	25.4	5.7	4.4	10.4	14.6	7.7	22.0	10.0	10.4	12.2	9.3	7.6	11.1	8.0	3.7	2.9	11.8	50.4	15.3	12.3	6.3	3.1	8.6	17.1	9.0	7.3	30.0	4.5	12.1	11.4	9.9	17.2	11.8	5.9	10.0	16.1	8.3	3.9	17.5	11.0	7.9	5.8	14.7	17.7	5.9	13.0	9.2	7.4	9.7	27.7	22.1	36.0	15.2	11.5	15.8	16.8	6.5	6.4	14.3	21.9	13.1	9.3	5.3	14.9	11.8	10.9	9.3	17.4	7.7	8.4	6.8	6.9	4.1	6.4	7.0	7.2	8.4	10.5	9.8	6.4	10.7	22.4	17.5	9.0	6.9	6.8	8.9	10.2	15.9	55.9	7.6	12.2	8.2	24.1	4.3	5.5	8.5	14.8	43.7	7.4	10.2	9.4	8.3	14.3	33.6	18.7	18.7	22.4	7.2	14.4	13.1	5.4	13.3	31.8	38.1	13.0	10.8	29.9	17.5	7.4	28.1	22.1	11.5	36.0	10.3	9.7	9.0	10.2	27.7	7.8	6.2	7.3	4.5	15.2	30.0	11.3	11.3	15.8	3.7	5.5	5.7	4.4	3.7	2.9	6.3	3.1	4.5	5.8
H3F3A	"H3.3A, H3F3"	ENSG00000163041	"H3 histone family member 3A"	P84243	1	226061851-226072001	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 258.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 258.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 258.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011481, CAB037178, HPA042570"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB011481: AB_880446, CAB037178: AB_532248, HPA042570: "	"unprognostic (1.82e-1)"	"unprognostic (1.95e-2)"	"unprognostic (1.00e-1)"	"unprognostic (2.19e-3)"	"unprognostic (2.83e-2)"	"unprognostic (3.74e-1)"	"unprognostic (9.83e-3)"	"unprognostic (4.71e-2)"	"unprognostic (1.77e-3)"	"unprognostic (3.69e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.29e-1)"	"prognostic unfavourable (1.21e-6)"	"unprognostic (3.66e-2)"	"unprognostic (8.03e-3)"	"unprognostic (2.21e-3)"	"unprognostic (6.03e-2)"	39.0	43.4	37.2	83.4	33.4	126.8	67.9	45.0	42.8	44.6	54.0	31.6	62.9	47.9	43.4	60.6	66.3	42.4	49.6	59.4	36.1	31.2	45.9	59.2	73.2	217.9	37.8	23.2	44.4	79.7	30.8	34.8	59.1	29.2	38.4	59.4	42.7	49.0	49.7	37.0	47.1	50.0	42.0	48.6	71.9	41.4	87.6	31.7	148.9	38.5	71.0	84.1	43.5	47.6	39.2	44.6	258.7	56.9	23.6	34.9	60.5	53.7	30.7	119.8	67.6	33.3	38.8	90.0	25.5	31.0	41.4	32.8	32.0	89.7	51.8	56.8	31.3	51.6	59.2	46.5	40.8	32.0	102.3	64.0	45.5	42.8	33.0	65.7	77.8	35.5	53.9	29.0	38.2	61.3	90.1	88.6	47.1	31.1	136.4	122.3	162.5	60.9	92.4	87.5	133.4	85.8	57.5	117.0	174.0	72.8	92.1	63.1	104.4	154.2	34.5	30.2	42.1	40.7	73.9	39.5	50.5	90.4	28.8	62.8	64.5	40.0	56.9	80.8	23.1	44.9	23.6	39.2	25.0	24.9	44.6	36.0	23.7	25.7	258.7	23.6	50.8	36.6	34.9	60.5	37.2	33.4	45.0	42.8	36.1	31.2	37.8	23.2	29.2	31.7
H3F3B	H3.3B	ENSG00000132475	"H3 histone family member 3B"	P84243	17	75776434-75785893	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 570.8;bone marrow: 441.9"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 570.8"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 570.8"									"CAB037166, CAB037187, CAB037221, HPA042570"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB037166: AB_2115285, CAB037187: AB_477069, CAB037221: AB_477076, HPA042570: "	"unprognostic (1.66e-1)"	"unprognostic (8.42e-3)"	"unprognostic (3.42e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.43e-3)"	"unprognostic (3.37e-2)"	"unprognostic (1.64e-1)"	"unprognostic (5.88e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.26e-3)"	"unprognostic (9.20e-2)"	"unprognostic (4.81e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.99e-1)"	57.2	41.2	38.1	58.9	48.6	441.9	71.4	60.2	47.0	86.6	44.6	65.9	42.7	37.9	60.5	77.7	93.2	70.2	75.8	35.1	38.5	33.9	42.8	48.1	64.2	62.3	50.4	41.2	141.0	90.9	33.0	41.5	58.5	42.7	60.5	26.6	65.8	58.4	55.4	71.1	114.0	58.0	63.7	51.8	65.9	45.1	66.9	46.2	78.6	58.9	69.1	55.7	78.5	71.9	78.9	88.1	570.8	98.4	80.0	77.2	203.5	118.3	105.1	43.9	43.3	25.1	39.4	60.7	56.1	49.7	68.9	55.3	112.5	84.2	59.3	53.6	32.6	46.6	34.7	77.5	39.3	32.3	78.2	52.9	56.1	95.2	56.7	87.8	68.1	42.9	48.0	70.6	91.1	51.7	74.8	106.6	35.4	174.1	126.0	73.7	35.2	117.5	93.8	80.4	64.6	54.4	70.3	89.1	99.0	56.9	83.5	120.3	65.4	94.8	48.2	123.7	109.4	53.3	148.4	129.0	76.3	71.2	65.4	83.8	67.4	182.8	98.4	259.3	74.4	86.9	70.2	78.9	71.8	70.5	86.7	65.3	77.2	64.5	570.8	80.0	78.9	88.1	76.0	203.5	38.1	48.6	60.2	47.0	38.5	33.9	50.4	41.2	42.7	46.2
H3F3C	H3.5	ENSG00000188375	"H3 histone family member 3C"	Q6NXT2	12	31791185-31792241	"Cancer-related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 34.7;testis: 23.5"	"Cell line enhanced"	"Detected in many"		"SH-SY5Y: 5.5"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in all"		"neutrophil: 34.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 34.7"									HPA042570	Approved									"HPA042570: "	"unprognostic (2.82e-1)"	"unprognostic (2.80e-4)"	"unprognostic (2.60e-2)"	"unprognostic (9.21e-2)"	"unprognostic (3.77e-2)"	"unprognostic (2.89e-2)"	"unprognostic (2.92e-1)"	"unprognostic (1.45e-1)"	"unprognostic (7.56e-2)"	"unprognostic (2.39e-1)"	"unprognostic (4.06e-2)"	"unprognostic (3.53e-2)"	"unprognostic (2.73e-3)"	"unprognostic (4.02e-2)"	"unprognostic (2.99e-2)"	"unprognostic (2.80e-2)"	"unprognostic (3.86e-2)"	1.8	0.5	0.5	2.1	0.9	4.2	1.6	0.6	0.6	2.0	0.8	0.6	1.3	0.9	1.8	1.7	1.9	0.8	0.8	0.5	1.1	0.5	0.5	1.1	1.0	0.7	0.6	0.9	3.1	1.0	0.5	0.6	0.7	0.6	1.5	0.3	1.5	1.7	1.4	0.6	1.3	1.2	1.7	0.6	1.9	1.0	23.5	0.9	0.9	1.0	3.3	1.1	1.7	0.8	6.7	6.1	34.7	7.0	6.7	6.1	14.9	3.6	0.7	1.6	0.7	0.4	0.0	1.4	0.5	0.2	0.9	0.4	1.1	1.5	0.5	1.4	0.0	1.2	0.1	0.1	0.2	1.1	0.0	0.1	0.9	0.5	0.0	1.0	1.3	0.2	0.1	0.0	1.2	0.1	0.4	1.6	0.0	0.1	2.7	3.6	0.7	0.2	1.7	0.8	2.4	0.2	0.6	2.9	5.5	0.1	2.1	4.0	1.2	3.5	0.3	2.0	3.5	1.4	4.5	2.7	1.0	1.4	1.7	1.7	1.7	13.8	6.7	18.9	5.1	7.0	4.5	6.7	5.3	5.0	6.1	5.2	5.6	5.3	34.7	6.7	6.1	5.9	6.1	14.9	0.5	0.9	0.6	0.5	1.1	0.5	0.6	0.9	0.6	0.9
HDAC10	DKFZP761B039	ENSG00000100429	"Histone deacetylase 10"	Q969S8	22	50245183-50251405	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Autophagy, DNA damage, DNA recombination, DNA repair"	Hydrolase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 18.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB045977	Supported									"CAB045977: AB_11124034"	"unprognostic (1.53e-1)"	"prognostic favourable (4.46e-4)"	"unprognostic (1.43e-2)"	"prognostic favourable (2.45e-5)"	"unprognostic (2.71e-2)"	"unprognostic (3.70e-2)"	"unprognostic (6.15e-3)"	"unprognostic (5.48e-2)"	"unprognostic (3.28e-1)"	"unprognostic (2.56e-2)"	"prognostic favourable (9.25e-4)"	"unprognostic (4.93e-2)"	"prognostic unfavourable (4.74e-11)"	"unprognostic (2.21e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.43e-2)"	"unprognostic (1.38e-3)"	8.9	9.3	10.1	14.7	10.3	16.9	6.8	10.9	8.8	8.6	13.9	4.7	14.6	12.9	7.7	13.5	10.2	7.9	13.1	4.0	8.4	6.1	11.4	15.1	8.2	12.5	4.9	8.8	7.8	15.0	6.4	13.2	7.0	6.1	10.2	3.7	8.8	18.6	12.9	9.2	12.1	14.2	7.1	4.4	17.1	14.2	2.4	4.7	16.1	9.3	7.6	19.2	8.2	7.7	1.1	3.1	5.4	4.2	1.1	1.9	2.5	4.1	2.3	0.6	3.4	3.0	2.3	7.6	2.7	2.4	1.6	0.9	4.3	4.5	2.7	3.9	2.1	6.9	1.4	4.1	0.3	3.4	3.9	5.8	6.1	7.2	5.2	6.8	18.9	4.9	3.0	1.5	0.9	2.9	4.0	4.1	1.4	12.8	3.8	17.0	1.4	5.1	9.1	2.2	16.7	2.5	7.0	1.8	4.5	2.8	1.0	4.8	7.8	11.0	4.7	2.7	3.9	4.6	1.6	5.1	1.7	2.3	4.4	4.3	2.1	0.8	4.0	5.4	1.9	4.2	1.6	1.0	0.9	1.2	3.1	1.1	0.8	1.0	2.0	1.1	2.3	2.7	1.6	2.5	10.1	10.3	10.9	8.8	8.4	6.1	4.9	8.8	6.1	4.7
HDAC2	"RPD3, YAF1"	ENSG00000196591	"Histone deacetylase 2"	Q92769	6	113933028-114011308	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005054, HPA011727"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB005054: AB_562295, HPA011727: AB_1850540"	"prognostic unfavourable (7.07e-4)"	"unprognostic (1.44e-1)"	"unprognostic (2.67e-1)"	"unprognostic (2.56e-2)"	"unprognostic (2.61e-2)"	"unprognostic (1.89e-2)"	"prognostic unfavourable (5.39e-10)"	"unprognostic (2.03e-1)"	"unprognostic (2.63e-2)"	"unprognostic (9.00e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.92e-1)"	"unprognostic (1.84e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.42e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.51e-1)"	25.8	33.8	25.8	30.1	31.3	34.9	58.7	32.8	36.5	32.1	30.7	25.6	32.2	22.0	38.7	36.7	36.3	32.7	23.3	27.6	26.5	26.9	31.6	22.2	29.9	41.5	29.6	26.5	39.2	31.5	31.7	45.1	38.1	27.9	32.1	36.1	17.5	29.3	39.0	33.9	30.8	26.1	36.1	31.1	30.7	29.9	47.4	27.4	64.0	35.1	31.3	32.5	33.1	47.3	27.0	35.7	28.2	32.6	26.3	32.6	24.3	24.2	16.7	78.2	44.9	20.2	23.0	32.8	28.9	23.7	34.2	41.0	44.3	17.9	20.0	24.2	26.0	19.1	53.0	29.3	57.6	28.5	36.6	48.2	21.7	25.6	26.9	48.9	21.8	18.6	19.7	36.4	34.2	39.8	62.0	20.4	56.5	20.3	43.8	44.3	44.2	23.1	29.8	39.0	18.4	35.3	29.3	52.3	44.4	22.9	21.6	24.1	15.7	57.1	32.1	21.8	25.1	22.8	47.9	16.2	21.3	47.9	18.5	47.2	36.9	23.1	27.6	28.2	21.1	26.6	28.1	27.0	25.9	22.7	35.7	22.3	32.6	29.7	16.3	26.3	32.6	30.9	24.5	24.3	25.8	31.3	32.8	36.5	26.5	26.9	29.6	26.5	27.9	27.4
HDAC5	"FLJ90614, KIAA0600, NY-CO-9"	ENSG00000108840	"Histone deacetylase 5"	Q9UQL6	17	44076746-44123702	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019400, HPA030991"	Approved		Supported	"Nuclear speckles,Golgi apparatus,Cytosol"				"Nuclear speckles"	"Golgi apparatus, Cytosol"	"CAB019400: AB_2116626, HPA030991: AB_10795286"	"unprognostic (1.30e-2)"	"prognostic favourable (6.14e-4)"	"unprognostic (6.65e-2)"	"unprognostic (8.06e-2)"	"unprognostic (3.49e-1)"	"unprognostic (3.52e-2)"	"prognostic unfavourable (3.12e-5)"	"unprognostic (8.80e-3)"	"unprognostic (3.80e-2)"	"unprognostic (2.37e-2)"	"unprognostic (4.91e-3)"	"unprognostic (4.30e-1)"	"prognostic favourable (3.30e-5)"	"unprognostic (1.51e-2)"	"unprognostic (3.11e-1)"	"unprognostic (6.00e-2)"	"unprognostic (1.76e-2)"	15.6	17.6	24.9	7.9	15.8	13.2	18.1	35.9	25.8	16.5	8.8	19.6	9.5	8.4	15.0	11.9	20.1	16.9	11.3	24.4	22.1	24.2	8.6	6.3	13.6	8.8	24.7	22.1	24.5	16.1	28.2	17.5	23.0	19.3	13.6	5.5	11.7	14.2	11.9	42.6	34.0	9.7	12.4	20.5	13.8	9.3	10.3	18.1	7.6	15.0	9.8	8.2	14.9	20.4	7.6	9.4	17.9	13.6	3.5	4.9	5.0	3.5	2.3	6.4	1.5	12.4	9.7	23.1	9.6	24.0	4.8	7.9	5.1	3.8	5.6	3.9	22.8	2.9	7.5	4.1	2.0	8.7	12.2	10.9	7.7	11.7	5.3	3.5	15.4	13.7	7.1	5.5	6.9	3.9	8.1	11.4	27.8	2.7	5.8	10.7	7.0	5.5	22.5	17.9	14.4	0.5	1.6	16.7	8.8	2.8	11.8	13.0	16.8	20.7	2.1	12.1	7.8	2.8	4.8	18.8	15.7	6.7	7.0	4.4	5.7	7.1	7.3	7.7	4.9	11.6	3.5	6.6	3.9	4.9	9.4	7.6	4.1	3.5	17.9	3.5	13.6	8.3	3.5	5.0	24.9	15.8	35.9	25.8	22.1	24.2	24.7	22.1	19.3	18.1
HERPUD1	"HERP, KIAA0025, Mif1, SUP"	ENSG00000051108	"Homocysteine inducible ER protein with ubiquitin like domain 1"	Q15011	16	56932048-56944863	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Unfolded protein response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HHSteC: 61.2;RPMI-8226: 76.8;U-266/70: 87.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037041, CAB037104, HPA040754, HPA041219"	Approved		Uncertain	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB037041: AB_1840910, CAB037104: AB_1840912, HPA040754: AB_10794068, HPA041219: AB_10794268"	"unprognostic (1.92e-1)"	"unprognostic (3.47e-1)"	"unprognostic (8.64e-2)"	"unprognostic (3.93e-3)"	"unprognostic (3.39e-1)"	"unprognostic (5.00e-3)"	"unprognostic (1.17e-1)"	"unprognostic (9.69e-3)"	"unprognostic (3.33e-1)"	"unprognostic (2.56e-1)"	"unprognostic (2.84e-1)"	"unprognostic (3.50e-1)"	"prognostic favourable (1.41e-9)"	"unprognostic (1.06e-1)"	"unprognostic (3.93e-2)"	"unprognostic (2.19e-2)"	"unprognostic (2.27e-3)"	22.7	38.8	16.2	35.6	20.7	21.6	39.4	17.7	20.0	30.1	32.1	20.0	48.8	21.4	21.6	51.6	15.0	20.2	32.5	28.8	15.8	15.5	42.9	57.7	30.4	40.0	25.6	12.5	44.8	148.6	37.6	26.7	26.2	25.6	49.5	32.3	35.3	108.6	76.1	34.6	18.3	24.7	17.6	24.2	38.3	37.2	10.6	20.8	9.6	64.2	20.4	53.8	24.4	25.9	50.8	121.9	29.0	39.5	22.4	33.4	46.5	4.4	4.9	4.8	10.0	11.2	14.6	17.2	10.6	16.9	13.7	10.7	6.8	10.2	18.1	13.6	10.2	7.7	8.2	3.7	13.6	10.4	4.9	1.5	8.2	24.5	61.2	3.2	8.1	17.7	35.8	6.2	19.7	10.4	2.4	25.9	38.2	3.7	6.1	6.7	3.1	11.1	4.2	12.2	76.8	29.4	5.0	5.3	6.1	9.2	45.4	46.9	5.0	12.2	6.3	5.7	5.7	5.0	4.2	87.6	28.5	28.3	8.1	4.5	7.4	23.9	39.5	18.0	16.1	31.0	17.4	50.8	17.5	21.1	30.6	37.8	11.4	17.4	29.0	22.4	21.5	121.9	33.4	46.5	16.2	20.7	17.7	20.0	15.8	15.5	25.6	12.5	25.6	20.8
HEY1	"bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1"	ENSG00000164683	"Hes related family bHLH transcription factor with YRPW motif 1"	Q9Y5J3	8	79764010-79767863	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Notch signaling pathway, Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 60.6"	"Cell line enhanced"	"Detected in many"		"HEK 293: 48.4;PC-3: 11.0;SK-MEL-30: 33.1;WM-115: 11.3"	"Cancer enhanced"	"Detected in all"		"glioma: 43.1"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	6	"neutrophil: 9.9"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 9.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055599, HPA063472"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Cytosol"				"Nucleoplasm, Cytosol"	"Nuclear membrane"	"HPA055599: AB_2682858, HPA063472: "	"unprognostic (1.15e-1)"	"unprognostic (5.06e-2)"	"unprognostic (5.13e-3)"	"unprognostic (2.12e-1)"	"unprognostic (1.86e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.21e-3)"	"unprognostic (9.56e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.22e-2)"	"unprognostic (1.25e-2)"	"unprognostic (6.71e-3)"	"unprognostic (5.92e-3)"	"unprognostic (5.77e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.74e-2)"	"unprognostic (1.00e-1)"	13.3	3.8	13.7	3.6	22.9	1.8	8.8	11.2	60.6	8.9	4.4	10.7	0.0	3.3	3.8	2.4	4.6	3.9	5.7	13.4	11.3	11.6	3.8	2.9	16.4	3.3	11.9	9.3	2.6	4.3	3.0	9.9	20.3	12.5	4.5	3.9	10.3	4.5	3.0	10.3	3.5	3.2	4.4	9.1	2.8	3.6	3.9	10.5	1.3	5.0	3.7	3.7	5.2	2.5	0.0	0.0	9.9	1.7	0.0	0.3	0.1	0.6	0.0	0.4	3.4	0.3	0.2	8.8	0.8	0.8	0.1	0.1	0.1	0.0	1.6	0.8	0.3	2.2	1.8	0.1	0.2	0.1	48.4	0.0	1.5	0.8	0.5	0.0	0.3	0.4	1.4	0.0	6.1	1.6	3.1	1.4	0.5	0.1	0.0	0.2	0.1	11.0	0.0	1.8	1.4	0.1	1.5	2.0	5.6	0.0	1.0	33.1	0.0	0.0	1.1	0.2	0.9	0.0	0.6	1.2	0.2	0.0	1.2	0.0	11.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	9.9	0.0	1.7	0.0	0.0	0.1	13.7	22.9	11.2	12.3	11.3	11.6	11.9	9.3	12.5	10.5
HGF	"DFNB39, F-TCF, HGFB, HPTA, SF"	ENSG00000019991	"Hepatocyte growth factor"	P14210	7	81699008-81770438	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Serine protease homolog"	"Cancer-related genes, Deafness, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 116.9"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 44.8;HHSteC: 35.1;HL-60: 19.6;hTEC/SVTERT24-B: 22.0;Karpas-707: 60.7;U-87 MG: 16.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	4	"basophil: 33.5"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 33.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB010333, HPA040360, HPA044088"	Approved		Approved	Centrosome,Cytosol	"Secreted to blood"			Cytosol	Centrosome	"CAB010333: AB_647965, HPA040360: , HPA044088: "	"unprognostic (5.24e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.72e-2)"	"unprognostic (5.12e-2)"	"unprognostic (1.85e-2)"	"unprognostic (7.45e-5)"	"unprognostic (1.66e-1)"	"unprognostic (9.28e-3)"	"unprognostic (3.28e-2)"	"unprognostic (2.97e-2)"	"unprognostic (2.74e-1)"	"unprognostic (5.29e-2)"	"prognostic unfavourable (5.59e-4)"	"unprognostic (7.90e-3)"	"unprognostic (2.92e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.06e-2)"	6.2	10.6	1.4	2.9	1.2	4.6	4.8	0.5	4.5	5.1	4.0	0.4	2.9	1.5	5.2	3.1	2.9	4.0	7.1	9.3	3.6	1.3	7.3	27.5	15.8	2.0	1.3	1.4	3.2	1.4	1.6	4.3	116.9	1.9	10.8	1.9	2.0	2.2	3.2	1.4	0.9	1.8	15.1	6.0	6.6	2.3	2.0	0.9	0.5	5.3	1.4	1.4	10.5	21.5	0.0	2.0	33.5	7.6	0.0	0.0	1.5	0.0	0.0	0.0	0.0	5.5	44.8	0.0	0.1	8.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	35.1	19.6	0.1	10.6	0.0	22.0	0.0	0.5	0.0	60.7	0.1	0.0	0.0	13.6	0.0	0.0	0.2	0.0	1.8	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.8	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	16.1	4.1	0.0	33.5	6.6	1.6	0.0	7.6	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	1.3	0.0	6.7	0.4	0.0	1.5	1.4	1.2	0.5	4.5	3.6	1.3	1.3	1.4	1.9	0.9
HGFAC	"HGFA, HGFAP"	ENSG00000109758	"HGF activator"	Q04756	4	3441887-3449495	"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	141	"liver: 128.0"	"Cell line enriched"	"Detected in some"	8	"Hep G2: 10.7"	"Cancer enriched"	"Detected in some"	22	"liver cancer: 26.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA058279, HPA059076"	Enhanced				"Secreted to blood"	11000000000	11000000000			"HPA058279: AB_2683665, HPA059076: AB_2683898"	"unprognostic (2.70e-2)"	"unprognostic (8.20e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.86e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.39e-2)"	"unprognostic (2.85e-3)"	"unprognostic (5.37e-3)"	"unprognostic (5.90e-2)"	"unprognostic (1.81e-1)"	"unprognostic (8.54e-3)"	"unprognostic (5.52e-2)"	"prognostic unfavourable (9.31e-4)"	"unprognostic (2.87e-1)"	"unprognostic (2.24e-1)"	"unprognostic (9.49e-2)"	"unprognostic (3.74e-4)"	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.1	128.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	10.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.2	1.2	0.7	0.4	0.1	0.0	0.0	0.6	1.1	0.0	0.0	0.3	0.1	0.0	0.0	0.5	0.7	0.0	0.1	0.3	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.4	0.1	0.1	0.0	0.0	0.0	0.1	0.0
HIF1A	"bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8"	ENSG00000100644	"Hypoxia inducible factor 1 alpha subunit"	Q16665	14	61695513-61748259	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"LHCN-M2: 117.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 47.8"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 47.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000907, HPA001275, CAB017442"	Supported		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane"				"Nucleoplasm, Nuclear bodies"	"Plasma membrane"	"CAB017442: AB_10621732, HPA000907: , HPA001275: AB_1079057"	"unprognostic (1.07e-2)"	"unprognostic (1.13e-3)"	"unprognostic (9.41e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.90e-1)"	"unprognostic (2.94e-3)"	"unprognostic (3.40e-1)"	"unprognostic (4.05e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.77e-2)"	"unprognostic (8.39e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.23e-2)"	"unprognostic (3.58e-1)"	"unprognostic (7.35e-2)"	"unprognostic (3.88e-2)"	31.9	62.0	15.6	45.2	17.8	125.2	24.9	22.7	18.5	45.7	15.3	12.3	23.5	10.8	17.7	31.3	31.2	21.7	50.0	19.4	17.5	16.5	76.4	42.7	42.8	27.3	18.3	11.0	34.5	12.7	13.7	26.8	24.2	25.1	17.6	13.9	14.0	24.6	36.2	8.0	17.4	16.9	18.7	27.2	57.3	16.0	21.1	12.4	24.7	26.9	18.4	28.8	37.8	21.5	6.6	6.0	47.8	6.8	6.2	7.9	5.1	37.6	15.0	15.1	43.2	24.0	38.7	20.5	31.3	37.8	39.5	35.6	6.5	12.5	9.2	23.6	38.7	8.9	9.7	51.5	49.4	4.0	5.0	5.6	13.8	11.2	53.6	2.3	6.2	67.6	16.3	28.9	31.0	24.8	3.8	0.0	117.8	7.8	7.3	2.9	13.6	19.8	0.5	34.0	2.7	50.9	25.1	12.7	14.1	58.8	8.4	20.7	8.8	4.5	14.7	89.7	20.1	29.7	26.3	4.9	7.2	10.4	47.3	4.7	24.2	11.2	6.8	47.8	3.8	5.5	4.9	6.5	5.0	4.4	6.0	6.6	7.9	5.1	18.2	6.2	5.6	2.9	3.4	5.1	15.6	17.8	22.7	13.2	17.5	16.5	18.3	11.0	25.1	12.4
HIP1	ILWEQ	ENSG00000127946	"Huntingtin interacting protein 1"	O00291	7	75533300-75738962	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation"	"Actin-binding, Activator"	"Cancer-related genes, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 27.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013606, CAB015334, CAB016402, HPA017964"	Enhanced		Enhanced	Vesicles				Vesicles		"CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719"	"unprognostic (8.23e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.20e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.59e-1)"	"unprognostic (2.73e-3)"	"unprognostic (1.03e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.02e-2)"	"unprognostic (2.70e-2)"	"unprognostic (7.98e-2)"	"unprognostic (1.73e-3)"	"unprognostic (9.67e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.00e-2)"	"unprognostic (1.09e-1)"	16.5	8.7	14.6	7.2	25.9	5.1	13.5	13.2	20.8	13.2	5.3	34.4	4.9	2.9	13.4	10.1	5.7	13.8	8.7	9.2	17.5	11.9	14.6	9.6	17.7	4.6	27.2	11.8	8.1	4.0	4.9	3.6	20.0	16.1	6.8	4.5	9.9	4.0	12.4	3.9	10.8	4.6	12.6	24.8	10.8	4.6	18.5	29.7	1.6	15.8	5.7	4.6	9.7	8.8	0.5	4.0	8.8	1.1	3.3	1.5	0.3	2.5	27.3	18.6	17.5	7.9	10.7	5.6	4.8	3.1	3.1	2.3	1.5	2.4	1.8	5.6	11.8	3.1	18.8	3.9	4.2	1.5	3.5	1.4	3.2	2.5	7.8	0.4	7.4	8.2	2.4	10.2	2.1	13.0	1.9	1.8	5.0	10.4	1.2	10.6	20.2	3.3	2.1	7.8	0.1	2.4	9.7	0.9	8.2	4.4	2.8	6.3	17.2	6.7	4.6	9.2	7.1	3.1	6.6	2.0	0.2	4.4	9.2	3.9	6.2	8.8	1.1	7.6	1.1	1.1	1.0	0.4	0.2	0.9	1.6	0.5	0.1	0.7	7.7	3.3	0.8	4.0	1.5	0.3	14.6	25.9	13.2	16.9	17.5	11.9	27.2	11.8	16.1	29.7
HIP1R	"FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655"	ENSG00000130787	"Huntingtin interacting protein 1 related"	O75146	12	122834453-122862960	"Cancer-related genes, Predicted intracellular proteins"	Endocytosis	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 9.5;naive B-cell: 12.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017187, HPA038135, HPA038136"	Enhanced		Supported	"Vesicles,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Vesicles	"CAB017187: , HPA038135: AB_2675851, HPA038136: AB_2675852"	"unprognostic (4.52e-1)"	"unprognostic (6.39e-2)"	"unprognostic (7.07e-2)"	"unprognostic (6.55e-3)"	"unprognostic (8.67e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.02e-2)"	"unprognostic (8.11e-2)"	"unprognostic (6.37e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.39e-2)"	"unprognostic (6.72e-2)"	"prognostic favourable (6.50e-7)"	"unprognostic (2.18e-2)"	"unprognostic (2.84e-1)"	"unprognostic (2.54e-3)"	"prognostic favourable (7.26e-4)"	9.8	14.5	24.6	13.2	26.5	11.6	8.0	11.5	31.6	4.6	11.6	40.5	19.7	29.2	4.0	9.1	7.0	4.0	7.8	10.8	29.5	21.7	16.2	9.0	6.3	15.3	31.4	20.6	3.2	27.7	7.4	15.6	5.2	18.0	8.6	5.4	2.9	52.0	24.1	5.7	26.5	21.3	3.0	27.4	11.1	30.4	4.0	30.6	8.1	8.1	5.9	12.6	7.4	6.5	12.3	0.0	2.7	0.0	0.6	3.2	1.6	17.3	5.0	3.8	15.6	1.1	3.0	18.7	2.7	4.5	2.8	2.2	7.7	5.2	16.5	9.2	2.0	15.0	4.6	10.0	0.2	2.6	6.6	0.3	5.7	8.1	3.5	1.3	11.8	1.8	7.1	3.8	6.4	19.3	4.3	0.9	1.6	24.9	7.8	4.0	3.5	6.0	4.1	4.8	5.7	9.4	21.0	3.8	8.5	3.2	8.5	4.5	17.4	0.7	15.2	1.8	13.4	5.5	2.6	11.9	6.3	9.8	2.9	2.8	1.5	0.0	0.0	2.7	2.9	0.0	1.7	9.5	1.8	2.2	0.0	12.3	3.2	2.0	0.2	0.6	0.0	0.0	0.4	1.6	24.6	26.5	11.5	19.8	29.5	21.7	31.4	20.6	18.0	30.6
HIST1H1E	"H1.4, H1e, H1F4, H1s-4"	ENSG00000168298	"Histone cluster 1 H1 family member e"	P10412	6	26156354-26157107	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"blood: 56.4;bone marrow: 102.3;lymphoid tissue: 123.9"	"Cell line enhanced"	"Detected in many"		"RPMI-8226: 9.7;U-266/70: 11.8;U-266/84: 13.2;U-87 MG: 12.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB011506, HPA055907"	Supported		Supported	"Nuclear speckles"				"Nuclear speckles"		"CAB011506: AB_470256, HPA055907: "	"unprognostic (6.96e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.06e-2)"	"unprognostic (1.86e-1)"	"unprognostic (9.62e-2)"	"unprognostic (1.04e-2)"	"unprognostic (5.78e-3)"	"unprognostic (2.31e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.37e-1)"	"unprognostic (7.72e-13)"	"unprognostic (4.54e-3)"	"unprognostic (3.46e-2)"	"unprognostic (1.30e-3)"	"unprognostic (2.18e-2)"	6.7	3.6	3.1	14.3	3.5	102.3	10.3	8.1	9.0	10.7	7.7	4.7	4.2	4.1	6.8	7.5	13.7	4.0	11.3	7.4	4.0	3.5	6.6	6.7	13.1	18.4	3.4	2.4	19.3	17.1	3.7	9.0	7.3	3.5	10.2	4.4	9.8	10.0	4.0	4.1	14.4	9.0	7.4	6.8	14.6	5.3	5.9	0.7	123.9	4.6	10.0	18.4	14.3	10.7	39.6	14.6	56.4	12.9	19.2	24.4	9.4	2.4	0.3	0.4	5.2	0.1	0.0	6.3	0.0	0.4	1.1	0.8	0.1	1.5	1.2	0.7	0.1	1.1	0.3	0.7	0.5	1.7	1.5	0.8	0.5	0.4	0.1	0.7	1.0	0.1	0.3	0.3	0.5	0.5	3.9	6.7	0.1	0.5	7.7	7.1	1.8	0.8	3.6	1.2	9.7	0.3	0.0	3.8	0.9	3.1	0.8	1.1	1.0	2.5	0.4	2.4	3.6	1.4	2.4	11.8	13.2	5.3	12.1	2.1	1.1	56.4	12.7	30.0	21.1	12.9	24.4	21.4	16.7	19.2	14.3	39.6	12.7	11.6	18.6	19.2	10.9	14.6	16.4	9.4	3.1	3.5	8.1	9.0	4.0	3.5	3.4	2.4	3.5	0.7
HIST1H2AC	H2AFL	ENSG00000180573	"Histone cluster 1 H2A family member c"	Q93077	6	26124145-26139116	"Cancer-related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in all"	4	"blood: 116.1;lymphoid tissue: 202.5"	"Cell line enhanced"	"Detected in many"		"HSkMC: 31.7;SiHa: 27.2;U-2 OS: 27.4;U-266/84: 27.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 116.1"	"Lineage enriched"	"Detected in all"	17	"granulocytes: 116.1"					"Low region specificity"	"Detected in all"			HPA041189	Supported									"HPA041189: "	"unprognostic (4.89e-2)"	"unprognostic (1.97e-1)"	"unprognostic (7.15e-3)"	"unprognostic (1.34e-1)"	"unprognostic (4.70e-1)"	"unprognostic (1.33e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.37e-1)"	"unprognostic (8.16e-2)"	"unprognostic (2.57e-1)"	"unprognostic (1.61e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.19e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.20e-1)"	"unprognostic (5.89e-3)"	13.6	14.5	13.6	22.5	16.4	19.0	29.9	7.3	9.8	35.6	21.0	12.2	17.9	18.1	13.2	32.8	27.5	23.6	13.9	12.6	18.5	12.4	21.4	34.1	29.2	28.5	18.6	8.5	23.8	15.7	3.7	13.4	26.2	8.5	37.2	15.0	21.1	10.4	17.0	17.5	15.4	21.6	14.4	27.0	26.4	26.9	16.3	10.4	202.5	24.5	9.2	34.9	29.6	25.8	6.6	4.5	116.1	3.6	1.9	2.1	48.3	5.6	1.6	1.9	0.6	16.2	8.9	0.8	2.8	1.8	8.6	7.4	2.1	1.4	0.2	14.0	5.6	6.7	1.6	2.9	6.2	5.3	0.9	0.9	0.7	0.3	12.8	0.9	6.5	31.7	5.0	1.8	5.6	0.5	14.0	10.3	3.8	4.6	0.9	1.0	2.3	0.5	0.6	1.0	16.5	8.2	0.6	3.0	1.2	27.2	5.8	8.8	13.2	1.4	1.9	5.3	27.4	2.3	1.2	13.4	27.2	1.5	1.9	14.2	2.2	36.0	2.0	24.4	1.4	1.5	1.2	3.3	1.5	1.0	1.4	6.6	2.1	1.1	116.1	1.9	3.6	4.5	2.0	48.3	13.6	16.4	7.3	9.8	18.5	12.4	18.6	8.5	8.5	10.4
HIST1H3B	"H3/l, H3FL"	ENSG00000274267	"Histone cluster 1 H3 family member b"	P68431	6	26031650-26032060	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	13	"lymphoid tissue: 343.5"	"Cell line enhanced"	"Detected in many"		"U-266/84: 11.9"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in some"		"T-reg: 1.4"	"Low lineage specificity"	"Detected in many"											HPA042570	Approved									"HPA042570: "	"unprognostic (2.82e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.59e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.34e-2)"	"unprognostic (2.31e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.08e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.31e-7)"	"unprognostic (8.52e-2)"	"unprognostic (2.78e-1)"		"unprognostic (1.90e-3)"	1.7	0.7	0.0	36.1	0.0	18.1	3.6	0.0	0.3	0.8	6.9	0.0	0.0	0.3	0.8	2.5	11.8	0.5	1.9	2.4	0.0		0.6	0.3	3.4	10.4	0.0	0.0	0.3	0.3	0.3	0.0	7.8	0.0	0.3	0.8	0.0	1.0	0.3	0.3	0.3	6.3	0.8	0.0	14.7	0.5	26.9	0.0	343.5	0.8	18.2	27.7	0.3	0.0	0.8	0.1	1.2	0.0	0.0	1.4	3.1	1.8	4.6	1.3	4.0	0.0	0.4	0.0	0.2	0.8	0.7	0.7	1.1	1.0	3.0	2.0	0.3	0.7	1.6	1.2	1.7	2.0	4.4	3.2	5.9	1.3	0.0	2.4	2.1	2.9	0.0	0.6	0.0	1.0	6.5	5.9	1.1	0.9	7.3	7.4	3.1	3.2	4.3	2.9	8.4	0.5	0.0	2.0	1.7	5.1	1.6	0.5	2.8	1.5	1.4	1.3	4.1	0.7	1.7	9.5	11.9	3.9	3.4	4.5	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.8	0.1	0.5	0.0	0.2	1.2	0.0	0.0	0.0	1.4	3.1										
HIST1H4E	"H4/j, H4FJ"	ENSG00000276966	"Histone cluster 1 H4 family member e"	P62805	6	26204552-26206038	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 71.9"	"Cell line enhanced"	"Detected in many"		"MOLT-4: 7.4;U-266/70: 14.6"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA042201	Supported					30000000	30000000			"HPA042201: "	"unprognostic (8.62e-2)"	"unprognostic (4.86e-2)"	"unprognostic (5.71e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.57e-1)"	"unprognostic (5.08e-3)"	"unprognostic (7.99e-2)"	"unprognostic (1.21e-1)"	"unprognostic (6.57e-2)"	"unprognostic (2.34e-3)"	"unprognostic (4.34e-2)"	"prognostic unfavourable (2.00e-6)"	"unprognostic (1.28e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.40e-1)"	"unprognostic (4.92e-2)"	2.2	4.8	2.4	5.4	6.8	13.0	4.6	15.1	17.3	7.3	4.7	5.2	5.1	7.4	4.9	6.6	5.2	6.5	5.0	5.1	2.0		3.0	1.9	2.6	5.1	1.3	5.7	11.2	1.6	2.5	2.6	4.7	2.4	10.5	5.0	6.7	7.5	4.6	1.8	2.2	4.6	6.5	2.0	4.9	4.8	7.7	1.8	71.9	6.5	2.7	7.7	7.8	0.0	10.4	5.1	4.8	8.0	3.7	5.9	2.1	1.3	0.9	1.7	3.9	0.6	0.0	0.9	1.5	0.4	0.7	0.5	0.5	1.4	0.5	2.0	0.4	2.4	0.8	0.1	1.0	1.1	1.0	0.4	1.6	0.8	0.0	0.6	1.6	0.4	0.1	0.6	0.4	0.5	2.8	3.3	0.2	0.5	7.4	3.5	1.6	1.3	3.3	1.8	3.3	0.6	0.5	4.8	1.2	1.1	1.6	0.5	1.5	0.7	0.7	2.0	2.7	0.6	1.2	14.6	5.6	2.1	0.4	1.4	1.4	3.2	3.7	2.9	3.8	3.1	5.3	3.9	5.5	3.6	5.1	10.4	5.9	4.5	4.8	3.7	8.0	4.7	3.3	2.1										
HIST1H4I	"H4/m, H4FM"	ENSG00000276180	"Histone cluster 1 H4 family member i"	P62805	6	27138588-27139881	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 14.5"	"Cell line enhanced"	"Detected in many"		"K-562: 29.3;SiHa: 17.6;U-2 OS: 30.2;U-266/84: 30.4"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA042201	Approved					30000000	30000000			"HPA042201: "	"unprognostic (2.49e-2)"	"prognostic favourable (9.70e-4)"	"unprognostic (1.97e-2)"	"unprognostic (2.51e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.16e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.29e-3)"	"unprognostic (1.86e-3)"	"unprognostic (1.95e-1)"	"prognostic unfavourable (1.32e-5)"	"unprognostic (6.28e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.02e-2)"	0.1	2.5		2.4		1.7	0.0		0.1	0.0	0.8			2.7	1.1	0.0	1.7	0.0	1.3	0.5			0.0	1.9	0.8	2.6			0.8	2.7	0.0		1.5		2.0	0.0		1.6	0.0	0.0	0.2	2.9	0.0		2.3	3.2	1.8			2.6		0.0	1.9		6.0	5.5	14.5	4.6	2.4	3.4	3.1	1.6	3.4	1.9	1.2	1.3	0.1	2.1	3.3	0.1	0.1	0.1	3.2	2.4	0.5	9.4	0.0	2.6	0.3	0.1	0.0	2.2	5.0	1.1	5.5	0.1	0.2	0.9	6.1	0.4	0.1	0.0	0.1	0.1	29.3	9.0	0.0	5.0	1.4	2.2	0.7	2.1	1.3	1.1	8.2	0.1	0.9	6.3	2.3	17.6	8.1	1.9	15.5	0.7	1.1	2.3	30.2	2.8	0.3	9.1	30.4	5.7	1.3	6.6	2.3	9.2	2.6	14.1	1.5	2.0	1.3	4.6	1.3	1.4	2.5	6.0	1.6	1.7	14.5	2.4	4.6	5.5	3.4	3.1										
HK1		ENSG00000156515	"Hexokinase 1"	P19367	10	69269984-69401884	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Glycolysis, Immunity, Inflammatory response, Innate immunity"	"Allosteric enzyme, Kinase, Transferase"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007043, HPA007044, CAB010052, HPA011956"	Supported		Supported	Mitochondria		16000000	16000000	Mitochondria		"CAB010052: AB_627721, HPA007043: AB_1850652, HPA007044: AB_1079049, HPA011956: AB_1850758"	"unprognostic (8.80e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.03e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.15e-2)"	"prognostic unfavourable (3.39e-6)"	"unprognostic (1.23e-1)"	"unprognostic (1.97e-1)"	"unprognostic (4.29e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.93e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.37e-3)"	"unprognostic (7.25e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.00e-3)"	"unprognostic (3.86e-2)"	17.5	10.5	21.1	19.9	30.4	23.5	15.8	40.0	48.6	16.6	16.9	10.1	7.6	6.3	13.5	9.4	44.8	15.2	12.6	61.6	19.8	23.3	10.8	4.4	17.2	14.3	19.8	31.3	9.0	4.6	12.5	14.7	22.6	31.3	25.5	15.4	21.2	21.5	26.8	62.1	30.7	8.6	25.6	9.7	13.3	20.3	28.9	10.6	18.9	33.6	32.6	23.0	25.8	23.1	11.4	25.5	17.8	39.3	8.9	23.0	29.6	17.4	9.9	13.3	12.7	14.9	11.2	8.5	17.4	45.8	23.3	25.2	2.9	1.9	1.2	13.8	29.1	15.3	12.4	38.9	22.3	11.6	9.7	43.4	10.6	0.2	17.0	0.8	32.9	16.9	22.7	33.3	74.5	24.1	72.3	9.2	31.9	28.9	5.0	2.2	20.4	44.3	7.7	8.1	0.1	16.1	20.6	13.7	16.1	19.9	38.7	11.5	21.1	2.8	24.7	34.8	15.9	19.1	24.2	11.0	7.2	3.0	45.1	22.8	10.0	17.8	27.3	13.4	14.0	39.3	23.0	11.4	16.2	15.8	25.5	6.8	14.5	11.5	6.6	8.9	39.3	2.9	17.8	29.6	21.1	30.4	40.0	48.6	19.8	23.3	19.8	31.3	31.3	10.6
HK2		ENSG00000159399	"Hexokinase 2"	P52789	2	74833981-74893359	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Glycolysis	"Allosteric enzyme, Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-87 MG: 53.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 26.2"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA028587	Enhanced									"HPA028587: AB_10602605"	"unprognostic (1.28e-1)"	"unprognostic (1.52e-3)"	"unprognostic (3.02e-1)"	"unprognostic (3.63e-2)"	"unprognostic (1.69e-1)"	"unprognostic (7.21e-2)"	"prognostic unfavourable (3.65e-4)"	"unprognostic (2.85e-2)"	"unprognostic (2.57e-1)"	"unprognostic (2.17e-1)"	"unprognostic (4.43e-3)"	"unprognostic (2.24e-2)"	"prognostic unfavourable (1.37e-4)"	"unprognostic (1.20e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.42e-1)"	"unprognostic (7.67e-2)"	27.0	2.2	4.4	9.5	5.0	20.4	10.8	0.7	4.5	5.3	23.2	7.3	5.7	1.3	2.6	40.1	13.6	4.8	9.1	8.3	2.8	2.3	2.1	1.4	16.5	5.0	8.5	1.1	14.9	3.5	1.1	1.7	13.2	5.4	4.0	19.2	9.6	10.3	0.5	29.3	9.7	8.9	1.7	10.9	7.4	8.7	24.8	7.4	4.3	7.1	22.3	9.2	29.0	8.3	0.8	6.2	26.2	7.1	0.0	0.8	2.0	16.2	0.1	3.8	13.7	32.3	3.4	14.0	6.3	9.2	7.1	10.3	13.0	2.9	11.8	6.1	2.9	5.6	17.2	13.3	20.8	3.3	3.7	16.0	3.7	17.8	10.2	23.3	26.3	5.6	14.5	13.6	23.8	3.4	13.9	0.0	2.0	11.5	5.6	23.9	13.6	11.3	9.2	7.9	9.2	4.3	22.9	2.7	13.4	4.0	20.4	8.0	1.0	3.7	2.7	22.8	4.0	9.4	11.4	8.1	2.3	5.9	53.2	17.1	5.8	6.6	7.1	26.2	0.1	5.7	0.3	0.6	0.4	0.1	6.2	0.8	0.7	0.7	5.9	0.0	3.7	0.1	0.8	2.0	4.4	5.0	0.7	4.5	2.8	2.3	8.5	1.1	5.4	7.4
HLA-A		ENSG00000206503	"Major histocompatibility complex, class I, A"	"P16188, P04439, P13746"	6	29941260-29945884	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 154.8;fHDF/TERT166: 41.4;HBEC3-KT: 42.5;RPMI-8226: 40.3;U-266/70: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											CAB078470			Supported	"Golgi apparatus,Plasma membrane"				"Plasma membrane"	"Golgi apparatus"	"CAB078470: AB_10985125"	"unprognostic (1.56e-2)"	"unprognostic (9.14e-2)"	"unprognostic (1.34e-2)"	"prognostic favourable (9.59e-4)"	"unprognostic (3.49e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.12e-1)"	"unprognostic (7.28e-2)"	"unprognostic (3.42e-2)"	"prognostic favourable (6.47e-4)"	"unprognostic (2.96e-1)"	"unprognostic (3.24e-1)"	"unprognostic (1.84e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.32e-2)"	"unprognostic (1.20e-2)"	"unprognostic (1.54e-2)"	69.4	57.5	16.0	69.1	18.2	41.2	40.8	9.1	20.7	54.4	92.6	20.4	28.6	105.7	38.4	76.2	48.4	27.8	92.3	59.1	14.6	16.6	80.5	47.6	112.0	90.5	19.5	8.9	57.2	30.0	22.5	33.3	38.7	22.7	64.1	38.5	52.4	28.3	19.2	44.0	110.4	129.4	30.3	22.8	150.0	115.9	26.6	12.3	71.1	62.3	38.5	97.7	86.4	41.0	23.0	10.9	65.8	25.2	25.9	46.7	45.4	154.8	3.9	0.0	0.0	25.0	23.6	0.1	0.1	0.3	0.2	0.2	0.0	0.0	0.4	0.0	41.4	3.8	0.0	42.5	0.0	0.3	1.5	27.0	1.2	0.8	1.4	0.0	1.8	0.2	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.1	2.4	0.3	0.4	3.3	0.3	40.3	29.0	31.8	0.0	1.4	3.5	0.0	1.4	0.1	3.6	0.5	2.3	0.1	0.7	0.4	41.3	10.5	8.7	0.0	22.8	0.0	65.8	25.2	35.4	38.3	17.9	28.8	23.0	29.6	34.4	4.1	14.9	21.7	29.7	47.9	25.9	19.8	10.9	46.7	45.4	16.0	18.2	9.1	20.7	14.6	16.6	19.5	8.9	22.7	12.3
HLA-B	AS	ENSG00000234745	"Major histocompatibility complex, class I, B"	"P30486, Q29836, Q31610, Q31612, P01889, P30480"	6	31269491-31357188	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 69.9;EFO-21: 63.8;U-266/70: 161.8;U-698: 44.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											CAB015418	Enhanced									"CAB015418: AB_831547"	"unprognostic (2.87e-2)"	"unprognostic (1.49e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.65e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.81e-1)"	"unprognostic (5.16e-3)"	"unprognostic (8.51e-2)"	"prognostic favourable (2.90e-4)"	"unprognostic (2.69e-3)"	"unprognostic (3.05e-2)"	"unprognostic (1.59e-1)"	"unprognostic (9.28e-3)"	"unprognostic (3.27e-1)"	"unprognostic (7.83e-2)"	"unprognostic (8.24e-3)"	"unprognostic (3.67e-2)"	83.5	40.1	11.7	91.4	14.2	11.0	52.6	6.7	13.1	41.4	96.5	18.2	15.6	2.0	52.8	51.5	46.1	30.8	100.3	76.8	11.9	13.4	63.3	57.1	194.5	214.9	17.3	10.5	40.2	21.8	16.2	20.2	39.5	19.1	70.4	56.1	45.4	108.9	23.4	37.4	56.4	164.1	20.6	23.8	200.6	43.2	32.1	11.9	54.1	44.5	19.1	136.3	117.6	48.6	45.6	41.4	118.7	56.5	46.5	64.3	81.8	69.9	0.0	0.0	0.0	1.7	12.0	0.4	0.0	0.3	0.1	0.2	0.0	0.5	2.5	63.8	12.4	29.4	14.5	12.8	0.0	0.2	3.4	0.9	0.0	0.0	9.4	0.0	0.6	23.6	0.0	0.0	1.6	0.0	0.1	3.4	0.0	0.0	0.3	18.2	0.2	0.0	2.1	0.4	0.4	19.3	0.0	0.1	0.5	0.6	0.1	0.1	11.1	0.7	15.0	3.8	0.6	0.6	0.2	161.8	36.0	44.3	0.2	0.7	0.1	20.6	56.5	59.1	64.3	42.7	62.2	45.6	54.9	58.5	41.4	35.1	42.1	55.2	118.7	46.5	37.4	33.9	56.2	81.8	11.7	14.2	6.7	13.1	11.9	13.4	17.3	10.5	19.1	11.9
HLA-G		ENSG00000204632	"Major histocompatibility complex, class I, G"	P17693	6	29826967-29831125	"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins"	Immunity		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"placenta: 66.0"	"Cell line enriched"	"Detected in single"	5	"CAPAN-2: 2.1"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"											CAB016158	Enhanced				"Secreted to blood"					"CAB016158: AB_627938"	"unprognostic (1.13e-2)"	"unprognostic (9.95e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.40e-2)"	"unprognostic (8.35e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.18e-3)"	"unprognostic (2.51e-1)"	"prognostic favourable (3.91e-5)"	"unprognostic (6.34e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.03e-2)"	"unprognostic (6.56e-3)"	"unprognostic (1.40e-1)"	"unprognostic (1.52e-2)"	"unprognostic (3.19e-3)"	0.2	0.1	0.0	0.5	0.1	0.2	0.3	0.1	0.1	0.2	0.5	0.1	0.0	1.2	0.2	0.6	0.1	0.1	0.2	0.3	0.2	0.0	0.5	0.2	2.8	0.7	0.1	0.1	0.3	1.9	0.1	15.2	66.0	0.1	0.2	0.2	0.3	0.4	0.6	0.2	0.2	0.8	0.1	0.2	1.2	0.9	2.2	0.2	1.3	0.4	0.2	0.2	0.2	0.3	0.3	0.3	2.2	0.9	0.2	1.2	5.7	0.4	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.2	0.0	0.2	0.0	2.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.3	0.0	0.1	0.0	0.1	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.2	0.6	0.9	1.2	0.7	0.5	1.2	0.3	0.1	0.5	0.3	0.3	0.6	1.2	2.2	0.2	0.6	0.1	0.5	5.7	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.2
HLF	MGC33822	ENSG00000108924	"HLF, PAR bZIP transcription factor"	Q16534	17	55265012-55325065	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in all"		"liver: 78.8"	"Cell line enriched"	"Detected in some"	6	"Hep G2: 58.6"	"Cancer enhanced"	"Detected in many"		"liver cancer: 13.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	7	"memory CD4 T-cell: 2.4;T-reg: 2.1"	"Lineage enriched"	"Detected in single"	25	"T-cells: 2.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA068156, HPA071210"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA068156: , HPA071210: "	"unprognostic (1.24e-1)"	"unprognostic (1.19e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.30e-1)"	"prognostic favourable (1.88e-4)"	"unprognostic (5.30e-3)"	"prognostic favourable (2.71e-7)"	"unprognostic (1.42e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.24e-3)"	"unprognostic (2.19e-1)"	"prognostic favourable (3.55e-6)"	"unprognostic (8.47e-2)"	"unprognostic (1.64e-1)"	"unprognostic (6.85e-2)"	"unprognostic (1.60e-2)"	9.5	15.2	13.3	2.0	26.2	1.0	10.8	15.2	38.0	10.5	10.6	6.4	2.4	1.7	10.3	8.5	18.1	9.3	6.1	15.9	12.6	6.9	9.2	78.8	9.5	2.1	6.6	24.5	34.6	2.7	2.8	8.0	1.5	12.3	9.9	3.1	23.7	15.9	9.5	5.3	11.6	3.0	14.3	5.5	5.7	4.7	3.4	6.3	0.0	23.4	7.1	5.6	9.2	5.2	0.0	0.0	0.0	0.0	0.0	2.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.2	0.0	0.0	0.1	0.0	0.0	9.7	0.2	0.0	0.0	58.6	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.4	0.0	0.0	0.9	0.0	0.1	0.1	4.8	0.0	4.1	0.2	0.0	2.6	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.1	1.9	1.7	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.1	13.3	26.2	15.2	38.0	12.6	6.9	6.6	24.5	12.3	6.3
HMGA1	HMGIY	ENSG00000137309	"High mobility group AT-hook 1"	P17096	6	34236873-34246231	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 107.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB032200, HPA065612, HPA068442"	Enhanced		Approved	Nucleoplasm,Nucleoli		18000	18000	Nucleoplasm	Nucleoli	"CAB032200: AB_2117771, HPA065612: , HPA068442: "	"unprognostic (1.81e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (7.13e-4)"	"unprognostic (1.57e-1)"	"unprognostic (1.20e-3)"	"prognostic unfavourable (1.29e-6)"	"prognostic unfavourable (3.36e-4)"	"unprognostic (8.54e-2)"	"unprognostic (1.84e-2)"	"prognostic unfavourable (8.71e-4)"	"unprognostic (1.55e-1)"	"unprognostic (8.22e-2)"	"unprognostic (4.52e-3)"	"unprognostic (1.19e-1)"	"unprognostic (4.37e-1)"	"unprognostic (2.65e-2)"	15.8	3.5	14.8	35.7	13.5	55.4	13.0	13.8	19.0	26.1	22.0	5.9	7.7	42.3	8.6	7.2	79.4	15.1	17.8	13.0	11.7	12.6	14.6	6.9	16.0	46.1	10.7	8.7	3.9	13.0	4.1	5.1	31.8	12.5	8.7	21.2	9.9	22.0	6.9	33.7	38.3	36.0	3.8	8.4	31.6	24.2	32.6	7.2	107.3	12.5	39.6	72.7	13.0	29.6	26.6	33.4	12.8	10.1	7.3	22.4	11.0	120.4	47.7	24.5	17.1	11.4	84.6	107.0	48.7	55.7	37.8	21.1	31.2	84.5	56.8	24.6	19.9	25.9	28.8	86.9	30.1	12.4	19.3	17.4	16.1	41.7	24.2	62.2	20.1	36.2	9.7	68.4	35.8	114.1	70.1	2.9	52.6	12.2	53.9	76.6	119.2	80.9	80.2	0.5	62.7	25.6	11.1	42.8	18.1	5.1	24.7	45.0	9.9	66.8	98.9	19.7	62.2	28.6	45.6	23.4	36.2	73.4	41.7	26.0	98.3	6.2	10.1	12.8	10.2	10.1	13.3	26.6	18.7	16.0	30.7	16.4	22.4	17.7	2.6	7.3	9.4	33.4	21.0	11.0	14.8	13.5	13.8	19.0	11.7	12.6	10.7	8.7	12.5	7.2
HMGA2	"BABL, HMGIC, LIPO"	ENSG00000149948	"High mobility group AT-hook 2"	P52926	12	65824131-65966295	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Cell division, DNA condensation, Growth regulation, Mitosis, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"testis: 25.3"	"Cell line enhanced"	"Detected in many"		"AF22: 66.0;NTERA-2: 38.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"							"CAB017809, HPA039076"	Approved		Supported	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"CAB017809: , HPA039076: "	"unprognostic (2.39e-1)"	"unprognostic (6.00e-2)"	"unprognostic (2.08e-1)"	"unprognostic (3.68e-3)"	"unprognostic (5.21e-3)"	"prognostic unfavourable (4.79e-4)"	"unprognostic (4.05e-3)"	"unprognostic (6.17e-3)"	"unprognostic (6.71e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.54e-6)"	"unprognostic (3.33e-2)"	"unprognostic (4.55e-5)"	"unprognostic (4.22e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.53e-2)"	"prognostic unfavourable (2.86e-4)"	6.5	0.3	0.5	3.8	0.8	8.1	2.1	0.2	0.6	2.5	7.6	0.4	0.0	2.4	2.7	0.1	1.1	2.4	3.3	0.5	0.3	0.4	1.0	0.4	0.5	0.1	0.3	1.3	2.1	1.7	0.0	1.7	0.3	0.6	0.5	4.6	0.4	0.5	1.8	2.0	0.7	5.1	0.7	1.7	0.8	2.1	25.3	0.0	0.8	1.1	3.0	0.1	0.8	2.8	0.7	0.3	3.8	2.1	1.3	0.7	0.1	9.5	4.2	66.0	9.4	3.1	17.3	0.0	30.5	13.9	5.4	5.4	5.4	4.0	0.0	19.8	1.4	4.2	10.9	26.2	25.7	0.0	11.4	0.0	0.1	33.0	1.7	0.9	0.1	13.1	1.6	11.5	20.8	21.1	0.0	0.1	30.5	0.0	0.1	5.4	38.7	19.0	2.6	3.2	0.0	14.2	0.0	0.0	0.0	0.0	0.0	16.7	0.1	0.1	24.6	19.4	5.8	14.8	9.1	0.0	0.0	0.0	23.4	0.0	4.4	3.8	1.0	0.7	0.5	0.6	0.3	0.3	0.4	0.5	0.2	0.7	0.4	0.7	2.5	1.3	2.1	0.3	0.3	0.1	0.5	0.8	0.2	0.6	0.3	0.4	0.3	1.3	0.6	0.0
HMGXB4	"HMG2L1, THC211630"	ENSG00000100281	"HMG-box containing 4"	Q9UGU5	22	35257452-35295807	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Wnt signaling pathway"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000725	Approved									"HPA000725: AB_1079073"	"unprognostic (2.22e-1)"	"unprognostic (1.12e-1)"	"prognostic favourable (3.24e-5)"	"unprognostic (4.81e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavourable (4.79e-4)"	"unprognostic (2.85e-2)"	"unprognostic (8.25e-3)"	"unprognostic (6.67e-3)"	"prognostic unfavourable (1.16e-4)"	"unprognostic (1.62e-1)"	"unprognostic (8.71e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.20e-1)"	"unprognostic (8.54e-2)"	13.6	11.6	11.4	11.4	17.6	28.6	13.6	17.4	15.1	14.4	10.9	17.2	9.5	10.6	17.4	8.4	14.4	14.5	10.8	9.8	10.0	8.6	8.6	8.0	10.2	10.5	14.4	13.8	21.7	10.9	9.4	7.6	20.2	12.4	12.4	12.2	8.7	11.9	12.7	17.2	14.4	13.1	15.0	12.6	10.0	10.3	12.1	16.9	20.0	10.6	10.2	11.6	14.8	13.5	11.8	9.4	22.6	12.5	7.4	13.1	4.7	12.9	2.9	20.2	10.1	4.9	9.7	5.8	13.4	17.7	13.1	12.2	2.2	4.8	15.5	6.0	13.3	8.0	8.7	9.4	15.3	13.6	9.8	14.2	3.8	2.8	6.7	29.8	14.5	8.8	8.2	11.0	8.4	9.0	11.1	12.9	9.7	5.9	18.0	7.2	9.4	8.7	14.5	19.1	5.4	7.4	9.5	12.8	12.6	12.0	8.7	9.6	6.0	9.3	8.3	12.0	26.5	13.9	11.0	13.8	13.5	19.3	10.1	9.1	17.0	22.6	11.1	13.8	12.6	12.5	10.8	8.9	12.1	13.1	8.8	11.8	8.1	9.2	16.8	7.4	11.5	9.4	10.1	4.7	11.4	17.6	17.4	15.1	10.0	8.6	14.4	13.8	12.4	16.9
HMOX1	"bK286B10, HO-1"	ENSG00000100292	"Heme oxygenase 1"	P09601	22	35380361-35394214	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 209.8"	"Cell line enhanced"	"Detected in many"		"BEWO: 110.9;U-138 MG: 64.7;U-87 MG: 62.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"classical monocyte: 17.7;intermediate monocyte: 40.5;non-classical monocyte: 53.4"	"Lineage enriched"	"Detected in many"	6	"monocytes: 53.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000635, CAB017444"	Enhanced		Uncertain	"Golgi apparatus,Plasma membrane"		17000	17000	"Golgi apparatus, Plasma membrane"		"CAB017444: AB_10617276, HPA000635: AB_1079089"	"unprognostic (3.12e-1)"	"unprognostic (1.00e-1)"	"unprognostic (9.42e-2)"	"unprognostic (6.94e-2)"	"unprognostic (5.57e-2)"	"unprognostic (2.47e-2)"	"prognostic unfavourable (1.59e-4)"	"unprognostic (7.56e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.91e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.76e-1)"	"unprognostic (1.95e-3)"	"unprognostic (1.91e-1)"	"unprognostic (4.82e-2)"	"unprognostic (2.26e-1)"	"unprognostic (7.54e-2)"	28.4	10.3	4.1	12.5	8.7	16.3	13.8	0.8	20.6	5.7	12.0	6.1	0.6	22.0	2.5	8.5	8.8	9.8	9.8	10.2	4.1	3.1	23.0	63.7	54.0	76.3	12.5	1.3	28.6	8.8	0.5	2.7	21.1	7.5	3.6	4.9	3.3	3.5	0.8	21.9	13.8	22.8	6.9	11.2	209.8	4.6	5.9	7.6	3.6	4.2	7.3	8.3	6.7	10.2	4.8	7.9	8.4	53.4	1.1	0.3	10.1	1.4	22.6	0.2	4.6	18.5	5.4	110.9	10.4	6.2	4.9	5.3	10.0	1.4	0.0	2.3	8.5	1.2	1.3	0.2	1.5	37.3	1.1	0.5	6.9	20.4	25.7	1.4	7.0	17.0	0.4	32.3	2.1	14.7	0.0	10.8	15.6	1.1	0.0	0.5	2.2	2.5	0.1	1.9	3.4	3.5	12.1	0.3	0.3	26.9	2.4	1.8	1.0	0.3	5.5	64.7	2.9	10.5	10.1	6.8	8.7	1.0	62.8	0.6	1.0	2.0	17.7	1.2	0.2	40.5	0.0	4.8	0.1	0.3	7.9	0.5	0.0	0.0	8.4	1.1	53.4	0.2	0.2	10.1	4.1	8.7	0.8	4.8	4.1	3.1	12.5	1.3	7.5	7.6
HNF1A	"HNF1, LFB1, MODY3, TCF1"	ENSG00000135100	"HNF1 homeobox A"		12	120978543-121002512	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Tissue enhanced"	"Detected in some"		"intestine: 24.2;kidney: 17.2;liver: 15.6"	"Group enriched"	"Detected in some"	7	"A549: 6.2;CACO-2: 20.6;Hep G2: 22.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB010430, HPA035231"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB010430: AB_2116746, HPA035231: "	"unprognostic (5.92e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.12e-3)"	"unprognostic (6.18e-3)"	"unprognostic (3.72e-1)"	"unprognostic (1.27e-2)"	"unprognostic (9.18e-2)"	"unprognostic (9.18e-2)"	"unprognostic (2.99e-1)"	"unprognostic (2.01e-1)"	"unprognostic (9.77e-3)"	"unprognostic (5.21e-2)"	"unprognostic (6.25e-3)"	"unprognostic (5.55e-2)"	"unprognostic (2.48e-1)"		"unprognostic (6.93e-3)"	0.1	0.0	0.1	0.8	0.1	0.0	0.1	0.1	0.1	0.1	17.3	0.1	0.1	13.7	0.1	1.5	0.1	0.8	5.1	0.1	0.1	0.0	17.2	15.6	0.1	0.1	0.1	0.1	0.2	6.3	0.0	0.1	0.1	0.1	0.1	2.1	0.1	0.1	0.1	0.1	0.0	24.2	0.5	0.1	0.1	3.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.5	0.5	1.8	0.3	0.3	0.4	0.2	0.0	6.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	20.6	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.3	0.2	0.2	0.3	0.2	0.3	0.4	0.4	0.1	0.5	0.4	0.4	1.6	0.3	0.3	0.5	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
HNRNPA2B1	HNRPA2B1	ENSG00000122566	"Heterogeneous nuclear ribonucleoprotein A2/B1"	P22626	7	26189927-26201529	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, mRNA processing, mRNA splicing, mRNA transport, Transport"	"Ribonucleoprotein, RNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001666, HPA005812, CAB012403, HPA065537"	Supported		Enhanced	Nucleoplasm	"Intracellular and membrane"	11000000	11000000	Nucleoplasm		"CAB012403: , HPA001666: AB_1850836, HPA005812: , HPA065537: "	"unprognostic (1.19e-1)"	"unprognostic (4.45e-1)"	"unprognostic (2.33e-1)"	"unprognostic (6.39e-2)"	"unprognostic (5.64e-2)"	"unprognostic (8.04e-3)"	"prognostic unfavourable (1.03e-6)"	"unprognostic (1.25e-2)"	"unprognostic (9.12e-3)"	"unprognostic (4.35e-3)"	"unprognostic (1.31e-1)"	"prognostic unfavourable (5.12e-4)"	"prognostic unfavourable (8.01e-5)"	"unprognostic (6.74e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.56e-2)"	82.2	97.4	85.1	105.3	106.3	90.9	74.4	123.3	87.4	77.1	85.7	89.4	68.7	87.5	92.6	71.9	90.4	75.1	51.7	87.9	82.4	71.8	113.4	103.7	76.2	127.7	118.6	57.0	121.0	75.7	107.2	121.2	100.7	96.3	75.5	98.6	64.4	71.4	66.5	167.2	58.7	94.8	73.7	139.7	116.5	74.1	73.1	135.4	180.3	81.9	104.4	140.7	74.2	128.8	33.7	46.5	35.1	52.4	32.1	42.5	36.0	122.0	104.2	151.7	113.7	39.0	35.7	70.2	78.3	61.1	86.5	78.4	96.2	88.9	223.1	74.9	72.5	85.2	162.2	102.3	122.0	69.4	98.9	135.2	125.7	115.0	32.8	145.5	92.7	33.7	53.6	82.3	75.1	89.3	159.0	73.0	87.4	98.7	155.7	170.3	134.3	80.3	144.7	123.3	93.5	99.9	106.8	88.6	108.7	94.1	92.7	57.2	103.9	126.8	77.1	48.7	100.8	65.9	133.6	97.0	192.2	212.4	62.7	166.0	91.7	17.4	38.7	35.1	42.5	52.4	38.6	33.7	35.5	36.6	46.5	29.2	35.6	35.6	13.0	32.1	48.4	43.6	36.1	36.0	85.1	106.3	123.3	87.4	82.4	71.8	118.6	57.0	96.3	135.4
HOOK3	HK3	ENSG00000168172	"Hook microtubule tethering protein 3"	Q86VS8	8	42896932-43030539	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA024756	Approved		Supported	"Golgi apparatus,Centriolar satellite,Cytosol"				"Centriolar satellite"	"Golgi apparatus, Cytosol"	"HPA024756: AB_1850913"	"unprognostic (1.84e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.73e-1)"	"unprognostic (8.61e-3)"	"unprognostic (6.05e-2)"	"unprognostic (1.77e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.78e-1)"	"unprognostic (3.97e-2)"	"unprognostic (1.13e-1)"	"unprognostic (4.13e-1)"	"prognostic unfavourable (1.32e-4)"	"unprognostic (1.63e-1)"	"unprognostic (3.78e-1)"	"unprognostic (2.55e-1)"	"unprognostic (7.12e-2)"	15.5	9.3	11.3	10.1	15.1	13.1	16.3	16.0	19.2	13.5	11.3	10.3	14.1	10.2	13.7	12.0	14.8	11.7	20.0	9.5	11.2	11.3	9.9	10.7	14.6	10.3	14.7	11.7	13.4	13.9	13.4	14.4	12.0	13.1	17.7	10.9	6.8	17.1	15.2	24.1	11.0	11.9	19.3	17.5	11.6	12.8	14.5	14.3	7.4	37.5	8.9	10.1	19.2	17.6	1.8	3.8	10.2	3.2	2.0	2.0	1.8	7.3	7.3	17.8	9.6	13.2	11.7	6.8	9.3	7.8	7.8	7.3	9.6	8.6	9.1	9.6	12.4	4.1	14.7	6.3	12.7	6.2	4.2	17.2	6.0	6.6	7.4	1.8	10.2	9.5	4.6	10.5	9.1	11.2	9.4	10.7	9.4	1.8	13.9	3.4	6.4	2.2	8.2	18.6	2.3	5.8	10.9	4.5	7.2	10.6	4.5	4.9	8.2	6.2	20.0	11.7	9.2	14.1	5.9	10.6	11.5	12.0	9.9	6.6	17.3	10.2	3.2	3.1	2.0	3.2	0.8	1.6	1.9	1.5	3.8	1.8	1.1	1.5	3.8	2.0	3.1	2.4	1.4	1.8	11.3	15.1	16.0	13.1	11.2	11.3	14.7	11.7	13.1	14.3
HOXA11	"HOX1, HOX1I"	ENSG00000005073	"Homeobox A11"	P31270	7	27181510-27185223	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 35.7;endometrium 1: 60.9;smooth muscle: 27.3"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 17.5;HEK 293: 24.6;THP-1: 17.6;U-937: 22.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA006770, HPA035623"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"HPA006770: , HPA035623: AB_10601576"	"unprognostic (5.95e-2)"	"unprognostic (9.23e-2)"	"unprognostic (3.07e-2)"	"unprognostic (2.70e-2)"	"unprognostic (6.29e-2)"	"unprognostic (9.78e-2)"	"unprognostic (2.82e-3)"	"unprognostic (4.36e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.05e-2)"	"unprognostic (2.08e-3)"	"unprognostic (1.73e-2)"	"prognostic unfavourable (2.57e-5)"	"unprognostic (2.17e-2)"	"unprognostic (6.90e-2)"	"unprognostic (2.03e-2)"	"unprognostic (2.56e-1)"	1.5	0.4	0.0	1.7	0.0	0.0	2.0	0.0	0.0	35.7	9.3	0.0	5.7	0.0	60.9	8.8	0.0	0.7	0.0	0.2	0.0	0.0	3.6	0.1	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	9.0	0.0	16.5	2.4	0.0	0.1	6.3	4.9	0.7	0.2	27.3	0.0	0.0	0.1	3.1	0.0	0.0	0.0	0.0	0.0	20.1	6.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.3	0.1	0.0	6.7	8.2	5.8	0.0	14.5	17.5	10.3	7.4	0.1	0.8	0.0	3.3	12.2	1.6	8.6	0.0	7.5	0.8	24.6	3.0	6.0	0.3	0.5	6.1	0.8	3.7	0.3	0.0	0.0	7.4	0.1	0.0	1.1	0.1	0.0	4.7	0.0	7.2	0.3	0.0	0.1	4.9	4.2	3.2	0.0	3.5	0.0	1.0	0.6	17.6	0.0	0.1	7.1	1.6	0.7	0.0	0.0	0.0	0.1	22.9	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HOXA13	"HOX1, HOX1J"	ENSG00000106031	"Homeobox A13"	P31271	7	27193503-27200106	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 48.5;prostate: 25.1"	"Cell line enhanced"	"Detected in many"		"HAP1: 15.2;HEK 293: 21.1;PC-3: 10.5;RT4: 23.5;THP-1: 10.0;U-937: 11.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			HPA069061			Supported	"Nucleoplasm,Intermediate filaments"				Nucleoplasm	"Intermediate filaments"	"HPA069061: "	"unprognostic (7.20e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.02e-1)"	"unprognostic (8.04e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.40e-2)"	"unprognostic (9.22e-3)"	"unprognostic (7.30e-3)"	"unprognostic (8.39e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.42e-11)"	"unprognostic (2.58e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.36e-2)"	0.6	0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.1	48.5	6.9	0.0	7.1	0.0	5.5	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	16.5	0.0	25.1	8.6	0.0	0.1	17.9	1.2	0.4	0.1	15.7	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.0	0.0	12.1	12.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.9	0.0	1.4	0.1	0.0	0.0	7.4	8.2	2.9	1.9	1.5	0.1	0.0	0.9	3.5	0.0	15.2	0.0	2.5	0.0	21.1	1.0	4.0	0.1	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	4.8	0.0	10.5	1.5	0.3	0.0	0.0	23.5	0.4	0.0	1.8	0.0	0.1	0.0	10.0	0.0	0.2	2.7	0.1	0.1	0.0	0.0	0.0	0.0	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
HOXA5	"HOX1, HOX1C"	ENSG00000106004	"Homeobox A5"	P20719	7	27141052-27143668	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 42.0"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 32.4;HEK 293: 55.2;RPTEC TERT1: 12.5"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	46	"pons and medulla: 16.3"	"Group enriched"	"Detected in some"	4	"basophil: 3.0;neutrophil: 1.6;NK-cell: 2.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 3.0;NK-cells: 2.5"	"Region enriched"	"Detected in single"	88	"pons and medulla: 23.0"	"Region enriched"	"Detected in single"	32	"pons and medulla: 5.5"												"unprognostic (2.43e-1)"	"unprognostic (3.98e-3)"	"unprognostic (2.99e-1)"	"prognostic unfavourable (2.28e-4)"	"unprognostic (1.87e-1)"	"unprognostic (7.80e-2)"	"unprognostic (4.07e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.02e-2)"	"unprognostic (5.54e-2)"	"unprognostic (2.31e-1)"	"unprognostic (5.47e-2)"	"unprognostic (3.00e-2)"	"unprognostic (4.37e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.47e-3)"	"unprognostic (2.00e-1)"	6.8	42.0	0.2	2.1	0.2	1.2	10.9	0.2	0.3	1.9	6.6	1.0	16.0	1.1	6.0	25.0	12.3	22.1	2.5	1.4	0.2	0.0	16.8	1.8	23.9	1.5	0.2	0.2	9.3	1.3	2.0	0.5	0.3	16.3	3.9	3.3	0.2	0.2	7.1	5.6	3.4	6.8	3.0	19.4	4.4	5.6	2.6	0.2	0.2	1.3	0.2	0.2	6.6	3.3	0.2	0.4	3.0	0.5	2.5	0.2	0.1	1.9	0.9	0.0	32.4	0.0	0.0	0.1	0.5	0.4	0.6	0.5	0.5	3.3	1.0	4.7	1.0	2.6	1.8	0.1	0.6	0.4	55.2	0.7	0.4	1.9	0.3	1.1	0.8	3.6	0.2	1.1	1.9	7.2	0.1	0.0	1.1	0.5	0.0	0.3	0.0	1.0	4.4	0.1	0.0	12.5	2.6	3.8	0.0	2.4	0.0	1.1	0.4	0.4	2.8	0.1	0.4	1.9	1.3	0.0	0.0	1.1	0.2	3.6	3.5	3.0	0.4	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.4	0.2	0.2	0.1	1.6	2.5	0.5	0.4	0.1	0.1	0.2	0.2	0.2	0.3	0.2	0.0	0.2	0.2	16.3	0.2
HOXA9	"HOX1, HOX1G"	ENSG00000078399	"Homeobox A9"	P31269	7	27162435-27175180	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 35.1"	"Cell line enhanced"	"Detected in some"		"HEK 293: 42.7;PC-3: 14.9;RPTEC TERT1: 14.7;SCLC-21H: 39.7;U-937: 14.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"basophil: 5.4;myeloid DC: 6.0;NK-cell: 11.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.0;granulocytes: 5.4;NK-cells: 11.7"									HPA061982	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA061982: "	"unprognostic (4.72e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.86e-1)"	"unprognostic (5.24e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.02e-1)"	"unprognostic (8.35e-2)"	"unprognostic (8.44e-3)"	"unprognostic (5.50e-2)"	"unprognostic (5.71e-2)"	"unprognostic (9.87e-3)"	"unprognostic (4.42e-2)"	"unprognostic (2.80e-3)"	"unprognostic (6.45e-2)"	"unprognostic (7.58e-2)"	"unprognostic (1.92e-2)"	"unprognostic (1.35e-1)"	3.2	3.4	0.2	8.8	0.1	2.4	8.7	0.1	0.2	15.5	12.8	0.2	4.1	0.0	10.4	16.8	1.4	12.2	0.3	0.1	0.1	0.0	35.1	0.1	0.8	0.7	0.1	0.1	2.0	0.1	0.0	0.1	1.4	0.4	16.6	4.5	0.2	0.5	5.6	21.0	13.3	8.2	13.1	0.7	1.0	0.0	2.4	0.1	2.6	0.3	0.3	0.3	16.2	11.4	0.5	6.0	5.4	1.0	11.7	1.5	0.5	12.4	0.0	0.0	6.3	2.1	1.6	0.0	5.0	4.0	0.4	0.4	0.8	0.5	0.1	0.5	2.7	11.7	8.1	0.0	0.4	0.0	42.7	0.1	0.3	0.0	0.2	0.0	0.1	2.1	0.0	0.0	0.0	10.5	0.0	0.0	0.4	0.0	0.0	0.3	0.0	14.9	2.7	0.0	0.0	14.7	0.2	39.7	0.0	5.3	0.0	0.1	0.0	10.5	0.4	0.0	4.0	4.8	0.0	0.0	0.0	0.0	0.0	14.2	0.0	5.4	1.0	0.0	1.5	0.2	0.2	0.2	0.0	0.1	6.0	0.5	0.3	0.1	0.9	11.7	0.4	1.9	0.2	0.5	0.2	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.4	0.1
HOXC11	HOX3H	ENSG00000123388	"Homeobox C11"	O43248	12	53973126-53977643	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 7.0;skin 1: 9.2"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 23.0;BJ hTERT+: 11.6;HaCaT: 10.1;T-47d: 18.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA038291	Uncertain		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA038291: AB_10674552"	"unprognostic (1.50e-3)"	"unprognostic (1.93e-2)"	"unprognostic (1.14e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.93e-3)"	"unprognostic (1.17e-2)"		"unprognostic (6.90e-3)"	"unprognostic (1.32e-2)"	"unprognostic (7.41e-3)"	"unprognostic (4.46e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.26e-3)"	"unprognostic (3.99e-2)"	"unprognostic (1.06e-1)"		"unprognostic (1.82e-1)"	4.8	0.0	0.1	0.1	0.1	0.0	1.2	0.1	0.1	2.5	0.1	0.1	0.1	0.8	2.0	1.0	0.1	0.7	0.1	0.1	0.1	0.0	2.0	0.1	0.1	0.7	0.1	0.1	0.5	0.1	0.0	0.1	0.6	0.3	0.5	0.0	0.1	0.1	2.0	7.0	9.2	2.7	0.4	0.1	0.1	0.0	1.6	0.1	0.5	0.1	0.1	0.1	1.2	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.7	0.0	23.0	2.2	3.3	0.0	3.3	11.6	4.9	3.6	0.2	0.9	0.0	0.2	3.1	10.1	4.4	0.0	2.2	0.6	0.1	0.1	7.5	0.0	0.0	0.1	0.1	0.6	0.9	0.0	0.3	0.0	0.9	0.0	3.1	1.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.8	0.0	0.1	2.1	5.2	2.0	18.1	0.0	0.0	0.0	4.0	0.3	0.2	0.0	0.0	0.0	0.0	0.3	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.3	0.1
HOXC13	"HOX3, HOX3G"	ENSG00000123364	"Homeobox C13"	P31276	12	53938765-53946544	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"breast: 4.4;skin 1: 13.5;tongue: 4.1"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 15.4;HaCaT: 32.4;SK-BR-3: 17.9;T-47d: 13.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA051634	Enhanced									"HPA051634: AB_2616459"	"unprognostic (5.16e-3)"	"unprognostic (1.46e-1)"		"unprognostic (1.29e-1)"	"unprognostic (2.27e-3)"	"unprognostic (2.78e-2)"		"unprognostic (1.20e-1)"	"unprognostic (2.20e-1)"	"unprognostic (4.04e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.77e-2)"	"unprognostic (9.74e-9)"	"unprognostic (2.41e-1)"	"unprognostic (1.41e-1)"		"unprognostic (1.68e-1)"	2.6	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.3	0.4	0.5	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.0	0.0	2.5	0.0	0.6	13.5	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	4.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.4	5.1	0.0	15.4	0.2	0.0	9.2	0.9	2.1	1.4	0.8	1.3	0.2	0.0	0.2	0.0	32.4	3.9	1.0	0.8	0.0	3.1	0.0	4.2	0.0	0.0	0.0	3.3	0.0	7.6	0.0	3.0	0.0	5.5	0.0	5.6	9.5	0.0	0.0	0.1	1.3	0.0	0.2	0.0	0.0	2.9	0.0	0.0	5.1	17.9	2.3	13.8	0.0	0.0	0.0	6.7	0.1	2.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0
HOXD11	"HOX4, HOX4F"	ENSG00000128713	"Homeobox D11"	P31277	2	176104216-176109754	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"endometrium 1: 15.8"	"Cell line enhanced"	"Detected in some"		"HEK 293: 20.3;SCLC-21H: 6.2;U-251 MG: 4.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA055155			Supported	Nucleoplasm				Nucleoplasm		"HPA055155: "	"unprognostic (1.99e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.32e-2)"	"unprognostic (9.05e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.48e-1)"		"unprognostic (1.93e-2)"	"unprognostic (2.13e-2)"	"unprognostic (6.73e-2)"		"unprognostic (5.00e-2)"	"unprognostic (2.11e-8)"	"unprognostic (2.09e-3)"	"unprognostic (2.49e-2)"		"unprognostic (2.27e-3)"	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	5.4	4.2	0.0	0.0	0.0	15.8	0.4	0.3	0.1	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	1.6	0.3	5.7	0.9	0.0	0.0	2.9	0.0	0.2	0.0	1.7	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	1.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.2	0.0	0.0	0.1	0.0	20.3	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.3	6.2	0.3	2.4	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0
HOXD13	"HOX4I, SPD"	ENSG00000128714	"Homeobox D13"	P35453	2	176092891-176095938	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 14.0;intestine: 13.1;prostate: 13.8;seminal vesicle: 19.0;vagina: 15.0"	"Group enriched"	"Detected in some"	4	"HAP1: 9.6;HEK 293: 27.6;HL-60: 30.7;NB-4: 18.3;SCLC-21H: 8.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA064064			Approved	Nucleoplasm				Nucleoplasm		"HPA064064: "	"unprognostic (2.04e-1)"	"unprognostic (1.13e-1)"	"prognostic unfavourable (6.95e-5)"	"unprognostic (2.52e-3)"	"unprognostic (7.25e-2)"	"unprognostic (2.08e-2)"		"unprognostic (4.62e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.66e-1)"		"unprognostic (1.01e-2)"	"unprognostic (2.82e-4)"	"unprognostic (4.95e-2)"	"unprognostic (3.70e-2)"		"unprognostic (9.98e-3)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	14.0	13.1	0.1	0.1	0.0	0.3	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.0	0.1	0.1	0.1	13.8	8.8	0.1	0.1	19.0	0.6	0.0	0.1	3.7	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	3.8	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	1.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	9.6	0.0	1.5	0.0	27.6	4.2	0.0	0.0	0.0	30.7	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	18.3	0.9	1.5	0.0	0.1	0.0	0.0	0.2	8.0	1.9	1.9	0.0	4.4	0.0	0.0	0.0	1.0	0.0	0.4	2.5	0.0	0.0	0.0	1.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1
HP		ENSG00000257017	Haptoglobin	P00738	16	72054592-72061055	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Immunity"	"Antibiotic, Antimicrobial, Antioxidant, Serine protease homolog"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	37	"liver: 1156.9"	"Group enriched"	"Detected in some"	5	"Hep G2: 64.7;HSkMC: 37.1"	"Cancer enriched"	"Detected in many"	81	"liver cancer: 1297.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"classical monocyte: 20.0;eosinophil: 30.9"	"Group enriched"	"Detected in many"	7	"granulocytes: 30.9;monocytes: 20.0"									"CAB003787, HPA047750"	Enhanced		Approved	Vesicles	"Secreted to blood"	140000000000	140000000000	Vesicles		"CAB003787: , HPA047750: "	"unprognostic (6.38e-3)"	"unprognostic (7.73e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.41e-2)"	"unprognostic (2.34e-3)"	"unprognostic (2.07e-1)"	"unprognostic (7.79e-3)"	"unprognostic (1.37e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.84e-1)"	"unprognostic (6.30e-2)"	"unprognostic (8.18e-2)"	"prognostic unfavourable (6.94e-13)"	"unprognostic (4.34e-4)"	"unprognostic (1.80e-1)"	"unprognostic (6.61e-2)"	"unprognostic (2.49e-2)"	9.8	0.0	0.3	0.4	0.3	4.4	0.3	0.3	0.3	1.5	0.4	0.3	0.3	0.0	0.3	0.5	0.3	1.1	0.3	3.0	0.3	0.0	0.4	1156.9	1.4	0.4	0.3	0.3	0.3	0.5	0.0	0.5	0.3	0.3	0.3	0.0	0.3	0.3	0.3	0.3	0.0	0.3	0.3	0.3	1.4	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.5	0.0	3.5	30.9	20.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	2.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	2.4	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	3.3	0.0	64.7	0.1	9.2	1.7	37.1	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.5	0.1	0.7	0.0	0.3	6.9	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	2.1	1.4	0.0	0.2	0.0	0.0	1.2	0.0	4.4	0.0	3.6	0.0	2.6	20.0	30.9	0.0	0.8	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	5.8	0.0	0.9	0.0	0.0	5.0	0.3	0.3	0.3	0.3	0.3	0.0	0.3	0.3	0.3	0.3
HPGD	SDR36C1	ENSG00000164120	"15-hydroxyprostaglandin dehydrogenase"	P15428	4	174490177-174523154	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism, Prostaglandin metabolism"	Oxidoreductase	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 193.3"	"Cell line enhanced"	"Detected in some"		"A549: 27.3;ASC diff: 16.9;HEL: 59.7;RT4: 92.8"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 52.4"	"Region enriched"	"Detected in single"	4	"pons and medulla: 3.8"	"Group enriched"	"Detected in many"	5	"basophil: 37.7;T-reg: 15.1"	"Group enriched"	"Detected in many"	71	"granulocytes: 37.7;T-cells: 15.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004919, HPA005679"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"HPA004919: AB_1079081, HPA005679: AB_1079080"	"unprognostic (1.23e-3)"	"unprognostic (1.61e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.08e-1)"	"unprognostic (4.28e-2)"	"unprognostic (3.54e-3)"	"unprognostic (2.34e-2)"	"prognostic favourable (3.20e-4)"	"unprognostic (2.44e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.37e-4)"	"unprognostic (2.33e-2)"	5.1	2.6	0.5	7.9	0.6	0.0	24.6	0.4	0.6	23.0	73.3	0.5	2.5	22.9	13.4	7.5	32.0	4.5	10.7	1.2	0.6	0.7	8.5	63.7	22.9	7.9	0.8	0.5	2.3	0.4	0.0	0.9	193.3	3.8	20.1	8.4	4.6	3.0	1.1	1.6	15.3	64.5	9.3	0.5	2.9	36.3	1.9	0.5	5.5	0.4	5.0	7.9	61.2	31.8	0.1	0.2	37.7	0.1	0.3	15.1	1.0	0.0	27.3	0.0	0.0	16.9	1.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	2.5	2.5	0.0	0.0	0.0	0.5	59.7	2.0	0.0	0.0	0.3	0.1	0.9	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	1.4	2.8	0.0	0.2	5.6	92.8	0.1	0.1	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	37.7	0.1	5.4	3.7	0.0	5.7	0.1	1.9	1.6	0.2	0.0	0.6	1.5	0.4	0.3	0.0	0.0	15.1	1.0	0.5	0.6	0.4	0.6	0.6	0.7	0.8	0.5	3.8	0.5
HPN	TMPRSS1	ENSG00000105707	Hepsin	P05981	19	35040506-35066571	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"kidney: 55.4;liver: 146.5;pancreas: 80.1"	"Group enriched"	"Detected in some"	9	"EFO-21: 19.4;Hep G2: 27.5;T-47d: 13.4"	"Cancer enhanced"	"Detected in many"		"liver cancer: 127.5"	"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 1.2;naive CD8 T-cell: 1.2"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA006804	Approved					1000000	1000000			"HPA006804: AB_1079046"	"unprognostic (6.74e-3)"	"unprognostic (6.00e-2)"	"unprognostic (4.10e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.72e-1)"	"unprognostic (9.96e-2)"	"unprognostic (4.22e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.13e-3)"	"unprognostic (9.54e-2)"	"unprognostic (3.54e-1)"	"unprognostic (1.16e-1)"	"prognostic favourable (5.45e-5)"	"unprognostic (1.22e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.12e-1)"	"unprognostic (7.96e-2)"	0.2	0.0	0.3	0.1	0.5	0.0	3.2	0.4	1.1	0.3	0.3	0.2	8.4	0.2	1.1	10.7	0.1	1.9	3.2	0.7	0.6	0.3	55.4	146.5	4.9	0.1	0.9	0.2	0.4	80.1	2.6	3.2	0.2	0.4	5.3	0.0	0.4	4.1	8.5	8.5	0.0	0.2	0.1	0.9	0.3	6.9	0.8	0.3	0.1	4.3	0.4	0.2	0.3	0.1	0.2	0.2	0.0	0.1	0.0	1.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	2.1	0.0	0.1	19.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.5	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.2	0.0	0.0	0.0	2.0	0.1	0.1	0.0	0.1	13.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.1	0.0	1.0	0.0	0.6	0.2	0.5	1.2	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.2	0.0	0.3	0.3	0.5	0.4	1.1	0.6	0.3	0.9	0.2	0.4	0.3
HRAS	HRAS1	ENSG00000174775	"HRas proto-oncogene, GTPase"	P01112	11	532242-537287	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"			"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002015, HPA049830, HPA070222"	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB002015: , HPA049830: , HPA070222: "	"unprognostic (3.06e-2)"	"unprognostic (2.98e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.08e-3)"	"unprognostic (3.49e-3)"	"unprognostic (3.87e-1)"	"prognostic unfavourable (2.32e-4)"	"unprognostic (1.07e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.88e-3)"	"unprognostic (9.85e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.38e-1)"	12.3	11.4	25.2	9.1	34.5	5.0	16.2	16.1	25.3	7.9	9.5	8.1	10.8	8.9	6.2	9.2	22.3	8.3	10.9	28.7	22.2	22.4	8.2	6.5	8.9	8.0	23.2	12.9	7.7	9.7	11.7	10.3	10.1	15.0	10.0	6.2	8.2	10.1	12.7	51.8	32.0	8.2	8.4	17.0	6.5	7.2	6.1	11.0	5.9	8.1	24.5	9.3	9.9	19.8	2.1	1.1	0.7	4.6	0.1	2.0	0.3	21.8	19.4	9.3	8.3	5.8	4.1	12.0	10.9	5.8	17.1	14.6	9.8	8.7	8.4	3.4	14.8	17.4	9.9	26.5	4.8	6.9	22.1	4.3	7.8	8.5	8.8	3.4	3.3	6.2	29.6	9.2	10.0	8.5	8.8	12.3	9.6	17.9	12.7	12.1	9.4	19.3	10.2	11.8	7.5	9.6	5.4	36.3	14.4	10.1	18.1	7.8	14.8	6.7	13.5	15.3	12.1	5.6	14.0	4.6	6.1	6.5	14.4	6.3	14.3	0.0	0.6	0.7	1.4	1.2	1.6	0.8	1.4	1.3	0.7	2.1	2.0	0.6	0.0	0.1	4.6	1.1	2.0	0.3	25.2	34.5	16.1	21.1	22.2	22.4	23.2	12.9	15.0	11.0
HSF1	HSTF1	ENSG00000185122	"Heat shock transcription factor 1"	Q00613	8	144291591-144314722	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"DNA damage, DNA repair, Host-virus interaction, mRNA processing, mRNA transport, Stress response, Transcription, Transcription regulation, Transport"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004239, HPA008888"	Supported		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB004239: AB_627753, HPA008888: AB_1079088"	"unprognostic (7.08e-2)"	"unprognostic (1.89e-2)"	"unprognostic (6.07e-2)"	"prognostic unfavourable (8.93e-4)"	"unprognostic (1.55e-1)"	"unprognostic (5.63e-2)"	"prognostic unfavourable (4.95e-4)"	"unprognostic (5.69e-3)"	"unprognostic (1.05e-1)"	"unprognostic (4.35e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.12e-1)"	24.7	22.9	17.4	21.0	20.9	20.8	30.8	24.4	23.6	21.3	26.9	18.3	17.7	18.9	23.3	16.7	25.5	28.5	22.9	42.8	17.0	17.5	21.2	19.5	20.3	23.6	17.4	15.9	32.4	36.8	25.8	21.8	22.8	17.8	26.7	15.2	20.7	26.4	24.6	55.2	20.3	17.8	35.1	14.4	20.3	23.6	42.6	17.8	23.2	29.9	24.2	19.8	30.3	33.9	16.9	20.3	20.3	24.2	12.9	18.4	14.2	14.6	19.9	8.6	7.3	14.5	13.6	14.3	11.0	10.0	10.9	9.5	13.3	12.9	16.9	16.2	15.2	10.7	13.1	15.8	7.0	10.7	15.1	21.2	20.4	18.1	22.9	6.1	16.4	13.2	14.9	15.3	28.3	14.7	14.0	10.2	10.9	29.7	20.6	9.4	11.0	57.4	13.4	7.5	21.4	7.8	14.9	13.0	10.5	16.8	13.5	19.4	15.2	12.6	14.8	11.2	25.4	17.6	18.0	7.1	5.4	14.5	16.0	11.5	10.7	10.6	18.9	20.3	14.5	19.9	15.2	16.9	15.7	18.4	20.3	15.5	15.6	13.9	8.1	12.9	24.2	10.3	18.1	14.2	17.4	20.9	24.4	23.6	17.0	17.5	17.4	15.9	17.8	17.8
HSP90AA1	"FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA"	ENSG00000080824	"Heat shock protein 90 alpha family class A member 1"	P07900	14	102080738-102139699	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 519.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002058	Approved		Supported	Cytosol		94000000	94000000	Cytosol		"CAB002058: "	"prognostic unfavourable (5.59e-4)"	"unprognostic (3.77e-2)"	"unprognostic (1.78e-2)"	"unprognostic (9.25e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.05e-3)"	"prognostic unfavourable (3.09e-5)"	"unprognostic (7.79e-3)"	"unprognostic (5.71e-2)"	"unprognostic (7.81e-3)"	"unprognostic (3.68e-2)"	"unprognostic (1.65e-2)"	"prognostic favourable (1.18e-5)"	"unprognostic (1.04e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.12e-1)"	50.8	75.3	96.1	46.7	106.8	64.1	118.6	81.3	113.4	51.0	47.3	50.7	43.0	31.0	40.7	55.5	40.9	94.7	61.0	70.9	99.6	113.3	75.6	62.5	51.7	48.1	134.4	58.6	53.4	40.1	94.9	121.6	67.2	143.6	63.2	53.3	23.4	57.0	57.0	65.2	35.6	38.9	51.0	139.7	35.7	41.3	84.6	132.7	53.5	91.5	34.3	59.5	54.2	519.3	30.7	46.9	31.8	29.9	57.7	63.1	21.9	86.3	118.1	75.4	52.0	45.8	38.8	100.2	96.1	46.2	117.9	66.5	71.7	81.2	106.2	90.5	61.8	95.9	216.5	94.0	215.1	80.3	71.3	82.0	67.5	91.5	22.7	122.0	63.3	36.4	40.0	75.3	27.8	65.0	113.2	54.6	106.6	116.8	130.4	56.1	78.4	111.7	125.8	102.5	45.8	68.4	111.7	99.4	71.7	121.5	91.5	53.6	117.6	48.7	46.0	82.5	53.4	122.6	182.5	51.7	161.1	157.1	78.1	75.4	99.4	31.8	19.9	24.0	47.8	29.9	63.1	29.6	40.5	49.0	23.9	30.7	30.1	43.5	13.5	57.7	27.5	46.9	39.2	21.9	96.1	106.8	81.3	102.7	99.6	113.3	134.4	58.6	143.6	132.7
HSP90AB1	"HSPC2, HSPCB"	ENSG00000096384	"Heat shock protein 90 alpha family class B member 1"	P08238	6	44246166-44253888	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005230, HPA055729, HPA072606, HPA074351"	Enhanced		Supported	Cytosol	"Intracellular and membrane"	62000000	62000000	Cytosol		"CAB005230: AB_2121392, HPA055729: AB_2682899, HPA072606: AB_2732203, HPA074351: AB_2732252"	"unprognostic (6.12e-3)"	"unprognostic (2.96e-3)"	"unprognostic (4.72e-2)"	"unprognostic (9.24e-2)"	"unprognostic (4.20e-1)"	"unprognostic (1.15e-3)"	"unprognostic (1.76e-3)"	"unprognostic (2.74e-1)"	"unprognostic (7.97e-2)"	"prognostic favourable (4.03e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.60e-1)"	"prognostic unfavourable (9.94e-4)"	"unprognostic (3.02e-1)"	"unprognostic (9.53e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.06e-1)"	79.9	116.1	88.0	65.9	105.0	74.6	107.8	92.1	118.2	92.3	60.4	61.7	80.9	40.6	113.3	107.6	71.6	138.4	63.8	115.0	89.0	110.5	72.0	70.7	76.2	73.8	109.7	94.4	238.4	113.9	151.6	95.3	83.6	133.7	93.5	76.4	52.7	64.8	100.3	197.1	67.9	49.0	102.1	93.9	57.5	77.3	45.9	100.2	58.3	133.8	89.8	102.5	86.2	223.4	75.9	50.5	7.2	45.7	55.7	82.5	74.9	138.6	89.0	79.1	97.1	54.3	56.9	82.8	62.7	61.5	116.1	81.8	133.0	42.5	177.7	68.0	65.2	80.9	192.3	93.3	143.7	58.8	77.8	138.3	50.4	173.8	39.3	138.0	95.8	52.5	63.2	91.2	78.8	111.1	184.5	66.3	78.9	140.0	114.9	83.3	92.2	68.2	110.9	80.8	97.5	78.5	84.4	115.8	70.8	48.7	70.6	87.9	91.8	69.1	69.6	69.3	116.0	56.6	143.1	76.8	120.4	321.0	75.3	101.5	78.9	7.2	30.2	6.8	49.3	45.7	82.5	75.9	55.2	56.4	50.5	63.2	75.2	71.3	3.7	55.7	43.3	31.4	42.6	74.9	88.0	105.0	92.1	118.2	89.0	110.5	109.7	94.4	133.7	100.2
HSP90B1	"GP96, GRP94, TRA1"	ENSG00000166598	"Heat shock protein 90 beta family member 1"	P14625	12	103930107-103953645	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 325.1;thyroid gland: 338.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA003901, CAB005224, HPA008424, CAB078151"	Enhanced		Enhanced	"Endoplasmic reticulum"	"Intracellular and membrane"	410000000	410000000	"Endoplasmic reticulum"		"CAB005224: AB_2119181, CAB078151: , HPA003901: AB_1851181, HPA008424: AB_1851184"	"unprognostic (1.03e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.18e-1)"	"unprognostic (5.70e-2)"	"unprognostic (1.17e-2)"	"unprognostic (7.14e-3)"	"unprognostic (3.00e-2)"	"unprognostic (7.22e-2)"	"unprognostic (8.77e-2)"	"unprognostic (8.30e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.43e-2)"	"prognostic unfavourable (1.03e-10)"	"unprognostic (2.95e-1)"	"unprognostic (2.39e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.28e-2)"	49.0	57.1	26.9	50.0	32.0	45.9	60.3	16.5	25.5	45.7	43.4	17.5	108.5	32.1	42.2	127.2	34.3	42.0	32.4	67.0	27.1	32.0	74.0	325.1	46.6	49.2	31.5	26.0	53.9	95.5	47.1	50.0	123.6	29.4	46.9	46.9	15.8	43.8	136.8	25.4	19.2	54.4	45.0	37.8	89.3	37.0	25.7	27.9	44.5	338.5	24.0	36.9	66.1	106.1	25.6	81.0	22.2	23.8	40.2	53.3	33.9	79.2	43.0	86.8	89.1	88.9	84.0	117.8	133.6	101.0	71.2	95.1	76.6	74.3	23.2	106.3	140.2	55.4	85.4	143.5	96.1	54.8	32.6	62.3	48.5	79.0	137.1	62.8	48.9	49.2	64.0	87.6	125.8	136.9	49.8	88.2	94.0	28.5	37.7	70.3	71.3	51.8	34.4	56.0	96.9	95.2	50.0	25.8	61.8	83.4	86.3	84.3	70.2	93.3	78.7	53.9	46.2	43.8	55.7	90.3	84.5	42.9	107.4	46.5	83.4	22.2	21.2	6.9	45.6	23.8	53.3	25.6	26.7	39.3	28.0	15.9	18.0	31.3	4.9	40.2	19.3	81.0	16.4	33.9	26.9	32.0	16.5	25.5	27.1	32.0	31.5	26.0	29.4	27.9
HSPA1L	"HSP70-HOM, hum70t"	ENSG00000204390	"Heat shock protein family A (Hsp70) member 1 like"	P34931	6	31809619-31815065	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"testis: 29.1;vagina: 17.0"	"Cell line enhanced"	"Detected in some"		"ASC diff: 1.9;EFO-21: 2.1;HEK 293: 6.7;U-266/70: 2.8;U-266/84: 2.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Lineage enriched"	"Detected in single"	4	"T-cells: 1.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			"HPA043285, HPA052504"	Enhanced		Approved	Nucleoplasm,Vesicles		49000000	49000000	Vesicles	Nucleoplasm	"HPA043285: AB_10962482, HPA052504: "	"unprognostic (1.80e-1)"	"unprognostic (8.70e-2)"	"unprognostic (2.52e-3)"	"unprognostic (6.97e-4)"	"unprognostic (2.69e-2)"	"unprognostic (1.17e-2)"	"unprognostic (4.24e-2)"	"unprognostic (4.33e-2)"	"unprognostic (1.71e-1)"	"prognostic favourable (1.02e-4)"	"unprognostic (5.26e-3)"	"unprognostic (9.96e-2)"	"prognostic favourable (4.63e-4)"	"unprognostic (4.48e-2)"	"unprognostic (4.30e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.53e-3)"	0.4	0.5	1.8	0.5	2.2	0.5	1.2	1.4	3.1	0.5	0.7	1.5	0.0	0.3	0.8	3.0	0.8	1.5	0.3	0.5	2.0	1.1	0.9	0.7	1.7	0.7	4.5	0.8	1.1	1.5	0.3	0.7	1.0	2.6	1.2	0.6	0.2	0.4	1.5	3.9	0.6	0.8	0.5	4.6	1.1	0.8	29.1	3.2	0.0	2.0	0.0	0.7	0.5	17.0	0.3	0.0	0.4	0.1	0.0	1.7	1.1	0.0	1.7	0.0	0.0	1.9	1.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.5	0.0	0.0	0.9	0.0	0.0	6.7	0.0	0.0	0.2	0.2	1.4	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.2	0.0	0.2	0.7	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.2	0.0	0.0	0.2	0.3	0.0	2.8	2.4	0.0	1.7	0.0	0.0	0.0	0.1	0.4	0.4	0.0	0.0	0.0	1.0	1.3	0.0	0.3	1.5	1.6	0.3	0.0	0.0	0.0	1.7	1.1	1.8	2.2	1.4	3.1	2.0	1.1	4.5	0.8	2.6	3.2
HSPA2		ENSG00000126803	"Heat shock protein family A (Hsp70) member 2"	P54652	14	64535905-64546173	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Spermatogenesis, Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 87.0;skeletal muscle: 90.5"	"Cell line enhanced"	"Detected in many"		"A549: 24.6;BEWO: 38.4;BJ hTERT+: 32.8;SCLC-21H: 34.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000798, HPA052504"	Enhanced	Supported	Approved	Nucleoplasm,Vesicles		77000000	77000000	Vesicles	Nucleoplasm	"HPA000798: AB_1079090, HPA052504: "	"prognostic favourable (1.78e-4)"	"unprognostic (1.72e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.08e-2)"	"unprognostic (3.78e-2)"	"unprognostic (2.90e-2)"	"unprognostic (7.11e-2)"	"prognostic unfavourable (9.11e-4)"	"unprognostic (1.31e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.09e-1)"	"unprognostic (2.60e-1)"	"unprognostic (5.31e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.90e-1)"	"unprognostic (8.36e-2)"	"unprognostic (1.25e-1)"	5.2	3.3	21.1	5.2	45.3	1.5	5.2	3.7	37.6	3.3	23.3	87.0	0.1	4.4	13.8	12.8	25.2	7.2	4.2	22.8	33.2	18.7	26.6	2.6	4.5	3.2	71.0	20.6	2.4	3.8	7.5	4.3	37.6	37.7	3.8	6.9	3.5	10.2	4.0	90.5	14.8	7.8	17.9	83.8	8.5	5.7	58.8	65.2	0.0	2.3	8.2	3.9	12.4	4.0	0.7	0.3	2.4	0.6	0.9	3.7	0.5	9.6	24.6	3.8	0.0	2.7	0.2	38.4	13.9	32.8	5.6	9.2	0.9	17.4	2.4	5.6	15.1	11.0	0.0	0.7	3.4	1.3	1.9	0.0	1.4	0.0	2.7	0.0	3.3	1.2	0.5	0.8	0.0	0.3	0.0	2.0	2.7	4.3	0.1	0.1	2.8	3.0	1.9	0.0	0.0	8.6	1.5	34.1	1.9	0.6	1.2	0.0	0.9	1.0	0.5	0.1	0.0	1.2	0.0	2.5	0.0	0.0	3.1	0.0	3.7	0.9	0.2	0.1	1.8	0.4	0.1	0.7	1.7	0.8	0.0	0.5	0.6	0.6	2.4	0.9	0.6	0.3	3.7	0.5	21.1	45.3	3.7	28.3	33.2	18.7	71.0	20.6	37.7	65.2
HSPA4	"HS24/P52, HSPH2"	ENSG00000170606	"Heat shock protein family A (Hsp70) member 4"	P34932	5	133051962-133106449	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Stress response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010023, CAB025529"	Uncertain		Supported	Nucleoplasm,Cytosol		10000000	10000000	"Nucleoplasm, Cytosol"		"CAB025529: , HPA010023: AB_1851206"	"unprognostic (2.54e-2)"	"unprognostic (3.59e-1)"	"unprognostic (2.91e-2)"	"unprognostic (2.62e-1)"	"unprognostic (5.30e-2)"	"unprognostic (2.52e-3)"	"prognostic unfavourable (4.13e-4)"	"unprognostic (2.31e-3)"	"unprognostic (2.90e-1)"	"unprognostic (2.40e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.85e-1)"	"unprognostic (4.44e-3)"	"unprognostic (2.54e-1)"	"unprognostic (1.09e-1)"	"unprognostic (4.05e-2)"	"unprognostic (1.41e-1)"	20.6	35.0	26.6	25.6	27.6	20.5	39.0	25.9	35.6	19.4	20.5	18.7	19.9	17.4	23.3	20.2	42.0	19.2	18.9	32.9	26.4	31.9	30.3	31.1	17.2	28.9	30.9	24.5	23.2	19.5	37.1	32.8	24.5	34.3	18.9	23.9	16.0	20.3	19.2	48.3	19.6	18.5	23.6	25.9	20.0	20.9	39.8	29.5	27.3	26.8	24.8	38.6	24.5	77.1	27.7	17.9	15.5	23.0	14.1	14.9	11.5	34.2	47.2	33.0	53.7	31.4	26.5	59.9	37.6	28.3	36.5	45.3	88.6	36.0	57.0	39.6	36.1	30.6	57.2	62.2	52.9	26.3	32.8	42.0	31.7	48.5	25.1	26.0	36.9	26.3	26.3	47.0	30.9	34.8	43.9	17.7	39.8	30.2	36.6	19.4	45.2	21.9	33.6	40.4	30.3	33.0	45.2	26.3	21.6	35.8	18.8	50.0	27.6	25.6	30.4	33.3	47.9	28.4	44.5	20.3	45.0	43.8	28.5	43.3	33.0	14.8	14.4	15.5	12.6	23.0	14.9	22.6	11.6	13.0	17.9	27.7	12.1	11.2	9.6	14.1	16.4	6.8	11.3	11.5	26.6	27.6	25.9	35.6	26.4	31.9	30.9	24.5	34.3	29.5
HSPA8	"HSC70, HSC71, HSP73, HSPA10"	ENSG00000109971	"Heat shock protein family A (Hsp70) member 8"	P11142	11	123057489-123063230	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, mRNA processing, mRNA splicing, Stress response, Transcription, Transcription regulation"	"Chaperone, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002056, HPA052504"	Uncertain		Approved	Nucleoplasm,Vesicles		210000000	210000000	Nucleoplasm	Vesicles	"CAB002056: , HPA052504: "	"unprognostic (2.28e-3)"	"unprognostic (1.19e-3)"	"prognostic favourable (6.14e-6)"	"unprognostic (1.75e-1)"	"unprognostic (1.84e-2)"	"unprognostic (5.70e-2)"	"prognostic unfavourable (1.93e-4)"	"unprognostic (9.65e-3)"	"unprognostic (3.82e-1)"	"unprognostic (9.64e-2)"	"unprognostic (2.93e-1)"	"unprognostic (3.22e-1)"	"prognostic favourable (3.81e-4)"	"unprognostic (2.53e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.74e-1)"	"unprognostic (7.16e-2)"	70.0	96.8	93.7	78.1	102.8	58.1	73.8	119.5	125.1	52.8	64.1	72.0	77.3	77.7	59.9	98.3	83.4	76.2	76.7	106.4	83.1	102.4	128.6	114.2	68.9	93.3	105.7	72.4	66.7	191.1	97.2	98.3	71.6	169.2	65.3	81.0	53.1	62.4	69.9	224.6	31.2	74.4	75.4	91.8	79.7	92.7	58.3	98.1	92.9	90.9	98.3	124.4	76.1	123.2	77.4	47.5	41.1	84.2	76.1	124.3	200.0	82.8	125.6	83.4	72.0	77.2	82.8	110.5	164.7	91.3	201.5	121.3	188.4	109.0	134.9	104.0	91.6	112.9	238.2	59.7	201.2	116.6	36.2	146.4	59.0	91.8	21.1	142.2	112.5	44.1	96.6	61.9	19.3	107.8	158.4	70.2	161.4	73.8	147.8	105.6	131.9	111.9	133.4	59.5	76.3	104.4	60.6	85.6	64.9	120.0	130.3	45.4	113.6	55.7	105.9	101.2	81.3	87.0	145.9	47.4	116.9	115.8	112.8	203.3	122.1	30.3	41.5	41.1	96.5	82.9	115.9	77.4	113.4	105.2	47.5	53.7	109.6	105.1	14.9	76.1	84.2	34.4	124.3	200.0	93.7	102.8	119.5	125.1	83.1	102.4	105.7	72.4	169.2	98.1
HSPB1	"CMT2F, Hs.76067, Hsp25, HSP27, HSP28"	ENSG00000106211	"Heat shock protein family B (small) member 1"	P04792	7	76302544-76304295	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Stress response"	Chaperone	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 565.5"	"Cell line enhanced"	"Detected in many"		"hTCEpi: 162.0;MCF7: 227.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000497, CAB004439, CAB047330, CAB047331, CAB047332"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		57000000	57000000	"Plasma membrane, Cytosol"		"CAB004439: AB_627755, CAB047330: , CAB047331: , CAB047332: , HPA000497: AB_1851172"	"unprognostic (2.55e-1)"	"unprognostic (7.25e-3)"	"prognostic unfavourable (9.94e-5)"	"unprognostic (7.07e-3)"	"unprognostic (3.47e-3)"	"unprognostic (6.61e-3)"	"unprognostic (4.08e-3)"	"unprognostic (4.50e-2)"	"unprognostic (1.27e-1)"	"unprognostic (9.78e-2)"	"unprognostic (8.70e-2)"	"unprognostic (2.21e-1)"	"unprognostic (5.72e-2)"	"unprognostic (5.18e-2)"	"unprognostic (2.67e-1)"	"unprognostic (2.56e-1)"	"unprognostic (3.63e-1)"	67.6	41.7	23.0	42.9	22.8	7.3	186.2	10.1	21.3	127.6	84.9	10.8	89.2	27.1	126.5	65.9	410.5	57.7	52.2	164.8	21.4	22.5	85.4	26.3	43.3	25.1	25.7	14.3	63.4	34.7	16.6	15.5	106.9	32.8	99.6	12.0	31.1	50.5	101.3	439.2	164.4	24.6	139.7	27.3	17.8	37.6	22.0	23.4	31.9	72.9	207.3	126.8	146.2	565.5	27.8	17.8	4.1	27.9	23.2	36.8	14.4	72.6	54.0	5.8	43.1	35.1	31.1	0.3	30.9	16.3	16.8	21.1	4.8	42.6	0.6	23.9	40.0	66.7	25.3	18.1	5.4	40.5	8.5	3.3	41.7	22.8	18.8	4.9	30.5	38.6	162.0	25.3	3.7	55.4	26.4	74.3	19.2	227.6	8.3	33.6	29.6	47.3	25.7	11.9	59.0	24.9	27.7	0.4	33.1	21.7	88.6	27.6	104.4	34.8	29.9	50.5	75.3	15.7	77.9	5.2	8.6	0.7	36.9	15.2	36.7	4.1	4.5	2.8	18.6	21.1	9.6	27.5	30.6	20.2	11.1	27.8	36.8	31.5	1.7	23.2	27.9	17.8	19.7	14.4	23.0	22.8	10.1	21.3	21.4	22.5	25.7	14.3	32.8	23.4
HSPD1	"GroEL, HSP60, SPG13"	ENSG00000144381	"Heat shock protein family D (Hsp60) member 1"	P10809	2	197486581-197516737	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Host-virus interaction"	"Chaperone, Isomerase"	"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Leukodystrophy, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 162.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA001523, CAB002775, HPA050025, CAB072816"	Supported		Enhanced	Mitochondria		53000000	53000000	Mitochondria		"CAB002775: , CAB072816: , HPA001523: AB_1079028, HPA050025: AB_2680995"	"unprognostic (2.79e-2)"	"unprognostic (1.72e-2)"	"unprognostic (5.21e-2)"	"prognostic unfavourable (1.61e-4)"	"unprognostic (2.59e-1)"	"unprognostic (3.57e-3)"	"prognostic unfavourable (2.25e-4)"	"unprognostic (3.51e-2)"	"unprognostic (9.91e-2)"	"unprognostic (8.63e-3)"	"unprognostic (3.47e-2)"	"unprognostic (7.83e-3)"	"unprognostic (5.64e-3)"	"unprognostic (1.73e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.61e-2)"	"unprognostic (4.10e-2)"	28.5	125.2	28.7	23.4	31.8	21.0	55.9	18.2	24.3	17.4	30.3	17.8	23.3	28.9	17.5	18.5	27.2	25.3	16.3	24.0	24.2	27.8	67.1	147.5	22.4	25.3	35.5	16.1	30.2	50.6	32.5	25.9	27.1	33.6	25.9	37.2	11.9	17.6	21.0	36.4	13.7	32.0	23.6	32.4	22.7	25.2	10.9	35.8	22.7	38.7	29.4	30.3	33.3	162.6	25.6	30.3	6.2	29.3	23.1	33.5	22.2	40.4	49.8	41.8	37.5	28.7	30.0	60.8	42.2	22.3	50.8	37.3	167.0	24.4	123.1	55.1	22.0	41.4	163.6	46.5	72.1	30.2	65.6	87.4	80.6	193.3	27.0	96.8	27.5	33.9	54.0	45.0	79.4	39.8	107.6	48.3	37.3	51.8	60.1	98.0	82.6	104.2	72.3	51.6	88.9	53.4	42.3	54.8	31.0	42.3	45.8	54.1	31.7	57.5	17.7	31.6	43.8	40.6	66.6	27.1	59.6	102.2	37.1	58.5	33.9	4.5	19.7	5.3	15.5	29.3	28.8	25.6	25.0	21.8	30.3	21.0	33.5	29.0	6.2	23.1	25.8	20.2	19.7	22.2	28.7	31.8	18.2	24.3	24.2	27.8	35.5	16.1	33.6	35.8
HSPE1	"CPN10, EPF, GroES, HSP10"	ENSG00000115541	"Heat shock protein family E (Hsp10) member 1"	P61604	2	197499994-197503457	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 196.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB017366, HPA038755, HPA048272"	Supported					9000000	9000000			"CAB017366: AB_10998950, HPA038755: , HPA048272: "	"unprognostic (2.75e-2)"	"unprognostic (6.89e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.43e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.85e-2)"	"unprognostic (5.83e-3)"	"unprognostic (4.14e-2)"	"unprognostic (1.26e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.39e-2)"	"unprognostic (6.21e-3)"	"unprognostic (2.63e-1)"	"unprognostic (4.51e-2)"	"unprognostic (6.30e-2)"	"unprognostic (1.94e-1)"	"unprognostic (7.08e-3)"	24.9	134.7	38.4	25.0	35.0	17.8	50.6	17.1	41.2	19.1	39.9	16.3	20.3	30.8	15.8	31.7	24.3	21.1	16.7	33.8	33.7	37.3	62.5	120.9	18.6	23.8	51.5	26.8	22.7	35.9	14.9	27.2	26.0	48.3	21.9	39.0	9.1	25.1	27.6	39.1	13.0	27.7	17.9	46.7	18.6	21.7	9.4	45.7	10.4	30.6	31.5	30.8	20.2	116.3	50.8	44.9	3.6	29.0	31.5	48.1	28.0	34.4	45.7	42.3	31.2	29.3	14.7	52.4	37.8	16.9	32.9	30.8	138.0	29.2	64.9	48.7	17.9	29.8	106.4	36.6	38.4	31.2	45.5	69.5	91.6	196.9	12.9	93.7	30.2	20.1	25.0	33.1	16.4	29.2	87.0	21.6	22.1	49.7	70.3	91.5	61.8	84.1	43.0	37.7	76.6	44.9	51.8	33.2	21.4	35.8	42.2	29.8	16.4	49.8	22.6	27.2	38.7	30.0	61.1	25.7	58.5	111.3	30.5	42.5	36.8	3.6	16.7	3.3	30.2	29.0	38.4	50.8	40.3	37.1	27.0	37.1	45.8	48.1	1.8	31.5	22.1	44.9	32.0	28.0	38.4	35.0	17.1	41.2	33.7	37.3	51.5	26.8	48.3	45.7
HSPH1	"HSP105A, HSP105B, KIAA0201, NY-CO-25"	ENSG00000120694	"Heat shock protein family H (Hsp110) member 1"	Q92598	13	31134974-31162388	"Cancer-related genes, Predicted intracellular proteins"	"Stress response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"vagina: 286.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002060, HPA028675, HPA031569"	Uncertain		Enhanced	Nucleoplasm,Cytosol		820000	820000	Cytosol	Nucleoplasm	"CAB002060: AB_563775, HPA028675: AB_10601581, HPA031569: AB_2673938"	"unprognostic (1.10e-2)"	"unprognostic (4.94e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.05e-1)"	"prognostic unfavourable (4.90e-4)"	"prognostic unfavourable (1.41e-5)"	"unprognostic (5.03e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.13e-1)"	"unprognostic (7.45e-3)"	"unprognostic (9.61e-2)"	"unprognostic (2.58e-1)"	"unprognostic (2.04e-1)"	"unprognostic (7.89e-2)"	13.7	19.8	36.6	12.2	57.1	9.8	33.7	11.7	44.0	14.7	10.6	9.8	13.0	6.1	13.3	21.7	13.9	31.0	18.1	14.2	34.8	40.3	16.6	14.8	15.9	17.4	36.5	16.3	13.4	10.1	15.1	24.1	19.8	32.7	14.5	14.5	3.6	7.0	17.3	10.5	11.0	6.4	15.7	34.8	9.0	12.2	35.0	34.6	12.1	22.5	7.8	23.8	17.0	286.1	9.0	6.8	2.1	14.6	13.7	12.8	5.5	14.5	27.8	23.0	2.2	22.1	12.6	15.3	25.2	22.4	39.2	18.3	32.7	22.6	37.7	15.8	17.5	28.2	88.5	22.4	50.6	29.5	11.1	32.7	15.4	28.8	7.3	22.6	26.1	7.9	51.8	26.1	15.0	22.6	27.3	6.0	27.4	19.8	32.4	25.9	32.7	20.8	25.6	18.8	12.5	29.5	17.7	23.8	19.8	22.9	22.6	11.6	7.5	22.0	13.7	13.5	17.2	19.4	27.8	4.7	15.4	32.3	11.2	27.5	22.5	1.0	3.9	2.1	6.6	9.6	8.1	9.0	8.4	10.0	6.8	7.8	12.8	11.9	0.4	13.7	14.6	5.3	5.3	5.5	36.6	57.1	11.7	44.0	34.8	40.3	36.5	16.3	32.7	34.6
HUWE1	"Ib772, KIAA0312, UREB1"	ENSG00000086758	"HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase"	Q7Z6Z7	X	53532096-53686729	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Biological rhythms, Differentiation, DNA damage, DNA repair, Ubl conjugation pathway"	"DNA-binding, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002548, CAB022718"	Approved		Enhanced	Nucleoplasm,Cytosol		3400	3400	"Nucleoplasm, Cytosol"		"CAB022718: , HPA002548: AB_1080489"	"unprognostic (4.73e-2)"	"unprognostic (9.06e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.59e-2)"	"unprognostic (6.64e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.21e-1)"	"unprognostic (3.56e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.33e-1)"	"unprognostic (8.89e-2)"	"unprognostic (8.10e-3)"	"unprognostic (2.17e-1)"	"unprognostic (1.32e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.45e-1)"	24.6	28.2	27.7	23.8	43.3	22.4	28.0	37.0	41.1	31.8	25.9	34.3	26.6	17.1	31.9	52.4	27.4	26.5	23.1	27.1	28.0	31.8	30.3	26.2	20.3	23.1	30.0	30.2	43.3	27.8	59.8	34.2	27.2	34.6	27.3	22.7	25.6	26.4	29.6	59.1	50.1	22.1	33.9	23.9	26.6	25.7	28.4	27.7	32.4	27.6	20.7	28.6	27.0	22.9	5.1	7.2	8.2	7.0	6.9	8.9	3.5	50.1	30.9	20.1	14.2	35.3	21.1	24.8	15.1	19.5	15.9	16.7	23.5	16.2	26.3	10.3	27.4	24.1	45.4	25.3	21.8	37.9	20.1	20.9	27.7	18.3	32.5	31.3	12.9	20.1	19.0	38.2	43.9	27.5	20.8	17.1	20.6	30.9	16.9	17.5	27.5	22.3	15.7	27.8	15.9	26.4	34.8	16.8	12.1	42.6	19.0	13.6	27.2	15.2	35.0	14.7	21.1	20.9	19.2	15.0	14.7	23.0	15.7	30.7	21.1	4.0	4.7	8.2	7.2	3.8	8.9	5.1	6.9	7.6	6.7	5.1	4.9	4.9	4.2	6.9	7.0	7.2	5.7	3.5	27.7	43.3	37.0	41.1	28.0	31.8	30.0	30.2	34.6	27.7
IBSP	"BSP, BSP-II, SP-II"	ENSG00000029559	"Integrin binding sialoprotein"	P21815	4	87799581-87812435	"Cancer-related genes, Predicted secreted proteins"	"Biomineralization, Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 4.5;cervix, uterine: 4.0;pituitary gland: 6.2"	"Cell line enriched"	"Detected in some"	6	"U-138 MG: 12.6"	"Cancer enhanced"	"Detected in many"		"glioma: 12.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"basal ganglia: 0.9"	"Not detected"	"Not detected"								"Secreted in other tissues"						"unprognostic (2.53e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.49e-2)"	"unprognostic (3.93e-1)"	"unprognostic (3.75e-2)"	"unprognostic (9.48e-3)"	"unprognostic (1.03e-3)"	"unprognostic (4.07e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.02e-3)"		"unprognostic (5.81e-11)"	"unprognostic (6.20e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.30e-3)"	"unprognostic (2.11e-1)"	0.2	0.0	1.9	0.6	0.4	1.0	0.1	2.0	4.5	4.0	0.1	0.0	0.0	0.0	0.7	0.0	0.1	0.1	0.8	1.3	1.0	0.1	0.0	0.0	0.2	0.1	0.9	0.0	0.0	0.2	0.8	6.2	1.1	2.6	0.4	0.0	0.0	0.3	0.0	0.6	0.1	0.0	0.3	0.2	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.0	1.8	0.3	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.4	2.0	1.5	1.0	0.1	0.9	0.0	2.6	0.0
ICAM1	"BB2, CD54"	ENSG00000090339	"Intercellular adhesion molecule 1"	P05362	19	10270835-10286615	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 68.3;lung: 91.3"	"Cell line enhanced"	"Detected in many"		"HHSteC: 31.1;Karpas-707: 88.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA002126, CAB002142, HPA004877"	Enhanced		Uncertain	"Plasma membrane,Cytosol"		3100000000	3100000000	"Plasma membrane, Cytosol"		"CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317"	"prognostic favourable (7.09e-4)"	"unprognostic (1.88e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.63e-2)"	"unprognostic (3.25e-3)"	"unprognostic (3.05e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.48e-1)"	"unprognostic (3.18e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.49e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavourable (1.32e-6)"	"unprognostic (2.77e-1)"	"unprognostic (2.16e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.70e-3)"	26.1	8.6	4.0	41.0	4.1	36.5	15.0	1.0	4.5	5.6	10.0	2.7	1.6	6.1	8.5	7.7	7.9	10.7	19.8	16.3	2.6	2.1	10.9	68.3	91.3	32.8	5.4	1.7	12.4	7.2	2.5	4.0	9.3	6.8	10.4	6.6	10.6	7.2	3.6	13.9	6.9	7.9	8.0	7.8	42.2	7.3	6.5	3.6	8.3	11.6	13.7	13.4	14.8	17.1	2.2	13.3	22.2	14.2	7.9	5.6	8.9	8.2	0.1	1.5	0.0	0.4	0.9	2.1	1.7	18.5	4.1	12.5	2.7	9.3	7.6	25.8	0.7	1.7	0.3	0.0	8.7	22.7	0.0	0.7	0.2	11.3	31.1	0.2	4.5	10.9	0.7	2.6	4.0	2.1	2.8	88.5	0.3	0.6	0.1	6.4	0.5	4.7	0.2	0.0	28.1	7.0	0.0	0.0	0.2	11.4	0.6	18.1	1.4	0.5	6.4	4.2	0.4	2.3	0.1	27.0	27.8	4.7	6.8	4.9	6.2	2.2	13.9	2.6	3.0	14.2	5.6	2.2	2.4	3.6	13.3	0.9	1.0	2.2	22.2	7.9	7.9	7.5	3.4	8.9	4.0	4.1	1.0	4.5	2.6	2.1	5.4	1.7	6.8	3.6
ID1	"bHLHb24, dJ857M17.1.2"	ENSG00000125968	"Inhibitor of DNA binding 1, HLH protein"	P41134	20	31605283-31606515	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Developmental protein, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"seminal vesicle: 163.1"	"Cell line enhanced"	"Detected in many"		"EFO-21: 75.1;HaCaT: 71.6;Hep G2: 59.5;PC-3: 74.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 3.9"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 3.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025915, HPA051456, HPA058518"	Approved		Enhanced	Nucleoplasm	"Intracellular and membrane"			Nucleoplasm		"CAB025915: , HPA051456: , HPA058518: "	"unprognostic (3.89e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.62e-2)"	"unprognostic (3.19e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.35e-1)"	"prognostic unfavourable (4.85e-4)"	"unprognostic (2.29e-1)"	"unprognostic (1.58e-1)"	"unprognostic (2.14e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.71e-3)"	"unprognostic (2.97e-1)"	"unprognostic (6.17e-3)"	"unprognostic (3.41e-3)"	28.6	12.3	8.2	15.2	9.1	4.4	33.2	5.6	13.8	36.3	33.3	15.4	38.5	36.4	25.9	11.6	78.0	25.1	19.0	33.5	8.7	8.4	22.3	23.4	57.4	17.9	10.0	7.9	12.3	5.8	4.0	25.7	22.1	14.3	56.4	13.1	34.9	10.5	163.1	23.0	16.5	40.6	16.9	8.1	15.3	48.6	7.8	4.0	2.4	78.8	36.2	21.0	80.0	26.4	0.4	0.7	3.9	0.7	0.3	0.5	0.5	10.5	35.1	0.4	7.1	4.6	2.1	27.4	45.0	1.8	8.3	0.9	18.5	16.0	0.0	75.1	12.0	71.6	5.8	2.5	1.3	0.8	3.7	5.8	30.4	59.5	6.3	0.1	0.3	8.6	10.2	0.0	0.6	5.0	12.9	0.3	15.9	13.8	1.5	0.2	25.2	74.9	0.1	29.3	0.5	1.6	29.4	13.7	12.8	37.4	13.4	0.3	8.2	1.0	26.8	22.3	43.5	7.1	30.2	0.8	0.8	0.6	26.0	5.6	3.0	0.0	0.6	0.9	0.1	0.2	0.0	0.1	0.1	0.0	0.7	0.4	0.0	0.5	3.9	0.3	0.7	0.0	0.0	0.5	8.2	9.1	5.6	13.8	8.7	8.4	10.0	7.9	14.3	4.0
ID2	"bHLHb26, GIG8"	ENSG00000115738	"Inhibitor of DNA binding 2"	Q02363	2	8678845-8684453	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Developmental protein, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 274.1"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 107.5;HEK 293: 69.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 110.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA027612			Approved	"Nucleoplasm,Nuclear bodies,Centrosome"				"Nucleoplasm, Nuclear bodies"	Centrosome	"HPA027612: AB_10599729"	"unprognostic (2.53e-1)"	"unprognostic (8.16e-3)"	"unprognostic (8.51e-2)"	"unprognostic (6.66e-2)"	"unprognostic (2.24e-1)"	"prognostic favourable (9.95e-4)"	"unprognostic (4.39e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.95e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.81e-1)"	"unprognostic (5.98e-2)"	"unprognostic (2.42e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.38e-3)"	"unprognostic (1.92e-3)"	34.2	37.4	24.9	19.1	20.6	69.8	31.5	11.3	57.3	21.9	34.0	22.9	13.2	20.7	18.6	11.6	12.1	28.1	33.5	46.1	20.0	14.6	31.2	117.5	25.4	22.4	19.0	35.3	59.7	15.0	274.1	17.2	14.8	20.0	27.2	26.4	13.3	24.5	72.7	8.8	16.6	20.4	19.2	15.8	21.3	16.2	7.1	14.2	19.0	46.8	15.1	10.2	31.8	38.0	0.3	25.0	110.4	26.0	90.9	42.4	18.0	0.2	19.9	8.2	10.1	13.2	2.1	31.4	22.7	2.7	10.2	4.3	39.8	1.0	0.5	27.0	38.8	17.1	5.3	0.1	3.0	107.5	69.6	14.3	12.2	48.6	3.9	10.6	40.3	3.6	0.4	4.6	0.2	0.2	0.8	17.0	15.7	6.7	1.1	1.2	14.9	15.7	1.4	5.7	10.7	10.2	8.9	15.5	22.0	1.2	17.3	1.7	2.8	6.3	4.1	12.6	2.2	18.6	1.3	1.3	1.0	12.4	15.9	32.8	6.8	9.0	8.2	110.4	42.4	24.2	25.3	0.3	13.1	29.5	25.0	0.2	16.4	31.4	11.2	90.9	26.0	1.1	1.0	18.0	24.9	20.6	11.3	57.3	20.0	14.6	19.0	35.3	20.0	14.2
ID3	"bHLHb25, HEIR-1"	ENSG00000117318	"Inhibitor of DNA binding 3, HLH protein"	Q02535	1	23557918-23559794	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Myogenesis, Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"seminal vesicle: 117.9"	"Cell line enhanced"	"Detected in many"		"U-698: 82.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 47.4;naive B-cell: 42.9"	"Group enriched"	"Detected in many"	37	"B-cells: 47.4;T-cells: 24.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB021353, HPA024677"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB021353: , HPA024677: "	"unprognostic (6.73e-2)"	"unprognostic (2.48e-1)"	"unprognostic (5.19e-2)"	"prognostic favourable (1.27e-5)"	"unprognostic (5.58e-3)"	"unprognostic (1.46e-1)"	"unprognostic (8.98e-2)"	"unprognostic (7.76e-2)"	"unprognostic (3.89e-2)"	"unprognostic (6.47e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.52e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.01e-1)"	"unprognostic (4.37e-3)"	"unprognostic (8.36e-2)"	33.5	12.2	13.3	18.9	15.5	6.0	41.6	2.4	14.4	22.0	25.9	16.6	31.4	18.9	21.7	17.8	20.6	33.8	22.9	42.2	21.1	12.4	21.3	11.1	25.8	15.3	16.6	9.1	27.2	10.2	4.2	31.1	31.3	17.7	38.9	13.0	42.6	9.1	117.9	17.0	14.2	17.0	13.3	16.9	12.4	21.6	6.9	20.7	20.5	82.8	19.3	10.7	35.0	72.1	47.4	0.9	0.5	0.2	0.0	24.9	6.1	3.2	20.0	6.9	24.0	3.1	0.4	8.0	24.1	2.1	13.5	1.7	1.2	0.1	21.4	24.9	9.0	27.6	8.5	3.2	1.3	0.1	8.8	0.3	26.1	10.7	9.7	0.0	0.0	10.1	16.9	0.3	0.2	12.0	0.1	0.2	12.2	7.9	2.8	0.0	6.0	5.0	26.7	12.7	0.7	0.1	7.6	10.1	7.9	23.0	17.1	1.7	4.4	0.5	24.7	19.1	10.2	9.5	12.5	6.7	6.0	82.5	4.2	0.2	11.1	0.0	0.2	0.0	0.6	0.2	0.2	47.4	10.9	2.1	0.7	42.9	18.2	7.2	0.5	0.0	0.2	0.9	24.9	6.1	13.3	15.5	2.4	14.4	21.1	12.4	16.6	9.1	17.7	20.7
IDH1		ENSG00000138413	"Isocitrate dehydrogenase (NADP(+)) 1, cytosolic"	O75874	2	208236227-208266074	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Glyoxylate bypass, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 108.5;RT4: 75.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB033218, HPA035248, HPA057936, CAB062556"	Enhanced		Approved	"Nuclear bodies,Cytosol"		16000000	16000000	"Nuclear bodies, Cytosol"		"CAB033218: AB_2123166, CAB062556: , HPA035248: AB_10600714, HPA057936: "	"unprognostic (2.79e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.47e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.39e-2)"	"prognostic unfavourable (6.93e-5)"	"unprognostic (3.32e-1)"	"unprognostic (2.20e-3)"	"unprognostic (8.03e-2)"	"unprognostic (5.54e-2)"	"unprognostic (4.18e-3)"	"prognostic unfavourable (2.45e-5)"	"unprognostic (2.09e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.69e-2)"	41.3	82.3	6.2	8.8	7.0	1.3	20.9	6.5	8.3	12.6	35.2	8.7	38.0	30.6	8.0	29.9	30.3	8.8	18.7	10.8	6.3	6.2	20.5	91.0	19.8	14.3	8.1	4.7	19.4	21.5	4.8	6.2	24.1	8.7	38.5	23.1	15.4	18.7	39.0	4.7	7.4	54.1	10.1	9.3	21.3	20.4	15.6	8.4	3.5	7.9	11.0	11.9	43.4	12.1	4.9	22.8	6.4	31.6	7.4	6.6	12.0	9.6	16.2	23.2	9.4	42.2	30.1	13.2	4.0	18.4	6.8	16.6	25.6	23.6	1.9	25.6	12.5	14.9	16.7	19.4	6.6	1.3	6.3	8.3	13.4	108.5	56.2	5.4	8.3	25.9	41.3	15.5	11.3	18.7	8.3	6.7	10.4	6.1	3.8	9.3	42.4	6.7	3.7	8.4	5.4	30.6	75.8	4.0	6.9	15.3	14.8	50.1	5.7	15.8	12.3	6.9	7.0	9.8	4.3	3.2	5.0	2.5	22.4	32.8	5.5	5.7	31.6	4.8	4.5	14.5	5.1	4.9	4.0	5.3	22.8	4.9	3.3	3.9	6.4	7.4	6.5	8.4	6.6	12.0	6.2	7.0	6.5	8.3	6.3	6.2	8.1	4.7	8.7	8.4
IDH2		ENSG00000182054	"Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial"	P48735	15	90083045-90102504	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Glyoxylate bypass, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 126.2;skeletal muscle: 190.7"	"Cell line enhanced"	"Detected in all"		"MOLT-4: 68.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007831	Enhanced		Supported	Mitochondria		53000000	53000000	Mitochondria		"HPA007831: AB_1851397"	"unprognostic (2.45e-2)"	"prognostic favourable (5.15e-5)"	"unprognostic (2.92e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.53e-1)"	"unprognostic (8.46e-2)"	"unprognostic (3.83e-2)"	"unprognostic (2.55e-3)"	"unprognostic (1.86e-2)"	"unprognostic (1.89e-2)"	"unprognostic (2.76e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.19e-3)"	"unprognostic (3.92e-3)"	"unprognostic (4.46e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.58e-2)"	5.4	2.0	14.9	10.1	16.6	22.6	8.8	4.9	19.1	6.4	16.2	13.8	12.4	16.1	5.9	15.3	23.7	6.0	9.4	126.2	10.2	9.3	25.0	93.2	6.9	15.8	14.4	12.0	3.0	25.1	8.4	3.3	15.1	11.9	13.3	14.5	6.0	28.0	21.9	190.7	11.0	13.9	15.8	11.0	7.5	27.9	1.2	7.6	28.2	3.4	69.0	13.6	11.0	8.6	16.8	32.8	17.2	56.3	22.2	29.5	31.2	10.2	5.8	30.2	30.0	4.2	5.2	25.7	12.8	19.5	12.1	13.0	2.7	8.9	12.2	3.6	10.6	3.5	4.4	3.9	5.8	23.9	2.9	20.8	2.2	20.3	5.1	14.2	21.1	10.8	2.2	2.9	2.3	24.8	3.1	10.5	9.3	29.8	68.3	22.1	9.0	2.4	57.9	21.7	36.3	18.7	12.3	43.6	22.1	15.9	63.6	5.1	51.3	43.9	5.9	21.7	3.1	2.8	5.9	17.3	3.2	1.4	6.9	30.0	12.5	9.0	26.4	17.2	26.1	48.0	12.4	16.8	18.7	29.5	32.8	9.8	10.2	18.2	5.1	22.2	56.3	17.8	15.9	31.2	14.9	16.6	4.9	19.1	10.2	9.3	14.4	12.0	11.9	7.6
IDO1	"IDO, INDO"	ENSG00000131203	"Indoleamine 2,3-dioxygenase 1"	P14902	8	39902275-39928444	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Immunity, Tryptophan catabolism"	"Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 77.7;placenta: 33.2"	"Cell line enriched"	"Detected in some"	7	"EFO-21: 35.7"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	17	"eosinophil: 77.7"	"Lineage enriched"	"Detected in many"	17	"granulocytes: 77.7"	"Region enriched"	"Detected in single"	13	"basal ganglia: 30.5"	"Low region specificity"	"Detected in all"			"HPA023072, HPA023149, HPA027772, CAB072820"	Enhanced		Supported	Nucleoplasm,Vesicles,Mitochondria,Cytosol				Cytosol	"Nucleoplasm, Vesicles, Mitochondria"	"CAB072820: , HPA023072: AB_1846220, HPA023149: AB_1846221, HPA027772: AB_1846222"	"unprognostic (1.68e-2)"	"unprognostic (1.71e-2)"	"unprognostic (4.08e-3)"	"unprognostic (7.21e-3)"	"unprognostic (1.90e-1)"	"unprognostic (1.09e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.06e-2)"	"prognostic favourable (5.27e-4)"	"prognostic favourable (3.32e-4)"	"unprognostic (3.59e-2)"	"unprognostic (2.74e-1)"	"prognostic unfavourable (1.12e-7)"	"unprognostic (4.18e-2)"	"unprognostic (4.42e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.97e-2)"	8.7	0.2	0.9	11.2	0.9	0.0	1.4	0.9	0.9	4.0	1.5	0.9	0.9	2.6	2.6	0.9	1.2	0.6	1.3	1.0	0.9	0.0	0.9	0.9	16.8	14.1	0.9	0.9	0.9	0.9	0.0	0.9	33.2	0.9	1.6	2.1	1.9	0.9	0.9	2.5	0.3	5.9	0.9	2.0	6.2	2.2	0.9	0.9	0.9	7.2	0.9	8.9	2.3	0.9	0.0	4.6	77.7	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.4	2.5	0.1	0.3	0.0	35.7	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.0	0.0	0.1	0.0	0.1	0.0	4.5	0.1	77.7	0.0	0.2	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.9	0.9	0.9	0.9	0.9	0.0	0.9	0.9	0.9	0.9
IFNA1	"IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA@, IFNA13"	ENSG00000197919	"Interferon alpha 1"	P01562	9	21440454-21441316	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Antiviral defense"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 2.3;urinary bladder: 2.1"	"Cell line enhanced"	"Detected in some"		"A549: 1.7;BJ: 1.0;HeLa: 6.6;NB-4: 1.5"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	13	"cerebellum: 2.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA047557	Uncertain				"Secreted to blood"					"HPA047557: "		"unprognostic (3.14e-1)"				"unprognostic (1.55e-1)"							"unprognostic (9.75e-2)"			"unprognostic (5.88e-2)"		0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0
IFNA13		ENSG00000233816	"Interferon alpha 13"	P01562	9	21367424-21368962	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Antiviral defense"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 2.1;epididymis: 3.7"	"Cell line enhanced"	"Detected in some"		"A549: 2.7;HeLa: 1.6;NB-4: 3.5;TIME: 1.4"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA047557	Uncertain				"Secreted to blood"					"HPA047557: "																		0.0	0.0	1.1	0.0	2.1	0.0	0.0	0.4	0.6	0.0	0.0			0.0	0.1	3.7	0.0	0.1	0.0	0.0	1.5	0.6	0.4	0.0	0.2	0.2	0.8		0.1	0.0	0.0	0.0	0.0		0.0	0.0		0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.0	0.3			0.0		0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	2.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4										
IFNAR1	"IFNAR, IFRC"	ENSG00000142166	"Interferon alpha and beta receptor subunit 1"	P17181	21	33324477-33359862	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA018015, HPA029226"	Uncertain					100000	100000			"HPA018015: AB_1851433, HPA029226: "	"unprognostic (2.42e-3)"	"unprognostic (2.95e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.15e-1)"	"unprognostic (4.93e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.01e-1)"	"unprognostic (3.02e-1)"	"unprognostic (4.69e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.31e-2)"	"unprognostic (2.38e-1)"	"unprognostic (9.38e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.01e-1)"	"unprognostic (8.45e-2)"	"unprognostic (3.06e-2)"	27.2	16.4	18.5	16.8	18.7	14.8	15.9	18.1	22.9	14.2	16.8	15.1	10.0	12.3	15.7	10.9	15.8	13.5	16.2	14.5	16.9	15.8	17.5	56.4	16.6	15.0	19.7	13.8	16.6	18.3	30.6	17.9	23.2	18.3	14.7	12.2	12.1	17.6	12.6	17.3	10.6	15.8	13.7	22.2	29.8	18.8	10.3	16.7	26.9	21.4	9.1	13.1	18.7	18.1	20.5	17.8	64.5	23.1	7.3	12.1	10.7	13.1	12.0	5.1	5.8	16.9	17.3	5.9	14.2	15.2	6.5	6.7	12.9	15.1	10.2	11.5	9.7	7.9	4.8	8.3	7.0	11.5	9.6	15.1	11.6	7.6	7.2	11.1	10.8	14.3	7.4	10.8	6.5	12.5	17.3	49.9	10.7	10.9	8.2	4.5	5.5	7.7	8.1	18.0	17.3	7.2	17.3	6.1	5.5	14.2	10.2	9.0	15.6	8.2	19.8	13.2	7.2	17.3	7.9	33.4	45.8	11.7	17.7	15.7	14.1	18.9	16.8	9.7	8.0	19.7	7.5	18.5	10.6	9.0	11.3	20.5	12.1	9.4	64.5	7.3	23.1	17.8	12.0	10.7	18.5	18.7	18.1	22.9	16.9	15.8	19.7	13.8	18.3	16.7
IFNAR2	IFNABR	ENSG00000159110	"Interferon alpha and beta receptor subunit 2"	P48551	21	33229901-33265675	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 51.1;U-266/70: 64.9;U-266/84: 33.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"																"Secreted to blood"	610000	610000				"unprognostic (2.00e-2)"	"unprognostic (7.83e-3)"	"unprognostic (4.98e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.50e-3)"	"unprognostic (8.05e-2)"	"unprognostic (4.17e-2)"	"unprognostic (2.11e-2)"	"unprognostic (7.65e-2)"	"unprognostic (4.42e-1)"	"prognostic unfavourable (7.54e-7)"	"unprognostic (9.70e-3)"	"unprognostic (2.39e-1)"	"unprognostic (5.12e-3)"	"unprognostic (1.85e-2)"	16.9	8.7	9.9	28.1	11.3	19.1	18.3	10.7	13.0	10.2	12.2	10.6	9.6	12.8	12.0	10.1	8.1	11.1	15.5	13.6	10.3	9.7	13.4	20.5	21.6	41.7	13.3	8.3	11.9	10.2	11.2	10.9	15.7	10.2	9.9	13.2	7.9	14.4	11.6	6.6	6.6	14.1	13.0	13.2	40.9	9.9	4.6	12.1	34.7	11.3	6.6	25.3	24.2	10.7	9.9	37.6	37.1	25.3	12.2	23.7	14.2	4.0	4.6	2.4	5.6	2.9	7.0	4.0	4.1	10.9	3.5	3.8	6.2	4.6	6.3	3.1	6.3	2.6	3.4	2.3	3.5	4.0	5.2	23.3	5.1	5.7	4.3	3.9	8.7	4.9	2.1	3.9	4.8	11.2	7.3	51.1	3.4	2.3	10.0	4.7	4.4	3.0	3.4	12.6	12.5	7.5	8.1	6.3	3.6	7.0	6.3	6.0	1.1	7.5	7.3	3.6	2.2	2.9	2.3	64.9	33.6	15.8	5.2	14.0	8.4	13.7	14.5	22.7	12.2	23.7	12.8	9.9	15.2	11.5	13.6	6.7	11.2	12.3	37.1	12.2	25.3	37.6	23.7	14.2	9.9	11.3	10.7	13.0	10.3	9.7	13.3	8.3	10.2	12.1
IFNB1	"IFB, IFF, IFNB"	ENSG00000171855	"Interferon beta 1"	P01574	9	21077105-21077963	"Cancer-related genes, Predicted secreted proteins"	"Antiviral defense"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"blood: 1.8;bone marrow: 3.7;breast: 5.9"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 4.8;NB-4: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive CD8 T-cell: 1.8"	"Lineage enriched"	"Detected in single"	8	"T-cells: 1.8"					"Low region specificity"	"Detected in some"			CAB009386	Uncertain				"Secreted to blood"					"CAB009386: AB_2248817"	"unprognostic (2.38e-1)"									"unprognostic (2.60e-4)"								0.1	0.3	0.0	0.0	0.0	3.7	5.9	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.1	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.1	0.6	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	4.8	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.5	0.0	0.0	0.2	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0
IFNG		ENSG00000111537	"Interferon gamma"	P01579	12	68154768-68159747	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Antiviral defense, Growth regulation"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.4;lung: 14.5"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 2.2;U-266/70: 2.2;U-698: 1.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	5	"gdT-cell: 7.3;memory CD4 T-cell: 3.3;memory CD8 T-cell: 8.6;naive CD8 T-cell: 5.2"	"Lineage enriched"	"Detected in many"	7	"T-cells: 8.6"					"Low region specificity"	"Detected in single"			CAB010344	Approved				"Secreted to blood"					"CAB010344: AB_2123447"	"unprognostic (2.16e-4)"	"unprognostic (1.93e-3)"	"unprognostic (9.21e-2)"	"unprognostic (1.04e-4)"	"unprognostic (5.14e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.17e-4)"	"unprognostic (7.79e-2)"	"unprognostic (7.97e-3)"	"unprognostic (1.63e-2)"	"unprognostic (5.36e-2)"	"unprognostic (7.62e-9)"	"unprognostic (3.54e-2)"	"unprognostic (5.36e-1)"	"unprognostic (6.32e-2)"	"unprognostic (7.38e-3)"	2.4	0.9	0.3	4.5	0.3	14.4	0.5	0.1	1.0	1.4	0.9	0.5	0.0	0.2	0.6	1.4	1.3	0.2	0.6	1.0	0.3	0.3	0.7	4.1	14.5	8.5	1.5	0.4	0.4	0.2	0.0	0.5	0.8	0.6	1.2	0.4	1.1	1.4	0.2	1.7	0.3	0.7	0.7	1.3	4.1	0.8	0.2	0.0	0.8	1.3	3.1	4.7	2.2	0.6	0.5	0.0	0.2	0.0	1.2	8.6	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	3.3	8.6	0.0	0.5	0.8	5.2	0.2	1.2	0.0	0.0	0.2	1.1	0.3	0.3	0.1	1.0	0.3	0.3	1.5	0.4	0.6	0.0
IGF1R	"CD221, IGFIR, IGFR, JTK13, MGC18216"	ENSG00000140443	"Insulin like growth factor 1 receptor"	P08069	15	98648971-98964530	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 7.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 7.7;T-cells: 2.9"	"Low region specificity"	"Detected in all"							"CAB010268, HPA045563"	Approved		Approved	Vesicles		36000	36000	Vesicles		"CAB010268: AB_671792, HPA045563: "	"unprognostic (1.30e-3)"	"unprognostic (5.81e-3)"	"unprognostic (1.53e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.29e-2)"	"unprognostic (6.87e-2)"	"unprognostic (2.64e-2)"	"unprognostic (2.87e-2)"	"unprognostic (8.56e-2)"	"unprognostic (1.62e-1)"	"prognostic favourable (3.75e-7)"	"unprognostic (1.57e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.06e-1)"	8.4	12.7	11.5	5.9	13.5	16.3	18.5	23.0	15.7	15.3	13.4	10.4	22.7	4.2	15.3	16.3	9.2	18.9	7.7	11.6	11.7	7.3	17.0	2.0	11.0	4.9	8.0	11.8	23.2	22.5	4.7	13.8	17.5	9.5	21.7	7.2	16.7	12.5	23.2	9.1	13.0	7.5	18.1	8.0	7.3	10.7	12.0	11.5	10.7	16.1	7.0	5.6	12.8	21.6	1.0	0.4	7.7	0.6	1.0	2.9	0.7	3.3	16.5	11.6	0.2	5.8	4.2	7.7	3.7	7.4	1.2	1.1	7.1	8.8	0.8	10.7	7.2	15.8	5.1	15.0	1.0	0.0	5.2	12.5	18.5	14.2	5.1	6.6	1.3	6.6	7.1	2.1	10.2	4.1	0.6	2.9	5.7	23.4	2.5	4.4	10.8	0.9	4.0	9.0	3.0	3.5	20.3	3.9	17.3	26.7	1.5	14.4	8.1	3.1	11.3	1.1	15.0	3.0	5.8	1.0	4.4	2.7	2.2	4.9	2.8	4.0	0.6	1.8	0.9	0.6	0.6	0.4	0.8	0.3	0.4	1.0	2.9	1.0	7.7	1.0	0.5	0.3	0.0	0.7	11.5	13.5	23.0	15.7	11.7	7.3	8.0	11.8	9.5	11.5
IGF2	"C11orf43, FLJ44734, IGF-II"	ENSG00000167244	"Insulin like growth factor 2"	P01344	11	2129112-2149603	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Carbohydrate metabolism, Glucose metabolism, Osteogenesis"	"Growth factor, Hormone, Mitogen"	"Cancer-related genes, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"placenta: 330.5"	"Cell line enhanced"	"Detected in some"		"CACO-2: 112.8;Hep G2: 77.4;LHCN-M2: 44.5;RH-30: 55.3;SH-SY5Y: 67.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"							"HPA007556, HPA007993"	Enhanced		Approved	Nucleoplasm,Vesicles,Cytosol	"Secreted to blood"	1700000000	1700000000	Vesicles	"Nucleoplasm, Cytosol"	"HPA007556: , HPA007993: AB_1851474"	"unprognostic (1.54e-1)"	"unprognostic (1.65e-2)"	"unprognostic (1.31e-1)"	"unprognostic (7.08e-2)"	"unprognostic (2.30e-3)"	"unprognostic (2.59e-1)"	"prognostic favourable (7.12e-4)"	"unprognostic (7.92e-2)"	"unprognostic (2.59e-2)"	"unprognostic (1.68e-2)"	"unprognostic (3.69e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.79e-3)"	"unprognostic (2.00e-2)"	"unprognostic (8.98e-2)"	"unprognostic (8.93e-3)"	"unprognostic (5.78e-2)"	16.6	8.0	1.3	4.5	2.0	0.5	23.3	2.3	1.9	23.4	5.0	3.4	4.7	1.0	9.9	32.0	5.2	17.2	4.5	20.5	1.5	1.6	8.1	39.7	1.9	1.1	3.5	1.6	20.4	5.5	0.7	5.0	330.5	7.6	10.4	1.0	33.2	2.6	6.7	21.9	1.7	2.3	7.5	17.0	2.0	3.2	12.4	0.2	1.8	2.6	14.5	1.8	15.2	14.1	0.0	0.1	0.5	0.2	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	14.9	0.1	0.4	0.0	112.8	0.0	0.0	1.1	0.0	0.0	0.1	0.9	1.0	0.0	0.0	0.0	0.0	77.4	19.8	0.0	0.0	24.1	0.0	0.1	0.0	0.1	0.0	0.0	44.5	0.2	0.0	0.1	0.1	0.2	0.0	55.3	0.1	0.0	0.1	4.4	67.3	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.0	0.0	1.3	2.0	2.3	1.4	1.5	1.6	3.5	1.6	7.6	0.2
IGF2R	"CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI"	ENSG00000197081	"Insulin like growth factor 2 receptor"	P11717	6	159969099-160113507	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 59.6;hTERT-HME1: 60.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009661, HPA011332"	Supported		Enhanced	"Golgi apparatus,Vesicles"		150000000	150000000	"Golgi apparatus, Vesicles"		"CAB009661: AB_2122795, HPA011332: AB_1846276"	"prognostic unfavourable (3.01e-4)"	"prognostic unfavourable (2.92e-5)"	"unprognostic (5.83e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.15e-1)"	"unprognostic (3.25e-1)"	"unprognostic (7.32e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.74e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.85e-1)"	"prognostic unfavourable (6.08e-4)"	28.0	22.2	6.8	13.5	8.1	16.7	39.4	6.4	8.2	14.9	17.3	9.5	13.0	9.4	19.6	16.0	16.7	13.1	17.9	27.9	6.7	6.2	20.6	26.6	32.6	44.7	12.3	3.6	18.0	19.6	23.5	13.6	15.5	10.0	14.1	13.3	13.9	18.2	13.5	62.0	15.9	15.4	16.5	7.6	30.2	14.4	13.8	9.0	37.9	18.5	17.3	14.1	16.3	26.9	0.4	2.9	13.3	2.0	1.0	3.6	0.9	7.7	7.0	12.4	17.4	45.3	25.0	16.8	12.2	26.4	10.1	17.4	10.6	12.2	3.2	13.7	13.4	10.4	9.3	59.6	17.0	16.8	6.6	1.4	12.2	19.1	26.8	7.4	12.1	19.9	19.1	21.0	60.7	6.5	13.9	17.4	15.9	5.7	3.4	7.4	5.5	7.5	8.0	8.5	16.3	14.3	7.8	4.1	9.1	16.5	14.8	16.5	6.2	21.0	9.8	9.8	10.3	21.1	22.3	10.3	14.4	3.3	18.9	10.2	15.1	0.1	2.0	1.1	3.6	0.8	1.4	0.3	1.2	1.7	0.3	0.4	1.0	2.4	13.3	1.0	1.4	2.9	0.7	0.9	6.8	8.1	6.4	8.2	6.7	6.2	12.3	3.6	10.0	9.0
IGFBP2	IBP2	ENSG00000115457	"Insulin like growth factor binding protein 2"	P18065	2	216632828-216664436	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Growth regulation"	"Growth factor binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 165.3;pancreas: 228.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 138.4;HMC-1: 322.9;NB-4: 66.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"NK-cell: 2.0"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA077723			Approved	"Endoplasmic reticulum"	"Secreted to blood"	1000000000	1000000000	"Endoplasmic reticulum"		"HPA077723: "	"unprognostic (2.58e-1)"	"unprognostic (5.95e-2)"	"unprognostic (1.94e-1)"	"unprognostic (3.32e-3)"	"unprognostic (9.50e-3)"	"unprognostic (2.36e-2)"	"unprognostic (2.06e-1)"	"unprognostic (9.11e-3)"	"prognostic unfavourable (2.43e-4)"	"unprognostic (2.34e-1)"	"unprognostic (1.63e-3)"	"unprognostic (1.82e-1)"	"prognostic unfavourable (2.22e-5)"	"unprognostic (5.04e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.83e-2)"	"unprognostic (1.22e-1)"	21.7	6.4	0.9	13.7	2.8	2.6	17.5	1.0	10.4	11.9	12.6	4.5	20.6	11.4	28.7	37.7	26.4	19.4	11.8	29.6	1.5	0.9	21.3	165.3	8.7	3.8	1.4	3.4	35.7	228.7	0.8	8.2	32.0	7.6	25.7	5.2	8.0	9.1	32.6	5.3	3.1	7.8	7.5	1.8	46.7	50.2	13.7	1.0	12.1	8.4	29.3	12.9	23.4	11.4	0.0	0.3	0.0	0.4	2.0	0.8	1.3	0.0	3.2	25.3	24.6	138.4	42.3	0.5	7.7	3.8	0.3	0.0	0.0	0.0	0.0	10.8	0.0	0.7	9.0	9.6	0.0	0.0	5.2	5.5	0.0	1.5	3.4	2.3	322.9	14.1	1.0	0.1	0.4	0.0	0.2	0.7	0.1	6.2	9.6	66.6	27.3	0.3	8.3	0.5	0.1	0.1	7.1	5.3	27.9	0.0	0.2	0.1	20.7	4.1	0.0	0.1	0.1	0.1	0.3	0.3	0.0	0.5	0.3	10.6	29.5	0.0	0.4	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.0	0.0	0.3	0.0	1.3	0.9	2.8	1.0	10.4	1.5	0.9	1.4	3.4	7.6	1.0
IGFBP3	"BP-53, IBP3"	ENSG00000146674	"Insulin like growth factor binding protein 3"	P17936	7	45912245-45921874	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Apoptosis	"Growth factor binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 320.7"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 412.2;U-2197: 171.0;U-87 MG: 88.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"plasmacytoid DC: 28.9"	"Lineage enriched"	"Detected in many"	5	"dendritic cells: 28.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			CAB010360			Approved	Nucleoplasm,Vesicles,Cytosol	"Secreted to blood"	5600000000	5600000000	Vesicles	"Nucleoplasm, Cytosol"	"CAB010360: AB_2233528"	"unprognostic (4.46e-3)"	"unprognostic (4.84e-2)"	"prognostic unfavourable (1.08e-4)"	"unprognostic (2.30e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.54e-2)"	"prognostic unfavourable (1.64e-4)"	"unprognostic (8.14e-3)"	"unprognostic (3.31e-2)"	"unprognostic (2.03e-1)"	"unprognostic (9.67e-3)"	"unprognostic (2.80e-1)"	"prognostic unfavourable (5.07e-7)"	"unprognostic (2.36e-2)"	"unprognostic (4.14e-2)"	"unprognostic (2.37e-3)"	"unprognostic (2.63e-1)"	47.4	1.6	4.4	10.6	2.7	0.0	52.1	2.7	4.1	44.3	21.3	1.7	3.2	6.9	58.4	8.1	11.7	14.9	5.4	41.6	4.4	2.6	11.1	80.4	11.7	12.7	3.7	1.9	49.2	2.2	0.6	19.2	320.7	4.1	22.5	6.1	9.1	6.4	9.3	13.9	23.9	10.2	22.9	3.8	18.7	8.3	12.1	3.1	2.2	5.6	8.6	8.3	32.0	26.3	0.0	28.9	0.0	0.0	0.0	6.0	1.7	9.3	2.8	5.5	0.0	4.2	1.7	0.0	41.2	7.5	3.5	1.9	0.0	7.6	0.0	13.1	412.2	22.6	0.0	0.1	1.4	0.0	0.0	0.0	1.0	0.0	1.1	0.0	0.0	14.4	0.6	0.7	2.6	0.0	0.0	0.1	1.3	0.0	0.0	0.0	0.3	0.5	0.0	0.0	3.8	2.6	20.4	0.6	1.6	14.2	0.5	0.7	0.0	0.0	0.0	40.7	0.0	171.0	2.3	0.5	0.0	0.0	88.5	0.0	13.7	0.0	0.0	0.0	5.2	0.0	4.3	0.0	6.0	5.6	0.0	0.0	2.8	4.7	0.0	0.0	0.0	28.9	0.3	1.7	4.4	2.7	2.7	4.1	4.4	2.6	3.7	1.9	4.1	3.1
IKBKB	"IKK-beta, IKK2, IKKB, NFKBIKB"	ENSG00000104365	"Inhibitor of nuclear factor kappa B kinase subunit beta"	O14920	8	42271302-42332653	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001249, CAB004447"	Enhanced		Approved	Cytosol				Cytosol		"CAB004447: AB_627785, HPA001249: AB_1079126"	"unprognostic (1.04e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.73e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.27e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.89e-2)"	"unprognostic (9.20e-2)"	"unprognostic (3.02e-1)"	"prognostic favourable (1.46e-6)"	9.1	10.8	10.9	17.0	16.7	9.3	10.0	26.1	16.9	10.3	10.3	12.4	11.4	4.7	15.3	13.2	17.9	16.4	14.9	7.9	13.1	6.9	12.4	9.9	14.9	12.2	20.3	7.9	9.6	13.3	18.0	13.6	11.2	11.9	14.0	10.9	10.5	11.4	9.7	17.6	22.2	9.8	16.4	10.5	18.7	10.8	8.3	18.6	12.9	14.3	8.4	17.1	18.1	12.8	12.6	14.8	14.1	9.6	11.9	11.2	5.8	3.6	13.1	3.7	6.4	14.5	12.6	4.8	3.2	11.5	9.7	8.5	3.0	6.8	7.2	5.6	8.9	4.2	5.1	13.0	12.5	7.0	5.8	10.1	6.1	2.3	11.1	1.9	10.6	8.4	9.9	9.3	14.4	14.3	8.5	3.5	21.2	4.2	7.0	3.2	3.6	4.1	7.2	6.4	4.2	10.9	3.3	1.1	2.1	2.1	3.6	5.3	4.8	8.5	7.4	6.8	3.6	5.3	2.3	2.1	2.2	5.1	8.1	4.8	7.7	14.1	9.6	10.4	10.1	7.6	10.3	9.4	10.5	11.2	8.9	12.6	10.2	10.4	11.4	11.9	9.0	14.8	9.9	5.8	10.9	16.7	26.1	16.9	13.1	6.9	20.3	7.9	11.9	18.6
IKZF1	"hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1"	ENSG00000185811	"IKAROS family zinc finger 1"	Q13422	7	50304068-50405101	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Cell cycle, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.7;bone marrow: 55.2;lymphoid tissue: 86.7"	"Cell line enhanced"	"Detected in some"		"Daudi: 26.6;HDLM-2: 45.2;HMC-1: 42.4;MOLT-4: 33.1;REH: 35.8;U-698: 68.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB009247, HPA035221, HPA035222"	Enhanced									"CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525"	"prognostic favourable (4.28e-4)"	"prognostic favourable (2.02e-4)"	"unprognostic (2.49e-3)"	"unprognostic (2.41e-3)"	"unprognostic (5.59e-1)"	"prognostic favourable (8.63e-4)"	"unprognostic (1.45e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.43e-1)"	"unprognostic (6.63e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.69e-3)"	"unprognostic (1.71e-1)"	"unprognostic (2.84e-2)"	"unprognostic (6.77e-2)"	"unprognostic (4.67e-2)"	3.5	1.5	2.9	25.5	3.8	55.2	2.3	0.7	1.8	1.6	3.6	2.8	0.8	2.4	1.6	2.1	2.2	2.4	2.9	1.6	3.4	1.8	2.5	2.3	8.3	44.4	5.9	1.1	1.1	1.3	0.2	1.2	1.2	3.4	2.2	2.5	1.5	5.2	0.7	0.9	1.9	14.5	1.4	5.1	31.0	3.7	1.1	4.1	86.7	2.4	1.2	26.3	4.5	2.9	24.0	12.6	12.8	23.6	12.8	28.7	12.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.6	0.0	0.0	0.0	0.0	0.0	0.0	45.2	0.0	9.1	0.0	0.0	0.0	16.1	42.4	0.0	0.0	0.0	0.0	0.0	11.7	3.1	0.0	0.0	33.1	16.0	0.4	0.0	35.8	0.0	7.5	0.0	0.0	0.3	0.3	0.1	0.2	0.1	0.0	22.2	0.0	0.0	0.3	0.0	0.0	14.5	7.4	68.0	0.1	17.5	0.1	10.2	7.7	12.8	20.4	23.6	17.0	24.0	21.2	19.9	8.2	21.3	28.7	20.7	11.2	12.8	22.3	12.6	17.1	12.7	2.9	3.8	0.7	1.8	3.4	1.8	5.9	1.1	3.4	4.1
IL10	"CSIF, IL-10, IL10A, TGIF"	ENSG00000136634	"Interleukin 10"	P22301	1	206767602-206772494	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 28.3"	"Group enriched"	"Detected in some"	8	"HMC-1: 18.2;U-266/70: 9.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 5.4;intermediate monocyte: 4.0"	"Lineage enriched"	"Detected in many"	5	"monocytes: 5.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB013120, HPA071391"	Approved				"Secreted to blood"					"CAB013120: , HPA071391: "	"unprognostic (3.65e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.03e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.20e-1)"	"unprognostic (2.63e-3)"	"unprognostic (2.58e-1)"	"unprognostic (1.54e-1)"	"unprognostic (9.59e-2)"	"unprognostic (4.26e-1)"	"unprognostic (8.01e-2)"	"unprognostic (4.00e-1)"	"unprognostic (4.66e-4)"	"unprognostic (7.11e-2)"	"unprognostic (1.93e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.96e-2)"	10.9	3.1	1.1	10.7	1.2	4.1	2.1	0.3	1.3	1.6	1.8	2.1	0.5	0.8	1.0	1.9	1.7	4.0	5.2	3.9	0.8	0.9	1.3	3.1	4.3	9.2	1.8	0.9	1.5	1.2	0.4	2.3	3.6	2.3	1.7	1.8	2.1	1.6	0.8	0.9	0.7	2.1	4.6	2.2	28.3	2.0	1.6	1.4	2.2	2.4	0.9	3.5	4.1	1.0	0.2	0.5	0.5	5.4	0.1	1.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	1.8	0.0	0.0	0.2	0.2	0.0	0.0	0.3	0.0	0.0	0.1	0.1	0.1	0.1	0.0	9.3	0.3	0.3	0.0	0.1	0.0	0.5	5.4	0.1	0.2	4.0	0.0	0.1	0.2	1.0	0.5	0.2	0.1	0.1	0.3	0.1	1.4	0.1	0.9	1.0	1.1	1.2	0.3	1.3	0.8	0.9	1.8	0.9	2.3	1.4
IL11	"AGIF, IL-11"	ENSG00000095752	"Interleukin 11"	P20809	19	55364389-55370463	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 9.2"	"Cell line enhanced"	"Detected in some"		"BJ: 17.9;BJ hTERT+: 20.3;hTEC/SVTERT24-B: 16.6;U-251 MG: 64.4"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"cerebellum: 9.2;hypothalamus: 3.7;pons and medulla: 2.7"	"Cell type enhanced"	"Detected in some"		"neutrophil: 2.8"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"								"Secreted to blood"						"unprognostic (6.60e-3)"	"unprognostic (7.23e-3)"	"unprognostic (1.12e-1)"	"unprognostic (3.18e-3)"	"unprognostic (3.32e-3)"	"unprognostic (6.33e-2)"	"unprognostic (1.04e-2)"	"unprognostic (7.84e-5)"	"unprognostic (2.47e-1)"	"unprognostic (2.52e-1)"	"prognostic unfavourable (7.50e-4)"	"unprognostic (4.83e-2)"	"unprognostic (4.07e-8)"	"unprognostic (1.23e-1)"	"unprognostic (1.41e-1)"	"unprognostic (3.82e-3)"	"unprognostic (3.08e-2)"	1.1	0.1	0.6	7.7	0.9	1.5	0.6	9.2	1.0	0.6	0.6	1.8	0.6	0.3	6.1	0.6	2.3	0.0	5.9	0.6	0.6	3.7	3.4	0.6	0.9	0.6	1.2	0.6	0.6	0.6	0.0	5.3	2.3	2.7	3.7	0.2	0.6	0.6	1.1	0.6	2.5	0.6	0.6	0.6	0.6	2.8	1.4	0.6	0.6	0.6	0.6	0.6	2.3	0.6	0.7	0.3	2.8	0.3	0.8	0.4	0.0	0.7	0.4	0.1	0.3	0.0	0.0	0.1	17.9	20.3	9.5	12.5	0.3	0.4	0.2	0.8	1.6	0.9	0.1	0.4	12.7	0.7	0.5	0.0	1.1	1.2	0.9	0.0	0.1	0.1	0.4	16.6	0.1	0.0	0.1	0.5	1.1	0.4	0.0	0.1	0.3	1.5	0.0	6.0	0.0	0.1	0.1	0.9	0.6	2.2	0.3	0.4	0.2	0.1	0.2	5.6	6.8	0.0	64.4	0.3	0.7	0.1	12.2	0.1	2.9	1.4	0.3	0.5	0.3	0.2	0.2	0.7	0.3	0.1	0.1	0.7	0.3	0.4	2.8	0.8	0.1	0.3	0.2	0.0	0.6	0.9	9.2	0.8	0.6	3.7	1.2	0.6	2.7	0.6
IL12A	"CLMF, IL-12A, NFSK, NKSF1, p35"	ENSG00000168811	"Interleukin 12A"	P29459	3	159988750-159996019	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 10.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+ RasG12V: 7.4;HDLM-2: 11.2;SK-BR-3: 16.8"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 5.1"	"Group enriched"	"Detected in many"	7	"B-cells: 5.1;granulocytes: 1.3;T-cells: 1.6"	"Region enhanced"	"Detected in single"		"cerebral cortex: 2.7"	"Low region specificity"	"Detected in some"			HPA001886	Uncertain				"Secreted to blood"					"HPA001886: AB_1079132"	"unprognostic (6.23e-2)"	"unprognostic (7.82e-5)"	"unprognostic (1.25e-1)"	"unprognostic (3.10e-2)"	"unprognostic (4.22e-1)"	"unprognostic (7.18e-2)"	"unprognostic (4.18e-5)"	"unprognostic (2.22e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.07e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.31e-2)"	"unprognostic (9.57e-10)"	"unprognostic (1.62e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.16e-1)"	"unprognostic (9.61e-2)"	0.7	1.4	3.4	1.6	6.2	3.3	2.0	2.6	5.6	0.5	1.6	1.0	0.0	1.5	1.2	0.8	10.1	5.7	0.6	1.4	3.1	2.2	1.2	0.6	5.2	2.9	3.2	1.7	1.6	1.1	0.1	1.0	0.4	5.4	0.9	1.3	0.2	2.1	1.1	0.4	0.2	1.5	0.8	2.7	2.8	1.2	0.9	4.1	0.0	0.5	0.5	2.1	0.9	1.1	5.1	0.1	1.3	0.3	0.0	1.6	0.3	2.7	0.3	0.4	2.3	0.0	0.1	0.2	3.1	1.9	3.5	7.4	1.2	0.1	0.0	0.2	0.5	0.3	0.8	0.5	3.3	11.2	3.9	0.1	0.1	0.8	2.5	0.6	5.2	0.6	0.9	6.3	2.4	1.1	0.0	1.9	2.2	0.0	0.1	0.0	0.3	1.6	2.2	0.0	0.4	0.4	0.2	0.1	1.1	0.0	16.8	0.4	0.8	1.2	0.8	0.9	0.8	2.1	5.7	1.2	0.0	0.0	1.4	5.1	0.7	0.0	0.1	1.3	0.9	0.3	1.4	1.3	0.4	1.6	0.1	5.1	0.0	0.5	0.0	0.0	0.0	0.0	1.4	0.3	3.4	6.2	2.6	5.6	3.1	2.2	3.2	1.7	5.4	4.1
IL13	"ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600"	ENSG00000169194	"Interleukin 13"	P35225	5	132656263-132661110	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"testis: 20.7"	"Cell line enriched"	"Detected in single"	177	"HDLM-2: 29.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA042421			Approved	"Plasma membrane,Cytosol"	"Secreted to blood"			"Plasma membrane, Cytosol"		"HPA042421: AB_10795504"	"unprognostic (2.17e-1)"	"unprognostic (2.29e-2)"	"unprognostic (7.48e-2)"	"unprognostic (2.18e-2)"	"unprognostic (1.92e-1)"	"unprognostic (5.21e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.69e-1)"	"unprognostic (5.20e-1)"	"unprognostic (7.10e-2)"	"unprognostic (3.61e-3)"	"unprognostic (3.34e-1)"	"unprognostic (5.97e-4)"	"unprognostic (4.70e-2)"	"unprognostic (2.05e-1)"	"unprognostic (7.39e-2)"	"unprognostic (1.38e-1)"	0.3	0.0	0.1	0.8	0.1	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.6	0.1	3.0	0.0	0.0	0.1	0.0	0.0	1.8	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.1	0.2	0.2	0.6	0.0	0.0	0.0	0.0	20.7	0.0	2.9	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0
IL13RA2	"CD213a2, CT19, IL-13R, IL13BP"	ENSG00000123496	"Interleukin 13 receptor subunit alpha 2"	Q14627	X	115003975-115019977	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pituitary gland: 16.1;testis: 31.5"	"Group enriched"	"Detected in some"	9	"PC-3: 26.4;U-2197: 84.9;U-251 MG: 57.0;U-87 MG: 33.8"	"Cancer enhanced"	"Detected in many"		"glioma: 17.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"olfactory region: 8.7"	"Low region specificity"	"Detected in many"			"HPA045831, HPA067363"			Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cell Junctions"				"Plasma membrane, Cell Junctions"	"Nucleoplasm, Vesicles"	"HPA045831: , HPA067363: "	"unprognostic (1.97e-1)"	"unprognostic (2.83e-1)"	"unprognostic (6.62e-4)"	"unprognostic (7.39e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.80e-1)"	"prognostic favourable (3.55e-4)"	"unprognostic (3.54e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.92e-2)"	"unprognostic (2.20e-3)"	"unprognostic (2.19e-2)"	"unprognostic (1.53e-5)"	"unprognostic (1.58e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.70e-3)"	"unprognostic (1.20e-1)"	0.5	4.8	3.7	3.9	11.3	0.0	0.8	0.3	3.1	1.2	0.4	2.1	5.7	0.3	0.9	4.4	0.5	0.1	0.8	0.6	5.1	11.2	3.5	9.6	1.0	0.1	1.2	2.6	0.1	0.1	0.5	16.1	2.1	3.9	4.3	0.7	1.6	0.8	3.7	0.0	0.1	0.3	0.4	0.6	0.2	0.1	31.5	1.4	0.0	1.3	0.2	0.2	1.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.7	0.0	5.8	5.5	0.0	0.0	0.0	0.0	0.0	0.1	2.9	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.0	0.1	0.9	5.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	26.4	0.0	0.0	0.0	0.4	0.0	0.0	1.3	0.4	0.0	0.1	0.0	0.0	0.0	3.0	0.0	84.9	57.0	0.0	0.0	0.0	33.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	11.3	0.3	3.1	5.1	11.2	1.2	2.6	3.9	1.4
IL15	"IL-15, MGC9721"	ENSG00000164136	"Interleukin 15"	P40933	4	141636599-141733987	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 15.5;Karpas-707: 15.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB004457, HPA037738"	Approved		Supported	"Nucleoplasm,Nuclear speckles"	"Secreted to blood"			"Nucleoplasm, Nuclear speckles"		"CAB004457: AB_2124575, HPA037738: "	"unprognostic (1.10e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.04e-2)"	"unprognostic (8.57e-2)"	"unprognostic (8.77e-3)"	"unprognostic (1.69e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.90e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.48e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.74e-2)"	"unprognostic (3.75e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.03e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.54e-1)"	7.7	3.7	1.1	21.3	1.5	2.9	9.2	1.8	2.2	6.0	8.8	0.8	2.2	6.3	11.3	7.4	5.6	4.6	9.9	9.3	1.1	1.5	6.9	3.7	14.4	18.8	2.3	1.6	3.2	3.1	0.5	4.5	9.9	2.1	7.7	5.7	5.9	6.9	3.6	9.1	3.2	14.2	7.1	2.6	17.0	5.3	2.6	2.0	9.8	18.1	5.9	11.0	9.8	16.9	3.7	4.6	8.1	14.0	2.6	4.5	4.4	2.4	5.2	0.2	0.5	0.8	4.7	1.3	5.6	5.3	5.8	4.7	2.8	6.8	2.3	7.3	4.8	3.6	0.1	3.0	3.2	15.5	1.4	0.4	13.7	0.4	3.9	1.6	1.1	1.7	1.2	3.8	0.4	3.7	3.8	15.2	3.7	0.8	3.4	0.3	2.6	1.6	0.9	13.4	0.3	7.6	0.6	0.5	1.3	2.4	3.7	2.7	0.9	0.2	5.5	5.9	3.8	1.7	3.4	10.7	1.3	0.7	6.3	0.6	2.1	8.1	14.0	0.8	2.5	12.4	4.5	3.7	2.9	2.2	4.6	3.4	1.2	1.3	1.0	2.6	12.5	0.1	1.5	4.4	1.1	1.5	1.8	2.2	1.1	1.5	2.3	1.6	2.1	2.0
IL16	"FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16"	ENSG00000172349	"Interleukin 16"	Q14005	15	81159575-81314058	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Chemotaxis, Host-virus interaction, Transcription, Transcription regulation"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 75.7;lymphoid tissue: 97.9"	"Cell line enhanced"	"Detected in some"		"Daudi: 12.2;HEL: 12.9;HMC-1: 23.3;RPMI-8226: 22.1;U-266/70: 27.7;U-698: 11.4;U-937: 15.5"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	6	"cerebellum: 40.1"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"cerebellum: 61.1;hippocampal formation: 29.7"	"Region enriched"	"Detected in single"	38	"cerebellum: 96.7"	"CAB005247, HPA018467, HPA048861"	Enhanced		Supported	"Nuclear speckles,Plasma membrane,Midbody ring,Cytosol"	"Secreted to blood"	14000	14000	"Nuclear speckles"	"Plasma membrane, Midbody ring, Cytosol"	"CAB005247: AB_2124730, HPA018467: AB_1851642, HPA048861: "	"unprognostic (8.23e-3)"	"unprognostic (2.70e-3)"	"unprognostic (1.97e-2)"	"unprognostic (9.61e-4)"	"unprognostic (2.01e-1)"	"unprognostic (5.26e-4)"	"unprognostic (2.63e-2)"	"unprognostic (6.72e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.91e-1)"	"unprognostic (1.47e-1)"	"unprognostic (6.21e-2)"	"unprognostic (3.16e-3)"	"unprognostic (1.21e-1)"	"unprognostic (3.23e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.29e-1)"	8.8	2.4	4.1	48.0	5.8	19.5	7.8	40.1	4.3	4.7	4.8	4.6	0.9	3.8	5.4	2.9	3.4	9.7	5.6	5.1	4.9	2.1	2.5	3.9	14.7	58.0	5.8	2.3	3.7	1.7	0.7	1.4	3.0	6.7	3.5	5.9	3.4	13.5	1.5	1.8	6.1	19.2	3.3	7.8	38.2	5.0	2.2	5.5	97.9	3.7	2.4	54.8	8.7	5.4	43.3	37.1	75.7	35.0	49.3	60.5	66.5	0.0	0.0	0.0	0.0	8.2	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	12.9	0.0	0.0	0.4	9.1	23.3	0.4	0.0	0.0	0.2	0.1	1.3	4.9	0.0	0.0	0.7	9.7	0.0	0.0	0.0	0.0	22.1	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	2.0	0.1	0.1	0.1	0.4	0.0	27.7	2.3	11.4	0.8	15.5	0.7	52.7	27.4	75.7	43.1	35.0	48.6	43.3	45.1	47.1	37.1	39.9	60.5	48.6	69.1	49.3	33.7	28.0	47.0	66.5	4.1	5.8	40.1	4.3	4.9	2.1	5.8	2.3	6.7	5.5
IL17A	"CTLA8, IL-17, IL-17A, IL17"	ENSG00000112115	"Interleukin 17A"	Q16552	6	52186387-52190638	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"lymphoid tissue: 7.6;tongue: 12.2;urinary bladder: 4.4"	"Group enriched"	"Detected in some"	37	"Karpas-707: 7.2;U-266/84: 4.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA052258	Uncertain				"Secreted to blood"					"HPA052258: "		"unprognostic (5.55e-1)"	"unprognostic (2.18e-4)"			"unprognostic (3.05e-4)"		"unprognostic (1.41e-2)"						"unprognostic (2.22e-2)"				0.2	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.4	0.0	0.0	1.3	0.5	0.6	0.0	0.1	0.0	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.1	0.1	1.0	0.1	0.0	0.1	0.3	0.1	0.0	0.0	0.0	12.2	7.6	4.4	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0
IL17B	"IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7"	ENSG00000127743	"Interleukin 17B"	Q9UHF5	5	149371324-149404202	"Cancer-related genes, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HEL: 4.4;Hep G2: 2.0;K-562: 1.6;Karpas-707: 3.6;NB-4: 2.5"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in some"	6	"midbrain: 8.9"	"Cell type enriched"	"Detected in single"	14	"basophil: 4.3"	"Lineage enriched"	"Detected in single"	14	"granulocytes: 4.3"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA042441	Uncertain				"Secreted to blood"					"HPA042441: AB_10797014"	"unprognostic (2.83e-4)"	"unprognostic (2.71e-2)"	"unprognostic (4.90e-3)"	"unprognostic (9.22e-2)"	"unprognostic (7.43e-2)"	"unprognostic (5.03e-2)"	"unprognostic (9.62e-3)"	"unprognostic (3.00e-1)"	"unprognostic (1.80e-1)"	"unprognostic (6.54e-2)"	"unprognostic (9.30e-3)"	"unprognostic (3.22e-1)"	"unprognostic (6.98e-8)"	"unprognostic (2.66e-1)"	"unprognostic (1.53e-1)"	"unprognostic (6.47e-2)"	"unprognostic (1.10e-1)"	2.1	3.3	0.1	2.2	0.1	0.6	7.5	0.1	0.8	4.7	4.2	0.1	2.8	0.7	6.8	3.6	4.1	1.6	1.1	5.1	0.1	0.0	0.8	0.1	0.9	0.1	8.9	1.2	0.7	0.1	0.0	0.1	0.4	1.4	3.6	0.4	2.4	7.1	5.6	1.5	1.3	1.7	5.3	5.4	1.1	1.3	5.9	0.4	0.4	0.6	1.6	0.3	1.8	1.3	0.0	0.2	4.3	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0	0.8	0.0	0.3	0.0	0.0	0.0	0.9	0.3	0.8	0.0	0.0	0.0	0.0	0.5	0.0	4.4	0.0	2.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	3.6	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.1	0.4	0.0	0.5	0.2	0.1	0.0	0.0	0.9	4.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.8	0.1	0.0	8.9	1.2	1.4	0.4
IL18	"IGIF, IL-18, IL-1g, IL1F4"	ENSG00000150782	"Interleukin 18"	Q14116	11	112143251-112164117	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Inflammatory response"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 53.9;skin 1: 57.2"	"Cell line enhanced"	"Detected in many"		"A-431: 26.0;CAPAN-2: 41.2;HaCaT: 37.8;HBEC3-KT: 28.4;hTCEpi: 43.5;PC-3: 25.2;U-2 OS: 49.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 17.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA003980, CAB007772"	Enhanced		Approved	"Nucleoplasm,Golgi apparatus,Cytosol"	"Secreted to blood"			"Nucleoplasm, Golgi apparatus"	Cytosol	"CAB007772: AB_562304, HPA003980: AB_1851670"	"unprognostic (2.31e-3)"	"unprognostic (3.25e-1)"	"prognostic favourable (2.78e-4)"	"unprognostic (3.41e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.15e-2)"	"unprognostic (3.23e-1)"	"unprognostic (2.78e-1)"	"unprognostic (1.96e-3)"	"unprognostic (4.13e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.19e-2)"	"unprognostic (3.15e-2)"	"unprognostic (9.01e-2)"	9.4	2.6	5.3	12.5	7.9	10.8	5.2	1.3	5.3	18.5	13.1	6.4	2.5	8.6	2.1	3.7	53.9	3.3	11.9	2.1	5.7	3.1	17.5	3.6	15.2	22.6	7.4	1.4	1.4	7.0	0.3	3.3	2.6	8.2	5.5	11.6	2.2	8.3	1.4	3.8	57.2	9.1	4.0	24.7	26.6	5.1	1.7	7.5	3.9	1.8	21.2	26.5	9.1	35.4	0.5	17.1	10.4	6.9	13.8	0.3	1.6	26.0	9.1	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	5.0	41.2	0.0	6.0	0.0	37.8	0.0	28.4	0.0	0.0	0.2	3.9	9.3	2.1	0.9	2.0	7.6	0.0	43.5	0.0	10.1	0.0	0.1	0.0	0.3	0.0	0.0	0.2	0.0	25.2	0.0	0.0	0.0	18.6	5.6	0.0	0.0	17.9	11.9	0.1	7.1	5.7	0.0	0.1	49.0	0.3	8.0	0.1	0.0	0.1	0.0	15.1	0.0	3.5	6.0	10.4	0.1	6.9	0.0	0.4	0.0	0.0	17.1	0.5	0.0	0.3	6.7	13.8	3.7	3.8	0.0	1.6	5.3	7.9	1.3	5.3	5.7	3.1	7.4	1.4	8.2	7.5
IL1A	"IL-1A, IL1, IL1-ALPHA, IL1F1"	ENSG00000115008	"Interleukin 1 alpha"	P01583	2	112773915-112784590	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Cytokine, Mitogen, Pyrogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 17.6;lymphoid tissue: 22.2;tongue: 17.9"	"Group enriched"	"Detected in some"	6	"HBEC3-KT: 84.8;hTCEpi: 41.9;hTERT-HME1: 55.5"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 22.3;urothelial cancer: 17.0"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (3.41e-2)"	"prognostic unfavourable (9.52e-4)"	"unprognostic (1.99e-2)"	"unprognostic (4.28e-2)"	"unprognostic (2.08e-1)"	"unprognostic (8.03e-3)"	"unprognostic (4.42e-3)"	"prognostic unfavourable (1.54e-4)"	"unprognostic (1.62e-1)"	"unprognostic (2.45e-1)"	"unprognostic (4.57e-3)"	"unprognostic (1.22e-1)"	"unprognostic (4.30e-3)"	"prognostic unfavourable (4.03e-4)"	"unprognostic (1.66e-1)"	"unprognostic (2.44e-1)"	"unprognostic (8.62e-2)"	0.7	0.3	0.7	1.2	1.4	0.8	0.3	0.2	1.2	5.8	0.3	2.3	0.5	0.0	2.6	0.7	17.6	0.3	2.4	0.3	3.1	0.8	0.2	0.2	3.7	0.2	1.2	0.1	0.3	0.2	0.3	0.4	3.1	2.1	0.3	0.1	0.0	1.9	1.2	0.2	1.2	0.3	0.0	1.8	0.5	0.2	10.9	1.2	0.0	0.2	17.9	22.2	5.4	1.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.1	0.1	0.0	10.2	0.0	0.6	0.0	84.8	0.3	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	41.9	0.7	55.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.0	10.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.4	0.2	0.9	3.1	0.8	1.2	0.1	2.1	1.2
IL1B	"IL-1B, IL1-BETA, IL1F2"	ENSG00000125538	"Interleukin 1 beta"	P01584	2	112829751-112836903	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Cytokine, Mitogen, Pyrogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 62.3;lymphoid tissue: 35.4"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 92.5;HBEC3-KT: 42.0;HMC-1: 34.3;hTEC/SVTERT24-B: 46.3;U-87 MG: 84.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 34.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 34.4"	"Low region specificity"	"Detected in some"												"Secreted to blood"						"unprognostic (1.55e-3)"	"prognostic unfavourable (1.31e-4)"	"unprognostic (2.75e-2)"	"unprognostic (5.71e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.12e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.63e-3)"	"unprognostic (3.72e-2)"	"unprognostic (5.57e-2)"	"prognostic unfavourable (7.49e-5)"	"unprognostic (1.29e-2)"	"unprognostic (4.42e-2)"	"unprognostic (5.09e-2)"	"unprognostic (4.01e-2)"	19.6	3.3	4.2	20.4	15.3	62.3	0.8	1.1	10.8	1.6	3.2	12.7	0.2	1.2	3.0	1.5	3.5	3.4	7.5	3.7	19.0	3.6	1.7	4.0	17.3	5.0	5.9	0.3	3.4	2.4	2.4	3.0	10.3	24.9	2.6	2.6	1.0	2.2	0.8	0.4	0.9	3.7	3.5	29.7	35.4	20.9	1.6	5.8	0.8	1.1	13.5	14.0	10.4	1.2	0.0	6.9	34.4	7.0	0.0	0.0	1.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	92.5	0.4	1.0	0.0	0.0	0.0	2.6	0.0	2.1	0.0	42.0	5.7	0.0	0.0	4.1	0.0	0.0	0.3	0.0	34.3	0.1	1.3	46.3	15.6	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	3.5	0.1	0.0	0.0	0.0	5.5	0.0	0.0	0.2	0.0	0.3	0.0	0.4	0.0	2.2	0.0	0.1	0.0	0.0	0.0	0.0	84.5	1.9	3.2	0.5	4.2	1.5	0.0	7.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	34.4	0.0	2.7	0.0	0.0	1.0	4.2	15.3	1.1	10.8	19.0	3.6	5.9	0.3	24.9	5.8
IL1R1	"CD121A, D2S1473, IL1R, IL1RA"	ENSG00000115594	"Interleukin 1 receptor type 1"	P14778	2	102064544-102179874	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 93.4;ASC TERT1: 41.7;HHSteC: 29.3;HSkMC: 115.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001237, HPA005823, CAB007779, HPA029560"	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"	"Secreted to blood"	1000000	1000000	"Nucleoplasm, Vesicles"	"Plasma membrane, Cytosol"	"CAB007779: AB_562073, HPA001237: , HPA005823: , HPA029560: "	"unprognostic (6.16e-3)"	"unprognostic (3.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.10e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.77e-2)"	"prognostic unfavourable (6.92e-6)"	"unprognostic (2.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (4.83e-2)"	"unprognostic (7.73e-2)"	48.6	25.2	2.6	18.2	5.2	4.0	92.4	2.4	3.9	47.8	21.0	2.5	34.3	5.2	15.2	30.2	18.2	17.1	25.8	27.0	4.2	2.5	23.7	74.8	40.5	28.0	5.6	1.1	25.1	17.1	16.9	7.3	66.2	10.9	26.0	8.4	8.6	12.7	36.4	15.5	13.5	13.0	15.1	10.0	19.2	15.6	13.4	2.8	3.5	33.6	9.0	9.6	32.0	36.4	0.1	0.1	4.0	0.5	0.8	1.8	0.2	0.2	1.8	0.0	1.5	93.4	41.7	0.6	3.9	17.7	2.8	4.2	0.8	0.4	0.0	2.9	7.8	0.7	0.0	0.3	2.3	7.7	0.0	0.1	0.4	4.3	29.3	0.0	0.0	115.0	0.3	3.1	0.7	1.2	0.4	0.1	4.0	0.7	0.0	0.1	0.1	0.1	0.0	0.2	0.0	2.6	1.9	0.0	0.0	1.7	1.1	0.0	1.6	0.1	0.0	8.0	0.5	13.4	0.3	0.0	0.0	0.0	3.1	0.0	0.5	0.6	0.5	0.1	0.0	0.0	0.7	0.1	1.1	0.0	0.1	0.1	0.0	0.1	4.0	0.8	0.0	0.1	1.8	0.2	2.6	5.2	2.4	3.9	4.2	2.5	5.6	1.1	10.9	2.8
IL1R2	"CD121b, IL1RB"	ENSG00000115590	"Interleukin 1 receptor type 2"	P27930	2	101991844-102028544	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 73.2;lymphoid tissue: 74.1"	"Cell line enriched"	"Detected in some"	19	"HDLM-2: 100.0"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	4	"midbrain: 9.2"	"Cell type enriched"	"Detected in some"	25	"neutrophil: 73.2"	"Lineage enriched"	"Detected in many"	25	"granulocytes: 73.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA027597, HPA027598"	Uncertain				"Secreted to blood"	21000000	21000000			"HPA027597: AB_10600768, HPA027598: AB_10601229"	"unprognostic (3.54e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.83e-2)"	"unprognostic (6.59e-2)"	"unprognostic (1.42e-1)"	"unprognostic (6.36e-2)"	"unprognostic (4.82e-3)"	"unprognostic (1.62e-2)"	"unprognostic (7.15e-2)"	"unprognostic (8.20e-3)"	"unprognostic (1.07e-1)"	"prognostic unfavourable (5.58e-12)"	"unprognostic (1.92e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.77e-1)"	"unprognostic (6.62e-2)"	9.1	3.2	1.2	16.4	1.9	22.3	1.6	1.2	1.9	6.4	13.4	0.4	0.1	0.1	1.3	1.3	20.4	9.7	3.4	15.1	1.2	0.5	5.8	8.2	25.5	74.1	9.2	0.2	2.5	1.4	0.0	2.4	24.9	2.2	1.1	20.0	1.8	4.3	0.8	2.8	14.1	2.2	1.3	4.4	47.5	14.6	1.6	1.1	1.6	1.8	8.5	25.1	3.2	9.1	0.0	2.8	73.2	0.8	0.0	1.1	0.2	1.5	0.1	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.0	0.0	1.6	0.0	0.0	3.3	0.0	0.6	0.0	0.1	0.0	100.0	0.1	0.0	0.0	0.8	0.5	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.0	73.2	0.0	0.0	0.0	1.1	0.2	1.2	1.9	1.2	1.9	1.2	0.5	9.2	0.2	2.2	1.1
IL1RN	"ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430"	ENSG00000136689	"Interleukin 1 receptor antagonist"	P18510	2	113107214-113134016	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 217.8;lymphoid tissue: 194.7;tongue: 123.7"	"Cell line enhanced"	"Detected in some"		"A-431: 20.6;HaCaT: 40.8;RT4: 39.8;THP-1: 11.5"	"Cancer enhanced"	"Detected in all"		"head and neck cancer: 92.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"classical monocyte: 17.1;myeloid DC: 17.1;neutrophil: 65.2"	"Group enriched"	"Detected in many"	332	"dendritic cells: 17.1;granulocytes: 65.2;monocytes: 17.1"	"Not detected"	"Not detected"							"HPA001482, CAB009633"	Enhanced		Approved	Nucleoplasm,Centrosome,Cytosol	"Secreted to blood"			Nucleoplasm	"Centrosome, Cytosol"	"CAB009633: AB_2125576, HPA001482: AB_1078437"	"unprognostic (3.85e-3)"	"unprognostic (3.96e-2)"	"unprognostic (1.00e-1)"	"prognostic unfavourable (3.00e-4)"	"unprognostic (2.21e-1)"	"unprognostic (3.63e-2)"	"unprognostic (3.15e-2)"	"unprognostic (2.55e-1)"	"unprognostic (4.46e-2)"	"unprognostic (9.54e-2)"	"prognostic unfavourable (6.85e-4)"	"unprognostic (5.59e-3)"	"prognostic unfavourable (2.66e-6)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (8.23e-4)"	"unprognostic (4.25e-2)"	"unprognostic (1.03e-1)"	17.3	0.2	0.2	7.2	0.3	32.9	1.1	0.2	0.5	27.2	3.8	0.6	1.4	1.1	1.5	0.7	217.8	0.2	4.1	0.5	0.2	0.0	0.5	23.5	2.9	1.9	0.3	0.2	0.4	0.4	0.1	0.3	3.1	0.6	1.6	0.3	0.4	30.9	1.3	0.5	14.4	3.7	0.7	0.2	3.6	5.7	1.4	0.2	1.0	0.7	123.7	194.7	3.3	42.2	0.0	17.1	65.2	17.1	0.0	0.0	4.9	20.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.1	0.0	0.2	0.1	0.1	0.0	40.8	0.0	1.1	0.0	0.0	0.0	0.1	0.0	6.9	0.0	0.1	7.7	0.0	5.3	0.2	0.0	0.0	0.1	0.1	0.0	0.1	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	39.8	0.0	0.0	0.0	0.3	0.0	0.0	11.5	0.1	0.5	0.0	0.3	0.0	0.3	0.0	0.0	3.9	4.6	0.1	0.0	17.1	0.3	0.0	7.6	0.0	0.0	0.0	0.0	17.1	0.0	0.0	0.0	65.2	0.0	3.4	0.1	0.0	4.9	0.2	0.3	0.2	0.5	0.2	0.0	0.3	0.2	0.6	0.2
IL2	"IL-2, TCGF"	ENSG00000109471	"Interleukin 2"	P60568	4	122451470-122456725	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	"Cytokine, Growth factor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 1.9;intestine: 2.4;lymphoid tissue: 1.9"	"Cell line enriched"	"Detected in single"	23	"MOLT-4: 2.3"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"memory CD4 T-cell: 1.9"	"Lineage enriched"	"Detected in single"	19	"T-cells: 1.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB010310	Uncertain				"Secreted to blood"					"CAB010310: AB_649346"	"unprognostic (8.87e-5)"	"unprognostic (6.13e-3)"		"unprognostic (1.38e-3)"				"unprognostic (9.79e-3)"			"unprognostic (2.56e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.06e-5)"	"unprognostic (5.21e-3)"	"unprognostic (8.01e-2)"			0.6	0.0	0.0	0.6	0.0	0.4	0.5	0.0	0.0	0.9	0.3			0.5	0.1	0.0	0.8	0.6	0.5	0.0	0.0	0.0	0.2	0.3	0.7	1.1	0.0		0.1	0.0	0.0	0.0	0.0		0.4	1.9		0.1	0.0	0.0	0.4	2.4	0.0	0.2	0.8	0.3	0.0			0.4		1.9	0.8	0.4	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
IL21R	CD360	ENSG00000103522	"Interleukin 21 receptor"	Q9HBE5	16	27402162-27452042	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 17.9;lymphoid tissue: 47.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 10.1;HDLM-2: 42.9;Karpas-707: 19.9;RH-30: 15.1;RPMI-8226: 24.0;U-266/70: 10.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA042296	Uncertain		Uncertain	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA042296: AB_10806236"	"unprognostic (2.91e-2)"	"unprognostic (2.65e-3)"	"unprognostic (6.64e-4)"	"unprognostic (1.58e-3)"	"unprognostic (2.14e-1)"	"prognostic favourable (7.29e-4)"	"unprognostic (8.33e-2)"	"unprognostic (2.06e-1)"	"unprognostic (8.50e-6)"	"unprognostic (2.26e-2)"	"unprognostic (1.13e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.34e-10)"	"unprognostic (8.79e-2)"	"unprognostic (4.42e-2)"	"unprognostic (1.50e-1)"	"unprognostic (9.58e-2)"	0.8	0.6	0.6	33.6	3.7	5.7	0.6	0.5	1.6	0.5	0.9	0.3	0.0	0.5	0.5	1.3	1.0	0.8	1.1	1.8	0.6	2.3	1.6	1.3	5.6	20.9	1.3	0.0	0.5	0.5	0.0	0.9	0.9	1.9	0.9	0.9	1.8	3.7	0.3	0.7	0.7	4.0	0.6	1.7	11.2	1.3	1.0	1.4	47.8	1.3	0.8	31.7	2.7	0.8	11.5	1.6	0.7	17.9	6.3	10.3	4.2	0.0	0.0	0.1	0.1	0.0	0.5	0.3	0.3	0.0	0.0	0.9	0.0	0.0	10.1	0.1	0.8	0.0	0.0	0.0	0.0	42.9	0.0	2.1	0.0	0.2	1.4	0.0	0.6	1.5	0.0	2.7	0.0	0.0	0.1	19.9	1.5	0.0	0.0	0.2	0.3	0.0	0.1	15.1	24.0	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.5	1.1	0.8	0.2	0.2	0.0	10.0	3.5	2.3	2.1	0.5	0.0	0.2	0.3	0.0	9.8	5.8	3.6	1.0	6.3	10.3	1.6	11.5	6.9	6.7	0.7	6.3	17.9	0.7	7.6	4.2	0.6	3.7	0.5	1.6	0.6	2.3	1.3	0.0	1.9	1.4
IL24	"C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16"	ENSG00000162892	"Interleukin 24"	Q13007	1	206897443-206904139	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	Apoptosis	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 18.7;lymphoid tissue: 22.5"	"Cell line enriched"	"Detected in some"	9	"BJ hTERT+: 62.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"B-cells: 18.7;T-cells: 12.0"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"cerebral cortex: 0.9"	CAB025972	Uncertain				"Secreted to blood"					"CAB025972: "	"prognostic favourable (5.09e-4)"	"unprognostic (3.79e-1)"	"unprognostic (2.89e-2)"	"unprognostic (4.09e-3)"	"unprognostic (3.98e-1)"	"unprognostic (2.68e-1)"	"unprognostic (2.85e-2)"	"unprognostic (2.20e-2)"	"unprognostic (3.98e-1)"	"unprognostic (3.35e-2)"	"unprognostic (8.04e-2)"	"unprognostic (7.63e-2)"	"unprognostic (3.43e-4)"	"unprognostic (5.41e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.91e-2)"	"unprognostic (3.33e-2)"	5.3	0.0	0.2	9.2	0.2	1.6	0.2	0.2	0.4	0.2	1.3	0.2	0.2	0.3	0.9	0.7	0.9	1.4	1.7	0.8	0.2	0.0	0.6	2.4	2.5	22.5	0.2	0.2	0.9	0.2	0.0	0.2	1.1	1.3	1.3	0.0	0.2	0.2	0.2	3.9	0.2	1.3	0.2	0.2	19.6	0.9	0.5	0.2	0.4	0.2	0.9	2.7	3.3	0.3	18.7	0.4	0.7	0.0	3.4	12.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	62.3	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.1	0.9	7.0	0.0	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	3.3	0.0	0.0	0.0	0.0	0.6	0.1	5.0	0.0	0.0	0.0	0.8	0.4	2.7	0.1	3.3	0.2	0.5	0.5	0.0	0.1	0.4	0.0	0.0	4.3	0.0	6.2	18.7	6.8	6.4	0.0	18.6	11.8	6.5	0.7	3.4	0.0	0.4	12.0	3.6	0.2	0.2	0.2	0.4	0.2	0.0	0.2	0.2	1.3	0.2
IL2RA	"CD25, IDDM10, IL2R"	ENSG00000134460	"Interleukin 2 receptor subunit alpha"	P01589	10	6010689-6062370	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7"	"Cell line enriched"	"Detected in some"	59	"HDLM-2: 153.9"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"pons and medulla: 2.4"	"Group enriched"	"Detected in many"	6	"basophil: 30.3;T-reg: 55.4"	"Group enriched"	"Detected in many"	12	"granulocytes: 30.3;T-cells: 55.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002419, HPA054622"	Enhanced					110000	110000			"CAB002419: AB_563538, HPA054622: "	"unprognostic (2.82e-1)"	"unprognostic (8.10e-3)"	"unprognostic (1.75e-2)"	"unprognostic (5.86e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.45e-3)"	"unprognostic (2.78e-2)"	"unprognostic (2.73e-1)"	"unprognostic (5.03e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.07e-1)"	"prognostic unfavourable (2.08e-9)"	"unprognostic (2.10e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.22e-1)"	"unprognostic (5.10e-2)"	16.5	2.5	0.3	10.9	0.6	0.1	1.4	0.3	0.3	0.6	3.1	0.1	0.0	1.3	0.8	4.9	1.9	0.8	2.2	1.9	0.4	0.5	2.6	1.3	4.0	50.4	0.5	0.0	0.6	1.0	0.0	1.8	1.8	2.4	1.1	1.6	3.4	2.2	0.5	0.8	0.6	10.3	3.5	2.2	56.7	1.4	0.4	0.0	4.5	4.2	2.0	16.8	5.0	0.6	3.6	0.0	30.3	0.0	2.9	55.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	153.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.6	0.0	0.0	0.0	30.3	0.0	4.5	0.1	0.0	0.5	3.6	6.8	0.7	0.0	1.5	0.5	0.0	0.2	2.9	0.0	0.0	55.4	0.7	0.3	0.6	0.3	0.3	0.4	0.5	0.5	0.0	2.4	0.0
IL2RB	"CD122, IL15RB"	ENSG00000100385	"Interleukin 2 receptor subunit beta"	P14784	22	37125838-37175054	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 104.1"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"gdT-cell: 14.7;NK-cell: 51.6"	"Group enriched"	"Detected in many"	32	"NK-cells: 51.6;T-cells: 14.7"	"Region enriched"	"Detected in single"	7	"basal ganglia: 1.6"	"Low region specificity"	"Detected in all"			HPA062657	Enhanced									"HPA062657: "	"unprognostic (3.38e-3)"	"unprognostic (1.21e-2)"	"prognostic favourable (6.76e-4)"	"prognostic favourable (3.18e-5)"	"unprognostic (2.44e-2)"	"unprognostic (9.69e-3)"	"unprognostic (2.60e-1)"	"unprognostic (5.22e-2)"	"unprognostic (1.03e-3)"	"unprognostic (5.37e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.74e-1)"	"prognostic unfavourable (3.50e-7)"	"unprognostic (4.63e-2)"	"unprognostic (7.96e-2)"	"unprognostic (3.94e-3)"	"unprognostic (2.46e-2)"	2.2	1.0	0.8	20.5	0.8	12.3	1.6	0.6	0.7	1.3	5.5	0.6	1.4	1.8	4.3	2.8	2.6	1.8	5.8	3.7	0.7	0.8	1.9	6.0	7.4	20.8	0.8	0.2	1.5	1.0	0.0	1.1	58.5	0.7	3.5	1.8	2.9	3.7	2.1	0.9	4.0	7.3	0.6	1.1	35.0	2.3	1.1	0.2	21.0	2.1	1.8	28.7	4.0	1.5	0.3	0.0	1.0	0.1	51.6	14.7	7.9	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	104.1	0.1	0.2	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.8	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.8	0.0	0.1	7.5	12.8	0.0	0.1	0.0	0.1	1.0	0.0	0.1	14.7	0.1	8.1	0.1	3.3	8.2	0.0	0.3	1.1	4.3	0.3	51.6	0.1	0.0	6.8	7.9	0.8	0.8	0.6	0.7	0.7	0.8	0.8	0.2	0.7	0.2
IL2RG	"CD132, CIDX, IMD4, SCIDX1"	ENSG00000147168	"Interleukin 2 receptor subunit gamma"	P31785	X	71107404-71112108	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 115.3;lymphoid tissue: 169.3"	"Cell line enriched"	"Detected in some"	6	"Karpas-707: 220.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA046641, HPA049691"	Enhanced		Approved	Vesicles				Vesicles		"HPA046641: AB_2679733, HPA049691: "	"unprognostic (2.97e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.23e-1)"	"prognostic favourable (1.73e-4)"	"unprognostic (8.25e-2)"	"unprognostic (1.93e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.91e-3)"	"unprognostic (1.23e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (2.28e-7)"	"unprognostic (1.73e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.54e-2)"	5.8	1.3	1.4	39.5	1.4	12.8	3.6	0.8	0.9	2.9	16.6	0.9	0.9	8.2	3.0	2.1	5.3	3.1	5.3	2.6	1.4	1.5	3.7	4.7	13.6	70.4	1.8	0.6	2.9	1.5	0.0	1.2	5.3	1.5	3.2	20.8	2.9	10.4	1.8	1.6	2.7	28.6	1.5	2.9	58.7	6.0	2.0	0.9	169.3	3.3	4.2	61.4	7.6	3.1	51.9	30.6	65.6	19.7	94.6	115.3	99.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.8	17.2	1.2	0.0	0.1	0.0	0.0	0.0	14.4	0.0	2.2	0.0	0.0	0.0	8.9	0.4	0.0	0.0	0.0	0.0	0.0	3.8	220.5	0.0	0.0	31.9	17.4	0.0	0.0	7.3	0.0	1.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	12.6	22.2	11.1	0.2	37.0	0.0	35.2	8.5	13.4	107.2	19.7	105.6	51.9	97.7	110.4	20.3	51.6	68.0	84.9	65.6	94.6	13.5	30.6	115.3	99.0	1.4	1.4	0.8	0.9	1.4	1.5	1.8	0.6	1.5	0.9
IL4	"BCGF-1, BCGF1, BSF1, IL-4, MGC79402"	ENSG00000113520	"Interleukin 4"	P05112	5	132673986-132682676	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"B-cell activation"	"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	16	"blood: 73.8"	"Cell line enriched"	"Detected in some"	5	"MOLT-4: 20.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	679	"basophil: 73.8"	"Lineage enriched"	"Detected in single"	679	"granulocytes: 73.8"					"Low region specificity"	"Detected in many"			HPA072995	Approved				"Secreted to blood"					"HPA072995: "	"unprognostic (3.40e-2)"	"unprognostic (9.19e-2)"		"unprognostic (1.41e-1)"	"unprognostic (2.49e-1)"	"unprognostic (2.02e-1)"		"unprognostic (1.96e-1)"	"unprognostic (1.69e-1)"	"unprognostic (7.33e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.47e-10)"	"unprognostic (9.21e-3)"	"unprognostic (2.88e-1)"	"unprognostic (4.93e-2)"	"unprognostic (1.24e-2)"	0.4	1.2	0.3	1.1	0.3	0.9	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.0	1.1	0.3	0.7	0.8	0.8	0.3	0.3	0.1	0.5	0.3	4.6	1.1	0.3	0.3	0.3	0.3	3.7	1.4	0.3	0.3	0.4	0.0	0.3	0.4	0.3	0.3	1.6	1.0	0.3	0.3	0.7	0.2	1.0	0.3	1.3	0.8	0.3	0.3	0.3	0.3	0.0	0.0	73.8	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	20.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	73.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.3	0.4	0.3	0.3	0.1	0.3	0.3	0.3	0.3
IL4R	CD124	ENSG00000077238	"Interleukin 4 receptor"	P24394	16	27313668-27364778	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 35.8;HBEC3-KT: 34.4;U-698: 33.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 34.4"	"Group enriched"	"Detected in all"	6	"B-cells: 34.4;granulocytes: 11.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004451, HPA050124, HPA070380"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Centriolar satellite"	"Secreted to blood"	49000	49000	"Plasma membrane"	"Nucleoplasm, Centriolar satellite"	"CAB004451: AB_626889, HPA050124: , HPA070380: "	"unprognostic (6.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (2.84e-1)"	"prognostic favourable (6.43e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.95e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.97e-1)"	"prognostic unfavourable (1.23e-5)"	"unprognostic (1.49e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.58e-2)"	20.7	14.8	8.7	31.6	10.6	36.9	12.0	4.4	7.7	20.8	30.3	5.9	11.5	10.9	18.0	12.8	24.7	13.6	25.1	12.3	6.7	4.4	13.3	39.1	40.9	44.8	10.8	1.7	14.7	11.3	3.8	5.5	16.1	10.1	18.8	15.1	12.3	7.7	11.5	7.2	9.9	18.6	39.6	13.6	31.8	21.1	10.4	9.8	9.1	8.6	13.7	38.4	31.6	15.4	34.4	1.6	11.9	2.6	3.3	4.0	1.8	11.3	3.0	1.9	3.9	0.9	4.5	4.1	7.2	8.3	2.9	2.3	6.1	31.4	35.8	9.0	11.3	12.1	2.1	34.4	2.5	31.0	1.0	6.7	1.8	9.3	13.0	1.8	19.1	6.9	13.9	13.2	7.9	15.4	2.9	3.0	4.6	5.0	0.1	5.4	2.4	2.6	0.1	14.9	2.9	13.3	13.0	0.6	0.3	1.0	6.9	1.5	2.6	6.9	23.0	6.5	2.9	5.8	5.0	1.8	0.5	33.3	0.7	6.0	0.0	0.5	2.6	4.7	1.7	1.1	1.3	7.7	2.6	1.7	1.6	34.4	4.0	1.9	11.9	3.3	0.6	1.6	1.8	1.8	8.7	10.6	4.4	7.7	6.7	4.4	10.8	1.7	10.1	9.8
IL5	"EDF, IL-5, TRF"	ENSG00000113525	"Interleukin 5"	P05113	5	132541444-132556838	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 3.8;testis: 10.6"	"Group enriched"	"Detected in some"	4	"CACO-2: 2.5;HEK 293: 2.1;Hep G2: 7.1;TIME: 3.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	6	"memory B-cell: 3.8"	"Lineage enriched"	"Detected in single"	6	"B-cells: 3.8"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB010304	Approved				"Secreted to blood"					"CAB010304: AB_2296159"	"unprognostic (1.66e-1)"	"unprognostic (4.76e-2)"	"unprognostic (5.30e-3)"	"unprognostic (2.35e-1)"	"unprognostic (9.07e-2)"		"unprognostic (7.98e-2)"	"unprognostic (2.03e-2)"		"unprognostic (3.51e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.27e-2)"	"unprognostic (5.84e-3)"	"unprognostic (1.91e-1)"	0.1	0.1	0.3	0.3	1.0	0.0	0.1	0.3	1.3	0.2	0.1	0.0	0.0	1.0	0.5	0.0	0.1	0.7	1.1	0.4	1.0	0.3	0.1	0.3	0.1	0.0	0.3	0.0	0.2	0.1	0.0	2.0	0.0	0.9	0.1	0.3	0.0	0.1	0.0	0.1	0.1	1.8	0.1	0.3	0.1	0.3	10.6	0.0	0.4	0.7	0.0	0.2	0.2	0.2	3.8	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.7	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	2.1	0.0	0.2	7.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.1	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.3	0.0	0.3	0.9	0.4	0.8	0.0	0.2	0.8	0.0	0.0	0.0	0.5	0.0	0.0	3.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	1.0	0.3	1.3	1.0	0.3	0.3	0.0	0.9	0.0
IL6	"BSF2, HGF, HSF, IFNB2, IL-6"	ENSG00000136244	"Interleukin 6"	P05231	7	22725884-22732002	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"	"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 60.1;lymphoid tissue: 48.0"	"Cell line enriched"	"Detected in some"	5	"BJ hTERT+: 221.9"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"basal ganglia: 10.0;cerebral cortex: 4.4;hippocampal formation: 3.9;pons and medulla: 12.8"	"Group enriched"	"Detected in some"	70	"memory B-cell: 6.1;naive B-cell: 7.7"	"Lineage enriched"	"Detected in single"	77	"B-cells: 7.7"					"Not detected"	"Not detected"			"CAB023406, CAB072821"	Supported		Approved	Vesicles	"Secreted to blood"			Vesicles		"CAB023406: AB_617317, CAB072821: "	"unprognostic (1.13e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.59e-2)"	"unprognostic (9.88e-3)"	"unprognostic (1.35e-1)"	"unprognostic (3.07e-3)"	"unprognostic (3.25e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavourable (1.10e-11)"	"unprognostic (2.45e-3)"	"unprognostic (2.10e-1)"	"unprognostic (4.31e-2)"	"unprognostic (7.80e-2)"	60.1	5.6	1.4	48.0	10.0	15.3	11.5	0.7	4.4	2.9	8.1	1.2	0.4	0.7	2.1	4.6	14.3	7.8	16.1	21.6	3.9	1.5	1.3	5.2	34.9	3.0	1.8	0.2	5.3	8.3	5.7	14.2	4.5	12.8	6.5	7.5	3.3	3.1	0.8	6.9	2.8	4.5	8.2	7.0	3.5	6.5	3.2	1.2	0.1	4.5	12.7	3.5	34.9	8.4	7.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.8	221.9	4.2	14.2	0.0	0.0	0.0	7.3	1.4	0.1	0.0	0.0	5.6	8.7	0.0	0.0	0.3	0.0	4.7	0.0	0.0	0.5	0.0	42.4	6.1	1.5	0.9	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	11.0	0.0	0.0	0.0	14.4	0.0	0.0	0.0	0.0	1.3	1.4	0.1	2.6	0.4	0.0	2.5	0.0	10.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.4	10.0	0.7	4.4	3.9	1.5	1.8	0.2	12.8	1.2
IL6R	CD126	ENSG00000160712	"Interleukin 6 receptor"	P08887	1	154405193-154469450	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 59.6"	"Cell line enhanced"	"Detected in many"		"THP-1: 54.6;U-266/84: 64.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 35.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	22000000	22000000				"unprognostic (1.19e-1)"	"unprognostic (3.97e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.95e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.27e-1)"	"unprognostic (6.42e-2)"	"prognostic favourable (1.65e-4)"	"unprognostic (7.94e-2)"	"unprognostic (1.05e-1)"	"unprognostic (7.75e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.07e-1)"	8.4	4.0	4.7	14.8	5.1	9.0	6.5	1.4	6.3	6.1	16.9	4.8	1.2	9.6	6.3	4.7	5.2	7.9	6.9	5.0	5.2	2.9	8.9	38.1	20.8	15.4	7.2	2.2	5.7	5.3	0.0	7.7	3.7	7.8	4.5	6.0	3.6	5.4	1.7	59.6	4.7	12.6	5.3	5.0	11.3	6.6	3.7	5.0	4.2	2.5	6.1	13.3	6.3	4.8	0.6	14.3	35.0	11.7	0.5	8.0	5.5	0.8	1.4	0.1	0.1	0.9	1.3	0.1	0.8	0.6	0.5	0.2	0.1	0.9	0.0	1.9	1.0	0.4	0.2	4.4	0.4	14.7	0.4	0.2	0.6	3.3	0.1	2.3	1.3	0.7	2.7	0.4	6.6	0.6	0.1	6.1	0.1	0.3	0.0	3.8	0.4	3.3	0.0	0.0	12.7	2.7	1.1	0.1	0.0	0.2	9.0	14.8	0.8	54.6	0.6	0.9	0.9	0.8	0.5	10.4	64.3	0.1	1.1	14.8	1.4	2.8	11.7	10.4	0.2	7.1	0.6	0.6	6.4	0.7	14.3	0.2	6.4	2.2	35.0	0.5	3.0	5.1	8.0	5.5	4.7	5.1	1.4	6.3	5.2	2.9	7.2	2.2	7.8	5.0
IL6ST	"CD130, GP130"	ENSG00000134352	"Interleukin 6 signal transducer"	P40189	5	55935095-55994993	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 57.0;BJ hTERT+: 58.0;HHSteC: 64.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 21.0"	"Lineage enriched"	"Detected in many"	5	"T-cells: 21.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010558, CAB025784"	Approved		Supported	"Golgi apparatus,Plasma membrane"	"Secreted to blood"	100000000	100000000	"Plasma membrane"	"Golgi apparatus"	"CAB025784: , HPA010558: AB_1078439"	"unprognostic (1.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.61e-2)"	"unprognostic (3.95e-2)"	"unprognostic (8.93e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.18e-2)"	"unprognostic (9.53e-3)"	"unprognostic (1.89e-2)"	"unprognostic (2.29e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavourable (5.05e-4)"	"unprognostic (3.69e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.25e-1)"	44.8	34.2	24.7	25.5	23.4	8.8	76.9	15.9	22.9	38.1	23.9	15.0	29.0	8.7	26.1	24.9	22.7	23.1	31.1	31.9	21.9	19.7	37.2	71.2	36.3	70.0	25.8	14.7	42.1	16.4	35.8	36.2	97.0	22.5	31.9	17.1	20.0	26.3	33.0	27.1	12.5	20.6	36.6	33.8	35.5	19.7	13.7	20.3	19.4	37.6	12.5	18.7	33.7	51.1	0.7	2.1	0.9	3.8	0.8	21.0	4.0	9.4	11.8	3.8	9.1	27.3	57.0	15.8	28.2	58.0	15.2	22.7	16.5	9.0	0.3	21.1	17.4	4.1	3.0	8.4	31.2	0.8	3.0	2.2	9.7	13.6	64.9	0.2	4.5	49.9	4.6	33.0	16.1	34.7	1.6	39.8	17.5	1.6	0.4	0.4	0.6	3.9	0.5	10.7	5.4	8.3	5.6	2.0	3.4	11.4	3.8	11.6	19.0	1.5	55.7	5.9	6.7	23.8	14.8	9.8	4.2	0.3	15.8	0.4	15.3	0.2	3.8	0.1	0.8	3.5	0.4	0.7	4.9	0.8	2.1	0.6	21.0	5.9	0.9	0.8	0.6	1.8	3.4	4.0	24.7	23.4	15.9	22.9	21.9	19.7	25.8	14.7	22.5	20.3
IL7	IL-7	ENSG00000104432	"Interleukin 7"	P13232	8	78675743-78805523	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"intestine: 20.5;lymphoid tissue: 26.3"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 5.8;HDLM-2: 12.9;HEL: 13.7;HMC-1: 20.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 10.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			HPA019590	Approved				"Secreted to blood"					"HPA019590: AB_10794621"	"unprognostic (3.19e-3)"	"unprognostic (1.44e-1)"	"unprognostic (9.57e-3)"	"unprognostic (5.45e-2)"	"unprognostic (9.37e-3)"	"unprognostic (3.36e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.65e-2)"	"unprognostic (2.28e-1)"	"unprognostic (2.47e-1)"	"unprognostic (3.02e-2)"	"unprognostic (2.28e-1)"	"prognostic unfavourable (2.69e-4)"	"unprognostic (1.38e-1)"	"unprognostic (1.33e-1)"	"unprognostic (6.55e-2)"	"unprognostic (2.11e-4)"	6.8	1.9	1.3	13.4	1.8	1.8	2.2	1.7	1.7	2.6	9.5	0.4	1.3	7.0	1.9	5.0	5.0	5.2	8.2	1.5	1.0	0.9	5.6	8.9	6.5	26.3	0.8	0.1	2.4	2.6	0.0	1.3	1.0	1.0	5.0	4.8	1.1	7.9	2.0	0.9	9.6	20.5	2.4	1.2	8.6	4.4	3.0	0.9	2.0	4.1	4.4	10.4	3.9	3.3	10.9	2.4	5.4	0.8	0.5	7.5	0.6	0.2	0.0	0.1	0.0	0.3	0.3	0.0	1.1	1.1	1.0	1.5	0.0	5.8	0.1	0.0	3.3	3.3	0.1	0.0	0.0	12.9	0.0	13.7	0.3	1.7	0.0	0.1	20.3	1.0	0.0	0.1	0.5	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	1.1	0.0	0.9	0.0	4.2	2.3	0.0	1.9	2.0	0.2	0.1	0.1	0.0	0.2	0.7	0.8	0.0	1.5	0.2	0.0	0.0	2.7	0.0	1.5	5.4	0.3	0.0	0.4	0.2	0.0	10.9	1.1	1.1	2.4	8.2	0.3	0.3	0.0	0.5	0.8	0.3	7.5	0.6	1.3	1.8	1.7	1.7	1.0	0.9	0.8	0.1	1.0	0.9
IL7R	CD127	ENSG00000168685	"Interleukin 7 receptor"	P16871	5	35852695-35879603	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1"	"Cell line enhanced"	"Detected in many"		"BJ: 21.7;fHDF/TERT166: 40.7;HBF TERT88: 37.4;REH: 84.6"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1"	"Group enriched"	"Detected in many"	33	"NK-cells: 19.1;T-cells: 70.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			CAB010215			Supported	"Plasma membrane,Centriolar satellite"	"Intracellular and membrane"	180000	180000	"Plasma membrane, Centriolar satellite"		"CAB010215: AB_673727"	"unprognostic (2.93e-3)"	"unprognostic (3.38e-2)"	"unprognostic (3.82e-3)"	"unprognostic (5.58e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.51e-3)"	"unprognostic (5.53e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.29e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.76e-2)"	"unprognostic (5.64e-2)"	"unprognostic (3.27e-3)"	"unprognostic (2.22e-1)"	"unprognostic (1.78e-1)"	6.7	3.6	0.7	34.0	0.7	3.1	4.8	0.5	0.6	4.8	20.6	0.3	0.9	3.5	1.8	2.9	6.6	3.7	8.5	1.9	0.7	0.7	7.0	2.7	52.6	133.1	0.8	0.1	2.5	1.7	0.0	1.5	1.2	0.8	3.3	5.4	1.7	13.2	1.8	0.9	1.8	34.0	1.2	1.5	32.3	7.8	3.0	0.4	130.9	5.1	5.3	42.9	12.6	4.6	0.4	0.3	1.3	0.2	19.1	70.3	12.7	0.1	0.0	0.1	0.1	0.1	0.1	0.2	21.7	11.0	19.6	11.6	0.1	0.1	2.1	0.0	40.7	3.5	0.0	1.3	37.4	1.8	0.2	0.6	2.3	0.0	0.3	0.1	1.5	0.3	0.0	4.2	0.9	0.5	0.1	0.3	15.4	0.0	0.5	0.2	0.1	1.0	84.6	1.1	0.1	0.0	1.2	0.0	0.0	3.6	0.3	0.0	0.1	0.0	1.5	7.7	13.1	3.3	2.8	0.1	0.0	2.4	3.9	2.0	5.9	0.5	0.2	0.1	19.2	0.2	70.3	0.2	39.9	28.0	0.1	0.4	34.5	22.5	1.3	19.1	0.2	0.3	6.7	12.7	0.7	0.7	0.5	0.6	0.7	0.7	0.8	0.1	0.8	0.4
IL9	"HP40, IL-9, P40"	ENSG00000145839	"Interleukin 9"	P15248	5	135892246-135895827	"Cancer-related genes, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in some"		"brain: 5.0;skin 1: 2.1"	"Cell line enriched"	"Detected in single"	267	"HDLM-2: 30.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"								"Secreted to blood"																							0.1	0.2	0.3	0.0	2.2	0.0	0.0	0.3	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.7	0.2	0.1	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.4	2.1	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	2.2	0.3	1.1	0.7	0.2	2.1	0.0	0.0	0.0
ILF3	"DRBP76, MPHOSPH4, MPP4, NF90, NFAR-1"	ENSG00000129351	"Interleukin enhancer binding factor 3"	Q12906	19	10654261-10692417	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Antiviral defense, Transcription, Transcription regulation"	"DNA-binding, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001897	Supported		Supported	Nucleoplasm,Nucleoli,Mitochondria		1100000	1100000	"Nucleoplasm, Nucleoli, Mitochondria"		"HPA001897: AB_1078703"	"unprognostic (2.39e-1)"	"unprognostic (9.44e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.25e-1)"	"unprognostic (7.53e-2)"	"unprognostic (5.55e-3)"	"unprognostic (1.11e-3)"	"unprognostic (2.96e-1)"	"prognostic unfavourable (1.57e-4)"	"unprognostic (3.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.38e-2)"	"prognostic unfavourable (9.65e-4)"	"unprognostic (7.57e-3)"	"unprognostic (7.61e-2)"	"unprognostic (1.03e-1)"	"unprognostic (6.20e-2)"	31.0	39.0	29.6	45.5	26.8	88.2	34.5	48.3	35.2	34.2	30.2	30.8	35.2	30.3	45.4	31.7	40.5	41.9	32.5	34.0	25.5	20.0	28.1	25.6	34.1	44.9	24.7	27.8	52.8	36.8	34.9	34.9	31.8	32.3	34.9	27.3	35.5	35.1	46.2	50.1	37.7	37.2	33.2	33.3	44.5	32.6	54.3	28.0	58.6	43.4	32.4	41.1	38.5	32.1	18.7	18.7	11.5	14.3	15.4	19.4	8.0	45.4	37.0	60.0	54.9	13.0	17.9	34.9	29.1	24.7	48.9	38.3	42.4	26.4	56.8	29.0	26.1	40.8	64.8	39.3	44.1	36.3	57.7	73.7	32.7	39.5	18.7	53.0	36.8	16.9	17.6	38.8	43.5	41.7	62.9	44.7	28.4	37.4	87.9	85.3	72.0	40.7	64.8	57.2	39.3	19.4	48.3	66.3	48.2	37.5	29.8	21.6	25.2	34.1	33.4	40.1	38.2	41.5	57.4	38.4	52.4	69.0	22.4	56.7	43.2	11.5	13.4	7.1	19.4	10.4	16.1	14.7	15.9	17.3	16.8	18.7	15.7	16.0	2.1	15.4	14.3	18.7	15.0	8.0	29.6	26.8	48.3	35.2	25.5	20.0	24.7	27.8	32.3	28.0
ILK		ENSG00000166333	"Integrin linked kinase"	Q13418	11	6603708-6610874	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004041, HPA048437"	Enhanced		Supported	"Nucleoplasm,Cell Junctions,Focal adhesion sites"		130000000	130000000	"Cell Junctions, Focal adhesion sites"	Nucleoplasm	"CAB004041: AB_2127050, HPA048437: "	"unprognostic (1.78e-1)"	"unprognostic (2.26e-2)"	"unprognostic (5.26e-2)"	"unprognostic (2.12e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.19e-3)"	"unprognostic (5.25e-3)"	"unprognostic (1.49e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.64e-1)"	"unprognostic (8.12e-2)"	"prognostic favourable (2.44e-4)"	"unprognostic (4.01e-3)"	"unprognostic (9.27e-2)"	"unprognostic (2.42e-1)"	"unprognostic (6.36e-3)"	20.9	17.6	11.0	22.3	11.9	7.5	37.0	9.4	14.6	40.2	75.1	14.7	41.9	13.5	75.4	25.2	35.7	33.2	41.1	35.1	11.1	9.2	21.6	15.1	21.9	18.9	11.5	14.0	24.2	22.3	20.4	10.9	22.2	11.5	39.9	24.6	19.3	19.4	89.9	18.5	12.4	22.2	103.5	10.6	20.2	33.2	14.2	11.0	8.2	17.5	14.1	13.6	60.8	25.9	19.5	45.9	76.5	49.4	45.3	25.8	63.7	23.8	18.4	29.1	10.0	44.9	31.9	13.2	35.1	69.4	41.6	50.8	19.2	28.1	9.0	9.3	57.4	19.2	16.2	29.7	41.8	15.7	14.8	12.9	17.6	14.9	30.1	10.3	14.8	30.6	14.0	28.1	21.5	39.6	11.8	10.7	54.2	17.9	9.1	17.7	18.3	21.6	9.6	15.2	9.5	30.5	19.1	5.0	11.4	16.6	23.0	19.3	16.0	11.8	45.8	52.2	23.6	21.6	17.0	7.8	4.8	12.6	38.7	15.6	24.3	48.3	49.4	76.5	25.8	47.9	25.1	19.5	23.3	24.4	45.9	17.1	14.7	18.5	31.7	45.3	44.4	18.5	25.7	63.7	11.0	11.9	9.4	14.6	11.1	9.2	11.5	14.0	11.5	11.0
ING1	"p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a"	ENSG00000153487	"Inhibitor of growth family member 1"	Q9UK53	13	110712736-110723339	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016136, CAB017773, HPA052591"	Approved		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB016136: AB_628077, CAB017773: , HPA052591: "	"unprognostic (1.14e-2)"	"unprognostic (3.25e-2)"	"unprognostic (3.51e-2)"	"prognostic favourable (5.81e-4)"	"unprognostic (4.62e-2)"	"unprognostic (3.47e-2)"	"unprognostic (3.36e-1)"	"unprognostic (1.87e-1)"	"unprognostic (9.43e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.36e-3)"	"unprognostic (1.35e-1)"	"unprognostic (7.05e-3)"	"unprognostic (6.78e-2)"	"unprognostic (2.40e-3)"	11.8	11.1	8.9	11.7	10.2	24.9	19.8	12.8	12.1	15.7	14.9	6.9	9.5	13.9	16.3	8.3	10.7	13.7	20.0	9.5	9.4	9.0	9.3	16.7	14.1	20.5	11.6	8.0	25.8	11.8	3.8	9.5	13.3	11.7	13.3	6.6	9.5	13.6	10.9	12.2	8.5	13.6	11.1	10.2	17.6	10.0	26.0	12.0	22.0	11.5	8.3	10.6	18.3	14.8	15.5	3.0	21.4	3.7	12.3	11.6	6.1	17.4	6.9	12.5	12.0	5.9	4.1	12.5	9.0	7.6	5.9	7.1	13.2	12.4	11.2	14.7	3.5	11.0	5.0	4.4	4.9	21.1	9.6	9.9	9.5	9.8	3.3	13.0	9.6	3.7	4.7	5.1	3.1	4.1	9.1	9.5	3.8	10.0	22.5	15.1	12.3	5.8	16.4	6.4	6.3	5.1	9.0	12.3	13.3	8.9	17.9	12.3	6.0	15.5	6.1	7.2	8.9	7.5	10.0	11.5	11.5	14.3	12.1	10.8	11.8	21.4	2.9	11.1	10.8	3.6	11.1	14.8	9.1	9.7	2.8	15.5	9.4	7.8	4.0	12.3	3.7	3.0	11.6	6.1	8.9	10.2	12.8	12.1	9.4	9.0	11.6	8.0	11.7	12.0
INHBA		ENSG00000122641	"Inhibin beta A subunit"	P08476	7	41667168-41705834	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"		"Growth factor, Hormone"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"placenta: 148.2"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 19.5;hTEC/SVTERT24-B: 59.6;hTERT-HME1: 24.7;TIME: 30.7;U-138 MG: 46.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"neutrophil: 1.8;non-classical monocyte: 1.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"								"Secreted to blood"	290000	290000				"unprognostic (4.11e-3)"	"prognostic unfavourable (1.46e-5)"	"unprognostic (4.22e-2)"	"unprognostic (1.08e-1)"	"unprognostic (5.18e-2)"	"prognostic unfavourable (4.34e-4)"	"unprognostic (2.05e-2)"	"prognostic unfavourable (7.72e-4)"	"unprognostic (1.44e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.04e-1)"	"prognostic unfavourable (7.91e-8)"	"unprognostic (6.22e-3)"	"unprognostic (1.11e-2)"	"unprognostic (3.25e-2)"	"unprognostic (3.18e-3)"	1.7	1.0	1.2	3.6	3.7	6.6	1.3	0.7	3.5	1.7	1.5	0.8	1.3	0.3	13.6	4.2	3.8	1.6	17.3	9.3	1.9	1.6	2.0	7.9	26.4	0.6	1.2	0.7	5.2	1.2	0.0	0.8	148.2	4.8	2.4	0.2	1.4	4.3	3.8	1.2	2.9	0.8	3.8	8.7	0.4	1.5	3.9	1.3	0.4	1.5	2.6	0.7	4.8	1.8	0.2	0.7	1.8	1.3	0.0	0.0	0.3	1.0	0.0	0.1	0.0	0.8	1.9	0.0	4.7	0.5	2.6	0.8	0.0	0.1	0.0	0.3	1.7	3.9	0.0	19.5	2.5	1.2	0.0	0.0	0.0	0.0	3.7	0.0	0.0	1.8	1.1	59.6	24.7	2.1	0.1	0.0	5.9	0.0	0.0	0.1	0.4	2.7	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.8	0.1	0.0	0.0	0.0	30.7	46.4	13.4	4.9	4.8	0.0	0.0	0.0	1.8	0.0	0.1	0.1	0.3	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	1.8	0.0	1.3	0.0	0.0	0.3	1.2	3.7	0.7	1.3	1.9	1.6	1.2	0.7	4.8	1.3
INHBB		ENSG00000163083	"Inhibin beta B subunit"	P09529	2	120346143-120351808	"Cancer-related genes, Predicted secreted proteins"		"Growth factor, Hormone"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 23.3"	"Cell line enhanced"	"Detected in some"		"A549: 15.1;ASC diff: 21.0;MCF7: 18.2;PC-3: 29.6;SK-BR-3: 52.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	14	"neutrophil: 1.3"	"Lineage enriched"	"Detected in single"	14	"granulocytes: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (7.80e-2)"	"unprognostic (1.86e-1)"	"prognostic unfavourable (1.44e-4)"	"unprognostic (1.26e-2)"	"unprognostic (4.26e-2)"	"unprognostic (3.61e-3)"	"unprognostic (2.13e-2)"	"unprognostic (5.52e-2)"	"unprognostic (6.99e-2)"	"unprognostic (3.59e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.56e-1)"	"prognostic unfavourable (3.02e-4)"	"unprognostic (1.57e-3)"	"unprognostic (4.14e-1)"	"prognostic favourable (1.02e-4)"	"unprognostic (1.76e-2)"	23.3	3.6	6.0	1.2	3.5	0.2	19.2	0.9	3.8	7.0	0.8	3.1	2.6	1.3	3.9	2.6	1.5	3.3	2.4	3.5	4.7	1.4	1.2	19.2	2.7	1.0	2.2	3.1	1.6	3.5	4.5	3.8	1.2	4.7	7.7	0.3	0.5	7.8	0.9	4.9	7.6	0.9	2.1	1.9	0.4	1.8	14.4	2.2	0.4	19.1	1.6	1.3	4.4	7.8	0.0	0.0	1.3	0.0	0.0	0.0	0.0	7.6	15.1	0.0	0.0	21.0	1.6	0.0	1.0	1.2	6.8	12.7	0.3	0.0	0.0	2.7	0.3	0.0	1.2	0.0	9.5	0.0	0.2	0.0	0.0	0.3	0.3	0.0	0.0	0.8	1.1	0.2	0.0	0.1	0.0	0.0	0.0	18.2	0.0	0.0	0.0	29.6	0.0	0.0	0.3	1.8	0.0	1.7	0.0	0.0	52.9	0.0	12.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	6.0	3.5	0.9	3.7	4.7	1.4	2.2	3.1	4.7	2.2
INPPL1	SHIP2	ENSG00000165458	"Inositol polyphosphate phosphatase like 1"	O15357	11	72223701-72239105	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell adhesion, Immunity"	"Actin-binding, Hydrolase"	"Cancer-related genes, Diabetes mellitus, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA037601	Approved		Supported	"Golgi apparatus,Cytosol"				"Golgi apparatus, Cytosol"		"HPA037601: AB_10672281"	"unprognostic (2.68e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.12e-1)"	"unprognostic (3.68e-3)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (7.37e-4)"	"unprognostic (2.49e-2)"	"unprognostic (3.54e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.64e-1)"	"unprognostic (4.34e-2)"	"unprognostic (3.66e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.99e-3)"	"unprognostic (2.07e-1)"	20.9	23.7	22.2	20.4	19.5	25.1	18.6	11.1	18.9	25.2	32.0	22.7	28.8	19.8	24.7	18.4	17.4	24.3	29.6	29.5	24.1	10.3	23.9	17.1	24.9	19.0	27.6	10.4	30.1	22.7	21.6	26.9	31.9	20.4	28.7	13.5	30.7	27.5	24.2	60.0	17.7	23.0	34.7	27.5	28.3	24.5	11.8	24.3	16.0	29.1	19.3	18.3	25.0	18.1	2.6	5.2	7.0	7.6	4.2	4.5	3.3	6.4	13.8	16.6	11.3	8.2	9.8	29.6	29.8	13.9	18.7	11.9	18.9	16.3	18.4	30.5	22.8	24.6	13.6	8.4	6.4	23.8	14.2	19.1	70.0	6.9	16.1	12.6	42.8	13.9	8.9	18.1	7.2	10.0	13.4	7.9	10.2	17.4	9.3	51.0	16.9	21.6	43.9	37.7	4.1	21.7	10.8	8.1	11.8	32.0	19.3	41.6	20.4	23.9	16.9	20.1	23.5	30.7	9.7	22.9	3.8	17.9	5.7	12.0	10.8	5.2	7.6	7.0	4.5	4.4	3.7	2.2	3.7	3.0	5.2	2.6	2.7	3.7	5.2	4.2	7.0	3.9	3.3	3.3	22.2	19.5	11.1	18.9	24.1	10.3	27.6	10.4	20.4	24.3
INS	"IDDM1, IDDM2"	ENSG00000254647	Insulin	P01308	11	2159779-2161341	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Carbohydrate metabolism, Glucose metabolism"	Hormone	"Cancer-related genes, Diabetes mellitus, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	193	"pancreas: 514.0"	"Group enriched"	"Detected in some"	9	"EFO-21: 52.5;U-2 OS: 68.8;U-698: 21.7"	"Cancer enriched"	"Detected in single"	7166	"pancreatic cancer: 1751.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Region enriched"	"Detected in single"	13	"midbrain: 1.7"	"CAB000048, HPA004932, CAB012098, CAB053843"	Enhanced				"Secreted to blood"					"CAB000048: , CAB012098: AB_300968, CAB053843: AB_620123, HPA004932: AB_1851816"											"unprognostic (7.61e-2)"							0.4	0.1	0.1	0.1	0.1	1.1	0.1	0.1	0.7	0.1	0.3	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	1.4	0.1	0.1	0.1	0.1	0.1	0.1	514.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	2.6	0.1	0.1	0.1	0.1	1.1	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52.5	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	68.8	0.0	5.2	0.0	2.4	21.7	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
INTS12	"INT12, PHF22, SBBI22"	ENSG00000138785	"Integrator complex subunit 12"	Q96CB8	4	105682627-105895986	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035772, HPA041814"	Approved		Approved	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"				"Nucleoplasm, Cytosol"	"Nuclear bodies, Plasma membrane"	"HPA035772: AB_10671109, HPA041814: "	"unprognostic (5.30e-2)"	"unprognostic (4.54e-2)"	"unprognostic (1.84e-3)"	"unprognostic (1.78e-1)"	"unprognostic (3.68e-2)"	"unprognostic (2.58e-3)"	"prognostic unfavourable (2.67e-4)"	"unprognostic (3.95e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.53e-3)"	"unprognostic (3.00e-2)"	"unprognostic (3.48e-2)"	"unprognostic (5.93e-3)"	"unprognostic (3.62e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.16e-2)"	"unprognostic (2.06e-1)"	16.7	13.5	18.7	12.5	20.7	25.3	20.0	17.3	18.1	14.5	17.0	13.4	11.6	17.0	16.1	17.9	13.6	14.4	12.3	19.3	18.3	15.3	18.2	21.4	15.4	12.1	16.5	11.5	15.0	16.0	17.3	20.7	11.2	17.4	18.1	15.4	10.4	14.8	13.7	28.2	14.1	21.0	16.6	19.3	15.9	14.9	12.6	13.8	22.1	31.1	15.9	15.4	13.8	12.6	20.6	27.6	33.3	17.0	27.1	21.9	14.0	12.5	6.7	15.4	15.9	15.2	18.2	11.2	14.9	15.5	18.8	19.6	9.4	14.3	18.1	8.3	16.7	7.3	16.8	21.5	23.4	18.9	10.2	13.6	10.9	13.2	24.5	23.9	12.4	17.1	28.0	18.6	28.1	17.2	20.2	14.3	20.2	13.2	28.0	14.9	6.6	10.3	14.4	16.7	13.8	17.5	8.5	16.6	13.3	10.5	17.4	16.3	14.1	14.1	11.2	12.4	12.7	13.3	15.9	22.1	20.4	27.0	13.7	16.4	24.4	33.3	15.9	24.1	17.9	16.8	20.0	20.6	20.6	20.2	18.0	19.3	21.6	20.2	12.1	27.1	17.0	27.6	21.9	14.0	18.7	20.7	17.3	18.1	18.3	15.3	16.5	11.5	17.4	13.8
IPO7	"Imp7, RANBP7"	ENSG00000205339	"Importin 7"	O95373	11	9384622-9448126	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Host-virus interaction, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019002, HPA056590"	Approved	Approved	Supported	Nucleoplasm,Cytosol		26000	26000	"Nucleoplasm, Cytosol"		"HPA019002: AB_1856059, HPA056590: "	"unprognostic (1.92e-1)"	"prognostic unfavourable (4.98e-4)"	"unprognostic (9.50e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.68e-1)"	"unprognostic (1.60e-2)"	"prognostic unfavourable (6.57e-4)"	"unprognostic (1.19e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.12e-1)"	"prognostic unfavourable (8.38e-6)"	"unprognostic (3.06e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.13e-1)"	"unprognostic (8.08e-2)"	"unprognostic (2.17e-1)"	"unprognostic (3.90e-3)"	23.9	20.6	21.8	18.6	24.4	12.3	36.0	24.1	30.6	24.3	27.4	14.4	19.3	17.0	25.7	19.3	29.0	20.3	20.3	37.7	22.8	23.4	26.5	24.7	22.0	23.2	23.3	17.4	23.4	25.9	33.1	19.1	26.5	24.8	24.4	22.1	12.0	21.4	22.4	88.2	17.1	16.1	53.4	25.7	16.6	21.5	9.7	16.8	20.8	34.3	28.5	20.9	43.7	33.9	3.8	5.8	1.3	6.3	6.9	5.4	1.6	37.3	29.2	34.4	27.3	34.9	45.1	27.6	45.5	29.3	33.7	36.5	25.3	34.4	35.1	16.6	35.0	29.4	48.8	35.3	56.3	16.7	40.3	29.0	33.2	25.3	21.8	44.3	22.1	28.8	38.3	22.1	52.2	39.7	43.4	21.1	43.8	15.2	26.7	21.7	33.9	34.0	28.1	54.2	15.8	27.8	35.3	13.7	26.9	20.3	40.3	32.8	18.5	22.3	31.1	41.5	28.6	42.7	48.6	6.1	23.4	24.2	27.2	23.9	22.5	0.1	2.5	0.6	2.7	4.8	5.4	3.8	3.1	3.9	5.8	3.1	3.9	3.2	1.3	6.9	6.3	2.7	2.8	1.6	21.8	24.4	24.1	30.6	22.8	23.4	23.3	17.4	24.8	16.8
IRF1	MAR	ENSG00000125347	"Interferon regulatory factor 1"	P10914	5	132481609-132490798	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Antiviral defense, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 103.0"	"Cell line enhanced"	"Detected in many"		"HHSteC: 46.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011662, HPA063131"	Supported		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB011662: AB_775784, HPA063131: "	"unprognostic (1.30e-3)"	"unprognostic (2.00e-2)"	"unprognostic (2.47e-3)"	"unprognostic (1.21e-1)"	"unprognostic (2.27e-1)"	"unprognostic (4.48e-2)"	"unprognostic (3.67e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.52e-2)"	"unprognostic (2.24e-2)"	"unprognostic (6.93e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavourable (1.09e-7)"	"unprognostic (1.93e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.21e-1)"	"unprognostic (9.53e-3)"	19.7	8.5	4.1	64.2	9.9	43.8	21.0	3.9	4.6	10.6	27.3	4.0	4.4	31.1	11.4	9.9	12.4	11.8	18.1	11.8	4.2	3.5	14.2	20.9	49.3	41.0	6.8	1.4	11.5	14.5	2.8	8.8	24.7	10.3	18.9	13.6	10.3	13.2	10.3	14.0	8.4	52.1	11.3	8.0	51.7	17.5	5.7	4.9	36.6	26.5	14.7	33.0	14.7	26.7	12.1	16.2	103.0	42.1	21.3	28.5	21.3	8.9	7.2	0.6	2.5	7.1	6.2	14.7	4.3	18.3	13.7	17.2	3.7	26.7	8.9	5.8	6.4	12.5	2.2	10.4	4.6	18.8	2.4	11.9	3.4	2.7	46.9	5.8	10.2	11.6	2.6	10.1	9.7	6.4	2.1	34.3	3.8	4.9	31.6	9.7	0.8	5.1	36.7	7.7	10.8	7.0	10.1	1.3	1.1	4.5	10.2	4.4	1.7	8.0	4.0	7.8	2.8	4.5	6.3	27.2	6.8	6.3	9.0	9.3	5.6	23.1	26.2	40.2	28.5	40.0	19.4	12.1	18.7	22.9	16.2	11.5	11.5	16.0	103.0	21.3	42.1	8.2	20.2	21.3	4.1	9.9	3.9	4.6	4.2	3.5	6.8	1.4	10.3	4.9
IRF4	"LSIRF, MUM1"	ENSG00000137265	"Interferon regulatory factor 4"	Q15306	6	391739-411447	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 48.7"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 49.1;Karpas-707: 45.6;RPMI-8226: 44.1;U-266/70: 41.3;U-266/84: 30.7;WM-115: 25.0"	"Cancer enriched"	"Detected in many"	9	"melanoma: 27.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"memory B-cell: 9.5;myeloid DC: 9.0;naive B-cell: 9.7;plasmacytoid DC: 10.4;T-reg: 4.8"	"Group enriched"	"Detected in many"	5	"B-cells: 9.7;dendritic cells: 10.4;T-cells: 4.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA002038, HPA002698, CAB013508"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB013508: , HPA002038: AB_1079148, HPA002698: AB_1851893"	"prognostic favourable (6.44e-4)"	"unprognostic (1.88e-3)"	"unprognostic (1.00e-3)"	"unprognostic (1.72e-4)"	"unprognostic (2.74e-1)"	"prognostic favourable (1.64e-6)"	"unprognostic (4.72e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.89e-2)"	"unprognostic (5.74e-4)"	"unprognostic (8.51e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.18e-7)"	"unprognostic (2.38e-1)"	"unprognostic (6.24e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.65e-2)"	7.1	0.5	0.4	36.6	0.4	18.4	4.0	0.4	0.4	17.4	13.9	0.1	0.4	5.0	2.2	0.7	6.4	1.2	4.1	1.6	0.4	0.5	1.4	5.6	4.2	31.5	0.5	0.0	1.9	0.7	0.0	0.7	0.5	0.1	1.5	4.8	15.8	21.3	1.9	0.7	4.5	11.1	0.3	0.6	33.8	4.6	1.7	0.1	15.2	1.3	2.4	48.7	8.4	4.2	9.7	10.4	0.0	1.6	0.2	4.8	1.3	0.0	0.0	0.0	0.0	5.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	45.6	0.0	0.0	0.0	0.0	0.2	0.0	5.8	0.0	44.1	0.0	0.0	0.1	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41.3	30.7	13.4	0.0	0.0	25.0	0.0	1.6	0.0	0.6	1.2	0.0	9.5	0.9	0.9	9.0	9.7	1.6	0.7	0.0	0.2	1.2	10.4	4.8	1.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.0	0.1	0.1
IRF6	"LPS, OFC6, VWS, VWS1"	ENSG00000117595	"Interferon regulatory factor 6"	O14896	1	209785623-209806175	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A-431: 16.0;HaCaT: 58.3;HBEC3-KT: 21.3;hTCEpi: 47.0;hTERT-HME1: 23.5;RT4: 20.8"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"cerebellum: 8.6;pons and medulla: 4.4"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA063121, HPA076162"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"HPA063121: AB_2684942, HPA076162: AB_2686780"	"unprognostic (2.59e-1)"	"unprognostic (1.79e-3)"	"unprognostic (1.74e-1)"	"unprognostic (7.80e-2)"	"unprognostic (1.33e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.36e-1)"	"unprognostic (7.82e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.74e-3)"	"unprognostic (2.03e-1)"	"prognostic favourable (0.00e+0)"	"unprognostic (2.70e-1)"	"unprognostic (2.66e-2)"	"unprognostic (2.14e-1)"	"unprognostic (4.42e-2)"	1.0	6.3	1.1	4.1	1.0	0.3	13.3	8.6	0.9	11.7	12.9	1.0	38.6	9.2	3.9	31.4	63.7	7.6	17.5	10.3	1.1	0.8	12.9	18.4	8.8	0.3	0.9	0.7	3.9	13.9	10.3	6.8	26.7	4.4	21.8	11.3	1.5	24.8	34.6	0.6	45.6	20.3	3.1	1.1	1.2	9.5	4.3	0.3	13.0	22.1	32.3	33.8	15.0	19.1	0.9	0.5	2.0	1.0	0.6	2.8	0.7	16.0	0.0	0.0	0.0	0.1	0.0	6.0	0.0	0.1	0.0	0.0	3.4	5.7	0.0	0.0	0.0	58.3	0.0	21.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.0	0.0	23.5	0.9	0.0	0.0	0.0	2.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	2.1	20.8	5.2	1.7	0.4	9.3	0.5	6.7	0.1	0.0	0.0	0.0	0.0	0.0	0.2	4.1	0.0	0.0	0.0	0.0	0.2	0.1	2.0	2.8	1.0	1.9	0.6	0.6	0.9	0.5	0.9	2.1	1.1	0.1	0.6	0.1	0.2	0.0	0.7	1.1	1.0	8.6	0.9	1.1	0.8	0.9	0.7	4.4	0.3
IRS2		ENSG00000185950	"Insulin receptor substrate 2"	Q9Y4H2	13	109752698-109786568	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Transducer	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 70.1"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 18.0;SH-SY5Y: 18.9;THP-1: 28.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 6.9"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 6.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016944, HPA054664"	Approved		Supported	Aggresome,Cytosol				Cytosol	Aggresome	"CAB016944: , HPA054664: "	"unprognostic (2.87e-3)"	"unprognostic (5.73e-3)"	"unprognostic (4.39e-2)"	"unprognostic (1.09e-3)"	"unprognostic (1.08e-1)"	"unprognostic (5.49e-3)"	"unprognostic (2.10e-1)"	"unprognostic (9.28e-2)"	"unprognostic (9.70e-2)"	"unprognostic (2.34e-3)"	"unprognostic (1.17e-1)"	"unprognostic (2.09e-2)"	"unprognostic (6.21e-3)"	"unprognostic (1.50e-1)"	"unprognostic (2.82e-1)"	"unprognostic (3.17e-2)"	"unprognostic (1.24e-1)"	38.9	24.3	27.6	10.9	25.2	70.1	33.5	19.6	30.6	13.5	10.9	13.0	6.7	8.7	14.4	12.2	7.1	7.7	8.4	13.5	23.6	14.6	7.7	24.6	11.6	5.3	24.2	22.1	27.1	7.9	6.1	23.0	13.6	19.5	20.0	7.5	9.3	11.5	12.2	20.9	15.3	9.7	9.7	25.1	9.0	8.3	6.3	21.3	2.0	10.7	4.7	5.3	8.4	17.8	0.5	0.1	6.9	1.4	0.2	0.5	0.2	2.6	3.0	1.9	0.0	16.5	3.3	1.0	2.9	3.4	1.7	1.5	0.2	3.2	0.0	1.8	2.0	1.2	1.0	2.6	2.2	1.0	13.6	1.2	4.3	0.0	16.7	4.7	1.5	6.9	13.9	0.5	18.0	0.6	0.8	0.0	17.0	1.3	0.0	13.9	2.1	0.6	5.9	1.8	1.2	4.9	0.7	2.9	18.9	1.5	0.0	11.6	0.3	28.3	0.0	3.7	0.0	0.2	3.8	0.0	1.3	0.9	2.7	4.6	6.3	2.7	1.4	1.9	0.2	0.3	0.3	0.1	0.4	0.1	0.1	0.5	0.5	0.4	6.9	0.2	0.4	0.1	0.5	0.2	27.6	25.2	19.6	30.6	23.6	14.6	24.2	22.1	19.5	21.3
IRS4	"IRS-4, PY160"	ENSG00000133124	"Insulin receptor substrate 4"	O14654	X	108732482-108736409	"Cancer-related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"pituitary gland: 56.0"	"Cell line enhanced"	"Detected in some"		"HEK 293: 13.6;NTERA-2: 1.7;RT4: 4.0;WM-115: 3.0"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	7	"hypothalamus: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"basal ganglia: 12.8;hypothalamus: 52.4"	"Group enriched"	"Detected in some"	6	"basal ganglia: 21.5;hypothalamus: 55.3"	HPA017372	Uncertain									"HPA017372: "	"unprognostic (3.74e-3)"				"unprognostic (3.27e-2)"			"unprognostic (1.32e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.89e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.65e-1)"		"unprognostic (1.05e-2)"	"unprognostic (1.77e-1)"	"unprognostic (9.28e-4)"	"unprognostic (8.71e-2)"	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.6	1.9	0.0	0.1	0.3	0.1	2.6	0.3	0.3	0.5	0.0	0.0	0.3	4.6	0.0	0.0	0.1	0.0	0.5	0.1	9.5	0.0	0.0	56.0	0.1	0.6	0.2	0.0	2.7	0.0	0.5	0.0	0.6	0.0	1.0	0.2	0.1	0.5	0.1	0.5	5.1	3.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	13.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.3	0.3	4.6	0.5	0.1	0.6	0.5
ITGA1	"CD49a, VLA1"	ENSG00000213949	"Integrin subunit alpha 1"	P56199	5	52787896-52959210	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 21.0;HHSteC: 25.8;WM-115: 19.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 1.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 1.2;T-cells: 1.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042555	Uncertain					2300000	2300000			"HPA042555: AB_10794281"	"unprognostic (1.48e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.38e-1)"	"unprognostic (9.89e-3)"	"unprognostic (2.74e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.79e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.62e-1)"	"unprognostic (9.86e-2)"	"prognostic unfavourable (2.24e-4)"	"unprognostic (3.13e-3)"	"unprognostic (2.06e-2)"	"unprognostic (1.07e-2)"	"unprognostic (1.62e-2)"	22.6	20.2	2.3	12.7	2.7	0.0	12.4	1.2	2.9	10.9	28.2	1.5	13.6	5.3	15.9	12.5	22.3	9.2	13.9	11.1	2.5	2.2	17.9	40.4	28.8	10.2	3.1	1.4	9.6	3.3	11.5	3.0	24.8	3.3	26.1	8.2	5.9	2.9	18.2	9.7	2.4	13.5	52.8	2.7	66.0	16.8	4.1	1.6	0.6	10.7	3.5	2.2	42.7	17.8	0.0	0.1	1.2	0.3	0.0	1.8	0.1	0.0	0.0	2.0	0.0	5.8	1.7	1.2	2.7	7.2	1.6	4.8	3.7	0.3	0.0	0.9	21.0	1.4	0.4	2.3	1.5	0.0	1.5	0.0	3.4	2.7	25.8	0.0	0.0	3.9	0.2	1.9	0.7	0.3	0.0	0.0	2.4	0.0	0.8	0.0	1.1	0.7	0.0	1.9	0.0	3.1	0.0	0.1	9.1	2.7	0.6	0.6	0.0	0.0	2.1	4.4	0.4	0.1	1.4	0.0	0.0	0.0	2.8	0.0	19.1	0.0	0.3	1.1	0.1	0.0	0.0	0.0	0.6	1.8	0.1	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.1	0.1	2.3	2.7	1.2	2.9	2.5	2.2	3.1	1.4	3.3	1.6
ITGA2	CD49b	ENSG00000164171	"Integrin subunit alpha 2"	P17301	5	52989326-53094779	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 30.1;HaCaT: 30.4;HUVEC TERT2: 28.0;TIME: 23.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB017690, HPA060991, HPA063556"	Enhanced		Approved	Nucleoplasm,Cytosol		46000000	46000000	Nucleoplasm	Cytosol	"CAB017690: AB_1124939, HPA060991: AB_2684405, HPA063556: AB_2685040"	"unprognostic (8.35e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.85e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.70e-2)"	"unprognostic (2.67e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.69e-2)"	"prognostic unfavourable (1.02e-5)"	"unprognostic (4.27e-1)"	"unprognostic (3.88e-2)"	"unprognostic (2.87e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.11e-1)"	1.9	14.0	2.9	4.7	13.4	0.4	7.9	1.8	6.8	7.1	6.5	22.5	12.1	7.6	5.1	10.4	16.7	2.8	9.3	2.5	5.4	3.6	15.1	1.8	17.2	1.4	18.3	4.5	1.8	2.7	16.1	2.5	4.8	10.7	8.5	6.0	0.8	15.8	16.8	1.2	16.9	17.0	2.5	8.4	9.1	7.4	1.3	13.0	1.5	2.5	7.4	10.0	7.5	11.1	0.5	1.5	1.7	0.6	0.2	0.6	0.3	19.5	5.0	0.4	0.2	1.3	2.4	1.5	19.8	30.1	0.7	1.2	9.4	13.8	0.0	3.4	8.4	30.4	1.6	22.2	2.9	0.0	1.5	1.4	1.3	5.6	4.6	0.2	0.4	1.0	3.9	19.9	3.5	28.0	0.0	0.0	0.5	3.6	0.2	0.0	1.2	10.1	0.0	0.1	0.0	6.3	10.4	0.2	1.1	1.0	1.3	2.0	3.2	0.0	23.9	3.6	2.1	0.5	3.9	0.0	0.0	0.0	21.8	0.0	15.9	1.7	0.6	0.2	0.6	0.2	0.4	0.4	0.5	0.5	0.1	0.5	0.5	0.6	0.8	0.2	0.1	1.5	0.4	0.3	2.9	13.4	1.8	6.8	5.4	3.6	18.3	4.5	10.7	13.0
ITGA2B	"CD41, CD41B, GP2B, PPP1R93"	ENSG00000005961	"Integrin subunit alpha 2b"	P08514	17	44372180-44389505	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8"	"Group enriched"	"Detected in some"	13	"HEL: 69.4;HMC-1: 118.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	10	"basophil: 28.5"	"Lineage enriched"	"Detected in single"	54	"granulocytes: 28.5"	"Low region specificity"	"Detected in single"							"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171"	Enhanced		Approved	"Plasma membrane"		1100000000	1100000000	"Plasma membrane"		"CAB018611: AB_2265153, HPA031168: AB_10670151, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773"	"unprognostic (6.11e-2)"	"unprognostic (3.23e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.59e-2)"	"unprognostic (3.98e-3)"	"unprognostic (4.23e-5)"	"unprognostic (1.25e-1)"	"unprognostic (1.33e-2)"	"unprognostic (7.22e-2)"	"unprognostic (2.97e-3)"	"unprognostic (1.30e-1)"	"unprognostic (8.83e-9)"	"unprognostic (7.82e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.25e-1)"	0.7	0.2	1.4	0.4	1.0	15.2	0.6	3.8	2.4	1.2	0.9	0.4	0.4	0.1	1.1	25.2	0.7	1.9	1.4	10.6	0.9	1.6	1.0	0.4	6.5	0.5	0.7	0.8	2.1	2.5	0.1	2.5	1.9	1.1	0.6	0.3	0.6	0.4	1.6	0.8	0.1	0.6	0.4	0.8	22.8	0.2	3.0	0.4	0.4	5.2	1.0	0.6	0.7	1.9	0.0	0.5	28.5	0.2	0.0	0.2	11.1	0.0	0.1	0.7	0.0	0.0	0.0	2.8	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.4	69.4	0.0	0.6	0.0	0.0	118.6	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	7.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.6	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	28.5	0.2	2.1	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.8	0.0	0.0	0.5	0.0	11.1	1.4	1.0	3.8	2.4	0.9	1.6	0.7	0.8	1.1	0.4
ITGA3	"CD49c, GAP-B3, MSK18, VCA-2, VLA3a"	ENSG00000005884	"Integrin subunit alpha 3"	P26006	17	50055968-50090481	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 74.7;hTERT-HME1: 64.9;RPTEC TERT1: 65.8;U-138 MG: 65.1;U-87 MG: 112.1;WM-115: 67.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 1.1"	"Lineage enriched"	"Detected in single"	4	"T-cells: 1.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008572, CAB018594"	Enhanced		Supported	"Plasma membrane"		180000	180000	"Plasma membrane"		"CAB018594: AB_668044, HPA008572: AB_2668094"	"unprognostic (3.24e-3)"	"prognostic unfavourable (6.75e-4)"	"unprognostic (9.51e-2)"	"unprognostic (3.46e-3)"	"unprognostic (3.45e-3)"	"prognostic unfavourable (1.36e-4)"	"unprognostic (8.28e-3)"	"unprognostic (2.76e-3)"	"unprognostic (1.26e-3)"	"unprognostic (1.82e-2)"	"prognostic unfavourable (5.95e-5)"	"unprognostic (7.05e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.28e-2)"	"unprognostic (2.35e-2)"	15.7	15.8	4.1	8.6	5.1	0.1	8.7	7.7	6.5	10.9	20.9	2.3	8.9	17.1	11.6	11.6	12.8	14.5	32.6	8.4	4.2	5.4	36.0	1.7	37.6	3.2	3.2	6.7	10.7	8.0	13.0	11.2	26.4	4.3	12.0	8.9	11.6	10.0	9.7	6.6	17.3	37.3	11.6	3.3	6.5	13.7	3.9	1.5	3.3	36.1	13.3	8.3	19.0	8.1	0.2	0.0	0.0	0.0	0.0	1.1	0.2	20.5	27.2	0.1	0.8	0.5	2.1	4.4	9.6	20.8	14.6	11.1	0.6	32.1	0.0	60.9	7.0	14.6	0.2	74.7	8.9	2.5	0.4	0.0	6.9	0.1	12.9	0.0	0.6	2.6	36.9	14.6	64.9	10.7	0.0	0.3	27.4	5.9	0.0	0.0	0.6	16.5	0.0	1.4	1.5	65.8	35.8	1.1	0.4	10.5	1.4	24.1	2.4	0.2	23.1	65.1	20.5	0.6	37.5	0.9	1.5	0.6	112.1	0.2	67.6	0.0	0.0	0.0	0.8	0.0	1.0	0.2	0.1	0.1	0.0	0.2	0.2	0.6	0.0	0.0	0.0	0.0	1.1	0.2	4.1	5.1	7.7	6.5	4.2	5.4	3.2	6.7	4.3	1.5
ITGA4	CD49d	ENSG00000115232	"Integrin subunit alpha 4"	P13612	2	181457202-181536187	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 38.4;lymphoid tissue: 101.6"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 38.7;HEL: 61.5;MOLT-4: 71.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	7	"cerebellum: 26.0"	HPA074961			Approved	"Plasma membrane"	"Intracellular and membrane"	100000	100000	"Plasma membrane"		"HPA074961: "	"unprognostic (5.31e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.99e-2)"	"unprognostic (3.94e-2)"	"unprognostic (3.76e-1)"	"prognostic favourable (8.29e-4)"	"unprognostic (1.27e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.67e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.94e-1)"	"prognostic unfavourable (3.08e-5)"	"unprognostic (2.26e-2)"	"unprognostic (8.64e-3)"	"unprognostic (2.49e-1)"	"unprognostic (2.57e-2)"	3.8	1.7	1.3	39.7	1.1	19.2	3.2	2.4	1.9	6.7	4.8	0.5	1.1	3.8	3.0	3.1	2.9	2.1	6.9	1.7	2.9	1.3	3.0	2.5	13.6	33.7	1.2	0.5	1.8	1.6	0.0	1.3	7.1	0.9	3.8	4.9	2.9	7.5	2.0	1.0	1.5	11.6	2.4	1.6	36.0	4.4	1.2	0.2	101.6	2.6	1.5	14.3	6.0	4.1	11.0	19.1	38.4	38.3	8.8	15.9	16.2	0.0	0.2	1.0	0.0	9.1	13.8	0.0	8.9	11.2	4.8	10.1	0.0	0.0	7.1	0.0	38.7	5.3	3.1	0.1	5.8	0.0	0.7	61.5	0.2	0.0	0.9	27.2	1.5	9.8	0.0	0.3	0.0	0.4	0.0	10.4	3.0	0.0	71.7	19.1	0.8	0.0	15.7	4.5	1.0	0.0	0.0	1.6	0.6	0.0	0.0	0.3	0.0	18.0	4.8	1.5	0.9	0.1	1.8	20.4	15.1	4.0	0.8	13.5	20.6	6.7	16.2	38.4	12.9	38.3	9.7	11.0	14.6	15.9	19.1	10.0	8.5	10.4	2.1	8.8	37.5	5.0	3.7	16.2	1.3	1.1	2.4	1.9	2.9	1.3	1.2	0.5	0.9	0.2
ITGA5	"CD49e, FNRA"	ENSG00000161638	"Integrin subunit alpha 5"	P08648	12	54395261-54419460	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 137.7"	"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 140.8;TIME: 134.1;U-87 MG: 66.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 31.5"	"Low lineage specificity"	"Detected in many"			"Region enriched"	"Detected in single"	7	"basal ganglia: 9.3"	"Low region specificity"	"Detected in some"			"HPA002642, CAB009008"	Enhanced					23000000	23000000			"CAB009008: AB_647474, HPA002642: AB_1078469"	"unprognostic (7.51e-3)"	"prognostic unfavourable (4.07e-6)"	"prognostic unfavourable (8.43e-4)"	"unprognostic (1.58e-1)"	"unprognostic (8.51e-3)"	"prognostic unfavourable (2.91e-4)"	"prognostic unfavourable (2.23e-5)"	"prognostic unfavourable (2.44e-4)"	"unprognostic (2.76e-2)"	"unprognostic (6.19e-2)"	"unprognostic (8.99e-2)"	"unprognostic (8.28e-2)"	"prognostic unfavourable (1.32e-8)"	"unprognostic (2.11e-3)"	"unprognostic (3.35e-2)"	"prognostic unfavourable (8.89e-4)"	"unprognostic (2.18e-3)"	23.3	7.9	2.1	32.2	2.8	9.2	30.5	1.2	2.2	16.0	66.9	2.2	19.0	3.4	19.3	13.8	18.2	12.0	12.4	20.3	2.9	0.8	4.6	15.2	20.4	9.2	3.2	1.2	13.6	5.3	3.7	1.8	57.7	3.3	26.6	10.2	4.9	4.4	28.9	10.0	8.8	14.9	137.7	3.5	3.1	19.7	6.6	2.5	3.0	7.3	5.8	4.5	82.1	20.6	0.1	22.2	31.5	22.9	9.1	5.6	12.4	6.6	2.4	4.6	0.0	14.3	30.5	12.0	30.0	31.2	30.9	22.8	1.6	1.5	0.0	21.9	31.3	1.0	1.2	8.3	21.4	0.0	1.2	2.9	3.3	0.1	19.8	9.0	4.6	22.0	4.1	36.2	27.9	140.8	2.4	0.0	17.5	0.6	1.3	10.1	1.8	1.9	1.4	3.1	0.6	4.9	0.1	0.0	0.0	6.0	0.4	0.2	0.7	8.1	134.1	37.6	6.7	9.2	12.4	0.0	0.3	0.0	66.9	8.6	12.2	5.6	22.9	0.1	5.6	10.0	4.4	0.0	4.2	4.2	22.2	0.1	3.1	2.6	31.5	9.1	7.6	1.2	1.7	12.4	2.1	2.8	1.2	2.2	2.9	0.8	3.2	1.2	3.3	2.5
ITGA6	CD49f	ENSG00000091409	"Integrin subunit alpha 6"	P23229	2	172427354-172506282	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BJ: 50.1;HaCaT: 55.2;HBEC3-KT: 108.5;hTCEpi: 47.3;hTERT-HME1: 48.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 16.2"	"Group enriched"	"Detected in many"	34	"granulocytes: 16.2;NK-cells: 5.5;T-cells: 10.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009009, HPA012696, HPA027582"	Enhanced					45000000	45000000			"CAB009009: AB_2128038, HPA012696: AB_1851822, HPA027582: AB_10602606"	"unprognostic (1.02e-1)"	"unprognostic (3.33e-1)"	"unprognostic (2.59e-2)"	"unprognostic (5.96e-2)"	"unprognostic (4.93e-2)"	"prognostic unfavourable (1.03e-4)"	"unprognostic (1.19e-1)"	"unprognostic (1.61e-3)"	"unprognostic (9.34e-2)"	"unprognostic (6.01e-2)"	"unprognostic (1.85e-3)"	"unprognostic (1.84e-1)"	"prognostic favourable (2.35e-11)"	"unprognostic (3.35e-2)"	"unprognostic (3.32e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.21e-3)"	28.0	3.1	9.8	19.1	10.5	1.6	30.1	3.0	8.4	27.0	34.9	9.4	42.3	28.5	28.2	11.3	17.0	11.1	23.8	21.7	9.7	8.2	22.0	4.9	29.0	14.9	9.8	5.1	7.6	31.3	7.4	4.9	38.7	12.6	14.3	25.2	17.6	37.1	32.4	13.5	17.5	44.2	15.2	9.6	14.9	25.0	12.4	6.9	15.1	11.5	35.2	13.2	24.1	17.3	0.3	0.1	16.2	0.2	5.5	10.0	3.3	11.4	9.8	4.3	7.7	0.2	0.1	23.6	50.1	5.4	5.1	3.2	5.5	22.0	0.1	14.1	13.3	55.2	2.8	108.5	9.3	0.1	2.6	0.2	10.5	9.1	0.7	3.1	0.3	1.0	47.3	0.3	48.1	32.8	0.0	0.8	6.4	0.5	0.8	2.7	7.8	8.4	0.1	12.8	0.2	7.8	16.1	0.1	0.5	9.2	0.0	10.7	2.0	0.2	14.7	7.2	6.5	13.2	8.6	0.7	0.5	0.3	0.2	1.1	28.9	2.6	0.2	16.2	4.2	0.0	8.5	0.2	5.4	5.0	0.1	0.3	10.0	4.6	0.5	5.5	0.0	0.0	5.7	3.3	9.8	10.5	3.0	8.4	9.7	8.2	9.8	5.1	12.6	6.9
ITGAM	"CD11b, CR3A, MAC-1"	ENSG00000169896	"Integrin subunit alpha M"	P11215	16	31259990-31332892	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Immunity, Innate immunity"	"Integrin, Receptor"	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 93.7"	"Group enriched"	"Detected in some"	4	"HMC-1: 32.7;NB-4: 11.6;U-937: 14.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basophil: 29.4;classical monocyte: 19.1;eosinophil: 23.8;gdT-cell: 12.2;intermediate monocyte: 7.6;neutrophil: 21.0;NK-cell: 18.8"	"Low lineage specificity"	"Detected in all"											"HPA002274, CAB025091, CAB072870"	Enhanced					900000	900000			"CAB025091: , CAB072870: , HPA002274: AB_1078435"	"unprognostic (1.82e-2)"	"unprognostic (1.70e-2)"	"unprognostic (8.78e-2)"	"unprognostic (2.54e-2)"	"unprognostic (2.40e-2)"	"unprognostic (4.20e-2)"	"prognostic unfavourable (3.43e-4)"	"unprognostic (1.86e-1)"	"unprognostic (1.73e-1)"	"unprognostic (3.29e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.80e-1)"	"prognostic unfavourable (6.93e-5)"	"unprognostic (9.89e-2)"	"prognostic unfavourable (6.93e-4)"	"unprognostic (3.99e-2)"	"unprognostic (5.03e-2)"	19.7	5.0	6.0	14.0	7.2	93.7	6.0	2.0	4.5	2.9	3.2	9.4	0.5	1.8	2.5	3.5	2.2	4.8	4.0	6.5	4.3	3.9	3.0	3.3	14.6	22.8	10.5	1.6	2.5	2.9	1.6	1.8	4.9	5.3	3.6	2.7	3.3	3.2	2.0	1.6	1.5	4.4	6.9	8.6	29.9	2.8	1.5	7.4	2.3	2.1	1.7	6.6	4.9	4.5	1.9	3.4	29.4	19.1	18.8	12.2	8.0	0.5	1.1	0.0	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.3	0.4	0.8	0.5	0.0	0.1	0.0	0.2	0.0	4.7	0.0	0.6	0.0	0.0	0.0	1.1	32.7	0.0	0.1	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.0	11.6	0.0	0.0	0.1	0.0	0.6	0.0	1.3	0.0	0.0	0.0	0.3	0.2	0.1	2.7	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	14.0	0.0	29.4	19.1	23.8	12.2	7.6	0.7	1.9	1.3	3.6	3.4	0.3	0.3	3.0	21.0	18.8	1.1	0.2	0.5	8.0	6.0	7.2	2.0	4.5	4.3	3.9	10.5	1.6	5.3	7.4
ITGAV	"CD51, MSK8, VNRA, VTNR"	ENSG00000138448	"Integrin subunit alpha V"	P06756	2	186590065-186680901	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RT4: 75.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.7"	"Group enriched"	"Detected in many"	4	"granulocytes: 7.7;monocytes: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002499, HPA004856"	Supported		Approved	"Focal adhesion sites,Cytosol"		750000	750000	"Focal adhesion sites, Cytosol"		"CAB002499: AB_563594, HPA004856: AB_1846316"	"unprognostic (4.03e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.22e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (2.08e-4)"	"unprognostic (1.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavourable (5.07e-4)"	"unprognostic (5.84e-2)"	"unprognostic (2.67e-2)"	"prognostic unfavourable (1.05e-6)"	"unprognostic (2.61e-1)"	"unprognostic (9.11e-2)"	"unprognostic (8.07e-2)"	23.2	22.1	17.9	18.3	21.8	3.1	25.8	16.7	23.1	22.9	13.6	23.4	11.6	8.4	26.0	11.4	14.2	14.5	25.2	40.7	16.8	12.3	51.5	9.5	20.6	7.6	24.2	11.6	35.4	18.7	65.0	11.0	29.6	22.1	16.5	11.9	83.4	17.9	15.9	13.1	21.5	10.1	29.6	33.0	12.1	17.3	11.2	17.0	7.8	33.1	10.9	11.1	17.6	17.9	0.3	0.9	7.7	2.3	0.4	1.1	0.5	9.7	11.7	7.8	24.9	28.7	19.4	29.7	19.2	15.5	6.8	6.8	10.2	33.8	0.0	37.9	21.6	12.3	3.9	18.1	9.8	1.9	3.5	2.3	15.4	14.0	11.3	1.6	1.4	14.1	8.6	15.2	12.9	16.2	2.2	4.9	18.1	3.8	0.9	1.3	5.9	5.9	0.0	15.9	1.3	17.6	75.3	1.6	4.8	22.2	6.9	8.1	5.4	4.5	49.1	42.2	13.2	8.6	16.2	1.2	2.0	1.1	17.0	0.6	20.8	7.7	1.1	1.6	1.0	2.3	0.7	0.3	0.5	0.8	0.9	0.1	0.5	0.5	0.5	0.4	1.2	0.4	1.1	0.5	17.9	21.8	16.7	17.3	16.8	12.3	24.2	11.6	22.1	17.0
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	"Integrin subunit beta 1"	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"		540000000	540000000	"Plasma membrane, Focal adhesion sites"	"Endoplasmic reticulum"	"CAB003434: AB_303570, HPA059297: , HPA069003: "	"unprognostic (3.07e-2)"	"prognostic unfavourable (5.01e-4)"	"unprognostic (8.67e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.87e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavourable (3.36e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.36e-3)"	"unprognostic (3.68e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.08e-2)"	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17.0	80.2	20.2	84.2	56.2	59.9	45.0	49.8	68.7	15.0	14.4	47.3	85.8	55.4	34.5	23.0	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58.0	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	47.4	69.7	37.6	41.7	90.9	78.3	32.8	159.7	92.6	76.1	69.6	15.6	111.2	12.8	28.9	133.9	33.2	11.3	90.9	84.9	12.6	9.2	15.4	33.2	18.2	64.0	3.4	15.3	79.3	49.7	80.0	32.6	93.4	10.6	5.7	125.4	7.8	5.9	3.5	8.4	35.4	3.9	27.9	2.3	108.5	13.8	8.9	22.3	49.8	8.5	35.8	11.4	12.4	104.5	98.0	56.9	69.6	53.2	5.2	1.1	7.2	72.2	14.6	38.4	1.6	9.8	4.3	25.5	17.8	6.0	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15.0	14.4	23.0	11.1	19.5	18.8
ITGB3	"CD61, GP3A, GPIIIa"	ENSG00000259207	"Integrin subunit beta 3"	P05106	17	47253846-47311816	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"thyroid gland: 36.6"	"Cell line enhanced"	"Detected in some"		"EFO-21: 45.5;HEL: 40.3;RPTEC TERT1: 26.2;U-87 MG: 20.6;WM-115: 65.7"	"Group enriched"	"Detected in many"	6	"melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	19	"basophil: 2.8;neutrophil: 2.8"	"Lineage enriched"	"Detected in single"	19	"granulocytes: 2.8"									HPA027852	Approved		Supported	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	710000000	710000000	"Plasma membrane"	Nucleoplasm	"HPA027852: AB_10601760"	"unprognostic (1.13e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.47e-1)"	"unprognostic (3.00e-2)"	"unprognostic (1.91e-2)"	"unprognostic (6.04e-3)"	"unprognostic (3.70e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.85e-1)"	"unprognostic (6.35e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.17e-3)"	10.0	0.6	1.0	6.2	2.5	2.7	7.0	0.4	1.6	4.6	13.6	0.9	2.4	2.2	9.7	5.7	6.4	6.4	2.8	8.5	0.7	0.6	16.0	3.7	5.2	1.2	2.3	0.1	4.6	0.6	0.7	1.6	23.5	1.6	6.4	4.8	1.8	2.5	11.5	4.9	2.4	5.0	17.0	1.8	9.5	3.6	2.6	0.6	0.2	36.6	1.9	0.9	11.0	7.8	0.1	0.0	2.8	0.1	0.0	0.0	9.5	0.0	0.4	0.1	0.0	2.3	1.0	0.0	1.2	6.0	2.6	2.4	0.0	0.0	0.1	45.5	0.3	0.0	0.0	0.0	3.4	0.8	0.0	40.3	0.1	0.0	1.9	0.0	0.0	0.9	0.0	15.2	0.3	11.3	0.1	0.0	0.5	0.0	0.2	0.0	0.0	0.1	0.0	1.0	0.0	26.2	0.0	0.0	0.1	1.5	0.0	8.2	0.0	0.0	12.3	0.5	0.6	0.3	2.8	0.0	0.0	0.2	20.6	0.0	65.7	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	9.5	1.0	2.5	0.4	1.6	0.7	0.6	2.3	0.1	1.6	0.6
ITGB4	CD104	ENSG00000132470	"Integrin subunit beta 4"	P16144	17	75721328-75757818	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 117.5;HaCaT: 45.0;HBEC3-KT: 100.3;hTCEpi: 34.3;RT4: 33.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 8.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB002422, CAB005258, HPA036348, HPA036349"	Enhanced		Supported	"Plasma membrane,Cell Junctions"		79000	79000	"Plasma membrane, Cell Junctions"		"CAB002422: AB_563480, CAB005258: AB_2129021, HPA036348: AB_2675077, HPA036349: AB_2675078"	"unprognostic (3.17e-3)"	"unprognostic (3.52e-1)"	"unprognostic (4.19e-1)"	"unprognostic (2.27e-1)"	"unprognostic (5.75e-2)"	"unprognostic (6.11e-3)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (7.18e-4)"	"unprognostic (1.05e-1)"	"unprognostic (4.14e-2)"	"prognostic unfavourable (6.39e-4)"	"unprognostic (1.02e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.43e-1)"	6.3	3.4	9.7	10.9	9.7	1.4	13.7	4.7	7.7	14.3	32.1	15.6	10.0	35.3	9.7	8.8	24.0	13.7	47.8	4.3	9.4	7.9	4.8	1.5	7.4	3.7	10.1	9.1	4.7	6.7	3.1	5.7	50.0	17.2	19.7	10.4	9.8	52.3	13.2	2.4	47.0	58.5	7.4	10.7	17.0	41.0	3.9	9.8	1.8	3.2	22.1	15.9	17.2	20.5	2.4	8.2	1.3	0.7	0.0	2.2	0.8	21.8	19.3	0.0	0.2	0.0	0.1	26.6	0.1	0.0	0.0	0.1	2.0	117.5	0.0	4.2	0.0	45.0	0.1	100.3	0.0	0.1	0.0	0.1	4.9	2.1	0.1	0.0	0.2	0.1	34.3	0.0	21.4	0.7	0.0	2.0	0.0	12.2	0.2	0.2	0.1	16.8	0.3	0.5	0.2	26.8	33.0	0.0	0.2	0.6	2.0	0.3	8.4	0.2	2.2	0.6	1.0	0.0	0.2	0.7	0.2	0.0	0.2	0.1	0.3	0.0	0.4	0.0	0.7	0.7	2.2	1.4	0.3	1.0	0.1	2.4	0.9	0.6	1.3	0.0	0.0	8.2	1.4	0.8	9.7	9.7	4.7	7.7	9.4	7.9	10.1	9.1	17.2	9.8
ITGB5		ENSG00000082781	"Integrin subunit beta 5"	P18084	3	124761948-124901418	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 74.0;WM-115: 77.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001820, CAB022050"	Approved		Approved	"Plasma membrane,Mitochondria"		95000	95000	"Plasma membrane, Mitochondria"		"CAB022050: , HPA001820: AB_1079142"	"unprognostic (2.63e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.57e-1)"	"unprognostic (4.44e-2)"	"unprognostic (1.37e-2)"	"unprognostic (6.07e-2)"	"unprognostic (3.49e-3)"	"unprognostic (3.16e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.53e-2)"	"prognostic unfavourable (1.40e-4)"	"unprognostic (1.16e-1)"	"unprognostic (2.16e-3)"	"unprognostic (2.49e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.01e-1)"	"unprognostic (4.38e-3)"	72.5	13.8	9.7	9.7	10.0	0.8	50.1	5.7	8.2	34.2	18.8	14.8	28.0	12.9	31.7	17.2	25.6	13.9	29.1	32.9	9.4	5.1	19.6	22.1	20.4	3.5	12.0	6.2	17.4	12.1	8.9	8.4	36.4	13.0	23.0	10.1	27.1	18.6	23.1	15.9	33.3	16.1	25.1	9.0	18.7	12.4	17.0	8.7	2.8	18.8	16.2	10.9	24.4	27.1	0.1	1.1	0.4	0.6	0.9	2.1	5.8	29.6	74.0	5.3	13.4	50.2	14.6	27.5	31.8	19.7	5.9	9.6	14.7	38.8	0.1	15.5	54.0	23.8	4.8	16.5	5.2	0.3	3.2	10.5	11.4	15.5	8.8	0.0	19.3	8.7	3.8	14.9	7.8	19.8	9.3	15.9	20.3	30.2	0.1	0.1	23.8	8.2	0.0	8.5	11.2	16.8	6.5	0.1	11.1	23.6	35.1	26.8	19.8	0.6	51.0	22.4	33.8	19.4	16.4	2.7	2.8	0.2	23.4	0.1	77.2	0.4	0.6	0.2	2.1	0.2	0.0	0.0	0.2	0.0	1.1	0.1	0.3	0.4	0.4	0.9	0.4	0.1	0.0	5.8	9.7	10.0	5.7	8.2	9.4	5.1	12.0	6.2	13.0	8.7
ITGB6		ENSG00000115221	"Integrin subunit beta 6"	P18564	2	160099666-160200313	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Amelogenesis imperfecta, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 62.1"	"Group enriched"	"Detected in some"	5	"CAPAN-2: 36.6;RPTEC TERT1: 73.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA023626, CAB073536"	Approved		Approved	"Nucleoplasm,Cell Junctions,Centrosome"				"Nucleoplasm, Cell Junctions"	Centrosome	"CAB073536: , HPA023626: "	"unprognostic (1.27e-1)"	"unprognostic (1.57e-2)"	"unprognostic (6.90e-2)"	"unprognostic (8.22e-3)"	"unprognostic (3.61e-3)"	"unprognostic (1.50e-2)"	"unprognostic (1.72e-3)"	"unprognostic (2.04e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.06e-2)"	"prognostic unfavourable (5.03e-6)"	"unprognostic (1.04e-1)"	"unprognostic (2.73e-1)"	"unprognostic (4.97e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.00e-1)"	0.3	0.3	0.3	3.1	0.3	0.0	8.7	0.3	0.3	4.1	8.3	0.1	4.5	3.5	2.1	2.5	18.7	1.2	12.0	0.7	0.3	0.3	62.1	0.3	28.8	0.1	0.3	0.1	1.5	3.8	7.0	2.2	18.7	0.2	7.5	3.0	0.1	3.8	4.8	31.5	1.9	11.7	2.0	0.3	0.3	7.9	0.6	0.1	0.1	4.9	6.8	5.9	12.8	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	36.6	0.0	0.2	0.0	7.5	0.0	11.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	8.4	0.0	0.0	0.0	0.0	0.0	1.0	1.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	73.2	12.1	0.0	0.0	0.0	11.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.2	0.1
ITGB7		ENSG00000139626	"Integrin subunit beta 7"	P26010	12	53191318-53207307	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 31.3;lymphoid tissue: 37.6"	"Group enriched"	"Detected in some"	99	"Karpas-707: 288.3;RPMI-8226: 225.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA042277			Uncertain	"Plasma membrane,Cytosol"		42000	42000	"Plasma membrane, Cytosol"		"HPA042277: AB_10793877"	"unprognostic (5.34e-2)"	"unprognostic (4.47e-2)"	"unprognostic (2.80e-3)"	"unprognostic (1.40e-2)"	"unprognostic (6.57e-4)"	"unprognostic (3.51e-5)"	"unprognostic (3.11e-3)"	"unprognostic (1.37e-2)"	"unprognostic (3.58e-1)"	"unprognostic (2.18e-1)"	"unprognostic (9.63e-3)"	"unprognostic (3.36e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.16e-1)"	"unprognostic (6.95e-2)"	"unprognostic (9.34e-2)"	"unprognostic (2.47e-4)"	1.8	1.4	1.4	29.1	1.8	7.5	1.5	0.6	1.2	1.8	8.7	2.9	0.8	6.7	2.3	2.8	6.6	2.0	5.6	1.4	1.5	1.0	5.4	5.1	4.9	26.4	1.9	1.0	1.1	1.3	0.7	1.7	1.8	2.4	2.7	5.6	2.1	10.7	2.2	1.0	6.4	15.1	1.5	2.0	26.7	4.3	0.9	2.0	7.8	3.6	4.4	37.6	4.6	3.0	10.1	15.4	31.3	1.9	7.5	23.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.5	0.0	0.0	0.5	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.0	0.0	288.3	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	225.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.5	0.9	0.2	0.2	0.1	0.0	22.6	1.9	31.3	19.3	0.5	14.3	10.1	19.4	23.0	15.4	8.3	16.3	17.1	0.5	7.5	0.1	4.2	22.7	5.2	1.4	1.8	0.6	1.2	1.5	1.0	1.9	1.0	2.4	2.0
ITGB8		ENSG00000105855	"Integrin subunit beta 8"	P26012	7	20330702-20415754	"Cancer-related genes, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 16.3;EFO-21: 21.0;RPTEC TERT1: 32.6;WM-115: 46.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	105	"basophil: 13.8"	"Lineage enriched"	"Detected in single"	105	"granulocytes: 13.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027796, HPA027797"	Enhanced		Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA027796: AB_10600299, HPA027797: AB_10600879"	"unprognostic (8.32e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.37e-3)"	"unprognostic (5.63e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.46e-1)"	"unprognostic (4.36e-2)"	"unprognostic (1.75e-2)"	"unprognostic (2.49e-3)"	"unprognostic (8.47e-2)"	"prognostic favourable (1.77e-4)"	"unprognostic (2.90e-1)"	"unprognostic (1.56e-1)"	"unprognostic (4.63e-2)"	"unprognostic (6.92e-3)"	4.7	4.1	18.0	5.8	20.0	1.2	12.7	7.8	24.3	22.1	4.6	19.4	9.0	4.6	10.5	19.0	8.8	10.4	11.7	3.9	19.4	12.5	28.1	1.7	3.7	1.3	29.3	14.5	7.1	17.5	8.1	7.7	10.7	22.8	9.6	4.4	37.5	16.6	13.1	0.9	8.5	6.0	7.0	23.1	0.8	6.2	8.7	24.0	0.0	3.4	1.3	9.0	6.8	9.9	0.0	0.0	13.8	0.1	0.0	0.1	0.0	10.0	0.4	16.3	2.0	1.4	5.7	0.0	0.0	0.1	0.1	0.5	0.1	2.5	0.0	21.0	0.7	11.2	0.7	1.6	0.2	0.0	0.2	0.0	7.8	0.0	0.7	0.0	0.0	0.6	4.6	0.2	0.8	0.8	0.0	3.0	0.3	0.0	0.0	0.0	1.2	1.8	0.0	1.4	0.0	32.6	0.8	0.2	0.7	3.1	0.0	8.1	0.2	0.0	1.1	4.3	2.8	1.2	2.1	3.8	0.0	0.0	1.0	0.0	46.6	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	18.0	20.0	7.8	14.2	19.4	12.5	29.3	14.5	22.8	24.0
ITIH4	"H4P, IHRP, ITIHL1"	ENSG00000055955	"Inter-alpha-trypsin inhibitor heavy chain family member 4"	Q14624	3	52812975-52831479	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	20	"liver: 461.4"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 5.4;U-266/70: 6.6"	"Cancer enriched"	"Detected in single"	27	"liver cancer: 7.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"NK-cell: 2.6"	"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA001835, HPA003948, CAB072872"	Enhanced		Approved	Vesicles	"Secreted to blood"	53000000000	53000000000	Vesicles		"CAB072872: , HPA001835: AB_1079432, HPA003948: AB_1079433"	"unprognostic (6.08e-2)"	"unprognostic (4.45e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.69e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.96e-1)"	"unprognostic (5.86e-2)"	"unprognostic (1.98e-2)"	"unprognostic (5.64e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.47e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.10e-14)"	"unprognostic (1.71e-3)"	"unprognostic (2.96e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.21e-5)"	0.5	1.8	0.1	0.1	0.1	1.0	0.1	0.1	0.2	0.4	0.2	0.1	0.1	0.1	0.1	1.3	0.2	0.1	0.1	0.6	0.1	0.0	0.2	461.4	0.2	0.1	0.1	0.2	0.2	22.8	0.0	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.2	4.1	0.1	0.1	0.2	0.1	0.5	0.1	0.3	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.3	0.3	0.6	0.6	2.6	0.8	0.0	0.0	0.4	1.0	2.1	1.1	0.0	0.4	0.1	0.0	0.0	0.2	0.3	0.2	1.3	0.0	0.5	1.1	0.0	0.0	0.5	5.4	0.2	2.2	0.0	2.9	0.9	2.5	0.2	0.3	0.4	0.0	0.1	0.0	0.6	1.8	0.0	0.2	0.5	0.7	1.0	0.0	1.8	1.0	0.0	0.8	0.7	0.1	1.0	0.7	0.0	0.4	1.1	0.7	0.2	0.0	0.9	1.0	0.0	6.6	3.1	0.5	0.1	0.7	1.2	0.0	0.6	0.0	0.1	0.1	0.1	0.3	0.7	0.0	0.0	0.2	0.0	0.8	0.6	2.6	0.1	0.3	0.4	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.2	0.2	0.1
ITK	"EMT, LYK, PSCTK2"	ENSG00000113263	"IL2 inducible T cell kinase"	Q08881	5	157142933-157255191	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Adaptive immunity, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 28.0;lymphoid tissue: 60.5"	"Cell line enriched"	"Detected in some"	5	"MOLT-4: 21.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	28	"gdT-cell: 13.8;MAIT T-cell: 9.1;memory CD4 T-cell: 19.5;memory CD8 T-cell: 18.9;naive CD4 T-cell: 28.0;naive CD8 T-cell: 22.8;NK-cell: 9.2;T-reg: 23.1"	"Group enriched"	"Detected in many"	29	"NK-cells: 9.2;T-cells: 28.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"														"unprognostic (2.08e-3)"	"unprognostic (6.57e-4)"	"unprognostic (5.06e-3)"	"unprognostic (4.96e-5)"	"unprognostic (1.52e-2)"	"unprognostic (1.12e-4)"	"unprognostic (8.45e-4)"	"unprognostic (1.56e-2)"	"unprognostic (1.87e-2)"	"unprognostic (5.99e-3)"	"unprognostic (1.76e-1)"	"unprognostic (2.52e-1)"	"unprognostic (4.52e-6)"	"unprognostic (3.64e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.46e-1)"	"unprognostic (3.26e-2)"	2.3	0.7	0.5	12.2	0.6	2.5	1.3	1.9	0.5	1.4	3.3	0.0	0.0	0.5	1.2	1.1	1.8	1.4	4.3	0.9	0.5	0.5	1.4	1.2	6.6	60.5	0.9	0.0	0.7	0.7	0.0	0.9	0.1	0.3	1.1	1.3	1.5	3.5	1.1	0.5	1.0	8.9	0.4	1.2	10.7	2.3	1.4	0.0	60.3	1.6	2.7	24.3	4.1	1.3	0.0	0.0	0.4	0.6	9.2	28.0	13.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	3.6	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.7	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	13.8	0.0	9.1	0.0	19.5	18.9	0.0	0.0	28.0	22.8	0.4	9.2	0.6	0.0	23.1	13.6	0.5	0.6	1.9	0.5	0.5	0.5	0.9	0.0	0.3	0.0
ITPKB	"IP3-3KB, IP3KB"	ENSG00000143772	"Inositol-trisphosphate 3-kinase B"	P27987	1	226631690-226739323	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Calmodulin-binding, Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 63.1"	"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 28.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030273, HPA072923"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"HPA030273: AB_10601127, HPA072923: "	"unprognostic (4.54e-2)"	"unprognostic (3.85e-2)"	"unprognostic (8.41e-3)"	"unprognostic (9.37e-3)"	"unprognostic (1.53e-1)"	"prognostic favourable (1.72e-5)"	"unprognostic (1.24e-1)"	"prognostic favourable (6.65e-4)"	"unprognostic (2.29e-1)"	"unprognostic (9.57e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.75e-2)"	"unprognostic (3.23e-3)"	"unprognostic (2.90e-2)"	"unprognostic (7.46e-2)"	"unprognostic (6.54e-3)"	"unprognostic (7.87e-2)"	23.8	4.2	34.7	13.0	35.1	14.8	15.2	11.1	33.6	14.3	19.7	32.4	8.5	6.0	27.1	15.6	12.6	15.3	8.9	7.8	27.9	24.8	9.7	3.2	13.4	22.7	50.4	16.3	8.8	4.8	10.1	4.2	13.5	40.0	13.1	6.3	20.8	24.9	21.3	9.8	10.5	12.5	32.6	63.1	19.0	12.4	3.2	34.0	20.0	5.9	4.3	17.1	19.6	8.5	3.1	0.9	7.7	3.5	3.0	7.9	2.6	2.8	3.0	4.9	5.6	3.8	2.5	1.3	0.7	3.3	1.5	3.6	0.5	3.5	12.8	4.6	0.7	4.1	6.2	2.5	0.7	1.7	4.2	5.7	3.3	0.0	1.5	5.3	10.2	2.8	3.6	1.7	1.6	10.5	0.0	1.8	0.2	2.6	9.7	7.1	10.6	4.9	3.8	8.8	2.8	11.3	4.5	2.9	3.7	2.3	1.7	28.1	7.2	6.0	7.3	2.0	1.5	1.8	4.5	0.1	4.6	15.7	0.5	4.8	7.4	1.2	1.4	7.7	4.4	2.1	3.9	1.9	5.3	4.5	0.9	3.1	7.9	5.7	5.4	3.0	3.5	0.8	3.0	2.6	34.7	35.1	11.1	27.9	27.9	24.8	50.4	16.3	40.0	34.0
JAK1	"JAK1A, JAK1B, JTK3"	ENSG00000162434	"Janus kinase 1"	P23458	1	64833229-64966504	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 69.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013088	Approved									"CAB013088: "	"prognostic favourable (9.63e-4)"	"unprognostic (1.24e-1)"	"prognostic favourable (2.81e-4)"	"unprognostic (5.10e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.21e-2)"	"unprognostic (1.53e-1)"	"unprognostic (7.00e-3)"	"unprognostic (8.40e-2)"	"unprognostic (7.88e-3)"	"unprognostic (1.66e-2)"	"unprognostic (8.84e-2)"	"prognostic favourable (2.67e-4)"	"unprognostic (2.35e-1)"	"unprognostic (2.04e-1)"	"unprognostic (7.30e-2)"	"unprognostic (3.51e-1)"	46.7	20.4	15.5	31.1	16.5	21.2	56.6	24.3	20.4	27.3	27.1	16.3	16.5	13.8	28.2	22.0	27.0	20.7	27.7	27.3	15.3	16.5	31.4	38.3	36.5	61.4	15.6	14.1	33.3	29.1	28.3	39.8	22.9	25.1	26.0	22.2	18.1	19.8	21.3	45.1	29.7	29.3	30.7	16.3	52.7	20.9	17.3	15.0	62.7	29.0	17.9	42.5	37.2	29.3	20.2	15.4	34.9	17.1	68.1	27.5	25.8	10.9	14.4	6.0	0.6	69.4	39.3	7.8	17.2	25.4	14.3	16.9	4.7	6.1	16.7	13.4	30.5	6.2	4.0	13.3	20.4	22.1	6.4	22.7	7.5	10.2	25.6	8.7	15.8	34.5	18.5	21.6	22.6	44.6	8.2	17.9	15.8	6.3	4.7	5.8	4.1	8.6	6.8	17.3	6.1	36.9	19.4	4.2	12.7	23.6	11.1	10.1	23.5	5.4	40.4	17.2	7.7	38.9	9.1	11.2	5.1	13.3	16.0	11.5	7.7	31.2	10.9	31.5	22.8	15.2	27.5	20.2	22.0	25.7	15.4	16.1	24.3	20.7	34.9	68.1	17.1	10.5	26.5	25.8	15.5	16.5	24.3	20.4	15.3	16.5	15.6	14.1	25.1	15.0
JAK2	JTK10	ENSG00000096968	"Janus kinase 2"	O60674	9	4984390-5128183	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"ASC diff: 18.9;HDLM-2: 26.7;HEL: 54.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 40.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 40.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013089, HPA040820, HPA043870"	Approved		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"				Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"CAB013089: AB_2533647, HPA040820: , HPA043870: "	"unprognostic (2.24e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (5.50e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.72e-2)"	"unprognostic (3.85e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.37e-3)"	19.8	8.8	11.5	19.0	10.5	19.0	17.7	14.7	14.4	17.8	10.6	7.0	10.3	7.2	14.8	13.6	12.4	13.4	14.6	27.6	10.3	6.7	7.7	5.6	16.1	19.4	7.0	10.5	15.9	6.7	10.1	7.5	12.0	10.0	12.0	7.4	9.4	7.2	7.4	14.4	19.0	12.3	10.4	11.7	21.5	14.1	10.1	9.0	13.6	8.6	6.5	13.5	13.9	15.6	2.1	9.6	40.8	7.5	3.4	2.1	2.5	2.5	1.4	1.4	2.5	18.9	4.9	0.4	3.4	2.9	2.6	1.7	0.1	0.8	0.1	0.8	2.0	0.8	1.5	2.1	1.9	26.7	0.5	54.8	2.9	0.7	3.9	3.7	2.8	4.0	0.9	1.1	1.8	2.4	3.9	6.4	4.7	0.9	0.9	5.2	1.3	1.7	1.9	2.7	0.7	2.0	1.3	1.6	0.9	1.0	1.5	1.0	0.7	6.5	5.0	4.0	1.3	4.1	2.4	1.2	2.2	0.5	5.2	1.8	2.0	40.8	7.5	13.4	2.1	7.3	1.7	2.1	1.6	1.2	9.6	1.9	0.9	1.1	7.1	3.4	5.8	3.6	1.6	2.5	11.5	10.5	14.7	14.4	10.3	6.7	7.0	10.5	10.0	9.0
JAK3	"JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK"	ENSG00000105639	"Janus kinase 3"	P52333	19	17824780-17848071	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 68.3"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 20.1;HEL: 9.0;HMC-1: 9.2;Karpas-707: 23.5;U-266/70: 9.1;U-266/84: 13.5;U-937: 13.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA070314	Enhanced		Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA070314: "	"unprognostic (5.59e-3)"	"prognostic favourable (6.42e-5)"	"unprognostic (5.71e-2)"	"unprognostic (2.34e-1)"	"unprognostic (6.13e-3)"	"unprognostic (1.11e-3)"	"unprognostic (4.21e-2)"	"unprognostic (2.60e-1)"	"unprognostic (2.38e-2)"	"unprognostic (2.36e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.94e-1)"	"prognostic unfavourable (2.89e-14)"	"unprognostic (2.28e-1)"	"unprognostic (2.21e-2)"	"unprognostic (4.43e-2)"	"unprognostic (7.61e-2)"	6.8	1.7	4.0	24.5	8.5	12.0	2.7	2.4	3.1	1.9	2.3	1.0	0.0	2.2	1.7	2.0	2.5	3.5	3.6	4.3	2.7	2.8	3.8	2.0	8.4	68.3	7.5	0.0	11.0	2.0	0.4	2.3	4.1	5.3	3.0	2.4	1.6	6.1	1.5	0.7	1.3	9.5	2.5	8.4	36.1	3.2	1.8	5.8	20.9	3.4	1.7	28.8	5.3	2.4	7.4	4.5	16.9	9.6	8.4	15.0	6.8	0.1	0.3	0.3	1.0	0.4	1.4	0.2	0.5	0.0	0.0	0.1	0.0	0.9	0.4	1.9	0.4	0.1	0.0	0.2	0.0	20.1	0.0	9.0	0.0	0.8	0.7	0.0	9.2	5.0	0.2	0.0	0.0	0.2	0.0	23.5	0.0	0.4	3.6	0.0	0.1	0.7	4.6	0.0	0.4	0.5	0.0	0.0	0.3	0.1	0.2	0.0	2.0	1.3	0.4	0.0	0.4	0.0	0.0	9.1	13.5	2.5	0.1	13.7	0.2	1.2	4.9	0.2	12.6	9.6	14.5	6.5	15.0	13.1	4.5	7.4	14.9	13.0	16.9	8.4	8.8	3.7	11.8	6.8	4.0	8.5	2.4	3.1	2.7	2.8	7.5	0.0	5.3	5.8
JKAMP	"C14orf100, CDA06, HSPC213, HSPC327, JAMP"	ENSG00000050130	"JNK1/MAPK8 associated membrane protein"	Q9P055	14	59484443-59505410	"Cancer-related genes, Predicted membrane proteins"	"Unfolded protein response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA031172, HPA071650"	Supported		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"HPA031172: AB_10670563, HPA071650: "	"unprognostic (1.48e-1)"	"unprognostic (2.19e-2)"	"unprognostic (4.95e-2)"	"unprognostic (5.88e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.49e-3)"	"prognostic unfavourable (3.09e-6)"	"unprognostic (2.68e-1)"	"unprognostic (3.52e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.09e-1)"	"unprognostic (3.14e-1)"	"prognostic favourable (1.36e-4)"	"unprognostic (1.76e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.73e-1)"	19.0	29.5	19.3	13.0	25.5	15.7	24.2	16.7	28.4	17.5	21.3	25.0	18.1	13.8	22.8	19.6	18.6	23.2	21.7	18.3	18.8	29.4	38.9	26.1	22.2	16.2	29.5	19.5	19.7	18.7	42.3	44.5	24.1	36.9	22.9	22.5	22.8	24.9	20.3	15.9	17.5	25.0	20.7	30.3	22.1	18.7	24.6	27.0	18.6	24.6	18.0	14.7	21.0	16.7	14.9	29.0	37.0	31.7	18.0	18.3	21.5	19.7	23.3	20.1	16.4	15.0	19.9	15.3	31.0	26.5	18.3	21.8	7.3	36.2	9.8	27.8	28.6	14.4	14.7	19.1	24.7	29.3	8.4	9.8	15.0	14.5	20.0	16.5	19.4	21.7	21.7	17.1	11.8	18.6	8.9	19.7	34.4	17.8	9.0	12.7	11.0	20.6	10.6	24.4	9.0	31.5	19.6	8.6	15.0	28.1	22.5	16.4	22.7	12.7	24.4	19.3	25.3	17.6	20.3	9.2	16.3	11.4	27.3	11.2	24.2	28.2	25.2	32.5	15.1	29.8	14.6	14.9	16.5	15.9	21.2	13.6	17.7	16.6	37.0	18.0	31.7	29.0	18.3	21.5	19.3	25.5	16.7	28.4	18.8	29.4	29.5	19.5	36.9	27.0
JTB	"hJT, PAR"	ENSG00000143543	"Jumping translocation breakpoint"	O76095	1	153974269-153977688	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"	"Apoptosis, Cell cycle, Cell division, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006514	Approved		Approved	"Vesicles,Actin filaments"				Vesicles	"Actin filaments"	"HPA006514: AB_1079164"	"unprognostic (1.33e-1)"	"unprognostic (1.77e-1)"	"unprognostic (8.01e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (3.40e-1)"	"unprognostic (5.66e-3)"	"unprognostic (8.62e-3)"	"unprognostic (5.60e-2)"	"prognostic favourable (7.87e-4)"	"unprognostic (1.00e-3)"	"unprognostic (8.16e-2)"	"prognostic unfavourable (6.65e-9)"	"unprognostic (1.36e-1)"	"unprognostic (4.25e-1)"	"unprognostic (5.48e-2)"	"unprognostic (2.58e-3)"	23.9	30.2	28.5	23.0	32.7	43.2	32.6	30.7	32.3	31.8	36.0	23.6	51.3	35.9	25.1	41.0	30.4	26.1	37.1	36.2	25.4	23.9	34.2	81.1	27.7	34.7	27.7	19.8	26.9	106.8	24.8	49.8	30.0	24.4	33.4	36.0	24.9	100.6	45.9	42.1	23.4	45.6	21.6	20.5	35.9	42.4	15.3	25.2	30.5	58.5	32.0	34.0	25.2	33.0	47.4	54.1	60.7	43.0	30.4	46.4	30.2	39.5	27.4	11.8	21.6	38.8	24.1	33.3	28.9	28.2	19.3	19.5	26.3	32.9	37.8	41.0	33.4	36.2	29.8	22.2	15.8	35.6	59.6	21.9	32.6	26.6	40.7	42.2	33.8	22.9	42.0	20.3	24.1	22.8	32.5	27.8	13.5	68.8	30.4	54.2	25.3	48.3	32.2	16.1	75.9	24.4	21.7	32.4	32.8	22.9	66.5	38.7	41.8	61.4	17.8	9.6	16.5	28.9	36.8	41.5	46.3	41.0	23.6	40.6	20.6	32.6	43.0	60.7	29.4	30.3	35.5	47.4	41.1	46.4	33.4	45.2	42.4	33.7	39.9	30.4	33.4	54.1	33.6	30.2	28.5	32.7	30.7	32.3	25.4	23.9	27.7	19.8	24.4	25.2
JUN	"AP-1, c-Jun"	ENSG00000177606	"Jun proto-oncogene, AP-1 transcription factor subunit"	P05412	1	58780788-58784327	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RH-30: 71.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB003801, CAB007780, HPA059474"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB003801: AB_365485, CAB007780: AB_562268, HPA059474: "	"unprognostic (2.06e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.85e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.11e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.82e-1)"	"unprognostic (5.15e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-3)"	64.5	29.4	26.7	33.7	17.2	68.4	61.7	19.5	20.6	60.0	32.7	30.8	28.4	13.3	40.5	21.8	34.1	72.6	48.5	31.3	20.2	12.4	21.2	39.3	55.1	14.3	15.3	12.0	49.8	48.7	15.0	16.7	21.6	24.1	48.6	16.7	40.5	59.4	39.3	32.2	51.3	28.6	40.7	17.6	22.9	47.0	18.2	18.1	9.0	61.0	35.2	23.3	41.5	33.1	7.4	1.3	4.0	5.1	3.2	2.5	1.2	16.0	2.3	5.2	1.0	8.3	9.4	0.1	20.5	7.5	14.5	8.8	4.2	1.2	0.6	9.9	12.7	5.6	0.4	6.6	9.2	12.7	37.3	0.2	0.9	4.7	6.8	1.1	3.7	10.1	17.1	18.7	7.8	10.8	5.6	9.3	5.6	3.0	1.0	9.0	4.1	14.6	0.4	71.1	3.2	13.6	1.5	14.4	4.2	14.2	14.9	6.0	5.3	0.6	19.0	33.1	15.0	12.0	25.6	20.7	3.3	1.2	34.5	2.1	9.4	1.2	5.1	2.0	2.4	1.1	1.3	4.1	1.2	2.5	1.3	7.4	0.3	1.7	4.0	3.2	0.4	0.2	0.9	1.2	26.7	17.2	19.5	20.6	20.2	12.4	15.3	12.0	24.1	18.1
JUND	AP-1	ENSG00000130522	"JunD proto-oncogene, AP-1 transcription factor subunit"	P17535	19	18279760-18281622	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 204.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB005268, HPA063029"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB005268: AB_2130177, HPA063029: "	"prognostic favourable (6.15e-5)"	"unprognostic (4.18e-3)"	"unprognostic (8.89e-2)"	"unprognostic (2.52e-1)"	"unprognostic (3.70e-1)"	"unprognostic (6.39e-2)"	"unprognostic (1.63e-2)"	"unprognostic (6.35e-2)"	"unprognostic (3.48e-2)"	"unprognostic (2.00e-1)"	"unprognostic (3.37e-3)"	"unprognostic (4.09e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.22e-1)"	"unprognostic (3.99e-1)"	"unprognostic (5.37e-2)"	"unprognostic (1.49e-1)"	75.7	52.7	35.4	38.9	32.4	204.7	51.5	34.7	56.5	42.4	49.5	42.6	21.1	35.7	43.4	31.0	31.7	55.7	43.5	35.9	31.5	32.1	26.9	66.5	55.7	17.2	21.6	22.6	78.1	64.3	21.7	47.8	80.3	27.0	45.5	21.0	35.2	39.0	33.3	29.2	44.5	61.8	34.4	31.5	39.3	46.2	34.9	19.2	32.0	27.2	33.7	23.1	41.7	30.8	8.6	10.7	19.0	7.8	4.5	6.3	1.7	22.0	9.3	9.3	10.5	7.4	8.3	41.2	9.2	11.1	5.2	7.1	10.1	19.9	11.4	10.9	9.4	12.0	2.2	2.1	2.7	22.6	20.2	16.8	7.6	21.8	16.5	7.8	22.0	8.0	9.4	5.6	7.3	4.2	22.9	33.3	1.4	29.3	23.1	24.5	19.3	13.4	8.5	5.8	23.9	7.6	3.4	50.7	20.8	11.4	12.6	30.0	10.5	11.8	14.4	3.2	15.2	20.3	5.6	46.6	18.5	9.2	11.3	11.9	7.4	8.0	6.4	5.8	4.9	7.8	3.8	7.4	6.3	4.4	4.6	8.6	4.7	4.9	19.0	4.5	7.4	10.7	5.1	1.7	35.4	32.4	34.7	56.5	31.5	32.1	21.6	22.6	27.0	19.2
JUP	"CTNNG, DP3, DPIII, PDGB, PKGB"	ENSG00000173801	"Junction plakoglobin"	P14923	17	41754604-41786931	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"		"Cancer-related genes, Cardiomyopathy, Disease mutation, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 146.3;skin 1: 126.1;tongue: 122.8"	"Cell line enhanced"	"Detected in many"		"HaCaT: 126.0;hTCEpi: 63.6;RT4: 77.4;SK-BR-3: 76.5;T-47d: 63.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 7.6;eosinophil: 14.8;intermediate monocyte: 12.8;memory B-cell: 7.9;myeloid DC: 7.8;naive B-cell: 7.4;non-classical monocyte: 20.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB002139, HPA032047"	Supported		Supported	"Vesicles,Plasma membrane,Cell Junctions"		61000000	61000000	"Plasma membrane, Cell Junctions"	Vesicles	"CAB002139: AB_563468, HPA032047: "	"unprognostic (3.96e-3)"	"unprognostic (3.40e-1)"	"unprognostic (2.32e-1)"	"unprognostic (4.71e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.02e-1)"	"unprognostic (8.11e-3)"	"unprognostic (1.41e-2)"	"unprognostic (9.85e-3)"	"unprognostic (2.29e-3)"	"unprognostic (9.60e-2)"	"prognostic favourable (2.06e-10)"	"unprognostic (2.50e-1)"	"unprognostic (9.49e-2)"	"unprognostic (9.05e-2)"	"unprognostic (1.51e-2)"	12.5	2.6	2.8	9.5	4.5	3.3	13.0	6.5	3.7	34.5	17.9	8.7	12.3	15.6	12.2	9.6	146.3	13.0	19.0	34.5	3.3	1.6	31.6	11.7	13.2	4.0	5.3	2.2	12.5	12.8	3.6	5.8	42.4	4.0	14.0	8.8	8.3	34.3	14.3	17.6	126.1	36.1	4.3	3.2	4.5	15.4	3.6	4.6	10.8	27.9	122.8	84.8	12.5	55.4	7.9	7.8	14.8	20.6	0.3	0.1	2.9	30.2	25.1	2.5	2.1	0.0	0.0	39.3	1.7	10.4	0.7	0.6	37.9	33.5	0.6	18.7	1.1	126.0	3.6	28.0	0.1	0.0	8.9	1.3	20.0	8.3	4.2	0.8	13.4	0.0	63.6	0.1	5.2	11.2	11.1	11.0	0.0	38.8	0.2	10.9	4.9	4.2	35.4	0.0	22.7	19.4	77.4	6.2	4.6	3.9	76.5	0.2	63.8	0.9	17.6	0.0	1.8	0.8	0.5	0.9	3.4	0.6	0.1	1.4	0.3	1.7	7.6	14.8	0.0	12.8	0.0	7.9	0.0	0.1	7.8	7.4	0.1	0.1	0.3	0.3	20.6	2.5	0.0	2.9	2.8	4.5	6.5	3.7	3.3	1.6	5.3	2.2	4.0	4.6
KALRN	"ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD"	ENSG00000160145	"Kalirin RhoGEF kinase"	O60229	3	124080023-124726325	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 35.2;retina: 31.2"	"Cell line enhanced"	"Detected in many"		"CACO-2: 32.1;HEL: 19.6;SH-SY5Y: 9.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.3"	"Lineage enriched"	"Detected in single"	5	"T-cells: 4.3"	"Low region specificity"	"Detected in many"							"HPA011913, CAB026456"	Approved		Approved	Nucleoplasm,Cytosol		110000	110000	"Nucleoplasm, Cytosol"		"CAB026456: , HPA011913: AB_1850494"	"unprognostic (2.54e-2)"	"unprognostic (3.43e-1)"	"unprognostic (2.08e-1)"	"unprognostic (3.12e-4)"	"unprognostic (2.54e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.41e-2)"	"unprognostic (8.58e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.26e-3)"	"unprognostic (5.58e-2)"	"unprognostic (2.67e-1)"	"unprognostic (3.70e-2)"	"unprognostic (2.81e-3)"	5.5	4.3	12.7	2.4	14.1	0.6	4.2	1.8	35.2	4.0	3.8	3.7	0.5	2.7	5.6	2.3	9.6	4.2	3.1	12.1	17.6	3.9	2.6	7.3	2.9	1.1	4.1	15.8	2.3	11.9	2.5	14.4	6.8	9.4	3.1	2.1	31.2	2.2	5.4	23.5	1.5	7.2	6.4	3.6	8.0	11.5	2.2	2.4	0.0	5.3	6.7	3.1	2.9	4.1	0.1	0.0	0.9	0.0	0.1	4.3	1.2	0.3	0.6	3.6	0.7	0.5	0.1	4.6	1.4	0.8	1.4	0.6	32.1	2.5	0.1	0.4	3.6	0.2	0.8	0.0	1.1	0.0	0.3	19.6	0.3	4.9	0.0	0.0	0.0	0.2	0.0	0.3	0.0	1.6	4.5	0.1	0.4	2.3	0.0	0.0	2.0	3.1	1.0	1.6	0.0	0.1	0.3	1.2	9.2	0.4	0.3	0.3	0.7	0.1	8.1	4.1	1.6	0.6	0.6	0.0	0.3	0.0	0.5	0.0	1.8	0.1	0.0	0.0	0.1	0.0	0.0	0.1	1.8	0.3	0.0	0.0	2.4	0.7	0.9	0.1	0.0	0.0	4.3	1.2	12.7	14.1	1.8	35.2	17.6	3.9	4.1	15.8	9.4	2.4
KAT2B	"GCN5, GCN5L, P/CAF, PCAF"	ENSG00000114166	"Lysine acetyltransferase 2B"	Q92831	3	20040023-20154404	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002470, CAB004526"	Supported		Supported	Nucleoplasm,Centrosome				Nucleoplasm	Centrosome	"CAB004526: AB_2128417, HPA002470: "	"unprognostic (2.91e-2)"	"unprognostic (6.85e-3)"	"unprognostic (9.05e-2)"	"unprognostic (2.25e-1)"	"unprognostic (2.66e-2)"	"unprognostic (3.01e-3)"	"unprognostic (2.44e-1)"	"unprognostic (3.83e-3)"	"unprognostic (2.44e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.23e-3)"	"unprognostic (7.13e-2)"	"unprognostic (7.03e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.59e-1)"	"unprognostic (5.16e-2)"	"unprognostic (4.63e-2)"	10.6	6.6	30.1	9.4	27.5	24.9	6.8	22.0	20.1	10.2	9.4	27.6	7.9	10.9	7.8	5.4	17.3	7.7	8.0	21.9	24.7	18.0	10.8	24.0	10.1	12.7	26.8	15.9	18.2	11.6	38.1	8.7	8.5	24.2	9.5	8.1	10.7	20.9	9.2	33.4	8.9	13.0	8.7	21.4	11.7	9.0	1.8	31.1	8.7	10.0	7.4	12.0	8.7	11.0	2.1	2.7	5.5	1.5	1.1	4.8	0.8	1.5	3.9	2.2	3.6	9.0	8.4	5.1	5.0	7.4	5.3	7.8	1.1	2.6	13.4	2.1	9.4	1.1	5.4	1.6	4.5	12.2	5.1	11.8	6.2	0.4	4.2	1.8	15.3	3.6	2.9	4.6	3.0	5.0	7.5	19.0	7.5	1.8	3.8	3.5	0.9	3.9	5.1	4.1	2.8	7.2	8.0	1.1	2.4	2.8	4.5	17.0	4.7	8.0	4.8	9.0	3.6	3.3	5.7	7.3	15.1	3.2	8.2	7.8	18.9	1.3	1.1	2.8	3.6	1.5	3.4	1.0	3.1	2.5	0.9	2.1	1.1	2.1	5.5	1.1	1.1	2.7	4.8	0.8	30.1	27.5	22.0	20.1	24.7	18.0	26.8	15.9	24.2	31.1
KAT6A	"MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220"	ENSG00000083168	"Lysine acetyltransferase 6A"	Q92794	8	41929479-42051990	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase"	"Cancer-related genes, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017023, HPA063266, HPA065052"	Supported		Approved	"Nucleoli,Nuclear speckles,Cytosol"				"Nuclear speckles"	"Nucleoli, Cytosol"	"CAB017023: , HPA063266: , HPA065052: "	"unprognostic (3.51e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.04e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.28e-1)"	"unprognostic (9.27e-3)"	"unprognostic (3.61e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.95e-1)"	"unprognostic (2.45e-2)"	"unprognostic (1.50e-1)"	"unprognostic (4.45e-2)"	"unprognostic (4.20e-3)"	"unprognostic (1.18e-1)"	"unprognostic (2.24e-1)"	"unprognostic (8.58e-2)"	"unprognostic (2.95e-2)"	20.8	10.9	15.3	19.8	20.3	36.8	22.6	29.9	18.7	19.7	14.6	19.4	14.4	10.7	20.6	12.1	16.9	16.5	14.3	13.0	15.5	11.5	12.3	13.6	26.9	28.2	23.2	10.3	27.2	13.1	26.8	22.3	20.9	15.7	14.1	12.0	12.8	15.1	17.0	21.0	25.5	18.0	25.0	22.9	20.4	14.0	14.1	21.7	30.4	17.9	14.3	20.1	16.9	24.2	4.7	1.8	10.9	1.6	3.1	3.9	1.4	12.9	10.6	17.5	11.1	9.8	11.2	5.9	8.7	11.3	10.8	8.4	6.7	6.2	19.2	8.7	8.5	8.3	13.6	8.2	12.7	9.9	7.9	27.6	6.6	5.0	7.4	14.5	12.7	9.3	9.4	10.0	12.4	10.3	23.1	12.2	9.8	5.7	29.5	4.6	6.7	4.2	23.6	19.6	6.1	5.3	14.9	10.9	9.4	10.1	6.8	7.0	15.6	6.4	12.0	13.3	9.4	11.8	9.3	10.0	16.1	20.8	7.1	6.6	11.5	3.5	1.6	2.8	3.5	1.2	3.9	2.4	2.6	3.3	1.0	4.7	3.6	2.9	10.9	3.1	1.2	1.8	3.5	1.4	15.3	20.3	29.9	18.7	15.5	11.5	23.2	10.3	15.7	21.7
KAT6B	"Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B"	ENSG00000156650	"Lysine acetyltransferase 6B"	Q8WYB5	10	74825582-75032622	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"PC-3: 22.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006104	Supported		Approved	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA006104: AB_1079445"	"unprognostic (4.17e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.32e-2)"	"unprognostic (7.83e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.56e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.09e-1)"	"unprognostic (9.47e-2)"	"unprognostic (8.78e-2)"	"prognostic favourable (4.82e-4)"	"unprognostic (2.52e-1)"	"unprognostic (3.70e-1)"	"unprognostic (2.59e-2)"	"unprognostic (3.15e-1)"	11.6	9.5	11.1	13.2	11.9	15.1	12.4	19.0	11.6	16.7	12.2	13.3	15.3	7.2	25.1	13.0	12.0	13.2	12.0	10.0	10.6	9.5	9.0	7.3	9.2	9.0	9.0	9.9	24.6	13.3	24.8	31.1	9.4	8.9	13.5	9.6	10.1	17.9	12.0	15.3	10.6	11.3	16.2	9.3	10.4	13.0	12.8	12.1	26.6	13.0	8.9	12.5	14.3	12.7	3.2	1.9	1.6	1.1	5.3	3.7	1.5	3.9	4.1	7.4	6.2	5.8	8.6	3.6	3.5	6.9	3.0	3.3	2.7	4.6	8.4	1.9	6.4	3.1	3.9	3.0	4.9	3.5	5.7	3.1	3.3	3.8	4.4	7.3	2.1	5.6	5.0	4.1	6.6	3.4	3.3	7.3	3.8	4.2	7.0	3.4	4.1	22.7	11.0	3.8	1.8	2.2	2.0	3.7	6.1	3.6	6.5	3.2	3.7	2.9	4.2	4.2	5.0	2.8	3.3	5.4	6.2	5.6	4.6	7.8	0.9	0.7	1.1	1.6	3.2	0.9	3.4	2.4	2.4	2.7	1.2	3.2	3.7	3.4	0.9	5.3	0.8	1.9	2.4	1.5	11.1	11.9	19.0	11.6	10.6	9.5	9.0	9.9	8.9	12.1
KCNJ5	"CIR, GIRK4, KATP1, Kir3.4, LQT13"	ENSG00000120457	"Potassium voltage-gated channel subfamily J member 5"	P48544	11	128891356-128921035	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"Cancer-related genes, Disease mutation, Long QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 40.7;ductus deferens: 54.6;pituitary gland: 23.4"	"Cell line enriched"	"Detected in some"	13	"HBEC3-KT: 17.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.9"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in many"	6	"basal ganglia: 3.1;hypothalamus: 8.0;midbrain: 2.2;thalamus: 4.0"	"Low region specificity"	"Detected in all"			"HPA014722, HPA017353, CAB022569"	Enhanced									"CAB022569: , HPA014722: AB_1852133, HPA017353: AB_1852135"	"unprognostic (2.01e-1)"	"unprognostic (2.43e-3)"	"unprognostic (2.56e-3)"	"unprognostic (5.81e-2)"	"unprognostic (4.24e-2)"	"unprognostic (3.60e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.54e-2)"	"unprognostic (6.83e-2)"	"unprognostic (1.96e-1)"	"unprognostic (3.17e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.81e-2)"	"unprognostic (6.82e-2)"	"unprognostic (9.49e-2)"	"unprognostic (1.88e-2)"	"unprognostic (2.23e-2)"	1.8	40.7	0.8	0.3	1.9	0.2	0.9	0.3	1.2	0.8	0.8	1.9	54.6	0.4	0.3	1.1	0.6	0.6	1.3	8.7	1.6	2.5	2.0	0.3	3.4	0.8	3.7	0.8	0.8	16.6	0.7	23.4	4.3	3.4	0.8	0.4	3.3	0.9	21.7	0.3	0.4	0.5	0.7	4.5	7.7	1.5	0.7	0.9	2.3	0.7	0.4	0.3	1.1	0.5	0.9	0.4	2.9	0.7	0.6	0.4	0.4	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.3	0.1	0.1	0.0	0.1	0.4	17.1	0.0	0.1	0.1	0.1	0.6	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.4	0.3	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.9	0.0	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.0	0.1	0.0	0.2	0.2	0.1	0.0	0.5	0.2	0.1	0.1	1.3	0.0	2.2	0.7	0.6	0.4	0.3	0.3	0.3	0.2	0.3	0.3	0.9	0.3	0.4	2.9	0.6	0.4	0.4	0.2	0.4	0.8	1.9	0.3	1.2	1.6	2.5	3.7	0.8	3.4	0.9
KDM5A	"JARID1A, RBBP2"	ENSG00000073614	"Lysine demethylase 5A"	P29375	12	280129-389454	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006201			Supported	"Nuclear bodies,Cytosol"				"Nuclear bodies"	Cytosol	"HPA006201: AB_1079160"	"unprognostic (2.75e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.12e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.60e-1)"	"unprognostic (3.53e-3)"	"unprognostic (1.81e-2)"	"unprognostic (5.81e-2)"	"unprognostic (3.19e-1)"	"unprognostic (1.77e-3)"	"unprognostic (6.11e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.60e-2)"	"unprognostic (7.69e-2)"	13.6	14.4	10.6	13.7	13.0	41.6	13.1	21.8	13.2	11.8	10.3	14.8	11.3	7.8	14.2	8.1	13.6	11.2	10.0	10.1	11.5	5.7	9.0	10.7	13.1	14.9	15.1	9.1	15.2	11.5	16.8	13.8	12.4	11.3	10.6	10.9	10.6	12.9	8.6	9.7	20.3	13.0	10.4	10.1	15.5	10.6	21.2	14.8	28.8	11.4	7.1	16.1	13.1	18.8	17.2	16.8	33.7	14.1	18.6	18.1	10.1	7.6	13.7	10.1	7.8	9.1	8.7	11.2	6.8	9.0	10.2	11.1	8.1	9.3	12.8	2.1	11.3	7.2	10.5	7.7	12.3	20.1	8.7	15.6	14.4	4.8	7.4	20.3	12.3	9.4	7.3	12.5	16.8	10.3	9.3	18.0	8.6	5.1	14.5	5.8	15.7	4.3	13.6	26.4	6.0	4.9	17.6	3.9	11.4	13.3	6.0	7.2	6.5	12.8	14.1	6.7	9.7	7.5	11.3	6.4	7.0	29.4	8.7	8.9	9.9	30.2	11.3	22.2	17.7	13.1	18.1	14.1	13.8	14.2	11.8	17.2	15.1	12.9	33.7	18.6	14.1	16.8	10.5	10.1	10.6	13.0	21.8	13.2	11.5	5.7	15.1	9.1	11.3	14.8
KDM5C	"DXS1272E, JARID1C, MRX13, SMCX, XE169"	ENSG00000126012	"Lysine demethylase 5C"	P41229	X	53191321-53225422	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Dioxygenase, Oxidoreductase, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038244, HPA046147"			Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA038244: , HPA046147: "	"unprognostic (1.19e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.56e-2)"	"unprognostic (7.10e-2)"	"unprognostic (9.75e-2)"	"unprognostic (2.19e-1)"	"prognostic unfavourable (2.11e-4)"	"unprognostic (2.08e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.24e-1)"	"unprognostic (5.45e-2)"	"unprognostic (1.58e-2)"	"unprognostic (5.05e-3)"	"unprognostic (1.96e-2)"	"unprognostic (6.91e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.00e-1)"	19.5	22.9	22.4	22.6	24.7	26.3	17.9	43.0	31.7	25.9	19.5	23.4	16.7	22.2	29.2	13.3	26.9	24.8	15.2	17.6	21.6	15.3	17.0	18.8	20.6	25.8	24.6	21.8	33.1	22.5	37.7	31.8	34.0	22.8	18.7	13.5	17.0	25.6	17.1	36.6	28.4	22.2	23.6	16.0	25.0	19.4	10.6	26.2	29.0	22.2	11.3	24.5	21.5	26.4	4.5	4.3	4.8	4.0	2.8	6.1	3.8	17.3	23.8	25.5	19.5	17.7	16.2	18.1	10.9	12.8	14.8	13.8	16.0	11.4	16.2	14.2	14.3	15.6	28.8	23.3	11.3	12.1	42.6	15.7	25.3	11.3	21.8	18.6	31.4	12.7	17.2	28.9	35.6	21.8	30.6	10.8	10.8	22.3	13.6	20.9	21.6	22.3	15.4	15.2	17.6	9.4	16.7	19.2	24.8	33.1	30.7	12.4	21.5	16.4	14.9	16.5	14.3	14.8	10.5	15.7	12.8	12.4	21.4	22.1	12.2	3.0	3.8	2.7	6.1	3.6	5.1	4.5	3.7	5.7	3.1	3.2	4.5	2.9	4.8	2.8	4.0	4.3	4.3	3.8	22.4	24.7	43.0	31.7	21.6	15.3	24.6	21.8	22.8	26.2
KDM6A	UTX	ENSG00000147050	"Lysine demethylase 6A"	O15550	X	44873177-45112602	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Chromatin regulator, Dioxygenase, Oxidoreductase"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000568, HPA001165, HPA002111"	Enhanced		Approved	Nucleoplasm,Nucleoli	"Intracellular and membrane"			Nucleoplasm	Nucleoli	"HPA000568: AB_1858705, HPA001165: AB_1080541, HPA002111: AB_1858704"	"unprognostic (1.73e-3)"	"unprognostic (6.86e-3)"	"unprognostic (1.45e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.58e-3)"	"unprognostic (8.22e-3)"	"unprognostic (3.23e-1)"	"unprognostic (2.44e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.73e-1)"	"unprognostic (2.24e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.26e-1)"	"unprognostic (3.16e-2)"	12.3	12.1	16.5	17.6	24.5	47.9	21.4	26.1	22.0	16.9	11.8	16.7	12.0	13.1	22.6	11.3	15.4	16.9	15.2	9.1	18.2	6.5	11.6	13.5	19.7	15.1	28.8	11.3	23.8	14.9	21.3	20.2	13.3	18.3	10.3	11.3	10.3	16.1	12.6	15.1	21.3	17.6	13.5	14.9	18.1	15.0	17.7	26.1	19.1	14.5	6.9	13.6	14.9	22.8	5.5	7.1	15.7	7.5	6.2	7.9	3.5	8.9	7.8	11.6	11.7	8.3	8.6	24.9	7.0	5.0	8.4	8.8	18.4	7.7	5.9	3.8	6.5	19.3	14.8	12.3	7.8	8.5	15.9	7.3	9.9	6.8	5.9	3.9	20.7	4.6	10.2	13.8	14.5	6.5	10.1	14.6	5.2	5.8	8.1	11.5	9.7	9.0	9.0	11.1	1.0	4.8	16.8	10.0	5.4	22.3	11.2	9.5	10.8	0.1	5.5	8.0	6.2	8.0	3.6	9.2	11.1	8.9	5.6	4.1	4.6	15.7	3.8	3.5	5.3	7.5	6.0	5.5	7.2	7.9	7.1	3.8	7.0	6.3	7.3	6.2	7.2	3.8	5.6	3.5	16.5	24.5	26.1	22.0	18.2	6.5	28.8	11.3	18.3	26.1
KDR	"CD309, FLK1, VEGFR, VEGFR2"	ENSG00000128052	"Kinase insert domain receptor"	P35968	4	55078259-55125595	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"HUVEC TERT2: 31.8;TIME: 35.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB004028	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	7400000	7400000	"Plasma membrane"		"CAB004028: AB_2212507"	"unprognostic (1.61e-1)"	"unprognostic (2.03e-1)"	"unprognostic (9.65e-2)"	"unprognostic (1.97e-1)"	"unprognostic (9.63e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.78e-3)"	"unprognostic (2.59e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.34e-1)"	"prognostic unfavourable (7.26e-4)"	"unprognostic (4.00e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.22e-1)"	"unprognostic (1.86e-1)"	19.7	6.2	1.8	4.4	3.1	0.4	20.5	1.1	2.2	11.4	6.0	1.8	11.5	2.3	28.8	10.2	5.2	9.5	6.2	12.1	2.3	1.7	7.8	10.4	13.2	14.1	3.1	2.9	6.0	8.1	8.0	6.8	34.5	3.9	9.5	1.4	27.6	7.1	10.3	5.3	3.0	3.8	7.7	2.6	4.4	4.2	5.3	1.2	0.5	20.0	5.3	3.0	4.4	12.0	0.1	0.1	0.7	0.0	0.2	0.2	0.1	0.0	0.0	1.7	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	3.7	0.0	0.0	0.3	0.0	0.0	0.2	31.8	0.0	0.0	0.2	0.0	0.0	0.0	0.8	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.9	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.7	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.1	1.8	3.1	1.1	2.2	2.3	1.7	3.1	2.9	3.9	1.2
KDSR	"DHSR, FVT1, SDR35C1"	ENSG00000119537	"3-ketodihydrosphingosine reductase"	Q06136	18	63327726-63367510	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Sphingolipid metabolism"	Oxidoreductase	"Cancer-related genes, Disease mutation, Palmoplantar keratoderma, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-266/70: 37.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003673, HPA044884"	Approved									"CAB003673: AB_425440, HPA044884: "	"unprognostic (4.44e-2)"	"unprognostic (8.57e-2)"	"unprognostic (2.52e-2)"	"unprognostic (4.56e-2)"	"unprognostic (5.88e-3)"	"unprognostic (7.50e-3)"	"unprognostic (1.80e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.97e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.70e-2)"	"unprognostic (6.81e-2)"	"prognostic favourable (9.53e-6)"	"unprognostic (3.32e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.16e-3)"	21.1	19.4	19.0	11.1	22.4	6.4	29.7	12.5	17.2	18.2	17.3	23.9	14.2	10.0	19.4	30.0	17.8	14.3	17.7	15.8	19.7	16.9	21.3	52.6	15.3	11.5	32.1	14.6	29.1	14.3	19.6	10.5	24.9	19.5	18.0	11.0	15.9	16.1	17.4	12.4	28.8	13.1	18.9	39.0	9.1	11.8	10.4	23.3	8.8	21.2	12.3	9.9	19.9	22.8	4.0	5.6	0.9	5.6	9.8	19.5	3.7	5.9	2.6	2.8	3.1	22.0	16.5	5.4	19.5	12.0	4.3	5.8	1.1	4.0	6.0	8.4	7.6	26.1	3.5	11.0	5.3	11.2	5.8	4.6	3.5	1.3	16.9	8.4	3.2	15.7	20.9	6.9	19.8	4.2	3.7	8.6	11.4	2.4	9.3	3.9	3.3	9.8	6.3	8.1	8.5	11.9	3.8	3.5	6.8	9.4	4.6	8.4	2.5	4.8	10.0	18.4	4.4	6.1	8.5	37.6	17.1	3.4	13.8	5.2	5.4	0.0	3.7	0.3	4.8	5.6	19.5	4.0	10.2	7.6	5.6	3.6	7.3	4.6	0.9	9.8	2.6	2.8	12.9	3.7	19.0	22.4	12.5	15.9	19.7	16.9	32.1	14.6	19.5	23.3
KEAP1	"INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454"	ENSG00000079999	"Kelch like ECH associated protein 1"	Q14145	19	10486120-10503741	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005558, CAB025337"	Approved		Supported	"Nucleoplasm,Centriolar satellite,Cytosol"				"Nucleoplasm, Centriolar satellite"	Cytosol	"CAB025337: , HPA005558: AB_1079175"	"unprognostic (1.98e-1)"	"prognostic favourable (3.28e-4)"	"unprognostic (1.61e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.48e-1)"	"unprognostic (5.22e-3)"	"unprognostic (2.04e-1)"	"unprognostic (9.99e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.71e-3)"	"unprognostic (5.06e-1)"	"unprognostic (8.18e-2)"	"unprognostic (1.60e-2)"	16.0	13.7	13.5	10.4	14.3	9.1	12.4	13.2	15.1	13.1	15.7	15.4	13.8	13.6	11.0	12.7	26.3	15.1	12.7	19.7	13.9	13.7	13.2	22.0	10.8	15.5	16.7	7.4	11.8	14.3	11.1	10.2	11.5	14.3	13.9	8.8	11.8	11.3	13.9	63.9	16.8	13.8	11.6	16.5	11.3	10.6	12.2	13.8	13.1	14.5	29.1	16.1	14.5	11.2	14.6	23.7	21.3	19.8	21.0	30.8	19.6	17.2	31.7	8.8	11.7	18.1	15.5	9.4	14.7	11.0	15.1	13.6	22.5	17.4	24.6	38.8	16.3	15.5	17.4	11.5	7.5	23.8	19.1	37.2	9.4	26.6	17.5	19.4	20.2	16.0	15.6	17.0	7.9	14.3	22.7	45.6	13.1	23.9	14.1	53.4	25.6	26.7	25.6	11.0	28.7	9.8	20.7	24.2	12.6	20.5	13.8	12.7	11.9	26.0	17.6	24.4	13.1	27.3	17.8	26.6	33.3	24.1	18.8	23.2	17.9	16.1	19.8	21.3	30.8	17.0	29.3	14.6	21.5	28.3	23.7	5.7	13.5	19.1	10.9	21.0	16.6	16.3	25.4	19.6	13.5	14.3	13.2	12.8	13.9	13.7	16.7	7.4	14.3	13.8
KEL	"CD238, ECE3"	ENSG00000197993	"Kell blood group, metallo-endopeptidase"	P23276	7	142941114-142962681	"Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Blood group antigen, Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"bone marrow: 21.1;testis: 36.4"	"Group enriched"	"Detected in some"	12	"HEL: 14.9;K-562: 12.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	7	"intermediate monocyte: 1.4"	"Lineage enriched"	"Detected in single"	14	"monocytes: 1.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			HPA064442			Supported	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA064442: "	"unprognostic (5.78e-3)"	"unprognostic (1.08e-5)"	"unprognostic (5.29e-3)"	"unprognostic (4.85e-3)"	"unprognostic (9.68e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.54e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.08e-2)"	"unprognostic (3.71e-2)"	"unprognostic (3.57e-2)"	"unprognostic (2.29e-3)"	"unprognostic (9.24e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.32e-2)"	"unprognostic (3.25e-3)"	0.2	0.0	0.9	2.5	1.1	21.1	0.2	0.2	0.4	0.4	0.2	0.3	0.2	0.0	0.2	0.2	0.6	0.1	0.2	0.2	1.4	0.7	0.4	0.2	1.4	5.0	2.0	0.2	0.2	0.2	0.0	0.2	1.1	0.3	0.2	0.0	0.3	2.5	0.2	0.2	0.0	0.5	0.2	4.4	3.8	0.0	36.4	0.3	0.4	0.2	0.2	3.7	0.2	0.2	0.0	0.0	0.0	1.4	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.1	0.1	0.0	0.0	0.5	0.2	0.3	0.0	0.1	0.0	0.1	0.0	1.1	0.0	0.1	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.9	1.1	0.2	0.4	1.4	0.7	2.0	0.2	0.3	0.3
KIAA1109	"FLJ21404, FSA, KIAA1371, Tweek"	ENSG00000138688	KIAA1109	Q2LD37	4	122152333-122362758	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038076	Approved		Approved	Nucleoplasm,Centrosome				"Nucleoplasm, Centrosome"		"HPA038076: AB_10670652"	"unprognostic (2.53e-1)"	"unprognostic (2.04e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.63e-3)"	"unprognostic (1.04e-1)"	"unprognostic (6.62e-2)"	"unprognostic (7.61e-2)"	"unprognostic (3.65e-2)"	"unprognostic (2.38e-1)"	"unprognostic (7.97e-2)"	"prognostic favourable (4.33e-8)"	"unprognostic (2.04e-1)"	"unprognostic (3.55e-1)"	"unprognostic (2.28e-2)"	"unprognostic (2.29e-2)"	18.4	17.1	25.6	18.0	34.1	42.9	26.1	33.4	34.2	22.9	18.7	24.1	17.9	15.6	20.9	25.4	12.3	16.8	16.4	15.3	25.5	22.0	24.0	17.4	19.5	14.8	26.4	26.2	34.3	16.6	68.2	33.1	14.3	33.6	19.1	18.8	22.6	16.6	21.5	40.1	23.1	20.8	18.6	29.3	20.0	15.2	20.4	24.2	15.3	25.4	12.6	13.6	18.0	18.5	3.1	2.3	7.7	3.6	1.7	3.5	0.7	16.7	5.5	12.8	8.4	21.4	27.9	6.7	7.6	14.3	7.9	8.7	4.0	8.9	8.8	4.4	18.0	6.3	7.9	9.4	12.8	6.6	5.0	9.7	10.0	7.6	11.1	9.1	5.4	16.0	11.3	9.4	13.0	16.7	6.3	10.7	16.1	5.6	7.8	7.1	4.2	6.1	4.5	17.8	2.2	13.8	12.7	7.5	6.7	4.8	5.5	10.7	6.0	7.5	22.3	9.8	9.7	8.0	7.7	10.4	6.7	6.4	10.4	8.0	7.1	3.3	1.4	7.7	3.3	3.6	3.5	2.5	2.3	2.3	1.4	3.1	2.0	2.3	6.6	1.7	1.7	2.3	2.9	0.7	25.6	34.1	33.4	34.2	25.5	22.0	26.4	26.2	33.6	24.2
KIF2A	"HK2, KIF2"	ENSG00000068796	"Kinesin family member 2A"	O00139	5	62306162-62537249	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation, Mitosis, Neurogenesis"	"Developmental protein, Motor protein"	"Cancer-related genes, Disease mutation, Lissencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004715, HPA004716"	Approved		Enhanced	Nucleoplasm,Nucleoli,Centrosome		2100000	2100000	"Nucleoplasm, Nucleoli, Centrosome"		"HPA004715: , HPA004716: AB_1079211"	"unprognostic (2.40e-2)"	"unprognostic (3.43e-1)"	"prognostic favourable (1.70e-4)"	"unprognostic (2.74e-2)"	"unprognostic (1.43e-1)"	"prognostic favourable (5.45e-4)"	"prognostic unfavourable (3.17e-6)"	"unprognostic (8.77e-3)"	"unprognostic (4.69e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.34e-1)"	"prognostic unfavourable (3.81e-5)"	"unprognostic (3.53e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.58e-1)"	11.3	9.3	25.4	21.9	26.4	12.4	15.5	15.4	40.1	19.7	13.5	19.4	8.0	10.3	12.9	7.6	14.3	17.5	13.7	7.2	26.2	24.1	8.2	5.8	10.6	29.4	24.9	24.6	13.0	12.3	15.2	14.3	27.8	37.0	10.2	14.5	6.8	10.7	11.9	7.4	7.9	15.8	13.5	34.3	17.4	9.6	39.2	26.4	28.7	13.0	5.6	26.7	17.4	14.8	9.0	8.4	7.1	3.0	15.8	25.4	9.7	17.2	17.3	28.9	25.6	10.9	15.4	23.6	18.5	15.3	20.2	25.6	18.6	18.9	42.8	20.4	16.3	11.0	21.9	14.9	27.0	42.9	15.3	43.0	16.2	10.1	12.9	23.4	16.4	12.7	9.8	19.6	17.8	18.4	30.4	26.1	16.8	13.0	39.1	11.6	16.8	10.9	28.9	22.9	23.6	9.0	21.0	25.9	21.5	25.1	10.6	13.0	13.8	13.2	15.9	12.0	19.9	13.9	18.4	24.7	35.6	45.2	13.9	28.2	14.7	7.1	3.0	3.4	20.2	2.6	22.8	9.0	20.3	20.6	4.0	7.8	17.9	18.4	5.3	15.8	1.8	8.4	25.4	9.7	25.4	26.4	15.4	31.2	26.2	24.1	24.9	24.6	37.0	26.4
KIF2C	"CT139, KNSL6, MCAK"	ENSG00000142945	"Kinesin family member 2C"	Q99661	1	44739818-44767767	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 39.9;testis: 61.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 5.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA006219			Supported	Nucleoplasm,Midbody,Centrosome				"Nucleoplasm, Centrosome"	Midbody	"HPA006219: "	"unprognostic (3.29e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.03e-2)"	"unprognostic (1.71e-3)"	"unprognostic (2.77e-1)"	"unprognostic (5.17e-2)"	"prognostic unfavourable (3.07e-7)"	"unprognostic (7.49e-3)"	"unprognostic (3.33e-3)"	"unprognostic (3.66e-1)"	"prognostic unfavourable (6.86e-4)"	"unprognostic (4.27e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (2.33e-3)"	"unprognostic (1.49e-1)"	"unprognostic (1.86e-2)"	"unprognostic (2.41e-1)"	1.1	0.7	0.4	8.7	0.4	12.7	0.8	0.5	0.5	1.2	2.4	0.4	0.2	2.1	1.3	1.4	4.6	0.6	0.7	0.9	0.6	0.5	0.7	0.6	1.6	6.7	0.4	0.2	0.7	0.4	0.3	0.6	2.2	0.6	0.6	3.2	0.4	1.1	0.2	0.4	2.3	2.2	1.1	0.4	3.3	1.4	61.4	0.2	39.9	0.8	4.7	12.0	0.9	1.7	1.3	1.5	0.0	0.2	3.9	5.8	1.0	28.7	11.2	25.0	20.0	1.3	2.9	16.8	21.6	15.4	44.2	38.6	18.9	20.8	33.1	10.4	10.6	13.7	25.4	14.5	40.5	21.4	10.9	39.2	19.8	15.7	0.1	28.9	18.2	0.7	1.4	31.5	15.4	14.2	30.9	28.4	27.9	11.2	30.4	17.5	24.4	14.1	24.4	37.8	20.8	7.4	10.4	17.2	12.3	28.7	20.5	18.1	11.8	22.0	8.4	16.1	31.9	17.4	37.8	15.1	15.3	47.8	10.3	28.2	30.9	0.0	0.0	0.0	1.9	0.0	0.1	1.3	3.4	2.6	0.3	0.2	0.7	0.5	0.0	3.9	0.2	1.5	5.8	1.0	0.4	0.4	0.5	0.5	0.6	0.5	0.4	0.2	0.6	0.2
KIF5B	"KNS, KNS1"	ENSG00000170759	"Kinesin family member 5B"	P33176	10	32009010-32056431	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Motor protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009846, HPA037589, HPA037590"	Approved		Enhanced	"Centriolar satellite,Cytosol"		260000	260000	"Centriolar satellite, Cytosol"		"CAB009846: AB_2280915, HPA037589: AB_2675563, HPA037590: AB_2675564"	"unprognostic (4.94e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.84e-1)"	"unprognostic (4.00e-2)"	"unprognostic (6.21e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.84e-1)"	"unprognostic (2.70e-1)"	"unprognostic (6.37e-3)"	"unprognostic (2.03e-1)"	"unprognostic (2.60e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.39e-1)"	"unprognostic (8.06e-2)"	"unprognostic (1.76e-1)"	26.3	19.9	55.7	20.2	55.5	34.1	23.0	22.2	42.4	23.8	34.2	21.7	20.9	23.5	25.7	17.8	28.0	20.3	28.0	48.4	51.5	39.3	21.1	15.3	23.8	16.5	62.9	26.1	18.2	18.9	56.8	22.4	27.7	38.3	31.8	30.0	8.9	20.1	25.6	34.3	17.6	28.6	37.2	80.4	21.1	23.1	27.7	43.7	25.0	23.5	21.5	16.1	33.8	28.1	13.8	27.6	30.0	18.9	13.4	16.5	9.2	29.4	25.1	34.0	23.8	24.4	26.9	14.5	40.7	19.3	31.5	26.9	27.5	32.6	20.2	17.7	48.3	24.5	31.0	26.0	42.3	17.4	16.9	25.7	23.5	26.8	28.1	17.8	28.3	21.8	37.0	36.3	25.4	40.2	30.9	21.3	43.5	17.7	18.6	10.1	5.5	11.5	24.4	63.4	8.3	24.3	20.7	33.1	24.2	31.5	12.6	30.3	15.2	25.6	33.5	32.1	30.1	37.1	30.1	6.4	7.4	23.9	30.6	36.9	30.1	20.8	15.2	24.2	11.8	18.9	11.4	13.6	14.9	12.5	14.2	13.8	13.3	13.0	30.0	13.4	18.9	27.6	16.5	9.2	55.7	55.5	22.2	42.4	51.5	39.3	62.9	26.1	38.3	43.7
KIFC3		ENSG00000140859	"Kinesin family member C3"	Q9BVG8	16	57758217-57863053	"Cancer-related genes, Predicted intracellular proteins"		"Motor protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 55.9;HMC-1: 54.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA021240	Uncertain									"HPA021240: AB_1852509"	"unprognostic (1.53e-1)"	"unprognostic (3.10e-3)"	"unprognostic (8.56e-3)"	"unprognostic (1.11e-1)"	"unprognostic (2.95e-3)"	"unprognostic (2.29e-1)"	"unprognostic (3.71e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.18e-1)"	"unprognostic (7.66e-3)"	"unprognostic (1.59e-2)"	"unprognostic (2.18e-2)"	"unprognostic (3.42e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.33e-2)"	11.0	10.3	10.0	12.9	14.5	7.7	13.0	5.3	16.2	7.3	16.6	18.4	4.6	15.2	8.6	18.8	11.5	5.8	10.9	21.6	10.0	11.5	36.3	36.3	16.8	6.5	19.3	10.3	9.7	29.0	20.2	12.6	20.5	18.7	10.1	6.8	30.3	8.1	11.9	6.3	40.2	31.0	9.9	13.7	8.4	8.4	24.7	18.7	0.9	26.6	7.4	6.1	10.5	13.4	2.3	0.5	2.3	1.6	0.3	4.6	1.5	10.5	55.9	4.3	8.9	1.9	2.8	7.4	13.3	17.2	20.3	9.7	15.1	16.6	1.6	17.2	8.5	11.4	0.4	12.2	7.1	0.6	2.7	8.8	17.5	19.3	7.9	1.4	54.9	4.0	4.4	10.7	10.9	5.3	15.5	2.3	7.5	7.8	1.9	15.5	2.7	12.0	1.2	6.1	8.4	13.0	5.7	1.4	3.1	22.6	16.2	14.1	4.9	6.7	10.5	26.4	18.7	12.2	18.3	1.9	1.0	1.3	13.4	1.0	24.8	0.6	0.7	0.6	4.6	0.0	0.7	2.3	2.0	4.2	0.5	2.0	1.0	1.3	2.3	0.3	1.6	0.5	0.2	1.5	10.0	14.5	5.3	16.2	10.0	11.5	19.3	10.3	18.7	18.7
KISS1		ENSG00000170498	"KiSS-1 metastasis suppressor"	Q15726	1	204190341-204196486	"Cancer-related genes, Disease related genes, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"placenta: 267.2"	"Group enriched"	"Detected in some"	22	"BJ: 54.6;U-2 OS: 22.2"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 9.2"	"Group enriched"	"Detected in some"	8	"basal ganglia: 11.3;hypothalamus: 4.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in all"			"CAB017775, HPA035542"	Enhanced		Approved	Vesicles	"Secreted in female reproductive system"			Vesicles		"CAB017775: , HPA035542: "	"unprognostic (9.64e-2)"	"unprognostic (1.78e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.18e-2)"	"unprognostic (3.89e-1)"	"unprognostic (6.87e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.28e-2)"		"unprognostic (1.28e-2)"	"unprognostic (4.51e-2)"	"unprognostic (1.63e-1)"	"unprognostic (8.98e-12)"	"unprognostic (2.25e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.76e-1)"	"prognostic favourable (6.29e-6)"	0.2	0.0	0.2	0.2	11.3	0.0	0.2	1.0	0.2	0.2	0.2	0.2	0.2	0.4	0.2	0.2	0.2	0.0	0.2	0.2	0.2	4.2	1.1	2.7	0.5	0.2	0.2	0.2	0.2	0.4	0.1	2.5	267.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.5	0.2	0.2	0.7	1.4	3.6	0.2	0.2	0.2	0.2	0.2	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	54.6	0.7	0.9	0.2	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	22.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	11.3	1.0	0.2	0.2	4.2	0.2	0.2	0.2	0.2
KIT	"C-Kit, CD117, PBT, SCFR"	ENSG00000157404	"KIT proto-oncogene receptor tyrosine kinase"	P10721	4	54657918-54740715	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 65.5"	"Group enriched"	"Detected in some"	13	"HEL: 47.7;HMC-1: 100.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7"	"Group enriched"	"Detected in many"	6	"granulocytes: 12.7;NK-cells: 9.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252"	Enhanced	Supported	Supported	"Plasma membrane"		48000000	48000000	"Plasma membrane"		"CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: "	"unprognostic (1.55e-2)"	"unprognostic (1.91e-1)"	"unprognostic (4.04e-2)"	"unprognostic (8.19e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.92e-2)"	"prognostic favourable (5.63e-4)"	"unprognostic (1.34e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.30e-1)"	8.1	1.6	9.5	6.6	11.8	3.7	65.5	18.3	12.0	12.1	10.3	6.5	10.2	5.8	8.9	4.2	9.9	2.5	15.5	2.4	36.0	4.4	9.4	1.1	13.8	3.8	3.6	6.0	28.5	2.1	1.3	2.3	6.2	5.7	9.6	10.4	20.7	12.9	6.9	1.3	14.6	8.9	10.2	3.9	3.2	12.8	4.0	4.5	0.4	28.9	4.3	4.9	9.8	12.5	0.0	1.8	12.7	0.9	9.7	1.9	0.1	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.6	0.9	2.5	3.2	0.0	0.0	0.0	0.0	1.4	0.0	0.5	0.0	2.1	0.0	1.1	47.7	0.0	0.0	0.0	0.0	100.2	0.0	0.0	0.0	0.0	5.6	0.6	0.1	0.0	0.0	0.2	0.4	1.3	0.0	0.1	0.0	0.0	0.0	4.7	1.2	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	12.7	0.0	10.0	0.1	0.0	1.9	0.0	0.3	0.7	1.8	0.0	0.0	0.0	0.8	9.7	0.9	0.0	0.0	0.1	9.5	11.8	18.3	12.0	36.0	4.4	3.6	6.0	5.7	4.5
KITLG	"DFNA69, FPH2, Kitl, KL-1, MGF, SCF, SF, SLF"	ENSG00000049130	"KIT ligand"	P21583	12	88492793-88580851	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Cell adhesion"	"Growth factor"	"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CACO-2: 81.7;SK-BR-3: 28.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070395	Approved		Approved	Vesicles	"Intracellular and membrane"	150000	150000	Vesicles		"HPA070395: "	"unprognostic (7.13e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.70e-1)"	"unprognostic (1.93e-2)"	"prognostic unfavourable (4.01e-4)"	"unprognostic (2.22e-3)"	"unprognostic (5.61e-3)"	"unprognostic (7.89e-2)"	"unprognostic (5.47e-3)"	"unprognostic (5.03e-2)"	"prognostic favourable (5.81e-7)"	"unprognostic (7.15e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.54e-2)"	10.1	3.8	7.8	8.0	6.4	0.0	11.2	4.8	11.5	9.6	16.1	2.9	8.5	6.2	11.7	8.7	16.7	4.7	13.9	5.6	8.4	3.9	21.9	2.8	22.9	6.1	3.3	7.7	4.4	5.0	1.9	3.2	10.1	4.0	17.9	15.9	7.8	11.8	14.8	4.8	5.3	9.5	21.0	3.7	2.6	13.0	5.8	2.9	0.7	6.5	5.8	6.6	17.5	17.8	0.0	0.2	0.0	0.5	0.0	0.0	0.0	3.4	1.9	1.8	0.2	7.1	15.3	0.0	21.0	15.0	3.6	1.6	81.7	3.3	0.0	0.6	17.6	12.7	2.7	4.7	3.4	0.0	2.4	0.0	2.9	0.6	1.1	0.4	0.0	13.2	5.0	11.4	6.8	4.3	0.0	0.0	1.6	0.6	0.0	0.0	1.2	4.7	0.0	3.3	0.0	6.0	1.7	0.5	1.2	5.1	28.5	0.5	14.6	1.0	2.9	16.5	2.3	19.2	1.6	0.0	0.0	0.0	2.1	0.0	1.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	6.4	4.8	11.5	8.4	3.9	3.3	7.7	4.0	2.9
KLF4	"EZF, GKLF"	ENSG00000136826	"Kruppel like factor 4"	O43474	9	107484852-107490482	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skin 1: 92.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 15.3;hTCEpi: 32.4;hTERT-HME1: 20.1;U-2197: 49.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	10	"classical monocyte: 5.2;intermediate monocyte: 7.4;myeloid DC: 4.4;non-classical monocyte: 2.9"	"Group enriched"	"Detected in many"	12	"dendritic cells: 4.4;monocytes: 7.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA002926	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"HPA002926: AB_1852541"	"unprognostic (2.06e-1)"	"unprognostic (1.42e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.55e-1)"	"unprognostic (6.58e-3)"	"unprognostic (3.44e-2)"	"unprognostic (6.49e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.29e-2)"	"unprognostic (1.18e-2)"	"unprognostic (1.08e-1)"	"prognostic favourable (3.93e-5)"	"unprognostic (2.55e-1)"	"unprognostic (1.67e-1)"	"unprognostic (8.13e-2)"	"unprognostic (8.32e-2)"	29.2	8.5	2.7	23.8	3.9	14.4	23.7	1.8	3.5	39.1	28.9	5.6	5.5	10.2	17.8	18.6	34.9	22.0	32.4	18.6	2.4	2.2	4.8	5.1	35.6	4.4	2.7	2.2	18.6	2.3	2.7	2.8	41.0	6.2	11.3	29.6	11.7	11.9	6.5	13.6	92.1	39.4	16.0	3.3	21.8	22.2	11.2	2.0	1.9	7.8	81.1	30.7	16.8	24.1	0.0	4.4	0.4	7.4	0.1	0.0	1.3	5.6	2.3	0.2	0.0	6.0	15.3	2.2	2.0	10.5	2.7	3.1	0.8	7.2	0.0	0.3	2.6	4.2	2.6	1.4	1.0	0.0	1.1	0.0	4.0	0.1	8.9	0.0	0.0	2.0	32.4	5.4	20.1	0.2	0.2	0.0	1.4	3.7	0.0	0.6	1.7	11.4	0.1	0.6	0.1	0.8	1.6	0.1	0.1	1.5	4.8	6.0	0.7	2.5	1.2	1.6	0.0	49.3	0.8	0.0	0.0	0.0	1.5	1.0	2.7	0.0	5.2	0.0	0.0	7.4	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.4	0.1	2.9	0.4	0.0	1.3	2.7	3.9	1.8	3.5	2.4	2.2	2.7	2.2	6.2	2.0
KLF5	"BTEB2, CKLF, IKLF"	ENSG00000102554	"Kruppel like factor 5"	Q13887	13	73054976-73077542	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 88.4;intestine: 88.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 29.8;HaCaT: 34.2;HBEC3-KT: 29.8;hTCEpi: 42.6;RT4: 36.0;SiHa: 30.4"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	5	"basal ganglia: 22.2"	"Cell type enriched"	"Detected in single"	18	"basophil: 16.3"	"Lineage enriched"	"Detected in single"	106	"granulocytes: 16.3"	"Group enriched"	"Detected in many"	4	"amygdala: 5.6;basal ganglia: 9.3;cerebral cortex: 6.9;hippocampal formation: 8.8;hypothalamus: 4.3"	"Low region specificity"	"Detected in many"			HPA040398	Approved		Supported	"Nucleoplasm,Golgi apparatus,Vesicles"				Nucleoplasm	"Golgi apparatus, Vesicles"	"HPA040398: AB_10673267"	"unprognostic (7.90e-3)"	"unprognostic (5.11e-2)"	"unprognostic (2.03e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.69e-2)"	"unprognostic (2.75e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.97e-2)"	"unprognostic (5.82e-1)"	"unprognostic (1.47e-2)"	"prognostic unfavourable (2.55e-4)"	"unprognostic (4.43e-2)"	"unprognostic (1.42e-3)"	"unprognostic (3.56e-3)"	"unprognostic (3.98e-1)"	"unprognostic (5.09e-2)"	"unprognostic (1.54e-2)"	2.3	1.5	4.1	24.3	22.2	12.9	8.1	0.7	1.2	19.6	74.4	0.4	4.3	28.7	4.8	3.7	88.4	8.3	48.4	1.3	1.4	1.2	3.9	1.2	12.8	0.1	0.9	1.1	5.0	3.5	0.0	7.3	22.8	4.3	17.6	32.9	1.8	26.4	5.4	10.0	59.4	88.1	4.1	2.4	0.8	17.9	12.2	1.4	3.0	20.7	64.4	61.8	23.4	34.1	0.0	0.0	16.3	0.0	0.0	0.1	0.0	5.7	8.1	0.0	0.1	0.3	0.4	9.2	3.4	7.9	1.5	1.9	7.4	29.8	0.1	18.1	3.0	34.2	10.4	29.8	2.4	0.2	2.7	0.1	17.0	0.7	2.1	2.7	0.5	2.2	42.6	0.4	16.7	0.0	0.4	0.6	6.8	2.0	0.5	0.2	0.3	11.5	0.5	7.6	0.6	23.6	36.0	0.7	0.3	30.4	4.9	2.1	0.6	0.6	0.0	2.1	6.2	0.0	1.4	0.9	0.4	1.0	2.9	0.5	2.5	16.3	0.0	0.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.1	0.0	4.1	22.2	0.7	1.2	1.4	1.2	0.9	1.1	4.3	1.4
KLF6	"BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9"	ENSG00000067082	"Kruppel like factor 6"	Q99612	10	3775996-3785281	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013529, HPA069585"	Supported		Approved	"Nucleoplasm,Nucleoli fibrillar center,Vesicles,Cytosol"				"Nucleoplasm, Nucleoli fibrillar center"	"Vesicles, Cytosol"	"CAB013529: AB_2533431, HPA069585: "	"unprognostic (1.23e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.47e-3)"	"unprognostic (4.53e-2)"	"unprognostic (1.47e-1)"	"unprognostic (7.55e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.08e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.83e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.35e-2)"	"prognostic favourable (2.28e-4)"	"unprognostic (8.07e-3)"	"unprognostic (4.85e-2)"	"unprognostic (6.87e-2)"	"unprognostic (1.37e-2)"	69.8	10.0	8.4	26.3	10.6	80.6	101.1	7.4	10.1	28.6	31.7	10.3	9.7	11.0	24.9	28.8	38.6	28.0	38.6	18.6	7.8	5.1	32.2	32.5	46.0	35.8	13.8	4.2	20.2	23.8	7.5	4.7	26.1	11.2	20.1	21.0	13.2	26.9	16.5	57.8	60.2	44.8	42.8	17.0	20.3	26.7	14.3	10.0	12.5	41.0	28.8	21.5	44.7	30.7	15.6	29.8	77.8	18.7	13.0	30.8	23.2	13.0	3.5	6.8	2.2	39.6	39.8	4.3	22.5	11.5	24.1	16.4	9.1	17.6	3.7	5.2	24.3	7.9	4.2	20.7	20.1	18.3	2.5	0.5	4.1	8.6	17.0	2.4	12.9	13.1	39.6	17.1	32.7	24.5	4.1	29.2	30.5	0.9	4.5	3.8	2.5	6.4	3.0	7.0	13.1	23.6	13.0	3.0	2.9	5.5	16.0	33.7	7.9	2.0	31.9	32.5	4.5	19.2	10.3	5.6	18.2	6.9	8.7	3.3	10.0	50.9	17.0	43.7	27.1	14.2	23.9	15.6	30.8	26.8	13.1	12.5	9.6	14.8	77.8	13.0	18.7	29.8	22.2	23.2	8.4	10.6	7.4	10.1	7.8	5.1	13.8	4.2	11.2	10.0
KLHL8	KIAA1378	ENSG00000145332	"Kelch like family member 8"	Q9P2G9	4	87160103-87240314	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"epididymis: 56.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013856, HPA017762"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"HPA013856: AB_1852594, HPA017762: "	"unprognostic (2.93e-2)"	"unprognostic (4.91e-3)"	"unprognostic (3.44e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.27e-2)"	"unprognostic (2.12e-1)"	"unprognostic (4.46e-3)"	"unprognostic (3.27e-2)"	"unprognostic (2.06e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.46e-1)"	"prognostic favourable (1.53e-5)"	"unprognostic (4.24e-3)"	"unprognostic (3.05e-1)"	"unprognostic (3.57e-3)"	"unprognostic (1.57e-3)"	6.8	7.3	6.9	5.6	8.1	3.0	12.0	10.0	10.7	9.2	7.5	5.3	3.8	7.3	8.3	56.2	5.3	5.4	5.0	7.4	7.7	7.2	11.4	10.3	9.0	8.1	6.3	5.6	6.1	6.3	7.1	14.2	6.6	7.3	5.7	8.5	4.6	6.5	7.7	23.4	4.8	8.2	6.6	8.0	6.9	5.5	4.2	6.5	7.0	17.3	2.9	4.7	6.8	10.9	3.8	10.3	8.6	12.1	8.7	4.9	5.0	6.5	5.7	10.4	4.6	9.5	7.0	5.6	8.4	4.5	5.6	6.6	9.2	5.0	9.5	6.8	6.1	2.8	11.0	8.3	12.2	9.0	6.9	11.5	4.3	5.4	8.1	18.9	7.3	8.7	6.0	8.6	8.6	6.6	14.9	8.7	5.8	7.2	22.6	9.6	2.6	2.3	8.5	8.9	5.8	9.5	6.8	21.9	7.6	5.5	13.5	6.2	4.6	14.0	6.2	7.1	8.8	7.5	6.9	13.0	8.5	16.9	5.4	9.0	7.8	1.9	12.1	7.3	3.0	9.2	4.9	3.3	2.4	2.5	10.3	3.8	4.4	4.3	8.6	8.7	9.0	2.7	0.9	5.0	6.9	8.1	10.0	10.7	7.7	7.2	6.3	5.6	7.3	6.5
KLK10	"NES1, PRSSL1"	ENSG00000129451	"Kallikrein related peptidase 10"	O43240	19	51012739-51020175	"Cancer-related genes, Enzymes, Predicted secreted proteins"	"Cell cycle"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 78.6;lymphoid tissue: 58.6;tongue: 136.3"	"Group enriched"	"Detected in some"	6	"CAPAN-2: 52.5;HaCaT: 79.7"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.1"	"Low lineage specificity"	"Detected in single"			"Region enriched"	"Detected in single"	4	"hippocampal formation: 1.7"	"Not detected"	"Not detected"								"Secreted in other tissues"	670000	670000				"prognostic favourable (8.32e-4)"	"unprognostic (6.06e-2)"	"unprognostic (1.73e-1)"	"unprognostic (4.26e-3)"	"unprognostic (3.81e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.10e-2)"	"unprognostic (3.94e-1)"	"unprognostic (3.38e-2)"	"prognostic unfavourable (6.46e-5)"	"unprognostic (2.71e-2)"	"unprognostic (2.46e-6)"	"unprognostic (9.34e-2)"	"unprognostic (7.81e-2)"	"unprognostic (2.66e-3)"	"unprognostic (1.52e-2)"	1.5	0.5	0.2	1.7	0.3	0.3	2.4	0.7	0.4	20.8	0.9	0.3	0.5	0.2	2.9	0.8	78.6	7.8	36.0	0.7	0.2	0.5	0.2	0.3	4.3	0.2	0.2	0.3	7.2	0.2	0.0	0.2	0.8	0.6	1.6	0.4	0.3	11.0	0.6	0.4	17.7	0.4	0.4	0.4	0.2	0.5	1.6	0.2	1.0	0.3	136.3	58.6	0.5	33.4	0.4	0.5	2.1	0.4	0.4	0.3	0.1	12.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	52.5	0.0	2.9	0.0	79.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.2	0.3	0.2	0.3	0.2	0.3	0.2	0.1	0.4	0.3	0.3	2.1	0.4	0.4	0.5	0.3	0.1	0.2	0.3	0.7	0.4	0.2	0.5	0.2	0.3	0.6	0.2
KLK11	"PRSS20, TLSP"	ENSG00000167757	"Kallikrein related peptidase 11"	Q9UBX7	19	51022216-51028039	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 103.4;lymphoid tissue: 88.5;salivary gland: 96.5"	"Group enriched"	"Detected in some"	4	"EFO-21: 9.4;HaCaT: 29.3"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	11	"pons and medulla: 10.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB026340	Approved				"Secreted in other tissues"	320000	320000			"CAB026340: "	"unprognostic (4.23e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.27e-1)"	"prognostic favourable (3.78e-4)"		"unprognostic (2.08e-2)"	"unprognostic (4.67e-1)"	"unprognostic (5.32e-2)"	"unprognostic (3.72e-1)"	"unprognostic (3.02e-1)"	"prognostic unfavourable (4.17e-4)"	"unprognostic (2.92e-2)"	"unprognostic (4.16e-6)"	"unprognostic (3.90e-2)"	"unprognostic (2.73e-1)"	"unprognostic (4.40e-2)"	"unprognostic (2.53e-1)"	5.5	0.0	0.2	1.1	0.2	0.0	4.9	0.2	0.6	24.5	1.7	2.0	0.4	0.0	5.1	2.7	103.4	9.7	61.8	0.4	0.9	0.0	0.2	0.6	12.3	0.2	0.2	0.2	2.3	25.0	0.0	2.1	0.4	10.7	18.8	0.0	5.1	96.5	1.6	0.3	49.8	0.6	0.3	0.2	0.2	18.7	7.7	0.2	0.9	0.2	65.2	88.5	0.7	33.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	4.5	0.0	9.4	0.0	29.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.6	0.9	0.0	0.2	0.2	10.7	0.2
KLK13	KLK-L4	ENSG00000167759	"Kallikrein related peptidase 13"	Q9UKR3	19	51056206-51065114	"Cancer-related genes, Enzymes, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"esophagus: 100.5"	"Cell line enriched"	"Detected in some"	11	"HaCaT: 20.3"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 42.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							HPA062136	Enhanced				"Secreted in other tissues"					"HPA062136: "	"unprognostic (1.99e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.66e-2)"		"unprognostic (3.43e-1)"		"unprognostic (2.99e-2)"	"unprognostic (1.69e-1)"	"unprognostic (6.76e-2)"	"unprognostic (2.18e-2)"	"unprognostic (8.30e-2)"	"unprognostic (7.07e-6)"	"unprognostic (7.33e-2)"	"unprognostic (2.53e-1)"	"unprognostic (6.38e-2)"	"unprognostic (7.06e-2)"	0.1	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.2	15.7	0.4	0.2	0.1	0.2	0.3	0.1	100.5	0.2	0.9	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.4	1.7	0.0	0.5	0.1	0.2	0.1	0.0	0.3	12.4	0.1	1.2	2.1	0.4	0.1	0.1	0.1	0.2	6.1	0.1	0.1	0.1	17.9	12.8	0.1	19.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	20.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.1	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.2	0.1
KLK14	KLK-L6	ENSG00000129437	"Kallikrein related peptidase 14"	Q9P0G3	19	51077495-51084245	"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"skin 1: 14.2"	"Cell line enhanced"	"Detected in some"		"HaCaT: 13.7;HEK 293: 3.9;U-266/84: 7.1"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 26.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB026228	Uncertain				"Secreted in other tissues"					"CAB026228: "	"unprognostic (2.08e-1)"	"unprognostic (1.22e-1)"	"unprognostic (2.44e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.23e-1)"	"unprognostic (6.12e-2)"	"unprognostic (4.91e-2)"	"unprognostic (5.79e-2)"	"unprognostic (7.84e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.60e-2)"	"unprognostic (8.87e-2)"	"unprognostic (2.04e-8)"	"unprognostic (1.93e-1)"	"unprognostic (3.74e-3)"	"unprognostic (1.94e-2)"	"unprognostic (8.08e-2)"	0.2	0.0	0.4	0.2	1.2	0.1	2.7	2.1	0.9	3.8	0.6			1.8	0.4	0.9	1.2	0.8	0.3	1.1	0.6	0.5	0.1	0.1	0.5	0.4	0.3		0.9	0.4	0.0	0.3	0.0		0.7	0.4		1.1	0.7	0.3	14.2	1.0	0.0	0.3	0.4	0.8	0.7			0.1		0.6	0.2	3.9	0.0	0.0	0.3	0.1	0.0	0.0	0.0	1.7	0.7	0.1	0.9	0.6	0.6	0.7	0.2	0.0	0.0	0.2	1.7	2.1	0.8	0.6	0.3	13.7	0.2	0.3	0.0	0.5	3.9	0.3	1.0	0.0	0.2	0.3	0.3	0.4	0.4	0.5	0.6	0.2	0.3	0.5	0.0	1.2	0.2	0.8	0.8	1.5	0.2	0.1	0.8	0.0	0.7	0.1	0.0	0.3	1.2	0.4	0.6	0.0	0.0	0.2	0.6	0.9	0.2	3.6	7.1	0.5	0.1	0.3	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0										
KLK15	"ACO, HSRNASPH, prostinogen"	ENSG00000174562	"Kallikrein related peptidase 15"	Q9H2R5	19	50825289-50837213	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"intestine: 5.7;salivary gland: 9.7"	"Cell line enriched"	"Detected in some"	5	"RPMI-8226: 7.2"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 3.5"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							HPA019802	Uncertain				"Secreted to blood"					"HPA019802: AB_1852601"		"unprognostic (6.06e-2)"	"unprognostic (2.85e-1)"	"unprognostic (8.13e-2)"		"unprognostic (2.90e-1)"				"unprognostic (2.29e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.17e-1)"		"unprognostic (1.55e-1)"	"unprognostic (2.52e-1)"	"unprognostic (2.72e-2)"		0.0	2.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	5.7			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0		0.0	0.2	0.0	0.0	0.0		1.4	2.1		9.7	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	2.1			1.7		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
KLK2		ENSG00000167751	"Kallikrein related peptidase 2"	P20151	19	50861568-50880567	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	29	"prostate: 163.5"	"Cell line enhanced"	"Detected in many"		"NB-4: 9.9"	"Cancer enriched"	"Detected in some"	1666	"prostate cancer: 989.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA000764	Supported				"Secreted in male reproductive system"					"HPA000764: AB_1079700"	"unprognostic (3.05e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.69e-1)"	"unprognostic (8.53e-2)"		"unprognostic (1.15e-1)"		"unprognostic (8.97e-2)"	"unprognostic (3.22e-1)"	"unprognostic (6.44e-2)"	"unprognostic (8.06e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.11e-3)"	"unprognostic (7.56e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.04e-1)"	0.0	0.1	0.0	0.1	0.0	1.1	0.2	0.0	0.6	0.0	0.0	0.0	0.6	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	163.5	0.0	0.1	2.3	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.6	0.0	0.0	1.1	0.0	0.0	0.2	0.0	2.2	1.9	5.7	2.2	1.6	1.3	0.5	1.7	1.1	0.6	1.6	0.0	0.8	4.9	0.5	0.3	0.2	0.2	0.6	0.7	1.8	0.2	0.0	2.0	0.2	0.0	0.3	1.7	1.1	0.0	1.3	0.4	0.0	0.3	3.1	0.4	0.3	0.3	0.4	0.0	1.4	1.9	0.3	1.8	1.2	9.9	1.1	0.0	0.9	0.0	2.8	0.0	1.6	0.9	1.5	0.3	1.3	1.3	1.2	0.4	0.8	1.3	1.9	4.8	1.6	1.8	3.2	0.8	1.9	1.7	1.4	0.9	2.2	1.6	1.2	1.0	1.0	1.0	0.8	1.0	0.5	2.2	0.8	1.3	5.7	1.6	0.8	1.9	0.4	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0
KLK3	"APS, PSA"	ENSG00000142515	"Kallikrein related peptidase 3"	P07288	19	50854915-50860764	"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	115	"prostate: 447.4"	"Group enriched"	"Detected in some"	135	"BEWO: 21.9;NB-4: 18.5;RPMI-8226: 12.2;SH-SY5Y: 7.3;U-2197: 7.5"	"Cancer enriched"	"Detected in some"	3905	"prostate cancer: 4241.6"	"Region enriched"	"Detected in single"	8	"cerebral cortex: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB000070, HPA000764"	Enhanced				"Secreted in male reproductive system"					"CAB000070: , HPA000764: AB_1079700"	"unprognostic (5.06e-3)"	"unprognostic (5.60e-2)"	"unprognostic (9.93e-2)"	"unprognostic (3.90e-2)"		"unprognostic (1.09e-2)"				"unprognostic (1.26e-2)"	"unprognostic (1.88e-2)"	"unprognostic (1.54e-1)"	"unprognostic (5.13e-3)"	"unprognostic (1.94e-1)"	"unprognostic (4.64e-1)"	"unprognostic (3.15e-1)"		0.1	0.3	0.0	0.1	0.0	0.0	0.7	0.0	1.0	0.1	0.1	0.0	0.2	0.1	0.1	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	447.4	0.0	0.1	3.8	1.3	0.0	0.0	0.1	0.3	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.5	0.0	0.0	0.0	0.0	12.2	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.0
KLK4	"EMSP, EMSP1, KLK-L1, PRSS17, PSTS"	ENSG00000167749	"Kallikrein related peptidase 4"	Q9Y5K2	19	50906352-50910738	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	Biomineralization	"Hydrolase, Protease, Serine protease"	"Amelogenesis imperfecta, Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	9	"prostate: 79.3"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 8.2;HaCaT: 10.1;SK-BR-3: 6.5"	"Cancer enriched"	"Detected in many"	55	"prostate cancer: 463.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA051839	Enhanced				"Secreted in male reproductive system"					"HPA051839: "	"unprognostic (3.58e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.66e-3)"	"unprognostic (3.11e-2)"	"unprognostic (4.35e-1)"	"unprognostic (3.18e-1)"	"unprognostic (6.66e-2)"	"unprognostic (9.69e-2)"	"unprognostic (8.23e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.07e-1)"	"unprognostic (4.20e-3)"	"unprognostic (3.27e-3)"	"unprognostic (2.21e-2)"	"unprognostic (1.64e-2)"	"unprognostic (1.34e-1)"	0.2	0.8	0.1	0.3	0.1	0.1	0.7	0.2	0.5	2.0	1.2	0.0	3.8	1.8	1.5	7.7	0.4	0.2	0.1	0.1	0.3	0.2	0.2	0.1	0.2	0.0	0.2	0.0	0.1	0.1	0.0	0.1	0.1	0.5	79.3	0.8	0.2	3.2	2.1	0.7	2.4	1.2	0.6	0.1	0.1	0.3	0.6	0.1	0.0	8.7	0.0	0.0	0.2	0.2	0.1	0.4	0.6	0.1	0.0	0.3	0.0	5.0	2.1	0.2	0.3	0.0	0.0	4.5	0.1	0.0	0.0	0.0	4.6	8.2	0.5	0.4	0.1	10.1	0.0	5.4	0.0	1.3	1.4	1.6	3.7	1.7	0.0	1.7	2.3	0.0	2.6	0.0	0.0	0.0	0.9	4.2	0.0	1.2	0.1	2.5	0.1	0.4	0.3	0.5	1.1	0.0	3.3	0.0	0.6	0.3	6.5	0.0	5.2	0.4	1.1	0.3	0.3	1.3	0.3	2.6	1.0	0.5	0.1	0.3	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.2	0.5	0.3	0.2	0.2	0.0	0.5	0.1
KLK5	"KLK-L2, SCTE"	ENSG00000167754	"Kallikrein related peptidase 5"	Q9Y337	19	50943303-50953093	"Cancer-related genes, Enzymes, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"skin 1: 69.2;tongue: 67.3"	"Group enriched"	"Detected in some"	40	"A-431: 85.3;HaCaT: 83.0"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 112.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA014343, CAB025503, CAB026341"	Enhanced				"Secreted in other tissues"					"CAB025503: , CAB026341: , HPA014343: AB_1852603"	"unprognostic (3.19e-2)"	"unprognostic (1.06e-1)"		"prognostic unfavourable (2.33e-4)"	"unprognostic (4.30e-4)"	"unprognostic (3.01e-1)"		"prognostic unfavourable (9.79e-4)"	"unprognostic (3.04e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.70e-3)"	"unprognostic (2.21e-1)"		"unprognostic (2.76e-1)"	"unprognostic (2.53e-1)"	"unprognostic (9.16e-3)"	"prognostic unfavourable (3.85e-6)"	1.1	0.0	0.7	0.4	0.2	0.0	12.1	0.2	0.5	3.8	0.3	0.2	0.2	0.1	1.4	0.9	6.5	0.2	0.3	0.2	0.2	0.1	0.6	0.2	2.5	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.4	0.2	0.0	0.3	7.0	0.2	0.4	69.2	0.2	0.2	0.2	0.2	0.0	3.3	0.2	0.4	0.3	67.3	4.4	0.2	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	85.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	83.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.2	0.5	0.2	0.1	0.2	0.2	0.4	0.2
KLK6	"Bssp, Klk7, neurosin, PRSS18, PRSS9"	ENSG00000167755	"Kallikrein related peptidase 6"	Q92876	19	50958631-50969673	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 97.6;esophagus: 48.9"	"Group enriched"	"Detected in some"	14	"A-431: 68.4;CAPAN-2: 163.7"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 131.3"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"pons and medulla: 175.6"	"Group enriched"	"Detected in many"	8	"midbrain: 106.3;pons and medulla: 164.1;thalamus: 62.4"	HPA051837			Supported	"Nucleoplasm,Nuclear membrane,Cytokinetic bridge"	"Secreted in other tissues"	6800000	6800000	Nucleoplasm	"Nuclear membrane, Cytokinetic bridge"	"HPA051837: "	"unprognostic (7.30e-2)"	"unprognostic (3.32e-1)"	"unprognostic (6.58e-2)"	"prognostic unfavourable (1.38e-5)"	"unprognostic (1.10e-1)"	"unprognostic (2.31e-1)"		"prognostic unfavourable (8.85e-4)"	"unprognostic (3.02e-1)"	"unprognostic (2.46e-1)"	"prognostic unfavourable (7.82e-4)"	"unprognostic (4.45e-1)"	"unprognostic (2.72e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.46e-1)"	"unprognostic (9.07e-2)"	"prognostic unfavourable (1.27e-4)"	0.9	0.9	9.7	0.9	23.5	0.9	6.5	3.3	42.2	10.0	1.0	82.0	0.0	1.1	2.0	1.2	48.9	24.6	3.8	0.9	20.1	11.8	9.0	0.9	0.9	0.9	46.1	14.9	0.9	0.9	0.9	0.2	0.9	44.3	1.0	0.9	0.0	5.9	2.8	0.9	2.9	0.9	1.0	97.6	5.1	1.0	1.5	32.6	0.0	0.9	15.7	28.1	0.9	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	68.4	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	8.1	163.7	0.0	1.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.2	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.2	0.0	0.1	5.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.7	23.5	3.3	23.1	20.1	11.8	46.1	14.9	44.3	32.6
KLK7	"PRSS6, SCCE"	ENSG00000169035	"Kallikrein related peptidase 7"	P49862	19	50976482-50984099	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"esophagus: 29.1;skin 1: 77.5;tongue: 90.2"	"Group enriched"	"Detected in some"	6	"CAPAN-2: 6.6;HaCaT: 25.9"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 139.8"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA018994, CAB026342, HPA062126"	Enhanced		Supported	"Nuclear membrane,Plasma membrane"	"Secreted in other tissues"	960000	960000	"Plasma membrane"	"Nuclear membrane"	"CAB026342: , HPA018994: AB_1852607, HPA062126: AB_2684691"	"unprognostic (1.88e-2)"	"unprognostic (6.41e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavourable (8.06e-5)"	"unprognostic (4.33e-3)"	"unprognostic (2.28e-1)"		"unprognostic (4.44e-3)"	"unprognostic (2.99e-1)"	"unprognostic (1.31e-1)"	"prognostic unfavourable (1.16e-4)"	"unprognostic (2.10e-1)"	"unprognostic (2.82e-3)"	"unprognostic (3.25e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.12e-2)"	"unprognostic (5.60e-3)"	2.1	0.3	5.4	0.3	4.3	0.4	5.6	0.5	11.3	5.4	0.3	0.0	0.0	0.5	0.7	0.3	29.1	7.8	3.3	0.2	4.8	0.5	2.6	0.2	1.6	0.3	0.3	3.5	1.0	0.2	0.2	0.1	0.5	4.2	0.3	0.2	0.0	7.4	0.3	0.6	77.5	0.3	0.4	0.3	0.5	0.4	0.3	0.0	0.0	0.4	90.2	15.3	0.2	9.0	1.1	0.4	1.3	0.8	2.1	1.0	0.6	2.6	0.0	0.0	0.2	0.0	0.0	1.3	0.0	0.0	0.0	0.0	1.5	6.6	0.0	1.0	0.0	25.9	0.0	0.8	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.2	0.0	2.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.1	1.3	0.8	0.4	0.4	0.4	0.7	0.6	0.6	0.4	0.4	1.1	1.0	0.9	0.9	2.1	0.4	0.4	0.7	0.6	5.4	4.3	0.5	11.3	4.8	0.5	0.3	3.5	4.2	0.0
KLK8	"HNP, neuropsin, ovasin, PRSS19, TADG14"	ENSG00000129455	"Kallikrein related peptidase 8"	O60259	19	50996007-51002711	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 43.6;skin 1: 40.4;tongue: 46.9"	"Group enriched"	"Detected in some"	7	"A-431: 31.5;CAPAN-2: 41.3;HaCaT: 30.5"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 29.9;ovarian cancer: 30.7"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	5	"hippocampal formation: 39.6"					"CAB019393, HPA035761"	Enhanced		Approved	Vesicles	"Secreted in other tissues"	950000	950000	Vesicles		"CAB019393: , HPA035761: "	"unprognostic (4.27e-3)"	"unprognostic (2.59e-1)"	"unprognostic (2.54e-1)"	"prognostic unfavourable (2.31e-4)"		"unprognostic (5.46e-2)"		"prognostic unfavourable (5.72e-4)"	"unprognostic (2.95e-1)"	"unprognostic (9.02e-2)"	"prognostic unfavourable (1.10e-4)"			"unprognostic (4.29e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.54e-1)"	"prognostic unfavourable (6.17e-4)"	1.6	0.0	0.1	0.4	0.1	0.0	4.5	1.0	0.3	8.1	0.7	0.1	0.1	0.0	1.1	0.7	43.6	6.7	0.3	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1	1.1	0.1	0.0	0.1	0.4	0.6	0.3	0.0	0.3	6.0	0.1	0.3	40.4	0.1	0.1	0.6	0.3	0.0	0.7	0.1	0.5	0.3	46.9	11.1	0.3	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.5	0.0	0.0	0.2	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.6	41.3	0.0	0.8	0.0	30.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.0	0.3	0.1	0.0	0.1	0.1	0.6	0.1
KLK9	KLK-L3	ENSG00000213022	"Kallikrein related peptidase 9"	Q9UKQ9	19	51003111-51009634	"Cancer-related genes, Enzymes, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"tongue: 37.6"	"Group enriched"	"Detected in some"	27	"HaCaT: 1.2;HBEC3-KT: 4.1"	"Cancer enriched"	"Detected in single"	6	"head and neck cancer: 0.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											CAB025049	Enhanced				"Secreted to digestive system"					"CAB025049: "						"unprognostic (3.22e-2)"												0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	37.6	3.8	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KLRK1	"CD314, D12S2489E, KLR, NKG2-D, NKG2D"	ENSG00000213809	"Killer cell lectin like receptor K1"	P26718	12	10372353-10391874	"Cancer-related genes, CD markers, Predicted membrane proteins, Transporters"	"Adaptive immunity, Differentiation, Immunity, Innate immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 50.8;lymphoid tissue: 30.7"	"Cell line enriched"	"Detected in some"	8	"U-698: 36.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	39	"gdT-cell: 49.4;MAIT T-cell: 18.5;memory CD8 T-cell: 44.0;naive CD8 T-cell: 44.3;NK-cell: 50.8"	"Group enriched"	"Detected in many"	47	"NK-cells: 50.8;T-cells: 49.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB021896, HPA068877"	Enhanced		Supported	"Plasma membrane"		33000	33000	"Plasma membrane"		"CAB021896: , HPA068877: "	"unprognostic (3.34e-4)"	"unprognostic (2.65e-4)"	"unprognostic (3.25e-1)"	"unprognostic (2.59e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.01e-5)"	"unprognostic (5.61e-4)"	"unprognostic (1.00e-3)"	"unprognostic (1.33e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.28e-2)"	"unprognostic (2.10e-2)"	"unprognostic (6.56e-10)"	"unprognostic (1.24e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.59e-2)"	"unprognostic (7.08e-10)"	4.1	0.9	1.3	18.3	1.1	10.6	2.1	0.4	0.8	2.8	4.5	1.2	0.6	2.0	2.4	2.7	3.1	2.0	7.7	1.3	1.3	1.1	2.4	3.6	13.6	22.2	2.1	0.1	1.5	3.3	0.0	1.2	1.6	1.2	2.2	2.1	2.4	7.0	0.6	0.5	1.1	13.1	1.3	2.1	30.7	3.3	1.9	0.6	6.0	2.9	2.8	11.4	11.3	2.5	1.0	0.2	0.8	0.1	50.8	49.4	16.7	0.2	0.0	0.4	1.8	0.1	4.6	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	1.6	0.0	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.2	0.1	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.5	0.0	0.0	0.0	0.0	36.0	0.1	0.0	0.2	0.0	0.0	0.0	49.4	0.1	18.5	0.8	0.3	44.0	0.1	1.0	0.4	44.3	0.8	50.8	0.1	0.2	0.1	16.7	1.3	1.1	0.4	0.8	1.3	1.1	2.1	0.1	1.2	0.6
KMT2A	"ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1"	ENSG00000118058	"Lysine methyltransferase 2A"	Q03164	11	118436490-118526832	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017794, CAB024270, HPA044910"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB017794: , CAB024270: , HPA044910: "	"unprognostic (6.80e-2)"	"unprognostic (8.93e-2)"	"unprognostic (1.83e-1)"	"unprognostic (4.56e-1)"	"unprognostic (4.96e-2)"	"unprognostic (1.72e-3)"	"unprognostic (4.52e-3)"	"unprognostic (6.07e-2)"	"unprognostic (1.61e-1)"	"unprognostic (8.46e-2)"	"unprognostic (3.21e-1)"	"unprognostic (1.16e-1)"	"unprognostic (5.91e-3)"	"unprognostic (7.90e-2)"	"unprognostic (3.73e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.02e-1)"	14.4	11.3	17.7	17.0	19.2	28.6	16.8	43.8	21.2	17.3	14.6	19.8	18.1	8.5	21.8	17.1	10.6	15.7	14.1	10.2	17.3	13.4	13.1	9.3	15.3	19.6	16.6	18.7	35.6	16.8	28.9	21.8	10.2	15.4	15.6	12.4	14.4	14.2	19.2	11.1	16.8	14.2	15.2	12.1	15.7	12.3	7.9	23.4	16.6	16.6	7.8	19.4	18.8	24.6	6.7	3.5	8.3	2.0	6.5	5.3	0.8	11.9	5.5	14.9	11.2	9.1	10.9	4.4	5.4	7.8	5.7	6.6	11.1	8.7	14.7	11.1	7.9	10.4	15.8	5.9	11.3	16.2	6.1	28.8	5.1	6.0	5.1	17.2	5.6	5.2	6.1	12.4	16.7	8.8	18.7	12.6	7.1	9.3	11.4	10.1	9.0	8.2	8.7	14.3	4.9	8.4	9.0	12.3	8.0	13.5	4.4	2.8	7.6	5.8	13.0	9.8	8.8	7.1	9.6	3.7	2.8	9.9	3.7	12.7	5.8	8.3	2.0	4.6	5.3	1.3	4.3	6.2	4.8	4.6	0.8	6.7	4.9	4.8	1.3	6.5	1.4	3.5	3.9	0.8	17.7	19.2	43.8	21.2	17.3	13.4	16.6	18.7	15.4	23.4
KMT2B	"CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7"	ENSG00000272333	"Lysine methyltransferase 2B"	Q9UMN6	19	35718019-35738878	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Dystonia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA006487			Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA006487: AB_1080587"	"unprognostic (1.09e-2)"	"unprognostic (3.53e-2)"	"unprognostic (3.41e-2)"	"unprognostic (7.95e-2)"	"unprognostic (9.92e-2)"	"unprognostic (3.53e-3)"	"unprognostic (2.33e-2)"	"unprognostic (4.57e-2)"	"unprognostic (7.28e-2)"	"unprognostic (2.07e-2)"	"unprognostic (3.13e-3)"	"unprognostic (2.63e-3)"	"unprognostic (9.47e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.37e-1)"	"unprognostic (3.77e-2)"	"unprognostic (2.24e-2)"	10.2	9.3	11.4	14.2	13.1	18.4	10.4	23.9	11.4	10.0	12.0	14.2	12.9	13.8	13.0	7.1	11.4	11.6	12.6	7.5	11.0	5.3	9.9	8.9	10.6	14.7	14.7	6.8	15.3	19.6	10.8	13.3	9.3	11.2	12.1	5.6	13.8	14.7	10.0	13.3	19.9	12.3	12.2	12.4	15.8	12.1	21.5	14.9	14.1	14.9	7.0	14.2	12.4	14.2	0.4	0.7	3.2	0.7	2.1	0.7	0.2	11.3	19.2	8.9	9.7	4.6	4.5	9.3	5.5	4.0	5.6	4.3	12.8	5.8	10.1	8.7	4.6	7.5	8.0	4.7	2.5	15.0	8.9	18.2	9.0	6.4	4.5	11.1	20.9	6.1	6.4	5.7	6.3	5.5	15.2	12.7	3.6	11.6	9.4	9.6	8.2	6.8	14.8	5.8	5.5	3.1	10.1	10.1	8.1	8.4	13.6	5.8	8.3	11.8	7.6	11.3	12.2	7.5	11.7	17.5	10.7	8.1	6.1	10.3	7.8	1.0	0.7	0.6	0.7	0.4	0.4	0.3	0.2	0.3	0.2	0.4	0.3	0.4	3.2	2.1	0.3	0.7	0.2	0.2	11.4	13.1	23.9	11.4	11.0	5.3	14.7	6.8	11.2	14.9
KMT2C	"HALR, KIAA1506, MLL3"	ENSG00000055609	"Lysine methyltransferase 2C"	Q8NEZ4	7	152134922-152436005	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA074736			Approved	Nucleoplasm				Nucleoplasm		"HPA074736: "	"unprognostic (7.75e-2)"	"unprognostic (3.10e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.31e-1)"	"unprognostic (5.23e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.45e-1)"	"unprognostic (1.06e-1)"	"prognostic favourable (8.01e-6)"	"unprognostic (1.78e-1)"	"unprognostic (3.83e-1)"	"unprognostic (3.04e-2)"	"unprognostic (2.64e-1)"	13.9	12.6	11.7	16.7	18.6	29.7	14.5	24.8	14.1	18.4	12.6	15.5	21.4	9.7	20.2	20.6	14.4	12.8	12.7	10.8	13.4	9.5	10.3	11.4	13.0	12.1	17.7	9.4	18.8	18.4	18.8	18.9	38.0	12.6	14.0	11.8	12.6	15.8	22.9	30.3	25.2	13.1	13.6	16.0	14.6	14.9	13.6	19.6	22.6	16.9	9.3	16.8	17.8	31.6	5.6	3.5	16.1	3.9	5.5	2.9	0.6	9.5	4.8	9.0	9.5	16.2	9.8	10.5	5.0	3.8	4.0	4.9	9.1	5.8	15.2	7.3	9.1	5.5	9.6	7.3	6.7	9.6	4.9	9.0	7.2	6.3	7.9	15.3	11.1	8.2	10.1	5.7	7.6	5.7	14.5	13.2	8.7	13.3	11.0	13.9	5.4	4.8	7.4	8.1	7.9	6.9	9.9	13.1	10.3	8.2	14.7	5.4	4.8	12.5	7.2	6.7	3.5	7.1	7.1	13.8	6.7	16.4	8.7	12.5	6.8	8.8	3.5	4.3	2.1	2.2	2.9	5.6	1.7	1.7	1.7	3.8	2.7	1.8	16.1	5.5	3.9	3.5	1.3	0.6	11.7	18.6	24.8	14.1	13.4	9.5	17.7	9.4	12.6	19.6
KMT2D	"ALR, CAGL114, MLL2, MLL4, TNRC21"	ENSG00000167548	"Lysine methyltransferase 2D"	O14686	12	49018975-49059774	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 5.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA035977	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoplasm	"HPA035977: AB_10670673"	"unprognostic (8.33e-2)"	"unprognostic (1.49e-1)"	"unprognostic (9.14e-2)"	"unprognostic (2.52e-1)"	"unprognostic (8.07e-2)"	"unprognostic (6.91e-3)"	"unprognostic (7.35e-2)"	"unprognostic (2.29e-1)"	"unprognostic (3.57e-1)"	"unprognostic (5.14e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.68e-2)"	"unprognostic (7.10e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.20e-2)"	"unprognostic (7.60e-2)"	12.1	7.6	4.9	6.7	10.8	26.1	6.8	11.7	10.5	9.5	6.5	5.8	13.0	5.5	15.7	7.4	8.8	8.9	5.8	9.1	6.1	3.5	6.2	6.5	22.9	9.6	6.7	3.3	9.7	11.6	13.3	9.2	12.9	13.7	6.7	6.6	9.8	7.6	8.0	16.1	13.6	9.4	7.1	9.1	13.6	8.3	7.3	5.7	6.2	11.0	6.1	7.6	7.0	6.3	2.0	2.2	5.9	0.5	1.5	0.8	0.6	17.0	16.2	16.4	13.2	17.0	11.4	17.6	9.0	9.4	11.7	6.3	28.4	7.2	17.7	11.7	12.6	11.6	21.6	10.0	9.8	10.3	17.3	22.5	16.9	15.2	11.7	26.7	22.6	9.7	14.3	16.4	17.0	17.4	28.2	9.8	13.2	18.7	13.2	24.9	15.5	14.0	19.9	10.1	6.4	9.8	18.9	13.7	11.6	13.9	13.7	9.5	13.6	23.4	23.1	9.2	16.5	8.1	15.1	14.0	9.0	17.2	10.6	13.8	6.9	0.6	0.5	3.0	0.8	0.2	0.4	0.3	0.3	0.5	0.3	2.0	0.3	0.8	5.9	1.5	0.1	2.2	0.0	0.6	4.9	10.8	11.7	10.5	6.1	3.5	6.7	3.3	13.7	5.7
KNL1	"AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7"	ENSG00000137812	"Kinetochore scaffold 1"	Q8NG31	15	40594020-40664342	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"lymphoid tissue: 54.7;testis: 35.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"							"HPA026624, HPA049647"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies"				Nucleoplasm	"Nuclear bodies"	"HPA026624: AB_10601696, HPA049647: "	"unprognostic (5.35e-2)"	"unprognostic (1.01e-1)"	"unprognostic (5.59e-3)"	"unprognostic (4.22e-2)"	"unprognostic (1.59e-2)"	"unprognostic (5.66e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavourable (2.11e-4)"	"unprognostic (2.06e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.20e-4)"	"unprognostic (2.22e-2)"	"unprognostic (1.93e-12)"	"unprognostic (3.07e-2)"	"unprognostic (3.08e-1)"	"unprognostic (8.45e-2)"	"unprognostic (7.36e-2)"	0.7	0.5	0.3	7.1	0.4	5.4	0.7	0.3	0.3	0.6	4.0	0.1	0.0	1.5	0.4	0.8	3.9	0.4	0.9	0.5	0.4	0.4	0.9	1.0	1.3	4.7	0.3	0.0	0.5	0.5	0.0	0.4	2.8	0.1	0.5	1.5	0.0	0.8	0.0	0.4	0.8	3.9	0.5	0.4	3.3	0.8	35.6	0.0	54.7	0.5	4.1	3.7	0.7	0.9	2.9	1.2	0.7	0.5	0.7	2.5	0.0	10.8	5.6	11.4	8.2	0.3	1.7	5.1	12.7	5.1	10.0	8.4	6.8	4.4	7.2	4.0	5.5	13.6	10.8	5.9	10.6	12.5	2.9	21.2	9.6	2.0	0.0	16.2	10.7	0.3	0.2	6.7	4.2	8.5	13.5	12.1	11.6	3.7	13.8	3.2	5.6	5.9	12.6	16.3	3.6	1.5	9.6	9.9	4.6	11.0	6.2	1.3	6.7	4.9	7.8	11.6	10.3	13.3	7.0	4.6	15.8	14.1	4.7	11.0	11.0	0.4	0.2	0.1	0.1	0.1	0.0	2.9	1.1	0.1	1.2	2.2	0.0	0.7	0.7	0.7	0.5	0.1	2.5	0.0	0.3	0.4	0.3	0.3	0.4	0.4	0.3	0.0	0.1	0.0
KRAS	"KRAS1, KRAS2"	ENSG00000133703	"KRAS proto-oncogene, GTPase"	P01116	12	25204789-25250936	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins"			"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049830	Approved					5800000	5800000			"HPA049830: "	"unprognostic (2.24e-2)"	"unprognostic (2.16e-2)"	"unprognostic (4.86e-3)"	"unprognostic (1.08e-2)"	"unprognostic (7.39e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.47e-2)"	"unprognostic (3.74e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.39e-1)"	"prognostic unfavourable (3.59e-4)"	"unprognostic (6.42e-2)"	"prognostic favourable (2.75e-5)"	"unprognostic (1.95e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-2)"	"unprognostic (9.97e-2)"	11.7	9.9	14.4	15.5	19.5	24.1	10.6	21.1	25.6	10.3	26.2	7.3	7.9	16.1	11.3	7.7	25.1	10.1	13.9	9.3	13.6	16.6	14.0	17.9	14.9	15.1	11.6	15.8	13.1	13.6	12.7	9.8	15.7	21.1	12.1	28.1	9.8	16.2	9.8	10.0	14.0	23.7	17.2	11.3	15.7	23.6	7.8	9.5	18.5	11.1	10.6	16.3	16.8	14.3	10.0	7.1	20.8	18.9	9.4	13.8	5.0	7.2	7.4	16.6	9.4	6.2	8.4	33.3	7.4	9.4	7.8	9.3	25.7	16.8	16.8	4.5	12.9	8.0	19.4	8.1	14.8	11.4	6.7	15.8	7.9	6.3	6.5	14.8	12.1	7.8	11.1	9.4	8.4	11.3	11.2	8.0	11.5	6.2	20.4	22.5	36.4	3.0	17.6	17.6	24.1	11.5	12.9	5.1	14.2	8.9	11.7	8.9	13.0	10.7	13.0	8.8	11.6	16.4	9.2	7.0	11.8	18.2	6.7	8.7	6.3	20.8	7.8	12.4	11.9	14.4	7.5	10.0	10.4	13.0	7.1	8.6	13.8	12.1	19.0	9.4	18.9	7.1	6.7	5.0	14.4	19.5	21.1	25.6	13.6	16.6	11.6	15.8	21.1	9.5
KRT13	"CK13, K13, MGC161462, MGC3781"	ENSG00000171401	"Keratin 13"	P13646	17	41500981-41505705	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 1075.6;lymphoid tissue: 404.8;tongue: 499.8"	"Group enriched"	"Detected in some"	100	"A-431: 211.8;HaCaT: 141.5"	"Group enriched"	"Detected in many"	5	"cervical cancer: 899.2;head and neck cancer: 758.7;urothelial cancer: 504.9"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"neutrophil: 1.1"	"Lineage enriched"	"Detected in single"	12	"granulocytes: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000133, HPA030877, HPA069771"	Enhanced		Enhanced	"Intermediate filaments"		1100000000	1100000000	"Intermediate filaments"		"CAB000133: , HPA030877: , HPA069771: AB_2732141"	"unprognostic (1.45e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.19e-2)"	"unprognostic (9.30e-5)"	"unprognostic (7.30e-3)"		"unprognostic (1.95e-1)"	"unprognostic (1.77e-1)"	"unprognostic (5.81e-3)"	"prognostic unfavourable (1.02e-4)"	"unprognostic (3.16e-1)"	"prognostic unfavourable (1.45e-6)"	"unprognostic (1.80e-1)"	"unprognostic (2.76e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.33e-1)"	0.3	0.3	0.0	0.3	0.0	0.5	0.3	0.0	0.3	250.9	0.3	0.0	0.0	0.3	13.7	0.3	1075.6	0.3	0.6	0.5	0.0	0.0	0.3	0.3	0.3	0.3	0.0	0.0	0.3	0.3	0.3	0.0	0.3	0.0	2.4	0.3	0.1	134.9	0.4	0.4	0.3	0.3	1.7	0.0	0.3	0.3	0.4	0.0	0.6	0.3	499.8	404.8	14.9	222.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	211.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	141.5	0.0	0.0	0.0	0.1	0.0	0.3	1.7	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.1	0.1	0.7	0.2	0.5	0.4	0.0	0.0	0.0	0.6	0.0	0.5	0.4	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KRT14	"EBS3, EBS4"	ENSG00000186847	"Keratin 14"	P02533	17	41582279-41586921	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Ectodermal dysplasia, Epidermolysis bullosa, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"skin 1: 439.2;tongue: 363.5"	"Cell line enhanced"	"Detected in some"		"HaCaT: 259.8;HBEC3-KT: 128.1;hTCEpi: 160.3;hTERT-HME1: 52.4;U-2197: 45.2"	"Group enriched"	"Detected in many"	6	"cervical cancer: 1263.1;head and neck cancer: 5910.5;melanoma: 1277.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in some"			"CAB000134, HPA000452, HPA000539, HPA023040"	Enhanced		Enhanced	"Intermediate filaments"		2200000000	2200000000	"Intermediate filaments"		"CAB000134: , HPA000452: AB_1079177, HPA000539: , HPA023040: AB_1852201"	"prognostic favourable (2.66e-4)"	"unprognostic (1.64e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.02e-2)"		"unprognostic (2.03e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.00e-2)"	"unprognostic (5.74e-3)"	"unprognostic (1.49e-8)"	"unprognostic (8.91e-2)"	"unprognostic (2.00e-1)"	"unprognostic (8.80e-3)"	"unprognostic (1.22e-2)"	0.2	0.1	0.2	0.2	0.2	0.2	23.1	0.2	0.2	27.0	0.2	0.2	0.2	0.1	0.3	0.2	69.3	0.1	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	7.6	0.2	2.1	0.1	0.2	30.8	0.3	1.0	439.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	4.6	0.2	363.5	47.6	0.2	37.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	259.8	0.0	128.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	160.3	0.1	52.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	45.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
KRT15	"CK15, K15, K1CO"	ENSG00000171346	"Keratin 15"	P19012	17	41513743-41522529	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"breast: 37.4;esophagus: 115.3;skin 1: 119.3;vagina: 38.6"	"Group enriched"	"Detected in some"	10	"HaCaT: 120.2;hTCEpi: 92.9"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 178.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA023910, HPA024554"	Enhanced		Supported	"Nucleoplasm,Intermediate filaments"		580000000	580000000	"Intermediate filaments"	Nucleoplasm	"HPA023910: AB_1852205, HPA024554: AB_1852207"	"prognostic favourable (4.50e-4)"	"unprognostic (9.14e-2)"	"unprognostic (3.28e-2)"	"unprognostic (1.19e-3)"	"unprognostic (3.57e-2)"	"unprognostic (8.84e-2)"	"unprognostic (6.12e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-1)"	"unprognostic (8.65e-3)"	"unprognostic (9.91e-3)"	"unprognostic (2.09e-1)"	"unprognostic (2.24e-11)"	"unprognostic (6.91e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.33e-5)"	"unprognostic (5.35e-2)"	0.6	0.0	1.4	0.6	1.5	0.0	37.4	0.6	1.1	14.6	1.1	0.6	0.6	0.0	0.6	0.6	115.3	2.7	10.6	0.6	1.3	0.0	1.1	0.6	2.1	0.6	0.6	0.6	0.6	0.6	0.0	0.6	3.0	1.1	16.4	0.0	1.4	15.1	0.6	0.6	119.3	3.5	0.6	0.6	0.6	0.0	0.6	0.6	0.6	0.6	1.9	6.2	0.8	38.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	5.9	0.8	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.6	2.1	0.0	0.2	0.0	120.2	0.0	4.1	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.4	0.0	92.9	0.2	0.7	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.6	0.0	0.0	10.2	0.3	0.7	0.2	0.0	0.1	1.7	0.1	2.3	0.0	2.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.8	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.4	1.5	0.6	1.1	1.3	0.0	0.6	0.6	1.1	0.6
KRT17	PCHC1	ENSG00000128422	"Keratin 17"	Q04695	17	41619437-41624842	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Ectodermal dysplasia, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skin 1: 109.0;tongue: 144.0"	"Group enriched"	"Detected in some"	7	"hTCEpi: 638.7;SiHa: 265.9"	"Cancer enhanced"	"Detected in all"		"head and neck cancer: 3317.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"CAB000029, HPA000452, HPA000453, HPA000539, HPA045062"	Enhanced		Enhanced	"Intermediate filaments"		750000000	750000000	"Intermediate filaments"		"CAB000029: AB_2133155, HPA000452: AB_1079177, HPA000453: AB_1079176, HPA000539: , HPA045062: "	"prognostic favourable (4.44e-4)"	"unprognostic (1.43e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.65e-3)"	"unprognostic (4.46e-2)"	"unprognostic (4.34e-1)"	"unprognostic (4.36e-3)"	"unprognostic (1.32e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.29e-1)"	"unprognostic (7.86e-3)"	"unprognostic (1.53e-1)"	"prognostic unfavourable (5.74e-4)"	"unprognostic (1.82e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.20e-1)"	"unprognostic (3.89e-1)"	0.7	0.0	0.7	0.7	0.7	0.1	52.3	0.7	0.8	12.6	0.8	0.7	1.2	0.0	1.0	3.1	38.6	0.9	0.9	0.7	0.7	0.0	0.8	0.7	3.7	0.7	0.7	1.0	0.8	0.7	0.0	0.9	4.1	0.8	15.0	0.0	0.7	26.8	33.4	0.7	109.0	0.7	1.2	0.7	0.7	0.0	0.8	0.7	5.1	0.8	144.0	19.7	55.6	25.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	6.4	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	64.6	0.0	66.0	0.0	0.0	0.0	0.0	28.9	0.0	0.0	0.0	0.0	0.0	638.7	0.0	49.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	24.2	0.0	0.0	265.9	0.1	0.0	0.0	0.0	0.0	0.0	13.1	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.7	0.7	0.8	0.7	0.0	0.7	1.0	0.8	0.7
KRT18		ENSG00000111057	"Keratin 18"	P05783	12	52948871-52952901	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Host-virus interaction"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 268.7"	"Cell line enhanced"	"Detected in many"		"A549: 225.8;BEWO: 142.5;CACO-2: 248.3;CAPAN-2: 180.4;MCF7: 330.6;SK-BR-3: 182.8"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"pons and medulla: 10.0"	"Cell type enriched"	"Detected in many"	5	"basophil: 28.6"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 28.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB000008, CAB000030, HPA001605"	Enhanced		Supported	Cytosol		140000000	140000000	Cytosol		"CAB000008: , CAB000030: , HPA001605: "	"unprognostic (1.98e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.31e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.26e-3)"	"unprognostic (4.09e-3)"	"prognostic unfavourable (5.06e-4)"	"unprognostic (8.81e-2)"	"unprognostic (4.17e-1)"	"prognostic unfavourable (1.78e-4)"	"unprognostic (3.05e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.19e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.13e-2)"	23.3	4.8	1.0	31.0	1.1	0.0	24.1	2.9	1.2	28.6	45.4	1.3	66.3	35.0	6.6	55.3	22.4	21.7	147.4	6.8	1.1	2.5	61.9	181.0	39.6	2.8	1.2	1.0	13.7	162.9	8.2	39.8	268.7	10.0	29.3	57.0	14.1	121.1	49.9	1.3	6.5	83.6	3.9	1.4	4.4	36.0	9.5	0.8	4.2	83.4	10.8	20.9	21.5	10.8	4.1	1.0	28.6	0.1	1.0	5.9	1.6	75.7	225.8	0.0	0.3	0.0	0.0	142.5	11.5	14.0	14.9	4.2	248.3	180.4	0.0	32.1	12.5	18.5	3.1	87.6	9.0	0.0	5.3	0.7	36.9	68.3	38.6	0.0	0.0	0.5	8.2	13.0	18.0	15.9	18.2	0.0	0.0	330.6	0.1	1.3	18.4	17.1	0.1	0.0	8.6	72.7	45.7	2.6	0.1	18.7	182.8	0.7	96.5	0.2	5.0	0.2	17.4	0.2	2.5	0.0	0.2	0.1	0.0	0.0	1.4	28.6	0.1	1.1	0.2	0.1	1.1	2.1	2.3	0.6	1.0	4.1	5.9	2.1	1.5	1.0	0.0	0.0	0.2	1.6	1.0	1.1	2.9	1.2	1.1	2.5	1.2	1.0	10.0	0.8
KRT19	"CK19, K19, K1CS, MGC15366"	ENSG00000171345	"Keratin 19"	P08727	17	41523617-41528308	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 205.3;intestine: 184.9;placenta: 179.4"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 100.7;HBEC3-KT: 151.7;MCF7: 111.9;RT4: 161.1;SK-BR-3: 284.6;T-47d: 191.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	4	"NK-cell: 2.7"	"Lineage enriched"	"Detected in single"	4	"NK-cells: 2.7"	"Not detected"	"Not detected"							"CAB000031, HPA002465"	Enhanced		Supported	"Intermediate filaments"		330000000	330000000	"Intermediate filaments"		"CAB000031: AB_2234418, HPA002465: AB_1079179"	"unprognostic (1.09e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.86e-2)"	"unprognostic (1.59e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.80e-2)"	"unprognostic (3.14e-1)"	"unprognostic (4.86e-2)"	"prognostic unfavourable (6.82e-5)"	"unprognostic (1.90e-2)"	"prognostic unfavourable (2.98e-5)"	"unprognostic (3.52e-2)"	"unprognostic (2.14e-1)"	"unprognostic (3.08e-2)"	"unprognostic (2.35e-2)"	9.8	1.6	0.7	22.8	0.9	0.0	50.1	2.9	0.8	37.4	126.7	1.0	38.0	37.8	9.9	53.0	102.1	19.5	205.3	2.3	0.8	0.2	35.0	2.1	50.6	0.7	0.8	0.8	16.7	7.5	1.2	2.6	179.4	1.3	39.2	40.1	1.8	103.0	46.3	0.7	15.8	184.9	11.7	0.6	0.6	69.1	6.4	0.7	33.3	4.9	21.2	89.2	77.0	35.4	0.0	0.0	0.0	0.0	2.7	0.6	0.2	0.1	17.6	0.0	0.3	0.0	0.0	61.6	21.2	0.0	0.6	0.1	50.6	100.7	0.0	20.8	10.1	53.9	0.0	151.7	0.1	0.0	0.5	0.0	11.4	34.6	1.6	0.0	4.3	0.0	27.6	0.4	0.0	1.3	7.3	0.1	0.0	111.9	0.2	0.1	0.9	25.6	0.1	0.0	0.3	69.5	161.1	2.1	0.0	0.1	284.6	0.0	191.7	0.0	0.0	0.1	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.2	0.7	0.9	2.9	0.8	0.8	0.2	0.8	0.8	1.3	0.7
KRT4	"CK4, CYK4, K4"	ENSG00000170477	"Keratin 4"	P19013	12	52806549-52814551	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"esophagus: 637.8;lymphoid tissue: 403.6;tongue: 174.6"	"Group enriched"	"Detected in some"	30	"HaCaT: 94.2;SK-BR-3: 38.2"	"Group enriched"	"Detected in many"	5	"cervical cancer: 94.3;head and neck cancer: 151.8;stomach cancer: 73.1;urothelial cancer: 38.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002154, HPA034881"	Enhanced		Supported	"Intermediate filaments"		540000000	540000000	"Intermediate filaments"		"CAB002154: AB_563803, HPA034881: "	"unprognostic (4.04e-1)"	"unprognostic (3.22e-3)"	"unprognostic (5.16e-3)"	"unprognostic (8.52e-3)"		"unprognostic (1.20e-1)"		"unprognostic (2.64e-1)"	"unprognostic (1.84e-1)"	"prognostic unfavourable (3.26e-4)"	"unprognostic (2.85e-3)"	"unprognostic (2.84e-2)"	"unprognostic (2.58e-11)"	"unprognostic (1.64e-1)"	"unprognostic (6.97e-2)"	"unprognostic (1.16e-1)"	"prognostic unfavourable (6.26e-4)"	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	25.5	0.1	0.0	0.0	0.1	2.5	0.1	637.8	0.3	0.1	0.2	0.0	0.0	0.1	0.1	0.6	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	48.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.1	174.6	403.6	0.2	20.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	94.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KRT8	"CARD2, CK8, CYK8, K2C8, K8, KO"	ENSG00000170421	"Keratin 8"	P05787	12	52897187-52949954	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 102.9"	"Cell line enhanced"	"Detected in many"		"A549: 224.1;BEWO: 150.2;CACO-2: 278.9;CAPAN-2: 176.2;MCF7: 376.4;SK-BR-3: 191.3;T-47d: 160.9"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"pons and medulla: 13.7"	"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 4.9"	"Group enriched"	"Detected in many"	4	"dendritic cells: 4.9;granulocytes: 3.2;NK-cells: 1.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB000131, CAB001696, HPA049866"	Enhanced		Supported	"Intermediate filaments"		920000000	920000000	"Intermediate filaments"		"CAB000131: AB_2281144, CAB001696: , HPA049866: "	"unprognostic (5.72e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.49e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.76e-2)"	"unprognostic (4.86e-3)"	"unprognostic (3.10e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.92e-1)"	"unprognostic (4.58e-1)"	"prognostic unfavourable (1.51e-4)"	"unprognostic (8.99e-2)"	"unprognostic (2.08e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.18e-1)"	"unprognostic (3.68e-1)"	"unprognostic (1.19e-2)"	13.4	4.8	2.0	11.0	1.5	0.0	13.9	2.7	1.3	15.1	90.2	2.1	29.8	87.2	11.1	18.3	19.3	10.4	20.3	17.6	1.1	0.2	28.8	55.8	20.1	18.4	1.4	1.2	10.6	75.9	4.0	31.8	28.9	13.7	25.2	45.0	12.1	36.9	46.0	3.7	5.0	102.9	5.2	3.3	14.3	61.8	5.1	1.2	2.9	27.6	9.2	11.6	27.1	10.5	0.7	4.9	3.2	0.7	1.6	0.6	0.5	99.5	224.1	0.0	0.2	0.0	0.1	150.2	0.4	1.7	0.2	0.2	278.9	176.2	0.0	42.6	0.5	34.8	0.6	27.6	0.2	0.1	4.8	0.1	46.7	79.7	8.1	0.0	0.0	0.3	0.4	0.5	1.9	0.6	17.1	0.0	0.0	376.4	0.2	0.3	15.6	4.9	0.1	0.0	0.5	44.4	49.4	4.8	0.1	39.0	191.3	0.3	160.9	0.3	0.6	0.2	16.9	0.3	0.3	0.0	0.2	0.2	0.1	0.0	0.4	3.2	0.5	0.6	0.6	0.7	0.4	0.3	0.4	0.3	2.1	0.7	0.4	0.5	1.4	1.6	0.3	4.9	0.5	0.5	2.0	1.5	2.7	1.3	1.1	0.2	1.4	1.2	13.7	1.2
KTN1	"CG1, KIAA0004, KNT"	ENSG00000126777	"Kinectin 1"	Q86UP2	14	55559072-55701526	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003178, CAB015331, HPA017876"	Enhanced		Enhanced	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"CAB015331: , HPA003178: AB_1079218, HPA017876: AB_1852652"	"unprognostic (7.00e-3)"	"unprognostic (2.99e-2)"	"unprognostic (8.60e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.49e-1)"	"prognostic unfavourable (6.83e-5)"	"prognostic unfavourable (3.76e-4)"	"unprognostic (1.75e-1)"	"unprognostic (1.21e-2)"	"unprognostic (1.01e-1)"	"unprognostic (9.08e-2)"	"unprognostic (8.72e-2)"	"prognostic favourable (1.01e-6)"	"unprognostic (1.27e-1)"	"unprognostic (2.75e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.04e-1)"	26.5	27.5	30.8	18.9	37.3	9.5	44.2	30.8	35.2	22.7	28.8	15.8	23.4	13.0	18.8	30.8	26.1	16.8	18.1	36.1	32.2	25.3	33.1	31.8	21.2	16.9	39.3	24.5	23.1	22.8	48.3	54.7	21.3	49.5	26.9	28.7	13.1	21.4	24.0	101.9	41.4	20.1	40.5	51.9	22.1	18.9	40.9	42.0	14.5	33.3	37.9	17.9	32.7	39.7	35.6	58.3	27.0	15.5	19.6	24.0	4.8	40.2	27.9	20.9	22.7	28.8	27.6	30.3	32.9	26.5	20.7	18.4	18.6	50.2	31.1	47.1	33.8	75.5	25.5	28.7	35.0	52.2	14.0	22.0	46.2	35.2	27.3	32.2	17.8	25.7	26.3	25.5	44.3	33.9	21.4	18.2	39.7	31.5	27.6	19.1	16.1	41.6	22.0	54.9	14.8	51.9	63.4	25.7	21.5	52.2	24.0	28.9	24.9	20.6	47.8	42.3	54.3	21.7	30.9	8.3	11.1	23.2	49.5	18.9	23.4	27.0	14.8	14.6	19.6	13.1	18.7	28.3	23.2	22.1	14.2	35.6	24.0	20.6	9.4	19.6	15.5	58.3	14.8	4.8	30.8	37.3	30.8	35.2	32.2	25.3	39.3	24.5	49.5	42.0
LALBA	LYZL7	ENSG00000167531	"Lactalbumin alpha"	P00709	12	48567684-48570066	"Cancer-related genes, Predicted secreted proteins"	"Lactose biosynthesis"	"Milk protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	194	"breast: 217.7"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 1.5;MCF7: 1.3"	"Cancer enriched"	"Detected in single"	599	"breast cancer: 29.9"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB026343, HPA029855, HPA029856"	Enhanced				"Secreted in female reproductive system"					"CAB026343: , HPA029855: AB_2673222, HPA029856: AB_10671362"															"unprognostic (7.85e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	217.7	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
LAMB1	CLM	ENSG00000091136	"Laminin subunit beta 1"	P07942	7	107923799-108003255	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes, Lissencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 81.0;ASC TERT1: 106.9;HSkMC: 104.6;TIME: 77.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004056, HPA004132, CAB004256"	Enhanced				"Secreted to extracellular matrix"	140000000	140000000			"CAB004256: AB_627867, HPA004056: AB_1079226, HPA004132: AB_1079225"	"unprognostic (2.39e-1)"	"unprognostic (6.45e-3)"	"unprognostic (2.01e-1)"	"unprognostic (6.75e-2)"	"unprognostic (3.45e-3)"	"unprognostic (8.26e-2)"	"prognostic unfavourable (2.07e-4)"	"unprognostic (3.77e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.04e-2)"	"unprognostic (3.44e-1)"	"unprognostic (5.01e-2)"	"unprognostic (2.87e-2)"	"unprognostic (4.50e-3)"	"unprognostic (1.75e-1)"	"unprognostic (4.45e-2)"	"unprognostic (1.46e-1)"	47.3	9.9	5.4	11.8	9.9	0.0	36.4	7.0	5.7	20.3	29.4	1.9	9.3	13.2	31.8	16.8	20.5	18.5	21.2	36.2	2.5	1.4	36.9	6.8	39.4	18.2	3.1	3.9	16.5	20.1	3.3	10.9	57.5	6.9	25.1	17.8	20.4	10.4	13.4	15.8	13.8	24.2	27.0	4.6	28.5	20.3	13.3	2.6	6.7	31.8	7.8	5.5	28.2	20.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	17.7	10.7	0.5	81.0	106.9	42.2	14.8	22.4	8.3	9.0	37.2	21.7	0.0	21.4	24.2	5.4	3.0	17.9	6.6	0.0	3.2	0.7	7.3	15.6	54.6	0.0	0.8	104.6	6.8	21.3	24.6	56.4	2.2	0.0	17.7	4.4	0.0	0.0	6.3	12.8	0.1	7.5	0.0	44.2	12.6	3.8	21.6	10.4	14.7	10.0	4.9	0.1	77.4	23.9	6.9	8.1	17.6	0.0	0.0	0.0	12.2	0.0	44.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	9.9	7.0	5.7	2.5	1.4	3.1	3.9	6.9	2.6
LAMC1	LAMB2	ENSG00000135862	"Laminin subunit gamma 1"	P11047	1	183023460-183145592	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 167.8;ASC TERT1: 92.4;HSkMC: 104.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"memory B-cell: 1.1;naive B-cell: 3.2;plasmacytoid DC: 1.3"	"Group enriched"	"Detected in many"	15	"B-cells: 3.2;dendritic cells: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001908, HPA001909, CAB004486, CAB078163"	Enhanced		Approved	"Endoplasmic reticulum,Plasma membrane"	"Secreted to extracellular matrix"	90000000	90000000	"Endoplasmic reticulum, Plasma membrane"		"CAB004486: AB_627870, CAB078163: , HPA001908: AB_1079229, HPA001909: AB_1079230"	"unprognostic (1.46e-1)"	"unprognostic (1.05e-2)"	"unprognostic (8.30e-2)"	"unprognostic (8.84e-3)"	"unprognostic (3.75e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.54e-2)"	"unprognostic (1.38e-2)"	"unprognostic (2.71e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.88e-3)"	"unprognostic (1.10e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.54e-1)"	"prognostic unfavourable (8.85e-5)"	49.0	6.8	2.9	11.3	4.0	0.2	51.5	5.9	3.4	30.4	27.7	2.8	12.8	4.9	30.5	28.7	31.5	21.5	25.9	39.5	3.4	2.0	10.0	6.8	22.5	10.6	3.9	2.7	22.7	9.8	7.4	4.1	73.1	3.5	23.9	11.4	11.7	11.6	17.3	32.2	15.6	17.6	41.3	3.0	4.7	22.3	16.1	2.7	3.5	21.7	16.4	7.3	40.2	37.6	3.2	1.3	0.0	0.1	0.0	0.0	0.2	5.1	8.4	27.7	7.8	167.8	92.4	42.0	38.0	38.2	15.3	9.1	24.9	5.9	1.8	17.6	18.2	12.9	5.2	10.0	11.8	0.0	5.3	0.0	7.6	9.0	26.4	1.6	0.9	104.0	5.4	18.3	14.5	26.7	0.0	5.7	18.6	2.2	0.0	1.7	11.2	1.6	1.3	23.4	0.9	24.8	13.7	1.8	5.2	10.0	0.0	9.7	2.1	4.3	49.2	18.8	7.4	17.3	9.5	2.2	0.0	1.2	15.5	1.2	18.1	0.0	0.1	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.2	2.9	4.0	5.9	3.4	3.4	2.0	3.9	2.7	3.5	2.7
LASP1	"Lasp-1, MLN50"	ENSG00000002834	"LIM and SH3 protein 1"	Q14847	17	38869859-38921770	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Transport"	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 124.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012072, CAB022049"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"		26000000	26000000	"Plasma membrane, Cytosol"	"Focal adhesion sites"	"CAB022049: , HPA012072: AB_1852714"	"unprognostic (1.23e-1)"	"unprognostic (2.09e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavourable (4.57e-4)"	"unprognostic (1.47e-1)"	"unprognostic (3.03e-2)"	"prognostic unfavourable (2.41e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-1)"	"unprognostic (9.60e-2)"	"unprognostic (9.87e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.65e-3)"	"unprognostic (1.29e-3)"	"unprognostic (3.95e-2)"	"unprognostic (1.60e-3)"	"unprognostic (4.53e-2)"	51.2	20.0	23.8	40.3	22.4	45.4	35.5	15.5	25.7	23.6	57.4	16.3	18.7	54.4	23.4	24.1	22.4	20.8	48.3	15.2	18.4	23.3	33.1	47.5	33.3	44.2	20.0	14.3	28.4	30.1	10.1	17.6	40.0	16.1	18.9	38.6	24.2	22.4	24.1	10.7	18.3	124.5	21.3	12.2	43.1	39.5	13.9	12.9	40.5	18.3	18.7	33.7	22.0	28.3	6.4	13.9	34.0	19.9	17.3	16.5	13.1	34.8	72.7	21.3	18.8	31.3	34.0	36.7	43.9	42.9	46.3	34.0	21.7	38.0	15.9	36.7	67.8	55.6	9.6	33.4	40.5	11.6	5.2	7.6	21.0	37.7	29.7	17.5	23.1	30.1	11.7	39.2	11.1	31.0	12.9	5.3	64.3	11.5	20.8	27.0	10.6	18.2	11.8	11.3	20.1	56.8	30.7	3.2	7.8	26.1	27.4	22.7	43.3	21.4	54.1	27.8	40.5	32.4	26.6	13.7	18.1	12.3	29.3	15.8	33.4	9.9	14.8	16.8	16.5	17.1	11.3	6.4	8.4	11.0	13.9	6.3	7.2	10.9	34.0	17.3	19.9	10.7	10.7	13.1	23.8	22.4	15.5	25.7	18.4	23.3	20.0	14.3	16.1	12.9
LCK		ENSG00000182866	"LCK proto-oncogene, Src family tyrosine kinase"	P06239	1	32251239-32286165	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 112.2;lymphoid tissue: 153.0"	"Group enriched"	"Detected in some"	6	"MOLT-4: 98.9;U-698: 57.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	14	"gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2"	"Group enriched"	"Detected in many"	13	"NK-cells: 42.8;T-cells: 112.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003494, CAB003816"	Enhanced		Approved	"Golgi apparatus"				"Golgi apparatus"		"CAB003816: AB_562158, HPA003494: AB_1852751"	"unprognostic (6.38e-3)"	"unprognostic (5.45e-3)"	"unprognostic (8.39e-2)"	"prognostic favourable (2.96e-6)"	"unprognostic (2.20e-2)"	"prognostic favourable (2.91e-4)"	"unprognostic (4.78e-3)"	"unprognostic (1.33e-2)"	"prognostic favourable (5.65e-5)"	"unprognostic (3.07e-2)"	"unprognostic (3.80e-2)"	"unprognostic (2.83e-1)"	"prognostic unfavourable (2.60e-5)"	"unprognostic (8.15e-2)"	"unprognostic (4.05e-2)"	"unprognostic (7.39e-2)"	"unprognostic (1.17e-2)"	2.6	0.7	0.4	28.2	0.5	3.8	1.3	0.3	0.5	1.7	3.9	0.5	0.9	2.2	1.1	4.5	2.3	1.6	3.8	1.0	0.4	0.4	3.0	2.3	6.6	34.9	0.9	0.5	1.2	0.8	0.0	0.8	0.7	0.6	2.2	1.9	1.3	8.4	1.3	0.9	1.0	16.5	0.7	1.0	28.9	3.5	0.7	0.5	153.0	2.9	1.5	27.1	5.8	2.1	6.1	0.5	2.5	0.3	42.8	112.2	109.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	12.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	98.9	0.0	1.1	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	57.0	0.0	0.0	0.0	0.6	0.3	0.4	83.4	0.3	77.5	4.0	86.1	90.2	0.3	6.1	97.0	91.3	2.5	42.8	0.3	0.5	112.2	109.3	0.4	0.5	0.3	0.5	0.4	0.4	0.9	0.5	0.6	0.5
LCN1	"MGC71975, PMFA, TLC, TP, VEGP"	ENSG00000160349	"Lipocalin 1"	P31025	9	135521438-135526532	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Sensory transduction, Taste, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"tongue: 204.2"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.3;U-87 MG: 2.0"	"Cancer enhanced"	"Detected in some"		"ovarian cancer: 3.1"	"Region enhanced"	"Detected in single"		"hippocampal formation: 2.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"								"Secreted in other tissues"	20000000	20000000				"unprognostic (5.50e-3)"		"unprognostic (1.10e-1)"	"unprognostic (7.12e-2)"	"unprognostic (3.99e-1)"	"unprognostic (1.08e-2)"		"unprognostic (1.11e-4)"	"unprognostic (1.22e-1)"	"unprognostic (7.84e-2)"	"unprognostic (9.47e-2)"		"unprognostic (3.94e-8)"	"unprognostic (2.07e-3)"	"unprognostic (3.03e-2)"		"unprognostic (5.83e-2)"	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.1	0.0	16.8	3.3	0.0	0.7	2.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.3	0.0	2.2	0.4	0.0	0.1	0.0	0.0	0.4	15.8	0.6	0.0	0.0	0.0	0.0	0.2	0.1	0.6	0.0	0.0	0.0	204.2	33.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.9	0.0	0.0	2.3	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.6	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	0.0	0.0	0.3	0.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	2.0	0.0	0.1	0.0	0.0	0.0
LCP1	"CP64, L-PLASTIN, LC64P, PLS2"	ENSG00000136167	"Lymphocyte cytosolic protein 1"	P13796	13	46125920-46211871	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 188.6;lymphoid tissue: 118.2"	"Cell line enhanced"	"Detected in many"		"Daudi: 82.6;HDLM-2: 75.5;HL-60: 80.2;HMC-1: 85.1;THP-1: 74.8;U-698: 106.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019493, CAB020673"	Enhanced		Approved	"Plasma membrane,Actin filaments,Cytosol"		2200000000	2200000000	"Plasma membrane, Cytosol"	"Actin filaments"	"CAB020673: , HPA019493: AB_1855457"	"unprognostic (2.79e-2)"	"unprognostic (8.20e-3)"	"unprognostic (1.19e-2)"	"unprognostic (3.95e-3)"	"unprognostic (1.19e-1)"	"unprognostic (2.84e-2)"	"unprognostic (2.70e-1)"	"unprognostic (4.99e-2)"	"unprognostic (6.70e-3)"	"unprognostic (2.54e-1)"	"unprognostic (5.47e-2)"	"unprognostic (3.63e-1)"	"unprognostic (3.32e-3)"	"unprognostic (2.51e-1)"	"unprognostic (1.02e-1)"	"unprognostic (7.50e-2)"	"unprognostic (2.92e-1)"	57.1	10.0	5.6	44.3	9.4	71.2	8.7	3.9	4.6	3.6	6.2	4.5	5.0	4.5	5.3	43.1	6.2	8.3	8.9	5.5	4.3	3.8	7.2	12.2	33.7	59.1	12.0	1.0	5.7	3.9	0.1	2.8	24.7	7.7	21.5	8.1	5.5	9.5	2.5	3.5	6.8	21.7	6.5	11.9	112.9	6.1	8.2	9.2	118.2	4.5	4.1	68.7	14.0	7.1	25.4	79.3	133.5	127.6	43.2	67.2	188.6	3.3	0.0	0.1	0.0	0.0	0.0	40.1	0.0	0.1	0.3	0.2	22.1	0.1	82.6	17.6	0.0	0.1	0.0	0.0	0.3	75.5	19.6	17.8	0.0	0.0	0.0	80.2	85.1	0.2	0.0	0.1	0.1	0.0	9.3	55.0	0.0	0.1	56.8	55.5	0.0	0.8	42.3	0.1	59.0	0.0	22.8	0.1	0.7	0.1	8.8	0.6	0.4	74.8	0.2	2.1	1.3	0.1	2.4	13.1	27.3	106.3	1.6	48.9	0.3	57.1	96.6	54.3	67.2	127.6	60.8	25.4	40.4	55.5	79.3	18.3	25.2	42.3	133.5	43.2	118.1	20.8	40.5	188.6	5.6	9.4	3.9	4.6	4.3	3.8	12.0	1.0	7.7	9.2
LCTL	"FLJ33279, KLG, KLPH"	ENSG00000188501	"Lactase like"	Q6UWM7	15	66547179-66565979	"Cancer-related genes, Predicted membrane proteins"	"Sensory transduction, Vision"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 10.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 6.4;NTERA-2: 5.9;U-2 OS: 16.6;U-251 MG: 7.0"	"Group enriched"	"Detected in some"	5	"glioma: 1.5;melanoma: 0.6"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.9"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA071640			Approved	"Endoplasmic reticulum,Plasma membrane"				"Plasma membrane"	"Endoplasmic reticulum"	"HPA071640: "	"unprognostic (4.60e-2)"	"unprognostic (5.46e-2)"	"unprognostic (8.70e-2)"	"unprognostic (1.56e-2)"	"unprognostic (3.22e-3)"	"unprognostic (3.53e-2)"	"unprognostic (6.67e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.59e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.47e-1)"	"unprognostic (4.51e-3)"	"unprognostic (4.44e-16)"	"unprognostic (6.06e-2)"	"unprognostic (3.39e-1)"	"unprognostic (5.48e-2)"	"unprognostic (1.39e-1)"	0.4	0.7	6.0	0.9	4.3	3.1	0.4	0.7	3.1	0.4	0.5	3.1	0.0	1.4	0.8	0.9	0.7	0.3	1.0	0.4	3.3	1.2	0.4	0.4	0.4	1.0	5.3	3.1	0.6	0.7	0.2	0.4	0.3	4.9	0.4	0.3	1.1	0.6	0.3	3.0	2.6	0.7	0.4	10.4	0.8	0.7	1.5	2.3	0.0	0.5	0.0	0.2	0.3	0.3	0.9	0.6	3.9	0.7	1.0	0.5	0.2	0.3	0.3	3.2	0.3	0.1	0.1	0.8	0.8	0.0	0.1	0.4	0.4	0.4	0.5	6.4	0.2	0.7	0.0	0.0	0.2	0.2	0.2	0.7	1.0	1.6	0.0	0.2	0.4	0.4	0.0	0.3	0.0	0.0	0.4	0.4	0.2	0.1	0.3	0.4	5.9	0.1	0.2	3.5	0.3	0.0	0.4	0.4	0.3	0.1	0.3	1.8	0.4	0.5	0.4	1.7	16.6	0.6	7.0	0.2	0.2	0.2	2.2	0.7	3.0	1.6	0.7	0.5	0.5	0.4	0.3	0.4	0.5	0.3	0.2	0.9	0.5	0.4	3.9	1.0	0.4	0.6	0.5	0.2	6.0	4.3	0.7	2.7	3.3	1.2	5.3	3.1	4.9	2.3
LDHA		ENSG00000134333	"Lactate dehydrogenase A"	P00338	11	18394388-18408425	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glycogen storage disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 249.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB015336, CAB069404"	Uncertain		Supported	Vesicles,Cytosol		300000000	300000000	Cytosol	Vesicles	"CAB015336: AB_2134947, CAB069404: "	"unprognostic (8.83e-2)"	"prognostic unfavourable (2.78e-5)"	"unprognostic (3.81e-2)"	"unprognostic (1.73e-1)"	"unprognostic (3.43e-3)"	"unprognostic (4.66e-3)"	"prognostic unfavourable (3.26e-8)"	"prognostic unfavourable (2.27e-6)"	"unprognostic (1.08e-1)"	"unprognostic (1.88e-2)"	"prognostic unfavourable (8.09e-6)"	"unprognostic (1.76e-2)"	"prognostic unfavourable (9.69e-9)"	"unprognostic (4.15e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.05e-2)"	84.2	56.4	24.5	52.6	32.5	64.0	56.0	22.3	40.2	38.1	53.5	13.5	9.1	60.5	24.9	36.2	77.7	29.0	31.6	59.4	24.4	33.0	100.1	249.1	37.1	59.4	29.7	25.7	49.7	34.1	10.5	16.4	49.7	44.3	33.3	51.2	45.9	46.3	37.0	199.6	70.2	128.3	50.7	35.5	45.0	31.2	25.9	23.9	45.0	56.4	90.6	60.1	81.9	44.8	27.6	76.5	29.1	61.2	32.8	52.2	72.1	131.7	82.0	3.1	46.2	72.2	49.3	44.0	127.5	135.5	112.0	166.7	36.6	21.7	99.7	41.9	128.8	106.6	82.0	195.4	242.9	34.0	48.5	34.5	74.9	62.8	17.8	85.1	25.9	49.2	90.1	44.0	44.1	66.1	48.6	48.0	131.1	34.9	70.0	53.9	19.8	102.6	45.4	32.7	83.5	178.0	30.6	24.6	30.4	69.1	57.0	23.6	26.8	20.3	59.5	140.3	50.9	122.1	1.5	38.2	55.9	95.9	200.8	44.1	47.2	28.9	53.1	29.1	38.1	61.2	42.6	27.6	50.2	40.1	76.5	19.2	32.8	33.3	18.1	32.8	59.5	25.8	52.2	72.1	24.5	32.5	22.3	40.2	24.4	33.0	29.7	25.7	44.3	23.9
LEF1	"TCF10, TCF1ALPHA, TCF7L3"	ENSG00000138795	"Lymphoid enhancer binding factor 1"	Q9UJU2	4	108047545-108168956	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 231.5"	"Group enriched"	"Detected in some"	5	"MOLT-4: 103.2;REH: 79.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 42.2"	"Lineage enriched"	"Detected in many"	5	"T-cells: 42.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002087, CAB019405"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"CAB019405: AB_823558, HPA002087: AB_1079245"	"unprognostic (1.03e-3)"	"unprognostic (7.36e-3)"	"unprognostic (2.97e-2)"	"prognostic favourable (1.37e-5)"	"unprognostic (9.08e-2)"	"unprognostic (5.24e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.77e-1)"	"unprognostic (5.21e-2)"	"unprognostic (9.99e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (2.47e-6)"	"unprognostic (1.12e-1)"	"unprognostic (5.22e-2)"	"unprognostic (7.88e-2)"	"unprognostic (8.91e-2)"	0.9	13.5	3.5	9.3	5.4	7.6	2.0	1.6	3.4	3.6	1.0	2.9	0.8	0.4	6.0	3.5	3.4	5.0	2.8	0.5	4.7	5.2	2.7	0.3	2.4	25.3	4.9	1.9	1.8	0.8	0.0	1.1	7.8	3.1	2.8	1.0	1.6	3.1	0.7	0.5	2.4	3.9	2.9	4.4	7.0	0.9	8.2	2.3	231.5	2.7	1.3	20.6	4.8	3.2	0.3	0.1	0.5	0.0	8.9	42.2	9.5	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	1.3	0.3	0.8	4.5	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.6	0.0	3.2	1.2	0.0	0.0	0.0	4.0	0.6	0.0	0.1	0.0	0.1	0.0	2.3	0.0	0.5	0.1	103.2	0.0	0.3	0.2	79.7	1.5	0.0	0.4	0.2	0.5	0.9	0.0	0.0	15.2	0.4	0.0	0.0	2.2	1.8	0.0	2.6	6.7	2.8	18.3	1.3	0.0	8.8	0.0	0.0	0.0	2.6	0.0	0.5	0.1	19.7	8.8	0.0	0.3	42.2	29.2	0.5	8.9	0.0	0.1	25.7	9.5	3.5	5.4	1.6	3.4	4.7	5.2	4.9	1.9	3.1	2.3
LEP	"OB, OBS"	ENSG00000174697	Leptin	P41159	7	128241284-128257628	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"			"Cancer-related genes, Diabetes mellitus, Disease mutation, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	15	"adipose tissue: 85.2;breast: 63.7;placenta: 24.3"	"Group enriched"	"Detected in some"	9	"BEWO: 6.8;HSkMC: 2.8"	"Cancer enhanced"	"Detected in some"		"breast cancer: 1.6"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 3.8"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 3.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			CAB010490	Approved				"Secreted to blood"	26000000	26000000			"CAB010490: AB_2296951"	"unprognostic (8.19e-3)"	"unprognostic (5.33e-1)"	"unprognostic (1.60e-4)"	"unprognostic (1.19e-1)"	"unprognostic (7.99e-3)"	"unprognostic (1.83e-1)"		"unprognostic (6.56e-3)"	"unprognostic (1.98e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.45e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.02e-3)"	"unprognostic (2.83e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.23e-2)"	"unprognostic (6.84e-2)"	85.2	0.3	0.0	1.5	0.0	0.0	63.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.7	0.0	0.0	0.1	0.0	0.4	2.0	0.0	0.0	0.1	0.7	0.0	0.0	24.3	0.0	0.0	0.1	0.0	0.4	0.0	0.6	1.1	0.4	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.0	1.5	2.1	0.4	0.4	3.8	0.5	0.5	0.3	0.2	0.0	0.2	0.2	0.4	0.3	0.0	6.8	0.1	0.0	0.0	0.0	0.0	0.2	0.4	0.2	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.1	0.3	2.8	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.4	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.0	0.3	0.2	0.3	0.2	0.4	0.1	0.3	0.1	0.0	0.2	0.3	0.5	0.2	0.2	0.1	0.3	0.4	0.2	0.4	0.9	0.5	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.1	0.4	0.2	0.3	3.8	0.5	0.4	0.4	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LEPR	"CD295, OBR"	ENSG00000116678	"Leptin receptor"	P48357	1	65420652-65641559	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 82.8"	"Cell line enhanced"	"Detected in many"		"K-562: 46.1;RPTEC TERT1: 22.3"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 13.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 6.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			HPA030899	Approved	Supported			"Secreted to blood"	8300000	8300000			"HPA030899: AB_10610003"	"unprognostic (1.59e-2)"	"unprognostic (1.09e-3)"	"unprognostic (3.09e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.59e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.41e-1)"	"unprognostic (7.53e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.27e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.73e-1)"	15.9	5.5	3.8	3.7	4.3	3.3	23.5	2.5	3.9	15.0	9.2	5.6	5.4	3.2	20.6	7.3	10.9	11.7	10.1	9.2	4.3	4.9	14.6	82.8	20.3	9.0	4.9	3.3	18.4	16.7	3.9	13.1	12.8	8.2	10.8	4.1	18.1	12.0	5.7	5.6	10.2	7.3	12.9	7.0	6.4	11.9	6.6	3.1	1.9	13.1	11.2	6.9	13.6	8.6	0.6	1.8	6.9	1.9	1.1	2.3	1.8	1.3	0.8	1.1	1.2	5.0	4.6	3.8	5.9	3.4	2.0	1.9	0.6	3.2	0.5	4.4	7.4	1.1	0.9	5.1	5.5	6.9	1.5	7.7	3.5	0.1	3.0	0.5	0.6	13.0	3.0	1.2	4.6	5.8	46.1	0.9	9.5	0.3	0.6	0.1	1.8	0.1	0.1	0.9	0.3	22.3	0.6	0.7	11.3	1.4	0.6	1.6	2.1	2.0	2.2	2.1	4.3	0.4	3.2	1.3	0.8	0.2	4.4	2.2	2.0	6.9	1.9	2.8	1.3	1.5	1.3	0.6	1.1	1.1	1.8	0.3	0.9	1.5	1.1	1.1	1.7	1.2	2.3	1.8	3.8	4.3	2.5	3.9	4.3	4.9	4.9	3.3	8.2	3.1
LGALS3	"GALIG, LGALS2, MAC-2"	ENSG00000131981	"Galectin 3"	P17931	14	55124110-55145413	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Differentiation, Immunity, Innate immunity, mRNA processing, mRNA splicing"	"IgE-binding protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 93.8;CAPAN-2: 74.5;SK-MEL-30: 175.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 67.4;intermediate monocyte: 55.4;myeloid DC: 41.7;non-classical monocyte: 44.2;T-reg: 25.9"	"Group enriched"	"Detected in all"	12	"dendritic cells: 41.7;monocytes: 67.4;T-cells: 25.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"HPA003162, CAB005191"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	2300000	2300000	"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB005191: AB_2136784, HPA003162: AB_1078937"	"unprognostic (1.42e-1)"	"unprognostic (9.79e-2)"	"unprognostic (1.14e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.46e-2)"	"unprognostic (3.34e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.00e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.08e-3)"	"unprognostic (5.97e-2)"	"unprognostic (8.52e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.96e-2)"	"unprognostic (2.65e-3)"	"unprognostic (7.60e-3)"	95.7	11.0	10.4	50.9	13.6	29.8	53.2	6.5	11.7	54.1	127.1	6.1	42.4	75.7	50.3	30.7	76.1	26.1	83.9	42.3	8.4	5.7	19.9	3.9	65.5	16.6	8.5	9.4	58.9	24.2	0.5	11.0	78.7	5.5	51.7	93.7	25.7	78.3	51.7	31.3	76.1	182.4	48.2	8.7	11.1	36.9	20.4	5.7	5.5	18.0	65.7	41.7	41.1	44.4	1.3	41.7	3.6	67.4	2.5	25.9	37.2	22.4	7.2	0.2	0.1	46.8	93.8	27.4	18.0	37.9	5.0	8.9	15.5	74.5	0.0	9.5	20.9	22.5	0.4	18.8	2.8	26.6	0.3	0.0	8.0	7.1	35.5	0.0	0.0	29.3	28.7	5.7	12.1	7.8	0.1	21.7	11.3	15.1	0.0	5.4	0.4	20.2	0.0	0.9	1.6	46.8	30.0	0.6	1.7	42.1	0.0	175.1	18.5	2.4	14.2	23.7	3.3	8.8	0.3	12.1	38.3	0.1	34.1	1.4	2.5	1.7	67.4	3.4	1.8	55.4	11.4	1.3	6.8	5.1	41.7	0.4	0.3	1.0	3.6	2.5	44.2	1.1	25.9	37.2	10.4	13.6	6.5	11.7	8.4	5.7	8.5	9.4	5.5	5.7
LGALS3BP	"90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B"	ENSG00000108679	"Galectin 3 binding protein"	Q08380	17	78971238-78980109	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 75.9;SK-BR-3: 172.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 30.2"	"Group enriched"	"Detected in all"	6	"monocytes: 10.6;T-cells: 30.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000410, HPA000554"	Uncertain				"Secreted to blood"	11000000000	11000000000			"HPA000410: , HPA000554: AB_1079246"	"unprognostic (1.23e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.22e-2)"	"unprognostic (9.63e-3)"	"unprognostic (1.62e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.12e-2)"	"unprognostic (1.57e-2)"	"unprognostic (4.55e-1)"	"unprognostic (1.40e-1)"	"prognostic unfavourable (1.07e-6)"	"unprognostic (1.58e-1)"	"unprognostic (1.65e-2)"	"unprognostic (2.53e-1)"	"unprognostic (5.43e-2)"	34.8	60.8	10.0	18.7	16.2	9.0	28.4	3.7	21.4	36.4	40.9	49.8	32.9	61.9	31.9	43.8	34.2	32.2	85.0	73.4	12.9	16.5	27.9	23.6	33.7	11.2	28.7	10.1	45.9	17.2	18.6	36.7	43.1	31.6	39.9	16.2	35.0	100.6	39.8	5.0	9.3	56.5	20.0	43.6	17.3	62.1	29.7	20.8	25.3	37.1	21.3	21.3	30.4	30.8	2.0	3.1	2.0	10.6	3.3	30.2	10.0	41.7	26.2	0.6	0.9	13.1	15.5	12.8	5.7	3.8	30.5	60.4	10.6	75.9	0.2	36.4	2.7	17.7	4.4	16.4	0.8	0.1	31.4	3.2	22.7	42.6	31.5	0.0	2.7	26.0	9.3	16.1	1.1	0.8	0.3	0.1	6.7	6.0	11.8	0.5	1.2	16.7	8.4	18.3	0.4	11.4	36.3	21.2	24.2	5.1	172.9	67.9	5.0	1.4	1.5	23.5	16.1	0.5	19.2	0.0	0.2	0.2	29.9	8.3	22.4	0.3	7.5	2.0	5.2	10.6	10.8	2.0	18.6	7.6	3.1	1.1	30.2	14.0	0.6	3.3	4.9	0.2	10.0	10.0	10.0	16.2	3.7	21.4	12.9	16.5	28.7	10.1	31.6	20.8
LGALS4	GAL4	ENSG00000171747	"Galectin 4"	P56470	19	38801671-38813364	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"gallbladder: 157.1;intestine: 326.8;lymphoid tissue: 83.5"	"Cell line enhanced"	"Detected in some"		"CACO-2: 3.0;NB-4: 2.6;RT4: 6.9;SH-SY5Y: 2.5"	"Group enriched"	"Detected in many"	21	"colorectal cancer: 450.7;liver cancer: 133.6;pancreatic cancer: 213.7;stomach cancer: 190.0"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	8	"basophil: 1.7"	"Lineage enriched"	"Detected in single"	8	"granulocytes: 1.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"CAB025653, HPA031184, HPA031185, HPA031186"	Enhanced		Uncertain	"Plasma membrane"		92000	92000	"Plasma membrane"		"CAB025653: , HPA031184: AB_2673776, HPA031185: AB_2673777, HPA031186: AB_2673778"	"unprognostic (1.11e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.57e-3)"	"unprognostic (7.88e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.61e-2)"	"unprognostic (5.01e-2)"	"unprognostic (5.34e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.58e-2)"	"unprognostic (3.80e-2)"	"unprognostic (1.48e-2)"	"prognostic unfavourable (2.28e-4)"	"unprognostic (1.69e-1)"	"unprognostic (3.38e-1)"	"unprognostic (9.71e-2)"	"prognostic favourable (3.21e-4)"	0.3	0.2	0.2	83.5	0.2	0.0	0.3	0.3	0.2	0.3	190.6	0.3	0.3	65.5	0.3	0.5	0.6	0.5	157.1	0.2	0.2	0.2	0.4	20.3	1.5	0.2	0.2	0.2	0.3	8.3	0.0	0.2	0.2	0.2	0.8	75.8	0.3	0.3	0.4	0.3	0.3	326.8	4.9	0.2	0.6	10.5	0.2	0.2	0.3	0.4	0.3	0.2	2.7	0.3	0.0	0.0	1.7	0.0	0.0	0.2	0.0	0.1	0.6	0.2	0.0	0.7	0.1	2.1	0.0	0.0	0.1	0.1	3.0	0.5	0.5	0.4	0.2	0.0	0.0	0.0	0.0	0.7	0.1	0.5	0.3	0.0	0.3	0.0	0.3	0.0	2.1	0.0	0.0	0.1	0.1	0.2	0.0	0.6	0.3	2.6	0.0	0.0	0.3	0.2	2.1	0.2	6.9	0.3	2.5	0.2	0.2	0.1	0.4	2.3	0.0	0.0	0.6	1.7	0.1	0.7	0.4	0.2	0.0	0.2	0.3	1.7	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
LGI1	"EPITEMPIN, EPT, ETL1, IB1099"	ENSG00000108231	"Leucine rich glioma inactivated 1"	O95970	10	93757809-93806272	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Epilepsy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 45.1"	"Group enriched"	"Detected in some"	5	"AF22: 13.2;NTERA-2: 8.9"	"Group enriched"	"Detected in some"	7	"glioma: 1.8;testis cancer: 0.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted in brain"						"unprognostic (1.26e-1)"			"unprognostic (4.68e-2)"	"unprognostic (2.45e-2)"	"unprognostic (1.01e-1)"	"unprognostic (8.20e-2)"		"unprognostic (1.28e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.24e-3)"	"unprognostic (1.85e-1)"	"unprognostic (4.07e-3)"	"unprognostic (8.71e-2)"	"unprognostic (2.21e-1)"	"unprognostic (5.93e-2)"	"unprognostic (4.65e-1)"	1.4	4.5	15.3	1.4	30.6	1.1	1.5	18.1	45.1	1.4	4.4	7.3	0.0	1.3	1.3	1.2	7.2	1.2	2.6	1.5	16.3	10.1	1.2	5.4	1.2	1.2	9.6	17.3	1.3	1.5	1.1	6.5	1.1	35.6	2.2	5.2	10.9	1.1	1.9	9.2	1.2	2.3	2.1	7.3	1.1	2.4	1.5	10.4	0.0	1.2	0.0	1.3	1.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.3	30.6	18.1	20.7	16.3	10.1	9.6	17.3	35.6	10.4
LGMN	"LGMN1, PRSC1"	ENSG00000100600	Legumain	Q99538	14	92703807-92748702	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"RPMI-8226: 127.6;U-266/70: 70.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	11	"plasmacytoid DC: 54.2"	"Lineage enriched"	"Detected in many"	11	"dendritic cells: 54.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001426	Enhanced		Approved	Nucleoplasm,Vesicles	"Intracellular and membrane"	1200000	1200000	Vesicles	Nucleoplasm	"HPA001426: AB_1079247"	"unprognostic (1.19e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.37e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.99e-1)"	"unprognostic (3.29e-2)"	"unprognostic (4.52e-2)"	"unprognostic (1.31e-1)"	"unprognostic (5.03e-2)"	"unprognostic (3.50e-2)"	"unprognostic (4.70e-2)"	"unprognostic (2.47e-1)"	"prognostic favourable (4.70e-4)"	"unprognostic (8.06e-2)"	"unprognostic (3.64e-2)"	"unprognostic (7.18e-3)"	"unprognostic (7.24e-2)"	42.9	16.3	8.6	17.4	10.7	3.5	19.9	5.8	17.9	13.3	22.3	11.7	13.9	24.2	12.1	48.1	17.4	14.1	32.7	38.8	10.3	10.1	87.6	44.6	31.5	42.4	8.3	10.1	20.5	14.6	54.4	9.7	113.6	9.9	22.0	24.5	23.2	22.6	8.4	17.3	11.9	37.1	23.3	11.5	58.3	23.7	14.0	7.9	17.2	36.8	19.2	17.3	31.4	18.2	4.7	54.2	0.7	0.8	1.0	4.3	1.7	4.8	7.0	4.7	8.6	14.6	11.8	16.4	10.5	10.0	10.9	12.9	5.4	8.7	2.7	15.5	17.1	12.1	0.0	9.0	5.2	0.2	5.4	0.1	3.9	6.2	4.3	0.1	0.4	8.3	4.4	10.5	6.0	12.9	1.0	22.6	0.7	6.5	1.2	0.2	2.3	4.8	1.2	4.1	127.6	11.8	19.0	5.1	3.5	14.5	8.9	7.5	6.6	0.0	7.0	5.4	6.9	9.7	3.1	70.2	8.2	3.6	3.0	0.1	10.3	0.7	0.4	0.1	0.2	0.8	0.4	4.7	1.4	0.4	5.0	3.4	4.3	2.5	0.5	1.0	0.2	54.2	2.6	1.7	8.6	10.7	5.8	17.9	10.3	10.1	8.3	10.1	9.9	7.9
LHB	"CGB4, hLHB, LSH-B"	ENSG00000104826	"Luteinizing hormone beta polypeptide"	P01229	19	49015980-49017081	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		Hormone	"Cancer-related genes, Disease mutation, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	13	"pituitary gland: 301.4"	"Cell line enhanced"	"Detected in many"		"A549: 6.5;U-266/84: 7.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 1.8;T-reg: 1.3"	"Lineage enriched"	"Detected in single"	12	"T-cells: 1.8"									"CAB022241, CAB022707, HPA038925"	Enhanced		Approved	Cytosol	"Secreted to blood"			Cytosol		"CAB022241: , CAB022707: , HPA038925: "	"unprognostic (8.12e-2)"	"unprognostic (3.59e-1)"	"unprognostic (2.34e-3)"	"unprognostic (1.41e-2)"	"unprognostic (8.89e-2)"	"unprognostic (6.25e-2)"	"unprognostic (3.90e-3)"	"unprognostic (5.69e-2)"	"unprognostic (7.04e-2)"	"unprognostic (6.06e-2)"	"prognostic unfavourable (6.78e-4)"	"unprognostic (2.47e-2)"	"unprognostic (1.68e-3)"	"unprognostic (1.38e-1)"	"unprognostic (4.46e-1)"	"unprognostic (9.52e-2)"	"unprognostic (4.86e-2)"	0.1	0.5	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	3.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.4	0.1	23.1	0.0	301.4	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.5	0.5	0.1	0.1	0.1	0.5	1.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	1.8	0.1	1.3	6.5	0.2	1.3	0.0	0.0	1.8	0.5	0.0	1.0	0.5	5.3	1.9	1.7	0.1	0.0	0.5	0.0	0.4	0.0	1.7	5.1	0.3	1.7	2.5	0.3	0.4	1.7	0.0	0.0	0.3	0.0	0.3	4.7	2.8	0.3	0.3	0.1	0.6	0.7	0.5	2.8	1.1	1.3	0.0	1.3	3.0	1.2	1.9	0.4	2.2	2.0	0.0	0.0	2.6	2.7	0.3	3.3	2.4	7.0	1.8	1.3	3.0	1.1	0.0	0.0	0.0	0.7	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.3	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.4	0.1	0.1
LHX1	"LIM-1, LIM1"	ENSG00000273706	"LIM homeobox 1"	P48742	17	36936785-36944612	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 15.0;kidney: 5.7;seminal vesicle: 7.1"	"Cell line enhanced"	"Detected in some"		"HAP1: 6.2;HMC-1: 2.6;WM-115: 11.4"	"Cancer enhanced"	"Detected in some"		"ovarian cancer: 8.1"					"Cell type enhanced"	"Detected in single"		"memory CD8 T-cell: 1.1"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.1"	"Region enhanced"	"Detected in many"		"cerebellum: 21.5"	"Region enriched"	"Detected in many"	4	"cerebellum: 20.4"	"HPA044307, HPA073521, HPA074382"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Golgi apparatus"				Nucleoplasm	"Nuclear membrane, Golgi apparatus"	"HPA044307: , HPA073521: , HPA074382: "	"unprognostic (3.86e-5)"	"unprognostic (1.64e-1)"		"prognostic unfavourable (3.63e-5)"	"unprognostic (3.85e-2)"	"unprognostic (1.06e-4)"		"unprognostic (2.67e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.52e-1)"	"unprognostic (4.20e-3)"		"unprognostic (1.74e-5)"	"unprognostic (1.33e-1)"	"unprognostic (8.62e-2)"		"unprognostic (3.05e-2)"	0.1	0.0	0.0	0.1	0.0	0.0	0.0	15.0	0.0	0.2	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1		5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	1.1	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.0	0.0	6.2	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	2.6	0.0	0.1	0.0	1.9	0.0	0.0	0.0	0.0	1.6	0.0	0.1	0.2	1.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	1.9	0.0	1.5	0.0	0.0	0.0	0.1	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.1										
LIF	"CDF, DIA, HILDA"	ENSG00000128342	"LIF, interleukin 6 family cytokine"	P15018	22	30240447-30246851	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 28.7"	"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 35.5;U-138 MG: 39.6;U-251 MG: 28.6;U-87 MG: 31.3"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"pons and medulla: 11.7"	"Cell type enriched"	"Detected in single"	5	"NK-cell: 1.2"	"Lineage enriched"	"Detected in single"	5	"NK-cells: 1.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"HPA018844, CAB025985"	Uncertain		Supported	Cytosol	"Secreted in other tissues"			Cytosol		"CAB025985: , HPA018844: AB_1852814"	"unprognostic (1.28e-2)"	"prognostic unfavourable (9.01e-4)"	"unprognostic (8.79e-2)"	"unprognostic (4.61e-2)"	"unprognostic (7.36e-3)"	"unprognostic (4.18e-3)"	"unprognostic (1.17e-2)"	"unprognostic (1.41e-2)"	"unprognostic (3.18e-3)"	"unprognostic (1.22e-1)"	"unprognostic (8.10e-2)"	"unprognostic (9.65e-2)"	"prognostic unfavourable (6.78e-8)"	"unprognostic (2.02e-1)"	"unprognostic (6.40e-2)"	"unprognostic (8.99e-2)"	"unprognostic (4.71e-3)"	20.3	1.7	1.4	21.6	3.3	0.6	5.2	0.9	4.3	4.4	3.9	1.8	1.6	3.7	6.9	2.6	2.0	7.3	28.7	14.2	1.2	0.6	5.7	3.4	17.4	3.8	2.2	0.5	7.9	7.5	0.2	7.3	1.3	11.7	8.6	4.7	3.5	3.2	1.2	1.9	6.0	5.2	4.6	4.3	1.6	4.1	2.0	1.8	0.9	3.4	2.2	5.4	20.8	1.7	0.0	0.0	0.0	0.0	1.2	0.2	0.1	8.7	14.7	0.4	3.3	0.0	1.2	5.4	1.2	5.3	1.6	3.8	2.3	14.3	0.0	3.2	0.0	2.2	0.3	4.0	2.1	2.0	0.6	1.1	5.0	3.2	1.4	0.0	11.5	1.4	0.7	35.5	1.0	0.0	0.2	0.0	6.9	6.5	0.1	0.0	0.5	9.1	0.2	5.0	0.0	12.7	3.4	0.0	0.1	1.4	0.1	2.6	0.3	0.1	0.1	39.6	14.6	14.9	28.6	0.0	0.0	0.0	31.3	0.0	18.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	1.4	3.3	0.9	4.3	1.2	0.6	2.2	0.5	11.7	1.8
LIFR	CD118	ENSG00000113594	"LIF receptor alpha"	P42702	5	38474963-38608354	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 39.8;HHSteC: 17.0;SCLC-21H: 26.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004478, CAB010252"			Approved	"Nuclear speckles,Golgi apparatus"	"Intracellular and membrane"	74000	74000	"Nuclear speckles"	"Golgi apparatus"	"CAB010252: AB_2128043, HPA004478: "	"unprognostic (6.00e-3)"	"unprognostic (2.53e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.81e-3)"	"unprognostic (8.80e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.11e-1)"	"prognostic favourable (1.92e-4)"	"unprognostic (1.78e-1)"	"unprognostic (9.80e-2)"	"unprognostic (2.73e-3)"	"unprognostic (1.06e-1)"	"prognostic favourable (1.40e-7)"	"unprognostic (3.69e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.65e-1)"	35.3	14.7	15.8	8.2	19.2	0.5	33.9	10.1	21.3	27.7	10.4	25.3	22.8	4.9	34.8	14.8	10.4	26.0	10.2	16.3	19.1	11.0	20.3	23.9	21.7	20.2	24.3	11.8	17.9	17.8	13.5	12.5	41.5	23.4	23.6	7.5	17.1	24.9	24.7	24.0	10.5	11.7	26.9	21.4	22.5	18.8	9.3	25.3	4.7	31.4	7.3	8.1	13.6	15.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	2.2	39.8	3.0	11.2	12.4	0.3	3.3	1.9	2.7	1.6	0.4	2.1	0.0	0.5	4.7	0.3	2.6	0.9	4.6	0.0	3.6	0.0	4.2	1.5	17.0	0.0	0.2	10.4	0.7	6.5	0.7	3.7	1.0	6.4	3.3	0.5	0.0	0.1	1.0	7.1	0.0	8.4	0.0	2.6	1.0	26.1	3.2	13.7	0.6	0.0	0.9	0.0	0.7	4.3	8.5	10.1	2.0	0.0	0.0	0.0	7.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8	19.2	10.1	21.3	19.1	11.0	24.3	11.8	23.4	25.3
LIG4		ENSG00000174405	"DNA ligase 4"	P49917	13	108207439-108218368	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA recombination, DNA repair, DNA replication"	Ligase	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001334, HPA057325"	Supported		Supported	"Nucleoplasm,Cytoplasmic bodies"				Nucleoplasm	"Cytoplasmic bodies"	"HPA001334: AB_1078689, HPA057325: "	"unprognostic (9.93e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.35e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.97e-1)"	"unprognostic (1.56e-1)"	"unprognostic (7.97e-2)"	"unprognostic (2.43e-1)"	"unprognostic (4.87e-1)"	"unprognostic (1.96e-2)"	"unprognostic (4.21e-3)"	"unprognostic (1.94e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.50e-2)"	"unprognostic (9.03e-3)"	8.8	12.4	11.6	10.4	15.9	4.3	9.1	14.2	20.6	5.4	7.1	10.2	7.8	8.9	5.8	11.4	8.1	5.9	8.7	8.8	15.6	14.4	11.2	16.7	8.7	12.7	15.5	10.6	7.9	8.3	17.0	20.3	8.3	19.6	7.5	8.7	3.8	6.7	7.1	9.5	6.6	8.6	8.4	14.4	12.6	9.7	11.7	13.6	18.6	10.0	5.4	10.2	8.1	5.3	3.3	2.1	6.8	10.7	2.7	2.7	1.5	9.4	3.6	9.8	6.5	8.2	8.8	3.5	9.4	7.1	7.2	8.7	4.3	4.3	16.2	7.7	6.1	3.9	6.5	6.3	12.5	9.4	6.2	7.6	8.3	2.2	9.8	10.2	8.1	8.0	10.5	7.0	6.3	8.6	2.7	3.0	11.1	5.1	16.8	7.4	2.5	2.3	15.5	3.9	2.6	9.4	6.1	6.2	6.4	2.1	5.8	7.1	4.9	15.7	12.7	4.3	4.7	4.8	8.4	8.0	5.2	26.3	16.6	5.9	9.7	0.8	2.3	6.8	1.8	3.8	2.5	2.6	2.0	1.9	2.1	3.3	2.0	2.7	3.2	2.7	10.7	1.4	2.7	1.5	11.6	15.9	14.2	20.6	15.6	14.4	15.5	10.6	19.6	13.6
LIMK1	LIMK	ENSG00000106683	"LIM domain kinase 1"	P53667	7	74082933-74122525	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 45.2"	"Cell line enhanced"	"Detected in all"		"U-87 MG: 51.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA028064, HPA028516"	Approved		Supported	"Nuclear speckles,Cytosol"				"Nuclear speckles, Cytosol"		"HPA028064: AB_10600111, HPA028516: AB_10601751"	"unprognostic (1.45e-2)"	"unprognostic (2.75e-1)"	"prognostic unfavourable (4.95e-5)"	"unprognostic (2.77e-2)"	"unprognostic (1.40e-3)"	"unprognostic (3.35e-2)"	"prognostic unfavourable (7.79e-6)"	"unprognostic (1.90e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.32e-2)"	"unprognostic (3.16e-2)"	"prognostic unfavourable (6.63e-8)"	"unprognostic (4.14e-2)"	"unprognostic (7.00e-2)"	"unprognostic (3.84e-2)"	"unprognostic (5.79e-2)"	8.8	8.6	31.6	18.2	18.6	6.3	7.4	14.3	44.1	11.5	6.6	7.1	6.6	6.9	7.3	5.3	6.4	6.0	10.8	6.3	26.8	32.9	5.2	2.6	12.5	22.0	33.4	22.2	12.1	8.1	4.0	7.2	8.0	45.2	6.1	4.7	4.8	18.1	9.6	10.9	6.8	7.2	7.6	10.8	18.4	7.8	10.4	6.5	4.3	7.5	3.7	18.1	14.1	7.2	4.6	8.6	3.8	7.7	6.9	2.4	3.1	17.2	13.5	10.3	17.1	13.6	18.5	7.5	10.7	10.3	8.7	9.7	7.8	17.0	10.7	4.8	13.1	10.4	3.8	6.6	3.3	18.5	6.7	7.9	4.6	8.9	15.6	6.0	29.0	18.2	5.9	7.0	3.7	12.9	5.3	3.4	10.8	15.1	5.1	10.8	19.5	8.4	7.5	16.0	6.7	9.6	3.7	4.1	9.4	6.9	16.5	8.6	5.2	5.4	15.3	13.9	12.9	35.7	17.1	3.9	4.3	19.5	51.4	4.4	9.4	0.1	6.5	3.8	2.4	7.7	1.8	4.6	0.6	1.5	8.6	2.4	0.2	0.7	0.7	6.9	4.7	0.8	0.4	3.1	31.6	18.6	14.3	44.1	26.8	32.9	33.4	22.2	45.2	6.5
LMNA	"CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1"	ENSG00000160789	"Lamin A/C"	P02545	1	156082573-156140089	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Cardiomyopathy, Charcot-Marie-Tooth disease, Congenital muscular dystrophy, Disease mutation, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"basophil: 10.4;memory CD4 T-cell: 8.9;myeloid DC: 34.8;T-reg: 35.4"	"Group enriched"	"Detected in all"	8	"dendritic cells: 34.8;granulocytes: 10.4;T-cells: 35.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004022, HPA006660, HPA012078"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies,Cytosol"		3200000	3200000	Nucleoplasm	"Nuclear bodies, Cytosol"	"CAB004022: AB_2136278, HPA006660: AB_1079231, HPA012078: "	"unprognostic (2.22e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.04e-2)"	"unprognostic (5.75e-2)"	"unprognostic (7.43e-3)"	"unprognostic (1.47e-1)"	"unprognostic (5.23e-3)"	"unprognostic (3.27e-2)"	"unprognostic (8.33e-2)"	"unprognostic (5.90e-2)"	"unprognostic (5.10e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.08e-2)"	"unprognostic (1.44e-2)"	64.0	37.3	7.4	51.4	11.8	21.3	88.6	9.0	10.8	62.8	32.6	21.9	27.2	28.6	69.1	52.3	62.2	40.1	77.7	62.5	8.8	7.5	25.9	26.6	51.8	39.6	15.7	11.2	60.3	30.9	15.2	17.4	73.3	18.1	34.0	15.2	32.7	37.5	26.4	36.3	68.7	29.9	63.0	10.3	22.4	36.7	30.2	12.9	9.4	31.5	140.0	35.6	46.4	51.2	1.1	34.8	10.4	3.5	1.7	35.4	6.4	58.6	58.2	6.4	17.3	32.6	56.6	19.9	63.4	80.9	47.9	33.2	14.7	58.1	0.5	37.7	97.5	68.7	9.4	49.2	12.4	19.9	5.5	18.5	46.9	34.0	29.5	3.2	54.7	33.9	21.4	38.9	26.8	42.7	9.9	4.5	52.4	46.3	0.1	10.2	4.8	74.2	0.2	22.6	17.2	47.4	28.2	6.6	13.2	42.8	46.5	58.9	39.3	15.3	76.1	45.7	29.1	56.4	51.2	4.4	1.1	1.2	74.7	3.0	136.2	10.4	3.5	0.1	1.2	0.8	1.0	1.1	8.9	3.4	34.8	0.0	0.1	0.3	0.8	1.7	0.1	0.3	35.4	6.4	7.4	11.8	9.0	10.8	8.8	7.5	15.7	11.2	18.1	12.9
LMO1	"RBTN1, RHOM1, TTG1"	ENSG00000166407	"LIM domain only 1"	P25800	11	8224304-8268716	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	5	"retina: 29.4;skeletal muscle: 29.1"	"Cell line enhanced"	"Detected in some"		"HeLa: 21.2;SCLC-21H: 8.3;SH-SY5Y: 25.4;SiHa: 5.1"	"Cancer enriched"	"Detected in many"	6	"glioma: 6.4"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (3.74e-3)"	"unprognostic (1.45e-1)"		"unprognostic (4.75e-6)"	"unprognostic (9.34e-2)"	"unprognostic (2.37e-1)"		"unprognostic (1.98e-1)"	"unprognostic (7.06e-3)"	"unprognostic (8.09e-2)"	"unprognostic (2.24e-1)"	"unprognostic (9.05e-2)"	"unprognostic (4.36e-12)"	"unprognostic (1.76e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.58e-2)"	"unprognostic (3.13e-2)"	0.3	1.7	2.5	0.3	2.1	0.2	0.6	0.4	3.0	0.2	0.2	1.5	0.1	0.4	0.3	2.1	0.6	0.3	0.2	0.5	2.3	5.9	1.0	0.2	0.2	0.2	3.5	0.6	0.2	1.6	0.2	2.1	0.3	2.1	0.3	0.2	29.4	0.2	0.2	29.1	6.4	0.3	0.5	1.2	0.6	0.6	1.6	2.0	0.1	0.2	0.1	0.2	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.9	0.0	21.2	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.9	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	8.3	25.4	5.1	2.9	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.1	0.4	3.0	2.3	5.9	3.5	0.6	2.1	2.0
LMO2	"RBTN2, RBTNL1, RHOM2, TTG2"	ENSG00000135363	"LIM domain only 2"	P25791	11	33858576-33892289	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HEL: 22.8;HL-60: 22.7;K-562: 23.0;THP-1: 30.1;U-937: 10.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basophil: 1.5;classical monocyte: 1.1;eosinophil: 3.0;intermediate monocyte: 3.1;myeloid DC: 4.3;neutrophil: 1.6;non-classical monocyte: 3.6"	"Group enriched"	"Detected in many"	7	"dendritic cells: 4.3;granulocytes: 3.0;monocytes: 3.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016258, HPA029285, HPA070901, HPA070910"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB016258: AB_2136572, HPA029285: , HPA070901: , HPA070910: "	"unprognostic (1.60e-1)"	"unprognostic (1.47e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.71e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.14e-3)"	"prognostic favourable (3.12e-4)"	"unprognostic (1.73e-3)"	"unprognostic (8.95e-2)"	"unprognostic (5.76e-2)"	"unprognostic (7.86e-3)"	"unprognostic (3.69e-1)"	"unprognostic (7.10e-2)"	"unprognostic (9.65e-2)"	"unprognostic (3.90e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.46e-2)"	18.2	6.1	13.8	13.6	15.6	28.8	14.5	5.2	18.4	9.4	5.5	10.3	6.4	6.2	9.7	9.9	6.9	8.6	9.1	6.4	15.8	12.2	12.9	5.5	15.9	22.2	14.2	7.2	5.1	3.9	4.2	8.3	8.5	11.9	8.3	2.7	14.6	4.5	4.0	25.0	4.2	5.5	6.6	13.9	22.0	4.4	3.6	11.1	1.0	10.7	8.1	13.3	11.1	14.8	0.5	4.3	3.0	3.6	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.9	0.5	5.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	22.8	0.0	0.0	0.1	22.7	7.9	0.0	0.0	0.0	0.0	4.4	23.0	0.0	0.0	0.1	2.1	9.7	0.4	0.0	6.4	0.3	0.0	0.0	0.3	1.9	0.0	0.1	0.2	0.0	0.0	30.1	0.3	0.0	0.1	0.7	0.0	0.0	0.1	0.2	2.1	10.6	0.1	1.5	1.1	3.0	0.0	3.1	0.1	0.5	0.0	0.0	4.3	0.0	0.0	0.0	1.6	0.0	3.6	0.3	0.0	0.5	13.8	15.6	5.2	9.5	15.8	12.2	14.2	7.2	11.9	11.1
LPP		ENSG00000145012	"LIM domain containing preferred translocation partner in lipoma"	Q93052	3	188153284-188890671	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 127.8;urinary bladder: 105.1"	"Cell line enhanced"	"Detected in many"		"Daudi: 28.8;EFO-21: 35.8;U-698: 59.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 18.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011133, HPA017342"	Enhanced		Enhanced	"Focal adhesion sites,Cytosol"		520000	520000	"Focal adhesion sites, Cytosol"		"HPA011133: AB_1853247, HPA017342: AB_1853249"	"unprognostic (1.50e-1)"	"unprognostic (4.97e-3)"	"unprognostic (1.41e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.05e-1)"	"unprognostic (2.43e-3)"	"unprognostic (7.97e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.56e-2)"	"unprognostic (3.44e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.57e-3)"	"unprognostic (2.25e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.82e-3)"	"unprognostic (1.48e-1)"	19.6	4.2	2.7	29.5	2.8	3.1	12.5	3.0	2.7	42.2	29.9	2.1	19.6	5.0	68.6	14.9	59.7	10.0	37.9	9.3	2.6	2.8	10.9	5.3	11.4	6.0	2.8	1.6	26.1	4.4	4.7	3.2	5.2	3.0	37.7	12.8	8.5	7.0	28.4	11.6	5.9	17.2	127.8	3.2	9.5	12.1	30.7	1.5	5.1	5.4	4.2	7.8	105.1	38.3	5.9	4.9	18.0	4.5	4.3	5.0	1.4	7.5	7.0	5.1	3.4	11.1	11.4	5.5	4.9	6.3	3.6	2.4	12.6	3.6	28.8	35.8	11.2	3.2	1.5	3.3	9.1	3.1	1.7	1.4	5.4	3.3	4.7	0.6	1.7	8.1	4.7	8.1	7.0	6.1	0.0	0.6	6.3	2.4	1.4	0.6	2.0	2.3	1.8	3.8	0.1	4.0	8.0	0.3	0.0	10.6	3.5	6.0	2.7	2.4	13.1	8.4	6.5	6.0	12.2	0.0	1.1	59.7	4.2	1.3	7.6	0.8	4.5	1.9	5.0	4.2	3.2	2.9	4.3	3.6	2.4	5.9	2.3	2.9	18.0	4.3	4.0	4.9	1.6	1.4	2.7	2.8	3.0	2.7	2.6	2.8	2.8	1.6	3.0	1.5
LRIG3	"FLJ90440, KIAA3016"	ENSG00000139263	"Leucine rich repeats and immunoglobulin like domains 3"	Q6UXM1	12	58872149-58920522	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 27.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010773	Approved		Approved	Cytosol				Cytosol		"HPA010773: AB_1853275"	"unprognostic (1.79e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.01e-2)"	"unprognostic (3.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.46e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.34e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.92e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.25e-2)"	"unprognostic (2.74e-3)"	"unprognostic (2.47e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.28e-2)"	"unprognostic (1.46e-2)"	15.8	1.7	3.6	11.8	4.1	0.0	16.4	1.0	3.7	18.7	14.8	7.8	12.1	8.4	14.2	13.8	17.1	9.9	17.8	4.7	4.6	1.8	6.5	6.1	9.6	5.0	3.6	2.6	14.7	15.3	4.8	10.3	6.8	5.8	15.5	16.0	13.5	24.9	11.6	5.0	25.9	10.0	21.6	3.0	7.2	13.5	6.4	6.6	5.4	37.6	15.0	12.8	15.7	20.7	0.0	0.0	0.0	0.0	0.0	0.4	0.1	2.0	1.9	7.3	0.5	13.4	15.6	1.7	4.9	14.1	4.7	5.0	5.7	2.6	1.9	9.9	5.4	9.4	2.7	12.4	3.4	14.4	9.5	0.5	3.3	2.8	2.6	0.7	0.2	15.5	27.0	5.0	10.8	12.9	0.1	2.4	3.1	0.9	2.3	0.0	7.8	2.9	0.0	6.2	4.7	3.6	10.4	7.4	0.0	4.3	2.7	4.4	5.0	0.1	5.5	6.5	4.4	3.8	6.3	1.0	0.0	0.0	1.3	0.0	3.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.6	4.1	1.0	3.7	4.6	1.8	3.6	2.6	5.8	6.6
LRP1B	"LRP-DIT, LRPDIT"	ENSG00000168702	"LDL receptor related protein 1B"	Q9NZR2	2	140231423-142131701	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.7;thyroid gland: 14.9"	"Cell line enhanced"	"Detected in some"		"ASC diff: 4.2;HEK 293: 4.4;HeLa: 2.3;HSkMC: 2.1;U-138 MG: 4.9;U-87 MG: 2.5"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"myeloid DC: 1.4;plasmacytoid DC: 1.2"	"Lineage enriched"	"Detected in single"	14	"dendritic cells: 1.4"	"Low region specificity"	"Detected in all"							"HPA069094, HPA074788"	Approved		Approved	Vesicles		63000	63000	Vesicles		"HPA069094: , HPA074788: "	"unprognostic (5.31e-4)"	"unprognostic (3.68e-2)"	"unprognostic (2.61e-1)"	"unprognostic (7.36e-4)"	"unprognostic (5.19e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.00e-2)"	"unprognostic (3.49e-1)"	"unprognostic (3.75e-1)"	"unprognostic (7.02e-3)"	"unprognostic (1.64e-3)"	"unprognostic (1.05e-1)"	"unprognostic (2.94e-3)"	"unprognostic (4.85e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.36e-1)"	4.8	4.5	17.6	1.3	14.1	1.2	2.6	23.2	25.7	1.4	1.3	6.5	0.0	1.2	1.3	6.8	1.3	1.9	1.4	1.6	18.3	9.3	2.2	1.6	1.4	1.2	10.8	16.7	3.0	1.2	1.1	12.7	1.2	12.8	3.5	1.3	0.1	2.5	3.8	10.5	1.7	1.3	1.3	8.2	1.2	1.5	1.9	10.6	0.0	14.9	0.0	1.3	1.2	1.4	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	4.2	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.9	0.2	0.2	0.6	4.4	0.0	2.3	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	0.2	0.0	0.0	0.0	0.0	0.0	4.9	0.1	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	17.6	14.1	23.2	21.3	18.3	9.3	10.8	16.7	12.8	10.6
LRP6	ADCAD2	ENSG00000070018	"LDL receptor related protein 6"	O75581	12	12116025-12267012	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Endocytosis, Wnt signaling pathway"	"Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 1.7"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004490, HPA029925"	Enhanced					270000	270000			"CAB004490: AB_627894, HPA029925: AB_10601768"	"unprognostic (1.80e-1)"	"unprognostic (3.72e-1)"	"unprognostic (2.76e-1)"	"unprognostic (1.91e-1)"	"unprognostic (6.11e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.56e-2)"	"unprognostic (1.37e-2)"	"unprognostic (3.35e-2)"	"unprognostic (6.98e-2)"	"unprognostic (1.82e-1)"	"unprognostic (5.00e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.44e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.47e-1)"	7.6	5.3	7.3	5.6	10.1	1.2	9.9	11.6	8.2	16.7	8.7	7.4	5.8	6.8	14.2	8.2	5.0	8.7	9.3	7.3	8.1	4.7	11.7	17.9	10.9	2.4	5.5	8.7	13.1	10.1	21.5	11.2	18.4	7.8	8.8	6.9	9.9	13.3	11.9	10.8	6.9	5.9	9.6	5.5	2.7	8.5	7.9	8.2	4.2	10.3	7.3	3.6	7.5	14.1	0.4	0.0	0.0	0.0	0.0	1.7	0.0	4.2	11.9	9.3	4.7	5.9	3.9	8.3	7.4	4.8	4.1	4.9	5.8	3.3	0.0	3.6	4.7	3.7	13.0	3.3	7.8	0.0	4.9	4.1	4.6	3.1	2.1	5.7	3.1	3.0	2.1	6.2	4.8	4.3	5.5	0.0	2.7	2.7	4.0	1.0	15.6	2.2	5.1	9.1	1.0	6.3	6.6	2.0	6.3	7.1	2.3	6.0	1.8	3.3	7.7	3.3	14.0	2.6	5.3	0.0	0.0	2.0	3.2	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4	1.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	7.3	10.1	11.6	8.2	8.1	4.7	5.5	8.7	7.8	8.2
LRRK2	"DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2"	ENSG00000188906	"Leucine rich repeat kinase 2"	Q5S007	12	40196744-40369285	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Autophagy, Differentiation"	"GTPase activation, Hydrolase, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Neurodegeneration, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"blood: 40.4;lung: 50.4"	"Cell line enhanced"	"Detected in some"		"A549: 9.7;ASC TERT1: 10.0;BJ hTERT+: 5.6;RPTEC TERT1: 10.7"	"Group enriched"	"Detected in many"	7	"lung cancer: 5.3;renal cancer: 17.1;thyroid cancer: 22.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	7	"neutrophil: 40.4"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 40.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA014293, CAB037160"	Approved		Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB037160: AB_1840989, HPA014293: AB_1853353"	"unprognostic (2.67e-1)"	"unprognostic (1.75e-1)"	"unprognostic (6.45e-3)"	"unprognostic (1.06e-1)"	"unprognostic (3.00e-2)"	"unprognostic (6.10e-3)"	"unprognostic (2.71e-1)"	"unprognostic (3.14e-1)"	"unprognostic (2.25e-1)"	"unprognostic (9.07e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.23e-1)"	"prognostic favourable (3.02e-6)"	"unprognostic (2.55e-2)"	"unprognostic (3.43e-2)"	"unprognostic (2.01e-3)"	"unprognostic (5.21e-3)"	3.7	3.4	2.3	7.0	3.9	8.6	3.0	1.7	5.0	5.1	4.5	1.7	2.6	0.7	5.3	2.9	5.3	3.8	4.5	4.0	1.8	1.4	10.6	4.5	50.4	6.8	2.2	3.6	5.8	3.3	10.9	2.5	1.0	1.9	3.6	1.6	3.3	4.2	2.0	5.6	2.6	3.4	6.7	4.9	8.6	2.7	1.2	2.4	0.5	3.9	2.7	4.9	4.6	6.8	0.9	1.5	40.4	5.8	0.0	0.0	0.8	0.0	9.7	0.1	0.0	3.9	10.0	0.1	2.1	5.6	0.4	0.3	0.0	0.0	0.0	0.0	1.9	0.0	0.3	0.0	0.4	0.0	0.7	0.3	0.2	0.0	0.7	0.5	0.1	2.5	0.7	0.0	0.2	0.6	0.0	0.0	0.7	0.0	0.0	1.2	0.2	0.1	0.0	0.0	0.0	10.7	0.0	0.1	0.6	0.0	0.2	2.7	2.8	2.2	1.4	1.1	1.1	1.2	0.7	0.0	0.0	0.0	2.3	0.0	0.5	0.0	5.8	1.2	0.0	3.1	0.0	0.9	0.0	0.0	1.5	0.9	0.0	0.0	40.4	0.0	3.0	0.2	0.0	0.8	2.3	3.9	1.7	5.0	1.8	1.4	2.2	3.6	1.9	2.4
LTA	"LT, TNFB, TNFSF1"	ENSG00000226979	"Lymphotoxin alpha"	P01374	6	31572054-31574324	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"lymphoid tissue: 25.3"	"Cell line enhanced"	"Detected in some"		"MOLT-4: 3.9;U-266/84: 1.7"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"cerebellum: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA007729	Uncertain				"Secreted to blood"					"HPA007729: AB_1852906"	"unprognostic (3.76e-2)"	"unprognostic (1.48e-2)"	"unprognostic (1.36e-3)"	"unprognostic (8.99e-5)"	"unprognostic (3.22e-1)"	"unprognostic (5.13e-3)"	"unprognostic (2.07e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.10e-2)"	"unprognostic (3.39e-4)"	"unprognostic (2.68e-2)"	"unprognostic (6.77e-2)"	"unprognostic (8.72e-12)"	"unprognostic (2.59e-1)"	"unprognostic (5.49e-2)"	"unprognostic (4.30e-2)"	"unprognostic (3.03e-1)"	0.4	0.1	0.2	25.3	0.6	1.1	0.1	1.3	0.2	0.2	0.5	0.1	0.0	0.1	0.1	0.1	0.9	0.2	0.1	0.1	0.2	0.1	0.3	0.4	2.0	7.2	0.1	0.0	0.3	0.1	0.1	0.1	0.3	0.0	0.6	0.4	0.2	2.4	0.5	0.3	0.2	2.8	0.2	0.3	10.0	0.4	6.0	0.0	11.2	0.2	0.5	17.5	0.7	0.1	0.2	0.0	0.5	0.6	0.1	0.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	3.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.8	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.1	0.1	0.0	0.0	0.1	0.6	0.5	0.1	0.6	0.0	0.1	0.0	0.2	0.6	1.3	0.2	0.2	0.1	0.1	0.0	0.0	0.0
LTA4H		ENSG00000111144	"Leukotriene A4 hydrolase"	P09960	12	96000828-96043520	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Leukotriene biosynthesis"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008399, CAB015221, HPA017017"	Supported		Approved	Nucleoplasm,Cytosol		85000000	85000000	"Nucleoplasm, Cytosol"		"CAB015221: , HPA008399: AB_1852816, HPA017017: AB_1852818"	"prognostic favourable (9.79e-4)"	"unprognostic (6.62e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.38e-2)"	"unprognostic (2.59e-2)"	"unprognostic (4.25e-3)"	"prognostic favourable (8.96e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.75e-2)"	"unprognostic (3.38e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.34e-1)"	27.9	33.2	11.2	21.5	16.7	55.7	19.0	24.1	15.6	27.2	29.1	13.1	16.7	27.6	27.6	14.1	53.4	22.7	14.5	19.2	10.6	12.2	27.2	19.4	68.0	33.4	12.3	11.3	49.9	28.2	21.2	31.8	11.3	13.3	29.6	17.8	20.7	21.1	16.1	20.6	23.6	41.2	21.5	13.3	44.3	22.1	13.7	11.5	29.2	38.8	22.3	43.1	30.1	25.2	20.6	35.3	6.1	84.2	14.2	9.0	54.6	23.5	25.4	35.7	21.3	31.0	34.7	15.6	9.9	29.3	19.6	22.8	18.6	20.5	52.9	12.4	14.7	31.1	29.2	40.3	26.8	18.1	28.3	19.4	16.3	22.5	18.3	10.2	11.8	33.0	34.0	27.0	33.1	38.7	11.8	9.3	28.2	16.2	26.8	31.5	41.6	34.5	25.2	26.6	30.5	35.9	30.1	18.5	21.9	20.0	23.4	21.4	29.0	12.5	13.8	8.3	14.0	11.8	10.7	12.6	21.8	24.5	5.9	18.6	6.5	0.4	76.0	2.2	4.5	84.2	8.4	15.1	6.3	5.8	35.3	20.6	9.0	6.7	6.1	14.2	73.2	8.7	6.3	54.6	11.2	16.7	24.1	15.6	10.6	12.2	12.3	11.3	13.3	11.5
LTB	"p33, TNFC, TNFSF3"	ENSG00000227507	"Lymphotoxin beta"	Q06643	6	31580525-31582522	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 44.1;lymphoid tissue: 81.5"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 6.0;Daudi: 19.4;HDLM-2: 10.9;NB-4: 12.6;REH: 11.9;U-698: 14.3"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA048884	Approved		Approved	Centrosome				Centrosome		"HPA048884: "	"unprognostic (1.43e-2)"	"unprognostic (3.89e-2)"	"unprognostic (7.29e-2)"	"prognostic favourable (2.36e-6)"	"unprognostic (2.91e-3)"	"prognostic favourable (1.74e-4)"	"unprognostic (1.45e-1)"	"unprognostic (9.49e-3)"	"unprognostic (1.42e-3)"	"unprognostic (4.26e-2)"	"unprognostic (4.52e-2)"	"unprognostic (1.49e-1)"	"prognostic unfavourable (3.31e-7)"	"unprognostic (8.91e-2)"	"unprognostic (4.92e-2)"	"unprognostic (6.56e-3)"	"unprognostic (1.99e-1)"	1.0	0.2	0.2	35.9	0.2	3.4	0.5	0.1	0.1	0.2	1.5	0.0	0.0	1.3	0.2	0.3	2.7	0.4	0.7	1.9	0.2	0.1	4.2	1.3	4.2	27.8	0.2	0.0	0.5	0.8	0.0	0.2	0.3	0.1	0.7	0.6	0.5	6.1	0.3	0.1	0.6	18.0	0.3	0.3	69.7	2.0	0.2	0.0	81.5	1.1	0.8	41.6	1.6	0.5	44.1	15.6	17.8	3.6	5.2	39.3	10.7	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	19.4	0.2	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.1	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	12.6	0.0	0.0	11.9	0.0	2.7	4.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	2.5	0.4	17.8	3.7	2.0	26.8	42.5	39.3	17.3	0.6	44.1	33.5	14.2	14.5	5.2	3.6	15.6	22.2	10.7	0.2	0.2	0.1	0.1	0.2	0.1	0.2	0.0	0.1	0.0
LTBR	"D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3"	ENSG00000111321	"Lymphotoxin beta receptor"	P36941	12	6375045-6391571	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 75.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 24.6;intermediate monocyte: 22.9;myeloid DC: 17.6;neutrophil: 15.8;non-classical monocyte: 16.4"	"Group enriched"	"Detected in many"	32	"dendritic cells: 17.6;granulocytes: 15.8;monocytes: 24.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB026202, HPA061617"	Uncertain		Supported	"Golgi apparatus"				"Golgi apparatus"		"CAB026202: , HPA061617: "	"unprognostic (2.60e-2)"	"unprognostic (1.24e-2)"	"unprognostic (7.75e-3)"	"unprognostic (2.23e-2)"	"unprognostic (3.01e-2)"	"unprognostic (3.24e-3)"	"prognostic unfavourable (5.13e-4)"	"unprognostic (2.08e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.45e-3)"	"unprognostic (1.91e-1)"	"prognostic unfavourable (5.92e-4)"	"unprognostic (3.66e-2)"	"unprognostic (9.84e-3)"	"unprognostic (6.91e-2)"	"unprognostic (2.86e-1)"	32.7	24.8	6.0	13.6	8.1	3.6	77.6	2.7	4.8	25.0	25.1	4.9	31.3	18.9	26.7	19.5	34.9	18.1	29.8	15.2	9.5	3.3	39.4	85.2	38.7	21.7	8.1	2.6	28.3	79.8	18.1	10.6	27.0	8.4	31.3	13.7	16.9	31.3	27.0	19.1	25.2	43.6	28.2	12.5	23.3	24.5	14.3	5.7	4.2	45.8	33.6	19.1	27.0	23.0	0.0	17.6	15.8	24.6	0.6	0.1	8.0	17.4	23.6	0.0	7.6	46.9	35.3	16.3	12.1	28.2	18.5	19.1	10.8	27.2	0.0	7.4	26.4	20.2	0.0	25.6	7.3	0.0	0.0	10.3	9.7	6.1	75.2	0.7	17.4	51.7	47.5	13.1	37.1	16.8	9.8	0.1	21.1	16.2	0.0	4.9	0.2	13.0	0.0	1.2	0.0	27.5	20.1	0.1	0.1	11.4	22.7	25.5	3.8	18.9	10.4	6.5	7.4	23.9	12.9	0.0	0.0	0.0	2.7	6.4	23.8	1.4	24.6	0.1	0.0	22.9	0.0	0.0	0.0	0.0	17.6	0.0	0.1	0.1	15.8	0.6	16.4	4.2	0.0	8.0	6.0	8.1	2.7	4.8	9.5	3.3	8.1	2.6	8.4	5.7
LTF	HLF2	ENSG00000012223	Lactotransferrin	P02788	3	46435645-46485234	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Immunity, Ion transport, Iron transport, Osteogenesis, Transcription, Transcription regulation, Transport"	"Antibiotic, Antimicrobial, DNA-binding, Heparin-binding, Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 277.8;salivary gland: 181.9;seminal vesicle: 177.1"	"Group enriched"	"Detected in some"	10	"RPMI-8226: 29.1;TIME: 10.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	27	"neutrophil: 4.0;non-classical monocyte: 13.5"	"Group enriched"	"Detected in many"	27	"granulocytes: 4.0;monocytes: 13.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB008646, CAB016201, HPA057177, HPA059976"	Enhanced				"Secreted in other tissues"	600000000	600000000			"CAB008646: AB_1618695, CAB016201: AB_629860, HPA057177: , HPA059976: "	"unprognostic (7.24e-3)"	"unprognostic (2.43e-1)"	"unprognostic (5.94e-2)"	"unprognostic (3.41e-2)"	"unprognostic (7.14e-3)"	"unprognostic (3.45e-2)"	"unprognostic (6.43e-3)"	"unprognostic (2.52e-1)"	"unprognostic (1.92e-1)"	"unprognostic (4.21e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.04e-1)"	"prognostic favourable (6.30e-5)"	"unprognostic (1.66e-2)"	"unprognostic (3.53e-1)"	"unprognostic (2.05e-1)"	"unprognostic (9.09e-3)"	1.0	0.3	0.4	8.8	0.5	277.8	23.0	0.3	0.3	53.1	0.3	3.2	108.0	0.0	0.7	39.3	3.8	0.9	2.2	2.5	0.6	0.6	20.8	0.6	10.8	1.3	0.6	0.0	0.3	2.7	0.0	1.2	0.8	1.5	13.0	0.0	0.2	181.9	177.1	0.4	1.2	0.9	0.1	0.7	9.1	22.6	2.8	0.1	4.0	1.6	13.4	30.7	2.3	1.0	0.0	0.3	4.0	13.5	0.0	0.0	14.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.5	0.1	0.0	0.0	1.4	0.3	0.0	0.2	0.0	0.2	0.0	0.0	0.5	0.1	0.0	0.0	0.5	29.1	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	10.1	0.0	0.2	0.8	0.1	0.4	0.0	0.1	0.1	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	13.5	0.3	0.0	14.7	0.4	0.5	0.3	0.3	0.6	0.6	0.6	0.0	1.5	0.1
LUM	"LDC, SLRR2D"	ENSG00000139329	Lumican	P51884	12	91102629-91111831	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"placenta: 344.8"	"Cell line enriched"	"Detected in some"	5	"BJ hTERT+: 182.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	103	"basophil: 10.2"	"Lineage enriched"	"Detected in single"	103	"granulocytes: 10.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA001522, CAB025783"	Supported				"Secreted to extracellular matrix"	59000000000	59000000000			"CAB025783: , HPA001522: AB_1079285"	"unprognostic (5.54e-2)"	"unprognostic (2.27e-1)"	"unprognostic (3.32e-1)"	"unprognostic (2.75e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.38e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.87e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.65e-2)"	"unprognostic (2.20e-2)"	"prognostic unfavourable (1.75e-6)"	"unprognostic (5.25e-3)"	"unprognostic (2.27e-2)"	"unprognostic (2.38e-2)"	"unprognostic (2.06e-2)"	44.8	25.3	0.8	15.1	0.7	0.0	19.7	0.7	0.7	56.7	26.9	0.7	28.1	5.1	64.8	77.8	28.1	12.2	76.6	48.8	0.8	0.7	26.9	6.4	77.1	32.0	0.9	0.6	73.0	9.1	0.7	2.7	344.8	2.8	77.4	13.3	1.4	5.6	9.9	9.1	8.3	24.0	48.7	4.0	1.3	8.2	30.9	0.3	1.7	18.1	32.3	11.5	65.3	20.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	22.5	11.1	0.0	36.9	182.3	1.5	2.3	0.0	0.0	0.0	0.0	30.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.3	0.0	17.6	0.0	0.0	15.2	0.0	3.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.9	0.0	0.0	0.0	1.5	0.4	1.3	0.0	0.0	0.0	0.0	0.8	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.7	0.7	0.7	0.8	0.7	0.9	0.6	2.8	0.3
LYL1	bHLHa18	ENSG00000104903	"LYL1, basic helix-loop-helix family member"	P12980	19	13099033-13103161	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 37.4;lymphoid tissue: 25.4"	"Cell line enhanced"	"Detected in some"		"HEL: 32.3;HL-60: 22.6;HMC-1: 54.5;K-562: 25.3;NB-4: 33.1;REH: 24.3;THP-1: 21.9;U-937: 21.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 8.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA075004			Approved	"Golgi apparatus"				"Golgi apparatus"		"HPA075004: "	"unprognostic (8.62e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.27e-2)"	"unprognostic (3.29e-3)"	"unprognostic (2.76e-1)"	"unprognostic (3.64e-3)"	"unprognostic (2.46e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.87e-2)"	"unprognostic (1.78e-3)"	"unprognostic (1.36e-1)"	"prognostic unfavourable (3.89e-4)"	"unprognostic (1.18e-1)"	"unprognostic (6.54e-2)"	"unprognostic (1.33e-1)"	"unprognostic (4.28e-1)"	6.3	3.0	3.4	19.9	5.8	37.4	8.0	1.1	3.8	4.0	3.7	5.5	1.3	3.0	5.3	3.9	5.9	3.8	3.5	4.9	4.5	2.9	3.9	2.0	8.1	24.0	7.1	1.6	3.2	1.6	0.8	1.7	8.0	5.1	6.2	1.4	4.4	6.4	2.4	3.5	2.0	8.8	3.3	6.0	25.4	4.2	11.9	4.1	3.6	3.5	1.4	18.9	3.3	7.0	4.6	1.4	8.8	3.6	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.0	6.3	2.2	0.0	0.0	0.1	0.0	0.0	3.7	0.0	32.3	0.0	0.3	0.3	22.6	54.5	0.1	0.0	0.0	0.0	8.3	25.3	1.1	0.0	0.0	0.1	33.1	0.0	0.8	24.3	0.0	2.7	0.0	0.0	0.0	2.4	0.7	0.0	1.5	0.0	21.9	13.3	0.0	0.0	0.9	0.0	0.0	0.0	5.1	0.0	21.8	0.0	2.5	2.3	8.8	0.1	2.9	0.2	2.8	0.3	0.2	1.4	4.6	0.2	0.2	3.6	0.0	3.6	0.4	0.5	0.6	3.4	5.8	1.1	3.7	4.5	2.9	7.1	1.6	5.1	4.1
LYN	JTK8	ENSG00000254087	"LYN proto-oncogene, Src family tyrosine kinase"	P07948	8	55879813-56014168	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Inflammatory response, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 70.9"	"Cell line enhanced"	"Detected in many"		"HEL: 56.8;HMC-1: 57.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 36.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001231, CAB004492"	Enhanced		Supported	"Golgi apparatus,Vesicles,Plasma membrane"		11000000	11000000	"Golgi apparatus, Plasma membrane"	Vesicles	"CAB004492: AB_627897, HPA001231: AB_1079286"	"unprognostic (7.87e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.04e-2)"	"unprognostic (3.74e-1)"	"unprognostic (8.12e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.70e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.79e-1)"	"unprognostic (8.80e-2)"	"unprognostic (3.68e-2)"	"unprognostic (7.15e-2)"	"prognostic unfavourable (3.43e-4)"	"unprognostic (2.13e-1)"	"unprognostic (2.72e-3)"	"unprognostic (1.21e-1)"	"unprognostic (7.39e-2)"	8.8	6.8	4.5	34.0	6.3	33.6	11.1	9.5	4.1	5.3	10.5	5.8	7.2	15.6	3.4	7.8	7.2	6.7	13.7	8.9	4.8	3.6	6.1	13.8	34.6	70.9	7.7	2.1	5.3	9.8	3.1	4.9	19.1	5.6	5.7	6.6	6.3	14.9	8.5	2.7	3.4	16.2	6.6	8.5	69.4	7.4	3.6	5.1	3.8	9.4	5.3	25.8	10.7	7.5	8.4	9.2	36.8	26.5	1.9	0.9	2.7	12.6	7.5	1.7	0.3	0.1	0.0	13.7	9.7	14.2	6.1	4.3	5.2	4.4	12.2	4.3	3.8	5.9	7.1	7.2	5.2	19.8	7.1	56.8	2.3	1.8	1.9	5.7	57.7	0.3	2.5	0.1	4.4	8.2	30.0	26.5	0.9	0.7	0.0	6.0	10.9	0.8	0.9	2.8	1.5	3.9	6.0	1.1	22.0	4.8	0.0	2.0	1.1	13.4	9.6	0.0	2.8	0.0	4.4	8.9	3.2	27.6	0.6	11.3	0.4	2.1	7.2	12.3	0.9	16.8	0.7	8.2	0.2	0.3	6.4	8.4	0.1	0.4	36.8	1.9	26.5	9.2	0.0	2.7	4.5	6.3	9.5	4.1	4.8	3.6	7.7	2.1	5.6	5.1
LZTR1	"BTBD29, LZTR-1"	ENSG00000099949	"Leucine zipper like transcription regulator 1"	Q8N653	22	20982013-20999038	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA067852, HPA068772, HPA071248"	Approved		Approved	Nucleoplasm,Centrosome,Cytosol				Nucleoplasm	"Centrosome, Cytosol"	"HPA067852: , HPA068772: , HPA071248: "	"unprognostic (1.88e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.44e-2)"	"prognostic unfavourable (5.15e-4)"	"unprognostic (9.81e-2)"	"unprognostic (3.55e-1)"	"unprognostic (3.78e-2)"	"unprognostic (1.01e-2)"	"unprognostic (2.64e-1)"	"unprognostic (1.16e-3)"	"unprognostic (4.29e-2)"	"unprognostic (1.65e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.25e-2)"	21.2	16.9	17.3	15.6	17.4	10.3	17.9	20.7	24.7	18.5	18.3	25.3	20.6	18.9	24.9	14.0	16.5	18.3	21.2	15.8	15.4	10.9	17.2	13.1	16.2	12.8	19.6	16.5	21.7	16.2	24.9	26.0	18.8	19.0	16.9	12.9	18.9	17.5	18.0	17.2	15.0	15.7	21.9	14.0	19.3	14.5	10.8	19.2	10.8	19.6	12.6	12.5	18.5	16.4	1.6	2.2	0.2	3.4	1.8	3.0	1.5	6.2	5.1	7.6	9.2	17.6	12.2	6.2	12.8	9.0	7.3	10.0	3.0	2.6	6.6	4.8	14.2	8.4	5.7	10.5	2.9	12.3	13.3	7.1	6.7	4.4	9.4	3.8	9.4	11.2	5.3	9.2	6.7	14.1	29.4	11.5	8.2	3.8	6.8	3.6	2.4	5.6	8.0	11.1	2.6	5.7	8.4	7.5	11.2	6.9	12.1	7.5	5.6	7.1	12.6	17.0	8.7	7.7	6.9	5.0	4.4	2.0	7.7	3.7	8.2	0.0	2.5	0.2	3.0	3.1	1.6	1.6	1.5	2.8	2.2	1.0	2.1	1.5	0.1	1.8	3.4	1.2	0.5	1.5	17.3	17.4	20.7	24.7	15.4	10.9	19.6	16.5	19.0	19.2
MAD2L1	"HSMAD2, MAD2"	ENSG00000164109	"Mitotic arrest deficient 2 like 1"	Q13257	4	120055608-120067074	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 27.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003348	Uncertain		Approved	Nucleoplasm				Nucleoplasm		"HPA003348: AB_10603014"	"unprognostic (4.08e-3)"	"unprognostic (7.31e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.27e-1)"	"unprognostic (5.54e-2)"	"prognostic unfavourable (5.15e-5)"	"prognostic unfavourable (2.17e-4)"	"unprognostic (6.74e-3)"	"unprognostic (1.47e-1)"	"unprognostic (3.20e-3)"	"unprognostic (3.87e-3)"	"prognostic unfavourable (3.07e-11)"	"unprognostic (3.06e-2)"	"unprognostic (4.05e-1)"	"unprognostic (1.03e-1)"	"unprognostic (9.70e-2)"	1.4	1.8	2.4	4.2	5.7	10.3	2.4	4.4	4.1	1.9	4.4	1.2	0.3	3.8	1.7	1.4	6.5	2.9	1.1	1.7	2.7	2.7	1.2	1.2	1.5	7.6	2.3	3.6	1.7	1.2	0.7	1.0	3.5	2.4	1.6	5.5	0.7	2.4	1.2	1.2	2.3	4.2	1.8	2.8	3.8	1.9	13.7	1.2	27.3	1.2	8.2	7.3	2.1	2.4	1.8	2.2	2.0	0.8	2.5	3.9	1.7	14.4	6.4	15.0	9.7	1.6	2.0	6.4	11.5	6.5	12.1	9.3	8.5	8.9	21.3	3.8	4.2	3.9	14.9	8.8	16.9	10.1	10.4	11.8	6.2	8.0	0.5	19.2	6.8	1.1	1.3	8.2	5.1	6.9	14.1	12.3	6.3	6.4	18.4	8.4	10.2	7.2	9.5	20.1	8.8	4.9	5.6	15.9	11.3	5.7	7.1	3.5	4.7	7.1	4.3	8.1	9.2	8.2	14.5	11.5	12.2	14.0	7.5	10.0	10.6	2.0	0.5	0.4	1.6	0.5	2.1	1.8	3.8	3.0	0.4	1.4	3.5	3.5	1.3	2.5	0.8	2.2	3.9	1.7	2.4	5.7	4.4	4.1	2.7	2.7	2.3	3.6	2.4	1.2
MAD2L2	"FANCV, MAD2B, POLZ2, REV7"	ENSG00000116670	"Mitotic arrest deficient 2 like 2"	Q9UI95	1	11674480-11691650	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008110, HPA024176, HPA024612"	Approved		Approved	Nucleoli,Cytosol				Cytosol	Nucleoli	"CAB008110: AB_217976, HPA024176: , HPA024612: "	"unprognostic (1.26e-2)"	"unprognostic (2.55e-1)"	"unprognostic (2.43e-1)"	"unprognostic (3.27e-1)"	"unprognostic (2.41e-1)"	"unprognostic (6.84e-2)"	"unprognostic (3.04e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.34e-1)"	"unprognostic (4.60e-2)"	"unprognostic (1.24e-1)"	"unprognostic (9.09e-3)"	"unprognostic (1.54e-1)"	"unprognostic (9.27e-2)"	"unprognostic (8.43e-2)"	"unprognostic (2.36e-1)"	12.4	10.1	15.4	15.7	15.6	37.9	13.7	15.5	13.5	10.0	10.5	14.5	11.9	8.6	10.4	11.8	9.8	9.9	10.3	17.3	13.2	11.2	13.2	34.4	12.9	18.3	19.6	9.7	14.6	23.0	5.8	11.1	8.2	12.4	11.8	6.1	8.4	21.0	9.2	23.0	12.0	7.4	11.5	15.0	11.9	12.4	37.0	15.8	42.1	12.0	10.4	19.0	11.9	13.4	19.5	46.9	13.8	31.7	13.2	29.8	27.7	11.5	10.6	17.9	20.1	5.5	10.8	7.2	10.8	12.1	21.2	18.9	13.7	11.2	16.3	13.2	11.3	5.1	22.2	11.1	12.3	24.6	24.6	7.3	16.4	16.9	9.7	14.7	12.1	7.0	11.4	15.5	13.4	9.6	30.0	26.2	10.4	17.1	67.9	69.8	46.0	17.3	46.2	19.7	20.0	7.6	2.5	33.2	23.3	17.9	6.9	31.1	10.1	32.0	5.0	17.6	22.3	16.3	15.2	21.0	14.7	42.4	13.0	51.9	13.4	11.9	29.4	13.8	29.8	31.7	23.9	19.5	20.1	23.1	34.0	15.9	13.7	20.3	12.5	13.2	27.2	46.9	22.9	27.7	15.4	15.6	15.5	13.4	13.2	11.2	19.6	9.7	12.4	15.8
MAF	c-MAF	ENSG00000178573	"MAF bZIP transcription factor"	O75444	16	79585843-79600714	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Cataract, Disease mutation, Dwarfism, Mental retardation, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	12	"Karpas-707: 49.1;RPMI-8226: 80.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"basophil: 20.7;MAIT T-cell: 6.3"	"Group enriched"	"Detected in many"	16	"granulocytes: 20.7;T-cells: 6.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB010296, HPA028289"	Approved									"CAB010296: AB_638562, HPA028289: AB_10602024"	"unprognostic (6.76e-2)"	"unprognostic (1.74e-2)"	"unprognostic (6.45e-2)"	"unprognostic (7.65e-2)"	"unprognostic (7.89e-3)"	"unprognostic (1.07e-2)"	"unprognostic (1.63e-2)"	"unprognostic (2.33e-1)"	"unprognostic (8.76e-2)"	"unprognostic (3.16e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (3.74e-4)"	"unprognostic (4.54e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.09e-2)"	"unprognostic (4.56e-3)"	19.0	10.2	15.4	17.3	13.5	2.5	28.5	9.3	11.2	25.6	31.8	10.7	9.1	41.7	18.8	15.6	16.7	15.1	12.4	19.0	14.3	5.8	28.7	18.0	16.8	38.1	20.5	9.9	31.4	3.1	59.1	4.8	21.7	13.9	15.8	7.2	14.1	9.7	10.4	26.3	37.2	57.7	15.8	18.7	19.8	9.5	12.4	14.0	10.2	18.4	16.7	14.3	14.6	23.4	0.0	0.0	20.7	0.8	0.6	6.3	0.4	0.0	0.0	5.2	0.0	0.2	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.0	1.6	1.9	0.0	0.0	0.0	0.2	0.0	3.4	0.0	1.5	0.0	0.0	0.0	0.5	49.1	0.3	0.0	0.0	0.0	3.2	0.0	0.0	1.4	80.0	0.0	0.4	0.1	0.0	0.2	0.0	0.1	0.0	0.0	1.0	0.0	1.7	0.1	0.2	0.0	0.0	0.0	0.2	0.0	0.3	20.7	0.2	0.0	0.8	0.8	6.3	0.0	2.4	1.9	0.0	0.0	0.2	0.3	0.0	0.6	0.2	0.0	3.1	0.4	15.4	13.5	9.3	11.2	14.3	5.8	20.5	9.9	13.9	14.0
MAFB	KRML	ENSG00000204103	"MAF bZIP transcription factor B"	Q9Y5Q3	20	40685848-40689240	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 87.6;parathyroid gland: 154.1"	"Cell line enhanced"	"Detected in some"		"HSkMC: 15.8;hTCEpi: 33.3;SCLC-21H: 9.1;SiHa: 8.2;U-138 MG: 9.0;U-2197: 13.1;U-87 MG: 8.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"intermediate monocyte: 27.4;non-classical monocyte: 36.7"	"Lineage enriched"	"Detected in many"	14	"monocytes: 36.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA005653	Approved		Approved	"Nucleoplasm,Nucleoli,Golgi apparatus,Cytosol"				Nucleoplasm	"Nucleoli, Golgi apparatus, Cytosol"	"HPA005653: AB_1079293"	"unprognostic (1.55e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.16e-3)"	"prognostic unfavourable (5.64e-4)"	"unprognostic (9.16e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.57e-2)"	"unprognostic (6.09e-2)"	"unprognostic (5.45e-3)"	"unprognostic (9.92e-2)"	"unprognostic (3.95e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.21e-3)"	"unprognostic (3.49e-2)"	"unprognostic (2.30e-2)"	38.3	7.9	3.2	13.0	4.0	17.0	19.5	1.0	9.7	10.6	6.9	3.0	1.2	3.3	5.6	8.9	16.8	7.0	9.2	12.4	3.6	2.3	10.9	14.0	21.9	28.9	4.7	3.4	7.0	6.1	154.1	2.3	9.4	5.0	7.6	3.3	5.6	10.4	2.7	11.0	41.6	7.6	5.5	7.7	87.6	4.7	7.5	3.8	6.9	18.2	20.5	11.4	8.2	10.9	0.0	2.5	0.7	36.7	0.0	0.0	2.5	0.0	0.0	0.0	1.4	0.8	0.1	0.2	0.2	0.0	0.1	0.0	0.2	0.1	0.0	1.0	0.2	2.0	0.0	0.0	0.0	0.0	0.7	0.0	0.6	0.1	0.5	0.0	0.1	15.8	33.3	0.1	1.1	0.2	0.0	0.0	0.0	0.5	0.1	3.8	1.4	0.0	0.0	0.0	0.0	0.3	0.2	9.1	0.7	8.2	0.8	2.0	0.8	0.1	0.2	9.0	0.1	13.1	0.0	0.0	0.0	0.0	8.7	0.3	0.0	0.1	7.3	0.0	0.0	27.4	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.7	0.0	36.7	0.0	0.0	2.5	3.2	4.0	1.0	9.7	3.6	2.3	4.7	3.4	5.0	3.8
MAGEA3	"CT1.3, HIP8, HYPD, MAGE3, MGC14613"	ENSG00000221867	"MAGE family member A3"	P43357	X	152698752-152702347	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	22	"testis: 12.8"	"Cell line enhanced"	"Detected in some"		"HMC-1: 23.4;K-562: 35.6;PC-3: 33.2;SH-SY5Y: 33.0;SK-BR-3: 37.6;U-266/70: 52.7;U-266/84: 58.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																										"unprognostic (1.29e-1)"	"unprognostic (9.34e-2)"	"prognostic unfavourable (3.58e-4)"	"unprognostic (4.20e-2)"	"unprognostic (2.48e-1)"					"unprognostic (2.53e-3)"	"unprognostic (3.95e-2)"		"unprognostic (2.92e-1)"	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	11.2	0.2	0.0	0.0	23.4	0.0	0.0	0.0	0.0	0.0	35.6	3.6	0.0	0.0	0.0	0.0	0.0	33.2	0.0	0.0	0.6	0.0	0.0	7.1	33.0	0.0	37.6	1.8	0.3	2.2	0.2	2.3	4.4	2.1	3.1	52.7	58.6	0.0	0.2	0.0	22.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MAGEA4	"CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336"	ENSG00000147381	"MAGE family member A4"	P43358	X	151912509-151925170	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	32	"placenta: 12.1;testis: 23.5"	"Cell line enhanced"	"Detected in some"		"A-431: 61.4;AN3-CA: 38.3;HMC-1: 73.1;U-266/84: 113.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA021942, CAB040535"	Enhanced		Approved	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"CAB040535: , HPA021942: AB_1853490"						"unprognostic (7.90e-3)"		"unprognostic (6.66e-3)"	"unprognostic (5.39e-1)"	"unprognostic (1.36e-1)"				"unprognostic (5.81e-2)"	"unprognostic (2.94e-2)"		"unprognostic (4.10e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.4	0.0	0.0	38.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	73.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	19.6	0.0	0.3	15.6	113.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0
MAGEA6	"CT1.6, MAGE-3b, MAGE3B, MAGE6"	ENSG00000197172	"MAGE family member A6"	P43360	X	152766136-152769747	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	20	"testis: 11.7"	"Cell line enhanced"	"Detected in some"		"HMC-1: 39.1;K-562: 31.8;PC-3: 36.1;SK-BR-3: 34.2;U-2 OS: 25.1;U-266/70: 43.7;U-266/84: 27.2"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"																							"unprognostic (3.09e-1)"			"unprognostic (5.94e-2)"	"unprognostic (3.77e-2)"	"prognostic unfavourable (1.93e-4)"	"unprognostic (3.50e-2)"	"unprognostic (1.74e-1)"					"unprognostic (5.33e-2)"	"unprognostic (8.33e-2)"		"unprognostic (6.00e-2)"	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0			0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.1		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	11.7			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	4.2	0.0	0.0	0.0	0.0	9.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	13.1	0.2	0.0	0.0	39.1	0.0	0.0	0.0	0.0	0.0	31.8	18.5	0.0	0.0	0.0	0.0	0.0	36.1	0.0	0.0	2.0	0.0	0.0	1.9	14.3	0.0	34.2	4.7	0.5	2.4	0.1	16.0	25.1	0.9	4.7	43.7	27.2	0.0	0.3	0.0	18.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MAGEB5	"CT3.3, MAGE-B5"	ENSG00000188408	"MAGE family member B5"	Q9BZ81	X	26216169-26218270	"Cancer-related genes, Predicted intracellular proteins"		"Tumor antigen"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in single"	10	"testis: 3.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA052627	Uncertain									"HPA052627: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MAGEB6	"CT3.4, FLJ40242, MAGE-B6, MAGEB6A"	ENSG00000176746	"MAGE family member B6"	Q8N7X4	X	26192440-26195646	"Cancer-related genes, Predicted intracellular proteins"		"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	87	"testis: 8.6"	"Cell line enriched"	"Detected in single"	10	"K-562: 9.8"	"Cancer enhanced"	"Detected in single"		"testis cancer: 0.5"					"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA041853, HPA076711"	Enhanced									"HPA041853: AB_10796785, HPA076711: "									"unprognostic (2.05e-1)"						"unprognostic (1.31e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.1	0.6	0.1	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MAGEC1	"CT7, CT7.1, MAGE-C1, MGC39366"	ENSG00000155495	"MAGE family member C1"	O60732	X	141903894-141909388	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	11	"testis: 23.5"	"Cell line enhanced"	"Detected in some"		"K-562: 22.3;Karpas-707: 22.4;U-2 OS: 15.1;U-2197: 28.5;U-266/70: 20.4;U-266/84: 18.0"	"Cancer enhanced"	"Detected in many"		"melanoma: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA004622, CAB015452"	Enhanced		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB015452: AB_784404, HPA004622: AB_1853495"	"unprognostic (5.63e-2)"				"unprognostic (1.59e-1)"		"unprognostic (1.68e-1)"	"unprognostic (4.52e-2)"	"unprognostic (9.96e-2)"	"unprognostic (3.47e-1)"					"unprognostic (8.56e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.3	22.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.0	15.1	28.5	0.0	20.4	18.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MAGEC2	"CT10, HCA587, MAGE-C2, MAGEE1"	ENSG00000046774	"MAGE family member C2"	Q9UBF1	X	142202345-142205290	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	319	"testis: 31.8"	"Group enriched"	"Detected in some"	8	"K-562: 34.9;U-266/84: 39.4"	"Cancer enhanced"	"Detected in many"		"melanoma: 19.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA062230	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA062230: "					"unprognostic (1.25e-1)"		"unprognostic (5.68e-2)"	"unprognostic (3.99e-1)"	"unprognostic (2.82e-1)"						"unprognostic (1.04e-1)"		"unprognostic (4.00e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	34.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.4	1.5	0.0	0.0	0.1	2.4	0.4	4.8	0.0	0.0	39.4	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MAGEC3	"CT7.2, HCA2, MAGE-C3"	ENSG00000165509	"MAGE family member C3"	Q8TD91	X	141838316-141897832	"Cancer-related genes, Predicted intracellular proteins"		"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 4.9;epididymis: 3.0;testis: 3.1"	"Group enriched"	"Detected in some"	4	"U-2197: 1.9;U-266/70: 2.9;U-266/84: 6.3"	"Cancer enriched"	"Detected in single"	7	"testis cancer: 0.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA052067	Approved									"HPA052067: "	"unprognostic (3.45e-1)"				"unprognostic (2.39e-1)"			"unprognostic (4.01e-1)"		"unprognostic (2.95e-1)"	"unprognostic (2.10e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.35e-11)"		"unprognostic (3.21e-2)"	"unprognostic (4.29e-2)"		0.1	0.1	1.6	0.0	2.5	0.1	0.5	0.5	2.5	0.2	0.0			0.0	0.2	3.0	0.1	0.4	0.2	0.0	3.3	2.0	0.1	0.1	0.2	0.0	2.8		0.4	0.0	0.0	0.7	0.0		0.3	0.0		0.5	0.3	0.0	0.1	0.2	0.3	4.9	1.1	0.1	3.1			0.5		0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.9	0.0	0.3	0.1	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.1	1.9	0.3	2.9	6.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MAGED1	"DLXIN-1, NRAGE"	ENSG00000179222	"MAGE family member D1"	Q9Y5V3	X	51803007-51902357	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Ubl conjugation pathway"	"Tumor antigen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 82.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043645			Approved	Cytosol				Cytosol		"HPA043645: "	"unprognostic (5.70e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.39e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.37e-1)"	"unprognostic (4.04e-3)"	"unprognostic (2.04e-2)"	"unprognostic (3.92e-1)"	"unprognostic (1.77e-1)"	"unprognostic (3.15e-3)"	"unprognostic (1.42e-1)"	"unprognostic (6.10e-3)"	"unprognostic (2.14e-3)"	"unprognostic (2.22e-1)"	"prognostic unfavourable (3.25e-4)"	"unprognostic (1.71e-3)"	15.4	57.6	35.3	16.8	52.9	6.9	18.6	34.6	61.8	50.9	18.8	25.9	38.9	15.2	27.6	67.4	13.1	31.6	28.1	32.4	42.2	58.4	22.5	48.6	17.5	13.6	32.2	38.0	30.7	37.2	42.9	69.6	53.5	39.4	35.1	19.3	34.7	38.1	45.5	19.6	12.7	13.4	36.3	25.7	15.9	25.8	33.8	16.1	24.6	35.4	12.5	17.9	23.9	15.8	10.1	28.8	1.5	3.2	7.7	11.6	6.9	3.2	11.8	37.9	32.6	30.0	54.2	20.4	43.8	56.3	24.3	38.6	24.2	11.1	4.6	8.6	82.7	2.4	33.8	15.6	18.3	4.8	13.1	3.1	0.0	31.3	23.0	11.5	5.7	50.9	5.6	20.5	4.7	29.1	4.7	9.1	48.8	29.6	13.1	3.8	29.8	24.4	13.4	24.6	0.6	25.0	5.8	9.8	54.5	0.0	12.8	6.4	23.0	2.8	28.9	10.6	27.3	37.3	4.8	6.0	8.8	9.4	41.5	1.0	27.5	0.7	2.2	1.5	11.6	3.2	10.3	9.3	7.6	10.0	6.8	10.1	9.6	11.3	0.7	7.7	2.8	28.8	10.5	6.9	35.3	52.9	34.6	61.8	42.2	58.4	32.2	38.0	39.4	16.1
MAGED2	"11B6, BCG1, HCA10, JCL-1, MAGE-D2, MAGED, MGC8386"	ENSG00000102316	"MAGE family member D2"	Q9UNF1	X	54807599-54816012	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Tumor antigen"	"Bartter syndrome, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA031572, HPA031573"	Supported		Enhanced	Nucleoplasm,Nucleoli,Cytosol				"Nucleoplasm, Nucleoli, Cytosol"		"HPA031572: AB_10599819, HPA031573: AB_10602181"	"unprognostic (1.33e-1)"	"unprognostic (8.60e-2)"	"unprognostic (3.32e-1)"	"unprognostic (1.69e-3)"	"unprognostic (4.79e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.41e-3)"	"unprognostic (1.39e-1)"	"unprognostic (2.97e-1)"	"prognostic favourable (2.88e-4)"	"prognostic favourable (2.82e-4)"	"unprognostic (6.34e-2)"	"unprognostic (3.55e-3)"	"prognostic unfavourable (9.43e-4)"	"unprognostic (1.58e-1)"	"unprognostic (9.77e-2)"	"unprognostic (3.58e-1)"	22.1	38.4	26.9	14.8	26.5	8.2	50.2	24.4	43.0	55.7	27.3	27.8	21.4	16.2	41.1	31.8	21.9	45.9	28.5	40.7	23.8	38.2	42.7	17.3	24.0	13.5	30.3	36.0	79.7	23.5	34.5	57.6	58.6	57.1	63.9	16.4	43.1	32.0	53.7	25.6	16.5	17.6	41.6	24.7	17.5	22.5	21.8	18.3	23.4	45.1	17.3	22.0	31.9	29.2	17.1	11.7	43.1	37.0	28.5	35.5	32.5	5.5	10.3	61.7	18.8	29.4	40.0	11.4	23.1	41.2	18.3	32.6	10.2	14.2	7.7	60.6	46.4	7.6	17.5	17.4	13.2	13.8	14.5	16.1	12.2	20.0	25.2	4.1	12.4	52.4	7.3	18.6	9.4	34.8	3.9	9.5	35.0	15.4	9.1	6.9	22.8	12.3	6.1	22.1	11.0	25.1	4.2	9.7	25.1	9.2	10.7	53.4	44.0	7.0	29.9	15.6	24.4	23.3	6.5	6.1	5.1	5.6	22.8	10.8	79.7	43.1	9.1	35.5	35.5	22.4	27.3	16.3	29.4	33.1	11.7	17.1	29.7	34.1	3.4	28.5	37.0	7.2	29.2	32.5	26.9	26.5	24.4	43.0	23.8	38.2	30.3	36.0	57.1	18.3
MAGI1	"AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3"	ENSG00000151276	"Membrane associated guanylate kinase, WW and PDZ domain containing 1"	Q96QZ7	3	65353525-66038834	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HEL: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031851, HPA031852, HPA031853, HPA077002"	Supported		Supported	"Nucleoplasm,Cell Junctions"				"Cell Junctions"	Nucleoplasm	"HPA031851: AB_10599289, HPA031852: , HPA031853: AB_10602095, HPA077002: "	"unprognostic (5.00e-2)"	"unprognostic (9.84e-2)"	"unprognostic (6.00e-3)"	"unprognostic (1.73e-3)"	"unprognostic (1.64e-1)"	"unprognostic (2.17e-2)"	"unprognostic (1.46e-3)"	"unprognostic (9.46e-3)"	"unprognostic (8.59e-2)"	"unprognostic (2.19e-1)"	"unprognostic (6.58e-2)"	"unprognostic (2.05e-3)"	"prognostic favourable (4.55e-8)"	"unprognostic (3.51e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.68e-2)"	"unprognostic (8.03e-2)"	18.0	6.0	10.1	6.4	9.8	1.0	16.5	38.6	16.8	6.9	11.2	10.1	25.7	10.7	11.6	7.6	9.4	12.6	19.7	11.1	9.4	11.8	14.3	17.6	13.3	2.9	8.8	10.4	4.3	16.7	18.7	13.1	11.1	9.6	9.2	9.5	7.7	17.4	37.9	7.7	13.0	11.6	7.9	8.3	13.9	19.8	10.7	7.7	0.6	23.2	5.8	4.4	6.9	13.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	2.8	1.5	8.7	0.9	1.7	1.3	3.9	4.8	4.1	1.8	2.8	10.3	2.4	0.0	0.7	5.7	0.8	2.4	1.6	2.9	0.0	1.3	24.5	3.0	6.9	1.1	0.0	0.8	1.9	1.4	6.3	1.3	4.2	10.3	0.0	1.9	2.1	0.0	0.0	11.6	1.5	0.0	2.4	0.6	2.2	9.3	2.8	7.6	1.9	2.3	0.0	4.5	0.0	1.1	5.9	4.3	1.5	1.9	0.0	0.0	0.0	3.4	0.0	0.7	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	9.8	38.6	15.5	9.4	11.8	8.8	10.4	9.6	7.7
MALT1	"MLT, PCASP1"	ENSG00000172175	"MALT1 paracaspase"	Q9UDY8	18	58671386-58754477	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Hydrolase, Protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RPTEC TERT1: 50.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB004494, HPA048432"	Enhanced		Approved	"Nucleoli fibrillar center,Cytosol"				"Nucleoli fibrillar center"	Cytosol	"CAB004494: AB_627909, HPA048432: "	"unprognostic (3.25e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.64e-2)"	"unprognostic (3.25e-2)"	"unprognostic (1.65e-3)"	"unprognostic (4.67e-2)"	"unprognostic (6.46e-2)"	"unprognostic (4.50e-2)"	"unprognostic (3.33e-2)"	"unprognostic (4.16e-3)"	"unprognostic (3.74e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.97e-1)"	"unprognostic (1.03e-1)"	"unprognostic (6.00e-2)"	11.2	3.9	4.1	21.7	5.6	10.2	10.6	9.1	6.8	11.0	10.7	3.9	10.9	5.5	8.1	10.5	16.4	6.6	8.1	8.7	4.0	4.3	14.9	10.5	14.3	29.0	4.1	1.8	8.1	6.2	10.0	9.3	8.8	4.9	18.1	7.9	7.5	10.7	8.4	10.7	12.6	12.2	6.6	6.2	19.9	6.2	11.8	4.8	22.4	7.9	12.4	24.0	9.6	12.3	6.3	3.6	1.2	1.7	1.6	4.8	1.1	7.4	10.6	13.0	3.2	2.6	5.8	5.8	13.3	9.4	11.6	9.9	8.6	9.6	11.8	6.0	16.5	7.3	5.6	5.5	14.3	7.9	3.1	4.2	7.6	13.8	4.2	8.5	5.7	3.6	11.7	9.1	9.2	2.5	6.8	20.6	6.3	2.4	1.8	3.6	3.2	3.6	6.4	7.7	8.3	50.8	3.1	1.4	3.0	7.3	3.8	5.0	3.7	4.9	3.4	15.0	6.6	4.4	12.2	18.4	21.8	10.3	6.0	6.4	5.9	0.8	1.5	1.0	2.7	1.7	2.1	3.6	4.8	2.9	2.2	6.3	4.3	2.8	1.2	1.6	1.6	3.6	2.9	1.1	4.1	5.6	9.1	6.8	4.0	4.3	4.1	1.8	4.9	4.8
MAML2	"KIAA1819, MAM3"	ENSG00000184384	"Mastermind like transcriptional coactivator 2"	Q8IZL2	11	95976598-96343180	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Notch signaling pathway, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 27.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA035223	Approved		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"				"Nuclear bodies"	"Nucleoplasm, Cytosol"	"HPA035223: AB_10671101"	"unprognostic (8.11e-2)"	"unprognostic (2.51e-1)"	"unprognostic (7.08e-2)"	"unprognostic (9.07e-2)"	"unprognostic (3.57e-3)"	"unprognostic (3.32e-2)"	"unprognostic (3.66e-2)"	"unprognostic (2.33e-1)"	"unprognostic (3.99e-2)"	"unprognostic (8.05e-2)"	"prognostic unfavourable (3.89e-4)"	"unprognostic (9.11e-2)"	"prognostic favourable (1.90e-4)"	"unprognostic (9.76e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.99e-1)"	"unprognostic (7.19e-2)"	26.3	5.5	10.2	16.1	8.1	4.2	19.7	27.8	13.4	15.8	9.2	10.4	8.4	4.3	11.2	8.5	9.3	11.7	10.8	8.9	10.5	6.9	13.8	3.5	15.0	10.9	6.9	3.4	11.7	8.2	13.3	15.2	18.8	9.3	12.3	8.9	10.8	16.6	12.3	4.4	14.2	8.9	10.2	14.4	16.8	6.5	4.3	10.6	21.2	11.8	4.8	13.6	16.0	15.3	2.1	1.2	4.7	1.1	4.2	6.4	2.0	5.5	1.1	9.6	2.5	10.0	11.6	2.1	6.4	9.6	4.2	4.4	0.6	11.8	1.2	15.2	14.8	5.1	1.9	6.2	5.9	27.4	0.7	0.7	2.0	2.1	5.8	0.0	0.0	16.9	0.6	7.5	4.5	2.4	3.1	1.7	7.5	0.4	0.1	1.5	1.0	1.8	1.9	1.8	6.4	6.3	7.8	0.1	0.8	2.4	1.0	2.7	0.9	0.2	10.4	7.5	1.8	2.5	4.0	1.2	0.2	1.8	3.6	1.1	13.7	0.1	1.1	0.0	1.5	0.6	2.6	1.9	3.2	4.1	1.2	2.1	6.4	4.3	4.7	4.2	0.7	0.9	1.2	2.0	10.2	8.1	27.8	7.0	10.5	6.9	6.9	3.4	9.3	10.6
MAP2K1	"MAPKK1, MEK1, PRKMK1"	ENSG00000169032	"Mitogen-activated protein kinase kinase 1"	Q02750	15	66386817-66492312	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003834, HPA026430"	Approved		Enhanced	"Plasma membrane,Cytosol"		62000	62000	"Plasma membrane, Cytosol"		"CAB003834: AB_562310, HPA026430: AB_1853742"	"unprognostic (4.05e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.92e-2)"	"prognostic unfavourable (1.95e-4)"	"unprognostic (1.81e-3)"	"unprognostic (5.78e-2)"	"unprognostic (9.91e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.45e-1)"	"unprognostic (7.62e-3)"	"unprognostic (1.20e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.15e-1)"	"unprognostic (9.40e-3)"	28.6	16.9	33.9	19.1	54.1	29.0	23.6	32.5	48.4	12.5	12.1	8.4	10.2	10.0	11.8	16.5	22.0	10.6	14.4	19.1	49.2	26.4	15.3	53.1	16.4	23.3	17.6	31.2	13.5	11.7	23.4	12.0	15.4	17.2	14.4	12.9	9.1	13.2	12.4	39.5	12.3	10.9	16.9	17.4	14.5	10.8	7.8	12.6	12.6	12.3	9.7	27.9	13.6	18.7	4.6	16.2	5.5	8.2	8.4	7.9	2.7	33.1	15.6	31.5	13.1	19.0	14.3	18.2	24.1	20.6	26.2	23.4	23.5	27.3	30.5	29.9	19.8	29.6	29.4	35.2	30.8	24.5	17.5	9.8	16.4	12.7	15.4	12.9	14.6	11.0	21.8	18.9	28.1	20.4	17.3	39.0	38.1	12.8	10.3	16.8	16.1	13.7	11.7	19.5	27.1	25.4	14.3	19.4	10.8	19.5	15.3	20.2	13.8	11.0	28.1	34.1	20.9	24.0	35.7	24.2	43.0	19.4	36.0	22.8	15.9	3.2	8.2	5.5	7.4	8.2	6.7	3.0	6.6	6.9	8.3	4.6	7.9	4.9	3.9	8.4	7.3	16.2	4.9	2.7	33.9	54.1	32.5	46.9	49.2	26.4	17.6	31.2	17.2	12.6
MAP2K2	"MEK2, PRKMK2"	ENSG00000126934	"Mitogen-activated protein kinase kinase 2"	P36507	19	4090321-4124129	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB003835, HPA051993"	Supported		Supported	Cytosol				Cytosol		"CAB003835: AB_562312, HPA051993: "	"unprognostic (4.39e-1)"	"prognostic favourable (3.72e-4)"	"unprognostic (4.24e-1)"	"unprognostic (1.26e-3)"	"unprognostic (2.58e-1)"	"prognostic favourable (7.98e-4)"	"unprognostic (2.08e-3)"	"unprognostic (2.11e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.06e-1)"	"unprognostic (7.45e-3)"	"unprognostic (4.95e-2)"	"unprognostic (1.32e-1)"	"prognostic favourable (5.43e-5)"	"unprognostic (2.91e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.90e-2)"	23.9	33.0	35.6	27.6	36.1	46.7	30.2	31.2	43.4	22.6	38.8	24.6	27.0	70.9	21.8	23.2	32.8	21.7	27.9	41.4	33.1	31.0	22.7	42.0	24.1	44.5	34.4	29.2	30.8	46.0	18.9	29.7	21.3	26.1	25.7	24.3	21.7	41.5	24.0	134.9	27.4	56.7	19.0	25.2	25.9	28.3	42.0	20.9	44.1	26.2	42.2	29.1	20.0	26.9	11.4	10.7	28.3	10.6	11.3	12.1	4.5	36.2	40.0	21.9	30.7	30.3	36.6	21.9	23.9	32.0	32.7	29.7	34.6	19.7	31.0	22.6	27.2	26.2	17.1	25.5	25.4	26.3	20.8	11.3	21.8	38.2	46.5	20.8	23.9	40.4	24.9	22.9	30.6	28.9	21.6	61.3	27.5	45.4	41.1	29.2	25.1	29.1	31.5	14.4	35.4	28.5	23.3	29.7	29.6	21.9	30.4	74.5	23.4	35.7	25.5	26.9	23.3	68.6	36.8	61.7	37.3	21.7	41.7	37.5	45.9	15.2	9.1	28.3	11.9	10.6	9.7	8.9	9.7	12.1	10.7	11.4	8.9	11.6	14.4	11.3	8.7	6.0	9.2	4.5	35.6	36.1	31.2	43.4	33.1	31.0	34.4	29.2	26.1	20.9
MAP2K4	"JNKK1, MEK4, MKK4, PRKMK4, SERK1"	ENSG00000065559	"Mitogen-activated protein kinase kinase 4"	P45985	17	12020824-12143830	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Stress response"	"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.2"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007751, HPA060074"	Enhanced		Approved	"Nucleoplasm,Cell Junctions"				Nucleoplasm	"Cell Junctions"	"CAB007751: , HPA060074: "	"unprognostic (1.55e-1)"	"unprognostic (1.85e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.89e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.93e-3)"	"unprognostic (2.53e-1)"	"unprognostic (2.76e-3)"	"unprognostic (4.82e-2)"	"unprognostic (5.32e-3)"	"unprognostic (3.13e-1)"	"unprognostic (2.30e-1)"	"unprognostic (7.00e-2)"	"unprognostic (1.79e-1)"	10.7	13.2	23.7	9.4	21.0	3.1	14.4	25.0	42.7	12.5	11.5	7.9	8.5	9.6	12.1	17.8	18.5	11.5	10.7	14.9	31.7	29.3	15.8	20.6	11.4	14.6	24.5	27.1	13.0	11.1	19.6	16.7	15.1	23.4	14.5	13.1	6.5	9.8	13.2	20.6	14.4	9.9	13.5	16.3	10.7	10.7	10.3	9.8	10.3	16.5	11.6	13.4	11.1	11.2	2.8	1.8	13.2	4.3	3.5	3.3	2.3	17.9	15.5	20.4	10.5	11.3	14.7	13.0	12.3	16.2	14.0	13.4	9.2	6.2	7.5	10.0	19.1	12.1	17.7	17.1	21.1	13.2	20.8	8.3	9.1	17.3	13.3	7.9	12.6	12.1	17.0	16.4	17.2	12.7	8.8	4.4	17.6	6.7	9.6	7.4	11.9	7.6	11.8	22.9	5.1	19.2	11.6	4.1	12.1	14.2	7.6	11.8	9.6	5.8	11.6	6.9	10.7	9.5	14.5	8.7	9.7	5.9	13.0	6.3	10.0	0.6	2.7	2.0	3.0	1.5	2.7	2.8	2.4	2.4	1.8	2.7	2.0	3.3	13.2	3.5	4.3	1.8	2.6	2.3	23.7	21.0	25.0	42.7	31.7	29.3	24.5	27.1	23.4	9.8
MAP3K1	"MAPKKK1, MEKK, MEKK1"	ENSG00000095015	"Mitogen-activated protein kinase kinase kinase 1"	Q13233	5	56815574-56896152	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SH-SY5Y: 27.0;THP-1: 25.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Region enriched"	"Detected in many"	6	"olfactory region: 22.5"	"Low region specificity"	"Detected in all"			"CAB004500, HPA046509"	Approved		Approved	Cytosol				Cytosol		"CAB004500: AB_627926, HPA046509: "	"unprognostic (1.77e-1)"	"unprognostic (1.71e-2)"	"unprognostic (4.09e-1)"	"unprognostic (2.18e-1)"	"unprognostic (3.48e-2)"	"unprognostic (5.39e-3)"	"unprognostic (5.20e-3)"	"unprognostic (2.52e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.18e-2)"	"unprognostic (1.58e-1)"	"unprognostic (9.92e-3)"	"unprognostic (1.11e-1)"	6.7	4.9	5.4	14.6	4.8	15.2	14.9	8.0	4.5	7.6	6.7	5.4	7.3	4.3	7.1	9.4	12.7	7.2	5.9	4.3	3.7	3.2	9.5	4.4	8.8	21.4	6.4	3.1	8.4	9.2	6.3	7.9	8.1	4.5	8.3	4.5	12.6	15.4	9.7	3.5	21.8	11.2	4.0	3.8	21.3	5.5	8.5	5.1	11.7	19.2	6.6	18.2	6.0	11.7	6.6	2.8	6.7	7.2	2.7	5.8	2.3	6.4	3.9	6.2	4.1	1.0	0.8	10.4	1.2	1.7	3.9	5.5	18.4	4.9	5.8	0.4	1.5	3.4	5.1	2.3	5.4	2.0	2.2	3.2	1.7	8.6	2.5	5.1	9.0	1.0	2.5	1.2	1.9	1.7	2.8	10.5	1.0	2.8	3.5	6.9	2.8	0.5	5.6	4.4	19.9	6.8	6.8	2.6	27.0	3.8	4.8	11.0	13.2	25.2	4.9	0.3	3.3	1.4	2.3	7.7	3.9	11.1	0.6	3.0	6.6	6.7	4.5	1.0	1.2	6.8	1.2	6.6	3.8	1.8	2.8	5.1	2.5	0.9	2.6	2.7	7.2	1.5	5.8	2.3	5.4	4.8	8.0	4.5	3.7	3.2	6.4	3.1	4.5	5.1
MAP3K13	"LZK, MEKK13"	ENSG00000073803	"Mitogen-activated protein kinase kinase kinase 13"	O43283	3	185282941-185489097	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016497, HPA036691, HPA036692"	Uncertain		Approved	"Nucleoplasm,Centriolar satellite,Cytosol"				"Centriolar satellite"	"Nucleoplasm, Cytosol"	"HPA016497: AB_10670027, HPA036691: AB_10673661, HPA036692: AB_10670845"	"unprognostic (8.95e-2)"	"unprognostic (6.72e-3)"	"unprognostic (9.46e-2)"	"prognostic unfavourable (1.28e-5)"	"unprognostic (5.16e-2)"	"unprognostic (2.81e-1)"	"unprognostic (2.61e-1)"	"unprognostic (1.23e-2)"	"unprognostic (9.04e-2)"	"prognostic favourable (1.11e-4)"	"prognostic unfavourable (7.27e-5)"	"unprognostic (2.70e-3)"	"unprognostic (1.54e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.82e-1)"	"unprognostic (6.64e-2)"	"unprognostic (9.31e-3)"	9.8	24.8	21.7	8.7	22.2	9.5	15.1	16.4	26.1	12.9	16.9	18.4	10.5	16.8	12.9	42.1	15.2	14.6	13.1	8.1	19.2	18.6	21.9	20.7	15.2	7.4	23.2	17.1	16.5	24.9	20.9	24.5	9.1	21.8	14.5	18.9	18.6	26.2	11.4	3.3	9.8	23.4	12.1	26.4	8.7	16.4	12.9	15.8	4.4	18.6	8.3	10.3	12.5	11.5	23.7	21.5	21.1	13.2	11.5	17.4	7.8	29.1	5.8	11.3	0.3	10.3	12.7	6.6	6.7	4.6	10.9	13.2	11.2	11.0	0.2	23.0	12.2	16.7	0.3	15.5	19.4	32.4	15.0	0.1	7.9	9.2	11.2	15.3	8.4	11.5	13.6	9.3	11.7	12.1	0.3	23.7	9.7	9.1	1.8	7.2	13.0	13.7	0.2	13.5	16.0	19.2	7.6	18.6	12.4	11.3	17.1	23.2	25.8	8.6	8.0	9.0	11.7	16.2	14.5	12.1	15.6	9.6	13.2	7.8	14.7	6.4	13.2	5.1	10.3	12.2	15.8	23.7	12.4	12.8	21.5	19.0	17.4	16.8	21.1	11.5	8.6	9.4	4.8	7.8	21.7	22.2	16.4	26.1	19.2	18.6	23.2	17.1	21.8	15.8
MAP3K3	"MAPKKK3, MEKK3"	ENSG00000198909	"Mitogen-activated protein kinase kinase kinase 3"	Q99759	17	63622415-63696303	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007764, HPA035410, HPA035411"	Uncertain		Approved	Nucleoplasm				Nucleoplasm		"CAB007764: AB_562314, HPA035410: , HPA035411: "	"unprognostic (9.65e-3)"	"unprognostic (1.33e-1)"	"unprognostic (5.14e-2)"	"prognostic unfavourable (1.13e-4)"	"unprognostic (1.16e-1)"	"unprognostic (4.12e-2)"	"unprognostic (1.03e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.37e-2)"	"unprognostic (1.46e-3)"	"unprognostic (5.51e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.79e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.08e-2)"	23.9	11.8	10.5	20.5	15.0	24.8	19.1	26.8	14.9	22.2	21.8	15.0	14.0	8.0	24.5	13.2	16.6	18.3	20.6	37.4	11.3	8.4	17.1	12.4	23.1	21.4	14.4	9.6	21.6	11.4	16.9	12.3	21.0	11.9	18.4	8.3	21.7	12.8	18.5	19.6	15.4	14.7	20.4	13.2	30.4	16.4	26.5	12.3	12.9	15.5	12.8	15.4	19.0	26.8	1.9	3.5	18.3	8.5	1.1	2.6	2.3	10.1	7.6	9.7	9.4	18.6	15.0	4.4	10.0	11.0	12.5	10.1	3.5	2.1	10.9	7.1	19.6	3.8	6.3	7.1	7.9	9.5	13.9	8.9	10.3	4.9	9.7	6.8	9.5	10.7	4.9	15.5	8.2	30.3	5.4	14.5	9.9	7.1	12.2	7.1	6.0	8.1	6.5	24.8	7.1	4.5	4.6	5.0	11.9	6.8	8.2	8.3	8.2	6.8	27.2	32.0	8.5	17.3	12.1	14.4	14.6	4.0	6.9	5.5	8.3	8.8	8.5	10.4	2.2	8.3	2.3	1.5	2.6	2.1	3.5	1.9	2.5	2.5	18.3	1.1	8.2	1.3	1.9	2.3	10.5	15.0	26.8	14.9	11.3	8.4	14.4	9.6	11.9	12.3
MAP3K4	"KIAA0213, MAPKKK4, MEKK4, MTK1"	ENSG00000085511	"Mitogen-activated protein kinase kinase kinase 4"	Q9Y6R4	6	160991727-161117385	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007625	Uncertain		Approved	Cytosol				Cytosol		"HPA007625: AB_1853770"	"unprognostic (3.05e-3)"	"unprognostic (2.19e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.44e-1)"	"unprognostic (2.06e-1)"	"unprognostic (7.65e-2)"	"unprognostic (1.35e-3)"	"unprognostic (6.38e-2)"	"unprognostic (2.09e-1)"	"unprognostic (3.81e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.16e-2)"	"unprognostic (5.86e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.93e-1)"	"unprognostic (6.84e-2)"	12.0	8.0	13.1	17.7	12.6	9.1	14.6	23.1	14.0	16.4	13.9	9.3	12.2	9.5	22.2	11.9	21.4	14.1	11.4	12.4	11.9	7.8	9.4	8.2	15.9	14.4	12.8	8.9	17.4	12.1	15.8	16.2	12.4	9.2	14.2	9.8	9.4	15.0	15.4	24.4	15.1	13.3	13.9	7.7	10.6	11.1	13.5	12.4	16.2	10.6	13.0	16.8	15.8	23.9	8.8	5.4	17.5	3.8	3.5	8.9	2.2	4.6	5.3	10.1	8.6	6.3	7.4	6.5	5.3	4.7	6.1	6.5	7.5	3.4	9.6	3.8	13.5	11.7	10.3	10.6	7.5	7.0	8.4	12.5	4.9	7.4	4.8	13.0	6.1	4.6	12.3	6.4	5.8	7.9	31.6	11.1	6.5	4.8	8.7	6.6	6.1	8.2	9.6	9.3	7.6	5.6	3.4	5.8	5.2	9.9	10.6	0.9	4.3	15.9	7.4	7.5	9.6	6.9	25.0	6.5	5.2	8.8	8.8	13.4	7.8	17.5	3.8	2.3	5.0	3.0	8.9	6.2	7.1	4.5	4.3	8.8	5.0	4.9	0.2	3.5	1.7	5.4	4.8	2.2	13.1	12.6	23.1	14.0	11.9	7.8	12.8	8.9	9.2	12.4
MAP4K3	"GLK, MAPKKKK3, RAB8IPL1"	ENSG00000011566	"Mitogen-activated protein kinase kinase kinase kinase 3"	Q8IVH8	2	39249266-39437312	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 40.8;RT4: 37.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030380	Approved		Approved	"Nucleoplasm,Centriolar satellite"				"Centriolar satellite"	Nucleoplasm	"HPA030380: AB_10601132"	"unprognostic (4.82e-2)"	"unprognostic (7.22e-2)"	"unprognostic (5.87e-3)"	"unprognostic (7.34e-3)"	"unprognostic (6.77e-2)"	"unprognostic (2.57e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.66e-1)"	"unprognostic (6.73e-2)"	"unprognostic (4.33e-3)"	"unprognostic (4.26e-2)"	"unprognostic (2.12e-1)"	"unprognostic (3.08e-2)"	"unprognostic (3.30e-1)"	"unprognostic (2.43e-1)"	"unprognostic (5.08e-2)"	19.7	18.9	17.6	15.4	17.6	9.6	17.8	37.1	19.6	19.2	16.9	14.6	9.8	13.7	23.5	14.8	11.1	15.3	18.7	19.5	15.4	12.5	26.2	15.4	15.6	5.8	15.4	13.4	24.6	14.0	25.7	24.6	30.8	14.4	18.6	14.1	17.9	13.3	15.7	33.0	17.8	17.2	18.6	15.3	11.5	26.1	21.0	16.5	9.4	25.9	11.3	7.5	18.8	32.6	0.7	0.5	2.5	1.9	1.0	1.3	0.4	9.7	6.1	40.8	6.4	6.6	13.4	11.2	8.7	11.1	8.6	7.4	5.1	4.9	2.1	9.8	5.9	5.3	15.3	7.7	13.2	2.4	6.3	3.5	4.3	11.9	17.3	1.5	5.8	11.9	7.7	11.2	12.1	7.4	4.5	4.0	11.5	5.3	3.4	2.3	12.3	9.3	3.7	13.3	1.6	11.4	37.8	7.3	8.3	5.1	8.2	22.6	5.5	2.2	6.0	6.7	8.0	6.0	4.7	6.1	3.4	0.7	8.3	2.5	7.8	2.5	0.7	0.0	1.2	1.1	0.1	0.1	1.2	0.9	0.1	0.7	1.1	1.3	0.0	1.0	1.9	0.5	0.6	0.4	17.6	17.6	37.1	19.6	15.4	12.5	15.4	13.4	14.4	16.5
MAPK1	"ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2"	ENSG00000100030	"Mitogen-activated protein kinase 1"	P28482	22	21754500-21867680	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 80.3"	"Cell line enhanced"	"Detected in all"		"K-562: 79.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003995, CAB004229, HPA005700, HPA030069"	Approved					250000	250000			"CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035"	"unprognostic (9.41e-3)"	"unprognostic (2.68e-1)"	"unprognostic (2.50e-3)"	"unprognostic (4.17e-1)"	"unprognostic (4.44e-3)"	"unprognostic (1.72e-1)"	"prognostic unfavourable (4.95e-4)"	"unprognostic (2.29e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.58e-1)"	"unprognostic (8.43e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.35e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.41e-1)"	"unprognostic (6.49e-2)"	16.1	21.1	32.9	18.3	80.3	20.2	13.6	31.0	54.5	18.6	18.5	23.2	9.6	13.7	17.4	10.6	25.7	16.9	14.9	22.8	32.4	23.4	21.7	16.4	19.9	16.6	18.4	23.6	16.0	19.8	27.4	10.9	17.2	27.6	16.4	19.9	14.2	15.8	17.8	28.2	17.5	15.1	22.8	20.4	19.8	17.2	24.2	21.5	19.5	23.0	11.1	21.4	17.7	15.3	2.5	3.2	13.5	4.9	7.0	13.7	2.5	19.3	12.2	15.7	9.0	18.7	18.9	6.0	21.4	20.0	19.2	18.6	9.7	10.3	10.7	10.6	28.6	18.4	18.5	17.1	25.1	43.1	17.3	19.4	11.5	11.4	15.4	27.3	20.1	14.0	13.7	23.2	21.5	26.2	79.5	12.2	23.4	7.9	17.6	6.0	5.9	12.1	19.4	39.0	2.9	11.0	15.9	12.9	7.1	23.1	14.0	12.5	10.5	9.2	22.9	16.1	21.0	18.4	13.6	11.7	14.3	16.7	15.2	13.3	17.4	1.0	4.0	5.8	13.7	4.6	3.9	2.0	2.9	4.9	3.2	2.5	2.8	5.1	13.5	7.0	4.9	3.2	2.7	2.5	32.9	80.3	31.0	54.5	32.4	23.4	18.4	23.6	27.6	21.5
MAPK14	"CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15"	ENSG00000112062	"Mitogen-activated protein kinase 14"	Q16539	6	36027677-36111236	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Stress response, Transcription, Transcription regulation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	5	"basophil: 32.1;neutrophil: 12.3"	"Lineage enriched"	"Detected in all"	7	"granulocytes: 32.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010285, CAB040578, HPA051825"	Approved		Supported	"Nuclear speckles,Cytosol"		7100000	7100000	"Nuclear speckles"	Cytosol	"CAB010285: AB_632140, CAB040578: , HPA051825: "	"unprognostic (6.76e-3)"	"unprognostic (6.28e-2)"	"unprognostic (6.30e-3)"	"unprognostic (3.30e-3)"	"unprognostic (6.98e-2)"	"unprognostic (4.04e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.93e-1)"	"unprognostic (2.20e-3)"	"unprognostic (8.39e-2)"	"unprognostic (6.27e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.47e-2)"	"unprognostic (3.66e-3)"	"unprognostic (6.66e-2)"	"unprognostic (3.25e-1)"	"unprognostic (1.58e-1)"	21.5	20.6	11.7	18.4	15.5	49.9	20.7	26.5	18.1	22.0	20.5	12.5	11.9	16.9	38.8	12.1	24.0	18.9	16.0	16.4	9.3	9.5	16.0	29.8	21.5	29.0	12.0	11.3	17.7	18.5	15.0	27.2	27.3	10.2	23.4	18.3	17.0	16.7	16.5	21.2	25.6	22.5	26.0	10.6	35.5	18.2	11.1	10.3	34.1	20.9	17.6	20.8	25.0	30.0	2.3	4.0	32.1	4.9	3.0	2.8	2.1	18.3	10.1	10.9	17.5	24.8	24.8	24.0	19.2	25.0	22.8	23.8	24.7	9.5	14.9	19.1	21.1	13.2	18.0	16.6	23.9	16.8	14.3	34.4	14.4	20.6	13.7	21.6	20.8	17.4	16.2	16.4	16.3	25.8	19.0	18.7	15.5	8.7	22.2	26.0	6.7	10.1	26.4	17.7	13.8	16.1	25.3	8.2	7.0	17.3	13.0	20.1	15.3	40.4	18.1	20.5	11.9	12.9	17.6	9.2	21.0	14.9	9.3	42.8	16.8	32.1	4.9	3.0	2.4	3.5	2.8	1.5	2.2	2.6	4.0	2.3	2.5	2.4	12.3	3.0	4.7	1.9	2.6	2.1	11.7	15.5	26.5	18.1	9.3	9.5	12.0	11.3	10.2	10.3
MAPK3	"ERK1, p44erk1, p44mapk, PRKM3"	ENSG00000102882	"Mitogen-activated protein kinase 3"	P27361	16	30114105-30123506	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Cell cycle, Host-virus interaction"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"eosinophil: 25.1;neutrophil: 11.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 25.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002683, HPA003995, HPA005700, HPA030069"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB002683: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035"	"unprognostic (5.03e-2)"	"unprognostic (4.62e-2)"	"unprognostic (3.46e-2)"	"unprognostic (1.60e-1)"	"unprognostic (4.70e-3)"	"unprognostic (2.75e-1)"	"prognostic unfavourable (1.11e-4)"	"unprognostic (2.09e-2)"	"unprognostic (3.59e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.51e-2)"	"unprognostic (8.78e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.01e-2)"	"unprognostic (2.38e-1)"	"unprognostic (1.19e-2)"	24.9	18.5	63.3	15.3	43.2	15.6	21.1	24.8	52.0	21.3	45.1	30.4	6.3	39.7	24.2	11.4	44.1	28.7	25.6	21.2	37.1	34.0	13.4	8.8	23.3	13.1	33.8	27.4	32.7	13.0	26.1	15.2	27.6	27.6	20.1	36.7	26.2	17.1	18.3	13.9	18.7	49.2	24.0	27.8	15.9	33.7	11.6	19.5	8.4	20.5	18.7	26.0	18.2	22.2	1.4	1.5	25.1	2.7	0.8	3.1	1.4	13.7	7.5	16.1	9.1	40.5	53.8	9.0	10.3	25.6	16.4	19.6	9.0	27.8	13.9	10.2	28.8	5.1	13.5	12.1	16.0	26.3	15.7	4.3	8.3	15.0	40.7	3.1	11.9	33.1	7.0	18.7	8.4	41.6	5.8	17.9	21.6	36.3	14.3	5.0	4.3	6.6	17.0	9.6	31.2	14.9	8.7	14.2	10.1	5.9	20.8	6.0	13.6	7.6	29.4	10.8	9.3	12.3	3.5	20.3	9.3	7.1	21.6	6.7	7.6	2.4	2.7	25.1	0.9	1.9	1.4	1.3	2.1	1.6	1.4	1.4	1.5	1.6	11.3	0.8	1.0	1.5	3.1	1.4	63.3	43.2	24.8	52.0	37.1	34.0	33.8	27.4	27.6	19.5
MAPK7	"BMK1, ERK5, PRKM7"	ENSG00000166484	"Mitogen-activated protein kinase 7"	Q13164	17	19377721-19383544	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Differentiation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 27.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018561, HPA031031"	Uncertain		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB018561: AB_2140544, HPA031031: "	"unprognostic (1.63e-1)"	"unprognostic (2.75e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.90e-2)"	"unprognostic (4.38e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavourable (1.86e-4)"	"unprognostic (5.67e-3)"	"unprognostic (1.62e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.75e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.71e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.78e-2)"	11.5	15.0	6.4	7.3	7.6	9.2	11.8	12.5	7.9	13.4	15.3	7.2	6.0	9.2	13.1	14.1	17.3	9.4	11.8	8.2	5.9	4.7	10.8	4.8	9.9	9.2	8.2	5.2	25.4	5.7	7.3	7.5	12.5	6.7	14.0	6.9	10.5	7.8	12.3	7.5	13.1	11.2	13.8	7.1	13.2	8.0	13.3	7.5	4.5	8.6	11.3	10.6	12.7	15.9	2.2	2.6	11.5	7.4	5.5	4.7	3.0	4.1	6.5	5.4	4.2	27.1	11.3	6.3	5.6	5.2	7.8	7.2	7.5	0.7	2.5	4.6	9.7	4.6	6.3	5.1	4.9	4.3	4.8	1.2	4.7	3.3	11.7	1.1	4.2	11.9	3.6	11.8	4.2	5.7	2.2	0.9	7.7	2.7	8.3	4.4	6.2	4.3	4.5	7.9	1.7	2.6	2.3	2.4	7.2	5.7	0.5	2.9	3.5	1.4	3.2	8.4	6.2	9.2	3.8	1.6	2.4	0.6	9.7	1.0	5.0	1.0	3.6	11.5	4.7	7.4	2.5	2.2	2.2	4.1	2.6	1.4	2.1	2.6	1.3	5.5	6.5	1.7	1.0	3.0	6.4	7.6	12.5	7.9	5.9	4.7	8.2	5.2	6.7	7.5
MAPK8	"JNK, JNK1, PRKM8, SAPK1"	ENSG00000107643	"Mitogen-activated protein kinase 8"	P45983	10	48306639-48439360	"Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004463, CAB069396"	Approved									"CAB004463: AB_675868, CAB069396: AB_1619977"	"unprognostic (7.49e-2)"	"unprognostic (1.47e-1)"	"unprognostic (2.74e-2)"	"unprognostic (1.46e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavourable (8.66e-4)"	"unprognostic (4.23e-2)"	"unprognostic (5.98e-2)"	"unprognostic (4.31e-3)"	"unprognostic (2.33e-1)"	"unprognostic (6.06e-2)"	"prognostic favourable (8.66e-4)"	"unprognostic (1.58e-1)"	"unprognostic (9.95e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.01e-3)"	13.4	11.7	15.3	11.5	18.5	13.3	22.1	33.6	35.2	15.2	13.9	12.9	19.5	16.7	17.1	10.8	16.1	12.4	15.1	11.2	20.0	18.0	20.1	23.6	11.7	12.0	15.9	16.7	18.9	15.3	12.7	23.7	12.2	23.6	13.0	14.3	12.4	17.2	15.9	18.9	10.8	17.7	14.6	13.7	9.6	12.2	23.4	12.2	20.5	22.3	9.0	13.8	11.8	13.0	4.5	4.3	5.2	4.3	4.7	5.7	3.5	15.7	4.3	14.3	8.1	5.5	6.5	11.1	23.8	16.3	14.3	11.7	4.9	16.4	5.7	6.5	13.3	9.7	5.0	9.2	18.7	34.1	8.2	8.2	5.0	6.7	9.1	14.0	9.6	5.5	10.6	10.6	21.1	13.1	13.1	10.6	9.3	4.6	17.1	7.4	8.9	3.1	11.2	14.7	5.7	8.7	6.1	24.1	19.1	9.3	7.8	10.7	8.5	6.7	11.2	10.7	25.6	8.1	17.9	3.3	8.1	11.6	7.4	14.9	6.1	0.0	3.3	3.0	4.1	2.8	4.7	4.5	5.7	5.0	3.3	2.9	5.6	3.9	5.2	4.7	4.3	4.3	2.9	3.5	15.3	18.5	33.6	35.2	20.0	18.0	15.9	16.7	23.6	12.2
MAPK8IP1	"IB1, JIP-1, JIP1, PRKM8IP"	ENSG00000121653	"Mitogen-activated protein kinase 8 interacting protein 1"	Q9UQF2	11	45885651-45906465	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Diabetes mellitus, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 73.5"	"Cell line enhanced"	"Detected in many"		"SCLC-21H: 38.6"	"Cancer enhanced"	"Detected in all"		"glioma: 51.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058921, HPA070332"			Enhanced	"Plasma membrane"				"Plasma membrane"		"HPA058921: , HPA070332: "	"unprognostic (3.96e-2)"	"unprognostic (8.73e-2)"	"unprognostic (1.08e-1)"	"unprognostic (6.88e-2)"	"unprognostic (5.59e-2)"	"unprognostic (2.82e-1)"	"unprognostic (8.25e-3)"	"unprognostic (3.42e-3)"	"unprognostic (1.27e-2)"	"unprognostic (9.54e-2)"	"unprognostic (3.22e-3)"	"unprognostic (2.20e-2)"	"prognostic favourable (1.23e-11)"	"unprognostic (7.19e-2)"	"unprognostic (4.01e-2)"	"unprognostic (4.46e-2)"	"unprognostic (1.80e-3)"	3.0	12.8	33.3	2.1	29.6	1.4	2.7	24.9	73.5	3.1	1.9	4.6	0.1	1.6	4.9	3.1	2.1	6.6	3.0	2.9	38.1	22.3	5.1	2.7	2.6	1.0	28.0	18.9	4.4	26.4	14.7	24.8	1.6	23.5	4.9	1.5	4.5	4.8	5.0	1.7	1.7	2.0	4.4	44.4	1.7	3.8	10.8	4.8	0.0	3.9	0.5	0.9	2.0	0.4	0.4	0.4	2.1	0.9	2.6	0.2	0.0	0.0	3.5	4.7	13.1	1.8	0.9	0.1	2.5	2.2	5.0	3.6	3.0	0.5	0.2	1.2	2.9	2.8	5.0	2.3	2.2	1.9	6.5	0.0	4.4	2.0	1.6	0.2	2.2	1.2	0.5	3.2	0.6	1.1	5.4	0.8	1.4	1.8	0.1	0.3	12.5	5.2	0.3	7.7	0.1	2.3	0.0	38.6	14.4	4.1	3.4	4.7	5.5	0.2	1.0	6.4	9.8	9.5	4.5	0.5	0.6	0.2	4.0	0.1	1.9	2.1	0.9	0.0	0.2	0.2	0.1	0.2	0.0	0.1	0.0	0.4	0.1	0.2	1.8	2.6	0.0	0.4	0.1	0.0	33.3	29.6	24.9	41.7	38.1	22.3	28.0	18.9	23.5	4.8
MAPKAPK2		ENSG00000162889	"Mitogen-activated protein kinase-activated protein kinase 2"	P49137	1	206684944-206734283	"Cancer-related genes, Enzymes, Predicted membrane proteins"	"DNA damage"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"plasmacytoid DC: 18.7"	"Lineage enriched"	"Detected in all"	6	"dendritic cells: 18.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010297, HPA045556, HPA063708, HPA064435"	Approved		Supported	Nucleoplasm,Centrosome				Nucleoplasm	Centrosome	"CAB010297: AB_2250405, HPA045556: , HPA063708: , HPA064435: "	"unprognostic (7.93e-2)"	"unprognostic (1.83e-1)"	"unprognostic (5.27e-2)"	"unprognostic (5.12e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.32e-2)"	"prognostic unfavourable (1.93e-4)"	"unprognostic (9.85e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (4.58e-6)"	"unprognostic (2.12e-1)"	"unprognostic (1.37e-1)"	"unprognostic (6.96e-2)"	"unprognostic (3.29e-2)"	23.0	25.3	11.6	21.2	15.7	58.6	23.9	11.1	14.5	19.3	25.6	17.2	14.5	25.7	20.0	18.5	23.5	17.3	26.0	89.2	12.3	8.7	33.7	26.7	26.7	21.5	16.7	6.5	23.3	19.1	16.9	22.8	13.6	15.7	20.2	14.4	17.8	19.8	14.4	62.9	18.3	32.9	18.3	14.6	37.7	23.1	21.3	14.6	26.9	24.3	25.2	28.2	22.9	46.1	1.1	18.7	3.2	1.1	2.3	1.6	0.5	20.9	8.3	11.5	12.9	34.0	20.0	14.3	14.6	33.1	22.3	21.1	15.8	10.2	10.1	10.2	29.4	15.9	8.6	15.5	16.1	11.7	6.5	16.9	10.3	10.2	26.3	24.9	56.6	27.5	19.9	21.4	23.7	18.2	19.4	45.9	18.0	26.0	10.0	18.0	13.3	11.6	25.8	24.1	3.2	16.8	12.8	9.2	11.9	17.2	29.1	20.2	14.1	24.2	17.3	20.1	17.0	23.3	19.8	59.8	53.1	8.2	22.8	15.2	6.6	1.1	0.7	1.4	1.6	1.1	1.5	1.0	1.2	1.5	0.6	1.1	0.6	1.1	3.2	2.3	1.0	18.7	1.4	0.5	11.6	15.7	11.1	14.5	12.3	8.7	16.7	6.5	15.7	14.6
MAST2	"KIAA0807, MAST205"	ENSG00000086015	"Microtubule associated serine/threonine kinase 2"	Q6P0Q8	1	45786987-46036124	"Cancer-related genes, Enzymes, Predicted membrane proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 83.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 4.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039722, HPA040155"	Approved		Approved	Cytosol				Cytosol		"HPA039722: AB_10795294, HPA040155: AB_10793957"	"unprognostic (7.80e-2)"	"unprognostic (3.02e-2)"	"unprognostic (5.77e-2)"	"unprognostic (1.52e-1)"	"unprognostic (3.82e-1)"	"unprognostic (3.17e-2)"	"prognostic unfavourable (4.31e-8)"	"unprognostic (8.86e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.75e-1)"	"prognostic unfavourable (6.85e-13)"	"unprognostic (4.82e-3)"	"unprognostic (2.43e-1)"	"unprognostic (9.73e-2)"	"unprognostic (4.90e-1)"	8.9	4.3	7.0	9.9	8.1	3.7	7.1	7.1	11.8	13.6	15.2	8.4	6.6	11.2	16.7	7.7	8.8	9.5	9.9	25.5	5.0	7.6	4.8	6.1	5.9	4.4	8.9	7.3	19.8	3.6	9.1	10.5	5.5	10.1	13.9	13.9	7.2	8.3	8.6	83.3	5.5	21.3	14.9	5.8	2.5	9.0	24.8	4.8	3.5	5.7	27.4	7.5	16.3	10.6	0.5	1.9	1.4	4.3	1.4	1.4	0.5	15.2	12.4	12.5	9.6	16.4	23.6	13.9	16.3	11.8	15.1	16.9	14.2	5.0	23.9	7.7	19.9	7.6	15.1	9.3	16.0	11.5	8.1	10.8	14.0	13.0	14.3	5.8	13.9	18.1	12.1	25.3	20.3	14.1	8.3	7.3	18.0	10.4	8.4	6.0	10.3	14.2	12.4	21.0	4.5	7.8	8.3	17.5	10.4	19.2	25.1	8.2	11.4	5.7	13.7	29.3	18.9	15.3	16.1	10.0	8.9	8.7	19.6	7.9	12.1	0.0	1.1	1.4	1.4	0.6	1.4	0.2	0.7	1.4	1.9	0.5	0.5	1.0	0.0	1.4	4.3	0.1	0.0	0.5	7.0	8.1	7.1	11.8	5.0	7.6	8.9	7.3	10.1	4.8
MATK	"CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101"	ENSG00000007264	"Megakaryocyte-associated tyrosine kinase"	P42679	19	3777970-3802129	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.3;bone marrow: 19.1;brain: 27.4"	"Cell line enhanced"	"Detected in some"		"HL-60: 40.7;HMC-1: 12.5;K-562: 18.1;MCF7: 13.2;NB-4: 28.4;SCLC-21H: 12.4;THP-1: 10.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 19.4;NK-cell: 29.3"	"Group enriched"	"Detected in many"	54	"NK-cells: 29.3;T-cells: 19.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004847, HPA066547"	Approved		Approved	"Microtubules,Cytokinetic bridge,Mitotic spindle,Centriolar satellite,Cytosol"				Microtubules	"Cytokinetic bridge, Mitotic spindle, Centriolar satellite, Cytosol"	"HPA004847: AB_1079316, HPA066547: "	"prognostic favourable (5.27e-4)"	"unprognostic (1.28e-2)"	"unprognostic (1.84e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.36e-1)"	"unprognostic (3.39e-2)"	"unprognostic (9.50e-2)"	"unprognostic (1.23e-1)"	"unprognostic (7.91e-2)"	"unprognostic (3.19e-3)"	"unprognostic (2.07e-2)"	"unprognostic (4.51e-2)"	"unprognostic (1.16e-2)"	"unprognostic (7.59e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.26e-1)"	"unprognostic (2.33e-2)"	11.2	1.6	22.1	6.8	18.1	19.1	2.2	1.5	27.4	1.5	2.3	1.7	0.0	7.0	1.2	0.4	1.1	4.7	5.1	1.7	25.1	10.0	1.1	2.8	7.3	9.6	7.0	11.0	1.0	1.6	0.1	1.4	1.4	6.1	1.2	1.4	0.6	3.8	1.0	0.8	1.6	6.7	1.1	2.8	14.8	4.1	2.1	1.3	3.5	0.9	0.0	4.5	2.4	0.7	0.4	0.3	0.4	0.0	29.3	19.4	2.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	4.1	5.4	0.1	0.0	0.0	7.0	4.5	0.5	1.1	0.0	40.7	12.5	0.0	0.0	0.0	0.0	0.0	18.1	0.0	0.0	13.2	0.1	28.4	3.3	0.1	0.0	0.0	0.0	0.0	0.0	12.4	0.0	0.0	0.0	0.0	0.0	10.7	1.3	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.4	0.0	13.2	0.0	2.5	12.2	0.3	0.4	1.2	7.1	0.4	29.3	0.0	0.1	0.1	2.7	22.1	18.1	1.5	27.4	25.1	10.0	7.0	11.0	6.1	1.3
MAX	"bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8"	ENSG00000125952	"MYC associated factor X"	P61244	14	65006174-65102695	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 92.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000328, HPA003474"	Supported		Supported	"Nucleoplasm,Golgi apparatus,Vesicles"				Nucleoplasm	"Golgi apparatus, Vesicles"	"CAB000328: AB_2281783, HPA003474: AB_1079317"	"unprognostic (4.50e-3)"	"unprognostic (1.51e-3)"	"unprognostic (4.08e-2)"	"unprognostic (2.87e-1)"	"unprognostic (8.37e-2)"	"unprognostic (2.42e-2)"	"unprognostic (1.13e-3)"	"unprognostic (1.30e-3)"	"unprognostic (1.53e-2)"	"unprognostic (7.36e-3)"	"unprognostic (7.19e-2)"	"unprognostic (1.66e-2)"	"prognostic unfavourable (5.57e-4)"	"unprognostic (2.99e-1)"	"unprognostic (4.68e-2)"	"prognostic favourable (2.12e-4)"	"unprognostic (6.03e-2)"	33.4	25.5	31.3	31.5	38.6	68.7	25.8	59.0	38.2	34.6	29.4	37.2	26.3	31.5	34.3	24.0	47.6	38.2	27.9	30.1	29.9	28.4	26.3	21.8	31.4	43.4	37.1	21.6	39.7	20.0	17.4	23.7	30.2	32.7	31.9	25.0	26.8	33.6	37.7	27.8	32.1	40.2	30.7	34.8	42.9	24.8	15.7	40.9	41.3	30.2	22.5	40.7	35.1	40.7	18.7	19.1	87.5	23.6	19.2	30.0	44.8	28.3	11.1	6.8	11.0	18.0	14.1	8.9	10.0	15.3	12.5	15.4	7.1	19.9	23.6	8.4	12.0	14.1	17.1	13.9	9.4	23.8	10.4	36.7	7.3	7.8	21.1	13.8	92.4	16.8	9.9	11.5	12.7	13.8	17.2	9.6	12.6	15.7	31.9	47.6	9.1	18.2	18.1	10.8	10.6	11.5	9.5	14.7	9.6	13.1	14.0	12.8	13.7	17.7	17.2	11.5	13.9	10.6	8.0	11.8	10.0	14.9	14.3	13.3	11.4	87.5	23.6	80.6	21.7	20.1	23.7	18.7	25.4	22.1	19.1	17.6	26.6	22.3	49.5	19.2	17.4	18.3	30.0	44.8	31.3	38.6	59.0	38.2	29.9	28.4	37.1	21.6	32.7	40.9
MBD1	"CXXC3, PCM1"	ENSG00000141644	"Methyl-CpG binding domain protein 1"	Q9UIS9	18	50266882-50281774	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009017, CAB036003, HPA068850"	Approved		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB009017: AB_2095559, CAB036003: , HPA068850: "	"unprognostic (2.12e-2)"	"unprognostic (5.05e-2)"	"unprognostic (6.88e-2)"	"unprognostic (5.01e-3)"	"unprognostic (9.20e-2)"	"unprognostic (6.85e-2)"	"prognostic unfavourable (5.08e-6)"	"unprognostic (5.91e-2)"	"unprognostic (2.61e-2)"	"unprognostic (4.65e-2)"	"unprognostic (1.96e-3)"	"prognostic unfavourable (1.70e-6)"	"unprognostic (7.06e-3)"	"unprognostic (7.70e-2)"	"unprognostic (7.05e-2)"	"unprognostic (4.61e-2)"	"unprognostic (1.31e-1)"	14.7	21.7	18.0	18.8	20.8	29.4	15.7	27.1	29.4	15.3	17.2	18.8	16.2	18.7	18.4	16.6	21.1	16.4	16.8	19.7	19.2	14.0	17.4	18.9	16.0	20.9	21.8	23.1	20.7	19.7	28.2	24.2	19.4	18.2	18.0	13.9	15.0	19.6	19.5	25.9	24.2	18.3	18.3	15.2	22.6	18.0	72.3	21.5	19.1	19.9	20.0	18.2	19.1	20.0	13.1	11.7	22.2	11.6	14.3	17.4	12.1	10.2	9.7	11.0	12.4	11.8	9.7	11.8	12.4	14.3	17.2	13.3	7.3	8.2	16.3	9.0	12.0	18.6	12.5	21.7	10.0	18.2	8.0	10.3	13.8	7.7	22.9	24.8	21.8	11.3	35.1	19.6	45.0	14.1	12.9	25.6	13.2	9.5	20.8	13.0	10.3	7.8	19.3	8.1	17.7	8.5	4.7	14.5	13.8	9.2	8.8	11.3	11.2	22.8	15.2	18.7	8.6	6.0	12.5	47.6	20.1	17.2	12.1	19.1	16.9	15.2	11.6	22.2	17.4	10.1	16.4	13.0	15.2	14.4	11.7	13.1	15.9	12.8	15.6	14.3	7.9	10.7	13.9	12.1	18.0	20.8	27.1	29.4	19.2	14.0	21.8	23.1	18.2	21.5
MBD2		ENSG00000134046	"Methyl-CpG binding domain protein 2"	Q9UBB5	18	54151601-54224788	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 8.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037282, HPA067582, HPA067615"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB037282: AB_477234, HPA067582: , HPA067615: "	"unprognostic (4.86e-2)"	"unprognostic (7.21e-2)"	"prognostic favourable (6.49e-4)"	"unprognostic (1.19e-1)"	"unprognostic (3.36e-2)"	"unprognostic (2.47e-1)"	"unprognostic (2.38e-3)"	"unprognostic (2.35e-2)"	"unprognostic (2.71e-2)"	"unprognostic (2.36e-3)"	"unprognostic (8.04e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.08e-1)"	"unprognostic (8.70e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.51e-3)"	"unprognostic (5.19e-2)"	29.8	11.9	8.5	27.9	9.8	15.3	24.0	9.9	9.0	17.5	22.5	7.4	20.1	10.5	12.5	14.8	33.1	11.3	18.7	17.9	7.9	8.1	23.3	23.2	21.3	33.7	10.0	5.3	15.3	19.3	13.1	12.5	38.1	8.6	18.3	15.0	12.1	23.3	17.3	13.9	24.1	26.7	15.7	11.7	36.9	12.5	26.1	9.4	31.0	31.0	25.4	32.2	22.8	27.1	2.0	1.5	2.2	8.2	0.4	2.6	0.8	12.6	5.7	10.7	5.2	12.6	10.7	10.4	11.9	15.0	13.8	12.1	3.7	7.0	29.8	6.1	18.4	20.2	9.0	16.1	15.2	22.2	4.9	4.4	9.0	7.9	13.0	13.9	8.1	9.3	18.1	10.5	15.5	15.9	3.4	27.7	12.4	6.0	14.0	7.8	11.1	7.6	9.5	6.2	12.0	19.8	13.1	11.6	4.9	9.2	9.4	6.2	4.8	7.1	13.7	14.2	6.5	4.9	10.5	30.1	16.3	23.0	12.4	11.9	8.4	0.1	2.6	1.2	1.2	4.6	1.6	1.4	1.3	1.9	1.5	2.0	0.7	1.2	2.2	0.4	8.2	1.2	2.6	0.8	8.5	9.8	9.9	9.0	7.9	8.1	10.0	5.3	8.6	9.4
MBD4	MED1	ENSG00000129071	"Methyl-CpG binding domain 4, DNA glycosylase"	O95243	3	129430944-129440179	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Hydrolase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002031	Supported		Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA002031: AB_1079319"	"unprognostic (2.70e-2)"	"unprognostic (3.48e-3)"	"unprognostic (1.18e-2)"	"unprognostic (6.37e-2)"	"unprognostic (4.31e-2)"	"unprognostic (7.11e-2)"	"unprognostic (4.70e-2)"	"unprognostic (3.25e-2)"	"unprognostic (2.02e-2)"	"unprognostic (5.73e-2)"	"prognostic unfavourable (2.18e-4)"	"prognostic unfavourable (4.75e-4)"	"prognostic unfavourable (2.73e-6)"	"unprognostic (9.27e-2)"	"unprognostic (1.59e-2)"	"unprognostic (8.58e-2)"	"unprognostic (3.35e-2)"	18.1	14.5	14.9	41.9	19.0	26.2	22.8	22.1	16.3	24.0	17.2	14.2	11.2	16.0	16.6	17.8	14.1	15.3	17.4	22.0	15.3	12.8	24.1	30.1	19.0	41.6	17.6	13.7	26.5	18.9	14.8	23.8	17.4	13.6	14.7	16.2	8.4	16.2	16.2	18.2	16.0	21.9	14.7	15.9	34.2	18.7	11.3	15.4	30.4	16.0	14.7	47.8	18.3	18.0	40.3	8.7	19.6	9.5	9.3	15.1	8.7	19.3	11.8	14.3	16.0	16.5	14.8	16.6	16.8	16.0	16.1	19.3	14.4	13.1	27.4	13.7	10.4	17.6	10.9	10.4	19.7	15.4	7.2	16.4	13.5	10.3	26.4	29.8	21.8	17.6	14.9	13.7	12.2	15.2	18.2	20.7	11.9	18.0	17.2	21.0	12.6	10.1	16.2	8.5	18.8	17.9	9.7	16.1	9.0	21.2	11.1	17.6	14.1	26.5	10.0	15.4	11.8	16.4	11.1	14.1	8.5	48.0	13.1	17.0	12.6	19.6	8.7	11.6	11.5	7.8	8.7	40.3	12.3	11.3	7.3	36.0	15.1	12.6	15.4	9.3	9.5	8.7	10.5	8.7	14.9	19.0	22.1	16.3	15.3	12.8	17.6	13.7	13.6	15.4
MCL1	"BCL2L3, Mcl-1"	ENSG00000143384	"MCL1, BCL2 family apoptosis regulator"	Q07820	1	150574551-150579738	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	12	"U-698: 328.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 42.1"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002781, HPA008455, HPA031125, CAB068195"	Approved		Enhanced	Mitochondria				Mitochondria		"CAB002781: , CAB068195: , HPA008455: AB_1079334, HPA031125: AB_10602026"	"unprognostic (3.82e-2)"	"unprognostic (8.79e-2)"	"unprognostic (9.15e-2)"	"unprognostic (2.05e-2)"	"unprognostic (1.34e-1)"	"unprognostic (3.91e-2)"	"unprognostic (3.16e-2)"	"unprognostic (2.43e-2)"	"unprognostic (1.29e-1)"	"unprognostic (8.60e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.65e-2)"	"prognostic unfavourable (7.16e-4)"	"unprognostic (3.22e-2)"	"unprognostic (1.94e-1)"	"unprognostic (4.87e-2)"	"unprognostic (4.46e-2)"	67.7	37.1	19.0	59.3	21.6	134.5	46.3	15.3	18.9	35.9	38.5	19.0	23.9	21.2	36.1	27.6	56.5	57.2	73.3	32.5	20.4	14.9	30.5	76.7	61.8	52.4	28.2	11.4	32.1	41.9	20.3	27.7	59.4	26.7	34.0	30.7	31.0	36.0	24.5	39.8	45.7	50.2	38.9	26.4	51.1	44.3	19.8	23.0	32.3	45.4	53.3	57.4	40.6	59.4	5.0	6.2	42.1	8.0	3.8	11.1	3.9	9.8	5.0	9.4	5.6	19.1	20.2	12.9	12.1	12.4	12.7	10.3	6.3	8.1	12.5	7.1	8.6	13.2	7.1	14.4	12.8	10.3	4.9	5.1	8.1	7.2	15.1	8.6	11.6	11.0	16.6	12.4	24.2	13.9	11.4	18.2	16.6	10.8	4.2	6.6	17.4	8.9	6.5	7.6	6.5	14.0	7.1	7.3	9.9	8.6	11.7	15.5	7.4	13.3	17.1	8.1	8.5	5.1	15.1	23.3	27.3	328.0	13.9	6.8	10.6	7.6	8.0	18.8	6.1	6.5	7.2	5.0	8.0	6.7	6.2	4.6	9.6	7.2	42.1	3.8	5.8	3.7	11.1	3.9	19.0	21.6	15.3	18.9	20.4	14.9	28.2	11.4	26.7	23.0
MCM2	"BM28, CCNL1, cdc19, CDCL1, D3S3194, DFNA70, KIAA0030"	ENSG00000073111	"Minichromosome maintenance complex component 2"	P49736	3	127598223-127622436	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 69.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000303, HPA031495, HPA031496"	Enhanced		Enhanced	Nucleoplasm		8600	8600	Nucleoplasm		"CAB000303: AB_322519, HPA031495: AB_2673904, HPA031496: "	"unprognostic (2.43e-1)"	"prognostic favourable (4.66e-4)"	"unprognostic (4.44e-2)"	"unprognostic (3.12e-3)"	"unprognostic (1.68e-1)"	"unprognostic (2.25e-2)"	"prognostic unfavourable (1.51e-7)"	"unprognostic (8.43e-3)"	"unprognostic (1.92e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.21e-2)"	"unprognostic (1.16e-2)"	"unprognostic (8.16e-3)"	"unprognostic (1.56e-1)"	"unprognostic (3.29e-2)"	"unprognostic (2.82e-1)"	2.9	3.7	2.1	24.3	4.0	32.5	3.5	6.7	3.2	4.7	7.1	3.3	2.2	4.7	4.7	5.9	11.2	4.8	5.4	3.6	2.0	2.3	3.9	3.4	3.4	14.6	2.2	3.5	5.1	3.0	2.4	2.4	26.4	3.0	3.2	6.0	2.5	4.7	1.9	7.0	6.0	7.1	2.9	2.9	13.3	3.8	20.3	3.9	69.9	4.1	16.6	20.7	3.4	5.1	10.4	3.6	0.9	1.4	5.8	10.6	3.4	24.8	21.2	23.2	20.3	1.4	3.0	22.7	13.1	8.4	26.3	28.7	35.1	16.5	26.8	12.8	6.4	20.0	41.5	15.0	16.4	22.1	25.9	44.3	28.4	25.5	0.9	41.4	19.4	1.6	1.7	17.8	2.7	8.2	22.1	24.6	9.6	33.0	38.3	30.4	34.0	18.7	43.1	33.3	38.4	5.4	19.3	28.9	21.9	33.5	10.0	3.4	21.4	32.5	4.2	20.5	17.5	25.2	17.6	25.5	28.9	66.6	14.2	31.4	7.8	0.0	0.6	0.2	4.7	1.4	5.9	10.4	4.1	5.5	2.8	9.2	3.9	5.0	0.9	5.8	0.3	3.6	10.6	3.4	2.1	4.0	6.7	3.2	2.0	2.3	2.2	3.5	3.0	3.9
MCM3		ENSG00000112118	"Minichromosome maintenance complex component 3"	P25205	6	52264009-52284881	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 82.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002162, HPA004789, HPA004790"	Supported		Enhanced	Nucleoplasm		29000	29000	Nucleoplasm		"CAB002162: AB_564115, HPA004789: AB_1079336, HPA004790: AB_1079335"	"unprognostic (9.14e-2)"	"prognostic favourable (1.89e-4)"	"unprognostic (2.37e-1)"	"unprognostic (1.53e-2)"	"unprognostic (2.14e-1)"	"unprognostic (5.48e-3)"	"prognostic unfavourable (1.40e-4)"	"unprognostic (1.36e-1)"	"prognostic unfavourable (4.40e-5)"	"unprognostic (1.01e-3)"	"unprognostic (2.96e-2)"	"unprognostic (1.15e-1)"	"unprognostic (8.35e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.00e-1)"	"prognostic favourable (3.13e-5)"	"unprognostic (1.34e-2)"	17.3	10.9	8.5	29.7	10.5	22.3	15.3	10.7	9.7	15.9	17.2	9.5	20.2	9.0	21.2	13.0	21.7	15.5	15.8	15.4	7.4	6.6	16.1	12.6	13.7	30.1	8.9	5.8	20.0	13.8	16.0	7.4	24.7	10.0	15.9	19.2	12.7	12.6	23.4	12.1	15.0	17.8	17.7	9.5	23.2	15.3	16.1	10.5	82.5	12.9	20.1	35.7	19.1	15.3	21.1	12.9	11.4	13.3	22.2	29.4	18.6	30.2	20.1	35.1	33.1	7.6	6.9	23.1	22.5	17.3	38.4	39.5	41.2	16.5	33.1	22.6	13.1	24.1	46.3	27.5	38.9	37.2	43.8	62.5	40.5	58.0	2.0	61.3	25.6	4.1	6.4	28.2	7.9	19.6	50.8	76.3	19.8	20.0	61.7	47.4	29.1	14.2	54.8	53.8	44.2	17.0	32.2	35.7	27.3	23.6	13.6	20.4	26.8	43.5	10.0	26.3	28.3	27.1	33.6	22.6	25.8	58.9	22.6	53.2	30.7	11.1	8.0	11.4	22.9	13.3	19.7	21.1	23.3	23.0	12.9	19.2	22.6	24.0	1.1	22.2	7.4	8.3	29.4	18.6	8.5	10.5	10.7	9.7	7.4	6.6	8.9	5.8	10.0	10.5
MCM5	CDC46	ENSG00000100297	"Minichromosome maintenance complex component 5"	P33992	22	35400063-35425430	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 57.0;lymphoid tissue: 60.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000101, HPA000845, HPA052880"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000101: AB_2235163, HPA000845: AB_1079338, HPA052880: "	"unprognostic (6.71e-2)"	"prognostic favourable (2.81e-6)"	"unprognostic (5.29e-3)"	"unprognostic (7.94e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.46e-2)"	"prognostic unfavourable (1.78e-4)"	"prognostic unfavourable (3.95e-4)"	"unprognostic (1.29e-1)"	"unprognostic (3.34e-2)"	"unprognostic (1.37e-1)"	"unprognostic (8.07e-2)"	"prognostic unfavourable (3.58e-5)"	"unprognostic (3.26e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.77e-3)"	"unprognostic (1.53e-1)"	12.1	4.9	6.1	27.5	9.0	57.0	9.1	6.7	5.7	10.4	11.5	12.3	5.0	9.5	10.8	10.8	15.8	8.7	9.4	5.2	4.4	3.4	6.8	8.0	9.3	31.1	8.8	3.7	17.9	10.8	6.2	3.6	19.3	5.8	7.2	8.3	6.5	8.9	5.1	8.8	10.3	16.7	6.0	7.8	31.2	8.4	16.4	8.8	60.6	9.0	17.7	33.0	8.7	9.6	46.8	30.9	19.0	26.0	21.3	32.9	24.0	38.9	28.3	22.4	22.8	2.1	4.4	19.6	26.0	13.8	38.9	37.0	18.8	19.4	25.8	15.1	13.2	19.4	22.3	20.6	12.5	20.8	41.0	36.8	28.4	37.5	0.7	75.9	33.3	2.4	1.9	23.2	6.3	17.2	22.7	38.6	14.7	32.1	61.8	25.3	29.7	16.8	70.0	31.7	32.5	7.7	22.6	17.3	18.4	35.8	14.4	8.0	15.0	29.0	10.1	39.3	29.9	24.4	26.8	21.5	26.4	48.5	25.4	28.7	30.0	19.0	20.7	14.5	18.4	24.1	13.1	46.8	16.1	19.4	27.1	37.0	13.1	14.8	9.9	21.3	26.0	30.9	32.9	24.0	6.1	9.0	6.7	5.7	4.4	3.4	8.8	3.7	5.8	8.8
MCM7	"CDC47, MCM2, PPP1R104"	ENSG00000166508	"Minichromosome maintenance complex component 7"	P33993	7	100092728-100101940	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002163, HPA003898, CAB016312"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002163: AB_564113, CAB016312: AB_627235, HPA003898: AB_1853632"	"unprognostic (1.87e-1)"	"prognostic favourable (1.28e-4)"	"unprognostic (1.36e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.94e-1)"	"unprognostic (7.03e-2)"	"prognostic unfavourable (2.18e-4)"	"unprognostic (2.08e-2)"	"unprognostic (5.79e-3)"	"unprognostic (2.16e-2)"	"unprognostic (2.42e-1)"	"unprognostic (9.34e-3)"	"unprognostic (3.83e-2)"	"unprognostic (5.41e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.32e-2)"	"unprognostic (2.38e-1)"	8.6	5.2	17.5	13.6	21.7	37.3	11.2	20.0	20.6	8.2	14.2	19.2	15.0	10.4	16.0	6.3	10.7	8.6	9.9	5.1	18.1	12.4	5.5	8.5	7.4	22.4	23.7	9.5	12.6	13.1	7.5	10.3	10.7	15.5	10.0	15.7	7.2	9.2	9.2	11.5	10.1	10.3	11.7	23.5	10.7	7.8	14.9	22.3	7.5	9.4	4.1	28.2	10.3	10.0	7.3	5.7	1.9	5.7	7.6	9.0	6.0	24.5	28.4	31.3	23.6	3.0	4.0	16.0	14.9	18.1	41.7	44.5	21.6	25.9	41.6	14.3	10.6	19.4	45.9	21.7	35.3	21.3	39.3	26.5	15.9	14.9	1.6	44.9	17.2	2.8	4.1	30.6	18.4	15.8	50.6	34.1	21.1	52.4	76.3	18.4	27.4	20.5	41.1	45.9	50.7	8.1	14.9	20.5	31.2	23.6	21.9	7.4	10.1	18.8	6.7	15.8	28.6	30.8	29.6	14.3	24.3	74.8	10.9	36.1	28.1	1.8	2.5	1.9	8.1	4.1	6.2	5.3	5.7	7.9	5.5	7.3	5.9	5.7	1.6	7.6	5.7	5.7	9.0	6.0	17.5	21.7	20.0	20.6	18.1	12.4	23.7	9.5	15.5	22.3
MDC1	"Em:AB023051.5, KIAA0170, NFBD1"	ENSG00000137337	"Mediator of DNA damage checkpoint 1"	Q14676	6	30699807-30717889	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 15.4;AN3-CA: 12.1;HEK 293: 29.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"NK-cell: 3.8"	"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA006915	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"				"Nuclear bodies"	Nucleoplasm	"HPA006915: AB_1853669"	"unprognostic (8.52e-2)"	"unprognostic (4.32e-1)"	"unprognostic (4.11e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.61e-1)"	"unprognostic (5.40e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.09e-2)"	"unprognostic (9.44e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.31e-1)"	"unprognostic (1.62e-2)"	"unprognostic (3.86e-2)"	"unprognostic (2.99e-1)"	"unprognostic (4.39e-3)"	"unprognostic (3.23e-1)"	10.8	3.6	5.7	9.5	5.9	4.9	5.5	10.2	8.0	6.9	6.3	8.5	3.8	3.8	9.9	5.1	3.7	8.3	5.0	5.0	5.2	2.4	5.1	6.2	5.1	5.4	4.9	3.7	11.3	5.7	3.1	12.5	3.1	6.0	6.4	2.9	9.4	5.5	3.5	11.1	11.7	6.4	6.1	5.5	7.1	7.7	26.7	5.3	11.4	11.9	2.4	13.0	5.2	5.4	2.0	1.8	0.4	0.2	3.8	1.2	0.3	15.4	1.0	1.2	12.1	3.9	3.8	1.0	1.3	0.7	2.7	1.0	1.0	1.7	2.6	6.6	7.7	1.6	2.4	4.4	2.5	2.1	29.3	1.9	2.9	0.6	0.4	1.1	1.4	0.9	0.9	4.1	1.9	0.4	3.8	2.9	0.4	1.4	0.7	0.2	0.8	0.8	2.2	1.3	2.9	4.5	3.3	2.6	1.3	0.6	3.1	0.5	2.8	2.2	0.9	1.0	1.5	2.0	1.4	1.9	7.2	6.7	0.3	4.3	2.1	0.4	0.1	0.3	1.1	0.2	0.9	0.8	0.9	1.2	0.2	2.0	1.0	0.8	0.1	3.8	0.1	1.8	0.0	0.3	5.7	5.9	10.2	8.0	5.2	2.4	4.9	3.7	6.0	5.3
MDH1		ENSG00000014641	"Malate dehydrogenase 1"	P40925	2	63588609-63607197	"Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 155.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA027296, CAB047333, HPA054276"	Uncertain		Supported	Centrosome,Cytosol		63000000	63000000	"Centrosome, Cytosol"		"CAB047333: , HPA027296: AB_10611118, HPA054276: "	"unprognostic (1.01e-1)"	"unprognostic (6.52e-3)"	"unprognostic (1.61e-2)"	"prognostic unfavourable (7.13e-4)"	"unprognostic (1.83e-1)"	"unprognostic (8.84e-3)"	"unprognostic (5.81e-2)"	"unprognostic (2.79e-2)"	"unprognostic (9.52e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.26e-1)"	"unprognostic (8.80e-2)"	"prognostic favourable (9.95e-4)"	"unprognostic (6.37e-2)"	"unprognostic (1.75e-1)"	"unprognostic (5.97e-2)"	"unprognostic (3.05e-1)"	32.0	28.6	28.0	10.5	58.1	9.2	18.4	38.0	69.5	12.4	21.4	12.5	9.0	19.3	13.4	22.6	16.7	14.7	11.5	155.8	33.6	37.5	47.6	33.2	11.2	14.7	33.4	40.1	10.9	8.9	26.0	18.3	11.4	65.9	16.1	24.9	13.8	15.4	19.9	91.1	11.1	17.1	21.5	18.6	9.4	22.4	8.6	12.2	14.1	15.6	47.1	20.2	15.6	10.2	61.7	57.1	50.7	61.5	46.7	74.5	67.8	44.0	36.1	48.8	31.9	69.4	51.4	50.6	34.7	51.3	52.9	53.7	42.7	39.1	55.5	20.6	45.4	38.8	54.9	64.3	75.9	33.6	42.4	52.1	33.8	67.8	38.1	59.9	41.3	50.9	43.9	49.5	29.3	40.3	28.8	40.4	69.5	26.5	52.4	60.5	28.6	45.0	41.9	57.5	54.4	87.5	41.8	45.3	27.0	29.1	46.9	66.5	34.2	62.5	23.4	40.6	39.8	33.7	43.6	50.4	44.2	67.9	50.1	54.2	33.5	50.7	45.8	45.8	52.7	61.5	55.0	61.7	61.3	57.6	57.1	56.4	60.5	57.5	7.0	46.7	55.7	43.3	74.5	67.8	28.0	58.1	38.0	69.5	33.6	37.5	33.4	40.1	65.9	12.2
MDK	"FLJ27379, MK, NEGF2"	ENSG00000110492	Midkine	P21741	11	46380756-46383837	"Cancer-related genes, Predicted secreted proteins"	Differentiation	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"ovary: 115.9"	"Cell line enhanced"	"Detected in many"		"AF22: 75.8;NTERA-2: 88.8;REH: 129.2;SH-SY5Y: 110.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.6;neutrophil: 4.9"	"Group enriched"	"Detected in many"	5	"B-cells: 3.6;granulocytes: 4.9;T-cells: 2.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010055, HPA057126"	Uncertain		Approved	Vesicles	"Secreted to blood"	1200000	1200000	Vesicles		"CAB010055: AB_627949, HPA057126: "	"unprognostic (8.87e-3)"	"unprognostic (6.65e-2)"	"unprognostic (4.02e-2)"	"unprognostic (7.24e-2)"	"prognostic unfavourable (5.48e-4)"	"unprognostic (1.90e-1)"	"unprognostic (5.67e-3)"	"unprognostic (1.02e-1)"	"unprognostic (3.66e-2)"	"unprognostic (1.11e-2)"	"unprognostic (4.01e-2)"	"unprognostic (4.15e-1)"	"prognostic unfavourable (3.06e-6)"	"unprognostic (8.78e-2)"	"unprognostic (1.31e-1)"	"unprognostic (3.48e-1)"	"unprognostic (1.12e-2)"	8.0	16.2	4.7	11.9	5.6	1.7	13.5	5.3	5.9	62.5	36.3	5.3	13.9	50.6	41.0	33.9	6.5	34.6	35.0	6.4	4.0	5.9	6.1	2.0	8.0	3.6	4.9	4.4	115.9	13.1	8.9	64.8	11.5	5.5	47.7	7.4	59.0	22.2	24.5	4.7	4.1	58.4	16.6	4.0	13.9	21.0	9.3	2.1	22.5	5.2	5.5	12.4	15.3	23.0	3.6	0.2	4.9	0.6	0.2	2.0	1.5	4.8	6.5	75.8	0.2	0.5	6.4	1.8	3.8	7.6	14.6	13.0	49.2	21.6	0.3	53.4	5.6	42.2	42.7	0.0	1.3	15.0	9.0	2.1	0.6	67.3	34.6	0.1	0.3	10.2	1.3	8.9	0.0	21.3	36.4	0.3	8.2	33.5	1.8	0.9	88.8	38.5	129.2	2.8	0.4	0.1	0.1	42.1	110.3	12.6	1.1	1.0	34.6	34.0	5.8	22.5	53.9	0.3	2.6	0.2	1.0	0.4	0.6	1.3	19.5	0.0	0.1	0.0	0.3	0.5	0.0	3.6	0.2	0.5	0.1	1.1	0.2	0.0	4.9	0.2	0.6	0.2	2.0	1.5	4.7	5.6	5.3	5.9	4.0	5.9	4.9	4.4	5.5	2.1
MDM2	"HDM2, MGC5370"	ENSG00000135679	"MDM2 proto-oncogene"	Q00987	12	68808176-68850686	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 93.7;U-698: 90.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000086, CAB016303"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB000086: AB_563872, CAB016303: AB_627920"	"unprognostic (1.16e-1)"	"prognostic favourable (3.23e-4)"	"unprognostic (6.16e-2)"	"prognostic favourable (4.51e-7)"	"unprognostic (7.25e-2)"	"unprognostic (6.91e-2)"	"unprognostic (3.77e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.45e-2)"	"unprognostic (3.23e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.36e-1)"	"unprognostic (4.22e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.68e-1)"	"unprognostic (8.95e-2)"	16.6	15.3	11.1	12.5	10.8	23.1	12.5	12.0	11.3	13.1	16.6	13.6	11.9	5.2	8.8	9.4	14.2	12.6	12.3	9.0	8.8	8.6	11.2	25.7	15.9	13.3	14.2	7.1	11.0	21.4	11.4	10.4	24.5	11.9	12.6	21.5	7.8	10.5	11.1	19.5	9.8	7.2	10.8	10.8	15.3	9.8	6.5	11.5	29.5	13.6	10.8	14.1	13.5	12.6	4.9	4.0	19.3	6.4	3.6	4.4	3.0	3.1	7.3	7.7	3.9	10.0	9.3	39.4	8.7	8.7	4.6	7.4	4.4	1.4	32.6	2.4	5.7	1.8	5.2	93.7	7.5	8.6	3.7	6.0	6.2	19.8	9.8	5.3	5.5	14.3	8.0	18.4	12.5	12.9	6.1	7.9	8.8	5.0	7.0	1.7	6.5	1.4	24.8	5.3	2.7	2.8	26.1	5.9	3.4	5.5	4.3	1.9	10.1	3.5	13.8	3.5	6.7	2.9	3.1	12.1	7.6	90.1	5.4	2.1	14.4	5.3	5.4	4.8	4.4	4.0	3.9	4.7	3.7	4.1	2.8	4.9	4.0	3.7	19.3	3.6	6.4	4.0	3.8	3.0	11.1	10.8	12.0	11.3	8.8	8.6	14.2	7.1	11.9	11.5
MDM4	"HDMX, MDMX"	ENSG00000198625	"MDM4, p53 regulator"	O15151	1	204516379-204558120	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"BEWO: 33.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018919, HPA048821"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA018919: AB_1853694, HPA048821: "	"unprognostic (4.63e-2)"	"unprognostic (3.73e-1)"	"unprognostic (6.38e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.84e-2)"	"unprognostic (1.68e-3)"	"unprognostic (2.33e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.17e-2)"	"prognostic unfavourable (9.87e-4)"	"prognostic unfavourable (7.06e-6)"	"unprognostic (1.20e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.49e-2)"	"prognostic favourable (2.49e-4)"	12.7	8.8	14.4	21.1	18.0	59.1	14.6	19.7	16.4	12.2	10.6	20.4	15.8	7.6	12.5	23.6	10.4	12.3	10.3	11.3	13.7	8.0	11.1	12.3	15.4	21.0	20.5	9.5	19.0	16.7	11.1	19.0	12.4	13.4	13.1	12.4	14.2	11.3	15.4	12.0	23.7	15.2	18.5	13.5	19.9	11.9	19.6	19.4	55.8	15.1	9.5	21.0	13.9	12.7	15.1	9.0	8.1	4.8	4.9	7.8	2.4	3.5	7.0	7.1	9.7	5.0	5.5	33.5	2.6	2.7	3.4	5.1	3.6	4.9	12.2	2.6	3.7	3.8	4.7	4.0	4.7	3.7	3.3	9.7	15.6	4.2	3.8	7.5	9.6	5.6	2.6	5.6	10.0	3.3	5.5	17.8	3.0	11.8	4.6	6.7	9.7	2.9	5.5	5.8	4.0	3.4	17.2	3.2	7.1	2.7	5.3	5.0	10.0	4.4	3.4	3.9	7.0	2.5	4.3	9.0	3.2	10.1	2.7	3.3	5.6	8.1	4.7	6.2	7.2	4.8	6.0	9.0	5.4	5.0	4.1	15.1	7.8	6.5	7.8	4.9	4.3	9.0	3.0	2.4	14.4	18.0	19.7	16.4	13.7	8.0	20.5	9.5	13.4	19.4
MECOM	"EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3"	ENSG00000085276	"MDS1 and EVI1 complex locus"	Q03112	3	169083499-169663618	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 21.5;RPTEC TERT1: 27.6;RT4: 43.5;TIME: 20.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 1.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA046537	Supported		Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA046537: "	"unprognostic (4.09e-2)"	"unprognostic (1.96e-1)"	"unprognostic (3.24e-3)"	"unprognostic (7.29e-2)"	"unprognostic (2.87e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.77e-3)"	"unprognostic (1.53e-2)"	"unprognostic (3.27e-3)"	"prognostic unfavourable (2.59e-4)"	"unprognostic (1.87e-1)"	"unprognostic (2.60e-3)"	"unprognostic (6.54e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.81e-2)"	"unprognostic (3.37e-3)"	25.9	0.7	3.3	5.7	5.6	0.3	9.1	3.4	5.3	13.5	13.9	1.6	22.1	11.2	15.4	5.7	10.4	14.3	8.1	8.2	3.3	2.9	32.2	2.6	30.0	1.5	4.6	1.4	6.2	27.8	1.1	5.3	10.0	4.7	9.3	17.5	4.2	5.9	25.3	16.0	2.3	5.9	5.6	5.8	6.4	39.4	2.7	3.5	0.2	4.7	3.3	3.5	18.1	18.5	0.3	0.0	0.6	1.5	1.8	1.0	0.0	9.6	0.1	0.2	0.0	1.3	1.0	0.1	1.3	1.5	0.5	0.8	3.8	9.9	0.0	15.2	0.2	5.1	4.0	5.9	1.1	0.5	6.3	6.1	1.6	0.1	0.1	0.0	1.9	2.1	0.8	0.3	4.5	21.5	4.6	0.7	3.8	1.0	0.0	0.0	0.2	2.5	3.6	4.9	0.2	27.6	43.5	0.3	1.1	0.4	2.5	0.1	2.9	0.0	20.4	3.8	2.5	1.0	6.4	0.5	0.1	0.3	1.9	0.0	0.5	0.3	0.0	0.6	0.4	0.2	1.0	0.1	0.1	0.0	0.0	0.3	0.2	0.0	0.3	1.8	1.5	0.0	0.1	0.0	3.3	5.6	3.4	5.3	3.3	2.9	4.6	1.4	4.7	3.5
MECP2	"MRX16, MRX79, RTT"	ENSG00000169057	"Methyl-CpG binding protein 2"	P51608	X	154021573-154137103	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000593, HPA001341, CAB037264"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"CAB037264: AB_477252, HPA000593: AB_1079348, HPA001341: AB_1079347"	"unprognostic (1.27e-3)"	"unprognostic (2.60e-3)"	"unprognostic (2.16e-3)"	"prognostic unfavourable (8.35e-5)"	"unprognostic (2.35e-1)"	"unprognostic (3.66e-1)"	"unprognostic (6.12e-2)"	"unprognostic (1.18e-2)"	"unprognostic (8.81e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.84e-3)"	"unprognostic (4.22e-1)"	"prognostic favourable (7.32e-9)"	"unprognostic (7.63e-2)"	"unprognostic (1.00e-1)"	"unprognostic (9.08e-2)"	"unprognostic (6.05e-2)"	18.6	21.4	29.2	17.0	27.1	33.8	17.6	39.1	33.5	20.2	19.2	17.6	15.9	13.9	20.0	15.1	18.8	21.1	19.5	23.1	22.5	14.0	17.1	16.4	22.8	19.7	22.5	26.7	29.0	21.2	24.3	22.9	13.9	25.4	23.0	8.0	20.8	18.7	23.7	31.6	14.1	15.3	16.2	21.1	23.3	15.0	9.7	24.4	13.8	19.1	8.7	14.3	18.7	28.6	5.6	4.2	22.4	4.9	2.9	6.8	1.8	19.2	11.5	9.7	12.1	8.4	6.0	8.2	9.7	10.9	11.9	19.4	8.9	9.4	23.2	23.0	8.5	9.2	14.5	11.3	6.0	17.6	17.6	8.9	10.5	5.6	10.2	11.2	18.8	6.1	6.5	11.1	13.1	9.2	9.6	19.8	7.1	11.5	13.5	12.8	7.6	12.9	11.7	10.6	7.6	8.4	8.8	13.7	7.9	7.6	8.8	18.5	5.7	14.6	9.6	9.1	17.9	18.3	19.5	23.8	17.7	26.4	13.1	22.1	15.5	22.4	3.5	13.3	6.8	3.2	4.8	5.6	4.8	5.5	2.4	4.9	4.6	4.4	16.9	2.9	4.9	4.2	5.0	1.8	29.2	27.1	39.1	33.5	22.5	14.0	22.5	26.7	25.4	24.4
MED1	"CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2"	ENSG00000125686	"Mediator complex subunit 1"	Q15648	17	39404285-39451286	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 85.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017696, HPA052818"	Approved		Supported	Nucleoplasm		170000	170000	Nucleoplasm		"CAB017696: AB_1128703, HPA052818: "	"unprognostic (1.77e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.26e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.18e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.21e-2)"	"unprognostic (4.50e-1)"	"unprognostic (7.86e-2)"	"unprognostic (1.95e-3)"	"unprognostic (4.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.78e-2)"	"unprognostic (2.00e-1)"	"unprognostic (5.94e-2)"	"unprognostic (9.40e-2)"	"unprognostic (5.79e-2)"	16.4	13.8	11.8	14.8	13.7	15.5	15.1	19.8	16.5	16.9	14.6	18.8	9.3	10.3	17.9	9.7	15.0	14.3	10.9	12.8	11.6	10.5	13.0	13.3	12.3	17.7	12.0	10.3	22.2	16.2	34.5	21.1	16.5	14.5	12.5	14.2	16.5	13.4	11.6	19.5	16.1	14.1	17.1	14.0	20.4	13.0	15.1	12.1	34.1	13.2	12.1	22.5	16.6	13.4	6.6	4.9	4.4	4.0	5.0	6.1	2.7	8.0	10.7	13.5	9.2	9.9	10.1	10.9	9.8	10.6	13.5	13.2	10.3	8.0	21.5	11.2	12.2	15.9	16.1	9.7	21.5	20.7	13.5	13.5	10.2	10.2	10.7	24.1	14.3	9.5	9.8	16.6	24.2	11.4	17.3	11.7	10.9	4.5	22.4	9.1	8.7	6.4	16.9	18.2	9.2	7.9	9.3	8.6	9.8	13.0	85.6	11.2	15.8	13.8	10.1	10.5	13.1	11.6	17.2	10.7	14.3	22.2	10.3	11.9	12.8	3.2	4.0	4.4	5.2	3.9	5.8	6.6	5.5	5.8	4.0	6.4	5.4	6.1	3.3	5.0	2.6	4.9	3.3	2.7	11.8	13.7	19.8	16.5	11.6	10.5	12.0	10.3	14.5	12.1
MED12	"CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230"	ENSG00000184634	"Mediator complex subunit 12"	Q93074	X	71118556-71142454	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003184, HPA003185"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"HPA003184: AB_1079349, HPA003185: AB_1079350"	"unprognostic (1.39e-1)"	"unprognostic (2.23e-1)"	"unprognostic (5.42e-2)"	"unprognostic (2.07e-1)"	"unprognostic (6.89e-3)"	"unprognostic (7.14e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.45e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.22e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.02e-1)"	"unprognostic (3.67e-1)"	"unprognostic (5.16e-2)"	18.2	31.3	12.3	15.3	14.7	16.6	18.1	18.0	15.1	16.8	12.8	19.8	21.3	10.2	21.7	16.5	13.1	17.7	14.2	12.9	12.9	8.5	13.3	9.8	14.0	15.3	15.7	10.7	28.8	14.2	20.1	17.9	23.0	11.6	16.5	11.8	18.6	14.6	20.3	14.9	17.6	14.8	16.4	11.2	27.3	14.2	15.3	12.9	33.1	17.8	12.6	15.9	15.4	16.4	4.0	5.1	9.7	3.7	5.0	7.4	3.6	8.6	10.2	16.1	9.6	11.8	10.6	23.8	6.1	8.8	9.8	7.0	12.2	8.2	11.4	8.2	10.6	8.6	18.8	7.7	7.8	11.9	14.6	18.8	23.0	16.5	9.3	17.3	16.7	12.3	8.4	12.8	14.9	15.0	17.5	19.9	9.6	14.5	18.1	9.9	9.2	13.4	17.1	18.0	8.6	7.4	17.2	9.0	10.8	14.1	7.2	8.0	8.7	8.6	13.1	10.7	12.7	9.8	4.3	9.8	5.5	8.3	6.3	9.7	7.1	9.7	3.7	7.2	5.9	3.6	5.0	4.0	4.1	5.4	3.9	4.0	4.6	3.9	7.7	5.0	2.4	5.1	7.4	3.6	12.3	14.7	18.0	15.1	12.9	8.5	15.7	10.7	11.6	12.9
MED13	"KIAA0593, THRAP1, TRAP240"	ENSG00000108510	"Mediator complex subunit 13"	Q9UHV7	17	61942605-62065282	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA067939			Supported	Nucleoplasm				Nucleoplasm		"HPA067939: "	"unprognostic (7.26e-2)"	"unprognostic (4.50e-2)"	"prognostic favourable (1.43e-4)"	"unprognostic (8.79e-2)"	"unprognostic (1.69e-2)"	"unprognostic (3.56e-1)"	"unprognostic (1.33e-1)"	"unprognostic (5.69e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.97e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.92e-2)"	"unprognostic (2.63e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.21e-1)"	"unprognostic (4.51e-3)"	"unprognostic (2.30e-1)"	10.4	7.6	6.3	6.6	9.1	19.3	8.8	8.8	7.5	8.7	9.0	13.8	6.8	7.1	13.6	9.0	9.7	6.8	8.2	8.4	12.6	5.3	9.0	14.3	12.7	7.3	8.2	3.5	9.9	8.6	15.3	5.9	9.6	15.6	7.1	8.3	6.4	21.6	5.9	31.8	10.0	8.1	12.0	13.8	6.7	7.4	11.9	8.3	15.1	10.4	12.4	8.9	10.7	8.4	3.2	5.6	7.9	5.0	2.7	3.5	0.7	12.9	15.4	11.9	9.7	11.0	12.0	9.1	7.1	10.4	14.5	14.0	11.7	7.1	13.8	6.8	11.2	8.0	15.2	9.3	20.3	8.9	8.9	22.5	11.2	7.4	11.5	19.7	10.5	9.2	10.8	15.8	18.0	10.9	18.4	23.8	9.9	21.9	17.7	5.9	6.3	8.0	14.6	30.6	8.4	10.2	15.3	9.4	17.9	14.9	4.3	9.3	15.6	14.0	13.6	16.7	24.5	8.6	13.4	11.6	13.1	19.0	8.8	8.8	9.4	1.6	2.1	2.5	2.8	1.0	3.5	2.0	2.7	2.9	2.1	3.2	1.9	3.5	7.9	2.7	5.0	5.6	3.0	0.7	6.3	9.1	8.8	7.5	12.6	5.3	8.2	3.5	15.6	8.3
MED17	"CRSP6, CRSP77, DRIP80, SRB4, TRAP80"	ENSG00000042429	"Mediator complex subunit 17"	Q9NVC6	11	93784227-93814963	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA046619			Approved	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"HPA046619: "	"prognostic unfavourable (4.94e-4)"	"unprognostic (2.92e-1)"	"unprognostic (2.72e-3)"	"unprognostic (1.38e-1)"	"unprognostic (6.71e-2)"	"unprognostic (1.42e-1)"	"prognostic unfavourable (4.04e-6)"	"unprognostic (1.50e-1)"	"unprognostic (4.48e-3)"	"unprognostic (7.73e-2)"	"unprognostic (1.41e-1)"	"unprognostic (4.59e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.22e-1)"	"unprognostic (5.56e-3)"	"unprognostic (1.48e-1)"	9.0	7.4	5.8	9.9	8.0	9.5	9.2	13.9	10.7	10.7	10.2	9.0	9.4	4.3	12.1	7.5	7.9	10.4	7.3	11.5	6.3	5.4	6.4	4.6	8.2	8.1	9.5	7.3	13.8	9.9	5.4	13.1	9.5	6.1	8.2	4.9	8.0	9.4	6.6	9.3	10.2	14.0	7.7	7.7	13.9	12.1	7.9	8.8	20.7	7.8	5.5	9.8	11.2	11.6	10.5	6.8	10.8	5.7	10.2	8.5	5.1	3.0	1.0	2.6	5.6	3.2	0.4	5.1	6.7	2.3	4.5	2.8	5.3	6.3	5.0	11.3	0.6	9.4	2.4	1.4	1.2	6.0	2.7	5.6	3.4	1.5	1.7	9.4	9.5	1.3	3.3	3.3	2.2	1.8	5.0	3.0	2.7	0.9	11.2	2.7	4.9	0.8	8.6	7.6	4.1	2.7	2.1	9.2	11.7	5.6	4.7	2.8	7.0	2.3	6.1	7.0	5.6	9.3	5.8	4.7	9.1	3.6	1.8	6.7	8.0	4.9	4.6	10.8	6.4	5.7	7.6	10.5	8.2	8.0	6.0	9.0	8.5	4.8	4.7	10.2	3.3	6.8	8.1	5.1	5.8	8.0	13.9	7.9	6.3	5.4	9.5	7.3	6.1	8.8
MED23	"CRSP130, CRSP3, DRIP130, Sur2"	ENSG00000112282	"Mediator complex subunit 23"	Q9ULK4	6	131573966-131628229	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070341			Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA070341: "	"unprognostic (1.11e-2)"	"unprognostic (4.66e-2)"	"unprognostic (5.51e-3)"	"unprognostic (1.80e-1)"	"unprognostic (3.06e-2)"	"unprognostic (1.14e-2)"	"unprognostic (6.62e-3)"	"unprognostic (4.47e-1)"	"unprognostic (1.64e-1)"	"unprognostic (6.81e-3)"	"unprognostic (1.44e-2)"	"unprognostic (3.59e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.82e-2)"	"unprognostic (2.21e-1)"	"unprognostic (2.44e-2)"	"unprognostic (2.53e-2)"	14.0	17.1	12.1	19.7	12.7	21.8	16.3	23.0	17.6	14.7	12.3	12.1	17.8	12.7	21.6	13.3	14.9	14.6	10.2	10.2	11.7	8.3	12.2	9.6	13.1	15.4	15.9	12.3	20.5	18.7	23.9	16.1	12.3	11.3	13.9	14.4	12.3	19.8	16.8	14.8	15.0	15.4	14.3	11.0	13.7	14.9	13.1	13.3	22.7	18.0	7.4	16.7	16.2	20.7	6.0	6.8	8.8	5.7	15.0	10.9	4.6	5.1	5.8	13.8	17.4	17.2	13.2	12.7	13.1	14.9	12.1	17.7	6.0	7.3	11.6	9.6	13.4	9.4	7.4	8.5	18.9	13.1	10.3	12.1	10.6	10.2	12.5	20.0	20.7	11.5	10.2	13.4	13.7	15.0	15.5	12.2	12.8	8.0	15.1	12.6	6.6	5.8	13.7	8.6	6.9	9.4	7.7	10.4	9.4	9.3	13.1	8.5	3.6	14.1	15.1	9.0	10.3	14.4	11.9	13.0	8.7	16.7	11.1	9.2	12.1	4.5	5.3	8.8	7.3	5.7	10.9	6.0	7.2	8.0	6.8	5.2	7.4	6.7	4.5	15.0	3.9	3.6	7.8	4.6	12.1	12.7	23.0	17.6	11.7	8.3	15.9	12.3	11.3	13.3
MEF2A	"RSRFC4, RSRFC9"	ENSG00000068305	"Myocyte enhancer factor 2A"	Q02078	15	99565417-99716466	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004499, HPA046597"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB004499: AB_627921, HPA046597: "	"unprognostic (1.89e-1)"	"unprognostic (8.82e-2)"	"unprognostic (5.91e-2)"	"unprognostic (8.04e-2)"	"unprognostic (8.68e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.25e-1)"	"unprognostic (6.26e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.91e-2)"	"unprognostic (7.08e-3)"	"unprognostic (1.46e-1)"	"prognostic favourable (6.93e-4)"	"prognostic unfavourable (7.96e-4)"	"unprognostic (4.69e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.69e-3)"	28.9	17.4	17.4	19.1	24.3	12.0	20.1	22.9	31.6	21.9	19.7	20.1	18.2	9.5	30.5	24.7	16.6	20.5	16.6	62.0	14.9	12.7	18.8	17.5	26.0	16.7	14.0	21.9	23.0	11.7	32.0	10.2	18.8	16.1	19.9	11.4	14.5	15.5	18.4	46.1	38.4	16.3	31.2	23.6	22.2	16.3	10.7	15.8	17.6	15.2	19.6	17.3	25.2	15.9	12.8	10.7	11.3	14.2	5.6	4.5	4.3	8.7	5.0	8.4	4.2	10.7	13.8	4.2	8.9	20.5	7.3	10.0	5.1	12.2	11.0	12.6	19.0	9.6	8.5	7.0	9.6	7.4	12.5	22.1	11.1	4.6	18.4	8.7	10.9	9.2	11.8	9.8	20.4	13.3	7.8	21.1	13.6	3.6	14.3	13.0	4.6	7.3	21.0	18.4	8.9	15.1	12.4	5.4	7.6	13.5	5.9	25.0	5.5	8.0	21.7	20.5	11.2	10.1	10.7	11.5	13.1	24.0	14.3	9.7	19.4	6.2	10.3	11.3	3.4	12.8	2.9	12.8	3.2	3.0	10.7	10.4	4.5	3.4	10.2	5.6	14.2	6.6	2.1	4.3	17.4	24.3	22.9	31.6	14.9	12.7	14.0	21.9	16.1	15.8
MEN1		ENSG00000133895	"Menin 1"	O00255	11	64803510-64811294	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030342	Uncertain		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA030342: AB_10610138"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-1)"	"unprognostic (3.78e-2)"	"unprognostic (2.31e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.41e-2)"	"prognostic unfavourable (1.08e-4)"	"unprognostic (2.66e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.42e-2)"	"unprognostic (4.96e-2)"	"unprognostic (1.36e-1)"	"unprognostic (7.39e-2)"	"prognostic favourable (6.31e-5)"	"unprognostic (1.40e-1)"	"unprognostic (3.03e-1)"	"unprognostic (3.76e-1)"	12.1	20.6	13.2	15.6	17.7	11.8	12.5	25.8	26.9	15.5	14.9	16.4	22.2	16.9	14.8	18.4	18.9	17.6	14.7	9.0	12.4	11.5	15.9	23.0	12.8	22.1	12.5	15.6	19.7	25.9	16.8	18.0	16.1	16.0	15.9	11.6	16.6	23.3	19.9	8.4	21.6	15.8	11.0	9.8	20.6	15.3	21.2	12.3	33.2	23.9	6.2	20.3	13.7	15.5	5.2	2.9	3.4	1.5	1.8	4.8	1.0	16.4	22.1	14.1	22.2	15.8	10.3	16.6	11.8	11.8	18.5	12.4	12.7	16.2	23.4	19.4	9.1	23.5	19.1	16.4	11.1	19.9	28.3	19.4	17.7	17.0	14.0	12.4	13.2	11.8	12.3	15.5	12.9	17.1	28.1	8.9	10.2	30.7	31.4	25.2	18.5	33.2	24.4	16.1	22.4	11.9	15.2	20.0	17.6	14.0	19.8	14.4	29.5	13.9	10.8	17.5	16.8	20.9	10.0	14.1	16.3	11.8	13.8	9.7	11.1	0.9	1.3	3.4	3.7	1.5	4.8	3.7	2.6	4.6	1.3	5.2	4.5	2.6	0.2	1.8	0.5	2.9	1.9	1.0	13.2	17.7	25.8	26.9	12.4	11.5	12.5	15.6	16.0	12.3
MET	"DFNB97, HGFR, RCCP2"	ENSG00000105976	"MET proto-oncogene, receptor tyrosine kinase"	P08581	7	116672390-116798386	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A-431: 45.4;CAPAN-2: 49.6;EFO-21: 43.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in many"	5	"amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1"	"Low region specificity"	"Detected in many"			"CAB005282, CAB018577, HPA055607"	Approved		Supported	"Plasma membrane,Cytosol"	"Secreted to blood"	70000000	70000000	"Plasma membrane, Cytosol"		"CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: "	"unprognostic (1.60e-2)"	"unprognostic (7.71e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.57e-3)"	"prognostic unfavourable (6.75e-4)"	"unprognostic (1.68e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (2.52e-2)"	"prognostic unfavourable (1.21e-7)"	"unprognostic (1.86e-1)"	"unprognostic (1.25e-1)"	"unprognostic (5.53e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.01e-2)"	"unprognostic (2.20e-1)"	16.2	1.1	1.8	4.5	2.3	4.3	11.2	0.9	15.2	9.9	6.5	2.4	2.4	4.4	7.5	5.2	5.1	4.6	12.3	5.4	5.7	1.8	20.1	30.2	15.6	1.4	3.6	2.1	2.0	9.3	0.7	8.1	24.4	2.6	8.0	6.6	34.1	12.2	8.4	12.8	7.2	8.6	4.0	2.3	5.7	10.6	2.7	2.4	0.5	21.4	7.0	2.1	10.1	15.0	0.2	0.3	1.2	0.2	0.3	0.4	0.0	45.4	26.1	0.0	0.1	2.0	2.0	1.8	26.0	10.6	14.0	11.8	5.4	49.6	2.0	43.3	16.3	12.0	4.5	24.7	28.7	0.1	5.6	0.0	27.1	4.7	0.3	0.0	0.0	2.6	9.8	9.1	30.1	9.6	0.9	0.2	25.9	1.0	0.0	0.0	3.9	26.7	0.0	22.0	0.0	24.6	5.2	3.8	0.0	10.7	3.4	10.1	0.0	0.2	17.7	20.9	7.4	11.0	20.1	0.5	4.0	0.2	23.0	0.0	2.9	1.1	0.2	0.4	0.4	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	1.2	0.3	0.1	0.3	0.1	0.0	1.8	2.3	0.9	15.2	5.7	1.8	3.6	2.1	2.6	2.4
METTL14	KIAA1627	ENSG00000145388	"Methyltransferase like 14"	Q9HCE5	4	118685368-118715433	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, Spermatogenesis"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038002	Supported		Supported	Nucleoplasm				Nucleoplasm		"HPA038002: AB_10672401"	"unprognostic (4.48e-1)"	"unprognostic (5.13e-2)"	"unprognostic (5.98e-3)"	"unprognostic (3.44e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.75e-2)"	"unprognostic (4.40e-1)"	"unprognostic (9.97e-2)"	"unprognostic (2.40e-2)"	"unprognostic (3.64e-2)"	"unprognostic (3.33e-3)"	"prognostic favourable (1.46e-5)"	"unprognostic (1.05e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.76e-3)"	"unprognostic (7.76e-3)"	17.3	16.4	15.5	12.4	19.2	25.8	18.0	25.9	19.4	21.8	16.1	12.8	11.7	13.4	19.1	17.2	16.4	15.9	12.0	12.3	13.3	11.3	17.4	22.0	13.9	15.9	16.4	16.0	22.6	14.6	17.1	34.5	13.6	16.0	20.0	13.0	12.3	13.7	14.9	13.5	16.4	15.4	14.5	17.3	17.3	14.2	26.6	18.4	24.1	18.7	10.6	16.2	23.0	16.1	18.9	12.3	24.1	17.5	17.1	18.4	10.7	14.4	6.7	14.6	13.7	9.2	11.7	10.7	12.9	9.9	9.8	11.3	9.6	17.3	16.4	7.7	9.0	7.1	12.4	10.6	12.6	12.9	7.5	13.7	8.4	10.6	10.5	22.1	16.4	10.3	12.3	11.3	7.5	8.8	14.6	14.0	13.3	9.7	21.6	18.6	12.5	5.8	12.4	18.3	8.3	10.6	9.6	12.0	13.5	9.1	16.9	12.3	7.7	21.1	11.9	14.2	13.0	12.6	10.2	11.8	12.2	18.7	10.1	12.4	11.5	24.1	10.6	22.3	14.7	15.6	16.6	18.9	15.4	15.1	12.3	18.1	18.4	16.6	8.5	17.1	17.5	9.8	16.2	10.7	15.5	19.2	25.9	19.4	13.3	11.3	16.4	16.0	16.0	18.4
MFGE8	"BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10"	ENSG00000140545	"Milk fat globule-EGF factor 8 protein"	Q08431	15	88898683-88913411	"Cancer-related genes, Predicted secreted proteins"	"Angiogenesis, Cell adhesion, Fertilization"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 177.8;ASC TERT1: 92.3;fHDF/TERT166: 62.5;HSkMC: 93.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 13.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 3.6;NK-cells: 6.3;T-cells: 13.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002753, HPA002807"	Supported		Approved	Cytosol	"Secreted to blood"	1100000	1100000	Cytosol		"CAB002753: , HPA002807: AB_1078072"	"unprognostic (1.28e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.63e-2)"	"unprognostic (7.68e-2)"	"unprognostic (2.75e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.32e-1)"	"unprognostic (1.42e-1)"	"unprognostic (8.11e-3)"	"unprognostic (6.27e-2)"	"unprognostic (8.49e-2)"	"unprognostic (3.99e-1)"	"prognostic unfavourable (6.06e-9)"	"prognostic unfavourable (3.08e-4)"	"unprognostic (4.85e-2)"	"unprognostic (7.36e-3)"	"unprognostic (2.41e-3)"	34.2	23.2	5.4	14.5	11.2	0.9	73.4	5.7	14.8	43.4	15.8	9.6	11.3	5.2	73.2	38.6	32.8	56.2	30.2	115.4	5.6	4.1	12.4	3.9	20.8	14.9	6.0	8.3	49.8	6.6	2.9	8.1	23.1	10.8	29.5	7.3	59.5	15.6	50.7	57.8	18.3	15.4	39.6	8.8	6.5	22.2	23.6	4.4	8.5	21.7	21.1	12.6	32.8	68.3	1.2	0.0	3.6	0.2	6.3	13.3	2.0	1.8	7.0	7.6	9.3	177.8	92.3	0.6	45.8	13.7	9.1	10.9	6.1	2.2	0.0	14.1	62.5	0.9	2.6	9.1	3.1	7.3	4.6	13.3	0.4	0.6	46.9	0.0	4.7	93.6	24.5	7.2	12.1	3.5	2.1	4.0	17.8	0.1	2.0	0.3	39.0	2.4	2.0	7.3	2.4	3.2	0.6	0.8	4.0	2.5	0.2	20.8	0.2	0.9	3.8	22.9	12.3	5.8	3.3	14.0	2.7	1.4	3.0	1.1	8.8	3.6	0.2	0.4	1.2	0.0	4.2	1.2	4.2	3.0	0.0	0.8	4.4	3.1	0.0	6.3	0.1	0.0	13.3	2.0	5.4	11.2	5.7	14.8	5.6	4.1	6.0	8.3	10.8	4.4
MGA	"FLJ12634, KIAA0518, MAD5, MXD5"	ENSG00000174197	"MGA, MAX dimerization protein"	Q8IWI9	15	41621224-41773081	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042278, HPA058183"	Approved		Supported	Nucleoplasm,Cytosol	"Intracellular and membrane"			Nucleoplasm	Cytosol	"HPA042278: AB_10794647, HPA058183: "	"unprognostic (5.78e-2)"	"unprognostic (7.97e-2)"	"unprognostic (2.97e-1)"	"unprognostic (7.20e-2)"	"unprognostic (6.26e-3)"	"unprognostic (5.82e-3)"	"unprognostic (8.61e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.90e-2)"	"unprognostic (3.96e-3)"	"unprognostic (3.71e-1)"	"unprognostic (3.80e-2)"	"unprognostic (1.43e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.93e-1)"	"unprognostic (2.50e-1)"	"unprognostic (3.89e-1)"	9.3	11.3	13.8	13.6	15.3	14.3	13.0	28.2	16.9	14.5	10.1	13.3	12.2	6.8	14.2	11.5	9.8	11.3	7.8	10.1	11.2	7.7	10.1	8.5	8.5	12.7	18.7	10.5	22.7	12.0	18.0	27.6	12.4	13.7	11.0	9.7	7.2	10.3	10.8	11.8	11.2	10.6	11.8	16.1	12.5	9.8	16.4	14.7	22.4	13.9	5.3	13.4	11.6	11.5	5.0	4.1	4.9	4.9	9.8	5.0	1.5	1.4	8.4	10.6	6.9	8.3	6.6	8.5	4.2	4.2	5.0	5.0	8.9	4.9	9.9	7.6	4.8	5.8	16.3	3.6	6.9	4.7	5.3	21.0	13.8	7.8	7.4	19.2	10.5	5.0	4.6	6.9	6.9	6.4	24.4	4.5	4.4	4.1	11.6	7.5	6.5	4.3	13.2	10.8	5.1	2.6	6.0	10.0	9.8	14.9	5.2	2.7	4.2	12.3	6.8	6.1	8.6	6.2	4.9	6.2	9.2	9.7	3.8	7.4	3.0	4.9	2.3	2.5	4.7	1.8	4.6	4.8	3.7	5.0	2.4	5.0	3.9	4.3	1.2	9.8	4.9	4.1	1.8	1.5	13.8	15.3	28.2	16.9	11.2	7.7	18.7	10.5	13.7	14.7
MGMT		ENSG00000170430	"O-6-methylguanine-DNA methyltransferase"	P16455	10	129467184-129768007	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002786, HPA032135, HPA032136, HPA069497, CAB069881"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002786: , CAB069881: AB_10002128, HPA032135: , HPA032136: , HPA069497: "	"unprognostic (1.10e-1)"	"prognostic favourable (9.42e-4)"	"unprognostic (1.48e-1)"	"unprognostic (5.81e-2)"	"unprognostic (7.84e-3)"	"unprognostic (1.67e-1)"	"prognostic favourable (1.54e-4)"	"unprognostic (6.54e-3)"	"unprognostic (4.71e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.26e-1)"	"unprognostic (6.32e-1)"	"unprognostic (4.89e-1)"	"unprognostic (2.75e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	11.7	11.3	7.4	15.5	7.6	7.1	11.3	3.5	9.1	8.3	12.2	10.0	19.6	10.8	15.3	17.1	9.9	15.2	14.1	10.5	7.1	7.1	12.6	45.6	7.5	11.6	8.6	6.6	12.3	16.5	5.7	5.8	4.5	9.2	11.2	3.4	11.8	14.9	24.5	14.4	9.2	9.6	10.9	8.1	8.6	9.9	11.7	3.9	16.0	10.2	14.9	14.7	12.6	13.0	20.3	17.7	6.5	15.3	18.2	21.2	16.6	0.0	2.6	2.8	13.3	5.8	12.1	10.4	5.9	6.6	4.3	4.2	16.2	17.3	12.1	9.5	7.6	7.9	1.7	6.3	1.9	0.0	1.0	2.4	5.9	10.3	9.0	0.2	6.9	7.7	0.0	2.5	0.0	0.0	0.0	8.5	5.3	21.8	9.5	12.4	0.6	10.4	11.0	0.0	4.7	7.9	5.9	2.8	7.0	7.1	2.9	0.0	11.4	9.4	0.0	5.7	2.9	0.0	0.0	0.0	0.0	6.1	0.0	3.9	0.0	2.6	15.3	6.5	19.1	14.8	18.6	20.3	17.5	17.8	15.8	19.9	17.6	18.9	1.8	18.2	13.7	17.7	21.2	16.6	7.4	7.6	3.5	9.1	7.1	7.1	8.6	6.6	9.2	3.9
MIA	CD-RAP	ENSG00000261857	"Melanoma inhibitory activity"	Q16674	19	40771648-40777490	"Cancer-related genes, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 16.1;breast: 28.7;pituitary gland: 33.5;salivary gland: 22.7;stomach 1: 28.9"	"Group enriched"	"Detected in some"	35	"AN3-CA: 21.3;CAPAN-2: 17.8;SK-MEL-30: 62.1;WM-115: 58.8"	"Cancer enriched"	"Detected in many"	5	"melanoma: 58.6"	"Region enriched"	"Detected in some"	8	"midbrain: 16.1"	"Cell type enhanced"	"Detected in some"		"basophil: 1.6;neutrophil: 3.0"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 3.0"									HPA042369	Approved				"Secreted to blood"					"HPA042369: AB_10794420"	"prognostic favourable (2.08e-4)"	"unprognostic (1.30e-1)"	"unprognostic (3.15e-1)"	"unprognostic (9.02e-3)"	"unprognostic (2.27e-1)"	"unprognostic (1.11e-1)"	"unprognostic (6.37e-3)"	"unprognostic (3.67e-2)"	"unprognostic (1.61e-1)"	"unprognostic (9.37e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.19e-1)"	"unprognostic (3.29e-8)"	"unprognostic (5.88e-2)"	"unprognostic (2.44e-1)"	"unprognostic (2.20e-1)"	"unprognostic (2.56e-1)"	0.7	1.5	0.6	3.5	0.6	1.4	28.7	0.9	0.4	3.7	6.1	0.5	2.2	0.8	2.8	3.2	4.0	1.0	3.2	4.1	0.4	0.4	0.9	0.8	1.4	0.7	16.1	0.4	2.6	0.4	0.0	33.5	0.9	2.1	2.2	1.9	6.0	22.7	1.7	0.8	4.5	2.2	3.4	3.1	2.4	28.9	1.0	0.4	0.5	1.1	5.9	4.4	2.0	1.5	0.7	0.0	3.0	0.1	0.0	0.3	0.1	0.0	0.1	0.2	21.3	0.2	0.2	0.2	0.0	0.0	0.0	0.1	0.1	17.8	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.7	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.9	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	62.1	0.1	0.2	0.0	0.0	0.8	0.0	0.2	0.0	0.0	0.2	0.0	0.1	58.8	1.6	0.0	0.7	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.3	3.0	0.0	0.1	0.0	0.0	0.1	0.6	0.6	0.9	0.4	0.4	0.4	16.1	0.4	2.1	0.4
MIF	"GIF, GLIF"	ENSG00000240972	"Macrophage migration inhibitory factor"	P14174	22	23894004-23895227	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Immunity, Inflammatory response, Innate immunity"	"Cytokine, Isomerase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEK 293: 127.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003868, CAB005284"	Approved		Approved	Nucleoplasm,Cytosol	"Secreted to blood"	14000000	14000000	Cytosol	Nucleoplasm	"CAB005284: AB_648587, HPA003868: AB_1079290"	"unprognostic (1.68e-1)"	"unprognostic (7.79e-3)"	"unprognostic (2.49e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.36e-2)"	"unprognostic (9.48e-2)"	"unprognostic (1.22e-3)"	"unprognostic (2.17e-2)"	"unprognostic (1.78e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.28e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.02e-1)"	30.6	49.8	43.9	42.0	39.9	46.0	71.6	19.0	66.1	23.0	42.7	10.4	55.6	39.9	22.5	113.3	51.9	23.3	42.5	60.7	42.8	40.3	71.8	58.8	46.2	113.9	33.5	43.7	24.5	80.2	16.2	41.1	30.5	45.2	54.8	11.6	15.0	57.3	101.2	36.0	63.3	50.6	26.7	78.3	42.5	56.2	24.9	19.2	19.0	28.9	43.7	16.7	21.4	44.6	56.8	42.5	17.6	23.8	38.3	52.7	66.0	48.9	10.9	2.4	11.0	0.9	2.2	18.4	18.5	3.1	5.9	7.7	8.1	8.1	23.3	14.7	1.3	21.8	2.5	11.2	0.7	19.6	127.1	8.8	9.9	16.9	4.8	34.0	20.7	4.7	6.7	3.5	1.7	4.7	13.6	11.8	2.0	24.6	23.1	63.0	14.0	59.3	29.7	4.1	65.3	4.6	3.4	31.9	37.2	11.8	12.5	30.5	16.1	10.2	13.5	5.2	35.0	3.1	0.4	51.4	18.1	24.0	21.1	12.7	10.6	16.3	23.8	17.6	37.4	22.3	52.7	56.8	51.8	40.4	31.6	49.1	46.1	38.0	7.1	38.3	14.6	42.5	48.3	66.0	43.9	39.9	19.0	66.1	42.8	40.3	33.5	43.7	45.2	19.2
MITF	"bHLHe32, MI, WS2, WS2A"	ENSG00000187098	"Melanogenesis associated transcription factor"	O75030	3	69739435-69968337	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Albinism, Cancer-related genes, Deafness, Disease mutation, Microphthalmia, Osteopetrosis, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HMC-1: 26.5;SK-MEL-30: 71.3"	"Group enriched"	"Detected in all"	8	"melanoma: 39.2;renal cancer: 9.1"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 4.5;classical monocyte: 10.9;intermediate monocyte: 3.6;myeloid DC: 6.8;non-classical monocyte: 5.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.8;granulocytes: 4.5;monocytes: 10.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002578, HPA003259"	Enhanced									"CAB002578: AB_564111, HPA003259: AB_1079381"	"unprognostic (3.29e-1)"	"unprognostic (4.26e-2)"	"unprognostic (2.98e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.75e-1)"	"unprognostic (5.31e-3)"	"unprognostic (3.87e-3)"	"unprognostic (1.94e-1)"	"prognostic favourable (8.35e-10)"	"unprognostic (6.37e-2)"	"unprognostic (1.08e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.73e-1)"	12.8	3.8	2.6	2.6	3.9	0.8	17.8	1.7	3.0	30.6	10.1	5.9	6.4	1.5	37.9	6.2	8.3	6.4	9.9	23.4	3.1	2.4	12.8	1.8	7.1	1.7	4.2	1.1	11.1	2.4	9.7	6.2	1.8	4.0	9.0	2.5	40.1	4.0	8.2	39.1	5.8	4.1	26.2	5.0	1.8	5.1	4.7	5.1	0.1	4.4	8.1	1.0	12.1	10.3	0.0	6.8	4.5	10.9	1.4	0.1	3.4	4.8	3.3	0.3	1.5	5.6	0.1	0.6	4.9	2.8	2.2	1.4	1.7	0.2	0.0	1.1	0.0	2.6	1.0	2.7	2.5	0.0	0.6	10.7	7.1	0.1	1.4	0.2	26.5	4.6	1.1	0.6	2.5	0.7	3.5	1.5	1.6	0.2	0.1	0.3	0.2	2.4	0.0	0.5	2.3	13.4	2.5	0.2	0.5	2.5	0.9	71.3	0.2	0.6	0.0	1.1	4.0	1.6	1.0	0.1	0.2	0.0	2.3	0.7	2.8	4.5	10.9	0.0	0.0	3.6	0.0	0.0	0.0	0.1	6.8	0.0	0.0	0.0	0.7	1.4	5.7	0.5	0.0	3.4	2.6	3.9	1.7	3.0	3.1	2.4	4.2	1.1	4.0	5.1
MKI67	"MIB-, PPP1R105"	ENSG00000148773	"Marker of proliferation Ki-67"	P46013	10	128096659-128126385	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 25.2;lymphoid tissue: 81.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 1.4;T-reg: 1.3"	"Group enriched"	"Detected in many"	13	"NK-cells: 1.1;T-cells: 1.4"									"CAB000058, HPA000451, HPA001164, CAB068198"	Enhanced		Enhanced	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"CAB000058: AB_2142367, CAB068198: , HPA000451: AB_1079186, HPA001164: AB_1079187"	"unprognostic (2.54e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.37e-1)"	"unprognostic (9.92e-3)"	"unprognostic (3.17e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (3.61e-6)"	"unprognostic (7.16e-3)"	"unprognostic (1.45e-2)"	"unprognostic (3.73e-1)"	"prognostic unfavourable (9.47e-5)"	"unprognostic (2.45e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (1.42e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.50e-1)"	"unprognostic (4.61e-1)"	1.8	1.2	0.2	9.9	0.5	25.2	1.8	0.3	0.5	1.5	5.0	0.6	0.2	3.6	0.7	1.4	13.4	0.3	1.2	1.3	0.2	0.2	1.2	1.0	1.9	8.8	0.2	0.2	0.5	0.4	0.0	0.4	2.9	0.5	0.7	5.8	0.5	2.2	0.6	0.5	3.9	6.2	1.3	0.8	6.5	3.5	2.5	0.2	81.5	0.4	5.2	10.0	1.3	3.5	0.0	0.0	0.0	0.0	1.1	1.4	0.4	47.3	24.1	25.1	17.8	1.0	2.1	7.8	18.0	13.3	17.1	15.3	19.7	19.7	35.7	5.2	12.3	28.9	26.3	13.5	25.8	37.6	12.7	30.6	17.8	12.3	0.0	43.0	16.6	0.5	0.6	17.6	18.0	16.7	14.0	34.4	16.9	18.8	25.6	13.1	10.0	11.0	19.1	32.9	4.7	6.2	13.3	8.7	9.5	25.5	9.2	4.4	7.5	9.2	15.4	9.1	18.2	12.8	48.6	15.7	12.4	43.3	7.5	19.7	7.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.1	0.0	0.0	1.4	1.0	0.0	1.1	0.0	0.0	1.3	0.4	0.2	0.5	0.3	0.5	0.2	0.2	0.2	0.2	0.5	0.2
MKL1	"BSAC, KIAA1438, MAL, MKL, MRTF-A"	ENSG00000196588	"Megakaryoblastic leukemia (translocation) 1"	Q969V6	22	40410281-40636702	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Actin-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 50.9"	"Group enriched"	"Detected in all"	5	"dendritic cells: 26.4;granulocytes: 50.9;monocytes: 15.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030782	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA030782: AB_10600930"	"unprognostic (7.90e-3)"	"unprognostic (4.51e-2)"	"unprognostic (2.99e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.04e-2)"	"unprognostic (9.37e-2)"	"unprognostic (4.38e-3)"	"unprognostic (1.02e-3)"	"unprognostic (1.30e-1)"	"unprognostic (1.35e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.74e-2)"	"prognostic unfavourable (1.58e-7)"	"unprognostic (9.05e-2)"	"unprognostic (8.15e-2)"	"unprognostic (1.30e-2)"	"unprognostic (3.98e-1)"	18.1	11.1	15.4	25.4	19.1	69.2	15.8	16.2	26.1	17.6	14.2	13.5	10.1	11.3	27.6	12.9	12.3	17.5	13.2	16.3	14.2	11.1	11.3	8.9	17.4	25.6	11.8	16.6	16.9	14.5	10.2	10.5	18.9	12.6	14.2	9.4	13.3	16.9	15.7	14.3	18.0	13.6	15.7	11.0	23.9	14.3	25.4	10.8	28.2	17.3	9.0	25.5	15.5	14.6	4.9	26.4	50.9	15.0	3.8	5.6	7.5	10.7	14.6	6.3	7.5	8.0	6.1	12.4	10.5	6.8	9.7	9.4	6.8	3.3	11.5	4.3	11.0	14.2	5.3	12.9	6.3	12.7	9.3	19.0	16.3	10.1	7.9	22.0	37.5	6.6	15.6	9.4	6.5	7.1	5.3	5.2	4.6	10.5	8.6	24.7	5.0	5.1	14.0	7.1	5.8	7.7	8.1	3.5	3.8	17.2	8.7	6.3	5.8	24.9	11.6	6.6	17.7	8.7	9.0	7.0	6.2	16.5	5.4	11.1	12.7	12.0	15.0	50.9	4.4	11.6	4.1	3.2	4.0	3.4	17.8	4.9	5.6	4.7	14.5	3.8	15.0	26.4	5.2	7.5	15.4	19.1	16.2	26.1	14.2	11.1	11.8	16.6	12.6	10.8
MLF1		ENSG00000178053	"Myeloid leukemia factor 1"	P58340	3	158571163-158607252	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Differentiation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 41.4;skeletal muscle: 53.6;testis: 101.1"	"Cell line enhanced"	"Detected in many"		"A-431: 34.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.4"	"Lineage enriched"	"Detected in single"	12	"T-cells: 10.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA069479			Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA069479: "	"unprognostic (6.49e-2)"	"unprognostic (1.98e-3)"	"unprognostic (1.98e-1)"	"prognostic unfavourable (2.15e-5)"	"unprognostic (1.72e-2)"	"unprognostic (2.65e-2)"	"unprognostic (8.55e-2)"	"unprognostic (4.11e-2)"	"unprognostic (2.01e-1)"	"unprognostic (2.07e-1)"	"unprognostic (7.21e-2)"	"unprognostic (1.07e-1)"	"unprognostic (7.82e-2)"	"prognostic unfavourable (5.54e-4)"	"unprognostic (9.34e-3)"	"unprognostic (2.47e-3)"	"unprognostic (3.36e-2)"	3.5	2.6	6.0	1.8	11.9	0.9	5.3	3.4	7.1	3.1	2.7	6.5	0.5	0.8	4.9	5.6	3.5	18.3	4.9	41.4	6.3	6.3	5.7	1.2	5.2	1.0	4.9	6.3	6.2	3.1	5.2	10.4	1.0	20.1	2.0	1.7	2.8	2.2	1.6	53.6	1.8	1.3	4.5	4.7	1.2	1.9	101.1	5.7	0.0	5.3	18.9	1.4	4.2	1.5	0.6	0.3	0.4	0.3	0.8	10.4	2.3	34.1	4.5	11.5	0.0	6.1	7.2	3.4	3.5	3.4	13.0	11.8	0.0	19.5	0.0	13.5	6.1	6.6	0.1	6.0	17.3	0.0	7.5	2.0	3.3	0.3	4.2	0.0	2.6	4.4	8.8	6.2	3.4	3.0	2.5	0.0	8.5	5.0	0.0	0.1	2.7	10.0	0.0	6.4	0.4	9.9	2.4	14.9	8.8	16.1	5.7	16.9	16.4	3.4	1.1	12.1	12.4	14.3	13.7	6.1	3.8	0.0	8.7	0.0	8.7	0.0	0.0	0.0	3.6	0.0	1.6	0.6	8.3	8.7	0.3	0.3	2.1	4.4	0.4	0.8	0.3	0.2	10.4	2.3	6.0	11.9	3.4	7.1	6.3	6.3	4.9	6.3	20.1	5.7
MLH1	"COCA2, FCC2, HNPCC, HNPCC2"	ENSG00000076242	"MutL homolog 1"	P40692	3	36993332-37050918	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013294, HPA052707, HPA060714, CAB070868"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB013294: AB_2533406, CAB070868: , HPA052707: , HPA060714: "	"unprognostic (1.26e-2)"	"unprognostic (3.88e-3)"	"unprognostic (2.36e-2)"	"unprognostic (1.82e-1)"	"unprognostic (3.33e-2)"	"unprognostic (1.05e-1)"	"prognostic unfavourable (8.24e-5)"	"unprognostic (3.36e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.32e-1)"	"unprognostic (8.54e-2)"	"unprognostic (8.63e-3)"	"unprognostic (2.10e-3)"	"unprognostic (4.37e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (8.86e-2)"	16.3	20.7	18.2	19.4	21.4	24.4	18.7	19.7	19.6	15.3	17.3	28.8	19.6	12.4	18.7	23.6	15.1	16.2	14.4	32.0	17.3	17.7	18.8	20.5	17.8	22.8	19.9	16.0	17.6	18.1	26.0	29.4	17.3	19.2	18.5	17.7	16.7	15.6	18.1	46.4	14.2	14.1	21.1	21.6	20.7	16.5	27.6	21.5	29.0	22.2	19.5	24.5	16.9	21.4	12.0	12.9	13.2	23.2	6.7	13.4	9.0	14.0	22.2	27.8	0.0	12.4	15.5	12.4	21.0	16.8	24.5	26.1	16.7	15.7	34.9	10.4	17.0	9.7	23.8	17.7	26.2	15.8	12.3	24.4	20.5	23.4	13.7	29.9	17.0	11.5	12.6	22.8	28.4	15.1	31.2	16.7	24.8	11.3	31.1	12.3	20.3	12.2	3.1	33.9	14.7	15.5	15.2	5.9	14.0	21.3	22.6	14.0	32.7	21.3	11.9	19.2	20.8	18.9	24.6	13.2	36.1	32.6	14.9	28.3	17.2	10.9	11.7	13.2	13.4	19.5	9.7	12.0	8.4	10.7	12.9	10.3	9.6	9.7	3.4	6.7	23.2	6.1	12.5	9.0	18.2	21.4	19.7	19.6	17.3	17.7	19.9	16.0	19.2	21.5
MLLT1	"ENL, LTG19, YEATS1"	ENSG00000130382	"MLLT1, super elongation complex subunit"	Q03111	19	6210379-6279948	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031166	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA031166: AB_10601874"	"unprognostic (3.21e-1)"	"unprognostic (2.75e-3)"	"unprognostic (4.84e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.47e-1)"	"prognostic favourable (6.03e-5)"	"unprognostic (1.30e-3)"	"unprognostic (1.44e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.98e-1)"	"unprognostic (3.93e-3)"	"unprognostic (4.76e-2)"	"unprognostic (3.65e-3)"	"unprognostic (1.14e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.66e-2)"	"unprognostic (7.99e-3)"	20.1	13.7	21.8	17.1	23.4	8.8	12.9	32.7	28.6	17.7	16.8	16.8	17.7	13.4	22.1	15.5	13.1	25.5	19.3	18.2	16.9	14.3	10.7	12.8	16.7	10.9	13.0	18.5	29.8	22.4	26.2	10.7	45.2	14.6	17.2	6.8	18.7	21.7	18.8	23.5	18.8	13.1	15.0	10.6	13.9	15.1	10.7	13.7	10.8	18.9	12.1	10.2	20.6	23.6	1.5	5.2	4.9	3.5	1.9	2.5	1.6	24.4	12.0	14.9	17.5	11.7	10.1	17.3	15.2	9.9	12.8	13.2	19.8	8.3	17.8	19.9	19.9	15.3	11.8	14.9	7.7	14.9	18.4	22.1	32.6	14.9	22.5	14.3	20.3	16.3	13.1	12.2	10.0	14.5	21.3	20.8	8.4	13.5	24.4	13.7	18.1	25.4	21.0	11.1	14.2	6.9	15.2	25.9	23.5	15.7	17.4	18.8	15.7	17.0	15.1	18.0	14.0	27.8	20.9	25.6	19.8	14.0	20.8	24.7	25.5	0.2	1.9	0.4	1.8	3.0	2.5	1.5	1.3	1.7	1.4	1.4	1.1	1.5	4.9	1.9	3.5	5.2	0.5	1.6	21.8	23.4	32.7	28.6	16.9	14.3	13.0	18.5	14.6	13.7
MLLT10	AF10	ENSG00000078403	"MLLT10, histone lysine methyltransferase DOT1L cofactor"	P55197	10	21524675-21743630	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 71.2"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005747	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"HPA005747: AB_1079393"	"unprognostic (6.58e-2)"	"unprognostic (1.57e-1)"	"unprognostic (7.32e-2)"	"unprognostic (1.47e-2)"	"unprognostic (1.31e-2)"	"prognostic favourable (8.75e-4)"	"unprognostic (1.03e-3)"	"unprognostic (9.56e-3)"	"unprognostic (9.29e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.69e-2)"	"unprognostic (7.85e-2)"	"unprognostic (6.57e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.67e-1)"	16.3	12.1	11.7	18.4	14.3	21.9	12.8	25.4	13.6	19.0	17.0	12.0	13.6	8.5	26.3	12.8	14.7	14.5	13.7	15.8	10.2	8.5	12.3	13.5	12.3	11.6	10.5	9.9	21.4	12.3	16.6	23.2	20.3	11.8	12.6	11.3	14.6	13.2	16.3	13.4	18.7	12.1	18.7	11.2	10.6	11.4	71.2	14.3	14.6	18.1	9.7	15.2	18.5	19.6	5.5	6.9	12.0	6.8	5.3	7.2	2.8	14.3	12.2	18.9	13.1	12.0	15.1	20.7	9.1	5.8	11.4	11.2	13.0	15.4	17.2	5.1	10.1	13.5	20.8	12.2	11.5	11.9	12.0	26.6	10.6	18.7	14.8	0.6	17.2	11.2	14.6	9.5	11.0	15.1	28.4	13.4	9.0	11.1	20.7	12.5	7.7	3.9	18.0	10.1	14.4	11.0	6.8	6.6	18.4	12.1	14.5	20.4	6.8	18.5	13.6	7.2	12.6	14.3	9.0	11.7	13.4	19.2	8.3	10.3	5.5	10.6	6.8	12.0	5.3	4.6	5.2	5.0	6.2	5.7	5.6	5.5	7.2	6.7	5.8	5.3	5.2	6.9	4.6	2.8	11.7	14.3	25.4	13.6	10.2	8.5	10.5	9.9	11.8	14.3
MLLT11	AF1Q	ENSG00000213190	"MLLT11, transcription factor 7 cofactor"	Q13015	1	151057758-151068497	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 42.1"	"Cell line enhanced"	"Detected in many"		"AF22: 38.4;EFO-21: 29.2;SH-SY5Y: 42.1;U-698: 35.8"	"Cancer enhanced"	"Detected in all"		"glioma: 29.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000540	Uncertain		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA000540: "	"unprognostic (2.96e-2)"	"unprognostic (1.98e-2)"	"unprognostic (1.08e-2)"	"prognostic unfavourable (4.26e-5)"	"unprognostic (1.69e-1)"	"unprognostic (1.96e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.01e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.01e-1)"	"prognostic unfavourable (4.25e-12)"	"unprognostic (5.66e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.94e-3)"	1.9	7.5	13.6	3.4	9.1	1.1	1.2	16.3	42.1	1.9	2.1	5.1	1.2	0.8	3.7	1.2	1.3	0.8	11.1	11.8	11.3	16.4	1.2	1.2	5.3	2.3	10.3	1.2	4.2	1.3	8.4	1.8	1.2	3.2	1.3	1.1	1.2	1.5	1.2	2.6	1.0	2.0	4.2	5.8	2.1	0.9	1.2	1.2	2.0	1.2	1.2	2.6	3.2	1.2	2.4	1.0	6.5	1.0	4.2	9.2	2.8	1.2	5.2	38.4	6.0	0.6	1.0	0.6	2.4	2.6	2.3	4.2	0.5	2.5	1.9	29.2	1.8	1.5	9.2	2.2	1.3	11.2	2.5	5.0	3.8	0.1	1.2	0.3	0.8	1.7	0.3	12.7	0.5	16.9	5.3	0.9	7.4	0.4	17.6	3.3	16.7	0.8	16.8	5.1	0.1	4.3	1.1	23.1	42.1	0.2	0.4	1.2	1.4	0.6	11.8	5.0	5.5	1.8	4.3	0.9	0.8	35.8	12.4	0.3	9.3	1.6	0.6	1.6	5.9	0.7	2.7	2.4	3.9	6.0	0.8	2.1	5.3	9.2	6.5	4.2	1.0	1.0	3.6	2.8	13.6	9.1	16.3	21.0	11.3	16.4	10.3	1.2	3.2	1.2
MLLT3	"AF-9, AF9, YEATS3"	ENSG00000171843	"MLLT3, super elongation complex subunit"	P42568	9	20341665-20622543	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 72.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 14.4"	"Group enriched"	"Detected in many"	5	"NK-cells: 3.8;T-cells: 14.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001824	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA001824: AB_1079394"	"unprognostic (3.31e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.27e-2)"	"unprognostic (1.99e-1)"	"unprognostic (7.57e-2)"	"unprognostic (3.83e-2)"	"unprognostic (1.01e-3)"	"unprognostic (2.12e-1)"	"unprognostic (3.92e-3)"	"unprognostic (1.05e-1)"	"unprognostic (2.03e-2)"	"prognostic favourable (1.84e-4)"	"unprognostic (1.85e-1)"	"unprognostic (4.81e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.68e-1)"	8.6	17.3	18.0	10.4	25.8	19.7	11.4	34.6	20.3	12.3	20.9	7.2	10.6	7.2	13.6	7.9	10.2	11.5	12.7	8.6	18.0	12.8	10.1	2.1	10.7	9.1	14.8	13.8	10.5	4.6	18.3	24.7	10.3	13.2	11.7	22.8	7.4	21.3	12.1	9.1	7.9	12.3	13.5	12.0	5.9	15.3	3.6	21.4	22.1	22.5	6.1	6.5	12.9	10.4	1.4	0.7	1.6	0.3	3.8	14.4	2.8	2.5	7.1	2.5	2.9	5.9	3.7	1.6	6.7	11.3	3.0	3.4	6.9	2.4	9.8	3.6	3.1	1.3	2.4	11.6	2.7	20.2	6.2	72.2	21.9	3.2	4.3	1.3	6.1	2.7	4.5	1.0	7.3	3.0	0.0	12.7	6.3	1.9	7.0	4.2	1.6	2.1	0.0	4.6	2.6	13.9	3.8	8.2	2.9	5.4	2.7	2.9	2.8	1.9	1.9	0.0	1.7	1.7	2.3	5.7	5.2	4.0	0.0	3.1	1.4	1.6	0.3	0.5	3.9	0.2	3.6	0.5	7.0	5.3	0.7	1.4	14.4	8.3	0.1	3.8	0.3	0.4	7.3	2.8	18.0	25.8	34.6	20.3	18.0	12.8	14.8	13.8	13.2	21.4
MLLT6	"AF17, FLJ23480"	ENSG00000275023	"MLLT6, PHD finger containing"		17	38705542-38729803	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"				"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004021	Approved		Approved	Nucleoplasm				Nucleoplasm		"HPA004021: AB_1853995"	"prognostic favourable (4.18e-4)"	"unprognostic (1.50e-1)"	"unprognostic (2.53e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.29e-1)"	"prognostic favourable (3.98e-4)"	"unprognostic (4.98e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.77e-1)"	"unprognostic (7.12e-3)"	"prognostic favourable (7.41e-4)"	"unprognostic (1.78e-1)"	"unprognostic (1.84e-2)"	"unprognostic (9.12e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.05e-1)"	"unprognostic (2.46e-3)"	6.5	7.6	10.0	10.3	10.6	7.3	6.3	14.1	16.9	6.2	6.8	7.2	11.1	7.2	9.2	8.6	5.5	10.3	9.2	7.5	9.7		5.8	1.2	8.5	11.8	8.5	9.6	13.0	9.0	12.8	10.1	4.8	7.2	7.3	5.7	10.0	10.3	12.5	22.3	8.5	8.9	8.2	8.1	11.7	6.7	4.1	9.2	6.3	7.2	4.8	10.1	5.5	11.5	1.4	0.9	2.0	0.8	2.8	6.0	1.7	5.7	6.4	6.5	14.2	7.2	6.5	3.4	3.6	6.6	4.4	5.3	2.3	11.3	16.4	5.2	4.2	15.0	4.2	7.4	3.9	17.5	11.4	6.0	10.7	10.5	3.5	9.2	8.2	6.6	7.6	3.9	8.8	7.2	10.0	13.9	3.8	4.8	18.0	8.9	0.8	3.3	10.6	8.9	15.1	5.1	13.3	14.6	16.1	3.8	12.4	10.6	12.3	6.8	9.5	5.2	7.7	7.2	6.5	23.6	7.7	11.0	7.6	8.5	5.5	1.7	0.8	0.4	6.0	0.5	4.6	1.4	3.2	4.2	0.4	1.4	3.1	4.1	2.0	2.8	0.3	0.9	1.7	1.7										
MME	"CALLA, CD10, NEP"	ENSG00000196549	"Membrane metalloendopeptidase"	P08473	3	155024124-155183729	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 61.1;intestine: 136.0;kidney: 64.9"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 95.0;BJ hTERT+: 142.9;HSkMC: 92.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	129	"neutrophil: 61.1"	"Lineage enriched"	"Detected in single"	129	"granulocytes: 61.1"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 26.8"	"CAB000013, HPA052583, HPA056072"	Enhanced					99000	99000			"CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027"	"unprognostic (1.36e-1)"	"unprognostic (1.02e-3)"	"unprognostic (8.52e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.78e-2)"	"unprognostic (6.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.67e-2)"	"unprognostic (8.67e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.30e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.71e-3)"	"unprognostic (1.50e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.37e-2)"	26.5	0.4	0.4	3.4	7.4	1.9	14.7	0.4	0.7	4.8	65.6	0.1	18.4	74.0	2.8	8.1	0.7	0.9	8.5	1.8	0.3	0.4	64.9	11.5	13.7	3.0	2.1	0.2	0.9	0.6	0.0	0.6	35.0	8.6	18.3	0.4	1.3	3.7	11.3	11.7	1.4	136.0	0.6	0.9	2.7	0.7	1.0	1.2	13.2	1.0	5.3	2.3	3.4	4.9	0.1	0.4	61.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	38.6	95.0	0.2	21.2	142.9	10.8	28.1	0.0	0.0	23.4	0.0	18.8	0.0	0.7	0.8	26.1	0.0	0.1	0.0	0.0	0.0	30.9	0.0	0.0	92.1	0.1	5.8	41.6	8.2	0.0	0.0	17.3	0.1	0.0	0.1	0.9	0.1	38.8	18.2	0.1	0.6	0.2	0.0	0.2	0.0	0.0	4.1	0.0	0.0	23.3	46.7	0.1	15.9	3.7	0.0	0.0	30.8	5.6	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	61.1	0.0	0.0	0.4	0.0	0.0	0.4	7.4	0.4	0.7	0.3	0.4	2.1	0.2	8.6	1.2
MMP1	CLG	ENSG00000196611	"Matrix metallopeptidase 1"	P03956	11	102789920-102798160	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation, Host-virus interaction"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 62.4;stomach 1: 27.2"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 88.1;HBF TERT88: 87.3;HUVEC TERT2: 229.4;WM-115: 113.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 344.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA004920			Approved	Vesicles	"Secreted to extracellular matrix"	430000	430000	Vesicles		"HPA004920: "	"unprognostic (4.11e-3)"	"prognostic unfavourable (4.66e-4)"	"unprognostic (4.20e-3)"	"unprognostic (1.19e-3)"	"unprognostic (6.46e-2)"	"unprognostic (6.50e-2)"	"prognostic unfavourable (4.22e-6)"	"unprognostic (7.83e-3)"	"unprognostic (2.94e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.11e-3)"	"unprognostic (1.75e-1)"	"prognostic unfavourable (9.86e-10)"	"unprognostic (1.67e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.26e-2)"	"unprognostic (5.11e-2)"	0.2	0.1	0.3	12.3	0.3	0.0	0.9	0.3	0.3	0.3	2.7	0.3	0.2	3.2	4.8	0.2	3.3	0.1	62.4	0.4	0.2	0.1	0.7	1.3	4.7	0.2	0.2	0.2	0.2	1.6	0.0	0.2	8.6	0.5	0.7	3.0	0.3	2.0	0.2	0.2	0.3	8.8	0.2	0.4	1.8	27.2	2.2	0.2	0.4	0.3	1.3	0.9	11.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.9	88.1	36.0	9.4	0.7	0.0	0.0	0.4	21.1	0.3	0.0	12.3	87.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	37.0	3.1	229.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	11.9	29.9	0.0	1.3	0.1	0.0	0.0	0.0	0.7	0.0	113.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.9	0.3	0.3	0.3	0.3	0.2	0.1	0.2	0.2	0.5	0.2
MMP10	STMY2	ENSG00000166670	"Matrix metallopeptidase 10"	P09238	11	102770503-102780628	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"endometrium 1: 89.4"	"Cell line enhanced"	"Detected in some"		"BJ: 12.3;HUVEC TERT2: 15.8;SCLC-21H: 5.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 102.2"	"Region enriched"	"Detected in single"	9	"pons and medulla: 2.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							CAB002159	Uncertain		Approved	"Plasma membrane,Cytosol"	"Secreted to extracellular matrix"			Cytosol	"Plasma membrane"	"CAB002159: AB_564103"	"unprognostic (8.76e-2)"	"unprognostic (3.38e-1)"	"unprognostic (1.98e-3)"	"unprognostic (2.72e-3)"	"unprognostic (7.17e-3)"	"unprognostic (1.52e-2)"	"unprognostic (5.67e-8)"	"unprognostic (2.08e-3)"	"unprognostic (2.20e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.67e-1)"	"unprognostic (6.99e-5)"	"unprognostic (2.66e-2)"	"unprognostic (7.98e-2)"	"unprognostic (5.46e-2)"	"prognostic favourable (7.12e-4)"	0.1	0.1	0.0	2.6	0.2	0.1	0.1	0.0	0.3	1.7	0.5	0.0	0.0	0.4	89.4	0.1	0.2	0.1	0.5	0.1	0.0	0.1	0.1	3.6	11.0	0.1	0.0	0.0	0.5	0.3	0.1	0.9	19.8	2.8	3.2	0.2	0.0	2.9	0.1	0.1	0.1	0.7	0.1	0.0	0.2	3.3	0.5	0.0	1.2	0.1	0.0	1.9	0.6	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.2	0.0	0.0	0.2	12.3	0.7	0.1	0.1	0.3	0.0	0.0	3.6	1.9	2.8	0.0	1.4	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.6	15.8	0.7	0.0	0.0	0.0	0.0	0.3	2.9	1.7	0.0	0.0	0.0	0.0	0.7	5.0	0.0	2.5	0.0	0.0	0.0	0.0	2.0	3.8	1.2	0.4	0.5	0.0	0.0	0.0	0.6	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	2.8	0.0
MMP11	STMY3	ENSG00000099953	"Matrix metallopeptidase 11"	P24347	22	23768226-23784316	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"endometrium 1: 44.1;placenta: 119.6"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 18.9;BJ hTERT+: 5.1;REH: 7.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 7.8"	"Group enriched"	"Detected in many"	5	"B-cells: 2.4;dendritic cells: 7.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002593, HPA068864"	Approved				"Secreted to extracellular matrix"					"CAB002593: , HPA068864: "	"unprognostic (1.06e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.84e-3)"	"unprognostic (2.77e-2)"	"unprognostic (6.73e-2)"	"unprognostic (2.14e-2)"	"unprognostic (5.15e-1)"	"unprognostic (2.73e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.89e-3)"	"unprognostic (7.04e-2)"	"prognostic unfavourable (2.62e-4)"	"unprognostic (8.05e-2)"	"unprognostic (6.78e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.68e-2)"	1.7	0.6	0.2	1.0	0.6	0.1	1.6	1.0	0.5	13.4	1.8	0.4	0.4	1.9	44.1	1.1	0.8	2.2	2.0	3.1	0.5	0.0	1.7	0.5	0.7	1.8	0.4	0.2	7.7	1.1	0.2	0.3	119.6	0.5	1.4	1.0	0.8	2.5	0.4	0.5	2.0	4.0	2.7	0.3	0.9	0.7	3.4	0.2	2.6	0.5	0.6	0.9	1.6	2.1	2.4	7.8	0.0	0.0	0.0	1.0	0.1	0.1	0.0	2.3	18.9	2.9	4.2	0.0	0.2	5.1	0.6	0.4	0.0	0.6	0.6	3.5	1.3	0.1	1.0	0.0	0.2	0.0	0.3	0.0	0.0	1.0	2.1	0.0	0.0	2.7	0.4	0.5	0.0	3.0	0.3	0.0	0.7	0.1	0.0	0.0	0.7	0.1	7.9	0.0	0.2	0.3	0.0	3.0	5.1	1.9	0.3	0.0	1.8	0.0	1.3	0.3	0.0	0.8	0.0	0.1	0.1	2.5	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	2.4	1.0	0.3	0.0	0.0	0.0	7.8	0.0	0.1	0.2	0.6	1.0	0.5	0.5	0.0	0.4	0.2	0.5	0.2
MMP12	HME	ENSG00000262406	"Matrix metallopeptidase 12"	P39900	11	102862736-102875034	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 42.4;urinary bladder: 13.2"	"Group enriched"	"Detected in some"	12	"BJ: 4.1;fHDF/TERT166: 14.3;hTEC/SVTERT24-B: 8.2"	"Low cancer specificity"	"Detected in all"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"								"Secreted to extracellular matrix"						"unprognostic (7.33e-2)"	"unprognostic (3.20e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavourable (1.42e-4)"	"unprognostic (1.69e-2)"	"unprognostic (7.31e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.52e-3)"	"unprognostic (5.45e-2)"	"unprognostic (3.05e-6)"	"unprognostic (1.08e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.73e-1)"	"unprognostic (6.92e-2)"	2.7	0.0	0.0	21.2	0.0	0.0	0.0	0.0	0.0	0.3	6.9	0.0	0.0	3.3	0.0	5.9	0.0	0.0	1.0	0.0	0.0		0.0	0.4	0.6	18.9	0.0	0.0	0.1	0.0	0.0	0.0	9.7	0.0	0.3	8.4	0.0	0.9	0.0	0.0	0.0	3.8	4.6	0.0	42.4	1.3	0.1	0.0	5.5	0.0	1.5	9.9	13.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.4	0.2	0.0	0.1	0.0	0.0	0.0	14.3	0.5	0.0	0.0	0.4	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.5	0.6	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MMP13	CLG3	ENSG00000137745	"Matrix metallopeptidase 13"	P45452	11	102942995-102955734	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lung: 12.6;vagina: 10.8"	"Group enriched"	"Detected in some"	5	"HaCaT: 19.1;PC-3: 7.2"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 70.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB002742	Supported				"Secreted to extracellular matrix"					"CAB002742: "	"unprognostic (8.98e-3)"	"unprognostic (1.54e-1)"	"unprognostic (4.75e-2)"	"unprognostic (4.57e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.59e-3)"		"unprognostic (1.32e-1)"	"unprognostic (6.35e-3)"	"unprognostic (1.69e-1)"	"unprognostic (7.55e-3)"	"unprognostic (2.24e-1)"	"unprognostic (1.73e-8)"	"unprognostic (2.12e-2)"	"unprognostic (3.14e-1)"	"unprognostic (4.14e-2)"	"unprognostic (4.33e-2)"	0.5	0.1	0.0	0.8	0.0	1.3	0.4	0.0	0.2	1.3	0.1	0.0	0.0	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.1	12.6	0.1	0.0	0.0	0.1	0.0	0.0	3.1	0.1	0.1	1.2	0.0	0.0	0.6	0.0	0.0	1.0	0.5	0.0	0.0	0.1	0.1	1.9	0.0	1.4	0.0	0.0	0.1	4.6	10.8	1.0	0.7	2.7	0.5	1.9	1.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	19.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.5	0.1	0.0	0.0	7.2	0.0	0.0	0.1	0.0	1.9	0.0	0.1	0.1	2.2	0.0	0.0	0.0	0.0	2.7	1.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	2.7	0.5	0.6	1.3	0.4	1.0	0.5	0.7	0.8	0.3	1.0	0.6	1.1	1.9	1.9	0.3	0.7	0.4	0.5	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.0
MMP14	MT1-MMP	ENSG00000157227	"Matrix metallopeptidase 14"	P50281	14	22836557-22849027	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 98.0;HHSteC: 92.7;HSkMC: 94.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009918, HPA051432"	Approved		Approved	"Intermediate filaments,Cytosol"		570000	570000	Cytosol	"Intermediate filaments"	"CAB009918: AB_2250767, HPA051432: "	"unprognostic (1.34e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.11e-2)"	"unprognostic (2.81e-1)"	"unprognostic (4.28e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.05e-3)"	"unprognostic (5.91e-3)"	"unprognostic (1.95e-1)"	"prognostic unfavourable (9.48e-4)"	"unprognostic (3.82e-3)"	"unprognostic (7.31e-2)"	"prognostic unfavourable (1.34e-4)"	"unprognostic (5.02e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.00e-2)"	"unprognostic (3.41e-3)"	60.9	10.5	2.4	16.6	4.7	0.2	64.2	2.2	3.2	56.3	35.0	8.2	12.7	12.0	53.1	24.1	47.0	21.9	39.6	17.5	3.4	1.8	16.8	9.0	29.8	16.9	5.8	2.9	39.3	11.2	34.4	4.7	73.5	16.4	39.1	11.3	27.1	24.4	16.7	20.4	37.0	22.9	28.5	20.7	22.5	18.2	26.3	4.6	5.4	22.3	14.6	16.7	52.5	53.9	0.1	0.7	0.0	0.7	0.0	0.0	0.1	7.9	0.1	2.4	0.1	98.0	62.3	45.0	25.1	50.6	7.6	13.6	2.3	29.9	0.1	14.0	26.4	20.3	0.0	26.1	9.8	0.1	0.1	3.7	0.1	0.5	92.7	0.0	0.1	94.2	15.8	31.7	27.2	46.0	0.1	0.2	17.9	0.1	0.0	9.0	1.5	4.3	0.3	8.6	0.0	6.9	13.7	0.0	0.0	16.4	0.0	54.4	0.1	8.1	40.7	61.9	5.3	18.0	28.6	0.1	0.1	0.1	37.7	0.0	35.8	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	4.7	2.2	3.2	3.4	1.8	5.8	2.9	16.4	4.6
MMP15	"MT2-MMP, MTMMP2, SMCP-2"	ENSG00000102996	"Matrix metallopeptidase 15"	P51511	16	58025566-58046901	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 43.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 36.8;Hep G2: 19.1;SK-BR-3: 18.5;WM-115: 30.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	30	"plasmacytoid DC: 2.9"	"Lineage enriched"	"Detected in single"	30	"dendritic cells: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002611, HPA040390"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoplasm	"CAB002611: , HPA040390: "	"unprognostic (1.76e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.69e-1)"	"unprognostic (6.85e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.68e-1)"	"unprognostic (6.88e-3)"	"unprognostic (1.40e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.24e-2)"	"unprognostic (4.81e-2)"	"unprognostic (1.81e-1)"	"prognostic favourable (8.54e-8)"	"unprognostic (3.63e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.28e-1)"	"prognostic favourable (3.08e-4)"	5.9	2.3	2.0	5.5	3.0	0.1	7.7	3.7	7.2	3.3	19.5	4.2	16.3	22.6	2.9	1.7	2.5	3.6	15.9	17.6	2.3	3.7	8.4	26.4	6.1	2.0	2.5	2.2	2.1	10.3	7.3	5.2	28.5	10.4	3.6	8.2	9.5	4.7	14.7	3.4	2.3	43.2	3.4	3.4	5.2	14.7	28.0	2.1	1.1	26.8	2.5	2.2	3.3	4.2	0.0	2.9	0.0	0.0	0.0	0.0	0.0	5.7	4.3	2.3	11.8	2.4	0.1	36.8	0.5	0.3	2.1	0.4	3.4	14.8	0.0	7.0	0.6	8.1	1.9	1.7	0.6	0.0	3.9	0.0	1.9	19.1	3.1	0.1	7.7	1.2	3.0	0.3	0.9	1.4	4.7	0.0	0.7	2.8	0.2	0.9	6.7	1.2	2.8	0.3	3.1	6.5	2.1	0.6	4.1	7.7	18.5	3.5	2.0	3.1	1.3	0.1	3.7	1.4	0.5	0.0	0.0	0.1	0.7	0.9	30.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	2.0	3.0	3.7	7.2	2.3	3.7	2.5	2.2	10.4	2.1
MMP16	"C8orf57, DKFZp761D112, MT3-MMP"	ENSG00000156103	"Matrix metallopeptidase 16"	P51512	8	88032009-88328025	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 15.9"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 20.0;HUVEC TERT2: 8.7;SH-SY5Y: 11.1;U-138 MG: 9.5;WM-115: 19.5"	"Cancer enhanced"	"Detected in many"		"glioma: 4.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023693	Uncertain		Approved	Vesicles,Cytosol	"Secreted to extracellular matrix"			Cytosol	Vesicles	"HPA023693: AB_1854025"	"unprognostic (2.58e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.87e-1)"	"unprognostic (7.09e-2)"	"unprognostic (3.31e-2)"	"unprognostic (2.39e-3)"	"unprognostic (1.45e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.61e-1)"	"unprognostic (9.42e-2)"	"unprognostic (2.92e-1)"	"unprognostic (2.09e-8)"	"unprognostic (6.90e-3)"	"unprognostic (1.16e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.19e-3)"	2.4	1.3	11.0	1.4	6.8	0.5	4.9	8.3	15.9	5.3	2.2	2.9	0.7	0.8	4.9	2.1	1.7	2.1	7.3	2.7	8.7	6.9	0.8	0.9	1.0	1.0	5.5	9.1	3.3	2.1	1.5	1.7	3.0	6.3	3.2	1.7	0.6	1.2	2.4	0.7	1.1	1.3	4.0	4.6	1.5	1.4	1.5	5.5	0.0	3.2	0.7	1.0	2.6	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	5.4	20.0	0.7	1.4	0.0	7.3	1.0	2.1	1.2	0.0	0.0	0.0	0.0	3.3	0.0	3.9	0.0	2.5	0.0	2.3	0.0	0.0	0.0	1.7	0.0	0.3	1.0	0.0	3.0	0.9	8.7	0.0	0.7	1.1	0.0	0.0	0.0	1.1	2.0	0.2	0.4	0.0	0.4	0.0	0.1	11.1	0.0	0.0	0.1	0.8	0.0	4.8	9.5	5.4	0.1	2.7	0.0	0.0	0.0	3.8	0.0	19.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	6.8	8.3	14.1	8.7	6.9	5.5	9.1	6.3	5.5
MMP2	"CLG4, CLG4A, TBE-1"	ENSG00000087245	"Matrix metallopeptidase 2"	P08253	16	55389700-55506691	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Angiogenesis, Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 335.4;ASC TERT1: 97.7;HSkMC: 83.3;U-138 MG: 91.2;U-87 MG: 106.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001939, CAB002788"	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	160000000	160000000	Vesicles		"CAB002788: , HPA001939: AB_1079395"	"unprognostic (7.26e-2)"	"unprognostic (1.36e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.14e-3)"	"unprognostic (5.03e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.74e-1)"	"unprognostic (9.36e-3)"	"unprognostic (4.81e-3)"	"unprognostic (3.79e-2)"	"unprognostic (4.59e-3)"	"unprognostic (6.12e-2)"	"unprognostic (1.28e-3)"	"unprognostic (1.59e-2)"	"unprognostic (8.00e-2)"	"unprognostic (8.98e-2)"	"unprognostic (4.63e-2)"	197.5	9.0	1.2	13.2	1.6	0.0	136.4	0.8	1.4	74.3	74.4	2.4	36.9	5.6	85.0	123.0	52.3	25.7	115.4	54.0	0.9	0.5	9.4	3.5	38.9	3.9	1.5	1.1	71.0	6.5	0.7	2.2	58.9	2.2	66.8	18.7	36.4	18.6	20.4	68.6	68.2	22.6	57.1	1.8	12.4	20.5	57.0	1.1	1.3	20.6	31.8	9.1	84.1	105.3	0.0	0.0	0.9	0.7	0.0	0.0	0.0	0.3	0.2	11.1	0.1	335.4	97.7	18.2	28.7	65.9	5.8	4.6	0.0	0.1	0.0	23.1	50.5	3.1	0.0	0.2	3.3	0.0	0.0	0.0	0.7	0.1	31.7	0.0	0.8	83.3	0.0	29.8	0.2	37.4	0.0	0.1	19.3	0.0	0.0	0.4	8.8	0.0	0.0	2.6	0.0	0.9	0.4	0.1	20.2	5.3	0.0	0.1	0.0	2.0	52.7	91.2	8.7	17.5	3.7	0.0	0.0	0.1	106.8	1.5	16.6	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.0	1.2	1.6	0.8	1.4	0.9	0.5	1.5	1.1	2.2	1.1
MMP3	"STMY, STMY1"	ENSG00000149968	"Matrix metallopeptidase 3"	P08254	11	102835801-102843803	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"epididymis: 177.5;salivary gland: 73.4"	"Group enriched"	"Detected in some"	17	"BJ: 98.9;BJ hTERT+: 269.1;fHDF/TERT166: 116.5"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 59.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in many"			HPA007875	Uncertain		Supported	Vesicles	"Secreted to extracellular matrix"	170000	170000	Vesicles		"HPA007875: AB_1079396"	"unprognostic (2.27e-1)"	"prognostic unfavourable (9.73e-4)"	"unprognostic (1.63e-3)"	"unprognostic (5.11e-3)"	"unprognostic (3.78e-1)"	"unprognostic (5.11e-2)"	"unprognostic (5.26e-6)"	"unprognostic (3.46e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.87e-1)"	"prognostic unfavourable (4.09e-4)"	"unprognostic (3.26e-2)"	"unprognostic (1.22e-15)"	"unprognostic (3.17e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.43e-2)"	"unprognostic (2.34e-1)"	19.1	0.0	0.2	14.4	0.3	0.0	6.9	0.2	0.5	0.2	1.5	0.3	0.2	1.8	28.3	177.5	0.2	0.0	1.4	0.2	0.2	0.0	0.3	0.5	0.4	0.2	0.2	0.2	0.3	0.2	0.0	0.2	0.2	0.2	1.2	1.7	0.2	73.4	1.5	7.3	12.6	0.7	5.9	0.2	0.2	2.8	1.4	0.2	0.2	0.6	1.5	0.9	7.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	98.9	269.1	1.7	0.5	0.0	0.0	0.0	0.0	116.5	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	7.9	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	9.2	0.8	0.1	0.0	0.0	0.0	0.0	3.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.2	0.5	0.2	0.0	0.2	0.2	0.2	0.2
MMP7	"MPSL1, PUMP-1"	ENSG00000137673	"Matrix metallopeptidase 7"	P09237	11	102520508-102530753	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 93.0;kidney: 129.5;salivary gland: 79.3"	"Cell line enhanced"	"Detected in some"		"A549: 22.6;CAPAN-2: 126.5;EFO-21: 30.0;RPTEC TERT1: 54.7"	"Cancer enhanced"	"Detected in all"		"pancreatic cancer: 352.1"	"Region enriched"	"Detected in single"	5	"pons and medulla: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB025869, HPA051358"	Supported		Approved	Nucleoplasm,Vesicles	"Secreted to extracellular matrix"			"Nucleoplasm, Vesicles"		"CAB025869: , HPA051358: "	"unprognostic (1.06e-3)"	"unprognostic (9.51e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.70e-3)"	"unprognostic (7.28e-2)"	"prognostic unfavourable (2.53e-4)"	"prognostic unfavourable (3.38e-4)"	"unprognostic (3.96e-2)"	"unprognostic (5.63e-2)"	"unprognostic (6.59e-3)"	"unprognostic (1.51e-1)"	"unprognostic (6.36e-3)"	"unprognostic (1.42e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.46e-1)"	6.8	0.2	0.2	1.2	0.2	0.0	28.8	0.2	0.2	5.2	0.2	0.2	2.1	0.0	17.2	12.3	3.3	16.4	93.0	0.2	0.2	0.2	129.5	1.4	5.0	0.9	0.2	0.2	3.9	23.5	0.0	0.7	2.7	1.3	42.0	0.0	0.2	79.3	6.7	0.2	7.8	0.3	0.5	0.2	0.2	0.9	9.4	0.2	1.2	0.3	1.4	4.5	19.9	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	22.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	126.5	0.0	30.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	54.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	1.3	0.2
MMP8	CLG1	ENSG00000118113	"Matrix metallopeptidase 8"	P22894	11	102711795-102727050	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"bone marrow: 119.3"	"Cell line enriched"	"Detected in some"	8	"WM-115: 39.2"	"Cancer enriched"	"Detected in single"	17	"melanoma: 5.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.7"	"Group enriched"	"Detected in some"	32	"neutrophil: 1.4;non-classical monocyte: 4.9"	"Group enriched"	"Detected in many"	32	"granulocytes: 1.4;monocytes: 4.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA021221, HPA022935"	Enhanced				"Secreted to extracellular matrix"	83000	83000			"HPA021221: AB_1854043, HPA022935: AB_1854044"	"unprognostic (3.03e-1)"	"unprognostic (8.49e-5)"	"unprognostic (1.08e-2)"	"unprognostic (3.95e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.01e-2)"		"unprognostic (7.68e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.92e-2)"	"unprognostic (6.64e-3)"		"unprognostic (2.45e-6)"	"unprognostic (2.33e-4)"	"unprognostic (1.33e-1)"	"unprognostic (4.97e-1)"	"unprognostic (2.30e-2)"	1.9	0.1	0.2	0.2	0.4	119.3	0.3	0.1	1.7	0.1	0.2	0.0	0.0	0.1	0.6	0.1	0.1	0.1	0.1	9.0	0.2	0.3	0.4	0.8	12.6	2.6	0.3	0.0	0.9	0.9	0.1	0.6	1.4	0.2	0.1	0.1	0.1	0.3	0.1	0.6	0.3	0.1	0.2	0.3	18.7	0.2	0.1	0.1	5.2	1.9	0.0	0.1	0.2	7.6	0.0	0.0	1.4	4.9	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	4.9	0.0	0.0	1.7	0.2	0.4	0.1	1.7	0.2	0.3	0.3	0.0	0.2	0.1
MMP9	CLG4B	ENSG00000100985	"Matrix metallopeptidase 9"	P14780	20	46008908-46016561	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adipose tissue: 64.0;blood: 63.2;bone marrow: 89.4;lymphoid tissue: 80.1"	"Cell line enriched"	"Detected in some"	12	"NB-4: 87.3"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	141	"neutrophil: 63.2"	"Lineage enriched"	"Detected in single"	339	"granulocytes: 63.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201"	Enhanced		Approved	Cytosol	"Secreted to blood"	57000000	57000000	Cytosol		"CAB000348: , CAB068199: , CAB068200: , CAB068201: , HPA001238: AB_1079398, HPA063909: AB_2685150"	"unprognostic (4.62e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.85e-2)"	"prognostic favourable (2.55e-4)"	"unprognostic (6.65e-3)"	"unprognostic (2.82e-1)"	"prognostic unfavourable (7.19e-4)"	"unprognostic (1.54e-1)"	"unprognostic (8.57e-2)"	"unprognostic (3.21e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.96e-1)"	"prognostic unfavourable (4.05e-5)"	"unprognostic (4.65e-1)"	"unprognostic (9.85e-3)"	"unprognostic (2.48e-2)"	"unprognostic (2.17e-3)"	64.0	0.5	0.6	38.6	0.7	89.4	4.3	0.4	0.6	0.8	1.2	0.1	0.0	2.8	0.6	0.2	0.9	1.5	0.6	4.0	0.5	0.6	1.4	2.0	13.3	80.1	0.6	0.0	2.7	1.4	0.0	0.8	2.6	0.5	0.6	0.8	0.5	12.5	0.0	1.3	1.3	4.2	0.3	0.5	53.7	2.5	2.7	0.0	23.6	1.3	2.3	44.5	4.5	2.9	0.0	0.0	63.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	7.3	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.9	0.0	87.3	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.3	0.0	2.6	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	63.2	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.4	0.6	0.5	0.6	0.6	0.0	0.5	0.0
MN1	"MGCR, MGCR1, MGCR1-PEN"	ENSG00000169184	"MN1 proto-oncogene, transcriptional regulator"	Q10571	22	27748277-27801498	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Developmental protein"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 62.7"	"Cell line enhanced"	"Detected in some"		"AF22: 22.0;HeLa: 8.9;RH-30: 8.9;TIME: 14.0;U-2 OS: 12.0;U-2197: 12.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	6	"non-classical monocyte: 1.7"	"Lineage enriched"	"Detected in single"	8	"monocytes: 1.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA003072	Approved		Approved	Nucleoplasm				Nucleoplasm		"HPA003072: AB_1079399"	"unprognostic (5.64e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.88e-2)"	"unprognostic (2.52e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.03e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.64e-1)"	"unprognostic (4.00e-2)"	"unprognostic (7.33e-2)"	"unprognostic (5.13e-7)"	"unprognostic (3.84e-2)"	"unprognostic (2.00e-1)"	"unprognostic (5.28e-3)"	"unprognostic (2.21e-4)"	3.7	2.0	3.4	4.2	17.3	2.4	1.9	1.3	5.6	5.9	4.2	2.6	2.5	2.1	3.0	9.0	7.0	3.4	11.1	5.1	2.5	2.7	1.6	1.4	4.3	1.3	3.3	3.5	12.4	1.5	1.3	2.3	2.6	4.5	3.1	2.2	10.8	2.1	2.7	62.7	2.9	2.1	5.8	1.0	1.5	3.5	2.0	5.4	0.0	1.8	14.8	2.1	5.0	4.7	0.0	0.2	0.0	1.7	0.0	0.1	0.0	0.0	1.0	22.0	0.6	0.4	0.9	0.0	0.5	0.8	0.0	0.0	0.0	0.0	0.0	2.2	3.9	1.8	1.1	1.3	0.0	0.0	0.6	0.0	8.9	0.0	0.5	0.0	0.2	0.0	2.5	0.5	2.2	0.2	0.0	0.1	0.7	0.0	0.0	0.2	2.9	2.0	3.6	8.9	0.0	0.3	0.0	0.0	0.3	1.9	0.0	0.0	0.2	0.0	14.0	0.7	12.0	12.7	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.2	0.0	0.0	3.4	17.3	1.3	4.2	2.5	2.7	3.3	3.5	4.5	5.4
MORC4	"FLJ11565, ZCW4, ZCWCC2"	ENSG00000133131	"MORC family CW-type zinc finger 4"	Q8TE76	X	106813871-107000244	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"placenta: 94.5"	"Cell line enhanced"	"Detected in all"		"A549: 46.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA000395, HPA015547, HPA050250"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA000395: AB_1079405, HPA015547: AB_2669216, HPA050250: "	"prognostic unfavourable (3.56e-5)"	"unprognostic (3.30e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.40e-1)"	"unprognostic (6.29e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.30e-2)"	"unprognostic (5.56e-2)"	"unprognostic (8.59e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.60e-2)"	"unprognostic (6.57e-2)"	"unprognostic (4.89e-2)"	"unprognostic (8.69e-2)"	8.7	20.0	3.2	6.0	4.8	5.1	6.2	4.9	3.6	8.0	5.3	4.6	12.7	4.6	8.8	8.5	6.8	7.3	6.7	5.3	4.3	2.8	4.9	9.7	6.0	2.2	4.9	2.2	12.3	9.1	6.0	4.9	94.5	5.8	7.7	4.9	4.2	8.7	8.8	9.4	8.6	4.9	7.4	5.4	2.6	5.6	12.5	5.0	2.3	7.6	7.5	5.2	6.3	15.1	6.0	4.6	10.5	3.8	2.8	4.0	0.7	11.5	46.3	4.6	10.6	14.1	16.3	24.2	11.3	12.0	5.7	7.3	24.5	5.3	1.8	5.9	11.6	9.1	15.4	9.9	6.9	2.7	8.9	2.8	15.7	10.3	10.4	2.0	5.9	8.6	9.6	7.8	11.4	5.1	1.6	17.6	12.7	10.2	4.2	2.8	4.1	17.6	2.0	9.3	2.0	18.5	9.2	4.0	5.1	13.7	13.4	8.9	8.0	2.0	5.3	9.2	9.3	18.2	6.2	5.0	6.5	4.6	9.8	1.8	6.6	10.5	3.8	3.1	3.7	3.0	3.2	3.3	3.6	2.8	1.6	6.0	4.0	3.4	8.2	2.8	3.6	4.6	2.6	0.7	3.2	4.8	4.9	3.6	4.3	2.8	4.9	2.2	5.8	5.0
MPL	"CD110, TPOR"	ENSG00000117400	"MPL proto-oncogene, thrombopoietin receptor"	P40238	1	43337849-43352772	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 8.6"	"Cell line enriched"	"Detected in single"	78	"HEL: 40.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.6"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.4"	"Low region specificity"	"Detected in all"			HPA007619			Supported	"Nuclear membrane,Plasma membrane"				"Plasma membrane"	"Nuclear membrane"	"HPA007619: AB_1854080"	"unprognostic (2.74e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.95e-1)"	"unprognostic (8.71e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.22e-2)"	"unprognostic (5.83e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.94e-4)"	"unprognostic (1.51e-1)"	"unprognostic (1.19e-4)"	"unprognostic (2.39e-1)"	"unprognostic (3.26e-1)"	"unprognostic (1.03e-4)"	"unprognostic (1.42e-1)"	1.1	0.3	0.9	0.5	0.8	2.0	0.9	0.5	2.2	0.6	0.6	0.5	0.5	0.3	0.9	1.7	0.9	2.1	0.5	3.9	0.8	0.6	0.5	0.5	2.0	0.5	0.9	0.5	6.6	1.1	0.6	0.6	2.2	0.5	1.5	0.7	0.5	0.5	0.7	0.6	0.4	1.2	2.1	2.5	8.6	0.5	2.1	0.5	0.5	2.2	2.4	0.5	0.9	0.5	0.0	0.0	1.6	0.3	0.0	0.0	4.0	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.2	0.0	40.7	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.4	0.2	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	4.0	0.9	0.8	0.5	2.2	0.8	0.6	0.9	0.5	0.5	0.5
MPO		ENSG00000005381	Myeloperoxidase	P05164	17	58269856-58280935	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Hydrogen peroxide"	"Oxidoreductase, Peroxidase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	15	"bone marrow: 315.2"	"Group enriched"	"Detected in some"	93	"HL-60: 212.9;NB-4: 279.1"	"Cancer enhanced"	"Detected in single"		"stomach cancer: 1.1"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"classical monocyte: 7.6;intermediate monocyte: 3.8;myeloid DC: 3.2;neutrophil: 2.0"	"Group enriched"	"Detected in many"	30	"dendritic cells: 3.2;granulocytes: 2.0;monocytes: 7.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000059, HPA021147, HPA061464"	Enhanced		Supported	Nucleoplasm,Vesicles	"Intracellular and membrane"	15000000	15000000	Vesicles	Nucleoplasm	"CAB000059: AB_2335676, HPA021147: AB_1854083, HPA061464: AB_2684531"	"unprognostic (1.91e-1)"	"unprognostic (9.08e-2)"	"unprognostic (4.62e-2)"	"unprognostic (2.90e-2)"	"unprognostic (2.13e-3)"	"unprognostic (2.78e-1)"	"unprognostic (3.23e-1)"	"unprognostic (2.91e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.68e-1)"	"unprognostic (6.92e-2)"	"unprognostic (8.34e-3)"	"unprognostic (4.91e-2)"	"unprognostic (3.07e-3)"	"unprognostic (2.83e-1)"	"unprognostic (1.14e-2)"	"unprognostic (8.05e-2)"	0.2	0.1	0.5	0.1	0.8	315.2	0.1	0.4	1.0	0.1	0.1	1.4	0.0	0.1	0.2	0.2	0.1	0.1	0.1	21.5	0.6	0.8	0.1	1.4	6.9	0.8	0.6	0.0	0.6	0.1	0.1	1.0	2.9	0.4	0.2	0.1	0.2	6.3	0.1	0.7	0.5	0.1	0.1	0.4	17.8	0.1	0.4	0.2	19.7	0.6	0.0	0.5	0.1	0.0	0.0	3.2	2.0	7.6	0.0	0.1	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	212.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	279.1	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	7.6	0.0	0.0	3.8	0.0	0.0	0.0	0.1	3.2	0.0	0.0	0.0	2.0	0.0	0.8	0.0	0.1	7.2	0.5	0.8	0.4	1.0	0.6	0.8	0.6	0.0	0.4	0.2
MRE11	"ATLD, MRE11A"	ENSG00000020922	"MRE11 homolog, double strand break repair nuclease"	P49959	11	94415578-94493908	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction, Meiosis"	"Endonuclease, Exonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Ciliopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002691, CAB004081"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB004081: AB_2145100, HPA002691: AB_1079409"	"unprognostic (5.59e-3)"	"unprognostic (4.35e-2)"	"unprognostic (8.55e-2)"	"unprognostic (2.76e-2)"	"unprognostic (9.82e-2)"	"unprognostic (5.17e-2)"	"prognostic unfavourable (7.14e-4)"	"unprognostic (2.85e-1)"	"unprognostic (1.03e-2)"	"unprognostic (1.34e-1)"	"unprognostic (8.66e-3)"	"unprognostic (6.96e-3)"	"unprognostic (1.57e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.22e-1)"	"unprognostic (8.06e-3)"	14.7	11.0	10.7	15.2	12.5	24.0	16.6	21.2	12.0	17.5	11.0	10.8	13.9	8.0	17.4	11.2	13.9	13.2	8.9	9.4	8.7	6.5	8.8	8.9	11.4	13.8	13.3	7.9	16.7	15.5	8.2	12.8	14.2	9.8	12.7	14.1	10.4	14.1	10.8	9.3	18.3	12.8	12.8	13.5	17.2	11.8	9.9	13.0	25.3	12.7	7.4	18.4	14.3	13.3	8.7	14.8	7.9	13.1	10.3	11.8	7.9	10.0	10.3	19.3	2.4	6.5	9.2	11.0	14.1	9.2	12.8	15.2	18.6	20.7	26.3	23.0	7.3	19.3	16.3	10.6	16.9	17.4	9.7	22.9	14.7	10.7	3.0	15.0	16.6	6.4	6.6	16.5	10.4	11.1	16.0	17.1	10.1	7.2	15.2	14.3	6.2	11.3	13.6	17.3	13.2	8.3	14.1	6.8	9.7	19.5	12.3	3.8	21.1	9.1	8.1	19.2	14.0	16.5	10.1	4.3	15.2	25.8	5.1	24.0	15.2	5.4	11.1	7.9	11.2	13.1	11.0	8.5	8.4	11.8	14.8	8.7	7.1	11.5	4.8	10.3	9.8	10.5	10.9	7.9	10.7	12.5	21.2	12.0	8.7	6.5	13.3	7.9	9.8	13.0
MSH2	"COCA1, HNPCC, HNPCC1"	ENSG00000095002	"MutS homolog 2"	P43246	2	47402969-47663146	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009572, HPA066845, CAB070867"	Approved		Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB009572: AB_2144828, CAB070867: , HPA066845: "	"unprognostic (2.35e-1)"	"unprognostic (1.54e-2)"	"unprognostic (2.89e-3)"	"prognostic unfavourable (4.44e-4)"	"unprognostic (2.23e-1)"	"unprognostic (6.31e-3)"	"prognostic unfavourable (1.72e-9)"	"unprognostic (1.77e-1)"	"unprognostic (7.09e-3)"	"unprognostic (8.57e-2)"	"prognostic unfavourable (4.63e-4)"	"unprognostic (5.38e-2)"	"unprognostic (3.29e-3)"	"unprognostic (1.20e-3)"	"unprognostic (5.74e-1)"	"unprognostic (8.46e-2)"	"unprognostic (1.48e-1)"	7.3	9.8	14.2	12.2	25.5	11.4	14.1	22.6	18.1	9.4	11.6	7.6	5.6	6.5	10.5	13.3	10.8	11.1	4.9	8.4	13.0	14.0	7.3	5.5	7.1	19.7	12.5	17.0	7.9	8.4	15.3	9.1	9.9	18.5	7.9	13.8	12.3	9.4	7.3	6.7	10.3	8.0	7.8	13.8	9.4	6.7	13.4	13.5	37.0	13.9	6.6	21.4	8.5	7.6	7.4	2.9	3.9	4.2	12.2	12.6	6.2	28.0	9.6	26.3	14.1	1.9	5.5	15.9	16.7	8.3	20.8	20.1	18.0	12.1	34.5	22.6	5.9	11.9	19.6	9.5	31.4	17.8	14.6	24.9	11.1	16.3	2.0	24.3	8.8	3.1	2.8	17.7	4.8	11.4	41.4	8.0	15.8	11.2	28.1	18.3	49.4	11.4	37.7	46.9	20.2	9.0	14.9	21.8	23.6	14.8	11.5	11.8	11.5	9.5	4.6	13.8	18.1	14.2	18.6	5.1	18.3	48.4	8.4	18.0	8.5	2.8	1.0	3.9	7.9	4.2	8.6	6.3	7.4	9.5	2.3	7.4	12.6	11.9	0.7	12.2	3.2	2.9	10.1	6.2	14.2	25.5	22.6	18.1	13.0	14.0	12.5	17.0	18.5	13.5
MSH6	GTBP	ENSG00000116062	"MutS homolog 6"	P52701	2	47695530-47810101	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction"	DNA-binding	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009091, HPA028376, HPA028446, CAB070870"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus,Vesicles"				Nucleoplasm	"Golgi apparatus, Vesicles"	"CAB009091: AB_670083, CAB070870: AB_2144959, HPA028376: AB_10598909, HPA028446: AB_10602182"	"unprognostic (5.10e-2)"	"unprognostic (5.87e-3)"	"unprognostic (3.29e-2)"	"prognostic unfavourable (1.34e-4)"	"unprognostic (1.98e-1)"	"unprognostic (3.09e-2)"	"prognostic unfavourable (7.86e-4)"	"unprognostic (1.79e-1)"	"unprognostic (2.35e-3)"	"unprognostic (1.01e-1)"	"unprognostic (1.74e-3)"	"unprognostic (8.99e-2)"	"prognostic unfavourable (1.06e-7)"	"unprognostic (1.22e-1)"	"unprognostic (2.31e-1)"	"unprognostic (9.68e-2)"	"unprognostic (3.48e-2)"	13.0	20.5	9.7	13.1	18.8	13.6	13.0	20.5	13.1	17.9	13.3	17.6	10.7	6.1	28.2	11.0	12.4	18.3	8.4	8.6	11.4	8.8	9.5	14.6	11.0	21.7	23.9	9.6	43.2	27.6	16.2	17.3	14.9	15.0	14.6	10.3	8.7	12.0	13.2	10.4	10.3	10.5	22.1	14.9	11.6	11.1	25.1	22.0	40.4	13.4	10.4	25.8	14.2	16.4	8.4	8.4	7.6	9.8	9.7	15.1	5.7	27.2	20.3	37.9	9.0	11.4	12.1	17.1	15.2	13.4	15.7	16.6	14.9	9.5	45.0	22.7	16.4	11.5	34.1	19.3	20.5	19.6	17.0	28.8	16.2	15.1	7.0	28.9	10.6	9.8	6.2	16.0	10.7	9.8	25.0	16.6	15.3	19.6	30.7	13.7	33.3	9.4	73.0	49.7	20.3	9.6	17.8	21.2	23.0	21.1	10.1	9.2	12.0	10.2	6.0	18.3	22.4	13.8	19.6	15.6	21.0	75.4	15.5	18.5	11.2	7.6	5.8	4.9	8.4	9.8	10.4	8.4	9.5	8.3	8.4	8.1	15.1	7.6	3.9	9.7	9.3	4.2	9.5	5.7	9.7	18.8	20.5	13.1	11.4	8.8	23.9	9.6	15.0	22.0
MSI2		ENSG00000153944	"Musashi RNA binding protein 2"	Q96DH6	17	57255851-57684685	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"REH: 48.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB022300	Approved		Supported	Cytosol				Cytosol		"CAB022300: "	"unprognostic (4.73e-2)"	"unprognostic (2.28e-1)"	"unprognostic (3.42e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.08e-1)"	"unprognostic (4.20e-2)"	"unprognostic (2.20e-2)"	"unprognostic (4.89e-2)"	"unprognostic (2.96e-1)"	"unprognostic (4.17e-2)"	"unprognostic (1.18e-1)"	"prognostic favourable (9.22e-8)"	"prognostic favourable (2.00e-4)"	"unprognostic (4.87e-2)"	"unprognostic (1.57e-1)"	"unprognostic (2.72e-3)"	3.4	34.7	20.0	22.4	21.5	8.4	8.8	18.0	25.3	9.7	14.4	7.7	14.2	5.0	6.7	36.3	4.6	11.1	23.5	28.5	13.9	16.9	18.0	3.6	6.9	9.6	21.0	6.4	22.8	6.1	41.4	23.1	10.7	19.7	10.5	7.4	14.6	9.8	48.5	25.6	3.6	5.4	4.6	14.8	8.7	7.7	7.5	9.5	23.7	12.4	8.4	8.6	11.6	5.0	1.9	3.0	4.8	1.5	1.9	4.1	0.5	3.4	5.8	20.1	7.7	2.3	2.2	15.8	3.8	4.4	5.0	3.0	6.9	5.8	15.8	13.5	2.3	3.4	12.8	5.1	9.3	22.0	8.9	6.9	12.9	15.8	5.0	7.6	7.0	2.8	6.7	0.6	8.2	5.1	15.0	11.9	17.5	7.9	34.2	2.1	7.2	9.4	48.0	30.1	12.5	12.2	22.2	22.3	41.5	6.2	5.9	17.7	10.6	5.9	6.5	3.2	8.3	2.8	6.5	16.5	14.0	19.2	8.4	4.6	19.3	4.4	0.4	4.8	2.0	0.3	1.5	1.9	1.9	1.8	0.6	1.1	1.8	1.7	0.4	1.9	1.5	3.0	4.1	0.5	20.0	21.5	18.0	25.3	13.9	16.9	21.0	6.4	19.7	9.5
MSLN	"CAK1, MPF"	ENSG00000102854	Mesothelin	Q13421	16	760762-768865	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 85.5;lung: 88.5"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 102.3;EFO-21: 15.8;HeLa: 31.2;hTCEpi: 22.7"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 343.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 9.0"	"Group enriched"	"Detected in many"	59	"dendritic cells: 9.0;monocytes: 2.6"	"Low region specificity"	"Detected in many"							"CAB002216, HPA017172"	Enhanced		Supported	Nucleoplasm,Vesicles	"Intracellular and membrane"	14000000	14000000	Vesicles	Nucleoplasm	"CAB002216: AB_563874, HPA017172: AB_1853819"	"unprognostic (1.73e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.06e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.43e-2)"	"unprognostic (3.95e-2)"	"unprognostic (2.46e-1)"	"unprognostic (9.47e-2)"	"unprognostic (8.57e-2)"	"unprognostic (4.69e-2)"	"prognostic unfavourable (6.66e-4)"	"unprognostic (2.63e-1)"	"prognostic favourable (5.91e-4)"	"unprognostic (2.00e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.14e-2)"	"unprognostic (3.35e-2)"	36.5	0.0	0.4	6.7	0.5	0.7	0.3	0.1	0.4	5.4	5.4	0.8	26.8	2.1	4.8	18.9	3.1	85.5	9.6	4.3	0.4	0.3	2.6	0.2	88.5	0.4	0.6	0.0	22.3	0.4	0.0	0.6	13.7	0.9	1.9	1.2	0.2	14.4	33.1	0.0	0.5	0.7	1.0	0.8	0.1	3.7	2.1	0.0	0.1	0.1	0.6	7.8	1.4	1.3	0.0	9.0	0.0	2.6	0.0	0.0	0.4	0.0	0.4	0.0	0.2	0.0	0.0	0.4	0.0	1.5	1.8	0.4	1.4	102.3	0.0	15.8	0.1	0.2	0.0	0.1	0.1	0.0	0.0	0.0	31.2	1.1	0.9	0.0	0.0	0.0	22.7	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.5	0.0	0.0	0.0	5.9	0.0	0.0	0.1	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	1.4	0.0	0.0	0.0	0.0	9.0	0.0	0.0	0.0	0.0	0.0	2.6	0.2	0.0	0.4	0.4	0.5	0.1	0.4	0.4	0.3	0.6	0.0	0.9	0.0
MSMB	"IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94"	ENSG00000263639	"Microseminoprotein beta"	P08118	10	46033307-46046269	"Cancer-related genes, Disease related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	15	"prostate: 437.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 20.0;NB-4: 16.1;RPMI-8226: 8.4;SH-SY5Y: 4.6;SK-BR-3: 4.7;U-2197: 9.5"	"Cancer enriched"	"Detected in many"	42	"prostate cancer: 3435.3"					"Cell type enriched"	"Detected in single"	5	"eosinophil: 1.9"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.9"									"CAB026357, HPA051257"	Enhanced				"Secreted in male reproductive system"	3700000	3700000			"CAB026357: , HPA051257: "	"unprognostic (6.47e-2)"	"unprognostic (7.21e-3)"		"unprognostic (1.37e-2)"		"unprognostic (8.18e-3)"	"unprognostic (4.28e-3)"	"unprognostic (9.24e-3)"	"unprognostic (1.66e-1)"	"unprognostic (8.66e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.55e-2)"		"unprognostic (2.01e-1)"	"unprognostic (7.04e-2)"	"unprognostic (1.39e-1)"	"prognostic favourable (7.19e-4)"	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	1.0	0.8	0.0	0.1	0.1	0.0	1.8	0.1	0.0	7.2	0.0	0.0		0.0	0.0	29.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	437.8	0.0	0.0	14.8	0.1	0.0	0.0	0.0	0.2	0.0	0.0	26.8	0.6	0.0	0.0	0.0	0.1	0.7	0.7	0.0	0.0	0.0	1.9	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	20.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.0	0.1	0.0	1.2	0.2	16.1	0.2	0.0	0.0	0.0	8.4	0.0	1.2	0.9	4.6	0.0	4.7	0.0	0.3	0.0	0.0	0.0	0.0	9.5	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
MSN		ENSG00000147065	Moesin	P26038	X	65588377-65741931	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047337, CAB047338"	Enhanced		Enhanced	"Plasma membrane"		340000000	340000000	"Plasma membrane"		"CAB010898: AB_260635, CAB047336: , CAB047337: , CAB047338: , HPA000263: AB_1856043, HPA011135: AB_1854053, HPA011227: AB_1854054"	"unprognostic (1.03e-1)"	"unprognostic (7.89e-2)"	"unprognostic (7.64e-2)"	"unprognostic (5.38e-2)"	"unprognostic (4.08e-3)"	"unprognostic (3.51e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.44e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.04e-3)"	"unprognostic (1.32e-1)"	"prognostic unfavourable (1.60e-5)"	"unprognostic (5.68e-3)"	"unprognostic (7.75e-2)"	"unprognostic (7.21e-2)"	"unprognostic (6.81e-2)"	36.3	17.6	10.2	40.7	14.4	38.5	98.2	8.6	18.6	25.1	21.3	19.2	7.6	6.5	33.4	14.2	15.7	21.8	20.2	53.8	11.5	10.4	25.6	29.5	102.8	85.0	17.5	5.4	28.8	19.4	5.7	10.2	24.2	30.0	23.1	13.0	16.6	16.3	21.9	13.6	19.5	18.3	41.4	21.8	31.6	17.3	9.0	12.9	18.7	26.2	17.6	38.1	22.7	28.9	16.0	36.4	54.1	69.0	28.0	37.1	81.8	27.8	21.4	21.0	17.3	25.2	33.3	0.1	70.7	45.8	39.2	30.4	0.0	4.9	23.4	63.2	62.5	19.2	22.1	50.4	51.2	43.3	6.1	64.9	37.1	0.0	23.8	78.8	105.1	24.9	10.9	72.1	63.8	86.5	31.4	73.0	62.0	0.0	46.5	59.1	26.0	40.7	24.4	37.7	17.8	41.9	0.0	0.1	0.0	56.8	0.4	22.5	0.2	42.9	137.0	44.7	28.4	60.1	46.8	26.5	40.1	25.4	32.7	100.1	49.7	30.8	44.4	30.0	37.1	58.9	27.9	16.0	20.4	29.1	36.4	13.9	14.0	21.3	54.1	28.0	69.0	5.2	15.5	81.8	10.2	14.4	8.6	18.6	11.5	10.4	17.5	5.4	30.0	12.9
MSR1	"CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII"	ENSG00000038945	"Macrophage scavenger receptor 1"	P21757	8	16107878-16567490	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"adipose tissue: 88.1;lung: 70.4"	"Group enriched"	"Detected in many"	7	"BJ hTERT+: 47.1;REH: 17.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 16.0"	"Lineage enriched"	"Detected in many"	5	"monocytes: 16.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA000272, CAB032491"	Enhanced					25000	25000			"CAB032491: AB_672722, HPA000272: AB_1846269"	"unprognostic (8.19e-3)"	"unprognostic (4.87e-2)"	"unprognostic (1.93e-2)"	"unprognostic (2.10e-1)"	"unprognostic (9.24e-2)"	"unprognostic (1.32e-2)"	"unprognostic (5.85e-3)"	"unprognostic (2.89e-1)"	"unprognostic (9.70e-2)"	"unprognostic (1.62e-2)"	"unprognostic (7.19e-2)"	"unprognostic (8.82e-2)"	"unprognostic (2.76e-2)"	"unprognostic (9.16e-2)"	"unprognostic (7.39e-2)"	"unprognostic (6.85e-2)"	"unprognostic (4.69e-2)"	88.1	9.0	2.2	6.1	4.5	3.7	6.9	10.4	3.3	4.5	3.1	1.8	1.0	2.1	3.1	6.2	2.4	4.5	11.4	8.0	3.8	3.1	9.5	13.6	70.4	6.9	4.3	0.8	6.7	3.8	1.2	2.6	10.4	7.7	3.2	3.9	4.5	6.2	2.3	3.2	1.6	4.0	6.5	11.9	10.9	2.5	4.9	3.1	1.5	2.2	1.7	0.7	10.8	1.8	1.5	1.0	3.0	16.0	0.3	1.3	0.5	0.6	0.9	1.3	0.6	0.6	0.6	0.6	0.3	47.1	0.1	0.2	1.6	0.1	1.5	2.4	0.4	0.3	0.3	0.4	0.9	0.2	1.9	1.9	1.8	1.8	0.4	1.0	1.1	0.3	0.3	0.3	0.7	0.0	0.7	1.4	0.9	1.8	0.6	0.6	0.2	0.6	17.8	1.0	0.4	0.9	2.7	1.0	0.5	0.4	1.2	0.1	0.1	0.5	1.1	1.2	0.5	4.9	1.2	4.8	3.7	3.2	0.5	0.6	1.0	1.1	3.1	0.5	0.9	16.0	0.4	0.9	0.7	0.7	1.0	1.5	1.3	0.9	3.0	0.3	7.8	0.5	0.6	0.5	2.2	4.5	10.4	2.7	3.8	3.1	4.3	0.8	7.7	3.1
MST1	"D3F15S2, DNF15S2, HGFL, MSP, NF15S2"	ENSG00000173531	"Macrophage stimulating 1"		3	49683947-49689501	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"				"Tissue enriched"	"Detected in many"	8	"liver: 117.0"	"Cell line enhanced"	"Detected in many"		"Hep G2: 41.5;NB-4: 8.4;U-266/70: 11.3"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 42.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;memory B-cell: 1.2"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA024036	Approved				"Secreted to blood"					"HPA024036: AB_1854147"	"unprognostic (5.13e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.16e-2)"	"unprognostic (9.42e-3)"	"unprognostic (8.24e-2)"	"unprognostic (2.97e-1)"	"prognostic favourable (7.14e-4)"	"unprognostic (3.07e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.48e-1)"	"unprognostic (8.03e-2)"	"unprognostic (1.68e-3)"	3.7	3.5	4.0	0.3	4.8	1.4	1.0	4.9	5.4	0.9	1.4	2.5	1.9	14.4	1.2	3.3	0.8	1.7	1.9	0.5	6.5	1.1	8.8	117.0	1.6	0.7	2.0	2.9	1.7	1.9	3.8	4.8	1.5	4.8	1.5	0.5	1.6	3.4	3.7	2.8	4.0	8.2	1.3	4.2	1.7	0.8	9.9	2.3	0.9	5.0	0.3	1.1	0.8	0.7	1.2	0.9	0.0	0.2	0.0	1.1	0.2	0.1	0.2	0.6	1.0	1.9	4.0	1.9	0.5	0.7	0.3	0.4	1.9	0.6	0.1	1.3	0.6	0.4	0.3	0.8	0.3	0.6	0.3	0.3	0.9	41.5	3.0	0.0	0.8	5.4	1.3	0.3	1.1	0.7	0.3	5.0	0.9	0.3	0.2	8.4	0.1	0.5	0.2	0.2	1.1	2.2	0.3	0.1	1.4	0.0	0.9	0.2	0.7	2.8	0.4	1.0	0.3	0.0	0.1	11.3	1.4	0.2	1.1	1.5	0.7	0.0	0.0	0.0	1.1	0.0	0.0	1.2	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.2	4.0	4.8	4.9	5.4	6.5	1.1	2.0	2.9	4.8	2.3
MT1A	"MT1, MT1S"	ENSG00000205362	"Metallothionein 1A"	P04731	16	56638666-56640087	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"adipose tissue: 108.5;liver: 146.5;skeletal muscle: 111.3"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 13.7;HHSteC: 9.5;HMC-1: 14.1;hTEC/SVTERT24-B: 38.1;NTERA-2: 18.9"	"Cancer enhanced"	"Detected in all"		"liver cancer: 33.3"	"Group enriched"	"Detected in many"	7	"basal ganglia: 35.4;cerebral cortex: 14.5;hippocampal formation: 15.3;pons and medulla: 37.2"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"											"CAB002161, CAB013056"	Approved									"CAB002161: AB_563878, CAB013056: "	"unprognostic (1.36e-1)"	"unprognostic (4.91e-3)"	"unprognostic (1.22e-1)"	"unprognostic (3.30e-1)"	"unprognostic (1.26e-3)"	"unprognostic (9.33e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.47e-2)"	"unprognostic (6.67e-3)"	"unprognostic (3.10e-2)"	"unprognostic (1.86e-1)"	"unprognostic (9.43e-2)"	"unprognostic (1.35e-2)"	108.5	14.2	2.7	8.0	35.4	1.0	35.2	0.6	14.5	11.3	10.2	0.7	0.2	4.8	1.8	4.1	17.4	11.0	16.1	16.2	15.3	1.8	20.7	146.5	16.1	14.2	3.6	0.0	7.1	46.1	1.2	11.0	1.4	37.2	4.4	7.8	3.8	3.0	2.6	111.3	4.4	12.4	9.2	16.9	4.6	6.1	2.0	2.1	0.0	18.6	4.1	1.7	10.7	7.1	0.4	0.6	0.0	0.1	0.3	1.1	0.2	0.0	2.9	0.0	0.0	8.9	13.7	0.1	0.9	3.7	0.6	0.7	1.0	2.2	0.0	1.1	0.5	0.2	0.0	0.1	1.4	0.0	0.0	0.0	1.3	4.5	9.5	0.1	14.1	4.0	0.0	38.1	0.0	3.6	0.3	0.0	2.6	0.0	0.0	0.0	18.9	0.0	0.0	0.0	1.7	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	2.9	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.6	0.0	0.6	0.4	0.8	1.1	0.6	0.0	0.5	0.9	0.0	0.3	0.0	0.3	1.0	0.2	2.7	35.4	0.6	14.5	15.3	1.8	3.6	0.0	37.2	2.1
MT1G	"MT1, MT1K"	ENSG00000125144	"Metallothionein 1G"	P13640	16	56666731-56668065	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	5	"intestine: 101.1;kidney: 210.7;liver: 396.4;pancreas: 217.1;thyroid gland: 278.4"	"Cell line enriched"	"Detected in some"	4	"U-937: 152.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"																"Intracellular and membrane"						"unprognostic (1.62e-1)"	"unprognostic (4.21e-1)"	"unprognostic (2.77e-2)"	"unprognostic (3.15e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.97e-2)"	"unprognostic (2.49e-2)"	"unprognostic (4.21e-1)"	"prognostic unfavourable (1.67e-7)"	"unprognostic (1.42e-1)"	"unprognostic (3.50e-2)"	"unprognostic (7.92e-2)"	"unprognostic (2.26e-2)"	10.1	1.0	11.7	10.4	50.7	0.7	2.8	1.1	27.4	1.0	78.1	3.1	1.9	49.6	1.5	15.9	21.7	4.6	23.2	0.9	25.1	7.6	210.7	396.4	2.4	7.0	23.6	11.3	0.6	217.1	0.4	1.0	0.6	46.9	21.6	48.9	22.4	2.4	1.0	0.6	2.9	101.1	7.9	7.7	0.5	47.4	0.6	3.6	0.0	278.4	1.9	1.8	2.4	1.2	0.1	1.1	0.7	1.1	0.3	2.9	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.2	0.2	0.1	0.0	0.0	0.0	0.0	2.3	0.0	0.2	0.0	0.1	0.1	0.1	0.0	0.6	0.0	0.4	0.6	0.1	0.0	0.2	0.0	1.6	0.0	0.0	0.0	0.1	0.1	0.0	0.5	34.8	0.0	0.0	0.0	0.1	9.9	5.8	0.0	3.1	0.4	0.0	0.1	0.1	0.0	15.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.3	152.3	0.0	0.7	1.1	0.3	1.5	1.1	1.4	0.1	1.7	2.6	1.1	0.0	1.6	2.9	0.1	0.3	0.5	0.3	2.8	1.5	11.7	50.7	1.1	27.4	25.1	7.6	23.6	11.3	46.9	3.6
MTA1		ENSG00000182979	"Metastasis associated 1"	Q13330	14	105419820-105470729	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004508, HPA005544"	Supported		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB004508: AB_627969, HPA005544: AB_1079420"	"unprognostic (6.79e-3)"	"unprognostic (4.22e-2)"	"unprognostic (1.06e-1)"	"unprognostic (6.36e-2)"	"unprognostic (2.91e-2)"	"unprognostic (7.74e-2)"	"prognostic unfavourable (4.62e-4)"	"unprognostic (6.59e-2)"	"unprognostic (1.47e-1)"	"unprognostic (6.72e-3)"	"prognostic favourable (9.48e-5)"	"unprognostic (4.57e-3)"	"unprognostic (1.39e-2)"	"unprognostic (2.88e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.18e-1)"	23.4	20.1	22.4	24.7	24.3	22.0	22.9	33.8	23.4	17.9	18.9	21.9	22.5	22.3	22.1	21.3	14.9	22.5	20.0	27.7	22.1	17.3	14.8	15.1	20.1	22.3	22.8	18.4	31.4	31.1	15.7	26.5	16.1	19.4	21.9	10.6	22.2	28.7	24.8	29.1	20.0	19.8	27.1	15.0	23.6	18.9	31.4	24.1	27.3	21.1	16.1	16.3	19.3	20.5	1.8	3.7	2.8	0.9	1.8	1.8	0.6	13.1	10.5	19.6	19.5	7.5	12.9	17.4	10.5	8.0	10.4	10.1	13.6	17.8	25.8	11.0	7.6	18.2	14.2	10.0	7.1	16.9	23.9	13.4	9.5	13.9	16.6	16.8	10.4	14.4	12.7	7.4	17.0	14.8	15.2	11.3	5.4	23.6	30.3	33.4	28.3	22.3	28.7	11.9	8.4	8.3	10.3	31.7	33.0	14.1	16.5	15.0	14.8	16.1	10.6	8.5	9.0	13.9	10.9	23.0	11.1	16.4	10.5	11.4	14.7	0.5	0.9	2.8	1.4	0.9	1.2	1.5	1.2	1.1	1.1	1.8	1.5	1.8	0.2	1.8	0.5	3.7	0.9	0.6	22.4	24.3	33.8	23.4	22.1	17.3	22.8	18.4	19.4	24.1
MTCP1	"P13MTCP1, p8MTCP1"	ENSG00000214827	"Mature T cell proliferation 1"	P56278	X	155061622-155147937	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HeLa: 14.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA032040			Approved	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"HPA032040: "	"unprognostic (2.42e-2)"	"unprognostic (2.07e-2)"	"unprognostic (1.14e-1)"	"unprognostic (6.29e-3)"	"unprognostic (8.30e-2)"	"unprognostic (4.10e-1)"	"unprognostic (2.40e-5)"	"unprognostic (9.30e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.94e-2)"	"unprognostic (5.72e-2)"	"unprognostic (1.15e-2)"	"prognostic unfavourable (4.52e-8)"	"unprognostic (1.55e-3)"	"unprognostic (1.06e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.75e-2)"	6.4	7.1	4.1	5.3	5.3	7.2	15.8	4.4	4.8	6.0	6.2	3.4	7.7	5.7	6.0	8.2	7.0	6.1	4.4	30.1	4.7	2.9	6.7	12.8	8.5	15.5	4.5	2.7	9.1	20.7	3.9	6.5	3.5	6.4	5.8	6.1	3.9	7.3	7.0	11.4	12.0	6.7	8.7	7.2	6.7	6.2	16.1	3.8	2.5	8.2	5.4	7.2	6.9	4.0	0.2	0.0	0.8	0.7	0.5	2.0	0.1	1.4	4.9	2.4	3.8	1.6	1.3	2.6	3.0	1.5	1.9	4.7	4.2	7.4	2.6	3.0	0.6	4.7	3.1	3.5	2.3	1.8	3.1	1.2	14.0	2.3	1.3	2.8	3.2	2.4	1.6	3.1	3.0	1.7	1.1	4.8	1.3	2.0	3.7	6.0	1.1	0.8	3.9	2.5	6.0	2.4	2.0	1.2	1.8	2.1	1.2	2.1	2.1	1.3	1.8	2.2	3.8	2.1	2.2	10.5	4.5	5.1	4.2	3.4	3.1	0.0	0.6	0.8	1.1	0.0	2.0	0.2	1.2	0.4	0.0	0.1	0.2	1.4	0.0	0.5	0.7	0.0	0.0	0.1	4.1	5.3	4.4	4.8	4.7	2.9	4.5	2.7	6.4	3.8
MTOR	"FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1"	ENSG00000198793	"Mechanistic target of rapamycin kinase"	P42345	1	11106535-11262507	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB069425, HPA071227"	Approved		Approved	Vesicles,Cytosol				"Vesicles, Cytosol"		"CAB069425: , HPA071227: "	"unprognostic (3.18e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.45e-3)"	"unprognostic (5.50e-2)"	"unprognostic (2.55e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.24e-3)"	"unprognostic (3.48e-2)"	"unprognostic (1.88e-1)"	"prognostic favourable (1.49e-5)"	"unprognostic (1.27e-1)"	"unprognostic (2.45e-1)"	"unprognostic (6.60e-2)"	"unprognostic (7.55e-2)"	11.3	13.9	18.7	13.0	22.5	12.3	14.9	25.2	25.2	11.3	14.5	18.2	10.4	11.2	13.8	23.6	13.1	10.5	15.7	14.2	14.5	13.6	15.8	19.4	10.8	14.3	14.0	14.4	10.7	16.6	26.5	16.0	12.5	15.5	15.2	17.1	14.4	14.2	15.2	24.6	16.5	13.6	15.2	10.4	15.4	13.1	38.6	13.1	16.6	13.2	9.9	15.7	11.7	10.2	3.9	4.0	3.0	6.4	2.6	5.6	2.3	15.2	13.8	18.7	14.1	22.6	10.8	9.3	12.9	12.4	17.2	17.0	14.2	14.1	16.9	11.1	15.2	18.2	25.2	19.7	22.3	13.5	18.4	22.5	28.6	17.9	14.2	21.9	16.8	13.8	15.0	24.6	25.0	21.8	25.1	14.6	12.0	17.4	15.1	16.7	14.1	13.1	15.2	22.0	11.3	15.2	13.8	18.9	13.8	27.6	14.9	16.9	12.1	13.0	23.2	15.1	13.7	11.5	17.2	14.4	13.4	33.3	10.9	23.7	15.8	0.7	2.9	3.0	5.2	6.4	4.3	3.9	3.0	2.7	4.0	3.4	3.6	3.1	2.0	2.6	3.3	3.1	5.6	2.3	18.7	22.5	25.2	25.2	14.5	13.6	14.0	14.4	15.5	13.1
MUC1	"ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM"	ENSG00000185499	"Mucin 1, cell surface associated"	P15941	1	155185824-155192916	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 168.1;kidney: 158.5;lung: 143.5"	"Group enriched"	"Detected in many"	7	"CAPAN-2: 139.8;RPTEC TERT1: 107.3;T-47d: 47.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.0"	"Group enriched"	"Detected in many"	10	"granulocytes: 1.3;T-cells: 4.0"									"CAB000036, CAB001986, HPA004179, HPA007235, HPA008855"	Enhanced		Supported	"Plasma membrane"	"Secreted in other tissues"	4900000	4900000	"Plasma membrane"		"CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283"	"unprognostic (4.74e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.19e-1)"	"unprognostic (8.01e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.61e-3)"	"unprognostic (6.34e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.23e-1)"	"prognostic unfavourable (4.60e-4)"	"unprognostic (4.75e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.12e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.21e-1)"	1.5	0.7	0.8	12.6	1.2	0.9	12.6	0.4	0.7	31.6	15.9	1.2	2.4	2.9	10.5	9.8	51.8	18.7	168.1	0.8	0.5	0.3	158.5	2.0	143.5	0.3	0.5	0.3	14.9	74.2	0.0	4.7	15.5	2.1	6.1	16.1	0.8	17.0	5.9	0.8	1.8	3.6	2.8	0.7	0.6	105.0	4.3	0.5	0.7	15.7	10.5	47.8	12.3	5.2	0.0	0.2	1.3	0.1	0.0	4.0	0.2	1.8	0.9	0.6	0.5	0.4	0.5	0.2	0.6	1.5	0.7	1.9	0.0	139.8	0.0	10.2	1.1	2.8	0.1	0.0	0.2	1.2	0.1	0.2	11.8	0.0	0.3	0.0	4.4	1.2	0.2	0.3	0.2	0.2	1.0	1.9	0.5	14.2	0.1	0.1	0.4	0.2	0.2	0.0	3.4	107.3	0.1	0.6	0.2	3.4	5.9	0.1	47.1	0.6	0.2	0.4	0.8	1.3	0.1	2.2	1.1	0.0	0.7	0.1	0.1	1.3	0.1	0.0	0.0	0.0	0.8	0.0	2.3	0.4	0.2	0.0	0.3	0.7	0.0	0.0	0.0	0.0	4.0	0.2	0.8	1.2	0.4	0.7	0.5	0.3	0.5	0.3	2.1	0.5
MUC17		ENSG00000169876	"Mucin 17, cell surface associated"	Q685J3	7	101020072-101058745	"Cancer-related genes, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	299	"intestine: 125.2"	"Cell line enhanced"	"Detected in single"		"BEWO: 1.3"	"Group enriched"	"Detected in some"	29	"colorectal cancer: 6.1;pancreatic cancer: 4.9;stomach cancer: 22.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA031634	Enhanced				"Intracellular and membrane"					"HPA031634: AB_10603021"			"unprognostic (2.37e-2)"	"unprognostic (2.41e-1)"		"unprognostic (8.17e-3)"					"unprognostic (5.57e-3)"	"unprognostic (6.07e-2)"	"unprognostic (8.79e-8)"	"unprognostic (1.28e-1)"	"unprognostic (2.47e-2)"			0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	64.7	0.0	0.0	15.8	0.0	0.0	0.1	0.0	0.4	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	2.5	0.0	0.1	0.0	0.1	0.1	125.2	0.1	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0
MUTYH	MYH	ENSG00000132781	"MutY DNA glycosylase"	Q9UIF7	1	45329163-45340470	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Glycosidase, Hydrolase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA008732	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA008732: AB_1854219"	"unprognostic (6.30e-3)"	"unprognostic (7.12e-2)"	"unprognostic (6.29e-2)"	"unprognostic (8.80e-2)"	"unprognostic (3.43e-1)"	"unprognostic (5.16e-3)"	"prognostic unfavourable (4.76e-8)"	"unprognostic (2.80e-2)"	"unprognostic (7.12e-3)"	"unprognostic (3.05e-2)"	"unprognostic (7.80e-2)"	"unprognostic (1.14e-1)"	"prognostic unfavourable (7.25e-5)"	"unprognostic (3.50e-3)"	"unprognostic (1.62e-1)"	"unprognostic (5.57e-2)"	"unprognostic (5.49e-3)"	7.7	8.4	10.3	12.7	14.8	11.1	8.3	31.6	12.4	10.5	10.1	15.1	11.0	11.1	11.5	9.8	8.3	11.0	10.0	6.1	10.9	7.3	9.7	9.0	7.2	14.0	13.6	10.1	12.9	8.4	7.5	12.5	12.5	11.6	9.1	11.0	12.6	9.5	11.7	8.5	11.1	9.8	7.5	12.6	12.8	11.8	4.9	16.6	14.1	11.9	7.4	12.0	9.3	9.2	7.2	6.5	1.9	8.9	6.6	15.4	6.3	4.9	4.4	10.3	7.0	7.4	5.5	17.9	3.5	4.8	7.5	6.2	9.3	7.1	14.1	6.2	2.4	7.8	5.4	6.4	3.5	11.6	4.1	6.9	7.0	6.6	6.8	5.9	5.0	3.6	6.6	10.1	16.9	5.4	10.7	5.5	3.2	8.1	16.2	5.6	25.9	5.4	22.0	7.9	7.6	3.9	9.5	9.3	7.4	7.6	5.9	11.7	4.7	6.8	3.4	6.6	4.1	5.0	5.5	8.4	9.6	8.6	5.7	9.0	5.0	1.5	5.6	1.9	9.8	8.9	15.4	7.2	10.2	9.9	6.5	7.2	11.3	11.0	0.9	6.6	6.8	5.5	10.3	6.3	10.3	14.8	31.6	12.4	10.9	7.3	13.6	10.1	11.6	16.6
MVP	"LRP, VAULT1"	ENSG00000013364	"Major vault protein"	Q14764	16	29820394-29848039	"Cancer-related genes, Predicted intracellular proteins, Transporters"	"mRNA transport, Protein transport, Translocation, Transport"	Ribonucleoprotein	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"TIME: 68.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002321, CAB002752, CAB022717, HPA064740"	Enhanced		Supported	Cytosol		38000	38000	Cytosol		"CAB002752: , CAB022717: , HPA002321: AB_1079277, HPA064740: "	"prognostic favourable (4.51e-4)"	"unprognostic (1.06e-1)"	"unprognostic (2.77e-1)"	"unprognostic (1.80e-1)"	"unprognostic (8.17e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.22e-2)"	"unprognostic (6.03e-3)"	"unprognostic (2.19e-1)"	"unprognostic (6.85e-3)"	"unprognostic (2.86e-1)"	"prognostic favourable (5.49e-5)"	"unprognostic (2.22e-1)"	"unprognostic (5.19e-2)"	"unprognostic (5.69e-3)"	"unprognostic (2.65e-2)"	32.4	55.4	6.8	37.8	17.9	13.9	20.7	5.4	11.4	20.5	49.5	12.0	11.7	48.7	29.5	29.0	28.6	21.0	46.6	27.8	6.6	6.0	58.9	43.6	57.9	59.4	20.4	4.9	42.7	37.2	8.9	14.6	22.8	13.2	18.3	32.6	14.5	23.3	14.8	16.9	17.6	81.5	24.4	14.6	38.8	34.2	27.4	13.5	17.4	27.1	23.5	23.3	25.4	21.6	10.1	28.7	41.1	53.1	17.6	22.4	33.3	10.4	31.0	0.9	1.0	36.9	48.4	4.5	26.6	43.8	16.2	21.0	4.7	35.5	1.9	21.7	38.9	13.5	1.5	23.3	7.8	25.3	1.6	0.6	13.4	13.9	33.3	1.0	11.4	63.2	18.3	36.0	10.6	47.1	0.7	15.1	28.6	5.2	0.5	2.7	1.0	3.8	2.4	1.6	6.6	39.1	17.9	3.7	2.0	7.6	9.8	5.5	2.3	3.7	68.7	21.1	10.5	20.3	10.6	11.9	8.4	1.1	49.3	1.9	4.4	9.7	33.8	13.4	19.3	53.1	15.1	10.1	21.8	19.8	28.7	7.1	16.8	14.9	41.1	17.6	47.5	17.5	22.4	33.3	6.8	17.9	5.4	11.4	6.6	6.0	20.4	4.9	13.2	13.5
MXI1	"bHLHc11, MAD2, MXD2, MXI"	ENSG00000119950	"MAX interactor 1, dimerization protein"	P50539	10	110207605-110287365	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 29.5;SK-MEL-30: 53.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035319, HPA035320, HPA056762"	Approved		Supported	Nucleoplasm,Nucleoli,Cytosol				Nucleoplasm	"Nucleoli, Cytosol"	"HPA035319: AB_10670588, HPA035320: , HPA056762: "	"unprognostic (1.77e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.34e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.59e-1)"	"unprognostic (9.26e-3)"	"prognostic unfavourable (9.17e-4)"	"prognostic unfavourable (1.02e-5)"	"unprognostic (3.05e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.96e-1)"	16.9	19.4	37.2	7.5	34.9	32.7	26.5	56.4	36.9	20.3	26.4	33.9	20.1	12.0	26.0	23.8	39.5	19.1	17.4	36.0	35.1	26.6	23.9	30.5	16.5	7.1	37.0	25.9	46.4	23.1	25.6	12.1	14.4	26.2	24.5	22.1	15.8	41.2	32.7	22.8	25.4	22.5	18.2	44.7	7.8	14.7	13.5	38.1	7.0	29.2	13.4	9.8	32.8	33.9	4.5	2.2	11.0	4.7	1.4	8.6	2.3	5.5	2.2	5.7	11.4	9.0	6.8	2.5	3.2	11.0	2.1	6.8	1.0	10.0	7.3	5.2	5.6	7.2	6.8	7.7	5.7	3.7	9.2	1.9	4.5	4.1	5.9	3.9	4.4	7.2	29.5	3.7	15.0	2.1	7.3	15.9	3.5	3.6	2.6	7.9	2.4	6.8	1.6	7.5	11.6	7.5	0.5	9.7	15.9	3.2	2.4	53.2	2.7	12.7	2.1	3.8	6.5	4.0	1.7	13.2	6.9	2.6	10.1	14.5	4.0	2.2	3.1	11.0	3.1	2.5	5.8	3.9	6.7	3.6	1.7	4.5	8.6	2.2	7.8	1.4	4.7	2.2	5.0	2.3	37.2	34.9	56.4	36.9	35.1	26.6	37.0	25.9	26.2	38.1
MXRA5	DKFZp564I1922	ENSG00000101825	"Matrix remodeling associated 5"	Q9NR99	X	3308565-3346641	"Cancer-related genes, Disease related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 49.4;pancreas: 46.6"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 12.5;BJ hTERT+: 47.9;fHDF/TERT166: 22.4;HaCaT: 19.9;HSkMC: 9.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA000508	Uncertain				"Secreted - unknown location"	1700000	1700000			"HPA000508: AB_2147995"	"unprognostic (7.51e-2)"	"unprognostic (6.45e-2)"	"unprognostic (8.00e-2)"	"unprognostic (2.51e-2)"	"prognostic unfavourable (1.81e-4)"	"unprognostic (7.05e-2)"	"unprognostic (7.25e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.53e-2)"	"unprognostic (6.32e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.65e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.90e-2)"	"unprognostic (1.50e-1)"	"prognostic unfavourable (8.94e-4)"	6.5	12.1	0.5	10.4	1.2	0.0	7.5	0.4	0.8	49.4	4.4	0.6	18.8	2.1	11.4	6.0	8.7	4.2	5.8	9.2	0.6	0.5	8.0	4.5	5.9	0.9	0.6	0.7	7.9	46.6	0.5	1.4	7.9	0.8	11.0	5.9	10.2	11.5	29.5	1.1	16.6	7.8	8.8	0.5	7.7	5.1	4.0	0.3	5.7	15.0	11.7	6.2	12.7	9.6	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.1	12.5	0.0	7.4	47.9	0.0	0.0	0.0	0.2	0.0	0.6	22.4	19.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.7	2.3	1.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.2	0.4	0.8	0.6	0.5	0.6	0.7	0.8	0.3
MYB	c-myb	ENSG00000118513	"MYB proto-oncogene, transcription factor"	P10242	6	135181315-135219173	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lymphoid tissue: 104.9"	"Cell line enhanced"	"Detected in many"		"HL-60: 38.9;MOLT-4: 70.8;NB-4: 36.9;REH: 43.7;THP-1: 61.8;U-937: 33.7"	"Cancer enhanced"	"Detected in many"		"breast cancer: 17.7"	"Region enhanced"	"Detected in some"		"basal ganglia: 4.7"	"Group enriched"	"Detected in some"	4	"basophil: 5.6;eosinophil: 10.0"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 10.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"CAB017704, HPA071605"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB017704: , HPA071605: "	"unprognostic (1.69e-1)"	"unprognostic (5.82e-2)"	"unprognostic (1.82e-3)"	"unprognostic (1.37e-2)"	"unprognostic (4.06e-1)"	"unprognostic (8.35e-3)"	"unprognostic (1.13e-3)"	"unprognostic (2.48e-2)"	"unprognostic (6.44e-2)"	"unprognostic (1.00e-1)"	"unprognostic (3.71e-2)"	"prognostic favourable (9.65e-4)"	"unprognostic (2.41e-11)"	"prognostic favourable (9.87e-4)"	"unprognostic (8.35e-2)"	"unprognostic (3.04e-2)"	"unprognostic (9.40e-2)"	0.5	0.7	1.3	9.1	4.7	18.9	13.2	0.3	0.6	1.4	15.4	0.5	0.3	6.5	0.9	1.0	3.7	5.0	1.7	0.6	0.7	0.7	0.4	0.5	1.8	3.3	0.3	0.5	1.0	0.3	0.4	0.3	0.6	0.5	1.6	16.7	0.5	0.8	1.5	1.0	3.5	5.9	0.7	0.4	1.4	0.9	2.0	0.6	104.9	0.4	2.0	4.7	0.7	1.5	0.1	1.7	10.0	0.8	0.0	0.5	0.1	0.3	0.0	0.3	0.5	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.0	0.2	1.8	0.0	0.0	0.1	1.0	0.0	0.1	3.1	0.4	24.8	0.1	0.0	0.0	38.9	19.6	0.0	0.0	0.1	0.0	0.0	20.1	3.7	0.2	2.0	70.8	36.9	0.2	0.3	43.7	1.0	6.0	0.0	0.2	1.9	1.2	0.0	1.9	0.0	1.4	61.8	0.0	0.0	0.3	1.4	0.4	4.7	1.2	12.0	0.0	33.7	0.4	5.6	0.8	10.0	0.0	0.1	0.2	0.0	0.0	0.0	0.2	0.1	0.1	0.2	0.0	0.0	0.0	1.7	0.5	0.1	1.3	4.7	0.3	0.6	0.7	0.7	0.3	0.5	0.5	0.6
MYBL2	"B-MYB, BMYB"	ENSG00000101057	"MYB proto-oncogene like 2"	P10244	20	43667019-43716496	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 35.9;bone marrow: 33.0;lymphoid tissue: 49.2"	"Cell line enhanced"	"Detected in many"		"MCF7: 101.9"	"Cancer enriched"	"Detected in all"	5	"testis cancer: 295.8"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	30	"plasmacytoid DC: 35.9"	"Lineage enriched"	"Detected in many"	30	"dendritic cells: 35.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB017114, HPA030530, HPA055416"	Uncertain		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB017114: , HPA030530: , HPA055416: "	"unprognostic (9.75e-3)"	"unprognostic (1.29e-2)"	"unprognostic (3.20e-1)"	"prognostic unfavourable (9.73e-4)"	"unprognostic (2.35e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavourable (2.11e-7)"	"unprognostic (2.66e-3)"	"unprognostic (9.23e-3)"	"unprognostic (1.78e-1)"	"unprognostic (2.38e-3)"	"unprognostic (1.32e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (1.42e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.84e-1)"	1.7	0.7	0.2	48.3	0.2	33.0	1.0	0.2	0.2	1.0	4.4	0.2	0.1	2.7	1.1	1.1	8.4	0.3	1.7	0.9	0.2	0.2	1.0	1.2	1.8	22.3	0.3	0.1	0.8	9.4	0.0	0.4	4.0	0.2	0.7	2.7	0.3	2.9	0.1	0.3	1.8	6.4	0.6	0.3	43.9	2.9	12.6	0.1	49.2	0.6	6.4	33.8	1.9	2.1	1.1	35.9	0.0	0.0	0.0	0.4	0.3	25.8	16.5	14.6	15.1	0.1	0.5	19.0	11.7	4.0	37.1	27.4	80.9	16.3	52.3	6.8	5.1	15.8	26.4	8.1	13.9	9.8	16.9	24.5	16.5	21.8	0.0	22.3	17.0	0.3	0.7	14.1	3.2	9.9	24.4	65.1	3.2	101.9	45.3	31.4	16.8	14.5	31.6	30.1	30.0	6.8	5.3	13.5	19.6	34.8	35.0	3.5	23.1	24.5	4.6	2.3	37.4	16.4	20.1	22.6	46.5	82.3	4.8	19.1	14.2	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	35.9	0.4	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.1
MYC	"bHLHe39, c-Myc, MYCC"	ENSG00000136997	"MYC proto-oncogene, bHLH transcription factor"	P01106	8	127735434-127741434	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 129.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000084, CAB010307, HPA055893, HPA066556"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000084: , CAB010307: AB_631274, HPA055893: , HPA066556: "	"unprognostic (1.45e-2)"	"unprognostic (4.00e-3)"	"unprognostic (3.94e-3)"	"unprognostic (2.41e-3)"	"unprognostic (8.14e-2)"	"unprognostic (3.36e-3)"	"unprognostic (5.80e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.59e-1)"	"prognostic unfavourable (7.52e-4)"	"unprognostic (5.19e-3)"	"unprognostic (9.86e-3)"	"prognostic unfavourable (5.49e-8)"	"unprognostic (7.85e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.48e-1)"	"prognostic unfavourable (4.96e-5)"	67.4	20.8	3.2	46.6	7.1	16.3	36.0	1.2	5.0	23.9	23.3	3.8	11.8	11.1	23.8	14.4	47.6	59.5	32.4	23.7	5.8	2.2	11.2	36.6	16.0	40.5	5.8	1.2	38.7	64.6	2.1	7.4	14.9	9.8	20.6	11.3	6.1	14.4	21.8	69.6	78.5	17.2	21.3	12.0	38.3	24.7	16.3	3.8	40.2	9.0	48.4	27.1	28.9	37.3	25.5	8.8	1.0	10.3	20.9	55.2	22.0	7.1	13.8	1.2	12.3	20.0	23.7	3.6	8.6	3.7	10.7	9.0	18.8	18.7	72.9	12.0	5.1	15.5	63.9	27.8	7.1	17.2	22.3	43.9	23.4	24.5	18.4	30.7	7.0	16.5	61.5	7.2	57.0	12.3	64.8	38.6	5.3	20.5	50.1	66.8	3.4	27.6	27.9	5.2	129.7	9.0	7.4	84.9	8.0	4.0	33.5	22.2	13.6	20.2	14.9	8.1	9.6	6.2	10.7	0.7	1.2	35.2	7.1	34.3	4.0	0.7	10.3	0.1	8.6	9.1	43.4	25.5	31.1	18.6	8.8	20.6	55.2	34.8	1.0	20.9	6.1	0.3	24.8	22.0	3.2	7.1	1.2	3.6	5.8	2.2	5.8	1.2	9.8	3.8
MYCL	"bHLHe38, LMYC, MYCL1"	ENSG00000116990	"MYCL proto-oncogene, bHLH transcription factor"	P12524	1	39895426-39902256	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"pancreas: 46.4;skin 1: 26.0"	"Group enriched"	"Detected in some"	7	"U-266/70: 94.1;U-266/84: 69.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 28.9"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"classical monocyte: 11.5;intermediate monocyte: 5.5;myeloid DC: 12.9;plasmacytoid DC: 15.4"	"Group enriched"	"Detected in many"	75	"dendritic cells: 15.4;monocytes: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA063132, HPA074515"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA063132: , HPA074515: "	"unprognostic (7.45e-2)"	"unprognostic (6.91e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.83e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.92e-3)"	"unprognostic (6.72e-3)"	"prognostic favourable (4.49e-4)"	"unprognostic (1.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.12e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.75e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.53e-2)"	"unprognostic (5.80e-2)"	0.3	0.3	1.2	4.4	2.1	0.1	1.7	0.8	1.7	3.6	7.5	1.8	8.5	2.6	1.0	4.0	17.8	1.6	2.3	0.7	1.1	0.9	0.8	6.4	1.9	2.9	0.6	1.4	0.5	46.4	0.0	2.1	11.2	1.8	5.3	3.6	1.8	4.6	16.6	0.6	26.0	7.3	1.2	1.1	4.0	3.3	1.5	0.6	6.4	4.2	3.1	6.0	18.4	7.3	0.0	15.4	0.1	11.5	0.0	0.1	3.8	0.2	0.0	2.9	0.7	0.0	0.0	7.0	0.1	0.0	0.2	0.1	0.1	0.1	0.4	0.3	0.0	0.7	2.0	0.5	0.1	0.4	1.0	0.1	0.0	0.1	0.0	0.0	1.7	0.2	2.3	0.0	0.2	0.2	0.7	0.0	0.1	0.2	0.0	0.0	2.7	0.1	0.2	3.3	0.6	0.2	11.3	0.5	0.7	0.2	0.4	0.1	0.7	3.6	0.0	0.0	1.1	1.3	0.1	94.1	69.1	0.1	0.0	0.4	0.0	0.0	11.5	0.0	0.0	5.5	0.0	0.0	0.0	0.1	12.9	0.0	0.0	0.0	0.1	0.0	2.3	15.4	0.0	3.8	1.2	2.1	0.8	1.7	1.1	0.9	0.6	1.4	1.8	0.6
MYCN	"bHLHe37, MYCNOT, N-myc, NMYC"	ENSG00000134323	"MYCN proto-oncogene, bHLH transcription factor"	P04198	2	15940564-15947007	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 16.8"	"Cell line enhanced"	"Detected in some"		"AF22: 12.7;BEWO: 68.9;HMC-1: 16.6;NTERA-2: 26.1;RH-30: 18.2"	"Cancer enhanced"	"Detected in many"		"testis cancer: 45.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA057420			Approved	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"HPA057420: "	"unprognostic (8.04e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.07e-2)"	"unprognostic (4.11e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.23e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.35e-3)"	"unprognostic (3.09e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.12e-3)"	"unprognostic (8.89e-2)"	"unprognostic (2.47e-1)"	"unprognostic (4.90e-2)"	"unprognostic (1.23e-1)"	0.9	1.9	5.1	1.8	5.5	1.6	1.2	1.4	8.4	3.1	1.2	12.1	0.0	3.0	1.9	0.8	1.3	1.4	2.6	2.3	7.0	4.7	6.0	1.5	1.6	2.9	6.0	2.2	10.3	0.7	0.4	0.7	16.8	6.8	0.6	1.3	1.1	6.6	0.7	1.0	2.4	1.7	0.9	8.9	0.9	8.5	6.5	4.0	5.7	5.1	2.3	3.5	2.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.7	0.0	0.0	0.0	68.9	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	26.1	0.0	0.0	18.2	3.5	0.0	0.8	0.2	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	5.5	1.4	7.0	7.0	4.7	6.0	2.2	6.8	4.0
MYD88		ENSG00000172936	"Myeloid differentiation primary response 88"	Q99836	3	38138478-38143022	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Immunity, Inflammatory response, Innate immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 68.0"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 54.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009104	Approved		Supported	Vesicles,Mitochondria,Cytosol				Cytosol	"Vesicles, Mitochondria"	"CAB009104: AB_2146724"	"prognostic favourable (8.45e-4)"	"unprognostic (1.19e-1)"	"unprognostic (4.31e-2)"	"unprognostic (2.51e-2)"	"unprognostic (4.77e-2)"	"unprognostic (4.38e-3)"	"unprognostic (4.37e-2)"	"unprognostic (3.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (7.28e-2)"	"unprognostic (1.01e-2)"	"unprognostic (7.30e-2)"	"unprognostic (2.11e-2)"	"unprognostic (4.41e-1)"	"unprognostic (4.17e-2)"	"unprognostic (1.65e-1)"	"unprognostic (2.08e-2)"	25.0	11.3	5.9	19.5	6.9	18.1	14.7	5.2	4.6	10.0	13.4	5.8	5.0	15.1	9.5	12.3	25.5	9.8	12.4	10.4	5.3	3.2	15.1	47.9	25.6	40.1	6.2	3.5	13.3	10.3	5.4	10.4	17.8	6.7	11.3	14.3	8.8	13.9	5.4	3.9	12.5	30.4	10.7	7.0	39.0	12.5	5.8	5.1	28.5	10.4	17.5	30.8	13.9	13.7	7.8	34.7	49.0	68.0	8.3	14.3	34.6	8.1	12.0	1.8	10.7	8.5	11.1	3.7	8.0	13.1	22.6	24.0	7.5	9.9	17.4	4.8	14.3	10.2	14.2	8.0	7.6	13.5	2.9	9.4	6.1	11.4	7.0	11.9	24.6	12.7	8.5	12.8	4.8	12.8	4.1	7.1	11.8	8.2	19.6	3.8	7.6	12.0	8.5	2.3	7.5	11.6	19.0	0.8	3.9	11.3	54.5	7.1	8.5	13.5	11.9	4.4	2.7	20.4	7.6	10.5	11.7	12.9	8.6	20.9	9.6	38.3	37.6	48.1	12.2	56.5	10.4	7.8	11.0	12.2	34.7	6.7	7.7	10.9	49.0	8.3	68.0	16.6	14.3	34.6	5.9	6.9	5.2	4.6	5.3	3.2	6.2	3.5	6.7	5.1
MYH11	"SMHC, SMMHC"	ENSG00000133392	"Myosin heavy chain 11"	P35749	16	15703172-15857033	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin"	"Aortic aneurysm, Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 507.4;urinary bladder: 394.5"	"Cell line enhanced"	"Detected in some"		"BEWO: 3.5;NB-4: 3.8;U-698: 9.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 173.2"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"midbrain: 54.5"	"CAB002302, HPA014539, HPA015310"	Enhanced		Supported	"Plasma membrane,Cytosol"		130000000	130000000	"Plasma membrane, Cytosol"		"CAB002302: AB_563902, HPA014539: AB_1854260, HPA015310: AB_1854261"	"unprognostic (7.99e-2)"	"unprognostic (3.07e-2)"	"unprognostic (4.18e-2)"	"unprognostic (9.21e-3)"	"unprognostic (6.70e-2)"	"unprognostic (2.75e-2)"	"prognostic favourable (1.10e-5)"	"unprognostic (1.41e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.19e-3)"	"unprognostic (4.06e-2)"	"unprognostic (9.53e-2)"	"unprognostic (5.00e-2)"	"unprognostic (5.45e-3)"	13.2	3.0	0.6	31.5	1.2	0.0	5.9	0.5	1.7	90.3	227.5	1.3	100.0	11.6	102.0	38.4	233.0	43.8	94.3	6.2	0.6	0.7	4.7	0.7	8.5	1.5	1.4	2.6	45.5	1.3	0.0	1.0	5.3	3.6	164.7	22.2	37.0	8.8	127.2	6.4	5.0	50.6	507.4	1.4	3.7	77.7	22.3	0.2	0.1	3.7	6.2	3.0	394.5	57.5	1.5	0.9	6.0	0.9	1.1	1.5	0.4	0.1	0.4	0.2	0.1	0.0	0.0	3.5	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.2	0.0	0.6	0.0	0.0	0.0	0.4	0.4	0.2	0.1	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.1	1.5	0.0	0.3	0.3	3.8	0.4	0.1	0.4	0.1	1.9	0.0	0.2	0.7	1.4	0.2	0.5	1.2	0.4	0.0	0.3	0.1	0.3	2.0	0.1	0.4	0.4	9.7	0.4	0.4	0.4	3.1	0.9	2.7	1.2	0.6	1.2	1.5	1.5	1.4	0.5	1.2	1.4	1.4	6.0	1.1	0.6	0.9	1.4	0.4	0.6	1.2	0.5	1.7	0.6	0.7	1.4	2.6	3.6	0.2
MYH9	"DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA"	ENSG00000100345	"Myosin heavy chain 9"	P35579	22	36281277-36388067	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Cell shape"	"Actin-binding, Calmodulin-binding, Motor protein, Myosin"	"Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001644, CAB015386, HPA064783"	Enhanced		Supported	"Plasma membrane,Actin filaments,Cytosol"		3100000000	3100000000	"Plasma membrane, Actin filaments"	Cytosol	"CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721"	"unprognostic (1.38e-1)"	"unprognostic (9.12e-2)"	"unprognostic (4.21e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.49e-1)"	"unprognostic (3.90e-2)"	"unprognostic (9.56e-2)"	"unprognostic (8.28e-2)"	"unprognostic (5.50e-2)"	"unprognostic (6.38e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.61e-1)"	"unprognostic (7.98e-2)"	"unprognostic (9.48e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.59e-2)"	115.5	26.1	11.9	43.7	12.9	55.6	59.0	9.3	16.8	67.1	44.6	18.0	26.4	26.9	120.8	39.7	48.3	45.6	66.9	39.2	11.0	8.1	45.0	42.8	74.4	57.7	15.1	9.2	56.4	43.9	19.0	15.4	65.7	17.9	47.6	23.6	32.4	66.2	27.2	36.9	40.3	49.8	46.7	13.5	91.5	37.1	25.8	11.9	76.0	42.5	38.4	65.0	56.0	53.7	6.9	8.2	28.5	11.5	4.2	16.6	19.3	60.6	28.2	9.0	7.6	16.8	21.1	45.7	40.7	52.7	58.2	43.7	30.4	17.5	15.7	24.2	68.1	42.1	13.1	79.7	60.0	35.4	12.4	30.3	30.3	25.9	51.5	34.4	48.6	24.9	24.6	78.6	66.8	47.9	6.6	21.3	46.5	16.1	12.2	20.3	5.3	17.4	23.3	27.9	14.6	32.9	59.1	13.5	5.5	57.2	22.5	26.2	16.8	17.8	137.0	129.1	39.2	24.7	73.5	14.1	11.1	13.3	48.9	17.4	37.4	26.8	10.4	28.5	16.6	9.6	14.7	6.9	12.0	13.2	8.2	6.4	9.6	10.1	19.7	4.2	11.5	3.8	12.6	19.3	11.9	12.9	9.3	16.8	11.0	8.1	15.1	9.2	17.9	11.9
MYO5A	"GS1, MYH12, MYO5, MYR12"	ENSG00000197535	"Myosin VA"	Q9Y4I1	15	52307283-52529050	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"	"Actin-binding, Calmodulin-binding, Motor protein, Myosin"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 34.5;parathyroid gland: 47.6"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 58.9;RPMI-8226: 39.9"	"Cancer enhanced"	"Detected in all"		"melanoma: 25.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001356	Enhanced		Approved	"Focal adhesion sites,Centriolar satellite"				"Focal adhesion sites, Centriolar satellite"		"HPA001356: AB_1079441"	"unprognostic (1.54e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.95e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.30e-2)"	"unprognostic (6.65e-2)"	"unprognostic (7.89e-2)"	"unprognostic (4.74e-2)"	"unprognostic (9.36e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.63e-3)"	"unprognostic (3.79e-3)"	"unprognostic (1.24e-1)"	"unprognostic (7.16e-2)"	"prognostic unfavourable (4.22e-4)"	8.4	7.1	16.6	9.5	27.5	15.7	5.5	27.4	34.5	6.2	4.4	7.8	0.4	3.3	4.2	3.2	5.0	3.6	7.3	4.6	15.9	15.4	4.6	2.7	7.3	11.2	15.6	17.6	5.4	4.3	47.6	10.5	5.2	29.3	4.5	5.2	9.9	4.0	3.4	4.1	10.4	3.9	7.7	10.1	7.3	4.1	4.6	7.1	3.1	6.8	2.7	10.3	7.3	4.2	2.3	5.2	6.3	4.4	0.7	4.5	1.9	5.4	9.6	5.1	6.1	5.2	6.4	5.5	9.9	9.0	5.3	4.2	0.9	2.2	5.2	2.6	11.8	4.5	11.7	10.2	6.6	29.4	2.7	4.8	2.5	1.1	2.7	2.5	4.7	4.2	6.4	7.8	15.5	30.8	0.1	58.9	10.2	9.6	2.2	0.3	2.3	7.7	4.1	8.2	39.9	4.4	3.9	3.8	2.2	9.2	7.6	18.0	4.0	2.8	14.7	10.7	4.6	5.0	9.6	6.1	13.5	6.3	11.7	7.3	15.4	0.9	4.4	5.4	2.9	3.6	4.5	2.3	2.9	1.9	5.2	1.6	0.5	1.0	6.3	0.7	2.6	3.1	4.1	1.9	16.6	27.5	27.4	34.5	15.9	15.4	15.6	17.6	29.3	7.1
MYOCD	MYCD	ENSG00000141052	Myocardin	Q8IZQ8	17	12665890-12768949	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 63.4"	"Cell line enhanced"	"Detected in some"		"BJ: 6.8;BJ hTERT+: 6.8;HBF TERT88: 11.3;hTEC/SVTERT24-B: 12.5;REH: 8.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Region enhanced"	"Detected in some"		"cerebellum: 6.4"	"CAB046485, HPA071528, HPA072582"	Approved		Approved	Nucleoplasm				Nucleoplasm		"CAB046485: AB_10600720, HPA071528: , HPA072582: "	"unprognostic (2.82e-1)"	"unprognostic (1.69e-1)"	"unprognostic (2.36e-2)"	"unprognostic (1.90e-1)"	"unprognostic (3.79e-2)"	"unprognostic (5.33e-2)"	"unprognostic (2.15e-4)"	"unprognostic (2.71e-2)"	"unprognostic (1.61e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.76e-1)"	"unprognostic (4.83e-2)"	"unprognostic (1.01e-4)"	"unprognostic (2.88e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.45e-2)"	"unprognostic (1.91e-2)"	3.1	0.8	0.6	5.1	1.0	0.0	1.9	0.3	0.5	19.6	19.9	0.2	17.6	2.1	16.6	10.9	14.4	7.4	12.2	18.6	0.4	0.4	0.9	0.4	2.5	0.0	0.5	0.8	10.6	0.4	0.0	0.5	2.6	0.6	17.2	4.2	5.1	0.4	18.7	1.2	1.5	6.6	63.4	0.6	0.5	6.7	3.7	0.1	0.0	1.0	1.2	0.0	33.4	9.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	6.8	6.8	2.6	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.3	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.3	0.0	12.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	8.6	1.7	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	0.3	0.5	0.4	0.4	0.5	0.8	0.6	0.1
MYOD1	"bHLHc1, MYF3, MYOD, PUM"	ENSG00000129152	"Myogenic differentiation 1"	P15172	11	17719568-17722131	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	7	"skeletal muscle: 31.8"	"Cell line enriched"	"Detected in some"	15	"RH-30: 101.2"	"Cancer enhanced"	"Detected in single"		"ovarian cancer: 0.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	6	"hippocampal formation: 0.5"	"HPA055436, HPA078647"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA055436: , HPA078647: "						"unprognostic (1.07e-3)"				"unprognostic (2.10e-1)"					"unprognostic (1.01e-1)"			1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.5	0.0	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	4.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.0	101.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0
MYOG	"bHLHc3, MYF4"	ENSG00000122180	Myogenin	P15173	1	203083132-203086036	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	5	"skeletal muscle: 60.0"	"Group enriched"	"Detected in some"	200	"HSkMC: 17.6;RH-30: 33.6"	"Group enriched"	"Detected in some"	6	"head and neck cancer: 3.9;testis cancer: 1.7"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA028336			Supported	Nucleoplasm				Nucleoplasm		"HPA028336: "	"unprognostic (1.71e-1)"				"unprognostic (1.64e-1)"	"unprognostic (1.05e-3)"				"unprognostic (2.22e-1)"			"unprognostic (2.79e-9)"	"unprognostic (3.96e-1)"	"unprognostic (2.56e-1)"			1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	1.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	1.3	0.0	0.0	2.4	0.0	60.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	1.7	13.3	1.7	0.0	0.0	0.8	0.8	2.3	1.3	1.8	1.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	33.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.3	0.4	0.8	0.4	0.7	1.0	0.8	0.5	0.6	0.3	0.6	0.9	1.0	1.4	1.8	1.3	0.8	0.8	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NAB2	MADER	ENSG00000166886	"NGFI-A binding protein 2"	Q15742	12	57088894-57095476	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004510, HPA027464"	Approved		Approved	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB004510: AB_627982, HPA027464: AB_10601138"	"prognostic favourable (7.41e-4)"	"unprognostic (4.04e-2)"	"unprognostic (2.20e-3)"	"unprognostic (2.43e-2)"	"unprognostic (4.74e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.88e-3)"	"unprognostic (1.80e-1)"	"unprognostic (5.85e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.13e-1)"	"unprognostic (6.98e-2)"	"prognostic unfavourable (9.38e-6)"	"unprognostic (1.95e-1)"	"unprognostic (9.76e-2)"	"unprognostic (5.67e-3)"	"unprognostic (6.19e-3)"	9.5	12.6	11.7	9.9	14.2	4.8	7.9	33.3	20.4	18.7	13.7	5.3	9.6	8.2	22.8	18.9	10.5	15.6	14.5	9.6	8.6	6.8	8.4	18.7	12.8	9.1	4.4	14.6	29.2	8.5	14.5	17.0	13.4	6.8	15.0	4.4	8.5	5.6	14.5	7.1	18.6	7.1	14.5	4.1	8.0	8.2	11.8	7.0	12.4	9.8	7.7	8.6	14.5	26.5	4.2	1.2	0.9	5.4	0.9	2.5	1.2	5.5	3.5	18.7	17.1	16.8	22.0	2.0	16.6	15.0	10.5	8.8	5.7	3.2	3.5	6.8	16.3	10.0	6.4	12.2	5.6	1.4	1.7	4.1	2.7	5.8	12.8	3.3	10.0	24.5	13.5	12.5	4.3	2.8	9.4	3.6	12.2	25.7	5.0	16.1	3.8	6.2	3.7	24.6	1.8	4.5	2.1	2.1	4.9	8.0	4.7	34.9	10.5	7.3	3.1	15.5	13.0	11.0	4.8	8.6	2.1	1.8	15.1	2.2	9.3	0.0	2.3	0.3	1.2	5.3	1.4	2.1	2.0	1.5	1.2	4.2	2.5	2.5	0.9	0.9	5.4	0.0	1.9	1.2	11.7	14.2	33.3	20.4	8.6	6.8	4.4	14.6	6.8	7.0
NAGA	D22S674	ENSG00000198951	Alpha-N-acetylgalactosaminidase	P17050	22	42058354-42070842	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Glycosidase, Hydrolase"	"Cancer-related genes, Disease mutation, Epilepsy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 65.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	8	"classical monocyte: 38.5;intermediate monocyte: 47.6;myeloid DC: 37.9;non-classical monocyte: 46.1;plasmacytoid DC: 23.2"	"Group enriched"	"Detected in all"	9	"dendritic cells: 37.9;monocytes: 47.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000649	Enhanced				"Intracellular and membrane"	2300000	2300000			"HPA000649: AB_1079448"	"unprognostic (3.74e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.45e-3)"	"unprognostic (1.55e-1)"	"unprognostic (1.28e-1)"	"unprognostic (3.02e-2)"	"unprognostic (4.27e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.53e-2)"	"unprognostic (1.93e-1)"	"unprognostic (3.64e-2)"	"unprognostic (3.68e-2)"	"unprognostic (1.92e-3)"	"unprognostic (8.95e-2)"	"unprognostic (2.53e-1)"	23.7	13.5	12.1	20.3	14.5	11.3	12.5	11.8	10.3	16.3	18.3	15.0	10.7	13.2	18.9	16.1	14.5	17.3	16.5	15.8	10.1	8.6	17.9	28.2	19.9	32.6	12.6	7.3	18.1	9.5	27.8	13.1	45.3	11.5	15.2	18.0	19.8	16.6	14.5	9.2	9.9	25.6	18.7	11.4	22.0	14.1	9.3	13.2	12.0	15.0	11.4	17.9	17.3	14.5	2.1	37.9	4.9	47.6	3.4	3.4	19.2	9.0	4.6	7.4	13.1	12.9	14.8	5.4	7.5	15.4	12.9	13.5	10.3	13.4	4.4	4.6	16.2	6.4	5.6	9.1	7.7	10.1	7.1	10.9	7.1	6.9	7.5	9.0	65.2	10.1	8.0	11.6	4.9	21.3	4.0	18.9	10.2	10.5	3.3	3.7	1.9	6.2	7.5	3.7	7.8	10.0	10.8	2.3	2.6	9.9	9.1	9.8	13.6	16.7	11.4	9.1	11.1	5.8	6.7	10.5	10.5	3.5	9.7	17.3	11.2	4.9	38.5	4.6	2.8	47.6	2.8	2.1	2.9	2.6	37.9	1.5	1.9	1.8	1.9	3.4	46.1	23.2	3.4	19.2	12.1	14.5	11.8	10.3	10.1	8.6	12.6	7.3	11.5	13.2
NAIP	"BIRC1, NLRB1"	ENSG00000249437	"NLR family apoptosis inhibitory protein"	Q13075	5	70968483-71025114	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Immunity, Inflammatory response, Innate immunity"	"Protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 8.1;lymphoid tissue: 17.5"	"Cell line enhanced"	"Detected in some"		"MOLT-4: 7.8;SiHa: 4.5;T-47d: 4.9"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"pons and medulla: 6.4"	"Group enriched"	"Detected in some"	10	"classical monocyte: 8.1;intermediate monocyte: 2.9;myeloid DC: 6.9;neutrophil: 5.9"	"Group enriched"	"Detected in many"	14	"dendritic cells: 6.9;granulocytes: 5.9;monocytes: 8.1"									HPA042438	Approved									"HPA042438: AB_10796578"	"unprognostic (9.03e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.31e-1)"	"unprognostic (7.50e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.23e-2)"	"unprognostic (4.36e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.54e-2)"	"unprognostic (5.13e-1)"	"unprognostic (1.69e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.38e-1)"	"unprognostic (9.96e-2)"	2.4	1.0	0.8	4.7	0.8	2.4	0.8	0.8	2.6	0.8	0.8	0.8	0.8	0.1	0.9	1.2	0.8	1.6	1.6	0.8	0.8	0.6	0.8	0.8	3.9	3.4	1.2	0.8	0.8	0.8	0.2	0.8	0.8	6.4	0.8	0.7	0.8	0.8	0.8	1.0	0.4	2.3	1.1	2.3	17.5	3.0	0.8	0.8	0.8	0.9	0.8	0.8	3.6	0.8	0.3	6.9	5.9	8.1	0.4	0.2	2.0	0.0	0.0	1.1	0.4	0.4	0.0	0.3	0.0	0.0	0.3	0.0	0.8	0.8	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.7	0.8	0.7	1.6	0.2	1.5	0.5	0.0	0.0	0.0	0.2	0.0	0.3	0.6	0.2	0.0	7.8	0.0	0.1	0.0	0.1	0.0	1.7	0.3	0.1	0.3	0.0	4.5	0.0	0.3	4.9	0.0	0.0	1.2	0.3	0.2	0.0	0.9	0.0	0.6	0.1	0.1	0.8	0.2	8.1	0.0	0.2	2.9	0.1	0.1	0.0	0.1	6.9	0.3	0.2	0.1	5.9	0.4	0.5	0.3	0.1	2.0	0.8	0.8	0.8	2.6	0.8	0.6	1.2	0.8	6.4	0.8
NAMPT	"PBEF, PBEF1"	ENSG00000105835	"Nicotinamide phosphoribosyltransferase"	P43490	7	106248285-106286326	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Biological rhythms, Pyridine nucleotide biosynthesis"	"Cytokine, Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-87 MG: 108.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	18	"neutrophil: 143.5"	"Lineage enriched"	"Detected in many"	20	"granulocytes: 143.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034349, HPA047776, HPA057722"	Approved		Approved	"Nuclear speckles,Cell Junctions"	"Secreted to blood"	410000	410000	"Nuclear speckles"	"Cell Junctions"	"CAB034349: AB_2251220, HPA047776: , HPA057722: "	"unprognostic (2.87e-1)"	"prognostic unfavourable (4.78e-4)"	"unprognostic (5.90e-3)"	"unprognostic (1.63e-2)"	"unprognostic (1.50e-2)"	"prognostic unfavourable (8.81e-4)"	"unprognostic (2.15e-1)"	"unprognostic (2.74e-2)"	"unprognostic (2.74e-1)"	"unprognostic (3.30e-1)"	"prognostic unfavourable (1.51e-4)"	"unprognostic (3.02e-1)"	"prognostic unfavourable (2.49e-6)"	"unprognostic (6.83e-2)"	"unprognostic (6.96e-2)"	"unprognostic (7.76e-2)"	"unprognostic (6.44e-3)"	67.3	22.2	8.1	113.6	18.1	110.4	52.6	7.8	12.9	11.6	18.2	2.9	9.5	9.3	9.9	13.5	53.4	27.8	28.1	84.4	13.4	6.3	13.5	92.9	48.9	117.5	10.3	5.2	27.3	18.3	5.5	10.0	23.9	29.2	17.4	10.5	8.2	32.9	14.3	41.0	12.9	14.1	44.9	59.1	41.1	26.4	11.9	7.1	6.2	13.5	40.7	13.2	48.8	26.4	0.8	2.0	143.5	7.3	1.0	1.5	1.3	18.9	12.6	4.6	7.6	19.4	22.6	7.5	6.0	34.0	12.2	21.6	7.4	11.5	15.9	14.4	6.7	15.0	8.4	18.1	26.8	9.4	9.1	6.4	5.4	5.8	72.5	12.4	11.9	21.6	20.7	21.8	25.5	38.8	13.4	60.9	14.5	9.9	12.3	5.2	8.8	10.2	5.9	6.5	34.9	11.6	17.8	9.3	5.1	8.4	18.5	21.4	5.9	3.6	33.0	18.2	14.1	26.1	11.0	42.0	23.8	22.8	108.1	14.1	26.9	8.1	2.3	3.5	0.4	5.6	0.7	0.8	0.5	0.6	2.0	0.7	0.8	0.4	143.5	1.0	7.3	0.8	1.5	1.3	8.1	18.1	7.8	12.9	13.4	6.3	10.3	5.2	29.2	7.1
NAT2	AAC2	ENSG00000156006	"N-acetyltransferase 2"	P11245	8	18391245-18401218	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Acyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	22	"intestine: 28.4;liver: 75.5"	"Cell line enhanced"	"Detected in some"		"RPTEC TERT1: 2.8;RT4: 4.1;SCLC-21H: 5.7;SK-BR-3: 3.6"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 4.0;liver cancer: 4.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA043704	Uncertain									"HPA043704: "	"unprognostic (2.74e-3)"	"unprognostic (4.03e-1)"	"prognostic favourable (4.61e-5)"	"unprognostic (1.43e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.52e-2)"	"unprognostic (2.67e-2)"		"unprognostic (1.27e-1)"	"unprognostic (1.33e-2)"	"unprognostic (4.07e-1)"	"unprognostic (6.05e-3)"	"unprognostic (1.02e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.64e-1)"	0.2	0.1	0.2	2.3	0.3	0.0	0.3	0.1	0.2	0.3	14.0	0.1	0.1	13.0	0.4	0.4	0.1	0.2	0.3	0.4	0.1	0.1	0.6	75.5	0.2	0.1	0.2	0.2	0.2	0.1	0.0	0.2	0.2	0.3	0.3	5.1	0.1	0.1	0.1	0.1	0.1	28.4	0.4	0.2	0.6	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.5	0.1	0.0	0.2	0.0	0.0	0.3	0.0	1.7	0.0	0.1	0.0	1.4	0.0	0.0	0.2	0.3	0.1	0.5	0.1	0.5	0.1	0.0	0.0	0.0	0.6	0.0	0.3	0.0	0.1	0.0	0.1	0.1	0.0	0.6	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.1	1.0	0.0	0.0	0.9	0.0	2.8	4.1	5.7	0.1	0.1	3.6	0.0	1.0	0.5	1.5	1.0	0.5	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.3	0.1	0.2	0.1	0.1	0.2	0.2	0.3	0.1
NAV3	"KIAA0938, POMFIL1"	ENSG00000067798	"Neuron navigator 3"	Q8IVL0	12	77324641-78213008	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.2;ovary: 29.6"	"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 23.4;THP-1: 20.5;U-138 MG: 15.7;WM-115: 19.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"basophil: 1.9;neutrophil: 3.8"	"Lineage enriched"	"Detected in single"	12	"granulocytes: 3.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA032111, HPA061392"	Approved		Approved	"Nuclear membrane,Cytosol"				"Nuclear membrane"	Cytosol	"HPA032111: AB_10603881, HPA061392: "	"unprognostic (3.51e-1)"	"unprognostic (6.72e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.79e-1)"	"unprognostic (8.98e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.78e-1)"	"unprognostic (3.25e-2)"	"unprognostic (3.03e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.99e-1)"	"unprognostic (1.90e-1)"	"unprognostic (5.68e-7)"	"unprognostic (6.86e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.58e-2)"	"unprognostic (2.29e-3)"	6.2	8.5	17.8	2.4	14.2	1.5	7.1	14.7	25.2	2.8	2.1	9.7	2.6	1.2	4.1	5.8	3.8	3.6	8.6	3.7	14.2	7.5	1.4	2.3	3.8	1.6	7.8	13.0	29.6	1.4	2.2	9.3	4.3	7.1	4.5	2.0	12.3	2.2	5.1	2.6	4.1	1.3	4.6	10.6	12.7	1.6	5.0	8.3	0.0	1.7	0.0	1.4	3.9	2.3	0.3	0.1	3.8	0.2	0.1	0.0	0.0	1.8	4.3	0.3	0.1	4.5	9.3	0.1	13.1	10.3	5.4	2.8	1.2	0.3	0.1	1.0	10.5	1.4	3.8	2.0	9.6	0.0	0.0	0.0	1.8	0.1	3.5	0.0	0.1	3.4	0.0	23.4	5.9	8.0	0.0	0.0	13.2	0.1	0.0	5.9	1.5	1.2	0.6	1.1	0.0	0.9	0.0	0.3	0.0	0.9	0.1	1.8	0.0	20.5	6.9	15.7	4.4	6.7	9.0	0.7	0.0	0.4	4.7	0.2	19.4	1.9	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	3.8	0.1	0.2	0.1	0.0	0.0	17.8	14.2	14.7	20.5	14.2	7.5	7.8	13.0	7.1	8.3
NBN	"AT-V1, AT-V2, ATV, NBS, NBS1"	ENSG00000104320	Nibrin	O60934	8	89933336-90003228	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 76.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001429, CAB003836"	Supported		Approved	"Nucleoplasm,Golgi apparatus"				"Golgi apparatus"	Nucleoplasm	"CAB003836: AB_562172, HPA001429: AB_1854460"	"unprognostic (1.52e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.32e-3)"	"unprognostic (7.46e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.05e-2)"	"prognostic unfavourable (5.46e-5)"	"unprognostic (5.05e-2)"	"unprognostic (4.61e-2)"	"prognostic unfavourable (4.20e-4)"	"unprognostic (1.15e-1)"	"unprognostic (6.68e-2)"	"unprognostic (3.14e-2)"	"unprognostic (3.28e-1)"	"unprognostic (2.84e-2)"	"unprognostic (1.03e-1)"	19.2	16.1	17.9	23.6	29.5	41.3	23.0	17.4	21.0	19.3	22.6	12.2	16.9	13.3	33.2	16.6	19.7	17.5	20.2	14.2	19.4	16.7	25.9	19.3	17.9	26.7	16.9	18.1	19.3	17.1	21.0	29.4	13.2	18.4	17.6	20.9	7.1	18.4	17.6	15.7	11.2	18.0	22.2	18.1	26.5	14.7	13.9	18.9	23.4	20.8	14.7	22.8	17.5	16.0	10.1	12.0	21.8	18.5	9.7	8.6	7.6	15.1	8.5	8.6	4.5	4.7	11.8	5.5	10.8	14.4	13.8	15.0	4.9	11.5	22.9	12.6	9.8	5.1	10.4	10.1	17.7	10.7	6.0	19.4	5.3	6.9	9.2	11.6	10.3	8.8	5.4	7.7	17.1	11.1	14.2	13.4	15.6	13.5	17.7	7.3	2.5	9.3	11.9	7.5	13.6	17.8	20.9	2.5	7.9	6.8	76.8	6.4	14.4	8.6	8.3	12.0	8.5	7.2	10.6	6.2	7.1	12.8	12.1	10.9	11.0	14.1	11.1	20.3	8.1	12.5	8.6	10.1	5.9	5.9	12.0	6.1	5.7	6.2	21.8	9.7	18.5	6.6	3.7	7.6	17.9	29.5	17.4	21.0	19.4	16.7	16.9	18.1	18.4	18.9
NBPF1	"FLJ20719, KIAA1693"	ENSG00000219481	"NBPF member 1"		1	16562319-16613562	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050"	Approved		Approved	"Nucleoplasm,Nuclear bodies"				"Nuclear bodies"	Nucleoplasm	"HPA038748: , HPA042595: , HPA043105: , HPA043692: , HPA044023: , HPA046971: , HPA058050: "	"unprognostic (8.16e-3)"	"unprognostic (6.96e-2)"	"unprognostic (1.33e-2)"	"unprognostic (6.09e-2)"	"unprognostic (3.49e-1)"	"unprognostic (4.76e-2)"	"unprognostic (1.15e-5)"	"unprognostic (2.16e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.99e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.14e-2)"	"prognostic favourable (1.06e-4)"	"unprognostic (1.57e-1)"	"unprognostic (1.05e-1)"	"unprognostic (5.18e-2)"	"unprognostic (1.68e-1)"	6.8	23.3	14.2	6.4	18.3	4.5	7.4	32.7	13.1	11.7	11.6	21.5	6.0	7.5	9.5	6.2	6.6	13.9	7.9	5.2	13.4	9.3	8.1	7.7	7.3	3.2	32.8	4.2	18.6	5.5	22.3	12.3	9.7	18.4	9.0	11.3	9.3	6.5	9.6	4.5	5.9	16.6	12.2	21.3	6.7	7.3	22.3	21.5	3.7	9.5	3.3	4.3	10.4	8.5	2.0	0.9	4.3	1.0	0.4	1.7	0.5	5.4	7.8	7.9	4.8	2.2	2.6	1.5	3.8	4.9	7.2	6.5	2.8	2.3	4.3	1.1	10.6	5.1	3.8	2.3	8.5	2.7	4.2	1.4	2.6	2.7	3.5	2.1	3.4	2.8	2.9	10.4	3.0	3.2	4.6	2.4	2.8	4.3	9.2	1.6	1.5	15.4	7.9	4.3	0.4	2.0	1.1	9.8	9.6	9.7	4.0	5.4	6.1	1.5	3.8	6.4	3.5	8.6	3.3	1.3	5.9	2.4	1.5	3.2	2.6	0.4	0.7	4.3	1.2	0.8	1.4	1.1	1.1	1.5	0.5	2.0	1.3	1.7	0.2	0.4	1.0	0.9	0.0	0.5	14.2	18.3	32.7	13.1	13.4	9.3	32.8	4.2	18.4	21.5
NBPF10	AG1	ENSG00000271425	"NBPF member 10"		1	146064699-146144804	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											"HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050"	Approved		Approved	"Nucleoplasm,Nuclear bodies"				"Nuclear bodies"	Nucleoplasm	"HPA038748: , HPA042595: , HPA043105: , HPA043692: , HPA044023: , HPA046971: , HPA058050: "	"unprognostic (2.05e-1)"	"unprognostic (8.84e-2)"	"unprognostic (5.84e-2)"	"unprognostic (5.61e-3)"	"unprognostic (1.06e-1)"	"unprognostic (5.16e-3)"	"unprognostic (3.26e-1)"	"unprognostic (2.17e-1)"	"unprognostic (9.49e-2)"	"unprognostic (6.64e-5)"	"unprognostic (1.60e-1)"	"unprognostic (6.01e-2)"	"unprognostic (1.11e-3)"	"unprognostic (2.19e-1)"	"unprognostic (1.61e-1)"	"unprognostic (9.61e-2)"	"unprognostic (6.68e-2)"	1.5	0.0		0.9		3.3	2.3		0.0	3.0	0.9			0.0	1.6	1.9	1.0	1.3	0.5	0.0			0.4	1.2	1.3	0.6			3.2	1.1	1.5		0.7		1.1	1.1		0.3	1.3	0.0	4.2	0.0	1.5		2.0	0.1	1.2			0.7		0.6	0.2		1.3	2.4	3.7	1.5	0.4	0.4	0.2	5.4	1.4	3.2	2.3	11.3	13.5	2.8	3.1	4.2	3.1	3.2	1.4	2.5	2.5	0.6	6.1	2.7	3.8	4.2	6.4	2.8	2.4	5.4	3.8	0.7	4.5	2.5	1.7	12.3	4.0	8.3	8.5	3.8	1.7	7.7	6.7	6.7	1.0	2.2	1.5	4.4	1.3	2.0	3.3	2.4	3.7	0.3	0.4	4.7	4.7	1.6	3.8	3.1	11.4	3.1	2.7	2.9	3.8	4.7	1.9	3.0	2.8	2.7	2.4	0.8	1.5	1.8	0.4	1.1	0.2	1.1	0.2	0.3	0.7	1.3	0.4	0.3	3.7	0.4	1.2	2.4	0.3	0.2										
NCAM1	"CD56, NCAM"	ENSG00000149294	"Neural cell adhesion molecule 1"	P13591	11	112961247-113278436	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 110.6;heart muscle: 67.7"	"Cell line enhanced"	"Detected in some"		"HEL: 19.1;RH-30: 43.1;SCLC-21H: 35.1;SH-SY5Y: 17.2;U-138 MG: 24.0;WM-115: 25.4"	"Cancer enriched"	"Detected in many"	8	"glioma: 31.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	14	"NK-cell: 27.2"	"Lineage enriched"	"Detected in many"	14	"NK-cells: 27.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000142, CAB018071, HPA039835"	Enhanced		Enhanced	"Plasma membrane,Cytosol"	"Intracellular and membrane"	2800000000	2800000000	"Plasma membrane"	Cytosol	"CAB000142: , CAB018071: AB_627129, HPA039835: "	"unprognostic (7.04e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.77e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.74e-3)"	"unprognostic (2.82e-1)"	"unprognostic (4.42e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.63e-2)"	"prognostic favourable (9.11e-6)"	"unprognostic (8.13e-2)"	"prognostic unfavourable (8.20e-4)"	"unprognostic (2.97e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.75e-2)"	"unprognostic (5.82e-5)"	3.5	36.4	22.7	3.0	35.7	1.8	2.1	20.2	110.6	13.3	9.0	55.8	0.3	3.4	24.7	3.0	4.8	8.3	3.6	67.7	22.5	19.2	2.3	2.6	2.0	1.7	45.0	27.1	21.9	2.3	1.1	9.1	1.4	38.8	8.4	4.6	5.5	2.5	10.9	14.6	1.8	5.3	25.6	27.6	3.4	6.7	2.9	39.2	0.0	16.9	0.7	1.7	7.0	6.5	0.0	0.0	0.4	0.1	27.2	2.0	0.9	0.0	0.0	6.7	0.1	0.0	0.1	0.1	0.3	0.0	0.2	0.4	0.1	0.1	0.9	6.0	6.3	0.1	0.0	0.0	0.0	0.1	3.8	19.1	0.0	0.0	0.7	0.0	3.1	4.1	0.0	0.0	6.1	0.0	0.0	0.3	6.7	0.0	0.0	1.6	0.5	0.1	0.0	43.1	3.1	0.0	0.0	35.1	17.2	0.0	0.1	0.0	0.0	0.2	0.0	24.0	11.2	0.1	10.0	0.0	0.1	0.0	2.7	9.0	25.4	0.0	0.1	0.0	2.0	0.0	0.6	0.0	0.1	0.2	0.0	0.0	0.0	0.8	0.4	27.2	0.0	0.0	0.1	0.9	22.7	35.7	20.2	41.6	22.5	19.2	45.0	27.1	38.8	39.2
NCOA1	"bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1"	ENSG00000084676	"Nuclear receptor coactivator 1"	Q15788	2	24491914-24770702	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RH-30: 40.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019402, HPA070213, HPA070520"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"				Nucleoplasm	"Plasma membrane, Cytosol"	"CAB019402: AB_2196189, HPA070213: , HPA070520: "	"unprognostic (2.73e-1)"	"unprognostic (5.82e-2)"	"unprognostic (2.46e-2)"	"unprognostic (9.89e-3)"	"unprognostic (7.60e-2)"	"unprognostic (2.36e-2)"	"unprognostic (7.06e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.93e-3)"	"unprognostic (1.16e-1)"	"unprognostic (2.10e-2)"	"unprognostic (7.15e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.92e-2)"	9.8	10.0	15.3	7.3	18.0	8.9	10.5	15.9	17.1	13.7	8.9	13.5	4.9	12.5	13.0	11.5	10.8	10.0	8.3	8.8	20.8	12.2	11.9	8.8	9.4	8.2	10.8	9.9	17.2	10.3	23.9	16.0	10.1	14.2	9.6	10.1	19.9	10.6	13.0	42.5	9.3	10.9	11.6	9.7	9.6	7.6	11.4	10.7	8.5	7.0	12.2	9.3	9.7	10.8	2.5	5.5	14.2	3.5	3.4	4.1	1.8	6.6	4.9	8.7	4.5	9.6	8.8	13.3	3.5	7.1	4.5	4.0	4.6	2.8	4.8	1.5	6.4	1.6	5.2	3.0	4.9	22.8	7.5	17.2	2.0	1.9	6.0	7.9	14.4	14.0	4.6	4.3	3.5	4.5	10.4	8.0	6.8	4.4	7.0	2.8	4.1	3.3	5.5	40.1	2.4	4.9	9.0	8.0	6.3	8.2	5.0	3.6	6.0	4.0	4.9	7.5	5.9	5.1	3.5	9.3	8.0	8.4	4.3	5.0	3.7	11.0	3.5	6.9	3.8	2.7	4.1	1.8	3.4	4.1	2.6	2.5	3.3	4.0	14.2	3.4	2.8	5.5	3.7	1.8	15.3	18.0	15.9	17.1	20.8	12.2	10.8	9.9	14.2	10.7
NCOA2	"bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2"	ENSG00000140396	"Nuclear receptor coactivator 2"	Q15596	8	70109762-70403805	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA060243			Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA060243: "	"unprognostic (9.79e-3)"	"unprognostic (1.40e-1)"	"unprognostic (2.72e-1)"	"unprognostic (4.94e-3)"	"unprognostic (1.91e-2)"	"unprognostic (2.18e-3)"	"unprognostic (1.30e-1)"	"unprognostic (6.77e-2)"	"unprognostic (2.06e-1)"	"unprognostic (7.00e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.63e-2)"	"prognostic favourable (5.08e-4)"	"unprognostic (2.52e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.76e-1)"	13.6	13.2	16.9	13.1	14.0	22.5	14.9	19.2	14.0	13.9	17.3	10.1	49.7	12.4	16.6	33.6	20.0	12.5	12.6	15.8	13.9	13.0	16.4	25.5	15.5	16.9	10.8	11.4	18.5	9.7	23.4	17.1	16.2	10.0	14.8	11.8	15.3	14.8	21.7	13.2	14.9	28.8	19.2	9.6	14.5	11.7	15.5	12.9	15.3	13.4	10.3	13.8	18.9	17.2	3.8	2.5	9.4	7.8	2.1	3.8	1.6	8.6	10.8	11.9	6.7	10.8	11.2	12.2	5.0	5.0	3.8	3.7	5.5	10.0	10.2	2.0	9.1	5.1	14.6	6.9	4.3	24.2	11.6	17.9	5.5	8.7	5.7	3.6	4.8	9.7	7.7	5.2	7.5	2.6	5.6	15.7	4.4	8.6	8.9	3.6	6.2	5.1	8.8	5.0	6.4	6.1	14.4	9.1	6.7	8.6	4.6	7.1	10.9	6.6	3.4	5.6	7.1	7.0	2.6	20.7	10.5	10.0	5.7	4.8	8.1	4.5	2.5	3.5	3.8	3.9	2.8	2.2	2.3	3.3	2.5	3.8	2.8	2.7	9.4	2.1	7.8	1.1	3.2	1.6	16.9	14.0	19.2	13.5	13.9	13.0	10.8	11.4	10.0	12.9
NCOA3	"ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1"	ENSG00000124151	"Nuclear receptor coactivator 3"	Q9Y6Q9	20	47501902-47656877	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 62.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009800, HPA024210"	Supported		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB009800: AB_2251314, HPA024210: AB_10602011"	"unprognostic (7.26e-3)"	"unprognostic (1.00e-1)"	"unprognostic (2.69e-1)"	"unprognostic (3.23e-2)"	"unprognostic (5.78e-2)"	"unprognostic (4.33e-2)"	"prognostic unfavourable (8.09e-4)"	"unprognostic (2.83e-2)"	"unprognostic (1.47e-1)"	"unprognostic (5.22e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.04e-2)"	"unprognostic (4.18e-1)"	"unprognostic (1.63e-1)"	20.1	8.9	6.6	34.0	7.4	11.1	15.7	11.9	9.9	12.3	10.1	8.1	9.0	6.7	15.5	8.8	16.7	12.0	8.6	11.5	6.7	4.8	9.1	9.3	17.4	25.8	7.9	4.7	13.3	10.7	13.5	13.5	54.7	7.9	9.7	9.0	10.8	13.5	10.0	32.5	15.0	17.1	11.3	9.5	30.8	11.4	9.2	7.2	17.6	13.5	10.5	33.3	15.1	17.7	13.0	6.7	6.0	7.3	2.7	4.0	3.5	5.7	18.8	5.3	7.2	12.5	14.7	37.3	5.6	8.4	9.6	5.1	9.0	6.4	20.1	3.7	9.6	14.2	4.1	6.9	7.3	10.6	2.2	2.7	5.3	12.5	7.4	2.1	15.0	6.7	19.8	9.1	10.6	6.8	6.2	4.7	5.3	62.6	3.2	3.7	1.8	7.2	6.0	3.7	8.6	5.3	13.6	1.0	1.9	14.1	17.6	6.0	8.1	5.5	11.8	5.7	5.0	6.9	2.4	12.9	11.8	20.7	6.6	2.2	3.8	3.4	5.2	4.0	3.5	7.3	3.2	13.0	3.2	3.1	6.7	10.0	3.7	4.0	6.0	2.7	7.0	5.5	4.0	3.5	6.6	7.4	11.9	9.9	6.7	4.8	7.9	4.7	7.9	7.2
NCOA4	"ARA70, DKFZp762E1112, ELE1, PTC3, RFG"	ENSG00000266412	"Nuclear receptor coactivator 4"	Q13772	10	46005088-46030714	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 100.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"dendritic cells: 30.2;granulocytes: 100.1;monocytes: 40.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA051260, HPA065208"	Uncertain		Approved	"Nucleoli,Golgi apparatus,Cytosol"				Nucleoli	"Golgi apparatus, Cytosol"	"HPA051260: , HPA065208: "	"unprognostic (4.23e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.44e-2)"	"unprognostic (1.82e-1)"	"prognostic favourable (3.26e-4)"	"unprognostic (1.34e-1)"	"unprognostic (1.80e-1)"	"unprognostic (9.34e-2)"	"unprognostic (4.67e-2)"	"unprognostic (5.22e-2)"	"unprognostic (9.16e-2)"	"unprognostic (2.04e-2)"	"prognostic favourable (8.04e-6)"	"unprognostic (1.35e-1)"	"unprognostic (4.71e-3)"	"unprognostic (1.14e-1)"	"unprognostic (2.78e-1)"	18.5	6.9	5.5	9.5	10.0	17.4	10.0	5.5	11.3	10.8	22.5	13.6	5.9	27.0	9.9	9.4	17.0	6.3	9.0	16.6	5.7		20.8	40.9	11.6	11.6	8.7	7.1	11.0	9.1	9.3	9.6	28.4	13.5	14.7	12.4	9.9	12.6	8.5	15.5	6.8	36.4	11.2	9.7	23.8	8.9	6.4	8.1	26.8	13.2	13.9	16.3	13.0	6.4	7.3	30.2	100.1	40.4	13.4	10.9	53.9	31.3	13.3	15.6	16.0	41.4	37.6	39.1	28.8	46.7	28.5	27.9	20.4	23.2	35.4	34.7	47.1	32.0	16.3	31.7	31.7	25.0	16.8	23.9	18.3	58.5	29.1	60.8	53.4	36.5	31.8	24.2	40.7	41.8	26.0	21.4	38.7	14.0	29.5	22.8	9.4	7.8	17.5	22.7	21.2	34.1	26.7	15.7	10.6	29.1	33.3	28.8	24.0	29.9	38.5	17.6	21.2	18.6	19.4	15.9	17.0	35.2	22.0	51.2	9.3	69.1	40.4	70.7	10.0	26.8	10.9	7.3	9.4	9.5	30.2	6.6	10.2	8.6	100.1	13.4	30.4	9.3	10.8	53.9										
NCOR1	"hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1"	ENSG00000141027	"Nuclear receptor corepressor 1"	O75376	17	16029157-16218185	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043246, HPA050288, HPA051168, CAB072830"	Supported		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB072830: , HPA043246: , HPA050288: , HPA051168: "	"unprognostic (1.83e-1)"	"unprognostic (3.05e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.38e-2)"	"unprognostic (3.59e-2)"	"unprognostic (2.55e-2)"	"unprognostic (4.27e-2)"	"unprognostic (4.87e-2)"	"unprognostic (4.06e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.52e-2)"	"prognostic favourable (7.92e-5)"	"unprognostic (4.40e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.33e-1)"	"unprognostic (5.42e-2)"	19.6	21.2	25.4	24.0	30.8	27.0	25.0	41.8	31.5	24.0	30.6	19.6	18.6	33.2	29.0	19.5	25.0	20.5	21.9	17.8	22.4	17.8	25.6	33.8	20.1	19.5	25.1	19.1	25.9	24.3	39.9	39.8	19.8	21.6	20.8	29.7	17.1	20.9	29.1	43.0	23.8	36.9	29.7	26.4	23.7	29.8	22.1	26.4	38.8	25.3	15.7	23.8	29.6	27.0	43.4	29.9	78.2	24.8	30.4	35.5	19.7	23.8	39.9	28.5	23.7	23.5	17.9	14.2	17.6	19.9	19.4	17.6	21.3	10.9	25.1	12.4	30.7	18.3	35.0	21.3	28.8	33.4	25.9	25.0	34.5	25.0	23.0	15.6	29.8	18.3	22.4	30.0	35.2	26.9	21.8	10.4	19.0	15.5	27.5	10.1	14.1	10.9	27.5	28.9	11.7	20.1	27.1	9.7	16.2	29.1	12.7	13.8	12.2	17.9	23.4	20.0	11.8	14.6	24.2	7.2	8.3	14.7	19.0	18.6	17.1	78.2	24.8	52.2	31.3	19.5	25.9	40.7	35.5	34.1	17.5	43.4	34.7	34.8	48.5	30.4	24.0	29.9	31.7	19.7	25.4	30.8	41.8	31.5	22.4	17.8	25.1	19.1	21.6	26.4
NCOR2	"CTG26, SMRT, SMRTE, TNRC14, TRAC-1"	ENSG00000196498	"Nuclear receptor corepressor 2"	Q9Y618	12	124324415-124567589	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 8.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001928	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA001928: AB_1079454"	"unprognostic (9.51e-3)"	"unprognostic (7.37e-3)"	"unprognostic (4.66e-2)"	"unprognostic (2.55e-3)"	"unprognostic (2.14e-1)"	"unprognostic (7.37e-2)"	"unprognostic (3.19e-2)"	"unprognostic (8.86e-2)"	"unprognostic (2.21e-2)"	"unprognostic (2.90e-3)"	"unprognostic (6.42e-3)"	"unprognostic (1.96e-1)"	"unprognostic (9.86e-2)"	"unprognostic (6.26e-2)"	"unprognostic (1.59e-1)"	"unprognostic (7.56e-2)"	"unprognostic (8.90e-2)"	24.0	22.0	21.3	21.3	19.0	16.8	18.3	33.8	33.5	24.5	17.2	24.3	17.7	16.4	21.3	19.0	15.7	16.3	21.5	18.2	22.0	14.8	16.0	11.2	23.4	11.9	19.0	15.6	28.6	30.0	13.8	39.5	13.2	28.3	21.3	7.6	32.7	29.2	24.5	62.4	22.8	22.2	17.4	12.2	17.4	24.0	10.8	22.0	9.3	16.7	25.0	7.6	16.3	14.7	0.6	1.7	8.1	4.0	0.2	1.9	0.4	19.4	36.7	10.5	10.0	6.1	8.3	31.4	20.2	10.1	11.8	5.3	19.5	14.4	19.8	15.0	16.4	18.5	4.1	21.5	4.8	20.8	8.1	15.9	34.6	11.8	12.3	11.9	20.2	13.3	8.1	14.7	8.8	11.2	20.4	5.9	10.5	16.8	42.9	13.8	14.6	35.8	13.9	17.5	10.0	5.6	22.8	27.7	20.2	24.8	21.0	12.7	17.1	15.1	53.9	27.5	47.6	27.1	42.9	11.3	11.4	12.1	15.6	8.9	25.7	8.1	0.7	1.6	1.9	0.4	0.5	0.6	0.5	1.5	0.3	0.4	0.6	0.5	1.6	0.2	4.0	1.7	0.0	0.4	21.3	19.0	33.8	28.4	22.0	14.8	19.0	15.6	28.3	22.0
NDRG1	"CAP43, DRG1, NDR1, RTP, TDD5"	ENSG00000104419	"N-myc downstream regulated 1"	Q92597	8	133237171-133302022	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Charcot-Marie-Tooth disease, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 69.0;hTERT-HME1: 139.1;U-87 MG: 93.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006881	Approved		Supported	Microtubules,Cytosol				Cytosol	Microtubules	"HPA006881: AB_1078392"	"unprognostic (6.96e-3)"	"unprognostic (3.31e-3)"	"unprognostic (8.53e-2)"	"unprognostic (1.41e-3)"	"unprognostic (1.54e-3)"	"unprognostic (2.60e-2)"	"prognostic unfavourable (1.47e-4)"	"unprognostic (3.04e-3)"	"unprognostic (5.33e-2)"	"unprognostic (4.29e-2)"	"unprognostic (9.09e-2)"	"unprognostic (2.46e-1)"	"prognostic unfavourable (4.13e-4)"	"unprognostic (7.27e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.47e-3)"	"unprognostic (4.28e-2)"	43.9	23.6	42.0	17.0	80.9	18.0	29.8	6.4	36.2	33.1	47.7	73.2	24.2	74.2	20.9	20.6	83.0	24.7	26.8	22.2	48.7	32.9	62.6	12.1	31.0	11.4	96.3	19.8	37.5	16.7	17.8	18.6	32.5	50.0	115.0	22.4	16.2	29.0	26.4	13.2	56.9	78.2	19.2	102.0	11.5	45.7	15.0	74.3	10.3	21.4	40.0	34.9	58.7	64.9	1.9	12.2	8.9	4.1	1.3	9.3	2.9	21.5	2.7	0.1	0.1	13.7	9.6	2.9	1.5	11.8	1.1	6.1	1.3	3.0	0.1	15.5	6.4	7.0	0.2	34.0	2.4	1.3	25.5	0.2	5.5	1.6	5.2	0.7	0.5	8.9	69.0	5.8	139.1	5.1	0.2	15.1	1.9	1.2	2.0	2.1	0.3	17.9	0.2	2.4	10.0	3.5	3.2	1.6	1.6	3.3	35.7	8.6	0.1	2.3	6.6	9.7	5.0	4.2	1.2	11.3	29.6	0.1	93.6	8.1	19.0	8.9	4.1	0.0	6.3	3.7	9.3	1.7	5.9	7.5	6.1	1.9	4.6	3.1	4.2	1.3	4.0	12.2	8.0	2.9	42.0	80.9	6.4	36.2	48.7	32.9	96.3	19.8	50.0	74.3
NEB	"NEB177D, NEM2"	ENSG00000183091	Nebulin	P20929	2	151485336-151734487	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes, Nemaline myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"skeletal muscle: 505.8"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 6.7;RH-30: 26.6;U-266/70: 10.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 3.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"cerebellum: 7.4;olfactory region: 4.9"	"Region enriched"	"Detected in some"	7	"cerebellum: 25.3"	HPA016601	Enhanced									"HPA016601: AB_1854361"	"unprognostic (2.40e-2)"	"unprognostic (6.71e-2)"	"unprognostic (2.13e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.85e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.07e-1)"	"unprognostic (4.45e-13)"	"unprognostic (6.80e-2)"	"unprognostic (2.22e-2)"	"unprognostic (4.07e-3)"	"unprognostic (4.06e-2)"	9.6	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	5.2	4.0	0.0	0.8	1.5	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.3	0.0	0.0	3.8	0.0	505.8	0.3	0.0	0.0	0.1	0.1	0.0	0.3	0.0	0.0	3.0	65.9	2.6	0.1	0.0	1.3	0.5	1.7	0.6	0.8	0.9	0.3	0.3	0.3	0.6	0.5	0.1	0.1	1.7	0.3	0.0	0.0	0.0	4.6	0.5	1.2	0.9	0.1	0.9	0.1	0.0	0.0	0.6	0.7	0.4	0.6	1.5	0.0	0.8	1.1	4.0	0.2	0.0	0.0	0.6	0.9	6.7	0.4	0.5	0.4	0.7	1.1	0.8	1.1	26.6	0.1	0.0	0.9	1.5	0.2	0.2	0.3	0.1	0.7	0.8	0.6	0.7	0.9	0.1	0.9	10.0	1.4	0.3	0.1	0.6	1.1	1.2	0.6	1.7	0.9	0.0	0.9	1.2	0.8	0.5	0.0	1.3	0.3	0.4	1.1	0.8	0.0	0.5	0.4	0.3	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.0	0.0
NEDD4L	"KIAA0439, NEDD4-2, RSP5"	ENSG00000049759	"Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase"	Q96PU5	18	58044367-58401540	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Differentiation, Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Hep G2: 50.1;SK-MEL-30: 39.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 8.1"	"Group enriched"	"Detected in many"	4	"granulocytes: 4.7;T-cells: 8.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA024618	Approved									"HPA024618: AB_1854362"	"unprognostic (2.56e-1)"	"unprognostic (2.41e-2)"	"unprognostic (1.58e-2)"	"unprognostic (3.14e-1)"	"unprognostic (3.90e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.11e-3)"	"unprognostic (2.26e-2)"	"unprognostic (9.24e-3)"	"unprognostic (4.39e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.27e-1)"	"prognostic favourable (6.55e-15)"	"unprognostic (2.42e-1)"	"unprognostic (8.26e-2)"	"unprognostic (8.49e-3)"	"unprognostic (4.75e-2)"	5.9	6.8	9.1	5.4	38.8	13.2	15.8	21.4	24.7	5.0	22.6	3.2	18.2	11.1	3.6	6.1	7.0	6.0	7.6	12.7	9.8	7.1	29.9	10.1	26.9	2.5	7.2	14.9	3.0	33.2	9.2	16.5	13.0	4.1	30.6	25.2	12.2	16.5	23.2	38.3	5.9	26.8	8.2	3.2	3.1	26.0	4.6	8.8	0.8	9.1	5.5	5.1	14.9	9.3	1.4	0.4	4.7	0.7	0.9	8.1	0.5	18.4	6.6	3.9	5.8	1.4	0.5	13.6	5.2	23.7	13.4	20.5	7.7	10.0	3.9	16.1	2.0	13.4	5.2	23.1	27.7	9.2	4.6	2.8	4.1	50.1	0.7	0.1	1.7	3.5	15.1	18.1	22.0	1.0	4.8	1.7	5.5	4.5	0.2	0.2	3.4	10.2	3.8	5.3	4.5	13.3	24.1	4.9	1.3	4.3	1.3	39.1	7.9	1.6	7.9	36.2	10.9	2.0	22.3	2.3	3.9	2.4	7.4	2.8	2.9	4.7	0.6	1.7	0.4	0.7	1.0	1.4	1.3	0.3	0.3	0.6	0.8	0.6	0.3	0.9	0.1	0.4	8.1	0.5	9.1	38.8	21.4	24.7	9.8	7.1	7.2	14.9	4.1	8.8
NEDD8	Nedd-8	ENSG00000129559	"Neural precursor cell expressed, developmentally down-regulated 8"	Q15843	14	24216852-24232454	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004082, HPA027583, HPA060254"	Uncertain		Enhanced	Nucleoplasm,Cytosol		5700000	5700000	Nucleoplasm	Cytosol	"CAB004082: AB_10695300, HPA027583: , HPA060254: "	"unprognostic (1.26e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.34e-3)"	"unprognostic (1.83e-3)"	"unprognostic (9.19e-2)"	"unprognostic (4.66e-1)"	"unprognostic (1.35e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.78e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.79e-2)"	"unprognostic (5.25e-3)"	38.2	48.1	55.5	30.7	58.1	34.6	42.2	34.1	62.4	41.0	36.3	26.8	32.6	25.0	32.2	59.9	40.3	34.3	31.3	50.7	47.1	49.5	46.5	48.4	30.5	31.5	49.4	54.6	34.3	33.4	101.1	31.3	39.7	45.5	31.6	40.0	27.4	37.2	40.7	70.7	36.5	28.4	43.0	36.0	34.9	29.9	25.7	34.3	26.9	37.5	44.7	46.8	30.7	32.0	60.2	76.1	90.2	60.1	43.2	64.1	89.9	25.5	44.8	36.5	25.7	41.4	36.2	26.5	35.0	37.1	41.2	38.1	30.9	31.3	22.1	20.5	49.2	27.0	36.3	54.6	58.0	31.2	22.0	23.6	41.3	105.3	36.0	39.0	24.7	38.4	36.3	34.7	27.3	49.2	21.0	25.9	63.5	56.9	31.0	37.0	26.9	52.5	22.1	28.9	22.5	47.5	48.7	15.4	35.9	30.2	30.8	25.1	18.6	31.0	36.8	23.5	23.6	30.0	30.9	30.8	46.4	32.0	16.8	22.5	22.2	73.5	57.9	90.2	46.8	60.1	50.7	60.2	54.4	51.9	56.9	51.1	51.2	52.0	62.2	43.2	59.0	76.1	64.1	89.9	55.5	58.1	34.1	62.4	47.1	49.5	49.4	54.6	45.5	34.3
NEO1	"HsT17534, IGDCC2, NGN, NTN1R2"	ENSG00000067141	"Neogenin 1"	Q92859	15	73051710-73305206	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 3.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009320, HPA027804, HPA027805, HPA027806"	Uncertain		Approved	"Nucleoplasm,Golgi apparatus,Plasma membrane"		280000000	280000000	"Nucleoplasm, Plasma membrane"	"Golgi apparatus"	"CAB009320: AB_2150998, HPA027804: AB_10600771, HPA027805: AB_10601755, HPA027806: AB_10601006"	"unprognostic (1.90e-1)"	"unprognostic (2.38e-2)"	"unprognostic (7.60e-3)"	"unprognostic (3.76e-2)"	"unprognostic (5.44e-1)"	"unprognostic (3.83e-2)"	"unprognostic (8.30e-2)"	"unprognostic (2.31e-1)"	"unprognostic (3.22e-1)"	"unprognostic (3.30e-2)"	"unprognostic (5.51e-2)"	"unprognostic (8.05e-2)"	"prognostic favourable (4.39e-4)"	"unprognostic (1.51e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.33e-2)"	"unprognostic (3.75e-1)"	7.3	5.8	19.2	6.2	22.4	1.2	11.4	12.7	23.9	13.4	30.0	44.5	14.8	17.9	14.2	7.2	8.0	15.4	13.4	6.8	20.1	14.1	16.2	5.9	10.7	2.7	27.1	15.7	17.5	11.5	44.4	6.9	1.5	19.3	23.1	36.9	16.0	11.5	25.5	17.9	24.6	19.0	16.0	22.3	3.6	15.1	9.0	22.5	2.1	12.5	3.8	4.7	10.1	9.5	0.0	0.3	1.4	0.3	0.8	3.1	0.3	3.7	18.2	21.8	14.4	13.2	3.9	5.4	1.4	1.7	3.6	0.7	2.7	18.4	1.0	2.1	4.0	0.8	15.2	8.3	1.5	6.6	11.2	12.2	0.2	2.5	3.8	0.3	0.4	9.5	15.5	0.7	7.1	0.0	0.0	23.4	0.8	11.2	4.3	0.2	20.8	1.5	10.0	11.7	2.4	6.9	10.0	9.9	14.0	17.1	7.6	9.0	8.0	2.2	0.0	16.8	9.0	5.4	3.9	10.0	18.5	2.6	3.6	3.5	4.7	0.0	0.3	0.4	1.8	0.0	3.1	0.0	1.1	1.4	0.0	0.0	0.6	0.5	1.4	0.8	0.0	0.3	0.0	0.3	19.2	22.4	12.7	23.9	20.1	14.1	27.1	15.7	19.3	22.5
NF1		ENSG00000196712	"Neurofibromin 1"	P21359	17	31094927-31382116	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"B-cells: 2.3;granulocytes: 6.5;T-cells: 8.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA045502	Uncertain		Approved	Mitochondria				Mitochondria		"HPA045502: "	"unprognostic (6.69e-2)"	"unprognostic (8.73e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.30e-2)"	"unprognostic (3.14e-2)"	"unprognostic (3.88e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.40e-1)"	"unprognostic (3.70e-1)"	12.9	15.9	22.6	13.3	25.9	5.5	18.5	30.2	26.0	17.6	13.6	19.8	12.2	11.0	16.9	17.0	10.5	15.2	13.1	17.3	21.6	19.6	20.0	15.1	12.7	11.5	19.4	25.6	22.9	16.5	34.1	19.0	19.4	20.9	16.1	14.7	12.1	14.4	20.5	14.8	12.0	12.1	14.5	21.4	11.9	13.0	15.4	21.5	11.6	31.1	7.6	12.4	15.3	19.5	2.3	0.7	6.5	0.4	0.9	8.4	1.0	9.7	12.7	15.5	8.3	13.2	17.2	7.8	8.4	15.3	12.5	14.2	11.4	6.6	9.4	2.4	15.8	17.1	14.0	11.9	21.3	4.5	8.8	8.3	12.0	5.8	9.4	14.8	6.9	13.6	7.6	13.3	16.3	6.0	11.9	9.4	11.9	7.7	12.3	5.4	4.5	4.2	9.7	23.7	7.5	9.5	14.0	6.4	9.6	15.7	5.3	8.7	16.0	9.5	8.8	10.0	14.0	11.8	3.2	8.5	4.1	10.4	8.2	6.3	10.4	6.5	0.4	0.9	2.3	0.2	1.6	2.3	4.4	3.9	0.5	2.1	3.3	3.2	1.0	0.9	0.4	0.7	8.4	1.0	22.6	25.9	30.2	23.5	21.6	19.6	19.4	25.6	20.9	21.5
NF2	"ACN, BANF, merlin, SCH"	ENSG00000186575	"Neurofibromin 2"	P35240	22	29603556-29698598	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Deafness, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003097, CAB005385"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane"	"Nucleoplasm, Cytosol"	"CAB005385: AB_2298548, HPA003097: AB_1079473"	"unprognostic (3.27e-1)"	"unprognostic (1.34e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.62e-1)"	"unprognostic (5.76e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.16e-2)"	"unprognostic (2.01e-3)"	"unprognostic (4.66e-1)"	"prognostic favourable (2.89e-5)"	"unprognostic (7.73e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.24e-1)"	"unprognostic (9.62e-2)"	11.8	12.4	23.6	11.1	20.1	10.0	15.4	20.8	28.1	10.8	9.7	9.0	11.8	7.8	10.5	11.3	14.2	11.3	8.0	19.7	26.6	16.4	13.5	11.1	11.9	24.1	18.0	13.5	11.0	12.9	46.8	8.6	6.9	11.4	10.2	8.7	9.5	9.3	15.4	25.7	12.1	8.5	11.9	10.7	10.4	8.8	21.6	10.1	14.9	15.6	11.5	9.9	10.6	10.2	8.5	13.6	6.6	17.3	11.6	15.0	9.8	26.3	10.6	3.7	24.3	7.3	7.3	3.6	21.4	12.1	23.5	20.3	10.5	6.5	7.0	17.8	22.0	9.3	7.7	12.4	21.1	10.2	6.1	8.3	7.9	7.5	7.8	11.9	9.9	6.7	5.7	16.6	20.3	16.5	4.0	6.5	22.8	11.0	7.2	4.7	2.8	10.1	7.5	20.0	6.7	23.8	12.3	5.8	4.0	12.3	8.3	4.8	5.3	4.8	30.6	35.0	39.9	15.2	36.1	10.2	8.1	8.4	9.3	4.7	22.3	6.6	9.5	3.6	15.0	13.5	12.8	8.2	11.3	10.1	13.6	8.5	9.8	9.2	2.3	11.6	17.3	9.3	9.4	9.8	23.6	20.1	20.8	28.1	26.6	16.4	18.0	13.5	11.4	10.1
NFATC2	"NF-ATP, NFAT1, NFATp"	ENSG00000101096	"Nuclear factor of activated T cells 2"	Q13469	20	51386957-51562831	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 44.6"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 14.2;HMC-1: 16.3;WM-115: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA008789, CAB018567, HPA024369"	Enhanced		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB018567: AB_628012, HPA008789: AB_1079474, HPA024369: AB_1854413"	"unprognostic (2.69e-3)"	"unprognostic (2.92e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.26e-2)"	"unprognostic (3.94e-2)"	"unprognostic (4.05e-2)"	"unprognostic (9.26e-2)"	"unprognostic (3.74e-3)"	"unprognostic (2.17e-2)"	"unprognostic (4.86e-2)"	"prognostic unfavourable (1.57e-4)"	"unprognostic (9.25e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.59e-2)"	8.6	2.4	4.1	44.6	8.2	4.4	9.8	1.1	5.1	8.4	7.8	6.8	3.9	8.4	7.0	7.6	4.0	5.6	19.4	8.5	4.1	3.3	3.4	6.7	6.1	25.2	8.4	0.7	5.0	8.7	3.9	3.7	8.1	10.4	5.4	4.1	6.2	7.9	7.2	5.4	7.0	11.7	5.9	6.5	16.0	11.0	4.5	6.5	8.6	7.0	13.2	18.7	4.5	4.9	1.6	1.7	3.8	0.7	7.6	7.7	1.6	1.5	1.7	0.0	2.1	0.0	0.0	4.5	0.2	1.1	0.7	0.3	8.2	1.5	10.9	1.3	0.5	0.0	0.5	0.0	0.6	14.2	0.2	4.6	1.2	2.1	0.0	1.3	16.3	0.0	0.0	0.6	0.0	5.0	4.5	7.3	0.0	1.8	1.9	7.7	0.1	3.9	0.8	0.0	4.8	0.2	0.0	0.1	0.0	5.1	1.2	11.9	2.0	3.1	0.5	1.0	1.9	2.5	0.1	6.2	4.0	11.2	1.0	5.1	24.5	0.3	0.0	3.8	7.7	0.7	3.2	1.6	4.3	6.1	1.7	1.6	2.4	4.4	0.2	7.6	0.2	0.6	2.3	1.6	4.1	8.2	1.1	5.1	4.1	3.3	8.4	0.7	10.4	6.5
NFE2L2	NRF2	ENSG00000116044	"Nuclear factor, erythroid 2 like 2"	Q16236	2	177227595-177392697	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002990, CAB020317, HPA043438"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Plasma membrane"	Cytosol	"CAB020317: , HPA002990: AB_1079476, HPA043438: "	"unprognostic (2.11e-1)"	"unprognostic (3.12e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.95e-2)"	"unprognostic (3.90e-1)"	"unprognostic (5.27e-2)"	"unprognostic (9.58e-2)"	"unprognostic (3.48e-2)"	"unprognostic (9.86e-2)"	"unprognostic (4.86e-2)"	"unprognostic (1.83e-1)"	"prognostic favourable (2.26e-4)"	"unprognostic (1.97e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.26e-1)"	"unprognostic (9.77e-3)"	30.9	24.4	25.4	19.3	34.7	15.0	24.6	36.4	29.7	31.7	28.3	25.8	22.2	28.1	27.7	30.9	82.5	27.0	28.9	32.3	28.0	16.9	44.8	49.3	29.0	19.7	49.0	18.7	53.1	16.3	21.7	52.5	29.4	33.5	39.0	25.4	21.7	34.7	28.1	25.9	48.1	29.2	42.1	42.7	26.8	45.9	21.9	41.6	21.1	49.5	35.8	25.5	43.7	47.1	23.5	41.1	42.4	35.6	25.8	43.2	22.6	10.9	12.7	11.5	12.4	39.0	42.1	13.2	18.7	26.1	17.1	19.4	16.8	21.0	10.8	20.4	21.2	20.4	13.5	28.6	24.0	8.4	8.2	13.9	22.3	32.6	49.9	8.2	13.2	28.9	67.3	24.3	36.2	16.9	14.5	21.3	23.5	10.9	8.4	21.8	12.6	11.9	6.9	10.1	10.9	26.1	41.4	15.1	9.8	42.5	13.7	44.4	10.6	22.3	25.5	17.8	11.8	19.7	11.5	15.0	9.0	9.1	17.8	9.2	34.0	42.4	35.6	21.4	23.0	34.1	26.6	23.5	26.9	23.6	41.1	19.9	43.2	28.2	39.9	25.8	31.9	15.5	25.0	22.6	25.4	34.7	36.4	29.7	28.0	16.9	49.0	18.7	33.5	41.6
NFIB	"NFI-RED, NFIB2, NFIB3"	ENSG00000147862	"Nuclear factor I B"	O00712	9	14081843-14398983	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"DNA replication, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 53.9;HBEC3-KT: 21.8;HUVEC TERT2: 21.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003956	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"				"Nucleoplasm, Nucleoli fibrillar center"		"HPA003956: AB_1854424"	"unprognostic (1.93e-1)"	"unprognostic (3.18e-2)"	"unprognostic (4.00e-1)"	"unprognostic (2.16e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.55e-2)"	"unprognostic (1.32e-1)"	"unprognostic (4.72e-3)"	"unprognostic (7.46e-2)"	"unprognostic (9.35e-2)"	"unprognostic (3.68e-1)"	"unprognostic (1.12e-1)"	"prognostic favourable (3.53e-4)"	"unprognostic (4.69e-1)"	"unprognostic (2.39e-1)"	"unprognostic (1.87e-2)"	"unprognostic (1.62e-1)"	29.3	9.5	22.6	9.2	12.9	1.0	39.7	30.0	22.9	14.8	17.0	13.6	34.1	11.3	16.8	22.3	11.5	17.0	18.0	24.1	22.0	9.3	18.8	22.3	16.3	9.8	10.8	15.5	18.7	17.5	8.2	6.0	14.7	13.7	21.3	10.4	9.2	40.0	41.3	20.8	23.6	16.8	24.2	14.9	10.4	14.2	7.6	15.6	2.7	18.8	13.9	7.7	27.4	23.4	0.3	0.3	2.4	0.4	0.5	1.0	1.3	6.3	4.5	2.8	53.9	13.6	7.9	0.1	0.1	0.0	1.3	4.7	0.0	2.6	0.1	4.2	0.4	1.4	2.6	21.8	2.3	0.9	2.6	19.4	10.1	0.6	4.5	0.5	0.1	6.8	3.0	4.9	18.1	21.8	0.6	0.1	1.8	2.9	0.0	0.1	1.0	5.3	0.0	2.5	0.0	4.0	2.3	4.5	16.8	4.6	5.7	1.8	11.5	0.0	21.2	4.2	6.3	3.2	4.0	0.5	0.4	1.5	3.7	0.0	5.3	1.3	0.1	0.2	0.3	0.2	1.0	0.2	0.2	0.2	0.1	0.3	0.2	0.1	2.4	0.5	0.4	0.3	0.5	1.3	22.6	12.9	30.0	18.8	22.0	9.3	10.8	15.5	13.7	15.6
NFKB1	"KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50"	ENSG00000109320	"Nuclear factor kappa B subunit 1"	P19838	4	102501329-102617302	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004031, HPA027305"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB004031: AB_330564, HPA027305: AB_1854429"	"unprognostic (1.06e-1)"	"unprognostic (1.61e-2)"	"unprognostic (4.37e-2)"	"unprognostic (2.38e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.04e-2)"	"unprognostic (8.98e-2)"	"unprognostic (1.96e-1)"	"unprognostic (9.03e-3)"	"unprognostic (2.28e-1)"	"unprognostic (2.71e-1)"	"prognostic favourable (1.76e-4)"	"unprognostic (1.84e-2)"	"unprognostic (6.75e-3)"	"unprognostic (1.74e-1)"	"unprognostic (6.92e-3)"	19.8	14.7	8.2	37.7	12.0	44.5	26.6	12.4	10.3	18.2	17.1	10.4	10.4	10.7	17.5	11.2	20.5	16.4	20.3	14.5	7.5	5.1	13.2	15.8	26.9	46.0	11.4	4.8	17.5	14.3	10.2	8.7	13.7	10.0	18.8	14.6	10.8	17.7	13.5	17.1	19.6	16.7	16.0	10.1	30.0	14.6	9.3	12.5	37.5	14.7	16.3	26.7	18.4	22.7	5.8	10.4	5.5	7.1	14.3	10.6	3.5	16.9	9.5	5.1	7.8	16.0	14.4	6.3	9.7	28.8	12.1	12.4	10.5	24.3	27.7	8.8	15.3	13.5	10.2	17.0	16.7	25.0	6.0	11.8	7.7	11.3	15.0	21.0	25.1	11.9	12.0	11.8	16.4	15.2	11.4	20.4	8.7	11.9	1.8	11.5	3.1	8.8	14.8	12.2	12.5	11.3	23.9	3.5	5.8	17.9	25.0	9.8	5.1	15.7	19.4	16.5	8.6	8.9	13.6	9.0	6.2	26.9	10.5	10.8	23.3	5.2	5.4	4.9	3.4	7.1	6.0	5.6	8.4	5.6	10.4	5.8	10.6	8.9	5.5	14.3	5.9	7.4	4.5	3.5	8.2	12.0	12.4	10.3	7.5	5.1	11.4	4.8	10.0	12.5
NFKB2	"LYT-10, NF-kB2, p105, p49/p100, p52"	ENSG00000077150	"Nuclear factor kappa B subunit 2"	Q00653	10	102394110-102402529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 49.5;Karpas-707: 54.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008422, CAB022098, HPA023900"	Enhanced		Approved	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435"	"unprognostic (1.10e-2)"	"unprognostic (1.43e-1)"	"prognostic unfavourable (3.86e-4)"	"unprognostic (1.53e-2)"	"unprognostic (8.08e-3)"	"unprognostic (2.15e-1)"	"unprognostic (2.38e-3)"	"unprognostic (3.98e-2)"	"prognostic favourable (8.45e-5)"	"unprognostic (4.04e-1)"	"unprognostic (8.34e-2)"	"unprognostic (4.14e-2)"	"prognostic unfavourable (6.69e-12)"	"unprognostic (2.37e-3)"	"unprognostic (1.63e-1)"	"unprognostic (4.90e-2)"	"unprognostic (1.56e-1)"	14.9	10.8	5.6	43.6	7.1	40.6	18.7	2.0	4.9	12.5	20.1	4.2	9.4	11.3	18.8	11.0	12.9	10.8	20.4	10.9	4.6	2.5	15.5	14.5	20.6	34.2	6.6	2.5	15.1	17.4	5.2	6.3	12.8	7.9	19.6	5.2	7.3	16.7	15.1	13.6	10.4	14.1	24.0	7.7	28.0	13.1	6.6	5.8	19.5	11.5	14.8	39.2	21.9	24.4	5.2	1.4	7.5	3.4	1.3	2.0	0.9	21.0	13.1	2.6	10.5	3.3	5.0	6.2	6.0	19.2	6.1	8.9	7.8	17.3	9.7	15.0	3.6	12.8	6.0	8.2	2.4	49.5	3.5	2.4	3.2	4.5	9.2	1.6	14.1	6.9	4.0	10.2	10.1	2.1	2.3	54.1	2.3	7.2	2.4	6.6	3.3	4.7	5.3	7.3	7.7	10.3	6.2	0.5	2.9	4.9	11.9	8.4	9.2	4.7	6.3	6.3	9.3	8.9	15.9	35.8	33.1	10.2	10.3	4.2	3.3	0.3	2.4	0.1	1.4	1.5	1.4	5.2	1.7	1.5	1.4	4.5	1.8	1.5	7.5	1.3	3.4	0.9	2.0	0.9	5.6	7.1	2.0	4.9	4.6	2.5	6.6	2.5	7.9	5.8
NFKBIA	"IkappaBalpha, IKBA, MAD-3, NFKBI"	ENSG00000100906	"NFKB inhibitor alpha"	P25963	14	35401511-35404749	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction"		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 209.1"	"Cell line enhanced"	"Detected in all"		"RT4: 83.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003815, HPA029207"	Approved		Enhanced	Cytosol				Cytosol		"CAB003815: AB_344886, HPA029207: AB_10603122"	"prognostic favourable (1.33e-5)"	"unprognostic (3.39e-1)"	"unprognostic (7.29e-2)"	"unprognostic (7.24e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.62e-1)"	"unprognostic (3.51e-1)"	"unprognostic (2.46e-1)"	"unprognostic (2.39e-1)"	"unprognostic (2.46e-1)"	"unprognostic (2.46e-1)"	"unprognostic (7.19e-2)"	"unprognostic (2.32e-2)"	"unprognostic (3.69e-1)"	"unprognostic (4.44e-2)"	"unprognostic (9.74e-2)"	"unprognostic (3.80e-2)"	49.0	38.5	14.9	63.7	25.7	209.1	60.8	16.1	27.8	33.8	32.8	10.3	36.7	13.5	21.3	15.6	50.4	30.5	34.3	30.9	18.8	10.5	30.6	45.1	73.0	47.7	29.7	7.8	57.4	22.1	6.5	25.3	25.5	21.8	28.7	18.6	19.5	44.2	64.6	33.1	48.2	42.3	24.9	23.0	47.4	26.1	19.6	23.9	35.0	27.8	46.2	38.1	41.8	45.2	45.3	55.0	118.2	58.3	33.2	37.3	51.7	12.9	11.5	4.3	3.9	25.7	17.1	15.6	5.4	52.0	11.7	10.5	3.6	7.8	7.8	14.5	8.5	17.1	8.2	22.4	16.9	47.8	3.2	3.9	8.3	21.2	15.4	6.1	3.2	18.6	22.7	7.9	20.4	10.5	3.2	12.7	8.3	15.2	8.0	14.8	4.0	7.1	18.3	5.0	6.5	20.1	83.5	3.9	6.8	14.4	25.3	6.0	14.3	13.1	19.6	16.1	5.8	4.6	8.6	15.5	15.7	13.4	13.4	4.6	3.3	35.8	58.3	36.6	24.2	33.4	37.3	34.0	29.3	25.4	55.0	45.3	25.6	21.7	118.2	33.2	22.1	29.7	19.5	51.7	14.9	25.7	16.1	27.8	18.8	10.5	29.7	7.8	21.8	23.9
NFKBIE	IKBE	ENSG00000146232	"NFKB inhibitor epsilon"	O00221	6	44258166-44265788	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002692, HPA005941, CAB010272"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"				"Nucleoli fibrillar center"	"Nucleoplasm, Cytosol"	"CAB010272: AB_2235977, HPA002692: AB_1079479, HPA005941: AB_1079478"	"prognostic favourable (1.72e-5)"	"unprognostic (1.43e-1)"	"unprognostic (1.39e-2)"	"unprognostic (2.37e-2)"	"unprognostic (6.32e-3)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (3.50e-4)"	"unprognostic (4.88e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.43e-2)"	"unprognostic (3.36e-1)"	"unprognostic (2.60e-1)"	"prognostic unfavourable (1.37e-6)"	"unprognostic (2.61e-2)"	"unprognostic (8.83e-2)"	"unprognostic (1.37e-2)"	"prognostic favourable (8.07e-4)"	5.8	5.2	7.6	24.6	5.4	24.0	5.2	9.4	7.8	3.7	8.0	4.2	3.2	6.7	4.7	5.5	6.9	3.0	9.8	4.6	7.9	5.5	11.5	8.7	15.9	17.1	6.0	4.1	6.1	7.1	3.5	4.1	6.0	4.8	7.1	5.9	3.6	7.7	4.1	3.7	7.4	9.5	3.6	5.0	29.6	6.3	7.9	3.7	14.5	5.5	4.6	22.7	6.7	6.7	8.1	8.2	7.1	10.2	0.8	3.5	1.6	14.4	3.7	5.1	8.0	2.0	1.5	2.7	2.5	12.6	8.0	8.4	7.8	6.8	7.8	9.2	2.6	3.1	5.4	8.1	9.0	13.4	3.0	4.0	1.5	8.7	6.2	13.2	12.2	3.9	3.6	7.4	4.6	5.4	3.7	20.9	2.0	7.4	2.5	27.0	2.7	2.0	4.9	4.5	7.2	18.4	15.8	3.3	4.1	1.8	6.7	10.5	4.6	15.5	9.5	4.5	5.3	2.8	8.0	13.3	5.6	14.4	4.0	14.7	8.5	7.1	8.1	3.8	1.8	9.4	3.5	8.1	2.4	1.6	6.8	7.3	1.1	1.7	3.2	0.8	10.2	8.2	3.0	1.6	7.6	5.4	9.4	7.8	7.9	5.5	6.0	4.1	4.8	3.7
NGF	NGFB	ENSG00000134259	"Nerve growth factor"	P01138	1	115285918-115338236	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor"	"Cancer-related genes, Disease mutation, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ: 37.6;BJ hTERT+ SV40 Large T+: 13.4;BJ hTERT+ SV40 Large T+ RasG12V: 9.9;hTEC/SVTERT24-B: 13.0;U-2197: 26.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Secreted in other tissues"						"unprognostic (7.55e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.53e-3)"	"unprognostic (8.85e-2)"	"unprognostic (4.12e-1)"	"prognostic unfavourable (1.80e-4)"	"unprognostic (1.03e-1)"	"unprognostic (5.30e-2)"	"unprognostic (8.73e-3)"	"unprognostic (4.28e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (8.08e-7)"	"unprognostic (1.15e-3)"	"unprognostic (2.13e-1)"	"unprognostic (7.99e-3)"	"unprognostic (1.62e-4)"	9.1	2.3	1.3	2.8	1.6	0.2	6.5	0.6	2.8	7.5	3.4	0.6	2.3	0.3	11.4	5.9	1.5	10.6	6.6	16.5	3.2	0.6	3.4	2.7	1.4	1.5	2.3	1.6	17.8	0.7	0.3	2.1	2.0	1.7	3.7	1.2	7.0	3.8	2.0	1.8	0.6	1.4	7.0	2.1	3.8	1.6	3.2	1.1	0.0	2.9	3.0	0.3	6.5	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	37.6	4.3	13.4	9.9	0.0	0.0	0.0	0.8	8.9	1.5	0.0	0.2	6.0	0.0	0.1	0.0	0.2	0.0	5.6	0.0	0.0	0.0	0.2	13.0	9.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.5	0.0	0.5	0.0	0.0	0.0	0.5	0.1	0.7	0.2	0.0	0.0	0.0	0.3	0.8	1.6	26.2	1.5	0.0	0.0	0.0	1.6	0.0	8.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.6	0.6	2.8	3.2	0.6	2.3	1.6	1.7	1.1
NGFR	"CD271, p75NTR, TNFRSF16"	ENSG00000064300	"Nerve growth factor receptor"	P08138	17	49495293-49515017	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Apoptosis, Biological rhythms, Differentiation, Neurogenesis"	"Developmental protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	7	"RH-30: 54.7;WM-115: 60.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"plasmacytoid DC: 4.2"	"Lineage enriched"	"Detected in single"	7	"dendritic cells: 4.2"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"basal ganglia: 13.1;hypothalamus: 8.2;pons and medulla: 3.7"	"CAB000143, CAB001995, HPA004765"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		100000	100000	Nucleoplasm	"Plasma membrane"	"CAB000143: , CAB001995: , HPA004765: AB_1079233"	"unprognostic (6.25e-3)"	"unprognostic (1.06e-3)"	"unprognostic (3.39e-3)"	"unprognostic (6.67e-2)"	"unprognostic (1.46e-2)"	"unprognostic (2.26e-1)"	"unprognostic (8.22e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.08e-2)"	"unprognostic (4.10e-3)"	"unprognostic (1.85e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.37e-2)"	"unprognostic (4.01e-2)"	"unprognostic (3.06e-2)"	"unprognostic (2.77e-3)"	"prognostic unfavourable (3.40e-4)"	30.9	24.0	1.2	9.2	7.4	1.0	11.7	6.1	4.5	7.6	9.4	10.4	7.9	3.2	6.8	15.0	11.3	12.6	10.8	22.2	2.4	2.9	4.8	29.1	1.4	11.6	13.8	1.3	7.6	6.2	2.8	6.7	16.7	15.9	17.7	3.4	20.2	17.2	9.7	4.8	8.4	5.0	10.7	22.4	18.9	4.9	12.2	4.4	0.4	25.8	7.4	7.0	13.1	6.8	0.0	4.2	0.0	0.4	0.0	0.5	0.2	0.0	0.0	1.7	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.3	0.4	1.2	0.0	0.1	0.2	0.1	0.0	1.0	0.1	0.0	0.1	5.8	0.0	0.1	0.4	0.0	0.0	0.0	7.9	0.1	0.0	0.0	1.0	0.0	1.0	54.7	0.0	0.0	0.0	0.5	0.3	0.0	0.0	3.6	0.1	0.0	0.0	0.0	0.9	0.1	2.7	0.0	0.0	0.0	0.0	0.5	60.7	0.0	0.0	0.0	0.5	0.2	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.4	4.2	0.0	0.2	1.2	7.4	6.1	4.0	2.4	2.9	13.8	1.3	15.9	4.4
NIN		ENSG00000100503	Ninein	Q8N4C6	14	50719763-50831121	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA005939, HPA070691"	Approved		Enhanced	Nucleoplasm,Nucleoli,Centrosome				Centrosome	"Nucleoplasm, Nucleoli"	"HPA005939: , HPA070691: "	"unprognostic (1.98e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.43e-2)"	"unprognostic (3.41e-2)"	"unprognostic (3.31e-1)"	"unprognostic (5.81e-3)"	"unprognostic (1.78e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.06e-1)"	"unprognostic (2.46e-2)"	"unprognostic (2.67e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.58e-2)"	"unprognostic (7.66e-3)"	13.0	6.1	15.1	24.9	10.3	34.8	9.7	12.6	14.0	8.0	9.2	7.6	4.5	5.0	11.8	6.1	11.8	8.2	7.6	16.4	11.7	4.9	6.7	5.2	10.7	30.2	7.6	10.0	11.0	5.4	9.1	12.3	20.2	7.1	6.5	7.7	6.2	8.2	5.1	16.9	10.9	8.3	12.0	7.1	18.2	9.3	4.6	9.0	16.4	7.8	5.1	25.8	11.7	10.3	6.8	6.3	18.4	2.3	1.5	6.0	1.3	12.2	8.7	18.1	15.4	7.0	11.2	7.6	10.5	9.1	8.9	7.5	5.6	6.5	28.8	7.2	14.1	12.9	14.5	6.6	18.7	13.9	4.5	10.6	5.3	5.3	4.1	18.4	30.6	7.7	5.3	15.5	6.4	14.1	2.6	11.8	13.4	13.4	13.9	7.4	2.5	9.6	15.8	33.5	2.0	8.0	13.9	8.4	9.5	13.2	4.0	11.3	7.5	16.4	20.5	22.6	31.4	8.6	11.6	9.5	4.8	19.9	5.9	15.0	12.2	12.6	2.3	18.4	3.3	1.7	3.5	6.8	2.2	6.0	1.5	5.5	4.4	3.8	8.3	1.5	1.5	6.3	1.9	1.3	15.1	10.3	12.6	14.0	11.7	4.9	7.6	10.0	7.1	9.0
NKX2-1	"BCH, NKX2A, TITF1, TTF-1, TTF1"	ENSG00000136352	"NK2 homeobox 1"	P43699	14	36516392-36521149	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	18	"lung: 51.5;thyroid gland: 122.8"	"Cell line enriched"	"Detected in some"	28	"SCLC-21H: 47.6"	"Group enriched"	"Detected in some"	39	"lung cancer: 30.9;thyroid cancer: 103.2"	"Group enriched"	"Detected in some"	6	"basal ganglia: 2.4;hypothalamus: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"basal ganglia: 3.4;hypothalamus: 12.0"	"Group enriched"	"Detected in some"	13	"basal ganglia: 6.4;hypothalamus: 16.1"	"CAB000078, CAB053633, HPA074316"	Enhanced		Uncertain	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"CAB000078: , CAB053633: AB_442138, HPA074316: "		"unprognostic (3.79e-1)"		"unprognostic (4.25e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.79e-2)"		"unprognostic (1.26e-2)"				"unprognostic (2.23e-1)"		"unprognostic (1.18e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.18e-1)"	0.1	0.1	0.0	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	2.5	0.0	0.0	51.5	0.1	0.0	0.1	0.0	0.0	0.0	4.9	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.4	0.0	122.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	47.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.4	0.0	0.1	0.2	2.5	0.0	0.1	0.1	0.4
NKX3-1	"BAPX2, NKX3.1, NKX3A"	ENSG00000167034	"NK3 homeobox 1"	Q99801	8	23678693-23682927	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"prostate: 95.3"	"Cell line enhanced"	"Detected in many"		"SiHa: 17.5;U-138 MG: 17.8;U-251 MG: 15.2"	"Cancer enriched"	"Detected in many"	65	"prostate cancer: 392.7"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	7	"eosinophil: 23.5;neutrophil: 23.4"	"Lineage enriched"	"Detected in many"	19	"granulocytes: 23.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA025693, HPA078571"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA025693: AB_1854522, HPA078571: "	"unprognostic (1.47e-2)"	"unprognostic (4.03e-2)"	"unprognostic (2.67e-1)"	"unprognostic (5.87e-2)"	"unprognostic (2.56e-6)"	"unprognostic (6.90e-3)"	"unprognostic (1.13e-1)"	"unprognostic (4.11e-3)"	"unprognostic (9.42e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.00e-2)"	"unprognostic (1.87e-1)"	"unprognostic (4.37e-2)"	"unprognostic (4.60e-2)"	"unprognostic (3.88e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.69e-1)"	0.6	1.3	0.3	0.6	0.9	0.6	1.5	0.1	0.8	1.1	0.6	0.2	0.5	0.5	0.7	0.5	1.2	0.7	0.8	2.4	0.8	0.3	0.4	1.6	0.8	0.7	0.6	0.2	1.6	0.6	0.5	0.4	0.3	1.2	95.3	0.2	0.5	17.9	0.7	2.0	0.2	0.4	0.7	0.6	0.3	0.5	12.3	0.7	0.0	0.6	3.2	20.5	0.7	2.5	1.0	0.0	23.5	0.0	0.2	1.2	0.1	3.2	2.4	0.0	5.9	2.2	0.5	4.9	4.4	2.8	9.5	11.2	1.4	3.7	0.0	0.6	3.3	0.8	2.3	5.1	7.5	0.0	1.2	2.2	1.8	3.5	4.2	0.0	0.8	0.8	1.3	9.6	0.5	0.5	0.1	0.0	3.7	1.0	7.6	0.6	1.4	1.7	0.0	3.8	0.3	0.5	3.8	1.1	0.3	17.5	3.3	0.3	2.3	0.3	0.6	17.8	6.3	1.3	15.2	0.0	0.0	0.0	8.7	1.7	2.1	3.4	0.0	23.5	0.5	0.0	0.1	1.0	0.2	0.5	0.0	0.9	0.7	1.2	23.4	0.2	0.0	0.0	0.0	0.1	0.3	0.9	0.1	0.8	0.8	0.3	0.6	0.2	1.2	0.7
NLRP3	"AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1"	ENSG00000162711	"NLR family pyrin domain containing 3"	Q96P20	1	247416156-247449108	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation"	Activator	"Amyloidosis, Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 40.3;bone marrow: 38.2"	"Cell line enhanced"	"Detected in some"		"NB-4: 7.1;THP-1: 40.7;U-937: 10.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 40.3"	"Group enriched"	"Detected in many"	20	"dendritic cells: 13.4;granulocytes: 40.3;monocytes: 12.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA012878	Uncertain				"Intracellular and membrane"					"HPA012878: AB_1846752"	"unprognostic (3.56e-2)"	"unprognostic (1.33e-1)"	"unprognostic (6.23e-2)"	"unprognostic (3.96e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.69e-1)"	"unprognostic (7.86e-2)"	"unprognostic (4.46e-2)"	"unprognostic (3.84e-1)"	"unprognostic (7.39e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.52e-2)"	"unprognostic (4.88e-3)"	"unprognostic (2.17e-4)"	"unprognostic (1.10e-1)"	"unprognostic (6.10e-2)"	7.4	1.4	2.8	8.3	3.3	38.2	3.2	0.7	3.7	1.8	1.5	6.9	1.5	0.8	4.5	0.9	2.4	3.0	8.9	2.0	3.0	3.1	1.3	1.8	8.2	8.9	3.3	0.8	1.3	1.4	1.1	1.2	3.0	5.2	1.0	1.7	2.4	1.5	0.7	0.9	0.8	2.5	4.1	4.9	8.5	1.6	0.6	3.3	1.0	1.0	3.2	2.8	3.3	0.9	0.0	13.4	40.3	12.5	0.0	1.1	3.9	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.2	0.0	0.2	0.0	0.1	0.0	0.0	0.0	1.2	1.5	0.2	0.0	0.7	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	7.1	0.0	0.2	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	40.7	0.0	1.7	1.3	0.0	0.1	0.0	0.0	0.0	3.9	10.1	1.2	40.3	12.5	0.1	0.2	7.7	0.6	0.0	1.1	0.4	13.4	0.0	0.4	0.2	3.0	0.0	3.6	0.6	0.0	3.9	2.8	3.3	0.7	3.7	3.0	3.1	3.3	0.8	5.2	3.3
NME1	"NDPKA, NM23, NM23-H1"	ENSG00000239672	"NME/NM23 nucleoside diphosphate kinase 1"	P15531	17	51153536-51162428	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Endocytosis, Neurogenesis, Nucleotide metabolism"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008467, CAB040571, HPA041113"	Supported		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	"Intracellular and membrane"	28000000	28000000	Cytosol	"Nucleoplasm, Plasma membrane"	"CAB040571: , HPA008467: AB_1079492, HPA041113: "	"unprognostic (2.24e-1)"	"unprognostic (2.01e-1)"	"unprognostic (3.48e-3)"	"unprognostic (5.96e-2)"	"unprognostic (9.71e-2)"	"unprognostic (2.33e-3)"	"prognostic unfavourable (2.60e-5)"	"unprognostic (4.54e-2)"	"unprognostic (3.35e-1)"	"unprognostic (2.33e-3)"	"unprognostic (2.90e-2)"	"unprognostic (1.01e-1)"	"prognostic unfavourable (2.07e-9)"	"unprognostic (9.01e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.83e-1)"	"unprognostic (9.46e-2)"	25.0	29.5	38.0	28.1	30.1	27.9	29.0	19.6	41.9	16.4	25.4	13.1	10.1	15.1	17.3	22.5	30.1	22.2	13.4	14.1	41.7	39.4	19.6	56.0	14.2	28.5	34.2	34.2	15.6	43.6	13.7	17.3	16.9	38.9	14.5	36.8	14.9	34.3	14.7	14.8	22.4	12.4	29.6	20.5	22.4	13.4	11.6	11.3	19.0	18.8	32.7	41.4	22.8	15.2	24.9	36.2	0.6	19.5	17.2	20.3	18.4	47.6	95.2	32.9	45.9	13.8	22.1	55.3	37.2	25.8	77.1	58.5	74.9	28.9	83.9	38.8	34.4	25.6	62.8	63.2	66.0	40.7	84.6	55.0	73.9	103.9	28.0	60.2	25.2	21.0	39.8	58.0	54.3	46.4	81.1	27.9	45.6	80.7	71.5	69.3	39.4	86.8	43.9	64.9	77.2	59.2	33.3	45.7	52.6	19.5	53.4	34.6	55.6	40.8	29.2	49.8	45.2	30.9	76.3	36.0	83.0	98.8	30.1	51.1	37.8	0.2	15.2	0.6	13.4	19.5	20.3	24.9	14.4	14.6	36.2	17.3	16.4	17.8	0.4	17.2	11.5	20.7	12.1	18.4	38.0	30.1	19.6	41.9	41.7	39.4	34.2	34.2	38.9	11.3
NME2	"NDPKB, NM23-H2"	ENSG00000243678	"NME/NM23 nucleoside diphosphate kinase 2"	P22392	17	51165435-51171747	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Nucleotide metabolism, Transcription, Transcription regulation"	"Activator, DNA-binding, Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB036213, CAB036214, CAB036215, HPA041113"	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB036213: , CAB036214: , CAB036215: , HPA041113: "	"unprognostic (7.21e-3)"	"prognostic unfavourable (4.74e-4)"	"unprognostic (4.85e-2)"	"unprognostic (1.15e-2)"	"unprognostic (8.86e-2)"	"unprognostic (1.42e-2)"	"prognostic unfavourable (7.09e-4)"	"unprognostic (6.62e-3)"	"unprognostic (5.68e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.38e-1)"	"unprognostic (6.41e-2)"	"prognostic unfavourable (1.55e-6)"	"unprognostic (2.82e-1)"	"unprognostic (9.09e-2)"	"unprognostic (8.87e-2)"	"unprognostic (3.19e-2)"	62.1	54.6	42.3	58.2	44.1	44.2	188.9	20.1	43.7	58.9	74.0	16.3	67.7	52.5	65.0	52.0	104.3	56.8	65.3	115.1	38.2	32.1	77.3	115.7	59.0	174.7	45.0	23.7	90.7	234.3	17.5	30.4	37.9	34.0	64.0	62.7	29.9	109.4	65.8	105.3	63.3	45.1	88.3	34.6	69.4	50.2	32.3	24.4	42.5	66.9	102.0	56.6	81.3	140.8	49.3	71.3	8.3	43.7	32.6	34.5	38.2	91.8	135.0	32.3	56.4	72.3	105.5	89.2	63.7	66.3	97.5	74.3	108.9	48.9	77.3	103.2	65.2	58.8	67.8	86.9	80.3	93.1	200.5	65.0	94.2	157.6	79.0	102.5	45.5	95.5	101.5	62.9	110.7	58.0	88.9	52.1	70.2	163.4	51.3	128.2	48.2	207.4	49.2	107.1	123.4	105.6	116.1	73.7	45.7	39.2	98.5	95.6	67.9	78.7	58.8	94.0	68.0	66.8	101.2	91.1	118.3	88.5	50.8	52.2	47.1	8.3	35.1	2.0	24.7	43.7	34.5	49.3	33.0	26.9	61.5	36.2	23.8	25.6	2.1	32.6	38.0	71.3	29.9	38.2	42.3	44.1	20.1	43.7	38.2	32.1	45.0	23.7	34.0	24.4
NONO	"NMT55, NRB54, P54, P54NRB, PPP1R114"	ENSG00000147140	"Non-POU domain containing octamer binding"	Q15233	X	71283192-71301168	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022069, HPA054094, HPA054559"	Enhanced		Enhanced	"Nucleoplasm,Nucleoli fibrillar center,Nuclear speckles"		150000	150000	Nucleoplasm	"Nucleoli fibrillar center, Nuclear speckles"	"CAB022069: , HPA054094: AB_2682376, HPA054559: AB_2682522"	"unprognostic (2.39e-3)"	"unprognostic (2.22e-2)"	"unprognostic (2.64e-1)"	"prognostic unfavourable (9.29e-4)"	"unprognostic (8.87e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.02e-3)"	"unprognostic (9.34e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.41e-2)"	"unprognostic (3.12e-1)"	"unprognostic (2.07e-1)"	"unprognostic (7.29e-3)"	"unprognostic (6.79e-2)"	"unprognostic (5.73e-3)"	"unprognostic (2.76e-2)"	"unprognostic (3.04e-2)"	37.2	55.9	30.2	37.7	30.8	51.2	37.2	54.8	38.6	45.4	33.4	36.0	38.4	29.9	52.4	40.5	41.0	40.5	37.2	30.5	27.5	29.0	40.1	43.3	37.3	45.7	28.8	31.7	69.2	61.0	39.4	48.2	42.4	27.5	40.8	37.5	42.5	39.8	41.4	37.2	38.4	35.2	40.5	38.3	45.9	40.3	34.4	29.0	98.4	51.0	39.1	57.4	43.6	36.8	44.1	47.3	35.3	51.8	45.4	51.8	58.9	58.5	64.8	89.7	49.2	36.6	37.8	49.1	48.0	44.7	65.0	57.4	51.4	43.5	66.6	53.5	44.2	43.8	133.8	41.7	71.6	50.7	89.4	54.6	68.0	51.1	31.0	76.6	48.0	40.0	29.8	65.7	44.1	53.3	69.6	69.9	59.9	52.0	99.0	69.8	111.6	52.6	89.1	94.0	57.1	49.8	51.8	62.3	77.3	62.2	40.6	55.1	38.2	49.6	48.9	42.1	63.2	58.8	55.5	40.3	76.3	75.8	31.4	89.1	60.1	35.3	44.8	34.9	45.8	47.6	51.8	43.7	46.6	44.9	47.3	44.1	50.8	50.2	20.8	45.4	51.8	41.2	50.1	58.9	30.2	30.8	54.8	38.6	27.5	29.0	28.8	31.7	27.5	29.0
NOS1	"nNOS, NOS"	ENSG00000089250	"Nitric oxide synthase 1"	P29475	12	117208142-117452170	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"brain: 13.4;skeletal muscle: 36.3"	"Cell line enhanced"	"Detected in some"		"HaCaT: 6.2;RH-30: 12.8;RPTEC TERT1: 8.0;U-2 OS: 2.5"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002167, HPA058312, HPA069509"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"				"Plasma membrane"	Nucleoplasm	"CAB002167: AB_564073, HPA058312: , HPA069509: "	"unprognostic (1.63e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.18e-2)"	"unprognostic (6.64e-3)"	"unprognostic (4.91e-2)"	"unprognostic (2.74e-1)"	"unprognostic (2.54e-1)"	"unprognostic (9.12e-3)"	"unprognostic (2.51e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.07e-1)"	"unprognostic (7.56e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.34e-1)"	"unprognostic (5.97e-4)"	"unprognostic (1.87e-1)"	0.5	0.6	3.8	3.5	13.4	0.7	0.6	4.4	4.8	0.7	2.0	1.1	0.0	0.5	0.6	0.7	1.3	0.8	0.5	0.5	2.8	4.4	1.9	0.5	1.4	0.6	2.4	1.6	0.5	1.9	0.4	0.8	0.4	5.9	1.6	0.9	0.6	3.8	0.6	36.3	2.2	0.6	0.8	1.2	0.5	0.5	0.9	3.0	0.0	0.6	0.0	0.5	0.9	0.6	0.9	0.6	2.1	0.5	0.8	0.5	0.0	0.0	0.4	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.0	6.2	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.2	1.4	0.0	12.8	0.1	8.0	0.0	0.3	1.3	0.0	0.0	0.0	0.1	0.0	0.1	0.1	2.5	0.0	0.0	0.1	0.0	0.1	0.3	0.1	0.0	2.1	0.5	0.5	0.5	0.4	0.4	0.7	0.4	0.3	0.2	0.9	0.5	0.5	1.9	0.8	0.5	0.6	0.3	0.0	3.8	13.4	4.4	4.8	2.8	4.4	2.4	1.6	5.9	3.0
NOS2	"HEP-NOS, iNOS, NOS, NOS2A"	ENSG00000007171	"Nitric oxide synthase 2"	P35228	17	27756766-27800499	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 20.8;lymphoid tissue: 15.6"	"Group enriched"	"Detected in some"	8	"CACO-2: 16.6;SCLC-21H: 13.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 16.0"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB002014	Enhanced									"CAB002014: "	"unprognostic (1.95e-3)"	"unprognostic (3.08e-3)"	"unprognostic (4.75e-3)"	"unprognostic (4.42e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.13e-2)"	"unprognostic (5.61e-2)"	"unprognostic (5.09e-2)"	"unprognostic (9.91e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.39e-2)"	"unprognostic (1.34e-1)"	"unprognostic (6.04e-2)"	"unprognostic (8.02e-2)"	"unprognostic (3.68e-1)"	"unprognostic (8.69e-2)"	"unprognostic (4.03e-2)"	1.0	0.7	1.6	15.6	1.6	0.0	0.5	1.5	7.3	0.4	6.8	0.0	0.0	11.8	0.4	0.0	1.0	0.5	0.4	0.7	1.3	1.1	1.7	0.2	3.8	1.8	1.0	2.2	1.0	0.3	0.1	2.1	3.4	0.4	0.9	9.0	1.2	0.2	0.2	0.7	0.4	20.8	1.7	0.8	0.2	0.3	0.4	0.2	0.2	0.5	5.3	1.7	5.4	0.3	0.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	13.6	0.9	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.6	1.5	7.3	1.3	1.1	1.0	2.2	0.4	0.2
NOS3	"ECNOS, eNOS"	ENSG00000164867	"Nitric oxide synthase 3"	P29474	7	150990995-151014588	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 70.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 11.2;HUVEC TERT2: 21.5;K-562: 7.6;TIME: 39.2"	"Low cancer specificity"	"Detected in all"			"Group enriched"	"Detected in all"	5	"basal ganglia: 32.4;cerebral cortex: 12.4;hippocampal formation: 18.8;pons and medulla: 35.3"	"Low cell type specificity"	"Detected in many"			"Lineage enriched"	"Detected in many"	5	"T-cells: 5.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002168	Enhanced									"CAB002168: AB_564072"	"unprognostic (6.53e-2)"	"unprognostic (3.36e-1)"	"unprognostic (1.63e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.36e-1)"	"unprognostic (6.97e-2)"	"unprognostic (2.56e-1)"	"unprognostic (9.40e-2)"	"unprognostic (2.36e-1)"	"prognostic unfavourable (3.63e-4)"	"unprognostic (1.25e-2)"	"unprognostic (6.63e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.01e-1)"	11.4	4.5	3.1	7.5	32.4	1.9	25.6	1.8	12.4	4.6	3.2	1.7	1.0	4.0	8.3	2.5	4.7	5.0	6.6	35.2	18.8	3.4	5.5	5.4	14.0	10.3	4.7	1.7	4.5	4.1	2.7	4.8	11.5	35.3	5.2	2.5	5.2	3.0	3.2	6.0	4.9	4.0	5.4	25.9	70.6	3.6	4.5	1.6	0.0	5.9	2.1	2.4	5.1	7.3	1.1	0.5	0.7	0.4	0.5	5.3	1.2	0.2	0.0	0.6	1.9	0.0	0.0	11.2	0.0	0.0	0.0	0.0	0.1	1.0	0.2	1.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	1.0	0.1	2.9	0.3	0.2	5.0	0.0	0.1	0.0	0.0	21.5	7.6	1.8	0.0	0.0	0.1	0.2	0.8	0.0	1.4	0.0	0.8	0.0	0.1	0.2	0.2	0.1	0.7	0.0	0.1	0.6	39.2	0.1	0.4	0.1	0.0	1.2	4.0	1.0	0.0	3.5	0.0	0.3	0.3	0.2	2.5	0.4	1.5	0.8	3.9	2.2	0.5	1.1	5.3	2.1	0.7	0.5	0.4	0.5	4.4	1.2	3.1	32.4	1.8	12.4	18.8	3.4	4.7	1.7	35.3	1.6
NOTCH1	TAN1	ENSG00000148400	"Notch 1"	P46531	9	136494433-136545786	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HaCaT: 24.5;HMC-1: 21.3;hTCEpi: 23.6;MOLT-4: 37.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 8.8"	"Group enriched"	"Detected in many"	4	"granulocytes: 8.8;NK-cells: 2.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008112, CAB022466, HPA067168"	Supported		Approved	Nucleoplasm		8100000	8100000	Nucleoplasm		"CAB008112: AB_2153490, CAB022466: , HPA067168: "	"unprognostic (1.77e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.16e-1)"	"unprognostic (8.38e-3)"	"unprognostic (3.04e-1)"	"unprognostic (1.13e-1)"	"unprognostic (7.56e-2)"	"unprognostic (1.02e-1)"	"unprognostic (5.74e-3)"	"unprognostic (5.50e-3)"	"unprognostic (8.78e-2)"	"unprognostic (8.50e-2)"	"prognostic unfavourable (5.45e-4)"	"unprognostic (2.14e-2)"	"unprognostic (1.92e-1)"	"unprognostic (5.65e-2)"	"unprognostic (8.84e-2)"	20.0	4.0	10.0	14.5	10.4	14.6	12.8	3.8	18.8	12.8	14.2	19.9	8.2	9.8	11.2	5.1	13.3	9.6	13.1	9.6	10.7	5.8	9.4	7.2	17.4	13.7	11.6	7.5	9.2	17.8	3.7	5.6	8.5	9.3	12.1	5.7	10.4	14.2	11.8	8.2	32.3	10.8	7.7	6.6	20.7	8.6	4.1	9.9	34.8	9.4	10.2	10.9	12.3	22.2	0.6	1.1	8.8	1.0	2.7	1.3	0.9	4.4	7.3	6.1	3.0	0.2	0.5	7.6	2.2	0.6	1.3	0.4	1.0	0.5	5.9	4.6	1.7	24.5	2.0	10.0	0.2	13.5	1.1	3.3	3.0	0.4	3.4	3.5	21.3	0.3	23.6	1.7	3.7	7.8	1.4	1.1	0.8	7.9	37.4	5.7	5.1	3.4	7.7	4.9	11.0	0.9	3.7	0.0	0.4	3.2	3.4	1.4	2.1	5.6	11.5	3.2	4.7	3.1	2.4	1.2	1.0	2.4	2.2	2.5	16.5	0.7	1.0	2.8	1.3	0.4	0.8	0.4	0.6	1.0	0.6	0.6	0.4	1.1	8.8	2.7	0.4	1.1	0.4	0.9	10.0	10.4	3.8	11.7	10.7	5.8	11.6	7.5	9.3	9.9
NOTCH2		ENSG00000134250	"Notch 2"	Q04721	1	119911553-120069626	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048743	Approved		Supported	"Nucleoplasm,Plasma membrane"		67000000	67000000	"Nucleoplasm, Plasma membrane"		"HPA048743: "	"unprognostic (1.33e-1)"	"unprognostic (1.43e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.40e-3)"	"unprognostic (7.98e-2)"	"unprognostic (4.01e-2)"	"unprognostic (1.22e-1)"	"unprognostic (7.32e-2)"	"unprognostic (1.18e-2)"	"prognostic unfavourable (5.24e-4)"	"prognostic unfavourable (9.48e-4)"	"unprognostic (3.86e-2)"	"unprognostic (6.12e-3)"	"unprognostic (1.55e-2)"	"unprognostic (2.65e-2)"	"unprognostic (1.12e-2)"	"unprognostic (7.35e-3)"	12.0	7.3	6.0	9.4	6.8	4.4	10.6	3.0	5.6	14.5	7.6	4.4	11.3	1.6	12.3	11.8	13.4	11.4	12.8	7.9	6.8	2.3	5.5	11.4	10.6	5.7	5.3	7.6	15.5	27.6	6.1	3.3	10.3	6.5	9.9	5.2	9.4	17.7	10.0	9.3	17.2	6.1	12.4	6.2	11.5	5.8	15.7	4.4	8.0	11.4	8.6	6.6	9.6	13.0	4.2	5.2	7.7	9.6	1.5	1.7	2.0	14.9	5.0	7.8	6.0	32.7	28.0	7.8	11.4	15.7	15.2	16.5	4.6	4.0	0.3	9.6	21.5	5.7	12.4	10.1	24.3	17.9	7.9	8.6	13.6	0.4	12.2	9.0	2.3	22.4	6.6	45.6	30.4	7.7	0.1	19.0	18.3	16.7	3.8	2.5	10.1	5.6	2.5	27.6	9.6	8.0	9.5	0.3	3.9	15.4	14.5	8.2	8.0	3.1	27.1	19.9	13.7	29.8	17.8	7.9	3.9	4.4	29.2	8.3	18.9	5.6	6.4	6.4	1.5	6.6	1.7	4.2	1.3	1.1	5.2	3.9	1.0	1.7	7.7	1.5	9.6	4.2	0.8	2.0	6.0	6.8	3.0	5.6	6.8	2.3	5.3	7.6	6.5	4.4
NOTCH3	"CADASIL, CASIL"	ENSG00000074181	"Notch 3"	Q9UM47	19	15159038-15200981	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 27.9;MCF7: 27.4;U-87 MG: 19.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 2.4"	"Group enriched"	"Detected in many"	10	"dendritic cells: 2.4;granulocytes: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005393, HPA044392"	Approved		Supported	"Nucleoplasm,Actin filaments,Cytosol"		18000000	18000000	"Nucleoplasm, Cytosol"	"Actin filaments"	"CAB005393: AB_2151246, HPA044392: "	"unprognostic (4.97e-2)"	"unprognostic (3.89e-2)"	"unprognostic (7.06e-3)"	"prognostic unfavourable (5.92e-4)"	"unprognostic (9.20e-2)"	"unprognostic (1.73e-2)"	"unprognostic (2.72e-1)"	"unprognostic (9.04e-2)"	"unprognostic (3.90e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.13e-1)"	"prognostic unfavourable (2.53e-7)"	"unprognostic (3.35e-2)"	"unprognostic (8.34e-3)"	"unprognostic (4.40e-2)"	"unprognostic (2.00e-3)"	35.9	3.7	4.7	6.4	6.4	0.5	53.7	2.7	7.5	25.9	7.3	6.2	9.2	3.7	22.9	23.1	33.8	14.6	22.7	25.0	4.6	3.6	9.2	1.6	16.2	11.7	5.0	6.4	14.1	6.9	10.1	4.9	37.3	6.4	13.4	3.0	8.3	11.4	11.4	16.6	48.3	6.2	11.0	2.8	11.8	5.5	10.1	3.9	44.4	14.9	36.7	10.3	14.9	24.6	0.1	2.4	1.0	0.1	0.1	0.1	0.0	5.2	3.3	27.9	12.7	3.9	3.2	12.6	4.2	0.2	0.2	0.1	6.3	5.5	0.1	3.3	7.7	6.2	5.0	0.1	0.2	0.0	1.3	0.1	5.2	1.4	1.9	0.0	0.5	3.6	3.1	6.5	0.7	0.3	0.2	0.2	0.5	27.4	6.3	0.0	16.3	0.0	0.0	1.6	0.1	0.0	16.9	0.8	9.0	0.0	15.9	0.0	16.9	0.0	0.0	0.8	9.1	0.1	0.1	0.0	0.3	0.0	19.5	0.1	0.4	1.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.6	0.1	0.0	2.4	0.0	0.0	4.7	6.4	2.7	7.5	4.6	3.6	5.0	6.4	6.4	3.9
NPM1	"B23, NPM"	ENSG00000181163	"Nucleophosmin 1"	P06748	5	171387116-171411137	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Host-virus interaction"	"Chaperone, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA011384, CAB012983"	Supported		Enhanced	Nucleoplasm,Nucleoli		810000	810000	Nucleoli	Nucleoplasm	"CAB012983: AB_2533084, HPA011384: AB_1854692"	"unprognostic (1.84e-3)"	"unprognostic (2.59e-1)"	"unprognostic (2.23e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.65e-1)"	"prognostic unfavourable (7.48e-4)"	"prognostic unfavourable (4.82e-6)"	"unprognostic (1.86e-2)"	"unprognostic (5.25e-3)"	"unprognostic (1.39e-1)"	"unprognostic (2.26e-3)"	"unprognostic (1.27e-1)"	"prognostic unfavourable (2.89e-6)"	"unprognostic (2.19e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.24e-2)"	56.8	44.7	29.9	61.1	33.6	76.0	67.0	37.7	34.6	113.5	57.8	24.8	39.3	36.7	78.2	50.5	81.6	65.0	44.0	48.5	28.8	31.6	64.9	78.8	59.5	128.1	36.1	27.9	177.4	102.0	27.1	57.9	65.2	36.1	87.2	49.3	29.5	47.3	48.2	67.9	42.7	52.8	92.4	43.2	85.9	54.0	56.7	31.3	111.3	112.6	66.5	82.1	116.8	65.7	85.3	54.1	12.3	29.1	59.0	126.6	91.4	118.4	80.2	97.5	138.1	59.6	108.9	145.4	107.8	98.5	146.1	131.6	191.5	83.7	317.2	85.7	62.3	69.5	135.3	245.1	190.4	98.7	107.3	111.9	78.7	141.0	88.4	225.3	92.8	96.0	86.4	99.1	195.6	109.0	136.0	73.0	106.0	147.1	147.0	160.3	122.0	98.6	132.0	107.6	162.6	124.6	83.6	76.9	61.8	64.4	105.4	195.1	129.3	100.0	68.0	48.9	107.8	56.2	181.5	58.5	106.3	190.8	73.9	183.5	97.4	12.3	26.9	8.4	45.7	29.1	84.6	85.3	85.1	66.2	54.1	62.8	126.6	99.0	4.0	59.0	23.1	48.7	73.2	91.4	29.9	33.6	37.7	34.6	28.8	31.6	36.1	27.9	36.1	31.3
NQO1	"DHQU, DIA4, DTD, NMOR1, QR1"	ENSG00000181019	"NAD(P)H quinone dehydrogenase 1"	P15559	16	69706996-69726951	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"stomach 1: 142.1"	"Cell line enhanced"	"Detected in many"		"A549: 162.9;Hep G2: 143.8;SiHa: 185.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007308, CAB012421"	Enhanced		Enhanced	Cytosol		310000	310000	Cytosol		"CAB012421: , HPA007308: AB_1079501"	"unprognostic (1.04e-2)"	"unprognostic (1.95e-3)"	"unprognostic (3.14e-1)"	"unprognostic (3.76e-3)"	"unprognostic (9.03e-2)"	"prognostic unfavourable (1.45e-4)"	"unprognostic (1.05e-3)"	"unprognostic (1.97e-1)"	"unprognostic (5.07e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.49e-2)"	"unprognostic (2.25e-1)"	"unprognostic (2.41e-2)"	"unprognostic (6.36e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.98e-1)"	"unprognostic (3.27e-1)"	31.3	24.2	12.8	6.4	20.7	0.6	77.1	2.7	9.1	7.6	23.2	7.8	5.7	29.5	3.9	8.6	36.3	8.2	77.2	9.3	9.9	7.5	44.7	1.2	17.2	6.9	11.3	6.0	3.7	2.5	7.0	3.7	3.5	25.5	9.8	20.8	20.2	10.5	7.6	7.6	2.3	17.7	22.7	10.4	6.0	142.1	3.8	4.9	0.1	25.7	69.7	16.2	21.2	18.9	5.2	3.2	0.9	3.2	15.1	12.3	4.4	14.3	162.9	13.7	61.0	34.1	49.4	5.1	24.3	43.7	25.1	38.8	19.8	93.0	0.4	28.9	125.7	15.0	5.3	27.4	12.9	5.8	0.2	0.7	40.4	143.8	45.2	3.4	11.7	11.6	17.4	43.5	5.0	62.2	5.9	1.0	134.1	46.5	0.6	6.3	7.2	15.9	1.1	2.9	6.6	50.0	52.2	4.9	1.1	185.1	26.3	108.3	42.5	11.4	42.1	25.3	10.5	9.4	19.1	0.8	3.2	0.6	32.4	1.8	125.1	0.6	3.2	0.2	5.7	0.3	2.9	5.2	6.6	7.2	3.2	2.1	2.1	4.7	0.9	15.1	0.3	1.2	12.3	4.4	12.8	20.7	2.7	9.1	9.9	7.5	11.3	6.0	25.5	4.9
NR0B1	"AHC, AHCH, DAX1, DSS"	ENSG00000169297	"Nuclear receptor subfamily 0 group B member 1"	P51843	X	30304206-30309598	"Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Receptor, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"adrenal gland: 23.9;testis: 36.0"	"Group enriched"	"Detected in some"	4	"A549: 34.3;RT4: 10.8"	"Cancer enhanced"	"Detected in many"		"lung cancer: 4.1"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA061948, HPA067207"			Supported	"Nuclear speckles,Vesicles,Centriolar satellite"				"Nuclear speckles"	"Vesicles, Centriolar satellite"	"HPA061948: , HPA067207: "		"unprognostic (1.50e-2)"			"unprognostic (9.68e-2)"			"unprognostic (9.47e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.81e-1)"	"unprognostic (7.45e-3)"		"unprognostic (4.83e-2)"	"unprognostic (9.00e-2)"	"unprognostic (1.33e-3)"			0.4	23.9	1.0	0.0	0.8	0.0	0.2	0.4	1.1	1.3	0.1	1.7	0.0	0.0	0.4	0.9	0.1	0.0	0.0	0.0	0.9	0.9	0.0	0.0	0.1	0.0	0.5	0.6	3.5	2.1	0.0	1.6	0.0	0.6	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.7	0.6	0.1	0.7	36.0	0.7	0.1	0.0	0.0	0.1	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.3	0.0	0.0	1.3	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	3.9	0.0	1.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	10.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	5.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.8	0.4	1.1	0.9	0.9	0.5	0.6	0.6	0.7
NR1H2	"LXR-b, NER, NER-I, RIP15, UNR"	ENSG00000131408	"Nuclear receptor subfamily 1 group H member 2"	P55055	19	50329653-50382982	"Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005446, HPA056838, HPA070212"	Uncertain		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA005446: , HPA056838: , HPA070212: "	"unprognostic (1.31e-1)"	"unprognostic (5.35e-2)"	"prognostic unfavourable (9.86e-4)"	"unprognostic (1.34e-3)"	"unprognostic (1.68e-1)"	"unprognostic (5.24e-3)"	"unprognostic (2.26e-2)"	"unprognostic (9.69e-2)"	"unprognostic (6.45e-2)"	"unprognostic (5.23e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.88e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.35e-1)"	"unprognostic (5.12e-2)"	"unprognostic (1.69e-3)"	30.1	27.5	24.5	24.7	27.5	98.0	24.4	20.6	33.5	25.1	30.9	23.1	25.2	30.9	31.2	23.1	27.9	26.9	28.7	36.8	23.8	19.4	27.1	31.4	28.3	23.3	31.7	25.9	26.5	37.6	22.0	18.6	30.5	28.1	27.9	10.5	23.2	33.8	33.8	76.2	25.3	30.3	29.9	22.9	29.9	26.7	21.2	29.1	20.4	27.1	24.4	21.7	33.2	27.6	34.1	34.2	63.0	37.7	22.3	28.6	32.5	16.0	42.2	4.1	10.3	12.1	12.8	13.2	22.2	18.9	13.2	15.1	8.7	15.6	10.3	19.9	13.3	15.0	2.6	12.1	3.2	25.7	22.7	9.9	14.2	9.0	23.3	16.3	27.1	13.4	16.6	13.5	9.2	12.0	16.1	21.5	7.4	17.8	11.6	13.4	8.3	36.3	7.0	10.7	17.9	11.3	18.0	4.6	16.1	14.4	17.9	13.9	12.3	13.6	15.1	17.7	14.4	18.0	19.7	26.9	22.2	7.5	35.3	10.8	17.7	39.1	35.9	63.0	27.7	35.0	27.0	34.1	27.4	25.9	34.2	34.1	28.6	24.9	55.4	22.3	37.7	29.5	24.4	32.5	24.5	27.5	20.6	33.5	23.8	19.4	31.7	25.9	28.1	29.1
NR4A2	"HZF-3, NOT, NURR1, RNR1, TINUR"	ENSG00000153234	"Nuclear receptor subfamily 4 group A member 2"	P43354	2	156324432-156342348	"Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"seminal vesicle: 102.1"	"Cell line enhanced"	"Detected in many"		"HeLa: 14.2;HMC-1: 10.5;U-266/70: 14.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 10.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA000543, CAB010481"	Uncertain		Supported	"Nuclear speckles"				"Nuclear speckles"		"CAB010481: AB_2298676, HPA000543: AB_1854631"	"unprognostic (4.26e-2)"	"unprognostic (2.14e-1)"	"unprognostic (3.42e-2)"	"unprognostic (4.10e-2)"	"unprognostic (3.04e-2)"	"unprognostic (5.26e-2)"	"unprognostic (2.30e-1)"	"unprognostic (6.14e-2)"	"unprognostic (8.63e-2)"	"unprognostic (3.88e-2)"	"unprognostic (1.60e-2)"	"unprognostic (2.89e-1)"	"unprognostic (2.39e-2)"	"unprognostic (3.58e-2)"	"unprognostic (3.43e-1)"	"unprognostic (9.29e-3)"	"unprognostic (1.11e-1)"	15.0	58.5	3.1	10.2	5.7	49.1	7.5	15.2	14.4	9.1	4.2	7.3	11.0	1.4	6.4	7.5	5.7	13.6	21.3	15.8	5.2	2.6	5.9	7.6	12.5	2.8	4.8	4.2	60.0	4.2	8.7	23.7	2.3	5.1	11.7	8.5	5.3	18.0	102.1	6.1	5.3	6.0	8.4	5.9	2.1	8.3	3.8	3.7	2.1	6.8	8.0	5.3	17.8	7.5	0.7	2.8	10.1	2.3	0.0	1.6	0.6	0.8	1.2	0.5	1.7	3.1	0.6	0.8	1.0	5.2	0.4	1.3	0.0	3.6	0.0	1.2	0.4	1.5	2.5	0.7	0.4	1.2	1.3	0.9	14.2	0.0	0.6	0.8	10.5	0.6	1.1	0.4	0.4	0.3	1.4	1.0	1.0	1.7	0.0	0.8	2.2	0.9	0.2	0.7	3.0	0.6	0.8	2.6	0.1	2.5	3.9	6.9	0.2	0.9	0.7	2.8	0.8	0.7	0.4	14.2	1.5	0.0	5.2	0.9	6.6	3.0	2.3	3.4	1.6	0.5	0.9	0.7	0.5	0.8	2.8	0.5	0.9	0.4	10.1	0.0	0.9	0.0	0.5	0.6	3.1	5.7	15.2	14.4	5.2	2.6	4.8	4.2	5.1	3.7
NR4A3	"CHN, CSMF, MINOR, NOR1"	ENSG00000119508	"Nuclear receptor subfamily 4 group A member 3"	Q92570	9	99821855-99866891	"Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"seminal vesicle: 80.6"	"Group enriched"	"Detected in some"	5	"BJ hTERT+: 21.0;HeLa: 7.3;SK-MEL-30: 14.5;U-266/70: 8.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 1.3;NK-cell: 1.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 1.3;NK-cells: 1.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA043360	Uncertain									"HPA043360: AB_10961186"	"prognostic favourable (5.97e-4)"	"unprognostic (6.92e-3)"	"unprognostic (5.34e-2)"	"unprognostic (2.78e-3)"	"unprognostic (1.40e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.65e-3)"	"unprognostic (1.40e-2)"	"unprognostic (2.28e-1)"	"unprognostic (3.30e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.29e-3)"	"unprognostic (6.11e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.69e-1)"	19.9	46.5	3.5	10.2	4.5	22.1	5.9	1.6	5.0	9.7	4.8	9.5	6.3	0.8	10.7	6.1	3.1	15.7	16.6	37.3	4.1	2.5	3.8	7.1	12.4	1.2	1.6	3.1	37.2	4.0	4.0	12.2	4.7	5.0	12.0	3.2	7.0	1.6	80.6	28.5	1.5	4.2	23.0	5.1	2.6	9.0	1.3	3.4	7.6	4.2	15.5	1.9	23.5	7.5	0.0	0.2	1.3	0.0	1.3	0.0	0.0	0.1	0.1	0.6	0.1	1.2	0.4	1.0	1.3	21.0	0.2	0.2	0.2	0.1	0.1	0.3	0.5	0.1	0.4	0.0	0.1	1.8	0.3	0.1	7.3	0.0	0.1	0.1	2.0	0.3	0.0	0.5	0.1	0.0	0.0	0.5	0.1	0.6	0.0	0.2	0.0	0.6	0.0	0.9	0.0	0.0	0.1	0.4	0.4	2.3	1.7	14.5	0.0	0.0	0.1	1.4	0.4	1.7	0.1	8.6	0.1	0.0	0.9	0.0	0.8	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	1.3	0.0	0.0	0.0	0.0	3.5	4.5	1.6	5.0	4.1	2.5	1.6	3.1	5.0	3.4
NRAS	N-ras	ENSG00000213281	"NRAS proto-oncogene, GTPase"	P01111	1	114704469-114716894	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins"			"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB010157, HPA049830"	Uncertain					4800000	4800000			"CAB010157: AB_632073, HPA049830: "	"unprognostic (4.75e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.09e-3)"	"unprognostic (2.11e-2)"	"unprognostic (8.59e-3)"	"unprognostic (1.14e-1)"	"prognostic unfavourable (3.03e-7)"	"unprognostic (7.76e-3)"	"unprognostic (1.57e-2)"	"unprognostic (1.01e-3)"	"prognostic unfavourable (1.36e-4)"	"unprognostic (6.60e-3)"	"prognostic unfavourable (7.87e-4)"	"unprognostic (2.68e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.33e-2)"	18.0	9.7	13.1	16.5	14.4	33.5	12.4	9.7	16.6	10.0	18.4	15.8	3.8	14.4	9.8	6.2	19.7	8.7	11.8	7.1	11.7	13.8	24.0	23.9	13.4	18.7	15.3	9.6	10.3	14.2	8.3	7.6	27.4	19.0	9.2	18.5	8.4	12.4	5.2	7.9	16.1	23.4	9.6	20.9	19.5	14.4	9.8	9.7	45.0	11.1	14.0	19.6	13.2	10.5	11.0	9.9	23.7	15.0	12.1	11.1	10.1	24.4	6.6	17.9	6.7	7.4	15.9	12.8	11.7	13.1	21.9	24.7	13.3	9.1	18.6	15.6	15.7	7.0	23.9	18.9	31.5	25.3	9.3	12.6	10.1	15.8	14.7	31.2	19.6	14.3	15.4	25.1	18.4	27.8	20.0	21.4	19.3	65.4	21.5	12.1	30.3	4.8	16.5	31.8	11.5	19.4	13.2	10.8	16.3	12.0	9.9	28.1	8.7	25.4	21.2	12.0	22.9	22.3	23.9	37.9	26.1	21.8	24.0	17.1	43.0	23.7	10.0	9.6	9.8	15.0	8.9	11.0	8.0	9.7	9.9	8.8	8.7	11.1	2.7	12.1	12.7	7.7	10.4	10.1	13.1	14.4	9.7	16.6	11.7	13.8	15.3	9.6	19.0	9.7
NRG1	"GGF, HGL, HRG, NDF, NRG1-IT2"	ENSG00000157168	"Neuregulin 1"	Q02297	8	31639386-32767959	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 28.3"	"Cell line enhanced"	"Detected in many"		"A549: 38.9;BJ: 26.6;fHDF/TERT166: 29.8;HBF TERT88: 26.2;hTEC/SVTERT24-B: 27.9;hTERT-HME1: 29.3"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 4.4"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"classical monocyte: 22.8"	"Lineage enriched"	"Detected in many"	5	"monocytes: 22.8"	"Low region specificity"	"Detected in all"							HPA010964	Uncertain		Approved	Nucleoplasm	"Secreted to blood"			Nucleoplasm		"HPA010964: AB_1854641"	"unprognostic (5.76e-3)"	"unprognostic (8.60e-2)"	"unprognostic (1.96e-4)"	"unprognostic (2.67e-1)"	"unprognostic (1.94e-4)"	"unprognostic (4.99e-2)"	"unprognostic (6.69e-2)"	"unprognostic (7.72e-2)"	"unprognostic (2.98e-1)"	"unprognostic (5.65e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.49e-2)"	"unprognostic (4.47e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.88e-1)"	"unprognostic (5.40e-2)"	"unprognostic (7.83e-2)"	0.7	2.1	4.6	5.0	3.3	1.2	8.8	14.8	8.1	10.6	4.2	0.3	2.1	3.5	2.5	1.1	3.7	2.0	4.8	2.2	4.7	15.4	11.5	23.6	5.7	0.6	6.2	3.5	2.9	0.9	0.8	23.9	0.2	28.3	3.2	5.4	3.6	2.5	1.6	0.2	4.3	5.7	1.1	2.5	1.7	3.1	6.4	0.8	0.2	13.8	7.2	2.2	7.2	3.5	0.0	4.9	0.8	22.8	0.0	0.0	4.6	0.1	38.9	0.7	0.0	0.3	0.8	0.0	26.6	18.9	22.1	16.9	0.0	0.8	0.0	4.9	29.8	21.0	0.2	10.6	26.2	0.0	0.2	0.5	0.5	0.5	0.1	0.0	0.0	0.3	1.1	27.9	29.3	12.7	0.0	0.1	7.9	0.0	0.0	0.0	0.9	0.0	0.0	0.2	0.0	16.3	1.1	1.1	1.3	2.0	0.0	0.0	0.0	0.0	9.2	15.4	4.7	24.5	14.8	0.0	0.0	0.2	7.9	0.0	1.8	0.0	22.8	0.2	0.0	2.1	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	4.6	4.6	3.3	14.8	8.1	4.7	15.4	6.2	3.5	28.3	0.8
NRG2	"Don-1, HRG2, NTAK"	ENSG00000158458	"Neuregulin 2"	O14511	5	139846779-140043299	"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.3"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;Karpas-707: 5.5;PC-3: 14.5;RPTEC TERT1: 7.4;SCLC-21H: 5.5"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.1"	"Lineage enriched"	"Detected in single"	4	"T-cells: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038935, HPA047973"	Approved		Supported	Nucleoplasm,Nucleoli	"Secreted to blood"			Nucleoplasm	Nucleoli	"HPA038935: AB_10672833, HPA047973: "	"unprognostic (8.66e-4)"	"unprognostic (2.17e-1)"	"unprognostic (1.21e-1)"	"unprognostic (6.04e-2)"	"unprognostic (3.22e-1)"	"unprognostic (2.96e-2)"	"unprognostic (8.66e-3)"	"unprognostic (1.11e-1)"	"unprognostic (3.99e-1)"	"unprognostic (1.88e-1)"	"unprognostic (4.26e-3)"	"unprognostic (4.00e-2)"	"unprognostic (7.79e-3)"	"unprognostic (3.64e-3)"	"unprognostic (9.54e-2)"	"unprognostic (2.23e-2)"	"unprognostic (2.07e-2)"	4.5	4.5	4.0	1.4	7.0	0.6	4.4	27.3	5.1	13.1	2.3	3.8	2.6	1.0	3.0	2.9	3.7	7.6	7.6	1.5	4.2	3.5	1.3	0.6	1.2	2.1	5.2	3.4	15.9	3.2	15.8	7.7	1.1	4.1	4.5	0.9	2.9	13.6	4.7	6.0	5.0	1.0	5.1	3.6	3.3	1.1	2.7	4.9	0.0	0.8	1.0	1.5	4.8	3.7	0.4	0.1	0.0	0.1	0.0	2.1	0.1	0.0	1.9	0.2	8.3	0.0	0.0	0.0	0.0	0.3	0.3	0.1	0.0	0.1	0.0	0.4	0.0	2.4	0.4	0.2	0.1	4.7	3.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.3	0.5	0.2	0.0	5.5	0.0	0.4	0.0	0.0	0.1	14.5	0.1	0.0	0.0	7.4	1.7	5.5	3.3	0.0	3.2	3.3	0.0	0.0	0.2	2.5	0.4	0.0	1.6	1.1	0.0	0.0	3.6	0.0	0.7	0.0	0.0	0.0	2.1	0.1	0.5	0.1	0.2	0.4	0.0	0.4	0.4	1.2	0.0	0.0	0.0	0.1	0.0	0.1	4.0	7.0	27.3	5.1	4.2	3.5	5.2	3.4	4.1	4.9
NRG3		ENSG00000185737	"Neuregulin 3"	P56975	10	81875314-82987179	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 30.6"	"Cell line enhanced"	"Detected in some"		"AF22: 1.5;HEK 293: 3.3;HUVEC TERT2: 1.6;SK-MEL-30: 7.2;U-2 OS: 6.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"							HPA075789			Uncertain	Vesicles	"Secreted in brain"			Vesicles		"HPA075789: "	"unprognostic (6.15e-3)"		"unprognostic (2.43e-2)"	"unprognostic (1.65e-5)"	"unprognostic (1.89e-1)"	"unprognostic (7.03e-4)"	"unprognostic (1.85e-2)"	"unprognostic (1.06e-1)"	"unprognostic (7.05e-2)"	"unprognostic (9.33e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.75e-2)"	"unprognostic (3.31e-4)"	"unprognostic (1.04e-1)"	"unprognostic (7.68e-3)"	"unprognostic (7.27e-4)"	0.9	1.5	15.6	1.2	8.2	0.6	2.8	1.9	30.6	0.8	0.9	4.8	0.0	0.8	0.7	0.7	0.9	8.0	5.3	0.9	14.5	6.2	1.2	1.5	1.6	0.8	4.9	8.0	0.7	0.9	0.7	1.6	1.2	6.5	0.9	0.9	3.1	5.0	1.1	0.7	0.8	0.9	0.9	5.6	0.8	0.8	3.3	6.0	0.0	0.9	0.0	0.8	1.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.2	0.0	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.6	8.2	1.9	12.8	14.5	6.2	4.9	8.0	6.5	6.0
NRP1	"CD304, NRP, VEGF165R"	ENSG00000099250	"Neuropilin 1"	O14786	10	33177492-33336262	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Angiogenesis, Differentiation, Neurogenesis"	"Developmental protein, Heparin-binding, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 69.8;TIME: 58.0;U-87 MG: 69.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	14	"plasmacytoid DC: 24.0"	"Lineage enriched"	"Detected in many"	14	"dendritic cells: 24.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB004511, HPA030278"	Approved				"Secreted in other tissues"	720000000	720000000			"CAB004511: AB_2282634, HPA030278: AB_10601976"	"unprognostic (3.19e-1)"	"prognostic unfavourable (7.10e-5)"	"unprognostic (1.50e-2)"	"unprognostic (3.80e-2)"	"prognostic unfavourable (5.79e-4)"	"unprognostic (6.17e-2)"	"unprognostic (1.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (6.66e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.82e-1)"	"unprognostic (4.78e-2)"	"prognostic unfavourable (3.87e-4)"	"prognostic unfavourable (1.22e-5)"	"unprognostic (3.83e-2)"	"unprognostic (5.48e-2)"	"unprognostic (7.79e-2)"	69.9	15.0	4.9	13.6	4.9	0.7	53.8	1.3	5.6	25.1	17.6	2.4	16.4	6.7	29.8	21.9	14.7	17.0	23.3	50.5	17.2	5.9	47.1	27.4	47.1	30.1	3.5	3.2	27.1	14.1	11.7	6.4	44.3	3.6	25.2	7.8	24.3	11.8	31.6	22.3	9.1	14.6	19.1	5.5	38.7	9.8	15.6	2.8	5.9	30.4	24.6	7.9	22.3	23.8	0.4	24.0	0.3	1.7	0.6	0.4	0.4	8.7	34.0	1.7	0.1	33.2	37.2	0.2	35.2	34.3	17.8	19.1	4.3	20.9	0.1	4.2	69.8	2.4	2.1	10.2	14.5	0.1	1.7	0.0	3.9	7.3	11.7	3.1	0.2	44.4	1.7	42.2	19.1	48.2	0.1	0.2	34.6	14.7	0.2	0.5	0.8	32.3	1.4	3.8	0.1	16.7	0.1	0.8	0.4	3.6	2.7	0.1	0.1	0.4	58.0	25.4	6.0	30.5	23.7	0.1	0.1	0.1	69.5	4.0	22.9	0.2	1.7	0.3	0.3	0.3	0.4	0.4	0.3	0.3	1.4	0.3	0.4	0.3	0.3	0.6	0.1	24.0	0.3	0.4	4.9	4.9	1.3	5.6	17.2	5.9	3.5	3.2	3.6	2.8
NRP2	VEGF165R2	ENSG00000118257	"Neuropilin 2"	O60462	2	205681990-205798133	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Differentiation, Host-virus interaction, Neurogenesis"	"Developmental protein, Heparin-binding, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 34.2;HUVEC TERT2: 30.0;TIME: 28.6;U-251 MG: 58.5;U-87 MG: 27.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.8;naive B-cell: 1.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA039980, HPA054974"	Enhanced		Supported	"Vesicles,Plasma membrane"	"Secreted in other tissues"	15000000	15000000	"Vesicles, Plasma membrane"		"HPA039980: AB_10795517, HPA054974: "	"unprognostic (4.28e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.12e-3)"	"unprognostic (3.38e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.57e-2)"	"unprognostic (9.36e-2)"	"unprognostic (3.70e-1)"	"unprognostic (2.15e-3)"	"unprognostic (2.90e-2)"	"unprognostic (2.56e-3)"	"unprognostic (4.17e-1)"	"prognostic unfavourable (7.68e-7)"	"unprognostic (2.22e-3)"	"unprognostic (5.45e-2)"	"unprognostic (6.41e-3)"	"prognostic unfavourable (7.80e-5)"	24.3	14.5	8.7	11.4	7.4	2.6	7.8	1.2	7.0	34.4	35.4	3.9	8.4	3.5	33.7	4.6	24.8	13.1	25.8	4.4	11.5	8.3	3.4	6.2	15.8	4.9	8.9	3.9	33.0	1.4	2.5	6.6	29.9	9.0	18.6	7.0	27.7	2.6	21.0	2.5	3.3	8.2	44.7	8.6	4.7	17.1	3.4	5.2	2.6	7.3	6.0	3.0	39.3	24.6	1.4	0.5	0.0	1.8	0.0	0.0	0.5	0.6	14.1	9.0	0.0	8.2	2.6	2.6	2.2	4.3	2.8	2.7	13.3	34.2	0.0	3.4	7.1	5.4	0.4	4.3	4.6	0.0	1.9	0.1	0.6	0.1	22.2	0.0	0.5	19.5	3.3	3.9	3.5	30.0	0.0	0.0	1.9	0.0	0.0	0.0	11.3	2.5	0.0	0.5	3.1	5.7	0.0	8.1	0.3	0.3	0.0	20.2	0.0	0.1	28.6	12.4	0.1	3.2	58.5	0.0	0.0	0.8	27.6	0.0	25.9	0.0	1.8	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.5	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	8.7	7.4	1.2	3.8	11.5	8.3	8.9	3.9	9.0	5.2
NSD1	"ARA267, FLJ22263, KMT3B, STO"	ENSG00000165671	"Nuclear receptor binding SET domain protein 1"	Q96L73	5	177133025-177300215	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048431, HPA070333, HPA073705"	Supported		Supported	"Nucleoplasm,Plasma membrane"				"Nucleoplasm, Plasma membrane"		"HPA048431: , HPA070333: , HPA073705: "	"unprognostic (3.48e-2)"	"unprognostic (7.46e-2)"	"unprognostic (7.14e-3)"	"unprognostic (2.64e-3)"	"unprognostic (1.38e-1)"	"unprognostic (9.67e-2)"	"unprognostic (2.29e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.68e-3)"	"unprognostic (8.04e-2)"	"unprognostic (1.48e-1)"	"unprognostic (2.09e-1)"	"unprognostic (7.77e-3)"	"unprognostic (3.53e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.51e-2)"	"unprognostic (7.32e-2)"	11.8	13.2	11.9	25.4	15.7	23.9	14.0	28.9	16.7	15.6	14.2	18.5	17.0	10.6	19.0	13.9	17.8	13.6	15.8	11.7	12.8	11.5	14.4	10.5	12.3	19.4	12.9	11.7	16.6	27.1	24.6	19.3	16.0	13.4	14.2	14.3	13.8	13.5	18.7	20.6	16.1	14.5	15.6	13.2	16.1	13.1	28.1	16.1	27.3	20.1	10.6	22.7	13.4	20.2	10.2	8.9	18.7	10.8	10.9	7.8	2.9	9.7	12.6	13.1	11.3	6.4	8.3	0.4	8.8	8.9	12.4	11.6	2.8	8.2	20.1	10.0	12.1	8.4	20.8	19.6	15.1	34.0	12.6	8.9	14.2	0.1	10.7	19.2	10.6	7.8	11.9	14.7	13.8	18.0	12.1	7.1	12.5	20.4	13.3	6.2	14.2	11.1	14.8	1.7	6.2	8.0	11.8	15.9	11.0	22.9	10.0	6.9	10.0	16.0	13.3	8.7	12.6	5.5	10.9	8.3	7.2	14.4	5.0	9.4	9.3	10.7	9.1	9.4	7.5	6.1	6.3	8.5	6.3	5.0	6.7	10.2	7.8	6.3	18.7	10.9	10.8	8.9	5.7	2.9	11.9	15.7	28.9	16.7	12.8	11.5	12.9	11.7	13.4	16.1
NSD2	"KMT3G, MMSET, WHSC1"	ENSG00000109685	"Nuclear receptor binding SET domain protein 2"	O96028	4	1871424-1982207	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015801, CAB068246, CAB068247"	Enhanced		Supported	Nucleoplasm				Nucleoplasm		"CAB068246: , CAB068247: , HPA015801: AB_1858830"	"unprognostic (3.70e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.33e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.01e-1)"	"unprognostic (1.31e-2)"	"prognostic unfavourable (2.61e-4)"	"unprognostic (3.24e-2)"	"unprognostic (6.22e-2)"	"unprognostic (7.66e-2)"	"unprognostic (2.09e-1)"	"unprognostic (9.25e-3)"	"prognostic unfavourable (7.19e-4)"	"unprognostic (3.89e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.31e-1)"	"unprognostic (6.15e-2)"	8.7	7.6	17.6	11.5	16.2	35.1	8.5	20.6	18.2	7.0	14.8	12.4	6.3	14.0	9.5	7.4	12.7	6.8	6.9	11.9	15.1	10.9	8.4	7.5	11.1	18.8	14.7	16.1	7.0	11.7	10.7	11.8	9.8	14.6	8.7	17.7	9.4	10.2	7.4	11.8	12.1	14.6	10.5	15.3	13.5	11.0	26.3	13.4	46.7	13.8	5.5	17.7	8.6	9.4	4.9	3.9	4.1	1.8	2.7	4.3	0.6	27.4	13.9	41.9	18.3	4.5	6.7	12.2	22.2	19.7	27.2	30.5	12.2	32.6	29.6	7.6	18.3	12.0	27.0	18.3	46.8	14.2	11.1	35.2	19.2	7.2	5.7	21.5	18.5	2.6	4.6	23.9	23.0	21.4	19.0	31.1	22.3	10.8	57.5	22.6	17.6	16.0	32.9	27.3	10.2	11.2	13.0	26.0	20.8	18.2	6.8	8.3	16.1	14.5	16.5	27.2	20.3	17.2	44.6	14.6	15.4	26.8	16.3	21.4	25.2	2.1	1.7	1.7	2.9	1.8	3.2	1.8	3.2	3.2	1.5	4.9	2.8	2.3	4.1	2.7	1.4	3.9	4.3	0.6	17.6	16.2	20.6	18.2	15.1	10.9	14.7	16.1	14.6	13.4
NSD3	"FLJ20353, KMT3F, WHISTLE, WHSC1L1"	ENSG00000147548	"Nuclear receptor binding SET domain protein 3"	Q9BZ95	8	38269697-38382272	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005659, CAB013721, HPA018893"	Uncertain		Approved	Nucleoplasm,Mitochondria				Mitochondria	Nucleoplasm	"CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833"	"unprognostic (6.21e-2)"	"unprognostic (3.73e-2)"	"unprognostic (2.18e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.53e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.49e-1)"	"unprognostic (5.72e-2)"	"prognostic unfavourable (7.48e-4)"	"unprognostic (5.06e-2)"	"unprognostic (5.60e-3)"	"unprognostic (6.69e-2)"	"unprognostic (4.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.60e-2)"	19.2	11.3	31.1	15.8	31.4	36.3	20.1	51.5	37.7	18.5	15.5	16.7	14.0	16.2	16.0	12.5	17.0	16.8	17.0	12.7	24.4	16.6	14.2	11.2	17.9	22.3	25.0	26.8	26.5	16.3	21.0	24.2	22.5	21.9	16.4	18.7	12.3	18.3	17.9	12.3	16.2	17.7	16.0	15.3	17.2	19.7	9.3	25.6	16.7	19.2	6.9	20.4	19.6	23.3	26.7	5.6	26.2	5.1	8.6	18.0	2.9	23.9	13.8	23.7	16.0	16.6	19.2	17.6	20.1	22.3	17.4	20.3	7.3	13.3	28.6	18.5	13.7	14.4	18.7	16.1	24.9	11.3	11.0	36.4	11.1	8.6	17.1	16.0	13.2	10.3	16.4	15.7	32.1	20.0	25.8	19.0	16.5	8.6	46.7	13.6	16.1	6.5	21.4	25.9	9.0	12.4	18.6	13.4	18.1	16.3	14.3	14.0	18.1	12.2	19.0	18.2	18.9	27.0	11.8	17.0	20.2	27.6	15.3	16.2	13.1	13.9	5.1	9.1	8.0	2.4	5.3	16.5	12.0	7.1	4.1	26.7	15.0	6.3	26.2	8.6	1.5	5.6	18.0	2.9	31.1	31.4	51.5	37.7	24.4	16.6	25.0	26.8	21.9	25.6
NT5C2	"cN-II, GMP, NT5B, PNT5, SPG65"	ENSG00000076685	"5'-nucleotidase, cytosolic II"	P49902	10	103088017-103193306	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Nucleotide metabolism"	"Allosteric enzyme, Hydrolase"	"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003751	Approved									"HPA003751: AB_1854664"	"unprognostic (8.18e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.55e-2)"	"unprognostic (2.46e-1)"	"unprognostic (5.54e-2)"	"unprognostic (4.87e-3)"	"unprognostic (2.24e-2)"	"unprognostic (1.72e-1)"	"unprognostic (6.41e-2)"	"unprognostic (9.59e-2)"	"unprognostic (2.93e-3)"	"unprognostic (6.20e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.70e-2)"	"unprognostic (6.40e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.50e-1)"	15.0	17.0	17.6	18.2	21.2	31.6	19.7	22.5	19.6	17.5	20.7	25.4	24.5	10.9	24.6	19.6	38.6	14.8	17.0	16.5	16.7	20.7	19.6	15.5	18.8	16.8	21.8	17.3	24.8	19.4	18.7	29.5	16.9	29.1	22.9	17.0	26.2	67.2	21.6	41.6	11.7	13.9	20.4	19.1	20.5	15.9	21.7	14.5	29.7	39.2	16.3	31.5	21.1	31.1	6.7	9.7	23.8	14.5	10.5	8.7	7.1	50.1	20.4	14.2	31.9	12.5	14.0	8.1	25.2	24.5	12.3	12.7	14.8	40.2	24.0	19.6	17.4	25.7	9.4	12.9	14.4	14.5	8.8	17.3	8.7	14.4	22.4	25.0	8.6	21.4	14.4	10.7	17.3	11.2	11.2	16.8	21.2	29.6	22.3	32.4	13.5	25.3	36.5	12.3	6.9	17.6	28.7	4.3	10.7	13.2	10.4	19.7	15.9	19.4	11.4	9.8	9.8	14.0	18.3	14.7	24.4	32.2	9.9	28.9	2.8	19.8	11.7	23.8	8.1	11.9	8.7	6.7	7.0	6.5	9.7	4.2	6.0	6.2	21.4	10.5	14.5	7.3	6.5	7.1	17.6	21.2	22.5	18.0	16.7	20.7	21.8	17.3	29.1	14.5
NTF3	NGF2	ENSG00000185652	"Neurotrophin 3"	P20783	12	5432112-5521536	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 29.2"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 9.0;BJ hTERT+ SV40 Large T+: 11.9;BJ hTERT+ SV40 Large T+ RasG12V: 15.8;HBF TERT88: 14.7;RT4: 6.7"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in some"	16	"cerebellum: 29.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"amygdala: 4.1;basal ganglia: 7.4;cerebellum: 12.3;hippocampal formation: 12.3"	"Low region specificity"	"Detected in all"			HPA032001	Uncertain		Approved	Vesicles	"Secreted in other tissues"			Vesicles		"HPA032001: "	"unprognostic (3.04e-2)"	"unprognostic (7.46e-2)"	"unprognostic (7.33e-3)"	"unprognostic (4.66e-3)"	"unprognostic (8.89e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.36e-3)"	"unprognostic (7.68e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.86e-1)"	"unprognostic (2.20e-1)"	"unprognostic (7.77e-4)"	"unprognostic (4.02e-3)"	"unprognostic (1.92e-1)"	"unprognostic (8.06e-3)"	"unprognostic (4.51e-3)"	4.9	2.7	0.5	2.4	0.5	0.0	5.4	29.2	0.6	12.9	4.7	0.3	5.6	2.7	9.2	6.8	5.0	2.2	5.3	4.1	1.7	0.2	4.3	10.4	2.5	1.0	0.7	0.2	16.8	0.4	0.1	1.3	2.7	1.2	8.9	1.5	8.9	4.6	3.7	3.6	3.7	6.6	11.5	0.4	8.5	3.0	3.5	0.0	0.2	1.2	3.9	2.0	10.4	9.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	5.4	0.0	0.0	0.0	0.0	3.4	9.0	11.9	15.8	0.1	0.2	0.0	5.4	5.6	1.9	0.0	0.0	14.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	1.5	0.0	0.0	0.0	3.5	3.7	6.7	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.1	0.0	0.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	29.2	0.6	1.7	0.2	0.7	0.2	1.2	0.0
NTF4	"GLC1O, NT-4/5, NTF5"	ENSG00000225950	"Neurotrophin 4"	P34130	19	49061066-49065054	"Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes, Glaucoma"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"skin 1: 24.3"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 8.1;HaCaT: 18.3;HBEC3-KT: 6.8;hTCEpi: 30.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA049376			Approved	"Golgi apparatus"	"Secreted in other tissues"			"Golgi apparatus"		"HPA049376: "	"unprognostic (4.15e-2)"	"unprognostic (1.07e-1)"	"unprognostic (9.27e-4)"	"unprognostic (1.76e-4)"	"unprognostic (2.36e-1)"	"unprognostic (1.02e-2)"		"unprognostic (1.60e-1)"	"unprognostic (2.73e-2)"	"unprognostic (4.87e-3)"	"unprognostic (3.90e-4)"	"unprognostic (2.97e-1)"	"unprognostic (1.40e-3)"	"unprognostic (3.71e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.89e-2)"	"unprognostic (2.46e-3)"	0.3	0.0	0.3	0.3	0.3	0.0	3.6	0.3	1.0	2.8	0.3	0.3	5.7	0.0	0.3	8.0	7.1	1.7	0.3	0.3	0.3	0.0	0.3	0.3	3.3	0.3	0.3	0.3	0.3	0.3	0.0	2.3	3.0	0.3	11.9	0.0	0.3	5.7	6.1	11.9	24.3	0.3	1.4	0.3	0.3	0.0	1.3	0.3	1.4	0.9	2.3	2.2	6.2	5.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	2.2	0.1	0.1	1.3	0.0	0.0	5.5	0.0	0.0	0.0	0.0	2.0	8.1	0.0	2.1	0.0	18.3	0.0	6.8	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	30.3	0.0	0.9	0.0	0.0	0.1	0.2	0.6	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	5.1	0.0	0.0	0.4	0.1	0.0	4.8	0.0	0.1	1.1	2.2	0.1	5.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	1.0	0.3	0.0	0.3	0.3	0.3	0.3
NTHL1	"NTH1, OCTS3"	ENSG00000065057	"Nth like DNA glycosylase 1"	P78549	16	2039815-2047866	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Glycosidase, Hydrolase, Lyase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB025152	Supported									"CAB025152: "	"unprognostic (1.06e-1)"	"unprognostic (9.71e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.54e-1)"	"unprognostic (7.89e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.86e-1)"	"unprognostic (2.46e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.77e-2)"	"unprognostic (6.78e-2)"	"unprognostic (6.53e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.34e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.62e-2)"	10.5	8.2	13.4	10.5	19.9	6.0	7.8	15.6	17.9	14.8	12.3	9.0	15.1	9.7	11.8	6.9	9.4	20.5	14.7	10.6	12.5	12.1	7.4	17.5	11.1	10.4	13.6	15.7	18.8	24.6	5.8	8.7	8.3	13.3	9.8	8.2	9.1	22.2	18.2	12.4	6.3	11.2	7.8	10.4	15.2	11.1	6.4	11.6	9.6	9.5	6.6	8.4	7.8	9.3	21.4	14.7	2.4	14.2	9.7	18.8	8.5	10.7	26.4	7.7	11.6	3.1	6.0	8.5	4.5	4.8	8.6	5.4	18.8	10.5	22.9	9.5	3.7	9.6	9.5	10.6	1.5	10.6	23.3	7.1	16.7	20.8	4.3	8.1	8.4	5.0	5.5	4.5	4.9	11.9	7.7	8.3	3.3	12.0	12.1	30.4	17.1	17.3	29.0	8.1	36.7	6.2	3.9	16.3	16.3	4.9	15.1	8.7	10.8	8.0	4.6	7.3	8.1	6.5	8.3	11.3	13.2	9.3	3.3	11.4	9.1	2.4	8.7	2.0	8.8	14.2	9.8	21.4	10.5	9.8	14.7	17.1	7.8	9.5	0.3	9.7	12.1	14.6	18.8	8.5	13.4	19.9	15.6	17.9	12.5	12.1	13.6	15.7	13.3	11.6
NTN1	NTN1L	ENSG00000065320	"Netrin 1"	O95631	17	9021542-9244000	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	Apoptosis		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BEWO: 19.9;T-47d: 11.8;U-2 OS: 10.5;U-251 MG: 15.4;WM-115: 9.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA056419	Approved				"Secreted to extracellular matrix"	150000	150000			"HPA056419: "	"unprognostic (2.72e-1)"	"unprognostic (2.59e-2)"	"unprognostic (7.12e-2)"	"unprognostic (5.25e-2)"	"unprognostic (2.51e-1)"	"unprognostic (9.33e-3)"	"unprognostic (9.42e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.15e-1)"	"unprognostic (2.49e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.60e-1)"	"unprognostic (6.07e-3)"	"unprognostic (8.31e-3)"	3.9	1.1	1.2	3.6	1.6	0.0	4.3	1.3	5.7	6.3	10.4	2.7	0.8	5.0	5.6	3.2	21.2	8.1	16.7	20.8	1.5	1.6	1.8	5.3	3.8	0.1	2.8	0.3	1.9	1.4	0.0	1.8	0.5	6.9	3.2	3.0	15.6	7.0	1.5	1.6	2.7	9.4	6.8	4.4	1.0	6.4	1.6	1.5	0.0	1.5	6.0	8.0	7.1	4.1	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	1.0	3.3	3.1	0.1	19.9	0.2	0.3	0.2	0.3	0.0	4.0	0.0	4.5	0.0	0.1	0.9	0.6	0.0	4.4	7.4	1.0	0.0	0.0	0.1	0.4	0.1	0.1	1.5	0.5	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.4	1.3	0.0	2.3	3.5	0.0	0.0	0.2	0.0	0.0	0.1	3.3	0.7	11.8	0.2	0.0	4.9	10.5	0.0	15.4	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.6	1.3	1.6	1.5	1.6	2.8	0.3	6.9	1.5
NTN4		ENSG00000074527	"Netrin 4"	Q9HB63	12	95657807-95791152	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 76.9"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 92.6;hTERT-HME1: 38.3;PC-3: 35.0;TIME: 52.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	11	"MAIT T-cell: 4.9"	"Lineage enriched"	"Detected in single"	49	"T-cells: 4.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049832	Approved				"Secreted to extracellular matrix"					"HPA049832: "	"unprognostic (3.08e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.33e-1)"	"unprognostic (4.15e-2)"	"unprognostic (2.11e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.03e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.58e-1)"	"prognostic unfavourable (9.50e-4)"	"unprognostic (2.85e-1)"	"prognostic favourable (8.12e-9)"	"unprognostic (3.52e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.93e-1)"	"prognostic favourable (6.67e-5)"	11.1	8.5	4.0	4.4	6.3	0.0	22.8	1.2	9.0	9.9	8.9	2.5	7.3	3.4	8.2	11.9	10.7	10.7	13.0	27.2	3.9	2.4	35.8	13.6	21.7	0.7	4.1	6.1	28.5	18.2	6.6	4.5	7.7	2.8	24.1	5.4	8.4	14.7	19.6	7.2	3.8	8.7	7.2	2.2	76.9	14.5	6.5	2.2	1.5	6.7	9.7	4.2	14.1	11.9	0.0	0.0	0.0	0.0	0.0	4.9	0.0	4.7	13.0	0.3	0.0	5.3	8.5	0.5	9.1	92.6	12.3	14.8	10.2	9.0	0.0	0.6	19.1	7.6	0.1	2.7	6.3	0.0	0.8	0.4	2.4	1.9	0.3	0.0	0.0	0.2	7.9	14.2	38.3	24.2	0.0	0.0	4.6	3.5	0.0	0.0	0.2	35.0	0.0	0.1	0.0	12.0	24.4	0.0	0.1	11.0	14.1	0.2	4.1	0.0	52.6	4.8	1.8	18.8	0.9	0.0	0.0	0.0	1.1	0.0	1.0	0.0	0.0	0.0	0.1	0.0	4.9	0.0	0.4	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	4.0	6.3	1.2	9.0	3.9	2.4	4.1	6.1	2.8	2.2
NTRK1	"MTC, TRK, TRKA"	ENSG00000198400	"Neurotrophic receptor tyrosine kinase 1"	P04629	1	156815640-156881850	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"adrenal gland: 15.8;blood: 32.3;brain: 28.3"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 41.1"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Region enriched"	"Detected in many"	5	"pons and medulla: 28.3"	"Cell type enriched"	"Detected in single"	127	"basophil: 32.3"	"Lineage enriched"	"Detected in single"	323	"granulocytes: 32.3"	"Region enhanced"	"Detected in some"		"basal ganglia: 8.2"	"Low region specificity"	"Detected in all"			"CAB004606, HPA035799, HPA076570"	Approved		Approved	Vesicles,Cytosol		140000	140000	"Vesicles, Cytosol"		"CAB004606: AB_628397, HPA035799: , HPA076570: "	"unprognostic (5.89e-3)"	"unprognostic (7.56e-2)"	"unprognostic (2.74e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.26e-2)"	"unprognostic (1.43e-3)"	"unprognostic (1.56e-1)"	"unprognostic (7.42e-3)"	"unprognostic (7.63e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.73e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.18e-11)"	"unprognostic (2.18e-3)"	"unprognostic (3.79e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.89e-1)"	1.0	15.8	0.5	0.8	6.0	0.9	0.4	0.0	0.7	0.9	1.1	0.1	0.0	0.8	1.6	2.0	0.7	0.6	2.1	1.5	0.0	1.2	2.9	0.2	1.9	0.3	2.1	0.6	0.3	0.3	0.3	1.1	0.5	28.3	2.2	0.2	3.1	1.2	0.5	0.7	0.2	0.4	1.1	1.2	0.2	1.0	2.4	1.5	0.4	0.3	0.0	0.4	0.7	0.8	0.0	0.0	32.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	5.6	0.0	6.6	0.0	0.0	0.0	0.0	41.1	0.0	0.0	0.0	0.0	0.0	2.1	0.7	0.0	0.0	0.0	1.1	0.0	0.6	1.2	0.0	0.1	0.0	0.0	0.7	9.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	1.6	0.2	0.0	0.0	0.0	0.0	32.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.0	0.0	0.6	0.0	1.2	2.1	0.6	28.3	1.5
NTRK2	TRKB	ENSG00000148053	"Neurotrophic receptor tyrosine kinase 2"	Q16620	9	84668551-85027070	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Epilepsy, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 133.8;thyroid gland: 63.4"	"Cell line enhanced"	"Detected in some"		"AF22: 10.4;HaCaT: 3.7;RPTEC TERT1: 11.6;SH-SY5Y: 13.3"	"Group enriched"	"Detected in many"	5	"glioma: 31.6;head and neck cancer: 8.0;lung cancer: 9.8;thyroid cancer: 26.4"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"T-reg: 1.4"	"Lineage enriched"	"Detected in single"	14	"T-cells: 1.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007637, CAB010346"	Enhanced		Approved	Cytosol		13000000	13000000	Cytosol		"CAB010346: AB_2155274, HPA007637: AB_1080385"	"unprognostic (2.75e-3)"	"unprognostic (3.48e-2)"	"unprognostic (1.82e-2)"	"unprognostic (3.26e-1)"	"unprognostic (9.26e-2)"	"unprognostic (2.56e-2)"	"unprognostic (1.29e-2)"	"unprognostic (9.16e-2)"	"unprognostic (6.13e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.25e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.20e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.39e-3)"	19.8	2.7	66.1	2.0	56.7	1.2	33.2	15.1	133.8	6.4	4.4	27.4	0.0	1.4	3.0	3.3	5.6	3.7	18.7	5.8	61.0	30.7	12.5	2.1	6.3	2.7	32.4	41.4	6.6	18.9	1.6	3.0	2.1	34.1	3.8	3.1	2.0	8.6	11.9	2.0	7.2	1.6	3.0	22.1	6.5	1.4	2.4	34.1	0.0	63.4	2.6	3.4	3.5	3.8	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	1.6	0.0	0.2	0.0	3.7	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	11.6	0.8	0.9	13.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.1	0.0	0.4	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	66.1	56.7	15.1	45.6	61.0	30.7	32.4	41.4	34.1	34.1
NTRK3	TRKC	ENSG00000140538	"Neurotrophic receptor tyrosine kinase 3"	Q16288	15	87859751-88256768	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 41.8"	"Cell line enriched"	"Detected in some"	8	"U-138 MG: 47.4"	"Cancer enhanced"	"Detected in some"		"glioma: 2.5"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009233, HPA027484, HPA048065"	Approved		Supported	"Nuclear membrane,Nucleoli"		11000000	11000000	Nucleoli	"Nuclear membrane"	"CAB009233: AB_632555, HPA027484: , HPA048065: "	"unprognostic (1.27e-3)"	"unprognostic (1.24e-2)"	"unprognostic (1.98e-2)"	"unprognostic (2.04e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.34e-1)"	"unprognostic (3.18e-2)"	"unprognostic (2.23e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.91e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.09e-1)"	"unprognostic (5.78e-3)"	"unprognostic (6.45e-3)"	"unprognostic (1.06e-2)"	"unprognostic (1.26e-2)"	"unprognostic (2.49e-3)"	20.8	7.4	22.0	2.5	28.1	1.5	6.2	30.4	41.8	7.0	4.0	8.4	1.3	2.0	12.4	6.7	3.4	9.5	3.9	5.5	22.0	11.1	5.1	2.0	5.7	3.1	11.2	18.7	5.1	2.9	1.6	7.9	2.8	14.7	6.8	4.7	8.0	11.5	8.7	1.9	2.9	2.5	7.7	13.7	4.1	3.0	13.8	13.7	0.0	2.5	0.7	4.3	7.1	4.8	0.7	0.4	1.3	0.5	0.5	0.8	0.0	0.0	5.9	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.1	0.0	0.0	1.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.4	0.9	0.0	0.5	0.0	0.0	0.0	1.4	0.0	0.1	1.2	0.5	0.4	0.3	0.1	0.2	0.4	0.3	0.3	0.1	0.7	0.4	0.4	1.3	0.5	0.1	0.4	0.8	0.0	22.0	28.1	30.4	28.9	22.0	11.1	11.2	18.7	14.7	13.7
NUDT1	MTH1	ENSG00000106268	"Nudix hydrolase 1"	P36639	7	2242222-2251146	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 59.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012636	Approved		Supported	Cytosol				Cytosol		"HPA012636: AB_1854696"	"unprognostic (1.31e-1)"	"unprognostic (1.19e-2)"	"unprognostic (2.13e-2)"	"unprognostic (2.37e-1)"	"unprognostic (3.01e-3)"	"unprognostic (3.37e-1)"	"prognostic unfavourable (4.44e-4)"	"unprognostic (2.15e-2)"	"unprognostic (4.77e-1)"	"unprognostic (3.81e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.53e-1)"	"prognostic unfavourable (1.30e-7)"	"unprognostic (1.29e-1)"	"unprognostic (6.71e-2)"	"unprognostic (3.49e-2)"	"unprognostic (1.70e-1)"	8.8	3.9	7.4	12.6	13.4	37.1	10.8	5.0	10.8	5.9	9.0	8.7	2.2	9.1	8.2	9.2	13.1	6.0	8.1	11.3	8.7	4.7	4.1	2.9	7.2	18.9	8.2	7.0	4.8	4.0	0.7	1.8	5.8	7.2	7.2	6.3	4.0	5.5	4.2	12.0	18.8	9.3	10.5	11.9	11.1	5.5	26.7	5.3	30.7	4.1	14.4	17.2	6.8	8.1	18.3	59.5	11.9	21.3	10.1	20.4	13.0	21.5	34.8	19.1	25.3	7.0	9.7	14.0	9.5	8.3	13.1	15.3	18.7	16.3	22.8	7.8	10.4	26.4	14.5	14.5	7.7	10.1	24.7	17.8	29.3	15.8	1.7	13.8	18.0	6.4	3.8	18.9	6.7	7.0	14.0	25.5	14.5	55.0	25.7	53.8	41.0	21.5	35.9	28.4	19.1	7.1	12.2	19.2	26.6	9.8	28.9	4.4	19.1	36.7	6.5	12.6	48.1	29.0	22.6	19.7	14.9	23.6	12.7	34.4	45.2	9.0	17.5	11.9	12.9	21.3	10.2	18.3	15.1	13.6	26.6	18.0	15.1	13.1	4.6	10.1	17.4	59.5	20.4	13.0	7.4	13.4	5.0	10.8	8.7	4.7	8.2	7.0	7.2	5.3
NUMA1		ENSG00000137497	"Nuclear mitotic apparatus protein 1"	Q14980	11	72002864-72080693	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019841, HPA019859, HPA029912"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA019841: AB_1854708, HPA019859: AB_1854709, HPA029912: AB_10602811"	"unprognostic (1.60e-2)"	"unprognostic (3.31e-1)"	"unprognostic (2.06e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.14e-1)"	"unprognostic (6.47e-2)"	"unprognostic (5.75e-2)"	"unprognostic (8.74e-3)"	"unprognostic (5.91e-2)"	"unprognostic (9.45e-2)"	"unprognostic (1.60e-2)"	"unprognostic (2.51e-2)"	"prognostic favourable (7.92e-4)"	"unprognostic (1.28e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.39e-1)"	29.7	33.5	23.6	20.6	28.1	26.8	33.1	38.4	31.8	51.9	37.7	55.6	40.1	25.5	58.3	30.9	34.1	37.8	31.2	21.2	21.6	19.4	23.0	13.1	28.3	23.3	37.6	24.8	51.4	30.0	70.7	29.5	26.0	28.3	50.3	24.2	41.2	35.3	40.1	43.7	41.9	30.2	45.3	29.5	23.0	31.2	25.9	39.5	39.4	32.6	22.5	31.8	50.5	37.2	10.3	12.9	4.9	5.7	7.0	9.7	6.6	18.5	23.6	29.6	19.9	26.3	27.5	15.1	25.1	29.1	26.2	22.9	24.5	34.4	25.3	22.0	30.7	39.9	27.0	25.4	24.0	26.0	12.7	31.0	37.1	18.6	21.2	23.4	22.6	29.0	16.8	25.6	25.9	22.1	18.2	30.6	17.8	35.8	30.2	13.1	18.4	17.0	37.1	51.6	19.5	19.6	29.1	35.8	50.8	40.0	37.1	37.3	49.9	13.7	30.4	27.8	21.7	39.2	16.6	19.8	19.6	35.6	18.6	11.1	15.8	4.9	5.6	2.5	9.7	3.5	7.4	5.2	6.0	7.5	4.9	10.3	7.5	5.2	4.6	7.0	5.7	12.9	7.2	6.6	23.6	28.1	38.4	31.8	21.6	19.4	37.6	24.8	28.3	39.5
NUMB	C14orf41	ENSG00000133961	"NUMB, endocytic adaptor protein"	P49757	14	73275107-73458617	"Cancer-related genes, Predicted intracellular proteins"	Neurogenesis	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 64.9"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002874, CAB011478"	Approved		Enhanced	"Cell Junctions"				"Cell Junctions"		"CAB011478: AB_443023, HPA002874: "	"unprognostic (5.28e-2)"	"unprognostic (7.23e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.32e-3)"	"unprognostic (2.02e-1)"	"unprognostic (2.01e-1)"	"unprognostic (2.43e-1)"	"unprognostic (9.49e-2)"	"unprognostic (1.33e-2)"	"unprognostic (4.08e-3)"	"unprognostic (2.65e-3)"	"unprognostic (4.14e-2)"	"prognostic favourable (2.32e-6)"	"unprognostic (9.12e-2)"	"unprognostic (1.63e-1)"	"unprognostic (3.92e-2)"	"unprognostic (2.87e-1)"	27.3	21.5	26.2	24.5	23.5	21.3	26.4	37.1	27.0	24.2	35.9	17.3	26.1	31.3	30.8	23.9	30.1	28.8	28.8	23.3	23.3	14.1	30.3	35.5	40.5	23.0	18.9	20.7	29.2	26.8	31.8	28.3	29.9	23.4	23.7	29.4	22.3	34.2	23.9	16.4	24.6	45.3	38.0	26.1	32.9	25.1	19.0	19.8	20.1	27.7	17.0	26.2	30.5	26.9	5.2	15.2	64.9	20.9	2.7	3.8	11.6	20.9	14.4	10.4	9.4	21.1	32.2	14.2	19.9	27.0	16.1	17.2	17.4	26.5	9.6	12.5	24.6	13.9	12.3	20.5	24.5	14.7	6.9	7.7	9.5	11.2	22.4	7.0	18.1	17.9	22.1	39.6	23.7	34.7	13.9	11.6	20.3	18.9	12.8	9.8	4.8	15.5	8.3	14.5	6.4	22.3	32.2	4.3	11.2	24.9	16.9	10.1	25.3	10.4	33.2	24.2	13.6	15.5	8.5	9.7	11.2	8.8	48.6	8.3	10.6	16.3	19.8	20.8	3.0	17.1	3.1	5.2	3.0	3.3	15.2	5.1	3.1	2.8	64.9	2.7	20.9	2.8	3.8	11.6	26.2	23.5	37.1	27.0	23.3	14.1	18.9	20.7	23.4	19.8
NUP210L		ENSG00000143552	"Nucleoporin 210 like"	Q5VU65	1	153992685-154155116	"Cancer-related genes, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"testis: 42.7"	"Cell line enriched"	"Detected in single"	43	"MCF7: 18.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA047195, HPA064245, HPA066707"	Enhanced		Approved	"Nuclear bodies"				"Nuclear bodies"		"HPA047195: , HPA064245: , HPA066707: "	"unprognostic (2.11e-1)"	"unprognostic (1.78e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.72e-3)"	"unprognostic (6.90e-2)"	"unprognostic (1.79e-3)"	"unprognostic (3.45e-2)"	"unprognostic (5.57e-2)"	"unprognostic (4.51e-4)"	"unprognostic (1.15e-1)"	"unprognostic (9.35e-10)"	"unprognostic (4.20e-2)"	"unprognostic (3.78e-2)"	"unprognostic (7.45e-2)"	"unprognostic (4.09e-2)"	0.2	0.1	0.1	0.1	0.3	0.2	0.1	0.1	0.9	0.1	0.1	1.5	0.0	0.0	1.1	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.2	0.0	0.4	0.4	0.6	0.1	0.0	0.8	0.9	0.4	0.1	0.1	0.1	3.4	0.2	0.1	0.1	42.7	0.0	0.3	0.3	0.0	0.1	1.2	0.1	0.6	0.6	1.8	0.2	0.9	0.8	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.3	0.0	0.3	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.4	0.3	0.1	0.2	0.6	0.4	0.5	0.0	0.5	0.8	0.3	1.8	0.9	0.0	0.6	0.7	0.0	0.1	0.3	0.1	0.9	0.1	0.2	0.1	0.0	0.6	0.0
NUP214	"CAIN, CAN, D9S46E, N214"	ENSG00000126883	"Nucleoporin 214"	P35658	9	131125561-131234670	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 131.5"	"Cell line enhanced"	"Detected in all"		"K-562: 71.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 43.7;neutrophil: 131.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 131.5;monocytes: 43.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048789			Approved	"Nucleoplasm,Vesicles,Focal adhesion sites"		100000	100000	Nucleoplasm	"Vesicles, Focal adhesion sites"	"HPA048789: "	"unprognostic (1.30e-1)"	"unprognostic (9.51e-3)"	"unprognostic (9.92e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.42e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.10e-2)"	"unprognostic (3.35e-1)"	"unprognostic (4.95e-1)"	"unprognostic (6.60e-3)"	"unprognostic (1.08e-1)"	"prognostic favourable (2.39e-5)"	"unprognostic (5.49e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.53e-1)"	16.9	10.3	11.5	13.8	13.9	29.4	12.9	13.0	14.4	10.2	11.4	19.8	10.4	9.0	15.0	13.7	16.1	12.1	10.2	9.7	9.5	8.1	19.0	15.1	11.7	13.3	13.2	8.8	14.2	17.0	16.7	16.9	13.0	11.3	11.1	10.8	15.3	13.0	11.1	15.5	17.5	11.7	11.1	14.3	35.8	12.3	63.7	13.3	27.4	11.8	7.6	16.8	10.7	11.2	1.2	16.8	131.5	43.7	1.2	0.8	17.9	6.7	9.6	8.2	4.9	6.6	6.4	8.6	6.0	6.2	7.8	6.3	7.8	4.9	10.9	4.8	8.2	15.4	11.0	7.8	7.6	7.9	5.4	6.8	13.7	15.2	5.8	10.6	7.3	7.0	7.2	10.0	8.1	8.0	71.4	6.3	8.0	12.5	13.9	16.0	8.9	8.5	4.8	10.3	10.9	9.0	6.2	7.0	7.2	10.0	9.2	5.2	12.1	26.4	6.8	13.8	7.8	9.0	9.6	5.5	10.7	10.5	6.7	6.4	8.3	3.5	43.7	17.3	0.7	18.4	0.8	1.2	0.7	0.6	16.8	1.1	0.7	0.7	131.5	1.2	15.0	1.5	0.4	17.9	11.5	13.9	13.0	14.4	9.5	8.1	13.2	8.8	11.3	13.3
NUP93	KIAA0095	ENSG00000102900	"Nucleoporin 93"	Q8N1F7	16	56730105-56850286	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017937	Uncertain									"HPA017937: AB_1854726"	"unprognostic (6.31e-2)"	"unprognostic (3.22e-2)"	"unprognostic (1.41e-1)"	"unprognostic (8.85e-2)"	"unprognostic (3.99e-3)"	"unprognostic (2.78e-3)"	"prognostic unfavourable (1.72e-6)"	"unprognostic (9.18e-2)"	"unprognostic (9.35e-3)"	"unprognostic (5.22e-2)"	"unprognostic (4.55e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.66e-2)"	"unprognostic (3.71e-1)"	"unprognostic (1.85e-1)"	"unprognostic (9.68e-2)"	"unprognostic (3.74e-2)"	14.2	12.2	14.8	15.6	29.7	33.7	12.6	16.8	29.1	12.7	12.4	14.4	4.4	7.2	15.0	9.8	16.8	12.0	8.6	11.5	26.1	11.2	9.9	6.9	12.6	19.1	13.1	16.7	13.4	9.8	16.5	9.6	14.1	23.8	13.9	14.5	23.0	10.4	10.2	15.5	16.3	11.2	14.5	20.7	17.8	11.1	29.3	13.9	28.0	27.4	10.4	22.5	11.5	13.2	12.0	16.9	54.1	21.3	15.1	14.6	11.9	19.1	23.8	21.6	23.5	8.3	9.1	23.9	16.8	13.7	41.8	28.7	32.7	19.2	30.1	16.9	15.8	34.4	40.9	23.9	41.3	9.2	22.3	20.1	17.2	26.7	10.2	26.6	24.1	9.1	10.5	28.3	17.9	24.0	24.3	6.0	20.6	13.7	35.7	22.9	27.4	26.7	43.4	36.4	30.4	16.2	12.8	19.1	12.6	43.8	15.4	13.8	11.7	16.6	16.0	19.9	22.3	16.6	19.0	10.4	14.2	50.2	14.0	25.2	19.4	5.1	14.3	54.1	11.9	21.3	14.6	12.0	9.1	12.9	16.9	11.6	9.5	13.2	3.6	15.1	20.9	8.8	11.0	11.9	14.8	29.7	16.8	29.1	26.1	11.2	13.1	16.7	23.8	13.9
NUP98	NUP96	ENSG00000110713	"Nucleoporin 98"	P52948	11	3671083-3797792	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA074810			Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA074810: "	"unprognostic (1.11e-1)"	"unprognostic (1.49e-1)"	"unprognostic (7.41e-2)"	"unprognostic (2.13e-1)"	"unprognostic (7.71e-3)"	"unprognostic (3.40e-1)"	"unprognostic (4.08e-3)"	"unprognostic (6.47e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.83e-2)"	"unprognostic (7.76e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.23e-1)"	"unprognostic (5.09e-1)"	"unprognostic (1.91e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.21e-1)"	20.2	13.5	8.7	23.5	11.7	40.8	23.5	14.2	13.2	18.0	15.3	14.6	17.8	11.2	19.2	17.5	18.6	17.3	17.1	18.2	7.8	8.0	12.8	20.1	20.7	17.4	11.4	8.7	25.5	19.0	25.7	23.6	20.7	12.7	18.6	15.2	17.8	17.4	25.0	35.2	18.5	15.7	20.8	10.4	18.3	16.0	57.0	10.6	27.5	20.9	15.0	26.6	22.6	19.3	8.9	9.9	24.9	10.0	6.1	13.2	8.7	29.8	23.4	19.3	21.3	21.4	17.6	17.0	21.3	24.9	29.3	26.4	25.7	37.1	29.2	10.1	25.5	32.2	33.9	21.0	40.0	20.7	24.5	31.3	19.2	17.6	18.0	39.9	26.4	20.0	14.5	16.1	29.4	22.7	38.9	23.5	31.1	12.2	40.1	13.0	24.4	18.0	24.5	23.5	14.0	16.7	23.6	17.8	11.9	30.9	25.1	14.2	15.4	15.7	16.6	23.5	20.4	25.6	19.4	14.2	24.2	31.0	15.9	17.2	24.7	19.1	7.9	15.5	11.0	10.0	11.0	8.9	10.7	9.7	9.9	7.8	12.2	10.5	24.9	6.1	6.3	2.7	13.2	8.7	8.7	11.7	14.2	13.2	7.8	8.0	11.4	8.7	12.7	10.6
NUTM1	"C15orf55, DKFZp434O192, FAM22H, NUT"	ENSG00000184507	"NUT midline carcinoma family member 1"	Q86Y26	15	34343315-34357737	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	127	"testis: 48.9"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.0;NTERA-2: 2.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA040421	Enhanced									"HPA040421: AB_10793965"	"unprognostic (4.14e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.11e-1)"	"unprognostic (7.38e-2)"	"unprognostic (1.99e-1)"	"unprognostic (8.37e-2)"		"unprognostic (8.66e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.34e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.34e-2)"	"unprognostic (5.97e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.77e-1)"	"unprognostic (4.27e-2)"	"unprognostic (4.79e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.1	48.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.2	0.0	0.1	0.4	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.0	0.5	0.3	0.0	0.0	0.4	0.5	0.1	0.2	0.1	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.1	2.2	0.3	0.2	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.6	0.2	0.0	0.7	0.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NUTM2A	FAM22A	ENSG00000184923	"NUT family member 2A"	Q8IVF1	10	87225448-87236908	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HMC-1: 14.2"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"eosinophil: 1.3"	"Low lineage specificity"	"Detected in single"											HPA064635			Approved	"Nuclear bodies"				"Nuclear bodies"		"HPA064635: "	"unprognostic (1.75e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.03e-1)"	"unprognostic (8.29e-2)"	"unprognostic (5.67e-2)"	"unprognostic (8.08e-2)"	"unprognostic (1.75e-2)"	"unprognostic (6.84e-2)"	"unprognostic (2.46e-3)"	"unprognostic (1.75e-2)"	"unprognostic (7.24e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.24e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.65e-1)"	3.5	1.8	2.8	0.4	2.5	1.7	1.1	1.5	2.9	1.1	1.8			1.3	1.7	2.1	0.9	1.9	0.8	3.0	3.4	2.2	1.5	1.3	1.6	0.9	2.9		3.0	2.4	2.9	2.0	1.3		2.5	1.0		5.9	0.8	2.3	4.4	2.0	0.7	3.6	1.7	1.8	2.4			2.6		0.2	1.4	1.2	0.4	0.0	1.3	0.2	0.0	0.2	0.2	1.4	0.2	0.7	0.0	1.8	0.9	0.9	0.6	1.8	0.8	0.5	0.2	0.7	1.4	0.1	0.0	1.4	0.0	0.9	0.1	0.3	1.5	1.7	0.4	0.2	0.7	0.6	14.2	0.5	4.1	0.9	1.1	0.0	1.8	0.4	0.2	0.7	1.1	2.4	3.2	0.5	1.7	0.2	0.0	0.5	0.1	1.8	2.7	0.7	0.6	0.6	0.3	0.9	1.4	0.0	0.2	0.8	0.1	0.0	0.1	0.7	0.8	1.4	0.0	0.0	0.2	1.3	0.1	0.2	0.0	0.4	0.0	0.1	0.0	0.0	0.1	0.2	0.4	0.0	0.2	0.0	0.0	0.2										
NUTM2B	"bA119F19.1, FAM22B"	ENSG00000188199	"NUT family member 2B"	A6NNL0	10	79703227-79714681	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"No human protein/transcript evidence"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HMC-1: 6.2"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"eosinophil: 1.0"	"Low lineage specificity"	"Detected in single"											HPA064635			Approved	"Nuclear bodies"				"Nuclear bodies"		"HPA064635: "	"unprognostic (9.51e-2)"	"unprognostic (6.09e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.10e-1)"	"unprognostic (3.63e-1)"	"unprognostic (6.60e-2)"	"unprognostic (2.47e-2)"	"unprognostic (7.66e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.95e-1)"	"unprognostic (7.79e-3)"	"unprognostic (1.15e-1)"	"unprognostic (9.70e-2)"	"unprognostic (9.97e-2)"	"unprognostic (5.72e-2)"	"unprognostic (5.37e-2)"	"unprognostic (2.32e-2)"	0.9	1.8	2.8	1.6	2.6	3.6	0.6	2.2	3.0	1.1	1.0			0.6	0.9	1.6	0.4	2.3	0.3	2.1	2.8	1.9	1.6	1.1	1.9	1.6	1.7		2.0	2.1	2.2	2.7	0.7		1.6	0.4		3.0	0.7	2.3	2.2	1.2	0.2	1.9	2.0	0.9	4.6			1.1		1.6	0.4	0.7	0.5	0.4	1.0	0.8	0.1	0.1	0.1	1.4	1.4	2.9	2.3	1.0	0.9	1.5	0.6	1.1	0.9	0.9	0.2	3.3	3.3	0.5	0.5	1.4	0.2	1.5	0.5	2.0	1.2	2.3	0.5	0.8	1.3	1.8	6.2	2.0	1.0	0.4	0.7	0.0	3.4	1.8	0.6	2.8	0.4	4.8	3.4	1.8	0.7	0.5	0.4	1.2	0.4	1.7	4.0	2.1	2.6	3.7	0.6	3.1	1.7	0.3	0.6	0.5	1.0	0.7	0.2	0.8	0.0	0.3	0.0	0.0	0.0	1.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.5	0.1	0.0	0.4	0.1	0.8	0.4	0.0	0.1										
ODAM	"APin, FLJ20513"	ENSG00000109205	"Odontogenic, ameloblast associated"	A1E959	4	70196496-70204576	"Cancer-related genes, Predicted intracellular proteins"	Biomineralization		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	15	"salivary gland: 157.7"	"Cell line enriched"	"Detected in some"	17	"Hep G2: 25.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA036279, HPA036543, HPA070297"			Supported	Nucleoplasm,Cytosol	"Intracellular and membrane"			Nucleoplasm	Cytosol	"HPA036279: , HPA036543: AB_10669797, HPA070297: "	"unprognostic (2.34e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.75e-1)"		"unprognostic (3.34e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.88e-2)"		"unprognostic (3.47e-1)"	"unprognostic (3.08e-1)"	"unprognostic (3.03e-1)"		"unprognostic (2.72e-1)"		"unprognostic (1.86e-2)"	"unprognostic (2.50e-2)"	0.0	0.2	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.2	0.8	0.0	2.5	0.2	0.1	1.9	0.1	0.1	0.1	0.0	0.0	0.2	0.5	0.0	1.4	0.0	0.0	0.0	0.0	0.2	0.5	0.2	0.2	0.0	0.4	0.1	0.0	157.7	2.6	0.0	0.0	0.3	1.9	0.1	0.0	2.5	0.0	0.0	0.0	5.1	10.6	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	25.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
OGG1	"HMMH, HOGG1, MUTM, OGH1"	ENSG00000114026	"8-oxoguanine DNA glycosylase"	O15527	3	9749944-9788219	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Glycosidase, Hydrolase, Lyase, Multifunctional enzyme"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027514, CAB047301"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB047301: , HPA027514: AB_10602189"	"unprognostic (6.95e-2)"	"unprognostic (7.82e-3)"	"unprognostic (7.19e-2)"	"unprognostic (1.24e-3)"	"unprognostic (9.69e-2)"	"unprognostic (1.97e-2)"	"prognostic unfavourable (5.77e-5)"	"unprognostic (7.83e-2)"	"unprognostic (2.45e-2)"	"unprognostic (3.43e-3)"	"unprognostic (9.66e-3)"	"unprognostic (4.23e-2)"	"prognostic favourable (2.65e-4)"	"unprognostic (2.06e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.59e-1)"	10.4	12.9	15.4	28.5	16.2	12.7	11.5	22.0	17.7	16.7	18.8	16.2	10.5	22.0	16.2	13.1	10.0	14.7	12.1	10.7	14.7	10.8	30.1	17.8	9.9	28.5	12.3	14.1	22.5	12.0	5.8	10.2	10.3	15.3	14.4	10.2	14.6	14.3	13.2	7.4	11.5	28.2	12.1	13.6	14.1	10.8	7.3	15.6	19.8	12.2	6.3	25.5	12.2	13.3	12.2	11.9	15.4	8.5	19.4	15.4	8.3	5.7	10.7	10.9	6.8	10.7	12.3	20.1	7.5	7.7	11.5	13.8	10.3	5.7	35.0	5.0	9.5	5.6	6.4	8.2	4.9	12.4	9.2	17.4	17.3	14.7	11.3	6.7	11.2	12.2	10.5	19.9	8.5	14.2	5.5	5.7	10.9	10.7	5.4	6.7	5.7	15.4	4.0	7.3	11.4	6.4	2.9	4.9	8.6	9.6	7.8	5.8	12.4	11.5	9.2	11.7	12.4	9.1	12.2	5.7	8.1	18.0	9.4	19.5	7.2	11.3	8.5	15.4	15.1	6.6	14.6	10.4	13.0	12.3	7.6	12.2	10.2	9.6	2.1	19.4	5.3	11.9	15.4	8.3	15.4	16.2	22.0	17.7	14.7	10.8	12.3	14.1	15.3	15.6
OLIG2	"BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17"	ENSG00000205927	"Oligodendrocyte transcription factor 2"	Q13516	21	33025845-33029196	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 66.2"	"Cell line enhanced"	"Detected in some"		"HMC-1: 29.3;NB-4: 21.2;THP-1: 18.4;WM-115: 6.0"	"Cancer enriched"	"Detected in some"	52	"glioma: 46.9"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	8	"eosinophil: 15.4"	"Lineage enriched"	"Detected in single"	154	"granulocytes: 15.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003254, CAB019381"	Enhanced		Uncertain	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"CAB019381: , HPA003254: AB_1854795"		"unprognostic (5.14e-1)"	"unprognostic (4.56e-1)"		"unprognostic (1.44e-2)"	"unprognostic (8.27e-2)"		"unprognostic (3.24e-2)"	"unprognostic (4.34e-2)"	"unprognostic (4.81e-2)"	"unprognostic (5.41e-2)"		"unprognostic (1.39e-1)"	"unprognostic (5.78e-5)"	"unprognostic (2.76e-1)"			1.3	1.3	24.1	1.4	19.1	1.4	1.3	4.2	66.2	1.3	1.3	41.4	0.0	1.7	1.3	1.3	1.3	1.3	1.3	1.3	23.6	15.6	1.3	1.3	1.3	1.3	20.9	15.5	1.3	1.3	1.3	0.0	1.3	17.1	1.3	1.3	0.0	1.3	1.3	1.3	1.3	1.5	1.3	16.8	1.3	1.4	1.3	16.6	0.0	1.3	0.0	1.3	1.4	0.0	0.0	0.0	15.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.6	4.2	0.0	0.0	0.0	0.8	29.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	21.2	1.9	0.0	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.4	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	6.0	1.8	0.0	15.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.1	19.1	4.2	27.6	23.6	15.6	20.9	15.5	17.1	16.6
OMA1	"FLJ33782, MPRP-1, YKR087C, ZMPOMA1"	ENSG00000162600	"OMA1 zinc metallopeptidase"	Q96E52	1	58415384-58546802	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA055120	Approved		Approved	Nucleoplasm,Mitochondria				"Nucleoplasm, Mitochondria"		"HPA055120: "	"prognostic favourable (1.63e-4)"	"unprognostic (2.67e-2)"	"prognostic favourable (7.70e-4)"	"unprognostic (1.60e-3)"	"unprognostic (1.61e-1)"	"unprognostic (9.57e-2)"	"unprognostic (3.94e-3)"	"prognostic favourable (8.52e-4)"	"unprognostic (8.22e-3)"	"unprognostic (6.91e-2)"	"unprognostic (4.10e-2)"	"unprognostic (1.40e-1)"	"unprognostic (9.54e-3)"	"unprognostic (2.52e-2)"	"unprognostic (3.93e-2)"	"unprognostic (1.74e-2)"	"unprognostic (5.24e-3)"	10.2	22.4	13.8	21.5	18.1	9.2	15.8	10.6	14.6	14.5	16.4	14.1	20.1	12.1	15.4	15.1	17.1	15.9	12.1	15.8	12.6	10.0	23.0	23.8	19.1	17.9	16.7	9.6	15.0	18.2	15.7	20.9	8.9	13.0	17.8	16.1	11.3	20.6	22.7	20.9	10.2	16.1	24.2	18.2	17.2	13.9	6.9	19.4	18.4	18.3	14.5	16.4	17.0	20.6	22.5	9.5	18.6	19.5	18.6	22.8	10.2	13.5	5.7	3.8	3.5	19.2	18.0	10.9	5.6	6.1	4.9	6.2	1.6	8.2	30.7	11.9	5.8	13.9	13.4	13.7	5.9	23.5	7.5	9.6	4.4	6.6	9.6	23.3	6.7	17.0	15.3	4.8	10.0	4.3	18.0	9.2	13.4	8.3	7.9	8.3	5.6	12.4	9.9	12.5	12.8	10.7	9.1	4.0	1.9	11.4	18.9	15.8	8.5	9.0	2.5	2.5	5.1	12.6	5.8	7.5	9.8	20.2	7.8	18.3	6.2	10.8	9.2	18.6	12.8	14.5	16.5	22.5	15.7	15.0	9.5	21.4	22.8	20.8	10.6	18.6	19.5	5.0	13.9	10.2	13.8	18.1	10.6	14.6	12.6	10.0	16.7	9.6	13.0	19.4
OR4A16	OR4A16Q	ENSG00000181961	"Olfactory receptor family 4 subfamily A member 16"	Q8NH70	11	55343151-55344231	"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"No human protein/transcript evidence"		"Tissue enriched"	"Detected in single"	5	"testis: 1.1"	"Cell line enhanced"	"Detected in single"		"SK-MEL-30: 1.6"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"																																							0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.2		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.4	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
OR51E2	PSGR	ENSG00000167332	"Olfactory receptor family 51 subfamily E member 2"	Q9H255	11	4680171-4697854	"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"prostate: 42.1;retina: 14.6"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 6.2;BJ hTERT+: 3.4"	"Cancer enriched"	"Detected in some"	274	"prostate cancer: 217.5"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"														"unprognostic (1.98e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.09e-3)"	"unprognostic (1.57e-2)"	"unprognostic (8.00e-4)"	"unprognostic (3.61e-2)"	"unprognostic (6.27e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.05e-2)"	"unprognostic (3.46e-2)"	"unprognostic (2.97e-1)"	"unprognostic (3.61e-1)"	"unprognostic (5.04e-5)"	"unprognostic (3.34e-2)"	"unprognostic (4.66e-2)"	"unprognostic (5.76e-2)"	"unprognostic (3.29e-1)"	0.7	0.2	0.2	5.0	0.2	0.1	1.7	0.1	0.5	0.6	8.2	0.0	0.5	0.2	1.6	1.3	0.6	0.6	0.3	1.1	0.2	0.2	0.4	0.1	0.1	0.0	0.2	0.0	1.1	0.2	0.1	0.2	5.1	0.4	42.1	2.2	14.6	0.2	2.4	0.5	0.3	0.9	2.0	0.2	0.1	0.5	0.7	0.0	0.0	0.2	0.4	0.0	1.6	0.3	1.6	0.9	2.2	0.6	0.8	1.2	0.4	0.1	0.0	0.1	0.1	0.7	6.2	0.3	0.0	3.4	0.0	0.2	0.2	0.3	0.3	0.1	0.0	0.1	0.0	0.0	0.1	0.1	1.2	1.2	0.3	0.0	0.0	0.3	0.4	0.1	0.0	0.1	0.0	0.0	0.1	0.5	0.0	0.1	0.0	0.5	0.1	0.1	0.4	0.0	0.3	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.0	0.5	0.4	0.7	0.3	0.0	0.5	0.0	0.1	0.4	0.0	0.0	1.5	0.6	0.5	1.2	0.5	0.8	0.8	0.8	0.6	0.3	1.6	0.8	1.1	2.2	0.8	0.5	0.9	0.4	0.4	0.2	0.2	0.1	0.5	0.2	0.2	0.2	0.0	0.4	0.0
OR52N1		ENSG00000181001	"Olfactory receptor family 52 subfamily N member 1"	Q8NH53	11	5786471-5791265	"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"No human protein/transcript evidence"		"Tissue enhanced"	"Detected in some"		"adipose tissue: 1.8;bone marrow: 1.4"	"Cell line enhanced"	"Detected in single"		"Karpas-707: 1.7"	"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"											HPA054028	Uncertain									"HPA054028: "																		1.8	0.0	0.0	0.3	0.0	1.4	0.3	0.0	0.2	0.0	0.1			0.0	0.4	0.1	0.1	0.2	0.9	0.2	0.0	0.0	0.1	0.1	0.2	0.2	0.1		0.1	0.1	0.0	0.1	0.1		0.3	0.0		0.1	0.0	0.3	0.1	0.6	0.0	0.0	0.2	0.1	0.4			0.0		0.0	0.1	0.0	0.5	0.7	1.2	0.6	1.0	0.7	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.4	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.2	0.0	0.2	0.1	0.0	0.0	0.0	0.3	0.0	0.2	1.7	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.6	0.3	0.0	0.1	0.7	0.5	0.0	0.2	0.3	0.0	0.1	0.0	0.7	0.8	0.7	0.2	0.1	0.2	0.0	0.1	0.4	0.6	1.2	0.6	0.2	0.5	0.4	0.6	0.5	0.7	0.6	0.0	0.5	0.7	0.7	0.5	1.0	0.5	0.7	0.1	0.0										
ORM1		ENSG00000229314	"Orosomucoid 1"	P02763	9	114323056-114326475	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Acute phase, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	16	"liver: 834.6"	"Cell line enriched"	"Detected in some"	11	"Hep G2: 157.9"	"Cancer enriched"	"Detected in many"	16	"liver cancer: 2506.9"					"Cell type enriched"	"Detected in some"	45	"neutrophil: 53.4"	"Lineage enriched"	"Detected in many"	45	"granulocytes: 53.4"									"CAB006265, HPA046438, HPA047725, HPA057726"	Approved		Approved	"Golgi apparatus,Vesicles"	"Secreted to blood"	120000000000	120000000000	Vesicles	"Golgi apparatus"	"CAB006265: AB_425575, HPA046438: , HPA047725: , HPA057726: "	"unprognostic (3.85e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.16e-2)"	"unprognostic (3.22e-2)"	"unprognostic (1.47e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.26e-1)"		"unprognostic (1.16e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.74e-1)"	"prognostic unfavourable (2.35e-4)"	"unprognostic (2.10e-1)"	"unprognostic (4.38e-2)"	"unprognostic (9.32e-3)"	"unprognostic (4.51e-2)"	0.1	0.0	0.0	0.2	0.0	6.7	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	834.6	0.3	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.6	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.4	0.0			0.0		0.0	0.0	0.0	0.0	0.0	53.4	1.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	157.9	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.0	13.9	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.6	0.0	0.0	1.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.4	0.0	0.2	0.0	0.0	0.3										
OSM	MGC20461	ENSG00000099985	"Oncostatin M"	P13725	22	30262829-30266840	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Growth regulation"	"Cytokine, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 24.9;bone marrow: 63.0"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 15.9;HL-60: 3.9;HMC-1: 11.7;Karpas-707: 3.6;NB-4: 6.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"basophil: 24.9;neutrophil: 17.5"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 24.9"					"Not detected"	"Not detected"								"Secreted to blood"						"unprognostic (5.15e-2)"	"unprognostic (8.80e-3)"	"unprognostic (1.01e-1)"	"unprognostic (6.02e-2)"	"unprognostic (7.37e-2)"	"unprognostic (2.61e-2)"	"unprognostic (6.78e-2)"	"unprognostic (3.77e-2)"	"unprognostic (2.81e-2)"	"unprognostic (4.60e-2)"	"unprognostic (1.58e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavourable (1.03e-5)"	"unprognostic (4.00e-2)"	"unprognostic (7.72e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.82e-1)"	5.3	2.6	0.9	8.5	2.5	63.0	3.7	0.7	1.7	1.6	1.0	5.3	0.4	0.6	1.2	1.9	0.8	3.8	4.1	2.2	3.8	1.7	1.9	1.8	11.4	9.4	2.0	0.0	3.0	1.0	1.0	2.5	6.4	5.9	1.2	0.7	1.8	1.4	0.5	1.7	0.4	1.0	2.1	7.8	6.9	1.4	2.3	1.2	0.6	1.1	0.5	2.2	6.8	0.9	0.1	0.4	24.9	0.2	1.9	3.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	15.9	0.0	0.3	0.0	0.0	0.0	3.9	11.7	0.0	0.0	0.0	0.0	0.0	0.1	3.6	0.0	0.0	0.5	6.7	0.0	0.0	0.6	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	2.4	0.0	24.9	0.2	0.9	1.0	0.1	3.4	0.0	2.5	1.3	0.4	0.1	0.5	1.2	17.5	1.9	0.0	0.1	0.7	0.8	0.9	2.5	0.7	1.7	3.8	1.7	2.0	0.0	5.9	1.2
OTUD7A	"C15orf16, CEZANNE2, OTUD7"	ENSG00000169918	"OTU deubiquitinase 7A"	Q8TE49	15	31475398-31870789	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 20.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 3.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044554	Uncertain		Approved	Nucleoli,Cytosol				"Nucleoli, Cytosol"		"HPA044554: AB_10794895"	"unprognostic (3.61e-2)"	"unprognostic (1.35e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.29e-1)"	"unprognostic (1.03e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.24e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.79e-11)"	"unprognostic (6.78e-2)"	"unprognostic (2.76e-1)"	"unprognostic (8.27e-2)"	"unprognostic (1.79e-1)"	2.6	2.0	12.4	1.7	13.9	5.9	1.5	13.2	17.0	1.8	3.4	16.0	0.0	1.5	1.9	1.9	1.9	2.0	2.3	2.1	10.0	4.6	2.3	1.0	1.5	3.5	20.4	7.1	2.0	2.5	4.6	1.7	0.9	10.5	1.2	3.1	0.7	1.6	2.0	1.8	3.2	2.1	2.9	9.1	2.2	2.3	8.2	17.4	0.0	2.3	0.0	2.4	1.9	1.3	0.1	3.2	0.3	1.4	0.1	0.7	0.4	3.6	4.1	4.5	6.0	0.4	1.3	3.2	2.5	1.3	3.9	1.9	2.5	3.2	2.9	2.2	0.9	4.6	4.8	2.0	3.2	5.9	6.6	3.7	8.3	2.0	0.3	4.0	5.7	0.0	0.2	3.8	4.3	3.5	6.0	5.4	1.8	2.9	3.1	3.9	2.0	2.0	5.6	3.0	1.4	1.6	3.9	10.9	6.0	3.4	3.0	1.0	2.5	4.3	2.3	5.3	5.2	3.0	6.2	3.3	2.4	3.0	2.9	5.8	4.5	0.0	0.4	0.3	0.6	0.5	0.3	0.0	0.3	0.7	0.2	0.1	0.2	0.2	0.0	0.1	1.4	3.2	0.0	0.4	12.4	13.9	13.2	13.8	10.0	4.6	20.4	7.1	10.5	17.4
P2RY8	P2Y8	ENSG00000182162	"P2Y receptor family member 8"	Q86VZ1	X	1462572-1537107	"Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 26.7;lymphoid tissue: 19.0"	"Cell line enhanced"	"Detected in some"		"Daudi: 33.2;RPMI-8226: 20.4;THP-1: 20.4;U-266/70: 27.9;U-698: 54.3;U-937: 16.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in many"			HPA003631	Enhanced									"HPA003631: AB_1079543"	"unprognostic (4.32e-2)"	"unprognostic (3.22e-5)"	"unprognostic (6.31e-2)"	"unprognostic (2.51e-2)"	"unprognostic (1.17e-1)"	"prognostic favourable (7.80e-5)"	"prognostic favourable (1.73e-4)"	"unprognostic (5.27e-3)"	"unprognostic (5.76e-3)"	"unprognostic (5.52e-3)"	"prognostic favourable (6.54e-4)"	"unprognostic (4.29e-2)"	"unprognostic (8.45e-3)"	"unprognostic (2.90e-1)"	"unprognostic (4.00e-2)"	"unprognostic (3.55e-1)"	"unprognostic (2.80e-1)"	2.9	4.8	0.5	8.9	2.2	13.9	8.2	0.9	1.8	4.7	1.6	0.5	0.5	1.3	7.1	0.5	0.8	0.8	1.6	11.8	0.9	0.2	13.5	0.8	2.1	19.0	3.6	1.7	5.8	1.1	1.0	6.9	3.4	2.7	1.6	1.3	0.5	1.6	0.5	1.1	0.4	7.8	0.5	3.9	16.6	2.0	0.5	2.0	0.5	8.1	0.5	16.7	2.7	2.8	18.5	5.8	17.8	7.3	15.6	26.7	18.3	0.1	0.1	0.1	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.2	33.2	0.1	0.0	0.1	0.0	0.0	0.0	1.2	0.1	0.3	0.3	1.6	0.0	14.5	3.5	0.0	0.0	0.0	0.0	0.0	0.3	14.0	0.0	0.0	16.4	16.4	0.2	0.3	14.8	0.1	20.4	0.0	0.2	0.0	0.2	0.1	0.3	0.1	0.1	20.4	0.0	0.3	0.3	0.1	0.0	27.9	5.2	54.3	0.0	16.9	0.0	17.8	7.3	12.4	26.7	5.5	24.6	15.4	20.2	25.1	5.8	18.5	16.1	16.5	4.7	15.6	2.2	1.5	15.9	18.3	0.5	2.2	0.9	1.8	0.9	0.2	3.6	1.7	2.7	2.0
PABPC1	"PAB1, PABP1, PABPC2, PABPL1"	ENSG00000070756	"Poly(A) binding protein cytoplasmic 1"	P11940	8	100685816-100722809	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Nonsense-mediated mRNA decay"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB011536, HPA045423, HPA067156"	Supported		Supported	Cytosol		2700000	2700000	Cytosol		"CAB011536: AB_777008, HPA045423: , HPA067156: "	"unprognostic (5.00e-2)"	"unprognostic (2.64e-2)"	"unprognostic (3.18e-1)"	"unprognostic (4.50e-1)"	"prognostic favourable (2.51e-4)"	"unprognostic (1.93e-2)"	"prognostic unfavourable (5.80e-4)"	"unprognostic (2.51e-3)"	"unprognostic (5.70e-2)"	"unprognostic (1.50e-2)"	"unprognostic (3.21e-3)"	"unprognostic (7.24e-2)"	"prognostic unfavourable (5.70e-12)"	"unprognostic (6.22e-2)"	"unprognostic (2.55e-1)"	"unprognostic (6.98e-3)"	"unprognostic (1.40e-2)"	85.6	49.6	33.6	66.1	38.8	94.2	80.5	35.8	32.5	84.2	80.7	41.9	57.2	64.1	85.3	48.8	195.5	54.6	56.4	35.1	32.3	19.3	43.6	83.2	72.8	156.2	40.6	24.3	111.1	106.9	31.8	34.1	50.6	36.8	88.2	71.5	43.4	192.9	79.0	35.1	95.4	104.0	89.9	65.2	135.3	73.4	98.7	37.6	137.2	65.4	63.0	157.9	120.9	116.4	70.8	98.4	32.3	106.7	65.9	106.0	90.6	180.2	45.1	35.3	64.1	66.2	131.6	61.0	44.1	63.9	47.5	51.8	53.9	84.9	228.8	172.1	77.6	70.0	55.3	86.3	81.3	69.9	36.5	118.0	34.0	69.3	82.1	50.5	83.5	122.2	136.7	44.2	217.6	74.2	99.1	88.1	70.4	52.5	251.4	105.3	79.1	64.1	83.0	42.9	82.6	57.4	117.4	49.3	54.9	29.4	46.0	103.0	82.8	83.8	69.1	42.8	79.9	62.8	74.2	86.4	59.8	128.2	50.4	113.5	43.0	27.6	83.3	28.8	39.7	99.9	84.2	70.8	78.3	64.4	98.4	62.6	106.0	85.1	32.3	65.9	106.7	65.5	67.4	90.6	33.6	38.8	35.8	32.5	32.3	19.3	40.6	24.3	36.8	37.6
PAFAH1B2		ENSG00000168092	"Platelet activating factor acetylhydrolase 1b catalytic subunit 2"	P68402	11	117144267-117176894	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051836	Approved		Supported	"Nucleoli,Plasma membrane,Cytosol"		1600000	1600000	Cytosol	"Nucleoli, Plasma membrane"	"HPA051836: "	"unprognostic (1.08e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.07e-2)"	"unprognostic (3.88e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.21e-3)"	"prognostic unfavourable (9.44e-4)"	"prognostic unfavourable (3.07e-4)"	"unprognostic (1.01e-1)"	"prognostic favourable (4.25e-4)"	"prognostic unfavourable (7.79e-5)"	"unprognostic (8.18e-2)"	"unprognostic (1.11e-2)"	"unprognostic (9.97e-2)"	"unprognostic (3.25e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.34e-1)"	21.5	34.1	30.6	19.2	29.7	33.5	32.3	43.5	41.3	21.6	20.2	33.3	12.7	21.1	23.4	22.8	23.3	20.8	19.3	26.2	31.9	36.8	24.6	22.5	20.5	17.7	39.3	31.6	23.6	23.0	23.1	24.2	26.9	39.6	22.2	19.6	17.3	19.3	17.4	14.1	20.8	18.0	19.9	51.6	18.3	21.4	29.9	26.3	15.1	30.9	10.8	20.4	25.9	20.3	26.8	21.6	36.8	35.7	18.9	31.4	26.9	14.8	17.0	19.7	28.3	22.0	15.4	15.3	25.0	21.9	13.9	12.7	31.0	32.8	16.1	35.9	29.9	23.9	28.5	32.3	18.4	14.3	11.0	41.3	15.6	19.9	19.7	14.2	15.8	17.0	25.6	27.8	35.1	22.8	21.9	12.3	21.3	9.5	13.7	21.0	18.0	13.4	15.4	22.3	17.6	21.3	23.3	21.9	29.1	28.8	21.8	9.5	24.3	12.3	36.4	25.5	16.9	12.4	17.7	3.9	5.9	21.6	10.3	27.4	21.4	32.1	30.8	26.7	24.2	33.3	28.2	26.8	28.0	25.3	21.6	25.4	29.3	31.4	36.8	18.9	35.7	15.8	19.5	26.9	30.6	29.7	43.5	37.8	31.9	36.8	39.3	31.6	39.6	26.3
PAGE4	"CT16.7, GAGEC1, PAGE-4"	ENSG00000101951	"PAGE family member 4"	O60829	X	49829260-49833973	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	13	"epididymis: 129.2;placenta: 199.4;prostate: 58.4"	"Cell line enhanced"	"Detected in some"		"CACO-2: 6.8;U-266/70: 8.4;U-266/84: 30.7"	"Group enriched"	"Detected in some"	17	"liver cancer: 14.8;prostate cancer: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			HPA023880	Enhanced		Approved	"Golgi apparatus,Vesicles"				Vesicles	"Golgi apparatus"	"HPA023880: AB_1854930"				"unprognostic (8.56e-2)"			"unprognostic (1.47e-1)"			"unprognostic (1.04e-1)"		"unprognostic (4.82e-3)"			"unprognostic (5.37e-2)"			0.2	0.7	0.5	0.1	0.1	0.0	0.1	0.2	0.2	0.6	0.1	0.2	5.7	0.0	6.6	129.2	0.1	6.8	0.1	0.1	0.4	0.5	0.8	0.1	0.2	0.1	0.1	0.2	0.9	0.1	0.0	0.6	199.4	0.2	58.4	0.0	0.1	0.1	9.8	0.8	0.1	0.1	2.4	0.2	0.1	0.1	2.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	6.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	8.4	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.1	0.2	0.2	0.4	0.5	0.1	0.2	0.2	0.1
PALB2	"FANCN, FLJ21816"	ENSG00000083093	"Partner and localizer of BRCA2"	Q86YC2	16	23603160-23641310	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB014895, HPA057000"	Approved		Supported	Nucleoplasm				Nucleoplasm		"CAB014895: , HPA057000: "	"unprognostic (1.11e-1)"	"unprognostic (5.67e-3)"	"prognostic favourable (2.83e-5)"	"unprognostic (1.43e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.61e-2)"	"unprognostic (2.00e-3)"	"unprognostic (5.18e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.00e-2)"	"prognostic unfavourable (2.35e-5)"	"unprognostic (2.05e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.25e-1)"	"unprognostic (7.20e-2)"	"unprognostic (3.21e-1)"	12.4	9.9	10.7	19.6	11.9	6.8	15.2	16.5	14.1	12.4	14.0	10.8	9.1	14.8	10.9	13.5	17.6	9.6	7.8	10.5	10.0	10.6	13.7	16.1	9.2	13.4	9.7	12.5	15.3	10.6	13.7	16.1	9.1	14.9	10.9	12.7	8.6	11.0	14.7	10.3	17.0	14.1	12.8	10.8	14.1	11.0	16.9	10.5	12.9	12.1	12.0	15.3	13.6	13.3	3.7	3.9	7.2	7.7	3.9	5.5	2.0	11.8	9.2	11.1	7.7	9.2	7.3	9.9	8.6	13.1	14.1	17.1	7.8	12.4	12.5	6.3	6.0	10.6	9.8	14.4	16.9	7.3	5.7	7.6	12.6	21.9	8.6	14.0	12.4	8.2	14.7	13.3	15.2	7.5	15.7	6.7	12.4	11.7	14.4	14.6	24.6	5.3	16.7	13.6	17.1	10.7	10.6	8.2	8.1	8.8	10.0	11.2	9.2	9.6	5.4	16.9	6.5	8.3	9.2	7.9	12.8	12.8	11.1	10.3	10.1	7.2	3.3	3.0	4.4	4.2	5.3	3.7	4.9	5.3	3.9	3.1	5.5	4.3	0.2	3.9	7.7	2.8	3.1	2.0	10.7	11.9	16.5	14.1	10.0	10.6	9.7	12.5	14.9	10.5
PAPD5	TRF4-2	ENSG00000121274	"Poly(A) RNA polymerase D5, non-canonical"	Q8NDF8	16	50152918-50235310	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, mRNA processing, rRNA processing"	"DNA-binding, DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042968, HPA048225"	Uncertain									"HPA042968: , HPA048225: "	"unprognostic (1.05e-2)"	"unprognostic (4.09e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.63e-1)"	"unprognostic (3.27e-1)"	"unprognostic (2.91e-2)"	"unprognostic (4.33e-2)"	"unprognostic (2.46e-1)"	"unprognostic (7.83e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.30e-1)"	"unprognostic (3.30e-2)"	"prognostic favourable (1.85e-4)"	"unprognostic (4.24e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (7.00e-2)"	9.4	9.9	5.9	8.8	8.6	19.2	12.6	14.9	10.8	15.9	10.0	4.5	8.8	11.1	13.1	6.3	7.4	10.8	6.3	8.0	7.7	6.9	10.0	11.9	8.5	11.2	6.4	8.0	10.5	7.9	18.5	13.4	9.2	7.5	10.0	6.4	6.7	7.6	9.8	9.9	8.1	9.4	9.7	6.1	6.0	8.0	12.3	8.0	6.8	7.5	6.0	6.6	13.1	30.8	3.5	4.9	4.6	2.9	7.2	5.6	1.2	11.3	8.7	7.1	12.7	11.2	9.5	9.1	10.2	10.4	12.3	5.7	12.0	8.1	13.7	12.2	12.4	8.6	13.3	7.6	16.2	8.0	8.7	8.2	4.7	15.5	12.6	6.8	12.7	5.7	9.4	10.1	12.8	8.5	8.4	4.8	11.3	4.9	9.5	10.2	9.2	9.4	12.8	14.2	17.9	3.5	4.2	9.1	5.4	10.3	13.3	7.0	4.4	5.0	7.3	11.4	10.0	9.9	5.8	9.6	7.4	18.1	6.8	6.3	8.1	4.6	2.6	1.3	4.0	2.9	3.5	2.9	4.3	4.8	2.0	3.5	4.8	5.6	4.0	7.2	2.1	4.9	3.7	1.2	5.9	8.6	14.9	10.8	7.7	6.9	6.4	8.0	7.5	8.0
PAPPA	"ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1"	ENSG00000182752	"Pappalysin 1"	Q13219	9	116153804-116402322	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	86	"placenta: 484.6"	"Cell line enhanced"	"Detected in some"		"ASC diff: 19.0;ASC TERT1: 14.5;HSkMC: 52.2;U-138 MG: 13.6"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	5	"midbrain: 10.4;olfactory region: 4.1;pons and medulla: 8.3;thalamus: 4.8"	"HPA001667, CAB016724"	Enhanced				"Secreted in female reproductive system"	41000	41000			"CAB016724: , HPA001667: AB_1854960"	"unprognostic (3.25e-1)"	"unprognostic (6.18e-6)"	"unprognostic (2.47e-1)"	"unprognostic (6.49e-2)"	"unprognostic (2.01e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.13e-1)"	"unprognostic (5.42e-3)"	"unprognostic (5.44e-2)"	"unprognostic (3.87e-2)"	"unprognostic (6.87e-3)"	"unprognostic (8.25e-2)"	"unprognostic (8.00e-3)"	"unprognostic (2.37e-3)"	"unprognostic (2.48e-1)"	"unprognostic (4.01e-1)"	"unprognostic (1.02e-3)"	4.8	2.3	0.5	1.0	0.5	0.0	0.8	0.4	0.6	3.6	2.4	0.6	1.0	0.1	3.5	1.0	3.6	2.0	1.1	3.7	0.4	0.0	4.3	0.5	2.4	0.7	0.4	0.4	1.4	0.7	5.6	0.7	484.6	0.7	1.4	0.9	0.9	0.5	1.2	0.5	1.1	0.9	2.4	0.6	0.6	1.0	0.8	0.5	0.4	1.3	1.0	1.0	2.3	3.4	0.2	0.0	0.2	0.0	0.0	0.1	0.0	0.0	5.4	8.3	0.0	19.0	14.5	0.0	4.4	7.8	1.2	2.1	0.0	0.0	0.0	0.0	3.1	0.6	0.0	0.0	5.9	0.0	0.0	0.9	4.5	0.0	9.2	0.0	0.0	52.2	0.0	6.1	0.7	0.0	0.2	0.0	1.4	0.0	0.0	0.0	2.4	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.4	0.6	0.0	0.0	0.0	0.0	10.5	13.6	0.7	0.3	0.5	0.0	0.0	0.0	9.7	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.4	0.6	0.4	0.0	0.4	0.4	0.7	0.5
PARP1	"ADPRT, PARP, PPOL"	ENSG00000143799	"Poly(ADP-ribose) polymerase 1"	P09874	1	226360691-226408079	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"	"DNA-binding, Glycosyltransferase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727"	Supported	Supported	Enhanced	Nucleoplasm		39000	39000	Nucleoplasm		"CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: , CAB075727: , HPA045168: "	"unprognostic (2.02e-1)"	"unprognostic (9.40e-2)"	"unprognostic (7.44e-3)"	"unprognostic (1.32e-1)"	"unprognostic (4.29e-1)"	"unprognostic (9.22e-2)"	"prognostic unfavourable (3.40e-4)"	"unprognostic (2.20e-1)"	"unprognostic (3.62e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.66e-1)"	"prognostic unfavourable (1.35e-5)"	"unprognostic (2.38e-2)"	"unprognostic (1.82e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.64e-1)"	17.3	16.6	31.2	35.7	31.2	14.3	15.3	21.1	29.2	14.3	21.8	37.4	10.3	15.0	18.2	13.0	18.1	15.0	10.8	24.2	27.8	21.9	13.4	24.8	14.1	56.3	40.7	21.8	14.6	28.1	62.6	22.9	28.7	30.4	22.0	19.2	16.3	17.0	24.7	47.3	11.7	19.6	25.5	49.1	32.7	15.9	22.5	34.8	29.5	14.5	16.5	70.2	19.9	13.7	53.0	16.5	9.0	17.5	11.1	21.8	11.5	28.5	15.3	42.6	30.1	11.2	9.2	24.3	18.9	16.9	25.8	21.2	24.3	14.0	83.2	28.3	11.5	21.5	58.5	18.6	22.7	34.9	81.7	32.2	20.4	15.9	6.7	53.4	15.6	9.1	7.4	20.7	14.7	20.0	51.2	42.5	13.3	13.6	17.1	19.3	78.4	30.4	51.8	73.0	76.9	12.1	20.4	42.9	37.6	24.6	27.6	15.5	23.2	33.5	15.2	13.7	22.7	18.5	35.4	17.3	29.0	71.5	11.4	18.1	30.7	9.0	6.7	6.9	18.3	11.3	21.6	46.8	19.4	18.0	14.3	53.0	15.2	16.4	1.0	11.1	17.5	16.5	21.8	11.5	31.2	31.2	21.1	28.4	27.8	21.9	40.7	21.8	30.4	34.8
PARVB	CGI-56	ENSG00000188677	"Parvin beta"	Q9HBI1	22	43999211-44172949	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 82.1"	"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 43.7;RPMI-8226: 42.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA062601, HPA072217"	Enhanced		Approved	Cytosol		90000000	90000000	Cytosol		"HPA062601: , HPA072217: "	"unprognostic (2.41e-1)"	"unprognostic (5.52e-3)"	"unprognostic (1.66e-1)"	"unprognostic (3.83e-2)"	"unprognostic (2.10e-3)"	"unprognostic (7.65e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.28e-1)"	"unprognostic (6.46e-2)"	"unprognostic (1.03e-2)"	"unprognostic (6.45e-2)"	"unprognostic (1.28e-2)"	"unprognostic (4.87e-3)"	"unprognostic (3.19e-2)"	"unprognostic (4.19e-2)"	"unprognostic (7.05e-3)"	15.9	10.7	6.4	9.7	7.3	16.8	17.4	3.1	8.3	8.0	7.2	3.5	6.3	3.7	8.6	8.7	7.3	6.8	5.3	28.5	5.6	8.8	7.3	7.3	12.6	19.7	8.0	6.3	13.4	4.8	8.6	9.3	10.2	5.8	7.8	4.4	9.3	5.3	7.2	82.1	5.1	6.3	11.9	8.3	15.2	5.4	5.7	4.5	2.3	4.9	22.4	7.9	11.7	26.0	6.3	14.1	4.8	6.4	0.7	2.2	8.3	6.3	7.5	0.1	5.3	8.0	10.2	0.0	8.9	5.5	5.8	4.4	7.8	3.8	0.0	4.9	23.8	0.2	12.7	0.5	3.2	8.9	7.9	27.1	13.2	0.0	13.4	20.4	24.4	15.9	6.7	4.2	0.0	43.7	9.7	18.6	6.3	4.2	0.1	13.4	2.7	5.2	0.0	0.2	42.7	0.1	0.1	6.9	4.8	2.3	0.4	22.4	4.4	8.3	27.2	5.3	5.7	8.2	0.9	4.6	4.0	0.2	23.4	6.0	29.3	4.5	6.1	1.4	1.0	6.4	1.6	6.0	1.7	1.4	6.8	6.3	0.4	0.9	4.8	0.7	2.6	14.1	2.2	8.3	6.4	7.3	3.1	8.3	5.6	8.8	8.0	6.3	5.8	4.5
PATZ1	"dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG"	ENSG00000100105	"POZ/BTB and AT hook containing zinc finger 1"	Q9HBE1	22	31325804-31346232	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047893, HPA048315"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA047893: , HPA048315: "	"unprognostic (3.25e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.88e-3)"	"prognostic favourable (1.06e-4)"	"unprognostic (1.77e-1)"	"unprognostic (8.34e-3)"	"prognostic favourable (8.71e-5)"	"unprognostic (1.14e-1)"	"unprognostic (1.41e-2)"	"unprognostic (1.99e-3)"	"unprognostic (1.76e-1)"	"prognostic favourable (8.54e-8)"	"unprognostic (9.22e-2)"	"unprognostic (2.15e-1)"	"unprognostic (1.51e-1)"	"prognostic favourable (7.79e-6)"	9.6	11.2	13.0	12.7	12.9	12.9	12.1	16.8	16.0	14.2	13.0	21.7	21.8	9.4	19.6	14.4	7.3	22.2	14.1	10.4	14.0	11.8	11.4	11.0	17.4	30.3	15.3	13.4	27.7	16.6	25.4	11.0	8.9	13.6	14.0	6.8	17.5	17.5	17.8	9.1	7.5	11.9	15.6	12.5	14.3	10.5	13.0	15.5	38.5	18.9	8.2	13.8	17.4	14.2	4.7	7.1	4.8	1.8	3.5	5.7	2.0	8.3	10.5	21.5	12.6	5.7	5.3	11.3	2.5	6.5	10.4	9.6	7.3	8.1	17.8	9.3	4.7	6.5	14.5	7.8	5.4	10.4	13.3	7.5	7.3	14.9	9.3	25.1	10.1	8.2	9.4	6.6	7.4	8.2	3.1	7.2	6.6	25.4	16.0	17.3	14.4	12.4	27.2	9.1	5.9	7.0	17.7	28.1	22.5	6.4	7.8	14.0	15.5	16.1	5.8	7.0	13.3	4.3	8.6	9.3	6.1	16.2	2.9	3.3	11.9	0.0	1.8	4.8	3.4	1.1	3.5	4.7	2.6	4.4	2.5	3.8	5.7	4.1	0.8	3.5	0.6	7.1	3.7	2.0	13.0	12.9	16.8	16.0	14.0	11.8	15.3	13.4	13.6	15.5
PAX3	"HUP2, WS1"	ENSG00000135903	"Paired box 3"	P23760	2	222199888-222298996	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Deafness, Disease mutation, Proto-oncogene, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 19.1;retina: 39.6"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+ SV40 Large T+: 7.5;BJ hTERT+ SV40 Large T+ RasG12V: 8.9;HBF TERT88: 6.6;RH-30: 12.9;SK-MEL-30: 22.7"	"Cancer enriched"	"Detected in some"	24	"melanoma: 20.3"	"Group enriched"	"Detected in some"	6	"cerebellum: 19.1;pons and medulla: 7.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"cerebellum: 3.9;midbrain: 1.6;pons and medulla: 1.4"	"Group enriched"	"Detected in many"	5	"cerebellum: 10.0;midbrain: 11.7;pons and medulla: 3.5"	"HPA063659, HPA069000"	Uncertain		Enhanced	Nucleoplasm				Nucleoplasm		"HPA063659: , HPA069000: "	"unprognostic (2.57e-2)"				"unprognostic (1.48e-2)"	"unprognostic (1.27e-2)"		"unprognostic (1.65e-1)"	"unprognostic (2.61e-2)"	"unprognostic (3.70e-1)"		"unprognostic (6.18e-2)"		"unprognostic (1.41e-1)"	"unprognostic (2.26e-1)"		"unprognostic (9.70e-2)"	0.8	0.1	0.0	0.1	0.8	0.1	2.9	19.1	0.2	0.3	0.1	0.1	0.3	0.1	0.2	0.1	0.1	0.1	0.1	0.3	0.0	0.2	0.1	0.1	0.1	0.2	2.2	0.0	0.1	0.2	0.1	0.0	0.1	7.8	0.4	0.1	39.6	7.9	0.2	8.6	7.9	0.1	0.1	4.2	0.1	0.2	2.9	0.8	0.0	0.1	3.9	0.5	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	5.1	5.1	7.5	8.9	0.0	0.5	0.0	0.0	3.4	0.0	0.0	0.0	6.6	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	5.3	0.1	0.0	0.0	12.9	0.0	0.0	0.0	1.3	0.0	0.0	0.0	22.7	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	2.8	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.8	19.1	0.1	0.0	0.2	2.2	0.0	7.8	0.8
PAX5	BSAP	ENSG00000196092	"Paired box 5"	Q02548	9	36833275-37034185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 21.6;lymphoid tissue: 33.4"	"Group enriched"	"Detected in some"	8	"Daudi: 21.0;REH: 61.0;U-698: 27.6"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	5	"midbrain: 1.6"	"Group enriched"	"Detected in some"	209	"memory B-cell: 20.1;naive B-cell: 21.6"	"Lineage enriched"	"Detected in single"	216	"B-cells: 21.6"	"Region enriched"	"Detected in single"	11	"midbrain: 4.7"	"Group enriched"	"Detected in some"	6	"hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2"	"CAB026269, CAB026869, HPA056394, HPA068498"	Enhanced	Supported	Approved	Nucleoplasm,Vesicles,Cytosol				Nucleoplasm	"Vesicles, Cytosol"	"CAB026269: , CAB026869: , HPA056394: , HPA068498: "	"unprognostic (4.69e-4)"	"unprognostic (3.83e-1)"	"unprognostic (9.13e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.95e-2)"	"unprognostic (2.48e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.11e-3)"	"unprognostic (3.15e-1)"	"unprognostic (8.96e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.01e-1)"	0.4	0.2	0.2	33.4	0.2	5.5	0.2	0.2	0.2	0.2	0.7	0.1	0.0	0.0	0.2	0.0	0.7	0.2	0.4	0.2	0.2	0.3	0.5	0.3	0.3	23.2	1.6	0.0	0.2	0.2	0.0	0.5	0.1	0.2	0.3	0.3	0.4	2.5	0.0	0.6	0.2	8.7	0.0	0.3	16.5	0.7	0.9	0.0	2.3	0.4	0.2	30.1	1.3	0.2	21.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.6	0.1	61.0	0.1	0.1	0.0	0.0	4.3	1.0	0.0	0.2	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.1	0.0	0.0	0.0	21.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.2	0.2	0.2	0.3	1.6	0.0	0.2	0.0
PAX7	Hup1	ENSG00000009709	"Paired box 7"	P23759	1	18631006-18748866	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"skeletal muscle: 12.9;tongue: 12.0"	"Group enriched"	"Detected in some"	7	"A549: 3.4;CAPAN-2: 3.7;U-2 OS: 8.0"	"Group enriched"	"Detected in some"	6	"breast cancer: 0.5;cervical cancer: 1.5;lung cancer: 1.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	17	"midbrain: 5.5"	"Low region specificity"	"Detected in some"														"unprognostic (8.41e-4)"	"unprognostic (2.07e-1)"			"unprognostic (5.35e-2)"	"unprognostic (3.96e-2)"		"unprognostic (4.21e-1)"						"unprognostic (1.96e-1)"	"unprognostic (1.34e-1)"			0.4	0.1	0.6	0.0	0.6	0.0	0.0	0.0	3.4	0.1	0.0	0.0	0.0	0.1	0.0	2.3	0.5	0.1	0.0	0.0	0.8	0.8	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	2.4	0.0	3.4	0.3	0.0	0.0	0.1	0.1	12.9	0.0	0.1	0.0	1.0	0.0	0.0	0.3	0.0	0.0	0.0	12.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.0	3.4	0.8	0.8	2.4	0.0	3.4	0.0
PAX8		ENSG00000125618	"Paired box 8"	Q06710	2	113215997-113278950	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"kidney: 69.3;thyroid gland: 120.5"	"Group enriched"	"Detected in some"	10	"EFO-21: 26.7;RPTEC TERT1: 63.0"	"Group enriched"	"Detected in many"	12	"endometrial cancer: 60.6;ovarian cancer: 63.5;renal cancer: 33.2;thyroid cancer: 122.2"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Region enriched"	"Detected in some"	4	"pons and medulla: 5.8"					"HPA030062, CAB055097, CAB061888, HPA064554"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB055097: AB_2236705, CAB061888: AB_10895719, HPA030062: AB_10603982, HPA064554: "	"unprognostic (2.63e-3)"	"unprognostic (3.80e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavourable (1.75e-5)"	"unprognostic (7.24e-2)"	"unprognostic (5.16e-5)"	"unprognostic (1.56e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.16e-1)"	"unprognostic (4.13e-2)"	"unprognostic (4.00e-2)"	"unprognostic (3.37e-2)"	"unprognostic (3.27e-1)"	"unprognostic (2.37e-1)"	"unprognostic (8.93e-3)"	"unprognostic (1.02e-1)"	0.9	1.4	1.1	0.5	0.4	0.0	0.6	0.2	0.8	3.8	0.4	0.2	11.7	0.1	2.2	15.2	0.6	9.6	0.8	0.6	0.5	0.5	69.3	0.4	0.5	0.7	0.4	0.3	3.8	0.6	0.1	0.7	0.8	1.5	1.1	0.1	0.5	0.5	10.0	0.3	0.5	0.6	0.4	0.8	0.3	0.4	1.9	0.2	0.4	120.5	0.0	0.2	0.8	1.9	4.4	2.8	1.5	3.4	1.9	2.5	1.1	2.9	0.2	0.1	0.0	0.1	0.0	1.0	0.8	2.6	0.2	0.4	1.8	0.5	0.5	26.7	0.2	0.0	0.5	0.8	0.2	1.2	0.0	0.4	0.2	1.0	0.3	0.0	0.0	0.7	0.1	0.2	0.6	0.0	0.4	2.0	0.8	0.6	0.3	1.2	0.1	1.8	0.0	0.2	0.6	63.0	4.6	0.5	0.0	3.3	0.0	1.8	0.0	1.1	0.9	4.6	0.1	0.8	2.3	0.4	1.3	0.1	4.0	0.6	0.0	1.5	3.4	0.0	0.6	1.8	1.5	4.4	1.5	1.1	2.8	1.9	2.5	1.5	0.5	1.9	1.3	1.1	0.8	1.1	1.1	0.4	0.2	0.8	0.5	0.5	0.4	0.3	1.5	0.2
PBRM1	"BAF180, PB1"	ENSG00000163939	"Polybromo 1"	Q86U86	3	52545352-52685917	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015629, HPA059373"	Uncertain		Enhanced	Nucleoplasm				Nucleoplasm		"HPA015629: AB_1855012, HPA059373: "	"unprognostic (1.87e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.91e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.15e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.02e-2)"	"unprognostic (9.54e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.99e-2)"	"unprognostic (4.32e-2)"	"unprognostic (2.89e-3)"	"unprognostic (3.06e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.06e-1)"	24.3	14.8	13.8	20.6	15.9	17.2	24.4	19.1	13.8	18.9	18.5	14.0	22.9	12.2	25.9	13.9	19.9	18.9	13.7	15.9	11.1	10.0	11.7	14.5	14.9	16.5	16.5	8.2	25.1	15.4	14.4	30.6	28.0	14.7	16.1	15.3	12.7	17.5	16.2	21.8	17.2	14.3	21.1	15.6	19.1	14.8	13.1	13.7	51.0	22.0	10.5	17.1	22.4	23.0	6.6	10.7	11.1	8.7	4.6	7.4	1.9	12.3	8.0	28.6	14.0	14.1	14.4	20.0	17.0	11.8	19.7	17.3	8.9	8.4	30.0	2.4	20.0	8.5	24.8	12.9	24.0	32.0	13.3	28.4	15.0	6.9	20.2	23.6	21.6	13.4	14.9	22.0	14.2	19.0	16.2	16.5	19.8	4.1	39.0	7.1	17.3	13.1	20.4	17.9	15.2	8.2	24.2	19.4	21.5	20.5	4.9	16.2	9.2	13.7	21.9	18.5	14.0	15.9	20.8	11.9	18.8	28.5	11.4	19.2	18.4	10.1	5.0	11.1	4.8	3.2	4.9	3.6	4.8	5.3	4.8	6.6	7.4	4.7	2.7	4.6	8.7	10.7	4.5	1.9	13.8	15.9	19.1	13.8	11.1	10.0	16.5	8.2	14.7	13.7
PBX1		ENSG00000185630	"PBX homeobox 1"	P40424	1	164555584-164899296	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Sexual differentiation, Steroidogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 30.5;NTERA-2: 29.9;SK-BR-3: 61.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 2.9"	"Lineage enriched"	"Detected in single"	9	"granulocytes: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003505, HPA003881, CAB018768"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies,Cytosol"				Nucleoplasm	"Nuclear bodies, Cytosol"	"CAB018768: AB_675783, HPA003505: AB_1855019, HPA003881: AB_1855020"	"unprognostic (2.26e-2)"	"unprognostic (1.95e-1)"	"unprognostic (9.09e-2)"	"unprognostic (2.14e-2)"	"unprognostic (5.21e-3)"	"unprognostic (6.94e-3)"	"unprognostic (5.95e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.65e-1)"	"unprognostic (2.24e-3)"	"unprognostic (2.30e-1)"	"unprognostic (8.81e-2)"	"unprognostic (1.34e-2)"	"unprognostic (2.13e-1)"	"unprognostic (5.07e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.25e-1)"	13.2	17.3	14.9	8.3	15.0	1.4	16.4	14.1	17.4	73.4	26.3	11.2	15.9	13.6	67.2	15.3	20.8	35.1	25.8	12.6	10.9	9.7	15.4	4.2	10.4	2.3	11.6	14.6	35.2	29.4	21.3	12.4	9.6	8.1	27.6	9.3	10.2	19.6	25.1	16.8	6.0	14.6	56.8	8.0	5.1	13.9	9.7	8.7	2.7	17.4	8.5	6.6	32.2	24.7	0.0	0.1	2.9	0.0	0.3	0.2	2.5	1.1	22.3	22.1	5.9	14.9	7.2	1.3	9.3	6.1	2.5	1.8	4.3	4.0	0.0	1.9	12.7	7.8	8.6	2.4	1.0	1.1	9.3	30.5	17.9	0.0	9.8	0.0	7.8	7.1	0.0	1.6	0.7	0.1	0.0	0.0	0.6	14.7	0.0	0.1	29.9	1.1	0.0	7.3	8.9	1.8	13.3	0.8	13.1	10.8	61.6	0.0	23.4	0.0	0.1	1.3	3.1	8.7	2.7	2.8	21.1	0.0	0.1	0.0	0.1	2.9	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.7	0.3	0.0	0.1	0.0	2.5	14.9	15.0	14.1	17.4	10.9	9.7	11.6	14.6	8.1	8.7
PCBP1	"hnRNP-E1, hnRNP-X, HNRPE1, HNRPX"	ENSG00000169564	"Poly(rC) binding protein 1"	Q15365	2	70087454-70089203	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Viral RNA replication"	"DNA-binding, Ribonucleoprotein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037113, HPA043803, HPA068497"	Supported		Enhanced	"Nuclear speckles,Cytoplasmic bodies"		12000000	12000000	"Nuclear speckles"	"Cytoplasmic bodies"	"CAB037113: AB_1840915, HPA043803: , HPA068497: "	"unprognostic (1.63e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.08e-2)"	"unprognostic (5.37e-1)"	"unprognostic (1.63e-2)"	"unprognostic (8.33e-2)"	"unprognostic (9.94e-3)"	"unprognostic (2.01e-1)"	"unprognostic (2.70e-1)"	"unprognostic (6.65e-2)"	"unprognostic (2.77e-1)"	"prognostic favourable (1.71e-5)"	"unprognostic (3.85e-2)"	"unprognostic (9.25e-2)"	"unprognostic (1.22e-1)"	"unprognostic (5.90e-2)"	52.7	57.6	34.4	49.7	36.7	79.5	149.6	33.3	39.9	38.8	47.2	32.4	45.7	41.1	54.1	39.3	55.6	39.3	45.4	55.1	34.0	31.2	41.6	69.5	46.3	77.8	43.5	29.8	42.3	88.3	42.8	30.5	52.7	37.5	36.3	31.2	29.6	47.9	42.0	149.0	41.5	39.6	59.7	39.1	52.0	43.2	31.6	42.1	91.0	43.8	59.9	48.4	49.6	148.0	15.1	29.2	49.6	32.1	31.6	30.3	28.9	61.4	63.5	54.9	42.8	59.3	45.4	88.5	46.1	42.7	45.8	38.6	73.5	41.4	84.6	23.8	52.3	55.1	64.4	67.2	47.0	60.3	49.7	67.6	38.9	112.2	66.9	55.9	65.1	39.5	43.9	37.7	52.7	58.1	69.1	62.7	57.4	76.4	72.0	84.1	55.4	42.0	58.3	60.1	84.8	62.2	63.7	52.2	42.0	37.9	77.8	54.5	46.2	50.9	53.3	43.1	54.1	36.4	58.1	83.6	85.8	85.9	45.6	77.7	52.9	12.6	30.8	45.5	30.3	32.1	27.8	15.1	23.7	26.0	29.2	14.4	24.2	26.9	49.6	31.6	26.7	21.0	27.7	28.9	34.4	36.7	33.3	39.9	34.0	31.2	43.5	29.8	37.5	42.1
PCM1	PTC4	ENSG00000078674	"Pericentriolar material 1"	Q15154	8	17922840-18029944	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cilium biogenesis/degradation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023370, HPA023374, CAB058695"	Enhanced		Enhanced	"Nuclear membrane,Centrosome,Cytosol"				Centrosome	"Nuclear membrane, Cytosol"	"CAB058695: , HPA023370: AB_1855072, HPA023374: AB_1855073"	"unprognostic (1.52e-2)"	"unprognostic (1.77e-2)"	"unprognostic (6.54e-3)"	"unprognostic (3.35e-2)"	"unprognostic (9.52e-2)"	"unprognostic (1.62e-2)"	"unprognostic (1.40e-1)"	"unprognostic (7.74e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.26e-1)"	"unprognostic (2.84e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.76e-2)"	"unprognostic (2.16e-1)"	"unprognostic (4.60e-1)"	"unprognostic (1.34e-1)"	"unprognostic (2.45e-1)"	19.6	19.0	26.2	26.7	40.4	25.1	25.1	29.2	29.0	25.0	21.1	21.6	22.8	12.4	23.3	27.3	16.4	26.4	17.8	23.0	22.9	18.4	18.8	22.0	19.1	21.1	24.5	24.9	29.1	27.0	42.0	35.8	19.8	26.4	20.2	16.3	16.2	19.4	25.3	63.1	17.6	18.3	26.7	27.2	20.8	17.9	80.0	28.0	40.2	28.2	19.1	20.4	27.0	22.6	11.5	14.9	19.9	7.5	11.2	13.0	4.3	20.3	21.7	33.4	44.2	18.9	19.7	17.3	17.2	21.2	18.4	20.8	14.7	12.2	26.7	11.9	17.1	14.8	21.3	15.8	31.4	8.8	8.2	45.8	15.4	29.8	21.1	20.0	11.8	17.1	16.9	21.3	23.7	21.1	30.9	20.8	22.4	10.2	42.9	33.2	27.5	6.3	25.9	29.9	9.5	15.2	28.3	25.6	19.3	18.4	10.1	26.4	15.9	29.3	18.8	16.8	13.7	20.5	14.5	8.9	19.6	23.9	14.2	22.1	17.1	19.9	6.0	14.4	11.5	3.8	12.0	11.1	10.4	13.0	5.9	11.5	11.6	11.6	6.4	11.2	7.5	14.9	10.3	4.3	26.2	40.4	29.2	29.0	22.9	18.4	24.5	24.9	26.4	28.0
PCNA		ENSG00000132646	"Proliferating cell nuclear antigen"	P12004	20	5114953-5126626	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication, Host-virus interaction"	DNA-binding	"Cancer-related genes, Deafness, Disease mutation, Dwarfism, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 115.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB000148, HPA030521, HPA030522, HPA030523"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000148: AB_628110, HPA030521: AB_10600218, HPA030522: AB_10602096, HPA030523: AB_10602199"	"unprognostic (5.21e-2)"	"prognostic favourable (1.86e-5)"	"unprognostic (2.96e-2)"	"unprognostic (2.43e-1)"	"unprognostic (3.17e-1)"	"unprognostic (5.60e-3)"	"prognostic unfavourable (2.61e-4)"	"unprognostic (1.47e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.89e-2)"	"unprognostic (1.01e-2)"	"unprognostic (9.78e-2)"	"prognostic unfavourable (3.03e-6)"	"unprognostic (2.12e-2)"	"unprognostic (2.29e-1)"	"unprognostic (7.11e-3)"	"unprognostic (7.46e-2)"	13.9	21.4	11.1	31.8	15.8	87.2	13.7	17.2	14.6	13.7	23.1	15.6	13.7	18.9	15.7	13.7	36.0	12.7	17.5	13.6	11.6	9.8	21.7	14.9	17.8	41.6	18.8	10.8	14.4	14.3	14.0	13.9	24.0	14.3	10.8	26.1	18.7	17.7	15.6	11.0	16.5	20.5	12.8	16.1	24.5	15.7	40.5	17.4	115.8	18.1	40.7	38.7	17.3	17.2	16.9	16.0	8.7	11.6	19.6	24.4	16.9	73.2	57.7	58.6	25.2	13.9	13.0	41.1	48.3	28.5	45.5	64.7	45.0	58.6	74.5	15.7	17.2	55.1	34.6	58.2	41.7	22.1	38.2	52.3	22.2	104.8	5.9	71.6	23.5	9.4	13.8	38.7	9.2	25.9	46.5	63.0	44.3	26.5	136.8	79.2	43.8	32.0	75.6	51.5	60.1	20.6	42.8	50.3	34.2	33.8	52.3	33.1	36.9	36.5	17.3	32.9	37.8	46.2	55.1	32.0	91.3	126.2	14.8	68.2	42.1	2.4	11.6	8.7	19.2	10.9	23.8	16.9	24.4	19.3	16.0	13.6	22.4	20.1	3.8	19.6	11.4	14.7	23.3	16.9	11.1	15.8	17.2	14.6	11.6	9.8	18.8	10.8	14.3	17.4
PDAP1	"HASPP28, PAP, PAP1"	ENSG00000106244	"PDGFA associated protein 1"	Q13442	7	99392048-99408829	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB021103, HPA050294, HPA060836"	Approved		Enhanced	"Plasma membrane,Cytosol"		40000	40000	Cytosol	"Plasma membrane"	"CAB021103: AB_10057973, HPA050294: , HPA060836: "	"unprognostic (2.27e-1)"	"unprognostic (1.45e-1)"	"unprognostic (3.87e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.41e-2)"	"unprognostic (4.01e-3)"	"prognostic unfavourable (6.67e-4)"	"unprognostic (5.77e-2)"	"unprognostic (3.50e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.63e-1)"	"unprognostic (3.35e-2)"	"unprognostic (1.45e-2)"	"unprognostic (3.51e-2)"	"unprognostic (1.79e-1)"	"unprognostic (3.49e-1)"	"unprognostic (2.97e-2)"	26.7	25.7	25.5	25.0	23.9	23.0	22.4	23.4	28.5	22.8	25.9	18.3	21.6	21.1	25.8	21.6	32.2	20.5	23.4	30.2	23.4	20.4	25.2	31.8	20.5	20.2	23.2	23.5	23.4	28.2	23.3	18.0	28.8	24.2	23.0	22.0	19.0	27.8	26.4	103.5	24.8	19.6	26.9	22.2	20.5	22.6	19.7	24.3	20.1	22.4	37.2	25.2	24.1	28.2	11.3	15.8	24.2	11.9	20.4	14.2	4.6	30.7	26.9	18.2	23.2	14.1	14.7	11.8	25.6	14.8	20.7	17.5	27.2	15.4	13.6	22.7	24.1	16.7	21.9	25.6	20.2	19.3	24.3	13.7	26.0	23.6	20.7	25.7	13.6	15.4	19.3	22.7	37.3	20.6	32.3	24.8	20.2	64.2	35.7	35.1	23.3	29.2	16.5	18.2	23.5	20.9	23.7	18.7	37.4	19.1	30.5	13.0	13.4	13.5	18.6	27.9	30.9	33.0	39.9	23.9	27.3	30.1	22.4	23.1	29.1	7.6	9.4	8.6	12.4	11.9	11.1	11.3	11.5	8.9	7.4	11.1	8.3	10.3	24.2	20.4	10.6	15.8	14.2	4.6	25.5	23.9	23.4	28.5	23.4	20.4	23.2	23.5	24.2	24.3
PDCD1LG2	"B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2"	ENSG00000197646	"Programmed cell death 1 ligand 2"	Q9BQ51	9	5510570-5571254	"Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 25.4;BJ hTERT+: 39.9;HDLM-2: 30.5;TIME: 17.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA013411	Approved		Approved	Cytosol	"Secreted - unknown location"	34000000	34000000	Cytosol		"HPA013411: AB_1855102"	"unprognostic (3.93e-2)"	"unprognostic (1.90e-1)"	"unprognostic (3.51e-3)"	"unprognostic (6.68e-3)"	"unprognostic (7.66e-2)"	"unprognostic (6.77e-2)"	"unprognostic (5.72e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.37e-3)"	"unprognostic (5.79e-2)"	"unprognostic (5.29e-2)"	"prognostic unfavourable (1.15e-4)"	"unprognostic (5.00e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.01e-1)"	"unprognostic (7.51e-3)"	15.2	1.8	1.2	7.7	1.4	0.2	9.5	0.7	1.2	7.0	1.9	2.3	0.0	0.8	2.9	7.2	3.9	3.8	4.0	5.8	1.2	1.3	2.5	6.4	13.3	10.8	1.6	0.5	4.1	1.8	0.5	1.1	12.9	1.9	5.0	2.5	2.4	2.9	1.7	5.5	3.6	2.5	4.6	3.7	19.5	1.9	4.2	1.2	8.1	3.5	3.5	8.1	6.0	5.4	0.5	0.9	4.1	3.6	0.0	3.0	0.7	2.0	0.0	0.0	0.0	1.7	2.0	0.0	25.4	39.9	12.3	14.9	0.0	0.1	0.0	0.0	10.3	0.2	0.0	3.4	12.2	30.5	0.0	0.0	0.0	0.0	9.9	0.0	0.0	1.8	0.0	5.7	6.7	8.0	0.0	3.0	14.7	0.0	0.0	0.0	0.0	0.0	0.0	15.2	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	17.6	8.8	0.5	4.2	7.0	0.4	0.0	0.0	5.0	0.0	1.0	4.1	0.9	0.0	1.4	3.6	1.9	0.5	2.2	0.9	0.9	0.3	0.0	1.0	2.0	0.0	0.5	0.0	3.0	0.7	1.2	1.4	0.7	1.2	1.2	1.3	1.6	0.5	1.9	1.2
PDCD2L	MGC13096	ENSG00000126249	"Programmed cell death 2 like"	Q9BRP1	19	34404384-34426168	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA052181	Approved		Approved	Mitochondria				Mitochondria		"HPA052181: "	"unprognostic (5.39e-2)"	"unprognostic (3.48e-1)"	"unprognostic (1.51e-1)"	"unprognostic (6.99e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.22e-1)"	"prognostic unfavourable (5.81e-4)"	"unprognostic (1.82e-1)"	"unprognostic (1.49e-1)"	"unprognostic (8.78e-2)"	"unprognostic (1.30e-2)"	"unprognostic (2.39e-1)"	"prognostic unfavourable (1.23e-5)"	"unprognostic (1.75e-1)"	"unprognostic (1.72e-1)"	"unprognostic (3.00e-2)"	"unprognostic (5.98e-2)"	6.2	6.6	7.7	7.3	8.9	4.5	6.1	8.8	15.6	5.4	5.8	6.8	6.3	4.6	5.8	6.1	5.8	6.9	6.3	9.3	7.1	7.8	4.5	9.7	4.0	7.1	5.8	6.2	6.9	16.0	4.0	6.8	4.4	5.7	5.7	6.1	5.5	8.9	8.1	26.7	7.4	4.2	5.4	5.8	5.8	7.3	22.9	4.3	6.2	6.1	12.2	7.7	5.3	4.2	9.9	17.4	0.5	3.8	8.5	10.5	4.1	10.7	18.6	2.4	4.5	1.1	2.3	7.4	3.5	2.6	5.9	6.0	17.3	8.0	9.0	15.5	2.0	3.7	9.4	7.9	6.0	13.3	19.5	8.9	2.9	13.5	7.8	17.1	5.0	2.8	7.0	3.4	11.7	6.0	17.7	4.8	5.3	13.8	6.4	6.4	9.1	18.5	9.8	4.2	13.3	7.6	6.3	13.8	4.8	0.3	11.4	6.2	4.9	7.2	3.1	3.9	4.8	4.7	11.7	10.7	16.3	16.4	4.9	15.2	3.2	0.0	2.5	0.0	7.3	3.8	10.0	9.9	7.2	7.0	5.1	7.5	10.5	8.0	0.5	8.5	2.3	17.4	8.1	4.1	7.7	8.9	8.8	15.6	7.1	7.8	5.8	6.2	5.7	4.3
PDE4DIP	"CMYA2, KIAA0454, KIAA0477, MMGL"	ENSG00000178104	"Phosphodiesterase 4D interacting protein"	Q5VU43	1	148808181-149048286	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	10	"heart muscle: 106.0;skeletal muscle: 276.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 62.3;ASC TERT1: 50.7;K-562: 50.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA012678			Supported	"Golgi apparatus"				"Golgi apparatus"		"HPA012678: AB_1855123"	"unprognostic (2.14e-1)"	"unprognostic (3.27e-1)"	"unprognostic (5.31e-2)"	"unprognostic (6.73e-2)"	"unprognostic (7.82e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.17e-1)"	"unprognostic (9.72e-2)"	"unprognostic (7.65e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.23e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.70e-3)"	"unprognostic (1.82e-1)"	"unprognostic (4.14e-2)"	"unprognostic (9.13e-2)"	"unprognostic (2.28e-1)"	4.8	2.9	9.2	4.3	8.3	2.3	9.0	12.1	15.1	4.8	6.2	8.3	5.6	3.8	3.1	11.8	6.1	3.3	5.0	106.0	9.7	7.8	6.6	9.3	5.5	3.8	15.6	8.1	2.3	3.4	13.6	7.7	10.2	9.3	4.6	4.1	7.2	5.4	4.5	276.2	4.1	7.7	3.1	18.5	2.9	4.4	1.7	11.2	1.5	3.1	18.1	3.8	3.6	6.1	12.0	6.7	7.4	5.9	4.7	13.2	4.3	7.8	1.5	2.2	2.4	62.3	50.7	13.0	9.2	8.7	9.0	11.8	7.2	5.0	4.0	2.8	13.2	4.0	5.3	6.5	15.3	2.9	7.6	2.0	3.2	2.8	16.5	1.7	2.1	36.0	13.0	38.2	20.8	3.5	50.9	9.4	15.9	13.3	1.3	1.0	7.8	3.3	2.9	5.6	1.5	5.4	8.1	10.7	0.9	9.0	26.3	7.2	7.8	2.3	4.6	10.4	2.3	26.1	20.4	4.1	5.8	5.9	42.6	1.6	6.4	7.4	5.3	4.1	5.4	5.9	5.5	12.0	10.9	7.2	6.7	11.7	8.4	4.6	1.2	4.7	1.9	2.9	13.2	4.3	9.2	8.3	12.1	10.2	9.7	7.8	15.6	8.1	9.3	11.2
PDGFA	"PDGF-A, PDGF1"	ENSG00000197461	"Platelet derived growth factor subunit A"	P04085	7	497258-520296	"Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 63.1"	"Cell line enriched"	"Detected in many"	4	"WM-115: 80.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005579	Approved		Approved	"Vesicles,Centriolar satellite"	"Secreted to blood"	300000	300000	"Vesicles, Centriolar satellite"		"CAB005579: AB_2161916"	"unprognostic (2.22e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.26e-1)"	"prognostic unfavourable (1.75e-4)"	"prognostic unfavourable (1.78e-4)"	"unprognostic (2.63e-3)"	"unprognostic (4.37e-2)"	"unprognostic (3.02e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.85e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.07e-2)"	"unprognostic (5.87e-2)"	"unprognostic (8.35e-2)"	"unprognostic (1.02e-1)"	"prognostic unfavourable (8.67e-4)"	9.5	6.1	13.1	6.6	20.4	2.1	16.5	9.0	16.6	11.1	14.8	33.4	5.8	16.3	15.5	11.2	8.5	12.1	10.0	14.0	14.9	14.2	10.4	5.4	16.5	8.1	29.8	12.5	6.6	54.7	5.7	6.1	21.5	21.1	14.4	12.7	7.4	16.6	10.2	63.1	10.6	20.3	10.7	26.4	11.8	20.9	4.5	22.7	1.6	6.0	8.6	2.7	11.0	12.7	3.0	3.3	11.6	4.6	5.3	3.6	2.9	5.7	3.9	0.4	5.6	1.1	0.2	13.3	1.3	0.7	1.7	1.1	6.0	6.5	0.1	2.3	1.1	14.6	0.4	17.7	0.9	3.2	0.6	0.1	3.2	2.1	7.2	0.6	0.7	0.8	7.0	0.8	5.6	3.2	0.5	0.8	4.1	7.2	0.8	1.3	10.4	0.8	2.9	0.4	0.6	2.3	1.3	0.6	0.4	19.7	1.1	3.3	2.8	0.6	9.5	3.6	10.0	2.1	7.8	0.2	0.3	0.2	3.3	1.8	80.7	11.6	2.6	3.5	2.7	2.9	3.6	3.0	2.7	2.5	2.3	3.0	3.3	3.3	7.6	5.3	4.6	3.3	2.8	2.9	13.1	20.4	9.0	14.5	14.9	14.2	29.8	12.5	21.1	22.7
PDGFB	"SIS, SSV"	ENSG00000100311	"Platelet derived growth factor subunit B"	P01127	22	39223359-39244751	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"EFO-21: 29.1;HUVEC TERT2: 22.4;SK-BR-3: 22.2;TIME: 27.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 10.8"	"Lineage enriched"	"Detected in single"	12	"T-cells: 10.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011604, HPA011972, CAB018341"	Supported		Approved	Vesicles	"Secreted to blood"	98000	98000	Vesicles		"CAB011604: AB_2162180, CAB018341: AB_2162187, HPA011972: AB_1855134"	"unprognostic (4.96e-2)"	"unprognostic (8.94e-3)"	"unprognostic (8.41e-2)"	"unprognostic (2.66e-1)"	"unprognostic (9.84e-2)"	"unprognostic (4.46e-3)"	"unprognostic (4.34e-1)"	"prognostic unfavourable (3.67e-5)"	"unprognostic (3.22e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.05e-1)"	"unprognostic (8.68e-2)"	"unprognostic (1.84e-3)"	"unprognostic (5.12e-3)"	"unprognostic (7.47e-2)"	"unprognostic (6.50e-2)"	"unprognostic (1.03e-1)"	23.5	6.4	10.4	6.4	9.3	0.6	22.5	5.7	13.0	8.3	14.3	12.4	4.2	4.7	10.8	6.5	6.5	5.6	10.8	13.8	9.7	6.1	10.9	3.8	20.8	6.1	14.7	7.3	4.0	8.3	9.2	3.5	37.3	9.6	5.8	3.7	12.1	7.9	8.6	15.2	7.5	6.7	8.9	11.4	5.6	6.2	5.2	10.3	0.8	12.6	8.6	2.3	6.9	5.0	0.0	0.9	0.1	0.4	0.0	10.8	2.3	13.3	1.0	3.5	0.0	0.0	0.0	4.1	0.0	0.1	0.0	0.0	5.3	4.2	0.0	29.1	0.0	5.0	0.2	1.2	0.0	0.0	0.1	0.3	0.4	1.9	1.9	0.0	7.5	0.0	0.1	0.0	0.2	22.4	0.5	2.5	0.8	5.5	0.0	0.0	1.3	1.4	0.0	0.1	9.0	12.1	0.0	0.1	0.0	0.2	22.2	0.1	10.1	0.0	27.8	0.0	2.7	0.0	3.0	0.0	0.1	0.1	0.0	0.6	12.9	0.0	0.0	0.0	8.1	0.1	10.8	0.0	4.7	6.1	0.0	0.0	4.1	2.2	0.1	0.0	0.4	0.9	2.4	2.3	10.4	9.3	5.7	13.0	9.7	6.1	14.7	7.3	9.6	10.3
PDGFRA	"CD140a, GAS9, PDGFR2"	ENSG00000134853	"Platelet derived growth factor receptor alpha"	P16234	4	54229097-54298247	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 81.5"	"Cell line enhanced"	"Detected in some"		"ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9"	"Cancer enhanced"	"Detected in all"		"glioma: 30.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004947, CAB018143"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Intracellular and membrane"	150000	150000	"Nucleoplasm, Plasma membrane, Cell Junctions"		"CAB018143: AB_2162351, HPA004947: "	"unprognostic (1.67e-1)"	"unprognostic (9.35e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.60e-1)"	"unprognostic (8.92e-2)"	"prognostic favourable (9.33e-4)"	"unprognostic (1.24e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (7.01e-2)"	"prognostic unfavourable (9.79e-6)"	"unprognostic (9.58e-3)"	"unprognostic (9.87e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.72e-3)"	35.0	12.4	12.6	16.1	7.6	0.9	17.2	2.4	20.1	33.2	19.1	9.2	6.4	9.6	27.6	14.6	21.9	22.5	16.2	15.3	8.9	7.4	22.8	8.4	24.1	26.9	9.2	4.0	81.5	6.8	1.6	2.1	25.1	7.2	18.6	15.2	19.2	8.5	8.3	11.9	7.0	17.4	19.7	8.8	51.6	13.6	19.0	9.3	0.5	11.3	12.8	4.3	35.9	24.6	0.9	0.4	2.5	0.4	0.3	0.8	0.3	0.0	0.0	0.2	0.1	81.0	37.9	0.1	4.2	47.0	0.0	0.1	11.2	0.0	0.1	0.1	32.7	0.1	3.2	0.0	0.0	0.4	0.1	0.1	0.1	0.2	27.4	0.0	0.0	68.9	0.0	5.3	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.2	0.6	0.1	0.1	0.0	0.0	0.0	0.3	0.1	6.6	0.0	0.1	0.0	0.1	0.0	0.1	14.8	0.5	16.2	0.0	0.0	0.0	0.1	0.4	0.0	0.3	2.5	0.4	0.2	0.5	0.2	0.2	0.6	0.8	0.4	0.0	0.9	0.7	0.4	2.3	0.3	0.3	0.4	0.2	0.3	12.6	7.6	2.4	7.3	8.9	7.4	9.2	4.0	7.2	9.3
PDGFRB	"CD140b, JTK12, PDGFR, PDGFR1"	ENSG00000113721	"Platelet derived growth factor receptor beta"	P09619	5	150113837-150155872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Chemotaxis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"ASC diff: 169.0;ASC TERT1: 58.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.9;non-classical monocyte: 4.1"	"Group enriched"	"Detected in many"	8	"monocytes: 4.1;T-cells: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003842, CAB018144, HPA028499"	Enhanced		Supported	"Golgi apparatus,Vesicles"		35000000	35000000	Vesicles	"Golgi apparatus"	"CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018"	"unprognostic (4.75e-2)"	"unprognostic (2.48e-1)"	"unprognostic (5.21e-2)"	"unprognostic (3.60e-2)"	"unprognostic (3.27e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.36e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.57e-3)"	"unprognostic (6.72e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavourable (5.87e-8)"	"unprognostic (3.13e-3)"	"unprognostic (1.25e-2)"	"unprognostic (5.47e-2)"	"prognostic unfavourable (8.11e-4)"	61.8	10.4	8.3	11.0	9.1	0.5	66.1	4.6	10.4	73.1	15.7	6.7	6.9	5.1	44.3	17.3	21.7	26.1	51.7	24.2	8.2	3.9	17.0	4.6	28.9	21.5	7.9	8.1	46.5	7.5	10.4	7.7	46.4	7.7	24.2	6.3	22.9	11.2	19.3	29.8	20.3	11.2	29.8	5.0	19.6	9.2	21.5	6.7	1.4	21.4	16.0	7.3	23.6	35.1	0.4	0.1	0.0	4.1	0.0	2.9	0.6	0.0	0.0	1.0	0.0	169.0	58.5	0.3	5.9	24.5	4.1	7.0	0.6	0.0	0.0	0.7	16.9	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.3	0.4	24.0	0.0	0.0	26.3	0.0	5.7	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	1.1	0.0	0.4	0.3	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	6.7	2.2	2.8	0.3	0.0	0.0	0.0	4.1	0.0	0.1	0.0	0.0	0.0	2.9	0.6	0.0	0.4	0.1	0.8	0.1	0.1	0.0	1.3	0.0	0.0	4.1	0.0	0.0	0.6	8.3	9.1	4.6	10.4	8.2	3.9	7.9	8.1	7.7	6.7
PDSS2	"bA59I9.3, C6orf210"	ENSG00000164494	"Decaprenyl diphosphate synthase subunit 2"	Q86YH6	6	107152557-107459564	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Isoprene biosynthesis, Ubiquinone biosynthesis"	Transferase	"Cancer-related genes, Disease mutation, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029685, HPA029686"	Approved		Enhanced	Cytosol				Cytosol		"HPA029685: AB_10600219, HPA029686: AB_10602309"	"prognostic unfavourable (1.34e-5)"	"unprognostic (1.44e-1)"	"prognostic favourable (5.74e-5)"	"unprognostic (5.76e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.30e-2)"	"unprognostic (3.26e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.38e-2)"	"unprognostic (2.19e-1)"	"prognostic favourable (3.75e-7)"	"unprognostic (2.25e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.11e-2)"	10.6	27.3	7.2	17.0	8.3	8.3	19.6	9.0	10.3	10.4	12.7	9.0	13.7	9.6	13.1	11.4	11.5	9.2	11.2	16.0	7.0	6.8	22.1	27.4	18.2	18.3	9.2	5.3	10.8	14.0	11.4	19.4	7.0	9.6	15.6	13.9	12.0	19.9	19.9	13.1	9.0	10.1	11.0	8.1	9.1	10.5	12.8	10.1	11.3	14.1	11.1	10.6	10.9	12.9	8.5	9.4	4.1	12.1	4.6	8.3	4.3	5.6	7.6	6.5	10.1	11.3	14.5	15.0	10.0	12.7	9.6	9.3	7.5	8.2	10.8	9.2	11.1	7.8	15.7	12.5	13.2	6.9	7.7	10.7	9.0	12.5	12.0	13.8	8.7	10.7	14.9	15.2	12.1	10.1	15.2	14.7	9.4	7.0	4.0	14.6	4.1	9.9	7.2	5.8	8.7	11.9	7.8	6.4	5.6	6.8	12.0	14.3	9.8	16.7	6.3	6.9	4.1	9.6	8.5	4.1	5.0	8.4	12.8	20.6	12.6	4.1	6.6	3.5	5.3	7.6	8.3	6.6	5.6	6.8	9.4	8.5	7.3	6.9	0.9	4.6	12.1	4.5	7.1	4.3	7.2	8.3	9.0	10.3	7.0	6.8	9.2	5.3	9.6	10.1
PDZD4	"FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L"	ENSG00000067840	"PDZ domain containing 4"	Q76G19	X	153802166-153830565	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"brain: 71.6"	"Cell line enhanced"	"Detected in some"		"AF22: 15.8;NTERA-2: 8.0;RH-30: 11.3;SCLC-21H: 19.2;SH-SY5Y: 18.7;U-2 OS: 9.4"	"Cancer enhanced"	"Detected in many"		"glioma: 20.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 3.5"	"Group enriched"	"Detected in many"	25	"NK-cells: 1.5;T-cells: 3.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003878	Enhanced									"HPA003878: AB_2162807"	"unprognostic (9.18e-3)"	"unprognostic (1.25e-1)"	"unprognostic (1.11e-4)"	"unprognostic (1.07e-1)"	"unprognostic (6.79e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.92e-3)"	"unprognostic (2.17e-1)"	"unprognostic (2.32e-3)"	"unprognostic (5.90e-2)"	"prognostic favourable (2.96e-5)"	"unprognostic (2.27e-1)"	"unprognostic (2.54e-4)"	"unprognostic (2.27e-2)"	"unprognostic (1.48e-1)"	"unprognostic (2.83e-2)"	"unprognostic (2.87e-2)"	3.3	5.8	42.8	2.6	36.7	2.5	2.0	40.1	71.6	2.3	3.5	5.1	0.4	2.5	4.4	2.2	3.3	7.9	2.8	3.3	40.8	14.8	1.6	1.7	3.0	2.6	9.9	24.9	1.7	2.6	1.5	7.4	1.2	9.0	4.5	2.3	1.8	4.3	10.5	3.6	4.8	3.3	5.0	7.0	7.0	2.3	3.4	6.4	0.0	1.6	0.0	1.6	2.4	1.4	0.0	0.0	0.0	0.0	1.5	3.5	0.6	0.0	1.0	15.8	4.1	0.0	0.1	0.0	0.4	0.0	0.5	0.5	0.4	0.0	0.0	0.2	0.0	0.1	2.8	0.0	0.1	0.0	0.5	0.0	1.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.1	0.1	0.5	8.0	0.2	0.0	11.3	0.0	0.0	0.0	19.2	18.7	0.8	0.0	5.6	1.8	0.1	0.0	0.0	9.4	0.2	1.1	0.0	0.0	0.0	0.1	0.0	5.0	0.0	0.0	0.0	3.5	0.0	0.8	0.0	1.5	2.0	0.0	0.0	0.1	0.9	0.0	1.5	0.0	0.0	0.0	0.6	42.8	36.7	40.1	49.2	40.8	14.8	9.9	24.9	9.0	6.4
PER1	"PER, RIGUI"	ENSG00000179094	"Period circadian regulator 1"	O15534	17	8140472-8156506	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 23.2;hTCEpi: 27.1;hTERT-HME1: 26.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047947, HPA067064"			Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"HPA047947: , HPA067064: "	"unprognostic (7.64e-2)"	"prognostic favourable (3.89e-4)"	"unprognostic (5.54e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.44e-2)"	"prognostic favourable (2.56e-4)"	"unprognostic (5.28e-2)"	"unprognostic (6.67e-2)"	"unprognostic (6.21e-3)"	"unprognostic (6.87e-2)"	"unprognostic (4.68e-2)"	"unprognostic (7.09e-3)"	"prognostic unfavourable (1.94e-4)"	"unprognostic (2.08e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.34e-2)"	39.4	33.4	13.2	21.6	15.0	27.3	31.3	19.5	23.9	27.8	24.6	20.9	27.8	6.9	19.5	17.2	31.6	25.2	36.9	24.0	13.3	6.3	14.2	18.6	25.8	10.8	15.6	11.3	50.1	61.8	19.3	29.8	12.7	20.1	23.1	8.1	36.6	23.3	43.5	70.3	47.9	16.9	29.3	17.5	16.7	23.6	13.8	17.1	4.6	28.5	33.1	12.1	30.2	25.0	1.6	4.9	3.3	3.6	0.5	2.1	1.2	1.0	3.8	4.4	6.3	14.5	10.7	2.5	1.5	2.7	1.9	2.3	3.8	2.5	7.1	1.2	2.2	3.1	4.4	23.2	1.3	2.2	5.5	3.7	8.3	1.1	20.0	1.5	5.7	16.0	27.1	3.3	26.5	4.2	4.7	9.9	3.5	3.5	4.3	2.9	3.8	2.5	6.0	2.5	3.7	4.6	0.8	1.9	4.7	3.2	3.7	3.0	2.7	1.1	7.2	2.2	4.3	0.8	1.3	5.8	2.2	2.5	3.0	1.8	1.6	0.0	3.6	1.7	1.9	2.5	2.1	1.0	1.7	1.2	4.9	1.6	1.6	1.1	3.3	0.5	1.2	0.7	1.1	1.2	13.2	15.0	19.5	23.9	13.3	6.3	15.6	11.3	20.1	17.1
PF4	"CXCL4, SCYB4"	ENSG00000163737	"Platelet factor 4"	P02776	4	73981077-73982124	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	Chemotaxis	"Cytokine, Heparin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	5	"blood: 50.5;bone marrow: 46.8;heart muscle: 46.0;lymphoid tissue: 42.6"	"Cell line enriched"	"Detected in some"	10	"HEL: 29.7"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 4.4"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	9	"basophil: 18.3;neutrophil: 16.5"	"Lineage enriched"	"Detected in many"	9	"granulocytes: 18.3"									"CAB026008, HPA052485"	Enhanced				"Secreted to blood"					"CAB026008: , HPA052485: "		"unprognostic (4.14e-4)"	"unprognostic (1.00e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.96e-4)"	"unprognostic (7.58e-2)"	"unprognostic (1.42e-1)"	"unprognostic (7.55e-2)"	"unprognostic (2.04e-1)"	"unprognostic (9.02e-3)"	"unprognostic (1.84e-2)"	"unprognostic (3.03e-2)"	"unprognostic (9.54e-5)"	"unprognostic (2.55e-1)"	"unprognostic (8.77e-2)"	"unprognostic (9.69e-2)"	"unprognostic (4.81e-2)"	0.7	0.4	0.2	0.7	0.9	46.8	0.8	0.2	0.3	0.3	1.1	0.0	0.0	0.1	0.2	0.4	0.2	0.5	0.8	46.0	0.8	0.3	0.5	1.7	9.1	3.3	2.6	0.3	3.0	0.4	0.1	0.4	4.8	1.9	0.2	0.9	1.0	0.4	0.2	1.0	0.2	0.3	0.2	0.9	42.6	0.9	0.6	0.0	0.0	1.8	0.9	0.1	1.0	3.0	0.3	1.9	18.3	1.4	0.0	0.3	50.5	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	29.7	0.0	0.0	1.5	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.3	1.4	0.4	0.3	0.3	0.3	0.0	0.0	0.0	0.5	0.3	0.2	0.1	16.5	0.0	1.1	1.9	0.2	50.5	0.2	0.9	0.2	0.3	0.8	0.3	2.6	0.3	1.9	0.0
PGC		ENSG00000096088	Progastricsin	P20142	6	41736711-41754109	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	Digestion	"Aspartyl protease, Hydrolase, Protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"ductus deferens: 249.6;pancreas: 798.6;stomach 1: 963.7"	"Cell line enriched"	"Detected in some"	13	"Hep G2: 73.2"	"Cancer enhanced"	"Detected in many"		"stomach cancer: 1050.3"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	7	"intermediate monocyte: 1.9"	"Lineage enriched"	"Detected in single"	7	"monocytes: 1.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA031717, HPA031718"	Enhanced		Approved	Nucleoplasm	"Secreted to digestive system"			Nucleoplasm		"HPA031717: AB_10670130, HPA031718: AB_10610148"	"unprognostic (9.18e-2)"	"unprognostic (1.87e-1)"	"unprognostic (9.83e-2)"	"unprognostic (2.27e-1)"	"unprognostic (7.18e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.47e-1)"	"unprognostic (8.50e-2)"		"unprognostic (1.86e-1)"	"unprognostic (9.23e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.33e-2)"	"unprognostic (2.92e-1)"	"unprognostic (1.65e-1)"		"unprognostic (8.74e-2)"	0.1	0.2	0.1	0.0	0.1	0.0	0.2	0.1	0.1	0.3	0.1	3.0	249.6	41.7	0.1	0.0	3.3	0.3	16.8	0.1	0.1	0.1	0.1	0.3	139.4	0.0	0.1	0.0	0.1	798.6	0.0	0.1	0.0	0.1	2.3	0.0	0.0	0.1	35.9	0.1	0.1	0.1	0.0	0.1	0.1	963.7	0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.2	0.0	0.0	0.0	1.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	73.2	0.0	0.1	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.2	1.7	0.0	0.8	0.0	1.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.1	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	1.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0
PGF	"D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760"	ENSG00000119630	"Placental growth factor"	P49763	14	74941834-74955784	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"placenta: 177.3"	"Group enriched"	"Detected in some"	6	"BEWO: 91.3;HUVEC TERT2: 43.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA041624			Approved	Nucleoplasm,Mitochondria,Cytosol	"Secreted to blood"			Nucleoplasm	"Mitochondria, Cytosol"	"HPA041624: AB_10794522"	"unprognostic (1.67e-2)"	"unprognostic (4.62e-2)"	"unprognostic (9.25e-3)"	"unprognostic (1.34e-3)"	"unprognostic (8.67e-3)"	"unprognostic (2.41e-1)"	"prognostic unfavourable (1.40e-4)"	"unprognostic (7.26e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.45e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.51e-3)"	"prognostic unfavourable (1.33e-6)"	"unprognostic (2.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.14e-1)"	4.3	2.7	1.9	4.4	2.4	0.0	4.3	1.6	3.5	13.1	2.3	2.3	4.0	1.3	2.9	6.3	3.9	9.2	3.4	5.1	2.4	4.1	3.1	2.6	3.6	4.9	2.9	2.0	3.8	1.9	5.4	2.0	177.3	4.6	7.5	1.1	3.5	3.8	6.7	3.3	6.0	4.3	4.6	1.7	1.2	1.7	3.3	2.0	1.4	24.2	4.4	2.9	5.1	5.9	0.7	0.7	1.1	1.0	0.0	2.4	0.2	0.3	0.3	0.3	0.2	0.4	0.0	91.3	0.8	0.8	0.4	0.5	2.1	0.1	0.0	2.0	0.6	0.1	0.4	4.1	0.3	0.0	0.5	0.0	0.0	2.2	0.3	0.0	2.4	1.0	1.0	1.6	0.4	43.0	0.0	0.0	12.1	0.1	0.0	0.1	0.4	0.7	0.0	11.3	0.0	0.1	0.2	6.9	3.7	0.0	0.1	1.6	0.0	0.1	8.7	0.0	2.3	0.0	3.6	0.0	0.0	0.1	1.4	0.1	0.1	0.0	0.2	1.1	2.4	1.0	0.0	0.7	0.3	0.7	0.3	0.3	0.6	1.0	0.0	0.0	0.8	0.7	0.5	0.2	1.9	2.4	1.6	2.2	2.4	4.1	2.9	2.0	4.6	2.0
PGR	"NR3C3, PR"	ENSG00000082175	"Progesterone receptor"	P06401	11	101029624-101130524	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"cervix, uterine: 50.7;endometrium 1: 116.4;smooth muscle: 31.2"	"Cell line enriched"	"Detected in single"	349	"T-47d: 60.8"	"Group enriched"	"Detected in some"	13	"breast cancer: 10.1;endometrial cancer: 11.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000068, HPA004751, HPA008428, HPA017176, CAB055100"	Enhanced									"CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728"	"unprognostic (2.59e-2)"	"unprognostic (9.80e-3)"	"unprognostic (5.23e-3)"	"prognostic favourable (5.76e-8)"	"unprognostic (2.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.11e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.50e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.77e-1)"	"unprognostic (7.71e-3)"	"unprognostic (1.90e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.15e-1)"	"unprognostic (5.44e-3)"	0.8	0.7	0.2	0.3	0.6	0.0	5.0	0.2	0.7	50.7	1.3	0.2	0.4	0.0	116.4	6.1	0.5	13.2	0.4	2.0	0.5	0.6	0.4	0.1	1.2	0.3	0.4	0.1	10.6	0.8	0.0	2.8	1.8	0.8	3.8	0.1	0.7	3.5	5.5	0.3	0.3	1.2	31.2	0.9	0.5	0.4	1.5	0.3	0.1	0.3	0.8	0.2	1.1	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	60.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.2	0.7	0.5	0.6	0.4	0.1	0.8	0.3
PHF20	"C20orf104, dJ1121G12.1, TDRD20A"	ENSG00000025293	"PHD finger protein 20"	Q9BVI0	20	35771974-35950381	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029619, HPA029620, HPA029621"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Cytosol"				Nucleoplasm	"Nuclear membrane, Cytosol"	"HPA029619: AB_10600090, HPA029620: AB_10601110, HPA029621: AB_10602201"	"unprognostic (1.21e-3)"	"unprognostic (7.30e-2)"	"unprognostic (3.20e-2)"	"unprognostic (2.35e-3)"	"unprognostic (1.36e-1)"	"unprognostic (1.95e-1)"	"prognostic unfavourable (2.49e-4)"	"unprognostic (2.76e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.64e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.92e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.07e-1)"	"unprognostic (7.23e-2)"	"unprognostic (1.01e-2)"	19.1	11.6	14.0	16.8	19.0	14.1	17.2	25.1	19.2	15.9	15.9	16.1	8.1	8.1	19.1	11.6	16.5	14.2	14.8	15.2	14.1	13.8	11.2	11.1	16.5	17.3	14.9	13.0	18.9	9.4	17.9	20.0	15.6	15.0	14.7	11.7	14.7	15.3	15.7	46.6	12.9	12.3	17.2	18.9	20.8	12.7	17.4	15.2	19.4	14.2	14.5	20.8	18.7	21.8	12.0	8.2	23.6	11.9	13.0	12.4	6.5	9.6	7.7	13.5	19.9	9.8	11.3	12.6	11.0	10.5	11.1	9.7	22.4	7.3	16.1	10.0	14.6	6.0	12.4	15.3	13.6	7.2	5.3	30.0	14.7	8.3	9.9	14.3	11.7	8.8	21.6	11.7	18.1	12.1	12.2	10.4	12.7	5.7	14.5	8.4	6.7	9.6	10.6	20.0	9.5	8.8	6.7	12.3	10.0	19.6	22.8	10.1	18.0	10.7	16.9	24.6	5.6	12.7	11.2	9.6	11.4	11.8	18.2	10.5	12.6	11.9	8.6	23.6	10.6	9.0	11.3	12.0	10.5	11.9	8.2	9.8	12.0	12.4	20.5	13.0	11.9	7.7	5.5	6.5	14.0	19.0	25.1	19.0	14.1	13.8	14.9	13.0	15.0	15.2
PHF6	"BFLS, BORJ, CENP-31, KIAA1823, MGC14797"	ENSG00000156531	"PHD finger protein 6"	Q8IWS0	X	134373253-134428791	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Epilepsy, Hypotrichosis, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001023	Enhanced		Supported	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"HPA001023: AB_1079606"	"unprognostic (2.38e-3)"	"unprognostic (8.21e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.04e-3)"	"unprognostic (6.03e-3)"	"unprognostic (5.20e-3)"	"prognostic unfavourable (3.38e-4)"	"unprognostic (1.81e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (9.96e-4)"	"unprognostic (1.09e-1)"	"unprognostic (5.96e-2)"	"unprognostic (4.84e-2)"	"unprognostic (7.45e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.29e-2)"	7.4	19.3	10.2	14.1	12.2	6.5	9.7	18.2	13.5	8.7	8.0	11.6	20.3	7.8	9.0	30.1	11.5	7.3	6.1	7.2	11.0	11.1	9.9	7.5	8.4	20.4	12.5	9.3	30.7	10.4	24.1	18.1	8.2	13.3	8.6	9.5	5.4	11.3	16.8	6.2	7.4	10.2	8.1	17.1	17.8	8.1	8.3	14.4	30.2	11.8	6.0	25.0	8.9	9.8	18.4	11.0	5.3	7.4	9.6	9.9	5.0	11.3	9.4	41.3	16.9	7.7	9.9	7.8	11.4	9.1	12.2	15.2	5.6	11.8	18.2	26.2	6.9	10.2	28.8	12.9	20.6	14.8	13.4	17.6	16.1	6.4	8.3	17.5	9.8	6.5	9.8	13.3	16.6	17.0	12.9	9.0	14.9	7.4	28.2	8.7	12.6	12.7	27.9	15.1	13.8	13.0	13.7	14.3	16.9	8.7	8.1	11.9	7.5	9.7	12.9	11.4	8.2	14.3	17.4	4.6	10.7	24.6	7.5	20.9	14.2	5.3	6.1	3.7	7.9	6.0	8.5	18.4	8.2	7.1	8.8	12.8	9.9	8.2	2.5	9.6	7.4	11.0	8.3	5.0	10.2	12.2	18.2	13.5	11.0	11.1	12.5	9.3	13.3	14.4
PHLDA1	"DT1P1B11, PHRIP, TDAG51"	ENSG00000139289	"Pleckstrin homology like domain family A member 1"	Q8WV24	12	76025447-76033932	"Cancer-related genes, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"salivary gland: 142.4"	"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 43.3;RPTEC TERT1: 54.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 2.4;MAIT T-cell: 3.9;memory CD4 T-cell: 2.5;memory CD8 T-cell: 2.5;non-classical monocyte: 2.5;T-reg: 4.1"	"Group enriched"	"Detected in many"	7	"monocytes: 2.5;T-cells: 4.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016160, HPA019000, HPA063520"	Enhanced		Supported	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"CAB016160: AB_628117, HPA019000: AB_1855309, HPA063520: "	"unprognostic (9.09e-2)"	"unprognostic (2.27e-2)"	"unprognostic (2.03e-1)"	"unprognostic (4.51e-3)"	"unprognostic (2.33e-1)"	"unprognostic (2.60e-3)"	"unprognostic (1.40e-1)"	"unprognostic (4.18e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.16e-1)"	"unprognostic (5.21e-3)"	"unprognostic (5.03e-2)"	"unprognostic (1.21e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.29e-1)"	"unprognostic (4.55e-3)"	13.2	15.9	9.4	8.4	12.1	9.0	13.5	6.4	15.7	11.5	4.5	11.1	4.8	3.4	7.1	3.1	33.3	5.1	20.0	9.6	8.2	7.9	13.8	33.2	14.2	3.0	8.4	5.6	10.8	8.8	2.6	6.0	7.1	10.0	4.8	5.5	24.9	142.4	6.5	3.3	6.3	7.0	7.6	9.7	14.6	10.8	2.3	10.1	2.5	18.0	13.2	19.9	17.0	17.8	0.3	0.1	0.4	2.5	0.3	4.1	0.6	13.5	16.3	12.8	7.0	6.0	12.4	0.9	11.5	31.1	5.2	7.3	9.0	16.6	0.0	3.5	4.8	7.0	0.3	19.3	11.3	2.0	0.2	0.3	0.8	15.2	8.7	0.3	3.5	3.8	14.2	21.8	43.3	12.5	1.1	0.4	26.8	1.7	0.0	1.7	4.6	25.2	0.0	3.3	0.4	54.9	30.8	0.9	2.4	2.0	0.1	37.4	8.2	0.1	11.6	17.9	1.7	20.8	11.3	0.2	0.0	0.0	30.2	0.2	22.3	0.3	0.1	0.2	2.4	0.2	3.9	0.3	2.5	2.5	0.0	0.2	0.5	0.6	0.4	0.3	2.5	0.1	4.1	0.6	9.4	12.1	6.4	7.7	8.2	7.9	8.4	5.6	10.0	10.1
PHOX2B	"NBPhox, Phox2b, PMX2B"	ENSG00000109132	"Paired like homeobox 2b"	Q99453	4	41744082-41748970	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 14.5;brain: 24.8"	"Cell line enriched"	"Detected in single"	91	"SH-SY5Y: 52.3"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	99	"pons and medulla: 24.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	17	"pons and medulla: 5.9"	"Region enriched"	"Detected in single"	38	"pons and medulla: 2.0"	"HPA074325, HPA074941"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA074325: , HPA074941: "			"unprognostic (1.01e-1)"								"unprognostic (2.47e-1)"			"unprognostic (5.27e-2)"				0.0	14.5	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.2	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.0	24.8	0.2	1.4	0.8	0.0	0.0	0.0	0.0	3.2	0.5	0.4	0.0	0.9	0.1	0.0	0.1	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	52.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	24.8	0.0
PICALM	"CALM, CLTH"	ENSG00000073921	"Phosphatidylinositol binding clathrin assembly protein"	Q13492	11	85957684-86069882	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 25.8"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019053, HPA019061"	Enhanced		Enhanced	Vesicles		28000	28000	Vesicles		"HPA019053: AB_1855361, HPA019061: AB_1855362"	"unprognostic (9.27e-3)"	"unprognostic (7.29e-2)"	"unprognostic (3.51e-1)"	"unprognostic (6.83e-2)"	"unprognostic (5.13e-2)"	"unprognostic (1.93e-1)"	"unprognostic (5.36e-3)"	"unprognostic (9.02e-3)"	"unprognostic (9.80e-2)"	"unprognostic (6.27e-3)"	"prognostic unfavourable (6.61e-4)"	"unprognostic (4.31e-1)"	"prognostic favourable (2.02e-6)"	"unprognostic (1.26e-2)"	"unprognostic (5.21e-3)"	"unprognostic (2.52e-1)"	"unprognostic (1.02e-1)"	72.9	24.2	35.6	43.1	51.4	37.1	51.3	30.2	39.7	38.7	35.9	60.0	27.7	39.6	41.6	26.0	41.3	31.5	48.1	41.4	43.7	34.2	63.9	53.8	45.1	35.2	52.0	33.5	38.2	29.7	70.6	23.8	76.7	50.7	29.9	32.0	26.7	31.8	37.0	35.5	35.0	45.3	49.9	70.7	49.5	30.7	22.9	55.1	31.0	30.8	28.5	34.8	44.0	49.2	2.1	7.1	25.8	8.5	3.9	5.3	3.1	28.9	13.8	21.9	15.3	33.6	35.3	41.4	37.3	48.5	29.5	26.1	54.4	39.5	22.6	38.5	59.8	24.0	22.9	27.2	42.7	6.7	8.2	64.2	18.8	17.3	34.3	15.0	28.9	30.6	29.5	55.3	46.1	32.0	41.1	18.7	55.5	17.0	17.6	13.8	12.0	7.9	12.2	33.2	16.0	57.3	24.5	13.3	10.8	45.8	15.5	12.3	21.0	12.2	34.6	54.6	19.0	64.4	29.7	6.7	17.5	20.7	12.9	11.9	36.8	3.6	8.5	4.2	3.9	7.2	3.3	2.1	2.9	5.3	7.1	1.4	3.0	2.7	25.8	3.9	7.2	2.5	3.8	3.1	35.6	51.4	30.2	39.7	43.7	34.2	52.0	33.5	50.7	55.1
PIGR		ENSG00000162896	"Polymeric immunoglobulin receptor"	P01833	1	206928518-206946466	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 139.0;intestine: 320.1;salivary gland: 398.1"	"Cell line enriched"	"Detected in some"	5	"EFO-21: 28.0"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 731.7"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA006154, CAB009454, HPA012012"	Enhanced				"Intracellular and membrane"	1900000000	1900000000			"CAB009454: AB_2164819, HPA006154: AB_1855370, HPA012012: AB_1855371"	"prognostic favourable (1.22e-5)"	"unprognostic (7.42e-2)"	"unprognostic (4.78e-3)"	"prognostic favourable (2.57e-4)"	"unprognostic (2.31e-2)"	"unprognostic (6.71e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.07e-2)"	"unprognostic (6.45e-2)"	"unprognostic (1.19e-1)"	"unprognostic (5.23e-2)"	"unprognostic (2.13e-1)"	"prognostic favourable (5.08e-5)"	"unprognostic (1.83e-1)"	"unprognostic (1.41e-1)"	"unprognostic (6.92e-3)"	"unprognostic (3.39e-2)"	0.3	0.3	0.3	74.2	0.3	0.0	6.9	0.3	0.3	35.1	232.8	0.6	0.4	158.9	2.6	0.5	2.6	0.7	139.0	0.3	0.3	0.3	52.5	5.0	25.1	0.3	0.3	0.3	0.6	4.2	0.0	0.9	0.4	0.3	3.0	75.6	0.4	398.1	0.6	0.4	0.4	320.1	2.0	0.3	0.4	25.3	0.6	0.3	0.4	0.4	23.9	22.5	4.9	0.6	3.4	1.1	1.4	0.5	0.5	0.5	0.2	0.2	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1	28.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	1.4	0.2	0.0	0.2	0.0	4.9	0.1	1.3	0.6	2.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	1.0	0.2	0.4	0.2	0.3	1.0	0.0	0.1	0.0	1.4	0.5	0.3	0.4	0.2	0.5	3.4	0.3	0.3	1.1	3.4	0.5	0.5	1.4	0.5	0.3	0.9	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
PIK3CA	PI3K	ENSG00000121879	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha"	P42336	3	179148114-179240093	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Angiogenesis, Phagocytosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009985, CAB017804"	Approved		Approved	Cytosol				Cytosol		"CAB017804: , HPA009985: AB_1079610"	"unprognostic (1.81e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.69e-3)"	"unprognostic (6.49e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.57e-3)"	"unprognostic (5.21e-2)"	"unprognostic (4.50e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.48e-1)"	"unprognostic (9.74e-2)"	"unprognostic (3.82e-2)"	20.1	12.3	13.7	11.5	13.4	25.7	22.4	17.1	24.5	12.9	14.0	5.2	5.7	6.5	15.3	7.9	11.6	11.1	13.2	14.2	18.4	9.7	11.7	10.8	13.2	13.8	9.8	15.7	15.4	9.2	24.7	11.6	16.5	16.3	10.7	8.9	7.2	10.9	10.9	15.2	12.0	10.5	12.8	14.4	16.2	10.6	9.3	9.8	29.6	11.0	7.3	13.9	15.1	15.7	6.2	2.6	7.8	3.8	2.4	5.0	1.1	14.4	4.9	7.9	7.3	18.7	21.8	5.7	9.2	12.5	9.1	14.4	4.2	10.7	13.2	15.8	11.0	5.9	6.4	8.0	13.2	22.0	5.7	18.1	5.3	3.7	8.9	10.1	10.3	13.7	8.5	10.0	11.5	13.0	9.0	14.7	13.0	5.7	7.7	9.1	6.2	6.7	11.8	8.0	15.8	7.2	8.8	4.4	7.6	10.0	8.9	12.0	14.9	8.7	13.8	8.6	5.6	13.5	9.2	7.1	10.1	23.7	7.7	7.6	5.0	2.1	3.8	1.6	5.0	2.9	3.9	5.8	4.2	2.8	2.2	6.2	4.6	3.8	7.8	2.4	3.0	2.6	4.1	1.1	13.7	13.4	17.1	24.5	18.4	9.7	9.8	15.7	16.3	9.8
PIK3CB	PIK3C1	ENSG00000051382	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta"	P42338	3	138652699-138834938	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Autophagy, Cell adhesion, Endocytosis"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEL: 41.2;HMC-1: 65.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB031938, HPA042288, HPA064207"	Approved		Supported	Nucleoplasm,Nucleoli,Vesicles,Midbody				Nucleoplasm	"Nucleoli, Vesicles, Midbody"	"CAB031938: AB_2165408, HPA042288: , HPA064207: "	"unprognostic (4.89e-2)"	"unprognostic (1.42e-2)"	"unprognostic (5.97e-2)"	"unprognostic (7.85e-2)"	"unprognostic (4.89e-2)"	"unprognostic (6.01e-2)"	"prognostic unfavourable (6.42e-4)"	"unprognostic (3.98e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.28e-1)"	"prognostic unfavourable (3.99e-5)"	"unprognostic (2.15e-1)"	"unprognostic (6.18e-3)"	"unprognostic (9.33e-2)"	"unprognostic (7.82e-2)"	"unprognostic (2.79e-1)"	"unprognostic (4.59e-2)"	12.5	9.9	10.6	9.7	20.6	17.4	11.5	29.9	25.0	12.4	14.6	11.9	11.7	13.7	9.6	6.9	15.2	10.9	8.7	12.7	12.2	14.2	22.6	9.3	9.5	9.1	11.9	15.2	8.8	20.3	20.2	10.9	18.1	24.1	13.4	15.7	12.2	14.9	15.9	33.4	19.6	16.4	8.3	12.5	9.9	11.0	6.4	10.7	14.4	37.4	7.1	11.9	13.4	11.0	4.6	9.1	11.3	7.8	1.3	6.5	2.6	22.6	9.8	4.2	3.5	3.9	5.2	28.7	5.3	5.1	5.4	5.8	10.5	8.6	9.1	14.5	5.2	9.7	5.5	8.4	9.7	11.6	6.2	41.2	6.7	6.3	4.0	10.0	65.3	4.4	6.5	3.8	7.7	8.1	15.7	6.8	6.7	10.3	5.8	7.0	6.0	9.2	4.2	4.4	6.5	8.3	12.5	3.7	2.7	14.7	6.4	18.9	16.0	23.9	8.5	3.5	4.4	7.5	7.4	11.5	7.5	8.3	8.5	9.7	4.8	7.0	7.8	11.3	4.0	4.5	2.7	4.6	5.2	3.0	9.1	4.1	6.5	4.4	10.0	1.3	4.3	1.4	2.2	2.6	10.6	20.6	29.9	25.0	12.2	14.2	11.9	15.2	24.1	10.7
PIK3CG		ENSG00000105851	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma"	P48736	7	106865278-106907145	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Angiogenesis, Chemotaxis, Endocytosis, Immunity, Inflammatory response"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 24.5;bone marrow: 27.8;lymphoid tissue: 40.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 12.2;HMC-1: 15.2;Karpas-707: 12.6;MOLT-4: 23.0;U-266/70: 30.9;U-937: 21.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA069976	Enhanced		Supported	"Plasma membrane,Cytosol"				"Plasma membrane"	Cytosol	"HPA069976: "	"unprognostic (8.34e-2)"	"unprognostic (2.01e-2)"	"unprognostic (1.44e-2)"	"unprognostic (1.71e-2)"	"unprognostic (3.20e-2)"	"unprognostic (3.82e-3)"	"unprognostic (3.02e-1)"	"unprognostic (6.77e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.06e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.97e-1)"	"unprognostic (1.77e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.23e-1)"	"unprognostic (5.38e-1)"	"unprognostic (5.24e-2)"	5.0	1.8	2.2	16.0	3.1	27.8	2.3	0.8	1.7	1.7	4.1	2.7	0.0	2.8	1.7	2.0	2.0	1.8	3.5	1.7	1.7	1.5	1.9	1.5	4.3	13.1	3.0	1.0	1.7	1.5	0.6	1.4	2.0	2.5	2.2	2.6	1.9	3.1	0.5	1.1	1.3	6.1	1.9	6.4	17.4	2.5	7.6	3.0	40.8	2.3	0.9	21.2	4.1	1.5	6.2	5.6	14.2	24.5	5.3	5.6	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.2	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	7.5	0.0	0.0	0.0	11.9	15.2	0.0	0.0	0.0	0.0	4.7	8.5	12.6	0.0	0.0	23.0	4.6	0.0	0.0	6.1	0.0	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1	1.2	0.0	0.1	0.0	0.0	30.9	0.0	11.5	0.0	21.8	2.9	4.6	3.4	14.2	5.6	10.6	5.1	4.7	2.6	4.2	5.6	6.2	2.8	3.8	13.9	5.3	24.5	4.9	2.6	3.6	2.2	3.1	0.8	1.7	1.7	1.5	3.0	1.0	2.5	3.0
PIK3R1	"GRB1, p85, p85-ALPHA"	ENSG00000145675	"Phosphoinositide-3-kinase regulatory subunit 1"	P27986	5	68215720-68301821	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction, Protein transport, Stress response, Transport"		"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 71.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001216, CAB004268"	Approved		Approved	Cytosol				Cytosol		"CAB004268: AB_628126, HPA001216: AB_1079612"	"unprognostic (5.74e-2)"	"unprognostic (6.58e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.31e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.33e-2)"	"prognostic favourable (8.09e-4)"	"unprognostic (3.78e-3)"	"unprognostic (1.78e-1)"	"unprognostic (2.71e-1)"	"unprognostic (6.10e-2)"	"unprognostic (1.32e-1)"	"unprognostic (4.59e-3)"	"unprognostic (5.66e-3)"	"unprognostic (1.27e-1)"	"unprognostic (5.92e-2)"	"unprognostic (1.54e-1)"	26.2	13.4	26.0	13.0	24.3	51.6	42.3	15.3	50.3	27.1	20.3	12.8	12.8	8.1	41.3	22.1	20.8	33.0	18.1	33.9	24.0	13.4	17.9	46.5	16.3	12.0	22.0	40.8	25.8	6.8	22.3	9.4	15.0	18.2	15.2	10.8	8.7	54.6	16.2	48.9	19.1	16.1	36.3	17.6	18.8	13.1	7.6	23.6	16.2	12.8	8.5	10.8	25.2	24.4	2.2	2.1	10.6	4.1	8.2	14.8	4.0	1.0	2.1	6.3	18.7	71.7	21.0	2.7	6.0	2.8	2.3	2.5	5.2	1.9	5.5	10.3	8.2	2.6	1.7	12.1	2.9	23.0	2.3	6.6	1.7	4.2	24.1	6.7	5.3	22.1	27.6	4.2	22.5	3.0	1.0	4.2	2.1	2.8	16.4	2.6	1.8	1.1	15.4	3.0	4.3	3.0	12.3	1.2	5.7	0.9	1.6	3.9	9.0	4.8	3.6	2.7	2.8	4.5	3.7	4.7	7.0	6.4	2.9	8.5	2.0	10.6	1.2	5.9	9.2	1.7	12.7	1.2	11.5	8.4	2.1	2.2	14.8	10.8	1.5	8.2	4.1	0.9	8.5	4.0	26.0	24.3	15.3	50.3	24.0	13.4	22.0	40.8	18.2	23.6
PIK3R2	"p85, P85B"	ENSG00000105647	"Phosphoinositide-3-kinase regulatory subunit 2"	O00459	19	18153118-18170540	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Protein transport, Stress response, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA069291	Approved		Approved	"Golgi apparatus"				"Golgi apparatus"		"HPA069291: "	"unprognostic (2.50e-1)"	"unprognostic (1.90e-3)"	"unprognostic (1.68e-2)"	"unprognostic (1.87e-1)"	"unprognostic (2.00e-2)"	"unprognostic (9.65e-3)"	"unprognostic (1.69e-3)"	"unprognostic (2.36e-3)"	"unprognostic (9.24e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.36e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.02e-1)"	"unprognostic (6.35e-3)"	"unprognostic (8.63e-2)"	"unprognostic (2.00e-2)"	6.4	20.9	27.5	7.2	30.1	10.1	7.2	14.4	36.6	14.5	13.5	11.4	6.7	21.7	13.9	12.0	19.0	17.8	17.2	12.5	33.2	11.5	10.3	10.3	8.4	6.3	10.1	18.1	20.2	13.0	24.3	16.7	10.2	7.9	11.6	10.1	11.4	14.5	11.9	10.9	26.2	16.5	11.1	7.4	7.1	15.9	9.8	11.0	11.3	9.0	9.4	10.4	13.9	11.6	2.5	1.9	3.1	1.8	1.9	3.2	0.8	18.8	9.7	13.3	17.7	17.7	17.9	20.1	15.1	19.0	11.4	8.4	9.9	9.2	14.9	23.9	21.0	14.2	8.0	16.5	6.3	12.2	29.1	5.7	13.1	23.6	14.2	12.9	7.0	22.3	16.3	7.6	11.7	2.8	16.2	5.4	14.0	29.4	8.8	11.0	15.5	21.7	9.3	18.5	11.4	16.3	14.0	29.9	33.9	14.3	13.8	13.1	8.8	7.1	5.7	20.3	10.5	25.1	13.4	10.2	13.0	6.7	16.2	18.9	12.8	0.7	1.7	3.1	3.2	1.8	2.0	2.5	1.7	1.5	1.9	2.3	1.6	1.8	1.0	1.9	1.0	1.4	0.3	0.8	27.5	30.1	14.4	36.6	33.2	11.5	10.1	18.1	7.9	11.0
PIK3R3	p55	ENSG00000117461	"Phosphoinositide-3-kinase regulatory subunit 3"	Q92569	1	46040140-46133036	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"RT4: 33.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 8.6"	"Group enriched"	"Detected in many"	8	"granulocytes: 8.6;monocytes: 3.1;T-cells: 3.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005751, HPA071988"	Approved		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"HPA005751: AB_1855350, HPA071988: "	"unprognostic (1.98e-1)"	"unprognostic (3.75e-3)"	"unprognostic (8.04e-2)"	"prognostic favourable (1.93e-4)"	"unprognostic (6.32e-2)"	"prognostic favourable (3.62e-4)"	"unprognostic (4.88e-2)"	"unprognostic (3.33e-3)"	"unprognostic (4.16e-2)"	"unprognostic (4.63e-2)"	"unprognostic (1.05e-2)"	"unprognostic (1.45e-1)"	"unprognostic (9.99e-3)"	"unprognostic (2.87e-2)"	"unprognostic (9.74e-2)"	"unprognostic (6.71e-2)"	"unprognostic (8.22e-3)"	33.7	10.9	7.4	7.0	8.2	0.8	24.7	36.4	11.0	16.9	6.3	3.5	9.1	3.3	15.8	11.0	8.4	7.6	10.9	28.7	6.8	8.5	10.4	4.1	20.0	6.0	8.7	3.1	4.6	4.0	18.7	10.2	13.4	10.4	9.0	5.3	13.6	9.4	8.0	14.8	4.6	6.0	12.3	7.1	10.9	7.4	24.0	4.5	5.9	12.7	6.2	5.3	12.3	8.7	0.5	0.6	8.6	3.1	0.1	3.5	0.9	4.6	1.6	21.4	10.8	2.1	0.9	6.8	2.8	2.0	3.7	4.6	0.9	1.4	6.1	8.5	1.0	2.8	7.4	2.5	2.4	4.8	6.7	3.8	19.2	0.7	0.7	3.5	5.3	2.6	1.5	3.9	1.4	7.6	1.4	4.4	5.2	7.1	14.0	2.1	7.5	4.3	18.0	5.7	7.3	9.2	33.3	15.5	11.2	9.0	23.9	2.5	6.6	3.1	14.2	3.9	3.7	0.6	2.7	6.3	6.5	3.7	3.1	4.7	2.0	0.0	0.3	8.6	3.3	0.5	3.0	0.5	0.8	2.9	0.0	0.0	0.3	1.9	0.1	0.1	3.1	0.6	3.5	0.9	7.4	8.2	36.4	8.9	6.8	8.5	8.7	3.1	10.4	4.5
PIM1	PIM	ENSG00000137193	"Pim-1 proto-oncogene, serine/threonine kinase"	P11309	6	37170203-37175426	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Cell cycle"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 34.8;HMC-1: 64.9;U-698: 116.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 64.6"	"Group enriched"	"Detected in all"	5	"granulocytes: 64.6;T-cells: 19.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003941, CAB017040"	Uncertain		Supported	Nucleoli,Cytosol				Cytosol	Nucleoli	"CAB017040: , HPA003941: AB_1079618"	"unprognostic (1.25e-2)"	"unprognostic (4.77e-1)"	"unprognostic (3.61e-2)"	"prognostic unfavourable (9.73e-4)"	"unprognostic (1.91e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.75e-1)"	"unprognostic (4.64e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.65e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.14e-3)"	"unprognostic (8.16e-3)"	"unprognostic (1.04e-1)"	"unprognostic (5.26e-3)"	"unprognostic (2.90e-1)"	39.3	5.4	7.4	18.5	8.9	80.9	20.1	8.1	9.9	23.0	17.9	4.7	4.2	17.9	15.4	9.8	56.3	21.6	24.7	20.8	8.2	3.7	7.5	24.5	14.5	35.7	7.4	2.2	20.0	9.6	2.0	5.6	28.7	12.7	15.6	8.8	6.9	12.8	4.5	26.5	31.3	26.1	31.6	10.7	21.4	12.1	6.8	7.6	15.0	7.2	20.1	28.8	32.6	31.2	1.7	1.4	64.6	1.7	8.4	19.0	8.5	3.0	1.2	2.0	1.1	4.6	2.4	23.5	1.0	3.3	2.2	3.6	4.5	4.2	6.0	1.7	1.2	3.5	2.0	3.2	2.0	27.5	1.3	34.8	1.3	5.8	4.7	0.6	64.9	8.3	4.0	2.0	1.3	0.6	29.9	9.8	0.3	0.7	1.9	3.1	3.7	1.9	4.6	3.6	7.1	0.6	18.4	9.7	1.9	2.3	0.2	0.6	0.5	1.0	1.1	1.3	3.9	5.8	1.3	4.6	2.4	116.6	0.5	8.8	1.3	64.6	1.7	24.4	14.7	1.6	19.0	1.7	13.1	12.9	1.4	1.3	11.9	9.0	14.1	8.4	0.9	0.4	9.4	8.5	7.4	8.9	8.1	9.9	8.2	3.7	7.4	2.2	12.7	7.6
PIM2		ENSG00000102096	"Pim-2 proto-oncogene, serine/threonine kinase"	Q9P1W9	X	48913182-48919024	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell cycle"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 63.4;lymphoid tissue: 71.2"	"Group enriched"	"Detected in many"	5	"HDLM-2: 58.9;Karpas-707: 73.0;RPMI-8226: 71.9;U-266/70: 133.0;U-266/84: 117.5"	"Cancer enriched"	"Detected in all"	6	"testis cancer: 171.3"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000285			Approved	Cytosol				Cytosol		"HPA000285: AB_1079619"	"unprognostic (2.34e-3)"	"prognostic favourable (4.05e-5)"	"unprognostic (8.04e-2)"	"unprognostic (7.30e-2)"	"unprognostic (6.41e-3)"	"unprognostic (2.74e-3)"	"unprognostic (2.84e-1)"	"unprognostic (5.23e-2)"	"unprognostic (2.47e-2)"	"unprognostic (4.01e-2)"	"unprognostic (1.33e-3)"	"unprognostic (2.73e-1)"	"prognostic unfavourable (1.17e-11)"	"unprognostic (3.36e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.27e-1)"	"unprognostic (4.38e-2)"	3.6	3.4	4.3	37.2	7.2	30.4	3.4	7.1	7.9	4.5	13.4	2.1	2.2	29.5	2.8	4.3	10.0	5.6	8.3	3.1	5.6	6.7	5.2	5.4	10.6	59.7	3.8	4.6	5.4	3.0	1.0	4.9	2.4	6.7	3.6	17.7	6.1	16.9	4.9	1.5	3.0	19.2	2.2	3.1	71.2	14.7	5.7	1.3	39.4	4.8	3.6	47.9	24.6	3.3	26.0	2.9	46.9	3.0	17.0	63.4	13.2	1.8	1.5	0.8	1.6	0.3	0.2	1.2	1.1	1.4	1.6	1.4	1.4	1.3	7.8	0.5	0.5	1.1	2.6	1.0	1.5	58.9	2.1	9.4	1.6	1.4	0.7	2.2	6.4	0.6	0.9	1.6	1.0	0.5	10.0	73.0	0.9	1.3	0.8	4.7	17.8	2.4	1.0	0.5	71.9	1.6	0.2	0.5	0.8	1.2	0.8	0.8	2.0	3.1	0.3	0.3	0.2	0.3	1.1	133.0	117.5	15.0	1.5	2.0	0.3	46.9	1.5	14.3	12.5	1.9	21.2	26.0	34.4	17.6	2.5	15.9	36.9	23.0	38.3	17.0	3.0	2.9	63.4	13.2	4.3	7.2	7.1	7.9	5.6	6.7	3.8	4.6	6.7	1.3
PIM3		ENSG00000198355	"Pim-3 proto-oncogene, serine/threonine kinase"	Q86V86	22	49960513-49964080	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell cycle"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 45.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 16.9"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA068758			Supported	Cytosol				Cytosol		"HPA068758: "	"unprognostic (3.67e-2)"	"unprognostic (7.69e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.67e-2)"	"unprognostic (5.83e-2)"	"unprognostic (1.48e-2)"	"unprognostic (1.13e-2)"	"unprognostic (2.71e-2)"	"prognostic unfavourable (9.68e-4)"	"unprognostic (2.00e-2)"	"unprognostic (1.00e-1)"	"prognostic favourable (8.09e-4)"	"unprognostic (5.59e-3)"	"unprognostic (1.71e-1)"	"unprognostic (3.92e-3)"	"unprognostic (7.27e-3)"	32.5	15.5	6.8	19.9	16.7	62.4	50.5	7.6	11.9	16.4	22.6	11.3	20.9	15.9	14.4	17.6	25.0	15.9	37.8	23.6	7.5	7.9	29.1	25.7	38.3	29.4	21.1	4.9	13.9	36.4	4.8	14.9	31.4	15.1	28.4	7.6	9.7	27.6	22.7	39.9	31.3	20.9	12.2	10.1	25.4	33.6	13.0	13.5	9.7	19.1	19.9	19.0	25.6	18.3	6.1	5.7	16.9	4.0	1.2	4.5	1.9	7.2	4.8	3.2	6.1	2.5	1.9	18.5	4.6	7.4	5.4	3.9	8.0	6.2	12.9	5.8	1.2	6.2	6.2	3.4	1.9	9.7	25.7	5.3	11.5	9.6	12.0	11.5	10.3	3.6	11.5	3.3	5.7	17.6	7.3	45.7	1.6	16.2	5.8	20.6	6.8	7.7	27.2	5.4	15.3	2.9	5.5	11.6	8.1	8.9	40.6	28.4	5.3	15.3	4.6	3.4	14.8	5.6	7.4	23.5	14.9	11.0	8.6	6.5	9.2	0.0	3.1	0.1	1.9	3.2	2.3	3.4	4.4	3.8	2.5	6.1	4.1	1.7	16.9	1.2	4.0	5.7	4.5	1.9	6.8	16.7	7.6	11.9	7.5	7.9	21.1	4.9	15.1	13.5
PIN1	dod	ENSG00000127445	"Peptidylprolyl cis/trans isomerase, NIMA-interacting 1"	Q13526	19	9835257-9849682	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle"	"Isomerase, Rotamase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 88.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB004528, CAB009326, HPA068650, HPA070887"	Approved		Enhanced	Nucleoplasm,Cytosol		30000	30000	Nucleoplasm	Cytosol	"CAB004528: AB_628132, CAB009326: AB_2237080, HPA068650: , HPA070887: "	"unprognostic (2.54e-1)"	"unprognostic (6.14e-3)"	"unprognostic (6.50e-2)"	"unprognostic (4.36e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.50e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.86e-2)"	"unprognostic (2.67e-1)"	"unprognostic (7.23e-3)"	"prognostic favourable (3.25e-4)"	"unprognostic (9.43e-2)"	"prognostic favourable (7.80e-5)"	"unprognostic (2.20e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.13e-2)"	"unprognostic (1.21e-2)"	24.5	36.3	40.0	18.7	38.8	25.6	9.3	27.4	66.0	9.2	15.8	18.1	8.5	22.9	14.0	8.3	11.3	16.4	10.1	25.9	38.0	35.2	17.4	14.5	13.2	14.8	38.7	37.2	13.9	21.1	9.5	13.6	13.3	57.3	23.2	6.5	14.1	21.3	15.7	50.2	10.2	21.7	11.1	19.6	15.4	19.6	24.8	15.0	19.7	9.9	8.1	9.3	11.1	9.7	36.4	72.8	88.2	44.9	40.7	53.8	46.2	25.9	23.8	17.8	16.5	6.2	5.6	10.5	19.4	8.4	14.5	14.0	22.1	8.3	16.1	31.0	7.2	13.3	12.2	11.7	4.6	34.3	52.0	41.8	29.3	19.0	10.1	19.5	24.6	7.6	7.9	9.4	4.4	11.8	18.9	24.5	8.7	18.2	29.5	76.2	17.0	36.6	27.0	18.5	27.0	10.4	12.8	22.4	26.4	18.7	9.4	21.7	12.0	23.4	19.9	20.1	16.1	31.1	31.1	31.6	29.7	21.7	21.5	25.0	24.7	52.2	43.4	88.2	42.0	44.9	39.2	35.6	41.5	42.1	39.7	36.4	33.1	37.2	26.8	40.7	41.7	72.8	53.8	46.2	40.0	38.8	27.4	66.0	38.0	35.2	38.7	37.2	57.3	15.0
PIP4K2B	"PIP5K2B, PIP5KIIB, PIP5KIIbeta"	ENSG00000276293	"Phosphatidylinositol-5-phosphate 4-kinase type 2 beta"	P78356	17	38765689-38800126	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 23.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047875, HPA062220"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA047875: , HPA062220: "	"unprognostic (7.77e-2)"	"unprognostic (8.37e-2)"	"unprognostic (3.74e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.91e-1)"	"prognostic unfavourable (4.54e-4)"	"unprognostic (2.64e-1)"	"unprognostic (2.33e-1)"	"unprognostic (1.50e-2)"	"unprognostic (6.10e-3)"	"unprognostic (3.79e-1)"	"unprognostic (4.82e-3)"	"unprognostic (3.38e-2)"	"unprognostic (3.22e-1)"	"prognostic favourable (1.36e-4)"	"unprognostic (2.48e-1)"	5.1	6.5	12.4	3.3	12.9	1.1	5.0	8.8	17.4	6.8	2.7	7.0	4.2	2.2	7.2	5.9	3.5	7.4	3.6	7.1	9.6		4.1	2.2	5.0	4.2	5.4	13.3	13.3	3.0	5.1	2.7	5.4	7.5	5.1	3.2	4.1	3.8	6.5	23.6	5.8	2.3	7.3	4.7	5.1	2.5	2.8	6.5	2.0	4.7	2.2	4.5	3.7	5.9	3.3	3.1	2.4	2.4	3.4	5.0	3.7	5.9	13.1	21.8	22.7	19.1	15.2	4.5	11.1	12.4	14.1	11.5	8.8	5.9	15.2	7.0	19.0	12.8	14.4	9.2	13.6	10.5	9.3	13.2	8.5	13.0	8.7	15.1	8.1	13.3	11.3	11.0	8.1	11.6	11.5	7.2	15.1	4.5	13.8	11.0	12.2	6.1	15.0	21.6	8.3	10.3	7.4	12.2	17.7	11.2	4.6	11.3	14.4	14.3	12.3	11.9	7.9	10.2	9.6	9.5	11.9	6.9	14.1	11.9	10.7	1.6	2.4	0.8	4.8	2.2	5.0	3.1	4.1	4.6	3.1	3.3	4.7	4.2	2.4	3.4	1.8	3.0	3.9	3.7										
PIP5K1A		ENSG00000143398	"Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha"	Q99755	1	151197949-151249536	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029366	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	Nucleoplasm	"HPA029366: AB_10602116"	"unprognostic (1.05e-1)"	"unprognostic (2.36e-2)"	"unprognostic (8.64e-2)"	"unprognostic (7.94e-3)"	"unprognostic (1.17e-1)"	"unprognostic (3.28e-2)"	"unprognostic (1.26e-2)"	"unprognostic (3.01e-1)"	"unprognostic (8.79e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.04e-1)"	"prognostic unfavourable (4.16e-7)"	"unprognostic (1.44e-1)"	"unprognostic (8.14e-2)"	"unprognostic (2.93e-1)"	"unprognostic (1.59e-1)"	18.1	19.5	15.7	15.4	21.0	9.6	20.2	22.6	27.6	19.8	18.0	20.3	14.7	16.4	24.8	22.6	20.7	19.4	20.7	18.9	17.3	13.4	17.8	18.3	21.7	17.1	12.7	17.5	20.4	16.6	21.8	25.3	44.6	14.6	17.3	15.6	29.5	17.8	15.2	26.1	20.4	20.4	27.2	16.1	20.1	16.8	42.1	14.0	19.3	20.1	13.9	22.3	16.2	17.7	9.1	8.7	11.7	6.2	4.7	5.9	6.3	17.7	13.8	21.4	24.6	14.1	14.9	21.0	23.4	33.0	43.8	39.3	25.1	17.2	16.1	25.0	24.9	15.1	27.7	16.1	38.4	24.3	19.8	12.8	18.2	11.9	26.7	22.9	16.2	19.9	14.9	27.2	34.5	17.8	12.5	13.8	22.0	24.8	22.8	11.4	31.7	21.4	22.1	18.7	12.0	22.5	10.3	14.3	19.0	31.6	24.4	20.6	25.5	21.7	17.0	17.4	24.4	16.0	28.1	19.3	32.1	36.4	16.9	6.7	20.8	0.1	5.5	7.3	5.3	6.2	4.1	9.1	5.0	5.9	8.4	4.6	5.4	4.2	11.7	4.7	4.8	8.7	3.9	6.3	15.7	21.0	22.6	27.6	17.3	13.4	12.7	17.5	14.6	14.0
PKM	"OIP3, PK3, PKM2, THBP1"	ENSG00000067225	"Pyruvate kinase M1/2"	P14618	15	72199029-72231822	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Glycolysis	"Allosteric enzyme, Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"skeletal muscle: 541.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019421, HPA029501"	Uncertain		Enhanced	Cytosol		540000000	540000000	Cytosol		"CAB019421: AB_2252325, HPA029501: AB_10602118"	"unprognostic (8.73e-3)"	"unprognostic (4.63e-3)"	"unprognostic (1.68e-2)"	"unprognostic (3.09e-1)"	"unprognostic (6.51e-2)"	"prognostic unfavourable (1.30e-4)"	"prognostic unfavourable (2.74e-6)"	"prognostic unfavourable (2.85e-4)"	"unprognostic (9.51e-2)"	"unprognostic (1.17e-2)"	"prognostic unfavourable (5.17e-5)"	"unprognostic (3.16e-1)"	"unprognostic (3.22e-1)"	"unprognostic (7.85e-2)"	"unprognostic (3.17e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.25e-2)"	23.2	76.8	53.8	49.8	70.4	57.5	41.6	56.6	85.9	65.7	31.2	32.1	31.5	26.4	24.7	41.8	76.4	37.9	32.9	94.8	50.1	57.1	60.9	6.1	33.3	39.4	62.5	63.6	26.2	15.6	33.3	28.3	27.1	80.5	34.8	31.9	54.4	47.1	47.5	541.2	51.8	25.1	44.7	34.9	30.7	26.7	29.0	29.4	23.5	23.8	114.4	60.6	53.1	40.9	25.1	79.6	14.9	90.6	11.6	37.4	114.9	81.5	209.8	42.3	50.0	50.9	57.2	35.0	88.5	206.7	142.1	143.9	59.0	100.5	62.1	89.6	165.6	118.9	133.7	180.0	111.4	109.0	63.2	38.0	105.5	48.8	35.5	49.3	82.0	51.9	83.9	109.5	45.0	83.6	9.5	49.8	224.1	50.7	18.4	21.2	52.3	80.1	54.7	135.4	118.3	188.7	105.0	44.0	48.0	115.4	71.2	90.5	49.9	35.9	65.1	161.9	88.6	158.2	160.5	64.0	90.4	54.7	199.3	81.6	158.6	12.6	90.6	14.9	23.5	52.6	22.8	25.1	31.3	23.2	79.6	16.1	27.3	20.2	11.8	11.6	40.2	16.2	37.4	114.9	53.8	70.4	56.6	85.9	50.1	57.1	62.5	63.6	80.5	29.4
PLAG1	ZNF912	ENSG00000181690	"PLAG1 zinc finger"	Q6DJT9	8	56160904-56211324	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 13.0;ASC TERT1: 17.2;HSkMC: 12.2;hTERT-HME1: 12.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA072290			Supported	"Nucleoplasm,Nuclear speckles,Centrosome,Cytosol"				"Nucleoplasm, Nuclear speckles"	"Centrosome, Cytosol"	"HPA072290: "	"unprognostic (1.89e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.22e-3)"	"unprognostic (1.63e-4)"	"unprognostic (6.81e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.63e-3)"	"unprognostic (8.56e-2)"	"unprognostic (1.18e-1)"	"unprognostic (7.99e-2)"	"unprognostic (3.42e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.32e-3)"	"unprognostic (2.83e-2)"	"unprognostic (3.94e-1)"	"unprognostic (1.21e-2)"	"unprognostic (6.14e-2)"	1.9	3.6	2.4	3.5	2.9	2.1	2.5	11.0	2.7	7.6	3.8	4.1	9.0	3.4	3.4	9.8	2.0	7.5	2.1	6.8	1.9	1.8	3.7	1.2	4.6	6.7	4.8	2.1	11.6	2.2	2.1	17.8	8.0	4.6	5.1	1.6	7.9	7.5	9.2	1.4	3.4	5.5	2.5	6.3	6.2	3.0	5.2	4.5	11.7	3.5	1.5	5.2	4.8	7.0	3.5	0.2	1.1	0.5	0.7	4.6	1.0	1.5	0.0	9.5	0.1	13.0	17.2	3.0	4.2	5.5	2.0	0.9	0.6	4.9	0.2	4.1	2.3	0.3	2.6	5.6	2.0	0.1	5.8	6.0	0.5	1.4	2.7	1.9	1.8	12.2	3.1	1.1	12.6	3.7	2.5	0.1	4.2	0.0	0.5	3.6	2.7	1.4	4.7	0.7	3.7	2.6	0.5	0.1	0.0	0.1	0.0	0.3	0.1	1.8	5.6	2.9	3.8	4.7	1.0	1.5	1.1	2.2	3.3	0.7	0.8	1.1	0.1	1.1	0.3	0.1	0.2	3.5	1.0	0.6	0.1	2.0	4.6	4.3	1.0	0.7	0.5	0.2	0.2	1.0	2.4	2.9	11.0	2.7	1.9	1.8	4.8	2.1	4.6	4.5
PLAT		ENSG00000104368	"Plasminogen activator, tissue type"	P00750	8	42175233-42207724	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 132.2"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 85.8;HMC-1: 55.1;LHCN-M2: 55.6;U-2197: 58.0;WM-115: 115.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.1;T-reg: 2.3"	"Group enriched"	"Detected in many"	7	"granulocytes: 1.6;T-cells: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003412, CAB009335"	Supported		Approved	"Actin filaments"	"Secreted to blood"	12000	12000	"Actin filaments"		"CAB009335: AB_2237146, HPA003412: AB_1858205"	"prognostic favourable (7.57e-4)"	"unprognostic (2.23e-1)"	"unprognostic (4.08e-1)"	"unprognostic (3.39e-1)"	"unprognostic (4.88e-3)"	"unprognostic (9.39e-2)"	"unprognostic (4.65e-3)"	"unprognostic (5.78e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.75e-1)"	"unprognostic (2.98e-3)"	"unprognostic (2.46e-1)"	"prognostic unfavourable (4.95e-4)"	"unprognostic (8.72e-3)"	"unprognostic (1.37e-2)"	"unprognostic (2.63e-2)"	"unprognostic (6.09e-2)"	19.3	14.9	5.2	12.9	6.8	0.4	13.3	2.2	6.2	24.5	17.1	9.1	19.0	11.2	35.5	28.1	18.1	19.1	18.5	7.3	6.0	5.9	67.6	2.8	15.9	1.9	8.2	3.6	18.4	5.8	132.2	5.1	15.5	9.4	27.4	12.2	39.4	6.1	12.7	5.8	2.0	31.7	23.0	7.0	1.0	14.6	12.2	3.8	0.6	11.2	14.7	7.4	47.9	13.7	0.3	0.1	1.6	0.0	0.0	2.3	0.3	0.5	0.2	4.2	1.0	7.7	10.5	0.1	18.0	32.0	7.7	6.6	0.2	85.8	0.0	0.6	2.3	1.4	0.0	4.0	15.9	7.8	1.4	0.1	0.1	0.1	37.9	0.0	55.1	10.5	0.0	18.8	0.7	14.4	0.5	0.1	55.6	0.0	0.0	0.0	5.6	7.6	0.0	15.6	0.0	2.5	0.0	0.0	0.9	0.0	0.1	24.5	0.1	0.0	27.5	1.5	5.7	58.0	1.8	0.0	0.1	0.0	1.2	0.0	115.3	1.6	0.0	0.0	0.3	0.0	1.0	0.3	2.1	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	2.3	0.3	5.2	6.8	2.2	6.2	6.0	5.9	8.2	3.6	9.4	3.8
PLAU	"UPA, URK"	ENSG00000122861	"Plasminogen activator, urokinase"	P00749	10	73909177-73917497	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 48.4"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 68.9;LHCN-M2: 66.5;RPTEC TERT1: 252.9;U-251 MG: 67.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"myeloid DC: 2.4;neutrophil: 4.5;plasmacytoid DC: 4.5"	"Group enriched"	"Detected in many"	11	"dendritic cells: 4.5;granulocytes: 4.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA008719	Approved				"Secreted to blood"	58000	58000			"HPA008719: AB_1858635"	"unprognostic (1.96e-2)"	"unprognostic (2.99e-2)"	"unprognostic (7.40e-2)"	"prognostic favourable (3.38e-4)"	"unprognostic (4.73e-2)"	"prognostic unfavourable (2.70e-4)"	"unprognostic (1.39e-2)"	"prognostic unfavourable (4.04e-4)"	"unprognostic (2.26e-1)"	"unprognostic (6.58e-2)"	"prognostic unfavourable (1.32e-4)"	"unprognostic (1.61e-1)"	"prognostic unfavourable (3.51e-4)"	"unprognostic (2.83e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.77e-2)"	26.7	2.4	1.0	15.5	2.1	11.3	9.7	1.6	1.5	6.9	5.8	2.9	4.9	3.8	10.7	21.2	9.1	6.5	10.7	14.3	1.3	1.0	23.3	2.3	23.4	5.5	1.6	1.5	6.8	3.7	3.6	1.8	48.4	3.1	7.5	6.7	4.5	10.6	5.0	12.2	9.0	8.1	8.4	2.5	23.8	7.8	5.8	1.3	4.8	10.9	11.6	8.2	16.3	9.3	0.1	4.5	4.5	0.4	0.0	0.0	0.3	13.0	7.0	3.0	0.1	0.2	5.0	0.1	7.9	37.2	3.2	5.1	0.1	68.9	0.0	14.7	1.1	9.0	0.0	13.3	3.7	0.7	0.0	0.0	0.3	0.1	6.1	1.1	2.6	13.3	1.6	22.2	8.6	9.2	0.0	0.0	66.5	0.0	0.0	1.7	0.8	18.3	0.0	9.0	0.0	252.9	10.3	0.0	0.0	0.0	0.3	0.2	0.0	1.8	23.3	0.2	1.6	1.7	67.9	0.0	0.1	0.1	17.9	1.9	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.4	0.0	0.0	0.0	4.5	0.0	0.0	4.5	0.0	0.3	1.0	2.1	1.6	1.5	1.3	1.0	1.6	1.5	3.1	1.3
PLAUR	"CD87, UPAR, URKR"	ENSG00000011422	"Plasminogen activator, urokinase receptor"	Q03405	19	43646095-43670547	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 118.0;bone marrow: 165.0"	"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 49.4;U-251 MG: 70.2;U-87 MG: 61.3;WM-115: 59.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 118.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA050843, CAB073533"	Uncertain		Supported	"Plasma membrane"	"Intracellular and membrane"	760000	760000	"Plasma membrane"		"CAB073533: , HPA050843: "	"unprognostic (9.28e-2)"	"unprognostic (9.65e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.29e-3)"	"unprognostic (3.59e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.18e-3)"	"prognostic unfavourable (2.33e-5)"	"unprognostic (8.08e-3)"	"unprognostic (4.30e-2)"	"unprognostic (2.29e-3)"	"unprognostic (5.30e-2)"	"prognostic unfavourable (7.83e-9)"	"unprognostic (4.99e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.45e-2)"	"unprognostic (9.33e-2)"	25.2	3.6	3.0	23.6	4.8	165.0	6.3	2.2	6.1	10.7	7.5	4.4	1.8	3.3	9.5	6.0	8.6	10.6	23.0	11.5	4.5	3.2	5.1	6.1	39.4	8.1	6.0	1.1	11.9	4.3	2.5	4.4	12.2	6.9	6.1	6.0	4.6	11.0	3.7	7.9	3.5	7.3	7.2	7.1	12.6	12.0	6.3	6.3	2.5	4.4	7.7	7.0	22.7	14.9	0.2	21.3	118.0	50.5	0.6	0.9	21.0	14.0	4.9	4.5	0.3	4.0	14.4	2.7	29.6	30.1	18.7	23.5	0.4	16.6	0.5	7.5	18.3	6.0	1.2	7.3	20.9	0.9	0.9	2.6	7.4	0.6	5.1	3.1	34.3	14.8	1.4	49.4	7.4	20.6	2.7	0.6	17.9	1.0	3.4	8.4	1.4	10.6	3.9	3.0	1.0	5.8	0.7	0.2	3.9	13.2	3.0	3.9	0.6	9.8	21.1	41.3	21.2	18.9	70.2	0.6	1.4	0.1	61.3	5.8	59.7	7.2	48.9	72.4	0.7	41.5	0.8	0.2	0.9	0.6	21.3	0.1	0.3	0.4	118.0	0.6	50.5	6.8	0.3	21.0	3.0	4.8	2.2	6.1	4.5	3.2	6.0	1.1	6.9	6.3
PLCG1	"NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1"	ENSG00000124181	"Phospholipase C gamma 1"	P19174	20	41136960-41196801	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction, Lipid degradation, Lipid metabolism"	"Hydrolase, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	7	"gdT-cell: 5.9;MAIT T-cell: 8.0;memory CD4 T-cell: 5.2;memory CD8 T-cell: 4.9;naive CD4 T-cell: 5.7;naive CD8 T-cell: 5.4;NK-cell: 4.0;T-reg: 4.4"	"Group enriched"	"Detected in many"	8	"NK-cells: 4.0;T-cells: 8.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004277, HPA036681, HPA036682"	Approved		Enhanced	Cytosol				Cytosol		"CAB004277: AB_628119, HPA036681: , HPA036682: "	"unprognostic (2.77e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.65e-1)"	"unprognostic (4.31e-2)"	"unprognostic (5.82e-2)"	"unprognostic (2.09e-2)"	"unprognostic (4.45e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.16e-1)"	"prognostic favourable (4.72e-4)"	"unprognostic (3.32e-1)"	"unprognostic (2.73e-3)"	"unprognostic (1.82e-1)"	"unprognostic (2.65e-1)"	"unprognostic (9.27e-2)"	"unprognostic (2.79e-2)"	20.2	15.1	25.1	20.9	22.1	8.3	34.9	52.6	26.8	19.9	13.9	23.4	12.5	16.5	27.6	13.9	13.5	17.0	18.7	20.9	25.4	13.6	15.3	6.8	19.3	30.7	18.5	20.5	28.7	9.1	16.9	14.2	22.2	18.7	18.4	13.2	20.0	13.2	20.6	13.4	22.3	17.1	22.2	15.4	20.1	12.4	19.9	23.9	48.1	28.5	11.9	21.9	17.1	21.1	0.7	0.0	0.0	0.0	4.0	8.0	3.3	5.3	6.8	32.9	24.1	13.2	9.3	10.5	8.8	11.4	17.8	15.2	16.4	1.8	12.0	10.9	9.6	10.0	14.3	15.8	10.4	3.4	7.6	0.8	11.4	19.3	10.0	4.7	3.3	11.8	8.9	13.1	10.3	19.9	8.9	7.9	16.1	40.1	28.9	3.7	12.2	12.6	23.1	24.0	5.9	9.8	9.9	11.7	22.4	15.8	7.4	15.9	8.6	5.5	21.4	42.7	13.9	13.6	10.7	8.9	3.9	10.0	10.2	5.1	17.7	0.0	0.0	0.0	5.9	0.0	8.0	0.3	5.2	4.9	0.0	0.7	5.7	5.4	0.0	4.0	0.0	0.0	4.4	3.3	25.1	22.1	52.6	26.8	25.4	13.6	18.5	20.5	18.7	23.9
PLCG2		ENSG00000197943	"Phospholipase C gamma 2"	P16885	16	81739097-81962693	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Lipid degradation, Lipid metabolism"	"Hydrolase, Transducer"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 55.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 39.6;HMC-1: 19.0;U-698: 87.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004280, HPA020099, HPA020100"	Enhanced		Approved	Vesicles		21000	21000	Vesicles		"CAB004280: AB_628120, HPA020099: AB_1855324, HPA020100: AB_1855325"	"unprognostic (2.86e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.09e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.58e-1)"	"prognostic favourable (6.71e-4)"	"unprognostic (6.23e-2)"	"unprognostic (5.01e-2)"	"unprognostic (2.22e-1)"	"unprognostic (4.58e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.71e-2)"	"prognostic favourable (4.88e-4)"	"unprognostic (1.52e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.40e-3)"	8.4	3.8	3.3	55.8	4.9	14.1	10.7	1.0	2.4	5.6	10.3	5.3	3.1	8.7	11.2	12.2	6.0	4.7	10.1	4.4	3.3	2.8	20.6	8.8	10.7	35.5	5.2	1.8	2.0	3.6	1.0	1.8	4.1	4.5	4.3	3.6	4.6	8.8	2.8	2.0	4.1	17.6	4.6	8.6	33.6	4.2	2.3	4.2	6.3	5.3	2.6	44.6	7.5	7.7	18.8	3.9	26.8	12.2	14.0	1.1	2.3	0.3	0.7	0.1	0.6	0.0	0.0	0.9	0.0	0.0	0.5	0.2	0.2	1.7	39.6	6.8	0.0	0.9	0.8	0.1	0.3	0.3	0.4	4.7	0.0	0.0	0.2	4.7	19.0	0.0	0.4	0.3	0.2	0.9	0.5	3.3	0.0	1.2	0.5	11.9	0.7	0.2	16.1	0.0	5.0	0.1	0.8	0.3	0.0	1.1	0.3	0.3	0.7	14.6	0.2	0.0	0.7	0.1	0.1	7.9	12.9	87.9	0.0	6.5	0.3	2.8	4.4	26.8	0.7	5.7	0.3	18.8	0.2	1.1	3.9	17.3	0.3	0.8	24.8	14.0	12.2	2.6	0.1	2.3	3.3	4.9	1.0	2.4	3.3	2.8	5.2	1.8	4.5	4.2
PLEC	"EBS1, PCN, PLEC1, PLTN"	ENSG00000178209	Plectin	Q15149	8	143915147-143976734	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes, Disease mutation, Epidermolysis bullosa, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 144.9"	"Cell line enhanced"	"Detected in many"		"PC-3: 72.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003847, HPA025967, HPA029906"	Enhanced		Enhanced	"Intermediate filaments,Focal adhesion sites,Cytosol"		7100000	7100000	"Intermediate filaments, Cytosol"	"Focal adhesion sites"	"CAB003847: AB_562198, HPA025967: AB_10601671, HPA029906: AB_10602279"	"unprognostic (1.02e-1)"	"unprognostic (1.37e-3)"	"prognostic unfavourable (4.29e-4)"	"unprognostic (2.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.76e-3)"	"prognostic unfavourable (5.33e-4)"	"unprognostic (1.72e-3)"	"unprognostic (1.13e-2)"	"unprognostic (2.85e-3)"	"unprognostic (5.48e-2)"	"prognostic unfavourable (7.98e-6)"	"unprognostic (2.30e-1)"	"unprognostic (4.04e-2)"	"unprognostic (6.58e-2)"	"unprognostic (5.58e-3)"	20.9	11.0	15.9	16.5	13.3	27.9	13.1	15.0	20.7	20.7	17.7	14.6	16.7	13.1	20.2	16.8	25.1	18.2	29.0	23.4	18.9	10.7	11.2	10.9	16.6	15.0	9.9	13.0	18.0	14.0	8.8	12.0	24.2	13.2	17.5	9.8	13.0	17.8	14.8	144.9	36.4	24.1	24.7	11.0	16.9	21.4	6.7	12.7	16.3	9.2	44.2	24.5	20.2	19.2	1.5	3.4	0.8	4.1	0.7	2.9	3.2	16.3	51.2	3.3	4.1	6.0	13.4	11.7	24.0	10.7	6.4	3.6	7.1	17.1	1.6	18.7	35.1	19.4	2.2	33.6	2.5	12.2	1.8	6.2	52.0	5.8	9.5	2.0	5.2	15.4	6.6	17.2	33.6	7.4	3.0	5.3	7.4	28.7	1.2	3.4	2.2	72.1	0.3	9.4	4.4	10.7	30.3	3.4	3.4	40.9	8.7	3.9	10.7	2.4	23.8	24.8	44.9	21.8	28.4	0.8	0.6	1.2	23.6	2.6	35.2	0.0	4.1	0.2	1.4	3.8	2.8	1.4	2.7	2.0	3.4	1.5	2.0	1.1	0.8	0.7	2.7	2.8	2.9	3.2	15.9	13.3	15.0	17.3	18.9	10.7	9.9	13.0	13.2	12.7
PLG		ENSG00000122194	Plasminogen	P00747	6	160702238-160753315	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	11	"liver: 269.9"	"Cell line enhanced"	"Detected in some"		"HL-60: 3.5;RH-30: 3.9;U-698: 2.0;U-937: 1.6"	"Cancer enriched"	"Detected in some"	84	"liver cancer: 180.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB000668, CAB016678, HPA021602, HPA048823"	Supported				"Secreted to blood"	41000000000	41000000000			"CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: "		"unprognostic (1.70e-1)"		"unprognostic (2.16e-3)"	"unprognostic (2.44e-1)"		"unprognostic (8.54e-3)"	"unprognostic (1.41e-1)"		"unprognostic (1.76e-3)"	"unprognostic (6.28e-2)"	"unprognostic (7.25e-2)"	"prognostic favourable (4.22e-4)"	"unprognostic (3.97e-3)"	"unprognostic (5.21e-2)"		"unprognostic (2.33e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.0	269.9	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.5	0.0	3.5	0.6	0.0	0.0	0.0	0.0	0.0	0.9	0.4	0.0	0.0	0.3	0.2	0.8	0.0	0.4	3.9	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	1.0	0.0	2.0	0.0	1.6	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
PLK1	PLK	ENSG00000166851	"Polo like kinase 1"	P53350	16	23677656-23690367	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 83.9;testis: 32.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"T-reg: 9.0"	"Lineage enriched"	"Detected in many"	5	"T-cells: 9.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA051638, HPA053229"	Approved									"HPA051638: , HPA053229: "	"unprognostic (7.21e-3)"	"unprognostic (1.77e-1)"	"unprognostic (1.98e-3)"	"unprognostic (4.97e-3)"	"unprognostic (9.56e-2)"	"unprognostic (5.12e-2)"	"prognostic unfavourable (2.70e-7)"	"prognostic unfavourable (2.28e-5)"	"unprognostic (2.55e-2)"	"unprognostic (1.89e-1)"	"prognostic unfavourable (4.12e-4)"	"unprognostic (1.24e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (1.33e-1)"	"unprognostic (8.10e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.26e-2)"	2.9	1.1	1.1	14.2	1.5	15.9	1.7	2.1	1.1	1.5	7.1	0.7	0.5	6.0	1.1	0.9	10.4	0.7	1.5	1.0	1.0	0.8	1.3	1.2	2.6	15.2	0.8	0.6	1.2	0.7	0.0	0.8	6.8	0.7	0.9	5.9	0.5	1.7	0.8	0.8	2.9	5.9	2.0	0.7	8.3	3.6	32.4	0.5	83.9	0.6	6.6	20.4	2.1	2.6	1.9	0.5	0.7	0.1	1.3	9.0	2.3	43.1	45.0	37.2	20.2	1.1	2.6	20.9	24.7	16.3	38.7	28.9	39.3	28.5	21.6	12.9	16.6	24.8	50.7	20.3	46.6	30.7	28.6	27.4	35.5	53.7	0.3	31.6	30.1	1.0	1.1	27.4	28.3	28.3	42.6	29.8	29.8	39.4	29.7	31.6	42.5	22.9	46.5	25.3	34.3	11.0	9.4	21.0	14.6	28.2	19.8	12.8	25.2	19.5	14.3	18.4	23.6	18.0	42.1	21.2	33.0	37.4	15.6	27.5	30.1	0.0	0.1	0.0	0.0	0.0	0.0	1.9	1.4	0.5	0.5	0.0	0.0	0.0	0.7	1.3	0.0	0.0	9.0	2.3	1.1	1.5	2.1	1.1	1.0	0.8	0.8	0.6	0.7	0.5
PLP1	"GPM6C, PLP, SPG2"	ENSG00000123560	"Proteolipid protein 1"	P60201	X	103773718-103792619	"Cancer-related genes, Disease related genes, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Leukodystrophy, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	26	"brain: 463.6"	"Group enriched"	"Detected in some"	5	"SK-MEL-30: 66.3;WM-115: 39.6"	"Group enriched"	"Detected in many"	22	"glioma: 160.5;melanoma: 75.4"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	9	"plasmacytoid DC: 2.3"	"Lineage enriched"	"Detected in single"	9	"dendritic cells: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004128	Enhanced									"HPA004128: AB_1079635"	"unprognostic (5.72e-2)"	"unprognostic (1.77e-2)"	"unprognostic (2.27e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.32e-1)"	"unprognostic (3.95e-2)"		"unprognostic (2.57e-2)"	"unprognostic (1.02e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.28e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.62e-5)"	"unprognostic (4.91e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.46e-2)"	"unprognostic (1.16e-2)"	3.6	5.6	90.6	2.8	109.9	1.9	3.1	8.9	463.6	3.9	5.7	208.1	0.0	3.3	3.6	3.5	4.2	2.5	4.0	5.0	143.8	73.8	2.1	2.1	2.1	2.0	174.8	42.2	3.0	2.2	17.9	0.3	1.9	124.4	3.6	5.4	0.0	3.4	9.3	2.2	7.3	5.1	7.0	453.8	2.0	2.8	9.2	145.2	0.0	2.0	0.0	2.0	2.7	0.8	0.0	2.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	5.9	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.2	0.5	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	39.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	90.6	109.9	8.9	68.1	143.8	73.8	174.8	42.2	124.4	145.2
PMEPA1	"STAG1, TMEPAI"	ENSG00000124225	"Prostate transmembrane protein, androgen induced 1"	Q969W9	20	57648392-57711536	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Ubl conjugation pathway"	"Signal transduction inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"cervix, uterine: 60.4;prostate: 67.3"	"Cell line enhanced"	"Detected in many"		"SiHa: 39.5;U-2 OS: 25.8;U-251 MG: 90.8;WM-115: 45.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"naive B-cell: 5.2;plasmacytoid DC: 18.4"	"Group enriched"	"Detected in many"	7	"B-cells: 5.2;dendritic cells: 18.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA072291			Supported	Vesicles	"Intracellular and membrane"			Vesicles		"HPA072291: "	"unprognostic (2.72e-3)"	"prognostic unfavourable (2.45e-4)"	"unprognostic (5.77e-2)"	"unprognostic (1.73e-1)"	"unprognostic (6.61e-2)"	"unprognostic (2.11e-3)"	"unprognostic (3.13e-2)"	"prognostic unfavourable (4.73e-5)"	"unprognostic (5.53e-1)"	"unprognostic (1.32e-3)"	"unprognostic (7.83e-3)"	"unprognostic (2.02e-1)"	"prognostic unfavourable (2.87e-7)"	"unprognostic (1.16e-1)"	"unprognostic (2.35e-1)"	"unprognostic (9.87e-3)"	"prognostic unfavourable (7.60e-4)"	27.0	7.8	7.5	10.6	34.8	1.3	9.5	2.6	12.6	60.4	10.8	11.0	4.2	4.4	22.1	6.7	7.1	7.7	21.8	10.7	7.5	8.6	5.3	1.7	8.5	4.5	10.2	5.9	6.2	18.6	2.6	5.6	3.0	12.1	67.3	5.7	21.3	11.6	13.3	17.4	6.8	7.6	17.6	8.1	4.0	5.3	3.2	9.1	1.3	5.4	6.0	6.2	8.4	13.0	5.2	18.4	0.1	0.3	0.0	1.6	0.4	5.9	14.5	0.4	0.7	0.4	0.0	0.1	0.9	0.0	0.3	0.1	0.2	18.8	0.0	3.5	1.4	23.0	0.3	19.4	0.2	0.1	0.7	0.0	4.0	0.0	0.3	0.0	0.1	0.2	10.9	0.8	2.4	2.5	0.1	0.2	1.2	12.3	0.7	0.1	1.8	1.8	0.0	7.0	2.1	4.7	0.0	3.4	2.7	39.5	23.5	2.7	3.6	0.7	6.3	3.5	25.8	0.3	90.8	1.1	0.1	0.0	1.6	0.2	45.8	0.0	0.3	0.0	0.0	0.0	0.0	2.2	0.6	0.2	0.0	5.2	1.6	0.9	0.1	0.0	0.0	18.4	0.4	0.4	7.5	34.8	2.6	12.6	7.5	8.6	10.2	5.9	12.1	9.1
PML	"MYL, RNF71, TRIM19"	ENSG00000140464	"Promyelocytic leukemia"	P29590	15	73994673-74047812	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Antiviral defense, Apoptosis, Biological rhythms, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008312, CAB010194, CAB016304"	Supported		Enhanced	"Nuclear bodies"				"Nuclear bodies"		"CAB010194: AB_2166848, CAB016304: AB_628162, HPA008312: AB_1079643"	"prognostic favourable (3.24e-4)"	"unprognostic (4.83e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.58e-3)"	"unprognostic (7.53e-3)"	"unprognostic (1.58e-1)"	"unprognostic (2.35e-2)"	"unprognostic (5.30e-3)"	"unprognostic (4.54e-3)"	"unprognostic (1.15e-1)"	"prognostic unfavourable (3.29e-4)"	"unprognostic (2.67e-2)"	"prognostic unfavourable (6.27e-8)"	"unprognostic (1.58e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.02e-1)"	"unprognostic (8.99e-2)"	46.2	15.4	13.5	29.9	13.0	30.0	50.0	11.4	17.2	24.7	21.9	8.3	22.1	16.9	29.4	22.1	19.3	23.0	25.6	17.6	10.7	7.5	20.5	12.9	37.2	27.3	11.9	12.4	21.2	11.0	9.6	15.0	22.4	16.1	21.2	8.7	14.6	38.0	27.7	18.7	24.2	19.6	20.1	14.3	25.9	21.4	8.7	13.1	25.3	25.9	23.3	23.0	20.7	35.6	11.8	12.9	19.1	18.2	12.7	13.2	7.8	13.8	5.2	4.6	4.4	13.2	18.7	15.9	7.2	12.8	22.3	25.8	5.5	25.0	6.2	25.4	12.9	25.5	6.3	14.4	3.2	21.7	9.7	13.4	8.2	6.0	15.3	12.7	12.3	35.1	10.4	15.1	7.9	15.5	11.3	11.1	13.1	6.5	10.4	19.9	5.0	9.6	8.1	5.5	11.6	24.9	23.1	4.0	4.4	11.5	6.3	17.1	4.9	10.7	25.8	22.6	6.2	11.2	14.3	11.6	7.3	3.0	15.6	16.2	7.2	5.4	12.7	19.1	12.4	18.0	9.6	11.8	9.9	13.2	12.9	9.8	8.1	8.2	11.0	12.7	18.2	8.3	12.9	7.8	13.5	13.0	11.4	17.2	10.7	7.5	11.9	12.4	16.1	13.1
PMP22	"GAS3, HNPP, Sp110"	ENSG00000109099	"Peripheral myelin protein 22"	Q01453	17	15229777-15265357	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"			"Cancer-related genes, Charcot-Marie-Tooth disease, Deafness, Dejerine-Sottas syndrome, Disease mutation, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 69.1;HMC-1: 54.6;WM-115: 83.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 14.1;eosinophil: 22.9;plasmacytoid DC: 12.8"	"Group enriched"	"Detected in many"	20	"dendritic cells: 12.8;granulocytes: 22.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (3.00e-1)"	"unprognostic (1.65e-1)"	"unprognostic (2.21e-1)"	"unprognostic (4.63e-1)"	"unprognostic (5.57e-3)"	"unprognostic (2.28e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.65e-1)"	"unprognostic (3.74e-1)"	"unprognostic (4.33e-2)"	"unprognostic (7.70e-2)"	"unprognostic (1.51e-1)"	"prognostic unfavourable (1.73e-4)"	"unprognostic (1.83e-2)"	"unprognostic (5.45e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.08e-2)"	66.8	20.9	27.1	22.4	31.4	2.4	43.5	5.7	34.2	69.1	46.0	96.5	11.7	16.7	43.7	28.4	31.3	37.9	40.8	47.5	33.0	17.9	9.0	5.3	47.7	14.0	72.6	22.7	34.9	8.3	3.5	6.7	77.5	42.9	28.0	32.4	39.4	19.2	35.0	91.3	27.0	95.2	48.6	63.9	10.0	25.1	16.5	44.9	1.6	26.4	25.8	8.6	51.6	39.0	0.0	12.8	22.9	0.9	0.0	0.0	0.4	1.4	8.2	11.5	12.4	69.1	29.1	2.6	11.7	12.0	10.4	7.4	8.5	0.2	0.0	1.5	31.8	0.1	13.7	0.1	3.2	0.0	3.0	0.6	15.9	3.0	37.0	0.0	54.6	25.3	0.2	6.3	0.3	11.7	4.4	0.2	6.5	0.9	0.1	0.5	0.7	12.5	3.7	7.5	0.0	10.8	0.8	0.1	7.3	3.0	0.0	29.4	0.0	0.1	14.5	2.8	9.4	40.6	11.3	0.0	0.0	0.0	15.4	0.0	83.2	14.1	0.9	22.9	0.0	0.5	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.1	12.8	0.0	0.4	27.1	31.4	5.7	33.4	33.0	17.9	72.6	22.7	42.9	44.9
PMS2	"H_DJ0042M02.9, HNPCC4, MLH4, PMSL2"	ENSG00000122512	"PMS1 homolog 2, mismatch repair system component"	P54278	7	5973239-6009125	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010235, HPA066490, HPA070310"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB010235: AB_2167281, HPA066490: , HPA070310: "	"unprognostic (5.13e-2)"	"unprognostic (6.55e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.43e-3)"	"unprognostic (5.14e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.02e-1)"	"unprognostic (7.43e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.86e-1)"	"unprognostic (7.38e-2)"	"prognostic favourable (1.23e-5)"	"unprognostic (5.31e-2)"	"unprognostic (2.01e-2)"	"unprognostic (3.67e-2)"	"unprognostic (2.81e-2)"	6.3	7.4	8.7	6.0	19.8	3.6	8.1	15.5	21.2	6.2	6.0	11.5	6.9	6.4	6.4	6.3	7.5	7.5	5.0	5.3	9.0	10.3	14.2	5.8	5.5	9.1	8.4	9.5	7.5	7.1	16.6	7.1	5.9	16.2	7.0	6.2	8.0	7.1	7.8	5.7	14.8	6.8	7.1	7.5	6.9	6.1	4.8	5.8	7.5	12.4	5.7	10.7	7.7	6.5	6.2	5.8	7.2	7.9	4.0	9.3	6.3	9.5	10.5	8.4	20.9	6.6	9.8	7.2	5.2	3.9	5.0	4.1	9.1	6.9	18.1	6.2	7.4	13.2	12.6	3.3	5.5	7.1	5.1	7.9	8.5	6.5	11.3	9.7	5.4	10.3	9.6	4.0	15.0	9.2	14.7	8.8	8.3	8.8	2.9	6.9	8.5	6.4	9.9	10.1	9.2	10.6	7.2	7.7	16.6	10.1	14.7	11.0	18.2	6.8	7.8	6.4	14.3	9.4	9.3	11.8	19.7	18.2	4.5	9.5	14.6	7.2	5.4	3.1	8.4	7.9	9.3	6.2	6.6	7.2	5.8	5.6	8.8	6.2	2.4	4.0	3.2	5.3	6.4	6.3	8.7	19.8	15.5	21.2	9.0	10.3	8.4	9.5	16.2	5.8
PNMT	PENT	ENSG00000141744	"Phenylethanolamine N-methyltransferase"	P11086	17	39667981-39670475	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 94.6;ductus deferens: 53.7;seminal vesicle: 40.7"	"Cell line enhanced"	"Detected in some"		"HEL: 4.7;K-562: 10.2;NB-4: 20.2;NTERA-2: 3.9;SCLC-21H: 5.5;SH-SY5Y: 5.0"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 27.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.5"	"Group enriched"	"Detected in many"	5	"B-cells: 1.0;T-cells: 2.5"	"Region enhanced"	"Detected in some"		"basal ganglia: 1.3"	"Low region specificity"	"Detected in single"			"CAB017029, HPA043412, HPA051005"	Enhanced									"CAB017029: , HPA043412: AB_2630373, HPA051005: AB_2681306"	"unprognostic (1.50e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (3.95e-5)"	"unprognostic (4.27e-2)"	"unprognostic (3.02e-1)"	"unprognostic (2.98e-2)"	"unprognostic (5.75e-2)"	"unprognostic (5.29e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.52e-4)"	"unprognostic (1.58e-1)"	"unprognostic (1.97e-1)"	"unprognostic (4.72e-2)"	"unprognostic (1.87e-2)"	2.3	94.6	3.9	0.8	13.8	1.6	5.4	0.9	3.0	1.3	1.9	1.5	53.7	0.9	1.0	2.7	0.9	1.9	0.8	4.9	1.7	5.4	1.0	0.7	1.6	0.8	9.1	1.5	0.9	0.7	2.4	12.9	2.4	3.6	4.3	0.7	0.9	0.7	40.7	10.5	0.8	1.0	0.8	0.7	0.9	0.9	1.3	2.7	0.0	0.7	0.8	0.7	1.3	1.7	1.0	0.0	0.3	0.3	0.0	2.5	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.2	0.0	0.1	0.1	0.0	0.0	0.0	1.4	4.7	0.1	0.4	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	20.2	3.9	0.0	0.1	0.0	0.3	0.0	0.0	5.5	5.0	0.0	2.1	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.5	0.0	0.4	1.0	0.4	1.5	0.0	0.4	0.0	0.7	0.3	0.0	0.3	0.0	0.0	0.3	3.9	13.8	0.9	3.0	1.7	5.4	9.1	1.5	3.6	2.7
POLD1	"CDC2, POLD"	ENSG00000062822	"DNA polymerase delta 1, catalytic subunit"	P28340	19	50384204-50418016	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA excision, DNA repair, DNA replication"	"DNA-binding, DNA-directed DNA polymerase, Exonuclease, Hydrolase, Nuclease, Nucleotidyltransferase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004375, HPA046524"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB004375: AB_675487, HPA046524: "	"unprognostic (2.45e-1)"	"unprognostic (7.02e-3)"	"unprognostic (1.59e-1)"	"unprognostic (4.35e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.85e-2)"	"prognostic unfavourable (2.87e-6)"	"unprognostic (4.12e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.83e-1)"	"unprognostic (5.08e-1)"	"unprognostic (3.92e-3)"	"unprognostic (4.01e-3)"	"unprognostic (1.28e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.70e-2)"	7.9	5.7	5.4	18.3	9.9	31.6	6.6	9.4	5.4	8.2	10.0	6.1	5.9	6.8	9.5	7.2	11.3	6.9	5.2	5.5	4.4	3.2	7.6	9.3	10.9	15.7	7.0	3.6	8.2	8.4	5.2	5.1	10.9	6.7	6.3	5.2	4.9	8.1	5.4	7.2	13.1	9.9	6.2	7.7	14.1	6.5	13.2	6.5	27.4	12.1	8.1	14.2	5.9	7.8	9.3	10.5	2.1	8.5	5.4	7.3	5.6	18.1	25.0	13.7	7.9	1.7	1.5	14.1	11.3	5.0	13.9	17.8	13.6	14.4	26.0	6.4	3.4	14.9	16.2	12.3	4.8	21.9	43.5	22.6	24.2	17.9	1.6	21.5	20.0	2.9	3.8	12.6	3.8	7.1	24.3	20.2	5.8	12.2	33.3	33.7	16.1	18.2	33.1	23.0	22.8	4.4	17.3	14.3	12.9	11.2	13.8	2.6	7.6	20.4	5.6	7.1	23.0	7.6	19.8	19.1	31.4	27.8	7.7	24.3	6.9	1.6	6.2	2.1	7.3	7.8	6.2	7.8	6.5	5.9	5.7	9.3	6.5	5.9	1.1	5.4	8.5	10.5	4.5	5.6	5.4	9.9	9.4	5.4	4.4	3.2	7.0	3.6	6.7	6.5
POLE	POLE1	ENSG00000177084	"DNA polymerase epsilon, catalytic subunit"	Q07864	12	132623753-132687365	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 34.8"	"Cell type enhanced"	"Detected in some"		"NK-cell: 4.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA058210, HPA067385"			Supported	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"HPA058210: , HPA067385: "	"unprognostic (1.60e-1)"	"unprognostic (1.77e-3)"	"unprognostic (2.00e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.01e-2)"	"unprognostic (3.96e-3)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (1.44e-4)"	"unprognostic (7.12e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavourable (3.19e-8)"	"unprognostic (8.60e-2)"	"unprognostic (3.18e-1)"	"unprognostic (1.28e-1)"	"unprognostic (9.95e-2)"	6.1	3.4	6.7	10.2	4.4	29.3	6.2	34.8	14.4	7.0	6.6	2.0	7.6	7.3	6.1	4.4	7.5	6.2	6.5	4.7	5.6	1.6	3.8	8.6	5.4	8.2	3.3	4.3	8.7	6.8	3.6	3.1	6.5	5.1	6.8	7.7	4.3	8.7	7.4	8.9	17.9	8.5	6.8	3.7	16.7	7.8	25.6	4.4	29.8	5.1	6.0	10.3	6.7	8.7	0.5	1.7	0.8	0.8	4.8	0.7	0.5	11.1	14.9	22.1	10.6	4.7	3.6	19.7	11.4	5.2	13.7	10.0	18.0	6.6	12.8	4.8	6.2	15.5	15.4	7.7	8.4	5.9	19.5	20.2	19.2	8.8	0.9	15.8	11.6	2.8	3.0	14.2	4.7	4.8	22.6	7.2	6.7	18.1	25.9	28.9	17.2	8.9	21.5	12.5	5.8	4.3	18.3	18.5	10.6	13.3	10.9	2.5	16.1	9.8	4.3	12.5	12.8	9.4	11.5	9.6	6.5	20.1	6.8	21.9	8.8	0.0	0.3	0.8	0.5	0.1	0.7	0.5	0.3	0.4	0.7	0.3	0.5	0.3	0.1	4.8	0.8	1.7	0.6	0.5	6.7	4.4	34.8	14.4	5.6	1.6	3.3	4.3	5.1	4.4
POLQ	POLH	ENSG00000051341	"DNA polymerase theta"	O75417	3	121431427-121546641	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 9.5;lymphoid tissue: 21.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.6"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"cerebellum: 5.2"	"HPA048931, HPA053359"			Uncertain	"Nucleoplasm,Golgi apparatus,Cytosol"				"Nucleoplasm, Golgi apparatus, Cytosol"		"HPA048931: , HPA053359: "	"unprognostic (1.59e-1)"	"unprognostic (4.18e-2)"	"unprognostic (2.66e-2)"	"prognostic unfavourable (5.46e-5)"	"unprognostic (2.70e-1)"	"unprognostic (6.23e-3)"	"unprognostic (3.09e-5)"	"unprognostic (8.55e-3)"	"unprognostic (1.09e-4)"	"unprognostic (2.86e-1)"	"unprognostic (5.59e-5)"	"unprognostic (2.06e-3)"	"unprognostic (0.00e+0)"	"prognostic favourable (1.04e-4)"	"unprognostic (1.76e-1)"	"unprognostic (6.01e-2)"	"unprognostic (5.76e-2)"	0.5	0.8	0.2	8.2	0.7	9.5	0.6	0.6	0.4	0.9	3.5	0.2	0.8	2.0	0.9	0.6	6.0	0.3	0.4	0.8	0.3	0.2	0.4	0.6	0.9	4.7	0.3	0.0	0.4	0.4	0.0	0.2	2.8	0.3	0.4	3.7	0.1	1.1	0.8	1.2	2.4	3.9	0.5	0.4	2.6	1.1	5.8	0.6	21.4	0.3	5.6	7.5	0.6	1.7	0.5	1.1	1.6	0.4	0.0	0.4	0.0	13.3	9.1	7.8	5.5	0.7	0.9	7.1	6.3	2.4	7.5	10.1	7.2	5.0	15.9	2.9	3.4	10.6	9.2	4.1	12.8	4.6	5.0	10.2	5.6	4.5	0.0	11.0	9.3	0.1	0.3	6.8	4.2	3.7	6.7	12.1	7.8	5.2	9.9	6.4	7.4	4.4	8.4	9.4	5.6	2.4	7.7	4.3	3.8	7.3	4.0	2.6	3.7	10.9	2.8	6.6	8.7	2.6	8.2	6.1	4.9	16.5	3.2	8.2	4.9	1.6	0.2	0.0	0.3	0.2	0.0	0.3	0.4	0.3	0.4	0.5	0.0	0.2	0.0	0.0	0.4	1.1	0.1	0.0	0.2	0.7	0.6	0.4	0.3	0.2	0.3	0.0	0.3	0.6
POMC	"ACTH, CLIP, LPH, MSH, NPP, POC"	ENSG00000115138	Proopiomelanocortin	P01189	2	25160853-25168903	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		"Endorphin, Hormone"	"Cancer-related genes, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	36	"pituitary gland: 811.1"	"Cell line enhanced"	"Detected in some"		"CACO-2: 2.6;HMC-1: 4.1;THP-1: 5.4"	"Cancer enriched"	"Detected in many"	6	"testis cancer: 18.5"	"Region enriched"	"Detected in single"	5	"hypothalamus: 1.8"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	4	"hypothalamus: 77.9"	"CAB002762, HPA046135, HPA063644"	Enhanced				"Secreted to blood"					"CAB002762: , HPA046135: AB_2679552, HPA063644: AB_2685071"	"unprognostic (8.02e-2)"	"unprognostic (1.47e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.96e-3)"	"unprognostic (3.15e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.09e-1)"	"unprognostic (4.30e-2)"	"unprognostic (8.74e-3)"	"unprognostic (1.38e-1)"	"prognostic favourable (5.70e-4)"	"unprognostic (8.02e-2)"	"unprognostic (4.29e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.37e-3)"	"unprognostic (3.84e-2)"	1.0	3.2	0.3	0.8	0.3	0.5	0.3	0.3	0.7	0.3	0.3	0.3	0.3	0.1	0.3	0.5	0.3	0.0	0.3	0.3	0.3	1.8	0.5	0.3	0.3	0.6	0.3	0.3	0.3	22.2	0.0	811.1	0.9	0.3	0.3	0.0	0.3	0.4	0.3	3.6	0.9	0.3	0.3	0.3	1.3	0.4	2.9	0.3	0.3	0.3	0.4	0.3	0.3	0.3	13.7	22.2	6.6	10.1	12.6	10.5	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	2.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.1	0.0	4.1	1.1	0.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.3	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	9.9	6.6	9.8	10.1	7.7	12.8	7.5	9.3	12.5	13.7	9.9	10.5	3.1	12.6	5.9	22.2	7.9	7.6	0.3	0.3	0.3	0.3	0.3	1.8	0.3	0.3	0.3	0.3
PON1	"ESA, PON"	ENSG00000005421	"Paraoxonase 1"	P27169	7	95297676-95324707	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters"		Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	23	"liver: 144.1"	"Cell line enhanced"	"Detected in some"		"A549: 1.4;RH-30: 1.0"	"Cancer enriched"	"Detected in some"	78	"liver cancer: 97.8"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"NK-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA001610	Approved				"Secreted to blood"	24000000000	24000000000			"HPA001610: AB_1079656"	"unprognostic (2.02e-2)"	"unprognostic (2.41e-2)"	"unprognostic (3.04e-1)"	"unprognostic (3.54e-2)"	"unprognostic (2.70e-1)"		"prognostic favourable (7.24e-7)"	"unprognostic (2.24e-1)"	"unprognostic (1.95e-1)"	"unprognostic (9.02e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.97e-2)"	"unprognostic (6.74e-9)"	"unprognostic (1.09e-3)"	"unprognostic (2.29e-2)"	"unprognostic (2.07e-1)"	"unprognostic (5.54e-3)"	0.0	1.7	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	144.1	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.6	0.0	1.0	0.1	0.0	0.0	1.4	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.6	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.4	0.4	0.2	0.0	1.0	0.0	0.0	0.3	0.6	0.1	0.0	0.3	0.0	0.4	0.0	0.5	0.0	0.1	0.0	0.2	0.9	0.3	0.0	0.0	0.2	0.2	0.6	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	1.0	0.0	0.5	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0
POSTN	"OSF-2, periostin, PN"	ENSG00000133110	Periostin	Q15063	13	37562583-37598844	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"hTEC/SVTERT24-B: 77.4;U-138 MG: 98.9;U-2197: 67.3"	"Cancer enhanced"	"Detected in all"		"breast cancer: 231.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA012306	Enhanced		Approved	"Nucleoplasm,Golgi apparatus"	"Secreted to extracellular matrix"	740000000	740000000	"Golgi apparatus"	Nucleoplasm	"HPA012306: AB_1854827"	"unprognostic (7.73e-2)"	"unprognostic (1.44e-3)"	"unprognostic (2.19e-2)"	"unprognostic (2.57e-2)"	"unprognostic (4.73e-2)"	"unprognostic (2.22e-2)"	"unprognostic (4.19e-3)"	"prognostic unfavourable (2.93e-4)"	"unprognostic (3.05e-3)"	"unprognostic (7.10e-2)"	"unprognostic (1.32e-2)"	"unprognostic (5.93e-2)"	"prognostic unfavourable (1.83e-7)"	"prognostic unfavourable (4.86e-4)"	"unprognostic (1.15e-1)"	"unprognostic (1.20e-1)"	"unprognostic (8.32e-3)"	60.9	2.0	5.3	12.7	4.0	0.0	26.9	0.5	2.7	17.6	14.1	0.6	11.7	0.6	29.0	20.0	16.5	20.3	14.5	34.1	6.2	0.5	47.5	3.0	28.4	19.5	0.5	1.1	21.0	3.1	8.2	1.7	17.3	2.5	12.4	19.7	0.8	10.8	10.2	14.2	46.1	9.6	14.5	1.7	0.7	37.3	21.5	0.1	3.1	8.0	5.5	1.7	23.5	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.1	0.2	13.7	8.3	0.0	3.5	0.0	0.8	0.1	0.0	0.2	0.0	0.0	2.8	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	14.6	0.0	77.4	0.3	0.1	0.0	0.0	1.8	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	98.9	0.0	67.3	0.5	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	4.0	0.5	2.7	6.2	0.5	0.5	1.1	2.5	0.1
POT1	"DKFZp586D211, hPot1"	ENSG00000128513	"Protection of telomeres 1"	Q9NUX5	7	124822386-124929983	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA068538			Supported	Nucleoplasm				Nucleoplasm		"HPA068538: "	"unprognostic (1.39e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.04e-1)"	"unprognostic (5.71e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.38e-3)"	"unprognostic (7.88e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.48e-2)"	"unprognostic (9.89e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.75e-2)"	"unprognostic (4.77e-3)"	"unprognostic (7.42e-2)"	12.0	13.2	11.1	8.3	14.3	6.2	15.8	13.0	16.6	13.4	10.1	16.0	12.0	7.8	17.0	13.4	10.1	12.6	11.3	11.2	15.5	11.3	16.6	14.7	9.9	14.0	15.0	12.4	15.7	9.4	15.5	29.6	11.1	16.4	12.0	9.7	12.2	8.7	10.1	9.5	8.0	8.8	13.1	16.4	13.6	9.5	15.8	14.8	17.9	21.5	9.3	12.9	13.6	9.8	4.8	3.6	2.7	3.3	5.2	7.4	2.7	12.7	5.5	8.1	6.2	5.4	10.2	5.7	7.2	8.5	8.2	12.4	4.4	12.9	11.5	5.8	5.4	5.1	8.8	7.3	12.9	14.9	12.9	11.2	5.4	4.7	12.2	10.8	6.7	7.2	8.7	7.5	11.9	10.4	19.9	27.6	9.2	2.5	14.4	11.4	9.1	9.0	8.5	8.5	16.4	7.0	7.1	8.6	11.5	7.3	9.8	10.1	4.3	10.4	3.4	9.9	4.4	11.9	9.5	15.3	15.7	16.4	10.0	12.4	12.2	0.9	3.1	2.7	4.3	3.3	6.3	4.8	4.5	5.0	3.1	3.4	7.4	5.5	0.7	5.2	3.0	3.6	4.4	2.7	11.1	14.3	13.0	16.6	15.5	11.3	15.0	12.4	16.4	14.8
POTEF	"A26C1B, POTE2alpha, POTEACTIN"	ENSG00000196604	"POTE ankyrin domain family member F"	A5A3E0	2	130074030-130129222	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"testis: 5.7"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 4.3;BEWO: 3.5;CACO-2: 4.0;MCF7: 2.9;U-2 OS: 9.6;U-266/70: 4.6"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA041264, HPA041271, HPA043260"	Uncertain									"HPA041264: , HPA041271: , HPA043260: "	"unprognostic (1.36e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.98e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.18e-2)"	"unprognostic (8.13e-3)"	"unprognostic (1.44e-2)"	"unprognostic (2.90e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.38e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.50e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.48e-1)"	"unprognostic (1.05e-2)"	"unprognostic (9.35e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0			0.0	0.1	0.2	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.2	0.7		0.5	0.0		0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	5.7			0.0		0.0	0.0	0.0	0.1	0.7	0.7	0.7	0.2	0.5	1.1	0.2	0.2	0.0	4.3	0.0	0.0	3.5	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.7	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	2.9	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.3	0.0	0.0	1.3	0.1	0.0	0.0	0.0	0.0	9.6	0.1	0.2	4.6	1.3	0.0	0.0	0.0	0.0	0.5	0.6	0.7	0.4	0.7	0.1	0.1	0.2	0.3	0.7	0.1	0.1	0.3	0.6	0.2	0.7	0.1	0.5	1.1										
POU2AF1	"BOB1, OBF1"	ENSG00000110777	"POU class 2 associating factor 1"	Q16633	11	111352252-111455630	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 21.2;lymphoid tissue: 84.0"	"Cell line enhanced"	"Detected in some"		"Daudi: 45.4;Karpas-707: 52.0;U-266/70: 50.7;U-266/84: 22.8;U-698: 93.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	11	"memory B-cell: 19.9;naive B-cell: 14.2"	"Lineage enriched"	"Detected in many"	13	"B-cells: 19.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB011193	Enhanced									"CAB011193: AB_532299"	"prognostic favourable (1.68e-4)"	"prognostic favourable (1.63e-4)"	"unprognostic (1.04e-2)"	"unprognostic (5.50e-3)"	"unprognostic (1.88e-1)"	"prognostic favourable (3.59e-4)"	"unprognostic (2.09e-1)"	"unprognostic (3.63e-3)"	"unprognostic (7.15e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.34e-1)"	"unprognostic (4.81e-2)"	"unprognostic (8.51e-8)"	"unprognostic (2.35e-1)"	"unprognostic (3.90e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.23e-1)"	0.9	0.5	0.6	62.7	0.7	2.0	1.4	0.4	0.6	1.9	7.8	1.8	0.0	6.7	0.7	0.3	8.7	1.1	1.4	0.5	0.8	0.7	2.1	1.0	2.6	42.6	1.0	0.5	1.2	0.5	0.0	0.4	0.5	1.2	1.3	4.1	1.2	8.4	0.9	0.4	0.4	21.2	0.0	1.4	74.2	12.2	1.0	0.9	5.0	1.7	1.4	84.0	5.0	1.4	19.9	0.1	1.5	0.2	0.3	0.7	0.6	0.1	0.1	0.0	0.0	0.8	0.8	0.1	0.0	0.0	0.0	0.0	0.1	0.0	45.4	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	1.7	52.0	0.0	0.1	0.2	0.2	0.0	0.0	9.7	0.1	12.2	0.0	0.1	0.0	0.9	0.1	0.0	0.0	0.2	0.1	0.4	0.0	0.4	0.0	0.0	50.7	22.8	93.3	0.0	0.1	0.0	1.5	0.1	0.3	0.1	0.1	0.1	19.9	0.2	0.1	0.0	14.2	0.2	0.1	0.9	0.3	0.2	0.1	0.7	0.6	0.6	0.7	0.4	0.6	0.8	0.7	1.0	0.5	1.2	0.9
POU2F2	"OCT2, OTF2"	ENSG00000028277	"POU class 2 homeobox 2"	P09086	19	42086110-42196585	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 33.1;brain: 12.0;intestine: 10.8;lymphoid tissue: 43.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 18.1;Daudi: 38.2;hTEC/SVTERT24-B: 15.0;U-266/70: 26.6;U-266/84: 25.7;U-698: 30.3;U-87 MG: 14.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 33.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002513, HPA049056, HPA062096, HPA064404"	Enhanced		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB002513: AB_442118, HPA049056: , HPA062096: , HPA064404: "	"unprognostic (2.07e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.16e-2)"	"unprognostic (8.89e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.44e-2)"	"unprognostic (1.62e-2)"	"unprognostic (3.34e-1)"	"unprognostic (8.39e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.52e-1)"	"unprognostic (8.56e-2)"	"prognostic unfavourable (7.57e-11)"	"unprognostic (2.31e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.61e-2)"	"unprognostic (1.54e-1)"	1.9	2.0	5.6	43.1	7.4	4.8	1.2	12.0	5.7	0.9	3.2	2.5	0.0	2.1	0.9	1.7	1.4	1.5	2.3	4.8	5.7	5.9	1.6	1.4	3.1	31.4	6.8	1.5	0.7	1.6	0.4	2.1	2.5	6.6	2.5	2.1	1.4	2.1	2.3	0.7	1.2	10.8	1.9	6.5	22.7	3.1	6.0	6.2	1.9	1.3	0.6	30.0	4.3	1.0	13.9	8.0	1.7	33.1	0.6	2.7	4.5	0.3	0.5	0.6	0.0	0.0	1.0	0.1	2.8	18.1	1.8	3.5	0.1	0.5	38.2	1.0	1.0	0.3	0.2	2.9	8.2	0.1	0.1	0.9	0.1	0.0	0.2	0.3	0.7	0.8	0.5	15.0	1.0	1.1	0.4	8.8	0.4	0.2	0.1	2.0	0.1	0.2	0.4	0.0	0.1	0.0	0.2	0.6	0.3	0.1	0.2	0.2	0.0	4.8	1.4	7.8	0.8	0.0	0.3	26.6	25.7	30.3	14.6	0.9	1.0	1.0	10.7	0.1	1.2	19.3	1.1	11.0	1.8	1.6	8.0	13.9	0.9	1.3	1.7	0.6	33.1	1.3	2.7	4.5	5.6	7.4	12.0	5.7	5.7	5.9	6.8	1.5	6.6	6.2
POU5F1	"MGC22487, OCT3, Oct4, OTF3"	ENSG00000204531	"POU class 5 homeobox 1"	Q01860	6	31164337-31180731	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"HAP1: 52.5;NTERA-2: 139.7"	"Cancer enriched"	"Detected in many"	34	"testis cancer: 355.9"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											"CAB025600, CAB026380, HPA058267, CAB079773"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB025600: , CAB026380: , CAB079773: AB_2687916, HPA058267: "	"unprognostic (3.25e-2)"	"unprognostic (3.12e-1)"	"unprognostic (2.87e-1)"	"unprognostic (1.06e-2)"	"unprognostic (3.02e-2)"	"unprognostic (2.11e-2)"	"unprognostic (2.62e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.27e-2)"	"unprognostic (2.27e-2)"	"unprognostic (4.79e-2)"	"unprognostic (1.19e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.86e-2)"	"prognostic favourable (2.04e-5)"	1.2	0.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	2.3	2.3	1.2	1.2	4.9	3.1	5.7	1.2	5.2	4.3	1.2	1.2	0.0	11.1	5.0	2.0	1.2	1.2	1.2	1.2	8.8	0.0	1.2	1.2	1.2	4.7	1.0	1.2	1.2	3.0	1.2	1.8	5.9	1.2	1.2	1.2	6.3	2.2	1.2	1.2	1.2	1.2	1.2	11.2	1.2	3.0	1.8	1.8	1.0	1.1	0.9	0.3	0.6	0.2	8.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.2	0.0	0.7	52.5	0.6	0.0	0.0	0.2	0.0	0.4	0.6	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.2	139.7	0.0	0.1	0.1	0.1	1.0	1.1	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.1	0.1	0.0	0.1	0.1	1.4	1.0	0.5	0.8	0.7	0.5	1.0	0.4	0.4	0.2	3.0	0.9	0.6	1.8	1.1	0.5	1.8	0.3	0.3	1.2	1.2	1.2	1.2	1.2	0.0	1.2	1.2	1.2	1.2
PPA2	FLJ20459	ENSG00000138777	"Pyrophosphatase (inorganic) 2"	Q9H2U2	4	105369077-105474081	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		Hydrolase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030888, HPA031671, HPA031672"	Supported		Approved	Nucleoplasm,Mitochondria		8300	8300	Mitochondria	Nucleoplasm	"HPA030888: , HPA031671: AB_10603986, HPA031672: AB_2673988"	"prognostic unfavourable (2.98e-4)"	"unprognostic (5.64e-2)"	"prognostic favourable (6.60e-4)"	"unprognostic (9.26e-3)"	"unprognostic (2.93e-2)"	"unprognostic (5.10e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.20e-1)"	"unprognostic (7.05e-2)"	"unprognostic (9.54e-2)"	"prognostic favourable (1.27e-11)"	"unprognostic (3.69e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.10e-1)"	9.2	18.0	18.4	17.2	15.4	24.0	20.6	12.3	17.6	10.2	19.8	9.3	20.3	18.1	13.3	20.7	14.8	10.7	18.7	42.5	15.6	15.3	23.7	21.2	23.1	34.8	17.2	12.1	9.5	25.0	10.4	15.0	9.3	15.4	16.1	16.7	12.6	21.4	26.8	29.6	15.0	16.8	22.8	12.4	12.1	15.0	9.7	10.7	9.4	14.3	28.2	10.6	12.2	9.5	20.0	35.3	14.7	20.8	22.0	17.0	14.6	11.5	5.5	10.7	18.1	6.8	5.5	7.8	6.5	8.6	8.0	5.7	12.1	17.0	9.5	8.7	5.3	5.8	21.4	10.3	9.5	13.4	7.6	8.5	8.9	11.0	5.4	20.1	8.2	5.3	10.7	5.5	4.3	7.7	14.1	13.1	7.3	14.6	17.1	14.5	7.8	18.7	15.2	6.6	9.3	26.5	8.9	11.0	6.6	4.5	26.7	9.4	14.0	16.4	4.1	5.8	11.3	6.2	11.3	11.6	14.6	9.9	10.1	10.9	7.8	14.7	15.0	9.7	15.3	20.8	13.3	20.0	16.0	16.2	35.3	16.6	15.5	17.0	6.4	22.0	16.2	17.7	15.9	14.6	18.4	15.4	12.3	17.6	15.6	15.3	17.2	12.1	15.4	10.7
PPARG	"NR1C3, PPARG1, PPARG2, PPARgamma"	ENSG00000132170	"Peroxisome proliferator activated receptor gamma"	P37231	3	12287368-12434356	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 97.6;breast: 102.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 33.5"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.8;intermediate monocyte: 2.3"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB004282, HPA051239, HPA063663"	Approved		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB004282: AB_628115, HPA051239: , HPA063663: "	"unprognostic (7.35e-3)"	"unprognostic (3.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavourable (3.41e-5)"	"unprognostic (9.13e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.77e-1)"	"prognostic favourable (1.59e-8)"	"unprognostic (1.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.68e-3)"	"prognostic favourable (5.52e-5)"	97.6	1.6	1.9	17.1	1.2	0.7	102.1	1.5	1.3	3.1	24.9	0.8	2.1	7.5	3.5	2.2	2.8	2.4	8.7	12.5	1.4	0.9	6.7	5.9	24.8	11.4	1.1	0.9	6.7	1.2	2.8	0.3	26.8	0.9	10.4	13.9	1.1	5.8	1.5	5.0	2.7	9.6	7.4	1.2	7.0	11.9	3.5	0.6	0.9	6.2	4.3	2.1	30.2	14.1	0.0	0.4	0.0	2.3	0.0	0.7	0.3	9.6	8.6	0.0	0.0	47.4	27.0	55.9	0.9	10.4	1.3	0.5	1.8	25.0	0.0	0.0	0.9	3.9	3.4	0.1	0.2	23.2	4.8	0.0	1.9	2.3	12.6	0.0	0.0	27.8	2.3	2.3	9.0	0.1	0.0	0.0	2.0	2.4	0.0	0.1	0.1	24.9	0.0	0.0	0.0	7.1	34.1	0.0	0.2	4.0	1.5	0.5	0.0	7.7	7.8	1.8	2.6	1.0	0.0	0.0	0.0	0.0	0.8	0.1	0.2	0.0	1.8	0.0	0.0	2.3	0.0	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.3	1.9	1.2	1.5	1.3	1.4	0.9	1.1	0.9	0.9	0.6
PPARGC1A	"PGC-1alpha, PGC1, PGC1A, PPARGC1"	ENSG00000109819	"PPARG coactivator 1 alpha"	Q9UBK2	4	23755041-23904089	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 49.5;liver: 49.7;skeletal muscle: 55.6"	"Cell line enriched"	"Detected in some"	7	"A-431: 42.9"	"Cancer enhanced"	"Detected in many"		"renal cancer: 7.7"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063136			Supported	Nucleoplasm				Nucleoplasm		"HPA063136: "	"unprognostic (1.08e-1)"	"unprognostic (7.47e-2)"	"unprognostic (6.85e-3)"	"unprognostic (2.28e-6)"	"unprognostic (5.00e-2)"	"unprognostic (1.15e-1)"	"prognostic favourable (3.35e-6)"	"unprognostic (3.04e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.69e-1)"	"unprognostic (6.77e-2)"	"unprognostic (4.58e-2)"	"prognostic favourable (1.49e-14)"	"unprognostic (3.62e-2)"	"unprognostic (2.31e-1)"	"prognostic unfavourable (5.80e-4)"	"unprognostic (3.07e-3)"	5.7	2.4	3.1	2.4	4.2	0.3	1.3	4.7	5.5	2.6	9.4	4.2	1.8	5.7	0.9	4.8	3.0	1.2	2.2	24.6	3.3	3.1	49.5	49.7	2.5	0.4	3.1	1.8	1.3	2.8	14.6	7.6	0.3	7.8	2.6	6.6	14.0	30.4	3.0	55.6	5.5	14.2	1.6	3.2	0.8	3.1	3.4	3.4	0.3	17.4	18.2	1.5	1.7	1.0	0.0	0.0	0.2	0.6	0.0	0.0	0.3	42.9	0.0	0.8	0.0	1.2	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	2.1	4.9	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	6.2	0.0	2.0	0.1	1.4	0.0	1.7	0.2	0.7	0.0	0.4	0.3	0.0	0.8	3.8	0.0	0.0	0.8	0.7	0.1	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	3.1	4.2	4.7	5.5	3.3	3.1	3.1	1.8	7.8	3.4
PPFIBP1	"hSGT2, hSgt2p, L2, SGT2"	ENSG00000110841	"PPFIA binding protein 1"	Q86W92	12	27523431-27695564	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 7.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA001924	Uncertain		Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA001924: AB_1079665"	"unprognostic (5.27e-2)"	"unprognostic (5.71e-2)"	"unprognostic (3.10e-2)"	"prognostic unfavourable (6.29e-4)"	"unprognostic (4.73e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.47e-1)"	"prognostic unfavourable (5.11e-4)"	"unprognostic (7.33e-2)"	"unprognostic (3.84e-2)"	"prognostic unfavourable (2.56e-4)"	"unprognostic (1.92e-2)"	"prognostic favourable (5.11e-7)"	"unprognostic (8.54e-2)"	"unprognostic (7.54e-2)"	"unprognostic (2.64e-1)"	"unprognostic (4.09e-2)"	21.3	17.1	15.5	8.0	16.8	2.2	22.6	4.9	25.0	18.3	15.4	13.3	13.0	7.1	28.1	9.3	17.1	16.5	12.2	43.3	17.1	9.0	23.8	15.7	25.0	7.8	13.1	16.4	53.1	13.7	12.7	22.2	34.5	15.3	15.3	11.1	8.1	14.2	18.4	13.7	17.8	10.0	20.5	11.2	16.6	15.1	7.1	13.3	6.2	23.9	14.9	6.2	17.2	18.4	7.0	2.0	1.5	0.6	0.3	1.8	0.6	4.5	9.2	7.5	6.4	12.5	34.9	13.4	16.6	18.7	9.8	14.2	24.2	13.9	3.4	19.4	33.6	11.4	4.0	15.2	17.7	7.8	2.2	7.6	7.0	3.5	5.4	2.3	4.3	27.1	10.6	28.5	29.3	33.5	4.0	3.5	34.8	3.5	2.1	0.6	13.4	7.1	3.5	18.7	1.3	14.5	10.1	0.6	3.1	8.3	4.4	23.1	5.7	3.5	32.5	27.7	9.3	15.1	16.9	0.0	0.0	0.2	30.7	3.3	43.6	1.5	0.6	0.3	0.7	0.2	1.4	0.7	1.3	0.7	0.6	7.0	1.3	1.3	1.5	0.3	0.2	2.0	1.8	0.6	15.5	16.8	4.9	25.0	17.1	9.0	13.1	16.4	15.3	13.3
PPM1D	"PP2C-DELTA, Wip1"	ENSG00000170836	"Protein phosphatase, Mg2+/Mn2+ dependent 1D"	O15297	17	60600183-60666280	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle"	"Hydrolase, Protein phosphatase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 26.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA022277	Approved		Approved	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"HPA022277: AB_1858839"	"unprognostic (1.48e-1)"	"unprognostic (1.36e-2)"	"prognostic favourable (3.52e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.12e-2)"	"prognostic unfavourable (4.27e-4)"	"unprognostic (5.50e-2)"	"unprognostic (1.70e-2)"	"unprognostic (6.07e-2)"	"unprognostic (2.52e-3)"	"unprognostic (3.46e-2)"	"unprognostic (1.95e-3)"	"unprognostic (7.33e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.98e-1)"	12.2	7.0	6.1	5.7	9.2	13.6	11.9	30.8	6.6	11.1	10.0	10.6	7.8	7.6	12.0	8.3	8.6	11.1	8.3	5.8	7.7	4.4	7.4	7.4	9.2	7.9	10.3	4.6	17.3	12.3	8.1	8.9	18.5	8.8	9.3	9.4	8.2	8.1	6.8	9.7	8.1	8.1	8.2	7.3	9.2	7.3	16.2	12.5	15.5	8.7	6.9	7.0	7.8	11.3	7.3	13.1	20.5	13.2	6.8	8.3	6.8	2.7	5.4	6.1	5.2	4.1	2.5	7.9	4.3	2.8	2.8	4.0	5.5	1.6	7.8	3.5	2.9	2.9	3.9	1.8	3.8	1.4	8.7	5.6	5.4	6.4	3.4	2.2	4.3	2.2	2.9	4.1	2.4	6.3	4.1	3.3	3.0	26.5	6.1	3.4	2.6	4.2	7.4	7.8	4.7	2.5	3.4	8.4	6.1	5.7	1.9	1.3	2.3	3.0	4.6	3.6	10.0	2.8	2.3	5.3	5.6	5.9	1.4	2.3	2.8	8.2	13.2	14.1	6.7	10.2	5.9	7.3	5.6	6.1	13.1	5.9	6.1	6.2	20.5	6.8	6.1	5.8	8.3	6.8	6.1	9.2	30.8	6.6	7.7	4.4	10.3	4.6	8.8	12.5
PPP1R15A	GADD34	ENSG00000087074	"Protein phosphatase 1 regulatory subunit 15A"	O75807	19	48872392-48876057	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Stress response, Translation regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 156.9"	"Cell line enhanced"	"Detected in all"		"HHSteC: 54.6;hTERT-HME1: 94.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 69.8"	"Group enriched"	"Detected in all"	5	"dendritic cells: 23.8;granulocytes: 69.8"					"Low region specificity"	"Detected in all"			"CAB018395, HPA020240"	Approved		Uncertain	Vesicles				Vesicles		"CAB018395: AB_2237473, HPA020240: AB_1849404"	"unprognostic (2.43e-3)"	"unprognostic (3.21e-1)"	"unprognostic (7.75e-2)"	"unprognostic (1.17e-3)"	"unprognostic (2.22e-2)"	"unprognostic (6.17e-2)"	"prognostic unfavourable (1.95e-4)"	"unprognostic (5.46e-2)"	"unprognostic (2.66e-2)"	"unprognostic (7.16e-3)"	"unprognostic (5.40e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.22e-1)"	"unprognostic (6.43e-3)"	"unprognostic (1.49e-1)"	"unprognostic (1.29e-2)"	"unprognostic (6.94e-2)"	39.8	29.1	16.2	33.6	12.9	156.9	56.3	12.1	12.8	26.3	19.7	13.6	12.0	12.0	37.8	19.5	28.2	34.0	32.3	42.0	14.6	13.9	18.6	18.6	56.5	10.6	29.5	6.3	24.5	10.9	9.8	16.2	44.7	31.5	28.2	15.6	12.4	9.2	23.6	35.2	40.0	16.0	36.2	17.7	13.3	19.8	14.5	17.8	3.4	18.6	46.7	19.0	41.1	114.7	8.1	23.8	69.8	10.3	2.5	6.1	6.6	9.9	4.3	4.7	3.8	13.7	7.8	7.4	17.5	27.5	20.1	18.2	6.6	5.1	3.4	4.7	12.6	7.2	1.7	9.1	15.2	1.9	2.6	15.6	2.5	3.2	54.6	3.6	22.5	10.6	25.5	27.7	94.1	10.4	20.9	29.1	12.9	1.1	1.9	5.0	1.1	7.9	2.2	4.3	1.1	4.1	11.7	2.6	4.6	9.0	6.2	39.6	2.2	6.5	11.1	24.0	6.0	16.8	10.7	15.7	12.4	3.3	8.8	2.5	28.7	27.4	10.3	17.7	4.9	6.3	4.3	8.1	4.8	4.0	7.3	5.5	2.7	2.4	69.8	2.5	7.1	23.8	6.1	6.6	16.2	12.9	12.1	12.8	14.6	13.9	29.5	6.3	31.5	17.8
PPP2R1A	"PP2A-Aalpha, PP2AA, PR65A"	ENSG00000105568	"Protein phosphatase 2 scaffold subunit Aalpha"	P30153	19	52190039-52229533	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Chromosome partition"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB018599			Approved	Cytosol		3400000	3400000	Cytosol		"CAB018599: AB_628178"	"unprognostic (1.78e-1)"	"unprognostic (2.31e-2)"	"unprognostic (4.52e-2)"	"unprognostic (2.87e-1)"	"unprognostic (6.67e-2)"	"unprognostic (7.82e-2)"	"prognostic unfavourable (1.76e-4)"	"prognostic unfavourable (2.50e-4)"	"unprognostic (4.30e-2)"	"unprognostic (3.06e-1)"	"unprognostic (6.48e-3)"	"unprognostic (8.28e-2)"	"prognostic favourable (1.20e-4)"	"unprognostic (1.97e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.19e-2)"	25.3	57.3	60.7	20.5	71.0	18.0	21.4	47.5	82.1	29.6	31.2	26.6	21.5	33.4	26.4	37.9	37.7	47.0	39.9	74.7	70.2	44.8	31.0	29.3	20.0	27.5	44.0	50.9	45.8	24.3	37.8	29.5	24.6	51.0	31.0	29.8	31.0	24.3	35.6	50.6	33.5	25.3	34.5	25.2	20.5	19.8	21.7	18.1	29.0	28.9	35.9	30.6	27.3	23.1	52.8	62.8	51.9	67.2	69.8	56.3	67.8	30.4	51.7	41.3	36.7	33.6	35.2	21.7	25.7	33.7	34.4	30.0	26.0	24.1	26.7	18.5	40.8	22.0	44.2	38.7	20.0	19.7	119.9	19.6	28.5	29.2	30.7	21.1	18.7	47.2	32.1	32.1	29.6	32.6	22.7	18.8	38.0	35.2	29.5	40.3	40.9	45.7	29.0	24.0	29.8	55.2	50.2	31.2	33.4	31.4	31.4	19.1	28.4	37.3	30.9	27.3	24.6	13.3	29.3	19.5	28.5	31.3	29.3	21.4	34.3	45.0	55.3	51.9	50.4	67.2	45.8	48.4	45.1	47.1	62.8	52.8	37.7	43.0	33.7	69.8	59.8	39.0	56.3	67.8	60.7	71.0	47.5	82.1	70.2	44.8	44.0	50.9	51.0	18.1
PPP6C	PP6	ENSG00000119414	"Protein phosphatase 6 catalytic subunit"	O00743	9	125146573-125189939	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Immunity, Innate immunity"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA050940	Uncertain									"HPA050940: "	"unprognostic (6.45e-2)"	"unprognostic (4.01e-3)"	"unprognostic (7.12e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.78e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.57e-3)"	"unprognostic (1.53e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.71e-2)"	"unprognostic (2.28e-2)"	"prognostic favourable (4.50e-6)"	"unprognostic (1.54e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.12e-1)"	21.7	20.1	20.1	15.7	24.5	24.8	21.2	20.8	26.2	17.0	19.1	25.9	15.1	13.9	15.6	17.2	21.2	14.0	12.9	15.3	19.8	16.6	22.8	17.8	16.3	21.5	20.1	16.1	17.5	27.7	21.3	17.3	17.6	17.8	14.5	21.8	16.8	26.9	14.6	50.5	19.3	17.3	16.3	22.6	19.4	16.5	22.8	23.7	34.1	22.2	20.5	24.0	13.8	15.6	17.3	14.8	32.2	19.5	13.9	23.3	13.8	14.3	10.5	19.2	18.1	20.6	17.3	19.4	15.3	16.6	22.6	18.9	16.8	15.3	20.7	11.9	20.5	29.4	25.9	16.6	26.3	18.5	12.5	17.0	16.5	14.9	16.9	29.6	23.6	14.2	22.8	18.5	17.8	21.0	19.9	24.1	24.3	21.4	27.9	18.7	17.8	19.6	22.8	29.0	27.7	19.2	14.5	19.9	19.7	27.3	22.0	17.7	34.0	18.7	20.4	13.9	13.3	27.0	20.2	26.6	48.0	27.5	18.7	19.4	22.6	27.2	13.2	21.4	14.7	17.4	18.0	17.3	18.9	16.6	14.8	13.3	18.9	17.5	32.2	13.9	19.5	10.7	23.3	13.8	20.1	24.5	20.8	26.2	19.8	16.6	20.1	16.1	17.8	23.7
PPY	PNP	ENSG00000108849	"Pancreatic polypeptide"	P01298	17	43940804-43942468	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	37	"pancreas: 275.8"	"Group enriched"	"Detected in some"	4	"BEWO: 7.0;EFO-21: 6.5;U-2 OS: 7.2"	"Cancer enriched"	"Detected in some"	132	"pancreatic cancer: 630.6"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	7	"myeloid DC: 4.1"	"Lineage enriched"	"Detected in single"	42	"dendritic cells: 4.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB016735, HPA032122"	Enhanced				"Secreted to blood"					"CAB016735: , HPA032122: "		"unprognostic (5.12e-3)"			"unprognostic (1.10e-1)"	"unprognostic (3.27e-2)"			"unprognostic (1.65e-2)"		"unprognostic (7.56e-3)"			"unprognostic (8.13e-2)"	"unprognostic (1.33e-1)"	"unprognostic (7.78e-3)"	"unprognostic (1.42e-1)"	0.1	0.1	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.6	0.1	0.1	0.1	0.1	1.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	275.8	7.5	0.1	0.1	0.1	0.1	2.5	0.1	0.1	0.1	0.1	2.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.3	1.4	0.0	0.0	6.5	0.0	0.0	0.0	0.6	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.6	1.0	0.0	7.2	0.8	0.9	0.0	0.5	1.4	0.2	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
PRCC	RCCP1	ENSG00000143294	"Papillary renal cell carcinoma (translocation-associated)"	Q92733	1	156750610-156800817	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017151, HPA019463, HPA019481"	Supported		Enhanced	"Nuclear speckles"				"Nuclear speckles"		"CAB017151: , HPA019463: AB_1855672, HPA019481: AB_1855673"	"unprognostic (6.12e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.68e-3)"	"prognostic unfavourable (5.55e-4)"	"unprognostic (3.19e-1)"	"unprognostic (1.72e-1)"	"prognostic unfavourable (8.63e-4)"	"unprognostic (3.03e-1)"	"unprognostic (9.16e-2)"	"unprognostic (3.27e-3)"	"unprognostic (1.14e-1)"	"unprognostic (6.80e-2)"	"prognostic unfavourable (8.99e-15)"	"unprognostic (1.72e-1)"	"unprognostic (2.74e-1)"	"prognostic unfavourable (3.72e-4)"	"unprognostic (1.02e-2)"	31.3	24.9	28.5	25.8	29.7	33.7	23.7	33.2	43.5	29.8	30.0	35.9	21.8	24.6	35.1	22.8	30.3	25.6	28.7	23.8	28.0	24.5	26.1	33.1	22.0	30.1	22.1	25.2	30.1	23.7	31.0	22.7	38.8	22.6	25.6	21.5	25.6	37.2	24.0	47.4	33.6	30.1	25.7	20.4	29.7	24.1	26.2	19.2	51.9	27.5	29.8	30.7	25.4	23.8	21.4	27.1	36.9	23.1	19.3	22.1	16.9	19.8	17.2	13.6	15.5	11.4	9.1	23.7	13.9	13.6	15.5	13.4	27.0	16.8	20.4	24.1	10.9	20.8	19.3	14.6	12.1	25.5	25.3	14.9	12.7	17.4	14.1	20.5	17.6	12.9	17.0	13.5	12.4	14.2	24.6	19.0	10.9	35.4	23.4	24.1	32.9	21.4	20.6	12.0	27.4	16.3	19.1	24.2	43.2	14.7	37.1	23.0	26.7	33.1	13.0	15.8	16.6	17.3	22.8	49.1	73.4	31.6	15.6	13.3	14.6	26.9	20.0	36.9	20.5	20.6	19.6	18.0	18.5	22.1	22.4	21.4	18.4	18.9	19.3	19.3	23.1	27.1	18.5	16.9	28.5	29.7	33.2	43.5	28.0	24.5	22.1	25.2	22.6	19.2
PRDM1	"BLIMP1, PRDI-BF1"	ENSG00000057657	"PR/SET domain 1"	O75626	6	106086320-106109939	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Immunity, Innate immunity, Transcription, Transcription regulation"	"DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 49.9"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 66.9;RPMI-8226: 12.5;U-266/70: 25.1;U-266/84: 16.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"eosinophil: 5.6;gdT-cell: 12.6;MAIT T-cell: 19.3;memory CD4 T-cell: 12.0;memory CD8 T-cell: 11.6;naive CD8 T-cell: 6.8;neutrophil: 6.8;T-reg: 15.4"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.8;T-cells: 19.3"	"Region enriched"	"Detected in single"	6	"olfactory region: 4.4"	"Low region specificity"	"Detected in all"			HPA030033	Approved		Approved	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"HPA030033: AB_10601050"	"unprognostic (9.60e-2)"	"unprognostic (3.28e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.98e-2)"	"unprognostic (4.03e-1)"	"unprognostic (3.77e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.50e-2)"	"unprognostic (7.56e-2)"	"prognostic unfavourable (9.81e-5)"	"unprognostic (1.52e-1)"	"unprognostic (3.51e-1)"	"unprognostic (2.45e-3)"	"unprognostic (7.90e-2)"	11.6	1.5	1.6	26.3	3.2	10.4	7.0	5.3	1.6	14.0	16.5	1.9	1.4	5.4	11.6	2.2	33.4	3.8	8.1	2.3	1.9	2.0	3.1	2.4	18.8	33.3	2.1	0.5	4.2	1.8	1.2	2.1	9.0	4.9	3.6	11.0	4.3	10.6	3.0	2.0	8.9	18.2	3.4	7.4	24.2	8.6	3.0	1.5	3.1	7.7	35.7	49.9	12.8	18.0	1.5	0.2	6.8	0.6	2.5	19.3	1.3	0.4	0.1	0.3	0.0	0.5	0.6	0.0	2.3	7.0	0.7	1.3	0.4	2.7	0.5	0.1	4.5	0.1	0.0	1.0	0.8	6.3	0.0	0.1	1.4	0.0	1.1	0.2	0.5	0.7	3.5	1.0	3.0	0.8	0.4	66.9	0.1	0.0	0.0	0.1	0.2	0.0	0.1	0.0	12.5	0.6	0.1	0.0	0.0	0.3	0.2	0.0	0.3	0.7	0.4	1.1	0.6	0.6	2.1	25.1	16.2	1.4	1.5	0.4	0.6	1.2	0.4	5.6	12.6	0.6	19.3	1.5	12.0	11.6	0.2	0.5	1.1	6.8	6.8	2.5	0.1	0.2	15.4	1.3	1.6	3.2	5.3	1.6	1.9	2.0	2.1	0.5	4.9	1.5
PRDM13		ENSG00000112238	"PR/SET domain 13"	Q9H4Q3	6	99606730-99615578	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in single"		"blood: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enriched"	"Detected in single"	5	"MAIT T-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"T-cells: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA070592	Uncertain									"HPA070592: "		"unprognostic (4.09e-1)"	"unprognostic (1.68e-2)"	"unprognostic (4.30e-1)"	"unprognostic (3.65e-1)"	"unprognostic (1.55e-1)"		"unprognostic (3.16e-2)"	"unprognostic (1.24e-2)"	"unprognostic (2.93e-1)"				"unprognostic (1.86e-2)"	"unprognostic (7.54e-2)"		"unprognostic (1.29e-1)"	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
PRDM16	"KIAA1675, KMT8F, MEL1, MGC166915, PFM13"	ENSG00000142611	"PR/SET domain 16"	Q9HAZ2	1	3069168-3438621	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 3.6;CACO-2: 3.4;HAP1: 3.2;HEK 293: 4.2;HHSteC: 4.9;MCF7: 3.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	13	"NK-cell: 5.4"	"Lineage enriched"	"Detected in single"	13	"NK-cells: 5.4"	"Region enriched"	"Detected in many"	5	"basal ganglia: 16.1"	"Low region specificity"	"Detected in many"			"HPA050343, HPA060467"			Supported	Nucleoplasm				Nucleoplasm		"HPA050343: , HPA060467: "	"unprognostic (2.44e-1)"	"unprognostic (1.44e-1)"	"unprognostic (5.31e-4)"	"unprognostic (1.27e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.95e-2)"	"unprognostic (9.15e-3)"	"unprognostic (5.68e-4)"	"unprognostic (2.58e-1)"	"unprognostic (2.07e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.71e-1)"	"unprognostic (7.80e-6)"	"unprognostic (2.14e-1)"	"unprognostic (1.73e-1)"	"prognostic unfavourable (4.70e-5)"	"unprognostic (4.06e-2)"	2.7	0.7	5.3	1.4	5.6	0.5	1.6	0.5	4.7	2.1	6.2	3.3	12.8	14.1	1.5	4.5	1.1	2.0	11.7	5.1	5.2	1.9	7.0	0.6	4.2	1.4	2.9	3.1	3.6	12.7	1.2	1.1	0.6	3.3	1.1	0.9	16.1	1.3	15.0	1.2	0.9	8.0	1.5	2.5	4.2	14.8	1.4	4.8	0.0	10.7	0.0	0.9	1.1	1.5	0.3	0.1	0.0	0.0	5.4	0.4	0.0	0.0	0.0	1.3	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.5	3.4	0.7	0.0	0.6	0.0	0.0	3.2	0.0	0.0	0.4	4.2	0.0	0.0	0.7	4.9	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	1.4	0.0	0.1	0.0	0.0	0.0	0.2	0.9	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.4	0.0	5.4	0.0	0.0	0.0	0.0	5.3	5.6	0.5	4.7	5.2	1.9	2.9	3.1	3.3	4.8
PRDX2	"MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA"	ENSG00000167815	"Peroxiredoxin 2"	P32119	19	12796820-12801859	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Antioxidant, Oxidoreductase, Peroxidase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											CAB008713	Approved					1100000000	1100000000			"CAB008713: AB_1620974"	"unprognostic (1.12e-1)"	"unprognostic (1.98e-3)"	"unprognostic (8.58e-2)"	"unprognostic (4.40e-2)"	"unprognostic (4.56e-2)"	"unprognostic (1.92e-2)"	"unprognostic (2.44e-1)"	"unprognostic (2.59e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.47e-1)"	"unprognostic (3.26e-2)"	"unprognostic (9.18e-2)"	"prognostic favourable (5.66e-11)"	"unprognostic (7.01e-3)"	"unprognostic (2.15e-1)"	"unprognostic (3.51e-2)"	"unprognostic (1.41e-1)"	39.8	95.1	54.7	17.9	55.6	119.1	27.7	52.1	80.8	22.5	39.9	27.8	42.2	53.6	28.1	33.8	49.9	31.5	36.4	142.0	49.2	54.4	44.5	79.4	15.9	22.7	62.2	41.6	40.0	43.0	32.8	49.4	20.9	70.9	30.6	30.8	35.9	42.3	41.5	136.8	44.3	44.9	27.6	27.5	18.1	31.5	13.7	23.5	38.9	36.8	69.9	29.5	31.5	24.6	42.1	24.6	9.5	20.6	23.3	76.8	72.3	44.8	0.1	62.0	80.2	9.0	6.2	45.7	20.8	20.7	28.4	16.1	47.2	11.3	13.2	48.7	20.0	42.9	39.1	33.7	8.2	56.5	61.8	23.9	63.6	70.4	24.3	0.0	0.1	26.6	15.5	21.3	10.4	26.2	51.0	20.8	10.8	81.4	52.8	20.3	45.7	86.9	52.3	0.0	63.6	37.7	48.7	76.8	60.7	49.3	50.6	16.4	45.3	34.4	11.5	21.3	17.9	59.1	45.0	25.5	24.9	60.6	20.2	8.0	4.8	2.8	20.6	9.5	53.6	14.3	56.2	42.1	73.5	54.8	24.6	29.2	74.9	58.5	2.7	23.3	15.4	14.4	76.8	72.3	54.7	55.6	52.1	80.8	49.2	54.4	62.2	41.6	70.9	23.5
PRDX4	AOE37-2	ENSG00000123131	"Peroxiredoxin 4"	Q13162	X	23664262-23686399	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Antioxidant, Oxidoreductase, Peroxidase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	6	"liver: 127.6;pancreas: 320.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008659, CAB027389, CAB047362"	Enhanced		Supported	"Endoplasmic reticulum,Cytosol"	"Intracellular and membrane"	11000000	11000000	"Endoplasmic reticulum, Cytosol"		"CAB008659: AB_1620984, CAB027389: , CAB047362: "	"unprognostic (3.82e-2)"	"unprognostic (6.05e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.06e-3)"	"unprognostic (1.64e-1)"	"unprognostic (1.65e-2)"	"unprognostic (1.29e-3)"	"unprognostic (1.08e-1)"	"unprognostic (8.32e-2)"	"unprognostic (3.75e-2)"	"unprognostic (2.97e-1)"	"unprognostic (1.79e-1)"	"prognostic unfavourable (1.33e-6)"	"unprognostic (7.44e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.56e-1)"	"unprognostic (4.10e-2)"	11.6	14.8	3.8	7.0	6.4	3.9	11.2	3.3	5.4	13.2	10.7	6.5	17.4	8.9	11.5	10.5	13.1	9.6	12.9	17.6	3.8	4.0	11.8	127.6	8.9	16.9	7.2	4.0	14.6	320.8	6.1	15.8	21.9	7.4	9.3	11.4	8.0	25.4	14.1	7.8	7.2	10.6	8.8	8.1	12.6	12.8	25.2	6.1	4.7	12.0	10.0	15.0	10.8	8.7	27.9	31.4	2.0	39.3	24.1	22.7	21.3	24.2	33.5	14.2	27.4	77.4	39.6	20.0	32.7	35.7	29.7	43.4	35.1	30.6	20.9	15.4	42.4	29.4	40.8	20.3	28.5	12.7	78.5	14.8	29.6	44.3	32.3	19.0	14.1	41.9	26.3	28.9	29.0	37.2	28.5	77.1	27.4	36.1	9.7	29.8	49.0	49.2	13.5	35.5	117.8	26.5	8.5	20.8	17.7	30.1	35.8	24.1	37.8	24.3	24.5	21.2	14.0	54.7	24.5	25.3	30.6	22.3	38.0	24.7	30.2	1.7	20.6	2.0	17.8	32.2	21.8	27.9	22.7	18.6	31.4	16.2	16.4	16.7	1.5	24.1	39.3	22.0	22.1	21.3	3.8	6.4	3.3	5.4	3.8	4.0	7.2	4.0	7.4	6.1
PREX2	"DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129"	ENSG00000046889	"Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2"	Q70Z35	8	67952118-68237030	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"AF22: 12.7;HUVEC TERT2: 17.3;NTERA-2: 11.0;RH-30: 5.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015234, HPA075956"	Enhanced		Approved	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"HPA015234: AB_1847604, HPA075956: "	"unprognostic (2.25e-1)"	"unprognostic (3.32e-2)"	"unprognostic (1.30e-2)"	"unprognostic (3.39e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.37e-2)"	"unprognostic (4.19e-1)"	"unprognostic (8.27e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.98e-2)"	"unprognostic (2.53e-2)"	"unprognostic (8.77e-2)"	"prognostic unfavourable (1.61e-7)"	"unprognostic (8.30e-3)"	"unprognostic (2.79e-1)"	"unprognostic (3.67e-2)"	"unprognostic (6.64e-2)"	18.8	3.0	14.1	3.3	17.9	1.0	8.5	11.4	16.4	10.8	4.4	13.1	3.0	4.3	6.2	4.5	4.4	12.4	7.6	7.6	15.5	8.1	4.1	3.2	9.1	2.4	12.4	10.0	5.2	3.1	3.7	4.4	17.5	17.2	6.3	4.4	2.6	3.0	5.7	4.9	4.4	4.0	6.1	12.7	3.5	4.1	2.7	16.2	0.0	12.1	3.9	2.9	5.9	15.8	1.1	0.3	0.8	0.1	0.2	0.4	0.0	0.0	0.0	12.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	3.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.3	0.0	0.0	0.0	0.0	2.6	0.0	11.0	0.0	0.0	5.0	0.0	0.6	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.1	0.1	0.4	0.1	0.2	0.5	0.2	0.2	0.0	1.1	0.2	0.3	0.5	0.2	0.1	0.3	0.0	0.0	14.1	17.9	11.4	13.6	15.5	8.1	12.4	10.0	17.2	16.2
PRF1	"HPLH2, P1, PFP"	ENSG00000180644	"Perforin 1"	P14222	10	70597348-70602775	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters"	Cytolysis		"Cancer-related genes, Disease mutation, Familial hemophagocytic lymphohistiocytosis"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 100.3;lymphoid tissue: 38.7"	"Cell line enriched"	"Detected in some"	11	"HDLM-2: 71.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	4	"gdT-cell: 100.3;MAIT T-cell: 70.9;memory CD8 T-cell: 54.9;naive CD8 T-cell: 36.1;NK-cell: 65.1"	"Group enriched"	"Detected in many"	48	"NK-cells: 65.1;T-cells: 100.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002436, HPA037940"	Approved		Approved	Cytosol	"Intracellular and membrane"	960000	960000	Cytosol		"CAB002436: AB_563955, HPA037940: "	"unprognostic (6.11e-3)"	"unprognostic (1.26e-2)"	"unprognostic (1.71e-1)"	"prognostic favourable (2.09e-4)"	"unprognostic (1.87e-2)"	"prognostic favourable (3.54e-4)"	"unprognostic (6.98e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.44e-3)"	"unprognostic (1.69e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (1.08e-5)"	"unprognostic (7.38e-2)"	"unprognostic (2.70e-1)"	"unprognostic (7.97e-3)"	"unprognostic (5.22e-3)"	8.8	1.3	0.9	5.5	1.1	15.3	2.4	0.5	0.7	1.7	3.8	0.4	0.2	1.4	4.4	2.9	2.7	1.7	5.3	4.1	0.8	0.9	1.8	6.5	19.6	11.3	2.5	0.3	2.1	1.6	0.0	1.1	3.1	1.2	3.3	0.8	3.9	2.5	3.3	2.6	0.9	5.1	1.2	1.4	38.7	3.1	1.6	0.2	12.7	2.8	1.0	10.3	3.2	1.7	0.4	0.3	1.7	0.2	65.1	100.3	46.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	71.0	0.0	0.4	0.0	2.1	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.2	0.0	100.3	0.1	70.9	0.4	14.6	54.9	0.2	0.2	6.2	36.1	1.7	65.1	0.2	0.3	11.1	46.7	0.9	1.1	0.5	0.7	0.8	0.9	2.5	0.3	1.2	0.2
PRKACA	PKACa	ENSG00000072062	"Protein kinase cAMP-activated catalytic subunit alpha"	P17612	19	14091688-14118084	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010361, HPA071185"	Approved		Approved	Cytosol		1300000	1300000	Cytosol		"CAB010361: AB_2268772, HPA071185: "	"unprognostic (1.08e-1)"	"prognostic favourable (6.28e-6)"	"unprognostic (2.09e-2)"	"prognostic unfavourable (6.26e-5)"	"unprognostic (1.38e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.64e-1)"	"unprognostic (9.36e-3)"	"unprognostic (7.01e-2)"	"unprognostic (3.41e-1)"	"prognostic favourable (6.47e-4)"	"unprognostic (2.86e-1)"	"unprognostic (1.17e-1)"	"unprognostic (4.68e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.66e-2)"	"unprognostic (6.14e-3)"	25.6	43.4	19.6	17.8	22.7	9.1	34.1	29.1	39.6	20.6	17.5	16.0	16.2	13.4	19.8	15.6	20.9	18.8	16.4	91.6	20.7	29.4	14.7	34.5	16.5	28.2	21.6	27.5	47.0	15.6	20.8	24.6	15.4	26.9	16.6	16.2	18.4	15.5	24.9	92.4	13.4	14.4	29.0	16.2	28.1	13.9	24.4	11.1	15.2	15.7	26.2	14.8	21.1	17.3	1.7	2.4	8.6	5.3	0.7	1.7	1.2	25.7	15.0	34.0	40.5	30.1	32.0	6.1	27.4	25.4	39.0	35.8	18.2	9.2	11.1	22.2	43.4	16.9	23.9	26.0	37.1	20.3	12.0	20.5	28.3	17.6	25.8	12.6	21.7	30.4	12.5	31.0	10.8	32.8	19.2	29.2	39.8	38.2	28.4	9.5	12.2	33.4	25.7	31.4	25.7	19.0	16.3	26.8	17.1	24.8	15.2	11.3	21.7	12.2	25.4	46.1	12.9	61.6	25.6	20.2	20.7	16.4	30.9	19.2	17.2	0.3	3.4	0.4	1.7	5.3	0.8	1.7	0.9	1.1	2.4	1.3	1.2	1.7	8.6	0.7	4.6	1.6	0.8	1.2	19.6	22.7	29.1	39.6	20.7	29.4	21.6	27.5	26.9	11.1
PRKAR1A	"CNC1, PRKAR1, TSE1"	ENSG00000108946	"Protein kinase cAMP-dependent type I regulatory subunit alpha"	P10644	17	68511780-68551319	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019378, HPA049979"	Approved		Approved	Cytosol		11000000	11000000	Cytosol		"CAB019378: , HPA049979: "	"unprognostic (8.69e-2)"	"unprognostic (6.97e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.39e-2)"	"unprognostic (2.61e-1)"	"unprognostic (6.42e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.19e-2)"	"unprognostic (5.55e-2)"	"unprognostic (8.56e-3)"	"unprognostic (6.26e-2)"	"unprognostic (6.92e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.11e-1)"	47.1	48.0	41.7	34.5	54.8	14.6	38.7	40.4	57.4	48.2	23.8	44.9	31.4	15.1	43.6	37.7	29.6	43.2	37.4	122.7	42.5	52.3	49.2	43.4	47.3	29.5	50.1	43.6	62.5	19.1	107.8	41.9	47.3	57.7	35.6	24.2	32.2	47.5	43.6	99.8	22.8	19.3	39.4	52.8	35.3	25.1	36.9	40.1	28.2	51.8	23.6	29.2	33.8	33.4	11.3	26.9	52.6	28.7	18.5	13.0	22.9	16.4	31.6	40.6	24.3	54.2	61.6	6.1	22.2	45.8	34.7	30.7	12.3	22.2	16.7	15.3	48.4	13.6	30.0	36.0	49.9	11.3	10.7	25.8	27.5	40.2	39.3	19.7	29.0	44.0	37.4	40.0	33.8	57.6	11.6	26.3	42.0	31.1	21.7	10.6	15.0	21.6	15.2	67.3	18.4	52.6	35.8	14.8	20.0	20.3	37.2	85.5	29.0	27.9	40.8	49.0	23.4	22.1	20.6	21.9	15.5	24.9	29.6	18.8	30.5	31.1	26.1	46.3	13.0	25.5	13.0	11.3	9.8	11.6	26.9	8.5	8.9	9.8	52.6	18.5	28.7	8.8	12.3	22.9	41.7	54.8	40.4	57.4	42.5	52.3	50.1	43.6	57.7	40.1
PRKCA	PKCA	ENSG00000154229	"Protein kinase C alpha"	P17252	17	66302636-66810743	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Angiogenesis, Apoptosis, Cell adhesion"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-87 MG: 53.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	17	"dendritic cells: 1.4;monocytes: 2.7;T-cells: 4.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003844, HPA006563, HPA006564, CAB016290"	Enhanced	Approved	Enhanced	"Plasma membrane,Cytosol"		1900000	1900000	Cytosol	"Plasma membrane"	"CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625"	"unprognostic (3.06e-1)"	"unprognostic (3.56e-2)"	"unprognostic (1.38e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.53e-1)"	"unprognostic (7.41e-3)"	"unprognostic (7.43e-2)"	"unprognostic (6.86e-3)"	"unprognostic (4.93e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.09e-1)"	"unprognostic (2.24e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.35e-3)"	"unprognostic (8.77e-2)"	4.0	19.6	26.5	9.0	22.8	2.5	3.0	10.8	33.9	7.0	13.8	19.0	3.5	14.6	14.8	6.7	4.7	6.1	10.8	5.8	31.6	15.6	16.7	6.5	6.0	8.4	18.7	15.6	20.4	5.5	1.7	6.0	6.5	17.6	17.2	11.2	7.0	3.1	22.3	6.6	3.8	12.7	13.7	15.0	7.9	7.9	3.7	14.4	0.4	4.5	1.3	5.9	9.5	9.5	0.0	1.4	0.1	2.7	0.1	4.0	1.0	2.3	12.3	2.5	2.6	6.2	15.9	0.3	13.3	8.7	9.6	8.2	1.4	1.5	3.1	3.6	21.4	0.3	1.3	1.5	20.9	5.1	3.0	0.0	7.3	6.4	8.5	3.8	20.9	6.9	0.6	12.0	10.3	8.2	8.0	0.0	14.8	0.7	7.7	2.3	1.0	6.6	1.4	18.8	0.0	3.4	2.0	1.5	8.5	4.4	2.5	0.1	0.3	5.4	24.5	16.7	9.7	10.4	8.3	0.0	0.0	0.3	53.0	0.0	8.2	0.1	0.6	0.0	0.5	0.8	1.5	0.0	2.5	1.2	1.1	0.0	4.0	2.3	0.0	0.1	2.7	1.4	0.5	1.0	26.5	22.8	10.8	28.2	31.6	15.6	18.7	15.6	17.6	14.4
PRKCB	"PKCB, PRKCB1, PRKCB2"	ENSG00000166501	"Protein kinase C beta"	P05771	16	23835946-24220611	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Adaptive immunity, Apoptosis, Immunity, Transcription, Transcription regulation"	"Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 57.2;lymphoid tissue: 31.2"	"Cell line enhanced"	"Detected in some"		"HEL: 40.8;HMC-1: 40.9;K-562: 58.1;THP-1: 18.4;U-937: 16.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003843, HPA048321, HPA054203"	Approved		Supported	Nucleoplasm,Cytosol		3400000	3400000	Nucleoplasm	Cytosol	"CAB003843: AB_562197, HPA048321: , HPA054203: "	"unprognostic (1.53e-3)"	"unprognostic (4.53e-4)"	"unprognostic (2.52e-3)"	"unprognostic (3.07e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.13e-3)"	"unprognostic (2.06e-1)"	"unprognostic (1.67e-3)"	"unprognostic (3.19e-2)"	"unprognostic (1.79e-1)"	"unprognostic (7.38e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.17e-3)"	"unprognostic (2.08e-1)"	"unprognostic (2.12e-2)"	"unprognostic (3.28e-1)"	"unprognostic (4.95e-2)"	4.0	1.9	13.9	20.8	55.6	20.4	1.8	14.1	57.2	4.1	4.7	4.4	0.6	4.9	3.5	1.2	3.2	2.6	3.9	1.5	23.4	7.8	1.8	3.7	5.4	31.0	11.0	20.4	1.2	1.4	0.9	1.4	2.5	8.3	6.2	4.4	3.5	1.9	8.4	1.2	4.6	9.1	5.8	7.3	31.2	3.8	6.4	6.4	24.1	3.9	0.0	27.7	7.6	1.7	23.6	18.5	21.8	14.6	20.1	19.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.7	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.8	40.8	1.9	0.0	0.0	5.9	40.9	0.0	0.1	0.0	0.0	0.0	58.1	0.1	0.0	0.0	12.9	12.9	0.3	0.0	12.3	0.1	2.3	0.1	3.6	7.1	0.0	0.0	0.0	0.6	0.0	18.4	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.3	0.0	16.4	0.0	17.5	7.6	14.4	14.5	10.7	6.7	23.6	9.5	17.2	6.2	22.1	7.8	19.0	21.8	20.1	14.6	18.5	6.7	7.5	13.9	55.6	14.1	57.2	23.4	7.8	11.0	20.4	8.3	6.4
PRKCD		ENSG00000163932	"Protein kinase C delta"	Q05655	3	53156009-53192717	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Cell cycle"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 63.3;THP-1: 45.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"basophil: 17.7;classical monocyte: 22.9;eosinophil: 17.0;intermediate monocyte: 22.2;myeloid DC: 17.6;neutrophil: 20.7;non-classical monocyte: 15.3;plasmacytoid DC: 8.5"	"Group enriched"	"Detected in all"	7	"dendritic cells: 17.6;granulocytes: 20.7;monocytes: 22.9"	"Group enriched"	"Detected in many"	5	"basal ganglia: 124.2;thalamus: 366.1"	"Low region specificity"	"Detected in all"			"HPA001863, HPA001890, CAB010469, CAB013225"	Enhanced		Enhanced	"Endoplasmic reticulum,Golgi apparatus,Cytosol"		300000	300000	Cytosol	"Endoplasmic reticulum, Golgi apparatus"	"CAB010469: AB_632229, CAB013225: , HPA001863: AB_1079627, HPA001890: AB_1079628"	"unprognostic (3.59e-1)"	"unprognostic (4.85e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.17e-1)"	"unprognostic (6.97e-2)"	"prognostic unfavourable (2.24e-4)"	"prognostic favourable (9.01e-4)"	"unprognostic (1.95e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.89e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.48e-2)"	"unprognostic (2.06e-3)"	"unprognostic (2.95e-3)"	27.8	33.4	9.4	29.7	11.5	30.3	17.6	5.7	10.7	10.3	27.8	10.1	43.7	21.4	5.5	21.3	18.3	16.1	33.7	11.9	8.3	3.7	16.5	4.5	29.2	24.5	10.2	5.6	8.1	13.4	6.1	5.1	7.5	7.1	17.9	16.1	10.3	14.1	40.7	3.9	17.1	42.9	17.4	10.2	32.1	24.8	9.6	8.0	10.5	26.9	13.4	26.3	22.9	12.7	3.1	17.6	20.7	22.9	2.4	1.5	6.4	7.7	3.0	1.2	2.0	9.0	5.2	11.2	4.7	5.9	5.8	5.7	7.3	7.6	20.0	2.1	10.2	3.5	7.9	11.5	4.7	17.4	6.0	11.1	4.1	7.8	5.7	14.6	25.1	4.1	8.4	5.9	5.5	5.0	2.2	2.9	8.3	19.1	1.6	24.9	3.1	5.5	1.7	3.0	4.7	6.3	16.7	2.0	1.4	3.6	63.3	9.7	5.3	45.2	7.2	2.8	3.6	3.7	4.4	4.4	6.8	10.2	6.7	25.2	5.4	17.7	22.9	17.0	1.5	22.2	1.0	3.1	1.1	1.2	17.6	2.9	0.8	0.7	20.7	2.4	15.3	8.5	1.1	6.4	9.4	11.5	5.7	10.7	8.3	3.7	10.2	5.6	7.1	8.0
PRKCE		ENSG00000171132	"Protein kinase C epsilon"	Q02156	2	45651345-46187990	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell adhesion, Cell cycle, Cell division, Immunity"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 36.5"	"Cell line enhanced"	"Detected in many"		"REH: 19.1;TIME: 19.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 5.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001948, HPA044496, HPA054252"	Enhanced	Supported	Approved	Vesicles				Vesicles		"CAB001948: , HPA044496: , HPA054252: "	"unprognostic (1.10e-1)"	"unprognostic (1.78e-1)"	"unprognostic (2.27e-1)"	"prognostic unfavourable (2.42e-4)"	"unprognostic (9.61e-2)"	"unprognostic (5.70e-2)"	"unprognostic (1.51e-1)"	"prognostic favourable (9.62e-4)"	"unprognostic (3.05e-1)"	"unprognostic (6.72e-2)"	"unprognostic (7.49e-3)"	"unprognostic (9.99e-2)"	"prognostic favourable (2.63e-7)"	"unprognostic (1.21e-1)"	"unprognostic (7.11e-2)"	"unprognostic (6.43e-3)"	"unprognostic (2.23e-2)"	5.5	7.4	15.3	7.2	14.2	9.3	8.1	28.8	36.5	6.6	5.5	3.8	5.9	3.6	5.6	4.6	4.7	7.6	4.7	7.7	22.5	10.0	12.8	15.5	17.5	6.9	6.0	15.0	4.1	4.2	16.3	6.0	10.4	9.1	3.6	4.7	3.7	3.6	8.6	7.2	3.0	3.7	6.2	4.4	4.9	4.4	7.2	3.7	1.5	6.5	1.2	5.4	5.0	6.5	5.5	2.2	1.7	1.4	0.9	1.3	0.6	5.3	2.0	2.8	2.8	4.3	5.1	2.3	3.8	6.8	3.2	3.4	0.5	5.3	8.1	3.6	3.9	1.3	1.8	2.0	4.5	4.8	3.4	0.0	1.4	1.1	4.9	0.6	2.9	4.5	2.2	4.7	3.4	11.6	1.1	1.9	3.6	2.7	2.6	0.3	1.0	1.0	19.1	13.5	8.6	2.9	3.7	2.0	4.3	1.7	5.7	12.3	4.6	1.9	19.2	6.2	6.5	4.5	3.7	0.0	0.0	6.8	5.1	4.5	6.2	0.0	1.2	1.7	1.0	0.4	1.1	3.6	0.7	0.7	2.2	5.5	1.3	0.4	0.4	0.9	1.4	0.9	0.0	0.6	15.3	14.2	28.8	33.2	22.5	10.0	6.0	15.0	9.1	3.7
PRKCH	"PKC-L, PKCL, PRKCL"	ENSG00000027075	"Protein kinase C eta"	P24723	14	61187559-61550976	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	Differentiation	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 29.9;HUVEC TERT2: 39.2;MOLT-4: 26.0;RT4: 16.5;TIME: 25.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	12	"gdT-cell: 30.0;MAIT T-cell: 23.9;memory CD4 T-cell: 23.0;memory CD8 T-cell: 35.3;naive CD4 T-cell: 28.5;naive CD8 T-cell: 27.6;NK-cell: 27.3;T-reg: 18.6"	"Group enriched"	"Detected in many"	14	"NK-cells: 27.3;T-cells: 35.3"	"Group enriched"	"Detected in many"	6	"basal ganglia: 25.0;thalamus: 19.5"	"Low region specificity"	"Detected in many"			"HPA026294, HPA053709"	Approved		Approved	"Plasma membrane,Cytosol"				Cytosol	"Plasma membrane"	"HPA026294: AB_10603988, HPA053709: "	"unprognostic (1.42e-1)"	"unprognostic (3.89e-3)"	"unprognostic (1.78e-1)"	"unprognostic (1.96e-3)"	"unprognostic (1.04e-1)"	"prognostic favourable (8.55e-6)"	"unprognostic (1.14e-2)"	"unprognostic (2.97e-2)"	"unprognostic (4.14e-1)"	"unprognostic (1.94e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.52e-3)"	"unprognostic (1.13e-1)"	"unprognostic (4.14e-2)"	"unprognostic (6.98e-2)"	"unprognostic (4.73e-3)"	17.5	5.4	5.0	21.6	22.0	11.2	14.7	2.8	6.1	13.6	10.3	6.2	6.9	5.1	19.1	7.0	20.1	8.6	12.7	10.1	6.8	4.4	8.1	5.5	24.1	27.6	5.9	2.5	7.1	5.9	8.8	15.5	22.7	7.2	9.8	5.0	9.1	24.7	10.8	9.1	15.9	16.0	10.5	5.7	25.9	6.0	4.3	6.4	54.6	15.1	10.6	34.6	13.2	14.4	0.4	2.2	1.5	0.7	27.3	35.3	17.9	6.2	2.2	0.3	1.7	1.0	0.2	29.9	0.1	0.5	0.3	0.3	0.6	3.7	0.1	4.5	0.0	4.4	0.2	4.8	0.5	0.7	2.8	0.0	0.7	0.2	0.4	0.0	0.9	0.8	5.0	0.2	3.4	39.2	0.0	0.1	2.2	11.5	26.0	0.2	0.5	3.0	2.2	1.1	0.0	0.0	16.5	1.1	1.9	0.7	5.8	3.6	5.7	0.5	25.7	0.7	5.2	0.7	0.3	0.5	0.1	0.2	1.1	0.3	1.2	0.1	0.7	0.5	30.0	0.4	23.9	0.4	23.0	35.3	2.2	0.3	28.5	27.6	1.5	27.3	0.2	0.7	18.6	17.9	5.0	22.0	2.8	6.1	6.8	4.4	5.9	2.5	7.2	6.4
PRKCI	"DXS1179E, PKCI"	ENSG00000163558	"Protein kinase C iota"	P41743	3	170222365-170305981	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026574, HPA038635"	Approved		Supported	"Microtubules,Cytokinetic bridge,Cytosol"				Cytosol	"Microtubules, Cytokinetic bridge"	"HPA026574: AB_1855428, HPA038635: "	"unprognostic (2.26e-1)"	"unprognostic (6.75e-2)"	"unprognostic (4.57e-2)"	"prognostic unfavourable (3.93e-6)"	"unprognostic (1.59e-1)"	"unprognostic (1.84e-2)"	"prognostic unfavourable (3.02e-4)"	"unprognostic (2.52e-1)"	"unprognostic (7.10e-2)"	"unprognostic (1.73e-2)"	"prognostic unfavourable (1.22e-4)"	"unprognostic (5.32e-3)"	"prognostic favourable (3.10e-4)"	"unprognostic (1.16e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.06e-1)"	"unprognostic (9.73e-2)"	10.3	7.5	11.4	5.9	15.5	2.1	9.5	14.8	16.6	12.5	11.1	7.0	6.0	10.4	13.1	8.4	20.6	15.1	10.5	10.1	9.5	7.7	13.0	6.7	14.8	3.9	5.6	9.4	15.2	7.7	12.4	14.7	9.8	11.0	16.3	12.2	7.3	25.8	12.6	12.7	11.0	11.6	12.5	6.8	6.1	30.2	15.0	5.3	12.6	23.1	8.4	9.9	16.3	13.0	1.9	1.8	1.0	1.3	5.8	4.8	1.4	35.9	9.1	9.2	9.8	8.2	11.4	14.9	9.2	13.7	12.3	13.3	13.3	17.6	11.0	30.5	13.0	16.9	17.3	18.1	21.1	8.0	10.7	10.2	11.6	7.4	13.0	9.2	4.6	10.2	12.7	10.4	16.5	9.5	11.2	9.1	12.3	12.4	13.3	3.6	19.3	10.2	9.6	14.2	18.2	19.3	11.0	14.6	11.9	20.0	26.3	9.0	28.9	6.3	10.1	12.8	9.9	11.9	15.2	15.7	15.1	15.7	9.2	7.2	5.0	0.1	1.3	1.0	2.6	1.2	4.0	1.8	3.6	4.8	1.8	1.9	3.9	2.2	0.7	5.8	1.1	1.8	2.3	1.4	11.4	15.5	14.8	16.6	9.5	7.7	5.6	9.4	11.0	5.3
PRKCQ		ENSG00000065675	"Protein kinase C theta"	Q04759	10	6427143-6580301	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Immunity, Inflammatory response"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 19.7;lymphoid tissue: 32.1;skeletal muscle: 63.4"	"Cell line enhanced"	"Detected in some"		"HEL: 30.9;MOLT-4: 23.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	10	"gdT-cell: 12.7;MAIT T-cell: 9.8;memory CD4 T-cell: 13.5;memory CD8 T-cell: 13.2;naive CD4 T-cell: 10.7;naive CD8 T-cell: 10.0;NK-cell: 6.5;T-reg: 19.7"	"Group enriched"	"Detected in many"	11	"NK-cells: 6.5;T-cells: 19.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065279, HPA073098"			Enhanced	"Centriolar satellite"		200000	200000	"Centriolar satellite"		"HPA065279: , HPA073098: "	"unprognostic (6.61e-3)"	"unprognostic (2.12e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.24e-1)"	"unprognostic (2.69e-3)"	"unprognostic (2.46e-1)"	"unprognostic (8.40e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.22e-1)"	"unprognostic (5.26e-2)"	"unprognostic (7.74e-2)"	"unprognostic (2.79e-1)"	"prognostic unfavourable (5.27e-4)"	"unprognostic (3.51e-2)"	0.9	0.7	3.6	9.4	4.3	3.1	0.8	0.9	5.2	1.3	1.1	7.4	0.1	1.2	1.8	5.4	1.6	2.6	1.3	0.5	4.4	4.0	4.6	0.9	3.3	6.6	4.0	2.2	1.1	7.7	0.3	1.0	0.4	2.7	1.4	1.3	5.4	2.8	1.0	63.4	0.6	2.5	0.8	3.6	3.4	1.4	0.9	4.5	32.1	9.1	7.5	6.8	1.9	0.8	0.0	0.1	1.1	0.2	6.5	19.7	5.2	0.0	2.9	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.1	0.2	1.8	0.2	0.0	0.0	0.0	1.8	3.3	0.0	0.0	2.1	30.9	0.0	0.2	0.4	1.5	0.3	0.1	2.0	0.1	0.1	0.3	6.7	0.0	0.0	0.0	23.2	4.3	3.2	0.0	4.5	0.7	0.0	6.5	1.6	0.2	1.2	0.0	0.0	0.0	0.0	3.1	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	1.1	0.1	0.1	12.7	0.2	9.8	0.0	13.5	13.2	0.1	0.0	10.7	10.0	0.8	6.5	0.0	0.0	19.7	5.2	3.6	4.3	0.9	5.2	4.4	4.0	4.0	2.2	2.7	4.5
PRKDC	"DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7"	ENSG00000253729	"Protein kinase, DNA-activated, catalytic polypeptide"	P78527	8	47773108-47960183	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity"	"DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005167, HPA035174"	Supported		Enhanced	Nucleoplasm		1100000	1100000	Nucleoplasm		"CAB005167: AB_2172845, HPA035174: "	"unprognostic (3.14e-2)"	"unprognostic (3.02e-3)"	"unprognostic (1.56e-2)"	"prognostic unfavourable (1.03e-4)"	"unprognostic (8.95e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.70e-3)"	"unprognostic (5.74e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.60e-2)"	"unprognostic (7.76e-3)"	"unprognostic (7.77e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.20e-1)"	"unprognostic (6.76e-3)"	"unprognostic (2.15e-2)"	21.3	20.5	16.0	22.3	22.0	27.4	30.2	16.5	23.1	19.6	20.6	17.3	18.1	12.0	26.2	14.5	27.4	24.4	13.0	21.1	20.8	15.2	16.7	18.4	17.0	33.6	16.6	18.2	24.6	23.8	33.4	29.4	20.5	17.3	17.9	20.3	17.8	17.9	17.8	34.0	23.9	18.4	27.0	20.3	24.4	19.1	20.5	15.9	44.4	20.8	15.9	27.9	21.3	19.1	17.0	13.9	7.1	11.5	11.5	11.3	2.3	32.4	27.8	27.1	25.7	16.9	17.9	11.5	13.8	13.6	19.5	19.2	18.1	10.7	31.0	12.0	16.9	18.5	35.8	18.9	30.6	6.8	22.2	60.9	25.0	22.2	7.3	23.1	12.7	12.9	6.2	30.7	32.2	20.0	40.5	13.1	21.4	15.2	32.6	19.1	29.8	8.4	16.0	21.3	10.9	9.8	28.0	13.6	17.3	42.6	13.9	13.4	19.9	16.0	23.2	25.5	21.7	20.1	27.7	11.5	14.6	44.6	14.4	26.3	20.6	6.7	8.1	3.5	8.7	6.3	10.9	12.6	10.8	8.8	5.9	17.0	11.3	10.3	7.1	11.5	11.5	13.9	7.4	2.3	16.0	22.0	16.5	23.1	20.8	15.2	16.6	18.2	17.3	15.9
PRL		ENSG00000172179	Prolactin	P01236	6	22287244-22297501	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	Lactation	Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	81	"pituitary gland: 1739.5"	"Cell line enhanced"	"Detected in some"		"Daudi: 17.6;SCLC-21H: 6.6;U-937: 3.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD8 T-cell: 1.2;non-classical monocyte: 1.0"	"Group enriched"	"Detected in many"	12	"monocytes: 1.0;T-cells: 1.2"					"Not detected"	"Not detected"			"CAB023353, HPA042416, HPA062017"	Enhanced				"Secreted to blood"	3300000	3300000			"CAB023353: AB_617369, HPA042416: AB_2677987, HPA062017: AB_2684660"	"unprognostic (1.66e-1)"	"unprognostic (4.08e-3)"	"unprognostic (5.89e-3)"	"unprognostic (4.83e-3)"	"unprognostic (2.87e-1)"			"unprognostic (1.11e-4)"	"unprognostic (4.54e-1)"	"unprognostic (1.57e-1)"	"unprognostic (3.79e-2)"			"unprognostic (4.29e-5)"	"unprognostic (2.20e-1)"			0.2	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1739.5	21.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.6	0.0	0.0	0.0	1.3	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	1.2	0.6	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.3	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.2	0.0	0.0	1.0	0.0	0.0	0.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.0
PROC		ENSG00000115718	"Protein C, inactivator of coagulation factors Va and VIIIa"	P04070	2	127418427-127429246	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 137.5"	"Cell line enriched"	"Detected in some"	16	"Hep G2: 57.5"	"Cancer enriched"	"Detected in many"	22	"liver cancer: 118.3"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	9	"plasmacytoid DC: 29.2"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 29.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA005550, CAB016721, CAB016792"	Supported				"Secreted to blood"	6400000000	6400000000			"CAB016721: , CAB016792: , HPA005550: AB_1079687"	"unprognostic (2.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.58e-1)"	"unprognostic (6.64e-2)"	"unprognostic (3.13e-2)"	"unprognostic (4.90e-3)"	"unprognostic (2.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.29e-1)"	"unprognostic (3.74e-3)"	"unprognostic (2.56e-2)"	"unprognostic (8.12e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.60e-3)"	"unprognostic (8.06e-2)"	0.0	0.0	0.4	0.1	0.1	0.2	0.0	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.2	4.2	137.5	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.5	0.0	0.1	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.0	0.4	29.2	3.1	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.5	0.0	0.3	0.0	3.6	0.0	0.1	0.0	0.0	0.0	0.0	2.7	57.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.1	0.2	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	3.1	0.0	0.0	29.2	0.0	0.1	0.4	0.1	0.1	0.2	0.4	0.2	0.1	0.1	0.4	0.0
PRPF8	"hPrp8, Prp8, PRPC8, RP13, SNRNP220"	ENSG00000174231	"Pre-mRNA processing factor 8"	Q6P2Q9	17	1650629-1684882	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	"Ribonucleoprotein, RNA-binding"	"Cancer-related genes, Disease mutation, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009941, CAB015457"	Supported		Enhanced	Nucleoplasm		240000	240000	Nucleoplasm		"CAB009941: AB_2171185, CAB015457: AB_831685"	"unprognostic (1.23e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.76e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.94e-2)"	"unprognostic (6.58e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.19e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.45e-3)"	"unprognostic (2.00e-1)"	"unprognostic (2.66e-1)"	"unprognostic (1.16e-1)"	"unprognostic (1.23e-1)"	30.0	37.4	23.1	25.7	40.3	39.0	26.2	43.1	57.2	31.2	28.0	36.5	29.5	19.4	35.6	28.4	29.4	35.4	28.1	34.0	22.2	24.3	23.3	35.5	27.9	30.7	21.3	23.9	47.7	25.9	66.5	45.4	31.1	32.5	30.7	27.2	45.1	30.5	33.1	46.3	30.7	27.5	36.3	17.9	34.1	26.4	45.9	19.6	63.4	30.9	22.2	41.2	32.2	27.9	14.5	20.1	10.0	12.3	10.1	17.1	5.4	18.4	40.2	24.2	19.6	21.0	16.4	19.5	13.8	17.7	27.1	21.9	37.3	9.1	27.1	14.7	24.8	25.7	59.1	23.7	31.3	17.1	37.9	21.5	34.9	31.8	12.3	25.4	23.9	15.6	15.2	34.9	24.4	23.8	21.2	21.6	19.4	20.1	18.3	31.8	16.7	14.9	36.0	13.8	13.0	10.4	20.5	12.4	18.7	27.8	10.1	13.6	14.9	17.0	21.9	16.5	14.2	25.2	31.5	7.9	8.1	19.1	13.7	18.4	20.4	10.0	6.5	6.7	15.7	8.9	17.1	13.3	14.7	15.7	9.7	14.5	13.0	16.4	7.1	10.1	12.3	20.1	14.8	5.4	23.1	40.3	43.1	57.2	22.2	24.3	21.3	23.9	32.5	19.6
PRRX1	"PHOX1, PMX1"	ENSG00000116132	"Paired related homeobox 1"	P54821	1	170662728-170739419	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 72.3;ASC TERT1: 57.7;BJ hTERT+: 40.4;HSkMC: 29.4;U-138 MG: 28.3;U-2197: 27.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA051084, HPA063566"	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA051084: , HPA063566: "	"unprognostic (2.03e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.00e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.97e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.88e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.29e-1)"	"prognostic unfavourable (6.60e-10)"	"unprognostic (4.23e-3)"	"unprognostic (4.48e-2)"	"unprognostic (2.68e-3)"	"unprognostic (1.69e-3)"	44.8	4.4	5.2	7.2	6.3	0.0	21.0	4.0	9.2	58.5	4.1	6.7	10.6	0.4	31.4	19.4	10.8	17.9	14.5	19.5	6.8	4.5	1.8	0.7	10.4	13.0	6.1	5.3	27.6	1.9	3.4	3.1	2.7	7.7	17.3	2.5	17.4	18.4	34.1	58.6	11.9	2.2	23.0	6.6	1.0	2.3	17.6	6.8	5.0	21.7	28.7	14.9	19.4	31.2	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	72.3	57.7	0.0	20.5	40.4	2.9	2.9	0.0	0.0	0.0	0.0	16.8	0.0	3.5	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	29.4	0.0	14.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	28.3	0.5	27.0	3.1	0.0	0.0	0.0	14.9	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	5.2	6.3	4.0	3.9	6.8	4.5	6.1	5.3	7.7	6.8
PRSS1	TRY1	ENSG00000204983	"Serine protease 1"	P07477	7	142749468-142753076	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Digestion	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	1708	"pancreas: 3057.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 3.5;HDLM-2: 1.7;RPMI-8226: 6.9;U-2 OS: 4.1;U-251 MG: 1.5;U-266/84: 2.5"	"Cancer enriched"	"Detected in many"	224	"pancreatic cancer: 1920.3"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.7"	"Low lineage specificity"	"Detected in many"											"CAB025487, CAB025538, HPA062452, HPA063471"	Enhanced		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to digestive system"	26000000000	26000000000	Vesicles	"Endoplasmic reticulum"	"CAB025487: , CAB025538: , HPA062452: , HPA063471: "	"unprognostic (6.55e-5)"	"unprognostic (5.28e-1)"	"unprognostic (7.58e-2)"	"prognostic unfavourable (6.41e-6)"				"unprognostic (8.26e-2)"		"prognostic favourable (7.05e-4)"	"unprognostic (1.35e-1)"			"unprognostic (3.93e-2)"	"unprognostic (1.96e-1)"	"prognostic favourable (4.91e-4)"	"unprognostic (3.12e-1)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	1.6	3057.4	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.4	0.2	0.1	0.0	0.4	0.1	0.1	0.1	0.5	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.0	0.0	1.7	0.0	0.0	0.9	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	1.5	0.0	2.5	0.6	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.0	0.9	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1
PSCA		ENSG00000167653	"Prostate stem cell antigen"	O43653	8	142670308-142682724	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 72.6;stomach 1: 230.2;urinary bladder: 112.0"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 11.5;HeLa: 22.2;RT4: 31.8;SK-BR-3: 8.1"	"Cancer enriched"	"Detected in many"	6	"urothelial cancer: 785.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA030783, HPA056418"	Approved		Supported	"Plasma membrane"				"Plasma membrane"		"HPA030783: , HPA056418: "	"unprognostic (1.21e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.20e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.93e-2)"	"unprognostic (7.81e-3)"	"unprognostic (8.25e-3)"	"unprognostic (2.13e-1)"	"prognostic unfavourable (5.60e-5)"	"unprognostic (6.82e-2)"	"unprognostic (2.38e-3)"	"unprognostic (4.93e-2)"	"unprognostic (2.68e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.06e-3)"	0.4	0.2	0.0	0.2	0.0	0.2	0.3	0.0	0.2	7.0	2.4	0.7	0.1	0.6	0.3	0.2	72.6	1.1	21.2	0.1	0.0	0.0	2.6	0.1	3.0	0.2	0.0	0.0	0.1	0.3	0.1	0.5	17.2	0.0	30.1	0.7	0.1	11.7	0.6	0.1	0.8	1.5	18.9	0.0	0.2	230.2	0.2	0.0	0.0	0.1	9.3	35.1	112.0	54.5	0.0	0.8	0.0	0.3	0.0	0.0	0.0	5.3	0.3	0.0	0.0	1.1	3.7	5.5	2.5	0.5	1.1	0.9	0.0	11.5	0.0	0.2	0.2	1.1	0.0	0.2	0.6	0.3	0.0	0.0	22.2	0.0	0.0	0.0	0.7	3.2	4.1	2.4	0.0	0.0	0.0	0.0	0.8	2.9	0.8	0.3	0.6	0.6	0.3	0.0	0.4	0.5	31.8	0.1	0.2	2.6	8.1	1.7	0.1	0.1	0.5	0.8	0.9	1.5	0.0	1.0	0.0	0.0	1.5	0.4	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
PSEN1	"AD3, FAD, PS1, S182"	ENSG00000080815	"Presenilin 1"	P49768	14	73136418-73223691	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Cell adhesion, Notch signaling pathway"	"Hydrolase, Protease"	"Alzheimer disease, Amyloidosis, Cancer-related genes, Cardiomyopathy, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB006844, HPA030760, HPA067496"	Approved		Approved	"Nucleoplasm,Golgi apparatus,Cell Junctions"				"Golgi apparatus"	"Nucleoplasm, Cell Junctions"	"CAB006844: , HPA030760: AB_10696211, HPA067496: "	"unprognostic (1.67e-1)"	"unprognostic (4.79e-2)"	"unprognostic (7.39e-2)"	"unprognostic (8.68e-3)"	"unprognostic (3.84e-1)"	"unprognostic (5.48e-3)"	"prognostic unfavourable (1.99e-5)"	"unprognostic (1.65e-1)"	"unprognostic (8.99e-2)"	"unprognostic (8.45e-2)"	"unprognostic (1.76e-3)"	"unprognostic (2.74e-1)"	"prognostic favourable (1.52e-8)"	"unprognostic (2.29e-1)"	"unprognostic (2.32e-1)"	"unprognostic (7.12e-3)"	"unprognostic (1.85e-1)"	16.3	15.3	21.0	13.4	34.9	19.2	15.7	15.5	24.7	16.5	26.2	66.1	9.5	26.6	14.2	15.4	19.0	12.6	17.1	9.9	28.6	18.2	19.7	16.9	16.9	10.8	42.1	20.7	13.5	15.0	21.8	9.2	22.7	31.8	13.6	25.6	15.0	16.8	13.4	13.0	24.7	27.9	14.6	61.9	14.6	16.3	16.8	39.7	15.4	19.7	8.7	15.9	17.2	13.5	9.0	24.4	38.1	34.0	11.7	10.5	17.1	14.2	21.9	20.5	8.1	28.7	20.5	18.7	21.0	24.1	21.5	27.2	27.2	35.7	9.3	13.9	19.9	38.0	17.2	15.9	23.6	21.2	10.7	10.6	14.9	13.2	26.5	10.7	20.8	21.0	28.9	17.8	22.0	17.2	11.8	19.0	20.1	28.3	8.1	13.9	8.9	16.3	10.3	17.4	11.8	30.0	30.3	11.4	15.2	22.9	21.5	18.7	26.6	23.9	18.2	21.9	18.1	17.9	9.9	12.4	18.2	9.4	18.4	13.0	13.3	29.2	27.1	27.1	7.2	30.8	7.0	7.2	7.0	5.9	24.4	9.0	6.6	6.4	38.1	11.7	34.0	12.8	10.5	17.1	21.0	34.9	15.5	24.7	28.6	18.2	42.1	20.7	31.8	39.7
PSIP1	"DFS70, LEDGF, p52, p75, PSIP2"	ENSG00000164985	"PC4 and SFRS1 interacting protein 1"	O75475	9	15464066-15511019	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEL: 130.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013718, HPA019697"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB013718: , HPA019697: AB_1852779"	"unprognostic (8.54e-2)"	"unprognostic (3.70e-2)"	"unprognostic (1.31e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.23e-1)"	"unprognostic (2.89e-3)"	"unprognostic (5.10e-2)"	"unprognostic (5.93e-2)"	"unprognostic (2.53e-2)"	"unprognostic (6.49e-3)"	"unprognostic (5.49e-2)"	"unprognostic (6.98e-2)"	"unprognostic (2.04e-1)"	"unprognostic (2.99e-1)"	"unprognostic (7.14e-2)"	"unprognostic (1.39e-1)"	15.1	20.3	42.7	20.8	48.8	24.9	12.2	65.3	49.4	22.6	16.1	19.0	11.5	10.8	27.9	18.2	12.9	20.0	14.9	16.0	38.7	42.7	16.1	10.5	15.6	35.4	34.1	30.2	43.6	8.1	18.8	24.9	18.7	32.4	18.3	15.3	12.3	9.0	21.1	16.3	12.3	14.2	21.3	37.7	24.6	12.5	37.2	29.3	70.4	18.1	6.5	31.9	17.0	16.1	11.4	2.6	8.5	4.3	8.0	16.4	1.9	17.6	11.7	40.0	29.2	8.6	10.5	8.9	21.3	15.2	19.2	22.8	4.9	9.2	37.6	4.9	11.2	4.9	24.8	11.5	27.8	24.7	15.0	130.0	30.7	9.1	10.5	15.1	14.4	8.8	3.4	16.0	11.8	16.7	21.4	20.9	12.4	6.4	31.3	37.7	62.0	18.2	29.3	21.8	7.6	10.7	6.2	25.4	28.0	19.0	8.4	9.9	8.5	20.4	11.8	14.0	14.1	10.4	20.1	9.0	12.6	33.9	11.1	15.3	8.0	8.5	2.1	4.2	5.5	1.6	6.7	8.4	11.0	7.6	2.4	11.4	16.4	10.1	7.2	8.0	4.3	2.6	9.8	1.9	42.7	48.8	65.3	46.6	38.7	42.7	34.1	30.2	32.4	29.3
PSMD4	"AF, AF-1, Rpn10, S5A"	ENSG00000159352	"Proteasome 26S subunit, non-ATPase 4"	P55036	1	151254703-151267479	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA038807, HPA039252, CAB047300"	Enhanced		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB047300: , HPA038807: AB_2676217, HPA039252: AB_10673418"	"unprognostic (3.83e-2)"	"unprognostic (7.89e-2)"	"unprognostic (6.86e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.63e-1)"	"unprognostic (2.89e-2)"	"unprognostic (1.79e-3)"	"unprognostic (2.16e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.57e-2)"	"unprognostic (2.11e-1)"	"prognostic unfavourable (6.66e-10)"	"unprognostic (9.80e-2)"	"unprognostic (6.60e-2)"	"unprognostic (2.03e-2)"	"unprognostic (3.91e-1)"	27.5	28.0	44.3	24.4	46.4	25.5	29.9	25.7	50.4	21.9	28.6	28.3	16.5	22.7	25.1	41.5	26.7	31.4	21.8	38.7	37.5	36.8	25.3	44.7	20.2	28.2	47.5	44.8	26.7	27.7	27.4	19.3	30.0	43.2	23.0	28.1	24.3	25.6	31.2	86.7	28.0	20.5	39.3	29.6	26.3	25.8	35.9	29.1	23.1	23.7	25.7	36.2	28.0	19.8	62.7	65.1	111.6	76.0	54.2	74.2	88.2	41.8	50.5	37.3	30.5	40.7	30.2	40.7	28.5	34.9	45.5	36.3	66.0	48.0	34.1	69.9	40.1	43.9	47.9	43.0	38.9	55.5	41.8	33.2	43.0	68.0	45.0	39.0	38.8	32.7	35.8	51.9	48.0	39.6	51.7	43.3	38.1	123.6	35.9	47.5	70.9	51.1	30.5	36.3	61.5	44.6	36.0	29.3	50.0	31.6	46.4	37.6	48.5	77.2	34.8	22.7	35.7	27.8	48.5	51.9	64.5	72.7	37.6	36.8	41.3	59.6	71.5	111.6	43.0	76.0	48.4	62.7	50.5	47.3	65.1	61.1	46.4	46.0	95.8	54.2	75.5	39.2	74.2	88.2	44.3	46.4	25.7	50.4	37.5	36.8	47.5	44.8	43.2	29.1
PTCH1	"BCNS, NBCCS, PTCH"	ENSG00000185920	"Patched 1"	Q13635	9	95442980-95517057	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Receptor	"Cancer-related genes, Disease mutation, Holoprosencephaly, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 15.5;WM-115: 37.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.9"	"Lineage enriched"	"Detected in many"	8	"T-cells: 8.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013717, HPA075072"	Uncertain		Approved	"Golgi apparatus"				"Golgi apparatus"		"CAB013717: , HPA075072: "	"unprognostic (1.46e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.16e-1)"	"unprognostic (1.79e-2)"	"unprognostic (3.22e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.13e-1)"	"unprognostic (3.54e-3)"	"unprognostic (2.63e-1)"	"unprognostic (8.66e-3)"	"unprognostic (1.52e-2)"	"unprognostic (2.82e-1)"	"unprognostic (1.13e-6)"	"unprognostic (8.63e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.76e-1)"	"unprognostic (2.82e-1)"	4.1	3.8	6.7	6.0	9.5	0.7	7.9	21.0	6.4	28.5	12.5	6.1	8.0	7.8	16.2	4.2	3.0	7.4	13.2	2.8	7.0	6.6	4.9	2.2	7.1	4.5	9.5	3.2	5.2	10.8	3.4	4.0	3.7	6.9	6.9	12.3	11.2	6.9	9.5	2.7	4.3	10.9	8.5	5.1	3.8	12.1	14.3	7.9	1.0	6.3	1.9	3.2	11.3	6.9	1.0	0.0	0.0	0.0	0.3	8.9	1.8	5.0	2.4	10.7	6.7	1.6	2.7	6.1	1.0	0.9	1.2	0.7	2.5	2.5	4.1	1.7	1.9	11.6	6.1	0.8	0.7	4.0	4.0	0.0	2.5	1.1	1.4	0.1	2.2	2.5	1.2	1.1	0.7	2.2	3.6	4.7	0.5	1.0	0.0	1.5	15.5	0.9	0.0	8.2	2.1	0.8	0.7	7.3	3.7	3.6	3.6	1.6	0.9	1.0	0.5	1.4	7.0	7.1	0.7	9.5	8.2	2.7	2.0	2.0	37.0	0.0	0.0	0.0	8.9	0.0	5.3	1.0	1.7	3.8	0.0	0.3	2.8	3.2	0.0	0.3	0.0	0.0	1.4	1.8	6.7	9.5	21.0	6.4	7.0	6.6	9.5	3.2	6.9	7.9
PTCH2		ENSG00000117425	"Patched 2"	Q9Y6C5	1	44819844-44843063	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in all"		"parathyroid gland: 82.4;salivary gland: 44.3;testis: 32.0"	"Cell line enhanced"	"Detected in many"		"U-266/84: 15.0"	"Cancer enhanced"	"Detected in many"		"testis cancer: 9.3"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"														"unprognostic (6.54e-5)"	"unprognostic (1.05e-1)"	"unprognostic (7.29e-3)"	"unprognostic (3.65e-3)"	"unprognostic (3.89e-1)"	"unprognostic (7.42e-3)"	"unprognostic (3.01e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.51e-1)"	"unprognostic (8.67e-2)"	"prognostic favourable (5.74e-5)"	"unprognostic (2.92e-1)"	"unprognostic (5.74e-6)"	"unprognostic (1.55e-2)"	"unprognostic (4.86e-2)"	"unprognostic (6.31e-2)"	"unprognostic (6.81e-2)"	2.5	1.9	8.0	2.4	5.2	6.0	2.2	9.7	7.2	2.5	2.0	1.2	1.3	1.5	6.7	1.9	1.3	2.7	2.4	3.3	6.2	6.1	1.0	1.2	1.2	2.2	2.5	5.8	19.1	1.1	82.4	6.8	1.0	6.0	1.8	1.4	4.6	44.3	1.7	2.0	2.3	1.3	6.6	5.5	1.8	1.2	32.0	5.2	0.0	3.1	2.4	1.3	2.2	2.3	3.4	7.6	3.3	3.8	2.0	2.4	0.5	0.3	0.4	1.5	3.6	1.2	1.3	1.4	1.1	2.4	0.7	0.7	0.4	0.5	1.5	0.7	0.5	0.1	1.5	0.1	0.3	3.1	2.8	0.9	1.2	1.1	0.4	0.9	1.7	0.5	0.6	1.4	0.1	0.2	1.0	1.6	0.1	0.8	1.8	2.9	0.5	0.5	1.4	0.3	0.7	0.3	0.1	2.2	0.9	0.4	0.6	1.0	0.3	1.7	0.2	0.3	0.8	1.8	0.7	2.7	15.0	4.4	0.8	4.3	0.5	3.3	3.8	0.3	1.1	2.0	2.4	2.2	1.4	1.4	2.5	3.4	1.7	1.3	1.3	2.0	1.8	7.6	0.7	0.5	8.0	5.2	9.7	7.2	6.2	6.1	2.5	5.8	6.0	5.2
PTEN	"BZS, MHAM, MMAC1, PTEN1, TEP1"	ENSG00000171862	"Phosphatase and tensin homolog"	P60484	10	87863113-87971930	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Lipid metabolism, Neurogenesis"	"Hydrolase, Protein phosphatase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 29.6"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB004076, HPA031335"	Approved		Supported	Nucleoplasm,Cytosol	"Secreted - unknown location"			Nucleoplasm	Cytosol	"CAB004076: AB_390810, HPA031335: "	"unprognostic (8.72e-2)"	"unprognostic (2.45e-1)"	"unprognostic (5.43e-1)"	"unprognostic (1.50e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.07e-1)"	"unprognostic (6.87e-2)"	"unprognostic (9.77e-2)"	"unprognostic (2.71e-1)"	"prognostic unfavourable (7.35e-4)"	"unprognostic (1.57e-1)"	"unprognostic (2.73e-1)"	"unprognostic (6.54e-3)"	"unprognostic (2.41e-1)"	42.4	24.1	17.7	20.9	17.7	13.5	32.8	39.9	19.7	43.1	26.7	9.9	19.0	15.1	29.8	22.8	26.8	30.3	21.0	19.1	16.0	17.4	19.6	32.4	27.2	30.4	15.7	19.5	29.1	21.3	16.4	23.6	36.4	14.2	35.3	17.7	21.6	16.8	20.8	16.8	20.4	25.4	26.0	11.7	40.9	17.8	18.7	12.5	49.7	25.2	13.3	18.6	29.6	30.9	4.3	5.1	29.6	11.0	4.3	4.7	2.0	10.4	4.9	5.7	5.1	13.1	9.0	5.1	5.6	12.5	6.6	9.3	5.0	12.9	12.3	3.8	9.2	6.3	7.5	6.4	10.5	6.2	2.1	4.1	12.8	6.1	14.0	13.8	7.1	6.1	17.9	8.3	10.8	9.3	3.1	33.6	6.0	8.0	7.7	25.1	2.1	0.0	12.0	3.0	9.1	10.3	6.0	2.0	9.2	7.5	3.5	9.4	9.9	20.0	8.1	21.9	5.1	8.5	4.5	11.1	14.3	14.1	6.8	13.1	1.3	8.3	7.9	12.2	3.6	11.0	3.9	4.3	4.0	3.5	5.1	3.7	4.7	4.5	29.6	4.3	7.2	4.2	3.5	2.0	17.7	17.7	39.9	19.7	16.0	17.4	15.7	19.5	14.2	12.5
PTGS1	"COX1, PGHS-1, PTGHS"	ENSG00000095303	"Prostaglandin-endoperoxide synthase 1"	P23219	9	122370530-122395703	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Dioxygenase, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 211.4;urinary bladder: 163.9"	"Cell line enhanced"	"Detected in some"		"ASC diff: 28.1;ASC TERT1: 22.3;BJ: 27.3;BJ hTERT+: 37.3;HEL: 17.1;HMC-1: 72.7"	"Cancer enhanced"	"Detected in all"		"ovarian cancer: 53.4"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"dendritic cells: 13.0;granulocytes: 14.4;monocytes: 8.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002834, CAB020315"	Enhanced		Supported	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	25000000	25000000	"Golgi apparatus"	Vesicles	"CAB020315: , HPA002834: AB_1079711"	"unprognostic (4.20e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.08e-2)"	"unprognostic (2.27e-2)"	"unprognostic (5.88e-2)"	"unprognostic (2.00e-2)"	"unprognostic (1.22e-3)"	"unprognostic (3.32e-1)"	"unprognostic (2.24e-1)"	"unprognostic (3.16e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.46e-1)"	"prognostic unfavourable (8.68e-4)"	"unprognostic (4.03e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.08e-1)"	"prognostic unfavourable (9.35e-4)"	4.5	1.1	1.8	9.1	3.1	2.6	2.5	0.5	2.7	2.6	35.3	4.6	3.0	3.9	2.5	1.6	25.7	16.7	9.4	4.9	1.9	1.6	3.9	1.8	4.0	1.4	3.5	0.7	3.6	1.0	0.7	2.4	0.8	2.5	60.9	9.3	1.5	1.9	2.3	0.7	55.9	6.5	211.4	4.9	3.6	7.8	1.0	3.1	0.4	1.5	5.3	4.2	163.9	19.5	2.5	13.0	14.4	8.5	1.9	0.1	13.7	0.0	0.1	0.1	0.0	28.1	22.3	0.0	27.3	37.3	0.2	0.2	0.0	0.0	0.9	1.3	4.6	1.7	0.0	2.5	0.2	0.0	0.0	17.1	0.1	0.0	8.1	1.1	72.7	11.4	0.2	1.4	0.0	10.1	0.0	0.0	0.5	0.0	0.0	1.5	0.3	0.1	0.0	0.3	2.0	3.5	0.0	0.1	0.1	0.1	2.3	0.0	0.0	1.9	0.2	0.1	0.1	0.4	0.0	0.0	0.0	0.0	0.1	7.4	0.0	12.0	7.6	14.4	0.0	8.5	0.0	1.7	0.0	0.0	13.0	2.5	0.0	0.0	3.5	1.9	6.1	0.9	0.1	13.7	1.8	3.1	0.5	2.7	1.9	1.6	3.5	0.7	2.5	3.1
PTGS2	COX2	ENSG00000073756	"Prostaglandin-endoperoxide synthase 2"	P35354	1	186671791-186680427	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Dioxygenase, Oxidoreductase, Peroxidase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	11	"ductus deferens: 324.6;seminal vesicle: 377.9"	"Cell line enriched"	"Detected in some"	4	"BJ hTERT+: 93.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"neutrophil: 12.8"	"Lineage enriched"	"Detected in single"	16	"granulocytes: 12.8"	"Region enhanced"	"Detected in many"		"hippocampal formation: 16.5"	"Low region specificity"	"Detected in many"			"CAB000113, HPA001335"	Approved		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"			"Endoplasmic reticulum"		"CAB000113: , HPA001335: AB_1079712"	"unprognostic (1.36e-3)"	"unprognostic (9.97e-3)"	"unprognostic (3.97e-2)"	"unprognostic (3.31e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.11e-1)"	"unprognostic (5.96e-2)"	"unprognostic (9.50e-2)"	"unprognostic (9.03e-3)"	"unprognostic (2.81e-1)"	"unprognostic (3.24e-2)"	"unprognostic (3.07e-2)"	"prognostic unfavourable (9.79e-4)"	"unprognostic (8.04e-3)"	"unprognostic (4.38e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.74e-2)"	5.7	2.1	1.2	3.7	1.1	32.6	1.5	0.8	1.9	21.1	11.4	1.1	324.6	0.4	2.3	1.8	1.7	4.0	9.5	9.1	1.1	1.0	3.3	2.7	22.1	2.3	1.3	0.8	1.6	0.4	3.1	2.2	2.5	1.9	9.2	2.7	3.9	0.9	377.9	1.0	1.1	2.4	7.7	4.7	0.9	11.4	1.0	0.9	0.6	1.5	3.4	1.3	17.3	1.9	0.0	0.5	12.8	0.8	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.5	0.5	0.0	21.3	93.1	0.1	0.8	3.3	3.9	0.0	0.0	0.1	2.8	0.0	1.7	0.3	0.0	0.0	0.1	0.5	0.0	3.1	0.0	0.1	0.2	0.6	2.6	6.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.3	0.0	0.2	0.0	0.2	0.0	0.1	0.3	4.5	0.1	3.1	0.1	0.0	0.0	0.0	6.5	0.1	0.5	0.0	0.4	0.3	0.0	0.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	12.8	0.0	0.4	0.0	0.0	0.0	1.2	1.1	0.8	1.9	1.1	1.0	1.3	0.8	1.9	0.9
PTH	PTH1	ENSG00000152266	"Parathyroid hormone"	P01270	11	13492055-13496181	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	7	"parathyroid gland: 963.9"	"Cell line enhanced"	"Detected in single"		"U-2197: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB000072, CAB023409, CAB026363, HPA048540"	Enhanced				"Secreted to blood"					"CAB000072: , CAB023409: AB_619175, CAB026363: , HPA048540: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	963.9	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	129.7	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PTHLH	"HHM, PLP, PTHR, PTHRP"	ENSG00000087494	"Parathyroid hormone like hormone"	P12272	12	27958084-27972705	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		Hormone	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 45.6"	"Group enriched"	"Detected in some"	4	"HaCaT: 63.2;HBEC3-KT: 78.1"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 64.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"T-reg: 3.0"	"Lineage enriched"	"Detected in single"	30	"T-cells: 3.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA035982	Approved	Approved	Supported	"Nucleoplasm,Golgi apparatus,Cytosol"	"Secreted in other tissues"			"Nucleoplasm, Cytosol"	"Golgi apparatus"	"HPA035982: AB_10794631"	"unprognostic (1.67e-1)"	"unprognostic (5.26e-3)"	"unprognostic (1.31e-1)"	"unprognostic (4.41e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.13e-1)"	"prognostic unfavourable (3.37e-4)"	"unprognostic (1.60e-2)"	"unprognostic (1.18e-1)"	"unprognostic (5.16e-2)"	"unprognostic (4.09e-3)"	"unprognostic (3.84e-1)"	"prognostic unfavourable (1.82e-9)"	"unprognostic (2.01e-2)"	"unprognostic (1.34e-1)"	"unprognostic (5.23e-3)"	"unprognostic (7.87e-3)"	2.9	1.0	6.5	3.5	5.3	0.0	20.2	1.4	8.7	11.0	2.3	1.4	2.1	2.4	11.2	2.0	17.0	1.2	45.6	4.0	4.3	3.5	0.4	0.2	1.3	1.1	1.4	4.3	2.6	1.7	0.7	2.3	3.6	3.1	5.5	1.8	2.4	5.3	2.6	0.7	1.5	1.6	13.4	0.8	3.6	1.9	1.3	1.0	0.1	1.4	15.8	3.4	8.0	12.3	0.0	0.0	0.0	0.0	0.0	3.0	0.1	0.3	2.1	0.0	0.0	0.6	0.6	0.0	0.0	0.2	0.1	0.2	0.0	1.7	0.0	0.1	0.5	63.2	0.2	78.1	0.0	1.5	0.3	0.1	0.4	0.0	0.1	0.0	0.1	0.0	4.3	2.0	7.7	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	3.6	0.0	0.3	0.1	7.6	0.0	0.0	0.0	3.5	0.0	0.4	0.1	0.0	1.2	0.3	1.9	1.1	16.6	1.0	0.0	2.5	1.6	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.1	6.5	5.3	1.4	6.2	4.3	3.5	1.4	4.3	3.1	1.0
PTK2	"FADK, FAK, FAK1, PPP1R71"	ENSG00000169398	"Protein tyrosine kinase 2"	Q05397	8	140657900-141002216	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Angiogenesis	"Developmental protein, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001842, CAB004036, HPA029671"	Approved		Supported	"Vesicles,Focal adhesion sites,Cytosol"		32000	32000	"Focal adhesion sites"	"Vesicles, Cytosol"	"CAB004036: AB_2269034, HPA001842: AB_1855891, HPA029671: AB_10610288"	"prognostic unfavourable (3.21e-4)"	"unprognostic (3.86e-2)"	"unprognostic (1.95e-1)"	"prognostic unfavourable (9.11e-4)"	"unprognostic (1.93e-1)"	"unprognostic (2.28e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.96e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.38e-1)"	"unprognostic (2.80e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.90e-2)"	22.6	20.4	36.0	14.4	42.3	3.1	19.3	20.5	40.8	24.9	17.9	55.7	23.5	14.5	20.2	29.9	14.6	18.7	18.4	20.0	43.5	23.9	22.3	17.0	21.5	13.0	41.4	31.4	19.4	18.2	33.1	13.0	42.1	30.0	19.2	20.7	11.0	21.9	25.5	17.9	13.5	16.3	21.9	38.0	12.2	17.5	21.2	46.1	2.8	22.5	10.2	14.0	22.2	17.8	8.6	7.2	1.8	3.9	5.2	5.7	4.1	14.6	23.4	32.5	11.7	13.7	14.7	21.0	14.5	20.2	13.6	13.4	10.2	12.2	8.9	33.0	18.6	17.4	19.1	33.3	20.6	0.1	8.9	19.7	12.9	14.0	18.7	0.0	9.4	10.0	16.4	17.0	24.0	40.1	19.8	0.2	18.2	25.5	0.2	0.2	12.6	26.2	13.1	17.8	0.4	28.7	33.5	12.9	16.1	22.7	7.3	14.7	17.2	0.3	24.2	13.4	25.3	15.8	16.3	0.0	0.1	0.9	17.4	0.1	18.1	1.8	3.9	0.0	0.3	1.6	0.0	6.8	0.8	0.1	5.3	8.6	5.7	2.0	1.7	5.2	0.9	7.2	0.2	4.1	36.0	42.3	20.5	40.8	43.5	23.9	41.4	31.4	30.0	46.1
PTK6	BRK	ENSG00000101213	"Protein tyrosine kinase 6"	Q13882	20	63528001-63537370	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 44.0;intestine: 24.2;skin 1: 24.2"	"Cell line enhanced"	"Detected in some"		"A-431: 11.3;CAPAN-2: 21.8;HaCaT: 17.7;hTCEpi: 24.0;RT4: 13.8;T-47d: 13.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB032952, HPA036070, HPA036071"	Approved		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"				"Nucleoplasm, Plasma membrane, Cytosol"	"Nuclear bodies"	"CAB032952: AB_634461, HPA036070: AB_10602292, HPA036071: AB_10669982"	"unprognostic (2.32e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.03e-1)"	"unprognostic (3.72e-2)"	"prognostic unfavourable (1.96e-4)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (1.26e-9)"	"unprognostic (4.19e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.73e-1)"	"unprognostic (4.24e-2)"	0.7	0.0	0.4	5.3	0.4	0.0	1.7	0.4	0.4	7.6	18.1	0.5	0.8	13.6	0.6	0.5	44.0	0.0	11.7	0.4	0.4	0.0	0.8	1.7	1.1	0.4	0.4	0.4	0.4	1.4	0.0	0.4	0.6	0.4	2.2	7.4	0.4	7.6	0.4	0.4	24.2	24.2	0.9	0.4	0.4	12.5	0.4	0.4	0.4	0.4	18.9	17.2	6.5	15.0	1.3	4.5	1.2	2.4	0.3	1.9	0.9	11.3	1.3	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	21.8	0.0	3.9	0.0	17.7	0.0	0.0	0.0	2.8	0.2	0.0	4.5	0.0	0.0	0.0	3.6	0.0	24.0	0.0	0.1	0.0	0.1	1.3	0.1	6.3	0.0	0.1	0.1	8.2	0.0	0.6	0.2	0.0	13.8	0.2	1.2	1.3	4.3	0.0	13.3	0.8	0.1	0.2	0.2	0.4	0.1	0.2	0.1	0.0	0.2	0.2	0.6	1.2	2.4	0.4	0.5	1.7	1.9	1.2	0.4	0.1	4.5	1.3	0.4	0.6	1.2	0.3	1.3	0.3	0.5	0.9	0.4	0.4	0.4	0.4	0.4	0.0	0.4	0.4	0.4	0.4
PTN	"HBGF8, HBNF, NEGF1"	ENSG00000105894	Pleiotrophin	P21246	7	137227341-137343865	"Cancer-related genes, Predicted secreted proteins"		"Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 160.7"	"Cell line enriched"	"Detected in some"	12	"AF22: 186.3"	"Cancer enriched"	"Detected in all"	11	"glioma: 514.1"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017685, HPA073913"	Enhanced		Supported	"Endoplasmic reticulum"	"Secreted to blood"	1800000	1800000	"Endoplasmic reticulum"		"CAB017685: AB_1128556, HPA073913: "	"unprognostic (1.51e-2)"	"unprognostic (7.87e-2)"	"unprognostic (5.44e-2)"	"unprognostic (4.23e-2)"	"unprognostic (1.92e-1)"	"unprognostic (7.19e-2)"	"unprognostic (2.81e-2)"	"unprognostic (7.29e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.09e-2)"	"unprognostic (3.86e-1)"	"unprognostic (1.22e-2)"	"prognostic favourable (1.35e-4)"	"unprognostic (2.34e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.16e-2)"	7.8	6.6	55.5	2.0	43.3	0.9	27.7	38.6	58.5	30.7	7.2	26.9	9.9	2.5	25.2	18.7	25.0	7.2	18.2	29.4	42.3	29.7	12.7	3.4	6.5	2.6	31.6	27.0	7.2	3.4	160.7	52.5	11.8	31.4	38.5	7.7	19.0	12.0	18.1	1.5	3.6	4.0	17.7	23.4	12.4	5.4	16.8	23.3	1.3	5.1	8.7	5.3	7.7	18.4	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	186.3	2.2	0.0	0.1	15.2	4.8	14.3	2.7	3.7	0.0	0.0	0.0	0.0	6.3	0.1	0.0	0.0	2.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.2	0.0	1.8	0.0	0.0	0.0	0.8	0.7	0.0	0.0	0.0	14.4	0.1	0.0	0.3	0.0	0.0	0.0	0.8	12.7	0.0	0.0	0.0	0.0	0.0	0.0	4.1	3.6	0.1	10.3	0.0	0.0	0.0	13.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.5	43.3	38.6	42.0	42.3	29.7	31.6	27.0	31.4	23.3
PTPN11	"BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2"	ENSG00000179295	"Protein tyrosine phosphatase, non-receptor type 11"	Q06124	12	112418351-112509913	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005377	Approved		Supported	"Nucleoplasm,Nucleoli,Actin filaments,Cytosol"		160000	160000	Nucleoli	"Nucleoplasm, Actin filaments, Cytosol"	"CAB005377: AB_632401"	"unprognostic (2.18e-3)"	"unprognostic (1.73e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.05e-2)"	"unprognostic (4.25e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.22e-2)"	"unprognostic (8.85e-2)"	"unprognostic (3.75e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.62e-2)"	"unprognostic (1.80e-2)"	25.4	16.8	38.6	14.4	39.0	17.7	30.8	17.5	39.5	18.3	14.7	26.9	9.9	11.9	19.1	13.3	17.6	11.1	13.1	30.1	38.0	32.2	18.0	23.1	15.1	14.5	45.3	22.5	13.1	14.0	29.3	12.9	16.6	26.2	16.2	13.9	9.4	12.0	20.0	34.0	14.1	11.1	28.0	45.7	10.9	12.8	7.6	32.1	10.9	21.2	8.2	13.7	17.4	15.4	17.3	17.1	22.0	11.8	11.3	15.4	6.3	34.8	33.3	24.3	23.0	35.4	34.6	28.8	42.4	46.3	33.4	25.2	33.1	13.5	36.9	22.1	39.2	20.9	31.2	37.6	55.7	28.0	25.7	53.7	31.0	18.1	35.4	43.0	34.3	28.0	37.9	35.9	51.1	27.6	40.7	13.0	32.2	25.2	30.2	20.9	29.4	21.8	31.1	35.9	21.2	30.8	39.2	16.9	20.8	40.8	31.3	26.0	36.0	29.9	33.6	39.4	35.3	23.4	37.1	25.2	41.5	36.9	32.7	30.2	36.8	22.0	11.0	15.0	14.8	9.5	14.1	15.5	13.4	12.1	12.6	17.3	15.4	11.8	10.3	11.3	11.8	17.1	9.8	6.3	38.6	39.0	17.5	39.5	38.0	32.2	45.3	22.5	26.2	32.1
PTPN13	"PTP-BAS, PTP-BL, PTP1E, PTPL1"	ENSG00000163629	"Protein tyrosine phosphatase, non-receptor type 13"	Q12923	4	86594315-86815171	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 44.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"intermediate monocyte: 3.0;MAIT T-cell: 2.3;memory CD4 T-cell: 2.2;non-classical monocyte: 4.9"	"Group enriched"	"Detected in many"	7	"monocytes: 4.9;T-cells: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002213, HPA063119"	Approved		Supported	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"				Nucleoplasm	"Nucleoli fibrillar center, Cytosol"	"CAB002213: AB_564089, HPA063119: "	"unprognostic (5.36e-2)"	"unprognostic (4.46e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.54e-3)"	"unprognostic (4.02e-1)"	"unprognostic (9.03e-3)"	"unprognostic (4.43e-2)"	"unprognostic (4.38e-2)"	"unprognostic (2.46e-1)"	"unprognostic (7.05e-2)"	"unprognostic (3.69e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.28e-3)"	"unprognostic (3.95e-3)"	"unprognostic (2.26e-1)"	"unprognostic (2.66e-1)"	"unprognostic (2.85e-2)"	10.3	5.9	10.8	2.7	16.9	0.7	9.9	5.7	11.6	15.9	4.1	13.0	7.6	1.2	10.8	21.2	18.7	11.4	6.5	5.3	10.4	5.7	22.1	1.6	18.0	4.3	16.9	7.9	24.1	4.3	26.6	38.3	3.0	14.2	12.0	2.4	39.0	5.9	9.4	1.0	43.0	2.3	8.7	10.3	3.5	3.6	12.2	17.6	1.9	16.9	12.4	11.8	15.7	17.6	0.0	0.5	0.1	4.9	0.1	2.3	0.1	5.0	2.5	44.4	4.3	18.8	16.4	0.0	9.3	19.1	3.5	4.5	0.0	2.5	0.0	2.0	10.3	16.7	7.7	14.1	6.9	0.1	5.7	4.2	5.5	0.0	2.3	7.4	0.0	10.5	4.5	2.6	8.6	0.0	0.0	7.2	0.0	2.2	0.6	2.7	10.1	1.9	1.5	0.0	0.0	13.5	21.2	2.6	3.7	2.8	6.2	5.1	3.6	0.2	0.0	3.4	2.7	0.0	1.2	7.6	0.0	0.0	3.6	0.0	1.5	0.0	0.2	0.0	0.2	3.0	2.3	0.0	2.2	0.3	0.5	0.0	0.0	0.0	0.1	0.1	4.9	0.0	0.1	0.1	10.8	16.9	5.7	11.6	10.4	5.7	16.9	7.9	14.2	17.6
PTPRB	PTPB	ENSG00000127329	"Protein tyrosine phosphatase, receptor type B"	P23467	12	70515866-70637440	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Angiogenesis	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"EFO-21: 11.1;HUVEC TERT2: 27.5;TIME: 40.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"memory B-cell: 3.5"	"Lineage enriched"	"Detected in single"	7	"B-cells: 3.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004782, HPA067868"	Uncertain		Approved	"Vesicles,Plasma membrane,Cell Junctions"		6700000	6700000	"Plasma membrane"	"Vesicles, Cell Junctions"	"CAB004782: , HPA067868: "	"unprognostic (3.18e-1)"	"unprognostic (2.99e-6)"	"unprognostic (1.56e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.55e-2)"	"unprognostic (1.77e-2)"	"prognostic favourable (6.05e-4)"	"unprognostic (4.59e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.40e-1)"	"prognostic favourable (1.02e-4)"	"unprognostic (2.91e-2)"	"unprognostic (7.18e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.38e-1)"	23.5	7.0	4.5	5.5	7.0	0.1	22.9	3.6	6.1	11.3	8.0	4.3	7.1	5.3	17.1	8.5	5.8	8.2	11.4	17.6	6.2	5.1	18.7	12.0	39.9	3.3	6.9	4.6	5.5	4.4	4.9	5.7	23.3	7.8	6.1	8.2	16.0	3.6	7.1	11.8	4.7	7.4	13.3	7.3	22.9	5.2	3.7	4.3	0.7	14.0	12.2	2.6	6.5	14.7	3.5	0.1	0.2	0.0	0.4	0.3	0.2	1.9	0.1	0.8	0.1	0.0	0.0	0.4	0.4	1.9	1.0	2.4	0.0	1.5	0.7	11.1	0.3	6.8	0.1	0.3	3.5	0.5	0.3	0.1	0.7	0.4	0.1	0.3	0.0	0.0	0.3	2.7	0.0	27.5	1.5	0.4	0.6	0.0	0.0	0.0	1.0	0.4	0.0	0.7	0.3	5.1	0.7	0.0	0.4	0.7	0.0	1.6	0.0	0.6	40.2	0.4	0.4	0.1	2.3	0.5	0.3	0.3	0.2	0.4	0.0	0.2	0.0	0.0	0.2	0.0	0.0	3.5	0.0	0.3	0.0	0.3	0.1	0.0	0.1	0.4	0.0	0.1	0.0	0.2	4.5	7.0	3.6	6.1	6.2	5.1	6.9	4.6	7.8	4.3
PTPRC	"CD45, GP180, LCA, T200"	ENSG00000081237	"Protein tyrosine phosphatase, receptor type C"		1	198638457-198757476	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Group enriched"	"Detected in many"	4	"blood: 116.9;lymphoid tissue: 172.5"	"Cell line enhanced"	"Detected in some"		"Daudi: 51.0;HEL: 28.8;HL-60: 26.0;MOLT-4: 38.5;THP-1: 21.4;U-266/70: 23.9;U-266/84: 21.6;U-698: 30.6;U-937: 23.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000052, HPA000440, CAB002800, CAB056154, CAB068221"	Enhanced		Uncertain	Nucleoplasm,Vesicles	"Intracellular and membrane"			"Nucleoplasm, Vesicles"		"CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: , CAB068221: , HPA000440: AB_1078468"	"unprognostic (1.51e-2)"	"unprognostic (1.24e-2)"	"unprognostic (5.10e-3)"	"unprognostic (2.33e-3)"	"unprognostic (1.30e-1)"	"unprognostic (2.40e-3)"	"unprognostic (1.62e-1)"	"unprognostic (3.17e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.18e-2)"	"unprognostic (8.08e-2)"	"unprognostic (3.95e-1)"	"prognostic unfavourable (2.42e-4)"	"unprognostic (2.31e-1)"	"unprognostic (3.43e-2)"	"unprognostic (6.41e-2)"	"unprognostic (7.06e-2)"	9.8	2.9	3.4	48.0	6.2	36.1	4.3	1.3	3.5	3.1	5.6	2.8	0.5	4.9	2.9	3.9	4.8	5.6	8.8	4.9	3.9	4.5	4.4	5.2	27.5	93.2	7.9	1.3	2.9	2.1	0.3	2.5	4.5	5.3	4.2	5.8	3.3	10.7	1.0	1.7	2.5	22.2	4.5	13.2	89.3	6.5	2.3	5.3	172.5	4.6	3.9	53.2	13.1	3.7	28.5	42.8	94.7	103.8	53.7	76.1	116.9	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	51.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	28.8	0.0	0.0	0.0	26.0	0.1	0.0	0.0	0.0	0.0	0.1	0.6	0.8	0.0	0.0	38.5	15.7	0.1	0.1	1.1	0.1	0.1	0.0	0.0	0.3	0.4	0.0	0.1	0.1	0.0	21.4	0.3	0.0	0.2	0.1	0.1	23.9	21.6	30.6	0.0	23.3	0.1	20.8	52.0	56.3	76.1	99.7	64.5	28.5	52.9	72.7	42.8	26.8	60.2	60.3	94.7	53.7	103.8	6.4	54.6	116.9	3.4	6.2	1.3	3.5	3.9	4.5	7.9	1.3	5.3	5.3
PTPRK	R-PTP-kappa	ENSG00000152894	"Protein tyrosine phosphatase, receptor type K"	Q15262	6	127968779-128520674	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"memory B-cell: 2.3;naive B-cell: 4.8;naive CD8 T-cell: 1.6"	"Group enriched"	"Detected in many"	7	"B-cells: 4.8;T-cells: 1.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054056, HPA054822"	Uncertain		Supported	"Vesicles,Plasma membrane,Cell Junctions"		13000000	13000000	"Cell Junctions"	"Vesicles, Plasma membrane"	"HPA054056: , HPA054822: "	"unprognostic (3.15e-2)"	"unprognostic (1.07e-2)"	"unprognostic (5.79e-3)"	"unprognostic (4.95e-3)"	"unprognostic (1.89e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.27e-1)"	"unprognostic (6.06e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (1.99e-4)"	"unprognostic (1.46e-1)"	"prognostic favourable (9.33e-5)"	"unprognostic (2.10e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.32e-2)"	12.0	5.2	18.6	10.7	20.3	1.2	20.9	4.7	24.4	12.2	21.9	25.6	11.2	25.7	12.1	10.3	9.1	13.2	29.6	11.4	17.2	12.6	13.3	23.6	17.4	5.7	20.5	19.3	15.6	25.7	11.4	12.2	17.4	14.9	16.3	23.4	3.9	18.3	17.5	9.1	13.5	27.4	14.6	17.1	6.4	24.6	2.7	23.7	15.3	10.1	6.5	7.6	18.4	15.1	4.8	0.0	0.0	0.0	0.4	1.6	0.2	4.4	4.8	2.9	0.2	6.1	8.2	2.9	12.1	23.5	5.0	4.6	8.0	3.7	0.0	3.7	11.1	12.7	3.0	9.6	7.1	13.4	4.9	0.1	7.4	11.1	7.5	0.0	0.4	6.0	8.9	10.5	14.4	13.7	0.0	0.2	12.3	9.0	6.8	0.0	3.0	6.2	24.5	6.2	0.8	12.4	9.2	15.3	0.0	12.5	14.0	0.7	3.8	0.3	23.1	7.9	5.5	15.3	10.9	0.1	1.6	0.0	10.1	0.0	8.3	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.1	0.1	0.0	4.8	0.4	1.6	0.0	0.4	0.0	0.0	0.1	0.2	18.6	20.3	4.7	24.4	17.2	12.6	20.5	19.3	14.9	23.7
PTPRO	"GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2"	ENSG00000151490	"Protein tyrosine phosphatase, receptor type O"	Q16827	12	15322397-15597399	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 26.1;intestine: 28.5;kidney: 21.6"	"Cell line enhanced"	"Detected in some"		"NTERA-2: 9.3;SCLC-21H: 5.7;SH-SY5Y: 11.2;THP-1: 4.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 8.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 5.2;intermediate monocyte: 10.5;memory B-cell: 8.3;myeloid DC: 7.4;naive B-cell: 7.0;naive CD4 T-cell: 2.9;non-classical monocyte: 10.5;plasmacytoid DC: 9.5"	"Low lineage specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"olfactory region: 215.3"	"Low region specificity"	"Detected in many"			HPA034525	Enhanced				"Intracellular and membrane"					"HPA034525: AB_10669785"	"unprognostic (3.68e-2)"	"unprognostic (3.49e-1)"	"unprognostic (9.64e-2)"	"unprognostic (1.25e-2)"	"unprognostic (7.87e-2)"	"unprognostic (2.08e-1)"	"unprognostic (5.93e-3)"	"unprognostic (5.37e-2)"	"unprognostic (2.03e-1)"	"unprognostic (3.72e-2)"	"unprognostic (2.00e-1)"	"unprognostic (5.43e-2)"	"unprognostic (4.89e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.99e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.44e-1)"	3.3	1.2	16.2	3.1	26.1	0.6	1.1	1.0	15.3	1.7	10.4	1.5	0.0	2.0	4.5	2.1	0.8	1.2	1.6	0.7	11.3	10.6	21.6	1.6	6.7	3.2	4.8	8.8	0.7	0.6	0.6	3.8	4.4	4.0	0.7	28.5	1.1	0.8	1.1	0.5	0.7	1.9	7.1	2.6	3.6	1.0	0.9	3.5	0.0	0.5	0.0	3.5	1.7	0.5	8.3	9.5	0.0	10.5	0.1	2.9	2.7	0.0	0.1	0.5	0.4	0.6	0.1	0.2	0.0	0.0	0.9	2.2	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.8	0.0	0.3	0.1	0.2	0.9	0.0	0.0	0.7	0.0	0.0	0.0	0.3	0.0	0.0	0.7	9.3	0.1	0.0	0.0	0.1	0.2	0.3	5.7	11.2	1.3	0.0	0.1	0.1	4.6	0.0	0.1	0.4	0.0	0.4	1.4	0.1	0.4	0.1	0.3	1.7	0.0	5.2	0.0	0.0	10.5	0.0	8.3	1.7	0.4	7.4	7.0	2.9	1.3	0.0	0.1	10.5	9.5	1.3	2.7	16.2	26.1	1.0	15.3	11.3	10.6	4.8	8.8	4.0	3.5
PTPRT	"KIAA0283, RPTPrho"	ENSG00000196090	"Protein tyrosine phosphatase, receptor type T"	O14522	20	42072752-43189970	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 23.5;fallopian tube: 17.0"	"Cell line enhanced"	"Detected in some"		"BEWO: 4.5;RPMI-8226: 1.2;SCLC-21H: 2.9;U-266/70: 1.0"	"Cancer enhanced"	"Detected in many"		"breast cancer: 5.1"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017336, CAB069423"	Approved									"CAB069423: AB_1622602, HPA017336: AB_1855943"	"unprognostic (7.17e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.61e-3)"	"unprognostic (1.08e-2)"	"unprognostic (5.95e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.31e-2)"	"unprognostic (6.93e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.37e-6)"	"unprognostic (3.16e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.17e-1)"	0.6	0.8	5.0	0.6	11.1	0.5	4.6	1.6	23.5	1.6	0.7	0.9	0.0	1.2	0.5	1.8	0.5	17.0	0.7	0.8	4.7	6.5	0.6	0.9	2.1	1.0	2.2	12.6	0.5	0.9	0.5	4.1	4.6	5.1	0.8	0.6	0.5	2.0	4.6	0.5	0.8	1.0	0.5	1.4	0.7	1.8	2.8	0.9	4.9	0.5	0.0	1.1	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	1.2	0.0	0.0	2.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	11.1	1.6	22.6	4.7	6.5	2.2	12.6	5.1	0.9
PTTG1	"EAP1, HPTTG, PTTG, securin, TUTR1"	ENSG00000164611	"Pituitary tumor-transforming 1"	O95997	5	160421822-160428744	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 54.5;testis: 100.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 54.5"	"Lineage enriched"	"Detected in all"	7	"T-cells: 54.5"									"CAB008373, HPA008890, HPA045034"	Enhanced		Supported	Nucleoli,Cytosol				Cytosol	Nucleoli	"CAB008373: AB_592493, HPA008890: AB_1079717, HPA045034: "	"unprognostic (6.48e-2)"	"unprognostic (1.03e-2)"	"unprognostic (1.40e-3)"	"unprognostic (4.46e-3)"	"unprognostic (5.81e-2)"	"unprognostic (1.29e-1)"	"prognostic unfavourable (1.62e-6)"	"unprognostic (7.50e-3)"	"unprognostic (5.24e-2)"	"unprognostic (3.47e-2)"	"unprognostic (2.13e-3)"	"unprognostic (6.70e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (7.17e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.23e-2)"	"unprognostic (3.35e-2)"	1.5	1.7	2.1	16.2	5.5	34.1	2.9	1.4	4.6	3.8	8.2	1.0	0.7	5.8	1.3	2.6	24.1	1.0	1.9	2.3	5.1	2.7	1.7	1.4	3.8	19.2	1.5	2.2	1.1	1.2	0.2	2.0	5.0	2.2	1.6	11.3	1.5	4.5	1.1	1.2	8.7	5.8	4.5	1.4	7.5	3.4	100.1	1.0	29.8	23.9	23.2	35.1	3.3	7.2	8.1	6.1	2.4	2.1	3.3	54.5	4.7	45.5	23.7	53.6	38.4	9.1	8.9	16.7	24.2	55.5	64.3	70.5	45.8	40.1	49.8	21.6	27.5	23.9	33.2	67.3	92.3	56.9	30.2	26.2	32.1	27.5	1.8	23.8	23.1	4.2	11.3	43.6	26.5	45.3	21.0	38.8	66.0	21.4	28.4	58.5	27.0	34.5	26.5	63.0	42.7	32.8	9.3	33.4	21.2	34.9	21.3	71.9	43.5	26.1	19.3	29.1	38.9	22.7	70.6	33.4	29.8	56.9	31.3	41.2	51.5	1.9	0.7	2.4	7.0	2.1	2.5	8.1	14.4	16.2	6.1	5.5	3.6	8.9	0.8	3.3	1.4	5.8	54.5	4.7	2.1	5.5	1.4	4.6	5.1	2.7	1.5	2.2	2.2	1.0
PURA	"PUR-ALPHA, PUR1, PURALPHA"	ENSG00000185129	"Purine rich element binding protein A"	Q00577	5	140107777-140125619	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"													150000	150000				"unprognostic (2.69e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.36e-1)"	"unprognostic (3.72e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.01e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.09e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.33e-1)"	"unprognostic (3.04e-1)"	"unprognostic (9.28e-2)"	"prognostic favourable (4.77e-5)"	"unprognostic (2.75e-1)"	"unprognostic (4.24e-1)"	"unprognostic (8.98e-2)"	"unprognostic (2.09e-1)"	10.5	14.4	13.9	9.0	20.3	2.0	10.4	23.4	21.4	15.9	17.3	13.0	13.7	11.8	12.6	10.8	13.6	10.5	10.9	12.3	14.2	12.2	18.8	13.7	9.5	8.8	16.6	10.2	16.2	10.7	30.9	14.8	12.0	14.4	17.0	8.3	11.7	12.4	14.8	14.6	11.2	26.0	17.9	14.6	15.1	10.6	7.5	18.8	10.4	19.4	6.2	9.5	17.1	18.5	3.0	1.8	3.3	1.4	3.7	3.7	0.8	6.9	3.1	2.4	10.5	9.9	14.3	6.8	13.7	8.7	7.7	7.1	8.1	6.4	8.9	12.0	9.7	5.6	8.0	10.4	12.4	9.0	10.1	5.9	6.1	3.1	5.4	5.3	7.0	5.7	8.6	8.0	8.0	3.8	5.2	6.8	7.0	5.8	7.1	6.0	1.8	6.9	6.1	9.1	5.3	7.6	5.6	6.1	5.2	8.2	8.6	9.8	7.0	7.7	11.2	13.7	5.1	4.0	10.1	9.5	5.1	7.0	7.4	6.5	10.5	3.3	1.4	2.2	2.6	0.9	2.4	2.2	2.8	2.6	1.2	3.0	2.6	3.7	0.7	3.7	1.2	1.8	2.2	0.8	13.9	20.3	23.4	14.3	14.2	12.2	16.6	10.2	14.4	18.8
PZP	CPAMD6	ENSG00000126838	"PZP, alpha-2-macroglobulin like"	P20742	12	9148840-9208370	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	16	"liver: 56.9"	"Group enriched"	"Detected in some"	8	"HeLa: 9.7;SiHa: 5.0"	"Cancer enhanced"	"Detected in some"		"endometrial cancer: 1.0"	"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 3.5;MAIT T-cell: 3.5"	"Lineage enriched"	"Detected in single"	12	"T-cells: 3.5"									"HPA041403, HPA041471"	Supported				"Secreted to blood"	13000000000	13000000000			"HPA041403: AB_10804003, HPA041471: AB_10795636"	"unprognostic (8.48e-3)"	"unprognostic (1.12e-2)"	"unprognostic (2.28e-1)"	"unprognostic (8.54e-4)"	"unprognostic (4.79e-1)"	"unprognostic (3.50e-2)"	"unprognostic (2.04e-4)"	"unprognostic (4.57e-2)"	"unprognostic (2.18e-1)"	"unprognostic (2.55e-2)"	"unprognostic (9.71e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.08e-5)"	"unprognostic (5.49e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.65e-2)"	"unprognostic (9.81e-3)"	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.0	1.3	0.0	0.0	0.8	0.1	0.0	0.7	0.0	0.0	0.9	0.6	0.0	56.9	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.1	0.1	0.0	1.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	3.5	0.0	0.7	0.9	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.2	1.4	0.0	0.0	0.9	0.6	0.0	0.0	1.4	0.6
QKI	QK3	ENSG00000112531	"QKI, KH domain containing RNA binding"	Q96PU8	6	163414000-163578596	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport"	"Developmental protein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 100.3"	"Cell line enhanced"	"Detected in all"		"AF22: 64.0"	"Cancer enriched"	"Detected in all"	6	"glioma: 42.0"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019123, CAB022602"	Enhanced	Supported	Supported	Nucleoplasm				Nucleoplasm		"CAB022602: , HPA019123: AB_1855980"	"unprognostic (2.42e-1)"	"unprognostic (5.81e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.06e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (1.27e-4)"	"unprognostic (1.34e-1)"	"unprognostic (7.06e-2)"	"unprognostic (1.76e-3)"	"unprognostic (1.08e-1)"	"unprognostic (5.15e-2)"	"prognostic unfavourable (2.31e-5)"	"prognostic unfavourable (3.69e-4)"	"unprognostic (1.16e-1)"	"unprognostic (3.86e-1)"	"unprognostic (4.09e-2)"	32.4	12.4	37.5	16.2	63.5	27.1	14.6	15.1	100.3	14.9	12.2	83.9	3.7	4.0	14.7	4.9	16.0	12.3	15.7	64.0	43.7	18.1	11.1	18.4	24.9	11.4	72.5	31.9	18.4	7.6	7.8	4.7	23.4	46.5	7.9	8.4	7.1	10.2	11.1	59.9	12.4	7.1	21.1	68.8	16.9	8.9	20.5	74.3	5.0	10.4	10.8	11.4	15.8	17.7	1.7	7.3	10.8	8.4	7.4	3.8	1.3	4.2	18.0	64.0	21.3	19.4	21.6	14.9	11.6	27.5	19.1	23.1	12.2	3.9	5.2	9.7	29.1	6.4	33.9	12.1	31.0	10.4	10.9	20.4	9.9	13.6	23.7	10.8	6.3	25.2	5.0	20.4	32.5	26.3	29.8	12.3	12.3	8.1	7.2	2.3	8.2	9.1	11.1	39.9	10.3	10.5	13.5	1.2	7.4	12.4	6.8	5.1	2.6	17.7	26.7	13.2	11.2	14.2	21.3	7.8	9.5	6.3	11.4	9.6	31.0	3.4	8.4	3.8	2.3	5.4	3.8	1.4	1.6	2.0	4.3	1.7	1.5	2.5	10.8	7.4	5.5	7.3	1.1	1.3	37.5	63.5	15.1	41.4	43.7	18.1	72.5	31.9	46.5	74.3
RAB11FIP3	"eferin, KIAA0665, Rab11-FIP3"	ENSG00000090565	"RAB11 family interacting protein 3"	O75154	16	425619-523011	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 70.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			"HPA028088, HPA028631, HPA030086"	Approved		Supported	"Vesicles,Cytokinetic bridge,Centriolar satellite"				"Vesicles, Cytokinetic bridge, Centriolar satellite"		"HPA028088: AB_10601672, HPA028631: AB_10601853, HPA030086: AB_10669596"	"unprognostic (6.65e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.51e-1)"	"prognostic favourable (1.22e-4)"	"unprognostic (2.87e-2)"	"unprognostic (1.85e-1)"	"prognostic unfavourable (9.87e-5)"	"unprognostic (6.71e-2)"	"unprognostic (4.74e-1)"	"unprognostic (9.66e-2)"	"prognostic favourable (3.16e-5)"	"unprognostic (1.12e-1)"	"prognostic favourable (7.99e-4)"	"unprognostic (1.39e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.44e-1)"	10.2	13.4	19.3	7.5	16.9	8.7	7.3	29.7	27.4	11.5	10.6	12.2	9.0	13.4	11.9	11.0	8.2	9.5	11.3	14.0	18.7	12.1	70.5	12.2	10.5	8.1	12.0	18.0	13.4	22.2	22.4	14.6	10.0	10.6	11.5	5.4	9.9	13.2	12.6	23.5	12.2	14.6	10.8	8.9	10.2	7.6	13.5	11.9	5.7	8.6	7.4	5.3	9.7	16.6	1.1	0.8	0.1	0.1	0.1	1.5	0.6	4.4	10.1	9.7	8.5	14.3	9.4	8.4	8.4	7.9	7.7	5.6	7.4	2.1	12.2	9.9	12.3	4.6	6.0	8.9	2.7	9.0	8.6	5.5	9.4	21.5	15.3	5.4	6.8	9.0	6.1	7.9	6.9	11.7	2.8	4.8	9.7	13.6	8.8	10.8	8.1	4.1	18.3	7.8	3.2	7.8	2.7	10.1	9.4	8.6	10.5	5.3	5.9	10.1	19.0	11.3	7.5	10.5	5.5	6.7	5.3	14.4	4.3	3.9	8.3	0.0	0.1	0.0	1.5	0.0	1.3	0.8	0.9	0.7	0.5	1.1	0.6	0.3	0.1	0.1	0.0	0.8	0.0	0.6	19.3	16.9	29.7	27.4	18.7	12.1	12.0	18.0	10.6	11.9
RAB18		ENSG00000099246	"RAB18, member RAS oncogene family"	Q9NP72	10	27504174-27542237	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Protein transport, Transport"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA025928	Uncertain					210000	210000			"HPA025928: AB_1855997"	"unprognostic (9.45e-3)"	"unprognostic (7.71e-2)"	"unprognostic (2.95e-1)"	"unprognostic (6.71e-2)"	"unprognostic (3.37e-2)"	"unprognostic (1.28e-2)"	"unprognostic (8.59e-3)"	"unprognostic (1.17e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.27e-2)"	"unprognostic (8.97e-2)"	"unprognostic (3.22e-1)"	"unprognostic (1.71e-3)"	"unprognostic (9.55e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.39e-1)"	"unprognostic (8.48e-2)"	29.3	45.2	36.4	20.8	45.1	58.3	38.3	34.0	42.9	26.8	25.3	24.5	26.6	25.0	25.7	32.8	40.6	20.0	20.6	40.3	40.9	42.5	36.6	38.9	22.4	17.8	35.9	42.2	24.6	23.8	27.0	33.3	34.8	43.5	32.5	27.4	21.8	26.2	27.9	49.1	33.8	27.2	28.1	38.2	21.6	27.4	25.0	26.8	24.2	32.8	28.7	24.0	25.7	28.5	6.4	10.3	49.6	14.2	11.3	24.8	11.1	21.8	15.6	19.0	13.7	32.3	18.5	12.7	33.8	15.6	29.6	28.3	15.0	14.7	8.9	14.5	29.0	14.7	12.4	21.6	24.4	13.6	11.3	12.6	15.2	19.1	23.4	5.4	15.3	24.2	41.2	18.4	10.7	22.7	7.1	18.5	24.8	14.2	11.9	3.7	8.2	7.3	8.8	31.5	10.8	28.0	12.3	10.3	12.5	16.7	19.1	21.4	38.4	11.4	22.5	13.6	16.9	25.7	19.5	8.1	14.8	11.3	23.3	31.9	7.5	44.9	13.8	33.5	11.3	12.6	24.8	6.4	9.9	12.2	10.3	6.3	8.4	9.9	49.6	11.3	14.2	6.7	10.5	11.1	36.4	45.1	34.0	42.9	40.9	42.5	35.9	42.2	43.5	26.8
RAB25	CATX-8	ENSG00000132698	"RAB25, member RAS oncogene family"	P57735	1	156061160-156070514	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 98.3"	"Cell line enhanced"	"Detected in some"		"BEWO: 26.9;CAPAN-2: 26.2;HaCaT: 23.8;hTCEpi: 23.5;MCF7: 36.3;RT4: 33.0;SK-BR-3: 53.7;T-47d: 50.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 3.3;naive CD4 T-cell: 3.4"	"Lineage enriched"	"Detected in single"	24	"T-cells: 3.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA010872, CAB033645"	Enhanced		Uncertain	"Cell Junctions,Cytosol"				"Cell Junctions, Cytosol"		"CAB033645: AB_1128883, HPA010872: AB_1079729"	"unprognostic (2.43e-1)"	"unprognostic (4.57e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.97e-1)"	"unprognostic (4.27e-2)"	"unprognostic (4.63e-2)"	"unprognostic (2.82e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.39e-1)"	"prognostic favourable (1.38e-6)"	"unprognostic (2.31e-2)"	"unprognostic (3.24e-2)"	"unprognostic (3.14e-2)"	"unprognostic (4.94e-2)"	0.4	0.3	0.3	10.9	0.3	0.0	10.8	0.5	0.4	23.6	28.4	0.3	28.1	14.8	4.0	15.9	98.3	9.7	33.3	0.3	0.3	0.3	18.2	1.0	19.1	0.6	0.3	0.2	2.3	27.4	8.6	9.5	19.1	0.3	13.3	16.2	0.4	44.1	26.8	0.4	48.0	43.0	2.1	0.4	0.3	16.2	1.1	0.2	3.7	36.1	74.6	60.9	13.0	31.8	0.1	0.0	0.0	0.0	0.0	3.4	0.8	19.7	0.0	0.0	0.0	0.0	0.0	26.9	0.0	0.0	0.0	0.0	19.3	26.2	0.0	0.0	0.0	23.8	0.0	11.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.0	36.3	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	33.0	2.9	0.0	0.0	53.7	0.0	50.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.1	2.8	0.8	0.0	0.0	3.4	2.9	0.0	0.0	0.0	0.0	0.9	0.8	0.3	0.3	0.5	0.4	0.3	0.3	0.3	0.2	0.3	0.2
RAB40A	"Rar-2, RAR2A"	ENSG00000172476	"RAB40A, member RAS oncogene family"	Q8WXH6	X	103499130-103519489	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"epididymis: 34.0"	"Cell line enhanced"	"Detected in many"		"AF22: 6.4;NTERA-2: 7.1"	"Low cancer specificity"	"Detected in single"			"Region enriched"	"Detected in single"	5	"basal ganglia: 4.2"	"Cell type enriched"	"Detected in single"	5	"memory B-cell: 1.2"	"Lineage enriched"	"Detected in single"	5	"B-cells: 1.2"									HPA076172			Uncertain	Vesicles				Vesicles		"HPA076172: "	"unprognostic (3.49e-1)"	"unprognostic (6.01e-2)"	"unprognostic (4.33e-2)"	"unprognostic (4.49e-3)"	"unprognostic (8.73e-2)"	"unprognostic (1.08e-1)"	"unprognostic (8.21e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.24e-1)"	"unprognostic (4.05e-1)"	"unprognostic (3.82e-2)"	"unprognostic (4.43e-1)"	"unprognostic (7.36e-4)"	"unprognostic (7.85e-3)"	"unprognostic (9.39e-5)"	"unprognostic (1.43e-1)"	"unprognostic (1.11e-3)"	2.0	1.4	0.6	0.6	4.2	0.0	0.8	0.6	1.1	2.8	0.8	0.6	11.9	0.5	5.5	34.0	10.6	2.6	2.9	0.6	0.6	0.9	1.3	0.6	2.0	1.7	0.6	0.6	5.4	0.6	0.6	2.4	0.8	0.8	5.5	0.4	0.6	0.6	6.2	0.6	0.7	0.9	1.3	0.6	0.8	0.5	7.8	0.6	0.6	0.6	0.6	0.6	1.5	2.0	1.2	0.2	0.0	0.0	0.0	0.1	0.0	0.4	1.7	6.4	0.2	1.4	1.9	3.1	1.9	0.4	0.3	0.5	1.3	0.9	1.6	2.4	0.3	0.1	0.4	0.1	0.3	0.0	3.7	0.5	2.9	0.3	0.6	0.1	0.2	1.5	0.3	0.6	0.4	0.3	2.3	1.0	0.6	0.4	0.4	0.2	7.1	1.0	0.0	0.5	0.1	0.1	0.6	2.7	3.3	0.6	0.1	1.3	0.0	0.2	3.2	2.6	1.5	4.0	1.8	1.1	0.7	1.2	2.9	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.6	4.2	0.6	0.6	0.6	0.9	0.6	0.6	0.8	0.6
RABEP1	"neurocrescin, RAB5EP, rabaptin-5, RABPT5"	ENSG00000029725	"Rabaptin, RAB GTPase binding effector protein 1"	Q15276	17	5282265-5385812	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Endocytosis, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004549, HPA019669, HPA024235, HPA024691"	Supported		Supported	Vesicles				Vesicles		"CAB004549: AB_628192, HPA019669: AB_1856019, HPA024235: AB_1856020, HPA024691: AB_1856021"	"unprognostic (3.22e-1)"	"unprognostic (2.90e-2)"	"unprognostic (2.45e-1)"	"unprognostic (8.75e-3)"	"unprognostic (1.64e-1)"	"unprognostic (8.25e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.60e-2)"	"unprognostic (7.73e-2)"	"prognostic favourable (6.43e-4)"	"unprognostic (1.14e-1)"	"unprognostic (6.09e-3)"	"unprognostic (7.67e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.00e-1)"	"unprognostic (9.00e-3)"	19.2	16.7	29.6	18.8	31.1	10.3	31.8	24.1	32.7	16.3	14.2	19.0	12.5	10.9	18.1	18.3	12.7	12.9	15.0	27.4	29.7	25.9	16.6	21.8	13.1	21.1	36.2	24.4	15.5	12.1	38.4	16.3	20.2	31.3	22.2	14.2	10.0	14.8	16.0	41.2	11.6	13.4	20.8	35.6	17.7	15.7	11.8	29.0	21.4	17.6	13.5	25.5	14.5	13.0	37.6	14.2	12.6	19.3	9.1	11.2	6.4	17.9	22.2	23.3	13.0	24.5	24.6	12.8	23.4	17.4	24.5	23.4	19.6	7.5	37.8	19.5	23.5	14.1	34.1	19.3	34.6	24.9	31.2	23.2	27.4	14.9	23.2	15.1	15.3	19.0	13.3	23.5	30.6	21.1	19.7	18.7	21.2	12.4	25.0	12.4	10.7	10.7	23.7	28.0	12.6	12.3	16.4	10.1	15.8	20.6	20.6	19.6	37.4	7.0	18.6	21.0	9.8	21.1	27.2	11.0	12.0	20.3	16.3	24.8	14.3	4.9	9.0	8.7	11.2	9.2	9.8	30.2	8.7	10.6	9.2	37.6	11.1	9.7	12.6	9.1	19.3	14.2	8.0	6.4	29.6	31.1	24.1	32.5	29.7	25.9	36.2	24.4	31.3	29.0
RAC1	"p21-Rac1, Rac-1, TC-25"	ENSG00000136238	"Rac family small GTPase 1"	P63000	7	6374523-6403977	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB035994, HPA047820"	Approved		Approved	Nucleoplasm,Nucleoli,Cytosol		44000000	44000000	"Nucleoplasm, Cytosol"	Nucleoli	"CAB035994: , HPA047820: "	"unprognostic (8.66e-3)"	"unprognostic (2.47e-1)"	"unprognostic (4.00e-1)"	"unprognostic (2.40e-2)"	"unprognostic (1.88e-3)"	"unprognostic (4.06e-2)"	"prognostic unfavourable (1.74e-5)"	"prognostic unfavourable (4.59e-4)"	"unprognostic (1.59e-1)"	"unprognostic (2.04e-1)"	"prognostic unfavourable (4.57e-5)"	"unprognostic (3.63e-1)"	"prognostic unfavourable (2.11e-4)"	"unprognostic (1.95e-1)"	"unprognostic (2.11e-2)"	"unprognostic (4.13e-2)"	"unprognostic (8.72e-3)"	45.2	35.0	71.0	28.4	64.0	24.4	46.5	42.1	93.0	48.7	58.9	75.5	22.5	51.6	48.7	49.5	93.4	47.2	40.0	48.4	73.8	59.8	47.8	42.9	45.6	38.3	76.7	60.9	45.1	29.2	51.0	25.2	55.8	54.9	40.5	64.0	37.2	43.3	48.9	57.4	58.6	49.8	57.3	88.2	35.0	49.7	28.1	47.1	41.3	40.9	42.8	50.7	52.2	54.0	11.0	32.0	49.1	31.9	7.3	11.8	10.7	73.9	33.6	34.7	37.7	41.2	52.7	20.7	41.7	51.3	55.7	56.8	32.9	70.0	20.9	27.1	58.2	52.8	37.0	50.6	71.4	9.7	30.7	21.0	27.2	23.8	49.6	18.9	17.2	35.1	45.3	40.1	45.0	49.0	37.4	16.5	60.0	53.9	10.4	44.4	62.2	40.3	18.4	35.3	30.6	71.6	46.9	26.3	44.3	29.4	107.9	33.5	60.8	56.9	51.4	36.6	55.1	44.8	48.1	12.6	13.8	19.6	33.7	36.1	69.3	7.6	31.9	16.4	7.2	22.2	4.5	11.0	8.1	9.2	32.0	11.0	9.8	6.5	49.1	7.3	22.1	18.2	11.8	10.7	71.0	64.0	42.1	93.0	73.8	59.8	76.7	60.9	54.9	47.1
RAD21	"hHR21, KIAA0078, SCC1"	ENSG00000164754	"RAD21 cohesin complex component"	O60216	8	116845935-116874866	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation"	"Activator, Developmental protein, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020044, CAB022065"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB022065: , HPA020044: AB_1856035"	"unprognostic (7.85e-2)"	"unprognostic (4.92e-1)"	"unprognostic (3.05e-1)"	"unprognostic (5.43e-3)"	"unprognostic (9.56e-2)"	"unprognostic (3.50e-1)"	"prognostic unfavourable (1.71e-4)"	"unprognostic (1.86e-3)"	"unprognostic (8.99e-2)"	"unprognostic (8.80e-2)"	"unprognostic (5.58e-3)"	"unprognostic (3.56e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.95e-1)"	31.6	40.9	48.2	30.5	52.2	78.5	37.7	58.8	55.3	24.2	36.3	37.5	21.5	24.8	30.5	25.3	32.1	23.1	22.0	37.8	45.6	44.1	30.5	27.9	29.6	49.2	54.3	35.4	33.5	18.2	29.1	30.0	38.9	45.5	26.5	37.3	19.0	25.3	31.0	37.8	24.0	26.0	33.4	49.7	31.2	31.5	37.6	56.2	58.3	41.9	20.9	50.4	37.1	36.0	8.7	5.4	17.9	7.1	8.0	25.4	6.2	42.6	21.0	41.1	23.1	20.7	17.9	18.4	29.7	28.2	33.0	30.5	17.2	40.3	63.1	16.4	21.1	23.8	35.0	19.1	38.7	83.7	22.5	64.3	25.8	21.9	13.0	20.6	37.9	15.2	15.7	19.3	23.4	25.8	25.8	88.4	28.4	25.7	94.3	12.1	24.1	26.5	34.6	29.9	31.7	19.6	25.1	52.0	26.8	31.1	84.0	20.0	35.2	25.5	18.8	23.3	34.2	24.4	31.1	46.8	53.8	56.8	19.9	29.7	27.9	17.2	4.5	15.5	11.0	5.3	11.2	8.7	12.9	13.0	5.4	8.3	13.5	13.0	17.9	8.0	7.1	4.5	25.4	6.2	48.2	52.2	58.8	55.3	45.6	44.1	54.3	35.4	45.5	56.2
RAD23A	"HHR23A, MGC111083"	ENSG00000179262	"RAD23 homolog A, nucleotide excision repair protein"	P54725	19	12945855-12953642	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"skeletal muscle: 225.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026418, HPA053901, HPA057003, HPA065599"	Approved		Enhanced	Nucleoplasm,Cytosol		3100000	3100000	Nucleoplasm	Cytosol	"HPA026418: , HPA053901: , HPA057003: , HPA065599: "	"unprognostic (2.09e-1)"	"unprognostic (1.58e-3)"	"unprognostic (1.23e-3)"	"unprognostic (7.90e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.48e-1)"	"unprognostic (3.78e-3)"	"unprognostic (3.57e-3)"	"unprognostic (3.13e-1)"	"unprognostic (3.12e-3)"	"unprognostic (1.09e-1)"	"unprognostic (4.08e-2)"	"unprognostic (2.09e-3)"	"unprognostic (2.32e-3)"	"unprognostic (9.99e-2)"	"unprognostic (8.56e-2)"	"unprognostic (6.59e-3)"	19.6	15.2	19.1	13.4	17.7	19.9	16.0	15.1	25.3	12.9	18.0	14.6	10.7	13.6	15.3	14.3	19.9	17.7	13.6	34.3	16.6	16.0	13.2	24.5	14.2	14.1	15.4	15.6	17.1	21.1	14.0	12.3	17.3	15.5	15.1	10.7	12.6	18.6	15.8	225.3	19.8	11.9	16.5	15.4	15.7	14.9	19.1	12.5	14.6	17.2	37.7	13.8	20.7	17.0	29.5	30.0	22.7	35.6	26.5	32.1	22.5	31.4	11.6	13.5	13.9	22.5	25.8	22.6	15.4	31.0	36.6	33.3	13.0	22.7	26.8	35.5	23.1	24.4	18.4	32.0	13.9	37.8	23.4	10.8	15.0	12.5	43.8	23.3	31.7	26.3	48.0	26.4	50.6	25.1	27.7	24.7	32.9	30.7	29.0	28.9	18.5	28.8	15.3	14.0	43.5	28.5	12.6	25.0	19.7	17.0	31.1	34.0	24.2	40.5	19.7	52.7	14.0	62.5	47.0	35.8	29.9	19.5	43.4	44.1	43.2	10.4	27.9	22.7	29.7	35.6	32.1	29.2	25.3	25.1	23.4	29.5	24.6	27.8	3.9	26.5	34.9	30.0	27.0	22.5	19.1	17.7	15.1	25.3	16.6	16.0	15.4	15.6	15.5	12.5
RAD23B	"HHR23B, HR23B, P58"	ENSG00000119318	"RAD23 homolog B, nucleotide excision repair protein"	P54727	9	107283137-107332194	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA029718, HPA029720, CAB033868"	Enhanced		Supported	Nucleoplasm,Cytosol		8200000	8200000	"Nucleoplasm, Cytosol"		"CAB033868: AB_1128418, HPA029718: AB_10600116, HPA029720: AB_10601008"	"unprognostic (3.95e-3)"	"unprognostic (1.01e-2)"	"unprognostic (2.28e-2)"	"unprognostic (8.14e-2)"	"unprognostic (4.71e-2)"	"prognostic unfavourable (2.58e-4)"	"unprognostic (2.94e-1)"	"prognostic unfavourable (6.71e-4)"	"unprognostic (1.34e-1)"	"unprognostic (3.72e-1)"	"unprognostic (3.31e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.94e-3)"	"unprognostic (2.69e-2)"	"unprognostic (2.43e-1)"	"unprognostic (7.49e-3)"	"unprognostic (1.04e-1)"	41.0	30.1	21.9	23.5	24.5	37.0	28.9	33.3	28.1	28.9	31.4	18.4	28.2	21.8	27.0	38.0	45.3	22.6	24.1	45.5	22.2	23.0	29.7	82.0	27.7	20.7	20.8	23.3	31.6	45.9	21.0	24.8	66.1	25.6	31.1	25.9	17.3	28.7	25.8	98.2	38.2	29.1	29.4	22.6	29.8	23.0	38.5	18.6	32.8	30.4	34.0	27.1	42.1	32.6	5.2	2.5	7.1	2.7	5.0	4.9	1.2	33.3	29.7	42.1	27.0	29.0	46.0	47.5	51.8	42.7	46.2	31.8	49.2	36.6	46.9	21.0	56.6	47.0	58.0	46.1	46.7	31.8	19.0	24.4	31.3	37.5	38.6	43.6	21.0	38.5	43.1	44.1	66.6	32.1	39.3	35.3	41.6	54.5	42.4	22.2	44.8	34.7	31.7	55.3	22.2	39.7	31.6	38.5	26.1	35.8	50.7	31.9	51.7	17.9	29.4	34.5	33.9	42.5	38.7	24.3	44.4	25.3	36.8	26.0	36.1	1.7	2.7	2.3	4.4	2.7	4.9	4.0	2.6	3.7	2.2	5.2	4.4	3.5	7.1	5.0	1.7	2.5	4.6	1.2	21.9	24.5	33.3	27.4	22.2	23.0	20.8	23.3	25.6	18.6
RAD51	"BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA"	ENSG00000051180	"RAD51 recombinase"	Q06609	15	40694774-40732339	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 27.9;testis: 24.0"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"CAB010381, HPA039310"	Enhanced		Supported	Nucleoli,Cytosol				Nucleoli	Cytosol	"CAB010381: AB_2253533, HPA039310: "	"prognostic unfavourable (7.94e-4)"	"unprognostic (7.20e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.72e-2)"	"unprognostic (8.23e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (9.33e-4)"	"unprognostic (3.40e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.41e-3)"	"unprognostic (2.53e-3)"	"unprognostic (0.00e+0)"	"unprognostic (2.26e-2)"	"unprognostic (2.34e-1)"	"unprognostic (9.59e-2)"	"unprognostic (1.94e-2)"	1.0	0.9	0.4	6.6	0.9	5.3	1.0	0.7	0.9	1.1	5.7	0.4	0.3	1.7	0.8	2.0	4.9	0.5	1.7	1.8	0.5	0.5	1.0	1.0	1.9	7.4	0.5	0.3	0.9	0.7	0.0	0.4	6.2	0.7	0.8	7.6	0.4	1.4	0.3	1.3	2.1	2.6	1.2	1.1	5.0	1.5	24.0	0.5	27.9	0.6	3.7	9.7	1.0	1.9	3.1	1.7	2.7	2.2	2.2	8.8	1.7	12.5	5.6	13.4	5.0	1.4	3.6	12.1	22.3	6.1	19.8	19.9	13.1	8.6	7.1	11.0	7.9	26.7	25.2	10.4	19.3	14.8	8.6	17.8	10.9	10.0	0.1	14.4	12.2	0.5	1.8	13.3	5.9	10.7	23.3	20.0	17.1	11.0	20.5	13.3	15.3	7.0	23.5	18.9	11.9	7.2	17.0	6.0	11.2	9.8	17.3	3.5	10.5	12.0	4.5	14.3	9.1	20.0	11.4	5.0	24.9	23.7	6.2	30.1	12.5	2.0	0.9	2.7	4.1	2.0	0.8	3.1	4.3	5.5	1.7	1.6	1.2	2.1	1.3	2.2	2.2	1.2	8.8	1.7	0.4	0.9	0.7	0.9	0.5	0.5	0.5	0.3	0.7	0.5
RAD51B	"hREC2, R51H2, RAD51L1, REC2"	ENSG00000182185	"RAD51 paralog B"	O15315	14	67819779-68730218	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB016191, HPA051869"	Enhanced		Approved	"Nucleoplasm,Nuclear bodies"				"Nuclear bodies"	Nucleoplasm	"CAB016191: AB_2238209, HPA051869: "	"unprognostic (9.10e-3)"	"unprognostic (5.45e-2)"	"unprognostic (4.92e-1)"	"unprognostic (6.65e-2)"	"unprognostic (2.38e-2)"	"unprognostic (4.85e-2)"	"unprognostic (6.42e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.08e-1)"	"unprognostic (6.80e-3)"	"unprognostic (1.47e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.49e-2)"	"unprognostic (6.79e-2)"	"unprognostic (8.13e-3)"	5.1	4.9	4.2	4.6	10.1	9.2	8.2	2.0	5.6	8.2	4.3	11.6	11.2	1.7	10.8	13.8	7.0	6.0	6.4	3.4	5.6	3.2	4.3	3.2	5.0	6.6	9.2	4.0	10.0	5.7	8.0	10.0	8.0	7.5	7.0	4.0	9.4	18.7	3.8	2.4	7.1	5.8	6.7	7.3	6.9	3.7	3.4	7.3	12.6	4.9	4.6	12.1	7.7	8.3	13.6	6.6	14.0	5.9	7.8	10.1	4.8	12.2	4.8	5.4	3.3	5.1	8.7	3.4	6.2	4.8	6.9	8.9	3.4	16.7	15.1	4.1	3.8	11.1	3.4	9.9	9.5	6.7	3.5	7.2	4.4	2.7	2.7	6.0	7.3	4.4	7.7	7.9	8.4	6.2	5.8	7.0	5.6	9.5	11.8	2.1	3.2	4.9	13.3	6.5	5.5	5.4	3.5	3.7	2.4	5.0	1.8	10.7	8.4	5.5	1.6	8.5	8.2	6.6	5.1	3.4	3.4	12.0	4.6	10.7	4.7	14.0	5.9	5.4	8.6	4.7	7.1	13.6	8.2	9.2	6.5	11.5	10.1	9.7	0.7	7.8	4.5	6.6	9.1	4.8	4.2	10.1	2.0	5.6	5.6	3.2	9.2	4.0	7.5	7.3
RAD51D	"HsTRAD, R51H3, RAD51L3, Trad"	ENSG00000185379	"RAD51 paralog D"	O75771	17	35092208-35121522	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (3.41e-2)"	"unprognostic (3.32e-2)"	"unprognostic (1.22e-1)"	"prognostic favourable (5.37e-5)"	"unprognostic (7.29e-2)"	"unprognostic (9.59e-2)"	"unprognostic (1.24e-3)"	"unprognostic (1.14e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.73e-2)"	"prognostic favourable (3.35e-6)"	"unprognostic (2.34e-2)"	"prognostic unfavourable (7.20e-9)"	"unprognostic (7.34e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.22e-2)"	7.9	7.1	9.5	9.9	11.1	8.6	9.2	8.8	13.3	9.0	7.5	10.4	4.3	8.4	10.3	7.6	6.9	7.9	7.3	7.0	9.0	9.8	8.0	6.2	8.0	10.3	10.7	9.2	13.2	11.4	9.5	6.3	9.1	7.4	7.5	7.2	8.6	6.7	9.5	4.1	5.7	7.6	11.7	8.0	10.2	6.0	21.1	10.1	13.9	10.8	3.9	10.9	8.6	8.3	9.0	8.1	5.0	5.8	11.4	10.8	5.0	7.0	12.5	3.2	6.6	3.1	5.2	4.5	13.9	7.3	10.6	10.1	7.4	8.0	16.0	9.4	7.8	9.8	7.2	4.2	6.3	8.8	7.9	8.0	8.5	4.8	6.5	15.7	14.7	6.5	4.3	10.0	6.7	7.7	10.2	22.7	8.8	7.6	19.5	7.9	4.6	6.0	14.9	8.2	10.1	4.0	7.3	4.9	5.0	7.4	3.8	9.0	7.9	10.5	6.2	5.2	6.5	7.8	11.4	4.5	7.3	9.5	7.7	11.1	9.0	4.5	4.7	5.0	10.8	4.7	8.2	9.0	6.8	9.6	5.1	8.2	6.6	8.4	1.0	11.4	5.8	8.1	6.3	5.0	9.5	11.1	8.8	13.3	9.0	9.8	10.7	9.2	7.4	10.1
RAD52		ENSG00000002016	"RAD52 homolog, DNA repair protein"	P43351	12	912077-990053	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA028957			Approved	"Nuclear speckles,Plasma membrane"				"Nuclear speckles"	"Plasma membrane"	"HPA028957: "	"unprognostic (4.53e-1)"	"unprognostic (8.08e-3)"	"unprognostic (4.68e-2)"	"unprognostic (5.27e-2)"	"unprognostic (7.37e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.82e-3)"	"unprognostic (1.88e-1)"	"unprognostic (2.80e-2)"	"unprognostic (8.43e-2)"	"unprognostic (1.03e-2)"	"unprognostic (3.27e-1)"	"prognostic unfavourable (2.22e-6)"	"unprognostic (1.54e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.74e-2)"	7.4	8.5	12.4	8.1	15.1	5.0	10.0	18.8	15.9	12.6	11.7	14.5	13.6	9.4	12.5	14.2	8.2	11.0	9.0	7.8	14.3	7.3	9.9	10.5	6.9	8.9	15.0	9.6	17.6	11.4	9.6	15.6	8.5	15.0	10.5	11.7	9.5	8.4	11.0	16.5	14.9	10.4	12.8	17.0	10.3	8.8	6.8	20.9	9.4	14.6	4.3	9.7	9.7	13.3	7.0	9.6	7.4	3.8	4.0	6.0	1.4	3.1	12.2	9.6	10.7	10.5	7.9	10.3	6.4	5.9	7.0	7.0	11.7	11.2	10.0	2.0	6.3	9.4	7.3	4.3	6.3	13.5	6.5	11.2	11.8	8.1	5.9	12.0	3.4	4.6	7.5	7.4	22.8	5.9	7.4	5.8	6.8	6.7	8.1	11.9	12.4	8.0	8.3	9.4	3.7	7.3	5.8	3.4	3.9	8.2	8.9	4.5	8.2	5.9	5.8	9.9	11.9	7.7	6.6	2.2	3.5	10.5	5.1	5.1	3.6	7.4	3.4	2.0	4.6	2.9	6.0	4.8	4.9	4.0	4.4	7.0	5.7	5.2	2.8	4.0	3.8	9.6	4.4	1.4	12.4	15.1	18.8	15.9	14.3	7.3	15.0	9.6	15.0	20.9
RAD54B	RDH54	ENSG00000197275	"RAD54 homolog B (S. cerevisiae)"	Q9Y620	8	94371960-94475109	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 21.2"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"gdT-cell: 1.4;MAIT T-cell: 4.4;memory B-cell: 1.7;memory CD4 T-cell: 2.4;memory CD8 T-cell: 1.3;naive B-cell: 2.6;naive CD4 T-cell: 1.8;naive CD8 T-cell: 2.6;T-reg: 1.4"	"Group enriched"	"Detected in many"	14	"B-cells: 2.6;T-cells: 4.4"									HPA007087	Uncertain									"HPA007087: AB_1856040"	"unprognostic (1.68e-3)"	"unprognostic (2.51e-1)"	"unprognostic (2.31e-2)"	"unprognostic (8.84e-3)"	"unprognostic (4.15e-2)"	"unprognostic (1.44e-1)"	"unprognostic (5.56e-8)"	"unprognostic (1.96e-2)"	"unprognostic (1.77e-2)"	"unprognostic (5.39e-2)"	"unprognostic (2.30e-2)"	"unprognostic (2.64e-1)"	"unprognostic (2.04e-12)"	"unprognostic (5.86e-2)"	"unprognostic (5.23e-1)"	"unprognostic (9.08e-2)"	"unprognostic (6.68e-5)"	2.7	3.9	3.9	7.7	8.6	4.6	4.7	11.8	9.1	6.1	4.7	3.8	4.4	3.8	4.0	4.7	5.4	7.7	2.3	3.5	7.7	3.5	3.5	4.3	2.6	6.3	5.4	4.2	5.2	4.1	5.0	6.6	3.7	7.2	5.2	4.8	3.1	3.7	5.7	1.9	4.2	3.4	3.1	9.4	3.2	4.2	10.5	6.7	21.2	3.6	5.0	6.7	6.7	3.8	2.6	0.2	0.0	0.2	0.2	4.4	0.9	14.1	9.8	13.9	7.5	1.1	1.5	7.6	10.7	5.7	15.1	14.4	5.0	9.7	10.2	16.2	3.0	7.7	12.3	5.3	16.5	11.7	7.3	15.5	5.6	4.0	1.3	5.8	5.5	1.3	0.7	7.6	9.3	5.5	11.5	6.7	15.3	6.6	19.7	3.8	9.6	8.7	4.7	15.2	5.8	6.3	6.8	8.9	6.2	7.6	1.8	5.7	9.6	3.3	4.3	10.3	5.5	11.4	11.7	3.5	7.5	5.3	5.5	10.4	10.3	0.0	0.0	0.0	1.4	0.0	4.4	1.7	2.4	1.3	0.2	2.6	1.8	2.6	0.0	0.2	0.2	0.1	1.4	0.9	3.9	8.6	11.8	9.1	7.7	3.5	5.4	4.2	7.2	6.7
RAF1	"c-Raf, CRAF, Raf-1"	ENSG00000132155	"Raf-1 proto-oncogene, serine/threonine kinase"	P04049	3	12583601-12664226	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 53.9"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 53.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002640, CAB019291"	Approved		Approved	"Nuclear speckles"				"Nuclear speckles"		"CAB019291: , HPA002640: AB_1856047"	"unprognostic (6.33e-2)"	"unprognostic (1.29e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.17e-3)"	"unprognostic (6.51e-3)"	"unprognostic (7.66e-3)"	"unprognostic (2.66e-3)"	"unprognostic (1.53e-2)"	"unprognostic (2.72e-1)"	"unprognostic (7.66e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.64e-2)"	"unprognostic (2.36e-2)"	19.5	15.6	15.1	14.7	17.1	32.2	17.5	35.2	18.9	19.9	20.3	21.1	19.6	18.4	24.9	15.7	24.6	18.6	20.2	39.3	15.3	11.0	21.7	36.2	19.7	15.7	16.0	13.4	24.9	31.3	30.7	16.9	24.8	14.3	18.8	19.2	25.0	18.3	18.4	79.7	23.9	29.6	23.7	13.8	22.1	23.7	16.7	17.8	27.7	26.9	27.9	26.1	20.5	20.4	6.6	9.3	53.9	9.9	8.5	8.6	7.7	15.1	17.4	26.6	20.5	23.1	18.7	53.5	23.1	39.2	30.6	34.8	13.6	12.5	15.9	11.1	35.8	9.7	28.0	20.5	31.9	27.7	21.9	21.4	21.0	12.6	23.4	20.8	20.3	17.2	20.7	31.5	25.6	21.9	15.5	41.8	29.5	25.9	26.7	15.3	27.0	23.7	21.6	23.4	20.0	18.3	22.9	8.3	17.5	18.9	18.3	12.3	30.4	27.5	15.7	21.1	20.1	17.6	25.7	32.6	51.8	34.2	18.2	24.3	22.4	11.3	9.7	18.4	7.4	9.9	7.5	6.6	7.3	7.2	9.3	6.3	7.5	7.6	53.9	8.5	9.6	4.2	8.6	7.7	15.1	17.1	35.2	18.9	15.3	11.0	16.0	13.4	14.3	17.8
RANBP2	"ADANE, ANE1, NUP358"	ENSG00000153201	"RAN binding protein 2"	P49792	2	108719481-108785811	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway"	"RNA-binding, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564"	Supported		Enhanced	"Nuclear membrane,Vesicles"				"Nuclear membrane, Vesicles"		"CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: , HPA049497: , HPA051675: , HPA067564: "	"unprognostic (2.51e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.22e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.28e-2)"	"unprognostic (9.30e-2)"	"unprognostic (5.47e-2)"	"unprognostic (2.91e-1)"	"unprognostic (4.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (4.23e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.62e-2)"	"unprognostic (8.74e-2)"	"unprognostic (3.08e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.53e-1)"	20.5	24.3	14.4	17.0	18.6	35.5	24.4	23.1	22.2	19.8	17.1	12.8	25.5	13.3	19.9	21.5	17.0	19.1	14.8	20.2	12.9	12.5	18.9	19.5	17.7	19.2	15.1	17.0	32.4	24.1	48.5	37.5	18.8	16.5	21.8	15.8	14.3	20.0	31.6	37.5	17.3	17.4	23.2	17.8	16.3	20.9	20.6	15.9	26.6	28.7	18.0	17.5	20.5	19.7	5.6	5.1	8.3	6.3	4.2	8.7	2.3	18.2	11.2	16.1	14.6	18.8	16.9	15.6	16.5	13.1	13.6	12.0	27.8	8.8	28.8	12.8	17.1	15.4	27.5	17.1	19.9	17.5	13.3	30.0	13.9	19.6	11.0	35.0	10.1	14.1	13.1	21.3	16.6	20.8	32.1	16.0	18.0	10.1	15.5	14.3	20.3	13.4	14.6	24.8	13.9	12.1	22.9	23.5	10.8	14.6	12.6	16.0	8.0	16.1	24.8	14.3	18.9	10.0	18.4	13.3	19.6	26.2	11.1	15.8	11.0	8.3	5.3	5.1	7.6	3.4	8.7	5.5	6.3	6.9	4.2	5.6	6.2	6.7	8.3	4.2	6.3	5.1	5.1	2.3	14.4	18.6	23.1	22.2	12.9	12.5	15.1	17.0	16.5	15.9
RANBP3		ENSG00000031823	"RAN binding protein 3"	Q9H6Z4	19	5916139-5978142	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043375, HPA043389"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA043375: AB_10959889, HPA043389: AB_10963696"	"unprognostic (1.81e-1)"	"unprognostic (1.18e-3)"	"unprognostic (3.61e-1)"	"prognostic favourable (1.22e-5)"	"unprognostic (4.24e-2)"	"unprognostic (1.42e-3)"	"unprognostic (5.44e-2)"	"unprognostic (3.90e-2)"	"unprognostic (3.58e-1)"	"unprognostic (1.08e-1)"	"prognostic favourable (4.14e-4)"	"unprognostic (2.27e-1)"	"unprognostic (3.80e-2)"	"unprognostic (2.91e-1)"	"unprognostic (5.15e-2)"	"prognostic favourable (8.14e-4)"	"unprognostic (1.06e-2)"	19.5	30.2	24.8	25.2	31.5	20.9	18.6	38.2	40.9	21.2	29.8	31.6	18.3	24.7	28.2	16.5	23.4	23.9	20.3	30.8	25.0	26.5	19.3	24.6	21.9	26.7	24.3	21.2	29.2	33.1	22.4	26.1	22.3	28.8	25.6	14.2	30.1	27.9	28.0	33.9	21.2	25.1	27.9	25.0	24.9	24.9	36.7	28.0	33.5	21.9	14.7	27.7	28.0	20.9	20.7	21.3	25.0	21.4	14.9	28.7	20.1	30.3	21.4	18.2	20.3	13.7	14.0	13.0	19.4	18.4	22.8	24.7	26.9	10.8	28.7	21.9	15.0	18.9	16.2	18.9	14.0	29.3	26.4	15.4	16.7	32.0	14.9	22.4	22.6	13.6	13.1	14.2	16.3	16.6	27.8	27.2	12.8	12.7	37.3	10.9	33.3	27.1	27.7	17.5	26.1	14.8	23.5	20.1	22.6	17.3	18.3	17.1	14.0	17.1	17.1	19.3	14.1	33.6	28.5	28.2	28.4	24.7	24.4	28.3	23.6	13.2	20.8	25.0	22.7	21.4	23.3	17.0	22.0	22.7	21.3	20.7	19.6	25.1	24.0	14.9	20.6	20.2	28.7	20.1	24.8	31.5	38.2	40.9	25.0	26.5	24.3	21.2	28.8	28.0
RAP1GDS1	SmgGDS	ENSG00000138698	"Rap1 GTPase-GDP dissociation stimulator 1"	P52306	4	98261384-98443861	"Cancer-related genes, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019060	Approved		Supported	Cytosol		120000	120000	Cytosol		"HPA019060: AB_1856068"	"unprognostic (8.12e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.69e-3)"	"unprognostic (1.66e-1)"	"unprognostic (9.11e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.57e-3)"	"unprognostic (3.44e-1)"	"unprognostic (6.31e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.60e-1)"	"prognostic favourable (2.00e-4)"	"unprognostic (7.11e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.76e-1)"	11.3	9.7	25.8	12.9	28.2	9.0	13.1	28.0	43.6	9.3	12.0	20.0	9.0	7.3	8.9	8.7	13.7	6.1	8.6	6.8	29.7	28.0	12.3	15.2	10.1	15.3	36.9	20.5	7.9	13.8	8.4	15.3	9.6	30.1	8.0	14.0	8.0	8.6	11.9	3.6	10.5	9.0	16.3	37.0	12.5	8.2	15.5	26.2	16.2	13.0	4.8	17.0	12.5	7.6	13.9	31.9	16.0	14.7	19.5	22.7	8.4	17.7	10.3	13.2	11.3	17.1	20.5	5.3	30.2	16.8	18.0	14.2	7.7	23.0	21.1	9.8	22.5	10.1	16.3	27.6	24.4	21.5	6.7	13.0	13.3	10.0	33.9	21.6	9.1	23.8	16.9	15.9	24.7	23.6	8.6	18.1	44.6	9.3	35.7	10.7	4.8	7.5	14.9	7.9	7.1	18.3	13.9	19.6	11.9	12.6	28.4	16.7	6.4	14.1	23.2	18.7	13.5	8.6	17.9	6.2	10.8	17.7	15.5	16.2	24.3	16.0	10.6	5.7	14.2	14.6	14.3	13.9	14.5	13.6	16.7	11.0	7.8	11.9	1.6	19.5	14.7	31.9	22.7	8.4	25.8	28.2	28.0	30.5	29.7	28.0	36.9	20.5	30.1	26.2
RARA	"NR1B1, RAR"	ENSG00000131759	"Retinoic acid receptor alpha"	P10276	17	40309192-40357643	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 63.1;SK-BR-3: 40.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 26.6"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA058282			Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA058282: "	"unprognostic (8.05e-3)"	"unprognostic (1.89e-1)"	"unprognostic (9.48e-3)"	"prognostic favourable (2.60e-4)"	"unprognostic (8.67e-3)"	"unprognostic (4.87e-3)"	"unprognostic (2.77e-1)"	"unprognostic (5.73e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.29e-3)"	"unprognostic (1.59e-2)"	"unprognostic (5.60e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.09e-2)"	27.6	13.5	5.0	18.6	7.6	32.3	23.7	11.5	15.2	30.2	29.6	5.0	16.8	18.0	23.8	23.9	17.3	23.3	30.2	24.3	5.9	6.1	14.6	24.0	32.0	23.4	4.6	7.8	50.0	9.3	7.4	18.1	16.6	6.5	22.9	8.5	26.8	12.1	32.7	43.1	14.3	31.6	18.6	3.7	31.1	14.3	21.8	2.9	9.7	16.3	15.4	20.2	31.5	20.3	1.0	6.1	26.6	9.3	2.5	2.6	1.9	5.0	11.9	3.6	6.0	7.0	10.8	3.6	4.2	6.3	6.2	4.0	8.2	4.4	2.7	6.6	9.4	14.9	4.1	9.9	3.5	20.2	6.1	7.7	6.0	8.0	11.3	2.7	24.4	15.1	2.9	6.5	8.3	9.1	4.8	5.9	6.9	63.1	1.7	9.4	3.1	3.8	3.6	21.1	10.2	3.6	4.0	1.5	12.2	8.9	40.1	12.2	37.8	11.1	10.6	7.7	13.2	13.5	4.5	14.2	4.7	2.3	12.9	5.5	22.8	8.7	4.2	15.7	1.6	6.9	2.6	1.0	1.7	1.7	6.1	0.9	0.8	1.3	26.6	2.5	9.3	1.8	1.4	1.9	5.0	7.6	11.5	15.2	5.9	6.1	4.6	7.8	6.5	2.9
RARB	"HAP, NR1B2, RRB2"	ENSG00000077092	"Retinoic acid receptor beta"	P10826	3	25174332-25597932	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Microphthalmia, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"retina: 39.1"	"Cell line enhanced"	"Detected in some"		"ASC diff: 9.9;HEK 293: 11.2;HUVEC TERT2: 9.3;WM-115: 25.6"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"basal ganglia: 22.6"	"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Region enriched"	"Detected in many"	9	"basal ganglia: 97.9"	"Low region specificity"	"Detected in all"			"CAB002617, HPA004174"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002617: , HPA004174: AB_1079744"	"unprognostic (2.04e-2)"	"unprognostic (3.53e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.56e-1)"	"unprognostic (6.72e-2)"	"unprognostic (1.30e-2)"	"unprognostic (2.70e-2)"	"unprognostic (2.43e-1)"	"unprognostic (4.71e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.86e-1)"	"prognostic favourable (3.43e-5)"	"unprognostic (9.24e-3)"	"unprognostic (2.28e-1)"	"unprognostic (9.99e-2)"	"unprognostic (6.56e-3)"	3.9	7.1	2.4	2.3	22.6	0.0	6.8	1.5	9.1	13.4	6.0	2.2	6.8	1.7	14.4	7.5	8.1	6.2	5.3	13.6	2.6	2.2	17.5	6.2	5.6	5.6	2.0	3.7	12.2	1.5	12.8	18.9	13.9	3.2	13.0	2.3	39.1	13.7	11.8	2.5	1.4	2.4	14.7	4.6	7.7	4.8	1.7	4.8	0.0	10.0	2.9	4.6	12.1	10.2	1.0	0.4	0.1	0.6	0.1	0.8	0.0	0.0	1.3	0.8	4.5	9.9	2.6	0.0	1.1	0.5	0.0	0.4	0.2	0.0	0.1	0.1	1.7	0.2	0.0	0.1	0.0	0.0	11.2	0.1	0.1	0.7	0.2	0.1	0.1	5.2	0.0	0.0	0.0	9.3	0.1	3.9	0.1	0.0	0.0	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.4	5.9	0.0	0.1	0.1	0.0	0.0	0.0	0.8	0.1	1.5	4.8	0.1	0.0	0.0	4.0	0.1	25.6	0.0	0.6	0.0	0.8	0.1	0.3	0.3	0.5	0.5	0.4	1.0	0.6	0.8	0.1	0.1	0.1	0.4	0.0	0.0	2.4	22.6	1.5	9.1	2.6	2.2	2.0	3.7	3.2	4.8
RARG	"NR1B3, RARC"	ENSG00000172819	"Retinoic acid receptor gamma"	P13631	12	53210567-53232980	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 49.4;skin 1: 52.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 33.2;MCF7: 35.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 17.0"	"Group enriched"	"Detected in all"	4	"dendritic cells: 5.6;T-cells: 17.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA053883	Supported		Supported	Nucleoplasm				Nucleoplasm		"HPA053883: AB_2682292"	"unprognostic (7.29e-2)"	"unprognostic (1.95e-2)"	"unprognostic (6.11e-2)"	"prognostic unfavourable (3.68e-6)"	"unprognostic (2.53e-1)"	"unprognostic (5.43e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.08e-2)"	"unprognostic (3.54e-3)"	"unprognostic (7.21e-3)"	"unprognostic (3.78e-3)"	"unprognostic (4.44e-2)"	"prognostic unfavourable (3.08e-6)"	"unprognostic (5.41e-3)"	"unprognostic (1.98e-2)"	"unprognostic (5.94e-3)"	"unprognostic (7.41e-2)"	4.8	5.0	2.7	7.0	3.6	1.3	10.8	6.3	3.8	26.8	6.3	1.8	7.3	1.0	14.6	6.0	49.4	10.6	8.6	6.9	3.0	1.4	3.7	1.9	7.4	6.7	2.4	2.3	12.6	2.7	4.2	2.8	4.4	1.6	11.3	3.4	10.3	9.5	10.6	2.6	52.1	3.0	9.7	1.5	4.7	6.0	3.9	1.7	2.3	7.3	30.6	26.8	10.9	19.8	1.8	5.6	1.5	2.5	1.7	17.0	2.9	7.2	8.0	1.8	16.9	18.8	16.2	0.5	7.6	16.6	10.0	7.8	2.7	33.2	0.1	4.1	30.5	24.4	6.1	14.6	2.5	1.9	3.1	1.0	6.1	2.3	7.9	0.0	3.0	11.9	21.4	9.5	2.1	4.2	0.2	3.2	3.9	35.0	0.4	0.3	5.4	14.1	2.3	0.6	5.8	2.9	12.0	1.5	7.6	15.4	16.7	10.1	14.5	0.4	4.5	12.0	5.6	7.9	0.4	1.5	0.8	0.5	14.7	1.2	16.9	1.5	2.5	0.7	6.6	0.8	17.0	1.8	5.7	4.8	5.6	0.6	4.8	4.1	0.0	1.7	0.0	0.4	1.5	2.9	2.7	3.6	6.3	3.8	3.0	1.4	2.4	2.3	1.6	1.7
RASA1	"CM-AVM, GAP, p120, p120GAP, p120RASGAP, RASA"	ENSG00000145715	"RAS p21 protein activator 1"	P20936	5	87267888-87391931	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	13	"placenta: 260.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007789, HPA036393, HPA064556"	Enhanced					7900	7900			"CAB007789: AB_598183, HPA036393: , HPA064556: "	"unprognostic (1.57e-1)"	"unprognostic (7.63e-2)"	"unprognostic (1.88e-3)"	"unprognostic (2.14e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.38e-2)"	"unprognostic (6.88e-2)"	"unprognostic (8.38e-3)"	"unprognostic (2.23e-1)"	"unprognostic (1.07e-2)"	"unprognostic (4.12e-3)"	"unprognostic (1.03e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.59e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.30e-3)"	12.4	8.8	12.3	8.9	12.8	6.4	11.4	17.3	16.3	11.3	8.1	8.6	9.3	6.9	12.4	11.4	10.2	9.5	9.3	7.2	12.0	10.9	8.7	6.5	8.4	9.2	10.1	13.8	15.9	8.2	20.3	12.2	260.6	9.3	8.0	9.8	9.6	10.6	9.6	6.9	9.7	10.0	9.0	9.4	13.7	7.4	14.4	10.0	10.7	14.4	5.7	9.6	11.3	9.8	2.0	1.3	3.1	2.6	8.1	3.5	1.1	11.5	6.5	11.3	7.3	9.6	14.2	8.8	18.5	12.0	11.4	18.9	4.3	30.6	7.5	4.5	20.2	5.4	5.2	15.0	34.7	7.3	4.2	5.6	5.6	4.7	9.7	4.1	6.7	8.0	9.6	32.1	18.2	15.9	3.1	16.2	39.3	7.0	5.0	6.1	5.9	12.1	6.2	25.7	11.1	9.9	10.0	6.9	7.5	6.8	8.8	9.7	7.9	6.4	23.5	14.6	6.4	7.5	23.0	5.7	5.9	7.6	21.3	8.5	10.4	3.1	1.3	1.4	2.0	2.6	3.5	1.4	2.4	1.9	1.1	2.0	2.1	1.9	1.7	8.1	2.4	1.3	3.0	1.1	12.3	12.8	17.3	16.3	12.0	10.9	10.1	13.8	9.3	10.0
RB1	"OSRC, PPP1R130, RB"	ENSG00000139687	"RB transcriptional corepressor 1"	P06400	13	48303726-48599436	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"MOLT-4: 57.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000095, CAB016687, HPA050082"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000095: , CAB016687: AB_1622010, HPA050082: "	"unprognostic (4.24e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.62e-2)"	"unprognostic (4.67e-2)"	"unprognostic (2.04e-2)"	"unprognostic (3.86e-1)"	"unprognostic (4.69e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavourable (6.92e-4)"	"unprognostic (4.06e-2)"	"unprognostic (9.40e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.79e-1)"	"unprognostic (9.99e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.70e-1)"	19.6	21.5	14.9	23.2	18.4	14.7	28.1	25.6	19.4	18.0	13.2	11.5	19.0	12.3	16.8	19.5	27.9	12.7	15.3	19.5	15.4	15.3	18.1	12.1	25.4	30.1	17.0	11.8	15.2	11.6	12.8	17.2	21.5	16.0	15.5	15.3	11.6	20.0	17.4	27.9	20.3	14.3	16.8	23.6	29.4	13.7	14.4	15.3	39.1	19.9	15.8	25.3	17.4	23.6	20.5	10.3	13.2	12.2	3.6	4.6	4.0	9.0	4.9	13.4	14.4	6.6	7.7	6.1	17.9	14.9	18.9	16.1	4.2	16.1	11.7	4.1	11.9	12.6	17.4	14.4	28.9	16.4	6.6	21.6	10.1	7.1	7.1	18.5	20.5	4.3	8.9	12.2	15.7	13.0	7.1	9.7	21.6	4.3	57.9	9.3	6.5	5.4	24.9	13.4	13.5	19.6	8.8	0.6	13.7	17.7	8.9	14.6	9.7	24.2	10.1	11.7	7.7	14.3	16.1	4.3	1.2	0.1	6.2	11.6	15.8	11.0	9.7	5.0	4.6	12.2	3.7	17.4	3.8	4.6	9.3	20.5	3.2	3.8	13.2	3.6	12.1	10.3	4.5	4.0	14.9	18.4	25.6	19.4	15.4	15.3	17.0	11.8	16.0	15.3
RBBP4	"lin-53, NURF55, RbAp48"	ENSG00000162521	"RB binding protein 4, chromatin remodeling factor"	Q09028	1	32651142-32686211	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA replication, Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB006264, HPA060710, HPA060724"	Supported		Enhanced	Nucleoplasm		27000	27000	Nucleoplasm		"CAB006264: AB_425651, HPA060710: , HPA060724: "	"unprognostic (1.18e-3)"	"unprognostic (1.79e-3)"	"unprognostic (2.96e-3)"	"unprognostic (1.82e-2)"	"prognostic favourable (9.23e-4)"	"unprognostic (1.62e-2)"	"prognostic unfavourable (1.89e-6)"	"unprognostic (1.24e-2)"	"prognostic unfavourable (6.45e-4)"	"unprognostic (1.57e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.36e-3)"	"unprognostic (3.05e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.29e-1)"	"unprognostic (1.88e-2)"	23.8	33.6	28.2	34.3	27.8	23.4	29.1	30.5	35.1	32.2	24.1	32.0	42.3	20.5	36.0	29.2	26.0	35.4	21.3	24.0	27.9	24.8	25.2	25.4	23.0	43.9	30.6	29.0	37.6	31.3	27.0	32.9	26.2	26.9	24.2	35.5	31.2	30.1	43.1	31.8	24.9	26.8	32.6	26.9	27.6	28.8	53.4	31.4	73.3	35.8	20.5	65.2	32.5	26.6	33.7	45.4	26.7	39.4	33.1	32.4	48.4	15.4	13.6	38.9	28.3	12.0	11.4	15.7	11.8	10.3	24.1	23.5	19.4	31.9	47.0	13.1	13.9	10.0	42.5	12.3	26.1	18.3	20.4	43.8	27.4	25.4	17.4	41.3	19.0	12.5	15.7	18.2	11.8	17.8	30.8	33.7	20.6	10.8	53.0	13.0	43.2	15.9	51.5	40.9	40.8	16.9	33.2	37.2	22.1	28.0	10.0	19.1	17.1	19.2	14.8	14.7	15.0	18.5	15.8	26.8	28.1	52.8	17.5	33.4	22.5	26.4	38.8	26.7	31.1	39.4	32.4	33.7	29.7	31.4	45.4	26.6	26.7	28.8	10.2	33.1	35.3	38.3	30.3	48.4	28.2	27.8	30.5	35.1	27.9	24.8	30.6	29.0	26.9	31.4
RBL1	"cp107, p107, PRB1"	ENSG00000080839	"RB transcriptional corepressor like 1"	P28749	20	36996349-37095995	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA054962, HPA056525"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA054962: AB_2682652, HPA056525: AB_2683165"	"unprognostic (1.97e-1)"	"unprognostic (2.47e-2)"	"unprognostic (1.30e-2)"	"unprognostic (3.70e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.51e-1)"	"unprognostic (6.25e-5)"	"unprognostic (6.91e-2)"	"unprognostic (7.19e-3)"	"unprognostic (1.20e-1)"	"unprognostic (4.49e-3)"	"unprognostic (3.23e-2)"	"prognostic unfavourable (2.52e-6)"	"unprognostic (3.15e-2)"	"unprognostic (2.75e-1)"	"unprognostic (1.47e-2)"	"unprognostic (1.26e-1)"	5.0	4.3	4.9	12.3	7.1	20.4	4.8	16.6	7.8	5.1	5.6	5.5	5.9	4.0	8.1	3.0	7.7	4.4	3.6	4.0	4.0	3.6	3.3	3.0	4.5	11.1	6.5	2.2	7.8	6.0	5.9	5.9	8.3	5.7	4.4	6.1	5.3	4.8	2.7	10.2	5.3	5.9	5.9	7.1	6.9	4.6	8.2	5.5	19.6	5.3	6.1	11.4	4.7	7.1	5.0	5.1	2.2	1.9	3.6	7.4	1.6	12.0	7.9	9.9	6.6	2.5	3.3	6.3	14.1	6.3	12.2	12.7	8.3	6.8	13.5	4.1	5.8	11.9	8.8	9.1	20.5	4.7	4.7	13.3	9.3	7.0	1.5	17.1	9.3	1.6	1.2	16.1	5.7	6.8	9.7	13.1	6.9	5.1	15.9	5.7	2.9	7.7	10.4	29.4	10.2	2.8	6.0	2.3	5.9	15.4	8.9	4.1	5.7	12.4	4.5	21.7	8.3	19.8	12.2	4.4	7.7	13.7	15.5	12.1	10.6	1.4	1.2	2.2	5.0	1.4	4.2	5.0	5.6	4.5	2.2	3.9	6.0	4.8	0.6	3.6	1.9	5.1	7.4	1.6	4.9	7.1	16.6	7.8	4.0	3.6	6.5	2.2	5.7	5.5
RBL2	"p130, Rb2"	ENSG00000103479	"RB transcriptional corepressor like 2"	Q08999	16	53433977-53491649	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016547, HPA019703"	Supported		Supported	Nucleoplasm,Nucleoli,Cytosol				"Nucleoplasm, Nucleoli"	Cytosol	"CAB016547: AB_785011, HPA019703: AB_1856106"	"unprognostic (1.51e-1)"	"unprognostic (4.38e-2)"	"unprognostic (4.00e-2)"	"unprognostic (1.26e-1)"	"unprognostic (6.88e-2)"	"unprognostic (6.43e-2)"	"unprognostic (5.03e-2)"	"unprognostic (2.46e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.11e-1)"	"unprognostic (4.70e-1)"	"unprognostic (8.12e-2)"	"prognostic favourable (3.57e-5)"	"unprognostic (9.57e-3)"	"unprognostic (1.02e-1)"	"unprognostic (8.70e-2)"	"unprognostic (7.51e-2)"	27.8	20.6	15.7	22.2	20.0	11.1	25.5	24.1	18.7	26.3	23.7	24.7	25.6	15.4	30.0	20.2	21.5	25.1	19.5	19.9	15.5	11.7	23.8	34.2	24.0	31.6	25.8	13.7	29.3	30.7	55.3	22.6	12.4	15.8	28.2	18.9	20.2	26.2	30.5	28.3	20.8	24.6	26.1	17.9	27.2	24.9	28.6	22.8	54.4	31.0	10.3	31.6	36.5	26.8	9.1	8.0	20.2	9.8	26.2	35.1	24.5	12.6	8.6	11.5	10.6	30.2	29.2	5.4	9.3	13.3	11.6	4.0	5.6	15.9	18.5	14.1	15.7	15.9	8.6	14.4	18.5	6.6	11.9	8.3	8.7	10.4	13.0	11.5	26.1	18.5	17.7	7.9	11.3	17.9	6.7	11.6	12.9	3.7	22.9	15.5	4.7	7.8	16.7	21.0	21.2	11.4	12.9	9.4	7.8	21.1	9.3	9.1	12.0	15.2	14.8	14.4	7.7	11.9	6.9	17.9	10.5	21.7	18.0	14.4	9.9	16.4	8.2	20.2	21.2	5.9	23.7	8.7	23.8	24.3	8.0	9.1	35.1	29.6	15.7	26.2	9.8	4.9	17.5	24.5	15.7	20.0	24.1	18.7	15.5	11.7	25.8	13.7	15.8	22.8
RBM10	"DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5"	ENSG00000182872	"RNA binding motif protein 10"	P98175	X	47144869-47186813	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA034972, HPA057372"	Approved		Enhanced	"Nuclear speckles"				"Nuclear speckles"		"HPA034972: AB_10602919, HPA057372: "	"unprognostic (9.07e-2)"	"prognostic favourable (6.71e-4)"	"unprognostic (7.83e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.47e-3)"	"unprognostic (8.11e-2)"	"unprognostic (9.86e-3)"	"unprognostic (1.76e-1)"	"prognostic favourable (2.86e-6)"	"unprognostic (1.18e-1)"	"unprognostic (6.23e-3)"	"unprognostic (3.33e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.40e-2)"	"unprognostic (1.20e-3)"	18.1	22.2	19.8	38.0	21.9	34.0	17.1	41.2	22.9	19.9	20.5	25.7	22.7	21.8	22.1	17.3	23.7	26.2	29.1	21.7	19.8	18.3	18.4	21.6	17.1	27.2	20.1	19.2	36.4	27.4	20.1	28.3	24.9	17.9	23.5	14.2	18.5	25.1	28.8	20.6	23.8	23.7	18.9	17.2	24.7	20.5	8.7	21.4	32.9	26.8	18.0	22.7	17.6	20.9	15.9	14.6	14.4	19.2	12.3	18.3	11.5	20.7	22.5	21.6	25.5	11.6	9.5	25.1	15.8	9.3	16.4	16.0	19.6	17.1	25.4	9.7	10.9	20.3	28.1	19.9	9.0	25.7	25.5	19.0	27.4	20.5	16.9	19.1	22.9	12.5	9.6	27.0	22.0	17.5	15.8	20.4	9.9	31.7	35.0	32.4	35.6	25.3	31.0	18.0	26.2	12.1	18.4	25.6	19.5	23.9	17.9	15.2	22.0	19.1	15.3	19.3	24.5	20.8	16.6	21.5	17.4	20.9	17.1	13.8	26.9	14.0	10.8	14.4	18.3	14.5	17.0	15.9	14.7	15.3	12.3	15.6	14.8	14.1	10.1	12.3	19.2	14.6	16.6	11.5	19.8	21.9	41.2	21.9	19.8	18.3	20.1	19.2	17.9	21.4
RBM15	"OTT, OTT1"	ENSG00000162775	"RNA binding motif protein 15"	Q96T37	1	110338506-110346681	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	RNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 48.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB015201, HPA019824, HPA049642"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB015201: , HPA019824: AB_1856113, HPA049642: "	"unprognostic (1.70e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.39e-2)"	"unprognostic (7.57e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.11e-2)"	"prognostic unfavourable (7.61e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.84e-2)"	"unprognostic (4.91e-2)"	"unprognostic (9.67e-2)"	"unprognostic (2.76e-2)"	"prognostic unfavourable (1.37e-4)"	"prognostic favourable (7.97e-4)"	"unprognostic (2.88e-1)"	"unprognostic (2.46e-2)"	"unprognostic (2.12e-1)"	8.5	7.6	6.3	12.2	7.6	48.7	7.9	18.6	8.3	6.6	8.8	7.6	8.3	7.3	8.5	7.2	8.0	7.3	6.6	8.8	5.2	4.3	6.3	11.0	10.5	13.7	8.3	6.0	8.6	7.5	7.1	8.1	7.1	5.9	5.7	5.7	8.1	7.4	6.4	17.2	7.2	11.3	5.5	5.0	12.5	8.3	14.0	7.9	21.8	7.0	5.3	13.4	6.5	8.6	10.5	4.8	9.8	6.9	5.0	9.9	5.5	7.0	7.7	6.9	7.1	4.4	4.6	10.9	3.7	4.9	5.9	7.8	9.4	6.5	13.3	6.0	4.2	10.0	10.8	9.4	8.8	13.8	10.0	10.8	11.7	6.8	6.2	11.7	11.5	4.2	6.6	8.2	7.7	6.3	15.2	23.4	5.9	7.2	10.5	9.2	14.8	4.3	12.5	10.5	9.1	4.8	7.1	8.4	4.2	8.2	10.3	7.9	7.2	14.1	4.3	5.7	10.2	6.1	6.8	18.0	9.1	28.9	8.5	11.8	7.0	8.2	6.9	9.4	7.0	6.0	9.9	10.5	7.7	6.0	4.8	10.0	6.8	8.2	9.8	5.0	6.4	4.7	7.5	5.5	6.3	7.6	18.6	8.3	5.2	4.3	8.3	6.0	5.9	7.9
RBM6	"3G2, DEF-3, DEF3, g16, NY-LU-12"	ENSG00000004534	"RNA binding motif protein 6"	P78332	3	49940007-50100045	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026272, HPA027164"	Enhanced		Approved	"Nuclear speckles,Cytoplasmic bodies"				"Nuclear speckles"	"Cytoplasmic bodies"	"HPA026272: AB_1847592, HPA027164: AB_1847593"	"unprognostic (3.81e-3)"	"unprognostic (2.13e-1)"	"unprognostic (3.52e-2)"	"unprognostic (2.40e-2)"	"unprognostic (4.53e-2)"	"unprognostic (2.88e-2)"	"unprognostic (1.40e-2)"	"unprognostic (7.97e-3)"	"unprognostic (8.84e-3)"	"unprognostic (5.09e-2)"	"prognostic favourable (1.41e-4)"	"unprognostic (4.31e-2)"	"prognostic unfavourable (8.83e-4)"	"unprognostic (7.82e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.45e-1)"	"prognostic favourable (5.13e-5)"	24.4	30.2	30.2	51.3	37.1	30.0	25.1	49.4	41.1	31.2	31.0	28.9	38.5	30.3	51.4	34.3	21.8	28.8	32.6	25.3	32.1	19.8	29.2	30.6	26.8	39.8	38.1	26.0	42.6	35.9	41.9	36.9	21.9	30.5	40.1	29.8	25.6	28.1	38.3	25.3	35.9	32.4	36.7	40.9	42.6	28.0	29.7	38.0	24.9	32.6	21.9	35.9	25.1	36.6	12.8	9.9	14.7	8.6	7.3	15.6	5.9	9.6	6.1	25.1	16.7	25.7	14.1	8.9	16.3	14.2	14.4	15.2	10.6	10.9	49.5	9.6	16.2	8.0	21.4	14.4	18.3	19.8	8.0	22.9	14.1	13.7	14.6	24.1	23.8	13.1	17.8	16.3	18.4	18.1	18.8	12.5	13.7	9.1	22.6	35.8	20.1	11.2	8.7	10.8	12.6	14.3	18.8	9.9	17.9	14.9	10.8	10.2	8.4	19.0	16.8	14.4	17.2	11.7	16.5	17.2	40.7	29.8	8.3	20.2	14.1	14.7	8.6	5.0	15.6	4.7	12.1	12.8	10.2	8.5	8.8	11.9	10.5	11.5	6.1	7.3	7.7	9.9	6.7	5.9	30.2	37.1	49.4	41.1	32.1	19.8	38.1	26.0	30.5	38.0
RBMX	"hnRNP-G, HNRNPG, RNMX"	ENSG00000147274	"RNA binding motif protein, X-linked"	P38159	X	136848004-136880764	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Transcription"	"Activator, Repressor, Ribonucleoprotein, RNA-binding"	"Cancer-related genes, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA057707	Supported		Approved	Nucleoplasm				Nucleoplasm		"HPA057707: "	"unprognostic (1.53e-1)"	"unprognostic (1.52e-3)"	"unprognostic (2.12e-3)"	"unprognostic (1.14e-2)"	"unprognostic (2.62e-2)"	"unprognostic (8.13e-2)"	"prognostic unfavourable (5.16e-6)"	"unprognostic (5.59e-2)"	"unprognostic (1.05e-2)"	"unprognostic (1.68e-2)"	"unprognostic (4.87e-2)"	"unprognostic (2.32e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.57e-1)"	"unprognostic (7.65e-2)"	"unprognostic (6.27e-2)"	"unprognostic (4.64e-3)"	31.0	25.0	30.6	57.1	41.1	48.0	40.6	28.7	33.0	44.2	28.3	32.5	32.7	24.6	45.9	31.7	26.7	38.9	22.1	31.4	26.5	18.0	25.6	20.9	34.4	64.6	34.0	29.3	81.9	39.1	30.1	30.1	25.3	30.5	28.4	33.4	27.5	29.9	29.4	50.0	27.6	27.3	43.0	44.2	27.4	30.1	23.6	29.2	70.1	31.5	34.4	44.8	36.1	33.4	47.1	41.9	25.0	44.9	39.4	60.7	62.9	39.9	43.7	80.1	35.6	20.0	34.0	46.8	39.9	43.5	55.3	58.7	46.6	40.2	72.8	41.3	28.5	26.8	85.0	41.7	64.1	31.4	40.0	55.7	43.0	49.6	17.6	60.7	51.3	27.8	20.2	43.0	60.3	44.5	49.9	37.4	44.9	50.9	88.6	41.0	50.8	36.6	73.7	53.6	44.9	41.0	47.9	46.8	50.6	31.8	28.8	36.9	33.1	41.0	28.2	31.4	34.1	21.7	50.7	26.8	35.7	77.1	22.4	44.4	42.7	25.0	37.5	20.8	36.4	44.9	50.3	47.1	47.4	43.1	41.9	45.0	60.7	49.6	6.0	39.4	39.2	25.4	46.8	62.9	30.6	41.1	28.7	33.0	26.5	18.0	34.0	29.3	30.5	29.2
RBP4		ENSG00000138207	"Retinol binding protein 4"	P02753	10	93591687-93601744	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Sensory transduction, Transport, Vision"		"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	23	"liver: 897.1"	"Cell line enriched"	"Detected in some"	4	"Hep G2: 151.8"	"Cancer enriched"	"Detected in all"	27	"liver cancer: 3135.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	14	"classical monocyte: 1.2;myeloid DC: 1.5"	"Group enriched"	"Detected in many"	14	"dendritic cells: 1.5;monocytes: 1.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001641, CAB004555"	Supported				"Secreted to blood"	420000000000	420000000000			"CAB004555: AB_670938, HPA001641: AB_1079795"	"unprognostic (9.42e-3)"	"unprognostic (3.40e-2)"	"unprognostic (1.90e-1)"	"prognostic unfavourable (1.50e-4)"	"unprognostic (2.60e-2)"	"unprognostic (6.69e-4)"	"prognostic favourable (1.74e-8)"	"unprognostic (2.39e-1)"	"unprognostic (5.76e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.26e-1)"	"unprognostic (3.44e-1)"	"unprognostic (7.14e-3)"	"unprognostic (9.88e-3)"	"unprognostic (2.31e-1)"	"unprognostic (1.03e-1)"	"unprognostic (8.60e-2)"	39.0	2.0	1.4	2.4	3.1	0.3	27.0	0.0	2.1	0.3	1.8	0.0	0.1	0.5	0.4	0.4	0.3	0.4	2.1	1.2	1.4	2.2	7.9	897.1	1.5	1.0	0.2	1.1	0.5	4.7	0.3	28.3	1.8	0.4	0.9	0.6	5.6	1.8	0.5	0.4	0.4	0.6	0.3	0.1	0.3	0.7	0.4	0.0	0.0	0.3	0.5	0.2	0.6	1.6	0.0	1.5	0.0	1.2	0.0	0.0	0.4	0.0	2.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	36.6	0.0	0.2	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.1	151.8	0.0	1.2	0.0	2.7	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	1.0	0.2	17.1	0.0	1.0	0.0	0.0	0.0	0.1	0.0	1.3	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.1	0.0	0.5	0.0	0.4	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.4	3.1	0.0	2.1	1.4	2.2	0.2	1.1	0.4	0.0
RECQL4	RecQ4	ENSG00000160957	"RecQ like helicase 4"		8	144511288-144517845	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Tissue enhanced"	"Detected in many"		"bone marrow: 21.0;lymphoid tissue: 18.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Group enriched"	"Detected in many"	14	"B-cells: 1.9;monocytes: 1.0;T-cells: 1.6"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB017800, HPA025821"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB017800: , HPA025821: AB_1856168"	"unprognostic (5.92e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.17e-2)"	"unprognostic (3.17e-2)"	"prognostic unfavourable (1.91e-4)"	"unprognostic (1.12e-2)"	"unprognostic (4.12e-2)"	"unprognostic (7.53e-2)"	"unprognostic (2.65e-2)"	"unprognostic (4.26e-2)"	"unprognostic (1.12e-3)"	"unprognostic (8.82e-3)"	"unprognostic (1.74e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.34e-1)"	2.0	1.6	2.6	12.3	5.6	21.0	2.8	11.5	3.7	1.8	4.3	1.5	1.6	5.6	2.5	4.9	9.4	1.5	1.9	1.9	2.3	1.7	1.6	1.9	1.6	5.9	1.5	2.2	1.9	3.5	0.3	2.4	2.7	2.2	7.7	1.5	1.4	5.4	0.9	2.1	9.4	4.8	1.1	1.7	4.7	3.0	18.1	1.8	18.9	2.5	5.3	8.0	1.6	1.8	1.9	0.1	0.0	1.0	0.0	1.6	0.2	10.3	18.5	8.7	18.2	0.5	0.8	15.2	10.5	1.9	7.8	6.6	18.2	15.3	7.1	7.0	1.7	12.6	5.7	4.5	2.1	12.4	21.8	25.5	31.7	13.5	0.1	6.4	21.2	1.1	0.6	8.7	1.7	2.1	25.3	9.2	2.6	32.0	23.5	17.5	6.0	22.2	24.6	6.8	11.8	2.1	11.2	17.1	10.3	14.2	11.9	3.7	14.5	14.2	2.9	12.6	38.3	15.1	19.3	5.1	5.4	11.9	7.3	20.0	12.6	0.0	0.1	0.0	1.1	1.0	0.0	1.9	0.5	1.1	0.1	0.0	0.9	1.6	0.0	0.0	0.0	0.1	0.0	0.2	2.6	5.6	11.5	3.7	2.3	1.7	1.5	2.2	2.2	1.8
REL	"c-Rel, I-Rel"	ENSG00000162924	"REL proto-oncogene, NF-kB subunit"	Q04864	2	60881521-60931610	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 26.6;U-698: 51.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB004404	Uncertain									"CAB004404: AB_670194"	"unprognostic (2.77e-1)"	"unprognostic (2.05e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.23e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.15e-2)"	"unprognostic (2.15e-1)"	"unprognostic (5.87e-2)"	"unprognostic (4.38e-2)"	"unprognostic (4.37e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.91e-2)"	"unprognostic (3.53e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.66e-2)"	11.2	4.7	3.5	25.9	5.4	35.1	7.7	9.8	5.0	9.7	8.4	4.3	6.2	4.8	8.7	6.6	11.9	6.9	10.1	5.7	3.2	3.1	4.5	8.0	20.5	15.3	5.5	1.8	13.3	7.1	10.8	9.1	6.3	4.7	10.8	5.3	6.0	7.9	6.9	5.0	14.2	9.3	7.7	10.6	22.5	6.0	5.0	5.2	15.3	7.2	6.4	23.8	21.3	14.1	20.8	9.5	11.2	12.9	6.5	7.2	5.5	3.0	1.8	1.4	1.8	1.1	1.1	3.1	1.0	1.6	1.0	1.2	1.3	2.6	26.6	2.6	0.9	3.6	2.4	1.7	2.1	7.2	2.4	2.7	2.8	1.4	0.6	5.3	3.2	1.0	4.6	2.1	3.3	2.4	3.5	1.7	0.7	1.6	3.8	2.1	1.7	0.7	5.4	3.9	1.1	1.1	12.0	1.3	1.5	3.0	3.3	0.9	1.9	2.3	2.6	2.2	2.5	1.5	1.5	2.3	1.0	51.6	1.3	4.6	1.1	6.5	9.6	6.0	7.2	10.9	5.0	14.4	3.8	5.5	9.5	20.8	2.4	5.4	11.2	6.5	12.9	6.7	4.6	5.5	3.5	5.4	9.8	5.0	3.2	3.1	5.5	1.8	4.7	5.2
RELA	"NFKB3, p65"	ENSG00000173039	"RELA proto-oncogene, NF-kB subunit"	Q04206	11	65653596-65663094	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004264, CAB005030, HPA063461"	Supported		Enhanced	Cytosol				Cytosol		"CAB004264: AB_628017, CAB005030: AB_562171, HPA063461: "	"unprognostic (9.17e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.04e-1)"	"unprognostic (3.22e-1)"	"unprognostic (7.67e-2)"	"unprognostic (5.39e-2)"	"prognostic unfavourable (9.18e-4)"	"unprognostic (1.30e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.33e-1)"	"unprognostic (6.03e-2)"	"unprognostic (2.37e-1)"	"prognostic unfavourable (5.66e-4)"	"unprognostic (2.78e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.81e-2)"	"unprognostic (2.53e-1)"	36.2	23.1	21.4	27.6	32.0	50.2	37.8	21.5	28.2	35.6	32.3	22.9	23.6	23.6	36.9	26.8	36.4	32.8	33.6	28.9	21.1	12.9	28.4	38.5	37.7	30.8	35.6	13.3	51.9	29.0	27.3	19.3	27.1	22.6	31.1	19.7	23.9	32.8	39.2	46.5	35.2	26.7	33.5	29.5	38.1	31.8	20.6	30.1	34.3	26.3	30.6	36.4	54.7	38.8	15.2	13.2	18.3	14.4	21.3	23.3	12.4	26.1	26.9	12.0	16.7	19.2	18.7	12.2	20.1	24.4	23.2	18.8	12.2	26.6	19.8	33.8	28.2	23.4	13.8	24.4	16.4	23.3	19.9	21.8	20.1	17.7	21.2	16.1	30.9	21.5	24.1	25.8	30.6	28.1	21.8	23.1	18.6	34.9	29.2	13.6	7.8	23.7	24.4	11.8	29.6	19.4	23.7	9.9	22.8	17.2	27.0	26.8	31.4	10.6	38.3	25.1	21.5	38.3	19.1	35.0	32.2	21.1	28.4	11.1	23.9	10.5	11.3	15.1	20.5	14.4	23.3	15.2	18.2	20.4	13.2	13.7	17.3	18.2	18.3	21.3	12.5	13.1	17.8	12.4	21.4	32.0	21.5	28.2	21.1	12.9	35.6	13.3	22.6	30.1
RELB	REL-B	ENSG00000104856	"RELB proto-oncogene, NF-kB subunit"	Q01201	19	45001430-45038198	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 25.0;HDLM-2: 31.8;U-698: 26.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 14.5"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007753, HPA040506"	Approved		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB007753: AB_562340, HPA040506: "	"prognostic favourable (1.55e-4)"	"unprognostic (1.20e-1)"	"unprognostic (7.13e-2)"	"unprognostic (5.52e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.41e-2)"	"unprognostic (1.71e-2)"	"unprognostic (4.30e-2)"	"unprognostic (5.81e-3)"	"unprognostic (1.02e-3)"	"unprognostic (6.01e-2)"	"unprognostic (6.48e-2)"	"prognostic unfavourable (2.99e-6)"	"unprognostic (2.68e-2)"	"unprognostic (4.69e-2)"	"unprognostic (2.09e-1)"	"unprognostic (2.20e-2)"	8.0	6.8	2.2	27.6	3.6	27.8	6.8	1.2	3.1	4.9	12.2	2.1	1.6	8.8	8.5	4.7	6.4	5.2	10.9	11.9	1.8	1.6	10.1	7.4	12.8	18.2	3.6	0.9	7.8	12.3	1.9	2.1	4.7	2.8	9.9	3.4	3.6	7.3	4.8	8.1	8.3	13.0	8.4	3.9	17.2	8.3	3.7	1.7	17.7	5.6	7.2	24.8	8.8	6.1	8.2	3.9	14.5	5.0	2.1	2.2	1.7	8.7	5.3	0.5	2.3	1.1	3.9	1.8	1.6	11.4	2.5	4.0	1.8	9.7	25.0	4.6	2.6	4.0	0.2	3.6	2.1	31.8	0.8	0.9	0.3	1.0	10.2	1.9	14.9	6.4	1.5	5.1	6.0	1.6	0.2	16.3	0.9	2.1	0.4	5.9	0.8	0.9	1.9	1.3	3.0	4.1	13.6	0.0	0.8	1.6	4.7	4.5	1.6	4.8	5.1	6.0	3.0	2.2	5.8	20.6	12.1	26.8	6.6	0.7	3.3	0.0	5.0	2.1	1.4	3.2	2.1	8.2	2.2	2.0	3.6	7.9	1.8	0.9	14.5	2.1	2.6	3.9	1.1	1.7	2.2	3.6	1.2	3.1	1.8	1.6	3.6	0.9	2.8	1.7
RET	"CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51"	ENSG00000165731	"Ret proto-oncogene"	P07949	10	43077027-43130351	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 63.9"	"Cell line enhanced"	"Detected in some"		"MCF7: 17.6;NB-4: 11.6;SH-SY5Y: 89.7;THP-1: 26.8"	"Cancer enhanced"	"Detected in many"		"breast cancer: 11.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 6.7"	"Group enriched"	"Detected in many"	13	"dendritic cells: 2.1;monocytes: 6.7"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	6	"midbrain: 95.5"	"CAB002581, HPA008356, HPA008495"	Approved	Supported	Approved	"Golgi apparatus,Plasma membrane,Cytosol"		260000	260000	"Golgi apparatus, Cytosol"	"Plasma membrane"	"CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: "	"unprognostic (7.94e-2)"	"unprognostic (3.68e-2)"	"unprognostic (4.49e-1)"	"prognostic unfavourable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (9.13e-4)"	"unprognostic (1.27e-2)"	"unprognostic (3.62e-2)"	"unprognostic (2.86e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.54e-3)"	"unprognostic (4.43e-1)"	"unprognostic (9.35e-5)"	"unprognostic (1.64e-3)"	"unprognostic (8.28e-2)"	"unprognostic (3.67e-3)"	"unprognostic (2.02e-2)"	1.8	15.2	1.1	1.8	1.3	0.7	1.2	4.1	9.0	1.9	3.1	0.9	1.1	1.5	0.9	0.6	1.2	0.7	1.0	1.2	1.5	5.8	1.0	11.7	0.7	0.8	17.5	1.2	0.8	1.3	63.9	6.3	0.8	16.8	2.2	1.5	2.8	13.6	2.0	4.5	1.1	2.6	1.1	2.8	0.6	2.1	2.0	0.0	0.1	0.8	5.1	0.6	1.9	1.4	0.2	2.1	0.0	6.7	0.0	0.3	0.4	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	17.6	0.0	11.6	2.1	0.0	0.0	0.0	0.0	0.0	0.0	1.3	89.7	0.0	0.0	0.0	1.2	26.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.2	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	6.7	2.1	0.3	0.4	1.1	1.3	4.1	9.0	1.5	5.8	17.5	1.2	16.8	0.0
RHEB	RHEB2	ENSG00000106615	"Ras homolog, mTORC1 binding"	Q15382	7	151466012-151520120	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							CAB019436	Uncertain					24000	24000			"CAB019436: AB_2178777"	"unprognostic (2.22e-2)"	"unprognostic (2.29e-2)"	"unprognostic (2.25e-2)"	"unprognostic (9.47e-2)"	"unprognostic (2.65e-2)"	"unprognostic (3.08e-3)"	"prognostic unfavourable (9.08e-5)"	"unprognostic (9.37e-2)"	"unprognostic (4.76e-3)"	"unprognostic (9.76e-3)"	"unprognostic (1.85e-3)"	"unprognostic (3.67e-2)"	"unprognostic (2.36e-3)"	"unprognostic (3.04e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.91e-1)"	"unprognostic (3.15e-1)"	21.8	37.2	30.9	15.1	32.4	23.8	28.0	21.1	34.6	16.5	22.3	14.6	26.7	13.3	24.2	44.4	18.3	15.4	14.9	26.2	31.4	29.3	25.0	27.4	19.8	9.8	28.9	18.2	18.7	20.4	19.0	48.6	37.0	27.3	21.0	16.1	24.8	20.4	27.1	34.2	11.5	13.4	30.0	29.7	15.2	17.1	15.8	25.4	10.8	40.6	12.8	11.6	19.6	14.1	16.5	32.2	30.9	24.3	23.5	30.1	26.0	57.1	17.5	31.0	29.4	38.7	31.8	23.4	42.3	37.4	35.6	43.5	25.1	62.4	14.8	66.7	37.4	19.5	22.2	20.4	46.3	15.6	17.1	12.6	21.4	18.7	60.5	23.3	20.7	24.3	32.8	28.3	38.2	27.4	39.0	68.9	49.0	37.0	32.9	33.4	50.8	25.5	16.0	27.3	29.8	41.3	20.6	29.8	37.5	43.0	41.8	47.8	15.6	29.3	29.9	28.2	11.7	48.6	68.0	25.9	35.3	21.3	68.2	43.8	76.2	22.7	24.3	30.9	18.5	20.6	30.1	16.5	25.7	23.1	18.4	15.1	18.8	23.2	23.9	23.5	22.3	32.2	24.9	26.0	30.9	32.4	21.1	34.2	31.4	29.3	28.9	18.2	27.3	25.4
RHOA	"ARH12, ARHA, Rho12, RhoA, RHOH12"	ENSG00000067560	"Ras homolog family member A"	P61586	3	49359145-49412998	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"	"Cell cycle, Cell division, Host-virus interaction"	Hydrolase	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005052	Approved		Supported	"Plasma membrane,Cytosol"		65000000	65000000	"Plasma membrane, Cytosol"		"CAB005052: AB_562216"	"unprognostic (1.50e-1)"	"unprognostic (3.38e-1)"	"prognostic favourable (3.08e-4)"	"unprognostic (8.75e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.24e-1)"	"prognostic unfavourable (9.15e-4)"	"unprognostic (1.39e-1)"	"unprognostic (8.83e-2)"	"unprognostic (9.44e-3)"	"unprognostic (2.21e-2)"	"unprognostic (4.29e-2)"	"prognostic favourable (3.21e-6)"	"unprognostic (5.14e-2)"	"unprognostic (7.50e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.52e-2)"	141.1	89.5	63.0	79.8	60.6	91.4	93.1	34.3	77.3	80.3	79.1	100.4	48.9	63.6	84.4	66.4	116.7	67.8	74.2	72.5	57.6	54.8	104.0	80.7	104.6	102.4	74.0	43.8	102.7	64.9	45.8	48.2	105.3	68.8	76.0	80.3	81.6	66.5	72.0	86.0	73.9	90.8	88.9	97.3	116.0	73.4	57.3	60.3	127.1	108.1	80.1	99.8	103.4	75.7	42.6	78.4	124.2	125.7	38.3	50.5	151.5	54.9	42.4	53.2	57.0	61.1	92.6	41.6	119.6	76.7	83.6	77.2	35.9	57.6	80.6	34.4	143.6	31.3	58.4	65.2	85.9	62.1	34.8	77.0	57.0	42.1	65.5	75.8	57.7	72.3	46.4	68.4	55.1	107.0	41.0	50.7	99.1	26.2	82.6	74.0	50.8	54.0	38.2	53.5	63.4	72.3	62.8	19.5	44.4	71.8	52.0	53.8	33.7	85.5	115.5	67.1	60.8	88.6	86.0	50.4	102.2	92.6	65.5	74.7	76.7	52.5	99.7	106.8	49.1	125.7	41.6	42.6	41.4	47.6	78.4	37.5	32.2	40.1	124.2	38.3	120.4	58.7	50.5	151.5	63.0	60.6	34.3	77.3	57.6	54.8	74.0	43.8	68.8	60.3
RHOB	"ARH6, ARHB, MST081, RhoB, RHOH6"	ENSG00000143878	"Ras homolog family member B"	P62745	2	20447074-20449445	"Cancer-related genes, Predicted intracellular proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Protein transport, Transport"	"Developmental protein"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 49.6;RPTEC TERT1: 77.0;SK-BR-3: 94.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 11.9;neutrophil: 15.4"	"Group enriched"	"Detected in many"	13	"granulocytes: 15.4;monocytes: 8.8"	"Low region specificity"	"Detected in all"																		"unprognostic (9.66e-3)"	"unprognostic (5.57e-3)"	"unprognostic (8.29e-2)"	"unprognostic (6.48e-2)"	"unprognostic (2.85e-1)"	"unprognostic (9.16e-3)"	"unprognostic (5.41e-3)"	"unprognostic (4.91e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.22e-2)"	"unprognostic (3.29e-1)"	"unprognostic (2.13e-2)"	"prognostic favourable (4.23e-4)"	"unprognostic (5.71e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.01e-2)"	"unprognostic (2.49e-2)"	122.0	153.1	26.7	25.6	38.9	18.7	80.8	25.5	40.6	74.2	69.5	49.4	80.8	11.9	53.8	52.8	46.2	76.9	78.6	41.3	27.4	28.4	38.5	171.9	59.9	14.4	49.8	25.9	80.4	22.5	6.8	16.3	46.6	44.1	67.1	23.8	32.2	28.9	132.3	60.8	41.4	21.9	119.5	74.0	24.0	57.9	32.2	44.5	4.4	30.5	32.0	5.9	83.0	41.7	0.2	0.9	15.4	8.8	0.6	0.4	0.6	4.6	6.9	13.4	3.2	34.8	8.3	19.0	22.0	8.0	9.8	3.3	4.4	5.4	0.0	2.3	11.1	2.6	0.2	4.5	3.5	5.3	14.4	0.2	19.8	36.0	9.1	0.0	14.5	15.3	15.7	5.8	7.7	49.6	1.3	8.5	5.9	12.5	0.2	1.7	5.9	2.9	1.2	6.0	8.3	77.0	10.9	10.9	6.7	4.6	94.2	12.7	16.4	1.1	29.4	4.4	10.4	1.8	8.3	16.2	2.3	0.0	1.1	0.0	4.0	3.3	1.8	11.9	0.4	7.8	0.0	0.1	0.0	0.3	0.9	0.2	0.0	0.1	15.4	0.6	8.8	0.0	0.0	0.6	26.7	38.9	25.5	40.1	27.4	28.4	49.8	25.9	44.1	44.5
RHOC	"ARH9, ARHC, RhoC"	ENSG00000155366	"Ras homolog family member C"	P08134	1	112701106-112707434	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"WM-115: 203.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 129.9"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051461	Uncertain					54000000	54000000			"HPA051461: "	"unprognostic (2.31e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-1)"	"unprognostic (8.34e-2)"	"unprognostic (1.74e-1)"	"prognostic unfavourable (2.68e-4)"	"unprognostic (2.08e-2)"	"unprognostic (9.90e-2)"	"unprognostic (1.40e-2)"	"unprognostic (6.79e-3)"	"unprognostic (3.95e-2)"	"prognostic unfavourable (3.65e-5)"	"unprognostic (1.26e-1)"	"unprognostic (1.76e-1)"	"unprognostic (3.08e-2)"	"unprognostic (2.51e-3)"	56.5	36.0	31.3	23.2	28.6	2.8	46.2	11.1	18.2	48.5	71.0	19.2	46.7	53.6	47.4	110.1	51.3	32.4	58.1	79.2	21.7	23.8	88.3	45.0	63.3	21.8	30.1	14.6	57.6	24.2	89.6	21.2	67.4	24.9	47.8	49.9	37.9	27.0	58.3	29.9	28.4	122.4	48.6	21.6	54.6	28.0	41.5	17.7	15.8	43.1	28.0	17.6	59.6	43.0	6.4	24.6	1.8	129.9	32.5	23.1	25.5	60.2	24.9	14.8	16.6	27.9	49.3	16.8	55.2	68.3	40.3	34.1	19.8	18.4	0.8	23.0	80.4	17.3	10.9	50.3	39.3	14.4	6.0	7.0	16.6	15.9	46.7	1.2	32.4	57.7	35.4	64.5	44.7	103.7	14.0	12.8	72.9	32.2	3.0	4.8	4.0	41.5	5.1	17.7	2.7	46.4	17.2	0.7	6.3	27.5	18.2	34.9	38.3	5.1	87.6	54.6	37.5	73.4	40.1	8.4	7.0	2.6	61.5	4.8	203.5	0.1	7.0	0.1	23.1	77.2	15.4	4.8	4.6	9.4	24.6	6.4	1.1	7.2	1.8	32.5	129.9	18.4	4.9	25.5	31.3	28.6	11.1	18.2	21.7	23.8	30.1	14.6	24.9	17.7
RHOH	"ARHH, RhoH, TTF"	ENSG00000168421	"Ras homolog family member H"	Q15669	4	40191053-40246967	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 54.8;lymphoid tissue: 94.7"	"Cell line enhanced"	"Detected in some"		"Daudi: 35.6;HMC-1: 27.4;MOLT-4: 49.6;U-266/70: 19.2;U-266/84: 15.4;U-698: 32.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA030345, HPA061314"	Uncertain		Approved	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"HPA030345: AB_10601607, HPA061314: "	"unprognostic (4.00e-2)"	"unprognostic (1.83e-4)"	"unprognostic (1.24e-2)"	"unprognostic (2.22e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.16e-1)"	"unprognostic (2.73e-2)"	"unprognostic (2.30e-2)"	"unprognostic (4.30e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.31e-6)"	"unprognostic (2.96e-1)"	"unprognostic (3.91e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.44e-2)"	1.8	0.6	0.6	33.8	1.1	21.7	5.2	0.4	0.4	1.3	2.4	0.5	0.4	1.6	2.0	0.9	2.5	1.5	4.1	1.1	0.6	0.7	1.6	1.7	4.8	43.2	0.8	0.2	0.7	0.8	0.0	0.9	0.3	0.8	2.1	2.0	1.0	7.8	0.6	0.5	1.2	15.1	0.7	1.2	33.1	2.7	0.7	0.6	94.7	1.6	1.9	41.0	5.1	1.5	41.2	4.7	32.2	0.2	12.3	54.8	21.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	35.6	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	5.3	0.0	0.0	0.0	5.8	27.4	0.4	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	49.6	3.7	0.6	0.1	5.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.6	0.1	0.1	0.0	0.1	0.0	0.0	19.2	15.4	32.9	0.0	1.2	0.0	32.2	0.2	29.6	21.6	0.1	19.4	30.5	34.6	29.1	0.3	41.2	54.8	43.3	1.6	12.3	0.2	4.7	47.0	21.1	0.6	1.1	0.4	0.4	0.6	0.7	0.8	0.2	0.8	0.6
RIT1	"MGC125864, MGC125865, RIBB, RIT, ROC1"	ENSG00000143622	"Ras like without CAAX 1"	Q92963	1	155897808-155911404	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA053249	Approved									"HPA053249: "	"unprognostic (1.84e-1)"	"unprognostic (1.07e-1)"	"unprognostic (7.27e-2)"	"unprognostic (3.66e-2)"	"unprognostic (1.35e-2)"	"unprognostic (3.11e-2)"	"prognostic unfavourable (8.64e-6)"	"unprognostic (3.80e-2)"	"unprognostic (4.99e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.45e-2)"	"unprognostic (2.19e-2)"	"unprognostic (9.22e-3)"	"unprognostic (4.82e-2)"	"unprognostic (3.74e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.33e-3)"	16.4	12.3	11.0	15.0	13.8	47.7	17.0	5.7	8.7	15.5	12.1	9.8	10.1	9.1	12.9	11.7	31.1	8.9	12.0	14.4	10.8	9.5	21.0	10.0	20.9	26.7	13.8	9.0	10.1	8.9	9.4	14.4	15.7	11.5	12.3	9.7	13.8	12.8	14.5	10.1	9.4	11.7	14.8	10.8	19.5	14.2	11.6	11.0	17.3	11.2	11.5	17.7	17.6	17.6	6.9	11.4	40.1	15.4	9.9	8.4	9.7	9.8	9.9	20.6	10.2	10.2	12.7	5.8	18.2	17.2	16.3	16.9	10.7	19.7	4.5	23.7	20.0	12.3	14.8	8.8	14.4	5.9	7.2	9.7	11.2	7.0	27.0	9.8	19.1	16.3	10.9	19.4	13.2	22.2	8.9	13.3	26.2	12.9	13.0	7.3	11.3	6.3	11.0	15.5	9.2	14.5	19.5	9.4	14.2	12.6	25.3	16.1	17.7	13.9	29.9	15.1	10.9	13.5	14.2	15.4	13.8	17.3	15.8	10.8	20.4	8.1	15.4	16.3	7.7	9.5	6.4	6.3	6.9	7.3	11.4	6.9	8.1	7.5	40.1	9.9	9.9	4.9	8.4	9.7	11.0	13.8	5.7	8.7	10.8	9.5	13.8	9.0	11.5	11.0
RMC1	"C18orf8, HsT2591, MIC1, WDR98"	ENSG00000141452	"Regulator of MON1-CCZ1"	Q96DM3	18	23503470-23531807	"Cancer-related genes, Predicted intracellular proteins"	Autophagy		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043589	Uncertain		Uncertain	Nucleoplasm				Nucleoplasm		"HPA043589: "	"unprognostic (6.45e-2)"	"unprognostic (6.43e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.78e-1)"	"unprognostic (5.51e-3)"	"unprognostic (8.16e-2)"	"prognostic unfavourable (3.94e-4)"	"unprognostic (4.26e-2)"	"unprognostic (3.77e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.27e-1)"	"unprognostic (3.03e-1)"	"unprognostic (3.76e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.13e-2)"	16.6	14.3	11.6	13.9	13.2	30.1	25.2	15.8	20.5	13.2	17.1	13.1	11.8	20.3	16.4	12.4	15.0	14.4	13.3	12.7	16.6	10.7	20.9	23.8	19.5	24.1	15.4	12.0	14.1	17.3	14.6	23.5	17.5	13.4	13.2	14.1	16.2	16.3	14.2	17.2	16.3	23.1	13.6	14.0	21.9	18.9	26.2	11.6	19.7	13.3	11.0	22.9	16.3	14.8	20.0	27.1	24.1	25.4	19.7	18.0	10.2	8.5	8.9	6.6	11.5	15.1	10.9	8.8	13.5	14.4	18.2	21.7	8.0	5.2	12.9	11.4	11.6	16.9	17.2	7.6	16.1	13.3	9.8	6.5	6.3	8.0	19.8	17.1	23.3	9.8	11.9	22.5	12.9	10.7	10.1	13.9	12.0	11.0	14.3	7.8	3.6	13.6	11.5	9.9	12.7	9.5	8.4	9.0	12.1	17.4	8.8	11.1	6.8	10.7	10.3	15.5	4.1	6.2	11.6	22.2	16.8	14.9	16.1	11.7	11.7	24.1	9.9	21.5	15.5	18.4	16.0	19.9	13.8	14.9	12.1	20.0	9.4	11.4	9.6	19.7	25.4	27.1	18.0	10.2	11.6	13.2	15.8	20.5	16.6	10.7	15.4	12.0	13.4	11.6
RMI2	"BLAP18, C16orf75, MGC24665"	ENSG00000175643	"RecQ mediated genome instability 2"	Q96E14	16	11249619-11351762	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA replication"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 31.7;testis: 29.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 6.5"	"Group enriched"	"Detected in many"	5	"B-cells: 6.5;T-cells: 3.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA040995	Uncertain		Supported	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"HPA040995: AB_10795531"	"unprognostic (2.76e-1)"	"prognostic favourable (5.69e-5)"	"unprognostic (1.17e-1)"	"unprognostic (3.09e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.80e-3)"	"prognostic unfavourable (2.77e-5)"	"unprognostic (3.98e-1)"	"unprognostic (1.16e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.44e-3)"	"unprognostic (3.89e-1)"	"unprognostic (2.18e-1)"	"unprognostic (5.50e-2)"	"unprognostic (3.68e-2)"	"unprognostic (3.60e-3)"	"unprognostic (1.03e-1)"	1.0	1.8	4.2	18.0	5.1	4.8	2.8	0.7	4.1	2.8	7.3	1.0	0.4	4.3	2.5	3.2	11.8	1.0	2.6	1.9	2.5	1.5	3.1	2.3	2.9	17.9	1.6	5.6	3.6	1.6	0.7	1.1	13.2	1.2	2.6	9.0	0.8	2.9	1.7	1.1	8.7	5.6	1.1	1.4	4.2	4.0	29.6	1.2	31.7	1.4	2.8	20.4	3.6	4.5	6.5	0.6	0.9	0.0	0.3	3.0	0.3	19.0	12.8	25.1	10.7	1.1	5.5	10.5	11.1	8.8	10.5	17.6	4.9	22.7	26.5	9.6	5.2	11.2	10.7	10.6	17.1	5.2	10.0	14.5	7.6	32.4	0.4	5.6	6.5	1.2	2.0	4.5	4.4	5.7	20.0	21.1	5.5	22.0	19.2	26.0	21.1	5.1	23.3	27.1	28.3	6.2	12.4	14.5	11.5	9.4	15.8	8.2	26.7	8.4	1.8	8.5	7.9	16.2	1.6	5.8	9.5	31.4	7.9	18.4	15.5	0.0	0.0	0.9	0.6	0.0	0.0	6.5	0.2	0.0	0.4	2.5	1.8	0.7	0.2	0.3	0.0	0.6	3.0	0.3	4.2	5.1	0.7	4.1	2.5	1.5	1.6	5.6	1.2	1.2
RNF213	"C17orf27, KIAA1554, KIAA1618, MYMY2, NET57"	ENSG00000173821	"Ring finger protein 213"	Q63HN8	17	80260866-80398786	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Angiogenesis, Ubl conjugation pathway"	"Hydrolase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 36.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003347, HPA026790"	Approved		Supported	Cytosol				Cytosol		"HPA003347: AB_1079204, HPA026790: AB_10602296"	"unprognostic (8.98e-2)"	"unprognostic (1.60e-1)"	"unprognostic (8.97e-3)"	"prognostic unfavourable (4.65e-5)"	"unprognostic (7.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (2.23e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.57e-2)"	"unprognostic (3.85e-1)"	"unprognostic (1.96e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.52e-3)"	"unprognostic (8.92e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.56e-2)"	17.0	15.1	7.4	16.9	10.3	22.4	10.2	4.7	7.5	11.0	12.2	15.6	14.9	8.5	16.6	13.0	13.2	9.7	12.1	8.5	7.8	7.8	17.1	11.6	15.4	17.9	10.9	5.6	11.5	9.0	41.1	11.4	15.1	10.0	11.2	8.0	12.3	11.7	12.5	9.0	8.7	14.8	13.6	14.3	17.0	10.6	5.9	8.7	24.5	15.9	7.5	18.2	13.6	15.4	7.2	13.9	37.9	9.6	11.4	12.1	1.8	16.1	28.7	2.9	2.0	10.5	16.1	2.2	4.1	8.9	18.5	15.8	3.0	7.5	1.0	3.5	8.5	9.4	3.9	5.3	6.3	36.5	1.7	2.5	11.6	5.3	4.5	2.6	2.6	8.8	3.6	10.4	4.5	14.2	4.6	6.0	6.9	3.9	10.5	1.1	2.1	6.6	7.2	6.7	1.2	5.1	14.0	2.8	3.9	9.9	21.1	7.5	4.8	3.3	18.3	10.3	8.2	6.0	4.2	2.6	2.4	2.9	7.7	3.1	3.7	6.9	9.6	4.2	12.1	8.0	8.1	6.2	8.6	9.7	2.3	7.2	6.9	8.5	37.9	11.4	6.9	13.9	6.4	1.8	7.4	10.3	4.7	7.5	7.8	7.8	10.9	5.6	10.0	8.7
RNF43	"DKFZp781H0392, FLJ20315, URCC"	ENSG00000108375	"Ring finger protein 43"	Q68DV7	17	58352500-58417595	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"	"Ubl conjugation pathway, Wnt signaling pathway"	"Developmental protein, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CACO-2: 14.9;Hep G2: 29.2"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 41.7"	"Region enriched"	"Detected in many"	7	"cerebellum: 30.6"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA008079	Uncertain									"HPA008079: AB_1856371"	"unprognostic (2.53e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.46e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.33e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.93e-1)"	"unprognostic (1.05e-1)"	"unprognostic (5.69e-2)"	"unprognostic (3.79e-1)"	"prognostic favourable (6.04e-9)"	"unprognostic (3.61e-3)"	"unprognostic (2.56e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.04e-2)"	0.4	9.4	2.2	6.2	3.5	1.9	4.5	30.6	4.3	3.4	26.4	0.9	21.3	18.5	1.7	9.1	10.0	3.9	8.1	3.3	1.9	1.3	8.0	7.0	6.1	2.7	0.8	1.1	1.6	13.2	3.0	13.3	8.7	4.1	8.0	16.3	3.8	13.7	19.0	0.5	8.9	29.0	0.9	0.8	0.9	4.9	3.1	0.7	3.0	1.8	5.7	6.6	4.0	4.4	0.9	1.1	1.7	1.8	5.6	3.6	1.2	0.7	10.4	1.9	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	14.9	5.0	4.2	5.3	0.0	2.9	0.4	4.0	0.0	8.8	7.3	3.4	0.5	29.2	0.0	4.2	3.0	0.0	8.2	0.0	1.3	0.0	0.3	3.6	0.0	0.1	2.2	3.9	0.3	0.7	6.9	0.0	2.2	3.7	5.6	1.2	0.3	0.9	0.4	0.3	1.3	1.2	0.0	0.1	1.2	0.0	0.0	3.8	1.7	3.3	0.4	0.4	2.4	1.7	0.2	1.6	3.1	0.8	3.2	0.9	2.5	3.6	0.4	0.9	2.3	3.0	0.8	5.6	1.8	1.1	1.2	1.2	2.2	3.5	30.6	4.3	1.9	1.3	0.8	1.1	4.1	0.7
ROS1	"c-ros-1, MCF3, ROS"	ENSG00000047936	"ROS proto-oncogene 1, receptor tyrosine kinase"	P08922	6	117288300-117425855	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"epididymis: 38.6;lung: 20.2"	"Group enriched"	"Detected in some"	5	"HSkMC: 9.3;hTCEpi: 19.3;LHCN-M2: 13.4"	"Cancer enriched"	"Detected in some"	13	"lung cancer: 6.9"	"Group enriched"	"Detected in some"	10	"cerebral cortex: 7.4;olfactory region: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA049098, HPA072424"	Uncertain		Approved	Vesicles				Vesicles		"HPA049098: , HPA072424: "	"unprognostic (8.18e-2)"	"unprognostic (4.64e-3)"	"unprognostic (1.60e-1)"	"unprognostic (2.37e-2)"	"unprognostic (7.57e-2)"	"unprognostic (2.05e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.79e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.42e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.56e-12)"	"unprognostic (1.09e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.91e-1)"	"unprognostic (2.12e-1)"	0.3	0.2	0.2	0.0	0.4	0.0	0.2	0.2	7.4	0.2	0.4	0.0	7.9	0.0	0.2	38.6	0.2	0.2	0.0	0.2	0.2	0.2	0.4	0.2	20.2	0.0	0.2	2.5	0.2	0.2	0.0	0.3	0.7	0.0	0.2	0.3	0.0	0.2	2.3	0.2	0.7	0.3	0.0	0.2	0.2	0.3	0.7	0.0	0.0	0.2	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	9.3	19.3	0.2	1.7	0.0	0.0	0.0	13.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	1.8	0.0	2.3	1.5	0.1	1.8	0.0	0.0	0.0	1.7	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.2	7.4	0.2	0.2	0.2	2.5	0.0	0.0
RPA2		ENSG00000117748	"Replication protein A2"	P15927	1	27891524-27914746	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair, DNA replication"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016538, HPA026306, HPA026309"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB016538: AB_670974, HPA026306: AB_10598913, HPA026309: AB_10601572"	"unprognostic (2.59e-1)"	"prognostic favourable (4.33e-4)"	"unprognostic (8.98e-2)"	"unprognostic (6.89e-2)"	"unprognostic (1.04e-1)"	"prognostic favourable (8.12e-4)"	"unprognostic (4.29e-3)"	"unprognostic (2.03e-2)"	"unprognostic (8.62e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.58e-2)"	"unprognostic (2.31e-1)"	"unprognostic (3.59e-2)"	"unprognostic (9.13e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.18e-3)"	"unprognostic (2.82e-2)"	18.6	17.1	33.6	24.3	38.8	20.5	26.6	23.6	30.5	20.0	15.4	17.2	17.6	9.9	19.5	26.3	18.7	28.8	19.2	22.5	31.4	22.1	19.5	18.4	19.3	37.1	22.0	26.7	32.6	15.3	16.4	27.0	17.2	25.4	17.2	19.0	18.0	16.2	19.8	45.0	22.6	16.8	18.6	22.1	28.4	15.3	34.6	27.7	25.4	30.7	17.2	37.9	20.3	17.1	46.2	31.5	48.4	18.1	49.3	55.9	65.9	13.0	12.5	21.0	15.7	14.3	13.2	12.7	24.3	16.5	31.1	27.1	17.7	16.2	33.3	15.6	9.6	12.2	29.6	13.7	30.4	24.6	27.5	38.7	16.9	15.2	7.2	51.3	27.3	5.7	7.7	30.0	15.5	13.4	40.4	29.0	18.0	13.3	36.5	22.5	41.1	26.7	24.4	31.1	15.5	11.1	14.2	17.9	17.3	26.8	10.8	21.2	11.2	15.2	8.5	7.7	16.7	41.5	15.9	23.6	52.5	28.9	19.0	45.5	13.9	42.8	18.1	48.4	51.6	14.0	55.9	46.2	48.8	47.3	20.4	39.0	55.8	53.9	18.1	49.3	18.1	31.5	42.5	65.9	33.6	38.8	23.6	30.5	31.4	22.1	22.0	26.7	25.4	27.7
RPGR	"COD1, CORDX1, CRD, RP15, RP3"	ENSG00000156313	"Retinitis pigmentosa GTPase regulator"	Q92834	X	38269163-38327564	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cilium biogenesis/degradation, Sensory transduction, Vision"	"Guanine-nucleotide releasing factor"	"Cancer-related genes, Ciliopathy, Cone-rod dystrophy, Deafness, Disease mutation, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pituitary gland: 55.4"	"Cell line enhanced"	"Detected in many"		"HL-60: 22.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 15.3"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 15.3"									"HPA001593, HPA073455"	Approved		Supported	"Golgi apparatus"				"Golgi apparatus"		"HPA001593: AB_1079835, HPA073455: "	"unprognostic (3.22e-2)"	"unprognostic (1.16e-2)"	"unprognostic (5.04e-2)"	"unprognostic (1.08e-1)"	"unprognostic (3.20e-1)"	"unprognostic (9.94e-2)"	"unprognostic (3.46e-2)"	"unprognostic (6.32e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.96e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.03e-6)"	"unprognostic (1.93e-1)"	"unprognostic (7.59e-2)"	"unprognostic (8.96e-3)"	"unprognostic (1.61e-3)"	16.4	5.9	6.1	7.1	9.0	17.4	13.8	7.2	7.0	8.3	8.4	7.1	2.5	5.1	8.8	9.4	5.4	20.8	9.4	6.3	7.2	9.4	4.9	4.9	10.7	7.8	8.9	4.2	7.9	7.2	3.8	55.4	6.3	14.6	5.9	6.4	6.3	3.7	4.8	13.3	4.3	6.2	8.3	9.9	5.1	4.9	11.6	5.7	5.8	8.3	3.6	5.4	7.7	10.9	1.9	2.6	15.3	2.6	1.6	3.1	1.7	3.3	4.4	2.5	2.3	2.9	4.1	1.9	4.2	4.9	3.1	3.6	1.9	1.7	4.9	1.4	2.7	3.2	3.0	1.3	4.3	5.2	5.5	1.8	2.1	3.9	2.6	22.5	4.3	5.9	1.8	6.2	7.0	14.1	2.3	0.0	4.2	1.3	6.6	12.6	6.5	5.6	4.9	8.6	4.6	2.7	2.2	1.9	3.7	4.6	1.9	5.0	1.2	3.9	16.4	3.4	6.0	8.0	5.0	1.4	2.7	4.3	8.0	4.4	4.6	1.4	2.6	5.7	1.4	2.3	3.1	1.9	1.7	1.8	2.6	1.8	2.5	2.0	15.3	1.6	1.8	1.8	1.9	1.7	6.1	9.0	7.2	7.0	7.2	9.4	8.9	4.2	14.6	5.7
RPL10	"DXS648, DXS648E, FLJ23544, L10, NOV, QM"	ENSG00000147403	"Ribosomal protein L10"	P27635	X	154389955-154409168	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"	"Translation regulation"	"Developmental protein, Ribonucleoprotein, Ribosomal protein"	"Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB010339, HPA011311"	Enhanced		Enhanced	"Endoplasmic reticulum,Cytosol"		130000	130000	"Endoplasmic reticulum, Cytosol"		"CAB010339: AB_2181277, HPA011311: AB_1856431"	"unprognostic (2.46e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.14e-2)"	"unprognostic (1.25e-2)"	"unprognostic (2.06e-1)"	"unprognostic (6.11e-2)"	"unprognostic (9.01e-3)"	"unprognostic (1.91e-1)"	"unprognostic (2.21e-1)"	"unprognostic (5.39e-2)"	"unprognostic (3.37e-1)"	"prognostic unfavourable (7.67e-6)"	"unprognostic (6.84e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.65e-2)"	"unprognostic (5.68e-2)"	103.6	65.3	41.4	108.0	48.5	103.7	152.6	82.4	70.7	118.2	80.6	44.6	107.8	51.3	100.4	75.5	105.2	122.3	52.6	82.5	38.2	31.9	112.1	155.0	97.6	190.2	48.2	37.4	223.5	242.3	35.0	51.9	87.4	53.1	83.6	77.1	66.7	109.9	101.5	125.9	121.8	108.9	78.7	51.4	93.9	90.5	33.9	47.2	158.9	198.9	137.9	134.4	86.9	119.3	252.9	168.6	64.4	124.1	149.1	304.9	445.3	187.8	87.1	87.3	66.8	198.2	375.4	77.2	72.2	167.6	139.1	177.0	77.2	84.5	372.4	175.0	120.5	73.0	170.8	173.0	119.6	81.8	135.4	50.2	62.4	84.6	233.1	107.9	74.4	283.3	274.0	83.6	261.3	218.2	70.7	119.0	135.8	94.3	117.5	105.0	68.7	150.6	140.9	82.7	206.9	151.8	67.1	70.0	117.0	17.4	153.8	213.5	56.0	150.9	105.0	48.7	92.6	109.6	159.9	283.6	204.8	370.4	74.0	155.8	60.8	64.4	124.1	18.1	149.9	107.7	256.2	252.9	251.6	186.2	151.2	243.2	304.9	231.1	13.0	149.1	94.9	168.6	178.0	445.3	41.4	48.5	82.4	70.7	38.2	31.9	48.2	37.4	53.1	47.2
RPL22	"EAP, L22"	ENSG00000116251	"Ribosomal protein L22"	P35268	1	6181269-6209389	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Heparin-binding, Ribonucleoprotein, Ribosomal protein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA068294			Approved	Nucleoplasm,Nucleoli		320000	320000	Nucleoli	Nucleoplasm	"HPA068294: "	"unprognostic (3.16e-3)"	"unprognostic (1.28e-1)"	"unprognostic (3.13e-1)"	"unprognostic (3.62e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.29e-3)"	"unprognostic (4.40e-2)"	"unprognostic (7.06e-2)"	"unprognostic (3.26e-1)"	"unprognostic (1.48e-1)"	"unprognostic (4.24e-2)"	"unprognostic (1.46e-3)"	"unprognostic (3.83e-1)"	"unprognostic (3.88e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.98e-1)"	75.5	71.5	54.3	79.7	42.8	124.7	75.0	46.7	39.5	95.8	73.9	39.2	53.9	66.5	133.6	63.9	103.9	59.1	61.8	50.8	47.4	38.6	58.8	90.2	55.3	142.6	50.6	39.7	163.1	154.8	30.4	57.0	49.8	37.4	90.8	46.4	57.0	140.3	66.8	114.0	79.7	62.6	106.6	58.3	79.1	62.0	38.2	35.0	95.3	91.0	112.8	81.1	101.5	91.9	75.6	62.3	11.0	38.9	42.2	98.8	73.9	88.0	25.1	53.5	54.6	37.7	59.3	42.3	76.9	30.9	28.3	24.2	49.8	76.6	136.7	63.3	28.5	50.9	40.2	40.0	37.3	66.9	65.4	132.8	57.2	61.7	37.4	175.7	53.3	52.3	33.1	25.2	52.2	35.3	109.4	82.8	32.5	38.8	76.8	143.4	33.3	55.7	74.1	111.0	105.8	41.4	30.6	74.0	67.9	62.6	181.4	140.8	58.4	139.3	86.3	40.4	44.5	53.3	72.2	66.7	91.4	206.8	26.7	181.7	25.0	11.0	38.9	8.8	38.0	34.3	66.9	75.6	71.1	52.3	59.8	72.4	98.8	78.1	2.9	42.2	27.8	62.3	54.0	73.9	54.3	42.8	46.7	39.5	47.4	38.6	50.6	39.7	37.4	35.0
RPL27	L27	ENSG00000131469	"Ribosomal protein L27"	P61353	17	42998273-43002959	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein"	"Cancer-related genes, Diamond-Blackfan anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002649	Approved					30000	30000			"HPA002649: AB_1079840"	"unprognostic (8.53e-3)"	"unprognostic (7.15e-2)"	"unprognostic (3.97e-2)"	"unprognostic (2.81e-2)"	"unprognostic (4.99e-2)"	"unprognostic (4.31e-2)"	"unprognostic (1.91e-3)"	"unprognostic (7.32e-2)"	"unprognostic (9.17e-2)"	"unprognostic (1.19e-1)"	"unprognostic (5.12e-2)"	"unprognostic (3.86e-1)"	"prognostic unfavourable (7.80e-8)"	"unprognostic (1.10e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.70e-1)"	"unprognostic (1.14e-1)"	78.4	66.9	61.7	82.2	45.7	150.0	148.7	63.1	82.7	75.1	76.8	27.2	65.4	48.8	74.8	80.1	91.9	64.9	80.8	120.6	46.2	38.5	76.2	121.7	109.5	222.2	49.2	49.0	123.7	185.0	17.2	44.1	81.0	48.3	65.3	55.0	43.8	119.1	78.5	127.5	113.8	61.9	82.4	43.6	84.4	69.7	40.3	28.8	72.6	70.5	153.8	78.5	86.1	80.9	178.5	152.7	44.2	99.0	111.4	184.7	216.0	112.4	142.6	87.4	126.5	154.8	229.6	141.1	131.0	107.7	140.9	101.1	201.9	88.6	213.2	111.5	103.0	98.7	100.1	167.3	135.6	98.7	238.1	83.8	119.6	213.4	191.0	240.5	88.1	216.3	143.3	95.0	122.0	116.8	155.7	132.0	130.0	110.0	200.1	203.8	132.3	91.3	140.5	246.1	240.9	119.0	152.0	98.3	108.5	51.4	101.4	208.6	170.6	254.1	131.7	105.0	104.0	128.2	192.7	115.3	185.7	208.7	94.4	149.4	106.9	44.2	99.0	29.5	106.6	87.9	150.2	178.5	159.0	124.5	118.6	168.3	184.7	159.1	20.4	111.4	67.3	152.7	112.5	216.0	61.7	45.7	63.1	82.7	46.2	38.5	49.2	49.0	48.3	28.8
RPL5	"L5, PPP1R135"	ENSG00000122406	"Ribosomal protein L5"	P46777	1	92831983-92841924	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding"	"Cancer-related genes, Diamond-Blackfan anemia, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA043717, HPA054444"	Approved		Supported	"Nucleoli,Endoplasmic reticulum,Cytosol"		130000	130000	"Endoplasmic reticulum, Cytosol"	Nucleoli	"HPA043717: AB_10964719, HPA054444: "	"unprognostic (5.81e-3)"	"unprognostic (3.96e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.52e-1)"	"unprognostic (9.44e-3)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-3)"	"unprognostic (9.95e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.98e-2)"	"unprognostic (3.48e-1)"	"prognostic unfavourable (6.81e-5)"	"unprognostic (2.26e-2)"	"unprognostic (3.12e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.97e-1)"	119.4	80.3	50.0	70.0	50.1	113.8	140.5	46.9	46.8	158.6	111.4	45.0	75.1	61.7	135.2	114.6	159.4	100.5	73.1	73.0	43.5	43.1	99.7	114.9	89.9	148.2	54.5	36.2	296.8	306.5	40.8	90.3	90.2	44.3	175.4	78.8	64.3	121.5	73.2	109.1	97.8	95.3	153.4	61.9	130.1	90.0	68.8	45.7	156.6	210.0	97.7	118.9	191.2	146.6	104.5	85.2	12.8	45.9	72.4	143.0	142.1	116.8	50.2	89.5	75.5	116.4	235.3	143.6	69.9	93.6	87.1	62.4	133.0	51.1	220.5	112.3	78.5	74.7	102.6	131.0	111.3	69.8	140.4	114.4	83.6	122.4	139.7	175.1	48.2	192.4	206.7	77.3	170.2	120.2	141.6	116.3	99.7	66.3	139.4	198.6	138.2	94.9	128.1	173.4	142.4	105.6	97.3	76.3	91.3	45.5	127.1	203.3	70.0	240.9	73.0	44.0	80.4	83.1	126.0	72.0	68.3	149.2	29.8	151.0	29.8	12.8	45.9	7.2	60.9	44.8	122.1	104.5	111.5	91.6	85.2	88.4	143.0	123.9	4.4	72.4	38.3	71.1	83.2	142.1	50.0	50.1	46.9	46.8	43.5	43.1	54.5	36.2	44.3	45.7
RPN1	OST1	ENSG00000163902	"Ribophorin I"	P04843	3	128619970-128681075	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009748, HPA026828, HPA051520"	Enhanced		Enhanced	"Endoplasmic reticulum"		8200000	8200000	"Endoplasmic reticulum"		"CAB009748: AB_2182230, HPA026828: AB_10610418, HPA051520: AB_2681521"	"unprognostic (4.83e-2)"	"unprognostic (5.92e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.67e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.12e-2)"	"prognostic unfavourable (4.80e-4)"	"unprognostic (2.71e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.28e-2)"	"unprognostic (4.58e-3)"	"unprognostic (2.87e-1)"	"unprognostic (7.68e-2)"	"unprognostic (7.86e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.44e-1)"	"unprognostic (9.74e-2)"	52.3	37.5	22.2	26.6	23.8	24.4	48.2	20.9	31.4	45.8	40.8	31.9	58.8	28.5	38.3	110.2	32.2	38.3	38.8	47.1	23.0	28.0	55.4	174.0	47.4	50.6	26.4	18.3	37.8	62.9	43.5	36.9	58.3	24.3	31.4	41.1	28.6	54.1	55.5	34.4	24.0	37.0	33.5	31.8	48.0	33.7	26.9	23.3	34.3	69.1	27.3	36.5	32.7	39.7	26.7	53.1	64.4	43.5	23.4	45.1	53.3	60.8	33.2	27.7	51.0	75.1	50.3	62.8	52.5	69.0	69.8	81.3	68.7	57.3	38.1	49.5	75.7	61.3	44.7	46.7	68.3	27.3	28.7	67.2	24.7	56.4	82.8	54.4	35.4	41.7	54.7	45.9	67.9	54.4	27.6	51.1	45.7	55.6	30.2	59.8	35.1	30.4	33.0	37.3	91.6	48.3	36.6	42.7	24.6	43.1	44.7	53.1	47.8	56.4	35.4	36.1	28.2	52.7	38.9	55.2	43.4	40.7	59.2	40.6	52.0	38.8	43.5	35.7	37.3	40.0	45.1	26.7	30.7	33.8	43.5	18.3	19.1	29.2	64.4	23.4	40.2	53.1	30.5	53.3	22.2	23.8	20.9	31.4	23.0	28.0	26.4	18.3	24.3	23.3
RPS15	"MGC111130, RIG, S15"	ENSG00000115268	"Ribosomal protein S15"	P62841	19	1438358-1440494	"Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA054510, HPA057793"	Enhanced		Approved	"Endoplasmic reticulum,Cytosol"		170000	170000	"Endoplasmic reticulum, Cytosol"		"HPA054510: AB_2682510, HPA057793: AB_2683528"	"unprognostic (4.47e-3)"	"unprognostic (1.30e-1)"	"unprognostic (6.58e-2)"	"unprognostic (1.08e-3)"	"unprognostic (5.98e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.33e-3)"	"unprognostic (4.42e-2)"	"unprognostic (2.58e-1)"	"unprognostic (2.73e-2)"	"unprognostic (3.28e-2)"	"unprognostic (5.00e-2)"	"unprognostic (1.44e-3)"	"unprognostic (5.21e-2)"	"unprognostic (5.21e-3)"	"unprognostic (1.46e-1)"	"unprognostic (2.61e-2)"	61.7	61.2	63.0	67.5	51.4	123.6	74.2	46.0	87.5	56.2	66.4	46.1	41.2	69.0	73.6	52.3	80.9	61.2	73.7	72.1	50.4	40.5	64.8	103.7	43.0	95.3	52.1	52.6	144.8	136.0	21.6	59.3	60.9	45.2	66.9	37.1	61.2	123.7	53.2	154.9	102.4	67.6	51.8	51.0	76.2	63.5	60.8	24.9	70.7	74.2	127.6	82.9	47.6	70.9	237.3	149.5	48.6	106.7	103.8	218.1	269.2	103.1	110.2	48.5	65.9	45.5	66.3	83.6	54.1	43.2	64.9	50.9	176.9	36.5	128.1	48.7	34.7	65.8	47.2	67.0	25.5	106.5	246.9	41.9	101.0	167.0	48.2	106.6	80.0	81.4	81.0	43.9	43.1	57.1	85.0	184.5	40.5	181.6	88.0	143.3	109.7	141.8	91.7	57.9	167.3	58.9	113.7	78.1	92.7	45.6	78.7	155.1	60.2	143.7	57.6	55.0	63.0	109.6	119.3	160.3	158.6	124.5	54.6	97.4	62.8	48.6	106.7	44.5	116.2	89.5	160.8	237.3	179.3	146.1	149.5	222.5	218.1	177.4	21.6	103.8	68.2	124.2	162.9	269.2	63.0	51.4	46.0	87.5	50.4	40.5	52.1	52.6	45.2	24.9
RPS2	"LLREP3, S2"	ENSG00000140988	"Ribosomal protein S2"	P15880	16	1962052-1964860	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 284.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA055133	Approved		Approved	"Endoplasmic reticulum,Cytosol"		140000	140000	"Endoplasmic reticulum, Cytosol"		"HPA055133: "	"unprognostic (2.98e-2)"	"unprognostic (2.44e-1)"	"unprognostic (8.43e-2)"	"unprognostic (3.49e-2)"	"unprognostic (4.15e-2)"	"unprognostic (4.39e-2)"	"prognostic unfavourable (7.70e-4)"	"unprognostic (7.43e-2)"	"unprognostic (3.17e-1)"	"unprognostic (7.23e-2)"	"unprognostic (2.00e-2)"	"unprognostic (3.33e-1)"	"prognostic unfavourable (3.04e-7)"	"unprognostic (1.61e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.47e-1)"	46.1	41.0	28.0	101.8	40.4	97.6	65.9	34.7	30.7	48.2	47.0	22.2	28.8	39.9	45.7	27.1	100.7	61.7	55.7	38.2	19.5	16.0	34.2	107.4	71.1	104.2	36.6	18.6	112.6	284.3	9.6	32.2	45.4	30.1	43.6	32.5	18.3	53.6	28.9	67.3	78.3	47.5	25.8	22.4	131.9	47.8	18.9	28.1	115.2	50.3	114.5	78.3	51.6	77.6	137.5	69.0	18.2	44.9	53.6	125.4	54.7	81.0	117.7	68.2	219.3	99.1	244.6	120.8	55.7	133.9	146.3	103.9	209.6	56.8	155.5	89.2	96.2	101.9	98.5	186.8	55.0	98.1	194.8	52.4	131.3	187.7	242.1	123.0	86.5	326.4	267.9	122.2	203.4	141.8	107.1	88.4	100.8	376.2	154.3	215.6	216.7	106.4	189.2	110.5	185.9	133.5	77.2	122.3	111.1	54.5	171.3	132.0	115.5	216.0	64.7	78.9	104.0	18.9	116.4	34.4	56.6	197.9	42.5	106.6	99.0	4.9	37.6	18.2	50.7	44.9	84.6	137.5	99.9	78.4	68.7	117.9	125.4	93.8	7.6	53.6	36.0	69.0	68.1	54.7	28.0	40.4	34.7	30.7	19.5	16.0	36.6	18.6	30.1	28.1
RPS3	"FLJ26283, FLJ27450, MGC87870, S3"	ENSG00000149273	"Ribosomal protein S3"	P23396	11	75399486-75422280	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"	"Apoptosis, Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation, Translation regulation"	"DNA-binding, Lyase, Ribonucleoprotein, Ribosomal protein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063339	Uncertain		Supported	"Endoplasmic reticulum,Cytosol"		430000	430000	"Endoplasmic reticulum, Cytosol"		"HPA063339: "	"unprognostic (3.62e-2)"	"unprognostic (6.94e-3)"	"unprognostic (2.64e-1)"	"unprognostic (1.44e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.69e-1)"	"unprognostic (5.75e-2)"	"unprognostic (3.27e-3)"	"unprognostic (1.96e-1)"	"prognostic unfavourable (6.92e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.89e-2)"	"unprognostic (2.19e-1)"	72.2	52.7	36.6	108.4	41.2	122.2	136.6	32.1	33.8	105.1	102.0	32.5	65.2	65.8	102.4	84.7	136.5	92.2	107.7	58.5	29.7	26.5	52.9	78.1	71.0	218.6	47.6	30.6	224.7	288.7	13.8	51.3	75.9	35.0	105.7	65.7	47.6	151.0	61.8	86.9	117.6	78.0	110.6	42.1	121.4	75.4	54.1	36.5	126.5	119.4	134.7	130.1	110.3	118.9	104.5	69.7	22.6	44.5	64.6	144.2	213.9	85.5	53.1	75.5	83.1	95.5	170.4	97.7	82.1	105.8	109.0	71.1	153.1	102.5	299.4	100.6	73.7	124.1	97.4	152.7	100.5	79.2	76.1	122.6	53.0	67.6	142.6	197.9	80.4	199.9	208.7	74.5	207.1	142.9	122.1	85.3	97.9	94.0	118.7	95.2	94.8	63.0	112.8	264.9	218.1	107.0	71.6	65.0	92.2	60.5	143.9	83.5	146.9	151.7	114.4	52.7	87.8	71.8	74.1	78.3	96.5	331.7	31.6	111.1	53.2	22.6	44.5	14.7	94.2	31.6	129.1	104.5	123.0	99.4	69.7	95.6	144.2	111.8	11.2	64.6	30.1	60.8	78.2	213.9	36.6	41.2	32.1	33.8	29.7	26.5	47.6	30.6	35.0	36.5
RPS6KA1	"HU-1, p90Rsk, RSK, RSK1"	ENSG00000117676	"Ribosomal protein S6 kinase A1"	Q15418	1	26529761-26575030	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Stress response"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 45.2"	"Cell line enhanced"	"Detected in many"		"HMC-1: 29.6;U-937: 31.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"cerebellum: 60.4"	"Low region specificity"	"Detected in all"			"CAB003852, HPA007981"	Enhanced		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"CAB003852: AB_289590, HPA007981: AB_1079850"	"unprognostic (1.04e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.61e-3)"	"prognostic favourable (7.20e-7)"	"unprognostic (7.35e-2)"	"unprognostic (3.69e-1)"	"unprognostic (6.93e-3)"	"unprognostic (1.12e-2)"	"unprognostic (1.09e-1)"	"unprognostic (7.51e-3)"	"unprognostic (2.37e-2)"	"unprognostic (9.64e-2)"	"prognostic favourable (1.84e-4)"	"prognostic favourable (4.58e-4)"	"unprognostic (4.77e-2)"	"unprognostic (7.61e-2)"	"prognostic favourable (8.33e-4)"	11.0	8.2	6.3	24.2	9.7	15.8	5.0	14.4	6.3	4.9	23.2	11.1	4.4	24.5	2.1	3.6	8.9	6.0	8.0	3.4	5.3	5.1	13.6	5.4	26.1	32.7	10.3	3.5	2.1	10.1	10.0	7.4	3.3	8.6	8.6	15.8	3.6	19.0	5.5	1.1	9.0	45.2	2.8	7.9	27.0	9.7	2.7	9.0	15.9	13.9	4.9	17.3	6.2	4.5	5.0	22.0	40.1	18.0	7.9	8.3	17.1	9.7	3.4	2.8	3.7	0.1	0.0	3.7	0.8	1.5	4.2	4.0	4.0	8.1	18.3	4.5	0.5	11.5	6.3	22.7	3.0	15.1	4.1	20.1	8.5	7.0	1.3	23.7	29.6	0.7	8.3	3.8	6.9	1.8	3.4	6.7	0.2	5.4	0.8	23.3	7.2	11.0	12.6	3.6	8.0	12.0	2.7	4.1	1.6	6.9	6.6	3.2	4.2	20.3	1.2	0.2	5.3	0.7	3.3	4.1	4.9	10.0	2.5	31.8	4.0	9.6	18.0	40.1	8.3	16.4	6.9	4.9	6.1	7.3	22.0	5.0	3.9	5.5	34.5	7.9	17.3	8.6	6.0	17.1	6.3	9.7	14.4	6.3	5.3	5.1	10.3	3.5	8.6	9.0
RPS6KA3	"CLS, HU-3, MRX19, RSK, RSK2"	ENSG00000177189	"Ribosomal protein S6 kinase A3"	P51812	X	20149911-20267519	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, Stress response"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Hep G2: 67.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003221, CAB003853, CAB013520"	Approved		Approved	Nucleoplasm,Nucleoli,Cytosol				Nucleoplasm	"Nucleoli, Cytosol"	"CAB003853: AB_562343, CAB013520: AB_2533378, HPA003221: AB_1853553"	"unprognostic (1.87e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.80e-2)"	"unprognostic (4.26e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.61e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.57e-1)"	"unprognostic (5.04e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.04e-1)"	"unprognostic (4.49e-3)"	"unprognostic (3.91e-1)"	"unprognostic (1.09e-1)"	"unprognostic (2.22e-1)"	19.7	12.5	9.9	23.0	12.5	8.2	16.5	15.2	12.1	11.4	23.2	4.4	22.1	13.7	12.4	10.1	13.6	12.7	15.7	21.3	9.7	8.8	14.1	25.8	21.6	34.0	9.9	10.0	12.7	14.0	36.6	9.8	11.0	10.2	14.5	18.8	7.7	14.3	11.3	45.2	11.7	23.7	16.1	11.7	25.8	11.8	4.8	9.7	29.4	13.5	15.0	18.2	20.3	19.0	4.2	8.6	12.5	6.9	8.3	11.3	2.7	12.6	22.2	8.4	4.3	8.2	14.5	2.5	11.0	16.8	8.2	11.3	25.1	16.4	8.3	3.8	11.5	9.0	9.6	9.3	15.3	7.0	7.6	9.8	14.0	67.5	8.4	19.0	10.2	9.2	7.5	12.9	16.3	29.8	6.4	23.9	8.6	6.0	12.3	5.8	6.0	13.4	6.6	17.8	9.6	7.1	10.6	3.9	3.8	14.8	4.5	16.0	0.0	5.7	16.6	9.0	6.3	28.5	6.2	19.1	11.6	9.3	17.0	9.5	21.2	12.5	4.7	9.5	6.3	6.9	11.3	2.9	7.3	6.9	7.0	4.2	5.0	6.0	7.5	8.3	6.9	8.6	3.5	2.7	9.9	12.5	15.2	12.1	9.7	8.8	9.9	10.0	10.2	9.7
RSBN1L	"FLJ42526, FLJ45813, MGC71764"	ENSG00000187257	"Round spermatid basic protein 1 like"	Q6PCB5	7	77696443-77783022	"Cancer-related genes, Predicted intracellular proteins"		"Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 31.5"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 31.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020406, HPA020413"	Approved		Supported	"Nuclear speckles,Plasma membrane"				"Nuclear speckles"	"Plasma membrane"	"HPA020406: AB_1856488, HPA020413: AB_2253910"	"unprognostic (2.02e-1)"	"unprognostic (2.61e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.34e-1)"	"unprognostic (3.62e-2)"	"unprognostic (2.43e-2)"	"prognostic favourable (3.74e-4)"	"unprognostic (1.27e-2)"	"unprognostic (3.78e-2)"	"unprognostic (1.25e-1)"	"unprognostic (9.02e-2)"	"unprognostic (7.30e-3)"	"unprognostic (1.93e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.25e-3)"	"unprognostic (1.53e-3)"	12.9	10.6	15.0	22.1	14.6	9.5	15.5	28.7	17.0	22.8	23.5	8.9	12.1	11.1	17.2	13.6	15.0	14.2	13.4	10.6	12.4	10.3	12.0	14.9	15.7	18.2	11.1	11.0	19.2	14.9	19.5	16.2	12.2	11.8	18.8	15.1	13.9	14.0	15.4	13.6	11.7	14.9	18.0	11.0	20.7	14.3	29.8	13.8	34.5	21.1	6.7	18.0	23.6	28.2	7.2	7.0	31.5	4.0	3.0	5.2	1.2	8.8	6.8	11.4	20.0	8.0	10.3	5.6	6.6	7.1	9.4	10.8	8.4	15.9	18.2	2.6	6.8	7.7	15.5	8.5	13.5	9.8	8.3	14.5	10.8	8.3	6.8	17.8	13.7	7.3	6.2	8.6	9.5	7.7	19.6	19.2	9.7	10.2	15.2	17.9	8.1	6.1	15.9	11.4	19.1	5.9	11.7	13.5	14.1	10.0	18.2	7.2	11.1	9.5	7.4	14.1	13.0	8.4	10.0	8.6	9.1	29.3	6.7	16.5	9.2	9.1	4.0	6.4	5.2	2.9	3.9	5.4	4.5	3.8	2.2	7.2	4.3	4.7	31.5	3.0	3.2	7.0	4.5	1.2	15.0	14.6	28.7	17.0	12.4	10.3	11.1	11.0	11.8	13.8
RSPO2	MGC35555	ENSG00000147655	"R-spondin 2"	Q6UXX9	8	107899316-108083648	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Sensory transduction, Wnt signaling pathway"	"Developmental protein, Heparin-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 27.0;placenta: 20.1"	"Cell line enhanced"	"Detected in some"		"HEK 293: 3.5;HEL: 3.3;NTERA-2: 2.0;U-138 MG: 3.5;U-266/70: 10.4"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	5	"intermediate monocyte: 1.6"	"Lineage enriched"	"Detected in single"	17	"monocytes: 1.6"	"Group enriched"	"Detected in some"	7	"amygdala: 8.2;cerebral cortex: 18.2;hippocampal formation: 23.2"	"Group enriched"	"Detected in many"	5	"amygdala: 23.3;cerebral cortex: 18.0;hippocampal formation: 24.1;midbrain: 33.2"	"HPA024764, CAB025900, HPA053068"	Uncertain				"Secreted in other tissues"					"CAB025900: , HPA024764: AB_10603236, HPA053068: "	"unprognostic (1.10e-2)"		"unprognostic (2.18e-1)"	"unprognostic (3.97e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.19e-1)"	"unprognostic (8.33e-3)"		"unprognostic (1.82e-1)"	"unprognostic (9.48e-2)"	"unprognostic (1.31e-1)"		"unprognostic (1.40e-1)"	"unprognostic (8.45e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.17e-2)"	0.4	0.5	3.9	1.4	6.3	0.5	0.2	1.9	27.0	3.6	12.0	4.2	3.6	5.1	0.3	3.6	8.9	0.2	4.8	0.5	5.8	10.5	0.2	1.1	9.3	0.2	15.7	5.4	1.1	0.2	0.2	2.8	20.1	2.0	11.6	10.1	15.5	0.2	3.4	0.3	0.3	5.8	0.7	1.3	0.2	8.3	2.0	1.7	0.0	0.2	0.0	0.2	2.2	1.2	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	3.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.0	0.1	0.0	0.0	1.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.2	0.0	3.5	0.2	0.1	0.0	10.4	0.0	0.0	1.0	0.4	0.0	0.0	0.3	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	6.3	1.9	27.0	5.8	10.5	15.7	5.4	2.0	1.7
RSPO3	"FLJ14440, THSD2"	ENSG00000146374	"R-spondin 3"	Q9BXY4	6	127118604-127197765	"Cancer-related genes, Predicted secreted proteins"	"Sensory transduction, Wnt signaling pathway"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	4	"A549: 23.4"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"cerebellum: 5.7;hippocampal formation: 20.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"hippocampal formation: 32.5"	HPA029957	Uncertain				"Secreted to blood"					"HPA029957: AB_10602087"	"unprognostic (4.77e-2)"	"unprognostic (3.95e-2)"	"unprognostic (1.27e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.99e-1)"	"unprognostic (9.71e-2)"	"unprognostic (1.49e-2)"	"unprognostic (3.77e-2)"	"unprognostic (3.21e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.37e-1)"	"unprognostic (1.07e-3)"	"unprognostic (7.94e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.64e-2)"	"unprognostic (7.89e-3)"	18.5	10.5	2.8	12.1	0.8	0.0	40.7	5.7	2.3	12.9	8.5	0.0	23.8	1.2	50.3	32.5	23.7	14.9	7.6	4.2	20.5	1.7	3.3	4.2	3.8	10.2	0.8	2.4	13.2	1.5	0.0	2.6	24.1	0.8	10.2	4.7	8.6	3.9	15.3	19.7	2.2	6.7	34.1	0.6	1.4	10.8	12.4	0.0	0.2	2.9	2.1	0.9	9.3	39.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.4	0.0	0.0	1.3	0.0	0.0	0.0	4.0	0.2	0.5	0.0	0.0	0.0	0.5	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	2.6	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.2	0.0	0.0	0.0	0.0	0.0	5.2	2.0	0.7	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.8	5.7	2.2	20.5	1.7	0.8	2.4	0.8	0.0
RUNX1	"AML1, AMLCR1, CBFA2, PEBP2A2"	ENSG00000159216	"Runt related transcription factor 1"	Q01196	21	34787801-36004667	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 54.3;lymphoid tissue: 58.6"	"Cell line enhanced"	"Detected in many"		"HEL: 65.0;HMC-1: 39.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 17.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA004176, HPA037912"	Enhanced		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA004176: AB_1078412, HPA037912: "	"unprognostic (4.06e-3)"	"unprognostic (2.35e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.62e-1)"	"unprognostic (5.87e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.12e-3)"	"unprognostic (2.33e-2)"	"unprognostic (3.47e-2)"	"prognostic unfavourable (3.44e-15)"	"unprognostic (1.48e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.17e-2)"	"unprognostic (5.47e-2)"	11.5	3.2	5.2	14.8	7.3	29.8	54.3	1.0	4.3	12.5	4.7	3.8	4.0	3.8	2.9	7.4	6.5	4.6	12.4	7.6	6.1	2.0	4.2	6.7	17.9	13.9	8.5	1.1	6.5	5.8	1.6	5.5	6.4	6.0	9.9	5.1	3.5	29.8	8.8	14.4	8.3	5.1	6.8	12.3	10.6	12.7	2.9	6.6	58.6	4.6	5.7	14.2	11.0	9.1	3.2	3.4	17.0	3.9	1.3	4.8	2.0	13.0	1.0	0.0	0.1	3.4	4.4	8.6	7.4	7.5	4.1	3.1	0.6	10.0	6.4	0.5	6.5	11.8	0.8	8.8	6.0	9.9	1.0	65.0	2.6	3.0	6.3	7.5	39.2	8.5	5.3	12.5	12.4	2.3	4.4	3.8	8.7	2.8	30.3	11.9	0.6	3.8	30.7	22.8	3.9	5.5	5.2	0.3	0.0	7.6	1.9	2.7	3.9	17.6	9.7	6.8	8.8	10.1	11.1	12.5	5.1	6.1	8.5	16.5	9.9	17.0	3.2	6.3	3.4	1.4	3.3	3.2	3.1	3.2	0.9	3.1	4.8	3.8	3.5	1.3	3.9	3.4	4.0	2.0	5.2	7.3	1.0	4.3	6.1	2.0	8.5	1.1	6.0	6.6
RUNX1T1	"AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2"	ENSG00000079102	"RUNX1 translocation partner 1"	Q06455	8	91954967-92103286	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 57.8"	"Cell line enhanced"	"Detected in many"		"Daudi: 12.9;fHDF/TERT166: 11.0;HEL: 23.7;HSkMC: 9.5"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in all"	4	"cerebellum: 57.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049852, HPA070951"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA049852: , HPA070951: "	"unprognostic (2.37e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.62e-1)"	"unprognostic (3.37e-4)"	"unprognostic (2.29e-4)"	"unprognostic (5.56e-3)"	"unprognostic (1.24e-2)"	"unprognostic (1.62e-2)"	"unprognostic (2.11e-2)"	"unprognostic (2.37e-1)"	"unprognostic (5.70e-4)"	"unprognostic (8.98e-3)"	"unprognostic (6.78e-2)"	"unprognostic (1.51e-1)"	"unprognostic (7.80e-3)"	9.6	4.6	7.7	4.5	11.5	0.4	6.9	57.8	13.0	14.0	7.8	1.1	2.0	2.0	11.8	5.9	4.1	7.7	7.8	12.3	5.8	4.0	2.5	1.3	6.0	2.0	3.6	9.6	7.7	1.8	1.7	8.6	8.7	4.2	4.2	4.0	5.3	4.7	4.1	5.5	3.6	3.6	10.3	3.0	2.9	4.2	5.6	3.7	0.0	5.2	3.3	1.8	5.7	5.9	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	1.3	3.5	5.1	0.0	5.1	7.8	3.4	5.3	0.0	0.0	12.9	0.0	11.0	0.0	2.7	0.3	2.3	0.0	2.1	23.7	0.0	0.0	1.4	0.0	0.0	9.5	0.0	5.7	0.2	7.3	0.1	0.0	0.8	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	7.7	4.1	0.0	0.0	0.0	0.0	0.0	0.8	0.3	0.0	0.6	0.0	2.6	0.0	4.1	0.5	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	7.7	11.5	57.8	13.0	5.8	4.0	3.6	9.6	4.2	3.7
RXRA	NR2B1	ENSG00000186350	"Retinoid X receptor alpha"	P19793	9	134317098-134440585	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HaCaT: 27.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 14.9;non-classical monocyte: 12.3"	"Group enriched"	"Detected in many"	8	"granulocytes: 14.9;monocytes: 12.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004565, CAB005352"	Supported		Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"CAB004565: AB_2184877, CAB005352: AB_2184874"	"unprognostic (2.68e-1)"	"unprognostic (7.94e-2)"	"unprognostic (3.67e-2)"	"unprognostic (7.22e-2)"	"unprognostic (2.07e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.15e-1)"	"unprognostic (3.45e-2)"	"unprognostic (1.65e-3)"	"prognostic favourable (7.02e-4)"	"unprognostic (7.72e-2)"	"prognostic unfavourable (5.58e-4)"	"unprognostic (1.25e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.59e-1)"	18.5	10.1	9.9	10.4	6.7	19.6	36.8	4.6	9.8	11.0	9.3	4.9	8.1	14.0	10.1	6.1	24.2	9.3	12.9	14.2	9.0	3.7	11.7	49.3	12.8	10.4	6.0	7.0	11.7	20.6	8.0	10.7	9.6	9.4	9.7	2.0	9.5	9.3	9.7	45.8	19.0	15.2	10.6	9.5	11.5	8.8	5.9	8.1	1.5	13.6	18.3	5.9	16.0	23.7	0.1	1.7	14.9	12.3	1.3	1.1	1.8	5.5	15.6	2.0	5.0	3.5	3.3	24.0	3.0	3.5	4.3	2.5	8.6	8.7	0.0	8.2	4.3	27.0	0.7	10.6	0.2	7.9	2.0	0.0	19.0	13.1	4.5	6.5	2.4	5.3	4.5	5.4	2.5	3.7	10.7	0.5	1.0	14.9	0.5	1.4	3.8	5.4	2.8	7.4	10.8	0.2	24.1	4.4	2.0	9.5	9.1	2.4	12.6	8.9	4.8	5.3	6.4	5.7	2.6	0.7	0.0	0.1	4.0	6.6	3.4	1.1	5.2	2.8	1.1	9.3	0.0	0.1	0.7	0.7	1.7	0.0	0.2	0.9	14.9	1.3	12.3	0.1	0.9	1.8	9.9	6.7	4.6	9.8	9.0	3.7	6.0	7.0	9.4	8.1
RXRB	"H-2RIIBP, NR2B2, RCoR-1"	ENSG00000204231	"Retinoid X receptor beta"	P28702	6	33193588-33200688	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"CACO-2: 7.0;RH-30: 8.7;RT4: 8.2;T-47d: 8.5;U-698: 8.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002003, HPA063653"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB002003: , HPA063653: "	"unprognostic (3.51e-1)"	"unprognostic (8.46e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.22e-2)"	"unprognostic (2.00e-2)"	"unprognostic (4.71e-3)"	"unprognostic (4.18e-2)"	"unprognostic (2.21e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.03e-1)"	"unprognostic (1.67e-3)"	"unprognostic (8.13e-3)"	"unprognostic (9.53e-3)"	"unprognostic (8.30e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.38e-2)"	"unprognostic (8.53e-3)"	24.9	18.9	13.0	14.0	16.1	9.8	16.0	24.7	23.2	22.8	17.1	17.7	17.3	19.0	17.4	56.6	13.7	18.5	17.1	27.7	13.5	12.3	14.1	17.4	16.5	9.8	16.4	15.6	19.1	16.2	3.6	17.5	19.2	15.5	20.1	8.4	16.0	16.2	22.0	19.7	25.5	14.1	28.4	10.4	19.8	13.9	10.4	18.2	18.5	22.0	10.9	24.5	14.0	14.5	1.9	1.4	5.2	1.2	1.9	2.5	0.7	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	7.0	0.0	5.3	4.0	0.0	3.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	5.8	0.0	0.0	0.0	0.0	0.0	5.2	0.0	5.2	0.0	0.0	0.2	3.1	0.0	0.0	8.7	0.0	5.3	8.2	0.0	4.7	0.0	0.0	0.0	8.5	0.0	0.0	0.0	3.8	0.0	0.0	6.8	5.8	8.4	0.0	0.0	0.0	5.2	0.8	2.9	2.5	0.9	1.8	1.9	2.5	2.4	1.3	0.8	2.4	1.5	1.9	1.9	1.2	1.4	2.5	0.7	13.0	16.1	24.7	23.2	13.5	12.3	16.4	15.6	15.5	18.2
RXRG	NR2B3	ENSG00000143171	"Retinoid X receptor gamma"	P48443	1	165400917-165445355	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 14.9;pituitary gland: 29.8;retina: 13.5;skeletal muscle: 44.8"	"Cell line enriched"	"Detected in some"	7	"SK-MEL-30: 28.3"	"Group enriched"	"Detected in many"	13	"melanoma: 25.7;thyroid cancer: 34.8"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	5	"basal ganglia: 89.8"	"Low region specificity"	"Detected in all"			"CAB002615, HPA012933"	Uncertain		Approved	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"CAB002615: , HPA012933: "	"unprognostic (2.29e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.29e-2)"	"unprognostic (6.19e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.05e-2)"	"unprognostic (9.13e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.95e-2)"	"unprognostic (5.41e-3)"	"unprognostic (2.52e-2)"	"unprognostic (6.12e-3)"	"unprognostic (1.18e-1)"	"prognostic favourable (9.40e-5)"	"unprognostic (5.03e-2)"	1.9	3.9	5.4	1.0	14.9	0.6	1.0	0.3	5.9	4.0	2.5	5.3	0.6	1.3	1.8	1.3	1.7	3.6	1.2	5.8	7.5	8.9	0.7	0.8	3.4	0.8	4.1	4.3	1.7	2.7	0.8	29.8	1.3	14.1	1.1	2.7	13.5	1.9	2.1	44.8	2.9	2.0	1.8	8.9	1.0	1.1	1.5	5.4	0.0	1.1	2.5	0.6	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.0	0.0	0.0	1.3	0.0	0.0	0.0	28.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	14.9	0.3	5.9	7.5	8.9	4.1	4.3	14.1	5.4
S100A1	"S100-alpha, S100A"	ENSG00000160678	"S100 calcium binding protein A1"	P23297	1	153627926-153632039	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"heart muscle: 465.5;skeletal muscle: 423.5"	"Group enriched"	"Detected in some"	5	"Hep G2: 42.7;SK-MEL-30: 146.4"	"Group enriched"	"Detected in all"	5	"melanoma: 210.5;ovarian cancer: 110.1;thyroid cancer: 123.9"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 2.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002599, HPA006462"	Enhanced					240000	240000			"CAB002599: AB_2315307, HPA006462: AB_1079857"	"unprognostic (6.13e-2)"	"unprognostic (7.60e-2)"	"unprognostic (5.96e-5)"	"prognostic unfavourable (1.12e-4)"	"unprognostic (1.19e-1)"	"unprognostic (3.24e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.34e-3)"	"unprognostic (6.83e-3)"	"unprognostic (5.22e-1)"	"unprognostic (5.04e-3)"	"unprognostic (9.62e-2)"	"prognostic unfavourable (3.08e-4)"	"unprognostic (1.68e-1)"	"unprognostic (4.56e-2)"	"unprognostic (2.70e-3)"	"unprognostic (9.74e-4)"	27.7	3.2	70.0	2.8	67.3	2.2	14.3	4.1	42.5	2.0	2.4	47.3	0.0	3.5	2.6	8.5	14.1	8.8	2.6	465.5	44.9	42.9	20.0	2.6	2.4	2.5	85.0	30.7	2.2	4.5	2.0	4.3	4.5	31.4	6.3	2.1	4.3	99.3	3.7	423.5	4.0	2.9	2.1	87.7	2.4	3.3	2.8	31.8	0.0	29.0	57.6	4.7	2.9	0.1	0.6	0.6	2.1	1.0	0.3	0.5	0.5	0.7	0.3	0.5	4.5	0.0	0.0	0.3	0.8	0.0	0.0	0.0	0.9	0.4	0.5	19.1	0.0	1.1	0.0	0.0	0.0	0.4	0.4	1.0	0.6	42.7	0.0	0.2	0.3	0.1	0.0	0.0	0.0	0.0	3.4	0.5	0.0	1.2	0.1	0.5	0.2	0.3	3.0	0.4	1.0	0.8	1.6	0.7	0.2	0.3	1.3	146.4	4.4	2.2	0.3	0.4	0.3	0.3	0.4	0.7	0.7	0.7	0.3	0.7	0.2	2.1	0.3	0.0	0.1	0.3	0.1	0.0	0.2	0.5	0.0	0.6	0.3	0.0	0.0	0.3	1.0	0.6	0.0	0.5	70.0	67.3	4.1	42.5	44.9	42.9	85.0	30.7	31.4	31.8
S100A2	"CAN19, S100L"	ENSG00000196754	"S100 calcium binding protein A2"	P29034	1	153561108-153567890	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"esophagus: 224.8;tongue: 246.5"	"Group enriched"	"Detected in some"	5	"HBEC3-KT: 656.0;RT4: 256.5"	"Cancer enhanced"	"Detected in all"		"head and neck cancer: 1229.1"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"basophil: 11.9"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 11.9"					"Not detected"	"Not detected"			"CAB002600, CAB047340, HPA062451"	Enhanced		Approved	"Nucleoplasm,Nucleoli,Plasma membrane,Cytosol"		130000	130000	"Nucleoplasm, Cytosol"	"Nucleoli, Plasma membrane"	"CAB002600: , CAB047340: , HPA062451: "	"unprognostic (8.47e-3)"	"unprognostic (5.54e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.42e-3)"	"unprognostic (1.98e-1)"	"unprognostic (3.20e-1)"	"unprognostic (4.21e-4)"	"unprognostic (9.00e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.23e-2)"	"prognostic unfavourable (2.04e-4)"	"unprognostic (3.52e-2)"	"unprognostic (8.91e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.70e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.68e-1)"	0.4	0.0	0.4	0.5	0.4	0.0	2.1	0.4	0.5	16.9	0.4	0.4	0.9	0.0	1.8	1.9	224.8	0.5	0.4	0.4	0.4	0.0	16.6	0.4	1.6	0.4	0.4	0.4	0.4	0.4	0.0	0.5	0.6	0.6	3.3	0.0	0.4	23.3	2.1	0.7	27.5	0.4	1.5	0.5	0.4	0.0	0.5	0.4	0.7	1.0	246.5	48.4	36.2	43.8	0.5	2.6	11.9	0.6	0.0	2.9	0.7	24.8	0.2	0.0	0.0	0.3	0.1	0.0	0.3	0.3	0.2	0.2	0.0	0.8	0.0	13.2	0.5	61.7	0.0	656.0	0.3	0.1	0.1	0.1	1.7	0.1	0.1	0.0	0.0	0.2	87.4	0.7	99.7	0.4	0.0	0.0	1.4	0.1	0.0	0.0	0.0	4.8	0.0	15.6	0.0	15.5	256.5	0.5	0.0	1.0	0.1	0.2	0.1	0.1	0.1	0.3	21.7	2.9	8.4	0.0	0.0	0.1	0.8	0.0	0.7	11.9	0.5	0.0	2.9	0.0	1.8	0.5	2.0	1.6	0.4	0.0	0.6	0.5	5.0	0.0	0.6	2.6	1.8	0.7	0.4	0.4	0.4	0.5	0.4	0.0	0.4	0.4	0.6	0.4
S100A4	"18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98"	ENSG00000196154	"S100 calcium binding protein A4"	P26447	1	153543613-153550136	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 419.2"	"Cell line enhanced"	"Detected in many"		"A549: 112.8;ASC diff: 146.4;BJ hTERT+: 281.6;fHDF/TERT166: 201.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228"	Enhanced		Enhanced	"Plasma membrane"		13000000	13000000	"Plasma membrane"		"CAB002618: , CAB027387: , CAB058698: , CAB068227: , CAB068228: , HPA007973: AB_1079858"	"unprognostic (1.56e-1)"	"unprognostic (6.10e-2)"	"unprognostic (2.84e-2)"	"unprognostic (8.20e-2)"	"unprognostic (6.21e-2)"	"prognostic favourable (4.03e-5)"	"unprognostic (8.35e-2)"	"unprognostic (4.81e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.20e-1)"	"unprognostic (2.78e-2)"	"unprognostic (3.39e-2)"	"prognostic unfavourable (2.90e-4)"	"unprognostic (1.05e-1)"	"unprognostic (3.05e-1)"	"unprognostic (2.76e-2)"	"unprognostic (3.16e-2)"	125.9	10.1	2.6	29.2	8.3	75.2	171.6	2.2	4.6	52.1	33.9	2.7	25.8	7.3	26.8	52.2	58.6	27.9	34.7	59.9	3.0	1.7	27.8	6.1	80.7	53.2	10.8	3.1	12.7	6.7	0.0	3.0	46.9	6.6	49.5	28.0	19.3	29.8	13.4	25.4	44.5	25.5	38.5	8.9	55.9	17.2	18.2	6.2	8.5	23.7	57.5	26.4	34.9	58.2	18.6	213.1	281.6	293.3	17.3	162.7	419.2	0.5	112.8	0.5	3.3	146.4	100.9	0.1	71.5	281.6	1.4	6.3	0.8	7.9	0.0	13.1	201.4	2.8	0.4	1.0	1.1	16.1	0.0	48.2	25.1	2.5	0.1	4.2	81.6	15.7	1.1	2.8	0.6	0.1	0.4	0.1	102.5	0.4	0.1	50.0	0.3	43.3	2.5	0.1	106.3	4.4	3.0	4.3	0.5	1.2	54.5	0.4	3.3	60.4	0.1	0.3	0.6	96.1	0.4	3.5	24.0	0.5	0.2	53.7	5.5	49.5	293.3	30.8	141.2	201.4	147.2	18.6	127.2	112.3	213.1	6.2	22.4	66.5	281.6	17.3	253.9	37.4	162.7	419.2	2.6	8.3	2.2	4.6	3.0	1.7	10.8	3.1	6.6	6.2
S100A6	"2A9, CABP, CACY, PRA"	ENSG00000197956	"S100 calcium binding protein A6"	P06703	1	153534599-153536244	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"RPTEC TERT1: 375.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB002601, HPA007575, CAB040549, CAB047354"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		5100000	5100000	"Plasma membrane, Cytosol"		"CAB002601: , CAB040549: , CAB047354: , HPA007575: AB_1079859"	"unprognostic (8.80e-3)"	"unprognostic (6.96e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.47e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.36e-1)"	"unprognostic (1.27e-1)"	"unprognostic (3.51e-1)"	"unprognostic (6.86e-3)"	"unprognostic (1.66e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.46e-2)"	"prognostic favourable (7.56e-4)"	126.4	32.6	14.8	104.9	29.9	73.8	223.6	13.3	14.6	95.4	176.8	10.1	51.2	70.2	65.0	135.5	126.5	42.2	264.5	112.3	13.0	22.5	103.4	6.0	151.9	61.5	45.6	7.9	38.1	13.5	0.5	17.7	100.1	27.3	85.1	85.5	28.5	58.7	55.2	59.1	45.1	98.1	88.9	35.5	27.5	69.9	29.6	17.8	4.9	76.9	183.0	36.2	150.9	145.0	30.7	130.1	303.7	180.7	9.1	69.2	201.7	77.6	86.9	0.0	7.2	146.3	189.8	0.2	95.2	237.8	48.3	63.4	6.0	162.4	0.1	30.2	141.3	33.7	1.5	136.7	22.8	31.9	0.0	16.2	58.1	5.3	55.4	0.7	11.2	88.5	113.7	51.7	89.5	107.1	0.0	0.1	120.3	11.7	0.2	6.6	0.1	143.0	0.0	10.8	28.1	375.0	72.1	22.4	3.9	129.5	131.9	97.9	18.1	25.2	156.4	46.7	12.2	95.3	154.5	0.2	0.2	0.2	181.3	17.4	99.6	139.8	180.7	74.1	62.0	96.8	67.3	30.7	58.5	60.3	130.1	17.2	37.3	49.5	303.7	9.1	86.9	68.3	69.2	201.7	14.8	29.9	13.3	14.6	13.0	22.5	45.6	7.9	27.3	17.8
S100A7	"PSOR1, S100A7c"	ENSG00000143556	"S100 calcium binding protein A7"	P31151	1	153457744-153460701	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 116.2;lymphoid tissue: 156.7;tongue: 409.9"	"Group enriched"	"Detected in some"	5	"HaCaT: 7.3;SK-BR-3: 16.9"	"Group enriched"	"Detected in many"	5	"cervical cancer: 458.9;head and neck cancer: 1201.5;melanoma: 638.4;urothelial cancer: 281.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB001453, HPA006997, CAB033766"	Enhanced		Uncertain	Cytosol	"Secreted in other tissues"	17000000	17000000	Cytosol		"CAB001453: AB_564004, CAB033766: AB_2269963, HPA006997: AB_1079860"	"unprognostic (3.28e-1)"	"unprognostic (9.85e-2)"	"unprognostic (1.32e-2)"	"unprognostic (2.16e-2)"	"unprognostic (3.17e-1)"	"unprognostic (2.94e-2)"		"unprognostic (1.03e-2)"	"unprognostic (4.00e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.27e-1)"			"unprognostic (2.99e-1)"	"unprognostic (5.41e-2)"		"unprognostic (1.21e-2)"	0.1	0.0	0.1	0.1	0.1	0.1	2.2	0.1	0.1	45.2	0.1	0.1	0.1	0.0	3.7	3.9	116.2	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.0	0.1	6.2	0.1	0.1	45.7	0.1	0.2	0.1	0.1	0.0	0.3	0.1	1.2	0.1	409.9	156.7	0.2	85.3	0.0	0.4	0.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	7.3	0.0	2.2	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.4	0.0	0.0	1.9	0.0	0.0	0.0	1.8	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.7	0.1	0.4	0.0	0.0	0.0	0.8	16.9	0.0	0.3	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
S100A8	"60B8AG, CAGA, CFAG, CGLA, MRP8, P8"	ENSG00000143546	"S100 calcium binding protein A8"	P05109	1	153390032-153391188	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity"	Antimicrobial	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 720.9;bone marrow: 718.8;esophagus: 532.3;tongue: 597.1"	"Group enriched"	"Detected in some"	28	"hTCEpi: 27.5;SK-BR-3: 100.9;THP-1: 53.6"	"Cancer enhanced"	"Detected in all"		"cervical cancer: 2290.9;head and neck cancer: 2382.0"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	8	"classical monocyte: 320.7;neutrophil: 720.9"	"Group enriched"	"Detected in many"	8	"granulocytes: 720.9;monocytes: 320.7"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB002791, HPA024372"	Enhanced		Supported	"Intermediate filaments,Cytosol"	"Secreted to blood"	530000000	530000000	"Intermediate filaments"	Cytosol	"CAB002791: , HPA024372: AB_1856536"	"unprognostic (1.98e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.79e-2)"	"unprognostic (1.58e-2)"	"unprognostic (8.60e-3)"	"unprognostic (9.26e-3)"	"unprognostic (4.92e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.83e-1)"	"unprognostic (6.13e-2)"	"unprognostic (3.77e-2)"	"unprognostic (2.24e-2)"	"prognostic unfavourable (8.94e-7)"	"unprognostic (1.17e-1)"	"unprognostic (8.90e-2)"	"unprognostic (8.27e-2)"	"unprognostic (8.94e-3)"	14.0	0.8	0.8	30.5	2.6	718.8	1.1	0.5	1.6	123.0	2.8	0.7	0.4	0.4	12.0	1.2	532.3	5.5	2.1	36.7	1.5	0.5	1.4	4.3	26.2	37.3	3.3	0.4	2.1	2.7	0.1	0.9	4.7	3.3	1.4	0.4	1.3	92.4	0.3	2.5	6.2	1.0	9.0	1.8	72.4	2.0	1.9	0.9	2.6	4.6	597.1	257.6	5.0	224.1	0.6	63.7	720.9	320.7	0.3	0.6	244.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.1	0.0	1.6	0.0	2.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.7	0.0	0.0	27.5	0.0	0.9	0.0	1.2	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.4	100.9	0.0	0.6	53.6	1.4	0.0	0.0	0.1	0.0	0.0	0.1	0.3	0.0	1.6	0.0	8.2	320.7	38.9	0.4	26.5	0.6	0.6	0.3	0.2	63.7	0.3	0.3	0.3	720.9	0.3	6.4	2.5	0.4	244.7	0.8	2.6	0.5	1.6	1.5	0.5	3.3	0.4	3.3	0.9
S100A9	"60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14"	ENSG00000163220	"S100 calcium binding protein A9"	P06702	1	153357854-153361027	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity"	"Antimicrobial, Antioxidant"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 638.3;bone marrow: 820.1;esophagus: 642.6;tongue: 477.6"	"Cell line enriched"	"Detected in some"	6	"SK-BR-3: 227.6"	"Cancer enhanced"	"Detected in all"		"cervical cancer: 5468.0;head and neck cancer: 6692.8"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"classical monocyte: 381.5;neutrophil: 638.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 638.3;monocytes: 381.5"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"HPA004193, CAB009441"	Enhanced		Supported	"Nucleoplasm,Cell Junctions,Cytosol"	"Secreted to blood"	1400000000	1400000000	"Nucleoplasm, Cell Junctions, Cytosol"		"CAB009441: AB_2184420, HPA004193: AB_1856537"	"unprognostic (1.72e-1)"	"unprognostic (3.33e-2)"	"unprognostic (2.40e-1)"	"unprognostic (3.94e-3)"	"unprognostic (1.36e-2)"	"unprognostic (5.45e-3)"	"prognostic unfavourable (1.13e-6)"	"unprognostic (1.10e-2)"	"unprognostic (4.31e-1)"	"unprognostic (3.06e-1)"	"unprognostic (1.35e-2)"	"unprognostic (5.59e-2)"	"prognostic unfavourable (8.10e-4)"	"unprognostic (1.48e-1)"	"unprognostic (7.52e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.75e-2)"	19.5	2.1	1.3	41.9	4.2	820.1	4.1	0.9	2.1	143.6	4.4	0.7	0.4	0.7	4.9	4.0	642.6	9.9	4.4	51.2	2.5	0.4	2.8	4.8	29.2	169.0	5.3	0.6	3.4	4.4	0.1	0.9	10.4	5.2	2.2	0.7	2.0	109.6	0.5	3.4	7.5	1.4	13.1	2.1	103.2	3.5	2.9	1.4	3.8	6.7	477.6	228.0	24.3	237.0	0.5	87.5	638.3	381.5	0.3	1.0	323.2	2.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.8	35.7	0.0	2.1	0.0	14.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.7	0.0	0.0	12.4	0.0	0.8	0.0	0.6	0.3	0.0	2.8	0.0	0.3	0.0	0.0	0.0	0.4	7.5	0.0	9.2	0.1	0.0	0.3	227.6	0.1	3.6	28.9	0.6	0.0	0.3	0.0	0.0	0.0	0.1	0.2	0.0	6.5	0.0	5.3	381.5	46.4	0.5	31.6	1.0	0.4	0.4	0.3	87.5	0.5	0.3	0.3	638.3	0.3	15.0	2.9	0.5	323.2	1.3	4.2	0.9	2.1	2.5	0.4	5.3	0.6	5.2	1.4
S100B	S100beta	ENSG00000160307	"S100 calcium binding protein B"	P04271	21	46598962-46605208	"Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"brain: 342.0"	"Group enriched"	"Detected in some"	7	"SK-MEL-30: 81.0;WM-115: 159.2"	"Group enriched"	"Detected in all"	58	"glioma: 463.5;melanoma: 495.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 78.0"	"Lineage enriched"	"Detected in many"	7	"T-cells: 78.0"	"Low region specificity"	"Detected in all"							"CAB000073, HPA015768, CAB078196"	Enhanced	Supported	Supported	Nucleoplasm,Vesicles,Cytosol		120000	120000	"Nucleoplasm, Cytosol"	Vesicles	"CAB000073: AB_10013383, CAB078196: , HPA015768: AB_1856538"	"unprognostic (5.67e-3)"	"unprognostic (6.39e-3)"	"unprognostic (2.08e-3)"	"unprognostic (2.08e-2)"	"unprognostic (4.54e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.68e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.37e-1)"	"unprognostic (8.57e-3)"	"unprognostic (6.70e-2)"	"unprognostic (4.41e-7)"	"unprognostic (3.55e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.74e-1)"	67.7	14.0	60.9	5.6	51.0	2.0	13.2	39.4	151.2	5.2	9.1	101.0	3.0	4.7	1.5	7.6	8.6	2.1	8.3	6.6	74.6	65.4	1.5	1.6	2.9	9.8	152.0	36.5	2.4	3.0	1.1	3.1	1.4	90.3	3.0	8.3	7.4	10.1	15.3	1.3	5.7	7.5	4.3	342.0	5.7	4.3	1.5	46.4	0.0	1.3	1.8	10.8	8.2	1.6	0.1	3.4	0.7	1.9	11.0	78.0	10.6	0.1	0.0	17.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	81.0	0.0	0.0	0.0	0.1	0.1	0.0	0.5	0.0	0.0	0.0	0.2	1.0	159.2	0.0	0.1	0.0	78.0	1.8	22.4	0.0	0.2	14.5	3.4	0.1	0.6	33.3	0.7	11.0	1.9	0.8	0.0	10.6	60.9	51.0	39.4	37.6	74.6	65.4	152.0	36.5	90.3	46.4
S1PR1	"CD363, D1S3362, edg-1, EDG1"	ENSG00000170989	"Sphingosine-1-phosphate receptor 1"	P21453	1	101236888-101241518	"Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Angiogenesis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 88.9"	"Cell line enhanced"	"Detected in many"		"BJ: 19.0;HUVEC TERT2: 53.7;TIME: 29.9;U-251 MG: 36.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010104, HPA075568"	Supported		Supported	Vesicles				Vesicles		"CAB010104: AB_2238920, HPA075568: "	"unprognostic (1.41e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.61e-1)"	"unprognostic (9.78e-2)"	"unprognostic (4.49e-3)"	"unprognostic (1.34e-3)"	"unprognostic (1.99e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.12e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.23e-1)"	"unprognostic (5.82e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.64e-1)"	"prognostic unfavourable (8.78e-4)"	72.3	8.4	24.7	16.6	26.2	9.7	46.3	21.6	21.8	13.3	10.5	9.5	2.5	5.7	12.1	5.0	14.7	11.5	17.6	43.5	22.9	15.4	8.9	20.5	35.7	24.5	23.2	14.0	7.9	11.0	13.4	4.7	29.6	21.2	8.9	7.0	9.3	7.5	5.6	21.7	8.2	9.8	19.0	11.0	35.2	8.0	5.8	13.9	4.4	17.0	8.7	15.7	15.2	18.5	27.4	0.2	88.9	0.2	33.4	49.8	30.8	3.5	0.0	3.8	0.0	0.4	9.1	0.0	19.0	3.4	11.5	4.1	0.0	0.1	0.0	4.7	6.6	0.0	0.5	0.2	7.7	1.3	0.3	1.3	0.1	0.0	1.8	0.0	0.8	12.2	0.0	0.0	0.9	53.7	0.0	3.9	3.6	0.0	4.5	0.0	1.0	1.2	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	29.9	1.9	0.7	0.4	36.8	0.3	0.0	0.2	0.1	0.0	0.1	88.9	0.1	4.9	49.8	0.1	40.2	25.1	45.3	44.1	0.2	27.4	35.7	36.2	1.4	33.4	0.2	0.2	26.8	30.8	24.7	26.2	21.6	16.8	22.9	15.4	23.2	14.0	21.2	13.9
SACS	"ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6"	ENSG00000151835	"Sacsin molecular chaperone"	Q9NZJ4	13	23328826-23433740	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		Chaperone	"Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 38.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			CAB017714	Uncertain									"CAB017714: "	"unprognostic (1.22e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.02e-3)"	"prognostic unfavourable (9.04e-4)"	"unprognostic (1.26e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.05e-3)"	"unprognostic (2.59e-2)"	"unprognostic (2.49e-1)"	"unprognostic (4.14e-2)"	"unprognostic (5.05e-1)"	"unprognostic (2.04e-1)"	"prognostic unfavourable (6.21e-6)"	"unprognostic (2.84e-1)"	"unprognostic (4.06e-2)"	"unprognostic (3.67e-2)"	"unprognostic (7.65e-4)"	6.3	6.0	15.9	7.9	20.3	9.6	7.1	7.7	20.2	5.6	6.4	7.8	2.6	2.8	8.8	6.3	5.5	5.1	5.2	7.4	13.5	10.2	2.8	2.8	4.0	8.1	12.5	11.5	8.6	4.6	38.5	7.5	3.4	21.4	8.0	4.0	2.4	6.0	5.4	13.6	4.8	4.3	13.5	11.6	8.3	4.7	7.8	15.2	6.6	3.2	8.7	7.4	6.9	6.7	2.5	2.0	1.0	0.9	1.3	2.8	0.5	3.8	5.1	10.6	3.2	3.3	12.6	1.6	8.9	11.5	3.5	2.9	2.4	2.1	2.7	3.8	19.0	0.8	15.3	5.3	11.5	6.2	6.2	10.0	3.9	3.6	2.5	18.2	4.0	4.0	1.2	22.2	10.8	11.3	5.7	1.3	15.7	1.8	6.5	7.0	8.7	4.1	7.7	19.5	8.0	6.0	0.4	7.7	7.4	4.9	1.8	3.9	0.9	4.9	24.5	10.7	8.8	5.7	16.8	2.5	2.7	6.6	5.0	6.5	9.3	0.0	0.8	1.0	1.1	0.9	2.0	1.1	1.7	0.8	2.0	2.5	1.2	1.4	0.0	1.3	0.3	1.7	2.8	0.5	15.9	20.3	7.7	20.2	13.5	10.2	12.5	11.5	21.4	15.2
SALL4	"dJ1112F19.1, ZNF797"	ENSG00000101115	"Spalt like transcription factor 4"	Q9UJQ4	20	51782331-51802520	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"parathyroid gland: 8.8;testis: 11.7;thyroid gland: 8.6"	"Cell line enhanced"	"Detected in some"		"AF22: 13.6;AN3-CA: 9.5;BEWO: 18.2;NTERA-2: 32.7;SiHa: 8.3"	"Cancer enriched"	"Detected in many"	11	"testis cancer: 22.7"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	9	"NK-cell: 6.3"	"Lineage enriched"	"Detected in single"	9	"NK-cells: 6.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA015291, HPA015791"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA015291: AB_1856548, HPA015791: AB_1856547"	"unprognostic (1.30e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.09e-3)"	"unprognostic (3.55e-2)"	"unprognostic (7.43e-2)"	"unprognostic (3.63e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.20e-1)"	"unprognostic (9.23e-2)"	"unprognostic (2.50e-2)"	"unprognostic (2.39e-2)"	"unprognostic (2.42e-8)"	"unprognostic (5.90e-3)"	"unprognostic (1.82e-1)"	"unprognostic (5.00e-5)"	"unprognostic (7.41e-2)"	0.3	0.4	0.3	0.3	0.9	1.2	0.3	0.8	0.9	0.4	0.7	0.3	2.2	0.1	0.3	0.8	0.3	0.2	0.3	0.3	0.3	0.1	0.5	1.9	0.3	0.3	0.3	0.3	0.3	4.6	8.8	0.6	0.3	0.9	3.1	0.2	4.5	2.2	0.4	0.3	0.3	0.7	0.3	0.3	0.8	0.3	11.7	0.3	0.3	8.6	0.3	0.3	0.9	0.3	0.1	0.1	0.6	0.1	6.3	0.2	0.0	0.0	0.9	13.6	9.5	0.0	0.1	18.2	0.0	0.1	0.0	0.1	4.7	0.1	0.0	0.1	0.1	2.3	0.1	0.0	0.2	0.2	0.0	0.0	3.2	0.2	0.1	0.0	1.0	0.4	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.9	0.0	0.0	32.7	0.2	1.2	0.0	0.0	0.0	0.3	3.1	1.7	8.3	0.0	0.8	0.0	0.5	0.0	0.5	1.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.6	6.3	0.1	0.1	0.0	0.0	0.3	0.9	0.8	0.9	0.3	0.1	0.3	0.3	0.9	0.3
SART1	"Ara1, HAF, SNRNP110, Snu66"	ENSG00000175467	"SART1, U4/U6.U5 tri-snRNP-associated protein 1"	O43290	11	65961689-65979828	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"		"Allergen, Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031188, HPA031189, HPA031190"	Supported		Enhanced	"Nuclear speckles,Golgi apparatus"				"Nuclear speckles"	"Golgi apparatus"	"HPA031188: AB_10600092, HPA031189: AB_10601854, HPA031190: AB_10602289"	"unprognostic (2.93e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.45e-1)"	"unprognostic (6.99e-2)"	"unprognostic (2.52e-3)"	"unprognostic (8.15e-2)"	"unprognostic (8.97e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.05e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.62e-1)"	"unprognostic (4.24e-2)"	22.3	17.5	26.4	25.0	27.8	50.7	21.7	28.5	27.2	21.4	19.6	17.7	20.9	22.7	26.3	17.4	19.0	20.3	20.7	19.5	23.8	16.8	15.8	18.2	19.0	26.2	23.0	25.7	26.8	28.4	22.5	19.2	22.4	25.2	18.1	12.0	15.9	27.1	27.2	34.6	26.2	19.9	27.9	29.2	29.2	20.3	20.4	25.6	24.0	20.5	19.1	19.0	20.6	41.3	5.9	5.8	12.1	5.3	4.1	8.1	2.7	22.5	27.3	12.5	16.8	12.3	9.8	19.2	17.5	12.4	20.3	13.3	19.7	15.7	25.7	20.2	15.2	22.2	15.7	16.0	10.3	20.6	15.6	29.7	19.4	18.2	18.5	25.6	25.0	12.3	12.3	18.8	16.9	12.6	18.7	18.3	11.6	40.7	32.9	36.9	21.3	26.1	36.2	18.2	27.0	8.4	15.1	14.2	20.1	16.6	17.1	20.3	19.1	20.9	18.7	25.4	25.1	24.9	24.5	28.0	21.8	22.5	21.1	13.0	21.5	2.0	4.5	12.1	7.1	5.3	6.0	5.9	8.0	7.4	5.8	5.4	5.9	6.6	6.3	4.1	3.1	4.9	8.1	2.7	26.4	27.8	28.5	27.2	23.8	16.8	23.0	25.7	25.2	25.6
SBDS	"CGI-97, FLJ10917, SDS, SWDS"	ENSG00000126524	"SBDS, ribosome maturation factor"	Q9Y3A5	7	66987677-66995601	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Ribosome biogenesis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028891	Approved		Supported	Nucleoplasm,Cytosol		55000	55000	"Nucleoplasm, Cytosol"		"HPA028891: AB_10601500"	"prognostic unfavourable (1.49e-4)"	"unprognostic (1.87e-2)"	"unprognostic (5.73e-2)"	"unprognostic (1.71e-3)"	"unprognostic (8.06e-3)"	"prognostic unfavourable (3.65e-4)"	"unprognostic (1.07e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.44e-1)"	"unprognostic (6.99e-2)"	"unprognostic (7.84e-3)"	"unprognostic (4.59e-1)"	"unprognostic (1.04e-2)"	"unprognostic (9.38e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.30e-1)"	"unprognostic (5.06e-3)"	40.9	34.5	37.7	18.7	44.0	41.7	44.5	23.6	43.2	30.7	37.5	35.3	20.2	39.1	35.6	27.3	40.8	27.7	34.0	70.0	39.2	40.9	36.9	38.4	32.1	16.7	50.6	36.6	31.9	27.5	50.4	26.9	38.6	44.6	35.1	35.7	20.1	23.5	40.5	130.7	26.1	34.4	52.0	63.2	16.7	32.8	15.9	48.2	7.2	33.9	38.7	15.6	54.0	38.0	21.6	15.5	20.8	12.6	16.6	39.1	19.4	31.0	13.2	11.7	10.6	42.7	31.9	13.1	52.9	43.6	40.5	31.2	27.1	16.0	11.5	40.2	48.3	15.1	19.7	31.4	43.6	11.0	26.0	5.7	24.6	16.2	38.0	14.4	7.9	28.8	42.3	30.8	53.6	24.9	41.7	12.6	62.9	18.6	7.6	21.0	13.0	31.4	5.8	25.2	24.2	42.7	13.9	18.0	12.4	26.5	45.9	35.1	34.2	12.2	33.1	54.8	18.7	27.7	38.5	7.8	9.2	26.4	18.8	23.7	30.3	20.8	11.1	20.2	23.4	12.6	29.6	21.6	30.6	27.2	11.3	18.7	39.1	31.5	4.7	16.6	11.2	15.5	25.9	19.4	37.7	44.0	23.6	43.2	39.2	40.9	50.6	36.6	44.6	48.2
SCGB1A1	"CC10, CC16, CCSP, UGB"	ENSG00000149021	"Secretoglobin family 1A member 1"	P11684	11	62405103-62423195	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Phospholipase A2 inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	18	"lung: 508.4"	"Cell line enriched"	"Detected in some"	69	"HaCaT: 207.4"	"Cancer enriched"	"Detected in many"	8	"lung cancer: 215.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB025686, HPA031828"	Enhanced				"Secreted in other tissues"	17000000	17000000			"CAB025686: , HPA031828: "		"unprognostic (2.40e-3)"		"unprognostic (1.55e-2)"	"unprognostic (5.46e-2)"	"unprognostic (2.70e-2)"		"unprognostic (4.69e-3)"		"unprognostic (2.12e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.31e-2)"		"unprognostic (2.63e-2)"	"unprognostic (1.63e-1)"		"unprognostic (2.40e-2)"	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	28.7	0.0	0.1	0.0	0.1	0.0	0.0	508.4	0.0	0.1	0.0	9.4	0.2	0.0	7.4	0.0	0.1	7.6	0.0	0.0	0.2	1.3	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.2	0.0	0.3	4.8	0.1	0.1	0.0	0.8	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	207.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0
SCGB1D2	"LIPB, LPHB"	ENSG00000124935	"Secretoglobin family 1D member 2"	O95969	11	62242210-62244808	"Cancer-related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 101.5;cervix, uterine: 315.2"	"Cell line enriched"	"Detected in some"	6	"SCLC-21H: 14.4"	"Group enriched"	"Detected in many"	6	"breast cancer: 625.1;endometrial cancer: 226.0"	"Region enriched"	"Detected in some"	6	"pons and medulla: 7.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA035318	Approved				"Secreted in other tissues"					"HPA035318: AB_10610421"	"unprognostic (8.76e-2)"	"unprognostic (2.14e-1)"		"prognostic favourable (3.46e-6)"	"unprognostic (2.39e-2)"				"unprognostic (5.89e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.99e-1)"	"unprognostic (6.43e-2)"	"prognostic favourable (8.03e-6)"		"unprognostic (1.55e-1)"	"unprognostic (1.15e-2)"		1.8	0.4	0.8	0.2	0.6	0.0	101.5	0.9	0.5	315.2	0.2	0.9	6.2	0.0	18.4	43.8	0.8	8.5	0.4	1.0	1.2	0.4	1.1	0.2	0.2	0.2	1.0	0.5	1.1	2.9	0.0	1.0	0.6	7.3	1.1	0.0	1.2	9.5	0.5	2.4	59.6	0.2	0.2	0.4	0.2	0.0	1.6	0.5	0.2	0.3	2.1	1.2	0.2	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	14.4	0.2	0.0	2.5	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.6	0.9	0.5	1.2	0.4	1.0	0.5	7.3	0.5
SCGB2A1	"LPHC, MGB2, MGC71973, UGB3"	ENSG00000124939	"Secretoglobin family 2A member 1"	O75556	11	62208668-62213939	"Cancer-related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"cervix, uterine: 191.8;epididymis: 135.9"	"Cell line enriched"	"Detected in some"	4	"EFO-21: 13.7"	"Group enriched"	"Detected in many"	10	"endometrial cancer: 971.9;ovarian cancer: 208.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA034584	Enhanced		Approved	Vesicles	"Secreted in other tissues"			Vesicles		"HPA034584: AB_10602221"	"unprognostic (7.73e-2)"	"unprognostic (3.77e-1)"	"prognostic favourable (1.22e-4)"	"prognostic favourable (1.54e-8)"		"unprognostic (2.98e-2)"	"unprognostic (1.86e-2)"	"unprognostic (3.39e-1)"		"unprognostic (1.95e-1)"	"unprognostic (2.69e-1)"	"unprognostic (6.87e-3)"	"prognostic favourable (6.36e-4)"	"unprognostic (5.67e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.18e-3)"	"unprognostic (3.35e-1)"	0.2	0.0	0.2	0.5	0.2	0.0	6.8	0.2	0.3	191.8	1.0	0.3	20.8	0.0	40.8	135.9	1.0	28.7	2.5	0.4	0.2	0.3	1.2	0.4	0.9	0.2	0.2	0.3	5.6	2.2	0.0	1.5	0.7	0.5	1.2	1.3	0.2	18.8	1.4	0.2	2.3	0.3	0.2	0.2	0.2	4.3	4.5	0.2	0.3	0.8	1.1	3.1	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.7	0.0	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.1	0.0	1.0	0.2	0.0	2.5	0.6	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.5	0.2
SCGB2A2	"MGB1, MGC71974, UGB2"	ENSG00000110484	"Secretoglobin family 2A member 2"	Q13296	11	62270155-62273156	"Cancer-related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"breast: 300.8"	"Cell line enriched"	"Detected in single"	118	"SK-BR-3: 19.8"	"Cancer enriched"	"Detected in many"	23	"breast cancer: 823.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											CAB026270	Enhanced				"Secreted in female reproductive system"					"CAB026270: AB_912980"	"unprognostic (2.38e-1)"	"unprognostic (7.28e-2)"		"prognostic favourable (9.57e-8)"						"unprognostic (4.17e-1)"				"unprognostic (3.75e-1)"				2.9	0.0	0.2	0.2	0.2	0.0	300.8	0.2	0.2	34.4	0.2	0.2	0.2	0.0	0.6	0.2	7.2	0.0	0.2	0.5	0.2	0.0	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.2	13.9	0.2	0.2	75.0	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.4	0.2	0.6	5.9	0.2	0.9	0.1	0.0	0.1	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
SDC1	"CD138, SDC, SYND1, syndecan"	ENSG00000115884	"Syndecan 1"	P18827	2	20200797-20225433	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 113.2;placenta: 228.8"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 60.9;hTCEpi: 56.3;U-251 MG: 58.0;U-266/70: 60.1;U-266/84: 126.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	17	"memory B-cell: 3.9"	"Lineage enriched"	"Detected in single"	40	"B-cells: 3.9"	"Group enriched"	"Detected in some"	4	"cerebellum: 10.7;olfactory region: 5.9"	"Not detected"	"Not detected"			"CAB002424, HPA006185, HPA067477"	Enhanced		Supported	"Focal adhesion sites"	"Secreted to blood"	1600000	1600000	"Focal adhesion sites"		"CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: "	"prognostic unfavourable (2.22e-4)"	"unprognostic (6.80e-3)"	"unprognostic (6.80e-2)"	"unprognostic (7.84e-2)"	"prognostic unfavourable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (4.02e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.66e-1)"	"unprognostic (2.27e-3)"	"unprognostic (1.79e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.94e-2)"	"unprognostic (4.27e-1)"	"unprognostic (1.62e-2)"	"unprognostic (1.52e-1)"	0.8	3.4	0.5	5.4	0.6	0.0	4.5	0.8	0.7	21.4	18.3	0.5	3.5	14.3	2.3	8.7	103.7	1.6	55.3	0.3	0.4	0.5	68.5	113.2	15.8	6.3	1.9	0.4	1.6	7.0	0.6	0.6	228.8	0.7	13.3	6.2	1.5	16.0	5.2	0.5	69.5	21.9	4.3	0.4	3.7	16.3	2.6	0.4	1.5	3.5	62.3	48.4	30.0	37.7	3.9	0.0	0.0	0.0	0.0	0.0	0.5	30.8	17.3	5.5	13.8	1.5	0.2	17.3	8.6	8.3	8.1	6.8	3.6	18.8	0.0	3.2	6.1	30.4	2.4	60.9	5.4	0.1	1.6	0.0	1.6	18.5	1.3	1.3	0.1	0.8	56.3	7.2	17.3	0.8	0.7	12.1	4.3	18.4	0.0	0.3	4.9	33.5	0.6	2.0	23.3	10.3	46.3	1.6	12.8	6.5	43.9	1.9	4.3	0.3	1.3	32.1	10.3	1.1	58.0	60.1	126.7	0.1	9.6	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.6	0.8	0.7	0.4	0.5	1.9	0.4	0.7	0.4
SDC4	"amphiglycan, ryudocan, SYND4"	ENSG00000124145	"Syndecan 4"	P31431	20	45325288-45348424	"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 141.1"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 73.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005716, CAB013240"	Enhanced		Approved	"Golgi apparatus,Plasma membrane"	"Secreted to blood"			"Golgi apparatus"	"Plasma membrane"	"CAB013240: AB_2533250, HPA005716: AB_1080160"	"unprognostic (1.34e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.71e-2)"	"unprognostic (2.16e-1)"	"unprognostic (5.39e-2)"	"unprognostic (6.59e-3)"	"unprognostic (1.16e-1)"	"unprognostic (5.93e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.95e-2)"	"prognostic unfavourable (4.20e-4)"	"unprognostic (1.97e-1)"	"prognostic favourable (2.44e-7)"	"unprognostic (3.00e-1)"	"unprognostic (2.18e-1)"	"prognostic favourable (2.67e-4)"	"unprognostic (7.42e-2)"	15.9	26.2	19.9	15.7	24.3	3.5	40.5	6.9	20.1	20.4	24.8	19.2	9.0	13.3	17.6	14.7	42.4	27.4	26.2	19.5	19.8	12.1	56.6	141.1	56.7	4.8	23.5	20.5	14.7	36.6	6.2	12.5	23.0	30.9	19.5	22.3	21.8	47.6	17.5	25.5	45.5	13.8	38.7	23.0	9.0	46.9	33.7	15.7	2.0	26.5	25.2	23.5	34.4	16.4	0.7	2.8	2.0	3.1	1.4	8.1	1.2	22.6	2.9	1.6	0.1	40.4	24.9	69.8	29.0	39.6	32.8	23.6	34.5	57.9	0.0	13.0	36.4	29.4	1.1	73.7	40.0	6.5	1.0	0.7	2.4	13.4	44.1	0.1	1.2	33.5	49.4	13.5	33.1	4.3	1.1	0.0	18.9	22.5	0.0	2.0	2.9	9.1	0.0	14.6	0.0	54.0	30.2	0.6	2.3	39.8	24.7	7.1	17.9	1.3	8.1	25.1	20.9	2.5	18.6	1.2	0.9	0.1	39.5	2.3	14.9	2.0	3.1	0.7	1.3	1.1	4.1	0.6	4.1	1.6	2.8	0.7	0.9	1.1	1.6	1.4	1.1	2.5	8.1	1.2	19.9	24.3	6.9	20.1	19.8	12.1	23.5	20.5	30.9	15.7
SDHA	"FP, SDH2, SDHF"	ENSG00000073578	"Succinate dehydrogenase complex flavoprotein subunit A"	P31040	5	218241-256700	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 100.1;skeletal muscle: 114.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034929, HPA041981, HPA064582"	Enhanced		Supported	Nucleoli,Mitochondria		780000	780000	Mitochondria	Nucleoli	"CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293"	"prognostic unfavourable (6.00e-4)"	"unprognostic (1.93e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.80e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.67e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.24e-1)"	"prognostic favourable (9.53e-8)"	"unprognostic (1.11e-2)"	"unprognostic (2.62e-1)"	"unprognostic (3.57e-1)"	"unprognostic (1.79e-1)"	17.6	31.4	15.3	11.5	20.3	10.6	12.8	18.8	29.0	10.2	29.4	17.3	10.0	44.3	11.3	12.1	15.3	12.6	14.8	100.1	15.8	14.5	36.5	55.4	10.7	11.7	19.6	19.3	14.5	14.7	23.2	9.5	9.2	29.7	10.7	24.6	14.5	17.3	12.0	114.0	11.5	39.9	16.5	13.2	13.9	21.2	14.6	14.8	15.7	12.5	39.6	12.5	13.2	11.1	28.3	31.9	29.1	29.2	27.1	48.9	32.4	18.4	29.9	12.3	20.1	21.2	15.9	33.4	14.2	18.1	24.5	25.0	32.4	25.1	22.8	45.0	16.2	23.9	21.7	29.0	14.5	48.6	19.9	11.6	82.6	42.0	13.1	14.4	15.1	15.8	18.7	18.3	9.7	26.5	18.6	19.0	11.5	28.2	19.1	39.0	4.2	37.9	24.7	17.9	44.2	52.2	24.5	13.6	7.8	67.0	43.3	17.6	26.3	18.3	19.2	18.2	17.9	10.8	11.7	20.2	8.6	16.8	17.6	20.9	11.5	17.8	24.4	29.1	36.4	29.2	32.1	28.3	34.8	35.1	31.9	24.5	34.5	31.7	5.9	27.1	24.1	20.5	48.9	32.4	15.3	20.3	18.8	29.0	15.8	14.5	19.6	19.3	29.7	14.8
SDHAF2	"C11orf79, FLJ20487, PGL2, SDH5"	ENSG00000167985	"Succinate dehydrogenase complex assembly factor 2"	Q9NX18	11	61430042-61447529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Chaperone	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039464, HPA039732"	Supported		Approved	Nucleoli,Mitochondria,Cytosol				"Mitochondria, Cytosol"	Nucleoli	"HPA039464: AB_10962146, HPA039732: AB_10962868"	"unprognostic (5.31e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.13e-1)"	"unprognostic (1.30e-2)"	"unprognostic (1.40e-1)"	"unprognostic (6.71e-2)"	"unprognostic (1.98e-3)"	"unprognostic (9.06e-2)"	"unprognostic (2.17e-1)"	"unprognostic (2.09e-3)"	"unprognostic (4.21e-3)"	"unprognostic (1.50e-1)"	"unprognostic (1.81e-2)"	"unprognostic (3.61e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.48e-2)"	23.7	33.0	22.2	22.4	27.2	34.1	24.8	19.9	33.8	20.5	22.1	23.4	21.0	22.3	23.3	33.5	25.3	25.8	21.1	32.5	20.8	26.9	26.8	39.1	19.9	36.7	24.3	25.0	25.7	22.7	23.3	38.4	26.7	25.2	26.1	24.9	32.0	28.1	21.5	31.4	22.9	27.9	26.6	20.8	32.2	24.3	19.2	21.1	36.1	27.0	20.2	30.9	24.0	19.2	31.3	23.2	44.6	25.4	32.7	43.7	26.7	15.3	22.0	13.1	9.1	19.0	15.5	10.2	11.9	17.2	16.1	12.4	20.6	16.5	15.4	21.8	17.1	16.6	17.0	16.9	17.3	22.8	16.1	13.3	18.1	29.6	19.8	15.6	18.5	19.2	20.7	17.5	17.1	25.9	15.2	19.9	19.4	33.8	15.9	35.5	20.2	32.4	17.2	16.9	28.5	22.9	22.7	14.0	17.5	16.3	19.1	33.0	29.7	18.7	16.1	16.4	13.3	19.4	14.1	12.3	19.0	19.6	15.9	13.9	17.1	41.9	25.4	44.6	32.4	22.8	38.4	31.3	35.9	34.7	20.3	29.9	39.5	38.4	37.0	32.7	17.9	23.2	43.7	26.7	22.2	27.2	19.9	33.8	20.8	26.9	24.3	25.0	25.2	21.1
SDHB	"SDH, SDH1"	ENSG00000117118	"Succinate dehydrogenase complex iron sulfur subunit B"	P21912	1	17018722-17054170	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002868, CAB009822, CAB068233, CAB068234, CAB068235"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Mitochondria"	"Intracellular and membrane"			Mitochondria	"Nucleoplasm, Plasma membrane"	"CAB009822: AB_2183458, CAB068233: , CAB068234: , CAB068235: , HPA002868: AB_1079889"	"unprognostic (1.06e-1)"	"unprognostic (2.86e-2)"	"unprognostic (2.19e-2)"	"unprognostic (2.93e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.79e-3)"	"unprognostic (1.58e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.19e-1)"	"unprognostic (8.45e-2)"	"unprognostic (5.51e-2)"	"unprognostic (3.93e-2)"	"prognostic favourable (2.93e-7)"	"unprognostic (1.46e-1)"	"unprognostic (2.75e-1)"	"unprognostic (7.82e-2)"	"unprognostic (3.82e-2)"	17.8	25.6	19.8	16.6	21.7	17.0	26.4	18.0	29.1	13.9	30.8	12.3	15.1	34.0	14.2	15.7	19.8	13.6	15.1	86.9	18.2	16.4	51.0	75.1	16.8	24.6	20.1	18.9	10.5	30.7	20.0	11.3	15.6	16.7	13.0	31.5	11.7	15.9	19.5	96.2	13.2	31.4	21.3	16.5	17.2	21.7	18.7	15.7	14.2	15.5	52.2	18.0	15.4	17.1	22.2	45.9	48.5	48.7	18.9	26.7	25.0	25.5	25.4	14.5	18.5	28.2	28.1	16.5	22.4	28.8	51.4	46.5	35.7	30.8	35.1	28.0	30.2	30.2	57.7	44.7	58.0	20.6	47.3	31.6	26.4	27.4	34.6	49.4	23.6	28.8	29.5	44.4	75.3	36.3	26.4	40.7	35.7	21.1	32.8	28.2	12.0	51.1	23.6	27.9	43.5	47.3	14.5	27.3	15.0	30.4	38.1	63.9	22.3	27.9	18.0	19.8	22.3	36.3	29.5	17.0	20.9	35.9	30.3	75.3	21.8	16.6	38.4	37.4	18.3	48.7	18.3	22.2	21.2	19.5	45.9	18.3	19.3	19.5	48.5	18.9	42.2	21.5	26.7	25.0	19.8	21.7	18.0	29.1	18.2	16.4	20.1	18.9	16.7	15.7
SDHC	"CYB560, cybL, PGL3"	ENSG00000143252	"Succinate dehydrogenase complex subunit C"	Q99643	1	161314257-161375340	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"																		"unprognostic (1.48e-2)"	"unprognostic (6.88e-2)"	"unprognostic (6.38e-3)"	"unprognostic (1.86e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.02e-2)"	"unprognostic (7.08e-2)"	"unprognostic (2.33e-1)"	"unprognostic (7.38e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.43e-2)"	"unprognostic (1.29e-1)"	"prognostic favourable (2.20e-4)"	"unprognostic (9.14e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.19e-3)"	"unprognostic (3.77e-1)"	36.8	49.7	25.6	17.1	27.3	14.1	24.1	14.4	36.2	20.6	29.1	31.2	17.0	34.3	22.1	19.7	35.2	21.4	19.3	35.5	21.5	21.8	65.9	75.3	17.8	20.9	28.6	20.1	20.1	17.2	28.8	17.0	19.2	28.0	20.8	28.4	23.9	28.5	21.9	98.0	21.6	33.4	23.2	24.9	21.2	24.3	17.0	16.2	25.7	35.9	45.4	22.4	20.6	19.2	31.3	60.4	28.3	48.2	29.0	38.6	47.9	30.0	22.0	31.0	26.7	40.9	32.8	34.3	33.3	26.6	25.9	20.0	32.5	37.4	8.9	43.4	33.6	35.2	41.4	35.0	30.0	31.9	40.6	20.6	21.0	33.4	23.3	38.2	22.2	34.5	28.9	30.1	20.3	26.9	29.0	8.4	41.7	28.9	27.1	22.1	30.5	23.3	28.5	30.3	37.9	54.6	29.9	21.7	36.9	40.1	75.6	47.7	61.7	48.0	23.7	18.0	27.6	25.4	28.8	44.0	53.7	52.9	26.3	25.0	34.8	27.7	48.2	28.3	36.0	44.9	38.6	31.3	32.3	35.5	60.4	30.6	36.3	35.7	23.9	29.0	38.8	44.8	35.2	47.9	25.6	27.3	14.4	36.2	21.5	21.8	28.6	20.1	28.0	16.2
SDHD	"cybS, PGL, PGL1"	ENSG00000204370	"Succinate dehydrogenase complex subunit D"	O14521	11	112086773-112120013	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"		"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA045727	Approved				"Intracellular and membrane"					"HPA045727: AB_10963114"	"unprognostic (9.13e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.47e-3)"	"unprognostic (4.21e-2)"	"unprognostic (1.93e-1)"	"unprognostic (4.98e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.83e-3)"	"unprognostic (7.10e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.80e-1)"	"prognostic favourable (1.99e-10)"	"unprognostic (5.14e-2)"	"unprognostic (1.58e-2)"	"unprognostic (1.56e-2)"	"unprognostic (7.51e-2)"	20.9	23.1	17.1	21.7	19.4	10.9	19.6	14.1	18.4	18.1	33.6	14.2	23.9	36.0	22.7	17.5	35.2	17.3	17.9	42.5	15.1	13.7	66.6	75.4	19.1	23.3	17.1	15.1	18.6	23.2	22.5	16.1	20.1	18.0	23.7	33.9	15.7	32.6	21.7	65.4	15.5	61.2	24.0	15.3	22.8	22.2	8.8	14.8	21.7	46.2	33.9	24.6	23.5	20.3	55.5	74.7	62.1	91.7	46.1	53.7	68.9	16.8	17.3	11.8	17.9	44.2	35.5	19.8	20.6	29.3	21.6	27.1	59.9	44.3	30.7	63.7	27.7	42.4	36.8	29.1	26.5	27.2	18.5	29.2	12.9	31.8	34.4	45.9	22.2	39.1	32.3	25.7	41.2	30.4	30.1	42.4	26.7	21.2	27.5	41.5	16.0	43.0	25.5	31.4	57.2	44.2	41.3	17.1	11.3	28.9	39.0	20.5	40.1	33.1	23.7	21.1	27.7	23.4	18.9	12.6	16.1	56.2	12.0	60.2	20.1	46.1	73.0	48.7	41.4	91.7	44.1	55.5	44.5	43.1	74.7	45.6	53.7	49.8	62.1	46.1	70.7	36.8	44.2	68.9	17.1	19.4	14.1	18.4	15.1	13.7	17.1	15.1	18.0	14.8
SELE	"CD62E, ELAM, ELAM1, ESEL"	ENSG00000007908	"Selectin E"	P16581	1	169722641-169764705	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"tongue: 50.0"	"Cell line enriched"	"Detected in single"	5	"HUVEC TERT2: 5.2"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	4	"pons and medulla: 5.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							CAB002143	Enhanced					640000000	640000000			"CAB002143: AB_563608"	"unprognostic (2.39e-1)"	"unprognostic (2.16e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.94e-1)"	"unprognostic (3.63e-1)"	"unprognostic (3.88e-1)"	"unprognostic (9.74e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.13e-3)"	"unprognostic (4.69e-2)"	"unprognostic (4.63e-2)"	"unprognostic (2.55e-1)"	14.9	2.7	0.9	30.4	1.2	0.2	8.3	0.3	1.0	13.7	2.7	1.9	4.4	0.4	18.1	3.2	6.7	20.1	7.4	4.4	0.9	0.9	2.5	4.9	10.6	2.0	1.2	0.0	9.8	1.4	21.0	3.1	0.9	5.4	21.2	1.9	4.3	2.0	4.6	2.2	3.7	2.4	13.1	4.8	0.2	3.4	5.6	0.5	0.9	9.0	50.0	15.5	16.4	4.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.9	0.0	0.9	1.2	0.3	1.0	0.9	0.9	1.2	0.0	5.4	0.5
SELL	"CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR"	ENSG00000188404	"Selectin L"	P14151	1	169690667-169711698	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 227.5;lymphoid tissue: 77.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 7.3;EFO-21: 7.1;MOLT-4: 13.4;U-266/70: 25.2;U-698: 11.7;U-937: 7.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002144, HPA051972"	Enhanced		Uncertain	Cytosol		8100000000	8100000000	Cytosol		"CAB002144: AB_563862, HPA051972: "	"prognostic favourable (3.76e-4)"	"prognostic favourable (2.25e-4)"	"unprognostic (1.52e-2)"	"unprognostic (2.89e-2)"	"unprognostic (7.87e-3)"	"prognostic favourable (6.43e-4)"	"unprognostic (1.39e-3)"	"unprognostic (3.43e-1)"	"unprognostic (2.70e-3)"	"prognostic favourable (3.14e-4)"	"unprognostic (1.42e-1)"	"unprognostic (4.21e-2)"	"prognostic unfavourable (4.96e-5)"	"unprognostic (4.76e-2)"	"unprognostic (8.71e-3)"	"unprognostic (9.57e-2)"	"unprognostic (1.01e-1)"	6.9	0.9	2.0	25.1	4.6	30.3	1.5	1.1	2.5	0.9	1.4	1.1	0.0	0.4	1.0	1.1	4.2	3.2	5.4	4.1	2.5	2.2	2.3	2.5	11.4	77.8	5.2	0.2	0.8	1.0	10.7	7.9	3.4	2.7	1.2	1.3	3.8	12.1	0.1	0.9	0.8	8.8	2.9	5.2	67.7	1.7	1.0	2.3	43.8	1.9	1.3	64.0	8.1	6.1	40.4	40.7	227.5	49.7	130.8	69.5	90.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.5	0.0	0.2	7.3	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	5.0	0.9	0.3	0.0	0.0	0.0	1.2	0.0	1.0	0.0	0.8	13.4	0.1	0.0	0.2	5.1	0.1	0.3	4.1	0.2	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	25.2	0.0	11.7	1.3	7.3	0.1	170.8	49.7	88.6	16.5	11.2	4.5	33.8	30.7	17.0	40.7	40.4	69.5	39.6	227.5	130.8	4.5	32.8	52.7	90.1	2.0	4.6	1.1	2.5	2.5	2.2	5.2	0.2	2.7	2.3
SELP	"CD62, CD62P, GMP140, GRMP, PADGEM, PSEL"	ENSG00000174175	"Selectin P"	P16109	1	169588849-169630193	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	37	"EFO-21: 24.7;HEL: 22.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	6	"basophil: 6.0;neutrophil: 2.4;T-reg: 8.9"	"Group enriched"	"Detected in many"	8	"granulocytes: 6.0;T-cells: 8.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002145, HPA002655, HPA005990"	Enhanced					830000000	830000000			"CAB002145: AB_563984, HPA002655: AB_1078480, HPA005990: AB_1078479"	"unprognostic (3.37e-2)"	"unprognostic (2.98e-4)"	"unprognostic (4.11e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.26e-2)"	"prognostic favourable (3.12e-4)"	"unprognostic (5.30e-4)"	"unprognostic (4.14e-2)"	"unprognostic (3.59e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.93e-2)"	"unprognostic (6.61e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.24e-3)"	"unprognostic (1.74e-2)"	"unprognostic (7.85e-3)"	"unprognostic (1.66e-1)"	14.2	2.1	0.4	8.4	0.4	1.0	10.9	0.4	0.4	14.8	3.7	0.6	7.5	3.3	10.6	6.2	5.6	7.7	7.0	9.6	0.4	0.4	7.5	4.6	11.3	12.9	0.4	0.4	5.0	1.5	3.8	2.8	7.4	1.3	14.8	2.9	24.7	3.4	4.3	3.7	2.3	5.2	10.5	1.0	1.9	3.5	3.1	0.3	1.4	4.9	7.7	13.0	11.5	27.2	0.9	0.1	6.0	0.5	0.4	8.9	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.0	0.5	0.7	0.0	0.2	0.0	0.9	0.6	0.3	0.0	0.2	0.2	0.1	2.4	0.4	0.0	0.1	8.9	8.8	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	1.3	0.3
SEMA3B	"LUCA-1, SemA, sema5, SEMAA, semaV"	ENSG00000012171	"Semaphorin 3B"	Q13214	3	50267558-50277546	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"placenta: 147.6"	"Cell line enhanced"	"Detected in many"		"HeLa: 22.5;Hep G2: 34.0;SK-BR-3: 17.7;WM-115: 55.3"	"Low cancer specificity"	"Detected in all"							"Cell type enriched"	"Detected in single"	7	"eosinophil: 3.3"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 3.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA030651	Approved				"Secreted in other tissues"	29000	29000			"HPA030651: AB_10602224"	"prognostic favourable (1.27e-4)"	"unprognostic (6.48e-2)"	"unprognostic (5.40e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.15e-1)"	"unprognostic (1.89e-1)"	"unprognostic (2.83e-2)"	"unprognostic (2.21e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.85e-2)"	"unprognostic (4.27e-1)"	"unprognostic (7.99e-2)"	"unprognostic (7.78e-2)"	"unprognostic (3.89e-1)"	"unprognostic (8.87e-3)"	"unprognostic (1.69e-2)"	3.3	18.8	2.5	2.0	7.4	0.0	1.0	0.3	9.2	9.2	6.0	18.6	2.3	13.3	4.4	3.5	2.5	3.4	5.6	3.4	3.6		7.7	0.0	8.1	0.0	12.9	4.9	2.6	5.6	3.5	0.0	147.6	8.2	2.8	2.8	8.5	1.2	6.8	1.5	0.5	19.7	3.9	5.9	0.3	11.9	0.5	9.5	0.0	1.6	0.6	0.0	1.9	0.6	0.0	0.4	3.3	0.0	0.0	0.0	0.0	3.9	2.6	0.2	2.5	0.2	0.3	0.6	5.2	7.1	1.5	2.5	1.9	9.9	0.0	4.8	5.0	0.6	0.1	8.3	0.6	0.0	0.2	0.0	22.5	34.0	5.6	0.0	0.2	1.7	0.1	1.7	1.3	0.0	0.0	0.6	0.2	7.0	0.0	0.2	0.3	1.4	0.1	0.4	0.1	2.4	0.4	0.3	1.2	1.3	17.7	2.6	1.2	0.0	0.1	0.4	5.2	1.4	1.6	1.4	0.0	0.0	2.6	0.0	55.3	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0										
SEPT12	FLJ25410	ENSG00000140623	"Septin 12"	Q8IYM1	16	4777669-4788521	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation, Spermatogenesis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	69	"testis: 99.8"	"Group enriched"	"Detected in some"	8	"BEWO: 2.5;SCLC-21H: 1.3;SK-BR-3: 2.0"	"Cancer enhanced"	"Detected in single"		"testis cancer: 0.5"	"Region enriched"	"Detected in single"	8	"cerebellum: 1.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA041128			Uncertain	Microtubules				Microtubules		"HPA041128: AB_10796568"	"unprognostic (2.11e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.56e-2)"	"unprognostic (2.29e-2)"	"unprognostic (2.71e-1)"	"unprognostic (5.45e-2)"		"unprognostic (7.40e-2)"		"unprognostic (1.39e-1)"	"unprognostic (3.80e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.49e-8)"	"unprognostic (7.41e-2)"	"unprognostic (9.87e-2)"		"unprognostic (8.36e-3)"	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	99.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	0.0	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.0	0.1	0.1	0.1	0.0	0.0	0.0
SEPT2	"DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3"	ENSG00000168385	"Septin 2"	Q15019	2	241315100-241354027	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation, Mitosis, Spermatogenesis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB017190, HPA018481"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Actin filaments,Cytokinetic bridge"		8800000	8800000	"Actin filaments"	"Nucleoplasm, Plasma membrane, Cytokinetic bridge"	"CAB017190: , HPA018481: AB_1856684"	"unprognostic (6.31e-2)"	"unprognostic (5.27e-2)"	"unprognostic (2.95e-2)"	"unprognostic (4.03e-2)"	"prognostic favourable (8.21e-4)"	"unprognostic (3.32e-1)"	"prognostic unfavourable (3.66e-4)"	"unprognostic (1.96e-3)"	"unprognostic (1.83e-2)"	"unprognostic (5.69e-2)"	"unprognostic (1.11e-3)"	"unprognostic (3.16e-1)"	"unprognostic (9.58e-3)"	"unprognostic (8.11e-2)"	"unprognostic (9.53e-2)"	"unprognostic (1.40e-1)"	"unprognostic (2.17e-2)"	64.2	46.4	76.5	42.9	69.9	29.1	58.7	34.9	61.8	69.3	48.4	85.2	57.4	37.8	59.5	59.8	46.8	48.2	54.0	56.2	65.8	55.4	64.6	31.4	51.2	51.3	76.5	52.7	63.4	73.0	56.6	56.3	58.9	60.7	53.7	53.3	48.8	43.6	64.7	39.5	32.0	42.2	81.8	100.8	51.5	45.6	67.7	57.2	36.2	64.2	39.0	47.5	56.5	42.6	25.5	51.2	38.5	50.5	51.3	36.9	59.4	31.9	28.8	78.5	51.3	73.1	79.8	40.6	70.8	69.8	45.5	58.0	16.1	34.8	13.0	16.9	80.9	28.5	51.2	47.9	74.9	32.8	36.4	52.2	28.8	59.4	44.8	49.7	31.9	71.0	31.4	37.9	36.6	79.2	46.5	19.1	66.9	23.0	29.4	30.4	57.1	21.1	29.1	98.7	27.5	67.5	48.9	56.3	37.9	49.0	33.9	46.7	20.3	44.9	74.8	55.8	23.7	53.8	41.8	37.7	32.8	45.8	48.0	30.4	77.0	38.5	46.0	26.3	30.3	50.5	36.9	25.5	29.6	31.2	51.2	21.6	26.2	27.4	16.3	51.3	37.2	38.6	29.5	59.4	76.5	69.9	34.9	52.3	65.8	55.4	76.5	52.7	60.7	57.2
SERPINA1	"A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1"	ENSG00000197249	"Serpin family A member 1"	P01009	14	94376747-94390693	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	16	"liver: 3314.2"	"Cell line enriched"	"Detected in some"	8	"Hep G2: 318.5"	"Cancer enriched"	"Detected in all"	10	"liver cancer: 3850.6"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	5	"classical monocyte: 110.2;intermediate monocyte: 165.9;neutrophil: 139.3;non-classical monocyte: 203.0"	"Group enriched"	"Detected in many"	5	"granulocytes: 139.3;monocytes: 203.0"					"Region enriched"	"Detected in many"	6	"cerebellum: 334.2"	"HPA000927, HPA001292, CAB013211, CAB016648, CAB073396"	Enhanced		Enhanced	Vesicles	"Secreted to blood"	210000000000	210000000000	Vesicles		"CAB013211: , CAB016648: AB_1611888, CAB073396: , HPA000927: AB_1844761, HPA001292: AB_1844762"	"prognostic favourable (1.61e-5)"	"unprognostic (3.37e-1)"	"prognostic favourable (5.86e-4)"	"unprognostic (1.38e-2)"	"unprognostic (1.98e-2)"	"unprognostic (5.50e-3)"	"unprognostic (3.81e-2)"	"unprognostic (6.78e-2)"	"unprognostic (2.54e-2)"	"unprognostic (7.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.54e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.30e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.96e-1)"	0.9	0.4	0.7	4.9	1.4	3.0	2.4	0.2	0.7	2.6	7.5	0.5	3.1	6.3	0.8	8.6	0.4	0.7	14.2	1.0	0.4	0.5	74.1	3314.2	13.6	5.3	1.0	0.2	0.6	7.4	0.0	0.4	0.8	0.8	0.6	4.1	0.6	0.9	3.6	0.2	0.3	36.2	1.4	1.3	8.9	7.0	0.8	0.8	0.5	0.8	0.2	0.9	0.5	0.6	0.3	33.5	139.3	203.0	0.2	0.3	100.0	2.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	12.6	40.1	0.1	1.1	0.0	0.1	0.0	0.8	0.0	4.9	0.0	0.2	0.1	318.5	0.0	1.1	0.1	0.2	0.4	0.0	1.4	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.1	0.5	0.1	1.1	0.1	21.5	0.2	0.0	0.0	0.4	0.1	0.1	18.9	0.1	0.1	0.1	5.0	0.1	0.6	0.2	0.1	0.4	0.3	2.8	0.0	0.4	110.2	29.1	0.2	165.9	0.3	0.3	0.1	0.2	33.5	0.1	0.2	0.1	139.3	0.2	203.0	0.7	0.2	100.0	0.7	1.4	0.2	0.7	0.4	0.5	1.0	0.2	0.8	0.8
SERPINA3	"AACT, ACT"	ENSG00000196136	"Serpin family A member 3"	P01011	14	94612377-94624055	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"liver: 1244.8"	"Cell line enriched"	"Detected in some"	7	"Hep G2: 96.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA000893, HPA002560, CAB016647"	Enhanced				"Secreted to blood"	95000000000	95000000000			"CAB016647: AB_1611882, HPA000893: AB_10794315, HPA002560: AB_1856717"	"prognostic favourable (8.92e-4)"	"unprognostic (3.33e-3)"	"unprognostic (9.21e-2)"	"unprognostic (1.53e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.23e-1)"	"unprognostic (9.60e-2)"	"unprognostic (1.20e-2)"	"unprognostic (9.92e-2)"	"unprognostic (3.74e-12)"	"unprognostic (6.47e-2)"	"unprognostic (1.33e-2)"		"unprognostic (2.02e-2)"	11.1	2.1	5.4	5.7	17.6	1.2	26.0	1.9	16.1	43.8	2.3	10.0	1.4	2.3	2.2	2.4	3.3	4.3	18.1	10.7	13.4	6.5	61.9	1244.8	4.9	53.0	16.3	0.8	8.3	182.4	1.0	14.0	2.7	34.2	18.3	2.6	10.2	62.1	7.9	6.8	1.5	2.3	10.2	47.2	8.2	9.7	9.5	7.4	0.0	3.5	0.5	1.7	7.6	11.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.1	1.0	0.0	0.2	0.0	0.9	0.0	0.5	0.0	0.2	0.0	96.2	13.1	0.4	0.1	11.9	14.3	0.0	0.5	0.0	0.0	0.0	0.0	3.6	0.1	0.1	0.1	0.0	0.1	0.5	0.0	0.8	0.0	0.0	0.0	0.4	0.5	14.0	0.5	0.0	0.1	0.0	1.8	0.0	4.1	0.2	0.3	0.4	0.1	0.1	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	5.4	17.6	1.9	9.6	13.4	6.5	16.3	0.8	34.2	7.4
SERPINA5	"PAI3, PCI, PLANH3, PROCI"	ENSG00000188488	"Serpin family A member 5"	P05154	14	94561442-94593120	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Fertilization, Lipid transport, Transport"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 100.4;ductus deferens: 126.6;liver: 112.4;seminal vesicle: 106.7;testis: 146.5"	"Cell line enriched"	"Detected in some"	14	"Hep G2: 74.3"	"Cancer enhanced"	"Detected in many"		"liver cancer: 121.1"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA056919			Approved	Mitochondria	"Secreted to blood"	2300000000	2300000000	Mitochondria		"HPA056919: "	"unprognostic (5.94e-3)"	"unprognostic (2.64e-4)"	"unprognostic (1.13e-1)"	"prognostic favourable (7.72e-4)"	"unprognostic (3.34e-3)"	"unprognostic (6.10e-3)"	"unprognostic (3.94e-2)"	"unprognostic (1.39e-3)"	"unprognostic (5.36e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.16e-2)"	"unprognostic (1.87e-2)"	"unprognostic (8.39e-3)"	"unprognostic (3.38e-3)"	"unprognostic (9.92e-2)"	"unprognostic (8.08e-2)"	"unprognostic (3.23e-1)"	1.1	100.4	0.4	1.8	1.8	0.0	7.7	0.2	0.5	4.0	1.0	1.6	126.6	0.6	4.8	5.0	0.5	3.6	34.3	5.6	0.6	0.4	33.6	112.4	0.3	1.9	3.1	0.3	6.4	33.8	0.0	0.8	0.2	1.9	1.9	0.0	0.9	10.9	106.7	6.6	0.7	0.7	0.4	1.5	36.1	2.0	146.5	0.6	0.1	0.9	1.5	0.6	1.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	3.9	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	74.3	0.1	0.1	0.0	0.5	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	1.2	0.0	0.1	5.1	0.0	0.0	2.4	0.0	0.0	0.1	0.0	0.1	0.1	0.4	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.8	0.2	0.5	0.6	0.4	3.1	0.3	1.9	0.6
SERPINB13	"headpin, HUR7, hurpin, PI13"	ENSG00000197641	"Serpin family B member 13"	Q9UIV8	18	63586989-63604639	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"cervix, uterine: 37.7;esophagus: 70.8;lymphoid tissue: 54.2;tongue: 107.2;vagina: 34.1"	"Group enriched"	"Detected in some"	132	"HaCaT: 64.1;hTCEpi: 24.4"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 45.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA052630, HPA057129"	Enhanced		Approved	"Nuclear speckles,Cytosol"		59000	59000	"Nuclear speckles, Cytosol"		"HPA052630: , HPA057129: "		"unprognostic (3.49e-2)"		"unprognostic (3.73e-1)"		"unprognostic (1.11e-1)"		"unprognostic (7.27e-2)"	"unprognostic (2.28e-1)"			"unprognostic (4.29e-2)"		"unprognostic (2.81e-1)"			"unprognostic (6.04e-3)"	0.1	0.1	0.0	0.1	0.0	0.1	1.0	0.0	0.1	37.7	0.1	0.0	0.0	0.1	3.1	0.1	70.8	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.4	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	10.9	0.1	0.2	5.7	0.1	0.1	0.0	0.1	0.1	0.1	0.0	1.0	0.1	107.2	54.2	1.5	34.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SERPINB2	"HsT1201, PAI2, PLANH2"	ENSG00000197632	"Serpin family B member 2"	P05120	18	63871692-63903890	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Plasminogen activation"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 70.6;placenta: 222.1"	"Group enriched"	"Detected in some"	5	"HaCaT: 79.8;U-138 MG: 95.5;U-2197: 145.1"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 26.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 16.3;eosinophil: 7.6"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 16.3"	"Region enriched"	"Detected in single"	14	"cerebellum: 2.9"	"Low region specificity"	"Detected in all"			HPA015480	Supported				"Intracellular and membrane"	110000	110000			"HPA015480: AB_1855456"	"unprognostic (2.11e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.46e-2)"	"unprognostic (1.36e-4)"	"unprognostic (1.17e-1)"	"unprognostic (1.65e-2)"		"unprognostic (1.37e-1)"	"unprognostic (1.92e-1)"	"unprognostic (9.69e-2)"	"unprognostic (3.76e-3)"	"unprognostic (1.90e-1)"	"unprognostic (4.33e-6)"	"unprognostic (3.89e-2)"	"unprognostic (3.94e-1)"	"unprognostic (3.29e-1)"	"prognostic unfavourable (1.55e-5)"	6.0	0.0	0.1	2.9	0.2	8.7	2.6	0.2	0.1	6.4	0.8	0.1	0.1	0.0	0.7	0.4	70.6	3.1	0.1	0.4	0.1	0.0	0.1	0.1	0.9	0.1	0.1	0.1	0.6	0.3	0.0	0.1	222.1	0.2	0.3	0.0	0.1	11.3	0.2	0.3	25.7	0.2	0.3	0.1	0.3	0.1	0.2	0.1	0.9	0.2	49.0	37.7	1.1	13.8	0.0	0.2	16.3	3.9	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	19.4	20.6	0.7	1.5	0.1	0.0	0.0	0.0	0.6	79.8	0.0	16.4	14.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.6	9.5	4.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.7	1.5	95.5	0.0	145.1	0.0	0.0	0.0	0.0	2.5	0.2	11.1	16.3	3.9	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.0	0.1	0.2	0.2	0.1	0.1	0.0	0.1	0.1	0.2	0.1
SERPINB3	"HsT1196, SCC, SCCA1, T4-A"	ENSG00000057149	"Serpin family B member 3"	P29508	18	63655197-63661963	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"cervix, uterine: 50.7;esophagus: 140.0;vagina: 80.0"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 2.5;HaCaT: 8.9;SiHa: 5.5;U-2197: 11.3"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 186.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992"	Enhanced		Approved	"Plasma membrane,Cytosol"		11000000	11000000	Cytosol	"Plasma membrane"	"CAB018772: AB_2285759, CAB036006: , CAB036007: , HPA048341: , HPA049988: , HPA055992: "		"unprognostic (2.95e-3)"		"unprognostic (1.66e-1)"		"unprognostic (2.03e-1)"		"unprognostic (2.91e-2)"	"unprognostic (2.11e-1)"		"prognostic unfavourable (3.19e-4)"	"unprognostic (6.68e-2)"		"unprognostic (2.58e-1)"			"unprognostic (4.19e-3)"	0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	50.7	0.2	0.2	0.2	0.0	3.8	0.2	140.0	0.0	0.2	0.2	0.2	0.0	0.2	0.2	5.4	0.2	0.2	0.2	0.2	0.2	0.0	2.4	0.2	0.2	1.1	0.0	0.2	13.0	0.2	0.2	7.1	0.2	0.2	0.2	0.2	0.0	0.2	0.2	1.4	0.2	21.3	3.1	13.1	80.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.1	8.9	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.9	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.3	0.0	0.0	11.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
SERPINB4	"LEUPIN, PI11, SCCA-2, SCCA1, SCCA2"	ENSG00000206073	"Serpin family B member 4"	P48594	18	63637259-63644298	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"cervix, uterine: 32.5;esophagus: 48.4;tongue: 18.4;vagina: 41.4"	"Cell line enhanced"	"Detected in some"		"HaCaT: 4.0;HSkMC: 2.0;SiHa: 3.1;U-2197: 10.9"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 104.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA048341, HPA049988, HPA055992"	Supported					5700000	5700000			"HPA048341: , HPA049988: , HPA055992: "		"unprognostic (8.81e-3)"				"unprognostic (9.43e-2)"		"unprognostic (8.96e-3)"	"unprognostic (4.38e-1)"	"unprognostic (1.63e-2)"	"prognostic unfavourable (5.48e-4)"	"unprognostic (2.46e-1)"		"unprognostic (4.37e-2)"			"unprognostic (1.27e-2)"	0.1	0.0	0.1	1.4	0.1	0.0	0.1	0.1	0.1	32.5	0.1	0.1	0.1	0.0	1.8	0.1	48.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	1.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.6	0.0	0.1	7.0	0.1	0.3	4.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	2.0	0.1	18.4	2.3	8.7	41.4	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.1	1.0	0.1	0.0	0.0	1.1	0.0	0.1	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	10.9	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
SERPINE1	"PAI, PAI1, PLANH1"	ENSG00000106366	"Serpin family E member 1"	P05121	7	101127089-101139266	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 253.6"	"Cell line enhanced"	"Detected in many"		"BJ: 140.2;HUVEC TERT2: 162.7;LHCN-M2: 157.1;TIME: 402.3;U-138 MG: 191.5;U-251 MG: 168.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	20	"NK-cell: 10.8"	"Lineage enriched"	"Detected in single"	20	"NK-cells: 10.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA050039, CAB068501"	Uncertain		Approved	Cytosol	"Secreted to blood"	14000000	14000000	Cytosol		"CAB068501: AB_1642775, HPA050039: "	"unprognostic (5.02e-2)"	"prognostic unfavourable (5.01e-4)"	"prognostic unfavourable (2.82e-4)"	"unprognostic (2.10e-2)"	"unprognostic (9.04e-3)"	"prognostic unfavourable (2.84e-5)"	"unprognostic (6.80e-3)"	"prognostic unfavourable (4.41e-6)"	"unprognostic (2.33e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.88e-3)"	"unprognostic (1.58e-1)"	"prognostic unfavourable (5.88e-8)"	"prognostic unfavourable (3.27e-6)"	"unprognostic (1.05e-1)"	"unprognostic (4.33e-2)"	"prognostic unfavourable (5.51e-4)"	45.5	14.0	1.1	16.7	1.8	0.1	11.4	0.5	1.5	13.3	7.0	3.4	3.3	1.2	6.6	14.4	6.8	9.3	69.6	29.2	1.5	0.6	7.8	65.3	56.3	3.3	4.1	1.8	19.7	24.7	1.4	2.6	253.6	5.9	7.6	0.9	2.3	2.4	6.2	12.4	4.1	2.3	13.5	4.1	5.8	6.6	8.6	2.2	0.6	11.3	3.7	2.8	71.7	18.1	0.2	0.4	0.5	0.2	10.8	0.3	1.0	3.0	2.5	0.0	0.2	32.1	64.0	3.6	140.2	26.5	70.7	61.8	0.3	0.2	0.1	33.6	44.6	0.7	0.0	10.8	73.1	0.1	0.0	0.0	0.2	2.4	64.6	0.0	0.1	25.0	4.3	108.5	57.1	162.7	0.2	0.1	157.1	0.0	0.0	0.0	0.7	1.6	0.0	0.2	0.1	0.2	1.2	0.0	0.0	11.5	3.1	0.3	0.1	0.3	402.3	191.5	8.4	65.2	168.3	0.0	0.1	0.1	47.8	0.0	1.8	0.5	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.3	0.3	0.2	0.0	0.1	0.2	10.8	0.0	0.4	0.0	1.0	1.1	1.8	0.5	1.5	1.5	0.6	4.1	1.8	5.9	2.2
SERPINF1	"EPC-1, PEDF, PIG35"	ENSG00000132386	"Serpin family F member 1"	P36955	17	1761959-1777574	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Dwarfism, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 360.1"	"Cell line enhanced"	"Detected in some"		"ASC diff: 121.4;ASC TERT1: 94.8;Hep G2: 55.4;HHSteC: 40.6;HSkMC: 128.9"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	8	"pons and medulla: 105.5"	"Cell type enriched"	"Detected in some"	18	"plasmacytoid DC: 143.3"	"Lineage enriched"	"Detected in many"	119	"dendritic cells: 143.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005825	Uncertain				"Secreted to blood"	85000000000	85000000000			"HPA005825: AB_1079921"	"unprognostic (3.85e-1)"	"prognostic favourable (5.49e-4)"	"unprognostic (9.44e-2)"	"unprognostic (2.32e-2)"	"unprognostic (2.96e-2)"	"unprognostic (2.09e-1)"	"unprognostic (3.32e-3)"	"unprognostic (2.33e-1)"	"unprognostic (7.88e-2)"	"unprognostic (5.92e-2)"	"unprognostic (1.69e-1)"	"unprognostic (4.18e-2)"	"prognostic unfavourable (1.40e-8)"	"unprognostic (2.11e-3)"	"unprognostic (2.82e-1)"	"unprognostic (4.53e-3)"	"unprognostic (1.25e-3)"	70.0	7.5	2.3	15.1	4.5	1.1	61.6	0.7	13.9	84.1	16.4	20.8	14.8	5.0	48.9	71.9	24.3	75.3	66.8	50.3	11.6	1.9	6.9	190.1	20.1	30.6	1.9	5.9	68.1	54.7	0.6	11.0	38.6	105.5	53.2	6.5	360.1	17.8	14.2	51.4	21.5	15.7	27.6	2.4	21.2	17.8	86.3	1.4	6.0	27.4	38.5	14.6	32.1	37.9	0.8	143.3	0.1	1.2	0.1	0.5	1.3	0.0	0.4	0.2	0.2	121.4	94.8	2.0	5.6	4.7	0.0	0.0	0.9	0.0	0.2	0.2	6.7	0.3	8.0	0.4	0.0	0.0	4.3	0.1	0.0	55.4	40.6	0.1	0.1	128.9	0.7	0.1	0.1	0.0	11.4	0.0	5.9	0.0	0.7	0.6	3.2	0.1	0.3	22.3	0.1	0.0	0.6	0.1	4.1	0.0	0.0	5.7	0.7	17.1	0.2	0.0	1.8	1.4	0.1	0.0	0.2	2.9	0.1	0.0	0.0	0.0	1.2	0.1	0.0	0.4	0.0	0.8	0.0	0.1	7.9	0.4	0.2	0.5	0.1	0.1	0.0	143.3	0.0	1.3	2.3	4.5	0.7	13.9	11.6	1.9	1.9	5.9	105.5	1.4
SET	"2PP2A, IPP2A2, PHAPII"	ENSG00000119335	"SET nuclear proto-oncogene"	Q01105	9	128683424-128696400	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Chaperone, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB005232, HPA063683"	Supported		Enhanced	"Nucleoplasm,Lipid droplets"		880000	880000	Nucleoplasm	"Lipid droplets"	"CAB005232: AB_2185634, HPA063683: "	"unprognostic (1.92e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.77e-1)"	"unprognostic (7.15e-2)"	"unprognostic (4.37e-3)"	"prognostic unfavourable (9.41e-7)"	"unprognostic (2.00e-2)"	"unprognostic (1.88e-2)"	"unprognostic (3.62e-1)"	"unprognostic (3.78e-2)"	"unprognostic (3.27e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.57e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.09e-1)"	"unprognostic (1.54e-2)"	47.2	49.7	66.5	59.3	65.8	71.8	56.5	64.2	61.2	54.4	51.3	55.3	45.6	40.1	64.8	33.1	71.6	51.6	48.9	81.6	63.6	57.3	51.7	57.8	51.2	91.1	65.4	56.1	76.5	61.3	55.0	38.7	65.4	47.3	59.2	56.4	36.3	52.1	46.9	76.3	53.6	45.7	59.0	73.5	62.8	46.8	34.8	58.6	152.9	69.1	46.2	92.7	74.4	84.1	72.2	66.4	43.2	56.5	78.8	77.9	69.7	50.4	57.6	82.9	65.6	24.8	38.9	76.5	41.7	46.2	60.3	41.6	79.2	62.0	130.6	35.3	42.9	94.7	122.5	62.7	69.0	59.5	52.2	75.1	89.7	64.4	55.4	137.0	49.2	32.3	49.1	51.3	103.0	56.3	145.7	53.0	49.3	85.2	114.7	50.6	138.4	61.4	105.0	103.1	105.7	46.5	57.0	84.5	53.1	91.8	61.7	49.8	76.9	42.7	53.9	71.3	53.5	43.9	68.9	41.7	119.8	155.4	33.9	73.0	67.9	34.5	53.9	43.2	58.9	56.5	72.1	72.2	67.9	62.8	52.7	66.3	65.8	77.9	35.4	78.8	45.6	66.4	52.3	69.7	66.5	65.8	64.2	61.2	63.6	57.3	65.4	56.1	47.3	58.6
SETBP1	"KIAA0437, SEB"	ENSG00000152217	"SET binding protein 1"	Q9Y6X0	18	44680173-45068510	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"AF22: 9.3;Karpas-707: 37.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 4.9;naive B-cell: 7.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049022, HPA057259"	Uncertain		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"				Nucleoplasm	"Nuclear bodies, Cytosol"	"HPA049022: , HPA057259: "	"unprognostic (1.25e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.97e-2)"	"unprognostic (4.63e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.91e-1)"	"unprognostic (3.57e-2)"	"unprognostic (3.49e-1)"	"unprognostic (2.01e-2)"	"unprognostic (2.71e-3)"	"unprognostic (6.52e-2)"	"prognostic favourable (6.34e-8)"	"unprognostic (2.18e-2)"	"unprognostic (2.29e-1)"	"unprognostic (6.06e-2)"	"unprognostic (7.81e-5)"	10.6	2.9	3.8	13.2	8.7	2.1	9.8	16.0	12.6	16.9	14.6	4.2	19.9	2.5	14.0	17.5	6.6	11.0	7.9	6.8	3.6	3.5	15.0	7.2	9.8	7.0	2.9	7.4	12.8	8.2	9.1	5.1	10.2	3.2	12.2	5.3	14.0	6.9	21.3	14.5	6.6	6.9	19.9	3.7	5.9	9.1	5.5	1.2	3.4	8.4	8.7	8.8	11.9	13.3	7.5	4.3	0.2	1.6	0.0	0.6	0.2	0.0	1.6	9.3	0.0	2.7	0.7	0.6	0.7	1.7	0.9	0.7	0.1	0.0	0.5	0.3	1.0	2.7	1.0	2.9	0.6	0.8	0.4	0.0	1.0	0.6	0.0	0.0	0.0	2.2	1.1	0.0	1.8	0.3	0.0	37.1	0.2	0.5	0.0	0.0	1.3	0.6	3.0	0.0	3.2	3.1	2.1	4.7	2.5	0.0	0.0	0.5	1.3	0.0	0.0	5.5	2.1	0.0	4.3	4.9	0.3	0.0	3.3	0.1	3.1	0.2	0.0	0.0	0.6	1.1	0.0	4.9	0.1	0.5	0.1	7.5	0.0	0.2	0.0	0.0	1.6	4.3	0.0	0.2	3.8	8.7	16.0	12.6	3.6	3.5	2.9	7.4	3.2	1.2
SETD2	"FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A"	ENSG00000181555	"SET domain containing 2"	Q9BYW2	3	47016429-47163967	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Antiviral defense, Differentiation, DNA damage, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, Methyltransferase, Transferase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042451	Approved		Approved	"Nuclear speckles,Cytosol"				"Nuclear speckles"	Cytosol	"HPA042451: AB_10806239"	"unprognostic (2.78e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.08e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.01e-2)"	"prognostic unfavourable (8.19e-4)"	"unprognostic (6.19e-2)"	"unprognostic (2.45e-1)"	"unprognostic (7.84e-2)"	"prognostic favourable (7.99e-6)"	"unprognostic (1.03e-1)"	"unprognostic (1.91e-1)"	"unprognostic (8.79e-2)"	"unprognostic (5.43e-2)"	13.2	10.5	12.2	15.2	15.4	20.0	11.7	22.4	16.4	13.4	14.0	9.1	12.9	9.5	15.8	7.5	10.8	11.4	8.7	8.8	10.6	6.8	11.4	10.3	10.4	11.8	11.7	9.5	16.0	13.4	21.4	16.3	10.7	11.3	12.4	10.9	7.7	12.7	14.8	27.6	12.5	11.5	11.9	9.8	13.8	10.4	12.8	12.8	23.2	15.8	5.5	12.8	16.1	15.5	4.8	2.6	6.0	2.3	7.1	3.9	1.0	11.4	9.0	15.2	7.8	9.1	10.6	6.4	10.6	10.3	12.4	11.3	9.5	7.5	25.3	6.6	14.5	7.0	16.4	10.1	16.8	14.5	6.5	25.9	15.1	7.3	6.8	19.4	15.0	9.1	9.7	12.2	15.2	11.4	16.6	9.6	10.1	6.0	14.2	2.6	11.5	7.5	9.4	14.7	13.1	6.2	15.1	6.6	10.5	17.8	7.0	6.6	7.4	14.4	14.6	13.6	10.2	11.6	16.8	12.2	13.6	25.5	7.9	11.1	7.9	2.4	2.2	5.2	3.9	2.3	2.4	3.7	2.4	3.0	2.5	4.8	3.5	3.0	6.0	7.1	1.9	2.6	1.0	1.0	12.2	15.4	22.4	16.4	10.6	6.8	11.7	9.5	11.3	12.8
SETDB1	"ESET, KG1T, KIAA0067, KMT1E, TDRD21"	ENSG00000143379	"SET domain bifurcated 1"	Q15047	1	150926263-150964744	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	5	"U-698: 88.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018142, HPA058484"	Uncertain		Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA018142: AB_1856757, HPA058484: "	"unprognostic (1.07e-1)"	"unprognostic (4.08e-1)"	"unprognostic (8.02e-2)"	"unprognostic (2.24e-3)"	"unprognostic (1.65e-2)"	"unprognostic (9.57e-2)"	"prognostic unfavourable (8.88e-4)"	"unprognostic (6.03e-2)"	"unprognostic (9.94e-3)"	"unprognostic (7.13e-2)"	"unprognostic (1.21e-1)"	"unprognostic (6.65e-2)"	"prognostic unfavourable (4.25e-4)"	"unprognostic (1.59e-1)"	"unprognostic (3.93e-2)"	"unprognostic (3.14e-2)"	"unprognostic (1.14e-1)"	16.9	15.4	9.5	21.2	15.9	16.9	17.7	21.6	18.2	18.6	15.4	25.2	18.6	13.0	22.8	18.9	15.6	16.8	14.0	10.9	9.6	8.5	13.3	12.7	15.6	20.7	15.3	13.2	23.9	17.6	21.0	15.4	18.4	13.7	14.9	16.8	20.6	16.1	18.5	20.0	18.0	17.1	17.9	13.7	21.9	15.0	33.5	14.2	24.5	18.6	12.0	20.7	18.6	16.3	11.2	12.8	6.9	14.9	7.6	9.1	5.3	5.7	6.7	9.8	6.4	4.7	6.3	16.3	4.8	5.5	6.9	5.9	4.5	8.0	11.4	6.6	5.3	7.3	9.1	5.1	5.5	5.5	11.3	6.4	6.9	5.2	6.7	11.3	6.1	8.2	5.8	5.7	9.2	8.1	10.8	9.3	4.9	11.1	7.8	6.6	13.4	5.4	9.1	6.3	8.4	5.3	6.6	7.1	13.0	7.3	8.6	5.8	9.3	15.4	5.4	4.0	4.2	4.4	6.7	9.7	10.4	88.6	4.2	4.0	3.9	6.8	10.7	6.9	8.3	14.9	8.7	8.7	7.4	9.1	12.8	11.2	8.3	8.3	6.5	7.6	10.6	8.6	4.7	5.3	9.5	15.9	21.6	18.2	9.6	8.5	15.3	13.2	13.7	14.2
SF3B1	"Hsh155, Prp10, PRPF10, SAP155, SF3b155"	ENSG00000115524	"Splicing factor 3b subunit 1"	O75533	2	197389784-197435091	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA050275	Approved		Enhanced	"Nuclear speckles"		840000	840000	"Nuclear speckles"		"HPA050275: "	"unprognostic (6.86e-2)"	"unprognostic (2.78e-1)"	"unprognostic (2.14e-1)"	"unprognostic (3.51e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.25e-3)"	"unprognostic (2.44e-3)"	"unprognostic (3.31e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.20e-1)"	"unprognostic (6.79e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.57e-2)"	"unprognostic (9.15e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.79e-1)"	"unprognostic (3.41e-2)"	53.9	49.9	36.5	54.5	44.9	88.0	57.9	60.8	47.3	72.3	54.2	44.3	45.6	36.8	64.6	72.0	50.5	53.3	43.1	39.6	34.7	26.0	49.7	50.7	53.1	65.3	56.5	27.7	73.6	60.5	66.2	81.4	64.6	46.7	50.0	51.0	37.0	54.4	45.4	49.3	48.5	67.8	41.2	50.2	88.1	48.8	33.3	53.5	113.0	53.3	38.0	65.7	62.4	56.0	32.7	41.9	41.1	37.8	39.6	45.9	29.4	30.7	28.2	63.6	34.7	49.3	50.4	53.4	43.0	44.0	37.6	46.1	53.8	33.2	58.7	29.0	43.7	29.8	63.5	34.9	58.8	44.9	39.5	62.1	69.0	63.2	37.2	65.9	45.3	52.6	34.1	39.1	48.2	43.7	44.4	40.5	41.6	27.0	60.6	63.5	50.0	44.6	53.4	54.4	39.0	52.2	78.2	35.7	44.3	41.1	25.2	29.4	24.9	50.5	44.0	29.5	25.4	29.8	30.5	37.0	60.1	84.3	28.3	39.9	32.6	27.7	33.1	39.1	37.5	37.8	40.6	32.7	32.5	35.3	41.9	30.8	33.9	33.9	41.1	39.6	36.1	23.8	45.9	29.4	36.5	44.9	60.8	47.3	34.7	26.0	56.5	27.7	46.7	53.5
SFN	YWHAS	ENSG00000175793	Stratifin	P31947	1	26863138-26864457	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 256.2;lymphoid tissue: 107.4;skin 1: 123.8;tongue: 256.0"	"Cell line enhanced"	"Detected in many"		"A-431: 68.6;HaCaT: 108.3;HBEC3-KT: 166.7;hTCEpi: 111.9"	"Cancer enhanced"	"Detected in all"		"head and neck cancer: 2526.8"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"basophil: 7.1"	"Lineage enriched"	"Detected in single"	12	"granulocytes: 7.1"	"Low region specificity"	"Detected in some"							"CAB006268, HPA011105, CAB040552, HPA061603"	Enhanced		Supported	Nucleoli,Cytosol	"Secreted in other tissues"	54000000	54000000	Cytosol	Nucleoli	"CAB006268: AB_425459, CAB040552: , HPA011105: AB_1844339, HPA061603: "	"unprognostic (5.70e-2)"	"unprognostic (1.26e-1)"	"unprognostic (8.37e-2)"	"prognostic favourable (1.92e-4)"	"unprognostic (1.26e-2)"	"unprognostic (1.85e-1)"	"prognostic unfavourable (5.68e-5)"	"unprognostic (1.71e-2)"	"unprognostic (2.99e-1)"	"unprognostic (3.96e-1)"	"prognostic unfavourable (6.01e-4)"	"unprognostic (3.83e-1)"	"prognostic unfavourable (7.45e-6)"	"unprognostic (7.90e-3)"	"unprognostic (3.25e-1)"	"unprognostic (8.12e-2)"	"unprognostic (2.06e-2)"	0.4	0.0	0.5	3.1	0.5	0.0	3.8	0.4	0.7	37.5	10.7	0.5	0.5	5.9	3.3	0.7	256.2	0.0	6.0	0.3	0.6	0.1	1.2	0.5	8.2	0.3	0.4	0.3	0.3	0.3	0.0	0.3	3.4	0.8	5.9	4.0	0.3	25.5	0.4	0.4	123.8	13.2	0.5	0.7	0.3	6.6	0.4	0.4	3.1	0.4	256.0	107.4	9.1	47.7	0.0	0.0	7.1	0.0	0.0	0.6	0.0	68.6	11.6	0.0	0.1	0.0	0.0	3.4	0.0	0.0	0.0	0.0	4.2	36.2	0.6	3.0	0.0	108.3	0.0	166.7	0.0	16.4	0.5	0.0	11.6	12.2	0.0	0.0	0.1	0.0	111.9	0.0	29.3	0.0	0.1	0.4	0.0	14.6	0.0	0.0	0.2	19.3	0.0	0.0	3.8	25.9	15.8	0.0	0.0	16.6	2.9	0.1	7.7	0.1	0.0	0.0	31.7	0.0	0.4	0.1	0.5	0.3	0.1	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.5	0.5	0.4	0.7	0.6	0.1	0.4	0.3	0.8	0.4
SFPQ	"PPP1R140, PSF"	ENSG00000116560	"Splicing factor proline and glutamine rich"	P23246	1	35176378-35193148	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009886, HPA047513, HPA054689"	Enhanced		Enhanced	Nucleoplasm		280000	280000	Nucleoplasm		"CAB009886: AB_2186937, HPA047513: AB_2680073, HPA054689: AB_2682574"	"prognostic favourable (9.56e-5)"	"unprognostic (1.01e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.99e-1)"	"unprognostic (5.53e-2)"	"unprognostic (1.86e-2)"	"prognostic unfavourable (7.91e-13)"	"unprognostic (3.10e-1)"	"unprognostic (4.00e-3)"	"unprognostic (3.85e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.03e-3)"	"unprognostic (1.25e-3)"	"unprognostic (1.16e-2)"	"unprognostic (3.97e-3)"	"unprognostic (3.07e-1)"	"unprognostic (3.77e-3)"	40.5	35.7	31.5	39.4	31.4	122.5	48.3	53.0	38.5	39.0	31.4	37.8	32.9	30.0	45.3	36.5	45.5	43.0	28.1	34.0	29.1	24.6	36.4	34.2	47.6	48.8	26.3	32.6	59.9	40.2	45.8	46.3	35.5	31.9	35.5	38.0	35.7	39.6	38.0	44.9	42.9	34.1	36.5	32.8	42.4	35.5	37.5	32.9	95.2	35.3	24.1	60.6	35.9	38.6	6.9	11.2	4.4	8.8	4.9	8.9	3.3	36.1	30.2	52.8	29.8	13.0	19.6	49.6	19.8	20.2	33.9	24.8	32.9	26.2	66.1	27.6	22.9	33.1	57.4	38.8	46.3	35.2	38.1	49.7	32.6	39.0	17.6	51.6	29.6	15.6	15.1	29.4	14.3	29.5	56.1	31.6	32.9	31.5	60.4	44.3	62.9	29.3	61.4	35.9	43.0	32.7	44.0	38.1	42.4	28.6	22.3	28.7	26.1	36.8	31.3	27.2	40.0	17.8	42.4	36.2	30.7	67.3	19.4	34.2	38.6	2.6	6.5	4.4	7.7	8.8	8.9	6.2	7.6	6.1	5.8	6.9	7.2	7.9	3.4	4.9	6.4	11.2	8.2	3.3	31.5	31.4	53.0	38.5	29.1	24.6	26.3	32.6	31.9	32.9
SFRP4	"FRP-4, frpHE, FRZB-2"	ENSG00000106483	"Secreted frizzled related protein 4"	Q6FHJ7	7	37905932-38025695	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Differentiation, Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 144.9;endometrium 1: 100.7;retina: 123.0"	"Cell line enhanced"	"Detected in some"		"ASC diff: 13.8;HSkMC: 5.4;U-937: 5.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"HPA009712, HPA050585"	Enhanced				"Secreted in female reproductive system"	1500000	1500000			"HPA009712: AB_1856778, HPA050585: AB_2681183"	"unprognostic (5.93e-2)"	"unprognostic (5.84e-3)"	"unprognostic (2.75e-2)"	"unprognostic (1.58e-3)"	"unprognostic (2.61e-1)"	"unprognostic (2.35e-2)"	"unprognostic (4.02e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.76e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (1.36e-5)"	"unprognostic (7.37e-3)"	"unprognostic (1.61e-1)"	"unprognostic (4.35e-3)"	"unprognostic (1.89e-3)"	4.6	2.3	0.5	0.9	0.9	0.0	12.5	0.3	0.4	144.9	0.8	1.7	5.4	0.0	100.7	11.5	3.2	35.1	2.5	5.5	0.4	0.4	1.2	0.2	3.9	0.8	0.8	0.7	42.7	1.4	0.1	4.0	0.4	1.3	4.9	0.2	123.0	2.3	7.1	1.4	0.3	0.5	14.5	3.3	4.1	0.5	5.8	0.3	0.4	3.3	2.5	0.5	8.8	14.8	0.4	0.8	0.4	0.6	0.1	0.1	0.0	0.0	2.5	2.8	0.0	13.8	0.6	0.1	0.0	0.1	0.0	0.0	0.4	0.0	0.1	0.1	2.9	0.1	0.0	0.3	0.3	0.0	0.0	0.2	0.2	2.0	0.1	0.4	0.0	5.4	0.7	0.6	0.0	0.2	0.0	0.3	0.2	0.4	0.0	1.6	0.1	0.0	0.2	1.7	0.0	0.1	0.2	0.1	0.3	0.0	0.0	0.3	0.0	0.0	0.9	0.0	1.2	1.6	0.2	0.5	0.1	0.2	0.3	5.2	0.9	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.0	0.0	0.1	0.1	0.1	0.0	0.4	0.1	0.0	0.8	0.0	0.0	0.5	0.9	0.3	0.4	0.4	0.4	0.8	0.7	1.3	0.3
SGK1	SGK	ENSG00000118515	"Serum/glucocorticoid regulated kinase 1"	O00141	6	134169246-134318112	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Stress response"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 141.3"	"Cell line enhanced"	"Detected in many"		"HHSteC: 50.1;RPTEC TERT1: 76.9;SK-MEL-30: 49.8;TIME: 59.8;U-266/84: 54.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 11.7;eosinophil: 45.9;neutrophil: 26.2"	"Group enriched"	"Detected in many"	7	"granulocytes: 45.9;monocytes: 11.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022085, CAB025148, HPA051251"	Approved		Enhanced	"Nuclear speckles"				"Nuclear speckles"		"CAB022085: , CAB025148: , HPA051251: "	"unprognostic (2.05e-2)"	"prognostic favourable (5.26e-4)"	"unprognostic (1.12e-1)"	"unprognostic (5.09e-3)"	"unprognostic (2.76e-1)"	"unprognostic (4.20e-2)"	"unprognostic (4.53e-2)"	"unprognostic (5.62e-2)"	"unprognostic (4.03e-1)"	"unprognostic (7.94e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.55e-1)"	"unprognostic (5.82e-3)"	"unprognostic (9.10e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.79e-1)"	"unprognostic (6.59e-2)"	45.6	35.5	16.8	12.8	43.2	15.8	22.9	10.6	25.0	18.4	62.3	51.7	10.8	14.2	14.9	11.2	30.0	16.1	47.8	12.5	22.9	9.6	37.5	51.1	31.2	8.4	48.8	16.6	47.2	47.8	141.3	4.7	19.2	28.3	18.3	11.3	45.8	26.2	18.4	12.4	25.8	131.8	13.6	40.3	7.6	31.1	12.2	50.1	6.2	22.3	24.8	20.4	26.1	31.7	0.6	4.0	45.9	11.7	0.9	0.7	3.1	0.6	1.1	0.7	0.0	8.6	2.1	0.9	12.3	25.7	16.1	13.2	1.9	1.7	2.0	1.8	12.7	0.4	1.1	1.9	11.9	0.0	0.5	0.1	30.7	1.4	50.1	0.1	1.1	12.9	12.4	15.8	20.6	27.0	3.9	31.4	5.7	0.1	0.1	0.4	0.7	1.3	0.3	1.4	0.2	76.9	0.2	0.3	3.0	38.7	0.1	49.8	0.0	0.3	59.8	4.7	2.0	28.9	2.7	5.9	54.8	6.3	4.4	1.9	6.3	0.6	11.7	45.9	0.2	6.8	0.5	0.6	0.4	0.2	4.0	0.4	0.5	0.6	26.2	0.9	3.7	0.2	0.7	3.1	16.8	43.2	10.6	25.0	22.9	9.6	48.8	16.6	28.3	50.1
SH2B3	"IDDM20, LNK"	ENSG00000111252	"SH2B adaptor protein 3"	Q9UQQ2	12	111405948-111451623	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 31.8;hTEC/SVTERT24-B: 36.4;U-87 MG: 55.3;WM-115: 42.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005483	Approved		Approved	Nucleoplasm				Nucleoplasm		"HPA005483: AB_1079260"	"unprognostic (2.77e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.09e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.65e-2)"	"unprognostic (8.17e-3)"	"unprognostic (9.08e-2)"	"prognostic unfavourable (6.20e-4)"	"unprognostic (2.86e-1)"	"unprognostic (3.89e-3)"	"unprognostic (1.11e-1)"	"unprognostic (2.24e-2)"	17.6	9.0	7.9	13.7	7.9	34.4	19.8	3.8	9.3	8.9	7.5	7.2	3.1	5.3	8.0	7.1	5.6	7.5	12.7	15.3	5.8	5.5	9.2	12.5	17.6	27.8	6.6	4.0	8.2	11.0	4.7	7.6	16.1	5.2	8.4	9.3	8.7	5.0	4.2	10.2	3.6	10.3	9.1	7.8	31.7	5.5	13.3	6.8	9.5	10.2	3.2	11.8	10.0	5.8	1.8	6.1	3.8	10.3	2.3	1.7	1.9	2.2	1.3	1.8	1.8	6.3	9.5	1.2	7.4	20.3	5.7	6.1	2.1	1.3	3.9	5.3	11.2	0.4	1.4	4.2	9.2	3.2	0.6	13.2	0.6	1.5	6.2	5.8	31.8	5.6	0.9	36.4	3.3	30.4	9.5	1.5	20.6	0.8	2.3	11.6	2.8	5.4	2.3	4.1	2.5	2.7	0.9	1.2	1.2	1.3	0.1	10.6	0.9	8.3	23.5	5.2	2.9	4.5	12.0	3.6	3.7	4.4	55.3	4.2	42.2	1.1	4.3	1.5	1.6	10.3	1.4	1.8	1.4	1.7	5.9	0.7	1.0	1.3	3.8	2.3	7.6	6.1	0.5	1.9	7.9	7.9	3.8	9.3	5.8	5.5	6.6	4.0	5.2	6.8
SH3GL1	"CNSA1, EEN, MGC111371, SH3D2B, SH3P8"	ENSG00000141985	"SH3 domain containing GRB2 like 1, endophilin A2"	Q99961	19	4360370-4400547	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA021485	Approved		Enhanced	Cytosol				Cytosol		"HPA021485: AB_1856816"	"unprognostic (1.32e-1)"	"prognostic favourable (1.50e-4)"	"unprognostic (6.85e-2)"	"prognostic favourable (1.86e-4)"	"unprognostic (1.84e-1)"	"unprognostic (1.02e-1)"	"prognostic unfavourable (1.10e-4)"	"unprognostic (1.92e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.42e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.54e-1)"	"prognostic unfavourable (9.36e-8)"	"unprognostic (5.48e-3)"	"unprognostic (2.45e-1)"	"unprognostic (1.02e-3)"	"unprognostic (4.10e-2)"	20.5	22.4	12.8	17.7	14.5	28.9	17.5	19.1	25.9	21.6	18.7	13.3	11.9	25.4	16.9	12.1	66.0	15.0	16.1	13.2	13.0	8.0	13.8	19.7	14.8	13.0	11.4	13.0	23.5	20.5	5.6	17.3	33.9	9.4	17.1	6.2	14.9	22.1	16.8	8.6	40.4	29.8	18.8	9.0	19.5	16.4	13.7	11.3	10.1	14.2	19.1	33.0	22.2	30.0	6.1	6.5	9.7	5.1	3.8	7.4	3.4	31.7	14.4	15.0	19.8	17.6	27.5	27.7	27.7	23.9	24.7	24.6	22.4	16.8	7.2	11.7	27.4	26.3	10.6	30.4	6.6	9.5	17.7	8.6	19.8	29.3	25.4	7.7	9.8	23.0	21.2	20.8	12.8	29.0	22.3	16.4	19.8	26.6	7.5	8.1	37.6	16.1	5.9	20.9	12.5	19.5	28.1	14.8	22.8	24.4	24.4	17.3	16.8	12.3	43.7	23.8	17.4	49.8	28.0	10.5	6.4	7.6	34.3	20.1	32.6	1.0	3.8	4.8	5.0	1.9	4.8	6.1	7.4	6.9	5.0	4.5	4.2	4.5	9.7	3.8	5.1	6.5	6.6	3.4	12.8	14.5	19.1	25.9	13.0	8.0	11.4	13.0	9.4	11.3
SHBG	"ABP, MGC126834, MGC138391, TEBG"	ENSG00000129214	"Sex hormone binding globulin"	P04278	17	7613946-7633383	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"intestine: 14.2;liver: 51.1"	"Cell line enhanced"	"Detected in some"		"ASC diff: 7.7;Hep G2: 5.0;HSkMC: 7.5"	"Cancer enriched"	"Detected in some"	28	"liver cancer: 14.3"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"myeloid DC: 1.2"	"Low lineage specificity"	"Detected in single"			"Region enhanced"	"Detected in single"		"olfactory region: 0.4"										"Secreted to blood"	15000000000	15000000000				"unprognostic (3.35e-3)"	"unprognostic (6.47e-2)"	"unprognostic (5.65e-2)"	"unprognostic (2.35e-1)"	"unprognostic (8.84e-2)"	"unprognostic (3.08e-1)"	"unprognostic (3.50e-1)"	"unprognostic (2.27e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.32e-3)"	"unprognostic (3.58e-3)"	"unprognostic (2.21e-1)"	"unprognostic (4.49e-2)"	"unprognostic (7.83e-3)"	"unprognostic (4.35e-1)"	"unprognostic (5.50e-3)"	"unprognostic (1.06e-1)"	0.5	0.9	1.0	0.0	1.3	0.1	0.2	0.4	0.8	0.6	2.7	0.4	0.0	3.5	0.3	0.6	0.2	0.5	0.4	0.9	0.9	0.5	2.3	51.1	0.3	0.1	0.8	0.7	0.5	0.8	0.3	1.4	0.3	1.1	0.3	0.2	1.1	0.3	0.3	0.5	0.0	14.2	0.2	1.1	0.2	0.2	8.0	1.0	0.0	0.6	0.0	0.1	0.2	0.1	0.0	1.2	0.0	0.6	0.0	0.0	0.0	0.2	4.1	3.8	0.6	7.7	3.6	0.2	1.0	1.6	1.7	0.8	1.6	0.6	0.0	0.9	1.4	0.6	0.2	0.3	0.9	0.2	0.6	0.0	1.0	5.0	2.5	0.0	0.1	7.5	0.6	2.9	1.4	0.1	0.4	0.3	0.4	0.9	0.0	0.4	0.6	0.0	0.1	0.3	0.5	0.6	0.5	0.2	0.6	3.1	0.0	0.4	0.6	0.0	1.3	0.8	0.0	0.0	0.3	0.6	0.6	0.3	1.9	0.1	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.3	0.4	0.8	0.9	0.5	0.8	0.7	1.1	1.0
SIN3A	"DKFZP434K2235, KIAA0700"	ENSG00000169375	"SIN3 transcription regulator family member A"	Q96ST3	15	75369379-75455842	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004506, HPA047213, HPA062123"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB004506: AB_2187766, HPA047213: AB_2679984, HPA062123: AB_2684689"	"unprognostic (1.94e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.90e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.26e-1)"	"unprognostic (2.15e-1)"	"unprognostic (8.52e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.17e-3)"	"unprognostic (7.33e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.33e-1)"	"unprognostic (3.52e-1)"	21.0	15.4	14.0	19.4	18.5	31.6	20.4	26.3	15.5	26.3	20.2	19.9	15.3	11.8	26.6	16.8	17.7	22.1	15.9	13.4	14.2	11.8	13.6	13.9	17.4	20.7	13.0	14.2	27.6	19.8	23.4	16.8	17.2	13.0	22.9	14.3	23.0	17.6	20.5	18.2	23.5	17.9	24.5	12.8	20.3	16.8	28.5	15.1	48.7	24.0	12.8	26.9	26.0	19.0	9.8	6.5	9.3	8.3	9.7	12.7	6.3	12.7	26.4	23.6	15.5	11.8	12.5	13.7	9.6	14.9	14.1	15.2	14.6	17.3	27.8	10.0	14.1	22.8	34.2	14.4	15.5	22.4	17.7	26.2	20.1	11.4	8.9	24.8	22.4	15.1	11.1	16.4	17.2	12.6	20.6	31.0	11.4	14.8	24.3	15.9	23.0	11.1	24.6	31.3	17.1	10.1	23.4	18.7	18.7	23.6	10.6	13.2	16.1	19.7	11.0	17.5	23.7	11.5	14.1	21.3	33.4	29.5	10.4	25.4	9.7	3.3	4.8	6.9	8.5	4.8	12.7	9.3	10.8	10.7	6.5	9.8	11.1	9.5	9.3	9.7	8.3	4.4	9.5	6.3	14.0	18.5	26.3	15.5	14.2	11.8	13.0	14.2	13.0	15.1
SIRT2	SIR2L	ENSG00000068903	"Sirtuin 2"	Q8IXJ6	19	38878555-38899862	"Cancer-related genes, Predicted intracellular proteins"	"Autophagy, Cell cycle, Cell division, Differentiation, Immunity, Innate immunity, Meiosis, Mitosis, Neurogenesis, Transcription, Transcription regulation"	Transferase	"Cancer-related genes, Neurodegeneration"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 86.6;skeletal muscle: 108.7"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004573, HPA011165"	Approved		Approved	Nucleoplasm,Nucleoli,Cytosol				Nucleoli	"Nucleoplasm, Cytosol"	"CAB004573: AB_2188600, HPA011165: AB_1856900"	"unprognostic (2.15e-2)"	"unprognostic (2.24e-2)"	"unprognostic (2.88e-1)"	"prognostic unfavourable (7.20e-7)"	"unprognostic (3.75e-3)"	"unprognostic (1.28e-2)"	"unprognostic (2.85e-2)"	"unprognostic (2.44e-3)"	"unprognostic (2.73e-1)"	"unprognostic (4.83e-2)"	"unprognostic (2.97e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.90e-1)"	"unprognostic (3.60e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.73e-2)"	"unprognostic (1.70e-1)"	14.1	11.0	30.2	8.1	36.0	10.7	9.1	14.3	38.8	11.0	8.4	78.1	4.0	9.3	9.7	7.8	17.1	12.9	10.7	20.3	36.9	23.5	9.0	12.0	10.8	8.8	52.3	20.5	17.3	9.5	10.1	6.2	7.7	40.8	9.8	7.6	5.8	14.9	11.2	108.7	13.7	9.3	12.8	86.6	9.9	9.0	7.9	46.3	3.2	10.1	23.4	8.9	10.6	7.1	13.2	21.5	28.0	33.0	16.6	23.5	22.1	8.1	5.1	4.4	11.0	25.3	17.4	3.0	6.0	10.7	9.4	12.2	9.2	5.2	2.8	13.1	11.2	4.4	8.0	12.9	5.7	13.0	8.3	5.5	5.8	5.5	17.8	3.8	12.2	18.1	15.6	7.7	9.2	16.4	5.2	22.6	14.3	4.6	7.7	3.0	0.7	7.2	10.2	12.4	7.8	7.5	7.3	11.1	5.0	7.0	9.4	6.6	4.2	9.9	15.6	12.7	2.8	19.6	8.9	9.3	4.5	6.5	10.2	9.6	11.7	19.5	27.3	28.0	23.5	33.0	14.6	12.2	11.4	16.1	21.1	13.2	7.5	12.5	20.7	16.6	25.8	21.5	15.5	22.1	30.2	36.0	14.3	38.8	36.9	23.5	52.3	20.5	40.8	46.3
SIRT4	SIR2L4	ENSG00000089163	"Sirtuin 4"	Q9Y6E7	12	120302316-120313249	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage"	Transferase	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 10.3"	"Low cancer specificity"	"Detected in many"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029691, HPA029692"	Enhanced									"HPA029691: AB_10600118, HPA029692: AB_10611520"	"unprognostic (2.62e-2)"	"unprognostic (7.08e-2)"	"unprognostic (4.46e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.35e-2)"	"unprognostic (2.37e-2)"	"unprognostic (4.53e-2)"	"unprognostic (1.25e-1)"	"unprognostic (4.49e-2)"	"unprognostic (1.56e-3)"	"unprognostic (1.54e-1)"	"prognostic favourable (1.75e-4)"	"unprognostic (4.97e-2)"	"unprognostic (2.11e-1)"	"unprognostic (9.74e-3)"	"unprognostic (2.31e-1)"	0.4	4.4	1.8	0.7	1.6	0.0	0.9	5.1	3.2	1.1	2.6			3.8	1.9	0.6	1.3	1.4	1.0	4.4	1.7	1.7	3.6	3.7	1.5	1.0	1.2		2.8	1.9	2.4	0.6	0.6		1.1	0.8		3.0	1.4	10.2	3.3	1.2	1.8	0.7	1.2	1.9	5.8			1.9		0.8	1.2	1.0	5.1	4.8	8.5	1.8	2.9	7.4	1.8	1.0	2.3	3.2	1.6	10.3	3.5	1.6	2.3	2.7	1.9	5.1	2.5	1.6	1.7	2.8	1.3	0.6	3.2	1.1	3.4	3.3	4.3	0.0	0.5	1.9	2.6	1.8	0.9	3.1	2.8	1.0	0.7	2.6	3.2	0.2	2.9	1.3	3.1	2.7	1.8	2.0	3.8	6.0	1.7	2.7	0.2	3.3	2.8	1.7	0.2	1.4	3.9	0.7	0.4	1.6	2.7	1.4	0.5	4.1	3.5	0.4	1.6	1.1	2.5	8.5	1.8	0.2	5.2	0.7	7.4	3.3	3.4	4.1	1.0	5.1	5.9	5.2	0.0	2.9	0.1	4.8	0.3	1.8										
SIX1	DFNA23	ENSG00000126778	"SIX homeobox 1"	Q15475	14	60643415-60658259	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pituitary gland: 39.1;salivary gland: 55.1;skeletal muscle: 59.0"	"Cell line enhanced"	"Detected in many"		"LHCN-M2: 52.7;RH-30: 28.8"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"olfactory region: 1.2;pons and medulla: 4.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001893, CAB058690"	Enhanced		Supported	Nucleoplasm,Nucleoli				Nucleoplasm	Nucleoli	"CAB058690: , HPA001893: AB_1079991"	"unprognostic (3.62e-1)"	"unprognostic (5.44e-2)"	"unprognostic (5.09e-2)"	"prognostic unfavourable (8.92e-6)"	"unprognostic (1.33e-2)"	"unprognostic (1.44e-2)"	"unprognostic (2.04e-3)"	"prognostic favourable (3.94e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.15e-2)"	"unprognostic (6.45e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.06e-8)"	"unprognostic (8.61e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.94e-1)"	"unprognostic (3.86e-1)"	7.1	0.4	0.3	0.1	0.5	0.1	4.7	0.3	0.6	7.4	0.2	0.2	0.0	0.1	0.2	2.1	1.3	0.5	0.4	0.4	0.3	0.3	0.3	0.2	1.8	0.3	0.4	1.2	0.3	0.3	16.8	39.1	0.1	4.5	8.7	0.1	2.0	55.1	0.2	59.0	0.4	0.2	0.7	0.5	0.2	0.5	1.6	0.0	6.5	2.4	22.5	3.0	1.4	9.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	8.2	1.9	0.2	11.7	6.8	8.0	0.1	2.0	4.5	2.3	2.0	0.0	3.7	0.0	1.1	0.4	2.7	3.9	3.6	0.8	0.0	9.4	0.9	0.8	2.7	0.0	0.0	0.1	6.0	1.7	1.6	0.3	0.1	2.6	0.0	52.7	1.3	0.0	0.2	0.0	4.7	0.0	28.8	0.0	2.2	6.4	1.1	0.1	2.3	0.1	2.4	1.3	0.2	6.7	3.1	3.2	3.6	2.9	0.2	0.0	0.0	0.8	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.3	0.5	0.3	0.3	0.4	1.2	4.5	0.0
SKP2	"FBL1, FBXL1, p45"	ENSG00000145604	"S-phase kinase associated protein 2"	Q13309	5	36151989-36184319	"Cancer-related genes, Predicted intracellular proteins"	"Antiviral defense, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 49.1"	"Cell line enhanced"	"Detected in all"		"BEWO: 73.6;RH-30: 92.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013491, CAB013533, HPA051196, HPA054633"	Approved		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB013491: AB_2533074, CAB013533: , HPA051196: AB_2681383, HPA054633: AB_2682550"	"unprognostic (2.32e-2)"	"unprognostic (2.87e-1)"	"unprognostic (1.26e-1)"	"unprognostic (5.74e-2)"	"unprognostic (9.56e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.21e-3)"	"unprognostic (2.22e-1)"	"prognostic unfavourable (3.72e-7)"	"prognostic favourable (8.57e-4)"	"unprognostic (5.06e-2)"	"unprognostic (2.71e-1)"	"prognostic unfavourable (4.77e-15)"	"unprognostic (2.50e-2)"	"unprognostic (3.73e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.19e-1)"	6.5	6.9	7.8	8.0	7.5	12.9	6.5	11.5	9.0	7.5	7.7	10.3	3.7	10.2	9.9	6.3	13.5	8.1	4.9	4.1	7.3	5.1	4.2	14.0	5.8	9.4	8.8	7.4	7.7	6.1	3.9	12.5	49.1	6.5	7.2	9.5	6.1	6.3	5.4	3.4	7.6	7.7	6.4	7.4	9.4	5.3	3.9	7.4	19.5	5.0	7.5	11.7	7.9	8.4	6.5	16.0	14.7	7.9	7.7	8.5	5.0	7.4	3.7	15.8	17.6	3.9	6.2	73.6	9.7	7.3	24.8	18.8	20.6	5.9	10.8	2.6	7.8	7.8	17.7	12.3	26.7	4.8	10.1	6.3	13.8	9.7	1.9	13.9	2.9	5.7	3.2	4.5	3.1	6.8	10.8	2.5	8.9	3.6	16.1	8.0	14.4	5.7	16.0	92.3	6.9	1.8	7.9	13.6	16.3	30.4	6.6	4.3	6.7	7.9	3.1	9.3	10.8	3.5	6.7	3.1	3.0	13.4	4.2	17.1	6.7	10.3	7.9	14.7	5.4	7.2	8.5	5.6	5.7	5.8	16.0	6.5	7.9	6.0	1.5	7.7	4.1	4.3	5.3	5.0	7.8	7.5	11.5	9.0	7.3	5.1	8.8	7.4	6.5	7.4
SLC19A1	"FOLT, RFC1"	ENSG00000173638	"Solute carrier family 19 member 1"	P41440	21	45493572-45544411	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Antiport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 37.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"neutrophil: 37.6"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 37.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA024802	Approved		Approved	"Plasma membrane"				"Plasma membrane"		"HPA024802: AB_10602892"	"unprognostic (4.31e-3)"	"prognostic unfavourable (4.15e-4)"	"unprognostic (5.23e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.11e-1)"	"unprognostic (3.04e-2)"	"unprognostic (7.34e-2)"	"unprognostic (2.87e-3)"	"unprognostic (4.04e-2)"	"unprognostic (4.09e-2)"	"unprognostic (2.85e-1)"	"unprognostic (2.39e-1)"	"prognostic unfavourable (1.07e-10)"	"unprognostic (1.44e-1)"	"unprognostic (2.31e-1)"	"unprognostic (7.97e-5)"	"unprognostic (3.10e-1)"	9.0	7.8	7.1	8.2	13.5	10.5	12.5	9.6	8.9	5.0	9.7	6.0	9.4	31.2	4.3	4.6	2.3	4.6	3.5	3.2	7.1	6.1	4.7	14.1	13.9	14.1	8.7	4.4	8.1	5.4	1.8	3.5	32.9	11.5	4.7	2.0	17.8	6.0	3.5	3.5	6.1	16.5	2.3	5.9	11.7	5.7	3.4	3.4	11.8	9.6	2.8	4.1	3.1	3.1	0.9	4.9	37.6	6.4	0.4	1.1	2.4	10.4	9.5	1.9	7.8	0.6	0.8	15.6	4.9	0.8	4.5	2.9	22.0	9.7	9.7	9.8	1.2	5.4	3.9	3.6	1.1	8.9	19.0	20.5	5.2	15.3	2.7	13.3	3.2	1.0	2.7	4.9	1.6	3.7	24.4	4.3	1.6	11.7	18.1	12.4	11.2	11.2	24.6	2.2	28.3	2.0	6.3	11.7	10.3	5.5	9.1	4.2	6.9	15.8	4.5	5.9	7.4	1.6	8.0	1.8	6.5	8.8	2.6	21.8	4.7	0.6	6.4	8.5	0.3	6.0	1.1	0.9	0.5	0.7	4.9	0.3	0.8	0.5	37.6	0.4	3.7	1.5	1.0	2.4	7.1	13.5	9.6	8.9	7.1	6.1	8.7	4.4	11.5	3.4
SLC1A3	"EA6, EAAT1, GLAST"	ENSG00000079215	"Solute carrier family 1 member 3"	P43003	5	36606355-36688334	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Amino-acid transport, Symport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	11	"brain: 188.6"	"Cell line enhanced"	"Detected in many"		"AF22: 21.2;CACO-2: 34.1;HaCaT: 25.8"	"Cancer enriched"	"Detected in all"	21	"glioma: 168.1"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	12	"classical monocyte: 4.3;intermediate monocyte: 2.1;myeloid DC: 3.4"	"Group enriched"	"Detected in many"	39	"dendritic cells: 3.4;monocytes: 4.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002573, HPA037467, HPA037468"	Enhanced	Supported	Approved	Nucleoli,Mitochondria				Mitochondria	Nucleoli	"CAB002573: AB_564088, HPA037467: AB_10795027, HPA037468: AB_10671371"	"unprognostic (1.23e-1)"	"unprognostic (2.15e-2)"	"unprognostic (2.58e-3)"	"unprognostic (1.74e-2)"	"unprognostic (1.02e-1)"	"unprognostic (7.70e-2)"	"unprognostic (3.89e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.84e-2)"	"unprognostic (4.17e-3)"	"unprognostic (3.28e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.06e-1)"	"unprognostic (4.17e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.31e-2)"	17.3	10.3	76.1	5.9	70.6	3.1	6.3	45.8	188.6	6.9	3.2	26.3	0.0	2.1	2.8	2.3	7.2	5.4	5.9	12.0	57.9	27.3	3.1	3.6	4.7	8.6	32.7	39.6	8.6	4.0	2.6	3.7	12.7	28.5	3.3	2.6	1.9	3.0	4.4	7.6	5.5	2.3	4.1	29.4	5.8	2.9	2.7	33.6	0.0	2.6	0.7	4.5	4.8	1.2	0.0	3.4	0.0	4.3	0.0	0.0	0.8	0.4	0.1	21.2	1.8	2.1	5.9	13.5	0.0	0.0	0.8	1.8	34.1	1.7	0.0	10.3	0.3	25.8	6.2	2.8	0.9	0.3	12.7	0.0	0.1	0.0	0.4	0.4	0.1	10.9	12.8	5.2	2.1	0.0	0.0	0.1	3.6	0.0	0.0	0.0	2.5	2.1	0.0	0.1	0.0	0.0	1.3	1.8	0.0	2.1	6.2	0.3	0.0	1.0	0.0	1.9	3.1	0.0	7.5	0.0	0.0	0.0	8.6	14.3	4.8	0.0	4.3	0.0	0.0	2.1	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.8	76.1	70.6	45.8	57.8	57.9	27.3	32.7	39.6	28.5	33.6
SLC26A3	"CLD, DRA"	ENSG00000091138	"Solute carrier family 26 member 3"	P40879	7	107765467-107803225	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Antiport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"gallbladder: 53.5;intestine: 110.1;lymphoid tissue: 42.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 2.2;CACO-2: 1.8;NB-4: 1.5;RPMI-8226: 7.5"	"Cancer enriched"	"Detected in many"	14	"colorectal cancer: 52.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA036055	Approved									"HPA036055: AB_10602401"	"unprognostic (1.26e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.12e-2)"	"unprognostic (2.69e-1)"	"unprognostic (4.02e-1)"	"unprognostic (4.09e-2)"	"unprognostic (3.05e-3)"	"unprognostic (6.31e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.05e-2)"	"unprognostic (8.85e-2)"	"unprognostic (8.01e-2)"	"unprognostic (5.52e-2)"	"unprognostic (2.54e-2)"	"unprognostic (3.58e-3)"	0.3	0.3	0.3	42.8	0.3	0.0	6.1	0.3	0.3	0.4	110.1	0.2	0.3	58.4	0.3	1.2	0.3	0.6	53.5	0.3	0.3	0.3	0.3	0.4	0.3	0.2	0.3	0.2	0.3	0.3	0.0	0.3	0.2	0.2	0.5	92.7	0.2	0.3	14.4	0.3	0.3	106.5	1.2	0.3	0.3	0.4	0.3	0.2	0.2	0.3	0.2	0.2	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	1.8	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	7.5	0.0	0.0	0.7	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.3	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2
SLC2A1	"CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR"	ENSG00000117394	"Solute carrier family 2 member 1"	P11166	1	42925375-42959176	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Sugar transport, Transport"		"Cancer-related genes, Cataract, Disease mutation, Dystonia, Epilepsy, Hereditary hemolytic anemia, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"placenta: 194.0"	"Cell line enhanced"	"Detected in many"		"BEWO: 44.2;CACO-2: 71.8;Hep G2: 49.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB002759, HPA031345, HPA058494"	Enhanced	Supported	Enhanced	"Plasma membrane"		36000000	36000000	"Plasma membrane"		"CAB002759: , HPA031345: , HPA058494: "	"unprognostic (3.60e-2)"	"unprognostic (5.85e-3)"	"unprognostic (7.59e-2)"	"unprognostic (1.31e-2)"	"unprognostic (4.10e-3)"	"unprognostic (3.22e-2)"	"prognostic unfavourable (3.65e-8)"	"prognostic unfavourable (1.09e-4)"	"unprognostic (1.10e-1)"	"unprognostic (4.84e-2)"	"prognostic unfavourable (4.39e-5)"	"unprognostic (1.87e-1)"	"prognostic unfavourable (4.55e-9)"	"unprognostic (1.11e-1)"	"unprognostic (9.49e-2)"	"unprognostic (1.17e-1)"	"prognostic unfavourable (4.05e-4)"	4.2	3.7	12.4	3.9	16.9	45.2	4.1	6.7	15.5	15.2	4.8	15.1	4.3	2.4	7.6	3.4	28.8	8.5	8.6	5.0	15.4	13.7	7.6	2.1	2.4	5.3	18.2	5.0	3.4	3.7	7.3	2.9	194.0	15.5	5.2	3.3	44.2	8.4	7.9	1.8	42.1	2.9	2.5	17.8	3.4	5.5	2.5	12.5	1.8	4.0	11.5	12.0	22.2	24.5	8.4	14.7	1.3	0.2	3.0	7.5	2.7	10.6	15.3	12.7	3.2	1.5	0.5	44.2	7.0	15.2	8.6	12.8	71.8	29.7	4.0	21.0	2.1	9.9	2.8	16.3	3.8	2.4	2.6	6.6	8.9	49.0	4.4	3.6	1.9	1.8	12.6	5.4	5.9	1.4	14.8	0.9	3.9	18.9	1.6	2.5	8.1	3.9	1.6	4.1	5.6	7.9	5.2	6.7	4.7	8.2	26.0	3.0	1.1	4.6	3.2	7.9	5.7	1.4	15.8	0.7	1.5	2.4	15.6	2.5	6.4	0.3	0.2	1.3	7.5	0.2	6.9	8.4	4.1	5.1	2.9	7.3	3.2	4.7	1.0	3.0	0.1	14.7	4.7	2.7	12.4	16.9	6.7	15.5	15.4	13.7	18.2	5.0	15.5	12.5
SLC34A2	NAPI-3B	ENSG00000157765	"Solute carrier family 34 member 2"	O95436	4	25648011-25678748	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"lung: 259.9;seminal vesicle: 69.1"	"Group enriched"	"Detected in some"	81	"BEWO: 12.3;EFO-21: 46.6;RPTEC TERT1: 33.6"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 585.2"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.9"	"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA037989	Enhanced		Supported	"Nucleoplasm,Golgi apparatus,Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"	"Nucleoplasm, Golgi apparatus"	"HPA037989: AB_10670536"	"unprognostic (1.60e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.38e-1)"	"unprognostic (4.25e-2)"	"unprognostic (7.33e-2)"	"unprognostic (9.83e-2)"	"unprognostic (2.37e-2)"	"unprognostic (6.60e-3)"	"unprognostic (6.27e-2)"	"unprognostic (1.89e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.24e-1)"	"unprognostic (7.08e-3)"	"unprognostic (3.25e-1)"	"unprognostic (6.75e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.93e-1)"	0.1	0.1	0.1	0.0	0.1	0.0	3.2	0.2	0.1	13.0	0.1	0.0	24.7	2.9	6.9	2.1	0.5	13.0	3.4	0.1	0.1	0.1	10.8	0.5	259.9	0.0	0.1	0.0	2.9	4.4	0.0	0.6	2.6	0.8	0.3	0.0	1.6	27.4	69.1	0.1	0.7	2.1	0.0	0.1	0.1	0.4	0.5	0.0	0.4	27.9	0.1	1.9	0.0	0.1	0.4	0.2	1.9	0.5	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	46.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	33.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.2	0.1	0.1	0.0	0.0	0.0	1.9	0.5	0.2	0.3	0.3	0.1	0.2	0.1	0.1	0.0	0.4	0.3	0.2	1.5	0.4	0.1	0.2	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.8	0.0
SLC3A2	"4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE"	ENSG00000168003	"Solute carrier family 3 member 2"	P08195	11	62856102-62888875	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTCEpi: 129.8;SiHa: 132.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010455, HPA017980"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		210000000	210000000	"Nucleoplasm, Plasma membrane, Cytosol"		"CAB010455: AB_638288, HPA017980: "	"unprognostic (1.79e-1)"	"unprognostic (9.61e-3)"	"unprognostic (3.59e-1)"	"unprognostic (7.87e-3)"	"unprognostic (2.06e-1)"	"unprognostic (2.41e-3)"	"prognostic unfavourable (8.17e-4)"	"unprognostic (2.09e-3)"	"unprognostic (2.62e-1)"	"unprognostic (4.16e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.71e-1)"	"prognostic favourable (8.22e-4)"	"unprognostic (2.92e-2)"	"unprognostic (5.52e-3)"	"unprognostic (3.49e-3)"	"prognostic unfavourable (1.48e-4)"	28.5	30.8	34.6	23.0	36.8	62.4	30.8	18.7	34.8	26.0	26.8	25.3	30.4	34.3	29.2	41.2	31.2	23.8	19.9	14.7	31.3	27.1	71.4	31.8	33.5	17.8	37.8	24.1	29.9	39.2	138.6	19.3	75.5	32.9	28.3	13.9	52.5	39.0	27.5	32.5	32.1	33.8	19.6	38.0	21.9	28.2	33.4	30.8	13.6	33.7	33.4	22.2	20.6	56.6	16.6	73.9	11.6	36.2	20.3	39.8	37.3	16.1	68.1	6.9	21.6	8.4	6.8	64.4	28.1	10.8	14.8	13.0	65.1	30.6	17.8	31.2	16.5	56.0	12.7	55.1	7.9	32.3	12.0	12.7	49.6	28.7	78.4	14.9	18.6	14.8	129.8	18.0	55.0	8.6	24.6	39.4	9.0	77.8	15.3	19.0	11.6	23.0	15.9	10.5	34.7	10.3	9.0	11.9	5.7	132.3	49.6	95.4	17.8	19.6	15.7	15.0	22.4	22.0	19.8	49.0	54.3	56.4	14.7	23.5	42.8	8.5	36.2	11.6	30.1	34.8	39.8	14.4	27.7	30.8	22.1	16.6	23.5	25.2	7.5	20.3	27.6	73.9	26.2	37.3	34.6	36.8	18.7	34.7	31.3	27.1	37.8	24.1	32.9	30.8
SLC44A3	"CTL3, MGC45474"	ENSG00000143036	"Solute carrier family 44 member 3"	Q8N4M1	1	94820342-94895246	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"RPTEC TERT1: 43.0;RT4: 28.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	4	"MAIT T-cell: 5.2"	"Lineage enriched"	"Detected in single"	52	"T-cells: 5.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA047433	Enhanced									"HPA047433: "	"unprognostic (8.06e-2)"	"unprognostic (7.65e-2)"	"unprognostic (4.63e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.53e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.03e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.46e-1)"	"unprognostic (5.78e-2)"	"unprognostic (2.44e-2)"	"prognostic favourable (7.63e-5)"	"unprognostic (9.09e-2)"	"unprognostic (8.28e-2)"	"unprognostic (5.95e-2)"	"unprognostic (3.31e-3)"	1.8	7.3	9.1	6.1	8.3	0.0	5.3	6.6	5.6	5.9	19.8	3.9	4.5	16.5	4.8	5.1	6.6	5.1	16.3	4.5	6.3	5.0	21.4	3.9	6.7	0.4	6.1	3.6	2.7	22.2	5.3	22.2	3.9	5.8	7.2	22.9	9.5	16.0	8.5	1.6	3.7	17.2	2.9	5.4	0.5	17.9	1.6	4.2	2.6	5.4	0.9	4.1	11.0	6.3	0.0	0.0	0.0	0.0	0.0	5.2	0.1	9.4	1.3	0.3	0.0	1.1	1.4	6.7	0.1	1.4	0.3	1.6	8.8	2.4	0.0	6.5	0.1	3.2	1.4	2.3	0.6	0.0	1.7	0.0	0.5	0.7	0.4	0.0	0.0	4.3	2.1	0.6	0.0	0.1	0.0	0.0	0.6	1.4	0.0	0.1	0.4	0.3	0.7	0.3	0.5	43.0	28.7	4.4	7.3	0.4	4.5	3.2	2.6	0.3	0.0	0.2	1.5	0.6	0.1	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.8	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	9.1	8.3	6.6	5.6	6.3	5.0	6.1	3.6	5.8	4.2
SLC45A3	"IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein"	ENSG00000158715	"Solute carrier family 45 member 3"	Q96JT2	1	205657851-205680459	"Cancer-related genes, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"prostate: 115.0"	"Cell line enriched"	"Detected in some"	30	"HMC-1: 138.2"	"Cancer enriched"	"Detected in all"	49	"prostate cancer: 539.9"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	226	"basophil: 22.6"	"Lineage enriched"	"Detected in single"	226	"granulocytes: 22.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA019073, HPA019075"	Enhanced		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"HPA019073: AB_1857177, HPA019075: AB_1857179"	"unprognostic (1.80e-1)"	"unprognostic (1.08e-3)"	"unprognostic (3.13e-2)"	"prognostic unfavourable (4.04e-5)"	"unprognostic (6.93e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.03e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.96e-1)"	"prognostic favourable (7.33e-5)"	0.8	1.5	2.5	1.5	6.2	0.7	0.8	0.4	5.8	1.9	2.1	19.0	0.0	2.1	0.9	0.6	0.9	1.1	1.8	0.7	4.2	2.0	1.1	4.0	1.7	1.6	13.2	1.6	1.0	0.7	0.5	1.9	0.6	7.2	115.0	1.6	0.2	0.9	0.7	2.2	0.9	2.1	0.8	12.4	5.0	6.4	1.4	11.1	0.0	0.5	0.7	0.7	1.5	0.4	0.0	0.0	22.6	0.0	0.0	0.0	0.2	1.5	0.4	0.4	0.4	0.0	0.0	0.3	0.2	0.0	0.5	0.4	1.1	2.9	0.4	0.7	0.0	0.5	0.2	0.5	0.0	0.6	0.4	4.6	0.1	0.3	0.3	0.7	138.2	0.0	0.1	0.3	0.0	1.5	0.7	0.2	0.2	0.3	0.1	1.3	2.0	1.7	0.1	0.6	0.2	0.6	2.1	0.2	0.4	0.2	3.4	0.6	0.7	0.2	1.5	0.2	1.5	0.5	1.1	0.0	0.1	0.0	0.3	0.2	1.1	22.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.5	6.2	0.4	5.8	4.2	2.0	13.2	1.6	7.2	11.1
SLC4A5	NBC4	ENSG00000188687	"Solute carrier family 4 member 5"	Q9BY07	2	74216242-74343414	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Anion exchange, Ion transport, Sodium transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"retina: 109.1"	"Cell line enhanced"	"Detected in many"		"U-266/70: 14.2"	"Cancer enriched"	"Detected in single"	11	"thyroid cancer: 3.3"	"Group enriched"	"Detected in many"	5	"cerebellum: 3.4;pons and medulla: 9.0"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			HPA036621	Uncertain									"HPA036621: AB_10696779"	"unprognostic (1.30e-1)"	"unprognostic (3.78e-2)"	"unprognostic (2.75e-2)"	"unprognostic (1.83e-4)"	"unprognostic (3.38e-1)"	"unprognostic (2.36e-2)"	"unprognostic (2.56e-3)"	"unprognostic (5.37e-4)"	"unprognostic (1.39e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.55e-3)"	"unprognostic (3.24e-2)"	"unprognostic (1.72e-5)"	"unprognostic (1.57e-1)"	"unprognostic (1.06e-2)"	"unprognostic (8.47e-2)"	"unprognostic (9.27e-4)"	1.2	0.4	1.0	0.8	0.8	1.6	1.1	3.4	1.2	0.7	0.8	2.5	0.6	0.3	0.9	1.7	0.6	1.4	0.8	0.7	1.2	1.0	0.7	3.2	1.7	1.0	1.0	0.6	1.3	0.9	1.5	2.3	0.6	9.0	0.9	0.3	109.1	1.3	0.8	1.1	3.7	0.7	0.9	1.6	0.7	0.5	16.1	0.7	1.0	21.4	0.6	0.7	0.9	0.9	2.5	5.8	6.1	0.9	1.7	2.5	0.6	0.4	0.8	1.4	1.4	1.5	2.5	1.8	0.4	1.3	0.8	1.2	0.4	1.0	2.1	0.4	0.0	0.1	1.5	0.2	0.3	1.8	0.9	3.2	1.4	0.8	0.2	1.1	2.3	0.7	1.9	0.1	0.3	0.5	0.7	2.3	0.3	5.1	0.5	2.2	1.1	0.3	1.1	1.3	0.0	0.3	1.0	1.0	2.0	0.5	1.7	2.3	1.6	2.2	0.0	1.5	2.4	1.5	0.5	14.2	2.0	1.6	0.9	1.2	0.3	6.1	0.9	0.9	1.5	0.8	1.0	1.8	2.3	2.0	0.6	2.5	2.1	2.5	4.2	1.7	0.3	5.8	2.4	0.6	1.0	0.8	3.4	1.2	1.2	1.0	1.0	0.6	9.0	0.7
SLPI	"ALK1, ALP, BLPI, HUSI, HUSI-I, WAP4, WFDC4"	ENSG00000124107	"Secretory leukocyte peptidase inhibitor"	P03973	20	45252239-45254564	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Immunity, Innate immunity"	"Antibiotic, Antimicrobial, Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"cervix, uterine: 934.9;ductus deferens: 268.3;salivary gland: 480.2;seminal vesicle: 548.7"	"Cell line enhanced"	"Detected in some"		"EFO-21: 155.4;hTCEpi: 182.5;SiHa: 54.7;THP-1: 46.2"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in single"	11	"pons and medulla: 4.7"	"Cell type enriched"	"Detected in single"	90	"neutrophil: 68.8"	"Lineage enriched"	"Detected in single"	90	"granulocytes: 68.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB002303, HPA027774"	Enhanced		Approved	"Golgi apparatus"	"Secreted to blood"	2600000	2600000	"Golgi apparatus"		"CAB002303: AB_564008, HPA027774: AB_10602405"	"unprognostic (2.31e-2)"	"unprognostic (3.07e-1)"	"unprognostic (3.10e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.63e-1)"	"unprognostic (3.16e-2)"	"unprognostic (9.98e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.23e-1)"	"unprognostic (1.83e-3)"	"unprognostic (4.01e-2)"	"unprognostic (2.33e-2)"	"prognostic unfavourable (6.91e-5)"	"unprognostic (1.53e-1)"	"unprognostic (2.15e-1)"	"unprognostic (8.81e-2)"	"unprognostic (8.31e-2)"	9.2	0.4	0.0	2.4	0.0	10.0	10.0	0.1	0.2	934.9	3.4	0.1	268.3	0.2	11.9	5.5	51.3	23.3	19.6	3.5	0.0	0.0	17.3	20.1	81.5	1.3	0.3	0.4	5.5	5.4	0.1	25.9	1.4	4.7	13.4	3.6	2.0	480.2	548.7	41.3	9.6	0.7	3.9	0.9	0.7	5.2	7.1	0.0	2.3	2.0	86.2	53.0	17.7	24.0	0.0	0.1	68.8	0.7	0.0	0.0	1.1	0.4	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	28.1	0.0	155.4	0.0	11.6	0.0	5.6	0.0	0.7	0.0	0.0	20.8	0.0	30.0	0.0	0.0	0.8	182.5	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	10.6	0.0	0.0	0.0	31.6	1.2	0.0	0.0	54.7	11.7	0.1	0.2	46.2	0.0	0.0	0.7	0.1	0.0	0.1	0.7	0.4	0.0	2.8	0.0	0.5	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	68.8	0.0	0.7	0.0	0.0	1.1	0.0	0.0	0.1	0.2	0.0	0.0	0.3	0.4	4.7	0.0
SMAD1	"JV4-1, MADH1, MADR1"	ENSG00000170365	"SMAD family member 1"	Q15797	4	145481194-145558079	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 45.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 22.2;non-classical monocyte: 11.9"	"Group enriched"	"Detected in many"	4	"granulocytes: 22.2;monocytes: 11.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005389	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB005389: AB_656608"	"unprognostic (8.20e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.76e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.74e-1)"	"unprognostic (6.85e-2)"	"unprognostic (1.70e-1)"	"unprognostic (6.02e-2)"	"unprognostic (2.30e-1)"	"unprognostic (8.24e-2)"	"unprognostic (5.31e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.48e-1)"	"unprognostic (5.88e-2)"	"unprognostic (1.14e-3)"	"unprognostic (3.15e-2)"	20.4	7.8	19.9	7.9	21.3	3.8	21.1	17.9	17.8	18.5	15.5	14.3	13.6	11.9	33.2	22.7	16.2	20.3	13.7	10.3	13.5	10.3	12.7	37.4	11.0	11.9	9.3	10.0	12.3	13.1	33.7	14.7	8.7	12.2	13.6	16.9	7.8	17.5	16.0	22.6	20.2	15.3	24.6	12.6	10.1	11.4	10.5	14.3	15.3	15.2	14.9	10.3	16.5	21.9	0.0	4.0	22.2	11.9	1.2	0.7	0.8	3.8	5.0	9.5	11.4	3.7	5.4	4.7	5.5	13.3	9.0	6.9	2.4	14.2	3.3	3.3	12.6	5.6	10.7	12.3	5.4	0.0	5.4	0.0	4.2	5.0	9.9	6.4	1.0	7.4	14.6	4.8	9.5	45.6	4.3	0.1	11.4	3.7	9.6	0.1	8.8	6.2	18.5	8.8	11.5	9.8	6.8	14.8	7.1	7.8	17.1	3.4	5.8	0.0	13.7	4.4	6.1	4.5	3.4	12.6	0.0	22.3	7.0	0.1	4.5	22.2	2.1	0.8	0.0	5.3	0.0	0.0	0.4	0.0	4.0	0.0	0.2	0.0	0.0	1.2	11.9	0.0	0.7	0.8	19.9	21.3	17.9	14.9	13.5	10.3	9.3	10.0	12.2	14.3
SMAD2	"JV18-1, MADH2, MADR2"	ENSG00000175387	"SMAD family member 2"	Q15796	18	47808957-47931146	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025507, HPA067203, CAB073546"	Approved		Supported	Nucleoplasm,Nucleoli,Cytosol				"Nucleoplasm, Nucleoli, Cytosol"		"CAB025507: , CAB073546: , HPA067203: "	"unprognostic (1.55e-1)"	"unprognostic (2.49e-1)"	"unprognostic (1.43e-2)"	"unprognostic (9.82e-3)"	"unprognostic (9.88e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavourable (9.44e-5)"	"unprognostic (1.91e-2)"	"unprognostic (7.59e-2)"	"unprognostic (1.41e-3)"	"unprognostic (6.46e-2)"	"unprognostic (4.91e-2)"	"unprognostic (9.20e-3)"	"unprognostic (2.68e-1)"	"unprognostic (6.13e-2)"	"unprognostic (3.20e-2)"	"unprognostic (6.28e-2)"	38.5	39.2	29.0	26.2	25.9	19.6	31.4	19.5	28.9	28.8	34.2	29.4	28.9	21.5	26.6	26.3	33.5	28.8	25.7	31.1	26.1	27.1	26.4	20.9	28.3	23.8	30.9	24.3	36.6	28.1	25.7	24.4	34.8	28.6	27.8	29.8	31.7	29.7	28.7	33.9	28.0	26.4	34.6	35.4	34.1	26.3	29.2	26.2	60.7	46.1	23.6	31.5	35.1	35.7	12.0	21.8	28.9	24.7	24.5	25.9	19.7	22.4	32.2	19.7	19.0	31.5	38.5	22.5	24.5	29.4	25.6	29.9	12.3	21.5	34.9	17.6	31.0	24.8	22.1	27.3	34.3	37.9	11.3	29.6	48.7	19.9	36.7	41.1	30.3	28.4	35.3	21.9	50.7	28.2	13.7	29.3	31.4	14.6	28.2	19.8	9.6	7.7	20.6	28.7	23.8	57.4	38.7	18.2	21.4	29.5	20.2	24.0	15.3	27.4	31.5	38.0	21.9	10.3	17.8	28.7	27.5	30.4	26.3	28.1	27.7	28.9	22.6	25.0	16.9	24.7	21.2	12.0	23.1	20.9	21.8	9.4	25.8	19.8	22.7	24.5	20.8	15.5	25.9	19.7	29.0	25.9	19.5	28.9	26.1	27.1	30.9	24.3	28.6	26.2
SMAD3	"HsT17436, JV15-2, MADH3"	ENSG00000166949	"SMAD family member 3"	P84022	15	67063763-67195195	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Aortic aneurysm, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008094, HPA046386, HPA067203, CAB069409"	Approved		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB008094: AB_2302271, CAB069409: AB_1622941, HPA046386: , HPA067203: "	"unprognostic (1.04e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.99e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.98e-2)"	"unprognostic (8.40e-3)"	"unprognostic (1.80e-2)"	"unprognostic (7.62e-2)"	"unprognostic (6.82e-2)"	"prognostic unfavourable (2.48e-4)"	"unprognostic (2.93e-1)"	"unprognostic (2.14e-2)"	"unprognostic (3.10e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.15e-1)"	"unprognostic (5.97e-2)"	25.3	4.6	12.2	18.5	12.4	12.4	21.6	5.0	12.7	20.9	17.9	7.6	9.5	12.7	19.9	16.6	35.3	14.3	27.7	19.7	7.5	4.8	15.6	13.6	13.9	14.0	6.0	7.5	23.0	12.6	7.0	10.8	11.5	8.2	20.5	9.2	30.8	12.5	10.8	37.3	19.6	19.0	23.2	5.5	11.2	15.8	7.0	7.7	10.5	21.8	23.4	29.7	31.4	24.6	4.8	2.5	3.2	1.9	0.4	6.3	1.8	12.5	42.1	7.9	3.8	13.9	32.1	6.2	7.3	30.0	10.1	8.2	8.7	33.7	4.2	9.8	20.7	29.8	8.2	30.7	10.1	3.3	3.1	0.4	11.9	6.5	10.5	1.6	0.7	29.0	7.2	8.9	7.6	34.1	10.1	11.7	12.6	6.5	0.3	6.3	4.7	13.2	0.4	2.3	1.5	6.8	40.4	0.2	2.7	9.6	5.3	8.3	1.4	7.8	28.7	13.7	12.8	9.8	8.2	4.5	1.2	5.2	12.4	1.8	12.2	0.0	1.9	3.2	5.5	1.5	5.7	2.1	6.2	6.3	1.8	4.8	2.8	2.4	0.1	0.4	1.5	2.5	3.1	1.8	12.2	12.4	5.0	12.7	7.5	4.8	6.0	7.5	8.2	7.7
SMAD4	"DPC4, MADH4"	ENSG00000141646	"SMAD family member 4"	Q13485	18	51028394-51085045	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019154	Approved		Supported	Nucleoplasm,Centrosome,Cytosol				"Nucleoplasm, Cytosol"	Centrosome	"HPA019154: AB_1853480"	"unprognostic (1.58e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.25e-2)"	"unprognostic (4.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (4.05e-1)"	"unprognostic (7.29e-3)"	"unprognostic (9.00e-2)"	"unprognostic (4.01e-2)"	"unprognostic (2.51e-2)"	"unprognostic (1.03e-3)"	"unprognostic (4.40e-2)"	"prognostic favourable (1.92e-5)"	"unprognostic (2.62e-2)"	"unprognostic (4.23e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.44e-1)"	25.6	17.5	16.0	14.0	16.7	11.4	24.9	29.7	16.0	27.9	22.6	17.9	21.3	15.1	28.2	18.8	21.7	20.5	17.5	19.6	15.3	11.5	21.0	22.0	20.1	16.0	17.2	13.3	30.5	25.0	30.0	28.9	30.6	14.2	27.8	17.4	18.4	23.1	22.8	39.7	18.2	23.4	27.6	13.9	21.7	19.3	17.6	18.4	38.8	35.0	13.9	18.1	29.0	24.1	3.6	3.6	3.4	1.8	2.9	4.7	1.3	8.5	11.3	30.7	8.8	12.7	19.6	17.3	15.0	16.5	20.2	25.4	6.9	2.0	14.2	4.5	13.0	14.1	17.2	6.7	21.5	12.3	9.7	9.8	11.3	7.9	12.6	17.1	7.7	8.9	11.4	9.9	14.6	14.6	11.0	13.1	11.9	4.5	10.1	4.9	16.0	7.1	13.2	15.6	13.9	9.7	3.7	19.0	11.3	14.0	2.6	9.3	7.0	10.0	11.0	17.1	7.9	4.3	9.9	19.7	13.7	12.3	11.1	6.7	11.3	0.8	1.8	1.8	3.2	1.1	3.7	2.2	3.3	2.6	3.6	3.6	4.0	4.7	3.4	2.9	1.3	2.9	4.3	1.3	16.0	16.7	29.7	16.0	15.3	11.5	17.2	13.3	14.2	18.4
SMARCA4	"BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2"	ENSG00000127616	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4"	P51532	19	10960825-11079426	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Neurogenesis, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Helicase, Hydrolase, Repressor, RNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB004208	Supported		Supported	Nucleoplasm		260000	260000	Nucleoplasm		"CAB004208: AB_626762"	"unprognostic (2.68e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.71e-1)"	"unprognostic (3.43e-3)"	"unprognostic (1.40e-1)"	"unprognostic (6.33e-3)"	"prognostic unfavourable (1.11e-4)"	"unprognostic (7.19e-2)"	"unprognostic (7.29e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.15e-2)"	"unprognostic (6.80e-3)"	"unprognostic (6.83e-3)"	"unprognostic (5.44e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.29e-1)"	10.3	12.4	15.5	18.0	21.3	20.5	10.9	29.1	28.0	13.2	12.8	16.6	9.7	14.3	16.6	9.4	24.7	15.7	12.8	11.6	14.4	17.7	13.0	9.9	13.0	18.1	17.1	16.8	13.6	13.4	18.1	11.5	14.6	16.1	13.3	9.4	17.3	18.2	12.5	21.9	20.4	12.0	10.6	16.1	13.2	14.5	22.2	12.4	58.2	15.5	10.1	21.5	15.2	12.6	9.8	11.2	8.6	13.5	11.4	13.7	5.9	20.5	1.1	36.7	34.7	7.2	6.1	16.1	14.3	8.6	17.5	13.0	28.7	0.9	48.3	22.2	12.5	15.1	28.6	17.7	9.7	19.8	21.5	38.5	18.2	33.3	10.9	27.9	19.2	10.3	8.6	14.7	15.2	15.6	34.4	18.2	13.7	42.0	46.2	23.9	37.3	31.1	49.3	23.2	25.0	11.2	26.1	41.8	37.9	15.2	19.6	16.3	16.6	20.9	20.7	26.1	13.6	23.8	23.6	37.7	41.8	48.0	14.8	26.8	22.2	8.1	8.3	8.6	13.7	9.5	12.2	7.4	10.4	11.6	8.5	9.8	11.4	11.2	5.2	11.4	13.5	11.2	8.8	5.9	15.5	21.3	29.1	28.0	14.4	17.7	17.1	16.8	16.1	12.4
SMARCB1	"BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1"	ENSG00000099956	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1"	Q12824	22	23786931-23838008	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation"	"Activator, Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 19.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009196, HPA018248, HPA019127"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"				Nucleoplasm	"Nucleoli fibrillar center"	"CAB009196: AB_2191983, HPA018248: AB_1851162, HPA019127: AB_1851165"	"unprognostic (2.15e-1)"	"unprognostic (5.62e-2)"	"unprognostic (6.60e-3)"	"unprognostic (1.63e-2)"	"unprognostic (4.01e-3)"	"unprognostic (2.14e-1)"	"prognostic unfavourable (6.52e-4)"	"unprognostic (4.10e-1)"	"unprognostic (1.86e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.10e-2)"	"unprognostic (4.43e-3)"	"prognostic favourable (1.14e-6)"	"unprognostic (1.24e-1)"	"unprognostic (4.58e-2)"	"unprognostic (4.57e-2)"	"unprognostic (7.04e-2)"	11.0	15.2	14.6	33.2	15.4	16.9	12.1	30.4	21.9	13.4	25.1	16.4	11.4	41.1	17.2	11.0	15.6	12.3	15.0	12.6	13.2	14.2	14.6	11.7	14.0	32.8	13.0	13.8	21.3	16.1	7.9	15.7	20.8	12.8	11.0	9.4	16.7	40.9	13.1	28.1	14.7	27.4	10.6	12.8	19.8	24.1	37.7	12.9	29.4	15.7	12.0	16.0	21.1	12.2	19.5	9.9	4.8	11.6	7.0	7.5	5.9	1.5	1.0	19.0	1.7	1.8	0.5	3.8	6.0	1.8	1.8	2.9	2.2	1.8	15.5	5.2	0.8	2.9	4.5	2.9	3.0	2.5	6.6	12.9	1.7	1.3	2.0	13.6	3.8	1.1	2.2	2.1	4.7	0.9	3.5	8.6	1.1	3.8	11.1	3.1	5.7	3.8	7.0	15.3	7.0	1.5	3.0	9.0	6.8	1.4	0.4	10.2	1.4	2.1	1.6	1.6	6.6	2.6	1.7	9.5	8.7	10.3	1.3	7.5	4.6	4.0	10.0	4.8	3.8	10.2	5.2	19.5	4.6	4.6	9.3	6.4	3.8	2.5	0.8	7.0	11.6	9.9	7.5	5.9	14.6	15.4	30.4	21.9	13.2	14.2	13.0	13.8	12.8	12.9
SMARCD1	"BAF60A, CRACD1, Rsc6p"	ENSG00000066117	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1"	Q96GM5	12	50084972-50100712	"Cancer-related genes, Predicted intracellular proteins"	Neurogenesis	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004101	Supported		Supported	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA004101: AB_1080026"	"unprognostic (1.88e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.11e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.76e-1)"	"prognostic unfavourable (2.53e-8)"	"unprognostic (3.62e-2)"	"unprognostic (1.44e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.10e-2)"	"unprognostic (1.20e-3)"	"unprognostic (2.18e-1)"	"unprognostic (3.45e-1)"	"unprognostic (1.38e-1)"	"unprognostic (5.04e-2)"	21.3	24.5	16.4	22.6	22.7	29.9	21.3	27.8	28.2	19.8	19.9	29.5	17.6	18.8	23.6	23.4	23.3	19.9	18.2	15.6	16.3	13.8	25.1	18.3	19.4	26.1	15.7	20.4	24.7	19.6	44.3	17.8	24.7	18.8	20.4	22.4	20.3	21.4	25.9	16.6	19.7	24.0	23.8	18.5	28.1	17.4	34.4	14.9	64.3	24.3	17.9	36.7	19.3	18.2	6.0	6.7	4.4	3.4	3.1	6.9	2.3	8.0	13.6	40.3	23.3	12.6	11.9	20.0	10.1	17.9	29.7	17.4	37.4	12.7	31.6	15.2	19.2	10.4	34.0	26.4	25.7	24.4	25.1	31.1	13.8	21.6	15.0	27.5	12.5	12.0	17.8	17.5	31.8	34.9	26.3	19.6	15.0	19.0	39.9	14.8	50.4	22.4	47.9	10.5	27.6	16.8	19.0	21.8	36.3	21.2	10.8	42.1	24.3	23.1	20.9	15.3	17.1	9.6	20.5	27.7	24.3	28.1	12.4	11.2	17.3	4.4	2.3	4.1	6.1	2.1	5.8	6.0	3.3	3.9	3.6	5.6	2.1	6.9	1.1	3.1	3.4	6.7	5.0	2.3	16.4	22.7	27.8	28.2	16.3	13.8	15.7	20.4	18.8	14.9
SMARCE1	BAF57	ENSG00000073584	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1"	Q969G3	17	40624962-40648864	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	Neurogenesis	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003916, CAB037318"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB037318: AB_476780, HPA003916: AB_1857279"	"unprognostic (7.91e-2)"	"unprognostic (2.68e-2)"	"unprognostic (2.09e-2)"	"unprognostic (8.06e-3)"	"unprognostic (1.87e-1)"	"unprognostic (2.55e-2)"	"unprognostic (4.48e-1)"	"unprognostic (1.25e-2)"	"unprognostic (2.20e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.04e-1)"	"unprognostic (9.80e-2)"	"unprognostic (5.93e-2)"	"unprognostic (7.63e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.27e-2)"	25.1	20.2	14.4	17.2	18.8	18.4	20.2	17.0	16.7	37.6	25.1	18.0	12.6	18.4	42.8	19.5	31.0	21.1	20.6	19.6	13.3	12.0	23.0	22.6	20.1	22.3	16.5	14.3	39.5	16.9	13.3	20.4	34.8	15.2	32.4	19.2	17.9	20.6	21.9	32.0	21.3	22.6	33.4	15.8	30.3	19.1	22.0	17.5	53.9	23.8	18.9	25.1	31.2	21.0	40.3	32.0	34.0	30.3	47.2	44.0	39.2	20.5	34.3	42.1	31.3	22.3	32.1	20.7	25.9	35.8	30.5	23.0	22.4	17.9	32.7	37.5	35.0	28.1	26.0	27.4	36.7	30.6	33.8	23.4	18.5	39.4	22.5	42.6	23.8	27.8	21.7	24.3	35.5	32.8	34.0	13.0	29.1	23.1	78.0	8.8	23.5	17.0	43.8	47.4	24.8	36.8	35.3	33.7	32.6	23.0	66.9	21.5	40.1	26.8	26.8	24.8	27.4	22.4	31.9	24.4	28.4	48.9	25.3	19.6	38.2	31.8	26.0	34.0	39.1	26.8	40.5	38.4	35.8	40.9	31.3	40.3	30.2	34.9	11.0	47.2	30.3	32.0	44.0	39.2	14.4	18.8	17.0	16.7	13.3	12.0	16.5	14.3	15.2	17.5
SMC1A	"DXS423E, KIAA0178, SB1.8, SMC1L1, Smcb"	ENSG00000072501	"Structural maintenance of chromosomes 1A"	Q14683	X	53374149-53422728	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005499, CAB025404"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB025404: , HPA005499: AB_1080028"	"unprognostic (2.00e-1)"	"unprognostic (1.52e-1)"	"unprognostic (4.00e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.04e-1)"	"unprognostic (9.89e-2)"	"unprognostic (1.29e-3)"	"unprognostic (1.89e-1)"	"unprognostic (9.80e-3)"	"unprognostic (9.49e-2)"	"unprognostic (4.48e-2)"	"unprognostic (6.55e-2)"	"unprognostic (2.58e-1)"	"unprognostic (4.18e-3)"	"unprognostic (6.28e-2)"	"unprognostic (2.89e-1)"	"unprognostic (9.39e-2)"	20.6	14.1	14.6	24.2	28.2	24.6	16.2	33.6	21.7	19.9	18.2	22.0	10.5	16.2	27.5	10.0	22.4	21.7	12.5	16.2	16.8	10.8	19.2	23.5	15.4	30.2	25.2	13.0	21.8	17.2	31.0	18.4	19.5	18.0	13.4	17.3	12.5	16.8	12.9	24.3	16.2	19.7	21.7	21.3	20.1	17.5	10.4	25.8	38.3	16.8	11.1	25.7	22.0	21.3	14.3	15.5	13.7	18.7	15.6	17.8	10.6	28.2	31.7	25.2	21.5	9.3	10.3	14.1	17.1	11.3	21.7	17.6	18.8	16.5	27.6	14.7	11.4	21.6	44.9	24.7	24.3	23.6	52.3	24.1	36.8	13.1	3.8	34.0	34.6	5.8	6.4	24.3	14.8	18.7	35.4	17.8	16.9	17.1	30.6	10.3	37.4	16.9	32.9	43.5	25.5	9.2	18.6	26.8	22.6	44.7	22.1	9.4	23.7	13.9	10.5	18.5	19.6	18.3	16.6	11.7	19.7	25.6	10.6	38.7	18.1	6.1	13.8	13.7	17.8	18.7	17.0	12.2	12.0	15.6	15.5	14.3	14.2	10.9	9.4	15.6	17.4	12.9	8.8	10.6	14.6	28.2	33.6	21.7	16.8	10.8	25.2	13.0	18.0	25.8
SMC3	"BAM, bamacan, CSPG6, HCAP, SMC3L1"	ENSG00000108055	"Structural maintenance of chromosomes 3"	Q9UQE7	10	110567691-110604636	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, DNA repair, Meiosis, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA037411, HPA043206"	Uncertain		Supported	Nucleoplasm		10000000	10000000	Nucleoplasm		"HPA037411: AB_10671753, HPA043206: "	"unprognostic (3.40e-1)"	"unprognostic (1.73e-2)"	"unprognostic (9.05e-2)"	"unprognostic (3.00e-2)"	"unprognostic (3.73e-2)"	"unprognostic (8.89e-3)"	"unprognostic (9.74e-3)"	"unprognostic (8.06e-2)"	"unprognostic (5.31e-2)"	"unprognostic (6.32e-2)"	"unprognostic (3.53e-2)"	"unprognostic (1.17e-2)"	"unprognostic (8.73e-3)"	"unprognostic (7.22e-2)"	"unprognostic (5.18e-2)"	"unprognostic (7.95e-2)"	"unprognostic (1.32e-1)"	17.1	13.4	16.8	15.4	22.9	32.7	21.3	37.8	18.0	19.2	15.1	9.9	10.7	13.3	20.1	14.3	19.7	15.6	9.9	11.9	16.7	11.2	16.6	17.2	12.6	23.7	18.6	15.4	26.5	18.4	22.2	36.6	22.9	17.7	14.6	15.1	8.8	15.3	14.3	18.4	18.4	18.8	19.6	22.2	18.1	13.5	32.0	23.2	47.4	19.4	11.4	20.8	20.7	19.7	13.2	11.0	19.1	10.5	15.1	17.7	7.4	26.8	16.8	36.6	26.0	12.2	10.5	15.8	21.8	21.8	20.2	19.9	21.2	22.7	35.1	9.6	14.6	21.5	26.2	13.2	30.9	28.6	22.5	28.3	21.2	19.0	12.2	40.2	21.9	8.3	10.8	22.3	35.2	14.8	22.5	27.2	17.4	14.1	30.9	21.4	25.2	13.5	26.3	66.3	19.0	12.5	12.0	20.9	23.9	23.5	6.8	17.9	10.9	19.7	15.2	16.3	25.8	18.3	31.4	15.8	14.1	38.0	14.5	38.8	13.3	19.1	7.7	18.6	13.0	10.5	16.1	13.2	15.1	14.0	8.4	13.1	15.5	15.1	8.4	15.1	8.9	11.0	17.7	7.4	16.8	22.9	37.8	18.0	16.7	11.2	18.6	15.4	17.7	23.2
SMO	"FZD11, SMOH"	ENSG00000128602	"Smoothened, frizzled class receptor"	Q99835	7	129188872-129213545	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"		"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 20.0;AN3-CA: 37.1;NTERA-2: 28.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB011446	Approved									"CAB011446: "	"unprognostic (2.48e-2)"	"unprognostic (2.69e-2)"	"unprognostic (7.09e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.16e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.63e-1)"	"unprognostic (5.89e-2)"	"unprognostic (5.38e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.17e-2)"	"unprognostic (8.74e-3)"	"unprognostic (1.62e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.09e-1)"	"unprognostic (2.25e-1)"	"unprognostic (2.61e-2)"	4.0	4.1	4.2	3.8	4.8	0.5	7.4	5.3	4.6	18.2	5.8	5.1	9.2	2.5	20.9	18.7	10.3	11.4	10.0	5.2	8.4	3.7	10.6	13.7	2.4	2.0	4.3	4.5	23.0	7.1	14.4	13.5	2.6	9.0	18.4	2.2	17.2	9.4	12.8	3.5	16.6	3.5	9.8	7.0	2.0	4.2	7.9	3.4	5.3	9.2	6.8	4.6	6.3	17.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	7.8	20.0	37.1	0.5	0.1	6.3	2.2	2.9	4.4	2.6	6.0	0.1	0.0	6.1	4.4	12.2	12.0	0.6	1.7	0.0	9.8	3.9	0.0	9.6	2.5	0.1	0.0	7.3	4.9	1.4	0.0	2.5	0.6	0.0	1.3	0.0	10.2	0.0	28.4	2.2	14.8	8.5	0.0	2.3	0.0	0.6	13.4	0.0	0.0	5.2	4.9	2.5	0.0	0.3	6.4	7.7	4.2	0.4	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	4.8	5.3	4.6	8.4	3.7	4.3	4.5	9.0	3.4
SMYD3	"KMT3E, ZMYND1, ZNFN3A1"	ENSG00000185420	"SET and MYND domain containing 3"	Q9H7B4	1	245749342-246507312	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 92.9;K-562: 35.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012229, HPA045821, HPA054352"	Approved		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB012229: , HPA045821: , HPA054352: "	"unprognostic (7.00e-3)"	"unprognostic (7.45e-2)"	"unprognostic (1.52e-1)"	"unprognostic (6.18e-3)"	"unprognostic (3.32e-2)"	"unprognostic (5.08e-3)"	"unprognostic (3.25e-3)"	"unprognostic (1.72e-3)"	"unprognostic (4.53e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.10e-1)"	"unprognostic (3.78e-5)"	"unprognostic (9.03e-3)"	"unprognostic (2.14e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.58e-1)"	6.0	12.0	9.9	9.7	16.2	7.6	10.6	25.9	14.7	8.9	6.5	6.4	3.7	4.5	8.7	21.8	6.1	10.0	7.7	5.8	10.3	12.0	8.9	5.5	9.2	6.3	12.0	10.2	8.0	7.2	6.7	11.9	4.6	15.3	6.8	8.3	9.5	5.3	5.9	9.5	6.7	5.2	7.6	6.8	5.3	6.1	10.5	8.1	7.5	18.8	3.6	9.3	8.3	6.6	11.3	5.9	8.3	3.4	19.4	12.9	8.7	4.6	2.8	4.1	3.5	4.7	6.4	4.1	6.5	4.9	7.7	17.3	3.7	5.4	7.6	5.3	6.0	3.0	3.7	7.3	25.9	4.0	3.8	4.4	4.2	4.4	8.8	4.4	92.9	17.3	1.7	10.2	6.6	5.2	35.1	2.6	7.5	1.6	8.5	8.6	3.7	4.5	7.9	5.0	10.9	5.6	6.8	9.8	4.7	3.1	0.4	5.9	3.8	7.6	4.0	3.7	2.6	2.6	7.7	13.3	3.6	3.9	7.1	6.1	4.3	8.1	3.4	8.3	10.5	3.0	10.8	11.3	11.1	12.8	5.9	11.1	12.3	12.9	2.4	19.4	3.3	3.8	11.8	8.7	9.9	16.2	25.9	14.7	10.3	12.0	12.0	10.2	15.3	8.1
SND1	"p100, TDRD11"	ENSG00000197157	"Staphylococcal nuclease and tudor domain containing 1"	Q7KZF4	7	127652180-128092609	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	"Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002529, HPA002632, CAB019323"	Enhanced		Enhanced	Cytosol		1200000	1200000	Cytosol		"CAB019323: , HPA002529: AB_1857317, HPA002632: AB_1857316"	"unprognostic (2.06e-1)"	"unprognostic (8.27e-3)"	"unprognostic (2.21e-1)"	"prognostic favourable (1.95e-4)"	"unprognostic (5.10e-3)"	"unprognostic (6.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.91e-2)"	"unprognostic (4.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.36e-2)"	"unprognostic (9.96e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.26e-3)"	21.5	29.8	25.3	25.3	19.8	22.5	45.4	28.1	28.1	33.3	20.0	13.0	57.7	21.3	36.1	38.4	24.8	26.7	25.3	28.3	20.9	16.6	17.3	39.6	38.8	64.2	20.2	19.0	39.7	130.3	22.2	30.3	33.7	27.6	24.5	20.2	13.9	37.5	66.7	20.5	21.5	19.2	41.0	40.1	24.9	30.8	37.0	18.0	22.3	26.6	13.5	24.9	26.5	24.2	28.1	34.9	16.1	30.0	21.0	30.9	28.5	27.9	25.4	19.5	35.3	29.5	30.9	26.7	33.0	39.0	30.2	34.0	32.8	24.3	37.2	16.7	40.4	23.5	27.4	35.8	29.6	20.3	23.2	20.5	30.4	31.4	53.8	31.7	20.2	45.5	39.9	25.8	43.3	37.5	22.7	37.4	30.1	20.9	34.5	23.8	21.8	31.7	24.1	17.4	83.2	23.7	19.8	24.5	26.5	23.9	111.1	38.2	13.9	22.6	37.2	24.6	16.1	44.6	25.6	46.1	17.3	39.1	49.4	27.4	44.5	16.1	30.0	5.9	26.1	28.1	30.9	28.1	19.8	21.0	32.3	16.2	14.3	15.8	2.2	21.0	22.8	34.9	15.8	28.5	25.3	19.8	28.1	28.1	20.9	16.6	20.2	19.0	27.6	18.0
SNX25	SBBI31	ENSG00000109762	"Sorting nexin 25"	Q9H3E2	4	185204237-185370185	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 27.8"	"Low cancer specificity"	"Detected in all"							"Cell type enhanced"	"Detected in some"		"naive B-cell: 3.6"	"Group enriched"	"Detected in many"	4	"B-cells: 3.6;T-cells: 1.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA036928			Supported	Vesicles				Vesicles		"HPA036928: AB_10669720"	"unprognostic (9.20e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.26e-1)"	"unprognostic (4.29e-3)"	"unprognostic (8.89e-2)"	"unprognostic (5.63e-2)"	"unprognostic (1.43e-2)"	"unprognostic (6.41e-2)"	"unprognostic (5.35e-2)"	"unprognostic (2.99e-2)"	"unprognostic (4.03e-3)"	"unprognostic (1.87e-1)"	"unprognostic (3.33e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.32e-2)"	"unprognostic (8.55e-3)"	3.0	3.7	2.6	2.9	5.3	0.1	4.6	11.9	4.2	2.7	5.6			1.1	3.3	2.8	3.1	4.7	3.9	4.4	3.3	5.6	5.6	4.1	15.1	4.9	4.6		3.4	4.6	7.2	5.7	5.6		7.9	3.0		2.8	4.3	4.8	2.5	3.5	3.1	2.1	4.2	2.6	5.9			8.5		6.0	3.8	2.2	3.6	0.2	0.0	0.2	0.6	1.5	0.2	5.8	3.1	3.9	5.6	10.6	7.9	5.9	18.0	8.6	9.1	7.6	2.6	4.1	16.8	2.0	12.8	2.3	4.5	3.9	10.3	27.8	7.5	2.8	3.8	6.1	6.2	1.9	4.1	5.4	4.3	7.9	4.4	7.9	5.9	16.9	12.0	1.7	0.7	3.3	3.2	3.0	2.4	4.5	4.2	22.1	2.2	8.5	6.2	3.7	1.0	14.7	2.1	2.4	15.2	5.2	3.4	5.0	7.8	15.3	6.2	3.6	8.6	1.4	6.5	0.0	0.0	0.0	0.6	0.2	1.0	2.5	1.3	1.5	0.0	3.6	0.4	0.9	0.0	0.6	0.0	0.2	0.8	0.2										
SOCS1	"Cish1, JAB, SOCS-1, SSI-1, TIP3"	ENSG00000185338	"Suppressor of cytokine signaling 1"	O15524	16	11254405-11256200	"Cancer-related genes, Predicted intracellular proteins"	"Growth regulation, Ubl conjugation pathway"	"Signal transduction inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 42.3;lymphoid tissue: 58.3"	"Cell line enriched"	"Detected in some"	5	"HDLM-2: 47.2"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	6	"cerebellum: 15.2"	"Cell type enhanced"	"Detected in many"		"basophil: 12.9"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB010355, HPA074108"	Approved		Supported	"Nucleoplasm,Cytoplasmic bodies"				Nucleoplasm	"Cytoplasmic bodies"	"CAB010355: AB_2193144, HPA074108: "	"unprognostic (4.50e-3)"	"unprognostic (3.30e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.25e-2)"	"prognostic favourable (1.10e-4)"	"unprognostic (1.71e-2)"	"unprognostic (4.09e-3)"	"unprognostic (5.31e-3)"	"unprognostic (4.82e-2)"	"unprognostic (1.17e-1)"	"unprognostic (5.39e-2)"	"prognostic unfavourable (1.08e-6)"	"unprognostic (1.56e-1)"	"unprognostic (5.68e-2)"	"unprognostic (6.08e-2)"	"unprognostic (1.67e-1)"	10.9	2.8	0.7	19.2	1.5	13.9	37.9	15.2	1.1	15.8	6.3	0.3	2.2	3.3	4.9	7.6	5.6	4.2	11.0	3.6	0.6	1.0	11.1	42.3	9.6	25.8	0.8	0.0	9.3	3.8	0.7	16.8	9.3	2.4	5.3	1.8	3.2	3.7	3.9	2.3	6.0	11.0	6.5	1.1	14.7	6.6	7.1	0.4	58.3	5.1	4.8	14.7	5.4	8.3	4.4	1.3	12.9	0.1	5.5	2.7	0.4	1.2	0.2	0.5	0.1	1.6	0.2	1.8	1.0	7.3	0.4	0.6	0.3	0.2	2.8	2.2	0.4	0.5	0.2	0.1	0.1	47.2	0.3	0.7	0.0	3.8	0.6	0.0	8.7	0.6	0.1	1.0	0.0	0.1	6.3	0.8	0.0	1.1	3.1	1.8	5.3	0.8	0.3	0.3	0.3	0.5	0.2	0.7	0.1	0.2	1.7	0.5	0.0	0.4	0.0	0.6	3.1	0.4	0.6	0.2	0.2	4.4	1.2	0.3	0.6	12.9	0.1	8.8	2.2	0.0	2.0	1.4	2.5	2.7	0.0	4.4	2.7	2.5	0.3	5.5	0.0	1.3	2.6	0.4	0.7	1.5	15.2	0.6	0.6	1.0	0.8	0.0	2.4	0.4
SOD1	"ALS, ALS1, IPOA"	ENSG00000142168	"Superoxide dismutase 1"	P00441	21	31659622-31668931	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Antioxidant, Oxidoreductase"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 282.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001401, CAB008670"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		91000000	91000000	"Nucleoplasm, Plasma membrane, Cytosol"		"CAB008670: AB_1623312, HPA001401: AB_1080132"	"unprognostic (1.73e-1)"	"unprognostic (1.18e-2)"	"unprognostic (4.43e-1)"	"unprognostic (6.19e-2)"	"unprognostic (1.39e-1)"	"unprognostic (9.59e-3)"	"unprognostic (8.34e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.47e-1)"	"unprognostic (5.28e-2)"	"unprognostic (9.33e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.74e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.26e-2)"	39.2	86.5	71.1	29.1	74.3	24.6	108.6	35.6	74.9	26.8	37.7	19.1	35.4	62.5	24.6	42.2	25.8	36.0	46.8	96.5	77.8	73.1	84.0	282.6	23.0	26.8	80.2	67.0	53.9	27.2	27.1	30.4	29.7	96.1	35.1	32.6	19.3	19.7	39.3	83.9	20.5	45.5	45.2	88.2	19.2	25.8	22.2	43.8	12.3	30.1	34.7	25.6	25.4	124.0	57.6	32.3	24.9	57.2	29.6	95.6	55.6	55.6	48.7	34.2	34.2	45.8	31.9	28.4	47.0	28.1	32.0	24.2	63.1	35.4	66.7	49.5	43.3	20.2	49.0	34.6	26.4	49.2	60.9	107.6	63.9	90.2	30.3	47.5	40.3	33.1	26.4	44.8	24.9	35.9	74.2	85.3	38.5	90.4	51.0	47.9	51.4	52.0	43.9	69.0	103.7	62.5	34.2	37.4	31.4	87.1	46.1	45.2	53.0	42.0	42.0	24.9	55.1	33.6	34.6	65.2	141.0	79.0	50.8	69.3	33.0	22.1	21.9	24.9	45.0	30.2	51.6	57.6	73.1	56.9	28.6	40.9	76.2	59.3	5.1	29.6	57.2	32.3	95.6	55.6	71.1	74.3	35.6	74.9	77.8	73.1	80.2	67.0	96.1	43.8
SOD2		ENSG00000285441	"Superoxide dismutase 2"	P04179	6	159679119-159762529	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 3.2;bone marrow: 4.9;seminal vesicle: 3.5"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 2.0"									"Cell type enhanced"	"Detected in single"		"memory B-cell: 3.2"	"Low lineage specificity"	"Detected in single"																	140000000	140000000																					0.0	0.0	0.0	0.2	0.4	4.9	0.3	0.0	1.7	0.0	0.1	1.6	0.0	0.0	0.0	1.3	0.0	0.1	0.0	0.0	0.0		0.3	1.0	0.6	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.0	1.6	0.5	0.2	1.0	0.1	3.5	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.2	0.7	0.0	0.0	0.0	0.2	0.0	0.0	3.2	0.4	0.9	0.4	0.2	0.8	0.2	0.0	0.3	0.4	0.4	1.4	1.3	0.5	0.1	2.0	0.8	1.4	0.5	0.2	0.1	0.4	0.4	0.3	1.0	1.8	0.5	0.2	0.0	0.2	0.4	0.7	0.6	0.1	0.1	1.0	1.4	1.6	0.0	0.1	0.2	0.6	0.4	0.0	0.7	0.1	0.1	0.0	0.5	0.3	0.4	0.4	0.0	0.7	0.5	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.3	0.3	0.0	0.6	0.6	0.2	0.2	0.2	0.1	0.6	0.4	0.4	0.7	0.2	0.1	3.2	0.6	0.4	0.4	0.9	0.8	0.4	0.9	0.2	0.4	0.2	0.5	0.2										
SOS1	"GF1, GINGF, HGF"	ENSG00000115904	"SOS Ras/Rac guanine nucleotide exchange factor 1"	Q07889	2	38981396-39124345	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"		"Guanine-nucleotide releasing factor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 55.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005396	Uncertain		Approved	Cytosol				Cytosol		"CAB005396: AB_2270724"	"unprognostic (6.68e-2)"	"unprognostic (2.12e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.14e-3)"	"unprognostic (4.02e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.74e-3)"	"unprognostic (4.55e-2)"	"unprognostic (1.10e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.24e-2)"	"unprognostic (3.18e-2)"	"unprognostic (1.38e-2)"	"unprognostic (8.96e-3)"	"unprognostic (7.61e-2)"	"unprognostic (5.59e-2)"	"unprognostic (1.33e-2)"	25.9	13.2	19.2	18.8	18.1	12.0	26.1	33.3	18.6	18.6	21.9	12.1	15.3	18.3	19.1	14.6	17.4	17.0	18.1	16.4	17.9	14.1	14.6	15.2	19.9	19.9	18.2	14.0	28.1	13.0	33.5	21.7	21.5	17.8	18.4	16.8	14.6	15.9	18.1	26.2	15.0	23.1	22.3	14.6	16.2	20.1	12.7	20.1	23.1	19.4	12.9	21.8	25.1	22.0	3.2	1.4	3.2	2.0	6.2	4.6	0.9	9.7	6.0	9.4	6.7	12.7	15.2	9.8	6.2	7.6	4.9	4.7	6.5	5.9	14.2	4.2	8.0	5.8	11.0	5.6	9.2	14.2	4.9	22.0	5.2	8.9	5.2	7.0	55.8	9.3	9.0	6.7	6.5	7.7	9.3	6.7	6.3	5.3	7.5	6.5	5.8	4.3	8.4	8.5	4.1	5.2	7.9	9.1	9.1	7.3	13.2	7.6	4.2	3.7	8.6	8.2	6.7	6.4	6.1	7.9	8.0	7.5	6.6	6.9	4.9	0.0	1.2	3.2	3.2	1.8	4.6	3.2	3.3	3.3	1.0	2.4	3.7	3.4	1.4	6.2	2.0	1.4	1.9	0.9	19.2	18.1	33.3	18.6	17.9	14.1	18.2	14.0	17.8	20.1
SOX1		ENSG00000182968	"SRY-box 1"	O00570	13	112067647-112070488	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 9.9;testis: 3.7"	"Cell line enriched"	"Detected in some"	5	"AF22: 31.1"	"Group enriched"	"Detected in some"	6	"colorectal cancer: 0.9;glioma: 2.3;melanoma: 2.0"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"																"unprognostic (1.12e-1)"		"unprognostic (4.95e-2)"	"unprognostic (1.71e-3)"			"unprognostic (6.03e-2)"	"unprognostic (6.41e-2)"				"unprognostic (4.85e-1)"	"unprognostic (5.93e-2)"			0.5	0.5	5.3	0.5	5.8	0.4	0.9	2.5	9.9	0.4	0.6	2.6	0.0	0.7	0.4	0.4	0.4	0.4	0.4	0.4	3.5	7.0	0.4	0.4	0.4	0.4	2.5	2.4	0.4	0.4	0.4	0.2	0.4	3.1	0.4	0.5	2.7	0.6	0.5	0.4	1.5	0.4	0.4	4.8	0.4	0.5	3.7	0.3	0.0	0.4	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	5.8	2.5	7.8	3.5	7.0	2.5	2.4	3.1	0.3
SOX17		ENSG00000164736	"SRY-box 17"	Q9H6I2	8	54457935-54460888	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	7	"EFO-21: 49.1"	"Group enriched"	"Detected in many"	12	"endometrial cancer: 122.8;ovarian cancer: 96.2;testis cancer: 25.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025594, HPA068399"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"CAB025594: , HPA068399: "	"unprognostic (1.87e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.76e-3)"	"prognostic favourable (2.76e-4)"	"unprognostic (1.01e-1)"	"unprognostic (3.85e-2)"	"unprognostic (3.34e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.39e-2)"	"unprognostic (7.90e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.18e-1)"	"unprognostic (4.98e-2)"	"unprognostic (7.28e-3)"	"unprognostic (1.12e-1)"	"unprognostic (3.76e-1)"	"unprognostic (1.88e-1)"	26.7	2.0	1.2	9.1	1.8	0.6	31.3	0.6	2.9	25.7	7.9	1.5	1.0	1.4	23.9	7.1	11.6	23.1	20.2	20.6	1.5	1.3	3.0	2.2	8.7	1.5	2.0	1.0	13.0	1.5	1.7	1.5	9.9	2.3	7.6	1.6	3.6	2.4	3.0	13.3	3.1	3.3	5.9	1.8	15.7	3.7	5.8	0.4	0.8	3.6	6.2	1.3	12.3	5.8	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.1	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.8	0.6	2.9	1.5	1.3	2.0	1.0	2.3	0.4
SOX2		ENSG00000181449	"SRY-box 2"	P48431	3	181711924-181714436	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 80.1"	"Cell line enhanced"	"Detected in some"		"AF22: 67.5;HAP1: 28.7;NTERA-2: 55.0;U-251 MG: 12.6"	"Cancer enhanced"	"Detected in many"		"glioma: 136.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045725, HPA062851, HPA071379, CAB079745"	Enhanced	Supported	Enhanced	Nucleoplasm				Nucleoplasm		"CAB079745: , HPA045725: , HPA062851: , HPA071379: "	"unprognostic (1.80e-2)"	"unprognostic (3.18e-3)"	"unprognostic (5.69e-2)"	"unprognostic (6.96e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.79e-2)"	"unprognostic (4.48e-3)"	"unprognostic (1.71e-1)"	"unprognostic (4.38e-3)"	"unprognostic (1.83e-1)"	"unprognostic (7.68e-2)"	"unprognostic (3.81e-9)"	"unprognostic (1.12e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.12e-2)"	1.8	2.5	30.3	2.0	25.8	1.5	1.6	13.9	80.1	1.8	2.3	24.3	0.0	2.0	1.5	1.8	15.9	5.0	1.8	1.7	36.0	19.2	1.5	1.5	3.4	1.5	19.4	18.5	1.7	1.6	1.5	5.8	1.5	18.6	3.9	2.0	1.0	6.3	1.9	1.6	1.8	2.3	1.7	18.4	1.6	9.7	3.0	22.4	0.0	1.5	2.1	6.9	2.3	1.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.1	67.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.1	28.7	0.7	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	55.0	0.1	0.0	0.1	0.0	7.4	0.1	0.1	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	12.6	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.3	25.8	13.9	20.0	36.0	19.2	19.4	18.5	18.6	22.4
SOX9	"CMD1, CMPD1, SRA1"	ENSG00000125398	"SRY-box 9"	P48436	17	72121020-72126420	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"salivary gland: 63.4"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 29.5;Hep G2: 35.3;U-251 MG: 24.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001758, CAB022456, CAB068240"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB022456: , CAB068240: , HPA001758: AB_1080067"	"unprognostic (6.92e-2)"	"unprognostic (1.73e-2)"	"unprognostic (4.47e-3)"	"unprognostic (4.43e-2)"	"unprognostic (2.55e-2)"	"unprognostic (7.96e-3)"	"unprognostic (4.32e-3)"	"prognostic unfavourable (2.07e-4)"	"unprognostic (4.87e-2)"	"unprognostic (3.31e-1)"	"unprognostic (8.92e-3)"	"unprognostic (1.21e-1)"	"unprognostic (3.26e-3)"	"unprognostic (2.77e-3)"	"unprognostic (1.15e-1)"	"unprognostic (8.88e-2)"	"unprognostic (1.21e-2)"	3.1	2.6	32.2	4.3	31.6	1.1	23.4	20.3	32.4	7.4	14.6	28.4	8.1	16.6	3.5	1.9	7.7	7.4	11.7	9.5	35.5	15.7	11.7	3.9	3.4	1.9	14.6	13.7	1.2	31.9	1.2	7.0	1.4	21.3	21.7	15.7	12.9	63.4	14.4	3.0	13.1	12.9	2.1	15.6	1.3	35.2	25.2	20.2	0.0	17.8	5.3	5.0	1.9	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.2	7.1	14.8	29.5	1.5	0.4	0.0	1.8	1.5	3.1	1.7	9.9	15.3	0.0	1.1	0.4	11.6	0.0	6.9	2.9	0.0	0.9	0.0	1.5	35.3	0.1	0.0	0.0	0.2	0.6	3.6	3.4	0.0	0.0	0.0	4.4	0.1	0.0	0.0	0.5	11.0	0.0	11.9	0.1	13.3	0.7	0.7	0.7	1.5	1.7	0.0	6.3	0.1	0.0	6.1	16.5	3.2	24.3	0.0	0.0	0.0	4.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.2	31.6	20.3	26.7	35.5	15.7	14.6	13.7	21.3	20.2
SP1		ENSG00000185591	"Sp1 transcription factor"	P08047	12	53380176-53416446	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000330, HPA001853, HPA012292"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000330: AB_2171049, HPA001853: AB_1080069, HPA012292: AB_1857394"	"unprognostic (1.12e-1)"	"unprognostic (8.52e-3)"	"unprognostic (6.11e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.03e-1)"	"unprognostic (4.64e-3)"	"unprognostic (1.08e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.66e-2)"	"prognostic unfavourable (1.43e-4)"	"unprognostic (6.38e-2)"	"unprognostic (5.14e-2)"	"unprognostic (4.05e-2)"	"unprognostic (1.37e-1)"	"unprognostic (4.77e-2)"	"unprognostic (2.12e-2)"	20.7	18.1	8.8	13.9	14.2	17.0	20.1	30.0	14.7	20.9	21.9	17.5	19.3	19.6	25.4	21.2	35.0	20.4	18.7	12.1	14.1	6.8	31.3	14.1	17.6	14.2	18.3	9.7	22.5	17.9	19.0	11.3	19.5	14.4	16.2	20.1	21.5	25.8	19.5	22.0	25.8	30.0	18.4	21.0	19.0	18.8	22.4	15.2	25.8	16.6	17.3	26.6	25.1	21.6	2.7	3.0	11.2	4.2	1.7	2.8	1.4	17.7	19.5	22.3	16.3	18.0	20.8	17.8	12.8	16.6	15.8	14.6	16.2	35.6	24.1	17.0	14.7	25.7	25.6	17.4	17.7	18.4	14.9	21.2	24.7	8.8	12.6	19.3	17.9	21.9	18.1	16.2	31.5	16.2	20.3	34.9	11.6	25.4	28.8	14.8	12.3	14.7	20.5	21.5	14.2	12.4	32.1	11.8	15.7	26.0	21.9	13.2	27.5	20.7	15.6	18.6	17.4	13.8	13.6	12.0	13.8	24.1	14.2	16.1	14.8	4.5	4.2	2.5	2.2	2.7	2.8	2.3	2.2	2.1	2.4	2.7	2.4	2.6	11.2	1.7	3.1	3.0	1.6	1.4	8.8	14.2	30.0	14.7	14.1	6.8	18.3	9.7	14.4	15.2
SPARC	ON	ENSG00000113140	"Secreted protein acidic and cysteine rich"	P09486	5	151661096-151687165	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 230.6;BJ: 188.2;fHDF/TERT166: 297.7;WM-115: 218.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 9.3"	"Group enriched"	"Detected in many"	7	"granulocytes: 9.3;monocytes: 3.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002306, HPA002989, HPA003020"	Supported		Approved	Vesicles	"Secreted to blood"	190000000	190000000	Vesicles		"CAB002306: AB_563919, HPA002989: AB_1079532, HPA003020: AB_1079531"	"unprognostic (3.34e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.31e-1)"	"unprognostic (3.97e-1)"	"unprognostic (7.01e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.05e-1)"	"unprognostic (8.36e-3)"	"unprognostic (5.27e-2)"	"unprognostic (1.22e-1)"	"unprognostic (4.09e-2)"	"unprognostic (1.78e-1)"	"prognostic unfavourable (3.53e-5)"	"unprognostic (2.59e-3)"	"unprognostic (1.17e-2)"	"unprognostic (3.53e-1)"	"unprognostic (4.93e-3)"	178.3	58.3	50.2	47.4	93.3	3.4	68.6	33.8	131.3	115.6	42.8	92.3	22.9	13.2	89.0	65.9	36.9	38.5	177.8	65.5	68.3	100.3	46.3	25.0	66.8	25.4	124.7	18.0	55.1	14.1	36.7	16.8	249.1	153.5	46.3	22.4	47.5	15.8	45.3	31.2	40.2	20.6	144.0	202.0	43.8	20.4	75.2	68.8	7.4	38.6	39.4	14.8	104.6	35.9	0.0	0.8	9.3	3.0	0.0	0.3	40.6	0.2	0.2	55.7	2.6	230.6	78.2	5.2	188.2	62.0	78.0	80.4	0.2	0.1	0.0	44.7	297.7	2.5	7.0	14.3	26.9	0.2	2.6	2.5	0.0	5.1	69.0	0.1	0.2	122.1	20.6	57.4	8.0	107.0	2.3	2.0	44.3	0.0	0.2	1.6	25.7	0.2	0.1	55.3	0.1	0.0	0.0	2.1	4.2	0.1	0.0	25.0	0.2	6.1	126.4	36.4	56.3	16.4	59.1	0.1	0.2	0.2	31.8	0.1	218.8	2.2	3.0	0.9	0.3	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	9.3	0.0	0.0	0.7	0.0	40.6	50.2	93.3	33.8	24.6	68.3	100.3	124.7	18.0	153.5	68.8
SPARCL1	MAST9	ENSG00000152583	"SPARC like 1"	Q14515	4	87473335-87531061	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"AF22: 22.1;U-266/70: 8.7"	"Cancer enhanced"	"Detected in all"		"glioma: 528.6"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB026225	Enhanced				"Secreted in other tissues"	660000000	660000000			"CAB026225: "	"unprognostic (1.02e-2)"	"unprognostic (2.81e-2)"	"prognostic unfavourable (4.06e-4)"	"unprognostic (1.19e-1)"	"unprognostic (1.79e-2)"	"unprognostic (4.93e-2)"	"unprognostic (1.63e-3)"	"unprognostic (1.73e-2)"	"unprognostic (3.88e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.45e-3)"	"unprognostic (1.76e-2)"	"unprognostic (5.72e-2)"	"unprognostic (2.88e-3)"	"prognostic unfavourable (3.33e-4)"	102.2	21.9	110.3	18.8	139.9	0.9	52.1	42.9	212.1	123.2	58.0	17.9	23.8	19.7	148.7	74.6	56.4	92.8	74.7	80.9	98.8	40.9	13.2	4.5	58.7	14.6	67.5	106.4	45.2	13.0	15.8	38.3	48.8	69.7	97.0	30.4	7.9	31.5	166.0	35.2	13.1	27.4	185.6	82.5	23.9	40.8	29.2	53.9	1.2	38.8	24.4	15.6	103.9	50.3	0.0	0.3	0.1	0.1	0.0	0.8	0.0	0.6	0.0	22.1	0.3	0.2	0.1	2.2	0.1	0.1	0.0	0.0	0.0	0.1	0.4	1.8	0.0	1.3	2.4	0.0	0.0	1.8	0.0	0.3	1.1	0.4	1.0	0.3	1.3	3.5	0.0	0.0	0.0	0.0	0.4	3.2	0.0	0.5	0.1	3.3	0.6	0.0	0.3	0.3	1.0	0.0	0.1	0.7	1.8	0.2	0.2	0.1	0.3	0.4	0.0	0.2	0.3	1.3	0.1	8.7	1.2	0.5	3.4	0.4	2.5	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.1	0.0	0.1	0.3	0.0	0.0	110.3	139.9	42.9	136.4	98.8	40.9	67.5	106.4	69.7	53.9
SPATA6	"FLJ10007, SRF-1, SRF1"	ENSG00000132122	"Spermatogenesis associated 6"	Q9NWH7	1	48295372-48472208	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, Spermatogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 61.8"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 10.4;ASC TERT1: 17.6;HSkMC: 12.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 8.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028234			Approved	"Nucleoplasm,Golgi apparatus,Vesicles"	"Intracellular and membrane"			"Golgi apparatus, Vesicles"	Nucleoplasm	"HPA028234: "	"unprognostic (1.36e-2)"	"unprognostic (2.96e-2)"	"unprognostic (3.38e-2)"	"unprognostic (2.87e-2)"	"unprognostic (3.22e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.77e-2)"	"unprognostic (4.69e-3)"	"unprognostic (2.40e-2)"	"unprognostic (2.61e-2)"	"unprognostic (8.41e-2)"	"unprognostic (6.50e-2)"	"unprognostic (3.41e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.01e-1)"	"unprognostic (7.89e-2)"	"unprognostic (5.71e-3)"	5.8	8.9	6.2	3.0	12.9	1.5	8.4	2.4	8.9	7.5	5.0	12.9	10.1	3.3	6.9	7.9	4.1	16.2	5.9	4.7	7.8	5.6	6.9	2.4	7.5	7.0	14.9	3.9	9.0	5.2	12.8	21.5	5.3	8.5	6.4	4.6	6.6	6.9	12.2	3.8	5.0	3.7	8.3	10.0	4.1	7.3	61.8	13.4	1.1	10.3	2.4	2.2	6.5	12.2	0.2	1.7	5.2	8.2	0.3	0.6	0.7	0.1	0.9	9.4	10.4	8.8	17.6	1.3	1.0	3.9	0.8	0.7	0.1	0.7	0.0	0.6	1.7	0.2	0.8	2.3	0.7	0.7	1.3	0.1	0.4	0.4	1.8	0.0	0.7	12.5	1.8	1.5	0.5	3.7	0.1	0.0	3.9	0.3	0.1	0.1	4.0	1.0	2.9	0.0	0.9	5.8	1.6	2.3	5.2	3.8	0.4	9.0	2.3	0.5	1.1	1.4	1.4	2.2	1.5	0.0	0.0	0.0	5.8	0.1	6.2	0.0	1.8	5.2	0.1	4.3	0.0	0.2	0.4	0.0	1.7	0.1	0.6	0.5	0.3	0.3	8.2	0.8	0.0	0.7	6.2	12.9	2.4	8.9	7.8	5.6	14.9	3.9	8.5	13.4
SPEN	"KIAA0929, MINT, RBM15C, SHARP"	ENSG00000065526	"Spen family transcriptional repressor"	Q96T58	1	15847864-15940460	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015825, HPA050257"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA015825: AB_1856823, HPA050257: "	"unprognostic (3.91e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.76e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.48e-1)"	"unprognostic (3.06e-2)"	"unprognostic (6.93e-3)"	"unprognostic (2.26e-1)"	"unprognostic (4.26e-2)"	"unprognostic (4.88e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.98e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.49e-1)"	"unprognostic (1.66e-1)"	"unprognostic (2.26e-1)"	"unprognostic (1.83e-1)"	18.2	11.2	18.2	18.2	22.2	27.2	17.3	38.2	25.9	18.5	13.4	20.7	17.7	11.9	19.0	12.7	16.7	19.4	11.8	13.5	17.6	11.5	14.4	13.2	17.8	16.6	23.4	17.5	31.2	23.9	35.1	17.5	16.2	19.0	14.9	13.3	11.6	16.2	16.2	24.0	22.8	16.0	15.1	22.0	16.5	13.7	13.6	23.3	18.3	20.1	8.7	18.0	17.1	41.9	5.0	2.7	7.7	2.4	1.3	1.7	0.6	12.5	10.7	13.4	10.0	13.4	8.2	7.2	6.5	8.6	7.1	6.0	9.6	9.8	17.8	7.8	12.8	18.2	12.5	11.6	11.5	15.9	34.7	22.3	9.4	6.1	6.1	18.3	10.7	6.0	8.4	10.6	15.4	8.0	23.1	18.3	5.7	7.0	15.1	7.2	6.0	8.2	14.6	13.0	11.0	4.0	11.3	10.3	10.4	18.3	9.0	7.8	3.2	9.0	14.5	6.5	8.1	12.6	9.3	11.1	7.2	20.3	6.4	14.7	9.1	7.7	1.5	0.9	1.6	2.4	1.3	1.8	1.7	1.4	0.7	5.0	0.9	1.3	4.2	1.3	1.2	2.7	1.1	0.6	18.2	22.2	38.2	25.9	17.6	11.5	23.4	17.5	19.0	23.3
SPINK1	"PCTT, PSTI, Spink3, TATI"	ENSG00000164266	"Serine peptidase inhibitor, Kazal type 1"	P00995	5	147824568-147831786	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	68	"pancreas: 1767.1"	"Group enriched"	"Detected in some"	8	"CACO-2: 43.1;RT4: 118.4"	"Cancer enhanced"	"Detected in many"		"pancreatic cancer: 513.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB026366, HPA027498"	Enhanced				"Secreted to digestive system"	7900000	7900000			"CAB026366: , HPA027498: AB_10603115"	"unprognostic (1.05e-1)"	"unprognostic (1.00e-1)"	"unprognostic (9.96e-3)"	"unprognostic (3.55e-1)"	"unprognostic (6.12e-3)"	"unprognostic (1.79e-4)"	"unprognostic (8.34e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.66e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.82e-2)"	"unprognostic (8.13e-2)"	"prognostic unfavourable (5.44e-7)"	"unprognostic (7.98e-2)"	"unprognostic (2.07e-1)"		"prognostic favourable (2.15e-5)"	0.3	0.0	0.3	1.6	0.3	0.0	0.3	0.3	0.3	0.3	6.0	0.3	0.3	6.3	0.3	0.3	0.3	0.0	1.5	0.3	0.3	0.0	2.0	13.3	0.4	0.3	0.3	0.3	0.3	1767.1	0.0	0.3	0.3	0.3	1.4	6.4	0.3	0.3	0.3	0.3	0.0	6.9	1.0	0.3	0.3	25.8	0.4	0.3	0.3	0.3	0.3	0.3	13.1	2.2	0.7	0.5	1.9	0.5	0.3	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	43.1	0.0	0.0	0.8	0.0	0.1	0.2	0.0	0.0	0.4	0.0	0.0	0.0	10.7	0.0	0.0	0.5	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.2	0.0	118.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.4	0.3	0.5	0.2	2.1	0.0	0.0	1.9	0.4	0.2	0.4	0.5	0.2	0.4	0.4	0.3	0.1	0.7	0.5	0.6	1.8	0.3	0.4	0.5	0.1	0.1	0.3	0.3	0.3	0.3	0.3	0.0	0.3	0.3	0.3	0.3
SPINT1	"HAI, MANSC2"	ENSG00000166145	"Serine peptidase inhibitor, Kunitz type 1"	O43278	15	40844018-40858207	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 121.0"	"Cell line enhanced"	"Detected in many"		"BEWO: 51.3;HaCaT: 58.6;hTCEpi: 41.7;RT4: 47.5;SK-BR-3: 88.0;T-47d: 42.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA006903, HPA031178"	Uncertain		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	3400000	3400000	"Plasma membrane, Cytosol"	Nucleoplasm	"HPA006903: AB_1079038, HPA031178: "	"prognostic unfavourable (6.97e-4)"	"unprognostic (1.00e-3)"	"unprognostic (3.00e-3)"	"unprognostic (5.03e-2)"	"unprognostic (6.06e-2)"	"unprognostic (3.19e-1)"	"unprognostic (5.94e-2)"	"unprognostic (6.04e-2)"	"unprognostic (8.24e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.09e-3)"	"unprognostic (1.01e-1)"	"prognostic favourable (1.37e-7)"	"unprognostic (5.37e-2)"	"unprognostic (2.22e-1)"	"unprognostic (6.45e-3)"	"unprognostic (2.17e-2)"	2.2	0.5	0.9	11.6	1.2	0.0	12.6	2.9	0.8	12.9	64.4	1.2	38.6	31.9	3.6	25.5	71.1	6.4	30.7	0.8	0.8	0.7	27.9	1.5	18.5	3.7	0.9	0.6	3.4	25.0	28.8	9.7	85.5	1.3	17.5	17.9	3.2	50.8	24.0	0.6	39.1	121.0	2.3	1.0	3.1	17.6	1.9	0.7	4.8	15.4	26.9	44.3	12.8	21.5	5.1	19.0	15.3	10.9	3.6	1.8	3.8	18.8	0.1	0.0	0.1	0.0	0.0	51.3	0.3	0.4	0.6	0.3	30.0	31.5	0.0	22.5	0.0	58.6	4.8	28.2	0.4	0.1	1.6	0.8	0.5	1.6	0.3	3.3	14.9	0.0	41.7	0.6	2.6	2.3	0.4	0.1	0.0	14.6	0.1	2.5	5.8	2.7	1.9	0.0	3.7	28.4	47.5	12.6	0.6	1.4	88.0	2.3	42.0	2.4	0.0	0.0	0.3	0.1	0.0	0.1	3.5	0.1	0.1	2.4	0.1	0.0	10.9	7.9	0.3	9.3	0.5	5.1	1.8	0.8	19.0	3.9	0.7	0.2	15.3	3.6	9.6	2.3	0.2	3.8	0.9	1.2	2.9	0.8	0.8	0.7	0.9	0.6	1.3	0.7
SPINT2	"HAI-2, Kop"	ENSG00000167642	"Serine peptidase inhibitor, Kunitz type 2"	O43291	19	38244035-38292614	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A-431: 81.3;CAPAN-2: 120.0;hTCEpi: 66.8;RPTEC TERT1: 89.5;RT4: 69.4;SK-BR-3: 78.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA011101, CAB018969"	Approved		Uncertain	"Plasma membrane,Intermediate filaments,Cytosol"				"Plasma membrane, Intermediate filaments, Cytosol"		"CAB018969: , HPA011101: AB_1079039"	"unprognostic (5.13e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.40e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.91e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.03e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.89e-2)"	"unprognostic (2.04e-1)"	"prognostic favourable (3.41e-4)"	"unprognostic (3.59e-1)"	"unprognostic (1.32e-1)"	"unprognostic (6.94e-2)"	"unprognostic (2.68e-2)"	1.5	7.2	11.9	15.1	14.0	10.7	29.2	14.3	20.8	24.0	46.3	4.7	63.2	38.3	7.1	44.9	60.6	30.4	51.8	3.3	10.4	22.9	47.5	2.8	25.6	10.3	9.3	14.6	15.3	78.7	30.2	82.7	77.3	11.0	29.6	40.3	15.3	143.1	61.6	0.7	41.7	82.3	13.1	5.6	9.4	34.1	87.0	2.8	15.0	95.6	32.0	37.5	27.1	25.0	23.1	73.9	70.7	17.9	2.6	13.2	17.6	81.3	59.1	0.3	0.3	0.0	0.0	38.7	1.5	0.1	0.1	0.2	41.8	120.0	0.6	6.6	0.4	27.0	4.2	57.9	0.1	0.7	4.9	15.3	1.5	0.0	0.1	0.1	0.0	0.0	66.8	0.0	28.3	0.2	0.3	0.0	0.1	63.0	2.4	0.2	5.9	16.6	8.3	0.0	36.6	89.5	69.4	22.3	0.3	24.2	78.7	0.2	35.1	10.1	0.0	0.1	0.4	0.3	0.3	5.5	7.0	4.5	0.1	1.0	0.1	57.2	17.9	70.7	0.5	12.5	1.1	20.0	6.5	3.2	41.7	23.1	13.2	11.9	7.8	2.6	8.4	73.9	2.5	17.6	11.9	14.0	14.3	20.8	10.4	22.9	9.3	14.6	11.0	2.8
SPOP	"BTBD32, TEF2"	ENSG00000121067	"Speckle type BTB/POZ protein"	O43791	17	49598884-49678234	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (1.96e-2)"	"unprognostic (1.43e-2)"	"unprognostic (8.83e-2)"	"unprognostic (3.23e-1)"	"unprognostic (2.15e-2)"	"unprognostic (4.51e-2)"	"prognostic unfavourable (6.88e-4)"	"unprognostic (1.89e-2)"	"unprognostic (7.20e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.67e-2)"	"unprognostic (2.81e-1)"	"unprognostic (3.45e-2)"	"unprognostic (1.10e-2)"	"unprognostic (3.29e-1)"	22.0	16.5	22.5	16.9	24.9	7.9	18.6	39.8	26.9	27.5	59.5	25.0	25.1	15.2	36.2	21.2	35.4	25.2	17.2	22.7	22.7	18.8	17.0	20.2	19.1	19.6	20.9	21.4	26.0	18.5	15.1	28.5	18.2	23.2	38.8	23.5	21.8	22.8	49.5	29.2	15.2	24.1	45.1	18.4	18.8	28.4	10.5	26.8	28.6	26.4	14.3	23.3	35.6	22.3	43.2	55.6	59.6	43.1	40.7	58.4	50.8	14.2	16.1	18.6	7.0	20.9	22.3	12.6	18.7	19.4	24.8	25.8	32.7	15.7	23.6	35.9	17.0	11.5	21.0	13.6	29.7	43.6	23.3	27.3	16.4	18.6	24.0	17.9	22.3	16.7	17.5	19.4	21.1	25.3	28.2	24.3	16.7	13.9	32.9	16.5	4.9	19.6	18.7	27.0	30.4	13.4	8.5	27.9	13.0	11.8	6.0	15.4	23.1	18.7	22.1	26.9	18.7	21.1	15.4	24.3	20.3	20.6	15.8	16.1	13.5	57.0	41.8	50.6	36.2	37.1	36.1	42.4	40.6	39.2	55.6	43.2	58.4	45.3	59.6	40.7	43.1	37.2	36.0	50.8	22.5	24.9	39.8	26.9	22.7	18.8	20.9	21.4	23.2	26.8
SPP1	"BNSP, BSPI, ETA-1, OPN"	ENSG00000118785	"Secreted phosphoprotein 1"	P10451	4	87975650-87983426	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"	"Biomineralization, Cell adhesion"	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 303.9;kidney: 700.7;placenta: 331.0"	"Cell line enhanced"	"Detected in some"		"EFO-21: 213.7;Hep G2: 105.2;RPTEC TERT1: 466.7"	"Cancer enhanced"	"Detected in all"		"glioma: 1690.9"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	11	"neutrophil: 19.2"	"Lineage enriched"	"Detected in single"	192	"granulocytes: 19.2"	"Region enhanced"	"Detected in all"		"pons and medulla: 331.4"	"Low region specificity"	"Detected in all"			"CAB002212, HPA027540, HPA027541"	Enhanced		Enhanced	"Golgi apparatus"	"Secreted to blood"	54000000	54000000	"Golgi apparatus"		"CAB002212: AB_564074, HPA027540: AB_10600222, HPA027541: AB_10601446"	"unprognostic (4.74e-2)"	"prognostic unfavourable (9.52e-4)"	"unprognostic (1.13e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.31e-2)"	"unprognostic (6.96e-3)"	"prognostic unfavourable (2.84e-6)"	"unprognostic (2.46e-3)"	"unprognostic (7.86e-2)"	"unprognostic (1.90e-2)"	"prognostic unfavourable (5.89e-4)"	"unprognostic (4.31e-2)"	"unprognostic (2.55e-1)"	"unprognostic (7.19e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.48e-1)"	"unprognostic (2.63e-2)"	20.7	4.1	25.5	8.3	42.7	1.1	8.7	4.3	61.0	4.7	2.7	27.3	0.0	2.1	17.3	2.3	1.5	4.2	303.9	2.6	37.2	26.4	700.7	3.9	3.2	2.0	97.0	9.1	3.1	23.6	1.3	1.5	331.0	52.3	2.4	1.9	3.9	7.3	3.9	2.5	1.1	2.1	5.6	147.9	2.1	2.0	2.4	58.9	0.0	1.7	0.0	1.6	5.3	0.3	0.0	0.0	19.2	0.0	0.0	0.0	0.0	0.0	6.1	0.8	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.4	0.0	0.0	0.0	213.7	0.1	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	105.2	0.0	0.2	0.2	0.0	0.0	1.5	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.9	9.9	0.0	0.1	0.0	50.1	466.7	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.2	0.0	0.5	1.1	0.0	1.1	0.0	0.3	0.4	19.5	0.0	19.9	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.2	0.0	0.0	0.0	0.0	0.0	25.5	42.7	4.3	28.8	37.2	26.4	97.0	9.1	52.3	58.9
SPRR1B	"GADD33, SPRR1"	ENSG00000169469	"Small proline rich protein 1B"	P22528	1	153031202-153032900	"Cancer-related genes, Predicted intracellular proteins"	Keratinization		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 264.7;lymphoid tissue: 188.6;tongue: 618.5"	"Cell line enriched"	"Detected in some"	9	"hTCEpi: 89.9"	"Group enriched"	"Detected in many"	6	"cervical cancer: 468.6;head and neck cancer: 1812.5;melanoma: 425.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																							"unprognostic (1.73e-1)"	"unprognostic (2.39e-1)"	"unprognostic (5.59e-2)"		"unprognostic (9.68e-2)"		"prognostic unfavourable (7.66e-5)"	"unprognostic (2.22e-1)"	"unprognostic (2.85e-1)"	"prognostic unfavourable (7.64e-5)"			"unprognostic (5.71e-2)"		"unprognostic (2.15e-1)"	"prognostic unfavourable (7.28e-4)"	0.1	0.1	0.1	0.1	0.1	0.2	1.0	0.1	0.1	94.9	0.1	0.1	0.1	0.1	9.5	0.2	264.7	0.2	2.2	0.2	0.1	0.0	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.6	0.1	0.1	0.1	0.1	48.7	0.1	0.2	33.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.9	0.1	618.5	188.6	0.2	113.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	9.5	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	89.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
SPRR3		ENSG00000163209	"Small proline rich protein 3"	Q9UBC9	1	153001747-153003856	"Cancer-related genes, Predicted intracellular proteins"	Keratinization		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 855.8;lymphoid tissue: 537.4;tongue: 389.6"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 6.7;hTCEpi: 10.9;RT4: 13.9;TIME: 3.9"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 423.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA044467	Enhanced					15000	15000			"HPA044467: "		"unprognostic (2.78e-2)"	"unprognostic (3.54e-1)"	"unprognostic (8.77e-2)"		"unprognostic (7.50e-3)"		"unprognostic (9.67e-3)"	"unprognostic (2.36e-1)"		"prognostic unfavourable (6.27e-5)"			"unprognostic (9.70e-2)"	"unprognostic (4.66e-2)"		"unprognostic (1.58e-2)"	0.2	0.2	0.0	0.2	0.0	0.2	0.2	0.0	0.2	157.6	0.2	0.0	0.0	0.2	11.5	0.2	855.8	0.2	1.8	0.5	0.0	0.0	0.2	0.3	0.2	0.2	0.0	0.0	0.2	0.2	0.2	0.0	1.2	0.0	0.2	0.2	0.0	93.4	0.2	0.4	0.2	0.2	0.3	0.0	0.2	0.2	0.2	0.0	0.0	0.2	389.6	537.4	0.6	163.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	6.7	3.5	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.2	0.0	0.0	10.9	0.0	0.0	0.0	2.8	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	13.9	0.0	0.0	0.4	3.2	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	1.4	1.2	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SPRY1	hSPRY1	ENSG00000164056	"Sprouty RTK signaling antagonist 1"	O43609	4	123396795-123403760	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adipose tissue: 139.1"	"Cell line enhanced"	"Detected in many"		"AF22: 29.6;AN3-CA: 59.8;ASC diff: 24.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 29.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013538, HPA051369, HPA070554"	Approved		Approved	"Nucleoplasm,Golgi apparatus,Cytosol"				"Golgi apparatus, Cytosol"	Nucleoplasm	"CAB013538: AB_2533452, HPA051369: , HPA070554: "	"unprognostic (1.27e-1)"	"unprognostic (9.08e-2)"	"unprognostic (2.06e-1)"	"unprognostic (7.15e-2)"	"unprognostic (5.33e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.36e-1)"	"unprognostic (9.43e-2)"	"unprognostic (6.99e-2)"	"unprognostic (4.32e-1)"	"unprognostic (4.06e-1)"	"unprognostic (3.11e-2)"	"unprognostic (8.77e-3)"	"unprognostic (1.21e-3)"	"unprognostic (4.48e-2)"	"unprognostic (1.54e-2)"	"unprognostic (1.27e-1)"	139.1	12.6	3.3	14.7	4.3	5.8	69.0	4.9	3.5	28.5	24.8	1.9	18.0	4.5	18.6	28.0	38.1	19.1	27.1	34.1	2.6	1.7	10.2	6.4	23.1	9.1	3.3	2.8	32.2	9.8	17.0	9.5	15.6	2.9	25.0	8.8	11.8	14.6	16.5	48.1	25.5	8.1	20.7	2.8	7.1	11.6	28.4	1.5	13.0	29.6	16.3	8.6	60.8	39.9	29.9	0.7	2.8	0.1	6.1	15.5	0.9	1.8	0.5	29.6	59.8	24.3	16.5	1.9	0.1	1.5	0.1	0.6	1.8	3.1	0.0	13.3	0.8	0.3	0.7	1.4	0.2	0.0	3.0	0.6	0.0	9.2	6.9	4.1	0.0	6.7	0.7	0.2	0.6	2.5	0.5	0.5	1.4	0.2	4.8	10.3	7.1	9.8	2.1	3.2	0.0	4.0	4.3	4.5	3.8	0.0	6.0	5.7	0.6	0.0	6.1	0.3	0.0	0.1	0.8	0.3	0.0	0.0	0.4	0.8	0.9	0.0	0.1	2.8	0.5	0.0	15.5	9.6	1.8	4.2	0.0	29.9	2.7	2.9	0.1	6.1	0.0	0.7	0.0	0.9	3.3	4.3	4.9	3.5	2.6	1.7	3.3	2.8	2.9	1.5
SRC	"ASV, c-src, SRC1"	ENSG00000197122	"SRC proto-oncogene, non-receptor tyrosine kinase"	P12931	20	37344685-37406050	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell adhesion, Cell cycle, Host-virus interaction, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 35.5;HBEC3-KT: 33.0;PC-3: 32.1;RT4: 34.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 5.3;non-classical monocyte: 4.4"	"Group enriched"	"Detected in many"	6	"dendritic cells: 3.0;monocytes: 5.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004023, HPA030875"	Approved		Supported	"Plasma membrane,Cell Junctions,Cytosol"		20000000	20000000	"Plasma membrane, Cell Junctions"	Cytosol	"CAB004023: AB_2106059, HPA030875: "	"unprognostic (5.58e-2)"	"unprognostic (9.83e-2)"	"unprognostic (3.56e-1)"	"unprognostic (4.54e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.54e-2)"	"prognostic unfavourable (4.90e-5)"	"unprognostic (3.89e-2)"	"unprognostic (7.04e-2)"	"unprognostic (8.13e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavourable (1.63e-4)"	"prognostic unfavourable (1.22e-4)"	"unprognostic (2.33e-2)"	"unprognostic (4.72e-2)"	"unprognostic (3.65e-2)"	"prognostic favourable (5.22e-5)"	6.9	17.5	12.8	11.1	12.0	5.4	9.9	6.4	16.0	16.0	16.4	3.5	15.1	29.5	20.3	9.7	16.2	14.2	42.1	5.8	11.3	6.6	13.4	2.9	10.4	7.0	3.3	9.9	15.8	19.1	6.6	11.3	6.3	5.1	19.9	13.1	13.1	7.5	22.5	3.4	7.7	28.1	27.2	3.6	12.2	29.8	27.3	4.8	4.0	6.6	10.5	10.4	26.4	20.0	0.3	3.0	0.1	5.3	0.6	0.1	1.6	7.6	35.5	8.1	7.3	3.1	4.9	17.0	7.1	6.1	8.6	5.5	13.3	6.9	0.2	4.4	12.8	14.0	4.9	33.0	3.4	0.0	4.4	1.9	1.2	20.7	7.4	0.1	3.0	5.3	11.2	5.6	7.5	7.8	0.2	0.0	1.4	5.2	1.8	0.2	3.8	32.1	8.3	2.1	0.2	3.6	34.0	7.6	27.5	8.0	11.3	8.8	10.1	2.8	11.5	10.4	7.0	3.8	6.3	0.1	0.2	0.1	7.3	0.0	7.7	0.0	2.6	0.0	0.0	5.3	0.0	0.3	0.0	0.1	1.1	0.3	0.0	0.0	0.1	0.6	4.4	3.0	0.1	1.6	12.8	12.0	6.4	16.0	11.3	6.6	3.3	9.9	5.1	4.8
SRD5A1		ENSG00000145545	"Steroid 5 alpha-reductase 1"	P18405	5	6633343-6674386	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Differentiation, Sexual differentiation"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 42.4"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA051402	Approved									"HPA051402: "	"unprognostic (1.40e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.30e-3)"	"prognostic unfavourable (8.73e-6)"	"unprognostic (9.38e-3)"	"unprognostic (8.90e-2)"	"unprognostic (3.78e-2)"	"unprognostic (5.90e-2)"	"unprognostic (3.83e-1)"	"unprognostic (1.42e-1)"	"unprognostic (7.70e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.56e-3)"	"unprognostic (3.01e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.59e-1)"	"unprognostic (5.47e-2)"	2.4	3.3	7.7	2.9	8.2	3.2	14.8	9.2	11.8	5.6	5.2	5.3	0.7	5.7	3.1	4.6	24.2	2.9	4.0	1.9	9.3	7.5	6.4	42.4	3.0	3.5	6.2	5.5	4.1	4.3	3.0	1.9	2.1	13.4	2.6	3.6	2.4	5.0	2.1	2.2	17.5	10.4	2.6	3.1	2.9	3.9	2.7	2.9	3.3	2.4	15.3	12.1	2.6	10.1	1.9	3.7	7.0	3.3	1.3	1.3	1.3	5.5	5.5	7.3	6.2	7.0	6.9	3.4	5.4	4.1	5.3	3.3	5.5	4.9	6.7	8.9	7.8	9.0	5.9	3.6	5.7	4.1	2.5	2.1	13.7	3.3	3.2	3.0	1.8	5.0	10.2	3.8	3.0	2.6	3.6	6.2	6.8	6.5	1.4	3.4	4.6	4.4	4.6	5.6	2.0	7.1	5.2	13.8	6.3	16.4	7.3	5.0	3.0	0.8	5.4	8.1	4.0	13.1	6.7	3.3	4.4	2.4	6.7	3.5	7.4	7.0	3.3	1.4	1.0	2.4	0.7	1.7	1.0	1.3	3.7	1.9	0.9	1.0	2.0	1.3	2.6	1.8	1.1	1.3	7.7	8.2	9.2	11.8	9.3	7.5	6.2	5.5	13.4	2.9
SRD5A2		ENSG00000277893	"Steroid 5 alpha-reductase 2"	P31213	2	31522480-31581067	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Differentiation, Sexual differentiation"	Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"epididymis: 17.9;liver: 30.9;prostate: 28.4"	"Group enriched"	"Detected in some"	7	"BJ hTERT+: 2.8;RT4: 5.4"	"Group enriched"	"Detected in some"	6	"endometrial cancer: 1.1;liver cancer: 4.2;prostate cancer: 3.2"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"														"unprognostic (6.75e-3)"	"unprognostic (2.00e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-3)"	"unprognostic (5.92e-3)"	"unprognostic (3.37e-2)"	"unprognostic (2.79e-3)"	"unprognostic (6.56e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.39e-2)"	"unprognostic (3.06e-2)"	"unprognostic (9.79e-3)"	"unprognostic (6.61e-6)"	"unprognostic (4.37e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.48e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.2	0.0	0.0	10.1	0.0	0.2	17.9	0.0	10.4	0.0	0.0	0.0		0.0	30.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.4	0.0	0.0	0.0	11.2	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	2.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.1	0.0	0.3	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0										
SRSF2	"PR264, SC-35, SC35, SFRS2, SFRS2A"	ENSG00000161547	"Serine and arginine rich splicing factor 2"	Q01130	17	76734115-76737374	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049905	Supported		Approved	Nucleoplasm,Cytosol		140000	140000	Nucleoplasm	Cytosol	"HPA049905: "	"unprognostic (2.50e-1)"	"unprognostic (2.16e-3)"	"unprognostic (2.73e-3)"	"prognostic unfavourable (8.73e-4)"	"unprognostic (1.75e-2)"	"unprognostic (4.19e-2)"	"prognostic unfavourable (3.53e-8)"	"unprognostic (1.19e-1)"	"unprognostic (7.79e-3)"	"unprognostic (7.03e-3)"	"unprognostic (1.92e-1)"	"unprognostic (1.07e-3)"	"prognostic unfavourable (1.05e-7)"	"unprognostic (3.85e-2)"	"unprognostic (8.05e-2)"	"unprognostic (1.95e-1)"	"prognostic favourable (9.87e-4)"	35.4	40.2	20.6	56.6	30.3	73.1	35.3	33.3	36.2	42.1	37.7	34.0	19.5	41.8	37.0	33.6	51.1	35.1	34.8	32.4	19.9	22.6	36.9	66.7	37.3	64.3	21.6	24.0	47.1	34.2	29.1	33.8	51.2	29.5	31.3	36.5	35.5	35.6	40.5	44.9	41.1	46.6	25.5	23.9	52.5	35.6	29.2	18.9	105.3	41.1	41.3	64.5	30.6	35.7	11.1	30.2	4.2	23.5	15.6	12.7	12.2	47.7	38.5	45.7	31.9	11.2	9.5	47.5	30.9	22.9	35.9	33.3	40.4	33.5	73.6	22.6	29.0	43.3	45.3	35.7	36.1	30.8	79.0	55.2	37.3	46.9	12.7	61.0	33.1	10.5	8.1	29.7	8.6	28.0	56.1	32.5	28.0	38.2	66.9	66.6	53.5	55.0	67.8	49.2	54.3	24.0	34.4	39.0	55.7	35.2	30.3	16.6	37.1	44.6	29.2	33.1	42.7	22.0	49.9	42.8	32.2	85.2	29.8	48.5	27.3	1.0	17.5	4.2	12.3	23.5	12.6	11.1	8.5	12.7	30.2	9.8	9.8	9.0	2.1	15.6	14.7	22.4	10.6	12.2	20.6	30.3	33.3	36.2	19.9	22.6	21.6	24.0	29.5	18.9
SRSF3	"SFRS3, SRp20"	ENSG00000112081	"Serine and arginine rich splicing factor 3"	P84103	6	36594353-36605600	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, mRNA transport, Transport"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012986, HPA056981"	Supported		Supported	Nucleoplasm		1600000	1600000	Nucleoplasm		"CAB012986: AB_2533150, HPA056981: "	"unprognostic (3.25e-1)"	"unprognostic (1.08e-3)"	"prognostic favourable (2.56e-4)"	"unprognostic (8.19e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.77e-2)"	"prognostic unfavourable (6.22e-5)"	"unprognostic (2.92e-2)"	"prognostic unfavourable (1.95e-4)"	"prognostic favourable (1.37e-4)"	"unprognostic (9.61e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavourable (2.02e-4)"	"unprognostic (9.88e-2)"	"unprognostic (3.33e-2)"	"unprognostic (8.33e-2)"	"unprognostic (1.06e-2)"	45.3	27.4	37.4	42.1	38.3	69.5	43.5	42.6	39.1	36.4	41.7	32.9	34.0	25.5	37.2	31.8	42.9	40.8	27.4	37.5	33.0	28.1	34.3	36.9	32.3	51.8	35.8	27.0	53.9	31.3	22.4	47.2	37.4	38.1	40.1	46.6	30.1	30.2	33.0	29.2	36.2	35.8	43.1	31.9	36.4	35.2	27.2	36.7	67.5	35.9	46.7	67.0	49.6	38.6	28.0	73.9	12.9	38.0	37.6	37.6	53.9	51.7	34.6	61.1	46.6	23.6	18.5	37.7	37.1	31.1	62.5	48.2	40.6	37.2	87.1	26.7	40.5	41.1	80.1	59.0	66.8	40.6	49.3	52.2	27.5	45.7	28.9	70.1	44.2	16.4	20.1	40.7	45.5	47.4	62.9	36.9	45.3	40.4	86.1	66.4	64.3	36.4	76.8	58.5	52.1	44.2	43.1	47.2	44.7	41.2	40.4	56.0	41.0	75.4	30.9	32.0	46.7	32.0	55.6	36.5	53.9	119.3	27.4	65.2	44.3	12.9	38.0	11.5	32.9	36.2	37.1	28.0	31.1	34.5	73.9	24.0	31.4	32.3	3.7	37.6	24.4	43.7	37.6	53.9	37.4	38.3	42.6	39.1	33.0	28.1	35.8	27.0	38.1	36.7
SS18	"SSXT, SYT"	ENSG00000141380	"SS18, nBAF chromatin remodeling complex subunit"	Q15532	18	26016253-26091217	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055741, HPA059539"	Supported		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA055741: , HPA059539: "	"unprognostic (2.03e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.95e-2)"	"unprognostic (3.39e-1)"	"unprognostic (8.74e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.53e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.47e-1)"	"prognostic favourable (4.86e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.30e-1)"	26.1	40.5	18.7	30.4	26.4	15.5	26.6	17.6	20.2	24.8	21.4	31.8	32.1	14.0	31.7	32.7	29.8	27.2	23.4	22.4	21.6	16.1	30.0	30.9	21.9	25.8	32.6	16.3	39.4	20.6	39.4	41.8	43.2	25.3	28.6	18.7	26.1	26.0	33.5	10.3	31.3	22.6	31.0	23.7	24.7	22.5	28.3	32.6	27.8	35.6	24.7	35.2	25.5	25.9	15.9	13.1	19.9	17.1	20.7	17.6	13.1	19.0	13.8	33.9	16.6	27.0	24.5	17.1	23.4	21.3	20.7	19.8	9.0	15.8	33.2	18.7	27.4	24.9	18.4	22.7	25.6	21.2	8.8	16.4	20.3	14.6	21.4	25.2	25.5	31.4	26.8	26.0	28.5	15.5	12.0	17.1	28.6	19.1	10.3	14.6	6.4	13.4	12.0	26.4	15.9	21.9	22.5	14.5	21.9	35.8	16.6	10.1	16.9	14.9	17.7	43.6	8.7	10.0	22.9	30.8	20.6	24.0	20.4	17.5	23.1	19.9	11.7	16.5	15.1	17.1	17.6	15.9	14.6	15.7	13.1	13.0	15.5	17.4	5.6	20.7	16.7	7.4	15.7	13.1	18.7	26.4	17.6	20.2	21.6	16.1	32.6	16.3	25.3	32.6
SS18L1	"CREST, KIAA0693"	ENSG00000184402	"SS18L1, nBAF chromatin remodeling complex subunit"	O75177	20	62143795-62182484	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011827, HPA059046"	Approved		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"CAB011827: AB_778216, HPA059046: "	"unprognostic (4.12e-2)"	"unprognostic (5.82e-2)"	"unprognostic (1.54e-1)"	"unprognostic (3.03e-2)"	"unprognostic (6.57e-2)"	"prognostic favourable (8.00e-5)"	"unprognostic (1.39e-1)"	"prognostic favourable (3.74e-4)"	"unprognostic (1.01e-1)"	"unprognostic (1.87e-1)"	"unprognostic (2.47e-3)"	"unprognostic (6.43e-2)"	"unprognostic (2.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.66e-1)"	"unprognostic (1.01e-1)"	"unprognostic (9.94e-3)"	6.6	8.9	11.9	7.7	12.7	7.7	8.6	35.9	15.8	7.0	7.0	9.9	12.2	9.5	9.7	10.9	9.3	6.9	7.2	6.4	11.5	10.9	11.5	33.3	8.2	7.4	11.2	14.5	10.0	10.4	8.4	10.7	8.8	13.1	8.7	7.8	7.4	8.6	11.8	19.2	23.7	9.0	7.7	9.9	9.2	8.8	10.7	10.9	6.0	8.3	6.7	7.1	6.8	8.6	3.6	1.3	2.5	2.7	1.6	2.8	0.5	6.4	7.7	10.7	9.7	4.8	5.6	7.8	6.1	2.4	10.2	5.1	26.3	6.0	3.9	8.1	3.4	16.7	6.6	5.8	9.3	2.7	4.3	17.5	16.1	13.6	3.6	6.3	15.6	3.4	12.8	5.2	4.4	4.6	11.7	7.6	5.7	7.6	9.6	9.9	4.3	8.8	10.7	13.9	4.4	7.6	8.2	20.4	11.3	10.9	13.3	9.1	12.5	10.2	5.4	19.5	11.8	7.2	8.5	8.5	7.6	3.5	9.7	6.3	6.4	0.3	1.6	0.6	1.7	1.1	1.1	0.7	0.9	1.4	1.3	3.6	2.8	0.9	2.5	1.6	2.7	0.8	0.8	0.5	11.9	12.7	35.9	15.8	11.5	10.9	11.2	14.5	13.1	10.9
SST	SMST	ENSG00000157005	Somatostatin	P61278	3	187668906-187670399	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 15.2;U-2 OS: 28.3;U-251 MG: 4.7;U-698: 5.9"	"Group enriched"	"Detected in many"	7	"ovarian cancer: 249.9;pancreatic cancer: 1039.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000075, HPA019472, CAB034105"	Enhanced	Supported			"Secreted to blood"					"CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360"		"unprognostic (2.44e-1)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (1.93e-5)"	"unprognostic (5.12e-3)"	"unprognostic (1.54e-2)"			"unprognostic (4.69e-1)"	"unprognostic (3.31e-2)"	"unprognostic (8.16e-3)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.19e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.45e-1)"	2.0	13.0	28.6	1.9	53.8	1.7	0.7	0.1	47.9	0.7	45.1	1.8	21.9	105.2	0.9	0.7	1.1	0.7	1.0	0.9	17.5	102.8	2.5	0.7	0.7	1.0	6.2	15.4	0.8	105.6	0.7	1.5	0.7	16.1	1.5	7.4	0.4	0.7	7.5	0.7	3.1	36.1	1.4	18.4	0.7	90.4	0.7	8.6	0.0	0.9	0.0	0.7	4.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	28.3	0.3	4.7	0.0	1.6	5.9	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.6	53.8	0.1	47.9	17.5	102.8	6.2	15.4	16.1	8.6
SSX1	CT5.1	ENSG00000126752	"SSX family member 1"	Q16384	X	48255317-48267444	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	14	"testis: 12.6"	"Cell line enhanced"	"Detected in some"		"Daudi: 28.1;Karpas-707: 40.8;U-2197: 9.5"	"Cancer enhanced"	"Detected in many"		"liver cancer: 7.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA045683	Supported		Approved	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"HPA045683: "					"unprognostic (2.25e-1)"		"unprognostic (3.51e-3)"		"unprognostic (2.36e-1)"	"unprognostic (4.32e-3)"				"unprognostic (3.38e-1)"	"unprognostic (5.41e-2)"	"unprognostic (6.94e-2)"		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.2	0.9	0.4	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	40.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	9.5	0.0	0.0	2.0	0.0	2.3	0.0	0.0	0.9	0.4	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.5	0.5	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SSX2	"CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX"	ENSG00000241476	"SSX family member 2"	Q16385	X	52696896-52707189	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	57	"testis: 24.1"	"Cell line enhanced"	"Detected in some"		"PC-3: 3.1;U-2197: 1.9"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA045683, CAB046020"	Enhanced		Approved	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"CAB046020: AB_2194010, HPA045683: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.1			0.4		0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.3	0.0	0.0	0.0	0.2	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.9	0.0	0.6	0.1	0.6	1.9	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0										
SSX2B	CT5.2b	ENSG00000268447	"SSX family member 2B"	Q16385	X	52751132-52790305	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	24	"testis: 13.5"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 1.8;HMC-1: 5.3;PC-3: 5.1;T-47d: 2.2;U-2197: 3.2"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA045683	Supported		Approved	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"HPA045683: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	13.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.9	0.0	0.8	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.7	0.5	0.5	0.1	0.0	0.0	0.2	5.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.7	0.0	2.2	0.0	1.0	0.0	0.5	3.2	0.0	0.1	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0										
SSX4	CT5.4	ENSG00000268009	"SSX family member 4"	O60224	X	48383516-48393347	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"		"Tissue enriched"	"Detected in single"	14	"testis: 6.8"	"Group enriched"	"Detected in some"	10	"BEWO: 3.5;Karpas-707: 8.6;U-266/70: 5.1;U-266/84: 9.3"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA045683	Approved		Approved	Nucleoplasm,Nucleoli				"Nucleoplasm, Nucleoli"		"HPA045683: "																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.3	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.1	0.6	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	8.6	0.0	0.0	0.0	0.0	0.3	0.3	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	5.1	9.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0										
ST14	"HAI, MT-SP1, PRSS14, SNC19, TMPRSS14"	ENSG00000149418	"Suppression of tumorigenicity 14"	Q9Y5Y6	11	130159562-130210376	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, Hypotrichosis, Ichthyosis"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 94.1"	"Cell line enhanced"	"Detected in some"		"CACO-2: 35.7;CAPAN-2: 72.1;HaCaT: 50.5;RPMI-8226: 47.3;SK-BR-3: 33.4;T-47d: 50.5;U-698: 34.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	4	"plasmacytoid DC: 18.2"	"Lineage enriched"	"Detected in many"	5	"dendritic cells: 18.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA047014			Approved	Nucleoplasm,Vesicles		220000	220000	"Nucleoplasm, Vesicles"		"HPA047014: "	"unprognostic (1.17e-1)"	"unprognostic (1.15e-1)"	"unprognostic (9.62e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.17e-2)"	"unprognostic (7.94e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.97e-2)"	"unprognostic (5.29e-1)"	"unprognostic (3.21e-1)"	"unprognostic (1.03e-3)"	"unprognostic (2.25e-1)"	"prognostic favourable (5.03e-11)"	"unprognostic (1.92e-2)"	"unprognostic (2.71e-1)"	"unprognostic (1.28e-2)"	"unprognostic (5.60e-2)"	10.1	1.8	0.7	21.9	1.8	0.5	5.5	0.8	1.4	8.9	48.6	0.5	23.8	33.8	2.8	16.9	38.9	9.7	32.4	1.1	0.5	0.5	30.5	3.2	9.5	7.5	1.8	0.6	3.6	34.3	8.4	9.5	12.7	1.5	12.1	15.4	0.7	25.1	15.8	0.7	17.8	94.1	1.2	1.8	4.0	16.7	2.1	1.5	5.2	24.0	20.1	28.4	8.3	14.9	3.8	18.2	2.3	2.7	0.0	0.1	0.8	26.2	0.0	0.0	0.1	0.0	0.0	14.3	0.0	0.0	0.0	0.0	35.7	72.1	26.0	2.7	0.0	50.5	0.0	16.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.4	0.1	0.0	8.1	0.0	0.0	0.0	0.0	0.0	0.0	20.3	0.0	0.1	0.2	0.1	0.0	0.0	47.3	4.7	21.5	2.9	0.0	0.2	33.4	0.0	50.5	5.1	0.0	0.0	0.4	0.1	0.1	0.0	0.0	34.4	0.0	8.0	0.0	0.0	2.7	2.3	0.0	1.5	0.1	3.8	0.0	0.0	4.5	2.3	0.0	0.0	0.3	0.0	0.2	18.2	0.0	0.8	0.7	1.8	0.8	1.4	0.5	0.5	1.8	0.6	1.5	1.5
STAG2	"SA-2, SA2, SCC3B"	ENSG00000101972	"Stromal antigen 2"	Q8N3U4	X	123960212-124422664	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Meiosis, Mitosis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002857	Supported									"HPA002857: AB_1079861"	"unprognostic (1.62e-1)"	"unprognostic (1.01e-2)"	"unprognostic (6.75e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.70e-2)"	"unprognostic (3.77e-2)"	"unprognostic (9.67e-3)"	"unprognostic (4.68e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.24e-1)"	"unprognostic (3.38e-1)"	"unprognostic (1.59e-3)"	"unprognostic (2.81e-1)"	"unprognostic (2.77e-2)"	"unprognostic (1.63e-1)"	"unprognostic (3.97e-1)"	24.0	18.8	21.5	23.9	23.7	39.7	30.1	35.4	23.5	28.1	25.1	16.4	25.2	14.9	24.3	21.0	24.3	20.0	16.3	15.7	21.4	17.9	22.2	18.1	23.4	26.2	24.9	17.5	31.1	19.7	46.1	27.6	25.5	20.6	25.9	18.3	14.2	20.7	27.8	27.6	18.9	21.9	25.9	30.6	26.7	17.6	9.3	26.4	69.3	32.0	19.7	27.1	37.7	37.8	12.8	12.5	30.3	14.4	12.1	15.5	6.7	17.2	16.3	24.5	15.4	10.5	15.9	15.8	16.4	17.7	17.0	21.5	15.1	18.5	31.9	23.2	14.7	15.8	50.1	13.9	24.2	22.6	21.4	29.5	32.6	9.9	10.9	38.5	23.2	12.5	13.8	20.1	32.6	14.2	28.7	34.0	12.5	18.8	49.2	17.4	12.8	24.2	34.9	32.4	26.6	13.2	33.0	22.1	17.7	37.0	13.8	19.4	8.2	17.7	17.3	0.1	9.1	20.0	18.6	14.7	22.1	40.1	10.7	23.7	17.1	16.8	10.2	18.1	10.8	13.1	12.6	10.0	11.2	10.1	12.5	12.8	15.5	12.4	30.3	12.1	14.4	11.2	8.7	6.7	21.5	23.7	35.4	23.5	21.4	17.9	24.9	17.5	20.6	26.4
STARD3	"es64, MLN64"	ENSG00000131748	"StAR related lipid transfer domain containing 3"	Q14849	17	39637065-39663484	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	6	"SK-BR-3: 87.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017021, HPA024307, HPA073948"	Uncertain		Approved	"Nucleoplasm,Endoplasmic reticulum,Vesicles"				"Nucleoplasm, Vesicles"	"Endoplasmic reticulum"	"CAB017021: , HPA024307: , HPA073948: "	"unprognostic (1.11e-1)"	"unprognostic (2.14e-2)"	"unprognostic (6.35e-2)"	"unprognostic (8.92e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.94e-1)"	"prognostic unfavourable (3.60e-5)"	"unprognostic (2.26e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.48e-1)"	"unprognostic (6.25e-3)"	"unprognostic (5.88e-2)"	"prognostic unfavourable (7.70e-4)"	"unprognostic (1.33e-1)"	"unprognostic (5.22e-2)"	"unprognostic (8.51e-3)"	"unprognostic (3.00e-2)"	22.2	34.8	23.3	27.5	28.0	33.5	22.8	27.7	30.1	17.1	23.7	38.1	21.7	26.6	20.6	20.7	22.4	25.6	27.7	17.8	21.0	16.8	18.2	24.0	27.0	31.5	28.5	25.7	21.5	32.7	21.9	23.7	26.9	25.7	19.0	9.7	17.9	21.4	26.7	20.8	24.5	34.2	15.8	27.8	32.3	25.3	26.7	26.1	33.0	21.1	15.1	24.8	28.8	18.7	15.3	23.2	35.3	21.2	21.4	25.3	17.4	7.8	12.3	5.5	9.9	6.7	8.2	8.3	6.4	8.3	8.3	7.6	7.3	12.8	6.9	13.9	5.8	14.9	3.4	7.5	1.9	9.4	12.6	4.7	5.4	8.4	9.5	9.5	10.5	8.9	6.2	9.4	4.5	8.0	10.9	9.0	7.6	6.9	8.9	9.0	6.1	6.8	7.1	9.6	10.3	5.7	8.8	7.0	7.6	4.8	87.9	15.8	10.3	11.4	7.6	11.7	8.1	12.8	11.9	8.6	10.6	5.5	10.4	10.3	12.0	12.5	21.2	29.3	25.3	19.6	18.5	11.9	18.3	19.0	23.2	15.3	18.4	16.9	35.3	21.4	15.6	10.8	20.4	17.4	23.3	28.0	27.7	30.1	21.0	16.8	28.5	25.7	25.7	26.1
STAT3	APRF	ENSG00000168610	"Signal transducer and activator of transcription 3"	P40763	17	42313324-42388568	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Diabetes mellitus, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001671, CAB003859, HPA058603, CAB068241, CAB068242"	Supported		Supported	Nucleoplasm,Cytosol		220000	220000	"Nucleoplasm, Cytosol"		"CAB003859: AB_347629, CAB068241: , CAB068242: , HPA001671: AB_1080102, HPA058603: "	"unprognostic (1.83e-2)"	"unprognostic (2.42e-1)"	"unprognostic (9.23e-3)"	"unprognostic (2.91e-1)"	"unprognostic (5.59e-3)"	"unprognostic (1.78e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.26e-1)"	"unprognostic (6.47e-3)"	"unprognostic (7.75e-3)"	"unprognostic (2.21e-2)"	"unprognostic (7.63e-2)"	"unprognostic (1.61e-1)"	44.6	30.7	23.2	34.4	27.5	35.3	49.3	15.7	23.5	25.1	31.5	18.4	21.7	20.5	33.2	27.4	36.4	32.7	34.0	82.9	20.1	14.7	34.5	90.0	45.7	45.5	26.0	11.1	40.6	32.1	18.6	27.9	24.6	27.6	28.9	21.8	24.3	29.3	22.9	53.4	28.4	28.6	49.7	25.1	41.4	29.4	15.4	25.7	16.8	38.0	31.2	28.8	40.4	53.1	10.8	13.7	69.7	20.2	13.9	21.7	26.7	16.6	31.7	14.0	13.8	30.0	28.6	10.2	19.6	24.9	17.0	16.6	8.3	16.2	5.2	19.4	19.4	25.5	12.7	20.0	13.9	43.0	8.7	36.2	19.3	17.1	22.2	8.8	23.6	44.6	19.7	13.5	19.6	23.0	22.2	16.6	11.2	11.8	32.6	8.8	8.1	0.0	7.2	37.4	7.7	26.9	21.7	12.9	8.4	22.6	53.6	8.1	28.1	13.3	19.4	26.3	13.5	15.6	16.0	25.7	20.0	4.4	16.3	9.4	11.6	26.2	19.4	24.9	21.7	20.2	17.3	10.8	16.0	16.8	13.7	10.4	16.6	15.8	69.7	13.9	18.7	7.5	12.0	26.7	23.2	27.5	15.7	23.5	20.1	14.7	26.0	11.1	27.6	25.7
STAT4		ENSG00000138378	"Signal transducer and activator of transcription 4"	Q14765	2	191029576-191151596	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.4;testis: 25.5"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 30.2;U-266/70: 17.0;U-266/84: 5.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	10	"NK-cells: 16.9;T-cells: 29.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA001860, CAB013108"	Enhanced									"CAB013108: , HPA001860: AB_1080104"	"unprognostic (3.90e-5)"	"unprognostic (1.30e-1)"	"unprognostic (4.16e-2)"	"unprognostic (6.45e-4)"	"unprognostic (3.77e-2)"	"unprognostic (4.79e-2)"	"unprognostic (3.49e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.49e-3)"	"prognostic favourable (5.88e-4)"	"unprognostic (2.43e-1)"	"prognostic unfavourable (1.07e-8)"	"unprognostic (2.65e-1)"	"unprognostic (6.02e-2)"	"unprognostic (2.15e-1)"	"unprognostic (2.88e-1)"	4.2	3.6	2.1	9.6	12.7	11.2	2.9	1.1	15.5	1.7	3.7	0.0	0.3	4.1	1.7	2.4	1.5	1.7	4.2	20.3	3.3	6.5	2.7	7.6	8.4	14.1	3.3	8.3	1.5	2.2	0.7	19.6	2.4	8.5	1.9	3.2	2.3	4.5	1.5	1.1	1.3	6.6	1.3	2.5	13.8	3.6	25.5	0.5	4.2	2.4	1.0	12.8	3.3	1.9	0.4	2.0	2.3	0.2	16.9	29.4	10.7	0.0	0.9	0.6	0.0	0.0	1.8	0.2	0.2	1.1	0.3	1.3	0.2	0.4	0.0	0.1	1.4	0.5	0.0	2.6	0.7	0.0	0.5	0.7	0.0	0.0	0.3	0.0	0.0	0.8	1.1	0.6	0.3	0.0	0.0	30.2	0.1	0.0	1.7	0.0	0.1	0.5	0.0	0.0	2.1	0.1	0.0	0.1	0.7	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	17.0	5.9	0.0	0.7	0.0	0.0	2.3	0.1	0.0	29.4	0.2	26.5	0.4	17.5	23.8	0.1	0.2	16.7	23.8	0.6	16.9	0.1	2.0	6.1	10.7	2.1	12.7	1.1	15.5	3.3	6.5	3.3	8.3	8.5	0.5
STAT5A	"MGF, STAT5"	ENSG00000126561	"Signal transducer and activator of transcription 5A"	P42229	17	42287547-42311943	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Lactation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 25.3;HEL: 38.3;HMC-1: 22.3;K-562: 63.7;MOLT-4: 46.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB003860, HPA027873, HPA042128, HPA049883, HPA051156"	Approved		Enhanced	Nucleoplasm,Cytosol		140000	140000	"Nucleoplasm, Cytosol"		"CAB003860: AB_562347, HPA027873: AB_10603893, HPA042128: , HPA049883: , HPA051156: "	"prognostic favourable (5.87e-4)"	"unprognostic (3.09e-3)"	"unprognostic (2.31e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.43e-1)"	"unprognostic (3.41e-3)"	"unprognostic (2.15e-1)"	"unprognostic (6.22e-2)"	"unprognostic (3.33e-1)"	"unprognostic (6.82e-3)"	"unprognostic (2.76e-1)"	"unprognostic (2.11e-1)"	"unprognostic (3.85e-2)"	"unprognostic (5.74e-2)"	"unprognostic (1.90e-2)"	"unprognostic (1.98e-1)"	"unprognostic (5.49e-3)"	44.0	21.5	3.6	16.5	8.1	30.0	24.1	3.4	4.0	12.6	12.8	6.3	10.5	5.1	11.0	11.4	11.6	9.6	15.3	9.8	3.9	4.7	8.9	5.5	12.8	26.7	9.1	3.2	15.6	8.3	1.9	7.0	11.3	6.1	13.9	5.8	11.9	11.9	11.7	18.3	9.7	11.6	13.6	7.4	17.3	7.9	8.5	6.1	21.9	8.6	9.1	17.0	19.9	20.2	7.2	15.0	15.2	18.5	14.3	16.2	8.8	1.0	1.2	0.1	0.0	9.1	4.4	0.0	0.5	2.0	1.0	0.6	0.1	1.0	0.0	2.3	2.0	0.0	0.2	0.0	0.2	25.3	0.0	38.3	2.9	0.3	3.7	3.2	22.3	10.2	0.7	0.3	0.5	3.0	63.7	0.0	0.5	0.1	46.2	18.2	0.3	0.0	1.1	0.3	3.3	0.3	0.7	0.1	0.0	2.3	1.1	4.2	0.7	4.1	1.7	2.3	0.6	1.1	0.0	0.0	0.0	0.0	0.2	6.2	0.5	6.8	11.8	5.9	9.1	15.1	12.8	7.2	15.8	13.2	15.0	6.7	16.2	13.0	15.2	14.3	18.5	5.7	11.2	8.8	3.6	8.1	3.4	4.0	3.9	4.7	9.1	3.2	6.1	6.1
STAT5B		ENSG00000173757	"Signal transducer and activator of transcription 5B"	P51692	17	42199168-42276707	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 43.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004298, HPA042128, HPA049883, HPA051156"	Approved					170000	170000			"CAB004298: AB_2197067, HPA042128: , HPA049883: , HPA051156: "	"unprognostic (1.49e-1)"	"unprognostic (3.60e-2)"	"unprognostic (4.06e-2)"	"prognostic favourable (9.37e-4)"	"unprognostic (2.68e-1)"	"unprognostic (4.29e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.06e-2)"	"unprognostic (7.98e-2)"	"prognostic favourable (1.63e-4)"	"unprognostic (1.36e-1)"	"prognostic favourable (2.39e-5)"	"unprognostic (9.19e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.13e-1)"	25.7	24.0	13.5	19.5	16.3	21.8	26.2	32.1	15.9	21.6	21.0	13.7	16.3	8.6	31.9	12.0	11.6	24.5	18.1	12.8	11.9	20.1	12.4	13.5	15.8	24.6	16.0	13.9	34.4	12.1	12.0	22.6	55.4	17.2	20.8	10.3	16.4	12.9	21.7	38.3	12.2	14.8	33.1	10.6	22.1	14.4	13.2	15.7	21.7	15.4	9.6	19.8	21.5	33.1	2.5	2.4	18.8	2.8	3.5	8.3	3.8	5.2	8.2	12.3	3.3	15.4	7.8	5.9	5.4	9.7	7.8	6.8	3.6	4.5	17.1	8.1	6.2	6.8	7.2	4.7	6.2	43.1	8.4	16.7	15.5	5.5	8.5	7.3	27.0	9.5	7.2	5.8	7.4	12.2	30.1	3.7	3.2	5.1	34.5	19.3	3.0	0.0	14.9	7.7	5.9	4.9	8.4	9.1	5.3	9.9	12.6	7.6	8.9	8.7	9.4	10.9	3.8	5.6	7.5	7.4	3.4	8.5	4.3	7.8	5.6	8.8	2.8	4.6	5.9	2.5	6.4	2.5	8.3	6.7	2.4	2.5	5.9	5.0	18.8	3.5	2.8	1.8	6.9	3.8	13.5	16.3	32.1	15.9	11.9	20.1	16.0	13.9	17.2	15.7
STAT6	"D12S1644, IL-4-STAT"	ENSG00000166888	"Signal transducer and activator of transcription 6"	P42226	12	57095408-57132139	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001861	Approved		Supported	Nucleoplasm,Cytosol				Cytosol	Nucleoplasm	"HPA001861: AB_1080106"	"unprognostic (3.43e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.37e-1)"	"prognostic favourable (1.69e-4)"	"unprognostic (4.14e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	"unprognostic (6.70e-2)"	"unprognostic (1.88e-2)"	"unprognostic (3.65e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.55e-1)"	"prognostic favourable (7.76e-4)"	"prognostic favourable (1.14e-4)"	33.6	34.9	10.4	35.9	12.8	12.8	27.9	4.6	11.6	37.8	47.3	6.2	28.4	23.9	44.5	26.6	40.8	31.8	33.8	20.9	10.2	3.9	35.0	31.0	34.9	25.2	13.3	12.0	41.9	21.2	18.1	9.2	22.0	9.8	42.3	26.2	23.3	30.1	26.5	11.4	39.1	59.4	43.8	12.2	48.4	32.1	13.3	7.9	29.3	31.1	24.4	42.8	43.1	34.0	6.2	9.6	27.6	13.0	4.7	5.9	14.0	16.8	16.8	4.1	6.8	41.0	39.8	11.9	13.4	29.5	14.9	10.9	7.6	22.9	40.4	21.0	29.7	23.5	5.1	26.0	11.0	18.1	1.9	9.3	17.9	9.4	24.5	10.7	30.5	55.4	21.5	18.1	16.1	26.3	6.5	5.7	19.2	5.7	11.7	12.0	6.3	3.4	13.6	0.3	13.7	25.8	28.1	0.1	0.4	12.5	10.5	12.6	15.6	24.7	21.8	0.3	8.8	15.5	0.2	0.1	0.4	10.1	13.5	10.5	17.9	9.8	12.5	6.8	5.9	13.0	5.2	6.2	4.8	4.8	9.6	6.2	4.7	4.3	27.6	4.7	11.0	4.6	4.9	14.0	10.4	12.8	4.6	11.6	10.2	3.9	13.3	12.0	9.8	7.9
STEAP1	"PRSS24, STEAP"	ENSG00000164647	"STEAP family member 1"	Q9UHE8	7	90154375-90164829	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Electron transport, Ion transport, Iron transport, Transport"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 44.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 29.1;CAPAN-2: 34.8;U-138 MG: 44.3"	"Cancer enriched"	"Detected in all"	6	"prostate cancer: 94.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"myeloid DC: 1.7"	"Low lineage specificity"	"Detected in single"											HPA030985	Uncertain									"HPA030985: "	"unprognostic (2.88e-3)"	"unprognostic (2.29e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.21e-3)"	"unprognostic (9.20e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.33e-2)"	"unprognostic (6.74e-3)"	"unprognostic (6.36e-2)"	"unprognostic (6.45e-3)"	"unprognostic (8.31e-3)"	"unprognostic (3.79e-1)"	"unprognostic (2.60e-2)"	"unprognostic (4.39e-2)"	"unprognostic (2.42e-1)"	"unprognostic (6.09e-2)"	"unprognostic (1.38e-1)"	19.8	1.5	2.9	16.5	1.4	0.0	26.0	0.9	6.3	5.5	10.0	0.1	0.7	2.7	3.0	4.4	10.0	7.3	8.4	7.1	1.4	0.5	5.3	21.2	9.3	2.9	0.5	2.7	12.4	6.5	0.2	5.8	0.5	1.4	44.7	7.3	1.2	9.8	5.3	3.9	3.3	7.4	13.7	1.4	2.8	7.4	2.1	0.7	0.0	4.6	6.5	3.7	12.5	16.1	0.8	1.7	0.0	0.0	0.0	0.0	0.2	6.7	13.6	0.8	2.5	29.1	24.2	0.2	4.6	5.7	0.6	0.8	10.2	34.8	0.0	0.2	7.5	1.4	5.9	6.4	1.2	0.0	2.2	0.0	0.1	3.4	1.1	0.0	0.0	17.0	0.9	19.2	10.2	25.0	0.3	19.4	7.9	0.1	0.0	0.1	4.1	6.5	0.0	0.0	0.0	5.5	1.4	0.0	0.3	1.7	0.0	3.1	7.7	0.1	12.8	44.3	2.2	22.2	5.6	3.6	0.1	0.0	21.7	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.9	1.4	0.9	6.3	1.4	0.5	0.5	2.7	1.4	0.7
STIL	"MCPH7, SIL"	ENSG00000123473	"STIL, centriolar assembly protein"	Q15468	1	47250139-47314147	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 36.0;testis: 23.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA046543			Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA046543: "	"unprognostic (2.07e-1)"	"unprognostic (6.29e-2)"	"unprognostic (5.54e-3)"	"unprognostic (2.67e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.56e-2)"	"unprognostic (2.90e-5)"	"unprognostic (7.35e-3)"	"unprognostic (4.04e-3)"	"unprognostic (1.41e-1)"	"prognostic unfavourable (1.33e-4)"	"unprognostic (5.81e-2)"	"unprognostic (3.36e-14)"	"unprognostic (5.76e-3)"	"unprognostic (2.58e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.28e-1)"	1.2	1.4	1.3	10.8	2.4	11.0	2.9	1.4	2.2	1.2	4.1	0.9	2.5	3.6	1.5	2.2	5.8	0.9	1.7	2.0	1.4	1.2	1.5	1.6	1.7	5.0	1.3	1.5	1.2	1.5	0.9	0.9	5.5	1.1	1.7	6.4	0.8	3.6	0.5	0.8	4.2	4.0	1.3	1.2	3.4	2.2	23.8	1.0	36.0	1.1	3.5	7.1	1.3	2.1	1.9	1.6	5.4	0.7	3.3	1.2	0.5	16.9	9.1	13.1	11.7	0.9	2.3	8.3	15.0	7.2	16.8	17.7	9.8	8.4	20.0	7.1	7.4	11.3	15.3	7.8	18.1	14.9	6.9	22.5	11.3	8.6	0.5	18.1	11.5	0.8	1.3	14.4	9.4	11.1	15.9	19.0	12.6	7.7	17.6	5.7	15.8	7.5	11.5	21.3	9.6	4.7	10.2	11.7	7.0	16.1	11.9	7.7	7.7	10.4	6.5	15.8	16.1	11.4	20.2	6.3	13.0	19.6	7.4	13.9	14.7	4.3	0.7	1.1	1.1	0.4	0.5	1.7	1.2	1.0	0.5	1.9	0.8	0.8	5.4	3.3	0.3	1.6	1.1	0.5	1.3	2.4	1.4	2.2	1.4	1.2	1.3	1.5	1.1	1.0
STK11	"LKB1, PJS"	ENSG00000118046	"Serine/threonine kinase 11"	Q15831	19	1177558-1228435	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Autophagy, Cell cycle, Differentiation, DNA damage, Spermatogenesis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 11.7"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016231, HPA017254, CAB022105, HPA067481"	Approved		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB016231: AB_627890, CAB022105: , HPA017254: AB_1852924, HPA067481: "	"unprognostic (8.60e-2)"	"unprognostic (1.68e-1)"	"unprognostic (5.00e-2)"	"prognostic favourable (3.69e-5)"	"unprognostic (2.04e-2)"	"prognostic favourable (1.96e-4)"	"unprognostic (9.11e-3)"	"unprognostic (3.19e-1)"	"unprognostic (9.08e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.95e-3)"	"unprognostic (7.70e-3)"	"unprognostic (3.54e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.60e-1)"	"unprognostic (3.31e-1)"	"unprognostic (3.12e-3)"	13.4	13.7	13.5	11.8	12.4	19.3	16.7	17.8	16.0	12.2	16.1	8.3	19.8	18.1	10.8	8.7	15.1	10.0	11.8	15.3	12.6	9.8	10.7	22.1	9.4	12.5	9.7	10.4	11.0	16.8	10.7	11.6	12.2	9.9	12.2	5.3	11.9	16.0	12.2	49.2	16.8	18.0	7.7	7.6	16.9	15.5	59.8	7.5	11.8	12.4	14.5	19.0	11.4	9.8	2.7	1.9	11.7	6.3	1.9	1.8	0.5	21.1	10.2	7.8	14.7	7.4	6.7	16.5	10.3	10.8	9.7	10.4	8.3	14.8	13.9	11.5	10.8	13.7	7.6	15.9	3.0	25.9	18.7	14.2	0.6	10.5	15.9	14.2	23.8	12.2	11.6	7.5	11.1	9.7	26.5	19.1	5.5	15.8	13.7	14.4	14.9	12.6	21.7	8.3	15.5	8.8	15.5	18.1	13.0	0.0	7.7	11.1	12.1	23.4	13.1	10.1	11.4	19.7	16.4	37.6	15.8	10.4	10.0	19.0	10.3	2.0	4.2	4.5	0.6	6.0	0.4	2.7	1.0	1.8	1.9	1.0	1.0	0.9	11.7	1.9	6.3	1.0	0.7	0.5	13.5	12.4	17.8	16.0	12.6	9.8	9.7	10.4	9.9	7.5
STK19	"D6S60, G11, RP1"	ENSG00000204344	"Serine/threonine kinase 19"	P49842	6	31971091-31982821	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 4.8;REH: 4.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031510, HPA031511, HPA068559"	Uncertain		Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA031510: AB_10603119, HPA031511: AB_2673915, HPA068559: "	"unprognostic (1.65e-1)"	"unprognostic (2.30e-1)"	"unprognostic (3.31e-1)"	"unprognostic (1.86e-1)"	"unprognostic (2.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.15e-2)"	"unprognostic (4.26e-2)"	"prognostic unfavourable (1.18e-4)"	"unprognostic (3.95e-2)"	"unprognostic (2.76e-3)"	"unprognostic (2.25e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.40e-1)"	"unprognostic (4.10e-1)"	6.4	8.2	3.8	4.3	6.5	2.9	4.0	9.9	6.3	5.7	6.6	5.5	4.2	2.2	6.0	5.5	5.3	3.5	5.3	3.6	5.0	3.5	3.9	6.6	4.1	2.5	4.3	7.5	5.7	12.4	4.7	4.6	6.3	4.0	6.2	2.7	5.6	2.9	6.7	6.1	6.8	2.6	5.9	3.7	7.0	6.3	7.9	4.2	2.6	4.7	4.1	3.8	4.4	4.2	2.1	2.7	0.4	3.8	0.9	1.1	0.5	0.0	0.3	0.0	1.1	2.9	1.7	0.0	2.3	0.3	0.5	1.1	0.0	1.9	1.5	0.6	1.2	2.0	0.0	0.6	0.9	4.8	0.9	3.6	0.9	0.2	1.4	3.7	0.0	1.5	0.1	0.8	0.3	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.6	0.0	4.4	2.4	1.1	0.0	0.0	1.0	0.9	0.3	0.6	0.2	1.7	0.0	0.0	0.0	1.1	1.1	0.0	0.1	2.3	0.1	1.9	0.6	0.1	0.0	3.8	0.1	0.6	1.4	0.7	2.1	0.9	0.1	2.7	1.0	1.1	0.5	0.4	0.9	1.4	1.5	0.1	0.5	3.8	6.5	9.9	6.3	5.0	3.5	4.3	7.5	4.0	4.2
STMN1	"C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN"	ENSG00000117632	"Stathmin 1"	P16949	1	25884181-25906991	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 143.4;lymphoid tissue: 117.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 79.3"	"Group enriched"	"Detected in all"	5	"dendritic cells: 79.3;T-cells: 26.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB010107	Enhanced		Supported	Cytosol		210000	210000	Cytosol		"CAB010107: AB_628297"	"unprognostic (6.30e-2)"	"unprognostic (2.40e-3)"	"unprognostic (5.31e-2)"	"unprognostic (7.94e-2)"	"unprognostic (1.89e-1)"	"unprognostic (5.02e-2)"	"prognostic unfavourable (9.90e-7)"	"unprognostic (9.45e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.78e-1)"	"unprognostic (3.33e-3)"	"unprognostic (1.02e-2)"	"unprognostic (1.68e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.00e-2)"	7.3	13.2	91.7	17.5	47.4	40.7	10.9	54.1	124.8	6.2	16.7	47.0	2.5	12.7	24.7	7.8	13.0	7.3	9.4	9.5	67.9	88.4	13.2	6.4	11.0	42.8	86.5	58.0	33.6	3.5	4.6	12.1	21.7	43.4	5.2	20.7	7.7	5.3	6.3	3.8	9.5	15.9	18.8	143.4	10.9	9.7	58.2	27.1	117.1	6.1	7.2	43.1	13.0	8.1	8.6	79.3	4.0	1.5	10.1	26.2	9.3	67.5	15.2	151.7	60.6	9.1	8.8	15.4	52.7	41.9	75.3	72.9	10.4	69.5	83.1	29.6	38.4	20.7	42.0	30.5	113.3	25.1	20.8	51.5	26.9	36.3	3.6	64.8	36.8	5.4	4.5	30.3	34.6	56.6	69.5	82.9	97.5	17.6	213.2	95.3	93.0	20.5	126.2	118.3	49.3	36.4	6.1	102.8	89.2	47.9	24.0	42.0	34.4	82.6	27.2	50.6	60.1	43.8	43.9	48.9	77.6	103.2	24.9	126.8	54.5	2.0	0.7	4.0	10.4	1.5	6.3	6.4	9.3	13.1	4.2	8.6	15.3	13.7	0.3	10.1	0.7	79.3	26.2	9.3	91.7	47.4	54.1	124.8	67.9	88.4	86.5	58.0	43.4	27.1
STRAP	"MAWD, pt-wd, UNRIP"	ENSG00000023734	"Serine/threonine kinase receptor associated protein"	Q9Y3F4	12	15882391-15903478	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027320, HPA055557, HPA073876"	Approved		Enhanced	Cytosol		290000	290000	Cytosol		"HPA027320: AB_1857614, HPA055557: AB_2682849, HPA073876: AB_2686639"	"unprognostic (4.64e-3)"	"unprognostic (2.25e-2)"	"unprognostic (9.88e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.88e-1)"	"unprognostic (4.05e-3)"	"prognostic unfavourable (6.83e-6)"	"unprognostic (1.69e-2)"	"unprognostic (3.71e-1)"	"unprognostic (2.15e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.02e-1)"	"unprognostic (3.60e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.54e-1)"	"prognostic unfavourable (9.07e-4)"	"prognostic unfavourable (5.10e-4)"	36.7	39.8	43.5	28.1	43.2	24.1	46.4	38.1	55.3	30.5	29.4	19.3	29.2	24.7	31.8	29.1	33.7	24.7	25.8	54.0	55.7	44.9	46.4	42.9	27.7	30.4	35.8	48.3	25.5	38.7	40.4	36.7	34.4	47.1	27.8	29.5	20.5	26.0	32.2	109.2	25.3	23.6	37.4	51.5	20.7	28.9	32.9	27.5	27.9	42.6	36.6	29.4	28.6	29.8	36.9	44.6	30.8	41.8	29.2	43.4	38.5	32.6	38.5	36.8	31.3	32.6	32.6	49.1	39.2	27.3	35.4	33.1	55.0	28.8	36.4	19.5	39.8	23.8	43.9	43.0	52.3	48.6	35.6	36.8	30.6	24.1	53.5	42.6	17.9	31.3	36.7	39.0	44.0	41.1	28.2	11.1	46.0	22.8	35.4	20.4	129.7	25.2	27.3	50.6	21.0	41.0	33.7	23.7	40.4	31.6	21.9	42.7	40.8	22.9	34.4	26.5	31.5	28.0	48.0	12.8	17.3	59.8	32.6	23.7	33.4	26.8	36.7	30.8	34.6	41.8	38.9	36.9	36.0	33.3	44.6	30.8	35.4	37.3	17.0	29.2	35.9	27.4	43.4	38.5	43.5	43.2	38.1	55.3	55.7	44.9	35.8	48.3	47.1	27.5
STRN	"PPP2R6A, STRN1"	ENSG00000115808	Striatin	O43815	2	36843640-36966472	"Cancer-related genes, Predicted intracellular proteins"		Calmodulin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017286	Approved		Approved	Nucleoplasm,Cytosol		11000	11000	Cytosol	Nucleoplasm	"HPA017286: AB_1857618"	"unprognostic (1.65e-1)"	"unprognostic (1.65e-1)"	"unprognostic (3.57e-3)"	"unprognostic (2.23e-2)"	"unprognostic (3.25e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.63e-3)"	"unprognostic (7.37e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.77e-3)"	"unprognostic (1.33e-1)"	"prognostic favourable (2.27e-4)"	"unprognostic (1.13e-1)"	"unprognostic (6.43e-2)"	"unprognostic (2.11e-1)"	"unprognostic (3.43e-2)"	11.8	8.1	11.4	11.0	22.1	17.4	13.3	16.4	14.2	11.2	14.0	10.9	8.9	10.1	8.6	7.1	25.9	6.8	8.4	25.7	16.2	10.2	11.6	10.2	10.3	9.6	16.9	9.4	9.9	7.1	11.3	6.3	12.6	10.5	8.1	13.7	5.6	16.2	6.9	16.0	16.1	13.2	11.1	34.3	10.9	11.4	9.8	14.8	18.6	8.1	15.5	16.7	11.3	14.4	1.5	0.8	3.7	1.5	0.5	2.1	0.4	23.0	11.7	15.6	6.6	8.6	12.0	15.7	9.3	8.8	9.1	8.4	11.9	7.5	15.3	7.5	11.8	11.0	13.1	10.3	11.3	17.3	10.1	24.8	10.3	6.1	8.2	14.9	13.9	7.2	9.0	14.5	11.5	11.6	18.5	12.2	11.2	6.6	14.7	6.5	12.5	5.9	9.6	24.7	6.7	7.5	19.1	2.9	9.5	14.0	10.8	8.8	7.7	5.8	15.4	16.4	16.5	10.1	12.2	12.3	18.6	13.5	8.3	14.9	11.3	3.4	0.8	1.4	2.1	1.5	0.7	1.5	1.5	1.3	0.4	0.9	0.8	0.9	3.7	0.5	1.4	0.8	0.3	0.4	11.4	22.1	16.4	13.0	16.2	10.2	16.9	9.4	10.5	14.8
STT3A	"ITM1, MGC9042, STT3-A, TMC"	ENSG00000134910	"STT3A, catalytic subunit of the oligosaccharyltransferase complex"	P46977	11	125591712-125625215	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Congenital disorder of glycosylation, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 202.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030735	Approved		Uncertain	Nucleoplasm,Vesicles,Cytosol				"Nucleoplasm, Cytosol"	Vesicles	"HPA030735: AB_10603342"	"unprognostic (8.25e-3)"	"unprognostic (5.45e-2)"	"unprognostic (3.02e-2)"	"prognostic favourable (1.32e-4)"	"unprognostic (5.10e-2)"	"unprognostic (1.72e-2)"	"prognostic unfavourable (3.57e-4)"	"unprognostic (8.40e-2)"	"unprognostic (4.80e-2)"	"unprognostic (1.16e-2)"	"unprognostic (8.96e-3)"	"unprognostic (1.31e-1)"	"prognostic unfavourable (4.96e-4)"	"unprognostic (2.60e-2)"	"unprognostic (6.38e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.82e-2)"	20.6	20.5	8.3	13.1	11.7	8.3	16.9	10.7	13.9	27.8	19.3	17.7	39.6	12.0	30.5	41.4	19.6	20.8	15.1	19.5	8.3	9.1	26.2	67.1	18.7	14.9	9.3	7.7	30.1	59.0	202.3	27.5	35.9	11.6	22.2	17.4	20.8	50.7	41.4	9.5	12.9	19.8	17.1	12.3	21.8	17.7	17.1	6.7	19.2	38.6	13.6	20.8	19.5	18.0	15.0	53.2	27.0	15.5	17.2	27.5	13.4	20.7	18.9	24.2	33.2	45.6	35.4	26.0	38.0	45.4	31.0	38.8	57.5	56.2	27.1	46.2	55.9	38.4	33.5	33.3	41.2	21.1	17.8	63.8	13.1	39.7	50.5	38.1	29.9	27.3	24.2	42.8	83.7	34.5	26.8	40.6	39.0	15.3	15.3	12.2	15.5	20.6	18.2	20.6	40.7	33.8	32.3	15.1	13.0	26.9	44.0	13.5	51.5	27.5	30.8	44.6	16.1	18.8	29.8	12.8	14.9	20.9	17.2	38.6	35.4	27.0	15.5	11.6	19.7	14.8	27.5	15.0	19.1	18.2	21.6	11.6	13.8	16.0	5.4	17.2	13.0	53.2	14.1	13.4	8.3	11.7	10.7	13.9	8.3	9.1	9.3	7.7	11.6	6.7
STX2	"EPIM, EPM, STX2A, STX2B, STX2C"	ENSG00000111450	"Syntaxin 2"	P32856	12	130789600-130839266	"Cancer-related genes, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038189, HPA069176, CAB079007"	Uncertain	Supported	Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB079007: , HPA038189: , HPA069176: "	"unprognostic (1.56e-2)"	"unprognostic (3.43e-2)"	"unprognostic (8.29e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.38e-2)"	"unprognostic (9.85e-2)"	"unprognostic (2.11e-2)"	"unprognostic (4.16e-2)"	"unprognostic (2.83e-1)"	"unprognostic (7.62e-2)"	"unprognostic (1.30e-2)"	"unprognostic (5.69e-2)"	"prognostic unfavourable (5.15e-5)"	"unprognostic (3.81e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.63e-2)"	"unprognostic (3.41e-3)"	15.9	14.5	16.0	15.4	13.4	8.8	27.0	12.5	18.7	13.1	18.8	15.3	8.8	6.1	18.1	15.4	9.6	19.4	14.5	16.4	15.5	11.4	12.2	12.0	18.3	11.9	12.7	12.4	16.0	10.7	11.9	16.3	18.0	17.9	10.2	10.2	9.8	5.2	15.7	6.3	6.1	10.7	23.5	24.8	12.3	11.7	23.2	12.3	9.7	12.6	6.9	9.4	13.5	22.2	2.6	1.6	4.6	2.4	1.4	3.1	0.9	4.7	9.5	13.8	10.7	12.8	29.1	1.4	20.1	16.2	24.9	16.5	2.6	3.3	6.1	3.2	22.0	1.3	12.6	3.3	25.9	9.2	4.3	3.2	8.3	7.4	13.8	4.7	8.0	10.8	4.1	12.1	9.7	12.2	12.7	5.7	21.2	2.8	6.6	4.8	9.2	13.1	7.0	9.0	3.2	13.7	1.0	13.2	12.9	10.2	0.9	8.5	3.2	3.0	16.4	14.3	10.1	15.7	8.8	4.2	3.3	4.0	16.5	5.2	11.2	4.6	2.2	2.8	2.4	2.4	2.4	2.6	2.7	2.7	1.5	1.7	2.9	3.1	3.0	1.4	1.2	1.6	1.9	0.9	16.0	13.4	12.5	18.7	15.5	11.4	12.7	12.4	17.9	12.3
SUFU	"PRO1280, SUFUH, SUFUXL"	ENSG00000107882	"SUFU negative regulator of hedgehog signaling"	Q9UMX1	10	102503987-102633535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes, Ciliopathy, Disease mutation, Joubert syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008700	Supported		Supported	Nucleoplasm				Nucleoplasm		"HPA008700: AB_1080125"	"unprognostic (1.55e-1)"	"unprognostic (4.00e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.33e-1)"	"unprognostic (4.69e-2)"	"unprognostic (5.68e-2)"	"unprognostic (3.69e-2)"	"unprognostic (5.99e-2)"	"unprognostic (1.64e-1)"	"unprognostic (3.15e-3)"	"unprognostic (9.60e-2)"	"unprognostic (2.13e-1)"	"unprognostic (3.72e-3)"	"unprognostic (1.82e-1)"	"unprognostic (1.44e-1)"	"unprognostic (5.10e-2)"	"unprognostic (3.82e-3)"	10.7	12.8	15.0	15.2	12.8	3.9	18.3	23.0	15.3	13.4	10.4	11.3	12.1	7.7	14.4	13.3	14.7	14.2	16.2	11.0	11.8	7.8	10.8	10.0	21.4	20.5	11.9	11.0	18.0	8.9	20.0	7.8	13.9	10.0	15.4	8.8	11.9	12.6	16.7	14.1	23.1	9.4	14.3	10.7	13.1	7.9	21.1	13.1	19.9	6.2	12.7	15.0	15.2	15.0	2.3	4.5	6.2	5.5	2.8	3.1	2.8	6.4	6.8	11.1	15.9	11.5	9.7	5.4	6.7	13.0	9.7	8.8	6.3	4.8	6.6	19.1	7.4	4.6	13.6	7.4	6.4	4.0	10.5	15.7	3.9	5.9	5.5	5.7	11.3	11.0	5.9	7.2	5.9	12.5	3.5	6.1	5.9	5.4	10.8	8.6	3.2	5.1	11.7	12.0	3.4	6.4	9.7	3.8	6.0	5.3	5.0	6.0	10.9	3.8	13.7	4.3	6.2	4.6	7.3	5.0	3.2	4.8	5.4	11.2	2.9	4.2	4.5	6.2	2.5	5.5	2.0	2.3	3.1	2.8	4.5	2.1	2.2	2.5	1.1	2.8	5.5	2.5	1.9	2.8	15.0	12.8	23.0	15.3	11.8	7.8	11.9	11.0	10.0	13.1
SULT1E1	"EST, STE"	ENSG00000109193	"Sulfotransferase family 1E member 1"	P49888	4	69841212-69860152	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 37.8;liver: 26.2;vagina: 15.8"	"Group enriched"	"Detected in some"	19	"HHSteC: 37.1;HSkMC: 16.8;hTCEpi: 14.0;HUVEC TERT2: 10.2"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	8	"pons and medulla: 3.3"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.7"	"Low lineage specificity"	"Detected in single"											"HPA028213, HPA028728, CAB047344"	Enhanced		Uncertain	"Nuclear membrane,Cytosol"				"Nuclear membrane, Cytosol"		"CAB047344: , HPA028213: AB_10599848, HPA028728: AB_10601894"	"unprognostic (5.60e-2)"	"prognostic favourable (4.06e-4)"	"unprognostic (2.48e-1)"	"unprognostic (1.07e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.70e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.22e-3)"	"unprognostic (8.62e-2)"	"unprognostic (6.48e-5)"	"unprognostic (2.48e-1)"	"unprognostic (4.11e-2)"		"unprognostic (5.55e-2)"	0.1	9.8	0.1	0.1	0.3	0.1	1.1	0.1	0.4	13.1	8.9	0.5	0.1	19.8	0.4	3.7	0.4	0.1	1.2	0.1	0.1	0.0	1.5	26.2	2.0	0.1	0.3	0.3	0.2	0.1	0.0	0.4	0.1	3.3	1.0	0.1	0.3	4.7	0.3	0.1	10.9	37.8	0.5	0.3	0.1	1.3	0.4	0.1	0.6	0.2	0.1	1.0	0.4	15.8	0.6	0.2	1.7	0.3	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	37.1	0.0	0.0	16.8	14.0	0.0	0.4	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.0	0.1	0.1	0.1	0.3	0.2	0.2	0.1	0.6	0.2	0.1	1.7	0.3	0.3	0.2	0.0	0.0	0.1	0.3	0.1	0.4	0.1	0.0	0.3	0.3	3.3	0.1
SUZ12	"CHET9, JJAZ1, KIAA0160"	ENSG00000178691	"SUZ12 polycomb repressive complex 2 subunit"	Q15022	17	31937018-32001045	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA057436	Approved		Supported	"Nucleoplasm,Nucleoli,Nuclear bodies"				"Nucleoplasm, Nucleoli, Nuclear bodies"		"HPA057436: "	"unprognostic (1.23e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.65e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.49e-1)"	"unprognostic (7.31e-2)"	"unprognostic (2.66e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.27e-2)"	"unprognostic (3.06e-2)"	"unprognostic (6.29e-2)"	"unprognostic (8.70e-2)"	"unprognostic (3.28e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.91e-2)"	"unprognostic (1.31e-1)"	10.1	10.8	13.4	15.4	10.4	25.5	33.5	16.0	13.8	11.2	11.4	7.5	13.6	10.1	12.5	8.1	12.3	9.8	7.7	9.7	9.1	7.6	10.9	11.5	10.6	19.9	9.3	9.9	10.0	10.1	15.5	10.4	15.3	9.5	10.7	10.9	6.9	10.1	9.6	8.7	9.9	12.2	9.6	7.7	15.2	10.7	17.1	12.5	31.8	12.0	6.5	18.9	10.8	19.5	5.5	4.6	4.1	2.6	4.4	5.5	1.2	14.0	12.5	11.8	13.5	6.8	8.8	12.1	13.7	12.1	16.9	20.5	9.4	7.9	30.8	10.6	8.5	12.5	17.5	7.9	27.5	10.8	17.0	21.3	10.6	6.8	8.0	33.5	21.9	6.1	8.9	16.8	12.9	10.3	20.5	42.8	14.5	4.9	39.8	19.5	6.7	7.6	23.8	30.2	24.9	9.9	13.8	15.1	11.8	22.1	7.2	13.2	20.8	28.0	7.6	13.4	12.2	16.1	21.1	23.4	29.1	38.1	9.8	20.7	12.1	1.4	1.9	3.8	3.8	2.6	3.0	5.5	4.1	4.0	1.4	4.4	3.9	5.5	4.1	4.4	1.8	4.6	4.2	1.2	13.4	10.4	16.0	13.8	9.1	7.6	9.3	9.9	9.5	12.5
SYK		ENSG00000165025	"Spleen associated tyrosine kinase"	P43405	9	90801787-90898549	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 38.5"	"Cell line enhanced"	"Detected in many"		"Daudi: 38.7;HEL: 22.3;HL-60: 30.8;HMC-1: 20.5;REH: 25.8;THP-1: 23.7;U-698: 18.3;U-937: 21.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	15	"classical monocyte: 21.4;eosinophil: 23.3;intermediate monocyte: 19.0;memory B-cell: 23.1;myeloid DC: 24.9;naive B-cell: 17.5;neutrophil: 32.8;NK-cell: 8.7;non-classical monocyte: 16.4;plasmacytoid DC: 18.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001384, CAB007773"	Enhanced		Approved	"Vesicles,Plasma membrane,Cytosol"		1000000	1000000	"Plasma membrane, Cytosol"	Vesicles	"CAB007773: AB_562232, HPA001384: AB_1080144"	"unprognostic (1.01e-1)"	"unprognostic (5.45e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.69e-2)"	"unprognostic (2.31e-1)"	"unprognostic (7.92e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.34e-1)"	"unprognostic (6.41e-2)"	"unprognostic (1.78e-2)"	"unprognostic (7.20e-2)"	"unprognostic (9.93e-2)"	"unprognostic (2.55e-3)"	"unprognostic (8.77e-2)"	"unprognostic (5.36e-3)"	"unprognostic (3.41e-2)"	"unprognostic (1.06e-2)"	7.2	3.3	6.0	38.1	9.6	18.2	6.7	1.1	4.5	3.7	10.3	6.7	1.5	12.3	2.3	6.7	16.2	6.9	6.6	5.5	7.2	3.2	8.6	2.5	13.7	36.4	9.1	2.5	2.1	8.9	25.9	3.1	5.0	6.1	4.1	8.3	2.8	8.9	1.8	1.4	8.3	22.2	3.5	11.3	38.5	7.4	5.5	7.9	30.5	18.1	7.8	32.2	8.6	7.5	23.1	24.9	32.8	21.4	8.7	0.1	10.2	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	38.7	1.1	0.0	6.0	0.8	3.2	0.0	0.0	5.3	22.3	0.0	0.0	0.0	30.8	20.5	0.0	4.4	0.0	0.4	0.0	0.6	3.1	0.0	4.7	0.0	13.5	0.2	0.0	25.8	0.0	10.6	0.8	5.8	2.0	1.8	0.0	2.7	0.0	2.5	23.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	18.3	0.0	21.7	0.0	1.4	21.4	23.3	0.1	19.0	0.1	23.1	0.0	0.0	24.9	17.5	0.0	0.0	32.8	8.7	16.4	18.5	0.0	10.2	6.0	9.6	1.1	4.5	7.2	3.2	9.1	2.5	6.1	7.9
SYNE1	"8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B"	ENSG00000131018	"Spectrin repeat containing nuclear envelope protein 1"	Q8NF91	6	152121684-152637801	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Spermatogenesis"	Actin-binding	"Cancer-related genes, Disease mutation, Emery-Dreifuss muscular dystrophy, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-266/70: 18.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"eosinophil: 33.8"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 33.8"									HPA019113	Approved		Supported	"Nucleoplasm,Nuclear membrane"				"Nucleoplasm, Nuclear membrane"		"HPA019113: AB_1857707"	"unprognostic (9.99e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.28e-1)"	"unprognostic (9.58e-3)"	"unprognostic (1.11e-1)"	"unprognostic (3.55e-3)"	"unprognostic (1.58e-1)"	"unprognostic (9.85e-2)"	"unprognostic (8.87e-3)"	"unprognostic (2.70e-1)"	"unprognostic (4.14e-3)"	"unprognostic (5.83e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.78e-1)"	12.7	11.5	18.2	9.1	30.2	41.7	9.0	62.0	25.0	16.8	7.3	9.8	12.4	2.7	15.2	18.4	6.2	12.9	7.9	22.7	21.0	17.5	18.4	11.2	16.1	13.7	13.2	15.1	27.7	10.6	37.3	37.0	4.7	19.7	10.1	6.3	10.5	3.6	12.5	22.0	16.9	5.3	19.1	9.7	15.5	9.0	8.3	11.6	9.0	20.6	9.5	12.1	10.0	12.3	3.2	0.8	33.8	1.5	4.7	6.4	1.4	0.1	3.9	2.8	3.2	3.9	8.6	1.0	8.8	4.6	2.3	4.2	0.8	0.1	8.3	0.5	4.8	0.2	1.0	2.3	2.4	10.0	2.7	3.5	2.6	2.7	9.0	0.6	1.6	5.5	0.5	5.0	10.3	4.4	0.0	9.5	6.2	0.4	1.4	0.1	0.6	1.5	1.9	5.5	2.3	8.9	0.1	1.7	2.6	1.4	0.5	6.1	0.5	0.3	5.9	10.7	14.5	3.7	4.8	18.9	8.0	13.3	5.9	1.9	3.1	3.0	1.1	33.8	6.4	0.7	4.1	2.9	4.2	6.1	0.8	3.2	4.0	5.1	1.1	4.7	1.5	0.7	5.1	1.4	18.2	30.2	62.0	25.0	21.0	17.5	13.2	15.1	19.7	11.6
TAF1	"BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250"	ENSG00000147133	"TATA-box binding protein associated factor 1"	P21675	X	71366239-71532374	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Acyltransferase, DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Dystonia, Mental retardation, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA001075, CAB016283"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB016283: AB_671202, HPA001075: AB_1080179"	"unprognostic (2.95e-2)"	"unprognostic (1.77e-1)"	"unprognostic (6.45e-3)"	"unprognostic (1.91e-2)"	"unprognostic (1.88e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.44e-1)"	"prognostic favourable (6.54e-4)"	"unprognostic (2.68e-2)"	"unprognostic (3.43e-2)"	"unprognostic (2.03e-1)"	"unprognostic (5.59e-2)"	"prognostic unfavourable (6.03e-4)"	"unprognostic (1.14e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.82e-2)"	"unprognostic (2.56e-2)"	20.1	16.2	15.0	17.1	19.8	16.3	17.7	20.7	18.0	20.7	15.5	23.8	17.1	10.0	25.4	17.1	14.4	19.1	16.1	12.9	15.4	12.0	11.9	12.9	13.8	17.8	18.5	16.5	23.9	17.5	25.5	19.3	15.4	17.3	16.9	15.4	20.8	14.5	16.1	19.6	16.8	17.1	18.3	17.2	21.3	15.8	12.2	21.3	19.4	20.1	12.0	18.7	18.4	15.8	5.0	4.7	5.2	4.8	4.2	4.9	1.8	11.2	9.8	11.2	7.5	9.0	15.6	7.0	8.4	7.8	8.9	7.4	7.3	6.8	10.5	7.2	9.4	10.7	15.6	6.7	11.4	6.9	13.7	12.5	12.9	7.2	6.5	23.7	12.1	9.1	6.8	9.5	18.0	9.2	17.0	25.5	9.0	7.9	13.1	10.5	12.9	12.9	12.1	22.8	12.8	6.0	14.6	5.9	9.2	23.4	8.2	10.4	6.0	12.6	11.6	10.5	8.8	8.4	5.8	10.9	10.1	13.6	5.8	19.1	7.8	4.4	4.1	1.1	4.4	2.8	3.8	3.0	4.6	4.5	4.7	5.0	4.4	4.9	5.2	4.2	4.8	3.5	3.1	1.8	15.0	19.8	20.7	18.0	15.4	12.0	18.5	16.5	17.3	21.3
TAF15	"hTAFII68, Npl3, RBP56, TAF2N"	ENSG00000270647	"TATA-box binding protein associated factor 15"	Q92804	17	35713791-35864615	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"DNA-binding, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA052059, HPA063647"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA052059: , HPA063647: "	"unprognostic (1.26e-1)"	"unprognostic (2.66e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.27e-1)"	"unprognostic (8.48e-3)"	"unprognostic (4.75e-2)"	"unprognostic (8.06e-3)"	"unprognostic (2.08e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.39e-2)"	"unprognostic (5.41e-2)"	"unprognostic (3.35e-2)"	"unprognostic (2.99e-1)"	14.0	12.9	12.7	15.3	16.2	13.9	11.0	13.7	14.1	10.5	11.7	15.0	13.2	12.7	10.2	11.0	12.6	8.0	11.5	13.1	11.8		9.8	15.0	8.9	19.4	14.7	8.3	10.7	11.3	14.6	18.1	11.1	11.1	11.4	10.1	9.2	9.8	15.3	26.9	14.7	13.4	17.5	15.9	12.7	11.0	11.3	15.5	21.1	9.4	12.8	15.8	12.0	9.8	3.7	3.2	3.8	3.6	4.7	7.2	2.2	28.7	47.3	25.3	24.5	20.3	11.5	16.6	32.9	11.2	15.0	14.7	31.6	20.8	57.2	23.7	21.3	30.6	33.6	33.1	21.7	16.1	43.9	32.9	34.4	33.1	20.0	53.1	22.1	18.3	17.4	22.7	35.7	20.2	30.8	23.7	16.9	34.3	57.9	12.9	15.6	13.6	34.6	37.6	21.4	19.0	51.7	19.2	18.9	41.0	12.4	13.0	29.0	18.3	27.3	11.6	25.3	16.7	39.5	22.4	27.3	41.7	22.9	26.2	19.0	3.8	3.5	3.5	4.9	3.4	7.2	3.0	3.5	3.8	2.5	3.7	3.3	3.7	2.0	4.7	3.6	3.2	3.9	2.2										
TAGLN	"DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10"	ENSG00000149591	Transgelin	Q01995	11	117199321-117204782	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 136.3;BJ hTERT+ SV40 Large T+: 129.6;CACO-2: 122.3;EFO-21: 162.6;fHDF/TERT166: 138.9;LHCN-M2: 95.9;U-138 MG: 126.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"intermediate monocyte: 19.0;non-classical monocyte: 26.6"	"Lineage enriched"	"Detected in many"	10	"monocytes: 26.6"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"midbrain: 176.0"	"CAB001447, HPA019467"	Enhanced		Approved	Microtubules,Mitochondria,Cytosol		8000000	8000000	"Microtubules, Mitochondria"	Cytosol	"CAB001447: AB_564012, HPA019467: AB_1857245"	"unprognostic (1.36e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.57e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.58e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.39e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.76e-1)"	"prognostic unfavourable (2.12e-7)"	"unprognostic (9.58e-3)"	"unprognostic (3.03e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.52e-3)"	73.3	22.6	2.3	67.6	5.9	0.2	60.8	2.1	7.7	278.3	328.7	6.1	156.2	22.3	399.7	156.8	337.9	133.3	227.5	48.7	3.1	3.0	49.5	12.9	44.1	38.6	7.1	11.8	159.2	9.3	1.5	8.0	36.2	14.9	237.5	51.6	39.1	24.1	347.5	36.6	17.9	81.0	481.9	9.1	26.0	114.7	65.1	2.1	1.1	47.3	30.0	11.2	473.0	78.1	2.6	1.4	0.8	26.6	0.0	0.3	0.9	1.2	0.3	21.4	0.5	10.0	9.0	18.0	136.3	59.1	129.6	48.5	122.3	1.9	0.2	162.6	138.9	3.2	0.3	1.1	36.9	0.4	0.2	0.3	4.5	8.3	55.7	0.1	0.3	23.7	4.6	18.9	2.4	0.2	0.2	0.4	95.9	0.2	0.1	1.0	6.5	0.1	0.1	1.6	0.6	0.2	1.7	0.1	0.5	2.1	0.7	0.1	0.6	0.3	14.6	126.3	21.3	0.9	5.8	0.6	0.4	1.0	0.7	0.4	0.3	0.8	1.1	0.0	0.1	19.0	0.2	1.6	0.0	0.0	1.4	2.6	0.1	0.0	0.1	0.0	26.6	0.7	0.3	0.9	2.3	5.9	2.1	7.7	3.1	3.0	7.1	11.8	14.9	2.1
TAL1	"bHLHa17, SCL, TCL5"	ENSG00000162367	"TAL bHLH transcription factor 1, erythroid differentiation factor"	P17542	1	47216290-47232220	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 33.1"	"Cell line enhanced"	"Detected in some"		"HEL: 52.8;HMC-1: 25.4;HUVEC TERT2: 11.0;K-562: 16.5;MOLT-4: 8.8;TIME: 12.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"basophil: 3.2;neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 3.2"	"Region enriched"	"Detected in some"	5	"midbrain: 17.1"	"Low region specificity"	"Detected in many"			"CAB017805, HPA047866, HPA073983"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB017805: , HPA047866: , HPA073983: "	"unprognostic (2.63e-1)"	"unprognostic (2.62e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.40e-2)"	"unprognostic (1.59e-1)"	"unprognostic (8.80e-3)"	"unprognostic (3.95e-3)"	"unprognostic (1.33e-1)"	"unprognostic (4.15e-2)"	"unprognostic (1.99e-2)"	"unprognostic (5.42e-3)"	"unprognostic (3.68e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.76e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.18e-2)"	9.1	2.7	7.0	1.8	5.7	33.1	7.1	1.6	6.9	3.3	2.4	12.0	2.3	1.6	3.7	3.3	2.5	4.1	4.2	3.9	8.8	3.5	4.5	2.4	14.6	2.2	11.1	4.4	1.5	1.3	2.2	2.1	9.8	7.3	2.4	2.4	2.1	1.4	3.0	3.1	2.0	3.3	4.4	9.4	8.5	2.1	1.8	9.2	0.0	6.7	4.1	1.5	2.5	5.5	0.3	0.1	3.2	0.3	0.4	0.4	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	52.8	0.0	0.0	0.0	0.0	25.4	0.0	0.0	0.0	0.0	11.0	16.5	0.0	0.0	0.0	8.8	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	12.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.1	0.2	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.3	0.4	0.1	1.2	0.4	0.1	0.1	0.1	2.2	7.0	5.7	1.6	6.9	8.8	3.5	11.1	4.4	7.3	9.2
TAL2	bHLHa19	ENSG00000186051	"TAL bHLH transcription factor 2"	Q16559	9	105662457-105663112	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	11	"blood: 8.8;kidney: 4.6;skeletal muscle: 17.3"	"Cell line enhanced"	"Detected in some"		"HAP1: 4.8;K-562: 12.6"	"Cancer enhanced"	"Detected in some"		"renal cancer: 1.6"					"Group enriched"	"Detected in some"	21	"memory B-cell: 8.8;naive B-cell: 7.9;plasmacytoid DC: 2.2"	"Group enriched"	"Detected in many"	18	"B-cells: 8.8;dendritic cells: 2.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA030886	Uncertain		Approved	Cytosol				Cytosol		"HPA030886: AB_10601596"	"unprognostic (3.89e-2)"	"unprognostic (1.45e-1)"	"unprognostic (8.51e-2)"	"unprognostic (5.54e-2)"	"unprognostic (2.24e-1)"	"unprognostic (9.06e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.70e-3)"	"unprognostic (2.63e-1)"	"unprognostic (7.00e-4)"	"unprognostic (2.84e-2)"	"prognostic favourable (2.69e-4)"	"unprognostic (2.70e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.29e-1)"	"unprognostic (7.39e-2)"	0.1	0.3	0.5	0.1	0.7	0.0	0.0	0.3	0.6	0.2	0.0			0.0	0.2	0.9	0.1	0.2	0.0	0.3	0.4	0.5	4.6	0.3	0.0	0.2	0.7		0.3	0.1	0.0	0.8	0.1		0.1	0.1		0.0	0.2	17.3	0.1	0.1	0.0	0.8	0.3	0.0	0.6			0.1		0.4	0.1	0.0	8.8	2.2	0.0	0.0	0.3	0.0	0.1	0.0	0.6	2.5	0.7	0.3	0.0	0.3	0.1	0.3	0.1	0.4	3.3	0.2	0.1	0.2	0.0	0.1	4.8	0.0	0.1	0.6	0.5	1.1	0.0	0.0	0.2	0.5	1.8	0.2	0.5	0.1	0.2	0.0	12.6	0.3	0.4	0.3	0.8	0.7	0.2	0.2	0.1	0.1	0.0	0.0	0.0	2.8	1.1	0.2	0.2	0.2	0.2	2.0	0.5	0.3	0.8	0.7	1.0	0.9	1.9	0.1	0.2	2.3	0.8	0.0	0.0	0.0	0.0	0.0	0.0	8.8	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.3	0.0	2.2	0.0	0.1										
TAP1	"ABCB2, D6S114E, PSF1, RING4"	ENSG00000168394	"Transporter 1, ATP binding cassette subfamily B member"	Q03518	6	32845209-32853978	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Adaptive immunity, Host-virus interaction, Immunity, Peptide transport, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 45.3"	"Cell line enhanced"	"Detected in many"		"BEWO: 16.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB009516, HPA072354"	Approved		Supported	"Endoplasmic reticulum,Centriolar satellite"		110000	110000	"Endoplasmic reticulum, Centriolar satellite"		"CAB009516: AB_2303048, HPA072354: "	"unprognostic (3.59e-2)"	"unprognostic (1.06e-1)"	"prognostic favourable (9.01e-4)"	"unprognostic (1.33e-1)"	"unprognostic (1.84e-1)"	"unprognostic (3.22e-2)"	"unprognostic (4.92e-2)"	"unprognostic (6.16e-3)"	"unprognostic (2.56e-2)"	"prognostic favourable (4.07e-4)"	"unprognostic (3.02e-3)"	"unprognostic (2.37e-1)"	"prognostic unfavourable (6.58e-5)"	"unprognostic (2.07e-2)"	"unprognostic (4.69e-2)"	"unprognostic (2.42e-2)"	"unprognostic (2.21e-2)"	10.7	7.9	3.8	20.4	5.2	6.1	8.7	3.1	4.9	6.5	12.6	4.5	1.9	9.1	8.2	3.9	10.5	6.4	9.6	6.5	3.5	3.3	6.5	6.4	17.6	26.9	6.4	3.6	5.0	4.4	3.0	3.6	8.7	6.0	9.0	5.4	6.6	9.4	4.4	7.5	15.3	19.5	5.7	5.2	24.2	12.6	5.8	4.9	20.8	13.1	8.9	20.3	6.6	7.6	22.7	8.8	45.3	10.9	14.4	25.3	21.0	2.8	1.8	0.0	1.7	0.9	1.2	16.6	1.5	3.4	6.9	9.4	0.1	3.0	5.9	3.9	1.1	5.5	1.1	2.4	0.4	10.1	1.5	6.6	1.3	2.3	4.3	0.0	2.4	1.3	2.1	1.9	1.2	1.7	0.4	5.6	0.8	1.7	1.1	13.1	0.0	1.9	5.9	1.2	3.9	8.9	0.5	0.0	0.3	1.6	4.2	5.7	3.8	11.8	0.9	2.6	1.0	6.3	0.0	7.5	10.4	1.7	1.7	4.0	1.8	27.7	10.6	44.2	15.5	10.9	16.3	22.7	17.5	16.4	8.8	20.9	25.3	19.4	45.3	14.4	10.5	7.2	21.7	21.0	3.8	5.2	3.1	4.9	3.5	3.3	6.4	3.6	6.0	4.9
TBC1D12	KIAA0608	ENSG00000108239	"TBC1 domain family member 12"	O60347	10	94402504-94535930	"Cancer-related genes, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 41.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 2.2"	"Group enriched"	"Detected in many"	13	"B-cells: 1.4;dendritic cells: 2.2;monocytes: 1.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038277, HPA038645"	Uncertain		Approved	"Nucleoplasm,Nuclear speckles"				"Nucleoplasm, Nuclear speckles"		"HPA038277: AB_10672584, HPA038645: AB_10672650"	"unprognostic (7.23e-3)"	"unprognostic (1.58e-2)"	"prognostic favourable (1.79e-5)"	"unprognostic (7.83e-2)"	"unprognostic (1.76e-1)"	"unprognostic (4.91e-2)"	"unprognostic (1.21e-2)"	"unprognostic (7.34e-2)"	"unprognostic (6.56e-2)"	"unprognostic (9.43e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.59e-1)"	"unprognostic (2.27e-2)"	"unprognostic (9.43e-2)"	"unprognostic (3.71e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.12e-1)"	6.9	4.9	8.9	4.0	18.1	1.2	8.1	7.5	14.8	5.3	8.4	39.2	7.1	6.2	5.6	4.0	4.7	4.3	5.1	4.4	12.4	8.5	5.8	4.1	5.2	3.0	25.5	8.7	5.8	7.1	16.8	3.2	7.8	23.1	6.0	9.7	5.9	3.6	6.5	4.3	5.7	6.9	6.0	41.6	5.6	4.2	10.9	21.3	0.2	4.3	1.5	3.5	5.7	4.9	1.4	2.2	0.0	1.1	0.0	0.1	0.2	7.6	3.4	4.5	6.7	6.3	7.7	5.9	5.0	10.3	5.6	5.3	13.6	3.4	0.0	3.0	7.3	4.3	5.4	3.7	7.2	0.0	6.1	2.4	3.1	4.3	4.8	0.0	1.9	5.2	4.7	5.9	7.6	6.0	3.5	8.0	9.0	4.2	0.0	0.0	1.4	3.6	0.0	5.8	4.0	5.0	3.4	1.9	4.5	5.0	4.3	4.0	9.4	4.6	5.9	3.9	5.4	6.3	3.9	5.7	5.4	0.0	3.9	0.0	2.1	0.0	1.1	0.0	0.0	0.7	0.0	0.5	0.0	0.0	2.2	1.4	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.2	8.9	18.1	7.5	13.4	12.4	8.5	25.5	8.7	23.1	21.3
TBL1XR1	"C21, DC42, FLJ12894, IRA1, TBLR1"	ENSG00000177565	"Transducin beta like 1 X-linked receptor 1"	Q9BZK7	3	177019340-177228000	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"Activator, Chromatin regulator, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 69.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019182	Supported		Approved	Nucleoplasm				Nucleoplasm		"HPA019182: AB_1857800"	"unprognostic (4.11e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.27e-3)"	"prognostic favourable (5.16e-5)"	"unprognostic (4.44e-2)"	"prognostic unfavourable (1.08e-7)"	"unprognostic (3.75e-1)"	"unprognostic (4.84e-2)"	"unprognostic (3.04e-1)"	"unprognostic (3.13e-3)"	"unprognostic (2.50e-1)"	"prognostic unfavourable (4.25e-5)"	"unprognostic (5.83e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.17e-1)"	20.7	26.0	27.4	24.3	26.8	27.3	20.3	27.5	28.1	28.9	29.9	22.6	15.4	24.0	23.9	20.5	23.8	21.9	22.7	30.3	26.2	20.7	19.9	21.8	30.8	27.8	21.4	25.9	26.5	19.9	30.6	11.3	24.0	19.7	24.4	23.2	24.7	21.3	17.7	21.1	17.8	24.3	21.9	19.6	24.7	21.3	17.4	22.3	28.4	45.6	14.9	32.1	29.1	25.5	7.4	13.3	12.9	4.6	6.8	8.3	4.1	23.4	12.0	15.6	8.8	13.3	14.5	9.3	7.4	11.5	6.4	8.9	13.8	19.4	24.0	35.1	10.6	14.5	11.7	15.5	13.0	25.2	3.7	13.5	20.6	8.2	11.4	21.4	8.0	21.3	8.0	9.5	23.6	10.0	10.1	42.6	8.3	8.4	20.0	2.9	9.9	8.2	11.5	19.9	25.6	5.8	33.2	5.6	9.0	10.0	7.9	9.3	28.6	16.4	15.3	10.6	8.9	5.9	16.0	23.3	29.8	69.5	7.1	16.0	12.0	11.4	3.0	3.8	5.8	4.6	5.1	7.3	5.7	6.6	4.0	7.4	5.0	6.4	12.9	6.8	3.9	13.3	8.3	4.1	27.4	26.8	27.5	28.1	26.2	20.7	21.4	25.9	19.7	22.3
TBX3	"TBX3-ISO, UMS, XHL"	ENSG00000135111	"T-box 3"	O15119	12	114670254-114684164	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 117.7"	"Cell line enhanced"	"Detected in many"		"BJ: 33.8;BJ hTERT+: 32.2;RT4: 42.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA005799, HPA075876"			Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA005799: AB_1857817, HPA075876: "	"unprognostic (3.27e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.84e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.40e-2)"	"unprognostic (5.97e-3)"	"unprognostic (1.56e-1)"	"unprognostic (2.99e-2)"	"unprognostic (9.43e-2)"	"unprognostic (1.15e-1)"	"unprognostic (3.35e-1)"	"unprognostic (3.06e-1)"	"unprognostic (3.64e-3)"	"unprognostic (1.09e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.01e-1)"	"prognostic favourable (3.28e-4)"	4.3	60.5	0.9	3.3	1.9	0.0	19.9	0.7	2.3	18.2	12.2	1.7	69.6	14.2	13.1	18.7	1.9	7.5	5.0	6.2	1.2	1.5	4.1	15.1	12.6	0.8	1.2	0.5	15.6	1.1	0.3	5.3	67.8	1.6	32.3	1.5	2.6	7.3	117.7	4.2	4.8	19.4	9.7	1.4	2.6	2.2	3.5	1.2	0.5	36.3	7.3	3.5	24.6	25.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	5.9	0.0	0.0	8.9	12.3	13.4	33.8	32.2	13.1	13.0	5.3	1.4	0.0	0.5	5.8	1.5	2.8	1.2	16.2	0.0	4.0	0.0	1.5	15.4	2.9	0.0	0.0	5.4	0.8	4.4	9.1	0.1	1.2	0.0	1.1	0.5	0.0	0.1	0.0	1.8	0.0	0.0	0.8	0.0	42.2	2.2	6.5	4.8	2.2	1.1	1.6	0.0	0.0	4.0	2.6	2.2	10.9	0.0	0.0	0.0	8.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.9	0.7	2.3	1.2	1.5	1.2	0.5	1.6	1.2
TCEA1	"GTF2S, SII, TCEA, TF2S, TFIIS"	ENSG00000187735	"Transcription elongation factor A1"	P23193	8	53966552-54022529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043786	Approved		Supported	Nucleoplasm,Nucleoli				Nucleoplasm	Nucleoli	"HPA043786: AB_10959468"	"unprognostic (5.35e-2)"	"unprognostic (9.90e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.11e-3)"	"unprognostic (3.34e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.72e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavourable (3.75e-5)"	"unprognostic (3.80e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.05e-2)"	26.7	25.3	30.7	40.5	31.5	29.6	31.1	26.1	27.4	26.0	28.3	21.9	26.6	20.3	27.3	20.9	27.5	23.6	24.7	21.4	27.8	24.2	26.5	56.8	22.3	39.2	29.7	17.6	28.5	38.4	32.2	28.7	21.1	27.1	31.3	22.5	20.6	25.4	25.4	21.8	22.8	22.4	38.9	36.8	30.0	26.1	17.3	31.3	39.9	54.6	18.6	46.9	39.6	37.3	60.0	31.9	20.5	17.8	25.2	40.1	17.8	26.8	27.2	24.3	25.0	17.3	21.5	17.4	21.3	25.0	25.2	28.2	15.5	22.5	65.9	24.3	24.4	20.7	30.7	19.5	36.8	37.7	15.4	49.8	13.3	22.9	54.3	19.5	21.5	15.4	52.8	23.7	104.8	21.5	31.6	57.3	22.9	12.7	40.4	13.7	39.6	8.1	31.3	8.5	11.8	34.8	18.3	22.8	16.6	17.6	15.5	57.2	22.4	21.9	19.0	18.6	17.1	20.8	19.1	35.4	22.1	44.7	32.7	22.4	26.1	18.1	17.8	20.5	30.1	16.8	28.6	60.0	31.4	27.7	22.1	44.4	28.0	29.1	6.4	25.2	15.6	31.9	40.1	17.8	30.7	31.5	26.1	27.4	27.8	24.2	29.7	17.6	27.1	31.3
TCF12	"bHLHb20, HEB, HsT17266, HTF4"	ENSG00000140262	"Transcription factor 12"	Q99081	15	56918623-57299281	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Craniosynostosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 89.4"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004432, HPA065827"	Approved		Supported	"Nucleoplasm,Nuclear speckles"				"Nucleoplasm, Nuclear speckles"		"CAB004432: AB_671267, HPA065827: "	"unprognostic (1.19e-1)"	"unprognostic (1.11e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.65e-1)"	"unprognostic (2.07e-3)"	"unprognostic (1.11e-1)"	"unprognostic (6.63e-2)"	"unprognostic (1.85e-1)"	"prognostic unfavourable (8.89e-4)"	"unprognostic (7.83e-2)"	"unprognostic (7.26e-3)"	"unprognostic (5.57e-3)"	"prognostic unfavourable (5.24e-5)"	"unprognostic (2.03e-1)"	"unprognostic (2.93e-1)"	"unprognostic (3.15e-2)"	"unprognostic (1.41e-1)"	20.9	14.3	24.9	12.6	37.5	10.9	18.4	32.7	41.8	48.2	16.5	33.6	14.0	16.0	28.1	15.0	14.8	28.2	21.4	15.7	28.4	16.4	17.0	14.4	17.3	13.7	33.9	15.3	26.2	12.5	29.2	15.7	19.1	27.9	26.3	17.9	14.7	20.1	17.5	18.1	16.0	15.8	25.8	25.3	13.6	17.3	14.7	41.3	89.4	17.0	9.6	15.8	23.3	21.2	11.8	15.9	16.0	19.3	12.2	17.6	10.2	6.5	12.3	54.2	17.5	24.7	21.7	9.5	13.5	23.8	12.0	16.0	8.0	5.3	9.0	11.1	20.4	7.9	21.2	9.7	15.4	11.8	7.9	18.1	13.4	9.5	17.1	11.3	9.5	19.1	17.6	11.0	29.2	21.4	20.2	11.4	16.3	2.2	26.7	6.3	14.6	5.3	36.6	63.0	8.4	16.5	12.2	11.1	32.1	14.6	5.3	13.1	8.2	22.3	16.5	19.4	14.8	8.2	19.7	6.5	11.6	15.0	10.8	22.1	23.1	16.0	11.2	8.7	15.0	14.3	12.4	10.8	12.2	13.6	15.9	11.8	14.1	12.7	1.3	12.2	19.3	6.6	17.6	10.2	24.9	37.5	32.7	26.9	28.4	16.4	33.9	15.3	27.9	41.3
TCF3	"bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR"	ENSG00000071564	"Transcription factor 3"	P15923	19	1609290-1652605	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 95.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018351, HPA049808, HPA062476"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB018351: AB_675504, HPA049808: , HPA062476: "	"unprognostic (8.82e-2)"	"unprognostic (4.74e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.91e-2)"	"unprognostic (8.25e-3)"	"prognostic unfavourable (2.46e-4)"	"unprognostic (2.07e-2)"	"unprognostic (7.99e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.42e-1)"	"unprognostic (9.29e-3)"	"prognostic unfavourable (1.53e-4)"	"unprognostic (4.87e-3)"	"unprognostic (1.88e-1)"	"unprognostic (3.07e-1)"	"unprognostic (8.05e-2)"	13.0	8.8	12.8	31.6	9.8	33.2	17.4	8.3	11.9	15.5	16.2	11.9	9.4	18.1	16.6	11.3	16.7	12.1	19.0	9.4	11.2	6.2	11.9	8.9	13.2	42.0	10.7	6.0	18.2	13.5	6.3	13.9	10.8	11.0	17.1	9.7	12.4	13.6	6.9	11.2	16.7	23.0	8.8	10.4	33.1	14.9	36.0	11.2	63.2	15.9	11.6	38.0	15.2	13.9	11.3	12.1	2.9	2.8	2.3	4.2	1.6	15.7	8.1	22.3	19.9	3.2	8.5	9.9	9.8	7.7	11.2	10.0	15.9	12.4	75.4	11.1	8.0	16.3	13.6	10.6	6.6	45.6	9.0	7.1	10.2	17.4	7.3	17.3	10.0	5.4	12.3	8.8	6.8	13.5	29.1	26.1	7.1	27.7	47.8	16.9	30.9	8.5	75.0	10.2	17.0	7.5	13.8	21.2	29.8	9.2	9.2	11.3	11.6	30.9	16.2	14.8	17.5	18.2	16.6	63.8	31.1	95.0	9.6	22.1	13.2	2.9	1.3	0.9	3.5	1.4	3.7	10.8	2.2	3.2	2.7	11.3	3.2	4.2	0.4	2.3	2.8	12.1	2.1	1.6	12.8	9.8	8.3	11.9	11.2	6.2	10.7	6.0	11.0	11.2
TCF7	TCF-1	ENSG00000081059	"Transcription factor 7"	P36402	5	134114711-134151865	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"lymphoid tissue: 326.1"	"Cell line enriched"	"Detected in many"	15	"MOLT-4: 166.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"MAIT T-cell: 10.3;memory CD4 T-cell: 17.8;memory CD8 T-cell: 10.4;naive CD4 T-cell: 35.8;naive CD8 T-cell: 21.8;NK-cell: 14.2"	"Group enriched"	"Detected in many"	19	"NK-cells: 14.2;T-cells: 35.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019403, HPA058863, HPA070505"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB019403: AB_2199302, HPA058863: , HPA070505: "	"unprognostic (3.63e-3)"	"unprognostic (1.98e-3)"	"unprognostic (1.03e-1)"	"unprognostic (5.08e-3)"	"unprognostic (1.70e-1)"	"unprognostic (6.74e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.38e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.65e-1)"	"unprognostic (5.35e-2)"	"unprognostic (2.32e-1)"	"unprognostic (3.04e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.90e-1)"	"unprognostic (4.10e-2)"	1.8	3.6	1.3	21.8	1.5	5.2	3.1	0.9	1.2	2.1	3.3	2.5	2.2	5.6	1.4	16.3	2.7	16.1	2.6	1.6	1.5	1.2	2.7	3.7	4.0	41.8	1.3	1.0	2.5	7.2	0.2	6.1	1.4	4.7	2.9	2.3	3.6	7.9	1.8	0.9	2.9	15.1	0.9	3.3	14.4	3.7	2.4	1.1	326.1	4.4	2.2	32.5	3.3	1.5	1.2	0.1	1.0	0.1	14.2	35.8	6.9	0.0	1.0	1.1	3.8	0.5	2.1	1.5	0.3	0.5	0.1	0.1	7.9	2.5	0.0	1.9	1.7	0.1	1.7	0.4	0.0	0.3	1.6	0.0	1.0	5.9	0.0	0.0	0.2	0.1	0.0	1.6	0.0	0.2	1.0	0.0	0.1	0.0	166.9	0.1	1.2	1.4	0.2	0.0	0.1	0.4	0.1	0.4	3.3	0.8	0.2	0.2	0.2	0.9	0.2	10.8	0.0	4.9	0.3	0.1	0.0	0.0	5.7	0.0	0.5	0.7	0.1	1.0	4.4	0.0	10.3	1.2	17.8	10.4	0.0	0.4	35.8	21.8	0.7	14.2	0.0	0.1	2.1	6.9	1.3	1.5	0.9	1.2	1.5	1.2	1.3	1.0	4.7	1.1
TCF7L2	"TCF-4, TCF4"	ENSG00000148737	"Transcription factor 7 like 2"	Q9NQB0	10	112950250-113167678	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"intermediate monocyte: 12.1;non-classical monocyte: 33.1"	"Lineage enriched"	"Detected in many"	13	"monocytes: 33.1"	"Group enriched"	"Detected in many"	8	"midbrain: 84.5;thalamus: 98.3"	"Group enriched"	"Detected in all"	5	"midbrain: 190.1;pons and medulla: 104.8;thalamus: 169.1"	"CAB013535, HPA038800"	Supported		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"				Nucleoplasm	"Nuclear bodies, Cytosol"	"CAB013535: AB_2533167, HPA038800: "	"unprognostic (1.79e-2)"	"unprognostic (3.36e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.31e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.72e-1)"	"unprognostic (2.09e-1)"	"unprognostic (9.84e-2)"	"unprognostic (5.09e-1)"	"unprognostic (7.10e-2)"	"unprognostic (6.10e-3)"	"unprognostic (3.46e-2)"	"unprognostic (7.25e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.64e-1)"	"unprognostic (7.36e-3)"	27.4	10.3	8.7	18.7	10.0	7.3	46.4	5.4	10.3	27.4	34.2	15.4	28.1	21.0	26.6	14.9	12.6	18.2	15.3	13.5	8.1	17.9	10.2	22.9	26.9	13.9	8.5	9.0	25.6	13.9	16.5	17.9	24.0	10.2	14.4	23.7	13.9	14.9	52.8	13.7	17.6	40.4	18.0	13.9	27.3	24.0	10.6	10.1	6.6	14.3	9.3	7.0	21.5	16.3	0.0	1.7	2.5	33.1	0.0	0.6	1.1	7.0	18.5	20.3	19.6	10.6	7.1	24.2	5.0	9.8	3.5	4.3	12.2	21.5	0.0	5.7	9.4	5.0	6.9	8.7	4.5	0.8	6.4	5.0	12.3	11.3	11.3	1.9	1.8	12.5	3.2	5.5	9.3	5.9	5.1	0.3	4.1	13.8	3.1	1.2	14.6	10.7	8.9	14.9	3.2	7.6	9.9	0.4	6.2	7.6	7.6	8.1	4.9	1.0	13.6	3.3	9.6	8.4	10.3	1.3	0.1	0.1	3.3	4.2	7.4	0.1	1.8	0.1	0.6	12.1	0.4	0.0	0.1	0.5	1.7	0.0	0.1	0.3	2.5	0.0	33.1	0.0	0.0	1.1	8.7	10.0	5.4	10.3	8.1	17.9	8.5	9.0	10.2	10.1
TCL1A	TCL1	ENSG00000100721	"T cell leukemia/lymphoma 1A"	P56279	14	95709967-95714196	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	12	"blood: 179.4;lymphoid tissue: 63.7"	"Group enriched"	"Detected in some"	157	"Daudi: 69.4;REH: 90.3;U-698: 92.2"	"Cancer enriched"	"Detected in many"	18	"testis cancer: 64.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	381	"memory B-cell: 45.6;naive B-cell: 179.4;plasmacytoid DC: 79.8"	"Group enriched"	"Detected in many"	487	"B-cells: 179.4;dendritic cells: 79.8"					"Not detected"	"Not detected"			"CAB004045, HPA016604"	Enhanced		Enhanced	"Nucleoplasm,Endoplasmic reticulum,Cytosol"				"Endoplasmic reticulum, Cytosol"	Nucleoplasm	"CAB004045: AB_2179419, HPA016604: AB_1857859"	"unprognostic (1.27e-3)"	"unprognostic (3.12e-4)"	"unprognostic (2.61e-4)"	"unprognostic (2.01e-2)"	"unprognostic (1.27e-1)"	"unprognostic (4.75e-4)"	"unprognostic (7.70e-2)"	"unprognostic (9.67e-3)"	"unprognostic (1.03e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.14e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.94e-1)"	"unprognostic (2.06e-1)"	"unprognostic (4.55e-1)"	0.4	0.2	0.2	53.4	0.2	4.8	0.3	0.2	0.2	0.2	0.9	0.0	0.2	0.0	0.3	0.0	0.8	0.3	0.6	0.3	0.2	0.2	1.1	0.4	3.2	63.7	0.2	0.0	0.3	0.2	0.0	0.2	0.6	0.0	0.4	0.2	0.1	2.9	0.0	0.2	0.2	10.4	0.1	0.2	33.5	0.5	5.3	0.0	4.7	0.8	1.2	53.6	3.6	0.3	179.4	79.8	0.2	0.1	0.0	0.1	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	69.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	90.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.5	92.2	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.1	45.6	0.0	0.0	0.1	179.4	0.1	0.0	0.2	0.0	0.1	79.8	0.0	6.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0
TCP11L2	MGC40368	ENSG00000166046	"T-complex 11 like 2"	Q8N4U5	12	106301929-106347015	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 32.1"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 32.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039483, HPA042188"	Uncertain		Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA039483: AB_10795291, HPA042188: AB_10794415"	"unprognostic (1.41e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.24e-1)"	"unprognostic (8.15e-2)"	"unprognostic (1.97e-1)"	"prognostic favourable (9.52e-4)"	"unprognostic (3.87e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.11e-1)"	"unprognostic (9.05e-3)"	"unprognostic (5.44e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.22e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.67e-1)"	9.1	12.0	8.1	6.2	18.2	22.3	9.0	10.4	13.0	9.7	8.6	31.5	3.3	6.2	10.3	7.1	20.1	11.6	8.1	18.9	8.3	5.8	6.1	5.6	14.4	12.9	22.2	9.4	9.7	8.6	11.1	7.2	12.3	16.2	7.5	7.9	9.5	15.9	5.9	18.0	14.0	10.3	10.2	14.6	10.2	10.2	8.7	18.4	16.4	12.2	6.3	14.0	11.3	11.8	6.2	0.8	32.1	3.2	1.9	6.3	1.7	2.6	6.6	1.0	1.9	9.2	10.7	4.2	1.7	8.6	1.1	2.8	1.0	3.6	0.9	2.7	6.7	12.6	0.8	3.7	2.0	1.4	2.8	0.5	2.5	4.0	9.0	0.3	1.8	13.4	8.7	1.3	6.5	6.2	1.6	1.3	1.5	1.9	1.6	1.4	1.2	4.2	0.8	0.2	3.0	8.7	12.5	4.2	3.1	4.5	1.4	5.2	3.9	0.3	4.7	1.6	1.4	2.4	0.4	8.4	0.6	3.2	4.6	0.2	0.8	10.8	3.2	4.9	2.4	1.4	1.8	6.2	4.9	2.7	0.8	5.7	6.3	4.1	32.1	1.9	2.2	0.6	5.6	1.7	8.1	18.2	10.4	13.0	8.3	5.8	22.2	9.4	16.2	18.4
TDRD10	DKFZp434M202	ENSG00000163239	"Tudor domain containing 10"	Q5VZ19	1	154502219-154548147	"Cancer-related genes, Predicted intracellular proteins"		RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"testis: 48.4"	"Group enriched"	"Detected in some"	10	"EFO-21: 2.2;HUVEC TERT2: 7.5;RPMI-8226: 2.1;TIME: 4.0"	"Cancer enhanced"	"Detected in many"		"testis cancer: 5.9"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in all"			HPA054327			Approved	Vesicles				Vesicles		"HPA054327: "	"unprognostic (1.30e-1)"	"unprognostic (6.33e-2)"	"unprognostic (1.78e-1)"	"unprognostic (5.33e-3)"	"unprognostic (9.69e-3)"	"unprognostic (5.80e-3)"	"unprognostic (2.99e-1)"	"unprognostic (5.97e-3)"	"unprognostic (2.44e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.00e-3)"	"unprognostic (1.61e-1)"	"unprognostic (1.34e-3)"	"unprognostic (1.15e-2)"	"unprognostic (1.13e-1)"	"prognostic favourable (8.04e-5)"	"unprognostic (1.62e-1)"	4.1	1.4	0.7	1.1	0.9	0.0	2.6	0.7	1.4	1.3	0.8	0.9	1.4	0.5	2.1	2.0	1.0	2.1	1.2	2.3	0.7	0.0	1.0	1.5	3.3	1.6	0.9	1.2	4.6	0.7	0.8	0.8	1.4	1.2	1.1	1.1	0.7	0.7	1.0	1.1	0.7	1.0	1.4	1.2	3.5	0.5	48.4	0.8	0.7	4.9	1.5	1.0	1.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.1	4.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.9	0.7	1.4	0.7	0.0	0.9	1.2	1.2	0.8
TDRD6	"bA446F17.4, CT41.2, NY-CO-45, SPATA36"	ENSG00000180113	"Tudor domain containing 6"	O60522	6	46687875-46704319	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Spermatogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"testis: 37.9"	"Cell line enhanced"	"Detected in some"		"HEK 293: 1.6;HeLa: 3.9;hTCEpi: 2.2;PC-3: 3.3;SCLC-21H: 1.6"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 2.1"	"Region enriched"	"Detected in many"	6	"cerebellum: 8.2"	"Cell type enhanced"	"Detected in some"		"classical monocyte: 2.4;intermediate monocyte: 1.4"	"Lineage enhanced"	"Detected in single"		"monocytes: 2.4"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA075923	Enhanced									"HPA075923: "	"unprognostic (2.01e-1)"	"unprognostic (7.41e-3)"	"unprognostic (7.25e-3)"	"unprognostic (3.88e-2)"	"unprognostic (3.54e-1)"	"unprognostic (4.10e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.32e-2)"	"unprognostic (7.97e-2)"	"unprognostic (2.50e-1)"	"unprognostic (2.20e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.79e-1)"	"unprognostic (2.86e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.16e-2)"	"unprognostic (4.38e-3)"	0.7	1.4	0.7	2.6	1.3	0.0	0.7	8.2	1.3	0.7	0.7	0.7	0.7	0.3	0.7	2.9	0.7	0.3	1.7	0.7	1.0	0.8	0.7	1.3	0.7	3.0	1.1	0.7	0.7	0.7	0.4	1.8	1.1	0.7	1.6	0.0	0.9	0.9	0.7	1.5	2.9	0.7	0.7	0.9	1.9	0.3	37.9	0.7	0.7	5.2	0.7	0.7	1.6	0.7	0.0	0.7	0.1	2.4	0.0	0.0	0.4	0.0	0.0	0.2	1.5	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	1.0	0.4	0.0	0.0	0.0	1.6	0.0	3.9	0.0	0.0	0.0	0.0	0.2	2.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	3.3	0.0	0.0	0.0	0.9	0.6	1.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.3	0.6	0.1	0.0	1.1	0.0	0.4	0.0	0.0	0.7	0.0	2.4	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.4	0.7	1.3	8.2	0.9	1.0	0.8	1.1	0.7	0.7	0.7
TEK	"CD202b, TIE-2, TIE2, VMCM, VMCM1"	ENSG00000120156	"TEK receptor tyrosine kinase"	Q02763	9	27109141-27230175	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"HUVEC TERT2: 35.8;NTERA-2: 17.8;TIME: 38.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010359, HPA073265"	Approved		Supported	"Plasma membrane,Centriolar satellite"	"Secreted to blood"	8300000	8300000	"Plasma membrane"	"Centriolar satellite"	"CAB010359: AB_2203226, HPA073265: "	"unprognostic (2.24e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.26e-3)"	"prognostic favourable (2.31e-5)"	"unprognostic (7.48e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.72e-1)"	"prognostic favourable (7.81e-4)"	"unprognostic (7.50e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.83e-1)"	"unprognostic (5.24e-3)"	28.6	7.8	8.1	4.6	5.9	0.4	17.9	3.4	5.4	10.8	4.7	4.6	3.4	3.2	14.5	5.3	6.7	5.9	9.1	13.0	7.1	6.1	25.4	8.7	27.8	2.9	6.9	3.4	6.1	4.5	3.5	4.0	36.3	6.9	5.4	4.7	12.4	3.4	5.5	7.8	3.0	5.3	10.6	5.3	23.4	4.0	3.7	3.5	0.3	9.7	8.4	2.4	6.4	12.4	0.0	0.1	2.2	0.6	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.2	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	2.3	1.0	0.0	0.6	0.0	0.0	0.7	0.0	0.8	0.3	35.8	0.0	0.0	0.3	0.0	0.0	0.0	17.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	38.8	0.0	0.2	3.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	8.1	5.9	3.4	5.4	7.1	6.1	6.9	3.4	6.9	3.5
TERT	"EST2, hEST2, TCS1, TP2, TRT"	ENSG00000164362	"Telomerase reverse transcriptase"	O14746	5	1253147-1295069	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"DNA-binding, Nucleotidyltransferase, Ribonucleoprotein, RNA-directed DNA polymerase, Transferase"	"Cancer-related genes, Disease mutation, Dyskeratosis congenita"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"bone marrow: 3.4;lymphoid tissue: 12.0;testis: 5.0"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 61.2;fHDF/TERT166: 58.1;HBEC3-KT: 118.1;hTEC/SVTERT24-B: 74.6;LHCN-M2: 33.7;TIME: 96.1"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA054641, HPA065897"	Supported		Supported	"Nucleoplasm,Nuclear speckles,Cytosol"				Nucleoplasm	"Nuclear speckles, Cytosol"	"HPA054641: , HPA065897: "	"unprognostic (1.21e-2)"	"unprognostic (2.88e-2)"	"unprognostic (1.24e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.43e-3)"	"unprognostic (6.42e-3)"	"unprognostic (1.85e-2)"	"unprognostic (2.21e-1)"	"unprognostic (6.91e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.59e-1)"	"unprognostic (9.16e-4)"	"unprognostic (8.84e-11)"	"unprognostic (1.92e-1)"	"unprognostic (2.15e-1)"		"unprognostic (3.35e-1)"	0.0	0.0	0.0	7.1	0.9	3.4	0.0	0.0	0.2	0.1	1.1	0.0	0.0	1.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	2.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.0	1.0	0.4	5.0	0.0	12.0	0.0	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	30.6	61.2	0.5	0.0	23.3	4.2	7.9	0.1	0.1	0.7	0.0	58.1	0.0	0.2	118.1	5.0	0.0	0.3	0.0	0.0	0.1	0.0	0.3	0.2	0.0	3.0	74.6	0.8	0.2	0.6	0.1	33.7	0.0	0.2	1.6	0.4	0.2	0.8	0.0	0.8	3.4	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.2	96.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0
TET1	"bA119F7.1, CXXC6, KIAA1676, LCX"	ENSG00000138336	"Tet methylcytosine dioxygenase 1"	Q8NFU7	10	68560656-68694482	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 15.1;HAP1: 17.2;K-562: 9.6;NTERA-2: 10.1"	"Cancer enriched"	"Detected in some"	15	"testis cancer: 10.4"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019032, HPA057273"			Supported	"Nucleoplasm,Nuclear membrane"				Nucleoplasm	"Nuclear membrane"	"HPA019032: AB_1847363, HPA057273: "	"unprognostic (1.60e-1)"	"unprognostic (8.30e-2)"	"unprognostic (9.85e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.27e-1)"	"unprognostic (8.15e-2)"	"unprognostic (3.60e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.00e-1)"	"unprognostic (7.90e-3)"	"unprognostic (1.83e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.18e-3)"	"unprognostic (2.88e-4)"	"unprognostic (4.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (9.52e-3)"	4.4	1.6	3.3	4.3	2.6	1.6	3.1	4.4	4.3	5.1	2.4	5.8	3.2	1.2	6.0	3.4	2.4	2.9	3.5	2.4	3.5	2.3	1.8	1.5	1.6	1.7	2.5	2.6	6.1	1.6	7.4	2.2	5.8	2.9	3.2	2.0	8.1	15.9	4.8	4.0	2.2	1.8	6.5	3.6	1.7	2.2	1.4	5.9	1.2	3.2	3.2	1.8	5.1	5.4	1.3	1.1	1.0	0.0	0.9	2.3	0.2	0.6	0.7	6.8	7.7	0.7	0.6	15.1	0.3	0.8	0.6	1.1	4.6	0.2	0.0	0.2	0.7	0.0	17.2	0.0	0.7	0.2	2.7	1.8	0.0	4.0	1.0	1.5	0.9	0.9	0.1	0.4	0.0	0.1	9.6	1.2	0.6	0.5	2.7	1.2	10.1	0.9	2.6	2.2	0.2	0.3	0.7	1.9	3.0	0.3	0.4	1.4	0.9	1.2	0.2	0.6	1.4	0.0	0.5	0.5	0.5	2.7	0.1	0.0	0.1	0.0	0.0	1.0	1.5	0.0	2.0	1.3	0.8	1.3	0.2	0.5	1.4	1.1	0.0	0.9	0.0	1.1	2.3	0.2	3.3	2.6	4.4	2.6	3.5	2.3	2.5	2.6	2.9	5.9
TET2	"FLJ20032, KIAA1546"	ENSG00000168769	"Tet methylcytosine dioxygenase 2"	Q6N021	4	105145875-105279816	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle"	"Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 29.0"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 29.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043135	Supported		Approved	Nucleoplasm				Nucleoplasm		"HPA043135: AB_10794177"	"unprognostic (6.83e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.69e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.15e-2)"	"unprognostic (5.88e-2)"	"unprognostic (6.12e-2)"	"unprognostic (1.19e-3)"	"unprognostic (1.15e-2)"	"unprognostic (1.57e-2)"	"unprognostic (5.77e-2)"	"unprognostic (7.29e-2)"	"unprognostic (2.70e-3)"	"unprognostic (6.10e-2)"	"unprognostic (1.89e-1)"	"unprognostic (9.15e-2)"	"unprognostic (7.84e-2)"	9.9	6.1	8.7	11.9	11.4	26.3	8.0	4.1	10.0	9.6	7.4	10.1	5.8	8.2	10.1	7.4	16.2	9.2	6.6	6.8	9.0	4.2	6.7	5.5	9.9	9.8	13.7	5.7	8.5	7.0	7.4	29.0	12.4	9.1	6.5	8.0	4.7	13.5	8.2	9.8	16.0	10.2	7.8	15.5	12.9	6.8	3.2	14.6	9.3	7.2	6.9	8.7	9.8	12.3	2.8	5.1	29.0	7.0	2.6	2.1	1.4	4.7	3.1	10.4	10.6	1.9	4.3	4.3	3.4	4.6	4.9	4.8	3.1	6.4	0.5	3.9	4.3	4.6	10.1	6.0	5.6	6.2	2.7	6.6	5.9	1.1	5.3	15.1	11.1	3.6	8.1	4.7	6.1	6.5	7.1	12.5	4.2	3.6	2.5	4.1	2.3	1.9	7.8	5.2	0.9	4.5	10.0	7.4	6.1	3.8	9.8	0.6	4.4	10.9	8.4	7.5	6.8	2.1	5.8	8.4	6.0	6.3	4.6	3.7	7.3	10.8	7.0	7.2	2.1	5.5	0.8	2.6	1.2	1.2	5.1	2.8	1.0	1.6	29.0	2.6	6.4	4.5	1.5	1.4	8.7	11.4	4.1	10.0	9.0	4.2	13.7	5.7	9.1	14.6
TF	"PRO1557, PRO2086"	ENSG00000091513	Transferrin	P02787	3	133745956-133796640	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Ion transport, Iron transport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"liver: 711.5"	"Cell line enriched"	"Detected in some"	48	"Hep G2: 129.1"	"Cancer enriched"	"Detected in many"	42	"liver cancer: 783.0"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			"HPA001527, HPA005692, CAB009538"	Enhanced				"Secreted to blood"	120000000000	120000000000			"CAB009538: AB_793365, HPA001527: AB_1080357, HPA005692: AB_1080354"	"prognostic favourable (4.05e-4)"	"unprognostic (2.45e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.50e-1)"	"unprognostic (8.99e-2)"	"unprognostic (5.18e-2)"	"unprognostic (6.63e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.82e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.37e-1)"	"unprognostic (7.60e-2)"	"prognostic unfavourable (2.35e-13)"	"unprognostic (2.17e-3)"	"unprognostic (5.49e-2)"	"unprognostic (3.47e-3)"	"unprognostic (9.70e-2)"	7.8	1.3	6.7	1.2	26.7	1.3	1.9	3.7	20.4	1.4	1.3	57.2	0.0	1.2	1.3	1.3	1.8	1.3	1.3	2.4	11.3	7.4	1.5	711.5	1.3	1.3	50.8	12.3	1.4	1.6	1.4	0.8	1.3	40.2	1.5	1.3	14.0	4.0	1.3	1.3	1.3	1.2	1.3	46.9	1.3	1.3	2.4	39.9	0.0	1.4	0.0	1.4	1.3	0.6	1.1	1.0	2.6	1.1	0.9	0.8	0.4	0.3	0.2	0.3	0.2	0.9	0.6	0.1	0.3	0.3	0.1	0.1	0.5	0.2	0.2	0.2	0.3	0.3	0.2	0.3	0.2	0.1	0.1	2.7	0.4	129.1	0.2	0.7	0.4	0.4	0.6	0.1	0.2	0.3	1.0	0.3	0.4	0.2	0.1	0.2	0.2	0.3	0.2	0.5	0.1	0.1	0.5	0.3	0.2	0.3	0.4	1.0	0.3	0.2	0.4	0.4	0.2	0.2	0.1	0.3	0.4	0.2	0.3	0.2	0.2	2.6	1.1	0.7	0.6	0.7	0.6	0.6	0.6	0.6	0.6	1.1	0.8	0.8	2.4	0.9	0.7	1.0	0.4	0.4	6.7	26.7	3.7	19.6	11.3	7.4	50.8	12.3	40.2	39.9
TFAP2B	AP2-B	ENSG00000008196	"Transcription factor AP-2 beta"	Q92481	6	50818723-50847613	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"epididymis: 65.5"	"Group enriched"	"Detected in some"	4	"AF22: 31.7;SH-SY5Y: 59.0"	"Cancer enriched"	"Detected in some"	8	"breast cancer: 12.1"	"Group enriched"	"Detected in some"	41	"cerebellum: 4.7;pons and medulla: 6.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"cerebellum: 11.2"	"Low region specificity"	"Detected in many"			"HPA034683, HPA062942"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"HPA034683: AB_10670966, HPA062942: "	"unprognostic (2.02e-1)"	"unprognostic (2.29e-2)"		"unprognostic (4.27e-2)"	"unprognostic (5.88e-4)"	"unprognostic (9.76e-2)"		"unprognostic (2.10e-1)"	"unprognostic (1.00e-1)"			"unprognostic (4.57e-1)"	"unprognostic (6.58e-6)"	"unprognostic (1.13e-2)"	"unprognostic (1.88e-1)"		"unprognostic (7.17e-3)"	0.2	3.0	0.0	0.0	0.0	0.0	9.4	4.7	0.0	0.2	0.2	0.0	8.8	0.0	0.0	65.5	5.8	0.0	0.0	0.1	0.0	0.1	6.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.2	6.3	0.1	0.0	12.2	7.0	0.6	0.0	6.3	0.0	0.0	1.1	0.0	0.0	1.5	0.0	0.0	0.0	0.3	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.2	0.0	0.0	59.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.1	0.1	0.0	6.3	0.0
TFDP1	"DILC, Dp-1, DP1, DRTF1"	ENSG00000198176	"Transcription factor Dp-1"	Q14186	13	113584721-113641470	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"basophil: 20.4"	"Low lineage specificity"	"Detected in all"											"CAB033605, HPA044754, HPA068909"	Enhanced		Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB033605: AB_783105, HPA044754: , HPA068909: "	"unprognostic (4.28e-2)"	"unprognostic (9.50e-3)"	"unprognostic (1.77e-2)"	"unprognostic (1.09e-1)"	"unprognostic (7.01e-2)"	"unprognostic (2.10e-2)"	"prognostic unfavourable (1.03e-4)"	"unprognostic (5.50e-3)"	"unprognostic (1.68e-2)"	"unprognostic (3.96e-1)"	"unprognostic (2.04e-2)"	"unprognostic (2.43e-2)"	"prognostic favourable (7.57e-4)"	"prognostic favourable (6.17e-4)"	"unprognostic (2.30e-1)"	"unprognostic (1.34e-1)"	"unprognostic (9.32e-2)"	16.0	13.3	20.1	28.0	21.1	71.6	16.4	24.4	22.4	19.3	19.6	16.3	28.6	16.0	16.8	20.5	36.2	18.0	27.0	26.3	19.0	16.8	17.9	20.9	16.5	32.5	18.0	12.7	14.4	26.7	9.9	16.3	21.8	15.2	16.0	23.0	20.2	18.9	24.2	26.9	22.3	21.3	18.4	23.5	25.6	16.4	37.5	10.3	38.8	21.7	32.7	34.4	18.5	20.8	3.6	4.7	20.4	4.0	1.6	5.4	2.0	62.0	15.3	19.8	16.8	26.9	24.0	22.5	35.0	31.8	45.5	42.1	31.8	29.2	57.9	11.7	33.5	29.9	34.3	31.1	44.7	39.4	39.9	33.6	25.0	19.9	16.9	84.3	29.7	19.8	28.0	28.8	16.8	30.5	27.6	15.6	40.4	21.3	37.0	32.8	18.2	19.7	25.3	17.6	33.1	17.3	23.8	51.2	15.1	15.7	43.2	10.5	29.7	68.0	21.2	14.8	23.6	31.3	38.5	13.3	16.3	59.7	33.0	52.3	25.0	20.4	2.3	3.6	2.6	3.0	2.9	3.6	3.5	3.1	4.7	2.6	5.4	2.7	3.1	1.6	4.0	2.4	4.2	2.0	20.1	21.1	24.4	22.4	19.0	16.8	18.0	12.7	15.2	10.3
TFDP2	Dp-2	ENSG00000114126	"Transcription factor Dp-2"	Q14188	3	141944428-142149544	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 140.3"	"Cell line enhanced"	"Detected in all"		"MOLT-4: 80.4;REH: 42.8;U-698: 70.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018396, HPA070399"	Supported		Supported	"Nucleoplasm,Vesicles,Mitotic spindle"				Nucleoplasm	"Vesicles, Mitotic spindle"	"CAB018396: AB_2287284, HPA070399: "	"unprognostic (1.35e-2)"	"prognostic favourable (6.32e-4)"	"unprognostic (8.08e-3)"	"unprognostic (2.90e-2)"	"unprognostic (4.69e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.14e-3)"	"unprognostic (2.60e-3)"	"unprognostic (5.42e-2)"	"unprognostic (1.46e-1)"	"unprognostic (5.04e-2)"	"unprognostic (2.04e-1)"	"prognostic favourable (9.84e-4)"	"unprognostic (6.04e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.08e-1)"	8.4	8.4	6.1	6.3	8.7	20.7	9.3	9.9	8.6	8.9	11.1	6.5	6.5	10.4	9.9	8.6	8.3	7.2	11.6	12.0	7.5	4.9	14.3	9.5	6.8	5.3	6.0	5.0	11.6	8.8	10.4	19.4	13.5	8.0	9.9	6.6	8.8	7.9	6.9	14.5	8.0	14.6	11.8	8.5	5.3	8.6	51.9	5.4	140.3	10.6	4.8	6.4	9.7	8.0	9.3	16.5	24.6	4.5	18.0	14.7	5.7	6.3	2.9	12.3	9.8	4.1	4.5	27.1	3.2	3.7	5.1	8.3	3.7	6.3	22.5	15.0	3.6	3.8	3.1	6.1	7.2	9.0	5.6	27.1	4.4	4.9	4.0	8.1	9.6	4.2	4.3	5.6	5.4	3.5	10.1	1.2	8.8	4.8	80.4	3.1	9.9	4.0	42.8	8.5	5.2	5.9	3.3	5.4	5.0	10.8	4.0	5.5	9.3	4.2	2.3	4.9	4.5	3.9	4.0	4.2	3.8	70.5	3.9	2.2	2.3	24.6	2.1	22.3	14.7	3.4	5.7	6.6	6.7	7.6	4.8	9.3	10.1	11.8	2.4	18.0	4.5	16.5	6.1	5.7	6.1	8.7	9.9	8.6	7.5	4.9	6.0	5.0	8.0	5.4
TFE3	"bHLHe33, TFEA"	ENSG00000068323	"Transcription factor binding to IGHM enhancer 3"	P19532	X	49028726-49043486	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 10.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023881	Approved		Supported	Nucleoplasm,Cytosol				"Nucleoplasm, Cytosol"		"HPA023881: AB_1857931"	"unprognostic (2.68e-2)"	"unprognostic (2.89e-3)"	"unprognostic (2.40e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.71e-2)"	"unprognostic (1.81e-1)"	"prognostic unfavourable (6.03e-5)"	"unprognostic (2.40e-1)"	"unprognostic (1.26e-1)"	"unprognostic (4.32e-2)"	"unprognostic (5.41e-2)"	"unprognostic (1.16e-1)"	"prognostic unfavourable (2.19e-8)"	"unprognostic (1.93e-1)"	"unprognostic (8.77e-2)"	"unprognostic (4.19e-2)"	"unprognostic (6.25e-1)"	31.3	20.9	12.6	18.2	14.4	22.6	53.1	16.5	18.1	22.6	17.7	16.6	30.0	9.9	22.8	21.9	20.5	18.8	16.4	15.1	11.3	11.8	21.6	14.1	22.8	10.3	13.2	9.4	24.4	15.9	16.5	16.3	22.0	15.9	21.2	10.4	15.7	12.6	30.6	13.6	14.1	13.5	21.2	14.8	23.0	14.7	10.4	15.2	4.2	21.7	10.8	10.5	28.6	20.5	1.2	1.9	10.5	4.4	0.4	1.4	1.6	11.9	15.3	5.1	14.8	16.7	15.1	5.1	15.7	18.2	16.1	13.8	9.4	9.5	4.5	6.7	23.1	9.8	9.7	14.2	13.0	9.8	5.2	4.1	11.4	8.7	22.5	4.3	10.2	13.1	9.2	26.3	18.9	7.7	7.9	19.7	13.7	7.0	2.8	4.0	13.9	13.8	4.3	8.9	10.2	10.2	5.5	4.9	4.9	16.8	7.2	5.5	10.3	3.9	16.3	17.6	18.9	17.6	8.6	12.1	11.4	3.7	21.0	5.3	12.0	0.0	3.5	1.6	0.5	4.3	0.9	0.6	0.9	0.5	1.9	1.2	0.6	0.4	10.5	0.4	4.4	0.4	1.4	1.6	12.6	14.4	16.5	14.9	11.3	11.8	13.2	9.4	15.9	15.2
TFEB	"bHLHe35, TCFEB"	ENSG00000112561	"Transcription factor EB"	P19484	6	41683978-41736259	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Autophagy, Immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 30.9;Daudi: 19.6;HDLM-2: 17.9;U-698: 28.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 29.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049532			Supported	Nucleoplasm				Nucleoplasm		"HPA049532: "	"unprognostic (3.63e-3)"	"unprognostic (1.51e-3)"	"unprognostic (1.75e-2)"	"unprognostic (4.48e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.64e-1)"	"unprognostic (4.22e-3)"	"unprognostic (1.39e-2)"	"unprognostic (4.13e-2)"	"prognostic favourable (4.77e-4)"	"unprognostic (2.12e-2)"	"prognostic favourable (1.06e-5)"	"unprognostic (1.44e-1)"	"unprognostic (3.51e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.31e-2)"	8.6	6.4	10.2	16.8	20.7	8.9	6.8	8.6	15.0	6.4	10.5	34.4	8.2	6.8	7.1	4.3	9.3	7.2	9.1	19.3	14.6	8.2	12.2	5.0	8.3	24.1	30.0	6.8	6.7	11.4	26.1	14.9	18.5	16.2	10.7	5.3	6.9	18.0	8.6	45.2	7.9	15.5	8.4	27.4	27.3	7.9	2.5	24.0	2.8	11.1	10.9	18.3	10.8	11.1	22.2	8.5	29.0	9.6	0.8	2.6	4.4	1.7	1.8	0.4	7.2	2.4	1.4	30.9	2.8	5.6	2.5	1.9	4.1	2.1	19.6	3.8	2.9	5.0	1.1	2.8	0.6	17.9	2.0	0.0	7.1	7.5	4.8	0.5	2.6	0.5	5.5	2.9	1.9	1.9	2.3	4.8	0.9	1.3	1.1	1.5	0.1	0.9	12.9	0.2	2.7	4.4	1.4	8.1	2.3	2.4	5.0	0.6	1.4	9.8	3.8	0.9	2.0	0.1	2.0	12.6	2.0	28.9	1.5	8.3	1.0	0.1	9.6	8.8	2.6	9.3	0.4	22.2	0.7	1.0	8.5	15.1	0.2	0.9	29.0	0.8	6.5	1.7	0.4	4.4	10.2	20.7	8.6	15.0	14.6	8.2	30.0	6.8	16.2	24.0
TFF1	"BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2"	ENSG00000160182	"Trefoil factor 1"	P04155	21	42362282-42366594	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	34	"gallbladder: 247.7;stomach 1: 375.3"	"Cell line enriched"	"Detected in some"	58	"MCF7: 484.6"	"Group enriched"	"Detected in many"	10	"breast cancer: 402.1;colorectal cancer: 268.3;pancreatic cancer: 805.7;stomach cancer: 744.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"CAB002170, HPA003425"	Enhanced				"Secreted to digestive system"	990000	990000			"CAB002170: AB_563985, HPA003425: AB_1848260"	"prognostic favourable (5.00e-4)"	"unprognostic (8.81e-3)"	"unprognostic (9.82e-2)"	"prognostic favourable (5.67e-4)"		"unprognostic (2.42e-1)"	"unprognostic (1.72e-3)"	"unprognostic (8.14e-2)"		"unprognostic (2.45e-1)"	"unprognostic (1.52e-1)"	"unprognostic (6.62e-2)"		"unprognostic (1.01e-1)"	"unprognostic (1.19e-1)"	"unprognostic (7.72e-3)"	"unprognostic (1.07e-1)"	0.1	0.0	0.1	1.0	0.2	0.0	3.5	0.1	0.1	0.5	4.9	1.4	0.1	1.4	0.1	0.1	1.1	0.1	247.7	0.1	0.1	0.0	0.1	0.3	0.5	0.1	0.1	0.1	0.1	0.9	0.0	0.1	0.1	0.1	1.9	4.7	0.1	5.0	0.2	0.1	0.0	5.6	0.1	0.1	0.1	375.3	0.1	0.1	0.1	0.2	1.1	9.2	1.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	484.6	0.1	0.0	0.2	8.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
TFF2	SML1	ENSG00000160181	"Trefoil factor 2"	Q03403	21	42346357-42351128	"Cancer-related genes, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"gallbladder: 361.8;stomach 1: 332.4"	"Group enriched"	"Detected in some"	15	"CAPAN-2: 14.8;PC-3: 53.3"	"Group enriched"	"Detected in many"	11	"pancreatic cancer: 320.9;stomach cancer: 244.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB025834, HPA036705"	Enhanced				"Secreted to digestive system"	670000	670000			"CAB025834: , HPA036705: "	"unprognostic (3.95e-2)"	"unprognostic (9.87e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.30e-1)"			"prognostic unfavourable (1.99e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.33e-1)"	"unprognostic (4.89e-2)"	"unprognostic (5.55e-2)"		"unprognostic (1.27e-9)"	"unprognostic (1.99e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.26e-3)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.5	0.1	62.9	0.1	0.1	0.5	0.0	361.8	0.2	0.1	0.0	0.1	0.5	0.1	0.1	0.1	0.1	0.1	3.2	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.0	0.1	0.1	0.1	0.1	332.4	0.1	0.1	0.1	0.3	0.1	0.5	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.8	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.8	0.0	0.7	53.3	0.2	0.0	2.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
TFG	"FLJ36137, SPG57, TF6"	ENSG00000114354	"TRK-fused gene"	Q92734	3	100709331-100748966	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"ER-Golgi transport, Transport"		"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Neuropathy, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019473, HPA052206"	Approved		Supported	Vesicles,Cytosol				Vesicles	Cytosol	"HPA019473: AB_1857936, HPA052206: "	"unprognostic (1.14e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.46e-1)"	"unprognostic (4.14e-2)"	"prognostic unfavourable (5.48e-4)"	"unprognostic (3.31e-3)"	"unprognostic (1.42e-1)"	"unprognostic (3.73e-2)"	"prognostic unfavourable (1.50e-4)"	"unprognostic (4.58e-3)"	"unprognostic (3.72e-2)"	"unprognostic (2.82e-1)"	"unprognostic (8.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (8.45e-2)"	36.4	40.3	27.2	21.9	33.8	29.7	31.0	28.1	40.5	31.2	34.7	33.3	44.2	52.5	31.2	45.8	46.7	29.0	40.8	46.2	28.1	30.7	44.6	68.6	29.9	25.4	28.2	21.5	33.5	49.2	52.3	45.1	63.3	33.7	27.5	40.7	31.9	39.6	45.8	38.6	31.0	67.1	37.5	31.7	28.3	28.9	33.5	23.0	27.6	43.6	42.9	41.2	29.5	30.1	25.8	27.8	43.2	28.4	27.7	26.8	21.8	48.4	26.4	32.9	20.9	41.6	47.2	40.7	35.1	47.3	45.9	54.8	33.3	24.2	6.5	25.8	43.6	36.4	35.4	40.1	54.7	29.8	20.8	24.4	20.3	30.9	46.5	18.0	14.6	38.6	54.1	27.5	48.5	40.6	17.5	18.1	47.4	33.9	15.8	14.3	31.3	39.8	14.0	19.3	21.1	55.7	32.7	26.0	23.8	23.1	30.1	40.9	35.4	24.4	27.1	27.8	33.6	12.8	25.4	15.4	15.5	23.3	44.4	19.7	32.6	43.2	28.3	27.0	21.8	28.4	26.4	25.8	22.6	24.4	27.8	22.9	21.6	21.6	18.7	27.7	26.4	19.4	26.8	21.8	27.2	33.8	28.1	40.5	28.1	30.7	28.2	21.5	33.7	23.0
TFRC	"CD71, p90, TFR1"	ENSG00000072274	"Transferrin receptor"	P02786	3	196027183-196082189	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 110.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000153, HPA028598"	Enhanced		Supported	Endosomes,Lysosomes	"Secreted to blood"	14000000	14000000	"Endosomes, Lysosomes"		"CAB000153: AB_2533029, HPA028598: AB_10601599"	"unprognostic (2.95e-2)"	"prognostic unfavourable (3.67e-4)"	"unprognostic (2.55e-1)"	"unprognostic (1.48e-2)"	"unprognostic (6.75e-2)"	"unprognostic (7.88e-3)"	"prognostic unfavourable (1.15e-4)"	"unprognostic (6.92e-2)"	"unprognostic (3.30e-3)"	"unprognostic (4.35e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.14e-2)"	"unprognostic (3.63e-3)"	"unprognostic (3.65e-2)"	"unprognostic (1.19e-2)"	"prognostic unfavourable (2.96e-4)"	"unprognostic (2.62e-2)"	24.3	11.9	11.9	20.6	11.3	73.8	7.6	9.6	17.8	11.8	25.0	9.5	3.8	11.9	12.1	7.5	18.5	11.7	11.4	18.7	9.5	8.3	15.3	13.6	28.1	8.1	7.4	9.5	50.0	7.8	18.0	6.9	110.0	26.5	7.2	19.4	8.5	8.3	5.0	25.6	9.9	37.4	10.9	13.2	7.9	10.0	8.3	6.1	14.3	7.0	10.5	12.9	11.2	8.0	5.7	7.5	2.2	12.4	1.8	6.5	2.1	21.9	20.0	9.2	18.6	20.4	11.8	57.5	31.4	23.9	22.1	36.7	48.7	20.2	22.5	59.6	11.6	33.9	31.5	10.4	27.1	107.6	10.7	85.3	17.0	22.6	16.1	69.9	17.3	13.3	10.3	19.0	17.2	7.3	35.5	21.6	17.2	20.3	22.9	14.8	28.0	41.0	12.2	13.7	27.0	19.8	55.6	21.0	8.7	30.3	79.7	7.1	77.4	14.6	9.4	26.3	21.4	23.0	47.0	6.1	47.5	35.2	30.8	19.0	15.9	0.0	1.6	2.2	2.5	7.9	1.7	5.7	2.7	1.7	3.7	3.2	2.5	1.9	0.3	1.8	12.4	7.5	6.5	2.1	11.9	11.3	9.6	17.8	9.5	8.3	7.4	9.5	26.5	6.1
TG	"AITD3, TGN"	ENSG00000042832	Thyroglobulin	P01266	8	132866958-133134903	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Thyroid hormones biosynthesis"	"Hormone, Thyroid hormone"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	247	"thyroid gland: 994.3"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 3.5;HSkMC: 4.2;Karpas-707: 9.7;PC-3: 4.8;U-266/70: 3.5"	"Cancer enriched"	"Detected in some"	1672	"thyroid cancer: 3072.8"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.0"	"Low lineage specificity"	"Detected in many"			"Region enriched"	"Detected in single"	5	"cerebellum: 1.3"	"Low region specificity"	"Detected in many"			"CAB000077, HPA002740, CAB056155"	Enhanced				"Secreted in other tissues"	1000000	1000000			"CAB000077: , CAB056155: , HPA002740: AB_1080277"	"unprognostic (1.18e-1)"	"unprognostic (6.86e-2)"	"unprognostic (7.40e-4)"	"unprognostic (1.20e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.77e-2)"	"unprognostic (7.38e-2)"	"unprognostic (4.96e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.08e-2)"	"unprognostic (3.68e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.82e-1)"	"unprognostic (5.11e-2)"	"unprognostic (3.64e-2)"	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.4	0.6	0.1	0.0	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.3	0.3	0.1	0.1	0.1	0.1	0.0	0.1	3.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	994.3	0.1	0.1	0.1	0.1	0.3	1.2	4.0	0.6	0.0	0.9	0.5	0.0	0.0	0.0	0.0	0.9	1.4	0.6	0.0	1.7	0.0	0.1	0.9	0.0	0.0	0.2	0.4	0.5	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	4.2	2.9	1.1	0.0	0.0	0.0	9.7	0.2	0.0	0.1	0.0	0.0	4.8	0.1	0.0	0.3	0.2	2.8	0.3	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.2	0.6	0.0	3.5	2.9	0.0	0.2	1.2	0.0	0.0	0.6	0.7	0.2	0.0	0.9	0.0	0.4	0.0	0.0	0.3	0.3	0.2	4.0	0.0	0.3	1.2	0.4	0.5	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
TGFA		ENSG00000163235	"Transforming growth factor alpha"	P01135	2	70447280-70554193	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A-431: 23.9;CAPAN-2: 29.5;EFO-21: 15.2;HBEC3-KT: 25.7;RPTEC TERT1: 25.9;U-87 MG: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"basophil: 6.3;eosinophil: 14.0;neutrophil: 14.7"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 14.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042297	Approved		Approved	Vesicles	"Secreted to blood"			Vesicles		"HPA042297: AB_10793878"	"unprognostic (1.23e-1)"	"unprognostic (1.06e-3)"	"unprognostic (3.57e-3)"	"unprognostic (6.39e-2)"	"unprognostic (1.41e-1)"	"unprognostic (8.49e-3)"	"unprognostic (1.52e-1)"	"unprognostic (3.00e-3)"	"unprognostic (6.69e-2)"	"unprognostic (9.21e-2)"	"prognostic unfavourable (1.20e-5)"	"unprognostic (7.74e-2)"	"unprognostic (3.70e-2)"	"unprognostic (1.60e-1)"	"unprognostic (9.21e-2)"	"prognostic favourable (1.52e-4)"	"unprognostic (9.19e-2)"	2.0	0.5	8.4	4.3	10.7	1.2	6.2	3.5	7.9	5.7	9.4	21.4	0.3	7.4	1.2	2.8	23.8	5.7	14.6	0.8	10.7	6.9	12.4	4.0	3.5	4.2	10.9	5.2	0.5	12.0	1.0	0.8	1.7	9.4	2.2	7.3	9.7	6.3	1.2	0.4	10.8	13.7	1.3	22.5	5.1	7.6	2.3	12.8	0.2	7.4	17.4	12.1	5.4	10.8	0.0	0.6	14.7	0.4	0.2	2.7	0.4	23.9	3.8	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.1	0.0	0.0	29.5	0.0	15.2	0.1	12.8	0.2	25.7	0.0	0.0	0.5	0.0	0.6	2.0	0.0	0.3	0.0	0.0	10.3	0.0	10.1	0.0	0.0	0.1	0.0	0.9	0.0	0.5	0.4	7.3	0.0	0.1	6.3	25.9	9.3	0.2	0.0	1.9	0.0	0.0	3.3	0.2	0.2	0.1	1.7	0.0	5.2	0.1	0.1	0.0	24.5	0.8	8.8	6.3	0.4	14.0	1.0	0.1	2.7	0.0	0.6	0.6	0.6	0.0	0.3	0.2	14.7	0.2	0.0	0.0	0.0	0.4	8.4	10.7	3.5	7.9	10.7	6.9	10.9	5.2	9.4	12.8
TGFB1	"CED, DPD1, TGFB, TGFbeta"	ENSG00000105329	"Transforming growth factor beta 1"	P01137	19	41301587-41353911	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Growth factor, Mitogen"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 7.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000361, HPA073356"	Approved		Approved	"Golgi apparatus,Cytosol"	"Secreted to blood"	38000000	38000000	"Golgi apparatus"	Cytosol	"CAB000361: AB_2201910, HPA073356: "	"unprognostic (1.49e-2)"	"unprognostic (5.43e-3)"	"unprognostic (3.29e-2)"	"unprognostic (4.90e-2)"	"unprognostic (3.75e-3)"	"prognostic unfavourable (3.38e-4)"	"unprognostic (8.51e-3)"	"unprognostic (5.63e-3)"	"unprognostic (2.47e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.88e-1)"	"prognostic unfavourable (1.19e-8)"	"unprognostic (1.65e-3)"	"unprognostic (2.79e-2)"	"unprognostic (6.39e-2)"	"unprognostic (4.86e-3)"	24.3	14.4	7.7	29.8	11.9	53.1	19.0	2.2	8.2	27.8	15.3	14.3	11.5	11.4	24.1	12.8	24.5	13.0	15.6	17.6	8.8	6.5	19.2	10.4	32.4	33.3	12.0	4.1	15.3	8.2	6.9	9.7	54.7	11.7	17.2	5.8	10.3	10.9	15.9	8.7	14.0	17.6	14.6	12.8	55.8	12.8	9.5	12.3	30.6	10.3	9.1	30.6	28.7	24.6	0.7	1.4	7.5	2.2	0.5	1.7	1.3	14.5	22.9	1.2	0.1	10.6	9.4	2.9	21.1	19.0	6.8	4.6	9.7	9.0	14.4	22.7	28.6	7.9	4.1	13.5	2.4	19.1	4.5	48.5	5.5	12.3	13.7	13.3	33.1	12.2	4.3	13.1	8.4	34.1	26.0	36.3	6.2	10.7	11.4	19.5	2.5	13.7	12.3	3.2	21.6	12.1	6.3	0.2	1.6	5.8	0.3	4.1	0.5	11.9	43.1	26.7	20.9	5.6	22.9	20.1	7.8	9.4	26.1	26.7	4.7	1.5	1.9	7.5	1.7	2.2	1.3	0.4	0.9	0.9	1.4	0.7	0.7	0.9	4.7	0.5	2.0	1.4	0.5	1.3	7.7	11.9	2.2	7.6	8.8	6.5	12.0	4.1	11.7	12.3
TGFB2		ENSG00000092969	"Transforming growth factor beta 2"	P61812	1	218346235-218444619	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		"Growth factor, Mitogen"	"Aortic aneurysm, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 20.9;EFO-21: 25.9;HHSteC: 21.5;U-2 OS: 25.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 1.3;naive B-cell: 2.6"	"Lineage enriched"	"Detected in single"	5	"B-cells: 2.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (7.24e-2)"	"unprognostic (7.23e-2)"	"unprognostic (6.32e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.79e-1)"	"unprognostic (3.86e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.99e-1)"	"unprognostic (2.19e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.64e-3)"	"unprognostic (1.23e-1)"	"unprognostic (4.90e-2)"	"unprognostic (6.04e-2)"	2.9	2.6	13.4	3.2	11.4	0.8	7.0	5.2	13.7	12.3	5.2	10.0	7.0	1.6	10.8	7.5	3.6	6.9	3.9	9.5	13.3	6.7	2.9	1.6	12.4	1.6	5.9	9.9	8.1	3.5	4.3	6.3	20.1	10.2	27.8	2.1	11.6	16.9	18.7	6.9	3.8	1.8	8.5	19.0	4.4	2.8	2.1	8.2	0.0	4.8	2.8	1.9	5.2	7.4	2.6	0.5	0.0	0.0	0.0	0.1	0.0	1.7	8.6	0.8	6.8	2.0	1.0	0.0	1.2	0.1	13.8	9.9	2.3	20.9	0.0	25.9	0.0	4.5	0.5	1.1	14.4	0.0	0.1	0.0	0.7	0.0	21.5	0.0	0.0	0.9	2.4	1.9	7.3	3.7	0.0	0.0	13.1	0.1	0.0	0.0	0.7	0.7	0.0	3.9	0.0	4.4	0.0	0.1	0.0	14.3	1.7	0.2	1.3	0.5	16.1	9.8	25.7	8.1	13.2	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.1	0.5	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.4	11.4	5.2	13.7	13.3	6.7	5.9	9.9	10.2	8.2
TGFB3	"ARVD, ARVD1"	ENSG00000119699	"Transforming growth factor beta 3"	P10600	14	75958099-75982991	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		"Growth factor, Mitogen"	"Cancer-related genes, Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"SK-BR-3: 49.2;T-47d: 34.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 1.8"	"Lineage enhanced"	"Detected in single"		"T-cells: 1.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA063582			Approved	Vesicles	"Secreted to blood"			Vesicles		"HPA063582: "	"unprognostic (7.84e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.32e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.27e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.24e-1)"	"unprognostic (9.79e-2)"	"unprognostic (2.83e-2)"	"unprognostic (1.51e-2)"	"unprognostic (5.63e-2)"	"unprognostic (4.10e-1)"	"prognostic unfavourable (4.01e-7)"	"unprognostic (6.38e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.22e-2)"	"unprognostic (3.27e-3)"	6.9	4.7	10.6	8.4	14.0	0.4	7.8	3.2	8.6	29.2	4.1	6.7	13.1	2.3	10.4	21.4	4.4	4.9	21.5	17.9	11.9	6.6	4.8	12.2	8.6	4.2	16.8	7.0	3.1	11.1	6.8	4.6	31.0	8.4	25.8	3.2	10.0	5.0	12.0	13.3	1.5	2.9	20.7	13.0	2.2	4.5	3.8	8.8	4.2	4.4	5.7	8.2	11.6	6.4	0.4	0.1	0.0	0.0	0.0	1.8	0.2	0.3	0.1	0.4	5.4	0.9	1.3	0.1	0.2	0.4	0.2	0.2	0.3	1.3	0.0	0.4	1.0	0.3	1.1	0.1	0.1	0.3	0.5	0.0	1.1	0.6	1.3	0.2	0.3	4.5	0.1	0.4	0.1	1.3	0.5	2.4	0.3	2.4	0.2	0.2	0.1	1.8	1.1	1.6	0.2	0.5	0.2	8.9	2.1	1.6	49.2	0.3	34.5	0.0	0.3	0.8	1.8	0.8	2.2	0.2	0.2	0.1	1.3	0.3	1.3	0.0	0.0	0.0	0.5	0.0	0.6	0.0	0.1	0.6	0.0	0.4	1.8	0.5	0.0	0.0	0.0	0.1	0.3	0.2	10.6	14.0	3.2	8.6	11.9	6.6	16.8	7.0	8.4	8.8
TGFBR2	"MFS2, TBR-ii, TBRII"	ENSG00000163513	"Transforming growth factor beta receptor 2"	P37173	3	30606502-30694142	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"	"Apoptosis, Differentiation, Growth regulation"	"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Aortic aneurysm, Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 53.4;ASC TERT1: 80.5;HSkMC: 69.5;LHCN-M2: 65.8;TIME: 60.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB073537			Supported	"Plasma membrane"		560000	560000	"Plasma membrane"		"CAB073537: "	"unprognostic (1.74e-1)"	"unprognostic (1.84e-2)"	"unprognostic (3.70e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.26e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.24e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.81e-2)"	"unprognostic (8.81e-2)"	"unprognostic (8.02e-2)"	91.8	24.6	6.7	24.6	10.3	7.3	88.3	3.6	7.3	36.5	42.6	9.8	18.6	13.2	42.6	23.3	36.2	28.4	42.6	73.5	6.9	5.2	32.6	21.9	52.6	75.7	12.6	3.7	22.2	26.0	17.4	10.3	24.2	9.9	35.2	17.5	27.9	22.5	19.5	34.9	17.0	31.3	37.2	12.0	68.7	26.8	15.4	8.2	19.3	40.9	16.8	26.9	48.0	82.0	5.3	6.8	20.0	6.6	1.4	19.7	3.9	2.4	14.4	0.9	0.0	53.4	80.5	2.4	12.5	17.6	4.3	4.3	3.2	13.3	0.3	45.3	16.8	5.0	0.6	18.3	7.2	1.0	1.3	1.4	1.6	16.2	22.8	2.2	11.8	69.5	16.3	18.6	18.0	46.7	0.2	0.0	65.8	0.2	2.3	1.6	0.4	5.8	2.0	5.8	0.3	23.2	5.8	0.0	0.9	3.7	1.0	3.5	0.0	2.4	60.3	21.2	5.2	9.6	4.7	0.4	0.0	2.0	12.7	2.5	8.5	6.9	2.9	20.0	3.5	3.0	3.2	4.0	5.4	4.2	2.6	5.3	19.7	9.1	12.6	1.4	6.6	6.8	1.2	3.9	6.7	10.3	3.6	7.3	6.9	5.2	12.6	3.7	9.9	8.2
TGFBR3	"betaglycan, BGCAN"	ENSG00000069702	"Transforming growth factor beta receptor 3"	Q03167	1	91680343-91906335	"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 65.7;ASC TERT1: 32.0;U-2197: 22.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 21.3;MAIT T-cell: 11.6;memory CD4 T-cell: 5.4;memory CD8 T-cell: 11.4;naive CD8 T-cell: 8.0;NK-cell: 9.0"	"Group enriched"	"Detected in many"	22	"NK-cells: 9.0;T-cells: 21.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008257, CAB018971"	Supported		Approved	Cytosol	"Secreted to blood"	29000000	29000000	Cytosol		"CAB018971: , HPA008257: AB_1080258"	"unprognostic (7.57e-2)"	"unprognostic (3.67e-1)"	"unprognostic (4.86e-2)"	"prognostic unfavourable (3.36e-4)"	"unprognostic (9.39e-3)"	"prognostic favourable (4.84e-4)"	"unprognostic (2.07e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.79e-1)"	"unprognostic (9.32e-2)"	"unprognostic (1.07e-1)"	"prognostic favourable (4.99e-4)"	"unprognostic (2.46e-1)"	"unprognostic (2.43e-1)"	"prognostic unfavourable (3.14e-4)"	"unprognostic (1.08e-2)"	40.1	15.9	3.2	6.8	3.1	1.6	63.5	1.8	4.4	30.1	15.2	3.5	30.0	3.4	17.6	21.0	22.2	17.6	23.3	16.3	3.9	1.9	12.5	11.9	18.4	18.1	2.6	2.0	62.4	8.9	4.4	4.4	25.1	4.5	21.7	5.6	8.8	14.7	46.5	19.2	13.4	9.8	34.4	4.1	27.1	11.1	14.0	3.0	1.1	7.5	6.5	3.1	39.2	42.1	0.0	0.6	0.6	0.6	9.0	21.3	3.9	2.7	2.6	4.0	0.6	65.7	32.0	12.7	2.0	10.0	2.3	2.8	1.2	0.4	0.0	0.5	3.6	0.4	1.0	0.2	1.8	9.3	2.1	0.0	3.3	11.1	1.4	0.1	0.0	7.7	1.3	5.1	1.1	1.1	6.4	0.2	0.6	0.0	0.0	0.0	1.6	0.9	0.1	1.3	0.5	0.9	16.0	0.1	0.0	0.9	0.0	5.5	0.3	1.0	3.6	3.9	1.0	22.3	0.4	9.9	0.9	0.0	0.8	0.5	0.4	0.6	0.0	0.0	21.3	0.1	11.6	0.0	5.4	11.4	0.0	0.0	1.7	8.0	0.3	9.0	0.6	0.6	2.4	3.9	3.2	3.1	1.8	4.4	3.9	1.9	2.6	2.0	4.5	3.0
TGIF1	"HPE4, TGIF"	ENSG00000177426	"TGFB induced factor homeobox 1"	Q15583	18	3411608-3459978	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Holoprosencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA062160			Supported	Nucleoplasm				Nucleoplasm		"HPA062160: "	"unprognostic (1.11e-2)"	"unprognostic (5.20e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.97e-1)"	"unprognostic (3.57e-3)"	"unprognostic (3.10e-2)"	"unprognostic (2.75e-1)"	"unprognostic (4.34e-2)"	"unprognostic (1.94e-2)"	"unprognostic (1.96e-3)"	"prognostic unfavourable (6.47e-4)"	"unprognostic (9.60e-2)"	"unprognostic (1.12e-2)"	"unprognostic (9.81e-2)"	"unprognostic (4.60e-1)"	"unprognostic (7.07e-2)"	"unprognostic (2.48e-3)"	31.9	16.6	6.9	17.2	9.3	11.2	22.0	2.7	6.2	26.8	23.8	15.5	48.4	9.6	32.7	47.3	27.1	24.8	31.4	12.9	6.5	7.2	24.7	33.6	27.9	10.6	8.1	5.9	23.0	20.2	5.3	10.2	49.6	9.9	33.2	22.4	15.3	25.1	29.8	21.2	22.9	16.6	18.5	8.6	23.1	19.8	23.1	9.2	18.1	60.2	11.2	21.0	40.5	29.0	18.2	14.0	20.4	17.3	7.4	27.5	12.7	6.1	28.3	18.6	5.9	19.0	25.7	45.5	11.9	45.7	9.8	12.5	11.2	28.4	0.3	4.0	9.7	6.4	7.1	13.4	12.9	2.5	2.9	0.8	13.5	21.1	35.7	8.9	7.4	17.8	57.5	17.7	47.2	20.8	6.4	0.1	19.1	12.1	5.8	11.0	47.4	6.2	6.1	8.3	2.0	40.1	30.5	5.2	5.2	31.5	24.7	17.4	5.7	8.0	8.9	15.3	13.3	18.0	7.4	1.0	0.1	2.8	15.7	3.4	19.2	20.4	17.3	2.9	25.9	6.5	27.5	18.2	21.6	25.2	14.0	12.8	15.5	18.0	7.8	7.4	6.1	1.4	11.4	12.7	6.9	9.3	2.7	6.2	6.5	7.2	8.1	5.9	9.9	9.2
TGM4	TGP	ENSG00000163810	"Transglutaminase 4"	P49221	3	44874608-44914990	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Acyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"prostate: 107.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 9.5;hTERT-HME1: 2.6;NB-4: 5.1;RPMI-8226: 3.6;SH-SY5Y: 2.8"	"Cancer enriched"	"Detected in single"	312	"prostate cancer: 75.4"	"Region enriched"	"Detected in single"	254	"cerebral cortex: 25.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"HPA032072, CAB033571"	Enhanced									"CAB033571: AB_2287329, HPA032072: AB_10603350"	"unprognostic (4.40e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.17e-3)"	"unprognostic (2.84e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.41e-2)"	"unprognostic (1.65e-1)"	"unprognostic (8.56e-3)"	"unprognostic (5.08e-2)"	"unprognostic (1.44e-8)"	"unprognostic (1.10e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.68e-1)"	"unprognostic (6.41e-2)"	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	25.4	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	107.8	0.0	0.0	2.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.0	0.6	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	9.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.4	0.1	2.6	0.3	0.0	0.0	0.1	0.0	0.0	5.1	0.0	0.2	0.0	0.0	3.6	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	1.4	0.5	0.0	0.7	0.7	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.2	0.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	25.4	0.0	0.0	0.0	0.0	0.0	0.0
TGM7	TGMZ	ENSG00000159495	"Transglutaminase 7"	Q96PF1	15	43276280-43302255	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Acyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 5.9;testis: 2.9"	"Cell line enriched"	"Detected in single"	78	"EFO-21: 8.9"	"Cancer enriched"	"Detected in single"	13	"endometrial cancer: 2.1"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"															"unprognostic (2.45e-2)"		"unprognostic (2.04e-1)"		"unprognostic (2.82e-2)"				"unprognostic (1.71e-2)"		"unprognostic (1.07e-1)"			"unprognostic (2.01e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0			0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.3	0.0		0.2	0.1	1.5	0.0	0.0	0.0	0.0	0.0	0.0	2.9			0.0		5.9	0.0	1.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0										
THBS1	"THBS, THBS-1, TSP, TSP-1, TSP1"	ENSG00000137801	"Thrombospondin 1"	P07996	15	39581079-39599466	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion, Unfolded protein response"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 162.1;HUVEC TERT2: 157.6;LHCN-M2: 117.7;TIME: 229.8"	"Low cancer specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basal ganglia: 3.4;pons and medulla: 8.1"	"Cell type enhanced"	"Detected in some"		"eosinophil: 14.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"CAB033678, HPA059756"	Approved		Approved	"Plasma membrane"	"Secreted to extracellular matrix"	1600000000	1600000000	"Plasma membrane"		"CAB033678: AB_793044, HPA059756: "	"unprognostic (1.72e-2)"	"unprognostic (9.55e-3)"	"unprognostic (7.49e-2)"	"unprognostic (3.31e-1)"	"unprognostic (4.34e-2)"	"unprognostic (1.03e-3)"	"unprognostic (3.60e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.07e-1)"	"unprognostic (6.40e-2)"	"unprognostic (9.16e-2)"	"prognostic unfavourable (8.47e-5)"	"prognostic unfavourable (8.50e-4)"	"unprognostic (1.00e-1)"	"unprognostic (9.25e-3)"	"unprognostic (1.48e-3)"	79.6	15.2	0.9	81.4	3.4	19.3	41.0	0.7	1.3	25.7	42.7	2.5	6.6	5.0	72.8	30.5	22.7	40.8	57.7	49.0	1.0	1.0	23.4	27.2	118.4	38.8	1.1	0.8	60.9	14.0	1.3	7.7	38.1	8.1	31.9	18.3	8.4	38.0	13.2	22.6	9.2	23.0	63.5	4.5	58.0	46.5	27.5	0.2	0.6	14.0	21.4	18.4	111.8	78.9	0.0	0.5	14.1	7.4	7.5	2.6	8.6	11.5	3.9	3.1	1.1	13.1	15.4	0.0	67.0	54.8	18.4	12.1	11.4	8.7	0.0	25.3	162.1	41.2	0.1	32.7	9.3	3.0	0.0	2.9	2.3	2.9	2.9	0.0	0.8	34.5	2.4	15.3	34.5	157.6	0.0	0.1	117.7	0.8	0.0	0.2	0.5	1.4	0.0	8.1	0.0	27.6	29.4	0.0	0.0	19.0	1.0	1.1	11.7	0.2	229.8	64.5	15.3	75.9	76.9	0.1	0.1	0.1	2.1	0.0	68.9	0.2	7.4	14.1	0.8	0.8	2.6	0.0	0.4	0.5	0.5	0.0	0.1	0.1	1.4	7.5	0.1	0.3	0.0	8.6	0.9	3.4	0.7	1.0	1.0	1.0	1.1	0.8	8.1	0.2
THBS2	TSP2	ENSG00000186340	"Thrombospondin 2"	P35442	6	169215780-169254044	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 84.6;urinary bladder: 67.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 81.9;ASC TERT1: 56.2;BJ hTERT+ SV40 Large T+ RasG12V: 27.2;HSkMC: 30.3;hTEC/SVTERT24-B: 29.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB017716, HPA044304"	Approved		Approved	"Nuclear speckles,Plasma membrane,Cytosol"	"Secreted to extracellular matrix"	22000000	22000000	"Plasma membrane"	"Nuclear speckles, Cytosol"	"CAB017716: , HPA044304: "	"unprognostic (2.85e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.87e-2)"	"unprognostic (8.90e-2)"	"unprognostic (3.64e-2)"	"unprognostic (8.73e-2)"	"unprognostic (2.93e-1)"	"unprognostic (5.10e-3)"	"unprognostic (1.39e-1)"	"unprognostic (4.71e-2)"	"unprognostic (4.00e-2)"	"unprognostic (2.56e-1)"	"prognostic unfavourable (3.77e-6)"	"unprognostic (2.19e-3)"	"unprognostic (4.38e-2)"	"unprognostic (4.16e-2)"	"unprognostic (2.48e-3)"	43.5	4.0	4.3	10.1	7.8	0.4	84.6	1.1	9.0	24.3	17.0	6.3	3.3	1.9	26.1	16.1	9.8	14.8	43.0	21.9	5.5	3.6	4.6	5.9	8.4	3.8	8.1	1.4	26.2	5.9	1.5	4.4	2.0	14.8	10.5	3.4	0.7	3.9	2.8	14.6	22.7	3.8	22.0	16.0	2.8	2.6	12.5	5.2	0.0	13.2	10.6	4.8	67.4	29.4	0.4	0.7	0.2	0.8	0.1	0.3	0.0	0.0	0.0	0.5	0.3	81.9	56.2	0.0	15.6	21.4	21.6	27.2	0.1	0.0	0.0	0.0	18.6	0.0	0.6	0.8	12.4	0.0	0.0	0.0	0.0	0.0	22.9	0.0	0.0	30.3	0.0	29.2	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.8	3.3	0.1	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	9.9	0.1	22.0	1.8	0.0	0.3	0.0	6.1	0.1	0.5	0.0	0.8	0.2	0.2	0.5	0.0	0.4	0.1	0.0	0.2	0.3	0.1	0.3	0.0	0.1	0.5	0.7	0.2	0.0	4.3	7.8	1.1	3.1	5.5	3.6	8.1	1.4	14.8	5.2
THBS4		ENSG00000113296	"Thrombospondin 4"	P35443	5	79991311-80083287	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion, Tissue remodeling, Unfolded protein response"	"Growth factor, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 69.8;heart muscle: 59.0;skeletal muscle: 61.7;smooth muscle: 94.0"	"Cell line enhanced"	"Detected in some"		"AF22: 5.0;THP-1: 10.7;U-2 OS: 4.6;U-266/70: 4.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	51	"eosinophil: 8.0"	"Lineage enriched"	"Detected in single"	51	"granulocytes: 8.0"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB004597, HPA042426"	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	420000000	420000000	Vesicles		"CAB004597: AB_628352, HPA042426: "	"unprognostic (1.41e-1)"	"unprognostic (5.33e-2)"	"unprognostic (4.26e-3)"	"unprognostic (3.64e-2)"	"unprognostic (9.94e-2)"	"unprognostic (8.10e-2)"	"unprognostic (5.64e-2)"	"unprognostic (7.12e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.25e-1)"	"unprognostic (2.06e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.96e-3)"	"unprognostic (2.74e-2)"	"unprognostic (3.98e-2)"	"unprognostic (1.76e-3)"	"prognostic unfavourable (3.33e-4)"	69.8	1.0	7.6	2.1	8.3	3.7	9.7	0.8	4.6	1.1	21.4	2.6	1.2	1.3	12.2	13.6	6.5	1.4	4.1	59.0	6.4	6.4	0.8	0.6	1.0	0.9	8.5	1.9	2.1	23.0	5.5	7.8	0.6	10.7	3.7	3.7	4.9	19.8	2.6	61.7	1.5	1.4	94.0	11.5	0.6	4.0	5.5	2.6	2.0	9.9	39.3	4.1	3.4	2.7	0.1	0.0	8.0	0.0	0.0	0.1	0.0	0.2	0.0	5.0	0.3	0.4	2.2	0.5	0.1	0.2	1.5	0.5	0.1	0.6	0.2	0.2	0.4	0.2	0.2	0.6	1.3	0.2	0.7	0.5	0.0	0.3	2.7	0.0	0.1	1.5	0.3	0.1	0.3	0.0	0.0	0.3	0.3	0.7	0.1	0.0	3.9	0.1	0.0	1.5	0.0	0.3	0.1	4.0	1.2	0.1	0.0	0.4	0.0	10.7	0.0	0.1	4.6	0.3	0.3	4.1	0.1	0.7	1.8	3.4	0.9	0.0	0.0	8.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.6	8.3	0.8	4.6	6.4	6.4	8.5	1.9	10.7	2.6
THPO	"MGDF, MPLLG, TPO"	ENSG00000090534	Thrombopoietin	P40225	3	184371935-184381968	"Cancer-related genes, Disease related genes, Predicted secreted proteins"		"Cytokine, Hormone"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	6	"liver: 55.5"	"Cell line enhanced"	"Detected in some"		"CACO-2: 6.8;Hep G2: 17.4;K-562: 3.1;RPMI-8226: 4.6"	"Cancer enriched"	"Detected in many"	5	"liver cancer: 8.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (5.57e-2)"	"unprognostic (3.15e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.21e-2)"	"unprognostic (6.20e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.37e-2)"	"unprognostic (2.75e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.81e-1)"	"unprognostic (8.40e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (2.48e-6)"	"unprognostic (1.40e-3)"	"unprognostic (4.13e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.25e-2)"	1.7	1.3	2.3	0.5	0.7	0.0	1.4	4.3	3.3	1.5	0.7	0.4	0.4	0.1	2.6	1.7	0.4	0.9	0.4	1.7	1.5	0.0	8.6	55.5	0.4	0.4	0.4	0.4	1.5	2.7	0.0	1.3	0.6	0.4	0.7	0.3	0.5	0.9	0.7	6.0	0.1	0.4	2.1	0.7	0.9	0.2	2.4	0.4	0.4	0.7	0.7	0.5	0.4	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.5	0.0	0.0	0.1	0.0	6.8	0.0	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	17.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	3.1	0.2	0.0	0.2	0.0	0.1	0.1	0.0	0.3	0.8	4.6	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.1	0.0	0.0	0.1	1.9	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.7	4.3	3.3	1.5	0.0	0.4	0.4	0.4	0.4
THRA	"AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3"	ENSG00000126351	"Thyroid hormone receptor, alpha"	P10827	17	40058290-40093867	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 90.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 37.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009654, CAB023349"	Approved		Supported	Cytosol				Cytosol		"CAB023349: AB_619577, HPA009654: AB_1854603"	"unprognostic (2.75e-2)"	"unprognostic (2.20e-1)"	"unprognostic (6.64e-2)"	"unprognostic (4.22e-2)"	"unprognostic (8.78e-2)"	"unprognostic (1.64e-1)"	"unprognostic (3.41e-3)"	"prognostic favourable (1.84e-4)"	"unprognostic (1.47e-1)"	"unprognostic (5.47e-2)"	"unprognostic (7.85e-2)"	"unprognostic (2.65e-2)"	"prognostic favourable (6.05e-8)"	"unprognostic (3.05e-1)"	"unprognostic (1.35e-1)"	"unprognostic (4.21e-1)"	"unprognostic (1.88e-3)"	17.1	20.7	58.6	5.7	90.7	9.9	12.9	37.4	73.1	19.8	12.6	24.1	8.2	15.1	19.3	11.5	9.7	29.3	12.7	30.1	43.8	38.1	12.1	2.7	11.6	4.5	34.3	45.5	46.5	12.3	13.0	10.7	8.5	29.6	12.4	9.6	10.4	13.7	18.8	38.5	10.0	16.7	17.4	29.4	6.1	11.9	7.8	43.6	1.8	12.5	7.9	3.3	10.0	18.6	1.0	1.5	3.7	0.7	5.1	4.7	1.4	2.1	17.2	5.4	13.4	37.1	13.6	1.9	8.8	10.6	9.2	8.6	14.3	12.5	2.5	14.7	17.2	5.2	10.5	5.4	5.0	0.9	9.9	4.6	20.5	6.1	12.5	7.5	5.2	21.6	4.4	8.6	3.3	12.3	9.3	2.4	7.6	3.2	10.0	12.4	4.9	5.4	14.4	10.6	12.4	3.1	1.5	9.1	8.3	6.8	10.9	15.4	12.7	8.9	8.5	9.2	9.2	8.2	2.6	5.6	3.9	1.5	5.7	8.7	4.9	0.3	0.6	3.7	4.7	0.3	2.0	0.6	1.9	2.8	0.8	1.0	3.4	4.1	2.5	5.1	0.7	1.5	2.2	1.4	58.6	90.7	37.4	41.8	43.8	38.1	34.3	45.5	29.6	43.6
THRB	"ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2"	ENSG00000151090	"Thyroid hormone receptor beta"	P10828	3	24117153-24495756	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"K-562: 26.0;RT4: 19.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 7.2;naive B-cell: 4.3"	"Group enriched"	"Detected in many"	11	"B-cells: 4.3;granulocytes: 7.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002008, CAB002009, HPA061035"	Approved		Supported	"Nuclear bodies"				"Nuclear bodies"		"CAB002008: , CAB002009: , HPA061035: "	"unprognostic (1.82e-1)"	"unprognostic (4.22e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.20e-6)"	"unprognostic (3.37e-1)"	"unprognostic (2.66e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.73e-1)"	"unprognostic (5.78e-3)"	"unprognostic (2.95e-2)"	"unprognostic (4.43e-1)"	"unprognostic (2.01e-2)"	"prognostic favourable (9.46e-8)"	"unprognostic (1.32e-3)"	"unprognostic (6.75e-2)"	"unprognostic (2.73e-2)"	"unprognostic (3.34e-2)"	10.7	5.5	12.5	3.2	14.8	1.1	12.0	2.6	27.0	3.6	11.2	1.9	5.5	2.7	7.5	2.2	7.0	4.3	2.5	7.9	9.2	5.7	12.9	20.8	5.4	1.6	4.3	20.1	2.9	9.6	6.8	20.3	4.7	3.5	8.2	9.0	3.2	6.1	10.4	21.9	7.1	4.0	11.1	3.0	5.7	8.1	1.0	4.0	0.0	4.9	4.7	1.6	9.8	14.6	4.3	0.5	7.2	0.1	0.0	0.0	3.5	5.9	1.8	0.4	0.0	10.7	5.6	4.0	0.2	1.3	1.0	1.9	3.9	5.9	0.0	1.5	4.2	9.0	6.4	2.5	0.7	0.0	3.9	0.0	1.6	5.1	0.3	0.0	0.0	9.9	4.4	0.1	0.7	0.0	26.0	0.0	0.9	0.3	0.0	0.0	3.9	2.2	0.0	0.0	0.0	6.1	19.3	1.1	0.4	9.8	5.3	0.1	5.8	0.0	0.5	2.4	1.9	0.0	1.1	0.1	0.3	0.0	1.7	0.0	0.2	7.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	4.3	0.0	0.0	1.6	0.0	0.0	0.0	0.0	3.5	12.5	14.8	2.6	27.0	9.2	5.7	4.3	20.1	3.5	4.0
TIE1	"JTK14, TIE"	ENSG00000066056	"Tyrosine kinase with immunoglobulin like and EGF like domains 1"	P35590	1	43300993-43323108	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"EFO-21: 27.9;HUVEC TERT2: 61.6;TIME: 53.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	22	"basophil: 3.4;NK-cell: 5.4"	"Group enriched"	"Detected in many"	22	"granulocytes: 3.4;NK-cells: 5.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	75000000	75000000				"unprognostic (1.88e-1)"	"unprognostic (1.26e-1)"	"unprognostic (7.60e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.91e-2)"	"unprognostic (1.53e-3)"	"unprognostic (1.19e-2)"	"unprognostic (7.83e-2)"	"unprognostic (2.02e-1)"	"unprognostic (9.34e-2)"	"unprognostic (1.91e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.17e-3)"	"unprognostic (2.16e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.35e-2)"	39.4	5.4	3.9	6.6	6.0	1.0	43.6	2.5	6.0	10.8	8.4	4.5	4.2	4.5	18.6	10.9	7.8	10.2	11.1	15.1	4.9	4.2	9.4	10.8	22.0	13.1	6.4	3.1	7.0	3.0	2.7	5.1	39.9	5.5	8.6	3.0	6.9	6.0	6.9	17.8	4.2	5.8	12.1	5.3	14.8	5.1	5.1	3.8	1.1	13.9	10.2	3.1	9.0	14.7	0.0	0.2	3.4	0.0	5.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.9	0.0	0.0	0.0	0.0	0.4	0.0	0.0	10.5	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	61.6	0.0	0.0	0.0	0.0	0.0	5.1	0.3	0.0	2.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.5	0.3	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	5.4	0.0	0.1	0.0	0.0	3.9	6.0	2.5	6.0	4.9	4.2	6.4	3.1	5.5	3.8
TIMM17A	"TIM17, TIM17A"	ENSG00000134375	"Translocase of inner mitochondrial membrane 17A"	Q99595	1	201955491-201970661	"Cancer-related genes, Predicted membrane proteins"	"Protein transport, Translocation, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA010083	Approved		Supported	Nucleoplasm,Mitochondria				"Nucleoplasm, Mitochondria"		"HPA010083: AB_10602899"	"prognostic unfavourable (1.98e-5)"	"unprognostic (3.28e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.80e-3)"	"unprognostic (7.58e-2)"	"unprognostic (4.15e-2)"	"unprognostic (7.45e-2)"	"unprognostic (1.64e-2)"	"unprognostic (8.54e-3)"	"unprognostic (2.02e-2)"	"unprognostic (2.01e-1)"	"unprognostic (6.45e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.44e-2)"	"unprognostic (2.81e-1)"	16.6	27.6	22.7	18.7	23.2	16.9	16.8	16.3	29.3	16.5	19.3	9.9	19.2	17.2	15.0	24.1	17.9	11.8	10.7	39.0	32.3	19.6	25.1	53.7	13.5	15.3	20.6	27.0	11.2	18.7	21.5	14.8	17.4	25.0	14.5	21.8	11.7	24.8	17.1	42.1	11.5	13.0	19.6	13.4	14.4	16.3	13.7	14.2	11.3	21.6	30.4	18.9	15.9	12.7	17.6	28.9	16.0	24.9	15.9	20.6	17.8	25.9	26.5	24.1	28.8	20.3	21.4	40.7	41.6	29.8	34.1	30.7	31.1	27.1	36.1	15.3	35.5	20.8	44.1	24.8	36.9	26.4	27.6	19.9	35.3	29.3	21.0	42.3	21.4	24.6	27.7	34.9	29.2	35.6	50.1	20.3	40.0	16.6	22.7	22.9	30.5	14.3	22.4	28.0	45.1	41.9	24.8	36.4	25.7	25.4	65.2	38.4	36.0	28.8	28.5	22.8	24.2	26.5	43.1	30.7	33.1	30.3	24.3	32.3	25.4	8.9	19.0	16.0	13.6	24.9	17.5	17.6	14.9	17.2	28.9	12.7	14.2	16.7	4.4	15.9	24.7	19.3	20.6	17.8	22.7	23.2	16.3	29.3	32.3	19.6	20.6	27.0	25.0	14.2
TIMP1	"CLGI, EPO, TIMP"	ENSG00000102265	"TIMP metallopeptidase inhibitor 1"	P01033	X	47582313-47586789	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Growth factor, Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 293.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 161.3;ASC TERT1: 216.0;HSkMC: 148.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB022360, HPA053417"	Approved		Approved	"Golgi apparatus"	"Secreted to blood"	750000000	750000000	"Golgi apparatus"		"CAB022360: , HPA053417: "	"unprognostic (5.86e-3)"	"unprognostic (1.30e-1)"	"prognostic unfavourable (2.09e-4)"	"unprognostic (4.68e-2)"	"unprognostic (1.81e-2)"	"unprognostic (1.07e-3)"	"unprognostic (4.99e-2)"	"unprognostic (8.24e-3)"	"unprognostic (9.12e-3)"	"unprognostic (9.69e-2)"	"unprognostic (9.10e-2)"	"unprognostic (2.17e-1)"	"prognostic unfavourable (2.90e-11)"	"unprognostic (1.88e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.92e-2)"	"unprognostic (2.66e-1)"	80.2	82.3	6.3	154.0	12.8	9.2	31.8	3.3	8.4	63.5	29.1	6.5	27.2	6.1	48.9	109.6	34.9	53.5	110.9	105.7	9.2	5.5	71.2	115.9	144.8	293.3	8.4	4.8	149.3	22.2	41.8	48.7	125.5	29.5	62.9	19.0	33.4	45.9	42.0	26.1	11.6	13.2	64.5	14.6	69.3	19.3	71.9	4.6	8.8	98.6	14.6	34.8	121.0	46.8	2.3	56.8	57.1	91.5	9.4	26.4	39.7	9.4	15.8	7.7	91.3	161.3	216.0	1.9	102.5	84.8	32.0	25.9	6.2	17.8	0.1	13.5	131.9	9.4	4.2	43.5	20.7	19.1	10.0	9.7	11.5	9.6	107.4	6.5	124.3	148.0	11.1	97.4	20.7	14.3	15.0	7.2	52.9	18.4	0.1	25.0	8.6	33.2	0.1	15.9	8.4	51.5	6.6	0.1	0.4	60.8	0.4	12.9	0.8	12.6	13.8	47.9	50.5	56.5	10.0	3.0	6.4	0.3	139.3	15.7	31.1	29.5	54.6	0.8	16.2	91.5	16.0	2.3	26.4	14.3	56.8	1.2	8.6	7.7	57.1	9.4	83.6	1.6	10.7	39.7	6.3	12.8	3.3	5.3	9.2	5.5	8.4	4.8	29.5	4.6
TIMP2	CSC-21K	ENSG00000035862	"TIMP metallopeptidase inhibitor 2"	P16035	17	78852977-78925387	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 269.8"	"Cell line enhanced"	"Detected in many"		"ASC diff: 124.8;ASC TERT1: 153.5;BJ hTERT+: 87.2;fHDF/TERT166: 95.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.3"	"Group enriched"	"Detected in many"	4	"granulocytes: 13.3;monocytes: 5.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB010203	Approved				"Secreted to extracellular matrix"	83000000	83000000			"CAB010203: AB_2204966"	"unprognostic (1.03e-1)"	"unprognostic (1.71e-2)"	"unprognostic (9.81e-2)"	"unprognostic (1.76e-3)"	"unprognostic (3.24e-2)"	"unprognostic (3.05e-1)"	"unprognostic (4.31e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.39e-1)"	"unprognostic (4.73e-2)"	"unprognostic (3.97e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.38e-3)"	"unprognostic (4.62e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.77e-3)"	75.2	35.1	30.9	17.7	18.9	3.4	45.6	4.6	25.8	95.8	40.5	36.8	28.2	12.9	87.9	41.5	37.4	39.8	72.3	38.5	23.2	29.6	21.1	12.2	38.4	15.4	25.3	23.2	182.4	14.4	15.8	17.2	269.8	34.0	44.6	20.3	49.7	16.9	51.6	24.5	38.4	22.0	70.7	32.6	37.9	24.2	51.7	26.1	28.4	25.3	24.0	11.3	60.2	58.1	0.2	2.1	13.3	5.0	0.2	0.3	0.8	14.8	7.5	8.5	16.2	124.8	153.5	4.6	52.6	87.2	25.8	20.5	2.7	26.0	0.0	18.6	95.6	2.9	2.6	2.2	27.1	0.3	1.5	0.0	15.2	4.2	37.0	0.2	0.1	60.3	1.1	25.4	4.1	34.1	0.0	0.0	26.5	1.7	15.3	2.6	1.5	11.1	10.3	19.5	6.3	16.4	0.2	4.3	26.8	32.9	15.6	67.1	7.9	3.7	40.4	69.2	13.3	40.1	9.0	7.7	6.4	0.1	15.8	2.8	33.3	0.0	5.0	6.8	0.0	3.3	0.0	0.1	0.1	0.0	2.1	0.2	0.3	0.3	13.3	0.2	3.8	1.4	0.1	0.8	30.9	18.9	4.6	25.8	23.2	29.6	25.3	23.2	34.0	26.1
TIMP3	SFD	ENSG00000100234	"TIMP metallopeptidase inhibitor 3"	P35625	22	32801701-32863043	"Cancer-related genes, Disease related genes, Predicted secreted proteins"	"Sensory transduction, Vision"	"Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 392.5;retina: 247.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 55.9;BJ: 125.0;BJ hTERT+: 55.2;fHDF/TERT166: 113.6;WM-115: 95.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	6	"NK-cell: 2.2"	"Lineage enriched"	"Detected in single"	6	"NK-cells: 2.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to extracellular matrix"						"unprognostic (4.98e-2)"	"unprognostic (1.77e-3)"	"unprognostic (1.60e-1)"	"unprognostic (8.53e-4)"	"unprognostic (1.67e-2)"	"unprognostic (1.05e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.22e-2)"	"unprognostic (8.42e-2)"	"prognostic unfavourable (1.90e-5)"	"unprognostic (3.92e-1)"	"unprognostic (1.95e-1)"	"prognostic favourable (1.50e-4)"	"unprognostic (2.66e-3)"	"unprognostic (1.44e-2)"	"unprognostic (2.55e-3)"	"unprognostic (3.11e-2)"	130.4	44.6	8.7	15.8	10.1	0.1	103.3	5.1	12.1	68.3	25.4	13.5	27.8	4.5	65.1	47.4	40.2	51.9	39.9	75.0	10.2	8.5	54.0	14.1	115.4	31.3	11.4	8.7	25.3	11.8	15.6	21.6	392.5	19.1	44.2	12.6	247.1	24.3	55.0	22.7	22.9	16.2	58.3	7.2	35.1	22.9	43.2	7.1	1.2	48.9	29.4	10.1	37.5	38.3	0.4	0.0	0.0	0.0	2.2	0.0	0.0	2.0	0.0	1.8	0.2	55.9	31.5	0.1	125.0	55.2	10.2	12.2	2.1	0.0	0.0	3.0	113.6	1.9	0.3	5.1	14.8	0.0	1.5	15.4	2.6	5.4	22.0	0.0	6.5	5.2	13.1	18.1	1.0	0.0	0.0	0.1	4.7	0.1	0.0	0.5	0.2	0.0	0.0	0.3	0.0	0.2	10.2	1.3	1.8	2.5	0.0	32.8	0.0	0.1	0.0	0.8	2.8	26.6	2.0	0.0	0.0	0.0	25.5	0.0	95.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	8.7	10.1	5.1	12.1	10.2	8.5	11.4	8.7	19.1	7.1
TJP2	"DFNA51, X104, ZO-2, ZO2"	ENSG00000119139	"Tight junction protein 2"	Q9UDY2	9	69121264-69255208	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Intrahepatic cholestasis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 53.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 4.0"	"Lineage enriched"	"Detected in single"	8	"monocytes: 4.0"									"HPA001813, CAB009228, HPA070714"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Cell Junctions"		790000	790000	"Plasma membrane, Cell Junctions"	Nucleoplasm	"CAB009228: AB_2203583, HPA001813: AB_1080764, HPA070714: "	"unprognostic (1.30e-1)"	"unprognostic (7.69e-2)"	"unprognostic (1.23e-3)"	"unprognostic (7.68e-2)"	"unprognostic (2.01e-1)"	"unprognostic (8.83e-3)"	"unprognostic (1.94e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.82e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.93e-3)"	"unprognostic (3.60e-1)"	"prognostic favourable (1.78e-14)"	"unprognostic (3.29e-2)"	"unprognostic (6.42e-2)"	"unprognostic (8.15e-3)"	"unprognostic (5.85e-2)"	25.2	9.5	23.7	8.0	29.7	5.7	20.7	35.6	24.9	9.0	20.0	50.3	20.6	27.2	11.9	7.3	28.9	12.6	13.2	19.8	35.1	12.7	23.3	34.5	23.9	5.8	39.7	20.5	20.9	13.2	43.2	3.6	18.0	32.0	13.5	16.7	19.1	18.0	23.1	8.3	18.6	25.7	15.3	39.7	3.5	30.4	17.8	41.1	11.1	22.5	9.0	10.8	26.5	26.6	0.0	0.2	0.4	4.0	0.0	0.5	0.5	53.2	1.7	4.2	4.7	20.1	19.7	23.2	8.1	5.9	12.9	7.0	6.4	19.4	7.6	8.1	4.5	32.7	6.9	17.0	14.7	27.2	5.0	7.4	4.6	32.8	5.6	3.0	14.0	15.3	12.3	10.1	6.0	27.1	4.4	5.2	6.7	7.4	1.1	0.4	10.4	11.6	3.9	6.1	0.8	33.3	35.5	1.9	3.3	2.9	20.7	0.6	6.7	1.6	38.8	9.7	10.5	7.5	8.2	5.3	1.1	0.1	11.1	4.3	3.5	0.0	0.7	0.0	0.0	1.5	0.4	0.0	0.2	0.0	0.2	0.0	0.0	0.1	0.4	0.0	4.0	0.1	0.5	0.5	23.7	29.7	35.6	17.5	35.1	12.7	39.7	20.5	32.0	41.1
TK1		ENSG00000167900	"Thymidine kinase 1"	P04183	17	78174075-78187233	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"DNA synthesis"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 32.8;lymphoid tissue: 41.8;tongue: 33.0"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"T-reg: 21.2"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			CAB004683	Enhanced									"CAB004683: AB_437067"	"unprognostic (7.09e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.82e-1)"	"unprognostic (2.14e-3)"	"unprognostic (3.22e-1)"	"unprognostic (1.94e-1)"	"prognostic unfavourable (6.87e-4)"	"prognostic unfavourable (3.03e-5)"	"unprognostic (4.05e-2)"	"unprognostic (3.18e-3)"	"unprognostic (6.64e-3)"	"unprognostic (2.76e-2)"	"prognostic unfavourable (6.50e-11)"	"unprognostic (5.55e-3)"	"unprognostic (1.92e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.94e-2)"	5.3	2.0	2.1	21.4	4.5	32.8	4.8	1.1	1.9	3.7	11.4	2.2	1.9	8.5	2.4	4.8	18.9	2.2	7.0	4.3	1.6	0.7	7.9	6.2	9.3	15.7	3.1	1.6	2.1	3.6	0.1	1.3	8.6	2.1	2.3	7.9	0.5	4.6	2.0	2.0	6.2	8.5	4.4	1.7	9.0	9.4	3.6	1.6	41.8	1.3	33.0	20.5	3.1	5.8	4.0	2.1	1.1	1.2	6.2	21.2	3.5	65.1	54.2	10.8	13.6	1.0	4.3	7.1	32.4	17.0	48.2	66.9	47.8	27.5	21.2	11.4	19.4	29.7	9.8	28.9	25.0	7.3	36.2	37.4	19.4	31.3	0.3	15.8	24.2	2.1	0.9	25.1	3.4	19.6	23.0	47.0	18.5	48.7	7.9	8.9	5.6	37.8	21.4	43.8	47.3	12.8	21.2	4.9	14.3	24.8	68.2	9.1	46.0	21.3	9.0	47.4	46.6	33.8	41.6	19.8	10.3	27.3	23.3	10.7	21.3	0.0	0.7	0.0	1.1	1.2	0.5	4.0	5.3	2.7	2.1	1.2	0.3	1.4	1.1	6.2	1.0	0.7	21.2	3.5	2.1	4.5	1.1	1.9	1.6	0.7	3.1	1.6	2.1	1.6
TLX1	"HOX11, TCL3"	ENSG00000107807	"T cell leukemia homeobox 1"	P31314	10	101130505-101137789	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"lymphoid tissue: 59.5;salivary gland: 19.5"	"Cell line enhanced"	"Detected in some"		"HAP1: 5.3;HEK 293: 3.0;K-562: 15.0;SCLC-21H: 2.5;SH-SY5Y: 3.7;SiHa: 2.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	13	"pons and medulla: 0.5"	"Region enriched"	"Detected in single"	20	"pons and medulla: 0.5"	HPA053185			Supported	Nucleoplasm				Nucleoplasm		"HPA053185: "	"unprognostic (8.67e-2)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (7.32e-4)"	"unprognostic (1.06e-5)"	"unprognostic (1.06e-1)"	"unprognostic (1.60e-1)"	"unprognostic (5.07e-1)"	"unprognostic (1.57e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.69e-2)"	"unprognostic (2.52e-3)"	"unprognostic (1.81e-1)"		"unprognostic (2.63e-1)"	"unprognostic (3.26e-1)"	"unprognostic (3.06e-1)"	"unprognostic (7.35e-2)"	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.1	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.1	0.2	0.0	0.0	19.5	0.0	0.1	0.0	0.6	0.0	0.0	59.5	0.0	0.1	0.1	0.0	0.0	4.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.5	3.7	2.5	0.0	0.0	0.1	0.4	0.2	0.0	1.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.1	0.1
TLX3	"HOX11L2, RNX"	ENSG00000164438	"T cell leukemia homeobox 3"	O43711	5	171309284-171312134	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	59	"brain: 46.6"	"Cell line enriched"	"Detected in some"	5	"SH-SY5Y: 24.0"	"Cancer enhanced"	"Detected in some"		"cervical cancer: 1.7"	"Region enriched"	"Detected in some"	22	"cerebellum: 46.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	7	"cerebellum: 2.5"	"Region enriched"	"Detected in some"	11	"cerebellum: 48.1"	"HPA030504, HPA060957, HPA069359"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA030504: , HPA060957: , HPA069359: "		"unprognostic (3.52e-2)"		"unprognostic (2.43e-2)"					"unprognostic (2.09e-1)"	"unprognostic (3.11e-1)"				"unprognostic (9.80e-2)"	"unprognostic (2.76e-2)"		"unprognostic (4.48e-2)"	0.4	0.5	0.0	0.0	0.0	0.0	0.0	46.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.6	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.2	0.0	0.0	24.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.6	0.0	0.0	0.0	0.0	0.0	2.0	0.0
TMEM127	"FLJ20507, FLJ22257"	ENSG00000135956	"Transmembrane protein 127"	O75204	2	96248516-96265994	"Cancer-related genes, Disease related genes, Predicted membrane proteins"			"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (5.15e-3)"	"unprognostic (2.67e-1)"	"unprognostic (1.72e-2)"	"unprognostic (6.51e-2)"	"unprognostic (5.82e-2)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (6.59e-4)"	"unprognostic (6.73e-2)"	"unprognostic (4.25e-1)"	"unprognostic (1.06e-2)"	"unprognostic (7.50e-2)"	"unprognostic (2.17e-1)"	"prognostic favourable (6.69e-5)"	"unprognostic (3.59e-1)"	"unprognostic (1.52e-1)"	"unprognostic (5.15e-2)"	"unprognostic (3.65e-2)"	27.6	27.8	16.4	18.7	22.6	31.8	26.1	20.2	40.6	22.9	27.2	18.7	27.3	22.2	24.8	18.9	29.3	18.2	24.2	45.6	15.6	16.5	29.3	43.3	22.9	19.8	14.8	13.1	23.4	26.2	50.7	23.7	21.6	21.4	20.5	21.5	26.5	29.8	31.5	18.7	24.0	41.8	24.4	11.2	28.5	20.0	12.7	12.8	19.6	22.4	19.3	26.9	26.1	22.3	2.4	4.5	14.7	6.7	1.5	3.4	2.9	11.8	16.0	8.5	13.1	37.8	19.2	15.8	15.6	28.0	16.6	15.3	15.8	16.9	7.4	22.9	30.6	19.1	9.8	14.4	11.7	14.9	7.7	12.9	7.7	15.4	24.4	10.9	23.3	23.2	20.6	20.6	15.3	18.8	7.9	16.0	16.9	13.5	7.1	6.9	11.6	17.3	6.7	10.7	11.0	18.6	20.4	9.6	10.1	11.4	27.2	13.0	10.1	11.7	22.0	27.8	15.9	24.0	10.7	12.2	11.7	5.9	18.5	12.9	14.7	4.1	6.5	7.9	3.1	6.7	3.4	2.1	2.3	3.3	4.5	2.4	1.8	2.4	14.7	1.5	5.3	2.7	1.6	2.9	16.4	22.6	20.2	40.6	15.6	16.5	14.8	13.1	21.4	12.8
TMF1	"ARA160, TMF"	ENSG00000144747	"TATA element modulatory factor 1"	P82094	3	69019827-69052339	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008729	Approved		Supported	"Golgi apparatus"				"Golgi apparatus"		"HPA008729: AB_1080310"	"unprognostic (2.71e-1)"	"unprognostic (2.11e-2)"	"unprognostic (8.02e-3)"	"unprognostic (7.19e-2)"	"unprognostic (2.74e-1)"	"unprognostic (6.75e-3)"	"unprognostic (6.73e-3)"	"unprognostic (1.79e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.37e-2)"	"unprognostic (1.08e-2)"	"unprognostic (2.83e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.03e-2)"	"unprognostic (1.80e-1)"	"unprognostic (3.51e-2)"	"unprognostic (1.01e-1)"	17.4	14.2	12.8	15.2	14.2	26.2	20.8	20.8	15.6	18.8	21.1	9.5	26.6	14.8	18.3	24.2	14.9	17.7	16.8	16.7	11.9	12.1	17.5	17.2	19.0	16.8	13.5	11.1	20.2	23.0	22.3	36.1	28.9	17.2	19.0	16.9	9.5	24.3	28.9	21.3	13.3	22.9	13.8	13.6	16.3	15.9	20.9	16.0	20.3	24.7	11.1	16.4	23.2	18.6	6.6	4.6	10.0	5.9	5.0	6.4	3.1	12.5	5.5	5.3	5.3	14.3	18.5	11.9	16.3	15.8	11.0	13.3	7.8	9.4	4.8	2.6	16.5	7.0	6.8	7.2	18.1	9.2	5.2	9.4	7.3	9.2	13.0	10.5	13.4	10.8	11.6	14.5	13.2	11.7	5.6	7.9	14.2	7.2	6.0	9.1	4.6	2.9	5.0	6.7	6.9	14.2	10.2	3.7	5.6	13.4	9.5	10.1	7.2	12.7	15.2	10.8	4.6	18.9	9.7	8.9	8.5	4.7	16.5	10.9	8.5	7.6	4.5	9.1	6.4	3.7	4.3	5.2	5.7	5.4	4.0	6.6	5.9	5.4	10.0	5.0	5.9	4.6	5.8	3.1	12.8	14.2	20.8	15.6	11.9	12.1	13.5	11.1	17.2	16.0
TMPRSS2	PRSS10	ENSG00000184012	"Transmembrane serine protease 2"	O15393	21	41464551-41531116	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 75.6;pancreas: 64.5;prostate: 68.2"	"Cell line enhanced"	"Detected in some"		"CACO-2: 14.6;MCF7: 6.3;RT4: 35.2;SK-BR-3: 7.2;T-47d: 5.4"	"Cancer enriched"	"Detected in many"	7	"prostate cancer: 250.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"HPA034493, HPA035787"	Enhanced		Supported	"Nucleoplasm,Cell Junctions"	"Intracellular and membrane"			"Cell Junctions"	Nucleoplasm	"HPA034493: , HPA035787: AB_2674782"	"unprognostic (4.80e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.16e-1)"	"prognostic favourable (2.56e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.05e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.51e-3)"	"unprognostic (9.43e-2)"	"unprognostic (9.02e-3)"	"unprognostic (6.24e-2)"	"unprognostic (6.43e-2)"	"prognostic favourable (7.86e-6)"	"unprognostic (2.00e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.15e-2)"	0.2	0.1	0.2	15.5	0.4	0.0	6.1	0.2	0.5	1.3	38.7	0.4	24.4	17.5	0.5	0.9	10.7	2.2	17.3	0.2	0.3	0.1	19.4	18.4	20.7	0.2	0.2	0.2	0.7	64.5	0.0	1.3	1.0	0.4	68.2	18.5	0.3	52.3	35.7	0.2	2.1	75.6	0.9	0.2	0.3	36.7	0.8	0.3	0.5	19.9	3.9	10.2	5.9	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	14.6	1.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.1	0.5	1.3	0.0	0.0	0.0	1.4	0.6	35.2	0.0	0.4	0.0	7.2	0.1	5.4	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.4	0.2	0.5	0.3	0.1	0.2	0.2	0.4	0.3
TMPRSS3	"DFNB10, DFNB8"	ENSG00000160183	"Transmembrane serine protease 3"	P57727	21	42371837-42396846	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 24.7"	"Group enriched"	"Detected in some"	5	"HEL: 18.3;U-266/84: 73.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 6.3"	"Lineage enriched"	"Detected in single"	7	"T-cells: 6.3"	"Region enriched"	"Detected in single"	7	"cerebellum: 0.9"	"Not detected"	"Not detected"														"unprognostic (8.47e-3)"	"unprognostic (2.83e-1)"	"prognostic unfavourable (3.64e-4)"	"unprognostic (2.85e-1)"	"unprognostic (2.45e-3)"	"unprognostic (3.97e-2)"	"unprognostic (1.43e-1)"	"unprognostic (8.17e-2)"	"unprognostic (9.62e-2)"	"unprognostic (4.81e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.42e-1)"	"prognostic unfavourable (8.24e-4)"	"unprognostic (2.66e-2)"	"unprognostic (2.73e-1)"	"unprognostic (8.00e-2)"	"unprognostic (1.33e-1)"	1.8	0.7	8.6	0.3	7.7	0.3	9.4	0.3	7.1	6.8	0.4	0.0	0.0	1.7	0.9	0.4	0.4	24.7	8.6	0.2	1.8	1.6	3.5	3.5	3.7	0.6	3.7	2.0	2.8	7.4	0.2	5.8	5.7	3.3	0.8	0.4	2.4	12.3	0.6	0.3	0.6	1.3	0.2	0.2	0.6	15.9	0.2	0.8	0.0	9.8	0.2	0.6	1.9	0.0	0.0	0.1	0.7	0.8	0.0	6.3	1.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	9.0	0.0	18.3	7.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.4	0.9	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.4	0.0	0.0	9.5	0.4	0.0	0.9	0.1	0.0	0.0	0.5	0.0	0.0	0.2	73.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.2	6.3	0.0	3.5	3.6	0.1	0.0	0.7	1.8	0.7	0.0	0.8	0.0	1.6	1.0	8.6	7.7	0.3	7.1	1.8	1.6	3.7	2.0	3.3	0.8
TNC	"DFNA56, HXB, MGC167029, TN"	ENSG00000041982	"Tenascin C"	P24821	9	115019578-115118257	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"		"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 111.4"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 83.7;hTEC/SVTERT24-B: 68.4;U-138 MG: 57.6;U-87 MG: 76.7;WM-115: 131.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.9"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB004592, HPA004823"	Approved				"Secreted to extracellular matrix"	760000000	760000000			"CAB004592: AB_628342, HPA004823: AB_1080243"	"unprognostic (5.46e-2)"	"unprognostic (3.76e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.69e-1)"	"unprognostic (9.20e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.07e-1)"	"unprognostic (9.68e-2)"	"unprognostic (7.86e-3)"	"unprognostic (2.68e-3)"	"unprognostic (1.59e-2)"	"unprognostic (1.82e-1)"	"unprognostic (4.87e-3)"	"unprognostic (1.79e-2)"	"unprognostic (1.92e-2)"	"unprognostic (7.60e-2)"	"unprognostic (1.97e-3)"	20.6	2.5	1.4	50.9	11.4	0.5	12.6	0.4	6.4	19.4	63.6	18.6	24.1	5.3	42.4	23.9	18.5	12.0	16.9	13.6	3.4	2.8	16.4	2.6	21.0	66.3	4.3	3.3	10.6	1.8	0.6	3.3	3.2	14.7	13.0	9.3	0.0	8.5	10.8	10.8	10.3	21.2	111.4	5.7	26.9	31.3	5.4	6.8	4.7	5.5	15.4	16.1	20.4	6.6	0.3	0.3	1.9	0.3	0.2	0.3	0.1	2.5	0.6	0.7	0.1	4.1	1.1	0.0	21.5	83.7	45.6	22.5	0.5	5.8	0.0	3.4	30.4	9.0	0.0	1.2	27.4	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.4	0.6	0.1	68.4	31.9	0.0	0.0	0.5	1.2	0.0	0.0	0.0	7.1	9.2	0.0	48.4	0.0	41.5	0.0	0.0	0.6	9.0	0.0	2.1	0.0	0.1	0.0	57.6	9.5	9.9	50.5	1.5	0.0	0.0	76.7	0.0	131.3	0.1	0.3	0.1	0.3	0.1	0.1	0.2	0.2	0.1	0.3	0.3	0.1	0.2	1.9	0.2	0.0	0.2	0.0	0.1	1.4	11.4	0.4	3.9	3.4	2.8	4.3	3.3	14.7	6.8
TNF	"DIF, TNF-alpha, TNFA, TNFSF2"	ENSG00000232810	"Tumor necrosis factor"	P01375	6	31575567-31578336	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.6;lymphoid tissue: 28.0"	"Group enriched"	"Detected in some"	5	"HDLM-2: 10.0;HMC-1: 9.6;NB-4: 28.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 10.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 3.5;monocytes: 10.8;T-cells: 6.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (1.93e-1)"	"unprognostic (1.07e-2)"	"unprognostic (3.85e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.19e-2)"	"unprognostic (1.94e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.46e-2)"	"unprognostic (1.82e-1)"	"unprognostic (9.85e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.04e-1)"	2.3	1.2	0.6	15.6	1.0	14.6	1.2	0.4	1.8	1.7	1.3	3.7	0.3	1.3	1.1	0.4	1.5	0.9	2.3	2.0	0.5	0.3	2.6	1.9	9.5	8.0	0.8	0.0	0.6	0.7	0.5	0.5	3.2	2.0	0.7	0.7	0.4	2.2	0.8	0.4	2.7	4.1	0.7	1.0	28.0	1.0	0.4	0.5	2.1	0.6	5.3	14.7	1.2	0.4	1.3	1.2	3.5	10.8	0.5	6.6	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	10.0	0.0	1.8	0.0	0.0	0.0	0.8	9.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.9	0.0	0.0	1.7	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.3	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	1.7	0.0	4.1	6.5	6.6	1.3	3.1	2.4	1.2	1.3	0.9	1.0	3.5	0.5	10.8	0.7	2.2	2.1	0.6	1.0	0.4	1.8	0.5	0.3	0.8	0.0	2.0	0.5
TNFAIP2	"B94, EXOC3L3"	ENSG00000185215	"TNF alpha induced protein 2"	Q03169	14	103123442-103137439	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Angiogenesis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enriched"	"Detected in many"	5	"RT4: 126.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 25.9"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB004598, HPA030624"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Golgi apparatus,Cytosol"				"Golgi apparatus, Cytosol"	"Nucleoplasm, Nuclear membrane"	"CAB004598: AB_628370, HPA030624: "	"unprognostic (5.01e-3)"	"unprognostic (4.93e-2)"	"unprognostic (1.56e-3)"	"unprognostic (8.02e-3)"	"unprognostic (3.39e-2)"	"unprognostic (2.98e-2)"	"unprognostic (5.52e-3)"	"unprognostic (5.97e-2)"	"unprognostic (1.94e-1)"	"unprognostic (7.02e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (4.10e-4)"	"prognostic favourable (2.79e-5)"	"unprognostic (1.75e-2)"	"unprognostic (3.83e-2)"	"prognostic favourable (7.17e-5)"	27.3	17.0	3.8	58.2	5.7	20.1	19.3	2.5	3.6	23.5	12.9	2.8	4.7	8.1	16.7	18.7	35.5	14.3	30.9	12.7	2.9	3.6	18.8	13.6	32.0	17.9	4.6	3.0	9.7	9.0	17.4	3.5	33.0	6.1	21.7	6.1	16.3	25.1	7.1	12.5	13.2	11.3	28.0	3.8	35.9	8.3	13.0	2.9	11.0	8.5	31.4	48.6	39.8	16.3	0.1	5.0	25.9	9.8	0.1	0.1	1.9	5.4	26.9	0.1	0.1	1.7	7.7	9.0	1.6	6.9	4.3	1.5	0.2	24.4	0.0	20.1	7.8	17.4	1.9	0.0	2.1	0.9	0.1	2.4	18.8	0.1	3.3	1.2	3.4	2.9	0.2	1.4	0.0	2.2	2.4	5.9	0.6	0.5	0.0	1.9	1.6	2.2	1.0	3.1	3.9	13.8	126.5	0.2	0.3	24.7	8.6	0.3	13.9	8.0	4.6	0.9	2.3	5.0	5.0	5.3	0.3	0.1	6.5	5.5	2.6	2.5	8.8	4.6	0.0	9.8	0.0	0.0	0.0	0.0	5.0	0.1	0.0	0.1	25.9	0.1	6.9	0.2	0.0	1.9	3.8	5.7	2.5	3.6	2.9	3.6	4.6	3.0	6.1	2.9
TNFAIP3	"A20, OTUD7C"	ENSG00000118503	"TNF alpha induced protein 3"	P21580	6	137867188-137883312	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Inflammatory response, Ubl conjugation pathway"	"DNA-binding, Hydrolase, Multifunctional enzyme, Protease, Thiol protease, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 112.4"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 48.4;REH: 42.0;U-266/84: 36.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA002116, HPA067479"	Approved		Supported	Vesicles				Vesicles		"HPA002116: AB_1858162, HPA067479: "	"unprognostic (5.50e-3)"	"unprognostic (9.98e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.01e-2)"	"unprognostic (4.01e-2)"	"unprognostic (9.47e-2)"	"unprognostic (5.01e-3)"	"unprognostic (4.40e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.06e-1)"	"prognostic unfavourable (6.05e-4)"	"unprognostic (6.06e-2)"	"unprognostic (3.55e-3)"	"unprognostic (1.27e-1)"	"unprognostic (6.29e-2)"	27.4	6.0	1.5	58.6	1.8	112.4	17.2	0.4	1.5	7.7	15.7	3.2	2.6	5.1	9.7	7.3	12.7	12.1	17.0	11.7	2.1	1.3	6.8	8.1	45.1	38.8	2.1	2.6	37.5	7.2	2.1	3.7	14.5	4.6	13.8	6.3	7.2	8.2	3.5	10.7	20.5	17.2	8.2	3.8	25.9	8.0	9.3	2.1	38.6	5.7	9.2	31.4	23.3	9.5	7.1	18.6	10.0	9.7	7.5	20.5	9.0	8.9	1.5	0.5	0.8	3.0	5.1	2.1	5.1	20.0	1.4	1.8	9.9	3.0	2.0	13.2	5.9	6.8	0.3	14.8	2.6	14.6	0.5	2.0	5.2	5.8	3.3	2.7	3.7	4.7	2.1	16.9	16.1	0.8	4.1	48.4	2.4	0.5	14.7	11.5	0.3	0.4	42.0	10.4	1.4	4.4	4.3	0.2	0.0	1.0	1.5	4.4	1.0	3.4	4.0	14.5	1.7	12.9	2.9	15.6	36.1	4.1	5.3	3.5	1.8	5.6	9.7	5.5	14.8	7.1	20.5	6.2	15.1	13.3	10.3	7.1	10.0	7.4	10.0	7.5	3.7	18.6	14.7	9.0	1.5	1.8	0.4	1.5	2.1	1.3	2.1	2.6	4.6	2.1
TNFRSF10A	"Apo2, CD261, DR4, TRAILR-1, TRAILR1"	ENSG00000104689	"TNF receptor superfamily member 10a"	O00220	8	23190452-23225126	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											"HPA050958, HPA054475"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA050958: , HPA054475: "	"unprognostic (3.66e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.19e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.44e-2)"	"unprognostic (8.39e-2)"	"unprognostic (5.32e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.48e-2)"	"prognostic unfavourable (1.00e-4)"	"unprognostic (1.49e-1)"	"unprognostic (1.99e-3)"	"unprognostic (1.91e-2)"	"unprognostic (1.61e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.87e-1)"	11.9	4.0	2.1	13.0	3.4	8.4	9.7	2.0	2.8	6.0	10.9	1.4	4.5	5.9	5.3	5.6	13.6	4.1	12.7	6.3	2.2	2.0	10.9	10.6	11.0	12.4	3.0	0.7	2.7	12.9	3.6	1.8	6.9	4.0	5.1	7.2	2.1	8.2	4.3	3.8	7.1	10.2	3.8	2.9	13.2	6.1	2.6	3.0	9.5	5.8	14.9	25.4	6.7	8.7	13.2	4.5	3.8	4.3	3.9	13.9	4.2	7.9	14.4	0.7	0.0	0.5	2.9	0.0	1.6	1.0	0.8	2.3	11.0	14.0	18.4	18.8	1.0	15.2	12.9	20.6	1.4	4.5	0.1	9.7	8.7	6.2	7.4	5.2	9.3	5.0	17.0	18.3	15.8	9.7	15.0	6.6	3.9	6.2	0.2	3.3	10.0	8.8	0.1	0.0	13.2	11.0	17.2	0.4	0.5	4.0	10.2	0.0	5.4	4.0	13.6	0.0	0.1	0.8	0.0	7.8	11.0	14.3	0.1	1.7	0.2	2.0	4.3	3.8	3.8	1.9	10.3	10.4	12.3	7.7	4.5	13.2	12.1	7.0	0.5	3.9	1.7	0.0	13.9	4.2	2.1	3.4	2.0	2.8	2.2	2.0	3.0	0.7	4.0	3.0
TNFRSF10B	"CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB"	ENSG00000120889	"TNF receptor superfamily member 10b"	O14763	8	23020133-23069179	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA023625	Approved									"HPA023625: AB_1847860"	"unprognostic (8.43e-3)"	"unprognostic (7.43e-3)"	"unprognostic (3.04e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.13e-1)"	"unprognostic (7.74e-2)"	"unprognostic (2.15e-1)"	"unprognostic (9.51e-3)"	"unprognostic (2.70e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.30e-3)"	"unprognostic (1.96e-2)"	"prognostic unfavourable (1.76e-4)"	"unprognostic (4.01e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.86e-1)"	"unprognostic (5.52e-2)"	29.6	18.5	5.2	16.4	7.3	7.6	19.6	2.3	5.8	11.5	23.1	7.5	13.3	14.1	10.4	13.9	12.1	11.4	22.1	13.2	6.4	3.2	14.3	36.1	21.3	11.6	7.9	2.6	16.2	20.0	14.8	6.1	8.5	8.2	15.1	14.3	7.9	11.5	14.5	15.5	6.1	31.2	10.5	8.6	17.4	11.2	7.8	6.4	4.1	17.7	13.0	15.2	17.9	9.9	3.1	12.1	2.8	12.9	0.8	4.0	5.2	8.5	22.7	33.3	10.1	15.6	20.4	32.6	20.6	26.5	11.2	17.5	9.4	8.6	5.1	14.0	11.2	8.3	8.7	39.0	20.0	5.1	7.3	0.0	8.9	17.6	52.3	1.9	8.6	30.3	35.0	24.9	26.6	35.5	3.6	0.0	22.0	2.8	0.2	2.8	8.3	8.2	4.6	12.1	3.2	21.7	13.5	0.0	5.6	10.3	2.9	10.9	5.0	2.4	31.4	16.4	8.5	5.2	14.8	6.6	1.1	2.4	16.7	3.7	23.4	2.8	12.9	0.4	1.6	9.3	2.7	3.1	1.9	1.6	12.1	1.6	4.0	1.6	2.6	0.8	11.9	0.0	1.3	5.2	5.2	7.3	2.3	5.8	6.4	3.2	7.9	2.6	8.2	6.4
TNFRSF10C	"CD263, DcR1, LIT, TRAILR3, TRID"	ENSG00000173535	"TNF receptor superfamily member 10c"	O14798	8	23102590-23117437	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"blood: 173.4"	"Group enriched"	"Detected in some"	5	"BEWO: 37.1;HUVEC TERT2: 30.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	7	"neutrophil: 173.4"	"Lineage enriched"	"Detected in many"	113	"granulocytes: 173.4"									CAB025635	Enhanced									"CAB025635: "	"unprognostic (2.63e-1)"	"unprognostic (4.49e-3)"	"unprognostic (7.21e-3)"	"unprognostic (2.07e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.81e-2)"	"unprognostic (2.11e-3)"	"unprognostic (5.56e-2)"	"unprognostic (4.37e-2)"	"unprognostic (8.98e-2)"	"unprognostic (1.94e-3)"	"unprognostic (2.74e-3)"	"unprognostic (4.83e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.34e-3)"	"unprognostic (6.54e-2)"	5.5	1.5	1.9	14.0	3.6	12.6	2.0	1.4	3.9	2.9	1.5	0.7	0.1	1.2	1.5	1.2	1.4	3.7	13.5	5.6	1.9	1.1	2.8	3.2	13.7	28.4	9.2	0.0	2.4	2.1	2.5	4.5	12.8	3.1	2.7	1.8	1.7	1.7	0.8	2.3	0.8	2.2	1.9	4.4	26.4	1.8	1.4	2.3	0.8	4.4	0.5	0.9	5.2	1.9	0.0	0.3	173.4	1.5	0.0	0.0	0.4	0.4	1.4	0.5	2.4	0.0	0.3	37.1	1.5	0.0	0.1	0.1	0.0	1.4	0.1	0.7	1.4	0.2	0.1	0.1	0.1	2.5	0.5	0.1	0.3	1.1	3.6	0.2	1.0	4.1	0.3	0.7	0.3	30.9	0.0	0.0	0.2	1.0	0.0	0.9	1.6	0.0	0.1	0.1	0.0	5.9	0.1	0.0	0.0	0.1	0.2	0.7	5.1	0.2	6.5	0.6	1.2	1.4	0.1	1.5	0.8	0.0	2.2	0.3	0.9	2.7	1.5	25.4	0.0	0.8	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	173.4	0.0	1.1	0.0	0.0	0.4	1.9	3.6	1.4	3.9	1.9	1.1	9.2	0.0	3.1	2.3
TNFRSF10D	"CD264, DcR2, TRAILR4, TRUNDD"	ENSG00000173530	"TNF receptor superfamily member 10d"	Q9UBN6	8	23135588-23164030	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 24.1;LHCN-M2: 60.9;WM-115: 57.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 9.0"	"Low lineage specificity"	"Detected in many"											HPA070971			Approved	"Plasma membrane,Actin filaments"				"Plasma membrane, Actin filaments"		"HPA070971: "	"unprognostic (1.49e-1)"	"prognostic unfavourable (1.70e-4)"	"unprognostic (1.41e-1)"	"unprognostic (8.78e-2)"	"unprognostic (8.13e-2)"	"unprognostic (7.49e-2)"	"unprognostic (2.69e-1)"	"unprognostic (7.06e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.61e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.35e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.72e-1)"	16.0	3.1	4.9	7.3	10.0	10.5	10.2	3.4	10.3	5.9	8.5	2.6	5.5	6.2	8.9	5.7	4.1	8.0	11.5	6.5	7.0	3.4	12.1	31.5	12.5	5.1	9.0	0.9	9.8	5.2	2.5	4.3	4.1	9.0	9.0	10.9	3.9	3.9	4.4	3.9	3.1	11.2	10.9	6.3	6.9	7.2	4.3	9.2	2.9	6.0	6.8	6.6	7.3	26.0	2.1	4.5	2.4	3.3	0.3	9.0	2.4	3.5	3.0	4.0	2.2	3.0	12.1	0.0	18.8	7.1	1.4	1.9	5.8	2.9	0.0	4.0	11.2	1.2	3.3	16.5	12.5	0.0	2.9	1.0	1.8	5.0	13.3	0.6	1.3	15.1	18.4	5.0	3.5	24.1	0.0	0.0	60.9	0.0	0.0	1.9	3.2	0.0	0.7	0.0	0.9	4.7	1.6	0.0	0.0	2.0	0.0	0.0	0.0	2.3	14.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	15.7	0.9	57.8	2.4	3.3	1.5	0.0	1.4	0.1	2.1	3.2	1.1	4.5	0.8	9.0	3.5	2.2	0.3	1.9	0.0	1.0	2.4	4.9	10.0	3.4	10.3	7.0	3.4	9.0	0.9	9.0	9.2
TNFRSF11B	"OCIF, OPG, TR1"	ENSG00000164761	"TNF receptor superfamily member 11b"	O00300	8	118923557-118952200	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	Apoptosis	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 18.6;thyroid gland: 52.8"	"Group enriched"	"Detected in some"	4	"BJ: 49.7;BJ hTERT+: 184.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	66	"plasmacytoid DC: 6.5"	"Lineage enriched"	"Detected in single"	66	"dendritic cells: 6.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB034939	Approved				"Secreted in other tissues"					"CAB034939: "	"unprognostic (1.39e-2)"	"prognostic unfavourable (6.22e-4)"	"unprognostic (5.27e-2)"	"unprognostic (2.33e-2)"	"unprognostic (4.27e-3)"	"unprognostic (1.10e-3)"	"unprognostic (1.21e-3)"	"unprognostic (5.50e-2)"	"unprognostic (9.94e-2)"	"unprognostic (6.32e-2)"	"unprognostic (3.53e-2)"	"unprognostic (2.43e-1)"	"prognostic favourable (6.79e-4)"	"unprognostic (1.32e-2)"	"unprognostic (4.52e-2)"	"unprognostic (1.61e-3)"	"prognostic unfavourable (3.88e-4)"	3.0	3.0	2.2	2.8	2.8	0.2	4.4	2.9	5.2	1.2	1.5	0.7	0.5	0.9	5.5	4.1	1.0	1.7	3.2	7.3	2.8	1.4	18.6	7.6	8.1	5.3	1.7	0.8	0.5	2.8	0.3	1.9	4.0	12.0	1.1	2.0	1.8	1.4	0.8	0.6	0.7	1.4	1.5	7.9	1.5	0.8	0.3	2.7	0.9	52.8	0.8	1.7	1.7	1.1	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	2.6	0.5	0.0	49.7	184.9	2.4	0.6	0.5	0.1	0.0	13.4	27.5	0.5	0.0	0.0	1.2	0.0	0.0	0.0	2.3	0.0	0.3	0.0	0.0	0.2	0.0	2.4	0.0	0.0	0.0	0.0	6.9	1.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.2	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.1	1.5	0.8	0.9	0.1	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	2.2	2.8	2.9	5.2	2.8	1.4	1.7	0.8	12.0	2.7
TNFRSF12A	"CD266, FN14, TweakR"	ENSG00000006327	"TNF receptor superfamily member 12A"	Q9NP84	16	3018445-3022383	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation"	"Developmental protein, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 81.3"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	5	"pons and medulla: 25.0"	"Group enriched"	"Detected in many"	8	"eosinophil: 38.1;neutrophil: 29.9"	"Lineage enriched"	"Detected in many"	9	"granulocytes: 38.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			HPA007853	Approved		Approved	"Plasma membrane,Cytosol"		170000	170000	"Plasma membrane, Cytosol"		"HPA007853: AB_1858463"	"unprognostic (1.44e-1)"	"unprognostic (2.46e-3)"	"unprognostic (8.90e-2)"	"unprognostic (2.60e-1)"	"unprognostic (4.06e-3)"	"prognostic unfavourable (5.50e-4)"	"unprognostic (7.04e-3)"	"unprognostic (1.98e-3)"	"unprognostic (4.17e-3)"	"unprognostic (2.85e-1)"	"unprognostic (5.02e-3)"	"unprognostic (3.88e-1)"	"prognostic unfavourable (8.78e-4)"	"unprognostic (2.98e-2)"	"unprognostic (6.00e-2)"	"unprognostic (2.80e-3)"	"unprognostic (2.17e-2)"	10.8	14.2	2.4	11.3	5.1	2.7	21.2	0.9	3.0	8.0	18.9	3.2	4.1	14.5	11.6	10.2	10.7	6.4	28.1	27.0	5.0	2.6	50.4	36.2	23.0	2.6	4.8	0.5	6.4	47.0	51.1	20.0	81.3	25.0	11.1	1.9	2.8	17.3	6.9	23.3	5.0	31.0	16.8	4.3	3.9	13.2	5.3	3.3	1.2	11.5	11.5	4.7	14.8	5.2	0.0	4.1	38.1	3.5	2.0	2.4	1.1	24.3	19.8	2.2	4.1	4.0	9.2	13.1	51.3	37.2	44.0	28.3	8.5	43.5	0.1	68.0	34.1	27.0	0.5	37.5	16.9	0.9	1.3	0.1	6.6	7.2	27.8	0.4	1.8	8.5	26.0	46.2	55.4	12.7	2.7	0.3	46.3	46.0	0.0	3.2	10.7	43.4	0.2	24.7	1.0	44.5	4.8	2.5	0.8	36.6	17.0	30.3	8.9	0.7	22.3	79.3	36.6	52.4	84.2	0.8	0.3	0.3	24.7	2.2	62.3	3.5	3.5	38.1	1.8	2.0	2.4	0.0	0.8	1.5	4.1	0.0	0.4	0.8	29.9	2.0	1.3	0.1	1.0	1.1	2.4	5.1	0.9	3.0	5.0	2.6	4.8	0.5	25.0	3.3
TNFRSF14	"ATAR, CD270, HVEA, HVEM, LIGHTR, TR2"	ENSG00000157873	"TNF receptor superfamily member 14"	Q92956	1	2555639-2565382	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 14.3;HDLM-2: 14.4;HHSteC: 16.9;Karpas-707: 13.3;SK-MEL-30: 27.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA006404, CAB026150, CAB030007"	Approved		Approved	"Cytosol,Rods & Rings"				Cytosol	"Rods & Rings"	"CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348"	"prognostic favourable (4.39e-5)"	"unprognostic (3.48e-2)"	"unprognostic (1.53e-2)"	"prognostic favourable (8.01e-6)"	"unprognostic (1.11e-2)"	"unprognostic (6.83e-3)"	"unprognostic (9.62e-3)"	"unprognostic (2.32e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.86e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.58e-1)"	"prognostic favourable (7.79e-6)"	15.9	24.9	4.9	38.9	2.8	11.0	21.9	2.0	4.5	16.8	36.3	3.2	18.5	36.3	15.2	20.5	13.7	12.3	36.7	12.7	4.9	2.5	19.3	20.5	30.3	33.2	3.6	5.7	12.8	7.3	3.5	9.3	8.3	3.9	21.5	8.2	44.1	20.9	22.6	5.2	8.4	41.9	14.6	4.1	36.7	16.7	5.9	2.7	23.5	10.8	10.6	25.0	15.4	17.2	18.2	9.7	30.2	25.8	8.1	25.1	14.2	1.3	0.1	0.1	2.3	5.0	2.7	0.7	0.7	2.3	1.3	1.9	0.2	14.3	0.8	0.1	2.1	1.3	0.0	0.8	0.2	14.4	0.0	8.4	0.4	2.6	16.9	1.1	10.4	2.6	1.4	0.7	0.1	3.7	1.1	13.3	1.2	0.0	4.6	1.3	0.0	1.2	3.8	0.0	4.1	0.2	2.0	0.4	0.0	0.5	0.1	27.9	0.4	0.3	9.4	0.2	0.6	0.2	0.1	10.8	2.6	0.4	2.3	1.2	1.0	3.0	15.1	8.2	17.2	25.8	14.9	16.6	18.0	14.8	9.7	18.2	17.3	14.9	30.2	8.1	24.1	8.7	25.1	14.2	4.9	2.8	2.0	4.5	4.9	2.5	3.6	5.7	3.9	2.7
TNFRSF17	"BCM, BCMA, CD269, TNFRSF13A"	ENSG00000048462	"TNF receptor superfamily member 17"	Q02223	16	11965107-11968068	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 25.3;RPMI-8226: 39.9;U-266/70: 118.6;U-266/84: 58.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	59	"memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9"	"Group enriched"	"Detected in many"	62	"B-cells: 34.1;dendritic cells: 27.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									2200000	2200000				"prognostic favourable (1.35e-5)"	"unprognostic (3.41e-2)"	"unprognostic (4.00e-3)"	"unprognostic (1.41e-2)"	"unprognostic (6.47e-2)"	"prognostic favourable (1.58e-6)"	"unprognostic (9.75e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.13e-2)"	"unprognostic (7.96e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.85e-6)"	"unprognostic (2.06e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.10e-1)"	0.6	0.4	0.4	24.0	0.9	0.3	5.4	0.5	0.4	1.5	17.8	0.2	0.2	12.3	0.5	0.2	3.7	1.1	4.9	0.7	0.4	0.4	1.3	0.8	3.0	22.4	0.4	0.2	0.9	3.1	0.0	0.5	0.3	0.2	1.0	9.4	0.6	14.2	0.2	0.4	0.4	11.7	0.2	0.4	22.2	9.4	2.2	0.3	3.1	1.1	1.4	28.8	7.6	0.7	34.1	27.9	0.5	0.1	0.2	0.1	3.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	25.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	118.6	58.9	9.2	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	34.1	0.0	0.0	0.0	26.9	0.0	0.0	0.5	0.2	0.0	27.9	0.0	3.7	0.4	0.9	0.5	0.4	0.4	0.4	0.4	0.2	0.2	0.3
TNFRSF1A	"CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60"	ENSG00000067182	"TNF receptor superfamily member 1A"	P19438	12	6328757-6342114	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 86.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004102, CAB010309"	Approved				"Secreted to blood"	170000	170000			"CAB010309: AB_2206639, HPA004102: AB_1846232"	"unprognostic (2.19e-2)"	"unprognostic (3.76e-2)"	"unprognostic (8.14e-2)"	"prognostic favourable (8.22e-4)"	"unprognostic (3.07e-2)"	"prognostic unfavourable (3.68e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.00e-1)"	"unprognostic (8.05e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavourable (2.70e-7)"	"unprognostic (1.43e-2)"	"unprognostic (2.92e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.74e-1)"	55.1	43.9	16.8	28.9	16.8	13.7	40.6	7.2	15.6	40.3	41.5	14.1	22.6	39.2	38.2	27.5	39.4	34.2	37.1	26.8	14.0	7.5	49.3	61.6	40.9	37.2	19.2	6.4	59.5	21.4	20.3	19.9	45.3	18.3	37.0	23.0	31.1	25.7	22.2	34.2	30.9	81.7	38.8	25.1	43.6	28.2	21.8	15.7	31.6	42.7	25.4	22.3	49.1	58.5	0.0	20.8	86.5	27.1	1.8	11.6	15.9	7.4	57.8	8.1	11.5	56.0	57.3	15.3	15.9	27.5	21.3	18.6	6.9	29.7	0.6	5.5	34.3	20.8	2.5	18.6	14.8	0.1	4.8	4.1	16.0	15.3	49.7	19.3	13.0	59.0	18.7	17.7	26.1	26.0	6.2	5.7	24.5	10.6	6.1	18.2	19.7	16.9	5.3	12.9	5.7	16.5	13.5	0.0	0.4	22.5	11.8	11.8	3.2	21.1	28.3	16.8	14.4	12.6	14.7	0.0	1.8	2.4	20.1	18.0	20.8	2.2	27.1	15.0	11.6	21.8	11.1	0.0	4.9	9.5	20.8	0.0	4.5	6.6	86.5	1.8	17.5	6.0	4.8	15.9	16.8	16.8	7.2	15.6	14.0	7.5	19.2	6.4	18.3	15.7
TNFRSF1B	"CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80"	ENSG00000028137	"TNF receptor superfamily member 1B"	P20333	1	12167003-12209228	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 70.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 17.1;K-562: 20.9;THP-1: 24.5;U-87 MG: 16.8;U-937: 17.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 70.1"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA004796	Approved				"Secreted to blood"	2500000	2500000			"HPA004796: AB_1078436"	"unprognostic (4.45e-2)"	"unprognostic (2.27e-3)"	"unprognostic (7.62e-2)"	"unprognostic (3.82e-3)"	"unprognostic (6.30e-2)"	"unprognostic (4.47e-3)"	"unprognostic (5.28e-3)"	"unprognostic (2.79e-1)"	"unprognostic (1.69e-2)"	"unprognostic (1.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (2.48e-1)"	"prognostic unfavourable (8.35e-5)"	"unprognostic (2.02e-1)"	"prognostic unfavourable (8.68e-4)"	"unprognostic (3.26e-2)"	"unprognostic (1.10e-1)"	43.4	4.7	4.6	44.3	13.8	29.2	42.3	2.1	6.1	13.3	13.1	6.6	1.9	11.9	9.7	10.2	6.5	11.3	11.6	21.8	8.5	6.2	6.2	22.2	24.5	60.6	9.1	2.2	9.4	4.2	2.3	4.4	24.9	15.0	7.3	8.2	8.3	5.7	3.7	11.5	6.2	17.3	11.5	22.6	48.3	10.5	6.0	6.1	10.9	6.2	5.6	16.2	18.3	8.4	2.7	13.2	25.7	70.1	2.5	12.7	19.9	0.0	0.1	2.0	0.0	5.5	7.5	4.3	0.5	1.0	2.0	2.2	0.8	17.1	0.1	0.3	1.8	0.0	0.4	0.0	1.1	6.8	0.0	0.0	0.1	0.0	12.9	0.1	1.8	7.4	0.0	6.8	0.0	10.4	20.9	3.1	0.9	0.0	0.0	3.9	0.1	0.6	0.5	0.2	12.0	0.0	0.4	0.0	0.0	0.3	0.1	0.6	0.0	24.5	3.6	3.0	0.1	13.0	0.0	0.9	0.0	0.0	16.8	17.7	0.7	0.0	20.7	3.0	9.4	49.3	5.4	2.7	6.6	7.7	13.2	1.7	2.0	3.0	25.7	2.5	70.1	2.8	12.7	19.9	4.6	13.8	2.1	6.1	8.5	6.2	9.1	2.2	15.0	6.1
TNFRSF4	"ACT35, CD134, OX40, TXGP1L"	ENSG00000186827	"TNF receptor superfamily member 4"	P43489	1	1211326-1214138	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 12.5;blood: 18.4;lymphoid tissue: 13.6"	"Group enriched"	"Detected in some"	9	"MOLT-4: 7.8;NB-4: 15.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"memory CD4 T-cell: 15.9;T-reg: 18.4"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			CAB016128	Enhanced									"CAB016128: AB_626897"	"unprognostic (2.24e-1)"	"unprognostic (8.69e-3)"	"unprognostic (1.36e-1)"	"unprognostic (8.55e-3)"	"unprognostic (1.02e-1)"	"prognostic favourable (3.50e-6)"	"prognostic unfavourable (6.03e-4)"	"unprognostic (3.30e-1)"	"unprognostic (1.48e-2)"	"unprognostic (7.04e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.47e-1)"	"prognostic unfavourable (4.52e-6)"	"unprognostic (1.61e-1)"	"unprognostic (5.46e-2)"	"unprognostic (2.42e-1)"	"unprognostic (5.91e-2)"	12.5	0.2	0.6	8.8	0.4	0.7	7.3	0.3	1.2	1.1	3.1	0.3	0.3	2.6	0.8	0.7	1.7	0.9	0.8	6.7	0.8	0.1	2.2	0.4	5.3	8.4	0.3	0.6	0.5	0.9	0.0	1.3	5.9	0.6	3.2	0.3	0.6	2.2	1.1	4.4	0.8	4.3	0.3	0.3	13.5	3.5	2.0	0.3	13.6	4.1	0.8	10.9	1.4	0.7	0.0	0.6	4.1	0.0	8.1	18.4	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	15.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.1	0.2	0.0	1.8	0.0	15.9	1.7	0.0	0.0	1.5	0.0	0.2	8.1	0.0	0.6	18.4	1.5	0.6	0.4	0.3	1.2	0.8	0.1	0.3	0.6	0.6	0.3
TNFRSF8	"CD30, D1S166E, KI-1"	ENSG00000120949	"TNF receptor superfamily member 8"	P28908	1	12063377-12144207	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.3"	"Cell line enriched"	"Detected in some"	21	"HDLM-2: 109.9"	"Cancer enriched"	"Detected in some"	12	"testis cancer: 9.3"	"Region enriched"	"Detected in single"	14	"basal ganglia: 13.1"	"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 21.7;non-classical monocyte: 33.3"	"Lineage enriched"	"Detected in many"	5	"monocytes: 33.3"					"Low region specificity"	"Detected in many"			"CAB000016, HPA014823, HPA032081, HPA032082"	Approved		Supported	"Plasma membrane"				"Plasma membrane"		"CAB000016: AB_563546, HPA014823: , HPA032081: , HPA032082: "	"unprognostic (1.07e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.52e-2)"	"unprognostic (5.98e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.46e-3)"	"unprognostic (2.19e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.18e-3)"	"unprognostic (1.86e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.17e-8)"	"unprognostic (3.31e-1)"	"unprognostic (8.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (2.31e-2)"	10.7	0.2	0.1	7.2	13.1	1.4	5.8	0.2	0.4	1.1	0.8	0.0	1.5	0.2	1.7	1.3	0.9	2.1	1.4	3.8	0.1	0.2	0.9	0.2	3.9	2.9	0.5	0.5	1.2	0.4	0.0	0.1	6.2	0.5	1.0	0.5	0.0	0.7	0.3	3.1	1.6	1.3	1.3	1.4	2.9	6.4	2.5	0.9	3.0	0.7	2.7	5.3	2.6	3.8	0.0	3.2	6.8	33.3	0.0	0.3	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	2.4	0.0	0.0	0.0	0.0	0.0	109.9	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.3	0.0	0.0	5.1	0.3	0.0	0.0	0.2	0.0	4.4	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.3	0.0	21.7	0.1	0.0	0.0	0.0	3.2	0.0	0.0	0.0	6.8	0.0	33.3	0.8	0.3	2.7	0.1	13.1	0.2	0.4	0.1	0.2	0.5	0.5	0.5	0.9
TNFRSF9	"4-1BB, CD137, ILA"	ENSG00000049249	"TNF receptor superfamily member 9"	Q07011	1	7915894-7943165	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"blood: 13.5;lymphoid tissue: 18.3"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 45.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	5	"memory CD8 T-cell: 8.0;neutrophil: 6.6;NK-cell: 4.1;T-reg: 13.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.6;NK-cells: 4.1;T-cells: 13.5"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA071425			Approved	"Nucleoli,Plasma membrane"				"Plasma membrane"	Nucleoli	"HPA071425: "	"unprognostic (7.23e-2)"	"unprognostic (1.72e-2)"	"unprognostic (8.26e-3)"	"unprognostic (1.32e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.98e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.19e-4)"	"unprognostic (9.47e-3)"	"unprognostic (2.17e-2)"	"unprognostic (2.02e-1)"	"prognostic unfavourable (2.69e-8)"	"unprognostic (1.64e-2)"	"unprognostic (2.25e-2)"	"unprognostic (1.19e-1)"	"unprognostic (9.55e-2)"	0.8	1.0	0.3	11.0	0.3	1.9	0.5	0.2	0.3	0.4	0.5	0.1	0.1	0.6	0.3	0.1	0.6	0.8	1.6	1.8	0.3	1.0	0.7	0.7	2.1	10.8	0.3	0.1	0.3	0.6	0.0	0.5	0.2	0.5	0.4	0.7	0.3	2.1	0.1	0.3	0.5	2.3	0.1	0.3	7.9	0.7	0.5	0.1	18.3	0.7	0.9	17.5	1.4	0.4	0.5	1.1	6.6	1.5	4.1	13.5	1.1	1.2	0.4	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.9	0.3	0.1	0.4	0.0	0.1	0.0	0.2	0.4	45.9	0.1	0.2	0.2	0.0	0.9	0.0	0.5	0.1	0.3	0.1	0.1	0.0	0.2	0.1	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.0	0.0	0.2	0.2	0.2	1.5	0.1	0.2	0.1	0.1	0.1	5.7	0.2	0.0	1.1	1.5	0.2	1.5	0.4	0.2	0.2	1.0	8.0	1.1	0.5	0.3	1.6	6.6	4.1	0.1	0.3	13.5	1.1	0.3	0.3	0.2	0.3	0.3	1.0	0.3	0.1	0.5	0.1
TNFSF10	"Apo-2L, CD253, TL2, TRAIL"	ENSG00000121858	"TNF superfamily member 10"	P50591	3	172505508-172523507	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 115.1"	"Cell line enhanced"	"Detected in many"		"BEWO: 20.5;CAPAN-2: 14.6;HMC-1: 67.6;RPTEC TERT1: 34.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 42.4;classical monocyte: 25.6;intermediate monocyte: 39.5;neutrophil: 50.3;non-classical monocyte: 38.3"	"Group enriched"	"Detected in all"	5	"granulocytes: 50.3;monocytes: 39.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054938	Uncertain		Approved	Microtubules	"Secreted to blood"			Microtubules		"HPA054938: "	"unprognostic (9.16e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.69e-3)"	"unprognostic (2.52e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.71e-2)"	"prognostic unfavourable (9.43e-4)"	"unprognostic (1.04e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.68e-2)"	"unprognostic (1.32e-1)"	"unprognostic (6.27e-2)"	30.9	22.1	3.4	14.6	4.7	2.0	23.3	3.0	5.4	31.4	25.8	4.4	17.1	20.6	13.0	10.3	33.3	9.6	10.7	9.9	3.8	3.2	115.1	44.4	91.5	23.5	5.5	3.4	13.5	11.6	10.9	6.7	100.8	6.7	37.6	19.5	12.0	50.6	12.9	13.9	13.0	54.0	7.9	5.6	35.8	9.5	6.0	4.6	8.3	28.2	17.7	16.1	22.4	24.0	3.4	9.5	50.3	39.5	9.3	7.0	11.9	3.3	0.1	0.0	0.0	2.4	1.8	20.5	0.0	0.1	1.0	1.6	0.0	14.6	2.1	9.8	0.0	14.4	0.0	1.8	0.2	5.2	0.0	0.0	0.4	0.3	0.1	3.8	67.6	2.4	2.3	0.4	0.0	7.4	0.0	2.4	0.0	0.0	0.4	5.1	0.0	0.1	0.7	0.0	0.9	34.1	1.3	0.0	0.1	7.5	0.3	0.1	4.1	2.2	0.3	0.0	0.0	0.0	0.2	2.6	0.3	2.6	0.2	2.2	0.0	42.4	25.6	2.7	2.3	39.5	3.1	3.2	6.4	3.5	9.5	3.4	4.7	1.8	50.3	9.3	38.3	0.6	7.0	11.9	3.4	4.7	3.0	5.4	3.8	3.2	5.5	3.4	6.7	4.6
TNFSF11	"CD254, ODF, OPGL, RANKL, TRANCE"	ENSG00000120659	"TNF superfamily member 11"	O14788	13	42562736-42608013	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Differentiation	"Cytokine, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 14.3;lymphoid tissue: 19.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.7;HSkMC: 5.2;NTERA-2: 7.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	8	"NK-cell: 14.3"	"Lineage enriched"	"Detected in many"	8	"NK-cells: 14.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB009193, HPA045142"	Enhanced				"Secreted to blood"					"CAB009193: , HPA045142: "	"unprognostic (3.97e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.01e-3)"	"unprognostic (3.81e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.09e-2)"	"unprognostic (7.70e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.94e-5)"	"unprognostic (1.87e-1)"	"unprognostic (9.67e-2)"	"unprognostic (5.46e-2)"	"unprognostic (7.74e-2)"	0.5	0.2	0.2	19.5	0.2	0.0	4.6	0.1	0.2	0.8	0.8	0.1	2.4	0.2	0.2	0.1	3.7	0.2	1.3	0.3	0.1	0.7	0.6	5.3	0.4	19.8	0.1	0.1	0.1	0.6	0.0	0.3	0.3	0.4	0.5	2.2	0.1	1.6	1.0	0.2	0.5	6.0	0.1	0.1	0.8	0.3	3.3	0.1	2.8	0.4	0.1	5.2	2.3	0.7	0.0	0.1	1.8	0.0	14.3	0.1	0.1	0.0	0.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.7	0.0	0.0	0.2	0.0	0.2	0.0	0.1	0.0	0.1	0.5	0.0	0.6	0.0	0.1	5.2	0.5	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	7.4	0.1	0.0	0.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.2	0.1	0.7	0.1	0.1	0.4	0.1
TNFSF13	"APRIL, CD256"	ENSG00000161955	"TNF superfamily member 13"	O75888	17	7558292-7561608	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"salivary gland: 102.8"	"Cell line enhanced"	"Detected in many"		"EFO-21: 18.4;RPTEC TERT1: 46.5;U-937: 17.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 63.5;eosinophil: 22.8;intermediate monocyte: 62.7;myeloid DC: 43.0;non-classical monocyte: 37.3;plasmacytoid DC: 19.8"	"Group enriched"	"Detected in many"	10	"dendritic cells: 43.0;granulocytes: 22.8;monocytes: 63.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA004863	Uncertain				"Secreted to blood"	29000	29000			"HPA004863: AB_1078187"	"unprognostic (2.46e-2)"	"unprognostic (2.20e-1)"	"unprognostic (3.42e-1)"	"unprognostic (6.53e-2)"	"prognostic unfavourable (9.73e-4)"	"unprognostic (3.57e-1)"	"unprognostic (3.32e-2)"	"unprognostic (3.70e-2)"	"unprognostic (3.75e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.95e-2)"	"unprognostic (2.65e-1)"	"prognostic favourable (1.30e-9)"	"unprognostic (4.69e-2)"	"unprognostic (1.42e-2)"	"unprognostic (3.46e-1)"	"unprognostic (3.38e-2)"	12.1	14.4	18.7	15.4	24.2	18.3	12.9	5.7	15.3	15.7	20.4	8.7	27.4	32.0	7.7	12.8	6.1	14.4	29.1	9.5	11.1	10.7	34.1	11.9	43.0	39.0	14.3	9.4	14.0	20.7	5.7	10.8	6.4	31.6	13.7	18.7	22.0	102.8	69.4	3.0	5.3	18.5	10.9	13.1	16.2	23.4	5.0	9.0	3.3	14.1	8.2	11.5	10.4	8.4	4.1	43.0	22.8	63.5	1.3	0.4	30.6	8.3	3.4	1.1	2.3	1.3	0.7	1.4	1.5	1.0	0.6	0.5	1.8	5.2	3.7	18.4	1.5	5.3	0.0	1.5	0.6	6.5	2.9	2.3	7.5	3.9	2.8	2.0	2.4	1.5	1.4	0.4	2.4	1.9	1.8	1.4	0.5	1.2	0.9	6.6	1.1	2.5	6.6	1.4	15.8	46.5	5.5	2.1	2.0	2.9	7.8	1.0	10.4	5.0	1.0	2.0	2.4	0.9	3.2	0.3	1.1	0.9	0.8	17.8	3.9	9.0	63.5	22.8	0.1	62.7	0.1	2.0	0.0	0.1	43.0	4.1	0.4	0.2	8.6	1.3	37.3	19.8	0.1	30.6	18.7	24.2	5.7	15.3	11.1	10.7	14.3	9.4	31.6	9.0
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	"TNF superfamily member 13b"	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 76.5;lymphoid tissue: 39.6"	"Cell line enriched"	"Detected in some"	7	"U-937: 59.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 76.5"	"Group enriched"	"Detected in many"	10	"dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB009188	Enhanced				"Secreted to blood"	530000	530000			"CAB009188: "	"unprognostic (6.48e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavourable (2.53e-11)"	"unprognostic (1.23e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.25e-1)"	7.2	8.2	3.0	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1.0	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5.0	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1.0	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1.0	31.0	76.5	53.7	0.6	5.3	20.8	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.1	0.3	0.2	0.7	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.3	0.1	0.0	0.1	3.5	0.1	0.7	0.1	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.4	0.1	0.0	0.0	0.1	0.0	7.9	0.0	0.1	0.0	0.0	0.1	3.7	0.1	0.0	3.8	59.5	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31.0	1.0	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3.0	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9
TNFSF4	"CD252, gp34, OX-40L, TXGP1"	ENSG00000117586	"TNF superfamily member 4"	P23510	1	173183734-173207313	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins"		Cytokine	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 11.5;testis: 14.4"	"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 18.3;HHSteC: 7.9;HUVEC TERT2: 35.9;LHCN-M2: 29.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA059579	Approved		Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA059579: "	"unprognostic (1.88e-2)"	"unprognostic (1.20e-1)"	"unprognostic (4.58e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.13e-3)"	"unprognostic (2.13e-1)"	"unprognostic (8.65e-2)"	"unprognostic (5.17e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.11e-7)"	"unprognostic (3.73e-3)"	"unprognostic (2.66e-1)"	"unprognostic (9.49e-2)"	"unprognostic (2.98e-2)"	2.1	4.0	1.7	8.2	2.3	0.9	3.7	4.5	3.4	1.7	1.8	1.0	0.8	0.3	1.5	1.5	1.6	1.4	2.1	2.1	3.0	2.0	1.5	1.6	2.5	11.5	1.9	0.8	2.7	2.1	1.0	3.3	1.2	1.2	2.8	2.5	1.0	0.8	1.0	0.8	0.3	2.5	1.6	1.9	9.7	1.4	14.4	1.2	9.3	0.8	0.8	3.7	1.6	1.6	1.3	2.6	1.7	0.2	3.4	1.2	6.5	0.0	0.0	0.2	0.5	1.2	6.5	0.0	1.8	0.4	0.1	0.1	0.0	0.0	0.0	0.3	18.3	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.2	0.7	7.9	0.1	0.0	2.8	0.1	0.9	0.1	35.9	0.0	0.2	29.9	0.0	0.3	0.1	0.1	0.3	0.8	0.0	0.2	0.3	0.0	0.0	0.3	0.1	0.1	0.3	0.0	0.3	0.3	0.0	0.0	0.1	0.1	0.4	0.5	0.1	0.1	3.3	1.9	0.0	0.2	0.3	1.1	0.1	0.8	1.1	0.7	0.9	0.8	1.3	1.2	1.1	1.7	3.4	0.1	2.6	0.9	6.5	1.7	2.3	4.5	3.4	3.0	2.0	1.9	0.8	1.2	1.2
TNFSF8	"CD153, CD30LG"	ENSG00000106952	"TNF superfamily member 8"	P32971	9	114893343-114930595	"Cancer-related genes, CD markers, Predicted membrane proteins"		Cytokine	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 18.6;lymphoid tissue: 48.1"	"Group enriched"	"Detected in some"	111	"Daudi: 34.3;U-698: 28.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"														"unprognostic (8.82e-2)"	"unprognostic (6.56e-3)"	"unprognostic (7.79e-2)"	"unprognostic (6.05e-2)"	"unprognostic (2.67e-1)"	"unprognostic (5.58e-3)"	"unprognostic (5.26e-3)"	"unprognostic (1.82e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.02e-1)"	"unprognostic (4.75e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.76e-2)"	"unprognostic (9.61e-2)"	"unprognostic (1.82e-1)"	3.6	1.7	1.1	12.0	1.7	12.7	1.8	0.5	0.9	1.6	2.4	1.4	0.6	0.3	1.1	2.5	1.4	1.5	4.6	2.8	1.1	1.2	1.8	1.4	4.9	48.1	1.6	0.6	0.9	1.1	0.0	0.8	2.2	1.0	1.3	1.9	1.4	3.7	0.9	0.7	1.0	7.0	1.3	2.8	14.9	1.7	1.1	1.0	45.6	1.6	0.8	18.5	3.2	1.3	1.7	7.3	3.9	14.1	1.0	18.6	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	28.1	0.0	0.0	0.0	0.0	14.1	0.0	4.1	7.3	13.8	1.0	16.4	9.8	7.3	1.7	18.6	13.5	3.9	1.0	0.9	4.0	5.9	8.7	1.1	1.7	0.5	0.9	1.1	1.2	1.6	0.6	1.0	1.0
TNK2	"ACK, ACK1, p21cdc42Hs"	ENSG00000061938	"Tyrosine kinase non receptor 2"	Q07912	3	195863364-195911945	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	Endocytosis	"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041954	Approved		Approved	Cytosol				Cytosol		"HPA041954: AB_10794164"	"unprognostic (1.97e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.15e-3)"	"prognostic unfavourable (8.96e-4)"	"unprognostic (1.34e-1)"	"unprognostic (8.92e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.30e-1)"	"unprognostic (8.89e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.92e-3)"	"unprognostic (4.49e-2)"	"prognostic unfavourable (1.30e-4)"	"unprognostic (6.82e-2)"	"unprognostic (9.76e-2)"	"unprognostic (1.44e-1)"	"prognostic favourable (1.00e-4)"	9.2	7.6	36.3	16.2	27.6	38.9	8.5	20.7	43.7	6.0	6.3	17.6	3.8	6.6	8.0	6.6	13.0	10.7	6.5	10.6	28.4	21.8	4.1	7.2	9.3	18.1	21.6	31.8	8.6	7.8	5.1	19.3	8.4	20.0	10.8	3.9	5.3	16.8	8.2	30.5	37.1	6.9	7.6	10.3	17.0	12.1	7.7	21.8	3.4	4.6	9.8	12.8	7.7	12.3	6.1	3.1	6.3	3.2	0.9	1.9	1.2	31.3	3.0	5.1	5.4	7.1	4.5	30.5	6.0	5.8	3.6	3.3	4.8	24.3	9.1	21.2	8.2	11.2	4.4	7.5	1.1	21.4	5.6	8.2	10.2	3.5	3.2	4.2	4.1	3.3	11.9	5.0	6.0	4.6	3.3	12.7	3.4	23.1	1.8	15.4	4.8	11.3	5.3	6.1	9.2	3.2	15.2	6.2	6.3	3.9	15.9	7.8	26.0	5.3	7.5	8.4	4.9	4.4	16.8	27.6	3.0	5.6	7.5	13.8	6.2	2.0	2.4	0.9	1.9	3.2	1.1	2.7	1.8	1.0	1.1	6.1	1.4	1.3	6.3	0.9	2.8	3.1	0.2	1.2	36.3	27.6	20.7	33.3	28.4	21.8	21.6	31.8	20.0	21.8
TOM1		ENSG00000100284	"Target of myb1 membrane trafficking protein"	O60784	22	35299275-35347994	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 83.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000818, HPA001749"	Approved		Approved	"Plasma membrane,Centriolar satellite,Cytosol"		14000	14000	Cytosol	"Plasma membrane, Centriolar satellite"	"HPA000818: , HPA001749: AB_1080323"	"unprognostic (3.75e-1)"	"unprognostic (8.07e-2)"	"unprognostic (5.18e-2)"	"prognostic favourable (2.20e-5)"	"unprognostic (1.11e-2)"	"unprognostic (7.55e-2)"	"unprognostic (4.07e-3)"	"unprognostic (2.24e-1)"	"unprognostic (9.92e-2)"	"unprognostic (2.32e-1)"	"unprognostic (3.71e-1)"	"unprognostic (8.16e-2)"	"prognostic favourable (3.72e-5)"	"unprognostic (1.22e-1)"	"unprognostic (1.30e-1)"	"unprognostic (7.54e-3)"	"unprognostic (3.31e-2)"	17.0	21.2	9.5	10.2	13.8	31.1	13.7	10.2	24.6	16.0	14.6	12.0	7.5	17.4	14.1	15.5	31.6	11.7	15.4	19.1	8.8	15.2	16.1	27.4	17.5	8.2	11.6	11.3	12.1	11.8	21.8	16.8	39.0	23.2	10.2	6.4	17.5	37.0	10.1	83.8	29.1	18.6	7.1	8.4	10.6	8.4	13.6	8.7	10.0	14.8	25.9	19.9	12.1	17.6	4.6	15.2	40.9	31.2	4.6	14.7	17.0	6.6	6.7	3.9	6.3	27.9	16.6	18.4	6.5	19.7	12.7	14.3	9.3	6.2	2.6	12.1	20.3	3.1	4.0	6.8	4.6	7.5	9.1	2.2	7.6	19.3	26.3	4.2	10.1	22.4	8.6	17.9	6.1	8.8	4.3	6.6	6.2	6.4	3.4	9.9	3.0	3.9	6.2	5.6	5.6	5.0	5.0	6.7	5.2	14.8	15.4	14.5	7.8	7.0	9.2	15.1	13.1	11.5	3.2	7.7	4.8	6.8	20.3	4.4	4.9	5.9	31.2	13.1	6.4	18.9	5.3	4.6	9.8	6.1	15.2	4.0	7.9	5.3	40.9	4.6	19.4	8.1	14.7	17.0	9.5	13.8	10.2	24.6	8.8	15.2	11.6	11.3	23.2	8.7
TOP1		ENSG00000198900	"DNA topoisomerase I"	P11387	20	41028818-41124487	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction"	"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009058, HPA019039"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"				"Nucleoplasm, Nucleoli fibrillar center"		"CAB009058: AB_2303554, HPA019039: AB_1858187"	"unprognostic (1.46e-1)"	"unprognostic (8.65e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.92e-3)"	"unprognostic (5.05e-2)"	"unprognostic (1.49e-3)"	"prognostic unfavourable (6.42e-4)"	"unprognostic (5.86e-2)"	"unprognostic (1.51e-1)"	"unprognostic (4.60e-2)"	"unprognostic (3.74e-3)"	"unprognostic (6.51e-2)"	"unprognostic (8.65e-2)"	"unprognostic (4.70e-2)"	"unprognostic (5.14e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.29e-1)"	26.6	31.0	24.6	46.3	25.3	55.3	37.4	39.6	31.1	21.3	30.0	11.1	26.7	29.7	22.9	22.5	36.0	20.5	29.2	21.0	23.0	18.3	31.8	32.7	37.9	38.6	21.9	20.9	25.5	22.5	22.2	39.9	43.9	25.2	23.3	27.2	13.6	25.3	34.3	26.2	24.6	48.4	23.1	27.4	36.9	26.7	14.2	24.2	54.2	31.5	25.1	40.6	25.2	41.7	9.0	17.2	18.4	11.1	5.8	8.2	4.6	21.5	15.1	28.3	23.1	11.5	13.7	28.0	19.5	17.2	22.7	20.7	39.6	27.2	61.5	20.9	10.1	21.0	33.9	31.2	33.3	13.3	17.3	78.4	12.1	28.1	29.9	33.8	27.0	15.5	16.7	22.1	36.4	23.7	34.0	21.4	25.6	47.9	47.7	21.4	22.8	28.1	40.8	26.6	32.7	24.2	20.1	23.5	16.3	30.6	19.0	19.8	21.1	30.3	23.2	18.4	15.6	17.0	20.9	13.6	15.2	71.7	24.7	19.0	17.4	9.1	9.2	14.3	6.5	9.2	8.2	9.0	7.2	6.8	8.6	8.7	7.7	6.9	18.4	5.8	11.1	17.2	7.9	4.6	24.6	25.3	39.6	31.1	23.0	18.3	21.9	20.9	25.2	24.2
TOP2A	TOP2	ENSG00000131747	"DNA topoisomerase II alpha"	P11388	17	40388516-40417950	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"lymphoid tissue: 146.3;testis: 36.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"T-reg: 5.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB002448, HPA006458, HPA026773"	Enhanced	Approved	Supported	Nucleoplasm,Nucleoli				Nucleoplasm	Nucleoli	"CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190"	"unprognostic (2.09e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.28e-3)"	"unprognostic (9.42e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.52e-1)"	"prognostic unfavourable (5.92e-6)"	"prognostic unfavourable (4.99e-4)"	"unprognostic (6.21e-3)"	"unprognostic (2.09e-1)"	"prognostic unfavourable (3.83e-5)"	"unprognostic (5.03e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (7.46e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.29e-1)"	2.7	2.0	0.4	20.0	0.5	14.6	4.1	0.4	0.5	3.0	6.9	0.5	0.5	7.0	2.0	3.4	18.2	0.7	2.4	2.3	0.6	0.5	1.4	1.9	5.5	15.4	0.6	0.4	1.2	1.1	0.0	0.4	10.7	0.6	1.2	8.0	0.6	3.2	0.3	0.6	5.9	9.2	2.6	1.8	7.3	4.5	36.8	0.3	146.3	0.9	11.8	16.7	3.2	5.7	1.3	0.3	0.3	0.3	3.2	5.7	1.1	33.7	44.9	57.2	26.1	2.8	5.8	12.7	46.4	25.0	42.7	37.9	21.0	25.9	54.5	23.6	15.7	53.8	43.9	18.5	57.4	29.1	29.3	36.0	28.7	35.1	0.2	50.4	38.3	1.2	1.5	30.0	30.6	22.4	38.9	37.4	46.1	11.7	58.4	33.9	23.7	17.9	49.6	88.8	22.6	10.3	21.6	33.8	24.3	37.4	46.7	14.7	39.2	23.2	14.7	28.2	39.7	32.5	44.5	21.5	24.3	47.6	15.9	34.8	46.9	0.3	0.0	0.0	0.6	0.0	0.0	1.3	0.9	0.9	0.3	0.4	0.2	0.1	0.3	3.2	0.3	0.0	5.7	1.1	0.4	0.5	0.4	0.5	0.6	0.5	0.6	0.4	0.6	0.3
TOP3A	"TOP3, ZGRF7"	ENSG00000177302	"DNA topoisomerase III alpha"	Q13472	17	18271428-18315007	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, Disease mutation, Dwarfism, Primary mitochondrial disease, Progressive external ophthalmoplegia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002449	Approved									"CAB002449: AB_564037"	"unprognostic (5.49e-2)"	"unprognostic (9.04e-2)"	"unprognostic (8.99e-2)"	"unprognostic (7.24e-3)"	"unprognostic (4.01e-2)"	"unprognostic (1.95e-2)"	"unprognostic (2.33e-3)"	"unprognostic (6.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.74e-1)"	"prognostic favourable (1.39e-4)"	"prognostic unfavourable (4.59e-4)"	"unprognostic (5.58e-2)"	"unprognostic (8.80e-2)"	"unprognostic (3.53e-2)"	"unprognostic (5.05e-2)"	"unprognostic (6.05e-2)"	12.5	11.6	10.9	12.5	14.0	23.8	12.0	21.4	17.9	11.0	11.2	13.8	9.1	10.3	13.3	10.4	12.1	11.8	9.5	8.4	9.3	10.5	9.3	15.6	10.8	15.5	9.4	9.0	11.4	16.1	15.0	15.1	10.7	11.1	11.0	13.1	12.8	11.6	9.0	13.0	19.1	10.8	14.1	9.0	16.6	10.5	17.9	11.8	25.9	10.3	7.4	16.2	11.6	10.7	2.1	2.7	10.4	5.9	4.1	4.0	3.3	8.1	13.7	11.2	13.6	5.7	5.8	10.2	8.6	6.2	15.2	15.0	24.9	3.6	14.1	5.6	7.8	11.5	16.8	7.3	16.1	10.4	13.5	12.9	14.2	8.5	5.7	6.4	11.5	3.7	4.7	16.1	9.4	7.0	11.1	5.8	8.8	8.4	14.3	8.1	8.7	7.6	16.3	26.7	13.3	4.5	8.4	8.0	15.0	13.2	8.3	8.5	16.6	6.8	6.7	10.9	8.7	20.7	14.8	6.4	11.5	9.9	6.8	8.9	10.4	1.4	5.9	6.5	4.0	5.8	2.6	1.7	3.0	3.1	2.6	2.1	2.6	2.7	10.4	4.1	2.9	2.7	2.2	3.3	10.9	14.0	21.4	17.9	9.3	10.5	9.4	9.0	11.1	11.8
TP53	"LFS1, p53"	ENSG00000141510	"Tumor protein p53"	P04637	17	7661779-7687550	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters"	"Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 102.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: , HPA051244: , HPA063532: "	"unprognostic (2.29e-2)"	"unprognostic (8.83e-3)"	"unprognostic (1.26e-2)"	"prognostic favourable (1.35e-4)"	"unprognostic (9.95e-2)"	"unprognostic (4.00e-2)"	"unprognostic (2.79e-3)"	"unprognostic (4.99e-2)"	"unprognostic (2.75e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.30e-1)"	"prognostic unfavourable (5.01e-4)"	"unprognostic (1.86e-3)"	"unprognostic (7.89e-3)"	"unprognostic (8.05e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.08e-1)"	18.5	11.1	6.0	28.6	6.8	9.0	17.5	2.5	7.3	18.5	14.6	6.8	8.3	9.7	20.3	15.0	25.3	16.7	22.6	8.1	5.0	3.8	10.6	20.8	11.2	26.0	6.6	3.1	33.8	13.8	4.9	6.0	22.8	6.9	16.5	14.5	9.9	15.3	16.1	12.5	24.6	14.0	12.8	6.2	24.2	12.0	14.1	6.9	102.6	13.2	23.5	31.2	16.9	15.0	15.2	19.6	2.2	14.1	11.0	11.3	8.2	19.2	35.6	19.4	14.0	9.1	10.8	20.6	6.9	15.6	19.2	24.3	1.0	9.9	45.3	31.5	13.6	42.5	28.2	19.1	18.0	10.1	18.9	18.3	20.0	16.9	27.4	0.4	9.5	13.7	22.2	9.3	25.7	18.8	0.9	1.7	9.8	34.2	30.7	22.4	19.6	0.7	59.7	13.7	15.7	14.3	21.3	11.6	20.0	22.8	15.4	5.9	26.7	1.7	24.3	23.0	7.6	0.3	11.6	11.9	8.7	19.5	6.0	2.3	19.4	0.8	13.3	2.2	9.1	14.1	11.1	15.2	9.4	10.2	19.6	14.5	9.9	10.8	1.7	11.0	11.9	17.9	11.3	8.2	6.0	6.8	2.5	6.4	5.0	3.8	6.6	3.1	6.9	6.9
TP53BP1	"53BP1, p202, TDRD30"	ENSG00000067369	"Tumor protein p53 binding protein 1"	Q12888	15	43403061-43510728	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004083, HPA008788, HPA022133"	Supported		Enhanced	"Nuclear bodies"				"Nuclear bodies"		"CAB004083: AB_10694558, HPA008788: AB_1078070, HPA022133: AB_1844382"	"unprognostic (2.12e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.85e-2)"	"unprognostic (4.42e-3)"	"unprognostic (2.32e-1)"	"unprognostic (2.03e-2)"	"unprognostic (3.96e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.81e-2)"	"unprognostic (3.34e-2)"	"unprognostic (4.07e-1)"	"unprognostic (8.06e-2)"	"unprognostic (9.11e-2)"	"unprognostic (1.52e-1)"	"unprognostic (6.99e-2)"	"unprognostic (3.38e-2)"	7.2	12.9	13.4	9.0	20.7	8.9	9.6	21.9	22.9	17.2	10.0	12.5	10.1	5.7	14.6	15.1	7.0	13.8	9.8	10.7	13.9	12.9	8.6	4.1	8.0	7.2	7.1	14.8	15.9	7.4	30.0	34.8	10.7	17.9	11.4	9.5	7.9	9.8	12.3	7.9	8.2	7.2	15.0	7.9	7.2	7.7	18.3	9.3	15.2	16.2	4.9	10.8	11.5	11.1	5.4	3.5	3.7	1.9	2.1	4.8	1.8	6.2	10.7	31.3	19.5	13.0	16.2	7.6	10.8	16.4	15.4	19.6	9.2	7.6	6.7	9.6	18.4	15.6	22.5	13.2	18.4	18.3	7.7	12.8	18.7	5.5	8.5	14.1	18.5	12.5	9.4	20.7	15.5	18.2	12.5	6.0	17.8	4.4	11.0	6.6	20.1	6.6	11.8	11.7	4.4	11.4	14.8	28.4	13.2	15.6	7.0	4.2	14.4	8.0	12.9	16.5	11.2	13.0	9.6	4.8	10.4	15.8	13.7	7.0	8.4	3.7	1.2	2.5	4.1	1.9	3.5	5.4	4.4	4.1	2.9	4.9	4.8	4.4	1.4	2.1	1.2	3.5	3.4	1.8	13.4	20.7	21.9	22.9	13.9	12.9	7.1	14.8	17.9	9.3
TP53BP2	"53BP2, ASPP2, PPP1R13A"	ENSG00000143514	"Tumor protein p53 binding protein 2"	Q13625	1	223779899-223845972	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021603, HPA050429"	Supported		Enhanced	"Cell Junctions,Cytosol"				"Cell Junctions, Cytosol"		"HPA021603: AB_1844384, HPA050429: "	"unprognostic (1.29e-1)"	"unprognostic (5.11e-2)"	"unprognostic (3.24e-1)"	"unprognostic (1.38e-3)"	"unprognostic (1.24e-1)"	"unprognostic (1.03e-1)"	"unprognostic (7.65e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.48e-2)"	"unprognostic (7.37e-2)"	"unprognostic (2.67e-1)"	"unprognostic (7.99e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.83e-1)"	10.0	8.3	26.5	17.2	28.7	38.8	20.8	9.3	17.9	10.9	12.0	12.6	8.1	7.9	11.9	9.8	15.9	9.4	17.4	10.9	17.3	14.7	10.1	13.9	21.4	18.6	18.7	8.6	15.5	13.0	16.4	8.3	8.2	12.9	9.6	9.5	17.7	10.2	8.1	12.0	9.9	9.5	12.2	13.0	10.6	9.7	10.2	14.9	17.3	22.1	7.4	11.7	11.8	14.8	2.2	2.9	6.7	2.7	7.2	4.0	2.0	15.3	7.7	21.0	13.2	7.5	7.3	13.4	9.9	14.1	14.5	12.5	15.9	9.3	0.0	8.7	8.2	10.5	16.3	5.9	19.5	29.6	16.1	20.3	7.5	5.4	15.2	16.7	14.3	8.7	6.5	13.3	13.7	8.5	25.7	15.4	12.0	4.4	12.7	10.3	18.1	7.5	16.9	21.9	1.7	13.0	9.7	18.2	23.5	10.9	13.6	14.3	7.7	23.0	9.9	14.9	10.5	16.0	18.5	7.6	7.9	12.7	9.0	11.3	16.9	6.7	2.7	1.6	2.3	2.6	2.8	2.2	2.6	4.0	2.9	1.9	2.7	1.9	3.2	7.2	2.0	1.7	1.6	2.0	26.5	28.7	9.3	17.9	17.3	14.7	18.7	8.6	12.9	14.9
TP63	"EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L"	ENSG00000073282	"Tumor protein p63"	Q9H3D4	3	189631416-189897279	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 83.2;skin 1: 54.2"	"Group enriched"	"Detected in some"	5	"HaCaT: 23.3;HBEC3-KT: 44.6;hTCEpi: 33.8;hTERT-HME1: 32.3;RT4: 49.0"	"Group enriched"	"Detected in many"	11	"cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000083, HPA006288, HPA006289, HPA007009, HPA007010"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336"	"prognostic favourable (1.07e-4)"	"unprognostic (1.30e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.02e-1)"	"unprognostic (4.38e-2)"	"unprognostic (3.50e-1)"	"unprognostic (1.29e-1)"	"unprognostic (5.17e-2)"	"unprognostic (2.78e-1)"	"unprognostic (5.37e-2)"	"unprognostic (2.09e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-5)"	"unprognostic (1.86e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.74e-3)"	2.9	0.1	0.2	0.7	0.1	0.0	7.2	0.1	0.2	9.5	0.1	0.1	5.7	0.0	0.3	8.0	33.7	0.3	0.0	0.2	0.1	0.1	0.4	0.1	1.2	0.2	0.1	0.2	0.1	0.1	0.0	0.3	7.8	0.8	9.6	0.0	0.3	9.0	7.8	83.2	54.2	0.1	2.7	0.6	0.1	0.1	1.2	0.0	9.0	0.4	36.7	26.1	9.6	19.2	3.7	1.3	3.0	0.9	1.2	1.2	0.2	0.6	1.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.1	0.0	23.3	0.0	44.6	0.0	0.3	0.0	0.5	0.3	0.1	0.0	0.0	0.1	0.0	33.8	0.0	32.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	49.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	6.8	0.1	0.3	0.1	0.0	0.2	2.0	0.4	1.1	0.9	0.5	0.7	3.7	1.2	1.0	0.4	1.7	0.8	0.7	3.0	1.2	0.9	1.3	0.8	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.8	0.0
TPD52	"D52, hD52, N8L"	ENSG00000076554	"Tumor protein D52"	P55327	8	80034745-80231232	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 46.3;SK-BR-3: 105.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 24.3"	"Group enriched"	"Detected in many"	6	"B-cells: 24.3;NK-cells: 6.8;T-cells: 11.1"									"HPA028427, HPA062167"	Enhanced		Approved	"Golgi apparatus,Cytosol"		42000	42000	Cytosol	"Golgi apparatus"	"HPA028427: AB_10610561, HPA062167: AB_2684704"	"prognostic unfavourable (1.11e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.37e-2)"	"unprognostic (3.77e-3)"	"unprognostic (8.24e-2)"	"unprognostic (3.75e-1)"	"unprognostic (7.99e-3)"	"unprognostic (6.47e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.49e-1)"	"prognostic unfavourable (4.77e-6)"	"unprognostic (2.06e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.70e-2)"	3.2	3.9	33.9	20.2	23.2	3.2	30.9	37.5	43.3	8.3	45.2	19.7	7.3	38.1	4.1	23.2	18.1	6.3	13.2	4.5	35.4	26.9	18.4	15.1	7.8	15.8	27.4	24.0	1.5	26.0	19.1	19.1	13.6	20.3	42.5	51.3	17.4	33.5	8.0	3.1	18.2	40.3	4.4	31.4	9.8	32.7	2.1	19.8	3.5	25.8	7.3	22.2	9.5	10.0	24.3	2.4	2.5	0.0	6.8	11.1	4.1	23.1	6.2	0.2	4.2	0.0	0.0	9.5	1.5	2.3	6.4	3.2	3.2	6.8	33.8	8.4	0.1	9.5	9.6	6.5	4.6	4.1	8.0	4.7	8.9	5.2	0.0	1.5	0.1	0.0	4.6	0.0	2.2	0.3	0.0	46.3	0.0	7.6	7.4	6.9	2.1	15.7	0.0	0.1	21.4	11.1	5.6	12.0	8.2	7.2	105.2	19.4	10.2	6.0	0.3	0.0	6.6	0.1	5.4	17.4	15.0	27.7	4.2	0.0	0.4	0.2	0.0	2.5	6.4	0.0	11.1	24.3	6.4	5.5	1.1	22.4	4.2	4.8	0.2	6.8	0.0	2.4	4.1	4.1	33.9	23.2	37.5	43.3	35.4	26.9	27.4	24.0	20.3	19.8
TPI1		ENSG00000111669	"Triosephosphate isomerase 1"	P60174	12	6867119-6870948	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Gluconeogenesis, Glycolysis"	"Isomerase, Lyase"	"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 234.8;skeletal muscle: 211.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA050924, HPA053568"	Uncertain		Approved	Nucleoplasm,Vesicles		270000000	270000000	Nucleoplasm	Vesicles	"HPA050924: AB_2681276, HPA053568: AB_2682193"	"unprognostic (2.85e-1)"	"unprognostic (5.58e-3)"	"unprognostic (1.65e-1)"	"unprognostic (1.62e-2)"	"unprognostic (6.94e-2)"	"unprognostic (2.31e-2)"	"prognostic unfavourable (1.04e-5)"	"unprognostic (4.14e-3)"	"unprognostic (7.49e-2)"	"unprognostic (2.13e-2)"	"unprognostic (2.11e-2)"	"unprognostic (1.63e-1)"	"prognostic unfavourable (6.54e-4)"	"unprognostic (7.04e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.11e-2)"	20.2	41.2	41.2	24.3	46.9	27.4	83.4	93.2	196.1	27.1	39.1	12.8	18.6	40.1	17.2	22.6	51.0	22.1	33.3	94.9	36.7	33.1	43.1	40.8	48.8	140.2	34.0	34.6	19.9	87.0	32.1	16.8	27.1	70.7	19.0	43.5	21.1	26.0	28.7	211.0	25.8	37.8	29.4	20.8	20.1	21.6	15.7	19.4	14.2	20.2	38.4	38.0	23.0	28.0	55.4	170.3	145.5	148.2	81.2	67.1	234.8	119.2	106.9	56.6	87.6	55.5	58.6	100.1	86.3	95.3	163.1	197.9	110.3	65.6	70.0	17.4	85.1	59.4	134.6	144.2	181.0	92.3	100.3	90.7	78.3	72.7	41.4	103.2	74.5	63.6	60.2	125.8	108.4	99.1	46.9	26.9	125.2	87.8	54.2	87.2	139.7	68.1	31.9	93.2	71.8	102.1	85.1	40.3	67.1	75.3	78.4	41.8	17.9	77.6	61.2	87.5	75.0	56.6	126.5	52.6	21.6	104.6	175.6	64.2	62.7	87.7	146.1	145.5	56.1	148.2	57.0	55.4	56.5	54.5	170.3	44.3	39.9	49.3	61.1	81.2	127.8	30.7	67.1	234.8	41.2	46.9	93.2	196.1	36.7	33.1	34.0	34.6	70.7	19.4
TPM1	"C15orf13, CMH3"	ENSG00000140416	"Tropomyosin 1"	P09493	15	63042632-63071915	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes, Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 544.2;skeletal muscle: 589.5"	"Cell line enhanced"	"Detected in many"		"BJ: 123.0;fHDF/TERT166: 122.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"basophil: 23.8"	"Group enriched"	"Detected in all"	4	"dendritic cells: 8.4;granulocytes: 23.8;monocytes: 11.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000261, HPA009066, CAB017698, HPA047089, HPA053624"	Supported		Approved	"Actin filaments,Cytosol"		280000000	280000000	"Actin filaments"	Cytosol	"CAB017698: AB_2272017, HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: , HPA053624: "	"unprognostic (1.07e-1)"	"unprognostic (4.20e-2)"	"unprognostic (1.00e-2)"	"unprognostic (6.20e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.45e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.35e-2)"	"unprognostic (3.27e-1)"	"unprognostic (1.27e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.66e-3)"	"unprognostic (3.38e-2)"	"unprognostic (1.78e-1)"	"unprognostic (5.53e-2)"	"prognostic unfavourable (7.30e-4)"	17.9	5.7	5.5	32.4	5.2	1.2	15.2	5.6	5.1	48.1	119.7	2.4	84.2	14.6	72.4	38.3	121.6	36.2	75.3	544.2	4.1	2.6	14.5	4.4	10.5	3.3	3.3	7.0	27.0	29.3	1.9	3.2	17.7	4.1	72.5	28.0	19.1	12.9	81.3	589.5	6.5	39.5	245.2	2.7	6.5	51.7	9.6	2.3	0.4	7.7	121.7	5.9	193.8	38.7	2.7	8.4	23.8	11.6	1.2	3.4	9.9	43.6	28.8	34.8	1.7	12.2	7.7	114.6	123.0	45.3	75.7	56.3	20.2	8.7	0.1	56.5	122.9	24.2	29.5	19.7	50.4	1.1	4.1	6.4	31.0	9.8	34.2	0.2	1.4	10.7	11.4	62.2	16.6	19.8	0.6	1.5	57.8	22.5	1.9	0.5	41.5	5.0	0.7	12.3	1.2	108.1	24.1	8.3	5.7	14.7	23.3	5.2	17.0	1.2	91.2	100.1	49.2	14.9	87.2	0.4	0.3	0.5	28.3	1.7	69.3	23.8	6.1	2.9	2.5	11.6	2.0	2.7	2.4	2.7	8.4	2.6	2.6	2.3	6.7	1.2	7.9	1.7	3.4	9.9	5.5	5.2	5.6	5.1	4.1	2.6	3.3	7.0	4.1	2.3
TPM2	"AMCD1, DA1, NEM4"	ENSG00000198467	"Tropomyosin 2"	P07951	9	35681992-35690121	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes, Disease mutation, Nemaline myopathy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 1091.5;tongue: 332.2"	"Cell line enhanced"	"Detected in many"		"BJ: 197.7;fHDF/TERT166: 107.9;HSkMC: 94.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	727	"plasmacytoid DC: 76.4"	"Lineage enriched"	"Detected in single"	727	"dendritic cells: 76.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047089, HPA053624"	Approved					290000000	290000000			"HPA047089: , HPA053624: "	"unprognostic (5.56e-2)"	"unprognostic (5.37e-2)"	"prognostic unfavourable (2.64e-4)"	"unprognostic (3.34e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.18e-3)"	"unprognostic (6.56e-3)"	"unprognostic (2.58e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.23e-1)"	"unprognostic (8.67e-2)"	"prognostic unfavourable (8.51e-10)"	"unprognostic (1.43e-2)"	"unprognostic (8.33e-2)"	"unprognostic (5.52e-2)"	"unprognostic (1.41e-2)"	14.5	8.2	1.8	24.5	1.6	0.7	9.1	3.7	1.7	47.5	101.0	1.4	76.0	8.4	86.6	51.1	166.5	26.8	100.3	34.6	1.9	1.4	9.5	1.1	10.0	5.3	1.5	3.1	29.2	2.2	1.1	2.6	8.6	3.4	72.2	9.6	15.0	21.0	81.0	1091.5	4.2	27.4	231.7	1.6	4.7	48.7	13.4	0.6	0.2	9.3	332.2	22.0	190.7	38.6	0.0	76.4	0.1	0.0	0.0	0.0	0.4	29.9	22.9	16.1	2.6	30.4	81.4	9.9	197.7	80.6	83.7	56.9	0.9	1.9	0.0	17.7	107.9	0.6	0.2	24.4	38.8	55.2	0.7	0.7	81.8	0.9	48.5	0.1	8.1	94.9	3.8	62.7	0.0	19.6	0.3	0.0	84.2	1.1	0.1	2.0	20.4	1.3	1.3	29.8	0.2	2.6	0.5	0.2	1.0	37.6	0.6	1.3	0.5	2.1	2.3	1.2	45.7	0.9	56.3	0.0	0.1	0.2	2.8	0.4	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	76.4	0.0	0.4	1.8	1.6	3.7	1.7	1.9	1.4	1.5	3.1	3.4	0.6
TPM3	"NEM1, TRK"	ENSG00000143549	"Tropomyosin 3"	P06753	1	154155304-154194648	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes, Disease mutation, Nemaline myopathy, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 738.4;tongue: 203.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA000261, HPA009066, HPA047089, HPA053624"	Approved		Approved	"Actin filaments,Cytosol"		410000000	410000000	"Actin filaments"	Cytosol	"HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: , HPA053624: "	"unprognostic (1.64e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.01e-3)"	"unprognostic (1.07e-1)"	"unprognostic (2.39e-1)"	"unprognostic (2.69e-3)"	"prognostic unfavourable (6.73e-6)"	"prognostic unfavourable (4.01e-4)"	"unprognostic (2.80e-1)"	"prognostic favourable (2.39e-5)"	"prognostic unfavourable (3.65e-4)"	"unprognostic (3.31e-2)"	"prognostic unfavourable (3.12e-5)"	"unprognostic (3.52e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.98e-2)"	"unprognostic (1.00e-2)"	10.1	7.3	10.8	10.8	10.5	26.5	6.2	6.4	11.2	4.6	9.6	3.9	3.2	7.9	4.1	27.9	18.3	4.4	6.7	29.7	7.7	8.1	7.2	6.8	9.6	12.9	8.9	5.8	4.8	23.2	3.6	3.2	6.7	5.0	5.7	10.7	4.4	20.5	2.5	738.4	5.9	8.2	5.2	7.7	11.7	6.9	5.4	4.4	6.7	9.3	203.6	28.6	6.8	4.9	38.9	72.6	154.8	95.9	35.4	54.4	146.1	67.5	33.7	43.2	28.3	36.6	47.8	43.5	58.1	53.7	77.1	58.2	62.8	63.4	50.9	47.3	65.5	62.6	42.8	61.1	82.2	35.2	23.3	62.6	32.9	42.2	29.1	91.6	83.2	36.0	33.5	67.9	52.3	118.6	47.0	54.7	95.1	40.5	71.3	94.6	97.2	73.3	61.1	30.0	72.1	55.6	51.6	30.3	56.9	44.1	58.8	57.6	82.0	109.5	88.6	67.5	48.9	64.7	91.0	46.6	76.5	68.0	61.0	69.0	106.6	70.8	64.7	154.8	54.4	87.8	48.6	38.9	48.5	51.1	72.6	30.1	36.6	47.3	74.9	35.4	95.9	36.0	52.1	146.1	10.8	10.5	6.4	11.2	7.7	8.1	8.9	5.8	5.0	4.4
TPM4		ENSG00000167460	"Tropomyosin 4"	P67936	19	16067021-16103005	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-2197: 225.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004685, HPA047089, HPA053624"	Approved		Approved	"Actin filaments,Cytosol"		950000000	950000000	"Actin filaments"	Cytosol	"CAB004685: AB_425723, HPA047089: , HPA053624: "	"unprognostic (1.27e-1)"	"unprognostic (1.53e-2)"	"unprognostic (3.62e-3)"	"unprognostic (7.38e-3)"	"unprognostic (3.80e-1)"	"unprognostic (2.40e-2)"	"unprognostic (3.11e-2)"	"unprognostic (2.75e-3)"	"unprognostic (1.38e-2)"	"unprognostic (3.61e-1)"	"prognostic unfavourable (3.07e-4)"	"unprognostic (1.03e-1)"	"prognostic unfavourable (1.26e-10)"	"unprognostic (3.85e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.78e-1)"	66.2	17.9	13.3	60.0	13.7	10.8	47.4	46.2	11.5	90.2	40.5	14.6	56.4	17.4	87.1	63.3	149.3	49.4	108.4	39.2	14.5	12.4	32.4	12.2	69.7	27.1	16.0	10.5	102.4	15.4	8.4	16.2	65.0	19.7	84.1	31.8	18.6	47.6	64.6	29.9	39.0	25.2	127.2	22.5	99.7	37.5	30.6	11.7	11.5	20.0	92.2	60.1	177.3	70.5	22.2	35.0	40.7	32.7	24.7	52.5	48.6	58.7	23.3	45.1	27.5	104.9	156.3	56.6	82.3	99.9	69.8	72.0	24.2	61.4	2.7	64.3	102.7	31.7	18.8	47.2	91.3	38.7	10.8	29.6	33.5	19.4	57.7	5.3	70.8	96.7	15.3	57.0	65.6	79.7	3.4	37.3	96.3	20.0	15.9	18.6	23.6	28.4	21.8	38.8	12.7	16.1	50.4	8.2	25.8	55.3	24.8	29.2	0.5	8.2	93.4	121.6	15.4	225.9	76.1	6.5	15.3	13.1	84.3	15.6	41.1	40.7	30.1	2.2	34.8	32.7	26.3	22.2	26.9	31.2	35.0	18.8	7.8	18.3	35.2	24.7	16.2	27.4	52.5	48.6	13.3	13.7	46.2	11.5	14.5	12.4	16.0	10.5	19.7	11.7
TPR		ENSG00000047410	"Translocated promoter region, nuclear basket protein"	P12270	1	186311652-186375693	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division, Mitosis, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019661, HPA019663, HPA024336"	Enhanced		Enhanced	"Nuclear membrane"				"Nuclear membrane"		"HPA019661: AB_1858215, HPA019663: AB_1858216, HPA024336: AB_1858217"	"unprognostic (4.51e-2)"	"unprognostic (9.87e-3)"	"unprognostic (2.48e-1)"	"unprognostic (7.56e-2)"	"unprognostic (9.88e-3)"	"prognostic favourable (4.71e-4)"	"prognostic unfavourable (1.06e-4)"	"unprognostic (1.71e-1)"	"unprognostic (3.71e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.63e-2)"	"unprognostic (1.31e-3)"	"unprognostic (3.75e-1)"	"unprognostic (4.19e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.98e-2)"	21.5	17.3	14.3	26.7	21.3	21.6	19.0	24.4	17.1	21.7	24.2	7.3	27.1	12.9	20.8	23.5	18.5	16.9	16.8	28.3	13.8	10.5	18.7	20.6	17.9	20.4	14.1	16.6	24.7	17.8	44.2	29.1	29.7	15.1	22.2	17.7	9.1	20.2	30.1	33.1	20.5	21.1	21.2	16.4	26.1	18.8	35.0	17.8	39.5	21.7	19.7	21.4	25.1	19.1	19.1	19.8	50.3	15.2	10.7	16.9	5.2	22.0	19.1	28.7	16.6	23.0	20.6	30.2	25.4	17.0	18.0	16.8	28.7	18.9	25.9	19.7	17.2	29.0	21.6	17.4	22.2	19.4	23.6	34.5	30.9	20.1	12.4	36.8	22.6	15.7	10.6	27.1	21.1	21.2	41.5	23.4	19.1	19.1	18.2	9.8	31.6	6.7	21.7	22.5	22.4	14.7	26.6	15.6	24.8	29.6	19.7	15.9	21.9	23.5	29.7	18.0	17.1	19.8	30.7	25.7	30.0	23.7	11.5	18.8	16.1	29.5	12.0	21.9	15.8	10.0	13.3	15.2	13.8	12.7	6.8	19.1	16.9	11.7	50.3	10.7	15.2	19.8	15.3	5.2	14.3	21.3	24.4	17.1	13.8	10.5	14.1	16.6	15.1	17.8
TPX2	"C20orf1, C20orf2, DIL-2, p100"	ENSG00000088325	"TPX2, microtubule nucleation factor"	Q9ULW0	20	31739271-31801805	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 92.7"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.4"	"Group enriched"	"Detected in many"	5	"granulocytes: 4.0;NK-cells: 4.8;T-cells: 10.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA005487	Enhanced		Supported	"Nucleoplasm,Cytokinetic bridge,Mitotic spindle"				Nucleoplasm	"Cytokinetic bridge, Mitotic spindle"	"HPA005487: AB_1858223"	"unprognostic (2.18e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.97e-2)"	"prognostic unfavourable (2.43e-6)"	"unprognostic (2.99e-1)"	"unprognostic (7.56e-2)"	"prognostic unfavourable (8.07e-7)"	"prognostic unfavourable (6.46e-4)"	"unprognostic (3.70e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (2.68e-5)"	"unprognostic (5.99e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (4.56e-2)"	"unprognostic (2.30e-1)"	"unprognostic (1.76e-2)"	"unprognostic (1.39e-1)"	1.8	1.7	1.0	13.4	2.0	21.7	1.2	2.2	1.7	2.2	5.7	0.5	0.3	4.6	1.2	2.3	13.3	0.5	1.9	1.5	0.8	0.7	1.2	2.7	2.6	12.9	0.7	1.1	0.8	0.5	0.0	0.7	6.6	0.9	0.7	7.4	0.5	2.3	0.5	2.2	5.9	4.7	3.2	0.9	5.9	3.2	22.0	0.6	92.7	0.7	11.0	16.2	2.2	3.8	1.0	1.4	4.0	0.1	4.8	10.4	1.3	69.6	23.4	28.3	22.1	2.2	4.2	27.3	29.3	16.6	42.6	32.2	49.6	30.1	32.8	17.3	16.3	36.8	32.3	26.6	48.6	14.1	12.5	64.3	22.4	33.8	0.7	24.6	16.6	1.4	1.4	26.7	19.5	22.9	47.5	30.0	33.3	28.6	41.2	19.2	31.5	25.3	23.4	76.4	19.8	11.4	11.4	20.6	13.8	44.8	17.0	13.2	29.5	15.0	15.4	47.8	29.4	21.9	44.9	12.0	20.7	29.4	14.9	87.9	31.0	4.0	0.0	0.5	0.6	0.0	0.3	1.0	1.9	2.3	0.6	0.4	0.4	0.7	0.4	4.8	0.1	1.4	10.4	1.3	1.0	2.0	2.2	1.7	0.8	0.7	0.7	1.1	0.9	0.6
TRAF1	EBI6	ENSG00000056558	"TNF receptor associated factor 1"	Q13077	9	120902393-120929173	"Cancer-related genes, Predicted intracellular proteins"	Apoptosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"HDLM-2: 35.1;WM-115: 44.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"dendritic cells: 2.8;T-cells: 11.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001852, CAB009593"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"CAB009593: , HPA001852: AB_1080344"	"unprognostic (1.45e-3)"	"unprognostic (4.51e-2)"	"unprognostic (1.21e-2)"	"unprognostic (3.17e-3)"	"unprognostic (2.32e-2)"	"unprognostic (1.48e-3)"	"unprognostic (1.03e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.02e-2)"	"unprognostic (1.39e-1)"	"prognostic favourable (2.19e-5)"	"unprognostic (3.23e-1)"	"prognostic unfavourable (4.42e-5)"	"unprognostic (1.85e-3)"	"unprognostic (5.70e-3)"	"unprognostic (2.64e-1)"	"unprognostic (9.87e-3)"	5.4	8.6	9.5	21.6	20.5	8.7	5.7	4.7	13.7	5.3	6.5	17.5	9.2	4.3	6.6	7.4	5.2	6.7	8.6	7.5	11.4	5.5	7.8	4.9	7.4	33.1	14.8	11.2	10.9	3.9	5.3	11.0	3.6	12.5	10.0	5.0	9.4	10.3	7.2	2.4	8.2	8.9	7.8	7.6	15.5	6.6	3.1	19.1	3.5	7.9	2.2	24.0	9.0	10.0	0.2	2.8	0.0	0.4	1.4	11.1	2.0	1.2	0.8	0.1	0.0	1.4	3.6	0.0	0.3	1.9	0.5	1.0	0.1	0.6	2.4	0.4	0.4	0.5	0.2	0.1	0.7	35.1	0.0	0.2	0.8	0.1	1.0	0.1	2.8	1.7	1.9	2.3	1.7	0.3	0.0	4.8	0.3	0.1	0.0	1.0	0.4	0.1	0.5	0.6	4.8	0.2	0.1	0.4	0.0	0.3	0.1	0.1	0.3	0.4	0.3	0.4	0.3	1.9	6.2	3.7	1.3	1.2	1.2	0.2	44.4	0.0	0.3	0.0	3.6	0.4	6.4	0.2	8.8	7.4	0.4	0.2	2.7	4.0	0.0	1.4	0.3	2.8	11.1	2.0	9.5	20.5	4.7	13.7	11.4	5.5	14.8	11.2	12.5	19.1
TRAF2	"RNF117, TRAP3"	ENSG00000127191	"TNF receptor associated factor 2"	Q12933	9	136881912-136926607	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004603, HPA009972, HPA010634"	Uncertain		Enhanced	Cytosol				Cytosol		"CAB004603: AB_628389, HPA009972: AB_1080350, HPA010634: AB_1080347"	"unprognostic (7.77e-2)"	"unprognostic (4.54e-3)"	"prognostic unfavourable (9.32e-4)"	"unprognostic (1.15e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (3.06e-4)"	"unprognostic (4.91e-2)"	"unprognostic (7.23e-2)"	"unprognostic (4.28e-2)"	"unprognostic (7.39e-2)"	"unprognostic (2.82e-2)"	"prognostic unfavourable (2.09e-4)"	"unprognostic (1.80e-3)"	"unprognostic (5.52e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.53e-2)"	7.3	6.6	8.7	20.3	10.4	15.9	8.6	16.0	10.0	7.3	8.7	7.4	7.3	11.1	12.3	6.9	12.3	9.0	8.3	8.3	7.5	6.5	8.5	12.3	11.5	19.7	11.2	8.3	6.8	13.9	5.9	8.8	12.1	8.1	10.2	6.2	7.5	13.0	10.1	6.4	13.0	10.4	10.6	8.2	13.8	10.7	13.7	6.4	16.4	14.7	5.2	15.9	8.4	37.5	12.6	11.5	6.7	8.3	10.1	17.4	6.2	10.6	32.9	8.9	7.9	2.5	4.0	17.4	8.8	4.9	12.9	8.8	20.3	19.3	13.3	11.5	5.5	28.1	12.2	14.4	5.3	20.2	9.9	10.0	29.7	12.6	3.7	9.8	10.4	3.0	4.4	10.5	6.0	6.0	16.8	15.2	5.7	15.5	15.9	14.1	14.5	14.8	15.1	13.7	18.1	7.9	8.4	14.6	6.8	11.0	25.8	10.0	18.5	11.6	6.8	16.9	10.9	11.0	14.7	6.3	10.3	13.2	6.0	8.1	12.4	1.3	3.7	6.7	10.4	4.2	14.6	12.6	11.1	13.0	4.9	10.0	9.1	10.9	3.3	10.1	8.3	11.5	17.4	6.2	8.7	10.4	16.0	10.0	7.5	6.5	11.2	8.3	8.1	6.4
TRAF3	"CAP-1, CD40bp, CRAF1, LAP1, RNF118"	ENSG00000131323	"TNF receptor associated factor 3"	Q13114	14	102777476-102911500	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Immunity, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002933	Uncertain									"HPA002933: AB_1080352"	"unprognostic (4.06e-2)"	"unprognostic (1.75e-2)"	"unprognostic (2.08e-2)"	"unprognostic (4.49e-3)"	"unprognostic (5.25e-2)"	"unprognostic (4.17e-2)"	"prognostic unfavourable (1.02e-5)"	"unprognostic (1.31e-1)"	"unprognostic (7.24e-2)"	"unprognostic (1.16e-1)"	"prognostic favourable (2.42e-5)"	"unprognostic (1.29e-1)"	"unprognostic (2.29e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.13e-2)"	"unprognostic (2.12e-1)"	7.6	5.3	13.6	23.3	9.1	18.8	7.7	12.5	16.0	4.2	8.9	8.8	5.8	8.4	7.5	3.9	7.5	8.9	7.1	7.3	16.6	12.7	6.7	7.0	8.1	26.0	11.5	8.0	4.8	5.1	10.0	10.3	6.8	8.5	6.1	8.0	7.9	5.7	8.0	5.5	7.9	11.8	7.8	9.8	14.2	7.1	12.2	6.6	10.5	7.5	4.1	25.4	11.1	9.3	12.0	6.7	4.3	5.7	2.4	5.1	4.9	11.9	13.6	7.6	4.7	4.4	6.3	11.5	9.4	10.3	10.1	8.5	6.6	17.8	9.5	11.7	10.0	7.3	10.8	10.3	10.4	23.7	7.0	8.9	6.0	4.9	7.2	10.1	26.7	6.3	7.8	7.0	10.1	7.3	9.1	28.4	6.4	12.1	21.6	5.9	4.0	10.3	11.9	10.5	4.8	9.0	14.7	20.2	7.2	10.2	7.1	6.6	6.8	11.5	15.5	9.6	7.4	24.9	13.3	20.6	23.5	17.4	10.4	5.2	11.3	2.6	5.7	1.7	3.7	4.6	3.0	12.0	5.1	3.3	4.1	11.5	3.7	2.6	4.3	2.4	2.8	6.7	4.4	4.9	13.6	9.1	12.5	16.0	16.6	12.7	11.5	8.0	8.5	6.6
TRAF4	"CART1, MLN62, RNF83"	ENSG00000076604	"TNF receptor associated factor 4"	Q9BUZ4	17	28743984-28750958	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 53.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"plasmacytoid DC: 27.7"	"Lineage enriched"	"Detected in many"	5	"dendritic cells: 27.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA052377	Enhanced									"HPA052377: "	"unprognostic (1.77e-1)"	"unprognostic (9.05e-2)"	"unprognostic (1.31e-2)"	"unprognostic (2.51e-3)"	"unprognostic (1.76e-1)"	"unprognostic (7.38e-3)"	"unprognostic (1.09e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.33e-1)"	"unprognostic (7.13e-2)"	"unprognostic (7.55e-2)"	"unprognostic (1.74e-3)"	"unprognostic (6.98e-2)"	"unprognostic (9.26e-2)"	"unprognostic (2.77e-2)"	"unprognostic (5.58e-3)"	5.0	8.1	13.8	13.1	14.5	19.9	15.9	6.3	12.4	7.9	22.2	24.7	14.0	32.8	6.8	5.7	15.4	9.5	17.1	2.8	12.7	7.6	20.7	30.1	13.5	12.5	17.9	7.7	7.2	33.8	3.1	8.1	11.8	12.4	16.7	16.0	6.0	32.2	10.4	0.9	7.5	31.4	5.1	10.9	10.2	21.7	7.4	16.4	5.9	16.4	7.1	16.5	15.9	6.0	5.3	27.7	2.7	0.6	0.8	1.4	0.9	11.3	18.2	25.1	12.2	3.6	4.2	39.0	7.7	6.7	8.4	11.1	14.4	14.6	17.8	11.4	8.6	17.3	11.4	17.7	3.4	5.6	16.0	6.3	30.1	16.4	14.0	3.0	7.1	8.0	17.5	9.9	11.8	6.5	16.6	1.6	7.6	19.1	9.6	6.4	19.4	4.2	14.2	11.4	8.7	23.8	33.5	15.8	18.2	12.2	53.7	23.2	20.4	4.9	4.3	5.3	11.1	6.0	10.8	2.4	5.7	22.2	4.2	5.1	24.0	2.7	0.2	0.9	0.6	0.6	1.4	5.3	1.0	1.0	1.5	5.3	0.7	0.7	0.1	0.8	0.4	27.7	0.5	0.9	13.8	14.5	6.3	12.4	12.7	7.6	17.9	7.7	12.4	16.4
TRAF7	"DKFZp586I021, MGC7807, RFWD1, RNF119"	ENSG00000131653	"TNF receptor associated factor 7"	Q6Q0C0	16	2155698-2178129	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041229	Approved		Supported	"Vesicles,Plasma membrane"				Vesicles	"Plasma membrane"	"HPA041229: AB_10794194"	"unprognostic (1.94e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.13e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.65e-2)"	"unprognostic (2.77e-3)"	"unprognostic (7.08e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.08e-1)"	"unprognostic (9.23e-2)"	"unprognostic (6.07e-2)"	"unprognostic (2.99e-2)"	"unprognostic (2.43e-1)"	"unprognostic (8.48e-2)"	16.0	18.2	18.3	22.3	20.6	28.5	39.1	28.7	25.6	22.1	29.4	9.1	21.1	37.3	20.4	18.3	32.9	21.9	36.9	21.0	18.3	14.8	21.3	47.3	18.3	40.9	13.4	14.7	19.3	41.6	17.7	20.3	19.5	12.8	16.2	16.9	13.0	24.4	23.1	25.5	32.2	37.8	28.8	14.1	21.4	25.1	13.2	10.6	26.1	20.3	30.9	21.9	21.9	28.9	6.7	12.3	7.7	13.9	3.0	7.1	5.2	20.8	26.7	15.3	27.3	15.8	30.0	18.0	16.1	20.3	19.0	17.1	32.4	27.0	13.4	19.1	20.5	24.5	14.3	28.6	7.2	21.1	18.3	19.1	35.6	24.8	21.0	20.3	27.7	29.6	23.9	18.3	24.0	36.7	20.3	18.1	18.0	47.7	20.8	23.6	30.0	13.1	38.9	25.4	26.8	15.3	11.2	30.8	25.6	13.5	25.9	17.6	29.4	25.0	27.6	23.1	32.5	21.5	17.5	26.2	19.4	17.7	13.2	13.2	17.9	3.7	10.0	7.7	5.4	13.9	5.0	6.7	5.3	5.7	12.3	4.9	3.8	4.5	6.9	3.0	9.4	6.0	7.1	5.2	18.3	20.6	28.7	25.6	18.3	14.8	13.4	14.7	12.8	10.6
TRIM23	"ARD1, ARFD1, RNF46"	ENSG00000113595	"Tripartite motif containing 23"	P36406	5	65589680-65625975	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA039605	Approved									"HPA039605: AB_10673146"	"unprognostic (4.06e-1)"	"unprognostic (1.07e-1)"	"unprognostic (5.11e-2)"	"unprognostic (3.63e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.00e-3)"	"unprognostic (6.51e-2)"	"unprognostic (1.89e-2)"	"unprognostic (1.73e-2)"	"unprognostic (3.19e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.62e-1)"	"unprognostic (6.55e-3)"	"unprognostic (2.70e-1)"	8.6	12.7	15.0	6.6	17.9	7.6	9.4	25.8	34.3	11.5	7.8	9.5	7.3	4.5	10.6	7.0	9.0	8.6	6.3	12.3	16.3	15.2	10.2	11.8	6.6	7.7	14.4	18.8	16.2	6.5	11.1	11.6	7.9	22.1	12.9	5.3	4.1	5.7	9.4	14.8	6.6	5.2	9.3	14.2	8.2	5.6	10.9	14.0	7.5	12.4	4.4	7.6	7.5	7.6	6.0	3.8	14.5	4.5	5.6	9.9	4.5	6.3	8.7	9.3	14.0	14.5	14.6	7.0	12.1	11.6	10.4	12.8	8.0	6.1	4.9	14.6	8.5	5.1	9.1	7.1	16.1	5.1	9.6	3.9	11.9	5.0	13.5	2.4	5.5	11.4	6.0	11.6	10.5	5.0	4.5	7.0	12.2	5.9	5.0	2.7	5.1	3.6	4.7	16.9	7.0	5.4	6.5	5.5	7.7	11.6	3.5	9.6	7.6	3.3	8.5	8.1	8.7	10.1	8.9	8.7	8.0	6.0	9.5	4.7	8.1	14.5	4.0	9.5	5.6	3.0	6.9	4.7	6.1	4.9	3.6	6.0	9.9	7.5	10.1	5.6	4.5	3.8	6.9	4.5	15.0	17.9	25.8	31.1	16.3	15.2	14.4	18.8	22.1	14.0
TRIM24	"hTIF1, RNF82, TIF1, Tif1a"	ENSG00000122779	"Tripartite motif containing 24"	O15164	7	138460334-138589993	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"AF22: 42.7;HMC-1: 57.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043495, HPA061717"	Approved		Enhanced	Nucleoplasm	"Intracellular and membrane"			Nucleoplasm		"HPA043495: AB_10962915, HPA061717: AB_2684592"	"unprognostic (2.40e-1)"	"unprognostic (9.52e-3)"	"unprognostic (2.23e-1)"	"unprognostic (3.96e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavourable (9.94e-4)"	"prognostic favourable (6.57e-4)"	"unprognostic (4.01e-2)"	"unprognostic (8.93e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.02e-1)"	"unprognostic (4.62e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.25e-2)"	"unprognostic (5.54e-2)"	"unprognostic (6.34e-2)"	10.3	31.4	10.4	11.2	10.6	8.8	8.8	8.5	10.7	9.4	9.2	14.6	5.7	9.4	9.0	8.5	11.3	7.0	10.3	9.7	8.4	8.5	9.6	21.5	10.7	8.5	10.5	8.0	29.9	11.6	20.7	7.3	13.5	8.4	13.6	9.1	7.5	10.1	7.1	16.0	9.8	14.1	9.4	8.0	8.5	10.8	24.1	11.3	34.8	8.8	9.2	8.9	11.3	11.2	1.3	1.9	3.7	2.5	2.2	2.7	0.8	4.1	5.1	42.7	12.3	2.9	2.6	3.3	3.9	4.1	3.0	3.0	8.1	3.9	8.0	3.9	3.7	2.2	20.7	3.2	4.5	6.1	5.1	17.7	3.8	24.9	3.9	13.7	57.8	2.3	3.4	2.5	4.1	7.2	20.0	4.9	3.6	8.1	23.4	12.5	16.3	4.6	18.6	5.0	6.8	6.8	12.5	8.9	20.2	7.3	6.5	2.1	4.5	9.1	3.0	3.5	2.9	6.2	5.3	4.6	4.9	13.7	5.9	9.1	5.2	1.1	2.3	3.6	2.2	2.5	0.4	0.9	1.9	1.2	1.9	1.3	1.8	2.0	3.7	2.2	1.1	1.4	2.7	0.8	10.4	10.6	8.5	9.7	8.4	8.5	10.5	8.0	8.4	11.3
TRIM25	"EFP, RNF147, ZNF147"	ENSG00000121060	"Tripartite motif containing 25"	Q14258	17	56887909-56914038	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Antiviral defense, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway"	"Ligase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	7	"neutrophil: 20.0"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 20.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA005909	Approved		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"		35000	35000	"Nucleoplasm, Cytosol"	"Nuclear bodies"	"HPA005909: AB_1078722"	"unprognostic (8.73e-3)"	"unprognostic (1.57e-2)"	"unprognostic (2.06e-2)"	"unprognostic (6.06e-2)"	"unprognostic (2.69e-1)"	"unprognostic (3.78e-2)"	"prognostic unfavourable (9.37e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.23e-1)"	"unprognostic (1.15e-1)"	"prognostic favourable (3.36e-4)"	"unprognostic (3.23e-1)"	"unprognostic (3.11e-2)"	"prognostic favourable (9.35e-4)"	"unprognostic (5.21e-2)"	"unprognostic (5.13e-2)"	"unprognostic (7.39e-2)"	20.0	19.7	7.5	23.6	8.9	32.6	19.3	11.6	7.8	15.3	22.5	5.0	8.0	15.3	13.4	12.6	17.7	15.3	18.4	8.3	5.8	6.3	10.1	27.0	20.8	15.9	6.7	5.5	13.3	15.3	13.6	11.5	55.0	7.4	12.2	14.3	12.5	14.5	11.5	11.7	23.1	20.7	10.1	5.2	35.8	14.1	12.8	6.5	26.2	11.8	15.1	18.5	10.6	35.9	1.7	2.4	20.0	2.3	0.8	1.5	0.7	28.8	14.3	3.5	11.9	26.7	22.6	0.0	11.4	23.1	27.3	23.6	13.9	15.9	28.2	23.7	10.9	17.2	17.2	15.3	15.3	24.0	13.6	18.2	11.1	15.4	23.0	21.7	13.1	10.1	25.8	14.2	30.3	18.1	4.4	17.3	13.8	19.3	24.2	15.7	2.2	27.8	17.4	11.9	17.7	15.9	22.8	6.9	6.4	9.0	14.5	26.5	19.6	17.7	12.0	12.8	9.2	19.6	11.8	9.8	18.7	4.7	12.4	15.0	5.0	3.0	2.3	0.9	0.9	1.9	1.1	1.7	0.8	0.8	2.4	1.4	0.6	0.8	20.0	0.8	1.4	1.7	1.5	0.7	7.5	8.9	11.6	7.8	5.8	6.3	6.7	5.5	7.4	6.5
TRIM27	"RFP, RNF76"	ENSG00000204713	"Tripartite motif containing 27"	P14373	6	28903002-28923989	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Transport, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048684, HPA053408"	Approved		Approved	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"HPA048684: , HPA053408: "	"unprognostic (1.57e-1)"	"unprognostic (1.48e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.14e-2)"	"unprognostic (1.70e-2)"	"unprognostic (2.56e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.17e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.12e-3)"	"unprognostic (4.76e-3)"	"unprognostic (1.16e-2)"	"prognostic unfavourable (3.50e-6)"	"unprognostic (1.27e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.47e-1)"	"prognostic favourable (2.71e-4)"	11.5	10.6	8.8	25.5	9.7	7.9	9.3	10.1	12.2	11.2	10.2	8.7	20.2	23.8	12.1	13.2	7.8	12.1	11.4	8.1	8.2	9.6	10.1	22.5	10.4	17.4	12.6	8.3	14.7	31.0	7.4	13.9	13.7	10.6	13.7	4.6	7.7	17.0	25.2	12.2	9.7	19.4	9.2	8.4	18.6	18.5	9.2	9.2	16.7	12.5	7.9	12.1	9.9	11.8	12.5	12.5	13.8	13.9	11.2	15.9	13.8	3.3	2.3	0.9	6.0	0.8	1.7	0.6	4.6	1.1	1.4	1.7	1.7	1.4	7.7	7.9	1.3	7.4	1.1	2.7	0.1	3.0	12.9	10.8	0.5	2.3	1.3	4.5	1.7	1.3	1.6	1.2	0.5	1.2	10.5	3.3	0.4	1.3	6.3	2.4	0.0	7.3	9.0	6.9	14.2	1.1	1.1	3.2	12.9	5.5	3.4	7.3	3.3	3.5	3.9	3.4	7.1	6.2	2.7	12.0	14.4	12.0	1.8	11.5	5.2	12.6	13.8	8.8	12.7	13.9	15.9	12.5	12.6	14.4	12.5	10.5	11.8	12.1	13.8	11.2	12.1	9.8	10.4	13.8	8.8	9.7	10.1	12.2	8.2	9.6	12.6	8.3	10.6	9.2
TRIM33	"FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA"	ENSG00000197323	"Tripartite motif containing 33"	Q9UPN9	1	114392777-114511160	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 48.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004345	Supported		Approved	Nucleoplasm,Vesicles				Vesicles	Nucleoplasm	"HPA004345: AB_1858287"	"unprognostic (8.90e-2)"	"unprognostic (5.86e-2)"	"prognostic favourable (6.20e-4)"	"unprognostic (1.09e-2)"	"unprognostic (8.42e-3)"	"prognostic favourable (8.93e-4)"	"unprognostic (1.34e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.75e-2)"	"unprognostic (4.58e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.27e-2)"	"unprognostic (4.84e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.68e-1)"	15.2	12.8	16.9	18.4	19.9	27.1	17.1	38.3	21.8	16.9	14.3	11.0	21.9	10.9	19.8	38.3	16.4	15.0	15.6	10.8	18.1	12.5	17.3	15.0	14.3	15.2	12.1	18.0	19.8	15.7	21.8	22.4	27.2	15.2	16.5	13.0	10.7	16.4	19.1	14.3	19.5	14.8	20.2	12.9	14.9	14.1	29.0	16.3	20.5	17.9	9.8	16.6	17.9	28.7	3.4	4.0	12.2	2.8	4.7	4.4	1.0	12.9	7.0	13.2	9.9	5.6	5.9	22.5	6.6	7.0	9.2	9.8	7.9	5.5	13.8	6.8	7.7	7.5	12.0	7.7	12.7	10.4	7.1	13.3	9.2	9.1	6.2	16.8	11.1	5.6	5.7	10.9	11.2	7.7	16.6	9.8	8.8	48.5	16.9	7.1	17.8	7.1	14.6	20.2	4.5	6.6	20.4	9.2	9.7	12.5	15.1	11.9	6.9	9.2	8.6	6.4	10.5	14.8	9.2	6.9	6.4	14.5	9.1	9.8	18.2	12.2	1.6	7.4	3.5	1.8	3.1	3.4	3.7	3.7	2.0	2.2	2.9	4.4	4.8	4.7	2.8	4.0	2.0	1.0	16.9	19.9	38.3	21.8	18.1	12.5	12.1	18.0	15.2	16.3
TRIM7	"GNIP, RNF90"	ENSG00000146054	"Tripartite motif containing 7"	Q9C029	5	181193924-181205293	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 81.8;tongue: 34.0"	"Cell line enhanced"	"Detected in many"		"HaCaT: 11.2;HDLM-2: 23.8;PC-3: 13.2;TIME: 10.8"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in some"	16	"cerebellum: 21.7"	"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"monocytes: 4.9;T-cells: 2.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA039213	Approved		Approved	Nucleoplasm,Vesicles,Cytosol				Vesicles	"Nucleoplasm, Cytosol"	"HPA039213: AB_10795173"	"unprognostic (6.58e-2)"	"unprognostic (1.17e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.10e-2)"	"unprognostic (6.85e-2)"	"unprognostic (1.80e-2)"	"unprognostic (3.89e-4)"	"unprognostic (3.45e-2)"	"unprognostic (3.72e-1)"	"unprognostic (1.64e-1)"	"unprognostic (3.48e-2)"	"unprognostic (1.97e-1)"	"unprognostic (7.16e-3)"	"unprognostic (1.26e-1)"	"unprognostic (3.90e-2)"	"unprognostic (6.17e-2)"	"unprognostic (1.15e-2)"	1.3	0.9	0.1	0.9	0.5	0.5	3.4	21.7	1.3	2.5	0.8	0.3	1.1	0.5	1.0	6.4	13.0	0.6	1.7	2.2	0.1	0.8	2.2	0.5	0.9	0.6	0.2	0.2	0.6	4.2	1.6	1.9	0.5	0.5	2.0	0.6	0.6	5.9	1.1	81.8	9.5	0.6	0.9	0.3	0.8	1.4	0.9	0.2	0.1	3.3	34.0	13.5	1.6	2.9	0.7	0.8	0.1	4.9	0.5	2.2	1.1	6.1	2.9	0.0	0.3	0.5	0.5	0.1	1.4	0.0	0.5	1.2	0.2	8.0	0.4	4.3	1.7	11.2	3.2	9.2	0.1	23.8	1.3	0.5	7.8	0.1	1.6	0.0	1.3	0.1	7.1	0.2	4.6	2.6	0.3	1.3	0.2	0.8	0.3	0.2	0.0	13.2	0.3	4.2	0.9	3.3	0.0	0.3	0.7	2.9	0.1	4.0	0.7	0.2	10.8	0.1	2.4	0.4	4.2	1.9	0.2	0.7	0.3	0.4	1.0	0.0	4.9	0.1	1.4	1.9	2.2	0.4	1.2	1.4	0.8	0.7	2.2	1.8	0.1	0.5	1.4	0.6	2.2	1.1	0.1	0.5	21.7	1.3	0.1	0.8	0.2	0.2	0.5	0.2
TRIO	ARHGEF23	ENSG00000038382	"Trio Rho guanine nucleotide exchange factor"	O75962	5	14143702-14532128	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-87 MG: 62.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008157, HPA064664"	Supported		Approved	Vesicles,Cytosol				Cytosol	Vesicles	"HPA008157: AB_1858327, HPA064664: "	"unprognostic (6.65e-2)"	"unprognostic (4.21e-3)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (1.90e-4)"	"unprognostic (9.39e-2)"	"unprognostic (4.13e-1)"	"unprognostic (2.18e-3)"	"unprognostic (2.55e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.82e-1)"	"prognostic unfavourable (3.11e-5)"	"unprognostic (1.78e-2)"	"unprognostic (1.96e-1)"	"unprognostic (4.58e-3)"	"unprognostic (2.23e-1)"	29.7	13.7	27.6	15.8	18.9	5.8	30.3	32.6	29.7	13.7	18.5	11.3	9.2	8.3	23.1	19.3	10.4	12.2	25.2	15.1	18.9	15.0	11.7	12.6	15.8	10.9	11.0	17.7	28.9	11.5	17.2	19.6	13.7	12.3	16.3	16.5	23.3	10.5	14.0	19.8	16.0	15.6	22.7	11.6	24.2	13.7	11.3	11.5	7.4	10.0	11.9	12.3	15.6	16.9	3.8	2.7	0.3	1.9	4.3	0.6	0.4	12.2	4.4	10.6	5.0	22.7	29.8	12.1	11.3	13.5	9.1	10.5	2.8	4.8	2.8	8.5	15.4	3.7	1.7	5.3	18.9	7.8	2.5	1.5	11.8	3.5	11.8	3.7	4.2	13.9	5.6	32.2	10.3	8.0	0.3	1.9	22.0	2.3	0.0	2.6	2.6	4.0	2.8	6.4	9.4	8.9	5.5	4.8	19.5	9.6	2.5	5.0	1.5	0.5	18.6	17.6	11.2	12.7	13.3	0.0	0.6	3.6	62.5	2.4	4.1	0.3	1.5	0.0	0.1	1.9	0.3	2.0	0.0	0.0	1.4	3.8	0.0	0.0	0.0	4.3	1.4	2.7	0.6	0.4	27.6	18.9	32.6	29.7	18.9	15.0	11.0	17.7	12.3	11.5
TRIP11	"CEV14, GMAP-210, GMAP210, Trip230"	ENSG00000100815	"Thyroid hormone receptor interactor 11"	Q15643	14	91965991-92040896	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002570, HPA070684"	Supported		Enhanced	"Nucleoplasm,Golgi apparatus"				"Golgi apparatus"	Nucleoplasm	"HPA002570: AB_1078995, HPA070684: "	"unprognostic (1.65e-1)"	"unprognostic (2.81e-2)"	"unprognostic (7.14e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.89e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.49e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.46e-1)"	"unprognostic (7.33e-3)"	"unprognostic (2.04e-1)"	"unprognostic (1.21e-1)"	"prognostic favourable (1.78e-6)"	"unprognostic (1.78e-1)"	"unprognostic (5.08e-1)"	"unprognostic (7.74e-2)"	"unprognostic (5.55e-2)"	13.0	15.0	10.5	10.8	12.5	7.7	12.1	18.5	14.1	17.4	13.0	8.8	15.2	11.1	13.3	12.7	14.7	11.4	11.2	12.9	9.2	6.7	15.5	16.1	10.6	9.4	12.2	11.1	16.0	27.1	27.1	34.9	24.4	15.2	14.5	11.0	9.4	15.1	15.3	24.0	12.4	15.9	11.2	10.7	15.2	16.2	14.0	13.5	16.4	18.4	11.1	11.9	15.8	12.5	20.0	12.7	17.0	13.0	12.1	14.1	3.9	12.4	12.6	8.2	8.6	14.5	22.5	12.5	19.8	15.2	9.8	11.3	7.6	20.3	8.7	14.6	17.4	16.4	10.8	9.6	21.5	13.2	3.3	9.8	11.4	7.2	11.1	11.5	9.8	8.6	11.8	17.3	14.9	15.6	6.4	10.1	15.3	17.4	6.5	2.8	3.7	9.0	8.1	15.7	4.3	8.8	20.4	6.0	5.4	16.0	9.4	6.1	20.5	5.8	20.6	11.4	8.1	11.9	8.9	9.0	13.8	7.8	13.4	6.5	14.3	8.2	8.8	17.0	13.3	8.0	12.8	11.8	14.1	12.1	6.9	20.0	13.5	14.1	8.7	12.1	13.0	12.7	12.2	3.9	10.5	12.5	18.5	14.1	9.2	6.7	12.2	11.1	15.2	13.5
TRIP4	"HsT17391, ZC2HC5"	ENSG00000103671	"Thyroid hormone receptor interactor 4"	Q15650	15	64387748-64455303	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Congenital muscular dystrophy, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016605, HPA050666"	Approved		Supported	"Nucleoplasm,Nuclear bodies"				"Nucleoplasm, Nuclear bodies"		"HPA016605: AB_1858339, HPA050666: "	"unprognostic (1.56e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.62e-1)"	"unprognostic (4.50e-2)"	"unprognostic (5.79e-2)"	"unprognostic (1.08e-1)"	"unprognostic (7.16e-2)"	"unprognostic (3.01e-2)"	"unprognostic (4.98e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.25e-1)"	"unprognostic (2.37e-2)"	"prognostic favourable (6.34e-6)"	"unprognostic (2.41e-1)"	"unprognostic (2.96e-1)"	"unprognostic (2.61e-2)"	"unprognostic (1.25e-1)"	17.1	14.7	14.2	18.8	15.1	13.7	18.3	15.9	19.6	14.3	20.8	16.6	23.5	17.5	17.1	14.6	22.6	15.3	15.6	15.5	12.4	11.2	28.5	15.8	15.3	15.0	17.1	14.6	15.9	19.9	22.9	19.6	19.3	15.3	15.7	20.4	12.7	16.5	13.6	14.6	20.6	26.2	17.3	15.7	20.0	17.4	15.0	14.4	28.0	27.1	17.4	18.6	16.8	17.5	8.6	10.4	30.9	19.7	9.7	11.5	8.3	10.8	16.2	14.3	10.1	11.8	15.6	13.4	11.6	15.0	20.1	19.6	13.5	24.5	7.8	3.9	17.6	15.5	23.1	13.2	19.2	15.8	6.5	11.4	11.6	14.1	21.1	12.3	21.7	19.4	17.4	15.9	16.7	17.5	13.1	9.9	18.4	12.5	7.7	12.8	8.3	8.7	11.9	10.8	13.0	19.7	20.9	7.7	12.2	10.4	12.6	20.9	15.9	18.5	15.4	14.4	9.8	9.5	16.3	8.3	14.8	7.8	11.9	12.7	17.9	30.9	11.4	26.6	11.3	14.6	9.6	8.4	10.8	11.4	10.4	8.6	9.2	9.7	16.1	9.7	19.7	8.2	11.5	8.3	14.2	15.1	15.9	19.6	12.4	11.2	17.1	14.6	15.3	14.4
TRO	"KIAA1114, MAGE-D3, MAGED3"	ENSG00000067445	Trophinin	Q12816	X	54920462-54931431	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 32.1"	"Cell line enhanced"	"Detected in many"		"AF22: 20.9;HEK 293: 12.9;HSkMC: 13.1;SCLC-21H: 14.0;SH-SY5Y: 18.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 5.2"	"Low lineage specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA053358			Approved	"Nucleoplasm,Nucleoli fibrillar center"				"Nucleoplasm, Nucleoli fibrillar center"		"HPA053358: "	"unprognostic (6.18e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.24e-2)"	"prognostic unfavourable (4.41e-5)"	"unprognostic (9.09e-3)"	"unprognostic (2.72e-1)"	"unprognostic (5.66e-2)"	"unprognostic (1.46e-1)"	"unprognostic (4.67e-2)"	"unprognostic (3.18e-1)"	"prognostic favourable (1.93e-4)"	"unprognostic (1.17e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.67e-4)"	"unprognostic (6.33e-2)"	"unprognostic (3.27e-2)"	"unprognostic (6.86e-2)"	4.5	4.2	21.7	2.1	15.5	1.6	3.7	11.3	23.8	8.0	2.5	7.9	1.4	1.7	16.3	8.6	2.4	7.1	5.6	2.9	17.9	15.6	5.3	13.2	2.5	2.3	10.5	13.2	21.7	5.7	7.6	20.2	5.5	22.3	7.4	3.2	5.0	1.5	6.9	32.1	1.5	1.8	10.9	8.9	1.4	2.0	3.6	14.2	4.2	9.2	0.1	2.4	3.6	5.0	0.7	2.6	0.0	0.2	5.2	1.2	0.4	0.0	0.2	20.9	0.0	4.1	5.7	0.0	1.1	7.2	1.1	0.4	0.0	0.0	0.0	3.0	7.5	0.1	0.1	0.3	0.6	0.0	12.9	9.6	0.0	0.8	1.5	0.0	0.1	13.1	0.0	6.7	0.0	0.5	0.0	0.1	7.7	0.0	0.1	0.0	10.7	0.0	6.1	9.1	0.1	2.0	0.1	14.0	18.8	0.0	0.3	1.8	0.0	1.2	0.0	8.8	9.2	0.1	1.1	3.3	0.4	0.0	1.3	0.0	7.6	0.0	0.0	0.0	1.2	0.0	0.7	0.7	0.1	0.4	0.0	0.5	0.3	0.7	0.0	5.2	0.2	2.6	0.0	0.4	21.7	15.5	11.3	23.8	17.9	15.6	10.5	13.2	22.3	14.2
TRRAP	"PAF400, TR-AP, Tra1"	ENSG00000196367	"Transformation/transcription domain associated protein"	Q9Y4A5	7	98877933-99050831	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054376			Supported	"Nucleoplasm,Golgi apparatus"				Nucleoplasm	"Golgi apparatus"	"HPA054376: "	"unprognostic (2.10e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.21e-1)"	"unprognostic (4.35e-2)"	"unprognostic (2.02e-1)"	"unprognostic (2.02e-1)"	"prognostic unfavourable (8.77e-4)"	"unprognostic (1.40e-2)"	"unprognostic (2.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (9.45e-2)"	"unprognostic (7.02e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.96e-1)"	9.6	14.2	10.7	18.4	13.4	18.8	14.9	22.8	14.4	14.1	11.3	15.4	10.0	10.6	15.1	10.1	11.3	17.1	11.4	11.4	10.7	9.5	10.8	11.0	13.1	17.1	12.4	9.4	22.4	16.2	26.7	29.9	12.2	9.6	11.8	10.2	13.7	11.8	16.7	11.7	16.9	13.3	16.9	14.2	14.5	11.5	19.3	12.1	37.1	16.6	7.7	19.3	12.8	11.5	2.7	3.1	5.7	0.9	1.3	2.7	0.3	12.1	14.3	14.8	12.5	7.3	7.6	7.4	5.4	7.2	8.5	8.2	11.1	5.4	17.0	8.6	10.0	6.4	15.3	7.4	9.4	9.8	15.0	10.4	10.4	6.4	5.4	18.6	7.7	7.0	4.4	13.9	11.9	10.9	17.7	32.3	7.9	23.5	22.7	7.4	11.3	8.8	16.8	8.5	13.0	4.4	13.6	11.7	14.6	13.7	9.0	4.6	4.5	8.4	11.4	11.4	16.7	15.1	12.5	13.3	15.1	25.2	8.1	9.6	11.3	5.7	0.9	0.6	1.5	0.6	2.7	2.0	2.7	1.3	0.9	2.7	1.9	1.8	2.9	1.3	0.9	3.1	2.0	0.3	10.7	13.4	22.8	14.4	10.7	9.5	12.4	9.4	9.6	12.1
TSC1	"hamartin, KIAA0243, LAM, TSC"	ENSG00000165699	"TSC complex subunit 1"	Q92574	9	132891348-132946874	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Chaperone	"Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB011568, CAB012481, HPA074132"	Supported		Enhanced	Cytosol				Cytosol		"CAB011568: AB_732752, CAB012481: , HPA074132: "	"unprognostic (1.88e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.40e-2)"	"unprognostic (2.56e-1)"	"unprognostic (6.67e-2)"	"unprognostic (4.23e-3)"	"prognostic unfavourable (6.03e-6)"	"unprognostic (1.96e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.24e-1)"	"prognostic favourable (8.01e-4)"	"unprognostic (1.84e-2)"	"prognostic favourable (7.91e-4)"	"unprognostic (9.49e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.16e-1)"	10.4	13.6	15.8	8.8	26.8	13.6	11.4	32.1	28.3	12.7	10.8	22.6	7.9	9.1	14.6	12.3	10.9	12.4	9.7	17.6	13.0	12.1	13.1	9.4	11.6	10.2	12.5	15.1	21.2	12.1	15.9	19.5	15.8	21.1	11.8	12.6	13.1	11.6	10.4	20.0	13.8	11.2	14.2	12.4	13.7	10.6	36.2	14.9	10.5	16.2	8.6	14.2	10.9	11.1	2.8	3.1	4.8	7.0	4.9	7.1	2.6	6.1	7.3	10.0	8.2	10.3	9.8	18.8	8.3	13.4	8.7	8.6	12.4	7.2	14.4	3.6	15.8	16.0	11.7	8.4	8.9	6.9	6.2	4.6	14.5	10.1	12.3	6.7	6.2	10.5	6.4	11.1	13.6	10.0	8.0	7.9	9.9	11.4	6.0	5.8	13.7	6.1	7.3	18.9	8.1	3.9	8.1	5.0	7.7	9.7	6.1	4.8	11.0	4.0	10.3	14.3	8.6	8.5	5.6	4.4	9.8	14.0	8.1	4.0	6.3	4.1	4.4	4.8	6.5	7.0	7.1	1.9	3.6	5.7	3.1	2.8	5.9	5.3	1.7	4.9	3.2	1.8	5.7	2.6	15.8	26.8	32.1	28.3	13.0	12.1	12.5	15.1	21.1	14.9
TSC2	"LAM, PPP1R160, TSC4, tuberin"	ENSG00000103197	"TSC complex subunit 2"	P49815	16	2047465-2089487	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"GTPase activation"	"Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002225, HPA030409, HPA049679"	Approved		Enhanced	Cytosol				Cytosol		"CAB002225: AB_564043, HPA030409: AB_10602483, HPA049679: "	"unprognostic (2.80e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.60e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.03e-3)"	"unprognostic (2.04e-2)"	"unprognostic (6.05e-3)"	"unprognostic (3.43e-1)"	"unprognostic (8.94e-2)"	"prognostic favourable (5.06e-4)"	"unprognostic (4.32e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.14e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.51e-2)"	"unprognostic (8.96e-2)"	13.9	11.9	16.9	12.4	20.0	10.9	13.2	35.1	26.9	20.5	17.0	19.4	17.9	14.0	20.1	12.2	13.0	18.6	15.0	14.0	13.3	8.8	11.8	9.8	12.7	10.1	13.8	14.7	21.1	16.1	20.0	18.1	10.6	14.6	13.8	10.8	16.7	22.9	19.6	31.7	14.5	13.2	13.5	11.4	12.9	16.6	21.4	12.9	14.1	20.1	11.3	10.9	18.0	14.0	4.7	5.6	7.7	4.9	3.6	7.0	3.7	7.2	11.6	16.1	18.2	19.2	16.2	13.6	17.4	11.9	13.1	11.2	13.9	13.8	10.9	15.5	14.3	12.0	9.6	12.6	9.8	8.3	15.8	10.3	22.5	5.7	13.2	12.8	12.5	19.1	8.0	10.6	7.9	12.3	10.0	9.8	11.6	14.4	15.2	3.8	16.7	11.4	24.2	17.6	13.9	5.3	6.5	12.2	23.1	24.8	16.4	8.8	15.0	9.5	19.4	13.8	9.4	12.3	8.8	21.9	21.8	21.8	5.7	5.2	16.3	6.2	4.9	5.4	7.0	4.7	6.7	4.4	4.4	4.1	5.6	4.7	3.1	4.8	7.7	3.6	3.7	1.5	3.2	3.7	16.9	20.0	35.1	26.9	13.3	8.8	13.8	14.7	14.6	12.9
TSG101	"TSG10, VPS23"	ENSG00000074319	"Tumor susceptibility 101"	Q99816	11	18468336-18527232	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Growth regulation, Host-virus interaction, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB004283, HPA006161"	Approved		Supported	"Nucleoli,Plasma membrane,Cytosol"		14000	14000	Cytosol	"Nucleoli, Plasma membrane"	"CAB004283: AB_671392, HPA006161: AB_1080408"	"unprognostic (1.42e-1)"	"unprognostic (7.91e-2)"	"unprognostic (2.11e-1)"	"unprognostic (6.77e-2)"	"unprognostic (1.82e-1)"	"unprognostic (2.72e-3)"	"prognostic unfavourable (3.74e-6)"	"unprognostic (5.67e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.00e-2)"	"unprognostic (4.15e-3)"	"unprognostic (4.27e-2)"	"prognostic favourable (5.52e-6)"	"unprognostic (1.92e-2)"	"unprognostic (1.02e-1)"	"unprognostic (4.02e-3)"	"unprognostic (1.06e-1)"	24.7	30.5	18.4	14.2	25.5	23.5	27.6	22.7	25.9	22.5	23.1	23.7	21.6	20.5	25.8	27.7	34.3	23.9	18.4	31.8	17.7	20.6	33.4	29.0	20.1	23.4	21.6	21.4	23.2	39.5	33.2	23.5	38.5	24.6	21.9	28.4	19.4	25.4	22.4	44.5	27.3	25.7	23.1	21.7	20.5	23.0	33.7	20.2	27.5	32.3	37.1	25.5	24.2	25.5	20.5	18.2	42.3	29.2	14.3	22.0	22.2	14.3	23.7	21.0	14.6	24.9	26.0	19.5	22.3	30.1	27.3	27.0	16.2	7.6	19.4	13.7	24.8	22.0	20.9	20.2	30.4	27.2	25.5	12.0	12.5	23.8	32.0	18.0	20.8	22.4	41.1	14.2	38.8	22.4	19.5	16.5	33.0	25.9	11.4	19.6	12.9	24.0	10.3	21.2	16.1	18.3	20.5	15.0	26.9	21.4	18.0	28.5	17.9	18.1	12.0	18.3	11.2	38.2	16.5	10.6	20.4	15.4	18.9	10.0	23.4	42.3	19.5	40.7	14.9	21.7	15.0	20.5	14.4	15.9	18.2	18.0	15.4	16.4	34.5	14.3	29.2	15.4	22.0	22.2	18.4	25.5	22.7	25.9	17.7	20.6	21.6	21.4	24.6	20.2
TSHR	LGR3	ENSG00000165409	"Thyroid stimulating hormone receptor"	P16473	14	80954989-81146302	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"thyroid gland: 158.0"	"Group enriched"	"Detected in some"	17	"MOLT-4: 18.1;SCLC-21H: 18.7;U-266/70: 9.2;U-266/84: 4.7"	"Cancer enriched"	"Detected in some"	116	"thyroid cancer: 100.4"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"T-reg: 9.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 9.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB000473	Approved				"Intracellular and membrane"					"CAB000473: AB_2303782"	"unprognostic (3.36e-3)"	"unprognostic (1.31e-3)"	"unprognostic (1.02e-2)"	"unprognostic (4.17e-6)"	"unprognostic (3.01e-3)"	"unprognostic (1.85e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.66e-2)"	"unprognostic (3.39e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.70e-1)"	"unprognostic (7.11e-3)"	"unprognostic (5.08e-7)"	"unprognostic (1.32e-1)"	"unprognostic (7.40e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.66e-1)"	0.1	0.2	0.1	0.2	0.4	0.3	0.2	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.3	0.3	0.5	0.1	0.0	0.8	0.2	0.0	0.1	0.3	0.1	0.0	0.2	0.2	0.1	0.1	0.1	27.3	158.0	0.2	0.4	0.1	0.1	1.8	0.8	1.3	0.3	0.1	9.9	0.1	0.3	0.2	0.6	0.4	0.1	0.1	0.3	0.1	0.1	0.0	0.1	0.3	0.4	0.6	0.2	0.1	0.2	0.7	0.0	0.1	0.2	0.1	0.3	0.6	0.3	0.0	0.2	0.3	0.3	0.1	0.1	0.2	0.1	0.3	0.6	0.1	0.4	18.1	0.4	0.4	0.2	0.6	0.2	0.7	0.0	0.4	18.7	0.3	0.1	0.2	0.2	0.3	0.0	0.2	0.5	0.4	0.5	0.2	9.2	4.7	0.4	0.2	0.2	0.3	0.6	0.2	0.2	0.2	0.1	0.2	1.0	0.8	0.5	0.1	1.8	0.3	0.2	1.3	0.1	0.3	0.8	9.9	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.1	0.0	0.5	0.1
TSPAN8	"CO-029, TM4SF3"	ENSG00000127324	"Tetraspanin 8"	P19075	12	71125085-71441898	"Cancer-related genes, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"intestine: 235.3"	"Cell line enhanced"	"Detected in some"		"CACO-2: 14.9;HeLa: 18.0;PC-3: 57.3;RPTEC TERT1: 11.0;RT4: 13.2"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 283.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"							"CAB026009, HPA044337"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"CAB026009: , HPA044337: "	"unprognostic (1.64e-1)"	"unprognostic (2.18e-2)"	"unprognostic (1.64e-1)"	"unprognostic (6.40e-2)"	"unprognostic (6.81e-2)"	"unprognostic (7.29e-3)"	"unprognostic (1.90e-1)"	"unprognostic (1.15e-1)"	"unprognostic (5.62e-2)"	"unprognostic (1.06e-1)"	"unprognostic (4.01e-3)"	"unprognostic (2.93e-1)"	"prognostic unfavourable (9.66e-5)"	"unprognostic (1.88e-2)"	"unprognostic (1.00e-1)"	"unprognostic (2.97e-2)"	"prognostic favourable (7.36e-5)"	1.9	0.8	0.7	24.1	2.3	0.0	1.1	0.6	1.3	2.0	139.5	2.8	1.5	83.2	1.2	1.5	1.1	1.3	30.8	1.0	0.7	0.7	7.6	3.7	5.1	1.0	4.7	1.0	6.9	9.9	0.0	0.8	0.7	3.5	14.2	79.5	2.6	11.7	1.0	12.5	2.4	235.3	3.4	9.7	0.6	55.5	1.6	2.7	0.6	1.8	3.1	5.0	3.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.7	0.2	0.9	0.0	0.0	0.0	0.0	14.9	1.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	18.0	1.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	4.0	0.0	0.0	0.1	0.0	0.0	1.0	0.1	57.3	0.0	0.0	1.5	11.0	13.2	1.3	2.7	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.3	0.6	1.3	0.7	0.7	4.7	1.0	3.5	2.7
TSPO	"BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS"	ENSG00000100300	"Translocator protein"	"B1AH88, P30536"	22	43151514-43163242	"Cancer-related genes, FDA approved drug targets, Predicted membrane proteins"	"Lipid transport, Transport"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 139.5"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB011232, HPA046260"	Uncertain		Approved	Vesicles,Mitochondria,Cytosol				"Mitochondria, Cytosol"	Vesicles	"CAB011232: , HPA046260: "	"unprognostic (5.29e-3)"	"unprognostic (1.41e-1)"	"unprognostic (3.31e-1)"	"unprognostic (4.02e-3)"	"unprognostic (3.95e-1)"	"unprognostic (1.46e-2)"	"prognostic unfavourable (1.61e-4)"	"unprognostic (2.16e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.07e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.53e-2)"	"unprognostic (3.03e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.34e-3)"	33.9	21.2	9.8	17.8	11.0	117.3	48.7	2.7	8.1	24.9	23.9	12.3	10.3	20.5	12.3	13.6	83.2	14.3	36.8	32.1	8.0	5.4	18.0	22.0	39.8	40.0	15.4	5.2	13.3	13.2	4.0	6.7	15.5	9.7	23.1	9.7	16.4	34.6	9.2	13.2	46.6	23.0	12.7	11.4	27.2	39.0	10.5	10.0	9.4	17.9	44.3	50.0	19.1	41.3	22.9	99.9	91.4	139.5	28.5	43.8	104.8	47.1	23.4	1.6	22.2	8.9	29.6	1.7	35.3	17.3	17.8	18.9	4.5	36.1	0.0	24.4	27.3	39.1	4.4	27.3	2.3	7.9	18.4	4.8	25.7	1.6	32.4	10.7	24.2	22.9	45.1	10.5	9.4	42.0	3.9	8.9	18.2	39.4	0.1	29.9	1.9	58.4	10.6	0.0	80.5	22.6	28.5	2.3	10.9	16.7	33.4	41.1	12.5	41.5	43.3	22.0	16.5	22.5	14.8	3.6	0.6	0.4	28.6	34.8	28.2	43.8	139.5	75.3	28.4	86.3	22.2	16.3	39.5	27.8	99.9	22.9	30.4	24.5	91.4	28.5	57.1	17.7	43.8	104.8	9.8	11.0	2.7	8.1	8.0	5.4	15.4	5.2	9.7	10.0
TTLL9	"C20orf125, dJ310O13.1"	ENSG00000131044	"Tubulin tyrosine ligase like 9"	Q3SXZ7	20	31870702-31944963	"Cancer-related genes, Predicted intracellular proteins"		Ligase	"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"brain: 16.0;epididymis: 8.9;fallopian tube: 9.2;testis: 11.0"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 1.0;REH: 2.0"	"Cancer enhanced"	"Detected in some"		"glioma: 1.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA041772, HPA055676"	Uncertain		Uncertain	Nucleoplasm,Microtubules				"Nucleoplasm, Microtubules"		"HPA041772: AB_10959904, HPA055676: "	"unprognostic (8.77e-2)"	"unprognostic (8.19e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.48e-1)"	"unprognostic (4.63e-1)"	"unprognostic (1.53e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.06e-1)"	"unprognostic (4.59e-1)"	"unprognostic (9.05e-3)"	"unprognostic (6.17e-2)"	"unprognostic (8.35e-3)"	"unprognostic (1.84e-1)"	"unprognostic (1.70e-1)"	"unprognostic (1.25e-3)"	"unprognostic (2.23e-2)"	0.4	0.6	3.4	0.5	8.9	0.4	1.3	1.0	2.8	0.6	0.5	10.9	1.8	0.6	1.1	8.9	0.6	9.2	0.8	0.5	4.8	3.7	0.8	0.5	1.7	0.7	5.2	0.6	1.8	0.4	2.8	2.8	0.7	16.0	0.6	0.5	0.0	0.5	1.8	0.4	0.6	0.4	0.6	4.5	0.5	0.6	11.0	4.0	0.0	2.1	0.0	0.6	0.5	0.2	0.0	0.0	0.0	0.3	0.0	0.5	0.1	0.1	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.8	0.0	0.1	0.0	0.3	0.2	0.0	0.0	0.3	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.0	0.0	0.9	0.0	0.4	0.0	0.0	2.0	0.0	0.0	0.3	0.0	0.4	0.8	0.0	0.0	0.0	0.3	0.3	0.0	0.3	0.6	0.3	0.0	0.1	0.5	0.0	0.0	0.9	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.4	8.9	1.0	2.7	4.8	3.7	5.2	0.6	16.0	4.0
TTR	"CTS, CTS1, HsT2651, PALB"	ENSG00000118271	Transthyretin	P02766	18	31591726-31599021	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	Transport	"Hormone, Thyroid hormone"	"Amyloidosis, Cancer-related genes, Disease mutation, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	11	"brain: 1008.0;liver: 680.8;retina: 332.4"	"Cell line enhanced"	"Detected in some"		"CACO-2: 30.7;EFO-21: 10.8;Hep G2: 47.1;U-2 OS: 14.2"	"Group enriched"	"Detected in many"	28	"liver cancer: 928.2;pancreatic cancer: 666.0"	"Region enriched"	"Detected in many"	9	"pons and medulla: 1008.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"basal ganglia: 1513.1;hippocampal formation: 5269.0;pons and medulla: 5831.5;thalamus: 3501.9"	"Region enhanced"	"Detected in many"		"pons and medulla: 1006.9"	"CAB002517, HPA002550, CAB062567, CAB073406"	Supported		Approved	"Golgi apparatus"	"Secreted to blood"	180000000000	180000000000	"Golgi apparatus"		"CAB002517: AB_563965, CAB062567: , CAB073406: , HPA002550: AB_1080419"	"unprognostic (6.79e-3)"		"unprognostic (3.38e-2)"	"unprognostic (4.10e-1)"	"unprognostic (1.74e-1)"		"unprognostic (1.84e-2)"	"unprognostic (8.15e-2)"	"unprognostic (3.74e-2)"		"unprognostic (9.66e-3)"	"unprognostic (8.72e-2)"	"unprognostic (1.23e-2)"	"unprognostic (8.35e-3)"	"unprognostic (5.26e-1)"		"unprognostic (3.52e-2)"	0.5	0.4	3.6	0.4	3.0	0.6	0.4	5.8	60.8	0.4	0.6	361.3	0.0	0.9	0.4	0.4	0.4	0.4	3.3	0.4	115.6	4.4	1.0	680.8	0.4	0.4	7.1	0.0	0.4	62.3	1.6	0.5	0.4	1008.0	0.4	0.5	332.4	0.4	0.4	0.4	1.0	0.6	0.4	4.9	0.5	2.0	0.4	0.6	0.0	0.4	0.0	0.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	30.7	0.0	0.6	10.8	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.1	0.0	47.1	0.0	2.6	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.3	0.0	14.2	0.0	1.0	0.0	0.6	4.4	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	3.0	5.8	60.8	115.6	4.4	7.1	0.0	1008.0	0.6
TUBA1A	"B-ALPHA-1, FLJ25113, TUBA3"	ENSG00000167552	"Tubulin alpha 1a"	Q71U36	12	49184796-49189324	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, FDA approved drug targets, Lissencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 270.7;smooth muscle: 166.4"	"Cell line enhanced"	"Detected in many"		"AF22: 222.1;SCLC-21H: 149.7"	"Cancer enriched"	"Detected in all"	9	"glioma: 942.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 151.2"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008686, HPA039247, HPA043684, HPA063394"	Enhanced		Enhanced	Microtubules				Microtubules		"CAB008686: AB_1624202, HPA039247: , HPA043684: , HPA063394: "	"unprognostic (3.11e-1)"	"unprognostic (1.61e-1)"	"unprognostic (3.77e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.73e-1)"	"unprognostic (1.15e-2)"	"unprognostic (2.56e-2)"	"unprognostic (2.12e-1)"	"unprognostic (3.49e-2)"	"unprognostic (3.80e-1)"	"unprognostic (1.11e-3)"	"unprognostic (9.79e-2)"	"prognostic unfavourable (2.90e-4)"	"unprognostic (1.07e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.27e-3)"	27.8	25.5	82.1	29.4	81.3	24.7	35.4	63.2	163.0	40.6	48.8	210.9	6.9	9.9	71.7	34.8	27.7	65.3	37.9	26.3	99.3	118.3	10.3	4.2	39.8	13.4	131.0	50.2	35.7	9.9	16.0	20.6	23.1	165.2	35.1	26.7	16.7	13.6	53.4	5.9	20.0	14.5	166.4	270.7	11.6	18.3	15.7	50.4	19.4	7.4	7.3	10.6	35.1	14.5	14.8	28.9	151.2	69.2	7.5	15.7	38.4	0.2	10.0	222.1	31.6	20.2	48.9	0.8	18.7	24.0	12.3	28.7	0.6	4.0	7.9	23.3	60.5	0.4	26.3	6.8	9.6	6.6	9.0	2.6	2.0	2.2	3.9	4.7	0.2	27.5	2.6	24.2	2.5	72.9	3.1	9.0	65.9	4.4	20.1	3.8	23.4	7.4	16.2	15.9	1.0	55.0	0.9	149.7	81.9	5.2	0.3	7.1	15.7	6.4	62.0	13.2	8.3	1.5	5.4	3.1	8.7	15.9	7.2	7.7	13.1	38.8	23.0	73.1	15.7	48.9	11.5	14.8	13.9	14.3	28.9	14.6	13.6	12.5	151.2	7.5	69.2	9.3	15.2	38.4	82.1	81.3	63.2	126.2	99.3	118.3	131.0	50.2	165.2	50.4
TUSC2	"C3orf11, FUS1, PAP, PDAP2"	ENSG00000114383	"Tumor suppressor candidate 2"	O75896	3	50320027-50328251	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA030116			Approved	Vesicles,Cytosol				Cytosol	Vesicles	"HPA030116: AB_10602253"	"unprognostic (1.58e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.73e-1)"	"unprognostic (8.46e-2)"	"unprognostic (2.73e-1)"	"unprognostic (2.81e-1)"	"prognostic unfavourable (2.84e-4)"	"unprognostic (2.53e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.47e-2)"	"unprognostic (1.99e-2)"	"prognostic favourable (8.70e-7)"	"unprognostic (9.22e-3)"	"unprognostic (1.98e-1)"	"unprognostic (3.15e-1)"	"unprognostic (6.34e-3)"	13.4	16.3	28.5	12.2	27.2	9.2	15.1	18.9	38.1	11.9	15.9	11.1	13.9	11.1	10.3	26.2	10.8	18.6	15.5	22.0	26.4	25.8	18.9	18.0	13.5	13.2	26.2	17.0	12.0	15.3	21.3	12.3	15.3	27.3	13.2	15.0	12.2	13.5	17.0	29.9	8.8	12.1	12.3	13.2	14.2	13.9	15.2	8.1	12.0	21.1	15.0	17.2	9.9	8.5	19.5	20.4	26.3	17.3	17.1	22.0	22.9	12.0	10.0	14.1	15.3	15.6	8.1	15.5	9.9	13.3	18.7	15.9	17.6	11.1	20.6	10.8	9.1	7.8	17.1	12.8	16.4	12.1	15.8	10.1	9.4	18.9	13.7	17.8	17.8	8.8	20.8	18.7	9.3	19.2	12.2	9.9	10.7	9.2	18.6	22.9	19.2	14.5	6.5	6.8	16.8	18.7	13.1	7.5	15.6	7.2	12.9	14.2	12.3	21.8	15.1	5.6	13.7	12.7	19.8	24.5	38.0	14.4	12.5	11.9	8.8	10.2	17.3	26.3	20.4	15.3	20.4	19.4	18.1	21.2	11.3	19.5	20.9	22.0	24.5	17.1	13.9	20.4	19.5	22.9	28.5	27.2	18.9	38.1	26.4	25.8	26.2	17.0	27.3	8.1
TWIST1	"ACS3, bHLHa38, BPES2, BPES3, CRS, CRS1, H-twist, SCS, TWIST"	ENSG00000122691	"Twist family bHLH transcription factor 1"	Q15672	7	19020991-19117672	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Craniosynostosis, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 50.0;placenta: 45.6"	"Cell line enriched"	"Detected in many"	6	"SH-SY5Y: 74.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in single"														"unprognostic (4.58e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.62e-1)"	"unprognostic (1.29e-2)"	"unprognostic (9.80e-3)"	"unprognostic (1.78e-2)"	"unprognostic (1.57e-2)"	"unprognostic (8.51e-3)"	"unprognostic (5.91e-2)"	"unprognostic (8.99e-3)"	"unprognostic (3.69e-1)"	"unprognostic (1.29e-9)"	"unprognostic (8.55e-3)"	"unprognostic (1.54e-1)"	"unprognostic (6.83e-3)"	"unprognostic (1.97e-2)"	19.9	5.1	0.6	2.6	0.6	0.1	50.0	0.4	1.2	4.6	3.3	0.5	1.4	0.2	19.6	4.0	7.0	2.2	7.5	3.3	0.6	0.4	0.7	0.3	0.4	2.8	0.7	1.1	6.2	0.4	0.2	5.3	45.6	1.6	7.6	0.6	2.2	6.4	1.0	3.5	12.0	0.4	11.3	1.0	0.1	4.5	3.6	0.5	0.0	2.8	8.6	5.3	12.6	11.4	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.4	0.5	2.5	0.0	12.8	5.3	0.0	10.4	4.9	8.1	10.6	0.0	0.0	0.0	1.1	8.6	0.0	1.0	0.8	5.3	2.2	2.8	0.0	1.1	0.0	7.6	2.6	0.0	12.8	2.7	1.6	4.4	0.0	0.0	0.0	8.5	0.0	0.0	0.1	1.0	4.3	0.0	0.0	0.0	0.0	0.0	4.4	74.0	1.7	0.0	2.1	0.2	3.3	0.0	10.0	0.0	7.8	1.7	0.0	0.0	0.0	5.4	0.0	12.5	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.6	0.4	1.2	0.6	0.4	0.7	1.1	1.6	0.5
TXLNA	DKFZp451J0118	ENSG00000084652	"Taxilin alpha"	P40222	1	32179686-32198285	"Cancer-related genes, Predicted intracellular proteins"	Exocytosis		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045383, HPA072477"	Supported		Approved	Nucleoplasm,Centrosome,Cytosol				Cytosol	"Nucleoplasm, Centrosome"	"HPA045383: AB_10967649, HPA072477: "	"prognostic favourable (6.24e-4)"	"unprognostic (1.19e-2)"	"unprognostic (3.01e-1)"	"unprognostic (1.99e-1)"	"unprognostic (5.04e-2)"	"prognostic favourable (5.53e-4)"	"prognostic unfavourable (1.57e-6)"	"unprognostic (3.67e-3)"	"unprognostic (2.75e-1)"	"unprognostic (5.25e-3)"	"prognostic favourable (8.69e-5)"	"unprognostic (5.06e-2)"	"prognostic unfavourable (7.21e-7)"	"unprognostic (3.94e-3)"	"unprognostic (3.28e-1)"	"unprognostic (7.24e-2)"	"unprognostic (1.03e-1)"	22.5	29.4	20.2	19.4	27.5	14.0	17.9	23.2	26.4	20.3	23.7	17.0	23.4	16.6	30.4	24.7	24.2	25.0	24.6	16.4	18.5	13.9	20.9	44.8	19.0	19.9	25.6	13.4	26.5	23.6	31.5	35.9	19.3	21.8	24.6	18.5	20.8	23.9	23.3	16.5	31.0	18.9	28.3	19.9	23.5	21.2	38.4	22.9	17.0	22.8	18.8	26.0	19.3	23.5	8.0	14.3	8.4	12.2	14.2	13.9	9.0	19.7	16.9	17.7	19.8	22.9	30.3	14.3	28.3	22.5	27.4	26.3	18.8	21.5	22.6	11.5	27.4	22.4	24.0	18.6	25.0	25.8	18.6	35.7	24.6	24.6	24.4	25.9	28.4	30.3	25.0	28.9	13.7	21.6	14.5	23.4	22.3	10.9	18.9	16.7	25.7	15.6	22.3	26.8	19.9	18.7	25.2	18.5	19.1	29.3	18.6	30.0	17.2	15.8	22.4	29.0	25.1	38.2	36.0	35.0	27.0	20.5	30.0	35.4	26.7	8.4	9.0	4.5	13.9	9.7	11.9	7.3	9.6	10.3	6.9	8.0	8.4	9.1	1.3	14.2	12.2	14.3	7.0	9.0	20.2	27.5	23.2	26.4	18.5	13.9	25.6	13.4	21.8	22.9
TXNDC8	"bA427L11.2, SPTRX-3, TRX6"	ENSG00000204193	"Thioredoxin domain containing 8"	Q6A555	9	110303521-110337884	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, Spermatogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	17	"testis: 23.9"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.3;HeLa: 1.4;NTERA-2: 1.0;SK-BR-3: 1.4;THP-1: 5.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.4"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.4"					"Low region specificity"	"Detected in single"															"unprognostic (1.50e-1)"				"unprognostic (1.13e-1)"												0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.3	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.6	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TXNIP	"ARRDC6, EST01027, HHCPA78, THIF, VDUP1"	ENSG00000265972	"Thioredoxin interacting protein"	Q9H3M7	1	145992435-145996600	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Transcription, Transcription regulation"		"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 110.2;HSkMC: 146.6;hTCEpi: 74.7"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031085, HPA053694"	Approved		Approved	"Plasma membrane,Cytosol"				"Plasma membrane"	Cytosol	"HPA031085: AB_10601706, HPA053694: AB_2682232"	"unprognostic (1.45e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.67e-2)"	"unprognostic (4.16e-2)"	"unprognostic (1.92e-2)"	"unprognostic (3.93e-2)"	"unprognostic (1.55e-2)"	"unprognostic (2.51e-1)"	"unprognostic (9.23e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.65e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.49e-3)"	"unprognostic (1.35e-2)"	"unprognostic (1.31e-1)"	"unprognostic (8.19e-2)"	"unprognostic (2.22e-3)"	127.7	10.6	4.1	17.0	4.6	10.5	73.6	2.5	6.0	45.9	49.8	16.1	25.0	6.3	39.3	22.8	41.0	20.3	20.4	55.3	4.8		34.8	11.7	52.3	82.6	6.5	4.2	34.1	25.8	9.3	20.2	19.1	8.3	47.4	16.1	18.8	18.5	19.5	97.0	15.3	27.7	34.6	9.2	39.0	13.6	23.1	6.0	29.0	85.3	16.0	41.5	52.5	32.3	64.9	35.5	134.9	58.3	65.3	90.0	132.5	6.0	0.0	1.4	0.1	33.5	110.2	3.3	7.2	14.5	6.5	9.0	3.8	8.2	1.7	42.9	1.9	1.6	1.4	13.7	17.6	7.9	0.7	4.9	2.2	3.5	1.5	20.1	10.3	146.6	74.7	13.3	23.5	2.5	19.5	13.5	3.3	8.2	3.3	19.3	4.0	5.4	3.0	12.1	52.3	17.1	13.4	6.9	11.2	31.1	9.0	24.6	3.2	28.8	6.1	18.2	1.1	34.0	11.8	19.0	18.1	1.5	4.4	9.3	9.5	94.7	53.3	123.0	90.0	58.3	83.1	58.8	76.5	79.9	35.5	64.9	76.0	80.3	134.9	65.3	49.9	16.7	70.6	132.5										
TXNRD1	"GRIM-12, Trxr1, TXNR"	ENSG00000198431	"Thioredoxin reductase 1"	Q16881	12	104215779-104350305	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Transport"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"fHDF/TERT166: 143.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001395, CAB004607, CAB015834, HPA043871"	Approved		Supported	Nucleoplasm		5900000	5900000	Nucleoplasm		"CAB004607: AB_628405, CAB015834: , HPA001395: AB_1858377, HPA043871: "	"unprognostic (2.52e-2)"	"unprognostic (1.16e-1)"	"unprognostic (5.48e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.94e-2)"	"prognostic unfavourable (1.12e-5)"	"unprognostic (5.55e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.08e-1)"	"unprognostic (6.42e-2)"	"unprognostic (2.21e-1)"	"prognostic unfavourable (1.20e-5)"	"unprognostic (2.13e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.18e-2)"	"unprognostic (8.80e-2)"	19.1	79.2	14.1	15.6	16.9	22.6	18.5	11.1	13.7	13.0	21.8	9.7	19.7	23.5	23.5	14.7	16.7	19.0	23.2	32.4	11.0	11.7	25.3	19.6	29.3	18.1	12.0	10.9	16.4	7.9	10.5	16.2	30.8	16.4	25.3	19.1	18.1	10.6	26.5	30.0	5.7	17.0	99.6	10.9	14.9	24.2	14.8	8.9	15.6	16.5	16.9	13.2	73.2	72.0	8.1	14.2	37.6	16.2	8.3	10.2	8.7	22.0	102.6	11.9	11.2	57.5	32.2	41.6	41.0	26.0	18.5	19.2	10.8	32.9	16.5	19.1	143.4	7.7	23.5	15.7	22.0	8.0	10.2	13.9	80.6	45.6	92.3	21.7	15.2	18.3	16.2	40.9	13.1	63.4	19.1	7.8	27.7	10.6	22.2	9.9	11.5	105.8	22.0	8.3	14.3	21.5	12.1	18.6	11.2	33.1	52.4	32.7	12.4	12.8	84.7	9.1	18.9	20.3	33.5	8.6	16.8	24.8	19.1	12.0	53.9	33.0	10.6	24.7	9.1	14.0	10.2	8.1	8.4	9.0	14.2	5.2	7.6	6.6	37.6	8.3	16.2	9.2	7.1	8.7	14.1	16.9	11.1	11.2	11.0	11.7	12.0	10.9	16.4	8.9
TYMP	"ECGF1, MNGIE"	ENSG00000025708	"Thymidine phosphorylase"	P19971	22	50525752-50530056	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Angiogenesis, Chemotaxis, Differentiation"	"Developmental protein, Glycosyltransferase, Growth factor, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 57.8"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 15.9;HHSteC: 39.3;Karpas-707: 38.0;U-266/70: 18.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"classical monocyte: 23.0;eosinophil: 18.2;intermediate monocyte: 22.4;myeloid DC: 12.2;neutrophil: 6.7;non-classical monocyte: 15.9"	"Group enriched"	"Detected in many"	18	"dendritic cells: 12.2;granulocytes: 18.2;monocytes: 23.0"	"Low region specificity"	"Detected in some"							"HPA000530, HPA001072, CAB002518"	Enhanced		Approved	"Nuclear bodies,Golgi apparatus"		16000000	16000000	"Nuclear bodies"	"Golgi apparatus"	"CAB002518: AB_563953, HPA000530: , HPA001072: AB_1080274"	"unprognostic (7.02e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.61e-1)"	"prognostic favourable (4.34e-5)"	"unprognostic (7.60e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.40e-1)"	"unprognostic (7.17e-2)"	"unprognostic (4.64e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.31e-2)"	"unprognostic (2.17e-1)"	"prognostic unfavourable (3.50e-8)"	"unprognostic (1.32e-1)"	"unprognostic (4.02e-2)"	"unprognostic (1.52e-2)"	"unprognostic (4.60e-2)"	25.2	7.9	2.8	41.6	8.4	12.1	19.0	1.5	4.4	10.7	10.7	3.8	2.3	10.4	4.4	15.7	22.0	13.7	9.6	15.0	7.0	2.6	18.6	38.1	28.8	57.8	6.5	0.4	7.5	5.8	1.7	3.9	11.5	9.1	7.9	4.9	5.4	16.5	3.8	10.0	8.8	13.9	7.3	15.2	43.9	12.4	3.0	5.0	13.3	12.5	25.5	28.8	12.4	9.4	0.9	12.2	18.2	23.0	0.8	0.9	2.6	6.5	0.7	0.0	0.1	0.9	1.2	0.6	1.1	0.1	2.4	5.3	0.0	15.9	0.5	0.8	2.7	5.8	0.2	0.2	0.0	2.8	1.4	0.3	1.1	0.4	39.3	0.1	7.6	2.4	2.4	3.2	0.0	0.0	0.2	38.0	0.2	0.1	0.0	1.0	0.0	2.1	0.2	0.0	7.6	0.0	0.0	0.0	1.4	6.1	8.3	0.5	0.6	4.8	1.5	0.0	0.6	0.1	0.2	18.2	3.7	0.4	0.2	0.1	0.2	2.5	23.0	18.2	0.3	22.4	0.2	0.8	0.3	0.2	12.2	0.9	0.2	0.1	6.7	0.8	15.9	1.1	0.9	2.6	2.8	8.4	1.5	4.4	7.0	2.6	6.5	0.4	9.1	5.0
TYMS	"HsT422, TMS, TS, Tsase"	ENSG00000176890	"Thymidylate synthetase"	P04818	18	657604-673578	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Nucleotide biosynthesis"	"Methyltransferase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 34.9;lymphoid tissue: 75.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 13.8"	"Group enriched"	"Detected in many"	6	"NK-cells: 6.8;T-cells: 13.8"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"cerebellum: 6.7;olfactory region: 8.8"	CAB002784	Enhanced									"CAB002784: "	"unprognostic (7.58e-2)"	"unprognostic (2.06e-3)"	"unprognostic (9.31e-2)"	"unprognostic (2.34e-2)"	"unprognostic (7.35e-2)"	"unprognostic (1.05e-1)"	"prognostic unfavourable (5.10e-6)"	"unprognostic (1.62e-3)"	"unprognostic (1.68e-2)"	"unprognostic (9.82e-2)"	"unprognostic (1.07e-3)"	"unprognostic (3.28e-2)"	"unprognostic (1.23e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.65e-3)"	"unprognostic (2.47e-1)"	3.0	2.6	4.6	15.5	5.8	34.9	2.8	1.2	6.3	3.4	10.1	10.2	1.5	4.8	2.5	3.6	12.3	2.4	4.6	2.0	5.8	2.9	4.8	5.1	4.2	15.4	3.4	4.5	2.0	3.1	1.1	1.3	14.3	3.4	3.0	12.9	1.1	3.4	0.8	0.7	3.6	6.9	5.5	4.6	8.9	4.2	21.5	5.3	75.5	1.7	10.9	19.3	4.8	4.3	1.2	1.8	1.0	0.1	6.8	13.8	2.5	13.7	21.2	44.3	21.4	4.9	8.2	22.5	32.5	19.4	35.1	42.1	17.9	11.0	21.4	12.7	17.5	6.2	30.9	12.2	30.4	20.1	34.3	36.3	19.9	30.7	1.1	74.5	39.8	7.3	2.9	22.1	6.9	29.3	29.1	34.4	44.1	15.8	89.7	41.3	15.9	15.9	59.4	39.9	25.8	13.2	12.2	15.1	24.5	27.4	12.7	8.2	8.7	34.0	11.6	40.6	80.2	37.1	63.3	42.7	52.5	48.9	10.7	32.3	46.4	0.0	0.0	1.0	1.1	0.1	0.0	1.2	2.9	2.2	1.8	0.0	0.0	0.7	0.6	6.8	0.1	0.3	13.8	2.5	4.6	5.8	1.2	6.3	5.8	2.9	3.4	4.5	3.4	5.3
TYRO3	"Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif"	ENSG00000092445	"TYRO3 protein tyrosine kinase"	Q06418	15	41557675-41583586	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 39.2;ovary: 48.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 33.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 5.0"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 5.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA071245	Approved					6400000	6400000			"HPA071245: "	"unprognostic (1.26e-1)"	"unprognostic (6.34e-2)"	"unprognostic (1.47e-1)"	"unprognostic (2.68e-1)"	"unprognostic (3.29e-1)"	"unprognostic (6.77e-2)"	"unprognostic (1.56e-3)"	"unprognostic (5.41e-2)"	"unprognostic (3.72e-1)"	"unprognostic (3.21e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.92e-10)"	"unprognostic (7.59e-2)"	"unprognostic (5.22e-1)"	"unprognostic (4.04e-3)"	"unprognostic (1.84e-2)"	18.3	4.1	18.7	2.1	16.6	1.5	7.7	27.3	39.2	2.3	1.8	25.6	1.2	2.3	5.0	4.2	12.7	11.7	3.1	2.5	15.1	7.8	6.4	1.6	3.2	1.9	19.6	18.2	48.2	9.5	1.3	0.8	5.9	14.0	3.3	1.7	1.7	2.4	6.7	1.4	13.0	2.9	4.8	23.1	5.4	3.6	17.9	16.6	0.0	1.8	2.2	4.1	2.9	2.8	1.2	1.0	5.0	0.9	1.0	0.8	0.2	4.7	3.1	9.9	10.8	9.3	6.4	33.5	6.9	4.4	6.9	6.4	17.6	1.6	0.1	8.9	5.6	11.2	11.1	1.7	3.2	2.7	7.4	1.4	10.0	8.3	6.6	2.4	0.2	2.0	3.5	5.2	1.8	5.1	8.7	2.0	3.7	4.5	1.1	0.4	22.9	3.2	14.7	9.0	1.7	0.6	9.2	11.9	3.4	6.5	10.3	7.7	8.5	2.8	3.9	13.7	6.0	10.1	10.4	0.8	1.6	1.4	8.3	15.8	8.2	2.6	0.9	0.8	0.6	0.5	0.6	0.7	0.6	0.8	0.3	1.2	0.7	0.7	5.0	1.0	0.5	1.0	0.5	0.2	18.7	16.6	27.3	32.7	15.1	7.8	19.6	18.2	14.0	16.6
U2AF1	"RN, RNU2AF1, U2AF35, U2AFBP"	ENSG00000160201	"U2 small nuclear RNA auxiliary factor 1"	Q01081	21	43092956-43107587	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA044833, HPA052083"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA044833: AB_10960990, HPA052083: "	"unprognostic (1.10e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.98e-2)"	"unprognostic (2.87e-2)"	"unprognostic (1.36e-1)"	"unprognostic (8.06e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.29e-4)"	"unprognostic (4.81e-4)"	"unprognostic (3.42e-2)"	"unprognostic (2.31e-3)"	"unprognostic (8.85e-2)"	"unprognostic (2.14e-6)"	"unprognostic (1.08e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.26e-2)"	20.0	15.1	20.8	19.2	21.1	48.5	61.0	25.6	20.8	16.1	21.5	9.7	12.3	17.6	28.8	26.5	19.3	27.6	17.1	19.5	19.7	15.8	14.6	17.1	35.2	33.5	25.7	2.9	22.1	48.3	15.3	27.8	21.2	20.8	23.9	13.7	9.6	44.5	19.8	33.0	16.6	20.4	38.7	23.9	21.0	17.5	33.9	22.7	20.6	27.3	26.5	20.0	22.9	31.7	58.4	82.8	81.2	54.1	33.1	55.5	53.8	25.0	27.5	15.0	11.3	8.8	6.3	35.1	21.8	15.1	17.8	15.9	63.9	9.2	42.9	11.9	14.1	12.3	31.3	23.1	9.2	33.6	70.7	69.4	14.1	24.0	21.5	29.8	17.1	8.7	14.3	28.8	18.4	14.7	38.0	19.4	12.4	47.1	24.7	33.1	31.8	31.7	40.8	14.4	21.6	11.8	10.6	22.8	17.4	23.4	14.1	11.5	17.2	17.4	18.3	14.8	20.2	13.4	22.7	26.0	30.6	35.5	14.2	55.0	22.8	48.4	52.6	50.9	42.2	52.5	41.4	55.9	46.4	42.1	54.1	58.4	46.4	44.8	81.2	33.1	54.1	82.8	55.5	53.8	20.8	21.1	25.6	20.8	19.7	15.8	25.7	2.9	20.8	22.7
UBA1	"A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X"	ENSG00000130985	"Ubiquitin like modifier activating enzyme 1"	P22314	X	47190861-47215128	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ubl conjugation pathway"	Ligase	"Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000289, HPA001506, CAB019435, CAB073410"	Approved		Enhanced	Nucleoplasm		16000000	16000000	Nucleoplasm		"CAB019435: AB_2211440, CAB073410: , HPA000289: AB_1080443, HPA001506: AB_2756305"	"unprognostic (7.18e-3)"	"unprognostic (1.52e-1)"	"unprognostic (7.54e-2)"	"unprognostic (2.40e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.02e-1)"	"prognostic unfavourable (6.10e-5)"	"unprognostic (7.22e-2)"	"unprognostic (2.42e-3)"	"unprognostic (3.43e-2)"	"unprognostic (8.50e-3)"	"unprognostic (2.17e-3)"	"unprognostic (1.85e-3)"	"unprognostic (1.13e-1)"	"unprognostic (5.38e-2)"	"prognostic favourable (1.78e-4)"	"unprognostic (1.21e-2)"	45.6	63.0	56.0	47.2	50.6	42.0	38.3	58.1	75.7	48.0	39.3	55.9	44.9	36.3	52.9	34.1	59.4	56.0	39.9	48.7	49.5	39.9	51.1	60.0	42.0	48.2	47.7	62.3	57.6	34.9	78.8	55.5	39.1	47.6	40.2	35.5	41.0	47.5	45.7	77.7	56.1	37.9	59.4	35.5	53.4	38.7	36.0	48.6	52.7	65.0	43.9	54.0	39.2	52.7	28.9	30.6	32.6	36.0	25.6	29.0	24.1	45.8	47.6	54.5	82.8	37.3	34.0	24.1	30.5	32.5	43.9	35.8	37.8	35.0	34.2	20.3	61.0	44.3	68.3	64.9	32.3	28.3	69.4	21.4	52.8	30.3	26.3	36.0	46.2	31.9	34.0	63.8	49.8	57.5	23.2	30.8	43.5	58.1	33.9	31.9	58.0	74.4	39.5	38.0	58.2	35.1	49.4	35.3	26.5	90.9	44.2	20.2	61.5	22.5	42.0	33.0	38.3	47.5	28.4	21.1	21.9	48.8	33.9	25.8	39.4	17.4	27.0	27.4	29.0	36.0	25.4	28.9	24.0	25.9	30.6	22.0	19.1	23.4	32.6	25.6	32.8	20.8	28.2	24.1	56.0	50.6	58.1	75.7	49.5	39.9	47.7	62.3	47.6	48.6
UBE2C	UBCH10	ENSG00000175063	"Ubiquitin conjugating enzyme E2 C"	O00762	20	45812576-45816957	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 130.8"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.0"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			"CAB011464, HPA034569, CAB035990, HPA054975"	Approved		Supported	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB011464: AB_442965, CAB035990: , HPA034569: , HPA054975: "	"unprognostic (1.45e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.11e-3)"	"unprognostic (2.54e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (6.24e-6)"	"unprognostic (2.27e-3)"	"unprognostic (2.59e-2)"	"unprognostic (1.04e-1)"	"prognostic unfavourable (6.91e-4)"	"unprognostic (3.76e-2)"	"prognostic unfavourable (0.00e+0)"	"unprognostic (3.09e-1)"	"unprognostic (3.61e-1)"	"unprognostic (4.65e-2)"	"unprognostic (2.68e-1)"	3.1	2.3	0.4	24.0	0.9	25.1	4.3	0.4	0.7	3.8	9.5	0.4	0.8	7.8	2.0	2.6	25.6	0.6	3.2	2.8	0.5	0.4	2.1	2.1	4.6	15.6	0.6	0.5	1.2	1.3	0.0	0.6	12.6	0.9	1.3	11.7	0.7	3.7	0.6	1.0	8.3	10.0	3.5	1.2	11.6	7.0	15.3	0.5	130.8	0.8	17.6	26.3	2.8	7.8	1.2	0.9	2.7	0.6	2.4	10.0	4.2	39.2	28.8	52.0	24.9	1.4	3.2	29.9	31.2	15.8	51.4	36.9	94.6	45.4	41.6	30.6	14.8	38.8	0.2	33.4	52.5	17.7	27.4	12.8	22.1	24.8	0.4	18.3	32.2	1.0	3.6	34.8	34.1	25.0	0.2	35.4	42.3	64.6	30.2	5.2	31.2	69.0	32.1	47.1	0.2	17.3	13.6	30.0	25.0	49.1	36.0	19.7	36.3	27.0	9.1	46.1	40.3	31.3	60.3	11.2	0.3	46.4	28.0	13.1	43.7	0.0	0.1	0.0	0.2	0.0	0.0	1.2	1.2	2.3	0.9	0.2	0.2	0.1	2.7	2.4	0.6	0.5	10.0	4.2	0.4	0.9	0.4	0.7	0.5	0.4	0.6	0.5	0.9	0.5
UBE2I	UBC9	ENSG00000103275	"Ubiquitin conjugating enzyme E2 I"	P63279	16	1308880-1327018	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division, Chromosome partition, Host-virus interaction, Mitosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003909, CAB009021"	Approved					120000	120000			"CAB009021: AB_2210610, HPA003909: AB_1858529"	"unprognostic (2.12e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.55e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.52e-1)"	"prognostic unfavourable (7.50e-4)"	"unprognostic (2.88e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.89e-2)"	"unprognostic (7.60e-3)"	"unprognostic (3.56e-1)"	"unprognostic (7.28e-2)"	"unprognostic (9.30e-2)"	"unprognostic (1.57e-1)"	"prognostic favourable (5.68e-4)"	"unprognostic (1.15e-3)"	34.3	43.1	28.8	36.3	36.9	48.4	45.2	45.6	48.5	38.1	32.0	28.6	28.1	28.9	55.4	32.9	43.4	35.6	30.3	41.8	27.4	28.4	29.4	26.6	29.1	44.2	22.7	32.9	62.5	35.5	33.4	36.2	47.2	21.4	40.7	31.0	34.1	37.8	32.2	31.6	35.8	32.2	40.0	23.2	43.7	29.4	43.6	21.6	78.0	42.5	31.8	53.9	38.7	38.8	82.2	58.0	85.4	67.4	50.9	57.8	60.0	24.9	34.5	58.2	34.3	25.0	30.3	25.2	36.0	26.0	33.5	33.5	40.8	41.1	43.5	30.0	31.1	30.5	41.6	33.8	43.3	31.3	29.4	27.2	31.9	39.4	39.6	40.3	32.5	28.0	22.0	32.8	39.3	36.2	38.9	27.4	31.6	53.3	71.2	40.6	47.4	25.5	90.4	36.9	49.5	31.2	23.0	33.0	34.8	31.6	35.9	35.9	36.5	48.9	29.8	33.3	38.2	29.2	32.5	29.0	34.3	88.8	18.7	30.0	35.2	63.9	59.3	85.4	48.0	67.4	57.8	82.2	49.0	48.7	58.0	61.8	44.1	44.2	41.3	50.9	62.3	50.1	50.9	60.0	28.8	36.9	45.6	48.5	27.4	28.4	22.7	32.9	21.4	21.6
UBE2N	"MGC8489, UBC13, UbcH-ben"	ENSG00000177889	"Ubiquitin conjugating enzyme E2 N"	P61088	12	93405673-93442262	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA044976	Enhanced		Supported	"Nucleoplasm,Nucleoli fibrillar center"		4600000	4600000	Nucleoplasm	"Nucleoli fibrillar center"	"HPA044976: "	"unprognostic (1.74e-2)"	"unprognostic (5.53e-1)"	"unprognostic (1.26e-2)"	"unprognostic (2.30e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.09e-2)"	"prognostic unfavourable (2.41e-4)"	"unprognostic (8.49e-3)"	"unprognostic (2.72e-1)"	"unprognostic (4.28e-3)"	"unprognostic (1.07e-1)"	"unprognostic (9.28e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.31e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.30e-3)"	24.7	25.0	29.0	28.7	39.1	29.0	21.2	29.2	44.3	18.4	26.6	15.6	15.1	20.7	23.2	20.0	30.4	19.7	17.0	27.7	31.0	33.7	25.4	22.3	19.3	36.1	27.6	34.5	17.4	17.6	13.9	18.2	24.2	34.9	23.4	22.6	13.7	18.0	18.5	35.7	19.1	20.4	21.3	24.6	21.5	19.3	83.7	17.4	32.2	15.5	16.8	35.1	22.7	18.8	53.8	35.5	29.9	39.2	29.5	57.3	51.9	35.8	26.0	43.9	28.1	17.0	16.9	30.6	50.2	26.8	40.3	33.8	46.2	15.6	73.0	11.4	29.3	28.6	48.4	36.8	38.4	60.7	25.1	49.1	14.3	40.7	21.7	58.6	32.8	17.7	15.2	24.0	30.0	31.0	54.5	11.4	41.8	29.5	57.8	54.5	57.1	36.4	45.0	35.6	35.7	33.5	54.3	42.9	39.1	26.5	31.2	24.5	40.8	36.1	32.0	27.3	22.8	24.6	36.1	19.7	53.3	62.0	10.7	31.3	33.3	29.9	27.1	28.9	31.7	35.4	36.9	53.8	40.2	39.2	35.5	38.6	36.0	34.4	8.2	29.5	39.2	26.7	57.3	51.9	29.0	39.1	29.2	44.3	31.0	33.7	27.6	34.5	34.9	17.4
UBR5	"DD5, EDD, EDD1, HYD, KIAA0896"	ENSG00000104517	"Ubiquitin protein ligase E3 component n-recognin 5"	O95071	8	102253012-102412841	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA053688			Supported	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"HPA053688: "	"unprognostic (3.79e-3)"	"unprognostic (7.44e-3)"	"unprognostic (1.25e-1)"	"unprognostic (2.10e-2)"	"unprognostic (2.44e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavourable (1.26e-4)"	"unprognostic (2.50e-1)"	"unprognostic (1.75e-2)"	"unprognostic (7.54e-3)"	"unprognostic (8.29e-3)"	"unprognostic (3.84e-2)"	"unprognostic (6.64e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.45e-1)"	27.0	16.7	27.1	29.5	31.7	30.3	29.2	40.8	32.8	24.9	25.0	19.1	21.1	14.4	26.8	24.0	23.8	22.0	17.6	22.7	25.5	15.3	17.9	17.0	24.2	29.6	21.9	20.6	29.7	22.2	32.4	25.5	25.0	23.6	20.2	17.1	19.7	22.9	21.8	39.9	29.7	22.4	29.3	17.5	21.9	21.1	39.7	28.3	37.9	20.3	15.9	27.0	27.5	28.6	5.0	4.0	6.3	5.5	2.4	7.1	2.1	23.2	10.4	20.2	10.3	19.9	20.3	18.6	17.6	15.6	13.8	12.1	10.4	15.7	46.4	15.2	16.5	14.2	17.2	15.3	19.4	20.0	8.4	38.7	14.2	18.7	17.7	12.0	21.4	23.2	15.3	14.2	24.8	16.5	18.6	26.4	13.5	21.0	30.5	14.4	15.2	11.8	17.8	11.9	22.0	12.6	22.9	14.9	12.4	12.3	12.0	12.2	19.2	12.8	16.5	14.7	17.2	13.2	12.2	14.1	13.6	47.7	14.6	18.8	11.9	3.1	3.4	5.0	5.6	3.4	5.6	5.0	6.0	5.9	4.0	3.9	4.8	7.1	6.3	2.4	5.5	3.6	7.1	2.1	27.1	31.7	40.8	32.8	25.5	15.3	21.9	20.6	23.6	28.3
UGT1A1	"GNT1, UGT1, UGT1A"	ENSG00000241635	"UDP glucuronosyltransferase family 1 member A1"	P22309	2	233760248-233773299	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	16	"intestine: 48.6;liver: 120.3"	"Cell line enhanced"	"Detected in some"		"CACO-2: 4.2;HaCaT: 11.0;PC-3: 5.0;RT4: 26.1"	"Cancer enriched"	"Detected in some"	19	"liver cancer: 16.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.7"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"																				"unprognostic (7.28e-2)"			"unprognostic (2.49e-2)"	"unprognostic (3.60e-1)"	"unprognostic (5.69e-2)"			"unprognostic (4.17e-3)"	"unprognostic (6.31e-3)"	"unprognostic (1.94e-5)"	"unprognostic (2.78e-3)"			"unprognostic (2.99e-4)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.2	35.6	0.1	0.1	48.6	0.1	0.1	4.3	0.0	0.3	0.1	0.1	0.0	4.5	120.3	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.3	0.4	0.1	0.7	0.1	0.1	0.9	48.2	0.5	0.1	0.1	1.3	0.2	0.1	0.1	0.2	0.1	0.1	5.2	0.8	1.0	0.4	4.7	0.4	1.1	0.5	0.2	0.2	0.8	0.1	0.2	0.1	0.1	0.5	0.0	0.0	0.0	0.0	4.2	0.3	0.1	2.0	0.0	11.0	0.0	0.2	0.0	0.2	0.1	0.1	0.4	1.1	0.0	0.4	0.1	0.2	0.5	0.0	0.0	0.0	0.1	0.4	0.0	0.5	0.1	0.2	0.4	5.0	0.1	0.1	0.4	0.0	26.1	0.2	0.3	2.0	0.3	0.0	0.1	0.0	0.0	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.6	0.3	0.2	2.1	0.4	0.4	0.4	0.3	0.3	0.4	0.4	0.3	0.1	1.0	0.4	0.5	4.7	1.1	0.4	0.4	0.3	0.2	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1
UGT1A10	UGT1J	ENSG00000242515	"UDP glucuronosyltransferase family 1 member A10"	Q9HAW8	2	233636454-233773305	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"esophagus: 9.4;gallbladder: 8.4;intestine: 31.1;stomach 1: 12.4"	"Cell line enriched"	"Detected in single"	142	"RT4: 106.4"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 9.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																"Intracellular and membrane"								"unprognostic (9.33e-2)"			"unprognostic (7.64e-2)"	"unprognostic (2.45e-3)"	"unprognostic (1.73e-1)"			"prognostic unfavourable (4.55e-4)"		"unprognostic (1.49e-10)"	"unprognostic (2.90e-1)"	"unprognostic (1.50e-1)"		"unprognostic (3.59e-3)"	0.3	0.0	0.3	2.6	0.3	0.0	0.3	0.3	0.3	0.3	19.2	0.3	0.3	31.1	0.3	0.3	9.4	0.1	8.4	0.3	0.3	0.0	0.3	1.4	0.6	0.3	0.3	0.3	0.3	0.3	0.0	0.3	0.3	0.3	0.3	14.3	0.3	0.9	0.3	0.3	0.3	20.2	0.5	0.3	0.3	12.4	1.0	0.3	0.3	0.3	0.3	1.4	0.9	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	106.4	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3	0.3	0.0	0.3	0.3	0.3	0.3
UGT1A3	UGT1C	ENSG00000243135	"UDP glucuronosyltransferase family 1 member A3"	P35503	2	233729108-233773299	"Cancer-related genes, Enzymes, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	15	"liver: 40.6"	"Cell line enriched"	"Detected in some"	9	"HaCaT: 16.4"	"Cancer enriched"	"Detected in single"	6	"liver cancer: 2.1"					"Not detected"	"Not detected"			"Not detected"	"Not detected"																												"unprognostic (5.15e-2)"	"unprognostic (9.93e-2)"			"unprognostic (2.97e-1)"	"unprognostic (4.59e-2)"	"unprognostic (1.04e-4)"	"unprognostic (8.22e-2)"			"unprognostic (2.08e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.6	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0			0.0		0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	16.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
UGT1A4	"HUG-BR2, UGT1D"	ENSG00000244474	"UDP glucuronosyltransferase family 1 member A4"	P22310	2	233718778-233773299	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	51	"liver: 99.4"	"Cell line enhanced"	"Detected in some"		"HaCaT: 1.6;HL-60: 1.3;RH-30: 2.2"	"Cancer enriched"	"Detected in single"	487	"liver cancer: 24.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																												"unprognostic (9.89e-3)"						"unprognostic (6.77e-5)"	"unprognostic (2.59e-1)"			"unprognostic (3.50e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	99.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	2.2	0.0	0.0	0.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
UGT1A9	"HLUGP4, LUGP4, UGT1AI"	ENSG00000241119	"UDP glucuronosyltransferase family 1 member A9"	O60656	2	233671853-233773300	"Cancer-related genes, Enzymes, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"kidney: 169.8"	"Group enriched"	"Detected in some"	20	"A549: 4.8;RT4: 3.9"	"Group enriched"	"Detected in some"	157	"liver cancer: 16.1;renal cancer: 16.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																												"unprognostic (2.46e-2)"				"unprognostic (3.56e-1)"		"prognostic unfavourable (5.04e-5)"	"unprognostic (4.26e-2)"			"unprognostic (1.60e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	169.8	39.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
UHRF1BP1L	KIAA0701	ENSG00000111647	"UHRF1 binding protein 1 like"	A0JNW5	12	100028455-100142848	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039671, HPA075150"	Uncertain		Approved	Nucleoplasm,Vesicles,Cytosol				Nucleoplasm	"Vesicles, Cytosol"	"HPA039671: AB_10794201, HPA075150: "	"unprognostic (4.80e-2)"	"unprognostic (3.17e-1)"	"unprognostic (2.34e-2)"	"unprognostic (1.14e-1)"	"unprognostic (8.96e-2)"	"unprognostic (7.36e-2)"	"unprognostic (8.10e-2)"	"unprognostic (5.75e-3)"	"unprognostic (2.06e-1)"	"unprognostic (5.43e-2)"	"unprognostic (1.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.94e-3)"	"unprognostic (6.84e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.81e-2)"	"unprognostic (1.28e-2)"	14.9	13.9	15.9	11.4	19.9	31.9	10.8	16.9	26.0	9.5	10.0	8.7	5.3	9.9	9.3	8.8	10.2	8.0	10.6	10.4	18.0	13.7	14.7	28.0	10.6	9.7	14.8	12.0	11.1	4.7	21.5	15.3	13.7	22.6	11.1	9.6	6.9	8.7	11.2	26.2	8.4	11.1	11.2	13.7	11.8	9.0	15.2	9.8	10.0	13.0	8.1	8.1	16.7	8.4	3.8	8.4	22.9	8.4	3.7	3.7	3.4	11.3	12.4	6.9	7.1	10.7	15.2	13.8	17.7	17.9	14.4	10.5	9.1	3.9	9.8	4.6	18.1	4.4	12.9	6.0	14.0	26.1	6.3	6.6	9.9	10.6	9.9	12.3	10.8	8.6	5.1	17.2	12.0	10.0	5.2	10.3	14.0	6.3	7.9	10.7	11.9	11.3	9.0	12.3	9.7	7.3	20.1	11.8	7.3	13.5	15.5	5.2	13.9	14.2	7.9	15.9	8.5	13.7	12.4	12.2	20.8	13.8	8.0	9.4	9.6	12.5	7.6	4.9	2.6	8.4	3.7	3.8	2.9	2.9	8.4	3.4	2.5	3.0	22.9	3.7	6.8	5.1	3.2	3.4	15.9	19.9	16.9	26.0	18.0	13.7	14.8	12.0	22.6	9.8
USH1C	"AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C"	ENSG00000006611	"USH1 protein network component harmonin"	Q9Y6N9	11	17493895-17544416	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Hearing"		"Cancer-related genes, Deafness, Non-syndromic deafness, Retinitis pigmentosa, Usher syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"gallbladder: 26.0;intestine: 57.0;kidney: 22.1"	"Group enriched"	"Detected in some"	5	"CACO-2: 35.2;HeLa: 12.5"	"Group enriched"	"Detected in many"	7	"colorectal cancer: 34.5;pancreatic cancer: 18.8;renal cancer: 29.4;stomach cancer: 15.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"olfactory region: 2.2"	"CAB013690, HPA027398, HPA027492, HPA028033"	Enhanced		Enhanced	Cytosol				Cytosol		"CAB013690: , HPA027398: AB_10601775, HPA027492: AB_10601898, HPA028033: AB_10601782"	"unprognostic (3.60e-2)"	"unprognostic (6.19e-2)"	"unprognostic (2.36e-1)"	"unprognostic (3.83e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.10e-1)"	"prognostic unfavourable (2.20e-4)"	"unprognostic (2.22e-1)"		"unprognostic (2.78e-1)"	"unprognostic (1.51e-2)"	"unprognostic (9.65e-2)"	"prognostic favourable (9.41e-4)"	"unprognostic (1.29e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.61e-1)"	0.1	0.1	1.6	4.3	7.1	0.0	0.0	0.8	3.3	0.1	23.8	6.2	0.0	40.5	0.0	6.3	0.0	1.3	26.0	0.3	5.0	2.3	22.1	0.4	0.0	0.0	4.8	1.9	0.3	2.1	0.0	5.2	0.0	3.5	0.1	20.7	1.8	0.0	0.1	0.0	0.0	57.0	0.9	10.2	0.0	11.5	0.2	3.6	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	35.2	4.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	12.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.6	7.1	0.8	2.3	5.0	2.3	4.8	1.9	3.5	3.6
USP6	"HRP1, Tre-2, TRE17, Tre2, TRESMCR"	ENSG00000129204	"Ubiquitin specific peptidase 6"	P35125	17	5116438-5175034	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Calmodulin-binding, Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	9	"skeletal muscle: 18.2;testis: 29.0"	"Low cell line specificity"	"Detected in many"			"Cancer enriched"	"Detected in single"	14	"testis cancer: 2.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA046969			Uncertain	Vesicles				Vesicles		"HPA046969: "	"unprognostic (3.89e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.50e-1)"	"unprognostic (1.85e-1)"	"unprognostic (9.32e-2)"	"unprognostic (3.50e-3)"	"unprognostic (1.29e-1)"	"unprognostic (1.67e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.46e-2)"	"unprognostic (7.91e-4)"	"unprognostic (6.28e-3)"	"unprognostic (3.24e-4)"	"unprognostic (3.75e-2)"	"unprognostic (3.13e-1)"	"unprognostic (2.71e-1)"	"unprognostic (7.09e-4)"	0.3	0.3	0.3	0.3	0.6	0.2	0.4	0.5	0.5	0.3	0.5	0.3	1.2	0.0	0.6	0.6	0.3	0.5	0.4	0.3	0.3	0.1	0.3	0.3	0.3	0.3	0.3	0.3	2.6	0.3	0.0	0.4	0.4	0.3	0.4	0.1	0.3	0.3	0.3	18.2	0.6	0.7	0.9	0.3	0.3	0.0	29.0	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.9	1.2	1.9	1.0	0.2	0.4	0.1	2.2	1.0	2.2	1.7	0.4	0.2	2.3	1.9	0.1	0.6	0.4	0.8	1.1	2.2	1.7	1.3	1.0	0.7	0.8	0.5	1.6	1.3	1.7	1.3	0.9	1.2	0.5	2.9	1.1	0.5	0.1	0.2	0.3	0.5	0.3	0.5	2.5	1.9	0.7	1.6	0.1	1.4	2.0	0.2	0.5	0.7	0.9	2.2	1.0	0.1	3.3	2.2	2.2	1.2	1.0	3.3	2.1	1.4	2.0	1.7	1.5	0.0	0.1	2.7	0.1	0.4	0.9	0.4	0.3	0.2	0.6	0.3	0.3	0.3	0.9	0.3	0.4	1.9	0.2	1.0	1.2	0.1	0.1	0.3	0.6	0.5	0.3	0.3	0.1	0.3	0.3	0.3	0.3
USP8	"HumORF8, KIAA0055, SPG59, UBPY"	ENSG00000138592	"Ubiquitin specific peptidase 8"	P40818	15	50424380-50514419	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Ubl conjugation pathway"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA050215	Approved		Supported	"Golgi apparatus,Cytosol"				"Golgi apparatus"	Cytosol	"HPA050215: "	"unprognostic (5.81e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.58e-2)"	"unprognostic (2.35e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.96e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.08e-2)"	"unprognostic (2.94e-1)"	"unprognostic (3.99e-2)"	"prognostic favourable (1.29e-5)"	"unprognostic (4.89e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.79e-1)"	"unprognostic (1.58e-1)"	19.4	21.9	21.0	20.6	20.6	21.6	18.1	27.3	21.6	21.4	23.9	13.8	19.5	20.2	22.1	17.4	22.3	17.4	15.5	17.4	19.7	18.2	28.2	26.4	17.0	25.4	21.8	15.2	21.9	16.7	42.6	43.2	29.1	29.7	16.7	18.9	10.7	19.9	17.9	24.3	17.8	32.1	19.2	29.3	30.3	17.7	27.5	26.1	28.9	24.1	12.7	20.9	22.3	18.4	16.7	10.6	38.1	15.1	9.5	11.9	6.9	11.0	15.9	8.9	15.7	16.3	18.3	12.4	15.9	18.9	15.5	18.4	10.6	7.3	11.7	12.3	18.2	21.5	12.2	11.9	18.4	10.2	8.1	21.6	14.8	10.9	16.8	14.4	14.6	14.2	14.3	13.7	23.3	15.0	12.3	14.2	14.5	22.7	9.2	5.7	10.2	7.3	8.4	16.6	17.5	14.7	26.1	11.4	10.4	16.8	25.1	20.8	13.7	17.7	17.0	16.1	9.1	49.6	21.0	11.1	23.1	12.9	12.9	29.2	15.5	38.1	13.3	22.4	11.1	12.4	10.7	16.5	11.4	11.1	10.6	16.7	11.9	10.7	22.7	9.5	15.1	9.9	8.5	6.9	21.0	20.6	27.3	21.6	19.7	18.2	21.8	15.2	29.7	26.1
VAMP3	CEB	ENSG00000049245	"Vesicle associated membrane protein 3"	Q15836	1	7771269-7781432	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (1.09e-2)"	"unprognostic (4.03e-1)"	"unprognostic (3.39e-3)"	"unprognostic (2.95e-1)"	"unprognostic (9.15e-3)"	"unprognostic (3.86e-3)"	"unprognostic (9.49e-3)"	"unprognostic (2.00e-1)"	"unprognostic (7.16e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.83e-3)"	"unprognostic (2.17e-1)"	"prognostic favourable (2.36e-4)"	"unprognostic (1.02e-1)"	"unprognostic (2.85e-1)"	"unprognostic (9.52e-2)"	"unprognostic (3.30e-2)"	52.6	35.6	36.0	20.3	43.9	42.4	35.9	14.8	37.6	37.1	28.8	92.8	19.3	27.0	45.3	30.1	40.5	29.4	28.2	32.8	38.9	30.4	38.3	27.2	39.3	25.8	63.3	26.1	35.9	17.8	31.7	24.9	45.4	50.2	31.4	32.9	41.3	23.1	37.9	34.8	33.6	41.5	37.7	90.6	34.2	26.3	25.4	48.2	14.7	30.0	37.1	26.8	36.4	29.9	5.1	15.8	31.2	26.0	6.8	7.4	9.5	18.9	13.5	14.6	17.4	40.0	45.3	10.3	34.3	39.0	36.9	35.0	14.7	24.6	2.5	19.3	43.0	16.6	15.9	23.1	47.5	1.9	19.8	12.2	12.7	20.5	26.0	7.2	12.2	36.8	17.4	26.2	21.5	44.5	12.5	11.7	51.4	8.5	5.4	6.4	6.4	23.8	4.5	21.3	7.7	28.8	10.9	4.0	15.3	29.7	14.7	30.6	14.8	7.7	39.3	33.2	11.4	34.3	16.4	9.6	13.0	7.4	38.0	29.4	26.1	17.4	22.6	22.3	6.3	26.0	6.4	5.1	6.0	5.5	15.8	4.4	4.9	5.2	31.2	6.8	22.5	5.2	7.4	9.5	36.0	43.9	14.8	37.6	38.9	30.4	63.3	26.1	50.2	48.2
VCAM1	CD106	ENSG00000162692	"Vascular cell adhesion molecule 1"	P19320	1	100719742-100739045	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"kidney: 69.6;lymphoid tissue: 129.2"	"Group enriched"	"Detected in some"	5	"HHSteC: 56.9;HSkMC: 38.0"	"Cancer enriched"	"Detected in all"	8	"renal cancer: 89.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	10	"gdT-cell: 1.3;memory CD8 T-cell: 2.9;naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	17	"T-cells: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000154, HPA034796, HPA069867"	Enhanced		Approved	"Cell Junctions"		960000000	960000000	"Cell Junctions"		"CAB000154: , HPA034796: , HPA069867: "	"unprognostic (2.96e-1)"	"prognostic favourable (3.82e-4)"	"unprognostic (1.31e-1)"	"unprognostic (7.49e-3)"	"unprognostic (1.04e-1)"	"prognostic favourable (7.19e-5)"	"unprognostic (1.60e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.20e-1)"	"unprognostic (3.95e-2)"	"unprognostic (8.23e-2)"	"unprognostic (1.80e-1)"	"unprognostic (5.47e-2)"	"unprognostic (1.68e-2)"	"unprognostic (3.12e-2)"	"unprognostic (2.55e-2)"	10.9	18.1	1.5	20.2	3.2	1.3	5.2	0.9	1.1	3.7	5.0	3.3	1.4	3.3	4.9	4.5	5.3	4.9	6.8	7.2	1.7	2.3	69.6	11.8	9.8	26.8	2.8	1.7	11.1	6.6	10.6	3.5	10.9	4.2	8.3	5.5	15.3	4.9	1.1	4.7	1.8	6.3	4.2	3.7	129.2	3.0	2.5	1.6	13.3	3.5	2.8	20.9	8.2	2.8	0.0	0.1	0.0	0.0	0.0	2.9	0.1	0.0	0.0	0.2	0.1	0.2	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	8.2	0.0	0.0	0.0	0.0	56.9	0.0	0.0	38.0	0.0	10.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.1	2.9	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	1.5	3.2	0.9	1.1	1.7	2.3	2.8	1.7	4.2	1.6
VEGFA	"VEGF, VEGF-A, VPF"	ENSG00000112715	"Vascular endothelial growth factor A"	P15692	6	43770184-43786487	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 49.7;hTERT-HME1: 49.5;U-87 MG: 108.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.2;eosinophil: 1.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 1.9;monocytes: 1.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005429, CAB039240, HPA069116, CAB069907"	Supported				"Secreted to blood"					"CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: "	"unprognostic (1.12e-1)"	"prognostic unfavourable (4.50e-4)"	"unprognostic (2.42e-2)"	"prognostic unfavourable (2.10e-4)"	"unprognostic (4.35e-2)"	"unprognostic (1.49e-1)"	"prognostic unfavourable (2.34e-5)"	"unprognostic (5.10e-2)"	"unprognostic (5.27e-3)"	"unprognostic (2.30e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.00e-2)"	"prognostic unfavourable (1.76e-5)"	"unprognostic (2.20e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.43e-1)"	"prognostic favourable (2.73e-4)"	35.0	17.5	16.6	11.4	20.1	12.8	39.5	6.5	32.3	11.8	25.9	8.7	15.0	16.0	54.1	9.4	19.4	10.4	27.5	57.0	13.4	5.4	25.8	58.6	30.0	2.9	15.8	3.7	16.4	25.1	20.6	7.3	16.7	19.8	40.5	7.2	24.4	15.1	23.8	52.9	11.9	26.3	19.2	35.1	19.0	20.5	4.5	15.4	0.3	87.9	19.6	13.6	47.5	15.7	0.0	0.1	1.9	1.2	0.0	0.0	0.0	12.4	2.2	2.1	12.2	3.6	5.8	14.4	7.6	13.7	5.1	10.1	7.1	1.6	4.1	6.1	4.6	5.1	5.7	15.4	9.0	4.5	1.8	3.1	2.9	4.8	38.7	3.3	6.9	10.1	30.7	49.7	49.5	1.3	5.7	20.7	18.5	5.1	0.3	4.6	1.3	3.5	0.3	2.0	9.8	19.7	10.4	3.8	8.0	11.0	7.5	26.4	2.9	12.5	1.7	21.2	5.7	30.6	12.5	11.8	6.9	8.0	108.8	7.9	7.3	0.0	1.2	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	16.6	20.1	6.5	32.3	13.4	5.4	15.8	3.7	19.8	15.4
VEGFB	"VEGFL, VRF"	ENSG00000173511	"Vascular endothelial growth factor B"	P49765	11	64234538-64238793	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	9	"plasmacytoid DC: 31.7"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 31.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to blood"						"unprognostic (4.88e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.33e-2)"	"unprognostic (3.55e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.27e-1)"	"unprognostic (5.38e-2)"	"unprognostic (2.45e-1)"	"unprognostic (4.68e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.35e-3)"	"unprognostic (1.08e-2)"	"unprognostic (1.67e-2)"	"unprognostic (8.08e-3)"	"unprognostic (2.00e-1)"	"unprognostic (4.15e-2)"	"unprognostic (4.31e-3)"	98.5	23.4	25.9	15.3	22.7	5.2	77.1	9.1	21.6	21.4	27.6	16.6	31.3	15.3	21.7	21.2	19.4	13.8	26.2	56.9	20.4	23.1	16.8	8.1	19.1	22.5	25.0	15.4	23.3	43.0	15.6	22.3	13.4	15.5	27.1	5.9	32.2	29.5	34.5	94.0	18.4	15.4	29.9	14.9	18.1	17.4	12.7	14.1	10.3	22.9	26.9	11.8	28.8	33.8	3.3	31.7	0.6	0.1	0.4	1.8	0.4	8.8	12.3	5.1	17.2	26.0	18.8	7.0	8.3	14.2	6.9	8.0	6.6	19.7	11.1	16.2	7.5	12.1	7.2	6.1	1.3	10.8	6.6	9.7	15.7	6.1	25.7	2.7	11.6	21.1	6.1	10.0	6.0	9.0	10.4	19.5	10.3	14.8	14.4	7.0	4.3	10.9	18.6	12.6	27.2	5.4	9.6	7.8	25.7	6.7	24.8	32.4	16.5	3.1	7.9	30.2	19.2	13.8	5.0	53.0	25.0	8.3	28.4	3.1	16.1	0.4	0.1	0.6	1.1	0.0	0.9	3.3	0.8	1.0	0.5	2.7	1.1	1.8	0.0	0.4	0.0	31.7	0.4	0.4	25.9	22.7	9.1	21.6	20.4	23.1	25.0	15.4	15.5	14.1
VEGFC	VRP	ENSG00000150630	"Vascular endothelial growth factor C"	P49767	4	176683538-176792727	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 20.1"	"Cell line enhanced"	"Detected in many"		"BJ: 41.2;HBF TERT88: 33.5;hTEC/SVTERT24-B: 33.7;LHCN-M2: 37.2"	"Low cancer specificity"	"Detected in all"							"Cell type enriched"	"Detected in single"	12	"neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	12	"granulocytes: 1.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"								"Secreted to blood"	50000	50000				"unprognostic (4.18e-1)"	"unprognostic (4.07e-2)"	"unprognostic (4.84e-3)"	"unprognostic (1.15e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.57e-1)"	"prognostic unfavourable (7.88e-5)"	"unprognostic (4.53e-1)"	"unprognostic (2.80e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.23e-1)"	"prognostic unfavourable (1.17e-4)"	"unprognostic (1.89e-3)"	"unprognostic (4.41e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.22e-1)"	8.9	2.0	0.5	1.9	2.0	0.0	20.1	1.5	1.9	4.8	4.5	0.7	2.9	0.8	6.2	1.5	5.5	5.1	7.7	5.9	0.8		1.5	1.7	16.0	3.5	0.0	0.1	3.9	0.5	0.6	0.0	11.6	1.6	4.8	1.6	3.4	4.3	2.7	6.2	0.2	1.6	3.8	1.7	2.6	0.4	2.4	0.4	0.3	17.7	3.4	2.3	6.8	9.2	0.0	0.0	1.2	0.0	0.0	0.0	0.1	1.5	0.8	0.5	0.0	7.5	7.5	0.0	41.2	24.9	23.0	18.3	0.0	0.2	0.0	0.0	23.2	1.2	0.3	15.5	33.5	0.0	0.8	0.0	1.1	0.0	4.1	0.0	0.0	8.0	0.7	33.7	23.5	14.1	0.0	0.0	37.2	0.6	0.0	0.0	0.3	13.5	0.0	2.4	0.0	0.0	0.9	0.0	0.0	0.6	0.9	0.0	0.2	0.0	6.8	24.4	2.6	6.0	11.6	0.0	0.0	0.0	10.1	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.1										
VEGFD	"FIGF, VEGF-D"	ENSG00000165197	"Vascular endothelial growth factor D"	O43915	X	15345591-15384376	"Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 39.0"	"Cell line enhanced"	"Detected in some"		"ASC diff: 7.1;ASC TERT1: 5.9;EFO-21: 2.6;HSkMC: 5.9"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			HPA027342	Uncertain				"Secreted to blood"	340000	340000			"HPA027342: AB_1848597"	"unprognostic (5.90e-2)"	"unprognostic (9.79e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.85e-2)"	"unprognostic (2.07e-1)"	"unprognostic (6.06e-3)"	"unprognostic (5.57e-2)"	"unprognostic (2.24e-3)"	"unprognostic (2.65e-2)"	"unprognostic (1.59e-5)"	"unprognostic (3.08e-2)"	"unprognostic (2.03e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.70e-1)"	"unprognostic (3.85e-1)"	"unprognostic (1.75e-2)"	9.5	7.4	0.6	1.8	1.0	0.1	19.5	1.1	0.7	10.5	7.6	0.2	4.1	1.1	10.1	12.9	15.4	2.7	3.5	27.8	0.6	1.1	1.0	1.3	39.0	0.7	0.8	0.2	7.3	2.6	0.2	4.4	0.2	0.8	22.2	1.9	0.2	1.5	1.8	12.0	0.5	4.3	9.8	0.6	2.3	3.4	14.9	0.1	0.0	2.0	17.5	1.2	12.3	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.1	1.8	7.1	5.9	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.3	2.6	0.0	0.5	0.5	0.0	0.0	0.0	0.1	0.0	1.5	0.6	0.4	0.0	0.8	5.9	0.7	0.0	0.0	0.6	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.2	0.0	0.5	0.5	0.4	0.3	0.1	0.6	0.0	0.7	0.3	0.0	0.1	0.3	0.3	0.4	1.1	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	1.1	0.7	0.6	1.1	0.8	0.2	0.8	0.1
VHL	VHL1	ENSG00000134086	"Von Hippel-Lindau tumor suppressor"	P40337	3	10141008-10152220	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Congenital erythrocytosis, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"BEWO: 53.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB005430, HPA031631, HPA031632"	Uncertain		Enhanced	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB005430: AB_2241850, HPA031631: , HPA031632: "	"prognostic unfavourable (9.02e-5)"	"unprognostic (1.10e-1)"	"unprognostic (4.46e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.33e-1)"	"prognostic unfavourable (1.32e-5)"	"unprognostic (3.55e-1)"	"unprognostic (3.03e-2)"	"unprognostic (4.36e-2)"	"unprognostic (5.82e-3)"	"unprognostic (1.81e-2)"	"unprognostic (2.51e-1)"	"prognostic favourable (7.84e-4)"	"unprognostic (1.46e-1)"	"unprognostic (2.92e-2)"	"unprognostic (1.28e-3)"	13.8	17.4	18.1	29.2	18.4	24.3	15.4	25.8	21.4	13.3	19.8	19.3	14.5	15.9	15.1	13.6	16.4	14.3	18.9	10.5	17.1	18.5	13.7	16.3	14.6	27.9	13.5	12.3	15.2	22.5	13.8	14.6	18.8	12.8	15.1	16.6	12.5	21.8	13.7	14.8	14.0	22.3	13.4	17.0	22.6	16.2	17.9	11.2	39.2	16.9	11.5	29.3	15.4	19.1	5.4	3.9	8.0	4.1	4.4	4.3	1.7	6.7	6.5	14.3	8.8	13.3	10.3	53.6	5.9	8.5	7.6	9.0	7.6	8.4	23.8	8.1	8.0	5.8	13.2	8.3	9.4	11.4	12.0	18.5	10.5	10.5	12.6	16.3	14.8	10.3	9.5	10.1	12.8	8.7	16.4	18.1	7.5	12.2	15.5	12.0	9.6	8.3	19.7	12.6	11.9	9.3	17.4	5.4	17.9	12.5	6.7	7.2	13.2	20.7	7.5	7.6	10.1	7.0	9.3	12.9	26.4	38.0	8.4	19.5	6.9	2.6	4.1	3.3	3.8	2.5	3.6	4.1	2.9	4.3	3.9	5.4	2.5	2.7	8.0	4.4	3.2	2.4	3.1	1.7	18.1	18.4	25.8	21.4	17.1	18.5	13.5	12.3	12.8	11.2
VIL1	"D2S1471, VIL"	ENSG00000127831	"Villin 1"	P09327	2	218419092-218453295	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Actin capping, Actin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"intestine: 129.3"	"Group enriched"	"Detected in some"	106	"CACO-2: 122.1;Hep G2: 57.3"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 56.4"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	6	"neutrophil: 2.5"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 2.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB002452, HPA006884, HPA006885"	Enhanced		Enhanced	"Plasma membrane"		41000000	41000000	"Plasma membrane"		"CAB002452: AB_564052, HPA006884: AB_1080566, HPA006885: AB_1080564"	"unprognostic (1.28e-1)"	"unprognostic (1.91e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.36e-1)"	"unprognostic (3.03e-1)"	"unprognostic (5.90e-2)"	"unprognostic (2.44e-2)"	"unprognostic (7.06e-2)"	"unprognostic (4.14e-1)"	"unprognostic (1.03e-1)"	"unprognostic (2.25e-3)"	"unprognostic (3.90e-1)"	"unprognostic (2.58e-1)"	"unprognostic (4.79e-2)"	"unprognostic (4.65e-2)"	0.3	0.2	0.6	5.7	0.8	0.0	0.3	0.7	0.4	0.3	36.6	0.3	0.3	68.9	0.3	1.2	0.3	0.2	22.6	0.3	0.5	0.5	4.6	6.1	0.3	0.3	0.5	0.3	0.3	7.2	0.0	0.4	0.3	0.3	0.3	32.6	0.3	0.5	0.3	0.3	0.3	129.3	1.2	0.5	0.4	0.9	0.6	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.4	2.5	0.1	0.1	0.1	7.8	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	122.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	57.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	2.5	0.1	0.0	0.4	0.0	7.8	0.6	0.8	0.7	0.4	0.5	0.5	0.5	0.3	0.3	0.3
VIP		ENSG00000146469	"Vasoactive intestinal peptide"	P01282	6	152750798-152759765	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 32.5;lymphoid tissue: 64.7"	"Group enriched"	"Detected in some"	4	"HeLa: 2.1;SH-SY5Y: 6.8;TIME: 4.8;U-2 OS: 2.0"	"Group enriched"	"Detected in some"	6	"colorectal cancer: 3.7;pancreatic cancer: 4.3;stomach cancer: 2.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA017324, CAB018649, HPA072701, CAB079780"	Supported	Supported	Approved	"Endoplasmic reticulum"	"Secreted to blood"			"Endoplasmic reticulum"		"CAB018649: AB_2304501, CAB079780: , HPA017324: AB_1858754, HPA072701: "	"unprognostic (9.58e-2)"	"unprognostic (2.29e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.34e-2)"	"unprognostic (3.33e-2)"	"unprognostic (2.48e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.22e-2)"	"unprognostic (2.89e-2)"	"unprognostic (2.36e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.92e-3)"	"unprognostic (7.47e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.30e-1)"	"unprognostic (5.90e-2)"	1.2	5.7	9.7	64.7	8.3	0.3	0.9	1.5	20.1	0.6	31.5	0.5	0.3	7.5	0.7	0.4	13.1	0.5	4.2	1.1	12.4	7.7	0.9	0.6	1.7	0.4	2.7	8.3	0.4	3.8	0.5	0.4	0.5	1.6	6.3	28.3	3.2	0.4	6.9	0.8	0.4	32.5	18.0	0.4	5.2	13.2	0.5	0.1	0.0	1.3	0.5	0.4	9.1	4.3	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.1	0.9	0.1	0.4	0.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.1	6.8	0.0	0.0	0.0	0.0	0.0	4.8	0.0	2.0	0.2	0.1	0.5	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	9.7	8.3	1.5	20.1	12.4	7.7	2.7	8.3	1.6	0.1
VTN	VN	ENSG00000109072	Vitronectin	P04004	17	28367276-28373091	"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins"	"Cell adhesion"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	42	"liver: 321.7"	"Cell line enriched"	"Detected in some"	11	"CACO-2: 164.9"	"Cancer enriched"	"Detected in many"	85	"liver cancer: 2216.6"					"Cell type enhanced"	"Detected in some"		"naive CD8 T-cell: 2.1"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016695, CAB016765, HPA060933"	Supported		Supported	"Endoplasmic reticulum,Vesicles"	"Secreted to blood"	32000000000	32000000000	"Endoplasmic reticulum, Vesicles"		"CAB016695: AB_1624536, CAB016765: , HPA060933: "	"unprognostic (1.19e-1)"	"unprognostic (2.12e-1)"	"unprognostic (2.29e-2)"	"unprognostic (6.13e-2)"	"unprognostic (9.74e-2)"	"unprognostic (8.42e-2)"	"prognostic favourable (3.74e-4)"	"unprognostic (6.20e-2)"	"unprognostic (3.97e-1)"	"unprognostic (8.95e-2)"	"unprognostic (3.24e-3)"	"unprognostic (1.01e-2)"	"prognostic unfavourable (4.10e-11)"	"unprognostic (8.82e-3)"	"unprognostic (2.27e-1)"	"unprognostic (4.86e-3)"	"unprognostic (7.09e-2)"	0.2	7.6	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	3.6	2.2	0.0	0.0	0.0	321.7	0.0	0.0	0.0		0.0	0.6	0.0	0.0	2.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4			0.0		0.0	0.0	0.0	0.3	0.2	0.6	0.2	0.7	2.1	0.1	0.0	2.9	0.0	0.0	0.0	0.0	0.7	0.2	0.1	0.1	0.0	164.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	8.5	0.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.1	15.1	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.0	1.0	0.0	0.9	0.0	0.9	0.9	0.1	0.3	0.6	2.1	0.6	0.7	0.0	0.2	0.0	0.1										
VWF	F8VWF	ENSG00000110799	"Von Willebrand factor"	P04275	12	5948874-6124770	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Cancer-related genes, Disease mutation, FDA approved drug targets, von Willebrand disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 91.7"	"Cell line enriched"	"Detected in some"	57	"HUVEC TERT2: 111.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001694, HPA001815, HPA002082, CAB072874, CAB072875"	Supported				"Secreted to blood"	6400000000	6400000000			"CAB001694: , CAB072874: , CAB072875: , HPA001815: AB_1080574, HPA002082: AB_1080575"	"unprognostic (3.66e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.91e-3)"	"unprognostic (7.09e-2)"	"unprognostic (4.63e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.92e-2)"	"unprognostic (4.69e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.98e-2)"	"prognostic unfavourable (2.31e-4)"	"unprognostic (1.55e-1)"	"unprognostic (3.12e-1)"	"unprognostic (2.73e-3)"	91.7	3.1	6.1	9.7	8.1	0.8	41.5	3.7	8.6	19.7	13.9	7.3	6.8	6.6	21.5	16.7	14.4	15.1	15.3	38.7	7.4	5.0	4.6	1.5	41.2	9.9	9.4	7.1	13.6	5.8	17.7	2.6	36.4	10.2	18.7	5.1	26.3	7.2	10.5	28.9	8.1	11.8	22.1	7.4	19.0	9.6	12.7	5.9	1.8	18.6	13.2	6.5	18.9	35.0	0.0	0.0	1.3	0.3	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	111.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	1.8	6.1	8.1	3.7	8.6	7.4	5.0	9.4	7.1	10.2	5.9
WAS	"IMD2, THC, WASP, WASPA"	ENSG00000015285	"Wiskott-Aldrich syndrome"	P42768	X	48676596-48691427	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 30.7;lymphoid tissue: 55.9"	"Cell line enhanced"	"Detected in some"		"Daudi: 21.3;HMC-1: 45.7;MOLT-4: 19.4;NB-4: 21.1;RPMI-8226: 26.0;U-266/70: 24.2;U-937: 24.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 20.3"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002022, CAB004290"	Enhanced		Approved	"Plasma membrane,Cytosol"		320000	320000	"Plasma membrane"	Cytosol	"CAB004290: AB_628445, HPA002022: AB_1080581"	"unprognostic (1.43e-3)"	"unprognostic (2.09e-3)"	"unprognostic (2.36e-2)"	"prognostic favourable (4.95e-4)"	"unprognostic (9.89e-2)"	"prognostic favourable (3.78e-4)"	"unprognostic (5.12e-3)"	"unprognostic (7.60e-2)"	"unprognostic (1.54e-2)"	"unprognostic (2.86e-1)"	"unprognostic (7.40e-2)"	"unprognostic (3.60e-1)"	"prognostic unfavourable (5.58e-6)"	"unprognostic (2.24e-1)"	"unprognostic (2.37e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.71e-1)"	7.6	4.0	4.9	28.9	7.8	30.7	3.3	2.0	5.1	2.7	4.4	5.9	0.5	4.8	2.4	5.6	3.7	4.5	4.4	3.0	4.6	4.1	4.1	5.0	12.6	29.9	7.6	1.3	2.6	2.2	0.7	2.6	5.4	6.0	3.2	3.2	3.5	5.4	1.9	1.4	2.2	14.3	3.7	12.8	55.9	4.1	1.7	7.3	53.2	2.8	1.4	33.2	5.8	2.5	2.1	3.5	20.3	5.3	2.1	3.2	2.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	21.3	0.0	0.0	0.7	0.0	0.0	0.0	12.2	0.1	18.8	0.2	0.0	0.2	9.6	45.7	0.0	0.0	0.0	0.0	0.0	0.2	13.1	0.0	2.1	19.4	21.1	0.1	0.1	16.9	0.0	26.0	0.0	0.0	0.1	0.2	0.3	0.2	0.2	0.1	19.2	0.1	0.0	0.1	0.3	0.0	24.2	11.8	14.9	0.1	24.4	0.0	1.8	4.6	20.3	3.0	5.0	2.2	1.8	2.3	2.5	3.5	2.1	2.1	2.3	18.1	2.1	5.3	1.8	3.2	2.0	4.9	7.8	2.0	5.1	4.6	4.1	7.6	1.3	6.0	7.3
WASF3	"KIAA0900, SCAR3, WAVE3"	ENSG00000132970	"WAS protein family member 3"	Q9UPY6	13	26557703-26688948	"Cancer-related genes, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 55.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 38.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.3"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037086, HPA066228"	Enhanced									"CAB037086: AB_1080585, HPA066228: "	"unprognostic (1.42e-1)"	"unprognostic (3.65e-2)"	"unprognostic (2.25e-1)"	"unprognostic (7.57e-2)"	"unprognostic (8.23e-2)"	"unprognostic (3.34e-1)"	"unprognostic (6.19e-2)"	"unprognostic (8.37e-2)"	"unprognostic (8.98e-2)"	"unprognostic (2.99e-1)"	"prognostic favourable (2.21e-4)"	"unprognostic (8.86e-3)"	"unprognostic (2.93e-3)"	"unprognostic (6.35e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.69e-3)"	"unprognostic (9.18e-2)"	18.7	17.3	27.3	3.4	33.2	1.1	11.8	30.9	55.1	7.1	3.4	18.6	2.0	1.9	8.7	6.0	4.8	7.1	4.6	7.3	22.7	19.7	8.0	7.6	7.9	3.0	22.1	22.5	22.4	6.0	6.8	4.5	1.3	18.4	10.1	4.1	8.9	6.6	10.8	7.4	3.7	2.5	8.4	17.1	5.5	5.3	12.9	14.1	0.0	17.7	0.7	2.4	4.3	5.0	0.2	0.0	1.3	0.0	0.0	0.0	0.8	0.0	0.1	17.5	0.0	38.6	7.5	1.6	6.7	10.2	10.0	5.2	0.0	1.6	6.6	0.9	15.4	1.5	4.9	5.0	8.7	0.0	4.1	0.3	0.0	6.6	5.8	2.2	5.0	15.8	4.9	2.5	7.9	15.5	0.1	0.0	3.7	1.4	0.0	0.0	4.8	1.6	0.0	9.8	0.0	1.3	2.8	4.1	8.2	3.4	3.2	5.1	0.0	0.2	7.8	7.9	3.2	3.8	3.6	0.0	0.0	6.4	4.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.8	27.3	33.2	30.9	30.7	22.7	19.7	22.1	22.5	18.4	14.1
WDCP	"C2orf44, FLJ21945"	ENSG00000163026	"WD repeat and coiled coil containing"	Q9H6R7	2	24029340-24049575	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041054	Approved		Approved	Nucleoli,Cytosol				Nucleoli	Cytosol	"HPA041054: AB_10796566"	"unprognostic (1.07e-1)"	"unprognostic (3.19e-2)"	"unprognostic (3.36e-1)"	"prognostic unfavourable (6.53e-4)"	"unprognostic (1.32e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavourable (5.14e-8)"	"unprognostic (7.69e-2)"	"unprognostic (9.01e-3)"	"unprognostic (2.05e-1)"	"unprognostic (1.07e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.76e-3)"	"unprognostic (1.85e-1)"	"unprognostic (1.97e-1)"	"unprognostic (7.76e-2)"	"unprognostic (3.00e-1)"	11.7	9.6	8.3	7.6	9.4	2.4	9.2	14.6	9.8	9.6	9.3	11.5	8.4	5.3	10.7	8.0	7.4	7.2	5.6	6.8	7.1	6.9	7.5	8.9	5.4	12.4	8.3	4.8	11.6	7.7	11.2	9.4	8.5	8.7	8.7	6.2	7.8	7.1	12.9	13.8	5.9	7.5	7.4	8.0	9.4	7.0	12.5	9.2	17.9	8.9	5.5	13.7	9.4	6.4	4.9	4.3	1.5	3.8	5.0	7.8	4.2	7.2	11.1	12.3	8.5	8.5	6.8	4.4	8.8	4.7	9.2	8.8	10.1	3.3	19.0	3.8	4.5	5.3	17.4	6.0	9.6	11.4	10.0	11.5	5.5	10.5	5.8	10.5	8.0	4.0	4.7	9.4	4.7	8.7	16.0	5.3	9.6	3.3	13.7	6.3	14.8	8.7	15.1	20.8	7.6	4.3	3.6	9.5	13.1	4.3	4.2	5.4	3.3	4.7	8.2	7.4	8.2	4.4	8.0	8.7	10.9	26.8	4.8	11.3	5.7	0.0	2.4	1.5	7.5	3.8	7.8	4.9	5.0	5.5	4.3	4.7	6.8	7.5	0.7	5.0	2.6	1.6	7.1	4.2	8.3	9.4	14.6	9.8	7.1	6.9	8.3	4.8	8.7	9.2
WEE1	WEE1A	ENSG00000166483	"WEE1 G2 checkpoint kinase"	P30291	11	9573681-9593457	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB004619, HPA068845"	Approved		Approved	Nucleoli				Nucleoli		"CAB004619: AB_628447, HPA068845: "	"unprognostic (6.04e-2)"	"unprognostic (1.90e-3)"	"unprognostic (1.09e-2)"	"unprognostic (9.29e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.39e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.48e-2)"	"unprognostic (1.22e-1)"	"unprognostic (1.79e-2)"	"unprognostic (3.21e-3)"	"unprognostic (3.73e-1)"	"prognostic unfavourable (5.19e-4)"	"unprognostic (1.07e-1)"	"unprognostic (3.06e-1)"	"unprognostic (2.08e-1)"	"unprognostic (3.80e-1)"	6.9	3.5	2.0	26.1	2.1	6.6	27.4	5.3	1.6	12.8	18.0	2.5	15.4	3.7	21.9	14.3	22.1	12.4	20.2	23.0	2.0	2.2	6.8	19.3	10.2	10.9	1.8	1.2	11.1	4.4	4.9	6.1	42.7	4.7	17.0	4.7	5.9	12.8	17.8	12.0	33.3	10.4	22.9	2.4	8.0	12.5	28.3	2.0	35.9	12.0	26.8	26.4	19.8	14.7	8.5	0.1	6.4	0.0	2.1	7.8	0.6	14.2	5.5	21.2	11.7	18.6	9.3	42.0	17.6	13.6	9.9	9.8	10.1	17.5	33.4	6.6	7.7	17.3	14.5	6.8	12.7	11.9	11.9	13.1	8.9	6.7	2.0	19.8	13.1	3.1	7.4	4.6	16.4	6.1	21.3	23.3	17.2	3.4	20.2	10.7	31.9	6.3	19.5	16.6	7.2	7.8	30.1	7.9	10.5	11.9	14.1	8.6	8.9	9.5	7.0	17.8	12.5	7.2	14.1	5.5	16.3	44.2	7.6	10.9	12.5	0.0	0.0	6.4	2.0	0.0	0.2	8.5	2.0	3.3	0.1	3.6	0.1	1.6	0.1	2.1	0.0	0.1	7.8	0.6	2.0	2.1	5.3	1.6	2.0	2.2	1.8	1.2	4.7	2.0
WFDC2	"dJ461P17.6, EDDM4, HE4, WAP5"	ENSG00000101443	"WAP four-disulfide core domain 2"	Q14508	20	45469706-45481532	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Aspartic protease inhibitor, Protease inhibitor, Serine protease inhibitor, Thiol protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"cervix, uterine: 352.3;ductus deferens: 143.4;epididymis: 385.4;kidney: 135.1;salivary gland: 343.7"	"Group enriched"	"Detected in some"	9	"A-431: 26.2;CAPAN-2: 49.1;EFO-21: 41.0;HaCaT: 35.8;RPTEC TERT1: 38.1"	"Cancer enhanced"	"Detected in all"		"endometrial cancer: 1815.6"	"Region enriched"	"Detected in single"	5	"basal ganglia: 3.0"	"Cell type enriched"	"Detected in single"	12	"plasmacytoid DC: 1.2"	"Lineage enriched"	"Detected in single"	12	"dendritic cells: 1.2"					"Group enriched"	"Detected in many"	13	"basal ganglia: 10.7;hypothalamus: 32.7;midbrain: 14.3;pons and medulla: 12.8;thalamus: 8.5"	HPA042302	Enhanced				"Secreted in other tissues"	1300000	1300000			"HPA042302: "	"unprognostic (5.75e-2)"	"unprognostic (2.23e-1)"	"unprognostic (4.37e-2)"	"unprognostic (2.99e-2)"	"prognostic unfavourable (3.04e-5)"	"unprognostic (7.19e-3)"	"unprognostic (1.94e-1)"	"unprognostic (5.49e-3)"	"unprognostic (3.71e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.40e-1)"	"prognostic favourable (4.44e-5)"	"unprognostic (1.82e-1)"	"unprognostic (1.09e-1)"	"unprognostic (2.00e-1)"	"unprognostic (3.20e-2)"	1.2	0.1	0.3	1.5	3.0	0.0	10.6	0.2	0.6	352.3	11.0	0.4	143.4	0.7	19.4	385.4	4.5	44.6	10.4	0.4	0.3	0.3	135.1	9.9	31.6	0.2	0.3	0.3	20.4	5.0	5.0	14.9	1.3	0.5	27.2	14.7	2.2	343.7	60.9	0.2	2.8	5.0	10.9	0.2	0.1	3.8	15.6	0.5	0.7	45.5	15.3	29.1	21.9	6.9	0.0	1.2	0.0	0.0	0.0	0.0	0.1	26.2	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	1.1	49.1	0.0	41.0	0.0	35.8	0.0	0.0	0.0	0.2	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.1	0.0	1.4	0.0	0.6	4.3	0.0	0.0	0.0	0.0	38.1	0.3	1.2	0.2	2.4	0.0	0.2	0.7	0.1	0.0	0.0	0.6	0.1	0.1	0.1	0.1	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.3	3.0	0.2	0.6	0.3	0.3	0.3	0.3	0.5	0.5
WIF1		ENSG00000156076	"WNT inhibitory factor 1"	Q9Y5W5	12	65050626-65121566	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 35.2;lung: 67.7;retina: 29.6"	"Cell line enhanced"	"Detected in some"		"HEK 293: 5.2;LHCN-M2: 2.4;NTERA-2: 6.8;SCLC-21H: 1.5"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 16.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"								"Secreted to extracellular matrix"						"unprognostic (5.96e-3)"	"unprognostic (2.00e-1)"	"unprognostic (4.29e-3)"	"unprognostic (3.26e-3)"	"unprognostic (9.66e-2)"	"unprognostic (1.91e-1)"		"unprognostic (1.26e-2)"	"unprognostic (7.94e-2)"	"unprognostic (2.44e-1)"	"unprognostic (2.92e-2)"	"unprognostic (3.17e-1)"	"unprognostic (2.30e-5)"	"unprognostic (3.02e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.22e-1)"	"unprognostic (7.24e-3)"	0.9	2.4	23.3	0.8	35.2	0.6	14.2	1.6	20.6	1.6	0.8	1.0	1.9	0.6	5.5	14.5	3.4	1.5	0.6	0.7	10.4	3.9	1.0	0.6	67.7	0.7	1.4	8.2	0.8	0.8	0.6	21.4	0.6	0.4	9.5	0.8	29.6	24.8	2.3	0.6	4.2	1.8	1.2	0.7	0.7	0.9	1.0	3.5	0.0	0.6	3.6	0.6	0.8	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.4	0.1	0.0	0.9	6.8	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.2	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	35.2	1.6	20.6	10.4	3.9	1.4	8.2	0.4	3.5
WISP1	"CCN4, WISP-1, WISP1-OT1, WISP1-UT1"	ENSG00000104415	"WNT1 inducible signaling pathway protein 1"	O95388	8	133191039-133231690	"Cancer-related genes, Predicted secreted proteins"	"Cell adhesion, Wnt signaling pathway"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HHSteC: 7.9;HSkMC: 44.5;hTEC/SVTERT24-B: 25.4;U-2197: 24.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	6	"olfactory region: 11.9"	"Not detected"	"Not detected"			"HPA007121, CAB012205"	Uncertain		Approved	Cytosol	"Secreted to extracellular matrix"			Cytosol		"CAB012205: , HPA007121: AB_1858844"	"unprognostic (7.77e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.30e-2)"	"unprognostic (3.20e-1)"	"unprognostic (7.72e-2)"	"unprognostic (6.63e-2)"	"unprognostic (8.61e-3)"	"unprognostic (3.26e-2)"	"unprognostic (2.07e-3)"	"unprognostic (1.41e-3)"	"unprognostic (3.01e-2)"	"unprognostic (2.67e-1)"	"prognostic unfavourable (1.91e-5)"	"unprognostic (7.52e-3)"	"unprognostic (2.55e-3)"	"unprognostic (6.03e-2)"	"unprognostic (5.67e-3)"	4.2	11.0	0.6	7.7	1.6	0.0	2.3	0.6	2.9	14.7	3.9	1.0	0.0	1.2	18.5	6.4	2.2	6.5	8.5	4.0	0.7	0.3	18.0	2.9	8.9	13.4	0.8	0.4	13.0	1.0	0.2	2.7	3.5	1.2	3.4	0.9	4.5	1.3	4.2	2.0	1.6	3.9	14.4	6.2	14.6	3.8	3.7	0.4	0.3	1.3	2.7	4.2	14.4	4.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.0	1.7	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	44.5	0.0	25.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	5.9	0.3	24.3	0.0	0.0	0.0	0.0	4.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	1.6	0.6	2.9	0.7	0.3	0.8	0.4	1.2	0.4
WNT1	INT1	ENSG00000125084	"Wnt family member 1"	P04628	12	48978453-48981676	"Cancer-related genes, Disease related genes, Predicted secreted proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes, Disease mutation, Osteogenesis imperfecta, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 7.7;brain: 6.5;placenta: 17.5"	"Cell line enhanced"	"Detected in single"		"CACO-2: 2.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"basal ganglia: 6.5;cerebral cortex: 1.8"	"Group enriched"	"Detected in some"	8	"gdT-cell: 5.3;MAIT T-cell: 7.7;memory CD4 T-cell: 3.0;memory CD8 T-cell: 4.8;naive CD8 T-cell: 3.2"	"Lineage enriched"	"Detected in single"	24	"T-cells: 7.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"cerebral cortex: 1.3;hippocampal formation: 1.5;midbrain: 3.5;olfactory region: 2.1"						"Secreted to extracellular matrix"						"unprognostic (2.02e-2)"	"unprognostic (5.80e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.64e-2)"	"unprognostic (1.03e-1)"	"unprognostic (7.65e-3)"	"unprognostic (5.29e-3)"	"unprognostic (5.68e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.20e-1)"	"unprognostic (4.08e-2)"	"unprognostic (4.97e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.70e-1)"	"unprognostic (7.35e-3)"	"unprognostic (2.76e-2)"	0.3	0.1	0.4	1.5	6.5	2.3	0.3	0.3	2.9	0.3	0.3	0.3	0.3	1.5	0.3	0.3	0.5	0.1	0.7	0.3	0.6	0.5	0.3	0.3	0.7	2.9	0.3	0.3	0.3	0.3	0.0	0.3	17.5	0.3	0.3	0.0	0.3	1.2	0.3	0.3	0.0	1.8	0.3	0.3	1.9	1.2	1.4	0.3	0.3	0.3	0.3	0.3	0.6	0.3	0.3	0.0	0.0	0.0	0.0	7.7	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.7	0.2	0.0	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	7.7	0.3	3.0	4.8	0.0	0.0	0.5	3.2	0.0	0.0	0.0	0.0	0.4	0.8	0.4	6.5	0.3	1.8	0.6	0.5	0.3	0.3	0.3	0.3
WNT2	"INT1L1, IRP"	ENSG00000105989	"Wnt family member 2"	P09544	7	117276631-117323289	"Cancer-related genes, Predicted secreted proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 10.4;lung: 10.9;placenta: 40.9"	"Cell line enriched"	"Detected in some"	5	"U-2197: 21.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"basal ganglia: 12.6"	"Low region specificity"	"Detected in all"			HPA020920			Approved	Vesicles	"Secreted to extracellular matrix"			Vesicles		"HPA020920: AB_1858850"	"unprognostic (1.90e-1)"	"unprognostic (6.97e-2)"	"unprognostic (2.88e-2)"	"unprognostic (4.11e-3)"	"unprognostic (9.14e-2)"	"unprognostic (2.47e-1)"	"unprognostic (2.54e-2)"	"unprognostic (2.75e-1)"	"unprognostic (2.74e-1)"	"unprognostic (5.70e-2)"	"unprognostic (1.36e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.43e-1)"	"unprognostic (4.05e-2)"	"unprognostic (2.50e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.10e-1)"	1.8	0.0	0.2	0.1	1.1	0.0	1.4	0.3	2.3	3.0	0.2	0.4	0.4	0.0	10.4	2.7	0.4	1.0	0.2	0.7	0.9	0.9	0.3	0.8	10.9	0.0	0.1	0.5	0.8	0.1	0.0	0.2	40.9	0.5	7.6	0.0	0.9	0.1	0.5	0.0	1.1	0.2	1.2	0.2	1.5	0.1	0.7	0.0	0.0	0.2	0.0	0.1	1.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	1.4	2.1	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	21.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.3	2.3	0.9	0.9	0.1	0.5	0.5	0.0
WRN	"RECQ3, RECQL2"	ENSG00000165392	"Werner syndrome RecQ like helicase"	Q14191	8	31033801-31173769	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Exonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028661	Approved		Supported	"Nuclear speckles"				"Nuclear speckles"		"HPA028661: AB_10602255"	"unprognostic (8.73e-2)"	"unprognostic (9.33e-2)"	"unprognostic (1.51e-3)"	"unprognostic (3.85e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.85e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.25e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.27e-2)"	"unprognostic (6.63e-2)"	"unprognostic (1.53e-2)"	"unprognostic (6.51e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.00e-2)"	"unprognostic (2.66e-1)"	10.1	9.2	5.6	8.5	6.6	15.6	11.1	10.7	7.3	14.2	8.0	7.7	7.7	5.5	24.4	8.8	7.6	9.7	6.9	7.0	5.9	4.0	5.1	7.7	7.2	6.7	8.2	5.3	12.0	9.9	7.8	28.1	8.5	7.0	8.6	7.8	8.3	10.8	7.8	7.7	10.2	7.0	12.1	14.9	8.9	8.3	10.4	7.3	11.8	7.9	6.3	9.3	10.8	8.7	3.9	2.7	1.3	1.9	2.9	6.2	1.6	6.4	6.3	13.1	8.3	7.8	12.5	8.3	7.3	7.1	8.9	9.3	4.0	3.9	15.1	6.7	7.3	3.3	8.1	5.2	13.4	4.2	6.9	15.4	6.0	3.3	9.8	9.1	5.7	9.1	5.8	8.5	10.2	8.6	24.3	9.6	8.2	4.1	18.9	4.4	11.2	4.6	10.9	9.9	6.0	3.7	7.0	2.8	7.5	8.8	5.0	6.9	3.5	4.5	13.7	9.7	6.0	5.0	6.1	2.5	2.7	19.0	7.2	7.2	6.6	1.2	1.9	1.3	3.3	1.9	6.2	3.9	3.8	3.3	2.7	3.5	2.5	3.2	0.5	2.9	0.8	2.0	2.8	1.6	5.6	6.6	10.7	7.3	5.9	4.0	8.2	5.3	7.0	7.3
WT1	"AWT1, GUD, NPHS4, WAGR, WIT-2"	ENSG00000184937	"Wilms tumor 1"	P19544	11	32387775-32435630	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, RNA-binding"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4"	"Cell line enhanced"	"Detected in some"		"HEL: 13.2;HMC-1: 17.0;K-562: 11.9;NB-4: 31.9;THP-1: 15.3"	"Cancer enriched"	"Detected in many"	14	"ovarian cancer: 55.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"pons and medulla: 0.5"	"Low region specificity"	"Detected in single"			"CAB000327, HPA035717, HPA053848"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000327: AB_2304486, HPA035717: , HPA053848: "	"unprognostic (3.09e-3)"	"unprognostic (9.97e-4)"	"unprognostic (3.32e-1)"	"unprognostic (8.24e-3)"	"unprognostic (5.20e-2)"	"unprognostic (1.98e-3)"	"unprognostic (2.94e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.23e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.31e-10)"	"unprognostic (2.65e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.96e-3)"	"unprognostic (1.30e-2)"	10.3	0.0	0.2	1.8	0.6	0.0	0.2	0.2	0.5	20.3	1.5	0.2	3.7	0.0	69.0	9.3	0.4	34.5	0.8	2.1	0.9	0.0	5.3	0.2	0.8	0.5	0.2	0.2	53.4	0.2	0.0	0.2	6.9	0.3	0.9	0.0	0.2	0.2	4.2	0.2	0.0	0.4	23.7	0.2	14.6	0.0	24.5	0.2	0.2	0.3	0.2	0.2	1.3	4.1	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.1	0.1	0.0	0.0	6.1	0.0	0.0	0.0	4.6	13.2	0.0	1.1	3.7	8.8	17.0	0.0	0.0	2.7	0.0	0.0	11.9	0.1	2.7	0.0	7.7	31.9	0.7	3.7	1.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	15.3	0.1	0.0	2.3	0.0	0.3	0.0	0.0	0.0	0.1	2.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.6	0.2	0.5	0.9	0.0	0.2	0.2	0.3	0.2
WWTR1	"DKFZp586I1419, TAZ"	ENSG00000018408	"WW domain containing transcription regulator 1"	Q9GZV5	3	149517235-149736714	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"EFO-21: 59.8;SK-MEL-30: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.6;memory CD8 T-cell: 2.8"	"Lineage enriched"	"Detected in single"	4	"T-cells: 2.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007415, CAB017483, CAB068248"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"				"Nucleoplasm, Nuclear bodies"	Cytosol	"CAB017483: AB_2216639, CAB068248: , HPA007415: AB_1080602"	"unprognostic (1.85e-2)"	"unprognostic (2.24e-2)"	"unprognostic (3.41e-3)"	"unprognostic (1.33e-2)"	"unprognostic (7.94e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.41e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.74e-2)"	"unprognostic (2.34e-1)"	"unprognostic (1.63e-2)"	"unprognostic (3.32e-1)"	"unprognostic (1.17e-3)"	"unprognostic (2.76e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.01e-3)"	25.1	9.9	9.3	16.0	18.6	0.2	20.4	7.7	10.5	27.2	38.5	18.4	15.0	5.6	27.2	17.6	41.2	16.4	25.8	20.6	14.7	9.0	31.0	13.1	29.8	6.2	15.2	5.6	30.9	21.7	10.4	8.5	29.0	20.7	34.6	9.1	29.4	15.8	22.4	12.1	13.4	11.7	81.5	25.8	13.8	20.8	12.0	16.4	0.7	18.2	13.2	7.1	68.4	31.0	0.2	0.1	0.6	0.1	0.1	2.8	0.4	16.5	19.7	10.5	13.9	12.5	22.4	11.0	9.6	14.1	4.4	4.6	11.0	14.0	0.0	59.8	10.8	9.8	6.8	7.0	4.3	4.6	5.2	0.0	5.1	9.1	7.1	0.0	0.0	11.8	1.8	15.2	6.6	33.9	0.0	0.0	15.1	2.2	0.0	0.0	2.4	24.9	0.0	14.0	0.1	37.2	2.4	0.0	0.1	6.3	4.5	41.3	7.6	0.3	27.6	8.6	4.1	6.9	18.8	0.1	0.1	0.2	18.4	0.0	21.8	0.4	0.1	0.1	2.6	0.0	0.0	0.0	0.3	2.8	0.0	0.2	0.1	1.3	0.6	0.1	0.0	0.1	1.9	0.4	9.3	18.6	7.7	10.5	14.7	9.0	15.2	5.6	20.7	16.4
XBP1	XBP2	ENSG00000100219	"X-box binding protein 1"	P17861	22	28794555-28800597	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Angiogenesis, Apoptosis, Autophagy, Differentiation, Lipid biosynthesis, Lipid metabolism, Myogenesis, Protein transport, Stress response, Transcription, Transcription regulation, Transport, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 321.9;salivary gland: 176.0"	"Cell line enhanced"	"Detected in all"		"MCF7: 108.1;SK-BR-3: 101.6;T-47d: 118.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"																																			15.6	14.3	5.4	20.5	7.2	20.6	75.2	4.2	5.9	39.3	21.9	4.2	73.1	15.6	14.7	26.4	16.9	17.6	22.1	22.9	4.8	5.3	23.1	104.0	23.7	37.3	7.4	3.6	19.0	321.9	10.9	27.4	31.3	8.7	29.3	19.6	8.7	176.0	72.2	15.5	12.6	27.8	10.1	7.3	37.2	39.7	7.4	6.7	30.5	42.7	12.1	47.5	29.2	24.9	10.0	22.1	44.2	7.6	25.0	29.9	9.6	8.6	5.8	8.4	12.9	15.9	17.5	21.3	15.1	25.9	15.1	20.1	9.4	12.1	32.9	7.4	13.9	12.0	15.5	7.4	13.1	14.6	9.8	9.9	5.2	40.1	34.5	18.5	9.5	10.9	44.5	10.0	43.3	12.0	8.8	41.5	9.1	108.1	2.5	17.6	5.8	9.2	18.9	9.2	44.6	13.8	12.0	11.1	10.7	9.1	101.6	39.3	118.2	21.4	6.8	8.7	8.4	9.2	5.3	70.7	49.9	19.7	11.6	23.8	13.0	44.2	7.6	6.1	22.9	4.0	29.9	10.0	16.5	23.6	6.9	8.2	16.4	13.7	0.6	25.0	2.8	22.1	5.5	9.6	5.4	7.2	4.2	5.9	4.8	5.3	7.4	3.6	8.7	6.7
XIAP	"API3, BIRC4, hILP"	ENSG00000101966	"X-linked inhibitor of apoptosis"	P98170	X	123859724-123913979	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Ubl conjugation pathway, Wnt signaling pathway"	"Protease inhibitor, Thiol protease inhibitor, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB009203, HPA042428"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB009203: AB_2257167, HPA042428: "	"prognostic unfavourable (9.21e-4)"	"unprognostic (8.43e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.40e-1)"	"unprognostic (9.41e-2)"	"unprognostic (1.95e-2)"	"unprognostic (8.51e-2)"	"unprognostic (9.17e-2)"	"unprognostic (3.90e-2)"	"unprognostic (7.50e-2)"	"unprognostic (4.41e-2)"	"unprognostic (3.15e-3)"	"unprognostic (8.21e-3)"	"unprognostic (2.26e-1)"	"unprognostic (4.99e-2)"	"unprognostic (4.65e-2)"	17.4	14.4	20.0	18.1	20.2	12.0	15.9	21.3	18.9	17.2	19.4	14.5	22.9	16.1	17.4	17.0	18.9	12.6	14.7	15.7	18.9	22.1	19.8	19.4	16.5	15.5	18.8	14.6	13.9	19.7	36.6	26.1	18.2	15.9	15.6	16.8	16.9	14.6	22.9	21.5	14.2	23.4	17.0	19.0	15.8	16.2	7.0	12.3	13.9	24.3	11.4	14.0	15.4	20.5	5.7	4.3	11.1	3.9	3.3	5.5	1.9	11.5	9.9	7.8	6.7	9.2	11.9	10.2	12.6	9.4	6.9	5.9	4.4	13.6	10.8	18.7	10.7	4.3	11.5	7.9	12.7	11.2	6.3	7.3	8.3	6.7	11.7	13.2	15.2	8.2	12.3	11.4	14.7	9.5	11.5	12.5	13.3	12.0	7.3	6.4	6.4	7.8	7.9	9.1	11.4	10.4	16.8	5.3	7.7	17.2	10.0	10.1	6.1	6.5	11.7	0.3	4.7	20.6	14.0	10.5	10.5	12.0	14.2	9.4	8.7	11.1	2.6	3.5	5.0	2.3	4.7	4.6	3.8	5.5	1.4	5.7	4.4	3.0	8.2	3.3	3.9	4.3	2.5	1.9	20.0	20.2	21.3	18.9	18.9	22.1	18.8	14.6	15.9	12.3
XIRP2	CMYA3	ENSG00000163092	"Xin actin binding repeat containing 2"	A4UGR9	2	166888487-167259753	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	6	"skeletal muscle: 292.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 3.2;HEL: 1.5;HUVEC TERT2: 8.5;U-2197: 6.0"	"Cancer enriched"	"Detected in some"	5	"head and neck cancer: 3.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA034813, HPA074599"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"				"Plasma membrane"	Nucleoplasm	"HPA034813: AB_10602588, HPA074599: "					"unprognostic (5.27e-4)"	"unprognostic (5.96e-3)"		"unprognostic (7.42e-2)"	"unprognostic (2.42e-1)"					"unprognostic (1.74e-1)"	"unprognostic (2.56e-1)"			7.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	3.3	0.0	0.0	24.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	4.3	0.0	292.8	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	2.3	51.0	2.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	1.5	0.0	0.2	0.2	0.0	0.0	0.9	0.0	0.2	0.7	8.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
XPA	"XP1, XPAC"	ENSG00000136936	"XPA, DNA damage recognition and repair factor"	P23025	9	97674909-97697357	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000155, HPA056856"	Supported		Approved	"Nucleoplasm,Cytokinetic bridge"				Nucleoplasm	"Cytokinetic bridge"	"CAB000155: , HPA056856: "	"unprognostic (8.76e-2)"	"unprognostic (1.05e-3)"	"unprognostic (1.60e-1)"	"unprognostic (2.30e-2)"	"unprognostic (4.17e-1)"	"unprognostic (1.84e-1)"	"unprognostic (5.26e-2)"	"unprognostic (2.38e-1)"	"unprognostic (3.90e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.97e-3)"	"unprognostic (9.55e-3)"	"prognostic favourable (4.28e-5)"	"unprognostic (2.19e-2)"	"unprognostic (1.56e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.17e-1)"	18.7	17.5	20.1	17.1	21.0	10.6	17.4	26.8	20.8	20.3	25.2	17.2	11.7	20.6	25.5	15.4	18.9	15.0	19.5	12.9	17.2	15.3	24.9	24.2	14.8	16.7	18.6	17.5	17.2	14.5	23.0	23.1	12.8	17.7	20.3	13.6	16.4	16.1	21.7	43.3	16.3	22.2	27.5	17.1	16.2	25.1	6.4	15.8	15.7	31.5	11.9	21.6	22.0	16.4	22.2	23.4	12.7	15.8	19.7	21.6	11.3	23.4	5.5	8.2	10.1	10.1	9.8	5.7	6.4	10.1	11.7	7.9	14.3	19.7	13.2	6.2	7.0	11.8	6.5	7.7	9.9	9.0	13.1	10.4	12.0	7.9	11.0	12.2	12.6	8.5	8.4	5.4	5.6	13.0	14.3	10.4	6.4	7.3	15.9	14.8	5.6	9.2	16.3	17.6	11.2	18.6	9.2	11.6	11.6	9.1	7.1	8.3	10.2	7.5	8.1	4.1	10.2	16.2	13.8	18.4	14.7	8.3	10.2	8.8	8.0	6.0	13.3	12.7	16.2	13.1	18.7	19.5	17.7	15.6	13.5	22.2	21.6	18.6	1.5	19.7	15.8	23.4	18.3	11.3	20.1	21.0	26.8	20.8	17.2	15.3	18.6	17.5	17.7	15.8
XPC	"RAD4, XPCC"	ENSG00000154767	"XPC complex subunit, DNA damage recognition and repair factor"	Q01831	3	14145147-14178783	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009932, HPA035707, HPA069673"	Supported		Enhanced	"Nucleoplasm,Plasma membrane"				Nucleoplasm	"Plasma membrane"	"CAB009932: AB_2241587, HPA035707: , HPA069673: "	"unprognostic (7.46e-2)"	"unprognostic (2.52e-2)"	"unprognostic (4.50e-2)"	"unprognostic (3.01e-1)"	"unprognostic (6.63e-2)"	"unprognostic (2.54e-2)"	"unprognostic (1.97e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.50e-1)"	"unprognostic (7.13e-3)"	"unprognostic (4.39e-2)"	"unprognostic (2.07e-1)"	"prognostic favourable (4.14e-7)"	"unprognostic (1.59e-1)"	"unprognostic (7.88e-2)"	"unprognostic (7.62e-2)"	"prognostic favourable (2.46e-4)"	20.2	17.1	14.2	24.0	30.2	8.4	21.4	16.1	19.3	22.3	18.9	20.8	27.5	18.0	24.6	18.3	16.9	24.9	25.1	12.4	16.2	14.4	24.6	23.4	19.9	21.1	33.4	15.2	35.0	20.9	35.4	26.7	28.0	22.1	20.9	15.9	16.7	17.6	30.3	22.4	30.5	23.6	17.7	22.6	23.3	15.9	12.9	30.6	18.5	25.7	12.4	20.8	22.4	22.3	10.9	7.0	34.6	8.8	8.8	12.2	6.1	4.4	11.5	13.0	8.3	19.5	13.5	44.0	11.1	32.0	10.8	8.4	4.2	5.4	15.0	4.9	13.5	5.6	8.5	17.8	8.9	6.0	7.3	7.9	12.2	7.7	17.3	5.9	15.1	19.1	21.1	14.3	28.8	12.8	10.9	8.1	12.0	9.4	4.9	5.7	7.7	7.8	6.2	5.9	12.0	13.6	13.4	2.8	10.1	12.1	10.1	8.0	10.6	4.8	20.0	4.2	11.4	6.3	5.1	18.7	13.6	8.9	10.0	7.0	15.1	12.0	8.2	9.4	9.8	6.3	9.6	10.7	11.2	9.6	7.0	10.9	12.2	8.7	34.6	8.8	8.8	6.7	9.2	6.1	14.2	30.2	16.1	19.3	16.2	14.4	33.4	15.2	22.1	30.6
XPO1	"CRM1, emb"	ENSG00000082898	"Exportin 1"	O14980	2	61477849-61538626	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Transport"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010184, HPA042933"	Supported		Enhanced	"Nucleoplasm,Nuclear membrane,Vesicles,Cytosol"		170000	170000	"Nucleoplasm, Nuclear membrane"	"Vesicles, Cytosol"	"CAB010184: AB_2215817, HPA042933: "	"unprognostic (7.34e-2)"	"unprognostic (7.04e-2)"	"unprognostic (6.37e-2)"	"unprognostic (1.67e-2)"	"unprognostic (5.61e-2)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (1.84e-5)"	"unprognostic (1.84e-1)"	"unprognostic (1.99e-3)"	"unprognostic (4.43e-1)"	"unprognostic (3.53e-3)"	"unprognostic (4.90e-2)"	"prognostic unfavourable (3.74e-4)"	"unprognostic (5.69e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.43e-1)"	"unprognostic (5.55e-2)"	20.7	27.9	36.1	28.1	39.6	21.6	35.1	41.5	36.3	28.2	23.2	19.5	26.0	16.5	35.7	35.3	26.1	36.0	20.3	20.1	33.0	19.2	19.5	22.2	22.0	34.5	42.0	19.5	45.0	34.6	33.4	27.6	30.8	33.6	25.8	24.5	18.0	20.2	29.9	34.9	29.8	25.0	28.4	32.1	24.5	21.9	32.1	39.3	51.1	28.2	16.4	35.7	26.0	57.8	6.1	5.4	12.6	5.1	6.2	5.1	2.5	38.8	34.7	47.1	35.3	21.4	28.7	34.7	43.0	27.7	45.2	38.8	46.1	29.2	57.0	30.1	29.4	33.0	71.8	29.8	66.7	34.8	26.4	56.1	35.8	28.8	15.5	56.5	38.4	16.2	22.3	35.7	39.0	36.9	64.7	33.3	41.6	20.4	47.0	24.8	54.8	26.6	42.1	53.8	34.6	20.6	29.5	37.7	20.0	41.8	35.4	20.9	28.9	27.9	24.6	42.5	48.3	34.6	42.2	27.0	44.6	82.7	26.4	48.5	38.3	12.6	5.1	5.8	5.1	5.0	4.7	4.3	3.6	4.5	3.9	6.1	4.3	3.7	12.4	6.2	3.2	5.4	3.2	2.5	36.1	39.6	41.5	36.3	33.0	19.2	42.0	19.5	33.6	39.3
XRCC1	RCC	ENSG00000073050	"X-ray repair cross complementing 1"	P18887	19	43543040-43580473	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005427, HPA006717"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"CAB005427: AB_2215661, HPA006717: AB_1858896"	"unprognostic (1.10e-2)"	"unprognostic (3.51e-3)"	"unprognostic (4.59e-1)"	"unprognostic (2.81e-2)"	"unprognostic (4.08e-1)"	"unprognostic (2.68e-2)"	"prognostic unfavourable (7.33e-5)"	"unprognostic (5.07e-2)"	"unprognostic (3.12e-1)"	"unprognostic (7.51e-2)"	"unprognostic (3.00e-2)"	"unprognostic (9.54e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.28e-1)"	"unprognostic (9.34e-3)"	"unprognostic (2.20e-2)"	"unprognostic (5.69e-2)"	16.6	17.5	20.8	18.7	22.4	22.4	16.9	23.6	22.7	20.3	17.4	19.2	18.0	13.6	23.8	18.9	20.2	24.9	16.9	15.7	16.5	16.3	16.3	10.4	16.3	22.8	15.8	21.1	34.2	22.1	19.4	32.0	19.7	15.7	16.7	12.6	21.8	16.4	19.2	18.8	20.4	14.2	18.8	15.3	19.5	17.2	25.0	17.9	38.9	21.5	12.0	21.6	18.1	17.2	14.2	13.6	20.3	14.2	10.6	17.7	12.9	25.2	20.8	24.7	22.0	12.1	11.3	13.1	14.2	16.1	18.8	20.5	13.0	18.5	19.1	18.1	12.6	13.1	14.7	16.3	11.2	21.0	15.1	24.4	20.3	15.1	12.2	13.7	21.2	13.1	11.2	23.7	11.9	16.8	15.3	19.4	16.5	20.9	28.3	24.7	7.7	9.2	23.8	15.4	10.9	16.0	20.2	20.4	13.0	17.6	17.3	8.5	16.3	33.7	9.4	24.9	19.4	7.4	17.6	21.4	20.6	14.0	20.1	12.4	27.0	20.3	14.2	16.8	12.9	13.4	14.6	14.2	16.1	17.7	13.6	12.6	14.0	12.8	16.3	10.6	8.3	10.5	16.2	12.9	20.8	22.4	23.6	22.7	16.5	16.3	15.8	21.1	15.7	17.9
XRCC2	FANCU	ENSG00000196584	"X-ray repair cross complementing 2"	O43543	7	152644779-152676165	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Fanconi anemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 12.7;testis: 11.7"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA065153			Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA065153: "	"unprognostic (9.31e-3)"	"unprognostic (8.25e-2)"	"unprognostic (1.62e-1)"	"unprognostic (5.53e-3)"	"unprognostic (9.10e-2)"	"unprognostic (2.52e-2)"	"unprognostic (3.36e-5)"	"unprognostic (9.98e-3)"	"unprognostic (5.82e-3)"	"unprognostic (4.04e-3)"	"unprognostic (1.06e-3)"	"unprognostic (2.43e-2)"	"unprognostic (1.55e-15)"	"unprognostic (4.52e-3)"	"unprognostic (3.01e-1)"	"unprognostic (5.14e-1)"	"unprognostic (1.73e-2)"	1.3	1.3	3.4	4.5	2.0	5.4	2.4	4.4	2.6	1.6	1.5	2.5	0.6	1.1	1.9	2.2	2.6	1.3	0.6	2.5	3.3	1.1	1.1	1.3	1.4	3.0	1.9	1.9	2.0	1.2	0.4	1.3	7.2	2.7	1.5	2.9	0.6	1.5	1.3	1.1	1.6	1.9	1.3	1.8	1.8	1.5	11.7	2.2	12.7	1.2	1.1	3.6	1.3	1.6	1.8	1.0	3.1	1.1	1.1	1.6	0.6	7.4	4.5	6.6	7.1	0.8	0.7	7.6	5.4	1.9	4.7	4.6	5.6	6.5	10.6	4.2	2.1	5.4	5.3	4.4	8.5	5.0	5.5	7.6	6.0	3.1	0.3	11.3	3.7	0.5	0.4	7.6	2.0	1.6	15.7	9.1	2.7	5.2	10.4	2.7	8.7	4.0	8.4	8.8	5.9	1.4	4.9	6.3	6.0	6.0	2.6	1.1	2.2	2.4	3.1	6.2	2.8	5.8	9.9	3.3	6.4	9.3	3.3	6.1	8.1	2.0	0.9	1.5	1.6	0.6	1.1	1.3	1.3	1.1	0.3	1.8	1.6	0.8	3.1	1.1	1.1	1.0	1.5	0.6	3.4	2.0	4.4	2.6	3.3	1.1	1.9	1.9	2.7	2.2
XRCC3		ENSG00000126215	"X-ray repair cross complementing 3"	O43542	14	103697609-103715504	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skin 1: 30.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA062422, HPA068953"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA062422: , HPA068953: "	"unprognostic (2.52e-2)"	"unprognostic (1.81e-3)"	"unprognostic (6.75e-2)"	"unprognostic (4.01e-2)"	"unprognostic (4.29e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.53e-4)"	"unprognostic (2.93e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.58e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.53e-2)"	"unprognostic (3.52e-7)"	"unprognostic (1.27e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.84e-2)"	"unprognostic (3.72e-2)"	5.4	3.3	8.1	15.1	7.3	22.0	5.4	11.3	8.0	5.5	5.8	6.5	4.6	5.4	6.4	5.1	8.5	6.1	5.3	4.4	6.9	2.6	4.1	3.8	6.0	11.1	7.3	5.4	7.0	7.8	2.1	4.4	5.6	6.8	7.7	6.2	5.3	11.1	2.9	8.9	30.3	7.0	2.3	5.3	13.5	6.8	10.1	5.0	17.6	5.6	6.7	14.2	5.3	9.0	4.5	2.0	3.0	3.3	2.5	3.9	3.6	12.6	23.1	12.7	15.8	1.1	3.3	23.1	14.0	4.6	19.8	21.4	12.8	20.3	20.1	12.1	2.9	20.2	13.9	20.8	12.2	12.4	14.4	19.6	11.3	11.8	2.0	17.6	12.8	2.5	2.1	17.4	11.1	8.1	12.1	12.4	10.2	27.6	30.4	13.9	11.0	16.5	24.8	18.4	7.9	4.4	17.4	12.6	10.4	16.5	8.9	5.7	14.1	13.7	6.9	10.3	12.1	32.7	15.3	10.6	9.6	25.0	6.4	14.6	15.8	2.6	1.6	3.0	3.8	3.3	3.9	4.5	3.3	3.2	2.0	4.0	3.3	2.2	1.2	2.5	2.5	1.4	2.5	3.6	8.1	7.3	11.3	8.0	6.9	2.6	7.3	5.4	6.8	5.0
XRCC4		ENSG00000152422	"X-ray repair cross complementing 4"	Q13426	5	83077498-83353787	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"		"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RH-30: 36.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA006801, HPA051538"	Supported		Enhanced	Nucleoplasm				Nucleoplasm		"HPA006801: AB_1858899, HPA051538: "	"prognostic unfavourable (1.80e-5)"	"unprognostic (3.05e-2)"	"unprognostic (5.12e-2)"	"unprognostic (3.91e-3)"	"unprognostic (1.55e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.44e-3)"	"unprognostic (2.23e-2)"	"unprognostic (2.19e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.38e-2)"	"unprognostic (8.24e-2)"	"unprognostic (4.46e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.34e-1)"	"unprognostic (6.91e-2)"	8.8	9.4	8.1	12.9	10.1	5.9	9.4	4.8	10.2	5.3	9.1	7.2	5.4	11.4	8.3	7.7	10.1	6.2	8.1	13.0	8.5	6.6	12.2	8.1	7.6	11.7	8.7	5.8	5.8	4.9	4.0	9.5	11.3	11.5	6.3	8.8	3.7	7.2	7.1	5.3	5.7	15.4	5.9	9.5	14.6	6.4	12.5	8.8	20.6	7.4	9.7	12.9	8.7	5.8	7.4	10.3	12.3	19.1	11.5	7.0	6.8	8.5	6.7	8.3	7.3	4.7	6.9	7.8	8.1	6.7	9.0	10.7	5.7	12.7	12.2	6.1	6.5	7.5	5.5	18.4	14.9	5.6	6.8	6.2	5.1	7.2	3.2	7.0	10.2	4.7	8.4	11.7	6.5	7.2	4.5	5.7	10.3	6.8	12.8	9.0	4.6	10.0	10.7	36.4	12.2	8.3	3.9	5.4	7.0	5.1	3.8	10.3	7.7	11.4	4.5	4.9	10.5	5.2	10.8	4.6	6.8	15.0	8.8	12.6	7.9	12.1	13.5	9.2	4.7	19.1	4.9	7.4	5.2	5.2	10.3	6.3	7.0	5.6	12.3	11.5	17.8	7.6	5.6	6.8	8.1	10.1	4.8	10.2	8.5	6.6	8.7	5.8	11.5	8.8
XRCC5	"KARP-1, KU80, Ku86, KUB2"	ENSG00000079246	"X-ray repair cross complementing 5"	P13010	2	216107464-216206303	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004468, HPA025813, HPA064685"	Supported		Enhanced	Nucleoplasm		140000	140000	Nucleoplasm		"CAB004468: AB_672929, HPA025813: AB_1858901, HPA064685: "	"unprognostic (4.23e-2)"	"unprognostic (1.75e-1)"	"unprognostic (9.07e-3)"	"unprognostic (3.44e-3)"	"unprognostic (2.44e-2)"	"unprognostic (7.00e-2)"	"prognostic unfavourable (2.10e-7)"	"unprognostic (4.42e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.38e-3)"	"unprognostic (1.96e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.30e-1)"	"unprognostic (2.88e-2)"	"unprognostic (3.58e-2)"	"unprognostic (6.01e-2)"	53.7	47.6	35.2	47.0	56.8	47.0	56.6	47.0	59.7	51.2	44.3	45.2	39.5	39.5	62.9	43.8	61.1	51.7	41.2	43.7	38.6	36.4	62.4	67.1	43.8	56.2	41.8	45.2	58.7	46.7	63.0	56.1	54.3	58.3	46.0	53.5	36.1	49.4	47.9	65.0	54.7	46.5	49.7	44.2	60.5	47.9	36.9	38.0	112.4	64.2	55.6	65.5	56.5	47.7	38.6	51.5	60.9	61.3	50.4	54.0	82.3	38.4	32.7	73.5	39.3	32.7	37.5	44.4	45.9	47.5	53.1	57.3	70.2	38.4	37.3	37.5	40.1	34.5	72.2	55.6	81.9	35.5	49.7	80.9	51.7	65.6	40.5	72.0	39.6	34.1	29.7	62.3	27.3	62.5	51.0	34.1	69.1	37.1	80.4	36.3	85.3	29.2	70.8	65.0	30.8	57.1	43.9	64.4	54.4	36.9	27.4	33.1	33.6	54.1	45.0	50.0	42.1	32.6	51.9	41.3	50.1	83.3	38.9	56.6	49.0	60.9	51.5	51.8	50.2	54.0	54.0	38.6	49.1	50.9	51.5	37.5	49.9	49.8	59.4	50.4	61.3	31.4	49.3	82.3	35.2	56.8	47.0	59.7	38.6	36.4	41.8	45.2	58.3	38.0
XRCC6	"D22S671, D22S731, G22P1, KU70, ML8"	ENSG00000196419	"X-ray repair cross complementing 6"	P12956	22	41621119-41664048	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding, Helicase, Hydrolase, Lyase, Multifunctional enzyme"	"Cancer-related genes, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004254, HPA047549, HPA062226"	Enhanced		Enhanced	Nucleoplasm		24000	24000	Nucleoplasm		"CAB004254: AB_628453, HPA047549: AB_2680085, HPA062226: AB_2684716"	"unprognostic (5.55e-2)"	"unprognostic (2.39e-2)"	"unprognostic (1.82e-3)"	"unprognostic (2.39e-1)"	"unprognostic (2.47e-2)"	"unprognostic (9.17e-2)"	"unprognostic (1.16e-3)"	"unprognostic (2.32e-2)"	"unprognostic (2.21e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.89e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.06e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.28e-1)"	"unprognostic (4.77e-2)"	"unprognostic (7.95e-2)"	49.2	67.9	44.4	47.8	54.3	62.3	49.7	44.5	57.5	51.2	51.3	39.5	44.1	44.7	59.9	41.0	68.6	52.4	35.2	63.0	59.3	39.2	50.1	61.6	48.1	66.9	37.2	50.6	61.5	44.0	48.4	53.1	63.5	51.5	46.1	56.4	39.7	59.2	52.1	100.9	58.6	46.9	58.2	68.4	54.4	50.8	113.6	34.2	83.8	49.5	59.2	70.9	51.4	50.1	51.9	63.7	42.7	57.0	46.6	62.6	96.7	64.2	46.4	64.6	56.2	39.4	35.1	50.9	46.9	56.4	98.6	81.3	68.1	40.8	103.7	39.4	56.8	48.4	89.2	58.7	99.5	57.6	112.0	55.6	56.8	67.5	35.7	131.2	64.4	31.8	40.5	61.5	34.0	61.2	54.2	44.0	63.4	70.7	68.2	49.0	59.3	55.0	78.1	68.0	82.3	55.7	48.2	30.1	21.5	76.2	40.7	54.1	46.7	53.1	43.2	49.3	68.6	43.3	61.5	43.7	76.3	105.7	46.2	52.1	58.2	24.5	50.1	42.7	51.1	57.0	53.5	51.9	56.8	55.8	63.7	48.2	62.6	55.8	13.5	46.6	55.5	37.7	61.8	96.7	44.4	54.3	44.5	57.5	59.3	39.2	37.2	50.6	51.5	34.2
YBX1	"BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1"	ENSG00000065978	"Y-box binding protein 1"	P67809	1	42682427-42702349	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding, Mitogen, Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"skeletal muscle: 128.1;testis: 426.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005875, HPA040304, HPA057159"	Approved		Enhanced	Vesicles,Cytosol	"Intracellular and membrane"	870000	870000	Cytosol	Vesicles	"CAB005875: AB_2219278, HPA040304: AB_10795364, HPA057159: "	"unprognostic (8.59e-2)"	"unprognostic (5.16e-2)"	"unprognostic (9.27e-3)"	"unprognostic (2.68e-3)"	"unprognostic (7.76e-2)"	"unprognostic (8.03e-3)"	"prognostic unfavourable (9.87e-10)"	"unprognostic (2.80e-2)"	"unprognostic (2.31e-2)"	"unprognostic (2.79e-3)"	"unprognostic (7.51e-2)"	"unprognostic (5.52e-2)"	"prognostic unfavourable (3.59e-7)"	"unprognostic (3.66e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.94e-2)"	"unprognostic (3.25e-1)"	47.5	20.6	15.6	36.4	18.4	57.6	35.2	13.7	14.4	27.9	44.5	21.2	20.1	25.6	35.1	36.4	40.0	25.6	32.5	57.8	15.2	12.3	33.1	38.1	35.3	49.8	17.6	13.2	30.2	36.7	9.4	12.2	26.1	15.5	32.0	33.1	31.1	26.6	23.0	128.1	22.5	27.1	50.0	21.0	47.9	33.2	426.5	15.9	53.2	31.4	64.1	37.2	39.4	41.0	23.5	26.9	21.8	40.5	11.6	23.0	10.6	91.5	54.0	86.5	86.7	84.3	76.3	77.1	67.6	63.0	94.0	73.8	74.0	85.6	116.2	70.9	67.8	55.5	97.4	102.6	93.4	62.0	90.3	118.6	107.3	94.9	68.0	159.2	88.9	70.2	88.4	93.8	116.2	77.7	123.3	50.7	87.5	57.7	179.8	155.0	195.0	73.0	108.8	155.5	125.6	93.1	67.8	119.7	84.4	66.3	89.8	126.2	29.9	317.1	60.6	66.8	114.0	90.5	137.5	74.3	93.1	132.3	63.2	119.4	70.8	4.3	18.1	21.8	16.3	37.8	19.9	23.5	19.5	15.8	26.9	20.1	16.8	17.2	3.3	11.6	40.5	20.9	23.0	10.6	15.6	18.4	13.7	14.4	15.2	12.3	17.6	13.2	15.5	15.9
YWHAB	YWHAA	ENSG00000166913	"Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta"	P31946	20	44885676-44908532	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003759, HPA007925, HPA011212, HPA061603"	Enhanced		Supported	Nucleoplasm,Nucleoli,Cytosol		210000000	210000000	Cytosol	"Nucleoplasm, Nucleoli"	"CAB003759: AB_289588, HPA007925: AB_1844340, HPA011212: AB_1844334, HPA061603: "	"prognostic unfavourable (9.18e-4)"	"unprognostic (1.48e-1)"	"unprognostic (9.06e-2)"	"prognostic unfavourable (5.46e-4)"	"unprognostic (3.80e-1)"	"prognostic unfavourable (6.14e-4)"	"prognostic unfavourable (1.91e-6)"	"prognostic unfavourable (6.01e-4)"	"unprognostic (8.92e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.53e-2)"	"unprognostic (2.35e-1)"	"prognostic favourable (2.52e-5)"	"unprognostic (6.72e-2)"	"unprognostic (2.40e-1)"	"unprognostic (6.60e-3)"	"unprognostic (8.59e-2)"	39.3	38.6	65.5	39.4	79.2	28.6	33.0	60.1	87.9	34.0	47.5	27.7	28.7	37.9	35.2	26.4	48.1	30.2	29.6	40.3	68.7	63.4	47.3	36.5	37.4	46.8	49.8	76.2	25.8	18.9	41.1	18.4	36.7	50.1	31.4	53.4	22.9	30.7	43.2	28.3	38.4	39.3	43.3	38.4	53.7	36.7	16.8	33.6	48.2	36.1	31.8	60.2	41.2	34.9	30.9	41.9	37.3	58.4	26.8	43.5	26.6	51.8	39.3	31.7	30.4	52.8	46.7	43.0	47.2	46.0	58.2	51.1	81.8	58.8	55.4	49.5	62.3	55.2	44.7	87.8	69.6	21.2	27.3	41.2	34.6	48.5	35.0	66.7	39.9	36.5	65.7	45.6	58.9	58.2	44.4	26.8	59.7	61.3	52.0	55.0	29.9	61.2	40.9	46.0	43.0	62.3	58.0	33.9	36.1	80.0	85.6	55.1	62.3	64.2	66.0	90.5	46.5	51.0	48.0	17.9	32.6	50.8	66.1	44.7	46.0	34.8	40.1	34.4	29.7	52.2	30.2	30.9	37.7	36.3	41.9	28.6	30.8	36.6	37.3	26.8	58.4	26.5	43.5	26.6	65.5	79.2	60.1	87.9	68.7	63.4	49.8	76.2	50.1	33.6
YWHAE	FLJ45465	ENSG00000108953	"Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon"	P62258	17	1344272-1400378	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008445, CAB016200, CAB021109, CAB047350, HPA061603"	Approved		Supported	Nucleoplasm,Nucleoli,Cytosol		160000000	160000000	Cytosol	"Nucleoplasm, Nucleoli"	"CAB016200: AB_626619, CAB021109: AB_10060396, CAB047350: , HPA008445: AB_1844336, HPA061603: "	"unprognostic (1.29e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.99e-2)"	"prognostic favourable (6.48e-6)"	"unprognostic (1.59e-1)"	"unprognostic (2.91e-2)"	"unprognostic (2.73e-2)"	"unprognostic (4.77e-3)"	"unprognostic (4.53e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.92e-3)"	"unprognostic (8.33e-2)"	"unprognostic (2.57e-1)"	"unprognostic (3.24e-2)"	"unprognostic (8.94e-2)"	55.2	54.3	107.5	35.3	87.1	32.7	37.3	71.5	118.4	28.4	40.2	60.9	23.8	40.2	35.9	54.1	43.1	44.2	23.4	57.7	92.3	81.9	64.5	50.9	32.8	25.4	94.1	77.9	40.2	40.2	41.0	37.9	45.1	73.7	35.0	42.5	27.9	42.4	27.7	135.9	36.8	36.2	32.2	101.1	26.2	38.5	46.0	53.6	30.9	47.5	36.5	37.2	31.6	32.1	19.2	41.5	17.2	36.2	15.0	23.3	31.5	77.8	58.2	70.5	59.3	31.2	36.1	67.8	50.4	29.7	45.0	34.9	104.0	32.0	52.9	59.2	41.7	54.1	59.7	50.9	63.8	36.5	111.3	36.9	48.6	44.5	37.3	35.3	37.8	32.7	37.6	45.0	69.0	54.1	42.3	38.2	57.8	37.9	46.7	28.2	64.6	37.8	56.8	33.3	37.5	45.8	45.1	39.3	59.7	60.6	24.9	39.4	47.2	32.7	51.1	43.7	37.1	55.1	88.9	24.0	44.3	44.4	52.4	42.3	63.1	17.2	31.8	8.6	12.4	36.2	15.6	19.2	18.7	13.9	41.5	16.1	17.0	14.3	10.8	15.0	30.9	28.8	23.3	31.5	107.5	87.1	71.5	90.2	92.3	81.9	94.1	77.9	73.7	53.6
YWHAH	YWHA1	ENSG00000128245	"Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta"	Q04917	22	31944461-31957603	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"brain: 154.3"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025918, HPA061603"	Uncertain		Approved	Nucleoli,Cytosol		130000000	130000000	Cytosol	Nucleoli	"CAB025918: , HPA061603: "	"unprognostic (3.77e-1)"	"unprognostic (6.13e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.73e-1)"	"prognostic unfavourable (1.59e-5)"	"unprognostic (8.62e-2)"	"unprognostic (1.63e-1)"	"unprognostic (4.51e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.59e-1)"	"unprognostic (5.60e-2)"	"unprognostic (7.00e-2)"	"unprognostic (6.81e-2)"	21.5	18.6	87.9	20.6	47.4	16.3	19.3	41.9	154.3	13.7	24.4	10.0	4.3	17.2	13.1	14.1	14.0	16.4	18.6	15.2	78.8	59.1	11.7	11.5	25.0	13.5	35.5	101.6	10.0	16.7	5.2	10.4	22.4	49.5	12.3	20.1	6.8	9.9	15.6	13.9	9.9	17.4	25.9	19.4	12.8	26.9	3.7	9.1	6.3	10.5	5.5	15.1	18.5	10.6	8.1	16.6	14.9	14.4	17.7	12.8	9.6	67.9	27.2	30.4	17.7	18.5	17.1	19.3	66.1	32.7	38.1	43.6	28.8	23.7	40.1	16.1	60.6	32.9	36.4	36.3	36.0	35.5	31.7	23.7	21.4	25.7	18.7	76.3	26.5	15.5	19.4	32.1	22.9	31.1	32.7	29.4	29.0	27.4	23.1	35.1	36.2	29.8	33.2	41.9	21.3	24.0	29.4	65.4	21.5	37.6	26.3	23.5	15.0	18.9	49.7	38.5	38.5	28.2	41.9	16.4	25.3	50.2	27.9	30.8	33.8	7.8	14.4	14.9	5.7	11.8	8.1	8.1	7.0	8.1	16.6	7.6	2.8	3.6	8.7	17.7	12.2	4.5	12.8	9.6	87.9	47.4	41.9	126.3	78.8	59.1	35.5	101.6	49.5	9.1
ZBTB16	"PLZF, ZNF145"	ENSG00000109906	"Zinc finger and BTB domain containing 16"	Q05516	11	114059593-114250676	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"ASC diff: 29.9;ASC TERT1: 17.3;HEL: 17.8;HHSteC: 12.9;HSkMC: 13.8;hTCEpi: 12.8;hTERT-HME1: 11.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 13.7;MAIT T-cell: 23.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001499, CAB004540"	Uncertain									"CAB004540: AB_2218941, HPA001499: AB_1079640"	"unprognostic (2.21e-1)"	"unprognostic (2.17e-1)"	"unprognostic (7.30e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.53e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.25e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.09e-1)"	"unprognostic (8.79e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"prognostic favourable (2.21e-4)"	"unprognostic (2.57e-3)"	"unprognostic (2.67e-1)"	"unprognostic (1.00e-1)"	"unprognostic (5.90e-2)"	38.0	16.0	10.0	6.3	14.6	6.3	20.5	18.0	22.8	18.7	14.9	6.7	15.7	1.8	19.6	8.5	24.0	17.3	11.8	25.5	11.8	4.5	8.3	9.3	17.3	6.2	16.1	8.9	41.6	51.5	14.5	9.5	8.3	12.6	10.0	3.0	7.8	10.4	15.1	58.8	17.5	10.4	15.1	10.8	11.1	12.8	4.6	14.2	0.0	24.1	10.9	2.5	21.9	27.5	6.9	0.0	0.6	2.4	5.5	23.5	2.7	0.0	0.0	6.1	0.0	29.9	17.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	17.8	0.0	0.0	12.9	0.3	0.2	13.8	12.8	0.0	11.2	2.1	0.0	0.0	0.1	0.0	1.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.4	0.6	13.7	0.6	23.5	0.1	0.6	2.0	0.0	6.9	0.8	0.4	0.2	5.5	0.5	0.0	0.2	2.7	10.0	14.6	18.0	22.8	11.8	4.5	16.1	8.9	12.6	14.2
ZFHX3	"ATBF1, ZNF927"	ENSG00000140836	"Zinc finger homeobox 3"	Q15911	16	72782885-73891871	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA059353	Uncertain									"HPA059353: "	"prognostic unfavourable (1.55e-4)"	"unprognostic (3.57e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.03e-2)"	"unprognostic (2.81e-2)"	"unprognostic (3.12e-1)"	"unprognostic (4.24e-2)"	"unprognostic (6.36e-2)"	"unprognostic (9.94e-3)"	"unprognostic (2.85e-1)"	"unprognostic (1.06e-1)"	"unprognostic (4.16e-2)"	"prognostic favourable (1.37e-5)"	"unprognostic (6.76e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.15e-2)"	7.9	6.0	2.5	2.3	4.6	1.1	11.3	1.5	4.1	7.5	7.7	5.4	14.5	2.0	7.4	7.3	4.5	4.9	18.2	4.9	4.3	4.8	4.4	6.5	6.1	1.4	4.0	2.6	4.4	5.7	23.8	6.3	8.1	5.5	12.0	3.5	10.5	5.0	19.5	16.9	3.6	3.6	15.5	9.7	3.9	5.0	2.3	5.2	0.5	10.8	4.0	1.0	16.7	14.7	0.8	1.0	0.2	1.6	2.5	0.1	0.2	4.4	7.8	12.7	10.5	4.7	6.0	13.1	3.4	3.7	2.1	2.4	8.8	2.5	1.9	5.9	6.3	3.1	8.0	4.0	3.0	7.7	1.9	0.3	10.6	12.6	4.4	1.3	3.2	2.2	2.4	6.3	5.7	4.0	0.9	0.5	5.4	9.1	0.4	2.6	2.2	1.3	5.8	3.4	0.6	3.5	7.4	9.5	3.4	5.9	1.8	4.2	2.6	0.6	8.7	5.3	6.3	5.6	4.4	4.9	1.6	1.3	2.5	1.2	4.0	0.2	1.6	0.2	0.1	0.9	0.1	0.5	0.0	0.0	0.7	0.8	0.0	0.1	0.2	2.5	1.1	1.0	0.1	0.2	2.5	4.6	1.5	4.1	4.3	4.8	4.0	2.6	5.5	5.2
ZFP36L1	"Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B"	ENSG00000185650	"ZFP36 ring finger protein like 1"	Q07352	14	68787660-68796253	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA transport, Transport"	"Developmental protein, DNA-binding, Ribonucleoprotein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"neutrophil: 212.7"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 212.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001301	Uncertain									"HPA001301: AB_1080644"	"unprognostic (1.18e-2)"	"unprognostic (2.64e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.58e-1)"	"unprognostic (7.00e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.64e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.17e-2)"	"unprognostic (3.81e-3)"	"unprognostic (1.13e-3)"	"unprognostic (1.30e-1)"	"unprognostic (1.11e-2)"	"unprognostic (6.45e-3)"	"unprognostic (5.77e-2)"	"unprognostic (2.97e-1)"	"unprognostic (5.68e-2)"	59.0	22.4	40.2	42.4	35.0	14.2	89.9	16.3	31.0	91.5	60.2	49.6	24.8	26.0	90.6	37.5	66.8	59.9	36.5	36.2	45.1	15.3	34.6	46.0	45.6	39.0	32.7	16.7	121.7	47.1	63.4	14.8	62.7	44.9	65.3	21.9	29.9	60.3	43.7	31.6	90.2	28.5	91.2	47.3	33.9	42.2	26.9	39.4	22.1	43.3	22.7	57.1	81.2	93.2	37.0	8.7	212.7	17.7	10.4	16.1	14.4	38.8	37.3	15.5	22.4	39.3	31.6	34.3	16.5	27.4	9.6	12.1	16.3	25.8	9.4	10.0	28.4	18.0	1.4	51.0	11.8	4.4	2.2	3.4	18.7	11.5	22.4	0.5	4.3	26.6	65.5	11.7	76.7	19.3	9.6	18.5	51.1	9.2	1.4	1.7	12.9	5.4	24.9	20.8	2.8	35.3	28.0	0.1	0.4	18.6	26.8	13.8	24.6	0.4	44.1	28.6	21.0	22.6	15.7	10.4	5.2	6.5	35.5	0.2	10.8	14.2	17.7	0.2	16.1	17.2	15.0	19.7	12.9	11.2	8.7	37.0	14.1	12.4	212.7	10.4	11.4	1.1	12.0	14.4	40.2	35.0	16.3	31.0	45.1	15.3	32.7	16.7	44.9	39.4
ZFP36L2	"BRF2, ERF2, RNF162C, TIS11D"	ENSG00000152518	"ZFP36 ring finger protein like 2"	P47974	2	43222402-43226609	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Developmental protein, DNA-binding, Ribonucleoprotein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA047428	Approved									"HPA047428: AB_10963428"	"unprognostic (2.07e-2)"	"unprognostic (1.81e-2)"	"unprognostic (9.77e-2)"	"unprognostic (6.10e-2)"	"unprognostic (9.66e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.41e-1)"	"unprognostic (7.62e-3)"	"unprognostic (2.04e-1)"	"unprognostic (4.50e-2)"	"unprognostic (9.67e-3)"	"unprognostic (1.65e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.50e-1)"	"unprognostic (4.52e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.98e-2)"	57.9	32.6	10.1	65.3	30.1	47.3	104.4	3.6	16.8	43.9	41.2	20.8	24.8	31.4	35.4	32.5	35.4	40.6	78.8	36.3	18.1	9.1	23.1	26.1	74.0	112.5	15.4	11.0	63.7	29.5	6.6	13.7	8.6	70.6	39.2	38.4	27.9	31.7	49.0	33.3	64.9	52.2	40.7	74.2	44.2	34.4	14.8	12.8	76.5	73.3	32.6	39.8	50.1	43.9	11.2	22.0	32.5	17.7	22.4	28.6	10.1	7.6	3.7	3.7	2.0	47.3	48.5	1.5	11.2	20.4	4.8	3.7	13.1	3.6	5.5	8.5	12.9	14.5	3.9	19.5	4.1	9.9	8.3	8.9	1.4	13.8	14.1	19.4	7.8	34.0	32.0	4.9	32.1	8.5	8.9	22.1	4.7	40.7	22.9	40.5	5.7	6.6	17.2	2.8	31.9	8.2	11.1	3.3	8.4	2.1	13.0	6.7	2.2	32.2	4.0	13.1	5.7	11.0	6.8	18.7	5.1	8.3	4.4	48.8	6.0	7.2	17.7	32.5	21.6	14.7	21.2	8.1	21.3	28.6	22.0	11.2	16.2	15.5	27.5	22.4	11.5	9.5	7.8	10.1	10.1	30.1	3.6	16.8	18.1	9.1	15.4	11.0	70.6	12.8
ZMYM2	"FIM, MYM, RAMP, ZNF198"	ENSG00000121741	"Zinc finger MYM-type containing 2"	Q9UBW7	13	19958670-20091829	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031765	Approved		Approved	"Nucleoplasm,Endoplasmic reticulum"				"Nucleoplasm, Endoplasmic reticulum"		"HPA031765: AB_10601927"	"unprognostic (2.96e-1)"	"unprognostic (3.42e-3)"	"unprognostic (1.85e-1)"	"unprognostic (1.69e-1)"	"unprognostic (7.71e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.66e-3)"	"unprognostic (1.16e-1)"	"unprognostic (6.78e-2)"	"unprognostic (5.88e-2)"	"unprognostic (4.60e-2)"	"unprognostic (2.80e-2)"	"unprognostic (6.65e-3)"	"unprognostic (2.05e-1)"	"unprognostic (8.74e-2)"	"unprognostic (1.06e-1)"	"prognostic favourable (6.07e-4)"	15.0	17.3	15.9	18.1	23.3	22.2	16.1	23.9	26.8	18.3	16.8	14.0	13.7	13.3	20.0	14.0	18.5	16.1	15.7	17.1	14.4	12.0	17.3	13.7	15.4	14.2	12.9	20.2	21.7	16.2	17.1	32.1	14.0	23.2	19.4	13.8	13.8	18.2	17.6	19.7	18.3	14.5	15.3	16.2	16.3	16.0	44.5	16.5	38.0	24.3	10.4	19.7	19.5	17.2	5.5	6.3	7.4	5.9	5.4	7.9	3.5	6.3	5.7	22.0	9.5	9.7	10.5	10.5	6.6	10.6	8.6	10.3	8.8	13.1	15.2	6.1	9.3	10.2	16.2	7.1	11.7	6.1	4.6	26.9	8.6	4.4	9.8	22.7	8.2	10.3	13.3	6.8	7.1	14.6	10.2	10.8	11.8	9.0	21.9	6.4	20.4	3.6	24.5	24.0	7.1	6.7	9.3	25.8	25.7	12.8	9.2	12.0	12.2	16.2	8.5	4.3	6.8	5.2	3.5	8.6	6.7	15.7	3.6	5.3	10.2	0.2	5.2	4.0	5.5	5.9	6.7	5.5	7.5	5.6	6.1	4.5	7.9	6.9	7.4	5.4	4.9	6.3	5.4	3.5	15.9	23.3	23.9	26.8	14.4	12.0	12.9	20.2	23.2	16.5
ZNF132	pHZ-12	ENSG00000131849	"Zinc finger protein 132"	P52740	19	58432814-58440222	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA008726	Uncertain		Approved	"Vesicles,Intermediate filaments"				Vesicles	"Intermediate filaments"	"HPA008726: AB_1080664"	"unprognostic (4.86e-2)"	"unprognostic (2.03e-1)"	"unprognostic (6.79e-3)"	"unprognostic (3.06e-2)"	"unprognostic (8.16e-2)"	"unprognostic (4.78e-2)"	"unprognostic (4.02e-2)"	"unprognostic (2.32e-3)"	"unprognostic (5.00e-2)"	"unprognostic (1.29e-1)"	"prognostic favourable (1.92e-4)"	"unprognostic (4.51e-1)"	"prognostic favourable (7.26e-13)"	"unprognostic (2.70e-1)"	"unprognostic (7.65e-2)"	"unprognostic (6.09e-2)"	"unprognostic (3.72e-1)"	2.9	4.7	4.0	2.5	5.9	0.8	5.1	11.8	8.5	5.9	4.1	6.6	4.5	2.5	4.2	7.2	3.5	7.9	4.7	5.9	6.0	4.5	6.2	2.1	3.6	3.3	4.4	5.5	7.6	4.3	15.3	12.1	3.7	5.9	6.1	2.4	5.4	5.8	6.7	3.7	4.7	2.6	5.9	4.2	4.5	3.6	7.2	6.0	3.1	10.8	2.8	4.3	5.7	6.3	3.9	2.9	2.0	2.6	2.6	5.7	2.1	1.7	2.1	4.8	1.7	5.6	4.6	0.2	3.6	4.5	3.0	2.7	0.1	1.4	4.5	0.3	4.4	1.8	0.0	5.4	2.1	0.7	8.2	0.8	1.4	1.0	5.0	1.7	3.0	5.1	1.9	5.1	3.2	2.6	0.7	0.5	5.6	0.6	1.0	0.1	4.9	1.7	0.6	1.1	1.3	1.8	2.0	4.3	4.4	1.4	1.3	1.5	0.3	4.4	3.3	3.1	0.4	0.8	0.7	5.9	1.1	0.0	1.5	0.1	1.9	0.0	1.9	2.0	2.2	2.2	5.7	2.9	2.9	1.2	2.9	3.9	4.6	3.7	0.2	2.6	2.6	2.4	2.5	2.1	4.0	5.9	11.8	8.5	6.0	4.5	4.4	5.5	5.9	6.0
ZNF180	HHZ168	ENSG00000167384	"Zinc finger protein 180"	Q9UJW8	19	44474428-44500524	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA028979, HPA028980"	Uncertain		Approved	Nucleoplasm				Nucleoplasm		"HPA028979: AB_10600328, HPA028980: AB_10611524"	"unprognostic (2.25e-1)"	"unprognostic (5.53e-2)"	"unprognostic (8.34e-3)"	"unprognostic (1.37e-2)"	"unprognostic (1.82e-1)"	"unprognostic (7.13e-3)"	"unprognostic (1.73e-1)"	"unprognostic (2.16e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.33e-1)"	"unprognostic (1.65e-2)"	"unprognostic (1.71e-1)"	"unprognostic (2.37e-2)"	"unprognostic (6.49e-2)"	"unprognostic (2.21e-1)"	"unprognostic (2.02e-2)"	"unprognostic (3.38e-3)"	8.2	8.6	7.3	10.0	9.1	6.7	10.5	13.4	8.7	10.3	7.7	7.1	10.4	8.8	11.1	6.3	7.5	9.7	8.0	5.9	6.8	5.6	9.4	9.5	7.0	10.7	6.9	5.1	11.9	8.0	16.4	13.7	7.5	8.7	12.3	8.7	6.7	7.4	11.6	6.0	8.8	10.7	7.7	6.6	12.8	7.7	8.1	8.3	17.7	11.2	7.2	8.6	8.2	8.7	6.0	3.8	6.5	3.4	3.6	9.6	3.0	8.1	2.3	10.1	7.0	2.1	4.1	6.8	4.2	4.3	6.7	8.1	4.4	1.6	1.0	5.2	5.7	2.1	5.8	9.9	8.4	8.4	4.3	10.0	2.7	2.9	2.2	12.4	6.0	4.4	3.9	4.6	5.6	4.9	4.9	6.9	5.3	1.6	6.3	4.1	6.1	4.6	4.4	5.2	5.4	6.7	14.7	8.5	6.7	7.9	7.2	4.4	4.3	10.3	3.9	12.2	5.3	1.4	6.7	1.9	5.6	3.8	4.0	5.4	6.0	5.8	3.4	6.5	3.5	2.4	4.6	5.4	4.5	5.5	3.8	6.0	5.8	5.4	2.9	3.6	2.7	1.8	9.6	3.0	7.3	9.1	13.4	8.7	6.8	5.6	6.9	5.1	8.7	8.3
ZNF300		ENSG00000145908	"Zinc finger protein 300"	Q96RE9	5	150894392-150904983	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 17.2;HeLa: 18.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 3.8"	"Low lineage specificity"	"Detected in all"											"HPA028975, HPA051777"	Uncertain		Supported	"Nucleoplasm,Nucleoli,Nuclear bodies"				"Nucleoplasm, Nucleoli"	"Nuclear bodies"	"HPA028975: , HPA051777: "	"unprognostic (5.06e-2)"	"unprognostic (1.05e-2)"	"unprognostic (8.41e-2)"	"unprognostic (2.31e-1)"	"unprognostic (7.61e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.23e-3)"	"unprognostic (4.21e-2)"	"unprognostic (3.23e-1)"	"unprognostic (8.62e-2)"	"unprognostic (6.85e-3)"	"prognostic unfavourable (3.21e-6)"	"unprognostic (3.62e-3)"	"unprognostic (2.99e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.50e-2)"	4.5	1.3	4.8	4.0	12.0	3.6	7.2	12.5	6.4	7.4	4.3	5.4	4.1	4.1	11.7	5.3	7.5	5.4	5.4	4.0	7.5	3.2	7.3	1.5	3.0	4.4	8.2	2.4	16.6	7.3	1.0	7.3	2.4	7.4	7.0	4.4	3.6	3.8	3.9	1.5	6.9	5.8	6.4	9.2	5.1	7.1	14.9	9.1	1.5	9.3	2.7	4.4	5.5	6.2	3.8	1.2	1.1	1.5	1.7	1.0	0.8	1.2	2.8	17.2	0.0	1.5	3.6	0.0	4.2	3.3	3.7	5.4	1.4	2.1	0.0	3.7	3.5	2.5	0.0	9.6	5.8	0.0	5.6	0.0	18.9	2.2	3.1	0.1	0.0	5.5	3.0	7.7	9.1	6.3	0.0	9.1	3.6	0.0	0.0	0.8	16.5	0.0	0.0	2.5	4.9	2.7	3.1	9.7	16.1	9.9	8.6	5.7	5.7	0.0	2.7	5.0	2.1	3.6	7.6	0.3	0.1	0.0	0.5	0.1	10.3	0.0	0.6	1.1	0.7	1.5	0.1	0.9	1.0	0.0	1.2	3.8	0.7	0.4	0.2	1.7	0.1	0.1	0.0	0.8	4.8	12.0	12.5	6.4	7.5	3.2	8.2	2.4	7.4	9.1
ZNF331	"RITA, ZNF361, ZNF463"	ENSG00000130844	"Zinc finger protein 331"	Q9NQX6	19	53520981-53580269	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 66.4;ovary: 86.4"	"Cell line enhanced"	"Detected in many"		"HEK 293: 36.6;RT4: 28.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA063157			Approved	Nucleoplasm				Nucleoplasm		"HPA063157: "	"unprognostic (2.19e-1)"	"unprognostic (1.79e-1)"	"unprognostic (5.18e-2)"	"unprognostic (1.55e-2)"	"unprognostic (4.24e-1)"	"unprognostic (8.16e-2)"	"unprognostic (7.62e-3)"	"unprognostic (3.25e-2)"	"unprognostic (1.84e-2)"	"unprognostic (4.40e-2)"	"unprognostic (5.68e-3)"	"unprognostic (2.69e-1)"	"unprognostic (4.73e-2)"	"prognostic unfavourable (4.79e-4)"	"unprognostic (2.08e-1)"	"prognostic unfavourable (7.43e-4)"	"unprognostic (6.74e-2)"	19.1	66.4	6.8	9.0	8.2	18.6	10.5	11.4	9.5	9.4	5.3	8.4	8.9	2.1	9.5	11.6	4.9	19.5	23.8	15.5	5.1	7.7	6.6	6.1	15.6	4.0	6.8	5.5	86.4	9.9	11.3	29.0	23.3	7.2	10.2	4.2	9.9	4.7	31.5	6.3	5.2	4.8	8.5	9.1	4.5	6.3	8.1	6.0	3.8	7.8	4.4	4.8	25.7	9.2	8.1	4.1	6.5	7.4	4.6	14.7	5.2	0.1	5.1	10.3	11.9	8.0	6.0	17.3	7.4	6.5	5.6	10.3	5.5	2.6	4.1	1.9	4.3	3.0	7.5	5.5	10.1	0.0	36.6	5.2	8.7	3.4	5.9	3.2	7.2	6.0	3.6	6.2	3.0	2.5	0.2	1.6	5.5	3.6	7.3	6.8	4.6	7.7	9.0	6.5	4.2	3.4	28.0	7.4	7.5	3.5	9.7	2.4	1.7	2.9	2.6	7.9	7.0	4.6	4.8	20.4	13.3	7.8	0.1	0.4	6.2	0.5	4.9	6.5	8.7	3.8	13.4	8.1	9.4	8.8	3.6	8.1	14.7	9.7	0.7	4.6	7.4	4.1	9.4	5.2	6.8	8.2	11.4	9.5	5.1	7.7	6.8	5.5	7.2	6.0
ZNF384	"CAGH1A, CIZ, NMP4, NP, TNRC1"	ENSG00000126746	"Zinc finger protein 384"	Q8TF68	12	6666477-6689572	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004051	Supported		Approved	Nucleoplasm				Nucleoplasm		"HPA004051: AB_1859228"	"unprognostic (1.90e-1)"	"unprognostic (5.11e-3)"	"unprognostic (1.76e-1)"	"unprognostic (6.16e-2)"	"unprognostic (1.79e-1)"	"unprognostic (3.04e-2)"	"unprognostic (1.87e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.35e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.25e-1)"	"unprognostic (1.24e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.06e-1)"	"unprognostic (8.13e-2)"	20.5	22.8	18.9	30.9	19.9	33.4	22.1	36.1	23.0	23.2	23.3	19.5	16.8	22.1	29.8	17.6	21.1	24.2	25.3	16.1	16.0	10.8	20.7	19.9	19.7	21.9	19.7	17.7	31.3	25.8	25.8	20.5	23.9	14.8	22.7	21.4	18.6	22.4	20.6	22.7	24.1	29.4	24.8	14.2	33.6	21.3	20.5	18.7	39.7	27.0	17.5	29.7	25.2	28.9	10.2	11.1	14.2	13.3	15.6	17.3	7.3	10.6	20.5	25.3	16.9	17.9	12.7	34.0	15.5	14.5	15.0	16.1	22.5	22.9	25.3	5.9	17.4	14.5	18.6	14.2	17.2	45.6	16.9	28.9	27.2	11.7	12.6	27.4	21.4	13.9	13.8	18.5	28.9	13.0	15.0	8.7	16.4	16.6	24.6	17.6	48.9	9.0	24.5	27.1	9.7	13.3	28.8	7.9	25.6	16.0	21.5	13.8	5.6	22.7	16.0	16.5	23.2	12.9	18.2	12.2	11.6	46.1	16.3	9.9	18.7	3.3	8.0	14.2	17.3	9.7	13.8	10.2	11.0	13.6	11.1	8.8	10.8	12.1	14.2	15.6	13.3	7.4	13.2	7.3	18.9	19.9	36.1	23.0	16.0	10.8	19.7	17.7	14.8	18.7
ZNF471	"KIAA1396, Z1971"	ENSG00000196263	"Zinc finger protein 471"	Q9BX82	19	56507843-56530221	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HSkMC: 10.9;U-138 MG: 9.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA066695	Uncertain		Supported	Nucleoplasm				Nucleoplasm		"HPA066695: "	"unprognostic (2.89e-2)"	"unprognostic (2.79e-4)"	"unprognostic (1.58e-1)"	"unprognostic (2.90e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.42e-3)"	"unprognostic (1.45e-1)"	"unprognostic (8.44e-2)"	"unprognostic (1.01e-2)"	"unprognostic (4.14e-2)"	"unprognostic (4.47e-4)"	"unprognostic (9.36e-2)"	"prognostic favourable (2.37e-4)"	"unprognostic (3.84e-3)"	"unprognostic (1.08e-1)"	"unprognostic (7.89e-2)"	"unprognostic (3.44e-3)"	5.8	7.2	18.5	4.1	18.5	3.0	7.8	23.1	19.3	7.8	8.2	11.2	5.9	2.1	14.2	17.8	5.4	9.8	7.4	5.8	17.4	7.5	5.5	2.6	6.2	3.2	12.2	13.3	24.7	3.9	16.3	10.9	6.6	15.1	9.3	5.1	4.6	6.5	8.5	4.9	10.1	3.2	10.4	11.5	4.6	4.5	8.7	21.3	1.6	10.6	3.1	2.2	6.7	9.9	3.1	1.6	5.4	1.3	3.0	2.1	0.3	0.6	0.6	6.2	0.9	5.2	5.8	0.7	5.6	2.0	2.6	2.3	0.9	0.9	0.9	3.8	6.0	0.5	0.8	0.5	2.6	1.3	2.3	4.4	1.5	0.7	5.1	1.3	4.0	10.9	2.0	3.3	0.3	0.2	1.4	2.0	2.9	0.7	0.5	0.8	1.6	2.4	0.7	4.0	0.6	4.5	4.7	1.0	3.7	0.6	0.3	0.3	0.8	0.9	0.9	9.7	4.2	1.0	4.2	1.5	1.3	0.6	0.8	0.7	0.7	3.9	1.3	0.9	1.9	1.0	1.5	1.2	1.7	1.2	0.7	3.1	1.7	2.1	5.4	3.0	1.0	1.6	1.0	0.3	18.5	18.5	23.1	19.3	17.4	7.5	12.2	13.3	15.1	21.3
ZNF483	"KIAA1962, ZKSCAN16, ZSCAN48"	ENSG00000173258	"Zinc finger protein 483"	Q8TF39	9	111525159-111577844	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 36.3;pituitary gland: 40.4"	"Cell line enhanced"	"Detected in many"		"NTERA-2: 11.5;SCLC-21H: 6.7"	"Cancer enhanced"	"Detected in some"		"testis cancer: 1.4"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA055041			Approved	Nucleoli				Nucleoli		"HPA055041: "	"unprognostic (4.33e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.34e-1)"	"unprognostic (4.11e-2)"	"unprognostic (5.95e-3)"	"unprognostic (9.18e-5)"	"unprognostic (2.02e-1)"	"unprognostic (9.50e-2)"	"unprognostic (4.44e-3)"	"unprognostic (5.49e-2)"	"unprognostic (5.19e-4)"	"unprognostic (7.19e-3)"	"unprognostic (1.74e-1)"	"unprognostic (4.30e-2)"	"unprognostic (6.17e-2)"	3.2	10.1	13.9	2.1	30.5	7.7	5.6	35.9	36.3	6.1	4.0	8.6	2.9	2.0	10.0	11.9	2.4	7.0	4.9	4.7	18.1	7.3	5.1	2.5	3.9	3.4	9.5	23.0	12.6	4.3	13.6	40.4	1.8	24.4	7.2	2.4	5.9	3.2	7.7	2.3	3.5	2.9	5.5	9.8	4.8	3.9	11.8	10.3	0.0	12.5	0.0	3.1	4.7	4.8	2.5	1.0	4.6	1.0	2.1	6.5	1.5	0.3	3.2	3.1	4.7	0.4	0.6	1.0	0.4	1.5	3.1	2.9	0.3	1.5	0.5	0.5	1.3	0.9	1.5	1.6	1.9	0.2	1.8	1.6	4.4	2.5	0.9	0.6	0.4	1.2	0.6	1.7	0.9	2.9	1.3	0.8	0.7	3.0	0.2	0.8	11.5	1.1	0.3	4.8	0.4	1.2	1.3	6.7	3.2	1.2	0.6	0.8	1.9	0.4	0.5	0.9	1.6	1.4	2.2	0.7	1.9	0.4	1.0	0.5	0.7	4.6	1.0	0.6	4.8	0.5	2.7	1.5	3.3	2.3	0.3	2.5	5.9	6.5	3.4	2.1	0.7	1.0	1.6	1.5	13.9	30.5	35.9	36.3	18.1	7.3	9.5	23.0	24.4	10.3
ZNF521	"EHZF, Evi3"	ENSG00000198795	"Zinc finger protein 521"	Q96K83	18	25061926-25352190	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 69.1"	"Cell line enhanced"	"Detected in many"		"AF22: 31.4;fHDF/TERT166: 14.7;HUVEC TERT2: 21.5;THP-1: 17.5"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	6	"cerebellum: 69.1"	"Group enriched"	"Detected in some"	5	"basophil: 8.8;plasmacytoid DC: 9.8"	"Group enriched"	"Detected in many"	5	"dendritic cells: 9.8;granulocytes: 8.8"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in all"	6	"cerebellum: 105.4"	"HPA023056, HPA023849"	Enhanced		Approved	Nucleoplasm				Nucleoplasm		"HPA023056: AB_1859315, HPA023849: AB_1859316"	"unprognostic (8.80e-3)"	"unprognostic (9.68e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.40e-2)"	"unprognostic (5.43e-2)"	"unprognostic (3.73e-3)"	"unprognostic (1.52e-3)"	"unprognostic (6.17e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.18e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.19e-3)"	"unprognostic (1.16e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.52e-3)"	"unprognostic (7.82e-4)"	9.2	11.3	5.2	2.8	7.0	1.9	9.1	69.1	11.5	11.0	3.4	9.1	4.7	1.7	19.8	5.9	3.8	9.0	10.0	7.0	5.8	5.1	3.1	1.2	6.4	4.0	8.4	2.8	20.5	1.4	1.4	16.8	8.0	12.2	4.4	3.5	6.7	8.7	3.0	3.8	4.6	3.2	13.3	12.2	18.5	2.4	3.4	8.9	0.5	5.3	6.9	2.6	7.4	5.4	0.0	9.8	8.8	0.1	1.7	0.0	0.1	0.0	0.0	31.4	0.0	5.0	8.8	0.1	4.5	6.6	1.6	1.0	0.0	0.0	0.0	0.0	14.7	0.1	0.0	0.0	1.3	0.0	1.8	6.2	0.3	0.2	0.9	0.0	9.4	10.9	0.0	0.1	0.0	21.5	0.1	0.0	2.8	0.0	4.0	0.0	2.1	0.0	0.0	7.1	0.5	0.0	0.0	4.1	2.6	0.4	0.0	0.0	0.0	17.5	12.2	12.5	1.0	3.6	0.6	0.0	0.0	0.1	4.7	0.0	10.2	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.1	9.8	0.0	0.1	5.2	7.0	69.1	4.3	5.8	5.1	8.4	2.8	12.2	8.9
ZNF620	MGC50836	ENSG00000177842	"Zinc finger protein 620"	Q6ZNG0	3	40505992-40518736	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 14.2"	"Low lineage specificity"	"Detected in all"											"HPA031452, HPA059383"	Uncertain		Approved	Centrosome				Centrosome		"HPA031452: AB_10603939, HPA059383: "	"unprognostic (1.42e-2)"	"unprognostic (4.23e-2)"	"unprognostic (1.14e-3)"	"unprognostic (1.48e-2)"	"unprognostic (5.62e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.04e-3)"	"unprognostic (2.15e-2)"	"unprognostic (7.73e-2)"	"unprognostic (3.78e-2)"	"unprognostic (1.71e-2)"	"unprognostic (4.09e-2)"	"unprognostic (1.21e-5)"	"unprognostic (1.28e-1)"	"unprognostic (4.78e-1)"	"unprognostic (2.61e-2)"	"unprognostic (9.19e-4)"	5.8	5.7	5.2	3.0	8.2	8.0	6.1	15.6	8.5	3.7	5.0	8.9	4.8	4.4	4.0	6.3	3.1	5.3	3.2	4.4	5.6	5.7	6.2	4.5	6.2	3.4	10.3	5.8	4.5	8.1	8.7	15.2	6.3	6.4	5.2	5.9	6.1	3.5	5.7	6.3	2.4	4.7	4.3	5.3	5.2	7.3	3.0	7.4	3.7	9.5	3.7	3.1	4.8	4.5	2.0	1.3	14.2	1.0	3.1	3.9	1.2	2.3	3.5	8.4	3.1	0.9	0.9	4.4	0.6	0.9	4.0	5.8	8.2	5.2	0.0	2.6	0.4	0.6	12.4	1.1	2.9	7.1	9.7	6.0	8.7	4.5	1.5	2.1	1.2	0.5	0.8	2.5	1.1	2.7	3.1	1.0	0.5	4.0	0.4	1.8	9.7	1.9	3.2	3.5	1.1	3.7	8.4	9.9	7.5	0.6	5.8	3.8	7.6	2.3	1.8	0.4	5.7	0.8	2.6	1.3	2.1	0.1	1.3	1.2	1.5	14.2	0.6	1.2	2.6	1.0	3.2	0.8	1.0	2.7	0.6	2.0	2.1	2.7	0.9	3.1	0.3	1.3	3.9	1.2	5.2	8.2	15.6	8.5	5.6	5.7	10.3	5.8	6.4	7.4
ZNF750	"FLJ13841, Zfp750"	ENSG00000141579	"Zinc finger protein 750"	Q32MQ0	17	82829435-82840578	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 59.3;lymphoid tissue: 54.2;skeletal muscle: 84.2"	"Cell line enhanced"	"Detected in some"		"BEWO: 17.0;hTCEpi: 6.3;MCF7: 4.5;SK-BR-3: 12.7"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.0"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA021573, HPA023012"	Enhanced									"HPA021573: AB_1859438, HPA023012: AB_1859439"	"unprognostic (3.46e-3)"	"unprognostic (1.94e-2)"	"unprognostic (7.51e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.45e-1)"	"unprognostic (9.73e-2)"	"unprognostic (4.48e-2)"	"unprognostic (6.55e-3)"	"unprognostic (1.34e-1)"	"unprognostic (4.33e-2)"	"unprognostic (6.30e-3)"	"unprognostic (1.23e-2)"	"unprognostic (5.30e-3)"	"unprognostic (3.04e-2)"	"unprognostic (5.94e-2)"	"unprognostic (2.04e-1)"	"unprognostic (4.25e-2)"	0.4	0.1	0.1	0.1	0.1	0.1	3.0	0.1	0.1	14.0	0.1	0.0	9.0	0.2	0.9	3.8	59.3	0.4	0.2	0.2	0.1	0.1	0.2	0.1	2.3	0.1	0.1	0.0	0.1	0.1	0.6	2.2	19.5	0.0	3.2	0.1	0.0	38.3	13.2	84.2	46.2	0.1	0.4	0.1	0.1	0.1	0.2	0.0	3.4	6.7	44.1	54.2	3.2	16.8	0.2	0.1	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.2	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.9	1.1	1.0	0.0	12.7	0.0	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
ZNF814		ENSG00000204514	"Zinc finger protein 814"	B7Z6K7	19	57848731-57889074	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 21.8;U-266/84: 20.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA043800, HPA053762, HPA072145"	Approved		Uncertain	Nucleoplasm				Nucleoplasm		"HPA043800: , HPA053762: , HPA072145: "	"unprognostic (3.74e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.29e-2)"	"unprognostic (6.01e-2)"	"unprognostic (2.12e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.69e-2)"	"unprognostic (6.78e-4)"	"unprognostic (5.05e-3)"	"unprognostic (2.41e-4)"	"unprognostic (1.56e-2)"	"unprognostic (4.99e-4)"	"unprognostic (3.94e-1)"	"unprognostic (2.33e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.54e-5)"	5.6	13.3	11.6	9.0	11.0	12.6	12.2	19.2	10.8	6.4	10.0	4.4	15.7	9.7	5.6	10.5	5.2	12.5	9.8	9.5	11.5	10.3	15.0	11.7	5.9	11.1	9.1	8.4	7.8	6.7	10.9	16.2	9.7	7.7	11.4	7.3	16.1	9.0	18.4	18.6	13.3	12.7	9.0	7.3	13.8	5.5	14.0	5.6	18.7	23.0	4.0	11.5	6.6	5.0	21.2	15.3	5.0	5.0	12.8	13.6	4.5	0.9	2.4	7.4	11.0	0.8	0.7	1.9	2.7	1.9	3.1	0.4	1.3	1.0	5.5	1.8	2.5	0.8	0.5	6.0	3.8	0.8	5.0	4.2	3.3	1.3	3.3	4.7	5.2	5.0	5.3	1.2	1.1	0.9	1.0	2.1	4.7	0.9	15.6	2.1	21.8	3.1	1.8	0.8	9.8	2.4	3.9	2.8	7.9	0.9	1.8	3.7	5.4	1.4	1.4	6.9	2.3	1.5	1.2	6.5	20.0	14.0	1.5	2.5	8.2	2.2	4.5	5.0	3.2	5.0	8.2	19.4	8.4	6.9	6.6	21.2	13.6	11.0	2.7	12.8	2.9	15.3	2.1	4.5	11.6	11.0	19.2	10.8	11.5	10.3	9.1	8.4	7.7	5.6
ZNF844	FLJ14959	ENSG00000223547	"Zinc finger protein 844"	Q08AG5	19	12064699-12081565	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RH-30: 11.3;U-266/84: 16.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA046982	Uncertain									"HPA046982: AB_10964399"	"unprognostic (2.07e-1)"	"unprognostic (1.50e-2)"	"unprognostic (1.75e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.92e-3)"	"unprognostic (9.68e-3)"	"unprognostic (1.93e-1)"	"unprognostic (1.87e-2)"	"unprognostic (1.86e-2)"	"unprognostic (5.86e-2)"	"unprognostic (2.47e-2)"	"unprognostic (6.74e-2)"	"prognostic favourable (0.00e+0)"	"unprognostic (1.99e-1)"	"unprognostic (1.65e-2)"	"unprognostic (1.35e-1)"	"unprognostic (3.63e-2)"	9.5	5.2	7.2	6.0	10.8	9.7	12.0	26.9	7.8	10.3	8.6	7.8	11.4	4.3	13.2	7.2	9.4	11.9	4.0	10.3	8.5	5.1	17.2	6.5	6.3	8.1	10.1	7.2	21.2	8.1	14.3	21.3	6.6	9.5	13.4	8.6	10.5	9.3	10.9	12.7	7.9	6.2	14.9	12.5	6.3	6.7	8.8	12.2	3.6	18.7	3.9	5.1	12.8	12.5	2.8	1.9	6.3	3.6	3.1	3.6	1.4	0.1	0.1	3.2	5.4	4.4	4.3	2.4	3.9	1.3	4.0	3.5	4.9	0.9	4.1	4.2	3.1	1.3	0.0	0.7	3.8	0.1	0.2	7.3	0.3	1.2	3.4	0.4	5.5	3.8	0.5	2.3	0.1	0.1	0.1	0.4	2.5	0.1	3.4	1.2	4.2	0.4	0.3	11.3	1.0	1.4	0.2	2.5	2.0	0.0	1.9	1.2	5.8	0.4	0.2	1.2	3.0	5.0	4.1	7.4	16.0	0.6	0.1	0.5	0.8	6.3	2.0	5.3	1.7	3.6	0.9	2.8	1.2	1.6	1.9	2.1	3.6	1.9	5.8	3.1	2.0	0.6	0.4	1.4	7.2	10.8	26.9	7.6	8.5	5.1	10.1	7.2	9.5	12.2
ZNF91	"HPF7, HTF10"	ENSG00000167232	"Zinc finger protein 91"	Q05481	19	23304991-23395560	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"																						"unprognostic (2.53e-1)"	"unprognostic (3.60e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.18e-2)"	"unprognostic (3.32e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.99e-3)"	"unprognostic (5.85e-2)"	"unprognostic (9.85e-4)"	"unprognostic (6.74e-3)"	"unprognostic (3.02e-2)"	"unprognostic (4.47e-2)"	"prognostic favourable (7.58e-4)"	"unprognostic (7.38e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.21e-2)"	"prognostic favourable (3.48e-4)"	9.5	11.0	16.2	13.4	20.1	5.5	15.6	47.0	21.1	14.2	17.0	8.6	11.9	19.9	12.8	13.6	11.9	11.4	7.4	10.0	15.7	8.5	13.0	11.4	9.8	12.3	16.6	11.8	16.4	9.5	17.6	32.7	23.2	16.9	13.3	17.9	8.4	13.7	13.9	15.6	12.1	21.6	9.4	18.3	11.1	11.8	6.5	18.7	10.2	17.8	6.0	11.2	13.8	11.9	9.1	6.3	5.1	3.4	5.3	12.6	3.4	4.1	0.7	13.3	6.3	3.9	6.2	7.4	3.0	5.0	7.8	9.7	3.3	4.2	0.2	6.3	3.8	5.2	10.4	3.2	9.7	0.4	10.1	1.8	3.2	2.5	3.1	0.1	3.3	5.2	6.3	6.1	7.4	2.7	6.3	0.9	5.8	2.4	12.0	4.6	9.2	3.7	9.1	8.6	6.9	4.7	10.3	8.1	6.4	0.2	0.3	3.4	3.9	7.7	3.7	2.4	1.4	3.6	5.6	0.4	3.4	12.3	0.1	0.3	1.3	4.5	2.2	2.7	7.4	1.8	6.6	6.8	8.8	7.7	2.6	9.1	12.6	9.6	5.1	5.3	3.4	6.3	4.9	3.4	16.2	20.1	47.0	21.1	15.7	8.5	16.6	11.8	16.9	18.7
ZRANB3	DKFZP434B1727	ENSG00000121988	"Zinc finger RANBP2-type containing 3"	Q5FWF4	2	135136916-135531236	"Cancer-related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Endonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA035234			Supported	Nucleoplasm				Nucleoplasm		"HPA035234: "	"unprognostic (6.98e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.52e-3)"	"unprognostic (4.09e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.53e-3)"	"unprognostic (1.74e-1)"	"unprognostic (3.58e-2)"	"unprognostic (4.68e-2)"	"unprognostic (2.77e-4)"	"unprognostic (1.57e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.00e-2)"	"unprognostic (9.88e-2)"	3.5	6.3	5.5	4.9	7.0	5.2	5.4	7.7	7.9	5.4	3.3	4.1	3.9	2.6	5.4	6.0	3.3	5.4	3.9	4.0	4.7	5.2	4.4	6.3	2.9	4.3	6.0	5.4	7.2	6.1	7.3	15.6	4.3	5.7	5.4	4.7	5.6	3.1	4.0	7.6	3.0	3.0	7.2	4.9	4.0	3.1	12.6	6.6	10.7	6.7	3.0	4.8	4.2	3.6	3.0	1.9	1.4	0.8	1.7	3.5	0.9	3.3	3.2	5.2	3.9	2.8	5.7	4.9	4.3	3.9	4.3	4.7	6.2	3.1	7.3	5.8	3.9	3.6	8.3	4.3	6.1	10.3	4.7	8.2	2.1	11.9	2.7	7.1	2.9	4.9	4.6	3.9	11.3	5.0	9.6	3.2	3.8	4.9	6.9	4.8	3.2	4.8	6.7	4.3	3.0	6.1	1.9	6.4	8.3	4.2	1.7	3.3	4.2	3.1	3.3	3.5	2.8	1.9	3.9	2.4	4.5	8.2	4.2	5.2	3.8	0.6	0.8	1.4	1.6	0.8	3.5	3.0	1.5	1.3	1.9	1.5	1.4	1.5	0.9	1.7	0.3	0.8	0.4	0.9	5.5	7.0	7.7	7.9	4.7	5.2	6.0	5.4	5.7	6.6
ZRSR2	"U2AF1-RS2, U2AF1L2, URP, ZC3H22"	ENSG00000169249	"Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2"	Q15696	X	15790472-15823260	"Cancer-related genes, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	"Ribonucleoprotein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"																		"prognostic favourable (7.96e-4)"	"unprognostic (1.54e-2)"	"unprognostic (7.31e-2)"	"prognostic favourable (8.50e-5)"	"unprognostic (8.08e-2)"	"unprognostic (1.69e-1)"	"unprognostic (6.14e-3)"	"unprognostic (5.72e-3)"	"unprognostic (8.46e-2)"	"unprognostic (3.47e-3)"	"unprognostic (6.90e-2)"	"unprognostic (2.85e-2)"	"prognostic unfavourable (4.87e-5)"	"unprognostic (8.14e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.65e-2)"	"prognostic favourable (2.97e-4)"	11.4	9.7	16.7	13.4	21.7	32.5	14.2	22.5	22.1	20.7	13.6	7.6	11.2	9.1	17.1	17.7	10.9	11.8	8.8	12.8	16.1	14.4	11.5	8.2	13.9	21.7	18.1	11.6	16.7	9.2	15.7	31.1	9.8	16.0	11.8	10.9	9.4	10.6	10.6	31.7	12.3	12.4	14.5	20.1	21.1	9.5	4.8	17.5	7.9	12.8	5.6	16.5	21.8	16.7	23.8	17.8	22.0	18.8	10.2	20.3	7.6	9.7	6.5	11.2	10.5	15.9	13.7	4.4	8.0	7.5	7.8	8.0	7.7	8.0	11.1	13.8	7.4	9.6	10.7	13.9	8.1	8.2	14.2	7.3	15.3	7.1	10.9	16.7	17.2	6.8	12.8	14.3	23.4	13.5	11.4	11.0	9.4	11.9	8.8	17.6	14.2	9.1	10.3	15.6	11.3	9.3	7.7	7.8	8.5	18.8	16.8	11.7	13.2	9.6	9.5	7.8	5.6	20.5	7.5	9.3	7.9	10.6	6.0	12.0	10.0	22.0	18.8	16.6	13.5	16.6	13.1	21.6	17.1	18.0	10.9	23.8	20.3	14.8	21.0	10.2	15.6	17.8	16.0	7.6	16.7	21.7	22.5	22.1	16.1	14.4	18.1	11.6	16.0	17.5
